P00001606T0076|0 9|Comparison
P00001606T0076|37 50|5-nucleotidase
P00001606T0076|14 33|alkaline phosphatases
P00008171T0000|30 47|hyperbilirubinemia
P00008171T0000|13 19|aspects
P00008997A0472|139 143|slope
P00008997A0472|60 63|rats
P00008997A0472|24 31|function
P00008997A0472|8 11|HCO3
P00008997A0472|44 47|data
P00008997A0472|98 105|controls
P00008997A0472|34 40|CSF PCO2
P00008997A0472|4 6|CSF
P00010943A0733|0 9|Flurazepam
P00010943A0733|100 104|night
P00010943A0733|62 65|dose
P00010943A0733|69 71|use
P00010943A0733|44 47|drug
P00010943A0733|81 88|practice
P00010943A0733|96 97|mg
P00012653T0045|0 3|Beta
P00012653T0045|12 17|agents
P00013683A0210|18 27|CO2 removal
P00013683A0210|54 57|VCO2
P00013683A0210|40 52|CO2 production
P00013683A0210|68 78|ventilation
P00015731A0090|92 107|dichlorphenamide
P00015731A0090|142 145|rise
P00015731A0090|191 191|p
P00015731A0090|226 230|blood
P00015731A0090|109 117|sulthiame
P00015731A0090|28 32|mg/kg
P00015731A0090|214 215|pH
P00015731A0090|197 200|p CO2
P00015731A0090|64 76|acetazolamide
P00015731A0090|44 62|anhydrase inhibitors
P00015731A0090|78 90|methazolamide
P00015731A0090|11 24|administration
P00015731A0090|181 188|increase
P00015731A0090|156 156|p
P00015731A0090|204 211|decrease
P00022143T0000|42 47|rabbit
P00022143T0000|13 17|study
P00022143T0000|36 38|rat
P00022143T0000|20 30|etoperidone
P00023348A0601|10 15|polyps
P00024600A0522|86 98|dosage regimen
P00024600A0522|11 26|HMG dosage regimen
P00024600A0522|44 53|advantages
P00025557A0100|28 28|%
P00025557A0100|32 38|animals
P00025557A0100|59 68|body weight
P00025557A0100|7 16|CO2 content
P00027739T0000|0 28|Serum gamma glutamyltransferase
P00027739T0000|34 42|diagnosis
P00027739T0000|45 56|liver disease
P00027739T0000|59 64|cattle
P00027967A0207|97 105|formation
P00027967A0207|124 133|antibodies
P00027967A0207|63 69|illness
P00027967A0207|20 31|HI antibodies
P00027967A0207|80 87|patients
P00027967A0207|148 153|levels
P00027967A0207|161 164|days
P00027967A0207|177 183|illness
P00027967A0207|170 174|onset
P00027967A0207|56 60|onset
P00027967A0207|2 9|contrast
P00029555A0861|31 42|quantitation
P00029555A0861|7 15|exception
P00029555A0861|102 134|shellfish microbiology laboratories
P00029555A0861|49 55|methods
P00029555A0861|18 27|virus assay
P00029953T0045|0 14|Characteristics
P00029953T0045|17 30|lipase activity
P00030183T0000|0 7|Takayasu
P00030183T0000|10 16|disease
P00030183T0000|33 38|HLA-B5
P00030183T0000|18 28|association
P00030937A0119|0 3|SGPT
P00030937A0119|5 8|SGOT
P00030937A0119|72 79|subjects
P00030937A0119|13 45|alkaline phosphatase concentrations
P00033873T0001|0 26|Gamma glutamyl transpeptidase
P00033873T0001|28 31|GGTP
P00033873T0001|53 57|fluid
P00033873T0001|33 40|activity
P00034935A0545|0 7|Patients
P00034935A0545|12 20|Parkinson
P00034935A0545|23 29|disease
P00034935A0545|77 89|drug treatment
P00034935A0545|62 70|psychoses
P00034935A0545|51 59|incidence
P00034935A0545|96 96|%
P00038408T0000|29 47|alpha-autoreceptors
P00038408T0000|57 65|treatment
P00038408T0000|70 85|alpha-methyldopa
P00038408T0000|9 19|stimulation
P00038408T0000|89 91|FLA
P00039271T0000|49 59|application
P00039271T0000|12 17|action
P00039271T0000|65 67|rat
P00039271T0000|20 27|diazepam
P00041512T0067|0 8|Abstracts
P00048373A0377|0 6|Removal
P00048373A0377|78 87|epithelium
P00048373A0377|61 67|absence
P00048373A0377|33 38|mucoas
P00050628A0202|71 81|proteinuria
P00050628A0202|93 99|patient
P00050628A0202|48 55|patients
P00050628A0202|15 24|gammopathy
P00050628A0202|2 4|IgG
P00050628A0202|40 44|serum
P00052597T0000|0 6|Studies
P00052597T0000|37 43|sojourn
P00052597T0000|48 61|Professor Dan H.
P00052597T0000|9 23|immunoglobulin E
P00052597T0000|28 33|impact
P00054900A0226|50 57|esterase
P00054900A0226|10 23|reaction stains
P00055040A0000|3 14|out-patients
P00055040A0000|138 156|degradation products
P00055040A0000|229 236|fraction
P00055040A0000|263 278|plasma fibrinogen
P00055040A0000|238 240|HPF
P00055040A0000|158 167|FR-antigen
P00055040A0000|104 113|deposition
P00055040A0000|192 195|skin
P00055040A0000|70 87|immunofluorescence
P00055040A0000|19 36|pustulosis palmaris
P00055040A0000|284 288|blood
P00055040A0000|116 125|fibrinogen
P00055040A0000|92 100|technique
P00055040A0000|243 254|cryoglobulin
P00056837A0000|97 105|carcinoma
P00056837A0000|74 84|operability
P00056837A0000|5 21|mediastinoscopies
P00056901A0308|27 46|hydroxy-ethyl-starch
P00056901A0308|23 23|%
P00056901A0308|1 7|mixture
P00056901A0308|68 75|dilution
P00056901A0308|15 21|albumin
P00056901A0308|57 64|solution
P00060529A0695|116 125|percentage
P00060529A0695|172 175|year
P00060529A0695|145 162|practice population
P00060529A0695|95 95|%
P00060529A0695|128 132|women
P00060529A0695|12 23|control group
P00060529A0695|27 42|acquisition-rate
P00060529A0695|98 103|figure
P00060529A0695|75 85|0acteriuria
P00060529A0695|215 218|A.B.
P00061478T0000|48 56|nutrition
P00061478T0000|19 33|catheterisation
P00061478T0000|4 16|complications
P00063680T0000|19 31|galactosaemia
P00063680T0000|8 16|diagnosis
P00064414A1098|0 4|Sings
P00064414A1098|36 49|erythropoiesis
P00066874T0000|89 95|results
P00066874T0000|21 47|fluid alpha fetoprotein levels
P00066874T0000|83 87|blood
P00066874T0000|100 109|experiment
P00066874T0000|61 73|contamination
P00072928T0000|0 13|Serum-ferritin
P00072928T0000|27 42|haemochromatosis
P00072928T0000|16 24|diagnosis
P00073344A0367|41 51|lymphocytes
P00073344A0367|3 10|subjects
P00073344A0367|68 76|treatment
P00073344A0367|14 35|phytomitogen reactivity
P00074758T0000|0 7|Patients
P00074758T0000|10 13|risk
P00074758T0000|16 29|hypothyroidism
P00083846T0000|0 6|Albumin
P00083846T0000|37 42|fluids
P00083846T0000|48 52|child
P00083846T0000|16 24|AMP levels
P00084275T0063|0 6|Preface
P00086313A0000|88 93|groups
P00086313A0000|11 17|strains
P00086313A0000|33 47|disease bacteria
P00086313A0000|106 113|findings
P00086313A0000|143 157|antibody testing
P00086313A0000|20 31|Legionnaires
P00086313A0000|99 103|basis
P00088391A0181|72 78|antigen
P00088391A0181|10 19|hand factor
P00088391A0181|22 29|activity
P00088391A0181|64 69|factor
P00088391A0181|43 59|coumarin treatment
P00089778A0000|298 313|cataract patients
P00089778A0000|114 116|FDP
P00089778A0000|133 140|activity
P00089778A0000|187 194|patients
P00089778A0000|165 170|humour
P00089778A0000|18 37|alpha 2-macroglobulin
P00089778A0000|228 235|patients
P00089778A0000|259 266|cataract
P00089778A0000|84 112|fibrinogen degradation products
P00089778A0000|216 224|dystrophy
P00089778A0000|70 82|C3-complement
P00089778A0000|199 203|Fuchs
P00089778A0000|39 56|alpha 1-antitrypsin
P00089778A0000|58 68|plasminogen
P00089778A0000|174 178|serum
P00089778A0000|3 15|concentration
P00092689A0352|12 19|patients
P00092689A0352|35 39|times
P00092689A0352|6 6|%
P00094639A0313|0 7|Prazosin
P00094639A0313|67 68|mg
P00094639A0313|27 32|volume
P00094639A0313|54 57|dose
P00094639A0313|43 50|patients
P00096241A0087|0 1|T4
P00096241A0087|38 43|groups
P00096241A0087|61 64|days
P00096241A0087|25 31|courses
P00096241A0087|157 157|P
P00096241A0087|5 8|FT4I
P00096241A0087|77 82|values
P00096241A0087|136 138|EGA
P00096241A0087|116 122|infants
P00096241A0087|145 155|term infants
P00096241A0087|130 134|weeks
P00097989A0106|42 49|patients
P00097989A0106|13 20|analysis
P00097989A0106|23 36|treatment plans
P00100540T0000|0 17|Aspirin intolerance
P00100540T0000|28 41|susceptibility
P00100540T0000|69 78|inhibition
P00100540T0000|81 87|aspirin
P00100540T0000|44 66|platelet cyclo-oxygenase
P00100791A0425|87 99|rhesus monkeys
P00100791A0425|24 40|cynomolgus monkeys
P00100791A0425|5 11|results
P00100791A0425|126 132|effects
P00100791A0425|135 144|norcocaine
P00101300A0257|43 44|T3
P00101300A0257|37 38|T1
P00101300A0257|99 104|months
P00101300A0257|40 41|T2
P00101300A0257|90 94|years
P00101300A0257|76 80|years
P00101300A0257|49 50|N1
P00101300A0257|63 70|followup
P00101300A0257|2 6|cases
P00101300A0257|46 47|N0
P00101300A0257|29 35|cancers
P00105401A0635|204 206|FT4
P00105401A0635|36 47|interference
P00105401A0635|75 77|TBG
P00105401A0635|11 13|CBZ
P00105401A0635|122 134|clearance rate
P00105401A0635|137 151|thyroid hormones
P00105401A0635|183 201|premedication levels
P00105401A0635|170 180|maintenance
P00105401A0635|3 8|effect
P00105401A0635|210 212|FT3
P00105401A0635|17 19|DPH
P00105401A0635|52 72|thyroid hormone binding
P00105903A0288|30 40|possibility
P00105903A0288|10 17|research
P00105903A0288|67 69|PEG
P00105903A0288|45 62|polyethylene glycol
P00111174A0351|146 152|stimuli
P00111174A0351|107 110|eyes
P00111174A0351|93 99|stimuli
P00111174A0351|115 121|neurons
P00111174A0351|26 35|properties
P00111174A0351|45 51|neurons
P00111174A0351|181 187|stimuli
P00111174A0351|74 80|neurons
P00111174A0351|157 163|neurons
P00112627A0542|147 151|mg/kg
P00112627A0542|157 164|fentanyl
P00112627A0542|49 59|combination
P00112627A0542|104 108|mg/kg
P00112627A0542|169 173|mg/kg
P00112627A0542|79 83|doses
P00112627A0542|125 129|mg/kg
P00112627A0542|111 121|anileridine
P00112627A0542|0 12|Pentobarbital
P00112627A0542|132 143|alphaprodine
P00112627A0542|28 32|mg/kg
P00112627A0542|86 98|normeperidine
P00113657A0628|0 5|Pb foil
P00113657A0628|11 15|gcm-2
P00113657A0628|39 49|improvement
P00114144A0189|220 231|enzyme defect
P00114144A0189|159 166|Andersen
P00114144A0189|56 69|result emphasis
P00114144A0189|136 157|glycogen storage disease
P00114144A0189|169 175|disease
P00114144A0189|130 133|Type
P00114144A0189|28 32|study
P00114144A0189|114 125|similarities
P00114144A0189|85 94|hypotheses
P00115974A0576|59 62|days
P00115974A0576|65 67|age
P00115974A0576|35 38|maze
P00115974A0576|3 8|groups
P00117748T0000|15 35|clindamycin resistance
P00117748T0000|38 63|Corynebacterium diphtheriae
P00117748T0000|68 78|skin lesions
P00117748T0000|0 11|Erythromycin
P00118044A0000|115 125|EMG activity
P00118044A0000|83 84|M2
P00118044A0000|37 41|wrist
P00118044A0000|66 73|activity
P00118044A0000|140 146|muscles
P00118044A0000|89 95|M3 peaks
P00118044A0000|75 81|terms M1
P00118044A0000|29 34|monkey
P00118044A0000|14 26|displacements
P00118044A0000|59 63|peaks
P00118810T0001|9 15|disease
P00119339A0400|142 153|degeneration
P00119339A0400|75 87|T. cruzi stocks
P00119339A0400|158 164|lesions
P00119339A0400|118 128|myocarditis
P00119339A0400|6 11|animal
P00119339A0400|94 99|strain
P00119339A0400|170 179|oesophagus
P00122718A0500|13 20|MRF units
P00122718A0500|3 10|majority
P00122718A0500|76 79|case
P00122718A0500|120 127|behavior
P00122718A0500|86 93|activity
P00129659T0000|0 10|Variability
P00129659T0000|32 41|trisomy-21
P00129659T0000|23 30|syndrome
P00129659T0000|79 81|IQs
P00129659T0000|17 20|Down
P00129659T0000|63 76|sex differences
P00130573T0054|0 2|VII
P00131739T0001|48 57|Uzbekistan
P00131739T0001|35 45|populations
P00131739T0001|18 24|indices
P00133214T0064|4 11|concepts
P00133214T0064|27 34|function
P00133214T0064|40 43|USSR
P00136175A1137|44 50|density
P00136175A1137|67 72|amount
P00136175A1137|111 114|week
P00136175A1137|153 155|ECA
P00136175A1137|140 150|enlargement
P00136175A1137|3 13|maintenance
P00136175A1137|95 95|h
P00136175A1137|75 82|exercise
P00136175A1137|98 105|exercise
P00137671A0896|100 110|coagulation
P00137671A0896|50 59|VIII-ratio
P00137671A0896|76 84|indicator
P00137671A0896|5 16|observations
P00139624A0318|5 9|hours
P00139624A0318|34 43|colchicine
P00139624A0318|48 70|serum ceruloplasmin level
P00139624A0318|112 115|rats
P00139624A0318|18 31|administration
P00139624A0318|95 98|rats
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|103 110|cortisol
P00139827A0000|68 70|DHA
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|193 200|delivery
P00139827A0000|137 138|ml
P00139827A0000|19 30|pregnenolone
P00139827A0000|74 90|alpha-hydroxy-DHA
P00139827A0000|147 152|plasma
P00139827A0000|127 131|total
P00139827A0000|172 177|course
P00139827A0000|92 98|estriol
P00139827A0000|32 43|progesterone
P00142718A0156|115 130|chest radiographs
P00142718A0156|93 102|99mTc-EHDP
P00142718A0156|9 16|patients
P00142718A0156|68 77|metastases
P00142718A0156|40 46|changes
P00146327A0147|100 106|trachea
P00146327A0147|65 74|incidences
P00146327A0147|110 120|stem bronchi
P00146327A0147|37 44|cavities
P00146327A0147|3 10|majority
P00146327A0147|93 98|larynx
P00146327A0147|13 18|tumors
P00149899T0001|0 9|Prediction
P00149899T0001|15 19|times
P00149899T0001|29 39|development
P00150066A0100|33 43|coagulation
P00150066A0100|52 59|thrombin
P00150066A0100|11 20|fibrinogen
P00150066A0554|16 27|haemorrhages
P00150066A0554|35 44|prostheses
P00154430A0906|73 85|transcription
P00154430A0906|35 46|localization
P00154430A0906|52 57|region
P00154430A0906|107 114|fragment
P00154430A0906|92 93|kb
P00154430A0906|3 19|Southern technique
P00155973A0387|157 157|%
P00155973A0387|194 198|min-1
P00155973A0387|79 84|system
P00155973A0387|26 31|limits
P00155973A0387|153 155|vol
P00155973A0387|237 241|min-1
P00155973A0387|116 141|carbon dioxide concentration
P00155973A0387|56 56|%
P00155973A0387|206 210|range
P00155973A0387|213 229|minute ventilation
P00155973A0387|172 183|gas flow rates
P00155973A0387|43 48|errors
P00159600A0871|0 1|SV
P00159600A0871|56 65|compliance
P00159600A0871|125 129|shift
P00159600A0871|91 99|ventricle
P00159600A0871|17 19|SHR
P00159600A0871|149 153|curve
P00159600A0871|84 86|SHR
P00163384A0000|28 42|Bubo virginianus
P00163384A0000|24 26|owl
P00163384A0000|80 86|Ontario
P00163384A0000|103 110|necropsy
P00163384A0000|3 9|carcass
P00167544A0067|157 180|surface specimen technique
P00167544A0067|64 70|regions
P00167544A0067|8 11|ears
P00167544A0067|25 39|microdissection
P00167544A0067|111 128|electron microscopy
P00168176A0000|0 6|Patulin
P00168176A0000|136 141|eluant
P00168176A0000|22 39|apple butter samples
P00168176A0000|62 68|extract
P00168176A0000|117 123|acetate
P00168176A0000|44 55|ethyl acetate
P00168176A0000|83 97|silica gel column
P00168431T0000|0 18|Steroid glucuronides
P00168431T0000|36 39|term
P00168431T0000|29 33|fluid
P00172199A0270|101 115|cross striations
P00172199A0270|23 30|clusters
P00172199A0270|3 8|matrix
P00172199A0270|50 59|morphology
P00172199A0270|74 83|appearance
P00173860A0475|0 9|Riboflavin
P00173860A0475|143 153|elimination
P00173860A0475|54 60|animals
P00173860A0475|129 140|disturbances
P00173860A0475|25 34|percentage
P00173860A0475|80 96|excretion patterns
P00173860A0475|115 123|magnitude
P00173860A0475|179 183|acids
P00176742T0000|0 10|Polyglactin
P00176742T0000|50 56|enzymes
P00176742T0000|36 39|role
P00176742T0000|14 29|suture absorption
P00183063A0300|112 119|patients
P00183063A0300|14 26|DNCB reactions
P00183063A0300|95 99|Stage
P00183063A0300|180 185|cancer
P00183063A0300|42 46|Stage
P00183063A0300|103 108|cancer
P00183063A0300|172 176|Stage
P00183063A0300|78 81|cent
P00183063A0300|35 38|cent
P00183063A0300|63 70|patinets
P00183063A0300|130 133|cent
P00183063A0300|3 11|incidence
P00183063A0300|53 59|cancers
P00183063A0300|136 143|patients
P00188387A0975|0 6|Studies
P00188387A0975|9 20|lipoproteins
P00188387A0975|75 76|FH
P00188387A0975|44 51|children
P00188387A0975|92 103|heart disease
P00188387A0975|56 63|families
P00193088A0196|18 25|subjects
P00193088A0196|34 43|Metyrapone
P00193088A0196|51 59|responses
P00193088A0196|31 31|g
P00193587T0000|29 37|phenomena
P00193587T0000|49 56|analysis
P00193587T0000|40 45|review
P00193587T0000|0 12|EEG theta waves
P00196255A0000|0 14|REM dream content
P00196255A0000|114 126|verbalization
P00196255A0000|167 174|salience
P00196255A0000|27 36|categories
P00196255A0000|79 88|hemisphere
P00196255A0000|154 158|music
P00196255A0000|138 147|hemisphere
P00196255A0000|99 101|ego
P00196255A0000|61 69|influence
P00196255A0000|176 186|bizarreness
P00198510T0000|0 10|Innervation
P00198510T0000|23 31|diaphragm
P00198510T0000|37 42|locust
P00198510T0000|44 60|Locusta migratoria
P00199012T0000|31 46|thyroid carcinoma
P00199012T0000|7 18|ACTH syndrome
P00201881A0487|26 32|studies
P00201881A0487|72 82|MSH contents
P00201881A0487|45 55|correlation
P00201881A0487|9 15|finding
P00201881A0487|63 68|PI ACTH
P00205074A0000|55 61|rickets
P00205074A0000|38 41|type
P00205074A0000|7 22|hypophosphatemia
P00209664A0836|28 34|serum LH
P00209664A0836|10 20|correlation
P00209664A0836|132 148|parallel phenomena
P00209664A0836|53 59|bone age
P00209664A0836|66 73|age group
P00209664A0836|95 105|correlation
P00210220X0000|34 38|drugs
P00210220X0000|9 22|neurochemistry
P00211881A0602|126 128|PBB
P00211881A0602|112 115|site
P00211881A0602|37 40|time
P00211881A0602|118 123|action
P00211881A0602|52 64|kidney lesions
P00211881A0602|29 34|amount
P00211881A0602|0 6|Efforts
P00216939T0001|0 5|Effect
P00216939T0001|21 29|intensity
P00216939T0001|76 80|brain
P00216939T0001|107 114|chloride
P00216939T0001|8 15|succimer
P00216939T0001|45 70|acid dehydrogenase reactions
P00216939T0001|83 86|rats
P00219533T0001|15 26|correlations
P00219533T0001|77 79|men
P00219533T0001|59 69|populations
P00219533T0001|29 42|serum uric-acid
P00219533T0001|88 92|women
P00219533T0001|0 11|Distribution
P00219565A0172|14 30|hepatitis B antigen
P00219565A0172|40 50|transfusion
P00219565A0172|65 68|cent
P00219565A0172|3 11|incidence
P00219674A0000|0 13|Technetium-99m
P00219674A0000|114 118|range
P00219674A0000|108 112|weeks
P00219674A0000|45 55|scintigrams
P00219674A0000|22 34|pyrophosphate
P00219674A0000|89 96|patients
P00219674A0000|146 155|infarction
P00221136A0984|39 44|humans
P00221136A0984|8 17|phenomenon
P00221725A0523|43 52|peroxidase
P00221725A0523|110 117|decrease
P00221725A0523|61 72|lipid content
P00221725A0523|25 41|cytochrome oxidase
P00221725A0523|3 9|decline
P00221725A0523|133 140|activity
P00221725A0523|85 95|neutrophils
P00221725A0523|15 22|activity
P00222102A0227|134 141|response
P00222102A0227|24 51|pseudohypoparathyroidism type
P00222102A0227|146 151|regard
P00222102A0227|157 169|normalisation
P00222102A0227|12 19|patients
P00222102A0227|57 67|vitamin-D-3
P00222102A0227|172 184|serum-calcium
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222102A0227|0 8|Treatment
P00222827A0000|59 63|depth
P00222827A0000|46 48|TDI
P00222827A0000|107 121|hyperreactivity
P00222827A0000|12 22|sensitivity
P00222827A0000|33 44|diisocyanate
P00222827A0000|68 74|attempt
P00222827A0000|86 95|mechanisms
P00222827A0000|0 6|Workers
P00224013A0661|26 31|groups
P00224013A0661|326 333|pressure
P00224013A0661|254 257|limb
P00224013A0661|392 405|vasodilatation
P00224013A0661|89 93|group
P00224013A0661|216 226|utilization
P00224013A0661|294 309|extraction ratios
P00224013A0661|95 104|beta-Block
P00224013A0661|131 134|limb
P00224013A0661|44 50|hypoxia
P00224013A0661|383 386|part
P00224013A0661|280 283|body
P00224013A0661|145 154|resistance
P00224013A0661|422 428|hypoxia
P00224013A0661|167 173|hypoxia
P00224013A0661|236 243|delivery
P00224013A0661|335 359|beta-Vasodilator receptors
P00224013A0661|260 269|comparison
P00224013A0661|5 7|VO2
P00224013A0661|54 60|limb VO2
P00224013A0661|117 120|fall
P00225352T0000|21 31|alterations
P00225352T0000|50 51|3H
P00225352T0000|37 46|metabolism
P00225352T0000|83 90|rat liver
P00225352T0000|53 61|vitamin D3
P00227393T0000|0 9|Modulation
P00227393T0000|12 45|25-hydroxyvitamin D3-24-hydroxylase
P00227393T0000|48 60|aminophylline
P00227393T0000|63 96|cytochrome P-450 monooxygenase system
P00227610A1593|54 63|messengers
P00227610A1593|73 86|polyoma viruses
P00227610A1593|11 18|respects
P00227610A1593|66 69|SV40
P00227610A1593|31 37|DBP mRNA
P00231555T0001|0 5|Effect
P00231555T0001|81 98|cortisol production
P00231555T0001|74 77|ACTH
P00231555T0001|46 61|combination drugs
P00232354A0286|0 8|Serum ACTH
P00232354A0286|24 30|insulin
P00232354A0286|34 43|metyrapone
P00232456T0000|84 91|leukemia
P00232456T0000|12 14|RNA
P00232456T0000|120 124|class
P00232456T0000|105 112|evidence
P00232456T0000|32 35|MC29
P00232456T0000|139 143|genes
P00232456T0000|60 71|tumor viruses
P00232456T0000|95 103|carcinoma
P00232456T0000|18 29|gene products
P00232456T0000|39 41|MH2
P00232456T0000|0 6|Anatomy
P00234206T0000|0 7|Bertioga
P00234206T0000|9 18|Guama group
P00234206T0000|54 64|arboviruses
P00234206T0000|31 45|Bunyamwera group
P00234206T0000|23 29|Anhembi
P00234206T0000|84 89|Brazil
P00234206T0000|75 82|Sao Paulo
P00234264A0164|0 34|Gamma glutamyl transpeptidase activity
P00234264A0164|104 114|aminopyrine
P00234264A0164|53 57|times
P00234264A0164|77 81|limit
P00234264A0164|121 125|weeks
P00234264A0164|84 91|children
P00234626T0036|0 2|XXI
P00239014A0000|90 100|blood plasma
P00239014A0000|79 82|CPIB
P00239014A0000|38 50|determination
P00239014A0000|26 31|method
P00239014A0000|84 87|acid
P00239169T0000|60 64|study
P00239169T0000|30 41|neuroleptics
P00239169T0000|0 23|Dopamine receptor blockade
P00240016T0033|0 1|V.
P00240518A0000|18 26|procedure
P00240518A0000|51 75|fungicide 5-fluorocytosine
P00240518A0000|78 82|serum
P00240518A0000|33 45|determination
P00242427T0001|4 8|field
P00242427T0001|11 16|stress
P00242427T0001|34 38|nurse
P00254537T0000|32 39|programs
P00254537T0000|25 29|types
P00254537T0000|49 59|state boards
P00254537T0000|5 13|graduates
P00261981A0434|60 63|rats
P00261981A0434|76 82|litters
P00261981A0434|18 34|serum somatomedin A
P00264240A1843|112 120|T clusters
P00264240A1843|85 92|residues
P00264240A1843|3 11|sequences
P00264240A1843|50 56|5S genes
P00264240A1843|24 39|X. borealis oocyte
P00264240A1843|144 149|region
P00264240A1843|152 170|X. laevis oocyte 5S DNA
P00265964A0562|4 12|mechanism
P00265964A0562|34 46|grain boundary
P00267764A0651|40 56|treatment failures
P00267764A0651|91 100|management
P00267764A0651|73 82|philosophy
P00267764A0651|30 36|reasons
P00267764A0651|4 9|report
P00294502T0001|0 8|Diagnosis
P00294502T0001|12 28|treatment planning
P00294502T0001|39 46|division
P00294502T0001|31 37|Class II
P00300314A0132|16 25|infections
P00300314A0132|89 90|mm
P00300314A0132|149 165|calcium leucovorin
P00300314A0132|203 214|methotrexate
P00300314A0132|173 177|mg/m2
P00300314A0132|27 31|fever
P00300314A0132|136 143|patients
P00300314A0132|96 110|hospitalization
P00300314A0132|194 197|days
P00300314A0132|54 74|degrees F. granulocytes
P00300314A0132|116 124|drug death
P00300314A0132|227 241|treatment cycles
P00303189A0247|14 16|way
P00303189A0247|122 128|process
P00303189A0247|36 42|patient
P00303189A0247|24 28|drugs
P00303189A0247|45 58|serum chemistry
P00303189A0247|79 86|efficacy
P00304240A0369|43 50|presence
P00304240A0369|66 72|disease
P00304240A0369|19 23|tests
P00304310A0000|3 11|end-stage
P00304310A0000|26 30|phase
P00304310A0000|54 64|retinopathy
P00304310A0000|104 110|periods
P00304310A0000|91 96|vision
P00304310A0000|76 88|stabilization
P00304310A0000|113 116|time
P00304806A0760|12 36|serum alpha1AT quantitation
P00304806A0760|136 138|mg%
P00304806A0760|5 9|basis
P00304806A0760|107 120|concentrations
P00304806A0760|45 51|infants
P00304806A0760|73 78|groups
P00313766A0666|83 89|control
P00313766A0666|53 62|depression
P00313766A0666|103 103|%
P00313766A0666|105 105|p
P00313766A0666|80 80|%
P00313766A0666|91 95|range
P00313766A0666|65 72|function
P00313766A0666|2 9|patients
P00316723A0558|0 6|Changes
P00316723A0558|9 18|body weight
P00316723A0558|31 38|behavior
P00321261A0104|191 195|women
P00321261A0104|159 163|cycle
P00321261A0104|105 110|routes
P00321261A0104|36 39|PGE2
P00321261A0104|20 34|prostaglandin E2
P00321261A0104|10 17|response
P00321261A0104|44 63|prostaglandin F2alpha
P00321261A0104|139 144|phases
P00330364A0132|230 241|laboratories
P00330364A0132|204 210|strains
P00330364A0132|74 76|BCG
P00330364A0132|125 132|children
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|10 19|BCG strains
P00330364A0132|95 101|strains
P00330364A0132|44 50|strains
P00330364A0132|157 163|strains
P00330364A0132|183 197|BCG-vaccination
P00330364A0132|114 122|abscesses
P00330364A0132|64 71|cultures
P00330364A0132|88 92|batch
P00330364A0132|173 177|cases
P00330364A0132|1 5|total
P00331128A0000|4 9|levels
P00331128A0000|12 26|serum calcitonin
P00331128A0000|62 68|failure
P00331128A0000|38 45|patients
P00331936T0000|0 8|Detection
P00331936T0000|26 35|antibodies
P00331936T0000|44 78|immunoperoxidase antiglobulin technic
P00336354A0543|13 19|serum GH
P00336354A0543|22 37|arginine infusion
P00336354A0543|74 85|hypoglycemia
P00336354A0543|3 10|response
P00336547A0000|233 241|C57/BL/6J
P00336547A0000|259 264|BALB/c
P00336547A0000|243 257|New Zealand Black
P00336547A0000|277 282|C3H/eB
P00336547A0000|213 224|mouse strains
P00336547A0000|136 148|C3H/eB origins
P00336547A0000|46 63|Nocardia asteroides
P00336547A0000|130 132|ICR
P00336547A0000|67 96|Nocardia brasiliensis infections
P00336547A0000|36 43|features
P00336547A0000|195 198|mice
P00336547A0000|266 272|CBA/LAC
P00336547A0000|124 127|mice
P00336547A0000|3 15|mortality rate
P00337102T0058|0 7|Williams
P00337102T0058|10 15|August
P00339289T0049|0 2|Use
P00339289T0049|16 23|isotopes
P00339289T0049|40 47|proteins
P00339289T0049|29 37|chemistry
P00340692T0033|1 8|Emeritus
P00340692T0033|10 37|John Henri Roosegaarde Bisschop
P00342623A0228|87 96|reactivity
P00342623A0228|20 38|whole-virus vaccines
P00342623A0228|9 16|vaccines
P00342623A0228|49 60|type B antigen
P00350465T0000|34 42|disorders
P00350465T0000|9 17|diagnosis
P00352569A0000|30 44|blood parameters
P00352569A0000|105 113|endotoxin
P00352569A0000|69 73|rates
P00352569A0000|7 18|oxygen supply
P00352569A0000|85 89|mg/kg
P00354315T0000|20 27|patients
P00354315T0000|7 17|dysfunction
P00354315T0000|32 51|ataxia telangiectasia
P00358945A0225|70 74|weeks
P00358945A0225|10 15|period
P00358945A0225|18 26|treatment
P00361059T0000|1 5|study
P00361059T0000|22 29|efficacy
P00361059T0000|93 101|% ointment
P00361059T0000|32 53|diflucortolone valerate
P00361059T0000|57 65|% ointment
P00361059T0000|69 88|clobetasol propionate
P00361340A0529|29 42|osteodystrophy
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00361340A0529|102 111|deficiency
P00361340A0529|92 100|condition
P00361340A0529|157 168|significance
P00361340A0529|9 17|phenomena
P00361340A0529|65 82|vitamin D deficiency
P00361340A0529|213 219|failure
P00361340A0529|187 205|hyperparathyroidism
P00369397A0280|5 7|FSH
P00369397A0280|88 95|LH values
P00369397A0280|43 49|addicts
P00369397A0280|74 80|addicts
P00369397A0280|11 18|LH levels
P00369397A0280|82 84|FSH
P00369397A0280|56 70|GnRH stimulation
P00369397A0280|134 141|controls
P00369683T0000|0 9|Adriamycin
P00369683T0000|11 20|comparison
P00369683T0000|62 70|treatment
P00369683T0000|73 84|breast cancer
P00369683T0000|49 56|schedule
P00369683T0000|30 37|schedule
P00377466A0188|30 36|hormone
P00377466A0188|155 166|healing phase
P00377466A0188|84 87|HPRL
P00377466A0188|118 118|P
P00377466A0188|143 151|catabolic
P00377466A0188|105 116|progesterone
P00377466A0188|74 82|prolactin
P00377466A0188|136 136|T
P00377466A0188|42 67|follicle stimulating hormone
P00377466A0188|101 102|E2
P00377466A0188|38 39|LH
P00377466A0188|9 16|controls
P00377466A0188|69 71|FSH
P00377466A0188|173 179|disease
P00377466A0188|123 134|testosterone
P00377466A0188|90 99|oestradiol
P00378492A0475|0 11|Renin studies
P00378492A0475|51 62|control group
P00378492A0475|37 44|patients
P00378492A0475|122 143|plasma aldosterone level
P00378492A0475|87 95|elevation
P00378492A0475|98 116|plasma renin activity
P00378492A0475|67 76|recipients
P00378492A0475|200 213|artery stenosis
P00378735A0000|259 266|carriers
P00378735A0000|128 141|dosage schedule
P00378735A0000|114 124|amoxycillin
P00378735A0000|188 202|chloramphenicol
P00378735A0000|270 281|relapse rates
P00378735A0000|19 23|trial
P00378735A0000|250 256|respect
P00378735A0000|207 212|regard
P00378735A0000|226 244|temperature response
P00378735A0000|68 72|fever
P00378735A0000|90 102|marrow culture
P00378735A0000|40 47|patients
P00378735A0000|171 174|days
P00378735A0000|145 145|g
P00378735A0000|82 86|blood
P00381783T0000|0 29|Bone marrow transplantation-1979
P00383169A0000|119 138|rye-ergot derivatives
P00383169A0000|198 207|properties
P00383169A0000|157 161|basis
P00383169A0000|25 31|actions
P00383169A0000|80 90|apomorphine
P00383169A0000|6 12|article
P00383169A0000|109 117|piribedil
P00383169A0000|46 61|dopamine receptor
P00383169A0000|97 107|derivatives
P00383169A0000|73 78|agents
P00384744T0000|23 34|hypofunction
P00385457A0187|84 90|healing
P00385457A0187|8 17|inhibition
P00385457A0187|101 105|ulcer
P00385457A0187|40 44|juice
P00385457A0187|20 25|pepsin
P00385457A0187|70 78|influence
P00386251A0899|26 34|detection
P00386251A0899|105 108|milk
P00386251A0899|72 80|detection
P00386251A0899|37 46|penicillin
P00386251A0899|3 19|IDF standard method
P00386251A0899|49 52|milk
P00386251A0899|83 102|sulphonamide residues
P00390932T0001|8 15|antigens
P00393598A0198|47 49|ALS
P00393598A0198|11 24|endotoxin fever
P00393598A0198|3 8|course
P00397806T0039|4 16|Algerian cases
P00401521A0138|20 27|patients
P00401521A0138|39 49|ticarcillin
P00401521A0138|11 17|percent
P00401676A0414|71 82|radiotherapy
P00401676A0414|18 24|staging
P00401676A0414|35 42|patients
P00406585T0001|8 17|hematology
P00406585T0001|23 25|age
P00409927A0570|0 7|Neomycin
P00409927A0570|32 44|staphylococci
P00409927A0570|66 77|streptococci
P00409927A0570|127 135|organisms
P00411465A0142|27 33|section
P00411465A0142|86 93|cavities
P00411465A0142|67 73|contact
P00411465A0142|42 45|cent
P00411465A0142|51 60|trabeculae
P00413854A0958|0 6|Changes
P00413854A0958|9 18|tissue PCO2
P00413854A0958|86 90|blood
P00414575T0000|10 19|evaluation
P00414575T0000|27 33|calculi
P00415543A0320|0 10|Recognition
P00415543A0320|98 102|films
P00415543A0320|107 114|patients
P00415543A0320|91 95|films
P00415543A0320|13 21|emphysema
P00415543A0320|56 62|quality
P00415543A0320|33 43|radiographs
P00415543A0320|133 143|lung disease
P00416758T0001|0 8|Isolation
P00416758T0001|11 28|T. gambiense strains
P00416758T0001|56 72|laboratory animals
P00416758T0001|31 35|Zaire
P00416758T0001|44 53|adaptation
P00417166T0000|15 21|profile
P00417166T0000|36 48|rhesus monkeys
P00417166T0000|24 33|clonazepam
P00417301T0001|30 40|brucellosis
P00417301T0001|11 20|mechanisms
P00417301T0001|43 48|humans
P00418341T0000|31 35|parts
P00418341T0000|10 19|adaptation
P00420460A0291|2 9|patients
P00420460A0291|48 77|log baseline plasma renin activity
P00420460A0291|34 46|drug treatment
P00420460A0291|142 142|r
P00420460A0291|111 112|SQ
P00420460A0291|150 150|P
P00420460A0291|93 105|blood pressure
P00420460A0291|81 86|change
P00423649A0259|56 60|claim
P00423649A0259|33 38|people
P00423649A0259|46 50|years
P00423649A0259|5 14|techniques
P00423649A0259|78 87|innovation
P00423649A0259|94 99|regard
P00425547A0000|2 9|patients
P00425547A0000|91 100|cephalexin
P00425547A0000|112 116|weeks
P00425547A0000|48 49|os
P00425547A0000|21 33|osteomyelitis
P00427715A0000|125 134|University
P00427715A0000|22 28|Hodgkin
P00427715A0000|10 17|patients
P00427715A0000|55 63|diaphragm
P00427715A0000|65 70|Stages
P00427715A0000|137 143|Florida
P00427715A0000|99 114|radiation therapy
P00427715A0000|82 82|B
P00427715A0000|31 37|disease
P00427715A0000|1 5|total
P00429151T0000|43 46|unit
P00429151T0000|59 69|Glasgow area
P00429151T0000|24 35|practitioner
P00429151T0000|0 3|Year
P00429893A0000|30 40|round window
P00429893A0000|79 84|system
P00429893A0000|135 140|trauma
P00429893A0000|49 60|implantation
P00429893A0000|126 132|minimum
P00429893A0000|164 174|stimulation
P00429893A0000|109 120|scala tympani
P00429893A0000|22 26|array
P00429893A0000|99 100|mm
P00429949A0000|206 214|prolactin
P00429949A0000|195 197|IRP
P00429949A0000|90 100|preparation
P00429949A0000|161 193|International Reference Preparation
P00429949A0000|44 58|Expert Committee
P00429949A0000|108 116|prolactin
P00429949A0000|61 85|Biological Standardization
P00429949A0000|119 126|ampoules
P00429949A0000|17 39|World Health Organization
P00429949A0000|218 228|immunoassay
P00430889T0001|15 22|fistulas
P00431832T0001|0 15|Plasma ion changes
P00431832T0001|24 28|blood
P00431832T0001|42 61|beta receptor blockers
P00432615A0541|134 145|interference
P00432615A0541|167 170|RIST
P00432615A0541|10 20|differences
P00432615A0541|91 103|gammaglobulin
P00432615A0541|46 55|literature
P00432615A0541|57 77|heterophile antibodies
P00432615A0541|151 164|Sephadex system
P00435187T0000|14 25|flowers bloom
P00437749A0242|42 48|context
P00437749A0242|75 84|physiology
P00437749A0242|7 25|treatment modalities
P00437749A0242|104 107|pain
P00437749A0242|54 63|psychology
P00439618T0001|0 15|Lethal Tachmalcor
P00439618T0001|54 61|ajmaline
P00439618T0001|39 51|hydroxypropyl
P00439618T0001|23 36|diethylamino-2
P00439618T0001|74 82|childhood
P00439618T0001|63 71|poisoning
P00439716T0001|32 48|blood flow velocity
P00439716T0001|67 73|fistula
P00439716T0001|20 29|evaluation
P00445259T0000|0 25|Serum ferritin concentration
P00445259T0000|29 48|bone marrow iron stores
P00445720A0263|28 30|SPG
P00445720A0263|66 71|atrium
P00445720A0263|11 26|pressure gradient
P00445720A0263|46 54|ventricle
P00445720A0263|91 122|high-fidelity pressure transducers
P00445720A0263|56 57|LV
P00445720A0263|73 74|LA
P00450367T0000|89 100|hysterectomy
P00450367T0000|12 16|trail
P00450367T0000|79 84|radium
P00450367T0000|26 37|hysterectomy
P00450367T0000|120 128|carcinoma
P00450367T0000|39 50|hysterectomy
P00450367T0000|62 67|radium
P00450367T0000|103 107|stage
P00450559A0269|13 19|patient
P00450559A0269|22 27|report
P00450559A0269|43 51|Clinitemp
P00450559A0269|5 9|basis
P00450559A0269|80 87|accuracy
P00450559A0269|94 104|thermometer
P00450760T0001|0 15|Cryoglobulinemia
P00450760T0001|27 34|syndrome
P00450760T0001|18 24|Raynaud
P00451192A0248|0 3|Data
P00451192A0248|36 50|computer program
P00451192A0248|81 85|curve
P00451192A0248|100 119|LV region-of-interest
P00453780A0430|15 30|serum IgA response
P00453780A0430|155 157|IgA
P00453780A0430|136 141|source
P00453780A0430|44 60|patient population
P00453780A0430|100 105|tissue
P00453780A0430|119 122|lung
P00454780A0340|0 17|Ultimate strengthes
P00454780A0340|36 51|cast cobalt alloys
P00454780A0340|101 112|fatigue limit
P00454780A0340|81 82|Ta
P00454780A0340|118 126|corrosion
P00454780A0340|60 73|titanium alloys
P00454780A0340|84 84|V
P00456424A0000|88 96|heart rate
P00456424A0000|26 34|injection
P00456424A0000|45 53|clonidine
P00456424A0000|36 41|i.c.i.
P00456424A0000|154 166|cisterna magna
P00456424A0000|141 148|catheter
P00456424A0000|119 125|rabbits
P00456424A0000|56 68|microgram kg-1
P00456424A0000|3 9|effects
P00456424A0000|72 84|blood pressure
P00463973A0000|116 118|age
P00463973A0000|124 130|infants
P00463973A0000|138 142|women
P00463973A0000|120 122|SGA
P00463973A0000|48 56|trimester
P00463973A0000|147 153|infants
P00463973A0000|166 177|birth weights
P00463973A0000|59 67|pregnancy
P00463973A0000|17 24|life span
P00463973A0000|72 76|women
P00463973A0000|0 13|Platelet number
P00464387A1185|58 72|disease activity
P00464387A1185|51 55|index
P00464387A1185|75 78|ABPA
P00464387A1185|25 32|serum IgE
P00464387A1185|6 17|measurements
P00465223A0373|58 64|delta PU
P00465223A0373|6 13|patients
P00465223A0373|50 55|values
P00465223A0373|90 91|SD
P00465223A0373|17 34|difference betweent
P00465223A0373|68 74|delta PM
P00465223A0373|93 96|mmHg
P00465681A0000|72 81|blood serum
P00465681A0000|159 161|atm
P00465681A0000|149 153|state
P00465681A0000|63 66|iron
P00465681A0000|89 92|mice
P00465681A0000|7 29|hemoglobin concentration
P00465681A0000|173 177|state
P00465681A0000|123 125|atm
P00465681A0000|106 119|oxygen pressure
P00465681A0000|131 134|hour
P00465681A0000|45 52|increase
P00465681A0000|1 4|rise
P00465829T0000|0 5|Nernst
P00465829T0000|42 54|state membrane
P00465829T0000|8 28|Planck analog equations
P00465829T0000|63 72|potentials
P00473229T0000|0 6|Effects
P00473229T0000|108 119|chick embryos
P00473229T0000|83 89|toluene
P00473229T0000|27 41|trichloroethane
P00473229T0000|9 25|methylene chloride
P00473229T0000|95 105|development
P00473229T0000|61 79|tetrachloroethylene
P00473229T0000|43 59|trichloroethylene
P00473249T0000|0 5|Effect
P00473249T0000|80 86|rabbits
P00473249T0000|40 52|streptolysin O
P00473249T0000|24 37|administration
P00473249T0000|58 77|electroencephalogram
P00474064A0205|115 127|phenoperidine
P00474064A0205|77 87|mg.kg-1 I.V.
P00474064A0205|177 180|I.V.
P00474064A0205|148 157|sufentanil
P00474064A0205|103 110|morphine
P00474064A0205|162 162|R
P00474064A0205|130 130|R
P00474064A0205|44 53|substances
P00474064A0205|18 36|convlusion threshold
P00474064A0205|89 99|piritramide
P00474064A0205|138 145|fentanyl
P00474064A0205|66 74|pethidine
P00474064A0205|6 14|situation
P00476020T0000|43 48|growth
P00476020T0000|25 29|fluid
P00476020T0000|3 14|biochemistry
P00476572A0139|94 98|cases
P00476572A0139|113 124|radiodensity
P00476572A0139|127 131|cases
P00476572A0139|24 29|lesion
P00477794T0000|0 6|Effects
P00477794T0000|26 35|tractotomy
P00477794T0000|41 56|response patterns
P00477794T0000|81 97|nuclei principalis
P00477794T0000|59 65|neurons
P00477794T0000|101 106|oralis
P00478714T0000|0 7|Efficacy
P00478714T0000|33 55|alcohol treatment program
P00479222A0682|0 9|Resistance
P00479222A0682|86 95|properties
P00479222A0682|143 146|PECF
P00479222A0682|35 45|environment
P00479222A0682|65 73|retention
P00479222A0682|152 159|degrees C
P00479222A0682|137 141|fluid
P00479222A0682|101 114|immersion times
P00479222A0682|176 180|years
P00479246T0000|28 40|osteomyelitis
P00481612A1121|58 66|ventricle
P00481612A1121|23 31|receptors
P00481612A1121|110 117|fentanyl
P00481612A1121|102 107|action
P00483716A0366|41 47|carotid
P00483716A0366|57 69|carotid artery
P00483716A0366|97 107|anastomosis
P00483716A0366|2 5|case
P00484177A0242|97 99|VT.
P00484177A0242|76 82|CT value
P00484177A0242|90 94|range
P00484177A0242|26 43|laminar flow regimen
P00484177A0242|50 59|expiration
P00484177A0242|4 13|expression
P00485615A0935|116 123|syndrome
P00485615A0935|126 130|order
P00485615A0935|19 27|existence
P00485615A0935|5 8|data
P00485615A0935|51 56|crisis
P00485615A0935|89 98|importance
P00485615A0935|176 186|performance
P00485615A0935|221 227|surgery
P00485615A0935|158 169|pancreatitis
P00485615A0935|68 73|entity
P00485615A0935|141 150|occurrence
P00488534A0308|2 9|addition
P00488534A0308|22 48|Treatment X Strain interaction
P00488534A0308|113 118|MR rats
P00488534A0308|66 82|defecation numbers
P00488534A0308|147 152|MR rats
P00490336A0181|43 47|m/sec
P00490336A0181|49 54|group C
P00490336A0181|5 22|conduction velocity
P00493818A0422|3 10|failures
P00493818A0422|68 70|fit
P00493818A0422|109 114|months
P00493818A0422|34 51|patient intolerance
P00493818A0422|120 128|insertion
P00493818A0422|95 98|days
P00494659A0391|15 25|metabolites
P00494659A0391|98 107|toloxatone
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00494659A0391|85 95|glucuronide
P00494659A0391|33 47|3-carboxyphenyl
P00495097A0663|101 106|tissue
P00495097A0663|83 88|matrix
P00495097A0663|42 49|activity
P00495097A0663|5 19|characteristics
P00495097A0663|63 76|fiber synthesis
P00497494A0112|32 36|PACO2
P00497494A0112|3 13|ventilation
P00499588T0000|0 21|Carbohydrate metabolism
P00499588T0000|49 55|insulin
P00499588T0000|41 47|glucose
P00499588T0000|28 39|semen profile
P00499588T0000|60 71|sperm studies
P00503336A0285|81 99|alkaline phosphatase
P00503336A0285|34 37|CIEC
P00503336A0285|162 170|diagnosis
P00503336A0285|73 78|levels
P00503336A0285|61 65|fever
P00503336A0285|45 51|attacks
P00503336A0285|121 125|serum
P00503336A0285|29 30|CC
P00503336A0285|103 115|transaminases
P00503336A0285|16 19|CAEC
P00503336A0285|139 146|findings
P00506559A0000|32 39|furfural
P00506559A0000|64 71|hamsters
P00506559A0000|12 29|inhalation toxicity
P00506649T0000|0 6|Changes
P00506649T0000|19 40|serum protein components
P00506649T0000|58 63|stress
P00509703A0581|5 15|differences
P00509703A0581|54 62|textbooks
P00510341T0036|1 5|study
P00510341T0036|11 20|E.O.R.T.C.
P00512215A0000|58 58|L
P00512215A0000|132 133|f1
P00512215A0000|148 149|L2
P00512215A0000|81 90|parameters
P00512215A0000|104 108|input
P00512215A0000|26 35|dependence
P00512215A0000|136 137|L1
P00512215A0000|10 14|study
P00512215A0000|113 117|f2/f1
P00512215A0000|139 140|L2
P00512215A0000|38 56|difference tone level
P00512215A0000|145 146|L1
P00512215A0000|110 111|f1
P00512215A0000|119 120|f2
P00512215A0000|60 64|f2-f1
P00513284A0000|146 160|pediatrics field
P00513284A0000|220 221|ml
P00513284A0000|112 123|drip infusion
P00513284A0000|224 238|glucose solution
P00513284A0000|128 133|series
P00513284A0000|54 59|Pfizer
P00513284A0000|26 36|doxycycline
P00513284A0000|191 194|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|76 87|tetracycline
P00513284A0000|246 250|mg/kg
P00513284A0000|136 140|study
P00513284A0000|168 174|results
P00513284A0000|13 23|preparation
P00513284A0000|38 41|DOTC
P00513284A0000|199 200|mg
P00513284A1255|14 17|days
P00513284A1255|36 50|laboratory tests
P00513284A1255|79 83|blood
P00513284A1255|23 34|DOTC infusion
P00513284A1255|54 58|liver
P00513284A1255|67 75|functions
P00516545T0001|30 48|erythrocyte membrane
P00516545T0001|50 70|peroxidation processes
P00516545T0001|10 24|characteristics
P00516545T0001|95 102|children
P00516545T0001|85 92|function
P00516545T0001|114 131|glomerulonephritis
P00517890A0468|71 76|levels
P00517890A0468|124 131|jaundice
P00517890A0468|50 59|hepatitis A
P00517890A0468|35 46|transmission
P00517890A0468|79 102|hepatitis A virus excretion
P00517890A0468|10 14|route
P00517890A0468|117 121|onset
P00517890A0468|29 32|mode
P00519173A0126|29 36|evidence
P00519173A0126|39 50|oesophagitis
P00519173A0126|5 12|patients
P00521732T0000|18 25|oestrone
P00521732T0000|81 107|steroid sulphatase deficiency
P00521732T0000|7 15|excretion
P00521732T0000|27 43|oestradiol-17 beta
P00521732T0000|57 67|pregnancies
P00521732T0000|47 54|oestriol
P00524451A0136|190 192|rat
P00524451A0136|108 120|hexobarbitone
P00524451A0136|63 67|death
P00524451A0136|41 44|mice
P00524451A0136|143 151|depletion
P00524451A0136|90 97|toxicity
P00524451A0136|154 167|catecholamines
P00524451A0136|22 38|locomotor activity
P00524451A0136|129 132|time
P00524451A0136|179 184|organs
P00524451A0136|72 82|amphetamine
P00528144T0000|27 32|uptake
P00528144T0000|35 41|gallium
P00528144T0000|11 21|transferrin
P00528144T0000|5 8|role
P00528144T0000|44 53|tumor cells
P00534613A0000|0 10|Irradiation
P00534613A0000|36 39|UV-A
P00534613A0000|18 31|blood platelets
P00534613A0000|95 102|collagen
P00534613A0000|82 90|challenge
P00534613A0000|68 76|aggregate
P00534613A0000|59 65|ability
P00535520A0239|74 88|cholangiography
P00535520A0239|11 20|exceptions
P00535520A0239|24 29|method
P00540707A0255|58 70|complications
P00540707A0255|126 139|pouch haematoma
P00540707A0255|204 211|approach
P00540707A0255|44 50|account
P00540707A0255|99 103|cases
P00540707A0255|215 229|PMK implantation
P00540707A0255|249 251|use
P00540707A0255|24 30|results
P00540707A0255|108 122|tip displacement
P00540707A0255|165 171|Authors
P00540707A0255|190 195|method
P00540707A0255|91 94|rate
P00540707A0255|257 269|vena cephalica
P00541752A1032|128 129|SD
P00541752A1032|87 92|values
P00541752A1032|76 82|October
P00541752A1032|38 44|samples
P00541752A1032|131 135|ng/ml
P00541752A1032|121 124|mean
P00541752A1032|47 52|plasma
P00541752A1032|7 20|determinations
P00541752A1032|68 73|adults
P00550399A0615|15 20|causes
P00550399A0615|50 55|groups
P00550399A0615|23 27|death
P00553858A0000|15 23|operation
P00553858A0000|8 12|Grice
P00553858A0000|111 122|publications
P00553858A0000|162 166|terms
P00553858A0000|63 69|account
P00553858A0000|134 142|technique
P00553858A0000|195 204|principles
P00553858A0000|91 100|literature
P00553858A0000|45 49|world
P00553858A0000|215 223|operation
P00555492A1034|42 50|blood flow
P00555492A1034|152 164|blood pressure
P00555492A1034|122 125|flow
P00555492A1034|106 114|injection
P00555492A1034|74 82|injection
P00555492A1034|5 11|changes
P00555492A1034|85 94|cimetidine
P00555495T0000|0 4|Study
P00555495T0000|25 33|ovulation
P00555495T0000|65 73|treatment
P00555495T0000|39 49|termination
P00555495T0000|137 144|delivery
P00555495T0000|7 22|re-establishment
P00555495T0000|117 124|abortion
P00555495T0000|88 100|re-appearance
P00555495T0000|103 111|ovulation
P00555583T0000|0 15|Pharmacokinetics
P00555583T0000|38 43|review
P00555583T0000|33 35|man
P00555583T0000|18 30|Carbamazepine
P00557559A0170|151 159|organisms
P00557559A0170|53 78|N-methylnitrone 1,4-dioxide
P00557559A0170|98 102|agent
P00557559A0170|21 25|alpha
P00557559A0170|5 13|compounds
P00564032A0724|14 20|content
P00564032A0724|70 77|pressure
P00564032A0724|92 95|duct
P00564032A0724|101 105|gland
P00564032A0724|54 63|mechanisms
P00564032A0724|0 6|Changes
P00564943A0444|0 5|Calves
P00564943A0444|67 67|T
P00564943A0444|9 16|MCT-milk
P00564943A0444|38 53|blood cholesterol
P00564943A0444|58 63|calves
P00564943A0444|71 78|SBO-milk
P00565136T0000|60 65|SO2Cl2
P00565136T0000|48 52|doses
P00565136T0000|70 72|Br2
P00565136T0000|31 40|inhalation
P00565136T0000|7 15|mortality
P00565136T0000|55 58|CH2O
P00565136T0000|18 21|mice
P00565314A0293|0 9|Guinea pigs
P00565314A0293|37 37|g
P00569989A0239|105 110|dPn/dt
P00569989A0239|154 169|pneumotachograph
P00569989A0239|132 136|apnea
P00569989A0239|75 102|acceleration pneumocardiogram
P00569989A0239|49 52|PnCG
P00569989A0239|5 23|halothane anesthesia
P00569989A0239|28 47|flow pneumocardiogram
P00569989A0239|60 63|time
P00574222T0000|31 41|development
P00574222T0000|51 60|prostheses
P00574222T0000|7 14|kindling
P00574222T0000|16 27|implications
P00574956A0304|115 125|equilibrium
P00574956A0304|226 236|development
P00574956A0304|163 169|systems
P00574956A0304|47 50|case
P00574956A0304|78 81|tone
P00574956A0304|253 265|manifestation
P00574956A0304|195 202|dopamine
P00574956A0304|17 26|stereotypy
P00575231A0422|0 3|None
P00575231A0422|41 60|detrusor contractions
P00575231A0422|9 23|cystometrograms
P00577440A0298|40 43|dose
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00577440A0298|19 22|part
P00577440A0298|5 12|duodenum
P00578648T0048|34 47|administration
P00578648T0048|10 16|effects
P00580106T0000|0 8|Treatment
P00580106T0000|11 16|Graves
P00580106T0000|18 24|disease
P00580151A0706|183 189|effects
P00580151A0706|61 72|testosterone
P00580151A0706|200 204|doses
P00580151A0706|164 167|cost
P00580151A0706|133 139|patient
P00580151A0706|108 112|range
P00580151A0706|83 92|se-T levels
P00580151A0706|117 127|convenience
P00583004A0445|64 87|1,8-diacetoxy-9-anthrone
P00583004A0445|116 122|lesions
P00583004A0445|160 163|skin
P00583004A0445|10 33|1,8-dihydroxy-9-anthrone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00583004A0445|142 154|inflammations
P00583522T0001|30 37|problems
P00583522T0001|52 63|inflammation
P00587791T0054|0 6|Nursing
P00587791T0054|9 16|patients
P00587791T0054|34 41|diseases
P00589073A0000|173 183|infertility
P00589073A0000|164 170|history
P00589073A0000|138 145|patients
P00589073A0000|103 109|control
P00589073A0000|86 90|phase
P00589073A0000|47 53|samples
P00589073A0000|111 115|women
P00589073A0000|15 43|plasma prolactin concentrations
P00589073A0000|129 133|group
P00590594T0000|7 25|allotransplantation
P00592887T0000|18 33|Patent Blue Violet
P00592887T0000|40 51|lymphography
P00592887T0000|8 15|reaction
P00593119T0001|0 8|Screening
P00593119T0001|50 62|comprehension
P00593119T0001|65 72|spectrum
P00593119T0001|11 24|asthma patients
P00593119T0001|90 102|IgE antibodies
P00593119T0001|27 39|determination
P00593119T0001|42 44|IgE
P00594466T0001|14 21|seizures
P00594466T0001|45 56|allylglycine
P00594466T0001|66 76|combination
P00594466T0001|25 34|Papio papio
P00594466T0001|3 11|induction
P00594466T0001|99 109|stimulation
P00594617A0192|89 91|FDP
P00594617A0192|258 262|fever
P00594617A0192|233 237|signs
P00594617A0192|129 141|insufficiency
P00594617A0192|18 28|correlation
P00594617A0192|47 54|presence
P00594617A0192|99 107|incidence
P00594617A0192|69 87|degradation products
P00594617A0192|186 190|Godal
P00594617A0192|161 168|presence
P00594617A0192|275 277|ESR
P00594617A0192|193 216|ethanol-gelification test
P00594617A0192|250 256|disease
P00594617A0192|110 120|nephropathy
P00594617A0192|177 184|monomers
P00597715A0256|14 16|men
P00597715A0256|21 31|azoospermia
P00597715A0256|39 50|sperm density
P00597715A0256|124 129|others
P00597715A0256|152 160|prognosis
P00597715A0256|79 90|FSH elevation
P00597715A0256|118 121|work
P00597715A0256|97 106|experience
P00597715A0256|0 8|One-third
P00598012A0174|28 32|stage
P00598012A0174|63 66|boys
P00598012A0174|76 81|change
P00598012A0174|84 98|prolactin levels
P00598012A0174|52 59|menarche
P00598012A0174|2 21|girls prolactin levels
P00599601A0260|132 141|physiology
P00599601A0260|104 114|alterations
P00599601A0260|37 46|procedures
P00599601A0260|166 168|rat
P00599601A0260|64 75|pinealectomy
P00600943T0001|13 31|lymphomononucleosis
P00600943T0001|1 5|cases
P00601401A0181|57 62|oxygen
P00601401A0181|6 23|hemoglobin solution
P00601401A0181|46 53|affinity
P00601401A0181|70 79|Bohr effect
P00601401A0181|96 119|delta log Po2/delta pH ratio
P00602622A0362|116 123|activity
P00602622A0362|25 32|atropine
P00602622A0362|44 48|Roter
P00602622A0362|36 42|Vikalin
P00602622A0362|9 20|ulcer therapy
P00602622A0362|82 90|reduction
P00602622A0362|68 68|p
P00602702A0309|84 91|function
P00602702A0309|108 127|estriol concentration
P00602702A0309|33 52|estriol concentration
P00602702A0309|22 29|diarrhea
P00602702A0309|55 59|serum
P00602702A0309|5 11|patient
P00602702A0309|148 155|diarrhea
P00603783A0647|0 10|Serum levels
P00603783A0647|19 21|IgM
P00603783A0647|13 15|IgG
P00603783A0647|53 60|findings
P00603783A0647|68 85|observers IgA levels
P00606849T0000|56 62|rabbits
P00606849T0000|41 53|thromboxane A2
P00606849T0000|20 31|heart disease
P00614915T0001|0 9|Vitrectomy
P00614915T0001|18 29|traumatology
P00616575A0000|86 99|decimeter waves
P00616575A0000|138 149|unit activity
P00616575A0000|101 103|EMF
P00616575A0000|79 83|field
P00616575A0000|34 48|brain structures
P00616575A0000|10 20|sensitivity
P00616575A0000|54 59|action
P00616575A0000|106 107|DW
P00616575A0000|117 129|investigation
P00617815A0215|12 25|L-R differences
P00618078A0367|1 8|decrease
P00618078A0367|54 64|improvement
P00618078A0367|79 88|meningitis
P00618078A0367|14 29|lysozyme activity
P00619305A0759|70 79|dimensions
P00619305A0759|47 55|dimension
P00619305A0759|18 23|groups
P00619782A0058|73 92|ultraviolet radiation
P00619782A0058|94 97|UV-A
P00619782A0058|33 42|volunteers
P00619782A0058|4 7|tans
P00619782A0058|55 62|exposure
P00619782A0058|26 30|backs
P00619948A0000|291 292|mg
P00619948A0000|314 324|propranolol
P00619948A0000|200 205|scales
P00619948A0000|145 147|CNV
P00619948A0000|135 143|variation
P00619948A0000|89 90|mg
P00619948A0000|40 43|dose
P00619948A0000|248 257|depression
P00619948A0000|94 106|nortriptyline
P00619948A0000|209 217|alertness
P00619948A0000|299 300|mg
P00619948A0000|150 161|reaction time
P00619948A0000|46 52|Motival
P00619948A0000|305 311|placebo
P00619948A0000|219 225|anxiety
P00619948A0000|19 26|subjects
P00619948A0000|281 288|diazepam
P00619948A0000|328 329|mg
P00619948A0000|227 233|tension
P00619948A0000|74 85|fluphenazine
P00619948A0000|235 244|detachment
P00619948A0000|109 110|mg
P00619948A0000|163 171|heart rate
P00619948A0000|173 185|blood pressure
P00619948A0000|4 10|effects
P00619948A0000|57 62|tablet
P00621626T0000|0 12|Stress effects
P00621626T0000|63 66|type
P00621626T0000|15 36|affiliation preferences
P00621626T0000|82 96|behavior pattern
P00621626T0000|42 49|subjects
P00622556A0111|16 23|collagen
P00622556A0111|64 69|tendon
P00622556A0111|30 35|tissue
P00623361A0221|28 39|contribution
P00623361A0221|51 61|dysfunction
P00623361A0221|0 6|Smoking
P00626014T0001|3 11|malignity
P00626014T0001|20 26|lentigo
P00627039T0000|0 10|Elimination
P00627039T0000|13 22|bagassosis
P00627039T0000|25 63|Louisiana paper manufacturing plant workers
P00627129A0944|174 191|beta-adrenoceptors
P00627129A0944|155 162|blockade
P00627129A0944|5 13|responses
P00627129A0944|123 131|labetalol
P00627129A0944|65 74|conditions
P00627129A0944|30 35|others
P00627129A0944|45 52|subjects
P00627129A0944|115 120|effect
P00627202T0000|0 8|Diuretics
P00627202T0000|23 34|pharmacology
P00627202T0000|49 51|use
P00628990A0000|33 37|units
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00628990A0000|63 76|reconstruction
P00628990A0000|5 12|patients
P00628990A0000|170 181|ureterostomy
P00628990A0000|157 160|loop
P00630713T0000|0 9|Evaluation
P00630713T0000|15 39|Du Pont aca ammonia procedure
P00633909A0000|43 64|Internal-External Locus
P00633909A0000|27 32|scores
P00633909A0000|171 177|control
P00633909A0000|67 78|Control Scale
P00633909A0000|35 40|Rotter
P00633909A0000|18 25|patients
P00633909A0000|98 106|treatment
P00633909A0000|135 142|patients
P00635143T0001|0 5|Action
P00635143T0001|23 30|metaphos
P00635143T0001|8 19|strontium-90
P00635143T0001|33 46|Cyprinus carpio
P00635194A0093|0 12|Kodak XV-2 film
P00635194A0093|65 80|dose distribution
P00636526T0033|0 8|Diagnosis
P00636526T0033|24 32|diagnosis
P00637637T0000|57 68|hypertension
P00637637T0000|27 45|plasma renin activity
P00637637T0000|11 17|factors
P00639410T0000|43 61|lipid clearing agents
P00639410T0000|16 26|bone changes
P00639410T0000|33 40|response
P00639410T0000|0 8|Cortisone
P00640584A0250|46 54|stability
P00640584A0250|17 25|principle
P00641395A0441|150 165|extraction method
P00641395A0441|89 99|fluorimeter
P00641395A0441|126 131|levels
P00641395A0441|80 82|ZPP
P00641395A0441|67 77|measurement
P00641395A0441|30 47|hyperbilirubinemia
P00641395A0441|18 25|patients
P00641395A0441|4 15|blood samples
P00644314T0000|29 35|effects
P00644314T0000|7 22|hypersensitivity
P00644314T0000|25 27|man
P00644314T0000|46 60|anticoagulation
P00644539A0783|39 44|saline
P00644539A0783|106 112|subject
P00644539A0783|71 71|%
P00644539A0783|115 123|reactions
P00644539A0783|18 27|inhalation
P00644539A0783|129 141|test solutions
P00644539A0783|53 56|FEV1
P00644539A0783|31 32|ml
P00644539A0783|66 66|%
P00646023T0058|51 62|transmission
P00646023T0058|12 18|studies
P00646023T0058|21 34|virus excretion
P00646193T0000|0 6|Potency
P00646193T0000|51 60|isoflurane
P00646193T0000|25 34|comparison
P00646193T0000|9 17|enflurane
P00646193T0000|39 47|halothane
P00646193T0000|20 23|dogs
P00656008T0000|0 9|Prevention
P00656008T0000|17 32|paraquat toxicity
P00656008T0000|35 38|rats
P00656008T0000|41 59|superoxide dismutase
P00657551T0000|0 10|Measurement
P00657551T0000|13 31|magnesium absorption
P00657551T0000|55 60|tracer
P00657551T0000|48 51|26Mg
P00657551T0000|34 36|man
P00659962T0000|16 34|riboflavin excretion
P00659962T0000|53 65|acid ingestion
P00663166A0000|181 201|Eisenmenger physiology
P00663166A0000|173 175|PDA
P00663166A0000|83 94|particulates
P00663166A0000|37 47|body imaging
P00663166A0000|12 22|angiography
P00663166A0000|138 145|patients
P00663166A0000|128 135|shunting
P00663166A0000|150 171|patent ductus arteriosus
P00664320T0000|32 38|pathway
P00664320T0000|7 15|detectors
P00665053A0276|67 80|group affection
P00665053A0276|39 43|06a6b
P00665053A0276|45 47|K13
P00665053A0276|49 50|H1
P00665053A0276|34 37|type
P00665214A0374|3 8|method
P00665214A0374|65 69|cycle
P00665214A0374|45 54|physiology
P00665336A0908|43 57|EEG-information
P00665336A0908|9 12|time
P00668122A0414|0 7|Analysis
P00668122A0414|67 75|variation
P00668122A0414|10 29|liver biopsy specimens
P00668122A0414|101 122|liver ferritin molecules
P00668122A0414|81 95|mean iron content
P00668122A0414|34 41|patients
P00668122A0414|46 54|hepatitis
P00669800A0579|42 50|infection
P00669800A0579|6 9|mice
P00669800A0579|55 59|males
P00676416A0320|42 54|liver biopsies
P00676416A0320|22 26|years
P00676790T0000|0 16|Angiotensin effect
P00676790T0000|27 32|kidney
P00681550A0000|0 6|Procion
P00681550A0000|91 102|relationship
P00681550A0000|152 162|termination
P00681550A0000|67 74|goldfish
P00681550A0000|176 181|macula
P00681550A0000|113 124|response type
P00681550A0000|146 149|site
P00681550A0000|51 64|auditory fibers
P00681550A0000|132 137|fibers
P00681571T0028|23 31|epidermis
P00681571T0028|54 74|eccrine sweat duct units
P00681571T0028|10 17|findings
P00682762T0001|0 17|Silicosis mortality
P00685922A0451|71 73|IHB
P00685922A0451|26 35|strictures
P00685922A0451|66 69|tree
P00686836A0000|0 6|Pentane
P00686836A0000|140 143|diet
P00686836A0000|90 102|breath samples
P00686836A0000|10 15|ethane
P00686836A0000|172 188|IU vitamin E acetate
P00686836A0000|33 49|lipid peroxidation
P00686836A0000|122 128|vitamin
P00686836A0000|105 108|rats
P00686836A0000|116 120|weeks
P00686836A0000|192 193|kg
P00686836A0000|71 87|gas chromatography
P00693987T0001|0 13|Thromboplastic
P00693987T0001|106 115|infarction
P00693987T0001|128 131|life
P00693987T0001|52 65|administration
P00693987T0001|122 125|year
P00693987T0001|80 82|men
P00693987T0001|68 77|intralipid
P00693987T0001|87 93|history
P00693987T0001|42 46|blood
P00693987T0001|29 36|activity
P00696680A0000|71 87|rhabdomyosarcomas
P00696680A0000|107 117|endometrium
P00696680A0000|36 43|findings
P00696680A0000|62 66|women
P00696680A0000|120 125|cervix
P00696680A0000|50 54|cases
P00696680A0000|3 9|authors
P00696858A0000|116 130|porcine pancreas
P00696858A0000|39 47|endocrine
P00696858A0000|3 8|effect
P00696858A0000|22 36|porcine secretin
P00696858A0000|69 77|secretion
P00701144T0000|30 38|lens power
P00701144T0000|9 16|analysis
P00701144T0000|79 86|implants
P00701144T0000|67 73|results
P00701144T0000|56 65|emmetropia
P00701462A0722|0 14|Urine antibodies
P00701462A0722|47 51|cases
P00702773A0327|0 9|Althoug RBF
P00702773A0327|88 90|GFR
P00702773A0327|101 106|output
P00702773A0327|34 40|therapy
P00702773A0327|76 81|change
P00702773A0327|84 86|RBF
P00703350A0418|29 33|99mTc
P00703350A0418|42 48|sulfide
P00703350A0418|13 24|198Au colloid
P00703350A0418|0 11|99mTc phytate
P00703932A0000|15 32|glomerulonephritis
P00703932A0000|35 45|association
P00703932A0000|106 112|therapy
P00703932A0000|99 103|modes
P00703932A0000|69 73|shunt
P00703932A0000|3 10|patients
P00704675A0199|129 135|trachea
P00704675A0199|120 123|mass
P00704675A0199|90 99|inhalation
P00704675A0199|46 56|bifurcation
P00704675A0199|9 11|UO2
P00704675A0199|31 37|bronchi
P00704675A0199|3 6|mass
P00704675A0199|84 84|d
P00710217T0001|18 25|hip joint
P00710217T0001|8 12|cysts
P00710372A0302|62 69|function
P00710372A0302|22 32|dysfunction
P00710372A0302|82 93|GH deficiency
P00710372A0302|125 132|features
P00712117A0521|39 42|base
P00712117A0521|49 56|February
P00712117A0521|122 130|prototpye
P00712117A0521|107 118|A/Victoria/3
P00712117A0521|88 92|virus
P00712117A0521|71 79|A/Texas/1
P00712117A0521|16 25|influenza A
P00712117A0521|6 13|outbreak
P00712117A0521|95 101|variant
P00713525A0268|69 80|presentation
P00713525A0268|137 141|model
P00713525A0268|91 103|stimulus words
P00713525A0268|38 47|stutterers
P00713525A0268|21 35|disfluency rates
P00713525A0268|7 15|decreases
P00713525A0268|108 111|data
P00715180T0074|0 5|Effect
P00715180T0074|21 31|alterations
P00715180T0074|8 11|time
P00715180T0074|53 79|plutonium-239 dioxide aerosol
P00715180T0074|15 18|dose
P00715180T0074|82 84|rat
P00715180T0074|41 50|inhalation
P00715753A0241|115 119|CK-MB
P00715753A0241|48 48|%
P00715753A0241|104 112|% fraction
P00715753A0241|40 42|CPK
P00715753A0241|2 22|biopsies CK-MB fraction
P00715753A0241|53 69|total-CPK activity
P00715753A0241|85 91|muscles
P00716366T0001|0 4|Value
P00716366T0001|106 119|liver cirrhosis
P00716366T0001|66 74|diagnosis
P00716366T0001|7 19|determination
P00716366T0001|22 50|alkaline phosphatase isoenzymes
P00716366T0001|88 95|jaundice
P00722298A0619|256 260|males
P00722298A0619|63 73|differences
P00722298A0619|157 163|females
P00722298A0619|18 25|variance
P00722298A0619|49 51|men
P00722298A0619|123 134|significance
P00722298A0619|101 115|field dependence
P00722298A0619|93 98|groups
P00722298A0619|8 15|analysis
P00722298A0619|237 242|groups
P00722298A0619|136 138|rho
P00722298A0619|198 202|field
P00722298A0619|55 59|women
P00722298A0619|172 177|famale
P00722652A0118|115 119|cecum
P00722652A0118|103 109|surface
P00722652A0118|68 77|micrometer
P00722652A0118|11 33|2nd-generation schizonts
P00722652A0118|48 55|diameter
P00725257A0452|40 42|DHE
P00725257A0452|52 53|M.
P00725257A0452|13 21|pD2 values
P00725257A0452|32 32|E
P00725336T0000|0 32|Newcastle disease virus surveillance
P00725336T0000|61 67|poultry
P00725336T0000|35 42|Hong Kong
P00725534A0888|29 37|challenge
P00725534A0888|40 47|M. leprae
P00725534A0888|139 151|IgA deficiency
P00725534A0888|228 234|leprosy
P00725534A0888|66 79|IgA immunocytes
P00725534A0888|121 129|tolerance
P00725534A0888|195 199|villi
P00725534A0888|205 212|patients
P00725534A0888|53 60|antigens
P00725534A0888|95 104|epithelium
P00725534A0888|173 179|atrophy
P00725752T0001|0 8|Treatment
P00725752T0001|76 82|obsidan
P00725752T0001|11 22|hypertension
P00725752T0001|90 100|vasodilator
P00725752T0001|28 38|combination
P00725752T0001|54 74|beta receptor blockader
P00725752T0001|102 109|apressin
P00726581T0122|0 5|Orthop
P00728718T0000|0 13|Thyroid disease
P00728718T0000|17 25|pregnancy
P00729003A1182|0 7|Residues
P00729003A1182|19 29|transcripts
P00729003A1182|32 39|splicing
P00733067A0188|28 31|loop
P00733067A0188|246 263|spiral introflexion
P00733067A0188|132 143|construction
P00733067A0188|149 159|anastomosis
P00733067A0188|182 189|creation
P00733067A0188|207 217|valve system
P00733067A0188|332 336|lumen
P00733067A0188|51 55|steps
P00733067A0188|91 97|section
P00733067A0188|110 114|stump
P00733067A0188|10 15|reflux
P00733067A0188|269 274|mucosa
P00733067A0188|233 243|anastomosis
P00733067A0188|34 39|number
P00733067A0188|290 297|stitches
P00736376A0371|27 35|mortality
P00736376A0371|101 105|skill
P00736376A0371|87 95|operation
P00736376A0371|6 10|stage
P00736376A0371|75 81|urgency
P00736376A0371|43 50|ischemia
P00737422A0832|0 8|Pathogens
P00737422A0832|133 139|numbers
P00737422A0832|96 102|numbers
P00737422A0832|84 88|staff
P00737422A0832|144 151|patients
P00737422A0832|76 81|member
P00737422A0832|45 51|bacilli
P00740409A0000|45 62|cerebellar deposits
P00740409A0000|3 16|histochemistry
P00740409A0000|20 33|ultrastructure
P00740409A0000|74 78|Tonge
P00741476A0000|45 50|mg p.d.
P00741476A0000|62 65|days
P00741476A0000|24 41|Ergotamine Tartrate
P00741476A0000|11 15|woman
P00741476A0000|74 81|abortion
P00741476A0000|89 93|birth
P00743335T0001|0 12|Reaction times
P00743335T0001|42 48|stimuli
P00743335T0001|51 59|diabetics
P00745775A0170|133 134|M.
P00745775A0170|45 57|arteriography
P00745775A0170|110 118|injection
P00745775A0170|88 100|complications
P00745775A0170|121 129|Urografin
P00745775A0170|12 19|patients
P00747722A0486|72 80|injection
P00747722A0486|120 122|sec
P00747722A0486|89 92|drop
P00747722A0486|52 56|Phase
P00747722A0486|40 50|B1 injection
P00747722A0486|27 34|reaction
P00747722A0486|3 6|data
P00747722A0486|98 107|parameters
P00748978T0000|0 17|Serum relaxin levels
P00748978T0000|20 34|prostaglandin E2
P00748978T0000|42 50|abortions
P00753237A0000|468 478|prophylaxis
P00753237A0000|461 464|cure
P00753237A0000|177 187|combination
P00753237A0000|436 451|blood circulation
P00753237A0000|371 381|compression
P00753237A0000|265 271|effects
P00753237A0000|325 339|PNEUMATIC INSOLE
P00753237A0000|90 93|PAIN
P00753237A0000|322 322|D
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|38 42|level
P00753237A0000|162 164|PPU
P00753237A0000|415 423|attrition
P00753237A0000|151 160|ulceration
P00753237A0000|48 51|ends
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|102 105|role
P00753237A0000|254 263|traumatism
P00753237A0000|481 483|PPU
P00753237A0000|130 130|B
P00753237A0000|133 139|Plantar
P00753237A0000|22 31|phenomenon
P00753237A0000|225 231|patient
P00753237A0000|77 86|body weight
P00753237A0000|387 390|ends
P00753237A0000|485 487|fig
P00753237A0000|108 116|outsentry
P00753237A0000|243 252|body weight
P00753237A0000|295 301|process
P00753237A0000|219 219|C
P00753237A0000|403 406|arcs
P00753237A0000|64 67|arcs
P00753237A0000|118 120|fig
P00755245A0000|70 79|chloralose
P00755245A0000|8 16|indoramin
P00755245A0000|92 95|cats
P00755245A0000|24 28|doses
P00755245A0000|41 53|vasomotor loci
P00755245A0000|122 126|sites
P00755245A0000|0 5|Effect
P00755671A0485|14 20|heparin
P00755671A0485|66 76|development
P00755671A0485|40 59|recalcification times
P00755671A0485|101 109|hematomas
P00755869A0216|0 21|Contingency contracting
P00755869A0216|29 35|clients
P00755869A0216|98 112|self-monitoring
P00755869A0216|128 133|intake
P00755869A0216|78 89|consequences
P00755869A0216|135 144|weight loss
P00755869A0216|44 61|parents/caregivers
P00755869A0216|149 156|exercise
P00756511T0036|0 8|Dietetics
P00756511T0036|11 19|childhood
P00756511T0036|32 39|diabetes
P00757244A0000|3 9|results
P00757244A0000|62 70|placentas
P00757244A0000|25 29|study
P00757244A0000|48 56|membranes
P00759049A0185|45 53|ferrozine
P00759049A0185|93 96|ICSH
P00759049A0185|18 30|microcuvettes
P00759049A0185|3 13|micromethod
P00759049A0185|60 87|bathophenanthroline chromogen
P00759400T0000|0 16|Platelet serotonin
P00759400T0000|39 44|factor
P00759400T0000|26 29|5-HT
P00759400T0000|18 21|5-HT
P00759400T0000|65 72|patients
P00759400T0000|47 52|plasma
P00762763A0253|44 49|births
P00762763A0253|10 18|incidence
P00762763A0253|21 24|SIDS
P00764737X0000|3 15|vigilance task
P00764737X0000|22 32|measurement
P00764737X0000|46 53|deficits
P00767155T0001|16 21|revolt
P00767155T0001|47 55|personnel
P00767155T0001|24 29|Moscow
P00767155T0001|3 10|December
P00767161A0837|113 117|hours
P00767161A0837|87 100|administration
P00767161A0837|11 19|increases
P00767161A0837|26 45|serum E2 concentration
P00767161A0837|77 81|hours
P00767161A0837|120 122|day
P00767161A0837|103 105|day
P00767161A0837|55 59|pg/ml
P00768220X0000|3 11|motor unit
P00771729X0000|17 22|system
P00771729X0000|52 59|hormones
P00771729X0000|41 49|responses
P00771729X0000|29 38|variations
P00775582T0000|22 30|sumithion
P00775582T0000|10 19|properties
P00779272T0001|44 48|virus
P00779272T0001|11 17|studies
P00779272T0001|20 29|antibodies
P00779272T0001|61 73|mononucleosis
P00780639X0000|16 22|antigen
P00780639X0000|28 37|procedures
P00780639X0000|24 26|CEA
P00780639X0000|49 58|evaluation
P00792847A0000|74 78|agent
P00792847A0000|81 86|humans
P00792847A0000|21 42|antilymphocyte globulin
P00792847A0000|44 46|ALG
P00799988A0554|96 102|placebo
P00799988A0554|115 121|therapy
P00799988A0554|74 83|imipramine
P00799988A0554|61 70|preference
P00799988A0554|19 36|assessment patients
P00799988A0554|5 9|basis
P00803867A0315|0 7|Patients
P00803867A0315|129 135|disease
P00803867A0315|40 45|groups
P00803867A0315|64 69|cancer
P00803867A0315|105 112|patients
P00803867A0315|84 89|cancer
P00803867A0315|147 152|months
P00806295A0193|98 105|subjects
P00806295A0193|33 36|cent
P00806295A0193|64 67|cent
P00806295A0193|47 56|absorption
P00806295A0193|0 9|Absorption
P00807356T0001|30 37|activity
P00807356T0001|40 59|hydroxy-9 ellipticine
P00808266T0000|0 7|Advances
P00808266T0000|36 41|cancer
P00808266T0000|13 22|management
P00808266T0000|44 59|radiation therapy
P00808898A0000|71 77|failure
P00808898A0000|79 82|IPRF
P00808898A0000|23 26|data
P00808898A0000|32 38|patient
P00811852T0001|61 68|patients
P00811852T0001|8 19|satisfaction
P00811852T0001|22 28|nursing
P00811852T0001|32 40|encounter
P00812183T0000|10 23|transfer factor
P00818380A0239|30 42|antibody tests
P00818380A0239|10 15|factor
P00818380A0239|128 138|populations
P00818380A0239|69 77|reactions
P00818380A0239|80 90|gold therapy
P00819176T0001|102 121|Pontella mediterranea
P00819176T0001|81 100|Anomalocera patersoni
P00819176T0001|22 29|pressure
P00819176T0001|71 79|crustacea
P00819176T0001|35 50|swimming activity
P00819176T0001|123 142|Labidocera wollastoni
P00819176T0001|3 8|effect
P00821833A0000|120 125|Panama
P00821833A0000|38 47|repertoire
P00821833A0000|50 62|howler monkeys
P00821833A0000|64 79|Alouatta palliata
P00821833A0000|20 27|analysis
P00821833A0000|96 105|field study
P00821833A0000|4 9|report
P00822611A0467|58 64|persons
P00822611A0467|10 15|number
P00822611A0467|18 25|patients
P00822611A0467|77 89|binephrectomy
P00823087A0608|28 35|patients
P00823087A0608|0 7|Deflunia
P00825571T0031|0 2|III
P00827364A0000|61 68|material
P00827364A0000|4 13|instrument
P00827364A0000|80 85|vacuum
P00827364A0000|71 75|ultra
P00827364A0000|32 48|freeze-fracturing
P00830568A0000|205 212|patients
P00830568A0000|96 102|persons
P00830568A0000|20 28|secretion
P00830568A0000|70 72|LTM
P00830568A0000|224 231|vagotomy
P00830568A0000|106 113|patients
P00830568A0000|126 136|gastrectomy
P00830568A0000|141 158|gastroduodenostomy
P00830568A0000|39 51|emptying rates
P00830568A0000|160 165|STG-BI
P00830568A0000|191 197|STG-BII
P00830568A0000|248 250|V&P
P00830568A0000|61 68|test meal
P00830568A0000|173 189|gastrojejunostomy
P00830568A0000|235 246|pyloroplasty
P00832096T0000|8 24|calcium metabolism
P00832096T0000|41 51|sarcoidosis
P00833472A0907|16 22|patient
P00833472A0907|54 64|institution
P00833472A0907|90 104|gallbladder bile
P00833472A0907|78 87|saturation
P00833472A0907|109 119|cholesterol
P00833472A0907|67 76|colestipol
P00833472A0907|35 44|gallstones
P00833472A0907|149 152|drug
P00836637A0000|134 144|EMR children
P00836637A0000|91 100|reinforcer
P00836637A0000|11 20|experiment
P00836637A0000|65 79|music-listening
P00836637A0000|213 222|reinforcer
P00836637A0000|196 205|preference
P00836637A0000|111 131|arithmetic performance
P00836637A0000|172 184|reinforcement
P00837262A0000|134 139|rabbit
P00837262A0000|117 127|stimulation
P00837262A0000|94 105|conditioning
P00837262A0000|113 115|OFF
P00837262A0000|25 30|cortex
P00837262A0000|107 108|ON
P00837262A0000|57 58|SC
P00837262A0000|32 33|VC
P00837262A0000|46 55|colliculus
P00837262A0000|3 16|responsiveness
P00837811A0675|56 83|fluid gamma globulin elevations
P00837811A0675|12 13|MS
P00837811A0675|44 48|signs
P00837811A0675|88 100|abnormalities
P00837811A0675|121 127|testing
P00837811A0675|1 9|diagnosis
P00838152A0863|14 32|mean temperature rise
P00838152A0863|153 165|triplet groups
P00838152A0863|175 186|predominance
P00838152A0863|61 68|degrees C
P00838152A0863|227 232|groups
P00838152A0863|203 216|qualifications
P00838152A0863|109 121|disappearance
P00838152A0863|47 54|degrees C
P00838152A0863|76 84|selection
P00838152A0863|134 147|qualifications
P00839378A0649|84 90|disease
P00839378A0649|98 104|therapy
P00839378A0649|21 28|RDS group
P00839378A0649|11 15|Viso V
P00839378A0649|54 69|airway resistance
P00839378A0649|39 46|increase
P00842406A0771|57 78|visuomotor coordination
P00842406A0771|83 97|recognition task
P00842406A0771|50 53|test
P00842406A0771|16 20|tests
P00842406A0771|44 47|task
P00842522T0000|76 84|emphysema
P00842522T0000|18 27|intubation
P00842522T0000|33 42|management
P00843232A0100|59 67|character
P00843232A0100|81 90|epithelium
P00843232A0100|70 75|lesion
P00843232A0100|47 52|factor
P00843232A0100|3 12|background
P00843670T0000|3 7|sense
P00843670T0000|10 13|self
P00846559A0000|172 179|capacity
P00846559A0000|81 87|species
P00846559A0000|6 12|strains
P00846559A0000|187 194|T-2 toxin
P00846559A0000|132 137|U.S.A.
P00846559A0000|67 73|strains
P00846559A0000|55 62|U.S.S.R.
P00846559A0000|30 47|F. sporotrichioides
P00846559A0000|15 26|Fusarium poae
P00846559A0000|118 127|tricinctum
P00846559A0000|96 116|F. sporotrichioides var
P00846559A0000|141 146|France
P00847967T0000|17 20|uses
P00847967T0000|55 62|medicine
P00847967T0000|35 44|tomography
P00851041A0000|40 46|anomaly
P00851041A0000|10 14|study
P00851041A0000|19 26|patients
P00851041A0000|31 37|Ebstein
P00851286A0375|0 5|Deaths
P00851286A0375|75 82|distress
P00851286A0375|62 64|ppm
P00851286A0375|25 44|copper concentrations
P00851286A0375|124 128|hours
P00851286A0375|141 145|death
P00851286A0375|68 72|signs
P00851286A0375|15 19|hours
P00857024A0888|0 9|Recurrence
P00857024A0888|76 90|properdin levels
P00857024A0888|12 24|bladder tumors
P00857024A0888|107 112|median
P00857024A0888|42 46|cases
P00863184T0043|60 63|load
P00863184T0043|24 39|transport maximum
P00863184T0043|69 71|rat
P00863184T0043|0 9|Adaptation
P00863773T0000|0 6|Dangers
P00863773T0000|9 11|use
P00863773T0000|14 31|live-virus vaccines
P00866577A0579|61 66|agents
P00866577A0579|21 41|plasminogen activators
P00866577A0579|96 103|function
P00866577A0579|13 19|heparin
P00866577A0579|135 138|term
P00866577A0579|156 162|therapy
P00866577A0579|122 128|patient
P00866577A0579|0 8|Treatment
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868301A0043|102 108|minutes
P00868301A0043|2 21|diethyl ether solution
P00868301A0043|83 95|retention time
P00868301A0043|117 125|condition
P00868301A0043|29 32|peak
P00868903A0000|0 7|Amikacin
P00868903A0000|53 62|infections
P00868903A0000|20 28|treatment
P00868903A0000|67 74|patients
P00870859A0121|71 83|recirculation
P00870859A0121|48 54|account
P00870859A0121|60 68|direction
P00870859A0121|107 112|factor
P00870859A0121|3 6|data
P00871237A0601|6 13|activity
P00871237A0601|37 42|angina
P00871237A0601|21 27|patient
P00872442T0000|0 9|Estimation
P00872442T0000|23 27|serum
P00872442T0000|12 20|L-alanine
P00872442T0000|30 35|plasma
P00872442T0000|44 66|LKB reaction rate analyser
P00872922A0204|3 7|acids
P00872922A0204|22 31|hydrolysis
P00872922A0204|82 89|activity
P00872922A0204|50 55|esters
P00874942T0000|49 54|report
P00874942T0000|12 21|amnionitis
P00874942T0000|25 35|prematurity
P00875778T0000|0 9|Evaluation
P00875778T0000|18 38|Gravigard IUCD inserter
P00876722T0000|30 36|abscess
P00876722T0000|9 18|meningitis
P00876722T0000|47 52|septum
P00877857A0763|0 11|Serum amylase
P00877857A0763|40 47|CU/100 ml
P00877857A0763|72 80|mEq/liter
P00877857A0763|58 65|serum FFA
P00879329A0176|29 34|weight
P00879329A0176|114 120|colloid
P00879329A0176|128 135|pressure
P00879329A0176|141 146|plasma
P00879329A0176|79 86|pressure
P00879329A0176|148 150|IIp
P00879329A0176|5 22|control preparation
P00879329A0176|88 90|Pci
P00879329A0176|101 104|mmHg
P00879829A0564|0 6|Infants
P00879829A0564|36 38|IVH
P00879829A0564|122 127|apnoea
P00879829A0564|61 73|birth asphyxia
P00879829A0564|103 109|symptom
P00879829A0564|26 30|hours
P00881630A0000|187 190|rats
P00881630A0000|127 132|N. naja
P00881630A0000|138 142|venom
P00881630A0000|49 60|A. piscivorus
P00881630A0000|106 114|compounds
P00881630A0000|90 104|Phospholipase-A
P00881630A0000|162 165|lung
P00881630A0000|40 45|N. naja
P00881630A0000|169 184|cremaster vessels
P00881630A0000|81 86|Factor
P00881630A0000|16 22|effects
P00881630A0000|28 38|snake venoms
P00885562A0281|15 24|components
P00885562A0281|121 132|GAG synthesis
P00885562A0281|78 91|osteoarthrosis
P00885562A0281|94 99|method
P00885562A0281|5 8|GAGs
P00885562A0281|135 141|culture
P00885562A0281|46 54|depletion
P00885562A0281|27 41|cartilage matrix
P00890028A0507|140 155|Kolmogoroff scale
P00890028A0507|77 86|macroscale
P00890028A0507|20 29|turbulence
P00890028A0507|104 119|Taylor microscale
P00890028A0507|51 64|Reynolds number
P00890028A0507|131 132|mm
P00890028A0507|167 168|mm
P00890028A0507|3 14|length scales
P00890028A0507|98 99|mm
P00891370A0000|15 26|arteriograms
P00891370A0000|141 148|patients
P00891370A0000|52 66|xeroradiography
P00891370A0000|94 108|contrast-medium
P00891370A0000|115 121|arm vein
P00891370A0000|32 36|limbs
P00891370A0000|83 91|injection
P00892353A0686|68 76|degrees C.
P00892353A0686|35 41|toxemia
P00892353A0686|23 30|patients
P00892353A0686|54 58|fever
P00892353A0686|2 12|hypotension
P00898500A0246|143 161|IgE antibody activity
P00898500A0246|30 37|patients
P00898500A0246|164 168|mites
P00898500A0246|109 112|test
P00898500A0246|60 72|mites skin test
P00898500A0246|15 24|secretions
P00898500A0246|3 6|sera
P00898500A0246|56 57|HD
P00898500A0246|114 117|RAST
P00903772A0359|0 7|Wherever
P00903772A0359|11 14|site
P00903772A0359|92 94|leg
P00903772A0359|78 86|ischaemia
P00903772A0359|49 61|modifications
P00903772A0359|20 42|conditioning stimulation
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|77 85|neoplasms
P00909114A0000|151 158|hamsters
P00909114A0000|104 112|incidence
P00909114A0000|35 46|nitrosamines
P00909114A0000|126 136|tract tumors
P00909114A0000|88 91|rats
P00909114A0000|19 21|DAN
P00909114A0000|166 167|sc
P00909114A0000|196 203|compound
P00909114A0000|186 190|doses
P00910823A0196|86 95|blood flows
P00910823A0196|26 35|conditions
P00910823A0196|64 65|pH
P00910823A0196|53 62|blood gases
P00910823A0196|67 73|uterine
P00910823A0196|4 7|term
P00911590T0000|35 49|bocurarine block
P00911590T0000|54 80|atropine-neostigmine mixture
P00911590T0000|12 20|responses
P00911590T0000|23 32|antagonism
P00911590T0000|83 90|children
P00913623A0242|88 100|pyrophosphate
P00913623A0242|43 55|diphosphonate
P00913623A0242|126 129|bone
P00913623A0242|113 123|capillaries
P00913623A0242|24 32|molecules
P00913623A0242|3 11|mechanism
P00913623A0242|69 72|EHDP
P00913623A0242|134 149|passive diffusion
P00913623A0242|102 105|pass
P00915090A0536|58 61|rads
P00915090A0536|77 82|number
P00915090A0536|11 14|days
P00915090A0536|39 44|Tc-99m
P00915090A0536|110 116|control
P00915090A0536|85 93|sperm hads
P00915090A0536|34 36|mCi
P00915090A0536|107 107|%
P00915090A0536|67 72|testis
P00915090A0536|20 28|injection
P00916099A0000|0 16|Self-emasculation
P00916099A0000|53 60|disorder
P00916099A0000|92 100|treatment
P00916099A0000|22 30|end result
P00917572T0001|0 10|Possibility
P00917572T0001|27 32|method
P00917572T0001|36 44|detection
P00917572T0001|47 60|hypothyroidism
P00917721A0484|4 11|analysis
P00917721A0484|52 70|presleep suggestions
P00917721A0484|93 104|dream content
P00917721A0484|31 38|evidence
P00918556A0000|15 38|hepatitis B surface antigen
P00918556A0000|49 56|anti-HBs
P00918556A0000|126 131|series
P00918556A0000|40 44|HBsAg
P00918556A0000|97 122|radio-immunoassay technique
P00918556A0000|153 165|liver diseases
P00918556A0000|3 12|prevalence
P00918556A0000|134 141|patients
P00918965A0728|171 174|PAO2
P00918965A0728|90 101|componenents
P00918965A0728|116 120|shunt
P00918965A0728|18 25|patients
P00918965A0728|125 132|parallel
P00918965A0728|72 82|ventilation
P00918965A0728|46 52|failure
P00920381T0000|43 51|injection
P00920381T0000|97 100|rats
P00920381T0000|16 23|glycogen
P00921032T0000|43 48|Beagle
P00921032T0000|10 19|evaluation
P00921032T0000|22 31|mibolerone
P00921911A0159|0 5|Levels
P00921911A0159|122 126|onset
P00921911A0159|67 72|labour
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00921911A0159|106 107|cm
P00921911A0159|129 134|labour
P00921911A0159|85 94|dilatation
P00926272A0000|13 17|cause
P00926272A0000|60 66|patient
P00926272A0000|25 37|deterioration
P00926272A0000|95 100|reflux
P00926272A0000|49 52|cord
P00926604A0504|131 136|effect
P00926604A0504|82 86|heart
P00926604A0504|68 76|apparatus
P00926604A0504|35 38|dose
P00926604A0504|157 169|strophanthin K
P00926604A0504|12 18|Inderal
P00926604A0504|98 108|development
P00926604A0504|199 208|myocardium
P00926604A0504|150 154|doses
P00926604A0504|0 10|Propranolol
P00926751A0000|71 79|irritancy
P00926751A0000|25 33|rat larynx
P00926751A0000|59 68|evaluation
P00926751A0000|49 53|organ
P00926751A0000|89 97|materials
P00926751A0000|6 12|studies
P00927633T0001|74 85|Rattus rattus
P00927633T0001|27 40|investigations
P00927633T0001|67 71|fiber
P00927633T0001|8 15|electron
P00927633T0001|46 54|formation
P00927633T0001|57 64|Reissner
P00928529T0001|0 14|Feeding behavior
P00928529T0001|26 35|body weight
P00928529T0001|39 56|hibernation rhythms
P00928529T0001|67 74|hamsters
P00928529T0001|110 116|bundles
P00929418T0001|0 3|Role
P00929418T0001|63 71|incidence
P00929418T0001|9 36|infectious-disease specialist
P00929418T0001|86 93|diseases
P00930947A0629|115 120|effect
P00930947A0629|67 75|secretion
P00930947A0629|173 176|drug
P00930947A0629|161 166|effect
P00930947A0629|13 28|drug interactions
P00930947A0629|50 59|probenecid
P00930947A0629|78 80|PZA
P00930947A0629|129 133|drugs
P00930947A0629|42 47|effect
P00931089T0001|22 34|operating room
P00931089T0001|11 16|arrest
P00932738A0116|99 100|BP
P00932738A0116|25 26|BP
P00932738A0116|37 53|C02 responsiveness
P00932738A0116|11 23|blood pressure
P00932738A0116|91 96|levels
P00932738A0116|32 35|mmHg
P00932817A0499|87 95|MTF values
P00932817A0499|76 79|turn
P00932817A0499|50 67|pinhole collimators
P00932817A0499|124 128|99mTc
P00932817A0499|0 9|Iodine-123
P00932817A0499|44 46|MEC
P00933251T0000|19 24|plaque
P00933251T0000|49 56|ear tumor
P00933251T0000|7 16|meningioma
P00935526A0000|144 145|ng
P00935526A0000|91 101|sensitivity
P00935526A0000|54 67|chromatography
P00935526A0000|24 37|prostaglandins
P00935526A0000|39 40|PG
P00935526A0000|159 168|resolution
P00935526A0000|180 186|columns
P00935526A0000|85 88|lack
P00935526A0000|3 14|difficulties
P00938594A0149|13 26|steroid therapy
P00938594A0149|106 108|HOA
P00938594A0149|61 74|manifestations
P00938594A0149|89 104|osteoarthropathy
P00938594A0149|129 146|laboratory features
P00938594A0149|30 36|patient
P00938594A0149|169 170|RA
P00938594A0149|2 10|cessation
P00938594A0149|159 167|arthritis
P00941050T0000|3 8|effect
P00941050T0000|11 14|food
P00941050T0000|17 38|procainamide absorption
P00947327A0000|295 307|sulfanilamide
P00947327A0000|455 461|TMP/SMZ
P00947327A0000|219 224|agents
P00947327A0000|159 169|combination
P00947327A0000|310 320|sulfamoxole
P00947327A0000|376 387|trimethoprim
P00947327A0000|44 53|resistance
P00947327A0000|253 263|combination
P00947327A0000|155 157|TMP
P00947327A0000|121 136|sulfamethoxazole
P00947327A0000|229 235|results
P00947327A0000|23 31|situation
P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
P00947327A0000|75 81|Bavaria
P00947327A0000|446 450|tests
P00947327A0000|142 153|trimethoprim
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|392 396|ratio
P00947327A0000|266 267|N1
P00947327A0000|138 140|SMZ
P00947327A0000|410 414|Nevin
P00947327A0000|110 117|activity
P00947327A0000|12 17|survey
P00947327A0000|189 199|antibiotics
P00947327A0000|403 404|CN
P00947327A0000|416 424|Supristol
P00947327A0000|238 242|tests
P00947327A0000|365 374|pyrimidine
P00947327A0000|59 64|region
P00947834X0000|0 6|RESULTS
P00947834X0000|13 21|IgE levels
P00947834X0000|29 36|tendency
P00951909X0001|57 65|diagnosis
P00951909X0001|12 23|loop syndrome
P00951909X0001|135 156|Billroth-II gastrectomy
P00951909X0001|80 91|loop syndrome
P00951909X0001|38 43|author
P00951909X0001|46 52|opinion
P00951909X0001|116 123|patients
P00952734T0000|0 5|Letter
P00952734T0000|80 88|cutis laxa
P00952734T0000|23 28|damage
P00952734T0000|90 93|PECL
P00952734T0000|66 76|elastolysis
P00952734T0000|41 45|cause
P00954819A1041|128 139|AChE activity
P00954819A1041|120 125|return
P00954819A1041|95 99|Sarin
P00954819A1041|72 83|intoxication
P00954819A1041|31 38|recovery
P00954819A1041|5 8|data
P00954819A1041|88 92|Soman
P00954819A1041|59 66|function
P00956364A0138|0 12|Batch cultures
P00956364A0138|54 60|MSB agar
P00956364A0138|46 51|growth
P00956364A0138|15 30|S. mutans serotype
P00956554A0414|14 18|serum
P00956554A0414|5 11|samples
P00956554A0414|95 107|IgE antibodies
P00956554A0414|45 64|solid-phase allergens
P00956554A0414|71 80|reactivity
P00958550T0001|0 5|Crisis
P00958550T0001|38 44|Britain
P00958550T0001|22 30|community
P00959656A0250|39 50|antithrombin
P00959656A0250|8 12|women
P00959656A0250|31 36|levels
P00959656A0250|15 18|term
P00961711T0000|0 16|Hematology problem
P00961711T0000|22 26|month
P00961711T0000|34 36|seg
P00961711T0000|28 31|band
P00962222A0633|58 64|changes
P00962222A0633|34 45|heme turnover
P00962222A0633|102 118|progesterone phase
P00962222A0633|22 31|variations
P00962222A0633|67 92|erythrocyte characteristics
P00962277T0000|0 12|Haemodilution
P00962277T0000|63 69|priming
P00962277T0000|30 35|bypass
P00962277T0000|42 59|gelatine derivative
P00964758T0001|31 42|parotid gland
P00964758T0001|14 25|plasmacytoma
P00967223T0059|0 1|I.
P00968181A0264|73 76|days
P00968181A0264|90 98|infection
P00968181A0264|12 17|calves
P00968181A0264|31 38|immunity
P00968181A0264|57 65|challenge
P00970320A0000|3 13|performance
P00970320A0000|64 66|SO2
P00970320A0000|90 99|conditions
P00970320A0000|103 115|copper smelter
P00970320A0000|33 60|chemical cartridge respirators
P00970488A0105|144 149|effect
P00970488A0105|75 92|DA receptor blocking
P00970488A0105|39 48|DA turnover
P00970488A0105|52 60|indicator
P00970488A0105|152 163|neuroleptics
P00970488A0105|22 29|increase
P00970488A0105|67 72|degree
P00970488A0105|200 207|symptoms
P00970488A0105|170 180|development
P00970839A0118|0 11|Rainbow trout
P00970839A0118|91 97|pellets
P00970839A0118|39 47|trout farm
P00970839A0118|62 66|water
P00970839A0118|105 109|weeks
P00970839A0118|70 76|feeding
P00974901A0080|0 10|Stimulation
P00974901A0080|39 62|Bordetella pertussis cells
P00974901A0080|13 30|macrophage function
P00974901A0080|105 118|susceptibility
P00974901A0080|86 91|effect
P00975314T0001|56 64|karyotype
P00975314T0001|68 69|xy
P00975314T0001|7 17|amenorrhoea
P00975314T0001|82 95|gonadoblastoma
P00975540T0000|14 20|methods
P00975540T0000|54 72|mass fragmentography
P00975540T0000|41 51|application
P00975540T0000|31 39|chemistry
P00975540T0000|75 95|high-accuracy analyses
P00980255T0000|44 51|coupling
P00980255T0000|16 38|2-deoxy-D-glucose method
P00980255T0000|62 71|metabolism
P00980255T0000|75 83|blood flow
P00980255T0000|0 10|Application
P00984209A0614|0 17|Serum gastrin levels
P00984209A0614|38 42|group
P00984209A0614|52 87|background serum gastrin concentrations
P00984209A0614|130 140|V&A patients
P00984209A0614|115 125|V&P patients
P00984209A0614|154 158|study
P00985110T0001|43 49|putamen
P00985110T0001|82 88|regions
P00985110T0001|8 18|projections
P00985110T0001|105 110|cortex
P00985110T0001|94 96|cat
P00985110T0001|31 37|portion
P00985276A0000|0 8|Preflight
P00985276A0000|124 133|evaluation
P00985276A0000|10 17|inflight
P00985276A0000|106 111|Skylab
P00985276A0000|92 104|Skylab mission
P00985276A0000|71 80|astronauts
P00985276A0000|22 52|postflight exercise response tests
P00985276A0000|170 183|weightlessness
P00985276A0000|149 158|adaptation
P00985276A0000|116 119|part
P00985279A0493|15 38|hemoglobin concentrations
P00985279A0493|58 58|h
P00985279A0493|81 86|groups
P00985279A0493|91 98|CO2 group
P00985279A0493|115 122|decrease
P00985279A0493|0 3|Mean
P00986800A0325|114 119|body Cu
P00986800A0325|105 110|values
P00986800A0325|91 99|exception
P00986800A0325|130 133|dams
P00986800A0325|73 83|mug Cu/g diet
P00986800A0325|55 69|saturation level
P00986800A0325|153 155|day
P00986800A0325|158 165|delivery
P00986800A0325|3 10|Cu values
P00986800A0325|26 31|organs
P00986925A0002|28 33|amount
P00986925A0002|80 108|plasma 47Ca radioactivity curves
P00986925A0002|36 42|calcium
P00986925A0002|11 20|calcitonin
P00986925A0002|70 77|glucagon
P00986925A0002|55 66|pentagastrin
P00986925A0002|111 118|subjects
P00986925A0002|3 8|effect
P00986925A0002|133 136|47Ca
P00987649T0001|0 4|State
P00987649T0001|47 53|rhythms
P00987649T0001|10 13|body
P00987649T0001|66 76|hypokinesia
P00987649T0001|16 24|disorders
P00988572A0000|185 190|oxygen
P00988572A0000|168 171|data
P00988572A0000|46 59|rabbit hind limb
P00988572A0000|23 34|lymph vessels
P00988572A0000|177 182|source
P00988572A0000|196 200|lymph
P00988572A0000|121 147|catheter-tip oxygen electrode
P00988572A0000|36 39|PLO2
P00988572A0000|97 103|chamber
P00988572A0000|0 12|Oxygen tension
P00989973A0000|3 10|response
P00989973A0000|196 203|busulfan
P00989973A0000|106 114|endotoxin
P00989973A0000|66 75|turpentine
P00989973A0000|146 152|rabbits
P00989973A0000|134 140|rabbits
P00989973A0000|95 103|injection
P00989973A0000|16 36|plasma fibrinogen level
P00989973A0000|55 63|injection
P00992316A0178|49 58|activities
P00992316A0178|127 135|gravidity
P00992316A0178|100 107|criteria
P00992316A0178|21 34|pressure curves
P00993176A0066|116 125|hemoglobin
P00993176A0066|79 85|portion
P00993176A0066|35 44|hemoglobin
P00993176A0066|138 149|2SO4 solution
P00993176A0066|50 61|heme pigments
P00993176A0066|134 136|NH4
P00993176A0066|91 97|extract
P00993176A0066|5 13|myoglobin
P00993176A0066|132 132|%
P00996272A0397|101 112|instructions
P00996272A0397|39 49|variability
P00996272A0397|62 74|investigation
P00996272A0397|25 29|error
P00996272A0397|16 22|sources
P00996364X0000|0 0|E
P00999494A0000|58 62|doses
P00999494A0000|91 106|agent propranolol
P00999494A0000|34 38|mania
P00999494A0000|18 26|diagnosis
P00999494A0000|3 10|patients
P01000378T0000|0 5|Effect
P01000378T0000|33 53|insulin concentrations
P01000378T0000|8 13|trauma
P01000378T0000|56 60|sheep
P01000378T0000|16 29|plasma glucagon
P01003819A0498|38 47|refraction
P01003819A0498|66 81|corneal curvature
P01003819A0498|7 10|help
P01003819A0498|53 62|axis length
P01003819A0498|14 24|nomogram one
P01004298A0744|58 58|%
P01004298A0744|73 80|students
P01004298A0744|103 107|level
P01004298A0744|24 28|score
P01004298A0744|85 90|scores
P01004298A0744|34 44|CA component
P01004298A0744|4 13|up-grading
P01009451A0728|28 34|OCS rats
P01009451A0728|75 83|reduction
P01009451A0728|10 17|controls
P01009451A0728|103 110|drinking
P01009451A0728|89 100|nocturnality
P01009451A0728|23 24|UB
P01009739T0001|0 5|Effect
P01009739T0001|50 52|ECG
P01009739T0001|8 19|indomethacin
P01009739T0001|42 47|effect
P01009739T0001|30 40|circulation
P01009841T0001|29 40|trunk muscles
P01009841T0001|21 26|fibers
P01009841T0001|43 55|lamprey larvae
P01009841T0001|4 14|innervation
P01010638A0161|3 6|feed
P01010638A0161|34 34|%
P01012640T0001|73 78|Sipple
P01012640T0001|81 88|syndrome
P01012640T0001|24 33|eye changes
P01012640T0001|48 63|pheochromocytoma
P01012640T0001|7 21|characteristics
P01012640T0001|36 43|patients
P01012904A0333|122 127|sample
P01012904A0333|141 146|format
P01012904A0333|13 30|interference effect
P01012904A0333|82 91|Stroop test
P01012904A0333|59 69|populations
P01019207A0232|99 103|range
P01019207A0232|30 39|conditions
P01019207A0232|47 56|dependence
P01019207A0232|87 89|lgC
P01019207A0232|73 83|betaI% value
P01019207A0232|113 125|mug ruscogenin
P01021091T0000|98 108|vasopressin
P01021091T0000|62 70|rabbit ear
P01021091T0000|35 42|response
P01021091T0000|110 120|Octapressin
P01021091T0000|24 29|nerves
P01021091T0000|45 56|blood vessels
P01021091T0000|3 11|influence
P01027644T0001|10 13|test
P01030985T0090|0 1|I.
P01035457A0623|45 54|importance
P01035457A0623|73 81|treatment
P01035457A0623|61 69|diagnosis
P01035457A0623|20 34|nipple discharge
P01035457A0623|5 10|tumour
P01036714A0072|0 6|Studies
P01036714A0072|36 42|changes
P01036714A0072|115 118|lung
P01036714A0072|83 92|chrysotile
P01036714A0072|123 136|cell population
P01036714A0072|67 73|animals
P01036714A0072|159 164|levels
P01036714A0072|102 109|increase
P01044338A0240|43 51|estimates
P01044338A0240|8 19|measurements
P01044338A0240|22 39|temperature changes
P01044338A0240|57 63|heating
P01047417T0000|8 32|National Health Dis-service
P01047895T0001|102 112|patient care
P01047895T0001|13 23|patient care
P01047895T0001|2 10|criticism
P01047895T0001|63 70|Patients
P01047895T0001|57 61|value
P01047895T0001|72 80|criticism
P01048020T0000|0 7|Critique
P01048020T0000|22 28|Effects
P01048020T0000|113 129|Course Information
P01048020T0000|62 78|A-F Grade Condition
P01048020T0000|31 41|Test Anxiety
P01048020T0000|45 59|Credit/No Credit
P01048968A0152|72 82|penicillin G
P01048968A0152|44 56|staphylococci
P01048968A0152|5 11|studies
P01048968A0152|108 121|beta-lactamase
P01048968A0152|84 95|erythromycin
P01048968A0152|28 35|majority
P01050144A0297|114 123|83A complex
P01050144A0297|29 34|number
P01050144A0297|37 43|strains
P01050144A0297|102 108|strains
P01050144A0297|16 23|decrease
P01050144A0297|66 76|antibiotics
P01050400T0000|0 10|Improvement
P01050400T0000|45 48|time
P01050400T0000|51 59|discharge
P01050400T0000|13 30|nursing instruction
P01050400T0000|67 70|ward
P01050400T0000|83 89|infants
P01057137A0192|2 11|difference
P01057137A0192|25 37|acceptability
P01057137A0192|69 74|groups
P01064124A0560|42 47|lesion
P01064124A0560|9 18|subsurface
P01064124A0560|7 7|d
P01064124A0560|64 72|specimens
P01067493A0119|28 32|women
P01067493A0119|51 57|percent
P01067493A0119|78 84|methods
P01067493A0119|16 22|pattern
P01071715A0903|16 24|technique
P01071715A0903|36 58|blood pressure recordings
P01075075T0038|0 1|I.
P01078982A0227|69 90|antilymphocyte globulin
P01078982A0227|52 67|cyclophosphamide
P01078982A0227|150 165|cyclophosphamide
P01078982A0227|92 94|ALG
P01078982A0227|142 147|dosage
P01078982A0227|96 104|treatment
P01078982A0227|109 125|ALG administration
P01080374A0709|86 89|form
P01080374A0709|38 54|aneurysm retinitis
P01080374A0709|69 74|entity
P01080374A0709|92 96|Coats
P01080374A0709|23 27|Leber
P01080374A0709|98 104|disease
P01080374A0709|0 7|Evidence
P01081904A0198|42 49|patients
P01081904A0198|22 29|catheter
P01081904A0198|110 117|symptoms
P01081904A0198|59 79|pull-out arteriography
P01082726A0248|44 49|DC-ERG
P01082726A0248|21 25|pupil
P01082726A0248|31 38|response
P01082726A0248|3 11|influence
P01082833A0000|149 158|guinea pigs
P01082833A0000|83 94|indomethacin
P01082833A0000|114 121|response
P01082833A0000|96 97|IM
P01082833A0000|251 254|rats
P01082833A0000|66 75|inhibition
P01082833A0000|40 45|Y-8004
P01082833A0000|238 248|peritonitis
P01082833A0000|34 38|agent
P01082833A0000|139 146|erythema
P01082833A0000|160 175|carrageenin edema
P01082833A0000|208 216|pleuritis
P01083321X0000|115 126|productivity
P01083321X0000|43 45|age
P01083321X0000|47 58|subalpine fir
P01083321X0000|2 7|stands
P01083321X0000|17 25|dominance
P01083321X0000|96 100|rates
P01083321X0000|132 137|stands
P01083321X0000|158 162|years
P01083375T0000|0 17|Alpha-1 antitrypsin
P01083375T0000|27 44|childhood cirrhosis
P01083784T0000|59 66|patients
P01083784T0000|25 32|serum IgE
P01083784T0000|41 56|eosinophil counts
P01083784T0000|80 85|asthma
P01083784T0000|0 23|Lymphocyte subpopulations
P01084413A0271|43 45|EMI
P01084413A0271|25 36|measurements
P01084413A0271|1 5|range
P01087288T0000|1 10|comparison
P01087288T0000|80 89|iodine-131
P01087288T0000|35 43|estimates
P01087288T0000|61 68|patients
P01087288T0000|93 108|thyroid carcinoma
P01087288T0000|46 58|radiation dose
P01088654T0001|0 8|Technique
P01088654T0001|45 48|mass
P01088654T0001|28 35|ceramics
P01090210A0417|0 3|Mean
P01090210A0417|9 20|lung capacity
P01090210A0417|246 250|cm H20
P01090210A0417|232 242|differences
P01090210A0417|40 47|capacity
P01090210A0417|194 198|cm H20
P01090210A0417|116 125|lung volume
P01090210A0417|139 144|volume
P01090210A0417|152 156|phase
P01090210A0417|95 111|mean closing volume
P01090210A0417|217 230|airway pressure
P01090210A0417|60 65|volume
P01092248T0000|15 28|zinc deficiency
P01092248T0000|93 101|disorders
P01092248T0000|34 45|pathogenesis
P01092248T0000|7 12|status
P01093055T0000|0 6|Calcium
P01093055T0000|39 44|uremia
P01093055T0000|10 29|phosphorus metabolism
P01093845A0208|0 12|Modern studies
P01093845A0208|94 101|identity
P01093845A0208|128 135|cannabis
P01093845A0208|27 37|Delta-9-THC
P01093845A0208|148 152|dream
P01093845A0208|140 144|sleep
P01093845A0208|107 119|modifications
P01093845A0208|48 58|voluntaries
P01093845A0208|75 84|comparison
P01093847A0000|21 44|tropatepine hydrochloride
P01093847A0000|66 72|effects
P01093847A0000|13 18|action
P01093847A0000|82 93|neuroleptics
P01093847A0000|126 131|states
P01096741X0000|29 35|animals
P01096741X0000|54 66|chickpea haulm
P01096741X0000|10 15|growth
P01096741X0000|82 96|supplementation
P01097100A0217|3 10|patients
P01097100A0217|30 37|regimens
P01098179A0167|76 92|dissolution curves
P01098179A0167|126 140|chloramphenicol
P01098179A0167|184 189|creams
P01098179A0167|171 178|activity
P01098179A0167|208 216|ointments
P01098179A0167|44 55|preparations
P01098179A0167|155 161|release
P01098179A0167|105 110|assays
P01098179A0167|0 6|Results
P01098592A0567|83 87|onset
P01098592A0567|45 51|samples
P01098592A0567|63 66|days
P01098592A0567|0 8|IgG levels
P01099693T0000|0 5|Letter
P01099693T0000|21 45|bone marrow transplantation
P01099693T0000|7 18|Perspectives
P01101272T0000|45 53|sweetners
P01101272T0000|70 84|cyclohexylamine
P01101272T0000|57 66|Cyclamates
P01101272T0000|15 29|carcinogenicity
P01101272T0000|0 9|Assessment
P01103390A0149|85 89|phase
P01103390A0149|13 21|behaviour
P01103390A0149|69 75|animals
P01103390A0149|101 108|increase
P01103390A0149|38 41|mice
P01103390A0149|53 62|occurrence
P01103390A0149|114 124|parasitemia
P01107226A0808|83 96|mg/ml dose level
P01107226A0808|37 41|feces
P01107226A0808|47 50|mice
P01107226A0808|8 20|amphotericin B
P01113908A0475|42 43|hr
P01113908A0475|90 99|experiment
P01113908A0475|59 64|values
P01113908A0475|50 55|tablet
P01113908A0475|30 40|transferrin
P01113908A0475|15 22|increase
P01116254A0000|179 188|myocardium
P01116254A0000|161 173|concentration
P01116254A0000|82 93|potassium-43
P01116254A0000|211 219|potassium
P01116254A0000|194 194|%
P01116254A0000|227 227|%
P01116254A0000|48 60|concentration
P01116254A0000|20 33|administration
P01116254A0000|130 137|thallium
P01116254A0000|231 238|rubidium
P01116254A0000|125 128|mice
P01116254A0000|243 249|minutes
P01116254A0000|98 108|rubidium-81
P01116254A0000|207 207|%
P01116254A0000|63 80|tracer thallium-201
P01116466A0185|0 17|Thromboplastin time
P01116466A0185|97 111|clotting factors
P01116466A0185|117 120|VIII
P01116466A0185|26 43|thromboplastin time
P01116466A0185|79 92|clot retraction
P01116466A0185|72 77|fibrin
P01116466A0185|125 125|X
P01116466A0185|115 115|V
P01116466A0185|133 145|platelet count
P01116466A0185|45 56|thrombin time
P01118293A0150|87 90|eyes
P01118293A0150|17 22|notion
P01118293A0150|3 6|data
P01118293A0150|61 67|rivalry
P01118293A0150|27 37|suppression
P01118293A0150|40 45|images
P01119586A0337|101 106|hearts
P01119586A0337|35 46|tissue levels
P01119586A0337|122 125|flow
P01119586A0337|67 69|ATP
P01119586A0337|49 65|creatine phosphate
P01119586A0337|74 80|lactate
P01119586A0337|0 18|Glycogen utilization
P01119658A0000|205 207|N2A
P01119658A0000|134 144|hypopharynx
P01119658A0000|95 100|cavity
P01119658A0000|211 213|N2B
P01119658A0000|53 60|patients
P01119658A0000|230 242|neck treatment
P01119658A0000|102 111|oropharynx
P01119658A0000|125 130|larynx
P01119658A0000|3 9|records
P01119658A0000|202 203|N1
P01119658A0000|73 85|cell carcinoma
P01119658A0000|177 195|lymph node metastases
P01119658A0000|262 277|radiation therapy
P01122015A0467|43 49|mumol/1
P01122015A0467|55 62|mg/100 ml
P01122015A0467|7 9|vol
P01122015A0467|12 12|%
P01122015A0467|30 35|values
P01122015A0467|82 89|mg/100 ml
P01122015A0467|70 76|mumol/1
P01123658A0000|128 132|spine
P01123658A0000|62 66|spine
P01123658A0000|137 139|L-4
P01123658A0000|83 93|description
P01123658A0000|21 29|technique
P01123658A0000|104 110|anatomy
P01123658A0000|47 56|tomography
P01123658A0000|3 9|authors
P01123658A0000|145 150|sacrum
P01124944A0830|28 38|protein diet
P01124944A0830|43 46|g/kg
P01124944A0830|15 22|attitude
P01125117A0183|112 117|groups
P01125117A0183|18 24|attacks
P01125117A0183|74 80|changes
P01125117A0183|30 33|type
P01125117A0183|13 16|type
P01125117A0183|2 5|none
P01125117A0183|36 42|attacks
P01128985A0000|101 108|patients
P01128985A0000|76 82|periods
P01128985A0000|27 32|method
P01128985A0000|85 89|apnea
P01130186A0568|73 83|tolbutamide
P01130186A0568|21 27|patient
P01130186A0568|63 70|response
P01130186A0568|47 60|insulin release
P01130531A0224|0 15|Nerve stimulation
P01130531A0224|59 68|reductions
P01130531A0224|71 73|CBF
P01130531A0224|23 30|cycles/s
P01130531A0224|88 94|percent
P01130531A0224|76 83|decrease
P01130531A0224|118 126|frequency
P01131946T0001|0 5|Effect
P01131946T0001|8 16|ingestion
P01131946T0001|19 28|Norbiogest
P01131946T0001|65 70|organs
P01131946T0001|47 52|period
P01138215T0001|0 3|Risk
P01138215T0001|20 28|treatment
P01138215T0001|6 14|infection
P01138215T0001|31 39|fractures
P01138330A0204|70 74|% NaC1
P01138330A0204|110 130|acetylcholine chloride
P01138330A0204|98 107|% solutions
P01138330A0204|6 12|pouches
P01138330A0204|59 66|% glucose
P01138330A0204|52 55|N HC1
P01138330A0204|43 47|% Na C1
P01138330A0204|81 88|% peptone
P01138330A0204|29 37|solutions
P01140184A0342|0 14|Liver microsomes
P01140184A0342|48 69|epoxide hydrase activity
P01140184A0342|105 112|capacity
P01140184A0342|137 139|rat
P01140184A0342|42 42|%
P01140184A0342|115 129|liver microsomes
P01140184A0342|86 86|%
P01141114A0188|56 59|mmHg
P01141114A0188|131 137|effects
P01141114A0188|76 79|PH-v
P01141114A0188|99 104|Pv-CO2
P01141114A0188|170 170|H
P01141114A0188|28 35|increase
P01141114A0188|155 165|temperature
P01141114A0188|68 70|P50
P01141114A0188|14 17|work
P01141114A0188|83 92|degrees C-v
P01145884T0028|34 38|study
P01147436T0000|36 49|progress report
P01147436T0000|11 33|Burkitt Lymphoma Registry
P01147502T0000|0 9|Vitrectomy
P01147502T0000|27 42|instrument system
P01148868A0284|27 38|progesterone
P01148868A0284|51 54|S.E.
P01148868A0284|12 24|clearance rate
P01148868A0284|56 60|1/day
P01150658A0683|55 61|hormone
P01150658A0683|70 71|M.
P01150658A0683|63 68|Sairam
P01150658A0683|4 11|sequence
P01156631A0658|57 62|mEq/kg
P01156631A0658|77 85|treatment
P01156631A0658|152 152|P
P01156631A0658|50 51|SD
P01156631A0658|138 139|SD
P01156631A0658|117 125|treatment
P01156631A0658|3 31|mean plasma sodium concentration
P01156631A0658|145 150|mEq/kg
P01156814T0000|0 8|Editorial
P01156814T0000|31 40|prevention
P01156814T0000|49 69|thromboembolic disease
P01156814T0000|18 24|heparin
P01157191A0536|13 22|dose levels
P01157191A0536|110 123|bladder tumours
P01157191A0536|46 60|sodium cyclamate
P01157191A0536|155 161|tumours
P01157191A0536|187 191|weeks
P01157191A0536|77 87|carcinogens
P01157191A0536|28 42|sodium saccharin
P01157614T0000|0 6|Effects
P01157614T0000|19 26|salience
P01157614T0000|75 82|children
P01157614T0000|32 52|matrix task performance
P01158512T0000|33 38|G-6-PD
P01158512T0000|40 49|deficiency
P01158512T0000|19 31|dehydrogenase
P01158838A0438|49 56|flow rate
P01158838A0438|62 67|ml/min
P01159822A0353|147 150|size
P01159822A0353|105 108|tilt
P01159822A0353|71 84|ultrastructure
P01159822A0353|125 132|increase
P01159822A0353|153 161|lysosomes
P01159822A0353|235 242|granules
P01159822A0353|181 186|bodies
P01159822A0353|91 103|invaginations
P01159822A0353|118 121|axes
P01159822A0353|39 45|animals
P01159822A0353|138 143|number
P01159822A0353|12 20|epithelia
P01159822A0353|200 206|numbers
P01168607A0672|86 100|prothrombin time
P01168607A0672|10 23|administration
P01168607A0672|104 116|serum vitamins
P01168607A0672|37 44|vitamins
P01168607A0672|124 132|intervals
P01168607A0672|121 121|E
P01168908A0000|0 14|Prostaglandins F
P01168908A0000|70 79|vein plasma
P01168908A0000|53 58|artery
P01168908A0000|142 146|cycle
P01168908A0000|41 44|vein
P01168908A0000|16 18|PGF
P01168908A0000|175 198|plasma progesterone levels
P01168908A0000|99 105|tissues
P01168908A0000|115 119|times
P01168956A0552|155 155|h
P01168956A0552|148 152|organ
P01168956A0552|10 13|date
P01168956A0552|121 141|maximum weight decrease
P01168956A0552|105 107|day
P01168956A0552|80 87|placenta
P01168956A0552|18 21|drug
P01168956A0552|64 74|sensitivity
P01168956A0552|43 52|weight gain
P01170143A0247|0 5|Groups
P01170143A0247|70 79|conditions
P01170143A0247|99 107|cylinders
P01170143A0247|26 35|saline mice
P01171020A0711|3 9|effects
P01171020A0711|26 46|nucleus accumbens septi
P01171935A0313|44 49|humans
P01171935A0313|25 41|movement disorders
P01171935A0313|101 113|manifestation
P01171935A0313|84 94|amphetamine
P01171935A0313|69 71|use
P01171935A0313|174 181|striatum
P01171935A0313|3 12|appearance
P01171935A0313|134 164|dopamine receptor site sensitivity
P01171935A0313|74 81|levodopa
P01172734T0035|0 10|Association
P01172734T0035|19 22|W-27
P01172917T0000|0 5|Letter
P01172917T0000|31 39|predictor
P01172917T0000|7 27|Lactose tolerance tests
P01172917T0000|42 54|milk tolerance
P01174873T0000|0 13|Retinoblastoma
P01174873T0000|40 48|prognosis
P01174873T0000|16 20|study
P01174873T0000|54 58|cases
P01174873T0000|30 36|history
P01176905A0094|43 50|mid-dark
P01176905A0094|20 33|serum melatonin
P01176905A0094|10 18|melatonin
P01176905A0094|59 67|mid-light
P01178153A0056|0 1|D.
P01178637T0001|0 14|Atherosclerosis
P01185956A0722|85 91|changes
P01185956A0722|3 9|authors
P01185956A0722|97 108|stroke volume
P01185956A0722|33 52|Doppler-cardiography
P01186344A0303|145 147|ova
P01186344A0303|151 160|end-points
P01186344A0303|136 142|release
P01186344A0303|125 131|pattern
P01186344A0303|53 67|characteristics
P01186344A0303|179 185|process
P01186344A0303|3 12|attainment
P01186344A0303|31 35|terms
P01186344A0303|21 28|maturity
P01186344A0303|100 103|male
P01186344A0303|84 94|spermatozoa
P01186344A0303|72 81|production
P01190120A0832|15 26|% lengthening
P01190120A0832|80 86|storage
P01190120A0832|39 56|thromboplastin time
P01190120A0832|73 77|hours
P01190251A0335|0 6|Caution
P01190251A0335|39 42|dyes
P01190251A0335|46 56|lymphograms
P01190251A0335|29 31|use
P01191955A0077|71 77|varices
P01191955A0077|36 47|incompetence
P01191955A0077|103 108|reflux
P01191955A0077|65 68|cent
P01191955A0077|15 18|test
P01191964A0000|60 65|Graves
P01191964A0000|253 282|serum thyrotrophin concentration
P01191964A0000|216 224|subgroups
P01191964A0000|135 139|years
P01191964A0000|162 175|serum thyroxine
P01191964A0000|44 56|thyroidectomy
P01191964A0000|181 185|level
P01191964A0000|177 179|T-4
P01191964A0000|68 74|disease
P01191964A0000|93 98|goitre
P01191964A0000|13 20|patients
P01191964A0000|123 128|goitre
P01191964A0000|5 10|groups
P01191964A0000|230 234|basis
P01193458T0001|89 94|reflux
P01193458T0001|51 59|detection
P01193458T0001|7 24|isotope cystography
P01193458T0001|63 71|follow-up
P01193458T0001|33 47|Tc sulfur colloid
P01193770T0000|0 11|Air ion action
P01193770T0000|14 21|bacteria
P01194673A0652|2 9|evidence
P01194673A0652|36 46|chemography
P01201977T0000|29 45|disc sensitivities
P01201977T0000|3 16|interpretation
P01202616A0466|91 103|lamina propria
P01202616A0466|9 21|retransfusion
P01202616A0466|123 126|loss
P01202616A0466|139 144|detail
P01202616A0466|44 49|lining
P01206772T0000|1 5|study
P01206772T0000|8 18|chromosomes
P01206772T0000|36 43|patients
P01206772T0000|21 31|lymphocytes
P01206772T0000|55 64|hycanthone
P01206896T0001|45 64|emergency lung surgery
P01206896T0001|0 14|Characteristics
P01206896T0001|17 26|anesthesia
P01206896T0001|30 42|resuscitation
P01208811T0001|0 4|Study
P01208811T0001|49 75|citrate solution-blood system
P01208811T0001|26 30|state
P01208811T0001|33 45|plutonium-239
P01209618A0409|99 104|action
P01209618A0409|37 42|effect
P01209618A0409|76 93|potentiating effect
P01209618A0409|47 55|dibecacin
P01209618A0409|12 13|mg
P01209618A0409|59 60|mg
P01209618A0409|107 120|d-tubocurarine
P01209618A0409|0 9|Tobramycin
P01211754A0192|116 123|deafness
P01211754A0192|74 81|patients
P01211754A0192|20 24|cases
P01211754A0192|60 70|improvement
P01211754A0192|29 37|operation
P01215067A0000|74 86|conductometry
P01215067A0000|49 53|fluid
P01215067A0000|91 95|cases
P01215067A0000|127 142|meningitis serosa
P01215067A0000|153 164|encephalitis
P01215067A0000|179 186|subjects
P01215067A0000|21 30|resistance
P01215067A0000|67 71|means
P01215067A0000|120 124|cases
P01215067A0000|146 150|cases
P01215067A0000|98 116|meningitis purulenta
P01217450A0295|52 56|block
P01217450A0295|75 78|dogs
P01217450A0295|2 18|Chemical occlusion
P01224116A0576|130 135|family
P01224116A0576|80 84|Busey
P01224116A0576|63 65|IgG
P01224116A0576|88 94|Barbeau
P01224116A0576|18 25|patients
P01224116A0576|35 54|serum immunoglobulins
P01224116A0576|74 78|Russe
P01225339A0590|40 43|time
P01225339A0590|49 58|infarction
P01225339A0590|17 26|occlusions
P01228258A0000|101 111|combination
P01228258A0000|128 131|5-FU
P01228258A0000|54 58|agent
P01228258A0000|13 23|preparation
P01228258A0000|37 40|type
P01228258A0000|25 30|OK-432
P01228258A0000|93 98|cancer
P01228258A0000|73 80|patients
P01228258A0000|135 153|Cytosine arabinoside
P01228258A0000|116 126|Mitomycin-C
P01228882A0437|164 171|diseases
P01228882A0437|113 120|response
P01228882A0437|63 80|CSF immunoglobulins
P01228882A0437|11 21|correlation
P01228882A0437|136 144|component
P01228882A0437|84 89|degree
P01228882A0437|47 60|concentrations
P01233561T0001|8 16|lactation
P01235347T0001|12 25|cardiotoxicity
P01235347T0001|28 37|adriamycin
P01236224T0001|8 16|pathology
P01237206A0199|0 12|Demonstration
P01237206A0199|146 160|Coxiella content
P01237206A0199|80 86|methods
P01237206A0199|124 140|antibody technique
P01237206A0199|88 92|Stamp
P01237206A0199|18 22|agent
P01237206A0199|54 60|day p.i.
P01237206A0199|198 200|hen
P01237206A0199|176 184|titration
P01237206A0199|96 111|auramine staining
P01237206A0199|203 206|eggs
P01241437A0152|71 78|morphine
P01241437A0152|81 87|Micoren
P01241437A0152|60 69|nalorphine
P01241437A0152|27 32|groups
P01241437A0152|3 10|patients
P01241437A0152|42 46|NLA II
P01241588A1470|56 60|brain
P01241588A1470|102 105|IDPN
P01241588A1470|23 34|5-HIAA levels
P01241588A1470|44 50|regions
P01241588A1470|108 120|neurotoxicity
P01241588A1470|152 159|neurones
P01241588A1470|16 19|5-HT
P01241588A1470|3 13|alterations
P01241588A1470|69 78|conditions
P01241866A0682|60 64|serum
P01241866A0682|89 95|phase-2
P01241866A0682|77 82|rabbit
P01241866A0682|44 57|administration
P01241866A0682|5 12|increase
P01241866A0682|15 30|leukocyte-counts
P01242636A0678|55 60|system
P01242636A0678|81 98|beryllium retention
P01242636A0678|3 9|results
P01243628A0286|67 70|COHb
P01243628A0286|44 65|blood carboxyhemoglobin
P01243628A0286|22 29|exposure
P01243628A0286|37 41|level
P01243628A0286|17 19|end
P01243628A0286|6 10|cases
P01243628A0286|80 80|%
P01244236A1122|3 9|results
P01244236A1122|215 220|amount
P01244236A1122|243 251|thickness
P01244236A1122|101 109|gestation
P01244236A1122|272 278|vessels
P01244236A1122|229 234|muscle
P01244236A1122|254 259|muscle
P01244236A1122|78 87|resistance
P01244236A1122|138 143|number
P01244236A1122|40 48|blood flow
P01244236A1122|165 183|vasomotor reactivity
P01244236A1122|146 152|vessels
P01244236A1122|197 204|increase
P01244236A1122|120 127|increase
P01245162A0262|0 8|Reduction
P01245162A0262|11 16|dosage
P01245162A0262|63 66|drug
P01245162A0262|109 126|transaminase levels
P01245162A0262|31 40|taste sense
P01246210A0648|95 95|%
P01246210A0648|56 58|men
P01246210A0648|49 52|TBCa
P01246210A0648|73 73|%
P01246210A0648|3 14|calcium ratio
P01246210A0648|79 83|women
P01246210A0648|16 24|mean ratio
P01247475A0000|82 94|deterioration
P01247475A0000|48 51|fact
P01247475A0000|100 106|outlook
P01247475A0000|5 13|diagnosis
P01247475A0000|65 70|growth
P01247475A0000|16 29|retinoblastoma
P01248124A0281|71 79|gestation
P01248124A0281|37 42|fluids
P01248124A0281|63 68|stages
P01248124A0281|5 15|cholesterol
P01249198A1097|3 23|serum FT3 concentration
P01249198A1097|53 58|ranges
P01249198A1097|80 90|GTD patients
P01249198A1097|106 120|hyperthyroidism
P01249198A1097|67 75|pregnancy
P01252223A0347|101 105|Winch
P01252223A0347|124 138|complementarity
P01252223A0347|91 98|contrast
P01252223A0347|119 122|type
P01252223A0347|108 116|principle
P01252223A0347|35 43|pugnacity
P01252223A0347|59 75|trait correlations
P01252223A0347|3 9|authors
P01252223A0347|28 31|fear
P01253191T0000|1 4|note
P01253191T0000|10 43|phase-plane technique representation
P01253191T0000|53 68|action potentials
P01256410T0001|1 10|activities
P01256410T0001|24 31|molecule
P01256410T0001|44 49|infant
P01256410T0001|16 21|factor
P01256410T0001|52 55|term
P01259027A0416|246 253|approach
P01259027A0416|207 213|concept
P01259027A0416|192 200|extension
P01259027A0416|271 283|design problem
P01259027A0416|79 93|model parameters
P01259027A0416|23 37|identifiability
P01259027A0416|156 159|data
P01259027A0416|3 9|concept
P01259027A0416|174 182|procedure
P01259027A0416|55 62|analysis
P01261005A0711|29 37|variation
P01261005A0711|78 85|bandpass
P01261005A0711|93 118|bandpass spectrophotometers
P01261005A0711|54 64|performance
P01261005A0711|41 51|differences
P01262596T0000|11 20|compromise
P01264640T0028|15 20|Saigon
P01264640T0028|1 4|case
P01265443A0159|148 154|stomach
P01265443A0159|10 16|glucose
P01265443A0159|184 189|effect
P01265443A0159|113 125|acid secretion
P01265443A0159|173 178|saline
P01265443A0159|45 63|Heidenhain pouch dogs
P01265443A0159|81 90|inhibition
P01265443A0159|133 137|pouch
P01265887T0001|43 50|patients
P01265887T0001|8 26|factor VIII inhibitor
P01267446A0210|0 15|Biohydrogenation
P01267446A0210|26 29|acid
P01267446A0210|46 49|acid
P01272816A0000|102 105|47Ca
P01272816A0000|69 76|controls
P01272816A0000|44 51|children
P01272816A0000|10 26|calcium metabolism
P01272816A0000|134 143|absorption
P01272816A0000|3 7|study
P01272816A0000|86 99|administration
P01275335A0158|66 70|phase
P01275335A0158|35 39|semen
P01275335A0158|10 15|agents
P01275335A0158|47 49|end
P01275541A0405|130 137|delivery
P01275541A0405|21 31|CPK activity
P01275541A0405|120 124|weeks
P01275541A0405|45 52|newborns
P01275541A0405|87 95|dystrophy
P01276105A0313|14 28|insulin response
P01276105A0313|57 61|value
P01276105A0313|2 9|contrast
P01276105A0313|81 90|puerperium
P01276105A0313|73 75|day
P01278251A0000|73 81|materials
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01278251A0000|50 54|tests
P01278251A0000|29 34|series
P01278251A0000|19 25|results
P01278251A0000|163 172|sensitizer
P01278251A0000|3 9|authors
P01278251A0000|203 211|materials
P01278251A0000|83 94|polyethylene
P01279197T0000|28 41|homology region
P01279197T0000|74 94|saturation mutagenesis
P01279197T0000|44 66|Mason-Pfizer monkey virus
P01279197T0000|10 17|analysis
P01279197T0000|69 71|use
P01279352A0297|3 6|site
P01279352A0297|8 10|PAL
P01279352A0297|29 48|bp sequence GGGGAGGAGG
P01279352A0473|157 164|proteins
P01279352A0473|124 127|PROX
P01279352A0473|91 98|proteins
P01279352A0473|7 14|extracts
P01279352A0473|50 58|cell lines
P01279352A0473|181 195|target sequences
P01279352A0473|60 69|mouse brain
P01279352A0473|131 142|PAL sequences
P01279352A0473|74 83|mouse liver
P01279352A1197|72 82|development
P01279352A1197|21 28|promoter
P01279352A1197|60 65|manner
P01279352A1197|93 96|mice
P01279352A1197|46 51|tissue
P01279352A1197|110 123|promoter region
P01279352A1197|133 162|beta-galactosidase reporter gene
P01279352A1197|19 19|H
P01279352A1197|16 17|NF
P01279374A0396|118 123|PET122
P01279374A0396|106 115|truncation
P01279374A0396|62 72|suppressors
P01279374A0396|30 34|genes
P01279696A0862|60 68|Kishimoto
P01279696A0862|25 32|Hisanaga
P01279696A0862|70 71|T.
P01279696A0862|37 44|Kusubata
P01279696A0862|8 14|studies
P01279696A0862|49 55|Okumura
P01279696A0862|57 58|E.
P01279696A0862|46 47|M.
P01279696A0862|34 35|S.
P01280413T0001|0 8|Treatment
P01280413T0001|53 66|microorganisms
P01280413T0001|12 19|staining
P01280413T0001|31 38|sections
P01280413T0001|22 27|smears
P01280413T0001|42 50|detection
P01280807A0575|18 41|MetRS/CAU operator complex
P01280807A0575|47 60|order magnitude
P01280807A0575|11 12|Kd
P01280807A0575|80 103|ThrRS/CGU operator complex
P01281322A0604|115 122|flow rate
P01281322A0604|77 82|muscle
P01281322A0604|51 68|percent area density
P01281322A0604|89 101|percent change
P01281322A0604|18 29|relationship
P01281472T0000|0 5|Rabbit
P01281472T0000|14 29|muscle glycogenin
P01281771T0000|0 15|Characterization
P01281771T0000|38 48|cytokeratin
P01281771T0000|26 29|gene
P01281771T0000|57 73|expression pattern
P01282014A0275|0 6|Animals
P01282014A0275|51 63|motor recovery
P01282014A0275|79 89|saline group
P01282014A0275|19 23|DSP-4
P01282638A0934|3 17|prophylactic use
P01282638A0934|177 180|life
P01282638A0934|298 304|patient
P01282638A0934|208 219|continuation
P01282638A0934|249 260|interruption
P01282638A0934|106 114|estimates
P01282638A0934|279 292|life expectancy
P01282638A0934|23 32|medication
P01282638A0934|75 86|chemotherapy
P01282638A0934|137 151|health care costs
P01282638A0934|90 98|agreement
P01282638A0934|188 195|patients
P01282638A0934|68 72|cycle
P01282638A0934|168 174|quality
P01282638A0934|36 43|patients
P01282638A0934|234 241|schedule
P01284032A0213|0 1|AP
P01284032A0213|79 82|acid
P01284032A0213|90 93|mmol
P01284032A0213|25 32|infusion
P01284032A0213|84 87|GDOC
P01284032A0213|47 60|concentrations
P01284032A0213|99 102|mmol
P01284595A0102|84 92|sequences
P01284595A0102|54 64|Y-231 cosmid
P01284595A0102|18 21|gene
P01284595A0102|77 79|CpG
P01284595A0102|35 48|identification
P01284595A0102|3 11|isolation
P01284595A0102|94 103|HTF islands
P01284595A0102|115 120|insert
P01284828T0001|59 70|fibrinolysis
P01284828T0001|119 126|prostate
P01284828T0001|47 56|parameters
P01284828T0001|80 87|patients
P01284828T0001|103 113|hypertrophy
P01284828T0001|0 25|Tissue plasminogen activator
P01284828T0001|73 77|blood
P01284828T0001|30 38|inhibitor
P01285009A0000|0 13|Gene constructs
P01285009A0000|187 189|cBA
P01285009A0000|235 244|medaka eggs
P01285009A0000|137 139|vTK
P01285009A0000|191 194|gene
P01285009A0000|45 47|hGH
P01285009A0000|111 113|mMT
P01285009A0000|214 222|cytoplasm
P01285009A0000|80 87|sequence
P01285009A0000|49 52|gene
P01285009A0000|90 109|mouse metallothionein
P01285009A0000|169 185|chicken beta-actin
P01285009A0000|161 164|rCCK
P01285009A0000|251 259|micropyle
P01285009A0000|31 43|growth hormone
P01285009A0000|142 159|rat cholecystokinin
P01285009A0000|121 135|thymidine kinase
P01285358A0396|0 11|Serum gastrin
P01285358A0396|65 72|interest
P01285358A0396|34 42|evolution
P01285358A0396|95 101|disease
P01285358A0396|15 23|AFP levels
P01285358A0396|84 89|course
P01285554T0000|31 37|systems
P01285554T0000|0 8|Prospects
P01285807A0365|14 17|PaO2
P01285807A0365|144 144|P
P01285807A0365|11 12|SD
P01285807A0365|77 84|infusion
P01285807A0365|42 45|mmHg
P01285807A0365|99 103|PaCO2
P01285807A0365|86 86|P
P01285807A0365|3 6|mean
P01285807A0365|139 142|mmHg
P01285807A0365|65 68|mmHg
P01286732A0572|172 183|complication
P01286732A0572|25 33|elevation
P01286732A0572|104 108|liver
P01286732A0572|91 101|involvement
P01286732A0572|82 89|patients
P01286732A0572|6 17|hepatomegaly
P01286732A0572|36 42|enzymes
P01286732A0572|123 131|hepatitis
P01286732A0572|70 79|proportion
P01286732A0572|186 204|P. falciparum malaria
P01286732A0572|134 150|liver cell necrosis
P01287197A0761|113 118|mmol/l
P01287197A0761|135 139|group
P01287197A0761|37 51|plasma potassium
P01287197A0761|148 156|decrement
P01287197A0761|62 71|salbutamol
P01287197A0761|11 15|group
P01287197A0761|198 203|mmol/l
P01287197A0761|27 34|decrease
P01287197A0761|213 214|po
P01287197A0761|210 211|iv
P01292230A0283|42 48|filling
P01292230A0283|22 25|rate
P01292230A0283|6 10|drugs
P01294345A0591|44 57|administration
P01294345A0591|157 163|tension
P01294345A0591|104 119|overreactiveness
P01294345A0591|171 180|weight gain
P01294345A0591|82 89|symptoms
P01294345A0591|128 142|prolactin levels
P01294345A0591|25 35|improvement
P01294345A0591|165 169|edema
P01294345A0591|184 199|breast tenderness
P01294345A0591|60 68|Bromergon
P01295373A0651|41 41|%
P01295373A0651|22 29|response
P01295373A0651|118 118|p
P01295373A0651|100 100|%
P01295373A0651|58 61|mean
P01295373A0651|91 91|B
P01295373A0651|65 66|SE
P01295373A0651|46 56|% baseline RL
P01295373A0651|105 105|C
P01295373A0651|3 11|magnitude
P01295373A0651|115 115|%
P01295373A0651|44 44|A
P01295500A0366|89 96|Deficits
P01295500A0366|9 16|patients
P01295500A0366|47 53|Attacks
P01295500A0366|57 57|%
P01295500A0366|100 100|%
P01296815A0059|57 72|sequence analysis
P01296815A0059|100 109|pseudogene
P01296815A0059|42 50|LD78 gamma
P01296815A0059|21 24|gene
P01296815A0059|31 34|LD78
P01297332A0983|100 107|proposal
P01297332A0983|161 167|element
P01297332A0983|44 47|SCBs
P01297332A0983|26 38|consideration
P01297332A0983|118 134|consensus sequence
P01297332A0983|4 11|analysis
P01297332A0983|84 88|genes
P01297332T0000|68 76|cell cycle
P01297332T0000|49 62|gene expression
P01297332T0000|10 17|analysis
P01297332T0000|21 31|DNA sequence
P01298173A0153|147 156|modalities
P01298173A0153|10 16|history
P01298173A0153|128 132|death
P01298173A0153|168 174|measure
P01298173A0153|111 118|survival
P01298173A0153|68 77|treatments
P01298173A0153|24 30|lesions
P01298173A0153|86 89|part
P01298173A0153|98 109|chemotherapy
P01298173A0153|44 53|efficiency
P01298398A0461|40 55|nadolol racemate A
P01298398A0461|25 37|determination
P01298398A0461|73 88|phase composition
P01298398A0461|59 64|change
P01298398A0461|3 8|method
P01299489A0788|87 97|performance
P01299489A0788|22 26|study
P01299489A0788|128 131|RDIs
P01299489A0788|62 76|supplementation
P01299489A0788|41 48|evidence
P01299489A0788|54 59|effect
P01299489A0788|101 108|athletes
P01300914A1066|171 175|walls
P01300914A1066|611 625|RV abnormalities
P01300914A1066|85 91|results
P01300914A1066|320 321|VT
P01300914A1066|448 463|amplification ECG
P01300914A1066|429 438|potentials
P01300914A1066|684 691|vaulting
P01300914A1066|191 194|ACRV
P01300914A1066|366 376|sensitivity
P01300914A1066|510 520|sensitivity
P01300914A1066|104 110|dangers
P01300914A1066|358 363|degree
P01300914A1066|255 262|criteria
P01300914A1066|414 422|existence
P01300914A1066|340 346|feature
P01300914A1066|697 702|stasis
P01300914A1066|389 399|stimulation
P01300914A1066|180 188|diagnosis
P01300914A1066|72 82|variability
P01300914A1066|26 33|criteria
P01300914A1066|127 132|biopsy
P01300914A1066|532 536|froms
P01300914A1066|275 285|arrhythmias
P01300914A1066|480 483|sign
P01300914A1066|220 228|existence
P01300914A1066|63 66|view
P01300914A1066|401 408|exercise
P01300914A1066|5 11|absence
P01301171A0979|15 22|enhancer
P01301171A0979|35 55|c-myc bearing sequences
P01301171A0979|58 67|chromosome
P01301171A0979|6 10|cases
P01302765A0999|97 98|ad
P01302765A0999|105 114|components
P01302765A0999|54 56|R2s
P01302765A0999|5 14|components
P01302765A0999|29 30|R2
P01304515A0178|55 64|volunteers
P01304515A0178|11 17|results
P01304515A0178|34 45|control group
P01304809T0001|3 7|years
P01304809T0001|10 18|dentistry
P01304809T0001|24 50|Friedrich Schiller University
P01304809T0001|53 56|Jena
P01309244A0798|115 121|context
P01309244A0798|45 48|acts
P01309244A0798|137 144|promoter
P01309244A0798|25 33|positions
P01309244A0798|64 74|orientation
P01309244A0798|87 95|cell types
P01309244A0798|3 8|target
P01309244A0798|99 105|species
P01309587A0715|101 108|Z protein
P01309587A0715|49 66|Z/c-myb combination
P01309587A0715|11 25|transactivation
P01309587A0715|31 43|BMRF1 promoter
P01309587A0715|118 129|c-myb protein
P01309587A0715|89 95|binding
P01309593A0095|3 17|UCR core sequence
P01309593A0095|77 86|regulation
P01309593A0095|89 108|MuLV promoter activity
P01309593A0095|52 57|factor
P01309593A0095|19 27|CGCCATTTT
P01309593A1092|199 210|protein genes
P01309593A1092|39 50|target motifs
P01309593A1092|101 115|virus P5 promoter
P01309593A1092|166 170|genes
P01309593A1092|20 24|UCRBP
P01309593A1092|180 187|elements
P01309593A1092|73 80|UCR motif
P01309593A1092|5 11|studies
P01309593A1092|119 126|elements
P01309593A1092|132 150|immunoglobulin light
P01309815A0972|122 127|arrest
P01309815A0972|12 25|scr1-1 mutation
P01309815A0972|130 141|AEP synthesis
P01309815A0972|71 76|arrest
P01309815A0972|39 55|signal recognition
P01309815A0972|96 106|maintenance
P01309860A0559|144 152|sequences
P01309860A0559|11 19|sequences
P01309860A0559|62 70|% identity
P01309860A0559|80 88|sequences
P01309860A0559|103 115|mouse L1 family
P01309860A0559|32 46|integration site
P01309894A0807|56 65|nucleotide
P01309894A0807|12 16|Rep68
P01309894A0807|4 8|Rep78
P01309894A0807|51 54|site
P01309894A0807|31 41|AAV sequence
P01309910A0428|0 25|Nucleotide sequence analysis
P01309910A0428|49 55|protein
P01309910A0428|74 85|CREB2 protein
P01310154A0879|72 86|transrepression
P01310154A0879|89 98|FBR protein
P01310154A0879|163 181|protein modification
P01310154A0879|5 11|results
P01310154A0879|124 132|mutations
P01310154A0879|187 200|gene regulation
P01310154A0879|28 28|N
P01310154A0879|203 212|FBR protein
P01310154A0879|43 51|mutations
P01310178A0876|39 48|amber codon
P01310178A0876|30 32|gp0
P01310178A0876|110 120|polypeptide
P01310178A0876|154 159|domain
P01310178A0876|3 27|JS78 mutation changes Gln243
P01310178A0876|66 75|production
P01310178A0876|162 186|host transcription shut-off
P01310879A0000|1 16|patient suffering
P01310879A0000|56 58|HAT
P01310879A0000|39 54|thrombocytopenia
P01310879A0000|134 140|heparin
P01310879A0000|113 121|treatment
P01310879A0000|70 86|arteriothromboses
P01310879A0000|101 107|failure
P01310899A0339|89 107|transmembrane domain
P01310899A0339|12 28|receptor structure
P01310899A0339|133 160|serine/threonine kinase domain
P01310899A0339|64 69|domain
P01310935T0000|59 64|enzyme
P01310935T0000|10 14|UbcD1
P01310935T0000|84 101|protein degradation
P01312005A0600|290 300|replication
P01312005A0600|250 254|bases
P01312005A0600|49 52|MDP1
P01312005A0600|223 232|structures
P01312005A0600|173 177|tract
P01312005A0600|26 33|mt genome
P01312005A0600|278 283|origin
P01312005A0600|71 80|chick mtDNA
P01312005A0600|128 138|target sites
P01312005A0600|95 95|H
P01312005A0600|158 158|A
P01312005A0600|285 286|OH
P01312005A0600|61 68|cleavage
P01312005A0600|0 7|Analysis
P01313715A0461|84 91|rp47phox
P01313715A0461|155 159|virus
P01313715A0461|19 23|study
P01313715A0461|104 107|U937
P01313715A0461|126 134|cell lines
P01313715A0461|229 238|CGD patient
P01313715A0461|192 198|EBV-BCL
P01313715A0461|41 51|feasibility
P01313715A0461|72 81|expression
P01313715A0461|97 100|HL60
P01313715A0461|54 63|retrovirus
P01313715A0461|171 190|B-lymphocyte cell line
P01313715A0461|3 6|goal
P01313846A0850|130 145|melanoma Ag MUC-18
P01313846A0850|147 153|members
P01313846A0850|63 91|immunoglobulin gene superfamily
P01313846A0850|52 57|member
P01313846A0850|42 48|Tactile
P01313846A0850|97 106|similarity
P01313846A0850|17 33|sequence databanks
P01313846A0850|187 204|poliovirus receptor
P01313846A0850|218 237|cell adhesion molecule
P01313846A0850|175 182|Ag family
P01313846A0850|0 9|Comparison
P01313894A1179|14 20|pattern
P01313894A1179|78 88|transcripts
P01313894A1179|148 153|levels
P01313894A1179|111 116|subset
P01313894A1179|23 29|results
P01313894A1179|45 51|respect
P01313894A1179|119 124|tumors
P01313894A1179|54 72|LMP2B mRNA expression
P01313909A0526|115 122|sequence
P01313909A0526|79 83|virus
P01313909A0526|140 153|nonsense mutant
P01313909A0526|3 12|phenotypes
P01313909A0526|18 36|ICP0 nonsense mutants
P01313909A0526|181 189|phenotype
P01314457T0000|72 76|L-DNA
P01314457T0000|10 27|nucleotide sequence
P01314457T0000|143 147|virus
P01314457T0000|44 46|kbp
P01314457T0000|49 66|herpesvirus saimiri
P01314457T0000|125 127|HVS
P01314457T0000|106 117|organization
P01314457T0000|85 96|conservation
P01314457T0000|68 70|HVS
P01314457T0000|0 7|Analysis
P01314841A0724|0 8|Treatment
P01314841A0724|64 67|drop
P01314841A0724|48 50|EEG
P01314841A0724|101 108|pressure
P01314841A0724|13 18|MK-801
P01314841A0724|79 82|mm Hg
P01314841A0724|89 92|mean
P01314841A0724|27 42|burst suppression
P01314953A1266|112 120|complexes
P01314953A1266|77 82|domain
P01314953A1266|66 69|HAP3
P01314953A1266|11 37|gel mobility shift experiments
P01314953A1266|2 9|contrast
P01314953A1266|90 102|hap3 mutations
P01314953A1266|60 63|HAP2
P01315706A0000|42 61|adenovirus E1a protein
P01315706A0000|67 85|rat L6 muscle cell line
P01315706A0000|8 22|differentiation
P01316125A0176|136 138|1O2
P01316125A0176|94 96|aid
P01316125A0176|152 155|BHPD
P01316125A0176|201 204|BHPD
P01316125A0176|118 124|ability
P01316125A0176|52 59|radicals
P01316125A0176|99 102|YHPD
P01316125A0176|66 67|OH
P01316125A0176|37 39|1O2
P01316125A0176|183 184|OH
P01316125A0176|71 74|YHPD
P01316125A0176|140 143|YHPD
P01316125A0176|186 189|YHPD
P01316125A0176|3 12|experiment
P01316125A0382|115 118|YHPD
P01316125A0382|96 103|radicals
P01316125A0382|296 297|OH
P01316125A0382|247 251|yield
P01316125A0382|46 51|damage
P01316125A0382|123 128|second
P01316125A0382|54 57|YHPD
P01316125A0382|254 256|1O2
P01316125A0382|164 167|YHPD
P01316125A0382|188 191|BHPD
P01316125A0382|214 219|damage
P01316125A0382|156 161|damage
P01316125A0382|81 83|1O2
P01316125A0382|110 111|OH
P01316125A0382|3 8|points
P01316459A0311|0 3|Acad
P01316461A1083|44 51|peptides
P01316461A1083|167 176|expression
P01316461A1083|183 189|protein
P01316461A1083|23 31|S2 protein
P01316461A1083|127 132|horses
P01316461A1083|157 164|evidence
P01316461A1083|200 206|animals
P01316461A1083|67 68|S2
P01316461A1083|98 101|sera
P01316476A0842|71 80|start sites
P01316476A0842|13 25|TATA sequences
P01316476A0842|53 55|VZV
P01316476A1428|40 42|ORF
P01316476A1428|45 48|gene
P01316476A1428|60 68|induction
P01316476A1428|74 78|genes
P01316476A1428|107 115|induction
P01316476A1428|7 10|gene
P01316476A1428|3 5|ORF
P01316680A0643|17 22|IR5 ORF
P01316680A0643|126 141|C-X2-4-C-X2-15-C
P01316680A0643|25 29|EHV-1
P01316680A0643|152 152|H
P01316680A0643|91 95|match
P01316680A0643|52 61|amino acids
P01316680A0643|101 124|consensus zinc finger motif
P01316680A0643|40 47|sequence
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|143 150|H-X2-4-C
P01316900A0000|60 63|K-12
P01316900A0000|19 40|sulfate activation locus
P01316900A0000|3 13|DNA sequence
P01316903A0296|19 22|form
P01316903A0296|52 54|IIA
P01316903A0296|80 83|form
P01316903A0296|25 37|RNA polymerase
P01316903A0296|96 98|IIO
P01316903A1040|0 15|RNA polymerase IIA
P01316903A1040|53 61|complexes
P01316903A1040|83 93|input enzyme
P01316903A1040|64 72|reactions
P01316903A1040|97 112|RNA polymerase IIA
P01317376A0981|0 19|Fructokinase activity
P01317376A0981|64 71|fructose
P01317376A0981|109 116|increase
P01317376A0981|45 53|Z. mobilis
P01317376A0981|81 87|glucose
P01317376A0981|119 131|frk mRNA levels
P01318310A0000|0 14|Plasma membranes
P01318310A0000|65 82|density lipoprotein
P01318310A0000|107 113|removal
P01318310A0000|25 29|cells
P01318310A0000|135 145|cholesterol
P01318310A0000|84 86|HDL
P01318310A0000|41 57|affinity receptors
P01318739A0410|58 62|VM-26
P01318739A0410|69 81|neurotoxicity
P01318739A0410|47 56|teniposide
P01318739A0410|15 33|patients vincristine
P01320255A0795|115 121|element
P01320255A0795|163 164|L1
P01320255A0795|134 137|role
P01320255A0795|74 83|L1 sequence
P01320255A0795|39 45|element
P01320255A0795|143 155|transcription
P01320255A0795|5 11|results
P01320255A0795|97 109|factor binding
P01320640A0336|0 9|Tumor cells
P01320640A0336|53 59|enolase
P01320640A0336|69 76|glucagon
P01320640A0336|80 82|VIP
P01320640A0336|61 67|insulin
P01321277A0342|96 98|CEF
P01321277A0342|56 58|ROS
P01321277A0342|71 94|chicken embryo fibroblasts
P01321277A0342|52 54|SRC
P01321277A0342|103 124|spindle shape morphology
P01321277A0342|19 21|end
P01321277A0342|35 37|end
P01321277A0342|42 44|ros
P01321277A0342|141 143|UR2
P01321277A0342|26 28|src
P01321277A0664|0 2|ROS
P01321277A0664|87 89|ros
P01321277A0664|79 84|domain
P01321277A0664|8 8|R
P01321277A0664|4 6|SRC
P01321277A0664|32 39|deletion
P01321280A0494|175 190|E7 fusion proteins
P01321280A0494|36 49|E7 gene products
P01321280A0494|165 171|BPV-1 E6
P01321280A0494|11 16|number
P01321280A0494|129 136|antisera
P01321280A0494|20 25|nature
P01321280A0494|78 82|cells
P01321280A0494|31 32|E6
P01321280A0494|95 124|immunoprecipitation experiments
P01321332A0970|219 225|amounts
P01321332A0970|181 195|transactivation
P01321332A0970|168 169|RA
P01321332A0970|106 114|apoAI gene
P01321332A0970|135 152|hepatoma HepG2 cells
P01321332A0970|241 245|ARP-1
P01321332A0970|37 41|site A
P01321332A0970|9 26|transfection assays
P01321332A0970|69 71|RXR
P01321332A0970|120 127|promoter
P01321332A0970|86 100|transactivation
P01321332A0970|158 165|presence
P01321336A0000|28 40|leukemia virus
P01321336A0000|52 72|sequence motif ACAGATGG
P01321336A0000|19 21|Akv
P01321336A0000|3 16|enhancer region
P01321336A0731|85 92|proteins
P01321336A0731|19 26|ALF1 cDNA
P01321336A0731|104 113|amino acids
P01321336A0731|3 16|splice variants
P01321336A0731|58 66|insertion
P01321337A0318|88 94|ability
P01321337A0318|49 51|kDa
P01321337A0318|165 175|calcineurin
P01321337A0318|224 234|calcineurin
P01321337A0318|68 77|properties
P01321337A0318|147 153|subunit
P01321337A0318|196 204|antiserum
P01321337A0318|145 145|B
P01321337A0318|15 23|component
P01321337A0318|43 46|mass
P01321337A0318|101 105|45Ca2
P01321337A1161|44 50|mutants
P01321337A1161|87 93|ability
P01321337A1161|26 37|MATa cna1 cna2
P01321337A1161|52 66|MATa cnb1 mutants
P01321337A1161|127 138|growth arrest
P01324172A0880|0 9|Antibodies
P01324172A0880|50 61|mitochondria
P01324172A0880|29 35|protein
P01324172A0880|44 47|RIM1
P01324385A0329|0 6|METHODS
P01324385A0329|217 228|control group
P01324385A0329|98 109|seronegative
P01324385A0329|23 27|HHV-6
P01324385A0329|150 154|stage
P01324385A0329|130 134|HIV-1
P01324385A0329|68 85|immunofluorescence
P01324385A0329|91 94|IVDA
P01324385A0329|164 168|IV-C1
P01324385A0329|213 215|age
P01324385A0329|195 202|subjects
P01324385A0329|8 20|IgG antibodies
P01324385A0329|171 173|CDC
P01324385A0329|29 42|anti-HHV-6-IgG
P01324404A0813|131 140|amino acids
P01324404A0813|93 108|carboxyl terminus
P01324404A0813|114 129|HNF-3 beta protein
P01324404A0813|60 66|regions
P01324404A0813|21 36|activation domain
P01324404A1208|0 8|HNF-3 beta
P01324404A1208|94 99|region
P01324404A1208|50 55|region
P01324404A1208|23 31|sequences
P01324404A1208|121 133|participation
P01324404A1208|139 156|region II-III domain
P01324404A1208|75 89|transactivation
P01324404A1208|102 109|activity
P01324406A1250|130 138|sequences
P01324406A1250|94 98|rates
P01324406A1250|8 12|roles
P01324406A1250|101 111|instability
P01324406A1250|15 18|RAD5
P01324406A1250|55 63|DNA repair
P01324406A1250|72 82|maintenance
P01324406A1250|27 52|ATPase/DNA helicase activity
P01324639T0000|0 15|Susceptibilities
P01324639T0000|64 78|amoxicillin-BRL
P01324639T0000|109 120|temafloxacin
P01324639T0000|52 62|amoxicillin
P01324639T0000|85 107|amoxicillin-clavulanate
P01324639T0000|43 49|bacilli
P01324639T0000|125 135|clindamycin
P01325221A0870|46 54|detection
P01325221A0870|76 84|MBP kinase
P01325221A0870|10 15|arrest
P01325221A0870|104 115|p41 MAP kinase
P01325221A0870|133 146|chromatography
P01325221A0870|18 27|DU249 cells
P01325386A0766|3 16|hit1-1 mutation
P01325386A0766|49 64|heat shock protein
P01325386A0766|24 29|defect
P01325386A0766|32 40|synthesis
P01326329A0703|193 222|glucocorticoid response elements
P01326329A0703|157 172|activator protein
P01326329A0703|44 50|CAP site
P01326329A0703|180 184|sites
P01326329A0703|146 155|CCAAT boxes
P01326329A0703|175 178|Ap-2
P01326329A0703|224 227|GREs
P01326329A0703|99 106|presence
P01326329A0703|109 117|sequences
P01326329A0703|71 74|lack
P01326329A0703|127 133|GC boxes
P01326329A0703|246 264|AMP response elements
P01326329A0703|135 144|CACCC boxes
P01326329A0703|86 92|TATA box
P01326329A0703|266 269|CREs
P01326329A0703|6 19|base pair region
P01326557T0000|0 6|Cloning
P01326557T0000|17 25|structure
P01326557T0000|106 110|brain
P01326557T0000|28 35|neurocan
P01326557T0000|74 103|chondroitin sulfate proteoglycan
P01327280A0000|60 61|pH
P01327280A0000|25 34|chloralose
P01327280A0000|125 134|electrodes
P01327280A0000|110 110|K
P01327280A0000|38 44|changes
P01327280A0000|105 106|pH
P01327280A0000|75 88|cord dorsal horn
P01327280A0000|65 65|K
P01327280A0000|2 5|rats
P01327758A0000|0 10|Replication
P01327758A0000|42 44|DNA
P01327758A0000|103 111|E2 protein
P01327758A0000|36 40|BPV-1
P01327758A0000|77 85|E1 protein
P01327758A0000|19 34|papillomavirus-1
P01327758A0000|61 72|gene products
P01327967A0668|119 124|serine
P01327967A0668|11 22|inactivation
P01327967A0668|25 27|sms
P01327967A0668|68 94|agent methylmethane sulfonate
P01327967A0668|105 115|requirement
P01327967A0668|132 142|metabolites
P01327967A0668|42 52|sensitivity
P01328197A0985|27 60|MAP kinase activator/MAP kinase system
P01328197A0985|91 119|ras signal transduction pathways
P01328197A0985|79 88|components
P01328197A0985|5 12|findings
P01328219A1397|0 5|NSCL-1
P01328219A1397|39 47|cell lines
P01328219A1397|26 31|number
P01328681A0149|89 101|transcription
P01328681A0149|168 177|inhibition
P01328681A0149|197 198|A.
P01328681A0149|131 138|proteins
P01328681A0149|47 66|c-myc hyperexpression
P01328681A0149|108 117|activities
P01328681A0149|180 195|protein synthesis
P01328681A0149|17 24|proteins
P01328681A0348|0 6|Ruddell
P01328681A0348|8 9|M.
P01328854T0000|42 48|element
P01328854T0000|156 166|muscle cells
P01328854T0000|93 99|subunit
P01328854T0000|60 72|transcription
P01328854T0000|110 135|phosphoglycerate mutase gene
P01328854T0000|7 15|MEF-2 site
P01328884T0000|0 17|Truncation variants
P01328884T0000|66 79|sequence motifs
P01328884T0000|40 47|MHC class
P01328884T0000|50 58|molecules
P01328884T0000|20 27|peptides
P01329039A0239|130 137|proteins
P01329039A0239|63 73|nucleotides
P01329039A0239|107 111|genes
P01329039A0239|11 24|E-box consensus
P01329039A0239|45 50|CANNTG
P01329039A0239|86 92|E-boxes
P01329039A0951|115 128|Ig kappa E2 E-box
P01329039A0951|20 31|gene activity
P01329039A0951|90 92|MCK
P01329039A0951|97 105|E-box site
P01329039A0951|69 75|E-boxes
P01329039A0951|47 58|TnI enhancers
P01329039A0951|0 17|Intermediate levels
P01330077A0000|0 17|T-cell receptor beta
P01330077A0000|89 97|leukemias
P01330077A0000|19 25|TCR beta
P01330077A0000|65 70|B-cell
P01330077A0000|99 102|ALLs
P01330077A0000|27 44|gene rearrangements
P01330309A1134|3 14|CANNTG motifs
P01330309A1134|113 120|myotubes
P01330309A1134|76 83|proteins
P01330309A1134|37 58|myogenin fusion proteins
P01330309A1134|30 33|MyoD
P01330309A1134|93 100|extracts
P01330975T0000|46 52|myeloma
P01330975T0000|10 23|polyneuropathy
P01331057A0000|40 43|gene
P01331057A0000|24 28|COX12
P01331057A0000|47 56|subunit VIb
P01331057A0000|82 99|cytochrome c oxidase
P01331060A0768|17 32|calcineurin A gene
P01331060A0768|73 85|cDNA sequences
P01331060A0768|48 57|comparison
P01331060A0768|3 11|structure
P01331086T0000|59 62|gene
P01331086T0000|8 23|promoter elements
P01331086T0000|90 98|ets motifs
P01331086T0000|121 140|transcription factors
P01331086T0000|32 56|cytochrome c oxidase subunit
P01331292A1425|100 106|variola
P01331292A1425|65 71|repeats
P01331292A1425|23 31|instances
P01331292A1425|78 83|region
P01331292A1425|109 121|vaccinia virus
P01331292A1425|44 58|oligonucleotide
P01331501A0397|28 35|peptides
P01331501A0397|105 108|p107
P01331501A0397|90 100|interaction
P01331501A0397|71 73|E1A
P01331501A0397|110 116|cyclin A
P01331501A0397|121 124|p130
P01331501A0397|60 68|sequences
P01331516A0103|115 125|C2 myoblasts
P01331516A0103|91 112|coinfection experiments
P01331516A0103|26 48|3T6 mouse fibroblast cells
P01331516A0103|5 11|mutants
P01331516A0103|84 88|virus
P01332589A0666|13 20|compound
P01332589A0666|78 85|S. aureus
P01332589A0666|38 46|organisms
P01332589A0666|125 137|micrograms/ml
P01332589A0666|30 30|%
P01332589A0666|3 6|MICs
P01332964A0247|68 75|elements
P01332964A0247|23 33|RII beta gene
P01332964A0247|10 17|promoter
P01333035T0000|0 6|Mapping
P01333035T0000|74 86|RNA polymerase
P01333035T0000|10 39|cAMP receptor protein contact site
P01333035T0000|45 56|alpha subunit
P01333047A0404|157 173|threonine residues
P01333047A0404|126 135|Nck protein
P01333047A0404|53 75|growth factor stimulation
P01333047A0404|23 34|growth factor
P01333047A0404|138 145|tyrosine
P01333047A0404|109 123|phosphorylation
P01333047A0404|147 152|serine
P01333047A0404|97 101|cells
P01333053A0110|121 124|ACTH
P01333053A0110|106 119|peptide hormone
P01333053A0110|138 141|cAMP
P01333053A0110|22 56|steroid hydroxylase gene transcription
P01333053A0110|6 14|mechanism
P01333053A0110|80 85|cortex
P01333125A0000|132 137|region
P01333125A0000|96 112|structure elements
P01333125A0000|139 141|UTR
P01333125A0000|25 40|sequence analysis
P01333125A0000|166 177|rhinoviruses
P01333125A0000|150 162|enteroviruses
P01333125A0000|57 63|methods
P01333125A0000|1 11|combination
P01333125A0000|74 85|conservation
P01333317A1008|58 64|protein
P01333317A1008|94 94|s
P01333317A1008|38 40|Sp1
P01333317A1008|66 66|s
P01333317A1008|10 15|region
P01333317A1008|98 102|PRF-I
P01333317A1008|87 92|factor
P01334428A1102|0 1|Km
P01334428A1102|52 54|Glu
P01334428A1102|37 43|peptide
P01334428A1102|5 8|Vmax
P01334428A1102|102 103|mM
P01334428A1102|47 50|poly
P01334428A1102|110 123|mumol min-1 mg-1
P01334428A1102|15 24|substrates
P01334428A1102|56 58|Tyr
P01334428A1102|81 94|mumol min-1 mg-1
P01334428A1102|73 74|mM
P01334493A0289|100 107|receptor
P01334493A0289|25 29|sHGFr
P01334493A0289|11 14|form
P01334493A0289|36 38|HGF
P01334493A0289|45 52|affinity
P01334493A0289|20 23|HGFr
P01334518T0000|0 9|Strategies
P01334518T0000|62 82|immunodeficiency virus
P01334518T0000|13 26|blood screening
P01334518T0000|89 98|risk groups
P01334518T0000|33 47|hepatitis C virus
P01337142A2043|13 45|glycoprotein alpha-subunit promoter
P01337142A2043|65 67|FSK
P01337142A2043|114 118|WORDS
P01337142A2043|92 99|ABSTRACT
P01337142A2043|70 75|GH4 rat
P01337142A2043|85 89|cells
P01338867A0503|0 9|Comparison
P01338867A0503|12 15|data
P01338867A0503|151 156|extent
P01338867A0503|168 177|activation
P01338867A0503|110 117|blockade
P01338867A0503|47 55|treatment
P01338867A0503|69 78|antagonist
P01338867A0503|31 37|results
P01338867A0503|186 191|system
P01338867A0503|130 142|fatiguability
P01339125A0153|0 16|Laboratory studies
P01339125A0153|114 124|bleach teeth
P01339125A0153|106 111|enamel
P01339125A0153|22 25|Ca45
P01339125A0153|81 90|dentifrice
P01339125A0153|33 37|teeth
P01339125A0153|60 64|teeth
P01339373T0000|0 8|Structure
P01339373T0000|25 28|gene
P01339373T0000|77 93|SNF1 protein kinase
P01339373T0000|12 21|expression
P01339373T0000|61 67|protein
P01339373T0000|33 51|Arabidopsis thaliana
P01339391A0000|42 60|DNA surrounding HRAS1
P01339391A0000|34 39|region
P01339468A0272|157 164|proteins
P01339468A0272|79 82|ORF2
P01339468A0272|110 118|analogues
P01339468A0272|94 101|proteins
P01339468A0272|55 77|potexvirus RNA replicases
P01339468A0272|3 13|ORF1 protein
P01339468A0272|127 131|potex
P01339773A0000|1 5|total
P01339773A0000|127 134|analysis
P01339773A0000|11 18|patients
P01339773A0000|64 72|diagnosis
P01339773A0000|105 114|spirometry
P01339773A0000|93 103|capnography
P01339773A0000|34 39|groups
P01339773A0778|116 141|ventilation-perfusion ratio
P01339773A0778|103 110|increase
P01339773A0778|3 15|relationships
P01339773A0778|49 51|CO2
P01339773A0778|33 41|pressures
P01339773A0778|72 80|gradients
P01339815A1545|57 61|tests
P01339815A1545|13 24|correlations
P01339815A1545|27 33|peak VO2
P01340470A0000|67 85|RNA recognition motif
P01340470A0000|13 23|protein gene
P01340470A0000|25 28|rbp1
P01340470A0000|103 104|RS
P01340470A0000|91 97|Arg-Ser
P01340470A0000|106 111|domain
P01341119A0450|59 67|ingestion
P01341119A0450|34 37|kind
P01341119A0450|4 18|research studies
P01341119A0450|70 81|H2 inhibitors
P01341119A0450|40 45|tumors
P01341119A0450|85 97|others antacid
P01346262A0377|174 180|protein
P01346262A0377|12 16|study
P01346262A0377|78 81|UC21
P01346262A0377|53 68|S. entomophila UC9
P01346262A0377|27 41|protein profiles
P01346262A0377|130 136|protein
P01346534T0000|0 15|Characterization
P01346534T0000|21 27|regulon
P01346534T0000|71 77|protein
P01347476T0000|0 6|Mapping
P01347476T0000|12 25|mouse ornithine
P01347476T0000|47 60|sequence family
P01347664A1026|72 77|mutant
P01347664A1026|50 56|CAD mRNA
P01347664A1026|60 66|protein
P01347664A1026|4 11|mutation
P01347664A1026|42 47|levels
P01347908T0000|62 70|Parkinson
P01347908T0000|37 47|stimulation
P01347908T0000|50 57|patients
P01347908T0000|73 79|disease
P01347908T0000|3 11|rationale
P01347944A0964|91 100|regulation
P01347944A0964|37 58|homeodomain binding site
P01347944A0964|61 68|sequence
P01347944A0964|10 16|studies
P01348504A0757|68 75|distance
P01348504A0757|8 30|pol alpha-primase complex
P01348508A0313|59 68|comparison
P01348508A0313|208 214|introns
P01348508A0313|194 197|date
P01348508A0313|112 121|activities
P01348508A0313|76 80|genes
P01348508A0313|136 145|literature
P01348508A0313|153 160|TGM1 gene
P01348508A0313|33 39|introns
P01348508A0313|17 25|positions
P01348590A0000|145 153|diagnosis
P01348590A0000|67 72|cohort
P01348590A0000|180 185|agents
P01348590A0000|218 224|outcome
P01348590A0000|103 107|stage
P01348590A0000|125 127|CD4
P01348590A0000|26 29|data
P01348590A0000|110 120|HIV-disease
P01348590A0000|36 40|cases
P01348590A0000|161 163|use
P01348590A0000|16 23|analysis
P01348590A0000|139 142|time
P01348590A0000|188 199|radiotherapy
P01348590A0000|91 98|patients
P01348590A0000|54 61|lymphoma
P01349705T0000|0 6|Effects
P01349705T0000|9 15|dioxins
P01349705T0000|18 32|thyroid function
P01349705T0000|42 47|babies
P01349837T0000|0 9|cDNA clones
P01349837T0000|116 124|heat shock
P01349837T0000|78 91|gene expression
P01349837T0000|98 112|seed germination
P01349837T0000|40 46|Zea mays
P01349837T0000|18 36|Arabidopsis thaliana
P01349837T0000|60 74|chaperonin HSP60
P01350780A0184|0 26|Amino acid sequence comparison
P01350780A0184|46 53|homology
P01350780A0184|64 68|yeast
P01350780A0184|123 129|lengths
P01350780A0184|87 107|gamma-glutamyl kinases
P01350932A1123|115 130|disulphide bridge
P01350932A1123|108 111|part
P01350932A1123|81 91|Asn-Cys-Ser
P01350932A1123|9 12|site
P01350932A1123|59 79|N-glycosylation sequon
P01350932A1123|44 53|C-terminus
P01350932A1123|15 27|glycosylation
P01350932A1123|100 102|Cys
P01352113A0002|95 109|inhalation model
P01352113A0002|53 54|NO
P01352113A0002|37 51|nitrogen dioxide
P01352113A0002|81 83|rat
P01352113A0002|57 64|exposure
P01352113A0002|134 141|measures
P01352113A0002|17 22|events
P01352113A0231|100 102|ppm
P01352113A0231|105 110|ppm NO2
P01352113A0231|12 18|effects
P01352113A0231|116 123|mg m-3 NO2
P01352113A0231|153 155|min
P01352113A0231|128 140|exposure times
P01352113A0231|62 78|NO2 concentrations
P01353478T0000|0 10|Interaction
P01353478T0000|13 17|H-2Eb
P01353478T0000|24 41|IAP retrotransposon
P01353478T0000|47 65|A20/2J B cell lymphoma
P01354506T0000|105 111|history
P01354506T0000|80 93|histopathology
P01354506T0000|39 46|advances
P01354506T0000|24 31|diseases
P01354506T0000|52 64|understanding
P01354506T0000|67 78|cytogenetics
P01357190A0726|130 134|cells
P01357190A0726|111 116|fusion
P01357190A0726|73 85|glycoproteins
P01357190A0726|7 15|exception
P01357190A0726|38 57|membrane anchor domain
P01357190A0726|18 24|mutants
P01357190A0726|97 103|ability
P01357528A0084|211 224|enterobacteria
P01357528A0084|141 148|strain 3b
P01357528A0084|73 86|subunit protein
P01357528A0084|48 60|amino terminus
P01357528A0084|169 174|fibres
P01357528A0084|105 112|fimbriae
P01357528A0084|192 208|surface organelles
P01357528A0084|185 189|class
P01357528A0084|63 68|SEF-17
P01357528A0084|19 23|curli
P01357528A0084|3 16|subunit protein
P01358190A0654|0 11|Substitution
P01358190A0654|74 95|alpha chain substitution
P01358190A0654|110 115|effect
P01358190A0654|62 72|recognition
P01358190A0654|33 41|H-2E beta k
P01358190A0654|17 28|DR1 beta chain
P01358190A0654|56 59|loss
P01358592A0752|57 64|cell fate
P01358592A0752|114 119|region
P01358592A0752|89 93|state
P01358592A0752|125 130|embryo
P01358592A0752|22 28|pathway
P01358758A0000|117 127|combination
P01358758A0000|9 15|portion
P01358758A0000|61 76|sequence elements
P01358758A0000|87 98|FLAT elements
P01358758A0000|47 49|DNA
P01358758A0000|21 35|rat insulin I gene
P01358758A0000|182 189|enhancer
P01358758A0000|81 83|Far
P01358880A0251|65 88|transglutaminase sequence
P01358880A0251|38 46|% identity
P01358880A0251|10 26|amino acid sequence
P01359588A0375|73 80|elements
P01359588A0375|37 43|network
P01359588A0375|4 14|computation
P01360180A0513|88 99|recombinants
P01360180A0513|35 47|baculoviruses
P01360180A0513|144 149|domain
P01360180A0513|68 73|kinase
P01360180A0513|8 14|efforts
P01360180A0513|124 129|kinase
P01360180A0513|152 159|mutation
P01360180A1568|27 42|P68 amino terminus
P01360180A1568|135 153|reporter gene product
P01360180A1568|176 178|RNA
P01360180A1568|122 131|properties
P01360180A1568|82 86|dsRNA
P01360294A0000|57 64|subjects
P01360294A0000|104 115|antithrombin
P01360294A0000|88 93|plasma
P01360294A0000|126 133|activity
P01360294A0000|4 9|August
P01360294A0000|80 85|levels
P01360294A0000|16 22|October
P01360294A0000|45 49|women
P01363080A0710|122 130|diuretics
P01363080A0710|143 161|anhydrase inhibitors
P01363080A0710|37 43|changes
P01363080A0710|6 11|acuity
P01363080A0710|95 112|agent metronidazole
P01363080A0710|69 80|sulfonamides
P01363080A0710|56 60|error
P01363166T0001|43 51|treatment
P01363166T0001|17 37|H2 receptor antagonists
P01363166T0001|54 59|ulcers
P01363166T0001|0 14|Currents aspects
P01364100A0377|2 9|addition
P01364100A0377|18 35|subrepeat structure
P01364100A0377|55 58|unit
P01370281A0461|0 9|Sequencing
P01370281A0461|57 63|protein
P01370281A0461|30 41|reading frame
P01370446A0818|5 9|sites
P01370446A0818|26 54|keratan sulfate attachment sites
P01371181A0688|87 101|characteristics
P01371181A0688|43 49|pADB201
P01371181A0688|108 117|regulation
P01371181A0688|125 135|copy numbers
P01371181A0688|37 41|pE194
P01371181A0688|59 63|share
P01371181A0688|54 57|pLB4
P01371181A0688|26 35|pLS1 family
P01371181A0688|13 20|plasmids
P01371272A1167|0 11|Perturbation
P01371272A1167|38 55|frameshift fidelity
P01371272A1167|14 22|dNTP pools
P01371272A1167|72 94|yeast DNA polymerase alpha
P01371275T0000|30 36|subunit
P01371275T0000|12 21|expression
P01371275T0000|55 60|ATPase
P01371275T0000|50 50|H
P01371275T0000|69 75|tissues
P01371275T0000|28 28|B
P01371413A0742|14 23|hGCSFR gene
P01371413A0742|76 93|segregation pattern
P01371413A0742|51 70|Southern blot analysis
P01371413A0742|146 154|cDNA probe
P01371413A0742|104 125|rodent-human hybrid DNAs
P01371413A0742|97 101|panel
P01371413A0742|2 9|addition
P01371863A0000|70 96|protozoan parasite Leishmania
P01371863A0000|55 64|gene family
P01372365A1202|56 56|M
P01372365A1202|37 50|concentrations
P01372365A1202|12 13|%T
P01372365A1202|6 10|sites
P01372365A1202|105 114|conditions
P01372365A1202|34 35|Cl
P01372365A1202|70 76|sites %T
P01372456A0426|0 7|Necrosis
P01372456A0426|72 72|h
P01372456A0426|45 50|extent
P01372456A0426|102 110|% necrosis
P01372456A0426|76 82|animals
P01372456A0426|64 64|%
P01372456A0426|22 31|TA infusion
P01372456A0426|58 58|h
P01372456A0426|92 95|area
P01372456A0426|16 16|h
P01372456A0426|42 42|%
P01372802A1481|237 244|residues
P01372802A1481|221 228|segments
P01372802A1481|370 376|protein
P01372802A1481|277 284|epitopes
P01372802A1481|110 110|D
P01372802A1481|155 165|C3 fragments
P01372802A1481|107 108|C3
P01372802A1481|23 24|C3
P01372802A1481|272 273|C3
P01372802A1481|38 54|amino acid residues
P01372802A1481|275 275|D
P01372802A1481|13 20|segments
P01372802A1481|191 209|fluid-phase fragment
P01372802A1481|321 322|C3
P01372802A1481|112 119|epitopes
P01372802A1481|356 364|fragments
P01372802A1481|2 8|summary
P01372900A0448|30 34|exons
P01372900A0448|91 112|alpha s1-casein variant A
P01372900A0448|65 81|amino acid residues
P01372900A0448|132 133|F.
P01372900A0448|5 9|exons
P01372900A1017|101 134|polymerase chain reaction experiments
P01372900A1017|37 48|organization
P01372900A1017|54 88|goat alpha s1-casein transcription unit
P01373374A0735|0 9|Homodimers
P01373374A0735|52 61|G-box motif
P01373374A0735|67 70|GBF1
P01373374A0735|115 122|sequence
P01373374A0735|20 27|proteins
P01373374A0735|74 84|GBF3 binding
P01374331A0636|44 52|start site
P01374331A0636|62 79|nuclease S1 analysis
P01374331A0636|7 10|gene
P01374392A0341|57 61|NHE-2
P01374392A0341|49 53|NHE-1
P01374392A0341|23 27|NHE-3
P01374392A0341|3 20|hydrophobicity plot
P01374398A0951|111 114|acid
P01374398A0951|40 43|cDNA
P01374398A0951|138 154|amino acid residues
P01374398A0951|127 127|%
P01374398A0951|52 54|kDa
P01374398A0951|10 27|translation protein
P01374398A0951|79 98|amino acid composition
P01374688A0471|96 110|micrograms/kg/0
P01374688A0471|49 60|% pentastarch
P01374688A0471|33 46|% pentafraction
P01374688A0471|113 116|hr E.
P01374688A0471|19 23|ml/kg
P01374688A0471|64 69|plasma
P01374688A0471|81 85|hours
P01374688A0471|4 8|group
P01375224A0152|147 162|growth regulation
P01375224A0152|129 136|proteins
P01375224A0152|41 45|v-Crk
P01375224A0152|111 118|activity
P01375224A0152|21 28|evidence
P01375224A0152|71 94|chicken embryo fibroblasts
P01375224A0152|55 68|transformation
P01375913A0484|141 147|plasmid
P01375913A0484|53 64|U14 snRNA gene
P01375913A0484|94 120|T7 RNA polymerase promoter site
P01375913A0484|32 50|DNA oligonucleotides
P01376319T0000|0 3|Gene
P01376319T0000|22 26|mouse
P01376319T0000|7 16|pseudogene
P01376319T0000|43 68|mannose 6-phosphate receptor
P01377696A0000|3 7|chick
P01377696A0000|23 52|surface glycoprotein neurofascin
P01377696A0000|107 137|antibody perturbation experiments
P01377696A0000|82 94|fasciculation
P01377696A0000|73 78|growth
P01377764A0309|60 64|layer
P01377764A0309|88 92|layer
P01377764A0309|34 43|epithelium
P01377764A0309|3 11|carcinoma
P01377818A0468|2 9|addition
P01377818A0468|11 19|C/EBP beta
P01377818A0468|23 32|C/EBP gamma
P01377818A0468|79 88|C/EBP alpha
P01377962A1012|2 9|contrast
P01377962A1012|11 21|tobacco GS-2
P01377962A1012|62 67|organs
P01377962A1012|53 56|size
P01377962A1012|34 41|subunits
P01378052A0594|87 89|N18
P01378052A0594|68 75|symmetry
P01378052A0594|160 163|NifA
P01378052A0594|108 110|N14
P01378052A0594|82 84|N11
P01378052A0594|153 156|NtrC
P01378052A0594|77 79|CAC
P01378052A0594|103 105|N10
P01378052A0594|113 115|ACA
P01378052A0594|14 20|acoXABC
P01378052A0594|41 49|sequences
P01378052A0594|132 140|sequences
P01378052A0594|98 100|TGT
P01378052A0594|34 38|types
P01378052A0594|92 94|GTG
P01378052A0594|7 10|acoR
P01378052A0594|172 189|activator sequences
P01378127A0841|42 58|calcium antagonist
P01378127A0841|11 17|effects
P01378127A0841|23 39|calcium supplement
P01378127A0841|95 103|responses
P01378431A0202|0 1|C.
P01378431A0202|10 12|Hsu
P01378431A0202|36 37|J.
P01378431A0202|20 34|Vallejo-Ramirez
P01378431A0202|7 8|J.
P01378431A0202|39 44|Inouye
P01378431A0202|52 57|Inouye
P01378431A0202|3 5|Sun
P01378431A0202|46 47|S.
P01378431A0202|14 18|M.-Y.
P01378431A0202|59 60|M.
P01378506A0884|16 34|full-deletion mutant
P01378506A0884|96 108|virus assembly
P01378506A0884|82 83|NC
P01378506A0884|48 52|block
P01378506A0884|55 66|virus release
P01378526A0535|29 45|FK506 plasma levels
P01378526A0535|66 75|appearance
P01378526A0535|82 87|effect
P01379032A0495|112 121|prednisone
P01379032A0495|108 109|mg
P01379032A0495|78 82|group
P01379032A0495|62 72|steroid dose
P01379032A0495|125 127|day
P01379032A0495|94 101|steroids
P01379032A0495|6 12|percent
P01379032A0495|15 22|patients
P01379032A0495|40 47|steroids
P01379150A0996|157 171|risk arrhythmias
P01379150A0996|143 149|therapy
P01379150A0996|126 133|patients
P01379150A0996|78 84|profile
P01379150A0996|5 15|cibenzoline
P01379150A0996|113 117|class
P01379150A0996|43 47|agent
P01379150A0996|119 123|drugs
P01380062A0097|45 55|T lymphocyte
P01380062A0097|121 123|Y-5
P01380062A0097|97 108|CTL clones Y-1
P01380062A0097|110 112|Y-2
P01380062A0097|114 116|Y-3
P01380062A0097|61 79|recognition epitopes
P01380062A0097|57 59|CTL
P01380062A0097|87 93|targets
P01380062A0097|0 7|T antigen
P01380076A0165|42 60|paired-ion technique
P01380076A0165|32 37|column
P01380076A0165|94 103|components
P01380076A0165|71 84|docusate sodium
P01380076A0165|3 8|method
P01380454A0451|85 103|Fos-Jun heterodimers
P01380454A0451|228 241|ATF/CREB family
P01380454A0451|43 51|ref-1 gene
P01380454A0451|65 82|DNA binding activity
P01380454A0451|125 144|Hela cell AP-1 proteins
P01380454A0451|105 121|Jun-Jun homodimers
P01380454A0451|24 37|protein product
P01380454A0451|200 208|NF-kappa B
P01380454A0451|210 212|Myb
P01380454A0451|216 222|members
P01380454A0451|171 190|transcription factors
P01380716A0174|9 15|tissues
P01380716A0174|77 90|calcium hydrate
P01380716A0174|40 45|molars
P01380825A0622|0 19|Northern blot analyses
P01380825A0622|52 56|mRNAs
P01380825A0622|165 172|function
P01380825A0622|128 134|protein
P01380825A0622|95 101|tissues
P01380825A0622|75 78|cDNA
P01383690A1023|3 14|ARG SH2 domain
P01383690A1023|38 45|affinity
P01383690A1023|49 51|BCR
P01383690A1023|105 116|ABL SH2 domain
P01383695A0100|56 61|embryo
P01383695A0100|90 98|IgM lambda
P01383695A0100|12 25|EBV B-cell clone
P01383695A0100|79 86|IgM kappa
P01383695A0100|27 31|E29.1
P01384040A1043|119 123|pCF10
P01384040A1043|81 91|orientation
P01384040A1043|18 27|activation
P01384040A1043|47 53|regions
P01384165A0000|70 76|trachea
P01384165A0000|130 134|stage
P01384165A0000|20 25|effect
P01384165A0000|106 115|epithelium
P01384165A0000|50 64|vascularization
P01384165A0000|30 36|omentum
P01384165A0000|144 159|tracheal grafting
P01384165A0000|2 5|rats
P01384165A0000|82 93|regeneration
P01384229A0175|234 237|gene
P01384229A0175|230 232|CAT
P01384229A0175|167 182|herpes TK promoter
P01384229A0175|105 113|BF-IV gene
P01384229A0175|91 99|sequences
P01384229A0175|152 157|copies
P01384229A0175|26 29|role
P01384229A0175|44 53|chicken ICS
P01384229A0175|239 245|pBLCAT2
P01384229A0175|197 228|chloramphenicol acetyl transferase
P01384229A0175|57 71|oligonucleotide
P01385462A0151|132 144|determination
P01385462A0151|150 159|monoamines
P01385462A0151|58 61|runs
P01385462A0151|103 119|acid determination
P01386210A0293|100 116|GM2 gangliosidosis
P01386210A0293|88 90|man
P01386210A0293|21 23|use
P01386210A0293|53 61|treatment
P01386210A0293|70 79|depression
P01386210A0293|43 49|therapy
P01386897A0000|56 59|form
P01386897A0000|65 75|CDC28 kinase
P01386897A0000|121 124|CLN1
P01386897A0000|105 111|cyclins
P01386897A0000|7 16|yeast cells
P01386897A0000|133 135|ref
P01386897A0000|128 131|CLN2
P01386897A0000|31 39|cell cycle
P01386897A0000|41 45|Start
P01386897A0000|0 4|Entry
P01387105A0933|29 31|DNA
P01387105A0933|151 159|sequences
P01387105A0933|208 223|mouse chromosomes
P01387105A0933|77 83|strains
P01387105A0933|95 105|cell hybrids
P01387105A0933|171 183|loci Cycb1-rs1
P01387105A0933|241 241|X
P01387105A0933|186 194|Cycb1-rs9
P01387105A0933|135 140|cyclin
P01387105A0933|7 26|Southern blot analyses
P01387105A0933|36 44|backcross
P01387105A0933|55 58|mice
P01387105A0933|117 120|loci
P01388160A1102|156 162|Ser-107
P01388160A1102|106 120|peptide sequence
P01388160A1102|21 24|beta
P01388160A1102|148 154|Ser-106
P01388160A1102|139 145|choices
P01388160A1102|68 81|epsilon peptide
P01388160A1102|166 172|Ser-108
P01388160A1102|5 18|residue Glu-381
P01388160A1102|54 60|residue
P01389362T0000|0 8|Porcelain
P01389362T0000|34 47|dentin adhesive
P01389362T0000|17 28|bond strength
P01389573A1071|82 83|P2
P01389573A1071|29 38|difference
P01389573A1071|61 71|measurement
P01389573A1071|73 76|TBPf
P01389573A1071|87 88|A1
P01389573A1071|90 91|A2
P01389573A1071|79 80|P1
P01389573A1071|16 23|quotient
P01389573A1071|0 3|TBPf
P01389585A0825|95 100|choice
P01389585A0825|73 92|dentine bonding agents
P01389585A0825|18 27|Scotchbond
P01389585A0825|32 50|Prisma Universal Bond
P01391001A0583|99 105|methods
P01391001A0583|50 50|%
P01391001A0583|26 38|yeasts species
P01391001A0583|67 75|ATB method
P01391001A0583|41 45|total
P01392012A0228|19 29|vasopressin
P01392012A0228|144 147|Hays
P01392012A0228|132 140|van Dongen
P01392012A0228|108 115|activity
P01392012A0228|63 75|pressor effect
P01392012A0228|33 47|oxytocin content
P01392012A0228|85 92|Dekanski
P01392277A0000|28 33|status
P01392277A0000|36 46|regulations
P01392277A0000|154 161|standard
P01392277A0000|64 76|swimming pools
P01392277A0000|80 84|baths
P01392277A0000|167 169|No.
P01392277A0000|113 126|KOK regulations
P01392277A0000|96 105|connection
P01392277A0000|57 61|water
P01392277A0000|163 165|DIN
P01392277A0000|0 7|Comments
P01392358A0389|4 8|reply
P01392358A0389|39 48|home visits
P01392358A0389|21 36|telephone contact
P01394200A0592|84 103|rebound lymphocytosis
P01394200A0592|33 48|T-cell activation
P01394200A0592|142 152|interleukin
P01394200A0592|166 171|CD45RO
P01394200A0592|62 72|lymphopenia
P01394200A0592|154 161|receptor
P01394200A0592|107 118|upregulation
P01394200A0592|124 140|subset markers CD25
P01394200A0592|181 185|cells
P01394200A0592|3 16|treatment group
P01394655A0615b|84 87|tube
P01394655A0615b|101 118|Jack bean meal urease
P01394655A0615b|34 50|ammonia production
P01394655A0615b|26 31|amount
P01394655A0615b|89 91|S/N
P01394655A0615b|79 80|ng
P01394655A0615b|55 58|urea
P01394655A0615b|0 13|Urease activity
P01395755A1023|84 95|oxygen uptake
P01395755A1023|178 183|ml/min
P01395755A1023|24 34|differences
P01395755A1023|105 110|ml/min
P01395755A1023|128 128|p
P01395755A1023|66 72|methods
P01395755A1023|185 185|p
P01395755A1023|242 242|p
P01395755A1023|204 209|output
P01395755A1023|220 224|L/min
P01395755A1023|236 240|L/min
P01395755A1023|161 166|ml/min
P01395755A1023|137 150|oxygen delivery
P01395755A1023|121 126|ml/min
P01396432A0388|29 37|functions
P01396432A0388|94 110|memory performance
P01396432A0388|61 67|seizure
P01396432A0388|82 91|assessment
P01396432A0388|13 17|range
P01396444A0934|128 135|activity
P01396444A0934|172 179|recovery
P01396444A0934|29 39|micromilieu
P01396444A0934|164 169|degree
P01396444A0934|72 73|AM
P01396444A0934|3 13|experiments
P01396444A0934|95 110|activation states
P01396444A0934|45 51|alveoli
P01396444A0934|58 66|condition
P01396572A0320|74 85|plasmid pUC19
P01396572A0320|114 120|segment
P01396572A0320|107 111|dG-dC
P01396572A0320|21 32|plasmid pUC19
P01396572A0320|126 131|Z-form
P01396572A0320|87 88|CG
P01396572A0320|146 155|competitor
P01396583A0204|1 11|cDNA library
P01396583A0204|42 52|interleukin
P01396583A0204|67 71|probe
P01396583A0204|14 24|tumour cells
P01396592A1113|41 46|target
P01396592A1113|148 162|differentiation
P01396592A1113|62 86|transcription factor GATA-1
P01396592A1113|28 34|SCL gene
P01396592A1113|3 13|experiments
P01396592A1113|128 136|regulator
P01396592A1113|97 110|SCL gene product
P01396601A0986|98 105|homology
P01396601A0986|21 27|domains
P01396601A0986|37 41|Stl1p
P01396601A0986|30 35|Sec12p
P01396601A0986|68 71|size
P01396601A0986|45 49|Stl2p
P01396601A0986|2 9|contrast
P01398068A0948|0 8|Complexes
P01398068A0948|45 50|his273
P01398068A0948|37 42|his175
P01398068A0948|57 67|p53 proteins
P01398068A0948|98 111|RGC DNA sequence
P01398071A0526|120 127|activity
P01398071A0526|77 88|BRF1 activity
P01398071A0526|130 143|RNA polymerases
P01398071A0526|58 65|extracts
P01398071A0526|152 154|III
P01398071A0526|5 15|temperature
P01398071A0526|34 40|strains
P01398073A0986|89 99|stimulation
P01398073A0986|109 125|activation domains
P01398073A0986|143 150|promoter
P01398073A0986|5 11|results
P01398073A0986|54 65|TFIID protein
P01398074A0697|44 46|RNA
P01398074A0697|75 100|RNase MRP enzyme preparations
P01398074A0697|3 14|gene sequence
P01398074A0697|54 61|yeast RNA
P01398074A1081|41 51|replacement
P01398074A1081|120 123|role
P01398074A1081|127 134|RNase MRP
P01398074A1081|3 17|RNase MRP RNA gene
P01398074A1081|84 92|viability
P01398098A0770|0 17|Clone pSRc200 hybrid
P01398098A0770|47 57|translation
P01398098A0770|28 31|mRNA
P01398098A0770|73 83|polypeptide
P01398104A0834|59 65|protein
P01398104A0834|101 106|factor
P01398104A0834|30 36|CArG box
P01398104A0834|9 15|results
P01398104A0834|17 21|CBF-A
P01398104A0834|39 43|ssDNA
P01398106A0754|0 7|Cleavage
P01398106A0754|48 49|bp
P01398106A0754|27 32|enzyme
P01398106A0754|34 39|I-CreI
P01398106A0754|91 94|exon
P01398106A0754|63 81|intron insertion site
P01398106A0754|119 125|strands
P01398106A0754|101 103|top
P01398106A0754|186 194|OH termini
P01398106A0754|54 55|bp
P01398106A0754|110 115|bottom
P01398106A0754|170 178|overhangs
P01398140A0488|87 88|bp
P01398140A0488|125 132|location
P01398140A0488|104 106|PSE
P01398140A0488|63 68|motifs
P01398140A0488|146 147|bp
P01398140A0488|16 28|Xenopus U7 gene
P01399206A0375|3 9|results
P01399206A0375|24 30|reports
P01399206A0375|78 93|blister formation
P01399206A0375|115 134|epidermolysis bullosa
P01399206A0375|35 55|collagenase inhibitors
P01400217T0000|72 82|involvement
P01400217T0000|65 68|traG
P01400217T0000|91 106|phage sensitivity
P01400217T0000|10 17|analysis
P01400217T0000|29 61|IncP alpha plasmid transfer genes traF
P01400217T0000|85 88|traF
P01400396A1265|3 10|promoter
P01400396A1265|35 47|phorbol esters
P01400396A1265|109 126|protein kinase C beta
P01400396A1265|97 106|activation
P01400401A0065|42 47|muscle
P01400401A0065|137 144|criteria
P01400401A0065|65 66|E2
P01400401A0065|52 56|liver
P01400401A0065|40 40|M
P01400401A0065|101 107|variety
P01400401A0065|2 7|humans
P01400401A0065|68 78|erythrocyte
P01400401A0065|50 50|L
P01400401A0065|59 60|E1
P01400401A0065|13 32|AMP deaminase variants
P01400401A0854|106 115|expression
P01400401A0854|128 136|AMPD3 cDNA
P01400401A0854|40 55|immunoreactivity
P01400401A0854|75 82|extracts
P01400401A0854|0 18|Western blot analyses
P01400775A0435|5 11|results
P01400775A0435|95 99|brain
P01400775A0435|66 83|N-methylsalsolinol
P01400775A0435|37 49|N-methylation
P01400775A0435|52 61|salsolinol
P01402647A0114|0 11|DR1 molecules
P01402647A0114|110 121|phage surface
P01402647A0114|80 95|peptide sequences
P01402647A0114|43 51|cell lines
P01403222A0391|73 85|blood donation
P01403222A0391|45 49|woman
P01403222A0391|36 39|care
P01403222A0391|4 10|article
P01403222A0391|101 111|transfusion
P01403391T0000|7 16|hepatitis B
P01403391T0000|34 41|children
P01404401A0740|85 99|chloroplast gene
P01404401A0740|9 21|ATPase cluster
P01404401A0740|30 42|reading frames
P01404612A0303|72 79|proteins
P01404612A0303|53 55|HIV
P01404612A0303|93 109|vaccine candidates
P01404612A0303|26 28|Ads
P01406630A0545|0 8|Alignment
P01406630A0545|209 216|proteins
P01406630A0545|165 176|DNA sequences
P01406630A0545|50 66|consensus sequence
P01406630A0545|185 203|sequence specificity
P01406630A0545|22 30|sequences
P01406630A0545|114 121|proteins
P01406630A0545|137 151|binding analysis
P01406630A0545|70 76|binding
P01406630A0965|114 120|binding
P01406630A0965|12 14|p50
P01406630A0965|30 40|kappa B motif
P01406630A0965|79 85|respect
P01406630A0965|152 167|NF-kappa B complex
P01406630A0965|68 74|binding
P01406630A0965|96 102|protein
P01406656A1075|96 98|DNA
P01406656A1075|53 56|gene
P01406656A1075|39 48|mouse alpha
P01406656A1075|163 165|ras
P01406656A1075|81 82|kb
P01406656A1075|70 71|kb
P01406656A1075|121 126|levels
P01406656A1075|129 139|fibroblasts
P01406656A1075|15 19|clone
P01406677A0000|150 168|nucleotide positions
P01406677A0000|23 37|control elements
P01406677A0000|67 76|expression
P01406677A0000|87 99|myoglobin gene
P01406677A0000|231 244|luciferase gene
P01406677A0000|140 148|sequences
P01406677A0000|205 213|start site
P01406677A0000|122 129|analysis
P01406688A0898|0 17|Sequencing analysis
P01406688A0898|54 69|nonsense mutation
P01406688A0898|34 44|rap1t allele
P01406688A0898|98 107|amino acids
P01406688A0898|85 90|region
P01406703A1435|58 65|H-2RIIBP
P01406703A1435|149 153|cells
P01406703A1435|73 91|hormone receptor cDNA
P01406703A1435|12 28|Y1 cell cDNA library
P01406703A1435|47 52|region
P01406703A1435|104 107|cDNA
P01407286A0427|101 106|traces
P01407286A0427|79 83|brain
P01407286A0427|23 30|survival
P01407286A0427|61 71|integration
P01407286A0427|48 52|cells
P01407286A0427|135 142|reaction
P01407286A0427|146 164|tyrosine hydroxylase
P01407286A0427|0 6|Autopsy
P01408090A0572|54 61|arteries
P01408090A0572|3 11|technique
P01408090A0572|17 32|TEE visualization
P01408137A0974|114 117|% G+C
P01408137A0974|102 110|mRNA start
P01408137A0974|3 10|sequence
P01408137A0974|45 45|%
P01408137A0974|32 41|G+C content
P01408137A0974|17 22|region
P01408137A0974|85 86|bp
P01408219A0670|105 112|analysis
P01408219A0670|10 17|patients
P01408219A0670|89 93|nodes
P01408219A0670|67 75|nontender
P01408219A0670|129 139|hyperplasia
P01408219A0670|43 58|lymph-adenopathy
P01408219A0670|60 62|PGL
P01408474A0531|0 12|PaO2 threshold
P01408474A0531|35 44|indwelling
P01408474A0531|47 60|sensor catheter
P01409581A0206|99 102|site
P01409581A0206|34 38|v-ets
P01409581A0206|68 75|factor PU
P01409581A0206|18 20|E26
P01409643A0618|147 153|protein
P01409643A0618|7 26|lambda gt11 expression
P01409643A0618|226 231|factor
P01409643A0618|77 97|immunodeficiency virus
P01409643A0618|205 215|TATA element
P01409643A0618|38 53|oligonucleotides
P01409643A0618|99 109|TATA element
P01409643A0618|187 189|kDa
P01409643A0618|122 135|identification
P01409643A0618|178 181|mass
P01409643A0618|233 235|TMF
P01410071T0000|0 10|Blood levels
P01410071T0000|23 31|serotonin
P01410071T0000|78 83|rhythm
P01410071T0000|33 40|cortisol
P01410071T0000|56 63|relation
P01410071T0000|45 53|prolactin
P01410071T0000|86 108|platelet serotonin uptake
P01410071T0000|13 21|melatonin
P01413984A0737|144 155|antithrombin
P01413984A0737|96 100|apo A1
P01413984A0737|289 301|blood pressure
P01413984A0737|108 112|HbA1C
P01413984A0737|81 94|LDL cholesterol
P01413984A0737|262 265|time
P01413984A0737|102 103|Lp
P01413984A0737|160 188|plasminogen activator inhibitor
P01413984A0737|219 250|von Willebrand factor concentration
P01413984A0737|133 142|factor VIII
P01413984A0737|19 24|effect
P01413984A0737|190 215|tissue plasminogen activator
P01413984A0737|30 46|FA supplementation
P01413984A0737|66 79|HDL cholesterol
P01413984A0737|114 120|glucose
P01413984A0737|122 131|fibrinogen
P01413984A0737|54 64|cholesterol
P01414219A0319|42 52|differences
P01414219A0319|112 114|OXC
P01414219A0319|10 19|volunteers
P01414219A0319|55 57|AUC
P01414219A0319|95 107|concentration
P01414219A0319|149 151|ERY
P01414219A0319|59 82|peak plasma concentrations
P01414219A0319|85 88|time
P01418272A1072|39 41|CEA
P01418272A1072|6 10|ng/mL
P01418272A1072|47 47|%
P01418272A1072|16 21|cutoff
P01418272A1072|26 36|sensitivity
P01418494T0000|8 13|spikes
P01418494T0000|26 33|function
P01418542A0000|3 8|effect
P01418542A0000|38 40|SGA
P01418542A0000|11 16|sodium
P01418542A0000|19 36|beta-glycyrrhetate
P01418542A0000|56 65|arrhythmia
P01418834A0987|42 42|P
P01418834A0987|39 39|H
P01418834A0987|143 143|P
P01418834A0987|65 68|fall
P01418834A0987|12 29|hematocrit decrease
P01418834A0987|71 83|blood pressure
P01418834A0987|125 128|mm Hg
P01418860A0797|74 82|diltiazem
P01418860A0797|193 196|role
P01418860A0797|204 215|interactions
P01418860A0797|12 20|diltiazem
P01418860A0797|138 146|diltiazem
P01418860A0797|48 59|potentiation
P01418860A0797|165 186|calcium channel blockade
P01418860A0797|111 115|cases
P01418860A0797|3 9|effects
P01419945A1386|0 11|Localization
P01419945A1386|76 87|interscalene
P01419945A1386|38 52|nerve stimulator
P01419945A1386|116 120|sites
P01419945A1386|25 30|plexus
P01420177A1065|42 44|Ser
P01420177A1065|136 143|activity
P01420177A1065|106 111|enzyme
P01420177A1065|34 38|Gly28
P01420177A1065|81 94|protein kinases
P01420177A1065|68 75|residues
P01420177A1065|20 24|Val33
P01420177A1065|28 30|Gly
P01420177A1065|0 11|Substitution
P01420223T0000|0 11|Significance
P01420223T0000|56 66|fiber typing
P01420223T0000|17 26|biopsy site
P01420223T0000|32 52|latissimus dorsi muscle
P01420363A0818|142 153|consensus TRE
P01420363A0818|111 117|binding
P01420363A0818|175 181|factors
P01420363A0818|51 64|c-Fos/c-Jun AP1
P01420363A0818|37 41|motif
P01420363A0818|127 136|AP1 factors
P01420363A0818|3 6|TIMP
P01420363A0818|207 218|consensus TRE
P01420363A0818|160 167|addition
P01420363A0818|16 22|AP1 site
P01420363A0818|98 107|competitor
P01420363T0000|0 10|Involvement
P01420363T0000|75 94|metalloproteinases-1
P01420363T0000|13 15|AP1
P01420363T0000|19 34|PEA3 binding sites
P01420363T0000|96 101|TIMP-1
P01420363T0000|103 115|transcription
P01420363T0000|40 49|regulation
P01420363T0000|58 72|tissue inhibitor
P01420579A0292|131 141|vaccination
P01420579A0292|23 24|SN
P01420579A0292|26 33|antibody
P01420579A0292|52 52|%
P01420579A0292|95 99|month
P01420579A0292|5 21|serum neutralizing
P01420579A0292|67 67|%
P01420579A0292|84 93|SN antibody
P01420579A0292|42 47|calves
P01421145A1190|0 12|Fractionation
P01421145A1190|37 65|heparin-agarose chromatography
P01421145A1190|79 84|PCAT-1
P01421145A1190|27 34|extracts
P01421145A1190|102 109|extracts
P01421145A1190|135 144|leaf tissue
P01421390T0000|90 104|body irradiation
P01421390T0000|187 194|leukemia
P01421390T0000|74 79|factor
P01421390T0000|115 126|chemotherapy
P01421390T0000|11 15|trial
P01421390T0000|206 213|lymphoma
P01421390T0000|141 165|bone marrow transplantation
P01421609A1067|54 59|trauma
P01421609A1067|64 66|CPB
P01421609A1067|24 27|DMVA
P01421609A1067|108 114|support
P01421609A1067|5 8|data
P01422265A0263|112 115|IgG4
P01422265A0263|129 137|magnitude
P01422265A0263|107 110|IgG3
P01422265A0263|76 83|controls
P01422265A0263|102 105|IgG2
P01422265A0263|153 169|subclass responses
P01422265A0263|32 45|coeliac disease
P01422265A0263|3 20|IgG subclass profile
P01422265A0263|186 200|coeliac patients
P01422265A0263|85 88|IgG1
P01423454A0309|86 95|vasculitis
P01423454A0309|106 114|indicator
P01423454A0309|38 49|contribution
P01423454A0309|152 164|effectiveness
P01423454A0309|13 16|ANCA
P01423454A0309|120 127|activity
P01423454A0309|70 78|diagnosis
P01423454A0309|133 139|disease
P01423454A0309|184 192|treatment
P01423454A0309|0 10|Examination
P01423738A0639|121 127|rhythms
P01423738A0639|104 115|deceleration
P01423738A0639|20 31|pinealectomy
P01423738A0639|10 13|hand
P01423738A0639|129 140|mean delta tau
P01423738A0639|147 147|h
P01423738A0639|69 75|rabbits
P01424674A0000|43 49|disease
P01424674A0000|11 20|pemphigoid
P01424674A0000|84 96|cicatrization
P01425653T0000|88 92|women
P01425653T0000|3 9|effects
P01425653T0000|23 39|caffeine ingestion
P01425653T0000|60 76|oxygen consumption
P01425653T0000|15 20|levels
P01425921A1286|161 164|V1J1
P01425921A1286|38 53|amino acid changes
P01425921A1286|153 158|region
P01425921A1286|103 119|consensus sequence
P01425921A1286|71 84|lysine deletion
P01425921A1286|17 24|features
P01426635A0496|18 22|ZFH-2
P01426635A0496|34 36|CNS
P01426635A0496|9 15|profile
P01426635A0496|88 102|dopamine neurons
P01426635A0496|63 65|DDC
P01426635A0496|76 84|serotonin
P01427034A0440|42 53|protein genes
P01427034A0440|90 97|S13 genes
P01427034A0440|145 150|length
P01427034A0440|9 15|introns
P01427034A0440|162 168|introns
P01427034A0440|120 131|DNA sequences
P01427034A0440|141 142|bp
P01427457A0000|131 143|sodium heparin
P01427457A0000|188 190|DVT
P01427457A0000|76 77|SC
P01427457A0000|51 58|efficacy
P01427457A0000|149 157|treatment
P01427457A0000|33 37|trial
P01427457A0000|98 98|h
P01427457A0000|100 113|calcium heparin
P01427457A0000|177 186|thrombosis
P01428490A0671|158 161|past
P01428490A0671|70 78|shortness
P01428490A0671|81 86|breath
P01428490A0671|48 52|cough
P01428490A0671|54 59|wheeze
P01428490A0671|10 19|prevalence
P01428490A0671|61 67|attacks
P01428490A0671|149 152|pets
P01428490A0671|135 142|children
P01428490A0671|119 124|asthma
P01428490A0671|30 39|pet allergy
P01428513A0440|45 51|persons
P01429596A1669|88 121|18K agglutination-aggregation factor
P01429596A1669|5 9|basis
P01429596A1669|23 32|properties
P01429596A1669|55 67|hemagglutinin
P01429596A1669|123 129|18K-LAF
P01429624A0328|87 94|activity
P01429624A0328|97 111|adenylylcyclase
P01429624A0328|61 66|guanyl
P01429624A0328|26 36|temperature
P01429624A0328|55 58|loss
P01429624A0328|3 7|shift
P01429714A0730|0 3|Clin
P01429724A0664|83 88|Gly451
P01429724A0664|38 43|domain
P01429724A0664|67 71|Ile59
P01429724A0664|92 97|Leu455
P01429724A0664|75 79|Phe96
P01429724A0664|3 6|data
P01429724A0664|46 50|Nmt1p
P01429740A1065|70 75|domain
P01429740A1065|39 49|presequence
P01429740A1065|92 96|exons
P01429740A1065|122 127|E2 gene
P01429768T0000|61 65|alloy
P01429768T0000|35 42|exposure
P01429768T0000|45 48|F-75
P01429768T0000|5 22|neutrophil response
P01429836A0457|0 9|Disruption
P01429836A0457|12 23|microtubules
P01429836A0457|125 136|microtubules
P01429836A0457|67 80|protein sorting
P01429836A0457|39 46|fidelity
P01429836A0457|49 56|kinetics
P01429836A0457|96 108|Vps1p function
P01429836A1205|13 17|Vps1p
P01429836A1205|45 50|domain
P01429836A1205|7 10|form
P01429836A1205|98 102|cells
P01429836A1205|73 86|protein sorting
P01431380A0244|286 293|antibody
P01431380A0244|225 235|rickettsiae
P01431380A0244|215 222|findings
P01431380A0244|246 256|patient sera
P01431380A0244|416 420|gland
P01431380A0244|334 341|electron
P01431380A0244|106 110|ticks
P01431380A0244|325 329|ticks
P01431380A0244|179 182|mice
P01431380A0244|147 162|group rickettsiae
P01431380A0244|355 366|observations
P01431380A0244|305 318|hemolymph cells
P01431380A0244|201 213|tick emulsions
P01431380A0244|164 167|SFGR
P01431380A0244|65 68|area
P01431380A0244|369 372|SFGR
P01431380A0244|14 26|field research
P01431380A0244|390 395|organs
P01431380A0244|169 176|antibody
P01431380A0244|423 427|ticks
P01431380A0244|296 299|JSFR
P01431380A0244|31 39|tick fauna
P01431380A0244|116 122|vectors
P01431602A0229|20 24|macro
P01431602A0229|62 81|micrograms phosphorus
P01431602A0229|36 51|sensitivity range
P01431602A0229|26 30|assay
P01431602A0229|9 14|method
P01431602A0229|93 108|microliters HClO4
P01431809T0000|0 17|Nucleotide sequence
P01431809T0000|49 62|polyhedrin gene
P01431809T0000|65 80|Spodoptera exigua
P01431809T0000|36 43|analysis
P01431809T0000|88 104|polyhedrosis virus
P01432453T0000|0 9|Validation
P01432453T0000|21 27|systems
P01432453T0000|30 45|system definition
P01433391A0594|98 102|value
P01433391A0594|165 168|area
P01433391A0594|66 69|area
P01433391A0594|40 46|density
P01433391A0594|3 13|consequence
P01433391A0594|20 26|rearing
P01433391A0594|127 133|kittens
P01433391A0594|57 63|neurons
P01433502A1163|72 76|cells
P01433502A1163|138 143|factor
P01433502A1163|38 53|enhancer activity
P01433502A1163|162 170|repressor
P01433502A1163|111 116|levels
P01433502A1163|90 93|part
P01433502A1163|32 36|class
P01433502A1163|5 11|results
P01433524A0788|92 101|activities
P01433524A0788|39 48|amino acids
P01433524A0788|51 53|IE1
P01433524A0788|7 12|domain
P01435698A0000|2 6|order
P01435698A0000|23 40|blood compatibility
P01435698A0000|77 88|prostacyclin
P01435698A0000|63 65|AVG
P01435698A0000|90 93|PGI2
P01435698A0000|95 104|production
P01435698A0000|114 123|harvesting
P01435698A0000|53 61|vein graft
P01435698A0000|68 74|changes
P01435698A0000|135 146|implantation
P01436261A0145|133 145|disappearance
P01436261A0145|154 165|incontinence
P01436261A0145|108 118|improvement
P01436261A0145|66 75|micrograms
P01436261A0145|181 196|calcitonin levels
P01436261A0145|121 129|diarrhoea
P01436261A0145|52 61|octreotide
P01436261A0145|31 50|somatostatin analogue
P01436261A0145|0 25|Subcutaneous administration
P01437562A0462|129 132|gene
P01437562A0462|39 46|extracts
P01437562A0462|64 72|agreement
P01437562A0462|49 61|C.fasciculata
P01437562A0462|8 17|antibodies
P01437562A0462|80 83|size
P01437562A0462|30 36|protein
P01437562A0462|100 117|nucleotide sequence
P01438224A0749|49 50|J.
P01438287T0000|59 63|genes
P01438287T0000|14 27|vaccinia vector
P01441120T0000|0 2|Use
P01441120T0000|16 23|minerals
P01441818T0001|0 13|Interferon type
P01441818T0001|56 74|Klebsiella infection
P01441818T0001|27 39|body reactions
P01443047A0773|29 49|differentiation status
P01443047A0773|64 74|association
P01443047A0773|79 94|Id-SCL expression
P01443047A0773|7 13|changes
P01443745T0000|58 66|midazolam
P01443745T0000|11 21|interaction
P01443745T0000|33 42|anesthesia
P01443745T0000|46 53|sedation
P01443748A1190|3 10|pressure
P01443748A1190|128 136|movements
P01443748A1190|25 30|atm abs
P01443748A1190|60 67|tadpoles
P01443748A1190|43 54|excitability
P01446132A0328|3 13|air embolism
P01446132A0328|37 42|filter
P01446132A0328|63 74|complication
P01446828A1088|13 16|ADH5
P01446828A1088|25 45|consensus binding sites
P01446828A1088|114 118|NF-E1
P01446828A1088|90 92|AP2
P01446828A1088|77 84|proteins
P01446828A1088|5 10|region
P01446828A1088|94 98|LF-A1
P01446828A1088|105 109|NF-A2
P01446828A1088|86 88|Sp1
P01446828A1088|100 103|NF-1
P01447139A0208|0 1|V.
P01447189A1546|85 92|granules
P01447189A1546|108 118|lymphocytes
P01447189A1546|21 29|RNK-Met-1
P01447189A1546|33 46|serine protease
P01447189A1546|5 8|data
P01447189A1546|57 64|activity
P01447189T0000|15 21|cloning
P01447189T0000|62 69|granules
P01447189T0000|83 100|killer cell leukemia
P01447189T0000|45 53|RNK-Met-1
P01447189T0000|30 43|serine protease
P01447189T0000|73 75|rat
P01447189T0000|0 11|Purification
P01448107A0361|80 86|absence
P01448107A0361|89 107|amino acid starvation
P01448107A0361|61 74|GCN4 expression
P01448107A0361|24 36|GCN2 mutations
P01448107A0361|47 58|derepression
P01448806A0135|0 13|Administration
P01448806A0135|62 75|bone maturation
P01448806A0135|16 28|growth hormone
P01448806A0135|42 47|growth
P01448917A0775|314 323|polymerase
P01448917A0775|155 162|CPSMV RNA
P01448917A0775|211 228|proteinase cofactor
P01448917A0775|47 65|sequence information
P01448917A0775|281 284|RNAs
P01448917A0775|250 252|VPg
P01448917A0775|123 142|clover mottle virus RNA
P01448917A0775|81 87|CPMV RNA
P01448917A0775|303 305|87K
P01448917A0775|27 42|amino acid residue
P01448917A0775|340 352|cleavage sites
P01448917A0775|110 117|sequence
P01448917A0775|241 248|helicase
P01448917A0775|89 96|sequence
P01448917A0775|44 45|aa
P01448917A0775|184 186|set
P01448917A0775|230 232|58K
P01448917A0775|286 298|24K proteinase
P01448917A0775|262 268|protein
P01448917A0775|199 206|proteins
P01448917A0775|0 10|Comparisons
P01448932T0000|0 41|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|14 20|utility
P01449183A0795|2 9|addition
P01449183A0795|23 26|beta
P01449183A0795|49 57|diagnosis
P01449183A0795|73 85|fluid otorrhea
P01449183A0795|28 43|transferrin assay
P01449301A0710|0 15|Cold cardioplegia
P01449301A0710|35 38|mm Hg
P01449301A0710|46 52|minutes
P01449301A0710|57 61|hours
P01450815A0337|29 32|IPRK
P01450815A0337|61 66|change
P01450815A0337|75 77|GFR
P01450815A0337|69 71|RPF
P01450815A0337|148 155|decrease
P01450815A0337|111 118|increase
P01450815A0337|3 10|addition
P01450815A0337|13 23|diatrizoate
P01451771A0619|189 196|husbands
P01451771A0619|153 155|MDS
P01451771A0619|67 70|data
P01451771A0619|114 116|PCA
P01451771A0619|12 19|analyses
P01451771A0619|174 185|health scores
P01451771A0619|137 151|scaling analysis
P01451771A0619|95 112|components analysis
P01451771A0619|27 41|family variables
P01451771A0619|203 207|wives
P01452037A0000|266 279|gap amber mutant
P01452037A0000|26 64|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|98 100|PGK
P01452037A0000|149 151|TIM
P01452037A0000|13 17|genes
P01452037A0000|167 190|Bacillus megaterium DSM319
P01452037A0000|220 228|gap operon
P01452037A0000|232 246|complementation
P01452037A0000|91 96|kinase
P01452037A0000|118 121|part
P01452037A0000|66 70|GAPDH
P01452037A0000|208 218|gene cluster
P01452037A0000|124 147|triosephosphate isomerase
P01452584T0000|73 85|Lindberg Award
P01452584T0000|53 64|wound healing
P01452584T0000|40 50|retardation
P01452584T0000|21 29|exotoxin A
P01452584T0000|34 37|role
P01452703A0782|0 16|Laboratory studies
P01452703A0782|203 204|ml
P01452703A0782|139 140|ml
P01452703A0782|194 199|bodies
P01452703A0782|151 159|ELISA kits
P01452703A0782|56 59|kits
P01452703A0782|87 90|case
P01452703A0782|130 135|bodies
P01454518A0336|86 92|homolog
P01454518A0336|10 21|significance
P01454518A0336|191 199|ERCC3 cDNA
P01454518A0336|135 158|stringency hybridizations
P01454518A0336|78 81|gene
P01454518A0336|61 72|conservation
P01454518A0336|29 35|domains
P01454518A0336|175 180|probes
P01454819A0000|0 20|Mono-ADP-ribosylation
P01454819A0000|173 181|reactions
P01454819A0000|186 206|ADP-ribosylation cycle
P01454819A0000|97 98|EC
P01454819A0000|65 95|arginine ADP-ribosyltransferases
P01454819A0000|34 45|modification
P01454819A0000|48 55|proteins
P01454819A0000|130 139|hydrolases
P01454819A0000|141 142|EC
P01454819A0000|61 63|NAD
P01456888A0074|261 268|sequence
P01456888A0074|281 308|myristylation consensus signal
P01456888A0074|17 24|particle
P01456888A0074|132 148|expression systems
P01456888A0074|161 168|bacteria
P01456888A0074|182 194|baculoviruses
P01456888A0074|227 240|core protein p55
P01456888A0074|76 92|core antigen p55 gag
P01456888A0074|7 12|reason
P01456888A0074|170 177|vaccinia
P01456888A0074|42 52|derivatives
P01456888A0074|32 39|capacity
P01456888A0074|58 67|HIV-1 group
P01457380A0000|101 113|ttk transcript
P01457380A0000|17 20|gene
P01457380A0000|81 88|splicing
P01457380A0000|13 15|ttk
P01457380A0000|55 62|proteins
P01457380A0000|3 11|tramtrack
P01457695T0000a|0 6|Removal
P01457695T0000a|9 27|beta 2-microglobulin
P01457695T0000a|65 68|year
P01457695T0000a|45 58|hemofiltration
P01457695T0000a|30 41|hemodialysis
P01457695T0000b|0 6|Removal
P01457695T0000b|9 27|beta 2-microglobulin
P01457695T0000b|65 68|year
P01457695T0000b|45 58|hemofiltration
P01457695T0000b|30 41|hemodialysis
P01458170A0155|0 9|Adapromine
P01458170A0155|148 155|increase
P01458170A0155|123 128|cortex
P01458170A0155|200 205|cortex
P01458170A0155|209 217|hippocamp
P01458170A0155|98 109|power spectra
P01458170A0155|45 53|amplitude
P01458170A0155|67 70|peak
P01458170A0155|180 183|beta
P01458170A0155|132 140|hippocamp
P01458170A0155|82 95|theta-activity
P01458170A0155|163 174|wave activity
P01458170A0155|185 189|range
P01458170A0155|32 39|decrease
P01458170A0155|115 117|EEG
P01459447A0484|28 32|clone
P01459447A0484|5 13|sequences
P01459447A0484|47 51|genes
P01459447A0484|69 75|library
P01459447A0484|57 61|yeast
P01459451A0478|18 31|antirepression
P01459451A0478|51 56|factor
P01459451A0478|68 83|co-antirepressor
P01459451A0478|124 130|embryos
P01459885A0705|13 32|haloperidol treatment
P01459885A0705|104 111|decrease
P01459885A0705|63 67|delta
P01459885A0705|118 121|beta
P01459885A0705|93 97|alpha
P01459885A0705|7 10|days
P01459885A0705|83 90|increase
P01459885A0705|41 47|changes
P01459921A0000|198 203|cis C18
P01459921A0000|192 196|C18:2
P01459921A0000|127 142|calcium linoleate
P01459921A0000|105 123|linoleoyl methionine
P01459921A0000|36 51|Hampshire wethers
P01459921A0000|164 167|flow
P01459921A0000|77 86|experiment
P01459921A0000|186 190|acids
P01460054A0478|71 73|ICS
P01460054A0478|105 120|DNA binding domain
P01460054A0478|9 13|ICSBP
P01460054A0478|152 164|amino terminus
P01460054A0478|45 54|amino acids
P01460054A0478|96 99|part
P01460054A0968|89 93|genes
P01460054A0968|66 73|activity
P01460054A0968|10 14|ICSBP
P01460054A0968|109 113|cells
P01460772T0001|1 4|case
P01460772T0001|35 48|hypothyroidism
P01460772T0001|65 83|interferon treatment
P01460772T0001|14 23|hepatitis C
P01462786T0000|0 20|Dynamic decision making
P01462786T0000|27 33|control
P01462786T0000|36 49|complex systems
P01464329T0000|61 79|prophase chromosomes
P01464329T0000|19 25|protein
P01464329T0000|45 51|regions
P01464606A0344|59 63|cells
P01464606A0344|150 156|elution
P01464606A0344|125 146|fragment affinity column
P01464606A0344|10 16|amounts
P01464606A0344|102 112|fibronectin
P01464606A0344|25 28|beta
P01464606A0344|161 164|EDTA
P01464606A0344|30 37|integrin
P01464606A0344|19 23|alpha
P01464606A0344|66 79|chromatography
P01464606A0344|82 98|detergent extracts
P01467088T0075|0 8|Abstracts
P01467828A0542|29 39|involvement
P01467828A0542|78 84|effects
P01467828A0542|52 65|opioid peptides
P01467828A0542|5 11|results
P01467828A0542|140 148|receptors
P01467828A0542|112 122|reperfusion
P01467828A0542|162 171|antagonism
P01467828A0542|100 108|ischaemia
P01468625A0282|16 19|LEU2
P01468625A0282|8 14|library
P01468625A0282|86 90|cases
P01468625A0282|23 31|HIS3 cDNAs
P01468625A0282|131 136|manner
P01468625A0282|48 56|frequency
P01468625A1080|30 34|times
P01468625A1080|11 14|ACT1
P01468625A1080|39 42|NSR1
P01468625A1080|48 52|times
P01469042A0355|72 98|mouse centromere satellite DNA
P01469042A0355|180 183|kind
P01469042A0355|37 43|species
P01469042A0355|105 113|satellite
P01469042A0355|47 57|CENP-B boxes
P01469042A0355|192 209|centromere function
P01469042A0355|148 158|interaction
P01469042A0355|5 14|CENP-B gene
P01469047A1606|15 21|portion
P01469047A1606|53 58|shares
P01469047A1606|38 39|aa
P01469047A1606|61 86|% amino acid sequence identity
P01469047A1606|109 118|mouse brain
P01469047A1606|140 156|acid decarboxylase
P01469047A1606|98 104|protein
P01469047A1606|27 36|tail domain
P01470243A0871|224 228|means
P01470243A0871|265 279|viscosity effect
P01470243A0871|91 99|mortality
P01470243A0871|178 178|%
P01470243A0871|43 43|n
P01470243A0871|213 221|viscosity
P01470243A0871|199 207|reduction
P01470243A0871|298 302|group
P01470243A0871|248 254|albumin
P01470243A0871|172 172|%
P01470243A0871|121 121|%
P01470243A0871|231 243|haemodilution
P01470243A0871|106 111|months
P01470243A0871|151 162|independence
P01470243A0871|13 20|subgroup
P01470243A0871|39 41|l/l
P01470243A0871|69 77|reduction
P01470243A0871|79 79|p
P01470243A0871|115 115|%
P01470243A0871|165 168|home
P01470243A0871|31 32|Ht
P01470243A0871|141 148|increase
P01470741T0062|0 11|Distribution
P01470741T0062|36 41|course
P01471602A0362|14 16|use
P01471602A0362|234 238|drugs
P01471602A0362|113 119|HMG-CoA
P01471602A0362|20 27|benefits
P01471602A0362|216 226|conjunction
P01471602A0362|200 209|approaches
P01471602A0362|144 151|probucol
P01471602A0362|121 139|reductase inhibitors
P01471602A0362|71 75|acids
P01471602A0362|30 49|bile acid sequestrants
P01471602A0362|60 63|acid
P01471602A0362|103 111|coenzyme A
P01473196A1016|19 30|reabsorption
P01473196A1016|51 59|clearance
P01473207A0582|61 70|hypoplasia
P01473207A0582|20 27|findings
P01473207A0582|45 57|prematuration
P01473207A0582|33 40|placenta
P01473234A1001|0 10|Green pepper
P01473234A1001|96 99|acid
P01473234A1001|65 77|acid formation
P01474990A0000|14 18|pTt21
P01474990A0000|155 168|trypomastigote
P01474990A0000|144 150|library
P01474990A0000|172 187|epimastigote cDNA
P01474990A0000|68 78|Trypanosoma
P01474990A0000|8 12|clone
P01474990A0000|84 98|trypomastigotes
P01474990A0000|30 32|DNA
P01475381T0001|0 10|Brucellosis
P01476376T0000|0 4|Assay
P01476376T0000|52 59|pH-meter
P01476376T0000|24 29|urease
P01476376T0000|7 10|urea
P01477021A0394|42 68|serum prolactin concentration
P01477021A0394|95 103|gestation
P01477021A0394|115 115|P
P01477021A0394|105 105|P
P01477021A0394|13 20|AGA group
P01477021A0394|0 6|RESULTS
P01478672A0795|3 12|phage clone
P01478672A0795|37 53|alpha satellite DNA
P01478672A0795|79 86|sequence
P01478672A0795|22 29|junction
P01480183A0000|14 19|region
P01480183A0000|82 88|library
P01480183A0000|30 44|lactoferrin gene
P01480183A1689|102 106|mouse
P01480183A1689|64 88|lactoferrin gene expression
P01480183A1689|37 50|estrogen action
P01480183A1689|22 31|mechanisms
P01480470A0323|0 5|BiP670
P01480470A0323|25 33|ionophore
P01480470A0323|50 59|activities
P01480470A0323|21 23|Ca2
P01482912A0617|14 32|registration updates
P01482912A0617|38 47|HL7 message
P01482912A0617|78 82|rules
P01482912A0617|102 119|relational database
P01482912A0617|88 96|interface
P01482912A0617|3 5|CEM
P01482912A0617|60 75|data dependencies
P01483755A0000|130 135|muscle
P01483755A0000|70 79|techniques
P01483755A0000|37 43|imaging
P01483755A0000|8 28|resonance spectroscopy
P01483755A0000|119 127|structure
P01483755A0000|86 90|study
P01483755A0000|30 32|MRS
P01483755A0000|101 110|metabolism
P01483755A0000|45 47|MRI
P01483771A1335|22 23|NA
P01483771A1335|38 43|change
P01483771A1335|46 70|plasma epinephrine response
P01485648A0000|100 105|Sweden
P01485648A0000|92 98|Uppsala
P01485648A0000|126 136|measurement
P01485648A0000|192 197|groups
P01485648A0000|50 67|Pharmacia CAP System
P01485648A0000|27 31|value
P01485648A0000|156 168|IgE antibodies
P01485648A0000|69 90|Pharmacia Diagnostics AB
P01485648A0000|171 180|comparison
P01485648A0000|185 188|RAST
P01485648A0000|45 48|test
P01485648A0000|200 207|patients
P01486836A0774|0 7|Patients
P01486836A0774|49 69|visuomotor performance
P01486836A0774|26 36|differences
P01486836A0774|117 137|visuomotor performance
P01486836A0774|39 47|attention
P01486836A0774|160 161|T3
P01486836A0774|17 19|VPA
P01486836A0774|77 80|span
P01486836A0774|154 157|span
P01486836A0774|112 113|T1
P01486836A0774|140 141|T2
P01486836A0774|91 109|discrimination tasks
P01486836A0774|197 198|T4
P01486836A0774|172 182|differences
P01487144A0505|14 24|gene segment
P01487144A0505|46 46|A
P01487144A0505|38 44|mu m poly
P01487144A0505|151 166|L cell fibroblasts
P01487144A0505|48 54|signals
P01487144A0505|107 129|transcription terminator
P01487144A0505|90 97|sequence
P01487144A0505|136 147|myeloma cells
P01487144A0505|68 69|bp
P01490493A0416|69 86|triglyceride levels
P01490493A0416|3 6|part
P01490493A0416|61 65|lipid
P01490493A0416|15 25|examination
P01490493A0416|39 54|serum cholesterol
P01492463T0001|0 4|Alena
P01492463T0001|62 66|ocean
P01492463T0001|8 12|nurse
P01492463T0001|49 52|trip
P01492463T0001|15 20|Prague
P01492463T0001|40 44|wages
P01493864A0619|58 70|pre-treatment
P01493864A0619|17 24|subjects
P01493864A0619|37 42|6-OHDA
P01493864A0619|75 83|GBR-12909
P01493864A0619|0 14|Dopamine neurons
P01495069A0392|0 3|DIBA
P01495069A0392|51 55|value
P01495069A0392|78 87|percentage
P01495069A0392|92 95|DFAT
P01496348A0000|0 5|Caries
P01496348A0000|9 20|parodontitis
P01496348A0000|47 54|diseases
P01496348A0000|57 63|mankind
P01496784A0939|58 62|cause
P01496784A0939|16 20|study
P01496784A0939|36 51|strongyloidiasis
P01496784A0939|3 9|results
P01496784A0939|71 75|death
P01497582A0593|127 134|placenta
P01497582A0593|86 94|pathogens
P01497582A0593|49 55|effects
P01497582A0593|12 16|group
P01497582A0593|30 38|pregnancy
P01497582A0593|19 27|disorders
P01497582A0593|73 78|mother
P01497582A0593|58 67|infections
P01497582A0593|116 121|embryo
P01498607A0000|29 33|boxes
P01498607A0000|60 73|responsiveness
P01498607A0000|9 27|nucleotide sequences
P01498607A0000|79 109|parsley chalcone synthase promoter
P01499213A0185|98 101|fall
P01499213A0185|65 84|hyperextension injury
P01499213A0185|36 38|man
P01499213A0185|115 122|fracture
P01499213A0185|43 52|ochronosis
P01499213A0185|90 94|spine
P01499213A0185|3 6|case
P01499213A0185|141 154|L2-L3 disk space
P01499616A0136|27 34|foreskin
P01499616A0136|107 116|anesthesia
P01499616A0136|138 138|%
P01499616A0136|87 87|%
P01499616A0136|63 63|g
P01499616A0136|7 15|blood flow
P01499616A0136|144 146|tip
P01499616A0136|169 180|foreskin flap
P01499616A0136|96 104|induction
P01502157A0000|0 4|ME1a1
P01502157A0000|115 124|P2 activity
P01502157A0000|26 42|factor binding site
P01502157A0000|61 67|c-MYC P1
P01502157A0000|71 100|P2 transcription initiation sites
P01504178T0000|13 17|years
P01504178T0000|20 29|prevention
P01504178T0000|38 44|country
P01504178T0000|56 62|complex
P01504178T0000|46 54|visionary
P01504853A0299|59 65|species
P01504853A0299|9 12|LHRH
P01504853A0299|36 49|mating behavior
P01505488A0231|41 43|EVL
P01505488A0231|76 79|July
P01505488A0231|63 68|August
P01505488A0231|53 58|period
P01505488A0231|22 29|patients
P01505516A0928|56 68|valine residue
P01505516A0928|76 84|formation
P01505516A0928|47 53|alanine
P01505516A0928|103 108|dimers
P01505516A0928|20 23|acid
P01505516A0928|29 34|lysine
P01506705A0282|16 27|hemodynamics
P01506705A0282|6 14|V-A bypass
P01506746A0476|0 18|Greater rupture force
P01506746A0476|40 43|pigs
P01506746A0476|58 61|pigs
P01509798A0520|68 68|%
P01509798A0520|38 38|%
P01509798A0520|52 53|AT
P01509798A0520|62 64|UEA
P01509798A0520|33 34|UT
P01509798A0520|2 8|rest AFF
P01509798A0520|57 57|%
P01511231A0085|42 45|year
P01511231A0085|17 29|smoking habits
P01511231A0085|88 95|nicotine
P01511231A0085|62 82|smoking cessation trial
P01511231A0085|32 40|relapsers
P01511231A0085|98 111|placebo patches
P01511950T0000|129 138|population
P01511950T0000|49 56|Hisayama
P01511950T0000|10 24|hepatitis B virus
P01511950T0000|37 46|population
P01511950T0000|86 93|antibody
P01511950T0000|96 119|hepatitis B surface antigen
P01511950T0000|64 75|significance
P01511950T0000|58 62|Japan
P01511950T0000|0 7|Exposure
P01512259A0867|141 145|furin
P01512259A0867|104 110|Dfurin2
P01512259A0867|61 73|cysteine motif
P01512259A0867|19 28|phenomenon
P01512259A0867|97 101|times
P01512654A0503|73 85|KLH challenges
P01512654A0503|39 53|saline injection
P01512654A0503|10 13|hand
P01512654A0503|22 30|phosphate
P01512654A0503|91 92|ES
P01512654A0503|61 62|ES
P01512654A0503|118 131|threshold level
P01512654A0503|146 152|latency
P01512941A0000|102 111|comparison
P01512941A0000|154 164|norfloxacin
P01512941A0000|146 149|OFLX
P01512941A0000|130 133|CPFX
P01512941A0000|116 128|ciprofloxacin
P01512941A0000|166 169|NFLX
P01512941A0000|136 144|ofloxacin
P01512941A0000|58 61|LVFX
P01512941A0000|63 69|DR-3355
P01512941A0000|45 56|levofloxacin
P01513114A1133|56 58|KTA
P01513114A1133|91 95|WORDS
P01513114A1133|62 65|mg/d
P01513114A1133|49 51|SPK
P01513114A1133|7 27|serum creatinine levels
P01513114A1133|44 47|year
P01513114A1133|69 76|ABSTRACT
P01513213A0231|0 15|Model predictions
P01513213A0231|105 109|women
P01513213A0231|22 27|accord
P01513213A0231|64 68|women
P01513213A0231|74 81|HIP trial
P01513213A0231|144 151|survival
P01513213A0231|94 102|exception
P01513213A0231|44 61|survival experience
P01513213A0231|115 119|years
P01513213A0231|128 134|HIP data
P01516427T0000|56 67|tuberculosis
P01516427T0000|38 46|diagnosis
P01516427T0000|23 32|tomography
P01516829A0113|119 125|complex
P01516829A0113|23 26|SNF2
P01516829A0113|81 90|activation
P01516829A0113|36 47|SNF6 function
P01516829A0113|28 31|SNF5
P01516829A0460|85 94|activation
P01516829A0460|10 18|LexA-GAL4
P01516829A0460|70 73|SNF5
P01516829A0460|78 81|SNF6
P01516829A0460|65 68|SNF2
P01516829A0460|131 143|lexA operators
P01516829A0460|33 46|fusion proteins
P01516829A0460|97 107|target genes
P01518396T0000|0 7|George T.
P01518833A0397|1 21|lambda gt10 cDNA library
P01518833A0397|63 68|leaves
P01518833A0397|48 50|RNA
P01518833A0397|40 43|poly
P01518833A0397|45 45|A
P01518833A0397|71 77|spinach
P01518849A0165|0 1|NE
P01518849A0165|131 140|activities
P01518849A0165|19 29|destruction
P01518849A0165|94 107|protein elastin
P01518849A0165|188 202|elastin peptides
P01518849A0165|150 184|alpha 1-proteinase inhibitor complexes
P01518849A0165|5 7|PR3
P01518849A0165|44 57|microorganisms
P01518926T0000|8 13|topics
P01518926T0000|25 39|ultrasonography
P01522699A0092|0 6|Methods
P01522699A0092|51 64|recipe analysis
P01522699A0092|36 46|menu weights
P01522699A0092|29 34|recall
P01523111A0769|0 6|Factors
P01523111A0769|56 66|temperature
P01523111A0769|38 40|age
P01523111A0769|21 29|afterdrop
P01523111A0769|86 93|body mass
P01524549A0241|99 109|association
P01524549A0241|152 160|GH therapy
P01524549A0241|114 125|GH deficiency
P01524549A0241|55 61|stature
P01524549A0241|136 139|time
P01524549A0241|90 96|puberty
P01524549A0241|33 38|growth
P01524549A0241|4 15|GH deficiency
P01524549A0241|73 82|occurrence
P01525153A0359|133 139|Gilbert
P01525153A0359|25 29|T2G4T
P01525153A0359|129 130|D.
P01525153A0359|11 11|d
P01525153A0359|141 142|W.
P01525153A0359|13 18|T2AG3T
P01525153A0359|125 127|Sen
P01525153A0359|23 23|d
P01525153A0359|54 70|monomer structures
P01525153A0359|31 34|form
P01525153A0359|84 103|K cation concentration
P01525153A0359|2 9|contrast
P01525966T0000|25 30|stones
P01526658A0454|0 2|IFI
P01526658A0454|64 72|cell lines
P01526658A0454|86 94|B lineages
P01526658A0454|54 58|cells
P01526658A0454|5 8|mRNA
P01526658A0454|82 82|T
P01526690T0000|18 23|action
P01526690T0000|26 33|warfarin
P01526690T0000|36 46|lymphocytes
P01527020A0511|114 117|gene
P01527020A0511|94 98|exons
P01527020A0511|11 19|junctions
P01527020A0511|75 83|positions
P01527020A0511|33 59|rat AdoMet decarboxylase genes
P01527020A0511|131 134|exon
P01527020A0511|140 146|rat gene
P01529530T0000|60 65|effect
P01529530T0000|92 116|ISGF3 transcription complex
P01529530T0000|77 86|activation
P01529530T0000|24 37|gene expression
P01529530T0000|68 74|ouabain
P01529530T0000|39 46|evidence
P01531086A0127|16 27|reading frame
P01531086A0127|67 73|protein
P01531086A0127|33 42|amino acids
P01531086A0127|3 6|cDNA
P01531214A0885|69 82|administration
P01531214A0885|21 26|RP-170
P01531214A0885|37 40|i.v.
P01531214A0885|59 62|g/kg
P01531214A0885|31 34|g/kg
P01531214A0885|9 12|LD50
P01531214A0885|15 18|mice
P01531632A0000|73 80|proteins
P01531632A0000|34 42|nucleolus
P01531632A0000|92 102|fibrillarin
P01531632A0000|11 18|proteins
P01531632A0000|104 107|SSB1
P01531632A0000|140 144|motif
P01531632A0000|111 114|NSR1
P01531632A0000|182 197|arginine residues
P01531632A0000|172 178|glycine
P01531632A0000|82 90|nucleolin
P01531632A0000|149 157|GAR domain
P01532229A1264|87 91|MEF-2
P01532229A1264|22 29|evidence
P01532229A1264|9 13|study
P01532229A1264|51 56|factor
P01532229A1264|149 158|expression
P01532229A1264|81 85|HF-1b
P01532229A1264|124 130|pathway
P01532229A1264|179 189|muscle cells
P01532229A1264|68 79|muscle factor
P01532229A1264|58 62|HF-1a
P01532796A0107|70 74|alpha
P01532796A0107|104 115|mitochondria
P01532796A0107|78 89|beta subunits
P01532796A0107|47 54|assembly
P01532796A0107|126 135|aggregates
P01532796A0107|17 20|gene
P01532796A0107|146 147|S.
P01532796A0107|137 144|Ackerman
P01532796A0107|57 58|F1
P01532796A0107|41 44|step
P01532796A0107|0 8|Mutations
P01532914A0067|0 6|Expense
P01532914A0067|104 111|strategy
P01532914A0067|62 73|immunization
P01532914A0067|122 128|studies
P01532914A0067|21 38|hepatitis B vaccines
P01532914A0067|16 18|use
P01533760T0000|0 25|Estrogen replacement therapy
P01533760T0000|35 46|breast cancer
P01533760T0000|29 32|risk
P01533760T0000|48 54|results
P01533760T0000|60 72|meta-analyses
P01535242A0557|43 48|GM-CSF
P01535242A0557|67 77|degradation
P01535242A0557|102 116|factor switching
P01535242A0557|36 40|M-CSF
P01535242A0557|9 14|FDC-P1
P01535242A0557|80 88|c-fms mRNA
P01535242A0557|28 33|growth
P01535242A0557|96 96|h
P01535242A0557|16 23|MAC cells
P01536153A0574|29 38|difference
P01536153A0574|129 137|skin tests
P01536153A0574|153 161|fish flour
P01536153A0574|208 214|dyspnea
P01536153A0574|195 197|IgE
P01536153A0574|44 53|prevalence
P01536153A0574|89 105|animal food workers
P01536153A0574|74 81|symptoms
P01536153A0574|145 148|dust
P01536575A1213|174 179|CYPIA1
P01536575A1213|189 193|genes
P01536575A1213|249 260|hydrocarbons
P01536575A1213|123 131|induction
P01536575A1213|152 172|cytochrome P450IA1 gene
P01536575A1213|204 228|detoxification/activation
P01536575A1213|25 32|presence
P01536575A1213|134 146|transcription
P01536575A1213|89 96|sequence
P01536575A1213|12 18|finding
P01536575A1213|35 42|position
P01536575A1213|64 69|dioxin
P01536575A1213|80 86|element
P01537334A0507|26 40|mouse chromosome
P01537334A0507|49 54|region
P01537334A0507|3 6|gene
P01537334A0507|60 82|coat colour mutation slaty
P01537334A0507|15 23|TRP-2 maps
P01537845A0571|45 48|rate
P01537845A0571|51 72|c-myb gene transcription
P01537845A0571|75 87|mRNA stability
P01537845A0571|108 116|cell cycle
P01537845A0571|34 39|change
P01537845A0571|20 30|c-myb clones
P01538401A1244|100 106|binding
P01538401A1244|35 45|nucleotides
P01538401A1244|60 67|S RNA gene
P01538401A1244|119 124|latter
P01538401A1244|3 26|base-pair oligonucleotide
P01538401A1244|158 169|DNA fragments
P01538403A1058|162 177|complex formation
P01538403A1058|49 70|transcription complexes
P01538403A1058|12 25|reconstitution
P01538403A1058|213 220|TATA-box
P01538403A1058|184 202|H5 promoter mutations
P01538403A1058|83 98|protein fractions
P01538403A1058|28 31|eUSF
P01538403A1058|121 125|TFIID
P01538403A1058|133 136|eUSF
P01539996A0588|112 121|similarity
P01539996A0588|199 204|enzyme
P01539996A0588|16 32|amino acid sequence
P01539996A0588|130 141|conservation
P01539996A0588|245 252|presence
P01539996A0588|276 284|C terminus
P01539996A0588|104 104|%
P01539996A0588|147 156|Ser residue
P01539996A0588|86 91|enzyme
P01539996A0588|263 270|residues
P01539996A0588|290 309|T. thermophilus enzyme
P01539996A0588|225 232|sequence
P01539996A0588|38 57|T. thermophilus enzyme
P01539996A0588|1 10|comparison
P01541556A1040|73 89|lipid modification
P01541556A1040|54 60|protein
P01541556A1040|13 21|palmitate
P01541556A1040|101 113|Cys-22 residue
P01541577A0000|58 73|Stanford Hypnotic
P01541577A0000|88 91|SHCS
P01541577A0000|95 100|Morgan
P01541577A0000|35 52|volunteer hearing Ss
P01541577A0000|104 105|J.
P01541577A0000|2 10|volunteer
P01541577A0000|82 86|Scale
P01541577A0000|15 16|Ss
P01542565A0220|59 71|protein L7/L12
P01542565A0220|6 22|tobacco L12 protein
P01542565A0220|28 45|% amino acid identity
P01542565T0000|35 44|protein L12
P01542565T0000|160 168|precursor
P01542565T0000|128 137|cDNA clones
P01542565T0000|110 125|sequence analysis
P01542565T0000|64 79|characterization
P01542565T0000|47 62|Nicotiana tabacum
P01542565T0000|98 106|isolation
P01542565T0000|88 94|protein
P01542667A0125|15 23|IFN-gamma
P01542667A0125|106 113|activity
P01542667A0125|61 75|enhancer element
P01542667A0125|135 144|expression
P01542667A0125|174 177|gene
P01542667A0125|3 6|gene
P01542686A0000|121 123|p65
P01542686A0000|125 131|subunit
P01542686A0000|9 15|cloning
P01542686A0000|62 84|p75 nucleoprotein complex
P01542686A0000|134 143|NF-kappa B.
P01542686A0000|21 40|polypeptide component
P01542686A0000|99 106|identity
P01542730A1982|203 209|devices
P01542730A1982|257 264|ABSTRACT
P01542730A1982|74 77|risk
P01542730A1982|99 105|AV block
P01542730A1982|247 254|patients
P01542730A1982|185 196|dual-chamber
P01542730A1982|55 61|patient
P01542730A1982|279 283|WORDS
P01542730A1982|234 239|number
P01542730A1982|109 117|DDD pacing
P01542730A1982|40 45|pacing
P01542730A1982|144 150|support
P01542730A1982|198 201|DDDR
P01542730A1982|86 96|development
P01543909A0787|44 45|Lg
P01543909A0787|182 185|gene
P01543909A0787|144 153|pseudogene
P01543909A0787|53 57|clone
P01543909A0787|117 131|characteristics
P01543909A0787|201 215|ferritin subunit
P01543909A0787|30 38|K562 cells
P01544854A0699|29 37|WR-168643
P01544854A0699|48 56|protector
P01544854A0699|62 64|DMF
P01544854A0699|5 9|drugs
P01544918A1240|0 15|Characterization
P01544918A1240|216 227|subunit sizes
P01544918A1240|23 31|R subunits
P01544918A1240|75 90|immunoreactivity
P01544918A1240|197 204|SDS-PAGE
P01544918A1240|255 275|RII alpha dephosphoform
P01544918A1240|279 281|kDa
P01544918A1240|230 236|RII beta
P01544918A1240|128 140|mobility shift
P01544918A1240|304 306|kDa
P01544918A1240|39 71|8-azido-cAMP photoaffinity labeling
P01544918A1240|143 155|sodium dodecyl
P01544918A1240|294 300|RI alpha
P01544918A1240|178 195|gel electrophoresis
P01544918A1240|240 242|kDa
P01544928A1252|0 9|Comparison
P01544928A1252|82 92|transcripts
P01544928A1252|136 143|pre-mRNA
P01544928A1252|22 32|DNA sequence
P01544928A1252|117 124|splicing
P01544928A1252|59 63|mRNAs
P01544928A1252|156 168|cassette model
P01545523A0000|105 121|antistreptolysin O
P01545523A0000|50 57|testings
P01545523A0000|78 84|protein
P01545523A0000|69 69|C
P01545523A0000|96 101|factor
P01545523A0000|16 30|quantifications
P01545787A0345|72 76|DNase
P01545787A0345|78 87|footprints
P01545787A0345|89 94|NFAT-1
P01545787A0345|98 104|NFIL-2B
P01545787A0345|31 35|sites
P01545787A0345|14 21|enhancer
P01545792A0000|29 33|MLC-2
P01545792A0000|10 27|myosin light chain-2
P01545792A0000|91 99|sequences
P01545792A0000|135 144|expression
P01545792A0000|35 46|gene promoter
P01545792A0000|120 129|regulation
P01545792A0492|0 18|Deletion mutagenesis
P01545792A0492|43 50|elements
P01545792A0492|87 108|MLC-2 gene transcription
P01545792A0492|75 84|regulation
P01545797A0587|0 18|Disruption mutations
P01545797A0587|81 88|degrees C
P01545797A0587|122 130|degrees C.
P01545797A0587|52 55|slk1
P01545797A0587|97 101|cells
P01545797A0587|60 66|mutants
P01545797A0587|43 50|SLK1 gene
P01545806T0000|32 36|yeast
P01545806T0000|49 72|recombination genes REC102
P01545806T0000|76 86|REC107/MER2
P01545806T0000|19 26|analysis
P01545818A0696|159 172|v-Src SH2 domain
P01545818A0696|90 94|v-Src
P01545818A0696|36 43|proteins
P01545818A0696|114 123|Rat-2 cells
P01545818A0696|10 12|p62
P01545818A0696|57 64|v-Src SH2
P01545818A0696|135 141|binding
P01545818A0696|3 6|p130
P01546522A0000|0 7|Probable
P01546522A0000|85 91|picture
P01546522A0000|70 74|basis
P01546522A0000|149 157|remission
P01546522A0000|49 51|PML
P01546522A0000|174 181|lymphoma
P01546522A0000|103 118|resonance imaging
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|133 135|man
P01547775A1024|168 195|ORF2a/ORF2b transframe protein
P01547775A1024|52 61|frameshift
P01547775A1024|35 46|significance
P01547775A1024|75 82|position
P01547775A1024|141 144|site
P01547775A1024|150 162|PLRV replicase
P01547775A1024|122 124|RNA
P01547775A1024|5 8|data
P01547787A0548|0 19|Proprotein processing
P01547942A0120|29 46|dimerization domain
P01547942A0120|77 81|clone
P01547942A0120|12 14|LAP
P01547942A0120|121 127|CHOP-10
P01547942A0120|113 119|protein
P01547942A0120|48 58|zipper probe
P01547957A1083|119 124|region
P01547957A1083|134 140|portion
P01547957A1083|250 252|PCR
P01547957A1083|150 153|CYP2
P01547957A1083|177 182|genome
P01547957A1083|226 248|polymerase chain reaction
P01547957A1083|276 284|substrate
P01547957A1083|143 146|CYP1
P01547957A1083|270 272|DNA
P01547957A1083|16 39|oligodeoxyribonucleotide
P01547957A1083|198 208|DNA fragment
P01547957A1083|67 76|aa sequence
P01547957A1083|259 262|GL81
P01548756A1102|72 80|EHS-1 loci
P01548756A1102|9 21|hybridization
P01548756A1102|153 167|rhesus monkey DNA
P01548756A1102|94 96|DNA
P01548756A1102|49 51|DNA
P01548756A1102|24 28|EHS-1
P01548756A1102|109 119|band pattern
P01548756A1102|122 134|chimpanzee DNA
P01548756A1102|146 150|locus
P01548891A0635|100 107|patients
P01548891A0635|38 44|hormone
P01548891A0635|62 77|thyroid carcinoma
P01548891A0635|115 130|thyroid carcinoma
P01548891A0635|3 7|level
P01548891A0635|50 57|patients
P01548891A0635|132 132|P
P01549118A0000|3 40|Caenorhabditis elegans vitellogenin genes
P01549118A0000|53 55|sex
P01549118A0000|126 147|hermaphrodite intestine
P01549118A0000|83 92|regulation
P01549118A0000|58 62|stage
P01549123A0480|27 34|sequence
P01549123A0480|75 80|family
P01549123A0480|86 89|bZIP
P01549123A0480|3 10|MET4 gene
P01549123A0480|105 114|activators
P01549123A0480|56 62|protein
P01549125A0140|43 46|IAPP
P01549125A0140|93 102|expression
P01549125A0140|22 29|portions
P01549125A0140|51 65|beta GK promoters
P01549125A0140|35 41|insulin
P01549125A0140|106 121|DNA binding assays
P01549125A0140|3 11|functions
P01549129A0356|75 86|interactions
P01549129A0356|108 118|functioning
P01549129A0356|21 27|domains
P01549129A0356|121 123|Src
P01549346A0000|3 20|c-Ets-1 oncoprotein
P01549346A0000|24 45|transcription activator
P01549346A0000|69 71|DNA
P01549465A0122|87 89|Ser
P01549465A0122|93 95|Val
P01549465A0122|83 85|Gly
P01549465A0122|129 142|discrimination
P01549465A0122|52 61|amino acids
P01549465A0122|8 33|transactivation experiments
P01549465A0122|76 81|region
P01551176A0000|0 7|GR63178A
P01551176A0000|34 44|mitoquidone
P01551176A0000|24 31|analogue
P01551176A0000|58 71|pyrroloquinone
P01551568A1476|0 19|Marker rescue analysis
P01551568A1476|52 58|segment
P01551568A1476|79 87|Rif domain
P01551568A1476|61 64|rpoB
P01551568A1476|32 34|ts8
P01551898A1084|128 140|culture medium
P01551898A1084|90 96|protein
P01551898A1084|4 9|vector
P01551898A1084|63 72|expression
P01551898A1084|112 113|mg
P01551898A1084|28 32|yeast
P01551898A1084|99 104|levels
P01551898A1084|116 125|LAPP/liter
P01551910A0313|0 18|Competition analysis
P01551910A0313|21 51|gel mobility shift electrophoresis
P01551910A0313|80 90|interaction
P01551910A0313|117 136|transcription factors
P01551910A0978|43 50|sequence
P01551910A0978|4 11|DNA motif
P01552052A0139|117 125|mg/kg/day
P01552052A0139|128 139|cyclosporine
P01552052A0139|13 17|study
P01552052A0139|69 83|serum creatinine
P01552052A0139|56 66|alterations
P01552052A0139|45 53|frequency
P01552052A0139|86 93|patients
P01552052A0139|98 106|psoriasis
P01552052A0139|0 8|OBJECTIVE
P01552457T0000|30 42|periodontitis
P01552457T0000|70 75|insert
P01552457T0000|86 94|ofloxacin
P01552457T0000|96 100|PT-01
P01552457T0000|0 22|Intrapocket chemotherapy
P01552662A0398|15 23|blood flow
P01552662A0398|77 79|LAD
P01552662A0398|70 75|artery
P01552662A0398|25 26|BF
P01552662A0398|28 32|probe
P01552853A1377|58 67|yop regulon
P01552853A1377|5 15|temperature
P01552853A1377|19 22|virF
P01552853A1377|44 52|induction
P01553407T0000|0 7|Problems
P01553407T0000|49 62|risk assessment
P01553407T0000|31 34|area
P01554334A0000|131 139|Committee
P01554334A0000|64 72|diagnosis
P01554334A0000|142 152|Agriculture
P01554334A0000|156 158|use
P01554334A0000|81 92|tuberculosis
P01554334A0000|95 100|cattle
P01554334A0000|37 45|IFN-gamma
P01554334A0000|20 35|gamma-interferon
P01554334A0000|47 57|assay system
P01554334A0000|161 169|Australia
P01555556A0565|0 13|Control Tmuscle
P01555556A0565|63 64|SD
P01555556A0565|50 52|max
P01555556A0565|40 48|control Wi
P01555556A0565|27 34|degrees C
P01555556A0565|69 74|W.kg-1
P01556068A0000|3 29|Klebsiella aerogenes gene maoA
P01556068A0000|112 120|compounds
P01556068A0000|62 77|monoamine oxidase
P01556068A0000|51 59|synthesis
P01556068A0000|146 166|ammonium ion repression
P01556068A0000|91 98|tyramine
P01556068A0000|133 142|catabolite
P01556111A0241|25 31|plasmid
P01556111A0241|13 19|regions
P01557217A0272|33 39|lesions
P01557217A0272|73 77|h p.i.
P01557411A1282|13 19|D1A gene
P01557411A1282|32 39|category
P01557411A1282|67 71|genes
P01557411A1282|97 105|promoters
P01558942A1369|7 18|observations
P01558942A1369|49 53|genes
P01559209T0000|15 25|CNS students
P01559209T0000|40 44|study
P01559209T0000|0 12|Preceptorship
P01560021A0379|32 42|differences
P01560021A0379|21 25|basis
P01560021A0379|63 78|brain AE3 variants
P01560021A0379|109 115|rat gene
P01560774A0885|14 21|fragment
P01560774A0885|60 67|fliA gene
P01560774A0885|6 7|kb
P01562659A0676|0 10|Institution
P01562659A0676|45 58|administration
P01562659A0676|307 309|CNS
P01562659A0676|185 193|C. immitis
P01562659A0676|213 224|encephalitis
P01562659A0676|107 120|administration
P01562659A0676|263 274|confirmation
P01562659A0676|172 182|association
P01562659A0676|198 210|CNS vasculitis
P01562659A0676|277 294|C. immitis infection
P01562659A0676|123 135|dexamethasone
P01562659A0676|152 161|situations
P01562659A0676|61 73|amphotericin B
P01563343A0548|0 11|Lac operators
P01563343A0548|82 88|plasmid
P01563343A0548|55 65|CAB promoter
P01563343A0548|37 45|positions
P01563343A0548|98 104|control
P01563635T0000|0 13|Overproduction
P01563635T0000|48 71|M.HinfI methyltransferase
P01563635T0000|78 91|deletion mutant
P01563635T0000|30 45|characterization
P01563635T0000|15 26|purification
P01564653A0307|33 36|lens
P01564653A0307|27 30|type
P01564653A0307|7 15|companies
P01565093A0179|98 105|hospital
P01565093A0179|136 160|disease surveillance system
P01565093A0179|176 192|Alabama Department
P01565093A0179|37 43|persons
P01565093A0179|69 83|blood lead levels
P01565093A0179|208 211|ADPH
P01565093A0179|195 206|Public Health
P01565093A0179|17 23|October
P01565093A0179|4 8|March
P01565093A0179|85 88|BLLs
P01565882A0737|226 226|%
P01565882A0737|23 38|perfusion defects
P01565882A0737|151 151|%
P01565882A0737|221 222|Ia
P01565882A0737|99 113|perfusion defect
P01565882A0737|153 156|Type
P01565882A0737|239 240|Ib
P01565882A0737|93 96|Type
P01565882A0737|244 244|%
P01565882A0737|119 125|RD image
P01565882A0737|173 181|subgroups
P01565882A0737|49 50|RD
P01565882A0737|189 203|perfusion defect
P01565882A0737|87 91|types
P01565882A0737|14 20|changes
P01565882A0737|54 62|ReI images
P01565882A0737|143 147|image
P01565882A0737|251 257|RD image
P01566576A0605|0 3|Keck
P01566576A0605|5 8|C.J.
P01567649A0139|134 140|infancy
P01567649A0139|117 126|evaluation
P01567649A0139|92 96|palsy
P01567649A0139|18 24|infants
P01567649A0139|47 56|hemorrhage
P01567649A0139|16 16|%
P01568960A1129|95 107|corner vessels
P01568960A1129|9 17|mechanism
P01568960A1129|40 47|pressure
P01568960A1129|67 72|output
P01568960A1129|126 136|VA/Q regions
P01568960A1129|82 90|blood flow
P01569015A0120|15 19|FRAME
P01569015A0120|111 119|direction
P01569015A0120|53 65|reading frames
P01569015A0120|21 28|analysis
P01569015A0120|67 70|ORFs
P01569015A0120|83 91|direction
P01569102A0708|0 5|Domain
P01569102A0708|75 86|conservation
P01569102A0708|31 41|LDL receptor
P01569102A0708|104 112|cysteines
P01569102A0708|57 63|repeats
P01569344A0404|97 115|HTLV-I/II prevalence
P01569344A0404|68 80|New Orleans age
P01569344A0404|22 31|prevalence
P01569344A0404|158 158|P
P01569344A0404|148 156|Baltimore
P01569344A0404|6 11|cities
P01569344A0404|58 60|age
P01569581A0482|14 21|evidence
P01569581A0482|38 41|mRNA
P01569581A0482|135 161|translation initiation region
P01569581A0482|92 101|start codon
P01569581A0482|107 110|fold
P01569581A0482|64 74|nucleotides
P01569581A0482|183 212|translation initiation frequency
P01569581A0482|118 126|base-pair
P01569581A0482|26 30|model
P01569584A0672|0 16|Hybridization data
P01569584A0672|93 97|6F6.1
P01569584A0672|142 146|genes
P01569584A0672|113 117|6F6.2
P01569584A0672|29 33|6F6.2
P01569584A0672|73 85|m6F6 cDNA clone
P01569584A0672|101 105|6F6.3
P01569945A0529|100 102|kDa
P01569945A0529|37 48|reading frame
P01569945A0529|92 95|mass
P01569945A0529|75 81|protein
P01569945A0529|3 10|SEN1 gene
P01572549A0000|100 107|products
P01572549A0000|168 188|growth factor receptors
P01572549A0000|23 26|PTKs
P01572549A0000|191 200|components
P01572549A0000|88 97|appearance
P01572549A0000|55 64|cell growth
P01572549A0000|46 52|control
P01572549A0000|120 128|oncogenes
P01572549A0000|145 161|signal transducers
P01572549A0000|67 72|virtue
P01572549A0000|0 21|Protein tyrosine kinases
P01573270A0000|69 80|immunization
P01573270A0000|129 134|killer
P01573270A0000|36 45|antibodies
P01573270A0000|136 138|LAK
P01573270A0000|152 170|EBV-B lymphocyte line
P01573270A0000|89 96|HLA class
P01573270A0000|3 8|IA4 mAb
P01573270A0000|54 63|BALB/c mice
P01573270A0000|28 33|series
P01577056A0178|60 71|theophylline
P01577056A0178|44 51|subjects
P01577056A0178|102 103|mg
P01577056A0178|73 79|mg.kg-1
P01577056A0178|185 188|days
P01577056A0178|107 109|day
P01577056A0178|152 155|days
P01577056A0178|137 143|periods
P01577056A0178|35 39|study
P01577056A0178|90 99|omeprazole
P01577056A0178|121 127|placebo
P01577056A0178|169 181|washout period
P01577056A0178|83 85|day
P01577740A1111|0 14|Primer extension
P01577740A1111|63 90|transcription initiation sites
P01577740A1111|18 25|mung bean
P01577740A1111|112 127|Northern analyses
P01577740A1111|29 45|S1 nuclease mapping
P01577819A0709|59 64|number
P01577819A0709|10 29|PRP-precursor alleles
P01577819A0709|76 83|domain C.
P01577819A0709|67 73|repeats
P01579472A1018|76 81|manner
P01579472A1018|36 41|region
P01579472A1018|16 30|enhancer element
P01579537A0000|31 34|uses
P01579537A0000|37 50|botulinum toxin
P01579537A0000|11 15|years
P01579537A0000|59 68|neurotoxin
P01580738T0001|0 8|Allagille
P01580738T0001|42 48|ascites
P01580738T0001|11 18|syndrome
P01581409A0398|101 107|results
P01581409A0398|113 116|skin
P01581409A0398|69 84|DPC AlaSTAT System
P01581409A0398|45 62|Pharmacia CAP System
P01581409A0398|122 125|test
P01581409A0398|87 96|comparison
P01581409A0398|14 24|specificity
P01581409A0398|0 10|Sensitivity
P01581577A1186|0 4|PSI-G
P01581577A1186|8 12|PSI-K
P01581577A1186|37 51|gene duplication
P01581577A1186|65 68|gene
P01581965A0388|30 35|domain
P01581965A0388|85 118|breakpoint cluster region gene product
P01581965A0388|200 206|GTPases
P01581965A0388|48 56|sequences
P01581965A0388|20 26|protein
P01581965A0388|134 139|rho GAP
P01581965A0388|5 14|C-terminus
P01581965A0388|120 129|n-chimerin
P01581965A0388|182 192|GAP activity
P01582413A0192|173 182|DNA binding
P01582413A0192|13 23|mutagenesis
P01582413A0192|108 114|helices
P01582413A0192|54 63|amino acids
P01582413A0192|39 46|clusters
P01582413A0192|85 90|region
P01582413A0192|135 140|domain
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|0 11|Dimerization
P01582413A0759|80 87|affinity
P01582413A0759|91 93|DNA
P01582413A0759|141 150|DNA binding
P01582413A0759|51 60|protein E12
P01582413A0759|111 125|transactivation
P01582413A0759|14 18|Myf-5
P01582500A0178|25 29|sleep
P01582500A0178|12 22|rhythmicity
P01583819A0377|57 58|Hz
P01583819A0377|64 75|Simson method
P01583819A0377|46 47|HZ
P01583819A0377|31 37|filters
P01583819A0377|0 2|SEA
P01584812T0000|15 24|expression
P01584812T0000|57 68|localization
P01584812T0000|74 77|gene
P01584812T0000|33 41|structure
P01584812T0000|100 124|transcription factor NGFI-C
P01585014A0000|347 350|I.U.
P01585014A0000|203 212|lupin grain
P01585014A0000|32 40|treatment
P01585014A0000|421 425|FSH-P
P01585014A0000|142 150|treatment
P01585014A0000|160 165|spring
P01585014A0000|359 380|mare serum gonadotrophin
P01585014A0000|102 102|h
P01585014A0000|216 221|autumn
P01585014A0000|303 312|Merino ewes
P01585014A0000|249 252|days
P01585014A0000|45 57|gonadotrophin
P01585014A0000|108 131|progestagen sponge removal
P01585014A0000|152 157|autumn
P01585014A0000|134 139|season
P01585014A0000|331 341|combination
P01585014A0000|283 291|ovulation
P01585014A0000|23 29|effects
P01585014A0000|382 385|PMSG
P01585014A0000|78 91|micrograms GnRH
P01585014A0000|258 270|sponge removal
P01585014A0000|171 176|effect
P01585014A0000|392 419|mg follicle stimulating hormone
P01585014A0000|277 280|time
P01585014A0000|2 11|experiment
P01585014A0000|67 73|hormone
P01585014A0000|233 236|days
P01586901A0000|117 122|window
P01586901A0000|68 78|medications
P01586901A0000|86 90|drugs
P01586901A0000|9 20|interactions
P01586901A0000|43 50|patients
P01587267A1144|87 92|enzyme
P01587267A1144|52 56|X-ray
P01587267A1144|166 176|mutagenesis
P01587267A1144|135 138|gene
P01587267A1144|109 118|expression
P01587267A1144|33 46|interpretation
P01587267A1144|99 105|cloning
P01587267A1144|3 14|sequence data
P01587267A1144|73 81|structure
P01587763A0402|61 66|scheme
P01587763A0402|108 111|days
P01587763A0402|93 95|day
P01587763A0402|71 79|fractions
P01587763A0402|5 19|body irradiation
P01587763A0402|97 98|hr
P01588270A1029|95 96|.9
P01588270A1029|12 24|blood pressure
P01588270A1029|53 57|study
P01588270A1029|103 106|mmHg
P01588270A1029|108 108|P
P01588270A1029|124 126|DBP
P01588270A1029|45 47|end
P01588270A1029|1 9|reduction
P01588315A0356|204 207|maps
P01588315A0356|79 88|polyhedrin
P01588315A0356|170 178|direction
P01588315A0356|111 124|polyhedrin gene
P01588315A0356|9 31|Orgyia pseudotsugata MNPV
P01588315A0356|52 56|terms
P01588315A0356|33 38|OpMNPV
P01588315A0356|96 103|sequence
P01588315A0356|181 188|relation
P01588315A0356|131 137|viruses
P01588315A0356|59 75|promoter structure
P01588315A0356|0 5|AgMNPV
P01588913A0000|127 134|P. putida
P01588913A0000|81 93|transcription
P01588913A0000|35 42|dnaA gene
P01588913A0000|1 4|gene
P01588961A0000|0 3|STP1
P01588961A0000|61 69|sequences
P01588961A0000|129 137|pre-tRNAs
P01588961A0000|19 27|yeast gene
P01588961A0000|89 96|families
P01588961A0000|41 47|removal
P01588963A1153|42 51|conditions
P01588963A1153|77 88|Cdc25 protein
P01588963A1153|10 19|antibodies
P01588965A0000|0 15|GCR1 gene function
P01588965A0000|49 62|gene expression
P01589576A0170|144 145|T3
P01589576A0170|126 127|ps
P01589576A0170|139 140|ps
P01589576A0170|129 130|T2
P01589576A0170|116 117|T1
P01589576A0170|3 13|decay curves
P01589576A0170|46 58|superposition
P01589576A0170|16 38|chlorophyll fluorescence
P01589576A0170|87 96|components
P01589576A0170|101 113|time constants
P01589576A0170|154 155|ns
P01592545A0726|85 85|p
P01592545A0726|103 103|%
P01592545A0726|40 46|average
P01592545A0726|51 51|%
P01592545A0726|21 33|blood pressure
P01592545A0726|124 131|patients
P01592545A0726|54 61|patients
P01594554A0845|129 136|function
P01594554A0845|5 11|results
P01594554A0845|47 63|trypsin inhibitors
P01594554A0845|32 36|roles
P01594554A0845|94 108|feedback control
P01594554A0845|41 43|CCK
P01596007A0908|30 35|Stages
P01596007A0908|46 48|REM
P01596007A0908|187 189|SWS
P01596007A0908|121 134|control studies
P01596007A0908|10 15|events
P01596007A0908|159 159|%
P01596007A0908|83 94|gamma OH study
P01596007A0908|203 210|ABSTRACT
P01596007A0908|106 106|%
P01596007A0908|225 229|WORDS
P01596007A0908|194 200|gamma OH
P01596007A0908|57 66|proportion
P01597170A0000|82 88|group Co
P01597170A0000|169 174|months
P01597170A0000|147 149|air
P01597170A0000|90 91|Cr
P01597170A0000|151 162|control group
P01597170A0000|73 74|Cr
P01597170A0000|76 78|NO3
P01597170A0000|45 49|CoCl2
P01597170A0000|120 126|group Co
P01597170A0000|34 41|mg/m3 Co2
P01597170A0000|62 69|mg/m3 Cr3
P01597170A0000|177 185|days/week
P01597170A0000|110 117|mg/m3 Co2
P01597170A0000|5 11|rabbits
P01597170A0000|191 196|hr/day
P01597272A0077|40 57|withdrawal symptoms
P01597272A0077|22 30|methadone
P01597272A0077|2 6|women
P01597462A0457|44 47|gene
P01597462A0457|26 30|CDC14
P01597462A0457|0 9|Disruption
P01600531A0483|54 54|%
P01600531A0483|26 26|%
P01600531A0483|32 46|phosphocreatine
P01600531A0483|60 71|control group
P01600531A0483|8 11|flow
P01601181A0842|82 89|mesoderm
P01601181A0842|20 26|protein
P01601181A0842|104 111|germ band
P01601181A0842|55 66|gastrulation
P01601181A0842|48 52|onset
P01601181A0842|3 16|60A transcripts
P01601869A1389|59 63|E-box
P01601869A1389|7 13|segment
P01601869A1389|106 111|region
P01601869A1389|30 35|region
P01601869A1389|175 188|BC3H1 myoblasts
P01601869A1389|150 159|activation
P01603088A1121|45 46|TR
P01603088A1121|70 79|activation
P01603088A1121|113 118|manner
P01603088A1121|83 92|repression
P01603088A1121|5 11|results
P01605038T0001|0 8|Influence
P01605038T0001|53 56|GABA
P01605038T0001|44 50|effects
P01605038T0001|17 26|regulation
P01605038T0001|59 62|rats
P01607223A0000|145 153|liposomes
P01607223A0000|45 60|release technique
P01607223A0000|6 19|investigations
P01607223A0000|76 85|laser light
P01607223A0000|69 73|pulse
P01607223A0000|96 102|release
P01607223A0000|177 187|vasculature
P01608239T0001|13 20|barriers
P01611699A0000|5 25|pyridoxine derivatives
P01611699A0000|54 61|stem bark
P01611699A0000|64 88|Albizzia julibrissin DURAZZ
P01612085A0624|131 136|U.ml-1
P01612085A0624|65 70|U.ml-1
P01612085A0624|111 125|distance runners
P01612085A0624|23 25|EPO
P01612085A0624|27 40|concentrations
P01612085A0624|138 138|P
P01612085A0624|49 59|triathletes
P01612085A0624|3 21|serum erythropoietin
P01613640A0158|3 18|coating materials
P01613640A0158|82 85|Brij
P01613640A0158|23 32|poloxamine
P01613640A0158|51 60|poloxamine
P01613640A0158|37 46|poloxamine
P01613640A0158|66 74|poloxamer
P01615049A0000|3 8|eating
P01615049A0000|74 78|cycle
P01615049A0000|12 27|drinking patterns
P01615049A0000|60 69|h light/12 h
P01615049A0000|35 39|goats
P01615049A0000|43 47|ad lib
P01615182A0206|102 103|mg
P01615182A0206|154 158|amoxy
P01615182A0206|76 92|combination tablet
P01615182A0206|10 14|study
P01615182A0206|162 163|mg
P01615182A0206|65 70|levels
P01615182A0206|120 121|mg
P01615182A0206|108 118|bromhexeine
P01615182A0206|94 98|amoxy
P01615182A0206|41 57|sputum amoxycillin
P01615182A0206|28 38|improvement
P01615182A0206|59 63|amoxy
P01615493A0408|3 4|HC
P01615493A0408|64 71|daughter
P01615493A0408|7 14|activity
P01615493A0408|37 37|%
P01615493A0408|18 30|antigen levels
P01615493A0408|92 97|levels
P01615493A0408|43 43|%
P01615493A0975|0 9|Argatroban
P01615493A0975|68 77|inhibition
P01615493A0975|36 37|HC
P01615493A0975|113 122|wall damage
P01615493A0975|40 49|conditions
P01615493A0975|80 95|thrombin activity
P01615493A0975|98 102|sites
P01616475A0756|86 98|family history
P01616475A0756|149 173|panic disorder presentation
P01616475A0756|101 113|panic disorder
P01616475A0756|32 39|validity
P01616475A0756|123 130|patients
P01616475A0756|48 61|CP/NCA patients
P01616475A0756|42 45|NFPD
P01616475A0756|5 11|results
P01616475A0756|74 81|patients
P01617242T0000|0 13|FDA regulations
P01617242T0000|40 47|products
P01617242T0000|17 29|growth factors
P01617776A0343|178 183|system
P01617776A0343|50 60|arrhythmias
P01617776A0343|210 213|days
P01617776A0343|186 192|reentry
P01617776A0343|27 32|system
P01617776A0343|151 154|role
P01617776A0343|112 122|innervation
P01617776A0343|128 132|heart
P01617776A0343|219 228|infarction
P01617776A0343|204 208|heart
P01617776A0343|74 83|infarction
P01617801A0088|0 5|DESIGN
P01617801A0088|7 22|Serum aldosterone
P01617801A0088|110 111|mg
P01617801A0088|26 44|plasma renin activity
P01617801A0088|82 88|minutes
P01617801A0088|57 62|supine
P01617801A0088|98 106|captopril
P01618027A1108|14 24|transcripts
P01618027A1108|34 37|size
P01618027A1108|67 73|profile
P01618027A1108|104 114|E10 fragment
P01618027A1108|148 156|remainder
P01618027A1108|168 173|region
P01618027A1108|131 136|probes
P01618243T0000|37 46|volunteers
P01618243T0000|11 27|amine pressor tests
P01618256A0521|118 131|micrograms.l-1
P01618256A0521|81 81|%
P01618256A0521|51 57|regimen
P01618256A0521|26 38|concentration
P01618256A0521|3 6|mean
P01618256A0521|109 114|regime
P01618256A0521|61 74|micrograms.l-1
P01619114A0383|67 85|Mini Speech Processor
P01619114A0383|11 15|study
P01619114A0383|19 29|performance
P01619114A0383|87 89|MSP
P01619114A0383|35 38|SMSP
P01619642A0131|4 10|parents
P01620118A0470|179 185|chicken
P01620118A0470|11 18|proteins
P01620118A0470|89 98|activation
P01620118A0470|142 147|repeat
P01620118A0470|109 129|immunodeficiency virus
P01620118A0470|30 36|ability
P01620118A0470|194 198|cells
P01620118A0470|59 63|kappa
P01620129A0417|144 145|J.
P01620129A0417|105 113|cell cycle
P01620129A0417|91 102|H4-FO108 gene
P01620129A0417|40 51|factor HiNF-D
P01620129A0417|20 30|interaction
P01620129A0417|138 142|cells
P01620129A0417|71 85|promoter element
P01620610A1070|159 167|sequences
P01620610A1070|101 106|vector
P01620610A1070|45 62|expression problems
P01620610A1070|31 32|TI
P01620610A1070|127 135|mutations
P01620610A1070|172 175|rule
P01620610A1070|185 196|MTI subregion
P01620610A1070|2 11|conclusion
P01620781A0611|147 153|stimuli
P01620781A0611|15 22|subjects
P01620781A0611|41 49|sequences
P01620781A0611|101 102|A3
P01620781A0611|216 220|class
P01620781A0611|188 195|sequence
P01620781A0611|78 82|words
P01620781A0611|107 108|B4
P01620781A0611|113 114|A5
P01620781A0611|66 72|control
P01620781A0611|95 96|B2
P01620781A0611|89 90|A1
P01620781A0611|200 206|members
P01620781A0611|174 181|position
P01620781A0611|121 128|reversal
P01621584A0183|0 5|UF-021
P01621584A0183|69 75|rabbits
P01621584A0183|35 35|%
P01621584A0183|63 66|eyes
P01621584A0183|140 146|IOP rise
P01621584A0183|16 23|solution
P01621584A0183|97 108|IOP reduction
P01621584A0183|118 121|mmHg
P01623900A0670|87 95|excretion
P01623900A0670|191 204|blood pressures
P01623900A0670|98 111|norepinephrine
P01623900A0670|136 142|Pl group
P01623900A0670|156 159|drop
P01623900A0670|307 311|month
P01623900A0670|53 59|changes
P01623900A0670|314 329|dF administration
P01623900A0670|263 285|norepinephrine excretion
P01623900A0670|65 76|plasma levels
P01623900A0670|165 170|supine
P01623900A0670|34 41|activity
P01623900A0670|5 17|blood pressure
P01623900A0670|232 250|norepinephrine level
P01624425A0907|67 85|consensus amino acids
P01624425A0907|102 110|azido-ATP
P01624425A0907|9 15|protein
P01624425A0907|38 44|mutants
P01624425A0907|49 61|substitutions
P01625131A0452|28 36|stoma site
P01625131A0452|63 71|rejection
P01625131A0452|45 48|risk
P01625131A0452|15 20|biopsy
P01625527A0000|166 189|maintenance haemodialysis
P01625527A0000|44 55|control group
P01625527A0000|118 133|treatment regimen
P01625527A0000|103 103|n
P01625527A0000|150 158|treatment
P01625527A0000|225 225|n
P01625527A0000|87 101|failure patients
P01625527A0000|160 160|n
P01625527A0000|68 72|group
P01625527A0000|209 223|transplantation
P01625527A0000|57 57|n
P01625527A0000|191 191|n
P01625527A0000|5 24|blood serotonin levels
P01626372T0000|0 6|Tissues
P01626372T0000|105 133|trimethoprim-sulfamethoxazole
P01626372T0000|10 17|exudates
P01626372T0000|64 71|bacteria
P01626372T0000|77 84|presence
P01626372T0000|97 102|levels
P01626372T0000|35 43|thymidine
P01626372T0000|47 52|growth
P01626430A1112|87 91|yeast
P01626430A1112|34 37|SNF2
P01626430A1112|26 30|RAD54
P01626430A1112|20 24|RAD16
P01626430A1112|95 109|Drosophila genes
P01626430A1112|3 12|homologies
P01626440A0449|28 50|instrument disinfectants
P01626440A0449|6 25|application solutions
P01626440A0449|79 81|day
P01626631A0557|145 153|elevation
P01626631A0557|168 172|level
P01626631A0557|62 70|brain stem
P01626631A0557|5 16|Rett syndrome
P01626631A0557|123 128|system
P01626631A0557|45 56|disturbances
P01627106A0320|134 151|isolation frequency
P01627106A0320|108 118|differences
P01627106A0320|10 19|experiment
P01627106A0320|63 84|S. enteritidis challenge
P01627106A0320|33 59|nitrofurazone administration
P01627106A0320|121 122|S.
P01627828A0475|27 34|blotting
P01627828A0475|156 162|SmN gene
P01627828A0475|102 111|pseudogene
P01627828A0475|37 44|mouse DNA
P01627828A0475|49 57|SmN probes
P01627828A0475|65 69|bands
P01627828A0475|2 10|agreement
P01627830A0000|83 86|CKI2
P01627830A0000|51 66|yeast cDNA library
P01627830A0000|3 7|cDNAs
P01627830A0000|76 79|CKI1
P01627830A0000|16 29|casein kinase-1
P01628201A0824|0 12|Incidence rate
P01628201A0824|95 102|datasets
P01628201A0824|58 61|year
P01628201A0824|39 42|year
P01628201A0824|72 78|minimum
P01628806A1347|99 112|helicase region
P01628806A1347|11 27|sequence variation
P01628806A1347|76 78|ORF
P01628806A1347|53 53|Y
P01628806A1347|44 46|ORF
P01628904A0386|42 49|kilobase
P01628904A0386|25 29|clone
P01628904A0386|8 16|screening
P01628904A0386|51 52|kb
P01628904A0386|54 59|insert
P01629768A0131|0 6|Lesions
P01629768A0131|89 105|glass micropipette
P01629768A0131|53 55|SOC
P01629768A0131|17 33|pressure injection
P01629768A0131|42 45|acid
P01630454A0635|44 52|regulator
P01630454A0635|11 15|dA-dT
P01630454A0635|55 74|Act1 promoter activity
P01630454A0635|6 9|poly
P01630454A0635|17 22|region
P01630455A0448|13 19|protein
P01630455A0448|156 168|IL-1 beta genes
P01630455A0448|39 45|NF beta A
P01630455A0448|80 90|DNA sequence
P01630455A0448|121 132|TATA box motif
P01630455A0448|27 37|NFIL-1 beta A
P01630569A0605|29 37|remission
P01630569A0605|21 23|AmB
P01630569A0605|7 19|amphotericin B
P01630569A0605|43 47|tumor
P01631229T0000|0 11|Cutis aplasia
P01633435A0743|119 125|Gossett
P01633435A0743|84 89|factor
P01633435A0743|106 113|Hauschka
P01633435A0743|91 95|MEF-2
P01633435A0743|25 39|characteristics
P01633435A0743|3 7|DRF-2
P01633435A0743|97 102|Buskin
P01633435A0743|15 21|protein
P01633816A0667|56 60|exons
P01633816A0667|12 16|clone
P01633816A0667|67 68|kb
P01633816A0667|136 144|start site
P01633816A0667|22 34|EcoRI fragment
P01633816A0667|84 89|region
P01633816A0667|95 101|opn gene
P01633816A0667|157 179|primer extension analysis
P01633816A0667|183 199|S1 nuclease mapping
P01634308A0191|0 24|Cardiovascular risk factors
P01634308A0191|51 60|techniques
P01634400A1101|0 14|Production costs
P01634400A1101|23 26|feed
P01634400A1101|55 75|replacement stock costs
P01634400A1101|36 44|operating
P01634464A0163|96 99|rise
P01634464A0163|9 15|patient
P01634464A0163|26 43|factor VII inhibitor
P01634464A0163|107 117|haemorrhage
P01634464A0163|65 88|penicillin administration
P01634464A0163|55 62|reaction
P01634861A1336|86 101|lactate clearance
P01634861A1336|33 52|oxygen debt hypothesis
P01634861A1336|8 15|contrast
P01634861A1336|73 82|oxygen debt
P01636339A0200|0 6|Account
P01636339A0200|100 111|pollen grains
P01636339A0200|91 98|crystals
P01636339A0200|39 46|elements
P01636339A0200|52 57|smears
P01636339A0200|71 75|mucus
P01636339A0200|120 128|fragments
P01636339A0200|132 136|fungi
P01636714A0845|143 145|CLP
P01636714A0845|40 44|areas
P01636714A0845|74 79|spleen
P01636714A0845|56 60|liver
P01636714A0845|137 137|h
P01636714A0845|110 112|MBF
P01636714A0845|48 50|MBF
P01636714A0845|3 9|results
P01636714A0845|67 72|cortex
P01636714A0845|99 104|serosa
P01637758A0532|2 9|addition
P01637758A0532|103 113|examination
P01637758A0532|48 52|group
P01637758A0532|78 79|cm
P01637758A0532|119 128|labour ward
P01637758A0532|149 149|%
P01637758A0532|65 74|dilatation
P01637758A0532|152 153|OR
P01637758A0532|176 176|P
P01637758A0532|18 27|proportion
P01637758A0532|30 34|women
P01637758A0532|161 163|% CI
P01637758A0532|138 138|%
P01639092A0776|0 4|Lewis
P01639092A0776|6 7|N.
P01639724A0452|1 12|control group
P01639724A0452|60 70|Nordette-28
P01639724A0452|102 110|pill cycle
P01639724A0452|90 94|times
P01639724A0452|25 27|age
P01639724A0452|45 58|contraceptives
P01639724A0452|33 37|years
P01639724A0452|19 23|women
P01640778A0485|20 25|method
P01640778A0485|76 84|screening
P01640778A0485|34 41|MLPA test
P01641628A0869|68 73|groups
P01641628A0869|49 56|subjects
P01641628A0869|108 115|research
P01641628A0869|100 105|points
P01641628A0869|156 170|reference values
P01641628A0869|21 35|reference values
P01641628A0869|3 12|modalities
P01642060A0471|73 80|patients
P01642060A0471|11 21|application
P01642060A0471|121 127|FIGO III
P01642060A0471|111 119|carcinoma
P01642060A0471|44 57|Phthalocyanine
P01643943A0300|55 57|TFR
P01643943A0300|11 27|lung cancer tissues
P01643943A0300|38 41|67Ga
P01644751A0590|100 114|msgB gene product
P01644751A0590|67 82|sequence analysis
P01644751A0590|8 19|reading frame
P01644796A0374|6 10|study
P01644796A0374|88 92|cells
P01644796A0374|52 56|furin
P01644796A0374|75 80|medium
P01644814A0068|72 77|T cells
P01644814A0068|22 28|protein
P01644814A0068|30 32|tax
P01644814A0068|55 69|immortalization
P01644814A0068|3 7|virus
P01644821A1259|219 234|butyrate response
P01644821A1259|148 156|sequences
P01644821A1259|8 15|butyrate
P01644821A1259|195 204|PSG1-I gene
P01644821A1259|183 189|regions
P01644821A1259|71 81|fusion genes
P01644821A1259|100 108|sequences
P01644821A1259|58 68|CAT activity
P01644831A0824|27 42|carboxyl terminus
P01644831A0824|197 204|activity
P01644831A0824|125 133|receptors
P01644831A0824|76 83|activity
P01644831A0824|149 156|portions
P01644831A0824|55 60|NGFI-B
P01644831A0824|162 177|carboxyl terminus
P01644831A0824|18 21|role
P01644831A0824|2 12|examination
P01644831A0824|135 141|mutants
P01644831A0824|99 108|accordance
P01645902A1462|114 115|TK
P01645902A1462|15 21|results
P01645902A1462|41 45|locus
P01645902A1462|178 185|activity
P01645902A1462|123 127|genes
P01645902A1462|77 78|gH
P01645902A1462|101 108|portions
P01645902A1462|166 175|expression
P01645902A1462|37 39|Syn
P01645902A1462|188 189|TK
P01645902A1462|63 66|gene
P01645902A1462|139 149|syn mutation
P01645902A1462|119 120|UL
P01645902A1462|83 88|region
P01645905A0341|0 12|Nucleoprotein
P01645905A0341|14 14|N
P01645905A0341|160 176|breakdown products
P01645905A0341|134 143|C-terminus
P01645905A0341|83 86|mass
P01645905A0341|58 61|TGEV
P01645905A0341|42 54|vaccinia virus
P01645905A0341|118 128|degradation
P01645905A0341|88 89|Mr
P01646157A0414|88 97|nucleotide
P01646157A0414|198 201|cDNA
P01646157A0414|139 139|%
P01646157A0414|166 185|alpha-galactosidase A
P01646157A0414|187 196|alpha-Gal A
P01646157A0414|110 126|amino acid homology
P01646157A0414|29 52|alpha-GalNAc cDNA sequence
P01646487A0874|0 7|Patients
P01646487A0874|73 75|IgA
P01646487A0874|182 189|activity
P01646487A0874|77 79|IgG
P01646487A0874|23 30|activity
P01646487A0874|150 157|patients
P01646487A0874|51 58|decrease
P01646487A0874|36 36|X
P01646487A0874|64 70|content
P01646487A0874|89 100|B lymphocytes
P01646487A0874|127 137|neutrophils
P01646487A0874|117 124|activity
P01646487A0874|81 83|IgM
P01646487A0874|85 85|T
P01646753A0336|3 8|reason
P01646753A0336|39 54|hydroxyl radicals
P01646753A0336|88 104|reduction proceeds
P01646753A0336|167 168|EO
P01646753A0336|114 116|N2O
P01646753A0336|184 185|V.
P01646753A0336|170 176|N2O/N2O
P01646753A0336|20 24|oxide
P01647070A0232|28 30|JCV
P01647070A0232|34 44|SV40 origins
P01647070A0232|9 20|JCV T antigens
P01647070A0232|47 60|DNA replication
P01647656A0000|175 187|regurgitation
P01647656A0000|135 150|LV volume overload
P01647656A0000|95 102|patients
P01647656A0000|70 71|LV
P01647656A0000|114 118|years
P01647656A0000|3 10|relation
P01647656A0000|73 80|function
P01647656A0000|43 50|receptor
P01647813A0512|41 47|protein
P01647813A0512|53 62|complexity
P01647813A0512|76 79|need
P01647813A0512|126 132|control
P01647813A0512|9 18|transcript
P01647813A0512|135 144|expression
P01648142A1170|139 139|P
P01648142A1170|88 95|survival
P01648142A1170|101 106|CAV arm
P01648142A1170|108 108|P
P01648142A1170|21 27|disease
P01648142A1170|133 137|PE arm
P01648142A1170|120 127|survival
P01648142A1170|32 39|survival
P01648142A1170|56 58|arm
P01648142A1170|2 9|patients
P01648530A0000|14 20|M region
P01648530A0000|133 161|actin-beta-globin reporter gene
P01648530A0000|113 122|expression
P01648530A0000|184 187|eggs
P01648530A0000|56 72|actin gene promoter
P01648530A0000|42 48|Xenopus
P01649173A0160|72 82|nucleotides
P01649173A0160|109 130|transcription start site
P01649173A0160|51 60|attenuator
P01649173A0160|139 148|attenuator
P01649173A0160|172 182|nucleotides
P01649173A0160|150 159|attenuator
P01649173A0160|2 9|addition
P01649318A0734|0 5|EBNA-2
P01649318A0734|74 123|herpes simplex virus TK promoter transcription start site
P01649318A0734|53 56|mRNA
P01649318A0734|22 32|CD23 element
P01649318A1222|5 15|experiments
P01649318A1222|79 86|evidence
P01649318A1222|91 96|EBNA-2
P01649318A1222|111 123|transcription
P01649318A1222|50 64|cell DNA fragment
P01649318A1222|126 134|cell genes
P01649539T0000|0 13|Plasma vitamin E
P01649539T0000|20 25|lipids
P01649539T0000|62 68|surgery
P01649539T0000|29 49|myeloperoxidase levels
P01649835A0822|143 150|affinity
P01649835A0822|106 107|3H
P01649835A0822|27 37|PBR/IBP cDNA
P01649835A0822|42 51|COS-7 cells
P01649835A0822|116 127|binding sites
P01649835A0822|97 104|affinity
P01649835A0822|109 110|PK
P01649835A0822|154 161|Ro5-4864
P01649835A0822|84 90|density
P01649835A0822|71 78|increase
P01650524A0837|146 151|A63162
P01650524A0837|34 45|permeability
P01650524A0837|10 14|phase
P01650524A0837|156 158|ICI
P01650524A0837|173 185|dexamethasone
P01650524A0837|61 66|cavity
P01650524A0837|70 83|LTB4 production
P01650524A0837|140 144|BW A4C
P01650524A0837|116 138|5-LO inhibitors phenidone
P01650524A0837|188 197|colchicine
P01650524A0837|87 90|dose
P01650557T0000|99 114|transplant donors
P01650557T0000|61 89|cytomegalovirus antibody status
P01650557T0000|22 43|latex agglutination test
P01650557T0000|10 16|results
P01650557T0000|49 58|assessment
P01651232A0152|85 87|UTP
P01651232A0152|76 82|mixture
P01651232A0152|91 98|thio-UTP
P01651232A0152|34 48|uridine residues
P01651232A0152|4 7|mRNA
P01651918A0000|151 164|bisphosphatase
P01651918A0000|40 52|cDNA fragments
P01651918A0000|131 136|kinase
P01651918A0000|138 147|fructose-2
P01651918A0000|80 96|amino acid sequence
P01651918A0000|99 127|rat testis fructose-6-phosphate
P01652372A0153|29 46|localization signal
P01652372A0153|48 50|NLS
P01652372A0153|74 77|cell
P01652372A0153|16 19|SWI5
P01652372A0153|120 126|protein
P01652372A0153|100 104|entry
P01652515A0379|119 120|DA
P01652515A0379|22 30|deviation
P01652515A0379|129 133|level
P01652515A0379|143 153|neostriatum
P01652515A0379|65 75|haloperidol
P01652515A0379|2 9|contrast
P01652515A0379|35 55|avoidance conditioning
P01652515A0379|89 103|microinjections
P01652755A1492|290 298|promoters
P01652755A1492|171 175|c-fos
P01652755A1492|243 246|IL-6
P01652755A1492|53 66|overexpression
P01652755A1492|191 200|beta-actin
P01652755A1492|18 40|transfection experiments
P01652755A1492|214 222|promoters
P01652755A1492|155 158|IL-6
P01652755A1492|79 117|retinoblastoma susceptibility gene product
P01652755A1492|43 51|HeLa cells
P01652755A1492|276 278|MHC
P01652755A1492|119 120|RB
P01653173A0619|215 234|preinitiation complex
P01653173A0619|32 38|binding
P01653173A0619|125 137|preincubation
P01653173A0619|183 189|extract
P01653173A0619|4 13|repression
P01653173A0619|57 60|site
P01653173A0619|44 45|E2
P01653173A0619|143 168|HPV-18 P105 promoter template
P01653173A0619|85 103|P105 promoter TATA box
P01653173A0619|201 209|formation
P01653236A0895|40 61|glucocorticoid receptor
P01653236A0895|19 29|association
P01653236A0895|123 139|hamster ovary cells
P01653236A0895|92 113|glucocorticoid receptor
P01653236A0895|64 69|L cells
P01653236A0895|14 16|p50
P01653238A1062|222 235|promoter region
P01653238A1062|131 147|consensus sequence
P01653238A1062|93 97|sites
P01653238A1062|49 51|TPA
P01653238A1062|53 68|response elements
P01653238A1062|181 188|TGF-beta
P01653238A1062|11 47|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1062|104 126|transcription factor AP-1
P01653238A1062|201 207|element
P01653238A1062|163 178|growth factor beta
P01653238A1715|0 2|TPA
P01653238A1715|59 64|enzyme
P01653238A1715|38 47|activities
P01653238A1715|6 13|TGF-beta
P01653918A0286|70 76|corneas
P01653918A0286|105 124|corneal pain threshold
P01653918A0286|56 61|cornea
P01653918A0286|80 87|strength
P01653918A0286|32 39|pressure
P01654349A0327|101 101|K
P01654349A0327|75 78|gain
P01654349A0327|38 58|NaHCO3 supplementation
P01654349A0327|131 136|NaHCO3
P01654349A0327|33 35|KCl
P01654349A0327|0 9|Feed intake
P01655126T0000|0 18|Extraction procedure
P01655126T0000|25 35|measurement
P01655126T0000|79 85|toluene
P01655126T0000|38 54|butyltin compounds
P01655126T0000|67 73|tissues
P01655126T0000|94 102|tropolone
P01655126T0000|87 89|HBr
P01655713A0294|25 30|region
P01655713A0294|111 113|Tn1
P01655713A0294|80 85|strain
P01655713A0294|125 132|mutation
P01655713A0294|89 92|exs1
P01655713A0294|69 77|phenotype
P01655713A0294|6 10|study
P01655713A0294|95 97|Tn1
P01656220T0000|0 2|axl
P01656220T0000|79 100|receptor tyrosine kinase
P01656220T0000|52 64|leukemia cells
P01656220T0000|17 20|gene
P01656221A1319|103 118|tyrosine residues
P01656221A1319|67 73|regions
P01656221A1319|81 85|FGFRs
P01656221A1319|141 150|FGFR family
P01656221A1319|129 135|members
P01656221A1319|0 8|Alignment
P01656221A1319|43 49|Tyr-766
P01656221A1319|14 31|amino acid sequences
P01656235A0946|83 92|CCAAT motif
P01656235A0946|22 28|element
P01656235A0946|64 69|region
P01656235A0946|47 54|analysis
P01656675A0236|0 16|Capnography curves
P01656675A0236|90 97|controls
P01656675A0236|21 31|HVS patients
P01656675A0236|68 77|complaints
P01656675A0236|42 49|patients
P01657246A0325|3 29|transcription initiation site
P01657246A0325|52 53|bp
P01657246A0325|77 79|Met
P01657249A1019|115 131|region determinant
P01657249A1019|46 51|chains
P01657249A1019|139 146|VH4-HV2a
P01657249A1019|38 40|VH4
P01657249A1019|18 19|CA
P01657249A1019|62 63|CA
P01657249A1019|93 95|VH4
P01657415A0837|0 13|Intron K1 cox1.2
P01657415A0837|58 65|location
P01657415A0837|68 75|K. lactis
P01657594A0472|71 74|cgs1
P01657594A0472|39 59|complementation groups
P01657594A0472|23 29|mutants
P01657594A0472|79 82|cgs2
P01657969A1420|134 139|enzyme
P01657969A1420|77 98|amino acid substitutions
P01657969A1420|157 173|calmodulin binding
P01657969A1420|48 59|interactions
P01657969A1420|8 18|alterations
P01657969A1420|123 128|change
P01658356A1369|87 92|FeLV-C
P01658356A1369|55 64|generation
P01658356A1369|19 30|coexpression
P01658356A1369|67 82|FeLV recombinants
P01658356A1369|192 196|mRNAs
P01658356A1369|161 166|levels
P01658356A1369|3 9|results
P01658356A1369|117 129|3201B cell line
P01658356T0000|116 122|viruses
P01658356T0000|26 47|leukemia virus subgroup B
P01658356T0000|64 74|env elements
P01658356T0000|0 12|Recombination
P01658356T0000|50 50|C
P01658356T0000|101 110|activities
P01658375A0854|119 123|genes
P01658375A0854|143 152|difference
P01658375A0854|164 166|end
P01658375A0854|172 180|LAT intron
P01658375A0854|34 37|ends
P01658375A0854|78 88|transcripts
P01658375A0854|45 51|introns
P01658375A0854|3 21|nucleotide sequences
P01658375A0854|183 184|GC
P01658375A0854|197 215|consensus sequence GT
P01658468A0123|68 75|hamsters
P01658468A0123|28 36|isolation
P01658468A0123|148 152|sites
P01658468A0123|61 66|cavity
P01658468A0123|10 15|months
P01658468A0123|114 120|culture
P01658468A0123|96 103|attempts
P01658468A0123|39 49|C. kutscheri
P01658741A1047|97 101|locus
P01658741A1047|36 44|kilobases
P01658741A1047|47 64|nucleotide sequence
P01658741A1047|93 95|ADE
P01658741A1047|3 10|strategy
P01659685T0000|14 22|promoters
P01659685T0000|45 51|regions
P01659685T0000|77 89|Dictyostelium
P01659685T0000|60 74|Dd ras expression
P01660486A1756|204 217|gene expression
P01660486A1756|192 201|activation
P01660486A1756|68 91|aminoglycoside resistance
P01660486A1756|49 62|gene cotransfer
P01660486A1756|105 110|marker
P01660486A1756|40 47|cell type
P01660486A1756|173 182|PKC pathway
P01660486A1756|3 9|results
P01660486A1756|147 163|control mechanisms
P01660925T0000|0 15|Transfer RNA genes
P01660925T0000|80 87|elements
P01660925T0000|98 111|consensus boxes
P01660925T0000|20 42|Dictyostelium discoideum
P01660925T0000|135 141|regions
P01661369A0825|117 124|moieties
P01661369A0825|50 55|probes
P01661369A0825|13 16|strD
P01661369A0825|93 100|capacity
P01661369A0825|20 28|strE genes
P01661369A0825|71 78|presence
P01662609A0398|71 77|R.HgiCI
P01662609A0398|46 52|M.HgiCI
P01662609A0398|60 69|amino acids
P01662609A0398|6 10|genes
P01662609A0398|35 44|amino acids
P01662609A0398|18 29|polypeptides
P01662794A0640|0 9|Expression
P01662794A0640|48 57|COS-1 cells
P01662794A0640|34 45|transfection
P01662794A0640|69 78|kDa protein
P01662794A0640|147 154|antisera
P01662794A0640|15 21|wt1 gene
P01662807A1182|3 8|factor
P01662807A1182|51 65|SV40 chromosomes
P01662807A1182|24 33|TR promoter
P01662807A1182|81 89|infection
P01662884A1029|15 22|mg b.i.d.
P01662884A1029|77 85|treatment
P01662884A1029|46 49|days
P01662884A1029|105 115|prostatitis
P01662884A1029|0 11|Temafloxacin
P01664192A1577|42 49|ED90 dose
P01664192A1577|52 61|vecuronium
P01664192A1577|16 22|effects
P01669611A0142|99 106|diseases
P01669611A0142|60 64|aorta
P01669611A0142|24 28|fever
P01669611A0142|3 9|patient
P01669611A0142|47 54|aneurysm
P01669611A0142|71 85|pleuropneumonia
P01671675A0483|71 77|pCAD142
P01671675A0483|124 139|sequence analysis
P01671675A0483|101 120|hybridization methods
P01671675A0483|12 21|clone pKB11
P01671675A0483|83 84|bp
P01671675A0483|184 191|amino end
P01671675A0483|166 177|cDNA sequence
P01671675A0483|49 58|cDNA insert
P01671675A0483|197 210|CAD polypeptide
P01671675A0483|46 47|bp
P01671675A0483|41 44|pair
P01671675A0905|28 51|Northern blotting analysis
P01671675A0905|68 73|region
P01671675A0905|76 82|CAD gene
P01671675A0905|4 13|conclusion
P01673220A0578|67 76|bol3 allele
P01673220A0578|64 65|Sn
P01673220A0578|11 19|isolation
P01673220A0578|32 41|cDNA clones
P01674177T0001|0 18|Histamine-2 blockade
P01674177T0001|21 29|psoriasis
P01674242A0358|57 57|%
P01674242A0358|373 383|ticlopidine
P01674242A0358|215 220|T-3262
P01674242A0358|270 278|verapamil
P01674242A0358|452 461|interferon
P01674242A0358|398 410|thiabendazole
P01674242A0358|79 90|erythromycin
P01674242A0358|385 396|idrocilamide
P01674242A0358|92 105|troleandomycin
P01674242A0358|280 288|diltiazem
P01674242A0358|466 473|caffeine
P01674242A0358|144 151|enoxacin
P01674242A0358|258 268|propranolol
P01674242A0358|436 450|BCG-vaccination
P01674242A0358|167 176|pefloxacin
P01674242A0358|475 491|half-life increase
P01674242A0358|107 127|triacetyloleandomycin
P01674242A0358|153 165|ciprofloxacin
P01674242A0358|290 299|nifedipine
P01674242A0358|350 359|viloxazine
P01674242A0358|412 421|disulfiram
P01674242A0358|190 198|ofloxacin
P01674242A0358|231 234|acid
P01674242A0358|236 245|cimetidine
P01674242A0358|343 348|agents
P01674242A0358|130 142|roxithromycin
P01674242A0358|178 188|norfloxacin
P01674242A0358|423 431|influenza
P01674242A0358|312 320|frusemide
P01674242A0358|361 371|allopurinol
P01674242A0358|247 256|etintidine
P01674242A0358|301 310|furosemide
P01674242A0358|3 11|clearance
P01674369A0417|53 67|restriction site
P01674369A0417|75 81|cloning
P01674369A0417|16 22|element
P01674662A0000|120 120|n
P01674662A0000|218 224|factors
P01674662A0000|163 173|progression
P01674662A0000|72 72|n
P01674662A0000|187 193|complex
P01674662A0000|104 118|lymphadenopathy
P01674662A0000|195 197|ARC
P01674662A0000|64 70|disease
P01674662A0000|140 144|study
P01674662A0000|245 253|relevance
P01674662A0000|201 204|AIDS
P01674662A0000|33 45|heroin addicts
P01674662A0000|176 179|AIDS
P01674817A0862|2 9|homology
P01674817A0862|60 67|proteins
P01674817A0862|25 29|RNA14
P01674817A0862|47 51|RNA14
P01674817A0862|33 37|RNA15
P01674817A0862|79 87|data banks
P01674817T0000|14 23|yeast RNA14
P01674817T0000|27 36|RNA15 genes
P01674817T0000|55 67|mRNA decay rate
P01674817T0000|105 110|domain
P01674817T0000|69 84|sequence analysis
P01674817T0000|116 127|RNA15 protein
P01674817T0000|0 8|Mutations
P01675154T0000|42 54|bypass surgery
P01675154T0000|10 19|infarction
P01675154T0000|22 29|patients
P01675424A0991|41 52|H-NR sequence
P01675424A0991|67 82|NADH-NR sequences
P01675424A0991|104 121|pyridine nucleotide
P01675424A0991|39 39|P
P01675424A0991|129 132|site
P01675424A0991|55 64|comparison
P01675424A0991|35 37|NAD
P01675424A0991|15 24|difference
P01675637T0033|73 80|activity
P01675637T0033|84 105|receptor dimer formation
P01675637T0033|7 25|amino acid difference
P01675637T0033|41 46|region
P01675763A1389|6 13|benefits
P01675763A1389|37 39|CD4
P01675763A1389|71 75|entry
P01675763A1389|25 32|children
P01675763A1389|64 68|liter
P01678287A1308|15 37|Antp TATAA binding protein
P01678287A1308|101 112|homeobox gene
P01678287A1308|160 167|function
P01678287A1308|78 82|cells
P01678287A1308|186 190|cells
P01678392A0648|99 107|cmH2O l-1 s
P01678392A0648|33 38|change
P01678392A0648|23 25|2SD
P01678392A0648|5 21|% confidence values
P01678392A0648|68 78|variability
P01678392A0648|41 43|Ros
P01679068A0000|154 163|Klebsiella
P01679068A0000|54 58|value
P01679068A0000|8 14|infants
P01679068A0000|166 180|Enterobacter spp
P01679068A0000|60 64|range
P01679068A0000|27 35|care units
P01679068A0000|46 46|%
P01679068A0000|129 135|strains
P01679124A1368|60 65|dorsal
P01679124A1368|96 102|animals
P01679124A1368|151 167|dorsal hippocampus
P01679124A1368|207 211|WORDS
P01679124A1368|76 85|hippocampi
P01679124A1368|128 141|norepinephrine
P01679124A1368|11 17|studies
P01679124A1368|143 144|NE
P01679124A1368|43 54|ChAT activity
P01679124A1368|185 192|ABSTRACT
P01679124A1368|170 182|MS/HSI animals
P01679124A1368|37 40|loss
P01679124A1368|120 125|levels
P01679749A1171|3 14|localization
P01679749A1171|60 71|availability
P01679749A1171|92 96|tools
P01679749A1171|21 37|proteoglycan locus
P01679749A1171|77 81|RFLPs
P01679749A1171|48 53|genome
P01679749A1171|120 127|diseases
P01679749A1171|106 112|studies
P01679749A1171|136 156|HSPG2 proteoglycan gene
P01681075A0429|99 111|determination
P01681075A0429|153 174|carbohydrate metabolism
P01681075A0429|11 29|dobutamine injection
P01681075A0429|144 149|energy
P01681075A0429|68 77|myocardium
P01681075A0429|6 8|min
P01681075A0429|45 63|pimobendan injection
P01681075A0429|131 141|metabolites
P01681075A0429|117 128|tissue levels
P01681075A0429|40 42|min
P01682484A0680|14 21|stenosis
P01682484A0680|156 167|hemodynamics
P01682484A0680|142 148|LCX flow
P01682484A0680|50 59|procaterol
P01682484A0680|116 126|dysfunction
P01682484A0680|69 72|dose
P01682484A0680|178 194|lactate metabolism
P01682484A0680|28 35|contrary
P01682509A0539|97 106|T-cell line
P01682509A0539|32 43|proteins IE86
P01682509A0539|108 113|HUT-78
P01682509A0539|88 93|HIV LTR
P01682509A0539|53 56|IE55
P01682509A0539|45 48|IE72
P01682509A0539|13 20|evidence
P01682542A0690|71 78|location
P01682542A0690|3 9|country
P01682542A0690|22 34|HIV prevalence
P01682542A0690|82 92|counselling
P01682542A0690|44 51|strategy
P01682542A0690|118 128|individuals
P01684791A0000|60 89|chicken glutamine synthetase gene
P01684791A0000|13 19|element
P01684791A0000|29 54|glucocorticoid inducibility
P01686909A0299|28 36|excretion
P01686909A0299|11 18|increase
P01686909A0299|115 120|kidney
P01686909A0299|66 76|elimination
P01686909A0299|105 108|acid
P01686909A0299|79 87|bretylium
P01687050T0000|30 49|fluid immunoglobulin G
P01687050T0000|10 14|value
P01687050T0000|78 85|diseases
P01687050T0000|51 53|IgG
P01688841A0430|0 9|Expression
P01688841A0430|26 29|ipaC
P01688841A0430|49 52|invK
P01688841A0430|21 24|ipaB
P01688841A0430|36 39|invG
P01688841A0430|89 101|regulator virF
P01688841A0430|15 19|genes
P01688841A0430|31 34|invE
P01688841A0430|41 44|invJ
P01688972A0803|9 10|VT
P01688972A0803|37 43|patient
P01690703A0285|0 9|Venkatesan
P01690703A0285|14 15|D.
P01690728A1166|3 10|presence
P01690728A1166|58 70|kilobase pairs
P01690728A1166|35 49|mRNA transcripts
P01690728A1166|129 153|S1 nuclease protection assay
P01690728A1166|103 127|Northern blot hybridization
P01690728A1166|82 92|fibroblasts
P01690728A1166|72 73|kb
P01690728A1166|161 183|polymerase chain reaction
P01690812A0000|30 32|DNA
P01690812A0000|111 124|gene insertions
P01690812A0000|34 37|rDNA
P01690812A0000|126 129|type
P01690812A0000|39 43|units
P01690812A0000|98 101|S RNA
P01690812A0000|134 137|type
P01690812A0000|15 15|%
P01691184A0995|127 142|precursor protein
P01691184A0995|108 121|disulfide bonds
P01691184A0995|36 37|Mr
P01691184A0995|81 96|cleavage products
P01691184A0995|18 34|polypeptide chains
P01691184A0995|0 4|Gap b3
P01692135A0783|172 176|mouse
P01692135A0783|77 81|mRNAs
P01692135A0783|126 132|Fc gamma
P01692135A0783|11 34|rtFc gamma R alpha cDNA clone
P01692135A0783|184 194|killer cells
P01692135A0783|93 104|CRNK-16 cells
P01692135A0783|142 152|mRNA species
P01692837A0390|131 139|kilobases
P01692837A0390|109 112|mRNA
P01692837A0390|81 93|kilobase pairs
P01692837A0390|22 26|exons
P01692837A0390|71 76|region
P01692837A0390|31 37|introns
P01692837A0390|4 8|genes
P01692962A0980|29 33|alpha
P01692962A0980|110 122|cAMP synthesis
P01692962A0980|140 160|protein kinase activity
P01692962A0980|40 51|s polypeptide
P01692962A0980|78 82|cells
P01692962A0980|61 72|hamster ovary
P01692962A0980|6 15|expression
P01692962A0980|74 76|CHO
P01694009A0112|97 107|polypeptide
P01694009A0112|78 91|signal sequence
P01694009A0112|56 61|region
P01694009A0112|18 21|exon
P01694009A0112|4 7|exon
P01694014A0716|0 8|Treatment
P01694014A0716|78 80|PMA
P01694014A0716|107 112|levels
P01694014A0716|48 76|phorbol 12-myristate 13-acetate
P01694014A0716|23 36|cell lines HL-60
P01694014A0716|135 142|LD78 cDNA
P01694014A0716|98 98|h
P01694014A0716|118 132|RNA hybridizable
P01694014A0716|40 43|U937
P01694280A0000|75 82|cisterns
P01694280A0000|23 37|ventriculoscope
P01694280A0000|41 51|observation
P01694280A0000|57 66|ventricles
P01694525A0000|0 22|Isopenicillin N isomerase
P01694525A0000|24 32|epimerase
P01694525A0000|106 115|N-terminus
P01694525A0000|84 100|amino acid sequence
P01695098A1116|0 7|Serum IgG
P01695098A1116|31 38|patients
P01695116A0078|45 47|CR1
P01695116A0078|65 76|chemotherapy
P01695116A0078|94 99|months
P01695116A0078|35 43|remission
P01695116A0078|3 9|patient
P01695314A0762|14 15|NS
P01695314A0762|8 12|mg/dl
P01695314A0762|18 30|glucose levels
P01695314T0000|0 18|Platelet aggregation
P01695314T0000|54 79|calcium antagonist treatment
P01695314T0000|31 37|control
P01695314T0000|82 85|type
P01695314T0000|88 103|diabetes mellitus
P01695322A0000|0 4|Wnt-1
P01695322A0000|47 55|insertion
P01695322A0000|74 78|mouse
P01695322A0000|23 30|oncogene
P01695322A0000|6 10|int-1
P01695322A0000|66 68|DNA
P01695322A0000|86 95|tumor virus
P01695378A1406|0 8|Induction
P01695378A1406|25 30|T cells
P01695378A1406|91 95|level
P01695378A1406|11 16|Jurkat
P01695378A1406|35 63|phorbol 12-myristate 13-acetate
P01695378A1406|67 75|ionomycin
P01695378A1406|98 105|FKBP mRNA
P01695905A0480|42 50|intestine
P01695905A0480|65 70|levels
P01695905A0480|88 93|muscle
P01695905A0480|73 78|kidney
P01695905A0480|98 110|adipose tissue
P01695905A0480|29 34|levels
P01695905A0480|0 8|GLUT5 mRNA
P01697611A0738|61 67|growths
P01697611A0738|20 25|tumors
P01697683T0000|0 13|Identification
P01697683T0000|38 45|promoter
P01697683T0000|52 65|cytotactin gene
P01697683T0000|17 32|characterization
P01697928A1214|227 235|promoters
P01697928A1214|22 37|sequence homology
P01697928A1214|197 206|alpha/beta
P01697928A1214|115 129|response element
P01697928A1214|79 87|consensus
P01697928A1214|49 54|region
P01697928A1214|57 61|Ly-6E
P01698761A1059|177 182|mucoid
P01698761A1059|197 205|phenotype
P01698761A1059|65 71|repeats
P01698761A1059|99 105|histone
P01698761A1059|149 155|strains
P01698761A1059|124 127|AlgP
P01698761A1059|113 121|structure
P01698761A1059|43 48|region
P01698761A1059|160 169|conversion
P01698761A1059|15 31|DNA rearrangements
P01698772A0238|6 7|J.
P01699944A1538|117 131|promoter element
P01699944A1538|5 11|results
P01699944A1538|137 140|VLC1
P01699944A1538|164 173|c-fos genes
P01699944A1538|149 159|alpha-actin
P01699944A1538|59 80|CArG box binding proteins
P01700272A0838|0 14|Polyadenylation
P01700272A0838|74 81|residues
P01700272A0838|126 136|recruitment
P01700272A0838|94 99|number
P01700272A0838|49 58|maturation
P01700272A0838|17 21|B4 RNA
P01701088A1335|0 11|Co-existence
P01701088A1335|64 74|AP-2 element
P01701088A1335|46 53|elements
P01701088A1335|77 84|CCAAT box
P01701088A1335|29 36|elements
P01702361A0621|86 107|angiogenesis inhibitors
P01702361A0621|35 51|collagen synthesis
P01702361A0621|18 23|agents
P01702361A0621|9 15|studies
P01702361A0621|55 64|deposition
P01702426A0196|31 34|gene
P01702426A0196|76 85|expression
P01702426A0196|138 153|acid synthase gene
P01702426A0196|61 70|regulation
P01702426A0196|19 24|region
P01702426A1006|4 6|set
P01702426A1006|9 18|cDNA clones
P01702426A1006|61 91|lambda-ZAP goose liver cDNA library
P01702426A1006|122 129|fragment
P01702426A1006|149 156|DNA clone
P01702426A1006|43 44|kb
P01702432A1296|0 23|Northern blotting analysis
P01702432A1296|52 56|genes
P01702432A1296|95 106|pollen tissue
P01702432A1296|77 82|clones
P01702432A1296|37 46|expression
P01702972A0613|116 120|cDNAs
P01702972A0613|166 170|genes
P01702972A0613|56 64|subfamily
P01702972A0613|7 23|cDNA hybridization
P01702972A0613|94 98|bands
P01702972A0613|67 76|G0S19 genes
P01702972A0613|33 40|DNA blots
P01702972A0613|84 91|patterns
P01702972A0613|131 139|G0S30 cDNA
P01703335T0000|19 27|disorders
P01703335T0000|40 56|immunosuppression
P01703335T0000|61 62|FK
P01703335T0000|94 113|transplant population
P01703335T0000|74 85|observations
P01703632T0000|42 52|polypeptide
P01703632T0000|13 22|suppressor
P01703632T0000|57 63|regions
P01703632T0000|91 98|proteins
P01703632T0000|30 33|gene
P01707659A0458|60 66|HLA-5.4
P01707659A0458|91 94|Ch28
P01707659A0458|76 89|chimpanzee gene
P01707659A0458|55 58|gene
P01707800A0354|144 146|N20
P01707800A0354|122 135|onset latencies
P01707800A0354|80 84|peaks
P01707800A0354|11 34|N13-N20 interpeak interval
P01707800A0354|96 109|conduction time
P01707800A0354|138 140|N11
P01707800A0354|61 73|parallel shift
P01708098A0922|43 48|series
P01708098A0922|62 86|alpha promoter DNA sequences
P01708098A0922|152 161|control GRE
P01708098A0922|102 110|basepairs
P01708098A0922|18 40|complex DNA binding assays
P01708098A0922|141 142|GR
P01708098A0922|173 180|receptor
P01708771A1215|0 20|Sequence determination
P01708771A1215|122 127|others
P01708771A1215|81 86|Asn109
P01708771A1215|52 57|Asn120
P01708771A1215|105 113|molecules
P01708771A1215|132 136|Asn72
P01708771A1215|73 77|Asn65
P01708771A1215|31 38|peptides
P01708774A0203|59 72|promoter region
P01708774A0203|24 35|AP-1 activity
P01708774A0203|3 13|DNA sequence
P01709486A0000|48 61|proto-oncogene
P01709486A0000|39 39|W
P01709486A0000|63 67|c-kit
P01709486A0000|9 16|mutation
P01709933T0000|0 8|Isolation
P01709933T0000|67 69|pS1
P01709933T0000|12 27|characterization
P01709933T0000|47 50|gene
P01709933T0000|93 98|statin
P01709933T0000|55 65|polypeptide
P01709933T0000|33 35|rat
P01710766A0349|72 90|amino acids C terminal
P01710766A0349|109 123|initiation codon
P01710766A0349|55 62|sequence
P01710766A0349|22 29|presence
P01710766A0349|32 38|absence
P01710766A0349|3 10|proteins
P01710768A1172|84 90|pattern
P01710768A1172|25 33|existence
P01710768A1172|36 44|sequences
P01710768A1172|62 63|kb
P01710768A1172|139 145|ability
P01710768A1172|152 155|gene
P01710768A1172|108 117|expression
P01710768A1172|123 132|HLA-B7 gene
P01710768A1172|167 181|gamma interferon
P01710768A1172|3 9|results
P01710979T0000|40 50|association
P01710979T0000|9 18|SH3 domains
P01710979T0000|77 88|proteins p130
P01710979T0000|92 95|p110
P01710979T0000|21 27|pp60src
P01710979T0000|55 62|tyrosine
P01710979T0000|3 5|SH2
P01710985A0315|0 3|Chem
P01711041A0348|87 87|%
P01711041A0348|5 10|clones
P01711041A0348|93 102|beta-chain
P01711041A0348|46 49|gene
P01711041A0348|69 81|C5 alpha-chain
P01711041A0962|84 92|kilobases
P01711041A0962|51 55|exons
P01711041A0962|105 109|exons
P01711041A0962|60 69|beta-chain
P01711041A0962|30 38|kilobases
P01711041A0962|3 15|C5 alpha-chain
P01711048T0000|114 135|osteogenesis imperfecta
P01711048T0000|25 25|G
P01711048T0000|51 59|pro-alpha
P01711048T0000|12 19|mutation
P01711048T0000|38 43|intron
P01711048T0000|94 104|RNA splicing
P01711048T0000|64 67|gene
P01711048T0000|69 74|COL1A2
P01711048T0000|28 35|position
P01712296A0157|29 33|genes
P01712296A0157|50 58|positions
P01712296A0157|76 95|amino acid differences
P01712296A0157|3 21|nucleotide sequences
P01713213A0000|42 66|pim-1 proto-oncogene shares
P01713213A0000|76 83|homology
P01713213A0000|24 31|sequence
P01713213A0000|138 148|Pim-1 enzyme
P01713213A0000|93 122|serine/threonine protein kinases
P01713213A0000|183 211|protein tyrosine kinase activity
P01713213A0000|3 9|protein
P01713213A0488|73 84|Pim-1 protein
P01713213A0488|123 146|glutathione S-transferase
P01713213A0488|17 25|pim-1 cDNA
P01713213A0488|148 150|GST
P01713213A0488|54 66|vector pGEX-2T
P01713213A0488|97 109|fusion product
P01714322A0969|44 50|kDa hsps
P01714322A0969|90 94|genes
P01714322A0969|61 68|products
P01714322A0969|53 57|maize
P01714322A0969|4 9|report
P01714358A0990|55 77|wheat etioplast membranes
P01714358A0990|92 94|ATP
P01714358A0990|5 18|kDa polypeptide
P01714358A0990|83 90|gamma 32P
P01714452A0559|116 120|sites
P01714452A0559|47 58|repeat domain
P01714452A0559|20 26|protein
P01714452A0559|73 84|conservation
P01714452A0559|87 93|serines
P01714452A0559|97 106|threonines
P01714452A0559|35 35|%
P01714452A0559|131 152|carbohydrate attachment
P01714452A0559|0 7|Homology
P01714902A0221|158 171|TCR stimulation
P01714902A0221|88 98|cell surface
P01714902A0221|39 82|Ti alpha-beta CD3 gamma delta epsilon TCR complexes
P01714902A0221|130 152|interleukin-2 production
P01714902A0221|2 9|addition
P01714902A0221|100 106|CD3 zeta
P01714902A0221|189 213|histocompatibility complex
P01715593A0838|28 30|hrs
P01715593A0838|4 14|desipramine
P01715593A0838|36 54|fluoxetine injection
P01715593A0838|56 66|brain levels
P01715593A0838|69 79|desipramine
P01715975A0885|17 20|CYP1
P01715975A0885|8 14|effects
P01715975A0885|57 61|cells
P01716292A0000|186 192|DR alpha
P01716292A0000|10 17|analysis
P01716292A0000|112 120|cell lines
P01716292A0000|195 203|H-2E alpha
P01716292A0000|93 98|series
P01716292A0000|35 41|HLA-DR1
P01716292A0000|134 141|products
P01716292A0000|53 72|T cell allorecognition
P01716292A0000|162 168|Eb genes
P01716292A0000|26 32|regions
P01716292A0000|155 159|DRB/H
P01716629A0000|15 24|cDNA clones
P01716629A0000|52 76|matrix glycoprotein undulin
P01717718A1255|142 148|Gag-Pol
P01717718A1255|88 89|PR
P01717718A1255|12 25|point mutations
P01717718A1255|178 179|RT
P01717718A1255|166 175|activation
P01717718A1255|67 68|RT
P01717718A1255|151 162|prerequisite
P01717718A1255|132 139|PR domain
P01717718A1255|31 45|Gag-Pol PR domain
P01717718A1255|55 64|activation
P01717718A1255|115 126|conformation
P01717833A1223|72 85|granulosa cells
P01717833A1223|102 112|CREB protein
P01717833A1223|61 69|forskolin
P01717833A1223|3 22|alpha inhibin promoter
P01717833A1223|41 43|CRE
P01717833T0000|0 9|Regulation
P01717833T0000|39 47|adenosine
P01717833T0000|72 83|transfection
P01717833T0000|54 66|monophosphate
P01717833T0000|15 30|alpha inhibin gene
P01717833T0000|88 104|rat granulosa cells
P01717925A0477|129 134|region
P01717925A0477|74 91|sequence similarity
P01717925A0477|15 33|nucleotide sequences
P01717925A0477|104 105|bp
P01717925A0477|0 9|Comparison
P01717925A0477|58 60|DNA
P01717994T0000|0 6|Cloning
P01717994T0000|48 62|complementation
P01717994T0000|40 45|kinase
P01717994T0000|83 90|mutation
P01717994T0000|15 18|cDNA
P01717994T0000|73 77|yeast
P01718043A0384|14 26|osteomyelitis
P01718043A0384|163 163|%
P01718043A0384|48 58|PMN elastase
P01718043A0384|121 148|erythrocyte sedimentation rate
P01718043A0384|78 78|%
P01718043A0384|35 41|empyema
P01718043A0384|150 160|sensitivity
P01718043A0384|63 73|sensitivity
P01718043A0384|2 9|patients
P01718043A0384|43 43|n
P01718983A1640|85 88|Cell
P01718983A1640|14 17|Goff
P01718983A1640|42 43|R.
P01718983A1640|45 50|Newman
P01718983A1640|19 20|D.
P01718983A1640|22 30|Griffiths
P01718983A1640|52 53|B.
P01718983A1640|76 77|R.
P01718983A1640|35 40|Tizard
P01718983A1640|65 66|G.
P01718983A1640|11 12|C.
P01718983A1640|71 74|Lobb
P01718983A1640|32 33|B.
P01718983A1640|55 63|Chi-Rosso
P01718983A1640|3 9|Hession
P01718983A1640|0 1|E.
P01719684A0494|148 164|sphincter function
P01719684A0494|8 14|results
P01719684A0494|52 60|receptors
P01719684A0494|69 76|prostate
P01719684A0494|26 33|increase
P01720555A1087|54 66|alfalfa organs
P01720555A1087|25 36|B2 transcript
P01720843A1506|27 41|sulfhydryl group
P01720843A1506|51 61|angiotensin
P01720843A1506|127 146|nitrovasodilator EDRF
P01720843A1506|106 111|effect
P01720843A1506|5 11|results
P01720843A1506|72 87|enzyme inhibitors
P01721261T0000|0 15|Pharmacokinetics
P01721261T0000|25 42|transplant patients
P01721261T0000|18 19|FK
P01721884A0962|255 276|RNase H crystal structure
P01721884A0962|207 209|Pol
P01721884A0962|72 84|ribonuclease H
P01721884A0962|26 30|match
P01721884A0962|222 222|P
P01721884A0962|249 249|D
P01721884A0962|211 218|helices O
P01721884A0962|238 244|helices
P01721884A0962|43 48|region
P01721884A0962|93 98|domain
P01721884A0962|186 191|RNase H
P01721884A0962|126 131|region
P01721884A0962|86 91|RNase H
P01721884A0962|160 172|investigators
P01722319A0849|0 7|Analysis
P01722319A0849|155 155|N
P01722319A0849|159 166|C termini
P01722319A0849|49 61|CHIP28 protein
P01722319A0849|20 36|amino acid sequence
P01722319A0849|89 95|domains
P01722319A0849|118 137|N-glycosylation sites
P01722479A0302|30 32|HCG
P01722479A0302|37 47|sensitivity
P01722479A0302|75 75|%
P01722479A0302|54 54|%
P01722479A0302|59 69|specificity
P01722479A0302|14 27|concentrations
P01723619A0766|130 138|intestine
P01723619A0766|162 172|F absorption
P01723619A0766|108 114|passage
P01723619A0766|10 13|rate
P01723619A0766|88 95|emptying
P01723619A0766|36 39|rise
P01723619A0766|42 61|plasma F concentration
P01723619A0766|149 154|factor
P01723619A0766|16 26|F absorption
P01723619A0766|117 117|F
P01723962A0165|82 82|h
P01723962A0165|88 96|injection
P01723962A0165|99 103|Na-Tc
P01723962A0165|71 77|maximum
P01723962A0165|3 10|activity
P01723962A0165|56 56|h
P01723962A0165|27 33|amylase
P01723962A0165|13 23|serum lipase
P01724982A0237|43 51|HCV EIA kit
P01724982A0237|77 78|IL
P01724982A0237|53 62|Abbott Lab.
P01724982A0237|64 75|North Chicago
P01725547A0354|86 94|blood flow
P01725547A0354|106 106|p
P01725547A0354|104 104|%
P01725547A0354|63 63|%
P01725547A0354|65 65|p
P01725547A0354|31 38|increase
P01725547A0354|51 58|diameter
P01725547A0354|96 98|CBF
P01725547A0354|0 8|Diltiazem
P01725622A0292|57 59|CCI
P01725622A0292|51 55|Gpt/l
P01725622A0292|8 18|transfusion
P01725622A0292|30 46|platelet increment
P01726211A0502|100 106|factors
P01726211A0502|63 69|factors
P01726211A0502|5 15|risk factors
P01726211A0502|33 38|groups
P01726211A0502|45 50|vessel
P01726211A0502|85 90|action
P01726631T0001|15 24|prevention
P01726631T0001|93 102|resistance
P01726631T0001|67 73|Sassari
P01726631T0001|75 81|profile
P01726631T0001|27 44|hospital infections
P01726631T0001|119 124|agents
P01726631T0001|50 64|Local Health Unit
P01726631T0001|132 136|usage
P01726631T0001|0 11|Epidemiology
P01727488A1146|17 21|cDNAs
P01727488A1146|82 95|gene expression
P01727488A1146|36 46|stimulation
P01727494A0000|42 47|nature
P01727494A0000|107 110|host
P01727494A0000|73 82|activation
P01727494A0000|50 59|VV proteins
P01727494A0000|26 34|immunogen
P01727494A0000|94 101|response
P01727494A0000|14 15|VV
P01727494A0000|0 12|Vaccinia virus
P01730412T0000|0 2|Max
P01730412T0000|39 43|c-Myc
P01730412T0000|24 34|interaction
P01730412T0000|14 20|domains
P01730747A0205|26 31|Reilly
P01730747A0205|33 34|C.
P01730747A0205|19 24|S phase
P01730747A0205|15 16|G1
P01731107A0928|0 12|Substitutions
P01731107A0928|68 82|pRNA replication
P01731107A0928|165 170|strand
P01731107A0928|143 151|structure
P01731107A0928|25 29|bases
P01731107A0928|181 186|genome
P01731107A0928|110 120|maintenance
P01731107A0928|44 52|ICR2 motif
P01731107A0928|60 65|levels
P01731933T0000a|0 1|Zn
P01731933T0000a|6 30|coordination domain mutants
P01731933T0000a|33 38|T4 gene
P01731933T0000a|41 47|protein
P01731933T0000b|0 1|Zn
P01731933T0000b|6 30|coordination domain mutants
P01731933T0000b|33 38|T4 gene
P01731933T0000b|41 47|protein
P01731979A1408|3 19|tissue specificity
P01731979A1408|22 35|gene expression
P01731979A1408|79 107|CaMV 35S domain B enhancer element
P01732033A0000|59 65|infancy
P01732033A0000|109 119|brain injury
P01732033A0000|123 127|model
P01732033A0000|3 17|pathophysiology
P01732033A0000|46 56|brain injury
P01732033A0000|69 77|childhood
P01732033A0000|29 38|management
P01732736A1076|0 10|Transcripts
P01732736A1076|37 42|Oct-25
P01732736A1076|22 35|POU-domain gene
P01732736A1076|68 74|oocytes
P01732736A1076|83 89|embryos
P01732736A1076|60 65|levels
P01732736A1076|131 142|gastrulation
P01732752A0156|58 72|pre-B-cell lines
P01732752A0156|20 26|Abelson
P01732752A0156|11 16|B cells
P01732752A0156|33 40|leukemia
P01732752A0156|74 79|LT mRNA
P01733105A0127|3 8|genome
P01733105A0127|11 22|Thogoto virus
P01733105A0127|35 42|segments
P01733105A0127|69 76|sense RNA
P01733358A0240|89 102|adenocarcinoma
P01733358A0240|107 121|mucin production
P01733358A0240|39 44|groups
P01733358A0240|63 80|cystadenocarcinoma
P01733358A0240|5 10|tumors
P01733358A0240|48 58|cystadenoma
P01733358A0240|136 139|cyst
P01733358A0240|85 87|III
P01734020A1318|0 13|Immunostaining
P01734020A1318|41 50|constructs
P01734020A1318|16 20|cells
P01734020A1318|124 129|nuclei
P01734020A1318|102 108|mutants
P01734020A1318|147 154|PKC alpha
P01734283A0817|27 38|RAP74 protein
P01734283A0817|101 118|translation product
P01734283A0817|51 59|HeLa cells
P01734283A0817|83 85|DNA
P01734283A0817|134 138|RAP30
P01734570T0000|0 6|Effects
P01734570T0000|9 39|thromboxane synthetase inhibition
P01734570T0000|84 87|rate
P01734570T0000|68 77|resistance
P01734570T0000|99 111|translocation
P01734570T0000|122 133|porcine model
P01735347A0482|127 135|extension
P01735347A0482|102 112|development
P01735347A0482|151 158|necrosis
P01735347A0482|51 59|treatment
P01735347A0482|20 25|insult
P01735347A0482|78 81|rise
P01735347A0482|84 95|plasma lipase
P01735347A0482|115 121|ascites
P01735447A0271|74 90|pre-super-pro-PrB
P01735447A0271|105 116|sec61 mutants
P01735447A0271|64 72|precursor
P01735447A0271|18 25|molecule
P01735447A0271|153 161|reticulum
P01735447A0271|3 6|size
P01735447A0271|122 134|translocation
P01735447A0833|131 139|reticulum
P01735447A0833|93 95|PrB
P01735447A0833|82 90|precursor
P01735447A0833|105 114|kDa pro-PrB
P01735447A0833|8 26|active-site mutation
P01735447A0833|47 56|processing
P01735721A0185|57 87|Bacillus stearothermophilus TyrTS
P01735721A0185|40 48|% identity
P01735721A0185|151 169|B. subtilis TyrTS gene
P01735721A0185|12 28|amino acid sequence
P01735721A0185|127 134|identity
P01735721A0185|93 101|% identity
P01735721A0185|181 184|tyrZ
P01735721A0185|195 195|%
P01735721A0185|116 120|TyrTS
P01736093A0731|74 81|promoter
P01736093A0731|14 24|CAT activity
P01736093A0731|97 106|CCAAT boxes
P01736093A0731|136 148|constructions
P01736093A0731|52 60|sequences
P01736093A0731|117 119|HSE
P01736651A0104|15 21|Infants
P01736651A0104|26 40|Children clinics
P01736651A0104|55 59|Minn.
P01736651A0104|9 13|Women
P01736651A0104|43 53|Minneapolis
P01736844T0000|165 172|function
P01736844T0000|86 98|androgen index
P01736844T0000|175 177|men
P01736844T0000|66 77|testosterone
P01736844T0000|105 127|testosterone measurement
P01736844T0000|17 28|testosterone
P01736844T0000|182 189|epilepsy
P01736844T0000|0 11|Testosterone
P01737741A0000|0 9|BACKGROUND
P01737741A0000|56 60|MAOIs
P01737741A0000|82 91|depression
P01737741A0000|131 135|study
P01737741A0000|29 54|monoamine oxidase inhibitors
P01737741A0000|14 26|effectiveness
P01737789A0800|147 152|intron
P01737789A0800|22 31|breakpoint
P01737789A0800|52 58|repeats
P01737789A0800|64 81|acceptor splice site
P01737789A0800|93 124|down-stream alpha-delta breakpoint
P01738470A0441|86 102|recognition memory
P01738470A0441|20 24|PDDAT
P01738470A0441|48 56|positions
P01738470A0441|71 75|order
P01738470A0441|0 7|Patients
P01738653T0014|0 3|Bone
P01738653T0014|7 11|bones
P01738936A0292|14 28|plasma C-peptide
P01738936A0292|3 10|patients
P01738936A0292|41 42|pM
P01738936A0292|70 77|analysis
P01739439A0257|0 6|Complex
P01739439A0257|138 148|control mice
P01739439A0257|50 56|mdx mice
P01739439A0257|41 47|muscles
P01739439A0257|62 68|complex
P01739439A0257|123 129|muscles
P01739439A0257|79 88|discharges
P01739439A0257|96 108|abnormalities
P01739439A0257|17 26|discharges
P01739956A0638|0 9|Management
P01739956A0638|53 57|drugs
P01739956A0638|80 84|drugs
P01739956A0638|23 26|beta
P01739956A0638|31 44|calcium channel
P01739956A0638|60 65|type IC
P01740121A0136|14 20|problem
P01740121A0136|54 91|baculovirus/insect cell expression system
P01740121A0136|41 45|Kex2p
P01740330A0329|0 1|J.
P01740437A0851|14 24|core protein
P01740437A0851|122 127|domain
P01740437A0851|74 81|antibody
P01740437A0851|30 49|liver HSPG preparation
P01740437A0851|130 140|fibroglycan
P01740448A1735|14 33|transmembrane regions
P01740448A1735|189 197|membranes
P01740448A1735|165 174|attachment
P01740448A1735|177 186|precursors
P01740448A1735|72 89|amino acid stretches
P01740448A1735|131 136|region
P01740682A0703|0 7|Toxicity
P01740682A0703|75 84|leukopenia
P01740682A0703|87 109|World Health Organization
P01740682A0703|127 127|%
P01740682A0703|43 43|%
P01740682A0703|181 181|%
P01740682A0703|66 72|courses
P01740682A0703|49 56|patients
P01740682A0703|203 209|courses
P01740682A0703|150 156|courses
P01740682A0703|162 177|thrombocytopenia
P01740682A0703|34 39|emesis
P01740682A0703|133 140|patients
P01740682A0703|187 194|patients
P01740682A0703|60 60|%
P01740682A0703|144 144|%
P01740682A0703|197 197|%
P01740682A0703|115 119|grade
P01741249A0177|0 3|W.G.
P01742341A0499|89 96|stressor
P01742341A0499|36 43|reaction
P01742341A0499|66 79|transportation
P01742341A0499|4 8|study
P01742341A0499|100 109|Beagle dogs
P01742606A0000|84 91|antibody
P01742606A0000|26 29|cDNA
P01742606A0000|50 76|lambda Gt11 expression library
P01742606A0000|124 146|kDa spectrin beta-subunit
P01742606A0000|1 23|mouse brain beta-spectrin
P01742879A0471|0 6|RESULTS
P01742879A0471|35 45|stimulation
P01742879A0471|116 128|water drinking
P01742879A0471|8 25|Plasma AVP responses
P01742879A0471|94 101|patients
P01742879A0471|61 70|inhibition
P01742879A0471|73 80|drinking
P01744039A0511|3 11|fragments
P01744039A0511|75 92|gel electrophoresis
P01744039A0511|39 61|polymerase chain reaction
P01744039A0511|114 137|conformation polymorphism
P01744039A0511|18 23|region
P01744042A1355|55 59|phase
P01744042A1355|62 66|cells
P01744042A1355|109 118|% glutamine
P01744042A1355|74 83|Luria broth
P01744042A1355|95 102|% glucose
P01744042A1355|3 12|csbA fusion
P01744119A0757|150 153|gene
P01744119A0757|183 191|templates
P01744119A0757|201 208|sequence
P01744119A0757|155 161|protein
P01744119A0757|111 138|oligoribonucleotide synthesis
P01744119A0757|82 88|effects
P01744119A0757|101 108|proteins
P01744119A0757|3 13|constraints
P01744119A0757|16 42|primase recognition sequences
P01744119A0757|44 74|nucleotide substrate requirements
P01747972T0000|12 18|therapy
P01747972T0000|40 55|artery dissection
P01748067A0000|56 58|men
P01748067A0000|45 52|patients
P01748067A0000|131 141|replacement
P01748067A0000|123 125|hip
P01748067A0000|201 204|neck
P01748067A0000|177 185|arthritis
P01748067A0000|188 195|fracture
P01748067A0000|97 101|years
P01748067A0000|210 214|femur
P01748067A0000|71 75|years
P01748067A0000|90 92|age
P01748067A0000|12 16|trial
P01748067A0000|64 66|age
P01748067A0000|80 84|women
P01748194A0767|124 138|cord transection
P01748194A0767|34 45|hemisections
P01748194A0767|8 14|lesions
P01748194A0767|140 140|N
P01748194A0767|81 88|recovery
P01748287T0000|16 23|proteins
P01748287T0000|36 45|properties
P01748287T0000|68 74|targets
P01748292A0000|14 18|cDNAs
P01748292A0000|37 56|G protein alpha subunit
P01748292A0000|91 92|cv
P01748292A0000|23 26|gene
P01748292A0000|61 66|tomato
P01748292A0000|68 89|Lycopersicon esculentum
P01748630A0125|0 22|Growth factor stimulation
P01748630A0125|97 101|Ser62
P01748630A0125|153 159|members
P01748630A0125|183 184|E.
P01748630A0125|210 211|F.
P01748630A0125|25 29|cells
P01748630A0125|79 94|activation domain
P01748630A0125|196 199|I.C.
P01748630A0125|39 53|phosphorylation
P01748630A0125|165 173|Myc family
P01748630A0125|186 194|Northwood
P01748630A0125|201 208|Gonzalez
P01748630A0125|121 126|region
P01748630A0125|59 63|c-Myc
P01748630A0125|175 181|Alvarez
P01751163A0000|44 56|complications
P01751163A0000|22 30|potential
P01751163A0000|107 118|Sarns/3M-VAD
P01751163A0000|126 131|calves
P01751163A0000|68 79|implantation
P01751163A0000|3 9|authors
P01751163A0000|100 105|device
P01751255A0529|14 15|CO
P01751255A0529|61 69|MBBF group
P01751255A0529|40 40|p
P01751255A0529|7 12|output
P01751970A0209|0 16|Amino acid residues
P01751970A0209|47 54|sequence
P01751970A0209|71 78|residues
P01752441A0000|118 141|TAR RNA stem-loop structure
P01752441A0000|95 112|trinucleotide bulge
P01752441A0000|183 193|transcripts
P01752441A0000|167 172|leader
P01752441A0000|61 68|residues
P01752441A0000|74 91|hexanucleotide loop
P01752441A0000|15 24|activation
P01752441A0000|30 44|HIV-1 Tat protein
P01752792A0000|98 104|neurons
P01752792A0000|81 87|stimuli
P01752792A0000|35 40|coding
P01752792A0000|53 67|time differences
P01752792A0000|138 147|albino rats
P01752792A0000|22 29|evidence
P01752792A0000|69 72|ITDs
P01752792A0000|118 123|cortex
P01753317A0879|5 11|results
P01753317A0879|116 126|bone defects
P01753317A0879|51 61|combination
P01753317A0879|81 93|bone formation
P01753317A0879|66 69|FDBA
P01753317A0879|46 48|TTC
P01754381A0000|146 156|Trypanozoon
P01754381A0000|25 40|characterization
P01754381A0000|11 14|step
P01754381A0000|188 205|DNA polymerase alpha
P01754381A0000|70 81|trypanosomes
P01754381A0000|170 173|gene
P01754381A0000|54 67|DNA polymerases
P01754381A0000|215 218|core
P01754381A0000|134 144|Trypanosoma
P01754381A0000|119 128|expression
P01754381A0000|220 227|pol alpha
P01756195A1117|102 102|r
P01756195A1117|66 79|concentrations
P01756195A1117|84 86|age
P01756195A1117|31 38|increase
P01756195A1117|2 9|addition
P01756195A1117|88 88|p
P01756539A0354|103 112|infarction
P01756539A0354|9 20|hypertension
P01756539A0354|51 59|narrowing
P01756539A0354|71 79|condition
P01757341A0591|86 89|area
P01757341A0591|35 36|Na
P01757341A0591|24 33|number/mm2
P01757341A0591|127 145|alkaline phosphatase
P01757341A0591|43 53|capillaries
P01757341A0591|92 96|brain
P01757341A0591|3 16|volume fraction
P01757341A0591|18 19|Vv
P01758750A0000|0 13|Airway pressure
P01758750A0000|61 68|children
P01758750A0000|53 56|tube
P01758750A0000|72 78|variety
P01758750A0000|17 23|air flow
P01758750A0000|81 91|ventilators
P01759052A0786|0 3|Appl
P01759282A0000|117 124|position
P01759282A0000|49 54|object
P01759282A0000|8 19|distribution
P01759282A0000|127 138|biomechanics
P01759282A0000|63 80|contact interaction
P01759282A0000|85 88|head
P01759282A0000|95 100|impact
P01759282A0000|0 5|Issues
P01759282A0000|29 34|energy
P01760166A0963|0 9|CONCLUSION
P01760166A0963|35 44|septum site
P01760166A0963|103 110|patients
P01760166A0963|21 24|SpO2
P01760166A0963|80 89|finger site
P01761736A0158|153 153|P
P01761736A0158|197 202|volume
P01761736A0158|26 38|body clearance
P01761736A0158|147 151|hours
P01761736A0158|188 194|changes
P01761736A0158|65 70|mL/min
P01761736A0158|101 120|elimination half-life
P01761736A0158|168 177|antipyrine
P01761736A0158|205 216|distribution
P01761736A0158|72 72|P
P01761736A0158|0 8|Diltiazem
P01762053A0557|26 33|material
P01762053A0557|73 81|particles
P01762053A0557|3 10|granules
P01762053A0557|53 57|space
P01762914A1218|85 104|translation start site
P01762914A1218|76 77|kb
P01762914A1218|9 19|uPA promoter
P01762914A1218|50 57|elements
P01762917A0615|27 29|Glu
P01762917A0615|33 35|Lys
P01762917A0615|105 114|DNA binding
P01762917A0615|99 102|loss
P01762917A0615|13 15|Ser
P01762917A0615|52 67|TGEK tetrapeptide
P01762917A0615|19 23|Gly69
P01762917A0615|70 75|finger
P01762917A0615|80 85|TFIIIA
P01763065A0913|0 1|P.
P01763106A0070|84 94|test session
P01763106A0070|49 58|locomotion
P01763106A0070|36 39|hole
P01763106A0070|17 24|behavior
P01764899A0399|114 124|cavity level
P01764899A0399|59 74|caries prevalence
P01764899A0399|95 100|caries
P01764899A0399|32 37|effect
P01764899A0399|3 7|model
P01764899A0399|40 56|water fluoridation
P01765095A0680|0 34|12-O-Tetradecanoylphorbol 13-acetate
P01765095A0680|110 123|regulators CMD1
P01765095A0680|127 134|myogenin
P01765095A0680|85 89|mRNAs
P01765095A0680|73 82|expression
P01765266A0000|2 14|Xenopus laevis
P01765266A0000|110 116|oocytes
P01765266A0000|125 131|embryos
P01765266A0000|64 73|EF-1 alpha O
P01765266A0000|80 80|O
P01765266A0000|34 56|elongation factor 1-alpha
P01765266A0000|90 95|oocyte
P01765266A0000|19 22|gene
P01765269A0308|5 11|introns
P01765269A0308|23 27|class
P01765269A0308|37 51|pre-mRNA introns
P01765269A0308|111 118|features
P01765269A0308|78 95|consensus sequences
P01765375A0290|72 82|transcripts
P01765375A0290|176 180|chain
P01765375A0290|163 170|clathrin
P01765375A0290|152 157|weight
P01765375A0290|101 102|kb
P01765375A0290|140 142|kDa
P01765375A0290|51 63|clathrin clone
P01765375A0290|3 6|mRNA
P01765375A0290|31 38|rat cells
P01765386A0305|69 72|gene
P01765386A0305|83 86|exon
P01765386A0305|117 118|bp
P01765386A0305|101 109|junctions
P01765386A0305|60 61|bp
P01765386A0305|24 34|DNA sequence
P01765386A0305|20 21|kb
P01765386A0305|6 11|report
P01765386A0305|126 129|gene
P01765386A0305|79 80|kb
P01765407A0866|96 104|excretion
P01765407A0866|110 116|mumol/l
P01765407A0866|52 70|plasma concentration
P01765407A0866|122 139|mmol/mol creatinine
P01765407A0866|77 88|postexposure
P01765407A0866|5 12|exposure
P01765407A0866|17 25|mg DMEA/m3
P01766666A0788|0 9|Antibodies
P01766666A0788|83 87|sites
P01766666A0788|127 133|factors
P01766666A0788|41 62|nucleoprotein complexes
P01766666A0788|20 23|rE12
P01766666A0788|27 33|rNFIL-6
P01766666A0788|102 112|interaction
P01766876A0000|155 171|replacement vector
P01766876A0000|109 121|point mutation
P01766876A0000|78 90|co-conversion
P01766876A0000|137 142|marker
P01766876A0000|38 43|events
P01766876A0000|94 104|co-exchange
P01766876A0000|49 50|mu
P01766876A0000|1 6|method
P01766876A0000|56 64|chain gene
P01766999A0000|72 81|volunteers
P01766999A0000|10 17|activity
P01766999A0000|105 112|allergen
P01766999A0000|51 52|AE
P01766999A0000|20 49|allergen extract Ambrosia elatior
P01767060A0000|222 225|head
P01767060A0000|108 115|duration
P01767060A0000|207 216|carcinomas
P01767060A0000|156 163|patients
P01767060A0000|96 104|frequency
P01767060A0000|35 53|c-DDP administration
P01767060A0000|229 232|neck
P01767060A0000|127 135|responses
P01767060A0000|4 8|study
P01767060A0000|71 82|radiotherapy
P01767060A0000|145 152|survival
P01767060A0000|191 196|stages
P01767592A0682|86 122|HAP2/HAP3 consensus recognition sequence
P01767592A0682|125 138|nucleotide-154
P01767592A0682|143 174|BAF1 consensus recognition sequence
P01767592A0682|22 30|sequences
P01767592A0682|78 83|region
P01767592A0682|34 51|DNA binding proteins
P01767592A0682|177 190|nucleotide-136
P01767899A0136|91 108|thromboplastin time
P01767899A0136|23 31|depletion
P01767899A0136|138 144|minutes
P01767899A0136|161 172|envenomation
P01767899A0136|6 21|thrombocytopenia
P01767899A0136|34 48|serum fibrinogen
P01767899A0136|61 71|prothrombin
P01768648A0853|81 87|domains
P01768648A0853|24 41|LexA fusion proteins
P01768648A0853|12 21|properties
P01768648A0853|52 63|dimerization
P01768648A0853|90 93|cRel
P01769189A0000|0 10|Plasma lipid
P01769189A0000|237 242|VO2max
P01769189A0000|216 220|years
P01769189A0000|196 200|women
P01769189A0000|170 171|SD
P01769189A0000|107 122|training distance
P01769189A0000|86 90|years
P01769189A0000|14 32|lipoprotein profiles
P01769189A0000|151 161|ml kg-1 min-1
P01769189A0000|205 205|n
P01769189A0000|235 235|%
P01769189A0000|202 203|UT
P01769189A0000|71 71|n
P01769189A0000|92 95|body
P01769189A0000|105 105|%
P01769189A0000|249 259|ml kg-1 min-1
P01769189A0000|68 69|RU
P01769189A0000|130 137|km week-1
P01769189A0000|222 225|body
P01769189A0000|163 166|mean
P01769189A0000|60 66|runners
P01769189A0000|139 144|VO2max
P01769919A0393|8 22|threshold shifts
P01769919A0393|53 69|brainstem response
P01769919A0393|104 106|kHz
P01770651T0001|102 110|thyroxine
P01770651T0001|55 76|radioimmunoassay system
P01770651T0001|80 90|measurement
P01770651T0001|93 97|serum
P01770651T0001|22 31|evaluation
P01770651T0001|34 52|equilibrium dialysis
P01771593A1152|14 15|TA
P01771593A1152|74 76|PCD
P01771593A1152|46 47|GD
P01771593A1152|31 38|decrease
P01771593A1152|41 43|AGD
P01771593A1232|14 19|adults
P01771593A1232|22 26|weeks
P01771593A1232|64 72|offspring
P01771593A1232|43 51|genitalia
P01771959A0442|56 56|p
P01771959A0442|45 45|%
P01771959A0442|205 213|deviation
P01771959A0442|126 134|deviation
P01771959A0442|176 183|segments
P01771959A0442|141 144|PTCA
P01771959A0442|161 164|PTCA
P01771959A0442|238 241|PTCA
P01771959A0442|220 223|PTCA
P01771959A0442|54 54|%
P01771959A0442|10 25|ejection fraction
P01771959A0442|5 8|PTCA
P01771959A0442|81 88|function
P01772201T0001|33 44|subjectivity
P01772201T0001|50 55|period
P01772201T0001|12 18|patient
P01772201T0001|23 26|work
P01772341A0852|173 177|agent
P01772341A0852|79 107|thromboxane receptor antagonist
P01772341A0852|140 158|digoxin intoxication
P01772341A0852|5 8|data
P01772341A0852|31 39|treatment
P01772341A0852|123 132|protection
P01772341A0852|45 74|thromboxane synthetase inhibitor
P01774062A0257|32 44|HLA-DQA1 locus
P01774062A0257|89 90|kb
P01774062A0257|11 16|A148A7
P01774062A0257|104 111|YAC B1D12
P01774062A0257|7 9|YAC
P01774062A0257|63 67|locus
P01774062A0257|55 61|Y3/Ring
P01774063A0161|185 194|chromosome
P01774063A0161|13 29|backcross analysis
P01774063A0161|114 131|thrombospondin gene
P01774063A0161|53 59|matings
P01774063A0161|83 84|F1
P01774063A0161|152 155|Fshb
P01774063A0161|63 81|C57BL/6J x Mus spretus
P01774063A0161|163 165|Ltk
P01774063A0161|170 176|B2M loci
P01774063A0161|35 41|progeny
P01774063A0161|86 97|C57BL/6J mice
P01774063A0161|157 161|Actcl
P01774093T0000|30 32|IgM
P01774093T0000|13 19|outcome
P01774093T0000|72 80|pregnancy
P01774093T0000|41 69|Chlamydia trachomatis infection
P01774822A0289|88 92|cycle
P01774822A0289|40 59|LV time-density curves
P01774822A0289|23 30|computer
P01776306A0572|19 20|VT
P01776306A0572|9 15|patient
P01776715A0489|75 78|loss
P01776715A0489|103 108|sample
P01776715A0489|25 38|centrifugation
P01776715A0489|45 55|measurement
P01776715A0489|139 142|PCO2
P01776715A0489|81 83|CO2
P01776715A0489|114 123|gas mixture
P01776715A0489|147 149|kPa
P01776715A0489|85 97|equilibration
P01776715A0489|160 170|measurement
P01776715A0489|2 6|delay
P01777841A0744|31 41|differences
P01777841A0744|11 20|mechanisms
P01777841A0744|105 112|neonates
P01777841A0744|67 72|muscle
P01777841A0744|56 62|effects
P01777841A0744|96 101|adults
P01777841A0744|85 93|afferents
P01779299A0000|41 49|cockroach
P01779299A0000|20 30|alterations
P01779299A0000|51 68|Periplaneta brunnea
P01779299A0000|85 99|acanthocephalan
P01779299A0000|101 124|Moniliformis moniliformis
P01779433A0694|28 42|Alu family repeat
P01779433A0694|48 55|junction
P01779433A0694|275 277|end
P01779433A0694|102 106|alpha
P01779433A0694|123 126|unit
P01779433A0694|201 208|position
P01779433A0694|74 79|block I
P01779433A0694|251 265|Alu family repeat
P01779433A0694|298 312|Alu family repeat
P01779433A0694|96 96|Y
P01779433A0694|129 134|rhesus
P01779433A0694|180 182|Alu
P01779433A0694|164 178|Alu family repeat
P01779433A0694|9 15|finding
P01779433A0694|230 238|insertion
P01779433A0694|83 90|homology
P01779769A0000|128 137|kDa protein
P01779769A0000|105 116|reading frame
P01779769A0000|65 70|phi C31
P01779769A0000|38 49|Streptomyces
P01779769A0000|16 29|repressor locus
P01779769A0000|31 31|c
P01779769A0000|3 10|sequence
P01779769A0000|59 63|phage
P01780235A0094|41 51|transfusion
P01780235A0094|91 101|transfusion
P01780235A0094|3 11|EPO levels
P01781923A0744|84 91|righting
P01781923A0744|189 193|lines
P01781923A0744|50 62|concentration
P01781923A0744|78 81|loss
P01781923A0744|120 123|rate
P01781923A0744|65 66|DB
P01781923A0744|139 166|barbiturate brain distribution
P01781923A0744|94 95|LS
P01781923A0744|170 180|elimination
P01781923A0744|16 26|sensitivity
P01781923A0744|29 30|DB
P01782424A0278|14 36|threshold concentrations
P01782424A0278|93 101|sentinels
P01782424A0278|55 63|phenomena
P01782424A0278|3 11|existence
P01782424A0278|87 90|role
P01782669A0496|47 54|addition
P01782669A0496|57 62|A23187
P01782669A0496|30 41|temperatures
P01782982A0155|0 9|Felodipine
P01782982A0155|24 35|baseline FEV1
P01782982A0155|95 97|AMP
P01782982A0155|105 123|bronchoconstriction
P01782982A0155|83 91|histamine
P01782982A0155|73 78|effect
P01783088A1136|126 136|fibronectin
P01783088A1136|226 232|disease
P01783088A1136|75 75|%
P01783088A1136|10 17|patients
P01783088A1136|235 242|ABSTRACT
P01783088A1136|77 86|hyaluronan
P01783088A1136|160 173|micrograms.l-1
P01783088A1136|109 122|micrograms.l-1
P01783088A1136|43 51|mast cells
P01783088A1136|33 39|disease
P01783088A1136|196 203|patients
P01783088A1136|257 261|WORDS
P01783375A1066|3 9|mapping
P01783375A1066|114 137|translocation breakpoints
P01783375A1066|76 84|disorders
P01783375A1066|47 50|gene
P01783375A1066|30 40|involvement
P01784589A0000|41 61|5-HT2 receptor activity
P01784589A0000|35 38|role
P01784589A0000|77 84|behavior
P01784589A0000|68 70|rat
P01785749A0695|70 75|weight
P01785749A0695|37 41|group
P01785749A0695|49 56|children
P01785749A0695|5 11|changes
P01786094T0001|7 14|contents
P01786094T0001|23 28|copper
P01787085A0331|39 49|control rats
P01787085A0331|63 69|colloid
P01787085A0331|10 20|experiments
P01788002T0001|29 29|B
P01788002T0001|32 39|children
P01788002T0001|16 25|hepatitis A
P01788002T0001|0 13|Magnetotherapy
P01791363A0208|86 92|testing
P01791363A0208|35 42|patients
P01791363A0208|5 11|results
P01791363A0208|69 75|sutures
P01791754T0000|75 89|secretion signal
P01791754T0000|27 30|role
P01791754T0000|52 59|features
P01791754T0000|10 17|analysis
P01791754T0000|107 116|haemolysin
P01792580A0198|59 72|blood donations
P01792580A0198|150 160|blood donors
P01792580A0198|77 86|percentage
P01792580A0198|21 28|Republic
P01792580A0198|51 56|number
P01792580A0198|5 15|blood donors
P01792580A0198|134 143|percentage
P01792580A0198|95 100|donors
P01792580A0198|31 36|Serbia
P01792914T0000|23 39|childhood leukemia
P01792914T0000|14 20|relapse
P01797459A0103|0 9|Mycoplasma
P01797459A0103|45 49|fluid
P01797459A0103|56 62|patient
P01797467A0000|0 4|RU486
P01797467A0000|73 81|pregnancy
P01797467A0000|60 70|termination
P01797467A0000|8 10|ONO
P01797467A0000|16 26|combination
P01798407A1011|58 67|hypothesis
P01798407A1011|113 116|lobe
P01798407A1011|75 80|cortex
P01798407A1011|37 44|patients
P01798407A1011|144 159|laughing seizures
P01798407A1011|18 30|abnormalities
P01798407A1011|133 138|origin
P01798407A1011|3 10|presence
P01804671A1001|27 31|QS/QC
P01804671A1001|36 42|results
P01804671A1001|18 23|values
P01804671A1001|108 111|lung
P01804671A1001|94 102|air spaces
P01804671A1001|226 231|mmHg-1
P01804671A1001|140 172|ventilation/perfusion distribution
P01804671A1001|201 206|CDCSF6
P01804671A1001|2 5|line
P01804671A1001|190 196|gas data
P01804671A1001|217 224|ml.min-1
P01806314A0322|4 8|cells
P01806314A0322|77 84|antibody
P01806314A0322|92 102|muscle actin
P01806314A0322|40 46|markers
P01808049A0262|0 14|CT abnormalities
P01808049A0262|22 31|term babies
P01808049A0262|108 108|%
P01808049A0262|132 132|%
P01808049A0262|185 185|%
P01808049A0262|85 85|%
P01808049A0262|40 49|hemorrhage
P01808049A0262|66 66|%
P01808049A0262|135 145|hypodensity
P01808049A0262|163 163|%
P01808049A0262|122 122|%
P01808049A0262|175 181|atrophy
P01808049A0262|88 98|hypodensity
P01808049A0262|150 159|hemorrhage
P01808136T0000|27 46|coagulation factor XII
P01808136T0000|12 24|contrast media
P01808136T0000|3 9|effects
P01808186A0984|0 3|Pigs
P01808186A0984|61 63|Exp
P01808186A0984|44 47|diet
P01808186A0984|57 58|kg
P01808602A0000|89 93|serum
P01808602A0000|9 16|patients
P01808602A0000|53 59|effects
P01808602A0000|38 49|hypertension
P01808602A0000|125 128|acid
P01808602A0000|68 86|nifedipine treatment
P01808602A0000|110 118|excretion
P01808602A0000|98 101|acid
P01808829A0510|0 3|TPTA
P01808829A0510|12 26|brain congestion
P01808829A0510|73 83|hemorrhages
P01809854A0106|0 7|Examples
P01809854A0106|20 27|subjects
P01809854A0106|91 103|meta-analysis
P01809854A0106|65 83|consensus statements
P01809854A0106|40 53|research design
P01810108A0000|57 68|inactivation
P01810108A0000|24 36|heat exchanger
P01810108A0000|109 112|milk
P01810108A0000|122 125|cows
P01810108A0000|4 16|phase slug flow
P01810108A0000|71 91|Listeria monocytogenes
P01810154A0491|7 14|children
P01811243A0000|118 122|years
P01811243A0000|193 199|ratings
P01811243A0000|26 29|rCBF
P01811243A0000|162 166|study
P01811243A0000|57 63|ratings
P01811243A0000|31 42|measurements
P01811243A0000|110 112|age
P01811243A0000|97 104|patients
P01811243A0000|144 148|years
P01811243A0000|16 24|blood flow
P01811243A0000|214 226|rCBF technique
P01811243A0000|0 7|Regional
P01811948A0289|167 168|bp
P01811948A0289|78 79|bp
P01811948A0289|159 160|bp
P01811948A0289|108 115|sequence
P01811948A0289|85 100|LpS1 beta promoter
P01811948A0289|12 16|study
P01811948A0289|142 152|cis-element
P01811948A0289|117 117|G
P01811948A0289|59 65|element
P01811948A0289|71 72|bp
P01812102A0101|129 138|NPN complex
P01812102A0101|103 107|women
P01812102A0101|185 189|state
P01812102A0101|160 168|responses
P01812102A0101|111 117|changes
P01812102A0101|54 68|pattern reversal
P01812102A0101|10 21|study reports
P01812102A0101|120 126|latency
P01812102A0101|70 74|VEP-P
P01812102A0101|86 94|trimester
P01812102A0101|43 51|responses
P01812690A0475|2 5|case
P01812690A0475|40 45|growth
P01812690A0475|8 10|SMF
P01814182A0000|86 92|heifers
P01814182A0000|9 13|doses
P01814182A0000|76 82|oestrus
P01814182A0000|111 113|day
P01814182A0000|63 72|luteolysis
P01814182A0000|16 34|15-methyl-PGF2 alpha
P01814182A0000|131 135|cycle
P01814182A0000|44 45|mg
P01814182A0000|99 108|treatments
P01816655T0000|0 5|Review
P01816655T0000|24 29|report
P01816655T0000|11 20|literature
P01816655T0000|33 36|case
P01816655T0000|47 50|cyst
P01817497A0715|0 9|Resolution
P01817497A0715|40 47|decrease
P01817497A0715|50 55|Delta T
P01817497A0715|25 33|asymmetry
P01817497A0715|108 117|population
P01817497A0715|88 88|%
P01822581A0533|71 77|reading
P01822581A0533|5 13|instances
P01822581A0533|25 40|alcohol responses
P01822581A0533|81 95|microgram/100ml
P01822581A0533|99 111|breath samples
P01822995T0000|0 24|Maize rbcS promoter activity
P01822995T0000|34 49|sequence elements
P01822995T0000|60 77|dicot rbcS promoters
P01823520A0183|0 11|Measurements
P01823520A0183|92 107|haematocrit value
P01823520A0183|35 61|haematofluorometer Buchler ZF
P01823524A0238|131 137|factors
P01823524A0238|209 227|xenobiotics toxicity
P01823524A0238|180 190|differences
P01823524A0238|154 162|influence
P01823524A0238|62 68|variety
P01823524A0238|193 206|susceptibility
P01823524A0238|19 24|number
P01823524A0238|92 99|exposure
P01823524A0238|72 81|complexity
P01823524A0238|27 34|examples
P01824713A0964|85 88|lack
P01824713A0964|91 101|stimulation
P01824713A0964|65 69|c-jun
P01824713A0964|32 42|TRE sequence
P01824713A0964|47 60|cotransfection
P01824713A0964|3 15|12S E1A product
P01824944A0988|104 106|IgE
P01824944A0988|74 85|polypeptides
P01824944A0988|5 13|treatment
P01824944A0988|18 28|tunicamycin
P01824944A0988|33 45|transfectants
P01825027T0000|85 91|ATPases
P01825027T0000|6 14|yeast gene
P01825027T0000|55 60|member
P01825027T0000|69 74|family
P01825027T0000|26 45|peroxisome biogenesis
P01825027T0000|0 3|PAS1
P01826003A0694|94 98|exons
P01826003A0694|45 51|members
P01826003A0694|24 25|bp
P01826003A0694|14 22|base pairs
P01826003A0694|3 6|gene
P01826003A0694|57 65|SIG family
P01826003A0694|70 79|beta TG gene
P01826043A0431|222 235|protein kinases
P01826043A0431|45 54|rsk-kinase
P01826043A0431|92 122|signal transducing protein kinases
P01826043A0431|206 208|Ca2
P01826043A0431|166 172|members
P01826043A0431|151 164|protein kinases
P01826043A0431|3 31|pp90rsk-protein kinase activity
P01826043A0431|178 197|protein kinase C family
P01827068T0000|31 49|transcription factor
P01827068T0000|66 75|expression
P01827068T0000|81 102|T cell receptor alpha gene
P01827068T0000|5 10|GATA-3
P01827203A0136|44 51|proteins
P01827203A0136|63 68|dimers
P01827203A0136|58 60|DNA
P01827203A0136|18 37|transcription factors
P01828248A0189|15 25|UvrA protein
P01828248A0189|123 134|UvrAB complex
P01828248A0189|111 113|DNA
P01828248A0189|66 75|activities
P01828248A0189|96 106|association
P01828248A0189|145 160|helicase activity
P01828248A0189|83 90|solution
P01828248A0189|42 52|UvrB protein
P01829060A0649|56 61|values
P01829060A0649|87 91|mg/kg
P01829060A0649|64 73|nifedipine
P01829060A0649|75 76|ED
P01829060A0649|3 12|ED30 values
P01829060A0649|26 30|mg/kg
P01829460A0329|0 23|Southwestern blot analysis
P01829460A0329|68 80|kappa B element
P01829460A0329|44 57|phosphoprotein
P01830114A1587|16 21|effect
P01830114A1587|52 64|P4 transcripts
P01830114A1587|24 26|NS1
P01830114A1587|112 120|integrity
P01830114A1587|77 89|amplification
P01830114A1587|134 140|repeats
P01830114A1587|92 105|gene copy number
P01830114A1587|44 49|levels
P01830928A0361|21 37|microtubule motors
P01830928A0361|117 133|attachment domains
P01830928A0361|42 48|dyneins
P01830928A0361|68 78|superfamily
P01830928A0361|97 104|proteins
P01832019A0265|81 85|weeks
P01832019A0265|61 67|animals
P01832152A0000|44 79|Agrobacterium tumefaciens oncogenicity
P01832152A0000|81 82|J.
P01832152A0000|3 33|incompatibility group W plasmid pSa
P01832152A0902|47 50|ORF1
P01832152A0902|54 57|ORF2
P01832152A0902|22 33|start signals
P01832197T0001|0 6|Imaging
P01832197T0001|9 26|D2 dopamine receptor
P01833185A0547|102 107|Thr161
P01833185A0547|33 41|phenotype
P01833185A0547|201 211|cytokinesis
P01833185A0547|47 58|fission yeast
P01833185A0547|145 159|phosphorylation
P01833185A0547|183 189|mitosis
P01833185A0547|3 19|Thr161Val mutation
P01833185A0547|167 180|uncoordination
P01833185A0547|120 123|acid
P01833185A0547|89 99|replacement
P01833637A0531|14 24|transcripts
P01833637A0531|110 120|temperature
P01833637A0531|137 146|transcript
P01833637A0531|155 163|HSP82 gene
P01833637A0531|76 80|cells
P01833637A0531|63 69|cdc68-1
P01833637A0531|185 191|fashion
P01833637A0531|45 49|genes
P01833637A0531|3 11|abundance
P01833637A0531|86 93|transfer
P01833716A0990|0 11|Deregulation
P01833716A0990|53 66|transformation
P01833716A0990|81 95|HTLV-1 infection
P01833716A0990|19 28|expression
P01837787T0000|45 56|organization
P01837787T0000|9 18|Mov-34 gene
P01837787T0000|31 34|cDNA
P01837842A1410|27 43|protein components
P01837842A1410|95 97|CRE
P01837842A1410|58 74|gel shift complexes
P01837842A1410|0 3|CREB
P01839414T0000|45 53|neoplasms
P01839414T0000|3 10|spectrum
P01839414T0000|56 60|Sabah
P01840513A1019|161 169|induction
P01840513A1019|106 113|increase
P01840513A1019|182 185|acid
P01840513A1019|65 66|bp
P01840513A1019|39 49|pCAT plasmid
P01840513A1019|29 37|SL-2 cells
P01840513A1019|80 85|region
P01840513A1019|192 203|8-bromo-cAMP
P01840513A1019|116 155|chloramphenicol acetyltransferase activity
P01840607A0294|66 67|bp
P01840607A0294|40 43|type
P01840607A0294|25 28|UTRs
P01840607A0294|48 51|type
P01840607A0294|105 107|PFP
P01840608A0823|82 85|nifB
P01840608A0823|52 55|nifA
P01840608A0823|26 37|reading frame
P01840608A0823|88 114|amino acid sequence comparison
P01840608A0823|3 12|N-terminus
P01840711A0000|14 19|rabbit
P01840711A0000|31 42|disease virus
P01840711A0000|44 47|RHDV
P01840711A0000|3 11|RNA genome
P01840902A1089|57 62|plants
P01840902A1089|124 131|monocots
P01840902A1089|26 31|system
P01840902A1089|135 140|dicots
P01840902A1089|95 112|transport machinery
P01842498A0000|134 144|Jurkat cells
P01842498A0000|6 14|cDNA clone
P01842498A0000|199 214|blood lymphocytes
P01842498A0000|76 93|phytohemagglutinin
P01842498A0000|47 59|hybridization
P01842498A0000|21 22|R2
P01842498A0000|95 97|PHA
P01842498A0000|63 73|cDNA library
P01842498A0000|162 172|cDNA library
P01842498A0000|100 115|phorbol myristate
P01842867A0696|29 47|regeneration ability
P01842867A0696|67 72|injury
P01842867A0696|83 88|mucosa
P01842867A0696|2 11|conclusion
P01844017A0410|42 45|drop
P01844017A0410|125 132|duration
P01844017A0410|95 107|vitamin E level
P01844017A0410|114 117|hand
P01844017A0410|20 31|relationship
P01844017A0410|48 89|glucose-6-phosphatase dehydrogenase activity
P01844017A0410|135 143|poisoning
P01844017A0410|148 160|sodium nitrite
P01844878A0000|131 142|DNA fragments
P01844878A0000|90 106|promoter sequences
P01844878A0000|71 74|gene
P01844878A0000|112 115|pool
P01844878A0000|1 6|vector
P01844878A0000|43 68|neomycin phosphotransferase
P01844982A0324|0 5|Chagas
P01844982A0324|56 70|schistosomiasis
P01844982A0324|82 87|factor
P01844982A0324|97 104|controls
P01844982A0324|23 35|leishmaniasis
P01844982A0324|7 13|disease
P01844982A0324|49 54|factor
P01845829A0158|102 108|factors
P01845829A0158|69 75|domains
P01845829A0158|26 33|sequence
P01845829A0158|8 15|analysis
P01845829A0158|123 132|brain cells
P01845885A1003|187 217|UL26 transcription initiation site
P01845885A1003|77 86|amino acids
P01845885A1003|65 71|protein
P01845885A1003|311 314|unit
P01845885A1003|106 113|proteins
P01845885A1003|24 27|unit
P01845885A1003|39 42|UL26
P01845885A1003|292 295|UL26
P01845885A1003|134 137|mRNA
P01845885A1003|240 264|methionine initiation codon
P01845885A1003|98 103|family
P01845885A1003|274 281|position
P01845899A0000|29 35|rep gene
P01845899A0000|68 72|Rep52
P01845899A0000|62 66|Rep68
P01845899A0000|25 27|AAV
P01845899A0000|114 130|AAV gene regulation
P01845899A0000|77 81|Rep40
P01845899A0000|56 60|Rep78
P01845899A0000|94 110|AAV DNA replication
P01845899A0000|19 23|virus
P01845899A0000|47 54|proteins
P01846206A0665|28 33|CMV dbp
P01846206A0665|46 56|replication
P01846206A0665|7 12|region
P01846206A0665|68 73|assays
P01846489A1119|65 79|protease domains
P01846489A1119|34 47|protease domain
P01846491A0459|219 228|divergence
P01846491A0459|105 107|SFV
P01846491A0459|240 247|ancestor
P01846491A0459|163 165|DNA
P01846491A0459|19 27|positions
P01846491A0459|195 201|viruses
P01846491A0459|140 160|complex rearrangements
P01846491A0459|109 127|genus Leporipoxvirus
P01846491A0459|171 176|genome
P01846491A0459|33 39|VV genes
P01846491A0459|99 102|ORFs
P01846491A0459|41 58|genus Orthopoxvirus
P01846803A0688|87 90|line
P01846803A0688|22 36|phosphorylation
P01846803A0688|113 120|residues
P01846803A0688|138 151|ATP binding site
P01846803A0688|63 83|p34cdc2 kinase activity
P01846803A0688|39 41|Thr
P01846803A0688|157 162|kinase
P01846803A0688|50 52|Tyr
P01846803A0688|4 9|result
P01846803A0688|98 105|location
P01847464A0856|206 210|c-myc
P01847464A0856|110 114|ori-P
P01847464A0856|171 180|amino acids
P01847464A0856|80 88|EBV origin
P01847464A0856|12 26|cotransfections
P01847464A0856|91 108|plasmid replication
P01847464A0856|152 169|EBNA-1 construction
P01847464A0856|68 72|sites
P01847464A0856|29 43|pFRTK-CAT target
P01847464A0856|218 235|localization signal
P01847665A1079|42 46|genes
P01847665A1079|31 34|idea
P01847665A1079|178 193|glia cell lineages
P01847665A1079|120 129|expression
P01847665A1079|111 115|genes
P01847665A1079|163 169|program
P01847665A1079|95 101|concert
P01847665A1079|55 67|PDGF receptors
P01847665A1079|3 10|findings
P01847665A1079|70 80|glioma cells
P01848300A0910|33 36|cstA
P01848300A0910|10 17|evidence
P01848300A0910|49 66|peptide utilization
P01848871A0392|234 244|tachycardia
P01848871A0392|53 57|drugs
P01848871A0392|166 177|prolongation
P01848871A0392|187 195|potential
P01848871A0392|122 128|portion
P01848871A0392|83 91|potential
P01848871A0392|18 27|hypothesis
P01848871A0392|106 120|amplitude signal
P01848871A0392|4 8|study
P01848871A0392|149 158|QRS complex
P01848871A0392|32 44|sodium channel
P01848871A0392|214 220|slowing
P01849509T0000|105 115|transposase
P01849509T0000|167 171|IS256
P01849509T0000|125 129|ISRm3
P01849509T0000|37 75|Rhizobium meliloti insertion sequence ISRm3
P01849509T0000|17 34|nucleotide sequence
P01849509T0000|175 202|Thiobacillus ferrooxidans IST2
P01849509T0000|77 86|similarity
P01849509T0000|0 13|Identification
P01849675A0167|14 25|relationship
P01849675A0167|65 66|KV
P01849675A0167|52 62|DNA sequence
P01849675A0167|33 39|viruses
P01849675A0167|83 84|bp
P01849734A1063|55 60|levels
P01849734A1063|8 25|PR55 beta transcript
P01849734A1063|86 99|cell line LA-N-1
P01849734A1063|36 37|kb
P01849734A1063|104 108|level
P01849734A1063|143 151|cell lines
P01849734A1063|66 78|neuroblastoma
P01849734A1063|114 117|mRNA
P01850096A0662|115 119|start
P01850096A0662|60 78|restriction fragment
P01850096A0662|38 40|E12
P01850096A0662|25 27|E12
P01850096A0662|129 152|alpha-actin transcription
P01850096A0662|31 34|MyoD
P01850096A0662|14 21|myogenin
P01850096A0662|0 11|Heterodimers
P01850105A1093|118 138|muscle differentiation
P01850105A1093|50 54|c-myc
P01850105A1093|12 16|c-myc
P01850105A1093|95 96|Id
P01850105A1093|65 79|differentiation
P01850105A1093|107 115|regulator
P01850105A1093|3 9|effects
P01850127A0000|99 105|protein
P01850127A0000|33 51|branchpoint sequence
P01850127A0000|63 71|pre-mRNAs
P01850127A0000|80 86|binding
P01850127A0000|111 129|polypyrimidine tract
P01850127A0000|6 16|association
P01850127A0000|19 25|U2 snRNP
P01850893A0286|17 26|antibodies
P01850893A0286|49 55|rabbits
P01850893A0286|72 76|farms
P01851386T0092|30 36|FONICAP
P01851386T0092|10 28|Lung Cancer Task Force
P01851527T0000|74 76|APP
P01851527T0000|24 27|gene
P01851527T0000|94 99|blocks
P01851527T0000|36 72|Alzheimer beta-amyloid precursor protein
P01851527T0000|110 118|sequences
P01851527T0000|3 18|promoter activity
P01851756A0743|0 3|Biol
P01851862A0273|0 18|Nucleotide sequences
P01851862A0273|47 51|SFV-1
P01851862A0273|29 35|env gene
P01851862A0273|42 44|LTR
P01851876A0129|28 37|EMBL3 mouse
P01851876A0129|4 10|element
P01851876A0129|45 51|library
P01852438A0928|41 44|case
P01852438A0928|31 35|level
P01852438A0928|3 11|MVV-value
P01852438A0928|52 58|percent
P01852603A0000|101 109|radiation
P01852603A0000|33 44|fission yeast
P01852603A0000|11 25|DNA repair mutant
P01852603A0000|3 6|rad9
P01852603A0000|88 89|UV
P01853796T0000|0 5|Review
P01853796T0000|49 52|role
P01853796T0000|22 37|glucose tolerance
P01853796T0000|7 19|deterioration
P01853796T0000|55 71|insulin resistance
P01853796T0000|42 44|age
P01854339A0221|57 74|consensus promoters
P01854339A0221|116 121|levels
P01854339A0221|94 102|sequences
P01854339A0221|22 39|sequence similarity
P01854339A0221|124 133|expression
P01854339A0221|5 10|region
P01855255T0000|30 34|yeast
P01855255T0000|9 18|initiation
P01855255T0000|61 66|GTPase
P01855255T0000|21 27|mitosis
P01855255T0000|42 45|RCC1
P01856021A0577|3 8|method
P01856021A0577|133 139|toluene
P01856021A0577|102 108|control
P01856021A0577|123 130|exposure
P01856021A0577|34 43|laboratory
P01856021A0577|146 151|xylene
P01856021A0577|48 51|year
P01856021A0577|77 85|procedure
P01857143A0351|57 65|diagnosis
P01857143A0351|35 45|skin lesions
P01857143A0351|25 28|male
P01857143A0351|68 80|myelofibrosis
P01857143A0351|3 9|patient
P01857326A0160|0 9|Oculus-500
P01857326A0160|24 46|resolution imaging boards
P01857326A0160|76 84|computers
P01857326A0160|50 52|use
P01857326A0160|13 17|group
P01857326A0160|57 62|IBM-AT
P01860846A0663|82 104|MARCKS gene transcription
P01860846A0663|36 60|tumor necrosis factor-alpha
P01860846A0663|128 147|leukemia cell line HL60
P01860846A0663|8 11|cDNA
P01861034A0798|27 34|fragment
P01861034A0798|61 68|pressure
P01861034A0798|87 102|scaphoid fragment
P01861034A0798|5 13|resection
P01861034A0798|47 57|contact area
P01861188A0000|128 132|plate
P01861188A0000|112 121|screw heads
P01861188A0000|53 56|PMMA
P01861188A0000|146 154|stability
P01861188A0000|165 172|fixation
P01861188A0000|223 227|bones
P01861188A0000|280 300|ASIF compression plates
P01861188A0000|78 82|plate
P01861188A0000|13 21|technique
P01861188A0000|246 256|osteotomies
P01861188A0000|89 92|bone
P01861188A0000|0 10|Plate luting
P01862027A0212|42 50|diagnosis
P01862027A0212|53 76|Rothmund-Thomson syndrome
P01862027A0212|5 12|features
P01862455T0000|0 14|Thyroid lymphoma
P01862455T0000|21 30|management
P01863768A0649|47 52|domain
P01863768A0649|19 24|ORF113
P01863768A0649|3 9|protein
P01863887A0174|0 15|Space limitations
P01863887A0174|54 68|pharmaceuticals
P01863887A0174|76 92|tissue plasminogen
P01863887A0174|113 120|hormones
P01863887A0174|173 187|clotting factors
P01863887A0174|157 170|erythropoietin
P01863887A0174|127 133|thyroid
P01863887A0174|35 40|review
P01863887A0174|192 204|blood products
P01863887A0174|143 155|growth hormone
P01863887A0174|135 141|insulin
P01863887A0174|103 111|substance
P01864510A0946|26 35|starvation
P01864510A0946|23 23|h
P01864510A0946|58 62|cells
P01864510A0946|0 7|Dd PK1 RNA
P01864821A0000|170 181|blood vessels
P01864821A0000|157 167|obstruction
P01864821A0000|48 54|feature
P01864821A0000|111 117|hypoxia
P01864821A0000|10 14|forms
P01864821A0000|23 33|cell disease
P01864821A0000|95 104|conditions
P01864821A0000|144 153|blood cells
P01864821A0000|131 138|sickling
P01864821A0000|67 77|globin chain
P01864837A1029|53 61|% homology
P01864837A1029|72 86|mouse contrapsin
P01864837A1029|124 150|rat alpha 1-protease inhibitor
P01864837A1029|90 97|contrast
P01864837A1029|10 18|structure
P01864837A1029|35 42|proteins
P01864837A1029|105 113|% homology
P01865010A0000|152 157|manner
P01865010A0000|251 253|rat
P01865010A0000|126 134|diamidino
P01865010A0000|112 122|Fluoro-Gold
P01865010A0000|218 225|auditory
P01865010A0000|10 20|connections
P01865010A0000|240 245|cortex
P01865010A0000|104 110|tracers
P01865010A0000|178 192|representations
P01865010A0000|45 55|integration
P01865010A0000|0 7|Patterns
P01867069A0000|127 132|effect
P01867069A0000|5 12|CD-1 mice
P01867069A0000|64 67|days
P01867069A0000|35 50|% nicotine sulfate
P01867069A0000|110 112|age
P01867069A0000|97 100|pups
P01867069A0000|166 171|molars
P01867069A0000|138 148|development
P01867069A0000|15 18|days
P01869565A1254|0 2|USF
P01869565A1254|72 82|ADH promoter
P01869565A1254|25 37|transcription
P01869565A1254|41 57|translation system
P01869565A1254|96 98|MLP
P01869907A2146|27 35|responses
P01869907A2146|103 105|H2O
P01869907A2146|108 115|ABSTRACT
P01869907A2146|130 134|WORDS
P01869907A2146|3 21|across-fiber pattern
P01869907A2146|47 59|NaCl solutions
P01869968A0000|63 67|HMPAO
P01869968A0000|8 27|radioactivity content
P01869968A0000|80 87|subjects
P01869968A0000|47 60|administration
P01869968A0673|96 99|rCBF
P01869968A0673|109 120|significance
P01869968A0673|79 83|HMPAO
P01869968A0673|51 56|result
P01869968A0673|122 122|p
P01869968A0673|6 23|regression analysis
P01869968A0673|69 77|clearance
P01870194A0302|85 95|homogeneity
P01870194A0302|32 36|HIV-1
P01870194A0302|5 29|immunodeficiency virus type
P01870428A0677|0 9|Thigh girth
P01870428A0677|40 45|HDL2-C
P01870428A0677|49 52|mass
P01870428A0677|61 75|LDL particle size
P01870428A0677|81 85|women
P01870428A0677|34 36|HDL
P01870500A0276|85 89|tumor
P01870500A0276|33 52|target volume elements
P01870500A0276|158 162|tumor
P01870500A0276|202 219|reciprocity theorem
P01870500A0276|24 29|source
P01870500A0276|126 134|host organ
P01870500A0276|17 21|pairs
P01870500A0276|68 74|S values
P01870500A0276|185 193|host organ
P01870500A0276|0 12|Contributions
P01871033A0434|0 4|Tests
P01871033A0434|24 33|impression
P01871033A0434|39 43|force
P01871033A0434|71 90|laboratory simulation
P01871033A0434|150 155|method
P01871033A0434|116 128|testing cement
P01871033A0434|99 112|clearing cement
P01871135A0295|68 77|amino acids
P01871135A0295|130 148|rat liver glucokinase
P01871135A0295|22 33|reading frame
P01871135A0295|119 127|% identity
P01871135A0295|107 113|protein
P01871135A0295|99 101|kDa
P01871135A0295|3 6|cDNA
P01871135A0295|91 94|mass
P01871135A0295|40 41|bp
P01871135A0295|56 62|protein
P01871971A0836|58 68|binding site
P01871971A0836|47 55|NFIII/OCT
P01871971A0836|120 125|growth
P01871971A0836|82 89|ATF motif
P01871971A0836|15 21|mutants
P01871971A0836|0 7|Analysis
P01872856A0277|0 7|Recovery
P01872856A0277|107 111|liver
P01872856A0277|23 24|BA
P01872856A0277|54 54|%
P01872856A0277|75 75|%
P01872856A0277|40 40|%
P01872856A0277|62 64|hrs
P01872856A0277|157 163|animals
P01872856A0277|45 50|faeces
P01872856A0277|133 140|recovery
P01872856A0277|145 145|%
P01872856A0277|92 104|radioactivity
P01872856A0277|32 36|urine
P01872856A0277|115 120|testis
P01873999A0000|158 161|host
P01873999A0000|47 57|model system
P01873999A0000|192 199|proteins
P01873999A0000|115 128|gene expression
P01873999A0000|135 150|secretion process
P01873999A0000|106 112|details
P01873999A0000|168 177|production
P01873999A0000|218 225|interest
P01874195A0139|60 77|sequence similarity
P01874195A0139|25 34|GH receptor
P01874195A0139|45 49|liver
P01874195A0139|80 88|receptors
P01874195A0139|98 125|signal transduction mechanisms
P01874195A0139|167 188|tyrosine kinase activity
P01874752A0948|62 69|cdc2/p62
P01874752A0948|41 58|conditions cdc2/p58
P01874752A0948|111 118|activity
P01874752A0948|84 94|differences
P01875922A0770|0 15|Mutation analysis
P01875922A0770|96 101|effect
P01875922A0770|34 41|segments
P01875922A0770|61 66|region
P01876836T0000|0 13|Identification
P01876836T0000|36 43|subunits
P01876836T0000|46 61|GA binding protein
P01876836T0000|16 18|Ets
P01878489A0959|36 44|monocytes
P01878489A0959|141 149|monocytes
P01878489A0959|12 19|response
P01878489A0959|80 99|NADPH oxidase activity
P01878489A0959|22 32|neutrophils
P01878489A0959|66 74|magnitude
P01878489A0959|124 134|neutrophils
P01878755A0496|115 125|chloroquine
P01878755A0496|55 55|P
P01878755A0496|11 21|enterotoxin
P01878755A0496|82 96|blood appearance
P01878755A0496|5 9|ileum
P01878755A0496|98 98|P
P01878755A0496|41 53|disappearance
P01881595A0476|0 7|Formalin
P01881595A0476|63 72|NS neurones
P01881595A0476|143 143|n
P01881595A0476|160 160|n
P01881595A0476|103 110|activity
P01881595A0476|21 25|SNO NS
P01881595A0476|74 74|n
P01881595A0476|116 126|NnS neurones
P01881595A0476|153 158|phases
P01881595A0476|96 100|phase
P01881595A0476|29 39|NnS neurones
P01881671T0001|0 5|Uptake
P01881671T0001|8 16|ofloxacin
P01882240A0526|84 87|AIDS
P01882240A0526|111 121|communities
P01882240A0526|74 81|research
P01882240A0526|65 71|quality
P01882240A0526|33 38|issues
P01882240A0526|95 103|behaviors
P01882240A0526|17 25|attention
P01882386A0000|157 160|lead
P01882386A0000|114 124|combination
P01882386A0000|66 101|N-benzyl-N-dithiocarboxy-D-glucamine
P01882386A0000|39 45|2-furyl
P01882386A0000|146 154|excretion
P01882386A0000|131 142|mobilization
P01882386A0000|103 105|NaB
P01882386A0000|54 57|acid
P01882386A0000|3 15|effectiveness
P01882386A0000|178 181|rats
P01882386A0000|18 36|alpha-mercapto-beta
P01882386A0000|59 61|MFA
P01883992A0922|120 133|maize endosperm
P01883992A0922|80 89|expression
P01883992A0922|66 74|regulator
P01883992A0922|23 28|beta-1
P01883992A0922|95 107|beta-zein gene
P01883992A0922|5 11|results
P01884435A0088|58 61|ptO2
P01884435A0088|135 148|microelectrode
P01884435A0088|65 80|ptH distributions
P01884435A0088|20 26|effects
P01884435A0088|195 197|ptH
P01884435A0088|91 101|tissue sites
P01884435A0088|188 191|ptO2
P01884435A0088|4 8|study
P01884435A0088|174 185|measurements
P01884435A0088|29 39|hypovolemia
P01884998A1135|42 54|transcription
P01884998A1135|93 96|site
P01884998A1135|3 9|members
P01884998A1135|59 67|promoters
P01885006A0995|46 51|subset
P01885006A0995|88 97|activation
P01885006A0995|20 34|superactivation
P01885006A0995|3 9|domains
P01885613A1298|0 10|Information
P01885613A1298|77 84|pro alpha
P01885613A1298|90 101|collagen gene
P01885613A1298|62 71|regulation
P01885613A1298|50 56|studies
P01885613A1298|31 39|sequences
P01885752A0198|0 19|Chlamydia trachomatis
P01885752A0198|23 39|Chlamydia psittaci
P01885752A0198|57 72|methanol fixation
P01885915A0000|104 116|P. haemolytica
P01885915A0000|78 89|endocarditis
P01885915A0000|13 22|infections
P01885915A0000|27 37|bacteraemia
P01885915A0000|43 62|Pasteurella multocida
P01886043A0380|39 40|pH
P01886043A0380|57 62|effect
P01886043A0380|18 24|complex
P01886043A0380|44 47|HPCD
P01886043A0380|8 9|pH
P01886043A0380|68 77|solubility
P01886043A0380|96 98|SMX
P01886043A0380|129 137|molecules
P01886043A0380|145 162|inclusion complexes
P01886043A0380|3 5|SMX
P01886043A0380|170 173|HPCD
P01886368A0000|0 14|PO2 measurements
P01886368A0000|103 106|pigs
P01886368A0000|109 116|normoxia
P01886368A0000|36 60|recess type microelectrodes
P01886368A0000|83 91|nerve head
P01886368A0000|120 128|hyperoxia
P01886774A0000|101 115|octamer sequence
P01886774A0000|51 64|Echerichia coli
P01886774A0000|68 83|characterization
P01886774A0000|24 30|domains
P01886774A0000|33 36|Oct3
P01886774A0000|86 95|DNA binding
P01888896A0505|1 14|deletion series
P01888896A0505|30 35|region
P01888896A0505|50 57|position
P01888896A0505|96 109|initiation site
P01888896A0505|142 148|tobacco
P01889753A0441|14 15|nt
P01889753A0441|48 57|boundaries
P01889753A0441|31 35|exons
P01889753A0441|82 88|regions
P01889753A0441|17 25|sequences
P01889753A0441|3 12|nucleotide
P01890362A0305|69 76|patients
P01890362A0305|101 105|years
P01890362A0305|38 53|eye complications
P01890362A0305|59 65|leprosy
P01890362A0305|7 14|patients
P01890989A1392|99 108|amphibians
P01890989A1392|81 85|genes
P01890989A1392|88 95|chickens
P01890989A1392|31 38|elements
P01890989A1392|55 71|estrogen induction
P01892680A0907|0 7|Toxicity
P01892680A0907|44 51|sedation
P01892680A0907|76 79|arm B
P01892680A0907|81 81|p
P01892680A0907|27 34|regimens
P01893195A0000|101 114|virus Issyk-Kul
P01893195A0000|35 42|hamsters
P01893195A0000|51 54|mice
P01893195A0000|21 27|monkeys
P01893195A0000|85 94|properties
P01893195A0000|58 64|authors
P01893927A0704|129 134|output
P01893927A0704|110 119|reductions
P01893927A0704|55 60|levels
P01893927A0704|22 29|pressure
P01893927A0704|92 94|NNA
P01893927A0704|32 52|phenylephrine infusion
P01893927A0704|86 88|NMA
P01894696A0301|0 1|J.
P01895358A0000|0 5|Limits
P01895358A0000|165 178|energy turnover
P01895358A0000|108 124|training programme
P01895358A0000|8 21|energy turnover
P01895358A0000|24 31|relation
P01895358A0000|88 92|limit
P01895358A0000|68 72|terms
P01895358A0000|94 100|changes
P01895358A0000|141 153|energy balance
P01895358A0000|42 52|performance
P01895370A0199|100 107|parallel
P01895370A0199|12 21|reductions
P01895370A0199|62 93|maximum shifted-frequency envelope
P01895370A0199|49 49|D
P01895370A0199|51 56|points
P01895370A0199|24 27|flow
P01895370A0199|37 37|S
P01895370A0199|32 35|peak
P01895370A0199|117 123|fashion
P01895370A0199|129 129|D
P01895370A0199|42 47|trough
P01895384A0746|84 91|promoter
P01895384A0746|38 48|IE1 promoter
P01895384A0746|64 73|expression
P01895384A0746|3 16|IE0 gene product
P01895393A0745|83 89|TATA box
P01895393A0745|9 17|promoters
P01895393A0745|60 67|Sp1 sites
P01895393A0745|73 79|absence
P01895393A0745|50 57|Sp1 sites
P01895393A0745|29 35|TATA box
P01895393A0745|141 148|promoter
P01895393A0745|125 137|RNA polymerase
P01895393A0745|41 47|absence
P01895555T0001|0 9|Evaluation
P01895555T0001|27 34|function
P01895555T0001|72 82|Tc-99m-MIBI
P01895555T0001|61 67|imaging
P01896777T0000|0 15|Ivermectin uptake
P01896777T0000|91 108|Onchocerca volvulus
P01896777T0000|19 30|distribution
P01896777T0000|36 41|plasma
P01896777T0000|45 50|tissue
P01896777T0000|71 78|patients
P01897515A0348|0 22|Bone marrow abnormalities
P01897515A0348|25 31|Hodgkin
P01897515A0348|95 104|mechanisms
P01897515A0348|65 77|understanding
P01897515A0348|34 40|disease
P01897515A0348|122 127|anemia
P01898113A0265|29 41|clearance rate
P01898113A0265|10 19|uptake rate
P01898113A0265|60 62|BCF
P01898113A0265|66 77|SWA killifish
P01898164A0839|99 102|arch
P01898164A0839|114 132|aorta diameter ratios
P01898164A0839|32 37|repair
P01898164A0839|65 69|group
P01898164A0839|134 144|arch indices
P01898164A0839|72 78|infants
P01898928A0260|87 94|DNA locus
P01898928A0260|125 131|fur gene
P01898928A0260|64 68|cells
P01898928A0260|71 72|Y.
P01898928A0260|0 23|DNA hybridization analysis
P01899209A0883|14 26|perfusate PCO2
P01899209A0883|38 47|perfusate H
P01899209A0883|114 130|oxygen consumption
P01899209A0883|132 133|r2
P01899209A0883|73 81|decreases
P01899209A0883|98 110|contractility
P01899209A0883|0 8|Increases
P01899287A0726|0 9|Expression
P01899287A0726|13 21|cell cycle
P01899287A0726|117 121|cells
P01899287A0726|49 57|RNA levels
P01899409T0000a|0 11|Determinants
P01899409T0000a|67 78|thrombolysis
P01899409T0000a|23 31|ischaemia
P01899409T0000a|94 119|tissue plasminogen activator
P01899409T0000a|35 61|revascularisation procedures
P01899409T0000a|137 145|occlusion
P01899846A0862|65 73|condition
P01899846A0862|13 26|rbcL-rbcS locus
P01899846A0862|93 98|growth
P01900194T0000|0 11|Relationship
P01900194T0000|81 91|hydrogenase
P01900194T0000|32 55|NADH-ubiquinone reductase
P01901405A0694|0 7|Analysis
P01901405A0694|68 74|tissues
P01901405A0694|10 23|mRNA expression
P01901405A0694|33 38|AT-BP1
P01901405A0694|42 47|AT-BP2
P01901443A0297|28 47|maintenance valproate
P01901443A0297|11 18|patients
P01901443A0297|112 121|hepatitis C
P01901443A0297|181 187|O stains
P01901443A0297|70 79|hepatitis C
P01901443A0297|151 159|steatosis
P01901664T0064|1 5|cases
P01901859A0000|0 6|UDP-Gal
P01901859A0000|169 172|apes
P01901859A0000|8 14|Gal beta
P01901859A0000|154 162|exception
P01901859A0000|71 89|glycosyltransferase
P01901859A0000|37 59|3-galactosyltransferase
P01901859A0000|132 138|species
P01901859A0000|20 31|4GlcNAc alpha
P01901859A0000|114 120|variety
P01901859A0000|165 167|man
P01901859A0000|177 191|Old World monkeys
P01901946A0243|218 239|affinity chromatography
P01901946A0243|38 48|SRE sequence
P01901946A0243|153 164|Southwestern
P01901946A0243|10 24|oligonucleotide
P01901946A0243|178 185|blotting
P01901946A0243|121 125|probe
P01901946A0243|166 176|DNA-protein
P01901946A0243|56 77|mouse c-fos gene promoter
P01901946A0243|132 149|mobility shift assay
P01901950T0000|0 19|Sequence requirements
P01901950T0000|65 70|intron
P01901950T0000|76 89|mouse c-fos gene
P01901950T0000|32 50|transcription arrest
P01903404A0688|15 30|ejection fraction
P01903404A0688|146 146|p
P01903404A0688|232 246|perfusion status
P01903404A0688|51 51|%
P01903404A0688|109 114|patent
P01903404A0688|191 206|ejection fraction
P01903404A0688|71 77|studies
P01903404A0688|100 105|artery
P01903404A0688|129 129|%
P01903404A0688|155 161|changes
P01903841A0125|97 102|eIF-5A
P01903841A0125|77 88|modification
P01903841A0125|50 57|hypusine
P01903841A0125|8 21|lysine residues
P01903841A0125|34 43|spermidine
P01903841A1449|99 108|yeast cells
P01903841A1449|3 25|plasmid shuffle technique
P01903841A1449|87 93|failure
P01903841A1449|54 57|gene
P01903841A1449|71 74|form
P01904154A0164|69 74|Ig loci
P01904154A0164|51 61|transcripts
P01904154A0164|11 14|case
P01904154A0164|33 48|characterization
P01904154A0164|112 135|gene rearrangement process
P01904154A0164|94 106|understanding
P01904154A0164|16 29|identification
P01904437A0000|0 12|Transcription
P01904437A0000|93 107|metR gene product
P01904437A0000|110 126|DNA binding protein
P01904437A0000|18 25|metH gene
P01904546A0671|0 9|Disruption
P01904546A0671|26 33|AAR1 gene
P01904546A0671|36 40|alpha
P01904546A0671|77 85|phenotype
P01904546A0671|93 107|a/alpha diploids
P01904546A0671|44 55|a/alpha cells
P01905199A0210|72 74|WBH
P01905199A0210|166 182|modality treatment
P01905199A0210|66 68|ADR
P01905199A0210|109 119|alterations
P01905199A0210|11 18|ICRF-187
P01905199A0210|24 40|antitumor response
P01905199A0210|3 8|effect
P01905199A0210|136 140|index
P01905199A0210|53 63|combination
P01905199A0210|96 100|order
P01905517A1076|86 95|homologies
P01905517A1076|39 46|features
P01905517A1076|3 5|ORF
P01905517A1076|54 70|sequence data bases
P01906111A1295|4 8|study
P01906111A1295|114 128|toxicity profile
P01906111A1295|38 44|regimen
P01906111A1295|80 82|use
P01906111A1295|91 96|marrow
P01906166A0119|0 10|Mitomycin-C
P01906166A0119|25 32|necrosis
P01906166A0119|90 96|tissues
P01906166A0119|79 82|skin
P01906166A0119|108 125|drug administration
P01906166A0119|36 45|ulceration
P01906509A0072|54 64|nidogen gene
P01906509A0072|38 43|region
P01906509A0072|6 10|study
P01906692A0321|0 12|INTERVENTIONS
P01906692A0321|36 42|heparin
P01906692A0321|14 21|Patients
P01906692A0321|47 53|aspirin
P01906692A0321|30 34|rt-PA
P01907265A0670|71 81|cell extract
P01907265A0670|23 28|result
P01907265A0670|48 60|endonucleases
P01907265A0670|109 127|DNA cleavage activity
P01907941A0275|69 71|Rel
P01907941A0275|60 66|binding
P01907941A0275|13 23|I kappa B beta
P01907941A0275|77 86|kappa B site
P01907941A0275|31 42|I kappa B alpha
P01909027A0922|0 15|Sequence analysis
P01909027A0922|48 50|ILF
P01909027A0922|161 166|family
P01909027A0922|60 67|homology
P01909027A0922|90 113|fork head DNA binding domain
P01909027A0922|142 156|protein fork head
P01909027A0922|169 178|hepatocyte
P01909027A0922|194 198|HNF-3
P01909027A0922|186 192|factors
P01909027A0922|30 45|DNA binding domain
P01909621A0119|18 29|hemodialyses
P01909621A0119|49 56|lithemia
P01909621A0119|67 72|ranges
P01909960A0134|160 167|NA levels
P01909960A0134|90 90|%
P01909960A0134|36 40|mg/kg
P01909960A0134|171 171|%
P01909960A0134|139 141|NMN
P01909960A0134|52 64|noradrenaline
P01909960A0134|11 19|injection
P01909960A0134|123 137|normetanephrine
P01909960A0134|108 120|concentration
P01909960A0134|66 67|NA
P01909960A0134|69 80|biosynthesis
P01909960A0134|146 146|%
P01910505A0000|73 82|leukopenia
P01910505A0000|6 21|wuzi yanzong pills
P01910505A0000|50 65|cyclophosphamide
P01910505A0000|85 88|mice
P01910505A0000|42 47|effect
P01911767T0000|28 58|ribulosebisphosphate carboxylase
P01911767T0000|82 90|catalysis
P01911767T0000|65 78|subunit binding
P01911767T0000|19 25|subunit
P01911767T0000|0 8|Mutations
P01913955A0177|376 379|type
P01913955A0177|219 222|wall
P01913955A0177|274 284|hypertrophy
P01913955A0177|70 75|number
P01913955A0177|137 145|pericytes
P01913955A0177|354 361|collagen
P01913955A0177|231 240|muscle cell
P01913955A0177|256 259|wall
P01913955A0177|105 119|muscularization
P01913955A0177|381 388|collagen
P01913955A0177|326 337|accumulation
P01913955A0177|346 351|amount
P01913955A0177|13 19|changes
P01913955A0177|161 165|cells
P01913955A0177|307 317|muscle cells
P01913955A0177|34 39|artery
P01913955A0177|288 298|hyperplasia
P01913955A0177|122 135|precursor cells
P01913955A0177|86 91|artery
P01913955A0177|60 67|increase
P01915580A0889|115 135|airway hyperreactivity
P01915580A0889|51 59|treatment
P01915580A0889|71 76|asthma
P01915580A0889|5 11|results
P01915580A0889|23 28|NZ-107
P01915580A0889|97 111|airway responses
P01915580A0889|41 44|drug
P01916168A0969|12 34|correlation coefficients
P01916168A0969|107 112|mucosa
P01916168A0969|174 181|learners
P01916168A0969|2 6|study
P01916168A0969|45 60|ISO2 measurements
P01916168A0969|150 157|observer
P01916168A0969|74 84|ulcer margin
P01916168A0969|117 125|delta ISO2
P01916405A0242|61 68|aerosols
P01916405A0242|113 118|stages
P01916405A0242|26 32|persons
P01916405A0242|93 94|PC
P01916405A0242|104 111|diseases
P01916405A0242|9 23|mucosa tattooing
P01916405A0242|96 97|DB
P01916405A0242|86 90|forms
P01916632A0431|20 23|PBMC
P01916632A0431|51 54|case
P01916632A0431|8 17|production
P01917943A0621a|0 15|Sequence analysis
P01917943A0621a|65 72|TATAA box
P01917943A0621a|21 25|sMtCK
P01917943A0621a|104 126|transfection experiments
P01917943A0621a|150 159|expression
P01917943A0621a|170 177|plasmids
P01917943A0621a|185 224|chloramphenicol acetyltransferase reporter
P01917943A0621a|94 95|bp
P01917943A0621a|41 49|sequences
P01917943A0621a|84 92|base pairs
P01917943A0621b|0 15|Sequence analysis
P01917943A0621b|65 72|TATAA box
P01917943A0621b|21 25|sMtCK
P01917943A0621b|104 126|transfection experiments
P01917943A0621b|150 159|expression
P01917943A0621b|170 177|plasmids
P01917943A0621b|185 224|chloramphenicol acetyltransferase reporter
P01917943A0621b|94 95|bp
P01917943A0621b|41 49|sequences
P01917943A0621b|84 92|base pairs
P01917962A0152|156 162|control
P01917962A0152|168 179|SV40 promoter
P01917962A0152|83 93|cDNA segment
P01917962A0152|3 13|cDNA segment
P01917962A0152|28 73|immunoglobulin gene recombination signal sequences
P01917962A0152|114 124|IL-2R L chain
P01918010A0000|0 16|Lipoprotein lipase
P01918010A0000|111 120|expression
P01918010A0000|27 32|enzyme
P01918010A0000|83 92|regulation
P01918010A0000|18 20|LPL
P01918010A0000|41 61|lipoprotein metabolism
P01918010A0000|74 80|pattern
P01918010A1730|0 7|Deletion
P01918010A1730|158 173|3T3-L1 adipocytes
P01918010A1730|135 144|expression
P01918010A1730|21 39|octanucleotide motif
P01918010A1730|177 192|HepG2 hepatocytes
P01918010A1730|47 53|plasmid
P01918010A1730|84 94|LPL promoter
P01918010A1730|71 78|fragment
P01918010A1730|128 132|level
P01918010A1730|114 122|% decrease
P01918070A0281|13 19|binding
P01918070A0281|163 169|potency
P01918070A0281|124 130|rGH T3RE
P01918070A0281|30 44|T3 receptor alpha
P01918070A0281|110 118|mutations
P01918070A0281|193 202|T3R binding
P01918070A0281|184 190|changes
P01918070A0281|46 53|T3R alpha
P01918073A0150|0 9|Comparison
P01918073A0150|153 191|protein kinase A phosphorylation target site
P01918073A0150|417 419|TnI
P01918073A0150|358 360|TnC
P01918073A0150|462 478|actin/TnC-binding
P01918073A0150|260 262|TnI
P01918073A0150|524 541|sequence divergence
P01918073A0150|444 453|TnIcardiac
P01918073A0150|34 61|TnIcardiac amino acid sequences
P01918073A0150|502 507|domain
P01918073A0150|555 573|TnIcardiac sequences
P01918073A0150|101 108|presence
P01918073A0150|423 425|TnC
P01918073A0150|217 223|segment
P01918073A0150|251 257|feature
P01918073A0150|370 381|site sequence
P01918073A0150|303 312|divergence
P01918073A0150|659 665|mammals
P01918073A0150|71 82|TnI sequences
P01918073A0150|123 139|extension sequence
P01918073A0150|654 656|TnI
P01918073A0150|597 620|protein kinase C target site
P01918073A0150|480 500|actomyosin-inhibitory
P01918073A0150|587 593|absence
P01918073A0150|348 356|troponin C
P01918073A0150|405 414|adaptation
P01918073A0150|645 651|feature
P01919831T0000|11 28|management casebook
P01921463T0000|2 17|ASSEMBLER routine
P01921463T0000|79 91|microcomputer
P01921463T0000|35 41|display
P01921463T0000|45 53|averaging
P01921463T0000|56 59|data
P01922082A0149|0 9|Expression
P01922082A0149|47 50|rise
P01922082A0149|61 65|mRNAs
P01922082A0149|97 102|region
P01922082A0149|15 30|mouse TSH beta gene
P01922734T0000|0 10|Habituation
P01922734T0000|49 53|snail
P01922734T0000|66 76|stimulation
P01922734T0000|31 37|neurons
P01922739A0336|229 235|average
P01922739A0336|17 20|ROSP
P01922739A0336|123 128|course
P01922739A0336|206 209|ROSP
P01922739A0336|301 310|electrodes
P01922739A0336|75 84|directions
P01922739A0336|325 329|level
P01922739A0336|151 159|operation
P01922739A0336|335 342|pia mater
P01922739A0336|109 117|amplitude
P01922739A0336|238 247|electrodes
P01922739A0336|39 50|fluctuations
P01922739A0336|272 280|dura mater
P01922739A0336|293 298|values
P01922739A0336|135 138|days
P01922739A0336|262 266|level
P01922739A0336|195 200|values
P01922739A0336|31 36|number
P01923167A0000|0 25|Blood flow velocity waveforms
P01923167A0000|46 63|Doppler examination
P01923167A0000|82 88|carotid
P01923167A0000|106 113|arteries
P01923167A0000|176 183|approach
P01923167A0000|147 151|route
P01923628T0001|30 42|flow cytometry
P01923628T0001|64 71|findings
P01923628T0001|12 19|analysis
P01923628T0001|90 96|myxomas
P01923628T0001|76 80|cases
P01923628T0001|22 24|DNA
P01923766A0485|0 15|Sequence analysis
P01923766A0485|54 60|variant
P01923766A0485|193 196|exon
P01923766A0485|129 137|exclusion
P01923766A0485|172 173|nt
P01923766A0485|160 170|nucleotides
P01923766A0485|107 114|splicing
P01923766A0485|70 80|mRNA species
P01923766A0485|30 37|addition
P01923803A0609|0 7|Position
P01923803A0609|37 57|SsoL12 protein sequence
P01923803A0609|68 75|AUA codon
P01923803A0609|14 23|isoleucine
P01923985A0111|0 7|Symptoms
P01923985A0111|24 41|mastocyte mediators
P01923985A0111|16 21|action
P01924315A0158|69 73|level
P01924315A0158|5 9|yeast
P01924315A0158|76 89|SOD1 expression
P01924315A0158|34 45|copper levels
P01924315A0158|55 61|control
P01924920A0115|113 119|agar RLK
P01924920A0115|10 16|samples
P01924920A0115|50 50|%
P01924920A0115|132 141|atmosphere
P01924920A0115|18 29|Mobiluncus SP
P01924920A0115|87 99|microorganism
P01924920A0115|81 81|%
P01924920A0115|57 68|Gram staining
P01925092A0000|98 105|meshwork
P01925092A0000|8 20|investigators
P01925092A0000|63 68|retina
P01925092A0000|71 74|part
P01925092A0000|48 52|blood
P01925092A0304|86 111|tissue plasminogen activator
P01925092A0304|141 146|saline
P01925092A0304|58 66|treatment
P01925092A0304|25 31|animals
P01925092A0304|11 15|hours
P01925092A0304|122 127|volume
P01925092A0304|74 83|micrograms
P01927421A0181|16 27|examinations
P01927421A0181|55 63|nystagmus
P01927421A0181|97 105|nystagmus
P01927421A0181|78 86|nystagmus
P01927845A0107|58 66|disorders
P01927845A0107|75 81|disease
P01927845A0107|23 29|lesions
P01927845A0107|8 17|morphology
P01927845A0107|68 72|Bowen
P01928923A0000|157 163|portion
P01928923A0000|176 181|horses
P01928923A0000|140 145|wounds
P01928923A0000|169 173|limbs
P01928923A0000|118 126|treatment
P01928923A0000|19 37|yeast cell derivative
P01928923A0000|0 11|Equine amnion
P01928923A0000|85 99|wound medicament
P01930470A0337|146 152|markers
P01930470A0337|21 29|incidence
P01930470A0337|165 169|units
P01930470A0337|90 93|AABB
P01930470A0337|44 46|PTH
P01930470A0337|106 112|testing
P01930470A0337|79 88|Blood Banks
P01930470A0337|172 176|blood
P01930470A0337|58 76|American Association
P01930660T0000|12 23|growth factor
P01930660T0000|26 30|IGF-1
P01930660T0000|38 45|patients
P01931966A0490|0 5|Fusion
P01931966A0490|19 24|pADPRP
P01931966A0490|8 16|ubiquitin
P01931966A0490|37 41|yield
P01931966A0490|44 49|pADPRP
P01931966A0490|96 101|enzyme
P01932650A0435|72 76|hours
P01932650A0435|11 18|patients
P01932650A0435|82 90|operation
P01932650A0435|50 62|drainage blood
P01932650A0435|123 126|MBRS
P01932650A0435|97 109|concentration
P01932650A0435|2 6|group
P01932695A1155|3 13|suppression
P01932695A1155|79 94|barley endosperms
P01932695A1155|45 59|expression assay
P01933614A0406|59 70|osteoporosis
P01933614A0406|39 43|women
P01933614A0406|11 26|salmon calcitonin
P01933614A0406|3 8|effect
P01933614A0406|32 36|spray
P01934378A1219|8 36|muscle metaboreceptor responses
P01934378A1219|50 61|heart failure
P01934378T0000|60 71|heart failure
P01934378T0000|8 44|muscle metaboreceptor exercise responses
P01936213T0000|0 9|Evaluation
P01936213T0000|25 34|drug effect
P01936213T0000|37 52|membrane fluidity
P01936348A0155|60 63|resp
P01936348A0155|49 56|AmF/SnF2
P01936348A0155|33 38|groups
P01936348A0155|3 14|examinations
P01936997A0795|0 16|RNA gel retardation
P01936997A0795|89 107|TAR RNA loop sequences
P01936997A0795|20 38|competition analyses
P01936997A0795|51 64|TRP-185 binding
P01937790A0292|56 61|adults
P01937790A0292|3 9|vaccine
P01937790A0292|45 52|children
P01937989A0383|56 59|test
P01937989A0383|66 67|R2
P01937989A0383|31 39|induction
P01937989A0383|4 9|groups
P01938178T0000|31 38|analysis
P01938178T0000|52 55|P300
P01938178T0000|0 11|Applications
P01939131A0871|29 34|BW2001
P01939131A0871|36 41|xth-11
P01939131A0871|49 59|strain cells
P01939131A0871|3 11|construct
P01939131A0871|43 47|nfo-2
P01939199A0588|160 172|transcription
P01939199A0588|39 51|transcription
P01939199A0588|73 80|extracts
P01939199A0588|153 157|level
P01939199A0588|106 118|TFIID fraction
P01939199A0588|123 131|HeLa cells
P01939199A0588|16 20|TFIID
P01939827A0150|173 174|pH
P01939827A0150|133 143|mmol/L CaCl2
P01939827A0150|161 171|mmol/L Hepes
P01939827A0150|96 108|precipitation
P01939827A0150|254 265|mmol/L KH2PO4
P01939827A0150|281 282|pH
P01939827A0150|190 202|precipitation
P01939827A0150|291 299|degrees C.
P01939827A0150|62 75|titanium powder
P01939827A0150|42 58|oxide surface layer
P01939827A0150|217 225|solutions
P01939827A0150|269 279|mmol/L Hepes
P01939827A0150|113 121|solutions
P01939827A0150|10 21|pretreatment
P01939827A0150|239 249|mmol/L CaCl2
P01939827A0150|146 157|mmol/L KH2PO4
P01939878A0765|58 63|casein
P01939878A0765|107 114|patients
P01939878A0765|135 141|acidity
P01939878A0765|14 27|solidification
P01939899A2043|99 104|amount
P01939899A2043|56 62|effects
P01939899A2043|107 118|perturbation
P01939899A2043|7 11|model
P01939899A2043|91 95|tones
P01939899A2043|72 80|variables
P01939899A2043|83 88|number
P01939899A2043|121 128|ABSTRACT
P01939899A2043|143 147|WORDS
P01939899A2043|44 50|account
P01939906A0233|223 240|parameter landscape
P01939906A0233|194 211|optimization method
P01939906A0233|67 78|cost function
P01939906A0233|126 131|source
P01939906A0233|96 106|search space
P01939906A0233|159 170|wave equation
P01939906A0233|145 153|solutions
P01939906A0233|4 17|generalization
P01939906A0233|20 22|MFP
P01939906A0233|112 122|environment
P01939906A0233|253 259|minimum
P01939906A0233|265 276|cost function
P01942033T0000|0 12|Determination
P01942033T0000|39 56|splicing inhibition
P01942033T0000|17 28|RNA structure
P01942033T0000|75 78|exon
P01943184A1050|83 83|%
P01943184A1050|26 35|University
P01943184A1050|104 104|p
P01943184A1050|90 95|% cells
P01943184A1050|38 54|Wisconsin solution
P01943184A1050|11 15|cells
P01943184A1050|63 68|trypan
P01945430A0660|131 145|neuroma suspects
P01945430A0660|60 67|ear fluid
P01945430A0660|11 19|technique
P01945430A0660|106 119|labyrinthotomy
P01945430A0660|81 89|procedure
P01947449A0191|201 203|PO2
P01947449A0191|45 49|terms
P01947449A0191|196 198|PO2
P01947449A0191|109 112|area
P01947449A0191|11 29|diffusion limitation
P01947449A0191|62 81|uptake/O2 requirement
P01947449A0191|84 91|fraction
P01947449A0191|3 8|effect
P01947449A0191|55 59|ratio
P01947449A0191|144 154|requirement
P01947449A0191|158 167|unit volume
P01947449A1082|188 203|cylinder diameter
P01947449A1082|40 48|model sets
P01947449A1082|164 169|models
P01947449A1082|61 76|requirement value
P01947449A1082|3 21|Diffusion limitation
P01947449A1082|119 129|requirement
P01948783A0000|85 92|patients
P01948783A0000|27 33|Estulic
P01948783A0000|62 67|period
P01948783A0000|19 24|effect
P01952827A0215|25 31|patient
P01952827A0215|47 56|test phrase
P01952827A0215|5 8|time
P01952827A0215|14 20|seizure
P01954355A0997|0 17|Monitoring patients
P01954355A0997|38 41|IL-1
P01954355A0997|27 34|leukemia
P01954355A0997|107 112|causes
P01954355A0997|122 129|episodes
P01954355A0997|75 80|course
P01954355A0997|45 53|TNF levels
P01954355A0997|83 89|disease
P01954835A0000|0 21|Echinococcus granulosus
P01954835A0000|92 97|female
P01954835A0000|68 75|lung cyst
P01954835A0000|107 114|Missouri
P01954835A0000|47 64|aspiration cytology
P01956285A0000|3 10|sequence
P01956285A0000|109 137|choline-glycine betaine pathway
P01956285A0000|30 40|nucleotides
P01956285A0000|56 63|bet genes
P01956491A0095|221 224|rats
P01956491A0095|79 92|filtration rate
P01956491A0095|94 96|GFR
P01956491A0095|194 203|comparison
P01956491A0095|127 145|creatinine clearance
P01956491A0095|115 123|clearance
P01956491A0095|251 256|ml/min
P01956491A0095|172 177|ml/min
P01956491A0095|6 14|treatment
P01956491A0095|32 40|mg/kg/day
P01956491A0095|17 29|amphotericin B
P01958368A0556|86 110|vitelliform classification
P01958368A0556|75 80|stages
P01958368A0556|11 17|lesions
P01958368A0556|49 59|progression
P01958368A0556|0 8|Evolution
P01958821T0000|38 48|cell biology
P01958821T0000|8 29|fluorescence microscopy
P01960974A0000|43 47|cases
P01960974A0000|12 19|chemical
P01960974A0000|65 72|solvents
P01960974A0000|0 6|Toluene
P01961213A0150|44 53|breast milk
P01961213A0150|67 71|years
P01961213A0150|23 32|HCB-levels
P01961747A0000|88 93|enzyme
P01961747A0000|122 139|transfection assays
P01961747A0000|97 110|substrate genes
P01961747A0000|1 29|herpesvirus proteinase activity
P01961996A0522|13 13|R
P01961996A0522|37 46|preference
P01961996A0522|65 75|opportunity
P01961996A0522|0 5|Adult H
P01963419A0501|114 124|13N reaction
P01963419A0501|47 56|MeV protons
P01963419A0501|102 104|16O
P01963419A0501|152 152|p
P01963419A0501|128 130|18F
P01963419A0501|154 154|n
P01963419A0501|94 96|13N
P01963419A0501|132 142|fluoride ion
P01963419A0501|148 150|18O
P01963419A0501|108 112|alpha
P01963419A0501|59 63|water
P01963419A0501|156 166|18F reaction
P01963419A0501|106 106|p
P01963419A0501|7 25|silver liquid chamber
P01963438T0000|31 41|cytochrome c
P01963438T0000|55 65|polypyrrole
P01963438T0000|13 28|electron transfer
P01963438T0000|105 114|electrodes
P01963438T0000|69 77|methylene
P01963438T0000|82 96|polypyrrole film
P01963858T0001|83 95|microdialysis
P01963858T0001|21 39|adrenaline secretion
P01963858T0001|9 18|activation
P01963858T0001|45 47|rat
P01963858T0001|57 71|neuroglycopenia
P01964989A0145|154 160|vinegar
P01964989A0145|162 179|potassium hydroxide
P01964989A0145|206 212|ammonia
P01964989A0145|192 201|2-propanol
P01964989A0145|132 145|sodium chloride
P01964989A0145|187 190|soap
P01964989A0145|97 100|acid
P01964989A0145|44 46|PCP
P01964989A0145|102 111|9-THC-COOH
P01964989A0145|147 152|bleach
P01964989A0145|0 13|Urine specimens
P01964989A0145|30 42|phencyclidine
P01967130A0645|41 51|acid protein
P01967130A0645|12 23|pair EFIA cDNA
P01967130A0645|103 120|DNA binding proteins
P01968043A0908|56 61|insert
P01968043A0908|63 68|pASB-1
P01968043A0908|88 99|orientations
P01968043A0908|20 29|cDNA clones
P01968061A0371|0 2|Sci
P01968156T0000|0 18|Dose standardisation
P01968156T0000|21 34|botulinum toxin
P01968224A0119|115 115|%
P01968224A0119|81 86|intron
P01968224A0119|101 102|bp
P01968224A0119|35 52|residue polypeptide
P01968224A0119|160 163|PCNA
P01968224A0119|237 243|leucine
P01968224A0119|128 144|amino acid sequence
P01968224A0119|181 183|rat
P01968224A0119|192 207|PCNA polypeptides
P01968224A0119|259 264|region
P01968224A0119|91 99|base pairs
P01968224A0119|3 16|coding sequence
P01968224A0119|228 234|repeats
P01970560A1024|263 271|organisms
P01970560A1024|286 295|efficiency
P01970560A1024|25 28|aroF
P01970560A1024|39 45|regions
P01970560A1024|160 169|regulation
P01970560A1024|248 256|operators
P01970560A1024|212 224|TyrR repressor
P01970560A1024|48 51|lacZ
P01970560A1024|92 95|copy
P01970560A1024|109 118|chromosome
P01970560A1024|13 19|fusions
P01970560A1024|120 143|beta-Galactosidase assays
P01970560A1024|172 190|aroF-lacZ expression
P01970801A0925|97 99|arm
P01970801A0925|25 29|genes
P01970801A0925|160 164|mouse
P01970801A0925|51 54|OSBP
P01970801A0925|39 42|Ly-1
P01970801A0925|46 49|CD20
P01970801A0925|138 140|end
P01970801A0925|102 111|chromosome
P01970801A0925|143 152|chromosome
P01970801A0925|83 87|group
P01970926A0000|58 75|concentration rises
P01970926A0000|50 56|plasma K
P01970926A0000|6 14|exercise K
P01970926A0000|41 46|muscle
P01970984A0668|59 59|T
P01970984A0668|63 63|E
P01970984A0668|51 57|groups E
P01970984A0668|9 17|treatment
P01970984A0668|19 38|serum estradiol levels
P01970984A0668|70 76|group C.
P01971191A1271|158 163|agents
P01971191A1271|63 71|influence
P01971191A1271|40 52|isoproterenol
P01971191A1271|129 145|outflow resistance
P01971191A1271|108 111|dogs
P01971191A1271|95 105|liver volume
P01971191A1271|82 92|capacitance
P01971191A1271|170 178|histamine
P01971191A1271|32 38|agonist
P01972379T0042|28 36|CPS domain
P01972379T0042|70 79|protein CAD
P01972379T0042|48 54|hamster
P01972379T0042|0 10|DNA sequence
P01972379T0042|14 22|evolution
P01973384A0206|28 39|binding sites
P01973384A0206|123 129|embryos
P01973384A0206|70 76|ability
P01973384A0206|86 98|transcription
P01974550A0362|14 16|CBF
P01974550A0362|63 80|ipratropium bromide
P01974550A0362|54 60|mg/kg iv
P01974550A0362|32 51|hexamethonium bromide
P01974550A0362|140 146|% saline
P01974550A0362|115 121|mg/kg iv
P01974550A0362|85 98|microgram/kg iv
P01974550A0362|101 112|indomethacin
P01974876A1051|15 51|restriction fragment length polymorphism
P01974876A1051|104 114|enzyme BglII
P01974876A1051|67 69|DNA
P01974876A1051|85 95|individuals
P01975157A0836|44 50|results
P01975157A0836|26 27|pH
P01975157A0836|10 23|transformation
P01975428A0151|0 8|Telomeres
P01975428A0151|26 32|fusions
P01975428A0151|71 73|end
P01975428A0151|111 118|function
P01975428A0151|50 60|degradation
P01975428A0151|85 95|DNA molecule
P01975428A0151|121 132|cell division
P01976638A1135|68 76|sequences
P01976638A1135|39 44|region
P01977585A0222|135 147|protein kinase
P01977585A0222|107 114|subunits
P01977585A0222|9 14|enzyme
P01977585A0222|63 67|cells
P01977856A1036|85 90|extent
P01977856A1036|64 72|diagnosis
P01977856A1036|52 54|AMI
P01977856A1036|74 81|location
P01977856A1036|4 8|study
P01977856A1036|21 25|BSPMs
P01977856A1036|103 109|infarct
P01977856A1036|40 49|assessment
P01977856A1036|57 61|terms
P01978834A0076|86 112|rabbit H,K-ATPase beta subunit
P01978834A0076|62 69|antibody
P01978834A0076|7 35|abomasum lambda gt11 cDNA library
P01978857A0504|14 30|laboratory testing
P01978857A0504|53 65|CD4 cell counts
P01978857A0504|41 50|monitoring
P01978857A0504|9 11|use
P01982061A0615|9 15|TATA box
P01982061A0615|50 76|transcription initiation site
P01982061T0000|0 15|Characterization
P01982061T0000|53 66|hamster CAD gene
P01982061T0000|23 25|end
P01982190T0001|5 13|cirrhosis
P01982190T0001|51 59|hepatitis
P01982190T0001|22 29|modality
P01982190T0001|35 43|evolution
P01982997A1104|162 171|expression
P01982997A1104|118 127|expression
P01982997A1104|66 75|MDI regimen
P01982997A1104|28 56|transcription factor expression
P01982997A1104|174 178|c-Fos
P01982997A1104|130 138|c-Jun mRNA
P01982997A1104|182 191|Jun-B mRNAs
P01982997A1104|88 89|RA
P01982997A1104|0 10|Examination
P01983026A0483|85 100|CA concentrations
P01983026A0483|62 71|intubation
P01983026A0483|121 131|study period
P01983026A0483|8 16|heart rate
P01983026A0483|47 52|degree
P01983026A0483|54 56|min
P01983026A0483|29 36|pressure
P01984665T0000|0 9|Processing
P01984665T0000|132 144|baculoviruses
P01984665T0000|24 39|immunoreactivity
P01984665T0000|11 19|secretion
P01984665T0000|42 48|carboxy
P01984665T0000|68 96|dengue-2 virus envelope proteins
P01984665T0000|114 118|cells
P01985301T0000|61 71|brain damage
P01985301T0000|19 24|MK-801
P01985301T0000|8 14|therapy
P01985301T0000|28 37|nimodipine
P01985301T0000|41 50|protection
P01985920A0156|118 130|pair cDNA clone
P01985920A0156|78 99|rat SCP2 protein sequence
P01985920A0156|7 15|screening
P01985920A0156|151 169|SCP2 protein sequence
P01985920A0156|19 37|rat liver cDNA library
P01985920A0156|44 63|oligonucleotide probe
P01985920T0000|0 6|Cloning
P01985920T0000|22 39|nucleotide sequence
P01985920T0000|8 17|expression
P01985920T0000|71 75|cDNAs
P01985920T0000|42 69|rat liver sterol carrier protein
P01985924A0554|85 94|holoenzyme
P01985924A0554|168 185|initiation activity
P01985924A0554|80 82|pol
P01985924A0554|24 30|complex
P01985924A0554|193 197|delta
P01985924A0554|128 135|presence
P01985924A0554|188 190|pol
P01985924A0554|138 141|urea
P01985924A0554|109 122|chromatography
P01985924A0554|3 10|addition
P01985924A0554|59 66|subunits
P01986225A0250|15 28|identification
P01986225A0250|31 33|HSF
P01986225A0250|39 50|fission yeast
P01986241A0117|85 92|CUP1 gene
P01986241A0117|20 34|ACE1 gene product
P01986241A0117|66 79|promoter region
P01986241A0117|56 60|sites
P01986241A0117|0 8|Induction
P01986254A0452|0 21|Gel mobility shift assays
P01986254A0452|37 43|E6 motif
P01986254A0452|122 130|HeLa cells
P01986254A0452|113 118|T cells
P01986254A0452|77 84|addition
P01986254A0452|68 74|complex
P01986254A0452|98 101|band
P01986360A0000|222 226|probe
P01986360A0000|154 158|mouse
P01986360A0000|166 218|oligoadenylate synthetase gene interferon response element
P01986360A0000|19 57|interferon response element binding factors
P01986360A0000|123 125|32P
P01986360A0000|79 114|mouse fibroblast lambda gt11 cDNA library
P01986360A0000|5 10|clones
P01986360A0000|143 148|trimer
P01988041A0281|17 22|clones
P01988041A0281|55 70|BAL cDNA structure
P01988041A0281|3 10|sequence
P01989561A0100|173 179|venting
P01989561A0100|80 95|perfusion cannula
P01989561A0100|38 46|occlusion
P01989561A0100|133 137|heart
P01989561A0100|21 31|instruments
P01989561A0100|124 127|apex
P01989561A0100|3 13|application
P01989561A0100|61 65|aorta
P01989999A0000|16 25|synthetase
P01989999A0000|142 144|IMP
P01989999A0000|130 139|conversion
P01989999A0000|27 29|IMP
P01989999A0000|80 83|role
P01989999A0000|86 103|purine biosynthesis
P01989999A0000|49 51|GDP
P01989999A0000|54 55|EC
P01989999A0000|31 47|L-aspartate ligase
P01989999A0000|147 149|AMP
P01990254A0791|0 16|Immunophenotyping
P01990254A0791|77 86|cell origin
P01990254A0791|23 27|cases
P01990254A0791|52 61|cell origin
P01990266A0678|162 169|proteins
P01990266A0678|81 93|sodium dodecyl
P01990266A0678|185 192|promoter
P01990266A0678|11 32|UV cross-linking studies
P01990266A0678|71 78|mobility
P01990266A0678|46 50|UHF-1
P01990266A0678|112 115|gels
P01990266A0678|204 207|site
P01990266A0678|133 135|kDa
P01991521A0481|3 9|results
P01991521A0481|23 32|conclusion
P01991521A0481|77 85|G4 content
P01991521A0481|108 114|muscles
P01991521A0481|57 64|activity
P01992459A0000|214 217|mRNA
P01992459A0000|237 245|cytoplasm
P01992459A0000|182 187|export
P01992459A0000|11 21|interaction
P01992459A0000|90 92|RRE
P01992459A0000|64 88|immunodeficiency virus mRNA
P01992459A0000|97 114|Rev response element
P01992459A0000|225 231|nucleus
P01992459A0000|167 176|regulation
P01992459A0000|47 53|element
P01992459A0000|135 144|protein Rev
P01992742A0000|42 49|neuritis
P01992742A0000|25 32|patients
P01992742A0000|74 79|period
P01992742A0000|13 19|records
P01992953A0247|87 90|test
P01992953A0247|7 12|levels
P01992953A0247|23 33|abnormality
P01992953A0247|110 117|patients
P01992953A0247|71 81|specificity
P01992953T0000|0 22|Alanine aminotransferase
P01992953T0000|33 40|practice
P01993181T0000|0 25|Nucleotide sequence analysis
P01993181T0000|78 81|nahG
P01993181T0000|48 76|PpG7 salicylate hydroxylase gene
P01993181T0000|100 105|region
P01993656A1860|69 75|guanine
P01993656A1860|94 101|proteins
P01993656A1860|6 13|ARF cDNAs
P01995951A0000|58 60|HIV
P01995951A0000|108 116|factor Sp1
P01995951A0000|22 24|LTR
P01995951A0000|36 56|immunodeficiency virus
P01995951A0000|82 86|sites
P01995951A0000|15 20|repeat
P01996312A0454|0 2|DNA
P01996312A0454|91 100|Dd kinase-2
P01996312A0454|7 9|PCR
P01996312A0454|43 62|lambda gt11 cDNA clones
P01997465A0276|83 87|weeks
P01997465A0276|35 41|alveoli
P01997465A0276|17 23|changes
P01997465A0276|45 49|septa
P01997465A0276|93 103|irradiation
P01997465A0276|29 32|area
P01997465A0276|58 72|collagen content
P01999035A0383|98 106|IHD events
P01999035A0383|37 44|interval
P01999035A0383|8 16|follow-up
P01999035A0383|73 77|years
P01999035A0383|50 54|years
P01999035A0383|80 88|Speedwell
P01999035A0383|57 66|Caerphilly
P01999459A0795|0 1|A.
P01999999T0001|62 70|treatment
P01999999T0001|28 33|injury
P01999999T0001|9 16|luxation
P02000093A0794|0 8|Landsberg
P02000093A0794|10 13|La-O
P02000093A0794|18 19|cv
P02001033A1907|120 124|drugs
P02001033A1907|26 39|concentrations
P02001033A1907|188 195|activity
P02001033A1907|211 218|decrease
P02001033A1907|41 50|desflurane
P02001033A1907|145 152|reflexes
P02001033A1907|54 63|isoflurane
P02001033A1907|229 236|pressure
P02001033A1907|111 117|absence
P02001033A1907|154 163|desflurane
P02001033A1907|2 8|summary
P02001033A1907|90 96|effects
P02002051A0276|15 23|isolation
P02002051A0276|38 46|cDNA clone
P02002051A0276|77 83|isoform
P02002051A0276|95 103|C-subunit
P02002051T0000|0 11|Isoform C beta
P02002051T0000|23 26|form
P02002051T0000|47 53|subunit
P02002051T0000|70 82|protein kinase
P02002511A0637|75 82|examples
P02002511A0637|49 56|problems
P02002511A0637|21 33|PB-PK modeling
P02002511A0637|7 18|applications
P02004521A0266|0 7|Patients
P02004521A0266|27 41|CT abnormalities
P02004521A0266|68 74|disease
P02004705A0686|100 101|Mr
P02004705A0686|63 70|fragment
P02004705A0686|38 47|amino acids
P02004705A0686|3 14|cdr1 sequence
P02004705A0686|82 88|product
P02005547A0121|161 172|practitioner
P02005547A0121|229 235|illness
P02005547A0121|90 100|development
P02005547A0121|115 132|hyperbilirubinemia
P02005547A0121|201 206|family
P02005547A0121|149 156|jaundice
P02005547A0121|49 56|pathways
P02005547A0121|222 226|child
P02005547A0121|15 27|understanding
P02006558A0000|0 21|Displacement thresholds
P02006558A0000|55 60|vision
P02006558A0000|34 38|sites
P02007045A0092|100 107|distress
P02007045A0092|17 20|case
P02007045A0092|3 9|authors
P02007045A0092|53 61|brain cyst
P02007045A0092|40 49|irrigation
P02008982A0463|0 4|ELISA
P02008982A0463|37 45|diagnosis
P02008982A0463|75 85|sputum smear
P02008982A0463|20 31|contribution
P02008982A0463|48 59|tuberculosis
P02010912A0366|39 47|structure
P02010912A0366|73 88|MalT binding sites
P02010912A0366|6 10|paper
P02010912A0366|64 67|role
P02010912A0366|121 125|pulAp
P02010912A0366|29 33|study
P02010912A0366|129 142|pulCp promoters
P02011924A0729|82 90|alpha-IFN
P02011924A0729|23 30|patients
P02011924A0729|74 79|MU/day
P02011924A0729|37 41|basis
P02011924A0729|48 53|report
P02011924A0729|103 111|treatment
P02011924A0729|132 143|cell leukemia
P02011924A0729|115 122|patients
P02011924A0729|15 20|number
P02012097T0000|45 71|Plasmodium falciparum malaria
P02012097T0000|10 21|fluctuations
P02012097T0000|32 42|parasitemia
P02012789A0051|10 22|family history
P02014928T0000|44 53|inhalation
P02014928T0000|12 17|asthma
P02014928T0000|21 39|rhinoconjunctivitis
P02014928T0000|73 90|serum albumin powder
P02015921A0523|59 62|node
P02015921A0523|8 18|subdivision
P02015921A0523|67 70|pN1b
P02015921A0523|21 31|Category pN1
P02015921A0523|36 39|pN1a
P02015921A0523|81 85|nodes
P02015921A0523|41 50|metastasis
P02016053A0752|0 27|Amino acid sequence comparisons
P02016053A0752|76 81|region
P02016053A0752|165 182|DNA binding activity
P02016053A0752|33 43|E74A protein
P02016053A0752|99 115|amino acid residues
P02016769A0720|67 74|contexts
P02016769A0720|36 44|promoters
P02016769A0720|22 30|strengths
P02017159A0646|0 5|Grasso
P02017159A0646|10 11|A.
P02017271A0502|86 89|none
P02017271A0502|21 31|improvement
P02017271A0502|6 11|months
P02017271A0502|34 41|strength
P02017271A0502|93 100|controls
P02017271A0502|73 80|patients
P02017414A0307|55 60|Line F.
P02017414A0307|5 7|POI
P02017414A0307|11 19|asymptote
P02017414A0307|40 47|Line RBC2
P02017414A0307|0 2|Age
P02019572A0000|87 91|genes
P02019572A0000|94 99|series
P02019572A0000|308 325|hepatoma HepG2 cells
P02019572A0000|209 217|base pairs
P02019572A0000|386 395|C2C12 cells
P02019572A0000|327 340|rat hepatocytes
P02019572A0000|122 166|chloramphenicol acetyltransferase reporter genes
P02019572A0000|102 111|constructs
P02019572A0000|358 370|fibroblast LTK
P02019572A0000|277 286|expression
P02019572A0000|372 376|cells
P02019572A0000|191 199|fragments
P02019572A0000|219 220|bp
P02019572A0000|13 24|DNA sequences
P02019572A0000|44 53|expression
P02019572A0000|239 249|gene cap site
P02019572A0000|400 407|CHO cells
P02019572A0000|292 303|introduction
P02019572A0000|350 356|culture
P02019572A0000|59 80|rat liver pyruvate kinase
P02020082A0356|98 108|dysfunction
P02020082A0356|191 200|difference
P02020082A0356|63 67|AaDO2
P02020082A0356|169 178|parameters
P02020082A0356|113 117|AaDO2
P02020082A0356|25 35|gas exchange
P02020082A0356|208 220|plasma colloid
P02020082A0356|134 145|relationship
P02020082A0356|56 60|value
P02020082A0356|228 235|pressure
P02020082A0356|3 13|disturbance
P02020082A0356|239 241|PCW
P02020314A1290|191 196|future
P02020314A1290|55 65|neutropenia
P02020314A1290|158 169|chemotherapy
P02020314A1290|90 129|carboplatin-cyclophosphamide chemotherapy
P02020314A1290|12 34|micrograms/kg/day GM-CSF
P02020314A1290|45 52|severity
P02020314A1290|69 84|thrombocytopenia
P02020314A1290|1 4|dose
P02020314A1290|180 185|cancer
P02021630A1104|131 141|alterations
P02021630A1104|79 81|DNA
P02021630A1104|92 105|guanine N7 sites
P02021630A1104|182 195|protein binding
P02021630A1104|116 121|groove
P02021630A1104|47 58|interactions
P02021630A1104|124 126|DNA
P02021630A1104|69 75|protein
P02021630A1104|5 15|differences
P02021630A1104|144 172|DNA phosphodiester conformation
P02022188A0112|160 180|mobility group proteins
P02022188A0112|64 74|nucleosomes
P02022188A0112|103 108|agents
P02022188A0112|11 18|analysis
P02022188A0112|92 100|chromatin
P02022188A0112|129 131|DNA
P02022188A0112|38 47|BJ1 protein
P02022188A0112|182 185|HMGs
P02022188A1463|98 109|prerequisite
P02022188A1463|123 136|gene expression
P02022188A1463|38 46|chromatin
P02022188A1463|17 28|gene products
P02022188A1463|81 94|order structure
P02022920A0334|68 78|nucleotides
P02022920A0334|86 88|UTR
P02022920A0334|3 15|C4BP alpha gene
P02022920A0334|45 53|exon codes
P02023097A0000|41 50|Rev protein
P02023097A0000|107 120|gene expression
P02023097A0000|81 89|regulator
P02023097A0000|35 39|HIV-1
P02023097A0000|8 32|immunodeficiency virus type
P02023097A0000|136 151|virus replication
P02023421A0343|83 90|strength
P02023421A0343|102 107|effect
P02023421A0343|63 70|increase
P02023421A0343|7 19|proliferation
P02023421A0343|110 121|wound healing
P02023421A0343|22 32|fibroblasts
P02023421A0343|36 52|collagen synthesis
P02023421A0343|168 173|agents
P02023904A0120|3 10|CDC7 gene
P02023904A0120|25 33|AUG codons
P02023904A0120|44 64|translation start sites
P02023904A0120|95 102|proteins
P02024252A0000|70 81|municipality
P02024252A0000|103 108|Norway
P02024252A0000|32 38|persons
P02024252A0000|22 26|total
P02024252A0000|9 13|years
P02024252A0000|47 64|disability pensions
P02024252A0000|84 92|Nordreisa
P02024488A0506|0 3|HeLa
P02024488A0506|51 61|CMV promoter
P02024488A0506|103 120|neomycin resistance
P02024488A0506|7 21|Jurkat cell lines
P02024488A0506|33 39|nef gene
P02024488A0506|89 99|coselection
P02024488A0506|67 74|HIV-1 LTR
P02024625A0202|86 97|similarities
P02024625A0202|65 69|cases
P02024625A0202|24 35|presentation
P02024625A0202|114 121|features
P02024625A0202|47 56|appearance
P02024625A0202|0 10|Differences
P02024791A0582|15 25|MAIN RESULTS
P02024791A0582|64 68|study
P02024791A0582|104 114|L atropine/0
P02024791A0582|52 56|entry
P02024791A0582|134 134|P
P02024791A0582|83 98|FEV1 measurements
P02024791A0582|33 38|groups
P02024791A0582|118 132|L metaproterenol
P02024791A0582|0 11|MEASUREMENTS
P02024816A0521|72 88|pneumonia patients
P02024816A0521|34 41|protein A
P02024816A0521|7 11|ELISA
P02024816A0521|43 46|SP-A
P02025515A0979|2 5|view
P02025515A0979|32 40|doses/day
P02025515A0979|16 19|t1/2
P02026144A0741|97 100|NRS2
P02026144A0741|8 14|control
P02026144A0741|133 142|domain UAS1
P02026144A0741|78 81|NRS1
P02026144A0741|17 29|GUS expression
P02026144A0741|68 76|sequences
P02026147A0000|104 113|properties
P02026147A0000|27 29|CaM
P02026147A0000|11 13|Ca2
P02026147A0000|132 135|type
P02026147A0000|138 147|CaM kinases
P02026147A0000|41 53|protein kinase
P02026147A0000|55 63|CaM kinase
P02026147A0000|72 76|yeast
P02026147A0000|16 25|calmodulin
P02026461A0760|44 54|individuals
P02026461A0760|78 82|panel
P02026461A0760|6 10|cases
P02026461A0760|85 90|probes
P02026491A0399|30 36|effects
P02026491A0399|102 105|pain
P02026491A0399|60 66|seizure
P02026491A0399|3 10|patients
P02026491A0399|41 43|NMF
P02027839A0250|3 9|muscles
P02027839A0250|104 113|fiber ratio
P02027839A0250|52 52|P
P02027839A0250|25 29|group
P02027839A0250|93 101|capillary
P02027839A0250|150 157|distance
P02027839A0250|65 70|values
P02027839A0250|180 184|group
P02027839A0250|83 89|density
P02028125A0101|28 36|infection
P02028125A0101|154 161|examples
P02028125A0101|89 102|tumour response
P02028125A0101|168 176|functions
P02028125A0101|51 62|AIDS patients
P02028125A0101|112 124|cancer therapy
P02028125A0101|69 79|probability
P02028125A0101|3 12|prevalence
P02029468A0296|0 21|Serum TNF concentrations
P02029468A0296|92 95|week
P02029468A0296|36 44|diagnosis
P02029468A0296|75 89|reference limits
P02030910A0000|33 40|ETS1 gene
P02030910A0000|7 12|clones
P02030910A0000|84 95|organization
P02030910A1070|0 30|Polymerase chain reaction analysis
P02030910A1070|67 74|products
P02030910A1070|97 104|splicing
P02030910A1070|33 40|ETS1 cDNA
P02033038A0309|71 76|pellet
P02033038A0309|108 109|E3
P02033038A0309|23 36|E3 polypeptides
P02033038A0309|130 137|fraction
P02033038A0309|42 46|bands
P02033062A1169|69 80|chicken IGF-I
P02033062A1169|6 21|promotor function
P02033062A1169|110 124|reporter plasmid
P02033062A1169|92 94|DNA
P02033062A1169|58 66|fragments
P02033062A1169|31 35|genes
P02034655A1224|3 7|alpha
P02034655A1224|9 12|gene
P02034655A1224|37 44|promoter
P02034655A1224|23 28|region
P02034655A1224|47 64|transfection assays
P02034655T0000|0 15|Characterization
P02034655T0000|21 25|alpha
P02034655T0000|27 46|integrin gene promoter
P02034669A0293|57 66|expression
P02034669A0293|41 47|tissues
P02034669A0293|13 22|transcript
P02034669A0293|116 121|system
P02034676A0267|3 12|homologues
P02034676A0267|18 30|rhombotin gene
P02035805T0000|0 25|Angina haemorrhagica bullosa
P02035805T0000|44 54|obstruction
P02036066A0000|13 19|effects
P02036066A0000|92 94|PHP
P02036066A0000|113 120|function
P02036066A0000|96 103|solution
P02036066A0000|131 139|rat hearts
P02036066A0000|31 39|perfusion
P02036066A0000|57 90|hemoglobin polyoxyethylene conjugate
P02038293A0919|0 9|Conclusion
P02038293A0919|11 22|inlet type VSD
P02038293A0919|88 93|bundle
P02038293A0919|127 136|VSD closure
P02038293A0919|40 46|type TOF
P02038293A0919|59 66|features
P02038326A0538|183 198|43S-48S particles
P02038326A0538|209 213|shift
P02038326A0538|81 87|couples
P02038326A0538|141 167|translation initiation factor
P02038326A0538|230 240|temperature
P02038326A0538|92 103|accumulation
P02038326A0538|40 45|runoff
P02038326A0538|170 179|eIF-2 alpha
P02038326A0538|69 71|80S
P02038326A0538|121 128|subunits
P02038326A0538|3 18|gcd2-503 mutation
P02038326A0538|47 58|accumulation
P02038784A0317|28 34|failure
P02038784A0317|5 12|patients
P02038784A0317|17 19|ARC
P02041088A1053|178 188|39K promoter
P02041088A1053|12 27|enhancer activity
P02041088A1053|78 81|DR60
P02041088A1053|36 50|reporter plasmid
P02041088A1053|101 144|reporter chloramphenicol acetyltransferase gene
P02041088A1053|153 159|control
P02041088A1053|30 33|DR60
P02044785A0000|100 103|cyst
P02044785A0000|7 10|case
P02044785A0000|67 70|cyst
P02044785A0000|15 28|adenocarcinoma
P02044785A0000|40 54|retroperitoneal
P02044950A0258|45 54|U6 RNA genes
P02044950A0258|59 67|organisms
P02044950A0258|8 30|polymerase chain reaction
P02044975A0380|126 136|application
P02044975A0380|87 98|instillation
P02044975A0380|8 13|volume
P02044975A0380|21 24|flow
P02044975A0380|52 52|P
P02044975A0380|152 152|%
P02044975A0380|158 161|flow
P02044975A0380|142 147|volume
P02044975A0380|118 120|min
P02044975A0380|166 166|%
P02044975A0380|81 81|h
P02045366A1149|0 21|Hydrophobicity analysis
P02045366A1149|92 106|KlaC polypeptide
P02045366A1149|155 161|domains
P02045366A1149|38 41|KlaA
P02045366A1149|45 60|KlaB polypeptides
P02045524A0000|131 137|ratings
P02045524A0000|187 197|conferences
P02045524A0000|97 105|mid-1970s
P02045524A0000|62 65|Food
P02045524A0000|158 162|drugs
P02045524A0000|52 57|agents
P02045524A0000|173 184|end-of-phase
P02045524A0000|69 86|Drug Administration
P02045524A0000|202 213|drug sponsors
P02045524A0000|15 26|availability
P02045524A0000|88 90|FDA
P02045809A0331|118 126|reduction
P02045809A0331|63 68|powder
P02045809A0331|25 44|B. sphaericus products
P02045809A0331|18 22|rates
P02045809A0331|85 95|concentrate
P02045809A0331|46 53|ABG-6184
P02045809A0331|2 9|contrast
P02045809A0331|72 76|BSP-2
P02046202A0625|17 17|%
P02046202A0625|26 39|IgA nephropathy
P02046202A0625|3 11|remainder
P02047597A0149|66 73|bacteria
P02047597A0149|23 30|vulvitis
P02047597A0149|48 61|field condition
P02047597A0149|108 114|strains
P02052544A0641|15 27|DNA polymerase
P02052544A0641|162 172|replication
P02052544A0641|61 66|dpb2-1
P02052544A0641|100 112|DNA polymerase
P02052544A0641|30 36|complex
P02052544A0641|73 77|cells
P02052544A0641|115 121|complex
P02052544A0641|130 133|DPB2
P02052592A0000|239 249|interleukin
P02052592A0000|42 49|products
P02052592A0000|74 85|bone turnover
P02052592A0000|228 236|secretion
P02052592A0000|425 429|cells
P02052592A0000|260 283|tumor necrosis factor alpha
P02052592A0000|105 115|development
P02052592A0000|159 165|effects
P02052592A0000|285 293|TNF-alpha
P02052592A0000|409 413|blood
P02052592A0000|65 71|changes
P02052592A0000|168 179|oophorectomy
P02052592A0000|132 143|osteoporosis
P02052592A0000|193 211|estrogen replacement
P02052592A0000|252 255|IL-1
P02052592A0000|303 320|phytohemagglutinin
P02052592A0000|330 338|secretion
P02052592A0000|381 386|factor
P02052592A0000|29 32|cell
P02052592A0000|388 393|GM-CSF
P02053289A0701|83 95|nt differences
P02053289A0701|15 27|nt differences
P02053289A0701|114 120|strains
P02053289A0701|58 63|groups
P02054754A0919|100 108|disorders
P02054754A0919|65 75|Sandostatin
P02054754A0919|11 20|principles
P02054754A0919|31 40|management
P02054754A0919|83 90|patients
P02055484A0538|29 37|mutations
P02055484A0538|50 53|ATG2
P02055484A0538|9 19|PCR products
P02055484A0538|40 43|ATG1
P02056553T0000|44 53|swine model
P02056553T0000|11 15|shock
P02056553T0000|28 40|translocation
P02060052A0954|41 48|radicals
P02060052A0954|78 89|mitochondria
P02060052A0954|64 74|hepatocytes
P02060052A0954|23 28|levels
P02060052A0954|5 8|data
P02060052A0954|31 36|oxygen
P02061282A0447|96 106|orientation
P02061282A0447|134 139|middle
P02061282A0447|89 90|bp
P02061282A0447|51 56|region
P02061282A0447|16 27|pMxL1 plasmid
P02061282A0447|120 128|pilin gene
P02061282A0447|79 84|repeat
P02061282A0447|3 10|sequence
P02061282A0447|145 169|recombination junction site
P02061333A0784|42 49|acvA gene
P02061333A0784|16 23|presence
P02061333A0784|2 9|evidence
P02061333A0784|26 32|introns
P02061333A1359|149 164|reaction sequence
P02061333A1359|5 16|observations
P02061333A1359|174 183|production
P02061333A1359|56 89|phosphopantetheine-attachment sites
P02061333A1359|33 42|occurrence
P02061333A1359|189 201|ACV tripeptide
P02061333A1359|102 117|thioesterase site
P02061333A1359|135 143|reference
P02062116A0688|0 8|Pargyline
P02062116A0688|11 35|monoamine oxidase inhibitor
P02062116A0688|61 63|max
P02062933A0738|96 103|controls
P02062933A0738|12 17|choice
P02062933A0738|67 69|AOF
P02062933A0738|121 127|partner
P02062933A0738|34 39|female
P02062933A0738|58 61|male
P02062933A0738|71 86|flutamide females
P02064119A1172|116 123|ABSTRACT
P02064119A1172|106 113|subjects
P02064119A1172|49 53|% SaO2
P02064119A1172|89 93|% SaO2
P02064119A1172|83 87|L/min
P02064119A1172|18 26|responses
P02064119A1172|138 142|WORDS
P02064119A1172|59 67|relatives
P02064119A1172|43 47|L/min
P02065022A0747|61 80|transforming activity
P02065022A0747|9 17|deletions
P02065022A0747|122 127|region
P02065022A0747|36 41|region
P02065022A0747|83 85|dbl
P02065022A0747|101 108|deletion
P02065022A0747|133 138|effect
P02066246A0258|41 45|files
P02066246A0258|51 77|Massachusetts Cancer Registry
P02066246A0258|81 85|cases
P02066246A0258|16 19|list
P02068085A1273|43 49|element
P02068085A1273|65 70|region
P02068085A1273|88 105|activation sequence
P02068085A1273|76 78|Mlu
P02068085A1273|13 20|evidence
P02069738A0000|1 6|method
P02069738A0000|39 45|ethanol
P02069738A0000|22 36|stimulus control
P02069873X0000|0 8|Mechanism
P02069873X0000|11 20|activation
P02069873X0000|26 41|vav protooncogene
P02069873X0000|97 101|cells
P02069873X0000|54 58|locus
P02069873X0000|140 161|differentiation lineage
P02069873X0000|117 122|origin
P02069873X0000|43 45|vav
P02070227T0000|11 21|cell seeding
P02072238T0000|0 15|Menetrier disease
P02072238T0000|19 23|child
P02072798A0330|73 77|ulcer
P02072798A0330|61 66|chance
P02072798A0330|39 45|therapy
P02072798A0330|33 36|goal
P02072798A0330|16 28|stabilization
P02073222A0269|115 124|conditions
P02073222A0269|11 18|patients
P02073222A0269|38 49|moclobemide n
P02073222A0269|20 33|amitriptyline n
P02073222A0269|69 80|week protocol
P02075876A0408|60 68|amplitude
P02075876A0408|47 55|variation
P02075876A0408|23 25|EER
P02075876A0408|3 19|stimulus threshold
P02075876T0001|0 7|Analysis
P02075876T0001|69 75|pathway
P02075876T0001|81 83|cat
P02075876T0001|37 39|EER
P02075876T0001|28 35|response
P02075876T0001|43 50|relation
P02076620A0548|85 95|gemfibrozil
P02076620A0548|12 33|plasma fibrinogen levels
P02076620A0548|77 82|effect
P02076620A0548|46 49|mean
P02076620A0548|56 56|%
P02076620T0000|0 10|Gemfibrozil
P02076620T0000|28 35|patients
P02076620T0000|82 88|actions
P02076620T0000|58 64|disease
P02076816T0000|28 45|sporulation control
P02076816T0000|82 107|IME1 transcript accumulation
P02076816T0000|18 24|pathway
P02077560T0000|3 6|role
P02077560T0000|24 32|profiling
P02077560T0000|35 50|safety assessment
P02078080T0040|16 25|Madagascar
P02078080T0040|27 36|advantages
P02078080T0040|40 52|disadvantages
P02078080T0040|3 13|application
P02078570A0287|5 9|cases
P02078570A0287|21 30|expression
P02078570A0287|50 58|integrins
P02079811A0407|29 36|efficacy
P02079811A0407|66 74|operation
P02079811A0407|39 44|EMB AZS
P02079811A0407|100 104|level
P02079811A0407|56 60|ulcer
P02079811A0407|148 155|bleeding
P02079811A0407|107 120|acid production
P02079811A0407|80 86|stomach
P02079811A0407|3 9|authors
P02080902A0183|16 19|rats
P02080902A0183|54 70|avoidance response
P02080902A0183|83 90|controls
P02080902A0183|2 10|adulthood
P02081463A0110|16 25|regulation
P02081463A0110|63 67|Spec1
P02081463A0110|48 53|region
P02081463A0110|111 115|sites
P02081463A0110|129 139|interaction
P02081463A0110|83 96|initiation site
P02081463A0110|28 43|Spec gene activity
P02083199A1175|0 20|Phosphopeptide mapping
P02083199A1175|105 108|EGFR
P02083199A1175|36 59|autophosphorylation sites
P02083199A1175|70 76|EGFR-IC
P02083230A0938|159 164|domain
P02083230A0938|103 122|N-glycosylation sites
P02083230A0938|138 143|domain
P02083230A0938|10 17|sequence
P02083230A0938|76 97|amino acid residue domain
P02083230A0938|169 178|amino acids
P02083230A0938|34 46|signal peptide
P02083253A1512|42 65|TCR alpha enhancer activity
P02083253A1512|139 148|TCF-1 alpha
P02083253A1512|167 185|transcription factor
P02083253A1512|91 98|extracts
P02083253A1512|103 108|Jurkat
P02083253A1512|3 23|TCF-1 alpha binding site
P02083253A1512|115 123|HeLa cells
P02083546A0000|207 213|disease
P02083546A0000|54 59|uptake
P02083546A0000|282 300|motor neurone disease
P02083546A0000|106 116|99mTc-HMPAO
P02083546A0000|18 23|method
P02083546A0000|217 224|patients
P02083546A0000|139 161|photon emission tomograms
P02083546A0000|184 191|patients
P02083546A0000|229 236|dementia
P02083546A0000|258 265|patients
P02083546A0000|95 104|amine oxime
P02083546A0000|196 204|Alzheimer
P02083546A0000|246 253|lobe type
P02083546A0000|270 277|dementia
P02083546A0000|173 180|subjects
P02088781A0653|126 137|compensation
P02088781A0653|101 108|accuracy
P02088781A0653|44 46|fog
P02088781A0653|36 39|base
P02088781A0653|59 70|density units
P02088781A0653|77 85|influence
P02088781A0653|29 33|level
P02088781A0653|20 22|fog
P02088781A0653|3 9|results
P02088781A0653|114 120|absence
P02089054A0121|0 2|IdB
P02089054A0121|165 174|UV detector
P02089054A0121|53 60|extracts
P02089054A0121|103 108|column
P02089054A0121|123 132|conditions
P02089054A0121|26 46|liquid-solid partition
P02091890A0614|102 112|interaction
P02091890A0614|116 126|exploration
P02091890A0614|63 69|profile
P02091890A0614|12 22|eltoprazine
P02091890A0614|170 176|measure
P02091890A0614|180 187|sedation
P02091890A0614|158 167|inactivity
P02091890A0614|6 10|model
P02091890A0614|81 90|aggression
P02092131T0000|40 55|hypersensitivity
P02092131T0000|23 30|transfer
P02092131T0000|66 79|transfer factor
P02092131T0000|4 9|method
P02093033T0001|0 5|Effect
P02093033T0001|107 110|rats
P02093033T0001|50 68|hexachlorobutadiene
P02093033T0001|36 48|plutonium-239
P02093033T0001|94 104|thymus gland
P02093033T0001|72 88|tributyl phosphate
P02093033T0001|27 33|effects
P02093741A0211|0 13|Data collection
P02093741A0211|43 54|data analysis
P02093741A0211|112 118|MAXITAB
P02093741A0211|107 110|tool
P02093741A0211|149 165|analysis technique
P02093741A0211|26 38|query language
P02093888A0293|0 4|ARPIA
P02093888A0293|82 90|computers
P02093888A0293|41 44|DBMS
P02094221A0247|29 36|drinking
P02094221A0247|39 41|tea
P02094221A0247|46 49|ml/h
P02094221A0247|0 7|Diuresis
P02094257T0000|56 64|effusions
P02094257T0000|10 14|value
P02094257T0000|17 42|adenosine deaminase activity
P02095150T0000|33 46|hip replacement
P02095150T0000|49 58|comparison
P02095150T0000|78 95|ingrowth components
P02095150T0000|7 22|strain adaptation
P02095150T0000|98 104|canines
P02099622A1046|0 19|Immuno-cytochemistry
P02099622A1046|159 167|structure
P02099622A1046|41 59|Campylobacter jejuni
P02099622A1046|82 89|staining
P02099622A1046|109 113|cells
P02099622A1046|26 33|antisera
P02099622A1046|143 151|organisms
P02099622A1046|178 193|Campylobacter spp
P02102823A0492|0 17|Promoter activities
P02102823A0492|36 53|beta-glucuronidase
P02102823A0492|85 103|reporter gene systems
P02102823A0492|57 82|neomycin phosphotransferase
P02102831A1282|57 64|features
P02102831A1282|22 38|soybean actin genes
P02102831A1282|92 100|stretches
P02102831A1282|78 84|repeats
P02102831A1282|75 76|CT
P02102831A1282|5 11|regions
P02102831A1282|118 120|DNA
P02103140A1088|149 165|retransplantation
P02103140A1088|8 8|%
P02103140A1088|10 17|patients
P02103140A1088|38 44|failure
P02103140A1088|108 113|grafts
P02103140A1088|56 61|grafts
P02103403A0149|13 19|history
P02103403A0149|2 8|patient
P02103403A0149|53 58|intake
P02103403A0149|80 87|steroids
P02103403A0149|72 76|drugs
P02103403A0149|28 40|alcohol intake
P02105497A1092|86 93|BiP genes
P02105497A1092|48 60|HSP70 proteins
P02105497A1092|162 171|eukaryotes
P02105497A1092|26 43|amino acid sequences
P02105497A1092|67 73|species
P02105497A1092|137 146|HSP70 genes
P02105497A1092|106 113|ancestor
P02105497A1092|154 157|time
P02105497A1092|14 23|comparison
P02106287A0478|0 11|Spore inocula
P02106287A0478|52 57|0.5-in
P02106287A0478|32 37|coupon
P02107073A0584|147 151|STE18
P02107073A0584|74 90|pheromone response
P02107073A0584|139 144|levels
P02107073A0584|38 50|STE18 proteins
P02107073A0584|95 108|overexpression
P02107073A0584|8 21|overexpression
P02107073A0584|111 114|STE4
P02107073A0584|120 127|presence
P02107073A0584|31 34|STE4
P02107548A0727|59 61|RNA
P02107548A0727|37 41|clone
P02107548A0727|105 110|psi ARF
P02107548A0727|51 54|poly
P02107548A0727|96 102|homolog
P02107548A0727|7 23|transcription-PCR
P02107548A0727|65 68|cDNA
P02107548A0727|56 56|A
P02107548A0727|130 132|ARF
P02109544A0000|205 212|antibody
P02109544A0000|229 234|option
P02109544A0000|132 165|leukocyte esterase urine dipstick test
P02109544A0000|214 216|DFA
P02109544A0000|251 259|treatment
P02109544A0000|20 27|benefits
P02109544A0000|79 83|males
P02109544A0000|47 66|Chlamydia trachomatis
P02109544A0000|239 247|screening
P02109544A0000|13 16|cost
P02109544A0000|97 117|decision analysis model
P02109544A0000|30 43|screening tests
P02109544A0000|170 176|culture
P02110145T0000|0 9|Sequencing
P02110145T0000|131 158|Bacillus cereus beta-lactamase
P02110145T0000|107 116|similarity
P02110145T0000|13 16|gene
P02110145T0000|59 62|CfiA
P02110145T0000|68 78|Bacteroides
P02110145T0000|52 57|enzyme
P02110145T0000|124 127|CfiA
P02110145T0000|87 93|TAL2480
P02110148A0423|242 244|IF2
P02110148A0423|80 83|half
P02110148A0423|9 23|HindIII fragment
P02110148A0423|89 108|B. subtilis IF2 protein
P02110148A0423|200 203|ClaI
P02110148A0423|255 258|gene
P02110148A0423|175 179|clone
P02110148A0423|40 58|DNA sequence analysis
P02110148A0423|168 172|probe
P02110148A0423|135 142|sequence
P02110148A0423|215 222|fragment
P02110148A0423|115 116|kb
P02111015A0574|58 63|domain
P02111015A0574|82 99|sequence similarity
P02111015A0574|142 146|IRF-2
P02111015A0574|115 132|IFN response factors
P02111015A0574|134 138|IRF-1
P02111015A0574|16 25|amino acids
P02113015A0295|33 41|pregnancy
P02113015A0295|8 15|seizures
P02113015A0295|49 52|cent
P02113174A0064|56 77|transcription factor Sp1
P02113174A0064|10 16|protein
P02113174A0064|26 36|zinc fingers
P02113174A0957|0 6|Krox-24
P02113174A0957|51 59|activator
P02113455A0207|55 67|consideration
P02113455A0207|97 111|threshold levels
P02113455A0207|18 28|variability
P02113455A0207|34 43|parameters
P02113699A0372|27 35|subgroups
P02113699A0372|145 145|N
P02113699A0372|119 123|spots
P02113699A0372|98 105|patients
P02113699A0372|204 204|N
P02113699A0372|178 182|spots
P02113699A0372|41 41|N
P02113699A0372|96 96|N
P02113699A0372|66 70|spots
P02113699A0372|43 50|patients
P02113699A0372|155 155|N
P02113699A0372|88 89|IM
P02113699A0372|86 86|N
P02113699A0372|157 164|patients
P02113699A0372|3 10|patients
P02113901A0000|29 32|hypo
P02113901A0000|88 94|tension
P02113901A0000|96 99|PaO2
P02113901A0000|36 46|normocapnia
P02113901A0000|8 10|CO2
P02113901A0000|18 24|changes
P02113901A0000|131 140|difference
P02115111T0000|59 71|reading frames
P02115111T0000|77 89|nif gene region
P02115111T0000|11 28|nucleotide sequence
P02115111T0000|103 115|strain PCC7120
P02115111T0000|42 49|analysis
P02115111T0000|92 101|Anabaena sp
P02115111T0000|0 9|Expression
P02115115A1053|128 137|yeast genes
P02115115A1053|66 72|CAR1 URS
P02115115A1053|102 108|regions
P02115115A1053|46 50|sites
P02115115A1053|32 41|suggestion
P02115116A1137|42 50|enhancers
P02115116A1137|61 76|promoter elements
P02115116A1137|22 34|sequence match
P02115116A1137|3 9|results
P02115118A0565|56 68|sodium dodecyl
P02115118A0565|112 152|sucrose density gradient ultracentrifugation
P02115118A0565|35 44|smg p25A GDI
P02115118A0565|91 108|gel electrophoresis
P02115118A0565|4 5|Mr
P02115121A0000|0 11|Yeast mutants
P02115121A0000|180 186|complex
P02115121A0000|166 174|component
P02115121A0000|25 51|pet complementation group G104
P02115121A0000|132 160|dihydrolipoyl transsuccinylase
P02115121A0000|118 126|mutations
P02115121A0000|110 115|result
P02115121A0000|86 106|dehydrogenase activity
P02115121A0000|162 164|KE2
P02115122A0562|122 126|c-Fos
P02115122A0562|27 36|repression
P02115122A0562|80 84|c-Fos
P02115122A0562|68 77|amino acids
P02115122A0562|91 95|v-Fos
P02115122A0562|8 15|residues
P02115122A0562|109 119|truncations
P02115572A1323|41 50|psi V lambda
P02115572A1323|54 55|kb
P02115572A1323|17 33|V lambda pseudogene
P02115572A1323|69 82|U266 lambda gene
P02115889A0436|52 58|Gx alpha
P02115889A0436|29 37|structure
P02115889A0436|6 10|paper
P02115889A0436|80 88|kilobases
P02115889A0436|45 48|gene
P02116071A0000|172 174|IgE
P02116071A0000|182 185|sera
P02116071A0000|247 252|amount
P02116071A0000|302 307|amount
P02116071A0000|322 324|IgG
P02116071A0000|153 157|titer
P02116071A0000|136 142|antigen
P02116071A0000|271 274|body
P02116071A0000|14 18|study
P02116071A0000|43 55|stage children
P02116071A0000|214 220|attacks
P02116071A0000|68 74|potency
P02116071A0000|259 265|antigen
P02116071A0000|288 296|reduction
P02116071A0000|92 119|type hypersensitivity reaction
P02116071A0000|122 129|exposure
P02116071A0000|233 241|reduction
P02116537A1237|58 60|AMK
P02116537A1237|53 55|MIC
P02116537A1237|5 13|influence
P02116537A1237|32 45|concentrations
P02117799T0000a|0 3|Uses
P02117799T0000a|23 33|prophylaxis
P02117799T0000a|36 44|rejection
P02117799T0000a|66 76|nonfunction
P02117799T0000a|48 56|induction
P02117799T0000a|6 19|orthoclone OKT3
P02117799T0000a|79 99|kidney transplantation
P02117799T0000b|0 3|Uses
P02117799T0000b|23 33|prophylaxis
P02117799T0000b|36 44|rejection
P02117799T0000b|66 76|nonfunction
P02117799T0000b|48 56|induction
P02117799T0000b|6 19|orthoclone OKT3
P02117799T0000b|79 99|kidney transplantation
P02118519A0516|32 46|consensus motifs
P02118519A0516|141 160|neurofilament protein
P02118519A0516|104 128|nerve growth factor receptor
P02118519A0516|93 97|genes
P02118519A0516|79 87|positions
P02118525A0737|71 78|enhancer
P02118525A0737|23 30|fragment
P02118525A0737|36 46|CCK promoter
P02118525A0737|161 168|position
P02118525A0737|97 109|transcription
P02118525A0737|196 201|manner
P02118525A0737|2 9|addition
P02118525A0737|117 157|herpes simplex virus thymidine kinase promoter
P02118612A0629|15 29|supine restraint
P02118612A0629|123 130|exposure
P02118612A0629|39 57|DOPAC concentrations
P02118612A0629|133 137|ether
P02118612A0629|6 12|minutes
P02118612A0629|150 155|effect
P02118612A0629|69 76|eminence
P02118612A0629|85 88|rats
P02119530T0000|60 71|fibrinolysis
P02119530T0000|11 29|metoprolol treatment
P02119530T0000|48 57|activation
P02119530T0000|0 8|Influence
P02119626A0471|47 56|dimensions
P02119626A0471|38 38|%
P02119626A0471|8 12|scars
P02119946T0000|41 52|introduction
P02119946T0000|8 16|dysphagia
P02119946T0000|27 37|care setting
P02120707A0594|74 82|V elements
P02120707A0594|51 58|proteins
P02120707A0594|103 129|HLA-DRA X-box oligonucleotide
P02120707A0594|40 43|Raji
P02120707A0594|70 70|W
P02120707A0594|18 23|assays
P02120833A0000|59 66|TAH-NANB
P02120833A0000|97 100|case
P02120833A0000|45 57|hepatitis NANB
P02120833A0000|111 115|units
P02120833A0000|16 20|cases
P02120833A0000|2 8|Denmark
P02121371T0000|3 10|NF1 locus
P02121371T0000|62 77|yeast IRA proteins
P02121371T0000|19 25|protein
P02121371T0000|56 58|GAP
P02122454A1042|71 76|lambda
P02122454A1042|22 27|Phe-62
P02122454A1042|9 19|replacement
P02122454A1042|55 65|determinant
P02122454A1042|137 144|molecule
P02122454A1042|122 130|transport
P02122454A1042|83 87|chain
P02122454A1042|32 34|Ser
P02123029A0478|129 134|probes
P02123029A0478|39 48|chain genes
P02123029A0478|76 92|spleen cDNA library
P02123029A0478|180 186|isotype
P02123029A0478|107 112|Raja VH
P02123029A0478|7 13|isotype
P02123029A0478|161 167|regions
P02123029A0478|16 33|Raja immunoglobulin
P02123293A0227|0 4|Petko
P02123293A0227|9 10|S.
P02123295A0645|0 9|Disruption
P02123295A0645|12 15|ARF2
P02123295A0645|34 42|phenotype
P02123300T0000|75 86|hemophilia A.
P02123300T0000|64 72|treatment
P02123300T0000|41 46|factor
P02123300T0000|98 117|Factor VIII Study Group
P02123300T0000|48 53|factor
P02123466A0272|115 124|DNA binding
P02123466A0272|63 68|domain
P02123466A0272|22 27|family
P02123466A0272|9 15|members
P02123466A0272|32 35|AP-4
P02123466A0272|39 43|motif
P02123467A0811|89 91|Sp1
P02123467A0811|178 180|Sp1
P02123467A0811|12 21|expression
P02123467A0811|27 34|promoter
P02123467A0811|81 85|MyoD1
P02123467A0811|68 72|cells
P02123467A0811|149 156|presence
P02123467A0811|121 125|sites
P02123467A0811|184 188|MyoD1
P02123820A0000|89 96|deprenyl
P02123820A0000|36 38|MAO
P02123820A0000|128 136|nialamide
P02123820A0000|184 186|FIA
P02123820A0000|115 126|MAO inhibitor
P02123820A0000|53 62|clorgyline
P02123820A0000|196 199|rats
P02123820A0000|43 51|inhibitor
P02123820A0000|19 34|monoamine oxidase
P02123820A0000|173 182|aggression
P02123820A0000|0 6|Effects
P02123820A0000|74 87|MAO-B inhibitor
P02123875A0223|30 37|residues
P02123875A0223|96 118|signal peptidase cleavage
P02123875A0223|229 232|core
P02123875A0223|49 56|c-region
P02123875A0223|259 269|NH2 terminus
P02123875A0223|281 286|region
P02123875A0223|349 355|apoA-II
P02123875A0223|143 155|translocation
P02123875A0223|73 80|fidelity
P02123875A0223|305 309|model
P02123875A0223|340 347|delta pro
P02123875A0223|20 27|features
P02123875A0223|201 212|COOH terminus
P02123875A0223|172 193|amino acid substitutions
P02123875A0223|241 253|substitutions
P02123875A0223|84 93|efficiency
P02123875A0223|291 300|+1 position
P02123877A1452|218 230|gene induction
P02123877A1452|21 25|c-fos
P02123877A1452|96 100|fra-1
P02123877A1452|79 88|liver cells
P02123877A1452|105 109|egr-2
P02123877A1452|191 200|regulation
P02123877A1452|90 94|fos-B
P02123877A1452|61 66|levels
P02123877A1452|29 38|egr-1 mRNAs
P02123877A1452|134 140|factors
P02123877A1452|156 174|serum response factor
P02123877A1452|143 150|addition
P02124433A0235|87 93|surgery
P02124433A0235|17 21|cases
P02124433A0235|133 139|surgery
P02124433A0235|95 97|MMC
P02124433A0235|80 85|Group A
P02124433A0235|47 53|patient
P02124433A0235|104 115|chemotherapy
P02124433A0235|126 131|group B
P02124433A0235|150 155|OK-432
P02124433A0235|34 44|description
P02124433A0235|141 143|MMC
P02124433A0235|162 179|immunochemotherapy
P02124433A0235|99 102|5-FU
P02124433A0235|187 192|group C
P02124433A0235|158 160|PSK
P02124433A0235|56 65|background
P02124433A0235|5 12|patients
P02124433A0235|194 200|surgery
P02124433A0235|145 148|5-FU
P02124433A0235|120 124|cases
P02124710A0193|99 128|osteoblast phenotype development
P02124710A0193|38 56|c-jun protooncogenes
P02124710A0193|10 17|proteins
P02124710A0193|78 96|proliferation period
P02124710A0193|30 34|c-fos
P02124710A1624|82 97|collagen promoter
P02124710A1624|59 66|AP-1 site
P02124710A1624|29 35|binding
P02124710A1624|4 8|model
P02124710A1624|72 80|type alpha
P02124710A1624|41 54|Fos-Jun complex
P02124710A1624|140 143|VDRE
P02125016A0145|0 3|PBSX
P02125016A0145|35 45|SOS response
P02125016A0145|15 20|agents
P02125153A0410|96 105|Z5 patients
P02125153A0410|69 70|R3
P02125153A0410|90 90|%
P02125153A0410|75 75|%
P02125153A0410|63 63|%
P02125153A0410|110 118|organisms
P02125153A0410|52 56|years
P02125153A0410|130 141|streptomycin
P02125153A0410|32 40|treatment
P02125153A0410|80 81|R5
P02125153A0410|145 153|isoniazid
P02125153A0410|16 22|relapse
P02126417A0408|117 125|advantage
P02126417A0408|5 12|controls
P02126417A0408|106 115|hemisphere
P02126417A0408|93 95|VHF
P02126417A0408|66 80|control subjects
P02126504A0602|48 56|mechanism
P02126504A0602|78 86|Rh-system
P02126504A0602|10 22|Rh-antibodies
P02129338A0568|41 48|homology
P02129338A0568|52 52|%
P02129338A0568|10 26|amino acid sequence
P02129338A0568|64 97|alga Scenedemus obliquus plastocyanin
P02131652A0883|143 151|ng.l-1 min
P02131652A0883|13 37|serum gastrin concentration
P02131652A0883|108 115|AUC0-120
P02131652A0883|93 106|gastrin release
P02131652A0883|63 68|ng.l-1
P02131652A0883|185 191|VTP-Cas
P02131652A0883|170 175|VTP-HM
P02131666A0483|15 19|group
P02131666A0483|62 70|anomalies
P02131666A0483|33 50|examinees class II/2
P02131902A0000|130 138|ventricle
P02131902A0000|117 120|view
P02131902A0000|33 40|location
P02131902A0000|81 90|transducer
P02131902A0000|77 79|TEE
P02131902A0000|140 143|S-LV
P02131902A0000|4 8|study
P02132636A0188|0 7|Subjects
P02132636A0188|25 38|schizophrenics
P02132636A0188|52 65|DST suppressors
P02132636A0188|70 83|nonsuppressors
P02133731A1572|16 16|%
P02133731A1572|20 21|S5
P02133731A1572|47 49|1/T
P02133731A1572|7 9|CBF
P02133731A1572|90 102|control levels
P02133731A1572|23 25|CBF
P02133731A1572|4 5|S3
P02133731A1572|107 107|p
P02133731A1572|34 37|%WTh
P02133731A1572|31 31|%
P02133731A1572|39 43|1/TPC
P02135343A0131|81 92|maloclusions
P02135343A0131|169 188|ANGLE3 classification
P02135343A0131|151 155|archs
P02135343A0131|6 12|article
P02135343A0131|123 134|relationship
P02135343A0131|34 43|percentage
P02135343A0131|67 78|distribution
P02135343A0131|52 60|occlusion
P02135536A0621|117 118|Hk
P02135536A0621|21 33|brush abrasion
P02135536A0621|196 204|degrees C.
P02135536A0621|104 111|hardness
P02135536A0621|139 152|micrograms/mm3
P02135536A0621|88 90|MPa
P02135536A0621|67 74|strength
P02135536A0621|120 134|water absorption
P02135536A0621|6 9|case
P02135536A0621|163 182|expansion coefficient
P02135536A0621|14 18|ratio
P02137704A0000|171 171|h
P02137704A0000|420 427|diameter
P02137704A0000|156 168|blood pressure
P02137704A0000|129 129|h
P02137704A0000|205 217|blood pressure
P02137704A0000|384 391|diameter
P02137704A0000|438 450|wall thickness
P02137704A0000|328 334|indices
P02137704A0000|269 279|office visit
P02137704A0000|511 514|mass
P02137704A0000|101 125|blood pressure measurements
P02137704A0000|460 472|wall thickness
P02137704A0000|40 47|patients
P02137704A0000|577 589|diameter ratio
P02137704A0000|518 526|mass index
P02137704A0000|15 19|group
P02137704A0000|191 197|morning
P02137704A0000|539 556|wall thickness/left
P02137704A0000|287 299|blood pressure
P02137704A0000|227 237|office visit
P02137704A0000|76 86|association
P02137704A0000|66 73|strength
P02137704A0000|482 494|wall thickness
P02137704A0000|245 257|blood pressure
P02137704A0000|408 410|end
P02137704A0000|356 372|target organ damage
P02138707A0198|200 219|transcription element
P02138707A0198|39 65|lambda gt11 expression library
P02138707A0198|150 188|histocompatibility complex A alpha gene X box
P02138707A0198|138 142|class
P02138707A0198|245 249|genes
P02138707A0198|238 242|class
P02138707A0198|124 126|end
P02138707A0198|98 105|sequence
P02138707A0198|73 83|protein mXBP
P02138915A1060|124 128|WORDS
P02138915A1060|44 51|sequence
P02138915A1060|21 22|kb
P02138915A1060|96 99|gene
P02138915A1060|3 9|p36 gene
P02138915A1060|102 109|ABSTRACT
P02138915A1060|90 90|%
P02138915A1060|68 69|kb
P02138915A1060|25 30|length
P02138992A0911|105 108|work
P02138992A0911|55 60|tumors
P02138992A0911|80 91|modification
P02138992A0911|17 25|treatment
P02138992A0911|122 129|approach
P02139473A1603|161 182|Shine-Dalgarno sequence
P02139473A1603|123 128|region
P02139473A1603|54 57|site
P02139473A1603|84 100|Fur concentrations
P02139473A1603|60 63|entC
P02139891A0532|130 138|EIIF sites
P02139891A0532|68 70|EIV
P02139891A0532|175 186|ATF/CREB site
P02139891A0532|52 64|activators EIA
P02139891A0532|96 104|TAGA motif
P02139891A0532|158 168|orientation
P02139891A0532|8 15|promoter
P02139891A0532|119 125|TATA box
P02139891A0532|86 93|elements
P02141425A0175|87 98|measurements
P02141425A0175|139 143|floor
P02141425A0175|62 66|stool
P02141425A0175|111 118|patients
P02141425A0175|39 44|method
P02141425A0175|34 37|MFTF
P02141425A0175|46 53|patients
P02141425A0175|160 164|level
P02141425A0175|15 32|fingertip-to-floor
P02141425A0175|170 174|floor
P02142240A0506|98 105|presence
P02142240A0506|37 49|response rates
P02142240A0506|13 23|differences
P02142240A0506|79 95|estrogen receptors
P02142240A0506|64 76|concentration
P02142240A0506|141 148|patients
P02142240A0506|108 127|progesteron receptors
P02142240A0506|134 138|group
P02142486A0367|0 10|Teicoplanin
P02142486A0367|108 112|cases
P02142486A0367|92 100|one-third
P02142486A0367|47 51|fever
P02142486A0367|74 84|bacteraemia
P02142921T0000|75 81|results
P02142921T0000|65 72|analysis
P02142921T0000|130 138|goserelin
P02142921T0000|11 47|hormone-releasing hormone analog therapy
P02142921T0000|94 102|buserelin
P02142921T0000|175 179|depot
P02142921T0000|57 63|fibroid
P02142955A0248|144 149|delays
P02142955A0248|75 79|basis
P02142955A0248|90 99|appearance
P02142955A0248|63 69|objects
P02142955A0248|31 36|adults
P02142955A0248|157 160|days
P02142955A0248|19 25|infants
P02142955A0248|2 12|Experiments
P02142955A0248|129 137|exemplars
P02142993A0176|132 139|patterns
P02142993A0176|11 17|picture
P02142993A0176|148 157|L. infantum
P02142993A0176|81 93|leishmaniasis
P02142993A0176|23 29|disease
P02142993A0176|196 201|France
P02142993A0176|176 182|pattern
P02142993A0176|102 110|L. tropica
P02143023A0729|82 94|transcription
P02143023A0729|38 53|adenovirus genome
P02143023A0729|137 151|repeat sequences
P02143023A0729|104 118|octamer elements
P02143023A0729|18 32|octamer elements
P02143186A0867|85 90|region
P02143186A0867|101 106|intron
P02143186A0867|21 27|introns
P02143186A0867|59 64|intron
P02143186A0867|38 41|AHA3
P02143186A0867|43 46|AHA2
P02143186A0867|122 133|coding region
P02143186A0867|2 11|comparison
P02143186A1306|0 19|Northern blot analysis
P02143186A1306|107 116|root tissue
P02143186A1306|64 66|RNA
P02143186A1306|99 104|levels
P02143186A1306|33 40|AHA2 mRNA
P02143186A1306|131 141|shoot tissue
P02143768T0000|0 8|Impaction
P02143768T0000|11 25|gastrostomy tube
P02143768T0000|40 43|wall
P02143961A0400|30 42|pain threshold
P02143961A0400|93 101|analgesia
P02143961A0400|4 18|antidepressants
P02143961A0400|72 75|pCPA
P02143961A0400|56 67|pretreatment
P02144290A1444|0 2|Sci
P02144558A1022|1 15|needs assessment
P02144558A1022|23 30|families
P02144610A1306|0 7|TCR alpha
P02144610A1306|145 152|proteins
P02144610A1306|119 129|AMP response
P02144610A1306|220 233|decamer element
P02144610A1306|70 77|proteins
P02144610A1306|93 99|element
P02144610A1306|181 187|element
P02144610A1306|174 179|T alpha
P02144610A1306|198 213|TCR alpha enhancer
P02144610A1306|271 286|TCR beta promoters
P02144610A1306|87 91|T beta
P02144610A1306|11 28|beta gene expression
P02144610A1306|108 110|set
P02144610A1306|57 62|T-cell
P02144610A1306|52 54|set
P02144610A1306|249 254|number
P02145195A0253|99 108|Sm proteins
P02145195A0253|47 53|species
P02145195A0253|5 13|stem-loop
P02145195A0253|33 41|structure
P02145195A0253|85 95|binding site
P02145268A0746|143 152|COL3A1 gene
P02145268A0746|10 27|nucleotide sequence
P02145268A0746|70 81|organization
P02145268A0746|58 64|analogy
P02145268A0746|92 104|collagen genes
P02145268A0746|42 50|sequences
P02145268A0746|132 135|exon
P02145268A0746|87 90|type
P02145268A1454|5 10|losses
P02145268A1454|52 66|cyanogen bromide
P02145268A1454|36 49|EDS-IV collagen
P02145268A1454|24 33|resistance
P02145268A1454|79 98|collagenase digestion
P02146266A0000|162 187|deoxyoligonucleotide probes
P02146266A0000|140 146|library
P02146266A0000|13 33|BamHI-HindIII fragment
P02146266A0000|111 115|sod-1
P02146266A0000|51 93|Neurospora crassa CuZn superoxide dismutase gene
P02146266A0000|215 239|N. crassa amino acid sequence
P02146495A0706|116 121|dimers
P02146495A0706|139 141|CRE
P02146495A0706|56 61|region
P02146495A0706|8 15|peptides
P02146495A0706|85 103|leucine zipper domain
P02147223A1047|27 39|c-fos promoter
P02147223A1047|2 9|contrast
P02147223A1047|77 79|E1a
P02147223A1047|86 89|HeLa
P02147223A1047|93 101|PC12 cells
P02147223A1047|70 73|cAMP
P02147223A1047|14 16|CRE
P02147422A0000|29 32|gene
P02147422A0000|49 66|U1-70K snRNP protein
P02148219A0508|130 136|muscles
P02148219A0508|78 85|rigidity
P02148219A0508|62 66|facts
P02148219A0508|19 28|hypothesis
P02148219A0508|106 111|flexor
P02148219A0508|95 102|extensor
P02148291A0173|76 92|HSE binding domains
P02148291A0173|25 43|HSE oligonucleotides
P02148291A0173|155 163|screening
P02148291A0173|110 142|tomato lambda gt11 expression library
P02148291A0173|50 54|types
P02148291A0173|57 62|clones
P02148508A0374|0 4|Fluid
P02148508A0374|6 9|AVLF
P02148508A1478|44 46|TCM
P02148508A1478|98 105|patterns
P02148508A1478|3 9|results
P02148508A1478|56 63|patients
P02148508A1478|33 41|principle
P02148799A0000|188 194|circuit
P02148799A0000|140 149|expression
P02148799A0000|124 128|genes
P02148799A0000|178 182|genes
P02148799A0000|38 41|gene
P02148799A0000|3 9|nmr gene
P02148799A0000|47 68|nitrogen control circuit
P02148799A0000|71 86|Neurospora crassa
P02149487A0348|4 35|days dexamethasone suppression test
P02149487A0348|52 63|% suppression
P02149487A0348|143 163|androstenedione levels
P02149487A0348|117 125|reduction
P02149487A0348|66 96|dehydroepiandrosterone-sulphate
P02149487A0348|128 139|testosterone
P02149487A0348|115 115|%
P02149566A0478|3 7|ratio
P02149566A0478|51 65|phosphocreatine
P02149566A0478|102 111|LVH baboons
P02149566A0478|67 69|PCr
P02149566A0478|10 18|P-31 NMR-S
P02149566A0478|151 151|P
P02149566A0478|96 99|rest
P02149566A0478|35 44|phosphates
P02149566A0478|46 47|Pi
P02149570T0000|31 48|protein S deficiency
P02149570T0000|9 16|necrosis
P02150473T0067|8 12|study
P02151229A0000|0 7|Regional
P02151229A0000|190 192|age
P02151229A0000|233 238|mmol/L
P02151229A0000|160 175|diabetes mellitus
P02151229A0000|106 115|tomography
P02151229A0000|16 24|blood flow
P02151229A0000|41 72|N-isopropyl-123I-iodoamphetamine
P02151229A0000|197 201|years
P02151229A0000|257 264|subjects
P02151229A0000|128 135|patients
P02151229A0000|177 181|NIDDM
P02151229A0000|117 118|CT
P02151229A0000|279 284|mmol/L
P02151229A0000|90 97|emission
P02151229A0000|270 274|years
P02151229A0000|210 229|fasting plasma glucose
P02151229A0921|0 15|Mean ROI-A/B ratio
P02151229A0921|107 107|p
P02151229A0921|101 105|group
P02151229A0921|84 84|%
P02151229A0921|43 47|group
P02151229A0921|29 29|%
P02153243A0965|120 125|factor
P02153243A0965|47 55|int-2 gene
P02153243A0965|35 41|product
P02153243A0965|76 103|fibroblast growth factor family
P02153243A0965|149 154|tumors
P02153243A0965|5 8|data
P02153683A1579|100 105|ATPase
P02153683A1579|65 70|fodrin
P02153683A1579|93 94|Na
P02153683A1579|81 90|uvomorulin
P02153683A1579|55 61|ankyrin
P02153683A1579|31 39|complexes
P02153683A1579|97 97|K
P02153683A1579|4 9|result
P02153977A0364|71 75|mRNAs
P02153977A0364|89 92|peak
P02153977A0364|54 64|development
P02153977A0364|5 9|genes
P02153977A0364|42 51|initiation
P02153977A0364|114 124|culmination
P02153977A0364|32 36|hours
P02153977A0364|97 98|hr
P02154467A0709|27 36|similarity
P02154467A0709|64 71|sequence
P02154467A0709|82 97|furin gene product
P02154467A0709|138 145|molecule
P02154467A0709|3 12|PC2 protein
P02154474A1504|20 28|sequences
P02154474A1504|39 56|cAMP responsiveness
P02154474A1504|77 84|P-450scc
P02154474A1504|109 118|P-450 genes
P02154599A0382|18 29|footprinting
P02154599A0382|142 147|motifs
P02154599A0382|154 156|DSL
P02154599A0382|95 111|Zta fusion proteins
P02154599A0382|33 60|gel mobility retardation assays
P02154599A0382|6 10|study
P02154599T0000|30 38|induction
P02154599T0000|93 103|lymphocytes
P02154599T0000|46 64|cycle gene expression
P02154599T0000|122 129|ZRE sites
P02154599T0000|115 118|AP-1
P02154599T0000|149 163|enhancer regions
P02154599T0000|3 19|zta transactivator
P02154599T0000|132 145|target promoter
P02154602A0092|12 18|homolog
P02154602A0092|24 37|mouse Mx protein
P02154602A0092|48 57|resistance
P02154602A0092|60 73|influenza virus
P02154686A0185|0 8|Fragments
P02154686A0185|50 57|enhancer
P02154686A0185|97 123|beta-galactosidase synthesis
P02154686A0185|149 174|polyomavirus enhancer region
P02154686A0185|66 70|virus
P02154686A0185|133 141|fragments
P02154686A0185|34 45|repeat region
P02154686A0185|193 198|levels
P02154885A0153|116 135|substrate recognition
P02154885A0153|31 38|residues
P02154885A0153|19 29|mutagenesis
P02154885A0153|3 7|sites
P02154885A0153|83 95|loop structure
P02154885A0153|141 146|enzyme
P02155017A1106|191 203|complications
P02155017A1106|39 47|frequency
P02155017A1106|11 18|benefits
P02155017A1106|143 159|observation period
P02155017A1106|50 57|bleeding
P02155017A1106|21 30|LMW heparin
P02155017A1106|169 177|incidence
P02155017A1106|59 69|alleviation
P02155017A1106|213 220|dialyses
P02155017A1106|72 91|hypertriglyceridemia
P02156828A0164|41 48|residues
P02156828A0164|91 97|cofilin
P02156828A0164|10 26|amino acid sequence
P02156828A0164|72 72|%
P02156828A0164|146 152|protein
P02156828A0164|29 35|destrin
P02157067A0610|0 6|Summers
P02157067A0610|8 15|Virology
P02157141A0923|86 94|sequences
P02157141A0923|150 156|changes
P02157141A0923|188 196|base pairs
P02157141A0923|69 71|DNA
P02157141A0923|29 36|presence
P02157141A0923|16 23|T antigen
P02157141A0923|39 51|topoisomerase
P02157141A0923|133 135|DNA
P02157764A1115|42 48|peptide
P02157764A1115|76 82|portion
P02157764A1115|104 115|cDNA sequence
P02157764A1115|1 15|rabbit antiserum
P02157882T0000|73 86|transformation
P02157882T0000|46 48|abl
P02157882T0000|63 70|proteins
P02157882T0000|14 21|function
P02157882T0000|98 102|cells
P02157882T0000|0 11|Conservation
P02158099A0487|59 64|pM1 DNA
P02158099A0487|125 146|pSV2CAT reporter plasmid
P02158099A0487|11 30|cotransfection assays
P02158099A0487|52 54|CCL
P02158099A0487|110 119|expression
P02158099A0487|36 50|Chang liver cells
P02158099A0487|99 104|effect
P02158927A0000|142 152|chromosome X
P02158927A0000|52 61|COR segment
P02158927A0000|101 104|UTR1
P02158927A0000|158 162|yeast
P02158927A0000|96 99|CYC1
P02158927A0000|19 28|nucleotide
P02158927A0000|78 84|cluster
P02158927A0000|106 109|UTR3
P02158927A0000|121 123|Gly
P02158927A0000|90 94|genes
P02158927A0000|111 114|OSM1
P02158927A0000|128 131|RAD7
P02158927A0000|116 119|tRNA
P02158927A0000|33 40|sequence
P02158927A0000|30 31|nt
P02159470A1432|127 139|transcription
P02159470A1432|162 169|subunits
P02159470A1432|39 43|sites
P02159470A1432|112 121|regulation
P02159470A1432|20 33|protein factors
P02159470A1432|8 14|binding
P02159470A1432|206 220|phosphorylation
P02159470A1432|149 153|genes
P02159470A1432|63 73|Mt sequences
P02159470A1432|93 96|role
P02159559A0779|48 63|DNA amplification
P02159559A0779|21 32|interference
P02160502A0471|58 75|recombination point
P02160502A0471|2 29|recombination signal sequences
P02160622A0000|162 172|combination
P02160622A0000|78 89|motor effects
P02160622A0000|177 184|morphine
P02160622A0000|57 70|hot-plate tests
P02160622A0000|199 202|rats
P02160622A0000|120 149|benzodiazepine agonist midazolam
P02160622A0000|18 27|properties
P02160622A0000|44 53|tail-flick
P02160955A0899|0 9|Constructs
P02160955A0899|99 100|bp
P02160955A0899|46 51|region
P02160955A0899|74 82|distances
P02160955A0899|27 32|AATAAA
P02162049A0291|13 17|issue
P02162049A0291|29 35|factor Y
P02162049A0291|22 25|gene
P02162049A0291|66 76|DNA sequence
P02162103A0000|173 173|A
P02162103A0000|103 107|PIV-2
P02162103A0000|23 27|cDNAs
P02162103A0000|153 158|length
P02162103A0000|225 232|proteins
P02162103A0000|130 132|RNA
P02162103A0000|244 253|amino acids
P02162103A0000|70 70|P
P02162103A0000|48 51|mRNA
P02162103A0000|79 95|parainfluenza type
P02162103A0000|204 216|reading frames
P02162103A0000|110 118|cDNA clone
P02162103A0000|42 44|RNA
P02162103A0000|97 101|virus
P02162103A0000|168 171|poly
P02162103A0000|55 68|phosphoprotein
P02162103A0000|140 150|nucleotides
P02162467A0311|10 23|cytR expression
P02162467A0311|88 102|cAMP/CAP complex
P02162467A0311|51 61|CytR protein
P02162754A0339|15 19|sites
P02162754A0339|31 47|amino acid sequence
P02162754A0339|88 92|mouse
P02162754A0339|53 82|3T3-L1 adipocyte insulin receptor
P02162754A0801|0 2|PAO
P02162754A0801|39 42|pp15
P02162754A0801|95 112|signal transmission
P02162754A0801|22 36|phosphoryl group
P02162754A0801|9 16|turnover
P02162754A0801|133 155|glucose-transport system
P02162754A0801|54 65|accumulation
P02162754A0801|120 127|receptor
P02162835A0989|126 132|enzymes
P02162835A0989|102 118|copper binding site
P02162835A0989|17 36|sequence similarities
P02162835A0989|80 95|heme binding sites
P02162835A0989|60 71|architecture
P02163347A0472|84 84|%
P02163347A0472|30 41|reading frame
P02163347A0472|61 77|amino acid sequence
P02163347A0472|138 149|ets-1 protein
P02163347A0472|118 127|amino acids
P02163347A0472|43 45|ORF
P02163347A0472|3 14|cDNA sequence
P02163382A0169|44 57|cosmids pJHCV31
P02163382A0169|144 152|lac operon
P02163382A0169|195 201|fusions
P02163382A0169|85 105|transposon mutagenesis
P02163382A0169|17 28|O7-LPS region
P02163382A0169|110 117|Tn3HoHo1
P02163382A0169|176 179|lacZ
P02163382A0169|61 67|pJHCV32
P02163382A0169|206 223|target DNA sequences
P02163394T0000|3 10|sacT gene
P02163394T0000|37 58|Bacillus subtilis shares
P02163394T0000|24 34|sacPA operon
P02163394T0000|92 106|antiterminators
P02163394T0000|65 72|homology
P02164585A0416|3 13|TraD protein
P02164585A0416|21 22|Da
P02164585A0416|48 54|regions
P02164585A0416|97 102|region
P02164585A0814|56 59|traX
P02164585A0814|111 117|alanine
P02164585A0814|43 49|tra gene
P02164585A0814|19 22|orfD
P02164585A0814|121 127|leucine
P02164585A0814|84 93|amino acids
P02164585A0814|3 16|protein product
P02164585A0814|72 72|%
P02164588A0266|160 173|HN glycoprotein
P02164588A0266|13 19|HN genes
P02164588A0266|122 129|assembly
P02164588A0266|47 50|role
P02164588A0266|115 118|tail
P02164588A0266|85 90|domain
P02164588A0266|53 60|residues
P02164588A0266|146 154|transport
P02164604A0399|87 95|promoters
P02164604A0399|43 63|E2 transactivation gene
P02164604A0399|21 28|findings
P02164604A0399|3 9|studies
P02164604A1574|147 158|E2 expression
P02164604A1574|12 19|analysis
P02164604A1574|77 88|BPV-1 mutants
P02164604A1574|51 59|cell lines
P02164604A1574|106 119|acceptor mutant
P02164604A1574|25 34|E2 proteins
P02164604A1574|140 144|modes
P02164637A0515|0 9|Disruption
P02164637A0515|150 160|cdc25 mutant
P02164637A0515|136 144|lethality
P02164637A0515|120 130|suppression
P02164637A0515|45 55|sensitivity
P02164637A0515|93 110|sporulation defects
P02164637A0515|58 66|heat shock
P02164637A0515|15 22|IRA2 gene
P02164637A0515|70 87|nitrogen starvation
P02165181A0299|4 9|cohort
P02165181A0299|36 40|basis
P02165181A0299|12 19|patients
P02165181A0299|51 55|stage
P02165589A0000|100 105|member
P02165589A0000|126 151|hormone receptor superfamily
P02165589A0000|52 56|2C1-3
P02165589A0000|68 74|portion
P02165589A0000|80 91|X-chromosome
P02165589A0000|1 4|gene
P02165589A0888|115 136|heterodimerization site
P02165589A0888|153 167|fos oncoproteins
P02165589A0888|10 17|Region II
P02165589A0888|31 34|part
P02165589A0888|63 75|leucine zipper
P02165589A0888|45 60|c-jun oncoprotein
P02165589A0888|84 87|turn
P02165589A0888|147 149|jun
P02165589A0888|1 7|portion
P02166040A0385|356 363|leukemia
P02166040A0385|221 238|phosphotransferase
P02166040A0385|100 108|deletions
P02166040A0385|18 25|vanadate
P02166040A0385|375 384|retrovirus
P02166040A0385|422 434|neo expression
P02166040A0385|318 324|methods
P02166040A0385|129 149|carboxykinase promoter
P02166040A0385|78 82|genes
P02166040A0385|38 59|PEPCK gene transcription
P02166040A0385|246 277|chloramphenicol acetyltransferase
P02166040A0385|329 337|infection
P02166040A0385|343 349|Moloney
P02166040A0385|462 494|chloroamphenicol acetyltransferase
P02166040A0385|191 195|genes
P02166040A0385|240 242|neo
P02166040A0385|410 418|selection
P02166040A0385|62 67|series
P02166040A0385|295 307|hepatoma cells
P02166040A0385|389 400|transfection
P02166040A0385|450 459|expression
P02166416A0419|3 11|diagnosis
P02166416A0419|21 32|tuberculosis
P02166416A0419|67 70|ARDS
P02166416A0419|80 85|origin
P02166825A0198|113 129|promoter mutations
P02166825A0198|34 41|elements
P02166825A0198|47 54|promoter
P02166825A0198|176 184|mutations
P02166825A0198|96 102|signals
P02166825A0198|105 110|number
P02166825A0198|65 67|way
P02166825A0198|156 158|set
P02166825A0198|2 6|order
P02166825A0198|200 213|promoter region
P02167321T0000|189 200|phorbol ester
P02167321T0000|85 88|site
P02167321T0000|36 42|element
P02167321T0000|1 8|DNA motif
P02167321T0000|177 186|activation
P02167321T0000|60 77|activator protein-2
P02167321T0000|158 167|expression
P02167321T0000|99 141|tissue-type plasminogen activator gene promoter
P02167321T0000|204 207|cAMP
P02167467T0000|3 16|26S rRNA binding
P02167467T0000|54 63|protein L11
P02167467T0000|26 42|protein equivalent
P02167467T0000|94 98|genes
P02167784A0109|57 57|%
P02167784A0109|50 50|%
P02167784A0109|31 33|air
P02167784A0109|86 88|min
P02167784A0109|39 41|min
P02167784A0109|65 67|min
P02167784A0109|127 140|CO2 measurement
P02167784A0109|15 22|subjects
P02168640A0268|131 136|ground
P02168640A0268|42 48|changes
P02168640A0268|51 54|SSEP
P02168640A0268|75 82|presence
P02168640A0268|11 22|correlations
P02168640A0268|57 64|response
P02168640A0268|108 119|disturbances
P02168640A0268|151 159|disorders
P02169887A0360|57 68|capstructure
P02169887A0360|125 134|initiation
P02169887A0360|3 13|transcripts
P02169887A0360|103 107|mRNAs
P02169887A0360|85 92|EMCV-RNA
P02170687A0000|85 101|transforming genes
P02170687A0000|65 74|expression
P02170687A0000|33 48|papillomaviruses
P02170687A0000|3 15|E6/E7 promoter
P02172672T0001|1 4|case
P02172672T0001|7 17|Goodpasture
P02172672T0001|20 27|syndrome
P02173399A0333|120 120|%
P02173399A0333|105 115|specificity
P02173399A0333|45 50|blocks
P02173399A0333|63 79|tissue radiographs
P02173399A0333|23 30|controls
P02173399A0333|122 132|sensitivity
P02173399A0333|81 84|STRs
P02173399A0333|136 136|%
P02173405A0270|49 54|period
P02173405A0270|13 23|abnormality
P02173405A0270|76 89|calcifications
P02174105A1232|75 79|cells
P02174105A1232|36 44|rat organs
P02174105A1232|55 62|staining
P02174105A1232|19 26|analysis
P02174427A1574|53 65|carbon sources
P02174427A1574|103 145|ubiquinol-cytochrome c oxidoreductase activity
P02174427A1574|91 91|%
P02174427A1574|4 10|strains
P02174861A0736|0 9|Regulation
P02174861A0736|102 109|sequence
P02174861A0736|89 92|dyad
P02174861A0736|12 15|irgA
P02174861A0736|24 33|V. cholerae
P02174861A0736|18 21|iron
P02174861A0736|164 168|sites
P02174861A0736|60 64|level
P02174861A0736|154 156|Fur
P02174861A0736|115 122|vicinity
P02174861A0736|128 135|promoter
P02174974A0000|0 12|Transcription
P02174974A0000|23 28|operon
P02174974A0000|68 77|TOL plasmid
P02174974A0000|113 127|xylR gene product
P02174974A0000|56 62|enzymes
P02174974A0000|133 140|presence
P02174974A0000|143 150|m-xylene
P02175433A0575|95 100|copies
P02175433A0575|57 60|gene
P02175433A0575|64 81|Ylp vector sequences
P02175433A0575|31 46|beta A-globin gene
P02175908A0805|115 121|element
P02175908A0805|73 77|locus
P02175908A0805|48 61|Ulysses element
P02175908A0805|144 151|mutation
P02175908A0805|9 17|mutations
P02175908A0805|39 42|copy
P02176021T0000|44 76|electron spin resonance spectroscopy
P02176021T0000|0 12|Determination
P02176021T0000|33 41|materials
P02176021T0000|15 20|diquat
P02176152A0896|43 50|activity
P02176152A0896|77 79|TPA
P02176152A0896|90 103|AP1 binding site
P02176152A0896|14 15|RA
P02176152A0896|54 65|reporter gene
P02176152A0896|114 126|HSV tk promoter
P02176209A0954|43 46|rise
P02176209A0954|113 121|cell types
P02176209A0954|82 89|extracts
P02176209A0954|32 38|CBF DNAs
P02176209A0954|25 28|NF-Y
P02176209A0954|95 101|variety
P02176209A0954|21 23|EFI
P02176209A0954|58 79|gel retardation patterns
P02176232T0001|58 62|stage
P02176232T0001|22 41|lymph nodes metastasis
P02176232T0001|0 10|Risk factors
P02176232T0001|69 72|IIIA
P02176232T0001|44 53|lung cancer
P02176822A0000|29 32|MFPK
P02176822A0000|159 174|glycogen synthase
P02176822A0000|95 103|threonine
P02176822A0000|107 112|serine
P02176822A0000|127 135|inhibitor
P02176822A0000|177 181|sites
P02176822A0000|79 83|sites
P02176822A0000|66 73|peptide B
P02176822A0000|90 91|BS
P02176822A0000|15 27|protein kinase
P02176822A0000|59 63|lyase
P02176822A0000|148 154|residue
P02176822A0000|85 86|BT
P02179052A1044|16 16|Y
P02179052A1044|26 41|sequence families
P02179052A1044|63 68|system
P02179052A1044|117 125|evolution
P02179052A1044|84 103|sequence interactions
P02179188A1223|59 66|presence
P02179188A1223|69 81|dinitrophenol
P02179188A1223|22 36|motile responses
P02179188A1223|84 97|cytochalasin B.
P02179815A0582|170 177|sequence
P02179815A0582|79 86|p68c-rel
P02179815A0582|151 155|cells
P02179815A0582|107 109|CEF
P02179815A0582|39 41|CEF
P02179815A0582|51 68|immunofluorescence
P02179815A0582|6 13|p59v-rel
P02179815A0582|226 233|sequence
P02179815A0582|180 187|p68c-rel
P02179815A0582|30 36|protein
P02179815A0582|273 280|p59v-rel
P02179815A0582|135 143|cytoplasm
P02180935A0535|87 96|HL-60 cells
P02180935A0535|103 104|Mr
P02180935A0535|38 40|min
P02180935A0535|7 17|experiments
P02180935A0535|125 166|chondroitin sulfate proteoglycan intermediate
P02180935A0535|57 72|precursor protein
P02181760A0311|0 8|Blood flow
P02181760A0311|107 115|direction
P02181760A0311|155 158|fold
P02181760A0311|12 19|velocity
P02181760A0311|76 83|diastole
P02181760A0311|34 50|Doppler ultrasound
P02181760A0311|118 136|cotyledon resistance
P02182240A0355|71 76|period
P02182240A0355|11 18|patients
P02182240A0355|109 116|symptoms
P02182240A0355|87 89|min
P02182240A0355|53 59|heparin
P02182240A0355|27 38|anistreplase
P02182240A0355|102 106|onset
P02182240A0355|1 5|total
P02182323A0121|89 104|growth conditions
P02182323A0121|41 43|Val
P02182323A0121|36 39|tRNA
P02182323A0121|50 53|gene
P02182323A0121|108 115|degrees C
P02182323A0121|149 154|region
P02182323A0121|46 48|UAC
P02182323A0121|15 25|transcripts
P02182618A0168|119 133|deletion mutants
P02182618A0168|150 155|region
P02182618A0168|55 86|chloramphenicol acetyltransferase
P02182618A0168|92 95|gene
P02182618A0168|88 90|CAT
P02182618A0168|3 18|promoter activity
P02182618A0168|42 51|expression
P02183467A0668|83 92|similarity
P02183467A0668|203 203|Y
P02183467A0668|128 130|vif
P02183467A0668|39 41|BIV
P02183467A0668|188 191|ORFs
P02183467A0668|132 134|tat
P02183467A0668|122 126|genes
P02183467A0668|150 161|lentiviruses
P02183467A0668|220 224|exons
P02183467A0668|233 237|genes
P02183467A0668|139 141|rev
P02183467A0668|15 18|ORFs
P02183467A0668|31 36|region
P02183467A0668|62 69|location
P02183467A0668|199 199|W
P02185140A0000|43 66|cytochrome P450 lanosterol
P02185140A0000|130 136|strains
P02185140A0000|26 33|14DM gene
P02185140A0000|145 151|control
P02185140A0000|233 239|control
P02185140A0000|211 214|pGPD
P02185140A0000|216 220|pPHO5
P02185140A0000|69 85|alpha-demethylase
P02185140A0000|248 255|promoter
P02185140A0000|205 209|pADC1
P02185140A0000|177 203|yeast transcription promoters
P02185140A0000|87 90|14DM
P02185250A0726|28 37|amino acids
P02185250A0726|74 90|reticulum membrane
P02185250A0726|95 107|translocation
P02185250A0726|0 10|Truncations
P02187091A0721|17 26|resistance
P02187091A0721|144 144|P
P02187091A0721|41 56|ejection fraction
P02187091A0721|87 102|relaxation period
P02187871T0000|47 84|protein synthesis initiation factor eIF-4D
P02187871T0000|3 11|ANB1 locus
P02188096A0955|30 43|splicing events
P02188096A0955|46 60|c-myb expression
P02188096A0955|70 82|c-myb function
P02188096A0955|3 14|contribution
P02188168A0000|0 8|Serum beta
P02188168A0000|131 138|carriers
P02188168A0000|192 196|serum
P02188168A0000|164 178|lymphadenopathy
P02188168A0000|24 29|levels
P02188168A0000|102 116|HIV-1 antibodies
P02188168A0000|258 262|years
P02188168A0000|205 212|patients
P02188168A0000|56 66|drug addicts
P02188168A0000|238 246|community
P02188168A0000|88 95|carriers
P02188168A0000|180 185|P.G.L.
P02188168A0000|31 38|beta-2-M
P02190122A0633|4 15|emancipation
P02190122A0633|107 112|mating
P02190122A0633|76 85|motivation
P02190122A0633|115 122|primates
P02190122A0633|50 58|influence
P02190122A0633|21 27|ability
P02190122A0633|96 104|regulator
P02190134A0572|28 38|progression
P02190134A0572|66 74|exception
P02190134A0572|192 202|hemorrhages
P02190134A0572|167 179|complications
P02190134A0572|153 159|attempt
P02190134A0572|77 106|laser photocoagulation treatment
P02190134A0572|44 50|disease
P02190134A0572|140 148|membranes
P02190134A0572|2 8|therapy
P02193033A0195|0 1|R.
P02194273A0913|30 38|pathogens
P02194273A0913|8 27|hyperimmune globulins
P02194273A0913|69 81|Streptococcus
P02194273A0913|56 65|influenzae
P02194972T0000|30 31|HR
P02194972T0000|109 112|mice
P02194972T0000|11 17|effects
P02194972T0000|69 88|Enterococcus faecalis
P02194972T0000|20 28|cefpirome
P02194972T0000|55 64|infections
P02195025T0000|0 9|Regulation
P02195025T0000|12 20|yeast LEU2
P02195715A0143|92 102|individuals
P02195715A0143|53 60|newborns
P02195715A0143|10 20|individuals
P02195715A0143|130 139|thrombosis
P02195715A0143|117 120|risk
P02195715A0143|152 159|embolism
P02195715A0143|74 80|protein
P02195715A0143|35 50|purpura fulminans
P02195715T0000|19 36|protein C deficiency
P02195715T0000|8 13|stroke
P02196176A0749|0 4|TREB7
P02196176A0749|8 13|TREB36
P02196176A0749|51 55|TREB5
P02196176A0749|31 37|repeats
P02196176A0749|78 83|repeat
P02196176A0749|45 46|bp
P02196311A1034|83 85|RNL
P02196311A1034|24 29|KE X 3/W
P02196311A1034|5 11|results
P02196311A1034|45 51|regimen
P02196311A1034|64 80|antitumor immunity
P02196450A0870|0 7|Analysis
P02196450A0870|169 171|QBP
P02196450A0870|48 67|sequence requirements
P02196450A0870|17 31|deletion mutants
P02196450A0870|71 77|binding
P02196450A0870|80 82|QBP
P02196450A0870|218 225|promoter
P02196450A0870|188 195|function
P02196450A0870|131 139|Q activity
P02196565A0606|75 78|RAP1
P02196565A0606|239 251|gal11 mutation
P02196565A0606|36 72|repressor/activator site binding protein
P02196565A0606|81 91|translation
P02196565A0606|206 218|GRFI/RAP1/TUF
P02196565A0606|107 109|TUF
P02196565A0606|100 105|factor
P02196565A0606|22 28|factor I
P02196565A0606|127 135|activator
P02196565A0606|174 177|PYK1
P02196565A0606|138 155|MAT alpha expression
P02196565A0606|30 33|GRFI
P02196565T0000|0 16|Yeast Gal11 protein
P02196565T0000|116 173|factor I/repressor/activator site binding protein 1/translation
P02196565T0000|92 95|Gal4
P02196565T0000|182 187|factor
P02196565T0000|84 90|factors
P02196565T0000|43 58|activation signal
P02198259A0685|0 7|Deletion
P02198259A0685|21 21|N
P02198259A0685|53 58|codons
P02198259A0685|118 126|initiator
P02198259A0685|35 38|ends
P02198259A0685|146 153|activity
P02198259A0685|94 105|reading frame
P02198259A0685|41 44|repA
P02198289A0436|117 119|DNA
P02198289A0436|34 43|amino acids
P02198289A0436|101 108|solution
P02198289A0436|12 19|peptides
P02198289A0436|93 98|dimers
P02198289A0436|135 139|dimer
P02198289A0436|70 79|amino acids
P02199311A0620|73 103|transcription termination signals
P02199311A0620|142 154|tRNA templates
P02199311A0620|117 125|RET1 cells
P02199311A0620|32 42|ret1-1 cells
P02199311A0620|7 27|transcription extracts
P02199311A0620|133 139|variety
P02200150A1381|59 62|team
P02200150A1381|104 114|pathologist
P02200150A1381|20 27|decision
P02200150A1381|93 102|geneticist
P02200150A1381|116 130|psychotherapist
P02200150A1381|82 91|oncologist
P02200150A1381|7 14|patients
P02200150A1381|134 147|plastic surgeon
P02200315A0278|0 2|IgG
P02200315A0278|52 59|dilution
P02200315A0278|62 66|serum
P02200315A0278|69 74|plates
P02200315A0278|6 24|IgM antibody activity
P02200315A0278|85 94|A60 antigen
P02200736A1003|71 74|MLTF
P02200736A1003|111 119|sequences
P02200736A1003|89 101|CACCTGTC motif
P02200736A1003|64 67|AP-4
P02200736A1003|5 11|factors
P02200736A1003|21 23|set
P02200736A1003|45 53|molecules
P02201770A0188|43 57|Anomiopsyllinae
P02201770A0188|24 41|genus Anomiopsyllus
P02201770A0188|10 19|flea larvae
P02201770A0188|109 114|adults
P02201770A0188|97 100|form
P02201770A0188|59 72|Anomiopsyllini
P02201901A0229|59 69|SSN6 protein
P02201901A0229|23 30|antibody
P02201905A1004|67 75|sequences
P02201905A1004|11 17|results
P02201905A1004|50 60|RAP1 protein
P02201905A1004|123 136|gene expression
P02201905A1004|111 120|regulation
P02201905A1004|31 41|ABFI protein
P02202496T0000|8 16|nutrition
P02202496T0000|24 29|horses
P02203672A1542|22 35|cytocentrifuge
P02204029A0184|0 20|RNase protection assays
P02204029A0184|35 38|gene
P02204029A0184|40 42|unr
P02204029A0184|133 137|point
P02204029A0184|77 81|N-ras
P02204029A0184|66 74|direction
P02204029A0184|113 121|base pairs
P02204029A0184|94 96|end
P02204029A0184|150 162|transcription
P02204621T0000|0 8|Isolation
P02204621T0000|93 96|gene
P02204621T0000|105 130|tRNA nucleotidyltransferase
P02204621T0000|52 77|tRNA nucleotidyltransferase
P02204621T0000|33 38|mutant
P02204621T0000|81 87|cloning
P02204621T0000|136 140|yeast
P02204623A0000|180 189|substrates
P02204623A0000|254 257|J.M.
P02204623A0000|43 44|IR
P02204623A0000|226 229|M.F.
P02204623A0000|220 224|White
P02204623A0000|46 57|beta-subunit
P02204623A0000|231 240|Livingston
P02204623A0000|99 104|Tyr960
P02204623A0000|259 264|Lauris
P02204623A0000|287 288|A.
P02204623A0000|266 267|V.
P02204623A0000|84 97|tyrosyl residue
P02204623A0000|293 296|Kahn
P02204623A0000|274 277|T.J.
P02204623A0000|142 163|tyrosyl phosphorylation
P02204623A0000|247 252|Backer
P02204623A0000|279 285|Ullrich
P02204623A0000|269 272|Dull
P02204623A0000|27 41|insulin receptor
P02204623A0000|3 21|juxtamembrane region
P02204623A0000|242 245|J.N.
P02204623A0000|298 301|C.R.
P02204623A0000|210 218|responses
P02204625A1130|16 20|group
P02204625A1130|88 95|mitogens
P02204625A1130|23 27|genes
P02204625A1130|73 79|insulin
P02204625A1130|63 70|response
P02204625A1130|33 39|members
P02204625A1130|4 7|gene
P02204810A1080|5 10|region
P02204810A1080|12 14|GA2
P02204810A1080|37 46|expression
P02206430A0197|0 3|Pups
P02206430A0197|22 32|environment
P02206430A0197|42 48|mothers
P02206430A0197|79 88|DA turnover
P02206430A0197|72 76|level
P02206789A0002|14 19|safety
P02206789A0002|122 132|environment
P02206789A0002|69 79|amethocaine
P02206789A0002|3 10|efficacy
P02206789A0002|40 61|anaesthetic preparation
P02206858A0000|56 59|girl
P02206858A0000|122 126|years
P02206858A0000|63 65|boy
P02206858A0000|10 17|protein C
P02206858A0000|103 106|ages
P02206858A0000|89 97|diagnoses
P02206858A0000|47 54|siblings
P02206858A0000|22 31|deficiency
P02206858A0000|19 20|PC
P02208762A0228|98 100|ear
P02208762A0228|40 47|microtia
P02208762A0228|20 32|granddaughter
P02208762A0228|135 144|appendages
P02208762A0228|75 82|daughter
P02208762A0228|117 122|meatus
P02208762A0228|57 63|atresia
P02208762A0228|3 13|grandfather
P02209237A0239|31 33|IPS
P02209237A0239|53 57|cases
P02209237A0239|82 89|scanning
P02209237A0239|94 102|99mTc-MAA
P02209237A0239|142 155|liver cirrhosis
P02209237A0239|22 29|shunting
P02209237A0239|125 129|cause
P02209237A0239|132 139|cyanosis
P02209243A0237|18 29|serum albumin
P02209243A0237|37 39|SCr
P02209243A0237|10 16|protein
P02209243A0237|61 71|improvement
P02209243A0237|31 33|BUN
P02209540A1362|14 17|Ets1
P02209540A1362|21 24|Ets2
P02209540A1362|38 50|transcription
P02209540A1362|61 65|genes
P02209605A0510|127 130|mass
P02209605A0510|21 28|MSAS gene
P02209605A0510|10 17|sequence
P02209605A0510|61 72|reading frame
P02209605A0510|96 105|amino acids
P02209605A0510|116 117|Da
P02209605A0510|83 89|protein
P02209811T0000|51 59|rat caudal
P02209811T0000|24 41|permeability marker
P02209811T0000|63 75|iliac arteries
P02209811T0000|11 20|peroxidase
P02212540A0473|58 63|ulcers
P02212540A0473|39 42|area
P02212540A0473|19 31|wall specimens
P02212540A0473|121 150|transmission electron microscopy
P02212540A0473|101 115|light microscopy
P02213566A0000|100 103|rats
P02213566A0000|52 59|capacity
P02213566A0000|12 22|coenzyme Q10
P02213566A0000|76 83|survival
P02213566A0000|61 72|hemodynamics
P02213566A0000|24 26|CoQ
P02213566A0000|31 39|captopril
P02213566A0000|3 9|effects
P02213566A0000|144 153|infarction
P02217307T0000|0 7|Evidence
P02217307T0000|23 33|alterations
P02217307T0000|62 77|emptying response
P02217307T0000|46 51|rhythm
P02217741T0001|29 43|glucocorticoids
P02217741T0001|21 26|levels
P02217741T0001|76 82|animals
P02217741T0001|47 53|insulin
P02217741T0001|3 15|interrelation
P02217741T0001|59 63|blood
P02218094A0395|16 21|tissue
P02218094A0395|24 31|transfer
P02218094A0395|33 34|Ft
P02218094A0395|67 68|Fm
P02218094A0395|55 65|utilization
P02219751A0517|71 75|speed
P02219751A0517|55 58|FEMs
P02219751A0517|64 68|basis
P02219751A0517|9 16|saccades
P02220102A0271|58 64|disease
P02220102A0271|37 46|hygiene und
P02220102A0271|26 30|grade
P02220102A0271|0 8|Incidence
P02220304A0501|153 158|Europe
P02220304A0501|20 23|area
P02220304A0501|34 51|medium MS risk region
P02220304A0501|66 71|thesis
P02220304A0501|129 142|MS distribution
P02220304A0501|74 79|Kurzke
P02220304A0501|93 99|MS areas
P02220304A0501|3 7|study
P02220304A0501|26 30|Alcoy
P02223652A0939|70 71|UH
P02223652A0939|34 35|CY
P02223652A0939|26 27|CY
P02223652A0939|4 24|antithrombin unit basis
P02223773A0000|0 34|Chick brain actin depolymerizing factor
P02223773A0000|88 100|actin monomers
P02223773A0000|66 79|actin filaments
P02223773A0000|36 38|ADF
P02223773A0000|49 55|protein
P02223928T0069|7 16|experience
P02223928T0069|22 37|serotonin agonist
P02225687A0546|0 16|Comprehensive care
P02225687A0546|22 28|patient
P02225687A0546|115 140|pregnancy management options
P02225687A0546|67 76|discussion
P02225687A0546|44 52|teratogen
P02225687A0546|97 106|procedures
P02227438A0492|0 22|Primer extension analysis
P02227438A0492|122 129|A residue
P02227438A0492|105 106|nt
P02227438A0492|26 38|RNA sequencing
P02227438A0492|58 80|transcription start point
P02227438A0492|135 144|start codon
P02227438A0492|83 92|rat ODC mRNA
P02228615A0974|120 128|formation
P02228615A0974|131 149|metal-oxyhydroxides
P02228615A0974|28 51|distribution coefficients
P02228615A0974|93 102|indication
P02228615A0974|69 89|desorption experiments
P02228615A0974|161 168|reaction
P02228615A0974|3 6|85Sr
P02229068A0156|0 13|Gene constructs
P02229068A0156|43 45|tat
P02229068A0156|47 49|rev
P02229068A0156|123 124|SU
P02229068A0156|151 160|rev protein
P02229068A0156|126 127|TM
P02229068A0156|101 114|precursor SU-TM
P02229068A0156|39 41|rev
P02229068A0156|89 98|COS-1 cells
P02229068A0156|129 134|gp120 x
P02229068A0156|55 62|env genes
P02229068A0156|35 37|tat
P02229068A0156|116 120|gp160
P02229072A1012|43 48|medium
P02229072A1012|76 80|cells
P02229072A1012|56 65|conditions
P02229072A1012|112 121|metabolism
P02229072A1012|4 15|growth arrest
P02229282A0454|0 7|Patients
P02229282A0454|22 35|serum TNF levels
P02229282A0454|109 114|levels
P02229282A0454|57 77|serum T3 concentrations
P02229541T0000|15 23|carcinoma
P02229541T0000|25 30|report
P02229541T0000|34 39|review
P02229541T0000|45 54|literature
P02229541T0000|0 4|Giant
P02231162T0000|43 54|tooth contact
P02231162T0000|26 33|movement
P02231162T0000|7 13|studies
P02231479A0585|43 45|son
P02231479A0585|48 55|daughter
P02231479A0585|128 139|task activity
P02231479A0585|4 9|parent
P02231479A0585|67 79|conversations
P02231479A0585|101 112|conversation
P02233626T0000|32 39|symptoms
P02233626T0000|63 79|strabismus surgery
P02233680A1115|145 148|gene
P02233680A1115|5 11|results
P02233680A1115|123 124|kb
P02233680A1115|41 48|elements
P02233680A1115|85 106|HaG3-A helianthinin gene
P02233680A1115|73 79|control
P02233680A1115|133 138|region
P02233715A0914|14 30|pseudorabies virus
P02233715A0914|61 71|IL-6 TATA box
P02233715A0914|151 153|Dex
P02233715A0914|124 132|MRE region
P02233715A0914|159 166|presence
P02233715A0914|35 47|IL-6 construct
P02233715A0914|92 100|initiator
P02233715A0914|78 89|RNA start site
P02233715A0914|3 11|induction
P02233715A0914|107 113|element
P02233715A0914|178 179|GR
P02233729A1065|4 12|mutations
P02233729A1065|90 104|Dhfr transcripts
P02233729A1065|39 44|manner
P02233729A1065|126 134|abundance
P02233729A1065|21 24|Dhfr
P02233729A1065|65 74|startpoint
P02233729A1065|148 162|Dhfr transcripts
P02234345A0215|26 29|part
P02234345A0215|51 60|epithelium
P02234345A0215|8 15|cyst wall
P02234731A0503|86 93|findings
P02234731A0503|96 106|condylomata
P02234731A0503|55 66|inflammation
P02234731A0503|29 34|smears
P02234731A0503|118 126|dysplasia
P02234731A0503|14 18|class
P02236002A0958|102 109|elements
P02236002A0958|112 130|chicken TCR beta cDNAs
P02236002A0958|24 42|nucleotide diversity
P02236002A0958|82 90|diversity
P02236002A0958|4 10|mammals
P02236002A0958|59 67|junctions
P02236022A0000|3 20|protooncogene c-myb
P02236022A0000|112 124|transcription
P02236022A0000|89 94|manner
P02236022A0000|36 54|transcription factor
P02236022A0000|66 68|DNA
P02236022A0000|150 154|genes
P02236060A1671|0 11|Modification
P02236060A1671|53 58|amount
P02236060A1671|24 31|compound
P02236060A1671|95 101|protein
P02236064A1178|0 17|S6 kinase activation
P02236064A1178|54 60|segment
P02236064A1178|26 37|displacement
P02236064A1178|107 121|phosphorylation
P02236276T0000|0 3|Rats
P02236276T0000|50 54|naris
P02236276T0000|20 23|bulb
P02236276T0000|70 74|odors
P02237431A0000|0 9|Expression
P02237431A0000|90 97|enhancer
P02237431A0000|61 61|T
P02237431A0000|124 125|kb
P02237431A0000|34 36|TCR
P02237431A0000|38 46|alpha gene
P02237431A0000|20 32|T cell receptor
P02237431A0000|134 150|C alpha gene segment
P02237431A0000|114 122|kilobases
P02237431A0833|41 44|pair
P02237431A0833|46 47|bp
P02237431A0833|49 54|region
P02237431A0833|3 18|Ets-1 binding site
P02237431A0833|64 66|end
P02237431A0833|69 74|T alpha
P02241742A0766|15 24|resistance
P02241742A0766|50 51|HD
P02241742A0766|8 11|flow
P02241742A0766|36 45|reductions
P02241892A0681|0 10|Utilization
P02241892A0681|150 156|regions
P02241892A0681|104 105|kb
P02241892A0681|123 128|length
P02241892A0681|24 45|polyadenylation signals
P02241892A0681|88 92|mRNAs
P02242222T0000|40 43|cold
P02242222T0000|12 18|address
P02243093A0000|58 64|protein
P02243093A0000|66 68|Tax
P02243093A0000|114 117|pair
P02243093A0000|122 128|repeats
P02243093A0000|30 35|HTLV-I
P02243093A0000|5 27|T-cell leukemia virus type
P02243093A0000|85 97|transcription
P02243093A0000|134 141|U3 region
P02243093A0000|119 120|bp
P02243386A0113|42 49|passages
P02243386A0113|52 54|MHV
P02243386A0113|62 66|DI RNA
P02243386A0113|68 72|DIssF
P02243386A0113|104 110|virions
P02243386A0113|27 32|serial
P02246362T0000|86 91|traits
P02246362T0000|49 56|evidence
P02246362T0000|81 84|type
P02246362T0000|3 23|Jenkins Activity Survey
P02246447A0460|28 43|regression slopes
P02246447A0460|134 145|portion sizes
P02246447A0460|112 119|r2 values
P02246447A0460|93 102|food groups
P02246447A0460|8 15|evidence
P02246447A0460|70 81|portion sizes
P02246803A0692|3 8|result
P02246803A0692|37 45|TTD method
P02246803A0692|108 113|output
P02247069A0261|25 30|screen
P02247069A0261|51 60|mating type
P02247069A0261|62 65|V.L.
P02247069A0261|34 38|genes
P02247069A0261|3 10|TUP1 gene
P02247072A0794|3 25|SUP44 suppressor mutation
P02247072A0794|112 123|ram mutations
P02247072A0794|37 42|region
P02247072A0794|48 54|protein
P02247072A0794|91 101|alterations
P02247072A0794|80 88|positions
P02247081A0223|134 139|growth
P02247081A0223|154 171|growth temperatures
P02247081A0223|14 23|disruption
P02247081A0223|29 38|VPS34 locus
P02247081A0223|71 82|growth defect
P02247081A0223|101 109|VPS34 gene
P02247924A0078|29 35|abscess
P02247924A0078|47 59|amphotericin B
P02247924A0078|11 14|case
P02247924A0078|63 73|nephrectomy
P02248732A1113|142 149|turnover
P02248732A1113|105 105|%
P02248732A1113|152 153|NA
P02248732A1113|93 99|LC cells
P02248732A1113|36 46|haloperidol
P02248732A1113|20 23|data
P02248732A1113|68 75|increase
P02248732A1113|81 90|firing rate
P02248732A1113|167 178|DOPAC changes
P02249872A1051|112 116|phase
P02249872A1051|147 151|phase
P02249872A1051|86 95|microC/cm2
P02249872A1051|55 67|charge density
P02249872A1051|30 34|range
P02249872A1051|103 108|charge
P02249872A1051|138 143|microC
P02249872A1051|4 14|interaction
P02249872A1051|41 50|parameters
P02250919A0404|0 10|Perceptions
P02250919A0404|166 174|headaches
P02250919A0404|78 93|headache symptoms
P02250919A0404|13 32|illness intrusiveness
P02250919A0404|152 163|muscle cramps
P02250919A0404|64 74|muscle cramp
P02250919A0404|117 135|assessment intervals
P02251119A0319|0 6|Results
P02251119A0319|68 74|regions
P02251119A0319|49 51|U14
P02251119A0319|91 97|introns
P02251119A0319|123 140|hsc70 heat shock gene
P02251119A0319|111 115|mouse
P02251119A0319|34 41|presence
P02252891T0000|88 92|sites
P02252891T0000|13 19|protein
P02252891T0000|114 118|sites
P02252891T0000|36 46|interleukin
P02252891T0000|48 58|stimulation
P02252953A0300|174 188|eating behaviour
P02252953A0300|140 146|effects
P02252953A0300|19 23|girls
P02252953A0300|108 121|susceptibility
P02252953A0300|76 80|girls
P02252953A0300|157 166|mood states
P02252953A0300|47 54|EAT score
P02252953A0300|100 106|mothers
P02253274A0000|133 144|mtDNA introns
P02253274A0000|116 130|characteristics
P02253274A0000|155 162|elements
P02253274A0000|92 93|kb
P02253274A0000|78 81|DNAs
P02253274A0000|3 14|Mauriceville
P02253274A0000|37 44|plasmids
P02253274A0000|18 23|Varkud
P02253663A0687|97 115|serum concentrations
P02253663A0687|64 70|minimum
P02253663A0687|47 56|difference
P02253663A0687|12 17|rhythm
P02253663A0687|77 77|h
P02253663A0687|82 88|maximum
P02253663A0687|123 123|%
P02253663A0687|95 95|h
P02254282T0000|87 103|glucose metabolism
P02254282T0000|78 84|enzymes
P02254282T0000|18 29|organization
P02254282T0000|33 59|Zymomonas mobilis gene cluster
P02254282T0000|0 7|Sequence
P02254418A0641|14 14|%
P02254418A0641|79 85|species
P02254418A0641|88 90|CNS
P02254418A0641|4 10|strains
P02254418A0641|18 30|S. lugdunensis
P02254418A0641|40 53|delta hemolysin
P02254749A0133|58 66|sequences
P02254749A0133|89 101|ATG start codon
P02254749A0133|41 51|170K protein
P02254749A0133|154 158|codon
P02254749A0133|147 149|TAA
P02254749A0133|26 28|60K
P02254749A0133|125 127|60K
P02254749A0133|8 12|cDNAs
P02254749A0133|108 111|cDNA
P02254749A0133|34 37|110K
P02254749A0133|134 141|sequence
P02254749A0133|191 198|sequence
P02254749A0133|30 32|87K
P02256678A1224|131 146|protein complexes
P02256678A1224|55 60|region
P02256678A1224|22 41|footprinting analysis
P02256678A1224|108 115|presence
P02256678A1224|89 97|HSC82 gene
P02257251T0000|0 14|Pathophysiology
P02257251T0000|36 42|animals
P02257251T0000|17 24|bone loss
P02257899T0000|31 40|generation
P02257899T0000|43 50|saccades
P02257899T0000|53 55|man
P02257899T0000|15 25|interaction
P02258918A0242|91 106|sampling fraction
P02258918A0242|10 13|lung
P02258918A0242|24 29|slices
P02258918A0242|47 55|disectors
P02259334A0205|43 50|sequence
P02259334A0205|11 18|promoter
P02259334A0205|87 88|Mr
P02259334A0205|63 66|gene
P02259334A0205|78 84|protein
P02259334A0205|103 110|function
P02259334A0205|91 93|kDa
P02259795A0570|55 66|calculations
P02259795A0570|100 103|mm Hg
P02259795A0570|132 137|uptake
P02259795A0570|34 37|skin
P02259795A0570|10 20|consumption
P02259795A0570|81 88|water PO2
P02259795A0570|154 157|skin
P02259795A0570|113 113|%
P02261254A0168|30 35|arrest
P02261254A0168|115 125|development
P02261254A0168|47 57|circulation
P02261254A0168|128 135|ischemia
P02261254A0168|63 72|conditions
P02261254A0168|161 166|tissue
P02261254A0168|89 99|circulation
P02261254A0168|0 10|Experiments
P02262439A0508|0 10|MCh infusion
P02262439A0508|41 48|increase
P02262439A0508|77 79|QBA
P02262439A0508|51 66|airway resistance
P02264601A0000|0 19|Taste reactivity tests
P02264601A0000|80 83|rats
P02264601A0000|78 78|P
P02264601A0000|127 133|alcohol
P02264601A0000|108 109|NP
P02264601A0000|49 57|responses
P02264601A0000|111 114|rats
P02264601A0000|60 66|alcohol
P02264601A0000|120 124|taste
P02264601A0000|87 106|alcohol nonpreferring
P02265055A0417|0 19|Plasma concentrations
P02265055A0417|131 141|laudanosine
P02265055A0417|22 31|atracurium
P02265055A0417|113 128|CSF concentration
P02265055A0417|35 45|laudanosine
P02265055A0417|85 98|micrograms ml-1
P02265055A0417|59 72|micrograms ml-1
P02265055A0417|151 156|ng ml-1
P02266679A0740|0 7|Plasma Al
P02266679A0740|40 49|drug course
P02266679A0740|29 36|baseline
P02268461A0224|27 34|patients
P02268461A0224|16 19|case
P02268461A0224|49 53|years
P02268461A0224|3 10|survival
P02269281A1276|103 112|structures
P02269281A1276|143 150|location
P02269281A1276|156 161|region
P02269281A1276|164 177|control signals
P02269281A1276|128 135|relation
P02269281A1276|36 46|involvement
P02269281A1276|62 70|sequences
P02269281A1276|3 12|occurrence
P02269281A1276|14 24|maintenance
P02269426A0428|0 2|IST
P02269426A0428|89 95|factors
P02269426A0428|206 219|mRNA expression
P02269426A0428|176 186|requirement
P02269426A0428|11 19|RNA target
P02269426A0428|136 145|RNA targets
P02269426A0428|108 110|IST
P02269426A0428|21 23|TAR
P02269426A0428|28 46|Tat trans-activation
P02269426A0428|149 167|Tat trans-activation
P02269426A0428|99 106|activity
P02270096T0000|9 16|activity
P02270096T0000|36 46|nitrosamine
P02270587A0000|56 64|magnitude
P02270587A0000|13 25|treatment need
P02270587A0000|49 53|order
P02270834A0123|7 12|method
P02270834A0123|21 29|HML method
P02272095A0832|74 81|patients
P02272095A0832|94 108|cluster headache
P02272095A0832|22 32|involvement
P02272095A0832|58 71|pain modulation
P02272095A0832|45 55|enkephalins
P02272095A0832|5 11|results
P02273690T0001|0 6|Effects
P02273690T0001|9 17|cisapride
P02273690T0001|42 49|motility
P02273690T0001|62 69|hormones
P02274343A0064|60 67|clawtoes
P02274343A0064|108 122|nail pathologies
P02274343A0064|69 75|bunions
P02274343A0064|77 89|hallux rigidus
P02274343A0064|24 31|heel pain
P02274343A0064|91 95|corns
P02274343A0064|33 45|metatarsalgia
P02274343A0064|124 132|arthritis
P02274343A0064|6 20|foot pathologies
P02274343A0064|99 106|calluses
P02274343A0064|47 56|hammertoes
P02274343A0064|137 148|neuropathies
P02274509A0623|0 15|Liver dysfunction
P02274509A0623|76 83|activity
P02274509A0623|101 121|indicator liver enzymes
P02274509A0623|89 98|blood serum
P02274509A0623|21 28|presence
P02274509A0623|151 158|function
P02274509A0623|47 55|reactions
P02276891T0000|0 10|Coenzyme Q10
P02276891T0000|12 22|blood levels
P02276891T0000|35 40|demand
P02277005A0227|3 19|CT characteristics
P02277005A0227|44 53|literature
P02277319A0211|88 103|product sterility
P02277319A0211|106 120|bioburden levels
P02277319A0211|67 72|assays
P02277319A0211|19 31|preservatives
P02277452A0116|56 64|PSP/LVESV
P02277452A0116|43 46|LVEF
P02277452A0116|48 52|LVESV
P02277452A0116|166 168|ECG
P02277452A0116|34 40|changes
P02277452A0116|88 96|detection
P02277452A0116|142 150|chest pain
P02277452A0116|16 29|angina pectoris
P02277452A0116|4 11|patients
P02277452A0116|115 122|ischemia
P02277452A0116|130 139|appearance
P02277452A0116|157 163|changes
P02278217A0372|41 47|therapy
P02278217A0372|87 97|section lead
P02278217A0372|100 107|delivery
P02278217A0372|66 75|medication
P02278217A0372|22 38|management failure
P02278217A0372|6 11|groups
P02278474A0000|0 29|Serum Fibrin Degradation Products
P02278474A0000|109 117|treatment
P02278474A0000|103 106|kind
P02278474A0000|82 92|individuals
P02278474A0000|57 70|cancer patients
P02278474A0000|31 33|FDP
P02280777T0000|61 67|element
P02280777T0000|3 21|uteroglobin promoter
P02280777T0000|43 50|estrogen
P02281118A1191|0 31|Prostaglandin synthesis inhibitors
P02281118A1191|80 90|limitations
P02281118A1191|52 58|healing
P02281118A1191|61 64|bone
P02281118A1191|117 126|situations
P02281118A1191|98 100|use
P02281330A0556|14 32|oxygen concentration
P02281330A0556|126 131|trauma
P02281330A0556|40 43|FiO2
P02281330A0556|95 100|manner
P02281330A0556|51 66|Horowitz quotient
P02281330A0556|118 120|day
P02281948A0245|3 6|corn
P02281948A0245|10 28|mineral oil emulsions
P02281948A0245|87 87|M
P02281948A0245|52 55|milk
P02281948A0245|102 110|ingestion
P02281948A0245|76 82|sucrose
P02282815T0000|0 11|Significance
P02282815T0000|56 63|children
P02282815T0000|28 44|basement membranes
P02283148T0000|0 11|Significance
P02283148T0000|62 76|immunopathology
P02283148T0000|35 51|adhesion molecules
P02283148T0000|14 31|cytokine production
P02283378A0385|97 115|ultrafiltration tube
P02283378A0385|9 17|procedure
P02283378T0000|15 27|determination
P02283378T0000|65 70|fluids
P02283378T0000|6 11|method
P02283378T0000|95 108|chromatography
P02283378T0000|33 52|cephalosporin DQ-2556
P02283873A0308|15 25|adolescents
P02283873A0308|128 135|enhancer
P02283873A0308|63 74|parents smoke
P02283873A0308|84 94|involvement
P02283873A0308|8 12|group
P02283873A0308|97 113|smoking prevention
P02284393A0751|74 103|EE/low EE research classification
P02284393A0751|7 14|research
P02284393A0751|41 52|coping styles
P02284573A0943|14 17|MoAB
P02284573A0943|25 32|BAL fluid
P02284573A0943|99 101|TBB
P02284573A0943|105 120|brushing material
P02284573A0943|74 92|methenamine staining
P02284573A0943|95 97|BAL
P02287860T0001|30 34|study
P02287860T0001|81 93|X-ray exposure
P02287860T0001|64 67|mice
P02287860T0001|47 61|parenchyma cells
P02289102A0114|27 36|headphones
P02289102A0114|53 66|hallucinations
P02289102A0114|40 47|duration
P02289102A0114|7 23|audiotape cassette
P02289639A0989|98 98|p
P02289639A0989|7 12|change
P02289639A0989|79 79|%
P02289639A0989|85 96|control group
P02289639A0989|15 18|HbA1
P02289639A0989|54 54|%
P02289639A0989|41 45|value
P02290216T0001|29 39|cholangitis
P02290216T0001|42 57|serum SPan-1 level
P02290216T0001|15 25|obstruction
P02290216T0001|0 5|Effect
P02291144A0493|114 118|MCHCH
P02291144A0493|60 60|H
P02291144A0493|88 103|reference methods
P02291144A0493|75 81|machine
P02291144A0493|8 15|accuracy
P02291144A0493|122 134|basophil count
P02291144A0493|17 17|r
P02291628A0264|40 51|applications
P02291628A0264|110 119|literature
P02291628A0264|62 68|aspects
P02291628A0264|89 96|examples
P02291628A0264|9 12|part
P02291628A0264|151 163|endocrinology
P02291628A0264|79 82|help
P02291628A0264|19 23|paper
P02291628A0264|71 73|NMR
P02292272T0000|0 20|Interlimb coordination
P02292272T0000|57 59|cat
P02292272T0000|34 43|locomotion
P02293019A0000|0 18|Antileukoproteinase
P02293019A0000|112 117|serine
P02293019A0000|51 57|protein
P02293019A0000|149 159|cathepsin-G
P02293019A0000|90 99|activities
P02293019A0000|127 145|proteinases elastase
P02293019A0000|30 32|mol
P02293019A0000|20 22|ALP
P02293019A0000|71 77|tissues
P02293664A0946|14 19|series
P02293664A0946|75 83|sequences
P02293664A0946|36 51|vimentin promoter
P02293664A0946|88 96|base pairs
P02293664A0946|121 129|base pairs
P02293664A0946|22 30|deletions
P02293664A0946|143 153|mRNA cap site
P02294048A0881|68 72|hsp70
P02294048A0881|20 49|% amino acid sequence similarities
P02294048A0881|93 110|Bacillus megaterium
P02295521A0922|58 62|level
P02295521A0922|8 16|relations
P02295521A0922|185 194|risk factor
P02295521A0922|37 47|correlation
P02295521A0922|198 208|development
P02295521A0922|139 160|muscle activity patterns
P02295521A0922|65 81|trapezius activity
P02295521A0922|85 94|complaints
P02295521A0922|227 236|complaints
P02295521A0922|117 126|individual
P02296509A0997|18 33|household members
P02296509A0997|81 95|serum p24 antigen
P02296509A0997|46 57|seronegative
P02298741A0809|0 7|Analysis
P02298741A0809|137 145|JKPE cells
P02298741A0809|68 75|gamma PKC
P02298741A0809|226 238|alpha antibody
P02298741A0809|104 106|PKC
P02298741A0809|55 59|alpha
P02298741A0809|121 127|JK cells
P02298741A0809|97 101|types
P02298741A0809|197 203|protein
P02298741A0809|34 43|antibodies
P02298741A0809|171 173|kDa
P02298741A0809|61 64|beta
P02299543A0317|43 49|outlook
P02300541A0000|100 103|MDIs
P02300541A0000|140 149|surfactant
P02300541A0000|125 128|dose
P02300541A0000|87 98|dose inhalers
P02300541A0000|51 57|surface
P02300541A0000|64 69|agents
P02300541A0000|35 41|barrier
P02300541A0000|180 187|rat lungs
P02300541A0000|155 161|airways
P02300541A0000|72 77|series
P02300541A0000|14 20|effects
P02300577A0852|103 111|beta chain
P02300577A0852|129 135|complex
P02300577A0852|63 86|endoglycosidase digestion
P02300577A0852|41 58|glycosylation sites
P02300577A0852|3 11|beta chain
P02300577A0852|148 157|side chains
P02300759A0000|116 121|T1B-T2
P02300759A0000|154 160|surgery
P02300759A0000|110 114|forms
P02300759A0000|65 75|epithelioma
P02300759A0000|142 150|radiology
P02300759A0000|14 22|protocole
P02300759A0000|32 53|Gustave Roussy Institute
P02300759A0000|88 93|cervix
P02303158T0000|68 78|trk oncogene
P02303158T0000|32 35|gene
P02303158T0000|49 55|protein
P02303158T0000|19 28|expression
P02303470A0242|3 9|introns
P02303470A0242|20 22|kbp
P02303874A1643|58 61|dose
P02303874A1643|120 135|micrograms/24 hrs
P02303874A1643|76 80|doses
P02303874A1643|113 116|mean
P02303874A1643|96 111|micrograms/24 hrs
P02303874A1643|32 41|adjustment
P02303874A1643|14 28|titration period
P02305014A0226|18 28|experiments
P02305014A0226|10 15|series
P02305014A0226|81 93|guide cannulas
P02305014A0226|48 51|rats
P02305014A0226|111 119|ventricle
P02306539T0000|44 47|food
P02306539T0000|51 62|Daphnia pulex
P02306539T0000|32 41|Microfeast
P02306539T0000|5 28|Selenastrum capricornutum
P02306539T0000|0 2|Use
P02307067A1348|152 159|evidence
P02307067A1348|111 111|%
P02307067A1348|162 172|adaptations
P02307067A1348|40 55|families Tydeidae
P02307067A1348|3 13|persistence
P02307067A1348|57 70|Nanorchestidae
P02307067A1348|113 135|concentration treatments
P02307067A1348|16 22|members
P02307067A1348|192 199|habitats
P02307067A1348|74 85|Tarsonemidae
P02307371A0263|86 102|c-myc deregulation
P02307371A0263|187 206|lymphoma c-myc alleles
P02307371A0263|217 221|cells
P02307371A0263|43 73|transcription elongation blockage
P02307371A0263|225 237|Xenopus oocyte
P02307371A0263|105 111|Burkitt
P02307371A0263|159 166|transfer
P02307371A0263|37 40|loss
P02307371A0263|246 253|vesicles
P02307371A0263|133 153|transcription patterns
P02307371A0263|114 121|lymphoma
P02307371A0263|11 19|mechanism
P02307371A0263|178 184|Burkitt
P02307613A0783|0 37|Erythrocyte protoporphyrin concentration
P02307613A0783|61 61|P
P02307613A0783|79 82|days
P02307613A0783|149 152|dogs
P02307613A0783|85 88|dogs
P02307613A0783|196 200|study
P02307613A0783|182 190|remainder
P02307613A0783|170 175|groups
P02307613A0783|100 103|diet
P02307848A0347|71 79|sequences
P02307848A0347|50 52|DNA
P02307848A0347|23 30|Crry gene
P02307848A0347|9 17|sequences
P02307848A0347|110 123|Eco-R1 fragment
P02307848A0347|46 47|kb
P02307848T0042|43 46|Crry
P02307848T0042|57 61|genes
P02307848T0042|28 37|complexity
P02307850A0000|6 29|RNK-16 lambda-gt11 library
P02307850A0000|63 83|cDNA rat NK cell protease
P02307850A0000|100 114|characteristics
P02307850A0000|86 91|RNKP-1
P02307850A0000|123 137|serine proteases
P02307850A1197|14 29|RNKP-1 expression
P02307850A1197|89 90|NK
P02307850A1197|74 82|increases
P02307850A1197|114 139|killer lymphocyte activities
P02307850A1197|35 37|Con
P02307850A1197|48 58|spleen cells
P02307850A1197|3 11|induction
P02308496A0000|113 119|session
P02308496A0000|122 132|respiration
P02308496A0000|174 179|GHM-10
P02308496A0000|88 96|C-peptide
P02308496A0000|60 62|STH
P02308496A0000|68 75|cortisol
P02308496A0000|153 159|mixture
P02308496A0000|43 52|blood level
P02308496A0000|64 66|TSH
P02308496A0000|77 78|T3
P02308496A0000|80 86|insulin
P02308496A0000|166 172|% oxygen
P02308496A0000|32 37|change
P02308496A0000|26 29|data
P02308496A0000|3 7|paper
P02308496A0000|55 58|ACTH
P02310261A0115|71 81|pericardium
P02310261A0115|3 9|abscess
P02310261A0115|54 58|layer
P02310261A0115|27 32|septum
P02310300A0298|4 16|% lymphography
P02310300A0298|38 39|CT
P02310350A0221|73 79|content
P02310350A0221|26 31|effect
P02310350A0221|34 42|intensity
P02310350A0221|10 14|study
P02310350A0221|52 59|polarity
P02310350A0221|44 47|rate
P02310350A0221|104 111|subjects
P02310350A0221|82 85|ABRs
P02310496X0000|60 63|band
P02310496X0000|126 146|nucleus basalis lesions
P02310496X0000|227 228|NB
P02310496X0000|104 116|memory defects
P02310496X0000|159 164|degree
P02310496X0000|190 197|cell loss
P02310496X0000|74 87|nucleus basalis
P02310496X0000|274 280|MS-VDBB
P02310496X0000|212 225|nucleus basalis
P02310496X0000|285 303|place navigation task
P02310496X0000|313 327|reference memory
P02310496X0000|7 23|memory impairments
P02310496X0000|66 70|Broca
P02310496X0000|96 99|rats
P02310496X0000|202 209|function
P02310496X0000|268 272|Broca
P02310496X0000|262 265|band
P02311544A0086|0 6|Studies
P02311544A0086|47 54|MSMR cyst
P02311544A0086|25 36|relationship
P02311544A0086|82 88|disease
P02311544A0086|65 69|signs
P02311544A0086|72 79|symptoms
P02312470A0774|57 58|Na
P02312470A0774|212 215|time
P02312470A0774|94 96|ELF
P02312470A0774|220 225|lavage
P02312470A0774|148 151|time
P02312470A0774|24 31|activity
P02312470A0774|75 78|urea
P02312470A0774|173 174|Na
P02312470A0774|166 169|urea
P02312470A0774|112 113|Na
P02312470A0774|126 126|s
P02312470A0774|3 15|BAL-to-plasma
P02312470A0774|34 37|urea
P02312470A0774|195 205|circulation
P02312689A0360|56 69|standard method
P02312689A0360|21 29|agreement
P02312689A0360|40 49|Patho Dx Kit
P02312689A0360|3 18|kappa coefficient
P02315151T0020|33 39|illness
P02315151T0020|6 12|systems
P02315151T0020|24 29|health
P02315151T0020|45 47|age
P02315472A0583|84 91|unit time
P02315472A0583|68 71|RASE
P02315472A0583|102 102|%
P02315472A0583|17 27|imaging time
P02315472A0583|78 80|C/A
P02315472A0583|32 41|parameters
P02317413A0364|161 168|patients
P02317413A0364|149 158|volunteers
P02317413A0364|68 85|neutrophil elastase
P02317413A0364|27 36|infarction
P02317413A0364|135 138|acid
P02317413A0364|188 199|heart disease
P02317413A0364|46 65|plasma concentrations
P02317413A0364|0 7|Patients
P02317413A0364|119 124|isomer
P02317413A0364|104 108|diene
P02317554T0000|0 12|Determination
P02317554T0000|57 72|microscope system
P02317554T0000|32 48|imaging properties
P02318208A0817|158 163|Ad2MLP
P02318208A0817|140 155|promoter sequence
P02318208A0817|115 126|core sequence
P02318208A0817|13 19|element
P02318208A0817|33 43|CACGTGACCCG
P02318208A0817|56 57|bp
P02318208A0817|73 99|transcription initiation site
P02319610A1527|27 34|findings
P02319610A1527|11 19|relevance
P02319610A1527|128 132|route
P02319610A1527|54 64|observation
P02319610A1527|76 82|results
P02319610A1527|99 103|P.HCl
P02320008A0651|0 5|TMBr-1
P02320008A0651|115 124|amino acids
P02320008A0651|105 110|region
P02320008A0651|54 63|amino acids
P02320008A0651|27 49|muscle alpha-tropomyosin
P02320999A0606|43 55|particle board
P02320999A0606|33 41|materials
P02320999A0606|183 191|compounds
P02320999A0606|67 77|gypsum board
P02320999A0606|165 172|mg m-2 h-1
P02320999A0606|95 101|plywood
P02320999A0606|82 90|wallpaper
P02320999A0606|106 124|polyurethane lacquer
P02320999A0606|3 11|procedure
P02320999A0606|149 163|emission factors
P02320999A0606|60 65|carpet
P02322535A0658|0 5|Intron
P02322535A0658|69 70|kb
P02322535A0658|12 13|kb
P02322535A0658|32 36|sizes
P02322535A0658|39 45|introns
P02323517A0557|113 144|prostaglandin generation technique
P02323517A0557|6 6|h
P02323517A0557|8 14|lesions
P02323517A0557|65 88|prostaglandin E2 synthesis
P02323517A0557|29 32|part
P02323517A0557|38 44|stomach
P02324102A1157|0 9|Comparison
P02324102A1157|128 135|Cassiman
P02324102A1157|79 82|48K5
P02324102A1157|12 24|transmembrane
P02324102A1157|39 45|domains
P02324102A1157|159 163|David
P02324102A1157|137 138|J.
P02324102A1157|125 126|J.
P02324102A1157|153 154|H.
P02324102A1157|108 114|Marynen
P02324102A1157|92 106|lung fibroblasts
P02324102A1157|116 117|P.
P02324102A1157|165 166|C.
P02324102A1157|66 77|proteoglycan
P02324102A1157|140 151|Vanden Berghe
P02324102A1157|119 123|Zhang
P02324104A0151|90 98|fractions
P02324104A0151|101 111|homogenates
P02324104A0151|40 65|phosphotransferase activity
P02324104A0151|149 157|C. elegans
P02324104A0151|136 146|populations
P02324104A0151|15 15|%
P02324104A0516|4 9|levels
P02324104A0516|73 83|development
P02324104A0516|12 20|C subunits
P02324104A0516|65 70|stages
P02324104A0929|13 20|C subunit
P02324104A0929|22 31|CeCAT alpha
P02324104A0929|37 44|residues
P02324104A0929|133 141|C pre-mRNA
P02324104A0929|83 88|region
P02324104A0929|120 127|splicing
P02324104A1195|14 17|exon
P02324104A1195|188 198|nucleotides
P02324104A1195|149 156|residues
P02324104A1195|36 51|carboxyl terminus
P02324104A1195|59 79|translation stop signal
P02324104A1195|119 126|sequence
P02324104A1195|159 168|CeCAT alpha
P02325208A0209|0 5|French
P02325208A0209|7 8|M.
P02325895T0000b|14 17|type
P02325895T0000b|103 106|skin
P02325895T0000b|109 115|raccoon
P02325895T0000b|81 92|displacement
P02325895T0000b|63 67|force
P02325895T0000b|46 53|function
P02325895T0000b|19 42|mechanoreceptor discharge
P02325895T0000b|119 136|squirrel monkey hand
P02326716A0139|161 164|tilt
P02326716A0139|152 159|rotation
P02326716A0139|66 71|convex
P02326716A0139|168 179|displacement
P02326716A0139|75 99|concave rib-vertebra angles
P02326716A0139|51 56|T7-T12
P02326716A0139|40 49|evaluation
P02326716A0139|18 26|Cobb angle
P02326716A0139|136 140|RVADs
P02326716A0139|0 6|Methods
P02326716A0139|119 134|angle differences
P02326716A0139|101 104|RVAs
P02326946T0000|47 54|activity
P02326946T0000|118 137|liver transplantation
P02326946T0000|79 87|predictor
P02326946T0000|42 45|LCAT
P02326946T0000|90 107|allograft viability
P02326946T0000|71 76|donors
P02326946T0000|0 40|Plasma lecithin/cholesterol acyltransferase
P02327159T0001|0 3|Lars
P02327159T0001|7 10|AIDS
P02327159T0001|27 30|life
P02327159T0001|35 38|care
P02327159T0001|41 44|home
P02328328A0419|160 162|yrs
P02328328A0419|13 18|status
P02328328A0419|20 51|tumour progesterone receptor status
P02328328A0419|164 171|patients
P02328328A0419|64 78|tumour detection
P02328328A0419|135 137|yrs
P02328328A0419|56 61|season
P02328328A0419|102 109|survival
P02329840A0383|89 89|o
P02329840A0383|69 75|changes
P02329840A0383|21 35|microelectrodes
P02329840A0383|41 51|measurement
P02329840A0383|3 13|application
P02329840A0383|86 86|K
P02330041A0335|0 9|Expression
P02330041A0335|41 60|transcription studies
P02330041A0335|230 235|manner
P02330041A0335|167 182|rRNA gene promoter
P02330041A0335|80 83|hUBF
P02330041A0335|209 215|binding
P02330041A0335|193 205|transcription
P02330041A0335|158 161|core
P02330041A0335|19 30|localization
P02330041A0335|141 154|control element
P02330041A0335|101 106|factor
P02330110A1085|73 79|outcome
P02330110A1085|41 45|value
P02330110A1085|17 33|laboratory studies
P02330333A0325|68 74|muscles
P02330333A0325|36 40|times
P02330333A0325|60 64|brain
P02330333A0325|20 29|202Tl label
P02330333A0325|88 93|plasma
P02330333A0325|49 50|Ga
P02330333A0325|0 12|Accumulations
P02330333A0325|81 85|times
P02330333A0325|15 18|Tl+1
P02331361A0268|16 23|increase
P02331361A0268|72 87|autopsy specimens
P02331361A0268|29 43|myocyte diameter
P02331361A0268|63 68|biopsy
P02331361A0268|55 57|age
P02332018A0538|159 159|P
P02332018A0538|35 40|asthma
P02332018A0538|10 16|absence
P02332018A0538|136 143|subjects
P02332018A0538|110 125|mean GH increments
P02332018A0538|153 157|ng/ml
P02332018A0538|75 82|patients
P02332018A0538|42 44|EIA
P02332018A0538|60 64|WH air
P02332798A0725|3 11|afferents
P02332798A0725|53 66|EVS stimulation
P02332798A0725|13 17|phase
P02332798A0725|20 27|response
P02333239T0000|15 21|problem
P02333239T0000|9 11|age
P02333545A0313|74 85|distribution
P02333545A0313|97 104|controls
P02333545A0313|22 37|fibrinogen levels
P02333545A0313|3 14|distribution
P02333749A0411|57 66|occurrence
P02333749A0411|89 100|P. orbiculare
P02333749A0411|140 145|eczema
P02333749A0411|39 41|SPT
P02333749A0411|125 129|value
P02333749A0411|69 86|serum IgE antibodies
P02333749A0411|19 36|regression analysis
P02333749A0411|45 52|RAST data
P02334972A0145|54 59|drusen
P02334972A0145|152 157|vision
P02334972A0145|26 35|assessment
P02334972A0145|139 142|loss
P02334972A0145|63 72|evaluation
P02334972A0145|123 135|complications
P02334972A0145|92 100|incidence
P02334972A0145|103 113|risk factors
P02334972A0145|3 13|examination
P02334972A0145|78 88|development
P02334972A0145|47 51|types
P02335034A0584|72 78|minutes
P02335034A0584|81 84|LBNP
P02335034A0584|58 62|suits
P02335034A0584|33 42|heat stress
P02335521T0000|49 61|transcription
P02335521T0000|13 40|vitellogenin activator element
P02335521T0000|87 119|Xenopus laevis vitellogenin promoter
P02335713A0905|44 55|ALAD activity
P02335713A0905|61 75|stearate workers
P02335713A0905|38 40|PbB
P02335713A0905|5 15|correlation
P02335815A0530|70 78|C assembly
P02335815A0530|104 111|activity
P02335815A0530|37 43|residue
P02335815A0530|5 20|carboxyl terminus
P02335815A0530|22 29|deletion
P02335815A0530|66 68|TRF
P02336338A0931|83 89|account
P02336338A0931|52 61|expression
P02336338A0931|12 24|mean luminance
P02336338A0931|3 9|effects
P02339005T0000|0 5|Effect
P02339005T0000|8 20|hyperglycemia
P02339005T0000|54 57|rats
P02339005T0000|23 35|pain threshold
P02339447A0162|87 94|9,11-2H2
P02339447A0162|158 158|A
P02339447A0162|74 80|7,7-2H2
P02339447A0162|252 259|subjects
P02339447A0162|104 105|E1
P02339447A0162|134 138|assay
P02339447A0162|18 24|7,7-2H2
P02339447A0162|163 164|E1
P02339447A0162|82 82|A
P02339447A0162|141 156|serum level 19-OHA
P02339447A0162|96 102|estrone
P02339447A0162|41 56|deuterium content
P02339447A0162|270 278|pregnancy
P02339447A0162|173 232|gas chromatography/mass spectrometry-mass fragmentography method
P02339447A0162|30 32|OHA
P02340595A0124|0 15|Sequence analysis
P02340595A0124|93 101|tRNA genes
P02340595A0124|106 122|plant mitochondria
P02340595A0124|23 27|genes
P02340595A0124|47 55|sequences
P02341669A0000|89 93|types
P02341669A0000|56 64|responses
P02341669A0000|66 70|BAERs
P02341669A0000|143 145|MLS
P02341669A0000|31 40|brain-stem
P02341669A0000|96 118|pseudorandom pulse trains
P02341669A0000|168 170|LGS
P02341669A0000|120 141|maximum length sequences
P02341669A0000|150 166|Legendre sequences
P02341669A0000|0 10|Experiments
P02342477A1292|201 218|sequence similarity
P02342477A1292|95 105|endometrium
P02342477A1292|254 261|function
P02342477A1292|78 89|biosynthesis
P02342477A1292|107 123|P4-responsiveness
P02342477A1292|53 60|features
P02342477A1292|233 236|UTMP
P02342477A1292|128 135|presence
P02342477A1292|72 75|site
P02342477A1292|15 18|UTMP
P02342477A1292|223 226|UfAP
P02342477A1292|141 147|mannose
P02342477A1292|168 184|recognition marker
P02342477A1292|8 11|UfAP
P02343033A0000|85 93|placentae
P02343033A0000|7 11|light
P02343033A0000|70 76|infants
P02343033A0000|35 43|placentae
P02343033A0000|15 26|dates infants
P02344529T0000|40 53|erythropoietin
P02344529T0000|13 19|anaemia
P02347102A0000|73 87|lymphadenopathy
P02347102A0000|67 71|fever
P02347102A0000|3 24|pseudolymphoma syndrome
P02347102A0000|46 54|condition
P02347102A0000|102 105|rash
P02347407A0217|30 36|animals
P02347407A0217|49 57|SE-sector
P02347407A0217|21 25|field
P02347655A0193|146 156|composition
P02347655A0193|99 118|blood inlet conditions
P02347655A0193|15 18|lung
P02347655A0193|162 171|gas mixture
P02347655A0193|214 224|consumption
P02347655A0193|134 144|temperature
P02347655A0193|179 189|ventilation
P02347655A0193|36 39|lung
P02347655A0193|88 97|parameters
P02347655A0193|191 210|blood tissue perfusion
P02347655A0193|120 132|blood flow rate
P02347655A0193|61 72|gas exchanges
P02347655A0193|53 59|tissues
P02348225A0192|0 3|Mean
P02348225A0192|69 77|half-life
P02348225A0192|198 205|jaundice
P02348225A0192|222 229|controls
P02348225A0192|25 33|clearance
P02348225A0192|98 102|hours
P02348225A0192|108 113|volume
P02348225A0192|186 193|patients
P02348225A0192|11 22|measurements
P02348225A0192|150 153|L/m2
P02348225A0192|116 127|distribution
P02348225A0192|8 9|SE
P02348225A0192|58 66|mL/min/m2
P02348408A0126|0 8|Attitudes
P02348408A0126|81 87|samples
P02348408A0126|50 59|dimensions
P02348728A1153|14 22|DNA ploidy
P02348728A1153|95 103|carcinoma
P02348728A1153|50 55|factor
P02348728A1153|70 80|determinant
P02349827A0193|28 36|Videoplan
P02349827A0193|21 26|system
P02349942A0287|47 53|cohorts
P02349942A0287|13 19|factors
P02349942A0287|83 88|recall
P02349998A0297|0 18|Dopamine SERS spectra
P02349998A0297|28 37|electrodes
P02349998A0297|73 82|electrodes
P02351239A0693|5 12|findings
P02351239A0693|218 232|gastrin infusion
P02351239A0693|81 86|mucosa
P02351239A0693|183 198|hypergastrinemia
P02351239A0693|25 40|hypergastrinemia
P02351239A0693|105 111|effects
P02351239A0693|142 163|histamine concentration
P02351239A0693|246 254|treatment
P02351239A0693|167 180|ECL cell density
P02351239A0693|130 140|HDC activity
P02351239A0693|268 284|antisecretagogues
P02351239A0693|92 94|rat
P02351239A0693|58 64|removal
P02351297A0000|174 180|percent
P02351297A0000|20 35|toxicity research
P02351297A0000|108 111|cent
P02351297A0000|64 97|atmosphere metal corrosion inhibitors
P02351297A0000|201 204|cent
P02351297A0000|157 161|level
P02351297A0000|145 148|cent
P02353453A1249|55 63|RUB genome
P02353453A1249|161 169|evolution
P02353453A1249|78 84|respect
P02353453A1249|177 183|viruses
P02353453A1249|90 105|alphavirus genome
P02353453A1249|32 49|nsP3 homology region
P02353453A1249|128 140|rearrangement
P02353453A1249|3 7|order
P02353453A1249|13 25|helicase motif
P02353875A0800|103 107|cases
P02353875A0800|116 126|eosinophils
P02353875A0800|73 86|hypersecretion
P02353875A0800|139 143|cases
P02353875A0800|35 45|eosinophils
P02353875A0800|49 59|neutrophils
P02353875A0800|3 9|results
P02353875A0800|17 26|followings
P02353875A0800|89 94|type Ib
P02354381A0207|29 29|C
P02354381A0207|67 70|cage
P02354381A0207|21 27|control
P02354381A0207|76 93|fiberglass rollaway
P02354381A0207|120 123|cage
P02354381A0207|174 177|back
P02354381A0207|148 150|H/S
P02354381A0207|72 72|S
P02354381A0207|10 19|treatments
P02354381A0207|206 206|N
P02354381A0207|125 125|H
P02354381A0207|154 160|nest box
P02354381A0207|183 186|cage
P02354381A0207|109 114|corner
P02354381A0207|56 61|corner
P02355293A0749|41 49|responses
P02355293A0749|181 188|strength
P02355293A0749|123 126|drip
P02355293A0749|112 117|grafts
P02355293A0749|52 73|failure characteristics
P02355293A0749|192 198|modulus
P02355293A0749|18 28|differences
P02355293A0749|164 170|tissues
P02355293A0749|133 147|bath environment
P02355765A0220|69 73|weeks
P02355765A0220|24 43|benzathine penicillin
P02355765A0220|54 60|U weekly
P02355765A0220|3 9|patient
P02355920A0681|1 20|consensus binding site
P02355920A0681|64 69|intron
P02355920A0681|87 120|proenkephalin germ cell cap site region
P02355920A0681|27 48|transcription factor SP1
P02356823A0063|29 37|principle
P02356823A0063|12 17|method
P02356823A0063|43 55|sets technique
P02356823A0063|90 93|time
P02356823A0063|96 110|alarm properties
P02357537A0451|68 72|mg/kg
P02357537A0451|35 39|paCO2
P02357537A0451|58 65|naloxone
P02357537A0451|111 117|animals
P02357537A0451|42 44|pHa
P02357537A0451|18 26|latencies
P02357537A0451|3 9|effects
P02358975A0709|59 66|symptoms
P02358975A0709|92 103|gluten intake
P02358975A0709|120 132|IgA deficiency
P02360336A0574|0 3|Drug
P02360336A0574|63 76|multidose vials
P02360336A0574|7 20|personnel costs
P02360336A0574|130 134|vials
P02360336A0574|36 53|batch manufacturing
P02361008T0000|0 6|Changes
P02361008T0000|24 29|births
P02361008T0000|36 40|years
P02361008T0000|9 17|prognosis
P02361575T0000|17 31|carcinogenicity
P02361575T0000|55 63|diepoxide
P02361575T0000|80 89|B6C3F1 mice
P02361575T0000|66 76|Fischer rats
P02361575T0000|6 13|toxicity
P02361812A1110|117 118|EX
P02361812A1110|162 170|treatment
P02361812A1110|172 172|P
P02361812A1110|50 56|EX group
P02361812A1110|125 128|cent
P02361812A1110|82 89|subjects
P02361812A1110|132 132|D
P02361812A1110|134 135|DE
P02361812A1110|110 115|values
P02361812A1110|30 43|baseline values
P02361812A1110|3 10|kg FFM SMR
P02361812A1110|143 146|cent
P02362161T0000|0 5|MK-927
P02362161T0000|48 65|anhydrase inhibitor
P02362803A0608|42 50|isolation
P02362803A0608|89 99|Arabidopsis
P02362803A0608|11 19|fragments
P02362803A0608|80 86|library
P02362803A0608|56 67|U3 snRNA genes
P02362803A0608|30 35|probes
P02368931A0587|2 31|addition serum IgE concentrations
P02370571A0663|188 188|s
P02370571A0663|154 158|women
P02370571A0663|101 106|cohort
P02370571A0663|64 68|cause
P02370571A0663|31 46|iodine deficiency
P02370571A0663|82 91|immigrants
P02370571A0663|122 131|population
P02370571A0663|181 186|factor
P02370571A0663|148 150|men
P02370571A0663|3 10|findings
P02370571A0663|71 76|goiter
P02371273A0144|54 66|kilobase pairs
P02371273A0144|18 21|unit
P02371273A0144|39 44|region
P02371273A0144|68 70|kbp
P02371517A0747|8 15|patients
P02372496A0782|159 175|5FU administration
P02372496A0782|64 69|artery
P02372496A0782|39 50|microspheres
P02372496A0782|79 90|drug exposure
P02372496A0782|152 156|ratio
P02372496A0782|23 33|angiotensin
P02372496A0782|104 114|compartment
P02372496A0782|189 194|artery
P02372496A0782|19 21|5FU
P02372496A0782|0 16|Co-administration
P02372712A0002|70 82|carbon dioxide
P02372712A0002|60 67|pressure
P02372712A0002|50 51|pH
P02372712A0002|12 14|tap
P02372712A0002|16 17|TW
P02372712A0002|134 141|broilers
P02372712A0002|92 104|plasma lactate
P02372712A0002|35 39|water
P02372712A0002|3 9|effects
P02372712A0002|32 33|CW
P02372712A0002|84 87|PCO2
P02373686T0000|29 56|chicken progesterone receptors
P02373686T0000|9 18|expression
P02373686T0000|116 119|mRNA
P02373686T0000|125 133|mechanism
P02373686T0000|95 104|initiation
P02373686T0000|147 162|receptor isoforms
P02373810A1118|82 82|p
P02373810A1118|76 80|weeks
P02373810A1118|33 43|risk factors
P02373810A1118|51 54|risk
P02373810A1118|68 68|%
P02373810A1118|19 19|%
P02373810A1118|2 9|contrast
P02374886A0305|88 94|ability
P02374886A0305|35 45|outcome data
P02374886A0305|127 142|presence/absence
P02374886A0305|145 158|symptomatology
P02374886A0305|75 86|productivity
P02374886A0305|189 197|admission
P02374886A0305|110 122|relationships
P02374886A0305|172 176|years
P02374886A0305|67 72|degree
P02374886A0305|161 167|average
P02374886A0305|3 26|Community Adjustment Scale
P02374886A0305|58 65|subjects
P02376023A0307|43 48|levels
P02376023A0307|105 111|infants
P02376023A0307|51 54|IgG1
P02376023A0307|12 17|months
P02376023A0307|153 156|kU/l
P02376023A0307|56 56|P
P02376023A0307|20 22|age
P02376023A0307|75 78|IgG4
P02376023A0307|126 128|IgE
P02376023A0307|80 80|P
P02376023A0307|179 183|level
P02378615A0807|91 96|region
P02378615A0807|141 152|carbohydrate
P02378615A0807|114 117|site
P02378615A0807|3 17|protein sequence
P02378615A0807|121 130|attachment
P02378615A0807|48 65|glycosylation sites
P02378945A0487|30 35|stress
P02378945A0487|4 13|adaptation
P02378945A0487|94 102|vagal tone
P02378945A0487|60 65|effect
P02383693A0301|116 120|pumps
P02383693A0301|53 60|solution
P02383693A0301|102 113|M KOH solution
P02383693A0301|136 160|chemiluminescence detector
P02383693A0301|71 79|lucigenin
P02383693A0301|83 93|Triton X-100
P02383693A0301|16 21|column
P02383771A0544|158 166|cytoplasm
P02383771A0544|137 142|nuclei
P02383771A0544|115 126|distribution
P02383771A0544|12 22|examination
P02383771A0544|34 43|epithelium
P02383771A0544|94 103|epithelium
P02383771A0544|55 62|membrane
P02384265A0947|30 33|risk
P02384265A0947|57 69|polyp patients
P02384265A0947|109 119|polypectomy
P02384265A0947|89 106|prophylactic effect
P02384265A0947|76 86|possibility
P02384265A0947|5 11|results
P02384265A0947|137 142|cancer
P02384265A0947|46 51|cancer
P02384389A0854|97 105|fed cattle
P02384389A0854|7 11|trend
P02384389A0854|32 38|heifers
P02384389A0854|88 94|seam fat
P02384389A0854|42 43|YG
P02384389A0854|76 85|deposition
P02384389A0854|27 28|YG
P02386485A0554|3 20|nucleotide sequence
P02386485A0554|124 129|bp poly
P02386485A0554|86 87|bp
P02386485A0554|106 111|region
P02386485A0554|133 136|tail
P02386485A0554|74 79|region
P02386485A0554|53 58|region
P02386485A0554|131 131|A
P02386485A0554|64 65|bp
P02386485A0554|33 34|bp
P02386895A0496|0 9|Toxicities
P02386895A0496|102 102|%
P02386895A0496|19 33|nausea/vomiting
P02386895A0496|72 81|tumor sites
P02386895A0496|51 51|%
P02386895A0496|108 119|hypertension
P02386895A0496|54 59|chills
P02386895A0496|85 85|%
P02386895A0496|37 37|%
P02386895A0496|40 47|headache
P02386895A0496|66 69|pain
P02386895A0496|88 98|hypotension
P02386895A0496|123 123|%
P02386895A0496|63 63|%
P02388685A0577|3 9|results
P02388685A0577|218 224|calcium
P02388685A0577|228 244|phosphorus content
P02388685A0577|187 188|CV
P02388685A0577|214 214|%
P02388685A0577|258 262|tibia
P02388685A0577|104 121|bone mineralization
P02388685A0577|163 174|coefficients
P02388685A0577|250 254|femur
P02388685A0577|76 102|alkaline phosphatase activity
P02388685A0577|177 185|variation
P02388685A0577|201 201|%
P02388685A0577|32 57|oyster shell supplementation
P02390538A0000|31 35|weeks
P02390538A0000|80 88|anomalies
P02390538A0000|7 13|infants
P02390538A0000|163 164|mm
P02390538A0000|38 46|gestation
P02390538A0000|94 100|airways
P02390538A0000|136 145|fiberscope
P02390538A0000|147 158|Olympus PF18 S
P02390633T0000|5 16|encephalitis
P02390633T0000|55 61|disease
P02390633T0000|20 26|patient
P02390989A0745|69 82|point mutations
P02390989A0745|37 40|exon
P02390989A0745|131 142|reading frame
P02390989A0745|106 114|stop codon
P02390989A0745|99 100|bp
P02390989A0745|86 94|insertion
P02390989A0745|13 23|counterpart
P02390989A0745|47 53|GPE gene
P02390989A0745|29 35|GPB gene
P02391344T0000|19 22|cDNA
P02391344T0000|79 82|gene
P02391344T0000|9 15|cloning
P02391344T0000|31 59|rat NADH-cytochrome b5 reductase
P02392032A0657|171 181|ambiguities
P02392032A0657|24 27|idea
P02392032A0657|70 80|information
P02392032A0657|107 118|architecture
P02392032A0657|35 43|structure
P02392032A0657|124 132|pore space
P02392032A0657|46 61|relaxation curves
P02392032A0657|3 9|results
P02392032A0657|86 98|distance scale
P02392511T0000|0 28|Serotonin 5-HT2 receptor binding
P02392511T0000|62 67|marker
P02392511T0000|31 44|blood platelets
P02392511T0000|48 52|state
P02392511T0000|84 91|disorder
P02393001A0324|143 149|results
P02393001A0324|39 39|r
P02393001A0324|107 118|densitometry
P02393001A0324|8 10|%BF
P02393001A0324|34 37|BMIs
P02393001A0324|102 104|%BF
P02393001A0324|82 88|obesity
P02393001A0324|69 79|definitions
P02393001A0324|96 99|BMIs
P02393895A0918|60 64|scale
P02393895A0918|207 220|regurgitations
P02393895A0918|243 246|ones
P02393895A0918|97 97|r
P02393895A0918|83 95|insufficiency
P02393895A0918|67 74|severity
P02393895A0918|105 105|p
P02393895A0918|3 10|RF values
P02393895A0918|168 182|differentiation
P02393895A0918|143 149|authors
P02394707A0789|116 120|CCAAT
P02394707A0789|76 89|initiation site
P02394707A0789|122 126|ATTGG
P02394707A0789|50 57|CCAAT box
P02394707A0789|150 168|nucleotide stretches
P02394707A0789|103 113|compliments
P02394707A0789|41 44|GTTA
P02394707A0789|33 39|TATA box
P02394707A0789|0 15|Promoter elements
P02394718A0130|134 150|amino acid sequence
P02394718A0130|9 13|genes
P02394718A0130|37 45|libraries
P02394718A0130|79 104|deoxyoligonucleotide probes
P02394718A0130|48 69|hybridization screening
P02394718A0130|164 169|enzyme
P02395868A0322|42 48|ligands
P02395868A0322|125 131|ligands
P02395868A0322|22 30|zinc sites
P02395868A0322|103 114|hydrogen bond
P02395868A0322|82 87|ligand
P02395868A0322|56 63|sequence
P02395868A0322|3 9|pattern
P02396415T0001|0 6|Results
P02396415T0001|35 43|treatment
P02396415T0001|21 31|observation
P02396415T0001|66 77|hypertension
P02396415T0001|46 53|patients
P02398897A0000|73 82|efficiency
P02398897A0000|10 29|transcription factors
P02398897A0000|85 94|elongation
P02398897A0000|128 136|RNA chains
P02398897A0000|43 55|RNA polymerase
P02399053A0153|42 48|% oxygen
P02399053A0153|63 64|RA
P02399053A0153|26 26|n
P02399053A0153|99 100|RA
P02399053A0153|87 90|life
P02399053A0153|55 61|room air
P02399053A0153|21 24|rats
P02399053A0153|81 84|days
P02399053A1032|41 54|recoil pressure
P02399053A1032|20 30|alveoli/mm2
P02399053A1032|3 4|Lm
P02400070T0000|0 9|Comparison
P02400070T0000|12 19|propofol
P02400070T0000|73 79|therapy
P02400070T0000|23 33|thiopentone
P02400070T0000|47 52|agents
P02400457A0469|215 226|Experiment I.
P02400457A0469|180 190|adjustments
P02400457A0469|154 160|manners
P02400457A0469|51 57|% VO2 max
P02400457A0469|64 70|minutes
P02400457A0469|109 113|women
P02400457A0469|35 47|supine cycling
P02400457A0469|2 11|Experiment
P02400457A0469|83 96|LBNP conditions
P02400457A0469|202 207|phases
P02402678A0463|202 216|mosquito control
P02402678A0463|43 60|% lambdacyhalothrin
P02402678A0463|98 118|aerosol space-spraying
P02402678A0463|21 32|formulations
P02402678A0463|125 139|diesel/kerosene
P02402678A0463|230 244|housefly control
P02402678A0463|170 185|application rates
P02402678A0463|91 93|ULV
P02402678A0463|193 198|g ai/ha
P02402678A0463|221 226|g ai/ha
P02402678A0463|83 87|water
P02402678A0463|38 38|%
P02402678A0463|150 156|fogging
P02403035A0621|68 75|fumarase
P02403035A0621|9 20|reading frame
P02403035A0621|44 52|precursor
P02403634A0788|0 15|Sequence analysis
P02403634A0788|253 280|muscle-CAAT consensus sequence
P02403634A0788|43 45|ATA
P02403634A0788|158 159|bp
P02403634A0788|246 247|bp
P02403634A0788|49 53|GC box
P02403634A0788|207 227|binding site homologies
P02403634A0788|302 308|cap site
P02403634A0788|73 79|domains
P02403634A0788|31 38|addition
P02403634A0788|107 116|regulation
P02403634A0788|59 64|region
P02403634A0788|139 143|genes
P02403634A0788|200 205|factor
P02403634A0788|146 152|CArG box
P02403634A0788|287 288|bp
P02403926A0000|261 266|Groner
P02403926A0000|124 160|trk proto-oncogene receptor kinase domain
P02403926A0000|256 259|S.M.
P02403926A0000|79 94|DNA-transfection
P02403926A0000|209 213|Kozma
P02403926A0000|279 282|N.E.
P02403926A0000|215 218|S.C.
P02403926A0000|249 254|Saurer
P02403926A0000|99 109|NIH3T3 cells
P02403926A0000|273 277|Hynes
P02403926A0000|181 189|amino acid
P02403926A0000|228 233|S.M.S.
P02403926A0000|268 269|B.
P02403926A0000|246 247|F.
P02403926A0000|38 66|breast carcinoma cell line MDA-MB
P02403926A0000|220 226|Redmond
P02403926A0000|3 16|trk-2h oncogene
P02403926A0000|200 207|sequence
P02403926A0000|235 244|Xiao-Chang
P02403926A0307|0 9|Antibodies
P02403926A0307|126 131|serine
P02403926A0307|94 109|kd phosphoprotein
P02403926A0307|145 152|tyrosine
P02403926A0307|182 192|NIH3T3 cells
P02403926A0307|43 80|beta gal-trk receptor kinase fusion protein
P02403926A0307|155 162|extracts
P02403926A0307|133 141|threonine
P02404451A1532|158 171|Cys-118 residue
P02404451A1532|78 85|activity
P02404451A1532|90 96|Cys-118
P02404451A1532|69 74|region
P02404451A1532|223 230|activity
P02404451A1532|192 204|glycosylation
P02404451A1532|104 110|Cys-118
P02404451A1532|132 139|activity
P02404451A1532|15 39|scanning-deletion analysis
P02404451A1532|233 238|GM-CSF
P02405393T0000|43 50|promoter
P02405393T0000|66 76|c-ets-2 gene
P02405393T0000|53 56|ETS2
P02405393T0000|22 37|characterization
P02405589A0000|0 10|Information
P02405589A0000|78 94|drug-use decisions
P02405589A0000|27 42|drug interactions
P02405589A0000|53 63|pharmacists
P02405818A0550|0 14|Branch occlusion
P02405818A0550|107 115|mechanism
P02405818A0550|35 45|perforators
P02405818A0550|26 31|artery
P02405818A0550|85 92|arteries
P02405818A0550|17 23|Heubner
P02405818A0550|118 127|infarction
P02406570A0466|15 19|sites
P02406570A0466|33 38|origin
P02406570A0466|52 54|UAS
P02406570A0466|83 94|test plasmids
P02406570A0898|144 153|activation
P02406570A0898|50 53|ARS1
P02406570A0898|80 83|ABFI
P02406570A0898|18 27|properties
P02406570A0898|123 126|ARS1
P02406570A0898|107 120|DNA replication
P02406570A0898|65 75|possibility
P02406570A0898|30 38|sequences
P02406570A0898|95 104|initiation
P02406570A0898|2 12|examination
P02406992A0192|34 42|disorders
P02406992A0192|105 114|evaluation
P02406992A0192|183 202|carotid artery studies
P02406992A0192|64 77|amaurosis fugax
P02406992A0192|139 149|examination
P02406992A0192|93 101|algorithm
P02406992A0192|151 167|laboratory studies
P02408248A0414|35 40|action
P02408248A0414|53 68|enzyme inhibitors
P02409297A0984|102 115|virus particles
P02409297A0984|10 18|antiserum
P02409297A0984|155 171|HBsAg determinants
P02409297A0984|33 45|fusion protein
P02409297A0984|121 132|polypeptides
P02409297A0984|86 97|polypeptides
P02411513A0667|5 19|characteristics
P02411513A0667|76 80|event
P02411513A0667|104 109|dipole
P02411513A0667|154 163|positivity
P02411513A0667|114 129|dorsal negativity
P02411513A0667|22 28|N22/P22
P02417023T0001|44 52|processes
P02417023T0001|67 79|determination
P02417023T0001|92 100|materials
P02417023T0001|56 61|method
P02417023T0001|6 24|superoxide dismutase
P02417023T0001|0 3|Role
P02417669A0218|177 183|animals
P02417669A0218|73 79|taurine
P02417669A0218|111 120|metabolite
P02417669A0218|38 47|amino acids
P02417669A0218|66 69|acid
P02417669A0218|2 24|maximum photosensitivity
P02417669A0218|136 153|amino acid aspartate
P02417669A0218|100 109|asparagine
P02418701A0000|14 23|likelihood
P02418701A0000|104 118|antigen staining
P02418701A0000|77 85|intensity
P02418701A0000|26 32|tissues
P02418701A0000|64 70|antigen
P02418701A0000|139 146|adenomas
P02418701A0000|185 192|adenomas
P02418701A0000|197 210|diverticulitis
P02418701A0000|168 175|adenomas
P02418701A0000|121 129|specimens
P02418701A0000|153 160|polypoid
P02418701A0000|244 252|technique
P02419327A0998|173 176|side
P02419327A0998|20 22|DNA
P02419327A0998|189 192|site
P02419327A0998|162 164|DNA
P02419327A0998|53 59|enzymes
P02419327A0998|3 17|priming activity
P02419327A0998|96 105|incubation
P02419588A0284|0 1|A.
P02420432A1060|72 78|history
P02420432A1060|36 48|pregnancy test
P02420432A1060|106 121|serum PAPP-A level
P02420432A1060|12 22|conjunction
P02420432A1060|55 61|patient
P02420432A1060|133 141|diagnosis
P02420432A1060|156 164|pregnancy
P02423533A1314|44 48|mRNAs
P02423533A1314|109 112|mRNA
P02423533A1314|80 84|brain
P02423533A1314|152 159|exposure
P02423533A1314|89 93|level
P02423533A1314|162 178|nerve growth factor
P02423533A1314|136 147|rat PC12 cells
P02423533A1314|3 8|levels
P02423533A1790|58 67|chicken DNA
P02423533A1790|45 47|rat
P02423533A1790|104 112|sea urchin
P02423533A1790|79 81|DNA
P02423533A1790|3 7|cDNAs
P02423533A1790|34 42|sequences
P02423533A1790|86 89|frog
P02423773T0001|44 48|blood
P02423773T0001|12 17|method
P02423773T0001|31 38|glycerin
P02423850A0292|0 15|Deletion analysis
P02423850A0292|90 95|region
P02423850A0292|101 113|yeast CYC1 gene
P02423850A0292|56 61|region
P02423850A0292|36 39|part
P02423850A0292|69 76|homology
P02424743A0280|26 34|amplitude
P02424743A0280|64 70|periods
P02424743A0280|8 9|P2
P02424743A0280|3 4|N1
P02427024X0000|0 8|Tolerance
P02427024X0000|143 152|generality
P02427024X0000|11 30|fenfluramine anorexia
P02427024X0000|38 44|fiction
P02427024X0000|52 59|findings
P02427024X0000|32 35|fact
P02427024X0000|169 178|phenomenon
P02427024X0000|80 85|regard
P02427024X0000|66 75|laboratory
P02427024X0000|99 118|fenfluramine anorexia
P02427024X0000|134 140|respect
P02427024X0000|88 96|tolerance
P02427797A0199|113 120|ischemia
P02427797A0199|15 18|limb
P02427797A0199|91 99|blood flow
P02427797A0199|152 160|time point
P02427797A0199|142 145|dogs
P02427797A0199|20 23|tail
P02427797A0199|196 202|lactate
P02427797A0199|4 7|dogs
P02427797A0199|188 194|Ringers
P02427797A0199|228 234|vessels
P02427797A0199|69 74|cavity
P02427797A0199|30 37|pancreas
P02427797A0199|80 88|cessation
P02427797A0199|136 138|min
P02427812A0865|42 47|6-OHDA
P02427812A0865|94 96|rat
P02427812A0865|22 25|view
P02427812A0865|75 88|pressor actions
P02427812A0865|128 133|action
P02427812A0865|30 38|clonidine
P02427812A0865|5 11|results
P02427812A0865|55 62|alpha-MD
P02427869A0939|30 40|sensitivity
P02427869A0939|12 15|beta
P02427869A0939|63 65|BHT
P02431314A0834|14 19|Hansel
P02431314A0834|92 97|Wright
P02431314A0834|64 77|eosinophiluria
P02431314A0834|51 61|recognition
P02436005A0707|71 80|inhibition
P02436005A0707|121 122|Ca
P02436005A0707|107 118|mobilization
P02436005A0707|51 60|nicorandil
P02436005A0707|83 90|Ca influx
P02436005A0707|5 11|results
P02436005A0707|43 48|action
P02437625A0197|103 105|AMD
P02437625A0197|90 101|degeneration
P02437625A0197|64 67|POHS
P02437625A0197|3 7|study
P02437625A0197|19 22|eyes
P02437625A0197|41 62|histoplasmosis syndrome
P02437792T0000|0 9|Comparison
P02437792T0000|77 85|diagnosis
P02437792T0000|12 21|elastase-1
P02437792T0000|26 32|amylase
P02437792T0000|34 39|lipase
P02437792T0000|93 104|pancreatitis
P02437792T0000|56 71|immunoreactivity
P02437895A0000|57 66|engagement
P02437895A0000|206 216|dysarthrics
P02437895A0000|129 134|groups
P02437895A0000|280 287|subjects
P02437895A0000|99 110|language task
P02437895A0000|155 164|hemisphere
P02437895A0000|223 232|hemisphere
P02437895A0000|255 262|patients
P02437895A0000|177 184|aphasics
P02437895A0000|81 91|hemispheres
P02437895A0000|199 204|stroke
P02437895A0000|166 167|LH
P02437895A0000|12 30|potentials procedure
P02437895A0000|1 5|probe
P02437895A0000|234 235|RH
P02437895A0000|144 149|adults
P02438637T0000|0 16|Mucolipidosis type
P02438637T0000|46 52|history
P02438637T0000|28 35|spectrum
P02442837A0060|13 18|groups
P02442837A0060|51 71|calcium channel blocker
P02442837A0060|76 84|verapamil
P02442837A0060|179 193|bypass procedure
P02442837A0060|35 43|dauricine
P02442837A0060|108 128|calcium channel blocker
P02442837A0060|206 212|minutes
P02442837A0060|149 155|minutes
P02442837A0060|196 201|period
P02442837A0060|171 173|end
P02443028A0695|2 7|reflow
P02443028A0695|33 39|percent
P02443028A0695|71 81|reperfusion
P02443028A0695|45 66|muscle microvasculature
P02443924A0083|73 78|cancer
P02443924A0083|93 100|survival
P02443924A0083|7 14|patients
P02444507A0240|0 15|Lysozyme activity
P02444507A0240|65 68|sera
P02444507A0240|83 90|patients
P02445751A0925|70 86|cytochrome oxidase
P02445751A0925|52 56|mRNAs
P02445751A0925|120 123|type
P02445751A0925|130 139|hem2 mutant
P02445751A0925|60 66|subunit
P02445751A0925|39 49|state levels
P02445751A0925|93 103|beta subunit
P02445751A0925|106 113|F1 ATPase
P02445751A0925|16 27|measurements
P02446871A1021|83 90|LSU rRNAs
P02446871A1021|10 18|structure
P02446871A1021|139 141|end
P02446871A1021|114 122|structure
P02446871A1021|94 101|contrast
P02446871A1021|48 53|region
P02446871A1021|149 157|molecules
P02449431A1121|0 18|ATP gamma S inhibition
P02449431A1121|63 68|araATP
P02449431A1121|38 51|concentrations
P02449431A1121|58 61|dATP
P02449431A1121|54 56|ATP
P02449431A1121|72 76|ddATP
P02451872A0391|3 10|recovery
P02451872A0391|21 35|methoxydextrane
P02451872A0391|44 44|%
P02452313A0114|214 215|M.
P02452313A0114|207 207|X
P02452313A0114|184 191|ASL-8123
P02452313A0114|80 98|guinea pig right atria
P02452313A0114|135 142|activity
P02452313A0114|197 197|X
P02452313A0114|168 181|concentrations
P02452313A0114|54 69|blocking activity
P02452313A0114|0 7|ASL-8123
P02452313A0114|160 165|tissue
P02452313A0114|104 106|pA2
P02454390T0000|0 7|Enhancer
P02454390T0000|78 99|alpha 1-fetoprotein gene
P02454390T0000|11 26|promoter elements
P02454390T0000|49 72|glucocorticoid repression
P02454390T0000|36 45|activation
P02454390T0000|102 112|hepatocytes
P02454976A0944|223 227|gyrus
P02454976A0944|166 170|gyrus
P02454976A0944|191 195|areas
P02454976A0944|12 18|results
P02454976A0944|230 237|primates
P02454976A0944|126 134|divisions
P02454976A0944|111 121|possibility
P02454976A0944|39 45|systems
P02454976A0944|94 96|cat
P02454976A0944|21 28|relation
P02454976A0944|84 88|gyrus
P02455821A0099|75 77|map
P02455821A0099|106 113|UL region
P02455821A0099|37 72|AccI-EcoRI restriction fragment mapping
P02455821A0099|119 129|EHV-1 genome
P02455821A0099|150 154|right
P02455821A0099|3 6|gene
P02456827A0899|84 86|TEA
P02456827A0899|32 39|decrease
P02456827A0899|89 91|Ba2
P02456827A0899|12 13|mM
P02456827A0899|52 59|activity
P02456827A0899|3 6|4-AP
P02456827A0899|15 20|effect
P02457922A0991|0 12|Hybridization
P02457922A0991|81 87|tissues
P02457922A0991|166 169|size
P02457922A0991|106 117|2.8-kilobase
P02457922A0991|52 56|blots
P02457922A0991|16 20|probe
P02457922A0991|162 163|kb
P02457922A0991|148 152|bands
P02457922A0991|122 128|message
P02457922A0991|119 120|kb
P02457922A0991|59 62|RNAs
P02457922A0991|29 34|region
P02458080T0000|0 8|Prognosis
P02458080T0000|31 37|myeloma
P02458234T0000|28 35|analysis
P02458234T0000|76 88|EEG recordings
P02458234T0000|38 50|sleep spindles
P02458234T0000|4 9|method
P02458699A0650|0 7|Svensson
P02459309T0000|89 91|rat
P02459309T0000|69 83|caudate-putamen
P02459309T0000|10 16|release
P02459309T0000|117 124|dialysis
P02459309T0000|27 35|serotonin
P02459309T0000|186 194|detection
P02459309T0000|156 169|chromatography
P02459309T0000|60 63|acid
P02461368A0162|97 106|sequencing
P02461368A0162|33 36|time
P02461368A0162|87 93|cloning
P02461368A0162|123 125|DNA
P02461368A0162|109 112|cDNA
P02461368A0162|55 63|structure
P02461368A0162|6 11|report
P02461368A0162|66 78|type X collagen
P02462047A0208|88 91|vein
P02462047A0208|104 106|day
P02462047A0208|6 14|flap areas
P02462047A0208|80 85|artery
P02462047A0208|67 73|vessels
P02462047A0208|112 127|flap replantation
P02462047A0208|47 61|pedicle ligation
P02462047A0208|134 139|island
P02462047A0208|147 151|flaps
P02462305A1071|28 40|glycosylation
P02462305A1071|43 57|phosphorylation
P02462305A1071|93 100|sequence
P02462305A1071|118 128|polypeptide
P02462305A1071|3 17|size discrepancy
P02462305A1071|60 63|Ag35
P02462523A0394|116 124|phenotype
P02462523A0394|63 64|Hw
P02462523A0394|36 45|DNA changes
P02462523A0394|7 23|KpnI-SalI fragment
P02462523A0394|66 74|mutations
P02462523A0394|104 105|su
P02462523A0394|148 170|germ-line transformation
P02462523A0394|107 108|Hw
P02462523A0394|60 61|su
P02463050A0514|86 99|corticosterone
P02463050A0514|125 129|males
P02463050A0514|103 107|level
P02463050A0514|48 52|mg/kg
P02463050A0514|80 83|rise
P02463050A0514|3 44|corticosterone synthesis inhibitor metyrapone
P02464097T0000|121 131|arrhythmias
P02464097T0000|83 90|ischemia
P02464097T0000|12 15|L655
P02464097T0000|45 79|prostaglandin endoperoxide antagonist
P02464097T0000|31 41|thromboxane
P02464097T0000|3 9|effects
P02466414A0000|119 123|steps
P02466414A0000|150 151|ml
P02466414A0000|126 144|exchange transfusion
P02466414A0000|154 159|plasma
P02466414A0000|207 209|mol
P02466414A0000|26 40|plasma viscosity
P02466414A0000|75 88|blood viscosity
P02466414A0000|42 43|Ep
P02466414A0000|222 228|% wt/vol
P02466414A0000|21 24|dogs
P02466414A0000|90 91|Ea
P02466414A0000|164 169|plasma
P02466414A0000|193 205|weight dextran
P02466665A0202|19 25|protein
P02466665A0202|51 55|fluid
P02468795A1086|89 89|r
P02468795A1086|61 71|correlation
P02468795A1086|126 134|parameter
P02468795A1086|14 34|acid phosphatase levels
P02468795A1086|76 87|cancer volume
P02468795A1086|0 4|Serum
P02469451A0239|3 15|investigation
P02469451A0239|77 82|mg dose
P02469451A0239|119 126|subjects
P02469451A0239|88 109|MAO-B inhibitor deprenyl
P02469451A0239|46 52|fashion
P02470955A0101|47 59|CSF AP activity
P02470955A0101|37 44|increase
P02470955A0101|70 81|meningitides
P02470955A0101|5 11|studies
P02470955A0101|97 108|meningitides
P02473156A0000|126 141|adhesion proteins
P02473156A0000|22 50|lymphocyte cell surface molecule
P02473156A0000|118 123|family
P02473156A0000|91 96|member
P02473156A0000|1 4|cDNA
P02473198A0613|0 7|Dopamine
P02473198A0613|54 59|efflux
P02473198A0613|91 96|effect
P02473198A0613|24 38|potassium efflux
P02473198A0613|109 114|glands
P02473198A0613|49 52|86Rb
P02473198A0613|71 76|glands
P02473619A0202|163 171|reactions
P02473619A0202|64 77|control animals
P02473619A0202|40 48|chemicals
P02473619A0202|202 209|exposure
P02473619A0202|52 61|proportion
P02473619A0202|187 194|blockers
P02473619A0202|11 23|sensitization
P02473619A0202|123 135|sensitization
P02473619A0202|138 145|patients
P02473619A0202|220 232|IgE antibodies
P02473693A0174|4 11|approach
P02473693A0174|40 46|protein
P02473693A0174|48 52|HGB F.
P02473718A0000|61 71|metabolites
P02473718A0000|86 98|catecholamine
P02473718A0000|313 317|years
P02473718A0000|35 46|relationship
P02473718A0000|269 276|subjects
P02473718A0000|145 156|T-suppressor
P02473718A0000|304 306|age
P02473718A0000|220 225|female
P02473718A0000|100 105|5-HIAA
P02473718A0000|251 256|stress
P02473718A0000|109 111|VMA
P02473718A0000|210 217|subjects
P02473718A0000|158 161|OKT8
P02473718A0000|193 197|cells
P02473718A0000|280 287|subjects
P02473718A0000|74 82|serotonin
P02473718A0000|138 141|OKT4
P02473718A0000|228 231|male
P02473718A0000|233 235|age
P02473718A0000|129 136|T-helper
P02473718A0000|242 246|years
P02473718A0000|299 302|male
P02473718A0000|114 120|T-cells
P02473718A0000|167 173|B-cells
P02473718A0000|3 15|investigation
P02473718A0000|290 295|female
P02473718A0000|122 125|OKT3
P02473907A1338|164 167|site
P02473907A1338|147 156|Fc epsilon R
P02473907A1338|7 10|C mAb
P02473907A1338|103 106|site
P02473907A1338|22 25|site
P02473907A1338|63 72|Fc epsilon R
P02473907A1338|28 30|IgE
P02473907A1338|80 83|site
P02473907A1338|109 111|IgE
P02473942A1207|16 20|plots
P02473942A1207|65 72|segments
P02473942A1207|99 119|transmembrane segments
P02474093T0000|0 10|Angiotensin
P02474093T0000|115 121|effects
P02474093T0000|21 36|enzyme inhibitors
P02474093T0000|73 81|diuretics
P02474093T0000|63 70|efficacy
P02474110A1039|86 102|inhibitor ramipril
P02474110A1039|37 49|blood pressure
P02474110A1039|26 34|reduction
P02474110A1039|210 225|echocardiography
P02474110A1039|121 130|regression
P02474110A1039|191 206|resonance imaging
P02474110A1039|82 84|ACE
P02474110A1039|158 168|hypertrophy
P02474110A1039|2 9|addition
P02474110A1039|54 64|angiotensin
P02474110A1039|75 80|enzyme
P02474204A0105|27 31|means
P02474204A0105|34 42|Grimelius
P02474204A0105|61 74|immunostaining
P02474204A0105|116 120|cells
P02474204A0105|78 89|chromogranin
P02474204A0105|50 57|staining
P02474204A0105|9 13|cells
P02474204A0105|99 104|marker
P02474356A0559|58 63|N ratio
P02474356A0559|142 152|circulation
P02474356A0559|25 30|tumour
P02474356A0559|125 130|portal
P02474356A0559|49 54|tissue
P02474356A0559|106 117|microspheres
P02474356A0559|10 22|radioactivity
P02474356A0559|3 7|ratio
P02474356A0559|56 56|T
P02474356A0559|159 164|animal
P02475506A0878|3 6|mRNA
P02475506A0878|21 24|cDNA
P02475506A0878|42 73|polymerase chain reaction technique
P02475717A0565|0 13|Tissue necrosis
P02475717A0565|31 58|triphenyltetrazolium staining
P02475717A0565|82 99|baseline predictors
P02475717A0565|145 158|collateral flow
P02475717A0565|122 133|risk zone size
P02475717A0565|102 112|infarct size
P02476030A0000|68 90|laser scanning tomography
P02476030A0000|17 23|surface
P02476030A0000|34 36|eye
P02476030A0000|56 61|states
P02476664A0563|58 59|D.
P02476664A0563|24 31|sequence
P02476664A0563|37 40|gene
P02476664A0563|54 56|K14
P02477373A0930|55 81|transcription initiation site
P02477373A0930|10 16|TATA box
P02477373A0930|28 36|base pairs
P02479635A0659|0 13|Cotransfection
P02479635A0659|51 53|PKI
P02479635A0659|35 42|plasmids
P02479635A0659|22 30|construct
P02479635A0659|97 103|phorbol
P02479635A0659|120 129|expression
P02479823A0727|0 15|Sequence analysis
P02479823A0727|52 58|GC boxes
P02479823A0727|76 82|TATA box
P02479823A0727|31 36|region
P02480419A0735|71 80|hepatitis B
P02480419A0735|88 96|infection
P02480419A0735|13 21|cirrhosis
P02480419A0735|65 65|%
P02480419A0735|112 112|%
P02480419A0735|43 43|%
P02480959A0470|28 38|consequence
P02480959A0470|110 113|days
P02480959A0470|148 160|gonadotropins
P02480959A0470|50 54|surge
P02480959A0470|95 99|cells
P02480959A0470|222 225|cAMP
P02480959A0470|177 186|modulation
P02480959A0470|189 197|prolactin
P02480959A0470|129 132|days
P02480959A0470|4 15|P-450scc mRNA
P02480959A0470|139 145|absence
P02481230A1258|57 64|placenta
P02481230A1258|23 42|bovine alpha transgene
P02481230A1258|77 80|mice
P02481429T0000|6 22|staining technique
P02481429T0000|26 44|Leishmania parasites
P02481429T0000|62 67|smears
P02481779A0213|0 6|NIK-244
P02481779A0213|246 254|mg/kg i.v.
P02481779A0213|189 197|mg/kg i.v.
P02481779A0213|111 121|arrhythmias
P02481779A0213|25 32|ligation
P02481779A0213|282 285|mean
P02481779A0213|54 64|arrhythmias
P02481779A0213|256 267|microgram/ml
P02481779A0213|296 299|mean
P02481779A0213|301 301|n
P02481779A0213|161 169|digitalis
P02481779A0213|215 223|mg/kg i.v.
P02481779A0213|289 290|SD
P02481779A0213|88 107|plasma concentrations
P02481779A0213|150 157|ligation
P02482293A1518|102 104|EGF
P02482293A1518|151 158|activity
P02482293A1518|108 119|phorbol ester
P02482293A1518|40 42|TNF
P02482293A1518|164 171|receptor
P02482293A1518|56 89|EGF-R tyrosine protein kinase activity
P02482293A1518|179 183|cells
P02482293A1518|15 38|T24 bladder carcinoma cells
P02482511A0860|135 152|withdrawal syndrome
P02482511A0860|98 104|stimuli
P02482511A0860|108 117|weight loss
P02482511A0860|67 74|syndrome
P02482511A0860|5 31|phosphodiesterase inhibitors
P02482511A0860|167 176|naltrexone
P02482511A0860|197 200|rats
P02483210A0000|58 64|trypsin
P02483210A0000|48 53|lipase
P02483210A0000|89 109|relapsing pancreatitis
P02483210A0000|13 17|value
P02483210A0000|67 79|exacerbations
P02483210A0000|20 29|blood serum
P02483210A0000|40 46|amylase
P02483438A0498|26 31|action
P02483438A0498|5 9|basis
P02483438A0498|75 101|phosphodiesterase inhibitors
P02483438A0498|36 41|groups
P02483438A0498|120 125|agents
P02483438A0498|15 23|mechanism
P02483438A0498|44 54|inodilators
P02484714T0000|10 21|organization
P02484714T0000|25 34|expression
P02484714T0000|40 60|mouse estrogen receptor
P02484994T0001|11 24|gamma globulins
P02485188A0415|89 103|dermatan sulfate
P02485188A0415|136 136|p
P02485188A0415|220 225|levels
P02485188A0415|81 86|levels
P02485188A0415|49 57|reactions
P02485188A0415|228 246|chondroitin sulfates
P02485188A0415|130 134|group
P02485188A0415|256 263|diabetes
P02485188A0415|193 200|diabetes
P02485188A0415|113 120|diabetes
P02485188A0415|269 273|group
P02485188A0415|275 275|p
P02485188A0415|9 24|chondroitinase AC
P02485188A0415|169 169|p
P02485188A0415|28 39|ABC digestion
P02486634A0632|129 149|collateral development
P02486634A0632|108 117|morphology
P02486634A0632|51 55|level
P02486634A0632|10 18|perfusion
P02486634A0632|85 89|level
P02486634A0632|121 126|degree
P02486634A0632|61 77|contrast injection
P02487898A0315|74 77|ways
P02487898A0315|80 96|NGF administration
P02487898A0315|4 20|NGF administration
P02488148A1156|41 47|program
P02488148A1156|66 74|diagnosis
P02488148A1156|9 15|program
P02488148A1156|89 89|%
P02488148A1156|95 98|time
P02488148A1156|18 20|use
P02488148A1156|26 36|RSNA meeting
P02489032A0000|190 197|VL region
P02489032A0000|54 60|chicken
P02489032A0000|128 139|gene segments
P02489032A0000|25 27|IgL
P02489032A0000|63 75|recombination
P02489032A0000|29 37|diversity
P02489032A0000|19 23|chain
P02489032A0000|125 126|JL
P02489032A0000|111 112|VL
P02489032A0000|0 13|Immunoglobulin
P02489032A0000|102 109|variable
P02489032A0000|160 174|diversification
P02489753A0581|41 51|EMG activity
P02489753A0581|95 102|position
P02489753A0581|54 60|FB group
P02489753A0581|122 128|GF group
P02489753A0581|149 156|position
P02489753A0581|3 9|results
P02489753A0581|117 118|CG
P02489753A0581|139 146|position
P02489895T0001|0 11|Muscle action
P02489895T0001|90 95|adults
P02489895T0001|79 86|children
P02489895T0001|35 40|rhythm
P02489895T0001|70 76|muscles
P02492111A0670|28 41|bone lead values
P02492111A0670|52 55|LXRF
P02492111A0670|19 26|children
P02492111A0670|123 128|adults
P02492111A0670|4 4|%
P02492111A0868|143 148|safety
P02492111A0868|135 140|margin
P02492111A0868|163 168|safety
P02492111A0868|88 94|results
P02492111A0868|45 52|children
P02492111A0868|36 42|effects
P02492111A0868|226 247|blood lead concentration
P02492111A0868|252 264|micrograms/dl
P02492111A0868|188 201|U.S. guidelines
P02492111A0868|68 75|exposure
P02492111A0868|59 64|levels
P02493644A0588|58 62|c-jun
P02493644A0588|43 47|level
P02493644A0588|18 22|jun-D
P02493644A0588|9 16|3T3 cells
P02493644A0588|66 70|jun-B
P02493644A0588|78 90|transcription
P02493644A0588|117 134|serum growth factors
P02495745T0000|15 21|effects
P02495745T0000|62 67|AK-124
P02495745T0000|97 106|thrombosis
P02495745T0000|30 60|tissue-type plasminogen activator
P02496090A0252|13 28|tracheostomy tube
P02496090A0252|5 7|CO2
P02496090A0252|108 124|sampling technique
P02496090A0252|56 71|mass spectrometry
P02496100T0000|43 53|aflatoxin B1
P02496100T0000|26 30|assay
P02496100T0000|100 104|study
P02496100T0000|82 85|feed
P02496100T0000|56 73|cottonseed products
P02496109A0754|262 267|region
P02496109A0754|40 50|transcripts
P02496109A0754|300 310|L17 interval
P02496109A0754|285 289|genes
P02496109A0754|23 31|S1 mapping
P02496109A0754|52 66|gene disruptions
P02496109A0754|155 163|promoters
P02496109A0754|295 297|IF1
P02496109A0754|114 125|fusion vector
P02496109A0754|72 82|alpha region
P02496109A0754|219 226|promoter
P02496109A0754|200 205|growth
P02496109A0754|8 18|experiments
P02496109A0754|233 243|alpha operon
P02497340A0989|84 85|Vk
P02497340A0989|49 50|JH
P02497340A0989|61 71|chain probes
P02497340A0989|54 55|VH
P02497340A0989|91 101|chain probes
P02497340A0989|79 80|Jk
P02497340A0989|20 32|antibody genes
P02498322A0226|100 119|oligonucleotide probe
P02498322A0226|22 30|complexes
P02498322A0226|142 147|region
P02498322A0226|47 66|gel retardation assays
P02498322A0226|72 79|HeLa cell
P02498322A0226|87 94|extracts
P02498652A0460|5 16|transfection
P02498652A0460|26 48|TSH beta promoter activity
P02498652A0460|118 129|cell cultures
P02498652A0460|96 98|GH3
P02500432A1416|84 86|DNA
P02500432A1416|116 122|segment
P02500432A1416|168 174|CAT gene
P02500432A1416|32 44|CAT expression
P02500432A1416|74 81|kilobase
P02500432A1416|158 162|front
P02500432A1416|145 155|orientation
P02500432A1416|96 98|end
P02502096A0462|56 73|excretion processes
P02502096A0462|18 26|blood flow
P02502602A0323|0 8|Tonometry
P02502602A0323|68 86|acid-base quantities
P02502602A0323|107 114|affinity
P02502602A0323|11 22|blood samples
P02502602A0323|27 34|patients
P02502602A0323|53 65|determination
P02502602A0323|119 121|p50
P02502960A0762|8 9|p.
P02504603T0000|0 8|Isolation
P02504603T0000|35 45|CDC group IIf
P02504603T0000|11 25|Weeksella virosa
P02504603T0000|59 64|sample
P02505087A1037|15 37|dimerization specificity
P02505087A1037|66 78|leucine zipper
P02505087A1037|40 42|Fos
P02505087A1037|91 94|GCN4
P02506390T0001|0 5|Growth
P02506390T0001|36 42|animals
P02506390T0001|16 26|anastomoses
P02506740A0742|28 32|hours
P02506740A0742|35 42|recovery
P02506740A0742|81 87|hypoxia
P02506740A0742|66 71|effect
P02506740A0742|98 106|blood flow
P02507523A0791|28 37|competence
P02507523A0791|44 47|ORF2
P02507523A0791|110 119|amino acids
P02507523A0791|98 104|protein
P02507523A0791|3 13|ORF1 product
P02507523A0791|74 77|ORF1
P02507815A0000|70 73|cats
P02507815A0000|26 31|cortex
P02507815A0000|33 34|VC
P02507815A0000|60 67|amygdala
P02507815A0000|0 7|Kindling
P02508306A0528|75 83|carcinoma
P02508306A0528|114 122|follicles
P02508306A0528|8 19|infiltration
P02508306A0528|36 46|plasma cells
P02508306A0528|22 32|lymphocytes
P02508726A0498|30 37|evidence
P02508726A0498|95 102|behavior
P02508726A0498|256 261|agents
P02508726A0498|74 82|treatment
P02508726A0498|230 240|conjunction
P02508726A0498|178 190|neurotoxicity
P02508726A0498|197 206|population
P02508726A0498|166 174|potential
P02508726A0498|42 46|LiCO3
P02508726A0498|131 141|brain injury
P02508726A0498|59 68|medication
P02508726A0498|5 15|case reports
P02508726A0498|115 125|instability
P02509123A0371|55 57|VEP
P02509123A0371|37 49|P100 component
P02509123A0371|25 31|latency
P02509123A0371|18 20|IFN
P02509123A0371|5 12|sessions
P02509123A0371|82 99|baseline conditions
P02510242A0313|87 92|search
P02510242A0313|173 177|tests
P02510242A0313|31 39|hepatitis
P02510242A0313|192 198|viruses
P02510242A0313|8 12|cases
P02510242A0313|131 137|viruses
P02510242A0313|96 100|HBs Ag
P02510242A0313|54 68|hepatitis B virus
P02510242A0313|209 211|CMV
P02511069A0532|15 23|mutations
P02511069A0532|90 91|3L
P02511069A0532|136 158|polytene chromosome bands
P02511069A0532|111 119|DRE region
P02511069A0532|93 95|RR2
P02511069A0532|76 84|lethality
P02511069A0532|98 105|deletion
P02511069A0532|45 51|failure
P02511069A0532|87 88|Df
P02511150T0025|7 12|status
P02511150T0025|22 33|perspectives
P02511207A0282|0 1|K.
P02511430A0000|146 152|factors
P02511430A0000|18 23|region
P02511430A0000|56 81|immunoglobulin gene enhancer
P02511430A0000|108 114|binding
P02511430A0000|29 37|mouse MOPC
P02511430A0000|40 44|kappa
P02511430A0000|15 16|bp
P02511898A0000|46 58|Chagas disease
P02511898A0000|20 26|reasons
P02511898A0000|30 38|countries
P02511898A0000|93 100|research
P02511898A0000|4 8|paper
P02512010A0801|86 91|return
P02512010A0801|36 46|compression
P02512010A0801|105 115|circulation
P02512010A0801|59 65|success
P02512010A0801|68 81|defibrillation
P02512010A0801|3 19|PETCO2 measurement
P02514498A0000|160 180|Henderson-Hasselbalch
P02514498A0000|7 14|CO2/HCO3
P02514498A0000|63 75|acid secretion
P02514498A0000|182 185|pCO2
P02514498A0000|78 82|intra
P02514498A0000|201 203|use
P02514498A0000|122 128|persons
P02514498A0000|210 218|electrode
P02514498A0000|51 60|inhibition
P02514498A0000|150 157|equation
P02514498A0000|99 117|pCO2/pH measurements
P02514498A0000|30 36|absence
P02515953A0459|42 54|effectiveness
P02515953A0459|22 22|%
P02515953A0459|9 13|study
P02515953A0459|30 37|patients
P02517008A0481|28 32|trial
P02517008A0481|48 52|doses
P02517008A0481|8 15|patients
P02517008A0481|55 65|monotherapy
P02518645T0001|61 64|life
P02518645T0001|8 20|Chagas disease
P02518645T0001|55 58|year
P02518645T0001|22 40|laboratory diagnosis
P02518691A0251|188 197|regulation
P02518691A0251|155 168|kappa B enhancer
P02518691A0251|12 38|IL2R alpha promoter constructs
P02518691A0251|65 80|DNA binding assays
P02518691A0251|200 222|IL2R alpha gene expression
P02518691A0251|50 61|transfection
P02518691A0251|102 110|sequences
P02519327T0001|11 20|rheumatism
P02519679T0000|0 9|Inefficacy
P02519679T0000|12 30|phosphine fumigation
P02519679T0000|38 42|ticks
P02520622A0200|90 97|symptoms
P02520622A0200|144 150|placebo
P02520622A0200|193 203|group design
P02520622A0200|65 76|transit times
P02520622A0200|155 159|month
P02520622A0200|5 12|patients
P02520622A0200|114 131|cimetropium bromide
P02520622A0200|134 141|mg t.d.s.
P02521217A1035|44 51|ribosome
P02521217A1035|55 71|membrane fractions
P02521217A1035|24 30|protein
P02521217A1035|74 85|mitochondria
P02521674T0000|0 6|Mapping
P02521674T0000|97 100|nsP4
P02521674T0000|50 54|virus
P02521674T0000|9 11|RNA
P02521674T0000|56 83|complementation group F mutants
P02521674T0000|34 40|mutants
P02521674T0000|88 94|lesions
P02522297A0000|28 31|TXA2
P02522297A0000|34 76|prostaglandin endoperoxide receptor antagonist
P02522297A0000|147 150|dogs
P02522297A0000|78 79|SQ
P02522297A0000|14 26|thromboxane A2
P02522297A0000|3 8|effect
P02522297A0000|102 109|ischemia
P02523800A1178|150 161|BAR1 promoter
P02523800A1178|36 43|CHS1 gene
P02523800A1178|172 173|J.
P02523800A1178|79 102|TGAAACA consensus sequence
P02523800A1178|23 30|sequence
P02523800A1178|69 75|repeats
P02523800A1178|49 56|fragment
P02523800A1178|163 170|Kronstad
P02525044A1026|60 67|patients
P02525044A1026|108 120|suxamethonium
P02525044A1026|79 88|mivacurium
P02525044A1026|33 40|infusion
P02525044A1026|17 23|T25-T75
P02525044A1026|3 15|recovery index
P02526165X0000|3 6|sign
P02526165X0000|9 20|Leser-Trelat
P02526165X0000|37 40|sign
P02526165X0000|108 117|malignancy
P02526165X0000|92 97|marker
P02526165X0000|43 54|Leser-Trelat
P02527365T0000|0 13|Xenopus homolog
P02527365T0000|54 64|fibroblasts
P02527365T0000|75 84|maturation
P02527365T0000|19 34|mos protooncogene
P02527365T0000|87 100|Xenopus oocytes
P02527745A0865|0 19|Southern blot analyses
P02527745A0865|66 69|gene
P02527745A0865|73 84|conservation
P02527745A0865|104 114|vertebrates
P02527745A0865|91 96|domain
P02527745A0865|49 58|copy number
P02528329A0000|144 150|subunit
P02528329A0000|153 156|gene
P02528329A0000|139 142|uncB
P02528329A0000|22 28|subunit
P02528329A0000|50 60|F1F0-ATPase
P02528329A0000|5 19|missense mutants
P02528329A0000|94 117|hydroxylamine mutagenesis
P02528329A0000|121 127|plasmid
P02528730A1073|70 72|use
P02528730A1073|21 25|share
P02528730A1073|86 101|donor splice sites
P02528730A1073|35 42|sequence
P02528730A1073|9 15|exons 2a
P02528730A1073|105 106|bp
P02528730A1073|117 120|gene
P02529378A0536|0 17|S1 nuclease analysis
P02529378A0536|188 194|element
P02529378A0536|20 22|RNA
P02529378A0536|150 156|portion
P02529378A0536|128 135|enhancer
P02529378A0536|102 111|adenovirus
P02529378A0536|137 139|SP1
P02529378A0536|141 144|TATA
P02529378A0536|72 80|HeLa cells
P02529378A0536|253 258|HIV LTR
P02529378A0536|238 247|activation
P02529378A0536|36 47|transfection
P02529378A0536|55 67|HIV constructs
P02530413A0195|2 15|supine position
P02530413A0195|55 59|pg/ml
P02530413A0195|74 78|level
P02530413A0195|92 96|pg/ml
P02530413A0195|44 48|pg/ml
P02530413A0195|17 31|plasma ANP levels
P02530470A0604|83 86|area
P02530470A0604|10 19|prevalence
P02530470A0604|46 57|staff members
P02530470A0604|22 31|HBV markers
P02530470A0604|67 77|blood donors
P02531203A0241|98 106|SSTS model
P02531203A0241|49 57|responses
P02531203A0241|12 22|predictions
P02531203A0241|71 79|negatives
P02532032A0385|0 19|Plasma concentrations
P02532032A0385|32 42|aldosterone
P02532032A0385|51 55|renin
P02532032A0385|22 24|ANF
P02532032A0385|26 29|pANF
P02532032A0385|57 59|PRC
P02532032A0385|96 105|parameters
P02532032A0385|44 46|PAC
P02532210A0000|28 34|protein
P02532210A0000|3 19|adenovirus E1A gene
P02532210A0000|75 79|genes
P02534067A0316|0 13|Administration
P02534067A0316|16 28|dexamethasone
P02534067A0316|257 267|alpha OH DHEA
P02534067A0316|231 245|etiocholanolone
P02534067A0316|72 90|alpha OH progesterone
P02534067A0316|127 141|androstenedione
P02534067A0316|186 194|excretion
P02534067A0316|212 229|beta OH androsterone
P02534067A0316|114 125|DHEA sulphate
P02534067A0316|64 69|plasma
P02534067A0316|145 156|testosterone
P02534067A0316|197 208|androsterone
P02534067A0316|247 250|DHEA
P02534067A0316|94 112|beta-desoxycortisol
P02534067A0316|57 61|rises
P02535460A1443|0 13|RNA transcripts
P02535460A1443|49 52|gene
P02536096A0327|221 256|chloramphenicol acetyltransferase gene
P02536096A0327|181 203|thymidine kinase promoter
P02536096A0327|2 10|HeLa cells
P02536096A0327|66 88|thymidine kinase promoter
P02536096A0327|157 167|orientation
P02536096A0327|23 35|transcription
P02536096A0327|43 64|herpes simplex virus type
P02536096A0327|263 270|sequence
P02536096A0327|100 135|chloramphenicol acetyltransferase gene
P02536160A0518|144 151|sequence
P02536160A0518|90 102|CAT expression
P02536160A0518|122 128|pUTKAT1
P02536160A0518|110 119|TK promoter
P02536160A0518|166 176|orientation
P02536160A0518|22 30|condition
P02536160A0518|47 54|sequence
P02536160A0518|32 36|Ren1d
P02536160A0518|60 75|sense orientation
P02537441A0231|0 3|None
P02537441A0231|68 75|globulin
P02537441A0231|88 94|disease
P02537441A0231|46 61|varicella-zoster
P02537441A0231|30 35|duties
P02537485A0841|86 90|mg/kg
P02537485A0841|135 138|dose
P02537485A0841|5 16|formalin test
P02537485A0841|106 122|morphine analgesia
P02537485A0841|26 33|naloxone
P02537485A0841|142 146|mg/kg
P02537485A0841|71 75|doses
P02537485A0841|44 60|morphine analgesia
P02538450A0000|28 35|rat brain
P02538450A0000|78 99|Na,K-ATPase beta subunit
P02538450A0000|66 72|isoform
P02538450A0000|44 48|liver
P02538450A0000|14 23|cDNA clones
P02538656A0172|56 63|R regions
P02538656A0172|74 79|mutant
P02538656A0172|120 139|transforming activity
P02538656A0172|172 177|genome
P02538656A0172|52 52|M
P02538656A0172|142 155|mouse C127 cells
P02538656A0172|103 108|region
P02538656A0172|27 35|E1 mutants
P02538720A0582|0 3|UbiA
P02538720A0582|71 77|introns
P02538720A0582|93 100|sequence
P02538720A0582|26 43|polyubiquitin genes
P02541251A1327|40 44|sites
P02541251A1327|192 197|T1 gene
P02541251A1327|9 14|T2 gene
P02541251A1327|101 114|CCAAT sequences
P02541251A1327|136 138|end
P02541251A1327|67 88|transcription factor SP1
P02541251A1327|95 98|TATA
P02541251A1327|159 166|features
P02541882A0251|0 15|Radiation therapy
P02541882A0251|52 61|metastasis
P02541882A0251|72 79|patients
P02542194A1496|83 94|astrocytomas
P02542194A1496|113 123|ependymomas
P02542194A1496|55 65|irradiation
P02542194A1496|24 31|patients
P02542194A1496|5 11|results
P02542194A1496|140 147|survival
P02542194A1496|72 76|grade
P02542270A0000|100 120|C4 photosynthesis genes
P02542270A0000|26 40|chloroplast DNAs
P02542270A0000|167 174|greening
P02542270A0000|141 154|mesophyll cells
P02542270A0000|126 137|bundle sheath
P02542270A0000|88 97|expression
P02542270A0000|189 193|maize
P02542270A0000|3 13|methylation
P02542270A0000|58 65|relation
P02542612A0530|0 17|S1 nuclease analysis
P02542612A0530|61 69|Vero cells
P02542612A0530|20 22|RNA
P02542612A0530|123 138|Z transactivation
P02542612A0530|183 196|RNA transcripts
P02542612A0530|112 112|Z
P02542612A0530|44 53|B95-8 cells
P02542612A0530|151 155|level
P02542612A0530|87 108|NotI repeat promoter-CAT
P02543226A1559|87 108|adipose tissue component
P02543226A1559|190 197|sampling
P02543226A1559|20 29|likelihood
P02543226A1559|124 137|breast biopsies
P02543226A1559|182 187|method
P02543226A1559|211 224|breast biopsies
P02543226A1559|255 261|maximum
P02543226A1559|328 333|tissue
P02543226A1559|281 290|parenchyma
P02543226A1559|266 271|blocks
P02543226A1559|298 301|case
P02543226A1559|373 383|hyperplasia
P02543226A1559|41 49|carcinoma
P02543226A1559|354 362|carcinoma
P02543226A1559|401 406|blocks
P02543226A1559|60 70|hyperplasia
P02543621A0788|0 7|Analysis
P02543621A0788|48 52|Wilms
P02543621A0788|22 26|cases
P02543621A0788|74 80|changes
P02543621A0788|99 121|translocation breakpoint
P02543621A0788|141 144|gene
P02543621A0788|54 58|tumor
P02543621A0788|13 15|DNA
P02543679A1291|68 71|DnaJ
P02543679A1291|116 126|propagation
P02543679A1291|75 95|DnaK heat shock proteins
P02543679A1291|35 41|lambda O
P02543679A1291|107 110|role
P02543679A1291|45 55|P initiators
P02543679A1291|129 145|lambda replication
P02543679A1291|13 20|evidence
P02543734A0414|85 106|IE1/2 enhancer/promoter
P02543734A0414|42 53|bp repeat unit
P02543734A0414|143 152|expression
P02543734A0414|109 128|cotransfection assays
P02543734A0414|9 24|oligonucleotides
P02543734A0414|72 79|activity
P02544059A0377|0 6|Effects
P02544059A0377|42 44|PHe
P02544059A0377|9 16|nitrogen
P02544059A0377|35 40|helium
P02544059A0377|18 20|PN2
P02544059A0377|53 55|MPa
P02544059A0377|28 30|MPa
P02545357A0000|3 29|mustard chloroplast gene rps16
P02545357A0000|60 65|intron
P02545357A0000|44 50|bp group
P02545903A0639|71 74|NS3A
P02545903A0639|35 46|immunization
P02545903A0639|65 67|NS3
P02545903A0639|49 52|mice
P02545903A0639|92 99|BHK cells
P02545903A0639|30 32|NS3
P02545903A0639|116 135|BTV-10 virus particles
P02545903A0639|0 9|Antibodies
P02546234A1382|59 65|efforts
P02546234A1382|26 36|tachycaydia
P02546234A1382|101 107|outcome
P02547079A0910|29 48|hyperparathyroidemia
P02547079A0910|11 24|calcium balance
P02547079A0910|92 93|Cd
P02547079A0910|136 142|calcium
P02547079A0910|125 133|excretion
P02547079A0910|76 89|administration
P02547611A0318|0 6|Clone 4c
P02547611A0318|48 55|clone 22c
P02547611A0318|12 13|bp
P02547611A0318|78 83|intron
P02547611A0318|89 90|bp
P02547611A0318|25 30|region
P02547706A0928|100 105|CMV-IP
P02547706A0928|70 83|classification
P02547706A0928|109 111|IIP
P02547706A0928|22 24|IHC
P02547706A0928|86 95|pneumonias
P02547706A0928|3 13|application
P02547706A0928|16 18|ISH
P02547706T0001|0 7|Validity
P02547706T0001|147 171|bone marrow transplantation
P02547706T0001|10 24|immunohistology
P02547706T0001|64 72|diagnosis
P02547706T0001|124 132|pneumonia
P02547706T0001|34 46|hybridization
P02547706T0001|75 98|cytomegalovirus pneumonia
P02547778A0786|97 106|expression
P02547778A0786|53 67|control elements
P02547778A0786|34 37|ANT1
P02547778A0786|9 14|nature
P02547778A0786|18 28|arrangement
P02548683T0001|31 38|Shanghai
P02548683T0001|46 55|hepatitis A
P02548683T0001|22 28|seminar
P02548683T0001|6 12|account
P02549036A0000|191 200|properties
P02549036A0000|30 38|repressor
P02549036A0000|156 160|order
P02549036A0000|143 153|homogeneity
P02549036A0000|86 92|protein
P02549036A0000|3 26|Bacillus subtilis phage phi
P02549036A0000|41 46|lambda
P02549343A1008|117 121|cells
P02549343A1008|245 251|rabbits
P02549343A1008|275 279|virus
P02549343A1008|98 100|gpI
P02549343A1008|17 19|gpI
P02549343A1008|188 193|weight
P02549343A1008|340 349|complement
P02549343A1008|48 51|mO74
P02549343A1008|227 234|antibody
P02549343A1008|288 307|neutralizing activity
P02549343A1008|31 35|cells
P02549343A1008|67 81|characteristics
P02549343A1008|141 166|immunoprecipitation pattern
P02549343A1008|316 323|reaction
P02549343A1008|200 210|polypeptide
P02549343A1008|2 12|consequence
P02549417A0000|37 45|parasites
P02549417A0000|12 17|stages
P02549417A0000|53 73|acristate mitochondria
P02549417A0000|79 87|functions
P02550118A0610|57 60|days
P02550118A0610|33 45|infiltrations
P02550682A0411|57 59|IIc
P02550682A0411|23 38|type IIc carcinoma
P02550682A0411|11 19|incidence
P02550682A0411|46 46|%
P02550682A0411|75 75|%
P02550682A0411|64 67|type
P02551886A0332|0 14|Restriction maps
P02551886A0332|26 33|plasmids
P02551886A0332|91 99|fragments
P02551886A0332|62 68|inserts
P02552143A0748|0 2|VP5
P02552143A0748|24 36|capsid protein
P02552143A0748|52 87|chloramphenicol acetyltransferase gene
P02552316A0526|69 73|woman
P02552316A0526|62 65|days
P02552316A0526|26 35|caretakers
P02552316A0526|125 131|percent
P02552316A0526|103 120|seroconversion rate
P02552316A0526|50 56|average
P02554310A0419|2 9|contrast
P02554310A0419|49 54|region
P02554310A0419|75 80|effect
P02554310A0419|19 26|fragment
P02555177A0488|14 17|LEU2
P02555177A0488|150 165|COX1 mRNA splicing
P02555177A0488|7 11|pet54
P02555177A0488|124 141|COX3 gene expression
P02555177A0488|78 96|COX1 introns aI5 alpha
P02555177A0488|168 182|mRNA translation
P02555177A0488|59 64|genome
P02555177A0488|100 106|aI5 beta
P02555418A0973|0 6|Insert2
P02555418A0973|39 47|sequences
P02555418A0973|67 74|sequence
P02555519A0798|131 142|conservation
P02555519A0798|112 119|H-chains
P02555519A0798|63 94|complementarity determining region
P02555519A0798|29 34|length
P02555519A0798|148 164|D-region structure
P02555519A0798|45 52|sequence
P02555519A0798|96 103|peptides
P02555519A0798|203 215|hapten binding
P02555519A0798|17 26|variations
P02555519A0798|58 61|CDR3
P02555703T0000|0 22|Tyrosine kinase oncogenes
P02555703T0000|81 97|signaling pathways
P02555703T0000|177 181|v-abl
P02555703T0000|69 73|cells
P02555703T0000|107 111|c-myc
P02555703T0000|136 153|c-myc transcription
P02555703T0000|124 133|regulation
P02555703T0000|31 53|interleukin-3 dependence
P02556264A0278|114 118|cells
P02556264A0278|167 181|cell specificity
P02556264A0278|39 49|kappa B motif
P02556264A0278|57 74|kappa chain enhancer
P02556264A0278|4 16|TC-II enhanson
P02556264A0278|187 197|kappa B motif
P02556269A0187|87 102|hypersensitivity
P02556269A0187|246 256|topoisomers
P02556269A0187|127 134|nuclease
P02556269A0187|33 45|13mer sequence
P02556269A0187|159 165|plasmid
P02556269A0187|3 10|DNA helix
P02556269A0187|190 192|DNA
P02556269A0187|226 243|gel electrophoresis
P02556603A0606|104 117|bile duct cancer
P02556603A0606|19 29|improvement
P02556603A0606|65 70|cancer
P02556603A0606|72 88|gallbladder cancer
P02557217A0000|0 13|Beta-endorphin
P02557217A0000|22 38|cortisol secretion
P02557217A0000|108 125|IU salmon calcitonin
P02557217A0000|86 104|spray administration
P02557217A0000|71 75|males
P02557217A0000|15 18|ACTH
P02557217A0398|3 6|data
P02557217A0398|51 58|increase
P02557217A0398|80 109|corticotrophin-cortisol release
P02557217A0398|19 28|calcitonin
P02557350A0632|43 49|SRP54sp
P02557350A0632|77 84|SRP54mam
P02557350A0632|65 65|%
P02557350A0632|22 29|proteins
P02557350A0632|3 14|DNA sequences
P02557350A0632|33 39|SRP54sc
P02557350A0632|59 59|%
P02559630A0270|15 20|values
P02559630A0270|50 68|thromboplastin times
P02559630A0270|130 165|fibrin/fibrinogen degradation products
P02559630A0270|70 85|prothrombin times
P02559630A0270|101 110|fibrinogen
P02559630A0270|112 125|platelet counts
P02559630A0270|87 99|thrombin times
P02560415T0012|14 18|tumor
P02560415T0012|35 39|mouth
P02560415T0012|23 32|metastasis
P02560415T0012|47 57|face regions
P02560415T0012|41 43|jaw
P02562787A0637|19 25|protein
P02562787A0637|40 43|CNBP
P02562787A0637|35 37|NBP
P02562825A0413|0 13|Responsiveness
P02562825A0413|55 60|agents
P02562825A0413|62 62|p
P02562825A0413|16 35|beta-2 agonist therapy
P02565405T0000|0 6|Drug use
P02565405T0000|9 21|trauma victims
P02565683A0841|71 79|instances
P02565683A0841|108 118|tachycardia
P02565683A0841|9 17|heart rate
P02565683A0841|82 90|reentrant
P02565683A0841|140 150|tachycardia
P02565683A0841|46 50|state
P02565807A1198|14 30|neu proto-oncogene
P02565807A1198|2 9|contrast
P02565807A1198|69 78|properties
P02565807A1198|122 129|ABSTRACT
P02565807A1198|109 119|NIH 3T3 cells
P02565807A1198|144 148|WORDS
P02565807A1198|41 54|kinase activity
P02565807A1198|101 106|levels
P02566613A0831|60 62|CRE
P02566613A0831|64 71|TGACGTCA
P02566613A0831|51 58|enhancer
P02566613A0831|8 15|sequence
P02566613A0831|73 83|nucleotides
P02566613T0000|0 25|Somatostatin gene expression
P02566613T0000|38 47|islet cells
P02566613T0000|105 112|proteins
P02566613T0000|73 90|DNA control elements
P02566680A0820|121 125|doses
P02566680A0820|195 195|%
P02566680A0820|53 63|I-methadone
P02566680A0820|178 190|response rates
P02566680A0820|2 9|contrast
P02566680A0820|67 77|levorphanol
P02566680A0820|139 143|times
P02566680A0820|88 88|%
P02566680A0820|27 42|agonists fentanyl
P02566680A0820|44 51|morphine
P02567030A0482|30 43|discrimination
P02567030A0482|48 55|controls
P02567030A0482|71 80|difficulty
P02567030A0482|99 106|reversal
P02568930T0000|0 8|Isolation
P02568930T0000|52 59|cytokine
P02568930T0000|12 27|characterization
P02568930T0000|76 86|stimulation
P02568930T0000|93 104|CD2 structure
P02568930T0000|112 123|T lymphocytes
P02568930T0000|31 34|cDNA
P02569411A0151|18 27|medication
P02569411A0151|5 15|termination
P02569411A0151|66 80|nucleus amygdala
P02569411A0151|31 37|animals
P02571924A0000|14 24|mating type A
P02571924A0000|122 134|undecapeptide
P02571924A0000|82 96|mating pheromone
P02571924A0000|7 11|cells
P02571924A0000|168 182|carboxy terminus
P02571924A0000|98 111|rhodotorucine A
P02571924A0000|45 73|yeast Rhodosporidium toruloides
P02571924A0000|145 162|S-farnesyl cysteine
P02572777T0000|0 19|Tumour necrosis factor
P02572777T0000|39 54|distress syndrome
P02572928T0000|0 9|Monitoring
P02572928T0000|22 30|arthritis
P02573303A0000|29 30|LV
P02573303A0000|72 79|pressure
P02573303A0000|81 84|PEEP
P02573303A0000|112 113|LV
P02573303A0000|3 10|decrease
P02573303A0000|134 149|contractile state
P02573303A0000|32 43|stroke volume
P02573336A0000|117 121|event
P02573336A0000|164 172|magnitude
P02573336A0000|145 150|retest
P02573336A0000|32 34|ROF
P02573336A0000|74 81|subjects
P02573336A0000|178 180|ROF
P02573336A0000|2 11|experiment
P02573336A0000|53 57|snake
P02573336A0000|84 88|order
P02573829T0000|45 49|sites
P02573829T0000|92 108|transcription unit
P02573829T0000|124 139|segmentation gene
P02573829T0000|12 23|conservation
P02573829T0000|58 66|sequences
P02573836A0244|87 90|mdr1
P02573836A0244|21 30|importance
P02573836A0244|104 125|amino acid substitutions
P02573836A0244|155 171|nucleotide binding
P02573836A0244|38 40|NBS
P02573836A0244|53 75|drug resistance phenotype
P02573836A0244|173 178|GXGKST
P02573836A0244|131 151|core consensus sequence
P02574016A0428|129 135|infants
P02574016A0428|139 146|children
P02574016A0428|105 110|adults
P02574016A0428|52 63|control value
P02574016A0428|90 102|micrograms/kg
P02574016A0428|114 126|micrograms/kg
P02574016A0428|49 49|%
P02574016A0428|65 75|neostigmine
P02574016A0428|20 22|TOF
P02574052A0910|45 58|Type A behaviour
P02574052A0910|62 86|beta-adrenoceptor blockade
P02574052A0910|13 23|differences
P02574052A0910|35 42|relation
P02574193A0663|0 8|Selection
P02574193A0663|16 20|items
P02574193A0663|139 146|baseline
P02574193A0663|186 193|subjects
P02574193A0663|236 243|diazepam
P02574193A0663|80 85|CIWA-B
P02574193A0663|158 174|withdrawal periods
P02574193A0663|204 211|symptoms
P02574193A0663|34 78|Institute Withdrawal Assessment-Benzodiazepines
P02574193A0663|226 232|placebo
P02574193A0663|254 261|subjects
P02574193A0663|121 131|differences
P02574193A0663|296 313|regression analysis
P02574193A0663|268 284|contingency tables
P02574551T0000|0 13|Antihistamines
P02574551T0000|16 21|asthma
P02575174A0229|144 160|airflow limitation
P02575174A0229|46 54|doxazosin
P02575174A0229|81 85|alpha
P02575174A0229|87 93|blocker
P02575174A0229|38 43|safety
P02575174A0229|27 34|efficacy
P02575174A0229|97 104|patients
P02575174A0229|117 128|hypertension
P02575490A1021|0 19|Northern blot analysis
P02575490A1021|95 105|transcripts
P02575490A1021|36 52|oIGF-I transcripts
P02575490A1021|76 86|nucleotides
P02575490A1021|61 64|band
P02575490A1021|123 128|weight
P02575490A1021|131 135|liver
P02575567T0001|59 63|wires
P02575567T0001|0 22|Materials science studies
P02575959A0643|53 58|values
P02575959A0643|87 88|T2
P02575959A0643|20 39|lactate concentration
P02575959A0643|78 85|training
P02575959A0643|3 13|latency time
P02576405A0223|134 141|platinum
P02576405A0223|34 42|therapies
P02576405A0223|172 179|patients
P02576405A0223|169 169|%
P02576405A0223|116 126|EDAP regimen
P02576405A0223|84 110|cyclophosphamide-BCNU-VP-16
P02576405A0223|58 66|melphalan
P02576405A0223|21 23|VAD
P02576405A0223|128 132|VP-16
P02576405A0223|69 82|CBV combination
P02576405A0223|151 159|responses
P02576405A0223|2 9|patients
P02577458A0412|122 139|calcium antagonists
P02577458A0412|48 58|angiotensin
P02577458A0412|39 43|drugs
P02577458A0412|3 12|discussion
P02577458A0412|69 84|enzyme inhibitors
P02577458A0412|102 117|receptor blockers
P02577867T0000|28 39|oncogene jun.
P02577867T0000|16 22|homolog
P02580830A1131|112 117|region
P02580830A1131|7 14|sequence
P02580830A1131|123 134|mouse AFP gene
P02580830A1131|49 55|cap site
P02580830A1131|66 72|AFP gene
P02580830A1131|30 35|region
P02580830A1131|81 91|% similarity
P02582240A1009|102 111|initiation
P02582240A1009|37 54|RNA primer synthesis
P02582240A1009|81 93|ATP/GTP ratios
P02582240A1009|25 34|initiation
P02582240A1009|60 69|dCTTT sites
P02582240A1009|4 16|ATP/GTP ratios
P02582240A1009|117 125|dCCC sites
P02582918A0000|85 92|anti-HBs
P02582918A0000|176 176|%
P02582918A0000|185 186|T0
P02582918A0000|162 162|%
P02582918A0000|182 183|T2
P02582918A0000|156 156|%
P02582918A0000|179 180|T1
P02582918A0000|104 106|S/N
P02582918A0000|123 124|T0
P02582918A0000|76 80|cases
P02582918A0000|190 192|T12
P02582918A0000|108 119|S/N Ratio Unit
P02582918A0000|35 55|serum antibody response
P02582918A0000|68 71|type
P02582918A0000|145 148|rate
P02582918A0000|5 33|hepatitis B vaccine immunization
P02582918A0000|168 168|%
P02584969A0119|15 20|design
P02584969A0119|94 101|end point
P02584969A0119|105 105|%
P02584969A0119|110 123|protection time
P02584969A0119|68 77|treatments
P02584969A0119|42 56|regression model
P02585492A1005|85 95|parB mutants
P02585492A1005|103 112|P1 proteins
P02585492A1005|13 32|complementation tests
P02585492A1005|46 55|P7 proteins
P02585492A1005|77 82|P1 parA
P02585492A1005|132 142|P7 mutations
P02586485A0511|0 4|GN101
P02586485A0511|6 12|YC819-9
P02586485A0511|17 19|SB3
P02586513A0622|0 7|Analysis
P02586513A0622|244 258|consensus Tyr Ser
P02586513A0622|64 71|identity
P02586513A0622|165 177|amino terminus
P02586513A0622|132 139|presence
P02586513A0622|271 273|Ser
P02586513A0622|228 236|heptamers
P02586513A0622|34 45|ama-1 product
P02586513A0622|86 92|subunit
P02586513A0622|95 98|RNAP
P02586513A0622|110 118|organisms
P02586513A0622|200 205|domain
P02586513A0622|262 267|Thr Ser
P02586513A0622|143 157|zinc finger motif
P02590097A0093|129 131|IgA
P02590097A0093|134 142|Type Kappa
P02590097A0093|7 17|involvement
P02590097A0093|34 45|infiltration
P02590097A0093|51 56|mucosa
P02590097A0093|71 82|lobe bronchus
P02590097A0093|118 127|gammopathy
P02590097A0093|27 30|lung
P02590391A0442|0 3|None
P02590391A0442|144 156|sphingomyelin
P02590391A0442|50 55|lipids
P02590391A0442|186 202|phospholipid class
P02590391A0442|76 94|phosphatidylcholine
P02590391A0442|165 179|acid composition
P02590391A0442|62 74|phospholipids
P02590391A0442|121 142|diphosphatidylglycerol
P02590391A0442|17 26|parameters
P02590391A0442|230 236|grading
P02590391A0442|28 40|heart contents
P02590391A0442|96 119|phosphatidylethanolamine
P02590391A0442|242 248|lesions
P02590540A0741|69 72|U/ml
P02590540A0741|51 56|levels
P02590540A0741|79 79|%
P02590540A0741|46 47|CA
P02590540A0741|5 9|women
P02590540A0741|59 64|excess
P02590540A0741|27 35|diagnoses
P02590540A0741|41 41|%
P02590540A0741|94 97|U/ml
P02590615A0636|44 47|meal
P02590615A0636|22 26|state
P02590615A0636|89 94|manner
P02590615A0636|98 113|pharmacokinetics
P02590615A0636|30 35|timing
P02590615A0636|148 154|tablets
P02590615A0636|116 125|nifedipine
P02590869A0743|98 102|serum
P02590869A0743|53 55|IgA
P02590869A0743|41 49|lavage IgG
P02590869A0743|129 136|bacteria
P02590869A0743|68 76|LNA titers
P02590869A0743|32 39|serum IgG
P02590869A0743|83 94|lavage fluids
P02590869A0743|115 120|SC dose
P02590869A0743|14 19|calves
P02591078A0000|204 207|time
P02591078A0000|6 19|investigations
P02591078A0000|186 194|epidermis
P02591078A0000|106 120|Langerhans cells
P02591078A0000|64 88|contact dermatitis reaction
P02591078A0000|151 168|electron microscopy
P02591078A0000|33 41|Grenz rays
P02591078A0000|134 147|OKT6 antibodies
P02591969A0961|99 104|region
P02591969A0961|25 49|glucocorticoid stimulation
P02591969A0961|52 71|ADH gene transcription
P02591969A0961|3 10|elements
P02592543A0106|103 109|patient
P02592543A0106|38 52|characteristics
P02592543A0106|142 149|organism
P02592543A0106|10 16|studies
P02592543A0106|54 79|Kanagawa hemolysin reactions
P02592543A0106|129 136|isolates
P02592543A0106|84 98|plasmid profiles
P02592640A0466|57 63|cheeses
P02592640A0466|223 229|retinol
P02592640A0466|16 22|retinol
P02592640A0466|75 79|cream
P02592640A0466|205 209|cream
P02592640A0466|238 250|beta-carotene
P02592640A0466|139 143|cream
P02592640A0466|129 129|g
P02592640A0466|157 162|cheese
P02592640A0466|195 195|g
P02592640A0466|91 96|cheese
P02592640A0466|4 9|values
P02592640A0466|26 38|beta-carotene
P02592961A0327|0 5|COGLAB
P02592961A0327|65 86|psychomotor performance
P02592961A0327|14 21|measures
P02595451A1136|115 118|MIC1
P02595451A1136|18 29|aniridia gene
P02595451A1136|108 112|sides
P02595451A1136|48 71|T-cell leukemia breakpoint
P02595451A1136|5 8|data
P02595451A1136|31 33|AN2
P02595451A1136|83 96|marker sequence
P02595451A1136|73 76|TCL2
P02595451T0000|15 25|deletion map
P02595451T0000|57 71|J1 series hybrids
P02595451T0000|33 45|chromosome 11p
P02595451T0000|47 54|analysis
P02597484A0624|133 141|materials
P02597484A0624|80 80|K
P02597484A0624|35 43|platelets
P02597484A0624|22 32|diffusivity
P02597484A0624|4 10|respect
P02597484A0624|45 46|De
P02597484A0624|98 108|differences
P02597484A0624|54 70|surface reactivity
P02597549A0964|81 87|aspirin
P02597549A0964|111 124|recovery period
P02597549A0964|178 196|thromboplastin times
P02597549A0964|91 96|mg/day
P02597549A0964|134 137|days
P02597549A0964|33 36|days
P02597549A0964|69 76|mg X 3/day
P02597549A0964|54 65|dipyridamole
P02597549A0964|157 167|prothrombin
P02597549A0964|16 23|patients
P02598034A0000|0 21|Middle-latency auditory
P02598034A0000|118 123|cortex
P02598034A0000|28 37|potentials
P02598034A0000|59 66|controls
P02598034A0000|39 43|MAEPs
P02598034A0000|70 77|patients
P02598034A0000|87 93|lesions
P02598745A0251|41 45|cases
P02598745A0251|24 37|Sylvius fissure
P02599995A1031|149 149|%
P02599995A1031|115 127|staphylococci
P02599995A1031|13 27|activity studies
P02599995A1031|137 144|survival
P02599995A1031|47 54|times MBC
P02599995A1031|87 94|activity
P02599995A1031|60 69|penicillin
P02600306A0140|59 80|envelope phase disparity
P02600306A0140|98 107|processing
P02600306A0140|138 144|AM tones
P02600306A0140|121 127|channel
P02600306A0140|48 56|detection
P02601707A0986|103 108|factor
P02601707A0986|38 49|footprinting
P02601707A0986|140 152|BC3H1 myocytes
P02601707A0986|127 136|C2 myotubes
P02601707A0986|53 84|diethyl pyrocarbonate interference
P02601707A0986|181 188|sequence
P02601707A0986|173 173|A
P02601707A0986|32 36|DNase
P02601707A0986|218 223|region
P02601707A0986|0 19|Gel retardation assays
P02602150A0993|202 214|virus replicon
P02602150A0993|139 148|generation
P02602150A0993|180 185|plants
P02602150A0993|151 157|vectors
P02602150A0993|62 77|sequence elements
P02602150A0993|52 59|analysis
P02602150A0993|161 177|gene amplification
P02602150A0993|121 132|construction
P02602150A0993|14 19|plants
P02602150A0993|87 109|replication origin region
P02603374A0383|60 75|patient morbidity
P02603374A0383|37 51|dorsal rhinotomy
P02603374A0383|7 15|rhinotomy
P02603374A0383|97 109|complications
P02603923A0220|96 97|ml
P02603923A0220|87 90|days
P02603923A0220|109 120|growth factor
P02603923A0220|146 160|lactate solution
P02603923A0220|138 143|Ringer
P02603923A0220|44 47|back
P02603923A0220|187 193|fashion
P02603923A0220|134 135|ml
P02603923A0220|18 30|skin incisions
P02603923A0220|79 81|day
P02603923A0220|58 61|pigs
P02603923A0220|125 129|ng/ml
P02604420A0234|16 23|rebiopsy
P02604420A0234|76 80|years
P02604420A0234|113 121|year study
P02604420A0234|102 104|end
P02604420A0234|35 53|reticulin antibodies
P02604420A0234|92 93|.0
P02604420A0234|82 86|range
P02604420A0234|6 14|challenge
P02605160A0000|128 131|rats
P02605160A0000|23 36|59Fe absorption
P02605160A0000|101 109|pregnancy
P02605160A0000|11 20|iron intake
P02605160A0000|78 85|Fe status
P02605160A0000|47 55|pregnancy
P02605160A0000|3 8|effect
P02605160A0000|96 98|end
P02605182A0936|75 87|signal peptide
P02605182A0936|10 24|protein sequence
P02605182A0936|125 135|polypeptide
P02605679A0306|116 120|delta
P02605679A0306|96 110|degradation rate
P02605679A0306|122 130|ester kdeg
P02605679A0306|148 161|hydrolysis rate
P02605679A0306|173 180|ester k24
P02605679A0306|13 25|rate constants
P02605679A0306|167 171|delta
P02605679A0306|42 61|isomerization rate k12
P02605679A0306|0 7|Analysis
P02607766A0000|354 358|salts
P02607766A0000|41 56|characterization
P02607766A0000|303 307|blood
P02607766A0000|164 176|micrograms/dL
P02607766A0000|370 371|Pb
P02607766A0000|255 266|micrograms/L
P02607766A0000|361 362|Cd
P02607766A0000|106 118|concentration
P02607766A0000|364 365|Hg
P02607766A0000|206 208|QCM
P02607766A0000|156 157|Pb
P02607766A0000|136 146|microgram/L
P02607766A0000|129 130|Cd
P02607766A0000|27 37|preparation
P02607766A0000|151 154|lead
P02607766A0000|83 85|QCM
P02607766A0000|272 273|Pb
P02607766A0000|325 341|spiking-solutions
P02607766A0000|219 220|Cd
P02607766A0000|247 248|Hg
P02607766A0000|279 291|micrograms/dL
P02607766A0000|225 236|micrograms/L
P02607766A0000|188 192|blood
P02607766A0000|121 127|cadmium
P02607766A0000|239 245|mercury
P02607766A0000|60 81|quality control material
P02607766A0000|1 8|protocol
P02609112A0000|0 12|Reagent strips
P02609112A0000|35 42|practice
P02609112A0000|93 104|laboratories
P02609112A0000|45 62|laboratory medicine
P02614668A0971|19 31|concentration
P02614668A0971|38 42|ng/ml
P02614668A0971|48 52|serum
P02615078A0283|38 50|actinomycetes
P02615078A0283|54 57|M.f.
P02615078A0283|13 22|antibodies
P02617623A0740|29 34|LON-71
P02617623A0740|9 16|isolates
P02617623A0740|98 104|village
P02617623A0740|61 69|altitudes
P02617623A0740|80 80|m
P02617623A0740|19 24|LON-73
P02617623A0740|41 46|LON-10
P02617623A0740|0 5|LON-72
P02620085A0656|74 92|replacement implants
P02620085A0656|112 119|material
P02620085A0656|50 55|screws
P02620085A0656|43 48|plates
P02620085A0656|29 40|applications
P02620085A0656|133 139|results
P02620085A0656|0 5|Animal
P02621983T0001|0 11|Significance
P02621983T0001|56 60|tests
P02621983T0001|34 45|acid analysis
P02623038A0632|2 8|changes
P02623038A0632|70 85|saline injections
P02623038A0632|32 42|performance
P02623038A0632|45 52|controls
P02627159A0899|42 46|index
P02627159A0899|19 30|IgG4 antibody
P02627159A0899|59 71|immunotherapy
P02629109A0000|206 215|1880 levels
P02629109A0000|11 26|fertility decline
P02629109A0000|37 46|population
P02629109A0000|52 67|Mississippi Delta
P02629109A0000|141 150|population
P02630543A0210|16 31|staining affinity
P02630543A0210|91 91|T
P02630543A0210|64 74|tissue cells
P02630543A0210|200 205|tissue
P02630543A0210|143 157|cell populations
P02630543A0210|94 94|T
P02630543A0210|172 177|volume
P02630543A0210|104 104|T
P02630543A0210|117 123|changes
P02630543A0210|97 97|T
P02630543A0210|41 50|antibodies
P02630543A0210|129 135|numbers
P02631505A0382|70 74|cases
P02631505A0382|11 13|AMP
P02631505A0382|43 45|AMI
P02631505A0382|53 61|treatment
P02631505A0382|0 9|Ampicillin
P02631505A0382|28 41|aminoglycoside
P02631566A0151|201 224|1-ethyloxymethylimidazol
P02631566A0151|229 253|chloromethyl alkyl sulfides
P02631566A0151|167 175|chlorides
P02631566A0151|69 88|3,4-dimethylpyridine
P02631566A0151|190 198|reactions
P02631566A0151|93 115|chloromethyl alkyl ethers
P02631566A0151|0 13|Alkoxymetgyl-3
P02631566A0151|17 43|dimethylpyridinium chlorides
P02631743A0275|98 103|plates
P02631743A0275|38 52|color deficiency
P02631743A0275|58 64|Koreans
P02631743A0275|75 79|H-R-R
P02631743A0275|70 72|use
P02631743A0275|17 25|incidence
P02631887A0000|47 55|lymphomas
P02631887A0000|26 29|HGGM
P02631887A0000|6 13|patients
P02632904A0619|58 68|correlation
P02632904A0619|78 78|p
P02632904A0619|18 23|VE/VO2
P02632904A0619|3 10|relation
P02632904A0619|70 70|r
P02632904A0619|27 31|Q/VO2
P02634490A0186|15 23|diagnosis
P02634490A0186|165 171|therapy
P02634490A0186|114 125|ATB treatment
P02634490A0186|81 93|CT examination
P02634490A0186|67 77|sialography
P02634490A0186|60 65|course
P02634490A0186|30 39|affections
P02634872A0000|0 9|Retrograde
P02634872A0000|34 50|endodontics system
P02634872A0000|70 73|zone
P02634872A0000|87 94|approach
P02636920T0001|28 70|Pharmacopoeia Heparin Sodium Reference Standard
P02636920T0001|13 17|study
P02637597A0362|28 39|relapse stage
P02637597A0362|77 79|IgA
P02637597A0362|107 114|decrease
P02637597A0362|122 123|C4
P02637597A0362|11 17|studies
P02637597A0362|101 103|IgG
P02637597A0362|83 90|IgM level
P02637597A0362|68 75|serum ANA
P02637597A0362|46 52|disease
P02637597A0362|117 118|C3
P02638964A0372|3 15|maximum stress
P02638964A0372|51 59|composite
P02638964A0372|75 85|equilibrium
P02638964A0372|109 117|composite
P02638964A0372|91 95|water
P02638964A0372|35 45|examination
P02638964A0372|67 72|kg/mm2
P02641762T0001|101 104|bull
P02641762T0001|107 116|eye display
P02641762T0001|93 97|SPECT
P02641762T0001|81 90|comparison
P02641762T0001|8 19|heart disease
P02641762T0001|67 78|scintigraphy
P02641762T0001|31 56|exercise stress thallium-201
P02642466T0000|0 15|Sequence analysis
P02642466T0000|47 63|membrane immunogen
P02642976A1474|9 26|consensus sequences
P02642976A1474|52 59|elements
P02644735A0427|95 104|S1 analysis
P02644735A0427|133 148|host cell sequence
P02644735A0427|77 87|transcripts
P02644735A0427|11 19|AcFP875-2
P02644735A0427|67 69|end
P02644735A0427|43 57|S. frugiperda DNA
P02644735A0427|32 40|insertion
P02644735A0427|2 9|FP mutant
P02645276T0088|0 11|Construction
P02645276T0088|68 74|mutants
P02645276T0088|36 44|isolation
P02645276T0088|15 32|RIP1 deletion strain
P02645431A1562|94 101|function
P02645431A1562|72 77|defect
P02645431A1562|20 33|hypocitraturia
P02645431A1562|53 60|acidosis
P02645431A1562|36 39|type
P02645431A1562|5 8|data
P02646007T0000|62 71|thrombosis
P02646007T0000|50 57|leukemia
P02646007T0000|76 93|protein C deficiency
P02646007T0000|29 36|leukemia
P02647403A0000|85 89|years
P02647403A0000|11 24|hallucinations
P02647403A0000|37 51|psychopathology
P02647918A0423|85 88|mean
P02647918A0423|21 22|GH
P02647918A0423|10 14|group
P02647918A0423|75 79|error
P02647918A0423|26 44|somatomedin-C levels
P02647918A0423|115 119|ng/ml
P02647918A0423|59 62|mean
P02647918A0423|147 150|U/ml
P02647918A0588|0 10|Application
P02647918A0588|50 57|patients
P02647918A0588|281 290|GH response
P02647918A0588|252 264|disappearance
P02647918A0588|104 104|%
P02647918A0588|240 247|criteria
P02647918A0588|217 217|%
P02647918A0588|71 78|GH levels
P02647918A0588|161 173|GH suppression
P02647918A0588|184 188|ng/ml
P02647918A0588|93 100|patients
P02647918A0588|206 213|patients
P02647918A0588|22 29|criteria
P02647918A0588|196 199|OGTT
P02647918A0588|32 35|cure
P02647918A0588|137 144|patients
P02647918A0588|293 304|TRH/GnRH test
P02647918A0588|115 133|somatomedin-C values
P02647918A0588|148 148|%
P02647918A0588|61 61|%
P02647918A0588|85 89|ng/ml
P02647937A0191|29 36|planning
P02647937A0191|11 18|sequence
P02647937A0191|88 95|problems
P02647937A0191|68 71|ways
P02648396A0565|82 88|agarose
P02648396A0565|33 41|c-jun mRNA
P02648396A0565|108 111|mice
P02648396A0565|62 68|ability
P02648396A0565|16 25|expression
P02648396A0565|92 101|form tumors
P02648396A0565|2 12|Rat-1a cells
P02648396A0565|71 75|clone
P02648396A1033|58 68|combination
P02648396A1033|40 43|RECs
P02648396A1033|12 20|formation
P02648396A1033|23 26|foci
P02648396A1033|92 138|tumor promoter phorbol 12-tetradecanoate 13-acetate
P02648646A0216|0 23|Platelet activating factor
P02648646A0216|103 116|expiratory flow
P02648646A0216|138 141|Vp30
P02648646A0216|37 41|doses
P02648646A0216|88 93|change
P02648646A0216|64 77|airway response
P02648646A0216|46 60|minute intervals
P02648646A0216|121 121|%
P02648646A0216|129 136|capacity
P02648646A0932|130 133|dose
P02648646A0932|108 117|micrograms
P02648646A0932|76 79|fall
P02648646A0932|39 62|baseline PC40 methacholine
P02648646A0932|137 146|micrograms
P02648646A0932|21 31|correlation
P02648646A0932|150 173|platelet activating factor
P02648646A0932|82 85|Vp30
P02649445A0412|67 72|medium
P02649445A0412|9 25|IRI concentrations
P02649445A0412|75 82|controls
P02649445A0412|35 38|OGTT
P02649445A0412|104 106|men
P02649445A0412|54 65|body builders
P02649445A0412|4 5|BG
P02649811T0000|10 22|contraception
P02649811T0000|25 43|family planning study
P02650663A0178|141 146|degree
P02650663A0178|35 42|subjects
P02650663A0178|176 183|dementia
P02650663A0178|62 71|impairment
P02650663A0178|157 165|diagnosis
P02650663A0178|4 9|rating
P02650663A0178|83 90|dementia
P02650663A0178|96 108|Alzheimer type
P02651448A0000|129 138|bioerosion
P02651448A0000|55 65|dissolution
P02651448A0000|20 23|drug
P02651448A0000|32 40|diffusion
P02651448A0000|102 117|depolymerization
P02651448A0000|165 169|Type B
P02651448A0000|148 163|depolymerization
P02651448A0000|119 123|Type A
P02651448A0000|87 94|material
P02651487A0000|59 69|contraction
P02651487A0000|104 112|knowledge
P02651487A0000|206 220|glucagon release
P02651487A0000|126 154|excitation contraction coupling
P02651487A0000|25 46|calcium channel blockers
P02651487A0000|196 202|insulin
P02651487A0000|169 174|glands
P02651487A0000|118 123|effect
P02651487A0000|86 91|muscle
P02655381A0000|28 38|possibility
P02655381A0000|167 176|occlusions
P02655381A0000|215 222|arteries
P02655381A0000|106 129|laboratory investigations
P02655381A0000|230 241|incompetence
P02655381A0000|73 81|impotence
P02655381A0000|99 103|means
P02655381A0000|254 265|neuropathies
P02655381A0000|135 146|hypogonadism
P02655381A0000|56 62|factors
P02655381A0000|200 203|site
P02655381A0000|4 10|studies
P02655381A0000|148 165|hyperprolactinemia
P02656257A0000|16 36|DNA inversion system Cin
P02656257A0000|49 63|bacteriophage P1
P02656257A0000|75 85|recombinase
P02656257A0000|135 142|enhancer
P02656257A0000|98 115|crossing-over sites
P02657388A1011|28 38|termination
P02657388A1011|41 51|transcripts
P02657388A1011|63 76|RNA polymerase I
P02657388A1011|3 18|terminator region
P02657883A0000|0 9|US-Doppler
P02657883A0000|27 35|attention
P02657883A0000|50 55|method
P02657883A0000|106 108|FAV
P02657883A0000|97 104|fistulas
P02657883A0000|72 81|evaluation
P02657883T0001|0 6|Doppler
P02657883T0001|36 43|fistulae
P02657883T0001|47 54|dialysis
P02664229A0138|155 167|Arap procedure
P02664229A0138|188 197|advantages
P02664229A0138|139 142|ease
P02664229A0138|75 80|repair
P02664229A0138|91 99|treatment
P02664229A0138|206 214|operation
P02664229A0138|125 131|fistula
P02664229A0138|240 257|hypospadias repairs
P02664229A0138|31 35|scope
P02664229A0138|8 15|cosmesis
P02664229A0138|17 25|extension
P02664229A0138|41 48|problems
P02666034A1520|27 32|course
P02666034A1520|172 184|placebo course
P02666034A1520|12 19|patients
P02666034A1520|35 41|therapy
P02666034A1520|109 120|vasodilation
P02666034A1520|56 83|vasodilator calcium antagonist
P02666034A1520|187 193|therapy
P02666404A0220|117 133|HepG2-erythrocyte
P02666404A0220|225 230|xylose
P02666404A0220|79 95|sugar transporters
P02666404A0220|234 251|arabinose permeases
P02666404A0220|53 60|homology
P02666404A0220|182 205|liver glucose transporters
P02666404A0220|66 76|superfamily
P02666404A0220|271 277|glucose
P02666404A0220|142 166|muscle glucose transporters
P02666404A0220|279 285|maltose
P02666404A0220|32 39|sequence
P02666404A0220|171 178|rat brain
P02666404A0220|290 310|galactose transporters
P02666404A0220|3 22|galactose transporter
P02666568A0000|55 68|protocol TCL821
P02666568A0000|24 31|patients
P02666568A0000|48 52|study
P02667259A0331|42 45|ADRs
P02667259A0331|64 69|nausea
P02667259A0331|101 104|flow
P02667259A0331|32 40|reactions
P02667259A0331|20 23|cent
P02667259A0331|54 57|case
P02667259A0331|71 79|dizziness
P02668691A0570|82 85|nagC
P02668691A0570|76 80|genes
P02668691A0570|23 26|nagB
P02668691A0570|89 92|nagD
P02668691A0570|30 33|nagA
P02668691A0570|4 7|mRNA
P02669199A0000|42 54|shock syndrome
P02669199A0000|78 86|endotoxin
P02669199A0000|88 90|LPS
P02669199A0000|20 22|TNF
P02669199A0000|0 18|Tumor necrosis factor
P02670457T0000|3 20|calcium requirement
P02670457T0000|54 60|explant
P02670457T0000|35 41|storage
P02674141A1202|27 30|CTSE
P02674141A1202|10 24|cysteine residue
P02674141A1202|77 85|proenzyme
P02674141A1202|49 71|activation peptide region
P02674327A0493|3 5|p34
P02674327A0493|22 35|codon usage bias
P02674327A0493|8 11|gene
P02674327A0493|75 88|polyhedrin gene
P02674671A0601|20 35|DNA transformants
P02674671A0601|39 39|%
P02674671A0601|52 62|replacement
P02674671A0601|76 87|met2 mutation
P02674671A0601|111 116|allele
P02674674A1308|28 33|notion
P02674674A1308|111 116|origin
P02674674A1308|53 57|sites
P02674674A1308|119 129|replication
P02674674A1308|64 74|OBF1 protein
P02674674A1308|96 106|ARS function
P02674674A1308|3 9|results
P02674679A1237|42 56|RNA preparations
P02674679A1237|101 105|genes
P02674679A1237|5 9|basis
P02674679A1237|164 183|start site utilization
P02674679A1237|151 161|specificity
P02674679A1237|127 136|expression
P02674679A1237|119 124|levels
P02674679A1237|68 79|mouse tissues
P02674679A1237|85 88|dhfr
P02674679A1237|12 39|S1 nuclease protection analysis
P02675492A0806|85 87|CRP
P02675492A0806|11 18|patients
P02675492A0806|79 81|ESR
P02675492A0806|33 43|improvement
P02675492A0806|55 67|Ritchie-Index
P02675492A0806|69 77|pain score
P02677002A0205|58 60|Asp
P02677002A0205|63 95|equilibrium N-carbamyl-L-aspartate
P02677002A0205|97 101|C-Asp
P02677002A0205|114 130|carbamyl phosphate
P02677002A0205|37 39|ATP
P02677002A0205|132 134|C-P
P02677002A0205|138 159|equilibrium Pi exchanges
P02677002A0205|110 112|32P
P02677002A0205|54 56|14C
P02677002A0205|29 35|enzymes
P02677429A0366|0 12|Survival rates
P02677429A0366|100 113|treatment group
P02677429A0366|127 127|%
P02677429A0366|238 238|%
P02677429A0366|137 142|months
P02677429A0366|182 187|months
P02677429A0366|207 214|subjects
P02677429A0366|67 72|months
P02677429A0366|219 222|AIDS
P02677429A0366|49 49|%
P02677429A0366|302 315|treatment group
P02677429A0366|258 265|subjects
P02677429A0366|230 230|%
P02677429A0366|57 57|%
P02677429A0366|164 164|%
P02677429A0366|119 119|%
P02677429A0366|282 288|complex
P02677429A0366|172 172|%
P02677429A0366|27 40|treatment group
P02677666A0356|0 6|Mapping
P02677666A0356|96 103|mutation
P02677666A0356|67 73|mutants
P02677666A0356|30 49|complementation group
P02677666A0356|88 94|ag alpha
P02679804A2000|13 22|genes ura10
P02679804A2000|3 10|products
P02679804A2000|59 68|channeling
P02679804A2000|71 92|orotidine monophosphate
P02679804A2000|26 29|ura3
P02680843A0724|26 35|REM latency
P02680843A0724|64 76|investigation
P02680843A0724|8 18|application
P02680843A0724|21 22|RS
P02680843A0724|53 58|groups
P02684159A0870|43 46|mRNA
P02684159A0870|34 37|size
P02684159A0870|57 65|kilobases
P02684159A0870|0 20|Hybridization analysis
P02684585T0001|0 23|Agranulocytosis treatment
P02684585T0001|28 35|rhGM-CSF
P02685331A0523|3 24|R. meliloti nifH promoter
P02685331A0523|195 203|promoters
P02685331A0523|46 57|nifH promoter
P02685331A0523|178 182|sigma
P02685331A0523|104 118|guanine residues
P02685331A0523|151 161|nucleotides
P02685331A0523|64 68|sigma
P02685331A0523|34 35|K.
P02685331A0523|81 101|methylation protection
P02685461A0380|57 64|patients
P02685461A0380|13 20|symptoms
P02685461A0380|50 54|group
P02685461A0380|26 32|disease
P02685565A0165|118 127|c-myb genes
P02685565A0165|50 53|mRNA
P02685565A0165|79 83|cells
P02685565A0165|31 34|form
P02686588A0592|15 22|analysis
P02686588A0592|77 95|alkaline phosphatase
P02686588A0592|49 58|hemoglobin
P02686588A0592|36 45|hematocrit
P02686588A0592|108 112|group
P02686588A0592|71 73|BUN
P02686749A0000|232 235|year
P02686749A0000|11 28|health significance
P02686749A0000|101 108|exposure
P02686749A0000|63 70|exposure
P02686749A0000|44 50|changes
P02686749A0000|150 158|excretion
P02686749A0000|121 129|discovery
P02686749A0000|182 202|retinol binding protein
P02686749A0000|161 179|beta 2-microglobulin
P02686749A0000|83 89|workers
P02686749A0000|73 79|cadmium
P02686749A0000|243 247|years
P02686980A0000|40 51|organization
P02686980A0000|138 142|yeast
P02686980A0000|67 75|nucleolus
P02686980A0000|123 132|components
P02686980A0000|2 6|order
P02686985A0811|84 89|stages
P02686985A0811|92 104|transcription
P02686985A0811|162 168|effects
P02686985A0811|203 209|complex
P02686985A0811|183 191|component
P02686985A0811|133 148|complex formation
P02686985A0811|54 65|PCF1 mutation
P02686985A0811|1 33|transcription factor exclusion assay
P02688772T0000|0 9|Psychiatry
P02688772T0000|16 19|skin
P02689136A1851|35 38|time
P02689136A1851|12 18|effects
P02689439A0000|43 44|EC
P02689439A0000|12 36|glutathione S-transferases
P02689439A0000|104 114|conjugation
P02689439A0000|78 87|isoenzymes
P02689439A0000|130 139|substrates
P02689439A0000|144 154|glutathione
P02689439A0000|38 41|GSTs
P02689439A0000|58 68|superfamily
P02689439A0402|59 64|degree
P02689439A0402|166 171|region
P02689439A0402|39 44|pmGT10
P02689439A0402|177 186|rat Yb2 gene
P02689439A0402|93 102|rat Yb1 gene
P02689439A0402|121 125|pmGT2
P02689439A0402|67 74|homology
P02689439A0402|30 36|regions
P02689439A0402|82 87|region
P02689439A0402|140 147|homology
P02689439A0402|113 118|region
P02689544A0456|0 4|Model
P02689544A0456|38 44|incisor
P02689544A0456|15 23|abutments
P02689544A0456|73 81|abutments
P02691557A0273|3 11|incidence
P02691557A0273|172 180|gestation
P02691557A0273|49 49|h
P02691557A0273|106 119|concentrations
P02691557A0273|164 169|period
P02691557A0273|85 87|age
P02691557A0273|19 36|breathing movements
P02691557A0273|122 130|plasma PGE
P02691811A0355|57 61|spite
P02691811A0355|129 141|concentration
P02691811A0355|79 91|blood acidosis
P02691811A0355|20 27|recovery
P02691811A0355|29 43|plasma potassium
P02691811A0355|15 17|min
P02691998A0672|128 131|ET-1
P02691998A0672|10 13|data
P02691998A0672|62 64|bed
P02691998A0672|107 125|bolus administration
P02691998A0672|86 88|bed
P02692881A0354|30 34|women
P02692881A0354|305 319|sodium excretion
P02692881A0354|179 186|function
P02692881A0354|218 221|acid
P02692881A0354|272 287|calcium excretion
P02692881A0354|298 302|level
P02692881A0354|71 73|PIH
P02692881A0354|161 171|derangement
P02692881A0354|225 233|reduction
P02692881A0354|209 213|serum
P02692881A0354|254 258|total
P02692881A0354|82 89|increase
P02692881A0354|236 250|sodium excretion
P02692881A0354|92 100|heart rate
P02692881A0354|62 66|women
P02692881A0354|199 206|increase
P02692881A0354|56 60|women
P02692881A0354|144 147|tone
P02692881A0354|2 11|comparison
P02693208A0166|59 67|mutations
P02693208A0166|90 108|repeat recombination
P02693208A0166|76 80|rad52
P02693208A0166|17 20|role
P02693208A0166|69 72|rad1
P02693208A0166|26 38|recombination
P02693208A0166|145 153|sequences
P02693593A0866|39 48|amino acids
P02693593A0866|10 16|protein
P02693593A0866|21 34|leader sequence
P02694731A0241|15 23|knowledge
P02694731A0241|155 161|profile
P02694731A0241|93 102|hypotheses
P02694731A0241|113 122|hypotheses
P02694731A0241|10 13|hand
P02694731A0241|29 40|epidemiology
P02694731A0241|43 51|Parkinson
P02694731A0241|176 182|testing
P02694731A0241|54 60|disease
P02695914T0000|3 19|stereoselectivity
P02695914T0000|22 31|drug action
P02700977A0444|28 38|penetration
P02700977A0444|69 80|XR bond/Silus
P02700977A0444|85 95|combination
P02700977A0444|0 9|Scotchbond
P02702566A0000|14 22|cisplatin
P02702566A0000|76 83|infusion
P02702566A0000|26 39|5-fluorouracil
P02702566A0000|106 109|head
P02702566A0000|113 122|neck cancer
P02702566A0000|58 61|days
P02702566A0000|1 11|combination
P02702849A0418|0 28|Metformin plasma concentrations
P02702849A0418|195 195|p
P02702849A0418|55 62|patients
P02702849A0418|97 98|mg
P02702849A0418|86 86|g
P02702849A0418|182 193|micrograms/l
P02702849A0418|117 144|patients plasma concentrations
P02703121T0000|0 8|Diagnosis
P02703121T0000|64 91|serum alanine aminotransferase
P02703121T0000|18 38|sclerosing cholangitis
P02703121T0000|42 51|blood donor
P02703925A0359|183 197|sedimentability
P02703925A0359|670 676|surface
P02703925A0359|263 269|S values
P02703925A0359|624 642|proteoglycan content
P02703925A0359|34 45|subgroupings
P02703925A0359|383 389|finding
P02703925A0359|735 740|amount
P02703925A0359|273 285|proteoglycans
P02703925A0359|326 331|values
P02703925A0359|550 567|S value distribution
P02703925A0359|93 114|polydispersity profiles
P02703925A0359|366 370|areas
P02703925A0359|574 591|cartilage thickness
P02703925A0359|221 224|sign
P02703925A0359|775 789|sedimentability
P02703925A0359|718 722|cases
P02703925A0359|455 471|matrix degradation
P02703925A0359|157 179|proteoglycan aggregation
P02703925A0359|418 426|inversion
P02703925A0359|313 317|areas
P02703925A0359|827 833|samples
P02703925A0359|136 146|conclusions
P02703925A0359|743 752|aggregates
P02703925A0359|227 252|cartilage matrix degradation
P02703925A0359|649 656|distance
P02703925A0359|694 707|cartilage layer
P02703925A0359|490 498|HW regions
P02703925A0359|151 154|loss
P02703925A0359|433 439|pattern
P02703925A0359|65 89|sedimentation coefficients
P02703925A0359|348 353|weight
P02703925A0359|812 815|zone
P02703925A0359|398 413|cartilage samples
P02703925A0359|531 535|areas
P02703925A0359|302 303|HW
P02703925A0359|355 356|LW
P02703925A0359|295 300|weight
P02704579A1078|118 118|P
P02704579A1078|77 97|gas exchange parameters
P02704579A1078|68 73|CRS/BW
P02704579A1078|54 60|disease
P02704579A1078|40 48|evolution
P02704579A1078|12 23|relationship
P02704579A1078|136 146|gas exchange
P02704579A1078|106 115|a/AO2 ratio
P02704579A1078|166 178|lung mechanics
P02704579A1078|99 102|FIO2
P02705072A0464|0 8|End points
P02705072A0464|52 61|infarction
P02705072A0464|66 69|rate
P02705072A0464|63 64|MI
P02705072A0464|73 77|death
P02705296A0231|72 74|kDa
P02705296A0231|60 70|kilodaltons
P02705296A0231|52 55|ORF1
P02705296A0231|21 26|weight
P02705296A0231|32 42|polyprotein
P02705556A1049|26 31|supply
P02705556A1049|8 13|demand
P02705556A1049|22 23|RC
P02705556A1049|4 5|RV
P02705556A1049|52 62|flow reserve
P02707909A0209|57 64|fraction
P02707909A0209|21 23|UKM
P02707909A0209|100 107|dialyses
P02707909A0209|2 18|alternative method
P02707909A0209|72 84|dialysate flow
P02708288A0139|46 50|LC/AD
P02708288A0139|36 44|detection
P02708288A0139|153 162|soybean oil
P02708288A0139|78 81|acid
P02708288A0139|142 149|soybeans
P02708288A0139|125 139|fluazifop-butyl
P02708288A0139|109 122|base hydrolysis
P02708288A0139|97 106|metabolism
P02708288A0139|0 19|Liquid chromatography
P02708288A0621|249 261|oxidation mode
P02708288A0621|107 112|column
P02708288A0621|184 192|potential
P02708288A0621|81 91|PRP-1 liquid
P02708288A0621|236 243|detector
P02708288A0621|57 64|aliquots
P02708288A0621|153 161|compounds
P02708288A0621|34 38|phase
P02708288A0621|123 126|acid
P02708288A0621|3 17|dichloromethane
P02708288A0621|200 200|V
P02708353A1080|88 91|gene
P02708353A1080|149 158|P-450e gene
P02708353A1080|78 85|position
P02708353A1080|42 68|transcription initiation site
P02708353A1080|0 25|Primer extension experiments
P02708353A1452|161 166|tissue
P02708353A1452|105 121|polysome fractions
P02708353A1452|69 79|transcripts
P02708353A1452|144 154|utilization
P02708353A1452|63 66|gene
P02708353A1452|17 39|polymerase chain reaction
P02709081T0000|0 9|Validation
P02709081T0000|35 48|profile measure
P02709081T0000|23 32|work styles
P02709081T0000|54 74|type A behaviour pattern
P02709081T0000|15 20|survey
P02709819A0495|32 51|ciprofloxacin therapy
P02709819A0495|7 9|ADR
P02711145T0000|0 16|HIV infectiousness
P02711145T0000|23 26|AIDS
P02711167A0818|14 20|turnout
P02711167A0818|112 117|damage
P02711167A0818|25 33|PFB-group
P02711167A0818|96 101|degree
P02711167A0818|125 131|animals
P02711167A0818|4 6|day
P02711167A0818|55 75|serum pepsinogen levels
P02711601A0601|73 82|guinea pigs
P02711601A0601|53 59|control
P02711601A0601|16 25|inhibition
P02711601A0601|91 91|%
P02711601A0601|28 50|acid phosphatase activity
P02711601A0601|100 100|%
P02712246T0042|29 43|characteristics
P02712450A0989|143 146|Type
P02712450A0989|97 104|response
P02712450A0989|211 216|groups
P02712450A0989|20 23|mm Hg
P02712450A0989|148 155|response
P02712450A0989|177 183|changes
P02712450A0989|12 16|PACO2
P02712450A0989|162 172|hypercapnia
P02712450A0989|64 64|p
P02712450A0989|186 190|drive
P02712450A0989|136 141|others
P02712450A0989|92 95|Type
P02712450A0989|36 40|drive
P02712450A0989|83 90|subjects
P02713310T0000|0 12|Fundus changes
P02713310T0000|40 57|glomerulonephritis
P02713310T0000|93 98|report
P02713310T0000|68 73|drusen
P02713310T0000|16 19|type
P02713520T0000|7 17|dose effects
P02713520T0000|37 46|nuthatches
P02713520T0000|65 79|ptilochronology
P02713520T0000|48 61|cholinesterase
P02713520T0000|20 34|methyl parathion
P02713994A0482|37 46|antibodies
P02713994A0482|52 58|mothers
P02713994A0482|3 7|titer
P02713994A0482|63 71|cord blood
P02713994A0482|29 35|HSV type
P02713994A0482|14 20|HSV type
P02714525A0529|115 124|dose levels
P02714525A0529|139 146|exposure
P02714525A0529|77 85|dose level
P02714525A0529|132 136|weeks
P02714525A0529|93 97|weeks
P02714525A0529|29 39|weight ratio
P02714525A0529|0 11|Kidney weight
P02714852T0000|46 54|evolution
P02714852T0000|60 71|HLA-B alleles
P02714852T0000|26 39|HLA-C sequences
P02714852T0000|7 15|variation
P02714852T0000|18 22|HLA-B
P02717133T0001|1 6|method
P02717133T0001|51 74|summary oxygen consumption
P02717133T0001|28 48|development conditions
P02717349A0311|0 2|Men
P02717349A0311|37 43|fitness
P02717349A0311|48 52|women
P02718683A0142|0 18|Handgrip dynamometry
P02718683A0142|46 53|patients
P02720966A0455|103 110|patients
P02720966A0455|91 100|meningitis
P02720966A0455|23 25|ADA
P02720966A0455|35 47|concentration
P02720966A0455|127 137|sensitivity
P02720966A0455|143 153|specificity
P02720966A0455|121 125|years
P02720966A0455|57 63|mu kat/L
P02720966A0455|161 170|efficiency
P02720966A0455|15 19|fluid
P02721169A0171|0 8|NERVTRACK
P02721169A0171|99 111|relationships
P02721169A0171|60 65|manner
P02721169A0171|31 39|data items
P02723503T0000|0 8|Swim-over
P02723503T0000|12 28|alternative method
P02723503T0000|48 58|spermatozoa
P02724227T0000|45 57|flap tolerance
P02724227T0000|60 67|ischemia
P02724227T0000|0 15|Perfusion washout
P02725495A0929|115 128|metazoan U2 RNAs
P02725495A0929|13 20|sequence
P02725495A0929|26 36|U2 RNA region
P02725495A0929|88 92|yeast
P02725495A0929|151 162|trypanosomes
P02725495A0929|56 85|pre-mRNA branchpoint recognition
P02725513A0617|71 74|rule
P02725513A0617|101 109|promoters
P02725513A0617|79 99|metazoan RNA polymerase
P02725513A0617|25 41|CHO spacer promoter
P02725513A0617|118 125|G residue
P02725513A0617|128 135|position
P02727909A0383|152 154|HLP
P02727909A0383|73 83|sensitivity
P02727909A0383|109 115|persons
P02727909A0383|86 88|ADP
P02727909A0383|120 127|types IIa
P02727909A0383|7 15|amplitude
P02727909A0383|34 39|plates
P02727909A0383|21 31|aggregation
P02727909A0383|44 51|decrease
P02727909A0383|131 136|IIb HLP
P02727909A0383|142 144|CHD
P02727909A0383|57 65|threshold
P02729666A0267|61 73|dentoskeletal
P02729666A0267|11 31|intergroup differences
P02729666A0267|81 102|tissue profile variables
P02731611A0134|145 167|Mental Research Institute
P02731611A0134|18 26|rationale
P02731611A0134|61 64|case
P02731611A0134|45 48|view
P02731611A0134|121 130|principles
P02731611A0134|3 8|author
P02731611A0134|85 91|hiccups
P02731671A0000|171 179|days/week
P02731671A0000|163 168|hr/day
P02731671A0000|186 190|weeks
P02731671A0000|21 31|nickel oxide
P02731671A0000|126 135|B6C3F1 mice
P02731671A0000|78 93|nickel subsulfide
P02731671A0000|63 67|NiSO4
P02731671A0000|141 158|inhalation exposure
P02731671A0000|38 61|nickel sulfate hexahydrate
P02731671A0000|70 72|H2O
P02731671A0000|95 99|Ni3S2
P02731671A0000|11 18|toxicity
P02731671A0000|113 122|F344/N rats
P02731671A0000|33 35|NiO
P02732341A0000|85 89|woman
P02732341A0000|78 81|year
P02732341A0000|65 72|neoplasm
P02732341A0000|156 176|chloroacetate esterase
P02732341A0000|47 53|studies
P02732341A0000|198 206|diagnosis
P02732341A0000|120 127|lymphoma
P02732341A0000|145 152|staining
P02733116T0000|27 32|Health
P02733116T0000|7 24|National Institutes
P02733690T0000|74 82|reductase
P02733690T0000|9 15|cloning
P02733690T0000|53 57|genes
P02733690T0000|19 34|characterisation
P02733690T0000|85 91|tobacco
P02735364A1330|59 59|p
P02735364A1330|10 14|model
P02735364A1330|51 57|results
P02735364A1330|133 133|p
P02735364A1330|108 110|age
P02735364A1330|22 22|p
P02735364A1330|124 131|variable
P02735364A1330|96 96|p
P02735364A1330|69 94|progesterone receptor status
P02735364A1330|16 20|grade
P02735364A1330|182 189|survival
P02736482A0550|43 57|brain metastases
P02736482A0550|26 41|radiation therapy
P02736482A0550|2 9|contrast
P02739739T0000|0 22|COUP transcription factor
P02739739T0000|37 62|steroid receptor superfamily
P02739739T0000|26 31|member
P02740196A0704|83 87|range
P02740196A0704|25 38|classification
P02740196A0704|72 77|center
P02740196A0704|51 58|standard
P02740196A0704|90 102|target numbers
P02740196A0704|2 11|Experiment
P02740347A0644|0 11|Cosmid clones
P02740347A0644|26 38|VNTR sequences
P02740347A0644|57 74|restriction mapping
P02740347A0644|99 100|kb
P02740627A0137|121 134|oxygen pressure
P02740627A0137|109 110|VA
P02740627A0137|63 64|fR
P02740627A0137|189 194|volume
P02740627A0137|219 223|space
P02740627A0137|16 18|VO2
P02740627A0137|41 44|VCO2
P02740627A0137|136 139|PAO2
P02740627A0137|225 226|VD
P02740627A0137|97 107|ventilation
P02740627A0137|21 39|carbon dioxide output
P02740627A0137|171 174|cows
P02740627A0137|67 83|minute ventilation
P02740627A0137|145 155|VE/VO2 ratio
P02740627A0137|243 248|horses
P02740627A0137|58 61|rate
P02740627A0137|196 197|VT
P02740627A0137|85 86|VE
P02740627A0137|3 14|oxygen uptake
P02740874A0957|70 72|SO2
P02740874A0957|10 15|damage
P02740874A0957|35 42|controls
P02740874A0957|54 60|tissues
P02740955A0333|86 95|deliveries
P02740955A0333|11 18|patients
P02740955A0333|66 73|patients
P02740955A0333|30 42|mortality rate
P02743842A0000|181 184|PGE2
P02743842A0000|363 365|min
P02743842A0000|132 140|influence
P02743842A0000|282 284|rat
P02743842A0000|49 59|cytoprotect
P02743842A0000|71 76|mucosa
P02743842A0000|102 117|stress ulceration
P02743842A0000|345 349|shock
P02743842A0000|292 297|mucosa
P02743842A0000|235 242|tissue pH
P02743842A0000|157 171|prostaglandin E2
P02743842A0000|314 317|acid
P02743842A0000|322 326|mM HCl
P02743842A0000|246 259|back-diffusion
P02743842A0000|10 14|study
P02743842A0000|353 357|ml/kg
P02743842A0000|271 279|blood flow
P02743842A0000|244 244|H
P02743842A0000|34 47|prostaglandins
P02743842A0000|207 221|lesion formation
P02743981A0347|0 10|Transcripts
P02743981A0347|55 58|L11e
P02743981A0347|197 206|transcript
P02743981A0347|126 133|NAB-L11e
P02743981A0347|74 97|L1e-L10e-L12e transcripts
P02743981A0347|150 163|NAB transcripts
P02743981A0347|181 183|ORF
P02744123A0237|43 49|species
P02744123A0237|137 140|time
P02744123A0237|175 193|background luminance
P02744123A0237|55 66|rhesus monkey
P02744123A0237|70 72|man
P02744123A0237|96 103|branches
P02744123A0237|17 23|results
P02744490A0894|0 7|Evidence
P02744490A0894|100 109|hypothesis
P02744490A0894|67 88|primer extension studies
P02744490A0894|54 63|S1 nuclease
P02744490A0894|35 44|cDNA clones
P02744490A0894|203 209|domains
P02744490A0894|117 125|PTHrP gene
P02744490A0894|144 171|mRNA transcription start points
P02744490A0894|15 23|structure
P02744490A0894|27 32|number
P02745280A0276|13 16|PaO2
P02745280A0276|181 183|ATP
P02745280A0276|127 140|concentrations
P02745280A0276|207 227|resonance spectroscopy
P02745280A0276|107 113|changes
P02745280A0276|196 198|31P
P02745280A0276|66 75|blood gases
P02745280A0276|39 46|measures
P02745280A0276|152 160|phosphate
P02745280A0276|6 10|level
P02745280A0276|162 176|phosphocreatine
P02745280A0276|83 102|lactate concentration
P02745444A0391|3 29|transcription initiation site
P02745444A0391|45 61|S1 nuclease mapping
P02745666A0000|100 123|replacement therapy cycles
P02745666A0000|22 37|plasma oestradiol
P02745666A0000|11 18|biopsies
P02745666A0000|143 149|failure
P02745666A0000|39 40|E2
P02745666A0000|58 59|P4
P02745666A0000|45 56|progesterone
P02745666A0000|71 78|patients
P02745666A0000|61 66|levels
P02746099A0000|3 10|mobility
P02746099A0000|90 96|contact
P02746099A0000|108 113|facets
P02746099A0000|64 71|relation
P02746099A0000|43 46|load
P02746099A0000|29 37|premolars
P02747653A0910|84 92|beginning
P02747653A0910|50 57|staining
P02747653A0910|110 114|stage
P02747653A0910|95 107|metamorphosis
P02747653A0910|19 25|protein
P02747653A0910|67 74|tadpoles
P02747653A0910|60 64|serum
P02748188A0091|113 114|PS
P02748188A0091|118 119|Ss
P02748188A0091|146 148|sec
P02748188A0091|217 223|studies
P02748188A0091|171 171|t
P02748188A0091|27 31|group
P02748188A0091|107 111|group
P02748188A0091|38 39|Ss
P02748188A0091|69 73|means
P02748188A0091|179 179|P
P02748188A0091|166 169|test
P02748188A0091|64 67|test
P02748188A0091|33 34|PT
P02748188A0091|82 84|sec
P02748595A0492|57 63|lineage
P02748595A0492|74 81|ADH-beta
P02748595A0492|34 36|ADH
P02748595A0492|17 32|baboon liver class
P02749215A0000|31 39|hematuria
P02749215A0000|64 70|finding
P02749215A0000|8 18|proteinuria
P02749215A0000|46 51|pyuria
P02751080A0176|14 17|shot
P02751080A0176|35 41|minutes
P02751080A0176|20 26|bullets
P02751080A0176|47 60|intensity level
P02751080A0176|76 77|dB
P02752303A0000|0 12|Lithium delays
P02752303A0000|64 83|plasma concentrations
P02752303A0000|25 30|rhythm
P02752303A0000|115 124|weight loss
P02752303A0000|54 61|hamsters
P02752303A0000|94 95|mM
P02752629A0163|0 6|Dynamic
P02752629A0163|46 67|methylene diphosphonate
P02752629A0163|107 114|fracture
P02752629A0163|97 101|weeks
P02752629A0163|16 26|scintigrams
P02752651A0480|28 36|September
P02752651A0480|150 160|disturbance
P02752651A0480|136 137|Th
P02752651A0480|89 98|impairment
P02752651A0480|74 84|paraparesis
P02752651A0480|111 120|modalities
P02752651A0480|46 52|patient
P02752651A0480|16 25|department
P02752651A0480|2 10|admission
P02752651A0480|129 133|level
P02756731T0001|0 13|Prostaglandins
P02756731T0001|17 26|gallstones
P02756878A0075|42 52|occurrences
P02756878A0075|82 89|patients
P02756878A0075|125 126|AF
P02756878A0075|95 101|history
P02756878A0075|3 8|nature
P02756878A0075|14 20|process
P02756878A0075|59 68|arrhythmia
P02757033A0905|144 156|transcription
P02757033A0905|164 168|genes
P02757033A0905|127 140|position effect
P02757033A0905|19 24|effect
P02757033A0905|64 66|arm
P02757033A0905|91 105|heterochromatin
P02757033A0905|41 45|genes
P02757862T0000|58 70|defibrillator
P02757862T0000|22 35|microprocessor
P02757862T0000|7 16|experience
P02758382A0478|0 6|Obesity
P02758382A0478|159 168|proportion
P02758382A0478|116 140|sex hormone binding globulin
P02758382A0478|80 88|estradiol
P02758382A0478|35 45|proportions
P02758382A0478|181 189|estradiol
P02758382A0478|142 145|SHBG
P02758382A0478|147 152|levels
P02760922A0000|44 56|core protein A1
P02760922A0000|65 73|component
P02760922A0000|38 42|hnRNP
P02760922A0000|92 101|S particles
P02760922A0000|20 36|ribonucleoprotein
P02760922A0000|85 89|hnRNP
P02761008X0000|0 26|Brain cholinesterase activity
P02761008X0000|42 47|egrets
P02761008X0000|101 119|brain cholinesterase
P02761008X0000|54 59|egrets
P02761008X0000|180 195|organophosphorus
P02761008X0000|171 175|death
P02761008X0000|161 168|exposure
P02761008X0000|76 87|night-herons
P02761008X0000|135 139|birds
P02761008X0000|125 132|activity
P02761008X0000|198 216|carbamate pesticides
P02761008X0000|89 98|inhibition
P02761008X0000|121 123|ChE
P02761150A0000|56 61|kidney
P02761150A0000|102 108|control
P02761150A0000|126 129|rats
P02761150A0000|149 157|pregnancy
P02761150A0000|49 54|spleen
P02761150A0000|134 137|days
P02761150A0000|11 24|zinc deficiency
P02761150A0000|43 47|liver
P02761150A0000|74 81|duodenum
P02761150A0000|143 146|days
P02761150A0000|63 70|pancreas
P02761150A0000|3 8|effect
P02761150A0000|27 37|trace metals
P02761492A0124|42 48|genesis
P02761492A0124|80 87|patients
P02761492A0124|61 71|involvement
P02761492A0124|21 24|view
P02761492A0124|3 10|findings
P02761537A0168|0 11|Heating cells
P02761537A0168|16 23|degrees C
P02761537A0168|213 223|readthrough
P02761537A0168|245 261|transcription unit
P02761537A0168|201 207|28S rRNA
P02761537A0168|75 75|%
P02761537A0168|60 63|rRNA
P02761537A0168|36 41|amount
P02761537A0168|154 159|region
P02761537A0168|127 150|transcription termination
P02761537A0168|81 92|control level
P02761537A0168|114 124|% inhibition
P02761537A0168|196 198|end
P02761537A0168|168 178|nucleotides
P02761540A0873|29 34|NF-4FA
P02761540A0873|82 97|enhancer activity
P02761540A0873|36 41|NF-4FB
P02761540A0873|46 58|AP-1 sequences
P02761540A0873|0 15|Deletion analysis
P02762006A0071|0 3|Cord
P02762006A0071|54 60|lesions
P02762006A0071|26 33|patients
P02762198T0001|15 21|reports
P02762198T0001|35 40|period
P02762198T0001|25 29|cases
P02762198T0001|6 13|syndrome
P02762198T0001|0 3|Reye
P02763467A0903|62 64|35S
P02763467A0903|259 264|N1L ORF
P02763467A0903|84 91|proteins
P02763467A0903|143 149|viruses
P02763467A0903|51 58|patterns
P02763467A0903|104 108|cells
P02763467A0903|19 35|polyacrylamide gel
P02763467A0903|230 234|point
P02763467A0903|164 167|spot
P02764797A0182|0 4|PULSE
P02764797A0182|51 55|delay
P02764797A0182|124 140|imaging parameters
P02764797A0182|36 45|parameters
P02764797A0182|103 115|sampling times
P02764797A0182|89 93|gates
P02764797A0182|20 22|NMR
P02764797A0182|59 66|duration
P02764797A0182|158 174|gradient waveforms
P02764797A0182|143 154|rf pulse shape
P02764797A0182|95 101|rf phase
P02764797A0182|69 70|rf
P02765001A0105|141 148|criteria
P02765001A0105|194 206|family history
P02765001A0105|105 108|rash
P02765001A0105|150 159|dactylitis
P02765001A0105|36 44|arthritis
P02765001A0105|8 11|JPsA
P02765001A0105|112 120|arthritis
P02765001A0105|187 190|rash
P02765001A0105|209 217|psoriasis
P02765001A0105|161 164|nail
P02765001A0105|15 22|patients
P02765214A0486|60 68|arguments
P02765214A0486|12 16|Kurti
P02765214A0486|19 24|demand
P02765214A0486|45 54|importance
P02766330A0779|3 8|author
P02766330A0779|77 83|effects
P02766330A0779|90 107|calcium antagonists
P02766330A0779|125 135|application
P02766330A0779|16 22|account
P02766508A0421|84 95|mean IQRST map
P02766508A0421|61 70|map pattern
P02766508A0421|45 54|similarity
P02766508A0421|1 22|correlation coefficient
P02766745T0000|73 81|dairy cows
P02766745T0000|52 59|placenta
P02766745T0000|25 36|relationship
P02766745T0000|63 70|mastitis
P02766745T0000|15 19|study
P02767166A0368|171 176|myopia
P02767166A0368|92 102|consequence
P02767166A0368|112 117|damage
P02767166A0368|52 62|development
P02767166A0368|152 159|diabetes
P02767166A0368|142 149|cataract
P02767166A0368|17 33|lipid peroxidation
P02767166A0368|71 78|cataract
P02767166A0368|128 139|pathogenesis
P02767733A0690|15 21|grading
P02767733A0690|101 101|%
P02767733A0690|51 52|G2
P02767733A0690|38 42|cases
P02767733A0690|46 47|G1
P02767733A0690|93 97|cases
P02767733A0690|72 77|spread
P02767733A0690|56 57|G3
P02772495A0641|0 5|Asthma
P02772495A0641|65 66|AT
P02772495A0641|62 62|%
P02772495A0641|45 52|ASA group
P02772495A0641|78 78|%
P02772495A0641|56 56|%
P02772495A0641|81 89|INTR group
P02773507A0750|83 87|value
P02773507A0750|75 76|CL
P02773507A0750|149 154|plasma
P02773507A0750|48 62|sample estimates
P02773507A0750|121 135|sample estimates
P02773507A0750|162 165|drug
P02773507A0750|11 14|l/kg
P02773507A0750|93 96|l/kg
P02773507A0750|65 73|clearance
P02773507A0750|1 5|value
P02773507A0750|25 25|V
P02773507A0750|167 171|CLunb
P02773507A0750|138 146|clearance
P02773930T0000|19 23|model
P02773930T0000|11 16|kidney
P02773930T0000|33 47|hyperfiltration
P02773930T0000|50 55|humans
P02774271A0000|89 92|acid
P02774271A0000|129 136|pathways
P02774271A0000|154 161|fluoride
P02774271A0000|94 97|TFAA
P02774271A0000|35 41|pathway
P02774271A0000|62 72|end products
P02774271A0000|163 163|F
P02774271A0000|110 111|Br
P02774271A0000|102 108|bromide
P02774271A0000|0 8|Halothane
P02774808A0194|99 104|winter
P02774808A0194|31 31|P
P02774808A0194|51 56|summer
P02774808A0194|69 84|micrograms/100 ml
P02774808A0194|3 8|values
P02775136A1151|59 75|breathing patterns
P02775136A1151|115 125|development
P02775136A1151|23 30|HAPE-S-S
P02775136A1151|182 198|breathing patterns
P02775136A1151|203 207|cause
P02775136A1151|128 130|AMS
P02775136A1151|82 89|altitude
P02775136A1151|5 11|results
P02775136A1151|220 222|AMS
P02775136A1151|212 217|effect
P02775333A1137|0 9|Buflomedil
P02775333A1137|11 14|i.v.
P02775333A1137|164 167|dose
P02775333A1137|72 76|mg/kg
P02775333A1137|38 45|increase
P02775333A1137|106 110|mg/kg
P02775333A1137|55 60|output
P02775333A1137|86 92|changes
P02775333A1137|121 128|decrease
P02775333A1137|148 155|increase
P02775333A1137|174 178|mg/kg
P02776471A0235|26 32|animals
P02776471A0235|47 56|responders
P02776471A0235|93 100|response
P02776471A0235|71 77|pattern
P02776742A0000|0 8|Heart rate
P02776742A0000|279 296|breathing apparatus
P02776742A0000|130 136|firemen
P02776742A0000|155 156|yr
P02776742A0000|142 144|age
P02776742A0000|73 87|humidity changes
P02776742A0000|213 214|SU
P02776742A0000|158 163|VO2 max
P02776742A0000|51 61|temperature
P02776742A0000|20 30|temperature
P02776742A0000|254 261|clothing
P02776742A0000|204 211|uniforms
P02776742A0000|229 232|fire
P02776742A0000|298 299|FE
P02776742A0000|94 101|clothing
P02776742A0000|191 201|fire fighter
P02776742A0000|10 11|HR
P02776742A0000|266 269|self
P02776742A0000|37 49|blood pressure
P02776742A0000|32 34|Tre
P02776742A0000|172 182|ml kg-1 min-1
P02776823A0000|183 190|i.v. dose
P02776823A0000|72 83|hydroxyethyl
P02776823A0000|50 55|sodium
P02776823A0000|23 38|pharmacokinetics
P02776823A0000|134 138|penem
P02776823A0000|11 19|tolerance
P02776823A0000|41 43|FCE
P02776823A0000|194 200|mg.kg-1
P02776823A0000|217 226|volunteers
P02776823A0000|57 58|5R
P02776823A0000|68 69|1R
P02776823A0000|88 127|carbamoyloxymethyl-2-penem-3-carboxylate
P02776823A0000|60 61|6S
P02777797A0720|0 19|DNA blot hybridization
P02777797A0720|35 43|rat genome
P02777797A0720|65 68|gene
P02777797A0720|77 97|PtdIns transfer protein
P02778237A0585|57 63|problem
P02778237A0585|36 37|IA
P02778237A0585|8 11|term
P02778237A0585|73 74|IA
P02778237A0585|84 111|maintenance prednisone therapy
P02778873A0761|16 19|CRL3
P02778873A0761|105 109|DR-A2
P02778873A0761|7 13|segment
P02778873A0761|47 62|enhancer function
P02778873A0761|97 101|DR-A1
P02778873A0761|87 95|sequences
P02779752A0000|3 12|1-Naphthyl
P02779752A0000|25 28|1-NP
P02779752A0000|142 155|agonist actions
P02779752A0000|14 23|piperazine
P02779752A0000|85 96|5-HT2 subtype
P02779752A0000|51 79|serotonin antagonist properties
P02779752A0000|99 106|receptor
P02779752A0000|161 169|5-HT1 site
P02779752A0776|3 16|m-Chlorophenyl
P02779752A0776|88 92|TFMPP
P02779752A0776|135 144|5-HT1 sites
P02779752A0776|211 214|1-NP
P02779752A0776|29 32|mCPP
P02779752A0776|18 27|piperazine
P02779752A0776|224 233|ketanserin
P02779752A0776|77 86|piperazine
P02779752A0776|53 75|m-trifluoromethylphenyl
P02779752A0776|41 45|mg/kg
P02779752A0776|194 205|methysergide
P02779752A0776|176 181|effect
P02779752A0776|101 105|mg/kg
P02780157A0576|232 239|MP system
P02780157A0576|132 139|reaction
P02780157A0576|207 214|standing
P02780157A0576|218 226|depletion
P02780157A0576|276 280|HBsAg
P02780157A0576|52 59|patients
P02780157A0576|151 158|spleen MP
P02780157A0576|26 30|liver
P02780157A0576|34 49|spleen MP function
P02780157A0576|111 114|lack
P02780157A0576|191 200|overstrain
P02780157A0576|17 23|feature
P02780157A0576|64 66|VHA
P02780157A0576|263 273|stimulation
P02780157A0576|145 148|part
P02780157A0576|81 96|HBsAg carriership
P02781495T0001|0 6|Changes
P02781495T0001|9 31|xanthine oxidase activity
P02781495T0001|34 41|patients
P02781495T0001|57 63|failure
P02781567A0544|1 4|soap
P02781567A0544|63 76|stratum corneum
P02781567A0544|22 29|solution
P02781567A0544|8 12|water
P02781567A0544|18 20|v/v
P02783181A0000|44 60|antacid magaldrate
P02783181A0000|105 113|blood flow
P02783181A0000|152 154|rat
P02783181A0000|29 38|activities
P02783181A0000|82 88|effects
P02783181A0000|62 69|ES Riopan
P02783181A0000|117 131|mucus secretions
P02784507A0000|117 121|cells
P02784507A0000|8 32|immunodeficiency virus type
P02784507A0000|35 39|HIV-1
P02784507A0000|133 139|periods
P02784507A0000|66 77|T lymphocytes
P02784507A0000|62 64|CD4
P02784507A0000|98 105|provirus
P02787430A0124|36 50|biopsy specimens
P02787430A0124|11 22|panniculitis
P02787430A0124|55 70|cytophagocytosis
P02789062A0000|42 45|gene
P02789062A0000|22 24|4F2
P02789062A0000|100 105|events
P02789062A0000|49 59|model system
P02789062A0000|36 40|4F2HC
P02789062A0000|62 68|studies
P02789062A0000|135 148|gene expression
P02789062A0000|166 181|T-cell activation
P02789062A0000|30 34|chain
P02789062A1420|1 4|cDNA
P02789062A1420|108 122|oligonucleotide
P02789062A1420|141 165|NF-4FB recognition sequence
P02789062A1420|69 89|lambda gt11 cDNA library
P02789062A1420|16 43|NF-4FB enhancer binding protein
P02789180A0407|74 84|hypertrophy
P02789180A0407|36 46|hypertrophy
P02789180A0407|88 95|patients
P02789217A1323|45 59|polyadenylation
P02789217A1323|79 86|distance
P02789217A1323|62 66|sites
P02789217A1323|6 19|IL6 mRNA species
P02789217A1323|92 100|kilobases
P02790009A0375|0 17|Sequencing analysis
P02790009A0375|105 110|region
P02790009A0375|80 90|nucleotides
P02790009A0375|122 129|fragment
P02790009A0375|47 55|fragments
P02790009A1052|60 65|region
P02790009A1052|90 113|serine protease inhibitors
P02790009A1052|115 122|residues
P02790009A1052|9 15|protein
P02792270A1220|149 160|flexion phase
P02792270A1220|80 88|responses
P02792270A1220|13 26|EPSP components
P02792270A1220|91 107|flexor motoneurons
P02792270A1220|131 139|amplitude
P02792430A0000|0 10|Experiments
P02792430A0000|129 139|development
P02792430A0000|194 201|vagotomy
P02792430A0000|97 119|prostaglandins synthesis
P02792430A0000|29 38|guinea pigs
P02792430A0000|185 188|rats
P02792430A0000|20 23|rats
P02792430A0000|85 94|inhibition
P02792430A0000|151 156|oedema
P02792430A0000|204 213|guinea pigs
P02792430A0000|178 182|serum
P02793216A0876|119 128|importance
P02793216A0876|10 13|hand
P02793216A0876|131 133|CgA
P02793216A0876|21 32|conservation
P02793216A0876|38 63|membrane attachment sequence
P02793216A0876|15 18|lack
P02793216A0876|89 92|acid
P02793620A0214|79 90|Red Poll bulls
P02793620A0214|106 113|pastures
P02793620A0214|54 64|parturition
P02793620A0214|67 75|Charolais
P02793620A0214|21 24|cows
P02793753A0354|53 57|l/min
P02793753A0354|117 126|dispersion
P02793753A0354|46 48|CFV
P02793753A0354|84 88|sites
P02793753A0354|10 13|lobe
P02793753A0354|77 78|PA
P02793753A0354|18 29|PA dispersion
P02793753A0354|63 66|flow
P02793753A0354|39 43|cmH2O
P02794828A0214|3 8|system
P02794828A0214|103 111|pacemaker
P02794828A0214|52 64|microcomputer
P02794828A0214|35 39|heart
P02795923A0000|2 6|order
P02795923A0000|36 48|CT appearances
P02795923A0000|63 71|pneumonia
P02795923A0000|143 147|lungs
P02795923A0000|105 109|study
P02795923A0000|152 158|autopsy
P02795923A0000|162 168|surgery
P02796216A0063|3 9|disease
P02796216A0063|23 28|course
P02796216A0063|62 74|enterorrhagia
P02796216A0063|39 54|jaundice syndrome
P02796216A0063|94 100|roseola
P02796216A0063|82 91|appearance
P02796988A0735|59 76|footprinting assays
P02796988A0735|80 95|gel shift analysis
P02796988A0735|37 41|sites
P02796988A0735|108 110|Sp1
P02796988A0735|3 24|transcription factor Sp1
P02797877A0475|72 79|regrowth
P02797877A0475|102 112|antibiotics
P02797877A0475|90 94|hours
P02797877A0475|19 28|micrograms
P02797877A0475|34 43|micrograms
P02797877A0475|30 32|PEF
P02797877A0475|3 16|combination PIP
P02798953A0307|13 19|mothers
P02798953A0307|112 122|consistency
P02798953A0307|153 161|stability
P02798953A0307|29 35|infants
P02798953A0307|5 10|sample
P02798953A0307|135 148|days postpartum
P02798953A0307|77 81|WPL-R
P02798953A0307|96 101|levels
P02798953A0307|66 75|instrument
P02798953A0307|168 182|administrations
P02798953A0307|45 53|subscales
P02799892A0154|86 96|transfusion
P02799892A0154|111 113|PNH
P02799892A0154|34 38|cells
P02799892A0154|72 80|hemolysis
P02799892A0154|40 44|WRBCs
P02799892A0154|99 106|patients
P02799892A0154|13 15|use
P02800417A0332|88 102|histamine values
P02800417A0332|112 112|p
P02800417A0332|104 104|r
P02800417A0332|46 56|correlation
P02800417A0332|5 9|group
P02800417A0332|72 84|PC20 PGF2 alpha
P02800417A0332|12 21|asthmatics
P02800435A0000|132 137|system
P02800435A0000|39 42|cats
P02800435A0000|107 111|field
P02800435A0000|113 115|PMF
P02800435A0000|89 89|T
P02800435A0000|46 50|mg/kg
P02800435A0000|80 85|effect
P02800435A0000|5 15|experiments
P02800435A0000|143 145|leg
P02802280A0495|43 44|TS
P02802280A0495|13 23|differences
P02802280A0495|51 53|PTS
P02805945A0000|259 265|degree C
P02805945A0000|108 115|cultures
P02805945A0000|22 26|cysts
P02805945A0000|153 157|years
P02805945A0000|308 315|seawater
P02805945A0000|279 292|microEin m-2 s-1
P02805945A0000|91 97|cosinor
P02805945A0000|163 182|laboratory conditions
P02805945A0000|268 275|lighting
P02805945A0000|217 225|view point
P02805945A0000|30 40|growth rates
P02805945A0000|241 251|temperature
P02805945A0000|3 13|percentages
P02805945A0000|118 143|Scripsiella trochoidea Stein
P02806916A0000|199 204|oc cDNA
P02806916A0000|24 36|oryzacystatin
P02806916A0000|178 180|DNA
P02806916A0000|103 125|lambda EMBL3 phage library
P02806916A0000|154 160|digests
P02806916A0000|163 166|rice
P02806916A0000|71 78|cystatin
P02806916A0000|208 212|probe
P02806916A0000|82 85|rice
P02806916A0000|141 146|Sau3AI
P02806916A0000|43 69|cysteine proteinase inhibitor
P02806916A0000|38 39|Oc
P02806916A0000|8 15|DNA clone
P02807780A0143|125 133|diagnosis
P02807780A0143|100 104|areas
P02807780A0143|78 85|staining
P02807780A0143|48 48|%
P02807780A0143|21 28|solution
P02807780A0143|108 110|CIS
P02807780A0143|64 66|min
P02807780A0143|54 58|M NaCl
P02807780A0143|3 5|use
P02807780A0143|31 43|methylene blue
P02808232A0681|16 28|micrograms/kg
P02808232A0681|57 67|reliability
P02808232A0681|71 71|%
P02808232A0681|5 10|limits
P02809116A0237|74 81|husbands
P02809116A0237|65 71|effects
P02809116A0237|25 31|effects
P02809116A0237|105 116|satisfaction
P02809116A0237|83 92|retirement
P02809116A0237|127 131|wives
P02809651A0492|98 106|questions
P02809651A0492|37 49|meta-analysis
P02809651A0492|31 34|role
P02809651A0492|6 9|turn
P02809651A0492|59 68|clinicians
P02809651A0492|72 83|policy makers
P02809722A0926|29 39|improvement
P02809722A0926|67 77|GH secretion
P02809722A0926|16 22|patient
P02809831A0799|14 17|PPSF
P02809831A0799|37 43|amounts
P02809831A0799|19 25|DBP side
P02809831A0799|46 58|bone formation
P02809831A0799|63 66|bone
P02809831A0799|2 9|contrast
P02810911A0372|15 22|presence
P02810911A0372|25 31|absence
P02810911A0372|34 46|neuroblastoma
P02810911A0372|92 103|tumor markers
P02810911A0372|66 81|131I-MIBG imaging
P02810911A0372|3 12|accuracies
P02811378A0250|98 102|ridge
P02811378A0250|66 71|mucosa
P02811378A0250|13 17|forms
P02811378A0250|108 114|maxilla
P02811378A0250|20 24|cases
P02811378A0250|120 127|mandible
P02811378A0250|45 51|infants
P02811378A0379|132 143|cell epulides
P02811378A0379|42 49|staining
P02811378A0379|80 89|cell tumors
P02811378A0379|105 108|none
P02811378A0379|53 63|S100 protein
P02811378A0379|19 25|studies
P02813369A0390|95 100|harems
P02813369A0390|61 71|territories
P02813369A0390|22 26|males
P02813369A0390|126 134|neighbors
P02813369A0390|47 51|years
P02813369A0390|106 110|years
P02813404T0000|69 74|stages
P02813404T0000|13 23|antigen gene
P02813404T0000|77 91|spermatogenesis
P02814182A1211|2 5|rats
P02814182A1211|57 64|ABSTRACT
P02814182A1211|79 83|WORDS
P02814182A1211|38 42|4-EPI
P02814820A0967|165 171|minutes
P02814820A0967|215 220|solids
P02814820A0967|120 123|t1/2
P02814820A0967|173 173|p
P02814820A0967|150 157|Billroth
P02814820A0967|9 16|Roux limb
P02814820A0967|62 69|emptying
P02814820A0967|72 78|liquids
P02814820A0967|130 133|Roux
P02814820A0967|36 45|pacemakers
P02814820A0967|93 96|rate
P02814820A0967|107 118|Billroth dogs
P02814820A0967|142 148|minutes
P02815229A0139|97 99|14C
P02815229A0139|75 78|dose
P02815229A0139|33 40|mg t.i.d.
P02815229A0139|101 109|diltiazem
P02815229A0139|49 52|days
P02815229A0139|19 26|mg t.i.d.
P02815229A0139|54 62|treatment
P02815229A0139|93 95|MBq
P02815229A0139|3 12|treatments
P02816251A0397|130 136|surface
P02816251A0397|25 35|capillaries
P02816251A0397|97 103|network
P02816251A0397|143 152|ventricles
P02817724A0075|56 61|planes
P02817724A0075|30 40|T2 sequences
P02817724A0075|25 26|T1
P02817724A0075|44 48|scans
P02817724A0075|3 13|examination
P02818122A0000|12 22|information
P02818122A0000|164 169|nuclei
P02818122A0000|150 155|cortex
P02818122A0000|122 134|relationships
P02818122A0000|107 118|distribution
P02818122A0000|54 62|claustrum
P02818122A0000|6 9|deal
P02818122A0000|39 48|morphology
P02818122A0000|72 84|animal species
P02818260T0000|9 14|glioma
P02820128A1333|2 6|terms
P02820128A1333|61 80|hexanucleotide ATTGTT
P02820128A1333|9 27|sequence repetitions
P02820128A1333|136 141|ORF T3C
P02820128A1333|106 117|dyad symmetry
P02820128A1333|50 55|copies
P02820128A1333|97 103|regions
P02820128A1670|196 206|palindromes
P02820128A1670|94 103|palindrome
P02820128A1670|219 227|T2 protein
P02820128A1670|249 253|units
P02820128A1670|151 158|homology
P02820128A1670|174 180|insulin
P02820128A1670|64 74|coincidence
P02820128A1670|111 113|end
P02820128A1670|129 143|protein sequence
P02820128A1670|46 48|ORF
P02820128A1670|166 171|B chain
P02820128A1670|80 82|end
P02820128A1670|33 39|domains
P02820128A1670|3 14|significance
P02821340A0434|17 24|exercise
P02821340A0434|142 146|speed
P02821340A0434|107 121|mm Hg X ml-1 X min-1
P02821340A0434|125 132|workload
P02821340A0434|153 157|grade
P02821340A0434|26 28|DCR
P02821340A0434|61 65|value
P02821340A0434|138 140|kph
P02821340A0434|34 39|UT dogs
P02821340A0434|79 93|mm Hg X ml-1 X min-1
P02821340A0434|151 151|%
P02824334A0972|5 8|data
P02824334A0972|23 41|G-protein gene family
P02824334A0972|77 87|chromosomes
P02825139A0661|16 18|DNA
P02825139A0661|66 78|acid sequences
P02825139A0661|35 42|homology
P02825750A0260|13 20|patients
P02825750A0260|24 35|response rate
P02825750A0260|41 41|%
P02825750A0260|58 65|response
P02826127A0709|186 194|cell lines
P02826127A0709|50 65|SV40 octamer motif
P02826127A0709|29 39|interaction
P02826127A0709|93 105|protein oct-B2
P02826127A0709|159 166|extracts
P02826127A0709|131 139|component
P02826717A0179|0 5|Anoxia
P02826717A0179|76 84|water flow
P02826717A0179|56 61|oxygen
P02826717A0179|90 93|gill
P02826717A0179|33 36|gill
P02826717A0179|41 45|water
P02826729A0790|57 65|B-6 intake
P02826729A0790|73 76|rats
P02826729A0790|42 43|WB
P02826729A0790|7 10|4-PA
P02826729A0790|0 5|Growth
P02826729A0790|14 28|14C turnover data
P02828926A1870|21 27|factors
P02828926A1870|117 124|programs
P02828926A1870|166 186|muscle differentiation
P02828926A1870|127 145|actin gene expression
P02829183A0117|0 18|DNA sequence analysis
P02829183A0117|66 76|translocase
P02829183A0117|36 41|clones
P02829183A0117|59 63|forms
P02830214A0000|42 51|activities
P02830214A0000|25 27|ACZ
P02830214A0000|39 40|Cl
P02830214A0000|11 23|acetazolamide
P02830214A0000|3 8|effect
P02830214A0000|31 34|HCO3
P02830214A0000|97 117|microelectrode methods
P02830214A0000|59 66|ear fluid
P02830265A0341|14 29|polypeptide chain
P02830265A0341|39 45|daltons
P02830265A0341|67 78|reading frame
P02830265A0341|0 5|RPA190
P02830282A0155|13 21|A1 protein
P02830282A0155|51 60|UP1 protein
P02830282A0155|135 144|amino acids
P02830282A0155|39 46|fragment
P02830282A0155|119 130|polypeptides
P02830282A0155|96 106|V-8 protease
P02831398A0346|0 6|Irmiere
P02831398A0346|11 12|W.
P02831556A0173|99 106|response
P02831556A0173|35 41|mothers
P02831556A0173|61 64|pain
P02831556A0173|5 13|offspring
P02831556A0173|109 116|morphine
P02831556A0173|19 27|alpha-MSH
P02831556A0173|70 75|adults
P02831796A0000|74 85|similarities
P02831796A0000|174 179|humans
P02831796A0000|35 44|lentivirus
P02831796A0000|93 113|immunodeficiency virus
P02831796A0000|28 30|SIV
P02831796A0000|142 165|immunodeficiency syndrome
P02831796A0000|127 131|agent
P02831796A0000|6 26|immunodeficiency virus
P02831796A0000|167 170|AIDS
P02832149A1009|211 220|activation
P02832149A1009|9 14|change
P02832149A1009|184 194|consequence
P02832149A1009|143 152|amino acids
P02832149A1009|120 128|insertion
P02832149A1009|164 177|myb transcripts
P02832149A1009|20 24|ratio
P02832149A1009|3 6|lack
P02832149A1009|94 96|myb
P02832149A1009|226 241|mouse myb oncogene
P02832149A1009|40 47|products
P02832293T0000|42 48|Cushing
P02832293T0000|51 58|syndrome
P02832293T0000|8 13|CRF-41
P02832293T0000|62 68|obesity
P02832293T0000|3 5|use
P02832293T0000|31 39|diagnosis
P02832744A0403|64 70|chicken
P02832744A0403|10 23|mos transcripts
P02832744A0403|74 85|quail ovaries
P02832744A0403|26 33|Northern
P02832744A0403|89 94|testes
P02832744A0403|39 46|analyses
P02832744A0403|35 37|RNA
P02832744A0403|49 51|RNA
P02833012A0428|115 124|amino acids
P02833012A0428|24 34|nucleotides
P02833012A0428|12 16|L mRNA
P02833012A0428|62 73|reading frame
P02833012A0428|91 98|L protein
P02833012A0428|130 131|MW
P02833021A1185|158 173|promoter function
P02833021A1185|24 35|organization
P02833021A1185|63 68|repeat
P02833021A1185|95 105|enhancement
P02833021A1185|48 52|units
P02833021A1185|3 9|results
P02833021A1185|116 123|promoter
P02833049A0630|0 9|Variations
P02833049A0630|23 24|U3
P02833049A0630|43 52|insertions
P02833049A0630|56 64|deletions
P02833049A1041|292 300|cell types
P02833049A1041|47 55|cell lines
P02833049A1041|167 176|RD-114 mRNA
P02833049A1041|21 34|state RNA levels
P02833049A1041|228 231|loci
P02833049A1041|148 155|majority
P02833049A1041|105 115|transcripts
P02833049A1041|2 9|analysis
P02833049A1041|131 138|products
P02833101T0000|36 53|bone marrow necrosis
P02833101T0000|62 80|parvovirus infection
P02833101T0000|22 34|cell disorders
P02833101T0000|8 13|crisis
P02833517A0467|43 50|cleavage
P02833517A0467|61 67|element
P02833517A0467|24 32|sequences
P02834478A0000|44 51|interest
P02834478A0000|12 25|weight heparins
P02834478A0000|97 104|Xa factor
P02834478A0000|89 94|action
P02834843A0000|144 153|rifampicin
P02834843A0000|128 130|CGP
P02834843A0000|205 208|test
P02834843A0000|155 157|RMP
P02834843A0000|53 61|rifabutin
P02834843A0000|94 96|RPE
P02834843A0000|15 22|activity
P02834843A0000|248 260|phase cultures
P02834843A0000|99 101|CGP
P02834843A0000|222 229|activity
P02834843A0000|184 191|log phase
P02834843A0000|82 92|rifapentine
P02834843A0000|108 110|C29
P02834843A0000|77 79|F22
P02834843A0000|31 50|rifamycin derivatives
P02834843A0000|68 70|FCE
P02834843A0000|137 139|C27
P02834843A0000|113 115|CGP
P02834843A0000|121 123|C70
P02834843A0000|289 293|H37Rv
P02834843A0000|263 287|Mycobacterium tuberculosis
P02834843A0000|63 65|RBU
P02836623A1094|0 1|Mo
P02836623A1094|22 28|animals
P02836623A1094|87 88|SV
P02836623A1094|50 70|months postinoculation
P02836623A1094|106 112|animals
P02836623A1094|134 154|months postinoculation
P02836623A1094|79 85|delta Mo
P02836623A1094|3 4|SV
P02837575A0979|0 12|Sodium dodecyl
P02837575A0979|77 82|enzyme
P02837575A0979|49 61|topoisomerase
P02837575A0979|111 113|end
P02837575A0979|119 121|DNA
P02837575A0979|29 36|cleavage
P02837763A0259|0 16|Amino acid sequence
P02837763A0259|75 97|muscle phosphatase 2A cDNA
P02837763A0259|38 42|HL-14
P02837763A0259|61 66|rabbit
P02837763A0259|105 123|% nucleotide identity
P02837763A0259|27 36|liver clone
P02838246A0225|0 19|Herpes virus infection
P02838246A0225|228 228|P
P02838246A0225|188 202|rejection crises
P02838246A0225|52 61|T4/T8 ratio
P02838246A0225|128 142|T8 subpopulation
P02838246A0225|166 173|findings
P02838246A0225|38 46|inversion
P02838246A0225|71 81|sensitivity
P02838246A0225|99 99|%
P02838246A0225|84 84|%
P02838246A0225|110 122|proliferation
P02838246A0225|86 96|specificity
P02838246A0225|176 183|patients
P02838319A0527|0 3|RVEF
P02838319A0527|7 10|LVEF
P02838319A0527|33 33|%
P02838319A0527|35 35|p
P02838319A0527|51 51|p
P02838710A0299|84 92|treatment
P02838710A0299|11 16|NPY-ir
P02838710A0299|22 24|rat
P02838710A0299|3 8|levels
P02839488A1314|28 35|activity
P02839488A1314|12 17|assays
P02839488A1314|177 181|error
P02839488A1314|50 57|alpha s-1
P02839488A1314|135 142|products
P02839488A1314|96 114|erythrocyte type-1 Gs
P02839488A1314|169 174|margin
P02839716A0673|86 112|HPV-11 enhancer-SV40 promoter
P02839716A0673|7 11|cells
P02839716A0673|47 52|effect
P02839716A0673|73 80|activity
P02839716A0673|13 22|E2 proteins
P02839716A1907|44 59|enhancer activity
P02839716A1907|145 152|ABSTRACT
P02839716A1907|93 94|E2
P02839716A1907|78 88|competition
P02839716A1907|139 142|site
P02839716A1907|167 171|WORDS
P02839716A1907|19 22|E2-C
P02839716A1907|3 11|mechanism
P02840034A1266|98 104|factors
P02840034A1266|23 31|treatment
P02840034A1266|53 70|lung cancer patients
P02840034A1266|8 17|evaluation
P02840034A1266|109 115|account
P02840376A0461|1 8|anti-IIa
P02840376A0461|13 18|Holmer
P02843495A0544|0 11|Introduction
P02843495A0544|24 28|CSF-1
P02843495A0544|90 103|tumorigenicity
P02843495A0544|69 86|factor independence
P02843495A0544|44 61|macrophage cell line
P02843495A0544|119 127|mechanism
P02843495A0544|14 18|v-fms
P02843694T0001|55 64|case report
P02843694T0001|7 23|E-B virus infection
P02843694T0001|45 52|lymphoma
P02844767A0191|149 154|Kallas
P02844767A0191|22 36|cotranscription
P02844767A0191|180 181|R.
P02844767A0191|156 157|T.
P02844767A0191|90 95|plants
P02844767A0191|167 168|S.
P02844767A0191|42 51|petCA genes
P02844767A0191|100 112|apocytochrome
P02844767A0191|159 165|Spiller
P02844767A0191|114 121|proteins
P02844767A0191|63 72|Rieske-FeS
P02844767A0191|10 18|structure
P02844767A0191|173 178|Malkin
P02844767A0596|69 79|photosystem
P02844767A0596|137 152|chloroplast genes
P02844767A0596|43 50|psbB gene
P02844767A0596|109 115|introns
P02844767A0596|82 92|polypeptide
P02844767A0596|3 18|Nostoc petBD genes
P02844767A1022|0 20|RNA blot hybridizations
P02844767A1022|51 62|cytochrome b6
P02844767A1022|39 42|mRNA
P02844767A1022|66 72|subunit
P02844767A1022|124 130|subunit
P02844767A1022|107 110|mRNA
P02844767A1022|133 141|gene probe
P02844797A1225|184 195|acid sequence
P02844797A1225|112 121|amino acids
P02844797A1225|138 148|replacement
P02844797A1225|124 129|length
P02844797A1225|66 88|sequence Ala-Ile-Leu-Glu
P02844797A1225|161 170|amino acids
P02844797A1225|10 22|muscle isoform
P02844797A1225|278 294|glycosylation site
P02844797A1225|248 264|consensus sequence
P02844797A1225|36 45|amino acids
P02844797A1225|218 236|transmembrane domain
P02844797A1225|99 105|isoform
P02845654A0510|0 11|Substitution
P02845654A0510|183 184|P1
P02845654A0510|218 227|processing
P02845654A0510|123 137|tyrosine residue
P02845654A0510|51 58|position
P02845654A0510|191 202|cleavage site
P02845654A0510|163 179|amino acid position
P02845654A0510|62 63|P2
P02845654A0510|15 30|threonine residue
P02845654A0510|71 82|cleavage site
P02845654A0510|92 99|cleavage
P02845654A0510|108 119|substitution
P02845654A0510|35 48|alanine residue
P02845654A0510|141 160|phenylalanine residue
P02846640A0643|60 61|pI
P02846640A0643|37 54|indoxyl phosphatase
P02846640A0643|24 31|bacteria
P02846852A1459|40 54|E strand promoter
P02846852A1459|11 21|polymerases
P02846852A1459|3 8|number
P02846852A1459|78 88|polymerases
P02846852A1459|94 108|L strand promoter
P02846852A1459|70 75|number
P02848842A0643|1 6|family
P02848842A0643|62 66|probe
P02848842A0643|75 78|gene
P02848842A0643|34 46|kilobase range
P02848842A0643|9 20|RNA molecules
P02848842A0643|109 113|cells
P02848842A0643|31 32|.2
P02849100A0441|103 108|anchor
P02849100A0441|71 78|molecule
P02849100A0441|114 127|plasma membrane
P02849100A0441|57 65|extremity
P02849100A0441|18 25|sequence
P02849759A0865|3 14|SV40 enhancer
P02849759A0865|24 34|replication
P02849759A0865|41 44|fold
P02850472A0112|14 23|origin core
P02850472A0112|42 55|DNA replication
P02850967T0000|75 90|characterization
P02850967T0000|109 115|element
P02850967T0000|11 40|proto-oncogene fos transcription
P02850967T0000|51 73|adenylate cyclase pathway
P02850967T0000|0 8|Induction
P02850971A0180|86 103|hybridization probe
P02850971A0180|7 26|oligodeoxynucleotide
P02850971A0180|113 124|Vitreoscilla
P02850971A0180|55 75|VtHb amino acid sequence
P02850971A0180|168 185|cosmid vector pVK102
P02850971A0180|132 138|library
P02850971A0180|44 49|region
P02852805A0216|58 66|influence
P02852805A0216|13 18|solids
P02852805A0216|78 87|treatments
P02852805A0216|35 49|characteristics
P02852894T0000|0 5|Causes
P02852894T0000|37 41|study
P02852894T0000|50 57|chickens
P02852894T0000|60 71|Thai villages
P02852894T0000|8 12|death
P02853799T0001|27 35|hepatitis
P02853799T0001|90 98|carcinoma
P02853799T0001|3 13|progression
P02853799T0001|45 52|diseases
P02853799T0001|60 73|transformation
P02853799T0001|16 20|non-A
P02853922A0596|49 53|study
P02853922A0596|24 31|patients
P02853922A0596|8 10|IOP
P02853922A0596|35 38|eyes
P02856622T0001|0 2|Use
P02856622T0001|66 75|carcinomas
P02856622T0001|81 87|thyroid
P02856622T0001|5 35|serum thyroglobulin determination
P02856622T0001|41 49|follow-up
P02859434T0000|0 11|Poor response
P02859434T0000|37 41|range
P02859434T0000|45 56|serum lithium
P02859434T0000|16 25|laboratory
P02861067A0000|12 16|study
P02861067A0000|54 64|ipratropium
P02861067A0000|92 96|order
P02861067A0000|151 165|beta agonist drug
P02861067A0000|36 42|effects
P02861067A0000|67 74|patients
P02861067A0000|3 5|aim
P02861067A0000|84 89|asthma
P02861067A0000|128 147|bronchodilator effect
P02861144A0242|46 50|genes
P02861144A0242|7 14|analysis
P02861144A0242|61 76|encoding proteins
P02861144A0242|21 31|DNA fragment
P02861144A0242|94 97|kDal
P02861238T0000|7 11|virus
P02862656T0000|0 6|Changes
P02862656T0000|38 43|humans
P02862656T0000|54 66|alcohol intake
P02862656T0000|9 35|dopamine receptor sensitivity
P02863492A0544|121 128|IgG index
P02863492A0544|13 23|differences
P02863492A0544|193 202|responders
P02863492A0544|91 94|mean
P02863492A0544|37 51|treatment groups
P02863492A0544|70 79|responders
P02863747T0000|0 10|Replacement
P02863747T0000|18 29|histone genes
P02863747T0000|48 56|sequences
P02865502T0000|77 83|placebo
P02865502T0000|40 70|tissue-type plasminogen activator
P02865502T0000|22 26|trial
P02865502T0000|101 110|infarction
P02868446A0184|174 178|alpha
P02868446A0184|228 245|core enzyme subunits
P02868446A0184|191 196|enzyme
P02868446A0184|61 71|dnaG protein
P02868446A0184|50 59|DNA primase
P02868446A0184|13 19|domains
P02868446A0184|31 46|RPase beta subunit
P02868446A0184|21 24|CTDs
P02868446A0184|249 255|primase
P02868446A0184|147 156|RPase alpha
P02868848A0167|104 114|penicillin G
P02868848A0167|8 17|vancomycin
P02868848A0167|142 145|mode
P02868848A0167|154 164|gas gangrene
P02868848A0167|21 30|fosfomycin
P02868848A0167|74 81|activity
P02868848A0167|118 125|imipenem
P02869125A0120|118 137|locomotor stimulation
P02869125A0120|158 167|tachypnoea
P02869125A0120|182 188|arousal
P02869125A0120|77 84|syndrome
P02869125A0120|29 43|receptor agonist
P02869125A0120|106 114|analgesia
P02869125A0120|146 156|tachycardia
P02869125A0120|0 7|Fentanyl
P02870249T0000|12 23|chemotherapy
P02870720A0188|0 9|Bisoprolol
P02870720A0188|104 117|guinea pig atria
P02870720A0188|90 101|isoprenaline
P02870720A0188|64 72|pA2 values
P02870720A0188|33 59|beta-adrenoceptor antagonist
P02870720A0188|121 134|tracheal muscle
P02870851A0349|0 5|Output
P02870851A0349|21 32|parotid gland
P02870851A0349|62 82|parotid saliva flow rate
P02870851A0349|8 15|99mTcO-4
P02870851A0349|48 59|fluctuations
P02872786A0147|19 26|equation
P02872786A0147|103 111|sandflies
P02872786A0147|75 81|foregut
P02872786A0147|61 69|parasites
P02872786A0147|114 122|blood flow
P02872786A0147|44 50|effects
P02873593A0581|148 153|reward
P02873593A0581|11 14|rats
P02873593A0581|168 185|5-HT uptake blockers
P02873593A0581|85 90|reward
P02873593A0581|92 94|BZP
P02873593A0581|203 209|effects
P02873593A0581|120 128|frequency
P02874078A0252|64 71|patients
P02874078A0252|13 33|luteal phase deficiency
P02874078A0252|52 52|%
P02874635T0000|102 105|rats
P02874635T0000|65 74|ballooning
P02874635T0000|53 63|torticollis
P02874635T0000|91 94|mice
P02874635T0000|8 15|exposure
P02874635T0000|78 88|cleft palate
P02874635T0000|21 36|fungicide dinocap
P02874635T0000|108 115|hamsters
P02875224A1059|0 10|Reperfusion
P02875224A1059|21 25|blood
P02875224A1059|77 82|damage
P02875224A1059|166 166|p
P02875224A1059|116 128|contractility
P02875224A1059|91 96|reflow
P02875224A1059|46 51|hearts
P02875224A1059|31 37|beating
P02875224A1059|134 141|instance
P02875224A1059|146 146|%
P02875967A0377|97 109|fertility rate
P02875967A0377|32 41|adrenaline
P02875967A0377|67 76|guinea pigs
P02875967A0377|3 13|sensitivity
P02876820A0841|67 68|mV
P02876820A0841|11 18|acidosis
P02876820A0841|34 44|stimulation
P02876899A0568|73 102|bevantolol plasma concentrations
P02876899A0568|108 122|absorption phase
P02876899A0568|32 39|subjects
P02876899A0568|64 70|decline
P02876899A0568|2 5|Days
P02877124A0000|464 469|sacrum
P02877124A0000|450 454|femur
P02877124A0000|247 252|agents
P02877124A0000|213 225|drinking water
P02877124A0000|365 366|Tc
P02877124A0000|456 460|ilium
P02877124A0000|151 165|trifluoperazine
P02877124A0000|410 412|end
P02877124A0000|48 55|tap water
P02877124A0000|255 272|bone mineral content
P02877124A0000|20 29|B6D2F1 mice
P02877124A0000|75 87|phenothiazine
P02877124A0000|376 384|indicator
P02877124A0000|139 147|H1 blocker
P02877124A0000|92 117|H1 receptor blocking activity
P02877124A0000|370 372|MDP
P02877124A0000|418 424|studies
P02877124A0000|322 334|body retention
P02877124A0000|441 447|weights
P02877124A0000|342 363|methylene diphosphonate
P02877124A0000|12 16|B6AF1
P02877124A0000|337 338|Tc
P02877124A0000|387 400|bone metabolism
P02877124A0000|187 204|H1 blocking activity
P02877124A0000|120 135|chlorpheniramine
P02877124A0000|168 180|phenothiazine
P02877124A0000|58 72|promethazine HCl
P02877124A0000|233 239|effects
P02878100A0674|62 73|transmission
P02878100A0674|7 13|results
P02878100A0674|40 49|inhibition
P02878100A0674|179 190|transmission
P02878100A0674|139 146|activity
P02878100A0674|100 108|diltiazem
P02878100A0674|76 84|diltiazem
P02879906A0000|0 6|Studies
P02879906A0000|74 85|relationship
P02879906A0000|52 61|rabbit face
P02879906A0000|93 127|beta adrenoceptor subtype distribution
P02879906A0000|40 44|veins
P02879906A0000|164 179|nerve innervation
P02879906A0000|146 149|tone
P02879951T0000|29 33|agent
P02879951T0000|35 42|SGB-1534
P02879951T0000|46 67|rat platelet aggregation
P02879951T0000|0 6|Effects
P02880841A0313|90 98|structure
P02880841A0313|155 158|gene
P02880841A0313|246 257|chloroplasts
P02880841A0313|104 114|beta subunit
P02880841A0313|220 221|F1
P02880841A0313|73 75|TF1
P02880841A0313|171 178|sequence
P02880841A0313|60 63|gene
P02880841A0313|236 244|membranes
P02880841A0313|41 49|structure
P02880841A0313|208 217|categories
P02880841A0313|19 21|TF1
P02880841A0313|132 149|nucleotide sequence
P02880841A0313|262 273|mitochondria
P02880841A0313|8 16|stability
P02880841A0313|190 193|beta
P02882893A0301|0 14|Body temperature
P02882893A0301|25 35|conductance
P02882893A0301|69 81|P. s. campbelli
P02882893A0301|98 99|sp
P02883327A0413|56 61|region
P02883327A0413|89 91|end
P02883327A0413|104 109|region
P02883327A0413|72 74|DNA
P02883327A0413|54 54|E
P02883327A0413|102 102|L
P02883327A0413|3 22|polyadenylation sites
P02883327A0413|40 42|end
P02883871A1075|1 4|drug
P02883871A1075|9 11|ISA
P02883871A1075|140 142|ISA
P02883871A1075|127 132|agents
P02883871A1075|53 56|drug
P02883871A1075|95 114|drug hypersensitivity
P02883871A1075|27 39|beta receptors
P02883871A1075|117 124|contrast
P02883963A0000|3 10|patients
P02883963A0000|78 80|HAM
P02883963A0000|38 46|virus type
P02883963A0000|49 54|HTLV-I
P02883963A0000|20 25|T-cell
P02883963A0000|67 76|myelopathy
P02883963A0000|113 119|methods
P02884860A0329|29 36|prazosin
P02884860A0329|104 110|therapy
P02884860A0329|50 54|alpha
P02884860A0329|21 26|analog
P02884860A0329|56 68|adrenoceptors
P02884860A0329|0 8|Terazosin
P02885517T0000|32 40|hepatitis
P02885517T0000|7 17|blood donors
P02885517T0000|21 25|non-A
P02889352A0000|113 127|enzyme inhibitor
P02889352A0000|20 32|blood pressure
P02889352A0000|34 35|BP
P02889352A0000|71 79|compounds
P02889352A0000|91 101|beta blocker
P02889352A0000|62 68|classes
P02889352A0000|4 11|patients
P02889352A0000|130 146|calcium antagonist
P02889495A0000|116 119|dose
P02889495A0000|25 29|study
P02889495A0000|125 127|end
P02889495A0000|78 89|flupenthixol
P02889495A0000|38 58|episode schizophrenics
P02889495A0000|68 75|pimozide
P02889495A0000|150 163|mg flupenthixol
P02889495A0000|135 144|mg pimozide
P02889495A0000|98 102|weeks
P02890200T0001|64 80|neurofibromatosis
P02890200T0001|41 45|tumor
P02890200T0001|48 61|Recklinghausen
P02892762A0296|17 30|repeat elements
P02892762A0296|62 63|nt
P02892762A0296|50 60|nucleotides
P02892762A0296|73 84|promoter site
P02894689A0000|27 38|DNA fragments
P02894689A0000|110 118|lithium-3
P02894689A0000|84 102|extraction procedure
P02894689A0000|72 75|help
P02894689A0000|124 139|diiodosalicylate
P02894689A0000|44 48|bases
P02894689A0000|51 64|chromatin loops
P02894741A0000|31 40|vecuronium
P02894741A0000|52 67|muscle relaxation
P02894741A0000|24 28|doses
P02894741A0000|84 99|NLA II anaesthesia
P02894789A0954|58 62|T1/T0
P02894789A0954|11 25|recovery indexes
P02894789A0954|66 70|T4/T1
P02894789A0954|88 88|%
P02894789A0954|83 83|%
P02894789A0954|42 46|times
P02895472A0178|72 75|cDNA
P02895472A0178|54 61|plasmids
P02895472A0178|105 119|mRNA translation
P02895472A0178|20 27|colonies
P02895472A0178|85 87|BiP
P02895566A0187|128 148|pressure pain component
P02895566A0187|54 75|pressure pain components
P02895566A0187|90 105|ischemia duration
P02895566A0187|16 23|increase
P02895566A0187|117 122|effect
P02895566A0187|29 37|intensity
P02895566A0187|0 2|DPA
P02895754A0000|234 241|syndrome
P02895754A0000|33 40|presence
P02895754A0000|222 224|eye
P02895754A0000|160 166|chamber
P02895754A0000|8 27|percent isoproterenol
P02895754A0000|226 231|Horner
P02895754A0000|46 83|phosphodiesterase inhibitor theophylline
P02895754A0000|120 123|rate
P02895754A0000|99 105|ability
P02895754A0000|133 141|humor flow
P02897651A0000|0 14|Hyperthyroidism
P02897651A0000|64 71|abortion
P02897651A0000|33 38|causes
P02897651A0000|41 51|infertility
P02898752A0683|86 102|platelets recovery
P02898752A0683|34 40|numbers
P02898752A0683|65 68|rate
P02898752A0683|7 17|correlation
P02898752A0683|43 48|CFU-GM
P02898752A0683|71 82|granulocytes
P02899177A0605|158 164|regions
P02899177A0605|125 129|drugs
P02899177A0605|88 94|effects
P02899177A0605|16 24|technique
P02899177A0605|135 146|excitability
P02899177A0605|69 73|model
P02899177A0605|27 47|low-frequency kindling
P02899792T0000|0 8|Oestrogen
P02899792T0000|16 23|overdose
P02900760A0073|133 151|transcription system
P02900760A0073|105 108|pol I
P02900760A0073|206 213|3T6 cells
P02900760A0073|90 103|RNA polymerase I
P02900760A0073|64 87|transcription termination
P02900760A0073|180 201|rDNA minigene constructs
P02900760A0073|166 177|transfection
P02900760A0073|5 20|sequence elements
P02901498A0354|43 50|proteins
P02901498A0354|135 158|chicken embryo fibroblasts
P02901498A0354|117 123|ability
P02901498A0354|83 93|erbB protein
P02901498A0354|3 14|biosynthesis
P02901498A0354|18 26|stability
P02901763A0977|102 106|genes
P02901763A0977|126 135|codon usage
P02901763A0977|61 66|codons
P02901763A0977|243 258|protein synthesis
P02901763A0977|12 36|C. reinhardtii mitochondria
P02901763A0977|162 179|C. reinhardtii mtDNA
P02901763A0977|210 214|tRNAs
P02901763A0977|202 207|number
P02901763A0977|0 9|Codon usage
P02902615A0000|44 56|polyarteritis
P02902615A0000|104 113|hepatitis B
P02902615A0000|80 88|treatment
P02902615A0000|126 133|patients
P02902615A0000|22 30|treatment
P02902615A0000|67 74|advances
P02902656A0481|114 118|cases
P02902656A0481|106 107|TE
P02902656A0481|123 134|hyperintense
P02902656A0481|52 54|fat
P02902656A0481|76 89|repetition time
P02902656A0481|101 104|time
P02902656A0481|39 49|hypointense
P02902656A0481|137 146|isointense
P02902656A0481|183 187|cases
P02902656A0481|158 171|TR/TE sequences
P02902656A0481|149 151|fat
P02902656A0481|11 16|testes
P02902656A0481|91 92|TR
P02902656A0481|57 65|sequences
P02902656A0481|29 34|testes
P02902844A1219|29 32|gene
P02902844A1219|99 108|atp operons
P02902844A1219|59 65|protein
P02902844A1219|12 15|gene
P02902844A1219|133 145|cyanobacteria
P02902844A1219|118 129|bacterium PS3
P02902927A0145|18 26|isolation
P02902927A0145|38 55|rat GHF-1 cDNA clones
P02903500A0278|140 153|immunoglobulin
P02903500A0278|22 31|properties
P02903500A0278|53 55|neu
P02903500A0278|37 43|protein
P02903500A0278|100 105|domain
P02903500A0278|67 76|fusion gene
P02903500A0278|108 110|neu
P02903500A0278|159 163|chain
P02903500A0278|129 135|portion
P02904322A0002|21 28|antelope
P02904322A0002|76 82|studies
P02904322A0002|49 61|model ruminant
P02906027A0553|128 143|CpG dinucleotides
P02906027A0553|23 28|blocks
P02906027A0553|92 100|CpG island
P02906027A0553|65 70|region
P02906027A0553|31 38|homology
P02906027A0553|2 19|sequence comparison
P02906027A1156|59 67|sequences
P02906027A1156|12 19|features
P02906027A1156|85 90|intron
P02906027A1156|42 42|G
P02906249A1195|100 105|Oxy-Hb
P02906249A1195|33 37|mg/kg
P02906249A1195|10 14|group
P02906249A1195|108 116|PGF2 alpha
P02906249A1195|20 28|% Prazosin
P02906249A1195|73 77|hours
P02906249A1195|87 97|application
P02906673T0000|0 7|Efficacy
P02906673T0000|77 96|floodwater mosquitoes
P02906673T0000|11 25|field evaluation
P02906673T0000|58 69|B. sphaericus
P02906673T0000|50 53|H-14
P02906673T0000|99 108|California
P02906673T0000|28 48|Bacillus thuringiensis
P02907308T0001|26 48|Richner-Hanhart syndrome
P02907308T0001|8 11|type
P02907308T0001|1 5|cases
P02907308T0001|14 24|tyrosinosis
P02907533A0362|45 60|correction factor
P02907533A0362|24 40|drug concentration
P02907533A0362|94 114|diazepam concentration
P02907533A0362|4 7|loss
P02907533T0000|44 58|diazepam binding
P02907533T0000|27 41|blood substitute
P02907533T0000|66 72|albumin
P02907533T0000|0 6|Effects
P02909528A1081|41 46|region
P02909528A1081|80 89|start sites
P02909528A1081|7 22|promoter activity
P02910496A0583|147 158|RNAase MRP RNA
P02910496A0583|20 32|CGA-CCCCUCC-3
P02910496A0583|1 15|decamer sequence
P02910496A0583|120 131|RNA substrate
P02910496A0583|90 101|cleavage site
P02910496A0583|60 67|sequence
P02910989T0000|0 6|Effects
P02910989T0000|9 13|aging
P02910989T0000|59 71|QT/QS2 changes
P02910989T0000|17 40|beta-adrenergic-blockade
P02911540A0478|111 114|care
P02911540A0478|47 51|hands
P02911540A0478|22 26|wound
P02911540A0478|58 61|face
P02911540A0478|53 56|feet
P02911540A0478|42 45|area
P02911540A0478|65 72|perineum
P02911540A0478|1 7|patient
P02913368A1037|0 18|Pharmacology studies
P02913368A1037|81 97|calcium antagonist
P02913368A1037|23 39|potassium chloride
P02913368A1037|111 116|influx
P02913368A1037|67 73|raveron
P02913368A1037|43 55|acetylcholine
P02913368A1037|132 138|calcium
P02914422A0409|0 15|Computer analysis
P02914422A0409|78 91|frequency bands
P02914422A0409|142 148|notches
P02914422A0409|113 126|frequency range
P02914422A0409|94 98|order
P02914422A0409|152 156|slurs
P02914422A0409|31 39|averaging
P02914492A0183|199 204|mEq/dl
P02914492A0183|16 18|ICU
P02914492A0183|158 164|percent
P02914492A0183|78 83|mEq/dl
P02914492A0183|148 155|patients
P02914492A0183|23 30|patients
P02914492A0183|134 139|mEq/dl
P02914492A0183|88 95|patients
P02914492A0183|110 124|normomagnesemia
P02914492A0183|99 105|percent
P02914492A0183|45 58|hypomagnesemia
P02914492A0183|169 183|hypermagnesemia
P02914492A0183|34 40|percent
P02914492A0183|60 66|serum Mg
P02914492A0183|2 10|admission
P02916764A0253|29 31|sex
P02916764A0253|33 44|hypertension
P02916764A0253|110 119|life-style
P02916764A0253|63 82|hypercholesterolemia
P02916764A0253|46 61|diabetes mellitus
P02916764A0253|84 99|cigarette smoking
P02916764A0253|124 136|family history
P02916764A0253|3 13|risk factors
P02918474A0817|85 98|subendocardium
P02918474A0817|56 64|blood flow
P02918474A0817|126 138|subepicardium
P02918474A0817|36 45|collateral
P02918474A0817|113 120|ml/min/g
P02918474A0817|7 15|verapamil
P02918474A0817|19 28|nifedipine
P02919483A0091|20 24|girls
P02919483A0091|35 37|age
P02919483A0091|11 14|boys
P02919483A0091|48 56|half years
P02919530A0000|150 159|wall motion
P02919530A0000|28 38|reperfusion
P02919530A0000|84 98|artery occlusion
P02919530A0000|184 194|alterations
P02919530A0000|123 128|effect
P02919530A0000|49 58|myocardium
P02919832A0144|74 96|Doppler echocardiography
P02919832A0144|7 13|disease
P02919832A0144|32 37|M-mode
P02920591A0251|75 87|micrograms/kg
P02920591A0251|66 72|digoxin
P02920591A0251|92 99|dopamine
P02920591A0251|11 20|assessment
P02920591A0251|106 122|micrograms/kg/min
P02920591A0251|50 63|administration
P02923687A0218|71 78|patients
P02923687A0218|39 42|side
P02923687A0218|93 103|cleft palate
P02923687A0218|60 68|cleft side
P02923687A0218|45 53|sinusitis
P02923687A0218|17 28|relationship
P02925013A1112|87 98|accumulation
P02925013A1112|38 45|aluminum
P02925013A1112|24 29|levels
P02925013A1112|111 123|citrate ligand
P02925013A1112|69 74|tissue
P02925568A0460|42 51|conditions
P02925568A0460|155 169|psychopathology
P02925568A0460|130 144|family stressors
P02925568A0460|71 77|samples
P02925568A0460|8 14|effects
P02925568A0460|17 29|father absence
P02925568A0460|99 105|effects
P02926499A0340|32 42|analog model
P02926499A0340|215 218|heat
P02926499A0340|107 109|CBF
P02926499A0340|125 127|CBF
P02926499A0340|201 201|c
P02926499A0340|175 177|rho
P02926499A0340|139 139|c
P02926499A0340|161 165|decay
P02926499A0340|45 52|heat flow
P02926499A0340|183 189|density
P02926499A0340|129 130|Cb
P02926499A0340|94 103|expression
P02926499A0340|62 66|brain
P02926499A0340|192 196|blood
P02926499A0340|146 148|tau
P02927391A0238|134 140|tissues
P02927391A0238|192 199|germ line
P02927391A0238|102 109|germ line
P02927391A0238|21 30|proviruses
P02927391A0238|164 174|integration
P02927391A0238|49 69|founder SWR/J-RF/J mice
P02927391A0238|225 232|lineages
P02928112T0000|54 60|protein
P02928112T0000|52 52|A
P02928112T0000|36 37|U2
P02928112T0000|9 15|cloning
P02928112T0000|21 24|cDNA
P02928376A0312|110 110|%
P02928376A0312|63 67|gases
P02928376A0312|23 27|water
P02928376A0312|80 89|heat defect
P02928376A0312|47 53|mixture
P02928376A0312|13 16|work
P02928376A0312|56 57|H2
P02929056T0000|15 38|transureteroureterostomy
P02929056T0000|10 12|use
P02929056T0000|84 90|failure
P02929056T0000|48 67|ureterosigmoidostomy
P02930623A0404|81 82|ms
P02930623A0404|88 93|impact
P02930623A0404|25 30|torque
P02930623A0404|63 71|direction
P02930623A0404|6 20|flexion whiplash
P02930623A0404|45 51|condyle
P02934778A0702|29 33|5-HT2
P02934778A0702|82 88|species
P02934778A0702|46 54|receptors
P02934778A0702|19 26|presence
P02934778A0702|3 6|data
P02934778A0702|69 74|artery
P02934889A0558|0 10|Oxfendazole
P02934889A0558|79 81|May
P02934889A0558|101 113|cent reduction
P02934889A0558|52 55|days
P02934889A0558|40 43|time
P02934889A0558|160 169|D viviparus
P02934889A0558|64 68|start
P02934889A0558|145 157|cent reduction
P02934889A0558|116 132|Ostertagia species
P02934889A0558|71 77|grazing
P02934891A0845|73 77|cells
P02934891A0845|175 177|end
P02934891A0845|140 150|nucleotides
P02934891A0845|11 16|method
P02934891A0845|169 170|Mu
P02934891A0845|57 59|ner
P02934891A0845|47 54|extracts
P02934891A0845|118 122|sites
P02935638A0000|63 99|sea urchin Strongylocentrotus purpuratus
P02935638A0000|35 43|structure
P02935638A0000|49 57|Spec1 gene
P02936163T0000|0 15|Platelet function
P02936163T0000|56 66|interaction
P02936163T0000|69 76|patients
P02936163T0000|90 117|platelet lipoxygenase activity
P02936284A0357|72 74|man
P02936284A0357|36 41|plasma
P02936284A0357|11 21|degradation
P02936284A0357|52 56|route
P02936284A0357|135 137|min
P02936284A0357|24 33|atracurium
P02936284A0357|97 116|elimination half-life
P02936284A0357|59 69|elimination
P02938185A0223|131 138|degrees C
P02938185A0223|78 84|viruses
P02938185A0223|47 61|E1b gene products
P02938185A0223|36 38|E1a
P02938185A0223|11 19|cell lines
P02938185A0223|178 189|architecture
P02938185A0223|147 154|degrees C
P02938185A0223|225 233|CREF cells
P02938185A0223|121 126|growth
P02938185A0223|41 43|E1a
P02939260A1553|209 224|Edman degradation
P02939260A1553|80 89|methionine
P02939260A1553|92 99|residues
P02939260A1553|201 206|cycles
P02939260A1553|61 72|42K T antigens
P02939260A1553|124 134|DNA sequence
P02939260A1553|55 57|43K
P02939260A1553|145 154|methionine
P02939260A1553|17 41|amino acid sequence analysis
P02939260A1553|173 183|39K T antigen
P02940334A0141|0 5|Group A
P02940334A0141|89 97|schedules
P02940334A0141|54 61|globulin
P02940334A0141|63 66|HBIG
P02940334A0141|31 35|doses
P02940334A0141|38 47|hepatitis B
P02941237A0160|174 188|pyrophosphatase
P02941237A0160|47 74|phosphorous ion concentrations
P02941237A0160|257 261|roles
P02941237A0160|76 83|tissue pH
P02941237A0160|11 18|instance
P02941237A0160|139 145|enzymes
P02941237A0160|97 104|hormones
P02941237A0160|152 170|alkaline phosphatase
P02941237A0160|22 29|addition
P02941237A0160|32 43|serum calcium
P02941237A0160|111 118|vitamin D
P02941237A0160|120 127|vitamin A
P02941237A0160|85 95|blood supply
P02943562T0000|0 22|Penicillinase production
P02943562T0000|62 71|importance
P02943562T0000|45 51|strains
P02947866A1416|17 24|analysis
P02947866A1416|27 44|thallium-201 uptake
P02947866A1416|123 133|angioplasty
P02947866A1416|72 79|evidence
P02947866A1416|48 54|washout
P02947866A1416|101 109|perfusion
P02949170A0184|4 8|study
P02949170A0184|19 25|effects
P02949170A0184|46 71|micrograms ethinyl estradiol
P02949170A0184|234 239|months
P02949170A0184|76 95|mg cyproterone acetate
P02949170A0184|112 120|prolactin
P02949170A0184|167 181|androstenedione
P02949170A0184|161 164|SHBG
P02949170A0184|98 110|gonadotropins
P02949170A0184|135 159|sex hormone binding globulin
P02949170A0184|200 216|testosterone index
P02949170A0184|242 250|treatment
P02949170A0184|122 133|testosterone
P02949170A0184|29 39|preparation
P02950216A0084|69 80|output signal
P02950216A0084|10 13|flow
P02950216A0084|114 118|terms
P02950216A0084|53 55|LDF
P02950216A0084|31 51|laser Doppler flowmetry
P02950216A0084|121 125|volts
P02950216A0084|82 94|blood cell flux
P02950216A0084|96 98|BCF
P02957125A0601|72 84|cent reduction
P02957125A0601|87 108|plasma ANP concentration
P02957125A0601|37 49|haemodialysis
P02957125A0601|23 29|failure
P02957125A0601|6 13|patients
P02958204A0175|59 74|HDL phospholipids
P02958204A0175|108 124|HDL-C subfractions
P02958204A0175|126 131|HDL2-C
P02958204A0175|183 188|course
P02958204A0175|53 57|HDL-C
P02958204A0175|76 81|HDL-PL
P02958204A0175|207 215|mg/kg/day
P02958204A0175|25 36|isotretinoin
P02958204A0175|220 228|treatment
P02958204A0175|158 165|patients
P02958204A0175|16 22|effects
P02958204A0175|97 102|apo A-1
P02958204A0175|135 140|HDL3-C
P02958204A0175|39 41|HDL
P02958204A0175|191 202|isotretinoin
P02958204A0175|237 248|acne vulgaris
P02958204A0175|84 95|apoprotein A1
P02958233A0123|60 80|serum sickness reaction
P02958233A0123|11 17|picture
P02958233A0123|21 40|laboratory parameters
P02958660A1094|96 105|experiment
P02958660A1094|63 71|LDF signal
P02958660A1094|108 117|experiment
P02958660A1094|44 59|conversion factor
P02958660A1094|32 40|existence
P02958660A1094|82 91|flow values
P02958660A1094|3 6|data
P02959089T0000|41 50|vasospasms
P02959089T0000|10 15|effect
P02959089T0000|18 25|ONO-3708
P02959089T0000|28 37|thrombosis
P02960012A0838|14 24|PPNG strains
P02960012A0838|3 11|frequency
P02960012A0838|53 53|%
P02960012A0838|41 41|%
P02962859A0276|75 79|clone
P02962859A0276|36 66|beta-galactosidase fusion protein
P02962859A0276|12 21|antibodies
P02962859A0276|94 95|U1
P02962859A0276|110 117|A antigen
P02963517A0453|99 106|increase
P02963517A0453|12 19|analysis
P02963517A0453|77 86|dilatation
P02963517A0453|138 141|area
P02963517A0453|166 168|mm2
P02963517A0453|66 69|PTCA
P02963517A0453|33 40|stenosis
P02964329A0000|114 122|incidence
P02964329A0000|24 36|Joint Mobility
P02964329A0000|38 40|LJM
P02964329A0000|44 51|diabetes
P02964329A0000|125 139|microangiopathy
P02964329A0000|3 14|pathogenesis
P02964329A0000|68 78|abnormality
P02965149A0727|17 22|Brandl
P02965149A0727|11 15|study
P02965149A0727|24 25|C.
P02966671A0151|171 175|weeks
P02966671A0151|53 58|tumors
P02966671A0151|201 209|treatment
P02966671A0151|94 101|survival
P02966671A0151|31 34|time
P02966671A0151|77 89|treatment size
P02966671A0151|104 112|stem cells
P02966671A0151|190 194|weeks
P02966671A0151|139 151|breathing rate
P02966671A0151|67 71|times
P02966671A0151|15 23|end points
P02966671A0151|126 131|crypts
P02966671A0551|0 7|Schedule
P02966671A0551|20 29|mg/kg c-DDP
P02966671A0551|124 138|radiation effect
P02966671A0551|103 108|degree
P02966671A0551|188 198|enhancement
P02966671A0551|214 223|mg/kg c-DDP
P02966671A0551|162 167|factor
P02966671A0551|248 252|start
P02966671A0551|272 283|radiotherapy
P02966671A0551|62 66|X-ray
P02966671A0551|111 121|enhancement
P02966671A0551|238 238|h
P02966671A0551|81 84|days
P02967496A0182|132 137|region
P02967496A0182|121 125|cpc-1
P02967496A0182|96 108|leader segment
P02967496A0182|16 25|transcript
P02967496A0182|43 55|reading frames
P02967915A0000|15 44|hormone 1,25-dihydroxyvitamin D3
P02967915A0000|103 116|calbindin-D28K
P02967915A0000|63 72|expression
P02967915A0000|129 141|target tissues
P02967915A0000|76 96|calcium binding protein
P02967915A0000|120 126|variety
P02967915A0968|72 80|sequences
P02967915A0968|126 132|signals
P02967915A0968|96 105|components
P02967915A0968|49 55|variety
P02967915A0968|2 9|addition
P02967915A0968|14 35|calbindin-D28K promoter
P02968055A0984|28 35|increase
P02968055A0984|38 40|ANF
P02968055A0984|3 5|HOI
P02969316A0002|218 223|pacing
P02969316A0002|93 95|ANP
P02969316A0002|46 65|plasma concentrations
P02969316A0002|23 27|atria
P02969316A0002|194 194|h
P02969316A0002|11 17|ability
P02969316A0002|183 186|dogs
P02969316A0002|109 115|changes
P02969316A0002|85 91|peptide
P02969316A0002|118 140|plasma ANP concentrations
P02969819A0814|0 19|Ig D-JH recombinations
P02969819A0814|62 71|T cell lines
P02969819A0814|103 116|Cmu transcripts
P02969819A0814|30 49|TcR gene recombination
P02970061A0271|83 88|weight
P02970061A0271|48 57|amino acids
P02970061A0271|36 42|protein
P02970061A0271|16 27|reading frame
P02970061A0271|3 11|RAD18 gene
P02970640A0341|161 164|zinc
P02970640A0341|143 153|acid protein
P02970640A0341|97 107|acid protein
P02970640A0341|116 122|zinc ion
P02970640A0341|6 32|absorption spectrophotometry
P02970640A0341|62 72|E1A proteins
P02971603A0883|30 38|injection
P02971603A0883|21 27|tablets
P02971603A0883|45 47|day
P02971603A0883|4 11|patients
P02971710A0734|0 4|Plots
P02971710A0734|75 84|hematocrit
P02971710A0734|17 24|2A weight
P02971710A0734|123 131|viscosity
P02971710A0734|87 87|%
P02971710A0734|10 11|LV
P02971710A0734|58 68|inflections
P02971710A0734|159 168|hematocrit
P02971710A0734|13 13|S
P02971710A0734|134 135|CO
P02971710A0734|108 111|role
P02971710A0734|7 8|RV
P02971710A0734|31 40|hematocrit
P02971957A0287|84 93|techniques
P02971957A0287|113 120|bleeding
P02971957A0287|62 66|cases
P02971957A0287|24 27|mesh
P02971957A0287|41 51|improvement
P02973304A0000|74 77|vein
P02973304A0000|12 17|course
P02973304A0000|142 156|cardiosclerosis
P02973304A0000|53 62|thrombosis
P02973304A0000|20 38|Budd-Chiari syndrome
P02973304A0000|107 122|patient suffering
P02975680A0000|208 212|group
P02975680A0000|215 222|patients
P02975680A0000|276 283|patients
P02975680A0000|80 85|nights
P02975680A0000|27 44|sleep EEG recordings
P02975680A0000|131 145|anxiety disorder
P02975680A0000|272 274|MDD
P02975680A0000|100 109|inpatients
P02975680A0000|166 175|depression
P02975680A0000|227 229|GAD
P02975680A0000|190 192|age
P02975680A0000|263 270|disorder
P02975680A0000|8 25|accommodation night
P02975680A0000|234 238|group
P02975680A0000|147 149|GAD
P02975753A1333|0 25|Oligonucleotide mutagenesis
P02975753A1333|106 115|E3 promoter
P02975753A1333|61 70|importance
P02975753A1333|33 46|binding domains
P02975753A1333|91 100|regulation
P02975753A1333|118 127|yeast cells
P02976332A1277|18 21|PGI2
P02976332A1277|46 52|surface
P02976332A1277|3 15|concentration
P02979426T0000|0 19|Organ transplantation
P02979426T0000|22 28|Denmark
P02979834T0000|106 119|ethyl carbamate
P02979834T0000|138 147|lung cancer
P02979834T0000|26 59|maltose tetrapalmitate immunotherapy
P02979834T0000|92 103|radiotherapy
P02979834T0000|61 88|cyclophosphamide chemotherapy
P02979834T0000|150 156|A/J mice
P02979834T0000|0 6|Effects
P02981457A0368|0 1|D.
P02981840A0907|90 90|d
P02981840A0907|9 20|pair sequence
P02981840A0907|92 93|AC
P02981840A0907|95 101|repeats
P02981840A0907|62 72|nucleotides
P02982332T0001|0 4|Phase
P02982332T0001|35 40|tumors
P02982332T0001|7 11|study
P02982332T0001|20 26|capsule
P02982332T0001|14 18|VP-16
P02983316A0310|233 240|sequence
P02983316A0310|167 177|caiman genes
P02983316A0310|281 298|nucleotide sequence
P02983316A0310|313 318|period
P02983316A0310|139 146|analysis
P02983316A0310|35 43|framework
P02983316A0310|106 119|probe sequences
P02983316A0310|333 336|time
P02983316A0310|47 80|complementarity-determining regions
P02983316A0310|267 278|preservation
P02983316A0310|89 93|genes
P02983316A0310|13 20|segments
P02983331T0000|0 7|Evidence
P02983331T0000|12 15|role
P02983331T0000|51 56|factor
P02983331T0000|64 68|ether
P02983331T0000|97 102|stress
P02983331T0000|70 83|immobilization
P02985812A0984|55 58|mRNA
P02985812A0984|34 38|genes
P02985812A0984|9 15|feature
P02985812A0984|103 106|mRNA
P02985812A0984|80 91|reading frame
P02985820A1287|130 132|MH2
P02985820A1287|9 24|sequence elements
P02985820A1287|106 121|retroviruses CMII
P02985820A1287|82 88|genesis
P02985820A1287|57 65|c-myc gene
P02985820A1287|123 126|MC29
P02985820A1287|44 50|vectors
P02986279A0000|28 33|donors
P02986279A0000|107 109|CMV
P02986279A0000|91 105|cytomegalovirus
P02986279A0000|35 38|days
P02986279A0000|42 47|months
P02986279A0000|79 88|occurrence
P02986279A0000|53 60|delivery
P02986279A0000|2 12|milk samples
P02987220A0472|44 45|kb
P02987220A0472|134 139|region
P02987220A0472|110 112|FBP
P02987220A0472|114 117|gene
P02987220A0472|12 23|DNA fragments
P02987220A0472|47 52|insert
P02987220A0472|55 59|pAVO4
P02987220A0472|72 82|DNA fragment
P02987220A0472|0 9|Subcloning
P02987777A0000|30 42|cell carcinoma
P02987777A0000|48 53|rectum
P02987777A0000|5 9|cases
P02988457A0650|56 72|Bestatin treatment
P02988457A0650|42 53|potentiality
P02988457A0650|88 97|malignancy
P02988457A0650|81 85|types
P02988457A0650|3 6|data
P02989637A0671|206 211|system
P02989637A0671|112 119|patients
P02989637A0671|284 286|men
P02989637A0671|5 8|data
P02989637A0671|268 281|renin secretion
P02989637A0671|32 41|regulation
P02989637A0671|51 79|zona glomerulosa corticosteroid
P02989637A0671|227 251|metoclopramide stimulation
P02989637A0671|134 149|cord transections
P02989637A0671|254 264|aldosterone
P02989637A0671|88 101|renin secretion
P02989637A0671|177 184|pathways
P02989786A0328|14 30|enhancer sequences
P02989786A0328|35 51|adenovirus E1A gene
P02989786A0328|5 11|absence
P02989786A0328|67 81|CATase synthesis
P02991060A0465|84 88|cases
P02991060A0465|23 28|babies
P02991060A0465|99 104|months
P02991060A0465|51 58|delivery
P02991060A0465|118 123|babies
P02991060A0465|107 110|ages
P02991060A0465|130 135|months
P02991060A0465|5 17|IgG antibodies
P02993630A1190|42 47|events
P02993630A1190|53 61|digestion
P02993630A1190|4 11|analysis
P02993630A1190|88 100|enzyme attacks
P02993630A1190|138 144|message
P02993630A1190|127 129|G-A
P02993630A1190|17 31|nucleotide level
P02993630A1190|66 75|nuclease S1
P02993630A1190|118 125|sequence
P02993630A1190|158 163|strand
P02994253A0482|218 218|%
P02994253A0482|25 39|mean NTE activity
P02994253A0482|235 241|animals
P02994253A0482|78 82|brain
P02994253A0482|48 51|cord
P02994253A0482|178 193|days postexposure
P02994253A0482|108 120|control values
P02994253A0482|74 74|%
P02994253A0482|163 175|cord pathology
P02994253A0482|105 105|%
P02994253A0482|5 11|dosages
P02994253A0482|129 142|hr postexposure
P02994336A0864|0 1|FK
P02994336A0864|83 95|bromocriptine
P02994336A0864|50 59|plasma ACTH
P02994336A0864|64 64|%
P02994336A0864|123 128|change
P02994336A0864|97 102|CB-154
P02994336A0864|31 38|analogue
P02994336A0864|72 76|level
P02995967T0000|15 27|protooncogene
P02995967T0000|128 146|gland adenocarcinoma
P02995967T0000|55 62|c-erbB-1
P02995967T0000|73 97|growth factor-receptor gene
P02995967T0000|29 36|c-erbB-2
P02995999A0000|3 18|sequence analysis
P02995999A0000|45 47|phi
P02995999A0000|124 133|attachment
P02995999A0000|206 223|recombination event
P02995999A0000|25 32|products
P02995999A0000|269 287|recombination events
P02995999A0000|194 201|position
P02995999A0000|63 81|recombination events
P02995999A0000|97 109|recombination
P02995999A0000|135 137|att
P02995999A0000|139 142|site
P02995999A0000|241 257|base-pair deletion
P02995999A0000|316 337|base-pair substitutions
P02995999A0000|173 178|joints
P02997622A0916|68 85|SCLC tumour specimen
P02997622A0916|9 16|sequence
P02997622A0916|104 110|patient
P02997622A0916|44 59|SCLC cell line DNAs
P02997777A0609|233 242|treatments
P02997777A0609|94 95|ts
P02997777A0609|158 163|blocks
P02997777A0609|174 180|killing
P02997777A0609|59 71|delta top1 top2
P02997777A0609|283 297|delta top1 top2 ts
P02997777A0609|269 277|cell death
P02997777A0609|51 55|cells
P02997777A0609|214 224|temperature
P02997777A0609|186 191|top2 ts
P02997777A0609|123 134|top2 ts strain
P02997777A0609|17 27|experiments
P02998016A0527|84 89|region
P02998016A0527|39 46|sequence
P02998016A0527|92 95|exon
P02998016A0527|49 52|exon
P02998016A0527|165 176|reading frame
P02998016A0527|101 111|nucleotides
P02998016A0527|190 194|c-mil
P02998016A0527|129 141|nonsense codon
P02998016A0527|3 10|homology
P02998016A0527|198 202|v-mil
P02998016A0527|13 17|v-mil
P02998043A1199|116 119|acid
P02998043A1199|121 136|carboxy-proximal
P02998043A1199|89 97|sequences
P02998043A1199|60 67|presence
P02998043A1199|156 157|G2
P02998043A1199|16 23|sequence
P02998043A1199|149 154|region
P02998043A1199|29 49|Punta Toro M gene product
P02998043A1199|0 10|Examination
P02999267A0606|82 90|intensity
P02999267A0606|68 74|uptakes
P02999267A0606|111 117|sternum
P02999267A0606|8 10|FAP
P02999267A0606|22 32|amyloidosis
P02999267A0885|164 173|appearance
P02999267A0885|235 245|hypertrophy
P02999267A0885|44 51|patients
P02999267A0885|175 176|GS
P02999267A0885|131 136|echoes
P02999267A0885|24 29|uptake
P02999267A0885|249 250|GS
P02999267A0885|32 41|Tc-99m-PYP
P02999267A0885|3 11|intensity
P02999267A0885|88 98|hypertrophy
P02999267A0885|206 213|patients
P03000457A1554|95 98|beta
P03000457A1554|75 77|kDa
P03000457A1554|6 17|kDa precursor
P03000457A1554|36 36|t
P03000457A1554|101 107|species
P03000457A1554|91 93|kDa
P03000457A1554|42 42|h
P03000457A1554|79 83|alpha
P03000457A1554|57 66|processing
P03000489A0822|144 153|activation
P03000489A0822|134 141|criteria
P03000489A0822|50 57|patients
P03000489A0822|82 82|%
P03000489A0822|102 105|mean
P03000489A0822|128 128|%
P03000489A0822|172 187|blood lymphopenia
P03000489A0822|8 18|lymphocytes
P03000489A0822|67 70|mean
P03000489A0822|93 93|%
P03000489A0822|98 100|CGL
P03000489A0822|84 88|range
P03000489A0822|119 123|range
P03000489A0822|117 117|%
P03000489A0822|62 65|AIDS
P03001054A0703|65 69|sites
P03001054A0703|25 29|nicks
P03001084A0406|70 71|bp
P03001084A0406|99 100|bp
P03001084A0406|88 92|alpha
P03001084A0406|105 112|psi alpha
P03001084A0406|37 40|pair
P03001084A0406|45 51|segment
P03001084A0406|79 85|cap site
P03001084A0406|3 10|sequence
P03001084A0406|42 43|bp
P03001086A0587|87 98|Xenopus hsp70
P03001086A0587|70 74|hsp70
P03001086A0587|76 85|trout hsp70
P03001086A0587|12 28|amino acid sequence
P03001086A0587|118 125|homology
P03001086A0587|100 109|yeast hsp70
P03001086A0587|43 50|homology
P03001086A0587|145 159|dnaK gene product
P03001110A0546|30 46|peptide substrates
P03001110A0546|161 163|mol
P03001110A0546|71 98|receptor self-phosphorylation
P03001110A0546|178 180|mol
P03001110A0546|166 174|phosphate
P03001110A0546|100 121|tyrosine kinase activity
P03001110A0546|4 18|phosphorylation
P03001110A0546|183 190|receptor
P03001110A0546|61 68|function
P03001353A0146|2 13|temperatures
P03001353A0146|42 49|6m2 cells
P03001353A0146|91 92|kb
P03001353A0146|27 40|transformation
P03001353A0146|149 152|mRNA
P03001353A0146|111 120|P85gag-mos
P03001353A0146|57 62|P58gag
P03001353A0146|99 107|RNA genome
P03001645A0785|3 7|pet56
P03001645A0785|11 19|his3 genes
P03001645A0785|89 90|bp
P03001645A0785|49 63|initiation sites
P03001705T0000|43 64|herpes simplex virus type
P03001705T0000|91 101|gene product
P03001705T0000|66 68|DNA
P03001705T0000|9 22|transformation
P03001705T0000|79 84|region
P03001705T0000|32 40|fragments
P03001952A0958|175 185|recurrences
P03001952A0958|110 120|recurrences
P03001952A0958|66 68|HSV
P03001952A0958|139 147|acyclovir
P03001952A0958|87 97|determinant
P03001952A0958|50 55|herpes
P03001952A0958|19 26|patients
P03001952A0958|60 63|type
P03001952A0958|157 162|effect
P03002501A1327|0 9|Comparison
P03002501A1327|38 40|rat
P03002501A1327|92 99|homology
P03002501A1327|12 20|sequences
P03002501A1327|44 72|guinea-pig alpha s1-casein mRNAs
P03002501A1327|131 137|regions
P03002786A0143|70 75|mg i.m.
P03002786A0143|9 9|n
P03002786A0143|3 7|group
P03002786A0143|32 40|midazolam
P03002786A0143|45 50|mg kg-1
P03002786A0143|55 62|atropine
P03003695A0395|0 9|Comparison
P03003695A0395|32 45|c-sis cDNA clone
P03003695A0395|102 113|kbp DNA region
P03003695A0395|47 53|Collins
P03003695A0395|131 139|c-sis exon
P03003695A0395|60 65|Nature
P03003695A0395|153 154|bp
P03004364A0775|96 101|MMCLIP
P03004364A0775|47 50|5-FU
P03004364A0775|87 92|ADRLIP
P03004364A0775|52 54|ADM
P03004364A0775|35 44|activities
P03004364A0775|63 68|FAMLIP
P03004364A0775|81 85|FULIP
P03004364A0775|58 60|MMC
P03004739A0753|14 14|C
P03004739A0753|108 116|promoters
P03004739A0753|148 164|CAT binding protein
P03004739A0753|135 142|affinity
P03004739A0753|17 29|G transversion
P03004739A0753|94 101|activity
P03004739A0753|52 69|CAT pentanucleotide
P03004739A0753|40 46|residue
P03004982A0199|27 28|bp
P03004982A0199|102 105|fbcB
P03004982A0199|37 49|R. sphaeroides
P03004982A0199|92 100|genes fbcF
P03004982A0199|61 63|DNA
P03004982A0199|109 112|fbcC
P03004982A0199|3 20|nucleotide sequence
P03004982A1094|49 58|FeS protein
P03004982A1094|13 20|sequence
P03004982A1094|91 106|fbcF reading frame
P03004982A1094|37 43|peptide
P03005231A0649|188 196|sequences
P03005231A0649|22 30|sequences
P03005231A0649|52 60|sequences
P03005231A0649|107 119|transcription
P03005231A0649|81 90|initiation
P03005231A0649|94 104|termination
P03005231A0649|141 149|promoters
P03006066A0653|86 93|proteins
P03006066A0653|35 52|translation product
P03006066A0653|27 28|Mr
P03006066A0653|6 20|P135gag-myb-ets
P03006066A0653|95 102|P54c-ets
P03006066A0653|55 59|c-myb
P03006066A0653|61 68|P75c-myb
P03007281A0905|40 41|2L
P03007281A0905|79 82|loci
P03007281A0905|103 104|kb
P03007281A0905|90 96|maximum
P03007281A0905|3 13|Dox-A2 locus
P03007281A0905|43 56|OD15 breakpoint
P03007281A0905|30 31|kb
P03007281A0905|37 38|Df
P03008094A0697|60 68|sequences
P03008094A0697|13 15|end
P03008094A0697|22 32|polypeptide
P03008094A0697|45 49|types
P03008405A0532|42 51|deer calves
P03008405A0532|24 30|disease
P03008405A0532|60 64|HVC-1
P03008405A0532|7 15|outbreaks
P03009366A0438|86 91|target
P03009366A0438|94 102|radiation
P03009366A0438|65 75|pneumocytes
P03009366A0438|181 185|weeks
P03009366A0438|109 115|release
P03009366A0438|36 42|studies
P03009366A0438|174 177|days
P03009366A0438|118 127|surfactant
P03009366A0438|155 162|exposure
P03009366A0438|59 62|Type
P03009826A0201|38 55|base-pair dimer unit
P03009826A0201|11 16|clones
P03009826A0201|61 66|repeat
P03010281A0220|42 51|activation
P03010281A0220|19 24|repeat
P03010281A0220|3 8|copies
P03010281A0220|54 67|gene expression
P03011793A0582|69 85|amino acid residues
P03011793A0582|22 25|rbsD
P03011793A0582|35 38|rbsC
P03011793A0582|7 19|reading frames
P03011793A0582|45 52|proteins
P03011793A0582|27 30|rbsA
P03013477A0000|290 295|group B
P03013477A0000|203 210|patients
P03013477A0000|76 85|metabolism
P03013477A0000|130 144|superoxide anion
P03013477A0000|212 216|group
P03013477A0000|162 166|blood
P03013477A0000|183 188|groups
P03013477A0000|17 25|influence
P03013477A0000|152 154|PMN
P03013477A0000|282 286|ng/ml
P03013477A0000|254 272|serum ferritin levels
P03013477A0000|105 116|hemodialysis
P03013477A0000|306 316|individuals
P03013477A0000|239 249|individuals
P03013477A0000|321 339|serum ferritin levels
P03013477A0000|62 70|leucocyte
P03013477A0000|88 95|patients
P03013477A0000|72 74|PMN
P03013477A0000|118 127|generation
P03013477A0000|349 353|ng/ml
P03013477A0000|2 6|order
P03013477A0000|28 39|iron overload
P03013841A0207|0 7|Cattaneo
P03013841A0207|12 13|J.
P03014515T0000|73 78|enzyme
P03014515T0000|26 43|nucleotide sequence
P03014515T0000|5 24|alpha-galactosidase A
P03014515T0000|47 55|cDNA clone
P03014593A0681|29 30|Ro
P03014593A0681|77 81|mg/kg
P03014593A0681|10 14|mg/kg
P03014593A0681|87 91|mg/kg
P03014593A0681|67 74|Ro 5-4864
P03014593A0681|0 7|Diazepam
P03015611A0331|3 19|amino acid sequence
P03015611A0331|37 44|residues
P03015611A0331|60 72|lysine residue
P03015611A0331|105 108|site
P03015628A1078|0 10|Osteocalcin
P03015628A1078|97 106|mechanisms
P03015628A1078|169 200|serum alkaline phosphatase activity
P03015628A1078|125 136|bone turnover
P03015628A1078|22 35|hydroxyproline
P03015628A1078|62 81|hyperphosphatasaemia
P03015628A1078|208 215|subjects
P03015953T0000|0 7|Analysis
P03015953T0000|10 23|glucocorticoid
P03015953T0000|54 80|mouse glucocorticoid receptor
P03015953T0000|94 101|DNA clone
P03015953T0000|36 47|cell variants
P03016301A0605|57 64|terminus
P03016301A0605|124 129|region
P03016301A0605|76 84|c-myc exon
P03016301A0605|8 18|v-myc codons
P03016301A0605|92 97|codons
P03016301A0605|113 117|c-myc
P03016506A0611|100 110|B95-8 strain
P03016506A0611|12 17|vector
P03016506A0611|19 22|p410
P03016506A0611|243 257|G-418 resistance
P03016506A0611|172 179|sequence
P03016506A0611|144 156|antigen EBNA-1
P03016506A0611|260 270|animal cells
P03016506A0611|187 201|BamHI-C fragment
P03016506A0611|225 234|marker gene
P03016506A0611|70 80|nucleotides
P03016506A0611|61 68|fragment
P03016883A0000|2 4|men
P03016883A0000|65 73|infection
P03016883A0000|59 63|HSV-2
P03016883A0000|123 129|urethra
P03016883A0000|10 16|history
P03016883A0000|35 56|herpes simplex virus type
P03016883A0000|133 146|virus isolation
P03016883A0000|104 110|samples
P03016883A0000|95 99|weeks
P03017225A0706|29 41|leather bottle
P03017225A0706|100 106|stomach
P03017225A0706|147 155|carcinoma
P03017225A0706|9 17|carcinoma
P03017225A0706|124 129|glands
P03017225A0706|193 200|Nakamura
P03017225A0706|178 182|focus
P03017225A0706|85 94|II c portion
P03017225A0706|68 74|stomach
P03017225A0706|203 208|theory
P03017225A0706|43 61|linitis plastica type
P03017996A0731|145 146|X3
P03017996A0731|53 65|signal peptide
P03017996A0731|37 48|polypeptides
P03017996A0731|9 20|biosynthesis
P03017996A0731|113 119|protein
P03017996A0731|150 161|cleavage site
P03017996A0731|133 141|mutants X2
P03018491A0840|86 93|sequence
P03018491A0840|149 151|end
P03018491A0840|53 63|GRE activity
P03018491A0840|113 118|region
P03018491A0840|3 16|hexanucleotide
P03018491A0840|20 27|TGTCCT-3
P03018491A0840|157 160|gene
P03018491A0840|183 197|receptor binding
P03019505A0390|31 36|spread
P03019505A0390|56 60|tumor
P03019505A0390|4 11|patients
P03020001A0781|139 151|kilobase pairs
P03020001A0781|177 186|insertions
P03020001A0781|78 89|DNA fragments
P03020001A0781|201 213|kilobase pairs
P03020001A0781|100 112|kilobase pairs
P03020001A0781|16 30|mini-Mu elements
P03020001A0781|69 75|cloning
P03020001A0781|166 171|clones
P03020001A0781|40 52|kilobase pairs
P03020513T0000|57 68|gyrA-protein
P03020513T0000|13 19|subunit
P03020513T0000|22 39|T4 DNA topoisomerase
P03020513T0000|71 76|gyrase
P03021050A0501|46 54|sulbactam
P03021050A0501|22 26|peaks
P03021050A0501|32 43|quantitation
P03021088A0135|145 148|days
P03021088A0135|9 15|periods
P03021088A0135|153 157|years
P03021088A0135|43 52|occurrence
P03021088A0135|177 181|years
P03021088A0135|165 171|average
P03021088A0135|66 71|ulcers
P03021088A0135|111 114|type
P03021088A0135|29 37|exclusion
P03021088A0135|117 130|reconstruction
P03021088A0135|86 96|gastrectomy
P03021088A0135|101 108|Billroth
P03022129A0842|72 75|loss
P03022129A0842|78 83|detail
P03022129A0842|125 130|extent
P03022129A0842|37 38|II
P03022129A0842|166 182|transcription rate
P03022129A0842|14 19|arrays
P03022129A0842|108 120|accessibility
P03022129A0842|30 35|MPE X Fe
P03022129A0842|189 192|gene
P03023067A0779|0 10|Translation
P03023067A0779|63 73|transcripts
P03023067A0779|29 33|genes
P03023679A0624|88 95|proteins
P03023679A0624|12 17|weight
P03023679A0624|129 140|modification
P03023679A0624|34 41|proteins
P03023682A0271|0 8|Insertion
P03023682A0271|12 13|bp
P03023682A0271|21 24|SV40
P03023682A0271|81 83|CAT
P03023682A0271|48 79|chloramphenicol acetyltransferase
P03023682A0271|85 94|expression
P03023859A0000|86 95|chromosome
P03023859A0000|150 152|bcr
P03023859A0000|74 83|breakpoint
P03023859A0000|102 114|Ph1 chromosome
P03023859A0000|138 142|probe
P03023859A0000|68 71|date
P03023859A0000|5 8|DNAs
P03023859A0000|154 176|breakpoint cluster region
P03023859A0000|43 58|leukemia patients
P03023887A0470|0 19|Nuclease footprinting
P03023887A0470|40 61|glucocorticoid receptor
P03023887A0470|156 157|Sa
P03023887A0470|104 110|borders
P03023887A0470|85 89|sites
P03023887A0470|132 144|sequence motif
P03023970A0922|100 109|generation
P03023970A0922|113 122|p53 product
P03023970A0922|64 74|termination
P03023970A0922|124 133|amino acids
P03023970A0922|24 40|termination signal
P03023970A0922|80 86|protein
P03023970A0922|8 13|insert
P03024343A0372|3 8|tumors
P03024343A0372|49 54|origin
P03024343A0372|33 46|neuroendocrine
P03024703A1036|114 126|hsp108 protein
P03024703A1036|9 14|region
P03024703A1036|94 99|weight
P03024703A1036|21 31|nucleotides
P03024703A1036|67 76|amino acids
P03024703A1036|46 61|polypeptide chain
P03025606T0000|15 28|control signals
P03025606T0000|109 116|terminus
P03025606T0000|122 125|mRNA
P03025606T0000|80 84|bases
P03025606T0000|32 53|herpes simplex virus type
P03025606T0000|67 73|gene lie
P03025606T0000|60 64|gamma
P03025655T0000|60 66|kinases
P03025655T0000|78 91|kinase function
P03025655T0000|13 18|domain
P03025655T0000|117 147|Fujinami sarcoma virus P130gag-fps
P03025655T0000|95 114|transforming activity
P03025661A0260|0 6|Gluzman
P03025661A0260|8 13|EMBO J.
P03025862A0860|115 115|A
P03025862A0860|7 10|exon
P03025862A0860|40 49|amino acids
P03025862A0860|110 113|poly
P03025862A0860|55 62|ssd chain
P03025862A0860|118 129|addition site
P03025862A0860|94 97|mRNA
P03025862A0860|83 88|region
P03026915A1024|31 35|parts
P03026915A1024|65 74|yeast genes
P03026915A1024|107 123|lacZ fusion vectors
P03026915A1024|19 27|sequences
P03026915A1024|47 55|sequences
P03027661A0000|3 12|activities
P03027661A0000|18 25|D protein
P03027661A0000|31 42|miniF plasmid
P03027779A0000|0 15|SPECT examination
P03027779A0000|124 130|normals
P03027779A0000|113 116|disc
P03027779A0000|54 61|patients
P03027779A0000|21 23|TMJ
P03027779A0000|32 37|Tc-MDP
P03027779A0000|97 107|dislocation
P03027905A0632|0 18|Plasma renin activity
P03027905A0632|66 75|lisinopril
P03027905A0632|29 50|plasma aldosterone level
P03029111A0155|15 28|representative
P03029111A0155|40 62|pet complementation group
P03029111A0155|3 9|mutants
P03031602A1001|68 72|genes
P03031602A1001|26 33|elements
P03031602A1001|9 13|group
P03031602A1001|56 61|region
P03032143A0218|172 180|chromatin
P03032143A0218|68 73|length
P03032143A0218|185 200|yeast kinetochore
P03032143A0218|134 141|proteins
P03032143A0218|64 65|bp
P03032143A0218|36 41|region
P03032143A0218|1 10|centromere
P03032143A0218|44 46|DNA
P03032143A0218|155 166|conformation
P03032143A0218|99 114|sequence elements
P03032964T0000|60 68|sequences
P03032964T0000|12 19|function
P03032964T0000|81 88|activity
P03032964T0000|42 49|promoter
P03033283A0837|95 105|DNA sequence
P03033283A0837|109 143|competition filter binding experiments
P03033283A0837|64 67|HCMV
P03033283A0837|88 91|case
P03033283A0837|75 77|DNA
P03033283A0837|230 235|region
P03033283A0837|154 160|maximum
P03033283A0837|177 197|consensus binding sites
P03033283A0837|22 25|loci
P03033283A0837|69 73|Towne
P03033283A0837|54 61|IE68 gene
P03033283A1415|206 210|sites
P03033283A1415|284 291|SCMV IE94
P03033283A1415|272 281|expression
P03033283A1415|260 268|host range
P03033283A1415|26 29|sets
P03033283A1415|304 311|HCMV IE68
P03033283A1415|151 161|arrangement
P03033283A1415|61 74|repeat elements
P03033283A1415|132 139|strength
P03034570A0943|190 196|vectors
P03034570A0943|98 101|gene
P03034570A0943|112 121|resistance
P03034570A0943|34 37|code
P03034570A0943|129 138|hygromycin
P03034570A0943|10 14|genes
P03034570A0943|17 28|gene segments
P03034570A0943|161 178|papillomavirus type
P03034570A0943|53 84|chloramphenicol acetyltransferase
P03034570A0943|146 150|ORF E7
P03034956A0666|28 41|androgen levels
P03034956A0666|91 98|subjects
P03034956A0666|125 134|prednisone
P03034956A0666|108 110|day
P03034956A0666|136 136|P
P03034956A0666|119 121|day
P03034956A0666|2 9|contrast
P03035056T0000|90 98|cell lines
P03035056T0000|47 53|Abelson
P03035056T0000|6 11|lambda
P03035056T0000|15 44|kappa antibody gene rearrangement
P03035056T0000|60 67|leukemia
P03035218T0000|0 13|Identification
P03035218T0000|41 49|sequences
P03035218T0000|64 86|T-cell leukemia virus type
P03035218T0000|100 105|repeat
P03035658A0355|145 147|VO2
P03035658A0355|48 56|ml/kg/min
P03035658A0355|176 178|VO2
P03035658A0355|153 161|ml/kg/min
P03035658A0355|88 91|dose
P03035658A0355|101 106|manner
P03035658A0355|74 84|epinephrine
P03035658A0355|19 28|anesthesia
P03035658A0355|184 192|ml/kg/min
P03035658A0355|139 143|ng/ml
P03035658A0355|38 40|VO2
P03035658A0355|109 128|plasma concentrations
P03035658A0355|170 174|ng/ml
P03036415T0000|0 8|Influence
P03036415T0000|11 35|cyclo-oxygenase inhibition
P03036415T0000|144 147|dogs
P03036415T0000|41 67|leukotriene receptor blockade
P03036415T0000|87 120|pressure/cardiac index relationships
P03036817A0213|83 85|ATG
P03036817A0213|91 97|yeast R.
P03036817A0213|24 34|mutagenesis
P03036817A0213|52 70|NdeI restriction site
P03036933A0774|0 10|ACTH release
P03036933A0774|40 47|children
P03036933A0774|62 74|ACTH treatment
P03037334A0932|33 47|promoter element
P03037334A0932|53 66|yeast RP39A gene
P03037334A0932|91 104|sequence motifs
P03038643A1374|122 125|gene
P03038643A1374|80 89|divergence
P03038643A1374|38 51|alpha-spectrin
P03038643A1374|5 8|data
P03038643A1374|61 71|duplication
P03038891A0935|0 15|Northern analyses
P03038891A0935|26 37|mouse tissues
P03038891A0935|63 75|p11 mRNA levels
P03038891A0935|18 21|RNAs
P03038891A0935|41 49|cell lines
P03039177A0503|13 22|cDNA clones
P03039177A0503|102 128|restriction site polymorphism
P03039177A0503|77 92|IR2 repeat element
P03039177A0503|135 144|enzyme SmaI
P03039177A0503|55 64|transcript
P03039177A0503|3 7|group
P03039387A0920|89 94|effect
P03039387A0920|136 147|methotrexate
P03039387A0920|123 133|combination
P03039387A0920|152 154|BCG
P03039387A0920|64 74|enhancement
P03039387A0920|30 45|cyclophosphamide
P03039387A0920|50 52|BCG
P03039387A0920|158 173|cyclophosphamide
P03039387A0920|178 187|levamisole
P03040023A0113|0 7|Morphine
P03040023A0113|52 62|tachycardia
P03040023A0113|31 41|bradycardia
P03040403A0155|3 9|PSS gene
P03040403A0155|59 69|YEp13 vector
P03040403A0155|33 40|fragment
P03040403A0155|46 53|yeast DNA
P03041046A0127|219 220|N.
P03041046A0127|49 59|Moloney MuLV
P03041046A0127|169 172|MuLV
P03041046A0127|102 107|A-MuLV
P03041046A0127|128 134|viruses
P03041046A0127|32 38|viruses
P03041046A0127|7 12|A-MuLV
P03041046A0127|145 150|BALB/c
P03041046A0127|209 217|potential
P03041802A0975|159 162|role
P03041802A0975|114 131|platelet activation
P03041802A0975|24 41|platelet aggregates
P03041802A0975|78 92|cleavage product
P03041802A0975|53 58|levels
P03041802A0975|141 150|deposition
P03041802A0975|186 193|disorder
P03041802A0975|168 179|pathogenesis
P03041802A0975|3 10|presence
P03041802A0975|61 75|fibrinopeptide A
P03042778A0643|3 6|gene
P03042778A0643|21 25|yeast
P03042778A0643|36 41|growth
P03045117A0936|156 160|Asp27
P03045117A0936|228 232|Leu47
P03045117A0936|191 193|Thr
P03045117A0936|35 41|methods
P03045117A0936|64 70|species
P03045117A0936|133 137|Glu24
P03045117A0936|108 112|order
P03045117A0936|205 209|Tyr29
P03045117A0936|118 121|type
P03045117A0936|48 56|agreement
P03045117A0936|82 93|growth factor
P03045117A0936|13 18|values
P03045725A0872|121 136|tumor sensitivity
P03045725A0872|76 95|breast cancer patients
P03045725A0872|38 52|prolactin levels
P03045725A0872|139 150|chemotherapy
P03045725A0872|17 27|suppression
P03046655A0000|58 60|eye
P03046655A0000|74 81|patients
P03046655A0000|122 127|period
P03046655A0000|9 23|prevalence study
P03046655A0000|94 102|keratitis
P03046655A0000|39 44|acuity
P03046931A0247|13 18|eIF-4A
P03046931A0247|62 65|cDNA
P03046931A0247|82 101|nucleotide difference
P03046931A0247|29 38|retroposon
P03048024A0418|71 71|p
P03048024A0418|13 19|culture
P03048024A0418|63 69|NIB rats
P03048024A0418|54 55|IB
P03048024A0418|32 37|tissue
P03049570A1242|33 42|E2 proteins
P03049570A1242|5 16|similarities
P03050147A0896|72 78|viruses
P03050147A0896|92 98|amounts
P03050147A0896|50 65|E1a-E1b functions
P03050147A0896|113 129|mRNA transcription
P03050147A0896|5 13|infection
P03050147A0896|19 23|cells
P03050147A1520|87 95|ribosomes
P03050147A1520|37 49|scanning model
P03050147A1520|128 135|mRNA site
P03050147A1520|147 163|initiator AUG codon
P03050147A1520|62 71|initiation
P03050147A1520|4 14|observation
P03050147A1520|170 177|C protein
P03052327A1474|88 93|choice
P03052327A1474|110 117|patients
P03052327A1474|77 85|treatment
P03052327A1474|33 62|pancreas-kidney transplantation
P03052327A1474|97 100|Type
P03052327A1474|2 5|view
P03052327A1474|13 19|results
P03052641A0204|14 22|compounds
P03052641A0204|35 42|vehicles
P03052641A0204|59 63|gases
P03053713A0752|0 12|DNA sequencing
P03053713A0752|18 25|DPM1 gene
P03053713A0752|40 51|reading frame
P03053713A0752|57 61|bases
P03057259A0514|3 14|relationship
P03057259A0514|68 78|thyroiditis
P03057259A0514|38 45|lymphoma
P03057259A0514|51 57|thyroid
P03059171A1232|104 111|symptoms
P03059171A1232|16 29|anticoagulants
P03059171A1232|36 42|heparin
P03059171A1232|62 72|ticlopidine
P03059171A1232|44 58|prostaglandin E1
P03059171A1232|134 146|deterioration
P03059171A1232|0 13|Administration
P03060846T0000|23 35|L1 binding site
P03060846T0000|38 44|23S rRNA
P03060846T0000|10 17|analysis
P03060953A0481|0 6|Animals
P03060953A0481|49 58|mechanisms
P03060953A0481|79 87|outbreaks
P03060953A0481|27 37|vaccination
P03061301A0624|118 133|radioimmunoassay
P03061301A0624|111 115|means
P03061301A0624|197 208|participants
P03061301A0624|36 48|excretion rate
P03061301A0624|183 188|period
P03061301A0624|142 155|urine specimens
P03061301A0624|219 223|smoke
P03061301A0624|245 254|cigarettes
P03061301A0624|60 96|metabolite 6-keto-prostaglandin F1 alpha
P03061301A0624|0 20|Prostacyclin formation
P03061301A1409|86 99|contraceptives
P03061301A1409|68 74|smokers
P03061301A1409|124 133|creatinine
P03061301A1409|8 16|excretion
P03061301A1409|135 135|p
P03061301A1409|39 45|F1 alpha
P03061301A1409|117 121|ng/gm
P03061383A0000|173 193|agar dilution technique
P03061383A0000|20 29|mecillinam
P03061383A0000|97 111|beta-lactamases
P03061383A0000|55 58|acid
P03061383A0000|10 17|activity
P03061383A0000|117 121|TEM-1
P03061383A0000|142 145|type
P03061383A0000|81 87|strains
P03061383A0000|165 169|broth
P03061383A0000|123 127|Oxa-1
P03062370A0000|59 63|genes
P03062370A0000|27 35|activator
P03062370A0000|38 46|amino acid
P03062370A0000|0 3|GCN4
P03062370A0384|100 120|amino acid availability
P03062370A0384|63 72|activation
P03062370A0384|24 34|GCN3 product
P03062370A0384|51 60|repression
P03062370A0384|75 88|GCN4 expression
P03062370A0384|5 11|results
P03064524A0160|3 10|efficacy
P03064524A0160|35 39|drugs
P03064811A0485|150 152|Asp
P03064811A0485|25 39|S. aureus peptide
P03064811A0485|51 65|phosphoryl group
P03064811A0485|3 19|amino acid sequence
P03065140A0273|46 61|DNA binding domain
P03065140A0273|31 41|GAL4 protein
P03065140A0273|22 28|regions
P03065140A0273|5 13|mutations
P03065140A0273|69 97|transcription activation domain
P03065141A0448|99 106|citB gene
P03065141A0448|32 35|citA
P03065141A0448|3 9|results
P03065141A0448|56 64|promoters
P03065141A0448|39 42|citB
P03065141A0448|26 30|genes
P03065141A0448|72 79|location
P03065141A0448|158 163|pMS185
P03065141A0448|112 135|Tn3411 nucleotide sequence
P03065141A0448|85 92|promoter
P03065610A0375|3 9|rci gene
P03065610A0375|22 25|lacZ
P03065610A0375|58 76|Western blot analysis
P03065610A0375|32 42|gene product
P03065621T0000|0 8|Structure
P03065621T0000|81 87|protein
P03065621T0000|12 21|regulation
P03065621T0000|32 35|gene
P03065621T0000|123 130|ribosome
P03065621T0000|74 78|MRP13
P03065621T0000|98 104|subunit
P03066131A0000|102 108|lesions
P03066131A0000|244 257|aggressiveness
P03066131A0000|114 121|amygdala
P03066131A0000|70 87|behaviour disorders
P03066131A0000|210 216|control
P03066131A0000|197 206|operations
P03066131A0000|6 11|survey
P03066131A0000|179 189|experiences
P03066131A0000|158 163|author
P03066131A0000|143 154|hypothalamus
P03066131A0000|59 67|treatment
P03066131A0000|43 47|basis
P03066208A0310|48 51|cyst
P03066208A0310|12 22|examination
P03066208A0310|71 83|cell carcinoma
P03066625A0756|88 98|risk factors
P03066625A0756|26 32|studies
P03066625A0756|65 77|contributions
P03066625A0756|138 144|studies
P03066625A0756|123 133|risk factors
P03066625A0756|177 185|questions
P03067505A0688|60 69|ear vessels
P03067505A0688|42 49|property
P03067505A0688|5 16|prostacyclin
P03069046A0126|28 36|precision
P03069046A0126|48 58|sensitivity
P03069046A0126|3 8|method
P03069980T0000|0 6|Factors
P03069980T0000|77 83|dentine
P03069980T0000|21 32|bond strength
P03069980T0000|40 57|glass polyalkenoate
P03069980T0000|67 73|cements
P03069980T0000|59 65|ionomer
P03072021A0696|26 30|yeast
P03072021A0696|111 122|polypeptides
P03072021A0696|56 73|targeting sequences
P03072021A0696|3 20|amino acid sequences
P03072580A0455|0 9|Van der Ende
P03072580A0455|11 12|R.
P03073091A0338|84 90|patient
P03073091A0338|66 70|order
P03073091A0338|25 41|% dextrose solution
P03073091A0338|105 109|mg/dl
P03073091A0338|93 100|glycemia
P03073091A0338|6 20|insulin infusion
P03073091A0338|55 63|Biostator
P03073091A0449|0 6|Amounts
P03073091A0449|295 303|mg/kg/min
P03073091A0449|272 272|K
P03073091A0449|210 222|indomethacine
P03073091A0449|266 270|drugs
P03073091A0449|244 252|mg/kg/min
P03073091A0449|156 169|spironolactone
P03073091A0449|177 182|mmol/l
P03073091A0449|224 224|K
P03073091A0449|48 66|hour insulin infusion
P03073091A0449|124 129|mmol/l
P03073091A0449|118 118|K
P03073091A0449|141 149|mg/kg/min
P03073091A0449|108 116|treatment
P03073091A0449|9 15|glucose
P03073091A0449|38 40|min
P03073091A0449|230 235|mmol/l
P03073091A0449|278 283|mmol/l
P03073091A0449|195 203|mg/kg/min
P03073091A0449|171 171|K
P03073192T0000|0 49|Mycobacterium avium-intracellulare complex infections
P03073192T0000|63 86|immunodeficiency syndrome
P03075154T0000|0 9|Recurrence
P03075154T0000|12 28|oxalate deposition
P03075154T0000|37 46|transplant
P03075154T0000|53 71|ciclosporin A therapy
P03076124A0496|62 65|acid
P03076124A0496|220 240|hypercholesterolaemia
P03076124A0496|312 312|%
P03076124A0496|281 285|total
P03076124A0496|259 278|plasma concentrations
P03076124A0496|81 90|inhibitors
P03076124A0496|157 167|simvastatin
P03076124A0496|289 303|LDL-cholesterol
P03076124A0496|188 192|drugs
P03076124A0496|24 37|cholestyramine
P03076124A0496|131 139|reductase
P03076124A0496|67 77|fenofibrate
P03076124A0496|93 122|hydroxymethylglutaryl coenzyme A
P03076124A0496|41 50|colestipol
P03076124A0496|145 154|lovastatin
P03076124A0496|196 198|use
P03076124A0496|201 208|patients
P03076124A0496|247 252|agents
P03076124A0496|124 129|HMG CoA
P03076124A0496|3 22|bile acid sequestrants
P03078268A0529|218 230|acidification
P03078268A0529|188 191|role
P03078268A0529|127 148|amphotericin B treatment
P03078268A0529|93 106|acidosis models
P03078268A0529|117 123|maleate
P03078268A0529|201 208|steroids
P03078268A0529|166 175|mechanisms
P03078268A0529|29 35|aspects
P03078268A0529|45 57|acidification
P03079276T0029|72 80|flare-ups
P03079276T0029|11 16|groups
P03079276T0029|19 26|patients
P03079276T0029|0 7|Analysis
P03080793T0000|43 52|prevention
P03080793T0000|76 84|workplace
P03080793T0000|27 36|guidelines
P03080793T0000|55 70|AIDS transmission
P03080793T0000|0 8|Statement
P03080793T0000|14 24|development
P03083441T0000|0 12|Modifications
P03083441T0000|54 59|people
P03083441T0000|29 43|postcontraction
P03088643A0000|105 115|control rats
P03088643A0000|77 78|CS
P03088643A0000|69 75|stimuli
P03088643A0000|28 37|preference
P03088643A0000|15 18|rats
P03090237A0202|140 150|response key
P03090237A0202|90 100|response key
P03090237A0202|102 108|work key
P03090237A0202|162 164|key
P03090237A0202|10 18|schedules
P03090237A0202|80 84|times
P03090237A0202|31 41|response run
P03090372A0607|75 77|CyA
P03090372A0607|11 31|glucose tolerance tests
P03090372A0607|51 59|operation
P03090372A0607|87 91|weeks
P03091849A0000|233 240|membrane
P03091849A0000|162 170|perfusion
P03091849A0000|186 189|mm Hg
P03091849A0000|76 87|rat mesentery
P03091849A0000|104 108|kinds
P03091849A0000|111 120|experiment
P03091849A0000|138 145|fixative
P03091849A0000|12 25|glutaraldehyde
P03091849A0000|41 54|ultrastructure
P03091849A0000|70 73|beds
P03091849A0000|174 181|pressure
P03091849A0000|195 205|superfusion
P03091849A0000|3 9|effects
P03091849A0000|28 37|dimensions
P03097509A0654|14 25|RNA molecules
P03097509A0654|75 83|base pairs
P03097509A0654|8 11|rise
P03097509A0654|45 51|regions
P03097643A1357|57 71|octamer sequence
P03097643A1357|125 130|region
P03097643A1357|33 44|substitution
P03097643A1357|8 17|BALB/c gene
P03097643A1357|151 160|expression
P03097643A1357|95 105|nucleotides
P03098018A0139|30 31|cm
P03098018A0139|8 15|findings
P03098018A0139|66 70|limbs
P03098018A0139|53 58|length
P03098018A0139|88 97|micropenis
P03098018A0139|33 38|weight
P03098018A0139|21 26|height
P03098018A0139|72 84|P2-A2 pilosity
P03098018A0139|41 42|kg
P03102289A0786|99 107|follicles
P03102289A0786|159 161|hCG
P03102289A0786|124 133|ultrasound
P03102289A0786|120 121|cm
P03102289A0786|166 178|serum E2 levels
P03102289A0786|136 143|cycle day
P03102289A0786|48 64|hCG administration
P03102289A0786|91 96|number
P03102289A0786|67 74|midcycle
P03102289A0786|203 210|follicle
P03102289A0786|3 6|data
P03102289A0786|194 199|pmol/l
P03104245A0402|143 147|range
P03104245A0402|176 180|range
P03104245A0402|77 77|p
P03104245A0402|169 174|months
P03104245A0402|35 42|addition
P03104245A0402|21 25|Ir192
P03104245A0402|136 141|months
P03104245A0402|53 61|radiation
P03104245A0402|155 160|months
P03104245A0402|4 11|patients
P03104245A0402|187 192|months
P03104245A0402|84 91|survival
P03104248A0322|17 24|patients
P03104248A0322|104 111|patients
P03104248A0322|89 93|tumor
P03104248A0322|52 53|G1
P03104248A0322|6 12|Stage IA
P03104248A0322|95 96|G2
P03104248A0322|136 137|G3
P03104248A0322|46 50|tumor
P03104914T0000|14 14|t
P03104914T0000|33 45|translocation
P03104914T0000|98 105|partners
P03104914T0000|57 64|analysis
P03104914T0000|0 8|Mechanism
P03104982A0690|116 120|years
P03104982A0690|86 98|sex difference
P03104982A0690|5 7|age
P03104982A0690|34 36|men
P03104982A0690|123 125|age
P03104982A0690|67 71|women
P03104982A0690|15 30|hemoglobin levels
P03108171A0088|0 9|Ritanserin
P03108171A0088|44 59|blocking activity
P03108171A0088|62 72|S2 receptors
P03108171A0088|76 79|5-HT
P03108171A0088|16 24|substance
P03108171A0088|99 104|system
P03109147A0000|0 13|Ethylene glycol
P03109147A0000|107 113|dosages
P03109147A0000|124 125|mg
P03109147A0000|79 84|groups
P03109147A0000|120 122|und
P03109147A0000|132 135|dose
P03109147A0000|96 103|NMRI mice
P03109147A0000|17 32|diethylene glycol
P03109147A0000|139 143|mouse
P03109147T0127|0 7|Research
P03109147T0127|10 23|ethylene glycol
P03109147T0127|58 64|effects
P03109147T0127|27 42|diethylene glycol
P03109954A0945|182 189|lowering
P03109954A0945|318 330|atherogenesis
P03109954A0945|106 115|inhibition
P03109954A0945|249 255|balance
P03109954A0945|284 295|relationship
P03109954A0945|41 49|influence
P03109954A0945|192 224|plasma HDL cholesterol concentration
P03109954A0945|126 146|artery atherosclerosis
P03109954A0945|67 73|ethinyl
P03109954A0945|303 314|plasma lipids
P03109954A0945|94 95|OC
P03109954A0945|270 278|influence
P03109954A0945|3 9|results
P03110119A0267|149 154|carina
P03110119A0267|87 95|side ports
P03110119A0267|134 143|cm cephalad
P03110119A0267|11 20|ventilator
P03110119A0267|60 64|l/min
P03110119A0267|117 119|tip
P03110119A0267|104 111|catheter
P03110119A0267|52 52|%
P03110119A0267|6 7|BH
P03110119A0267|40 47|bias flow
P03110678A0702|191 204|treatment modes
P03110678A0702|158 167|convection
P03110678A0702|174 182|diffusion
P03110678A0702|113 131|beta 2-microglobulin
P03110678A0702|230 242|urea clearance
P03110678A0702|50 69|polysulphone membrane
P03110678A0702|12 15|beta
P03110678A0702|73 85|haemodialysis
P03110678A0702|31 37|removal
P03110678A0702|218 226|blood flow
P03110678A0702|0 9|Comparison
P03110678A0702|89 103|haemofiltration
P03110692A0156|80 87|patients
P03110692A0156|346 348|day
P03110692A0156|151 158|dialysis
P03110692A0156|210 218|bone cysts
P03110692A0156|16 17|SD
P03110692A0156|92 100|bone cysts
P03110692A0156|176 176|P
P03110692A0156|270 277|dialysis
P03110692A0156|198 205|patients
P03110692A0156|47 52|beta 2m
P03110692A0156|310 320|urine volume
P03110692A0156|32 32|P
P03110692A0156|234 239|beta 2m
P03110692A0156|11 14|mg/l
P03110692A0156|290 293|year
P03110692A0156|250 257|patients
P03110692A0156|113 116|mg/l
P03110692A0156|226 231|months
P03110692A0156|141 148|duration
P03110692A0156|338 342|litre
P03110746A0146|27 30|acid
P03110746A0146|36 48|triglycerides
P03110746A0146|7 16|percentage
P03110746A0146|66 78|adipose tissue
P03110746A0146|80 85|PLASAT
P03110746A0146|94 101|subjects
P03110746A0146|142 146|group
P03110794A0991|2 10|overdoses
P03110794A0991|42 48|effects
P03110794A0991|16 27|g fluvoxamine
P03110801A0532|49 58|micrograms
P03110801A0532|20 42|plasma prolactin response
P03111946A0309|26 33|behavior
P03111946A0309|2 7|effect
P03112028A0404|44 44|n
P03112028A0404|15 22|patients
P03112028A0404|57 57|n
P03112028A0404|68 77|parameters
P03112412A0985|105 123|thr operon expression
P03112412A0985|162 165|none
P03112412A0985|171 177|mutants
P03112412A0985|21 26|strain
P03112412A0985|143 153|temperature
P03112412A0985|187 192|change
P03112412A0985|72 89|synthetase mutation
P03112412A0985|2 9|addition
P03114188A0907|89 104|chest wall sarcoma
P03114188A0907|116 123|patients
P03114188A0907|28 35|problems
P03114188A0907|148 153|breast
P03114188A0907|59 64|decade
P03114188A0907|68 75|patients
P03114188A0907|170 174|areas
P03114188A0907|144 145|Gy
P03114829T0000|33 43|panic states
P03114829T0000|21 30|correlates
P03114995T0000|0 6|Effects
P03114995T0000|39 52|gastrin release
P03114995T0000|55 58|dogs
P03114995T0000|28 36|nutrition
P03115087A0515|52 59|standard
P03115087A0515|7 12|weight
P03115087A0515|39 39|%
P03115087A0515|16 31|height velocities
P03115087A0515|46 46|%
P03115787A0633|200 205|months
P03115787A0633|39 56|hexamethylmelamine
P03115787A0633|126 133|response
P03115787A0633|22 37|cyclophosphamide
P03115787A0633|144 152|responses
P03115787A0633|164 169|months
P03115787A0633|81 86|CHAP-5
P03115787A0633|58 67|adriamycin
P03115787A0633|3 10|patients
P03115787A0633|181 189|responses
P03115787A0633|71 79|cisplatin
P03115787A0633|103 109|disease
P03117046T0000|59 69|fibroblasts
P03117046T0000|12 27|characterization
P03117046T0000|31 42|vinculin cDNA
P03117046T0000|0 8|Isolation
P03117147A1059|58 72|oesophageal EMGd
P03117147A1059|138 150|investigation
P03117147A1059|123 126|tool
P03117147A1059|48 54|surface
P03117147A1059|91 101|surface EMGd
P03117147A1059|32 40|agreement
P03117147A1059|14 18|study
P03118631A0140|89 96|cochleas
P03118631A0140|2 12|differences
P03118631A0140|49 56|cochleas
P03118631A0140|77 85|perfusion
P03118631A0140|15 29|fixation quality
P03118631A0140|121 129|perfusion
P03119227A0079|144 153|amino acids
P03119227A0079|164 169|region
P03119227A0079|75 100|c-abl proto-oncogene product
P03119227A0079|49 64|sequence homology
P03119227A0079|3 13|DNA sequence
P03119227A0079|35 44|amino acids
P03119227A0079|22 28|protein
P03119227A0079|182 203|tyrosine kinase activity
P03119227A0079|116 128|amino terminus
P03119485A0476|158 162|shock
P03119485A0476|39 43|acids
P03119485A0476|147 155|prognosis
P03119485A0476|121 127|respect
P03119485A0476|109 116|interest
P03119485A0476|164 169|sepsis
P03119485A0476|92 97|injury
P03119485A0476|3 13|requirement
P03119485A0476|133 143|development
P03119485A0476|46 53|patients
P03119485A0476|188 203|distress syndrome
P03119485A0476|73 81|nutrition
P03120334A0893|4 4|%
P03120334A0893|77 82|system
P03120334A0893|64 67|vein
P03120334A0893|100 104|veins
P03120334A0893|41 46|origin
P03120334A0893|18 21|vein
P03123310A0000|69 75|pathway
P03123310A0000|54 63|activities
P03123310A0000|25 32|Gart gene
P03123310A0000|91 99|synthesis
P03123310A0000|79 84|purine
P03123983T0000|29 36|response
P03123983T0000|39 43|drugs
P03123983T0000|9 23|neuroplasticity
P03123983T0000|3 6|role
P03125420A0421|0 3|Biol
P03125422A0202|58 75|activator sequences
P03125422A0202|95 103|induction
P03125422A0202|106 114|galactose
P03125422A0202|77 79|UAS
P03125422A0202|3 9|results
P03125422A0202|17 27|experiments
P03126531T0000|0 7|Reversal
P03126531T0000|89 116|dopamine agonist pretreatments
P03126531T0000|83 86|rats
P03126531T0000|67 74|REM sleep
P03126531T0000|55 64|aggression
P03126531T0000|42 51|stereotypy
P03126531T0000|13 20|increase
P03127034A0591|58 67|resistance
P03127034A0591|24 27|rate
P03127034A0591|3 11|heart rate
P03127463A1017|170 177|cultures
P03127463A1017|5 9|rIL-3
P03127463A1017|79 93|bone marrow cells
P03127463A1017|21 29|COS7 cells
P03127463A1017|140 145|marrow
P03127463A1017|148 161|cord blood cells
P03127463A1017|134 138|My-10
P03127463A1017|119 131|proliferation
P03127463A1017|47 57|CSF activity
P03127463A1017|69 76|cultures
P03132498A0730|149 153|hours
P03132498A0730|4 11|patients
P03132498A0730|47 50|torr
P03132498A0730|129 132|torr
P03132498A0730|104 108|PaCO2
P03132498A0730|119 122|mean
P03132498A0730|79 89|asthma score
P03132498A0730|63 66|torr
P03132498A0730|52 56|range
P03132498A0730|17 21|PaCO2
P03132498A0730|140 143|mean
P03133250A0000|193 199|program
P03133250A0000|155 167|fertilization
P03133250A0000|186 191|IVF-ET
P03133250A0000|23 27|study
P03133250A0000|131 137|hormone
P03133250A0000|139 142|hFSH
P03133250A0000|99 101|hMG
P03133250A0000|171 184|embryo transfer
P03133250A0000|56 66|stimulation
P03133250A0000|86 97|gonadotropin
P03133360A1215|72 81|inhibition
P03133360A1215|45 68|transcription attenuation
P03133360A1215|97 104|trpE mRNA
P03133360A1215|25 34|mtr product
P03133360A1215|3 10|findings
P03133360A1215|84 94|translation
P03134872T0029|0 6|Apropos
P03134872T0029|10 13|case
P03137105A0146|60 71|gonadotropin
P03137105A0146|109 113|phase
P03137105A0146|34 42|pregnancy
P03137105A0146|151 155|cycle
P03137105A0146|207 218|oocyte donors
P03137105A0146|163 178|oocyte collection
P03137105A0146|222 237|embryo recipients
P03137105A0146|199 204|cycles
P03137105A0146|84 86|end
P03137105A0146|1 21|prostaglandin analogue
P03137346A0319|57 61|exons
P03137346A0319|78 94|amino acid residues
P03137346A0319|100 106|protein
P03137346A0319|31 40|base-pairs
P03137346A0319|3 15|nucleolin gene
P03137601A0212|155 158|mice
P03137601A0212|38 41|DOPS
P03137601A0212|96 105|immobility
P03137601A0212|185 200|NE neurotoxin DSP4
P03137601A0212|56 69|norepinephrine
P03137601A0212|119 122|DOPS
P03137601A0212|71 72|NE
P03137601A0212|8 36|L-threo-dihydroxyphenylserine
P03137601A0212|143 152|immobility
P03137601A0212|114 117|mice
P03137601A0212|74 82|precursor
P03138190A0347|29 38|ampicillin
P03138190A0347|11 17|amounts
P03138190A0347|64 75|Kupffer cells
P03138190A0347|80 90|target cells
P03138190A0347|124 134|inoculation
P03138449A0759|70 79|conditions
P03138449A0759|93 100|w6 supply
P03138449A0759|32 53|desaturation activities
P03138449A0759|88 90|C18
P03138449A0759|17 21|delta
P03138449A0759|26 30|delta
P03139750A0000|55 60|rabbit
P03139750A0000|10 14|basis
P03139750A0000|21 30|expression
P03139750A0000|40 49|VH allotype
P03142875A0366|95 103|structure
P03142875A0366|23 44|6-kilobase cDNA sequence
P03142875A0366|55 59|chain
P03142875A0366|66 75|amino acids
P03143048A1091|71 84|concentrations
P03143048A1091|36 52|apolipoprotein A-I
P03143048A1091|18 18|%
P03143048A1091|56 56|%
P03143048A1091|20 20|P
P03143048A1091|0 14|HDL-cholesterol
P03143048A1091|58 58|P
P03143485A0366|173 199|liverwort chloroplast genomes
P03143485A0366|62 74|protein operon
P03143485A0366|153 157|genes
P03143485A0366|19 36|protein gene cluster
P03143485A0366|94 109|gene organization
P03143485A0366|163 169|tobacco
P03143485A0366|134 138|order
P03143485A0366|3 9|Euglena
P03144705A0859|42 51|resolution
P03144705A0859|137 137|%
P03144705A0859|208 223|Alu family repeats
P03144705A0859|20 24|sites
P03144705A0859|3 14|distribution
P03144705A0859|96 113|sequence divergence
P03144705A0859|185 185|X
P03144705A0859|86 93|gradient
P03144705A0859|143 143|X
P03146017A0983|86 93|presence
P03146017A0983|161 163|mol
P03146017A0983|139 158|amino acid polypeptide
P03146017A0983|52 58|ORFtrpA
P03146017A0983|26 31|region
P03146017A0983|119 125|ORFtrpB
P03146017A0983|44 45|M.
P03146017A0983|107 117|nucleotides
P03146017A0983|3 20|nucleotide sequence
P03146017A0983|98 100|ORF
P03146150T0000|0 11|Potentiation
P03146150T0000|29 36|efficacy
P03146150T0000|51 59|urokinase
P03146150T0000|77 83|heparin
P03146150T0000|61 73|Pro-urokinase
P03146784A0158|147 162|stretch receptors
P03146784A0158|210 223|chemoreceptors
P03146784A0158|25 29|phase
P03146784A0158|4 12|receptors
P03146784A0158|34 44|ventilation
P03146784A0158|92 107|stretch receptors
P03146784A0158|164 166|PSR
P03146784A0158|225 227|IPC
P03147912A0422|103 106|time
P03147912A0422|81 88|baseline
P03147912A0422|11 26|hyperventilators
P03147912A0422|37 42|number
P03147912A0422|126 131|PETCO2
P03147912A0422|67 78|fluctuations
P03147912A0422|45 49|sighs
P03147912A0422|118 121|time
P03149774A0173|178 198|bicuculline methiodide
P03149774A0173|52 61|picrotoxin
P03149774A0173|153 161|retention
P03149774A0173|40 49|injections
P03149774A0173|130 130|h
P03149774A0173|260 266|barrier
P03149774A0173|65 75|bicuculline
P03149774A0173|5 10|IA task
P03149774A0173|111 119|retention
P03149774A0173|139 146|training
P03149774A0173|98 108|enhancement
P03149774A0173|201 222|GABA receptor antagonist
P03150015T0001|45 53|hepatitis
P03150015T0001|8 15|research
P03150015T0001|18 22|non-A
P03150296A0594|217 235|creatinine clearance
P03150296A0594|77 90|filtration rate
P03150296A0594|35 53|creatinine clearance
P03150296A0594|149 154|method
P03150296A0594|92 94|GFR
P03150296A0594|104 110|caution
P03150296A0594|259 266|practice
P03150296A0594|133 143|limitations
P03150296A0594|20 22|use
P03150296A0594|181 195|serum creatinine
P03150296A0594|170 179|techniques
P03150296A0594|117 127|recognition
P03154072A0862|3 17|protein mixtures
P03154072A0862|34 45|soybean flour
P03154072A0862|20 30|sesame flour
P03159903A0352|5 7|end
P03159903A0352|103 119|amino acid sequence
P03159903A0352|65 81|amino acid sequence
P03159903A0352|122 124|IHF
P03159903A0352|19 24|region
P03166458A1356|1 16|protein footprint
P03166458A1356|38 49|GC box element
P03166458A1356|52 62|nucleotides
P03167060A0000|60 64|mRNAs
P03167060A0000|27 31|IGFII
P03167060A0000|92 96|forms
P03167060A0000|126 129|gene
P03167060A0000|12 23|growth factor
P03167060A0000|105 114|derivation
P03167060A0000|45 55|polypeptide
P03168709A0000|70 78|threshold
P03168709A0000|16 21|fields
P03168709A0000|40 51|glaucoma eyes
P03168709A0000|86 107|suprathreshold strategy
P03171221A0531|27 32|result
P03171221A0531|56 60|exons
P03171221A0531|75 92|elastin transcripts
P03171221A0531|3 13|variability
P03171221A0531|46 53|splicing
P03171279A0158|185 188|vein
P03171279A0158|138 143|grafts
P03171279A0158|60 64|toe MP
P03171279A0158|39 44|artery
P03171279A0158|12 21|conclusion
P03171279A0158|70 75|grafts
P03171279A0158|108 113|artery
P03171279A0158|127 132|toe PIP
P03171279A0158|170 175|dorsal
P03172863T0000|0 5|Effect
P03172863T0000|51 56|stress
P03172863T0000|76 79|rats
P03172863T0000|31 44|susceptibility
P03172863T0000|15 28|undernutrition
P03175942A0706|51 54|dams
P03175942A0706|103 107|doses
P03175942A0706|74 83|experiment
P03175942A0706|32 36|doses
P03175942A0706|4 9|effect
P03175942A0706|16 19|fact
P03178097A0000|3 19|CHARGE association
P03178097A0000|35 45|multisystem
P03178097A0000|23 32|collection
P03178097A0000|81 87|atresia
P03178097A0000|56 64|anomalies
P03178161A0000|147 150|risk
P03178161A0000|98 100|B12
P03178161A0000|51 69|blood concentrations
P03178161A0000|179 186|Transkei
P03178161A0000|26 34|screening
P03178161A0000|107 110|acid
P03178161A0000|139 144|adults
P03178161A0000|114 123|methionine
P03178161A0000|190 195|Ciskei
P03178161A0000|164 172|carcinoma
P03178161A0000|72 85|micronutrients
P03178161A0000|197 210|Southern Africa
P03178161A0000|10 14|brush
P03178161A0000|96 96|E
P03178161A0000|174 175|EC
P03178161A0000|87 94|vitamin A
P03178626A0137|0 7|Aviators
P03178626A0137|20 29|Attack Wing
P03178626A0137|80 91|aircraft type
P03178626A0137|31 37|Pacific
P03178626A0137|56 62|results
P03179496T0000|0 9|Evaluation
P03179496T0000|26 52|modified-hemoglobin solution
P03179496T0000|78 99|blood volume replacement
P03179496T0000|70 74|fluid
P03180595A1040|45 60|ejection fraction
P03180595A1040|7 30|gallbladder visualization
P03180595A1040|107 113|disease
P03180595A1040|34 42|reduction
P03180595A1040|88 97|indicators
P03181276A0422|2 14|micrograms PAF
P03181276A0422|47 52|cavity
P03181276A0422|72 88|allergen challenge
P03181276A0422|59 59|h
P03181276A0422|54 54|h
P03181276A0422|17 23|placebo
P03182802A0278|0 2|Sci
P03182872A1122|0 3|Chem
P03183103A0000|82 88|h period
P03183103A0000|101 110|volunteers
P03183103A0000|52 58|sinuses
P03183103A0000|10 23|MR examinations
P03183103A0000|34 39|cavity
P03183127A0068|0 9|Comparison
P03183127A0068|84 101|CT ventriculography
P03183127A0068|69 70|CT
P03183127A0068|106 126|CT myelocisternography
P03183127A0068|72 82|myelography
P03183127A0068|43 59|imaging modalities
P03184267A0000|178 183|humans
P03184267A0000|19 33|broiler chickens
P03184267A0000|3 6|feed
P03184267A0000|85 92|serotype
P03184267A0000|163 175|food poisoning
P03184267A0000|122 131|infections
P03184267A0000|152 159|chickens
P03185322A1305|120 120|%
P03185322A1305|79 83|class
P03185322A1305|72 77|result
P03185322A1305|5 15|correlation
P03185322A1305|108 116|diagnosis
P03185322A1305|123 135|class-2 smears
P03185322A1305|165 173|dysplasia
P03185540T0000|0 6|Factors
P03185540T0000|65 76|purification
P03185540T0000|49 61|RNA polymerase
P03185540T0000|130 134|TFIID
P03185540T0000|25 37|transcription
P03185540T0000|85 95|specificity
P03185540T0000|100 127|TATA box-promoter interactions
P03186091T0000|0 5|Change
P03186091T0000|105 116|hypertension
P03186091T0000|8 33|plasma cystyl aminopeptidase
P03186091T0000|77 85|predictor
P03186091T0000|65 73|gestation
P03186091T0000|35 45|oxytocinase
P03186091T0000|59 63|weeks
P03186270T0001|10 18|diagnosis
P03190481A0292|133 143|correlation
P03190481A0292|79 98|infiltration area unit
P03190481A0292|170 180|macrophages
P03190481A0292|112 118|abscess
P03190481A0292|69 74|number
P03190481A0292|35 46|quantitation
P03190481A0292|24 31|esterase
P03190481A0292|162 167|number
P03190481A0292|197 203|capsule
P03190481A0292|49 59|macrophages
P03190481A0292|187 191|width
P03190481A0292|3 6|test
P03190914A0149|61 74|responsiveness
P03190914A0149|12 33|migration differentials
P03190914A0149|107 111|group
P03192537A0370|116 120|HMG-I
P03192537A0370|149 158|amino acids
P03192537A0370|35 42|sequence
P03192537A0370|62 65|cDNA
P03192537A0370|20 28|amino acid
P03192537A0370|92 108|amino acid sequence
P03192537A0370|177 183|protein
P03192537A0370|54 58|HMG-I
P03192537A0370|60 60|Y
P03192724A0000|62 65|Ryan
P03192724A0000|93 112|FIRO-B interpretation
P03192724A0000|13 28|style differences
P03192724A0000|85 90|system
P03192724A0000|34 44|drug abusers
P03192799T0000|14 28|American Academy
P03192799T0000|31 46|Implant Dentistry
P03192799T0000|0 8|Statement
P03192950A0566|0 3|Sera
P03192950A0566|78 82|range
P03192950A0566|54 62|TSH levels
P03192950A0566|42 46|women
P03194410A0771|2 11|UOxase mRNA
P03194410A0771|46 48|rat
P03194410A0771|60 76|tissue specificity
P03194410A0771|37 43|tissues
P03194410A0771|79 88|expression
P03194410A0771|95 104|UOxase gene
P03195167A0104|73 90|haemocompatibility
P03195167A0104|30 35|layers
P03195167A0104|123 125|PUR
P03195167A0104|154 164|polystyrene
P03195167A0104|146 148|PVC
P03195167A0104|128 144|polyvinylchloride
P03195167A0104|3 22|platelet adhesion rate
P03195167A0104|189 200|test chambers
P03195167A0104|96 121|basic-polymers polyurethane
P03195167A0104|166 167|PS
P03195167A0104|59 67|valuation
P03198436T0000|48 57|cystectomy
P03198436T0000|12 20|treatment
P03198436T0000|23 38|bladder carcinoma
P03198436T0000|73 79|iridium
P03198525A0164|115 117|d-1
P03198525A0164|176 183|mg MGA/hd
P03198525A0164|51 56|medium
P03198525A0164|101 103|MGA
P03198525A0164|24 30|heifers
P03198525A0164|136 143|DEPO-MGA
P03198525A0164|8 19|feedlot trial
P03198525A0164|65 70|weight
P03198525A0164|130 132|MGA
P03198525A0164|45 49|light
P03198525A0164|120 126|control
P03198525A0164|161 165|ml/hd
P03198525A0164|107 113|mg.hd-1
P03198525A0164|146 146|d
P03198525A0164|83 92|treatments
P03199043A0248|101 124|permeability coefficients
P03199043A0248|128 141|transport rates
P03199043A0248|24 32|solutions
P03199043A0248|12 21|uniqueness
P03199043A0248|90 93|case
P03199043A0248|49 69|boundary value problems
P03199043A0248|195 203|constants
P03199043A0248|179 188|resistance
P03199043A0248|150 170|diffusion coefficients
P03199043A0248|0 8|Existence
P03199436A1060|29 52|photosynthesis components
P03199436A1060|62 80|psbB-psbH-petB-petD
P03199436A1060|9 20|gene clusters
P03199436A1060|87 103|psbE-psbF clusters
P03200488A0439|43 54|turnover rate
P03200488A0439|123 128|period
P03200488A0439|131 134|mice
P03200488A0439|73 87|dopamine neurons
P03200488A0439|3 9|results
P03200488A0439|30 32|TIQ
P03200488A0439|101 114|administration
P03200844A1211|146 151|family
P03200844A1211|10 17|sequence
P03200844A1211|63 72|similarity
P03200844A1211|161 177|pore glycoproteins
P03200844A1211|36 51|pore glycoprotein
P03200844A1211|93 100|proteins
P03200844A1211|124 131|features
P03200844A1211|135 140|member
P03207975A0709|47 66|plasma concentrations
P03207975A0709|21 34|administration
P03207975A0709|11 15|hours
P03207975A0709|37 45|vitamin K1
P03207975A0709|72 78|vitamin
P03208493A0849|42 57|lithium clearance
P03208493A0849|13 26|filtration rate
P03208493A0849|66 66|%
P03209019A0662|14 30|promotion bioassay
P03209019A0662|32 37|groups
P03209019A0662|163 174|test material
P03209019A0662|109 115|acetone
P03209019A0662|101 105|mg/ml
P03209019A0662|75 84|microliter
P03209019A0662|192 196|weeks
P03209019A0662|155 158|week
P03209019A0662|93 96|DMBA
P03209019A0662|46 53|CD-1 mice
P03209019A0662|127 131|weeks
P03212551T0001|28 38|contracture
P03212551T0001|17 25|Dupuytren
P03212551T0001|3 14|pathogenesis
P03212929A0000|71 97|Dirofilaria immitis infection
P03212929A0000|52 62|IgE response
P03212929A0000|65 68|dogs
P03212929A0000|2 15|ELISA procedure
P03214709A0559|42 67|plasma corticosterone levels
P03214709A0559|77 82|stress
P03214709A0559|138 142|group
P03214709A0559|24 29|stress
P03214709A0559|103 107|group
P03214709A0559|5 7|min
P03214709A0559|13 19|release
P03216131A0559|16 34|Aeromonas hydrophila
P03216131A0559|52 62|enterotoxin
P03216131A0559|7 13|isolate
P03218714A0000|74 82|tetralogy
P03218714A0000|85 90|Fallot
P03218714A0000|56 58|DWM
P03218714A0000|92 94|TOF
P03218714A0000|31 54|Dandy-Walker malformation
P03218714A0000|14 17|girl
P03219107A0212|27 37|convulsions
P03219107A0212|68 73|births
P03219107A0212|3 11|incidence
P03219107A0212|47 52|babies
P03220077A0274|58 62|years
P03220077A0274|9 16|survival
P03220077A0274|49 52|time
P03223123T0001|61 68|maturity
P03223123T0001|8 17|evaluation
P03223123T0001|27 33|methods
P03223123T0001|79 83|fluid
P03223123T0001|47 53|markers
P03227288A0542|55 60|months
P03227288A0542|7 13|infants
P03227288A0542|29 32|loss
P03227288A0542|70 72|age
P03227568T0001|0 6|Variety
P03227568T0001|9 12|cows
P03227568T0001|88 93|cattle
P03227568T0001|32 36|types
P03227568T0001|16 20|sires
P03227568T0001|80 85|mirror
P03227568T0001|55 62|patterns
P03227568T0001|39 53|dermatoglyphics
P03228518A0339|110 119|dimensions
P03228518A0339|38 44|samples
P03228518A0339|64 85|Personal Responsibility
P03228518A0339|55 62|Academic
P03228785A1047|184 190|control
P03228785A1047|84 87|week
P03228785A1047|161 163|cm2
P03228785A1047|31 41|improvement
P03228785A1047|194 201|ABSTRACT
P03228785A1047|165 165|p
P03228785A1047|120 123|area
P03228785A1047|61 70|parameters
P03228785A1047|149 153|weeks
P03228785A1047|216 220|WORDS
P03228785A1047|0 7|Recovery
P03229917A0099|57 72|remnant infection
P03229917A0099|26 34|resection
P03232410A1467|40 49|lung cancer
P03232410A1467|89 95|smoking
P03232410A1467|33 37|cases
P03232410A1467|69 72|year
P03233862T0000|0 18|Neuromyelitis optica
P03233862T0000|27 34|syndrome
P03233862T0000|54 62|sclerosis
P03234790T0001|0 5|Effect
P03234790T0001|45 64|methyl isobutyl ketone
P03234790T0001|11 17|methods
P03234790T0001|70 77|toxicity
P03234790T0001|29 42|administration
P03235487A0404|0 12|Incorporation
P03235487A0404|104 112|diltiazem
P03235487A0404|79 86|decrease
P03235487A0404|23 48|M sodium dihydrogen phosphate
P03235487A0404|92 101|shelf-life
P03235487A0404|54 67|sugar solutions
P03237446A0377|0 3|None
P03237446A0377|62 72|lymphopenia
P03237446A0377|34 43|infections
P03237446A0377|12 18|history
P03239106A0856|74 82|magnesium
P03239106A0856|64 70|calcium
P03239106A0856|13 29|phosphorus content
P03239106A0856|35 38|diet
P03239106A0856|50 61|reabsorption
P03243027T0000|20 29|regulation
P03243027T0000|41 61|protein gene expression
P03243027T0000|81 103|Dictyostelium discoideum
P03243027T0000|68 78|development
P03243920A0591|89 96|modeling
P03243920A0591|106 115|regression
P03243920A0591|20 58|plasma concentration-effect relationships
P03246999A0483|28 33|b-wave
P03246999A0483|43 58|adaptation period
P03246999A0483|103 110|controls
P03246999A0483|89 96|subjects
P03246999A0483|3 10|increase
P03246999A0483|13 22|amplitudes
P03249792A0241|147 155|psychoses
P03249792A0241|111 123|stress factors
P03249792A0241|63 77|group activities
P03249792A0241|90 102|group dynamics
P03249792A0241|84 87|role
P03249792A0241|21 31|development
P03249792A0241|8 14|factors
P03249792A0241|174 187|manifestations
P03249792A0241|43 56|symptomatology
P03249840A0411|0 19|Baseline measurements
P03249840A0411|47 47|s
P03249840A0411|49 52|FEV1
P03249840A0411|81 84|SGaw
P03249840A0411|225 231|smoking
P03249840A0411|128 137|% reduction
P03249840A0411|103 106|dose
P03249840A0411|109 117|carbachol
P03249840A0411|63 79|airway conductance
P03249840A0411|140 143|SGaw
P03249840A0411|157 166|% reduction
P03249840A0411|210 216|subject
P03249840A0411|169 172|FEV1
P03249840A0411|196 200|entry
P03249840A0411|38 43|volume
P03249840A0411|174 177|PD20
P03249840A0411|145 148|PD35
P03251210A0981|16 18|BGC
P03251210A0981|113 123|dysfunction
P03251210A0981|51 64|calcifications
P03251210A0981|36 46|development
P03251210A0981|96 100|forms
P03251210A0981|4 11|children
P03253219T0000|40 66|anthracycline cardiomyopathy
P03253219T0000|77 81|study
P03253219T0000|6 12|voltage
P03253219T0000|33 37|leads
P03256150A1866|47 50|task
P03256150A1866|3 9|results
P03256150A1866|32 43|requirements
P03257146A1037|132 140|childhood
P03257146A1037|80 87|maturity
P03257146A1037|40 55|neutrophil counts
P03257146A1037|24 28|CSFHU
P03257146A1037|5 11|results
P03257146A1037|93 118|marrow neutrophil precursors
P03257146A1037|125 129|types
P03257146A1037|71 76|number
P03257146A1037|148 158|neutropenia
P03258069A0000|215 220|effect
P03258069A0000|206 212|changes
P03258069A0000|52 60|intensity
P03258069A0000|225 228|time
P03258069A0000|182 186|wrist
P03258069A0000|125 141|acupuncture points
P03258069A0000|156 168|pain threshold
P03258069A0000|17 21|study
P03258069A0000|3 10|purposes
P03258069A0000|65 73|frequency
P03258069A0000|98 113|nerve stimulation
P03258069A0000|40 45|effect
P03259437A0140|13 43|neonates serum alpha-amylase value
P03259437A0140|151 158|neonates
P03259437A0140|102 109|controls
P03259437A0140|137 140|IU/l
P03259437A0140|88 88|%
P03259437A0140|223 226|IU/l
P03259437A0140|182 182|p
P03259437A0140|205 209|value
P03259437A0140|66 77|starch method
P03259437A0140|118 122|value
P03259437A0140|241 248|neonates
P03261005A0216|0 6|Records
P03261005A0216|11 18|children
P03261005A0216|79 86|care unit
P03261005A0216|106 112|failure
P03261005A0216|23 26|AIDS
P03261005A0216|132 137|period
P03261005A0216|41 47|complex
P03261223A0644|64 68|SPECT
P03261223A0644|35 46|disease group
P03261223A0644|8 15|patients
P03261223A0644|76 78|TCT
P03261331A0563|0 4|SPECT
P03261331A0563|75 87|understanding
P03261331A0563|111 120|mechanisms
P03261331A0563|37 55|AIDS dementia complex
P03261331A0563|127 134|disorder
P03261331A0563|18 20|aid
P03261331A0563|26 34|diagnosis
P03263357A0112|29 40|relationship
P03263357A0112|183 186|IL-1
P03263357A0112|124 127|iron
P03263357A0112|90 99|variations
P03263357A0112|129 132|zinc
P03263357A0112|102 121|plasma concentrations
P03263357A0112|164 180|plasma interleukin
P03263357A0112|68 82|body temperature
P03263357A0112|188 195|activity
P03263357A0112|60 65|rhythm
P03263357A0112|145 159|leukocyte counts
P03263465T0000|85 89|genes
P03263465T0000|24 28|H-2Dq
P03263465T0000|32 36|H-2Lq
P03263465T0000|9 16|MHC class
P03263465T0000|73 77|H-2Ld
P03263465T0000|18 22|genes
P03263465T0000|120 127|antigens
P03264073A0224|145 154|albino rats
P03264073A0224|69 76|activity
P03264073A0224|111 120|albino mice
P03264073A0224|9 19|derivatives
P03264073A0224|135 142|activity
P03264073A0224|32 37|series
P03264299A0679|28 35|activity
P03264299A0679|81 84|days
P03264299A0679|90 100|ip injection
P03264299A0679|11 14|mice
P03264299A0679|48 58|macrophages
P03264299A0679|75 77|day
P03264886A0000|118 122|croup
P03264886A0000|74 78|areas
P03264886A0000|174 183|physicians
P03264886A0000|45 47|age
P03264886A0000|94 100|Germany
P03264886A0000|146 157|months period
P03264886A0000|24 31|children
P03264886A0000|50 55|medium
P03264886A0000|38 42|years
P03264886A0000|61 65|towns
P03264886A0000|111 115|cases
P03264886A0000|109 109|%
P03264886A0000|6 15|population
P03267732A0788|132 137|effect
P03267732A0788|153 159|therapy
P03267732A0788|106 112|thrombi
P03267732A0788|46 51|method
P03267732A0788|15 32|Ga-fbg scintigraphy
P03268555T0000|60 80|millipore filter method
P03268555T0000|22 37|biocompatibility
P03268555T0000|7 16|assessment
P03268555T0000|46 54|materials
P03270085A0382|43 48|kidney
P03270085A0382|22 37|magnesium wasting
P03270085A0382|0 13|Hypomagnesemia
P03274204A0642|57 65|dentition
P03274204A0642|93 109|cent alkaline fuxin
P03274204A0642|42 46|index
P03274204A0642|0 11|Dentalplaque
P03275867A0187|43 50|elements
P03275867A0187|133 135|UAS
P03275867A0187|124 131|sequence
P03275867A0187|52 60|silencers
P03275867A0187|11 19|sequences
P03275867A0187|94 97|HMR E
P03275867A0187|148 160|transcription
P03275867A0187|166 178|MAT alpha genes
P03275867A0187|73 90|mating type loci HML E
P03275867A0187|0 3|GRFI
P03275873A0379|28 40|RNA polymerase
P03275873A0379|91 95|genes
P03275873A0379|164 168|cells
P03275873A0379|76 82|ability
P03275873A0379|133 144|transfection
P03275873A0379|118 127|resistance
P03275873A0379|43 50|activity
P03275873A0379|3 9|effects
P03275873A0379|17 25|mutations
P03276246A0037|42 48|colloid
P03276246A0037|64 70|TAC-WBC
P03276246A0037|93 104|appendicitis
P03276246A0037|11 13|use
P03276246A0037|81 90|evaluation
P03276246A0037|54 62|blood cell
P03276924A0090|56 64|insertion
P03276924A0090|75 88|MoMuLV provirus
P03276924A0090|29 41|rearrangement
P03276924A0090|12 17|tumors
P03278829A0082|3 13|indications
P03278829A0082|65 73|candidate
P03278829A0082|106 112|tension
P03278829A0082|20 22|use
P03278829A0082|80 88|tip grafts
P03278829A0082|120 128|deformity
P03280021A1615|126 129|NaBr
P03280021A1615|65 69|M NaCl
P03280021A1615|88 92|M NaBr
P03280021A1615|12 13|dT
P03280021A1615|96 124|measure alpha log Kobsd/alpha log
P03280021A1615|165 167|T/O
P03280021A1615|43 49|buffers
P03280021A1615|153 157|value
P03280021A1615|15 22|affinity
P03280807A0000|157 176|UAG nonsense mutations
P03280807A0000|132 134|CCX
P03280807A0000|136 141|codons
P03280807A0000|151 153|UGA
P03280807A0000|109 115|glycine
P03280807A0000|124 130|proline
P03280807A0000|0 8|Mutations
P03280807A0000|117 119|GGX
P03280807A0000|88 106|frameshift mutations
P03280807A0000|14 23|suf12 locus
P03280807A0000|73 83|suppressors
P03280807A1447|30 42|heterozygotes
P03280807A1447|216 220|SUF12
P03280807A1447|188 196|variation
P03280807A1447|170 177|proteins
P03280807A1447|56 60|suf12
P03280807A1447|222 229|activity
P03280807A1447|3 10|behavior
P03280807A1447|100 104|suf12
P03280807A1447|13 28|suf12-null/SUF12
P03280807A1447|120 130|suppression
P03280912T0000|0 21|Antituberculosis agents
P03280946A0375|147 150|gene
P03280946A0375|69 76|proteins
P03280946A0375|11 25|immunity protein
P03280946A0375|118 135|lac promoter control
P03280946A0375|167 183|expression vectors
P03280946A0375|192 198|control
P03280946A0375|87 95|minicells
P03280946A0375|46 48|35S
P03280946A0375|202 224|bacteriophage T7 promoter
P03280946A0375|104 106|cni
P03282232A0743|0 9|Antibodies
P03282232A0743|21 33|fusion protein
P03282232A0743|91 101|immunoblots
P03282232A0743|79 82|DP-I
P03282232A0743|47 55|DP1A clone
P03282813A0794|116 122|failure
P03282813A0794|134 138|slope
P03282813A0794|31 46|oxygen extraction
P03282813A0794|157 161|slope
P03282813A0794|20 24|range
P03282813A0794|124 124|r
P03282813A0794|147 147|r
P03282813A0794|169 169|p
P03282813A0794|59 66|patients
P03282813A0794|27 29|QO2
P03282813A0794|71 74|ARDS
P03282813A0794|85 92|patients
P03283881A0216|47 54|evidence
P03283881A0216|24 37|hypersecretion
P03283881A0216|62 73|inflammation
P03283881A0216|6 13|patients
P03285764A0675|0 18|Hyperprolactinaemia
P03285764A0675|100 107|leakages
P03285764A0675|54 65|neuropathies
P03285764A0675|212 218|factors
P03285764A0675|28 39|hypogonadism
P03285764A0675|166 177|consequences
P03285764A0675|75 82|stenoses
P03285764A0675|126 129|role
P03285764A0675|253 260|failures
P03285764A0675|148 155|cofactor
P03286611A1198|0 3|Yang
P03286611A1198|7 8|H.
P03287597T0000|9 16|function
P03287597T0000|22 34|prostate gland
P03292076A0820|208 229|eicosanoid biosynthesis
P03292076A0820|157 170|refractoriness
P03292076A0820|91 98|tendency
P03292076A0820|75 86|permeability
P03292076A0820|149 154|degree
P03292076A0820|7 17|endotoxemia
P03292076A0820|193 204|hemodynamics
P03292076A0820|118 128|circulation
P03292082A0486|84 89|system
P03292082A0486|141 149|neurinoma
P03292082A0486|25 38|concentrations
P03292082A0486|119 130|glioblastoma
P03292082A0486|47 54|patients
P03292082A0486|103 112|meningioma
P03292082A0486|2 9|contrast
P03292082A0486|59 64|tumors
P03293844T0000|0 3|Diet
P03293844T0000|13 18|eczema
P03296019T0000|28 39|bond strength
P03296019T0000|54 63|Silicoater
P03296019T0000|0 15|Time delay effects
P03296212A0603|347 353|history
P03296212A0603|155 159|order
P03296212A0603|386 394|potential
P03296212A0603|269 282|tumor debulking
P03296212A0603|360 367|diseases
P03296212A0603|147 151|terms
P03296212A0603|408 413|agents
P03296212A0603|179 187|potential
P03296212A0603|451 456|agents
P03296212A0603|225 229|agent
P03296212A0603|23 32|interferon
P03296212A0603|60 66|Efforts
P03296212A0603|239 245|disease
P03296212A0603|317 325|community
P03296212A0603|11 18|research
P03296212A0603|297 305|diagnosis
P03296212A0603|54 58|areas
P03296212A0603|194 201|research
P03296212A0603|190 192|IFN
P03296212A0603|116 122|synergy
P03296212A0603|3 8|future
P03296254A0556|29 37|latamoxef
P03296254A0556|112 121|depression
P03296254A0556|124 129|factor
P03296254A0556|72 86|prothrombin time
P03296254A0556|5 15|differences
P03296254A0556|135 143|factor VII
P03296254A0556|61 69|elevation
P03297181A0127|157 160|SR-F
P03297181A0127|152 155|food
P03297181A0127|65 80|quinidine sulfate
P03297181A0127|141 147|product
P03297181A0127|91 97|release
P03297181A0127|62 63|RR
P03297181A0127|40 44|doses
P03297181A0127|14 21|subjects
P03297181A0127|99 100|SR
P03297181A0127|54 60|release
P03297181A0127|102 119|quinidine bisulfate
P03297181A0127|130 133|dose
P03298134A0000|27 30|work
P03298134A0000|61 75|Schering-Plough
P03298134A0000|53 59|Intron A
P03298134A0000|82 90|treatment
P03298134A0000|35 51|interferon alfa-2b
P03298134A0000|111 113|HCL
P03298134A0000|4 9|report
P03298134A0000|98 109|cell leukemia
P03300118A0392|0 13|Oxygen delivery
P03300118A0392|17 26|base excess
P03300118A0392|56 59|pigs
P03304015T0000|8 16|chemistry
P03304866T0001|0 16|Revascularization
P03304866T0001|52 60|osteotomy
P03305875T0000|32 42|microstomia
P03305875T0000|20 29|management
P03305875T0000|6 13|orthoses
P03306340A0537|146 160|pancreaticogram
P03306340A0537|68 76|carcinoma
P03306340A0537|91 94|body
P03306340A0537|103 113|obstruction
P03306340A0537|78 85|hardness
P03306340A0537|98 101|tail
P03306340A0537|18 23|spread
P03306340A0537|58 65|invasion
P03306340A0537|29 37|carcinoma
P03306340A0537|130 133|duct
P03308909A0485|9 15|enzymes
P03308909A0485|27 35|cartilage
P03309892A0637|187 191|yeast
P03309892A0637|125 135|nucleotides
P03309892A0637|37 38|S.
P03309892A0637|44 48|genes
P03309892A0637|93 111|actin gene transcript
P03309892A0637|149 167|initiation start site
P03309892A0637|72 76|yeast
P03309892A0637|13 23|observation
P03311954A0000|114 123|ranitidine
P03311954A0000|90 99|ranitidine
P03311954A0000|150 167|reflux oesophagitis
P03311954A0000|12 16|study
P03311954A0000|127 133|mg nocte
P03311954A0000|34 45|institutions
P03311954A0000|139 147|treatment
P03311954A0000|103 110|mg b.i.d.
P03311954A0000|82 87|safety
P03311954A0000|71 78|efficacy
P03312033A0501|15 25|ceftazidime
P03312033A0501|95 103|cefazolin
P03312033A0501|107 116|tobramycin
P03312033A0501|73 90|combination therapy
P03312033A0501|0 10|Monotherapy
P03312514A0756|142 148|animals
P03312514A0756|202 215|control animals
P03312514A0756|102 121|preischemia amplitude
P03312514A0756|162 162|%
P03312514A0756|69 76|recovery
P03312514A0756|14 17|SSEP
P03312514A0756|96 96|%
P03312514A0756|180 184|group
P03312514A0756|168 168|%
P03312514A0756|90 90|%
P03312514A0756|190 190|%
P03312514A0756|3 8|N3 wave
P03312514A0756|196 196|%
P03315359A0732|0 10|Proctoscopy
P03315359A0732|112 122|suppuration
P03315359A0732|53 56|part
P03315359A0732|124 129|masses
P03315359A0732|137 144|fissures
P03315359A0732|82 89|patients
P03315359A0732|30 36|studies
P03315359A0732|59 68|evaluation
P03317796A0853|32 38|picture
P03317796A0853|48 61|osteoarthritis
P03317796A0853|5 16|control group
P03319621A0707|68 76|myoblasts
P03319621A0707|23 23|%
P03319621A0707|80 87|myotubes
P03319621A0707|16 19|mRNA
P03319621A0707|34 47|beta actin mRNAs
P03319621A0707|2 9|contrast
P03319621A0707|26 30|alpha
P03319646T0000|0 18|Plasma renin activity
P03319646T0000|52 59|efficacy
P03319646T0000|62 75|chlorthalidone
P03319912A0000|0 9|Cephradine
P03319912A0000|175 183|frequency
P03319912A0000|44 62|prophylactic measure
P03319912A0000|73 80|patients
P03319912A0000|107 113|history
P03319912A0000|156 161|median
P03319912A0000|13 14|mg
P03319912A0000|94 98|years
P03319912A0000|17 21|night
P03319912A0000|165 172|episodes
P03319912A0000|190 196|dysuria
P03319912A0000|130 135|months
P03319912A0000|83 89|mean age
P03319912A0000|27 32|months
P03320875A2090|42 47|record
P03320875A2090|89 97|infection
P03320875A2090|24 31|Supramid
P03320875A2090|77 86|resistance
P03320875A2090|55 73|tissue compatibility
P03322829A0952|193 193|%
P03322829A0952|173 181|deviation
P03322829A0952|101 105|group
P03322829A0952|158 161|dose
P03322829A0952|12 16|group
P03322829A0952|94 97|size
P03322829A0952|203 214|prescription
P03322829A0952|66 78|digoxin marker
P03322829A0952|140 140|%
P03322829A0952|35 52|compliance category
P03322829A0952|108 115|patients
P03322829A0952|3 6|size
P03322829A0952|58 60|use
P03325081A0524|7 17|keratopathy
P03325081A0524|81 91|keratopathy
P03325081A0524|113 117|cause
P03325081A0524|127 137|keratopathy
P03325081A0524|93 95|PBK
P03325081A0524|37 42|origin
P03326381A0423|88 94|effects
P03326381A0423|18 25|findings
P03326381A0423|45 62|C-peptide excretion
P03326381A0423|163 170|pancreas
P03326381A0423|140 144|drugs
P03326381A0423|129 134|action
P03329716A0187|3 10|activity
P03329716A0187|126 134|calf serum
P03329716A0187|92 102|stimulation
P03329716A0187|64 80|receptor RNA levels
P03329716A0187|51 60|E1A protein
P03329716A0187|107 118|phorbol ester
P03329716A0187|16 34|EGF receptor promoter
P03330711T0000|29 32|neem
P03330711T0000|34 52|Azadirachta indica A.
P03330711T0000|19 26|activity
P03331525T0001|82 91|isocyanate
P03331525T0001|49 65|urethane molecules
P03331525T0001|9 13|study
P03331525T0001|74 79|groups
P03331525T0001|16 29|dentin adhesion
P03331525T0001|32 40|adhesives
P03331933T0048|2 14|Felix Lagrange
P03332022A1094|200 213|protein kinase C
P03332022A1094|8 31|cysteine clustering region
P03332022A1094|87 104|nucleotide sequence
P03332022A1094|113 136|cysteine clustering region
P03332022A1094|235 250|cysteine clusters
P03332022A1094|192 197|region
P03332022A1094|66 72|product
P03332022A1094|46 51|region
P03332022A1094|57 61|c-raf
P03332848A0000|63 70|analysis
P03332848A0000|94 114|carotid artery stenosis
P03332848A0000|25 37|Doppler probes
P03334950A0000|177 185|radiation
P03334950A0000|153 159|control
P03334950A0000|106 116|combination
P03334950A0000|53 68|Cooperative Ewing
P03334950A0000|164 170|surgery
P03334950A0000|119 130|chemotherapy
P03334950A0000|71 82|Sarcoma Study
P03334950A0000|18 34|Pediatric Oncology
P03334950A0000|3 15|German Society
P03334950A0000|84 87|CESS
P03335127A0176|41 45|order
P03335127A0176|34 38|BASIC
P03335127A0176|3 9|program
P03335127A0176|55 63|procedure
P03335398A0568|58 64|surface
P03335398A0568|78 89|immunization
P03335398A0568|9 14|levels
P03335398A0568|91 116|passive transfer experiments
P03335398A0568|70 72|NVS
P03335398A0568|17 31|immunoglobulin G
P03335444A0000|1 5|study
P03335444A0000|61 62|Pu
P03335444A0000|44 50|mixture
P03335444A0000|53 57|241Am
P03335444A0000|26 29|male
P03335651A0000|102 108|concept
P03335651A0000|142 149|approach
P03335651A0000|58 66|resonance
P03335651A0000|68 69|MR
P03335651A0000|185 186|T1
P03335651A0000|194 210|hydrogen weighting
P03335651A0000|10 15|method
P03335651A0000|188 189|T2
P03335651A0000|122 132|sensitivity
P03335651A0000|71 77|imaging
P03335651A0000|175 181|indexes
P03335651A0000|30 47|parameter weighting
P03335923A0257|180 185|ulcers
P03335923A0257|214 221|patients
P03335923A0257|106 113|patients
P03335923A0257|159 166|patients
P03335923A0257|199 202|bulb
P03335923A0257|93 102|volunteers
P03335923A0257|63 74|presentation
P03335923A0257|134 150|reflux gastropathy
P03335923A0257|226 233|Moynihan
P03335923A0257|204 206|RUD
P03335923A0257|152 154|DRG
P03335923A0257|10 17|patients
P03335923A0257|33 38|groups
P03335923A0257|236 242|disease
P03337024A0000|173 179|testing
P03337024A0000|64 75|procainamide
P03337024A0000|114 117|rate
P03337024A0000|103 107|mg/kg
P03337024A0000|95 98|dose
P03337024A0000|139 146|practice
P03337024A0000|10 16|studies
P03337024A0000|34 50|pharmaco-dynamics
P03337024A0000|122 127|mg/min
P03338154T0000|4 17|concentrations
P03338154T0000|66 73|patients
P03338154T0000|36 51|trypsin inhibitor
P03340548A1018|100 117|lipopolysaccharide
P03340548A1018|5 16|chicken liver
P03340548A1018|76 78|Cu2
P03340548A1018|59 64|metals
P03340548A1018|82 96|glucocorticoids
P03340548A1018|66 68|Cd2
P03340548A1018|18 23|levels
P03340548A1018|71 73|Zn2
P03340548A1018|26 38|chicken MT mRNA
P03340726A1103|16 20|Evans
P03340726A1103|25 34|injections
P03340726A1103|4 12|histology
P03340726A1103|93 96|dose
P03340726A1103|101 102|Gy
P03340726A1103|47 64|barrier alterations
P03340726A1103|83 86|days
P03340774A0328|125 126|Gy
P03340774A0328|27 32|organs
P03340774A0328|103 110|estimate
P03340774A0328|10 18|estimates
P03340774A0328|71 72|Gy
P03340774A0328|117 119|rad
P03340774A0328|58 60|rad
P03343730A0486|31 43|family history
P03343730A0486|88 107|calcium stone patients
P03343730A0486|12 22|association
P03343730A0486|61 62|pH
P03344586T0000|29 42|classification
P03344586T0000|45 54|malignancy
P03344586T0000|17 25|diagnosis
P03344586T0000|0 14|New technologies
P03344812A0924|281 290|individual
P03344812A0924|176 177|BP
P03344812A0924|219 224|animal
P03344812A0924|243 251|influence
P03344812A0924|298 305|HR levels
P03344812A0924|126 132|factors
P03344812A0924|14 17|data
P03344812A0924|269 275|ranking
P03344812A0924|211 215|cycle
P03344812A0924|293 294|BP
P03344812A0924|181 188|HR values
P03344812A0924|89 95|factors
P03344812A0924|38 51|HR measurements
P03344812A0924|160 164|state
P03344812A0924|315 324|population
P03344812A0924|33 34|BP
P03345706A0561|29 33|PtcO2
P03345706A0561|36 38|RDS
P03345706A0561|21 25|PaCO2
P03345706A0561|3 13|correlation
P03345706A0561|68 76|judgement
P03346157A0000|88 90|AHS
P03346157A0000|151 156|x-rays
P03346157A0000|256 260|doses
P03346157A0000|228 239|examinations
P03346157A0000|195 198|RERF
P03346157A0000|219 225|numbers
P03346157A0000|14 18|times
P03346157A0000|133 141|exposures
P03346157A0000|71 86|Adult Health Study
P03346157A0000|55 66|examinations
P03346157A0000|34 42|ABCC/RERF
P03346157A0000|92 99|subjects
P03346157A0000|201 205|order
P03346157A0000|174 185|institutions
P03346210A0000|120 147|self-phosphorylation reaction
P03346210A0000|157 169|EGF activation
P03346210A0000|25 27|EGF
P03346210A0000|12 23|growth factor
P03346210A0000|60 88|protein tyrosine kinase activity
P03346210A0000|29 36|receptor
P03348382A0785|42 45|HCO3
P03348382A0785|13 19|ouabain
P03348382A0785|47 55|secretion
P03351478A0371|41 50|% G residues
P03351478A0371|35 36|% C
P03351478A0371|23 26|runs
P03351478A0371|8 14|regions
P03352254A0203|15 23|structure
P03352254A0203|80 88|syllables
P03352254A0203|64 69|vowels
P03352254A0203|32 41|prediction
P03352439T0000|5 31|cord abduction rehabilitation
P03352439T0000|50 60|anastomosis
P03352727T0000|0 1|UK
P03352727T0000|24 34|specialists
P03352727T0000|4 16|biotechnology
P03352947T0001|27 33|ARC/LAS
P03352947T0001|38 49|health worker
P03352947T0001|19 25|complex
P03352947T0001|1 4|case
P03354295A0157|70 81|micrograms/l
P03354295A0157|50 56|serum Tg
P03354295A0157|25 32|patients
P03354295A0157|36 36|%
P03354295A0157|7 12|spread
P03354341A0177|44 53|plasma flow
P03354341A0177|79 93|clearance method
P03354341A0177|114 121|infusion
P03354341A0177|13 26|filtration rate
P03354341A0177|124 129|inulin
P03354341A0177|151 154|acid
P03355122A0238|29 47|plasma glucose levels
P03355122A0238|105 105|h
P03355122A0238|8 11|meal
P03355122A0238|22 27|potato
P03355122A0238|95 100|levels
P03355122A0238|73 75|min
P03359860A0000|75 84|aggression
P03359860A0000|94 108|undercompliance
P03359860A0000|54 68|characteristics
P03359860A0000|184 207|New York Longitudinal Study
P03359860A0000|120 123|mood
P03359860A0000|86 92|anxiety
P03359860A0000|128 137|adjustment
P03359860A0000|157 159|use
P03359860A0000|3 11|relations
P03359860A0000|162 165|data
P03360667A0000|174 181|subjects
P03360667A0000|97 101|youth
P03360667A0000|124 129|status
P03360667A0000|21 28|altitude
P03360667A0000|229 229|n
P03360667A0000|203 210|subjects
P03360667A0000|50 60|development
P03360667A0000|159 166|sea level
P03360667A0000|13 18|effect
P03360667A0000|41 46|growth
P03360667A0000|184 195|mid-altitude
P03360667A0000|220 227|altitude
P03360667A0000|197 197|n
P03360667A0000|139 146|grouping
P03360667A0000|67 72|groups
P03360667A0000|168 168|n
P03360667A0000|235 242|subjects
P03360948A0477|103 105|CAP
P03360948A0477|10 12|CAP
P03360948A0477|21 29|variables
P03360948A0477|112 118|MHI Loss
P03360948A0477|49 56|behavior
P03360948A0477|121 152|Behavioral/Emotional Control scale
P03360948A0477|70 81|relationship
P03361653A0459|17 22|system
P03361653A0459|33 51|contour digitization
P03361653A0459|114 120|objects
P03361653A0459|79 89|limitations
P03366720A1335|75 78|acid
P03366720A1335|113 122|glycolysis
P03366720A1335|37 47|utilization
P03366720A1335|103 109|glucose
P03366720A1335|91 100|metabolism
P03366720A1335|5 10|change
P03366864A0099|60 67|catheter
P03366864A0099|81 85|blood
P03366864A0099|47 54|segments
P03366864A0099|3 10|skin site
P03368701A0113|70 75|choice
P03368701A0113|63 67|place
P03368701A0113|41 53|arteriography
P03368701A0113|91 107|imaging techniques
P03368701A0113|17 27|reliability
P03370815T0000|60 69|radioassay
P03370815T0000|72 81|vitamin B12
P03370815T0000|5 13|detection
P03370815T0000|45 53|test serum
P03371139A0829|63 68|groups
P03371139A0829|36 43|material
P03371139A0829|9 13|group
P03371806A0000|120 126|species
P03371806A0000|25 27|EDP
P03371806A0000|130 148|organ identification
P03371806A0000|99 103|serum
P03371806A0000|67 81|acid phosphatase
P03371806A0000|10 23|data processing
P03371806A0000|163 168|stains
P03371806A0000|29 44|latex immunoassay
P03371894A0355|0 17|Vimentin positivity
P03371894A0355|62 71|components
P03372422A0558|56 60|phase
P03372422A0558|23 27|phase
P03372422A0558|153 157|lungs
P03372422A0558|38 39|N2
P03372422A0558|91 98|position
P03372422A0558|64 69|slopes
P03372422A0558|33 34|Ar
P03372422A0558|121 143|tracer gas concentrations
P03372422A0558|3 20|maximum deflections
P03373755T0001|59 63|ulcer
P03373755T0001|39 45|factors
P03373755T0001|85 92|problems
P03373755T0001|6 17|developments
P03373755T0001|94 118|gastrin receptor blockaders
P03373755T0001|20 24|drugs
P03373755T0001|74 81|efficacy
P03375184A0000|27 32|member
P03375184A0000|135 145|n-1 CH2CH2OH
P03375184A0000|78 95|polyethoxyethanols
P03375184A0000|54 76|alkylphenol-ethoxylates
P03375184A0000|127 133|CH2CH2O
P03375184A0000|106 124|formula C9H19-C6H6-O
P03375184A0000|3 23|spermicide nonoxynol-9
P03375184A0000|46 51|series
P03377864A0000|29 37|diffusion
P03377864A0000|80 91|Lorentz force
P03377864A0000|95 107|Maxwell stress
P03377864A0000|50 58|particles
P03377864A0000|61 69|solutions
P03377864A0000|14 19|fields
P03377891A0652|43 57|life stress group
P03377891A0652|213 222|depression
P03377891A0652|155 166|somatization
P03377891A0652|103 115|severity index
P03377891A0652|13 23|disturbance
P03377891A0652|234 254|psychoticism subscales
P03377891A0652|121 139|Symptom Checklist-90
P03377891A0652|82 91|elevations
P03377891A0652|201 211|sensitivity
P03377891A0652|143 152|elevations
P03377891A0652|224 230|anxiety
P03378994T0000|47 61|extraction ratio
P03378994T0000|64 67|dogs
P03378994T0000|23 35|sodium cyanate
P03378994T0000|7 20|administration
P03379058A0188|0 19|Nucleotide sequencing
P03379058A0188|108 109|bp
P03379058A0188|90 101|reading frame
P03379058A0188|74 79|length
P03379058A0188|129 134|region
P03379058A0188|69 70|bp
P03379058A0188|37 52|E1 alpha cDNA clone
P03379058A0188|59 67|base pairs
P03379058A0188|140 141|bp
P03380547A0169|0 2|SPA
P03380547A0169|7 14|PAG sites
P03380547A0169|32 39|aversion
P03381039A0364|57 61|range
P03381039A0364|39 50|distribution
P03381039A0364|2 9|contrast
P03381039A0364|94 100|maximum
P03381039A0364|106 111|micron
P03381039A0364|84 89|micron
P03381039A0364|14 16|MAN
P03382310A0903|72 86|polyarthralgias
P03382310A0903|108 118|arthropathy
P03382310A0903|8 19|technetium Tc
P03382310A0903|39 46|patients
P03382310A0903|132 150|management decisions
P03382310A0903|175 182|outcomes
P03382310A0903|32 36|scans
P03382772A0319|0 16|Practical interest
P03382772A0319|23 29|studies
P03382772A0319|62 71|parameters
P03382772A0319|115 120|trials
P03382772A0319|109 113|phase
P03382772A0319|100 102|man
P03382855A0368|70 78|adhesions
P03382855A0368|101 107|picture
P03382855A0368|3 12|artery cuff
P03382855A0368|40 43|wrap
P03383897A0189|161 169|treatment
P03383897A0189|78 83|effect
P03383897A0189|143 150|patients
P03383897A0189|86 97|leukopoiesis
P03383897A0189|153 158|course
P03383897A0189|128 137|conditions
P03383897A0189|17 22|action
P03383897A0189|29 44|radiation therapy
P03384033A0155|153 153|%
P03384033A0155|7 11|units
P03384033A0155|107 107|%
P03384033A0155|46 47|Hz
P03384033A0155|34 39|motion
P03384033A0155|52 55|cm/s
P03384033A0155|134 138|input
P03384033A0155|63 63|%
P03384033A0155|170 179|modalities
P03384033A0155|83 94|otolith input
P03384272A0145|14 21|location
P03384272A0145|34 37|mass
P03384272A0145|59 71|presentations
P03384272A0145|25 28|size
P03384272A0145|91 96|lesion
P03384272A0145|44 48|range
P03387665A0000|3 13|development
P03387665A0000|62 68|T brucei
P03387665A0000|74 77|skin
P03387665A0000|53 58|T vivax
P03387665A0000|80 84|goats
P03387665A0000|31 41|Trypanosoma
P03387665A0000|104 110|animals
P03387665A0000|17 28|distribution
P03387665A0000|131 156|Glossina morsitans centralis
P03390074A0000|0 18|Electroglottography
P03390074A0000|89 99|dysfunction
P03390074A0000|41 49|technique
P03390074A0000|68 77|assessment
P03395009A1750|145 153|diameters
P03395009A1750|48 62|cord compression
P03395009A1750|24 30|degrees
P03395009A1750|207 209|T12
P03395009A1750|228 233|T11-12
P03395009A1750|77 87|group-1 dogs
P03395009A1750|191 199|locations
P03395009A1750|243 244|L2
P03395009A1750|212 213|L1
P03395009A1750|224 226|T11
P03395009A1750|249 254|region
P03395009A1750|111 116|ratios
P03395009A1750|11 18|analysis
P03395009A1750|265 276|intervention
P03395009A1750|235 238|L1-2
P03395009A1750|175 186|cord sections
P03395164A0000|18 24|effects
P03395164A0000|35 45|compound WEB
P03395164A0000|50 51|FU
P03395249A1044|63 66|type
P03395249A1044|82 85|dams
P03395249A1044|69 79|pneumocytes
P03395249A1044|116 120|cells
P03395249A1044|147 157|development
P03395249A1044|160 167|neonates
P03395249A1044|192 196|WORDS
P03395249A1044|170 177|ABSTRACT
P03395249A1044|48 60|proliferation
P03395249A1044|17 27|examination
P03395249A1044|89 101|proliferation
P03396437A0321|36 42|strains
P03396437A0321|7 14|problems
P03396628A0207|169 173|spots
P03396628A0207|123 126|mice
P03396628A0207|52 56|spots
P03396628A0207|67 75|ventricle
P03396628A0207|130 130|%
P03396628A0207|78 87|BALB/c mice
P03396628A0207|203 206|mice
P03396628A0207|146 154|incidence
P03396628A0207|9 25|observation period
P03396628A0207|112 116|weeks
P03396628A0207|210 210|%
P03396628A0207|34 38|weeks
P03396628A0207|191 195|weeks
P03398433T0001|13 17|liver
P03398433T0001|51 59|infection
P03398433T0001|3 7|state
P03398433T0001|31 35|forms
P03398714A0594|84 90|radical
P03398714A0594|23 23|%
P03398714A0594|34 42|solvation
P03398714A0594|13 14|RH
P03398714A0594|106 131|propagation transition state
P03398714A0594|48 60|peroxy radical
P03398823A0459|43 55|mg/kg p-xylene
P03398823A0459|90 95|effect
P03398823A0459|24 37|administration
P03398823A0459|150 157|exposure
P03398823A0459|136 142|removal
P03398823A0459|131 133|min
P03398823A0459|105 112|p-xylene
P03398823A0459|79 80|hr
P03398823A0459|3 9|effects
P03398823A0459|58 64|toluene
P03400694A0245|0 7|PATIENTS
P03400694A0245|67 70|rest
P03400694A0245|144 154|sarcoidosis
P03400694A0245|41 52|scintigraphy
P03400694A0245|11 17|METHODS
P03400694A0245|99 110|dipyridamole
P03400694A0245|83 87|mg/kg
P03400694A0245|19 30|Thallium-201
P03400694A0245|121 127|minutes
P03400694A0245|132 139|patients
P03401060A0000|4 12|melanomas
P03402183A0171|28 32|forms
P03402183A0171|112 122|circulation
P03402183A0171|243 253|circulation
P03402183A0171|171 172|Hz
P03402183A0171|185 202|voltage stimulation
P03402183A0171|105 107|MVC
P03402183A0171|52 63|contractions
P03402183A0171|84 95|contractions
P03402183A0171|97 99|MVC
P03402183A0171|153 164|contractions
P03402183A0171|227 238|contractions
P03402183A0171|3 10|TA muscle
P03403313A0298|86 93|excision
P03403313A0298|112 119|excision
P03403313A0298|166 173|excision
P03403313A0298|102 102|%
P03403313A0298|49 63|treatment groups
P03403313A0298|137 152|radiation therapy
P03403313A0298|33 37|years
P03403313A0298|156 156|%
P03403313A0298|182 182|%
P03403313A0298|17 28|control rates
P03403412A0000|58 67|efficiency
P03403412A0000|35 45|composition
P03403412A0000|20 27|implants
P03403412A0000|124 135|grain content
P03403412A0000|3 9|effects
P03403412A0000|30 33|rate
P03403412A0000|70 75|growth
P03403412A0000|98 105|fed diets
P03403412A0000|115 120|forage
P03403480A0299|175 181|density
P03403480A0299|9 18|suspension
P03403480A0299|115 122|diameter
P03403480A0299|76 92|femur middiaphysis
P03403480A0299|194 215|collagen concentrations
P03403480A0299|183 189|mineral
P03403480A0299|170 173|area
P03403480A0299|126 126|%
P03403480A0299|38 43|change
P03403480A0299|58 70|configuration
P03403480A0299|149 159|alterations
P03403826T0000|91 106|stenosis severity
P03403826T0000|133 140|analysis
P03403826T0000|187 197|flow reserve
P03403826T0000|201 247|exercise/redistribution thallium-201 scintigraphy
P03403826T0000|109 118|comparison
P03403826T0000|154 166|cineangiogram
P03403826T0000|77 88|measurements
P03404334T0000|0 11|Water content
P03404334T0000|50 58|cartilage
P03404334T0000|15 39|equilibrium water partition
P03404495A0172|0 19|Thyroid function tests
P03404495A0172|38 47|admissions
P03406054A0351|68 71|slit
P03406054A0351|62 63|mm
P03406054A0351|9 26|line spread function
P03406054A0351|135 145|polystyrene
P03406054A0351|51 55|image
P03406054A0351|127 131|front
P03406054A0351|79 86|tungsten
P03406054A0351|116 124|isocentre
P03406054A0351|0 3|Data
P03406054A0351|28 30|LSF
P03407676A0585|7 15|infection
P03407843T0000|0 5|Papers
P03407843T0000|11 17|Society
P03407843T0000|37 43|Surgery
P03413681A0659|113 120|function
P03413681A0659|59 65|patient
P03413681A0659|36 40|years
P03413681A0659|48 51|fact
P03413681A0659|21 23|age
P03413681A0659|8 19|heart disease
P03413681A0659|90 99|predictors
P03413681A0659|70 74|woman
P03413890T0001|0 8|Prognosis
P03413890T0001|11 15|Bowen
P03413890T0001|50 55|region
P03413890T0001|18 24|disease
P03417104A0536|17 23|results
P03417104A0536|78 92|stimulus effects
P03417104A0536|35 50|chlorphentermine
P03417104A0536|95 101|animals
P03417588T0000|60 63|corn
P03417588T0000|0 5|Liquid
P03417588T0000|21 26|method
P03417588T0000|67 70|rice
P03417588T0000|30 42|determination
P03417588T0000|45 57|citreoviridin
P03417668A1233|76 86|beta subunit
P03417668A1233|25 43|autophosphorylation
P03417668A1233|116 127|CaM-kinase II
P03417668A1233|104 113|transition
P03417668A1233|53 64|alpha subunit
P03417668A1233|149 152|form
P03417668A1233|46 51|Thr286
P03417668A1233|69 74|Thr287
P03417668A1233|5 12|findings
P03417668A1233|133 135|Ca2
P03418727A0992|120 129|treatments
P03418727A0992|93 102|myelopathy
P03418727A0992|79 85|insight
P03418727A0992|21 31|penetration
P03418727A0992|59 70|chemotherapy
P03420266A0000|119 129|animal model
P03420266A0000|91 104|adenocarcinoma
P03420266A0000|28 39|hyperthermia
P03420266A0000|3 13|interaction
P03420266A0000|69 81|Dunning R3327G
P03420266A0000|16 24|radiation
P03420266A0000|147 152|cancer
P03420324A0178|134 147|h/day beginning
P03420324A0178|67 70|days
P03420324A0178|204 206|day
P03420324A0178|195 197|day
P03420324A0178|165 165|%
P03420324A0178|48 48|%
P03420324A0178|114 114|%
P03420324A0178|150 152|day
P03420324A0178|82 84|day
P03420324A0178|60 60|%
P03420324A0178|170 171|N2
P03420324A0178|119 120|N2
P03420324A0178|99 107|pregnancy
P03420324A0178|126 126|%
P03420324A0178|33 41|following
P03420324A0178|8 11|rats
P03420324A0178|53 54|N2
P03420466A0000|14 30|cryptosporidiosis
P03420466A0000|3 11|incidence
P03420466A0000|38 45|children
P03420466A0000|77 85|specimens
P03420466A0000|61 68|staining
P03420466A0000|99 105|Kinyoun
P03421425A0878|17 23|percent
P03421425A0878|34 47|hypothyroidism
P03421425A0878|5 12|patients
P03421425A0878|72 85|determinations
P03423732A0341|0 7|Addition
P03423732A0341|92 92|%
P03423732A0341|22 27|De-Nol
P03423732A0341|10 19|sucralfate
P03423732A0341|38 47|increments
P03423732A0341|147 150|PGE2
P03423732A0341|57 69|HCO3 secretion
P03423732A0341|152 157|dmPGE2
P03423732A0341|119 130|HCO3 response
P03423732A0341|86 86|%
P03427474A0853|87 104|saccharin solutions
P03427474A0853|34 40|animals
P03427474A0853|51 58|aversion
P03427474A0853|71 84|concentrations
P03427474A0853|15 25|control rats
P03427613A0659|30 35|system
P03427613A0659|107 111|brain
P03427613A0659|75 85|pineal organ
P03427613A0659|44 50|vessels
P03427613A0659|94 101|portions
P03428084A0430|84 97|pattern onset C1
P03428084A0430|4 17|degrees stimuli
P03428084A0430|35 52|scalp distributions
P03428084A0430|112 118|striate
P03428084A0430|148 154|origins
P03428084A0430|59 77|pattern reversal P100
P03428274A0000|26 32|protein
P03428274A0000|37 45|HeLa cells
P03428274A0000|7 12|factor
P03428274A0000|179 184|factor
P03428274A0000|91 93|Ad2
P03428274A0000|152 157|origin
P03428274A0000|75 88|adenovirus type
P03428274A0000|95 108|DNA replication
P03428274A0000|17 21|NFIII
P03428274A0000|63 72|initiation
P03428274A0000|129 146|nucleotide sequence
P03428274A0000|186 200|recognition site
P03429306T0000|39 44|cortex
P03429306T0000|21 25|layer
P03429306T0000|1 10|Golgi study
P03429371A1051|14 33|cephalothin clearance
P03429371A1051|65 74|phagocytes
P03429371A1051|49 52|site
P03429371A1051|122 125|site
P03430221A1236|42 51|properties
P03430221A1236|66 74|detectors
P03430221A1236|3 10|findings
P03430221A1236|28 34|context
P03434347A0358|0 7|Mean rCBF
P03434347A0358|34 38|weeks
P03434347A0358|23 30|patients
P03434347A0358|44 50|surgery
P03434347A0358|67 70|side
P03436119A0000|20 29|tomography
P03436119A0000|79 89|sensitivity
P03436119A0000|93 107|reproducibility
P03436119A0000|51 68|bone mineral content
P03436529A1066|131 141|nt positions
P03436529A1066|167 174|template
P03436529A1066|50 53|pair
P03436529A1066|17 24|enhancer
P03436529A1066|3 11|structure
P03436529A1066|78 98|oligodeoxynucleotides
P03436529A1066|189 196|enhancer
P03436529A1066|118 123|region
P03436877A0950|0 1|Kf
P03436877A0950|268 272|WORDS
P03436877A0950|178 178|P
P03436877A0950|246 253|ABSTRACT
P03436877A0950|122 122|P
P03436877A0950|74 89|lung mass % delta Kf
P03436877A0950|102 106|% mass
P03436877A0950|171 171|r
P03436877A0950|225 243|blocker pretreatment
P03436877A0950|7 8|CT
P03436877A0950|91 91|c
P03436877A0950|158 162|% mass
P03436877A0950|62 71|reductions
P03436877A0950|3 3|c
P03436877A0950|115 115|r
P03436877A0950|32 39|lung mass
P03436877A0950|192 204|relationships
P03436877A0950|139 146|% delta CT
P03439248A0000|179 191|artery disease
P03439248A0000|46 65|exercise thallium-201
P03439248A0000|31 42|dipyridamole
P03439248A0000|16 22|methods
P03439248A0000|150 157|patients
P03439248A0000|120 133|artery stenosis
P03439248A0000|76 91|perfusion imaging
P03440780A0779|99 120|calcium entry mechanisms
P03440780A0779|9 15|results
P03440780A0779|176 180|EDLFs
P03440780A0779|152 173|vasoconstrictor effects
P03440780A0779|136 146|differences
P03440780A0779|46 70|vasoconstrictor properties
P03440780A0779|34 37|EDLF
P03440780A0779|185 191|respect
P03440780A0779|211 214|beds
P03441587A0000|0 7|Research
P03441587A0000|48 52|serum
P03441587A0000|36 42|factors
P03441587A0000|165 170|method
P03441587A0000|132 138|results
P03441587A0000|173 181|reference
P03441587A0000|92 102|polystyrene
P03441587A0000|78 82|tests
P03441587A0000|68 72|means
P03441587A0000|58 65|patients
P03441587A0000|113 124|erythrocytes
P03443144A0409|87 95|reactions
P03443144A0409|4 26|aspirin esterase activity
P03443144A0409|45 50|factor
P03443144A0409|71 77|aspirin
P03443566A0675|30 33|gain
P03443566A0675|6 16|experiments
P03443566A0675|37 53|gain-to-feed ratio
P03443566A0675|68 69|TR
P03443566A0675|73 74|CR
P03443573A0329|122 122|g
P03443573A0329|125 130|tissue
P03443573A0329|77 79|fat
P03443573A0329|103 104|mg
P03443573A0329|7 19|least-squares
P03443573A0329|45 61|longissimus muscle
P03443609A0000|88 95|products
P03443609A0000|55 63|technique
P03443609A0000|138 154|column methodology
P03443609A0000|22 40|fluid chromatography
P03443609A0000|3 6|role
P03443609A0000|42 44|SFC
P03446332A0831|0 12|Nitrofurazone
P03446332A0831|53 56|LHRH
P03446332A0831|36 39|rise
P03446332A0831|42 43|LH
P03448035T0000|15 23|pregnancy
P03448035T0000|7 12|tumors
P03449358T0001|15 19|study
P03449358T0001|22 34|polyarteritis
P03450438A0446|28 31|need
P03450438A0446|11 25|Yates correction
P03450438A0446|54 59|method
P03450438A0446|0 5|X2 test
P03451761A0215|86 89|base
P03451761A0215|109 111|RNV
P03451761A0215|45 55|stimulation
P03451761A0215|6 18|baseline study
P03451761A0215|20 30|WPW syndrome
P03451761A0215|95 104|ventricles
P03451761A0215|72 76|sites
P03452920T0001|0 2|Man
P03452920T0001|6 11|insect
P03452920T0001|13 16|past
P03457330A0271|71 79|operation
P03457330A0271|3 10|patients
P03457330A0271|22 26|assay
P03457330A0271|17 18|CA
P03457330A0271|45 48|week
P03459385T0000|0 6|Allergy
P03459385T0000|10 17|Tourette
P03459385T0000|20 27|syndrome
P03459736A0184|58 64|variety
P03459736A0184|67 71|pills
P03459736A0184|30 37|sessions
P03459736A0184|75 82|capsules
P03459736A0184|3 11|criterion
P03459736A0184|41 54|generalization
P03463537T0001|46 54|anomalies
P03463537T0001|8 13|method
P03463537T0001|63 66|bite
P03463537T0001|20 28|treatment
P03463537T0001|31 35|Class
P03463543A1613|57 59|UTI
P03463543A1613|35 43|treatment
P03463543A1613|0 7|Enoxacin
P03465957A1008|0 18|Mean fluorosis scores
P03466730A0210|42 47|pupils
P03466730A0210|9 20|dysfunctions
P03473253A0000|159 171|U.S. companies
P03473253A0000|28 47|cohort mortality study
P03473253A0000|67 81|chemical workers
P03473253A0000|123 150|chloromethyl ether manufacture
P03473379A0183|14 24|amyloidosis
P03473379A0183|57 67|gland biopsy
P03473379A0183|3 11|diagnosis
P03476002A0148|0 3|Hair
P03476002A0148|7 18|blood samples
P03476002A0148|34 41|vitamin C
P03476002A0148|88 96|intervals
P03476002A0148|44 65|placebo supplementation
P03476002A0148|115 120|months
P03478354A0436|15 18|cows
P03478354A0436|45 56|corpus luteum
P03478354A0436|9 13|herds
P03478354A0436|65 84|prostaglandin F2 alpha
P03478354A0436|29 39|d postpartum
P03479897A0961|28 35|angle ANB
P03479897A0961|89 96|Class III
P03479897A0961|10 13|hand
P03479897A0961|62 66|angle
P03479897A0961|79 86|relation
P03484075T0001|0 17|Emergency treatment
P03484075T0001|49 56|injuries
P03484894A0782|4 8|cases
P03484894A0782|90 97|biotypes
P03484894A0782|47 53|biotype
P03484894A0782|10 17|isolates
P03484894A0782|65 71|biotype
P03484894A0782|103 104|V.
P03485064A0135|41 48|patients
P03485064A0135|11 23|EVS treatments
P03485064A0135|1 5|total
P03486405A0341|98 106|IL-1 alpha
P03486405A0341|92 95|form
P03486405A0341|74 78|exons
P03486405A0341|135 139|exons
P03486405A0341|19 25|portion
P03486405A0341|31 50|precursor polypeptide
P03487348A0000|59 80|afterhyperpolarization
P03487348A0000|40 44|model
P03487348A0000|11 17|version
P03487348A0000|20 26|Kernell
P03487348A0000|82 84|AHP
P03488532A0235|71 78|symptoms
P03488532A0235|83 100|acyclovir treatment
P03488532A0235|18 23|report
P03488532A0235|53 67|dermatomal signs
P03488532A0235|41 50|resolution
P03491190A0233|67 71|scans
P03491190A0233|49 49|%
P03491190A0233|21 27|defects
P03491190A0233|35 43|LAD region
P03491190A0233|74 86|stress studies
P03491190A0233|30 32|RCA
P03491190A0233|3 15|detectability
P03493240T0000|60 64|drugs
P03493240T0000|13 22|properties
P03493240T0000|37 42|agents
P03494649A0472|72 77|change
P03494649A0472|80 83|MABP
P03494649A0472|60 66|absence
P03494649A0472|52 54|CBF
P03494649A0472|20 28|challenge
P03494649A0472|42 49|increase
P03499608A1054|46 66|heterozygote detection
P03499608A1054|78 86|diagnosis
P03499608A1054|35 42|reagents
P03499608A1054|139 143|cause
P03499608A1054|91 116|beta-hydroxylase deficiency
P03499608A1054|163 173|hyperplasia
P03499608A1054|5 8|data
P03499657A0000|0 10|Osteocalcin
P03499657A0000|214 227|hypercalcaemia
P03499657A0000|188 191|PHPT
P03499657A0000|12 31|serum bone-Gla protein
P03499657A0000|39 62|serum alkaline phosphatase
P03499657A0000|168 186|hyperparathyroidism
P03499657A0000|230 239|malignancy
P03499657A0000|78 107|hydroxyproline/creatinine ratio
P03499657A0000|109 127|uOH-Prol/creatinine
P03499657A0000|33 36|sBGP
P03499657A0000|202 209|patients
P03499657A0000|64 66|sAP
P03499657A0000|149 156|patients
P03499657A0000|241 242|HM
P03499822A0182|119 126|employee
P03499822A0182|129 135|country
P03499822A0182|93 102|prevalence
P03499822A0182|138 142|birth
P03499822A0182|20 37|regression analysis
P03499822A0182|51 64|seropositivity
P03499822A0182|150 152|age
P03499822A0182|105 114|hepatitis B
P03504971A0000|0 5|Hexsyn
P03504971A0000|141 145|bonds
P03504971A0000|11 22|Goodyear Tire
P03504971A0000|119 124|source
P03504971A0000|149 161|vulcanization
P03504971A0000|52 67|polyolefin rubber
P03504971A0000|98 113|% methylhexadiene
P03504971A0000|26 47|Rubber Company tradename
P03507689A0000|191 212|beta-galactosidase gene
P03507689A0000|108 113|origin
P03507689A0000|159 181|bacteriophage T7 promoter
P03507689A0000|131 145|bacteriophage f1
P03507689A0000|98 100|DNA
P03507689A0000|8 37|phage-plasmid expression vectors
P03507689A0000|116 126|replication
P03507689A0000|57 72|pUC18/19 plasmids
P03507689A0000|102 106|ssDNA
P03508698A0535|2 6|order
P03508698A0535|38 40|jaw
P03508698A0535|49 57|adductors
P03508698A0535|24 36|finger flexors
P03508698A0535|62 76|triceps reflexes
P03508698A0535|109 114|groups
P03508698A0535|19 22|rate
P03510185A0187|0 4|Natl.
P03513989A0580|17 24|estrogen
P03513989A0580|61 67|animals
P03513989A0580|7 13|ethanol
P03513989A0580|44 58|UROD-deficiency
P03513989A1149|172 178|effects
P03513989A1149|194 199|agents
P03513989A1149|115 121|insight
P03513989A1149|57 67|disturbance
P03513989A1149|21 28|disorder
P03513989A1149|95 103|countries
P03513989A1149|70 88|porphyrin metabolism
P03513989A1149|136 147|pathogenesis
P03515840A0000|176 180|death
P03515840A0000|140 145|months
P03515840A0000|60 68|granuloma
P03515840A0000|25 29|cases
P03515840A0000|149 153|years
P03515840A0000|159 172|generalization
P03515840A0000|95 107|histiocytosis
P03515840A0000|41 48|symptoms
P03515840A0000|120 126|sarcoma
P03516189A0406|3 10|patients
P03516189A0406|39 48|mg kg-1 i.v.
P03516189A0406|23 35|suxamethonium
P03517388A0763|58 60|U/L
P03517388A0763|72 74|U/L
P03517388A0763|76 76|p
P03517388A0763|48 49|BC
P03517388A0763|23 32|CK-MB level
P03517388A0763|62 63|CC
P03517388A0763|45 46|BC
P03520729A0381|57 69|renin activity
P03520729A0381|43 54|plasma levels
P03520729A0381|10 16|changes
P03520729A0381|73 96|aldosterone concentration
P03520729A0381|19 27|heart rate
P03520729A0381|29 38|body weight
P03522105A1011|4 31|trough serum TOB concentrations
P03522105A1011|75 82|recovery
P03522105A1011|50 54|death
P03522105A1011|65 70|levels
P03526279T0000|23 33|nursing R.N.
P03526279T0000|14 20|schools
P03528748A0414|3 16|maxicell system
P03528748A0414|51 56|weight
P03528748A0414|18 24|protein
P03531317A0930|85 89|model
P03531317A0930|92 97|Fisher
P03531317A0930|22 31|recessives
P03531317A0930|16 19|loss
P03531317A0930|56 69|hypergeometric
P03534581A0976|57 61|group
P03534581A0976|50 50|%
P03534581A0976|138 149|control group
P03534581A0976|103 118|cyclophosphamide
P03534581A0976|73 86|5-fluorouracil
P03534581A0976|3 11|incidence
P03534581A0976|154 154|%
P03534581A0976|88 98|doxorubicin
P03534581A0976|29 37|neoplasms
P03536682A0572|0 8|Ovulation
P03536682A0572|27 27|%
P03536682A0572|29 36|patients
P03536864A0000|10 13|work
P03537686A0099|205 209|cells
P03537686A0099|152 160|mutations
P03537686A0099|289 298|background
P03537686A0099|8 11|size
P03537686A0099|241 249|mutations
P03537686A0099|101 106|vector
P03537686A0099|50 71|supF suppressor tRNA gene
P03537686A0099|29 45|mutagenesis marker
P03537686A0099|214 223|plasmid DNA
P03537686A0099|182 193|transfection
P03537686A0099|15 23|placement
P03537686A0099|130 138|frequency
P03537711A0181|0 1|W.
P03537721A0491|60 67|PEP4 gene
P03537721A0491|24 47|recombination experiments
P03537721A0491|78 81|GAL4
P03537721A0491|6 13|analysis
P03537721A0491|84 96|chromosome XVI
P03537721A0876|116 127|yeast vacuole
P03537721A0876|33 37|model
P03537721A0876|53 70|precursor molecules
P03537721A0876|10 21|observations
P03537721A0876|164 173|hydrolases
P03537721A0876|86 106|PEP4 gene self-activate
P03537727A0243|3 6|poly
P03537727A0243|10 16|segment
P03537727A0243|90 96|protein
P03537727A0243|79 85|protein
P03537727A0243|22 24|RNA
P03537727A0243|8 8|A
P03540591A0330|149 160|reading frame
P03540591A0330|7 17|translation
P03540591A0330|47 51|cDNAs
P03540591A0330|115 121|protein
P03540591A0330|20 22|RNA
P03540591A0330|64 76|P0 transcripts
P03540853A0652|58 75|DNA binding proteins
P03540853A0652|13 29|amino acid sequence
P03540853A0652|38 53|sequence homology
P03540853A0652|32 34|Mop
P03541263A0368|45 51|control
P03541263A0368|10 19|techniques
P03541263A0368|54 61|diabetes
P03542945T0000|0 12|Ciprofloxacin
P03542945T0000|33 43|experiences
P03542945T0000|16 23|overview
P03543485A0069|62 79|space flight effects
P03543485A0069|52 59|response
P03543485A0069|20 29|mechanisms
P03543485A0069|43 49|changes
P03543936A0000|44 49|family
P03543936A0000|65 72|homology
P03543936A0000|78 94|ras oncogene family
P03543936A0000|3 10|rho genes
P03544858A0374|72 76|sexes
P03544858A0374|89 98|metabolism
P03544858A0374|102 116|HDL-cholesterol
P03544858A0374|120 126|females
P03544858A0374|5 13|component
P03544858A0374|49 55|insulin
P03544858A0374|130 134|males
P03544858A0374|59 64|VO2 max
P03545955A0751|250 256|lactose
P03545955A0751|239 242|milk
P03545955A0751|208 212|Study
P03545955A0751|215 221|glucose
P03545955A0751|96 102|glucose
P03545955A0751|130 137|mmol X h/l
P03545955A0751|104 111|fructose
P03545955A0751|146 152|glucose
P03545955A0751|173 178|apples
P03545955A0751|51 55|Study
P03545955A0751|76 80|juice
P03545955A0751|199 206|mmol X h/l
P03545955A0751|119 126|fructose
P03545955A0751|227 234|ice cream
P03545955A0751|164 168|juice
P03545955A0751|260 267|mmol X h/l
P03545955A0751|186 195|apple juice
P03545955A0751|41 45|foods
P03545955A0751|58 64|glucose
P03545955A0751|139 143|Study
P03545955A0751|3 14|glucose areas
P03545955A0751|27 35|ingestion
P03545955A0751|85 91|sucrose
P03545955A1378|3 22|serum insulin response
P03549045A0878|0 2|SCL
P03549045A0878|25 33|verapamil
P03549045A0878|85 89|group
P03549045A0878|38 48|sinus arrest
P03549045A0878|91 97|animals
P03549045A0878|67 71|group
P03550444T0000|14 24|yeast system
P03550444T0000|27 31|assay
P03550444T0000|42 52|specificity
P03550444T0000|0 10|Development
P03552363A0568|161 172|correlations
P03552363A0568|104 106|men
P03552363A0568|83 101|blood pressure levels
P03552363A0568|11 28|serum insulin levels
P03552363A0568|142 149|subjects
P03552363A0568|48 59|correlations
P03552363A0568|206 223|blood pressure level
P03553149A0299|30 40|mutagenesis
P03553149A0299|81 92|cleavage site
P03553149A0299|49 52|site
P03553149A0299|95 98|LexA
P03553149A0299|55 58|MucA
P03553439A0404|43 53|tumor tissue
P03553439A0404|156 165|tumor cells
P03553439A0404|90 99|tumor cells
P03553439A0404|183 192|tumor cells
P03553439A0404|3 8|latter
P03553439A0404|113 123|tumor tissue
P03553439A0404|167 170|Type
P03553439A0404|32 35|Type
P03553439A0404|101 104|Type
P03555318T0000|3 14|pharmacology
P03555318T0000|17 25|carnitine
P03556834T0000|5 22|inhalation toxicity
P03556834T0000|25 36|T-2 mycotoxin
P03556834T0000|39 42|mice
P03559193A0000|87 90|FTAS
P03559193A0000|81 85|scale
P03559193A0000|10 22|investigation
P03559193A0000|142 151|correlates
P03559193A0000|66 79|Framingham Type
P03559193A0000|51 60|dimensions
P03559232T0000|27 35|arthritis
P03559232T0000|12 16|study
P03559287T0000|0 9|Legionella
P03559287T0000|20 26|ecology
P03559287T0000|44 54|consumption
P03561036T0000|0 9|Lymphatics
P03561036T0000|22 25|rats
P03561036T0000|46 55|oil extract
P03561036T0000|15 19|aorta
P03561036T0000|57 66|lipofundin
P03561622A0659|186 206|term vancomycin therapy
P03561622A0659|164 176|blood cultures
P03561622A0659|80 103|DiaTAP button graft complex
P03561622A0659|7 12|resort
P03561622A0659|49 56|dialysis
P03561622A0659|40 46|patient
P03561622A0659|69 74|health
P03563399A0534|42 45|SoNo
P03563399A0534|100 109|difference
P03563399A0534|49 62|S pi No threshold
P03563399A0534|3 17|signal durations
P03563399A0534|28 29|ms
P03563604A1075|52 52|%
P03563604A1075|85 100|drug intervention
P03563604A1075|75 75|%
P03563604A1075|23 31|villagers
P03563604A1075|59 70|parasite rate
P03563604A1075|34 35|RK
P03563604A1075|3 12|spleen rate
P03567017A0000|99 107|half-life
P03567017A0000|8 13|dosing
P03567017A0000|51 52|mg
P03567017A0000|38 47|indoprofen
P03567017A0000|153 160|subjects
P03567017A0000|32 35|days
P03567017A0000|109 112|t1/2
P03567017A0000|123 138|drug accumulation
P03567017A0000|18 22|times
P03567017A0000|85 88|drug
P03568311A0273|100 106|indexes
P03568311A0273|76 78|IPP
P03568311A0273|64 66|PWP
P03568311A0273|4 11|patients
P03568311A0273|31 39|tamponade
P03568311A0273|50 62|wedge pressure
P03568311A0273|69 71|RAP
P03568311A0273|117 124|function
P03568311A1361|91 101|correlation
P03568311A1361|127 127|r
P03568311A1361|12 20|tamponade
P03568311A1361|106 110|TMFP1
P03568311A1361|121 125|TMFP2
P03568311A1361|112 112|r
P03568311A1361|24 45|pericardiocentesis data
P03568311A1361|143 147|TMFP3
P03568311A1361|62 76|stroke work index
P03570455A0433|0 6|Rabbits
P03570455A0433|79 83|mg/dl
P03570455A0433|103 108|TSST-1
P03570455A0433|41 46|levels
P03570455A0433|24 35|hypocalcemia
P03570455A0433|92 100|influence
P03571135T0000|31 38|language
P03571135T0000|77 84|children
P03571135T0000|21 28|features
P03571135T0000|6 10|value
P03572706A0329|159 168|F-K indices
P03572706A0329|155 155|F
P03572706A0329|179 189|MMPI profile
P03572706A0329|86 95|therapists
P03572706A0329|46 54|protocols
P03572706A0329|141 149|elevation
P03572706A0329|19 33|interpretations
P03572706A0329|120 137|treatment condition
P03575656A0120|129 132|time
P03575656A0120|25 36|chemical form
P03575656A0120|121 126|period
P03575656A0120|74 77|bone
P03575656A0120|38 41|90Sr
P03575656A0120|95 101|portion
P03575656A0120|68 71|lung
P03577670A0102|59 77|matter hypodensities
P03577670A0102|3 7|study
P03577670A0102|28 34|atrophy
P03577670A0236|3 11|diagnosis
P03577670A0236|42 44|MLD
P03577670A0236|27 40|leukodystrophy
P03577670A0236|90 92|ASA
P03577670A0236|127 133|sisters
P03577670A0236|75 88|arylsulfatase A
P03577670A0236|63 69|finding
P03577670A0236|94 99|levels
P03577670A0236|110 120|fibroblasts
P03578948A0448|44 49|volume
P03578948A0448|77 83|c X min-1
P03578948A0448|10 20|ventilation
P03578948A0448|65 68|rate
P03578948A0448|54 60|ml X kg-1
P03581160A0583|148 155|controls
P03581160A0583|79 107|artery pulse amplitude responses
P03581160A0583|132 141|TH subjects
P03581160A0583|18 36|heart rate reactivity
P03582149T0001|100 114|Jiangxi Province
P03582149T0001|34 45|valve disease
P03582149T0001|58 62|fever
P03582149T0001|84 97|school students
P03582149T0001|17 22|survey
P03582184A0448|0 4|Drugs
P03582184A0448|26 30|phase
P03582184A0448|61 76|dosage adjustment
P03582184A0448|33 41|reactions
P03582982A0000|41 43|RNA
P03582982A0000|1 5|study
P03582982A0000|13 17|genes
P03582982A0000|27 28|U4
P03583001A0111|141 145|fluid
P03583001A0111|148 157|vitrectomy
P03583001A0111|53 58|bubble
P03583001A0111|39 50|gas injection
P03583001A0111|121 128|drainage
P03583001A0111|19 27|procedure
P03584426A0706|16 26|enterotoxin
P03584426A0706|146 146|%
P03584426A0706|50 62|stool isolates
P03584426A0706|66 66|%
P03584426A0706|86 93|isolates
P03584426A0706|28 29|LT
P03584426A0706|96 96|%
P03584426A0706|199 206|material
P03584426A0706|121 128|activity
P03584426A0706|171 177|strains
P03584426A0706|131 142|suckling mice
P03586925T0001|46 63|descriptor language
P03586925T0001|68 99|Roentgenology and Medical Radiology
P03586925T0001|112 126|Medinform system
P03586925T0001|104 106|use
P03586925T0001|0 10|Development
P03590911T0001|45 60|light sensitivity
P03590911T0001|22 31|dermatosis
P03591464A0840a|14 17|test
P03591464A0840a|37 51|disease activity
P03591464A0840a|68 93|calcium antagonist treatment
P03591464A0840a|58 65|efficacy
P03591464A0840b|14 17|test
P03591464A0840b|37 51|disease activity
P03591464A0840b|68 93|calcium antagonist treatment
P03591464A0840b|58 65|efficacy
P03592297A0138|0 14|Dorsal foot TcpO2
P03592297A0138|223 234|vasodilation
P03592297A0138|155 167|vasomotor tone
P03592297A0138|204 211|degrees C
P03592297A0138|178 181|skin
P03592297A0138|108 113|theory
P03592297A0138|135 142|activity
P03592297A0138|191 199|electrode
P03592297A0138|47 56|electrodes
P03592297A0138|97 104|degrees C
P03592297A0138|247 254|degrees C
P03592297A0138|84 91|degrees C
P03592297A0138|171 175|TcpO2
P03592297A0138|263 274|vasodilation
P03592297A0138|61 79|surface temperatures
P03592297A0138|115 121|changes
P03592297A0679|86 90|TcpO2
P03592297A0679|163 170|degrees C
P03592297A0679|106 122|vasodilation index
P03592297A0679|75 84|cord trauma
P03592297A0679|52 55|tone
P03592297A0679|11 11|n
P03592297A0679|2 9|subjects
P03592297A0679|95 102|degrees C
P03592297A0679|19 30|quadriplegia
P03592297A0679|141 144|mmHg
P03592297A0679|154 158|TcpO2
P03595418A0688|41 67|ornithine decarboxylase mRNAs
P03595418A0688|77 85|% homology
P03595418A0688|110 116|regions
P03595418A0688|3 21|nucleotide sequences
P03597218A0901|173 178|shifts
P03597218A0901|27 31|alpha
P03597218A0901|181 191|plasma water
P03597218A0901|75 86|antithrombin
P03597218A0901|103 110|exercise
P03597218A0901|225 234|inhibitors
P03597218A0901|256 256|P
P03597218A0901|51 70|alpha 2-macroglobulin
P03597218A0901|210 217|quantity
P03597218A0901|138 151|concentrations
P03597218A0901|11 24|concentrations
P03597218A0901|41 49|inhibitor
P03597218A0901|115 115|P
P03597218A0901|198 205|exercise
P03597269A0409|42 49|constant
P03597269A0409|8 12|model
P03597269A0409|65 65|b
P03597269A0409|67 69|exp
P03597269A0409|55 60|form La
P03597269A0409|27 37|exponential
P03597269A0409|71 74|cVO2
P03600633A1069|0 3|Cell
P03600705T0000|0 5|Timing
P03600705T0000|8 15|symptoms
P03600705T0000|19 33|oocyst excretion
P03600705T0000|41 57|cryptosporidiosis
P03601275A0601|131 135|ratio
P03601275A0601|138 160|dopamine/norepinephrine
P03601275A0601|23 27|women
P03601275A0601|67 74|controls
P03601275A0601|180 185|groups
P03601275A0601|5 20|dopamine infusion
P03601275A0601|95 108|plasma dopamine
P03601275A0601|110 123|norepinephrine
P03601275A0601|82 92|state levels
P03601275A0601|47 54|syndrome
P03601533T0001|60 67|children
P03601533T0001|10 19|importance
P03601533T0001|36 57|complement constituents
P03601533T0001|82 92|thyroiditis
P03602261A0238|260 273|norepinephrine
P03602261A0238|135 135|r
P03602261A0238|251 251|r
P03602261A0238|211 222|correlations
P03602261A0238|126 133|dopamine
P03602261A0238|230 238|melatonin
P03602261A0238|180 180|r
P03602261A0238|62 73|correlations
P03602261A0238|242 249|dopamine
P03602261A0238|158 158|r
P03602261A0238|75 75|p
P03602261A0238|275 275|r
P03602261A0238|300 300|r
P03602261A0238|31 39|condition
P03602261A0238|110 122|blood pressure
P03602261A0238|168 178|epinephrine
P03602261A0238|286 298|growth hormone
P03602261A0238|143 156|norepinephrine
P03605895A0888|99 108|population
P03605895A0888|70 92|carbon monoxide poisoning
P03605895A0888|4 11|patients
P03605895A0888|51 51|%
P03605895A0888|16 38|carboxyhemoglobin levels
P03605895A0888|41 46|excess
P03607109A0370|55 63|pregnancy
P03607109A0370|48 52|month
P03607109A0370|8 16|processes
P03607109A0370|80 86|picture
P03607109A0370|92 99|controls
P03607961T0001|58 73|diabetes mellitus
P03607961T0001|12 17|action
P03607961T0001|47 55|mechanism
P03607961T0001|28 39|zhuang qi gong
P03608916A0790|112 119|increase
P03608916A0790|36 37|OH
P03608916A0790|24 29|plasma
P03608916A0790|10 19|degrees HPT
P03608916A0790|74 74|P
P03608916A0790|39 45|2D level
P03608916A0790|100 106|pattern
P03608916A0790|68 72|cases
P03608916A0790|2 6|cases
P03608989A0668|115 123|rod region
P03608989A0668|93 109|filament formation
P03608989A0668|50 61|interactions
P03608989A0668|4 9|region
P03608989A0668|14 23|amino acids
P03610663A0201|41 51|calculation
P03610663A0201|111 119|precision
P03610663A0201|103 108|effect
P03610663A0201|31 35|error
P03610663A0201|166 171|states
P03610663A0201|22 28|sources
P03610663A0201|4 11|approach
P03610663A0201|54 72|nutrient utilization
P03610674T0000|42 57|fiber zinc content
P03610674T0000|63 76|rat hippocampus
P03610674T0000|18 31|zinc deficiency
P03610674T0000|3 8|effect
P03612316A0102|115 118|days
P03612316A0102|73 78|saline
P03612316A0102|24 27|diet
P03612316A0102|6 9|rats
P03612316A0102|106 108|g BW
P03612316A0102|31 41|low-protein
P03612316A0102|53 56|diet
P03612316A0102|81 89|thyroxine
P03612648A0085|103 113|cardiolipin
P03612648A0085|93 100|antibody
P03612648A0085|68 85|thromboplastin time
P03612648A0085|22 39|lupus anticoagulant
P03615550A0000|122 124|FCN
P03615550A0000|25 32|agonists
P03615550A0000|45 62|antagonist naloxone
P03615550A0000|126 133|schedule
P03615550A0000|77 80|rats
P03615550A0000|3 9|effects
P03615550A0000|97 120|fixed-consecutive-number
P03615550A1094|18 24|effects
P03615550A1094|38 43|U50488
P03615550A1094|27 34|morphine
P03615550A1094|79 87|mg/kg dose
P03615550A1094|90 97|naloxone
P03615763A0170|0 3|Data
P03615763A0170|101 108|relation
P03615763A0170|219 225|smoking
P03615763A0170|189 200|hypertension
P03615763A0170|131 137|measure
P03615763A0170|19 23|women
P03615763A0170|227 232|angina
P03615763A0170|182 187|income
P03615763A0170|258 269|heart disease
P03615763A0170|178 180|sex
P03615763A0170|271 290|Type A behavior pattern
P03615763A0170|140 154|atherosclerosis
P03615763A0170|11 13|men
P03615763A0170|62 72|opportunity
P03615763A0170|295 303|hostility
P03615763A0170|42 52|angiography
P03615763A0170|234 241|diabetes
P03615763A0170|202 217|serum cholesterol
P03615763A0170|243 255|family history
P03615763A0170|174 176|age
P03615763A0170|87 98|associations
P03616174A1069|83 91|blood flow
P03616174A1069|12 17|change
P03616174A1069|180 190|circulation
P03616174A1069|133 139|tissues
P03616174A1069|111 119|blood flow
P03616174A1069|20 30|temperature
P03616174A1069|45 52|degrees C
P03616237T0001|42 50|cisplatin
P03616237T0001|10 26|status epilepticus
P03616237T0001|32 39|infusion
P03618039A0126|27 36|antibodies
P03618039A0126|103 132|catecholamine biotransformation
P03618039A0126|91 100|disruption
P03618039A0126|52 64|noradrenaline
P03618039A0126|39 48|adrenaline
P03618039A0126|3 10|presence
P03618039A0126|17 24|patients
P03619249A0428|225 229|serum
P03619249A0428|152 156|HBc Ag
P03619249A0428|214 219|non-Bc
P03619249A0428|43 46|skin
P03619249A0428|93 97|HBs Ag
P03619249A0428|243 244|Ag
P03619249A0428|146 148|HBs
P03619249A0428|101 105|HBe Ag
P03619249A0428|196 203|antibody
P03619249A0428|50 54|liver
P03619249A0428|162 166|liver
P03619249A0428|107 114|anti-HBs
P03619249A0428|89 91|HBV
P03619249A0428|12 18|markers
P03619249A0428|60 67|patients
P03619249A0428|37 41|serum
P03619249A0428|191 192|Ag
P03619249A0428|79 87|hepatitis
P03619249A0428|231 235|non-A
P03619249A0428|250 254|liver
P03619249A0428|140 144|serum
P03622423A0000|0 5|Groups
P03622423A0000|50 66|Hartley guinea pigs
P03622423A0000|131 137|control
P03622423A0000|36 45|B6C3F1 mice
P03622423A0000|86 87|hr
P03622423A0000|94 107|concentrations
P03622423A0000|21 27|Fischer
P03622423A0000|144 159|methyl isocyanate
P03622423A0000|165 169|vapor
P03622423A0000|161 163|MIC
P03622423A0000|8 11|male
P03622423A0000|31 34|rats
P03622423A0000|139 141|ppm
P03622571A0208|0 16|Radionuclide study
P03622571A0208|58 69|degeneration
P03622571A0208|34 39|biopsy
P03622571A0208|72 81|myocardium
P03625688A0372|0 13|Immobilization
P03625688A0372|77 83|methods
P03625688A0372|39 47|cuff sling
P03625688A0372|19 26|fracture
P03625688A0372|30 35|collar
P03625762A0308|0 9|Comparison
P03625762A0308|80 84|serum
P03625762A0308|168 177|sub-groups
P03625762A0308|114 122|phenytoin
P03625762A0308|12 19|patients
P03625762A0308|29 37|phenytoin
P03625762A0308|148 157|difference
P03625762A0308|182 188|respect
P03625762A0308|191 200|vitamin B12
P03625762A0308|203 224|behaviour problem rating
P03626129T0001|0 6|Effects
P03626129T0001|48 53|embryo
P03626129T0001|20 28|laser beam
P03626129T0001|34 38|cells
P03627720A0196|48 54|sac cyst
P03627720A0196|26 33|features
P03628532A0000|3 6|role
P03628532A0000|21 35|taste perception
P03628532A0000|9 14|saliva
P03628532A0000|63 73|experiments
P03628532A0000|54 59|series
P03628596A0000|117 121|fluid
P03628596A0000|63 67|value
P03628596A0000|27 34|patients
P03628596A0000|70 92|acid alpha 1-glycoprotein
P03628596A0000|0 6|Samples
P03628713A0961|70 73|days
P03628713A0961|33 44|86RbCl uptake
P03628713A0961|8 18|experiments
P03628713A0961|162 168|trap AIB
P03628713A0961|150 159|tumor cells
P03628713A0961|27 29|AIB
P03628713A0961|140 147|capacity
P03628713A0961|117 129|radiation dose
P03628713A0961|47 57|36B-10 cells
P03628713A0961|171 172|Rb
P03628713A0961|85 97|Gy irradiation
P03628794A0648|101 106|choice
P03628794A0648|36 42|disease
P03628794A0648|62 82|I-131 MIBG scintigraphy
P03628794A0648|88 98|examination
P03628794A0648|3 10|patients
P03628794A0648|47 50|data
P03629973A0240|0 1|W.
P03629974A1468|0 9|Comparison
P03629974A1468|86 107|Rift Valley fever viruses
P03629974A1468|50 63|Uukuniemi virus
P03629974A1468|198 200|end
P03629974A1468|74 82|Punta Toro
P03629974A1468|37 47|M RNA product
P03629974A1468|165 172|proteins
P03629974A1468|130 137|homology
P03629974A1468|120 124|cases
P03629974A1468|206 214|precursor
P03629974A1468|15 31|amino acid sequence
P03632739T0000|0 20|Cyclosporine treatment
P03632739T0000|35 46|polymyositis
P03635597A0377|115 121|mothers
P03635597A0377|44 50|mothers
P03635597A0377|126 126|P
P03635597A0377|2 9|addition
P03635597A0377|32 36|scale
P03635597A0377|16 21|Cohler
P03635597A0377|84 90|passive
P03635597A0377|71 77|infants
P03637037T0000|40 47|patients
P03637037T0000|13 27|teaching booklet
P03645733T0001|0 14|Hyperthyroidism
P03649340A1119|30 39|precursors
P03649340A1119|61 66|choice
P03649340A1119|137 151|splicing process
P03649340A1119|90 102|exon sequences
P03649340A1119|69 79|splice sites
P03651330T0000|22 28|lesions
P03651840A0266|72 77|effect
P03651840A0266|103 117|tranylcypromine
P03651840A0266|55 59|MAO-B
P03651840A0266|120 128|pargyline
P03651840A0266|6 22|MAO inhibition data
P03651840A0266|44 52|inhibitor
P03651840A0266|32 37|DPGPEA
P03652083A0720|68 76|crosslink
P03652083A0720|10 15|region
P03652083A0720|21 38|vessel pyridinoline
P03652083A0720|79 86|collagen
P03653226A0833|91 94|fate
P03653226A0833|97 107|perhexiline
P03653226A0833|22 45|tissue-distribution study
P03658866A0081|8 25|lupus erythematosus
P03659603A0797|68 75|increase
P03659603A0797|30 38|responses
P03659603A0797|5 11|evening
P03659603A0797|50 52|CO2
P03659603A0797|78 91|CO2 sensitivity
P03659603A0797|16 24|amplitude
P03659805A0404|102 106|model
P03659805A0404|80 86|methods
P03659805A0404|109 111|Cox
P03659805A0404|14 25|significance
P03659805A0404|31 46|prognosis factors
P03659805A0404|120 123|help
P03659805A0404|59 61|uni
P03659805A0404|128 138|IMB computer
P03659994A0150|143 157|signal intensity
P03659994A0150|170 175|images
P03659994A0150|107 108|T1
P03659994A0150|47 57|abnormality
P03659994A0150|90 104|signal intensity
P03659994A0150|23 31|injection
P03659994A0150|117 122|images
P03659994A0150|80 87|increase
P03659994A0150|5 11|changes
P03659994A0150|17 20|site
P03659994A0150|160 161|T2
P03663789A0568|43 50|activity
P03663789A0568|53 56|RHAL
P03663789A0568|5 11|results
P03663789A0568|123 125|HAL
P03663789A0568|105 114|conversion
P03663789A0568|74 77|test
P03663789A0568|117 120|RHAL
P03664038A0000|52 55|form
P03664038A0000|91 93|GSS
P03664038A0000|123 135|reliabilities
P03664038A0000|16 20|study
P03664038A0000|61 89|Gudjonsson Suggestibility Scale
P03664038A0000|151 164|suggestibility
P03664038A0000|95 98|Form
P03664038A0000|3 9|purpose
P03666957A0219|29 39|conjunctiva
P03666957A0219|95 103|infection
P03666957A0219|144 147|cats
P03666957A0219|129 137|infection
P03666957A0219|50 54|weeks
P03666957A0219|0 8|Organisms
P03668003T0000|42 52|skin lesions
P03668003T0000|21 30|microscopy
P03668396A0171|72 87|convex polyhedron
P03668396A0171|51 58|vertices
P03668396A0171|5 24|equilibrium solutions
P03668736A0177|49 56|elements
P03668736A0177|25 35|X-ray counts
P03668736A0177|121 127|element
P03668736A0177|103 107|count
P03668736A0177|10 19|deviations
P03668736A0177|64 69|series
P03668736A0177|134 138|block
P03672532A1111|42 46|doses
P03672532A1111|24 30|effects
P03673640A0533|3 13|MAO subjects
P03673640A0533|79 81|KSP
P03673640A0533|206 222|suicide attempters
P03673640A0533|154 172|personality profiles
P03673640A0533|127 142|KSP Socialization
P03673640A0533|191 201|psychopaths
P03673640A0533|36 41|scores
P03673640A0533|99 110|Irritability
P03673640A0533|44 59|KSP Impulsiveness
P03673640A0533|180 189|alcoholics
P03673640A0533|21 27|pattern
P03673640A0533|243 261|platelet MAO activity
P03673640A0533|89 95|Anxiety
P03673640A0533|61 74|EPQ Neuroticism
P03673640A0533|146 149|line
P03673640A0533|119 124|scores
P03673881A0000|222 233|valve disease
P03673881A0000|21 28|accuracy
P03673881A0000|170 176|devices
P03673881A0000|125 141|pressure gradients
P03673881A0000|81 84|HPRF
P03673881A0000|143 161|Doppler examinations
P03673881A0000|41 44|wave
P03673881A0000|46 47|CW
P03673881A0000|56 79|pulse repetition frequency
P03673881A0000|86 92|Doppler
P03673881A0000|204 211|patients
P03676054A0865|13 18|delta V
P03676054A0865|134 148|injector cannula
P03676054A0865|32 33|VT
P03676054A0865|20 23|PaO2
P03676054A0865|9 11|Paw
P03676054A0865|2 6|group
P03676054A0865|83 83|E
P03676054A0865|121 128|diameter
P03676054A0865|72 79|pressure
P03676054A0865|25 28|Vinj
P03676174A0730|99 101|day
P03676174A0730|53 58|g DM/kg
P03676174A0730|32 36|diets
P03676174A0730|106 111|calves
P03676174A0730|90 90|%
P03676174A0730|2 7|calves
P03676174A0730|60 70|milk intakes
P03678269A0633|0 4|Today
P03678269A0633|138 142|years
P03678269A0633|31 53|plasma cholesterol levels
P03678269A0633|83 94|modification
P03678269A0633|106 114|childhood
P03678269A0633|14 18|doubt
P03678269A0633|130 132|age
P03678372A0170|54 64|pellets/day
P03678372A0170|102 108|pellets
P03678372A0170|125 131|pellets
P03678372A0170|43 47|weeks
P03678372A0170|16 22|pellets
P03678372A0170|137 141|weeks
P03678372A0170|3 8|number
P03678372A0170|113 117|weeks
P03679407A0556|159 171|bladder cancer
P03679407A0556|152 155|risk
P03679407A0556|99 109|association
P03679407A0556|5 11|results
P03679407A0556|23 40|N-nitroso compounds
P03679407A0556|71 77|bladder
P03679407A0556|130 139|infections
P03679756A0830|85 90|plexus
P03679756A0830|10 26|nerve fiber defects
P03679756A0830|53 64|architecture
P03679756A0830|35 41|absence
P03679756A0830|110 118|terminals
P03680791A0230|96 100|heart
P03680791A0230|51 56|hearts
P03680791A0230|13 17|grade
P03680791A0230|36 39|site
P03680791A0230|82 86|sites
P03682805A0375|102 105|days
P03682805A0375|80 88|postshock
P03682805A0375|107 121|skin lymph levels
P03682805A0375|136 138|Day
P03682805A0375|33 58|coagulation protein activity
P03682805A0375|71 78|preshock
P03682805A0375|21 28|globulin
P03682805A0375|13 19|albumin
P03682805A0375|0 10|Serum levels
P03684378A0653|72 72|r
P03684378A0653|36 46|correlation
P03684378A0653|178 181|milk
P03684378A0653|122 125|role
P03684378A0653|60 70|cholesterol
P03684378A0653|12 15|milk
P03684378A0653|156 164|vitamin K1
P03684378A0653|92 96|lipid
P03684378A0653|49 57|vitamin K1
P03684378A0653|129 139|cholesterol
P03684378A0653|145 153|secretion
P03684517A0462|29 36|increase
P03684517A0462|79 84|fibers
P03684517A0462|39 47|stiffness
P03684517A0462|63 70|decrease
P03684517A0462|9 16|training
P03684517A0462|73 76|type
P03685073A0200|16 19|dose
P03685073A0200|105 117|atropine doses
P03685073A0200|80 90|combination
P03685073A0200|38 66|acetylcholinesterase inhibitor
P03685073A0200|22 34|physostigmine
P03685073A0200|98 102|range
P03687078T0001|0 9|References
P03687078T0001|81 85|lungs
P03687078T0001|49 56|diseases
P03687078T0001|25 31|fitness
P03687078T0001|34 44|adolescents
P03687078T0001|73 77|tract
P03687148T0187|0 7|Salzburg
P03687148T0187|13 21|September
P03687313A0000|28 31|BAY m
P03687313A0000|61 70|volunteers
P03687313A0000|101 110|conditions
P03687313A0000|39 42|BAY o
P03687313A0000|74 77|type
P03687313A0000|6 26|glucosidase inhibitors
P03687313A0000|80 88|diabetics
P03688202A0377|3 8|models
P03688202A0377|63 64|CN
P03688202A0377|37 46|boundaries
P03688202A0377|57 59|PBB
P03688301A0129|13 17|cases
P03688301A0129|114 118|type B
P03688301A0129|51 58|invasion
P03688301A0129|139 148|carcinomas
P03688301A0129|83 87|cases
P03688301A0129|104 112|extension
P03688301A0129|154 160|bladder
P03688301A0129|31 36|spread
P03688301A0129|60 64|type A
P03688676A0487|54 59|result
P03688676A0487|8 18|conversions
P03688676A0487|23 24|mm
P03688676A0487|77 85|infection
P03688676A0487|69 74|spread
P03690262A0428|60 64|trunk
P03690262A0428|146 156|stimulation
P03690262A0428|177 180|rami
P03690262A0428|165 166|T4
P03690262A0428|162 163|T3
P03690262A0428|90 94|ramus
P03690262A0428|3 18|maximum amplitude
P03690262A0428|170 171|T5
P03690262A0428|159 160|T1
P03690262A0428|83 84|T2
P03690262A0428|27 35|responses
P03691316A0560|17 30|contact allergy
P03691316A0560|33 36|K-CG
P03692331A0000|29 38|antagonist
P03692331A0000|64 69|muscle
P03692331A0000|84 88|women
P03692331A0000|3 8|effect
P03692331A0000|40 47|pindolol
P03692331A0000|130 134|women
P03692331A0000|72 75|term
P03693543A0405|224 230|species
P03693543A0405|74 81|patterns
P03693543A0405|202 207|number
P03693543A0405|175 188|N. brasiliensis
P03693543A0405|235 244|separation
P03693543A0405|210 214|peaks
P03693543A0405|108 119|elution times
P03693543A0405|35 52|Rhodococcus species
P03693543A0405|255 260|genera
P03693543A0405|153 170|N. otitidiscaviarum
P03693543A0405|124 131|patterns
P03693543A0405|134 151|Nocardia asteroides
P03694102A0000|70 88|ECG computer programs
P03694102A0000|58 66|reference
P03694102A0000|126 130|leads
P03694102A0000|3 13|development
P03694102A0000|17 24|data base
P03696899T0001|0 28|Blood serum erythropoietin level
P03696899T0001|92 98|infants
P03696899T0001|50 56|indices
P03696899T0001|66 75|adaptation
P03697587T0000|3 24|XXXXY chromosome anomaly
P03697587T0000|35 41|variant
P03697587T0000|44 54|Klinefelter
P03697587T0000|57 64|syndrome
P03697798T0001|0 10|Contraction
P03697798T0001|36 43|activity
P03697798T0001|24 29|muscle
P03697798T0001|67 73|trachea
P03697798T0001|46 61|stretch receptors
P03697971A0311|59 63|liver
P03697971A0311|53 57|blood
P03697971A0311|19 47|glutathione peroxidase activity
P03697971A0311|122 130|diet group
P03697971A0311|152 160|diet group
P03697971A0311|68 80|stomach mucosa
P03697971A0311|3 15|selenium level
P03698251T0000|0 13|Oxygen delivery
P03698251T0000|36 43|patients
P03698251T0000|63 72|infarction
P03698251T0000|31 33|P50
P03698251T0000|17 27|consumption
P03700952A0273|0 6|Infants
P03700952A0273|90 106|laboratory setting
P03700952A0273|74 81|McDonald
P03700952A0273|39 46|acuities
P03700952A0273|31 32|PL
P03700952A0273|13 18|sample
P03701640A1178|27 32|effect
P03701640A1178|81 89|FR30 FI600
P03701640A1178|5 11|results
P03701640A1178|38 44|isomers
P03701640A1178|150 157|ABSTRACT
P03701640A1178|172 176|WORDS
P03703493A0654|57 61|areas
P03703493A0654|22 29|deposits
P03703493A0654|3 8|number
P03703493A0654|67 93|RPE-choriocapillaris complex
P03704087A0394|84 90|anxiety
P03704087A0394|76 80|anger
P03704087A0394|105 135|State-Trait Personality Inventory
P03704087A0394|64 73|components
P03704087A0394|140 159|Anger Expression Scale
P03704087A0394|167 189|State Anger Reaction Scale
P03704087A0394|92 102|Spielberger
P03704087A0394|34 44|instruments
P03704087A0394|5 12|subjects
P03709191A0125|41 43|rat
P03709191A0125|60 65|volume
P03709191A0125|30 35|cortex
P03709191A0125|77 85|asymmetry
P03709191A0125|122 128|neurons
P03709191A0125|94 108|side differences
P03709191A0125|114 119|number
P03709627A0247|140 149|production
P03709627A0247|3 10|subjects
P03709627A0247|119 119|h
P03709627A0247|109 113|urine
P03709627A0247|37 53|acetaminophen i.v.
P03709627A0247|122 126|order
P03709627A0247|73 78|plasma
P03709627A0247|152 162|metabolites
P03709627A0247|97 103|minutes
P03709627A0247|29 34|mg dose
P03709627A0247|57 70|concentrations
P03710973A0817|0 3|Mean
P03710973A0817|12 26|skin temperature
P03710973A0817|89 99|acclimation
P03710973A0817|41 41|P
P03710973A0817|132 149|Tre-to-Tsk gradient
P03710973A0817|64 74|acclimation
P03710973A0817|28 30|Tsk
P03710973A0817|118 118|P
P03712050T0000|0 25|Indium-111 leukocyte imaging
P03712050T0000|50 58|arthritis
P03712050T0000|28 35|patients
P03712106A0000|43 53|utilization
P03712106A0000|11 37|L-methionine supplementation
P03712106A0000|57 73|soy protein isolate
P03712106A0000|75 77|SPI
P03712106A0000|103 124|nitrogen balance studies
P03712106A0000|3 8|effect
P03712106A0000|132 136|women
P03712153T0000|15 47|Haemophilus influenzae type b disease
P03712153T0000|66 75|assessment
P03712153T0000|78 88|risk factors
P03713187A0691|219 225|lesions
P03713187A0691|8 14|lesions
P03713187A0691|228 237|comparison
P03713187A0691|171 175|sites
P03713187A0691|67 75|frequency
P03713187A0691|143 152|carcinomas
P03713187A0691|128 133|muscle
P03713187A0691|34 46|lamina propria
P03713187A0691|255 261|lesions
P03713187A0691|78 87|occurrence
P03713187A0691|98 104|lesions
P03713187A0691|190 198|frequency
P03714348A0833|73 79|portion
P03714348A0833|106 113|NIH score
P03714348A0833|49 51|CIC
P03714348A0833|177 184|serum IgG
P03714348A0833|28 38|correlation
P03714348A0833|138 159|peak expiratory flow rate
P03714348A0833|124 133|patient age
P03714348A0833|85 97|CIC population
P03714348A0833|0 6|Factors
P03714473A0496|0 8|Induction
P03714473A0496|24 34|transcripts
P03714473A0496|42 50|heat shock
P03717475A0208|0 2|New
P03717475A0208|35 51|immunodiagnostics
P03717475A0208|115 125|infertility
P03717475A0208|53 65|immunotherapy
P03717475A0208|70 86|immunoprophylaxis
P03717475A0208|16 20|steps
P03717936A0252|0 7|Amikacin
P03717936A0252|76 85|conditions
P03717936A0252|54 67|aminoglycoside
P03717936A0252|27 36|tobramycin
P03720615A0434|28 32|trend
P03720615A0434|79 85|infants
P03720615A0434|61 69|gestation
P03720615A0434|47 57|birthweight
P03720615A0434|16 19|part
P03720966A1043|16 30|acid N absorption
P03720966A1043|39 45|N intake
P03720966A1043|36 36|%
P03721594A0000|0 7|Adhesion
P03721594A0000|75 83|reduction
P03721594A0000|129 143|fibrinogen level
P03721594A0000|316 322|animals
P03721594A0000|273 292|Shwartzman phenomenon
P03721594A0000|9 20|phagocytosis
P03721594A0000|96 113|exudate neutrophils
P03721594A0000|42 50|migration
P03721594A0000|117 127|macrophages
P03721594A0000|226 235|New Zealand
P03721594A0000|177 204|dilution protamine sulfate test
P03721594A0000|241 247|rabbits
P03721594A0000|145 152|gelation
P03721594A0000|298 302|colon
P03721594A0000|61 71|tetrazolium
P03721666A0000|0 5|Nickel
P03721666A0000|36 52|contact dermatitis
P03721666A0000|55 63|Singapore
P03721666A0000|95 104|patch tests
P03721666A0000|21 25|cause
P03721666A0000|84 92|reactions
P03721666A0000|118 118|%
P03722016A0797|28 28|P
P03722016A0797|45 56|meal interval
P03722016A0797|3 11|FFA levels
P03728230A0104|40 43|cyst
P03728230A0104|12 19|hospital
P03732252A0556|196 201|change
P03732252A0556|92 97|VO2max
P03732252A0556|203 207|delta
P03732252A0556|54 56|VO2
P03732252A0556|220 227|m run time
P03732252A0556|99 99|r
P03732252A0556|285 292|m run time
P03732252A0556|163 168|extent
P03732252A0556|188 193|amount
P03732252A0556|15 22|analyses
P03732252A0556|262 269|delta VO2
P03732252A0556|68 68|P
P03732252A0556|60 60|r
P03732252A0556|138 153|m race performance
P03732252A0556|275 279|delta
P03732252A0556|28 31|data
P03732252A0556|249 259|combination
P03733563A0716|54 65|serum dextran
P03733563A0716|12 33|herd X period interaction
P03733563A0716|78 102|cholesterol concentrations
P03733563A0716|44 50|liver TG
P03733563A0820|0 6|Liver TG
P03733563A0820|10 32|serum NEFA concentrations
P03734641A0203|58 62|force
P03734641A0203|80 86|failure
P03734641A0203|18 22|nerve
P03734641A0203|100 111|biomechanics
P03734641A0203|3 9|results
P03734641A0203|26 30|roots
P03736081A0465|306 315|difference
P03736081A0465|178 178|p
P03736081A0465|354 354|p
P03736081A0465|342 352|% saturation
P03736081A0465|79 83|index
P03736081A0465|200 203|rise
P03736081A0465|221 228|pressure
P03736081A0465|171 176|ml/min
P03736081A0465|321 321|%
P03736081A0465|107 114|L/min/m2
P03736081A0465|335 335|%
P03736081A0465|37 40|torr
P03736081A0465|62 69|decrease
P03736081A0465|15 27|sinus pressure
P03736081A0465|328 328|%
P03736081A0465|275 282|increase
P03736081A0465|116 116|p
P03736081A0465|255 255|p
P03736081A0465|194 197|rate
P03736081A0465|140 148|blood flow
P03738919A0000|0 13|Calcifications
P03738919A0000|27 31|aorta
P03738919A0000|92 96|women
P03738919A0000|121 130|tomography
P03738919A0000|37 41|level
P03738919A0000|83 85|men
P03738919A0000|69 77|vertebrae
P03743683A0000|99 101|age
P03743683A0000|25 33|autopsies
P03743683A0000|92 96|years
P03743683A0000|50 56|plaques
P03743683A0000|74 84|individuals
P03743683A0000|3 8|series
P03743683A0000|58 59|PP
P03743702A0158|58 62|intra
P03743702A0158|135 140|nerves
P03743702A0158|218 223|micron
P03743702A0158|150 154|range
P03743702A0158|207 208|SD
P03743702A0158|272 277|micron
P03743702A0158|195 198|area
P03743702A0158|37 43|neurons
P03743702A0158|102 109|alveolar
P03743702A0158|15 15|%
P03743702A0158|74 83|structures
P03743702A0158|18 27|cell bodies
P03743702A0158|171 176|micron
P03743702A0158|111 117|lingual
P03743702A0158|235 240|micron
P03743702A0158|200 203|mean
P03743702A0158|252 257|micron
P03744168T0001|15 20|action
P03744168T0001|23 32|eptazocine
P03744168T0001|86 109|methano-1H-4-benz azonine
P03744168T0001|72 82|hexahydro-1
P03744168T0001|34 36|l-1
P03745833A0258|140 151|arborization
P03745833A0258|25 31|voltage
P03745833A0258|76 76|%
P03745833A0258|107 111|areas
P03745833A0258|66 73|pressure
P03745833A0258|93 96|flow
P03745833A0258|103 103|%
P03745833A0258|52 55|fall
P03745833A0258|203 212|cerebellum
P03745833A0258|166 174|formation
P03745833A0258|117 121|brain
P03745833A0258|192 199|cerebrum
P03745833A0258|83 90|increase
P03745833A0258|2 11|transition
P03746053A0670|0 7|Findings
P03746053A0670|38 39|N1
P03746053A0670|102 107|column
P03746053A0670|55 58|area
P03746053A0670|123 134|dorsal column
P03746053A0670|111 112|N2
P03746053A0670|18 27|potentials
P03746053A0670|72 77|matter
P03746107A0192|41 47|tumours
P03746107A0192|23 26|cent
P03746508A0390|0 7|Failures
P03746508A0390|54 63|conditions
P03746508A0390|22 31|additivity
P03746601A0299|96 103|exposure
P03746601A0299|26 38|extravasation
P03746601A0299|50 55|sepsis
P03746601A0299|90 93|days
P03746601A0299|61 68|hematoma
P03746601A0299|78 82|total
P03746601A0299|17 24|problems
P03746896A0890|143 155|Type A behavior
P03746896A0890|22 28|results
P03746896A0890|74 78|means
P03746896A0890|51 61|possibility
P03746896A0890|107 120|susceptibility
P03746896A0890|134 140|effects
P03746906A0000|28 38|reliability
P03746906A0000|21 25|types
P03746906A0000|3 9|studies
P03746906A0000|44 71|student Jenkins Activity Survey
P03746906A0000|78 97|questionnaire measure
P03746906A0000|73 75|JAS
P03746906A0000|100 112|Type A behavior
P03747493A0000|73 82|infections
P03747493A0000|14 21|patients
P03749226A0506|45 56|response rate
P03749226A0506|105 109|doses
P03749226A0506|4 16|phencyclidine
P03749226A0506|76 81|errors
P03750700T0001|0 12|Possibilities
P03750700T0001|26 30|wrist
P03750700T0001|36 49|endoprosthesis
P03750700T0001|16 22|outlook
P03751308T0001|0 4|Study
P03751308T0001|10 25|energy metabolism
P03751308T0001|50 60|hippocampus
P03751308T0001|31 46|sensomotor cortex
P03751308T0001|67 69|14C
P03751308T0001|124 129|states
P03751308T0001|100 110|development
P03751308T0001|71 90|2-deoxyglucose method
P03753022A0000|58 65|behavior
P03753022A0000|38 42|terms
P03753022A0000|9 16|lymphoma
P03755623A1233|74 83|properties
P03755623A1233|7 20|investigations
P03755623A1233|86 89|DLIS
P03755673A0054|12 16|cases
P03757294A0414|55 59|cases
P03757294A0414|20 20|%
P03757294A0414|49 49|%
P03757294A0414|14 16|PLD
P03757294A0414|64 67|APCD
P03757294A0414|5 9|cases
P03757294A0414|39 43|cysts
P03757294A0414|81 90|liver cysts
P03758250A0000|131 137|muscles
P03758250A0000|106 116|EMG activity
P03758250A0000|26 34|movements
P03758250A0000|50 58|extremity
P03758250A0000|98 103|bursts
P03759330A0713|69 70|G1
P03759330A0713|58 67|population
P03759330A0713|49 51|CHD
P03759330A0713|3 13|combination
P03759330A0713|102 115|trunk adiposity
P03759330A0713|21 22|F2
P03759330A0713|38 46|predictor
P03759330A0713|16 17|F1
P03759731A0992|43 44|m2
P03759731A0992|75 76|m2
P03759731A0992|5 13|clearance
P03759731A0992|78 82|group
P03759731A0992|64 71|ml/min/1
P03759731A0992|32 39|ml/min/1
P03759731A0992|46 50|group
P03761122T0000|87 94|children
P03761122T0000|51 58|behavior
P03761122T0000|83 84|IQ
P03761122T0000|68 78|achievement
P03761122T0000|19 31|type A behavior
P03761122T0000|3 11|relations
P03761523A0000|40 45|sepsis
P03761523A0000|31 37|effects
P03761523A0000|21 25|study
P03761523A0000|76 83|emulsion
P03761523A0000|51 61|utilization
P03761523A0000|3 6|rats
P03763241A0446|16 23|weakness
P03763241A0446|34 44|extremities
P03763836T0001|43 47|sites
P03763836T0001|26 31|tumors
P03763836T0001|9 23|electron therapy
P03763836T0001|0 6|Results
P03765552A0582|87 92|system
P03765552A0582|94 96|RES
P03765552A0582|36 41|detail
P03765552A0582|98 115|Fc receptor blockade
P03765552A0582|3 11|mechanism
P03765552A0582|119 129|suppression
P03765552A0582|144 160|antibody synthesis
P03765552A0582|14 19|action
P03765731A0918|0 9|Incidences
P03765731A0918|37 46|infarction
P03765731A0918|80 90|hypertrophy
P03765731A0918|20 25|stroke
P03765731A0918|48 64|angina pectoris und
P03766370A0546|64 65|LV
P03766370A0546|10 16|r values
P03766370A0546|34 43|deviations
P03766370A0546|92 98|regions
P03768208A0879|58 75|bone formation rates
P03768208A0879|5 11|results
P03768208A0879|112 115|mass
P03768208A0879|93 101|increases
P03768208A0879|47 55|increases
P03768208A0879|30 38|pregnancy
P03769224A0000|59 61|SLE
P03769224A0000|10 13|data
P03769224A0000|74 81|biopsies
P03769224A0000|20 27|patients
P03769224A0000|40 57|Lupus Erythematosus
P03770143A1209|27 34|disorder
P03770143A1209|65 78|fibre structure
P03770143A1209|50 55|defect
P03770143A1209|3 13|possibility
P03770143A1209|119 125|lesions
P03771670T0058|0 9|Prevention
P03771670T0058|36 46|combination
P03771670T0058|13 32|heparin-antithrombin
P03771703A0000|90 97|analysis
P03771703A0000|13 36|trimethylsilylcarbamates
P03771703A0000|61 68|reagents
P03771703A0000|72 74|gas
P03771749A0465|0 3|MICs
P03771749A0465|98 105|isolates
P03771749A0465|155 159|media
P03771749A0465|20 25|agents
P03771749A0465|115 128|Candida species
P03771749A0465|55 66|ketoconazole
P03771749A0465|177 206|microtiter broth dilution systems
P03771749A0465|71 83|amphotericin B
P03771749A0465|162 173|agar dilution
P03771749A0465|27 42|5-fluorocytosine
P03771749A0465|44 53|miconazole
P03772471A1054|141 144|case
P03772471A1054|23 29|Group II
P03772471A1054|11 18|patients
P03772471A1054|48 58|tumor biopsy
P03772471A1054|33 38|tumors
P03772471A1054|112 115|time
P03772471A1054|118 124|surgery
P03772471A1054|98 106|diagnosis
P03774111T0000|0 7|Evidence
P03774111T0000|31 34|part
P03774111T0000|43 50|response
P03774111T0000|18 26|addiction
P03776080A0400|104 106|E/S
P03776080A0400|93 99|animals
P03776080A0400|54 60|animals
P03776080A0400|110 120|CWE antigens
P03776080A0400|15 36|post-mortem examination
P03776438A0000|0 13|Glucocorticoid
P03776438A0000|130 131|Na
P03776438A0000|76 83|contrast
P03776438A0000|21 32|hypertension
P03776438A0000|110 121|hypertension
P03776438A0000|63 68|sodium
P03776438A0000|70 71|Na
P03776438A0000|86 102|mineralocorticoid
P03776779A0238|42 49|steroids
P03776779A0238|21 29|treatment
P03777398A0156|0 7|Examples
P03777398A0156|30 40|therapy unit
P03777398A0156|13 15|use
P03779182A0370|59 63|cases
P03779182A0370|10 20|drug problem
P03779182A0370|51 56|number
P03779182A0370|93 98|deaths
P03779182A0370|66 75|hepatitis B
P03779205A0459|143 147|years
P03779205A0459|9 16|patients
P03779205A0459|82 93|presentation
P03779205A0459|67 71|years
P03779205A0459|120 130|secondaries
P03779205A0459|99 106|patients
P03779205A0459|42 48|disease
P03780248A0274|119 121|IMV
P03780248A0274|123 130|settings
P03780248A0274|38 44|infants
P03780248A0274|8 18|differences
P03780248A0274|107 117|ventilation
P03780248A0274|158 164|infants
P03780248A0274|208 209|pH
P03780248A0274|186 193|hospital
P03780248A0274|213 222|PCO2 values
P03780248A0274|137 145|transport
P03780248A0274|62 66|group
P03780248A0274|74 80|changes
P03780371A0792|43 49|introns
P03780371A0792|10 18|sequences
P03780371A0792|87 91|exons
P03780371A0792|108 113|region
P03780371A0792|55 77|cytochrome P-450PBc2 gene
P03780704A0573|101 108|increase
P03780704A0573|80 87|quotient
P03780704A0573|61 68|exercise
P03780704A0573|141 142|CW
P03780704A0573|114 124|utilization
P03780704A0573|151 152|CC
P03780704A0573|6 13|increase
P03780704A0573|126 127|WW
P03780704A0573|44 53|conditions
P03780704A0573|16 27|serum ketones
P03781000A0101|118 124|disease
P03781000A0101|10 20|correlation
P03781000A0101|81 88|implants
P03781000A0101|55 62|activity
P03781000A0101|107 112|stages
P03781000A0101|4 7|lack
P03781000A0101|31 40|variations
P03781948T0000|30 36|hypoxia
P03781948T0000|11 20|adaptation
P03781948T0000|46 49|rats
P03783160A0285|0 7|Compound
P03783160A0285|59 70|21-O-tigloyl
P03783160A0285|85 97|R1-barrigenol
P03783160A0285|17 29|21-O-angeloyl
P03783160A0285|43 55|R1-barrigenol
P03785212A0091|15 40|hamster S14 protein sequences
P03785212A0091|55 59|cDNAs
P03785212A1128|0 11|RPS14 introns
P03785212A1128|28 39|Alu sequences
P03788231A0802|188 197|ventricles
P03788231A0802|207 211|chest
P03788231A0802|51 58|survival
P03788231A0802|20 26|aspects
P03788231A0802|94 105|implantation
P03788231A0802|124 128|heart
P03788231A0802|63 68|animal
P03788231A0802|167 175|placement
P03789052A0527|173 179|effects
P03789052A0527|13 26|tissue response
P03789052A0527|98 105|reaction
P03789052A0527|81 88|chemical
P03789052A0527|40 56|cyanoacrylate site
P03789052A0527|119 132|tissue adhesive
P03789052A0527|147 154|evidence
P03791645A1124|57 68|pathogenesis
P03791645A1124|35 46|relationship
P03791645A1124|75 84|narcolepsy
P03791645A1124|89 91|OSA
P03791645A1124|5 12|findings
P03791645A1124|71 73|MAL
P03795488A0487|18 24|lesions
P03795488A0487|99 99|%
P03795488A0487|73 74|PR
P03795488A0487|81 92|response rate
P03799323A0501|101 111|sickle cells
P03799323A0501|125 129|cells
P03799323A0501|25 38|flow conditions
P03799323A0501|12 21|hematocrit
P03799323A0501|49 72|oxygen saturation decrease
P03799323A0501|43 46|rate
P03799790A0146|86 90|light
P03799790A0146|133 139|margins
P03799790A0146|108 116|light pipe
P03799790A0146|8 15|examiner
P03799790A0146|73 83|point source
P03799790A0146|40 42|eye
P03799790A0146|55 68|ophthalmoscopy
P03799790A0146|155 160|plaque
P03799790A0146|27 34|interior
P03802195A0481|100 110|ToxR protein
P03802195A0481|148 154|portion
P03802195A0481|78 94|DNA binding domains
P03802195A0481|65 74|activation
P03802195A0481|5 18|fusion proteins
P03802195A0481|33 44|localization
P03805090A0645|29 36|patients
P03805090A0645|151 155|years
P03805090A0645|113 119|disease
P03805090A0645|14 21|analyses
P03805090A0645|132 135|cent
P03805090A0645|220 235|Maffucci syndrome
P03805090A0645|205 212|patients
P03805090A0645|76 89|chondrosarcoma
P03805090A0645|56 64|incidence
P03805090A0645|194 202|certainty
P03805090A0645|92 99|patients
P03805090A0645|141 143|age
P03805090A0645|173 184|degeneration
P03806696A0000|29 33|HgCl2
P03806696A0000|227 231|trial
P03806696A0000|9 16|toxicity
P03806696A0000|106 121|Coturnix japonica
P03806696A0000|54 68|mercury chloride
P03806696A0000|92 104|Japanese quail
P03806696A0000|142 146|hatch
P03806696A0000|201 210|injections
P03806696A0000|83 90|Coturnix
P03806696A0000|154 162|adulthood
P03806696A0000|46 52|CH3HgCl
P03806696A0000|134 137|ages
P03810361A0576|159 165|Cushing
P03810361A0576|94 117|plasma cortisol estimation
P03810361A0576|136 142|adjunct
P03810361A0576|168 175|syndrome
P03810361A0576|79 82|mean
P03810361A0576|148 156|diagnosis
P03810361A0576|29 52|plasma cortisol estimation
P03810867A0305|54 54|%
P03810867A0305|87 103|Lederman-Gadeberg
P03810867A0305|77 85|TNM system
P03810867A0305|105 116|Sisson-Jesse
P03810867A0305|9 16|patients
P03810867A0305|35 41|lesions
P03810867A0305|45 48|T3-4
P03811852A0109|192 199|maturity
P03811852A0109|95 110|magnesium sulfate
P03811852A0109|53 59|factors
P03811852A0109|143 145|use
P03811852A0109|129 135|agonist
P03811852A0109|3 6|risk
P03811852A0109|148 169|adrenocortico-steroids
P03811852A0109|82 92|combination
P03811852A0109|69 77|gestation
P03811852A0109|15 27|complications
P03814493T0000|15 24|interferon
P03814493T0000|49 56|lymphoma
P03814493T0000|31 35|grade
P03814493T0000|0 11|Chlorambucil
P03818467A0180|0 7|Selenium
P03818467A0180|122 148|plasma glutathione peroxidase
P03818467A0180|150 155|GSH-Px
P03818467A0180|88 103|Se concentrations
P03818467A0180|22 26|IU/kg
P03818467A0180|11 13|ppm
P03818467A0180|157 164|activity
P03818467A0180|18 18|E
P03818467A0180|48 51|diet
P03818467A0180|28 42|supplementation
P03818467A0180|69 84|plasma tocopherol
P03818866A0116|59 71|blood pressure
P03818866A0116|15 22|behavior
P03818866A0116|80 80|p
P03818866A0116|102 106|women
P03818866A0116|73 73|r
P03818866A0116|0 13|Framingham Type
P03820222A0203|124 128|group
P03820222A0203|23 29|potency
P03824908A0116|56 65|nucleotide
P03824908A0116|39 46|sequence
P03824908A0116|102 130|arginine amino acid substitution
P03824908A0116|138 153|carboxy-terminus
P03824908A0116|94 99|lysine
P03824908A0116|182 196|paramyxoviruses
P03824908A0116|171 179|M proteins
P03824908A0116|3 15|M reading frame
P03826871A0000|2 4|ion
P03826871A0000|44 48|Br ion
P03826871A0000|61 70|Greyhounds
P03826871A0000|20 25|method
P03826871A0000|54 58|urine
P03827071T0040|0 1|II
P03828209T0000|42 51|intubation
P03828209T0000|14 20|changes
P03828209T0000|54 59|adults
P03828500T0001|0 14|Intensification
P03828500T0001|63 72|blood serum
P03828500T0001|32 50|contractile activity
P03829848T0001|0 18|Autotransplantation
P03829848T0001|62 65|vein
P03829848T0001|37 41|valve
P03829848T0001|47 55|treatment
P03829848T0001|74 86|insufficiency
P03829848T0001|22 32|vein segment
P03829848T0001|97 105|extremity
P03830147A0000|344 347|OBLA
P03830147A0000|362 373|blood lactate
P03830147A0000|300 304|value
P03830147A0000|456 466|performance
P03830147A0000|252 254|VO2
P03830147A0000|308 309|mM
P03830147A0000|352 354|VO2
P03830147A0000|54 69|lactate threshold
P03830147A0000|434 439|VO2max
P03830147A0000|88 112|blood lactate concentration
P03830147A0000|486 493|students
P03830147A0000|144 148|level
P03830147A0000|199 210|blood lactate
P03830147A0000|425 432|capacity
P03830147A0000|262 286|blood lactate concentration
P03830147A0000|312 316|onset
P03830147A0000|319 342|blood lactate accumulation
P03830147A0000|38 52|lactate increase
P03830147A0000|245 247|LT2
P03830147A0000|446 448|min
P03830147A0000|71 72|LT
P03830147A0000|221 222|mM
P03830147A0000|182 184|LT1
P03830147A0000|382 394|concentration
P03830147A0000|25 35|descriptors
P03830147A0000|78 80|VO2
P03830147A0000|168 179|exercise test
P03830147A0000|238 242|level
P03830147A0000|189 191|VO2
P03830147A0000|3 15|relationships
P03830147A0000|398 399|mM
P03830255A0074|55 66|distribution
P03835413A0616|32 43|irradiations
P03835413A0616|51 62|space flights
P03835413A0616|20 26|effects
P03835413A0616|113 117|risks
P03835413A0616|128 147|duration space flights
P03835413A0616|70 81|difficulties
P03835413A0616|3 13|observation
P03836777T0001|99 112|hepatitis stage
P03836777T0001|15 28|interpretation
P03836777T0001|36 52|hepatitis B markers
P03836777T0001|63 68|biopsy
P03836777T0001|71 83|HBs Ag carriers
P03836777T0001|0 11|Practical use
P03836853A0204|39 39|%
P03836853A0204|49 49|%
P03836853A0204|35 35|%
P03836853A0204|43 43|%
P03836853A0204|12 28|year survival rates
P03836854T0000|0 9|Inhibition
P03836854T0000|54 55|RP
P03836854T0000|92 96|agent
P03836854T0000|38 46|secretion
P03837609T0000|42 51|blood cells
P03837609T0000|64 76|mononucleosis
P03837609T0000|20 24|study
P03838797A0903|0 15|Northern blotting
P03838797A0903|63 69|absence
P03838797A0903|127 130|rise
P03838797A0903|94 97|mRNA
P03838797A0903|110 120|cDNA library
P03838797A0903|81 88|sequence
P03838797A0903|33 47|oligonucleotide
P03838797A0903|142 145|cDNA
P03840480T0000|14 21|families
P03840480T0000|46 61|peptide sequences
P03841627T0001|0 11|Chemotherapy
P03841627T0001|27 38|breast cancer
P03843496A0919|132 145|extrapolations
P03843496A0919|64 70|variety
P03843496A0919|8 12|years
P03843496A0919|113 119|ability
P03843496A0919|154 167|risk assessment
P03843496A0919|95 103|chemicals
P03843496A0919|37 42|models
P03843676A0381|100 104|doses
P03843676A0381|91 94|risk
P03843676A0381|6 18|extrapolation
P03843676A0381|45 48|data
P03848527T0020|70 74|years
P03848527T0020|50 57|industry
P03848527T0020|38 47|counsellor
P03848527T0020|0 11|Hisako Minowa
P03857577A0413|116 124|HeLa cells
P03857577A0413|45 56|DNA sequences
P03857577A0413|149 161|transcription
P03857577A0413|96 113|level transcription
P03857577A0413|0 21|Deletion mapping studies
P03860162A0000|0 12|Incorporation
P03860162A0000|49 51|AMB
P03860162A0000|125 131|potency
P03860162A0000|91 102|drug toxicity
P03860162A0000|109 112|loss
P03860162A0000|35 47|amphotericin B
P03860162A0000|80 88|reduction
P03860162A0000|18 24|polyene
P03860162A0000|55 63|liposomes
P03861687A0000|88 96|treatment
P03861687A0000|65 68|care
P03861687A0000|132 139|response
P03861687A0000|119 129|alterations
P03861687A0000|169 185|system stimulation
P03861687A0000|26 30|males
P03862898A0563|0 7|Serum IgM
P03862898A0563|111 128|risk classification
P03862898A0563|62 75|tumor E2R status
P03862898A0563|11 27|IgE concentrations
P03862898A0563|46 54|IgE scores
P03862898A0563|172 181|components
P03863231A0530|3 12|M-3 subtype
P03863231A0530|35 40|factor
P03863561A0405|89 96|cricetus
P03863561A0405|53 62|difference
P03863561A0405|116 122|respect
P03863561A0405|129 137|clump size
P03863561A0405|98 98|p
P03863561A0405|9 13|Strep
P03863561A0405|76 87|mutans/Strep
P03863561A0405|70 74|Strep
P03863561A0405|15 25|mutans group
P03865743A0859|29 34|LDL-C.
P03865743A0859|51 54|apo B
P03865743A0859|36 41|HDL-C.
P03865743A0859|123 134|heart disease
P03865743A0859|24 27|T.C.
P03865743A0859|72 85|apo A-II/B ratio
P03865743A0859|56 68|apo A-I/B ratio
P03865743A0859|5 11|results
P03865743A0859|43 49|HDL2-C.
P03865743A0859|99 109|risk factors
P03866085A0795|26 47|suppository formulation
P03866085A0795|91 98|children
P03866085A0795|164 168|drugs
P03866085A0795|139 146|children
P03866085A0795|50 54|CZX-S
P03866085A0795|79 88|infections
P03866085A0795|125 133|disorders
P03866085A0795|68 76|treatment
P03866085A0795|184 191|vomiting
P03869442A0223|44 51|disorder
P03869442A0223|84 95|hypertension
P03869442A0223|58 70|abnormalities
P03869442A0223|131 148|vasopressin therapy
P03869442A0223|17 28|hypertension
P03869442A0223|2 9|addition
P03871298A0217|135 146|localization
P03871298A0217|6 19|photon emission
P03871298A0217|117 123|promise
P03871298A0217|104 109|Tl-201
P03871298A0217|43 47|SPECT
P03871298A0217|32 41|tomography
P03871298A0217|149 151|CAD
P03871298A0217|78 91|representation
P03871445T0000|0 7|Computer
P03871445T0000|55 79|positron emission tomograms
P03871445T0000|37 44|analysis
P03871445T0000|16 22|mapping
P03873141A0304|86 93|patients
P03873141A0304|114 114|%
P03873141A0304|4 19|patients vagotomy
P03873141A0304|65 71|therapy
P03873141A0304|36 43|bleeding
P03873141A0304|73 78|Visick
P03873141A0304|99 111|mortality rate
P03874921A0862|175 182|drawback
P03874921A0862|38 50|fertilization
P03874921A0862|112 113|EP
P03874921A0862|55 62|delivery
P03874921A0862|123 133|anovulation
P03874921A0862|66 73|term baby
P03874921A0862|96 106|feasibility
P03874921A0862|0 12|Documentation
P03874921A0862|147 155|procedure
P03875231A0627|203 215|abnormalities
P03875231A0627|55 55|%
P03875231A0627|161 170|hemorrhage
P03875231A0627|181 184|cyst
P03875231A0627|35 47|abnormalities
P03875231A0627|101 115|differentiation
P03875231A0627|149 156|hematoma
P03875231A0627|79 82|loss
P03875231A0627|68 74|kidneys
P03875231A0627|0 2|MRI
P03875231A0627|129 133|fluid
P03877298A0718|59 78|Cremophor formulation
P03877298A0718|147 165|emulsion formulation
P03877298A0718|107 115|induction
P03877298A0718|94 104|variability
P03877298A0718|3 9|results
P03877298A0718|119 131|recovery times
P03878585A0507|84 84|r
P03878585A0507|94 112|oxygen flow rate index
P03878585A0507|248 271|machine/min CPB time/m2 bsa
P03878585A0507|273 273|r
P03878585A0507|173 190|blood flow rate index
P03878585A0507|35 37|CPB
P03878585A0507|137 158|bubble oxygenator/m2 bsa
P03878585A0507|160 160|r
P03878585A0507|72 82|CPB duration
P03878585A0507|209 214|volume
P03878585A0507|217 221|blood
P03878585A0507|30 32|end
P03878585A0507|55 65|correlation
P03878585A0507|192 195|BFRI
P03878585A0507|3 24|percentage RFR reduction
P03878585A0507|114 117|OFRI
P03880838T0000|44 66|captopril administration
P03880838T0000|26 38|artery lesions
P03880838T0000|0 8|Diagnosis
P03881260A0000|28 35|gene CP A1
P03881260A0000|64 107|arginine pathway carbamoyl-phosphate synthetase
P03881260A0000|52 58|subunit
P03881260A0000|1 16|yeast DNA fragment
P03882029A0000|14 18|study
P03882029A0000|60 75|granuloma complex
P03882029A0000|101 104|cats
P03882029A0000|37 40|cats
P03882029A0000|119 128|antibodies
P03882029A0000|149 161|cat epithelium
P03882029A0000|90 90|%
P03882029A0000|131 140|components
P03882029A0000|27 30|sera
P03883052T0001|2 7|memory
P03883052T0001|10 27|Magdelaine Comtesse
P03883541A0200|27 40|sucralfate cost
P03883541A0200|3 23|H2 receptor antagonists
P03883541A0200|67 73|effects
P03885983A0254|61 68|activity
P03885983A0254|39 46|Class III
P03885983A0254|23 31|indoramin
P03885983A0254|5 11|results
P03887085A0000|86 93|mexamine
P03887085A0000|153 153|%
P03887085A0000|111 120|conditions
P03887085A0000|39 43|doses
P03887085A0000|97 101|mg/kg
P03887085A0000|178 183|F1 mice
P03887085A0000|77 81|mg/kg
P03887085A0000|49 63|pharmaceuticals
P03887085A0000|168 176|CBA X C57Bl
P03887085A0000|5 12|efficacy
P03887085A0000|65 73|cystamine
P03887085A0000|142 148|hypoxia
P03887085A0000|26 28|use
P03887769A0093|3 6|Mean
P03887769A0093|48 62|micrograms J/g Cr
P03887769A0093|21 35|micrograms J/g Cr
P03887769A0584|42 51|population
P03887769A0584|111 111|%
P03887769A0584|54 69|iodine deficiency
P03887769A0584|89 104|iodine deficiency
P03887769A0584|5 10|region
P03887769A0584|83 83|%
P03888621A0185|73 74|Da
P03888621A0185|64 67|mass
P03888621A0185|13 16|gene
P03888621A0185|39 52|protein product
P03888621A0185|20 30|hydrogenase
P03890486A0000|102 111|propensity
P03890486A0000|129 138|malignancy
P03890486A0000|66 71|source
P03890486A0000|52 56|cause
P03890486A0000|157 167|obstruction
P03890486A0000|19 38|lymph node enlargement
P03890486A0000|74 89|imaging confusion
P03891766A1473|0 11|Interference
P03891766A1473|26 31|factor
P03891766A1473|52 56|ELISA
P03891766A1473|93 107|latex adsorbents
P03891766A1473|68 71|sera
P03894482A0549|73 85|binding values
P03894482A0549|125 136|control serum
P03894482A0549|30 47|serum IgE antibodies
P03894482A0549|105 109|times
P03894482A0549|22 27|levels
P03894482A0549|3 10|patients
P03894482A0549|58 71|soybean extract
P03896991T0000|0 12|New techniques
P03896991T0000|44 51|products
P03896991T0000|19 34|mass spectrometry
P03898382A0000|16 33|subtraction imaging
P03898382A0000|64 68|99mTc
P03898382A0000|39 44|spleen
P03898382A0000|197 201|image
P03898382A0000|137 154|radiogallium survey
P03898382A0000|50 60|67Ga citrate
P03898382A0000|172 184|sulfur colloid
P03898382A0000|97 103|lesions
P03904004A1577|203 206|124I
P03904004A1577|61 66|window
P03904004A1577|26 31|energy
P03904004A1577|123 141|breakthrough signals
P03904004A1577|34 56|medium energy collimation
P03904004A1577|177 189|energy photons
P03904004A1577|83 98|keV 123I photopeak
P03904004A1577|157 170|Compton scatter
P03904952T0000|0 15|Nursing education
P03904952T0000|21 38|computer obligation
P03908196T0000|0 16|Shear bond strength
P03908196T0000|44 55|glass ionomer
P03908196T0000|29 33|resin
P03908493A0246|53 77|immunoperoxidase technique
P03908493A0246|12 20|advantage
P03908493A0246|94 101|sections
P03908493A0246|30 34|resin
P03910310A0666|26 38|understanding
P03910310A0666|5 11|concept
P03910310A0666|44 52|pathology
P03911052A0909|14 19|DIL-CP
P03911052A0909|78 79|CP
P03911052A0909|102 112|CABG surgery
P03911052A0909|85 92|patients
P03911052A0909|43 53|CABG surgery
P03911052A0909|39 40|CP
P03911702A0530|174 183|anesthesia
P03911702A0530|140 145|trauma
P03911702A0530|148 151|pigs
P03911702A0530|34 38|model
P03911702A0530|74 94|microembolism syndrome
P03911702A0530|201 210|conditions
P03911702A0530|41 45|means
P03911965A0513|120 136|Galphimia dilution
P03911965A0513|179 185|placebo
P03911965A0513|101 111|Galphimia D6
P03911965A0513|88 98|superiority
P03911965A0513|77 81|trend
P03911965A0513|21 32|significance
P03912247A0282|39 44|ml/min
P03912247A0282|149 156|flap ages
P03912247A0282|135 143|blood flow
P03912247A0282|11 15|blood
P03912247A0282|46 66|collateral circulation
P03912247A0282|21 24|flap
P03912247A0282|72 75|flap
P03912247A0282|3 8|volume
P03912247A0282|115 120|change
P03913522A0000|14 20|aspects
P03913522A0000|4 8|aging
P03913522A0000|29 42|function change
P03914875T0001|4 14|candidiasis
P03915540A0863|102 105|gcn3
P03915540A0863|94 97|gcn2
P03915540A0863|2 9|addition
P03915540A0863|71 83|GCN4-lacZ mRNA
P03915540A0863|107 111|cells
P03915540A0863|14 29|gcd1-101 mutation
P03915540A0863|59 68|efficiency
P03920700A0491|87 91|alpha
P03920700A0491|93 105|adrenoceptors
P03920700A0491|46 59|responsiveness
P03921727A0523|28 34|apo A-II
P03921727A0523|19 24|apo A-I
P03921727A0523|106 113|controls
P03921727A0523|37 46|abstainers
P03921727A0523|97 103|changes
P03921727A0523|3 16|concentrations
P03922116A0197|3 14|distribution
P03922116A0197|53 65|gamma-therapy
P03922116A0197|76 80|group
P03922116A0197|131 135|cases
P03922116A0197|210 228|luc type installation
P03922116A0197|91 103|gamma-therapy
P03922116A0197|255 259|cases
P03922116A0197|17 24|patients
P03922116A0197|69 73|cases
P03922116A0197|155 172|radiation treatment
P03922116A0197|232 251|iliac lymphadenectomy
P03922116A0197|113 127|lymphadenectomy
P03922116A0197|199 202|beam
P03922116A0197|38 42|group
P03922116A0197|140 144|group
P03922116A0197|177 184|megavolt
P03923828A1031|121 128|patients
P03923828A1031|95 102|reversal
P03923828A1031|35 39|DDAVP
P03923828A1031|71 79|treatment
P03923828A1031|153 162|procedures
P03923828A1031|111 118|bleeding
P03923828A1031|17 31|cryoprecipitate
P03923828A1031|3 14|availability
P03923976T0001|0 15|Thrombophlebitis
P03923976T0001|28 35|embolism
P03923976T0001|48 66|factor XII deficiency
P03925712A0229|43 56|enzyme activity
P03925712A0229|73 91|transport mechanisms
P03925712A0229|20 25|mucosa
P03925712A0229|59 70|deficiencies
P03925712A0229|0 7|Biopsies
P03928357A0340|0 18|Laboratory pyrolyses
P03928357A0340|38 41|PCBs
P03928357A0340|96 100|PCDFs
P03928357A0340|65 69|PCDFs
P03928357A0340|104 108|PCDDs
P03928357A0340|57 62|yields
P03928357A0340|74 87|chlorobenzenes
P03928442A0463|79 86|phage SPR
P03928442A0463|50 54|genes
P03928442A0463|122 144|modification specificity
P03928442A0463|61 69|Mtase gene
P03928442A0463|12 17|degree
P03928442A0463|20 27|homology
P03928442A0463|103 108|enzyme
P03928678T0000|36 46|contraction
P03928678T0000|67 72|muscle
P03928678T0000|49 56|urethral
P03929486A0309|26 33|patients
P03929486A0309|161 167|placebo
P03929486A0309|18 22|trial
P03929486A0309|43 52|NYHA II-III
P03929486A0309|105 109|LV-EF
P03929486A0309|181 188|releases
P03929486A0309|123 123|%
P03929486A0309|235 239|doses
P03929486A0309|38 41|COCM
P03929486A0309|88 103|ejection fraction
P03929486A0309|190 191|SR
P03929486A0309|210 214|drugs
P03929486A0309|155 158|mg/d
P03929486A0309|196 201|mg/d SR
P03929486A0309|169 172|PLAC
P03929486A0309|145 145|D
P03929486A0309|175 175|P
P03929486A0309|58 68|sinus rhythm
P03929610A0268|35 42|patients
P03929610A0268|11 20|discomfort
P03930549A0209|32 45|centrifugation
P03930549A0209|63 73|supernatant
P03930549A0209|93 96|form
P03930549A0209|105 113|injection
P03930549A0209|54 57|acid
P03930549A0209|121 136|gas chromatograph
P03930549A0209|3 8|sample
P03930894T0000|0 6|Changes
P03930894T0000|112 116|drugs
P03930894T0000|96 109|administration
P03930894T0000|67 71|aging
P03930894T0000|53 56|lung
P03930894T0000|121 128|vagotomy
P03930894T0000|58 64|effects
P03930894T0000|19 40|acetylcholine receptors
P03930894T0000|87 94|allergen
P03930894T0000|73 82|inhalation
P03931293A0437|87 91|virus
P03931293A0437|66 81|thermoresistance
P03931293A0437|19 29|stabilizers
P03931293A0437|40 46|sucrose
P03931293A0437|5 11|absence
P03931293A0437|97 104|% albumin
P03931797A0134|41 43|men
P03931797A0134|10 19|prevalence
P03931797A0134|51 51|%
P03931797A0134|38 38|%
P03931797A0134|22 30|psoriasis
P03931797A0134|54 58|women
P03933232T0000|56 71|animal morphology
P03933232T0000|23 31|structure
P03933232T0000|5 14|classicism
P03933232T0000|46 53|pathways
P03933784A0420|26 37|CSF prolactin
P03933784A0420|11 16|origin
P03933784A0420|20 23|role
P03934667A0124|30 34|crsA1
P03934667A0124|189 193|sigma
P03934667A0124|16 28|crsA mutations
P03934667A0124|97 119|B. subtilis plasmid pRPD11
P03934667A0124|45 50|crsA47
P03934667A0124|154 157|rpoD
P03934667A0124|204 226|B. subtilis RNA polymerase
P03934667A0124|36 40|crsA4
P03934667A0124|164 171|sequence
P03934667A0124|73 86|gene conversion
P03934667A0124|231 236|pUB110
P03934667A0124|196 201|factor
P03934667A0124|88 94|process
P03935117T0000|67 73|rat lung
P03935117T0000|9 14|effect
P03935117T0000|26 31|oedema
P03935117T0000|34 64|prostaglandin E2 pharmacokinetics
P03935375A0414|72 83|biochemistry
P03935375A0414|194 205|degeneration
P03935375A0414|136 138|RPN
P03935375A0414|164 170|changes
P03935375A0414|40 43|data
P03935375A0414|113 121|pathology
P03935375A0414|4 10|article
P03935375A0414|180 183|rise
P03935375A0414|49 58|morphology
P03935375A0414|218 226|carcinoma
P03935375A0414|60 67|function
P03935375A0414|100 106|medulla
P03935797A0183|217 220|beta
P03935797A0183|93 99|embryos
P03935797A0183|127 131|sites
P03935797A0183|184 190|regions
P03935797A0183|3 6|data
P03935797A0183|211 215|order
P03935797A0183|230 234|delta
P03935797A0183|222 226|alpha
P03935797A0183|60 75|sry messenger RNAs
P03936828T0000|21 30|risk factor
P03936828T0000|33 46|B-cell lymphoma
P03936828T0000|52 63|thyroid gland
P03936828T0000|7 17|thyroiditis
P03937294A0404|0 19|Plasma secretin levels
P03937294A0404|94 97|hour
P03937294A0404|79 83|delay
P03937294A0404|113 125|acid secretion
P03937294A0404|57 72|ethanol solutions
P03937294A0404|106 110|onset
P03937294A0404|41 54|administration
P03937481T0001|78 89|preparations
P03937481T0001|58 61|acid
P03937481T0001|18 30|microanalysis
P03939317A0352|29 35|regions
P03939317A0352|115 120|region
P03939317A0352|62 71|HS promoter
P03939317A0352|77 98|soybean HS-protein genes
P03939317A0352|1 10|comparison
P03940426A0618|0 6|Results
P03940426A0618|213 223|agar culture
P03940426A0618|157 159|fir
P03940426A0618|105 109|tests
P03940426A0618|77 85|anaerobes
P03940426A0618|50 54|acids
P03940426A0618|177 195|genus identification
P03940426A0618|138 147|morphology
P03940426A0618|13 17|study
P03940426A0618|40 44|chain
P03940426A0618|30 32|GLC
P03940426A0618|65 74|agar medium
P03940426A0618|116 119|Gram
P03940733A0755|41 45|doses
P03940733A0755|9 14|method
P03940733A0755|26 35|absorption
P03940733A0755|100 109|assessment
P03940733A0755|48 55|vitamin A
P03940733A0755|90 97|approach
P03940733A0755|115 127|malabsorption
P03940818T0000|28 37|HBV carrier
P03940818T0000|9 18|hepatitis A
P03944212A0166|15 18|rCBF
P03944212A0166|104 115|MCA territory
P03944212A0166|23 34|water content
P03944212A0166|55 60|matter
P03944212A0166|93 98|margin
P03944212A0166|121 121|h
P03944212A0166|127 130|MCAO
P03944212A0166|73 76|core
P03944212A0166|0 13|Tissue pressure
P03944239A0780|149 150|T3
P03944239A0780|90 106|amiodarone therapy
P03944239A0780|49 75|plasma thyroid hormone changes
P03944239A0780|10 13|time
P03944239A0780|128 129|T4
P03944239A0780|121 122|T4
P03944239A0780|18 25|patients
P03944239A0780|134 136|rT3
P03946125T0000|0 3|Drug
P03946125T0000|7 26|nutrient interactions
P03952387A0336|95 98|HbO2
P03952387A0336|33 39|tissues
P03952387A0336|51 58|reaction
P03952387A0336|6 16|compartment
P03952387A0336|64 68|place
P03952387A0336|81 93|oxyhemoglobin
P03953361A0000|234 237|dogs
P03953361A0000|22 32|propranolol
P03953361A0000|153 154|CK
P03953361A0000|131 137|calcium
P03953361A0000|142 149|contents
P03953361A0000|13 19|effects
P03953361A0000|158 167|lactic acid
P03953361A0000|45 54|metabolism
P03953361A0000|80 97|serial measurements
P03953361A0000|110 123|creatine kinase
P03953361A0000|196 205|sinus blood
P03953361A0000|68 78|reperfusion
P03953361A0000|139 140|Ca
P03953361A0000|125 126|CK
P03953361A0000|169 170|LA
P03953361A0000|172 185|concentrations
P03956647A1063|216 224|densities
P03956647A1063|136 142|erosion
P03956647A1063|82 96|charge densities
P03956647A1063|230 242|microC/cm2 X ph
P03956647A1063|154 175|iridium microelectrodes
P03956647A1063|54 79|scanning electron microscopy
P03956647A1063|122 126|A/cm2
P03956647A1063|107 119|microC/cm2 X ph
P03956647A1063|21 40|%Ir microelectrode tip
P03956647A1063|246 250|A/cm2
P03956647A1063|200 205|charge
P03956647A1063|0 10|Dissolution
P03956695A0617|0 16|Cortisol excretion
P03956695A0617|105 110|stress
P03956695A0617|51 56|season
P03956695A0617|70 76|factors
P03959045A0000|15 26|relationship
P03959045A0000|112 115|MCAT
P03959045A0000|51 64|coaching course
P03959045A0000|84 110|Medical College Admission Test
P03959045A0000|68 78|performance
P03959045A0000|3 9|studies
P03963860A0137|1 5|total
P03963860A0137|10 17|patients
P03963860A0137|49 52|MY-1
P03963860A0137|73 77|group
P03964489A1195|18 21|PaO2
P03964489A1195|23 26|NADH
P03964489A1195|7 15|% decrease
P03964855A0254|0 10|Angiography
P03964855A0254|35 43|rCBF study
P03964855A0254|83 92|angiograms
P03964855A0254|50 55|degree
P03964855A0254|58 66|vasospasm
P03965012A0163|97 109|heart diseases
P03965012A0163|145 159|reference cohort
P03965012A0163|162 177|paper mill workers
P03965012A0163|111 120|ICD A83-A84
P03965012A0163|26 30|years
P03965012A0163|3 9|results
P03965012A0163|68 76|mortality
P03966687A0000|99 105|Allergy
P03966687A0000|12 17|impact
P03966687A0000|108 112|years
P03966687A0000|91 96|Annals
P03966687A0000|66 71|Taylor
P03966687A0000|85 88|data
P03966687A0000|20 34|childhood asthma
P03966687A0000|58 62|Vance
P03967144T0001|0 12|Hypersplenism
P03970191A0275|89 90|DC
P03970191A0275|10 17|activity
P03970191A0275|52 69|electrocorticogram
P03970191A0275|97 105|potential
P03970191A0275|110 114|sites
P03970191A0275|71 74|ECoG
P03972038A0000|16 27|trajectories
P03972038A0000|116 124|technique
P03972038A0000|78 80|STR
P03972038A0000|33 49|commissural fibers
P03972038A0000|71 76|region
P03972038A0000|3 12|topography
P03972185A0137|146 150|times
P03972185A0137|38 54|insulin deficiency
P03972185A0137|94 106|hyperglycemia
P03972185A0137|78 85|controls
P03972185A0137|11 15|state
P03972185A0137|56 67|plasma levels
P03972185A0137|122 140|plasma glucose levels
P03972185A0137|75 75|%
P03974790A0053|41 52|brain infarct
P03974790A0053|10 19|CT findings
P03974790A0053|64 69|tumour
P03976323A0821|30 48|blood pressure change
P03976323A0821|52 61|SCR-change
P03976323A0821|12 22|correlation
P03977577T0000|0 21|Shoulder forearm support
P03977577T0000|36 43|shoulder
P03977603A0326|0 8|Piroxicam
P03977603A0326|23 31|incidence
P03977603A0326|41 46|ulcers
P03977603A0326|68 79|indomethacin
P03977603A0326|61 65|doses
P03978045A0857|145 152|syndrome
P03978045A0857|99 113|hyperreactivity
P03978045A0857|185 190|origin
P03978045A0857|66 71|stages
P03978045A0857|223 233|alterations
P03978045A0857|45 46|0T
P03978045A0857|48 49|0N
P03978045A0857|74 76|VWF
P03978045A0857|38 43|stages
P03978045A0857|136 142|Raynaud
P03978045A0857|126 132|vessels
P03978045A0857|78 83|stages
P03978045A0857|164 172|disorders
P03978045A0857|5 12|findings
P03978132A0108|103 120|distribution curves
P03978132A0108|53 76|photoacceptor sensitivity
P03978132A0108|35 51|surface reflection
P03978132A0108|20 33|source emission
P03978132A0108|2 14|MCCP functions
P03979084A1019|58 66|functions
P03979084A1019|91 94|IBPK
P03979084A1019|28 29|hr
P03979084A1019|8 14|kidneys
P03979084A1019|85 88|IMPK
P03980386A0000|158 162|lambs
P03980386A0000|51 58|infusion
P03980386A0000|11 17|effects
P03980386A0000|38 48|angiotensin
P03980386A0000|89 92|lung
P03980386A0000|61 72|distribution
P03980386A0000|104 116|perfusion lung
P03980386A0000|75 83|blood flow
P03980386A0000|28 34|hypoxia
P03981421A0246|1 8|flow rate
P03981421A0246|76 82|results
P03981421A0246|19 22|mL/h
P03981421A0246|52 57|volume
P03981421A0246|62 63|mL
P03981421A0246|43 50|receptor
P03981640A0168|46 50|mRNAs
P03981640A0168|21 24|ends
P03981952T0000|61 70|estimation
P03981952T0000|78 87|salt intake
P03981952T0000|39 55|chloride titrators
P03981952T0000|3 10|efficacy
P03982288T0000|0 13|Doctor Berglund
P03982288T0000|19 25|members
P03982288T0000|28 40|union pitfalls
P03984683A0000|30 39|hemiplegia
P03984683A0000|81 94|stroke patients
P03984683A0000|57 66|spasticity
P03984683A0000|5 14|appearance
P03984683A0000|17 27|hemiparesis
P03985849A0221|43 48|groups
P03985849A0221|154 159|nature
P03985849A0221|114 121|patients
P03985849A0221|51 58|patients
P03985849A0221|166 174|condition
P03985849A0221|66 76|development
P03985849A0221|126 129|CVID
P03985849A0221|86 99|rhinosinusitis
P03985849A0221|196 208|IgA deficiency
P03985849A0221|14 27|rhinosinusitis
P03987818A0440|5 8|data
P03987818A0440|20 23|AP-A
P03987818A0440|51 60|management
P03987818A0440|63 74|heart failure
P03987857A0733|28 38|floor region
P03987857A0733|10 16|muscles
P03987857A0733|119 129|stimulation
P03987857A0733|108 116|intensity
P03987857A0733|86 93|mass unit
P03988001A0227|21 44|rat blood chloroform levels
P03988001A0227|89 92|ClO2
P03988001A0227|76 84|treatment
P03989827T0000|14 30|lactase phenotypes
P03989827T0000|33 46|Aymara children
P03989827T0000|3 11|frequency
P03992022A0330|0 9|Activities
P03992022A0330|84 99|TMO N-demethylase
P03992022A0330|69 79|aminopyrine
P03992022A0330|56 62|enzymes
P03992022A0330|158 161|rats
P03992022A0330|144 155|pretreatment
P03992022A0330|166 175|cimetidine
P03992022A0330|189 192|rats
P03992022A0330|19 28|cytochrome
P03992022A0330|223 238|enzyme activities
P03992022A0330|103 128|aniline hydroxylase activity
P03992022A0330|207 216|ranitidine
P03995513T0000|0 10|Doxorubicin
P03995513T0000|95 108|leiomyosarcoma
P03995513T0000|12 22|dacarbazine
P03995513T0000|39 54|cyclophosphamide
P03995513T0000|24 34|vincristine
P03995513T0000|60 68|treatment
P03997467A0000|3 8|effect
P03997467A0000|64 71|patients
P03997467A0000|20 37|antagonist naloxone
P03997467A0000|84 91|ischemia
P03998071T0000|46 51|levels
P03998071T0000|54 62|vitamin K1
P03998071T0000|65 76|osteoporosis
P03998071T0000|0 23|Electrochemical detection
P03998813A0406|95 102|ontogeny
P03998813A0406|12 22|experiments
P03998813A0406|125 129|mouse
P03998813A0406|40 43|role
P03998813A0406|63 69|pattern
P03998813A0406|78 85|activity
P03998813A0406|105 119|frequency tuning
P03998813A0406|145 150|system
P03999219A0463|0 13|Ultrastructure
P03999219A0463|127 135|chromatin
P03999219A0463|181 194|alum irrigation
P03999219A0463|19 23|tumor
P03999219A0463|75 79|weeks
P03999219A0463|53 61|resection
P03999219A0463|27 33|patient
P03999219A0463|164 170|changes
P03999219A0463|85 98|alum irrigation
P04000347A0442|140 142|BEN
P04000347A0442|150 160|individuals
P04000347A0442|19 26|criteria
P04000347A0442|80 85|groups
P04000347A0442|112 114|BEN
P04000347A0442|56 62|persons
P04000347A0442|181 187|disease
P04000347A0442|168 172|signs
P04001413A0093|123 127|scans
P04001413A0093|77 83|patient
P04001413A0093|93 106|breath-holding
P04001413A0093|41 46|device
P04001413A0093|7 13|purpose
P04001490T0001|45 58|Endocrinopathy
P04001490T0001|70 78|component
P04001490T0001|80 83|Skin
P04001490T0001|17 30|Polyneuropathy
P04001490T0001|32 43|Organomegaly
P04001490T0001|3 15|POEMS syndrome
P04002131A0506|102 102|P
P04002131A0506|33 40|increase
P04002131A0506|75 90|hyperheparinuria
P04002131A0506|43 54|GAG secretion
P04002131A0506|7 22|disease remission
P04002131A0506|59 63|urine
P04002667A0181|17 24|patients
P04002667A0181|76 77|cm
P04002667A0181|95 106|localization
P04002667A0181|150 163|lung parenchyma
P04002667A0181|109 118|lung tissue
P04002667A0181|33 39|results
P04002667A0181|56 69|tumor diameters
P04002667A0181|132 139|cm tumors
P04004168A0000|105 112|syndrome
P04004168A0000|24 29|anemia
P04004168A0000|38 71|triosephosphate isomerase deficiency
P04004168A0000|156 165|tract signs
P04004168A0000|130 138|movements
P04004168A0000|170 177|evidence
P04004168A0000|140 145|tremor
P04004168A0000|186 207|motor neuron involvement
P04004168A0000|3 10|siblings
P04005190A1288|3 9|extract
P04005190A1288|23 32|PCA content
P04011338A0620|112 112|r
P04011338A0620|196 199|loss
P04011338A0620|169 175|placebo
P04011338A0620|38 48|steatorrhea
P04011338A0620|202 208|taurine
P04011338A0620|65 68|loss
P04011338A0620|91 102|relationship
P04011338A0620|119 119|p
P04011338A0620|143 148|extent
P04011338A0620|159 166|acid loss
P04011338A0620|7 14|patients
P04011338A0620|182 189|decrease
P04011338A0620|52 59|decrease
P04011338A0620|81 81|%
P04011338A0620|30 35|degree
P04011466T0000|62 65|data
P04011466T0000|17 23|infants
P04011466T0000|6 14|diameters
P04011466T0000|32 39|children
P04013576A0981|157 165|exception
P04013576A0981|113 124|distribution
P04013576A0981|10 22|investigation
P04013576A0981|127 136|Leptospira
P04013576A0981|74 96|Leptospira phospholipids
P04013576A0981|194 204|carbon atoms
P04013576A0981|184 187|acid
P04013576A0981|67 71|acids
P04013576A0981|41 52|distribution
P04013576A0981|223 235|phospholipids
P04013576A0981|144 149|lipids
P04013604A0412|92 112|slow-release tablet use
P04013604A0412|12 20|frequency
P04013604A0412|63 67|cases
P04013604A0412|77 89|patient-years
P04013604A0412|40 49|ulceration
P04014833A0400|0 13|Hydrocortisone
P04014833A0400|129 136|mitogens
P04014833A0400|116 127|concanavalin
P04014833A0400|95 112|phytohemagglutinin
P04014833A0400|57 64|response
P04014833A0400|20 30|lymphopenia
P04014833A0400|77 92|blood lymphocytes
P04014861A0000|131 138|catalase
P04014861A0000|105 123|superoxide dismutase
P04014861A0000|9 19|feasibility
P04014861A0000|76 81|effect
P04014861A0000|67 71|lungs
P04014861A0000|56 61|agents
P04014861A0000|125 127|SOD
P04014861A0000|27 35|liposomes
P04014861A0000|150 163|oxygen toxicity
P04014861A0000|176 179|rats
P04015988T0000|0 17|Marrow cell necrosis
P04015988T0000|49 58|starvation
P04015988T0000|20 34|anorexia nervosa
P04017295A0139|47 54|dialyses
P04017295A0139|64 71|patients
P04017295A0139|25 31|heparin
P04017295A0139|3 12|comparison
P04018444A0000|16 19|acid
P04018444A0000|86 88|man
P04018444A0000|50 53|urso
P04018444A0000|63 83|cholesterol gallstones
P04018444A0000|21 25|cheno
P04018444A0000|45 48|acid
P04019066A0000|178 181|rats
P04019066A0000|79 81|MRF
P04019066A0000|13 27|field potentials
P04019066A0000|154 162|halothane
P04019066A0000|69 77|formation
P04019066A0000|115 120|cortex
P04019066A0000|122 124|SCX
P04019066A0000|96 97|CG
P04019066A0000|147 151|doses
P04021281T0001|0 13|Ultrastructure
P04021281T0001|78 85|training
P04021281T0001|54 60|infarct
P04021281T0001|19 29|heart muscle
P04021305A0530|15 30|desympathization
P04021305A0530|107 114|dopamine
P04021305A0530|91 103|noradrenaline
P04021305A0530|54 69|hyper-reactivity
P04021305A0530|79 88|pacemakers
P04021305A0530|179 183|cells
P04021305A0530|129 135|changes
P04021305A0530|41 51|development
P04021305A0530|186 199|catecholamines
P04021305A0530|141 150|regulation
P04021305A0530|164 171|activity
P04021431A0000|0 3|OODG
P04021431A0000|209 218|dilatation
P04021431A0000|129 134|system
P04021431A0000|89 102|blood pressures
P04021431A0000|51 61|pulse curves
P04021431A0000|33 42|assessment
P04021431A0000|224 229|pupils
P04021431A0000|197 200|eyes
P04021431A0000|74 86|determination
P04021431A0000|17 22|method
P04021431A0000|161 174|blood pressures
P04021437A0000|58 63|number
P04021437A0000|5 14|infections
P04021437A0000|49 54|agents
P04021437A0000|71 85|ear dysfunctions
P04024685A0650|238 240|RBV
P04024685A0650|131 132|cm
P04024685A0650|71 75|mVolt
P04024685A0650|176 177|ml
P04024685A0650|206 207|ml
P04024685A0650|46 53|increase
P04024685A0650|93 93|p
P04024685A0650|18 27|parameters
P04024685A0650|150 151|HV
P04024685A0650|194 196|EDV
P04024685A0650|219 220|ml
P04024685A0650|179 179|p
P04024685A0650|108 110|EDD
P04024685A0650|87 91|mVolt
P04024685A0650|249 250|ml
P04024685A0650|222 222|p
P04024685A0650|55 61|RS index
P04024685A0650|261 262|ml
P04024685A0650|7 7|%
P04024685A0650|264 264|p
P04024685A0650|134 134|p
P04024685A0650|162 163|ml
P04025178A0126|118 122|ml/m2
P04025178A0126|52 59|decrease
P04025178A0126|81 82|LV
P04025178A0126|27 31|death
P04025178A0126|13 20|analyses
P04025178A0126|109 112|EDVI
P04025178A0126|126 126|%
P04025178A0126|97 107|volume index
P04025179A0955|25 33|variables
P04025179A0955|8 13|adults
P04025179A0955|2 6|group
P04026903A0512|158 163|barium
P04026903A0512|79 87|rat uterus
P04026903A0512|30 38|stimulant
P04026903A0512|63 76|guinea pig ileum
P04026903A0512|134 146|acetylcholine
P04026903A0512|165 183|5-hydroxytryptamine
P04026903A0512|148 156|histamine
P04026903A0512|213 218|manner
P04026903A0512|187 195|carbachol
P04026903A0512|113 124|contractions
P04026903A0512|41 54|relaxant effect
P04026903A0512|0 10|Polysorbate
P04026972T0000|10 32|alcohol reaction profiles
P04027182T0000|0 7|Vitiligo
P04027182T0000|10 25|diabetes mellitus
P04028871A0133|61 72|blister fluid
P04028871A0133|39 43|serum
P04028871A0133|106 118|mg lymecycline
P04028871A0133|124 136|mg doxycycline
P04028871A0133|25 36|tetracycline
P04028871A0133|145 147|day
P04028871A0133|96 100|doses
P04028871A0133|3 18|pharmacokinetics
P04031488A1091|13 23|correlation
P04031488A1091|5 10|degree
P04031488A1091|46 55|conception
P04031488A1091|29 33|sense
P04031488A1091|95 103|syndromes
P04031488A1091|58 74|brain localization
P04032268A0358|25 26|nm
P04032268A0358|121 124|drug
P04032268A0358|7 16|UV detector
P04032268A0358|87 100|Ag/AgCl/3 M NaCl
P04032268A0358|50 57|detector
P04032268A0358|64 72|potential
P04032268A0358|47 48|EC
P04032268A0358|79 79|V
P04032349A0000|27 36|occlusions
P04032349A0000|165 178|Lys Plasminogen
P04032349A0000|44 58|graft thromboses
P04032349A0000|92 99|ischemia
P04032349A0000|126 132|therapy
P04032349A0000|134 142|Urokinase
P04032349A0000|148 160|units/kg/hour
P04032349A0000|2 9|patients
P04032716A0299|215 221|oviduct
P04032716A0299|109 121|transfer ratio
P04032716A0299|89 93|blood
P04032716A0299|44 50|tissues
P04032716A0299|190 199|myometrium
P04032716A0299|178 183|cervix
P04032716A0299|26 29|drug
P04032716A0299|3 20|mean transfer ratios
P04032716A0299|56 68|concentration
P04033402A1112|127 152|triglyceride lipase activity
P04033402A1112|24 31|hormones
P04033402A1112|38 66|HDL-cholesterol concentrations
P04033402A1112|73 99|HDL2-cholesterol subfraction
P04034220A0205|143 151|treatment
P04034220A0205|53 62|ampicillin
P04034220A0205|165 179|tract infections
P04034220A0205|182 189|children
P04034220A0205|81 92|H. influenzae
P04034220A0205|112 128|tolerance Cefaclor
P04034220A0205|16 23|spectrum
P04034220A0205|72 78|strains
P04034220A0205|26 33|activity
P04034666T0000|5 26|extremity weight bearing
P04034666T0000|94 104|hemiparesis
P04034666T0000|39 56|standing conditions
P04034666T0000|82 89|patients
P04036838A0918|146 146|r
P04036838A0918|40 43|data
P04036838A0918|154 154|p
P04036838A0918|5 10|factor
P04036838A0918|82 82|p
P04036838A0918|126 144|pressure differences
P04036838A0918|60 73|pressure ratios
P04036838A0918|47 51|RV/LV
P04036838A0918|75 75|r
P04037809A0964|38 44|KW-2083
P04037809A0964|23 35|dose schedules
P04038454A0984|98 111|micrograms dl-1
P04038454A0984|22 39|plasma retinol level
P04038454A0984|204 217|micrograms dl-1
P04038454A0984|222 227|mg dl-1
P04038454A0984|42 52|conjunction
P04038454A0984|57 59|RBP
P04038454A0984|193 198|cancer
P04038454A0984|141 156|cancer recurrence
P04038454A0984|116 121|mg dl-1
P04038454A0984|85 92|patients
P04038702A0768|3 9|results
P04038702A0768|190 200|disruptions
P04038702A0768|45 53|tethering
P04038702A0768|97 106|experience
P04038702A0768|272 293|cortisol concentrations
P04038702A0768|79 85|penning
P04038702A0768|179 184|estrus
P04038702A0768|130 135|rhythm
P04038702A0768|220 223|type
P04038702A0768|244 249|stalls
P04038702A0768|138 145|cortisol
P04038702A0768|296 300|gilts
P04038702A0768|35 42|response
P04039109A0139|73 79|vessels
P04039109A0139|109 115|seconds
P04039109A0139|27 31|power
P04039109A0139|119 130|power density
P04039109A0139|90 91|mm
P04039109A0139|137 141|W/cm2
P04039109A0139|4 8|laser
P04039109A0139|44 54|fluid medium
P04039109A0139|94 101|diameter
P04039307A0613|29 29|P
P04039307A0613|7 18|progesterone
P04039307A0613|2 2|d
P04039307A0613|77 91|treatment groups
P04039307A0613|59 65|heifers
P04039439A0000|58 59|Mn
P04039439A0000|102 105|diet
P04039439A0000|122 125|days
P04039439A0000|89 93|Mn3O4
P04039439A0000|12 16|quail
P04039439A0000|74 87|manganese oxide
P04039439A0000|45 56|ppm manganese
P04039439A0000|128 130|age
P04039439A0842|84 90|rodents
P04039439A0842|4 8|study
P04039439A0842|67 79|Mn3O4 exposure
P04039439A0842|33 37|quail
P04039525A0475|0 5|Plasma
P04039525A0475|70 72|DDP
P04039525A0475|9 36|bladder platinum concentration
P04039525A0475|171 175|order
P04039525A0475|98 108|examination
P04039525A0475|142 155|blood chemistry
P04039525A0475|110 119|urinalysis
P04039525A0475|185 192|toxicity
P04039525A0475|129 138|blood count
P04039525A0475|207 209|DDP
P04039667T0000|90 98|monocytes
P04039667T0000|13 25|visualisation
P04039667T0000|69 73|means
P04039667T0000|28 46|Walker carcinoma-256
P04039667T0000|49 66|Sprague-Dawley rats
P04039744A0141|127 132|period
P04039744A0141|100 116|i.u. vitamin D3/day
P04039744A0141|87 96|supplement
P04039744A0141|135 143|lactation
P04039744A0141|147 150|days
P04039744A0141|74 80|mothers
P04039744A0141|5 11|results
P04039744A0141|44 51|D mothers
P04039744A0141|55 58|pups
P04040083A0000|0 9|Rabbit eyes
P04040083A0000|51 58|chambers
P04040083A0000|75 80|saline
P04040307A0145|47 52|nerves
P04040307A0145|81 88|NE levels
P04040307A0145|6 10|birth
P04040339T0001|0 16|Monitoring changes
P04040339T0001|91 101|partusisten
P04040339T0001|105 111|Pre-par
P04040339T0001|56 64|tocolysis
P04040339T0001|22 30|heart rate
P04040339T0001|45 49|fetus
P04040858A0000|43 50|patients
P04040858A0000|20 23|June
P04040858A0000|62 67|cancer
P04040858A0000|5 13|September
P04041307A0614|42 50|diltiazem
P04041307A0614|24 40|calcium antagonist
P04041307A0614|64 70|effects
P04041307A0614|3 9|results
P04041307A0614|95 102|function
P04041307A0614|73 82|isoflurane
P04041346T0000|16 26|arrhythmias
P04041346T0000|29 35|digoxin
P04041346T0000|39 47|quinidine
P04043489A0648|0 6|Visidex
P04043489A0648|23 29|storage
P04043489A0648|33 42|re-reading
P04048245A0331|0 8|Treatment
P04048245A0331|33 46|hydrocortisone
P04048245A0331|13 29|oxyphenylbutazone
P04048245A0331|71 84|serum CPN levels
P04050771A0474|99 106|survival
P04050771A0474|80 86|factors
P04050771A0474|51 55|order
P04050771A0474|3 5|Cox
P04050771A0474|45 48|data
P04050771A0474|18 29|hazards model
P04050821A0531|131 138|hospital
P04050821A0531|104 111|episodes
P04050821A0531|46 53|increase
P04050821A0531|66 77|oxygen demand
P04050821A0531|16 25|mechanisms
P04051521T0001|0 7|Duration
P04051521T0001|10 18|remission
P04051521T0001|78 80|MTX
P04051521T0001|72 75|dose
P04051521T0001|36 49|cancer patients
P04051521T0001|84 87|5-FU
P04052919A0205|318 326|indicator
P04052919A0205|253 263|measurement
P04052919A0205|329 337|ovulation
P04052919A0205|20 40|progesterone secretion
P04052919A0205|227 236|thresholds
P04052919A0205|411 417|results
P04052919A0205|155 162|subjects
P04052919A0205|241 243|use
P04052919A0205|166 183|progesterone levels
P04052919A0205|362 367|nmol/l
P04052919A0205|340 348|threshold
P04052919A0205|70 80|luteal phase
P04052919A0205|390 395|number
P04052919A0205|5 8|data
P04052919A0205|266 277|progesterone
P04052919A0205|93 101|frequency
P04052919A0205|146 150|phase
P04052919A0205|293 297|phase
P04052919A0205|117 121|phase
P04055593A0523|132 145|gas composition
P04055593A0523|114 120|effects
P04055593A0523|38 39|N2
P04055593A0523|123 129|changes
P04055593A0523|81 92|compensation
P04055593A0523|23 32|processing
P04055593A0523|97 107|corrections
P04055593A0523|43 53|flow signals
P04055593A0523|149 159|temperature
P04056218A0463|69 70|dB
P04056218A0463|51 52|L1
P04056218A0463|4 8|slope
P04056218A0463|54 55|L2
P04056218A0463|42 46|dB/dB
P04056256A0416|0 18|Histamine reactivity
P04056256A0416|80 83|mean
P04056256A0416|118 122|% fall
P04056256A0416|170 174|mg/ml
P04056256A0416|95 107|concentration
P04056256A0416|50 66|nifedipine aerosol
P04056256A0416|177 185|histamine
P04056256A0416|187 187|p
P04056256A0416|133 149|airway conductance
P04058985A0000|20 28|vitamin B6
P04058985A0000|13 17|doses
P04058985A0000|52 56|women
P04058985A0000|83 97|plasma prolactin
P04061342A0512|126 126|p
P04061342A0512|99 99|p
P04061342A0512|47 52|uptake
P04061342A0512|120 124|state
P04061342A0512|61 75|min postexercise
P04061342A0512|82 82|%
P04061342A0512|30 38|elevation
P04061342A0512|41 44|mean
P04062128T0028|0 17|National Institutes
P04062128T0028|20 64|Health Consensus Development Conference Statement
P04063732A0509|2 9|controls
P04063732A0509|59 66|activity
P04063732A0509|75 75|%
P04063732A0509|20 25|output
P04063732A0509|33 39|conduit
P04063732A0509|54 57|type
P04066194A0163|0 17|Greater attenuation
P04066194A0163|31 50|baseline-P2 amplitude
P04066194A0163|23 27|N1-P2
P04066194A0163|117 119|ear
P04066194A0163|56 63|probe EPs
P04066194A0163|132 139|material
P04066194A0163|82 94|probe stimulus
P04066194A0163|180 201|stimulation arrangement
P04066194A0163|158 160|ear
P04066274A0265|104 104|%
P04066274A0265|11 18|patients
P04066274A0265|91 96|T.C.P.
P04066274A0265|35 43|neoplasms
P04066274A0265|24 24|%
P04066274A0265|77 89|parotidectomy
P04066274A0265|124 125|En
P04066274A0265|108 111|S.P.
P04066274A0265|120 120|%
P04067540A0413|279 285|victims
P04067540A0413|100 106|victims
P04067540A0413|297 302|spouse
P04067540A0413|195 205|suicide note
P04067540A0413|143 150|ex-lover
P04067540A0413|3 13|comparisons
P04067540A0413|136 140|lover
P04067540A0413|48 59|perpetrators
P04067540A0413|121 125|homes
P04067540A0413|214 220|weekend
P04067540A0413|161 165|crime
P04068663A0452|148 154|rabbits
P04068663A0452|41 46|values
P04068663A0452|21 34|mouse CRF-flora
P04068663A0452|9 15|rabbits
P04068663A0452|107 119|unsuitability
P04068663A0452|122 134|mouse CRF flora
P04068663A0452|72 78|animals
P04068663A0452|86 95|parameters
P04068774A1292|97 100|bone
P04068774A1292|27 27|F
P04068774A1292|87 94|elements
P04068774A1292|72 79|contents
P04068774A1292|61 66|effect
P04068774A1292|35 36|Mg
P04068774A1292|7 19|relationships
P04068774A1292|31 32|Zn
P04068969A0300|0 4|L3-L4
P04068969A0300|39 43|model
P04068969A0300|61 65|trunk
P04068969A0300|81 86|system
P04068969A0300|49 55|anatomy
P04068969A0300|16 19|load
P04069756T0025|31 49|leukoencephalopathy
P04069756T0025|0 8|Diagnosis
P04070725A0442|0 12|Component P100
P04070725A0442|38 47|negativity
P04070725A0442|104 112|generator
P04070725A0442|75 84|hypothesis
P04070725A0442|57 63|latency
P04071063A0863|116 121|levels
P04071063A0863|10 20|differences
P04071063A0863|170 174|group
P04071063A0863|35 42|decrease
P04071063A0863|79 94|fibrinogen levels
P04071063A0863|72 77|groups
P04071063A0863|45 58|platelet counts
P04071063A0863|98 102|alpha
P04073848T0000|0 6|Failure
P04073848T0000|35 43|diagnosis
P04073848T0000|9 29|stapedius reflexometry
P04073848T0000|46 61|myasthenia gravis
P04074214A0000|45 49|boars
P04074214A0000|70 80|environment
P04074214A0000|18 37|semen characteristics
P04074214A0000|0 6|Factors
P04075021T0000|46 59|administration
P04075021T0000|29 40|distribution
P04075021T0000|6 24|beta-phenethylamine
P04075021T0000|69 74|routes
P04075021T0000|97 122|monoamine oxidase inhibitors
P04075021T0000|88 94|effects
P04075021T0000|77 80|cats
P04075021T0000|1 3|14C
P04075061A0355|26 26|L
P04075061A0355|16 20|total
P04075061A0355|29 33|water
P04075061A0355|3 9|runners
P04075061A0355|43 46|race
P04079738A0677|108 115|degrees C
P04079738A0677|25 28|mean
P04079738A0677|124 132|degrees C.
P04079738A0677|32 33|SD
P04079738A0677|57 64|kJ X min-1
P04079738A0677|66 66|P
P04079738A0677|3 7|rates
P04079738A0677|15 23|energy use
P04081425T0016|18 24|therapy
P04081425T0016|8 14|aspects
P04082267A0720|14 17|days
P04082267A0720|50 57|degrees C
P04082267A0720|37 44|degrees C
P04082267A0720|99 103|virus
P04082267A0720|62 67|vexans
P04082267A0720|59 60|Ae
P04082267A0720|19 28|incubation
P04082592T0000|0 15|Blood eosinophils
P04082592T0000|18 25|patients
P04082592T0000|30 35|Taenia
P04084607A0663|3 13|imino proton
P04084607A0663|23 27|O6meG
P04084607A0663|39 40|G3
P04084607A0663|16 17|T3
P04084607A0663|130 134|field
P04084607A0663|46 50|O6meG
P04084607A0663|204 206|ppm
P04084607A0663|172 192|Watson-Crick base pairs
P04084607A0663|90 105|modification site
P04084607A0663|158 169|imino protons
P04084607A0663|59 63|helix
P04084607A0663|52 52|N
P04084607A0663|29 29|T
P04084607A0663|144 146|ppm
P04084896A0569|99 120|intervention strategies
P04084896A0569|3 16|recommendation
P04084896A0569|35 44|sub-groups
P04084896A0569|47 56|attempters
P04085589A0264a|133 149|tract colonization
P04085589A0264a|115 119|rates
P04085589A0264a|53 58|status
P04085589A0264a|10 20|correlation
P04085589A0264a|28 41|secretor status
P04085589A0264a|94 112|serum lysozyme levels
P04085589A0264a|60 81|spirometry measurements
P04085589A0264b|133 149|tract colonization
P04085589A0264b|115 119|rates
P04085589A0264b|53 58|status
P04085589A0264b|10 20|correlation
P04085589A0264b|28 41|secretor status
P04085589A0264b|94 112|serum lysozyme levels
P04085589A0264b|60 81|spirometry measurements
P04086403A1016|0 4|Gains
P04086403A1016|35 48|feed conversion
P04086403A1016|108 111|gain
P04086403A1016|89 95|% AS-VFA
P04086403A1016|62 62|P
P04086403A1016|115 128|feed conversion
P04086403A1016|19 19|P
P04086403A1016|134 140|control
P04086403A1016|83 85|fed
P04086403A1016|60 60|%
P04086403A1016|17 17|%
P04086657T0000|45 50|cortex
P04086657T0000|56 58|rat
P04086657T0000|19 29|development
P04086993T0000|58 66|compounds
P04086993T0000|84 91|hamsters
P04086993T0000|45 50|pineal
P04086993T0000|109 118|conditions
P04086993T0000|16 26|rhythmicity
P04086993T0000|32 42|methylation
P04086993T0000|0 4|Daily
P04088233A0309|3 13|transit time
P04088396A0145|30 30|%
P04088396A0145|88 95|patients
P04088396A0145|8 26|patients grades 1-2-3
P04088396A0145|112 112|%
P04088396A0145|68 78|abnormality
P04088733T0001|0 7|Activity
P04088733T0001|10 23|acid hydrolases
P04088733T0001|36 50|blood leukocytes
P04088733T0001|81 88|children
P04088733T0001|70 78|pneumonia
P04088936T0001|88 103|thrombophlebitis
P04088936T0001|76 83|patients
P04088936T0001|38 42|level
P04088936T0001|23 34|antithrombin
P04088936T0001|11 17|studies
P04088936T0001|46 73|plasminogen activator activity
P04093211A0560|31 37|ability
P04093211A0560|63 74|orientations
P04093211A0560|51 59|attitudes
P04101003T0001|0 8|Relations
P04101003T0001|72 74|man
P04101003T0001|79 81|dog
P04101003T0001|62 69|activity
P04101003T0001|34 41|activity
P04101003T0001|88 93|rabbit
P04102280T0000|0 8|Treatment
P04102280T0000|11 15|Paget
P04102280T0000|18 24|disease
P04103248T0000|0 10|Improvement
P04103248T0000|30 37|averager
P04103248T0000|16 25|CRT display
P04113011T0000|2 16|desensitization
P04113011T0000|21 35|ragweed hay fever
P04114211T0000|16 29|sulphadimidine
P04114211T0000|48 55|subjects
P04114211T0000|5 13|excretion
P04115870T0000|0 10|Experiences
P04115870T0000|41 43|use
P04115870T0000|46 63|Urat-I lithotriptor
P04123217T0000|0 8|Formation
P04123217T0000|20 33|chlamydospores
P04123217T0000|11 16|hyphae
P04123217T0000|36 56|Cryptococcus laurentii
P04123662T0000|0 9|Evaluation
P04123662T0000|12 26|thyroid function
P04138224T0095|12 25|tissue emulsion
P04138224T0095|3 8|effect
P04138224T0095|49 62|gamma-globulin
P04138224T0095|27 34|vitamin A
P04138224T0095|68 81|blood clearance
P04138224T0095|84 90|rabbits
P04139081T0001|30 37|patients
P04139081T0001|4 13|antibodies
P04139943T0001|0 12|Demonstration
P04139943T0001|49 53|Corti
P04139943T0001|78 91|silver staining
P04139943T0001|33 46|guinea pig organ
P04139943T0001|19 27|structure
P04139943T0001|59 66|electron
P04140567T0001|0 18|Histamine metabolism
P04140567T0001|44 48|shock
P04143528A0394|26 37|nomenclature
P04145244T0000|0 9|Relaxation
P04145244T0000|12 16|catch
P04145244T0000|35 40|muscle
P04152725T0001|0 6|Studies
P04152725T0001|18 28|liver injury
P04160980T0000|29 39|circulation
P04160980T0000|12 18|control
P04160980T0000|45 47|dog
P04164595T0020|0 7|Evidence
P04164595T0020|66 70|types
P04164595T0020|73 81|infection
P04164669T0000|45 48|skin
P04164669T0000|24 37|kinin formation
P04172166T0000|0 12|Poliomyelitis
P04172166T0000|18 24|vaccine
P04175007T0001|55 60|tumors
P04175007T0001|33 38|growth
P04175007T0001|105 115|antibiotics
P04175007T0001|5 11|problem
P04175007T0001|63 69|animals
P04175007T0001|17 27|stimulation
P04176249T0001|0 9|Assessment
P04176249T0001|30 38|diagnosis
P04176249T0001|20 24|media
P04176249T0001|41 49|diptheria
P04176268T0000|0 13|Aluminium resin
P04176268T0000|34 45|hyperkalamia
P04176268T0000|53 59|failure
P04176268T0000|20 28|treatment
P04176625T0000|0 4|Value
P04176625T0000|10 12|EMG
P04176625T0000|30 43|cardiomyopathy
P04176625T0000|18 26|diagnosis
P04176625T0000|67 74|myopathy
P04179445T0036|0 1|D.
P04189158T0000|0 9|Prevention
P04189158T0000|49 56|globulin
P04189158T0000|20 34|Rh sensitization
P04194466T0000|0 14|Serotonin levels
P04194466T0000|17 36|infant hypothyroidism
P04196986T0000|31 37|studies
P04196986T0000|76 81|system
P04196986T0000|13 28|fluid transferrin
P04196986T0000|48 56|disorders
P04213917T0001|13 27|D-penicillamine
P04213917T0001|39 46|fibroses
P04213917T0001|4 10|dosages
P04214345T0000|74 93|Zambian African adults
P04214345T0000|7 14|relation
P04214345T0000|46 52|glucose
P04214345T0000|22 42|serum IgG concentration
P04214345T0000|56 71|xylose absorption
P04226360T0001|0 8|Disorders
P04226360T0001|11 26|platelet function
P04226360T0001|43 51|leukemias
P04239041T0045|61 66|sodium
P04239041T0045|11 25|anticonvulsants
P04239041T0045|54 59|ATPase
P04239041T0045|71 78|potassim
P04239041T0045|81 86|cortex
P04239041T0045|3 8|effect
P04246054T0028|14 24|lymphocytes
P04246054T0028|77 87|macrophages
P04246054T0028|106 126|incubation temperature
P04246054T0028|61 65|RAMLG
P04246054T0028|30 59|rabbit-anti-lymphocyte globulin
P04246054T0028|0 5|Effect
P04247472T0001|18 21|rats
P04247472T0001|37 45|mountains
P04247472T0001|48 56|Kirghizia
P04247472T0001|6 10|cycle
P04247966T0000|0 8|Lactation
P04247966T0000|25 46|protein maintenance diet
P04247966T0000|11 17|baboons
P04262268T0001|0 6|Studies
P04262268T0001|19 24|matrix
P04262268T0001|32 42|ear ossicles
P04263748T0042|21 26|review
P04281856T0001|42 65|Ornithodoros tatarovski Ol
P04281856T0001|30 39|population
P04281856T0001|6 17|sex structure
P04281856T0001|0 2|Age
P04282315T0001|15 29|hyperlactatemia
P04282315T0001|39 48|phenformin
P04282315T0001|62 69|ablation
P04282315T0001|75 82|pancreas
P04282315T0001|0 12|Sensitization
P04284435T0000|0 8|Vitamin D3
P04284435T0000|12 28|calcium absorption
P04284435T0000|34 38|chick
P04289156T0000|28 35|chickens
P04289156T0000|3 11|incidence
P04289156T0000|14 20|tumours
P04291759T0048|0 16|Laboratory aspects
P04291759T0048|42 53|chemotherapy
P04291759T0048|57 63|control
P04291759T0048|31 39|reference
P04295031T0062|16 24|guinea pig
P04295031T0062|5 10|effect
P04305850T0000|0 8|Androgens
P04305850T0000|12 17|growth
P04308979T0000|0 5|Effect
P04308979T0000|39 47|treatment
P04308979T0000|102 106|lungs
P04308979T0000|52 54|BCG
P04308979T0000|20 31|time interval
P04308979T0000|122 131|lymph nodes
P04308979T0000|8 17|variations
P04308979T0000|58 67|quartz dust
P04308979T0000|85 94|quartz dust
P04308979T0000|70 82|translocation
P04311951T0001|76 82|otology
P04311951T0001|43 53|association
P04311951T0001|11 16|action
P04311951T0001|61 73|instillations
P04315233T0128|21 30|experiment
P04316696T0001|0 5|Enzyme
P04316696T0001|56 60|horse
P04316696T0001|47 50|body
P04316696T0001|19 26|findings
P04321861T0001|76 86|erythrocyte
P04321861T0001|8 37|glutathione reductase deficiency
P04321861T0001|41 48|disorder
P04321861T0001|51 70|glutathione synthesis
P04323641T0000|0 6|Studies
P04323641T0000|9 26|swine enteroviruses
P04325736T0001|15 24|ectromelia
P04325736T0001|27 40|laboratory mice
P04325736T0001|0 12|Serodiagnosis
P04328746T0073|0 15|Ultrasound effect
P04328746T0073|21 45|cytochrome oxidase activity
P04335965T0000|0 9|Metastasis
P04335965T0000|12 25|colon carcinoma
P04335965T0000|31 33|lip
P04350410T0000|0 6|Genesis
P04350410T0000|9 17|foam cells
P04350410T0000|51 58|Cloforex
P04350410T0000|19 23|study
P04350410T0000|35 48|administration
P04350410T0000|26 29|rats
P04364369T0000|0 20|Pre-beta-1 lipoprotein
P04364369T0000|62 73|heart disease
P04364369T0000|40 50|risk factors
P04364369T0000|29 37|detection
P04369884T0000|61 63|CSF
P04369884T0000|21 30|inhibitors
P04369884T0000|54 59|factor
P04369884T0000|0 9|Conditions
P04371279T0000|0 6|Absence
P04371279T0000|9 24|action potentials
P04371279T0000|27 30|frog
P04371279T0000|35 46|muscle fibres
P04371279T0000|58 71|botulinum toxin
P04377003A0000|199 206|patients
P04377003A0000|180 182|CNS
P04377003A0000|214 219|tumors
P04377003A0000|184 189|tumors
P04377003A0000|69 78|spermidine
P04377003A0000|48 67|polyamines putrescine
P04377003A0000|82 89|spermine
P04377003A0000|105 109|fluid
P04377003A0000|35 42|analysis
P04377003A0000|11 16|method
P04377003A0000|131 140|CSF samples
P04377003A0000|173 178|system
P04377003A0000|111 113|CSF
P04377003A0000|147 154|patients
P04377328T0027|0 1|I.
P04385060T0000|0 9|Disulfiram
P04385060T0000|37 44|motility
P04385060T0000|28 34|effects
P04387103T0000|0 8|Particles
P04387103T0000|59 64|glands
P04387103T0000|67 70|dogs
P04387103T0000|19 29|microbodies
P04392584T0000|17 24|malarias
P04392584T0000|34 50|hemisphere monkeys
P04394290T0000|1 5|study
P04394290T0000|24 32|receptors
P04394290T0000|63 71|sphincter
P04394290T0000|38 43|rectum
P04394290T0000|77 79|cat
P04407649T0000|36 40|fossa
P04407649T0000|12 24|arachnoid cyst
P04407649T0000|63 84|99mTc brainscintigraphy
P04418687T0000|0 6|Effects
P04418687T0000|63 67|fetus
P04418687T0000|20 34|glucocorticoids
P04418687T0000|9 16|estrogen
P04418687T0000|47 57|development
P04423347T0001|0 5|Copper
P04423347T0001|39 43|women
P04423347T0001|9 28|ceruloplasmin content
P04423347T0001|78 85|diseases
P04423347T0001|49 53|women
P04428800T0001|42 52|GPT activity
P04428800T0001|36 38|LAP
P04428800T0001|8 12|noise
P04428800T0001|25 33|increases
P04428800T0001|58 63|plasma
P04428800T0001|66 69|rats
P04428800T0001|0 5|Effect
P04428981T0000|0 7|Kinetics
P04428981T0000|10 26|calcium metabolism
P04429269T0000|16 20|mucus
P04429269T0000|5 13|transport
P04429269T0000|36 44|simulants
P04429269T0000|55 61|systems
P04437406T0000|103 110|exchange
P04437406T0000|13 23|description
P04437406T0000|36 56|reflection coefficient
P04437406T0000|77 86|pore theory
P04437406T0000|61 71|application
P04445874T0001|0 8|Pathology
P04445874T0001|37 41|horse
P04445874T0001|11 18|neuritis
P04446923T0001|8 22|characteristics
P04446923T0001|42 61|Platynothrus peltifer
P04446923T0001|26 39|verticillation
P04460692T0000|16 39|laboratory animal medicine
P04460692T0000|8 13|topics
P04468264T0053|29 42|anesthesiology
P04468264T0053|16 25|pediatrics
P04468264T0053|0 7|Problems
P04482661T0001|42 55|decubitus ulcer
P04482661T0001|8 13|course
P04482661T0001|81 94|buckwheat chaff
P04482661T0001|63 69|pillows
P04482661T0001|30 37|patients
P04482661T0001|58 60|use
P04482661T0001|17 27|nursing care
P04487835T0001|2 8|parents
P04487920T0001|7 33|Icelandic Red Cross activities
P04488232T0001|0 6|Effects
P04488232T0001|24 29|family
P04488232T0001|9 18|alcoholism
P04488271T0001|0 8|Treatment
P04488271T0001|23 38|diabetes mellitus
P04488271T0001|12 15|care
P04488271T0001|46 49|coma
P04495034T0000|37 45|treatment
P04495034T0000|26 32|toluene
P04495034T0000|12 24|methylbenzene
P04495034T0000|49 67|Ancylostomum caninum
P04506738T0000|0 8|Junctions
P04506738T0000|31 41|enamel organ
P04506738T0000|16 20|cells
P04510102T0000|0 17|Electrocardiograms
P04510102T0000|23 27|month
P04511139T0001|0 9|Composites
P04511139T0001|12 31|restoration materials
P04512496T0000|0 6|Hodgkin
P04512496T0000|9 15|disease
P04515631T0000|0 4|Value
P04515631T0000|37 46|assessment
P04515631T0000|49 61|liver function
P04515631T0000|7 15|Normotest
P04515631T0000|19 30|antithrombin
P04518624T0000|0 20|Glutathione peroxidase
P04518624T0000|47 53|disease
P04518624T0000|38 43|health
P04518624T0000|31 35|cells
P04524081T0000|15 22|response
P04524081T0000|53 77|aluminum chloride solutions
P04524081T0000|33 39|tissues
P04524081T0000|80 106|tissue displacement materials
P04524081T0000|42 49|hemodent
P04533208T0083|0 6|Changes
P04533208T0083|27 33|surgery
P04536964T0000|27 53|H ion permeability coefficient
P04536964T0000|56 72|bullfrog toe muscle
P04536964T0000|13 14|pH
P04536964T0000|16 23|H ion flux
P04539552T0001|22 27|SF-837
P04539552T0001|13 19|studies
P04543036T0001|0 9|Directives
P04543036T0001|27 30|care
P04544430T0001|0 10|Proceedings
P04544430T0001|49 55|surgery
P04544430T0001|68 79|heart defects
P04544430T0001|30 39|heart block
P04544704T0001|0 5|Method
P04544704T0001|32 37|factor
P04544704T0001|8 16|synthesis
P04544704T0001|61 67|studies
P04546974T0000|42 57|bundle recordings
P04546974T0000|15 20|timing
P04546974T0000|23 33|deflections
P04546974T0000|0 9|Variations
P04547933T0000|81 83|eye
P04547933T0000|13 27|fibril formation
P04547933T0000|40 44|cells
P04547933T0000|63 70|junction
P04548483T0001|15 32|coagulation factors
P04548483T0001|83 95|rhesus monkeys
P04548483T0001|76 80|shock
P04548483T0001|47 58|organ changes
P04548483T0001|0 13|Blood platelets
P04551650T0001|0 12|Cell viability
P04551650T0001|25 31|enzymes
P04552263T0000|32 35|R.N.
P04552263T0000|14 20|schools
P04552263T0000|23 29|nursing
P04562038T0001|7 19|investigation
P04562038T0001|62 72|lymphocytes
P04562038T0001|53 59|hormone
P04562038T0001|36 44|influence
P04563045T0000|0 6|1,3-bis
P04563045T0000|25 35|nitrosourea
P04563045T0000|8 20|2-chloroethyl
P04563045T0000|81 86|review
P04563045T0000|37 40|bcnu
P04563045T0000|50 61|nitrosoureas
P04563045T0000|64 78|cancer treatment
P04578686T0000|0 11|Pneumothorax
P04578686T0000|21 31|lung abscess
P04578686T0000|42 58|transplant patient
P04579436T0000|97 103|pigment
P04579436T0000|39 58|Brevibacterium linens
P04579436T0000|24 36|colour changes
P04580044T0047|8 20|relationships
P04580044T0047|27 42|development phase
P04583791T0000|28 32|Lagos
P04583791T0000|6 12|history
P04583791T0000|34 40|Nigeria
P04583791T0000|15 25|dermatology
P04598670T0000|47 63|immunosuppression
P04598670T0000|25 31|adjunct
P04598670T0000|5 20|graft irradiation
P04600603T0001|0 5|Letter
P04600603T0001|17 25|detection
P04613073T0001|0 3|Role
P04613073T0001|36 52|Shigella virulence
P04613073T0001|21 33|manifestation
P04613073T0001|6 15|biocenosis
P04615525T0001|74 81|immunity
P04615525T0001|31 39|formation
P04615525T0001|25 28|sera
P04615525T0001|3 8|effect
P04615525T0001|84 87|mice
P04615525T0001|42 56|transplantation
P04615828T0001|14 36|colonel prof. e.cerny m.d.
P04615828T0001|4 11|birthday
P04621188T0000|0 9|Morphology
P04621188T0000|12 25|bacteriophages
P04621188T0000|28 44|Klebsiella bacilli
P04622430T0000|43 54|Rhesus monkey
P04622430T0000|8 16|afferents
P04622430T0000|32 37|cortex
P04624863T0001|0 8|Mechanism
P04624863T0001|11 23|immunogenesis
P04624863T0001|26 36|vaccination
P04624863T0001|72 82|salmonellae
P04624863T0001|86 94|shigellae
P04624863T0001|63 69|mutants
P04627477T0001|0 16|Resistance pattern
P04627477T0001|19 43|Mycobacterium tuberculosis
P04627477T0001|48 49|Rv
P04627477T0001|68 78|lividomycin
P04627477T0001|45 45|H
P04632967T0000|42 52|patas monkey
P04632967T0000|67 80|administration
P04632967T0000|17 24|pressure
P04632967T0000|83 98|aminorex fumarate
P04632967T0000|28 36|structure
P04638365T0001|0 5|Effect
P04638365T0001|8 16|triftazin
P04638365T0001|52 59|activity
P04638365T0001|20 27|aminazin
P04640155T0045|0 7|Sex ratio
P04640155T0045|10 14|birth
P04645078T0001|12 20|processes
P04645078T0001|26 36|cervix uteri
P04646045T0001|27 35|esophagus
P04646045T0001|16 21|tumors
P04653144T0000|0 14|General formulae
P04653144T0000|28 39|heritability
P04653144T0000|64 70|parents
P04653144T0000|43 52|population
P04654249T0000|0 10|Measurement
P04654249T0000|65 68|bulb
P04654249T0000|71 73|cat
P04654249T0000|22 30|responses
P04654249T0000|43 53|stimulation
P04656185T0000|0 23|Glucose disappearance rate
P04656185T0000|27 33|changes
P04656185T0000|126 133|newborns
P04656185T0000|36 50|plasma nutrients
P04656185T0000|76 82|glucose
P04661961T0001|28 32|blood
P04661961T0001|36 45|bone marrow
P04661961T0001|65 71|hamster
P04661961T0001|6 11|values
P04676734T0000|3 14|relationship
P04676734T0000|62 76|corticosteroids
P04676734T0000|90 92|age
P04676734T0000|48 59|plasma levels
P04679438T0001|28 32|heviz
P04679438T0001|10 15|effect
P04679438T0001|21 23|mud
P04679807T0000|8 24|acid concentration
P04679807T0000|39 57|breathalyzer ampules
P04704137T0001|0 3|Role
P04704137T0001|31 41|prophylaxis
P04704137T0001|19 25|studies
P04704137T0001|55 63|abortions
P04704186T0000|0 12|Range behavior
P04704186T0000|24 31|Hereford
P04704186T0000|65 71|heifers
P04704186T0000|33 40|Holstein
P04704186T0000|44 51|Holstein
P04704186T0000|15 22|Hereford
P04712626T0000|0 19|Chemical constituents
P04712626T0000|65 87|Swertia chirata Buch.-Ham
P04712626T0000|54 62|xanthones
P04712626T0000|25 37|gentianaceae V
P04718233T0000|0 24|Methyl mercury intoxication
P04718233T0000|27 36|rat kidneys
P04727344T0000|0 17|Microdetermination
P04727344T0000|50 62|isotope method
P04727344T0000|34 41|steroids
P04729063T0000|62 68|Koreans
P04729063T0000|27 36|investment
P04729063T0000|12 18|justice
P04730467T0000|0 6|Effects
P04730467T0000|51 66|enzyme activities
P04730467T0000|9 17|cortisone
P04730467T0000|92 95|rats
P04730467T0000|69 87|epiphyseal cartilage
P04730467T0000|19 28|starvation
P04730467T0000|33 39|rickets
P04733391T0000|0 25|Metal coordination compounds
P04733391T0000|28 40|thiabendazole
P04746559T0053|0 9|Estimation
P04746559T0053|12 29|renin secretion rate
P04746559T0053|38 47|plasma flow
P04746559T0053|70 84|vein renin levels
P04752455T0000|30 37|security
P04752455T0000|0 18|Disability insurance
P04753073T0000|0 5|Choice
P04753073T0000|8 13|vessel
P04753286T0000|28 30|rat
P04753286T0000|33 39|tung oil
P04753286T0000|13 22|food intake
P04753286T0000|0 10|Suppression
P04757217T0000|0 6|Studies
P04757217T0000|9 21|lipoprotein-X
P04757217T0000|50 63|LCAT deficiency
P04757217T0000|23 26|LP-X
P04757217T0000|31 39|bile acids
P04758799T0000|0 11|Pneumothorax
P04758799T0000|32 47|steroid treatment
P04759722T0000|0 16|Polycythemia-1973
P04760826T0000|17 32|Vietnam returnees
P04760826T0000|8 14|anxiety
P04760826T0000|36 49|undergraduates
P04764049T0001|16 31|nephronophthisis
P04766888T0000|40 54|meningococcemia
P04766888T0000|23 30|children
P04766888T0000|5 18|heparin therapy
P04778129T0000|0 16|9,11-Seco steroids
P04778129T0000|28 49|estradiol 3-methyl ether
P04782788T0001|46 64|kidney insufficiency
P04782788T0001|27 34|patients
P04782788T0001|13 24|examinations
P04784432T0001|60 66|animals
P04784432T0001|48 57|substances
P04784432T0001|25 38|administration
P04784432T0001|0 12|Possibilities
P04787472T0001|0 5|Change
P04787472T0001|22 26|blood
P04787472T0001|11 16|makeup
P04787472T0001|78 82|field
P04787472T0001|52 57|action
P04787472T0001|93 96|body
P04787716T0000|0 11|Observations
P04787716T0000|35 54|Chrysops caecutiens L.
P04787716T0000|17 32|flight activities
P04788701T0001|0 10|Combination
P04788701T0001|68 73|uterus
P04788701T0001|47 52|tumors
P04788701T0001|58 64|breasts
P04789916T0001|0 7|Analysis
P04789916T0001|10 23|clearance curve
P04789916T0001|30 41|bengal-I-131
P04791420T0000|0 10|Proceedings
P04791420T0000|62 67|possum
P04791420T0000|12 18|Barrels
P04791420T0000|22 31|somatotopy
P04791420T0000|36 44|neocortex
P04791420T0000|34 34|S
P04794218T0001|11 17|K agents
P04796997T0000|89 94|organs
P04796997T0000|6 17|reproduction
P04796997T0000|35 43|injection
P04796997T0000|19 25|effects
P04796997T0000|46 71|medroxyprogesterone acetate
P04796997T0000|100 104|bitch
P04801663T0049|27 36|properties
P04803629T0001|34 40|allergy
P04803629T0001|13 18|system
P04810131T0000|0 5|Letter
P04810131T0000|36 42|smoking
P04810131T0000|7 32|Aryl hydrocarbon hydroxylase
P04813394T0000|0 9|Evaluation
P04813394T0000|50 67|acid determinations
P04813394T0000|12 30|1,10-phenanthroline
P04813394T0000|34 40|reagent
P04820791T0001|20 23|acid
P04820791T0001|56 63|diseases
P04820791T0001|66 73|children
P04820791T0001|39 48|conditions
P04824747T0000|44 52|compounds
P04824747T0000|33 40|potatoes
P04824747T0000|19 22|rats
P04824747T0000|0 16|Nonteratogenicity
P04826272T0074|0 2|VII
P04828587T0000|0 8|Isolation
P04828587T0000|38 42|virus
P04828587T0000|11 13|tha
P04828587T0000|44 50|strain T
P04837183T0000|0 11|Observations
P04837183T0000|46 57|hypergravity
P04837183T0000|24 27|rats
P04837183T0000|14 21|saccules
P04839176T0001|0 5|Effect
P04839176T0001|36 57|blood coagulation system
P04839176T0001|23 30|SHF field
P04843031T0000|42 45|sera
P04843031T0000|67 74|patients
P04843031T0000|11 39|galactosyltransferase activity
P04843031T0000|85 92|fibrosis
P04843031T0000|56 63|children
P04843031T0000|3 8|levels
P04852635T0000|0 3|Lack
P04852635T0000|17 42|appetite stimulant pizotifen
P04852635T0000|6 11|effect
P04852635T0000|55 64|absorption
P04852635T0000|44 45|BC
P04852635T0000|67 87|isonicotinylhydrazine
P04863895T0000|0 11|Relationship
P04863895T0000|92 98|poultry
P04863895T0000|78 84|disease
P04863895T0000|24 30|lesions
P04863895T0000|49 57|serotypes
P04863895T0000|86 88|CRD
P04871589T0001|27 35|ankylosis
P04871589T0001|7 14|solution
P04871589T0001|64 67|flap
P04871589T0001|17 21|elbow
P04878680T0000|0 6|Effects
P04878680T0000|17 25|radiation
P04878680T0000|49 58|oropharynx
P04878680T0000|60 66|results
P04878680T0000|40 45|cavity
P04878680T0000|70 75|survey
P04884060T0000|28 51|Pomeranian Medical Academy
P04884060T0000|3 22|Twentieth Anniversary
P04890336T0001|29 44|Wassermann reagin
P04890336T0001|63 76|appearance time
P04890336T0001|91 103|FTA antibodies
P04890336T0001|48 57|comparison
P04890336T0001|84 87|RPCF
P04890336T0001|20 26|pattern
P04909355T0000|15 29|Actinomycetales
P04911925T0001|0 31|Electrocardiographic QRS complexes
P04911925T0001|54 60|QRS loop
P04919613T0001|0 4|Study
P04919613T0001|18 31|autoantibodies
P04919613T0001|34 58|immunofluorescence technic
P04919613T0001|61 76|collagen diseases
P04921762T0000|7 18|preservation
P04925617T0000|6 8|bar
P04941419T0000|0 24|Yusuf Dawood Docrat L.R.C.P.
P04941951T0000|0 2|Dr.
P04942414T0000|30 43|5-fluorouracil
P04942414T0000|3 12|metabolism
P04942414T0000|16 27|pharmacology
P04947347T0000|14 17|rats
P04947347T0000|41 58|homograft rejection
P04947347T0000|24 35|tumour growth
P04947347T0000|0 11|Spleen weight
P04948325T0000|0 8|Isolation
P04948325T0000|61 66|effect
P04948325T0000|11 17|Proteus
P04948325T0000|26 30|MC-63
P04948325T0000|35 43|carcinoma
P04948325T0000|89 104|Ehrlich carcinoma
P04948325T0000|69 82|Crocker sarcoma
P04959816T0000|19 27|detection
P04959816T0000|13 17|fluid
P04959816T0000|34 42|component
P04967824T0000|0 6|Effects
P04967824T0000|38 53|melanin synthesis
P04967824T0000|31 35|cycle
P04967824T0000|9 19|temperature
P04967824T0000|59 62|newt
P04970131T0001|43 47|study
P04970131T0001|61 69|embolisms
P04970131T0001|4 20|reflexions apropos
P04970918T0069|0 9|LA-3848-MS
P04973523T0000|33 40|antigens
P04973523T0000|14 20|studies
P04975676T0000|58 76|allotransplantation
P04975676T0000|26 36|alterations
P04975676T0000|47 52|baboon
P04976988T0000|0 12|Heterogeneity
P04976988T0000|20 31|serum albumin
P04989251T0000|0 7|Analysis
P04989251T0000|10 24|corticosteroids
P04990556T0000|0 11|Reactivities
P04990556T0000|34 41|globulin
P04990556T0000|14 18|horse
P04992478T0000|0 16|Plasma histaminase
P04992478T0000|38 43|asthma
P04992478T0000|19 26|patients
P04992478T0000|50 55|effect
P04992478T0000|70 83|administration
P04999086T0001|87 93|monkeys
P04999086T0001|46 53|analyzer
P04999086T0001|12 16|study
P04999086T0001|30 32|end
P04999086T0001|69 79|ontogenesis
P04999086T0001|97 99|man
P05000171T0000|27 38|distribution
P05000171T0000|18 21|flow
P05000171T0000|92 112|toad bladder epithelium
P05000171T0000|84 89|spaces
P05000171T0000|3 8|effect
P05000171T0000|41 61|horseradish peroxidase
P05005311T0000|0 13|Immunogenicity
P05005311T0000|54 59|levels
P05005311T0000|23 34|mycobacteria
P05005311T0000|94 100|species
P05005311T0000|62 77|cross-protection
P05012220T0000|31 45|proctocolectomy
P05012220T0000|53 61|ileostomy
P05012220T0000|8 17|experience
P05015678T0000|43 50|chlorins
P05015678T0000|17 27|tautomerism
P05015678T0000|30 39|porphyrins
P05020660T0000|0 6|Factors
P05020660T0000|45 58|chlorpromazine
P05020660T0000|19 28|inhibition
P05020660T0000|31 42|phagocytosis
P05021912T0000|16 26|sensitivity
P05021912T0000|67 75|pigeon eye
P05025918T0000|0 10|Angiography
P05025918T0000|23 30|bone cyst
P05027295T0034|0 13|Cholinesterase
P05027799T0000|0 16|Sodium restriction
P05027799T0000|26 32|failure
P05028628T0001|73 80|arteries
P05028628T0001|23 34|examinations
P05028628T0001|37 52|occlusion disease
P05031074T0001|0 16|Serum lipid changes
P05031074T0001|23 31|pregnancy
P05031074T0001|41 61|calcium administration
P05031659T0000|21 31|candidiasis
P05031659T0000|10 18|treatment
P05031659T0000|36 49|transfer factor
P05034373T0000|56 66|requirement
P05034373T0000|24 50|function oxidase enzyme system
P05034373T0000|83 85|rat
P05034373T0000|9 12|role
P05034373T0000|70 77|selenium
P05045351T0000|20 24|apnea
P05045351T0000|34 40|infants
P05045351T0000|8 16|breathing
P05049711T0000|7 19|session report
P05049711T0000|35 43|screening
P05060388T0000|17 23|studies
P05060388T0000|36 41|tumors
P05060388T0000|47 51|ovary
P05065548T0075|19 37|Dryopteris polylepis
P05065548T0075|5 16|constituents
P05066316T0001|43 53|composition
P05066316T0001|31 39|materials
P05066316T0001|21 25|ratio
P05066316T0001|80 95|aluminosilicates
P05066316T0001|56 63|products
P05066316T0001|69 77|synthesis
P05066316T0001|0 7|Relation
P05068271T0000|0 8|Influence
P05068271T0000|11 14|diet
P05068271T0000|24 35|VMA excretion
P05075857T0000|45 54|transients
P05075857T0000|61 71|sweep speeds
P05075857T0000|0 28|Oscilloscope triggering circuit
P05081814T0000|0 10|Derivatives
P05081814T0000|22 26|acids
P05083872T0000|59 67|audiology
P05083872T0000|11 19|education
P05083872T0000|3 8|status
P05083872T0000|23 38|training programs
P05083872T0000|41 55|speech pathology
P05087496T0000|8 15|arteries
P05091970T0000|9 14|agents
P05093030T0001|59 65|methods
P05093030T0001|68 93|medium-tension intophoresis
P05093030T0001|41 45|urine
P05093030T0001|30 38|compounds
P05093030T0001|97 119|partition chromatography
P05093030T0001|0 9|Separation
P05095988T0001|37 50|system injuries
P05095988T0001|12 20|treatment
P05101762T0000|0 12|Spasmus nutans
P05101762T0000|15 22|syndrome
P05110049T0001|29 35|therapy
P05110049T0001|38 48|scleroderma
P05110049T0001|3 6|data
P05114515T0000|15 27|enzyme release
P05114515T0000|49 53|drugs
P05114515T0000|34 46|normalization
P05114515T0000|72 84|polyarthritis
P05119546T0001|0 8|Treatment
P05119546T0001|18 26|neoplasms
P05120197T0000|26 29|pigs
P05120197T0000|12 23|pancreatitis
P05123884T0000|21 42|4-chlorophenoxyacetate
P05123884T0000|9 18|metabolism
P05124707T0001|0 7|Dynamics
P05124707T0001|10 21|hospital stay
P05124707T0001|30 42|ulcer patients
P05124972T0042|0 1|I.
P05128149T0001|0 16|Surgical treatment
P05128149T0001|46 52|infarct
P05128149T0001|29 33|scars
P05132558T0000|16 23|caffeine
P05132558T0000|25 36|theophylline
P05132558T0000|55 80|monoamine oxidase inhibitors
P05132558T0000|40 50|theobromine
P05132558T0000|3 13|interaction
P05133723T0000|0 5|Effect
P05133723T0000|20 34|gluconeogenesis
P05133723T0000|8 17|phenformin
P05133723T0000|45 52|rat liver
P05135168T0000|0 11|New alkaloids
P05135168T0000|22 42|Erythrophleum ivorense
P05135168T0000|16 19|bark
P05138738T0001|1 4|case
P05138738T0001|7 21|M hemoglobinosis
P05145925T0000|73 83|spleen cells
P05145925T0000|14 19|nature
P05145925T0000|54 62|potential
P05152314T0001|10 21|oscillations
P05152314T0001|25 44|gas dilution indicator
P05154132T0000|28 35|nitrogen
P05154132T0000|61 64|calf
P05154132T0000|19 25|sources
P05154132T0000|38 42|diets
P05154132T0000|3 7|value
P05162342T0001|17 25|childhood
P05162342T0001|9 14|tumors
P05170106T0034|105 111|trypsin
P05170106T0034|129 130|NF
P05170106T0034|62 79|enzyme preparations
P05170106T0034|20 29|inspection
P05170106T0034|114 118|means
P05170106T0034|0 6|Results
P05170106T0034|133 139|methods
P05170106T0034|90 101|chymotrypsin
P05172320T0001|0 6|Studies
P05172320T0001|53 61|reference
P05172320T0001|64 75|interdigital
P05172320T0001|34 39|prints
P05172320T0001|22 27|nature
P05172320T0001|79 86|triradii
P05172970T0001|3 9|problem
P05172970T0001|37 48|tuberculosis
P05172970T0001|12 22|disablement
P05172970T0001|77 83|history
P05172970T0001|64 71|analysis
P05172970T0001|89 93|cases
P05172970T0001|117 121|years
P05172970T0001|106 111|Gdansk
P05172970T0001|55 59|basis
P05174753T0001|13 22|dysostosis
P05177935T0001|0 8|Proposals
P05177935T0001|11 23|authorization
P05177935T0001|56 64|hospitals
P05177935T0001|35 40|nurses
P05177935T0001|28 32|group
P05203499T0001|91 96|spleen
P05203499T0001|53 63|description
P05203499T0001|98 107|comparison
P05203499T0001|82 87|kidney
P05203499T0001|69 80|thyroid gland
P05203499T0001|48 50|BSP
P05203499T0001|112 119|131-I-RB
P05203499T0001|19 31|scintillation
P05210791T0001|0 8|Pneumonia
P05210791T0001|11 18|children
P05253274T0001|0 11|Osteosarcoma
P05253274T0001|20 34|3,4-benzopyrene
P05274128T0001|41 46|tartar
P05274128T0001|26 38|galactosamine
P05274128T0001|12 22|glucosamine
P05274128T0001|3 9|content
P05274526T0000|0 6|Relapse
P05274526T0000|9 16|leukemia
P05274526T0000|31 39|remission
P05276380T0000|0 8|Influence
P05276380T0000|11 26|cigarette smoking
P05276380T0000|33 53|blood coagulation tests
P05284310T0000|13 20|fluoride
P05284310T0000|73 75|rat
P05284310T0000|35 47|plasma calcium
P05284310T0000|26 32|control
P05285978T0076|6 11|report
P05285978T0076|26 38|Cancer Society
P05299993T0000|0 11|Modification
P05299993T0000|25 35|Tetrahymena
P05299993T0000|71 79|mechanism
P05299993T0000|38 46|compounds
P05299993T0000|17 22|growth
P05303700T0066|0 11|SAM-TR-68-54
P05305671T0000|18 34|color deficiencies
P05305671T0000|6 15|discussion
P05308271T0000|0 2|BIM
P05309471T0000|0 7|Problems
P05309471T0000|49 65|influenza vaccines
P05309471T0000|40 46|content
P05309471T0000|13 25|determination
P05316745T0000|43 55|Singapore City
P05316745T0000|13 14|L.
P05316745T0000|19 33|Aedes albopictus
P05316745T0000|35 39|Skuse
P05316745T0000|0 11|Aedes aegypti
P05322558T0000|0 16|Homograft response
P05322558T0000|83 86|mice
P05322558T0000|20 42|hemagglutinin production
P05322747T0034|27 34|overload
P05322747T0034|40 50|tolbutamide
P05322747T0034|54 63|tolazamide
P05322747T0034|11 15|study
P05322747T0034|83 90|subjects
P05340801T0000|0 9|Mycotoxins
P05340801T0000|20 24|foods
P05344097T0000|59 72|Vibrio cholerae
P05344097T0000|25 56|skin permeability factor production
P05344097T0000|0 6|Factors
P05353667T0000|29 39|micturition
P05353667T0000|6 23|cord representation
P05356107T0001|59 62|dogs
P05356107T0001|10 15|action
P05356107T0001|45 56|tritium oxide
P05356107T0001|19 26|kinetics
P05356107T0001|32 42|elimination
P05357390T0001|0 3|Auto
P05357390T0001|8 14|isotopy
P05357390T0001|20 30|conjunctiva
P05359464T0000|0 7|Pitfalls
P05359464T0000|13 15|use
P05359464T0000|18 45|chromosome aberration analysis
P05359464T0000|59 76|radiation dosimetry
P05362866T0000|0 13|Renin secretion
P05362866T0000|39 50|hypertension
P05363816T0001|3 6|need
P05363816T0001|48 51|list
P05363816T0001|34 42|expertise
P05363816T0001|81 87|actions
P05364951T0001|0 13|Histopathology
P05364951T0001|17 28|pathogenesis
P05364951T0001|44 50|viroses
P05368978T0000|0 9|CNS effects
P05368978T0000|17 27|anesthetics
P05368978T0000|60 74|amine mechanisms
P05372511T0105|0 16|Diethylene benzene
P05379901T0000|14 26|flood channels
P05379901T0000|0 11|Midge control
P05388567T0000|59 64|muscle
P05388567T0000|25 37|aminophylline
P05388567T0000|12 21|taloximine
P05388567T0000|3 9|effects
P05389125T0000|44 47|mice
P05389125T0000|14 22|behaviour
P05394352T0000|0 11|Genitography
P05394352T0000|25 30|states
P05394461T0001|0 12|Tolerance test
P05394461T0001|22 38|animal experiments
P05394461T0001|15 16|HB
P05410590T0000|26 35|prevention
P05410590T0000|3 6|role
P05410590T0000|38 58|bladder tumor formation
P05410590T0000|17 20|acid
P05410641T0000|14 24|Venturi mask
P05410641T0000|38 50|airway disease
P05410641T0000|6 12|percent
P05412122T0000|3 8|Methyl
P05412122T0000|57 58|,7
P05412122T0000|22 40|8-phenyl derivatives
P05412122T0000|10 17|8-methyl
P05412122T0000|60 72|benzomorphans
P05412687T0000|71 83|tract neurones
P05412687T0000|10 17|invasion
P05412687T0000|40 59|collateral inhibition
P05412687T0000|20 27|impulses
P05413428T0000|3 14|distribution
P05413428T0000|64 79|combat casualties
P05413428T0000|36 45|hemorrhage
P05413428T0000|49 61|resuscitation
P05413428T0000|17 26|body fluids
P05414186T0001|30 40|Netherlands
P05414186T0001|8 24|Hong Kong influenza
P05417431T0001|30 33|cent
P05417431T0001|5 14|disagnosis
P05417431T0001|39 46|patients
P05417431T0001|17 22|cancer
P05421537T0001|0 11|Difficulties
P05421537T0001|30 44|sputum viscosity
P05424220T0001|0 17|Lipid concentration
P05424220T0001|21 34|lipase activity
P05424220T0001|40 48|epiphysis
P05424220T0001|80 83|food
P05424220T0001|67 70|rats
P05424220T0001|97 109|sodium content
P05425195T0001|0 7|Behavior
P05425195T0001|10 34|aspartate aminotransferase
P05425195T0001|115 131|radiation syndrome
P05425195T0001|73 74|EC
P05425195T0001|36 37|EC
P05425195T0001|49 71|alanine aminotransferase
P05425195T0001|146 162|body X-irradiation
P05425195T0001|85 92|rat serum
P05425195T0001|102 107|course
P05437405T0000|77 89|salt retention
P05437405T0000|10 16|forearm
P05437405T0000|27 41|dilator capacity
P05437405T0000|92 94|man
P05441564T0001|0 6|Studies
P05441564T0001|38 42|virus
P05441564T0001|49 55|mutants
P05441564T0001|12 24|pathogenicity
P05441564T0001|33 36|HILL
P05441564T0001|59 70|suckling mice
P05441564T0001|27 30|ECHO
P05445187T0000|60 64|water
P05445187T0000|68 78|heat balance
P05445187T0000|43 50|passages
P05445187T0000|52 57|effect
P05445187T0000|15 26|heat exchange
P05451324T0000|0 10|Calibration
P05451324T0000|34 40|content
P05451324T0000|51 53|Po2
P05451324T0000|27 31|blood
P05451324T0000|15 24|correction
P05451324T0000|57 68|CO saturation
P05456002T0000|13 26|doctor shortage
P05456002T0000|0 6|Mae West
P05460466T0001|0 10|Elimination
P05460466T0001|55 70|drug preparations
P05460466T0001|13 29|gamma-irradiation
P05460466T0001|37 45|oxidation
P05463837T0023|43 46|acid
P05463837T0023|26 28|C-2
P05463837T0023|11 23|configuration
P05466177T0001|20 31|actinomycin D
P05466177T0001|11 17|effects
P05466177T0001|34 37|rats
P05471866T0000|3 34|plasma growth hormone concentration
P05471866T0000|46 49|lamb
P05472485T0000|31 37|rodents
P05472485T0000|7 28|cochlear response curves
P05474466T0001|55 60|factor
P05474466T0001|38 42|assay
P05474466T0001|4 23|hemagglutination test
P05488121T0000|0 14|CO2 assimilation
P05488121T0000|17 28|chloroplasts
P05488121T0000|42 52|filter paper
P05492285T0000|3 9|biology
P05492285T0000|12 30|Hyostrongylus ruidus
P05496619T0000|17 45|air pollution control activities
P05496619T0000|7 14|profiles
P05497793T0000|0 6|Effects
P05497793T0000|52 59|activity
P05497793T0000|110 121|environments
P05497793T0000|90 93|rats
P05497793T0000|16 35|metaraminol treatment
P05500957T0001|16 24|clopamide
P05500957T0001|91 99|pregnancy
P05500957T0001|53 61|treatment
P05500957T0001|38 46|Brinedine
P05500957T0001|3 13|association
P05500957T0001|80 88|syndromes
P05500957T0001|28 36|hydergine
P05501347T0001|57 65|rat kidney
P05501347T0001|44 51|function
P05501347T0001|75 82|ischemia
P05501347T0001|31 40|metabolism
P05501347T0001|3 8|effect
P05501347T0001|14 28|dosage radiation
P05502054T0000|0 7|Leukemia
P05502054T0000|10 14|twins
P05502054T0000|26 31|review
P05502054T0000|42 46|cases
P05525652T0064|11 16|report
P05529283T0000|0 11|Quantitation
P05529283T0000|39 44|health
P05529283T0000|22 24|IgA
P05529283T0000|48 54|disease
P05529283T0000|32 36|serum
P05532854T0001|16 29|manifestations
P05532854T0001|40 48|sclerosis
P05533214T0001|0 15|Iodine metabolism
P05533214T0001|25 35|thyroiditis
P05536803T0001|71 80|furosemide
P05536803T0001|63 68|effect
P05536803T0001|5 13|body water
P05536803T0001|45 49|space
P05536803T0001|15 28|rhodanide space
P05544291T0031|0 1|V.
P05552149T0000|0 2|18F
P05552149T0000|26 30|study
P05552149T0000|6 20|85Sr scintimetry
P05552149T0000|40 52|arthropathies
P05552642T0000|0 10|Propagation
P05552642T0000|69 72|rats
P05552642T0000|56 66|trophoblast
P05552642T0000|14 30|hormone production
P05553261T0000|0 5|Health
P05553261T0000|20 28|reticulum
P05555149T0001|46 55|S-S-groups
P05555149T0001|40 41|SH
P05555149T0001|21 26|method
P05556977T0001|0 12|Morphogenesis
P05556977T0001|45 56|regeneration
P05556977T0001|62 86|phasmid Carausius morosus Br
P05556977T0001|18 27|trochanter
P05560428T0001|46 50|sleep
P05560428T0001|54 64|wakefulness
P05560428T0001|27 36|expression
P05560428T0001|67 74|reptiles
P05567721T0000|15 29|thromboplastins
P05567721T0000|32 50|factor VII deficiency
P05567721T0000|0 12|Sensitivities
P05572662T0000|0 6|Central
P05572662T0000|13 20|catheter
P05572662T0000|49 65|electrocardiogram
P05574818T0000|28 30|use
P05574818T0000|102 107|muscle
P05574818T0000|36 40|study
P05574818T0000|3 5|Lab
P05574818T0000|7 24|computer programmes
P05574818T0000|66 91|contractile characteristics
P05593469T0001|14 21|injuries
P05594277T0051|85 90|medium
P05594277T0051|33 45|Jensen sarcoma
P05594277T0051|17 25|P32 uptake
P05594277T0051|63 70|peroxide
P05594277T0051|3 14|modification
P05595036T0001|0 7|Students
P05595036T0001|35 43|disorders
P05595036T0001|9 15|parents
P05595036T0001|17 24|teachers
P05621339T0001|28 43|Cs137 irradiation
P05621339T0001|21 25|doses
P05627251T0000|46 50|sleep
P05627251T0000|8 13|shifts
P05627251T0000|21 34|skin potentials
P05642051T0000|17 36|department management
P05671267T0000|51 56|pyrido
P05671267T0000|64 70|azepine
P05671267T0000|30 45|dihydro-5H-benzo
P05671267T0000|3 21|Dimethylaminopropyl
P05672903T0001|0 21|Osteogenesis imperfecta
P05683363T0001|0 12|Investigation
P05683363T0001|65 78|analysis method
P05683363T0001|18 25|exchange
P05683363T0001|49 52|rats
P05683363T0001|28 31|Ca45
P05683809T0000|0 5|Effect
P05683809T0000|81 92|blood vessels
P05683809T0000|35 39|drugs
P05683809T0000|110 116|studies
P05683809T0000|45 72|surface charge characteristics
P05684081T0001|0 11|Measurements
P05684081T0001|14 21|activity
P05684081T0001|64 77|osimeter VA-J18
P05684081T0001|44 58|chamber VA-K-254
P05689427T0052|3 36|N-Alkyl-N-2-chloroethylaminomethyl
P05689427T0052|59 59|b
P05689427T0052|69 82|hydrochlorides
P05692759T0001|0 10|Nephrectomy
P05692759T0001|20 25|cattle
P05693602T0001|0 9|Evaluation
P05693602T0001|21 37|blood cell counters
P05693605T0001|15 27|transaminases
P05693605T0001|34 45|autoanalyzer
P05693605T0001|0 12|Determination
P05715613T0000|0 6|Sterols
P05715613T0000|9 14|pollen
P05718386T0001|18 25|skin flap
P05718386T0001|31 42|complication
P05718386T0001|48 56|treatment
P05718386T0001|7 10|cyst
P05718386T0001|68 73|hernia
P05718500T0001|29 35|decidua
P05718500T0001|53 61|pregnancy
P05718500T0001|12 23|observations
P05718500T0001|47 50|half
P05718994T0000|49 59|coarctation
P05718994T0000|71 75|aorta
P05718994T0000|11 25|fibro-elastosis
P05718994T0000|33 44|incompetence
P05719031T0000|0 6|Studies
P05719031T0000|20 32|size reduction
P05719031T0000|12 17|method
P05719031T0000|44 52|compounds
P05719746T0001|0 7|Children
P05719746T0001|21 26|vision
P05722341T0000|0 13|Identification
P05722341T0000|47 59|disaccharides
P05722341T0000|79 92|chromatography
P05722341T0000|17 26|estimation
P05722341T0000|29 43|monosaccharides
P05722341T0000|62 66|urine
P05725509T0000|0 7|Steroids
P05725509T0000|10 17|germfree
P05725509T0000|33 36|rats
P05727222T0000|3 9|effects
P05727222T0000|43 59|oxygen consumption
P05727222T0000|62 76|Callionymus lyra
P05727222T0000|33 37|pumps
P05732641T0001|29 42|mosquito larvae
P05732641T0001|8 21|sevine activity
P05732641T0001|0 5|Trials
P05733952T0001|75 81|culture
P05733952T0001|27 35|integrity
P05733952T0001|3 14|significance
P05733952T0001|46 51|tissue
P05733952T0001|55 72|antibody production
P05733953T0001|28 32|field
P05733953T0001|3 8|effect
P05733953T0001|48 55|activity
P05733953T0001|58 66|Paramecia
P05734847T0000|0 6|Studies
P05734847T0000|24 46|Glossina morsitans colony
P05734847T0000|49 54|Lisbon
P05740389T0001|0 8|Relations
P05740389T0001|26 35|mechanisms
P05740389T0001|48 54|effects
P05742879T0000|0 14|Transformations
P05742879T0000|20 33|morphine series
P05749438T0001|71 76|CI-581
P05749438T0001|26 39|o-chlorophenyl
P05749438T0001|12 22|anesthetics
P05749438T0001|44 69|methyl-amino cyclohexane HCL
P05750950T0001|0 5|Estrus
P05750950T0001|19 27|abilities
P05750950T0001|49 52|rats
P05751819T0000|70 77|calvings
P05751819T0000|12 17|season
P05751819T0000|80 90|Hariana cows
P05751819T0000|21 28|sequence
P05751819T0000|51 54|male
P05751819T0000|31 37|calving
P05751819T0000|3 9|bearing
P05751819T0000|40 48|frequency
P05758469T0001|0 18|Hemodynamics changes
P05758469T0001|21 23|man
P05758469T0001|30 35|flight
P05760665T0000|0 15|Caries prevention
P05760665T0000|27 32|office
P05763287T0063|0 1|I.
P05763347T0000|62 72|propranolol
P05763347T0000|22 31|inhibition
P05763347T0000|8 19|applications
P05763347T0000|49 57|receptors
P05769307T0000|0 15|Automatic view box
P05774062T0000|0 10|Measurement
P05774062T0000|35 46|conductivity
P05774062T0000|20 32|acid secretion
P05779953T0000|42 44|FSH
P05779953T0000|8 17|castration
P05779953T0000|32 38|serum LH
P05779953T0000|70 73|rats
P05779953T0000|0 5|Effect
P05781385T0000|89 103|Nocardia species
P05781385T0000|20 48|phenolphthalein sulphatase test
P05781385T0000|55 69|differentiation
P05781385T0000|3 14|significance
P05781385T0000|73 86|identification
P05782943T0001|0 11|Relationship
P05782943T0001|50 53|skin
P05782943T0001|25 44|sarcoidosis granuloma
P05782943T0001|14 22|mast cells
P05787318T0000|29 37|Atromid-S
P05787318T0000|41 51|serum lipids
P05787318T0000|9 15|effects
P05787318T0000|54 56|man
P05787318T0000|18 27|clofibrate
P05789870T0001|46 63|hyperbilirubinemia
P05789870T0001|0 38|Phosphate glucose dehydrogenase deficiency
P05792868T0000|0 33|Evidence forthe electroosmosis theory
P05792868T0000|36 44|transport
P05792868T0000|50 55|phloem
P05792911T0000|0 6|Effects
P05792911T0000|92 99|subjects
P05792911T0000|42 58|airway conductance
P05792911T0000|24 39|receptor blockade
P05792911T0000|62 71|lung volume
P05794247T0000|0 5|Effect
P05794247T0000|34 55|serum lipoprotein lipase
P05794247T0000|61 65|liver
P05794247T0000|20 31|inactivation
P05794247T0000|8 14|heparin
P05794247T0000|82 85|dogs
P05796272T0000|12 34|chlorpromazine cataracts
P05797287T0069|0 1|I.
P05798063T0000|0 9|Specialist
P05798063T0000|28 36|prototype
P05798063T0000|12 25|family practice
P05798063T0000|40 45|doctor
P05799686T0001|103 115|incorporation
P05799686T0001|82 84|aid
P05799686T0001|25 36|chemotherapy
P05799686T0001|66 74|carcinoma
P05799686T0001|3 13|possibility
P05799686T0001|124 134|idoxuridine
P05799686T0001|87 99|cytodiagnosis
P05805644T0001|30 41|distribution
P05805644T0001|52 56|224Ra
P05805644T0001|107 119|colloidal ThO2
P05805644T0001|92 104|incorporation
P05805644T0001|62 64|RES
P05805644T0001|44 48|228Ra
P05805644T0001|79 86|skeleton
P05805644T0001|0 8|Variation
P05806615T0001|86 90|value
P05806615T0001|9 19|degradation
P05806615T0001|64 69|stages
P05806615T0001|42 46|study
P05806615T0001|110 115|solute
P05806615T0001|22 40|adrenaline solutions
P05806615T0001|97 103|control
P05806936T0000|0 9|Absorption
P05806936T0000|12 23|electrolytes
P05806936T0000|38 42|cases
P05806936T0000|31 35|colon
P05806936T0000|74 81|subjects
P05806936T0000|55 61|colitis
P05807222T0052|0 11|Ion injection
P05810259T0001|0 15|Polyvinyl alcohol
P05810259T0001|19 34|solution mediator
P05819249T0000|0 5|Mining
P05819249T0000|19 25|iron ore
P05822499T0034|14 25|digiprogenin
P05822499T0034|3 11|structure
P05823624T0031|3 6|need
P05823624T0031|17 24|hospital
P05826818T0098|0 1|I.
P05833022T0001|70 77|epilepsy
P05833022T0001|47 57|brain tissue
P05833022T0001|16 22|changes
P05833022T0001|5 13|character
P05833022T0001|28 41|enzyme activity
P05836483T0000|14 21|teratoma
P05836483T0000|24 28|liver
P05836483T0000|31 39|childhood
P05837169T0001|0 13|Methoxyflurane
P05837169T0001|22 29|function
P05839844T0000|0 13|Histochemistry
P05839844T0000|63 73|Aflatoxin B1
P05839844T0000|42 53|liver lesions
P05839844T0000|76 84|ducklings
P05839844T0000|17 34|electron microscopy
P05847772T0001|50 56|surgery
P05847772T0001|24 29|ureter
P05847772T0001|10 18|disorders
P05850652T0001|0 4|Study
P05850652T0001|92 94|rat
P05850652T0001|53 66|I-131-triolein
P05850652T0001|10 20|alterations
P05850652T0001|33 42|absorption
P05850652T0001|78 81|body
P05850652T0001|46 50|means
P05857301T0000|0 7|Chemical
P05857301T0000|65 70|routes
P05857301T0000|49 53|CC1-4
P05857301T0000|73 86|administration
P05857301T0000|32 40|responses
P05857301T0000|43 46|rats
P05858571T0000|18 24|1,3-bis
P05858571T0000|26 38|2-chloroethyl
P05858571T0000|8 13|trials
P05858571T0000|43 53|nitrosourea
P05858571T0000|55 64|NSC-409962
P05859016T0000|0 24|Hydroxypropyl methacrylate
P05859016T0000|44 58|embedding medium
P05859016T0000|62 79|electron microscopy
P05879595T0094|0 9|Statistics
P05879595T0094|20 24|years
P05881833T0001|53 63|Lower Saxony
P05881833T0001|22 29|leucosis
P05881833T0001|36 42|control
P05881833T0001|5 13|diagnosis
P05884183T0001|0 9|Experience
P05884183T0001|83 90|cultures
P05884183T0001|98 100|use
P05884183T0001|114 119|method
P05884183T0001|30 52|agglutination properties
P05884183T0001|17 27|restoration
P05884183T0001|103 111|Rzhaninov
P05890093T0000|0 4|Study
P05890093T0000|53 59|hypoxia
P05890093T0000|23 32|mouse fetus
P05890093T0000|104 116|mother animals
P05890093T0000|82 99|hypervitaminosis-A
P05890093T0000|7 17|micromelias
P05890093T0000|61 66|trypan
P05890093T0000|41 51|x-radiation
P05890093T0000|123 131|pregnancy
P05890093T0000|71 79|injection
P05890351T0001|30 35|wealth
P05890351T0001|5 20|antitetanus serum
P05893495T0001|0 6|Studies
P05893495T0001|26 34|infection
P05893495T0001|37 43|rabbits
P05896996T0001|14 25|aminoketones
P05896996T0001|39 41|age
P05896996T0001|2 11|catabolism
P05901778T0000|31 40|deposition
P05901778T0000|43 46|mice
P05901778T0000|18 25|patterns
P05901778T0000|3 8|effect
P05902458T0001|0 10|Naphthalene
P05902458T0001|43 52|toxicology
P05902458T0001|14 32|paradichlorobenzene
P05909034T0000|0 6|Studies
P05909034T0000|17 28|preparations
P05917315T0026|1 10|case report
P05917315T0026|36 40|study
P05919308T0001|46 71|monoamine oxidase inhibitors
P05919308T0001|0 11|Interactions
P05919308T0001|19 29|adrenergics
P05919308T0001|31 42|adrenolytics
P05930797T0000|27 45|isoprecipitin system
P05930797T0000|7 13|studies
P05930797T0000|47 62|Australia antigen
P05933228T0000|31 44|neurosecretion
P05933228T0000|10 16|rhythms
P05933228T0000|19 28|indicators
P05938720T0000|0 4|Story
P05938720T0000|8 15|hospital
P05938720T0000|29 54|employee orientation program
P05939748T0000|15 22|Pap smear
P05942953T0049|0 1|I.
P05947377T0001|58 73|growth deficiency
P05947377T0001|26 31|uptake
P05947377T0001|37 43|thyroid
P05947377T0001|46 53|children
P05947377T0001|9 18|test iodine
P05947377T0001|20 24|I-132
P05949971T0000|0 10|Persistence
P05949971T0000|13 21|toxaphene
P05949971T0000|31 35|lakes
P05959588T0000|0 6|Studies
P05959588T0000|24 38|virus infections
P05959588T0000|9 22|Coxsackie B Type
P05960999T0001|0 4|Value
P05960999T0001|155 159|serum
P05960999T0001|115 125|capillaries
P05960999T0001|81 87|protein
P05960999T0001|10 15|method
P05960999T0001|129 142|slide latex test
P05960999T0001|45 59|polysaccharide C
P05960999T0001|18 40|passive hemagglutination
P05960999T0001|100 112|precipitation
P05967610T0000|45 63|noradrenaline uptake
P05967610T0000|80 87|membrane
P05967610T0000|66 68|cat
P05967610T0000|10 22|nerve function
P05967610T0000|93 110|reserpine treatment
P05967610T0000|24 41|noradrenaline level
P05969185T0001|0 9|Concussion
P05969185T0001|21 24|cord
P05982700T0000|0 4|Study
P05982700T0000|10 20|evagination
P05982700T0000|23 43|Cysticercus pisiformis
P05985275T0000|36 47|acorn extract
P05985275T0000|13 21|substance
P05992157T0001|18 38|Achromobacter puntatum
P05992157T0001|46 52|blooded
P05992157T0001|67 73|animals
P05992157T0001|3 15|pathogenicity
P05994421T0045|0 12|Consanguinity
P05994421T0045|44 49|region
P05994421T0045|52 56|Nunoa
P05994421T0045|30 38|marriages
P05994421T0045|16 24|migration
P05994421T0045|58 65|Santiago
P05995140T0001|40 51|glucose level
P05995140T0001|54 59|tumors
P05995140T0001|5 10|amount
P05995140T0001|14 25|significance
P05999607T0001|0 6|Studies
P05999607T0001|9 19|lipogenesis
P05999607T0001|53 55|rat
P05999607T0001|30 39|precursors
P06012827T0000|15 21|studies
P06012827T0000|41 46|system
P06012827T0000|74 77|rats
P06027841T0000|13 17|249Bk
P06027841T0000|48 63|emission spectrum
P06027841T0000|25 42|hyperfine structure
P06027841T0000|7 10|spin
P06035001T0000|33 42|guinea pigs
P06035001T0000|52 61|injections
P06035001T0000|21 30|resorption
P06035001T0000|64 73|trypan blue
P06035001T0000|7 18|observations
P06048505T0000|0 10|Derivatives
P06048505T0000|13 20|fluorene
P06051644T0000|32 44|determination
P06051644T0000|47 56|creatinine
P06051644T0000|12 17|method
P06051644T0000|6 9|Slot
P06054411T0000|29 45|gas chromatography
P06054411T0000|51 56|series
P06054411T0000|59 76|combination columns
P06054411T0000|19 26|steroids
P06054411T0000|0 16|Retention behavior
P06065507T0000|17 27|hypertrophy
P06065507T0000|40 43|rats
P06070204T0025|0 2|XXI
P06072512T0000|31 36|action
P06072512T0000|39 42|urea
P06072512T0000|7 16|evaluation
P06073427T0001|61 65|blood
P06073427T0001|69 73|urine
P06073427T0001|15 30|characteriaztion
P06073427T0001|76 82|rabbits
P06073427T0001|46 55|interferon
P06074093T0001|0 3|Iron
P06074093T0001|25 33|pregnancy
P06074093T0001|7 22|folate deficiency
P06074640T0001|0 8|Symposium
P06074640T0001|26 41|encephalopathies
P06084279A0218|17 24|patients
P06084279A0218|29 32|rise
P06084279A0218|64 67|ERCP
P06084279A0218|43 54|serum amylase
P06084810A0169|58 61|cDNA
P06084810A0169|100 106|library
P06084810A0169|18 21|mRNA
P06084810A0169|79 80|D.
P06084810A0169|27 41|polysome complex
P06084864T0001|16 32|alpha fetoproteins
P06084864T0001|53 61|prognosis
P06084864T0001|36 46|oligoamnios
P06085839A0721|18 28|possibility
P06085839A0721|63 70|etiology
P06088722A0171|0 6|Courses
P06088722A0171|40 55|myelosuppression
P06088722A0171|30 37|recovery
P06089575A0464|59 67|cGMP level
P06089575A0464|101 103|min
P06089575A0464|78 87|fmol/gland
P06089575A0464|134 136|min
P06089575A0464|126 130|level
P06089575A0464|0 10|Stimulation
P06089575A0464|48 56|elevation
P06089575A0464|15 17|MCh
P06090369A0000|59 65|studies
P06090369A0000|21 28|patients
P06090369A0000|41 47|WR-2721
P06090369A0000|50 54|Phase
P06090458A0407|86 91|TK gene
P06090458A0407|107 117|orientation
P06090458A0407|3 23|PEPCK promoter fragment
P06090458A0407|68 80|transcription
P06090458A0407|54 64|orientation
P06091914A0000|99 104|genome
P06091914A0000|62 69|provirus
P06091914A0000|26 30|mouse
P06091914A0000|38 47|tumor virus
P06091914A0000|49 52|MMTV
P06091914A0000|79 84|region
P06091914A0000|11 16|tumors
P06091914A0000|158 162|int-1
P06091914A0000|144 151|oncogene
P06091914A0000|115 124|expression
P06092048A1111|13 20|asbestos
P06092048A1111|54 61|fibrosis
P06092048A1111|38 43|burden
P06092048A1111|7 11|cases
P06092588T0000|0 14|Hepatitis B virus
P06092588T0000|18 25|hepatoma
P06093354A0000|43 55|leukemia virus
P06093354A0000|57 60|MuLV
P06093354A0000|130 143|Balb/c mouse DNA
P06093354A0000|121 127|library
P06093354A0000|70 81|DNA sequences
P06093354A0000|16 24|DNA clones
P06093363A0612|0 2|USA
P06093363A0612|36 46|% identities
P06093363A0612|22 29|proteins
P06093363A0612|54 70|amino acid sequence
P06093363A0612|76 84|alignment
P06093363A0612|97 100|gaps
P06094591A0000|171 185|carboxy terminus
P06094591A0000|48 51|gp85
P06094591A0000|111 116|domain
P06094591A0000|76 83|membrane
P06094591A0000|188 191|gp37
P06094591A0000|26 41|Rous sarcoma virus
P06094591A0000|95 98|acid
P06094591A0000|55 58|gp37
P06094591A0000|144 147|acid
P06094591A0000|160 165|domain
P06094591A0000|3 23|envelope glycoproteins
P06094591A0000|43 45|RSV
P06095372A0435|27 30|dose
P06095372A0435|36 39|g/m2
P06095372A0435|44 44|h
P06095372A0435|56 73|radiation treatment
P06095372A0435|3 6|drug
P06095774T0001|32 39|nephroma
P06095774T0001|12 18|aspects
P06096246T0000|0 5|Effect
P06096246T0000|34 39|stress
P06096246T0000|90 93|rats
P06096246T0000|76 83|hormones
P06096380A0662|120 123|mRNA
P06096380A0662|140 145|enzyme
P06096380A0662|151 153|rat
P06096380A0662|82 87|length
P06096380A0662|22 53|phosphoenolpyruvate carboxykinase
P06096380A0662|59 65|chicken
P06096380A0662|6 9|mRNA
P06096380A0662|71 79|kilobases
P06096863T0000|28 35|CYC1 gene
P06096863T0000|114 120|TATA box
P06096863T0000|8 22|activation sites
P06097027A0000|14 21|provirus
P06097027A0000|103 121|myeloblastosis virus
P06097027A0000|140 151|tumor viruses
P06097027A0000|32 55|erythroblastosis virus E26
P06097027A0000|123 125|AMV
P06097027A0000|83 93|comparisons
P06097285A1077|17 27|haloperidol
P06097285A1077|97 110|motor behaviour
P06097285A1077|49 54|animal
P06097285A1077|57 64|capacity
P06098719A0369|28 45|laboratory findings
P06098719A0369|11 16|effect
P06098719A0369|55 58|drug
P06098828A0352|57 65|sequences
P06098828A0352|90 102|RNA polymerase
P06098828A0352|25 30|report
P06098828A0352|45 48|SV40
P06098828A0352|128 135|elements
P06098828A0352|3 9|results
P06099656T0000|86 101|cotransformation
P06099656T0000|53 83|adenovirus DNA binding protein gene
P06099656T0000|19 27|cell lines
P06099656T0000|109 119|HSV-1 tk gene
P06099656T0000|0 11|Construction
P06101359T0000|0 8|Diagnosis
P06101359T0000|40 46|tumours
P06101359T0000|12 20|treatment
P06108610A0518|0 7|Theories
P06108610A0518|32 50|modality shift effect
P06109017A0000|249 257|blood flow
P06109017A0000|27 32|beta-1
P06109017A0000|54 69|4-hydroxyphenoxy
P06109017A0000|43 49|agonist
P06109017A0000|200 204|dP/dt
P06109017A0000|235 242|pressure
P06109017A0000|261 269|heart rate
P06109017A0000|104 114|prenalterol
P06109017A0000|283 286|dogs
P06109017A0000|191 198|diameter
P06109017A0000|179 180|LV
P06109017A0000|72 96|isopropylamino-2-propanol
P06109017A0000|149 160|measurements
P06109017A0000|182 189|pressure
P06109017A0000|206 213|velocity
P06109017A0000|3 9|effects
P06110026T0000|0 9|Endorphins
P06110026T0000|25 29|death
P06110026T0000|15 22|approach
P06111283T0032|0 13|Trial treatment
P06111283T0032|33 55|des-Tyr-gamma-endorphin
P06111283T0032|16 28|schizophrenia
P06113084T0000|34 55|calcium binding activity
P06113084T0000|78 91|cardiomyopathy
P06113084T0000|7 19|taurine levels
P06113443T0000|0 9|Separation
P06113443T0000|28 39|erythrocytes
P06113443T0000|55 57|use
P06113443T0000|91 109|separation technique
P06113443T0000|49 53|blood
P06119262T0000|3 15|roll-over test
P06119262T0000|25 31|toxemia
P06119262T0000|34 42|pregnancy
P06120429T0000|3 20|thyroglobulin assay
P06120429T0000|53 60|patients
P06120429T0000|79 91|thyroid cancer
P06120429T0000|35 45|radioiodine
P06121577A0280|151 159|decreases
P06121577A0280|90 90|%
P06121577A0280|102 102|%
P06121577A0280|75 79|doses
P06121577A0280|110 111|mg
P06121577A0280|12 21|reductions
P06121577A0280|116 116|%
P06121577A0280|174 192|plasma renin activity
P06121577A0280|162 170|heart rate
P06121577A0280|85 86|mg
P06121577A0280|41 53|blood pressure
P06121577A0280|96 97|mg
P06130348T0000|0 8|Isolation
P06130348T0000|11 19|Aeromonas
P06130348T0000|24 29|faeces
P06131038A0000|0 5|Plasma
P06131038A0000|92 98|rabbits
P06131038A0000|120 128|incidence
P06131038A0000|34 58|lipoprotein lipase activity
P06131038A0000|9 30|erthrocyte lipid profile
P06131038A0000|61 77|postheparin plasma
P06131038A0000|165 168|beds
P06131038A0000|131 145|atherosclerosis
P06131378A0818|128 135|DHFR cDNA
P06131378A0818|89 110|polyadenylation signals
P06131378A0818|60 62|end
P06131378A0818|44 52|sequences
P06131378A0818|8 11|mRNA
P06131378A0818|68 75|DHFR cDNA
P06136374A0151|58 73|swimming velocity
P06136374A0151|24 26|VO2
P06136374A0151|6 22|water temperatures
P06137028A0624|0 10|Propranolol
P06137028A0624|47 52|tremor
P06138015T0114|5 10|report
P06138313A0948|95 100|volume
P06138313A0948|34 49|elimination phase
P06138313A0948|75 83|mean value
P06138313A0948|87 89|min
P06138313A0948|103 114|distribution
P06138313A0948|65 73|half-life
P06138313A0948|3 19|distribution phase
P06141764A0339|120 130|information
P06141764A0339|92 97|clones
P06141764A0339|71 80|plasmid DNA
P06141764A0339|51 53|RNA
P06141764A0339|0 26|Hybrid-selection experiments
P06142279T0000|0 3|Risk
P06142279T0000|6 18|HTLV infection
P06142279T0000|21 28|patients
P06142279T0000|31 43|haemodialysis
P06143734T0000|19 30|progesterone
P06143734T0000|52 57|testis
P06143734T0000|7 16|metabolism
P06147504A0086|3 10|patients
P06147504A0086|23 29|therapy
P06147504A0086|76 79|mass
P06147504A0086|45 51|reasons
P06150069A0422|40 44|weeks
P06150069A0422|49 64|dose modification
P06150069A0422|25 29|mg/m2
P06150069A0422|68 80|neurotoxicity
P06150069A0422|19 21|VCR
P06150069A0422|3 10|patients
P06151518A0000|15 18|dose
P06151518A0000|118 127|injections
P06151518A0000|57 66|sodium salt
P06151518A0000|8 11|acid
P06151518A0000|31 34|LD50
P06151518A0000|98 101|days
P06151518A0000|90 93|rats
P06151518A0000|130 137|dexazone
P06151518A0000|51 54|form
P06151942A0235|0 4|Serum
P06151942A0235|127 137|cholesterol
P06151942A0235|88 98|risk factors
P06151942A0235|13 16|acid
P06151942A0235|139 150|triglyceride
P06151942A0235|152 160|gamma-GTP
P06151942A0235|67 79|blood pressure
P06151942A0235|44 54|association
P06151942A0235|108 120|blood pressure
P06151942A0235|164 170|obesity
P06152670T0000|15 26|pancreozymin
P06152670T0000|48 54|hormone
P06152670T0000|69 83|failure patients
P06152670T0000|0 13|Plasma secretin
P06152844T0000|0 5|Effect
P06152844T0000|62 69|subjects
P06152844T0000|20 32|growth hormone
P06152844T0000|8 17|bromazepam
P06152844T0000|36 53|prolactin secretion
P06153936A0784|42 58|gland examinations
P06153936A0784|24 26|SjS
P06153936A0784|76 87|year interval
P06153936A0784|150 156|changes
P06153936A0784|9 13|cases
P06153936A0784|106 114|occasions
P06155967A1132|42 58|reporting terminal
P06155967A1132|23 29|machine
P06155967A1132|129 134|effort
P06155967A1132|3 14|radiologists
P06155967A1132|149 152|time
P06155967A1132|99 111|abnormalities
P06158844A0000|0 10|Thalamotomy
P06158844A0000|54 69|gamma irradiation
P06158844A0000|126 135|malignancy
P06158844A0000|89 94|series
P06158844A0000|117 120|pain
P06158844A0000|22 33|CM-Pf complex
P06158844A0000|99 106|patients
P06161823A0129|87 89|men
P06161823A0129|9 16|capsules
P06161823A0129|109 119|hypertrophy
P06161823A0129|37 38|mg
P06161823A0129|41 56|ethinyl estradiol
P06162419A0118|85 95|development
P06162419A0118|39 45|maximum
P06162419A0118|55 59|doses
P06162419A0118|128 131|cent
P06162419A0118|98 115|lymphadenosis NK/Li
P06163433T0000|0 5|Effect
P06163433T0000|26 41|cyclopropylamine
P06163433T0000|11 24|p-chlorophenyl
P06163433T0000|101 108|rat brain
P06163433T0000|75 98|monoamine oxidase activity
P06163433T0000|59 71|concentration
P06165068A0547|41 48|duodenum
P06165068A0547|19 23|juice
P06165132A0000|85 94|spray lento
P06165132A0000|107 114|vaccines
P06165132A0000|65 69|farms
P06165132A0000|178 189|pseudoplague
P06165132A0000|205 209|virus
P06165132A0000|145 154|pseodopest
P06165132A0000|42 49|broilers
P06165132A0000|34 38|fowls
P06165132A0000|2 11|experiment
P06165132A0000|162 165|RIHA
P06165132A0000|130 137|immunity
P06165551A0793|171 176|window
P06165551A0793|62 67|spikes
P06165551A0793|160 165|length
P06165551A0793|181 183|sec
P06165551A0793|51 59|isolation
P06165551A0793|121 128|duration
P06165551A0793|107 110|view
P06165551A0793|76 80|waves
P06165551A0793|232 252|segmentation algorithm
P06165551A0793|6 22|inappropriateness
P06165551A0793|135 144|transients
P06165551A0793|147 154|relation
P06165551A0793|195 209|autocorrelation
P06165551A0793|33 44|segmentation
P06167806A0000|192 195|days
P06167806A0000|215 224|infarction
P06167806A0000|67 75|induction
P06167806A0000|26 44|dimethylpropranolol
P06167806A0000|139 141|dog
P06167806A0000|98 113|tachyarrhythmias
P06167806A0000|46 54|treatment
P06167806A0000|3 9|ability
P06167806A0000|19 24|UM-272
P06167806A0000|179 189|stimulation
P06173032T0000|59 66|pressure
P06173032T0000|37 44|response
P06173032T0000|11 23|echothiophate
P06173032T0000|69 78|dipivefrin
P06173032T0000|47 52|rabbit
P06173032T0000|3 8|effect
P06173860A0000|129 145|segment elevations
P06173860A0000|6 10|cases
P06173860A0000|54 71|segment depressions
P06173860A0000|82 99|contralateral leads
P06173860A0000|28 37|infarction
P06175691T0000|0 28|Bacillus cereus cross-infection
P06175691T0000|32 45|maternity-unit
P06181216A0070|33 40|patients
P06181216A0070|52 73|serum IgA concentrations
P06181216A0070|80 84|years
P06182979A0807|29 36|emphasis
P06182979A0807|104 132|cisplatinum diammine dichloride
P06182979A0807|11 18|category
P06182979A0807|79 89|doxorubicin
P06182979A0807|93 101|analogues
P06182979A0807|55 76|anthracycline analogues
P06184276T0001|15 27|plasmocytosis
P06184276T0001|7 12|course
P06184487A1485|85 93|synthesis
P06184487A1485|166 168|RNA
P06184487A1485|66 73|AcNPV map
P06184487A1485|102 112|30K proteins
P06184487A1485|38 60|HindIII-P/EcoRI-B region
P06184487A1485|182 209|HindIII-A/EcoRI-C/SstI-G cDNA
P06184487A1485|135 137|31K
P06184487A1485|19 22|cDNA
P06184487A1485|96 98|31K
P06184487A1485|4 7|mRNA
P06184487A1485|141 151|30K proteins
P06185014A0642|19 37|complement factor C3c
P06185014A0642|51 51|%
P06185014A0642|58 75|alpha 1-antitrypsin
P06185014A0642|111 111|%
P06185014A0642|99 106|increase
P06185493A0468|41 62|yeast amino acid sequence
P06185493A0468|21 28|residues
P06185493A0468|100 113|ADP binding site
P06185493A0468|80 94|peptide sequence
P06185493A0468|122 141|muscle pyruvate kinase
P06185493A0468|1 16|polypeptide chain
P06189698A0246|130 131|N2
P06189698A0246|61 70|components
P06189698A0246|89 97|amplitude
P06189698A0246|135 146|P3 amplitudes
P06189698A0246|111 121|task demands
P06189698A0246|3 15|P165 component
P06191243T0000|47 57|brain damage
P06191243T0000|12 22|drawing size
P06193351A1010|59 67|incidence
P06193351A1010|108 122|artery occlusion
P06193351A1010|36 40|drugs
P06193351A1010|70 71|VF
P06193351A1010|84 90|release
P06193351A1010|16 29|administration
P06198241A0209|5 11|fusions
P06198241A0209|139 143|yeast
P06198241A0209|61 78|replication origins
P06198241A0209|26 33|plasmids
P06198241A0209|47 51|yeast
P06198241A0209|152 156|cells
P06198241A0209|92 98|markers
P06198532A0982|100 102|RHD
P06198532A0982|64 71|patients
P06198532A0982|38 45|tendency
P06198532A0982|123 128|causes
P06198532A0982|76 77|MS
P06198532A0982|162 176|thromboembolism
P06198532A0982|179 188|comparison
P06198532A0982|151 159|incidence
P06198532A0982|196 198|RHD
P06199132A0179|0 7|Toxicity
P06199132A0179|99 106|patients
P06199132A0179|32 36|cases
P06199132A0179|60 62|WBC
P06199132A0179|43 50|patients
P06199132A0179|115 120|sepsis
P06200300A0409|56 70|scalp electrodes
P06200300A0409|8 17|electrodes
P06200300A0409|49 53|skull
P06200300A0409|32 44|VEP amplitudes
P06203843A0757|0 7|Products
P06203843A0757|44 54|lymphokines
P06203843A0757|91 95|group
P06203843A0757|16 20|cells
P06203843A0757|27 40|transfer factor
P06203843A0757|116 121|agents
P06204120T0001|0 2|Use
P06204120T0001|8 31|immunofluorescence method
P06204120T0001|51 63|enteroviruses
P06204120T0001|35 48|identification
P06204120T0001|66 77|cell cultures
P06208024A0168|86 95|hydrolysis
P06208024A0168|25 34|digestions
P06208024A0168|46 52|RNase T1
P06208024A0168|37 41|DNase
P06208024A0168|4 11|fraction
P06208477A0000|3 14|construction
P06208477A0000|23 29|library
P06208477A0000|76 82|Pietras
P06208477A0000|32 36|mouse
P06208477A0000|47 49|DNA
P06208477A0000|96 103|Acids Res
P06209403A0562|8 14|repeats
P06209403A0562|23 32|pseudogene
P06209403A0562|38 46|U2/4 locus
P06209499A0682|56 58|MAP
P06209499A0682|9 15|effects
P06209499A0682|74 86|pressor effect
P06209499A0682|50 53|fall
P06209499A0682|18 35|transmitter release
P06209499A0682|101 111|bradycardia
P06209499A0682|127 137|tachycardia
P06212776A0000|99 104|people
P06212776A0000|146 153|diseases
P06212776A0000|164 173|prevention
P06212776A0000|9 16|Oristano
P06212776A0000|55 66|thalassaemia
P06212776A0000|44 52|incidence
P06212776A0000|20 23|town
P06212776A0000|2 7|Cabras
P06212776A0000|70 83|G6PD deficiency
P06212776A0000|128 136|knowledge
P06214605A0123|83 93|experiments
P06214605A0123|3 8|number
P06214605A0123|11 18|elements
P06214605A0123|27 31|sizes
P06214605A0123|45 57|configuration
P06214605A0123|71 76|series
P06216125A0470|2 9|addition
P06216125A0470|99 100|mm
P06216125A0470|51 52|ET
P06216125A0470|89 96|follicle
P06216125A0470|21 26|chance
P06216125A0470|129 133|cycle
P06216125A0470|66 70|cycle
P06216125A0470|32 38|patient
P06216125A0470|153 160|follicle
P06217859T0000|0 9|Experience
P06217859T0000|39 42|flap
P06217859T0000|17 22|tensor
P06218005A0948|30 36|L-L size
P06218005A0948|9 16|patients
P06218005A0948|47 57|A-P diameter
P06223586A0000|0 17|Immunochemotherapy
P06223586A0000|22 34|schizophyllan
P06223586A0000|68 73|agents
P06223586A0000|100 108|tumor-C3H
P06223586A0000|112 123|mouse systems
P06223586A0000|36 38|SPG
P06223586A0460|145 148|mice
P06223586A0460|74 87|administration
P06223586A0460|24 33|mitomycin C
P06223586A0460|90 92|SPG
P06223586A0460|52 59|interval
P06223586A0460|118 126|life-span
P06224974A0833|58 60|CPA
P06224974A0833|95 99|agent
P06224974A0833|46 55|metabolite
P06224974A0833|32 43|beta-hydroxy
P06224974A0833|0 3|Data
P06225279A0498|57 61|layer
P06225279A0498|12 18|surface
P06225279A0498|84 89|tissue
P06227570A0523|29 31|ENL
P06227570A0523|2 9|contrast
P06227570A0523|47 64|suppressor response
P06227570A0523|13 22|LL patients
P06229542T0045|29 36|fraction
P06229542T0045|10 25|characterization
P06229542T0045|52 59|activity
P06229542T0045|69 87|template rescue assay
P06230499A0128|284 290|results
P06230499A0128|174 184|irradiation
P06230499A0128|52 55|form
P06230499A0128|251 256|period
P06230499A0128|107 109|day
P06230499A0128|61 73|fractionation
P06230499A0128|88 91|dose
P06230499A0128|211 221|performance
P06230499A0128|95 96|Gy
P06230499A0128|155 161|surgery
P06230499A0128|129 130|Gy
P06230499A0128|165 168|days
P06230499A0128|36 46|irradiation
P06230499A0128|316 332|dose fractionation
P06230499A0128|114 124|summary dose
P06230499A0128|141 144|days
P06230499A0128|227 232|course
P06233924T0000|0 9|Fibrin gels
P06233924T0000|26 36|implication
P06233924T0000|70 76|disease
P06233924T0000|40 58|surface hemorheology
P06233924T0000|61 66|health
P06234369T0000|11 21|vaccination
P06234786A0606|0 18|Radiogallium imaging
P06234786A0606|39 48|evaluation
P06234786A0606|65 74|cell tumors
P06234786A0606|34 36|use
P06234786A0606|77 80|bone
P06237518A0117|133 135|KCN
P06237518A0117|115 120|system
P06237518A0117|104 107|flow
P06237518A0117|80 83|acid
P06237518A0117|12 26|coupling reagent
P06237518A0117|139 148|chloramine
P06237518A0117|37 40|acid
P06237518A0117|85 88|CNCl
P06238540A0798|60 62|LVH
P06238540A0798|167 171|slope
P06238540A0798|150 152|LVH
P06238540A0798|11 25|volume stiffness
P06238540A0798|97 115|wall muscle stiffness
P06238540A0798|32 57|mean wall stress relationship
P06238540A0798|122 147|mean wall stress relationship
P06238704T0001|0 8|Synthesis
P06238704T0001|23 38|acid diethylamide
P06239545A0649|0 9|Weight loss
P06239545A0649|113 120|activity
P06239545A0649|25 32|pressure
P06239545A0649|75 80|output
P06239545A0649|96 99|fall
P06239545A0649|36 43|decrease
P06239545A0649|59 64|volume
P06240448A0652|226 242|pretreatment level
P06240448A0652|147 156|resistance
P06240448A0652|74 82|reduction
P06240448A0652|198 205|increase
P06240448A0652|187 192|LV mass
P06240448A0652|11 19|treatment
P06240448A0652|263 270|decrease
P06240448A0652|124 129|change
P06240448A0652|95 103|reduction
P06240448A0652|215 220|output
P06240448A0652|47 52|phases
P06240448A0652|3 8|effect
P06240448A0652|64 68|phase
P06240448A0652|288 297|resistance
P06240448A0652|169 173|phase
P06240448A0652|113 118|output
P06240448A0652|85 90|LV mass
P06241900A0000|42 52|hypothermia
P06241900A0000|155 160|period
P06241900A0000|33 39|effects
P06241900A0000|169 177|ischaemia
P06241900A0000|91 98|recovery
P06241900A0000|56 75|chemical cardioplegia
P06241900A0000|125 133|rat hearts
P06241900A0000|4 8|study
P06241980A0855|0 13|Oxygen profiles
P06241980A0855|114 122|diffusion
P06241980A0855|96 101|models
P06241980A0855|53 61|diffusion
P06241980A0855|30 39|Krogh model
P06242113T0001|0 18|Cultivation technics
P06242113T0001|22 39|Codonopsis pilosula
P06244732T0000|0 15|Radioimmunoassay
P06244732T0000|78 87|infarction
P06244732T0000|52 60|diagnosis
P06244732T0000|18 46|serum creatine kinase B isoenzyme
P06245672T0000|54 62|reduction
P06245672T0000|65 74|metastasis
P06245672T0000|9 28|macrophage inhibition
P06246254A0676|0 16|Restriction enzyme
P06246254A0676|103 108|center
P06246254A0676|53 61|sequences
P06246254A0676|20 39|heteroduplex analyses
P06246254A0676|146 158|kilobase pairs
P06246254A0676|114 123|FeSV genome
P06246254A0676|161 166|length
P06246254A0676|70 73|FeSV
P06246254A0676|75 86|src sequences
P06251469A0830|17 31|library isolates
P06251469A0830|125 134|occurrence
P06251469A0830|52 59|IAP units
P06251469A0830|65 80|restriction sites
P06251469A0830|107 112|others
P06251469A0830|138 145|position
P06252520T0000|0 13|Catecholamines
P06252520T0000|25 32|learning
P06252520T0000|35 40|review
P06252883A0100|41 44|O149
P06252883A0100|90 92|PWD
P06252883A0100|79 85|piglets
P06252883A0100|125 130|number
P06252883A0100|50 52|H10
P06252883A0100|26 31|strain
P06252883A0100|98 106|rotavirus
P06252883A0100|46 48|K88
P06252883A0100|133 141|occasions
P06254403A0000|86 98|blocking assay
P06254403A0000|3 15|antibody titer
P06254403A0000|21 28|chickens
P06254403A0000|31 44|SA-11 rotavirus
P06254973A1757|288 289|dT
P06254973A1757|159 160|dT
P06254973A1757|219 229|binding site
P06254973A1757|277 284|residues
P06254973A1757|176 177|dT
P06254973A1757|111 113|HDP
P06254973A1757|291 292|n.
P06254973A1757|63 77|polynucleotides
P06254973A1757|242 244|HDP
P06254973A1757|246 257|accumulation
P06254973A1757|162 162|n
P06254973A1757|20 32|calf thymus DNA
P06254973A1757|147 155|molecules
P06254973A1757|95 106|accumulation
P06254973A1757|168 169|dT
P06254973A1757|117 118|dT
P06254973A1757|5 6|dT
P06254973A1757|0 3|Poly
P06258699T0000|33 43|Polybactrin
P06258699T0000|51 69|GU bladder irrigation
P06258699T0000|13 17|trial
P06258699T0000|72 81|cystoscopy
P06258806A0963|57 64|terminus
P06258806A0963|80 83|gene
P06258806A0963|106 115|expression
P06258806A0963|41 47|element
P06258806A0963|17 25|insertion
P06258806A0963|144 149|enzyme
P06259220A0000|218 230|shock exposure
P06259220A0000|82 89|reaction
P06259220A0000|181 190|reexposure
P06259220A0000|193 197|shock
P06259220A0000|130 134|shock
P06259220A0000|26 34|influence
P06259220A0000|4 14|experiments
P06259220A0000|200 201|hr
P06259220A0000|109 116|exposure
P06259220A0000|101 103|min
P06259220A0000|159 166|reaction
P06259220A0000|43 53|antagonists
P06259220A0464|0 9|Experiment
P06259220A0464|115 119|shock
P06259220A0464|103 112|reexposure
P06259220A0464|86 95|naltrexone
P06259220A0464|70 83|administration
P06259220A0464|42 49|reaction
P06259389A0000|53 56|foot
P06259389A0000|24 29|August
P06259389A0000|73 76|HFMD
P06259389A0000|88 101|Gifu prefecture
P06259389A0000|60 71|mouth disease
P06259389A0000|48 51|hand
P06259389A0000|9 14|period
P06259389A0000|19 21|May
P06270347A0740|1 14|22K polypeptide
P06270347A0740|29 46|translation product
P06270347A0740|76 86|DNA fragment
P06270347A0740|53 55|RNA
P06272844A0000|30 40|chromosomes
P06272844A0000|124 131|nuclease
P06272844A0000|25 28|SV40
P06272844A0000|139 147|digestion
P06272844A0000|133 137|MNase
P06272844A0000|78 88|chromosomes
P06272844A0000|105 110|extent
P06272844A0000|202 214|SV40 chromatin
P06272844A0000|98 101|rate
P06272844A0000|17 21|virus
P06277159T0033|1 10|hypothesis
P06278424A0145|96 102|gamma 2b
P06278424A0145|112 123|mouse myeloma
P06278424A0145|38 49|CH gene switch
P06278424A0145|79 90|gamma 2b genes
P06278424A0145|125 130|MPC-11
P06278424A0145|21 32|requirements
P06278544T0027|0 9|Physiology
P06278544T0027|13 27|Physiopathology
P06279309A0000|103 112|activities
P06279309A0000|91 96|v-erbB
P06279309A0000|154 158|virus
P06279309A0000|82 87|v-erbA
P06279309A0000|77 80|loci
P06279309A0000|16 36|erythroblastosis virus
P06279309A0000|138 148|oncogenesis
P06279309A0000|3 8|genome
P06281759A1086|40 52|sib regulation
P06281759A1086|110 121|int mRNA decay
P06281759A1086|86 101|endoribonuclease
P06281759A1086|77 79|sib
P06281759A1086|7 11|RNase
P06281759A1086|133 144|int synthesis
P06281759A1086|54 63|processing
P06281759A1086|69 74|PL mRNA
P06281759A1086|15 25|host mutants
P06281786A1222|39 46|addition
P06281786A1222|10 14|clone
P06281786A1222|121 131|nucleotides
P06281786A1222|134 139|length
P06281786A1222|102 104|RNA
P06281786A1222|52 63|histone genes
P06281786A1222|16 24|lambda HHG
P06281786A1222|66 71|region
P06281891A0399|97 112|pain transmission
P06281891A0399|21 28|pathways
P06281891A0399|68 72|roles
P06281891A0399|78 94|complex modulation
P06281891A0399|54 63|substances
P06286191T0000|0 10|Restoration
P06286191T0000|27 35|functions
P06286191T0000|43 49|animals
P06286443A0498|13 27|serum ACTH levels
P06286549A0000|0 6|WR-2721
P06286549A0000|159 163|lungs
P06286549A0000|51 54|acid
P06286549A0000|101 104|lung
P06286549A0000|137 139|FSa
P06286549A0000|124 135|fibrosarcoma
P06286549A0000|109 114|testis
P06286549A0000|81 87|ability
P06286549A0000|8 10|S-2
P06286549A0000|166 169|mice
P06286549A0000|14 29|aminopropylamino
P06286549A0000|97 99|gut
P06286549A0000|141 152|tumor nodules
P06286549A0000|174 194|gamma-radiation injury
P06287212A1352|101 103|VP1
P06287212A1352|55 65|translation
P06287212A1352|107 107|T
P06287212A1352|7 14|families
P06287212A1352|122 127|result
P06287212A1352|206 209|AUGs
P06287212A1352|83 91|sequences
P06287212A1352|17 28|polypeptides
P06287212A1352|68 76|AUG codons
P06287212A1352|2 5|fact
P06287212A1352|130 158|transcription initiation events
P06287212A1352|43 52|initiation
P06287231A0914|57 60|size
P06287231A0914|11 25|TRP1 RI Circle DNA
P06287231A0914|101 118|bulk yeast chromatin
P06287231A0914|2 9|addition
P06287231A0914|64 70|spacing
P06287231A0914|41 51|nucleosomes
P06287737A0477|89 96|type NANB
P06287737A0477|78 86|carcinoma
P06287737A0477|157 180|posttransfusion hepatitis
P06287737A0477|52 60|cirrhosis
P06287737A0477|141 149|incidence
P06287737A0477|339 350|type B disease
P06287737A0477|280 291|transfusions
P06287737A0477|42 50|hepatitis
P06287737A0477|248 255|jaundice
P06287737A0477|221 233|liver diseases
P06287737A0477|22 32|transfusion
P06287737A0477|239 245|history
P06287737A0477|197 197|%
P06287737A0477|116 116|%
P06287737A0477|262 270|hepatitis
P06287737A0477|3 11|frequency
P06287737A0477|323 330|type NANB
P06290859A0426|97 106|antibodies
P06290859A0426|76 76|%
P06290859A0426|5 22|hepatitis B patients
P06290859A0426|50 72|hepatitis Bs antigenaemia
P06290859A0426|114 114|%
P06290859A0426|131 143|liver function
P06290859A0426|31 36|months
P06290859A0426|39 39|%
P06290899T0000|0 5|Survey
P06290899T0000|53 65|chicken flocks
P06290899T0000|23 47|egg drop syndrome-1976 virus
P06290899T0000|8 15|antibody
P06290899T0000|68 72|Japan
P06291369A0000|60 74|catheterization
P06291369A0000|234 241|pressure
P06291369A0000|169 184|ejection fraction
P06291369A0000|126 133|portions
P06291369A0000|23 49|equilibrium ventriculography
P06291369A0000|4 11|patients
P06291369A0000|96 106|day interval
P06291369A0000|186 189|RVEF
P06295429A0412|143 152|protection
P06295429A0412|103 115|sensitization
P06295429A0412|23 29|WR-2721
P06295429A0412|170 174|doses
P06295429A0412|48 55|response
P06295429A0412|126 130|doses
P06295429A0412|16 19|MISO
P06295429A0412|3 13|combination
P06295429A0412|74 77|drug
P06296833A0000|28 55|cuticle protein gene expression
P06296833A0000|93 98|strain
P06296833A0000|3 11|mutations
P06298014A0647|44 51|activity
P06298014A0647|37 41|forms
P06298014A0647|91 95|units
P06298014A0647|104 110|columns
P06298014A0647|3 11|ensembles
P06298720A0893|42 55|repeat sequence
P06298720A0893|9 20|conservation
P06298720A0893|96 107|VL30 elements
P06298720A0893|111 124|MuLV proviruses
P06298720A0893|73 92|integration mechanism
P06300662T0000|29 38|expression
P06300662T0000|1 17|cDNA cloning vector
P06300662T0000|63 67|cells
P06300662T0000|41 51|cDNA inserts
P06300836A0285|105 112|presence
P06300836A0285|80 89|genome RNAs
P06300836A0285|199 213|rotavirus genome
P06300836A0285|49 59|RR1 colonies
P06300836A0285|115 137|DNA clones representative
P06300836A0285|175 193|constituent segments
P06300836A0285|151 162|reovirus RNAs
P06300836A0285|0 12|Hybridization
P06304771A1284|58 71|polyomaviruses
P06304771A1284|167 177|JCV sequence
P06304771A1284|112 115|role
P06304771A1284|47 51|times
P06304771A1284|138 150|transcription
P06304771A1284|7 14|sequence
P06304771A1284|16 23|GGGXGGAG
P06304771A1284|118 131|DNA replication
P06304771A1284|75 86|adenoviruses
P06306342A1156|122 131|disruption
P06306342A1156|37 40|LiCl
P06306342A1156|169 183|Heidenhain pouch
P06306342A1156|80 92|acid secretion
P06306342A1156|18 24|studies
P06306342A1156|151 157|barrier
P06306342A1156|2 11|conclusion
P06307099A1005|0 10|Lung density
P06307099A1005|65 71|animals
P06308536T0001|27 34|anti-HAV
P06308536T0001|52 64|liver diseases
P06308536T0001|3 25|hepatitis A virus antibody
P06308607A0375|86 96|nucleotides
P06308607A0375|35 43|sequences
P06308607A0375|141 158|polymerase sequence
P06308607A0375|104 114|p30 sequence
P06308607A0375|3 11|junctions
P06308607A0375|123 133|nucleotides
P06308607A0375|60 78|DNA sequence analysis
P06309020A0473|0 7|Naloxone
P06309020A0473|57 61|doses
P06309020A0473|67 84|lipopolysaccharide
P06309020A0473|22 32|mg X kg-1 X h-1
P06309020A0473|10 19|mg/kg bolus
P06309855T0000|0 18|Gel route preparation
P06309855T0000|24 29|fusing
P06309855T0000|36 48|porcelain frit
P06309969T0055|0 1|I.
P06310159A0000|69 81|retrovirus MH2
P06310159A0000|5 7|RNA
P06310159A0000|55 61|protein
P06310159A0000|34 36|DNA
P06310457A0000|46 51|tectum
P06310457A0000|13 22|recordings
P06310457A0000|57 60|carp
P06310553T0000|33 38|origin
P06310553T0000|53 67|muscle actin gene
P06310553T0000|9 17|structure
P06310608A0749|128 134|Moloney
P06310608A0749|105 115|Ableson MuLV
P06310608A0749|154 158|M-MSV
P06310608A0749|141 152|sarcoma virus
P06310608A0749|24 35|substitution
P06310608A0749|3 9|mutants
P06310608A0749|68 70|DNA
P06310608A0749|50 54|clone
P06310608A0749|117 123|Ab-MuLV
P06310608A0749|97 103|viruses
P06310608A0749|57 65|M-MuLV DNA
P06314276T0000|14 20|cloning
P06314276T0000|84 87|SV40
P06314276T0000|72 78|control
P06314276T0000|24 33|expression
P06314276T0000|99 110|gene promoter
P06314276T0000|62 66|cDNAs
P06314276T0000|0 7|Plasmids
P06314312A0359|227 232|levels
P06314312A0359|176 176|%
P06314312A0359|44 47|diet
P06314312A0359|128 135|purities
P06314312A0359|72 74|ppm
P06314312A0359|157 162|chicks
P06314312A0359|204 210|average
P06314312A0359|101 107|sources
P06314312A0359|52 57|levels
P06314312A0359|188 201|feed efficiency
P06314312A0359|215 215|%
P06314312A0359|14 27|soybean protein
P06314312A0359|165 171|average
P06314312A0359|237 237|P
P06314312A0359|145 154|weight gain
P06316347A0852|72 97|beta-galactosidase activity
P06316347A0852|18 25|rnh-lacZ
P06316347A0852|3 11|dnaQ-lacZ
P06316347A0852|31 35|genes
P06316347A0852|60 67|proteins
P06316623A0188|80 84|goats
P06316623A0188|37 40|cent
P06316623A0188|61 65|sheep
P06316623A0188|7 17|prevalences
P06316623A0188|74 77|cent
P06316623A0188|99 117|immunodiffusion test
P06316623A0188|55 58|cent
P06316623A0188|43 48|cattle
P06316623A0188|20 27|antibody
P06318078T0000|0 9|Expression
P06318078T0000|37 46|gamma genes
P06318078T0000|12 33|herpes simplex virus beta
P06318078T0000|81 89|induction
P06318078T0000|94 109|alpha gene product
P06318078T0000|68 72|cells
P06318091A0395|3 20|splice acceptor site
P06318322A0350|56 68|recombination
P06318322A0350|189 200|messenger RNA
P06318322A0350|113 117|virus
P06318322A0350|121 129|proto-sis
P06318322A0350|21 25|model
P06318322A0350|39 41|SSV
P06318322A0350|84 86|DNA
P06318322A0350|137 143|introns
P06318322A0350|96 102|sarcoma
P06319040A1627|189 196|increase
P06319040A1627|35 48|system activity
P06319040A1627|207 214|pressure
P06319040A1627|111 118|reflexly
P06319040A1627|127 135|reduction
P06319040A1627|82 91|activation
P06319040A1627|146 154|blood flow
P06319040A1627|56 75|carotid chemoreceptor
P06319040A1627|176 178|dog
P06319071A0173|214 223|creatinine
P06319071A0173|55 74|calcium stone-formers
P06319071A0173|181 183|AMP
P06319071A0173|99 107|AMP levels
P06319071A0173|6 13|subjects
P06319071A0173|141 150|difference
P06319071A0173|34 41|subjects
P06319071A0173|200 211|units mumol/g
P06319071A0173|121 132|counterparts
P06319072A0711|146 151|groups
P06319072A0711|90 107|cell receptor number
P06319072A0711|48 55|patients
P06319072A0711|162 186|beta-adrenoceptor function
P06319072A0711|124 130|results
P06319072A0711|18 27|morning dip
P06319072A0711|110 117|affinity
P06319072A0711|81 87|changes
P06319421A0937|118 123|uptake
P06319421A0937|11 21|desipramine
P06319421A0937|91 107|mianserin blockade
P06319421A0937|40 49|inhibition
P06319421A0937|75 87|amitriptyline
P06319421A0937|3 8|effect
P06319421A0937|140 161|alpha 2-adrenoreceptors
P06319421A0937|60 65|uptake
P06319740A1331|147 161|Rauscher disease
P06319740A1331|140 144|phase
P06319740A1331|48 57|initiation
P06319740A1331|60 72|amplification
P06319740A1331|17 20|gp54
P06319740A1331|31 34|gene
P06319740A1331|85 107|erythroblast hyperplasia
P06320380T0001|0 16|Surgical treatment
P06320380T0001|28 37|metastases
P06321505A0401|99 111|transcription
P06321505A0401|178 190|transcription
P06321505A0401|87 96|initiation
P06321505A0401|127 143|S1 nuclease mapping
P06321505A0401|80 84|point
P06321505A0401|36 42|TATA box
P06321505A0401|193 202|rat PTH mRNA
P06321505A0401|18 33|Goldberg-Hogness
P06321505A0401|56 64|base pairs
P06321505A0401|1 16|promoter sequence
P06321634A0123|98 102|bases
P06321634A0123|134 149|TRs/IRs sequences
P06321634A0123|74 79|intron
P06321634A0123|40 53|leader sequence
P06321634A0123|18 22|mRNAs
P06321634A0123|59 63|bases
P06321770A1353|102 106|virus
P06321770A1353|65 65|h
P06321770A1353|126 131|nature
P06321770A1353|82 86|cells
P06321770A1353|137 145|promoters
P06321770A1353|3 12|expression
P06321770A1353|71 79|infection
P06321770A1353|15 46|chloramphenicol acetyltransferase
P06322183A1070|42 60|kanamycin resistance
P06322183A1070|25 39|agar plate assays
P06322183A1070|120 127|presence
P06322183A1070|66 84|immunoprecipitation
P06322183A1070|90 101|NPT II protein
P06322183A1070|157 163|absence
P06322183A1070|130 137|cysteine
P06322183A1070|0 13|NPT II synthesis
P06323556A0126|100 107|catheter
P06323556A0126|37 50|EOE-13 infusion
P06323556A0126|9 19|tomographic
P06323556A0126|70 85|perfusion pattern
P06324089A0453|97 101|genes
P06324089A0453|51 58|features
P06324089A0453|24 27|GAL7
P06324089A0453|10 18|structure
P06324089A0453|38 43|region
P06324121A0256|66 70|codon
P06324121A0256|12 14|12K
P06324121A0256|38 45|IEmRNA-5
P06324121A0256|100 103|base
P06324121A0256|75 86|reading frame
P06324121A0256|120 125|region
P06324121A0256|9 10|MW
P06324121A0256|18 28|polypeptide
P06325415A0757|140 149|amino acids
P06325415A0757|37 43|Ad5 DBPs
P06325415A0757|49 55|absence
P06325415A0757|62 71|Ad7 protein
P06325415A0757|77 86|amino acids
P06325415A0757|11 20|difference
P06325415A0757|31 33|Ad7
P06325415A0757|117 123|domains
P06325415A0757|129 138|Ad5 protein
P06327039A0743|60 74|body surface area
P06327039A0743|76 78|age
P06327039A0743|39 41|LVM
P06327039A0743|133 142|resistance
P06327039A0743|215 228|catecholamines
P06327039A0743|187 190|CD25
P06327039A0743|44 56|wall thickness
P06327039A0743|256 256|r
P06327039A0743|80 92|blood pressure
P06327039A0743|111 116|output
P06327039A0743|247 254|patients
P06327039A0743|13 23|correlation
P06327039A0743|169 178|wall stress
P06327039A0743|94 102|heart rate
P06327039A0743|264 264|p
P06327292A0846|14 36|Shine-Dalgarno sequences
P06327292A0846|81 91|start codons
P06327638A0155|3 12|gene cat-86
P06327638A0155|114 116|DNA
P06327638A0155|96 107|1.1-kilobase
P06327638A0155|49 80|chloramphenicol acetyltransferase
P06328002A0000|60 78|Moloney sarcoma virus
P06328002A0000|51 57|passage
P06328002A0000|95 98|mice
P06328002A0000|21 32|sarcoma virus
P06328002A0000|80 86|Mo-MuSV
P06328002A0000|34 37|MPSV
P06328012A0549|73 79|BamHI-K
P06328012A0549|108 121|I1f subfragment
P06328012A0549|126 128|kbp
P06328012A0549|13 23|EBNA protein
P06328012A0549|57 68|transfection
P06328012A0549|84 96|kilobase pairs
P06328012A0549|98 100|kbp
P06328485A0277|236 255|chicken proto-myc gene
P06328485A0277|62 69|delta gag
P06328485A0277|184 186|mht
P06328485A0277|156 160|virus
P06328485A0277|107 112|MH2 DNA
P06328485A0277|23 40|nucleotide sequence
P06328485A0277|46 47|kb
P06328485A0277|77 79|end
P06328485A0277|116 120|order
P06328485A0277|214 220|viruses
P06328485A0277|142 150|structure
P06328485A0277|57 59|end
P06328504A0161|0 2|USA
P06328504A0161|65 71|portion
P06328504A0161|38 53|clone lambda PGK-1
P06328504A0161|116 118|PGK
P06328504A0161|93 114|phosphoglycerate kinase
P06328504A0161|85 89|locus
P06330082A0329|0 1|A.
P06330478A0304|61 62|mg
P06330478A0304|19 28|cimetidine
P06330478A0304|3 10|patients
P06330478A0304|32 39|mg q.i.d.
P06330478A0304|83 87|doses
P06331684A0607|70 73|risk
P06331684A0607|22 28|stomach
P06331684A0607|13 16|test
P06331684A0607|77 89|stomach cancer
P06331684A0607|48 56|screening
P06331684A0607|32 44|tumor antigens
P06333433A0000|174 176|LPS
P06333433A0000|141 147|profile
P06333433A0000|62 69|outbreak
P06333433A0000|27 41|influenzae type b
P06333433A0000|80 103|H. influenzae type b disease
P06333433A0000|155 172|lipopolysaccharide
P06333433A0000|6 13|isolates
P06333878T0000|11 22|acid overdose
P06336045A0261a|125 127|TRP
P06336045A0261a|17 24|frog type
P06336045A0261a|28 29|Ft
P06336045A0261a|102 123|threshold response phase
P06336045A0261a|10 12|Ft I
P06336045A0261a|48 49|SA
P06336045A0261a|79 94|indentation phase
P06336045A0261a|64 69|spikes
P06336045A0261a|51 55|units
P06336045A0261a|153 157|spike
P06336045A0261a|138 142|phase
P06336045A0261a|0 7|Frog type
P06336045A0261b|125 127|TRP
P06336045A0261b|17 24|frog type
P06336045A0261b|28 29|Ft
P06336045A0261b|102 123|threshold response phase
P06336045A0261b|10 12|Ft I
P06336045A0261b|48 49|SA
P06336045A0261b|79 94|indentation phase
P06336045A0261b|64 69|spikes
P06336045A0261b|51 55|units
P06336045A0261b|153 157|spike
P06336045A0261b|138 142|phase
P06336045A0261b|0 7|Frog type
P06340643A0598|0 3|DMCM
P06340643A0598|15 23|extension
P06340643A0598|69 79|donor organs
P06340643A0598|29 41|possibilities
P06340703A0324|0 8|Grimelius
P06340703A0324|26 38|Masson Fontana
P06341139A0213|0 11|Blood glucose
P06341139A0213|76 78|min
P06341139A0213|97 104|g glucose
P06341139A0213|176 182|g apples
P06341139A0213|15 27|plasma insulin
P06341139A0213|46 49|time
P06341139A0213|152 152|g
P06341139A0213|128 133|g honey
P06341139A0213|116 122|lactose
P06341139A0213|143 147|bread
P06341139A0213|158 161|rice
P06341139A0213|106 113|fructose
P06341139A0213|84 92|ingestion
P06341139A0213|188 195|g carrots
P06341139A0213|164 171|potatoes
P06341139A0213|137 137|g
P06341661T0001|47 61|Blalock-Taussig
P06341661T0001|35 44|acid suture
P06341661T0001|64 72|operation
P06341661T0001|8 10|use
P06342141A0226|402 405|type
P06342141A0226|34 46|understanding
P06342141A0226|140 147|efficacy
P06342141A0226|90 100|specificity
P06342141A0226|245 249|needs
P06342141A0226|215 218|type
P06342141A0226|161 170|modalities
P06342141A0226|49 69|family pathophysiology
P06342141A0226|408 411|care
P06342141A0226|506 510|study
P06342141A0226|354 365|consequences
P06342141A0226|450 456|attempt
P06342141A0226|76 86|sensitivity
P06342141A0226|277 283|members
P06342141A0226|327 336|importance
P06342141A0226|255 260|family
P06342141A0226|372 395|health care delivery system
P06342141A0226|424 439|literature review
P06342141A0226|487 495|questions
P06342141A0226|470 476|queries
P06342141A0226|221 224|care
P06342141A0226|181 196|family health care
P06342141A0226|290 304|value judgements
P06342141A0226|131 136|safety
P06342141A0226|113 122|techniques
P06345840A0348|86 93|velocity
P06345840A0348|34 35|CI
P06345840A0348|37 45|heart rate
P06345840A0348|12 17|group A
P06345840A0348|117 119|TPR
P06345840A0348|52 55|mean
P06345840A0348|95 98|mVCF
P06345840A0348|27 28|CI
P06345840A0348|2 9|patients
P06345840A0348|71 75|fiber
P06346427A0000|71 74|rats
P06346427A0000|96 105|test-meals
P06346427A0000|23 35|insulin levels
P06349364A1051|70 82|serum globulin
P06349364A1051|172 180|infection
P06349364A1051|48 54|passive
P06349364A1051|103 128|group B Streptococcus antigen
P06349364A1051|84 93|antibodies
P06349364A1051|96 99|type
P06349364A1051|5 11|results
P06350092A0916|38 41|CCHD
P06350092A0916|139 145|disease
P06350092A0916|100 106|degrees
P06350092A0916|46 55|occurrence
P06350092A0916|24 26|AMI
P06350092A0916|189 193|death
P06350092A0916|68 71|VPBs
P06350092A0916|157 167|possibility
P06350092A0916|17 21|phase
P06354594A0114|42 45|lime
P06354594A0114|13 20|mandarin
P06354594A0114|65 74|processing
P06354594A0114|22 31|grapefruit
P06354594A0114|5 11|oranges
P06355483A0134|97 101|locus
P06355483A0134|56 64|sequences
P06355483A0134|108 117|base-pairs
P06355483A0134|82 91|base-pairs
P06355483A0134|3 7|genes
P06355483A0134|14 18|locus
P06360426A0501|72 83|colour change
P06360426A0501|89 99|pH indicator
P06360426A0501|22 25|urea
P06360426A0501|10 19|hydrolysis
P06360426A0501|34 40|ammonia
P06361318A0440|127 127|%
P06361318A0440|103 118|committee members
P06361318A0440|77 81|cases
P06361318A0440|151 151|%
P06361318A0440|11 23|efficacy rates
P06361318A0440|38 42|cases
P06361318A0440|44 53|KS-R1 group
P06361318A0440|162 166|group
P06361318A0440|134 143|KS-R1 group
P06361318A0440|93 100|criteria
P06361318A0440|68 72|group
P06361318A0440|58 62|cases
P06361318A1127|0 9|Side effect
P06361318A1127|159 168|KS-R1 group
P06361318A1127|95 99|cases
P06361318A1127|81 90|KS-R1 group
P06361318A1127|105 109|group
P06361318A1127|152 152|%
P06361318A1127|176 176|%
P06361318A1127|127 139|incidence rate
P06361318A1127|211 220|difference
P06361318A1127|75 79|cases
P06361318A1127|41 48|symptoms
P06361318A1127|187 191|group
P06361318A1127|114 118|cases
P06362143A0565|56 75|isoprenaline infusion
P06362143A0565|50 53|tilt
P06362143A0565|81 88|patients
P06362143A0565|33 40|response
P06362143A0565|0 18|Plasma renin activity
P06362239T0001|0 11|Martin Luther
P06362239T0001|18 27|physicians
P06362602T0001|0 10|Enhancement
P06362602T0001|93 97|swine
P06362602T0001|22 29|response
P06362602T0001|105 109|swine
P06362602T0001|79 90|immunization
P06362602T0001|49 64|vaccine additives
P06362602T0001|41 46|action
P06364265T0062|7 27|gamma-ray spectroscopy
P06367414A0000|58 62|hours
P06367414A0000|10 26|calcium antagonist
P06367414A0000|113 126|crossover trial
P06367414A0000|32 40|half-life
P06367414A0000|79 85|placebo
P06367414A0000|0 7|Bepridil
P06369355A0834|0 7|Analysis
P06369355A0834|127 144|replication protein
P06369355A0834|66 75|trfA region
P06369355A0834|92 100|A2 protein
P06369355A0834|10 17|proteins
P06369355A0834|31 38|plasmids
P06369355A0834|147 156|plasmid RK2
P06369355A0834|56 60|forms
P06369954T0000|0 6|Effects
P06369954T0000|24 31|pressure
P06369954T0000|49 60|hemodynamics
P06370553A0444|87 88|wk
P06370553A0444|158 162|ng/ml
P06370553A0444|75 81|therapy
P06370553A0444|48 53|levels
P06370553A0444|46 46|E
P06370553A0444|126 133|plasma NE
P06370553A0444|105 114|guanfacine
P06370553A0444|28 29|NE
P06370553A0444|7 26|plasma norepinephrine
P06370553A0444|94 103|withdrawal
P06370553A0444|164 170|plasma E
P06370553A0444|34 44|epinephrine
P06370553A0444|195 199|ng/ml
P06370553A0444|118 124|control
P06372563T0000|87 98|hyponatremia
P06372563T0000|63 73|natriuresis
P06372563T0000|5 12|response
P06372563T0000|77 84|reversal
P06372563T0000|51 60|furosemide
P06372563T0000|32 43|heart failure
P06372563T0000|45 48|role
P06372563T0000|15 23|captopril
P06373409A1163|0 8|Lauciello
P06373409A1163|34 42|placement
P06373409A1163|115 119|teeth
P06373409A1163|80 91|restorations
P06373409A1163|66 72|amalgam
P06373409A1163|19 27|technique
P06373855A0000|117 121|acuta
P06373855A0000|53 59|lesions
P06373855A0000|39 43|dusky
P06373855A0000|26 32|papules
P06373855A0000|6 20|biopsy specimens
P06373855A0000|123 127|PLEVA
P06373855A0000|169 192|immunoperoxidase technics
P06373855A0000|81 101|pityriasis lichenoides
P06373855A0000|69 76|patients
P06373855A0000|148 165|immunofluorescence
P06374369A1112|99 102|diet
P06374369A1112|46 55|food intake
P06374369A1112|125 130|events
P06374369A1112|35 43|reduction
P06374369A1112|26 29|part
P06374369A1112|5 8|data
P06374369A1112|69 72|rats
P06374418A0877|27 30|cyst
P06374418A0877|80 86|hormone
P06374418A0877|61 66|amount
P06374418A0877|3 10|aspirate
P06376227A0217|0 2|EGV
P06376227A0217|59 68|conditions
P06376227A0217|18 23|effect
P06376227A0217|26 36|PP secretion
P06379363A0415|78 84|therapy
P06379363A0415|130 137|practice
P06379363A0415|11 15|tests
P06379363A0415|104 119|diabetes mellitus
P06379363A0415|34 39|HDL-2M
P06381438A1280|0 25|Lung prostacyclin production
P06382374A0206|13 15|min
P06382374A0206|105 112|patients
P06382374A0206|25 45|insulin administration
P06382374A0206|179 186|disorder
P06382374A0206|56 61|change
P06382374A0206|50 53|rate
P06382374A0206|64 76|glucose levels
P06382374A0206|132 139|disorder
P06382374A0206|198 212|control subjects
P06382374A0206|158 165|patients
P06384983T0000|0 9|Management
P06384983T0000|12 23|hypertension
P06385474T0001|42 48|allergy
P06385474T0001|8 16|treatment
P06385474T0001|19 26|children
P06388189T0001|0 14|Transplantation
P06388189T0001|47 56|recipients
P06388189T0001|34 39|donors
P06388189T0001|17 23|kidneys
P06388818A0000|56 64|lymphomas
P06388818A0000|183 188|rescue
P06388818A0000|169 171|HDC
P06388818A0000|111 130|chemotherapy regimens
P06388818A0000|213 230|bone marrow infusion
P06388818A0000|156 167|chemotherapy
P06388818A0000|31 37|Hodgkin
P06388818A0000|232 235|ABMT
P06388818A0000|3 10|patients
P06391496T0000|29 40|polypeptides
P06391496T0000|79 86|antacids
P06391496T0000|63 70|almagate
P06391496T0000|46 60|antacid activity
P06391496T0000|19 25|enzymes
P06391496T0000|0 5|Effect
P06394228T0073|0 6|Results
P06394228T0073|20 24|study
P06394347A1024|29 36|increase
P06394347A1024|39 57|plasma renin activity
P06394347A1024|68 76|excretion
P06394347A1024|79 91|noradrenaline
P06394347A1024|0 11|Hydrallazine
P06395804A0382|0 13|Urease activity
P06395804A0382|18 18|%
P06395804A0382|56 58|min
P06395804A0382|26 34|organisms
P06397009A0204|56 71|conductor Bozzini
P06397009A0204|113 121|physician
P06397009A0204|26 29|life
P06397009A0204|144 151|medicine
P06397009A0204|35 45|explanation
P06397009A0204|74 78|merit
P06397009A0204|172 184|possibilities
P06397009A0204|5 15|description
P06397009A0204|97 105|invention
P06401749T0000|3 8|effect
P06401749T0000|39 66|arginine vasopressin secretion
P06401749T0000|11 17|lithium
P06401749T0000|23 36|osmoregulation
P06402480A0373|219 227|treatment
P06402480A0373|127 138|surveillance
P06402480A0373|53 63|antibiotics
P06402480A0373|77 90|plasmid pattern
P06402480A0373|188 202|recommendations
P06402480A0373|107 115|necessity
P06402480A0373|22 32|PPNG strains
P06402480A0373|151 160|infections
P06402480A0373|3 16|susceptibility
P06402480A0373|173 182|evaluation
P06402859A0000|0 14|Antithrombin III
P06402859A0000|61 69|inhibitor
P06402859A0000|25 37|plasma protein
P06402859A0000|115 125|coagulation
P06402859A0000|91 99|modulator
P06402859A0000|72 79|thrombin
P06404842A0127|129 136|duration
P06404842A0127|8 15|patients
P06404842A0127|112 116|weeks
P06404842A0127|67 83|depot testosterone
P06404842A0127|142 146|years
P06404842A0127|54 62|treatment
P06404842A0127|87 88|mg
P06406060A0000|43 44|ip
P06406060A0000|63 66|mice
P06406060A0000|14 22|cisplatin
P06406060A0000|54 57|mice
P06406060A0000|74 80|Sarcoma
P06406060A0000|38 39|iv
P06407348A0516|0 2|New
P06407348A0516|116 123|blockade
P06407348A0516|136 144|receptors
P06407348A0516|79 88|situations
P06407348A0516|169 183|muscle receptors
P06407348A0516|16 20|drugs
P06407348A0516|185 189|beta2
P06407348A0516|146 150|beta1
P06411659A0264|59 62|rate
P06411659A0264|2 11|facilities
P06411659A0264|31 41|consumption
P06411659A0264|15 26|measurements
P06411659A0793|90 98|mg/kg/day
P06411659A0793|50 66|energy expenditure
P06411659A0793|20 31|energy intake
P06411659A0793|73 79|N intake
P06411659A0793|42 46|times
P06412385A0356|297 305|pneumonia
P06412385A0356|258 267|dependence
P06412385A0356|229 233|PaCO2
P06412385A0356|208 227|carbon dioxide tension
P06412385A0356|115 126|lung capacity
P06412385A0356|282 292|atelectasis
P06412385A0356|101 108|capacity
P06412385A0356|131 137|maximum
P06412385A0356|191 196|volume
P06412385A0356|44 57|muscle weakness
P06412385A0356|22 32|lung disease
P06412385A0356|7 14|patients
P06412385A0356|172 180|increases
P06412385A0356|246 255|likelihood
P06412385A0356|85 93|decreases
P06412385A0356|270 280|ventilators
P06412385A0356|147 157|ventilation
P06413492A0990|0 5|Commun
P06414990A0057|40 45|sample
P06414990A0057|24 27|data
P06414990A0057|150 153|area
P06414990A0057|30 36|TRH test
P06414990A0057|118 136|thyrotropin response
P06414990A0057|101 106|limits
P06414990A0057|57 66|volunteers
P06414990A0057|81 90|evaluation
P06414990A0057|14 21|analysis
P06415299A0233|15 19|doses
P06415299A0233|22 32|doxorubicin
P06415299A0233|51 52|mg
P06415299A0233|55 56|m.
P06419251T0000|0 18|Movement programming
P06419251T0000|53 64|requirements
P06419251T0000|28 40|understanding
P06426493A0331|84 92|heart rate
P06426493A0331|127 131|group
P06426493A0331|134 141|patients
P06426493A0331|108 110|CVP
P06426493A0331|49 60|measurements
P06426493A0331|22 37|state anaesthesia
P06426493A0331|181 191|pancuronium
P06426493A0331|150 159|atracurium
P06426493A0331|75 82|pressure
P06426493A0331|11 13|min
P06426493A0331|63 65|IOP
P06426493A0331|99 103|FE'CO
P06426493A0331|94 97|FIO2
P06426493A0331|164 169|mg kg-1
P06426493A0331|195 200|mg kg-1
P06428116T0000|33 46|hypothyroidism
P06428116T0000|68 78|thyroiditis
P06428116T0000|52 57|course
P06429992T0000|0 17|Gonadotropin levels
P06429992T0000|20 26|mothers
P06429992T0000|46 52|DZ twins
P06429992T0000|40 43|sets
P06433442T0000|0 7|Freezing
P06433442T0000|37 42|factor
P06433442T0000|48 49|C.
P06433442T0000|10 15|plasma
P06433442T0000|30 34|yield
P06434572A0157|146 146|n
P06434572A0157|128 144|growth retardation
P06434572A0157|42 51|categories
P06434572A0157|276 280|tests
P06434572A0157|210 210|n
P06434572A0157|283 291|GH reserve
P06434572A0157|109 109|n
P06434572A0157|177 182|growth
P06434572A0157|78 78|n
P06434572A0157|5 12|children
P06434572A0157|93 107|hypopituitarism
P06434572A0157|65 76|GH deficiency
P06434572A0157|170 174|delay
P06434572A0157|234 241|criteria
P06434572A0157|202 208|stature
P06434587A0551|58 66|secretion
P06434587A0551|4 10|patient
P06434587A0551|79 80|LH
P06434587A0551|24 25|LH
P06434587A0551|98 100|LRH
P06434587A0551|84 95|FSH responses
P06434587A0551|29 37|FSH levels
P06435565A0648|28 35|decrease
P06435565A0648|172 179|dynes/cm
P06435565A0648|99 99|p
P06435565A0648|38 46|afterload
P06435565A0648|19 24|result
P06435565A0648|5 11|changes
P06435565A0648|132 141|resistance
P06435565A0648|94 97|mmHg
P06435565A0648|191 191|p
P06435565A0648|58 65|pressure
P06437579A0727|0 9|Cimetidine
P06437579A0727|22 26|night
P06437579A0727|45 46|mg
P06437579A0727|13 14|mg
P06437579A0727|122 130|treatment
P06437579A0727|88 104|patient compliance
P06437579A0727|67 77|dose regimen
P06439114A0677|0 10|Ceftazidime
P06439114A0677|16 22|promise
P06439114A0677|37 43|therapy
P06439114A0677|76 85|infections
P06439135A0250|0 10|Regional CBF
P06439135A0250|89 98|procedures
P06439135A0250|49 56|patients
P06439135A0250|37 41|xenon
P06439135A0250|26 34|clearance
P06439135A0250|75 80|bypass
P06441624A0263|41 51|measurement
P06441624A0263|54 67|bone metabolism
P06441624A0263|22 29|serum BGP
P06441624A0263|3 9|results
P06443550T0000|27 33|patient
P06443550T0000|3 12|management
P06443639T0001|0 4|Study
P06443639T0001|33 40|movement
P06443639T0001|16 23|motility
P06443639T0001|53 69|circuit television
P06443639T0001|27 30|rate
P06443714T0001|9 28|Rhodnius prolixus Stal
P06443714T0001|37 52|babassu palm trees
P06444119A0340|177 183|factors
P06444119A0340|41 50|preference
P06444119A0340|80 87|salinity
P06444119A0340|13 20|organism
P06444119A0340|68 78|temperature
P06444119A0340|113 125|growth factors
P06444119A0340|54 64|requirement
P06444119A0340|89 90|pH
P06444119A0340|100 108|nutrients
P06444119A0340|133 146|toxin formation
P06446048A0356|102 108|problem
P06446048A0356|48 55|solution
P06446048A0356|32 38|by-pass
P06451557A0777|0 10|Deformities
P06451557A0777|24 32|olecranon
P06451557A0777|108 114|Weseloh
P06451557A0777|73 79|De Palma
P06451557A0777|49 55|process
P06451557A0777|16 18|tip
P06451557A0777|96 102|Ahlberg
P06451557A0777|85 90|Jordan
P06452461A0930|58 71|post AVR studies
P06452461A0930|48 54|pre-AVR
P06452461A0930|32 37|LVM/M2
P06452461A0930|19 29|correlation
P06452461A0930|41 44|PWVn
P06452827T0001|17 25|recording
P06452827T0001|28 44|Huntington choreas
P06453290A0000|100 107|material
P06453290A0000|65 69|ducts
P06453290A0000|32 43|organization
P06453290A0000|113 117|weeks
P06453290A0000|3 13|development
P06454625A0000|161 184|magnification angiography
P06454625A0000|88 97|hemostasis
P06454625A0000|59 69|vasculature
P06454625A0000|73 82|parenchyma
P06454625A0000|38 48|alterations
P06454625A0000|18 33|animal experiment
P06454625A0000|186 204|magnification factor
P06454625A0000|109 136|Infrared-Contact-Coagulation
P06459831T0001|0 13|Cardiovascular
P06459831T0001|43 51|reactions
P06459831T0001|59 74|tobacco poisoning
P06460889A0111|135 143|blood flow
P06460889A0111|23 27|SG-75
P06460889A0111|11 20|injections
P06460889A0111|145 147|PBF
P06460889A0111|72 74|SBP
P06460889A0111|35 39|mg/kg
P06460889A0111|58 70|blood pressure
P06460889A0512|57 69|pulse pressure
P06460889A0512|112 119|pressure
P06460889A0512|128 137|LVdP/dt max
P06460889A0512|15 25|.3 mg/kg i.v.
P06460889A0512|2 6|doses
P06460889A0512|121 123|LVP
P06460889A0512|71 79|heart rate
P06460889A0512|27 31|SG-75
P06460889A0512|87 95|blood flow
P06463429A0414|31 31|%
P06463429A0414|20 24|phase
P06463429A0414|7 8|VE
P06463429A0414|62 66|phase
P06466804A0686|58 70|tape recording
P06466804A0686|171 175|shear
P06466804A0686|10 20|endothelium
P06466804A0686|115 123|flowmeter
P06466804A0686|188 195|dyne/cm2
P06466804A0686|32 44|shear stresses
P06466804A0686|141 146|injury
P06466804A0686|86 98|flow waveforms
P06466804A0686|149 158|denudation
P06466804A0686|0 7|Exposure
P06467241A0000|0 18|Modern cancer therapy
P06467241A0000|80 92|immunotherapy
P06467241A0000|38 49|radiotherapy
P06467241A0000|51 62|chemotherapy
P06467241A0000|96 107|hyperthermia
P06467241A0000|30 36|surgery
P06467797A0233|85 89|ratio
P06467797A0233|131 131|P
P06467797A0233|49 50|NT
P06467797A0233|122 123|rs
P06467797A0233|148 153|Swedes
P06467797A0233|75 75|D
P06467797A0233|101 105|urine
P06467797A0233|91 98|D/4-OH-D
P06467797A0233|112 120|Ghanaians
P06467797A0233|155 156|rs
P06467797A0233|14 24|correlation
P06467797A0233|53 68|10-hydroxylation
P06467797A0233|164 164|P
P06467797A0233|32 46|plasma clearance
P06468565A0000|158 179|frequency gain constants
P06468565A0000|80 89|parameters
P06468565A0000|23 25|cat
P06468565A0000|114 116|tau
P06468565A0000|181 182|Gm
P06468565A0000|122 143|frequency gain constants
P06468565A0000|51 51|N
P06468565A0000|36 49|canal afferents
P06468565A0000|100 112|time constants
P06468565A0000|3 20|response properties
P06468565A0000|145 146|G1
P06468632A0135|0 10|Endothelium
P06468632A0135|23 31|ear artery
P06468632A0135|108 113|vessel
P06468632A0135|90 92|ear
P06468632A0135|48 53|rabbit
P06468632A0135|72 84|artery forceps
P06468673A0358|112 112|P
P06468673A0358|56 66|mucus scores
P06468673A0358|106 110|group
P06468673A0358|23 38|E2 concentrations
P06468694A0441|0 10|Stimulation
P06468694A0441|126 138|deterioration
P06468694A0441|112 120|phenamine
P06468694A0441|63 67|means
P06468694A0441|168 177|components
P06468694A0441|49 54|system
P06468694A0441|98 107|micrograms
P06468694A0441|57 60|dogs
P06468694A0441|70 83|administration
P06468694A0441|16 29|caudate nucleus
P06468694A0441|187 195|behaviour
P06468694A0441|86 94|dophamine
P06473219T0000|0 4|Value
P06473219T0000|7 23|urine glucose tests
P06473219T0000|29 38|management
P06473219T0000|47 62|diabetes mellitus
P06473219T0000|41 44|type
P06473252A1073|42 44|sex
P06473252A1073|111 115|WORDS
P06473252A1073|89 96|ABSTRACT
P06473252A1073|4 13|experiment
P06473252A1073|81 86|factor
P06473252A1073|53 65|egg production
P06479362A0680|0 13|Hydrocortisone
P06479362A0680|67 80|muscle membrane
P06479362A0680|124 130|changes
P06479362A0680|102 108|hormone
P06479362A0680|136 149|muscle membrane
P06479362A0680|92 96|doses
P06479362A0680|40 61|postdenervation changes
P06479976A0386|103 111|diagnosis
P06479976A0386|114 120|illness
P06479976A0386|40 47|patients
P06479976A0386|19 29|differences
P06479976A0386|180 187|patients
P06479976A0386|82 93|survival time
P06479976A0386|69 71|AMB
P06479976A0386|158 167|nerve signs
P06479976A0386|122 122|P
P06479976A0386|189 189|P
P06480542A0000|16 20|study
P06480542A0000|23 32|apalcillin
P06480542A0000|75 78|unit
P06480542A0000|49 56|patients
P06482179A0497|0 13|Catch-up growth
P06482179A0497|50 57|children
P06482179A0497|76 80|years
P06482179A0497|63 69|bone age
P06482179A0497|41 46|period
P06482318A0117|0 18|Thrombocyte function
P06482318A0117|35 42|patients
P06482318A0117|70 88|platelet shape change
P06482665A0735|3 10|findings
P06482665A0735|103 106|peak
P06482665A0735|26 43|AMPH administration
P06482665A0735|112 125|caudate nucleus
P06482665A0735|76 81|height
P06482665A0735|180 188|increases
P06482665A0735|128 141|pigtail monkeys
P06482665A0735|242 246|state
P06482665A0735|63 70|increase
P06482665A0735|252 257|animal
P06483863A0000|144 147|days
P06483863A0000|129 131|oil
P06483863A0000|246 255|Experiment
P06483863A0000|219 229|Experiments
P06483863A0000|179 182|days
P06483863A0000|207 217|concretions
P06483863A0000|82 91|injections
P06483863A0000|107 120|beta-estradiol
P06483863A0000|150 153|life
P06483863A0000|95 104|micrograms
P06483863A0000|239 244|silica
P06483863A0000|185 187|age
P06483863A0000|43 60|BALB/cfC3HCrgl mice
P06483863A0000|31 40|BALB/cCrgl
P06483863A0000|5 15|experiments
P06483863A0000|196 199|time
P06486932A0000|41 46|people
P06486932A0000|135 139|death
P06486932A0000|11 16|deaths
P06486932A0000|20 20|%
P06486932A0000|62 75|Malumfashi area
P06486932A0000|86 92|Nigeria
P06486932A0000|22 30|occurring
P06486932A0000|94 97|data
P06486932A0000|54 56|age
P06486932A0000|113 120|symptoms
P06487290A0000|219 223|cycle
P06487290A0000|177 184|controls
P06487290A0000|24 32|E2-17 beta
P06487290A0000|37 48|progesterone
P06487290A0000|19 22|beta
P06487290A0000|111 117|females
P06487290A0000|50 50|P
P06487290A0000|8 16|estradiol
P06487290A0000|143 152|trimesters
P06487290A0000|73 98|radioimmunoassay techniques
P06487290A0000|200 204|phase
P06492188A0615|44 49|number
P06492188A0615|33 38|effect
P06492188A0615|9 9|d
P06492188A0615|52 59|implants
P06493655A0415|76 76|%
P06493655A0415|8 23|FHR decelerations
P06493655A0415|26 37|bradycardias
P06493655A0415|97 104|patients
P06493655A0415|57 70|nonstress tests
P06493655A0415|87 87|%
P06494215A0248|46 61|food presentation
P06494215A0248|79 86|schedule
P06494215A0248|22 30|component
P06494215A0248|3 15|response chain
P06494297A0939|114 124|stimulation
P06494297A0939|64 74|acquisition
P06494297A0939|103 108|effect
P06494297A0939|77 81|HPC SS
P06494297A0939|56 61|effect
P06494297A0939|19 26|kindling
P06494297A0939|3 9|results
P06494766A0241|18 27|dispersion
P06494766A0241|77 82|septum
P06494766A0241|38 56|Hiss bundle fragments
P06494766A0241|104 114|explanation
P06495195A0536|57 75|alkaline phosphatase
P06495195A0536|143 153|liver damage
P06495195A0536|51 53|U/l
P06495195A0536|35 42|activity
P06495195A0536|25 29|tests
P06495195A0536|100 107|patients
P06497671T0001|43 51|responses
P06497671T0001|9 27|plasma cortisol level
P06497671T0001|0 6|Changes
P06501086A0165|120 140|vas deferens granulomas
P06501086A0165|11 21|alterations
P06501086A0165|39 42|rats
P06501086A0165|190 195|levels
P06501086A0165|47 54|sham rats
P06501086A0165|99 107|formation
P06501086A0165|156 167|serum protein
P06501086A0165|238 266|sperm agglutinin antibody titers
P06501086A0165|205 224|serum electrophoresis
P06501086A0165|87 97|hypertrophy
P06503132A0784|29 30|Hn
P06503132A0784|32 32|s
P06503132A0784|0 2|SFP
P06503329A0588|67 78|control group
P06503329A0588|47 48|SD
P06503329A0588|99 99|P
P06503329A0588|10 18|birth mass
P06503329A0588|97 97|g
P06503329A0588|90 91|SD
P06503329A0588|54 54|g
P06503329A0588|26 33|newborns
P06503885A0342|115 127|x-ray tube heat
P06503885A0342|154 167|overestimation
P06503885A0342|61 71|temperature
P06503885A0342|49 53|water
P06503885A0342|43 46|rise
P06503885A0342|196 199|rCBF
P06503885A0342|267 284|interscan intervals
P06503885A0342|205 224|xenon/CT rCBF protocol
P06503885A0342|4 15|machine drift
P06503885A0342|186 194|blood flow
P06503885A0342|247 251|scans
P06505014A1192|41 45|Vinca
P06505014A1192|34 37|Y-12
P06505014A1192|23 31|dosimetry
P06505014A1192|5 17|uncertainties
P06506074A0456|0 11|E2 treatments
P06506074A0456|20 30|hen plasma TG
P06506074A0456|46 46|C
P06506074A0456|72 72|X
P06506074A0456|50 50|X
P06506074A0456|74 75|PL
P06506074A0456|88 89|X.
P06506074A0456|84 84|C
P06506074A0456|61 68|plasma TG
P06506074A0456|41 41|X
P06506074A0456|36 37|PL
P06506074A0456|34 34|X
P06506074A0456|79 79|X
P06507629A0717|2 9|contrast
P06507629A0717|113 127|mumol X min-1 X g-1
P06507629A0717|11 17|kidneys
P06507629A0717|79 81|NH3
P06507629A0717|95 100|groups
P06507629A0717|22 25|rats
P06507629A0717|46 53|acidosis
P06508393T0000|15 29|trypanosomiasis
P06508393T0000|78 88|Testryp CATT
P06508393T0000|41 46|camels
P06508393T0000|53 76|card agglutination test set
P06508393T0000|0 12|Serodiagnosis
P06513456T0001|58 62|ulcer
P06513456T0001|38 45|patients
P06513456T0001|30 35|mucosa
P06513456T0001|77 85|treatment
P06513456T0001|0 20|Adenyl cyclase activity
P06516369T0001|0 10|Proteinuria
P06516369T0001|50 57|problems
P06516847A0393|34 44|pneumococci
P06516847A0393|55 63|mortality
P06516847A0393|68 78|pneumococci
P06516977T0000|0 7|Reaction
P06516977T0000|25 32|exercise
P06516977T0000|15 22|organism
P06517816A0388|82 82|p
P06517816A0388|96 98|Msw
P06517816A0388|60 66|b X min-1
P06517816A0388|43 50|degrees C
P06517816A0388|102 110|g X m-2 X h-1
P06517816A0388|22 22|p
P06517816A0388|36 38|Tre
P06517816A0388|0 1|HA
P06517816A0388|121 137|saline experiments
P06517816A0388|55 56|HR
P06520418A0325|87 94|patients
P06520418A0325|111 133|LVIT flow velocity pattern
P06520418A0325|140 147|patients
P06520418A0325|158 158|p
P06520418A0325|3 9|results
P06520418A0325|152 155|type
P06520418A0325|99 102|type
P06520418A0325|41 56|valve orifice area
P06520418A0325|58 60|MVA
P06521802A0251|0 20|Scientific cooperation
P06521802A0251|76 86|sponsorship
P06521802A0251|164 172|framework
P06521802A0251|92 114|Cancer Research Institute
P06521802A0251|23 41|CMEA member countries
P06521802A0251|140 153|Czechoslovakia
P06521802A0251|116 128|Slovak Academy
P06521802A0251|131 138|Sciences
P06521802A0251|175 178|CMEA
P06521999A0677|46 54|melanomas
P06521999A0677|64 74|enucleation
P06521999A0677|23 29|results
P06524202A0167|82 87|method
P06524202A0167|98 105|training
P06524202A0167|132 141|spasticity
P06524202A0167|30 41|multichannel
P06524202A0167|149 159|antagonists
P06524202A0167|179 195|motor coordination
P06524202A0167|16 28|EMG-BFB method
P06524202A0167|4 10|variant
P06524202A0167|114 120|muscles
P06524727A0601|0 10|Lymphocytes
P06524727A0601|121 133|blood dilution
P06524727A0601|61 68|prelabel
P06524727A0601|40 48|responses
P06524727A0601|113 113|C
P06524727A0601|19 25|species
P06524727A0601|93 108|incubation period
P06524727A0601|80 83|hour
P06524761A0596|144 152|challenge
P06524761A0596|17 26|difference
P06524761A0596|274 281|RH strain
P06524761A0596|209 216|hamsters
P06524761A0596|225 246|live-toxoplasma vaccine
P06524761A0596|254 262|challenge
P06524761A0596|50 54|fever
P06524761A0596|107 130|killed-toxoplasma vaccine
P06524761A0596|164 172|T-1 strain
P06524761A0596|186 192|changes
P06524761A0596|41 48|immunity
P06524761A0596|82 89|hamsters
P06524761A0596|32 38|quality
P06524761A0596|58 71|body weight loss
P06527379T0044|74 84|DNA sequence
P06527379T0044|11 33|proline/alanine sequence
P06527379T0044|36 48|beta B1 subunit
P06527872T0000|145 149|means
P06527872T0000|154 168|acid phosphatase
P06527872T0000|112 115|cord
P06527872T0000|81 100|substantia gelatinosa
P06527872T0000|70 75|nerves
P06527872T0000|138 142|study
P06527872T0000|23 33|projections
P06527872T0000|170 172|ACP
P06527872T0000|118 121|rats
P06527872T0000|174 179|method
P06531286A0382|0 6|Removal
P06531286A0382|9 22|lipid fractions
P06531286A0382|25 40|plant extractions
P06531286A0382|82 91|HPLC column
P06531286A0382|45 50|hexane
P06531286A0382|71 76|damage
P06535384A1115|143 150|ABSTRACT
P06535384A1115|50 59|difficulty
P06535384A1115|120 126|success
P06535384A1115|133 140|subjects
P06535384A1115|107 117|possibility
P06535384A1115|87 91|items
P06535384A1115|30 34|items
P06535384A1115|165 169|WORDS
P06535384A1115|15 21|subtest
P06539738T0000|28 45|chlorofluorocarbon
P06539738T0000|49 51|CFC
P06539738T0000|16 25|evaluation
P06541019A0555|42 49|response
P06541019A0555|3 10|patients
P06541019A0555|27 34|toxicity
P06541932A0000|0 6|Methods
P06541932A0000|32 42|algesimetry
P06541932A0000|81 87|effects
P06541932A0000|120 129|analgesics
P06542372A0159|102 106|terms
P06542372A0159|110 119|additivity
P06542372A0159|36 48|discrepancies
P06542372A0159|10 14|paper
P06542372A0159|123 134|potentiation
P06542372A0159|70 80|terminology
P06542372A0159|147 156|similarity
P06542918A1131|69 78|evaluation
P06542918A1131|114 124|P3 latencies
P06542918A1131|25 38|discrimination
P06542918A1131|55 58|time
P06545651A0346|45 54|treatments
P06545651A0346|57 63|finding
P06545651A0346|96 121|protein nitrogen degradation
P06545651A0346|144 146|NH3
P06545651A0346|135 142|nitrogen
P06545651A0346|88 93|effect
P06545651A0346|0 19|Ammonia concentration
P06546392A0542|71 98|erythrocyte sedimentation rate
P06546392A0542|22 42|protein concentrations
P06546392A0542|61 69|cell count
P06546392A0542|103 113|temperature
P06546392A0542|136 148|antiproteases
P06546392A0542|6 13|respect C
P06546392A0542|120 133|concentrations
P06548953T0001|29 43|thyroid diseases
P06548953T0001|23 25|HTS
P06548953T0001|5 21|thyroid stimulator
P06555107A1227|14 27|administration
P06555107A1227|75 79|value
P06555107A1227|104 116|beta-mimetics
P06555107A1227|91 99|treatment
P06555107A1227|33 58|calcium antagonist Verapamil
P06568939A0000|0 8|Brainstem
P06568939A0000|87 97|information
P06568939A0000|33 37|BAERs
P06568939A0000|114 121|pathways
P06568939A0000|23 31|responses
P06568939A0000|62 79|eye movement studies
P06568939A0000|135 143|brainstem
P06568939A0000|103 111|integrity
P06571587T0000|0 6|Effects
P06571587T0000|45 65|body tissue oxygenation
P06571587T0000|9 16|ketamine
P06571587T0000|68 71|dogs
P06571587T0000|33 41|functions
P06571587T0000|97 106|conditions
P06579147A0060|30 37|problems
P06579147A0060|62 71|approaches
P06579147A0060|40 49|management
P06579147A0060|77 90|reconstruction
P06579147A0060|120 126|disease
P06579147A0060|18 25|features
P06579147A0060|99 109|deformities
P06579152A1061|86 88|way
P06579152A1061|62 83|velopharyngeal activity
P06579152A1061|50 59|activation
P06579152A1061|43 46|tool
P06579152A1061|30 32|NPF
P06579152A1061|97 112|feed-back control
P06582285A0222|97 101|weeks
P06582285A0222|103 111|gestation
P06582285A0222|38 40|D&E
P06582285A0222|24 29|safety
P06582285A0222|32 34|U-P
P06582285A0222|68 79|D&E abortions
P06582285A0222|57 59|U-P
P06584416A0157|44 47|data
P06584416A0157|108 110|PGF
P06584416A0157|35 42|patients
P06584416A0157|24 32|knowledge
P06584416A0157|89 100|examinations
P06584416A0157|5 16|radiologists
P06584416A0157|51 59|treatment
P06584416A0157|70 79|angiograms
P06585277A0000|160 168|existence
P06585277A0000|92 96|serum
P06585277A0000|103 110|presence
P06585277A0000|3 5|man
P06585277A0000|36 46|association
P06585277A0000|67 89|acid phosphatase activity
P06585277A0000|24 31|leukemia
P06585277A0000|120 130|bone lesions
P06585277A0000|133 147|roentgenography
P06585277A0000|192 200|carcinoma
P06588306A0076|42 48|therapy
P06588306A0076|17 37|prophylactic treatment
P06588306A0076|69 71|AIL
P06588306A0076|54 65|meningopathy
P06588306A0076|73 86|AIEOP protocols
P06588501T0059|23 27|study
P06591992A0569|43 50|solution
P06591992A0569|2 13|anisotropism
P06593862T0001|0 16|Hepatitis B vaccine
P06594105A0560|79 82|pulp
P06594105A0560|181 188|lambda tp
P06594105A0560|203 213|temperature
P06594105A0560|21 28|lambda tb
P06594105A0560|145 151|gingiva
P06594105A0560|49 63|cent haematocrit
P06594105A0560|233 241|degrees C.
P06594105A0560|13 18|values
P06594105A0560|95 100|tongue
P06594105A0560|126 130|gland
P06594105A0560|161 168|lambda cp
P06594105A0560|157 159|dog
P06594105A0560|33 40|degrees C
P06597709A0596|174 178|cases
P06597709A0596|60 70|lung volumes
P06597709A0596|35 44|asbestosis
P06597709A0596|77 81|ratio
P06597709A0596|127 133|results
P06597709A0596|141 152|measurements
P06597709A0596|84 97|transfer factor
P06597709A0596|117 122|volume
P06599282T0001|28 40|cell carcinoma
P06599282T0001|11 17|pattern
P06599282T0001|56 62|gingiva
P06600533T0000|56 66|lobe bronchi
P06600533T0000|30 33|wall
P06600533T0000|75 83|CT variant
P06600533T0000|0 9|Azygos vein
P06602580A0664|145 151|normals
P06602580A0664|105 132|alpha 1-antitrypsin deficiency
P06602580A0664|90 100|individuals
P06602580A0664|11 17|history
P06602580A0664|31 43|complications
P06602580A0664|48 58|otitis media
P06602580A0664|74 82|frequency
P06602600A0582|3 10|Sarns 51F
P06602600A0582|21 27|cannula
P06602600A0582|49 54|system
P06602600A0582|84 91|cannulas
P06606043A0598|68 78|phenyl group
P06606043A0598|29 39|6-positions
P06606043A0598|104 111|decrease
P06606043A0598|8 14|changes
P06606043A0598|114 121|activity
P06606043A0598|52 62|replacement
P06606043A0598|81 88|position
P06607427A0000|63 69|lesions
P06607427A0000|215 223|behaviour
P06607427A0000|117 127|projections
P06607427A0000|5 15|experiments
P06607427A0000|159 164|cortex
P06607427A0000|144 155|hypothalamus
P06607427A0000|98 103|dorsal
P06607427A0000|29 35|effects
P06607427A0000|229 231|rat
P06607427A0000|183 199|body weight changes
P06607714T0000|0 13|Limb allografts
P06607714T0000|40 52|cyclosporin A.
P06607714T0000|16 19|rats
P06609166A0209|88 98|microliters
P06609166A0209|54 65|acetonitrile
P06609166A0209|76 84|injection
P06609166A0209|130 152|C18 reversed-phase column
P06609166A0209|3 8|method
P06609166A0209|45 51|volumes
P06609166A0209|31 37|samples
P06610347A0581|85 90|AV node
P06610347A0581|10 16|periods
P06610347A0581|65 74|conduction
P06610347A0581|22 31|AV junction
P06610347A0581|56 62|fashion
P06612373A0000|86 88|use
P06612373A0000|103 107|drugs
P06612373A0000|50 56|sources
P06612373A0000|130 134|1970s
P06612373A0000|4 8|paper
P06612373A0000|63 68|extent
P06612373A0000|23 26|data
P06612373A0000|71 82|prescription
P06612373A0000|117 121|1960s
P06612373A0000|41 47|variety
P06615053A0202|41 53|resuscitation
P06615053A0202|34 38|hours
P06615053A0202|91 98|ejection
P06615053A0202|142 147|RVEDVI
P06615053A0202|135 140|volume
P06615053A0202|7 14|patients
P06615053A0202|100 103|RVEF
P06615403A0718|42 47|series
P06615403A0718|50 50|n
P06615403A0718|93 99|minutes
P06615403A0718|148 154|minutes
P06615403A0718|105 112|ligation
P06615403A0718|34 40|minutes
P06615403A0718|56 65|microns TMs
P06615403A0718|116 125|microns TMs
P06615403A0718|13 24|LAD occlusion
P06625058A0666|60 63|cost
P06625058A0666|67 72|capita
P06625058A0666|3 12|population
P06627123A0000|71 78|calories
P06627123A0000|6 15|Wistar rats
P06627123A0000|35 42|Sustacal
P06627123A0000|92 98|sucrose
P06627123A0000|68 68|%
P06627123A0000|30 33|diet
P06627123A0000|58 64|ethanol
P06627569T0001|0 1|HL
P06627569T0001|4 27|type oculomotor stimulator
P06629370A0252|28 54|basement membrane nephropathy
P06629370A0252|13 17|group
P06629370A0252|106 121|basement membrane
P06629370A0252|156 163|syndrome
P06629370A0252|23 26|type
P06629370A0252|90 100|lamellation
P06629370A0252|4 11|patients
P06629370A0252|125 131|pattern
P06629370A0252|148 153|Alport
P06630319A0244|0 6|Brain pH
P06630319A0244|101 111|barbiturate
P06630319A0244|33 40|ischemia
P06630319A0244|59 63|value
P06630319A0244|115 133|halothane anesthesia
P06630319A0244|17 17|h
P06630319A0244|82 88|animals
P06634712A0557|3 9|results
P06634712A0557|36 44|phosphate
P06634712A0557|48 54|calcium
P06634712A0557|24 33|importance
P06634712A0557|88 89|CT
P06634712A0557|71 79|secretion
P06634712A0557|92 97|uremia
P06634712A0557|82 84|PTH
P06643612A0000|62 68|studies
P06643612A0000|92 96|urine
P06643612A0000|25 31|methods
P06643612A0000|83 88|plasma
P06643612A0000|71 80|imipramine
P06648156T0034|12 18|remarks
P06652293A0353|72 72|%
P06652293A0353|103 103|%
P06652293A0353|88 98|specificity
P06652293A0353|57 67|sensitivity
P06652293A0353|36 44|responses
P06652293A0353|20 24|point
P06653755A0192|30 50|autoregulation borders
P06653755A0192|5 26|clofelin administration
P06653755A0192|68 71|i. e.
P06653755A0192|85 92|AP levels
P06654047A0694|58 66|cell death
P06654047A0694|135 138|case
P06654047A0694|89 97|apoptosis
P06654047A0694|30 36|variant
P06654047A0694|150 165|rhabdomyosarcoma
P06654047A0694|4 13|phenomenon
P06654686T0001|72 75|girl
P06654686T0001|0 10|Combination
P06654686T0001|42 68|granulocyte function disorder
P06654686T0001|14 30|Shwachman syndrome
P06655634A0195|84 87|rate
P06655634A0195|110 110|%
P06655634A0195|9 14|series
P06655634A0195|37 39|TOL
P06655634A0195|62 79|cesarean deliveries
P06655634A0195|17 24|patients
P06655634A0195|134 142|morbidity
P06655634A0195|97 104|delivery
P06656249T0000|0 20|Nursing home discharges
P06656249T0000|31 38|practice
P06657559A0489|0 4|Trial
P06657559A0489|65 69|weeks
P06657559A0489|185 193|heart rate
P06657559A0489|37 47|control feed
P06657559A0489|150 153|feed
P06657559A0489|72 74|age
P06657559A0489|243 244|hr
P06657559A0489|197 209|blood pressure
P06657559A0489|114 115|hr
P06657559A0489|227 234|half hour
P06657559A0489|6 20|broiler chickens
P06657559A0489|104 107|feed
P06657559A0489|82 85|time
P06657559A0489|167 180|ppm ochratoxin A
P06657559A0489|137 147|control feed
P06658029A0086|60 66|battery
P06658029A0086|93 108|hazard evaluation
P06658029A0086|46 54|component
P06658029A0086|82 86|tests
P06658029A0086|3 20|carcinogen bioassay
P06658445A0140|16 22|animals
P06658445A0140|75 80|intake
P06658445A0140|66 72|amounts
P06658445A0140|26 28|man
P06658445A0140|7 13|effects
P06658586T0001|0 22|Angionephroscintigraphy
P06658586T0001|28 36|diagnosis
P06658586T0001|52 57|kidney
P06658586T0001|39 46|diseases
P06659982A0231|3 10|analysis
P06659982A0231|302 305|life
P06659982A0231|254 259|months
P06659982A0231|153 161|increases
P06659982A0231|95 99|stage
P06659982A0231|212 217|change
P06659982A0231|16 24|structure
P06659982A0231|182 186|phase
P06659982A0231|279 282|ones
P06659982A0231|101 102|DS
P06659982A0231|142 151|parameters
P06659982A0231|293 296|year
P06659982A0231|189 193|sleep
P06659982A0231|109 110|QS
P06659982A0231|30 40|sleep period
P06659982A0231|79 81|age
P06659982A0231|195 196|PS
P06662623A0124|43 49|Br-MISO
P06662623A0124|34 40|samples
P06662623A0124|6 9|MISO
P06662623A0124|102 109|n cm-2 s-1
P06662623A0124|53 67|SLOWPOKE reactor
P06662623A0124|83 93|neutron flux
P06662623A0124|72 72|h
P06662623A0124|1 4|82Br
P06667015A0832|131 145|serum CK-MB level
P06667015A0832|66 74|ischaemia
P06667015A0832|105 112|recovery
P06667015A0832|10 17|findings
P06667015A0832|81 87|surgery
P06667015A0832|31 41|sensitivity
P06667015A0832|60 63|wall
P06667868T0001|116 126|BR-1 benzene
P06667868T0001|106 113|exposure
P06667868T0001|53 56|rats
P06667868T0001|77 84|variants
P06667868T0001|33 40|elements
P06667868T0001|46 50|blood
P06667868T0001|16 21|status
P06668316A0178|214 223|phenacetin
P06668316A0178|78 82|phase
P06668316A0178|118 128|metabolites
P06668316A0178|243 245|min
P06668316A0178|18 37|reversed-phase column
P06668316A0178|205 212|standard
P06668316A0178|84 101|baseline separation
P06668316A0178|104 113|antipyrine
P06668316A0178|43 57|phosphate buffer
P06668316A0178|60 71|acetonitrile
P06669864T0001|3 7|liver
P06670732A0000|114 121|Fentanyl
P06670732A0000|23 30|patients
P06670732A0000|101 111|combination
P06670732A0000|126 127|mg
P06670732A0000|217 226|parameters
P06670732A0000|73 79|effects
P06670732A0000|183 191|mg/kg b.w.
P06670732A0000|132 141|Droperidol
P06670732A0000|94 95|mg
P06670732A0000|47 55|induction
P06670732A0000|148 154|Innovar
P06670732A0000|170 177|Atropine
P06670732A0000|144 145|mg
P06670732A0000|156 165|Thalamonal
P06670732A0000|13 17|study
P06670732A0000|82 89|Fentanyl
P06670732A0000|32 34|ASA
P06670732A0000|58 68|anaesthesia
P06671047A1124|234 238|tonus
P06671047A1124|225 226|DA
P06671047A1124|336 341|states
P06671047A1124|52 55|test
P06671047A1124|39 41|NOM
P06671047A1124|61 69|diagnosis
P06671047A1124|164 172|existence
P06671047A1124|187 199|Prolactinomas
P06671047A1124|135 139|CD/LD
P06671047A1124|98 103|states
P06671047A1124|252 262|possibility
P06671047A1124|292 298|factors
P06671047A1124|5 11|results
P06671047A1124|124 132|responses
P06671047A1124|141 142|LD
P06671047A1124|146 148|DOM
P06671047A1124|176 184|sub-group
P06671047A1124|29 36|validity
P06671065A0000|14 25|lipoproteins
P06671065A0000|54 61|children
P06671065A0000|104 109|status
P06671065A0000|115 122|patients
P06671065A0000|30 36|insulin
P06671065A0000|0 10|Serum lipids
P06671385A0856|115 131|body sodium content
P06671385A0856|36 54|plasma renin activity
P06671385A0856|62 63|PA
P06671385A0856|8 8|A
P06671385A0856|3 4|NA
P06671925T0000|0 21|Amikacin concentrations
P06671925T0000|24 28|serum
P06671925T0000|53 62|volunteers
P06671925T0000|68 75|patients
P06671925T0000|32 43|blister fluid
P06671925T0000|85 94|impairment
P06672094A0390|170 176|mammals
P06672094A0390|66 69|face
P06672094A0390|137 146|fasciculus
P06672094A0390|75 91|oculomotor nucleus
P06672094A0390|31 36|rectus
P06672094A0390|107 113|neurons
P06672094A0390|3 10|subgroup
P06674374T0000|0 28|Hepatitis B vaccination strategy
P06674374T0000|32 49|health-care workers
P06674374T0000|53 59|country
P06674374T0000|74 93|hepatitis B endemicity
P06674516A0350|119 123|field
P06674516A0350|13 24|drip infusion
P06674516A0350|40 45|dosage
P06674516A0350|89 96|diseases
P06674516A0350|27 29|AMK
P06674977A1181|57 57|%
P06674977A1181|22 22|%
P06674977A1181|10 17|families
P06674977A1181|88 94|table VI
P06674977A1181|78 86|diagnosis
P06674977A1181|34 42|pregnancy
P06674977A1181|44 48|table
P06675047A0000|70 78|Berthelot
P06675047A0000|89 97|Berthelot
P06675047A0000|23 34|interference
P06675047A0000|62 68|methods
P06675047A0000|113 125|determination
P06675047A0000|3 9|authors
P06675047A0000|137 140|urea
P06675047A0000|40 49|hemoglobin
P06683807A0160|42 51|prevalence
P06683807A0160|12 19|patients
P06683807A0160|54 63|alcohol use
P06683876A0244|86 98|daughter cells
P06683876A0244|67 74|clusters
P06683876A0244|52 58|fission
P06683876A0244|5 9|cells
P06683876A0244|20 26|microns
P06683876A0244|29 36|diameter
P06684624A0298|61 64|rats
P06684624A0298|80 86|diet 41B
P06684624A0298|16 26|mortalities
P06684624A0736|85 90|groups
P06684624A0736|41 52|mg creatinine
P06684624A0736|7 37|N-acetylglucosaminidase activity
P06685004A0000|132 136|women
P06685004A0000|41 56|globulin capacity
P06685004A0000|98 104|fitness
P06685004A0000|124 126|men
P06685004A0000|82 84|BMI
P06685004A0000|68 80|body mass index
P06685004A0000|58 61|SHBG
P06685004A0000|3 14|associations
P06685004A0000|64 66|age
P06685177T0000|0 11|Dipetalonema
P06685177T0000|24 41|hydrochoerus subgen
P06685177T0000|13 22|Alafilaria
P06685177T0000|48 49|n.
P06685536A0502|43 46|ewes
P06685536A0502|8 12|years
P06685536A0502|76 86|enucleation
P06685536A0502|32 38|control
P06685643A0179|99 104|stages
P06685643A0179|19 20|C4
P06685643A0179|24 29|C1-INH
P06685643A0179|52 56|stage
P06685643A0179|59 65|disease
P06685643A0179|3 16|concentrations
P06685643A0179|84 93|mean values
P06686454A0585|17 24|activity
P06686454A0585|55 61|bacilli
P06686454A0585|80 102|Klebsiella-Enterobacter
P06686454A0585|104 111|Shigella
P06686454A0585|129 146|Serratia marcescens
P06686454A0585|150 156|Proteus
P06687953T0000|43 58|leukocyte enzymes
P06687953T0000|10 24|defence capacity
P06689413A0174|127 129|KeV
P06689413A0174|48 50|mCi
P06689413A0174|24 29|Am-241
P06689413A0174|38 43|source
P06689413A0174|77 78|mm
P06689413A0174|92 97|K alpha
P06689413A0174|109 114|x-rays
P06689413A0174|148 153|iodine
P06689413A0174|59 68|Ge detector
P06689413A0174|3 11|apparatus
P06689413A0174|72 75|mm2 X
P06689513T0001|15 21|studies
P06689513T0001|24 34|retinopathy
P06689513T0001|46 52|infants
P06691304A0284|129 137|age groups
P06691304A0284|103 107|males
P06691304A0284|65 74|deviations
P06691304A0284|111 117|females
P06691304A0284|34 39|values
P06691304A0284|10 28|serum concentrations
P06691304A0284|3 7|range
P06691304A0284|82 88|analyte
P06691304A0284|47 52|values
P06692517T0000|60 66|thrombi
P06692517T0000|82 106|indium-111 platelet imaging
P06692517T0000|68 77|assessment
P06692517T0000|26 30|drugs
P06692517T0000|33 40|patients
P06692517T0000|125 140|echocardiography
P06692517T0000|3 9|effects
P06692631A0129|41 63|microstress distribution
P06692631A0129|7 15|interface
P06692631A0129|32 37|stress
P06692631A0129|96 99|bone
P06692631A0129|69 72|bone
P06694380A1483|111 115|WORDS
P06694380A1483|31 35|group
P06694380A1483|89 96|ABSTRACT
P06694380A1483|71 71|P
P06694380A1483|40 47|mg/liter
P06694380A1483|56 57|SD
P06694380A1483|0 7|Plasma NE
P06694778A0000|104 109|course
P06694778A0000|11 30|hemodialysis patients
P06694778A0000|112 123|hemodialysis
P06694778A0000|82 88|imaging
P06694778A0000|46 71|redistribution thallium-201
P06698047A0445|99 103|cases
P06698047A0445|64 66|TRH
P06698047A0445|3 17|Prolactin levels
P06698047A0445|53 61|responses
P06698047A0445|44 48|norms
P06700231A0259|99 104|months
P06700231A0259|12 25|tumor resection
P06700231A0259|111 114|year
P06700231A0259|50 61|tumor nodules
P06700231A0259|71 75|sizes
P06700469T0000|7 27|hospital accreditation
P06702257T0001|0 14|Antithrombin III
P06702257T0001|17 26|hip surgery
P06702643A0000|154 155|SA
P06702643A0000|35 50|arch interruption
P06702643A0000|111 117|Celoria
P06702643A0000|121 126|Patton
P06702643A0000|104 108|type B
P06702643A0000|23 23|%
P06702643A0000|8 19|infant hearts
P06702643A0000|95 102|arteries
P06702643A0000|147 152|artery
P06702643A0000|71 77|carotid
P06704467A0539|13 23|sensitivity
P06704467A0539|26 36|photoperiod
P06704467A0539|66 72|mammals
P06704467A0539|89 99|pineal gland
P06704467A0539|45 48|bats
P06705456A0346|28 31|time
P06705456A0346|42 44|min
P06705456A0346|34 37|peak
P06705456A0346|0 9|Absorption
P06707357A0180|164 168|types
P06707357A0180|119 129|differences
P06707357A0180|92 107|valve replacement
P06707357A0180|13 24|observations
P06707357A0180|59 71|regurgitation
P06707357A0180|171 184|volume overload
P06707357A0180|29 36|patients
P06709310A0000|1 4|case
P06709310A0000|21 29|nystagmus
P06709310A0000|36 40|onset
P06709310A0000|55 58|girl
P06709700A0230|43 52|depression
P06709700A0230|22 30|dimension
P06709700A0230|9 19|compartment
P06709700A0230|67 89|Hamilton Depression Scale
P06709700A0230|33 40|severity
P06709700A0230|197 205|treatment
P06709700A0230|167 180|outcome measure
P06709700A0230|54 61|subscale
P06709700A0230|96 111|Melancholia Scale
P06709700A0230|148 157|perfection
P06711642A0093|219 226|oliguria
P06711642A0093|11 28|immunoglobulinuria
P06711642A0093|188 189|gm
P06711642A0093|48 58|development
P06711642A0093|200 214|urine collection
P06711642A0093|157 164|dipstick
P06711642A0093|92 110|creatinine clearance
P06711642A0093|61 68|azotemia
P06711642A0093|123 133|proteinuria
P06712314A0148|18 22|cases
P06712314A0148|50 61|institutions
P06712314A0148|6 11|number
P06713200A0630|0 19|Epileptiform activity
P06713200A0630|93 103|projections
P06713200A0630|78 82|layer
P06713200A0630|59 63|layer
P06713200A0630|142 150|phenytoin
P06713200A0630|43 49|laminae
P06713204A0867|54 58|state
P06713204A0867|64 66|rat
P06713204A0867|77 87|V1 component
P06713204A0867|3 14|AD components
P06714298X0000|242 242|%
P06714298X0000|45 51|preload
P06714298X0000|229 238|resistance
P06714298X0000|156 165|nifedipine
P06714298X0000|286 291|output
P06714298X0000|208 208|%
P06714298X0000|114 134|calcium channel blocker
P06714298X0000|75 85|nisoldipine
P06714298X0000|252 261|maxLVdP/dt
P06714298X0000|70 73|pigs
P06714298X0000|275 275|%
P06714298X0000|90 110|micrograms X kg-1 X min-1
P06714298X0000|197 204|pressure
P06714354A0194|0 6|Monkeys
P06714354A0194|62 68|removal
P06714354A0194|87 92|cortex
P06715792A0295|0 15|HBB concentration
P06715792A0295|49 60|accumulation
P06715792A0295|21 27|fetuses
P06716977A0136|58 63|losses
P06716977A0136|20 26|decline
P06716977A0136|3 9|samples
P06716977A0136|94 101|mg% range
P06716977A0136|29 48|ethanol concentration
P06718064T0001|0 16|Plasma lactoferrin
P06718064T0001|23 32|blood count
P06718064T0001|46 56|neutrophils
P06719057A0181|73 81|hematuria
P06719057A0181|50 59|evaluation
P06719057A0181|112 118|urogram
P06719057A0181|3 12|importance
P06719057A0181|85 97|filing defects
P06719057A0181|29 44|vein phlebography
P06720371T0000|0 9|Pilot study
P06720371T0000|12 27|blood coagulation
P06720371T0000|30 41|gout patients
P06721188A0200|14 21|analysis
P06721188A0200|49 56|Snedecor
P06721188A0200|34 38|F test
P06721188A0200|59 70|contrast test
P06723849A0197|87 97|transection
P06723849A0197|52 54|MRF
P06723849A0197|12 16|tract
P06723849A0197|42 50|Formation
P06726257A1179|62 64|LSD
P06726257A1179|140 145|cortex
P06726257A1179|216 227|methiothepin
P06726257A1179|157 164|striatum
P06726257A1179|22 40|5-hydroxytryptophan
P06726257A1179|184 213|autoreceptor antagonist activity
P06726257A1179|237 244|ABSTRACT
P06726257A1179|79 89|differences
P06726257A1179|92 101|inhibition
P06726257A1179|104 115|methiothepin
P06726257A1179|48 59|accumulation
P06726257A1179|259 263|WORDS
P06726257A1179|11 19|reduction
P06726257A1179|42 46|5-HTP
P06726257A1179|117 128|hypothalamus
P06726257T0000|0 6|Effects
P06726257T0000|50 65|serotonin release
P06726257T0000|9 20|methiothepin
P06726257T0000|76 93|serotonin synthesis
P06726257T0000|32 47|acid diethylamide
P06726257T0000|109 116|relation
P06726257T0000|119 147|serotonin autoreceptor function
P06728580A0291|26 31|El Paso
P06728580A0291|87 92|result
P06728580A0291|72 79|criteria
P06728580A0291|99 106|students
P06728580A0291|33 34|TX
P06728580A0291|9 15|measles
P06728580A0291|43 49|records
P06731302A0930|13 27|bradyarrhythmia
P06731302A0930|66 70|block
P06731302A0930|36 38|SCD
P06731302A0930|79 89|branch block
P06731302A0930|2 8|patient
P06732946A0281|143 151|Videoplan
P06732946A0281|153 157|scale
P06732946A0281|76 80|times
P06732946A0281|19 23|areas
P06732946A0281|107 119|magnification
P06732946A0281|35 40|tissue
P06732946A0281|123 123|X
P06732946A0281|3 13|measurement
P06732946A0281|44 55|fibrinolysis
P06732946A0281|129 141|image analyser
P06734713T0000|0 9|Diclofenac
P06734713T0000|30 38|poisoning
P06735247A0803|122 122|r
P06735247A0803|129 129|p
P06735247A0803|12 44|plasma enteroglucagon concentration
P06735247A0803|52 58|minutes
P06735247A0803|70 77|patients
P06735247A0803|112 120|excretion
P06738410T0000|0 12|Blood pressure
P06738410T0000|15 22|children
P06740373A0891|28 34|captive
P06740373A0891|39 48|cynomolgus
P06740373A0891|6 10|study
P06740373A0891|105 120|drug testing model
P06740373A0891|83 88|rhesus
P06740697A0318|45 60|guinea pig strains
P06740697A0318|23 33|sensitivity
P06740697A0318|3 9|results
P06740919A0162|58 67|heartwater
P06740919A0162|80 82|Bos
P06740919A0162|90 93|calf
P06740919A0162|43 46|goat
P06740919A0162|31 36|nymphs
P06740919A0162|5 20|Amblyomma lepidum
P06743061A0239|85 92|tinnitus
P06743061A0239|10 16|percent
P06743061A0239|24 31|patients
P06743061A0239|45 51|disease
P06744024A0000|0 7|Morphine
P06744024A0000|79 90|formalin test
P06744024A0000|65 73|analgesia
P06744024A0000|44 46|rat
P06744024A0000|124 127|pain
P06744024A0000|30 38|ventricle
P06748227A0423|55 59|right
P06748227A0423|9 12|Case
P06748227A0423|106 111|thorax
P06748227A0423|3 6|maps
P06748227A0423|88 91|side
P06748227A0423|25 31|maximum
P06749072A0116|61 65|urate
P06749072A0116|129 132|hour
P06749072A0116|27 35|clearance
P06749072A0116|142 155|water immersion
P06749072A0116|97 110|water immersion
P06749072A0116|50 58|excretion
P06749072A0116|7 20|urate excretion
P06750608A1442|0 8|Mutations
P06750608A1442|45 47|mak
P06750608A1442|49 57|phenotype
P06750608A1442|21 28|lts genes
P06751455A0117|55 63|remainder
P06751455A0117|26 35|gallstones
P06751455A0117|83 90|glucagon
P06751455A0117|67 74|patients
P06751455A0117|96 102|placebo
P06753902A0437|124 128|death
P06753902A0437|5 12|patients
P06753902A0437|33 41|captopril
P06753902A0437|99 106|class IIM
P06753902A0437|68 73|months
P06753902A0437|115 117|IIS
P06753902A0437|26 30|month
P06754662T0001|35 46|eosinophilia
P06754662T0001|7 30|angiolymphoid hyperplasia
P06755468A0180|56 61|intron
P06755468A0180|89 105|amino acid homology
P06755468A0180|76 80|yeast
P06755468A0180|26 38|reading frames
P06755468A0180|41 44|cobA
P06755468A0180|67 73|cob gene
P06755468A0180|0 6|Regions
P06755986A0382|48 64|toxico-infections
P06755986A0382|105 111|strains
P06755986A0382|14 20|strains
P06755986A0382|33 38|humans
P06755986A0382|83 86|mice
P06755986A0382|122 139|hospital infections
P06760394T0001|29 31|aid
P06760394T0001|37 39|ITI
P06760394T0001|6 21|tooth replacement
P06760394T0001|75 79|type F
P06760394T0001|41 73|International Team fur Implantologie
P06762025A0171|45 53|PGF2 alpha
P06762025A0171|97 102|effect
P06762025A0171|38 41|PGE2
P06762025A0171|3 35|13,14-dihydro-15-keto-metabolites
P06762321T0000|0 17|Nucleotide sequence
P06762321T0000|54 79|maltosaccharide utilization
P06762321T0000|20 43|DNA controlling expression
P06762321T0000|82 94|Streptococcus
P06762321T0000|46 50|genes
P06763897A0216|74 79|analog
P06763897A0216|70 72|AII
P06763897A0216|81 84|Sar1
P06763897A0216|91 93|ALL
P06763897A0216|27 29|PRA
P06763897A0216|3 14|hypertension
P06763897A0216|56 66|angiotensin
P06763897A0216|86 89|Ile8
P06764669T0001|34 37|iron
P06764669T0001|77 83|reagent
P06764669T0001|12 24|determination
P06764669T0001|51 63|deferoxamine B
P06767648A0734|0 11|Measurements
P06767648A0734|52 57|values
P06767648A0734|69 75|therapy
P06767648A0734|14 22|perfusion
P06772370A0342|0 5|Volume
P06772370A0342|150 153|ages
P06772370A0342|131 135|women
P06772370A0342|48 51|l/kg
P06772370A0342|102 106|range
P06772370A0342|74 83|correction
P06772370A0342|142 144|men
P06772370A0342|8 19|distribution
P06772370A0342|65 68|DMDZ
P06772370A0342|87 100|protein binding
P06772370A0342|115 118|l/kg
P06772370A0342|32 36|range
P06772370A0342|27 30|DMDZ
P06772612A0000|43 53|haloperidol
P06772612A0000|9 16|dopamine
P06772612A0000|98 104|hypoxia
P06772612A0000|108 118|hypercapnia
P06772612A0000|35 41|blocker
P06772612A0000|151 154|cats
P06772612A0000|71 95|carotid body chemoreceptors
P06772612A0000|60 68|responses
P06772612A0000|0 6|Effects
P06775834A0000|0 4|HLA-A
P06775834A0000|89 94|regard
P06775834A0000|114 120|relapse
P06775834A0000|24 31|patients
P06775834A0000|108 111|form
P06775834A0000|8 18|B phenotypes
P06775834A0000|54 62|melanomas
P06776918T0000|0 15|Trypanosoma cruzi
P06777229A0243|72 78|disease
P06777229A0243|33 40|subjects
P06777229A0243|16 20|study
P06777229A0243|46 53|patients
P06777229A0243|3 10|subjects
P06781339A0501|73 81|treatment
P06781339A0501|67 70|mode
P06781339A0501|104 118|hypoventilation
P06781339A0501|4 8|study
P06781339A0501|45 53|follow-up
P06781339A0501|84 91|patients
P06781728A0690|16 30|differentiation
P06781728A0690|78 91|mineralization
P06781728A0690|154 173|fluorochrome labeling
P06781728A0690|199 202|rats
P06781728A0690|128 140|bone formation
P06781728A0690|69 75|failure
P06781728A0690|33 52|osteoprogenitor cells
P06781728A0690|3 13|alterations
P06781728A0690|121 125|rates
P06782612A0142|85 100|lithium clearance
P06782612A0142|102 104|CLi
P06782612A0142|11 17|measure
P06782612A0142|62 72|urine volume
P06782612A0142|74 74|V
P06782612A0142|24 33|impairment
P06782612A0142|55 59|ratio
P06782869A0263|148 171|serum alkaline phosphatase
P06782869A0263|131 134|SGPT
P06782869A0263|39 51|complications
P06782869A0263|81 95|serum creatinine
P06782869A0263|97 115|creatinine clearance
P06782869A0263|117 124|serum CO2
P06782869A0263|77 79|BUN
P06782869A0263|136 143|serum LDH
P06782869A0263|126 129|SGOT
P06782869A0263|0 14|Nitrogen balance
P06784123A0286|85 89|locus
P06784123A0286|48 60|recombination
P06784123A0286|12 18|C mu RNAs
P06784123A0286|75 80|region
P06784123A0286|26 32|mu mRNAs
P06784123A0286|82 83|JH
P06784123A0286|0 9|Production
P06784123A0771|115 120|mu chin
P06784123A0771|60 66|mu chain
P06784123A0771|28 49|sequence characteristic
P06784123A0771|9 14|C mu RNA
P06784123A0771|84 90|species
P06784123T0000|0 10|Transcripts
P06784123T0000|77 87|development
P06784123T0000|55 62|splicing
P06784123T0000|43 51|structure
P06784123T0000|16 36|immunoglobulin C mu gene
P06785113A0337|78 82|mucus
P06785113A0337|42 49|activity
P06785113A0337|92 99|patients
P06786756T0000|57 66|expression
P06786756T0000|9 24|DNA rearrangement
P06786756T0000|69 92|immunoglobulin delta genes
P06786756T0000|39 51|RNA processing
P06786756T0000|3 6|role
P06788388A0000|115 121|studies
P06788388A0000|22 27|action
P06788388A0000|11 19|mechanism
P06788388A0000|131 139|compounds
P06788388A0000|30 37|ICRF-159
P06788388A0000|145 152|interest
P06790572A0330|28 37|lincomycin
P06790572A0330|48 55|nystatin
P06790572A0330|39 46|colistin
P06790572A0330|105 114|anisomycin
P06790572A0330|91 100|polymyxin B
P06790572A0330|71 89|trimethoprim lactate
P06790572A0330|5 12|isolates
P06790572A0330|57 69|amphotericin B
P06791500A0622|57 67|cornerstone
P06791500A0622|78 87|management
P06791500A0622|23 37|fluid delta OD450
P06791500A0622|3 12|evaluation
P06793764T0001|0 9|Host lipids
P06793764T0001|23 31|infection
P06794480A0785|58 63|others
P06794480A0785|65 65|p
P06794480A0785|24 33|difference
P06794480A0785|41 48|age group
P06794666A0208|100 127|neurotransmitter biosynthesis
P06794666A0208|74 80|measure
P06794666A0208|55 58|ATCI
P06794666A0208|41 50|myocardium
P06794666A0208|141 168|cardiomyocyte adrenoreceptors
P06794666A0208|131 138|function
P06794666A0208|14 35|neuroeffector influence
P06794666A0208|86 94|intensity
P06795119T0000|44 52|cataracts
P06795119T0000|0 18|Lens aldose reductase
P06795654A0434|15 19|doses
P06795654A0434|109 126|minimum requirement
P06795654A0434|41 54|mg/kg/infusion
P06795654A0434|70 96|self-administration behavior
P06795654A0434|128 129|FR
P06795654A0434|0 11|Fenfluramine
P06795832A0148|13 22|Hepatitis A
P06795832A0148|72 85|HBe-antibodies
P06795832A0148|59 61|IgG
P06795832A0148|49 51|HBc
P06795832A0148|53 55|IgM
P06795832A0148|5 10|course
P06795832A0148|30 40|HBe-antigen
P06795900A0000|98 101|rate
P06795900A0000|19 58|acid cyclo-oxygenase inhibitor indomethacin
P06795900A0000|105 110|oxygen
P06795900A0000|164 167|rats
P06795900A0000|112 116|CMRO2
P06795900A0000|69 77|blood flow
P06795900A0000|79 81|CBF
P06795900A0000|3 8|effect
P06795971A0000|26 36|model system
P06795971A0000|51 61|amelgenesis
P06795971A0000|3 12|rat incisor
P06796300A0759|73 96|oestradiol administration
P06796300A0759|35 46|nursing women
P06796300A0759|18 32|prolactin levels
P06797063A0000|0 5|Factor
P06797063A0000|10 29|procoagulant activity
P06797063A0000|116 120|times
P06797063A0000|77 94|ristocetin cofactor
P06797063A0000|54 74|von Willebrand activity
P06797063A0000|137 139|DIC
P06797063A0000|125 132|patients
P06797063A0000|31 50|antigen concentration
P06798609A0000|142 148|periods
P06798609A0000|107 113|mg/kg IP
P06798609A0000|90 92|GVG
P06798609A0000|28 31|rats
P06798609A0000|119 122|days
P06798609A0000|51 58|protocol
P06798609A0000|74 88|gamma-vinyl GABA
P06801778T0001|0 11|Significance
P06801778T0001|26 44|gas exchange reaction
P06801778T0001|98 111|commissurotomy
P06801778T0001|77 89|effectiveness
P06801778T0001|55 61|loading
P06802500T0001|0 16|Thyreoliberin VUFB
P06802500T0001|19 36|thyroid gammagraphy
P06803634A0810|73 79|respect
P06803634A0810|195 198|sons
P06803634A0810|54 57|sons
P06803634A0810|90 111|blood gas determinations
P06803634A0810|151 158|patients
P06803634A0810|126 134|responses
P06803634A0810|23 35|relationships
P06803634A0810|144 148|Paco2
P06803634A0810|2 10|silicosis
P06803634A0810|184 192|responses
P06803634A0810|43 50|patients
P06805504A0629|66 71|weight
P06805504A0629|19 25|N values
P06805504A0629|60 61|kg
P06805504A0629|130 136|mg/kg W0
P06805504A0629|92 101|N excretion
P06805504A0629|117 117|N
P06805504A0629|39 45|mg/kg W0
P06805537T0001|45 50|factor
P06805537T0001|55 65|concentrate
P06805537T0001|10 28|hemophilia treatment
P06805537T0001|0 7|Advances
P06807149A0222|41 47|ability
P06807149A0222|64 68|forms
P06807149A0222|81 83|EIB
P06807149A0222|4 8|study
P06807149A0222|71 73|DSG
P06807149T0000|0 9|Comparison
P06807149T0000|65 74|prevention
P06807149T0000|26 37|preparations
P06807149T0000|40 59|disodium cromoglycate
P06807149T0000|119 123|study
P06807149T0000|93 104|bronchospasm
P06807192A0312|0 3|LCBF
P06807192A0312|78 81|LCGU
P06807192A0312|115 124|conditions
P06807192A0312|126 130|Duffy
P06807192A0312|22 28|puppies
P06807192A0312|59 76|glucose utilization
P06807659T0001|0 11|Phagocytosis
P06807659T0001|22 28|bacilli
P06807659T0001|31 41|macrophages
P06808287T0001|0 8|Detection
P06808287T0001|11 29|hemophilia A carriers
P06808529A0167|14 31|isoniazid solutions
P06808529A0167|63 65|NTA
P06808529A0167|68 84|EDTA concentration
P06808529A0167|90 95|mmol/l
P06808529A0167|3 11|stability
P06809474A1156|0 12|Bile bilirubin
P06809474A1156|50 56|finding
P06809474A1156|77 89|investigation
P06809474A1156|37 48|haem infusion
P06809474A1156|31 31|h
P06809586T0000|0 25|Autoimmune manipulation aids
P06809586T0000|34 51|diabetes management
P06810070A0502|17 18|Hg
P06810070A0502|52 64|control spores
P06810070A0502|23 31|Cd-spores
P06810070A0502|5 14|properties
P06810694A0328|13 27|HDL-cholesterol
P06810694A0328|111 116|apo A-I
P06810694A0328|101 108|decrease
P06810694A0328|3 10|decrease
P06810694A0328|42 59|VLDL-triglycerides
P06810694A1000|0 10|Apo A-I level
P06810694A1000|79 87|adiposity
P06810694A1000|25 27|age
P06810694A1000|45 62|ethanol consumption
P06812389A0658|0 4|TEMTU
P06812389A0658|8 11|DPTU
P06812389A0658|29 38|teratogens
P06815368A0203|18 25|mannitol
P06815368A0203|45 52|patients
P06816053A0849|29 41|drug reactions
P06816053A0849|52 55|cent
P06816053A0849|83 94|mast cell test
P06816053A0849|5 12|patients
P06816053A0849|70 77|response
P06816123A0526|0 7|Selenium
P06816123A0526|53 56|role
P06816123A0526|114 118|roles
P06816123A0526|25 45|glutathione peroxidase
P06816123A0526|12 22|constituent
P06816123A0526|122 129|selenium
P06816123A0526|92 95|body
P06816123A0526|73 86|defense systems
P06816442T0001|33 37|cases
P06816442T0001|10 14|value
P06816442T0001|53 59|disease
P06816442T0001|17 30|serum myoglobin
P06816609A0639|42 44|kPa
P06816609A0639|47 54|decrease
P06816609A0639|86 92|CBF fall
P06816609A0639|28 31|PCO2
P06816609A0639|4 26|% blood pressure reduction
P06816609A0639|97 97|%
P06817410A0982|39 44|change
P06817410A0982|124 132|incidence
P06817410A0982|111 118|increase
P06817410A0982|69 78|hepatitis A
P06817410A0982|47 58|epidemiology
P06817410A0982|145 153|hepatitis
P06817410A0982|159 169|drug addicts
P06817410A0982|139 142|type
P06817410A0982|14 19|months
P06817410A0982|25 29|study
P06818113A0384|30 38|responses
P06818113A0384|141 149|responses
P06818113A0384|9 16|patients
P06818113A0384|152 171|plasminogen activator
P06818113A0384|57 66|adrenaline
P06818113A0384|71 78|controls
P06818113A0384|45 54|parameters
P06818113A0384|205 212|infusion
P06818113A0384|175 188|clotting factor
P06818113A0384|102 124|corticosteroid treatment
P06821147A0468|0 16|Sulphur amino acids
P06821147A0468|57 62|flours
P06821147A0468|22 23|g N
P06821147A0468|40 47|isolates
P06822645T0039|0 3|Time
P06822645T0039|10 37|increase growth hormone release
P06823837A0562|32 41|wavefronts
P06823837A0562|105 116|outflow tract
P06823837A0562|96 101|groove
P06825641A0076|71 79|knowledge
P06825641A0076|124 128|waste
P06825641A0076|11 28|landfill operations
P06825641A0076|108 118|containment
P06826813A0264|0 7|Vesicles
P06826813A0264|38 46|exposures
P06826813A0264|49 51|UVA
P06828396A0095|28 32|wound
P06828396A0095|60 82|biopsy fixation technique
P06828396A0095|10 22|contamination
P06828396A0095|3 7|level
P06829082A0187|119 140|incubation temperatures
P06829082A0187|190 193|rats
P06829082A0187|35 42|degrees C
P06829082A0187|155 162|degrees C
P06829082A0187|76 106|brain tissues glutaminase activity
P06829082A0187|63 70|increase
P06829082A0187|183 186|rats
P06829082A0187|21 31|hypothermia
P06829082A0187|199 209|hypothermia
P06830033A0661|57 61|cmH2O
P06830033A0661|67 69|min
P06830033A0661|41 52|pneumothorax
P06830033A0661|7 18|observations
P06830351A0397|84 84|%
P06830351A0397|62 67|Type Ib
P06830351A0397|11 17|Sugiura
P06830351A0397|50 55|Type Ia
P06830351A0397|89 92|Type
P06830351A0397|100 100|%
P06830351A0397|74 77|Type
P06830351A0397|72 72|%
P06830351A0397|20 33|classification
P06830351A0397|60 60|%
P06833047A0000|120 123|HFOV
P06833047A0000|108 118|ventilation
P06833047A0000|4 8|study
P06833047A0000|33 41|mechanism
P06833047A0000|59 68|inhibition
P06833422T0000|0 12|Determination
P06833422T0000|39 52|alpha-pregna-4
P06833422T0000|68 73|plasma
P06833422T0000|84 96|ion monitoring
P06833422T0000|56 65|dien-3-one
P06833422T0000|17 35|alpha-hydroxy-9 beta
P06835516A0000|1 4|case
P06835516A0000|43 49|cistern
P06835516A0000|13 26|epidermoid cyst
P06835914A0192|58 69|copper intake
P06835914A0192|107 116|feed intake
P06835914A0192|50 55|levels
P06835914A0192|89 99|differences
P06835914A0192|159 166|industry
P06835914A0192|129 136|practice
P06835914A0192|0 15|Copper treatments
P06837312A0000|86 87|IU
P06837312A0000|62 66|aorta
P06837312A0000|13 19|intimal
P06837312A0000|183 189|lesions
P06837312A0000|148 166|vitamin D3 withdrawal
P06837312A0000|104 107|diet
P06837312A0000|90 101|vitamin D3/kg
P06837312A0000|140 145|months
P06837312A0000|116 129|months duration
P06837312A0000|72 76|swine
P06838388A0896|172 174|day
P06838388A0896|66 70|place
P06838388A0896|156 163|function
P06838388A0896|119 131|normalization
P06838388A0896|94 108|parenchyma areas
P06838388A0896|137 141|organ
P06838388A0896|41 51|tissue scars
P06838388A0896|15 25|development
P06838388A0896|144 152|structure
P06840803A0397|30 37|reaction
P06840803A0397|99 102|days
P06840803A0397|66 78|i.v. challenge
P06840803A0397|12 16|signs
P06840803A0397|59 60|hr
P06842629A0446|40 44|shock
P06842629A0446|51 65|treatment groups
P06842629A0446|11 24|GMBF reductions
P06848729A0000|17 29|neuroblastoma
P06848729A0000|39 41|St.
P06848729A0000|5 12|children
P06849842T0000|45 58|granulopoiesis
P06849842T0000|0 30|Penicillin-G degradation products
P06851280A0144|0 15|Plasma fibrinogen
P06851280A0144|45 50|method
P06851280A0144|53 57|timol
P06851280A0144|71 75|units
P06851327A0000|16 19|type
P06851327A0000|38 46|infection
P06851327A0000|107 112|period
P06851327A0000|64 79|Neisseria species
P06851327A0000|4 11|patients
P06853042A0282|59 81|bicarbonate reabsorption
P06853042A0282|13 25|acidification
P06853042A0282|32 40|threshold
P06853042A0282|116 123|capacity
P06853042A0282|98 102|urine
P06854957T0066|0 8|Detection
P06854957T0066|27 34|asynergy
P06854957T0066|43 58|echocardiography
P06856306T0000|59 70|significance
P06856306T0000|35 43|Hennebert
P06856306T0000|46 49|sign
P06856306T0000|20 30|fistula test
P06856306T0000|3 18|Tullio phenomenon
P06856669A1004|44 53|metabolism
P06856669A1004|5 11|results
P06856669A1004|94 99|output
P06856669A1004|78 83|5-HIAA
P06856669A1004|56 59|5-HT
P06856669A1004|123 133|circulation
P06856669A1004|70 75|efflux
P06858449A0335|0 11|Disturbances
P06858449A0335|23 32|maturation
P06858640A0262|29 36|findings
P06858640A0262|87 97|fibroblasts
P06858640A0262|5 9|basis
P06858640A0262|49 55|amyloid
P06858640A0262|41 46|origin
P06858805A0314|59 66|Candidin
P06858805A0314|39 54|hypersensitivity
P06858805A0314|25 29|tests
P06858805A0314|82 91|Tuberculin
P06858805A0314|68 78|Trycophytin
P06858805A0314|4 9|groups
P06858967A0167|0 24|Serum lactate dehydrogenase
P06858967A0167|64 72|bilirubin
P06858967A0167|28 44|haptoglobin levels
P06863087A0664|17 18|mg
P06863087A0664|23 24|DB
P06863087A0664|76 82|control
P06863087A0664|8 8|D
P06863087A0664|33 34|mg
P06863087A0664|63 71|parameter
P06864837T0000|0 7|Efficacy
P06864837T0000|18 43|spine immobilization methods
P06864955T0000|12 15|MMWR
P06868345A0000|13 23|visna-maedi
P06868345A0000|52 55|time
P06868345A0000|26 30|Italy
P06868345A0000|3 10|presence
P06869215A0347|4 9|levels
P06869215A0347|12 13|IC
P06869215A0347|35 52|hypocomplementemia
P06869986A0000|103 111|ruminants
P06869986A0000|82 88|lesions
P06869986A0000|11 19|platelets
P06869986A0000|57 64|collagen
P06872800T0000|26 33|patients
P06872800T0000|5 8|type
P06872800T0000|10 18|hepatitis
P06872800T0000|45 56|HBV infection
P06873504T0000|44 51|acidosis
P06873504T0000|55 81|sodium metabolism alterations
P06873504T0000|12 24|relationships
P06873504T0000|84 97|liver cirrhosis
P06875478A0542|1 19|microU/l thyrotropin
P06875478A0542|45 45|%
P06875478A0542|23 23|%
P06875478A0542|33 33|%
P06876006A0930|0 14|Echosismography
P06876006A0930|90 94|cases
P06876006A0930|34 42|diagnosis
P06876006A0930|68 77|sonography
P06876006A0930|87 87|%
P06876317T0033|0 12|Relationships
P06876317T0033|34 51|deficiency syndrome
P06880563A0516|39 42|type
P06880563A0516|44 51|diabetes
P06880563A0516|152 165|administration
P06880563A0516|31 34|type
P06880563A0516|3 12|prevalence
P06880563A0516|119 133|administrations
P06880563A0516|76 78|men
P06880563A0516|168 181|chlorpropamide
P06880563A0516|65 69|women
P06880563A0516|15 18|CPAF
P06880604A0167|127 133|January
P06880604A0167|18 31|prevalence data
P06880604A0167|90 97|province
P06880604A0167|109 121|prevalence day
P06880604A0167|100 104|Vaasa
P06880604A0167|1 12|reassessment
P06880604A0167|68 74|Uusimaa
P06880604A0167|58 65|province
P06880650A0316|3 9|results
P06880650A0316|34 37|work
P06880650A0316|45 55|researchers
P06882578A0464|127 134|training
P06882578A0464|61 69|beginning
P06882578A0464|176 180|ng/ml
P06882578A0464|199 211|hours training
P06882578A0464|102 106|ng/ml
P06882578A0464|5 23|ultramarathon runner
P06882578A0464|166 170|hours
P06882578A0464|190 192|end
P06882578A0464|75 89|training session
P06882578A0464|27 44|testosterone levels
P06882578A0464|217 221|ng/ml
P06882578A0464|114 118|ng/ml
P06883385A0509|2 9|patients
P06883385A0509|88 93|values
P06883385A0509|45 49|tumor
P06883385A0509|31 39|remission
P06883385A0509|54 72|neopterine excretion
P06884450A0234|58 60|TBN
P06884450A0234|23 29|results
P06884450A0234|51 51|%
P06884450A0234|76 76|%
P06884450A0234|9 15|tumours
P06884450A0234|46 47|FB
P06886031A0898|100 107|test dose
P06886031A0898|24 28|fluid
P06886031A0898|110 117|tolmetin
P06886031A0898|64 75|patient group
P06886031A0898|5 13|PGE levels
P06886031A0898|120 122|day
P06886031A0898|81 85|hours
P06886948A0750|13 22|weight gain
P06886948A0750|6 10|rates
P06886948A0750|70 70|%
P06886948A0750|43 55|energy intakes
P06886948A0750|73 84|requirements
P06890622A0067|134 144|coagulation
P06890622A0067|55 61|effects
P06890622A0067|158 170|pre-eclampsia
P06890622A0067|110 121|hypertension
P06890622A0067|36 43|platelet
P06890622A0067|101 108|ischemia
P06890935T0001|0 5|Behcet
P06890935T0001|8 15|syndrome
P06891051A0587|73 82|correction
P06891051A0587|38 46|platelets
P06891051A0587|60 67|patients
P06891051A0587|85 97|platelet count
P06891051A0587|0 7|Survival
P06891270A0000|102 110|rat atrium
P06891270A0000|67 79|contractility
P06891270A0000|35 37|EPS
P06891270A0000|3 8|effect
P06891270A0000|51 63|extensibility
P06891270A0000|28 33|stress
P06895559A0000|105 115|combination
P06895559A0000|141 143|day
P06895559A0000|119 131|rabbit fetuses
P06895559A0000|54 79|phosphodiesterase inhibitor
P06895559A0000|40 51|aminophyllin
P06895559A0000|146 154|gestation
P06895559A0000|29 35|agonist
P06895559A0000|0 10|Terbutaline
P06895663A0810|57 59|RLF
P06895663A0810|33 43|association
P06895663A0810|51 53|RBT
P06895663A0810|97 97|P
P06895663A0810|6 12|therapy
P06895663A0810|84 95|significance
P06897114A0240|73 75|CAP
P06897114A0240|13 17|motif
P06897114A0240|49 70|DNA sequence recognition
P06902722T0000|44 53|infarction
P06902722T0000|13 17|phase
P06911559T0000|0 9|Statistics
P06911559T0000|13 25|nurse managers
P06916588A0304|97 97|p
P06916588A0304|87 95|catheters
P06916588A0304|37 44|patients
P06916588A0304|49 64|Hickman catheters
P06916588A0304|23 27|times
P06916588A0304|3 15|infection rate
P06919347T0001|12 19|planning
P06919347T0001|54 62|Stockholm
P06919347T0001|6 9|year
P06919347T0001|79 98|laboratory assistants
P06919347T0001|46 51|School
P06919347T0001|67 75|education
P06919347T0001|25 44|Laboratory Assistants
P06928974T0000|3 19|electrocardiogram
P06931124A0109|43 50|NH4Mg PO4
P06931124A0109|12 16|place
P06931124A0109|78 82|water
P06931124A0109|65 73|reactants
P06931124A0109|24 39|complex formation
P06931124A0109|53 55|H2O
P06931124A0109|57 57|n
P06935514A0000|133 143|alterations
P06935514A0000|35 42|research
P06935514A0000|183 191|component
P06935514A0000|115 119|order
P06935514A0000|53 63|preparation
P06935514A0000|3 9|Authors
P06935514A0000|149 162|dentinogenesis
P06935514A0000|100 111|desametazone
P06938948T0001|15 34|serum immunoglobulins
P06938948T0001|90 98|leukemias
P06938948T0001|77 82|mucosa
P06938948T0001|37 43|indices
P06938948T0001|9 11|IgA
P06938948T0001|54 61|immunity
P06946314T0000|0 13|Serum IgE levels
P06946314T0000|16 31|Tauranga children
P06946693T0000|0 2|Use
P06946693T0000|38 43|cattle
P06946693T0000|26 34|PGF2 alpha
P06946693T0000|5 24|prostaglandin F2 alpha
P06948398A0523|32 36|blood
P06948398A0523|20 29|management
P06948398A0523|63 72|importance
P06948493T0026|0 4|Range
P06948493T0026|6 15|variations
P06948493T0026|29 37|potential
P06948868A0082|45 62|faculty evaluations
P06948868A0082|32 42|reliability
P06948868A0082|23 26|part
P06948868A0082|3 8|scores
P06950004T0047|0 4|Study
P06950004T0047|21 25|metal
P06950004T0047|7 18|distribution
P06950004T0047|45 57|iontophoresis
P06950004T0047|31 35|teeth
P06950004T0047|73 81|specimens
P06953957A0503|133 141|peak value
P06953957A0503|166 176|correlation
P06953957A0503|93 100|episodes
P06953957A0503|66 74|myoglobin
P06953957A0503|7 28|creatine kinase activity
P06953957A0503|61 64|peak
P06957125T0000|30 35|effect
P06957125T0000|56 71|stimulating drugs
P06957125T0000|38 41|beta
P06957125T0000|15 23|blood flow
P06957633T0001|73 79|patient
P06957633T0001|110 114|years
P06957633T0001|23 30|leukemia
P06957633T0001|54 69|erythroblastosis
P06957633T0001|102 107|anemia
P06957633T0001|85 91|history
P06957633T0001|35 41|trisomy
P06957633T0001|0 10|Development
P06959130A0996|41 50|conversion
P06959130A0996|104 116|Arg145-Ala146
P06959130A0996|120 132|Arg180-Val181
P06959130A0996|74 76|IXa
P06959130A0996|3 21|arginyl peptide bonds
P06959130A0996|79 87|factor XIa
P06959130A0996|58 63|factor
P06962492A0612|99 107|bone bases
P06962492A0612|8 13|growth
P06962492A0612|78 87|hypotrophy
P06962492A0612|37 44|eruption
P06962634A0190|118 126|clearance
P06962634A0190|12 18|methods
P06962634A0190|97 114|porphyrin transport
P06962634A0190|49 69|porphyrin binding sites
P06962634A0190|33 43|information
P06963337T0000|54 65|hypertension
P06963337T0000|39 49|hyperplasia
P06966678A0523|119 122|acid
P06966678A0523|214 223|injections
P06966678A0523|235 240|atrium
P06966678A0523|24 32|clearance
P06966678A0523|183 189|changes
P06966678A0523|260 265|atrium
P06966678A0523|291 291|r
P06966678A0523|249 249|n
P06966678A0523|102 111|metabolism
P06966678A0523|18 21|rate
P06966678A0523|298 298|n
P06966678A0523|274 274|n
P06966678A0523|283 289|ear vein
P06966678A0523|267 267|r
P06966678A0523|204 208|index
P06966678A0523|58 64|portion
P06966678A0523|35 40|tracer
P06966678A0523|146 151|lipids
P06966678A0523|242 242|r
P06966678A0523|87 91|curve
P06969638A0180|148 156|prognosis
P06969638A0180|113 124|determinants
P06969638A0180|40 55|CNS abnormalities
P06969638A0180|130 136|therapy
P06969638A0180|79 97|meningeal infections
P06969638A0180|4 15|examinations
P06969638A0180|163 175|complications
P06969638A0180|28 37|indicators
P06972179A0556|73 77|range
P06972179A0556|8 16|IgE levels
P06972443A0375|15 24|evaluation
P06972443A0375|37 43|carrier
P06972443A0375|60 72|abnormalities
P06972501A0615|0 10|Correlation
P06972501A0615|51 57|outcome
P06972501A0615|29 39|involvement
P06973664A0000|15 30|cleavage syndrome
P06973664A0000|51 57|patient
P06973664A0000|1 4|case
P06975206A0279|45 49|weeks
P06975206A0279|68 77|absorption
P06975206A0279|24 36|betamethasone
P06975206A0279|90 98|phosphate
P06975206A0279|8 21|administration
P06975206A0279|110 119|growth rate
P06975206A0279|80 86|calcium
P06977605T0000|0 9|Endorphins
P06977605T0000|18 23|issues
P06978566A0197|116 120|units
P06978566A0197|80 90|maximum dose
P06978566A0197|123 132|M. pulmonis
P06978566A0197|51 61|lung lesions
P06978566A0197|12 15|days
P06978566A0197|2 9|necropsy
P06978566A0197|33 40|F344 rats
P06978566A0197|96 96|X
P06981991A0756|0 13|Aneurysmectomy
P06981991A0756|199 211|artery disease
P06981991A0756|166 175|ECG changes
P06981991A0756|144 148|group
P06981991A0756|33 36|CABG
P06981991A0756|84 93|ECG changes
P06981991A0756|20 30|performance
P06981991A0756|102 113|bypass grafts
P06981991A0756|233 237|group
P06981991A0756|117 123|patient
P06984225A0367|0 3|REV I
P06984225A0367|8 14|vessels
P06984225A0367|35 45|patent graft
P06984225A0367|21 21|%
P06986168A0304|8 16|sequences
P06986168A0304|53 60|peptides
P06986168A0304|88 95|peptides
P06986168A0304|103 112|V8 protease
P06992600A0405|55 67|contamination
P06992600A0405|76 82|outflow
P06992600A0405|3 24|extraction measurements
P06993660A0000|59 59|K
P06993660A0000|49 57|potassium
P06993660A0000|100 109|papaverine
P06993660A0000|213 216|days
P06993660A0000|22 35|norepinephrine
P06993660A0000|157 162|strips
P06993660A0000|11 19|responses
P06993660A0000|65 81|relaxant responses
P06993660A0000|283 290|controls
P06993660A0000|193 196|rats
P06993660A0000|37 45|serotonin
P06993660A0000|198 200|AHR
P06993660A0000|84 96|isoproterenol
P06994035T0001|42 57|radioimmunoassay
P06994035T0001|19 39|steroid concentrations
P06994035T0001|2 16|line calculation
P06994049T0001|0 8|Detection
P06994049T0001|50 56|infants
P06994049T0001|21 34|hypothyroidism
P06997203A0325|44 45|HI
P06997203A0325|52 55|test
P06997203A0325|151 151|%
P06997203A0325|126 143|antibody conversion
P06997203A0325|157 164|patients
P06997203A0325|111 117|PHA test
P06997203A0325|90 90|%
P06997203A0325|75 79|rises
P06997203A0325|97 104|patients
P06997203A0325|2 16|rubella patients
P06997203A0325|30 41|confirmation
P07004236A0741|90 105|formate oxidation
P07004236A0741|22 36|folate compounds
P07004236A0741|156 164|treatment
P07004236A0741|144 150|folates
P07004236A0741|138 140|use
P07004236A0741|45 63|formate accumulation
P07004236A0741|108 118|utilization
P07004236A0741|69 76|methanol
P07004236A0741|186 202|methanol poisoning
P07004236A0741|174 178|cases
P07004236A0741|3 9|results
P07007181T0000|31 34|diet
P07007181T0000|43 52|microflora
P07007181T0000|11 25|sodium saccharin
P07007181T0000|3 8|effect
P07007591A0324|3 18|residue functions
P07007591A0324|28 34|C-11 CPZ
P07007591A0324|199 199|t
P07007591A0324|197 197|E
P07007591A0324|138 138|E
P07007591A0324|38 55|In-113m transferrin
P07007591A0324|189 195|formula
P07007591A0324|140 140|t
P07007591A0324|89 93|areas
P07007591A0324|212 212|t
P07007591A0324|209 210|RR
P07007591A0324|96 103|interest
P07007591A0324|206 206|t
P07007591A0324|203 204|RT
P07007591A0324|20 20|R
P07007591A0324|22 22|t
P07007591A0324|279 289|transferrin
P07007591A0324|222 222|t
P07007591A0324|127 136|extraction
P07007591A0324|177 180|msec
P07007591A0324|254 269|residue functions
P07007591A0324|164 168|areas
P07007591A0324|273 275|CPZ
P07007591A0324|74 77|time
P07007591A0324|219 220|RR
P07007591A0324|236 237|RR
P07007591A0324|111 113|CPZ
P07007591A0324|231 232|RT
P07015018A0395|38 56|migration inhibition
P07015018A0395|11 18|extracts
P07015018A0395|69 74|assays
P07015262A0396|3 6|days
P07015262A0396|109 120|microgram/ml
P07015262A0396|9 25|cefadroxil therapy
P07015262A0396|61 74|tract infection
P07015262A0396|134 138|group
P07015262A0396|78 86|CRP values
P07015262A0396|42 49|children
P07016141A0238|70 78|clearance
P07016141A0238|11 19|blood flow
P07016141A0238|62 66|Xenon
P07016141A0238|35 43|blood flow
P07016141A0238|21 23|RBF
P07016141A0238|45 47|NBF
P07018810A0002|0 23|Plasma renin concentration
P07018810A0002|171 177|medulla
P07018810A0002|153 156|half
P07018810A0002|67 73|outflow
P07018810A0002|126 132|outflow
P07018810A0002|183 191|cat kidney
P07018810A0002|162 167|cortex
P07018810A0002|100 105|cortex
P07021505A0510|5 15|acclimation
P07021505A0510|74 77|mmHg
P07021505A0510|40 42|DPB
P07021505A0510|53 53|P
P07021505A0510|24 29|supine
P07026328A0369|112 112|%
P07026328A0369|65 70|mmol/1
P07026328A0369|92 99|glucagon
P07026328A0369|19 27|infusions
P07026328A0369|153 153|p
P07026328A0369|75 78|fall
P07026328A0369|36 39|rise
P07026328A0369|42 50|plasma Ca2
P07026328A0369|15 17|Ca2
P07026328A0369|151 151|%
P07026328A0369|5 13|diabetics
P07026328A0369|132 138|glucose
P07026328A0369|114 114|p
P07034479A1050|29 40|placebo group
P07034479A1050|76 76|p
P07034479A1050|11 13|RMI
P07034479A1050|68 74|AC group
P07037479T0000|18 25|syndrome
P07037479T0000|4 16|cracked-tooth
P07038189A2301|27 29|CXD
P07038189A2301|12 18|results
P07038189A2301|37 44|efficacy
P07038189A2301|103 107|field
P07038189A2301|48 53|safety
P07038189A2301|77 80|drug
P07038684A1050|199 201|p62
P07038684A1050|104 106|p60
P07038684A1050|51 62|sequence data
P07038684A1050|7 28|peptide map similarities
P07038684A1050|165 186|p60 initiator methionine
P07038684A1050|126 143|amino acid sequences
P07038684A1050|110 112|p62
P07038684A1050|80 85|origin
P07038684A1050|188 194|residue
P07040659A0212|98 102|group
P07040659A0212|64 67|PEFR
P07040659A0212|78 85|patients
P07040659A0212|111 121|improvement
P07040659A0212|3 10|patients
P07040659A0212|16 27|control group
P07040659A0212|46 56|improvement
P07044389T0000|0 4|Facts
P07044389T0000|56 67|pathologists
P07044389T0000|10 31|Economic Recovery Tax Act
P07044389T0000|71 82|audiologists
P07044562T0000|4 6|Pap
P07044562T0000|9 12|ApUp
P07044842A2062|29 41|complications
P07044842A2062|79 85|Bartter
P07044842A2062|3 14|relationship
P07044842A2062|62 76|pathophysiology
P07044842A2062|88 95|syndrome
P07045156A0204|130 137|antibody
P07045156A0204|49 56|rat model
P07045156A0204|32 36|assay
P07045156A0204|93 106|immunoglobulin
P07045156A0204|59 67|GBS sepsis
P07049690T0000|10 16|lesions
P07049690T0000|24 33|allografts
P07053251A0666|29 35|effects
P07053251A0666|64 68|tract
P07053251A0666|96 100|study
P07053251A0666|37 46|bone marrow
P07053251A0666|73 77|heart
P07061263A0293|82 83|Px
P07061263A0293|61 72|air inflation
P07061263A0293|12 19|pressure
P07061263A0293|21 24|Pvas
P07061263A0293|78 80|min
P07061263A0293|54 58|cmH2O
P07061350A0042|118 122|f2-f1
P07061350A0042|7 13|Science
P07061350A0042|69 72|COCB
P07061350A0042|143 150|pressure
P07061350A0042|86 94|magnitude
P07061350A0042|62 67|bundle
P07061350A0042|100 116|distortion product
P07062036A0072|0 3|Rats
P07062036A0072|25 28|% JIB
P07062036A0072|32 44|sham operation
P07062269A0798|121 127|effects
P07062269A0798|90 100|l-methadone
P07062269A0798|64 72|tolerance
P07062269A0798|140 148|mechanism
P07062269A0798|54 61|naloxone
P07062269A0798|35 42|receptor
P07063606T0000|0 8|Microwave
P07063606T0000|40 57|barrier alterations
P07064662A0222|41 50|occurrence
P07064662A0222|22 28|lesions
P07064662A0222|53 64|target fibres
P07064662A0222|123 133|dorsal roots
P07064662A0222|81 87|muscles
P07064662A0222|108 117|neurolysis
P07064923T0000|46 60|phenylketonuria
P07064923T0000|11 44|phenylalanine hydroxylase deficiency
P07064923T0000|0 8|Diagnosis
P07065206A0398|97 99|min
P07065206A0398|20 42|plasma TXB2 concentration
P07065206A0398|102 107|bypass
P07065206A0398|60 73|ng/ml prebypass
P07065206A0398|4 15|control sheep
P07065206A0398|84 88|ng/ml
P07068493A0414|27 37|breaths/min
P07068493A0414|77 87|inspiration
P07068493A0414|129 132|Torr
P07068493A0414|65 69|cycle
P07068493A0414|48 48|%
P07068493A0414|145 147|SIP
P07068493A0414|14 17|rate
P07068493A0414|139 142|runs
P07068493A0414|98 108|CO2 pressure
P07068493A0636|27 43|oxygen consumption
P07068493A0636|53 60|subjects
P07068493A0636|17 24|increase
P07068493A0636|98 100|SIP
P07068493A0636|84 92|pressures
P07068496A0000|60 69|water space
P07068496A0000|84 100|sucrose indicators
P07068496A0000|124 134|rabbit lungs
P07068496A0000|75 80|sodium
P07068496A0000|149 158|techniques
P07068496A0000|13 18|volume
P07068887A0000|15 25|reliability
P07068887A0000|27 34|validity
P07068887A0000|154 161|lifetime
P07068887A0000|108 138|Michigan Alcoholism Screening Test
P07068887A0000|38 51|dimensionality
P07068887A0000|54 59|scores
P07068887A0000|172 185|symptomatology
P07068887A0000|97 97|N
P07068887A0000|86 95|inpatients
P07072635A0000|32 35|iron
P07072635A0000|64 78|desferrioxamine
P07072635A0000|7 12|method
P07072635A0000|48 61|administration
P07072635A0000|80 81|DF
P07073520A0153|87 94|decrease
P07073520A0153|110 120|fluid volume
P07073520A0153|80 84|mEq/L
P07073520A0153|152 162|fluid volume
P07073520A0153|37 53|substitution fluid
P07073520A0153|18 31|hemofiltration
P07073520A0153|59 60|Na
P07073520A0153|62 74|concentration
P07075024A0540|30 34|fever
P07075024A0540|16 20|cases
P07075024A0540|88 92|cases
P07075024A0540|58 61|CMIR
P07075438T0000|11 31|serial xeroradiography
P07076222A0543|0 14|Recommendations
P07076222A0543|40 45|issues
P07078263T0000|0 2|Use
P07078263T0000|17 28|deferoxamine
P07078263T0000|97 102|anemia
P07078263T0000|41 55|hemochromatosis
P07078263T0000|32 36|child
P07078263T0000|104 109|type I.
P07079595A0848|60 60|r
P07079595A0848|20 30|correlation
P07079595A0848|137 144|sections
P07079595A0848|103 122|diameter measurements
P07079595A0848|165 179|sperm production
P07079595A0848|56 58|spg
P07079595A0848|45 52|diameter
P07079595A0848|67 67|P
P07080496A0097|30 41|lipoproteins
P07080496A0097|92 100|fractions
P07080496A0097|159 170|lipoproteins
P07080496A0097|217 223|attacks
P07080496A0097|139 145|respect
P07080496A0097|186 193|infarcts
P07080496A0097|172 174|LDL
P07080496A0097|76 86|lipoprotein
P07080496A0097|88 90|HDL
P07080496A0097|15 27|investigation
P07081327A0546|120 126|samples
P07081327A0546|78 88|differences
P07081327A0546|39 52|concentrations
P07081327A0546|68 71|zinc
P07081327A0546|55 64|phosphorus
P07081327A0546|21 25|fluid
P07084198T0000|0 13|Selenium status
P07084198T0000|34 46|United Kingdom
P07084198T0000|16 28|thoroughbreds
P07084617A0204|81 82|wk
P07084617A0204|88 96|treatment
P07084617A0204|12 20|follow-up
P07084617A0204|64 67|drug
P07084617A0204|22 30|parasites
P07084617A0204|45 52|patients
P07084814T0000|0 10|Preparation
P07084814T0000|20 38|phospholipid reagent
P07084814T0000|42 58|coagulation assays
P07088195T0019|1 4|note
P07088195T0019|25 32|UV vision
P07088195T0019|11 22|consequences
P07088195T0019|35 39|birds
P07090151A0165|15 22|morantel
P07090151A0165|6 12|turnout
P07090151A0165|91 98|category
P07090151A0165|45 48|MSRB
P07090151A0165|32 43|release bolus
P07090151A0165|71 76|animal
P07094856A0115|57 65|intervals
P07094856A0115|79 87|gestation
P07094856A0115|15 19|study
P07094856A0115|31 37|fetuses
P07094856A0115|72 76|weeks
P07094905A0644|31 40|injections
P07094905A0644|112 122|hippocampus
P07094905A0644|43 44|KA
P07094905A0644|84 88|cells
P07094905A0644|69 72|loss
P07094905A0644|99 106|CA3 field
P07096587A0267|158 165|material
P07096587A0267|89 93|month
P07096587A0267|125 132|strategy
P07096587A0267|52 66|training program
P07096587A0267|16 23|patients
P07097182A0480|135 138|ears
P07097182A0480|172 175|ears
P07097182A0480|93 102|overgrowth
P07097182A0480|39 47|potential
P07097182A0480|3 10|duration
P07097182A0480|85 88|ears
P07097182A0480|17 25|amplitude
P07105635A0412|0 6|Samples
P07105635A0412|25 34|volunteers
P07105635A0412|102 107|effect
P07105635A0412|63 70|patients
P07105635A0412|50 57|majority
P07105635A0412|90 95|asthma
P07105635A0412|117 123|beating
P07106323A0560|42 46|fetus
P07106323A0560|78 84|E3-16-G
P07106323A0560|66 75|production
P07106323A0560|24 34|possibility
P07106323A0560|57 60|role
P07106323A0560|92 100|pregnancy
P07106323A0560|5 11|results
P07106534A0160|110 113|mass
P07106534A0160|100 104|curve
P07106534A0160|74 79|length
P07106534A0160|6 8|way
P07106534A0160|91 93|man
P07106534A0160|34 47|growth function
P07106534A0160|64 68|curve
P07106534A0160|81 88|increase
P07106534A0160|115 122|increase
P07106534A0160|125 127|rat
P07107287A1083|27 33|drivers
P07107287A1083|10 14|doses
P07107287A1083|62 75|99Mo generators
P07107287A1083|53 59|numbers
P07107462A0202|27 43|dissociation curve
P07107462A0202|92 95|Hill
P07107462A0202|67 80|training period
P07107462A0202|3 11|steepness
P07107462A0202|82 89|increase
P07107462A0202|98 98|n
P07107773A0000|119 126|subjects
P07107773A0000|44 44|m
P07107773A0000|222 238|gas chromatography
P07107773A0000|283 295|ion monitoring
P07107773A0000|161 169|ingestion
P07107773A0000|97 102|plasma
P07107773A0000|154 157|meal
P07107773A0000|303 348|trifluoroethyl-pentafluoropropionyl derivatives
P07107773A0000|37 40|acid
P07107773A0000|70 73|acid
P07107773A0000|189 203|amine precursors
P07107773A0000|140 150|consumption
P07107773A0000|245 270|resolution mass spectrometry
P07107773A0000|172 180|deuterium
P07109788A0333|13 20|patients
P07109788A0333|45 52|vagotomy
P07109788A0333|56 67|pyloroplasty
P07109788A0333|2 8|concept
P07110999A0160|49 60|incontinence
P07110999A0160|64 82|oculomotor paralysis
P07110999A0160|26 34|disorders
P07110999A0160|36 47|tetraparesis
P07112320A0086|30 32|ADA
P07112320A0086|54 57|time
P07112320A0086|0 28|CSF adenosine deaminase activity
P07112471A0639|99 104|worker
P07112471A0639|47 53|workers
P07112471A0639|77 85|factories
P07112471A0639|133 139|factory
P07112471A0639|0 18|Histamine reactivity
P07112654A0388|58 67|prevalence
P07112654A0388|75 82|carriage
P07112654A0388|103 115|hospital staff
P07112654A0388|38 47|difference
P07112654A0388|122 129|patients
P07113365A0737|0 4|Ficat
P07113365A0737|8 12|Bizou
P07113365A0737|67 76|Brattstrom
P07113365A0737|53 64|surface angle
P07113365A0737|111 117|methods
P07113365A0737|23 32|depth index
P07113365A0737|120 130|measurement
P07113897A0285|142 142|%
P07113897A0285|98 99|NS
P07113897A0285|170 180|correlation
P07113897A0285|50 56|studies
P07113897A0285|94 94|%
P07113897A0285|128 128|%
P07113897A0285|202 207|groups
P07113897A0285|144 144|p
P07113897A0285|217 221|rest r
P07113897A0285|22 32|differences
P07113897A0285|146 147|NS
P07113897A0285|243 243|p
P07113897A0285|35 36|EF
P07113897A0285|108 115|exercise
P07113897A0285|210 215|values
P07113897A0285|96 96|p
P07113897A0285|228 236|exercise r
P07113897A0285|64 67|rest
P07113897A0285|80 80|%
P07114083A0153|86 108|glucocerebrosidase level
P07114083A0153|25 33|remission
P07114083A0153|112 124|disappearance
P07114083A0153|36 42|Hodgkin
P07114083A0153|127 133|Gaucher
P07114083A0153|68 80|normalization
P07114083A0153|5 15|MOPP therapy
P07114083A0153|45 51|disease
P07114083A0153|136 140|cells
P07116298A1079|176 178|BCG
P07116298A1079|225 227|BCG
P07116298A1079|208 215|patients
P07116298A1079|275 282|patients
P07116298A1079|264 267|DTIC
P07116298A1079|114 134|Corynebacterium parvum
P07116298A1079|72 79|survival
P07116298A1079|18 21|type
P07116298A1079|97 104|patients
P07116298A1079|246 251|months
P07116298A1079|159 166|patients
P07116298A1079|185 190|months
P07116298A1079|84 91|stage IVA
P07116298A1079|147 152|months
P07116298A1079|196 201|months
P07116298A1079|293 298|months
P07116298A1079|61 68|interval
P07116298A1079|32 38|therapy
P07116298A1079|229 232|DTIC
P07116962A0299|3 18|COP-PAWP gradient
P07116962A0299|83 87|edema
P07116962A0299|62 69|patients
P07116962A0299|45 49|shock
P07119890T0000|0 1|Re
P07119890T0000|43 52|blood cells
P07119890T0000|12 17|method
P07119890T0000|30 37|labeling
P07119890T0000|3 3|A
P07119890T0000|57 62|Tc-99m
P07124743A1223|59 69|measurement
P07124743A1223|354 363|absorption
P07124743A1223|332 336|hands
P07124743A1223|33 45|As2O3 exposure
P07124743A1223|371 375|lungs
P07124743A1223|247 267|microgram/g creatinine
P07124743A1223|132 141|evaluation
P07124743A1223|16 31|glassware factory
P07124743A1223|96 108|determination
P07124743A1223|151 168|mouth contamination
P07124743A1223|310 315|intake
P07124743A1223|171 177|arsenic
P07124743A1223|237 242|levels
P07124743A1223|195 203|workshift
P07124743A1223|8 12|study
P07124743A1223|144 147|hand
P07124743A1223|118 124|arsenic
P07124743A1223|85 91|arsenic
P07125064T0000|89 106|Schistosoma mansoni
P07125064T0000|48 54|monkeys
P07125064T0000|67 86|Schistosoma japonicum
P07125064T0000|30 37|findings
P07125238T0000|25 29|entry
P07125238T0000|32 43|blood vessels
P07125238T0000|16 19|site
P07125238T0000|3 10|pia mater
P07125238T0000|65 70|system
P07126067T0000|44 48|fever
P07126067T0000|12 23|reproduction
P07126067T0000|51 60|Bali cattle
P07126413A0000|57 61|drugs
P07126413A0000|9 22|delivery system
P07126413A0000|123 127|resin
P07126413A0000|98 104|coating
P07126413A0000|129 137|Eudragit S
P07126413A0000|92 95|site
P07126413A0000|67 71|colon
P07130335A1081|153 157|ng/dl
P07130335A1081|64 66|day
P07130335A1081|58 62|times
P07130335A1081|19 46|dopamine agonist bromocriptine
P07130335A1081|51 52|mg
P07130335A1081|109 126|plasma 18-OHB levels
P07130335A1081|0 13|Administration
P07130335A1081|87 87|P
P07130335A1081|71 74|days
P07132408A0387|30 50|magnesium cardioplegia
P07132408A0387|10 13|time
P07134924A0640|13 17|types
P07134924A0640|20 32|malformations
P07134924A0640|37 46|eye defects
P07134924A0640|54 60|coeloms
P07135112T0000|0 5|Repair
P07135112T0000|17 22|defect
P07135112T0000|33 35|leg
P07135112T0000|57 60|flap
P07136524A0180|14 23|literature
P07136524A0180|50 56|tumours
P07136524A0180|63 70|contrast
P07136524A0180|97 108|osteosarcoma
P07136524A0180|84 90|tumours
P07136524A0180|120 142|retinoblastoma survivors
P07136569A0000|73 81|scoliosis
P07136569A0000|21 34|school children
P07136569A0000|8 13|Sweden
P07136569A0000|101 104|ages
P07136569A0000|87 90|year
P07136569A0000|2 6|Malmo
P07136569A0000|44 48|years
P07136569A0000|113 117|years
P07137927A0000|5 8|past
P07137927A0000|10 19|immunology
P07137927A0000|50 57|serology
P07137927A0000|22 30|Singapore
P07137927A0000|92 99|diseases
P07137927A0000|64 72|diagnosis
P07140060T0000|31 37|patella
P07140060T0000|15 25|dislocation
P07140493A1045|99 111|acid secretion
P07140493A1045|21 29|secretion
P07140493A1045|91 91|%
P07140493A1045|53 59|stomach
P07140493A1045|69 72|rate
P07140493A1045|32 42|bicarbonate
P07140493A1045|4 8|study
P07141130A0615|203 207|cells
P07141130A0615|141 156|cells/100 microns
P07141130A0615|228 233|groups
P07141130A0615|166 171|mucosa
P07141130A0615|123 128|number
P07141130A0615|178 187|mean height
P07141130A0615|93 97|cells
P07141130A0615|12 21|evaluation
P07141130A0615|99 99|p
P07141130A0615|46 53|increase
P07141130A0615|59 64|number
P07143347T0000|0 5|Cramps
P07143347T0000|22 30|disorders
P07147622T0000|29 34|cattle
P07147622T0000|13 26|storage disease
P07149047A0260|55 62|Torr/cm2
P07149047A0260|10 19|dog vessels
P07149047A0260|49 49|X
P07149047A0260|27 30|Q/Dk
P07149303T0000|14 19|action
P07149303T0000|67 70|cats
P07149303T0000|22 30|lidocaine
P07149303T0000|33 35|CNS
P07149303T0000|57 64|behavior
P07149303T0000|46 53|activity
P07154928T0001|0 11|Modification
P07154928T0001|21 30|resorption
P07154928T0001|43 49|therapy
P07155579T0001|30 38|fertility
P07155579T0001|12 26|bacteriospermia
P07158726T0001|0 6|Triumph
P07158726T0001|25 30|policy
P07160491A0547|66 73|increase
P07160491A0547|76 82|LD50/30
P07160491A0547|13 18|effect
P07160491A0547|90 108|dose reduction factor
P07162146A0000|16 30|ultrafiltration
P07162146A0000|3 13|application
P07162146A0000|83 96|ethylene glycol
P07162146A0000|107 123|gas chromatography
P07162146A0000|67 80|quantification
P07162146A0000|55 63|detection
P07162146A0000|33 49|sample preparation
P07162146A0000|99 104|plasma
P07165767T0000|0 11|Mastocytosis
P07168531T0001|41 46|cattle
P07168531T0001|23 30|parasite
P07168531T0001|50 56|Senegal
P07168531T0001|4 20|Onchocerca species
P07169630A0983|58 67|conditions
P07169630A0983|87 96|complexity
P07169630A0983|111 114|type
P07169630A0983|21 27|absence
P07169630A0983|102 105|task
P07169630A0983|40 50|differences
P07172690A0547|234 245|% restriction
P07172690A0547|44 58|energy transport
P07172690A0547|108 118|calcium pump
P07172690A0547|125 130|ATPase
P07172690A0547|183 190|decrease
P07172690A0547|256 264|blood flow
P07172690A0547|158 160|SPR
P07172690A0547|78 98|creatine phosphokinase
P07172690A0547|205 214|properties
P07172690A0547|36 41|system
P07172690A0547|9 14|factor
P07172690A0547|220 229|myocardium
P07172690A0547|19 30|disturbances
P07172690A0547|120 121|Ca
P07172690A0547|148 156|reticulum
P07172690A0547|60 76|creatine phosphate
P07173729A0000|117 121|mucus
P07173729A0000|7 22|penetration tests
P07173729A0000|47 51|mucus
P07173729A0000|101 105|sperm
P07173729A0000|68 72|order
P07173729A0000|30 34|sperm
P07173729A0000|83 93|interaction
P07174046T0000|0 14|Vibrio fluvialis
P07174046T0000|31 41|Maharashtra
P07174046T0000|16 27|group F vibrio
P07174122A0000|0 18|Serum creatine kinase
P07174122A0000|20 22|SCK
P07174122A0000|93 108|bicycle ergometry
P07174122A0000|113 123|lifting task
P07174122A0000|53 62|laboratory
P07174122A0000|80 90|performance
P07174122A0000|40 47|subjects
P07174437A0181|0 8|Organisms
P07174437A0181|30 36|bobcats
P07174437A0181|52 59|counties
P07175474A0102|98 102|death
P07175474A0102|125 132|official
P07175474A0102|90 95|manner
P07175474A0102|10 14|death
P07175474A0102|70 77|findings
P07175474A0102|137 146|difficulty
P07175474A0102|3 7|cause
P07179412A1131|42 43|US
P07179412A1131|23 26|head
P07179412A1131|29 38|population
P07179412A1131|46 46|X
P07179412A1131|16 19|cost
P07180901A0539|132 139|necrosis
P07180901A0539|25 33|blood flow
P07180901A0539|105 113|ibuprofen
P07180901A0539|63 85|prostaglandin synthetase
P07180901A0539|96 102|effects
P07181985A0107|42 48|mg/40 ml
P07181985A0107|8 23|mg mitomycin/20 ml
P07181985A0107|101 108|catheter
P07181985A0107|89 95|bladder
P07181985A0107|33 37|water
P07181985A0107|148 150|min
P07181985A0107|58 62|water
P07182523A0462|60 75|SOA concentration
P07182523A0462|31 33|SOA
P07182523A0462|53 57|times
P07182523A0462|4 9|groups
P07183576A0157|145 156|micrograms/g
P07183576A0157|102 106|fluid
P07183576A0157|16 28|concentration
P07183576A0157|133 140|synovium
P07183576A0157|71 83|micrograms/ml
P07183576A0157|187 198|micrograms/g
P07183576A0157|55 63|operation
P07183576A0157|158 159|SD
P07183576A0157|124 125|SD
P07183576A0157|85 86|SD
P07183576A0157|111 122|micrograms/g
P07183576A0157|217 220|bone
P07183576A0157|200 201|SD
P07183576A0157|31 44|flucloxacillin
P07183576A0157|177 180|bone
P07184375T0001|60 61|VM
P07184375T0001|19 29|vincristine
P07184375T0001|117 124|lymphoma
P07184375T0001|65 87|combination chemotherapy
P07184375T0001|12 16|study
P07184375T0001|47 58|prednisolone
P07184375T0001|31 42|methotrexate
P07184375T0001|63 63|P
P07184598T0001|19 33|hyperthyroidism
P07184598T0001|8 16|secretion
P07184774T0000|0 13|Re-examination
P07184774T0000|19 27|ED01 study
P07184795A0517|72 76|liter
P07184795A0517|10 23|determinations
P07184795A0517|67 70|I.U.
P07184795A0517|39 54|serum CPK activity
P07184795A0517|28 34|control
P07190627T0000|15 41|plasminogen activator release
P07190627T0000|8 12|study
P07190627T0000|54 59|agents
P07190627T0000|81 86|dog leg
P07190869A0316|0 3|CDDP
P07190869A0316|21 25|agent
P07190869A0316|41 48|lymphoma
P07191183A0505|0 8|Treatment
P07191183A0505|88 93|lipids
P07191183A0505|11 20|meat muscle
P07191183A0505|74 85|autoxidation
P07191183A0505|68 71|rate
P07191183A0505|24 24|V
P07191183A0505|30 30|s
P07191804A0000|98 98|h
P07191804A0000|11 18|response
P07191804A0000|111 118|activity
P07191804A0000|87 92|course
P07191804A0000|132 137|h sleep
P07191804A0000|34 52|bicycle exercise test
P07191804A0000|71 76|cadets
P07191972A0391|85 89|phase
P07191972A0391|11 21|temperature
P07191972A0391|55 61|cooling
P07191972A0391|38 46|responses
P07191972A0391|26 33|degrees C
P07192369T0000|1 6|method
P07192369T0000|65 78|administration
P07192369T0000|111 114|rats
P07192369T0000|41 48|toxicity
P07192369T0000|81 102|l-alpha-acetylmethadol
P07192722A0682|142 143|CL
P07192722A0682|23 39|parathyroidectomy
P07192722A0682|90 94|group
P07192722A0682|63 77|serum iPTH levels
P07192722A0682|53 60|decrease
P07192722A0682|166 166|p
P07192722A0682|96 99|PMNs
P07192722A0682|106 112|ability
P07192722A0682|121 124|sera
P07192722A0682|86 87|CL
P07192722A0682|115 119|group
P07192722A0682|152 155|PMNs
P07194905A0332|0 2|TCZ
P07194905A0332|40 49|indication
P07194905A0332|97 106|hemorrhage
P07194905A0332|118 132|brain maturation
P07194905A0332|52 65|tissue necrosis
P07195615A0087|100 111|accumulation
P07195615A0087|37 44|increase
P07195615A0087|114 115|Cd
P07195615A0087|50 57|duration
P07195615A0087|78 88|association
P07195615A0087|20 23|rats
P07195615A0087|148 153|region
P07195615A0087|60 75|Cd administration
P07195615A0087|3 8|number
P07195615A0087|159 163|brain
P07195615A0087|130 133|bulb
P07195880A0621|4 7|test
P07195880A0621|37 41|means
P07195880A0621|49 55|leprosy
P07202224A0452|27 35|vis-a-vis
P07202224A0452|57 66|injections
P07202224A0452|45 49|males
P07202224A0452|111 117|females
P07202224A0452|92 105|attractiveness
P07202224A0452|69 70|TP
P07202224A0452|82 90|castrates
P07202224A0452|3 13|preferences
P07202525A0200|115 122|stimulus
P07202525A0200|20 24|light
P07202525A0200|91 97|seconds
P07202525A0200|79 83|shock
P07202525A0200|61 67|stimuli
P07202525A0200|41 47|seconds
P07202525A0200|4 8|trial
P07202525A0200|28 33|buzzer
P07202919A0142|0 4|Ulcer
P07202919A0142|63 71|ulcer scar
P07202919A0142|46 49|week
P07202919A0142|30 36|stomach
P07202919A0142|18 24|angulus
P07202919A0142|77 84|42nd week
P07203410T0000|0 11|Family visits
P07203410T0000|50 62|state hospital
P07203410T0000|15 25|involvement
P07203410T0000|39 46|patients
P07203410T0000|28 36|treatment
P07205120T0000|42 53|ECG wave forms
P07205120T0000|12 18|overlay
P07205120T0000|31 39|amplitude
P07205967T0000|46 53|response
P07205967T0000|92 98|partner
P07205967T0000|7 14|reaction
P07205967T0000|37 43|partner
P07205967T0000|56 66|improvement
P07208984A0000|74 90|tomography studies
P07208984A0000|50 57|MAA brain
P07208984A0000|42 48|albumin
P07208984A0000|92 93|CT
P07208984A0000|136 143|diseases
P07208984A0000|112 119|patients
P07208984A0000|0 4|Brain
P07214230T0000|0 9|Inhibition
P07214230T0000|68 78|pitch canker
P07214230T0000|12 33|Fusarium moniliforme var
P07214230T0000|57 61|agent
P07214230T0000|35 46|subglutinans
P07214230T0000|85 111|soil bacterium Arthrobacter sp
P07214665A0000|147 151|women
P07214665A0000|65 72|triazeno
P07214665A0000|12 22|combination
P07214665A0000|74 84|vincristine
P07214665A0000|116 125|prednisone
P07214665A0000|132 132|P
P07214665A0000|25 56|fluorouracil imidazole carboxamide
P07214665A0000|127 130|FIVB
P07214665A0000|86 111|bis-chloroethyl nitrosourea
P07214665A0000|166 177|breast cancer
P07217329A0000|184 192|biofluids
P07217329A0000|92 102|metabolites
P07217329A0000|74 77|LAAM
P07217329A0000|167 179|dinormethadol
P07217329A0000|259 268|UV detector
P07217329A0000|53 72|alpha-acetylmethadol
P07217329A0000|217 230|chromatography
P07217329A0000|105 121|noracetylmethadol
P07217329A0000|249 254|column
P07217329A0000|274 275|nm
P07217329A0000|36 48|determination
P07217329A0000|143 150|methadol
P07217329A0000|1 6|method
P07217329A0000|123 141|dinoracetylmethadol
P07217329A0000|152 162|normethadol
P07217523A0364|0 6|Results
P07217523A0364|105 115|recognition
P07217523A0364|64 70|voicing
P07217523A0364|12 26|recognition task
P07217523A0364|72 79|position
P07217523A0364|46 52|effects
P07217523A0364|83 94|vowel context
P07218008T0000|57 61|areas
P07218008T0000|169 173|areas
P07218008T0000|77 92|Aotus trivirgatus
P07218008T0000|26 32|neurons
P07218008T0000|108 117|comparison
P07218008T0000|67 75|owl monkey
P07218008T0000|6 23|response properties
P07219297T0000|8 15|approach
P07219297T0000|38 46|allergens
P07219297T0000|21 35|standardization
P07219821T0028|21 34|considerations
P07221179A0156|15 18|fall
P07221179A0156|135 141|minutes
P07221179A0156|79 92|administration
P07221179A0156|104 108|nadir
P07221179A0156|113 115|min
P07221179A0156|44 55|GABA decrease
P07221179A0156|21 31|GABA content
P07221179A0156|68 70|min
P07221354T0000|0 5|Theory
P07221354T0000|9 20|applications
P07221354T0000|36 42|summary
P07221354T0000|23 33|pulse dosing
P07221354T0000|48 56|symposium
P07225300A0968|94 104|sensitivity
P07225300A0968|75 81|effects
P07225300A0968|87 90|drug
P07225300A0968|51 57|respect
P07225300A0968|23 29|neonate
P07225300A0968|5 11|results
P07225300A0968|67 72|nature
P07225300A0968|44 48|adult
P07225540A0193|13 15|gas
P07225540A0193|80 92|plasma samples
P07225540A0193|115 124|techniques
P07225540A0193|31 60|electron capture detection method
P07226440T0000|45 51|failure
P07226440T0000|57 59|rat
P07226440T0000|3 14|hemodynamics
P07228955A0000|48 67|theophylline analysis
P07228955A0000|7 13|authors
P07228955A0000|116 125|metabolite
P07228955A0000|83 102|1,7-dimethylxanthine
P07228955A0000|34 45|interference
P07228955A0000|128 135|caffeine
P07228955A0000|70 81|paraxanthine
P07234308A0121|28 31|CHOP
P07234308A0121|21 26|C-MOPP
P07234308A0121|101 107|disease
P07234308A0121|72 76|cases
P07234308A0121|49 62|remission rates
P07234308A0121|5 16|drug regimens
P07234308A0121|35 39|BACOP
P07234308A0121|92 95|cure
P07234755A0838|28 35|Hematrak
P07234755A0838|3 11|monocytes
P07234755A0838|46 46|%
P07234974T0000|23 34|Jat dentition
P07234974T0000|13 20|features
P07235317T0000|8 15|accuracy
P07235317T0000|37 52|Phadebas RAST test
P07235317T0000|25 31|version
P07235355A0462|57 61|tests
P07235355A0462|47 54|sequence
P07235355A0462|11 18|subjects
P07235355A0462|111 127|density dependence
P07235355A0462|100 108|flow rates
P07235355A0462|23 26|COPD
P07235355A0462|80 80|%
P07235355A0462|92 97|change
P07236351A0812|17 24|recovery
P07236351A0812|78 85|areas CA3
P07236351A0812|36 38|EEG
P07236351A0812|89 91|CA4
P07236351A0812|72 75|loss
P07237123T0000|88 91|bulb
P07237123T0000|48 59|nerve volleys
P07237123T0000|24 36|unit responses
P07237123T0000|73 78|turtle
P07237560A1038|83 87|genes
P07237560A1038|61 70|inactivity
P07237560A1038|26 33|sequence
P07237560A1038|8 16|deletions
P07237560A1038|89 100|substitution
P07237560A1038|52 55|tRNA
P07237560A1038|113 119|portion
P07237560A1038|156 164|gene units
P07237560A1038|134 147|Hind III linkers
P07237560A1038|173 185|transcription
P07237817T0000|0 14|Cross reactivity
P07237817T0000|17 34|theophylline RIA kit
P07240343A0000|43 45|day
P07240343A0000|21 24|i.v.
P07240343A0000|63 66|p.c.
P07240343A0000|48 61|post conception
P07240343A0000|37 40|rats
P07240343A0000|0 11|Strontium-90
P07242929T0001|29 36|activity
P07242929T0001|101 107|methods
P07242929T0001|47 57|extremities
P07242929T0001|0 8|Recording
P07243380A0327|93 96|torr
P07243380A0327|60 62|P50
P07243380A0327|50 57|decrease
P07243380A0327|36 36|P
P07243380A0327|9 16|acidosis
P07243380A0327|5 6|hr
P07247059A0775|0 14|Catheter transit
P07247059A0775|23 30|response
P07247059A0775|34 45|step increase
P07247059A0775|174 174|s
P07247059A0775|72 72|s
P07247059A0775|93 96|cent
P07247059A0775|48 60|concentration
P07247059A0775|133 140|catheter
P07247059A0775|183 184|N2
P07247059A0775|83 89|cent-90
P07247059A0775|112 122|transit time
P07249497A0688|70 74|women
P07249497A0688|142 149|patients
P07249497A0688|164 170|courses
P07249497A0688|109 111|PPI
P07249497A0688|36 46|estrogen PPI
P07249497A0688|80 84|risks
P07249497A0688|5 9|women
P07249497A0688|96 106|estrogen use
P07249544A0343|28 52|serum creatine kinase levels
P07249544A0343|7 17|temperature
P07249544A0343|68 75|patients
P07249660T0000|0 12|Determination
P07249660T0000|21 34|distensibility
P07249660T0000|41 50|variations
P07249660T0000|61 72|hypertension
P07249895A0177|178 186|inhibitor
P07249895A0177|255 262|recovery
P07249895A0177|18 31|prostaglandins
P07249895A0177|189 210|prostaglandin synthesis
P07249895A0177|127 138|indomethacin
P07249895A0177|236 246|esophagitis
P07249895A0177|73 86|LES hypotension
P07249895A0177|101 109|treatment
P07249895A0177|224 233|production
P07249895A0177|46 56|esophagitis
P07249895A0177|116 122|animals
P07249895A0177|12 15|role
P07249895A0177|143 155|micrograms/kg
P07251564A0569|57 65|diagnosis
P07251564A0569|17 22|sample
P07251564A0569|11 11|%
P07251564A0569|82 93|ASDC nosology
P07252346A0223|35 41|problem
P07252346A0223|9 17|technique
P07253335T0000|58 63|stroke
P07253335T0000|37 41|onset
P07253335T0000|66 77|stroke-prone
P07253335T0000|9 31|prostaglandin inhibitors
P07253335T0000|103 106|rats
P07253335T0000|44 54|proteinuria
P07253335T0000|0 6|Effects
P07256543A0814|59 66|presence
P07256543A0814|231 236|injury
P07256543A0814|132 137|sputum
P07256543A0814|90 94|burns
P07256543A0814|191 202|airway injury
P07256543A0814|30 37|criteria
P07256543A0814|6 10|study
P07256543A0814|96 118|carboxyhemoglobin levels
P07256543A0814|41 56|inhalation injury
P07256543A0814|147 157|space injury
P07256543A0814|179 186|patients
P07259325A0394|0 7|Survival
P07259325A0394|59 67|diagnosis
P07259325A0394|53 56|date
P07259325A0394|38 42|onset
P07259325A0394|32 35|date
P07260389A0221|29 35|blocker
P07260389A0221|69 79|development
P07260389A0221|108 116|serotonin
P07260389A0221|38 55|serotonin receptors
P07260389A0221|16 20|mg/kg
P07260389A0221|100 105|effect
P07260389A0221|0 11|Methisergide
P07260987A0336|115 121|rabbits
P07260987A0336|108 112|hours
P07260987A0336|66 69|hour
P07260987A0336|24 47|disposition phase t1/2 beta
P07260987A0336|137 146|impairment
P07260987A0336|3 17|plasma half-life
P07260987A0336|94 101|function
P07260987A0336|72 78|rabbits
P07262239T0000|0 6|Effects
P07262239T0000|23 33|deprivation
P07262239T0000|36 46|development
P07262239T0000|83 85|cat
P07262239T0000|67 77|projections
P07262625A0000|0 20|Corticosteroid therapy
P07262625A0000|189 200|Giardia muris
P07262625A0000|214 220|effects
P07262625A0000|95 118|host parasite relationship
P07262625A0000|251 259|parasites
P07262625A0000|223 237|corticosteroids
P07262625A0000|279 284|course
P07262625A0000|76 84|mechanism
P07262625A0000|265 273|intestine
P07262625A0000|243 248|number
P07262625A0000|43 50|patients
P07262625A0000|130 137|steroids
P07262625A0000|171 187|protozoal parasite
P07262625A0000|295 303|infection
P07262625A0000|55 69|occult infection
P07263374T0000|32 44|pneumonectomy
P07263374T0000|20 26|puppies
P07263374T0000|6 17|lung function
P07263421A0351|4 7|Sair
P07263421A0351|24 31|capacity
P07263421A0351|51 57|control
P07263421A0351|11 13|So2
P07263421A0351|46 46|%
P07263745T0000|9 28|Charnley arthroplasty
P07263745T0000|38 46|procedure
P07264787A0351|95 95|%
P07264787A0351|59 69|thyroiditis
P07264787A0351|100 114|hyperthyroidism
P07264787A0351|123 123|%
P07264787A0351|8 15|patients
P07264787A0351|42 49|evidence
P07266969A0246|44 52|Tamoxifen
P07266969A0246|3 14|relationship
P07266969A0246|32 41|properties
P07266969A0246|56 77|breast cancer management
P07267675A0000|71 76|number
P07267675A0000|24 36|cephalosporin
P07267675A0000|38 40|CGP
P07267675A0000|91 98|patients
P07267675A0000|110 119|infections
P07268828A0000|132 151|solid-phase particles
P07268828A0000|24 36|determination
P07268828A0000|39 43|serum
P07268828A0000|60 70|propranolol
P07268828A0000|46 57|plasma levels
P07268828A0000|187 192|tracer
P07268828A0000|174 184|propranolol
P07268828A0000|100 110|propranolol
P07268828A0000|1 17|fluoroimmunoassay
P07268828A0000|88 97|antibodies
P07270163A0684|187 194|controls
P07270163A0684|111 115|layer
P07270163A0684|159 165|vessels
P07270163A0684|121 125|villi
P07270163A0684|181 183|CNF
P07270163A0684|24 34|projections
P07270163A0684|84 92|structure
P07270163A0684|68 70|CNF
P07270163A0684|132 137|lining
P07270991A0149|27 38|grass species
P07270991A0149|4 17|pollen allergen
P07270991A0149|92 97|values
P07270991A0149|60 66|results
P07274042A0249|72 79|patients
P07274042A0249|0 2|DMI
P07274042A0249|52 56|group
P07274042A0249|14 27|concentrations
P07274428A0000|116 131|cholecystography
P07274428A0000|135 144|Bengal pink
P07274428A0000|152 159|affinity
P07274428A0000|254 263|liver cells
P07274428A0000|209 222|indigo-carmine
P07274428A0000|180 191|RCA triombrin
P07274428A0000|101 109|bilignost
P07274428A0000|249 250|PM
P07274428A0000|16 26|experiments
P07274428A0000|97 99|RCA
P07274428A0000|239 247|membranes
P07274428A0000|61 66|anions
P07274428A0000|83 95|contrast agent
P07274482A0000|55 65|selectivity
P07274482A0000|9 15|neurons
P07274482A0000|100 104|sound
P07274482A0000|90 97|movement
P07274482A0000|122 129|movement
P07274482A0000|73 87|afterdischarges
P07274482A0000|21 23|cat
P07274482A0000|148 152|deg/s
P07274482A0000|109 116|velocity
P07274482A0000|40 43|body
P07274505A0660|2 9|controls
P07274505A0660|21 31|differences
P07276210T0000|0 4|Assay
P07276210T0000|40 49|blood spots
P07276210T0000|26 32|trypsin
P07276210T0000|7 11|serum
P07276210T0000|61 69|detection
P07276210T0000|78 85|fibrosis
P07277222A1391|160 171|interactions
P07277222A1391|65 74|oscillator
P07277222A1391|40 48|motor unit
P07277222A1391|7 11|waves
P07277222A1391|95 104|occurrence
P07277222A1391|137 145|existence
P07278104T0001|0 22|Leukocyte enzyme activity
P07278104T0001|26 59|blood lymphocyte blast transformation
P07278104T0001|69 78|bronchitis
P07278578T0001|30 36|Hodgkin
P07278578T0001|7 12|status
P07278578T0001|39 45|disease
P07278578T0001|15 26|chemotherapy
P07280654A0000|16 18|HBE
P07280654A0000|53 67|averaging method
P07280654A0000|37 47|application
P07280654A0000|2 11|literature
P07282444A0075|50 55|tumour
P07282444A0075|10 14|cases
P07282444A0075|37 44|approach
P07282444A0075|90 94|shunt
P07282444A0075|65 69|cases
P07282552A0990|87 92|tissue
P07282552A0990|109 121|subepicardium
P07282552A0990|20 25|tissue
P07282552A0990|94 98|ratio
P07282552A0990|73 76|zone
P07282552A0990|2 7|Group V
P07282552A0990|132 145|subendocardium
P07282943A0097|177 183|tension
P07282943A0097|143 149|changes
P07282943A0097|79 85|control
P07282943A0097|27 35|decreases
P07282943A0097|71 73|PO2
P07282943A0097|112 115|mmHg
P07282943A0097|38 54|superfusate oxygen
P07282943A0097|92 99|aeration
P07282943A0097|101 103|PO2
P07282943A0097|89 89|%
P07282943A0097|62 69|pressure
P07283110A0000|41 46|values
P07283110A0000|8 9|B1
P07283110A0000|11 20|deficiency
P07283110A0000|56 63|exercise
P07286057A0159|140 141|mg
P07286057A0159|149 162|administration
P07286057A0159|7 25|AUC infinity analyses
P07286057A0159|120 128|injection
P07286057A0159|48 57|buflomedil
P07286057A0159|111 112|mg
P07286057A0159|116 117|i.
P07286057A0159|30 45|pharmacokinetics
P07286057A0159|86 89|dose
P07293100T0001|0 15|Gastrin secretion
P07293100T0001|22 36|food stimulation
P07293100T0001|48 61|system diseases
P07293327T0001|0 22|Fibrinogen determination
P07293327T0001|31 40|KZM-1 meter
P07295033A0513|70 70|%
P07295033A0513|76 80|urine
P07295033A0513|21 21|%
P07295033A0513|58 63|faeces
P07295033A0513|27 30|dose
P07295033A0513|5 10|period
P07295033A0513|15 18|days
P07295417A0092|30 36|regions
P07295417A0092|46 54|ventricle
P07295417A0092|90 98|technique
P07295417A0092|101 112|phase imaging
P07296303A0418|0 8|Responses
P07296303A0418|22 27|nuclei
P07296303A0418|11 19|brainstem
P07296303A0418|45 62|lateralis posterior
P07296303A0418|36 43|dorsalis
P07296303A0418|87 93|latency
P07296997A0125|49 51|OCG
P07296997A0125|67 93|Tc-99m-PyG cholescintigraphy
P07296997A0125|8 15|patients
P07296997A0125|34 44|gallbladder
P07297576A0454|18 39|drinking water ad libitum
P07297576A0454|62 68|Aludrox
P07297576A0454|76 88|drinking water
P07297978A0570|30 40|case history
P07297978A0570|10 13|data
P07297978A0570|83 84|C.
P07297978A0570|79 79|A
P07297978A0570|42 54|smoking habits
P07298209A0291|129 144|bicycle ergometer
P07298209A0291|78 83|VO2 max
P07298209A0291|63 63|%
P07298209A0291|26 44|performance capacity
P07298209A0291|55 58|W170
P07298209A0291|3 15|determination
P07298209A0291|118 125|work load
P07298259T0000|15 18|lead
P07298259T0000|21 25|blood
P07298259T0000|0 12|Determination
P07298523T0000|58 62|swine
P07298523T0000|8 19|indomethacin
P07298523T0000|45 55|parturition
P07298523T0000|23 42|prostaglandin F2 alpha
P07298523T0000|0 5|Effect
P07299857A0294|0 9|LD50 values
P07299857A0294|117 120|male
P07299857A0294|19 20|KP
P07299857A0294|273 274|KP
P07299857A0294|143 148|KP-T10
P07299857A0294|48 52|mg/kg
P07299857A0294|69 74|KP-CMC
P07299857A0294|250 254|mg/kg
P07299857A0294|133 138|female
P07299857A0294|12 16|terms
P07299857A0294|240 244|males
P07299857A0294|38 41|rats
P07299857A0294|126 130|mg/kg
P07299857A0294|266 270|terms
P07299857A0294|219 228|LD50 values
P07299857A0294|207 212|KP-CMC
P07299857A0294|257 263|females
P07299857A0294|233 237|mg/kg
P07299857A0294|61 64|rats
P07299857A0294|110 114|mg/kg
P07299857A0294|164 177|intrarectally.
P07299857A0294|191 204|administration
P07299857A0294|27 31|mg/kg
P07304905A0336|0 14|Autotransfusion
P07304905A0336|37 49|Heparin-ACD-B
P07304905A0336|51 61|Heparin-DPD
P07304905A0336|63 79|Heparin-ACD-B etc.
P07306839T0001|0 7|Electron
P07306839T0001|39 44|cortex
P07306839T0001|19 25|picture
P07306839T0001|61 68|degrees C
P07306839T0001|47 50|rats
P07308849A0817|41 60|sham operation animals
P07308849A0817|12 22|differences
P07308849A0817|107 112|weight
P07308849A0817|35 37|gut
P07308849A0817|79 82|data
P07309562T0000|59 62|acid
P07309562T0000|80 84|acids
P07309562T0000|36 48|determination
P07310206A0154|102 119|resin casting method
P07310206A0154|67 92|scanning electron microscopy
P07310206A0154|3 14|architecture
P07310206A0154|17 32|microvasculature
P07310206A0154|43 49|regions
P07311881T0000|0 10|MSMS Council
P07311881T0000|25 38|health director
P07312707T0000|0 7|Chordoma
P07312707T0000|19 22|cord
P07312707T0000|26 32|F344 rat
P07320153T0000|105 121|injection analysis
P07320153T0000|88 95|detector
P07320153T0000|21 26|liquid
P07320153T0000|140 149|body fluids
P07320153T0000|42 47|system
P07320153T0000|124 137|catecholamines
P07320153T0000|57 65|precolumn
P07320153T0000|0 4|Micro
P07323063A0000|189 194|degree
P07323063A0000|94 97|SHRs
P07323063A0000|198 207|time course
P07323063A0000|57 60|rats
P07323063A0000|249 256|recovery
P07323063A0000|146 149|dose
P07323063A0000|89 92|rats
P07323063A0000|154 174|mg/kg dl-isoproterenol
P07323063A0000|229 235|failure
P07323573A0644|7 10|zone
P07323573A0644|26 37|dissociation
P07326596A0061|3 15|IgA deficiency
P07326596A0061|33 35|IgE
P07327097A0647|98 98|%
P07327097A0647|100 100|p
P07327097A0647|2 7|PB mice
P07327097A0647|132 143|granule cells
P07327097A0647|120 126|deficit
P07327097A0647|87 94|controls
P07327097A0647|27 33|deficit
P07327097A0647|70 76|neurons
P07327097A0647|39 44|number
P07328000T0000|0 19|Nutritional cataracts
P07328000T0000|22 33|timber wolves
P07330073T0000|57 66|blood cells
P07330073T0000|12 31|transfusion reactions
P07330073T0000|42 47|saline
P07330073T0000|37 39|use
P07330073T0000|0 9|Prevention
P07337609A0531|164 175|immunization
P07337609A0531|111 118|chickens
P07337609A0531|202 210|challenge
P07337609A0531|43 56|antibody titers
P07337609A0531|12 15|mean
P07337609A0531|58 60|GMT
P07337609A0531|186 197|immunization
P07337609A0531|139 147|intervals
P07340196T0001|30 34|HBSAG
P07340196T0001|64 77|infectiousness
P07340196T0001|46 48|aid
P07340196T0001|80 102|hepatitis B virus carriers
P07340196T0001|15 27|determination
P07341346A0174|16 27|shunt vessels
P07341346A0174|63 70|arteries
P07341346A0174|95 100|system
P07345217A0000|75 84|malignancy
P07345217A0000|10 22|complications
P07345217A0000|51 59|treatment
P07347728T0000|0 12|Arachnoid cyst
P07349416A0337|16 25|summer coat
P07354367A0162|0 10|Hypotension
P07354367A0162|24 27|head
P07354367A0162|30 33|tilt
P07355527A0467|57 62|adults
P07355527A0467|12 20|procedure
P07355527A0467|23 34|Lich-Gregoir
P07356273T0022|48 54|tissues
P07356273T0022|24 37|cell carcinomas
P07365183A0000|206 209|SECT
P07365183A0000|155 161|therapy
P07365183A0000|111 118|response
P07365183A0000|87 92|safety
P07365183A0000|6 13|patients
P07365183A0000|34 42|diagnosis
P07365183A0000|198 204|therapy
P07365183A0000|80 84|terms
P07365183A0000|163 167|MMECT
P07365183A0000|55 64|depression
P07365183A0000|96 103|efficacy
P07369183T0000|6 14|artifacts
P07369183T0000|26 43|coagulation testing
P07369458A0606|117 131|amputation level
P07369458A0606|62 78|muscle temperature
P07369458A0606|38 46|technique
P07369458A0606|97 103|adjunct
P07372433A0000|100 104|years
P07372433A0000|39 53|guinea pig ureter
P07372433A0000|24 36|relationships
P07372433A0000|89 94|months
P07372433A0000|82 86|weeks
P07372433A0000|107 109|age
P07372433A0000|74 80|animals
P07372928A0105|0 4|Tests
P07372928A0105|145 150|source
P07372928A0105|30 44|Mossbauer source
P07372928A0105|10 15|method
P07372928A0105|128 134|cochlea
P07372928A0105|68 75|membrane
P07372928A0105|170 177|membrane
P07372928A0105|94 122|signal-transmission properties
P07375836T0000|44 53|metastasis
P07375836T0000|22 28|patient
P07375836T0000|12 18|work-up
P07375836T0000|64 72|carcinoma
P07375864A0431|174 184|platelet MAO
P07375864A0431|141 145|proof
P07375864A0431|63 71|correlate
P07375864A0431|161 168|findings
P07375864A0431|107 119|schizophrenia
P07375864A0431|22 35|nonspecificity
P07375864A0431|90 97|disorder
P07375864A0431|133 138|burden
P07375864A0431|3 9|authors
P07375864A0431|41 51|platelet MAO
P07376165T0001|14 20|disease
P07376165T0001|0 6|Ecthyma
P07377378A0143|0 18|Estrogen replacement
P07377378A0143|128 132|rates
P07377378A0143|155 162|heat loss
P07377378A0143|196 203|controls
P07377378A0143|94 101|capsules
P07377378A0143|30 43|beta-estradiol
P07377378A0143|46 70|beta-estradiol-3-benzoate
P07377378A0143|135 148|heat production
P07377954A0117|116 132|oxygen consumption
P07377954A0117|155 170|health volunteers
P07377954A0117|307 314|subjects
P07377954A0117|103 111|pulse rate
P07377954A0117|63 68|system
P07377954A0117|38 43|effect
P07377954A0117|71 75|terms
P07377954A0117|134 136|VO2
P07377954A0117|271 302|postexercise ankle pressure changes
P07377954A0117|210 229|gastrocnemius muscles
P07377954A0117|358 365|diseases
P07377954A0117|254 263|volunteers
P07377954A0117|236 243|exercise
P07377954A0117|94 101|pressure
P07377954A0117|191 198|tibialis
P07377954A0117|12 18|aspects
P07377954A0117|144 151|exercise
P07377954A0117|175 185|emg activity
P07377954A0117|376 386|extremities
P07379334A0503|0 6|Changes
P07379334A0503|49 62|transfer factor
P07379334A0503|114 120|placebo
P07379334A0503|20 29|reactivity
P07379334A0503|32 39|subjects
P07379334A0503|97 104|subjects
P07380615A0478|31 41|possibility
P07380615A0478|49 54|nature
P07380615A0478|90 93|loss
P07380615A0478|234 237|jobs
P07380615A0478|159 172|work efficiency
P07380615A0478|61 70|collar jobs
P07380615A0478|245 257|collar workers
P07380615A0478|106 111|tissue
P07380615A0478|206 215|efficiency
P07385543T0001|0 9|Importance
P07385543T0001|26 46|blood sulfhydryl groups
P07385543T0001|92 100|infection
P07385543T0001|49 57|fractures
P07385543T0001|74 78|bones
P07385920A0189|3 9|results
P07385920A0189|64 79|blood haemoglobin
P07385920A0189|27 40|blood lead level
P07385920A0189|110 119|delta amino
P07385920A0189|129 132|acid
P07385920A0189|99 107|excretion
P07385933A0085|99 103|14CO2
P07385933A0085|124 132|intervals
P07385933A0085|38 49|kg body weight
P07385933A0085|89 97|galactose
P07385933A0085|25 34|g galactose
P07385933A0085|64 67|mu Ci
P07385933A0085|9 19|iv injection
P07385933A0085|142 145|hour
P07386500A0174|44 53|deficiency
P07386500A0174|8 27|clotting factor assays
P07386500A0174|56 62|factor X
P07386500A0174|93 106|determinations
P07386500A0174|82 85|cent
P07386864T0000|20 27|dialysis
P07387242A0236|29 37|intervals
P07387242A0236|136 152|clotting functions
P07387242A0236|124 131|elements
P07387242A0236|107 116|hemoglobin
P07387242A0236|88 101|plasma proteins
P07387242A0236|60 68|operation
P07387242A0236|0 13|Blood variables
P07392519T0001|7 13|changes
P07392519T0001|26 36|retinopathy
P07392519T0001|39 46|children
P07393856A0314|83 93|Experiments
P07393856A0314|64 80|reference standard
P07393856A0314|10 19|beta-apo-8
P07393856A0314|3 8|result
P07393856A0314|32 45|acid ethyl ester
P07393856A0314|47 52|apo-EE
P07393976A0000|43 56|sodium barbital
P07393976A0000|203 207|water
P07393976A0000|76 88|taste aversion
P07393976A0000|177 200|% sodium saccharin solution
P07393976A0000|12 30|sodium phenobarbital
P07393976A0000|93 99|hr fluid
P07393976A0000|148 170|bottle taste aversion task
P07393976A0000|34 38|mg/kg
P07393976A0000|108 111|rats
P07393976A0000|129 142|discrimination
P07393976A0000|3 9|ability
P07393976A0000|60 64|mg/kg
P07394364A0738|213 215|VO2
P07394364A0738|123 128|levels
P07394364A0738|91 98|organism
P07394364A0738|61 67|mammals
P07394364A0738|25 45|gas exchange parenchyma
P07394364A0738|186 195|adaptation
P07394364A0738|159 163|rates
P07394364A0738|201 204|lung
P07395750A0294|0 15|Underestimations
P07395750A0294|66 78|methodologies
P07395750A0294|45 52|problems
P07395750A0294|28 28|%
P07396545A0217|45 50|course
P07396545A0217|56 63|disorder
P07396545A0217|0 11|Chemotherapy
P07397066T0000|0 13|Drug inhibition
P07397066T0000|21 40|blood aspirin esterase
P07401318A0823|74 82|staircase
P07401318A0823|96 97|Hz
P07401318A0823|37 45|staircase
P07401318A0823|15 25|temperature
P07405701T0000|20 28|responses
P07405701T0000|32 55|platelet monoamine oxidase
P07405701T0000|79 88|alcoholism
P07405701T0000|58 65|patients
P07406527A0212|57 72|porphyrin content
P07406527A0212|75 80|lijver
P07406527A0212|134 134|%
P07406527A0212|5 7|end
P07406527A0212|148 158|HCB controls
P07406527A0212|33 50|porphyrin excretion
P07406527A0212|13 22|experiment
P07406527A0212|118 124|animals
P07406527A0212|84 87|skin
P07408970A0706|43 44|Gf
P07408970A0706|35 40|uterus
P07408970A0706|99 108|difference
P07408970A0706|3 7|hours
P07408970A0706|20 33|administration
P07408970A0706|137 137|p
P07408970A0706|48 53|Cv mice
P07408970A0706|58 63|weight
P07408970A0706|80 82|mg%
P07408970A0706|69 71|mg%
P07410037A0752|215 224|propensity
P07410037A0752|180 185|factor
P07410037A0752|105 116|control group
P07410037A0752|146 154|magnesium
P07410037A0752|135 143|excretion
P07410037A0752|167 173|calcium
P07410037A0752|8 20|stone-formers
P07410037A0752|55 73|magnesium metabolism
P07410037A0752|45 52|features
P07410037A0752|157 164|relation
P07413144T0018|0 7|Analysis
P07413144T0018|19 28|population
P07413242A0000|26 36|paraplegics
P07413242A0000|17 21|study
P07413242A0000|49 55|lesions
P07413242A0000|60 64|T1-L3
P07413441T0070|16 27|localisation
P07413441T0070|41 52|distribution
P07413441T0070|58 63|kidney
P07413781A0169|106 116|stimulation
P07413781A0169|149 159|preexposure
P07413781A0169|132 143|conditioning
P07413781A0169|11 21|stimulation
P07413781A0169|44 62|stimulus preexposure
P07413781A0169|71 81|attenuation
P07413781A0169|90 99|inhibition
P07413806T0000|44 47|rats
P07413806T0000|33 41|pathology
P07413806T0000|15 22|amygdala
P07414817T0001|0 17|Cataract extraction
P07414817T0001|27 34|glaucoma
P07415340A0280|0 5|Number
P07415340A0280|9 12|size
P07415340A0280|24 33|structures
P07415340A0280|39 52|pneumocytes typ
P07416204A0437|201 202|t0
P07416204A0437|100 111|extrasystole
P07416204A0437|155 166|potentiation
P07416204A0437|216 227|potentiation
P07416204A0437|80 81|t0
P07416204A0437|181 182|t1
P07416204A0437|140 141|t1
P07416204A0437|11 16|animal
P07416204A0437|89 94|timing
P07416204A0437|65 78|pacing interval
P07416204A0437|35 46|potentiation
P07416204A0437|113 114|t1
P07416204A0437|120 121|t0
P07418498A0217|116 128|amphotericin B
P07418498A0217|153 163|lung abscess
P07418498A0217|21 33|complications
P07418498A0217|103 111|treatment
P07418498A0217|140 147|excision
P07418498A0217|36 50|corticosteroids
P07418498A0217|2 6|spite
P07418498A0217|64 71|recovery
P07418498A0217|85 93|infection
P07418829A0191|0 11|Implications
P07418829A0191|32 41|pediatrics
P07418829A0191|18 28|observation
P07419485A0158|39 43|waves
P07419485A0158|55 59|waves
P07419485A0158|6 10|study
P07419485A0158|73 80|solution
P07419485A0158|131 134|cost
P07419485A0158|144 157|simplification
P07419485A0158|16 25|transition
P07423803T0001|0 8|Treatment
P07423803T0001|22 32|peritonitis
P07425838A0182|15 30|pheochromocytoma
P07425838A0182|67 75|pregnancy
P07425838A0182|9 12|case
P07425838A0182|56 64|trimester
P07426101A0124|105 122|alcohol consumption
P07426101A0124|144 153|mileage run
P07426101A0124|171 186|bicycle ergometer
P07426101A0124|47 84|adipose tissue lipoprotein lipase activity
P07426101A0124|86 103|anthropometric data
P07426101A0124|157 167|performance
P07426101A0124|7 12|plasma
P07426101A0124|16 45|lipoprotein lipid concentrations
P07426101A0124|216 229|training period
P07426101A0124|124 136|smoking habits
P07426604A0397|3 7|C18:1
P07426604A0397|111 115|acids
P07426604A0397|30 36|measure
P07426604A0397|9 16|C10 value
P07426604A0397|44 50|changes
P07426745A0177|74 77|rats
P07426745A0177|91 106|gamma-irradiaton
P07426745A0177|12 17|growth
P07426745A0177|20 49|blood erythrocyte membrane injury
P07426745A0177|124 125|Gy
P07426745A0177|110 113|dose
P07428037A0989|70 87|bp hairpin structure
P07428037A0989|159 165|subunit
P07428037A0989|137 139|RNA
P07428037A0989|199 213|mRNA binding site
P07428037A0989|215 220|ACCUCC
P07428037A0989|92 99|sequence
P07428037A0989|36 49|mouse mt 12S rRNA
P07428037A0989|21 31|nucleotides
P07428037A0989|171 177|systems
P07428037A0989|115 125|nucleotides
P07428037A0989|238 257|corn chloroplast rRNAs
P07429009T0121|21 42|cell population dynamics
P07429009T0121|11 17|anatomy
P07431059A0000|57 61|order
P07431059A0000|252 255|vein
P07431059A0000|209 213|Galen
P07431059A0000|226 234|Rosenthal
P07431059A0000|126 137|relationship
P07431059A0000|36 36|X
P07431059A0000|341 346|nerves
P07431059A0000|279 282|vein
P07431059A0000|98 109|pineal region
P07431059A0000|220 223|vein
P07431059A0000|305 309|notch
P07431059A0000|42 54|magnification
P07431059A0000|186 201|cerebellar artery
P07431059A0000|287 290|size
P07431059A0000|265 269|sinus
P07431059A0000|6 18|cadaver brains
P07431059A0000|171 176|artery
P07431059A0000|143 152|pineal body
P07431059A0000|203 206|vein
P07431059A0000|86 92|anatomy
P07432288A0218|0 17|Serum antibody titre
P07432288A0218|83 91|infection
P07432288A0218|54 67|recurrence rate
P07432288A0218|73 80|duration
P07434431A0203|13 21|refeeding
P07434431A0203|50 59|activation
P07434431A0203|38 46|mechanism
P07434431A0203|74 83|infections
P07434431A0203|106 111|famine
P07434456A0286|158 162|fluid
P07434456A0286|97 112|% glycerol content
P07434456A0286|183 191|osmometry
P07434456A0286|117 128|measurements
P07434456A0286|40 49|blood cells
P07434456A0286|59 66|glycerol
P07434456A0286|16 20|units
P07434456A0286|175 179|index
P07435185A0074|68 76|diagnosis
P07435185A0074|53 60|lymphoma
P07435185A0074|96 106|drill biopsy
P07435185A0074|23 30|findings
P07435185A0074|3 10|symptoms
P07436187A0147|141 150|disability
P07436187A0147|104 108|range
P07436187A0147|132 138|factors
P07436187A0147|85 88|time
P07436187A0147|3 7|study
P07436187A0147|66 71|entity
P07436187A0147|27 33|studies
P07436459A0245|151 170|tryptophan metabolism
P07436459A0245|95 113|vitamin B6 deficiency
P07436459A0245|141 148|response
P07436459A0245|173 178|stress
P07436459A0245|60 68|acid ratio
P07436702A0156|27 34|reaction
P07436702A0156|37 40|DNFB
P07436702A0156|3 16|control persons
P07436794A0148|41 43|CCA
P07436794A0148|25 39|carotid arteries
P07436794A0148|3 14|control group
P07438346A0381|2 3|pH
P07438346A0381|110 110|%
P07438346A0381|82 87|action
P07438346A0381|115 118|Vmax
P07438346A0381|79 79|%
P07438346A0381|125 125|%
P07438346A0381|97 105|amplitude
P07438346A0381|15 37|lidocaine concentrations
P07438482A0145|102 111|oestradiol
P07438482A0145|96 97|E1
P07438482A0145|113 114|E2
P07438482A0145|12 16|right
P07438482A0145|72 84|determination
P07438482A0145|87 94|oestrone
P07438482A0145|44 55|blood samples
P07440085T0061|0 15|Arm function tests
P07440430A1074|56 58|end
P07440430A1074|12 20|B breeding
P07440430A1074|43 50|Hb levels
P07440430A1074|144 149|B lambs
P07440430A1074|93 100|S x B lambs
P07440430A1074|117 124|Hb levels
P07440430A1074|164 164|P
P07440430A1074|81 87|NB lambs
P07440430A1074|64 73|experiment
P07440430A1074|89 89|b
P07440430A1074|132 139|D x B lambs
P07440430A1074|185 208|hemoglobin concentrations
P07440430A1074|3 7|lambs
P07440430A1074|111 111|P
P07445971A0241|61 73|nerve ligation
P07445971A0241|7 14|response
P07445971A0241|77 80|week
P07445971A0241|28 37|acrylamide
P07449221A0086|71 76|repair
P07449221A0086|47 50|slip
P07449221A0086|25 32|excision
P07449221A0086|82 87|tendon
P07449221A0086|36 37|mm
P07449221A0086|3 11|operation
P07449253A0411|14 18|group
P07449253A0411|92 99|diuresis
P07449253A0411|134 134|%
P07449253A0411|109 116|decrease
P07449253A0411|62 62|h
P07449253A0411|46 49|mmHg
P07449253A0411|119 129|blood volume
P07449253A0411|27 34|pressure
P07450031A0691|93 99|dioxide
P07450031A0691|152 167|benzothiazepin-6
P07450031A0691|101 104|NF19
P07450031A0691|171 177|dioxide
P07450031A0691|179 182|NF20
P07450031A0691|6 21|sedative activity
P07450031A0691|74 89|benzothiazepin-6
P07450388A0406|14 19|effect
P07450388A0406|63 70|bile duct
P07450388A0406|22 27|CCK-PZ
P07450388A0406|33 40|movement
P07450388A0406|107 123|duodenofiberscope
P07450388A0406|54 57|part
P07450388A0406|87 100|pressure sensor
P07450388A0406|2 9|patients
P07453919A0000|121 128|alkaline
P07453919A0000|237 252|blood neutrophils
P07453919A0000|132 146|acid phosphatase
P07453919A0000|160 167|esterase
P07453919A0000|106 119|determinations
P07453919A0000|308 311|head
P07453919A0000|77 90|blood cell count
P07453919A0000|16 21|Horton
P07453919A0000|45 58|investigations
P07453919A0000|195 197|IgM
P07453919A0000|189 193|tests
P07453919A0000|290 293|area
P07453919A0000|24 31|headache
P07453919A0000|330 333|side
P07453919A0000|274 277|pain
P07453919A0000|201 210|IgG binding
P07453919A0000|299 302|skin
P07453919A0000|4 11|patients
P07453919A0000|345 350|finger
P07453919A0000|268 271|area
P07455042A0457|191 196|atrium
P07455042A0457|54 61|machines
P07455042A0457|214 217|vein
P07455042A0457|71 97|Dynamic Spatial Reconstructor
P07455042A0457|155 163|injection
P07455042A0457|23 29|imaging
P07455042A0457|123 139|density resolution
P07455042A0457|166 178|contrast agent
P07455042A0457|247 258|measurements
P07455521A0414|30 38|NEXT study
P07455521A0414|19 24|result
P07455521A0414|3 6|ESEG
P07456774A0448|26 30|drugs
P07457931A0655|14 17|mice
P07457931A0655|45 51|5-OH-DA
P07457931A0655|6 11|series
P07457931A0655|34 42|injection
P07457931A0655|93 97|study
P07458171A0086|30 43|Platyhelmintha
P07458171A0086|48 55|Nematoda
P07458171A0086|63 71|Crustacea
P07458171A0086|17 23|species
P07461226A0958|2 9|symptoms
P07461226A0958|63 79|plasma epinephrine
P07461226A0958|48 58|correlation
P07461226A0958|22 26|flush
P07461226A0958|82 101|norepinephrine levels
P07461848A0230|109 121|micrograms/m3
P07461848A0230|18 31|concentrations
P07461848A0230|68 69|CO
P07461848A0230|144 156|micrograms/m3
P07461848A0230|52 63|tobacco smoke
P07461848A0230|97 104|nicotine
P07461848A0230|74 76|ppm
P07461848A0230|83 85|ppb
P07461848A0230|134 139|matter
P07461848A0230|37 46|components
P07461848A0230|93 95|ppb
P07461848A0230|78 79|NO
P07461848A0230|87 89|NO2
P07461848A0230|3 12|mean values
P07462481A0422|144 152|occlusion
P07462481A0422|88 96|occlusion
P07462481A0422|38 41|time
P07462481A0422|107 113|regions
P07462481A0422|50 56|regions
P07462481A0422|78 82|weeks
P07462481A0422|10 31|backscatter coefficient
P07462481A0422|116 122|infarct
P07462481A0422|134 138|weeks
P07462481A0422|59 65|infarct
P07463294A1216|39 43|group
P07463294A1216|115 115|p
P07463294A1216|79 83|group
P07463294A1216|64 68|group
P07463294A1216|45 54|responders
P07463294A1216|98 102|group
P07463294A1216|128 132|group
P07463294A1216|104 113|responders
P07463294A1216|3 4|wk
P07463294A1216|13 24|tumor relapse
P07463465A0297|68 73|infant
P07463465A0297|5 13|infection
P07463465A0297|34 45|control women
P07463465A0297|53 57|birth
P07466831A0714|31 35|onset
P07466831A0714|125 135|disturbance
P07466831A0714|141 156|porphyrin pattern
P07466831A0714|89 106|porphyrin excretion
P07466831A0714|58 62|words
P07466831A0714|38 49|HCB porphyria
P07466831A0714|0 16|Pentachlorophenol
P07467975A0316|0 13|Family planning
P07467975A0316|121 127|periods
P07467975A0316|252 259|approach
P07467975A0316|89 102|contraceptives
P07467975A0316|317 322|Europe
P07467975A0316|152 161|primiparae
P07467975A0316|130 133|time
P07467975A0316|215 228|multigravidity
P07467975A0316|298 314|behaviour patterns
P07467975A0316|182 187|births
P07467975A0316|203 212|percentage
P07467975A0316|35 38|role
P07467975A0316|262 273|reproduction
P07467975A0316|63 70|patients
P07467975A0316|165 176|secundiparae
P07467975A0316|232 241|parameters
P07467975A0316|54 57|cent
P07467975A0316|139 149|percentages
P07469692A0000|131 138|families
P07469692A0000|48 58|bone disease
P07469692A0000|71 81|inheritance
P07469692A0000|109 115|members
P07469692A0000|3 23|term osteomesopycnosis
P07471210A0384|3 12|87K protein
P07471210A0384|52 58|daltons
P07471210A0384|26 33|proteins
P07471210A0384|162 170|positions
P07471210A0384|106 118|messenger RNAs
P07471210A0384|149 154|genome
P07472582A0993|43 59|99mTc-tetrofosmin
P07472582A0993|25 34|myocardium
P07472582A0993|98 103|degree
P07472582A0993|3 16|identification
P07472582A0993|109 116|severity
P07472582A0993|63 67|201Tl
P07472582A0993|130 137|activity
P07472582A0993|119 127|reduction
P07472582A0993|157 163|defects
P07472736A0278|59 66|eminence
P07472736A0278|11 19|component
P07472736A0278|37 41|fossa
P07473169A0133|0 4|EUK-8
P07473169A0133|59 65|complex
P07473169A0133|82 100|superoxide dismutase
P07473169A0133|104 121|catalase activities
P07473742A0187|3 14|protein ELT-1
P07473742A0187|140 146|element
P07473742A0187|56 65|GATA family
P07473742A0187|37 40|gene
P07473742A0187|68 97|vertebrate transcription factors
P07474078A0838|146 146|%
P07474078A0838|95 108|CA dinucleotide
P07474078A0838|10 17|contrast
P07474078A0838|65 74|alteration
P07474078A0838|120 125|mutant
P07474078A0838|46 63|integration studies
P07474078A0838|158 176|integration activity
P07474085A0932|86 90|codon
P07474085A0932|12 19|R protein
P07474085A0932|34 39|codons
P07474085A0932|74 81|V protein
P07474085A0932|55 68|frameshift site
P07474124A1360|146 157|requirements
P07474124A1360|127 133|respect
P07474124A1360|112 122|differences
P07474124A1360|5 11|results
P07474124A1360|95 101|viruses
P07474124A1360|35 37|PI2
P07474124A1360|66 88|parainfluenza virus genus
P07474124A1360|41 50|PI3 viruses
P07474124A1360|184 196|F glycoprotein
P07474124A1360|175 178|tail
P07474140A1036|15 25|mutagenesis
P07474140A1036|113 125|ICP27 homologs
P07474140A1036|171 175|C-483
P07474140A1036|153 157|E-358
P07474140A1036|180 184|C-488
P07474140A1036|216 223|activity
P07474140A1036|165 169|C-400
P07474140A1036|66 82|amino acid residues
P07474140A1036|51 55|ICP27
P07474140A1036|159 163|H-479
P07474140A1036|133 145|herpesviruses
P07474140A1036|147 151|D-357
P07474451A0000|69 77|pathology
P07474451A0000|25 27|MRI
P07474451A0000|93 107|signal intensity
P07474451A0000|80 90|differences
P07474451A0000|8 23|resonance imaging
P07474617A1035|0 7|Patients
P07474617A1035|54 62|PRL levels
P07474617A1035|24 28|drugs
P07474772A0274|138 145|function
P07474772A0274|50 60|examination
P07474772A0274|84 93|comparison
P07474772A0274|112 121|appearance
P07474772A0274|3 29|Laser Scanning Ophthalmoscope
P07475733T0000|0 6|Malaria
P07475733T0000|19 35|HIV-1 transmission
P07475733T0000|8 14|anaemia
P07475733T0000|45 50|Africa
P07475793T0000|0 2|BSE
P07475793T0000|6 16|farmworkers
P07476164A1602|145 155|CspB protein
P07476164A1602|66 69|K13Q
P07476164A1602|122 130|structure
P07476164A1602|97 103|mutants
P07476164A1602|41 56|resonance studies
P07476164A1602|78 81|F27Y
P07476164A1602|2 9|addition
P07476164A1602|71 74|F15Y
P07476164A1602|61 64|F17A
P07476701A0654|86 99|correspondence
P07476701A0654|65 71|pollens
P07476701A0654|24 36|IgE antibodies
P07476701A0654|16 21|levels
P07476963A0000|32 40|receptors
P07476963A0000|70 73|RXRs
P07476963A0000|51 68|retinoid X receptors
P07476963A0000|146 149|acid
P07476963A0000|42 46|PPARs
P07476963A0000|85 100|hormone receptors
P07476963A0000|124 128|acids
P07476963A0000|0 9|Peroxisome
P07476971A0381|57 80|transcription factor Pit-1
P07476971A0381|35 49|SKUT-1B-20 cells
P07476975A0492|88 95|controls
P07476975A0492|36 46|thyrotropes
P07476975A0492|11 21|lactotropes
P07476975A0492|51 62|gonadotropes
P07476975A0492|184 192|cell types
P07476975A0492|23 34|somatotropes
P07476975A0492|170 181|distribution
P07476975A0492|3 8|number
P07476975A0492|121 129|pituitary
P07476975A0492|135 142|products
P07477245A0625|139 143|mg/kg
P07477245A0625|73 76|ones
P07477245A0625|4 10|strains
P07477245A0625|117 126|aflatoxins
P07477245A0625|90 91|G1
P07477245A0625|101 114|concentrations
P07477245A0625|13 25|A. parasiticus
P07477245A0625|41 58|aflatoxins B1 B2 G1 G2
P07477245A0625|85 88|AF B1
P07478514A0237|40 44|clone
P07478514A0237|25 27|rat
P07478523A0551|2 9|addition
P07478523A0551|32 45|amino acid forms
P07478523A0551|124 140|RET protein isoform
P07478523A0551|91 100|amino acids
P07478525A1177|41 46|dimers
P07478525A1177|4 10|classes
P07478525A1177|79 90|dimerization
P07478525A1177|13 25|MHBst proteins
P07479004A0421|73 74|P2
P07479004A0421|114 117|HeLa
P07479004A0421|102 109|extracts
P07479004A0421|70 71|P1
P07479004A0421|78 79|P3
P07479004A0421|123 127|cells
P07479004A0421|40 43|PERE
P07479004A0421|17 35|mobility shift assays
P07479004A0421|85 92|proteins
P07479004A0421|60 68|complexes
P07482069A0606|56 73|vasculitis symptoms
P07482069A0606|38 43|months
P07482069A0606|25 31|mg/week
P07482069A0606|19 21|MTX
P07483276A0139|204 224|varicella-zoster virus
P07483276A0139|187 199|herpesvirus-1
P07483276A0139|13 20|sequence
P07483276A0139|158 174|pseudorabies virus
P07483276A0139|130 149|herpes simplex virus-1
P07483276A0139|151 155|HSV-1
P07483276A0139|80 82|UL2
P07483276A0139|76 78|UL1
P07483276A0139|53 56|ORFs
P07483276A0139|120 127|proteins
P07483276A0139|108 115|homology
P07483276A0139|91 93|UL3
P07483276A0139|39 51|reading frames
P07483276A0139|176 178|PRV
P07483276A0139|84 86|UL3
P07483276A0139|0 7|Analysis
P07483285A0322|130 138|induction
P07483285A0322|5 19|HPV16 E6/E7 cDNAs
P07483285A0322|65 71|MMTV LTR
P07483285A0322|113 126|transformation
P07483285A0322|38 58|SV40 enhancer/promoter
P07483285A0322|184 196|E7 gene product
P07483285A0322|149 160|DNA synthesis
P07483285A0322|84 93|activities
P07483857A0350|85 91|protein
P07483857A0350|33 48|reference methods
P07483857A0350|52 54|NIT
P07483857A0350|150 174|connective-tissue-protein
P07483857A0350|70 74|water
P07483857A0350|95 134|connective-tissue-protein frei meat protein
P07483857A0350|0 22|Correlation coefficients
P07487067A0592|28 33|clones
P07487067A0592|105 111|lengths
P07487067A0592|55 58|APS1
P07487067A0592|135 143|sequences
P07487067A0592|122 126|amino
P07487067A0592|154 168|transit peptides
P07487067A0592|172 190|plastid localization
P07487067A0592|67 75|% identity
P07487067A0592|3 21|translation products
P07487363A0447|3 13|serum levels
P07487363A0447|23 27|asIgE
P07487363A0447|16 18|IgE
P07487363A0447|51 63|food allergens
P07487363A0447|31 35|IgG-4
P07487811A0000|30 36|effects
P07487811A0000|132 136|PSE-1
P07487811A0000|150 160|spaceflight
P07487811A0000|72 83|bone turnover
P07487811A0000|112 130|Systems Experiment-1
P07487811A0000|49 59|spaceflight
P07487811A0000|176 181|flight
P07487811A0000|165 169|PSE-2
P07487811A0000|3 13|experiments
P07487908A0230|120 125|origin
P07487908A0230|127 132|AR-42J
P07487908A0230|97 100|gene
P07487908A0230|93 95|CAT
P07487908A0230|142 146|cells
P07487908A0230|4 11|sequence
P07487908A0230|163 168|origin
P07487908A0230|31 43|transcription
P07487908A0230|170 172|Rat
P07487908A0230|61 91|chloramphenicol acetyltranferase
P07487908A0230|177 179|IEC
P07487908A0230|103 107|cells
P07488247T0000|121 126|system
P07488247T0000|78 100|aryl hydrocarbon receptor
P07488247T0000|106 110|yeast
P07488247T0000|50 73|translocator interactions
P07488247T0000|10 17|analysis
P07488247T0000|20 42|aryl hydrocarbon receptor
P07488291A0934|134 155|triamcinolone acetonide
P07488291A0934|56 77|triamcinolone acetonide
P07488291A0934|41 52|somatostatin
P07488291A0934|100 104|signs
P07488291A0934|115 124|structures
P07488291A0934|15 26|observations
P07488959T0000|28 32|model
P07488959T0000|35 51|lymphocytopoiesis
P07488959T0000|2 9|approach
P07489502A0000|131 135|mRNAs
P07489502A0000|115 118|poly
P07489502A0000|85 94|inhibition
P07489502A0000|139 148|inhibition
P07489502A0000|107 112|export
P07489502A0000|151 166|pre-mRNA splicing
P07489502A0000|55 63|regulator
P07489502A0000|3 26|influenza virus NS1 protein
P07489502A0000|74 83|activities
P07490079A0825|58 65|evidence
P07490079A0825|89 95|homolog
P07490079A0825|11 17|regions
P07490079A0825|78 81|STEP
P07490079A0825|34 40|synteny
P07490079A0825|107 114|STEP gene
P07490079T0000|88 94|mapping
P07490079T0000|26 32|homolog
P07490079T0000|114 117|loci
P07490079T0000|65 68|STEP
P07490079T0000|9 15|cloning
P07490079T0000|53 63|phosphatase
P07490079T0000|70 73|gene
P07490083A0000|57 61|liver
P07490083A0000|8 17|anhydrase V
P07490083A0000|77 83|tissues
P07490083A0000|49 54|matrix
P07490083A0000|19 21|CA V
P07490156A0647|102 112|correlation
P07490156A0647|78 84|modulus
P07490156A0647|64 67|mass
P07490156A0647|13 29|nicotine treatment
P07490156A0647|46 54|increases
P07490156A0647|0 8|Vitamin D3
P07490278A0799|45 49|Num1p
P07490278A0799|9 14|domain
P07490278A0799|55 70|mother cell cortex
P07490742A0636|98 107|subdomains
P07490742A0636|30 35|notion
P07490742A0636|43 61|dsRNA binding domains
P07490742A0636|4 10|finding
P07490766T0000|64 66|Max
P07490766T0000|125 136|interactions
P07490766T0000|25 32|parallel
P07490766T0000|70 88|c-Myc leucine zippers
P07490766T0000|91 101|description
P07490766T0000|167 184|heterodimerization
P07490766T0000|154 164|specificity
P07490766T0000|44 52|formation
P07490770A0267|0 9|Comparison
P07490770A0267|17 25|coxI genes
P07490770A0267|47 52|intron
P07490770A0267|89 93|yeast
P07490770A0267|154 168|DNA endonuclease
P07490770A0267|41 45|group
P07490770A0267|67 74|homology
P07490770A0267|98 106|intron aI4
P07491111A0221|16 26|DMS-79 cells
P07491111A0221|12 13|GR
P07491111A0221|63 76|cell lung cancer
P07491305A0102|182 188|reports
P07491305A0102|4 8|study
P07491305A0102|98 107|QRS complex
P07491305A0102|27 38|localization
P07491305A0102|85 92|polarity
P07491305A0102|130 139|surface ECG
P07491305A0102|114 124|sinus rhythm
P07491305A0102|153 169|delta wave polarity
P07491305A0102|43 58|accessory pathway
P07491791A0263|42 52|E1A products
P07491791A0263|70 89|helper adenovirus type
P07491791A0263|92 94|Ad5
P07491791A0263|3 18|promoter mutation
P07493327A0507|42 50|integrity
P07493327A0507|53 54|U2
P07493327A0507|62 69|U6 snRNAs
P07493327A0507|56 57|U4
P07493627A0882|0 8|Treatment
P07493627A0882|11 14|PCC4
P07493627A0882|45 51|agonist
P07493627A0882|80 87|EC-1 mRNA
P07493627A0882|93 101|treatment
P07493627A0882|68 77|expression
P07493627A0882|121 127|agonist
P07493627A0882|135 148|EC-1 expression
P07493627A0882|16 25|aza1R cells
P07494244A0335|61 65|c-fos
P07494244A0335|5 11|absence
P07494244A0335|93 108|ATF/CREB proteins
P07494244A0335|21 23|YY1
P07494244A0335|46 58|transcription
P07494244A0335|122 124|CRE
P07494244A0335|14 19|E1A243
P07494274A1015|116 126|disfunction
P07494274A1015|10 20|experiments
P07494274A1015|55 63|reduction
P07494274A1015|165 180|virion maturation
P07494274A1015|129 136|alpha TIF
P07494274A1015|66 75|virus yield
P07494274A1015|94 104|temperature
P07494274A1015|143 151|infection
P07494293A0585|133 142|activation
P07494293A0585|27 29|tip
P07494293A0585|101 103|Lck
P07494293A0585|5 11|results
P07494293A0585|43 47|stage
P07494293A0585|53 83|T-cell signal transduction cascade
P07494303A0000|31 33|Vpr
P07494303A0000|65 71|protein
P07494303A0000|116 136|monocytes/macrophages
P07494303A0000|103 113|replication
P07494303A0000|5 29|immunodeficiency virus type
P07494306A0240|130 137|fraction
P07494306A0240|83 87|cells
P07494306A0240|208 218|protein VP22
P07494306A0240|154 164|polypeptide
P07494306A0240|99 102|VP16
P07494306A0240|16 24|potential
P07494306A0240|47 58|interactions
P07494306A0240|28 31|VP16
P07494314A1287|31 38|splicing
P07494314A1287|94 106|LMP2A homologs
P07494314A1287|66 88|tyrosine phosphorylation
P07494314A1287|40 61|kinase interaction sites
P07494314A1287|20 29|regulation
P07494314A1287|142 163|sequences heterogeneity
P07494314A1287|180 192|repeat regions
P07494314A1287|223 226|EBVs
P07495059T0078|0 6|Results
P07495059T0078|12 39|ECAT Angina Pectoris Study Group
P07495120A0260|129 138|recurrence
P07495120A0260|69 76|efficacy
P07495120A0260|22 26|Phase
P07495120A0260|79 89|cryosurgery
P07495120A0260|99 114|radiation therapy
P07495120A0260|60 65|safety
P07495120A0260|29 33|trial
P07495120A0260|117 119|men
P07495726A1189|97 115|Bcl-2 proto-oncogene
P07495726A1189|5 10|motifs
P07495726A1189|137 147|breakpoints
P07495726A1189|150 159|T-ALL lines
P07495726A1189|66 91|recombination hotspot region
P07495726A1189|19 26|Chi motif
P07495726A1189|119 123|close
P07495726A1189|39 45|element
P07496184T0001|16 24|prospects
P07496184T0001|35 44|gynecology
P07496184T0001|63 84|Vienna University Clinic
P07496184T0001|50 56|Charite
P07496184T0001|6 12|history
P07496400A0525|183 191|seedlings
P07496400A0525|101 105|plant
P07496400A0525|89 95|tissues
P07496400A0525|201 214|inflorescences
P07496400A0525|193 197|roots
P07496400A0525|107 116|HMGR1L mRNA
P07496400A0525|78 83|levels
P07496400A0525|35 43|HMGR1 mRNA
P07496400A0525|2 9|contrast
P07496400A0525|45 54|HMGR1S mRNA
P07496400A0525|153 162|expression
P07496400A0525|141 146|levels
P07498727A0724|159 173|T.A transversion
P07498727A0724|34 43|production
P07498727A0724|24 27|rev3
P07498727A0724|11 21|requirement
P07498727A0724|52 67|T.A transversions
P07498727A0724|153 155|G.C
P07498727A0724|107 119|substitutions
P07498727A0724|46 48|G.C
P07498727A0724|73 84|rad18 mutator
P07498791A0680|69 72|gene
P07498791A0680|135 157|osmolarity stress pathway
P07498791A0680|100 112|protein kinase
P07498791A0680|74 77|PBS2
P07498791A0680|9 16|mutation
P07498791A0680|55 60|allele
P07499242A0898|49 63|RAFTK expression
P07499242A0898|7 13|tissues
P07499252A0150|143 152|PI 3-kinase
P07499252A0150|38 54|consensus sequence
P07499252A0150|18 21|hGMR
P07499252A0150|131 140|activation
P07499252A0150|67 76|PI 3-kinase
P07499252A0150|78 81|hGMR
P07499252A0150|58 64|binding
P07499252A0150|2 16|hGM-CSF receptor
P07499252A0150|98 106|mechanism
P07499252A0150|113 123|association
P07499394A0187|0 1|J.
P07499401A0444|67 67|F
P07499401A0444|50 50|%
P07499401A0444|47 47|F
P07499401A0444|34 34|%
P07499401A0444|62 62|H
P07499401A0444|70 70|%
P07499401A0444|3 10|identity
P07499401A0444|43 43|H
P07499401A0444|18 24|hnRNPs H
P07499401A0444|28 28|H
P07499409A0367|0 3|TPBF
P07499409A0367|64 69|region
P07499409A0367|44 49|region
P07499409A0367|107 123|targeting sequence
P07499409A0367|86 94|N terminus
P07499409A0367|30 36|regions
P07499421A0237|59 80|rat hepatocytes plasmids
P07499421A0237|12 16|study
P07499421A0237|93 98|CYP3A1
P07499421A0237|127 173|chloramphenicol acetyltransferase reporter plasmid
P07499421A0237|49 56|cultures
P07499421A0237|110 118|sequences
P07499848A0409|96 113|epsilon transcripts
P07499848A0409|129 137|cytokines
P07499848A0409|63 70|Sf9 cells
P07499848A0409|37 42|B cells
P07499848A0409|10 20|stimulation
P07499848A0409|78 91|germ-line gamma
P07500386A0870|73 79|domains
P07500386A0870|12 32|GapIII protein activity
P07500386A0870|109 113|yeast
P07500386A0870|34 43|constructs
P07500386A0870|154 157|IRA1
P07500386A0870|138 144|ability
P07500597A0212|27 29|age
P07500597A0212|45 48|days
P07500597A0212|22 25|BPVs
P07500597A0212|71 72|SD
P07500597A0212|5 8|time
P07500597A0212|61 64|mean
P07500597A0212|76 80|years
P07500597A0212|55 59|years
P07500950A0000|100 119|Nicotiana tabacum L. cv
P07500950A0000|18 22|trolC
P07500950A0000|42 74|Agrobacterium rhizogenes Ri-plasmid
P07500950A0000|1 16|tobacco homologue
P07500950A0000|29 36|rolC gene
P07500953A0305|69 76|proteins
P07500953A0305|101 108|ADR1 gene
P07500953A0305|30 42|transcription
P07500953A0305|92 95|copy
P07500953A0305|45 49|genes
P07500953A0305|4 17|ADR1 gene dosage
P07501016T0000|34 51|galaxy TXFS2226-184
P07501016T0000|13 22|giga-maser
P07501458A0578|15 35|C/EBP family inhibitors
P07501458A0578|37 42|Ig/EBP
P07501458A0578|50 56|CHOP-10
P07501458A0578|62 67|Ig/EBP
P07501458A0578|44 46|LIP
P07501700A0000|68 70|MLA
P07501700A0000|24 42|pretreatment regimen
P07501700A0000|140 149|occlusions
P07501700A0000|47 66|monophosphoryl lipid A
P07501700A0000|74 90|micrograms/kg i.v.
P07501700A0000|184 187|dogs
P07501700A0000|3 9|effects
P07501992A0125|150 158|strontium
P07501992A0125|143 147|lines
P07501992A0125|69 88|spectroscopy analysis
P07501992A0125|26 41|scanning electron
P07501992A0125|106 115|microscopy
P07501992A0125|164 173|rat incisor
P07501992A0125|5 12|incisors
P07501992A0125|90 96|SEM-EDS
P07501992A0125|180 185|dentin
P07504171A0715|45 58|phosphopeptide
P07504171A0715|38 43|PDGF-R
P07504171A0715|156 158|Src
P07504171A0715|136 152|PDGF-R binding site
P07504171A0715|69 75|Tyr-857
P07504171A0715|17 36|growth factor receptor
P07504171A0715|103 114|Src SH2 domain
P07504171A1214|84 88|light
P07504171A1214|75 81|results
P07504171A1214|37 53|binding properties
P07504171A1214|100 123|crystal structure solution
P07504171A1214|16 28|Src SH2 mutants
P07504171A1214|130 141|Src SH2 domain
P07504712A0843|5 16|observations
P07504712A0843|21 39|actin plaque assembly
P07504712A0843|51 71|cell substrate adhesion
P07505349A0702|32 39|resectio
P07505349A0702|8 16|lethality
P07505349A0702|78 83|months
P07505349A0702|64 71|survival
P07505349A0702|44 44|%
P07505798A0000|100 104|class
P07505798A0000|167 178|T lymphocytes
P07505798A0000|111 135|histocompatibility complex
P07505798A0000|76 77|HA
P07505798A0000|180 183|CTLs
P07505798A0000|62 74|hemagglutinin
P07505798A0000|137 139|MHC
P07505798A0000|22 26|sites
P07505798A0000|32 55|type A influenza A/Japan/57
P07505798A0000|57 60|H2N2
P07506253A0742|41 49|promoters
P07506253A0742|34 35|TK
P07506253A0742|52 60|HeLa cells
P07506253A0742|4 11|enhancer
P07506253A0742|28 30|K19
P07507187T0000|90 99|adenovirus
P07507187T0000|11 21|enhancement
P07507187T0000|49 65|cointernalization
P07507187T0000|24 36|DNA expression
P07507187T0000|113 122|plasmid DNA
P07507187T0000|0 8|Mechanism
P07507207A0991|17 30|IRF binding site
P07507207A0991|48 60|IRF-2 promoter
P07507207A0991|124 138|IRF-1 expression
P07507207A0991|80 88|IRF-2 gene
P07507207A0991|65 74|expression
P07507458A0250|130 140|RIBA methods
P07507458A0250|38 45|patients
P07507458A0250|104 113|antibodies
P07507458A0250|53 55|aim
P07507458A0250|84 98|hepatitis C virus
P07507458A0250|122 126|ELISA
P07507458A0250|100 102|HCV
P07507458A0250|72 81|prevalence
P07508082A0821|29 36|activity
P07508082A0821|89 96|chlorine
P07508082A0821|10 17|decrease
P07508082A0821|61 69|bleaching
P07508140A0448|0 23|Hepatitis B surface antigen
P07508140A0448|38 45|patients
P07508140A0448|59 81|hepatitis C virus antibody
P07508250A0537|231 243|investigation
P07508250A0537|104 104|p
P07508250A0537|53 66|selenium intake
P07508250A0537|97 97|r
P07508250A0537|70 95|liver selenium concentration
P07508250A0537|121 129|treatment
P07508250A0537|138 154|time liver selenium
P07508250A0537|117 118|mo
P07508250A0537|30 40|correlation
P07508250A0537|171 174|time
P07508250A0537|182 192|correlation
P07508441A0487|0 9|Antibodies
P07508441A0487|311 316|member
P07508441A0487|206 222|amino acid sequence
P07508441A0487|267 273|56K cDNA
P07508441A0487|240 248|annexin XI
P07508441A0487|166 171|degree
P07508441A0487|66 72|protein
P07508441A0487|188 197|nucleotide
P07508441A0487|103 117|HeLa cell extract
P07508441A0487|300 308|annexin XI
P07508441A0487|228 228|%
P07508441A0487|201 201|%
P07508441A0487|86 99|56K autoantigen
P07508441A0487|174 181|homology
P07508441A0487|322 323|Ca
P07508441A0487|148 160|56K cDNA shares
P07508441A0487|289 297|homologue
P07508441A0487|119 132|cDNA sequencing
P07508441A0487|350 369|binding protein family
P07508954A0000|86 92|results
P07508954A0000|127 139|Ziehl-Neelsen
P07508954A0000|141 142|ZN
P07508954A0000|40 45|method
P07508954A0000|16 32|complex peroxidase
P07508954A0000|34 38|ABC-P
P07508954A0000|61 78|Mycobacterium bovis
P07508954A0000|144 152|technique
P07509053A0139|14 22|processes
P07509053A0139|38 45|function
P07509053A0139|48 52|c-Myb
P07509053A0139|77 89|establishment
P07509053A0139|108 114|lineage
P07509053A0139|3 6|role
P07509449A0000|15 18|gene
P07509449A0000|127 135|sequences
P07509449A0000|53 65|fusion protein
P07509449A0000|67 76|p47gag-crk
P07509449A0000|181 183|SH2
P07509449A0000|79 83|v-Crk
P07509449A0000|187 198|SH3 sequences
P07509449A0000|157 174|Src homology regions
P07509449A0000|29 44|sarcoma virus CT10
P07509449A0000|100 111|Gag sequences
P07509450A0705|155 171|HSV tk gene activity
P07509450A0705|36 47|inactivation
P07509450A0705|53 61|HSV tk gene
P07509450A0705|12 29|methylation pattern
P07509450A0705|68 78|methylation
P07509450A0705|109 126|nucleotide sequence
P07509450A0705|84 99|cytosine residues
P07509450A0705|147 152|effect
P07509472A1320|15 28|study documents
P07509472A1320|33 42|regression
P07509472A1320|54 71|neovascularization
P07509472A1320|88 111|alpha interferon treatment
P07509472A1320|0 9|CONCLUSION
P07509624T0000|43 63|chromosome aberrations
P07509624T0000|91 108|gel electrophoresis
P07509624T0000|129 138|chromosome
P07509624T0000|10 16|mapping
P07509624T0000|114 118|yeast
P07509624T0000|22 32|11q23 region
P07509624T0000|71 76|tumors
P07509811A1357|0 3|GTRE
P07509811A1357|181 183|TRE
P07509811A1357|413 432|transcription factors
P07509811A1357|103 116|protein binding
P07509811A1357|230 232|TRE
P07509811A1357|403 410|families
P07509811A1357|373 392|transcription factors
P07509811A1357|12 30|CRE oligonucleotides
P07509811A1357|303 309|members
P07509811A1357|188 206|CRE oligonucleotides
P07509811A1357|394 401|CREB/ATF
P07509811A1357|225 228|GTRE
P07509811A1357|284 291|proteins
P07509811A1357|176 179|GTRE
P07509811A1357|237 255|CRE oligonucleotides
P07509811A1357|436 450|chromaffin cells
P07509811A1357|5 7|TRE
P07509811A1357|59 72|protein binding
P07509811A1357|142 157|oligonucleotides
P07509811A1357|315 321|Jun/Fos
P07509811A1357|87 95|congeners
P07510461A0731|3 9|patient
P07510461A0731|20 36|test abnormalities
P07510635A0479|86 98|transcription
P07510635A0479|197 199|Pol
P07510635A0479|52 58|epitope
P07510635A0479|12 17|mAb1C2
P07510635A0479|190 192|Pol
P07510635A0479|138 146|promoters
P07510635A0479|3 10|antibody
P07510635A0479|32 38|peptide
P07510724A1208|25 32|patients
P07510724A1208|122 132|association
P07510724A1208|140 150|sarcoidosis
P07510724A1208|47 55|arthritis
P07510724A1208|84 94|granulomata
P07510724A1208|164 172|arthritis
P07510724A1208|3 12|lymph nodes
P07510724A1208|73 79|sarcoid
P07511444A0728|0 11|HCV infection
P07511444A0728|123 127|years
P07511444A0728|90 99|hepatitis C
P07511444A0728|133 135|BMT
P07511444A0728|105 111|patient
P07511444A0728|55 64|hepatitis C
P07511444A0728|33 35|BMT
P07511444T0000|0 23|Hepatitis C virus infection
P07511444T0000|70 76|disease
P07511444T0000|82 106|bone marrow transplantation
P07511444T0000|27 36|risk factor
P07511444T0000|40 51|liver failure
P07511496A1511|33 42|E-selectin
P07511496A1511|96 100|death
P07511496A1511|82 92|dysfunction
P07511496A1511|4 23|plasma concentrations
P07511818A0485|146 150|cells
P07511818A0485|156 160|cells
P07511818A0485|114 117|rate
P07511818A0485|179 191|control vector
P07511818A0485|91 93|IFN
P07511818A0485|30 44|cell populations
P07511818A0485|206 221|IFN-beta sequence
P07511818A0485|248 254|protein
P07511818A0485|74 83|production
P07512159A0992|0 10|Improvement
P07512159A0992|51 68|splicing efficiency
P07512159A0992|76 81|degree
P07512159A0992|117 135|branchpoint mutation
P07512159A0992|16 34|polypyrimidine tract
P07512258A0441|0 19|Liver transplantation
P07512258A0441|113 123|neutropenia
P07512258A0441|78 85|PMN count
P07512258A0441|49 61|complications
P07512258A0441|25 31|patient
P07512258A0441|138 142|G-CSF
P07512258A0441|101 106|status
P07512552A0270|0 3|Joys
P07512552A0270|7 8|F.
P07513703T0000|92 99|peptides
P07513703T0000|111 136|insulin receptor substrate-1
P07513703T0000|56 62|SH-PTP2
P07513703T0000|29 54|protein tyrosine phosphatase
P07513703T0000|0 9|Activation
P07514295A0000|0 22|Tyrosine phosphorylation
P07514295A0000|80 100|T-cell antigen receptor
P07514295A0000|66 70|event
P07514295A0000|154 171|signaling machinery
P07514295A0000|106 116|stimulation
P07514295A0000|33 40|proteins
P07514295A0000|102 104|TCR
P07514301A0000|117 125|infection
P07514301A0000|34 46|protein kinase
P07514301A0000|81 84|role
P07514301A0000|211 220|properties
P07514301A0000|98 104|defense
P07514301A0000|48 50|PKR
P07514301A0000|162 180|tumor suppressor gene
P07514301A0000|132 139|addition
P07516337A1119|112 122|Jurkat cells
P07516337A1119|78 84|binding
P07516337A1119|63 75|stoichiometry
P07516337A1119|50 55|p95Vav
P07516337A1119|9 11|Lck
P07516466A1054|99 106|activity
P07516466A1054|162 181|phosphorylation state
P07516466A1054|23 29|plasmid
P07516466A1054|11 19|injection
P07516466A1054|56 63|t antigen
P07516466A1054|44 48|virus
P07516466A1054|151 156|effect
P07516466A1054|121 144|phosphoprotein substrates
P07516466A1054|184 187|CREB
P07516466A1054|83 86|PP2A
P07516466A1054|2 9|contrast
P07516466A1054|214 224|NIH 3T3 cells
P07516469A1025|7 9|Src
P07516469A1025|64 68|cells
P07516469A1025|21 28|proteins
P07516597A1017|118 134|antigen processing
P07516597A1017|67 84|polyprotein segment
P07516597A1017|155 157|MVE
P07516597A1017|103 115|proteinase NS3
P07516597A1017|51 53|MVE
P07516597A1017|138 149|presentation
P07516597A1017|36 45|processing
P07516597A1017|174 189|T cell determinant
P07516597A1017|17 22|effect
P07516866A0000|42 44|DNA
P07516866A0000|78 99|pigeon crop sac libraries
P07516866A0000|12 22|PRL receptor
P07516866A0000|112 124|transcription
P07516866A0000|24 27|PRLR
P07516866A0000|49 55|pigeons
P07516866A0000|136 158|polymerase chain reaction
P07517544A0515|191 194|time
P07517544A0515|90 101|pancreatitis
P07517544A0515|117 124|recovery
P07517544A0515|242 250|mg/kg/day
P07517544A0515|152 159|pancreas
P07517544A0515|139 146|function
P07517544A0515|23 32|regression
P07517544A0515|183 188|period
P07517544A0515|49 59|alterations
P07517544A0515|6 9|days
P07517544A0515|199 203|L-364
P07517869A0411|14 30|dephosphorylation
P07517869A0411|185 203|sodium orthovanadate
P07517869A0411|111 119|increases
P07517869A0411|143 163|phosphatase inhibitors
P07517869A0411|70 80|C/EBP-delta
P07517869A0411|125 132|presence
P07517869A0411|61 67|ability
P07517869A0411|178 181|acid
P07518257A0351|28 44|S1 nuclease mapping
P07518257A0351|65 66|bp
P07518257A0351|100 101|P2
P07518257A0351|119 120|bp
P07518257A0351|92 95|gene
P07518257A0351|46 47|P1
P07518257A0351|3 11|promoters
P07518426A0000|72 86|C-X-C chemokines
P07518426A0000|64 69|family
P07518426A0000|14 17|IL-8
P07518426A0000|40 47|mediator
P07518426A0000|0 12|Interleukin-8
P07518460A0771|15 19|cells
P07518460A0771|10 13|hand
P07518460A0771|119 129|phosphatase
P07518460A0771|55 58|site
P07518460A0771|31 35|PTP1C
P07518460A0771|84 94|mutagenesis
P07518561A0496|78 91|TCR/CD3 complex
P07518561A0496|140 157|receptor triggering
P07518561A0496|104 111|tyrosine
P07518561A0496|164 169|T cells
P07518561A0496|177 182|p56lck
P07518561A0496|22 48|p72syk protein tyrosine kinase
P07518578A0000|15 21|protein
P07518578A0000|24 39|Rous sarcoma virus
P07518578A0000|189 197|pp60v-src
P07518578A0000|174 187|binding ability
P07518578A0000|147 158|localization
P07518578A0000|79 87|pp60c-src
P07518578A0000|277 285|pp60c-src
P07518578A0000|71 77|homolog
P07518578A0000|41 49|pp60v-src
P07518578A0000|263 268|matrix
P07519447T0000|0 11|Organization
P07519447T0000|23 26|gene
P07519447T0000|55 67|oxide synthase
P07519463A0000|74 84|consumption
P07519463A0000|37 50|work efficiency
P07519463A0000|52 71|segment work/regional
P07519463A0000|123 128|inflow
P07519481A1275|87 91|stage
P07519481A1275|95 100|result
P07519481A1275|149 152|role
P07519481A1275|23 26|mice
P07519481A1275|124 136|follicle cells
P07519481A1275|163 174|oocyte growth
P07519481A1275|16 17|Sl
P07519481A1275|156 160|c-kit
P07519481A1275|19 21|pan
P07519481A1275|110 121|KL expression
P07519481A1275|11 13|pan
P07519481A1275|35 53|follicle development
P07519481A1275|8 9|Sl
P07519606A1269|0 12|Anti-NPROSP-C
P07519606A1269|85 98|lamellar bodies
P07519606A1269|71 82|proSP-C forms
P07519606A1269|50 60|appearances
P07519606A1269|102 112|homogenates
P07520098A0211|99 103|class
P07520098A0211|62 63|Db
P07520098A0211|56 60|class
P07520098A0211|35 38|bm13
P07520098A0211|40 45|strain
P07520098A0211|23 33|B6.CH-2bm13
P07520098A0211|47 50|part
P07520098A0211|82 87|groove
P07520098A0211|15 16|Db
P07520098A0211|115 122|sequence
P07521009A0377|5 11|mutants
P07521009A0377|49 56|MW104-1B
P07521009A0377|150 155|Kramer
P07521009A0377|126 128|G/T
P07521009A0377|25 28|pms3
P07521009A0377|13 16|pms1
P07521009A0377|130 132|A/C
P07521009A0377|18 21|pms2
P07521009A0377|134 136|G/G
P07521009A0377|112 124|DNA mismatches
P07521009A0377|162 166|1989a
P07521009A0377|138 141|etc.
P07521009A0377|93 100|plasmids
P07521285A1109|173 187|F wave parameters
P07521285A1109|303 314|F wave studies
P07521285A1109|248 255|addition
P07521285A1109|69 72|CIDP
P07521285A1109|44 55|nerve lesions
P07521285A1109|222 228|latency
P07521285A1109|153 162|assessment
P07521285A1109|25 33|frequency
P07521285A1109|296 300|yield
P07521285A1109|110 137|motor conduction abnormalities
P07521285A1109|268 281|minimum latency
P07521285A1109|63 65|GBS
P07521285A1109|3 10|findings
P07521285A1109|236 244|amplitude
P07521285A1109|258 264|absence
P07521285A1109|201 216|chronodispersion
P07521601A0000|107 120|cancer patients
P07521601A0000|63 74|myelopoiesis
P07521601A0000|13 25|growth factors
P07521601A0000|53 60|recovery
P07521601A0000|93 104|chemotherapy
P07521916T0000|0 6|Effects
P07521916T0000|36 48|site sequences
P07521916T0000|9 19|alterations
P07521916T0000|82 92|replication
P07521916T0000|56 80|immunodeficiency virus type
P07522163T0000|0 11|Presentation
P07522163T0000|104 110|C57BL/6
P07522163T0000|89 91|MHC
P07522163T0000|63 87|histocompatibility complex
P07522163T0000|48 56|H-2b class
P07522163T0000|93 101|molecules
P07522163T0000|165 180|MHC anchor residue
P07522163T0000|135 146|T lymphocytes
P07522163T0000|148 155|presence
P07522163T0000|215 228|CTL recognition
P07522163T0000|15 37|horse cytochrome c peptide
P07523363A0440|30 43|fragment island
P07523363A0440|91 119|USF2 translation initiation site
P07523363A0440|21 25|HpaII
P07523363A0440|69 77|base pairs
P07523710T0000|0 8|Diagnosis
P07523710T0000|107 121|ultrasonography
P07523710T0000|40 52|serum prostate
P07523710T0000|20 28|carcinoma
P07523710T0000|82 92|examination
P07523710T0000|33 37|yield
P07523710T0000|61 67|antigen
P07524265T0000|45 49|G-CSF
P07524265T0000|27 43|stimulating factor
P07524265T0000|80 92|complications
P07524265T0000|51 56|levels
P07524265T0000|59 66|neonates
P07525548A1380|118 120|CS1
P07525548A1380|80 87|rsVCAM-1
P07525548A1380|128 146|fibronectin variants
P07525548A1380|89 107|fibronectin variants
P07525548A1380|30 45|ligand affinities
P07525548A1380|19 27|hierarchy
P07525548A1380|71 78|activity
P07525548A1380|3 9|results
P07525596A0584|61 64|Fpr3
P07525596A0584|92 97|domain
P07525596A0584|122 135|PPIase activity
P07525843A0859|259 265|removal
P07525843A0859|125 129|lysis
P07525843A0859|176 179|H-2d
P07525843A0859|99 109|target cells
P07525843A0859|157 166|affinities
P07525843A0859|185 218|histocompatibility complex molecules
P07525843A0859|300 306|removal
P07525843A0859|17 30|H-2d NP peptides
P07525843A0859|227 234|peptides
P07525843A0859|47 50|logs
P07525843A0859|278 285|H-2b mice
P07525843A0859|241 247|account
P07525843A0859|336 337|NP
P07525843A0859|268 272|NP CTL
P07525843A0859|11 14|H-2b
P07525843A0859|169 172|H-2b
P07525843A0859|55 67|H-2b NP peptide
P07525843A0859|309 316|H-2d mice
P07525843A0859|0 8|Dilutions
P07526609A0736|59 78|PKR activator sequence
P07526609A0736|35 40|UTR/S1
P07526609A0736|8 17|expression
P07526609A0736|102 103|S4
P07526609A0736|137 138|S4
P07526609A0736|30 31|S4
P07526609A0736|20 24|sigma
P07526609A0736|83 84|S1
P07526609A0736|97 99|UTR
P07527168A0524|0 11|Microvessels
P07527168A0524|50 53|area
P07527168A0524|26 34|x200 field
P07527168A0524|63 74|angiogenesis
P07527168A0524|41 43|mm2
P07528028A1192|86 92|studies
P07528028A1192|106 118|transfectants
P07528028A1192|143 147|FGF-1
P07528028A1192|39 63|FGF-1 cell surface receptors
P07528028A1192|217 221|WORDS
P07528028A1192|23 31|cell lines
P07528028A1192|165 177|transfectants
P07528028A1192|195 202|ABSTRACT
P07528325A0165|217 230|gene expression
P07528325A0165|115 122|tyrosine
P07528325A0165|195 206|DNA sequences
P07528325A0165|157 163|nucleus
P07528325A0165|6 12|studies
P07528325A0165|67 71|Stat1
P07528325A0165|45 54|GH receptor
P07528325A0165|85 103|transcription factor
P07528531A0904|57 58|rs
P07528531A0904|51 55|cells
P07528531A0904|144 145|rs
P07528531A0904|78 92|blood cell counts
P07528531A0904|102 102|P
P07528531A0904|122 123|rs
P07528531A0904|18 22|G-CSF
P07528531A0904|94 95|rs
P07528531A0904|152 152|P
P07528531A0904|130 130|P
P07528531A0904|65 65|P
P07528531A0904|110 120|neutrophils
P07528531A0904|7 16|infections
P07528531A0904|140 142|CRP
P07528667A0834|5 19|initiation sites
P07528667A0834|31 39|positions
P07528746A1049|0 23|Phosphoamino acid analysis
P07528746A1049|135 150|phosphoamino acid
P07528746A1049|99 99|%
P07528746A1049|183 190|presence
P07528746A1049|214 214|%
P07528746A1049|108 108|P
P07528746A1049|157 167|polypeptide
P07528746A1049|193 195|Tyr
P07528746A1049|104 106|Thr
P07528746A1049|133 133|%
P07528746A1049|218 221|RHL1
P07528746A1049|197 197|P
P07528746A1049|65 65|P
P07528746A1049|38 50|ASGPR subunits
P07528746A1049|61 63|Ser
P07528772A0616|262 267|region
P07528772A0616|223 230|peptides
P07528772A0616|43 59|ZAP-70 interaction
P07528772A0616|162 164|NH2
P07528772A0616|286 295|TCR zeta cyt
P07528772A0616|185 194|SH2 domains
P07528772A0616|309 315|TCR zeta
P07528772A0616|67 69|TCR
P07528772A0616|111 148|glutathione S-transferase fusion proteins
P07528772A0616|197 202|ZAP-70
P07528772A0616|273 284|TCR zeta chain
P07528772A0616|83 94|binding assay
P07528772A0616|238 245|sequence
P07528772A0616|28 39|requirements
P07528772A0616|319 337|CD3 epsilon TAM motifs
P07528772A1539|13 20|tyrosine
P07528772A1539|93 102|SH2 domains
P07528772A1539|105 110|ZAP-70
P07528772A1539|35 45|TAM peptides
P07529124A0119|176 193|amino acid sequences
P07529124A0119|110 117|subunits
P07529124A0119|67 77|heterodimer
P07529124A0119|195 202|residues
P07529124A0119|128 134|weights
P07529124A0119|137 139|kDa
P07529124A0119|20 28|structure
P07529124A0119|31 32|RT
P07529124A0119|145 147|kDa
P07529504A0000|149 155|studies
P07529504A0000|71 97|X-ray contrast agent iopromide
P07529504A0000|109 111|CAS
P07529504A0000|99 107|Ultravist
P07529504A0000|33 47|characteristics
P07529516A0474|59 62|EDXR
P07529516A0474|13 20|patients
P07529516A0474|53 56|dose
P07529516A0474|66 74|mg/m2/day
P07530128A0578|51 55|ng/ml
P07530128A0578|37 44|serum PSA
P07530502A0974|0 7|Addition
P07530502A0974|38 53|SI4-h220 cultures
P07530502A0974|106 123|protein degradation
P07530502A0974|62 70|reduction
P07530502A0974|33 35|SLF
P07530502A0974|85 99|c-kit expression
P07530502T0000|89 93|c-kit
P07530502T0000|14 24|Steel factor
P07530502T0000|106 112|protein
P07530502T0000|79 86|life span
P07530502T0000|127 130|form
P07530502T0000|46 69|tyrosine kinase activation
P07530549A0956|201 205|genes
P07530549A0956|102 107|clones
P07530549A0956|37 49|GRAIL programs
P07530549A0956|146 151|clones
P07530549A0956|121 129|sequences
P07530549A0956|170 178|sequences
P07530549A0956|79 86|evidence
P07530549A0956|13 21|sequences
P07530549A0956|188 195|portions
P07530549A0956|29 33|BLAST
P07530549A0956|0 7|Analysis
P07531321A0369|0 7|Patients
P07531321A0369|23 33|PVC/24 hours
P07531321A0369|63 65|PVC
P07531321A0369|49 60|distribution
P07531321A0369|69 80|CI evaluation
P07532278A0833|0 6|Horvath
P07532278A0833|8 9|I.
P07533527A0128|127 136|marker loss
P07533527A0128|60 72|hybridization
P07533527A0128|23 28|tumors
P07533527A0128|106 115|chromosome
P07533527A0128|79 84|status
P07533527A0128|121 123|PCR
P07533527A0128|0 8|Cell lines
P07533758A1038|42 53|RfbB homologs
P07533758A1038|76 76|%
P07533758A1038|106 106|%
P07533758A1038|60 69|identities
P07533758A1038|112 112|%
P07533758A1038|88 97|similarity
P07533758A1038|82 82|%
P07533758A1038|35 38|RfbA
P07533758A1038|118 127|similarity
P07533758A1038|3 20|amino acid sequences
P07533858A1503|92 106|oligomerization
P07533858A1503|121 127|GP64 EFP
P07533858A1503|110 118|transport
P07533858A1503|66 78|substitutions
P07533858A1503|38 44|proline
P07533858A1503|16 35|alanine substitutions
P07533880T0000|46 48|RNA
P07533880T0000|33 36|FinP
P07533880T0000|62 69|traJ mRNA
P07533880T0000|16 27|IncF plasmids
P07533880T0000|55 60|target
P07533880T0000|82 96|duplex formation
P07533880T0000|3 13|FinO protein
P07534285A0155|117 125|BaF3/mMpl
P07534285A0155|23 35|ligand binding
P07534285A0155|6 10|paper
P07534285A0155|105 115|Mpl receptor
P07534285A0155|43 65|tyrosine phosphorylation
P07534285A0155|68 76|BaF3 cells
P07534286A0842|56 62|protein
P07534286A0842|78 78|%
P07534286A0842|95 103|paxil-lin
P07534286A0842|1 19|chicken paxillin cDNA
P07534297A0141|135 137|CAT
P07534297A0141|74 91|AP endonuclease gene
P07534297A0141|50 55|region
P07534297A0141|93 95|APE
P07534297A0141|102 133|chloramphenicol acetyltransferase
P07534297A0141|21 42|pair HindIII DNA fragment
P07534297A0141|139 142|gene
P07534306A0444|134 140|studies
P07534306A0444|27 41|GrsA derivatives
P07534306A0444|183 208|carboxyl thioester formation
P07534306A0444|79 88|properties
P07534306A0444|275 282|D-isomer
P07534306A0444|94 108|deletion mutants
P07534306A0444|216 222|ability
P07534306A0444|251 263|phenylalanine
P07534306A0444|163 181|amino acid activation
P07534306A0444|268 268|L
P07535593A0714|0 2|CD7
P07535593A0714|32 44|V delta 2D delta
P07535593A0714|9 24|T-cell precursors
P07535593A0714|5 7|CD3
P07535593A0714|46 59|rearrangements
P07535768A1076|0 7|HVH2 mRNA
P07535768A1076|80 83|PAC1
P07535768A1076|67 75|mouse MKP1
P07535768A1076|45 49|CL100
P07535768A1076|108 128|MAP kinase phosphatases
P07535768A1076|56 64|homologue
P07535768A1076|16 32|expression pattern
P07537267A2094|59 68|breakpoint
P07537267A2094|74 87|HPFH-3 deletion
P07537267A2094|25 33|sequences
P07537267A2094|5 8|data
P07537267A2094|252 255|life
P07537267A2094|167 177|specificity
P07537267A2094|103 111|structure
P07537267A2094|130 137|enhancer
P07537267A2094|118 125|function
P07537267A2094|188 204|gamma-globin genes
P07537267A2094|231 240|expression
P07537362A1112|70 90|coimmunoprecipitation
P07537362A1112|24 49|Shb-SH3 domain proteins v-Src
P07537362A1112|53 56|Eps8
P07537362A1112|6 16|association
P07537736A0453|101 106|region
P07537736A0453|154 160|members
P07537736A0453|166 192|cytokine receptor superfamily
P07537736A0453|22 32|interaction
P07537736A0453|40 43|Jak2
P07537736A0453|112 119|receptor
P07537736A0453|47 50|PRLR
P07537736A0453|3 9|results
P07537736A0453|85 92|membrane
P07537736A0453|72 79|sequence
P07537851A0000|0 12|Transcription
P07537851A0000|153 176|tumor necrosis factor alpha
P07537851A0000|48 53|VCAM-1
P07537851A0000|88 105|lipopolysaccharide
P07537851A0000|26 45|cell adhesion molecule
P07537851A0000|55 58|gene
P07537851A0000|124 149|cytokines interleukin-1 beta
P07537851A0000|178 186|TNF-alpha
P07537851A0000|72 76|cells
P07537851A0891|0 10|Experiments
P07537851A0891|214 214|I
P07537851A0891|111 117|binding
P07537851A0891|185 187|p50
P07537851A0891|26 33|proteins
P07537851A0891|130 137|VCAM1 IRF
P07537851A0891|156 160|IRF-1
P07537851A0891|218 224|protein
P07537851A0891|77 83|protein
P07537851A0891|216 216|Y
P07537851A0891|73 73|I
P07537851A0891|44 50|p50/p65
P07537851A0891|75 75|Y
P07537851A0891|145 148|site
P07537851A0891|120 124|IRF-1
P07538068A1094|71 78|boundary
P07538068A1094|12 18|results
P07538068A1094|44 45|AX
P07538068A1094|109 122|Hoxa-7 enhancer
P07538068A1094|81 93|Hox expression
P07538068A1094|29 42|control element
P07538122A0800|6 11|report
P07538122A0800|25 33|isolation
P07538122A0800|49 53|Fab A8
P07538122A0800|101 102|nM
P07538122A0800|37 47|Fab fragment
P07538122A0800|89 96|receptor
P07538122A0800|75 82|affinity
P07538173A0307|117 124|strength
P07538173A0307|83 85|Mg2
P07538173A0307|54 66|ATP hydrolysis
P07538173A0307|73 80|presence
P07538173A0307|23 45|DNA-RNA helicase activity
P07538173A0307|87 90|ions
P07538173A0307|0 8|MBP-Rep68
P07538818A0197|221 224|IL-3
P07538818A0197|236 240|Ba/F3
P07538818A0197|207 219|interleukin-3
P07538818A0197|92 113|amino acid substitutions
P07538818A0197|244 256|FDCP cell lines
P07538818A0197|68 76|deletions
P07538818A0197|154 160|hG-CSFR
P07538818A0197|146 151|domain
P07538818A0197|18 24|regions
P07538818A0197|34 57|growth signal transduction
P07538818A0197|174 178|cDNAs
P07538818A0197|60 66|hG-CSFR
P07539119A0291|86 98|G128R mutation
P07539119A0291|37 45|mutations
P07539119A0291|106 119|transformation
P07539119A0291|155 165|G128R mutant
P07539119A0291|70 81|NH2-terminus
P07539119A0291|51 67|c-abl kinase domain
P07539119A0291|186 190|cells
P07539119A0291|201 207|reasons
P07539119A0985|44 55|Abl SH3 domain
P07539119A0985|32 38|binding
P07539119A0985|70 83|target proteins
P07539119A0985|4 12|mutations
P07539119A0985|101 105|assay
P07539314T0000|87 98|nifurpirinol
P07539314T0000|19 23|gills
P07539314T0000|109 114|P-7138
P07539314T0000|77 84|exposure
P07539314T0000|100 107|Furanace
P07539314T0000|56 66|fingerlings
P07539314T0000|41 46|chanos
P07539314T0000|0 6|Changes
P07540607A0709|0 10|Retreatment
P07540607A0709|68 81|immunoglobulin
P07540607A0709|19 22|dogs
P07540607A0709|53 60|response
P07540773A0576|53 55|PVB
P07540773A0576|17 19|MBP
P07540773A0576|11 13|NSE
P07540773A0576|3 8|levels
P07540773A0576|25 28|IJVB
P07540866A1069|14 26|insulin effect
P07540866A1069|87 98|A/K1018 cells
P07540866A1069|37 51|ras GTP formation
P07540866A1069|125 133|Y/F2 cells
P07540866A1069|55 71|MAP kinase activity
P07541589A0652|103 121|lymph node metastasis
P07541589A0652|28 39|cancer volume
P07541589A0652|11 19|variables
P07541589A0652|65 75|penetration
P07541589A0652|84 98|vesicle invasion
P07541589A0652|51 55|grade
P07541912A0485|0 15|Sequence analysis
P07541912A0485|99 100|P2
P07541912A0485|37 43|CAAT box
P07541912A0485|67 83|G-C content regions
P07541912A0485|23 29|regions
P07541912A0485|54 59|exon 1a
P07541912A0485|94 95|P1
P07542577A0438|29 33|ELISA
P07542577A0438|77 81|order
P07542577A0438|52 56|panel
P07542577A0438|37 46|reactivity
P07542577A0438|93 98|nature
P07542577A0438|104 111|epitopes
P07542577A0438|3 16|fusion proteins
P07542577A0438|71 74|sera
P07542616A0313|0 4|GCD10
P07542616A0313|50 58|repressor
P07542616A0313|61 64|GCN4
P07542616A0486|99 121|yeast initiation factor-3
P07542616A0486|10 12|RNA
P07542616A0486|150 156|complex
P07542616A0486|49 56|evidence
P07542616A0486|123 127|eIF-3
P07542616A0486|90 96|subunit
P07542616A0486|130 134|eIF-3
P07542616A0486|171 191|translation initiation
P07542616A0486|217 221|steps
P07542616A0486|0 4|GCD10
P07542698A0137|0 6|Sources
P07542698A0137|21 27|signals
P07542698A0137|9 13|noise
P07542698A0137|43 54|preparations
P07542698A0137|83 93|probe RH-414
P07543592A0624|48 56|E5 protein
P07543592A0624|25 30|mutant
P07543592A0624|118 132|down-regulation
P07543592A0624|66 73|receptor
P07543592A0624|84 114|receptor tyrosine phosphorylation
P07543684A1027|14 17|cAMP
P07543684A1027|65 82|CFTR gene expression
P07543684A1027|125 133|cell types
P07543684A1027|49 57|regulator
P07543684A1027|109 112|CFTR
P07543684A1027|32 34|PKA
P07543684A1027|98 106|induction
P07543868A0414|134 134|A
P07543868A0414|129 132|poly
P07543868A0414|62 73|cDNA fragment
P07543868A0414|11 26|restriction sites
P07543868A0414|107 114|sequence
P07543868A0414|136 139|tail
P07544357A0808|147 157|CD44 variant
P07544357A0808|129 139|correlation
P07544357A0808|77 86|LNCap cells
P07544357A0808|12 23|ALVA-31 cells
P07544357A0808|31 43|tumorigenesis
P07544357A0808|108 116|phenotype
P07544357A0808|65 68|mice
P07544357A0808|165 174|expression
P07544357A0808|4 8|PPC-1
P07544357A0808|188 208|prostate tumor behavior
P07544357A0808|47 58|invasiveness
P07544357A0808|159 163|CD44v
P07545510A0735|56 63|SDS-PAGE
P07545510A0735|47 53|Cot40-2
P07545510A0735|136 145|cotS region
P07545510A0735|16 19|cotS
P07545510A0735|67 80|immunoblotting
P07545510A0735|3 13|gene product
P07545510A0735|116 122|plasmid
P07545920A1336|80 82|DNA
P07545920A1336|23 32|hsiggll150
P07545920A1336|7 11|genes
P07545920A1336|36 45|hsiggll295
P07546256A0000|29 33|study
P07546256A0000|112 121|Casablanca
P07546256A0000|96 99|unit
P07546256A0000|106 109|care
P07546256A0000|71 78|children
P07546256A0000|58 65|injuries
P07546293A0968|71 80|expression
P07546293A0968|48 56|sequences
P07546293A0968|21 34|protein binding
P07546293A0968|3 9|results
P07546294A0000|120 130|sporulation
P07546294A0000|3 15|RAD6/UBC2 gene
P07546294A0000|105 115|mutagenesis
P07546294A0000|72 77|enzyme
P07546294A0000|88 96|DNA repair
P07546794A0100|0 15|Echocardiography
P07546794A0100|49 56|collapse
P07546794A0100|92 100|tamponade
P07546794A0100|58 61|RVDC
P07546794A0100|78 82|signs
P07547220A0229|60 65|slides
P07547220A0229|106 110|slide
P07547220A0229|10 28|screening programmes
P07547220A0229|70 73|test
P07547220A0229|33 46|Haemoccult test
P07547500A0066|129 134|growth
P07547500A0066|140 144|yeast
P07547500A0066|23 35|fusion protein
P07547500A0066|78 81|GAL4
P07547500A0066|37 44|GAL4-p40
P07547500A0066|70 75|domain
P07547500A0066|96 115|chicken l kappa B-alpha
P07547500A0066|117 119|p40
P07547500A0066|85 93|sequences
P07547510A0261|244 266|HNF-3 beta gene expression
P07547510A0261|206 214|LF-H3 beta
P07547510A0261|105 111|factors
P07547510A0261|269 279|hepatocytes
P07547510A0261|153 156|site
P07547510A0261|171 181|binding site
P07547510A0261|56 72|HNF-3 beta promoter
P07547510A0261|199 204|factor
P07547510A0261|42 46|sites
P07548425A0000|189 197|lesioning
P07548425A0000|92 94|Sur
P07548425A0000|137 157|tail muscle motoneurons
P07548425A0000|21 27|effects
P07548425A0000|38 43|inputs
P07548425A0000|200 208|S2-3 level
P07548425A0000|65 70|nerves
P07548425A0000|86 90|nerve
P07548425A0000|13 16|cats
P07548858A0000|43 48|dermis
P07548858A0000|63 70|function
P07548858A0000|80 87|pressure
P07548858A0000|30 35|saline
P07548858A0000|3 10|flow rate
P07548858A0000|13 21|phosphate
P07549005A0530|55 66|Epon sections
P07549005A0530|8 27|parallax measurements
P07549005A0530|78 82|place
P07549005A0530|45 52|collapse
P07550216A0195|20 25|limits
P07550216A0195|27 33|latency
P07551787A0917|57 69|investigation
P07551787A0917|127 147|radiotherapy technique
P07551787A0917|3 9|outcome
P07551787A0917|81 87|results
P07551787A0917|15 26|optimization
P07551787A0917|43 46|plan
P07552974A0217|61 68|arginine
P07552974A0217|37 46|amino acids
P07552974A0217|8 19|requirements
P07552974A0217|48 56|glutamine
P07553942A0810|40 44|rrn26
P07553942A0810|80 85|genome
P07553942A0810|48 51|cox3
P07553942A0810|121 126|intron
P07553942A0810|3 16|pea rps10 intron
P07553942A0810|95 113|Marchantia rps10 gene
P07553942A0810|31 37|introns
P07553942A0810|57 66|Marchantia
P07554541A0587|68 90|electrolyte disturbances
P07554541A0587|51 60|management
P07554541A0587|37 47|recognition
P07554541A0587|10 13|care
P07554541A0587|16 25|CHF patient
P07555373A0000|0 13|Serum magnesium
P07555373A0000|76 83|controls
P07555373A0000|39 47|neoplasms
P07555373A0000|18 25|patients
P07555373A0000|59 67|cisplatin
P07557091A0314|0 6|METHODS
P07557091A0314|8 11|rHb1
P07557091A0314|21 32|serum albumin
P07557091A0314|74 83|volunteers
P07557276A0526|0 22|Alanine aminotransferase
P07557276A0526|77 86|hepatitis B
P07557276A0526|28 33|levels
P07557276A0526|92 100|infection
P07557276A0526|24 26|ALT
P07557276A0526|66 73|patients
P07557276A0526|55 60|months
P07557387A0241|72 78|program
P07557387A0241|38 46|C/EBP beta
P07557387A0241|120 137|NIH-3T3 fibroblasts
P07557387A0241|6 10|study
P07557387A0241|95 103|C/EBP beta
P07557387A0241|32 35|role
P07557424A0124|0 3|XYL1
P07557424A0124|50 53|lacZ
P07557424A0124|33 43|fusion clone
P07557424A0124|67 79|fusion library
P07557446T0000|59 66|splicing
P07557446T0000|37 45|VCSA1 gene
P07557446T0000|92 94|rat
P07557446T0000|77 86|processing
P07557446T0000|7 17|transcripts
P07557446T0000|108 112|gland
P07557446T0000|70 73|poly
P07557446T0000|75 75|A
P07557717A0184|88 96|morbidity
P07557717A0184|8 15|division
P07557717A0184|81 84|pain
P07557717A0184|49 57|diathermy
P07557717A0184|21 36|chest wall muscles
P07558263T0000|0 6|Closure
P07558263T0000|75 80|device
P07558263T0000|29 53|guillotine amputation wound
P07558583A0562|84 100|peptide substrates
P07558583A0562|25 33|synthesis
P07558583A0562|137 158|tyrosine kinase activity
P07558583A0562|67 71|order
P07558583A0562|3 7|study
P07558583A0562|181 190|inhibitors
P07558583A0562|206 210|class
P07558583A0562|40 50|derivatives
P07558583A0562|115 123|detection
P07558583A0562|213 219|enzymes
P07558583A0562|57 64|sequence
P07559233A0534|0 22|Citrate synthase activity
P07559233A0534|53 53|%
P07559233A0534|85 85|P
P07559233A0534|145 148|head
P07559233A0534|76 79|head
P07559233A0534|120 124|R rats
P07559233A0534|154 154|P
P07559233A0534|98 117|triceps brachii muscle
P07559233A0534|46 49|head
P07559233A0534|152 152|%
P07559233A0534|55 55|P
P07559233A0534|83 83|%
P07559347A0000|72 75|bglP
P07559347A0000|26 36|operon bglPH
P07559347A0000|78 81|lacZ
P07559347A0000|39 54|Bacillus subtilis
P07559347A0000|97 103|fusions
P07559347A0000|3 12|expression
P07559355A0066|148 165|Proteus gene cluster
P07559355A0066|23 27|genes
P07559355A0066|40 53|urease activity
P07559355A0066|99 110|organization
P07559355A0066|114 123|regulation
P07559355A0066|134 138|genes
P07559355A0066|190 195|detail
P07559356T0000|99 109|mutagenesis
P07559356T0000|21 54|Rhizobium leguminosarum biovar viciae
P07559356T0000|115 122|fnrN gene
P07559356T0000|80 87|promoter
P07559356T0000|3 16|hypBFCDE operon
P07559402A0622|59 72|protein kinase C
P07559402A0622|21 27|peptide
P07559402A0622|18 19|VT
P07559402A0622|109 111|PKA
P07559402A0622|94 107|protein kinase A
P07559402A0622|74 76|PKC
P07559430A0909|0 1|R.
P07559478A0389|21 22|T.
P07559478A0389|13 19|O'Neill
P07559488A0440|157 162|type ER
P07559488A0440|75 90|estradiol-17 beta
P07559488A0440|53 71|affinity binding site
P07559488A0440|32 44|fusion protein
P07559488A0440|136 140|yeast
P07559488A0440|122 133|reporter gene
P07559488A0440|0 17|Control experiments
P07559510A0000|143 144|L.
P07559510A0000|136 141|Gordon
P07559510A0000|103 115|endonuclease V
P07559510A0000|8 38|Micrococcus luteus UV endonuclease
P07559510A0000|66 71|enzyme
P07559510A0000|120 134|bacteriophage T4
P07559510A0000|84 91|homology
P07559524A0000|28 40|growth factors
P07559524A0000|48 65|G1 phase progression
P07559524A0000|16 24|oncogenes
P07559524A0741|0 23|Cyclin D1 promoter activity
P07559524A0741|39 52|overexpression
P07559524A0741|72 84|protein kinase
P07559524A0741|96 102|c-Ets-2
P07559524A0741|123 131|base pairs
P07559524A0741|86 92|p41MAPK
P07559555A0557|13 17|c-Jun
P07559555A0557|82 88|complex
P07559555A0557|7 9|ERM
P07559555A0557|45 51|EBS-CRE
P07559563A0282|36 38|Ca2
P07559563A0282|54 61|activity
P07559563A0282|8 15|residues
P07559639A0996|14 33|R206S HSF substitution
P07559639A0996|97 100|HSE2
P07559639A0996|69 78|activation
P07559639A0996|84 95|consensus HSE
P07559639A0996|2 9|addition
P07559640A1230|110 114|bases
P07559640A1230|35 37|end
P07559640A1230|6 10|bases
P07559640A1230|43 49|element
P07559640A1230|89 98|UAS element
P07559640A1230|78 85|function
P07559640A1230|137 145|core motif
P07559650A0558|56 58|E2F
P07559650A0558|5 11|results
P07559650A0558|44 53|target gene
P07559650A0558|27 34|PCNA gene
P07560137T0000|28 49|MMPI-2 depression scales
P07560137T0000|53 61|subscales
P07560137T0000|12 22|sensitivity
P07560662A0496|5 12|recovery
P07560662A0496|25 39|saline challenge
P07562775A0596|29 29|%
P07562775A0596|73 77|nadir
P07562775A0596|10 20|eosinophils
P07562775A0596|80 80|%
P07562775A0596|35 40|number
P07562775A0596|3 7|range
P07562775A0596|58 67|blood cells
P07563072A0773|0 10|Comparisons
P07563072A0773|75 78|rpoD
P07563072A0773|13 33|rrnB P1-lacZ expression
P07563072A0773|80 84|P504L
P07563072A0773|126 130|ppGpp
P07563072A0773|108 123|hypersensitivity
P07563072A0773|45 55|ppGpp levels
P07563076A0766|229 244|splicing proteins
P07563076A0766|52 59|elements
P07563076A0766|179 181|bi4
P07563076A0766|166 170|cores
P07563076A0766|5 18|intron chimeras
P07563076A0766|37 45|sequences
P07563076A0766|136 143|portions
P07563076A0766|111 118|activity
P07563076A0766|73 83|splice sites
P07563076A0766|173 175|ai4
P07563076A0766|200 204|cores
P07563076A0766|217 223|targets
P07563090A0124|197 204|sequence
P07563090A0124|110 117|boundary
P07563090A0124|137 142|repeat
P07563090A0124|144 147|PPT1
P07563090A0124|206 209|PPT2
P07563090A0124|91 95|sites
P07563090A0124|159 164|middle
P07563090A0124|43 54|DNA synthesis
P07563090A0124|170 176|pol gene
P07563090A0124|60 74|yeast Ty1 element
P07563090A0124|182 190|integrase
P07563090A0624|43 54|DNA fragments
P07563090A0624|23 26|ends
P07563090A0624|149 156|majority
P07563090A0624|105 108|PPT2
P07563090A0624|262 266|model
P07563090A0624|238 246|agreement
P07563090A0624|181 192|DNA fragments
P07563090A0624|80 87|fragment
P07563090A0624|286 308|RNA reverse transcription
P07563090A0624|198 201|copy
P07563090A0624|219 235|primer binding site
P07563090A0624|0 15|Characterization
P07563994A0488|167 167|p
P07563994A0488|106 106|p
P07563994A0488|120 128|blood loss
P07563994A0488|145 146|ml
P07563994A0488|149 151|OLB
P07563994A0488|102 104|min
P07563994A0488|63 66|VTLB
P07563994A0488|130 133|VTLB
P07563994A0488|80 82|min
P07563994A0488|21 24|VTLB
P07563994A0488|164 165|ml
P07563994A0488|57 61|times
P07563994A0488|3 10|patients
P07563994A0488|86 88|OLB
P07564004A0292|17 31|Cr2O3 inhalation
P07564004A0292|5 11|minutes
P07564004A0292|33 38|FEV1.0
P07564004A0292|55 55|%
P07564210A0557|86 86|h
P07564210A0557|63 71|analgesia
P07564210A0557|108 112|signs
P07564210A0557|49 59|anaesthesia
P07564210A0557|34 40|regimen
P07564210A0557|74 77|pigs
P07565031A0454|240 250|milk dessert
P07565031A0454|161 165|pasta
P07565031A0454|308 315|tuna fish
P07565031A0454|215 228|spinach ravioli
P07565031A0454|97 107|cream cheese
P07565031A0454|109 124|apricot marmelade
P07565031A0454|260 264|cocoa
P07565031A0454|51 55|Ogawa
P07565031A0454|208 211|meat
P07565031A0454|81 87|strains
P07565031A0454|337 340|milk
P07565031A0454|266 278|milk confiture
P07565031A0454|317 323|ricotta
P07565031A0454|196 206|meat sausage
P07565031A0454|143 152|mayonnaise
P07565031A0454|89 95|yoghurt
P07565031A0454|38 49|V. cholerae O1
P07565031A0454|133 141|marmelade
P07565031A0454|280 285|starch
P07565031A0454|230 238|margarine
P07565031A0454|126 128|hip
P07565031A0454|170 178|empanadas
P07565031A0454|300 306|lettuce
P07565031A0454|289 297|additives
P07565031A0454|6 17|food products
P07565049A1032|116 118|age
P07565049A1032|37 43|outline
P07565049A1032|174 175|g.
P07565049A1032|89 90|NB
P07565049A1032|152 157|weight
P07565049A1032|121 124|term
P07565104A0084|28 31|tcpA
P07565104A0084|48 51|ToxR
P07565104A0084|59 62|ToxT
P07565104A0084|18 26|pilin gene
P07565104A0084|3 12|expression
P07565113A0000|151 158|excision
P07565113A0000|172 179|plasmids
P07565113A0000|108 129|Clostridium perfringens
P07565113A0000|29 44|transposon Tn4451
P07565113A0000|72 79|deletion
P07565113A0000|87 105|parent plasmid plP401
P07565669T0000|0 8|Ras p21Val
P07565669T0000|45 54|DNA binding
P07565669T0000|116 122|factors
P07565669T0000|72 81|activities
P07565669T0000|17 26|myogenesis
P07565672A0798|42 46|arg-2
P07565672A0798|80 84|cox-5
P07565672A0798|50 54|cpc-1
P07565672A0798|30 39|expression
P07565672A0798|124 133|components
P07565672A0798|68 77|expression
P07565672A0798|2 6|cells
P07565685A0420|32 37|factor
P07565685A0420|60 67|GABP beta
P07565685A0420|48 56|GABP alpha
P07565685A0420|73 75|Ets
P07565685A0420|79 89|Notch motifs
P07565685A0420|3 18|peptide sequences
P07565688A0797|148 156|cytoplasm
P07565688A0797|76 82|protein
P07565688A0797|174 178|cells
P07565688A0797|122 128|protein
P07565688A0797|160 166|nucleus
P07565688A0797|0 27|Immunofluorescence microscopy
P07565688A0797|31 55|cell fractionation analyses
P07565688T0000|0 9|Expression
P07565688T0000|66 83|adenosine deaminase
P07565688T0000|93 97|cells
P07565688T0000|13 22|regulation
P07565688T0000|113 117|forms
P07565688T0000|25 34|interferon
P07565688T0000|99 106|evidence
P07565688T0000|123 131|deaminase
P07565709A0000|0 15|T-cell hybridomas
P07565709A0000|67 75|cell death
P07565709A0000|98 111|T-cell receptor
P07565709A0000|78 87|activation
P07565709A0000|17 26|thymocytes
P07565709A0000|31 36|T cells
P07565712A0286|0 8|Deletions
P07565712A0286|76 82|inserts
P07565712A0286|138 153|quasipalindromes
P07565712A0286|26 33|LYS2 gene
P07565712A0286|57 63|inserts
P07565712A0286|118 126|structure
P07565712A0286|41 43|set
P07565712A0286|97 105|potential
P07565713A0634|0 13|Overexpression
P07565713A0634|107 119|Hsp60 activity
P07565713A0634|40 55|HSP60-null allele
P07565713A0634|71 81|suppression
P07565713A0634|16 19|SCS1
P07565720A0256|86 105|Schistosoma japonicum
P07565720A0256|21 24|NirA
P07565720A0256|60 83|glutathione S-transferase
P07565720A0256|3 18|DNA binding domain
P07565720A0256|40 52|fusion protein
P07565723A0200|70 75|growth
P07565723A0200|55 57|CTD
P07565723A0200|35 49|phosphorylation
P07565723A0200|79 93|differentiation
P07565723A0200|3 8|kinase
P07565731A1629|28 42|mRNA degradation
P07565731A1629|8 12|model
P07565731A1629|62 65|role
P07565731A1629|128 135|proteins
P07565731A1629|96 113|ribonucleoproteins
P07565736A2134|90 94|cells
P07565736A2134|51 77|GM-CSF receptor alpha promoter
P07565736A2134|25 34|C/EBP alpha
P07565740T0000|0 10|Endocytosis
P07565740T0000|38 43|plasma
P07565740T0000|22 32|degradation
P07565740T0000|94 104|transporter
P07565740T0000|62 65|Pdr5
P07565740T0000|77 84|cassette
P07565775A1265|114 125|EpG formation
P07565775A1265|21 26|motifs
P07565775A1265|104 112|catalysis
P07565775A1265|74 79|enzyme
P07565775A1265|52 58|effects
P07565775A1265|150 155|enzyme
P07565775A1265|90 93|rate
P07565775A1265|133 140|transfer
P07565775A1265|37 37|V
P07565775A1265|158 160|RNA
P07565775A1265|64 71|affinity
P07565775A1265|10 18|mutations
P07565775A1265|143 145|GMP
P07565775A1265|83 85|GTP
P07565775T0000|120 122|RNA
P07565775T0000|67 76|GTP binding
P07565775T0000|10 17|analysis
P07565775T0000|107 117|GMP transfer
P07565775T0000|20 23|mRNA
P07565775T0000|94 102|formation
P07565775T0000|31 36|enzyme
P07565775T0000|47 56|amino acids
P07565776A0612|0 9|Disruption
P07565776A0612|141 148|increase
P07565776A0612|60 76|HSP12 inducibility
P07565776A0612|178 182|shift
P07565776A0612|22 30|PBS2 genes
P07565776A0612|104 117|overproduction
P07565776A0612|91 95|cells
P07565776A0612|190 206|salt concentration
P07565776A0612|167 172|levels
P07565776A0612|47 54|decrease
P07565776A0612|120 123|Hog1
P07565776A0612|15 18|HOG1
P07565797A0116|0 7|Deletion
P07565797A0116|10 21|inactivation
P07565797A0116|24 27|CRY1
P07565797A0116|64 71|CRY2 mRNA
P07565797A0116|56 61|levels
P07567079A0014|144 150|numbers
P07567079A0014|69 75|percoll
P07567079A0014|181 193|contamination
P07567079A0014|26 43|Cryptosporidium spp
P07567079A0014|153 159|oocysts
P07567079A0014|89 103|density gradient
P07567079A0014|14 23|separation
P07567079A0014|162 169|C. parvum
P07567079A0014|45 51|oocysts
P07567079A0014|121 126|choice
P07567079A0014|113 118|method
P07567079A0014|6 11|method
P07567079A0014|56 60|feces
P07567300T0000|42 48|illness
P07567300T0000|14 24|enterotoxin
P07567300T0000|26 36|involvement
P07567300T0000|68 74|patient
P07567830A0072|118 124|females
P07567830A0072|80 87|patients
P07567830A0072|126 128|age
P07567830A0072|140 144|years
P07567830A0072|101 106|tremor
P07567830A0072|110 114|males
P07567830A0072|0 6|METHODS
P07567830A0072|60 65|curves
P07567979A1266|69 75|ligands
P07567979A1266|36 46|development
P07567979A1266|25 29|basis
P07567979A1266|49 54|assays
P07567979A1266|78 91|testis receptor
P07567979A1266|3 10|findings
P07567979A1266|96 100|hERR1
P07567980T0000|73 75|DNA
P07567980T0000|55 62|elements
P07567980T0000|4 6|p53
P07567980T0000|18 31|domain peptides
P07568026A0622|39 45|protein
P07568026A0622|51 60|amino acids
P07568026A0622|17 20|size
P07568026A0622|3 12|Stat5b mRNA
P07568026A0622|26 27|kb
P07568116A0902|86 98|signal peptide
P07568116A0902|53 58|region
P07568116A0902|65 71|absence
P07568116A0902|3 16|hydropathy plot
P07568118A1267|44 61|Shc phosphorylation
P07568118A1267|23 27|G beta
P07568118A1267|104 119|p21ras activation
P07568118A1267|79 82|step
P07568118A1267|5 11|results
P07568118A1267|152 186|growth factor tyrosine kinase receptors
P07568118A1267|133 141|mechanism
P07568118A1267|88 94|pathway
P07568576A0074|41 53|Type A behavior
P07568576A0074|22 33|relationship
P07568576A0074|4 9|report
P07568576A0074|67 83|emotion dimensions
P07568865A0305|172 177|CFU/ml
P07568865A0305|150 158|threshold
P07568865A0305|120 120|%
P07568865A0305|179 184|Figure
P07568865A0305|22 34|contamination
P07568865A0305|138 145|bacteria
P07568865A0305|3 11|carcasses
P07568865A0305|69 73|range
P07568865A0305|56 63|bacteria
P07568865A0305|96 101|CFU/ml
P07569075A0585|81 88|response
P07569075A0585|7 11|stage
P07569075A0585|148 156|histology
P07569075A0585|134 141|cytology
P07569075A0585|16 33|lung cancer patients
P07569075A0585|130 132|FBS
P07569075A0585|35 36|CR
P07569075A0585|76 76|%
P07569075A0585|127 128|CT
P07569075A0585|58 58|%
P07569075A0585|110 125|chest radiography
P07569075A0585|68 69|PR
P07569532T0001|0 8|Pediatric
P07569532T0001|38 45|hospital
P07569532T0001|58 63|locale
P07569532T0001|16 26|emergencies
P07569640A0539|0 21|Protein electrophoresis
P07569640A0539|80 81|G2
P07569640A0539|37 49|albumin levels
P07569640A0539|72 77|values
P07569640A0539|56 61|groups
P07569770A0298|0 6|METHODS
P07569770A0298|18 31|non-responders
P07569770A0298|60 66|vaccine
P07569770A0298|139 143|years
P07569770A0298|102 112|booster dose
P07569770A0298|47 50|dose
P07569770A0298|68 73|months
P07569770A0298|131 137|vaccine
P07569770A0298|86 97|immunization
P07571766A0122|16 25|percentage
P07571766A0122|64 64|%
P07571766A0122|40 47|patients
P07571766A0122|114 117|pain
P07571766A0122|83 97|catheterization
P07571766A0122|140 160|ST-segment depressions
P07571766A0122|194 201|arteries
P07571953T0000|60 65|smears
P07571953T0000|28 39|mycobacteria
P07572582A0000|0 9|Mibefradil
P07572582A0000|11 12|Ro
P07572582A0000|110 123|calcium channel
P07572582A0000|54 66|chemical class
P07572582A0000|29 45|calcium antagonist
P07574064A1416|126 132|l.min-1
P07574064A1416|165 184|response relationship
P07574064A1416|24 46|concentration anesthesia
P07574064A1416|97 100|mmHg
P07574064A1416|84 85|VE
P07574064A1416|155 159|shift
P07574064A1416|89 92|PCO2
P07574682T0000|0 3|cDNA
P07574682T0000|51 69|alkaline phosphatase
P07575416A0000|207 216|properties
P07575416A0000|39 44|enzyme
P07575416A0000|15 17|PKC
P07575416A0000|110 115|family
P07575416A0000|184 195|localization
P07575416A0000|154 171|tissue distribution
P07575416A0000|131 140|isoenzymes
P07575416A0000|60 69|regulation
P07575416A0000|89 97|processes
P07575416A0000|0 13|Protein kinase C
P07575416A1970|98 108|PKC zeta mRNA
P07575416A1970|63 77|oligonucleotide
P07575416A1970|36 45|importance
P07575416A1970|81 90|cDNA probes
P07575416A1970|4 7|work
P07575416A1970|55 60|choice
P07575438A1409|4 9|action
P07575438A1409|39 45|factors
P07575438A1409|56 64|E1 element
P07575947T0000|13 21|electives
P07575947T0000|3 8|debate
P07576178A0000|90 98|receptors
P07576178A0000|27 35|cytokines
P07576178A0000|59 67|functions
P07576178A0000|0 23|Polypeptide growth factors
P07576179A0781|37 52|CpG dinucleotides
P07576179A0781|26 34|frequency
P07576307A0144|113 122|regulation
P07576307A0144|64 65|bp
P07576307A0144|72 84|rat enkephalin
P07576307A0144|86 89|rENK
P07576307A0144|91 94|gene
P07576307A0144|47 54|cassette
P07576307A0144|18 21|role
P07576307A0144|128 146|enkephalin phenotype
P07576307A1654|76 84|complexes
P07576307A1654|28 33|motifs
P07576307A1654|155 157|ENK
P07576307A1654|130 133|HeLa
P07576307A1654|116 128|tumor cell line
P07576307A1654|96 103|extracts
P07577904A0141|160 170|dislocation
P07577904A0141|116 126|buphthalmos
P07577904A0141|26 36|persistence
P07577904A0141|136 138|eye
P07577904A0141|142 155|microphthalmos
P07577904A0141|92 103|camera aquosa
P07577904A0141|76 86|dislocation
P07577904A0141|200 203|body
P07577904A0141|57 60|body
P07577904A0141|214 216|eye
P07577904A0141|13 17|years
P07579023A0214|61 70|medication
P07579023A0214|25 32|patients
P07579023A0214|9 20|dose-finding
P07579023A0214|77 83|patient
P07579023A0214|112 117|levels
P07579023A0214|120 131|liver enzymes
P07579164A0409|28 36|sequences
P07579164A0409|41 56|RNA editing events
P07579164A0409|2 11|comparison
P07579164A0409|72 80|atp9 genes
P07579164A0409|14 17|cDNA
P07579328A0653|0 4|MZF-1
P07579328A0653|79 93|cell lines NIH 3T3
P07579328A0653|42 57|GAL4 binding sites
P07579328A0653|14 38|CAT reporter gene expression
P07579328A1345|138 146|cell lines
P07579328A1345|38 42|MZF-1
P07579328A1345|92 100|cell lines
P07579328A1345|52 73|reporter gene expression
P07579328A1345|113 122|expression
P07579328A1345|21 36|DNA binding domain
P07579683A0660|0 7|Analyses
P07579683A0660|152 159|activity
P07579683A0660|54 60|regions
P07579683A0660|10 31|hGMR beta subunit mutants
P07579683A0660|71 80|activation
P07579683A0660|86 98|c-myc promoter
P07579695A0336|76 84|mutations
P07579695A0336|97 128|yeast centromere protein genes-CEP1
P07579695A0336|46 54|mutations
P07579695A0336|130 138|CBF1/CPF1
P07579695A0336|57 60|MIF2
P07579695A0336|140 149|NDC10/CBF2
P07579695A0336|154 163|CEP3/CBF3B
P07579695A0336|29 38|phenotypes
P07579695A0693|127 131|order
P07579695A0693|61 65|Cep1p
P07579695A0693|37 47|Mif2 protein
P07579695A0693|19 22|data
P07579695A0693|91 105|yeast centromere
P07579695A0693|143 149|complex
P07579695A0693|71 80|centromere
P07579704A0085|120 129|cell growth
P07579704A0085|89 98|components
P07579704A0085|112 116|sites
P07579704A0085|63 71|cell cycle
P07579704A0085|31 37|patches
P07579704A0085|17 27|actin cables
P07580058A0000|88 116|plasminogen activator inhibitor
P07580058A0000|118 120|PAI
P07580058A0000|155 166|heart disease
P07580058A0000|12 29|Codonopsis pilosula
P07580058A0000|48 78|tissue-type plasminogen activator
P07580058A0000|34 39|liquor
P07580058A0000|137 144|patients
P07580058A0000|127 132|plasma
P07580058A0000|171 181|blood stasis
P07580058A0000|80 83|t-PA
P07580058A0000|3 9|effects
P07580058A0000|41 44|CPOL
P07580330A0331|30 35|person
P07580330A0331|95 103|microgram
P07580330A0331|22 25|EDIs
P07580330A0331|107 114|dieldrin
P07580330A0331|149 157|microgram
P07580330A0331|14 20|intakes
P07580330A0331|161 163|HCB
P07580330A0331|44 52|microgram
P07580330A0331|69 77|microgram
P07580330A0331|138 140|DDT
P07580330A0331|61 63|HCH
P07580330A0331|81 89|gamma-HCH
P07580330A0331|120 129|micrograms
P07580782T0000|0 14|Imaging features
P07580782T0000|52 62|correlation
P07580782T0000|24 37|epidermoid cyst
P07581364A0500|39 41|SMA
P07581364A0500|21 24|type
P07581364A0500|83 86|C212
P07581364A0500|12 16|cases
P07581364A0500|74 79|Ag1-CA
P07581364A0500|32 35|type
P07581364A0500|50 58|deletions
P07581364A0500|68 71|copy
P07582316A0696|25 32|isolates
P07582316A0696|115 124|MTB strains
P07582316A0696|66 86|IS6110 banding patterns
P07582316A0696|51 54|case
P07582316A0696|34 37|case
P07582316A0696|18 22|pairs
P07582592A0545|57 62|damage
P07582592A0545|151 173|botulinum toxin injection
P07582592A0545|81 90|dilatation
P07582592A0545|179 187|treatment
P07582592A0545|121 134|administration
P07582592A0545|109 111|LES
P07582592A0545|190 198|achalasia
P07582592A0545|0 3|HRES
P07583190A0306|158 182|phrase structure violations
P07583190A0306|128 131|area
P07583190A0306|65 69|parts
P07583190A0306|79 88|hemisphere
P07583190A0306|105 119|brain potentials
P07583190A0306|270 279|assignment
P07583190A0306|226 233|area lead
P07583190A0306|238 247|impairment
P07583190A0306|20 28|processes
P07583190A0306|213 219|lesions
P07583562A1826|2 4|men
P07583562A1826|19 20|OR
P07583562A1826|9 11|BMI
P07583562A1826|87 92|models
P07583562A1826|46 46|P
P07583562A1826|115 119|LDL-C
P07583562A1826|75 76|RP
P07583562A1826|43 44|TG
P07583562A1826|78 78|P
P07583562A1826|112 113|TG
P07583562A1826|124 135|hypertension
P07585246T0000|0 16|SL1 trans-splicing
P07585246T0000|62 64|end
P07585246T0000|67 95|Caenorhabditis elegans pre-mRNA
P07585246T0000|44 46|RNA
P07585559A0000|113 115|SCH
P07585559A0000|175 207|muscle alpha-actin promoter activity
P07585559A0000|69 73|amino
P07585559A0000|28 38|6-methoxy-4
P07585559A0000|63 67|ethyl
P07585559A0000|225 229|cells
P07585559A0000|146 152|ability
P07585559A0000|103 111|quinoline
P07585559A0000|78 95|methyl-1M-pyrazo lo
P07585559A0000|19 26|compound
P07585559A0000|45 60|2-hydroxyethoxyl
P07585559A0000|97 101|3,4-b
P07586403A0765|28 52|risk factor-selection scale
P07586403A0765|5 9|basis
P07586403A0765|106 112|weights
P07586403A0765|120 129|risk factor
P07586403A0765|17 25|relations
P07586403A0765|54 57|RFSS
P07586403A0765|60 64|range
P07588240A0000|103 119|interleukin-1 beta
P07588240A0000|141 146|enzyme
P07588240A0000|3 46|Caenorhabditis elegans death susceptibility gene
P07588240A0000|48 52|ced-3
P07588240A0000|58 63|number
P07588240A0000|66 73|homologs
P07588240A0000|86 92|species
P07588240A0000|166 170|CPP32
P07588240A0000|121 128|IL-1 beta
P07588240A0000|148 150|ICE
P07588245T0000|0 9|Repression
P07588245T0000|12 25|glucocorticoid
P07588245T0000|80 101|thyroid hormone receptor
P07588245T0000|108 109|TR
P07588245T0000|58 67|activation
P07588245T0000|103 104|TR
P07588603A1054|30 40|flexibility
P07588603A1054|72 76|sites
P07588603A1054|46 52|spacing
P07588603A1054|3 9|results
P07588603A1054|60 61|DH
P07588608A1687|0 10|Obstruction
P07588608A1687|79 83|genes
P07588608A1687|56 62|members
P07588608A1687|121 127|control
P07588608A1687|145 161|cell proliferation
P07588608A1687|196 202|effects
P07588608A1687|85 99|i.e.gag-myb-ets
P07588608A1687|68 76|ets family
P07588608A1687|16 35|ERF repressor function
P07588608A1687|130 134|genes
P07588628A0318|0 13|Overexpression
P07588628A0318|39 47|apoptosis
P07588628A0318|52 54|LCL
P07588628A0318|25 27|p53
P07588633A0362|83 89|protein
P07588633A0362|168 178|NIH 3T3 cells
P07588633A0362|10 14|c-Fos
P07588633A0362|156 165|efficiency
P07588633A0362|19 43|c-fos protooncogene product
P07588633A0362|182 184|Mos
P07588750T0061|0 6|Cloning
P07588750T0061|8 17|sequencing
P07588750T0061|54 63|kinase gene
P07588750T0061|66 81|Pyrococcus woesei
P07588750T0061|21 30|expression
P07588750T0061|123 129|protein
P07588750T0061|102 117|characterization
P07588777A1524|96 112|p44mapk MAP kinases
P07588777A1524|86 92|p42mapk
P07588777A1524|26 33|proposal
P07588777A1524|5 16|observations
P07588777A1524|47 49|CTD
P07588777A1524|65 70|target
P07588777A1524|41 44|RNAP
P07589069A1245|160 166|CD6-PB1
P07589069A1245|37 41|forms
P07589069A1245|63 71|sequences
P07589069A1245|97 103|regions
P07589069A1245|49 55|CD6 cDNA
P07589069A1245|120 125|domain
P07589069A1245|146 157|reading frame
P07590264A0373|87 90|DHFR
P07590264A0373|160 170|differences
P07590264A0373|221 221|A
P07590264A0373|250 263|gene expression
P07590264A0373|223 227|sites
P07590264A0373|175 190|end RNA processing
P07590264A0373|79 84|levels
P07590264A0373|94 98|mRNAs
P07590264A0373|43 57|polyadenylation
P07590264A0373|243 247|level
P07590264A0373|216 219|poly
P07590264A0373|30 40|differences
P07590264A0373|194 197|gene
P07590264A0373|142 146|sense
P07590264A0373|118 123|allele
P07590268A0350|41 44|cDNA
P07590268A0350|113 121|MAPKAPK-2
P07590268A0350|38 39|Dm
P07590268A0350|81 98|sequence similarity
P07590268A0350|54 64|polypeptide
P07590268A0740|44 54|development
P07590268A0740|7 22|MAPKAPK-2 message
P07590268A0740|93 94|kb
P07590268A0740|71 81|transcripts
P07590268A0740|131 138|germline
P07590283A0820|30 43|Pol beta protein
P07590283A0820|252 258|Pol beta
P07590283A0820|215 221|finding
P07590283A0820|82 99|polymerase activity
P07590283A0820|112 113|aa
P07590283A0820|25 27|TdT
P07590283A0820|244 249|domain
P07590283A0820|301 302|J.
P07590283A0820|168 189|polymerization reaction
P07590283A0820|281 288|activity
P07590283A0820|290 294|Kumar
P07590283A0820|140 158|template utilization
P07590283A0820|3 9|finding
P07590283A0820|120 126|Pol beta
P07590525A0811|29 40|revertants/g
P07590525A0811|10 15|values
P07590525A0811|47 56|hamburgers
P07590525A0811|63 66|dogs
P07590657A0624|0 14|Cholangiography
P07590657A0624|32 36|cases
P07590657A0624|99 106|patients
P07590657A0624|60 65|system
P07590744A0829|17 28|cDNA sequence
P07590744A0829|43 50|analysis
P07590744A0829|78 83|clones
P07590744A0829|95 102|GAR1 gene
P07590744A0829|3 11|integrity
P07592072A0217|111 119|injection
P07592072A0217|31 36|farrow
P07592072A0217|47 47|d
P07592072A0217|122 141|prostaglandin F2 alpha
P07592072A0217|84 89|farrow
P07592072A0217|144 144|d
P07592072A0217|52 53|NF
P07592072A0217|2 6|Trial
P07592072A0217|150 158|gestation
P07592220A0846|83 88|PETCO2
P07592220A0846|62 67|VE/VO2
P07592220A0846|25 41|minute ventilation
P07592220A0846|101 103|Hyp
P07592220A0846|105 105|P
P07592220A0846|9 11|PO2
P07592220A0846|18 22|ratio
P07592220A0846|44 60|oxygen consumption
P07592337A0891|5 11|results
P07592337A0891|25 28|NfxB
P07592337A0891|55 64|expression
P07592337A0891|67 70|nfxB
P07592439A0000|0 3|A511
P07592439A0000|32 39|myovirus
P07592439A0000|43 63|Listeria monocytogenes
P07592467A0000|14 36|peroxisome proliferation
P07592467A0000|3 11|mechanism
P07592485A0734|15 28|gene expression
P07592485A0734|112 115|gene
P07592485A0734|52 58|pathway
P07592485A0734|118 127|expression
P07592485A0734|148 164|ure2 delta mutation
P07592485A0734|83 86|case
P07592485A0734|95 108|NCR sensitivity
P07592647A0797|60 68|complexes
P07592647A0797|18 46|DNA Pur alpha recognition element
P07592647T0000|0 10|Association
P07592647T0000|33 53|retinoblastoma protein
P07592647T0000|94 122|DNA Pur alpha recognition element
P07592647T0000|18 25|Pur alpha
P07592647T0000|55 56|Rb
P07592658A0309|29 35|complex
P07592658A0309|54 71|p50/p65 heterodimer
P07592676A0466|83 91|NIP region
P07592676A0466|12 21|conditions
P07592676A0466|36 44|complexes
P07592676A0466|122 138|repressor activity
P07592706A1465|0 7|Exchange
P07592706A1465|19 24|HL lids
P07592706A1465|106 109|role
P07592706A1465|36 43|reversal
P07592706A1465|142 152|specificity
P07592706A1465|116 121|region
P07592706A1465|13 15|LPL
P07592706A1465|70 80|lipase ratio
P07592710T0000|23 38|protein kinase PKR
P07592710T0000|66 75|activation
P07592710T0000|78 100|immunoglobulin kappa gene
P07592711T0000|57 86|G protein alpha subunit deficiency
P07592711T0000|22 33|yeast protein
P07592711T0000|9 13|forms
P07592711T0000|107 117|beta subunit
P07592711T0000|45 53|lethality
P07592721A0827|29 38|amino acids
P07592721A0827|13 20|mutation
P07592721A0827|67 74|contacts
P07592721A0827|79 81|DNA
P07592723A0814|74 82|sequences
P07592723A0814|40 53|CSK 35H proteins
P07592723A0814|134 146|PKC substrates
P07592723A0814|23 37|phosphorylation
P07592723A0814|102 119|PKC binding activity
P07592723A0814|0 12|Phorbol esters
P07592730A0204|0 5|Levels
P07592730A0204|155 167|phase proteins
P07592730A0204|178 192|TSG-14 synthesis
P07592730A0204|228 232|liver
P07592730A0204|128 135|contrast
P07592730A0204|204 211|organism
P07592730A0204|64 67|mice
P07592730A0204|8 20|TSG-14 protein
P07592730A0204|71 76|humans
P07592730A0204|104 121|lipopolysaccharide
P07592730A0204|82 90|injection
P07592730A0204|172 175|bulk
P07592730A0204|32 36|PTX-3
P07592730A0204|57 61|serum
P07592771A0258|116 120|alpha
P07592771A0258|103 110|position
P07592771A0258|24 27|gene
P07592771A0258|75 84|homologues
P07592771A0258|55 59|exons
P07592771A0258|32 40|kilobases
P07592771A0258|133 136|gene
P07592771A0258|3 11|mouse beta
P07592790A1457|29 32|PEDF
P07592790A1457|126 133|activity
P07592790A1457|13 16|data
P07592790A1457|95 100|region
P07592790A1457|139 145|protein
P07592790A1457|45 52|subgroup
P07592790A1457|68 74|serpins
P07592946A0261|15 21|cloning
P07592946A0261|91 103|determination
P07592946A0261|33 44|p44 MAP kinase
P07592946A0261|75 80|kinase
P07592946A0261|109 129|intron/exon boundaries
P07592946A0261|137 152|characterization
P07592946A0261|83 86|gene
P07592946A0261|158 165|promoter
P07592946A0997|170 172|Sp1
P07592946A0997|23 31|TATA boxes
P07592946A0997|302 309|factor-5
P07592946A0997|52 67|start sites region
P07592946A0997|187 199|binding factor
P07592946A0997|155 166|binding sites
P07592946A0997|271 275|Zeste
P07592946A0997|72 78|AP-1 box
P07592946A0997|94 100|Malt box
P07592946A0997|220 222|Myb
P07592946A0997|207 213|CTF-NF1
P07592946A0997|249 254|NF-IL6
P07592946A0997|105 111|GAGA box
P07592946A0997|261 264|MyoD
P07592946A0997|238 242|Ets-1
P07592946A0997|136 142|element
P07592946A0997|83 89|AP-2 box
P07592946A0997|116 119|half
P07592946A0997|285 294|hepatocyte
P07592946A0997|229 231|p53
P07593266A1174|71 87|pair stem structure
P07593266A1174|45 50|region
P07593896A1053|66 80|P0.1 measurement
P07593896A1053|105 113|equipment
P07593896A1053|127 135|lung model
P07593896A1053|21 40|measurement technique
P07594047T0000|120 129|QT syndrome
P07594047T0000|93 103|epinephrine
P07594047T0000|39 58|afterdepolarizations
P07594047T0000|21 31|propranolol
P07594047T0000|9 17|verapamil
P07594047T0000|73 83|arrhythmias
P07594047T0000|0 6|Effects
P07594592A0755|0 7|Deletion
P07594592A0755|66 76|interaction
P07594592A0755|92 99|proteins
P07594592A0755|13 41|NF-IL6 beta leucine zipper domain
P07595221A0733|97 104|MHC class
P07595221A0733|61 65|genes
P07595221A0733|182 186|cells
P07595221A0733|128 139|transfection
P07595221A0733|107 115|promoters
P07595221A0733|35 39|CIITA
P07595221A0733|51 58|MHC class
P07595221A0733|5 9|cells
P07595374A1215|156 163|residues
P07595374A1215|107 115|promoters
P07595374A1215|36 45|amino acids
P07595374A1215|202 213|LMP1 promoter
P07595374A1215|12 16|EBNA2
P07595374A1215|91 100|activation
P07595374A1215|134 140|domains
P07595374A1215|3 9|domains
P07595374A1215|26 33|deletion
P07595857A0521|3 16|peak velocities
P07595857A0521|75 88|flow velocities
P07595857A0521|154 157|flow
P07595857A0521|127 130|wave
P07595857A0521|275 278|days
P07595857A0521|132 135|PVS1
P07595857A0521|389 402|cardiomyopathy
P07595857A0521|159 167|durations
P07595857A0521|94 96|PVA
P07595857A0521|329 331|day
P07595857A0521|284 296|cardioversion
P07595857A0521|46 56|transmitral
P07595857A0521|225 230|motion
P07595857A0521|90 90|A
P07595857A0521|243 249|systole
P07595857A0521|188 192|waves
P07595857A0521|334 346|cardioversion
P07595857A0521|36 40|waves
P07595857A0521|370 377|patients
P07595857A0521|352 359|patients
P07595857A0521|197 205|amplitude
P07596283A0396|72 81|tributyrin
P07596283A0396|27 34|activity
P07596283A0396|16 21|enzyme
P07596283A0396|66 68|oil
P07596283A0396|42 54|triglycerides
P07596283A0396|100 108|emulsions
P07596287A0183|58 70|reading frames
P07596287A0183|231 236|uptake
P07596287A0183|39 42|fimA
P07596287A0183|96 110|protein products
P07596287A0183|79 82|ORF1
P07596287A0183|136 146|superfamily
P07596287A0183|126 132|members
P07596287A0183|3 20|nucleotide sequence
P07596287A0183|160 192|cassette membrane transport proteins
P07596287A0183|240 252|export systems
P07596287A0183|72 75|ORF5
P07596287A1724|94 108|mutagenesis data
P07596287A1724|32 43|bp transcript
P07596287A1724|61 64|size
P07596287A1724|67 70|ORF3
P07596287A1724|3 11|ORF3 probe
P07596558A0824|99 108|hemorrhage
P07596558A0824|75 83|treatment
P07596558A0824|26 39|concentrations
P07596558A0824|5 11|results
P07596558A0824|42 49|IL-1 beta
P07596697A0971|99 106|children
P07596697A0971|38 53|motilin responses
P07596697A0971|112 123|control group
P07596697A0971|24 34|polypeptide
P07596697A0971|57 60|meal
P07596697A0971|85 92|children
P07597030A0260|75 81|subunit
P07597030A0260|23 32|expression
P07597030A0260|90 90|h
P07597030A0260|48 63|characterization
P07597030A0260|104 111|hTAFII32
P07597030A0260|92 96|TFIID
P07597030A0260|15 21|cloning
P07597488T0000|43 53|kernicterus
P07597488T0000|22 35|G6PD deficiency
P07597488T0000|9 16|jaundice
P07597804A1007|68 87|glycoprotein gene EUS4
P07597804A1007|19 20|kb
P07597804A1007|3 13|transcripts
P07597804A1007|27 28|kb
P07598106A0709|0 16|Mean growth changes
P07598106A0709|100 112|malocclusions
P07598106A0709|30 35|sample
P07598106A0709|195 200|groups
P07598106A0709|124 132|age period
P07598106A0709|23 27|Class
P07598106A0709|145 154|similarity
P07598106A0709|94 98|Class
P07598106A0709|169 179|development
P07598106A0709|82 89|subjects
P07598303A1728|102 116|survival benefit
P07598303A1728|45 55|prophylaxis
P07598303A1728|58 82|bone marrow transplantation
P07598303A1728|14 20|studies
P07599449A0445|59 67|menopause
P07599449A0445|75 87|control groups
P07599449A0445|49 53|years
P07599449A0445|3 16|fracture groups
P07599653A0898|143 148|organs
P07599653A0898|50 56|factors
P07599653A0898|110 119|activities
P07599653A0898|34 40|binding
P07599653A0898|125 132|promoter
P07599653A0898|61 66|shoots
P07599653A0898|18 28|differences
P07599653A0898|77 81|roots
P07599653A0898|2 9|addition
P07599653A0898|85 93|agreement
P07600111A0000|203 208|cohort
P07600111A0000|211 224|police officers
P07600111A0000|96 105|virus types
P07600111A0000|227 239|Guinea-Bissau
P07600111A0000|153 163|association
P07600111A0000|137 146|infections
P07600111A0000|113 121|HTLV-I/II
P07600111A0000|16 24|incidence
P07600111A0000|70 74|HIV-2
P07600111A0000|32 57|immunodeficiency virus types
P07600111A0000|64 68|HIV-1
P07600111A0000|3 12|prevalence
P07600111A0000|176 185|infections
P07600986A0605|100 104|sites
P07600986A0605|62 68|classes
P07600986A0605|75 82|affinity
P07600986A0605|9 28|immunoprecipitations
P07600986A0605|139 156|transcription units
P07600986A0605|32 45|gel shift assays
P07601078A1003|0 7|Subjects
P07601078A1003|128 129|OR
P07601078A1003|153 160|hypoergy
P07601078A1003|18 33|postexposure time
P07601078A1003|174 176|% CI
P07601078A1003|164 165|OR
P07601078A1003|38 49|dioxin burden
P07601078A1003|88 95|hypoergy
P07601078A1003|138 140|% CI
P07601078A1003|54 58|pg/m3
P07601078A1003|109 116|subjects
P07601078A1003|82 85|risk
P07601078A1003|118 126|hypoergy I
P07601121A0153|73 78|region
P07601121A0153|153 161|sequences
P07601121A0153|100 104|start
P07601121A0153|107 119|transcription
P07601121A0153|0 7|Analysis
P07601121A0153|14 21|sequence
P07601445A0207|55 60|rat p47
P07601445A0207|153 159|members
P07601445A0207|169 181|protein family
P07601445A0207|43 49|homolog
P07601445A0207|79 102|WM6 Drosophila gene product
P07601445A0207|119 125|Ce08102
P07601445A0207|197 208|RNA helicases
P07601445A0207|16 37|BAT1 translation product
P07601445A0207|128 148|Caenorhabditis elegans
P07601445A0207|68 74|protein
P07601827A0778|118 123|region
P07601827A0778|81 90|repression
P07601827A0778|7 17|lacZ fusions
P07601827A0778|45 56|DNA sequences
P07601827A0778|96 98|pfl
P07601828A0095|26 41|characterization
P07601828A0095|52 56|class
P07601828A0095|87 100|orfX-fliP locus
P07601828A0095|6 11|report
P07601828A0095|59 72|flagellar genes
P07603726T0000|32 39|recovery
P07603726T0000|64 79|neuroma resection
P07603726T0000|10 28|adaptation exercises
P07603726T0000|46 50|stage
P07603956A0115|127 134|chickens
P07603956A0115|121 121|%
P07603956A0115|106 108|RSB
P07603956A0115|91 103|incorporation
P07603956A0115|83 88|levels
P07603956A0115|44 54|arrangement
P07603956A0115|15 20|design
P07603956A0115|57 66|treatments
P07604047A0704|245 248|GA19
P07604047A0704|238 241|GA44
P07604047A0704|169 178|capability
P07604047A0704|91 113|transcription-PCR method
P07604047A0704|134 142|cDNA clone
P07604047A0704|55 62|sequence
P07604047A0704|36 37|GA
P07604047A0704|251 254|GA20
P07604047A0704|121 128|identity
P07604047A0704|184 196|fusion protein
P07604047A0704|1 9|cDNA clone
P07604047A0704|232 235|GA53
P07604783A0952|84 102|bile acid composition
P07604783A0952|105 108|bile
P07604783A0952|22 28|changes
P07604783A0952|69 76|lecithin
P07604783A0952|45 59|acid composition
P07604794A0958|69 74|mg/day
P07604794A0958|102 107|mg/day
P07604794A0958|62 62|%
P07604794A0958|44 44|%
P07604794A0958|5 15|cholesterol
P07604794A0958|116 116|%
P07604794A0958|48 53|mg/day
P07604794A0958|32 35|week
P07604794A0958|124 129|mg/day
P07604794A0958|94 94|%
P07604794A0958|82 85|week
P07605990A1110|15 21|studies
P07605990A1110|190 195|levels
P07605990A1110|146 150|ratio
P07605990A1110|123 132|importance
P07605990A1110|54 57|role
P07605990A1110|103 110|findings
P07605990A1110|60 64|PEBP2
P07605990A1110|162 174|PEBP2 isoforms
P07605990A1110|70 91|GM-CSF promoter activity
P07605990A1110|201 216|promoter activity
P07606548T0000|0 7|Benefits
P07606548T0000|39 53|pharmacotherapy
P07606548T0000|19 36|board certification
P07606587A0266|0 22|Piperacillin-tazobactam
P07606587A0266|38 46|treatment
P07606587A0266|49 58|infections
P07606587A0266|115 122|bacteria
P07607197A1048|82 89|controls
P07607197A1048|25 27|PRA
P07607197A1048|62 62|P
P07607197A1048|53 60|training
P07607197A1048|5 23|plasma renin activity
P07607213A0140|154 163|expression
P07607213A0140|68 73|issues
P07607213A0140|23 52|structure/activity relationship
P07607213A0140|93 101|evolution
P07607213A0140|114 121|peptides
P07607213A0140|128 137|mechanisms
P07607233A0186|44 54|epilancin K7
P07607233A0186|13 16|gene
P07607233A0186|84 85|K7
P07607233A0186|101 118|nucleotide sequence
P07607342A0703|171 178|patients
P07607342A0703|62 67|trials
P07607342A0703|105 112|patients
P07607342A0703|154 163|drug trials
P07607342A0703|136 142|results
P07607342A0703|70 94|aldose reductase inhibitors
P07607342A0703|4 8|paper
P07607342A0703|34 41|evidence
P07607537A0954|13 22|phenotypes
P07607537A0954|36 44|mutations
P07607537A0954|3 10|spectrum
P07607537A0954|71 79|mutations
P07607537A0954|98 117|VP16 activation domain
P07607537A0954|85 91|adaptor
P07607607T0000|0 7|Increase
P07607607T0000|39 54|fructose infusion
P07607607T0000|17 23|calcium
P07607607T0000|27 33|oxalate
P07607669A1112|27 28|GC
P07607669A1112|77 88|binding sites
P07607669A1112|13 18|region
P07607669A1112|92 94|Sp1
P07607669A1112|46 56|CpG doublets
P07608268A0194|173 173|n
P07608268A0194|21 29|disorders
P07608268A0194|137 138|DP
P07608268A0194|140 140|n
P07608268A0194|130 130|n
P07608268A0194|70 95|melatonin secretion profiles
P07608268A0194|164 171|controls
P07608268A0194|121 128|males IGD
P07608268A0194|32 45|GnRH deficiency
P07608649A1429|28 39|CyA treatment
P07608649A1429|9 21|blood pressure
P07608649A1429|67 76|ET-1 levels
P07608968A0836|0 7|Analysis
P07608968A0836|66 76|core domains
P07608968A0836|83 96|transactivator
P07608968A0836|17 26|Tat mutants
P07608968A0836|149 151|TBP
P07608968A0836|132 144|transcription
P07609037A0775|245 253|sequences
P07609037A0775|22 26|Oct-1
P07609037A0775|11 19|depletion
P07609037A0775|2 9|addition
P07609037A0775|69 77|antiserum
P07609037A0775|98 113|DNA affinity resin
P07609037A0775|207 214|promoter
P07609037A0775|41 47|extract
P07609037A0775|159 170|MMTV promoter
P07609037A0775|174 178|level
P07609037A0775|130 142|transcription
P07609079A0387|186 195|activation
P07609079A0387|243 251|sequences
P07609079A0387|48 62|receptor mutants
P07609079A0387|148 171|transcription factor TFIIB
P07609079A0387|257 259|LTR
P07609079A0387|112 119|T3R alpha
P07609079A0387|30 37|T3R alpha
P07609079A0387|20 27|HIV-1 LTR
P07609079A0387|101 109|A/B region
P07609079A0387|0 14|Transactivation
P07609372A0261|81 85|cases
P07609372A0261|89 98|HR patients
P07609372A0261|102 111|LR patients
P07609372A0261|19 25|minutes
P07609372A0261|70 76|minutes
P07609372A0261|51 60|LR patients
P07609372A0261|30 34|cases
P07609372A0261|38 47|HR patients
P07609372A0261|0 5|M.M.C.
P07610052A1064|114 128|EMSA experiments
P07610052A1064|72 80|rat cortex
P07610052A1064|39 41|C25
P07610052A1064|49 60|C35 complexes
P07610052A1064|164 175|observations
P07610052A1064|102 111|SAA element
P07610052A1064|187 197|functioning
P07610052A1064|88 95|extracts
P07610052A1064|18 26|complexes
P07610052A1064|203 216|rat APP promoter
P07610052A1064|43 45|C30
P07610052A1064|143 151|relevance
P07610324A0319|176 182|centers
P07610324A0319|36 42|aspects
P07610324A0319|95 99|years
P07610324A0319|124 137|reconstruction
P07610716A0117|57 68|MS-frequency
P07610716A0117|16 31|prevalence values
P07610716A0117|3 10|analysis
P07610716A0117|119 126|latitude
P07610735A1471|0 8|Diltiazem
P07610735A1471|77 87|sinus rhythm
P07610735A1471|65 74|conversion
P07610735A1471|26 33|decrease
P07610735A1471|50 57|response
P07612174A1064|85 90|humans
P07612174A1064|77 80|PCBs
P07612174A1064|8 15|primates
P07612174A1064|68 74|effects
P07612557A0635|87 94|children
P07612557A0635|13 20|children
P07612557A0635|61 65|pairs
P07612557A0635|42 50|pathology
P07614762A0224|15 25|antigen test
P07614762A0224|46 63|latex agglutination
P07615541T0000|20 26|DNase-I
P07615541T0000|41 45|sites
P07615541T0000|10 17|analysis
P07615541T0000|51 88|mouse porphobilinogen deaminase gene locus
P07615634A0535|101 102|kD
P07615634A0535|5 15|transcripts
P07615634A0535|41 46|region
P07615634A0535|62 69|sequence
P07615634A0535|89 95|protein
P07616056A0278|40 57|feedback inhibition
P07616056A0278|65 86|chain gene rearrangement
P07616056A0278|9 15|gamma 2b
P07616056A0278|21 30|chain genes
P07616056A0278|4 5|mu
P07616563A0532|95 103|stretches
P07616563A0532|89 90|bp
P07616563A0532|8 11|CarP
P07616563A0532|65 69|DNase
P07616563A0532|29 46|carAB control region
P07616563A0532|143 154|GATC sequence
P07616569A0168|202 204|srn
P07616569A0168|69 82|apocytochrome b
P07616569A0168|107 130|NADH dehydrogenase complex
P07616569A0168|150 163|ATPase subunits
P07616569A0168|250 254|rps11
P07616569A0168|208 210|lrn
P07616569A0168|264 268|rpl16
P07616569A0168|192 195|RNAs
P07616569A0168|11 15|genes
P07616569A0168|140 144|nad4L
P07616569A0168|165 168|atp6
P07616569A0168|42 58|cytochrome oxidase
P07616569A0168|215 219|tRNAs
P07616569A0168|245 248|rps3
P07616569A0168|132 135|nad1
P07616569A0168|84 86|cob
P07616569A0168|197 200|rrn5
P07616569A0168|94 101|subunits
P07616569A0168|236 243|proteins
P07616569A0168|172 175|atp9
P07616569A0168|60 63|cox1
P07616569A0168|256 260|rps12
P07616569A0168|29 36|subunits
P07616802A0315|98 98|p
P07616802A0315|110 115|return
P07616802A0315|32 44|platelet count
P07616802A0315|4 6|day
P07616802A0315|22 29|increase
P07616802A0315|90 96|heparin
P07616802A0315|128 132|value
P07616802A0315|164 173|responders
P07616802A0315|138 153|heparin cessation
P07616802A0315|71 78|patients
P07618280A0550|24 33|structures
P07618280A0550|55 83|density gradient centrifugation
P07618548T0000|3 23|Babcock Surgical Clinic
P07620491T0000|0 8|Resources
P07620491T0000|19 26|patients
P07620491T0000|33 39|smoking
P07622058A0411|44 45|aa
P07622058A0411|96 115|segmentation gene runt
P07622058A0411|3 20|PEBP2 alpha proteins
P07622058A0411|47 52|region
P07622060A0967|43 52|ME activity
P07622060A0967|90 104|thyroid hormones
P07622060A0967|20 24|cells
P07622521A0418|27 49|G beta gamma binding region
P07622521A0418|206 215|G beta gamma
P07622521A0418|219 229|PIP2 binding
P07622521A0418|72 79|residues
P07622521A0418|124 130|mutants
P07622521A0418|188 195|residues
P07622521A0418|136 151|carboxyl terminus
P07622521A0418|154 160|beta ARK
P07622521A0418|15 21|mapping
P07622521A0418|89 96|PH domain
P07622521A0418|163 167|order
P07622521A0418|116 121|series
P07622521A0418|52 58|beta ARK
P07622932T0000|17 24|features
P07622932T0000|35 41|leprosy
P07623807A0162|14 23|mechanisms
P07623807A0162|78 83|system
P07623807A0162|141 145|cells
P07623807A0162|158 166|membranes
P07623807A0162|96 110|plasma membranes
P07623807A0162|43 55|Raf-1 proteins
P07623807A0162|115 119|v-Ras
P07623814A1040|42 58|estrogen receptors
P07623814A1040|31 38|retinoid
P07623814A1040|92 99|activity
P07623814A1040|155 171|breast cancer cells
P07623814A1040|12 25|cotransfection
P07623814A1040|120 129|inhibition
P07623814A1040|70 79|inhibition
P07623814A1040|2 10|CV-1 cells
P07623814A1040|132 141|ER activity
P07623821A0649|18 22|HRF-1
P07623821A0649|10 16|factors
P07623821A0649|78 82|motif
P07623821A0649|35 44|cis element
P07623821T0000|43 53|combination
P07623821T0000|12 39|Gax homeobox gene transcription
P07623821T0000|64 70|factors
P07623821T0000|96 109|enhancer factor
P07623821T0000|0 9|Regulation
P07623825T0000|43 57|heat shock factor
P07623825T0000|20 40|transactivation domain
P07623825T0000|83 88|stress
P07623838A1112|0 1|D.
P07623840A0352|118 121|tRNA
P07623840A0352|38 46|sequences
P07623840A0352|49 52|GCN2
P07623840A0352|143 161|amino acid limitation
P07623840A0352|78 83|kinase
P07623840A0352|65 72|activity
P07623844A0639|88 99|growth arrest
P07623844A0639|25 38|E1B 19K proteins
P07623844A0639|140 156|cell proliferation
P07623844A0639|125 136|DNA synthesis
P07623844A0639|106 115|expression
P07623844A0639|193 195|p53
P07623844A0639|60 68|apoptosis
P07623844A0639|162 169|presence
P07623844A0639|176 181|levels
P07623844A0639|14 18|Bcl-2
P07624119A0528|27 57|PAX3-FKHR transactivation domains
P07624119A0528|106 109|GAL4
P07624119A0528|76 88|test fragments
P07624119A0528|12 15|PAX3
P07624119A0528|136 145|activation
P07624119A0528|183 191|cell types
P07624119A0528|121 126|domain
P07624119A0528|149 160|reporter gene
P07624581A0312|261 263|T45
P07624581A0312|40 65|blood pressure determination
P07624581A0312|134 154|glutamine transaminase
P07624581A0312|106 112|glucose
P07624581A0312|125 132|nitrogen
P07624581A0312|234 236|T30
P07624581A0312|209 210|T0
P07624581A0312|26 28|ECG
P07624581A0312|156 166|cholesterol
P07624581A0312|102 104|PRL
P07624581A0312|170 194|triglycerides plasma levels
P07624581A0312|114 123|creatinine
P07624581A0312|220 232|treatment days
P07624581A0312|249 259|days washout
P07624581A0312|83 85|TSH
P07624581A0312|201 207|therapy
P07624581A0312|3 10|subjects
P07624581A0312|87 100|thyroid hormone
P07624615A0267|57 60|mmHg
P07624615A0267|150 154|ratio
P07624615A0267|240 248|phosphate
P07624615A0267|214 223|phosphorus
P07624615A0267|15 29|body temperature
P07624615A0267|41 45|PaCO2
P07624615A0267|184 186|SID
P07624615A0267|250 251|Pi
P07624615A0267|225 226|PT
P07624615A0267|79 83|mEq/L
P07624615A0267|107 109|pHa
P07624615A0267|91 95|mEq/L
P07624615A0267|66 69|HCO3
P07624615A0267|191 194|Atot
P07624615A0267|141 142|OH
P07624615A0267|31 32|TB
P07624615A0267|147 147|H
P07624615A0267|5 12|decrease
P07624615A0267|175 180|effect
P07626378T0000|0 16|Hepatitis B vaccine
P07626378T0000|29 36|problems
P07626469A1341|117 124|CHO cells
P07626469A1341|44 51|M1 domain
P07626469A1341|90 93|MLTC
P07626469A1341|5 20|promoter activity
P07626469A1341|68 88|mouse Leydig tumor cells
P07626806A1098|3 10|RAT3 gene
P07626806A1098|48 57|similarity
P07626806A1098|30 40|acid protein
P07626806A1098|70 77|proteins
P07627317A1502|3 4|Al
P07627317A1502|37 41|shift
P07627317A1502|23 27|mg/m3
P07627317A1502|9 16|exposure
P07627317A1502|64 76|concentration
P07627317A1502|100 120|microgram/g creatinine
P07627317A1502|90 94|shift
P07627317A1502|82 84|end
P07628389A0145|0 24|Tumor necrosis factor-alpha
P07628389A0145|26 33|TNF alpha
P07628389A0145|108 123|mouse Leydig cells
P07628389A0145|84 105|testosterone production
P07628389A0145|52 59|cytokine
P07628438T0000|83 98|receptor isoforms
P07628438T0000|62 72|development
P07628438T0000|13 34|insulin receptor homolog
P07628438T0000|37 40|gene
P07628438T0000|112 129|signaling potential
P07628451A0114|14 15|RA
P07628451A0114|65 74|kDa protein
P07628451A0114|76 79|p300
P07628451A0114|19 21|E1A
P07628451A0114|90 104|differentiation
P07628451A0114|107 113|F9 cells
P07628451A0114|28 42|phosphorylation
P07628456A0000|201 203|PKR
P07628456A0000|165 169|RNase
P07628456A0000|35 39|dsRBD
P07628456A0000|88 94|variety
P07628456A0000|140 142|RNA
P07628456A0000|18 33|RNA binding domain
P07628456A0000|194 199|kinase
P07628456A0000|60 73|amino acid motif
P07628456A0000|97 104|proteins
P07629103T0000|102 106|sites
P07629103T0000|112 134|beta-casein gene promoter
P07629103T0000|80 84|cells
P07629103T0000|22 40|protein isoforms beta
P07629103T0000|44 48|delta
P07629113A0726|0 2|SCA
P07629113A0726|48 63|metalloproteases
P07629113A0726|84 99|N-ethylmaleimide
P07629113A0726|36 43|aspartyl
P07629113A0726|17 26|inhibitors
P07629113A0726|29 34|serine
P07629122A0323|87 100|protein kinases
P07629122A0323|66 69|NIMA
P07629122A0323|115 118|NIMA
P07629122A0323|39 58|phosphorylation sites
P07629122A0323|10 17|analysis
P07629122A0323|71 75|NIM-1
P07629123A0885|131 140|activation
P07629123A0885|53 60|position
P07629123A0885|43 50|arginine
P07629123A0885|103 112|DNA binding
P07629123A0885|84 101|heterodimerization
P07629123A0885|27 40|leucine residue
P07629123A0885|16 23|mutation
P07629123A0885|72 81|alteration
P07629150A0155|0 9|Expression
P07629150A0155|39 46|hormones
P07629150A0155|15 25|CYP11A1 gene
P07629150A0155|54 72|adrenocorticotropin
P07629150A0155|145 152|promoter
P07629150A0155|106 111|number
P07629150A0155|114 126|growth factors
P07629150A0155|87 93|hormone
P07629150A0155|173 180|elements
P07629150A0155|202 227|signal transduction pathways
P07629163A0770|0 2|NH2
P07629163A0770|154 167|transformation
P07629163A0770|20 35|deletion analysis
P07629163A0770|124 136|zinc butterfly
P07629163A0770|68 105|guanine nucleotide exchange factor domains
P07629163A0770|55 56|PH
P07629196A0274|127 129|Jun
P07629196A0274|112 121|activation
P07629196A0274|63 74|alpha 12Q229L
P07629196A0274|18 27|expression
P07629196A0274|78 82|alpha
P07629196A0274|167 174|JNK/SAPK
P07629196A0274|153 165|protein kinase
P07629196A0274|55 59|alpha
P07629196A0274|46 52|mutants
P07629196A0274|176 182|pathway
P07629196A0274|86 97|alpha 13Q226L
P07630687A0010|205 224|protein S deficiencies
P07630687A0010|194 201|protein C
P07630687A0010|250 257|children
P07630687A0010|132 142|development
P07630687A0010|280 284|event
P07630687A0010|17 21|study
P07630687A0010|42 44|sex
P07630687A0010|229 247|lupus anticoagulants
P07630687A0010|154 164|involvement
P07630687A0010|79 82|site
P07630687A0010|121 130|evaluation
P07630687A0010|65 77|family history
P07630687A0010|38 40|age
P07630687A0010|166 175|prevalence
P07630687A0010|3 11|objective
P07630687A0010|54 63|conditions
P07630687A0010|178 189|antithrombin
P07630687A0010|84 102|catheter association
P07630934A0343|0 4|Harel
P07630934A0343|6 9|E.M.
P07631267T0001|0 11|Radiotherapy
P07631267T0001|49 57|carcinoma
P07631267T0001|20 30|orchiectomy
P07631267T0001|33 39|stage D1
P07633444T0000|60 83|mouse WD-repeat gene DMR-N9
P07633444T0000|116 129|dystrophy locus
P07633444T0000|10 21|organization
P07633444T0000|38 54|expression pattern
P07633756A0690|254 272|artefact propagation
P07633756A0690|155 161|version
P07633756A0690|44 46|sum
P07633756A0690|68 88|background EEG activity
P07633756A0690|224 228|sweep
P07633756A0690|54 60|signals
P07633756A0690|165 179|reference signal
P07633756A0690|234 239|signal
P07633756A0690|137 141|noise
P07633756A0690|3 21|ARX2 procedure models
P07633756A0690|33 38|signal
P07633756A0690|116 122|process
P07633756A0690|198 208|information
P07635140A0172|101 103|use
P07635140A0172|33 38|enzyme
P07635140A0172|126 135|mechanisms
P07635140A0172|60 63|part
P07635140A0172|82 90|promoters
P07635140A0172|18 21|gene
P07635140A0172|3 12|expression
P07635140A0172|40 44|CYP19
P07635312A0692|97 109|act1 mutations
P07635312A0692|36 44|mutations
P07635312A0692|112 119|interest
P07635312A0692|5 15|mutagenesis
P07635312A0692|69 74|domain
P07635572A1153|115 120|effect
P07635572A1153|108 109|RB
P07635572A1153|93 105|re-expression
P07635572A1153|123 146|CIITA mRNA induction levels
P07635572A1153|88 91|line
P07635572A1153|74 78|lines
P07635572A1153|30 38|IFN-gamma
P07635572A1153|41 45|class
P07635572A1153|0 8|CIITA mRNA
P07636179A0000|116 122|kinases
P07636179A0000|38 46|molecules
P07636179A0000|73 82|protein pRb
P07636179A0000|9 17|cell cycle
P07636179A0000|132 141|inhibitors
P07636179A0000|87 95|G1 cyclins
P07636187A0585|17 37|protein expression data
P07636187A0585|90 94|lines
P07636187A0585|39 43|V beta
P07636187A0585|111 118|promoter
P07636187A0585|47 61|gene transcripts
P07636337A0687|70 88|serum estradiol level
P07636337A0687|48 55|hormones
P07636337A0687|105 109|women
P07636337A0687|91 93|HRT
P07636337A0687|5 11|results
P07636337A0687|41 45|doses
P07636408T0000|0 9|Comparison
P07636408T0000|91 100|evaluation
P07636408T0000|53 68|resonance imaging
P07636408T0000|112 133|intervertebral foramina
P07636408T0000|15 19|Tesla
P07636408T0000|27 44|Tesla field strength
P07636648A1229|43 48|groups
P07636648A1229|124 137|concentrations
P07636648A1229|74 100|serum antibody concentrations
P07636648A1229|205 205|p
P07636648A1229|153 169|pertussis antigens
P07636648A1229|196 203|children
P07636648A1229|106 113|antigens
P07636648A1229|16 37|DTaP booster vaccination
P07636648A1229|3 7|month
P07636962A1288|119 126|activity
P07636962A1288|66 77|HSV-alpha TIF
P07636962A1288|32 42|determinant
P07636962A1883b|141 148|activity
P07636962A1883b|16 22|fusions
P07636962A1883b|107 111|amino
P07636962A1883b|48 51|GAL4
P07636962A1883b|57 64|activity
P07636962A1883b|30 45|DNA binding domain
P07636962A1883b|82 93|BHV-alpha TIF
P07636962A1883b|115 129|carboxyl termini
P07636984A1349|31 33|SP1
P07636984A1349|77 81|cells
P07636984A1349|52 59|extracts
P07636984A1349|25 28|role
P07637718A0218|86 98|epimastigotes
P07637718A0218|115 129|trypomastigotes
P07637718A0218|64 70|repeats
P07637718A0218|35 50|trans-sialidases
P07637718A0218|14 26|messenger RNAs
P07638517A0000|82 103|individuals AIDS victims
P07638517A0000|72 79|cadavers
P07638517A0000|24 33|necropsies
P07638517A0000|118 123|deaths
P07638517A0000|135 154|police investigations
P07638517A0000|4 6|May
P07638517A0000|52 69|Sao Paulo City Morgue
P07639106A0678|71 76|height
P07639106A0678|61 66|weight
P07639106A0678|93 95|fit
P07639106A0678|104 112|body TBBMC
P07639106A0678|38 40|fit
P07639106A0678|10 12|age
P07639106A0678|44 48|TBBMD
P07639106A0678|16 21|weight
P07639106A0678|1 5|model
P07639106A0678|57 59|age
P07639703A1703|142 165|islet cell differentiation
P07639703A1703|10 13|acid
P07639703A1703|107 113|element
P07639703A1703|77 85|processes
P07639703A1703|133 139|process
P07639703A1703|17 30|thyroid hormone
P07640309A0000|134 149|splice mechanisms
P07640309A0000|173 174|X.
P07640309A0000|13 28|peptide sequences
P07640309A0000|62 74|mobility group
P07640309A0000|81 107|box transcription factor TCF-1
P07640309A0000|162 166|exons
P07640309A0000|76 78|HMG
P07640422A0649|0 12|Thromboxane B2
P07640422A0649|114 125|hemodialysis
P07640422A0649|145 152|Wilcoxon
P07640422A0649|81 87|heparin
P07640422A0649|92 103|hemodialysis
P07640422A0649|138 138|p
P07640422A0649|44 48|pg/ml
P07640422A0649|160 164|pairs
P07640422A0649|175 178|test
P07640422A0649|130 136|heparin
P07642490A0318|46 53|analysis
P07642490A0318|11 17|pHBK280
P07642490A0318|4 9|vector
P07642538A0138|57 60|RSK3
P07642538A0138|49 55|RSK cDNA
P07642538A0138|333 337|N-Ser
P07642538A0138|211 217|N/C-Lys
P07642538A0138|125 128|K91A
P07642538A0138|23 35|RSK activation
P07642538A0138|327 331|S218A
P07642538A0138|114 123|RSK mutants
P07642538A0138|167 171|K444A
P07642538A0138|12 20|mechanism
P07642538A0138|308 311|VIII
P07642538A0138|159 164|mutant
P07642538A0138|339 344|mutant
P07642538A0138|130 134|N-Lys
P07642538A0138|255 260|mutant
P07642538A0138|375 381|residue
P07642538A0138|243 247|T570A
P07642538A0138|274 296|MAPK phosphorylation site
P07642538A0138|249 253|C-Thr
P07642538A0138|317 324|C-domain
P07642538A0138|173 177|C-Lys
P07642538A0138|203 208|mutant
P07642538A0138|236 241|mutant
P07642538A0744|40 45|levels
P07642538A0744|23 27|C-Thr
P07642538A0744|48 61|kinase activity
P07642538A0744|90 100|stimulation
P07642538A0744|2 9|contrast
P07642538A0744|15 19|C-Lys
P07642544A0868|43 53|phosphatase
P07642544A0868|106 109|loss
P07642544A0868|83 99|phenylarsine oxide
P07642544A0868|11 19|treatment
P07642544A0868|127 143|NF-kappa B activity
P07642544A0868|74 78|cells
P07642633T0000|150 154|TEF-1
P07642633T0000|81 84|cell
P07642633T0000|10 17|promoter
P07642633T0000|53 72|transcription factors
P07642633T0000|113 116|gene
P07642633T0000|98 107|regulation
P07642633T0000|120 148|transcription enhancer factor-1
P07642633T0000|28 39|binding sites
P07644127A0000|28 35|neurones
P07644127A0000|79 84|fibres
P07644127A0000|182 183|SI
P07644127A0000|211 219|carbachol
P07644127A0000|54 63|cell bodies
P07644127A0000|273 281|glutamate
P07644127A0000|15 25|stimulation
P07644127A0000|158 180|rat substantia innominata
P07644127A0000|224 230|effects
P07644127A0000|90 94|study
P07644127A0000|142 152|stimulation
P07644127A0000|195 208|microinjection
P07644127A0000|237 256|acetylcholine agonist
P07644466A0578|156 166|translation
P07644466A0578|36 52|NS3-4A polyprotein
P07644466A0578|121 132|NS4A cofactor
P07644466A0578|110 112|NS3
P07644466A0578|23 27|assay
P07644466A0578|61 82|serine proteinase domain
P07644466A0578|209 218|substrates
P07644466A0578|179 194|trans-processing
P07644466A0578|54 56|NS3
P07644466A0578|100 107|residues
P07644503A0729|117 127|target genes
P07644503A0729|11 25|over-expression
P07644503A0729|91 98|RAR gamma
P07644503A0729|105 114|activation
P07644503A0729|53 67|differentiation
P07644503A0729|2 9|contrast
P07644503A0729|28 34|RAR beta
P07646439A0535|14 21|proteins
P07646439A0535|91 118|mAb F11 affinity chromatography
P07646439A0535|67 80|chromatography
P07646439A0535|31 47|platelet membranes
P07647303T0000|70 77|seedling
P07647303T0000|56 64|shoot apex
P07647303T0000|21 39|Arabidopsis thaliana
P07647303T0000|119 124|plants
P07647303T0000|93 105|inflorescence
P07647303T0000|3 18|homeobox gene ATK1
P07647303T0000|83 89|flowers
P07647570A0713|13 23|explanation
P07647570A0713|88 93|cortex
P07647570A0713|37 40|gold
P07647570A0713|102 106|cells
P07647570A0713|124 133|deiodinase
P07647570A0713|119 122|Type
P07647570A0713|68 79|Kupffer cells
P07648338A0815|102 112|TNF response
P07648338A0815|127 143|SMA occlusion model
P07648338A0815|163 172|laparotomy
P07648338A0815|32 37|models
P07648338A0815|50 57|ischemia
P07648338A0815|71 86|cytokine profiles
P07648338A0815|5 11|results
P07649098A0676|240 241|nt
P07649098A0676|102 103|nt
P07649098A0676|302 315|cotransfection
P07649098A0676|162 179|reporter expression
P07649098A0676|366 372|plasmid
P07649098A0676|570 576|subunit
P07649098A0676|454 456|PKA
P07649098A0676|252 255|exon
P07649098A0676|619 636|reporter expression
P07649098A0676|107 114|promoter
P07649098A0676|411 417|subunit
P07649098A0676|52 72|transfection construct
P07649098A0676|519 532|cotransfection
P07649098A0676|538 544|plasmid
P07649098A0676|230 237|presence
P07649098A0676|384 396|alpha-isoform
P07649098A0676|201 218|reporter expression
P07649098A0676|440 452|protein kinase
P07649098A0676|498 510|PGE2 treatment
P07649098A0676|36 47|observations
P07649098A0676|318 360|IGF-I promoter-luciferase-reporter constructs
P07649098A0676|90 100|nucleotides
P07649098A0676|579 581|PKA
P07649098A0676|276 282|context
P07649098A0676|132 134|UTR
P07649098A0676|596 599|cAMP
P07649098A0676|285 297|IGF-I promoter
P07649098A0676|466 472|results
P07649098A0676|122 123|nt
P07649098A0676|3 10|evidence
P07650958A0123|119 128|indicators
P07650958A0123|45 60|electromyography
P07650958A0123|76 91|motor improvement
P07650958A0123|3 9|changes
P07650958A0123|15 23|treatment
P07651131A1407|117 123|targets
P07651131A1407|63 81|kDa repressor isoform
P07651131A1407|127 133|binding
P07651131A1407|25 47|footprinting experiments
P07651131A1407|10 15|assays
P07651131A1407|140 146|protein
P07651131A1407|95 98|CIRs
P07651131A1407|19 23|DNase
P07651141A0265|44 54|nucleotides
P07651141A0265|65 70|p-gvpF
P07651141A0265|77 82|p-gvpE
P07651141A0265|6 13|terminus
P07651141A0265|19 30|p-gvpF-M mRNA
P07651340A0286|0 15|Retransformation
P07651340A0286|112 113|UV
P07651340A0286|95 105|restoration
P07651340A0286|141 146|levels
P07651340A0286|72 84|transformants
P07651340A0286|45 51|cosmids
P07651340A0286|18 30|uvsH77 mutants
P07651340A0286|117 129|MMS resistance
P07651386A0925|30 41|p53 induction
P07651386A0925|69 78|adenovirus
P07651386A0925|16 22|element
P07651386A0925|88 95|promoter
P07651398A0257|58 67|Drosophila
P07651398A0257|105 107|DER
P07651398A0257|11 21|dShc protein
P07651398A0257|139 146|tyrosine
P07651398A0257|77 103|growth factor receptor homolog
P07651398A0257|149 151|DER
P07651398A0257|2 6|flies
P07651398A0803|27 39|dShc PTB domain
P07651398A0803|61 63|DER
P07651398A0803|10 20|binding site
P07651398A0803|51 58|Tyr-1228
P07651398T0000|14 24|gene product
P07651398T0000|39 47|signaling
P07651398T0000|53 77|DER receptor tyrosine kinase
P07651400A0335|58 67|splice site
P07651400A0335|110 126|consensus sequence
P07651400A0335|4 13|inhibition
P07651400A0335|46 49|exon
P07651424A0487|28 32|Ssm1p
P07651424A0487|90 96|subunit
P07651424A0487|62 65|part
P07651424A0487|118 121|pool
P07651424A0487|11 18|analysis
P07651424A0487|46 52|protein
P07651424A0487|128 135|proteins
P07651424A0743|60 75|SSM1a transcripts
P07651424A0743|115 122|majority
P07651424A0743|128 136|Ssm1p pool
P07651424A0743|53 57|level
P07651424A0743|11 15|cells
P07651424A0743|91 95|SSM1b
P07651424A0743|17 32|SSM1b transcripts
P07651734A0961|0 19|Northern blot analysis
P07651734A0961|94 103|LIMK-2 mRNA
P07651734A0961|125 127|rat
P07651734A0961|113 119|tissues
P07651734A0961|31 40|expression
P07651734A0961|82 91|expression
P07651734A0961|71 75|brain
P07651734A0961|43 52|LIMK-1 mRNA
P07651835A0652|19 33|binding affinity
P07651835A0652|40 45|motifs
P07652066A0677|218 222|scars
P07652066A0677|48 56|procedure
P07652066A0677|191 194|risk
P07652066A0677|24 30|concept
P07652066A0677|117 122|fascia
P07652066A0677|170 178|incisions
P07652066A0677|5 9|basis
P07652066A0677|207 215|migration
P07652066A0677|97 103|arm flap
P07652066A0677|83 91|anchoring
P07652066A0677|235 242|contours
P07652066A0677|156 167|system repair
P07652575A0435|44 48|forms
P07652575A0435|12 25|microinjection
P07652575A0435|51 53|Rac
P07652575A0435|114 125|DNA synthesis
P07652575A0435|69 93|Rho inhibitor C3 transferase
P07652575A0435|57 61|Cdc42
P07652582A0000|0 15|INF-alpha therapy
P07652582A0000|56 58|CML
P07652582A0000|45 53|treatment
P07652582A0000|29 39|development
P07653094A0169|84 93|processing
P07653094A0169|22 36|deletion mutants
P07653094A0169|50 52|d31
P07653094A0169|240 248|HeLa cells
P07653094A0169|65 67|d73
P07653094A0169|9 13|amino
P07653094A0169|38 40|d10
P07653094A0169|42 44|d20
P07653094A0169|214 229|pcDL-SR alpha-296
P07653094A0169|189 193|genes
P07653094A0169|46 48|d27
P07653094A0169|95 115|cell surface expression
P07653094A0169|171 180|expression
P07653094A0169|148 157|attributes
P07653094A0169|54 56|d40
P07653094A0169|120 130|maintenance
P07653094A0169|58 60|d44
P07653094A0169|200 212|plasmid vector
P07653094A0169|1 6|series
P07653094A0169|233 236|CV-1
P07653812T0000|89 97|clonidine
P07653812T0000|11 40|acetyl cholinesterase inhibitors
P07653812T0000|78 85|morphine
P07653812T0000|48 56|analgesia
P07653812T0000|100 103|rats
P07653892A0306|118 118|n
P07653892A0306|31 40|triplicate
P07653892A0306|66 72|agonist
P07653892A0306|110 116|U50488H
P07653892A0306|102 108|agonist
P07653892A0306|16 28|isoflurane MAC
P07653892A0306|83 83|n
P07653892A0306|42 46|birds
P07653892A0306|74 81|morphine
P07654239A0698|43 47|level
P07654239A0698|54 73|cell cycle progression
P07654239A0698|0 2|Max
P07654712A0774|145 146|pH
P07654712A0774|3 13|yeast enzyme
P07654712A0774|45 51|enzymes
P07654712A0774|122 129|analysis
P07654712A0774|134 141|degrees C
P07654740A0563|13 28|selection process
P07654740A0563|194 210|disease etiologies
P07654740A0563|131 147|inclusion criteria
P07654740A0563|70 84|transplantation
P07654740A0563|246 262|contraindications
P07654740A0563|214 227|co-morbidities
P07654740A0563|105 121|transplant work-up
P07654740A0563|176 182|factors
P07654740A0563|56 67|alternatives
P07654740A0563|89 99|composition
P07654740A0563|0 7|Key areas
P07655184A0852|44 63|transmembrane protein
P07655184A0852|79 94|ER leader sequence
P07655184A0852|128 134|protein
P07655184A0852|147 156|ER sequence
P07655184A0852|3 11|transport
P07655505A0527|158 164|pattern
P07655505A0527|108 118|development
P07655505A0527|167 192|phytochrome A gene expression
P07655505A0527|92 97|stages
P07655505A0527|21 31|GT-2 protein
P07655505A0527|135 138|role
P07655505A0527|6 11|shoots
P07655505A0527|60 65|tissue
P07655505A0527|15 19|roots
P07655509T0000|103 114|Pisum sativum
P07655509T0000|21 32|motif signals
P07655509T0000|40 48|targeting
P07655509T0000|99 101|pea
P07655509T0000|71 78|proteins
P07656588A0101|197 203|D19S412
P07656588A0101|161 164|FUT1
P07656588A0101|106 109|FUT1
P07656588A0101|222 223|cM
P07656588A0101|205 212|lod score
P07656588A0101|128 134|cluster
P07656588A0101|242 249|lod score
P07656588A0101|187 188|cM
P07656588A0101|75 76|kb
P07656588A0101|98 103|region
P07656588A0101|11 29|DNA sequence analysis
P07656588A0101|39 67|Genethon microsatellite D19S596
P07656588A0101|234 240|D19S571
P07656588A0101|168 176|FUT2 genes
P07657162A1412|73 79|process
P07657162A1412|39 43|LEF-1
P07657162A1412|127 134|addition
P07657162A1412|103 124|trans-activation domain
P07657162A1412|140 148|HMG domain
P07657162A1412|14 36|transcription activation
P07657668A0642|0 12|TH-SH3 binding
P07657668A0642|48 69|amino acid substitutions
P07657668A0642|79 89|Btk TH domain
P07657668A0642|95 106|Fyn SH3 domain
P07657705A1181|5 11|results
P07657705A1181|77 87|development
P07657705A1181|24 33|K-glypican
P07657705A1181|54 57|HSPG
P07658262A0944|115 124|correction
P07658262A0944|79 87|infusions
P07658262A0944|101 106|plasma
P07658262A0944|50 58|admission
P07658262A0944|160 166|factors
P07658262A0944|44 47|time
P07658262A0944|132 143|procoagulant
P07658262A0944|0 13|Protein S levels
P07658471A0000|3 19|plant hormone auxin
P07658471A0000|51 55|genes
P07658777A0400|28 35|patients
P07658777A0400|3 6|test
P07658777A0400|45 61|contraindications
P07659085A1520|116 129|kidney extracts
P07659085A1520|13 50|transcription factor Oct-1 forms complexes
P07659085A1520|82 85|FPIV
P07659085A1520|179 196|androgen regulation
P07659085A1520|166 176|partnership
P07659085A1520|154 162|candidate
P07659085A1520|108 112|liver
P07659085A1520|137 141|Oct-1
P07659085A1520|57 68|octamer motif
P07659085A1520|88 103|gel shift analysis
P07659515T0000|74 81|elements
P07659515T0000|11 25|retrotransposon
P07659515T0000|84 117|Crithidia fasciculata miniexon arrays
P07659515T0000|34 41|evidence
P07659529A0135|47 68|reporter gene constructs
P07659529A0135|25 42|transfection assays
P07659529A0135|81 108|transcription control elements
P07659529A0135|140 147|EpoR gene
P07659529A0135|124 129|region
P07659529A0135|6 21|deletion analysis
P07659746A1464|87 92|ovules
P07659746A1464|104 117|d post-anthesis
P07659746A1464|3 30|CVA16.4 proteolipid transcript
P07659746A1464|57 75|proteolipid messages
P07659757A0191|0 9|Incubation
P07659757A0191|66 70|assay
P07659757A0191|23 36|fusion proteins
P07659757A0191|52 54|ATP
P07659757A0191|106 124|autophosphorylation
P07659757A0191|85 92|proteins
P07659757A0191|42 50|gamma-32P
P07660712A0118|28 35|response
P07660712A0118|100 106|respect
P07660712A0118|87 95|risk group
P07660712A0118|65 70|adults
P07660712A0118|109 111|VHB
P07660712A0118|50 57|children
P07660712A0118|3 11|character
P07663138A0835|56 58|PBF
P07663138A0835|50 52|PBV
P07663138A0835|13 21|heart rate
P07663138A0835|39 39|%
P07663138A0835|5 11|nadolol
P07663160A0287|101 109|avoidance
P07663160A0287|12 22|DNA sequence
P07663160A0287|149 158|codon usage
P07663160A0287|97 99|RNA
P07663160A0287|209 219|preferences
P07663160A0287|129 137|structure
P07663160A0287|172 188|protein expression
P07663160A0287|85 87|16S
P07663160A0287|55 65|base pairing
P07663160A0287|191 196|accord
P07663963A1588|179 192|control animals
P07663963A1588|10 25|system activation
P07663963A1588|117 121|month
P07663963A1588|93 97|males
P07663963A1588|81 84|time
P07663963A1588|155 160|levels
P07663963A1588|38 66|metanephrine/epinephrine ratio
P07663963A1588|124 135|cohabitation
P07663963A1588|137 144|turnover
P07663998T0000|22 25|type
P07663998T0000|14 19|repair
P07663998T0000|51 59|aneurysms
P07664278A0135|0 1|A.
P07665172A0000|0 19|Transcription factors
P07665172A0000|109 114|number
P07665172A0000|101 105|genes
P07665172A0000|58 62|motif
P07665172A0000|135 141|systems
P07665172A0000|74 83|expression
P07665187A0208|0 14|Primer extension
P07665187A0208|67 76|Nramp1 mRNA
P07665187A0208|18 28|cDNA cloning
P07665187A0208|59 61|end
P07665187A0824|0 14|Primer extension
P07665187A0824|114 121|presence
P07665187A0824|94 99|Nramp1
P07665187A0824|65 91|transcription initiation site
P07665187A0824|147 161|initiation sites
P07665187A0824|18 45|S1 nuclease mapping experiments
P07665477A0901|0 3|EsaR
P07665477A0901|20 29|expression
P07665477A0901|54 63|expression
P07665477A0901|66 69|esaI
P07665567A0495|0 15|Sequence analysis
P07665567A0495|216 224|NF-kappa B
P07665567A0495|95 103|base pairs
P07665567A0495|283 286|gene
P07665567A0495|122 148|transcription initiation site
P07665567A0495|226 230|Egr-1
P07665567A0495|195 214|transcription factors
P07665567A0495|167 182|binding sequences
P07665567A0495|62 69|presence
P07665567A0495|43 50|CD69 gene
P07665567A0495|32 37|region
P07665567A0495|267 276|expression
P07665567A0495|82 92|TATA element
P07665567A0495|232 235|AP-1
P07665605A1127|18 18|D
P07665605A1127|80 87|DD dimers
P07665605A1127|41 47|product
P07665633A0284|44 56|disk diffusion
P07665633A0284|125 143|Laboratory Standards
P07665633A0284|11 18|isolates
P07665633A0284|97 113|National Committee
P07665633A0284|60 81|agar dilution procedures
P07665948A0591|43 53|individuals
P07665948A0591|57 65|IgE levels
P07665948A0591|78 91|children groups
P07665948A0591|21 26|values
P07665948A0591|130 138|infection
P07665948A0591|119 127|intensity
P07665948A0591|98 103|adults
P07665948A0591|0 8|IgE levels
P07666414A0614|30 38|tmy-1 gene
P07666414A0614|54 67|microinjection
P07666414A0614|71 93|promoter/lacZ fusion gene
P07666414A0614|160 176|anti-tropomyosins
P07666414A0614|15 24|expression
P07666414A0614|101 120|immunohistochemistry
P07666415A0000|41 43|DNA
P07666415A0000|26 36|chloroplast
P07666415A0000|48 52|maize
P07666415A0000|38 39|cp
P07666415A0000|3 20|nucleotide sequence
P07666415A0000|54 60|Zea mays
P07666523T0000|0 12|Investigation
P07666523T0000|18 24|control
P07666523T0000|98 111|RNA transcripts
P07666523T0000|48 64|mRNA transcription
P07666523T0000|27 37|coronavirus
P07666538A0000|0 9|Initiation
P07666538A0000|109 114|region
P07666538A0000|53 61|RNA genome
P07666538A0000|140 145|manner
P07666538A0000|12 22|translation
P07666538A0000|78 90|ribosome entry
P07666538A0000|49 51|HCV
P07666538A0000|33 47|hepatitis C virus
P07666538A0000|118 120|NCR
P07666966A0207|0 3|Mean
P07666966A0207|38 43|lesion
P07666966A0207|16 24|extension
P07666966A0207|59 66|segments
P07667097A0267|57 63|finding
P07667097A0267|138 153|splicing products
P07667097A0267|91 98|splicing
P07667097A0267|102 118|immunoprecipitate
P07667097A0267|24 40|splicing complexes
P07667097A0267|68 73|mAb CC3
P07667097A0267|3 13|association
P07667097A0267|132 134|RNA
P07667097A0267|16 19|p255
P07667195A0146|0 4|L-735
P07667195A0146|64 71|solution
P07667195A0146|13 16|base
P07667195A0146|105 114|Beagle dogs
P07667195A0146|53 62|suspension
P07667195A0146|19 29|sulfate salt
P07667195A0146|81 91|dosage forms
P07667621T0001|0 23|Doppler ultrasound studies
P07667621T0001|35 43|follow-up
P07667621T0001|46 53|children
P07667621T0001|74 81|syndrome
P07668009A0172|24 41|hepatitis A diseases
P07668009A0172|12 21|cumlations
P07669351A1278|3 12|properties
P07669351A1278|23 38|SSB-ssDNA complex
P07669351A1278|18 20|phi
P07670504A0834|117 128|binding assay
P07670504A0834|41 54|banding pattern
P07670504A0834|95 99|G-box
P07670504A0834|152 154|GBF
P07670504A0834|57 61|plant
P07670504A0834|69 76|proteins
P07670943A0308|27 34|patients
P07670943A0308|12 15|male
P07670943A0308|130 132|CAD
P07670943A0308|85 92|families
P07670943A0308|115 121|sibling
P07670943A0308|44 46|CAD
P07672821A0763|131 138|proteins
P07672821A0763|33 44|factor H genes
P07672821A0763|23 26|FHR2
P07672821A0763|11 17|linkage
P07672821A0763|80 90|relatedness
P07672821A0763|63 70|evidence
P07672821A0763|93 109|complement factor H
P07672821A0763|116 121|factor
P07672822T0000|30 37|location
P07672822T0000|7 15|structure
P07672822T0000|58 74|receptor alpha gene
P07672822T0000|43 47|mouse
P07673128A0989|28 46|cAMP response element
P07673128A0989|8 13|domain
P07673128A0989|20 24|motif
P07673128A0989|48 50|CRE
P07673154A0688|100 107|3Y1 cells
P07673154A0688|26 30|state
P07673154A0688|33 39|CAK beta
P07673154A0688|112 122|fibronectin
P07673154A0688|83 90|response
P07673154A0688|55 68|trypsinization
P07673178A0982|132 147|MCK-L type E-boxes
P07673178A0982|102 123|MDF/bH-L-H heterodimers
P07673178A0982|92 99|spectrum
P07673178A0982|182 188|factors
P07673178A0982|30 46|muscle gene E-boxes
P07673178A0982|3 9|results
P07674649A0508|70 91|treatment effectiveness
P07674649A0508|36 49|baseline design
P07674649A0508|24 27|ABAB
P07675445A0463|70 95|sequence length polymorphism
P07675445A0463|51 52|CA
P07675445A0463|49 49|p
P07675445A0463|5 10|clones
P07675445A0463|34 39|domain
P07675445A0463|54 61|n repeats
P07675445A0463|97 100|SSLP
P07675449A0848|72 76|PDGFR
P07675449A0848|5 24|glioblastoma cell line
P07675449A0848|41 44|p190
P07676492A1000|29 35|reports
P07676492A1000|112 114|IHD
P07676492A1000|45 51|regions
P07676492A1000|70 89|transplant recipients
P07676492A1000|17 26|comparison
P07676492A1000|99 102|risk
P07676587T0000|10 22|certification
P07676587T0000|26 40|livestock export
P07676655A0214|3 20|serum concentration
P07676655A0214|23 24|iP
P07676655A0214|40 41|HD
P07676655A0214|77 77|D
P07676655A0214|103 106|mmol
P07676655A0214|31 38|dialysis
P07676655A0214|68 73|mmol/l
P07677573A0000|118 123|mucosa
P07677573A0000|49 58|parameters
P07677573A0000|68 76|secretion
P07677573A0000|12 22|correlation
P07677573A0000|78 86|incretion
P07677573A0000|31 36|number
P07677573A0000|153 161|gastritis
P07677573A0000|134 141|patients
P07677573A0000|102 108|changes
P07677715A1076|3 11|TAF factor
P07677715A1076|48 50|OCD
P07677836A1356|131 137|absence
P07677836A1356|12 23|matter injury
P07677836A1356|79 86|deficits
P07677836A1356|91 109|leukoencephalopathy
P07677836A1356|140 151|chemotherapy
P07677836A1356|41 49|radiation
P07678006A0472|0 22|RNase protection analyses
P07678006A0472|106 119|CaM PDE isoforms
P07678006A0472|78 88|transcripts
P07678006A0472|47 56|CaM PDE mRNA
P07678006A0472|150 155|manner
P07678006A0901|43 48|cortex
P07678006A0901|110 112|RNA
P07678006A0901|93 104|T-lymphocyte
P07678006A0901|10 19|protection
P07678006A0901|57 63|medulla
P07678006A0901|65 69|liver
P07678006A0901|71 82|kidney cortex
P07678006A0901|84 89|spleen
P07678051A1303|85 94|production
P07678051A1303|3 14|PDGFR mutants
P07678051A1303|40 47|PLC gamma
P07678051A1303|97 114|inositol phosphates
P07678242A0473|14 24|correlation
P07678242A0473|75 78|rate
P07678242A0473|89 94|growth
P07678242A0473|61 68|acc genes
P07678242A0473|35 40|levels
P07678242A0473|43 55|transcription
P07678593A0708|44 46|DNA
P07678593A0708|21 32|V. vulnificus
P07678593A0708|60 78|V. cholerae fur mutant
P07678593A0708|14 18|clone
P07678602A0153|134 140|parents
P07678602A0153|114 120|disease
P07678602A0153|64 71|patients
P07678602A0153|22 42|B lymphoblast cell lines
P07678602A0153|47 54|controls
P07678695A0604|60 67|promoter
P07678695A0604|129 136|promoter
P07678695A0604|22 26|Oct-3
P07678695A0604|10 19|expression
P07678695A0604|31 41|hybrid cells
P07678695A0604|98 107|activation
P07679390A0721|86 97|DDT1 aFGF mRNA
P07679390A0721|67 70|exon
P07679390A0721|151 152|bp
P07679390A0721|111 132|transcription start site
P07679390A0721|18 38|primer extension assays
P07679390A0721|178 191|splice junction
P07679390A0721|198 201|exon
P07679390A0721|0 14|RNase protection
P07679836A0387|54 58|agent
P07679836A0387|61 81|kidney transplantation
P07679836A0387|23 24|FK
P07679836A0387|5 11|results
P07680035A0221|3 7|roles
P07680035A0221|49 60|GnRH response
P07680035A0221|10 22|phorbol esters
P07680035A0221|32 34|AMP
P07680120A1008|0 5|RT-PCR
P07680120A1008|77 81|D mRNA
P07680120A1008|23 29|primers
P07680120A1008|124 129|source
P07680120A1008|40 45|kidney
P07680120A1008|101 105|brain
P07680120A1008|133 143|aFGF protein
P07680120A1008|92 97|kidney
P07680120A1008|47 51|brain
P07680120A1008|55 62|prostate
P07680629T0000|102 111|cell fusion
P07680629T0000|53 57|gp138
P07680629T0000|114 136|Dictyostelium discoideum
P07680629T0000|9 15|cloning
P07680629T0000|40 44|genes
P07680629T0000|19 34|characterization
P07680629T0000|60 82|cell surface glycoprotein
P07681147A1420|119 125|ability
P07681147A1420|95 99|cells
P07681147A1420|66 71|Ser-12
P07681147A1420|29 36|analyses
P07681147A1420|49 63|phosphorylation
P07681147A1420|141 149|pp60c-src
P07681147A1420|177 186|signalling
P07681147A1420|75 80|Ser-48
P07681513A0000|0 9|Piroximone
P07681513A0000|36 44|inhibitor
P07681513A0000|16 32|phosphodiesterase
P07681513A0000|69 89|vasodilator properties
P07681539A0000|101 103|mSv
P07681539A0000|11 17|studies
P07681539A0000|33 43|lymphocytes
P07681539A0000|82 90|radiation
P07681539A0000|48 62|hospital workers
P07681539A0000|75 79|doses
P07682842A0294|143 152|copy number
P07682842A0294|75 87|receptor genes
P07682842A0294|10 15|origin
P07682842A0294|107 126|fMLF-R gene expression
P07682842A0294|211 218|sequence
P07682842A0294|184 195|organization
P07682842A0294|165 172|location
P07682842A0294|95 104|regulation
P07682842A0294|229 238|fMLF-R gene
P07682842A0294|55 61|linkage
P07682842A0294|27 43|fMLF-R transcripts
P07682842A0771|57 60|exon
P07682842A0771|21 22|bp
P07682842A0771|43 50|sequence
P07682842A0771|8 11|exon
P07682842A0771|96 104|sequences
P07682842A0771|72 77|coding
P07683131A0885|121 126|family
P07683131A0885|25 31|members
P07683131A0885|10 18|structure
P07683131A0885|37 46|SRC-family
P07683131A0885|109 114|domain
P07683131A0885|70 90|exon/intron boundaries
P07683375A0000|28 40|growth factors
P07683375A0000|66 67|E2
P07683375A0000|19 25|effects
P07683375A0000|44 47|cAMP
P07683375A0000|119 134|estrogen receptor
P07683375A0000|252 253|ER
P07683375A0000|99 103|genes
P07683375A0000|239 246|activity
P07683375A0000|156 162|studies
P07683375A0000|71 80|regulation
P07683375A0000|187 196|activators
P07683375A0000|83 92|expression
P07683375A0000|136 137|ER
P07683375A0000|199 212|protein kinases
P07683375A0000|56 64|estradiol
P07685263A0503|48 59|DNA fragments
P07685263A0503|65 73|base pairs
P07685263A0503|8 30|polymerase chain reaction
P07685263A0503|92 107|Whipple bacterium
P07685263A0503|81 86|genome
P07685263A0503|109 127|Tropheryma whippelii
P07685823A1234|0 12|RNA polymerase
P07685823A1234|76 80|DNase
P07685823A1234|104 112|start site
P07685823A1234|26 34|A promoter
P07685823A1234|55 71|base-pair sequence
P07685823A1234|82 90|digestion
P07685874A0258|15 21|calcium
P07685874A0258|8 13|sodium
P07685874A0258|77 87|SLE patients
P07685874A0258|143 163|protein concentrations
P07685874A0258|26 48|magnesium concentrations
P07685874A0258|214 221|controls
P07685874A0258|126 134|potassium
P07685874A0258|167 181|amylase activity
P07685874A0258|100 117|lupus erythematosus
P07686619A0704|0 3|Chem
P07687320A0526|89 91|ge6
P07687320A0526|52 58|ability
P07687320A0526|11 23|plasmid pFV100
P07687320A0526|61 86|complement B-band expression
P07687541A0200|175 183|degrees C.
P07687541A0200|120 134|mtr1/prp20/srm1
P07687541A0200|70 77|mutation
P07687541A0200|91 94|gene
P07687541A0200|168 170|RNA
P07687541A0200|165 165|A
P07687541A0200|136 142|mutants
P07687541A0200|43 54|fission yeast
P07687541A0200|160 163|poly
P07687541A0992|113 116|CNR1
P07687541A0992|5 9|RCC1p
P07687541A0992|120 123|CNR2
P07687541A0992|23 25|Ran
P07687541A0992|85 92|homologs
P07687541A0992|51 64|ras superfamily
P07687541A0992|16 19|GNRP
P07687541A0992|95 97|Ran
P07687541A0992|40 45|GTPase
P07687745T0000|33 47|amino acid import
P07687745T0000|20 24|FK506
P07688112A0274|0 7|Prostate
P07688112A0274|41 45|cases
P07688112A0274|53 62|correction
P07688112A0274|84 98|acid phosphatase
P07688112A0274|16 22|antigen
P07689154A0168|0 21|Protein phosphorylation
P07689154A0168|50 66|uPA gene expression
P07689154A0168|80 92|protein kinase
P07689154A0168|260 272|uPA mRNA levels
P07689154A0168|105 117|phorbol esters
P07689154A0168|74 78|cells
P07689154A0168|190 193|cAMP
P07689154A0168|186 188|AMP
P07689154A0168|165 171|uPA mRNA
P07689154A0168|229 234|agents
P07689154A0168|44 47|role
P07689154A0168|131 139|pp60v-src
P07689154A0168|248 251|cAMP
P07689154A0168|205 211|protein
P07689501A0420|7 14|carriers
P07691837A1359|157 177|NFkB consensus sequence
P07691837A1359|91 98|promoter
P07691837A1359|193 197|GC box
P07691837A1359|141 146|motifs
P07691837A1359|7 8|bp
P07691837A1359|111 118|clusters
P07691837A1359|20 27|sequence
P07691837A1359|30 42|K3 keratin gene
P07691885T0000|0 13|Identification
P07691885T0000|137 148|c-kit product
P07691885T0000|76 99|mast cell leukemia cell line
P07691885T0000|49 67|proto-oncogene c-kit
P07691885T0000|125 134|activation
P07691885T0000|36 43|sequence
P07691885T0000|16 24|mutations
P07692366A0000|0 9|BACKGROUND
P07692366A0000|11 21|Delineation
P07692366A0000|78 81|ARMD
P07692366A0000|65 76|degeneration
P07692366A0000|38 44|aspects
P07692366A0000|94 104|correlation
P07692366A0000|120 127|features
P07692366A0000|162 173|pathogenesis
P07692668A0326|216 226|arrangement
P07692668A0326|42 44|RNA
P07692668A0326|183 203|transcription strategy
P07692668A0326|229 232|ORFs
P07692668A0326|85 88|RNAs
P07692668A0326|109 110|kb
P07692668A0326|139 155|blot hybridization
P07692754T0000|0 10|Risk factors
P07692754T0000|80 90|blood donors
P07692754T0000|30 43|seroprevalence
P07692754T0000|46 69|hepatitis C virus infection
P07693132A0100|49 57|Zm-ERabp4
P07693132A0100|39 47|Zm-ERabp1
P07693132A0100|26 33|analysis
P07693132A0100|62 75|Zm-ERabp5 genes
P07693132A0100|7 13|cloning
P07693372A0115|60 68|mechanism
P07693372A0115|92 103|cyclosporine
P07693372A0115|25 30|fungus
P07693372A0115|71 76|action
P07693372A0115|4 8|agent
P07693672A0259|0 4|DNase
P07693672A0259|6 17|footprinting
P07693672A0259|51 57|regions
P07693672A0259|31 38|promoter
P07693672A0259|60 69|protection
P07693699A0831|100 103|urea
P07693699A0831|87 97|sensitivity
P07693699A0831|25 49|nucleotide binding function
P07693699A0831|11 19|stability
P07693699A0831|58 65|proteins
P07693708A0000|32 40|protein-2
P07693708A0000|66 73|rat liver
P07693708A0000|12 17|growth
P07693708A0000|51 63|transcription
P07693708A0000|42 49|IGF-BP-2
P07693708A0000|97 99|age
P07693708A0000|103 109|fasting
P07693967A0905|3 10|presence
P07693967A0905|63 73|translation
P07693967A0905|23 32|SL sequence
P07693967A0905|55 60|effect
P07693967A0905|16 17|RV
P07693975A1418|14 21|proteins
P07693975A1418|93 94|PR
P07693975A1418|36 45|methionine
P07693975A1418|55 61|residue
P07693975A1418|82 90|N terminus
P07693975A1418|2 9|contrast
P07693975A1418|115 125|proteolysis
P07693975T0000|48 81|leukosis virus Gag-Pol fusion proteins
P07693975T0000|23 40|protease activities
P07693975T0000|7 19|transcriptase
P07693975T0000|99 103|cells
P07695629A0489|13 24|mck1 mds1 mrk1
P07695629A0489|31 40|disruptant
P07695629A0489|2 9|addition
P07696183A0567|86 88|Rak
P07696183A0567|280 299|membrane localization
P07696183A0567|307 309|Rak
P07696183A0567|74 83|expression
P07696183A0567|179 187|cell lines
P07696183A0567|423 428|p54rak
P07696183A0567|245 251|glycine
P07696183A0567|214 216|Rak
P07696183A0567|391 410|fractionation studies
P07696183A0567|454 460|nucleus
P07696183A0567|367 375|SH2 domain
P07696183A0567|161 165|liver
P07696183A0567|21 30|properties
P07696183A0567|125 133|cell lines
P07696183A0567|169 174|kidney
P07696183A0567|344 361|localization signal
P07696183A0567|63 69|kinases
P07696183A0567|190 195|breast
P07696183A0567|264 276|myristylation
P07696183A0567|137 143|tissues
P07696183A0567|33 35|Rak
P07696183A0567|199 209|colon origin
P07696450A0271|0 7|PATIENTS
P07696450A0271|217 221|weeks
P07696450A0271|161 174|Nestle-Clintec
P07696450A0271|182 192|Switzerland
P07696450A0271|49 56|children
P07696450A0271|156 159|Diet
P07696450A0271|30 39|experience
P07696450A0271|11 17|METHODS
P07696450A0271|72 81|bowel Crohn
P07696450A0271|129 136|TGF-beta
P07696450A0271|204 212|nutrition
P07696450A0271|84 90|disease
P07696450A0271|119 122|feed
P07696450A0271|176 180|Vevey
P07696878A0222|3 16|leader sequence
P07696878A0222|63 75|reading frames
P07696878A0222|144 161|homeodomain protein
P07696878A0222|89 103|initiation codon
P07696878A0222|30 38|cDNA clone
P07696878A0222|120 131|reading frame
P07697294A0329|14 24|HSP81-1 mRNA
P07697294A0329|6 11|amount
P07697294A0329|42 46|roots
P07698219A0551|0 11|Cell adhesion
P07698219A0551|124 130|PE cells
P07698219A0551|51 54|beta
P07698219A0551|66 80|laminin receptor
P07698219A0551|45 49|alpha
P07698219A0551|15 29|migration assays
P07698219A0551|99 105|F9 cells
P07698727A0386|27 35|infection
P07698727A0386|7 17|destruction
P07698727A0386|20 24|tumor
P07698727A0386|64 75|HIV infection
P07699632A0522|13 23|race persons
P07699632A0522|76 84|arthritis
P07699632A0522|27 40|Chukcha-Eskimo
P07699632A0522|86 88|PsA
P07699632A0715|116 126|populations
P07699632A0715|93 95|SPA
P07699632A0715|22 28|studies
P07699632A0715|3 16|data complement
P07699632A0715|80 90|prevalences
P07699632A0715|99 105|HLA-B27
P07699632A0715|42 52|populations
P07699845A0537|88 98|pharyngitis
P07699845A0537|127 144|lacunar tonsillitis
P07699845A0537|308 320|lymphadenitis
P07699845A0537|205 209|fever
P07699845A0537|216 233|impetigo contagiosa
P07699845A0537|362 366|doses
P07699845A0537|69 76|diseases
P07699845A0537|160 169|bronchitis
P07699845A0537|273 287|balanoposthitis
P07699845A0537|331 338|vulvitis
P07699845A0537|252 266|tract infections
P07699845A0537|183 191|pertussis
P07699845A0537|386 391|t.i.d.
P07699845A0537|400 403|days
P07699845A0537|347 353|colitis
P07699845A0537|322 329|S.S.S.S.
P07699845A0537|40 47|patients
P07699845A0537|110 120|tonsillitis
P07699845A0537|8 20|studies SY5555
P07699845A0537|171 179|pneumonia
P07699845A0537|380 384|mg/kg
P07700361A0125|56 60|types
P07700361A0125|63 71|molecules
P07700361A0125|112 115|type
P07700361A0125|20 31|interactions
P07701266A0808|0 6|RESULTS
P07701266A0808|8 18|Closure time
P07701266A0808|48 50|TPN
P07701266A0808|52 63|somatostatin
P07701266A0808|31 38|patients
P07701266A0808|21 28|fistulas
P07701266A0808|117 120|days
P07701266A0808|142 144|TPN
P07702327T0000|46 71|tissue plasminogen activator
P07702327T0000|12 30|adhesion prophylaxis
P07702378A0668|41 50|dermatitis
P07702378A0668|76 78|VO2
P07702378A0668|23 30|children
P07702378A0668|16 20|sleep
P07702752A0545|278 291|mouse cell lines
P07702752A0545|90 106|gene transcription
P07702752A0545|155 163|base pairs
P07702752A0545|322 337|Leydig MA-10 cells
P07702752A0545|30 47|rat P450c17 promoter
P07702752A0545|235 256|reporter gene luciferase
P07702752A0545|187 200|rat P450c17 gene
P07702752A0545|108 125|deletion constructs
P07702752A0545|177 179|DNA
P07702752A0545|300 307|Y-1 cells
P07702752A0545|16 24|sequences
P07702752A0545|214 221|plasmids
P07702808A0427|44 59|corn oil treatment
P07702808A0427|101 104|mm Hg
P07702808A0427|14 26|BP differences
P07702808A0427|34 40|fish oil
P07702808A0427|116 118|ABP
P07702808A0427|74 80|Dinamap
P07702808A0427|139 142|mm Hg
P07704040A0000|56 58|NAD
P07704040A0000|98 100|NAD
P07704040A0000|138 153|quinone reductase
P07704040A0000|107 121|quinone acceptor
P07704040A0000|184 185|EC
P07704040A0000|104 104|H
P07704040A0000|62 62|H
P07704040A0000|171 182|DT diaphorase
P07704040A0000|102 102|P
P07704040A0000|161 169|reductase
P07704040A0000|64 86|menadione oxidoreductase
P07704040A0000|60 60|P
P07704040A0000|123 136|oxidoreductase
P07704040A0000|27 39|mouse NMO1 cDNA
P07704273A0000|145 163|Citrobacter freundii
P07704273A0000|53 62|strain HfrH
P07704273A0000|25 50|ampD ampE deletion derivative
P07704273A0000|95 104|expression
P07704273A0000|125 142|beta-lactamase gene
P07704273A0000|174 186|plasmid pNU305
P07704273A0000|15 20|JRG582
P07704456A1014|5 13|mechanism
P07704456A1014|53 62|conditions
P07704456A1014|22 33|acceleration
P07704456A1014|126 136|HMS subjects
P07704456A1014|92 101|prevalence
P07704456A1014|108 117|conditions
P07704689T0000|8 20|thyroid nodule
P07704730T0000|29 34|future
P07704730T0000|4 16|contraception
P07704730T0000|18 22|ideas
P07705476A0292|86 96|urine volume
P07705476A0292|59 70|protein level
P07705476A0292|10 19|food intake
P07705476A0292|130 136|protein
P07705476A0292|72 82|water intake
P07705627A1107|43 52|components
P07705627A1107|19 23|Medea
P07705627A1107|63 73|dpp pathways
P07705627A1107|84 94|development
P07705627A1107|13 15|Mad
P07706273T0000|15 24|regulation
P07706273T0000|79 88|THP-1 cells
P07706273T0000|38 38|H
P07706273T0000|43 61|ATPase B2 subunit gene
P07706287A0698|85 89|phase
P07706287A0698|50 58|cytoplasm
P07706287A0698|38 44|nucleus
P07706287A0698|11 19|inability
P07706287A0698|28 30|RNA
P07706287A0698|95 111|cell division cycle
P07706291T0000|2 12|E box element
P07706291T0000|122 132|development
P07706291T0000|75 84|ftz-f1 gene
P07706291T0000|64 72|homologue
P07706291T0000|29 38|expression
P07706291T0000|44 52|ad4bp gene
P07706299A0563|148 155|features
P07706299A0563|124 129|detail
P07706299A0563|166 195|oligosaccharide-protein binding
P07706299A0563|87 95|compounds
P07706299A0563|0 15|Inhibition assays
P07706307A0914|82 83|S.
P07706307A0914|107 108|C.
P07706307A0914|25 31|protein
P07706307A0914|48 64|specificity pocket
P07706307A0914|102 102|B
P07706307A0914|37 42|region
P07706307A0914|91 99|proteases
P07706307A0914|3 19|amino acid sequence
P07706396T0000|14 22|VPS45 gene
P07706396T0000|79 90|accumulation
P07706396T0000|25 37|SEC1 homologue
P07706396T0000|69 75|defects
P07706396T0000|93 108|membrane vesicles
P07706396T0000|55 61|protein
P07706396T0000|0 8|Mutations
P07707523A0704|26 43|NF-kappa B inhibitor
P07707523A0704|11 20|expression
P07707523A0704|80 87|activity
P07707523A0704|90 92|LMP
P07707523A0704|5 9|cells
P07707523A0704|45 57|I kappa B-alpha
P07707531A0550|43 48|effect
P07707531A0550|104 108|alpha
P07707531A0550|110 126|gene transcription
P07707531A0550|76 86|binding site
P07707531A0550|51 62|displacement
P07707531A0550|68 72|alpha
P07707531A0550|92 101|repression
P07707531A0550|16 21|design
P07707531A0550|129 132|ICP4
P07707544T0000|61 76|characterization
P07707544T0000|97 107|transcripts
P07707544T0000|35 59|channel catfish virus genome
P07707544T0000|15 27|transcription
P07708058A0178|85 88|AP-1
P07708058A0178|8 17|nucleotide
P07708058A0178|90 94|motif
P07708058A0178|38 41|cGRE
P07708058A0178|101 114|c-jun homodimer
P07708058A0178|34 36|GRE
P07708058A0178|66 83|activator protein-1
P07708058A0178|118 139|c-jun/c-fos heterodimer
P07708058A0178|3 5|GRE
P07708488A0151|2 9|contrast
P07708488A0151|74 76|ref
P07708488A0151|55 69|sequence variant
P07708488A0151|16 22|results
P07708497A0000|75 84|T3 receptor
P07708497A0000|53 64|interactions
P07708497A0000|27 40|thyroid hormone
P07708497A0000|92 109|T3 response elements
P07708497A0000|42 43|T3
P07708497A0000|129 134|copies
P07708497A0000|155 160|AGGTCA
P07708497A0000|111 114|TREs
P07708497A0000|137 145|sequences
P07708497A0000|86 87|TR
P07708497A0000|15 24|activation
P07711667A0766|204 223|consolidation therapy
P07711667A0766|105 116|marrow blasts
P07711667A0766|284 292|isolation
P07711667A0766|259 280|GVHD prophylaxis regimen
P07711667A0766|52 54|age
P07711667A0766|37 43|relapse
P07711667A0766|296 310|decontamination
P07711667A0766|13 20|analysis
P07711667A0766|71 80|blast count
P07711667A0766|225 238|marrow cell dose
P07711667A0766|132 137|number
P07711667A0766|185 202|maintenance therapy
P07711667A0766|255 257|sex
P07711667A0766|23 33|risk factors
P07711667A0766|56 58|WBC
P07711667A0766|93 102|percentage
P07711667A0766|61 69|diagnosis
P07711667A0766|140 164|remission induction courses
P07711667A0766|83 91|diagnosis
P07711667A0766|320 331|airflow rooms
P07711667A0766|118 127|FAB subtype
P07711667A0766|175 183|remission
P07711730A0000|0 28|Carnitine palmitoyltransferase
P07711730A0000|36 45|deficiency
P07711730A0000|112 117|muscle
P07711730A0000|80 94|lipid metabolism
P07711730A0000|70 77|disorder
P07711730A0000|30 32|CPT
P07713421A1435a|86 107|sex determination signal
P07713421A1435a|68 74|ability
P07713421A1435a|113 117|SxlM4
P07713421A1435a|138 142|SxlM1
P07713421A1435a|20 42|gain-of-function mutants
P07713421A1435b|86 107|sex determination signal
P07713421A1435b|68 74|ability
P07713421A1435b|113 117|SxlM4
P07713421A1435b|138 142|SxlM1
P07713421A1435b|20 42|gain-of-function mutants
P07713936A0393|129 136|presence
P07713936A0393|9 13|meAda
P07713936A0393|61 73|response genes
P07713936A0393|139 143|meAda
P07713936A0393|94 106|transcription
P07713936A0393|35 47|transcription
P07713936A0393|109 112|aidB
P07713936A0393|0 6|Binding
P07714608A1252|45 50|groups
P07714608A1252|113 125|glucose levels
P07714608A1252|54 55|pH
P07714608A1252|13 23|differences
P07714608A1252|57 61|PaCO2
P07714608A1252|94 109|brain temperature
P07714608A1252|84 92|heart rate
P07714608A1252|75 82|pressure
P07714758A1193|0 12|Blood pressure
P07714758A1193|31 39|lidocaine
P07714758A1193|42 47|mg kg-1
P07715200A0000|0 16|Anesthesiologists
P07715200A0000|89 101|blood pressure
P07715200A0000|60 73|target response
P07715200A0000|36 39|drug
P07715200A0000|43 49|patient
P07715602A1088|58 77|cytochrome c haem lyase
P07715602A1088|37 41|parts
P07715602A1088|17 32|gene cluster codes
P07715922A0188|42 46|shape
P07715922A0188|121 123|PRK
P07715922A0188|33 38|number
P07715922A0188|110 115|months
P07715922A0188|49 55|corneal
P07715922A0188|6 10|paper
P07715922A0188|92 99|patients
P07715922A0188|67 71|cells
P07715922A0188|13 22|comparison
P07717823A0328|60 64|child
P07717823A0328|105 111|support
P07717823A0328|128 136|functions
P07717823A0328|77 82|height
P07717823A0328|96 101|kcal/d
P07717823A0328|0 23|Standard reference sources
P07719527T0000|30 39|hirudin CGP
P07719527T0000|46 51|REVASC
P07719527T0000|4 16|allergenicity
P07719527T0000|70 79|volunteers
P07720572A0701|15 26|myoD promoter
P07720572A0701|84 87|mice
P07720572A0701|56 67|conservation
P07720572A0701|75 80|humans
P07720572A0701|31 42|myoD enhancer
P07720572A0701|117 124|position
P07720572A0701|2 9|contrast
P07720572A0701|97 104|sequence
P07720572A1584|14 23|difference
P07720572A1584|37 45|myoblasts
P07720572A1584|49 59|10T1/2 cells
P07720572A1584|209 219|10T1/2 cells
P07720572A1584|128 143|myoD core enhancer
P07720572A1584|94 111|chromatin structure
P07720572A1584|79 87|cell types
P07720572A1584|197 206|mechanisms
P07720572A1584|162 173|myoD enhancer
P07720709A0755|119 135|cell proliferation
P07720709A0755|197 214|AP1 transrepression
P07720709A0755|60 61|RA
P07720709A0755|23 30|3T3 cells
P07720709A0755|34 44|model system
P07720709A0755|167 182|growth inhibition
P07720709A0755|82 90|retinoids
P07720710A0861|3 5|Oct
P07720710A0861|9 20|HMG2 proteins
P07721074A0766|114 125|multiplicity
P07721074A0766|166 172|itching
P07721074A0766|137 150|trigger factors
P07721074A0766|75 97|patient treatment program
P07721074A0766|6 15|dermatitis
P07721074A0766|21 24|itch
P07721074A0766|30 35|rashes
P07721074A0766|43 46|rash
P07721422A0241|0 25|Primer extension experiments
P07721422A0241|77 78|bp
P07721422A0241|89 97|mouse type
P07721422A0241|47 74|transcription initiation sites
P07721422A0241|99 110|receptor gene
P07721878A1163|39 60|tyrosine phosphoprotein
P07721878A1163|19 29|Fc epsilon R1
P07721878A1163|111 116|report
P07721878A1163|125 144|Fc epsilon R1 beta chain
P07721878A1163|3 13|beta subunit
P07721878A1163|68 70|p33
P07721878A1163|83 89|protein
P07721878A1163|151 158|identity
P07723247A0187|28 36|magnitude
P07723247A0187|166 182|pressure recording
P07723247A0187|89 97|dialysate
P07723247A0187|111 122|computerized
P07723247A0187|74 81|products
P07723247A0187|10 19|mechanisms
P07723247A0187|215 220|inflow
P07723247A0187|42 62|transmembrane transfer
P07723247A0187|224 235|outflow ports
P07723247A0187|130 142|dialysis model
P07723247A1161|42 47|IL-1Ra
P07723247A1161|81 96|radioimmunoassay
P07723247A1161|7 20|hour incubation
P07723247A1161|51 58|IL-1 beta
P07724452A0344|31 33|pen
P07724452A0344|11 19|treatment
P07724452A0344|50 55|chicks
P07724452A0344|59 61|pen
P07724452A0344|67 68|d.
P07728201A0660|2 9|contrast
P07728201A0660|49 73|sickle-hemoglobin C disease
P07728201A0660|148 168|penicillin prophylaxis
P07728201A0660|114 118|years
P07728201A0660|96 103|asplenia
P07728201A0660|37 44|children
P07728201A0660|121 123|age
P07728201A0660|17 24|evidence
P07729427A0942|145 152|hTAFII30
P07729427A0942|57 63|domains
P07729427A0942|66 73|hTAFII28
P07729427A0942|35 42|hTAFII18
P07729427A0942|75 82|hTAFII18
P07729427A0942|29 31|TBP
P07729427A0942|134 141|hTAFII28
P07729427A0942|100 102|TBP
P07729427A0942|0 15|Deletion analysis
P07730273A1309|26 47|amino acid substitutions
P07730273A1309|10 21|NarQ proteins
P07730273A1309|115 128|NarL-phosphate
P07730273A1309|67 83|histidine position
P07730273A1309|3 6|NarX
P07730328A0000|90 97|spectrum
P07730328A0000|125 129|genes
P07730328A0000|39 45|changes
P07730328A0000|19 23|cells
P07730328A0000|58 67|activation
P07730328A0000|100 103|cell
P07730328A0000|77 86|expression
P07730336A0606|56 58|CRE
P07730336A0606|35 54|cAMP response elements
P07730336A0606|75 82|sequence
P07730336A0606|7 11|ATF-1
P07730336A0606|103 105|CRE
P07730336A0606|94 100|kappa E3
P07730336A0606|15 18|CREM
P07730337A1439|71 81|development
P07730337A1439|38 54|expression pattern
P07730337A1439|12 25|PKC-gamma genes
P07730337A1439|60 64|brain
P07730337A1439|3 8|Ng/RC3
P07730337T0000|0 8|Structure
P07730337T0000|12 21|regulation
P07730337T0000|80 90|neurogranin
P07730337T0000|92 101|RC3 protein
P07730337T0000|57 70|protein kinase C
P07730337T0000|27 30|gene
P07730795A0104|3 20|amino acid sequences
P07730795A0104|66 72|species
P07730795A0104|38 45|subunits
P07730795A0104|48 52|DdRPs
P07730795A0104|95 101|regions
P07731686A0000|72 85|T-cell leukemia
P07731686A0000|51 64|translocations
P07731686A0000|89 93|T-ALL
P07731686A0000|34 37|site
P07731686A0000|3 11|TTG-2 gene
P07731898A0823|216 233|catalase activities
P07731898A0823|50 64|bicarbonate ions
P07731898A0823|147 150|ions
P07731898A0823|18 27|blood cells
P07731898A0823|197 212|erythrocyte SOD-1
P07731898A0823|7 13|studies
P07731898A0823|110 121|hemodialysis
P07731898A0823|67 80|concentrations
P07731898A0823|237 272|erythrocyte membrane lipid peroxidation
P07731898A0823|170 195|superoxide anions generation
P07731898A0823|41 47|acetate
P07733075A1200|60 63|i.d.
P07733075A1200|74 77|mg/q
P07733075A1200|221 224|mg/d
P07733075A1200|209 218|omeprazole
P07733075A1200|150 157|H. pylori
P07733075A1200|55 58|mg/b
P07733075A1200|104 114|combination
P07733075A1200|79 82|i.d.
P07733075A1200|68 70|CBS
P07733075A1200|38 51|clarithromycin
P07733075A1200|238 239|wk
P07733075A1200|16 25|omeprazole
P07733075A1200|132 147|% eradication rate
P07733075A1200|5 11|therapy
P07733075A1200|169 185|ulcer healing rates
P07733075A1200|33 36|i.d.
P07733075A1200|28 31|mg/b
P07735590A0990|141 164|micrograms Fel d milligrams
P07735590A0990|186 188|cat
P07735590A0990|62 72|p milligrams
P07735590A0990|133 135|cat
P07735590A0990|79 87|house dust
P07735590A0990|22 29|allergen
P07735590A0990|123 127|homes
P07735590A0990|103 113|cat allergen
P07735590A0990|175 179|homes
P07735590A0990|49 58|micrograms
P07735590A0990|3 15|concentration
P07735590A0990|193 216|micrograms Fel d milligrams
P07735833A1078|0 10|CONCLUSIONS
P07735833A1078|89 99|synthetases
P07735833A1078|13 22|comparison
P07735833A1078|55 64|structures
P07735833A1078|67 71|seryl
P07735833A1078|28 47|LysU crystal structure
P07735833A1078|117 120|core
P07737024A1003|70 74|drugs
P07737024A1003|61 67|passage
P07737024A1003|40 48|technique
P07737024A1003|91 97|pylorus
P07737024A1003|5 19|bowel irrigation
P07737118A0317|55 65|LexA protein
P07737118A0317|11 22|reading frame
P07737118A0317|3 6|MPS1
P07737118A0317|71 80|GST protein
P07737118A0317|115 119|yeast
P07737118A0317|95 104|constructs
P07737508A0649|82 85|gene
P07737508A0649|7 8|U6
P07737508A0649|23 26|gene
P07737508A0649|53 59|tRNAIle
P07737508A0649|33 41|tRNA genes
P07737508A0649|4 5|Tb
P07737508A0649|43 49|tRNAGln
P07737944A0000|58 76|transfusion practice
P07737944A0000|203 216|erythropoietin
P07737944A0000|152 157|states
P07737944A0000|13 25|growth factors
P07737944A0000|103 106|need
P07737944A0000|193 200|decrease
P07737944A0000|113 133|blood cell transfusions
P07737944A0000|50 55|impact
P07737944A0000|137 143|variety
P07738026A0216|56 60|forms
P07738026A0216|11 15|mouse
P07738026A0216|63 65|ADH
P07738839A0173|57 67|CO2 pressure
P07738839A0173|69 71|PET
P07738839A0173|43 46|rest
P07738839A0173|6 14|IC breaths
P07738839A0173|27 28|EC
P07738839A0173|32 40|VC breaths
P07738839A0173|73 75|CO2
P07738839A0173|96 99|mmHg
P07739382A0457|169 176|proteins
P07739382A0457|12 19|analyses
P07739382A0457|141 148|ancestor
P07739382A0457|52 63|protein types
P07739382A0457|24 41|amino acid sequences
P07739382A0457|92 99|proteins
P07739382A0457|109 116|gelsolin
P07739520A1250|2 9|homologs
P07739520A1250|80 81|D.
P07739520A1250|101 109|rpL7a gene
P07739520A1250|94 99|Surf-3
P07739520A1250|29 46|Surfeit gene cluster
P07739520A1250|66 74|proximity
P07739520A1250|17 23|members
P07739542A1419|98 126|retinoblastoma protein function
P07739542A1419|86 90|cells
P07739542A1419|30 37|contrast
P07739542A1419|20 26|cyclin E
P07739542A1419|66 79|G1/S transition
P07739542A1419|40 47|cyclin D1
P07739544A0364|58 63|region
P07739544A0364|116 121|domain
P07739544A0364|12 28|amino acid sequence
P07739544A0364|34 48|SGC1 gene product
P07739544A0364|127 135|Myc family
P07739544A0364|79 88|similarity
P07739544A0364|149 156|proteins
P07739566A1076|107 112|domain
P07739566A1076|163 173|specificity
P07739566A1076|10 33|Pax-6-BSAP fusion proteins
P07739566A1076|61 76|amino acid stretch
P07739566A1076|139 149|differences
P07739566A1076|92 95|part
P07740487A0167|86 90|cases
P07740487A0167|153 167|SSC Subcommittee
P07740487A0167|207 216|Thrombosis
P07740487A0167|80 83|data
P07740487A0167|99 108|affections
P07740487A0167|185 204|International Society
P07740487A0167|46 62|dysfibrinogenemia
P07740487A0167|20 30|association
P07740487A0167|125 129|study
P07740487A0167|66 78|thrombophilia
P07740487A0167|220 230|Haemostasis
P07740487A0167|170 179|Fibrinogen
P07740487A0167|139 147|framework
P07740490T0000|34 37|time
P07740490T0000|40 46|uraemia
P07740490T0000|63 71|serotonin
P07740490T0000|10 18|estrogens
P07740490T0000|57 60|role
P07741255A0194|46 55|population
P07741255A0194|23 26|area
P07741255A0194|8 16|districts
P07741255A0194|35 37|km2
P07742024A0121|144 148|types
P07742024A0121|26 40|imaging features
P07742024A0121|184 189|extent
P07742024A0121|107 111|tumor
P07742024A0121|92 101|directions
P07742024A0121|157 162|clival
P07742024A0121|11 18|symptoms
P07742024A0121|71 76|places
P07742024A0121|20 24|signs
P07742024A0121|150 155|sellar
P07742024A0121|42 58|operation findings
P07742363A0135|48 50|HCR
P07742363A0135|209 213|eIF-2
P07742363A0135|96 98|dsI
P07742363A0135|173 183|nucleotides
P07742363A0135|197 205|recycling
P07742363A0135|158 165|exchange
P07742363A0135|12 18|enzymes
P07742363A0135|114 119|Ser-51
P07742363A0135|38 46|repressor
P07742363A0135|86 94|inhibitor
P07742363A0135|125 136|alpha subunit
P07742363A0941|28 42|yeast eIF-2 alpha
P07742363A0941|13 15|Ala
P07742363A0941|108 129|casein kinase activities
P07742363A0941|22 25|form
P07742363A0941|7 9|Ser
P07742363A0941|90 94|yeast
P07742550A0407|208 209|FL
P07742550A0407|234 236|MCL
P07742550A0407|259 271|cell lymphomas
P07742550A0407|51 53|DAL
P07742550A0407|41 49|lymphomas
P07742550A0407|133 141|lymphomas
P07742550A0407|163 171|lymphomas
P07742550A0407|69 78|mixed-cell
P07742550A0407|214 232|mantle cell lymphomas
P07742550A0407|198 206|lymphomas
P07742550A0407|273 276|SNCL
P07742550A0407|173 175|TFL
P07742550A0407|3 7|cases
P07742917T0001|0 6|Icterus
P07742917T0001|10 25|beta-thalassemia
P07742917T0001|37 44|children
P07742917T0001|47 57|Brazzaville
P07743472A0181|101 107|New York
P07743472A0181|6 13|patients
P07743472A0181|138 160|cigarette smoking history
P07743472A0181|93 99|Buffalo
P07743472A0181|166 169|time
P07743472A0181|177 185|diagnosis
P07743472A0181|18 29|breast cancer
P07743472A0181|120 130|information
P07743472A0181|86 89|RPCI
P07743472A0181|59 84|Roswell Park Cancer Institute
P07743515A0223|86 90|cells
P07743515A0223|92 107|cytotrophoblasts
P07743515A0223|37 40|AAMP
P07743515A0223|17 34|tissue distribution
P07743515A0223|4 11|analysis
P07743515A0223|163 172|lymphatics
P07743515A0223|132 155|colon adenocarcinoma cells
P07743697A0703|128 134|disease
P07743697A0703|245 275|hydralazine/isosorbide dinitrate
P07743697A0703|100 112|treatment arms
P07743697A0703|63 82|plasma norepinephrine
P07743697A0703|211 219|enalapril
P07743697A0703|195 209|enzyme inhibitor
P07743697A0703|35 43|follow-up
P07743697A0703|11 16|V-HeFT
P07743697A0703|57 60|rise
P07743697A0703|152 160|treatment
P07743697A0703|223 240|vasodilator therapy
P07743697A0703|0 3|Data
P07744763A0514|0 14|Binding activity
P07744763A0514|198 202|HNF-4
P07744763A0514|172 178|element
P07744763A0514|80 115|electromobility supershift experiments
P07744763A0514|181 187|CYP2C11
P07744763A0514|53 67|orphan receptors
P07744763A0514|17 24|rat liver
P07744763A0514|123 129|results
P07744763A0514|151 159|receptors
P07744763A0514|32 39|extracts
P07744776A0617|0 17|Transcript analysis
P07744776A0617|35 53|B block substitutions
P07744776A0617|60 73|U6 RNA synthesis
P07744846A1006|0 7|Analysis
P07744846A1006|16 36|Bcl-2 homodimerization
P07744846A1006|299 309|combination
P07744846A1006|186 194|sequences
P07744846A1006|216 222|A domain
P07744846A1006|150 170|Bcl-2 homodimerization
P07744846A1006|75 79|yeast
P07744846A1006|104 111|evidence
P07744846A1006|53 65|binding assays
P07744846A1006|136 140|model
P07744846A1006|10 14|Bcl-2
P07744846A1006|90 95|method
P07744846A1006|114 120|support
P07744846A1006|277 285|carboxyl B
P07744846A1006|289 296|C domains
P07744846A1006|236 244|structure
P07744846A1006|144 148|Bcl-2
P07744846A1006|260 267|presence
P07744954A0418|99 105|epitope
P07744954A0418|121 128|antibody
P07744954A0418|75 77|NH2
P07744954A0418|62 68|domains
P07744954A0418|161 165|stalk
P07744954A0418|81 91|COOH termini
P07744954A0418|3 9|protein
P07744954A0418|43 49|portion
P07745008A0892|0 17|Radioligand binding
P07745008A0892|65 74|constructs
P07745311A0264|0 8|Diagnosis
P07745311A0264|11 14|FHCS
P07745311A0264|45 52|findings
P07745684T0000|30 43|gene expression
P07745684T0000|94 106|RNA processing
P07745684T0000|62 74|protein kinase
P07745684T0000|5 22|papillomavirus type
P07745684T0000|85 91|changes
P07745685A1442|118 134|CAT fusion partners
P07745685A1442|14 20|virions
P07745685A1442|41 48|proteins
P07745685A1442|64 73|antibodies
P07745685A1442|113 114|SN
P07745685A1442|88 104|accessory proteins
P07745693A0914|130 138|component
P07745693A0914|140 140|s
P07745693A0914|81 91|translation
P07745693A0914|105 115|proteolysis
P07745693A0914|0 6|Studies
P07745693A0914|32 43|Lb proteinase
P07745693A0914|14 22|inhibitor
P07745693A0914|57 67|stimulation
P07745696A0932|0 25|Restriction mapping analysis
P07745696A0932|137 141|SalI L
P07745696A0932|39 42|cDNA
P07745696A0932|123 128|genome
P07745696A0932|93 95|end
P07745696A0932|48 53|HHV-6A
P07745696A0932|55 59|U1102
P07745696A0932|111 117|segment
P07745696A0932|145 158|SalI O fragments
P07745696A0932|68 81|BamHI G fragment
P07745696A0932|194 206|repeat regions
P07745696A0932|168 171|left
P07745726A0960|42 43|E2
P07745726A0960|77 93|expression vectors
P07745726A0960|113 121|half sites
P07745726A0960|139 142|role
P07745726A0960|95 102|distance
P07745726A0960|37 38|E1
P07745726A0960|157 169|relationships
P07745726A0960|3 31|replication reporter constructs
P07745726A1496|41 50|palindrome
P07745726A1496|134 151|E1 recognition motif
P07745726A1496|169 176|half site
P07745726A1496|69 97|nucleotide sequence information
P07745726A1496|101 109|E1 binding
P07746397A0233|206 210|value
P07746397A0233|81 88|patients
P07746397A0233|186 189|aPTT
P07746397A0233|55 58|July
P07746397A0233|104 112|embolisms
P07746397A0233|66 73|December
P07746397A0233|194 198|times
P07746397A0233|167 184|thromboplastin time
P07746397A0233|16 23|patients
P07746397A0233|136 140|hours
P07746397A0233|33 47|anticoagulation
P07746397A0233|121 127|heparin
P07746397A0233|145 149|onset
P07746397A0233|0 6|METHODS
P07746794A0000|133 137|agent
P07746794A0000|63 71|Sandimmun
P07746794A0000|37 47|formulation
P07746794A0000|50 61|Cyclosporin A
P07746794A0000|100 110|Cremophor EL
P07746794A0000|90 98|castor oil
P07746937A0100|0 16|Lung function tests
P07746937A0100|54 59|period
P07746937A0100|72 77|months
P07746937A0100|18 20|EFR
P07746937A0100|42 49|patients
P07747462A0332|100 120|metal coordination site
P07747462A0332|32 44|RCR initiators
P07747462A0332|146 158|tyrosine motif
P07747462A0332|200 217|replicator proteins
P07747462A0332|57 59|set
P07747462A0332|73 78|motifs
P07747462A0332|0 18|Sequence comparisons
P07748451A0343|15 25|discrepancy
P07748451A0343|91 95|stone
P07748451A0343|133 152|medium-viscosity poly
P07748451A0343|65 76|restorations
P07748451A0343|39 50|restorations
P07748451A0343|110 113|poly
P07748451A0343|115 127|vinyl siloxane
P07748451A0343|154 166|vinyl siloxane
P07748451A0343|3 6|mean
P07748493A1045|157 161|gland
P07748493A1045|105 107|ELH
P07748493A1045|66 69|role
P07748493A1045|141 145|cells
P07748493A1045|75 84|processing
P07748493A1045|16 29|Aplysia Afurin2
P07748493A1045|33 43|candidate PC
P07748493A1045|97 103|hormone
P07748493A1045|117 126|precursors
P07748502A0794|0 3|Rats
P07748502A0794|67 80|discrimination
P07748502A0794|46 52|ability
P07748502A0794|15 23|8-OH-DPAT
P07748502A0794|84 92|water maze
P07748848A0263|3 6|term
P07748848A0263|19 38|papillary haemangioma
P07748952A0462|115 135|translation start sites
P07748952A0462|40 44|P1hfq
P07748952A0462|79 89|nucleotides
P07748952A0462|22 30|promoters
P07748952A0462|32 36|PmiaA
P07748952A0462|2 9|addition
P07748952A1329|131 135|genes
P07748952A1329|76 85|mechanisms
P07748952A1329|179 192|RNase E activity
P07748952A1329|157 172|promoter strength
P07748952A1329|104 118|cotranscription
P07748952A1329|24 27|mutL
P07748952A1329|37 49|hfq expression
P07748952A1329|137 146|modulation
P07748952A1329|96 101|degree
P07748952A1329|5 11|results
P07748952A1329|29 32|miaA
P07749088A0119|13 14|T2
P07749088A0119|23 28|images
P07749088A0119|8 9|T1
P07749461A0632|69 74|region
P07749461A0632|108 119|sGTH alpha-G1
P07749461A0632|47 62|sGTH alpha subunit
P07749461A0632|19 24|region
P07749461A0632|102 106|clone
P07749461A0632|34 35|kb
P07749461A0632|4 5|kb
P07749461A1022|174 183|expression
P07749461A1022|61 72|transfection
P07749461A1022|115 126|rainbow trout
P07749461A1022|103 110|plasmids
P07749461A1022|23 46|sGTH alpha subunit promoter
P07749461A1022|10 17|analysis
P07749461A1022|82 94|sGTH alpha/CAT
P07749461A1022|136 140|cells
P07750217T0000|0 23|Indium-111 OncoScint CR/OV
P07750217T0000|27 33|F-18 FDG
P07750217T0000|56 75|carcinoma recurrences
P07751848A0222|43 52|activities
P07751848A0222|106 110|value
P07751848A0222|138 155|nmol/min/mg protein
P07751848A0222|33 35|CPT
P07751848A0222|179 186|subjects
P07751848A0222|68 85|nmol/min/mg protein
P07751848A0222|3 31|carnitine palmitoyltransferase
P07752223A0960|3 7|Myc LZ
P07752223A0960|36 47|interactions
P07752223A0960|63 74|Myc inability
P07752454A0341|75 79|DMPPC
P07752454A0341|63 73|methicillin
P07752454A0341|23 25|CNS
P07752454A0341|46 60|resistance rates
P07752644A1031|71 85|plasma drug level
P07752644A1031|108 117|conduction
P07752644A1031|18 31|defibrillation
P07752644A1031|5 6|VF
P07752886A0595|42 58|amino acid residues
P07752886A0595|77 84|residues
P07752886A0595|17 30|FecR derivative
P07752886A0595|96 99|FecR
P07753027A0240|61 67|strands
P07753027A0240|24 32|psbH-psbN
P07753027A0240|3 20|gene pairs psbB-psbT
P07753030A0173|0 19|Hybridization signals
P07753030A0173|76 83|phaseoli
P07753030A0173|51 74|Rhizobium leguminosarum bv
P07753030A0173|45 48|DNAs
P07753030A0173|138 160|Xanthomonas campestris pv
P07753030A0173|85 105|Rhodobacter capsulatus
P07753030A0173|162 171|campestris
P07753796A0625|58 66|sequences
P07753796A0625|37 43|regions
P07753796A0625|12 28|amino acid sequence
P07753796A0625|94 116|liver eIF-2B alpha subunit
P07753796A0625|69 76|peptides
P07753796A0743|0 9|Expression
P07753796A0743|80 101|SDS/polyacrylamide gels
P07753796A0743|34 40|peptide
P07753796A0743|67 77|eIF-2B alpha
P07753796A0743|16 19|cDNA
P07753837A0724|57 70|plakoglobin RNA
P07753837A0724|106 117|accumulation
P07753837A0724|90 95|effect
P07753837A0724|30 39|desmoglein
P07753837A0724|18 27|tail domain
P07753837A0724|4 6|RNA
P07753837A0724|120 130|plakoglobin
P07754713A0227|15 19|PRP21
P07754713A0227|91 94|gene
P07754713A0227|38 41|CDC6
P07754713A0227|51 54|gene
P07754713A0227|10 13|NUC1
P07754713A0227|75 84|protein S24
P07754713A0227|31 35|SPP91
P07754713A0227|43 46|CRY2
P07754713A0227|117 123|protein
P07754713A0227|129 138|amino acids
P07755884A0000|98 102|motor
P07755884A0000|165 178|dopamine system
P07755884A0000|140 146|lesions
P07755884A0000|13 18|grafts
P07755884A0000|37 43|tissues
P07755884A0000|106 125|sensorimotor deficits
P07755914A0000|117 120|AIDS
P07755914A0000|24 29|impact
P07755914A0000|35 46|introduction
P07755914A0000|95 102|survival
P07755914A0000|66 77|azithromycin
P07755914A0000|49 62|clarithromycin
P07755914A0000|105 112|patients
P07755914A0000|136 160|Mycobacterium avium complex
P07755914A0000|83 91|treatment
P07755914A0000|162 165|DMAC
P07755914A0000|0 8|OBJECTIVE
P07757315A1227|44 49|% value
P07757315A1227|103 119|observation period
P07757315A1227|89 93|level
P07757315A1227|51 51|h
P07757315A1227|14 24|aggregation
P07757315A1227|122 129|ABSTRACT
P07757315A1227|57 71|drug application
P07757315A1227|144 148|WORDS
P07758167A1488|85 85|%
P07758167A1488|40 47|clone CA9
P07758167A1488|25 37|proliferation
P07758167A1488|65 70|% serum
P07758167A1488|53 60|presence
P07758167A1488|98 106|clone ME10
P07758167A1488|0 11|Growth curves
P07758246A0469|16 21|region
P07758246A0469|62 66|exons
P07758246A0469|49 54|intron
P07758246A0469|3 9|protein
P07758246A0469|28 30|bps
P07758459A1277|171 198|ABF1 consensus binding sequence
P07758459A1277|11 18|AAC2 gene
P07758459A1277|45 50|motifs
P07758459A1277|126 149|core HAP2/3/4 binding motif
P07758459A1277|80 89|activators
P07758459A1277|3 5|UAS
P07758837A1118|96 101|probes
P07758837A1118|235 238|exon
P07758837A1118|11 20|complexity
P07758837A1118|188 196|sequences
P07758837A1118|113 118|exon 1B
P07758837A1118|38 43|region
P07758837A1118|222 231|P1 promoter
P07758837A1118|133 146|intron boundary
P07758837A1118|49 62|GH receptor gene
P07758837A1118|81 91|observation
P07759094A0634|31 37|n repeat
P07759094A0634|12 23|dinucleotide
P07759094A0634|52 61|NHE5 cosmid
P07759094A0634|25 29|GT/CA
P07759094A0634|92 114|microsatellite PCR marker
P07759525A0417|85 85|%
P07759525A0417|102 113|casein kinase
P07759525A0417|24 24|%
P07759525A0417|54 72|protein kinase domain
P07759525A0417|133 138|region
P07759525A0417|3 10|proteins
P07759525A0417|115 122|isoforms
P07759529A0288|53 61|repressor
P07759529A0288|37 43|CDP/cut
P07759529A0288|9 18|approaches
P07759529A0288|64 86|gp91-phox gene expression
P07760790A0327|82 104|MEF2 site binding activity
P07760790A0327|17 32|MEF2 reporter gene
P07760790A0327|50 53|line
P07760790A0327|56 66|NIH 3T3 cells
P07760790A0327|0 13|Serum induction
P07760819A0731|132 146|differentiation
P07760819A0731|105 110|effect
P07760819A0731|49 57|molecules
P07760819A0731|10 19|activation
P07760819A0731|113 129|cell proliferation
P07760819A0731|59 84|PDGF beta receptor activation
P07760841A0221|0 3|UAS1
P07760841A0221|9 19|binding site
P07760841A0221|41 54|regulator Adr1p
P07760841A0647|177 186|helix phase
P07760841A0647|39 44|region
P07760841A0647|17 20|ADH2
P07760841A0647|5 11|context
P07760841A0647|123 136|gene activation
P07760841A0647|92 107|promoter elements
P07760841A0647|151 161|orientation
P07760841A0647|55 58|UAS1
P07760841A0647|69 75|concert
P07760841A0647|83 86|ADH2
P07760841A0647|163 172|copy number
P07760844A0413|0 8|Induction
P07760844A0413|11 24|AP-1 DNA binding
P07760844A0413|51 68|GH trans-activation
P07760844A0413|79 88|c-fos genes
P07760844A0413|71 75|c-jun
P07761091A0294|0 11|Inactivation
P07761091A0294|54 58|MKP-1
P07761091A0294|14 23|MAP kinases
P07761091A0294|42 52|phosphatase
P07761216T0000|56 63|patients
P07761216T0000|12 31|amphotericin B therapy
P07761216T0000|35 44|candidemia
P07761420A0909|60 62|Ca2
P07761420A0909|42 46|CCaMK
P07761420A0909|24 29|assays
P07761434A1084|57 64|findings
P07761434A1084|116 127|antioxidants
P07761434A1084|5 8|AP-1
P07761434A1084|22 29|mediator
P07761434A1084|32 50|tumor promoter action
P07761434A1084|98 105|activity
P07761467A0666|43 59|protein components
P07761467A0666|78 84|protein
P07761467A0666|9 15|complex
P07762431A0356|83 84|mg
P07762431A0356|88 92|litre
P07762431A0356|3 9|protein
P07762431A0356|69 74|yields
P07762431A0356|32 35|cDNA
P07762431A0356|53 65|culture medium
P07762504A0648|84 88|doses
P07762504A0648|44 53|amiodarone
P07762504A0648|107 107|g
P07762504A0648|24 37|administration
P07762504A0648|70 73|days
P07762504A0648|57 65|mg/kg/day
P07762504A0648|94 97|dose
P07762504A0648|3 7|study
P07763727A1035|15 20|pAMS13
P07763727A1035|24 29|pAMS14
P07763727A1035|141 156|wine yeast strains
P07763727A1035|50 65|laboratory strain
P07763727A1035|99 104|pAMS15
P07763727A1035|0 13|Plasmids pAMS12
P07765118A0967|59 59|h
P07765118A0967|65 72|excision
P07765118A0967|82 102|maximum enzyme activity
P07765118A0967|21 42|ACC-oxidase transcripts
P07765118A0967|118 119|h.
P07765118A0967|3 18|maximum induction
P07766885A0405|160 173|junction region
P07766885A0405|75 83|plant CDPK
P07766885A0405|11 26|polypeptide chain
P07766885A0405|85 90|kinase
P07766885A0405|56 63|features
P07766885A0405|100 108|sequences
P07766885A0405|146 151|domain
P07767011A0689|0 5|Repair
P07767011A0689|103 110|mutation
P07767011A0689|12 20|insertion
P07767011A0689|57 64|activity
P07767011A0689|70 78|hprt locus
P07767011A0689|33 45|recombination
P07767011A0689|97 100|site
P07768824A0167|131 138|proteins
P07768824A0167|33 41|cell cycle
P07768824A0167|11 27|fla gene expression
P07768824A0167|74 86|RNA polymerase
P07768824A0167|93 102|appearance
P07768824A0167|109 118|activation
P07768824A0167|3 8|timing
P07768824A0167|67 71|forms
P07768836A1126|0 25|Primer extension experiments
P07768836A1126|41 67|transcription initiation site
P07768836A1126|99 107|start site
P07768836A1126|71 72|bp
P07768848A1880|0 11|Polypeptides
P07768848A1880|78 82|basis
P07768848A1880|217 220|coat
P07768848A1880|47 52|spores
P07768848A1880|162 167|layers
P07768848A1880|110 119|cotJ operon
P07768848A1880|97 104|products
P07768848A1880|173 176|coat
P07768848A1880|202 211|components
P07768848A1880|143 151|formation
P07768848A1880|64 69|mutant
P07768848A1880|56 59|cotE
P07768848A1880|29 33|sizes
P07768898A0492|57 61|terms
P07768898A0492|166 172|protein
P07768898A0492|135 141|apobec1
P07768898A0492|103 115|suhstitutions
P07768898A0492|39 54|apobec1 sequences
P07768898A0492|119 122|site
P07768898A0492|19 24|values
P07768898A0492|67 73|numbers
P07768898A0492|27 36|divergence
P07768953T0039|0 3|EEA1
P07768953T0039|63 70|cysteine
P07768953T0039|39 53|membrane protein
P07768953T0039|110 116|IQ motif
P07768953T0039|72 78|fingers
P07770033A0978|0 18|Nucleotide sequences
P07770033A0978|163 199|Neurospora crassa copper metallothionein
P07770033A0978|24 29|clones
P07770033A0978|153 160|homology
P07770033A0978|113 116|acid
P07770033A0978|51 54|cap3
P07770033A0978|84 86|ORF
P07770033A0978|45 49|clone
P07770033A0978|131 137|peptide
P07770033A0978|71 82|reading frame
P07771671T0000|44 59|carbon electrodes
P07771745A0442|14 20|tissues
P07771745A0442|63 70|forehead
P07771745A0442|94 103|cheekbones
P07771745A0442|80 85|region
P07771745A0442|26 29|face
P07771745A0442|0 8|Elevation
P07772036A1000|104 110|CTF/NF1
P07772036A1000|4 9|region
P07772036A1000|35 41|factors
P07772036A1000|69 101|transcription factor/nuclear factor
P07772036A1000|43 50|USF/MLTF
P07774137A0000|70 78|treatment
P07774137A0000|46 54|Strep A OIA
P07774137A0000|121 131|pharyngitis
P07774137A0000|169 174|clinic
P07774137A0000|12 17|impact
P07774137A0000|58 66|detection
P07774137A0000|81 86|group A
P07774137A0000|41 44|test
P07774137A0000|115 119|GABHS
P07774807A0405|134 146|family members
P07774807A0405|46 55|activators
P07774807A0405|7 14|proteins
P07774807A0405|73 77|genes
P07774807A0405|87 98|heterodimers
P07774925A0084|142 145|head
P07774925A0084|30 40|BRCA1 region
P07774925A0084|6 18|cosmid contigs
P07774925A0084|78 82|cDNAs
P07774925A0084|108 116|HeLa cells
P07774925A0084|99 106|placenta
P07774925A0084|57 66|cDNA clones
P07774925A0084|71 75|pools
P07774925A0084|0 2|YAC
P07774925A0084|127 132|T cells
P07775428A0172|27 27|s
P07775428A0172|11 16|clones
P07775428A0172|32 50|nucleotide sequences
P07775428A0172|92 97|region
P07775428A0172|64 72|Ash-l cDNA
P07775428A0172|18 22|Ash-m
P07776685A0000|148 156|resection
P07776685A0000|52 64|immunotherapy
P07776685A0000|111 123|interleukin-2
P07776685A0000|20 30|feasibility
P07776685A0000|34 41|toxicity
P07776685A0000|128 135|patients
P07776685A0000|182 191|lung cancer
P07776685A0000|69 73|tumor
P07776685A0000|4 8|study
P07776685A0000|86 96|lymphocytes
P07776685A0000|160 164|stage
P07776711A0295|53 57|years
P07776711A0295|26 28|men
P07776711A0295|60 62|age
P07776711A0295|34 38|women
P07776711A0295|11 17|METHODS
P07776711A0295|137 150|polyneuropathy
P07776711A0295|79 83|motor
P07776711A0295|94 107|neuropathy type
P07776711A0295|0 7|MATERIAL
P07776882A0000|27 44|cell volume dynamics
P07776882A0000|53 61|rat hearts
P07776882A0000|10 14|study
P07776882A0000|69 76|ischemia
P07776882A0000|85 95|reperfusion
P07776979A0702|28 33|effect
P07776979A0702|11 17|COUP-TF
P07776979A0702|53 72|reporter gene activity
P07776979A0702|2 9|contrast
P07777518A0483|0 12|DNA sequencing
P07777518A0483|54 63|cDNA clones
P07777518A0483|90 94|genes
P07777518A0483|16 35|Southern blot analyses
P07779558T0000|0 19|Muscle GSH-Px activity
P07779558T0000|55 77|selenium supplementation
P07779558T0000|34 41|exercise
P07779558T0000|43 50|training
P07779811A0901|0 7|Mutation
P07779811A0901|79 94|reporter activity
P07779811A0901|38 47|Sp1 binding
P07779811A0901|68 76|reduction
P07779811A0901|13 22|Sp1 element
P07779812A0000|110 118|cell types
P07779812A0000|76 79|role
P07779812A0000|102 107|number
P07779812A0000|93 98|growth
P07779812A0000|30 36|variety
P07779812A0000|3 11|c-myc gene
P07779812A0000|39 48|tumor types
P07780148A1153|81 85|level
P07780148A1153|49 55|M phases
P07780148A1153|11 13|PML
P07780148A1153|88 94|G1 phase
P07780148A1153|34 38|level
P07780148A1153|41 41|S
P07780148A1153|43 44|G2
P07780525A0495|0 8|Schooling
P07780525A0495|62 72|differences
P07780525A0495|33 38|health
P07780525A0495|85 96|health inputs
P07780719A0477|25 31|driving
P07780738A0091|82 88|antigen
P07780738A0091|34 42|cell cycle
P07780738A0091|71 74|cell
P07780738A0091|22 28|S phases
P07780738A0091|104 117|DNA replication
P07780738A0091|8 11|Cdks
P07780738A0091|90 93|PCNA
P07780738A0091|17 18|G1
P07782087A0559|145 159|primer extension
P07782087A0559|61 69|positions
P07782087A0559|166 177|RACE analyses
P07782087A0559|19 46|transcription initiation sites
P07782087A0559|109 119|combination
P07782087A0559|122 143|ribonuclease protection
P07782087A0559|81 88|position
P07782113A0726|72 82|blood levels
P07782113A0726|3 20|roxithromycin doses
P07782113A0726|43 49|studies
P07782302A0479|98 116|affinity interaction
P07782302A0479|75 80|domain
P07782302A0479|25 38|DEDDDL sequence
P07782302A0479|141 152|HTF9A/RanBP1
P07782302A0479|61 63|Ran
P07782302A0479|49 51|GDP
P07782302A0479|133 139|protein
P07782775A0889|83 97|BBTV coat protein
P07782775A0889|50 57|proteins
P07782775A0889|11 14|ORFs
P07782775A0889|74 77|size
P07782775A0889|17 26|components
P07782775A0889|67 69|kDa
P07783064A0452|14 25|strength data
P07783064A0452|60 75|creatinine kinase
P07783064A0452|77 78|CK
P07783064A0452|80 85|levels
P07783064A0452|30 37|patients
P07783641A0591|0 3|CodY
P07783641A0591|33 42|data-bases
P07783641A0591|18 27|homologues
P07783822A0000|0 8|OBJECTIVE
P07783822A0000|38 49|presentation
P07783822A0000|26 34|incidence
P07783822A0000|80 87|beriberi
P07783822A0000|98 113|district hospital
P07784061A0894|59 61|TTF
P07784061A0894|93 97|cells
P07784061A0894|104 115|kb transcript
P07784061A0894|20 28|G proteins
P07784078A1064|98 110|APL cell growth
P07784078A1064|64 69|levels
P07784078A1064|34 47|gene expression
P07784078A1064|2 12|explanation
P07784078A1064|82 84|PML
P07784078A1064|28 31|lack
P07784078A1064|72 79|RAR alpha
P07784079A1018|118 133|expression vector
P07784079A1018|181 183|FGF
P07784079A1018|25 40|expression vector
P07784079A1018|166 173|presence
P07784079A1018|91 98|activity
P07784079A1018|65 75|acquisition
P07784079A1018|149 156|activity
P07784079A1018|112 115|form
P07784079A1018|0 11|Transfection
P07784079A1018|45 55|NIH3T3 cells
P07784197A0827|176 200|BALB/c 3T3 mouse fibroblasts
P07784197A0827|94 99|HeLa S3
P07784197A0827|50 59|monkey Cos7
P07784197A0827|9 16|extracts
P07784197A0827|22 28|variety
P07784197A0827|40 48|cell lines
P07784197A0827|161 171|cell extract
P07784197A0827|149 158|band shifts
P07784197A0827|68 85|mouse fibrosarcomas
P07784197A0827|120 127|TGF-beta
P07784199A0000|174 179|factor
P07784199A0000|107 111|sites
P07784199A0000|12 18|protein
P07784199A0000|154 157|site
P07784199A0000|124 141|gene regulator Rap1p
P07784199A0000|23 35|gene promoters
P07784199A0000|181 185|Abf1p
P07784199A0000|20 21|rp
P07784870A0119|14 20|reports
P07784870A0119|156 169|histochemistry
P07784870A0119|50 57|findings
P07784870A0119|200 219|immunohistochemistry
P07784870A0119|145 154|microscopy
P07784870A0119|91 101|information
P07784870A0119|74 80|reports
P07784870A0119|125 138|investigations
P07784870A0119|181 198|electron microscopy
P07784870A0119|226 237|microbiology
P07784942T0001|33 41|knowledge
P07784942T0001|11 24|thrombomodulin
P07784942T0001|51 59|prospects
P07786820A0284|0 5|CPT-11
P07786820A0284|48 51|dose
P07786820A0284|74 75|ml
P07786820A0284|82 87|saline
P07786820A0284|33 44|i.v. infusion
P07786820A0284|94 98|weeks
P07786820A0284|57 61|mg/m2
P07786821A2292|42 78|consecutive-days-every-3 weeks schedule
P07786821A2292|107 115|mg/m2/day
P07786821A2292|85 101|patient population
P07786821A2292|20 25|CPT-11
P07786821A2292|14 16|MTD
P07786821A2292|0 9|CONCLUSION
P07787179A0312|99 120|ethylene responsiveness
P07787179A0312|126 137|reporter gene
P07787179A0312|3 12|bp fragment
P07787179A0312|28 41|PRB-1b promoter
P07787179A0312|14 21|X1 region
P07787179A0312|57 65|positions
P07789275A0325|86 110|loss-of-function mutations
P07789275A0325|11 18|function
P07789275A0325|33 45|metamorphosis
P07789275A0325|24 26|E74
P07789275A0325|125 141|transcription unit
P07789275A0325|20 20|s
P07789342A1352|59 73|affinity binding
P07789342A1352|35 39|TSH-R
P07789342A1352|76 78|TSH
P07789342A1352|119 137|transmembrane domain
P07789342A1352|24 29|domain
P07789342A1352|148 157|TSH binding
P07789342A1352|97 107|hyt mutation
P07789396A0504|0 7|Lipiodol
P07789396A0504|35 38|EDTB
P07789809A1246|43 47|types
P07789809A1246|64 65|Vc
P07789809A1246|9 20|Western blots
P07789809A1246|99 116|household functions
P07789809A1246|86 88|Ypt
P07789809A1246|131 146|vesicle transport
P07789809A1246|50 52|Ypt
P07789809A1246|168 182|differentiation
P07789809A1246|59 60|Cr
P07789971A0758|26 38|hybridization
P07789971A0758|75 83|sequences
P07789971A0758|179 183|genes
P07789971A0758|142 147|genome
P07789971A0758|108 118|pseudogenes
P07789971A0758|208 212|GSTT2
P07789971A0758|3 9|absence
P07789971A0758|17 23|regions
P07790271A1185|65 74|techniques
P07790271A1185|11 18|lens dose
P07790271A1185|23 36|Gy/25 fractions
P07790377A0561|0 9|Antibodies
P07790377A0561|38 44|protein
P07790377A0561|20 24|PTS1R
P07790377A0561|53 58|monkey
P07790377A0561|67 78|hamster cells
P07790377A0561|60 62|rat
P07790719A0098|56 69|family violence
P07790719A0098|16 21|effort
P07790719A0098|43 50|patients
P07791760A0424|86 97|MAPK activity
P07791760A0424|51 66|tyrosine residues
P07791760A0424|121 138|complex kinase assay
P07791760A0424|34 48|phosphorylation
P07791760A0424|69 72|MAPK
P07791760A0424|0 12|GnRH treatment
P07791763T0000|59 62|cDNA
P07791763T0000|9 15|cloning
P07791763T0000|79 106|phosphatidylinositol 3-kinase
P07791763T0000|66 76|involvement
P07791763T0000|124 146|Xenopus oocyte maturation
P07791763T0000|29 52|insulin receptor substrate
P07791764A0357|26 37|Jurkat T cells
P07791764A0357|62 69|antibody
P07791764A0357|80 97|adapter protein Grb2
P07791764A0357|39 41|Cbl
P07791768A0930|83 86|swi6
P07791768A0930|121 129|mutations
P07791768A0930|60 76|hmr delta A mutation
P07791768A0930|16 34|cell cycle regulators
P07791768A0930|163 175|establishment
P07791768A0930|178 186|silencing
P07791768A0930|88 91|swi4
P07791768A0930|132 135|SIR1
P07791768A0930|144 147|gene
P07791768A0930|53 57|rap1s
P07791768A0930|3 8|effect
P07791768A0930|96 108|clb5 mutations
P07791769A0826|127 133|TATA box
P07791769A0826|135 136|C.
P07791769A0826|108 122|ICP4 binding site
P07791769A0826|76 82|protein
P07791769A0826|61 64|TATA
P07791769A0826|32 40|complexes
P07791769A0826|93 95|DNA
P07791769A0826|86 90|TFIIB
P07791769A0826|0 3|ICP4
P07791771A0183|0 3|Otte
P07791771A0183|5 7|Mol
P07791776T0000|0 15|Characterization
P07791776T0000|92 102|conjugation
P07791776T0000|18 21|fus1
P07791776T0000|75 82|function
P07791783A0000|60 62|box
P07791783A0000|24 30|protein
P07791783A0000|127 155|rainbow trout testis cDNA library
P07791783A0000|11 14|cDNA
P07791783A0000|104 109|SOX-LZ
P07791783A0000|67 84|leucine zipper motif
P07791783A0000|56 58|HMG
P07793783A0189|0 9|Scalp flaps
P07793783A0189|109 115|closure
P07793783A0189|32 36|point
P07793783A0189|121 129|donor site
P07793783A0189|80 101|scalp flap transposition
P07793783A0189|65 69|weeks
P07794556A0000|101 107|service
P07794556A0000|171 186|mutation analysis
P07794556A0000|5 10|Center
P07794556A0000|19 26|Genetics
P07794556A0000|137 147|DNA-linkage
P07794556A0000|113 120|November
P07794556A0000|46 56|DNA-testing
P07794556A0000|29 34|Leuven
P07794556A0000|60 69|Huntington
P07794556A0000|72 78|disease
P07795104T0000|0 4|Risks
P07795104T0000|7 16|chronicity
P07795104T0000|57 62|review
P07795104T0000|31 54|hepatitis B virus infection
P07795576A0126|0 10|Examination
P07795576A0126|25 31|factors
P07795576A0126|91 109|plasma renin activity
P07795576A0126|70 75|system
P07795576A0126|81 88|increase
P07796935A0284|55 61|hTR beta
P07796935A0284|123 132|peroxisome
P07796935A0284|207 210|TREs
P07796935A0284|155 162|receptor
P07796935A0284|221 222|DR
P07796935A0284|164 168|hPPAR
P07796935A0284|213 219|TRE-PAL
P07796935A0284|228 234|TRE-LAP
P07796935A0284|23 28|effect
P07796935A0284|92 98|mutants
P07796935A0284|100 110|c-erbA alpha
P07796935A0284|198 205|elements
P07796935A0284|83 90|hTR alpha
P07797077A0842|60 67|homology
P07797077A0842|177 186|ISGF3 gamma
P07797077A0842|156 160|IRF-1
P07797077A0842|28 33|domain
P07797077A0842|52 57|degree
P07797077A0842|136 141|family
P07797077A0842|132 134|IRF
P07797077A0842|162 166|IRF-2
P07797077A0842|105 114|interferon
P07797077A0842|125 130|factor
P07797077A0842|168 172|ICSBP
P07797077A0842|36 38|Pip
P07797077A0842|93 99|members
P07797077A0842|84 90|domains
P07797346T0000|42 50|Amsterdam
P07797346T0000|12 21|hepatitis A
P07797346T0000|37 39|men
P07797346T0000|2 9|outbreak
P07797476A1001|71 76|region
P07797476A1001|90 100|stimulation
P07797476A1001|50 57|activity
P07797476A1001|127 134|residues
P07797476A1001|3 14|RAP74 subunit
P07797476A1001|17 21|TFIIF
P07797583A0222|231 236|factor
P07797583A0222|50 58|deletions
P07797583A0222|106 112|respect
P07797583A0222|206 212|binding
P07797583A0222|22 38|base substitutions
P07797583A0222|256 263|activity
P07797583A0222|274 290|Drosophila Kc cells
P07797583A0222|74 92|nucleotide positions
P07797583A0222|70 72|DRE
P07797583A0222|151 158|PCNA gene
P07797583A0222|307 311|flies
P07797583A0222|241 248|PCNA gene
P07797583A0222|215 218|DREF
P07797583A0222|194 200|effects
P07797583A0222|118 144|transcription initiation site
P07798134T0000|3 17|hsp70 gene family
P07798134T0000|37 43|cloning
P07798134T0000|116 121|member
P07798134T0000|20 35|Neurospora crassa
P07798134T0000|62 71|expression
P07798134T0000|45 60|sequence analysis
P07798134T0000|83 89|mapping
P07798207A0759|142 164|Paracoccus denitrificans
P07798207A0759|122 124|ETF
P07798207A0759|135 137|rat
P07798207A0759|80 88|% identity
P07798207A0759|10 27|amino acid sequences
P07798207A0759|195 195|%
P07798207A0759|109 116|subunits
P07798207A0759|39 53|W3A1 ETF subunits
P07798207A0759|174 178|group
P07798217T0000|71 77|control
P07798217T0000|10 24|phosphorylation
P07798217T0000|27 33|CREB341
P07798217T0000|80 93|gene expression
P07798217T0000|36 41|Ser129
P07798217T0095|1 4|role
P07798217T0095|37 43|control
P07798217T0095|8 31|glycogen synthase kinase-3
P07798217T0095|46 59|gene expression
P07798271A0330|78 85|extracts
P07798271A0330|25 29|sites
P07798271A0330|8 13|region
P07798271A0330|113 124|Ets-1 protein
P07798271A0330|66 70|liver
P07798271A0330|49 56|proteins
P07799437A0656|5 10|assays
P07799437A0656|54 63|pNeo.Myc-2
P07799437A0656|41 51|replication
P07799437A0656|93 107|control plasmids
P07799437A0656|83 90|labeling
P07799925A0526|44 64|src family kinase p59fyn
P07799925A0526|143 145|p62
P07799925A0526|16 24|complexes
P07799925A0526|35 37|p62
P07799925A0526|169 171|SH3
P07799925A0526|92 107|complex formation
P07799925A0526|67 75|HeLa cells
P07799925A0526|175 184|SH2 domains
P07799925A0526|118 140|tyrosine phosphorylation
P07799925A0526|187 192|p59fyn
P07799925A0526|0 13|Reconstitution
P07799931A0287|115 118|fate
P07799931A0287|51 57|control
P07799931A0287|122 133|organization
P07799931A0287|63 76|L7 gene insights
P07799931A0287|146 151|system
P07799931A0287|84 93|mechanisms
P07799931A1232|2 9|contrast
P07799931A1232|53 64|c-Maf actions
P07799931A1232|23 29|protein
P07799931A1232|31 33|Nrl
P07799939A0628|102 108|nucleus
P07799939A0628|10 16|element
P07799939A0628|45 74|serine/threonine phosphoprotein
P07799939A0628|123 130|3T3 cells
P07799948A0777|115 119|Raf-1
P07799948A0777|66 76|Raf-1 kinase
P07799948A0777|79 81|Src
P07799948A0777|11 18|deletion
P07799948A0777|101 103|Ras
P07799948A0777|138 147|mechanisms
P07799948A0777|95 97|Src
P07799948A0777|36 39|site
P07799948A0777|54 63|activation
P07799948A0777|2 9|contrast
P07799950A0282|2 8|studies
P07799950A0282|90 98|prototype
P07799950A0282|63 86|somatostatin gene promoter
P07799950A0282|123 129|element
P07799950A0282|141 144|CREB
P07799950A0282|46 50|cells
P07799950A0282|55 57|CRE
P07800479A0201|115 122|proteins
P07800479A0201|104 112|transport
P07800479A0201|39 42|gene
P07800479A0201|52 58|protein
P07800479A0201|78 90|RNA maturation
P07800479A0201|8 11|gene
P07800479A0201|130 136|nucleus
P07800479A0201|13 16|NSR1
P07800505T0000|0 15|Characterization
P07800505T0000|21 28|promoter
P07800505T0000|54 72|phospholipase A2 gene
P07800505T0000|42 44|kDa
P07801180A0197|54 68|study approaches
P07801180A0197|34 44|limitations
P07801180A0197|21 30|advantages
P07801180A0197|4 8|paper
P07802355T0000|71 79|analyzers
P07802355T0000|38 51|blood cell count
P07802355T0000|81 91|Coulter STKS
P07802355T0000|11 15|study
P07802355T0000|93 100|Sysmex NE
P07802355T0000|108 119|Technicon H-1
P07802655T0000|0 15|Characterization
P07802655T0000|96 98|L14
P07802655T0000|108 119|protein genes
P07802655T0000|91 92|L1
P07802655T0000|85 88|exon
P07802655T0000|18 25|FIII/YY1
P07802655T0000|28 40|Xenopus laevis
P07802655T0000|61 74|protein binding
P07803809A1852|160 167|ABSTRACT
P07803809A1852|126 156|protein kinase C inhibitor Compound
P07803809A1852|52 66|beta-globin mRNA
P07803809A1852|182 186|WORDS
P07803809A1852|7 13|studies
P07803809A1852|42 49|increase
P07803809A1852|88 119|tyrosine kinase inhibitor genistein
P07806492A1162|71 79|precursor
P07806492A1162|4 12|structure
P07806492A1162|15 23|cucumisin
P07806507A0121|34 47|CD3-TCR complex
P07806507A0121|9 18|dissection
P07806507A0121|93 99|CD3 zeta
P07806507A0121|103 112|CD3 epsilon
P07806507A0121|198 214|activation cascade
P07806507A0121|171 176|events
P07806507A0121|80 91|polypeptides
P07806507A0121|141 156|recognition event
P07806532A0659|0 11|Protein cHMGI
P07806532A0659|40 42|DNA
P07806532A0659|48 67|half-saturation value
P07806532A0659|73 74|nM
P07806651A0097|102 109|MF scales
P07806651A0097|97 97|K
P07806651A0097|95 95|L
P07806651A0097|24 29|degree
P07806651A0097|79 89|performance
P07806651A0097|61 77|Mexican-Americans
P07806651A0097|4 8|study
P07806651A0097|115 120|MMPI-2
P07806651A0097|43 50|identity
P07806820A0091|70 75|artery
P07806820A0091|102 111|fascia flap
P07806820A0091|34 40|pedicle
P07807002A0500|91 112|luciferase reporter gene
P07807002A0500|9 16|segments
P07807002A0500|59 76|germline epsilon RNA
P07807002A0500|182 184|IgE
P07807002A0500|19 21|DNA
P07807002A0500|31 35|flank
P07807002A0500|134 148|mouse B cell lines
P07807002A0500|41 55|initiation sites
P07808210A1510|30 30|%
P07808210A1510|21 25|value
P07808210A1510|36 36|%
P07808210A1510|43 48|NCEP I.
P07809128T0000|9 16|capacity
P07809128T0000|22 29|E2F1 gene
P07809410A0606|191 197|therapy
P07809410A0606|33 46|serum TSH levels
P07809410A0606|76 86|131I protein
P07809410A0606|101 108|131I-PBI
P07809410A0606|11 15|cases
P07809410A0606|94 99|iodine
P07809410A0606|48 71|serum thyroglobulin values
P07809410A0606|148 158|differences
P07809410A0606|26 31|lesion
P07811639A0222|0 16|Endo16 transcripts
P07811639A0222|80 92|gastrula stage
P07811639A0222|154 159|midgut
P07811639A0222|50 54|plate
P07811639A0222|125 135|archenteron
P07811639A0222|65 76|stage embryos
P07811639A0222|97 100|gene
P07811964A1252|100 103|role
P07811964A1252|66 71|domain
P07811964A1252|22 34|repeat element
P07811964A1252|119 130|dimerization
P07811964A1252|74 79|EmBP-1
P07812450A0849|58 65|nspC gene
P07812450A0849|11 13|ORF
P07812450A0849|35 40|strand
P07813466A0074|26 28|rat
P07813466A0074|135 145|protein gene
P07813466A0074|147 151|hsc70
P07813466A0074|54 58|trout
P07813466A0074|75 81|introns
P07813466A0074|3 10|U14 genes
P07813466A0074|30 36|hamster
P07813466A0074|44 50|Xenopus
P07813466A0074|13 17|mouse
P07813786A0641|61 75|XMyoDa TATA motif
P07813786A0641|37 44|proteins
P07813786A0641|10 14|cDNAs
P07814321A0850|14 17|prfA
P07814321A0850|21 24|ponA
P07814321A0850|58 66|reduction
P07814321A0850|48 53|growth
P07814321A0850|69 89|sporulation efficiency
P07814321A0850|0 7|Deletion
P07814323A0313|43 46|FliQ
P07814323A0313|23 30|proteins
P07814323A0313|50 53|FliR
P07814323A0313|15 20|family
P07814323A0313|96 112|flagellum assembly
P07814323A0313|72 84|export pathway
P07814323A0313|0 8|Inclusion
P07814388A0662|98 128|pertussis toxin substrate activity
P07814388A0662|8 22|L-cell membranes
P07814388A0662|49 55|M6P/IGF
P07814388A0662|37 40|type
P07814388A0662|70 74|nM IGF
P07814388A0662|58 66|receptors
P07814403A0433|0 3|Chem
P07814405A1170|156 163|proteins
P07814405A1170|25 32|deletion
P07814405A1170|11 14|time
P07814405A1170|81 104|guanylyl cyclase receptors
P07814405A1170|36 49|point mutations
P07814405A1170|120 128|formation
P07814405A1170|59 78|plasma membrane family
P07814717A0669|0 7|Increase
P07814717A0669|79 92|concentrations
P07814717A0669|47 63|AA supplementation
P07814717A0669|10 18|blood NEFA
P07814717A0669|100 102|Met
P07814717A0669|95 97|Lys
P07814717A0669|105 109|blood
P07814717A0669|40 42|fat
P07814717A0669|70 76|changes
P07815546A0411|0 4|Virol
P07815811A1487b|104 117|concentrations
P07815811A1487b|163 168|bypass
P07815811A1487b|81 94|norepinephrine
P07815811A1487b|8 23|vasoconstriction
P07815811A1487b|32 43|endothelin-1
P07815811A1487b|56 75|ischemia-reperfusion
P07816025A0196|0 9|Comparison
P07816025A0196|107 110|Coix
P07816025A0196|81 95|gamma-prolamins
P07816025A0196|22 38|amino acid sequence
P07816025A0196|98 102|maize
P07816025A0196|70 78|sequences
P07816025A0196|134 140|domains
P07816025A0196|41 53|gamma-kafirin
P07816049A0686|0 5|Atcys1
P07816049A0686|73 80|polarity
P07816049A0686|211 223|transcription
P07816049A0686|7 12|Athyp1
P07816049A0686|160 167|elements
P07816049A0686|101 107|regions
P07816049A0686|26 28|ORF
P07816049A0686|141 142|kb
P07816049A0686|198 208|termination
P07816049A0686|14 19|AKin10
P07816049A0686|185 194|initiation
P07816049A1157|59 62|copy
P07816049A1157|107 126|Northern blot analysis
P07816049A1157|81 86|AKin10
P07816049A1157|184 188|roots
P07816049A1157|151 155|genes
P07816049A1157|90 102|haploid genome
P07816049A1157|46 53|presence
P07816049A1157|65 70|Atcys1
P07816049A1157|72 77|Athyp1
P07816049A1157|0 35|Southern blot hybridization experiments
P07816617A0763|5 11|results
P07816617A0763|51 55|genes
P07816617A0763|23 26|HAC1
P07816619A0000|74 82|phenotype
P07816619A0000|141 161|cAMP phosphodiesterase
P07816619A0000|112 121|pde1 mutant
P07816619A0000|20 48|Arabidopsis thaliana cDNA clones
P07816619A0872|15 28|identification
P07816619A0872|93 99|protein
P07816619A0872|40 46|protein
P07816619A0872|156 178|transcription initiation
P07816619A0872|115 120|genera
P07816619A0872|137 145|mechanism
P07816619A0872|49 58|A.thaliana
P07816619A0872|79 86|ubiquity
P07816619A0872|191 193|Dr1
P07816630A1333|29 36|sequence
P07816630A1333|127 132|region
P07816630A1333|52 75|translation terminator TGA
P07816630A1333|138 145|H4-I gene
P07816630A1333|81 92|beta-tubulin
P07816630A1333|25 26|bp
P07816630A1333|95 98|BTU2
P07816630A1333|100 103|gene
P07816808A1102|127 136|Arthropoda
P07816808A1102|5 8|data
P07816808A1102|59 66|nematode
P07816808A1102|38 42|genes
P07816808A1102|140 147|Chordata
P07816808A1102|118 121|rise
P07816808A1102|27 35|STR family
P07816808A1102|72 79|ancestor
P07818416A0895|86 88|g/L
P07818416A0895|125 127|g/L
P07818416A0895|115 117|THR
P07818416A0895|148 158|revision THR
P07818416A0895|63 67|group
P07818416A0895|23 47|haemoglobin concentrations
P07818416A0895|134 142|instances
P07819225A1094|100 106|Lys-220
P07819225A1094|62 72|suppression
P07819225A1094|25 31|residue
P07819225A1094|166 187|tetracycline resistance
P07819225A1094|110 116|Gln-220
P07819225A1094|78 92|Asn-285 mutation
P07819225A1094|140 152|Asn-285 mutant
P07819225A1094|128 134|mutants
P07819225A1094|212 216|WORDS
P07819225A1094|43 46|site
P07819225A1094|3 14|introduction
P07819225A1094|190 197|ABSTRACT
P07820057A0000|0 23|Tumor necrosis factor alpha
P07820057A0000|66 78|growth control
P07820057A0000|121 130|properties
P07820057A0000|107 110|bone
P07820057A0000|28 35|cytokine
P07820057A0000|86 97|cell leukemia
P07821790A1084|112 125|transactivator
P07821790A1084|62 70|repressor
P07821790A1084|12 16|UCRBP
P07821790A1084|145 155|UCR elements
P07821790A1084|129 136|reporter
P07821790A1084|166 186|co-transfection assays
P07821790A1084|86 90|UCRBP
P07822161A1172|13 23|monkey opsin
P07822161A1172|61 70|nucleotide
P07822161A1172|136 143|residues
P07822161A1172|77 91|amino acid levels
P07822161A1172|48 55|sequence
P07822161A1172|3 10|sequence
P07822161A1172|117 127|differences
P07822329A0773|128 131|mass
P07822329A0773|52 56|cells
P07822329A0773|3 9|complex
P07822329A0773|149 151|kDa
P07822329A0773|73 79|binding
P07822329A0773|99 104|factor
P07822333A0376|0 3|Chem
P07823919A1422|30 37|promoter
P07823919A1422|23 27|Oct-3
P07823919A1422|40 42|RAR
P07823919A1422|11 20|activation
P07823919A1422|89 96|COUP-TFI
P07823919A1422|83 87|EAR-3
P07823919A1422|102 106|ARP-1
P07823919A1422|44 58|RXR heterodimers
P07823951A1100|73 88|globin expression
P07823951A1100|147 151|CACCC
P07823951A1100|136 144|regulator
P07823951A1100|111 114|idea
P07823951A1100|168 180|transcription
P07823951A1100|27 30|EKLF
P07823951A1100|47 69|transactivation function
P07823951A1100|5 11|results
P07823951A1100|119 122|EKLF
P07823951A1100|192 196|cells
P07823953A0777|110 115|region
P07823953A0777|15 33|I kappa B alpha mutants
P07823953A0777|262 271|inhibition
P07823953A0777|274 283|DNA binding
P07823953A0777|400 407|subunits
P07823953A0777|243 248|region
P07823953A0777|215 219|dimer
P07823953A0777|118 129|I kappa B alpha
P07823953A0777|49 53|dimer
P07823953A0777|296 305|inhibition
P07823953A0777|161 167|binding
P07823953A0777|361 366|region
P07823953A0777|384 389|region
P07823953A0777|178 181|mask
P07823953A0777|66 85|I kappa B alpha molecule
P07823953A0777|331 341|interaction
P07823953A0777|6 12|battery
P07823953A0777|413 417|dimer
P07823953A0777|192 209|localization signal
P07823964A0922|44 49|domain
P07823964A0922|102 106|trans
P07823964A0922|77 83|segment
P07823964A0922|21 28|activity
P07823964A0922|86 91|Pho81p
P07824325A0714|29 38|procedures
P07824325A0714|107 114|patients
P07824325A0714|207 217|microgram/g
P07824325A0714|177 179|MIC
P07824325A0714|126 149|vancomycin concentrations
P07824325A0714|40 52|thorax opening
P07824325A0714|162 168|tissues
P07824325A0714|64 69|period
P07824325A0714|101 101|%
P07824325A0714|249 260|micrograms/g
P07824325A0714|56 62|closure
P07824325A0714|11 15|times
P07824325A0714|87 92|bypass
P07824325A0714|117 121|group
P07824464A0169|207 216|mechanisms
P07824464A0169|26 36|tissue flaps
P07824464A0169|123 134|fissurations
P07824464A0169|82 102|artery wall dissections
P07824464A0169|149 160|haemorrhages
P07824464A0169|50 54|lumen
P07824464A0169|104 117|plaque ruptures
P07824464A0169|18 23|images
P07824464A0169|227 240|artery stenosis
P07824464A0169|179 184|colour
P07824464A0169|74 80|thrombi
P07824657A1456|54 60|sulfite
P07824657A1456|11 27|cysteine formation
P07824657A1456|78 86|leaf discs
P07824657A1456|31 41|pCSK4F plant
P07824726A0454|56 59|body
P07824726A0454|72 79|pancreas
P07824726A0454|134 149|fatty replacement
P07824726A0454|63 66|tail
P07824726A0454|151 155|type b
P07824726A0454|110 113|type
P07824726A0454|25 33|subgroups
P07824726A0454|4 7|type
P07824726A0454|175 190|fatty replacement
P07824726A0454|93 108|fatty replacement
P07824726A0454|39 43|basis
P07825888A0715|60 70|differences
P07825888A0715|78 91|cortisol levels
P07825888A0715|10 18|subgroups
P07825888A0715|21 37|dementia disorders
P07826412T0112|58 71|gamma-subunits
P07826412T0112|4 13|hypothesis
P07826412T0112|48 55|subunits
P07826412T0112|75 84|activation
P07826412T0112|16 25|mechanisms
P07826412T0112|100 109|transducin
P07826412T0112|88 97|holoenzyme
P07826625X0000|86 102|activation domains
P07826625X0000|71 77|protein
P07826625X0000|216 230|proline residues
P07826625X0000|20 41|transcription apparatus
P07826625X0000|258 274|activation domains
P07826625X0000|129 134|domain
P07826625X0000|361 382|polyglutamine stretches
P07826625X0000|183 189|Regions
P07826625X0000|299 303|parts
P07826625X0000|167 180|enhancer domain
P07826625X0000|196 201|serine
P07826625X0000|43 55|RNA polymerase
P07826625X0000|136 138|CTD
P07826625X0000|142 154|RNA polymerase
P07826625X0000|327 334|proteins
P07826625X0000|5 14|components
P07826625X0000|203 211|threonine
P07828584A0681|0 10|Mutagenesis
P07828584A0681|36 40|c-Fos
P07828584A0681|13 15|IM1
P07828584A0681|53 70|AP1 bearing promoter
P07828584A0681|27 33|ability
P07828600A0095|0 6|Binding
P07828600A0095|17 36|stage selector element
P07828600A0095|170 173|K562
P07828600A0095|9 11|SSP
P07828600A0095|38 40|SSE
P07828600A0095|101 109|silencing
P07828600A0095|119 131|beta-promoter
P07828600A0095|55 74|gamma-globin promoter
P07828600A0095|149 168|stage erythroleukemia
P07828600A0095|175 179|cells
P07828811A0556|29 38|G1/S arrest
P07828811A0556|63 79|thermosensitivity
P07828811A0556|96 102|ability
P07828811A0556|4 10|failure
P07828824A0307|0 8|Mutations
P07828824A0307|95 103|deletions
P07828824A0307|47 57|development
P07828824A0307|18 43|photoreceptor cell structure
P07828852A0153|55 63|functions
P07828852A0153|36 41|nuclei
P07828852A0153|19 27|telomeres
P07829057A1097|3 14|marker orders
P07829057A1097|32 37|RH maps
P07829057T0000|0 24|Integrated mapping analysis
P07829057T0000|52 61|chromosome
P07829057T0000|30 49|Werner syndrome region
P07829097A0000|16 20|DXS52
P07829097A0000|76 78|G+C
P07829097A0000|103 107|genes
P07829097A0000|34 37|gene
P07829097A0000|24 29|Factor
P07829097A0000|63 66|band
P07829097A0000|48 51|Xq28
P07829097A0000|3 8|region
P07829097A0000|84 91|isochore
P07829102T0000|103 111|parasites
P07829102T0000|77 85|infection
P07829102T0000|61 74|susceptibility
P07829102T0000|40 53|mouse Nramp gene
P07829102T0000|19 34|sequence analysis
P07829102T0000|0 15|Haplotype mapping
P07829519A1251|145 160|immunoglobulin mu
P07829519A1251|166 170|chain
P07829519A1251|64 72|exon usage
P07829519A1251|90 98|mechanism
P07829519A1251|4 14|utilization
P07829519A1251|196 200|locus
P07829519A1251|135 139|forms
P07829519A1251|27 45|polyadenylation site
P07829554A0257|236 243|antibody
P07829554A0257|128 139|wear products
P07829554A0257|211 215|ELISA
P07829554A0257|263 268|metals
P07829554A0257|160 166|devices
P07829554A0257|98 114|protein conjugates
P07829554A0257|226 232|testing
P07829554A0257|217 222|method
P07829554A0257|50 63|system response
P07829554A0257|116 124|corrosion
P07829554A0257|252 259|immunity
P07829554A0257|12 20|knowledge
P07829554A0257|205 209|assay
P07830112A0532|229 229|p
P07830112A0532|149 152|TPFR
P07830112A0532|63 65|EDV
P07830112A0532|239 246|patients
P07830112A0532|271 277|normals
P07830112A0532|131 131|p
P07830112A0532|210 218|mass index
P07830112A0532|70 81|stroke volume
P07830112A0532|22 25|rate
P07830112A0532|103 107|ratio
P07830112A0532|251 260|acromegaly
P07830112A0532|145 147|PFR
P07830112A0532|56 61|volume
P07830112A0532|139 142|time
P07830112A0532|11 14|peak
P07830112A0532|110 119|PFR-to-PER
P07830112A0532|167 167|p
P07830112A0532|83 84|SV
P07830112A0532|2 9|contrast
P07830112A0532|27 29|PFR
P07831310A0000|69 78|polymerase
P07831310A0000|113 123|protoplasts
P07831310A0000|48 63|tobacco etch virus
P07831310A0000|105 110|plants
P07831310A0000|8 28|complementation system
P07831310A0000|155 164|TEV mutants
P07831310A0000|65 67|TEV
P07831310A0000|80 82|NIb
P07831799T0000|0 17|Nucleotide sequence
P07831799T0000|68 73|Bombyx
P07831799T0000|49 65|DNA polymerase gene
P07831799T0000|36 43|analysis
P07831799T0000|85 101|polyhedrosis virus
P07831829A1324|0 9|Comparison
P07831829A1324|52 62|furoviruses
P07831829A1324|38 42|SBWMV
P07831829A1324|24 27|PMTV
P07831829A1324|97 114|genome organization
P07831829A1324|82 94|heterogeneity
P07831829A1324|15 21|genomes
P07831829A1324|29 33|BNYVV
P07832086A1023|114 123|fosfomycin
P07832086A1023|46 46|%
P07832086A1023|80 83|MINO
P07832086A1023|125 127|FOM
P07832086A1023|24 24|%
P07832086A1023|50 57|imipenam
P07832086A1023|101 103|AMK
P07832086A1023|110 110|%
P07832086A1023|66 66|%
P07832086A1023|39 41|VCM
P07832086A1023|88 88|%
P07832086A1023|70 78|minomycin
P07832086A1023|3 17|drug sensitivity
P07832086A1023|92 99|amikacin
P07832086A1023|59 61|IMP
P07832086A1023|28 37|vancomycin
P07832779A0719|0 14|Deglycosylation
P07832779A0719|54 62|receptors
P07832779A0719|84 104|oligosaccharide chains
P07832779A0719|19 34|endoglycosidase H
P07834582A0115|84 91|property
P07834582A0115|104 109|humans
P07834582A0115|38 44|n-3 EFAs
P07834582A0115|21 27|fish oil
P07834582A0115|136 147|hypertension
P07834582A0115|7 16|supplement
P07834582A0115|94 100|animals
P07835088A0238|130 151|chromosome 1p13.1 region
P07835088A0238|12 22|HSD3B2 genes
P07835088A0238|34 38|types
P07835088A0238|112 124|hybridization
P07835088A0238|46 63|beta-HSD isoenzymes
P07835088A0238|3 8|HSD3B1
P07835214A0603|30 37|diabetes
P07835214A0603|52 52|%
P07835214A0603|12 22|prevalences
P07835214A0603|41 43|GDM
P07835214A0603|60 60|%
P07835273A0000|61 75|insulin receptor
P07835273A0000|36 45|adipocytes
P07835273A0000|18 33|glucose transport
P07835273A0411|29 38|adipocytes
P07835273A0411|153 168|3T3-L1 adipocytes
P07835273A0411|50 63|EGFR expression
P07835273A0411|171 179|5000/cell
P07835273A0411|115 118|cell
P07835273A0411|17 26|conversion
P07835273A0411|5 13|selection
P07835273A0411|86 95|adipocytes
P07835273A0411|43 47|level
P07835710T0000|25 38|porcine I kappa B
P07835710T0000|53 56|gene
P07835710T0000|11 19|structure
P07835826A0195|0 7|Fraction
P07835826A0195|50 51|OH
P07835826A0195|25 35|2-vitamin D3
P07835826A0195|54 62|vitamin D3
P07835826A0195|37 45|vitamin D3
P07835826A0195|22 23|OH
P07835826A0195|77 87|3-vitamin D3
P07835826A0195|74 75|OH
P07835886A0894|58 76|chromosome 14q31-q32
P07835886A0894|109 131|alpha 1-antichymotrypsin
P07835886A0894|90 100|serpin genes
P07835886A0894|38 50|hybridization
P07835886A0894|151 168|alpha 1-antitrypsin
P07835886A0894|3 17|kallistatin gene
P07835886A0894|195 202|globulin
P07835886A0894|133 149|protein C inhibitor
P07835888A0402|84 100|haplotype analysis
P07835888A0402|36 37|Xd
P07835888A0402|59 62|part
P07835888A0402|119 131|backcross mice
P07835888A0402|19 24|XD gene
P07835888A0402|65 79|mouse chromosome
P07835888A0402|3 7|locus
P07836218A0128|13 20|exercise
P07836218A0128|35 55|beta-endorphin release
P07836218A0128|144 157|beta-endorphin
P07836218A0128|92 99|evidence
P07836218A0128|112 119|acidosis
P07836218A0128|69 82|exertion levels
P07836218A0128|4 10|studies
P07836218A0128|135 141|release
P07836228A1052|84 87|drop
P07836228A1052|103 110|pressure
P07836228A1052|13 25|communication
P07836228A1052|50 59|LV function
P07836228A1052|38 47|impairment
P07836364A0000|0 3|Self
P07836364A0000|92 94|MHC
P07836364A0000|36 43|peptides
P07836364A0000|21 28|proteins
P07836364A0000|66 90|histocompatibility complex
P07836364A0000|125 146|antigen presenting cells
P07836364A0000|116 122|surface
P07836364A0000|148 150|APC
P07836364A0000|96 100|class
P07836364A0000|47 58|presentation
P07836364A0000|102 110|molecules
P07836390A1152|105 116|IncP plasmids
P07836390A1152|127 136|initiation
P07836390A1152|92 102|relaxosomes
P07836390A1152|3 17|characteristics
P07836390A1152|139 160|transfer DNA replication
P07836390A1152|176 186|conjugation
P07836390A1152|43 58|cleavage reaction
P07836406A0884|163 176|chromatography
P07836406A0884|49 53|MHC-B
P07836406A0884|98 111|phosphopeptide
P07836406A0884|72 81|cdc2 kinase
P07836406A0884|146 156|performance
P07836406A0884|28 35|peptides
P07836471A0375|30 30|%
P07836471A0375|10 24|protein sequence
P07836471A0375|49 52|hNUC
P07836471A0375|72 88|osteosarcoma cells
P07838156A0789|158 166|repressor
P07838156A0789|41 43|RVR
P07838156A0789|113 124|reporter gene
P07838156A0789|8 28|cotransfection studies
P07838156A0789|169 184|ROR alpha function
P07838156A0789|80 101|hormone response element
P07838156A0789|59 71|transcription
P07840643A1006|105 112|identity
P07840643A1006|170 174|forms
P07840643A1006|118 118|%
P07840643A1006|64 83|glycosylasparaginase
P07840643A1006|94 94|%
P07840643A1006|16 49|Flavobacterium glycosylasparaginase
P07840643A1006|126 135|similarity
P07840643A1006|180 185|enzyme
P07840643A1006|1 10|comparison
P07841230T0000|15 26|complexation
P07841230T0000|47 60|antimicrobials
P07841230T0000|0 11|Dissociation
P07841663A0685|0 18|Superoxide dismutase
P07841663A0685|153 158|medium
P07841663A0685|95 104|comparison
P07841663A0685|56 60|sperm
P07841663A0685|110 116|control
P07841663A0685|24 31|activity
P07841663A0685|20 22|SOD
P07841663A0685|122 127|sample
P07841663A0845|118 121|part
P07841663A0845|77 89|oxygen species
P07841663A0845|50 60|stimulation
P07841663A0845|148 158|sperm motion
P07841663A0845|5 11|studies
P07841663A0845|162 170|viability
P07841663A0845|99 109|SOD activity
P07844142A0640|99 105|SR alpha
P07844142A0640|19 28|sequencing
P07844142A0640|118 123|member
P07844142A0640|9 15|cloning
P07844142A0640|109 113|SRP54
P07844142A0640|62 67|SR beta
P07844142A0640|129 145|GTPase superfamily
P07844142A0640|44 49|SR beta
P07844142A0640|32 35|cDNA
P07844142A0640|84 90|protein
P07844155A0327|161 169|processes
P07844155A0327|68 78|development
P07844155A0327|40 59|tyrosine phosphatases
P07844155A0327|144 149|system
P07844155A0327|15 22|function
P07844155A0327|98 108|LAR isoforms
P07844155A0327|194 201|splicing
P07844155A0327|180 182|LAR
P07844201T0000|0 11|Sex selection
P07844201T0000|39 45|results
P07844201T0000|32 36|years
P07844201T0000|15 28|albumin columns
P07844425A0289|15 19|count
P07844425A0289|42 46|urine
P07844425A0289|32 40|eggs/10 ml
P07844425A0289|65 73|eggs/10ml
P07844425A0289|3 10|students
P07844555A0406|116 120|birth
P07844555A0406|20 27|E mu pim-1
P07844555A0406|38 41|mice
P07844555A0406|108 113|M-MuLV
P07844555A0406|64 82|lymphoma development
P07845672A0368|129 137|% identity
P07845672A0368|26 37|blk sequences
P07845672A0368|120 125|domain
P07845672A0368|62 79|% amino acid identity
P07845672A0368|97 102|region
P07845672A0368|0 9|Comparison
P07846153A0403|0 9|Chrispeels
P07846153A0403|16 20|EMBO J
P07846163A0422|13 20|GRF genes
P07846163A0422|36 40|exons
P07846163A0422|58 64|introns
P07846163A0422|3 7|mRNAs
P07846199A0000|3 8|effect
P07846199A0000|11 17|ethanol
P07846199A0000|25 46|sensorimotor reactivity
P07846199A0000|80 94|startle response
P07846942A0717|0 18|Digitalis glycosides
P07846942A0717|63 69|therapy
P07846942A0717|88 99|fibrillation
P07846942A0717|127 131|drugs
P07846942A0717|76 79|form
P07846942A0717|107 111|class
P07846942A0717|21 44|beta-receptor antagonists
P07846942T0001|6 17|fibrillation
P07846942T0001|40 45|system
P07847036A0353|14 18|times
P07847036A0353|62 70|inhibitor
P07847036A0353|6 10|doses
P07847036A0353|42 54|haemophiliacs
P07848358A0254|15 47|aspartate aminotransferase activity
P07848358A0254|76 83|d onwards
P07848358A0254|66 74|mg/kg b.w.
P07848358A0254|1 9|reduction
P07851643A1365|86 98|germline cells
P07851643A1365|10 16|studies
P07851643A1365|112 132|oocyte differentiation
P07851643A1365|39 45|isoform
P07851643A1365|65 77|proliferation
P07851758A0330|46 49|TPK2
P07851758A0330|26 38|chromosome XVI
P07851758A0330|53 57|spt14
P07851758A0330|8 23|analysis maps SAL6
P07852037A0548|15 29|DCT method yields
P07852037A0548|38 41|data
P07852037A0548|53 55|TBF
P07852361A0868|0 6|Removal
P07852361A0868|9 12|PDMP
P07852361A0868|74 78|cells
P07852361A0868|93 98|S phase
P07852361A0868|20 29|cell medium
P07852361A0868|53 68|cell cycle changes
P07852361A0868|40 47|reversal
P07852400A0519|0 26|Rho GDP/GTP exchange inhibitor
P07852400A0519|56 59|RhoA
P07852400A0519|49 52|Rac2
P07852400A0519|67 70|Rac1
P07852400A0519|28 33|Rho GDI
P07853448A0601|56 61|nature
P07853448A0601|76 80|model
P07853448A0601|86 99|sport performer
P07853448A0601|6 9|task
P07853448A0601|13 28|sports scientists
P07853476A0159|0 6|Schnell
P07853476A0159|8 9|J.
P07853488T0000|15 33|poliovirus replicons
P07853488T0000|58 82|immunodeficiency virus type
P07853488T0000|153 157|trans
P07853488T0000|136 150|P1 capsid protein
P07853488T0000|84 90|gag gene
P07853488T0000|99 119|complementation system
P07853488T0000|0 12|Encapsidation
P07853524A1944|0 6|Removal
P07853524A1944|34 41|thrombin
P07853524A1944|25 31|GST-Tax
P07853524A1944|50 52|Tax
P07853524A1944|12 20|GST domain
P07853524A1944|55 61|ability
P07853524A1944|110 117|ABSTRACT
P07853524A1944|80 107|Tax-CREB-21-bp-repeat complex
P07853524A1944|132 136|WORDS
P07854130A1387|16 19|PilE
P07854130A1387|103 107|pilus
P07854130A1387|112 129|twitching-motility
P07854130A1387|22 36|pilus biogenesis
P07854130A1387|79 98|pilE insertion mutants
P07854130A1387|3 13|requirement
P07854130T0000|118 121|type
P07854130T0000|53 67|pilus biogenesis
P07854130T0000|123 138|prepilin proteins
P07854130T0000|107 115|N-termini
P07854130T0000|69 99|shares amino acid sequence identity
P07854130T0000|3 17|pilE gene product
P07854324A0281|137 145|mutations
P07854324A0281|77 90|vertebrate wee1
P07854324A0281|64 73|expression
P07854324A0281|148 152|yeast
P07854324A0281|22 33|conservation
P07854324A0281|36 59|cell cycle control elements
P07854324A0281|93 103|mik1 homolog
P07854324A0742|101 116|growth conditions
P07854324A0742|19 23|clone
P07854324A0742|52 57|causes
P07854324A0742|3 12|expression
P07854324A0742|69 81|cell phenotype
P07856102A1616|84 96|virus assembly
P07856102A1616|38 45|M protein
P07856102A1616|62 66|sites
P07856102A1616|21 35|phosphorylation
P07856102A1616|5 8|data
P07857086A0949|84 89|H White
P07857086A0949|55 73|Non Insulin Dependent
P07857086A0949|19 25|Insulin
P07857086A0949|50 50|%
P07857086A0949|92 96|Class
P07857086A0949|80 80|D
P07857086A0949|15 15|%
P07857086A0949|82 82|F
P07857163A0551|13 30|6-fluoroquinolones
P07857163A0551|53 63|derivatives
P07857163A0551|3 10|activity
P07857344A0591|68 73|change
P07857344A0591|76 106|pidotimod administration schedule
P07857344A0591|49 52|data
P07857344A0591|5 13|half-life
P07857344A0591|19 26|compound
P07857344A0591|118 118|h
P07857344A0591|44 44|h
P07857762A0611|41 50|eukaryotes
P07857762A0611|80 88|responses
P07857762A0611|3 18|MAP kinase cascade
P07858986A0310|148 153|valves
P07858986A0310|69 74|valves
P07858986A0310|168 190|glutaraldehyde treatment
P07858986A0310|106 115|BioImplant
P07858986A0310|12 16|study
P07858986A0310|81 101|Carpentier-Edwards SAV
P07858986A0310|49 55|porcine
P07858986A0310|122 127|Valcor
P07858986A0310|30 43|interferometry
P07859238A1150|9 19|side effects
P07859301A0325|121 145|transcription factor family
P07859301A0325|35 40|domain
P07859301A0325|70 89|leucine-zipper motifs
P07859301A0325|4 9|region
P07859301A0325|91 98|features
P07859371A1246|58 71|mouse fragments
P07859371A1246|53 55|rat
P07859371A1246|90 97|extracts
P07859371A1246|8 14|binding
P07859665A0498|3 12|mean jitter
P07859665A0498|60 62|day
P07859665A0498|19 30|fiber density
P07859665A0498|101 103|day
P07859665A0498|75 86|microseconds
P07859665A0498|117 128|microseconds
P07859739T0000|0 3|Lack
P07859739T0000|39 43|cells
P07859739T0000|62 67|levels
P07859739T0000|6 25|cyclin D-Cdk complexes
P07859739T0000|70 108|p16INK4/MTS1 tumour suppressor gene product
P07859777A0000|29 32|rHSA
P07859777A0000|152 165|technetium-99m
P07859777A0000|90 102|microcapsules
P07859777A0000|196 203|chloride
P07859777A0000|115 121|microns
P07859777A0000|52 63|fermentation
P07859777A0000|175 183|reduction
P07859777A0000|124 131|diameter
P07859777A0000|84 87|form
P07859777A0000|16 27|serum albumin
P07860208A0000|26 42|interleukin-1 beta
P07860208A0000|109 117|monocytes
P07860208A0000|79 81|TNF
P07860208A0000|259 266|controls
P07860208A0000|52 77|tumour necrosis factor-alpha
P07860208A0000|224 241|glomerulonephritis
P07860208A0000|132 149|lipopolysaccharide
P07860208A0000|17 23|release
P07860208A0000|97 105|monocytes
P07860208A0000|44 47|IL-1
P07860208A0000|151 153|LPS
P07860208A0000|190 197|patients
P07860208A0000|243 245|AGN
P07860208A0000|180 184|blood
P07860646A1363|6 17|intervention
P07860646A1363|46 54|treatment
P07860646A1363|37 39|use
P07860646A1363|79 86|diseases
P07860646A1363|96 100|FGF-2
P07862092A0302|150 163|haploid strains
P07862092A0302|211 219|libraries
P07862092A0302|105 119|mutation pol3-11
P07862092A0302|178 190|pol3-11 sdp5-1
P07862092A0302|222 231|singlecopy
P07862092A0302|17 21|clone
P07862092A0302|96 101|sdp5-1
P07862092A0302|44 54|suppressors
P07862092A0302|78 92|mutation pol3-14
P07862092A0302|61 69|ts mutants
P07862092A0302|71 74|sdp1
P07862092A0302|171 174|sdp1
P07862092A0302|243 249|vectors
P07862108A0987|0 25|UV cross-linking experiments
P07862108A0987|80 82|kDa
P07862108A0987|34 36|TEP
P07862108A0987|59 62|mass
P07862129A1391|132 138|TTR gene
P07862129A1391|103 112|expression
P07862129A1391|13 18|livers
P07862129A1391|90 97|decrease
P07862129A1391|39 47|reduction
P07862129A1391|50 69|HNF-3 alpha expression
P07862129A1391|118 127|target gene
P07862141A0317|30 36|alleles
P07862141A0317|92 106|differentiation
P07862141A0317|55 62|cAPK lead
P07862141A0317|68 76|inability
P07862141A0317|39 43|genes
P07862141A1412|15 20|family
P07862141A1412|22 25|RFX1
P07862141A1412|53 59|variety
P07862141A1412|78 82|genes
P07862141A1412|3 8|member
P07862141A1412|30 48|transcription factor
P07862150A0429|72 79|mink lung
P07862150A0429|194 201|TGF-beta
P07862150A0429|114 136|TGF-beta binding activity
P07862150A0429|64 69|series
P07862150A0429|183 191|responses
P07862150A0429|90 99|cell clones
P07862150A0429|57 62|vector
P07862150A0429|4 9|mutant
P07862154A0340|0 6|Cloning
P07862154A0340|55 62|analysis
P07862154A0340|9 23|complementation
P07862154A0340|83 86|RAF1
P07862162A0408|26 32|choline
P07862162A0408|104 116|UASINO element
P07862162A0408|61 68|OPI1 gene
P07862162A0408|78 90|transcription
P07862162A0408|49 55|product
P07862162A0408|5 12|presence
P07862162A0408|15 22|inositol
P07862165A0184|28 43|oligonucleotides
P07862165A0184|166 179|helix formation
P07862165A0184|52 59|psoralen
P07862165A0184|139 143|cells
P07862165A0184|102 106|virus
P07862165A0184|110 113|SV40
P07862165A0184|10 23|monkey COS cells
P07862165A0184|84 92|mutations
P07862165A0184|115 120|vector
P07862168A0000|15 33|receptor alpha-chain
P07862168A0000|35 44|IL-2R alpha
P07862168A0000|87 94|response
P07862168A0000|79 84|T cells
P07862168A0000|106 112|stimuli
P07862168A0000|46 49|gene
P07862168A0000|3 13|interleukin
P07862533A0000|175 179|EGR-1
P07862533A0000|33 35|WT1
P07862533A0000|3 7|Wilms
P07862533A0000|181 187|protein
P07862533A0000|9 31|tumour suppressor protein
P07862533A0000|73 79|protein
P07862533A0000|132 147|sequence homology
P07862533A0000|88 98|zinc fingers
P07862533A0000|158 173|growth response-1
P07863047A0229|144 154|correlation
P07863047A0229|162 164|ACE
P07863047A0229|208 216|parameter
P07863047A0229|113 116|CAOT
P07863047A0229|24 39|serum ACE activity
P07863047A0229|99 111|oxygen therapy
P07863047A0229|54 57|COPD
P07863047A0229|42 49|patients
P07863047A0229|0 9|OBJECTIVES
P07863619A0098|145 151|objects
P07863619A0098|105 110|object
P07863619A0098|75 83|fragments
P07863619A0098|23 29|contour
P07863619A0098|45 50|system
P07863619A0098|123 131|fragments
P07863619A0098|2 6|order
P07863619A0098|14 18|shape
P07863992A0908|70 77|evidence
P07863992A0908|33 38|result
P07863992A0908|103 115|mean follow-up
P07863992A0908|144 151|episodes
P07863992A0908|119 123|years
P07863992A0908|6 10|group
P07863992A0908|179 188|medication
P07863992A0908|90 101|heart disease
P07863992A0908|58 64|testing
P07863992A0908|218 225|exercise
P07863992A0908|154 160|syncope
P07863992A0908|12 19|patients
P07864652A0753|0 9|Constructs
P07864652A0753|143 159|amino acid sequence
P07864652A0753|45 48|E2L1
P07864652A0753|79 80|L2
P07864652A0753|166 173|portions
P07864652A0753|74 77|E2H1
P07864652A0753|50 51|H1
P07864652A0753|34 37|E2L1
P07864652A0753|60 63|E2L2
P07864652A0753|101 102|L2
P07864652A0753|116 122|numbers
P07864652A0753|98 99|H1
P07864652A0753|207 215|construct
P07864652A0753|125 135|parentheses
P07864652A0753|93 96|E2L1
P07864652A0753|179 189|E2 component
P07864652A1901|85 88|E2L1
P07864652A1901|92 95|E2L2
P07864652A1901|25 40|domain constructs
P07864652A1901|78 82|roles
P07864652A1901|132 140|processes
P07864709A0324|0 6|METHODS
P07864709A0324|122 138|enzyme immunoassay
P07864709A0324|22 25|H3N2
P07864709A0324|75 84|resistance
P07864709A0324|51 59|outbreaks
P07864709A0324|171 174|acid
P07864709A0324|11 20|influenza A
P07864709A0324|113 117|means
P07864709A0324|213 221|M2 protein
P07864709A0324|100 110|rimantadine
P07864709A0324|202 207|domain
P07864709A0324|27 33|viruses
P07864709A0324|144 153|sequencing
P07864709A0324|87 96|amantadine
P07865129A0293|16 22|ATF/CRE
P07865129A0293|26 47|TBP/TATA sequence motifs
P07865129A0293|61 66|region
P07865786A0457|0 13|Gene expression
P07865786A0457|77 82|plants
P07865786A0457|50 54|light
P07865786A0457|32 37|rhythm
P07865786A0457|57 62|leaves
P07865787A1086|73 73|s
P07865787A1086|39 51|octamer motifs
P07865787A1086|26 32|hexamer
P07865787A1086|156 173|wheat histone H3 gene
P07865787A1086|141 150|expression
P07865787A1086|77 86|regulation
P07865787A1086|3 9|results
P07865787A1086|68 71|role
P07865876A1292|131 139|phenotype
P07865876A1292|18 27|expression
P07865876A1292|105 113|DRTF1/E2F
P07865876A1292|145 148|cell
P07865876A1292|60 70|combination
P07865876A1292|30 44|DP family members
P07865876A1292|73 90|DP/E2F heterodimers
P07865888A1309|70 77|membrane
P07865888A1309|107 118|mitochondria
P07865888A1309|21 30|cells PBP74
P07865888A1309|47 57|pre-protein
P07865888A1309|97 102|import
P07865888A1309|125 134|maturation
P07865895A0896|112 120|rationale
P07865895A0896|9 18|experiment
P07865895A0896|187 191|event
P07865895A0896|124 134|LGL/NK cells
P07865895A0896|85 95|LGL/NK cells
P07865895A0896|62 64|mAb
P07865895A0896|175 181|absence
P07865895A0896|34 51|lung clearance assay
P07865895A0896|79 82|rats
P07865895A0896|158 162|event
P07865917A0191|120 126|results
P07865917A0191|20 23|FSGS
P07865917A0191|98 110|ACE inhibitors
P07865917A0191|80 93|plasmapheresis
P07865917A0191|0 8|Treatment
P07865917A0191|62 73|cyclosporine
P07865917A0191|44 51|steroids
P07865917A0191|75 77|CSA
P07867604A1777|218 221|cAMP
P07867604A1777|228 240|phorbol esters
P07867604A1777|195 203|promoters
P07867604A1777|114 122|promoters
P07867604A1777|92 106|initiation sites
P07867604A1777|167 174|elements
P07867604A1777|31 49|inhibin/activin beta
P07867604A1777|3 9|results
P07867604A1777|249 258|conditions
P07867604A1777|59 63|mRNAs
P07867622X0000|164 170|protein
P07867622X0000|174 179|p21rac
P07867622X0000|96 102|protein
P07867622X0000|212 217|events
P07867622X0000|182 188|protein
P07867622X0000|106 111|p21rac
P07867622X0000|34 37|unit
P07867622X0000|113 128|alpha 1-chimaerin
P07867622X0000|46 61|alpha 1-chimaerin
P07867622X0000|0 13|Promoter region
P07867944A0365|0 7|Upstream
P07867944A0365|130 138|promoters
P07867944A0365|39 41|tsp
P07867944A0365|45 62|nucleotide sequence
P07867944A0365|112 116|sigma
P07867944A0365|84 105|consensus sequence motif
P07867944A0365|15 37|transcription start point
P07869721A0000|27 34|dynamics
P07869721A0000|89 108|heart valve prosthesis
P07869721A0000|14 21|analysis
P07869721A0000|6 10|paper
P07869721A0000|57 64|occluder
P07869721A0000|40 51|closing phase
P07869913A1076|86 98|control values
P07869913A1076|113 120|subjects
P07869913A1076|6 19|ISO+AT infusion
P07869913A1076|33 41|blood flow
P07869937A1142|84 86|RMR
P07869937A1142|120 120|%
P07869937A1142|133 138|P group
P07869937A1142|104 111|decrease
P07869937A1142|78 78|%
P07869937A1142|39 41|GIT
P07869937A1142|16 33|kilogram body weight
P07869937A1142|56 62|dF group
P07869937A1142|127 127|%
P07869937A1142|71 71|%
P07870305A1015|188 207|haloperidol influence
P07870305A1015|98 120|nucleus entopeduncularis
P07870305A1015|170 171|ms
P07870305A1015|26 72|thalami-nucleus ventralis lateralis thalami neurons
P07870305A1015|2 17|nucleus ventralis
P07870305A1015|173 173|P
P07870305A1015|89 93|input
P07870305A1015|135 144|inhibition
P07871718A1132|74 89|factors GABP alpha
P07871718A1132|52 63|ICP4 promoter
P07871718A1132|8 16|inclusion
P07871718A1132|125 134|activation
P07871718A1132|93 96|beta
P07871718A1132|33 44|CGGAAR motifs
P07871721A0000|117 119|kDa
P07871721A0000|105 111|protein
P07871721A0000|12 23|reading frame
P07871721A0000|61 66|genome
P07871721A0000|38 53|scorch carlavirus
P07871721A0000|55 59|BBScV
P07871721A0000|121 124|p223
P07871721A0392|49 55|viruses
P07871721A0392|118 133|proteinase domain
P07871721A0392|93 96|p223
P07871721A0392|66 76|tymoviruses
P07871721A0392|170 182|histidine1075
P07871721A0392|156 166|cysteine994
P07871721A0392|4 21|sequence alignments
P07871754A0857|4 10|finding
P07871754A0857|62 78|HPV gene expression
P07871754A0857|109 113|model
P07871754A0857|142 154|cooperativity
P07871754A0857|120 124|study
P07871754A0857|46 54|mechanism
P07871755A0521|16 19|VLPs
P07871755A0521|64 79|characterization
P07871755A0521|9 14|method
P07871755A0521|34 43|quantities
P07871757A0846|71 86|promotor sequence
P07871757A0846|60 67|presence
P07871757A0846|35 49|initiation codon
P07871757A0846|13 20|sequence
P07871757A0846|0 7|Analysis
P07871891A0227|0 4|SUP46
P07871891A0227|19 37|translation fidelity
P07871891A0227|60 69|protein S13
P07872673A0332|133 151|SV40 promoter complex
P07872673A0332|41 45|c-fos
P07872673A0332|63 79|expression plasmid
P07872673A0332|107 115|c-fos gene
P07872673A0332|22 33|relationship
P07872673A0332|49 50|Rb
P07872673A0332|121 127|control
P07872788A1717|158 168|duplication
P07872788A1717|111 115|genes
P07872788A1717|172 181|divergence
P07872788A1717|56 56|C
P07872788A1717|7 12|degree
P07872788A1717|34 34|%
P07872788A1717|89 94|region
P07872788A1717|200 203|gene
P07872788A1717|132 148|carboxylesterases
P07872788A1717|15 30|sequence identity
P07872788A1717|43 52|hydrolase B
P07873631A0114|15 27|tooth fracture
P07873631A0114|3 9|regions
P07873831T0000|19 29|involvement
P07873831T0000|77 80|mass
P07873831T0000|32 47|mycosis fungoides
P07873876A1035|151 156|region
P07873876A1035|45 50|probes
P07873876A1035|57 62|region
P07873876A1035|23 26|tool
P07873876A1035|98 103|probes
P07873876A1035|33 39|mapping
P07873876A1035|118 125|deletion
P07873876A1035|3 11|NR2 hybrid
P07873876A1035|139 145|cloning
P07874060A0810|0 4|TDEYA
P07874060A0810|22 26|mg/kg
P07874060A0810|111 124|administration
P07874060A0810|50 64|xanthine oxidase
P07874060A0810|7 11|doses
P07874060A0810|66 67|XO
P07874060A0810|69 76|activity
P07874060A0810|82 94|stomach tissue
P07875595A0910|14 27|PITSLRE PK genes
P07875595A0910|30 37|chickens
P07875595A0910|134 155|chicken microchromosome
P07875595A0910|101 112|localization
P07875595A0910|4 9|humans
P07875595A0910|120 124|genes
P07875595A0910|82 94|hybridization
P07875595A0910|96 99|FISH
P07876134A0348|116 127|reading frame
P07876134A0348|64 71|AFAP-110
P07876134A0348|58 61|form
P07876134A0348|107 108|bp
P07876134A0348|16 31|characterization
P07876134A0348|98 105|base pair
P07876191A0808|0 9|Expression
P07876191A0808|19 25|ADH mRNA
P07876191A0808|12 16|class
P07876191A0808|44 50|stomach
P07876191A0808|57 61|liver
P07876192A0443|2 9|ICE gamma
P07876192A0443|102 118|ICE autoprocessing
P07876192A0443|20 29|propeptide
P07876192A0443|91 98|catalyst
P07876192A0443|31 40|amino acids
P07876194T0000|0 10|Endocytosis
P07876194T0000|110 129|tyrosine kinase domain
P07876194T0000|23 31|targeting
P07876194T0000|85 93|sequences
P07876194T0000|43 63|growth factor receptors
P07876210A0275|147 162|Barbie box element
P07876210A0275|129 136|proteins
P07876210A0275|80 86|regions
P07876210A0275|59 63|genes
P07876210A0751|0 7|Mutation
P07876210A0751|229 234|levels
P07876210A0751|71 78|P450BM-3
P07876210A0751|172 178|protein
P07876210A0751|182 189|response
P07876210A0751|124 135|P450BM-3 gene
P07876210A0751|205 213|induction
P07876210A0751|55 64|expression
P07876210A0751|82 86|Bm3P1
P07876210A0751|100 103|gene
P07876210A0751|13 29|P450BM-3 Barbie box
P07876300A0994|15 20|nuclei
P07876300A0994|55 67|protein import
P07876562A1646|86 91|T cells
P07876562A1646|103 113|stimulation
P07876562A1646|128 141|HIV-1 infection
P07876562A1646|62 75|responsiveness
P07876562A1646|10 16|outcome
P07876562A1646|35 41|effects
P07877308A1175|42 42|%
P07877308A1175|7 14|protocol
P07877308A1175|31 38|patients
P07877308A1175|53 58|cohort
P07877619A1284|101 126|base pair nucleotide sequence
P07877619A1284|35 45|suppression
P07877619A1284|2 9|addition
P07877619A1284|163 168|region
P07877619A1284|61 80|zif268 gene expression
P07877619A1284|174 183|zif268 gene
P07878029A0721|51 68|CBF-A-CBF-C complex
P07878029A0721|100 104|CBF-A
P07878029A0721|10 14|CBF-A
P07878029A0721|107 111|CBF-C
P07878029A0721|150 167|CBF-A-CBF-C complex
P07878029A0721|76 80|CBF-B
P07878029A0721|18 22|CBF-C
P07878040A0505|87 90|loss
P07878040A0505|21 29|sequences
P07878040A0505|124 127|mice
P07878040A0505|93 100|activity
P07878040A0505|46 58|mouse enhancer
P07879204T0000|0 14|OKT3 prophylaxis
P07879204T0000|81 92|cyclosporine
P07879204T0000|61 68|patients
P07879204T0000|37 49|graft survival
P07879204T0000|102 108|results
P07879204T0000|148 156|US studies
P07880442A0236|57 71|primer extension
P07880442A0236|75 94|S1 nuclease protection
P07880442A0236|8 41|PKC beta transcription initiation site
P07880449A0091|151 159|cGy X-rays
P07880449A0091|90 100|suppression
P07880449A0091|57 59|ICR
P07880449A0091|70 73|mice
P07880449A0091|111 118|behavior
P07880449A0091|129 143|body irradiation
P07880449A0091|5 10|course
P07880449A0091|14 18|study
P07880449A0091|24 40|dose X-rays effects
P07880650A0493|72 83|electron dose
P07880650A0493|48 55|function
P07880650A0493|26 45|diffraction intensity
P07880650A0493|13 20|analysis
P07880650A0493|95 105|possibility
P07880650A0493|124 142|diffraction patterns
P07880650A0493|151 160|resolution
P07880650A0493|172 193|crotoxin complex crystal
P07881077A0195|0 29|Supplementary Phase Contraste RSE
P07881077A0195|47 56|Excitation
P07881077A0195|59 67|sequences
P07881077A0195|86 93|patients
P07883167A0157|2 6|yeast
P07883167A0157|24 27|UPF1
P07883167A0157|166 170|decay
P07883167A0157|192 196|mRNAs
P07883167A0157|58 69|decay pathway
P07883167A0157|98 111|identification
P07883167A0157|11 18|products
P07883167A0157|31 39|UPF3 genes
P07883167A0157|143 149|factors
P07883167A0157|80 85|report
P07883167A0157|115 130|characterization
P07883168A0090|0 8|Mutations
P07883168A0090|11 18|UPF1 lead
P07883168A0090|104 113|decay rates
P07883168A0090|33 45|stabilization
P07883168A0090|125 129|mRNAs
P07883168A0090|48 52|mRNAs
P07883168A0090|68 84|nonsense mutations
P07883193A0000|175 198|glutathione S-transferase
P07883193A0000|94 102|regulator
P07883193A0000|34 39|domain
P07883193A0000|163 166|gene
P07883193A0000|119 131|pGEX-KT vector
P07883193A0000|146 150|frame
P07883193A0000|41 50|amino acids
P07883193A0000|1 11|DNA fragment
P07883754A0993|29 33|HepG2
P07883754A0993|66 73|presence
P07883754A0993|5 24|gel retardation assays
P07883754A0993|107 117|NRE fragment
P07883754A0993|41 47|extract
P07883754A0993|85 91|protein
P07885999A0000|14 20|factors
P07885999A0000|61 66|region
P07885999A0000|37 45|sequences
P07885999A0000|110 118|band shift
P07885999A0000|122 150|methylation interference assays
P07885999A0000|72 90|mouse tyrosinase gene
P07886610A0000|85 94|prevalence
P07886610A0000|46 53|patients
P07886610A0000|5 14|population
P07886610A0000|106 115|population
P07886610A0000|71 75|India
P07886610A0000|58 68|hemophilia A
P07887226A0858|60 88|serum transferrin receptor assay
P07887226A0858|225 230|anemia
P07887226A0858|32 55|hemoglobin determinations
P07887226A0858|215 217|IDA
P07887226A0858|123 129|surveys
P07887226A0858|240 246|disease
P07887226A0858|160 166|measure
P07887226A0858|100 107|addition
P07887226A0858|16 28|serum ferritin
P07887226A0858|179 192|iron deficiency
P07887859A0315|21 28|patients
P07887859A0315|105 107|TBI
P07887859A0315|109 115|indices
P07887859A0315|42 47|ulcers
P07887859A0315|51 55|tcPO2
P07887859A0315|85 87|ABI
P07887859A0998|0 15|TcPO2 measurement
P07887859A0998|36 44|technique
P07887859A0998|70 84|ulcer management
P07888156A0169|117 122|access
P07888156A0169|12 29|University Hospital
P07888156A0169|96 109|section service
P07888156A0169|183 192|discussion
P07888156A0169|210 215|issues
P07888156A0169|166 173|findings
P07888156A0169|125 140|video conferences
P07888156A0169|54 62|hospitals
P07888156A0169|32 37|Tromso
P07888156A0169|147 152|review
P07888156A0169|73 78|Norway
P07888156T0000|15 27|telepathology
P07888156T0000|7 12|status
P07888306A1659|0 9|Expression
P07888306A1659|182 195|concentrations
P07888306A1659|208 215|ABSTRACT
P07888306A1659|18 27|COS-1 cells
P07888306A1659|90 93|cGMP
P07888306A1659|118 125|activity
P07888306A1659|198 205|rolipram
P07888306A1659|148 150|Ca2
P07888306A1659|103 111|substrate
P07888306A1659|158 161|cGMP
P07888306A1659|12 15|h6.1
P07888306A1659|36 45|production
P07888306A1659|153 155|CaM
P07888306A1659|230 234|WORDS
P07888306A1659|62 72|PDE activity
P07888306A1659|79 82|cAMP
P07888306A1659|56 59|type
P07888623A0721|0 12|PMEK1 displays
P07888623A0721|48 58|tobacco NTF3
P07888623A0721|62 85|Arabidopsis ATMPK1 kinases
P07888623A0721|122 141|plant MAP kinase MsERK1
P07888623A0721|20 28|% identity
P07888623A0721|96 96|%
P07888623A0721|146 152|alfalfa
P07888629A0344|0 10|Translation
P07888629A0344|125 138|signal sequence
P07888629A0344|48 53|MsPRP2
P07888629A0344|22 28|segment
P07888629A0344|237 257|lipid transfer proteins
P07888629A0344|163 170|sequence
P07888629A0344|88 104|Da cell wall protein
P07888629A0344|206 213|sequence
P07888788A1010|175 187|aspergillomas
P07888788A1010|3 10|presence
P07888788A1010|148 155|response
P07888788A1010|18 33|hypersensitivity
P07888788A1010|47 59|aspergillomas
P07888788A1010|37 44|subgroup
P07888788A1010|99 105|disease
P07888788A1010|84 92|component
P07888788A1010|158 168|Aspergillus
P07888788A1010|13 16|type
P07888828A0765|27 40|identification
P07888828A0765|65 72|primates
P07888828A0765|50 54|genes
P07888828A0765|4 10|concept
P07890485A0827|144 148|g.min
P07890485A0827|36 48|photoreceptor
P07890485A0827|10 21|illumination
P07890485A0827|104 106|QO2
P07890485A0827|152 155|cats
P07890485A0827|135 136|ml
P07890485A0827|50 52|QO2
P07890485A0827|82 86|g.min
P07890485A0827|73 74|ml
P07890599A0132|139 149|acid protein
P07890599A0132|188 193|n-Sec1
P07890599A0132|202 227|Caenorhabditis elegans unc18
P07890599A0132|167 175|% identity
P07890599A0132|117 120|cDNA
P07890599A0132|92 98|isoform
P07890599A0132|255 259|Sec1p
P07890599A0132|37 48|MIN6 cell line
P07890599A0132|195 200|rbSec1
P07890599A0132|180 186|munc-18
P07890599A0132|17 32|mouse cDNA library
P07890599A0132|71 79|beta cells
P07890674A0916|127 134|catenins
P07890674A0916|118 124|absence
P07890674A0916|23 32|E-cadherin
P07890674A0916|108 115|presence
P07890674A0916|60 69|E-cadherin
P07890674A0916|54 56|APC
P07890674A0916|43 49|fashion
P07890674A0916|3 10|catenins
P07890674A0916|17 19|APC
P07890680A1193|130 143|primer terminus
P07890680A1193|8 15|addition
P07890680A1193|113 117|gamma
P07890680A1193|53 59|complex
P07890680A1193|18 34|core DNA polymerase
P07890680A1193|80 89|holoenzyme
P07890680A1193|100 110|replacement
P07890680A1193|120 124|alpha
P07890740A0997|3 10|PSD2 gene
P07890740A0997|39 47|infection
P07890740A0997|111 118|increase
P07890740A0997|80 90|baculovirus
P07890740A0997|50 64|Sf-9 insect cells
P07890740A0997|121 131|PSD activity
P07891638T0000|31 39|asymmetry
P07891638T0000|12 20|detection
P07891638T0000|49 64|chest radiographs
P07891685A1051|59 65|binding
P07891685A1051|68 72|Cat8p
P07891685A1051|36 40|genes
P07891685A1051|115 119|Mig1p
P07891685A1051|128 139|CAT8 promoter
P07891685A1051|109 113|Cat4p
P07891685A1051|79 87|synthesis
P07891685A1051|5 11|results
P07891685A1051|100 106|release
P07891708A0690|42 51|Hep3B cells
P07891708A0690|60 68|HeLa cells
P07891708A0690|33 37|liver
P07891708A0690|8 12|HNF-4
P07891708A0690|4 6|Epo
P07891708A0690|26 31|kidney
P07891708A1192|86 95|Hep3B cells
P07891708A1192|27 36|expression
P07891708A1192|117 128|HNF-4 delta C.
P07891708A1192|52 58|Epo gene
P07891709A1542|74 83|transcript
P07891709A1542|106 118|deadenylation
P07891709A1542|45 54|mechanisms
P07891709A1542|5 16|observations
P07891713T0000|59 68|repressors
P07891713T0000|74 97|NF-E2 transcription factor
P07891713T0000|5 15|Maf proteins
P07891713T0000|34 36|Fos
P07891720A0818|26 28|C1F
P07891720A0818|17 23|binding
P07891720A0818|52 64|concentration
P07891720A0818|67 77|calcium ions
P07892076A0578|0 7|Survival
P07892076A0578|37 45|infection
P07892076A0578|13 23|development
P07892076A0578|65 80|transmission mode
P07892076A0578|47 49|P-2
P07892353A0667|75 80|cortex
P07892353A0667|139 146|patterns
P07892353A0667|96 101|cortex
P07892353A0667|50 53|rCBF
P07892353A0667|114 119|factor
P07892353A0667|4 10|factors
P07892353A0667|174 185|brain regions
P07892353A0667|34 45|correlations
P07892353A0667|149 160|correlations
P07894021A1130|69 71|DNA
P07894021A1130|36 38|DS2
P07894021A1130|76 86|desiccation
P07894021A1130|23 30|function
P07894021A1130|47 56|protection
P07894021A1130|5 8|data
P07894359T0000|45 46|RU
P07894359T0000|53 58|sepsis
P07894359T0000|28 35|abortion
P07894359T0000|61 64|rats
P07894359T0000|10 21|hemodynamics
P07894761A0000|84 93|hemorrhage
P07894761A0000|169 175|surgery
P07894761A0000|125 130|vision
P07894761A0000|25 29|study
P07894761A0000|95 97|ECH
P07894761A0000|109 115|success
P07894761A0000|3 5|aim
P07894761A0000|59 63|cases
P07896088A0720|100 110|rap1 alleles
P07896088A0720|180 186|effects
P07896088A0720|74 77|RAP1
P07896088A0720|26 29|tail
P07896088A0720|139 142|tail
P07896088A0720|89 98|factor RIF1
P07896088A0720|32 50|telomere maintenance
P07896088A0720|146 167|RIF1 interaction domains
P07896088A0720|3 10|function
P07896088A0720|189 202|telomere length
P07896291A0693|100 104|genes
P07896291A0693|127 138|WAGR syndrome
P07896291A0693|53 55|map
P07896291A0693|68 75|resource
P07896291A0693|82 97|characterization
P07896615A0554|100 107|skin flow
P07896615A0554|30 36|changes
P07896615A0554|110 125|laser flow Doppler
P07896615A0554|46 57|nm absorption
P07896615A0554|151 164|water immersion
P07896615A0554|3 14|contribution
P07896615A0554|17 24|skin flow
P07896615A0554|129 141|NIR recordings
P07896615A0554|87 97|measurement
P07896817A0204|0 7|Proteins
P07896817A0204|184 194|Immobilon-P
P07896817A0204|65 68|BAEC
P07896817A0204|132 167|SDS-polyacrylamide gel electrophoresis
P07896817A0204|39 45|control
P07896817A0204|73 80|antisera
P07896817A0204|83 102|phospholipase C-gamma
P07896817A0204|30 36|lysates
P07896817A0204|104 112|PLC-gamma
P07896846T0000|121 129|chain gene
P07896846T0000|105 115|beta-myosin
P07896846T0000|79 94|suppressor region
P07896846T0000|22 29|isoforms
P07896846T0000|59 65|protein
P07896852T0000|0 10|Involvement
P07896852T0000|45 77|apolipoprotein AI gene transcription
P07896852T0000|18 42|growth response factor Egr-1
P07897359A0354|96 103|vaccinia
P07897359A0354|64 74|HeLa T4 cells
P07897359A0354|22 26|forms
P07897359A0354|55 60|BHK-21
P07897359A0354|77 79|use
P07897359A0354|118 135|T7 polymerase system
P07897359A0354|32 39|F protein
P07897696A0000|0 10|Erythrocyte
P07897696A0000|47 50|ALAD
P07897696A0000|259 271|micrograms/dl
P07897696A0000|131 132|UC
P07897696A0000|52 59|activity
P07897696A0000|236 246|blood levels
P07897696A0000|134 146|concentration
P07897696A0000|116 129|coproporphyrin
P07897696A0000|175 184|indicators
P07897696A0000|249 254|excess
P07897696A0000|280 287|subjects
P07897696A0000|96 104|heme ratio
P07897696A0000|208 219|lead exposure
P07897696A0000|61 89|erythrocyte zinc protoporphyrin
P07897696A0000|31 45|acid dehydratase
P07897696A0000|91 93|ZPP
P07898178A0849|117 138|cyclosporin maintenance
P07898178A0849|43 54|azathioprine
P07898178A0849|93 104|azathioprine
P07898178A0849|171 174|risk
P07898178A0849|67 75|graft loss
P07898178A0849|11 14|risk
P07898178A0849|17 25|graft loss
P07898178A0849|81 90|conversion
P07898178A0849|31 40|conversion
P07898178A0849|177 188|patient death
P07898275A0254|148 157|test object
P07898275A0254|73 90|31P MRS measurements
P07898275A0254|255 261|systems
P07898275A0254|230 240|performance
P07898275A0254|267 270|ISIS
P07898275A0254|5 11|classes
P07898275A0254|301 307|31P MRS.
P07898275A0254|273 298|volume localization sequence
P07898275A0254|14 24|test objects
P07898275A0254|119 127|sequences
P07898275A0254|204 214|test objects
P07898275A0254|60 69|test object
P07898275A0254|177 181|1H MRS
P07898589T0000|4 15|tobacco issue
P07898840X0000|0 17|Pregnancy screening
P07898840X0000|162 170|gestation
P07898840X0000|191 195|power
P07898840X0000|112 125|Doppler studies
P07898840X0000|185 188|test
P07898840X0000|365 373|waveforms
P07898840X0000|264 266|FGR
P07898840X0000|27 50|artery Doppler velocimetry
P07898840X0000|80 88|OBJECTIVE
P07898840X0000|246 262|growth restriction
P07898840X0000|145 155|circulation
P07898840X0000|279 286|analysis
P07898840X0000|226 237|hypertension
P07898840X0000|400 407|analysis
P07898840X0000|389 395|results
P07898840X0000|334 344|assessments
P07898840X0000|58 66|criterion
P07898840X0000|295 305|combination
P07899581A0000|188 191|rats
P07899581A0000|181 181|n
P07899581A0000|97 108|nitrendipine
P07899581A0000|84 94|combination
P07899581A0000|55 73|superoxide dismutase
P07899581A0000|174 179|groups
P07899581A0000|112 130|superoxide dismutase
P07899581A0000|3 8|effect
P07899581A0000|150 157|function
P07899581A0000|14 39|Ca entry blocker nitrendipine
P07899581A0000|75 77|SOD
P07899634A0000|0 6|PURPOSE
P07899634A0000|45 53|anchorage
P07899634A0000|11 13|aim
P07899634A0000|128 129|mu
P07899634A0000|20 24|study
P07899634A0000|80 92|surface effect
P07899634A0000|97 107|alloy Ti Al Va
P07900915A0000|28 32|water
P07900915A0000|187 197|restitution
P07900915A0000|18 21|food
P07900915A0000|249 258|hematocrit
P07900915A0000|79 89|blood volume
P07900915A0000|224 228|Evans
P07900915A0000|54 58|tract
P07900915A0000|168 182|min-1 hemorrhage
P07900915A0000|93 105|plasma protein
P07900915A0000|111 120|hemorrhage
P07900915A0000|239 246|dilution
P07900915A0000|159 166|ml.kg-1 x
P07900915A0000|122 124|fed
P07900915A0000|66 76|restitution
P07900915A0000|200 210|blood volume
P07900915A0000|144 147|rats
P07901121T0000|0 22|Cooperative dimerization
P07901121T0000|50 52|DNA
P07901121T0000|31 47|class homeo domains
P07901125A0416|57 62|DAHPSs
P07901125A0416|74 80|species
P07901125A0416|24 29|degree
P07901125A0416|90 103|ARO3 homologues
P07901125A0416|32 49|aa sequence homology
P07901125A0416|6 14|advantage
P07901125A0416|121 140|yeast Candida albicans
P07902532A0312|29 34|BOX DNA
P07902532A0312|6 10|study
P07902532A0312|63 77|thymidine kinase
P07902532A0312|43 55|transcription
P07902532A0312|79 80|TK
P07902532A0312|82 89|promoter
P07902532A0312|99 105|EC cells
P07902532A1655|0 15|Deletion analyses
P07902532A1655|82 87|BOX DNA
P07902532A1655|21 29|construct
P07902532A1655|45 57|transcription
P07902532A1655|148 152|cells
P07902532A1655|121 127|EC cells
P07902532A1655|60 68|BOXF1 gene
P07902583A0545|0 7|Analysis
P07902583A0545|76 84|half-life
P07902583A0545|130 134|Grf10
P07902583A0545|45 65|Grf10-Swi5-DNA complex
P07902583A0545|10 28|disassociation rates
P07902583A0545|124 127|Swi5
P07902583A0545|100 108|complexes
P07903099A0918|42 50|IVS2C beta
P07903099A0918|59 66|terminus
P07903099A0918|79 86|cleavage
P07903099A0918|22 31|transcript
P07903099A0918|92 105|splice acceptor
P07903099A0918|3 10|presence
P07903670A1202|20 37|alpha 1-tubulin gene
P07903670A1202|51 56|tua1-1
P07903670A1202|9 14|allele
P07905413A0585|203 209|placebo
P07905413A0585|27 46|plasma concentrations
P07905413A0585|153 160|workload
P07905413A0585|78 78|h
P07905413A0585|13 21|treatment
P07905413A0585|190 190|%
P07905413A0585|95 95|h
P07905413A0585|225 230|points
P07905413A0585|211 211|P
P07905413A0585|68 74|ng.ml-1
P07905413A0585|110 126|segment depression
P07905413A0585|233 236|time
P07905413A0585|84 90|ng.ml-1
P07905453A0281|0 6|Results
P07905453A0281|54 72|maxicell experiments
P07905453A0281|95 97|ORF
P07905453A0281|18 50|transcription-translation analysis
P07906265A0897|60 70|fasD mutants
P07906265A0897|77 84|products
P07906265A0897|11 21|experiments
P07906265A0897|112 117|export
P07906265A0897|121 128|assembly
P07906616A0191|122 132|anaesthesia
P07906616A0191|23 30|response
P07906616A0191|91 95|goats
P07906616A0191|53 63|stimulation
P07906616A0191|67 68|Hz
P07907846A0623|0 4|Group
P07907846A0623|135 145|combination
P07907846A0623|82 84|min
P07907846A0623|55 79|cholinesterase degradation
P07907846A0623|31 39|mg/kg i.v.
P07907846A0623|91 115|bupivacaine administration
P07907846A0623|14 26|physostigmine
P07907846A0623|148 172|physostigmine pretreatment
P07907846A0623|120 124|Group
P07907846A0623|191 201|stimulation
P07908012A0678|60 65|groups
P07908012A0678|153 168|medication levels
P07908012A0678|108 115|analyses
P07908012A0678|12 22|possibility
P07908012A0678|134 145|relationship
P07908012A0678|97 106|medication
P07908012A0678|172 181|LNNB scores
P07908012A0678|27 41|LNNB performance
P07908187T0000|0 3|ISIS
P07908187T0000|5 17|possibilities
P07908827A1200|212 214|RAR
P07908827A1200|36 49|identification
P07908827A1200|149 156|COS cells
P07908827A1200|88 96|complexes
P07908827A1200|113 121|sequences
P07908827A1200|225 231|element
P07908827A1200|132 135|RARs
P07908827A1200|16 25|antibodies
P07908827A1200|3 5|use
P07908827A1200|59 65|RAR beta
P07909936A0672|163 165|use
P07909936A0672|168 176|cytokines
P07909936A0672|40 48|disorders
P07909936A0672|10 26|treatment strategy
P07909936A0672|80 85|effect
P07909936A0672|202 208|factors
P07909936A0672|97 113|radiochemotherapy
P07909936A0672|125 148|stem-cell transplantation
P07910716A0359|306 314|IU/m2/day
P07910716A0359|200 204|weeks
P07910716A0359|47 53|SC rIL-2
P07910716A0359|78 86|IU/m2/day
P07910716A0359|121 128|patients
P07910716A0359|231 244|SC rIFN-alpha 2b
P07910716A0359|105 109|total
P07910716A0359|257 270|U/m2/day thrice
P07910716A0359|384 388|weeks
P07910716A0359|90 93|days
P07910716A0359|358 361|days
P07910716A0359|347 355|IU/m2/day
P07910716A0359|211 218|patients
P07910716A0359|97 100|week
P07910716A0359|317 320|days
P07910716A0359|3 14|study cohorts
P07910716A0359|113 117|weeks
P07910716A0359|192 196|total
P07910716A0359|365 368|week
P07910716A0359|140 151|rIFN-alpha 2b
P07910716A0359|56 60|doses
P07910716A0359|168 181|U/m2/day thrice
P07910716A0359|28 35|patients
P07910716A0359|281 287|SC rIL-2
P07910946A0323|0 7|Analysis
P07910946A0323|97 106|luciferase
P07910946A0323|84 95|reporter gene
P07910946A0323|108 115|activity
P07910946A0323|170 185|promoter activity
P07910946A0323|11 13|set
P07910946A0323|45 62|transfection assays
P07910946A0323|203 209|L2 cells
P07910946A0323|152 157|region
P07910946A0323|16 33|deletion constructs
P07911736A1715|58 73|myelosuppression
P07911736A1715|37 44|toxicity
P07911736A1715|10 18|mg/m2/day
P07911736A1715|51 55|agent
P07911736A1715|5 7|MTD
P07912123A0711|15 37|lymphocyte proliferation
P07913080A0564|1 30|decanucleotide promoter sequence
P07913080A0564|108 116|horse gene
P07913080A0564|64 67|mice
P07913080A0564|55 60|humans
P07913080A0564|97 102|region
P07913891A0174|130 137|Hox genes
P07913891A0174|11 17|targets
P07913891A0174|89 100|relationship
P07913891A0174|67 78|interactions
P07913891A0174|146 165|transcription factors
P07913891A0174|39 47|molecules
P07913891A0174|204 220|tissue specificity
P07913926A0878|116 122|absence
P07913926A0878|67 76|ntcA mutant
P07913926A0878|54 61|cultures
P07913926A0878|90 96|amounts
P07913926A0878|18 27|RNA samples
P07913926A0878|132 141|transcript
P07913926A0878|99 109|glnA message
P07913926A0878|0 15|Northern analysis
P07914192A0211|0 22|HER2 overexpressing cells
P07914192A0211|165 171|CAAT box
P07914192A0211|142 157|bases down-stream
P07914192A0211|190 196|TATA box
P07914192A0211|65 68|site
P07914192A0211|125 130|GAGGAA
P07914192A0211|106 123|ets response element
P07914192A0211|207 218|HER2 promoter
P07914192A0211|45 49|DNase
P07914192A0844|0 14|Gel-shift assays
P07914192A0844|215 235|GAGGAA response element
P07914192A0844|172 175|HER2
P07914192A0844|80 93|promoter region
P07914192A0844|26 33|extracts
P07914192A0844|153 157|cells
P07914192A0844|37 60|oligonucleotide sequences
P07914192A0844|122 128|complex
P07914192A0844|195 201|binding
P07914507A1029|84 87|poly
P07914507A1029|89 89|A
P07914507A1029|12 24|cDNA sequences
P07914507A1029|62 67|result
P07914507A1029|92 104|addition sites
P07914507A1029|79 81|use
P07914507A1029|0 9|Comparison
P07914507A1029|43 53|mRNA species
P07914700A0000|3 6|gene
P07914700A0000|50 52|PKR
P07914700A0000|26 48|eIF-2 alpha protein kinase
P07914700A0000|69 73|mouse
P07914700A0000|81 83|DNA
P07915144A0000|102 106|hours
P07915144A0000|40 50|hippocampus
P07915144A0000|24 34|stimulation
P07915144A0000|78 85|efficacy
P07915144A0000|60 67|increase
P07915144A0000|0 13|High-frequency
P07916003A0688|152 155|gene
P07916003A0688|110 121|octamer motif
P07916003A0688|12 20|mouse gene
P07916003A0688|63 69|TATA box
P07916003A0688|85 98|mouse CD79 alpha
P07916003A0688|35 40|region
P07916003A0688|48 56|CD79 alpha
P07916326A0000|61 67|regions
P07916326A0000|34 39|coding
P07916326A0000|106 110|Msx-1
P07916326A0000|101 104|gene
P07916326A0000|17 28|organization
P07916327A0250|15 21|cloning
P07916327A0250|46 48|GSC
P07916327A0250|75 82|sequence
P07916327A0250|32 44|goosecoid gene
P07916327A0250|62 68|library
P07916327A0250|95 101|protein
P07916577A0190|161 165|cDNAs
P07916577A0190|82 95|gene expression
P07916577A0190|24 37|candidate genes
P07916577A0190|50 58|disorders
P07916577A0190|140 143|zinc
P07916577A0190|122 130|sequences
P07916577A0190|2 6|order
P07916588A0471|41 66|passion fruit woodiness virus
P07916588A0471|161 164|part
P07916588A0471|136 142|strains
P07916588A0471|206 208|PWV
P07916588A0471|68 70|PWV
P07916588A0471|176 183|subgroup
P07916588A0471|33 38|strain
P07916588A0471|186 196|potyviruses
P07916588A0471|117 119|CPs
P07916588A0471|4 8|virus
P07916588A0471|145 147|PWV
P07916588A0471|83 92|CP sequence
P07916685A0455|13 20|activity
P07916685A0455|142 151|activities
P07916685A0455|3 7|ratio
P07916685A0455|23 44|arogenate dehydrogenase
P07916685A0455|53 75|prephenate dehydrogenase
P07916685A0455|120 131|purification
P07916689A0312|89 94|oleate
P07916689A0312|37 48|kb RNA species
P07916689A0312|101 112|carbon source
P07916689A0312|11 20|POT1 clones
P07916689A1407|84 86|kbp
P07916689A1407|89 91|DNA
P07916689A1407|22 29|POT1 gene
P07916689A1407|56 57|bp
P07916689A1407|104 123|Y. lipolytica LEU2 gene
P07916689A1407|3 14|Y. lipolytica
P07916689A1407|69 76|sequence
P07916729T0000|1 19|leucine zipper domain
P07916729T0000|75 80|effect
P07916729T0000|25 34|suppressor
P07916729T0000|47 53|protein
P07916729T0000|83 98|enhancer function
P07916983A0623|58 73|N1-N3 neck disease
P07916983A0623|46 53|patients
P07916983A0623|109 120|prescription
P07916983A0623|17 18|CT
P07917016A0581|24 54|zinc finger domain protein sequence
P07917016A0581|12 22|DNA-binding
P07917540A0000|101 105|times
P07917540A0000|76 93|interferon-alpha 2b
P07917540A0000|61 70|mg/m2/week
P07917540A0000|96 99|U/m2
P07917540A0000|109 112|week
P07917540A0000|50 58|vindesine
P07917540A0000|36 40|study
P07917540A0000|134 143|interferon
P07917540A0000|2 9|patients
P07917540A0000|185 192|melanoma
P07917540A0000|116 124|vindesine
P07917540A0000|155 163|treatment
P07918097T0000|55 74|growth factor-repeats
P07918097T0000|104 118|neuroepithelium
P07918097T0000|8 31|Notch homologue mouse Notch
P07918128A0000|55 71|hydroxytryptamine
P07918128A0000|47 48|EF
P07918128A0000|103 110|patients
P07918128A0000|74 78|5-HT3
P07918128A0000|38 40|MDL
P07918128A0000|80 97|receptor antagonist
P07918128A0000|23 27|phase
P07918128A0000|130 141|chemotherapy
P07918128A0000|0 9|BACKGROUND
P07918494A1163|101 107|mutants
P07918494A1163|32 37|system
P07918494A1163|150 153|mole
P07918494A1163|142 146|dCTPs
P07918494A1163|75 79|NADPH
P07918494A1163|51 70|thioredoxin reductase
P07918494A1163|120 128|formation
P07918494A1163|5 12|presence
P07918494A1163|39 49|thioredoxin
P07918494A1163|156 161|enzyme
P07919540A0240|98 105|AUG codon
P07919540A0240|12 22|alterations
P07919540A0240|108 111|exon
P07919540A0240|53 64|c-myc protein
P07919540A0240|34 42|synthesis
P07919540A0240|66 68|p64
P07919540A1119|42 46|forms
P07919540A1119|18 21|exon
P07919540A1119|108 124|reporter construct
P07919540A1119|74 86|transcription
P07919540A1119|52 63|c-Myc protein
P07919540A1119|135 139|level
P07919540A1119|2 9|addition
P07919540A1119|27 30|exon
P07922709T0000|35 47|growth factors
P07922709T0000|10 19|activities
P07922709T0000|72 82|application
P07925022A0285|0 9|Expression
P07925022A0285|52 57|stages
P07925022A0285|35 37|CNS
P07925097A1205|74 82|8-Br-cAMP
P07925097A1205|14 22|AR content
P07925097A1205|64 71|exposure
P07925097A1205|36 45|COS-1 cells
P07925282A0705|27 31|genes
P07925282A0705|135 144|ER membrane
P07925282A0705|82 91|cell growth
P07925282A0705|106 125|protein translocation
P07925282A0705|58 68|SRP proteins
P07925282A0705|0 9|Disruption
P07926729A0000|85 90|events
P07926729A0000|127 134|programs
P07926729A0000|115 124|activation
P07926729A0000|7 17|alterations
P07926729A0000|137 153|gene transcription
P07926729A0000|36 63|signal transduction mechanisms
P07926729A0000|20 27|elements
P07926739A0766|143 161|trichome development
P07926739A0766|22 24|GL2
P07926739A0766|103 117|progenitor cells
P07926739A0766|48 60|hybridization
P07926739A0766|123 128|stages
P07926739A0766|78 81|gene
P07926739A0766|3 19|expression pattern
P07926748A0383|0 3|NOT4
P07926748A0383|74 77|NOT4
P07926748A0383|52 65|overexpression
P07926748A0383|24 27|NOT3
P07926748A0383|88 91|not1
P07926748A0383|17 20|NOT1
P07926748A0383|43 47|assay
P07926748A0383|95 107|not2 mutations
P07926748A0383|68 71|NOT3
P07926749A0471|114 136|hormone response elements
P07926749A0471|203 206|RORE
P07926749A0471|66 73|ROR alpha
P07926749A0471|7 19|site selection
P07926749A0471|78 85|ROR alpha
P07926749A0471|104 111|monomers
P07926749A0471|87 94|isoforms
P07926749A0471|44 51|proteins
P07926749A0471|159 166|sequence
P07926749A0471|99 101|DNA
P07926749A0471|186 201|core motif PuGGTCA
P07926774A0652|53 55|MCB
P07926774A0652|62 64|SCB
P07926774A0652|67 74|E2F sites
P07926774A0652|3 25|p73pct1/p85cdc10 complex
P07926775A0895|170 171|hh
P07926775A0895|134 137|time
P07926775A0895|63 73|slp activity
P07926775A0895|100 110|maintenance
P07926775A0895|86 96|requirement
P07926775A0895|49 55|embryos
P07926775A0895|15 21|stripes
P07926775A0895|142 156|wg transcription
P07926775A0895|40 42|slp
P07926775A0895|113 124|wg expression
P07926789A0960|83 90|products
P07926789A0960|3 13|DNA sequence
P07926789A0960|134 140|fusions
P07926789A0960|67 77|fusion genes
P07926789A0960|27 34|lacZ gene
P07927130A0625|0 30|CMV hyperimmunoglobulin treatment
P07927130A0625|41 47|Biotest
P07927130A0625|70 72|day
P07927130A0625|165 174|myocardium
P07927130A0625|140 149|infiltrate
P07927130A0625|116 126|eradication
P07927130A0625|90 93|days
P07927130A0625|32 39|Cytotect
P07927130A0625|83 87|ml/kg
P07927130A0625|61 67|ml/kg bw
P07927130A0625|153 159|CMV-DNA
P07927267T0000|15 22|drainage
P07927267T0000|38 45|drainage
P07927267T0000|65 76|regeneration
P07927267T0000|110 120|hepatectomy
P07927267T0000|90 97|rat liver
P07927711A0698|0 2|ORF
P07927711A0698|34 40|protein
P07927711A0698|49 50|Da
P07927711A0698|84 90|regions
P07927838A0000|157 165|stiffness
P07927838A0000|127 132|finger
P07927838A0000|7 12|groups
P07927838A0000|79 83|years
P07927838A0000|150 153|pain
P07927838A0000|141 148|numbness
P07927838A0000|88 102|prevalence rates
P07927838A0000|57 61|tools
P07927838A0000|184 194|extremities
P07927838A0000|134 136|VWF
P07927838A0000|15 22|subjects
P07928954A0545|42 43|bp
P07928954A0545|163 199|consensus prolipoprotein processing site
P07928954A0545|73 79|protein
P07928954A0545|94 99|weight
P07928954A0545|136 159|lipoprotein signal peptide
P07928954A0545|32 35|gene
P07928954A0545|0 18|DNA sequence analysis
P07929165T0000|28 38|actVI region
P07929165T0000|103 104|A3
P07929165T0000|68 78|gene cluster
P07929165T0000|44 55|actinorhodin
P07929165T0000|0 10|DNA sequence
P07929165T0000|14 22|functions
P07929238A0734|6 13|Genomics
P07929411A0087|202 215|enzyme activity
P07929411A0087|103 107|yeast
P07929411A0087|165 171|regions
P07929411A0087|25 43|polypeptide sequence
P07929411A0087|95 99|mouse
P07929411A0087|49 65|Drosophila protein
P07929411A0087|83 90|subunits
P07929411A0087|1 10|comparison
P07929431A0949|0 7|Plasmids
P07929431A0949|149 158|INS-1 cells
P07929431A0949|105 107|CAT
P07929431A0949|60 103|reporter gene chloramphenicol acetyltransferase
P07929431A0949|30 48|mouse promoter region
P07929559A0000|177 186|organelles
P07929559A0000|11 16|dynein
P07929559A0000|129 137|movements
P07929559A0000|107 113|variety
P07929559A0000|69 74|enzyme
P07929559A0000|166 174|transport
P07929560T0000|0 13|Identification
P07929560T0000|68 81|plaque assembly
P07929560T0000|46 55|desmoglein
P07929560T0000|38 43|domain
P07929560T0000|97 113|filament anchorage
P07929560T0000|62 65|role
P07931490A0237|0 7|PATIENTS
P07931490A0237|139 154|granisetron doses
P07931490A0237|84 92|cisplatin
P07931490A0237|11 17|METHODS
P07931490A0237|200 211|chemotherapy
P07931490A0237|168 180|micrograms/kg
P07931490A0237|58 65|patients
P07931490A0237|101 105|mg/m2
P07932095A0000|115 122|root bark
P07932095A0000|25 33|compounds
P07932095A0000|40 40|V
P07932095A0000|125 143|Oroxylum indicum Vent
P07932095A0000|88 89|VI
P07932095A0000|7 17|naphthalene
P07932095A0000|91 94|XIII
P07932095A0000|42 48|VII-XII
P07932095A0000|71 79|compounds
P07932943A0113|100 124|Five-Step Approach strategy
P07932943A0113|52 68|awareness strategy
P07932943A0113|87 94|strategy
P07932943A0113|35 43|influence
P07932943A0113|132 147|control condition
P07932943A0113|17 21|study
P07933066T0000|17 27|interaction
P07933066T0000|62 86|retinoblastoma gene product
P07933066T0000|116 119|DP-1
P07933066T0000|108 112|E2F-1
P07933066T0000|49 55|protein
P07933066T0000|99 105|domains
P07933066T0000|33 46|adenovirus E4-6
P07933076A0211|18 22|EBNA2
P07933076A0211|40 48|promoters
P07933076A0211|65 80|membrane proteins
P07933095A0000|119 123|sites
P07933095A0000|138 159|transcription factor Sp1
P07933095A0000|93 101|promoters
P07933095A0000|22 26|v-Rel
P07933095A0000|52 66|retrovirus Rev-T
P07933095A0000|31 41|oncoprotein
P07933095A0000|79 88|expression
P07933095A0000|162 185|chicken embryo fibroblasts
P07933095A0000|187 188|S.
P07933101A0131|8 14|studies
P07933101A0131|38 48|TATA element
P07933101A0131|81 99|HIV-1 gene expression
P07933107A0991|84 86|E75
P07933107A0991|108 117|virus Ba71V
P07933107A0991|78 80|E70
P07933107A0991|39 45|p54 gene
P07933107A0991|66 76|ASFV strains
P07933107A0991|16 33|nucleotide sequence
P07933107A0991|1 10|comparison
P07933107A0991|127 137|% similarity
P07933116A0412|86 89|U937
P07933116A0412|77 84|cell line
P07933116A0412|47 57|T-cell lines
P07933116A0412|3 9|p55 mRNA
P07933116A0412|42 42|B
P07934331T0037|35 45|improvement
P07934331T0037|23 31|incentive
P07934331T0037|7 18|registration
P07934666A0158|85 86|T2
P07934666A0158|77 79|T2f
P07934666A0158|13 25|magnetization
P07934666A0158|58 67|components
P07934666A0158|92 94|T2s
P07934666A0158|70 71|T2
P07934666A0158|96 104|component
P07935094A0516|0 6|RESULTS
P07935094A0516|121 128|FDG study
P07935094A0516|95 109|liver background
P07935094A0516|21 27|quality
P07935094A0516|30 38|FDG images
P07935094A0516|68 85|Tl-201 counterparts
P07935370A0000|14 23|expression
P07935370A0000|26 28|CD4
P07935370A0000|81 95|maturation state
P07935370A0000|101 105|T cell
P07935370A0000|32 34|CD8
P07935370A0000|41 57|T-cell development
P07935375A1197|30 36|ras gene
P07935375A1197|68 72|v-src
P07935375A1197|47 65|TIS10/PGS2 induction
P07935375A1197|0 9|Expression
P07935379A0347|60 66|changes
P07935379A0347|23 27|cells
P07935379A0347|83 87|cells
P07935379A0347|98 106|apoptosis
P07935383A0108|58 64|subunit
P07935383A0108|7 11|RNase
P07935383A0108|178 198|adenovirus L3 pre-mRNAs
P07935383A0108|22 37|mapping technique
P07935383A0108|112 118|regions
P07935383A0108|67 70|CstF
P07935383A0108|164 168|virus
P07935383A0108|95 103|pre-mRNAs
P07935383A0108|141 152|cleavage site
P07935395A0094|112 119|molecule
P07935395A0094|85 92|clusters
P07935395A0094|103 106|ends
P07935395A0094|22 24|kDa
P07935395A0094|3 9|protein
P07935395A0094|41 56|zinc finger motifs
P07935415T0000|46 54|inhibitor
P07935415T0000|80 86|cloning
P07935415T0000|101 112|localization
P07935415T0000|118 121|gene
P07935415T0000|88 96|structure
P07935415T0000|15 24|expression
P07935418A0447|73 77|RLD-1
P07935418A0447|65 71|protein
P07935418A0447|6 16|v-erbA probe
P07935418A0447|124 132|receptors
P07935418A0447|108 114|domains
P07935418A0447|29 32|cDNA
P07935426A0714|12 19|isoforms
P07935426A0714|87 104|TdT promoter binding
P07935426A0714|40 55|zinc finger domain
P07935447A0972|198 207|expression
P07935447A0972|219 230|alpha-myosin
P07935447A0972|210 215|MLC-2v
P07935447A0972|23 30|evidence
P07935447A0972|104 108|HF-1a
P07935447A0972|113 121|PRE B sites
P07935447A0972|72 90|leucine zipper family
P07935447A0972|99 102|MLE1
P07935447A0972|40 45|member
P07935447A0972|153 168|protein complexes
P07935447A0972|35 37|USF
P07935447A0972|242 246|genes
P07935447A0972|142 150|component
P07935447A0972|4 8|study
P07935451T0000|129 137|induction
P07935451T0000|5 27|T-cell leukemia virus type
P07935451T0000|96 107|I kappa B alpha
P07935451T0000|83 93|degradation
P07935451T0000|65 79|phosphorylation
P07935451T0000|111 114|RelA
P07935451T0000|116 118|p65
P07935451T0000|44 56|NF-kappa B/Rel
P07935451T0000|143 151|c-rel gene
P07935451T0000|29 41|Tax activation
P07935468T0000|59 78|growth factor receptor
P07935468T0000|12 30|c-fos gene expression
P07935468T0000|0 9|Activation
P07935471A0613|157 167|maintenance
P07935471A0613|182 186|state
P07935471A0613|106 111|system
P07935471A0613|81 90|Xenopus HSF
P07935471A0613|115 128|mapping regions
P07935471A0613|17 19|HSF
P07935471A0613|57 64|antibody
P07935471A0613|131 135|hHSF1
P07935471A0613|31 38|activity
P07935472A0276|0 8|Enhancers
P07935472A0276|107 108|E1
P07935472A0276|126 135|LVb element
P07935472A0276|28 32|Ets-1
P07935472A0276|156 171|enhancer activity
P07935472A0276|93 105|T-cell line EL4
P07935472A0276|197 199|LVb
P07935472A0276|241 256|enhancer activity
P07935472A0276|40 44|sites
P07935472A0276|221 227|phorbol
P07935472A0276|66 81|expression assays
P07935472A0276|110 120|alterations
P07935472A0276|202 211|LVc element
P07935472A0276|178 185|mutation
P07935472A0790|14 28|binding activity
P07935472A0790|35 39|Ets-1
P07935472A0790|99 117|mobility shift assays
P07935472A0790|74 82|complexes
P07935491A0495|98 111|gene expression
P07935491A0495|38 43|family
P07935491A0495|25 31|members
P07935491A0495|5 15|RZR subtypes
P07935491A0495|59 67|receptors
P07935491A1182|61 68|affinity
P07935491A1182|80 122|acid receptor-retinoid-X receptor heterodimers
P07935491A1182|19 34|response elements
P07935577A0305|29 39|flucytosine
P07935577A0305|61 68|symptoms
P07935577A0305|90 104|micro-organisms
P07935577A0305|13 25|amphotericin B
P07935577A0305|45 55|improvement
P07935577A0305|125 129|fluid
P07935577A0305|131 133|CSF
P07935577A0305|0 8|Treatment
P07935626A1249|57 68|mitochondria
P07935626A1249|13 20|presence
P07935626A1249|41 54|gene transcript
P07935626A1249|26 29|tRNA
P07935626A1249|36 38|CCA
P07935626A1249|31 33|trp
P07935997A0000|134 148|cervix carcinoma
P07935997A0000|33 40|immunity
P07935997A0000|3 12|parameters
P07935997A0000|177 180|year
P07935997A0000|115 122|patients
P07935997A0000|108 112|group
P07935997A0000|43 62|serum immunoglobulins
P07935997A0000|72 80|complexes
P07935997A0000|162 165|IIIB
P07935997A0000|150 158|Stages IIB
P07936635A1134|0 7|Mutation
P07936635A1134|10 13|KRKR
P07936635A1134|77 83|protein
P07936635A1134|47 57|compartment
P07936635A1134|110 116|nucleus
P07936635A1134|16 19|NGER
P07936635A1134|27 30|MO15
P07936640A0900|215 220|levels
P07936640A0900|12 18|binding
P07936640A0900|35 39|sites
P07936640A0900|21 27|protein
P07936640A0900|101 107|portion
P07936640A0900|202 205|gene
P07936640A0900|151 158|rat liver
P07936640A0900|42 46|cells
P07936640A0900|75 94|footprinting analysis
P07936640A0900|113 128|TGF alpha promoter
P07936640A0900|169 177|cell lines
P07936650A0656|88 97|p58c-ets-2
P07936650A0656|113 115|BEC
P07936650A0656|119 128|Ets-1-beta
P07936650A0656|145 152|sequence
P07936650A0656|70 85|activating region
P07936650A0656|15 23|subdomain
P07936650A1752|31 35|ets-1
P07936650A1752|74 77|time
P07936650A1752|37 45|ets-2 gene
P07936650A1752|107 115|evidences
P07936650A1752|48 56|evolution
P07936650A1752|20 24|model
P07936650A1752|4 7|work
P07937106A0100|86 107|amino acid substitutions
P07937106A0100|122 131|isoleucine
P07937106A0100|224 226|end
P07937106A0100|228 236|mutation C
P07937106A0100|109 115|alanine
P07937106A0100|137 143|c-ets-1
P07937106A0100|61 80|progenitor p68c-ets-1
P07937106A0100|188 188|B
P07937106A0100|161 166|valine
P07937106A0100|3 15|v-ets oncogene
P07937106A0100|169 173|v-ets
P07937106A0100|175 183|mutations
P07937106A0100|26 38|retrovirus E26
P07937108A0325|22 26|mRNAs
P07937108A0325|52 66|RNA polymerase I.
P07937112A0220|72 83|denaturation
P07937112A0220|60 64|cells
P07937112A0220|13 20|subunits
P07937112A0220|23 24|Ku
P07937112A0220|125 126|Ku
P07937127A0645|149 159|herpesvirus
P07937127A0645|91 97|regions
P07937127A0645|53 69|activation domains
P07937127A0645|103 115|herpesviruses
P07937127A0645|9 14|method
P07937127A0645|123 139|pseudorabies virus
P07937132A0819|86 92|28S rRNA
P07937132A0819|76 83|sequence
P07937132A0819|11 13|U21
P07937132A0819|37 38|nt
P07937132A0819|43 57|complementarity
P07937132A0819|27 33|stretch
P07937147A0205|125 134|Filutowicz
P07937147A0205|80 81|DR
P07937147A0205|35 50|pi protein mutants
P07937147A0205|8 13|system
P07937147A0205|75 76|IR
P07937147A0205|136 137|J.
P07937147A0205|118 121|York
P07937147A0205|93 96|Gene
P07937147A0205|83 86|York
P07937147A0205|98 101|Amst
P07937656A0182|0 9|Univariate
P07937656A0182|198 221|serum alkaline phosphatase
P07937656A0182|303 303|p
P07937656A0182|189 189|p
P07937656A0182|276 288|activity index
P07937656A0182|252 263|serum albumin
P07937656A0182|21 28|analysis
P07937656A0182|131 142|disease stage
P07937656A0182|233 235|U/l
P07937656A0182|153 165|NSE serum level
P07937656A0182|176 187|micrograms/l
P07937656A0182|116 122|factors
P07937656A0182|144 144|p
P07937656A0182|36 57|Kaplan-Meier-estimates
P07937656A0182|291 297|minimum
P07937656A0182|265 265|p
P07937656A0182|237 237|p
P07937656A0182|61 73|Log-Rank-Test
P07937841A0790|86 93|pathways
P07937841A0790|108 124|myb oncogene family
P07937841A0790|67 75|cell cycle
P07937841A0790|5 11|results
P07937841A0790|19 26|evidence
P07937841A0790|30 35|bypass
P07937841A0790|97 102|member
P07937954A0612|0 2|HBx
P07937954A0612|36 38|Ras
P07937954A0612|108 116|MAP kinase
P07937954A0612|66 68|Raf
P07937954A0612|19 24|levels
P07937965T0000|0 3|Role
P07937965T0000|51 62|DNA synthesis
P07937965T0000|19 23|virus
P07937965T0000|74 95|3T3-L1 mouse fibroblasts
P07937965T0000|6 10|c-myc
P07937965T0000|31 35|tumor
P07938137A0384|102 106|signs
P07938137A0384|39 46|naloxone
P07938137A0384|51 55|mg/kg
P07938137A0384|115 124|withdrawal
P07938137A0384|3 8|groups
P07938137A0384|73 83|environment
P07941174T0001|0 11|Laser therapy
P07941174T0001|20 28|carcinoma
P07941739A0000|67 79|chromosome XIV
P07941739A0000|20 30|yeast genome
P07941739A0000|59 64|region
P07941739A0000|89 95|mapping
P07941739A0000|5 14|kb fragment
P07941750A0344|83 86|half
P07941750A0344|32 37|length
P07941750A0344|23 26|half
P07941750A0344|89 103|hydatoinase HyuB
P07941750A0344|54 69|hydantoinase HyuA
P07942076A0497|14 36|estradiol concentrations
P07942076A0497|116 122|patient
P07942076A0497|50 66|estradiol valerate
P07942076A0497|155 158|type
P07942076A0497|80 97|estradiol ingestion
P07942076A0497|125 127|age
P07942448A1227|69 73|WORDS
P07942448A1227|20 28|NYHA class
P07942448A1227|10 17|patients
P07942448A1227|47 54|ABSTRACT
P07942448A1227|38 42|class
P07942722T0000|0 11|Constipation
P07942722T0000|83 88|agents
P07942722T0000|18 27|risk factor
P07942722T0000|56 60|study
P07942722T0000|31 41|hemorrhoids
P07943556A0694|58 67|Og4C3 assay
P07943556A0694|5 11|persons
P07943556A0694|29 29|%
P07944461A0321|0 5|TG-day
P07944461A0321|9 16|TG-night
P07944461A0321|49 51|mm3
P07944461A0321|31 31|%
P07944461A0321|43 43|%
P07944542T0000|0 17|Vibrio cholerae O139
P07944542T0000|20 27|Calcutta
P07945134A0079|113 118|sounds
P07945134A0079|39 39|m
P07945134A0079|136 149|head microphone
P07945134A0079|31 32|ft
P07945134A0079|73 74|ft
P07945134A0079|3 12|volunteers
P07945134A0079|96 96|m
P07945330A0103|31 34|acid
P07945330A0103|36 37|RA
P07945330A0103|40 52|transcription
P07945330A0103|58 66|Rex-1 gene
P07945330A0103|4 18|differentiation
P07945937A0358|0 15|Sequence analysis
P07945937A0358|120 128|exception
P07945937A0358|79 83|mouse
P07945937A0358|180 185|region
P07945937A0358|66 73|homology
P07945937A0358|40 45|region
P07945937A0358|216 226|Egr1 protein
P07945937A0358|97 105|Egr1 genes
P07945937A0358|21 33|zebrafish egr1
P07945937A0358|198 210|amino terminus
P07945937A0358|144 174|triplet nucleotide repeat sequence
P07945937A0358|59 63|level
P07945937A0358|85 87|rat
P07947930A0499|44 51|membrane
P07947930A0499|71 71|%
P07947930A0499|78 78|%
P07947930A0499|75 75|%
P07947930A0499|65 66|Cm
P07947930A0499|28 40|sodium heparin
P07947930A0499|3 12|fibrinogen
P07947930A0499|84 84|%
P07947930A0499|14 26|serum proteins
P07948129A0297|217 219|NEO
P07948129A0297|74 105|chloramphenicol acetyl transferase
P07948129A0297|37 42|repeat
P07948129A0297|44 48|chLTR
P07948129A0297|111 122|reporter gene
P07948129A0297|7 13|vectors
P07948129A0297|107 109|CAT
P07948129A0297|163 176|region promoter
P07948129A0297|59 68|expression
P07948129A0297|149 157|SV40 virus
P07948129A0297|188 213|neomycin phosphotransferase
P07948129A0297|221 224|gene
P07948921A0051|0 5|Optima
P07948921A0051|54 73|stilbene synthase cDNA
P07948921A0051|77 81|probe
P07948921A0051|14 20|library
P07949137A0000|126 132|January
P07949137A0000|29 36|patients
P07949137A0000|56 65|bone marrow
P07949137A0000|105 110|period
P07949137A0000|78 88|mafosfamide
P07949137A0000|90 94|ASTA Z
P07949137A0000|16 23|leukemia
P07949137A0000|67 68|BM
P07949137A0000|1 5|total
P07949137A0000|113 119|January
P07949137A0532|16 22|regimen
P07949137A0532|54 58|mg/kg
P07949137A0532|68 82|body irradiation
P07949137A0532|34 49|cyclophosphamide
P07949164A0799|42 45|IL-6
P07949164A0799|47 56|CAT plasmid
P07949164A0799|90 109|IL-6 promoter activity
P07949164A0799|16 23|mutation
P07949164A0799|78 87|abrogation
P07949164A0799|117 121|cells
P07949164A0799|29 39|kappa B motif
P07949205A0286|90 104|breast carcinoma
P07949205A0286|10 23|testololactone
P07949205A0286|55 71|aminoglutethimide
P07949551A0000|0 2|Use
P07949551A0000|37 40|vein
P07949551A0000|8 15|vena cava
P07949551A0000|44 65|cadaver transplantation
P07949770T0000|85 88|pigs
P07949770T0000|63 82|liver transplantation
P07949770T0000|39 53|prostaglandin E1
P07949770T0000|21 29|blood flow
P07951235A0277|72 77|muscle
P07951235A0277|3 6|gene
P07951410A0647|82 90|formation
P07951410A0647|67 68|RB
P07951410A0647|45 49|E2F-1
P07951410A0647|20 28|A549 cells
P07951410A0647|154 158|E2F-1
P07951410A0647|51 54|DP-1
P07951410A0647|56 62|cyclin A
P07951410A0647|134 140|factors
P07951410A0647|161 164|DP-1
P07951410A0647|12 15|U937
P07951410A0647|97 105|complexes
P07951410A0647|119 131|participation
P07951410A0647|30 42|participation
P07951410A0647|167 172|others
P07951410A0647|3 6|HeLa
P07951410A1332|0 16|E1A autoactivation
P07951410A1332|106 116|E1A promoter
P07951410A1332|32 36|sites
P07951410A1332|73 82|activation
P07951874A0320|102 107|system
P07951874A0320|27 38|host organism
P07951874A0320|75 83|radiation
P07951874A0320|89 95|hamster
P07951874A0320|0 14|Cestode invasion
P07951874A0320|59 64|effect
P07953785A0648|54 65|% restriction
P07953785A0648|92 95|food
P07953785A0648|104 112|H/L ratios
P07953785A0648|6 17|heat exposure
P07953785A0648|124 133|resistance
P07953785A0648|19 24|chicks
P07953785A0648|136 163|marble spleen disease infection
P07954475A0714|0 7|Analyses
P07954475A0714|207 225|tumor suppressor gene
P07954475A0714|102 114|C3H/HeJ x A/J F1
P07954475A0714|177 182|allele
P07954475A0714|35 38|mice
P07954475A0714|64 76|A/J x C3H/HeJ F1
P07954475A0714|131 135|C3AF1
P07954475A0714|160 171|inactivation
P07954475A0714|20 25|tumors
P07954475A0714|196 205|chromosome
P07954475A0714|93 97|AC3F1
P07954475A0714|146 153|evidence
P07954475A0714|56 62|crosses
P07954891T0000|0 3|ERV1
P07954891T0000|43 53|maintenance
P07954891T0000|32 36|cycle
P07954891T0000|69 75|genomes
P07956578A0851|0 14|Lesion diameters
P07956578A0851|30 31|mm
P07956578A0851|112 118|removal
P07956578A0851|55 68|configurations
P07956578A0851|73 79|factors
P07956869A0000|141 145|years
P07956869A0000|161 173|flow cytometry
P07956869A0000|77 84|archives
P07956869A0000|127 133|storage
P07956869A0000|90 108|Pathology laboratory
P07956869A0000|37 54|breast cancer tissue
P07956869A0000|189 203|S-phase fraction
P07956869A0000|111 113|Dar
P07956869A0000|177 185|DNA ploidy
P07957085A0207|0 3|Cbf3
P07957085A0207|40 44|Cbf3c
P07957085A0207|26 30|Cbf3a
P07957085A0207|32 36|Cbf3b
P07957085A0207|17 24|proteins
P07957106A0471|6 16|interaction
P07957106A0471|38 57|GST-POU fusion protein
P07957106A0471|65 88|glutathione-agarose beads
P07957106A0875|5 13|mutations
P07957106A0875|100 111|VP16 contacts
P07957106A0875|35 40|region
P07957106A0875|49 69|HSV transactivator VP16
P07957158A1532|159 165|control
P07957158A1532|171 184|Starling forces
P07957158A1532|37 41|areas
P07957158A1532|85 93|parameter
P07957158A1532|13 26|filtration rate
P07957243A1316|42 48|domains
P07957243A1316|13 20|residues
P07957559A1557|8 16|rapamycin
P07957559A1557|90 108|p70 S6 kinase activity
P07957559A1557|78 87|inhibition
P07957559A1557|26 38|proliferation
P07957559A1557|115 119|cells
P07957559A1557|41 52|Ba/F3-EpoRgp
P07957559A1557|63 70|MEL cells
P07957632A0000|95 101|agonist
P07957632A0000|223 230|pmol/rat
P07957632A0000|117 134|glutamate receptors
P07957632A0000|28 29|2S
P07957632A0000|138 141|rats
P07957632A0000|41 41|R
P07957632A0000|72 78|glycine
P07957632A0000|16 24|injection
P07957632A0000|169 176|recovery
P07957632A0000|80 85|DCG-IV
P07957632A0000|37 37|R
P07957632A0000|203 211|dose range
P07957632A0000|33 33|R
P07957632A0000|181 199|halothane anesthesia
P07958446A0000|163 182|helix DNA binding motif
P07958446A0000|20 27|factor-3
P07958446A0000|36 43|forkhead
P07958446A0000|140 147|homology
P07958446A0000|116 129|gene regulators
P07958446A0000|77 82|family
P07958446A0000|49 56|proteins
P07958446A0000|3 12|hepatocyte
P07958446A0000|29 33|HNF-3
P07958446A0000|45 47|fkh
P07958865A1152|14 20|embryos
P07958865A1152|83 92|conclusion
P07958865A1152|49 64|heart development
P07958865A1152|34 46|abnormalities
P07958865A1152|97 99|Tek
P07958865A1152|154 164|development
P07958865A1152|136 147|interactions
P07958898A1050|91 110|transcription factors
P07958898A1050|14 23|dTFIIA-L/S
P07958898A1050|132 136|NTF-1
P07958898A1050|120 122|Sp1
P07958898A1050|71 80|activation
P07958898A1050|124 127|VP16
P07958911A0500|130 136|complex
P07958911A0500|51 58|location
P07958911A0500|101 104|gene
P07958911A0500|7 26|trithorax binding site
P07958911A0500|64 75|fork head gene
P07958915A1507|159 161|Ca2
P07958915A1507|184 197|protein kinases
P07958915A1507|91 94|cAMP
P07958915A1507|35 37|Ca2
P07958915A1507|13 19|changes
P07958915A1507|152 156|forms
P07958915A1507|106 118|transcription
P07958915A1507|82 88|ability
P07958915A1507|134 141|presence
P07958920A1157|0 9|Antibodies
P07958920A1157|82 89|extracts
P07958920A1157|147 155|RNase P RNA
P07958920A1157|57 67|RNase MRP RNA
P07958920A1157|28 38|SNM1 protein
P07959011A0379a|0 9|C/EBP alpha
P07959011A0379a|26 33|promoter
P07959011A0379a|39 55|rat class-I ADH gene
P07959011A0379a|76 81|manner
P07959011A0379a|83 88|Potter
P07959011A0379a|95 98|Arch
P07959011A0379b|0 9|C/EBP alpha
P07959011A0379b|26 33|promoter
P07959011A0379b|39 55|rat class-I ADH gene
P07959011A0379b|76 81|manner
P07959011A0379b|83 88|Potter
P07959011A0379b|95 98|Arch
P07959015A0478|41 50|amino acids
P07959015A0478|99 108|identities
P07959015A0478|90 94|rAMPK
P07959015A0478|62 64|kDa
P07959015A0478|131 138|nt levels
P07959015A0478|120 120|%
P07959015A0478|21 23|ORF
P07959015A0478|52 53|aa
P07959015A0478|3 9|results
P07959015A0478|26 30|hAMPK
P07959015A0478|126 127|aa
P07959734A0194|58 74|peptide sequencing
P07959734A0194|101 117|glycoprotein Gp135
P07959734A0194|7 11|brain
P07959734A0194|13 21|contactin
P07959734A0194|42 46|amino
P07959760A0763|88 91|STSs
P07959760A0763|14 22|YAC contig
P07959760A0763|212 213|kb
P07959760A0763|334 342|Fli-1 gene
P07959760A0763|158 162|Fli-1
P07959760A0763|277 290|microsatellite
P07959760A0763|149 153|c-ets
P07959760A0763|179 187|ets family
P07959760A0763|303 303|n
P07959760A0763|52 55|YACs
P07959760A0763|126 147|Ewing sarcoma breakpoint
P07959760A0763|292 298|D11S912
P07959760A0763|113 114|Mb
P07959760A0763|101 107|minimum
P07959760A0763|300 301|CA
P07959760A0763|240 245|contig
P07959760A0763|167 173|members
P07959760A0763|82 86|sites
P07959760A0763|59 64|orders
P07959760A0763|227 229|DNA
P07959952A1446|129 133|mouse
P07959952A1446|24 33|pseudogene
P07959952A1446|155 166|mast cell line
P07959952A1446|88 123|polymerase chain reaction amplification
P07959952A1446|54 74|mouse mast cell chymases
P07959952A1446|1 4|cDNA
P07959953A0423|0 4|IFI16
P07959953A0423|75 76|kb
P07959953A0423|18 22|exons
P07959953A0423|65 73|kilobases
P07959953A0423|80 82|DNA
P07959953A0423|41 47|introns
P07960608A0228|0 6|Courses
P07960608A0228|28 32|weeks
P07960796A0154|0 9|Peter Elfer
P07960796A0154|38 43|ruling
P07960796A0154|21 32|implications
P07961545A1314|59 65|placebo
P07961545A1314|22 31|incidences
P07961545A1314|93 100|sweating
P07961545A1314|12 17|events
P07961545A1314|125 135|ejaculation
P07961545A1314|80 91|constipation
P07961545A1314|70 78|dizziness
P07961545A1314|102 112|nervousness
P07961755A0474|0 7|Homology
P07961755A0474|113 127|leader sequences
P07961755A0474|65 81|cysteine synthase C
P07961755A0474|41 62|transit peptide sequence
P07961957A1565|15 18|data
P07961957A1565|70 75|factor
P07961957A1565|34 41|addition
P07961957A1565|44 48|TEF-1
P07961957A1565|96 117|alpha-MHC gene EM element
P07961958T0000|0 24|Rat kidney carboxylesterase
P07963540A0795|60 73|factor-kappa B1
P07963540A0795|75 78|RelA
P07963540A0795|140 152|cross-linking
P07963540A0795|113 114|UV
P07963540A0795|101 107|studies
P07963540A0795|185 205|kappa B oligonucleotide
P07963540A0795|11 23|I-kappa B alpha
P07963540A0795|33 50|kappa B motif binding
P07963540A0795|83 87|c-Rel
P07963782A0000|129 132|pain
P07963782A0000|22 30|stability
P07963782A0000|47 51|drugs
P07963782A0000|34 44|combination
P07963782A0000|111 119|treatment
P07963782A0000|100 104|space
P07964162A0941|101 113|specification
P07964162A0941|124 132|responses
P07964162A0941|10 19|mechanisms
P07964162A0941|46 61|MAP kinase cascade
P07964162A0941|31 40|activation
P07964458A0179|77 81|Nramp
P07964458A0179|183 189|animals
P07964458A0179|59 75|macrophage protein
P07964458A0179|140 154|membrane protein
P07964458A0179|17 19|Bcg
P07964458A0179|1 13|candidate gene
P07964459A0845|4 8|motif
P07964459A0845|38 46|LIM domain
P07964459A0845|106 112|regions
P07964459A0845|53 68|RING finger family
P07964624A0491|113 119|P131 ORF
P07964624A0491|145 145|r
P07964624A0491|89 107|UGA termination codon
P07964624A0491|73 83|readthrough
P07964624A0491|37 39|ORF
P07964624A0491|143 143|M
P07964624A0491|130 140|polypeptide
P07964624A0491|3 9|P131 ORF
P07964624A0491|154 157|P191
P07964770A0172|15 22|patients
P07964770A0172|38 41|year
P07964770A0172|47 58|arthroplasty
P07964814T0000|43 50|epilepsy
P07964814T0000|32 39|migraine
P07964814T0000|16 29|hallucinations
P07964918A0000|29 35|factors
P07964918A0000|68 77|evaluation
P07964918A0000|92 96|signs
P07964918A0000|52 62|variability
P07964918A0000|3 11|influence
P07965152A0764|0 7|Segments
P07965152A0764|112 118|reserve
P07965152A0764|38 47|MIBI uptake
P07965152A0764|49 59|mismatching
P07965152A0764|23 33|BMIPP uptake
P07965152A0764|79 88|wall motion
P07965152A0764|125 145|dobutamine stimulation
P07966565A0901|99 114|replication cycle
P07966565A0901|21 24|mRNA
P07966565A0901|10 15|length
P07966565A0901|74 76|RNA
P07966565A0901|48 56|agreement
P07966565A0901|134 139|stages
P07966565A0901|31 41|nucleotides
P07966565A0901|142 150|infection
P07966583A1268|158 161|mass
P07966583A1268|122 134|fusion protein
P07966583A1268|9 21|transfections
P07966583A1268|166 168|kDa
P07966583A1268|25 33|construct
P07966583A1268|112 119|Env/Mlvi
P07966583A1268|47 59|RNA transcript
P07966583A1268|82 89|D17 cells
P07966583A1268|69 75|clone B1
P07966583A1268|98 107|expression
P07966602A0130|0 6|Roizman
P07966602A0130|8 9|J.
P07966873A0693|0 7|Articles
P07966873A0693|78 87|infarction
P07966873A0693|26 37|heart disease
P07966873A0693|90 95|Chagas
P07966873A0693|40 51|heart failure
P07966873A0693|97 103|disease
P07967360A1048|42 56|TGBM nephropathy
P07967360A1048|116 133|glomerulonephritis
P07967360A1048|77 90|IgA nephropathy
P07967360A1048|10 13|data
P07967360A1048|30 37|patients
P07967725A0262|58 64|domains
P07967725A0262|131 146|carboxyl terminus
P07967725A0262|10 18|receptors
P07967725A0262|107 125|ligand binding domain
P07967725A0262|96 101|domain
P07967725A0262|152 159|receptor
P07968409A0123|101 108|Diseases
P07968409A0123|69 85|Outpatient Service
P07968409A0123|143 157|General Hospital
P07968409A0123|116 122|Bologna
P07968409A0123|126 141|Ospedale Maggiore
P07968409A0123|172 175|days
P07968409A0123|185 188|July
P07968409A0123|3 8|sample
P07969115A0000|190 199|DNA origins
P07969115A0000|137 145|intervals
P07969115A0000|113 119|binding
P07969115A0000|206 220|promoter regions
P07969115A0000|95 99|level
P07969115A0000|7 32|organello footprint analysis
P07969115A0000|71 82|mitochondria
P07969115A0000|163 168|region
P07969116A0196|131 137|stimuli
P07969116A0196|101 105|genes
P07969116A0196|108 115|response
P07969116A0196|79 88|expression
P07969116A0196|3 14|Nur77 protein
P07969116A0196|30 51|transcription activator
P07969132A0268|100 108|histidine
P07969132A0268|183 190|gcn2-507
P07969132A0268|81 85|cells
P07969132A0268|62 72|suppression
P07969132A0268|10 17|plasmids
P07969132A0268|115 122|plasmids
P07969132A0268|3 7|class
P07969132A0268|36 40|genes
P07969132A0268|134 145|gcn2 deletion
P07969132A0268|27 30|tRNA
P07969135A0913|8 15|presence
P07969135A0913|74 80|protein
P07969135A0913|21 34|Cln2 PEST domain
P07969136A0273|15 33|mobility shift assays
P07969136A0273|49 57|sequences
P07969136A0273|114 126|NF-kappa B site
P07969136A0273|70 78|complexes
P07969136A0273|83 92|mobilities
P07969136A0273|134 138|kappa
P07969136A0273|150 153|gene
P07969152A0721|260 270|hsp70 family
P07969152A0721|107 114|response
P07969152A0721|26 28|HSF
P07969152A0721|88 104|CUP1 transcription
P07969152A0721|121 135|heat shock stress
P07969152A0721|236 242|members
P07969152A0721|223 227|genes
P07969152A0721|139 155|glucose starvation
P07969152A0721|44 59|activation domain
P07969152A0721|192 210|heat shock activation
P07969152A0721|76 85|activation
P07969152A0721|161 166|region
P07969181A0313|123 132|p53 protein
P07969181A0313|34 40|CKB mRNA
P07969181A0313|26 31|levels
P07969181A0313|43 51|HeLa cells
P07969181A0313|62 66|study
P07969181A0313|114 120|amounts
P07969181A0313|142 150|HeLa cells
P07969954T0000|44 51|serum IgM
P07969954T0000|91 103|immunotherapy
P07969954T0000|143 158|cyclophosphamide
P07969954T0000|115 128|plasma exchange
P07969954T0000|11 29|motor neuron syndrome
P07969954T0000|71 81|improvement
P07969954T0000|60 69|antibodies
P07971282A0000|0 9|Regulators
P07971282A0000|95 103|metazoans
P07971282A0000|63 92|pre-mRNA splicing characteristic
P07971709A0907|15 22|response
P07971709A0907|88 92|state
P07971709A0907|70 77|activity
P07971709A0907|56 62|rhG-CSF
P07972012A0956|140 151|ANP-receptor
P07972012A0956|75 81|protein
P07972012A0956|12 20|cDNA clone
P07972012A0956|163 168|domain
P07972012A0956|120 125|domain
P07972012A0956|226 242|phosphatase domain
P07972012A0956|34 47|rat lung library
P07972012A0956|187 202|carboxyl terminus
P07972012A0956|97 109|amino terminus
P07972237A0665|16 29|restriction map
P07972237A0665|89 102|subcloning YACs
P07972237A0665|53 55|DNA
P07972237A0665|39 40|kb
P07972237A0665|66 70|N-myc
P07972237A0665|107 113|cosmids
P07972831A0563|0 10|PAI-1 levels
P07972831A0563|54 60|iohexol
P07972831A0563|35 42|patients
P07972831A0563|85 93|ioxaglate
P07973364A0325|69 90|carcinogenicity studies
P07973364A0325|168 170|OF1
P07973364A0325|23 28|causes
P07973364A0325|153 159|studies
P07973364A0325|12 18|article
P07973364A0325|109 111|OFA
P07973364A0325|139 148|Wistar rats
P07973364A0325|94 100|studies
P07973364A0325|31 35|death
P07973364A0325|174 181|NMRI mice
P07973397T0001|44 47|salt
P07973397T0001|0 12|Determination
P07973397T0001|15 29|potassium iodide
P07973825A0445|3 15|recovery value
P07973825A0445|26 33|pressure
P07973825A0445|67 79|pulse pressure
P07973825A0445|56 63|pressure
P07975763A0000|15 29|hepatitis C virus
P07975763A0000|47 51|cause
P07975763A0000|61 72|liver disease
P07975763A0000|94 105|introduction
P07975763A0000|31 33|HCV
P07975763A0000|35 43|infection
P07975763A0000|117 132|detection methods
P07975763A0000|3 12|importance
P07975882T0000|32 37|fibers
P07975882T0000|5 18|adenovirus type
P07977239A1283|0 17|Outflow obstruction
P07977239A1283|50 57|stenosis
P07977239A1283|106 113|patients
P07977239A1283|149 156|patients
P07977239A1283|124 130|papilla
P07977239A1283|167 173|papilla
P07977239A1283|243 247|juice
P07977239A1283|273 282|dorsal duct
P07977239A1283|161 164|type
P07977239A1283|223 230|drainage
P07977239A1283|260 267|pressure
P07977239A1283|194 205|pancreatitis
P07977239A1283|68 74|papilla
P07977239A1283|118 121|type
P07977239A1283|30 34|juice
P07977648A0880|0 9|Sequencing
P07977648A0880|34 38|exons
P07977648A0880|65 73|mutations
P07977648A0880|88 93|allele
P07977648A0880|106 111|tumors
P07977648A0880|15 29|TP53 transcripts
P07978229T0000|35 41|patient
P07978229T0000|9 20|complication
P07978406A0998|68 70|g-1
P07978406A0998|73 80|response
P07978406A0998|121 128|ABSTRACT
P07978406A0998|56 63|mL.min-1
P07978406A0998|83 93|hypercapnia
P07978406A0998|24 26|CBF
P07978406A0998|16 22|pre-DEX
P07978406A0998|143 147|WORDS
P07978406A0998|5 12|ISO group
P07978406A0998|95 98|PCO2
P07978406A0998|114 117|mmHg
P07979810A0340|28 34|density
P07979810A0340|126 134|pregnancy
P07979810A0340|36 43|motility
P07979810A0340|53 56|test
P07979810A0340|58 72|penetration test
P07979810A0340|17 26|parameters
P07979827A0722|0 6|KRN2391
P07979827A0722|10 19|cromakalim
P07979827A0722|70 78|blood flow
P07979827A0722|43 50|increase
P07980440A0138|117 129|phorbol esters
P07980440A0138|65 68|cAMP
P07980440A0138|107 113|insulin
P07980440A0138|24 38|glucocorticoids
P07980440A0138|2 22|H4IIE rat hepatoma cells
P07980440A0138|48 51|acid
P07980440A0138|70 99|increase PEPCK gene transcription
P07980440A0138|61 63|AMP
P07980440A0138|145 150|effect
P07980468A0298|0 3|Acta
P07980669A0373|68 82|plasma NPY levels
P07980669A0373|104 110|samples
P07980669A0373|23 32|AVP release
P07980669A0373|5 19|plasma AVP levels
P07980669A0373|46 51|change
P07981143A0633|12 22|nucleotides
P07981143A0633|1 7|stretch
P07981143A0633|59 74|IL-4 inducibility
P07981143A0633|122 128|factors
P07981143A0633|40 45|IL-4RE
P07981143A0633|84 105|nucleoprotein complexes
P07981246A0112|44 46|IAP
P07981246A0112|158 171|c-fos induction
P07981246A0112|131 143|hormones/IBMX
P07981246A0112|105 111|process
P07981246A0112|80 88|G-protein
P07981246A0112|114 128|differentiation
P07981246A0112|69 75|protein
P07981246A0112|11 15|study
P07981246A0112|77 77|s
P07981246A0112|29 42|pertussis toxin
P07982964A1017|0 2|ATX
P07982964A1017|8 11|PC-1
P07982964A1017|92 104|monophosphate
P07982964A1017|35 38|type
P07982964A1017|40 89|phosphodiesterase substrate p-nitrophenyl thymidine-5
P07982995A0000|59 70|growth factor
P07982995A0000|154 158|gland
P07982995A0000|107 108|Na
P07982995A0000|77 89|beta-receptor
P07982995A0000|24 32|mutations
P07982995A0000|113 121|exchanger
P07982995A0000|92 101|activation
P07982995A0000|38 42|mouse
P07982995A0000|186 197|hamster ovary
P07982995A0000|72 75|PDGF
P07982995A0000|199 201|CHO
P07982995A0000|170 174|NMuMG
P07982995A0000|111 111|H
P07982995A0000|3 8|effect
P07982995A0000|203 207|cells
P07983011A0617|0 15|Sequence analysis
P07983011A0617|307 313|segment
P07983011A0617|343 348|domain
P07983011A0617|395 401|domains
P07983011A0617|108 114|members
P07983011A0617|182 217|fibroblast growth factor receptor family
P07983011A0617|284 287|acid
P07983011A0617|95 100|hybrid
P07983011A0617|431 450|domain binding regions
P07983011A0617|427 429|SH3
P07983011A0617|43 48|domain
P07983011A0617|69 91|serine/threonine kinases
P07983011A0617|28 33|kinase
P07983011A0617|150 175|protein kinase kinase kinases
P07983011A0617|245 263|leucine zipper motifs
P07983011A0617|414 424|src homology
P07983011A0617|120 125|family
P07983704A0330|0 3|Type
P07983704A0330|65 73|structure
P07983704A0330|153 156|type
P07983704A0330|26 33|sequence
P07983704A0330|135 146|HERV-K family
P07983704A0330|5 11|genomes
P07983704A0330|111 129|retrovirus ancestors
P07983704A0330|176 183|sequence
P07983704A0330|158 164|genomes
P07983712A0914|69 79|replication
P07983712A0914|12 17|domain
P07983712A0914|61 66|levels
P07983712A0914|49 55|plasmid
P07983712A0914|22 27|domain
P07983715A0996|0 13|Point mutations
P07983715A0996|75 77|arm
P07983715A0996|140 155|complex formation
P07983715A0996|88 95|activity
P07983715A0996|38 44|binding
P07983715A0996|193 208|expression assays
P07983715A0996|109 118|P4 promoter
P07983715A0996|47 50|NF-Y
P07983715A0996|160 162|USF
P07983715A0996|217 238|luciferase reporter gene
P07983716A1082|147 154|Y88L RNAs
P07983716A1082|94 98|COS-7
P07983716A1082|26 37|blot analysis
P07983716A1082|178 183|levels
P07983716A1082|13 20|Northern
P07983716A1082|80 91|transfection
P07983716A1082|124 127|RNAs
P07983716A1082|140 143|Y88S
P07983716A1082|22 24|RNA
P07983716A1082|48 65|transcriptase-PCRs
P07983716A1082|101 109|HeLa cells
P07983744A0920|155 159|IE175
P07983744A0920|121 125|IE110
P07983744A0920|65 69|IE175
P07983744A0920|148 152|forms
P07983744A0920|27 31|IE110
P07983744A0920|59 62|form
P07983744A0920|81 98|punctate structures
P07983744A0920|20 24|forms
P07983744A0920|173 190|punctate structures
P07983744A0920|115 118|form
P07984088A0592|0 12|Transcription
P07984088A0592|39 48|expression
P07984088A0592|25 35|ivanolysin O
P07984088A0592|66 85|virulence gene cluster
P07984088A0592|56 60|genes
P07984088A0592|88 97|L. ivanovii
P07984088A0592|18 21|gene
P07984088A0592|113 116|PrfA
P07984105A1509|86 99|mouse virulence
P07984105A1509|63 82|yersiniabactin uptake
P07984105A1509|11 25|complementation
P07984105A1509|31 42|WA fyuA mutant
P07984105A1509|54 61|fyuA gene
P07984261A0536|42 50|reduction
P07984261A0536|21 26|cortex
P07984261A0536|89 95|tissues
P07984261A0536|67 72|centre
P07984261A0536|3 6|ICBF
P07985305T0001|14 27|hydronephrosis
P07985305T0001|3 11|treatment
P07985305T0001|30 37|children
P07987924A0670|56 78|USCI Tuohy-Borst Y adaptor
P07987924A0670|110 122|probe hypotube
P07987924A0670|20 24|probe
P07987924A0670|3 14|inflation hub
P07988559A0836|20 29|RBP-J kappa
P07988559A0836|37 44|affinity
P07988559A0836|8 14|element
P07988730A0220|144 155|transfection
P07988730A0220|26 35|constructs
P07988730A0220|76 78|LTR
P07988730A0220|129 134|assays
P07988730A0220|187 194|presence
P07988730A0220|158 166|HeLa cells
P07988730A0220|211 234|transactivator tax protein
P07988730A0220|49 57|deletions
P07988730A0220|125 127|CAT
P07988730A0220|8 23|promoter strength
P07988730A0220|169 181|Jurkat T-cells
P07988730A0220|63 70|U5 region
P07988730A0220|92 123|chloramphenicol acetyltransferase
P07988730A0220|197 203|absence
P07988731A0002|174 178|G-box
P07988731A0002|12 17|number
P07988731A0002|180 187|CCACGTGG
P07988731A0002|67 75|promoters
P07988731A0002|142 157|promoter activity
P07988731A0002|97 104|presence
P07988731A0002|120 127|elements
P07988731A1301|69 85|GBF protein complex
P07988731A1301|27 30|GF14
P07988731A1301|10 16|protein
P07988945T0000|0 2|New
P07988945T0000|13 22|strategies
P07988945T0000|26 44|lupus anticoagulants
P07988945T0000|64 73|antibodies
P07990136A1124|83 107|tRNA gene transcription unit
P07990136A1124|197 205|complexes
P07990136A1124|157 166|properties
P07990136A1124|12 18|ability
P07990136A1124|21 47|selectivity arrest elongation
P07990136A1124|184 189|polIII
P07990136A1124|50 55|polIII
P07990136A1124|65 73|positions
P07990136A1124|123 136|identification
P07991437A1032|0 10|Propafenone
P07991437A1032|31 38|majority
P07991437A1032|46 53|patients
P07991582A1023b|20 28|yeast CEG1
P07991582A1023b|10 17|analysis
P07991582A1023b|67 72|motifs
P07991582A1023b|95 108|enzyme function
P07992027A0485|1 8|patients
P07992027A0485|67 81|transplantation
P07992027A0485|12 12|%
P07992027A0485|46 49|days
P07992027A0485|28 36|morbidity
P07993559A0233|43 49|Pendrys
P07993559A0233|76 81|review
P07993559A0233|7 11|index
P07993559A0233|13 30|Fluorosis Risk Index
P07994021A1223|122 132|association
P07994021A1223|64 78|PECAM-1 isoforms
P07994021A1223|35 38|tail
P07994021A1223|94 108|phosphorylation
P07994021A1223|11 18|splicing
P07994021A1223|137 154|affinity modulation
P07994021A1223|166 172|protein
P07995173A0585|0 7|Transfer
P07995173A0585|50 50|r
P07995173A0585|42 48|juice pH
P07995173A0585|59 59|P
P07995910A0119|116 125|laparotomy
P07995910A0119|77 79|way
P07995910A0119|17 27|sensitivity
P07995910A0119|32 42|specificity
P07995910A0119|4 12|technique
P07995910A0119|54 54|%
P07995910A0119|95 105|involvement
P07997174A0936|44 50|His-304
P07997174A0936|81 89|functions
P07997174A0936|92 107|A. vinelandii NifL
P07997174A0936|3 6|data
P07997174A0936|27 41|phosphorylation
P07999066A0238|142 148|tat gene
P07999066A0238|74 94|IL-2 gene transcription
P07999066A0238|151 162|phorbol ester
P07999066A0238|192 202|Jurkat cells
P07999066A0238|9 14|HIV tat
P07999066A0238|127 136|expression
P07999066A0238|218 221|IL-2
P07999066A0238|246 280|acetyltransferase reporter constructs
P07999066A0238|30 44|enhancing factor
P07999066A0238|53 55|LTR
P07999066A0238|62 71|regulation
P07999066A0238|166 172|calcium
P07999066A0238|3 6|role
P07999363A0000|60 63|FGFR
P07999363A0000|35 58|transmembrane FGF receptor
P07999363A0000|157 168|kinase domain
P07999363A0000|18 22|genes
P07999363A0000|94 103|ectodomain
P07999363A0000|6 15|variations
P07999363A0000|73 80|isoforms
P07999363A0000|118 136|juxtamembrane domain
P07999604A0139|67 73|lesions
P07999604A0139|20 27|patients
P07999982A0086|172 177|search
P07999982A0086|60 64|D9S15
P07999982A0086|53 56|FRDA
P07999982A0086|39 42|D9S5
P07999982A0086|32 35|FRDA
P07999982A0086|136 154|recombination events
P07999982A0086|9 24|maximum lod scores
P07999982A0086|183 186|gene
P07999982A0086|97 117|recombination fraction
P07999995A0000|14 26|protein kinase
P07999995A0000|52 55|rice
P07999995A0000|57 67|Oryza sativa
P07999995A0000|28 33|OsPK10
P08000074A0162|71 81|translation
P08000074A0162|50 57|sequence
P08000074A0162|132 139|fragment
P08000074A0162|94 106|reading frames
P08000074A0162|120 124|kb DNA
P08000074A0162|1 8|sequence
P08000074A0162|28 28|%
P08000112T0000|0 10|Goodpasture
P08000112T0000|51 75|membrane oxygenator support
P08000112T0000|18 25|syndrome
P08000112T0000|29 34|effect
P08000427A0000|1 13|cDNA clone pCZ1
P08000427A0000|118 127|kDa protein
P08000427A0000|60 81|tobacco cell cDNA library
P08000427A0000|23 30|kb insert
P08000427A0000|132 141|amino acids
P08000427A0000|158 159|pI
P08000497A0179|0 6|METHODS
P08000497A0179|105 110|volume
P08000497A0179|39 65|methacholine provocation test
P08000497A0179|76 79|test
P08000497A0179|124 126|VTG
P08000497A0179|25 34|spirometry
P08000497A0179|88 94|airways
P08000497A0179|120 122|gas
P08001136T0000|0 11|Relationship
P08001136T0000|52 71|CTD kinase TFIIH/TFIIK
P08001136T0000|28 33|kinase
P08001136T0000|37 49|RNA polymerase
P08001792A0284|13 16|git5
P08001792A0284|90 122|adenylate cyclase activation pathway
P08001792A0284|23 26|git8
P08001792A0284|30 39|git10 genes
P08001792A0284|18 21|git7
P08001792A0284|8 11|git3
P08001792A0284|53 68|adenylate cyclase
P08001792A0284|3 6|git1
P08001966A0563|72 77|skin-1
P08001966A0563|9 15|regions
P08001966A0563|32 39|homology
P08001966A0563|66 68|CNC
P08001966A0563|108 118|development
P08001966A0563|57 64|proteins
P08001966A0563|146 166|Caenorhabditis elegans
P08002564A0249|116 123|position
P08002564A0249|39 46|mutation
P08002564A0249|140 148|rpoAL290H
P08002564A0249|130 138|histidine
P08002564A0249|78 89|alpha subunit
P08002564A0249|67 72|region
P08002564A0249|100 113|leucine residue
P08002564A0249|0 18|DNA sequence analysis
P08002857A1070|0 10|CONCLUSIONS
P08002857A1070|172 177|attack
P08002857A1070|180 183|bile
P08002857A1070|91 96|degree
P08002857A1070|42 48|barrier
P08002857A1070|99 108|protection
P08002857A1070|51 71|oesophageal surfactant
P08002857A1070|17 24|findings
P08002857A1070|134 139|reflux
P08003700T0000|91 100|sugar-beet
P08003700T0000|36 48|cDNA libraries
P08003700T0000|12 20|screening
P08003700T0000|108 127|genome rearrangements
P08003700T0000|130 133|atp6
P08003700T0000|137 144|atpA loci
P08004442A0265|133 136|axis
P08004442A0265|80 86|animals
P08004442A0265|129 131|HPA
P08004442A0265|170 192|corticosterone secretion
P08004442A0265|45 61|locomotor activity
P08004442A0265|18 26|isolation
P08004442A0265|142 148|animals
P08004442A0265|3 9|effects
P08004442A0265|205 217|adrenalectomy
P08005230A0222|61 70|activation
P08005230A0222|76 88|c-fos promoter
P08005230A0222|127 135|elevation
P08005230A0222|9 26|reporter gene system
P08005230A0222|146 163|luciferase activity
P08005412A0608|116 122|PS sites
P08005412A0608|138 149|interactions
P08005412A0608|21 34|gene expression
P08005412A0608|60 68|formation
P08005412A0608|39 39|P
P08005412A0608|169 171|DNA
P08005412A0608|72 85|protein complex
P08005438A1185|0 4|SPP41
P08005438A1185|123 131|regulator
P08005438A1185|87 100|suppressor srn1
P08005438A1185|48 52|spp43
P08005438A1185|134 147|gene expression
P08006101A1142|0 35|Standard curve correlation coefficients
P08006101A1142|104 115|study samples
P08006101A1142|94 101|analysis
P08006101A1142|70 90|validation experiments
P08006772A0000|34 38|fetus
P08006772A0000|100 105|labour
P08006772A0000|74 78|women
P08006772A0000|8 20|pulse oximeter
P08006772A0000|45 50|labour
P08006773A0836|144 155|preeclampsia
P08006773A0836|49 54|figure
P08006773A0836|22 41|plasma concentrations
P08006773A0836|207 207|p
P08006773A0836|102 113|preeclampsia
P08006773A0836|66 73|patients
P08006773A0836|220 223|TxA2
P08006773A0836|160 178|plasma concentration
P08006773A0836|44 47|PGI2
P08006773A0836|181 184|PGI2
P08006773A0836|244 244|p
P08006773A0836|60 63|TxA2
P08006773A0836|10 19|difference
P08006773A0836|84 96|blood pressure
P08006773A0836|117 127|hypotension
P08007835A0538|128 132|event
P08007835A0538|105 114|importance
P08007835A0538|48 56|formation
P08007835A0538|26 34|variables
P08007835A0538|152 159|response
P08007835A0538|165 168|news
P08007835A0538|136 140|level
P08007835A0538|7 14|analysis
P08007835A0538|98 102|level
P08007835A0538|59 68|FB memories
P08007954A0374|0 14|Deletion studies
P08007954A0374|92 101|properties
P08007954A0374|130 137|enhancer
P08007954A0374|32 46|response element
P08007954A0374|70 85|cytokine response
P08007975A0000|3 10|IPL1 gene
P08007975A0000|24 57|high-fidelity chromosome segregation
P08007975A0000|70 74|yeast
P08011017A0169|2 5|drop
P08011017A0169|25 28|SaO2
P08011017A0169|8 23|oxygen saturation
P08011017A0169|105 125|repeat polysomnography
P08011017A0169|38 45|evidence
P08011017A0169|81 83|EEG
P08011017A0169|85 92|arousals
P08011166A0207|98 113|characterization
P08011166A0207|52 58|results
P08011166A0207|79 84|clones
P08011166A0207|156 163|segments
P08011166A0207|11 26|gene organization
P08011166A0207|64 71|sequence
P08011166A0207|116 130|polymerase chain
P08012448T0000|0 3|INO2
P08012448T0000|80 98|bud pattern formation
P08012448T0000|22 26|yeast
P08012448T0000|39 50|biosynthesis
P08012448T0000|66 76|segregation
P08012448T0000|16 19|gene
P08012566A0254|87 91|limit
P08012566A0254|110 114|ng/ml
P08012566A0254|123 134|plasma sample
P08012566A0254|69 71|m/z
P08012566A0254|32 46|clonidine yields
P08012566A0254|94 102|detection
P08012566A0254|3 29|pentafluorobenzyl derivative
P08012566A0254|56 66|ion fragment
P08013348A0143|16 20|SHBGs
P08013348A0143|60 76|binding properties
P08013348A0143|88 94|species
P08013348A0143|25 35|sex steroids
P08013348A0143|9 12|ABPs
P08013348A0143|44 51|affinity
P08013457A0342|45 56|interactions
P08013457A0342|71 110|tyrosine kinase receptor signal transduction
P08013457A0342|12 13|SH
P08013457A0342|15 20|domain
P08013457A0342|0 10|Src homology
P08014228A0278|29 33|order
P08014228A0278|99 110|racemization
P08014228A0278|64 88|labetalol diastereoisomers
P08014228A0278|52 61|extraction
P08014228A0278|117 126|extraction
P08014228A0278|0 14|Sample treatment
P08014377A1277|131 141|interaction
P08014377A1277|65 72|outflows
P08014377A1277|110 117|subjects
P08014377A1277|23 36|activity levels
P08014377A1277|12 21|conditions
P08014377A1277|174 182|divisions
P08014377A1277|46 50|vagal
P08014919A0530|149 151|DGR
P08014919A0530|37 41|units
P08014919A0530|141 146|length
P08014919A0530|109 115|rostral
P08014919A0530|124 132|direction
P08014919A0530|49 59|progression
P08014919A0530|71 76|fields
P08014919A0530|100 103|body
P08015672A1282|2 16|control patients
P08015672A1282|118 121|Type
P08015672A1282|51 54|Type
P08015672A1282|67 70|Type
P08015672A1282|87 90|Type
P08015672A1282|41 44|Type
P08015672A1282|124 131|baseline
P08015672A1282|18 31|baseline images
P08015850A1076|13 20|analysis
P08015850A1076|49 64|Ga administration
P08015850A1076|66 74|preinjury
P08015850A1076|163 170|efficacy
P08015850A1076|23 34|dose response
P08015850A1076|177 184|compound
P08015850A1076|128 134|barrier
P08015850A1076|36 39|time
P08015850A1076|106 107|Ga
P08015850A1076|92 103|availability
P08015850A1076|77 86|postinjury
P08015850A1076|43 46|mode
P08016102A1238|85 88|AP-2
P08016102A1238|95 104|activation
P08016102A1238|23 31|sequences
P08016102A1238|47 66|transcription factors
P08016102A1238|201 204|HO-1
P08016102A1238|38 44|binding
P08016102A1238|214 230|defense mechanisms
P08016102A1238|154 159|injury
P08016102A1238|73 81|NF-kappa B
P08016102A1238|133 140|response
P08016102A1238|168 177|indication
P08016102A1238|192 195|role
P08016102A1238|238 249|tissue injury
P08016102A1238|146 149|cell
P08016102A1238|3 10|presence
P08016189A0741|0 10|Granisetron
P08016189A0741|97 103|regimen
P08016189A0741|45 50|nausea
P08016189A0741|62 73|intervention
P08016189A0741|34 41|vomiting
P08016189A0741|18 23|saline
P08017290A1347|42 48|lactate
P08017290A1347|77 96|potassium differences
P08017290A1347|67 68|pH
P08017290A1347|108 112|group
P08017290A1347|25 39|sinus difference
P08017290A1347|120 125|pacing
P08017290A1347|70 73|PCO2
P08018361A0636|29 42|neutron fluency
P08018361A0636|53 57|n/cm2
P08020702A0000|0 10|Endotoxemia
P08020702A0000|124 127|wall
P08020702A0000|33 40|bacteria
P08020702A0000|130 136|lipid A.
P08020702A0000|57 61|shock
P08020702A0000|101 109|component
P08020702A0137|144 167|antibodies administration
P08020702A0137|108 121|dog experiments
P08020702A0137|32 37|lipid A
P08020702A0137|23 29|ability
P08020702A0137|95 105|endotoxemia
P08020702A0137|78 89|disturbances
P08020702A0137|48 57|antibodies
P08020702A0137|3 7|study
P08020702A0137|131 138|efficacy
P08020806A0187|69 75|disease
P08020806A0187|62 66|Crohn
P08020806A0187|108 115|outcomes
P08020806A0187|167 177|feeding tube
P08020806A0187|137 140|diet
P08020806A0187|191 197|peptide
P08020806A0187|203 206|diet
P08020806A0187|152 155|% fat
P08020806A0187|123 131|amino acid
P08020806A0187|22 26|trial
P08020806A0187|44 51|patients
P08020806A0187|219 222|% fat
P08020962A1226|83 85|Alu
P08020962A1226|100 102|MER
P08020962A1226|13 18|region
P08020962A1226|92 93|L1
P08020962A1226|24 33|V beta locus
P08020962A1226|51 56|number
P08020962A1226|69 79|DNA elements
P08020962A1226|130 137|elements
P08020965A0465|71 80|transcript
P08020965A0465|19 24|region
P08020965A0465|107 110|ends
P08020965A0465|85 86|kb
P08020965A0465|117 126|transcript
P08021175A0486|147 151|sites
P08021175A0486|98 115|AMP receptor protein
P08021175A0486|80 88|consensus
P08021175A0486|55 63|sequences
P08021175A0486|3 6|pexB
P08021175A0486|33 43|nucleotides
P08021175A0486|15 20|region
P08021175A0486|119 139|integration host factor
P08021177A0000|59 73|transport system
P08021177A0000|114 122|promoters
P08021177A0000|148 166|Fur repressor protein
P08021177A0000|35 55|enterobactin synthesis
P08021177A0000|184 193|conditions
P08021177A0000|3 11|fepA-entD
P08021177A0000|15 29|fes-entF operons
P08021225A0000|0 15|Sequence analysis
P08021225A0000|142 149|DNA probe
P08021225A0000|49 68|Alcaligenes eutrophus
P08021225A0000|104 119|dihydrolipoamide
P08021225A0000|151 152|A.
P08021225A0000|33 46|EcoRI-fragment
P08022212A0071|238 256|phase angle alpha pi/2
P08022212A0071|106 124|low-frequency region
P08022212A0071|258 268|conductance
P08022212A0071|131 132|Hz
P08022212A0071|227 236|parameters
P08022212A0071|181 184|line
P08022212A0071|287 297|frequency G0
P08022212A0071|307 326|ion relaxation time tau
P08022212A0071|25 37|two-frequency
P08022212A0071|39 50|AC excitation
P08022212A0071|67 72|method
P08022212A0071|77 95|admittance locus plot
P08022212A0071|299 302|1/R0
P08022212A0071|97 99|ALP
P08023662T0000|43 60|thromboplastin time
P08023662T0000|14 24|measurement
P08023662T0000|64 78|prothrombin time
P08023662T0000|94 100|monitor
P08024139A0393|28 37|hypothesis
P08024139A0393|99 109|differences
P08024139A0393|182 191|impairment
P08024139A0393|52 58|volumes
P08024139A0393|2 9|addition
P08024139A0393|158 166|solutions
P08025074A0000|116 119|shot
P08025074A0000|11 15|study
P08025074A0000|89 99|suture lysis
P08025074A0000|21 25|nylon
P08025074A0000|146 152|prolene
P08025074A0000|134 139|Dacron
P08025074A0000|62 79|laser energy density
P08025669A0724|30 33|rpoN
P08025669A0724|62 66|sigma
P08025669A0724|69 76|activity
P08025669A0724|3 10|proteins
P08028671A0687|42 50|antiserum
P08028671A0687|94 97|cAMP
P08028671A0687|108 115|promoter
P08028671A0687|76 88|transcription
P08028671A0687|16 29|microinjection
P08028671A0687|55 65|fibroblasts
P08029001A1020|173 194|transcription machinery
P08029001A1020|155 160|target
P08029001A1020|47 63|activator proteins
P08029001A1020|5 11|results
P08029001A1020|67 79|RNA polymerase
P08029001A1020|28 32|class
P08029001A1020|119 127|component
P08029334T0000|0 6|Cloning
P08029334T0000|32 46|acid desaturases
P08029334T0000|15 26|plant omega-3
P08030239A0833|29 32|form
P08030239A0833|167 181|EHV-1 tk promoter
P08030239A0833|196 202|ability
P08030239A0833|126 141|activation domain
P08030239A0833|60 76|amino acid residues
P08030239A0833|40 50|polypeptide
P08030239A0833|221 235|EHV-1 IE promoter
P08030243A1011|118 121|NS35
P08030243A1011|25 39|RNA capture assay
P08030243A1011|44 52|multimers
P08030243A1011|85 92|activity
P08030704A1503|0 9|CONCLUSION
P08030704A1503|23 27|birth
P08030704A1503|108 112|women
P08030704A1503|117 128|preterm labor
P08030704A1503|140 143|term
P08030704A1503|62 96|progesterone/17 beta-estradiol ratios
P08031424T0000|0 7|Ketamine
P08031424T0000|52 62|ventilation
P08031424T0000|24 35|bronchospasm
P08031424T0000|13 21|treatment
P08033490A0875|89 95|disease
P08033490A0875|2 11|conclusion
P08033490A0875|136 143|patients
P08033490A0875|106 121|dosage adjustment
P08033490A0875|43 64|O-desmethylvenlafaxine
P08033490A0875|180 185|ml/min
P08033490A0875|16 26|disposition
P08033490A0875|148 172|creatinine clearance values
P08033490A0875|29 39|venlafaxine
P08034318A0724|141 160|transcription factors
P08034318A0724|91 100|similarity
P08034318A0724|103 108|motifs
P08034318A0724|76 82|UBE site
P08034318A0724|117 123|members
P08034318A0724|17 24|sequence
P08034318A0724|37 43|species
P08034318A0724|3 14|availability
P08034318A0724|129 138|NF-1 family
P08034486A0579|14 18|HSV-2
P08034486A0579|127 131|areas
P08034486A0579|3 11|incidence
P08034486A0579|36 40|HSV-2
P08034486A0579|90 99|population
P08034486A0579|42 59|HSV-1 antibody ratio
P08034486A0579|27 34|subjects
P08034680A0180|131 133|kDa
P08034680A0180|88 100|I kappa B kinase
P08034680A0180|112 115|mass
P08034680A0180|168 175|I kappa B.
P08034680A0180|67 76|activation
P08034680A0180|35 43|NF-kappa B
P08034680A0180|19 25|zeta PKC
P08034680A0180|3 11|mechanism
P08034682T0000|72 85|3T3 fibroblasts
P08034682T0000|27 69|inositol 1,4,5-trisphosphate receptor subunits
P08034682T0000|6 15|expression
P08034708A0000|32 42|progenitors
P08034708A0000|104 108|genes
P08034708A0000|139 153|differentiation
P08034708A0000|48 64|eosinophil lineage
P08034708A0000|12 16|basis
P08034708A0000|20 29|commitment
P08034708A0000|68 77|mechanisms
P08034741A0000|28 43|characterization
P08034741A0000|51 56|myosin
P08034741A0000|120 133|border myosin I.
P08034741A0000|61 63|rat
P08034741A0000|11 24|identification
P08034741A0000|46 48|myr
P08034741A0000|83 89|myosin I
P08034742A0307|0 1|M.
P08034742A0307|6 7|D.
P08035498A0833|60 71|A stem element
P08035498A0833|11 26|computer analysis
P08035498A0833|39 47|sequences
P08035498A0833|96 113|AAV promoter regions
P08035498A0833|2 9|addition
P08035499A0941|28 36|stability
P08035499A0941|136 144|complexes
P08035499A0941|83 98|dissociation rate
P08035499A0941|72 75|fact
P08035499A0941|52 60|complexes
P08035499A0941|104 117|A stem substrate
P08035499A0941|45 49|kinds
P08035499A0941|16 25|difference
P08035499A0941|196 197|TR
P08035505A0586|0 9|Processing
P08035505A0586|21 32|B polyprotein
P08035505A0586|15 17|NS3
P08035517A0753|31 35|IEP86
P08035517A0753|77 81|IEP72
P08035517A0753|12 19|promoter
P08035517A0753|67 74|addition
P08035796A0890|102 116|phosphorylation
P08035796A0890|226 241|growth conditions
P08035796A0890|195 201|strains
P08035796A0890|68 79|casein kinase
P08035796A0890|165 174|eIF-2 alpha
P08035796A0890|158 162|forms
P08035796A0890|119 128|eIF-2 alpha
P08035796A0890|33 40|analysis
P08035796A0890|82 88|mutants
P08035796A0890|43 52|eIF-2 alpha
P08035796A0890|0 11|32Pi labeling
P08035833A1556|84 98|import machinery
P08035833A1556|31 34|RMIP
P08035833A1556|5 8|YMIP
P08035833A1556|22 28|homolog
P08035833A1556|52 60|component
P08035833A1556|66 70|yeast
P08036004A0292|99 113|binding activity
P08036004A0292|191 200|expression
P08036004A0292|74 78|cells
P08036004A0292|49 55|element
P08036004A0292|3 10|R2 region
P08036004A0292|185 189|class
P08036004A0292|20 24|class
P08036004A0292|26 33|enhancer
P08036004A0292|159 163|cells
P08037338A0000|73 84|pathogenesis
P08037338A0000|128 134|infants
P08037338A0000|31 44|erythropoietin
P08037338A0000|21 28|kinetics
P08037338A0000|95 105|prematurity
P08037338A0000|50 59|production
P08037338A0000|155 158|life
P08037338A0000|87 92|anemia
P08037338A0000|149 152|year
P08037338A0000|46 48|EPO
P08037338A0000|117 125|EPO levels
P08037338A0000|0 6|PURPOSE
P08039422A0000|29 32|NGFB
P08039422A0000|61 65|group
P08039422A0000|87 101|mouse Chromosome
P08039422A0000|73 82|chromosome
P08039422A0000|3 27|nerve growth factor beta gene
P08040336A0435|30 44|collagen element
P08040336A0435|22 28|element
P08040336A0435|110 124|albumin promoter
P08040336A0435|69 76|homology
P08040336A0435|84 104|LAP binding cis-element
P08040336A0435|131 132|bp
P08040391T0000|44 51|clusters
P08040391T0000|9 12|size
P08040391T0000|98 105|features
P08040391T0000|71 81|correlation
P08040391T0000|109 123|tumour behaviour
P08040391T0000|61 69|seminomas
P08040391T0000|0 5|Number
P08040468A0303|15 35|mast cell degranulation
P08040468A0303|149 157|reactions
P08040468A0303|89 112|fibroblast enzyme activity
P08040468A0303|54 65|pathogenesis
P08040468A0303|68 78|necrobiosis
P08041362T0000|119 127|auxotroph
P08041362T0000|52 59|vulgaris
P08041362T0000|9 15|cloning
P08041362T0000|81 95|complementation
P08041362T0000|115 117|Cys
P08041362T0000|19 38|cysteine synthase cDNA
P08041362T0000|61 70|watermelon
P08041793A0242|121 125|genes
P08041793A0242|127 131|COX5b
P08041793A0242|9 15|studies
P08041793A0242|79 88|activation
P08041793A0242|45 52|elements
P08041793A0242|99 108|repression
P08043523A0000|29 38|antibodies
P08043523A0000|53 73|acetylcholine receptor
P08043523A0000|117 124|patients
P08043523A0000|16 26|serum levels
P08043523A0000|151 160|antibodies
P08043523A0000|136 145|dyskinesia
P08043523A0000|75 79|nAChR
P08043523A0000|207 214|patients
P08044794A0000|3 17|tumor suppressor
P08044794A0000|62 68|protein
P08044794A0000|36 44|factor p53
P08044800A0550|54 61|entirety
P08044800A0550|105 109|sites
P08044800A0550|4 32|DNA containing promoter activity
P08044802A0462|128 130|p53
P08044802A0462|92 105|rearrangements
P08044802A0462|75 84|copy number
P08044802A0462|8 19|Southern blot
P08044802A0462|111 117|p53 gene
P08044802A0462|23 39|karyotype analyses
P08044802A0462|66 72|changes
P08044802A0462|132 140|cell lines
P08045431A0894|0 3|HupI
P08045431A0894|54 61|proteins
P08045431A0894|26 35|rubredoxin
P08045431A0894|16 23|identity
P08045431A0894|75 82|bacteria
P08045834A0783|70 81|ATP synthesis
P08045834A0783|22 22|P
P08045834A0783|51 54|rate
P08045834A0783|83 83|P
P08045834A0783|3 20|PCr resynthesis rate
P08046923A0000|29 36|patients
P08046923A0000|90 98|resection
P08046923A0000|62 73|osteomalacia
P08046923A0000|2 12|examination
P08048582A0821|164 166|g-1
P08048582A0821|101 103|g-1
P08048582A0821|146 160|ml O2.min-1 times
P08048582A0821|111 119|LAD region
P08048582A0821|16 19|MVO2
P08048582A0821|54 56|CFX
P08048582A0821|83 97|ml O2.min-1 times
P08048582A0821|43 48|extent
P08048916A0000|0 3|IGF I
P08048916A0000|7 22|insulin receptors
P08048916A0000|36 43|proteins
P08048916A0000|79 86|pathways
P08049401A0428|44 65|glucocorticoid activity
P08049401A0428|100 106|changes
P08049401A0428|34 41|increase
P08049401A0428|109 123|thyroid hormones
P08049401A0428|75 80|cortex
P08049401A0428|0 15|Immunodepression
P08049444A0351|100 106|protein
P08049444A0351|139 143|SATB1
P08049444A0351|210 212|DNA
P08049444A0351|65 71|protein
P08049444A0351|201 207|regions
P08049444A0351|7 14|cleavage
P08049444A0351|214 222|MARs/SARs
P08049444A0351|123 136|binding protein
P08049444A0351|18 40|peptide sequence analysis
P08049521T0000|76 81|action
P08049521T0000|8 29|protein phosphorylation
P08049521T0000|107 111|yeast
P08049521T0000|32 39|tyrosine
P08049521T0000|84 92|pp60v-src
P08049885T0000|5 16|pancreatitis
P08049885T0000|19 36|multisystem disease
P08051019A0365|8 19|biosynthesis
P08051019A0365|52 60|mechanism
P08051059A1000|99 111|RhlR regulator
P08051059A1000|81 92|binding sites
P08051059A1000|24 35|rhlA promoter
P08051059A1000|55 61|repeats
P08051059A1000|3 10|sequence
P08051074A0000|142 150|digestion
P08051074A0000|91 94|type
P08051074A0000|36 41|region
P08051074A0000|136 140|DNase
P08051074A0000|23 34|footprinting
P08051074A0000|103 110|promoter
P08051074A0000|69 89|immunodeficiency virus
P08051074A0000|97 101|HIV-1
P08051102A0532|0 6|Heparin
P08051102A0532|89 93|forms
P08051102A0532|37 60|chain phosphatase activity
P08051102A0532|12 17|effect
P08051102A0532|20 31|rAC-st myosin
P08051102A0532|70 70|B
P08051151A0347|133 141|cell lines
P08051151A0347|96 108|chain reaction
P08051151A0347|11 19|abundance
P08051151A0347|46 49|mRNA
P08051151A0347|123 129|tissues
P08053697A0000|0 9|BACKGROUND
P08053697A0000|127 134|diameter
P08053697A0000|64 80|hyperpigmentation
P08053697A0000|92 95|dots
P08053697A0000|13 18|DESIGN
P08053697A0000|58 61|foci
P08053697A0000|184 193|correlates
P08053697A0000|41 44|nevi
P08053697A0000|123 124|mm
P08053697A0000|203 206|dots
P08054281A0731|59 67|potential
P08054281A0731|157 167|201Tl uptake
P08054281A0731|91 100|prediction
P08054281A0731|38 46|indicator
P08054281A0731|103 111|prognosis
P08054281A0731|19 28|201Tl SPECT
P08054281A0731|138 149|relationship
P08054281A0731|124 130|insight
P08054281A0731|171 180|malignancy
P08054281A0731|3 16|retention index
P08055939A0159|46 52|regions
P08055939A0159|62 72|H1 molecules
P08055939A0159|121 136|hexapeptide motif
P08055939A0159|170 180|H1 molecules
P08055939A0159|138 145|variants
P08055939A0159|97 102|domain
P08055939A0159|18 23|domain
P08055939A0707|172 175|exon
P08055939A0707|137 140|exon
P08055939A0707|121 126|region
P08055939A0707|63 68|tomato
P08055939A0707|36 41|intron
P08055939A0707|25 30|length
P08055939A0707|96 101|intron
P08055939A0707|3 10|location
P08055939A0707|165 170|domain
P08055939A0707|116 119|nose
P08055939A0707|72 87|Arabidopsis genes
P08055941A1264|14 18|chain
P08055941A1264|65 70|capsid
P08055941A1264|98 101|beta
P08055941A1264|92 96|alpha
P08055941A1264|48 62|artifactual beta
P08055941A1264|104 109|enzyme
P08055941A1264|3 10|topology
P08055941A1264|31 42|beta subunits
P08056474A0438|27 27|%
P08056474A0438|36 36|%
P08056474A0438|84 84|%
P08056474A0438|59 59|%
P08056474A0438|48 48|%
P08056474A0438|7 10|NMSC
P08056474A0438|76 76|%
P08057356A0531|72 88|response regulator
P08057356A0531|34 45|substitution
P08057356A0531|90 95|region
P08057356A0531|19 22|form
P08057356A0531|47 50|V88A
P08057356A1824|0 10|Comparisons
P08057356A1824|112 118|spacing
P08057356A1824|62 74|NarL heptamers
P08057356A1824|20 39|operon control regions
P08057356A1824|97 108|orientations
P08057421A1583|148 159|CD23 promoter
P08057421A1583|196 201|Cp site
P08057421A1583|166 186|EBV LMP-1 promoter sites
P08057421A1583|119 122|CBF1
P08057421A1583|16 32|competition assays
P08057421A1583|6 12|binding
P08057421A1583|44 64|oligonucleotide probes
P08057421A1583|90 105|CBF1 binding sites
P08057762A0878|129 129|%
P08057762A0878|113 114|T1
P08057762A0878|61 61|%
P08057762A0878|24 38|reproducibility
P08057762A0878|53 53|%
P08057762A0878|47 48|T1
P08057762A0878|55 56|T2
P08057762A0878|122 123|T2
P08057762A0878|120 120|%
P08057762A0878|72 86|reproducibility
P08057833A0573|118 129|reading frame
P08057833A0573|90 100|start codons
P08057833A0573|36 41|result
P08057833A0573|6 17|ParA proteins
P08057833A0573|55 75|translation initiation
P08058326A0463|57 71|tal-1 expression
P08058326A0463|140 151|counterparts
P08058326A0463|89 97|sequences
P08058326A0463|12 19|insights
P08058326A0463|36 45|mechanisms
P08058326A0463|109 112|gene
P08058948A0810|45 48|role
P08058948A0810|91 93|CRF
P08058948A0810|79 86|patients
P08058948A0810|22 32|angiography
P08058948A0810|54 62|detection
P08058948A0810|70 76|nodules
P08058948A0810|0 9|CONCLUSION
P08062824A0626|28 34|FKBP-33
P08062824A0626|75 91|isomerase activity
P08062824A0626|13 18|domain
P08062824A0626|120 129|activities
P08062824A0626|134 140|FKBP-12
P08062833A0000|57 71|mouse desmin gene
P08062833A0000|10 11|nt
P08062833A0000|99 109|binding site
P08062833A0000|87 90|E box
P08062833A0000|194 203|expression
P08062833A0000|174 178|level
P08062833A0000|139 148|regulators
P08062833A0000|92 93|E1
P08062833A0000|25 51|transcription initiation site
P08063108A0109|70 76|protein
P08063108A0109|25 26|nt
P08063108A0109|67 68|aa
P08063108A0109|3 10|acfD gene
P08063766A0595|69 72|rate
P08063766A0595|10 13|beta
P08063766A0595|137 141|rates
P08063766A0595|61 65|times
P08063766A0595|16 18|PKC
P08063766A0595|75 82|alpha PKC
P08063766A0595|122 127|lamin B
P08063766A0595|40 53|envelope lamin B
P08063766A0595|95 101|kinases
P08063775T0000|46 50|PTHrP
P08063775T0000|52 65|gene expression
P08063775T0000|38 44|protein
P08063775T0000|0 9|Regulation
P08063791A1370|120 130|Ras proteins
P08063791A1370|5 11|results
P08063791A1370|35 37|set
P08063791A1370|91 103|modifications
P08063791A1370|57 70|sequence motifs
P08063791A1370|133 137|yeast
P08063836A0904|14 18|c-Abl
P08063836A0904|62 72|requirement
P08063836A0904|76 85|DNA binding
P08063836A0904|28 45|c-myc transcription
P08063836A0904|88 92|c-Abl
P08064351A1020|0 11|Long-latency
P08064351A1020|35 40|shocks
P08064351A1020|76 77|ms
P08064351A1020|64 70|latency
P08064351A1020|51 56|jitter
P08064351A1020|19 23|units
P08065310A1144|138 146|inhibitor
P08065310A1144|47 64|heterodimerization
P08065310A1144|168 185|receptor gene family
P08065310A1144|157 162|member
P08065310A1144|23 28|heptad
P08065310A1144|109 119|interaction
P08065324A0458|41 45|maize
P08065324A0458|73 75|USE
P08065324A0458|17 26|expression
P08065324A0458|64 68|plant
P08065324A0458|124 136|transcription
P08065324A0458|29 38|snRNA genes
P08065324A0458|79 90|TATA elements
P08065327A0000|82 101|germ line micronucleus
P08065327A0000|40 50|development
P08065327A0000|63 74|macronucleus
P08065327A0000|112 121|protozoans
P08065327A0000|9 24|DNA rearrangement
P08065331A0279|146 146|t
P08065331A0279|162 170|leukemias
P08065331A0279|56 67|DNA sequences
P08065331A0279|112 126|E2A-HLF proteins
P08065331A0279|16 37|site selection procedure
P08065331A0279|98 100|HLF
P08065338T0000|3 7|Oct-2
P08065338T0000|81 90|duplicates
P08065338T0000|113 125|transcription
P08065338T0000|37 53|activation domains
P08065365A0000|0 6|Binding
P08065365A0000|52 59|pre-mRNA
P08065365A0000|9 10|U2
P08065365A0000|41 45|snRNP
P08065365A0000|23 39|ribonucleoprotein
P08065365A0000|81 84|step
P08065365A0000|98 105|assembly
P08065366A0918|59 79|chromosome segregation
P08065366A0918|53 56|role
P08065366A0918|17 20|data
P08065366A0918|32 36|Dbf8p
P08065368A0839|0 4|Ariga
P08065368A0839|6 12|Biochem
P08065901A0997|85 97|transcription
P08065901A0997|156 167|KRAB-A domain
P08065901A0997|209 217|apparatus
P08065901A0997|25 34|KRAB domain
P08065901A0997|171 180|components
P08065901A0997|134 145|interactions
P08065901A0997|69 76|ZFP genes
P08065901A0997|3 9|results
P08065901A0997|57 62|region
P08066094T0000|0 9|Marine oils
P08066094T0000|27 36|reactivity
P08067013T0001|105 112|diseases
P08067013T0001|13 24|significance
P08067013T0001|27 57|creatine phosphokinase antibodies
P08067013T0001|70 75|muscle
P08067123A0248|232 246|anti-HCV-C100-3
P08067123A0248|44 46|use
P08067123A0248|222 227|donors
P08067123A0248|23 28|assays
P08067123A0248|252 256|blood
P08067123A0248|150 155|Moscow
P08067123A0248|49 70|assay systems ORTHO ELISA
P08067123A0248|74 85|ABBOTT HCV EIA
P08067123A0248|110 124|anti-HCV-C100-3
P08067123A0248|137 147|blood donors
P08067123A0248|14 20|results
P08067123A0248|212 212|%
P08067123A0248|95 107|detection rate
P08067123A0248|87 89|USA
P08067123A0248|264 264|p
P08067123A0248|163 163|%
P08067123A0248|261 261|%
P08067123A0248|195 207|HBsAg carriers
P08067546A0000|220 242|vasoconstrictor activity
P08067546A0000|38 55|vasomotor responses
P08067546A0000|171 172|NO
P08067546A0000|107 109|STP
P08067546A0000|68 70|ETO
P08067546A0000|165 169|oxide
P08067546A0000|90 105|sodium thiopental
P08067546A0000|254 256|dog
P08067546A0000|184 198|vasodilator tone
P08067546A0000|140 146|effects
P08067546A0000|13 22|hypothesis
P08067546A0000|73 80|propofol
P08067607A0568|99 102|dogs
P08067607A0568|37 57|serum CRP concentration
P08067607A0568|24 33|CBC results
P08067607A0568|11 21|alterations
P08067607A0568|108 119|control group
P08067607A0568|71 84|baseline values
P08069298A0492|44 46|RNA
P08069298A0492|90 109|leptomeningeal tissue
P08069298A0492|152 154|LMC
P08069298A0492|126 129|line
P08069298A0492|66 72|sources
P08069298A0492|16 29|splice variants
P08069298A0492|132 150|leptomeningeal cells
P08069427T0000|0 25|Roux-en-Y gastroenterostomy
P08069427T0000|55 65|gallbladder
P08069427T0000|42 49|emptying
P08069481A0736|43 53|calf muscles
P08069481A0736|12 22|experiments
P08069481A0736|25 32|phantoms
P08070004A0782|17 25|variation
P08070004A0782|127 134|patients
P08070004A0782|76 90|plasma half-life
P08070004A0782|122 124|min
P08070004A0782|32 46|PCZ plasma levels
P08070004A0782|92 100|t1/2 alpha
P08070004A0782|147 154|mg/m2 PCZ
P08070004A0782|55 59|ng/ml
P08070393A0631|28 35|ng/ml EGF
P08070393A0631|57 58|h.
P08070393A0631|10 15|effect
P08070393A0631|42 48|time lag
P08070654A0000|57 59|SPB
P08070654A0000|22 30|component
P08070654A0000|90 103|SPB duplication
P08070654A0000|48 55|pole body
P08070654A0000|78 86|karyogamy
P08070654A0000|36 40|yeast
P08070654A0000|0 3|KAR1
P08070654A0574|58 64|protein
P08070654A0574|111 117|protein
P08070654A0574|18 31|SPB duplication
P08070654A0574|153 156|body
P08070654A0574|91 108|caltractin/centrin
P08070654A0574|135 147|Chlamydomonas
P08070654A0574|0 4|CDC31
P08071356A0232|73 91|transcription bubble
P08071356A0232|6 25|transcript elongation
P08071356A0232|109 130|transcription complexes
P08071356A0232|40 51|DNA footprint
P08071356A0232|148 164|template positions
P08071356A0232|30 34|sizes
P08071982T0000|32 39|syndrome
P08072352A0567|29 29|%
P08072352A0567|46 46|%
P08072352A0567|51 68|aspirin sensitivity
P08072352A0567|100 100|%
P08072352A0567|75 75|%
P08072352A0567|80 91|eosinophilia
P08072352A0567|34 39|asthma
P08072352A0567|6 13|patients
P08072352A0567|119 127|IgE levels
P08072352A0567|17 22|polyps
P08072547A0690|61 65|c-Jun
P08072547A0690|84 92|positions
P08072547A0690|68 81|serine residues
P08072547A0690|130 137|activity
P08072547A0690|30 43|protein kinases
P08072547A0690|0 2|Ras
P08072547A1009|85 88|part
P08072547A1009|125 129|c-Fos
P08072547A1009|57 61|c-Jun
P08072547A1009|6 13|sequence
P08072547A1009|75 79|c-Fos
P08072547A1009|33 54|JNK phosphorylation site
P08072547A1009|94 109|activation domain
P08072547T0000|0 4|c-Fos
P08072547T0000|55 67|protein kinase
P08072547T0000|80 82|JNK
P08072547T0000|20 27|activity
P08072547T0000|86 88|ERK
P08073505T0000|58 64|example
P08073505T0000|4 13|generation
P08073505T0000|44 53|biologists
P08073505T0000|70 84|ExPASy WWW server
P08073505T0000|16 40|information retrieval tools
P08075070A1632|69 81|operator sites
P08075070A1632|155 160|motifs
P08075070A1632|52 56|helix
P08075070A1632|60 66|contact
P08075070A1632|179 186|proteins
P08075070A1632|86 101|repressor domains
P08075070A1632|9 16|features
P08075070A1632|151 153|HTH
P08075070A1632|109 126|sequence homologies
P08075070A1632|23 27|model
P08075070A1632|43 45|DNA
P08075421A0621a|39 47|C terminus
P08075421A0621a|10 12|ORF
P08075421A0621a|50 54|HrpJ2
P08075421A0621b|39 47|C terminus
P08075421A0621b|10 12|ORF
P08075421A0621b|50 54|HrpJ2
P08076631A0000|220 225|SaOs-2
P08076631A0000|12 34|transcription factor AP-1
P08076631A0000|121 124|VDRE
P08076631A0000|136 150|osteocalcin gene
P08076631A0000|116 119|AP-1
P08076631A0000|232 252|osteosarcoma cell lines
P08076631A0000|38 53|vitamin D receptor
P08076631A0000|73 76|AP-1
P08076631A0000|3 9|binding
P08076631A0000|55 57|VDR
P08076631A0000|191 195|MG-63
P08076631A0000|101 114|promoter region
P08076937A0851|87 100|mismatch primer
P08076937A0851|82 84|DNA
P08076937A0851|5 13|detection
P08076937A0851|20 27|mutation
P08076937A0851|137 156|Tru9I restriction site
P08076937A0851|40 59|restriction digestion
P08076937A0851|116 128|point mutation
P08077236A0243|70 78|COS7 cells
P08077236A0243|55 60|levels
P08077236A0243|63 66|COS1
P08077236A0243|17 24|Epo cDNAs
P08077236A0243|0 7|Wild type
P08078167A0000|0 8|OBJECTIVE
P08078167A0000|22 25|risk
P08078167A0000|53 61|travelers
P08078167A0000|28 37|hepatitis A
P08078167A0000|86 93|measures
P08078416A0581|102 115|concentrations
P08078416A0581|121 133|disinfectants
P08078416A0581|23 35|disinfectants
P08078416A0581|43 54|biofilm cells
P08078416A0581|15 20|effect
P08078473A1107|0 9|Expression
P08078473A1107|12 20|ME31B cDNA
P08078473A1107|23 24|S.
P08078473A1107|43 55|ste13 mutation
P08079268T0028|0 2|Use
P08079268T0028|5 25|Medi-Jector EZ dermojet
P08079268T0028|46 52|surgery
P08079268T0028|29 38|anesthesia
P08082215A0230|55 62|patients
P08082215A0230|35 49|cytomegalovirus
P08082215A0230|9 16|response
P08082215A0230|65 68|RTID
P08082215A0230|19 32|past-infection
P08082286A0748|0 16|Acupuncture effect
P08082286A0748|23 31|receptors
P08082286A0748|50 54|point
P08082286A0748|90 95|effect
P08082286A0748|72 75|area
P08082292T0000|90 101|tuberculosis
P08082292T0000|7 16|NK activity
P08082292T0000|37 43|disease
P08082292T0000|50 57|patients
P08082292T0000|46 48|HIV
P08082360A0411|0 13|Smoking history
P08082360A0411|39 42|SaO2
P08082360A0411|22 37|oxygen saturation
P08082440A0339a|1 3|LH P
P08082440A0339a|10 16|LH/FSH P
P08083011A0584|111 124|R-L brain weight
P08083011A0584|103 106|cats
P08083011A0584|23 29|weights
P08083011A0584|11 11|R
P08083011A0584|161 168|estrogen
P08083011A0584|95 96|RH
P08083011A0584|155 159|males
P08083011A0584|141 152|testosterone
P08083011A0584|72 85|R-L brain weight
P08083011A0584|171 177|females
P08083220A0988|17 32|complex formation
P08083220A0988|190 196|complex
P08083220A0988|161 173|serum response
P08083220A0988|99 107|formation
P08083220A0988|37 44|contrast
P08083220A0988|148 155|assembly
P08083220A0988|120 126|complex
P08083220A0988|62 69|promoter
P08083220A0988|75 92|c-fos protooncogene
P08083220A0988|4 7|mode
P08083963A0795|30 35|a1/EBP
P08083963A0795|53 66|extract protein
P08083963A0795|40 45|B-cell
P08083963A0795|26 28|VBP
P08083963A0795|121 149|methylation interference assays
P08083963A0795|105 116|footprinting
P08083963A0795|90 97|gel shift
P08083963A0795|99 103|DNase
P08083963A0795|14 23|activities
P08083998A1723a|42 65|coronavirus transcription
P08083998A1723a|5 11|results
P08083998A1723a|23 39|leader-mRNA fusion
P08083998A1723a|86 103|RNA-RNA interaction
P08083998A1723a|124 132|sequences
P08083998A1723b|42 65|coronavirus transcription
P08083998A1723b|5 11|results
P08083998A1723b|23 39|leader-mRNA fusion
P08083998A1723b|86 103|RNA-RNA interaction
P08083998A1723b|124 132|sequences
P08083999A0501|159 171|transcription
P08083999A0501|43 48|HPV-16
P08083999A0501|104 113|affinities
P08083999A0501|137 137|M
P08083999A0501|52 66|BPV-1 E2 proteins
P08083999A0501|115 116|Kd
P08083999A0501|73 87|consensus E2 site
P08083999A0501|0 7|Vaccinia
P08084339A0907|185 204|amino acid polypeptide
P08084339A0907|105 115|nucleotides
P08084339A0907|49 60|reading frame
P08084339A0907|85 90|J alpha
P08084339A0907|95 100|region
P08084339A0907|24 33|transcript
P08084339A0907|131 139|beginning
P08084339A0907|145 159|TCR C alpha region
P08084592A0145|2 5|HeLa
P08084592A0145|7 27|fibroblast cell hybrids
P08084592A0145|55 68|tumorigenicity
P08084592A0145|31 40|expression
P08085228A0000|101 109|infection
P08085228A0000|52 58|clients
P08085228A0000|169 185|testing facilities
P08085228A0000|141 143|HIV
P08085228A0000|196 199|Tex.
P08085228A0000|156 165|counseling
P08085228A0000|11 25|characteristics
P08085228A0000|87 98|distribution
P08085228A0000|151 153|use
P08085228A0000|188 194|Houston
P08085228A0000|119 139|immunodeficiency virus
P08085228A0000|29 42|risk factor data
P08085609A0384|117 135|crown fissure termini
P08085609A0384|19 24|KNM-LU
P08085609A0384|74 82|distances
P08085609A0384|51 63|chimpanzee M1s
P08085609A0384|99 108|dimensions
P08085609A0384|0 6|Results
P08085782A0164|30 34|tumor
P08085782A0164|12 16|cases
P08085782A0164|37 38|cm
P08086450A0467|0 9|Comparison
P08086450A0467|51 56|region
P08086450A0467|23 26|gene
P08086450A0467|178 180|Sp1
P08086450A0467|104 105|GC
P08086450A0467|87 102|guanine-cytosine
P08086450A0467|62 70|hATP1 gene
P08086450A0467|134 146|binding motifs
P08086450A0467|182 185|AP-2
P08086450A0467|111 116|region
P08086450A0467|164 170|factors
P08086450A0467|190 192|GCF
P08086453T0000|0 8|Structure
P08086453T0000|40 49|assignment
P08086453T0000|10 25|promoter analysis
P08086453T0000|60 67|APEX gene
P08087887A1067|3 19|polyubiquitin gene
P08087887A1067|123 136|post-inversion
P08087887A1067|66 70|peaks
P08087887A1067|111 118|cleavage
P08087887A1067|82 91|mRNA levels
P08087887A1067|47 61|Volvox life cycle
P08088022A1417|144 151|ischemia
P08088022A1417|56 67|heart disease
P08088022A1417|106 110|heart
P08088022A1417|31 37|disease
P08088022A1417|88 92|links
P08088513A0419|89 104|DEAH protein Prp16
P08088513A0419|21 28|evidence
P08088513A0419|112 113|U6
P08088513A0419|68 78|interaction
P08088513A0419|117 118|U2
P08088513A0419|131 136|snRNAs
P08088777A0754|122 125|Pbx3
P08088777A0754|144 147|Acra
P08088777A0754|81 86|Col5a1
P08088777A0754|133 134|.2
P08088777A0754|109 112|Fpgs
P08088777A0754|136 137|Hc
P08088777A0754|51 57|crosses
P08088777A0754|94 102|Spna2-Ab l
P08088777A0754|139 141|Gsn
P08088777A0754|72 77|Notch1
P08088777A0754|105 107|Ak1
P08088777A0754|68 70|Dbh
P08088777A0754|116 120|Grp78
P08088777A0754|39 42|data
P08088777A0754|60 65|D2Mit1
P08088777A0754|3 20|consensus gene order
P08088777A0754|88 91|Rxra
P08088818A1053|121 126|strain
P08088818A1053|90 93|host
P08088818A1053|39 47|deletions
P08088818A1053|140 148|RAD52 gene
P08088818A1053|7 11|level
P08088818A1053|58 61|YACs
P08089184A0825|14 27|megabase region
P08089184A0825|2 9|addition
P08089184A0825|42 50|dagA locus
P08089834A0561|15 23|deletions
P08089834A0561|50 57|residues
P08089834A0561|65 80|amino acid residue
P08089834A0561|5 11|mutants
P08089887A0742|9 22|OUTCOME MEASURE
P08089887A0742|56 65|evaluation
P08090571T0001|0 10|Elimination
P08090571T0001|20 29|antibodies
P08090571T0001|42 51|xenografts
P08090746A1288|134 159|tomato fruit-ripening E4 gene
P08090746A1288|65 72|homology
P08090746A1288|6 13|sequence
P08090746A1288|77 93|promoter sequences
P08090746A1288|105 126|ethylene responsiveness
P08090746A1288|15 22|ATTTCAAA
P08090746A1288|42 53|region shares
P08090767A0000|172 191|DNA methylation damage
P08090767A0000|91 99|viability
P08090767A0000|9 16|evidence
P08090767A0000|143 160|base excision repair
P08090767A0000|114 124|replication
P08090767A0000|67 72|enzyme
P08090767A0000|21 38|DNA polymerase delta
P08091655A0000|57 71|EcoRI-B fragment
P08091655A0000|26 37|Disease Virus
P08091655A0000|19 23|Marek
P08091655A0000|39 41|MDV
P08091655A0000|74 79|MDV-GA
P08091655A0000|87 89|DNA
P08091655A0000|43 47|genes
P08091665T0000|0 10|Cowpox virus
P08091665T0000|22 27|copies
P08091665T0000|74 77|type
P08091665T0000|37 40|gene
P08091665T0000|65 68|form
P08091665T0000|80 90|TNF receptor
P08091669A0828|69 71|p35
P08091669A0828|37 47|39k promoter
P08091669A0828|62 64|IE1
P08091669A0828|117 127|ie1 promoter
P08091669A0828|76 87|reading frame
P08091669A0828|105 111|control
P08091669A0828|18 20|P35
P08091669A0828|53 59|absence
P08093450A0688|0 10|Mutagenesis
P08093450A0688|181 184|loss
P08093450A0688|143 153|NRF-1 motifs
P08093450A0688|76 117|chloramphenicol acetyltransferase expression
P08093450A0688|32 43|ALAS promoter
P08093450A0688|17 26|NRF-1 motif
P08093450A0688|126 136|mutagenesis
P08093450A0688|68 73|levels
P08093450A0688|187 196|expression
P08093616A1214|0 4|DNase
P08093616A1214|72 93|DNA polymerase alpha gene
P08093616A1214|6 25|footprinting analysis
P08093616A1214|39 42|DREF
P08093616A1214|116 124|sequences
P08093616A1214|58 66|DRE region
P08093616T0000|75 87|binding factor
P08093616T0000|5 22|8-base pair sequence
P08093616T0000|56 62|element
P08093616T0000|131 148|DNA polymerase alpha
P08093616T0000|123 127|genes
P08093616T0000|34 36|DNA
P08093616T0000|176 182|antigen
P08093616T0000|165 168|cell
P08093616T0000|101 110|expression
P08093642A0600|157 167|lambda clone
P08093642A0600|12 43|microsatellite repeat polymorphism
P08093642A0600|67 67|%
P08093642A0600|49 62|heterozygosity
P08093642A0600|175 185|D10S94 locus
P08093642A0600|127 140|heterozygosity
P08093642A0600|228 241|linkage mapping
P08093642A0600|73 80|RET locus
P08093642A0600|2 9|addition
P08093642A0600|265 271|testing
P08093642A0600|145 145|%
P08093642A0600|85 121|restriction fragment length polymorphism
P08094464A0869|96 99|aroF
P08094464A0869|51 58|promoter
P08094464A0869|87 93|portion
P08094464A0869|8 11|tyrA
P08094464A2014|15 30|attenuator region
P08094464A2014|9 12|span
P08094464A2014|105 126|base-residue divergence
P08094464A2014|56 65|structures
P08094464A2014|152 158|regions
P08094464A2014|81 93|configuration
P08094464A2014|68 71|mRNA
P08094464A2014|98 102|spots
P08094498A0614|64 72|prognosis
P08094498A0614|25 30|spouse
P08094498A0614|38 42|truth
P08094498A0614|52 60|diagnosis
P08094927A0311|99 105|virions
P08094927A0311|25 33|mutations
P08094927A0311|60 66|release
P08094927A0311|39 47|6K protein
P08094927A0311|8 14|studies
P08095698T0000|0 9|Metabolism
P08095698T0000|88 95|patients
P08095698T0000|12 18|calcium
P08095698T0000|33 40|patients
P08095698T0000|68 76|nephritis
P08095698T0000|22 30|vitamin D3
P08095698T0000|79 83|study
P08095698T0000|100 120|nephropathia epidemica
P08095872A1672|44 51|inotropy
P08095872A1672|117 130|LONG/CIRC ratio
P08095872A1672|16 20|study
P08095872A1672|56 62|timolol
P08095872A1672|81 91|contraction
P08095872A1672|133 142|transition
P08095872A1672|159 177|contraction efficacy
P08095875T0000|0 6|Effects
P08095875T0000|61 64|rats
P08095875T0000|54 58|He-O2
P08095875T0000|17 27|hypercapnia
P08095875T0000|30 40|hypothermia
P08096066A0623|3 14|RFLP patterns
P08096066A0623|136 149|drug resistance
P08096066A0623|108 111|band
P08096066A0623|20 27|isolates
P08096066A0623|123 133|development
P08096066A0623|42 49|patients
P08096066A0623|82 88|strains
P08096944A0951|58 67|indication
P08096944A0951|109 113|women
P08096944A0951|79 88|assessment
P08096944A0951|22 32|stimulation
P08096944A0951|94 100|ovaries
P08096944A0951|131 141|stimulation
P08097666A1135|0 5|A23187
P08097666A1135|21 33|modifications
P08097666A1135|91 99|frequency
P08097666A1135|52 60|potential
P08097666A1135|65 72|ampullar
P08097666A1135|119 124|spikes
P08097732A0000|0 9|Activation
P08097732A0000|108 113|region
P08097732A0000|64 79|sea urchin embryos
P08097732A0000|153 155|RSR
P08097732A0000|38 47|Spec2a gene
P08097732A0000|137 151|sequence element
P08097732A0000|174 189|Spec1/Spec2 genes
P08097732A0000|120 123|part
P08098228A0625|1 10|transcript
P08098228A0625|19 20|kb
P08098228A0625|38 40|PPO
P08098842A0660|55 76|transcription start site
P08098842A0660|12 17|region
P08098842A0660|119 122|exon
P08098842A0660|190 197|increase
P08098842A0660|90 97|homology
P08098842A0660|101 108|sequence
P08098842A0660|161 167|element
P08098842A0660|31 32|bp
P08098842A0660|234 243|regulation
P08098842A0660|205 218|gene expression
P08098842A0660|125 129|c-fos
P08098842A0660|0 8|Mutations
P08098882T0001|12 26|desensitization
P08098914A0400|141 141|P
P08098914A0400|62 66|slope
P08098914A0400|52 55|left
P08098914A0400|90 92|Ees
P08098914A0400|133 139|mmHg/ml
P08098914A0400|6 13|exercise
P08098914A0400|80 88|elastance
P08098914A0400|18 32|Pes-Ves relation
P08098914A0400|130 131|SD
P08099443A0359|118 132|GCN4 translation
P08099443A0359|135 139|yeast
P08099443A0359|10 12|HRI
P08099443A0359|37 51|yeast eIF-2 alpha
P08099443A0359|16 23|dsRNA-PK
P08099443A0359|96 106|GCN2 protein
P08100057A0577|45 55|populations
P08100057A0577|99 109|dendrocytes
P08100057A0577|71 81|macrophages
P08100765A0361|121 132|compartments
P08100765A0361|76 80|lines
P08100765A0361|25 51|transgene expression patterns
P08100765A0361|61 70|cerebellum
P08100843A0134|0 15|Southern analysis
P08100843A0134|162 163|kb
P08100843A0134|50 58|cell lines
P08100843A0134|25 27|DNA
P08100843A0134|40 46|tissues
P08100843A0134|132 136|mCD22
P08100843A0134|146 153|copy gene
P08100843A0134|70 81|mouse strains
P08100843A0134|87 95|mCD22 cDNA
P08100843A0134|115 123|Cd22 locus
P08101134A0376|59 59|%
P08101134A0376|19 28|plasma ACTH
P08101134A0376|65 77|MPTP treatment
P08101134A0376|53 53|%
P08101134A0376|3 16|concentrations
P08101134A0376|32 39|cortisol
P08101171A0924|84 93|boundaries
P08101171A0924|11 17|results
P08101171A0924|64 69|memory
P08101171A0924|137 146|regulators
P08101171A0924|36 50|Pc group products
P08101171A0924|122 124|gap
P08101171A0924|28 31|idea
P08101839A0000|16 25|regulation
P08101839A0000|87 93|signals
P08101839A0000|48 55|mdr1 gene
P08101839A0000|60 67|response
P08101839A0000|73 84|mdr1 promoter
P08101839A0000|104 120|cell proliferation
P08101839A0000|28 37|expression
P08101843A0151|83 84|bp
P08101843A0151|27 28|TH
P08101843A0151|52 63|consensus CRE
P08101843A0151|99 125|transcription initiation site
P08101843A0151|74 81|base pair
P08101843A0151|45 48|copy
P08101843A0151|3 25|tyrosine hydroxylase gene
P08102364A0000|0 6|Tobacco
P08102364A0000|27 33|tobacco
P08102364A0000|35 53|Nicotiana tabacum var
P08103379A0577|45 54|MADS domain
P08103379A0577|8 14|stretch
P08103379A0577|62 69|proteins
P08103379A0577|19 28|amino acids
P08103379A0577|106 127|amino acid substitutions
P08103935T0000|30 49|SRF accessory proteins
P08103935T0000|12 27|characterization
P08103935T0000|0 8|Isolation
P08104189A1168|69 76|reaction
P08104189A1168|145 150|ATPase
P08104189A1168|93 94|pH
P08104189A1168|24 38|proSRIF cleavage
P08104189A1168|5 8|data
P08104189A1168|55 57|TGN
P08105727A0099|0 9|Fenoldopam
P08105727A0099|51 67|animal experiments
P08105727A0099|12 34|dopamine receptor agonist
P08105727A0099|83 91|perfusion
P08105994T0000|32 61|serum gamma-glutamyl transferase
P08105994T0000|22 29|increase
P08105994T0000|8 14|aspects
P08105994T0000|72 81|infarction
P08106087A0139|71 78|sequence
P08106087A0139|28 38|kDa zein gene
P08106087A0139|108 115|sequence
P08106087A0139|135 154|polyadenylation sites
P08106087A0139|58 66|sequences
P08106087A0139|15 20|region
P08106245A0325|220 224|Bq m-3
P08106245A0325|174 178|Bq m-3
P08106245A0325|196 201|period
P08106245A0325|265 276|measurements
P08106245A0325|147 158|measurements
P08106245A0325|85 90|winter
P08106245A0325|125 129|Bq m-3
P08106245A0325|259 262|year
P08106245A0325|69 73|Bq m-3
P08106245A0325|44 49|period
P08106245A0325|9 26|radon concentration
P08106245A0325|184 189|summer
P08106245A0325|230 235|winter
P08106245A0325|141 144|year
P08106245A0325|32 37|summer
P08106313A1492|139 148|expression
P08106313A1492|22 26|hrpRS
P08106313A1492|99 102|hrpL
P08106313A1492|87 96|expression
P08106313A1492|37 40|part
P08106313A1492|68 71|HrpR
P08106313A1492|75 78|HrpS
P08106313A1492|120 130|sigma factor
P08106313A1492|54 60|cascade
P08106313A1492|106 109|HrpL
P08106313A1492|166 170|genes
P08106313A1492|30 33|hrpL
P08106313A1492|3 9|results
P08106325A0000|0 3|DtxR
P08106325A0000|140 158|diphtheria toxin gene
P08106325A0000|50 56|protein
P08106325A0000|71 81|tox operator
P08106325A0000|100 117|nucleotide sequence
P08106369A0000|178 179|V2
P08106369A0000|171 173|V1b
P08106369A0000|108 124|membrane receptors
P08106369A0000|49 59|nonapeptide
P08106369A0000|12 14|AVP
P08106369A0000|158 165|subtypes
P08106369A0000|84 84|G
P08106369A0000|167 169|V1a
P08106369A0000|32 38|hormone
P08106369A0000|203 212|messengers
P08106369A0000|0 10|Vasopressin
P08106398A1003|66 80|nisin maturation
P08106398A1003|60 63|step
P08106398A1003|25 32|cleavage
P08106398A1003|38 50|leader peptide
P08106398A1003|124 130|peptide
P08106398A1003|5 11|results
P08106512A0522|117 132|interferon-alpha
P08106512A0522|74 87|promoter region
P08106512A0522|166 171|factor
P08106512A0522|7 20|promoter region
P08106512A0522|137 141|gamma
P08106512A0522|47 58|reporter gene
P08106512A0522|105 115|interferons
P08106512A0522|146 155|interferon
P08107167A0222|105 107|IFA
P08107167A0222|38 43|anti-B
P08107167A0222|139 139|%
P08107167A0222|178 184|IFA-ABS
P08107167A0222|26 34|turicatae
P08107167A0222|145 156|serum samples
P08107167A0222|200 200|%
P08107167A0222|99 103|assay
P08107167A0222|0 5|Anti-B
P08107167A0222|45 61|parkeri antibodies
P08107208A0673|88 90|EBV
P08107208A0673|109 110|B.
P08107208A0673|40 47|strategy
P08107208A0673|104 107|DNAs
P08107208A0673|57 68|recombinants
P08107208A0673|3 10|approach
P08108099T0000|0 9|Evaluation
P08108099T0000|68 76|disorders
P08108099T0000|12 23|desmopressin
P08108099T0000|46 53|patients
P08108099T0000|33 43|extractions
P08108343A0000|175 179|signs
P08108343A0000|95 102|patients
P08108343A0000|251 270|gonadotropin reserves
P08108343A0000|11 18|analysis
P08108343A0000|189 201|insufficiency
P08108343A0000|155 162|patients
P08108343A0000|212 220|diagnosis
P08108343A0000|223 227|order
P08108343A0000|84 91|subjects
P08108343A0000|37 44|niftolid
P08108343A0000|136 147|hypogonadism
P08108343A0000|57 60|GnRH
P08108343A0000|119 122|ones
P08108413A0964|116 120|brain
P08108413A0964|50 58|cell lines
P08108413A0964|90 103|PANG expression
P08108413A0964|68 74|tissues
P08108413A0964|148 158|transcripts
P08111035A0098|148 160|tobacco plants
P08111035A0098|126 135|expression
P08111035A0098|61 78|B. napus oleosin gene
P08111035A0098|40 57|bp promoter fragment
P08111035A0098|207 212|fusion
P08111035A0098|122 124|GUS
P08111035A0098|103 120|beta-glucuronidase
P08111035A0098|23 32|properties
P08111035A0098|93 100|analysis
P08111035A0098|173 191|oleosin promoter-GUS
P08111974A1034|130 140|involvement
P08111974A1034|62 72|tubulin mRNA
P08111974A1034|36 37|CX
P08111974A1034|20 28|mechanism
P08111974A1034|152 163|trans-factor
P08111974A1034|49 59|degradation
P08111974A1034|105 115|translation
P08112341A1128|0 1|L.
P08112341A1128|19 20|G.
P08112341A1128|9 10|J.
P08112341A1128|3 7|Greer
P08112341A1128|12 17|Carter
P08112526A0443|104 110|control
P08112526A0443|26 45|calcium concentration
P08112526A0443|54 74|detrusor contractility
P08112526A0443|124 131|bladders
P08112526A0443|92 97|manner
P08112601T0000|73 81|synthesis
P08112601T0000|10 21|organization
P08112601T0000|27 30|gene
P08112601T0000|98 104|protein
P08112601T0000|47 55|lipocalin
P08112611A0404|26 37|reading frame
P08112611A0404|59 68|amino acids
P08112611A0404|47 53|protein
P08112611A0404|3 10|sequence
P08112870A0484|0 14|Western blotting
P08112870A0484|141 143|kDa
P08112870A0484|96 103|proteins
P08112870A0484|37 45|antiserum
P08112870A0484|126 131|masses
P08112870A0484|56 58|SOD
P08112870A0484|16 29|immunoblotting
P08113736A0309|188 190|ORF
P08113736A0309|100 105|mosaic
P08113736A0309|107 111|SCNMV
P08113736A0309|65 70|mosaic
P08113736A0309|51 56|clover
P08113736A0309|113 126|dianthoviruses
P08113736A0309|86 91|clover
P08113736A0309|147 155|CRSV RNA-1
P08113736A0309|134 142|exception
P08113736A0309|21 29|CRSV RNA-1
P08113736A0309|3 18|gene organization
P08113736A0309|72 76|RCNMV
P08114702A0000|0 6|Members
P08114702A0000|159 163|genes
P08114702A0000|65 84|transcription factors
P08114702A0000|57 62|family
P08114702A0000|52 55|MEF2
P08114702A0000|107 114|sequence
P08114702A0000|44 49|factor
P08114702A0000|120 133|control regions
P08114710A0137|72 78|binding
P08114710A0137|39 56|HIV-1 transcription
P08114710A0137|25 29|LBP-1
P08114710A0137|81 85|TFIID
P08114710A0137|91 97|TATA box
P08114745A0953|158 179|transcription complexes
P08114745A0953|182 184|pol
P08114745A0953|110 114|class
P08114745A0953|75 81|ability
P08114745A0953|40 41|La
P08114745A0953|153 155|use
P08114745A0953|44 56|RNA production
P08114745A0953|5 11|results
P08114745A0953|92 107|termination sites
P08114745A0953|33 36|role
P08114745A0953|118 126|templates
P08115744A0462|86 92|microns
P08115744A0462|3 7|films
P08115744A0462|45 61|laser densitometer
P08115744A0462|26 33|scanning
P08115744A0462|72 79|aperture
P08115744A0846|58 65|analysis
P08115744A0846|13 18|method
P08115744A0846|99 121|quality assurance program
P08115744A0846|50 55|method
P08116245A0174|60 68|specimens
P08116245A0174|12 14|RNA
P08116245A0174|23 31|reactions
P08116245A0174|79 88|infant rats
P08118044A0318|0 9|GATA-1 mRNA
P08118044A0318|53 61|cell lines
P08118044A0318|72 76|level
P08118044A0318|79 89|FDC-P1 cells
P08118044A0318|32 37|levels
P08119149A0000|103 109|effects
P08119149A0000|112 115|bone
P08119149A0000|26 33|TNF alpha
P08119149A0000|68 74|factors
P08119149A0000|0 24|Tumor necrosis factor-alpha
P08119907A0000|87 91|IGF-I
P08119907A0000|21 24|role
P08119907A0000|93 109|signaling pathways
P08119907A0000|50 56|insulin
P08119907A0000|35 47|p21ras protein
P08119907A0000|72 85|growth factor-I
P08119958A0273|41 44|PKCs
P08119958A0273|173 180|subgroup
P08119958A0273|191 194|PKCs
P08119958A0273|149 153|PKC mu
P08119958A0273|162 167|member
P08119958A0273|102 114|signal peptide
P08119958A0273|51 58|presence
P08119958A0273|3 6|lack
P08119958A0273|132 137|domain
P08119958A0273|80 87|sequence
P08119958A0273|25 26|Ca
P08119958A0273|12 19|C2 domain
P08119995A0814|86 95|half-sites
P08119995A0814|115 125|orientation
P08119995A0814|26 33|function
P08119995A0814|165 169|parts
P08119995A0814|57 72|response elements
P08119995A0814|36 54|T3R-RXR heterodimers
P08119995A0814|207 215|half-site
P08119995A0814|135 145|nucleotides
P08119995A0814|186 193|sequence
P08120019A1500|120 129|mechanisms
P08120019A1500|13 22|Hm1 mutants
P08120019A1500|63 72|PI turnover
P08120019A1500|88 100|sequestration
P08120029A0864|19 39|decay reaction mixtures
P08120029A0864|64 81|sense RNA transcript
P08120029A0864|92 104|stabilization
P08120029A0864|107 115|R2 message
P08122364A0954|0 15|Deletion analyses
P08122364A0954|139 147|synthesis
P08122364A0954|37 39|use
P08122364A0954|21 30|pCD41 ORF-A
P08122364A0954|169 175|protein
P08122364A0954|110 122|pCD41 sequence
P08122364A0954|93 100|promoter
P08122364A0954|42 59|promoter constructs
P08122370A0331|55 59|HSV-1
P08122370A0331|111 115|EHV-1
P08122370A0331|36 52|herpes simplex type
P08122370A0331|94 108|herpesvirus type
P08122370A0331|80 82|PRV
P08122370A0331|62 78|pseudorabies virus
P08122370A0331|32 33|US
P08122370A0331|15 26|counterparts
P08123787A0554|192 199|analysis
P08123787A0554|11 27|amino acid sequence
P08123787A0554|137 143|enzymes
P08123787A0554|94 117|metal cofactor requirement
P08123787A0554|79 88|difference
P08123787A0554|164 177|overexpression
P08123787A0554|47 57|HemB protein
P08124785A0445|0 6|METHODS
P08124785A0445|217 217|P
P08124785A0445|121 126|artery
P08124785A0445|45 48|dogs
P08124785A0445|22 31|open-chest
P08124785A0445|10 16|RESULTS
P08124785A0445|101 108|decrease
P08124785A0445|61 84|circumflex artery stenosis
P08124785A0445|193 215|mean transit time Tmicro-1
P08124785A0445|146 149|flow
P08124785A0445|159 169|flow reserve
P08124912A0456|71 73|LDH
P08124912A0456|75 93|beta 2-microglobulin
P08124912A0456|48 51|IL-8
P08124912A0456|9 19|correlation
P08124912A0456|38 45|SF levels
P08124912A0456|63 69|lactate
P08124912A0456|97 103|glucose
P08124956T0000|88 91|pigs
P08124956T0000|43 54|pancreatitis
P08124956T0000|75 85|oxygenation
P08125258A0142|18 22|cells
P08125258A0142|76 82|variety
P08125258A0142|34 43|conditions
P08125258A0142|48 55|CHOP gene
P08125258A0142|142 154|perturbations
P08125258A0142|93 100|stresses
P08125258A0142|119 129|deprivation
P08125319A1085|98 110|data libraries
P08125319A1085|80 88|sequences
P08125319A1085|43 50|proteins
P08125319A1085|68 75|homology
P08125319A1085|3 11|ipiO genes
P08125337A0940|0 13|Sterol analysis
P08125337A0940|49 60|accumulation
P08125337A0940|91 104|Erg24p activity
P08125337A0940|63 72|ignosterol
P08125337A0940|85 88|loss
P08125337A0940|28 33|mutant
P08125949A1162|30 40|translation
P08125949A1162|246 255|eubacteria
P08125949A1162|113 123|Arabidopsis
P08125949A1162|101 110|rpl12 genes
P08125949A1162|73 81|AUG codons
P08125949A1162|172 177|copies
P08125949A1162|180 202|L12/chloroplast ribosome
P08125949A1162|142 151|mechanisms
P08125949A1162|43 56|spinach L12 mRNA
P08126096A0478|220 224|forms
P08126096A0478|7 17|experiments
P08126096A0478|123 131|sequences
P08126096A0478|112 114|rat
P08126096A0478|75 80|domain
P08126096A0478|146 152|studies
P08126096A0478|44 52|functions
P08126096A0478|92 101|homologies
P08126096A0478|58 62|alpha
P08126096A0478|176 190|domain antiserum
P08126096A1071|97 97|A
P08126096A1071|101 109|B form RNAs
P08126096A1071|3 16|alpha 7A form RNA
P08126096A1071|127 139|reading frames
P08126096A1071|64 68|B form
P08126096A1071|80 91|coding region
P08126096A1071|40 50|nucleotides
P08127950A0000|2 6|order
P08127950A0000|251 258|TSH-IRMA
P08127950A0000|159 174|triiodothyronine
P08127950A0000|216 220|means
P08127950A0000|20 27|function
P08127950A0000|184 208|thyroid stimulating hormone
P08127950A0000|83 92|depression
P08127950A0000|210 212|TSH
P08127950A0000|140 148|thyroxine
P08127950A0000|69 72|axis
P08127950A0000|271 278|controls
P08127950A0000|64 66|HPT
P08127950A0000|117 133|0800h plasma levels
P08127950A0000|328 335|subjects
P08127950A0000|244 249|assays
P08127950A0000|97 103|authors
P08127950A0000|176 178|FT3
P08127950A0000|150 152|FT4
P08128629A1164|0 10|CRS function
P08128629A1164|106 111|LTR RNA
P08128629A1164|62 68|ability
P08128629A1164|75 80|p60CRS
P08128629A1164|84 89|p40CRS
P08128629A1164|26 44|gene expression assay
P08129955A0572|68 68|h
P08129955A0572|39 43|CK-MB
P08129955A0572|29 36|activity
P08129955A0572|6 11|levels
P08129955A0572|80 89|unclamping
P08129955A0572|14 22|troponin T
P08130942A0051|0 14|Regionalization
P08130942A0051|41 46|method
P08130942A0051|17 28|drug delivery
P08130942A0051|58 64|problem
P08131545A0158|84 89|living
P08131545A0158|22 26|group
P08131545A0158|228 243|Coxiella burnetii
P08131545A0158|50 52|men
P08131545A0158|217 226|adenovirus
P08131545A0158|67 69|age
P08131545A0158|158 167|Mycoplasma
P08131545A0158|179 199|Legionella pneumophila
P08131545A0158|150 154|tests
P08131545A0158|31 46|community members
P08131545A0158|78 82|years
P08131545A0158|248 256|Chlamydia
P08131545A0158|201 215|cytomegalovirus
P08131545A0158|57 61|women
P08131746A0140|0 2|MEK
P08131746A0140|54 69|activator kinases
P08131746A0140|92 100|MEK kinase
P08131746A0140|23 43|serine phosphorylation
P08131746A0140|80 84|c-raf
P08131746A0140|86 88|mos
P08132541A0000|7 15|DNA clones
P08132541A0000|49 55|MAL gene
P08132574A0831|0 6|Members
P08132574A0831|61 69|kilobases
P08132574A0831|88 90|HLA
P08132574A0831|9 11|SVA
P08132574A0831|99 118|cytochrome CYP1A1 gene
P08132574A0831|80 82|RP1
P08132574A0831|31 46|complement C2 gene
P08132667T0000|73 81|promoters
P08132667T0000|22 52|proprotein processing enzyme furin
P08132667T0000|0 9|Expression
P08133502T0105|0 26|European Community Huntington
P08133502T0105|29 58|Disease Collaborative Study Group
P08134108A0277|3 7|c-myc
P08134108A0277|113 120|elements
P08134108A0277|50 64|YY1 binding sites
P08134108A0277|19 42|alpha-actin gene promoters
P08134115A1161|130 132|H-P
P08134115A1161|141 149|consensus
P08134115A1161|184 185|TT
P08134115A1161|97 99|myc
P08134115A1161|42 44|GST
P08134115A1161|111 117|ACT-ATT
P08134115A1161|126 128|myc
P08134115A1161|25 37|fusion protein
P08134115A1161|174 182|A/TCTA/TA
P08134115A1161|86 91|TCTTAT
P08134115A1161|101 103|H-P
P08134115A1161|0 5|MSSP-1
P08136383A0359|18 29|MR tomography
P08136383A0359|8 12|hours
P08136383A0359|33 40|patients
P08138180A0593|120 128|functions
P08138180A0593|23 29|alleles
P08138180A0593|90 101|SPT10 protein
P08138180A0593|62 71|growth rate
P08138180A0593|37 47|suppressors
P08138180A0593|7 11|spt10
P08138364T0000|0 8|Varieties
P08138364T0000|18 27|experience
P08139001A1235|52 69|NS1 protein molecule
P08139001A1235|25 29|amino
P08139001A1235|119 133|tubule formation
P08139001A1235|33 46|carboxy termini
P08139001A1235|87 94|residues
P08139001A1235|76 84|cysteines
P08139001A1235|3 9|results
P08139004A0278|68 79|UGC sequences
P08139004A0278|24 31|hairpins
P08139004A0278|64 66|A/U
P08139004A0278|5 7|UTR
P08139017A1465|155 159|cells
P08139017A1465|68 82|primer extension
P08139017A1465|111 124|Ets-1 cDNA clone
P08139017A1465|103 105|end
P08139017A1465|38 47|initiation
P08139017A1465|191 200|Tpl-1 locus
P08139017A1465|163 168|tumors
P08139017A1465|178 185|provirus
P08139017A1465|17 20|site
P08139017A1465|86 87|bp
P08139031A1168|312 327|ORF4 inducibility
P08139031A1168|52 62|mutagenesis
P08139031A1168|250 261|interactions
P08139031A1168|195 210|cysteine residues
P08139031A1168|106 120|ORF4 polypeptide
P08139031A1168|126 130|C-421
P08139031A1168|85 100|cysteine residues
P08139031A1168|154 175|transactivator function
P08139031A1168|134 138|C-426
P08139031A1168|287 302|acid interactions
P08139539A0446|13 26|m1R stimulation
P08139539A0446|105 108|cAMP
P08139539A0446|78 84|calcium
P08139539A0446|59 62|rise
P08139539A0446|101 103|AMP
P08139539A0446|29 46|phospholipase C beta
P08139539A0446|134 143|activation
P08139539A0446|110 118|synthesis
P08139539A0446|146 160|protein kinase A.
P08139539A0446|2 11|Rat 1a cells
P08139542A1229|27 36|repression
P08139542A1229|39 42|CPA1
P08139542A1229|3 11|mutations
P08139542A1229|45 52|arginine
P08139542T0000|70 77|arginine
P08139542T0000|25 37|leader peptide
P08139542T0000|43 50|CPA1 gene
P08139542T0000|93 111|yeast gene transcript
P08139542T0000|10 13|mRNA
P08139542T0000|58 67|repression
P08139542T0000|1 7|segment
P08139543A0427|68 84|suppression screen
P08139543A0427|11 15|genes
P08139543A0427|35 50|SLK1-SLT2 pathway
P08139543A1520|74 77|SLT2
P08139543A1520|41 45|NHP6A
P08139543A1520|49 61|NHP6B function
P08139543A1520|20 27|analysis
P08139562A0404|71 74|GCN4
P08139562A0404|140 152|GCN4 start site
P08139562A0404|25 29|lines
P08139562A0404|47 55|ribosomes
P08139562A0404|32 39|evidence
P08139562A0404|112 119|scanning
P08139562A0404|6 11|report
P08139562A0404|99 103|uORF1
P08139577T0000|121 125|genes
P08139577T0000|76 88|transcription
P08139577T0000|91 94|TATA
P08139577T0000|9 18|components
P08139577T0000|21 48|yeast transcription factor IIIB
P08139914A0554|86 90|cells
P08139914A0554|53 67|differentiation
P08139914A0554|70 75|muscle
P08139914A0554|30 44|dnHLH protein Id1
P08139928T0000|0 3|RNP1
P08139928T0000|9 29|ribonucleoprotein gene
P08139928T0000|35 39|yeast
P08140847X0001|0 4|Crohn
P08140847X0001|130 134|study
P08140847X0001|215 219|order
P08140847X0001|160 164|Crohn
P08140847X0001|25 33|remission
P08140847X0001|104 106|aim
P08140847X0001|167 181|disease patients
P08140847X0001|193 201|remission
P08140847X0001|115 118|year
P08140847X0001|66 71|intake
P08140847X0001|91 98|subjects
P08140847X0001|235 244|body weight
P08140847X0001|296 301|intake
P08140847X0001|7 13|disease
P08140847X0001|203 206|CDAI
P08140847X0001|343 350|controls
P08142875A0877|115 119|cases
P08142875A0877|93 104|intervention
P08142875A0877|17 26|dissection
P08142875A0877|67 70|lens
P08143198T0001|0 10|Restoration
P08143198T0001|54 82|composites dorsal pedal skin flap
P08143198T0001|13 20|opponens
P08143198T0001|93 116|m. extensor hallucis brevis
P08143198T0001|33 47|transplantation
P08143236A1055|73 84|day-1 regimen
P08143236A1055|7 20|ethanol regimen
P08143236A1055|113 118|trials
P08143236A1055|40 50|alternation
P08143236A1055|97 103|percent
P08143236A1055|59 71|g ethanol.kg-1
P08143667A0222|29 36|pressure
P08143667A0222|77 80|MUCP
P08143667A0222|140 144|ratio
P08143667A0222|38 40|IVP
P08143667A0222|11 12|sd
P08143667A0222|3 6|mean
P08143667A0222|159 161|IVP
P08143667A0222|152 155|MUCP
P08143667A0222|60 75|closure pressures
P08143667A0222|115 119|cmH2O
P08144035A0387|71 79|C terminus
P08144035A0387|52 60|N terminus
P08144035A0387|22 28|regions
P08144037A0000|0 10|Thioredoxin
P08144037A0000|50 55|enzyme
P08144037A0000|12 13|TR
P08144037A0000|84 89|plants
P08144037A0000|73 80|bacteria
P08144470A0711|100 111|substitution
P08144470A0711|20 32|asgB480 allele
P08144470A0711|126 139|protein product
P08144470A0711|56 65|transition
P08144470A0711|3 10|mutation
P08144497T0000|43 46|zinc
P08144497T0000|62 70|liposomes
P08144497T0000|24 34|raf-1 kinase
P08144497T0000|88 94|segment
P08144497T0000|104 110|GTP-ras
P08144497T0000|16 21|region
P08144504T0064|18 28|requirement
P08144504T0064|7 14|coupling
P08144504T0064|32 44|ATP hydrolysis
P08144572A0786|0 2|ATP
P08144572A0786|126 128|BiP
P08144572A0786|22 39|polypeptide binding
P08144572A0786|52 56|level
P08144572A0786|101 116|Ssa Hsp70 proteins
P08144572A0786|132 135|DnaK
P08144572A0786|42 48|Ssb1/2p
P08144615A0533|0 8|Digestion
P08144615A0533|21 37|endoprotease Asp-N
P08144615A0533|106 111|domain
P08144615A0533|67 69|TCD
P08144615A0533|11 16|NF-IL6
P08144615A0533|89 92|NFBD
P08144615A0533|47 52|domain
P08144615A0533|133 139|absence
P08144615A0533|145 152|presence
P08144615A0533|155 157|DNA
P08144615A0533|71 87|NF-IL6 bZIP domains
P08144631A0000|88 94|domains
P08144631A0000|105 127|tyrosine phosphorylation
P08144631A0000|40 51|associations
P08144631A0000|11 25|tyrosine kinases
P08144631A0000|98 102|sites
P08144631A0000|84 86|SH2
P08144631A0000|59 66|proteins
P08144631A0000|71 81|Src homology
P08144631A0000|0 8|Signaling
P08144668A0802|114 117|GPHe
P08144668A0802|52 55|exon
P08144668A0802|162 178|membrane anchoring
P08144668A0802|73 77|shift
P08144668A0802|151 158|sequence
P08144668A0802|25 29|exon V
P08144668A0802|60 65|exon VI
P08144668A0802|87 98|reading frame
P08144668A0802|119 120|P2
P08144852A0000|3 11|responses
P08144852A0000|137 141|males
P08144852A0000|18 31|stress hormones
P08144852A0000|208 216|inhibitor
P08144852A0000|106 111|factor
P08144852A0000|64 74|vasopressin
P08144852A0000|42 57|11-deoxycortisol
P08144852A0000|76 78|AVP
P08144852A0000|159 176|cortisol deficiency
P08144852A0000|218 227|metyrapone
P08144852A0000|59 62|ACTH
P08144852A0000|113 115|CRF
P08144852A0000|144 151|response
P08144852A0000|84 96|corticotropin
P08144852A0000|33 40|cortisol
P08145646T0000|0 8|Structure
P08145646T0000|92 100|relevance
P08145646T0000|118 138|nifU2-rpoN superoperon
P08145646T0000|38 48|sigma factor
P08145646T0000|12 21|expression
P08145646T0000|50 53|RpoN
P08145646T0000|57 77|Rhodobacter capsulatus
P08145770A1078|59 74|retinoid pathways
P08145770A1078|7 18|observations
P08145770A1078|53 55|PKC
P08145770A1078|39 42|link
P08145770A1078|121 130|activities
P08145770A1078|133 156|differentiation processes
P08148463A0000|29 32|CSFs
P08148463A0000|21 27|factors
P08148463A0000|96 109|granulocyte CSF
P08148463A0000|133 135|CSF
P08148463A0000|70 80|neutrophils
P08148463A0000|84 92|monocytes
P08148463A0000|58 67|production
P08148463A0000|154 164|interleukin
P08148463A0000|137 149|macrophage CSF
P08148756A0358|3 8|degree
P08148756A0358|82 98|hemoglobin content
P08148756A0358|104 108|fluid
P08148756A0358|11 25|lung destruction
P08148756A0358|50 59|hemorrhage
P08148756A0358|121 125|lungs
P08149484A0151|0 17|Expression plasmids
P08149484A0151|65 72|PKC delta
P08149484A0151|54 61|PKC alpha
P08149484A0151|40 51|kinase domain
P08149484A0151|74 82|PKC alpha K
P08149484A0151|86 94|PKC delta K
P08149484A1551|28 35|PKC alpha
P08149484A1551|157 165|sequences
P08149484A1551|142 145|AP-1
P08149484A1551|37 43|calcium
P08149484A1551|57 64|PKC delta
P08149484A1551|126 130|genes
P08149484A1551|66 72|calcium
P08149484A1551|5 11|results
P08149484A1551|98 110|transcription
P08150970A0434|38 42|pg/ml
P08150970A0434|90 95|TSST-1
P08150970A0434|46 52|samples
P08150970A0434|19 24|TSST-1
P08150970A0434|5 15|cutoff level
P08150970A0434|67 74|patients
P08151787A0355|0 8|Insertion
P08151787A0355|109 113|IE110
P08151787A0355|82 86|IE175
P08151787A0355|209 214|motifs
P08151787A0355|260 271|localization
P08151787A0355|90 104|500-VRPRKRR-506
P08151787A0355|136 140|forms
P08151787A0355|48 77|amino acid motifs 726-GRKRKSP-732
P08151787A0355|149 156|proteins
P08151787A0355|16 31|oligonucleotides
P08151787A0355|179 187|phenotype
P08151787T0000|0 6|Mapping
P08151787T0000|22 40|localization domains
P08151787T0000|55 80|colocalization interactions
P08151787T0000|135 152|herpes simplex virus
P08151787T0000|99 103|IE175
P08151787T0000|111 132|transactivator proteins
P08151787T0000|44 51|evidence
P08151787T0000|91 95|IE110
P08151790A0354|86 88|LTR
P08151790A0354|75 81|context
P08151790A0354|160 170|infectivity
P08151790A0354|138 143|effect
P08151790A0354|112 119|deletion
P08151790A0354|100 110|Sp1 mutation
P08151790A0354|45 58|HIV replication
P08151790A0354|122 125|site
P08151790A0354|35 42|kinetics
P08151790A0354|182 184|HIV
P08151790A0354|3 20|revertant TATA boxes
P08151980T0001|10 18|emphysema
P08152800A0357|183 185|ERM
P08152800A0357|108 111|PEA3
P08152800A0357|54 59|region
P08152800A0357|147 152|member
P08152800A0357|164 180|Molecule PEA3-like
P08152800A0357|8 16|ETS domain
P08152800A0357|90 90|%
P08152800A0357|84 84|%
P08152800A0357|39 45|carboxy
P08152800A0357|115 118|ER81
P08152800A0357|72 78|protein
P08152800A0357|154 156|Ets
P08152800A0709|159 169|Ets proteins
P08152800A0709|81 95|oligonucleotide
P08152800A0709|109 143|consensus nucleotide core sequence GGAA
P08152800A0709|43 52|ERM protein
P08152800A0709|0 15|Gel shift analysis
P08153130T0000|90 93|rats
P08153130T0000|20 29|worm burden
P08153130T0000|9 17|estradiol
P08153130T0000|0 6|Effects
P08153130T0000|43 52|leukocytes
P08153146A0327|0 9|Dotarizine
P08153146A0327|26 33|dilation
P08153146A0327|118 127|artery flow
P08153146A0327|173 181|pressures
P08153146A0327|151 160|artery mean
P08153146A0327|202 210|pressures
P08153146A0327|60 70|circulation
P08153146A0327|90 99|resistance
P08154171A0649|119 127|treatment
P08154171A0649|92 102|conjunction
P08154171A0649|33 40|patients
P08154171A0649|156 163|embolism
P08154171A0649|75 84|infarction
P08154171A0649|135 142|patients
P08154171A0649|5 10|issues
P08154171A0649|21 23|use
P08154171A0649|53 62|thrombosis
P08154171A0649|26 30|LMWHs
P08154182A0955|3 12|usefulness
P08154182A0955|91 119|Neurospora crassa cDNA libraries
P08154182A0955|34 56|lambda AD5 cloning vectors
P08154182A0955|18 27|lambda PG15
P08156332T0000|76 84|ischaemia
P08156332T0000|23 35|sympathectomy
P08156332T0000|46 54|treatment
P08157009A0264|0 18|Sequence comparisons
P08157009A0264|32 36|Aps1p
P08157009A0264|111 115|Aps2p
P08157009A0264|140 169|plasma membrane AP-2 sigma subunit
P08157009A0264|55 66|sigma subunit
P08157009A0264|96 106|AP-1 complex
P08157009T0000|100 107|evidence
P08157009T0000|80 98|clathrin AP-1 complex
P08157009T0000|26 33|APS1 gene
P08157009T0000|149 160|Golgi complex
P08157009T0000|136 143|clathrin
P08157009T0000|121 131|interaction
P08157009T0000|42 48|homolog
P08157009T0000|59 65|subunit
P08157663A0882|141 146|member
P08157663A0882|123 130|envelope
P08157663A0882|49 60|organization
P08157663A0882|150 155|family
P08157663A0882|96 110|membrane protein
P08157663A0882|5 11|results
P08157663A0882|64 77|vertebrate gene
P08157663A0882|158 169|polypeptides
P08157663A0882|181 189|evolution
P08157674T0000|47 53|protein
P08157674T0000|56 85|protein tyrosine kinase substrate
P08157674T0000|11 26|characterization
P08157674T0000|101 105|cells
P08159174A0581|41 56|Southern analysis
P08159174A0581|23 26|gene
P08159174A0581|3 10|presence
P08160054A0224|15 28|deterioriation
P08160054A0224|66 77|liver enzymes
P08160054A0224|91 115|alanine aminotransaminases
P08160054A0224|79 87|aspartate
P08160054A0224|37 42|status
P08160054A0224|126 137|coagulopathy
P08160054A0224|56 63|increase
P08160054A0224|3 10|patients
P08160387T0000|19 29|development
P08160387T0000|63 66|role
P08160387T0000|35 37|rat
P08160387T0000|90 96|rearing
P08160387T0000|75 84|experience
P08160387T0000|109 119|deprivation
P08160387T0000|51 56|cortex
P08160905A0217|59 63|HBsAg
P08160905A0217|34 57|hepatitis B surface antigen
P08160905A0217|6 13|patients
P08163183T0000|104 114|XylA enzymes
P08163183T0000|39 70|Clostridium thermosaccharolyticum
P08163183T0000|27 30|gene
P08163183T0000|32 35|xylA
P08163183T0000|80 89|sequencing
P08163183T0000|93 101|phylogeny
P08163183T0000|72 78|cloning
P08163183T0000|3 8|xylose
P08163498A0789|63 76|SGASGLLTSEHHSR
P08163498A0789|146 152|peptide
P08163498A0789|39 52|SGASGLLTSEHHSR
P08163498A0789|56 56|S
P08163498A0789|109 123|phosphorylation
P08163498A0789|127 140|trypsinization
P08163498A0789|59 61|32P
P08163498A0789|35 37|32P
P08163498A0789|3 17|phosphopeptides
P08163498A0789|31 32|RS
P08163528T0000|13 38|Mas70p signal anchor sequence
P08163546A1230|157 168|intersection
P08163546A1230|48 53|Ypt53p
P08163546A1230|91 97|pathway
P08163546A1230|38 43|Ypt52p
P08163546A1230|128 137|hydrolases
P08163546A1230|31 36|Ypt51p
P08163546A1230|198 211|sorting pathway
P08163546A1230|111 117|sorting
P08163546A1230|68 76|transport
P08163546A1230|16 19|data
P08164302A0547|101 111|energy level
P08164302A0547|133 139|glucose
P08164302A0547|89 98|difference
P08164302A0547|13 24|TPN solutions
P08164302A0547|57 75|nutrient composition
P08164661A0414|29 36|homology
P08164661A0414|13 23|TFIIIC alpha
P08164661A0414|102 107|degree
P08164661A0414|122 131|divergence
P08164661A0414|47 51|yeast
P08164661A0414|151 157|factors
P08164661A0414|135 147|RNA polymerase
P08164661A0414|58 65|subunits
P08164679A0809|0 20|Transactivation domain
P08164679A0809|93 102|Runt domain
P08164679A0809|59 76|runt homology region
P08164680A1086|17 32|protease activity
P08164680A1086|64 69|B cells
P08164680A1086|81 85|cells
P08164684A1266|29 32|acid
P08164684A1266|89 95|complex
P08164684A1266|12 14|RXR
P08164684A1266|48 53|effect
P08164684A1266|3 8|ligand
P08166402A0631|0 17|Cerebral125 albumin
P08166402A0631|39 49|proportions
P08166402A0631|57 62|groups
P08166402A0631|74 88|hyperosmolality
P08167396A0154|20 26|neurons
P08167396A0154|65 91|substantia nigra pars compacta
P08167555A0972|0 7|Response
P08167555A0972|10 18|treatment
P08167555A0972|105 108|ones
P08167555A0972|46 57|pretreatment
P08167555A0972|71 80|treatments
P08167555A0972|30 37|patients
P08167555A0972|176 176|p
P08167555A0972|131 138|relation
P08169201A0291|48 58|carA product
P08169201A0291|114 122|organisms
P08169201A0291|27 34|sequence
P08169201A0291|154 163|amino acids
P08169201A0291|90 107|nucleotide sequence
P08169709T0000|28 35|analysis
P08169709T0000|23 26|jaws
P08169709T0000|10 17|bone cyst
P08169709T0000|40 44|cases
P08170400T0000|0 7|Location
P08170400T0000|62 80|transcription factor
P08170400T0000|11 21|orientation
P08170400T0000|82 84|FNR
P08170400T0000|36 41|region
P08172416A0860|14 18|times
P08172416A0860|110 125|folliculogenesis
P08172416A0860|127 135|ovulation
P08172416A0860|164 174|development
P08172416A0860|157 161|phase
P08172416A0860|83 93|performance
P08172416A0860|68 70|cow
P08172416A0860|33 36|dose
P08172416A0860|59 65|effects
P08172416A0860|0 9|Moxidectin
P08172598A0237|43 55|N. patriciarum
P08172598A0237|23 26|mRNA
P08172598A0237|13 20|analysis
P08172598A0237|66 69|xynB
P08172598A0237|86 98|kb mRNA species
P08172653A1589|101 109|sequences
P08172653A1589|11 17|regions
P08172653A1589|116 119|rise
P08172653A1589|38 48|TnT isoforms
P08172653A1589|122 128|members
P08172653A1589|146 151|family
P08172653A1589|80 91|modification
P08172653A1589|134 136|TnT
P08172653A1589|69 76|addition
P08172905A0000|59 73|RNA miniduplexes
P08172905A0000|25 45|alanine tRNA synthetase
P08172905A0000|136 146|U70 base pair
P08172905A0000|94 104|acceptor end
P08172905A0000|107 117|alanine tRNA
P08172905A0000|3 7|class
P08172905A0000|133 134|G3
P08173532A0000|86 87|S1
P08173532A0000|6 17|reaction time
P08173532A0000|120 121|ms
P08173532A0000|48 49|S2
P08173532A0000|103 112|S2 location
P08173532A0000|145 156|facilitation
P08173532A0000|82 84|cue
P08173532A0000|19 20|RT
P08173532A0000|41 46|target
P08173532A0000|128 138|target onset
P08173693A0390|60 67|patients
P08173693A0390|7 16|study group
P08173693A0390|78 96|angina pectoris class
P08173693A0390|35 45|innervation
P08173814A0132|5 11|viruses
P08173814A0132|128 141|host physiology
P08173814A0132|61 72|interference
P08173814A0132|23 39|host cell machinery
P08173814A0132|48 56|existence
P08173814A0132|82 90|processes
P08175031A0566|0 8|Treatment
P08175188A0685|1 13|concentration
P08175188A0685|101 101|%
P08175188A0685|77 77|%
P08175188A0685|20 25|ppm SO2
P08175188A0685|46 59|baseline values
P08175188A0685|108 110|CBF
P08175188A0685|34 41|decrease
P08175188A0685|84 86|MCA
P08176742A0190|58 77|transposition pathway
P08176742A0190|23 37|assay conditions
P08176742A0190|46 52|studies
P08177143T0000|5 17|cell carcinoma
P08177143T0000|49 58|experience
P08177143T0000|20 27|children
P08177143T0000|36 46|institution
P08178446A1160|87 90|role
P08178446A1160|18 22|ICP10
P08178446A1160|115 131|signaling pathways
P08178446A1160|64 72|TM segment
P08178446A1160|46 56|ras activity
P08178446A1160|3 6|data
P08178490A0879|44 57|anchor function
P08178490A0879|23 36|signal function
P08178490A0879|66 74|K SA domain
P08178572A1118|96 101|region
P08178572A1118|49 57|base pairs
P08178572A1118|81 87|protein
P08178572A1118|4 30|concensus poly A addition sites
P08179827T0000|74 78|Korea
P08179827T0000|48 71|hepatitis B virus infection
P08179827T0000|34 45|transmission
P08179827T0000|0 6|Factors
P08180129A1256|0 7|Exposure
P08180129A1256|45 51|content
P08180129A1256|16 32|TPA concentrations
P08180129A1256|59 69|transcripts
P08181755A0989|0 15|Northern analysis
P08181755A0989|61 70|transcript
P08181755A0989|99 102|mRNA
P08181755A0989|29 43|pcbAB transcript
P08182041A1067|71 80|inhibition
P08182041A1067|3 9|results
P08182041A1067|83 89|insulin
P08182041A1067|65 67|PKA
P08182041A1067|103 122|CREB activation domain
P08182041A1067|170 182|hepatoma cells
P08182041A1067|47 55|induction
P08182041A1067|32 43|requirements
P08182041A1067|129 145|PEPCK TATA sequence
P08182041A1067|58 62|PEPCK
P08182056A0695|85 92|NQO2 gene
P08182056A0695|110 115|member
P08182056A0695|34 37|NQO2
P08182056A0695|64 71|sequence
P08182056A0695|121 133|NQO gene family
P08182056A0695|7 12|degree
P08182056A0695|15 26|conservation
P08182056A0695|41 60|NQO1 gene organization
P08182171A0000|14 42|Propionibacterium acnes product
P08182171A0000|57 72|coliform mastitis
P08182171A0000|106 113|infusion
P08182171A0000|46 54|treatment
P08182171A0000|3 10|efficacy
P08183552T0000|27 49|tyrosine kinase substrate
P08183552T0000|76 79|maps
P08183552T0000|8 16|eps15 gene
P08183552T0000|64 72|evolution
P08183915A0000|181 184|p105
P08183915A0000|104 120|p70 I kappa B protein
P08183915A0000|52 61|p50 subunit
P08183915A0000|38 46|precursor
P08183915A0000|25 31|protein
P08183915A0000|33 36|p105
P08183915A0000|64 91|transcription factor NF-kappa B
P08183915A0000|122 133|I kappa B gamma
P08183915A0000|3 6|gene
P08183915A0000|169 178|amino acids
P08183915T0000|122 131|activities
P08183915T0000|11 18|splicing
P08183915T0000|53 69|p105 NF-kappa B gene
P08183915T0000|21 34|RNA transcripts
P08183915T0000|79 98|I kappa B gamma isoforms
P08184923A0829|58 58|%
P08184923A0829|62 65|CeBF
P08184923A0829|36 43|increase
P08184923A0829|86 93|exposure
P08184923A0829|74 74|%
P08184923A0829|7 11|L-NNA
P08184923A0829|46 49|CoBF
P08185288A0106|3 12|experiment
P08185288A0106|78 96|respiration chambers
P08185288A0106|123 131|afternoon
P08185288A0106|22 25|male
P08185288A0106|113 119|morning
P08185288A0106|168 171|kg m.
P08185288A0106|43 50|subjects
P08185288A0106|135 144|min cycling
P08185288A0106|69 72|stay
P08185288A0106|157 160|work
P08187085A0086|30 38|formation
P08187085A0086|64 83|tyrosine kinase domain
P08187085A0086|49 53|genes
P08187085A0086|103 114|end sequences
P08187085A0086|126 130|genes
P08187085A0086|5 18|rearrangements
P08187085A0086|86 88|ret
P08187088A0530|114 115|8p
P08187088A0530|155 157|13q
P08187088A0530|210 210|%
P08187088A0530|94 95|5q
P08187088A0530|104 105|6p
P08187088A0530|202 204|19q
P08187088A0530|101 101|%
P08187088A0530|152 152|%
P08187088A0530|124 125|9p
P08187088A0530|73 85|chromosomes 3p
P08187088A0530|177 179|17q
P08187088A0530|29 31|LOH
P08187088A0530|141 141|%
P08187088A0530|196 196|%
P08187088A0530|144 146|11p
P08187088A0530|91 91|%
P08187088A0530|134 135|9q
P08187088A0530|188 190|18q
P08187088A0530|38 38|%
P08187088A0530|163 163|%
P08187088A0530|14 27|heterozygosity
P08187088A0530|185 185|%
P08187088A0530|131 131|%
P08187088A0530|121 121|%
P08187088A0530|8 11|loss
P08187088A0530|166 168|17p
P08187088A0530|111 111|%
P08187088A0530|55 59|cases
P08187088A0530|174 174|%
P08187177A0405|27 29|CPY
P08187177A0405|38 50|sorting signal
P08187177A0405|7 21|amino acid change
P08187177A0405|63 73|interaction
P08188258A0000|87 97|synthetases
P08188258A0000|26 46|prolyl-tRNA synthetase
P08188258A0000|13 22|synthetase
P08188258A0000|64 70|classes
P08188258A0000|153 160|pathways
P08188290A0544|102 106|assay
P08188290A0544|40 56|TCRAC/TCRDC region
P08188290A0544|119 128|expression
P08188290A0544|8 19|sequence data
P08188290A0544|73 87|polymerase chain
P08188290A0544|144 160|TCRAJ gene segments
P08188603A0230|58 65|homology
P08188603A0230|96 103|CPA2 gene
P08188603A0230|120 126|subunit
P08188603A0230|50 55|degree
P08188603A0230|33 36|arg4
P08188603A0230|4 11|analysis
P08188603A0230|148 157|synthetase
P08188603A0230|28 31|gene
P08188603A0230|159 163|CPS-A
P08188606A1034|162 178|cadmium resistance
P08188606A1034|64 69|Tn5422
P08188606A1034|54 61|presence
P08188606A1034|126 132|strains
P08188606A1034|184 193|chromosome
P08188606A1034|22 42|Southern hybridization
P08188606A1034|147 153|strains
P08188606A1034|0 18|Restriction analysis
P08188978A0822|28 36|ECG R-wave
P08188978A0822|103 107|sleep
P08188978A0822|52 64|MSNA burst peak
P08188978A0822|13 19|latency
P08188978A0822|123 141|pulse-synchronicity
P08188978A0822|96 96|s
P08189174A0148|0 5|DESIGN
P08189174A0148|113 116|city
P08189174A0148|102 107|living
P08189174A0148|55 59|years
P08189174A0148|119 125|Utrecht
P08189174A0148|78 98|breast cancer screening
P08189174A0148|19 23|study
P08189174A0148|41 45|women
P08189498T0000|73 84|repeat region
P08189498T0000|42 46|Marek
P08189498T0000|33 36|gene
P08189498T0000|49 60|disease virus
P08189498T0000|117 127|polypeptide
P08189498T0000|0 13|Identification
P08189503A0000|86 88|RNA
P08189503A0000|22 30|cDNA clone
P08189503A0000|101 119|cassette mutagenesis
P08189503A0000|162 174|mRNA synthesis
P08189503A0000|34 61|mouse hepatitis virus strain A59
P08189503A0000|90 96|pMIDI-C
P08189503A0000|130 138|mechanism
P08189503A0000|141 151|coronavirus
P08189533A0203|71 74|NS53
P08189533A0203|38 44|product
P08189533A0203|165 170|vTF7-3
P08189533A0203|172 187|expression system
P08189533A0203|106 132|baculovirus expression system
P08189533A0203|64 68|forms
P08189533A0203|33 36|gene
P08189533A0203|148 163|vaccinia virus/T7
P08189533A0919|0 17|Gel electrophoresis
P08189533A0919|152 162|association
P08189533A0919|140 146|cytosol
P08189533A0919|111 117|amounts
P08189533A0919|120 123|NS53
P08189533A0919|89 93|cells
P08189533A0919|182 187|matrix
P08189533A0919|28 45|immunoblot analyses
P08189533A0919|61 69|fractions
P08190633A0000|69 76|HLA locus
P08190633A0000|51 60|chromosome
P08190633A0000|38 41|gene
P08190633A0000|3 25|transcription factor AP-2
P08190633A0273|52 57|region
P08190633A0273|9 16|AP-2 mRNA
P08190633A0273|71 73|DNA
P08190633A0273|62 63|kb
P08190633A0273|31 35|exons
P08191910A0228|100 109|strategist
P08191910A0228|89 97|abilities
P08191910A0228|57 62|lodges
P08191910A0228|122 126|ruler
P08191910A0228|24 29|traits
P08191910A0228|42 45|work
P08191910A0228|0 8|San Martin
P08192140A0209|97 108|San Francisco
P08192140A0209|110 110|n
P08192140A0209|87 87|n
P08192140A0209|75 85|New York City
P08192140A0209|69 69|n
P08192140A0209|3 14|participants
P08192140A0209|34 56|hepatitis B vaccine trials
P08192140A0209|29 31|men
P08192140A0209|59 67|Amsterdam
P08192451A0885|28 35|decrease
P08192451A0885|79 87|NAO uptake
P08192451A0885|8 16|treatment
P08192451A0885|51 56|uptake
P08192451A0885|69 76|increase
P08192451A0885|59 63|Rh123
P08192795T0000|43 60|lupus erythematosus
P08192795T0000|26 32|purpura
P08193147A0831|0 9|Comparison
P08193147A0831|106 113|topology
P08193147A0831|170 171|Pf
P08193147A0831|35 52|Desulfovibrio gigas
P08193147A0831|54 55|Dg
P08193147A0831|149 156|elements
P08193147A0831|57 58|Fd
P08193147A0831|182 185|Dg Fd
P08193147A0831|17 32|crystal structure
P08193147A0831|60 68|Kissinger
P08194139A0498|0 10|CONCLUSIONS
P08194139A0498|12 39|Serum prolactin concentrations
P08194139A0498|54 63|variations
P08194139A0498|83 85|men
P08194139A0498|44 46|age
P08194549A0000|88 89|CP
P08194549A0000|129 132|OBLA
P08194549A0000|82 86|power
P08194549A0000|22 29|kayakers
P08194549A0000|104 127|blood lactate accumulation
P08194549A0000|55 66|relationship
P08194549A0000|97 101|onset
P08194753A0157|116 121|region
P08194753A0157|76 78|DNA
P08194753A0157|96 102|element
P08194753A0157|30 34|rhp51
P08194753A0157|20 27|sequence
P08194753A0157|45 48|MluI
P08194753A0157|59 63|boxes
P08194970A0000|0 4|Women
P08194970A0000|79 83|carer
P08194970A0000|27 30|work
P08194970A0000|106 115|Trudy Wynne
P08194970A0000|93 98|family
P08194970A0000|66 69|role
P08194970A0000|7 19|opportunities
P08194970A0000|41 44|home
P08195186A0000|263 264|K.
P08195186A0000|63 66|gene
P08195186A0000|169 177|ecoR/CAT1
P08195186A0000|251 254|C.L.
P08195186A0000|222 233|T lymphocytes
P08195186A0000|256 261|Finley
P08195186A0000|80 86|protein
P08195186A0000|183 190|RNA blots
P08195186A0000|36 46|T lymphocyte
P08195186A0000|8 19|cDNA sequence
P08195186A0000|243 249|MacLeod
P08195186A0000|68 70|Tea
P08195186A0000|273 274|D.
P08195186A0000|237 241|liver
P08195186A0000|121 130|retrovirus
P08195186A0000|266 271|Kakuda
P08195186A0000|207 219|Tea expression
P08195186A0000|148 167|amino acid transporter
P08195216A1022|160 174|GCN4p activation
P08195216A1022|28 31|HIS3
P08195216A1022|49 54|subset
P08195216A1022|21 24|case
P08195216A1022|66 74|sequences
P08195216A1022|116 120|GCN4p
P08195216A1022|177 180|TRP3
P08195216A1022|144 152|sequences
P08195216A1022|86 98|transcription
P08195216A1022|101 111|conjunction
P08195217A0799|46 81|reticulocyte lysate translation product
P08195217A0799|114 120|protein
P08195217A0799|158 161|gels
P08195217A0799|20 26|protein
P08195217A0799|123 135|sodium dodecyl
P08195233A0147|142 147|stages
P08195233A0147|79 83|genes
P08195233A0147|150 162|tumorigenesis
P08195233A0147|105 114|chromosome
P08195233A0147|90 97|position
P08195233A0147|2 9|addition
P08195233A0147|15 20|kinase
P08196607A0280|0 15|Deletion analysis
P08196607A0280|93 99|UASICL1
P08196607A0280|103 112|CATTCATCCG
P08196607A0280|77 91|sequence element
P08196607A0280|21 32|ICL1 promoter
P08196607A0280|199 210|reporter gene
P08196607A0280|152 157|carbon
P08196607A0280|174 183|regulation
P08196607A0280|41 54|identification
P08196616A1112|30 35|ZAP-70
P08196616A1112|107 122|tyrosine residues
P08196616A1112|65 72|presence
P08196616A1112|148 153|ZAP-70
P08196616A1112|79 94|ZAP-70 SH2 domains
P08196616A1112|203 209|binding
P08196616A1112|17 27|interaction
P08196616A1112|218 227|SH2 domains
P08196616A1112|170 192|phosphotyrosine residues
P08196616A1112|128 132|motif
P08196616A1112|43 47|motif
P08196618A0473|0 4|PRL-1
P08196618A0473|81 95|cysteine residue
P08196618A0473|109 116|activity
P08196618A0473|57 64|mutation
P08196618A0473|28 52|phosphotyrosine substrates
P08196624A0593|158 166|receptors
P08196624A0593|109 119|association
P08196624A0593|21 25|cells
P08196624A0593|142 148|ligands
P08196624A0593|37 50|T beta R-I signal
P08196624A0593|58 60|set
P08196624A0593|2 10|Mv1Lu lung
P08196624A0593|152 155|type
P08196624A0593|98 106|responses
P08196624A0593|27 33|ActR-IB
P08198524A1134|15 17|kDa
P08198524A1134|2 4|kDa
P08199204A0746|73 95|tyrosine phosphorylation
P08199204A0746|46 58|PKC activation
P08199204A0746|110 121|P2 production
P08199204A0746|65 70|effect
P08199204A0746|99 104|PtdIns
P08199204A0746|0 2|H-7
P08199878T0000|74 86|brain ischemia
P08199878T0000|20 39|glucose concentration
P08199878T0000|3 9|effects
P08199878T0000|42 56|brain metabolism
P08200528A0970|101 103|PAL
P08200528A0970|156 159|REP2
P08200528A0970|141 147|control
P08200528A0970|4 11|strategy
P08200528A0970|33 44|Tn903 neo gene
P08200528A0970|114 117|gene
P08200528A0970|51 99|Rhodosporidium toruloides phenylalanine ammonia lyase
P08200528A0970|150 153|pPGK
P08201352A0239|96 107|skin necrosis
P08201352A0239|90 93|risk
P08201352A0239|21 38|protein C deficiency
P08201352A0239|5 8|case
P08201352A0239|40 58|vitamin K antagonists
P08201758A0125|48 58|obstruction
P08201758A0125|68 77|laparotomy
P08201758A0125|13 19|patient
P08201758A0125|83 87|times
P08201932A0355|65 70|joints
P08201932A0355|10 20|examination
P08201932A0355|37 49|polyarthritis
P08202546A1206|27 50|hUBF-promoter interaction
P08202546A1206|107 113|adducts
P08202546A1206|85 91|effects
P08202546A1206|2 9|addition
P08203260A1204|17 20|SIMV
P08203260A1204|38 45|neonates
P08203260A1204|53 62|ventilator
P08204348T0000|0 4|VP-16
P08204348T0000|6 15|ifosfamide
P08204348T0000|50 63|cell lung cancer
P08204348T0000|19 27|cisplatin
P08204348T0000|29 31|VIP
P08204403A0000|11 15|males
P08204403A0000|126 130|I-131
P08204403A0000|20 26|females
P08204403A0000|99 121|radioimmunoscintigraphy
P08204403A0000|86 96|sensitivity
P08204403A0000|162 171|antibodies
P08204403A0000|67 71|study
P08204403A0000|28 35|patients
P08204403A0000|142 147|CEA/CA
P08204403A0000|1 5|total
P08204426T0001|104 114|indications
P08204426T0001|67 75|childhood
P08204426T0001|50 64|diaphragm pacing
P08204426T0001|80 100|implantation technique
P08204426T0001|34 44|ventilation
P08204824A0000|120 137|Catharanthus roseus
P08204824A0000|99 106|cultures
P08204824A0000|62 67|S phase
P08204824A0000|77 85|cell cycle
P08204824A0000|109 118|periwinkle
P08204824A0000|139 143|cells
P08204824A0000|8 12|clone
P08204824A0000|19 27|cyc07 gene
P08205827A0940|132 144|translocation
P08205827A0940|69 73|tract
P08205827A0940|106 122|animal experiments
P08205827A0940|12 24|Translocation
P08205827A0940|27 34|bacteria
P08205827A0940|164 171|patients
P08205827A0940|81 91|bloodstream
P08205827A0940|37 45|endotoxin
P08205827A0940|187 191|shock
P08205827A0940|0 10|CONCLUSIONS
P08206848A0296|26 37|polypeptides
P08206848A0296|80 82|kDa
P08206848A0296|10 18|pyrP genes
P08206848A0296|3 6|pyrR
P08206848A0296|61 66|masses
P08206867A0874|0 23|Southern blotting analysis
P08206867A0874|54 63|COXVb genes
P08206867A0874|34 43|occurrence
P08206867A0874|69 77|rat genome
P08206991A0466|146 150|Cys-6
P08206991A0466|139 143|Cys-3
P08206991A0466|112 124|palmitylation
P08206991A0466|163 168|serine
P08206991A0466|47 51|Gly-2
P08206991A0466|84 98|N-myristylation
P08206991A0466|64 70|alanine
P08206991A0466|16 30|palmitate analog
P08206991A0466|0 8|Acylation
P08207022T0000|0 17|Subunit composition
P08207022T0000|78 93|Bacillus subtilis
P08207022T0000|21 35|domain structure
P08207022T0000|41 75|Spo0A sporulation transcription factor
P08207232A0503|15 35|mobility shift analysis
P08207232A0503|134 145|IL-8 promoter
P08207232A0503|77 83|members
P08207232A0503|90 95|family
P08207232A0503|49 55|NF-IL-6
P08207232A0503|118 128|NF-IL-6 site
P08207405A0372|188 197|HSP70 genes
P08207405A0372|103 125|kb amplification products
P08207405A0372|50 53|BYSV
P08207405A0372|39 48|stunt virus
P08207405A0372|164 172|fragments
P08207405A0372|75 93|fleck virus templates
P08207405A0372|24 26|CTV
P08207405A0372|58 66|carnation
P08207405A0372|143 152|sequencing
P08207405A0372|4 22|citrus tristeza virus
P08207405A0372|0 2|BYV
P08207405A0372|29 32|beet
P08207795A0409|84 104|mutagenesis procedures
P08207795A0409|63 69|protein
P08207795A0409|33 51|phosphorylation site
P08207795A0409|20 27|location
P08207805A0000|117 125|repressor
P08207805A0000|105 113|activator
P08207805A0000|3 31|p53 tumor suppressor gene product
P08207805A0000|62 68|protein
P08208247T0030|44 49|region
P08208247T0030|10 17|analysis
P08208247T0030|71 91|acid decarboxylase gene
P08208247T0030|31 41|segment 64AB
P08208540A0000|0 13|Rearrangements
P08208540A0000|82 93|significance
P08208540A0000|53 64|malignancies
P08208540A0000|19 27|NFKB2 gene
P08208540A0000|101 111|alterations
P08208540A0417|128 133|p84/85
P08208540A0417|38 42|cDNAs
P08208540A0417|71 78|splicing
P08208540A0417|108 115|proteins
P08208540A0417|125 126|kD
P08208540A0417|10 19|sequencing
P08208540A0417|93 101|gene codes
P08208540A0417|250 262|ankyrin repeat
P08208540A0417|184 197|ankyrin repeats
P08208540A0417|160 168|rel domain
P08208540A0417|215 230|carboxy-terminus
P08208540A0417|0 6|Cloning
P08208540A1114|105 112|NFKB2 p85
P08208540A1114|64 68|kappa
P08208540A1114|171 178|NFKB2 p52
P08208540A1114|39 60|NFKB2 expression vectors
P08208540A1114|9 29|co-transfection assays
P08208540A1114|138 155|repressor functions
P08208540A1114|77 92|reporter plasmids
P08208618A1334|56 65|Sp1 binding
P08208618A1334|19 25|HR21Xap
P08208618A1334|5 10|HR21ap
P08208618A1334|44 53|inhibition
P08209051T0000|59 62|home
P08209051T0000|36 43|fibrosis
P08209051T0000|21 27|therapy
P08209051T0000|47 54|hospital
P08209423T0000|72 79|evidence
P08209423T0000|24 41|nucleotide sequence
P08209423T0000|48 70|MDV-1 BamHI-D DNA fragment
P08209423T0000|110 125|glycoprotein gene
P08209423T0000|11 16|frames
P08209423T0000|93 96|mRNA
P08209423T0000|83 90|splicing
P08209772A0167|73 74|ns
P08209772A0167|76 82|protein
P08209772A0167|38 40|ORF
P08209772A0167|25 36|reading frame
P08209772A0167|88 97|amino acids
P08209772A0167|121 124|mass
P08209772A0167|3 9|ns2 gene
P08212571A0597|0 14|Co-transfection
P08212571A0597|67 81|tat ORF mutations
P08212571A0597|164 166|tat
P08212571A0597|141 147|effects
P08212571A0597|154 160|mutants
P08212571A0597|18 20|tat
P08212571A0597|31 37|plasmid
P08212571A0597|106 120|virus production
P08212571A0597|47 53|viruses
P08212571A0597|98 103|levels
P08212571A0971|0 7|Analysis
P08212571A0971|19 29|rev proteins
P08212571A0971|46 50|cells
P08212571A0971|201 219|tat expression vector
P08212571A0971|72 79|proteins
P08212571A0971|164 172|mutations
P08212571A0971|122 131|tat mutants
P08212571A0971|13 15|gag
P08212571A0971|99 103|cells
P08212897A0404|29 45|methyltransferase
P08212897A0404|3 23|hydrophobicity profile
P08212897A0404|56 63|presence
P08212897A0404|86 105|transmembrane domains
P08213235A1024|0 10|Measurement
P08213235A1024|52 55|care
P08213235A1024|85 91|infants
P08213235A1024|13 16|SaO2
P08213235A1024|75 82|newborns
P08213235A1024|27 34|altitude
P08213747A0000|495 504|Los Angeles
P08213747A0000|77 85|infection
P08213747A0000|259 265|authors
P08213747A0000|218 225|diseases
P08213747A0000|424 430|centers
P08213747A0000|190 196|history
P08213747A0000|484 490|Chicago
P08213747A0000|71 75|HIV-1
P08213747A0000|134 136|men
P08213747A0000|44 68|immunodeficiency virus type
P08213747A0000|331 346|HIV-1 risk factors
P08213747A0000|182 188|factors
P08213747A0000|413 415|men
P08213747A0000|153 163|differences
P08213747A0000|291 298|analysis
P08213747A0000|470 471|DC
P08213747A0000|301 327|baseline HIV-1 seroprevalence
P08213747A0000|449 468|Baltimore/Washington
P08213747A0000|246 254|behaviors
P08213747A0000|116 118|men
P08213747A0000|436 447|United States
P08213747A0000|27 36|prevalence
P08213747A0000|88 89|US
P08213747A0000|473 482|Pittsburgh
P08216115A0158|145 150|labour
P08216115A0158|91 100|percentile
P08216115A0158|110 117|activity
P08216115A0158|16 20|group
P08216115A0158|56 63|oxytocin
P08216115A0158|36 44|catheters
P08216115A0158|3 10|patients
P08216115A0158|162 167|parity
P08217862A1336|219 224|states
P08217862A1336|81 87|ability
P08217862A1336|25 47|rat conditioning paradigm
P08217862A1336|9 19|development
P08217862A1336|184 190|strains
P08217862A1336|107 119|nerve activity
P08217862A1336|153 158|number
P08217862A1336|134 141|subjects
P08218056A0000|3 16|ultrastructure
P08218056A0000|67 74|patients
P08218056A0000|51 54|eyes
P08218056A0000|26 32|vessels
P08218056A0000|81 84|eyes
P08218056A0000|96 103|subjects
P08218230A1505|130 138|positions
P08218230A1505|76 94|transcription factor
P08218230A1505|13 18|region
P08218230A1505|121 125|HNF-1
P08218230A1505|47 57|binding site
P08218230A1505|113 118|factor
P08218230A1505|96 105|hepatocyte
P08218230A1505|27 34|sequence
P08218230A1920|212 222|liver tissue
P08218230A1920|162 194|Xenopus fibrinogen B beta subunit gene
P08218230A1920|51 76|glucocorticoid inducibility
P08218230A1920|101 108|promoter
P08218230A1920|121 132|determinants
P08218230A1920|22 24|GRE
P08218230A1920|150 156|control
P08218230A1920|82 90|HNF-1 site
P08218230A1920|197 201|cells
P08219072A0287|0 3|Acad
P08219081A0000|3 12|PRB-1b gene
P08219081A0000|34 42|component
P08219081A0000|68 84|PR-1 protein family
P08219227A0830|0 10|Replacement
P08219227A0830|119 126|sequence
P08219227A0830|147 154|AP-1 site
P08219227A0830|172 179|activity
P08219227A0830|57 61|level
P08219227A0830|160 162|CRE
P08219227A0830|131 141|replacement
P08219227A0830|79 86|activity
P08219227A0830|30 33|copy
P08219227A0830|16 18|CRE
P08219227A0830|39 46|AP-1 site
P08220494A0231|125 140|promotor activity
P08220494A0231|36 41|origin
P08220494A0231|148 151|stem
P08220494A0231|8 15|promoter
P08220494A0231|52 57|planta
P08220494A0231|155 163|root cells
P08220494A0231|143 146|leaf
P08220494A0231|166 178|tobacco plants
P08220494A0231|66 79|bp cyt-1 element
P08220494A0231|96 101|region
P08220621T0000|9 19|manuscripts
P08220621T0000|42 47|system
P08221251A0239|56 59|area
P08221251A0239|33 41|diagnosis
P08221251A0239|44 49|tumors
P08221251A0239|13 14|CT
P08222384A0455|0 4|SIN-1
P08222384A0455|38 47|parameters
P08222384A0455|10 18|influence
P08222384A0455|78 80|ECG
P08222384A0455|53 76|surface electrocardiogram
P08222384A0455|100 102|ECG
P08222556T0000|0 5|Effect
P08222556T0000|8 12|aging
P08222556T0000|34 40|muscles
P08222618A0000|29 47|logit transformation
P08222618A0000|54 61|analysis
P08222618A0000|8 23|computer programs
P08222618A0000|72 77|curves
P08223425T0000|3 15|yeast SSS1 gene
P08223425T0000|102 110|reticulum
P08223425T0000|39 58|protein translocation
P08223425T0000|79 85|protein
P08223554A0574|3 9|lengths
P08223554A0574|92 99|residues
P08223554A0574|23 38|polypeptide chain
P08223554A0574|55 60|enzyme
P08223554A0574|67 80|transit peptide
P08223576A1261|56 65|conditions
P08223576A1261|3 9|absence
P08223576A1261|82 90|H4PteGlun
P08223576A1261|12 20|H4PteGlun
P08223576A1261|31 38|T protein
P08223576A1261|117 124|T protein
P08223592A0424|0 3|TATA
P08223592A0424|176 195|polyadenylation sites
P08223592A0424|108 113|leader
P08223592A0424|7 16|CCAAT boxes
P08223592A0424|150 153|gene
P08223592A0424|67 88|transcription start site
P08223592A0424|118 128|nucleotides
P08223613A0105|85 111|synthase/phosphatase complex
P08223613A0105|19 22|TPS1
P08223613A0105|136 139|byp1
P08223613A0105|148 160|cif1 mutations
P08223613A0105|141 144|glc6
P08223613A0105|131 134|fdp1
P08223613A0105|52 58|subunit
P08223613A0105|0 3|GGS1
P08223613A0105|13 16|gene
P08223613A0519|183 190|function
P08223613A0519|48 55|products
P08223613A0519|110 117|subunits
P08223613A0519|123 146|trehalose synthase complex
P08223613A0519|73 81|genes TPS2
P08223613A0519|17 24|sequence
P08223613A0519|169 172|TPS3
P08223613A0519|155 167|TSL1 homologue
P08223613A0519|85 88|TSL1
P08223823T0000|0 17|Stroop interference
P08223823T0000|46 65|Stroop Color-Word Test
P08223823T0000|19 30|aging effects
P08223875A0711|0 10|Stimulation
P08223875A0711|126 133|activity
P08223875A0711|54 54|%
P08223875A0711|17 28|PA production
P08223875A0711|75 78|CD45
P08223875A0711|96 100|cells
P08223875A0711|80 84|cells
P08223875A0711|149 153|cells
P08223875A0711|136 141|p59fyn
P08223875A0711|91 94|CD45
P08223875A0711|14 15|3H
P08223875A0711|33 48|CD3 cross-linking
P08223875A0711|144 147|CD45
P08224260A1248|0 9|CONCLUSION
P08224260A1248|128 133|masses
P08224260A1248|154 154|%
P08224260A1248|139 149|specificity
P08224260A1248|47 61|ultrasonography
P08224260A1248|67 76|efficiency
P08224260A1248|81 81|%
P08224260A1248|99 111|endometriomas
P08224260A1248|14 18|study
P08224907A0000|29 35|rat EFIA
P08224907A0000|103 123|cDNA subfragment probes
P08224907A0000|37 62|gene encoding enhancer factor
P08224907A0000|88 98|band pattern
P08224907A0000|7 26|Southern blot analysis
P08224907A0000|64 71|subunit A
P08225657A0000|3 8|effect
P08225657A0000|11 19|ibopamine
P08225657A0000|50 59|NYHA Class I
P08225657A0000|63 76|II heart failure
P08225657A0000|38 45|patients
P08225657A0000|23 32|furosemide
P08225657A0000|153 157|trial
P08225657A0000|91 98|parallel
P08226616A0000|28 49|fungus Neurospora crassa
P08226616A0000|105 108|step
P08226616A0000|77 82|enzyme
P08226616A0000|64 72|reductase
P08226616A0000|3 11|nit-3 gene
P08226616A0000|118 129|assimilation
P08226776A0990|55 59|delta
P08226776A0990|75 82|delta Hva
P08226776A0990|48 52|ratio
P08226776A0990|35 41|process
P08226777A0936|1 25|Dictyostelium transformant
P08226777A0936|40 45|DdPTPa
P08226780A0160|54 57|case
P08226780A0160|60 66|ankyrin
P08226780A0160|101 108|proteins
P08226780A0160|30 48|protein interactions
P08226780A0160|4 8|motif
P08226794A0501|1 5|Ala85
P08226794A0501|37 44|activity
P08226794A0501|7 8|Dk
P08226798A1124|145 154|inhibition
P08226798A1124|178 186|functions
P08226798A1124|140 143|part
P08226798A1124|15 24|CaM binding
P08226798A1124|92 100|mechanism
P08226798A1124|78 84|effects
P08226798A1124|27 45|HIV envelope proteins
P08226798A1124|115 126|cytotoxicity
P08226956A1397|26 42|growth temperature
P08226956A1397|82 91|type plants
P08226956A1397|18 23|effect
P08226956A1397|68 75|fad7 mRNA
P08226956A1397|60 65|levels
P08227129T0000|86 106|immunoglobulin C2 motif
P08227129T0000|38 49|muscle MyBP-C
P08227129T0000|22 27|domain
P08227129T0000|51 58|C protein
P08228805A0540|116 136|protein tyrosine kinase
P08228805A0540|26 46|TCR signal transduction
P08228805A0540|146 154|mechanism
P08228805A0540|110 112|TCR
P08228805A0540|52 82|guanine nucleotide binding protein
P08228805A0540|84 89|p21ras
P08228805A0540|16 23|molecule
P08228997A0866|33 49|lipid accumulation
P08228997A0866|69 79|oxygenation
P08228997A0866|3 9|results
P08229102A0768|41 49|potential
P08229102A0768|88 95|patients
P08229102A0768|76 77|QL
P08229102A0768|54 63|instrument
P08229102A0768|17 33|QLMI questionnaire
P08229330A0000|28 34|smoking
P08229330A0000|4 10|smokers
P08229826A1145|87 94|activity
P08229826A1145|23 26|taps
P08229826A1145|13 20|response
P08229826A1145|111 117|muscles
P08229826A1145|148 154|objects
P08230418A0812|56 61|effect
P08230418A0812|245 254|amino acids
P08230418A0812|205 214|frameshift
P08230418A0812|177 184|activity
P08230418A0812|100 128|urokinase plasminogen activator
P08230418A0812|48 50|nef
P08230418A0812|132 135|type
P08230418A0812|36 45|expression
P08230418A0812|11 13|nef
P08230418A0812|67 74|activity
P08230418A0812|94 98|c-fms
P08230418A0812|30 32|LTR
P08230418A0812|260 266|protein
P08230418A0812|86 90|virus
P08230418A0812|3 8|action
P08230418A0812|137 159|acid phosphatase promoter
P08230445A0000|41 65|immunodeficiency virus type
P08230445A0000|133 142|quantities
P08230445A0000|161 163|Gag
P08230445A0000|22 33|reading frame
P08230445A0000|3 9|product
P08230445A0000|119 125|virions
P08230445A0000|68 72|HIV-1
P08230445A0000|97 103|protein
P08230445A0000|15 17|vpr
P08230452A0551|381 394|capsid proteins
P08230452A0551|288 302|vaccinia viruses
P08230452A0551|83 99|processing defects
P08230452A0551|208 222|assembly defects
P08230452A0551|337 352|poliovirus genome
P08230452A0551|14 21|vaccinia
P08230452A0551|310 324|capsid precursor
P08230452A0551|43 56|P1 polyproteins
P08230452A0551|102 106|cells
P08230452A0551|396 397|D.
P08230452A0551|168 188|poliovirus 3CD protease
P08230452A0551|195 204|processing
P08230452A0551|133 145|vaccinia virus
P08230452A0551|147 150|VVP3
P08230452A0551|236 256|complementation system
P08230452A1489|97 105|VP1-G001V
P08230452A1489|178 184|virions
P08230452A1489|39 49|P1 precursor
P08230452A1489|11 24|capsid proteins
P08230452A1489|55 72|valine substitution
P08230452A1489|78 90|amino terminus
P08230452A1489|93 95|VP1
P08230452A1489|121 135|capsid particles
P08230452A1489|2 9|contrast
P08231398A0802|0 6|RESULTS
P08231398A0802|92 99|episodes
P08231398A0802|177 197|immunodeficiency virus
P08231398A0802|102 111|bacteremia
P08231398A0802|79 88|isolations
P08231398A0802|33 37|total
P08231398A0802|242 244|CD4
P08231398A0802|218 234|immunosuppression
P08231398A0802|14 23|moth period
P08231398A0802|51 63|blood cultures
P08231398A0802|236 239|mean
P08231398A0802|143 156|prison patients
P08231398A0802|114 127|M. tuberculosis
P08231398A0802|258 258|l
P08231577A1027|0 3|Acid
P08231577A1027|90 94|apnea
P08231577A1027|34 40|rabbits
P08231577A1027|18 23|larynx
P08231816A1473|135 150|promoter fragment
P08231816A1473|49 77|penicillin producing conditions
P08231816A1473|104 111|activity
P08231816A1473|20 27|extracts
P08231816A1473|187 193|IPNS tsp
P08232304A1166|1 6|series
P08232304A1166|36 43|fragment
P08232304A1166|59 61|TSS
P08232304A1166|12 20|deletions
P08232304A1166|75 90|promoter activity
P08232304A1166|133 173|chloramphenicol acetyltransferase construct
P08232412A1342|27 49|expression vector pALTNEO
P08232412A1342|114 118|cells
P08232412A1342|134 144|vinblastine
P08232412A1342|155 160|levels
P08232412A1342|77 87|L. enriettii
P08232412A1342|184 188|cells
P08232412A1342|3 12|lemdr1 gene
P08234166A0425|115 126|RT conditions
P08234166A0425|32 39|capsules
P08234166A0425|91 96|humans
P08234166A0425|3 17|bioavailability
P08234166A0425|57 66|conditions
P08234166A0425|20 27|etodolac
P08234166A0425|84 87|dogs
P08234166A0425|99 106|capsules
P08234276A0556|87 107|NF-kappa B binding sites
P08234276A0556|78 83|NF-IL6
P08234276A0556|18 27|activation
P08234276A0556|44 55|IL-8 promoter
P08234308T0000|0 5|Notice
P08234308T0000|8 17|retraction
P08237112A0553|28 37|36K protein
P08237112A0553|46 55|structures
P08237112A0553|2 9|homology
P08237112A0553|58 65|proteins
P08237171A0000|13 16|case
P08237171A0000|83 95|hydrocephalus
P08237171A0000|49 54|recess
P08237171A0000|58 64|patient
P08237171A0000|25 35|enlargement
P08237578A0253|130 145|Norplant-2 rod use
P08237578A0253|123 127|years
P08237578A0253|72 86|LDL-cholesterol
P08237578A0253|152 157|months
P08237578A0253|114 116|end
P08237578A0253|9 23|lipid metabolism
P08237578A0253|28 37|mean values
P08237578A0253|46 58|triglycerides
P08237578A0253|185 200|preinsertion mean
P08237578A0253|60 70|cholesterol
P08237578A0253|90 104|HDL-cholesterol
P08238626A0248|12 15|mmHg
P08238626A0248|74 82|blood flow
P08238626A0248|17 32|baseline brain pHi
P08238626A0248|106 110|min-1
P08238626A0248|102 104|g-1
P08238626A0248|3 7|PaCO2
P08238626A0248|96 97|ml
P08239164A0551|155 162|patients
P08239164A0551|64 70|dyspnea
P08239164A0551|78 85|patients
P08239164A0551|11 17|isotime
P08239164A0551|175 185|lung disease
P08239164A0551|100 110|lung disease
P08239164A0551|41 46|minute
P08239164A0551|120 125|values
P08239164A0551|49 56|exercise
P08239164A0551|58 60|VO2
P08239164A0551|0 3|CPAP
P08239586T0000|0 6|Effects
P08239586T0000|54 60|rabbits
P08239586T0000|9 17|diltiazem
P08239586T0000|38 51|nephrotoxicity
P08240170A0000|68 70|sea
P08240170A0000|40 47|feedlots
P08240170A0000|11 23|salmonellosis
P08240170A0000|57 65|transport
P08240170A0000|4 8|forms
P08241139A0378|71 74|none
P08241139A0378|51 58|presence
P08241139A0378|102 112|nucleotides
P08241139A0378|25 34|DNA binding
P08241139A0378|61 66|MgdTDP
P08241139A0378|7 7|%
P08241139A0378|93 99|absence
P08241656A0189|28 31|case
P08241656A0189|96 103|syndrome
P08241656A0189|5 13|knowledge
P08241656A0189|48 58|association
P08241656A0189|66 79|cholelithiasis
P08241656A0189|83 93|Wildervanck
P08242861A0368|38 43|p.p.b.
P08242861A0368|4 14|4,8-DiMeIQx
P08242861A0368|18 24|A alpha C
P08243476A1177|90 99|reductases
P08243476A1177|114 129|Paracoccus enzyme
P08243476A1177|20 37|tryptophan residues
P08243476A1177|5 12|cysteine
P08244034T0000|59 85|baculovirus expression system
P08244034T0000|11 43|Leishmania surface glycoprotein GP63
P08244034T0000|95 111|metalloproteinase
P08245013A0000|63 66|mRNA
P08245013A0000|188 196|receptors
P08245013A0000|23 27|basis
P08245013A0000|199 205|agonist
P08245013A0000|85 93|receptors
P08245013A0000|46 60|destabilization
P08245013A0000|111 133|receptor down-regulation
P08245013A0000|152 164|understanding
P08245013A0000|176 185|regulation
P08245125A0822|31 43|F-actin nuclei
P08245125A0822|99 107|degrees C.
P08245125A0822|47 56|phalloidin
P08245125A0822|65 74|L266D actin
P08245125A0822|77 83|ability
P08245125A0822|0 7|Addition
P08245456A0501|70 85|O2-dibutyryl cAMP
P08245456A0501|113 115|PMA
P08245456A0501|165 168|mRNA
P08245456A0501|21 25|level
P08245456A0501|175 187|protein levels
P08245456A0501|87 93|Bt2cAMP
P08245456A0501|50 52|PMA
P08245456A0501|67 68|N6
P08245456A0501|146 159|IL-5 production
P08245456A0501|5 9|cells
P08245456A0501|98 108|combination
P08245456A0501|28 31|IL-5
P08245461A0700|0 21|Hu-Met-1 mRNA expression
P08245461A0700|108 118|development
P08245461A0700|90 98|phenotype
P08245461A0700|101 105|stage
P08245461A0700|43 57|T cell tumor lines
P08245461A0700|30 35|number
P08245933A0617|32 41|treatments
P08245933A0617|7 17|engorgement
P08246984A0512|0 7|Northern
P08246984A0512|13 20|analysis
P08246984A0512|50 59|PI 3-kinase
P08246984A0512|9 11|RNA
P08246984A0512|75 83|cell lines
P08246984A0512|65 71|tissues
P08246984A0512|33 42|expression
P08246984A0923|74 79|family
P08246984A0923|103 112|PI 3-kinase
P08246984A0923|26 34|existence
P08246984A0923|5 11|results
P08246984A0923|82 86|genes
P08246984A0923|150 152|p85
P08246984A0923|46 63|PI 3-kinase isoforms
P08246984A0923|122 129|subunits
P08246987A0260|59 69|Src homology
P08246987A0260|118 123|region
P08246987A0260|76 78|SH2
P08246987A0260|2 9|addition
P08246987A0260|82 84|SH3
P08246987A0260|31 42|kinase domain
P08246987A0260|86 92|domains
P08246987A0260|44 49|p56lck
P08247005A0584|0 6|Strains
P08247005A0584|104 111|subunits
P08247005A0584|39 50|20S precursor
P08247005A0584|62 68|18S rRNA
P08247005A0584|92 94|40S
P08247005A0584|17 35|drs2 mutation process
P08247043T0000|0 9|Hepatitis B
P08247043T0000|13 32|liver transplantation
P08248246A0838|43 49|complex
P08248246A0838|72 78|binding
P08248246A0838|97 100|role
P08248246A0838|126 141|R1 gene expression
P08248246A0838|3 9|complex
P08248246A0838|29 31|Sp1
P08248253A1785|59 74|chicken L-CAM gene
P08248253A1785|13 24|observations
P08248253A1785|32 39|promoter
P08248253A1785|45 52|enhancer
P08248688A0726|42 48|nitrate
P08248688A0726|16 26|stimulation
P08248688A0726|113 120|molecule
P08248688A0726|87 98|NO production
P08248688A0726|3 6|rate
P08248688A0726|73 76|rate
P08249319A0578|59 62|peak
P08249319A0578|26 40|mislocalization
P08249319A0578|88 92|field
P08249319A0578|46 53|position
P08249390A0111|13 28|diabetes mellitus
P08249390A0111|61 65|years
P08249390A0111|36 43|patients
P08249390A0111|52 57|months
P08249390A0111|108 117|infarction
P08249390A0111|75 82|patients
P08249390A0111|3 10|duration
P08251506A0503|146 163|DRE oligonucleotide
P08251506A0503|10 16|complex
P08251506A0503|225 235|cross-links
P08251506A0503|55 63|complexes
P08251506A0503|107 114|proteins
P08251506A0503|190 198|complexes
P08251506A0503|88 90|kDa
P08251622A0000|146 155|expression
P08251622A0000|22 27|region
P08251622A0000|101 109|sequences
P08251622A0000|33 69|Brassica napus 2S storage protein napA gene
P08251622A0000|3 10|promoter
P08252067A0917|44 46|NH2
P08252067A0917|112 123|conservation
P08252067A0917|32 38|domains
P08252067A0917|50 60|COOH termini
P08252067A0917|74 79|degree
P08252067A0917|82 91|similarity
P08252067A0917|15 25|comparisons
P08252976A0467|0 4|Rinit
P08252976A0467|108 113|system
P08252976A0467|39 43|Rdiff
P08252976A0467|25 35|resistances
P08252976A0467|83 102|pressure dissipations
P08253386A0800|127 143|splicing complexes
P08253386A0800|194 212|branch site sequences
P08253386A0800|167 177|interaction
P08253386A0800|112 119|assembly
P08253386A0800|17 25|mechanism
P08253386A0800|183 189|U2 snRNP
P08253386A0800|81 89|SE element
P08253386A0800|39 65|fibronectin splicing enhancer
P08253386A0800|28 33|action
P08253387A0801|89 93|TCF-2
P08253387A0801|12 26|enhancer mutants
P08253387A0801|169 172|site
P08253387A0801|39 54|trans-activation
P08253387A0801|178 185|enhancer
P08253387A0801|57 65|hLEF/GAL4
P08253387A0801|137 145|sequences
P08253387A0801|119 125|protein
P08253387A0801|0 9|Inspection
P08253387A1291|14 22|sequences
P08253387A1291|142 145|hLEF
P08253387A1291|52 55|cell
P08253387A1291|76 85|activation
P08253387A1291|123 134|interactions
P08253387A1291|91 106|TCR alpha enhancer
P08253387A1291|169 175|factors
P08253387A1291|35 44|hLEF HMG box
P08253387A1291|190 197|enhancer
P08253777A0301|130 135|manner
P08253777A0301|105 107|Kv1
P08253777A0301|77 80|cAMP
P08253777A0301|25 39|consensus signal
P08253777A0301|110 113|gene
P08253777A0301|21 23|CRE
P08253777A0301|93 102|expression
P08253777A0301|70 75|region
P08253777A0301|1 19|cAMP response element
P08253958A0000|74 93|serum immunoglobulin G
P08253958A0000|95 97|IgG
P08253958A0000|47 58|Helicobacter
P08253958A0000|37 44|presence
P08253958A0000|20 24|tests
P08253958A0000|1 6|number
P08254738A0428|131 135|TS677
P08254738A0428|103 112|activities
P08254738A0428|88 93|origin
P08254738A0428|190 197|T antigen
P08254738A0428|51 63|baculoviruses
P08254738A0428|20 28|T antigens
P08254738A0428|6 11|series
P08254738A0428|66 73|Sf9 cells
P08254738A0428|119 123|TS677
P08254738A0428|161 175|T-antigen kinase
P08255022A0827|60 60|%
P08255022A0827|62 64|V25
P08255022A0827|11 23|hypoperfusion
P08255022A0827|75 82|increase
P08255022A0827|3 8|degree
P08255022A0827|96 106|blood volume
P08255022A0827|123 137|blood cell counts
P08255022A0827|54 57|FEV1
P08255022A0827|68 71|PaO2
P08255341A0554|87 96|diloxanide
P08255341A0554|106 115|amoebicide
P08255341A0554|39 49|combination
P08255341A0554|52 64|metronidazole
P08255341A0554|67 82|tissue amoebicide
P08255341A0554|3 10|patients
P08255758A0000|131 143|homeoproteins
P08255758A0000|35 40|region
P08255758A0000|61 75|retrotransposon
P08255758A0000|88 90|LTR
P08255758A0000|93 100|sequence
P08255758A0000|119 128|regulation
P08257666A0662|71 73|IHA
P08257666A0662|60 68|afferents
P08257666A0662|97 102|effect
P08257666A0662|12 16|study
P08257666A0662|119 137|learning performance
P08257666A0662|77 78|HD
P08257666A0662|52 57|source
P08257666A0662|18 24|lesions
P08257666A0662|30 39|OPT complex
P08257754A0711|30 36|results
P08257754A0711|9 12|dose
P08257754A0711|125 136|HB antibodies
P08257754A0711|115 115|%
P08257754A0711|88 92|IU/ml
P08257754A0711|46 56|individuals
P08257754A0711|107 110|ones
P08257754A0711|148 152|IU/ml
P08257754A0711|42 42|%
P08257754A0711|61 72|HB antibodies
P08258025A1131|0 10|CONCLUSIONS
P08258025A1131|70 72|age
P08258025A1131|109 115|disease
P08258025A1131|37 41|range
P08258025A1131|135 141|factors
P08258025A1131|17 24|patients
P08258025A1131|44 61|treatment variables
P08258025A1131|74 87|Karnofsky index
P08258025A1131|158 166|mortality
P08259650A0640|0 25|Nucleotide sequence analysis
P08259650A0640|47 53|mutants
P08259650A0640|66 67|HA
P08259650A0640|31 36|HA gene
P08259650A0640|69 77|phenotype
P08260635A0926|28 35|position
P08260635A0926|102 111|GAPDH genes
P08260635A0926|113 116|GapA
P08260635A0926|69 88|transit peptide region
P08260635A0926|133 138|plants
P08260635A0926|57 62|intron
P08260635A0926|120 123|GapB
P08260635A0926|4 9|intron
P08261398A0392|72 90|alpha mRNA transcript
P08261398A0392|39 48|P388/ADR/7
P08261398A0392|66 69|topo
P08261398A0392|93 100|addition
P08261398A0392|112 121|transcript
P08261398A0392|148 161|P388/4 cell line
P08261398A0392|17 35|cell lines P388/ADR/3
P08261398A0838|29 32|cDNA
P08261398A0838|112 122|transcripts
P08261398A0838|37 44|strategy
P08261398A0838|58 62|cDNAs
P08261398A0838|131 140|P388/ADR/3
P08261398A0838|81 87|termini
P08261398A0838|144 158|P388/ADR/7 cells
P08261398A0838|14 26|amplification
P08262041A0727|25 38|phosphoprotein
P08262041A0727|43 48|extent
P08262041A0727|89 97|cell cycle
P08262041A0727|54 68|phosphorylation
P08262041A0727|3 14|phi AP3 factor
P08262054A0565|117 120|copy
P08262054A0565|152 156|motif
P08262054A0565|126 136|Tyr-X-X-Leu
P08262054A0565|92 96|virus
P08262054A0565|180 183|role
P08262054A0565|69 73|LMP2A
P08262054A0565|186 204|B cell transformation
P08262054A0565|51 67|membrane protein 2A
P08262054A0565|98 100|EBV
P08262054A0565|34 39|domain
P08262067A1608|95 98|link
P08262067A1608|134 146|establishment
P08262067A1608|73 84|cell polarity
P08262067A1608|164 183|cell wall biosynthesis
P08262067A1608|13 20|homology
P08262067A1608|64 70|control
P08262067A1608|23 26|Cwg2
P08262067A1608|149 160|cell polarity
P08262067A1608|122 127|events
P08262067A1608|31 35|Cdc43
P08263933T0000|42 70|cyanobacterium Synechocystis sp
P08263933T0000|25 34|ATPase gene
P08263933T0000|9 15|cloning
P08264579A1209|3 9|cloning
P08264579A1209|62 77|characterization
P08264579A1209|12 15|PTR2
P08264579A1209|91 110|peptide transport gene
P08264579A1209|34 40|example
P08264582A0750|147 163|amino acid residues
P08264582A0750|109 122|point mutations
P08264582A0750|166 169|LIFR
P08264582A0750|79 87|deletions
P08264582A0750|32 37|domain
P08264582A0750|182 187|region
P08264582A0750|97 105|deletions
P08264582A0750|200 208|signaling
P08264582A0750|41 47|mutants
P08264583A0520|98 106|cell lines
P08264583A0520|51 58|extracts
P08264583A0520|23 27|basis
P08264583A0520|124 130|ability
P08264583A0520|137 157|test plasmid substrates
P08264583A0520|33 35|end
P08264583A0520|80 86|variety
P08264591A1190|58 62|TFIIB
P08264591A1190|204 211|proteins
P08264591A1190|178 188|interaction
P08264591A1190|75 86|determinants
P08264591A1190|31 37|subunit
P08264591A1190|89 119|transcription start site selection
P08264591A1190|152 159|function
P08264591A1190|5 8|data
P08264591A1190|40 52|RNA polymerase
P08264617A0000|103 108|events
P08264617A0000|53 69|NIH 3T3 fibroblasts
P08264617A0000|123 146|ErbB-3 signal transduction
P08264617A0000|32 40|EGFR/ErbB
P08264617A0000|11 20|expression
P08264617A0000|151 166|ligand activation
P08264617A0000|43 50|receptor
P08264628A0418|0 25|Oligonucleotide competitors
P08264628A0418|83 88|TIF-IB
P08264628A0418|77 80|site
P08264628A0418|90 94|TFIID
P08264628A0418|47 59|accessibility
P08264628A0418|99 104|TFIIIB
P08264631A0746|99 119|ADH2 promoter sequences
P08264631A0746|56 58|TAD
P08264631A0746|26 37|ADR1 activity
P08264631A0746|13 18|region
P08264631A0746|68 71|ADR1
P08264631A0746|73 86|ADR1 DNA binding
P08264650A0925|0 7|Analysis
P08264650A0925|131 137|meiosis
P08264650A0925|28 43|mds1 null mutation
P08264650A0925|10 16|strains
P08264650A0925|60 63|MDS1
P08264650A0925|100 105|growth
P08264664A0128|42 57|AP-1 binding sites
P08264664A0128|79 87|promoters
P08264664A0128|8 17|expression
P08264664A0128|94 97|gene
P08264664A0128|0 6|TGF beta
P08265602T0000|0 2|Val
P08265602T0000|6 17|Ala mutations
P08265602T0000|79 97|phage M13 coat protein
P08265602T0000|57 76|transmembrane segment
P08265602T0000|45 51|packing
P08265955T0000|20 22|NHS
P08265955T0000|9 14|change
P08267658A0391|72 76|MgSO4
P08267658A0391|47 47|K
P08267658A0391|114 125|preservation
P08267658A0391|128 141|rat hepatocytes
P08267658A0391|52 63|lactobionate
P08267658A0391|65 70|KH2PO4
P08267658A0391|18 25|solution
P08267658A0391|80 88|raffinose
P08267658A0391|152 171|drug transport studies
P08267658A0391|147 148|hr
P08267658A0391|30 31|UW
P08267667A0748|30 34|mg/kg
P08267667A0748|246 246|F
P08267667A0748|298 313|h memory retention
P08267667A0748|315 315|F
P08267667A0748|24 27|GRg2
P08267667A0748|155 155|d
P08267667A0748|177 177|F
P08267667A0748|389 389|F
P08267667A0748|157 175|learning acquisition
P08267667A0748|401 401|p
P08267667A0748|372 387|h memory retrieval
P08267667A0748|189 189|p
P08267667A0748|327 327|p
P08267667A0748|123 126|rate
P08267667A0748|258 258|p
P08267667A0748|8 21|administration
P08267667A0748|87 94|deficits
P08267667A0748|227 244|h memory acquisition
P08268718A0676|47 55|complexes
P08268718A0676|38 40|p50
P08268718A0676|5 15|bcl3 protein
P08268833T0000|14 19|action
P08268833T0000|35 43|Sandimmun
P08268833T0000|22 33|cyclosporin A
P08268833T0000|49 59|application
P08268833T0000|72 80|arthritis
P08268912A0657|71 77|protein
P08268912A0657|53 55|RNA
P08268912A0657|83 90|mobility
P08268912A0657|7 28|translation experiments
P08268912A0657|102 122|SDS polyacrylamide gels
P08268912A0657|42 45|cDNA
P08268912A0657|98 99|kD
P08269424A0339|15 28|administration
P08269424A0339|83 91|tumor side
P08269424A0339|45 54|ACTH levels
P08269424A0339|35 37|CRF
P08269424A0339|41 43|TRH
P08269424A0339|97 104|patients
P08269439X0000|29 33|niche
P08269439X0000|112 115|pain
P08269439X0000|11 19|analgesia
P08269439X0000|89 98|management
P08269439X0000|37 44|Talwin Nx
P08269439X0000|78 82|agent
P08269439X0000|46 56|Pentazocine
P08270257A0551|100 109|boundaries
P08270257A0551|141 147|species
P08270257A0551|50 60|homolog gene
P08270257A0551|37 43|nm23-H1
P08270257A0551|66 68|rat
P08270257A0551|1 24|sequence homology analysis
P08270257A0551|70 78|NDP-K beta
P08270580A0155|64 76|cotrimoxazole
P08270580A0155|11 18|response
P08270580A0155|48 60|amphotericin B
P08270580A0155|35 45|combination
P08270985A0590|0 16|Response durations
P08273122A0708|176 196|component transfusions
P08273122A0708|27 38|QA/QI process
P08273122A0708|93 100|variance
P08273122A0708|52 79|blood administration practices
P08273122A0708|168 172|blood
P08273122A0708|13 21|beginning
P08273122A0708|159 165|percent
P08273122A0708|40 49|monitoring
P08273122A0708|0 6|RESULTS
P08273122A0708|118 142|blood administration policy
P08274774A0958|116 126|mosaic virus
P08274774A0958|53 57|range
P08274774A0958|11 21|REP21 plants
P08274774A0958|154 164|mosaic virus
P08274774A0958|128 133|TMV-U5
P08274774A0958|140 145|tomato
P08274774A0958|82 98|tomato mosaic virus
P08274774A0958|169 187|ribgrass mosaic virus
P08274774A0958|60 72|tobamoviruses
P08274774A0958|2 9|addition
P08274774A0958|100 106|tobacco
P08275618A0457|0 9|Drug effect
P08275618A0457|225 232|patients
P08275618A0457|105 109|ratio
P08275618A0457|237 245|cirrhosis
P08275618A0457|112 121|effect area
P08275618A0457|162 166|curve
P08275618A0457|137 153|concentration area
P08275618A0457|130 134|curve
P08275618A0457|178 188|sensitivity
P08275618A0457|53 60|patients
P08275618A0457|169 175|measure
P08275618A0457|65 73|cirrhosis
P08275618A0457|84 91|subjects
P08275618A0457|259 266|subjects
P08276234A0119|130 141|DNA structure
P08276234A0119|78 85|activity
P08276234A0119|21 23|YY1
P08276234A0119|9 16|evidence
P08276234A0119|91 103|c-fos promoter
P08276234A0119|58 64|protein
P08276234A0119|122 127|effect
P08276336A0371|59 66|patients
P08276336A0371|85 96|relationship
P08276336A0371|130 135|polyps
P08276336A0371|41 53|colonoscopies
P08276336A0371|16 23|analysis
P08276732A0799|82 95|susceptibility
P08276732A0799|9 17|decrement
P08276732A0799|20 33|DPOAE amplitude
P08276732A0799|109 114|trauma
P08276732A0799|73 79|measure
P08276732A0799|49 58|time period
P08276732A0799|3 6|rate
P08276762T0000|14 30|base substitutions
P08276762T0000|33 48|glycine-870 codon
P08276762T0000|79 95|proline activation
P08276762T0000|51 71|gramicidin S synthetase
P08276762T0000|73 76|gene
P08276762T0000|0 5|Effect
P08276851A0347|120 127|proteins
P08276851A0347|80 92|relationships
P08276851A0347|55 61|domains
P08276851A0347|12 24|Pay4p sequence
P08276851A0347|148 156|processes
P08276851A0347|257 266|regulation
P08276851A0347|205 220|protein transport
P08276851A0347|222 237|cell cycle control
P08276851A0347|178 187|biogenesis
P08276854A1894|83 102|proteoglycan promoter
P08276854A1894|21 29|structure
P08276854A1894|139 152|pur/pyr segment
P08276854A1894|3 9|results
P08276854A1894|168 177|regulation
P08276854A1894|35 53|decorin gene promoter
P08276854A1894|159 162|role
P08276854A1894|180 196|gene transcription
P08276865A1188|73 78|growth
P08276865A1188|115 123|MAP kinase
P08276865A1188|94 103|activation
P08276865A1188|106 111|p21ras
P08276865A1188|176 186|LPA receptor
P08276865A1188|189 204|p21ras activation
P08276865A1188|153 165|protein kinase
P08276865A1188|3 30|kinase inhibitor staurosporine
P08276865A1188|33 38|microM
P08276871A1001|33 40|identity
P08276871A1001|50 50|%
P08276871A1001|77 85|% identity
P08276871A1001|106 118|transmembrane
P08276871A1001|133 139|domains
P08276900A0543|0 1|S.
P08276900A0543|3 4|K.
P08277632A0997|3 14|survival rate
P08277632A0997|32 39|patients
P08277632A0997|22 27|months
P08277632A0997|65 76|R2b operation
P08277632A0997|44 52|N2 disease
P08277632A0997|82 82|%
P08278423A0147|0 6|Mothers
P08278423A0147|78 85|children
P08278423A0147|106 129|disaccharide intolerances
P08278423A0147|27 39|abnormalities
P08278423A0147|47 49|HIV
P08278423A0147|69 70|TB
P08278480T0002|0 1|G.
P08278548A0597|13 16|psaH
P08278548A0597|152 159|isoforms
P08278548A0597|8 11|psaF
P08278548A0597|21 32|psaL products
P08278548A0597|134 144|psaE product
P08278548A0597|83 92|mobilities
P08278548A0597|95 126|polyacrylamide gel electrophoresis
P08278548A0597|3 6|psaD
P08278548A0597|40 47|isoforms
P08278929A0866|168 175|controls
P08278929A0866|48 49|ml
P08278929A0866|73 77|ml CRS
P08278929A0866|62 64|CRS
P08278929A0866|177 177|P
P08278929A0866|10 24|SPF type V embryos
P08278929A0866|136 136|%
P08278929A0866|52 59|% ethanol
P08278929A0866|118 129|VSD incidence
P08278929A0866|104 110|embryos
P08278929A0866|79 86|controls
P08278929A0866|153 162|% incidence
P08279098T0001|42 55|myopia patients
P08279098T0001|29 39|dystrophies
P08280476A0602|127 130|site
P08280476A0602|35 56|HIV-1 Z2Z6 core enhancers
P08280476A0602|87 99|point mutation
P08280476A0602|23 31|HIV-1 HXB2
P08280476A0602|5 11|studies
P08280476A0602|67 76|Z2Z6 strain
P08280925A0261|116 121|groups
P08280925A0261|153 155|IgM
P08280925A0261|53 63|C57Bl/6 mice
P08280925A0261|38 46|responses
P08280925A0261|123 133|differences
P08280925A0261|104 107|mice
P08280925A0261|79 82|mice
P08280925A0261|170 179|antibodies
P08280925A0261|159 161|IgG
P08281153A0543|84 90|species
P08281153A0543|25 30|degree
P08281153A0543|33 44|conservation
P08281153A0543|47 61|intron sequences
P08281536A0626|0 12|Interleukin-6
P08281536A0626|53 58|myxoma
P08281536A0626|34 43|metastasis
P08281634A1801|17 30|iron metabolism
P08281634A1801|41 48|ferritin
P08281634A1801|79 82|risk
P08281634A1801|5 14|parameters
P08281740A0000|14 39|Plowright Rinderpest vaccine
P08281740A0000|147 156|ELISA assay
P08281740A0000|103 115|IgG antibodies
P08281740A0000|60 65|cattle
P08281740A0000|44 49|calves
P08281740A0000|91 100|production
P08281740A0000|134 138|weeks
P08281740A0000|68 73|Uganda
P08281740A0000|0 8|Responses
P08282501A0358|159 165|grade-2
P08282501A0358|169 175|grade-3
P08282501A0358|110 120|differences
P08282501A0358|80 90|conclusions
P08282501A0358|183 188|events
P08282501A0358|33 53|angiography procedures
P08282501A0358|17 22|number
P08282501A0358|144 149|agents
P08282576A0297|0 6|Tumours
P08282576A0297|24 33|oropharynx
P08282576A0297|12 20|cavum oris
P08282576A0297|36 43|T1-stage
P08282576A0297|65 69|cases
P08282749A1474|128 133|arrest
P08282749A1474|79 88|myocardium
P08282749A1474|111 118|duration
P08282749A1474|59 64|demand
P08282749A1474|7 22|Hospital solution
P08282749A1474|35 38|% CO2
P08282749A1474|0 5|Thomas
P08282749A1474|30 30|%
P08283292A0779|188 199|control group
P08283292A0779|132 136|diets
P08283292A0779|123 128|groups
P08283292A0779|72 78|control
P08283292A0779|7 9|LDL
P08283292A0779|160 164|fiber
P08283292A0779|103 109|control
P08283292A0779|13 42|liver cholesterol concentrations
P08283292A0779|0 5|Plasma
P08283292A0779|147 152|pectin
P08283531A0700|101 112|localization
P08283531A0700|157 162|gantry
P08283531A0700|129 135|calculi
P08283531A0700|40 61|Dornier HM3 lithotriptor
P08283531A0700|79 91|visualization
P08283531A0700|3 26|Stryker frame modification
P08284227A0336|172 179|cultures
P08284227A0336|74 81|contrast
P08284227A0336|46 61|kb mRNA transcript
P08284227A0336|65 67|Id1
P08284227A0336|89 104|cell types Id1 mRNA
P08284227A0336|131 142|cycling cells
P08284227A0336|19 23|cells
P08284337A0825|30 40|IHD patients
P08284337A0825|152 159|patients
P08284337A0825|81 93|cardiologists
P08284337A0825|97 106|internists
P08284337A0825|66 70|means
P08284337A0825|126 131|levels
P08284337A0825|19 27|screening
P08284337A0825|134 141|distress
P08285710A0634|111 114|site
P08285710A0634|117 126|initiation
P08285710A0634|77 80|maps
P08285710A0634|49 51|RNA
P08285710A0634|53 64|blot analysis
P08285710A0634|40 47|Northern
P08285710A0634|94 95|bp
P08285710A0634|129 144|protein synthesis
P08285710A0634|13 26|transcript mRNA
P08285710A0634|84 91|position
P08286035A0587|87 89|RNA
P08286035A0587|36 40|c11/1
P08286035A0587|166 168|PCR
P08286035A0587|142 164|polymerase chain reaction
P08286035A0587|129 139|combination
P08286035A0587|79 82|poly
P08286035A0587|13 31|sequence information
P08286035A0587|59 62|cDNA
P08286035A0587|170 176|methods
P08286035A0587|112 124|transcription
P08286035A0587|84 84|A
P08286035A0587|98 102|PMNLs
P08288240A0304|3 20|sequence similarity
P08288240A0304|108 112|genes
P08288240A0304|37 41|SCG10
P08288240A0304|45 52|stathmin
P08288240A1343|87 98|modification
P08288240A1343|55 63|SCG10 gene
P08288240A1343|5 8|data
P08288240A1343|124 141|stathmin/Lap18 gene
P08288240A1343|73 83|duplication
P08288240A1343|29 32|idea
P08288554A0295|113 131|mouse BALBc/3T3 cells
P08288554A0295|64 66|p32
P08288554A0295|10 26|amino acid sequence
P08288554A0295|104 110|protein
P08288554A0295|32 44|mouse HO-1 gene
P08288596A0663|60 66|rGH-TRE
P08288596A0663|20 20|M
P08288596A0663|149 153|front
P08288596A0663|253 260|sequence
P08288596A0663|11 12|T3
P08288596A0663|43 55|transcription
P08288596A0663|134 137|TREs
P08288596A0663|71 76|TREpal
P08288596A0663|95 100|F2-TRE
P08288596A0663|159 161|rGH
P08288596A0663|238 251|binding protein
P08288596A0663|194 214|TATA box binding protein
P08288596A0663|113 121|templates
P08288596A0663|169 176|promoter
P08288596A0663|85 90|ME-TRE
P08288606A0240|185 188|gene
P08288606A0240|6 20|polymerase chain
P08288606A0240|35 42|approach
P08288606A0240|79 88|sialymotif
P08288606A0240|137 141|clone
P08288606A0240|61 72|pair fragment
P08288606A0240|130 134|probe
P08288606A0240|194 204|cDNA library
P08288606A0240|98 109|placenta mRNA
P08288606A0240|153 166|coding sequence
P08288622A0725|44 56|heterogeneity
P08288622A0725|138 157|splicing acceptor site
P08288622A0725|13 20|analysis
P08288622A0725|81 89|insertion
P08288622A0725|62 68|HDC mRNA
P08288622A0725|102 115|intron sequence
P08288622A0725|167 170|exon
P08288622A0725|130 132|use
P08288633A0144|191 203|protein region
P08288633A0144|240 247|proteins
P08288633A0144|253 264|Rho subfamily
P08288633A0144|82 98|amino acid residues
P08288633A0144|65 75|polypeptide
P08288633A0144|207 209|Bcr
P08288633A0144|166 172|segment
P08288633A0144|100 104|CeGAP
P08288633A0144|120 125|domain
P08288633A0144|32 52|Caenorhabditis elegans
P08288633A0144|14 16|DNA
P08288633A0144|130 147|sequence similarity
P08289339A0527|100 101|E1
P08289339A0527|10 20|exonuclease
P08289339A0527|54 63|core region
P08289339A0527|126 134|sequences
P08289339A0527|24 33|protection
P08289339A0527|80 84|sides
P08289341A1202|72 77|copies
P08289341A1202|80 84|E2-RS
P08289341A1202|50 53|E2-C
P08289341A1202|36 37|E2
P08289341A1202|0 9|Repression
P08289342A0931|57 70|DNA replication
P08289342A0931|83 87|assay
P08289342A0931|38 40|trs
P08289342A0931|23 36|resolution site
P08289342A0931|1 6|mutant
P08289342A0931|12 14|AAV
P08289357A0724|72 79|elements
P08289357A0724|44 51|function
P08289357A0724|22 24|rep
P08289357A0724|3 9|results
P08289357A0724|85 87|LTR
P08289593A1404|116 122|vehicle
P08289593A1404|175 180|MK-801
P08289593A1404|80 90|cocaine dose
P08289593A1404|156 156|n
P08289593A1404|49 54|MK-801
P08289593A1404|133 136|rats
P08289593A1404|108 108|n
P08289593A1404|150 154|mg/kg
P08289593A1404|223 230|toxicity
P08289593A1404|262 265|rats
P08289593A1404|242 249|urethane
P08289593A1404|102 106|mg/kg
P08289593A1404|233 239|cocaine
P08289593A1404|30 33|rats
P08289783A0000|3 7|Oct-3
P08289783A0000|10 20|gene product
P08289783A0000|39 47|POU family
P08289783A0000|50 69|transcription factors
P08289783A0000|78 86|candidate
P08289783A0000|107 130|differentiation decisions
P08289783A1476|161 170|repression
P08289783A1476|81 90|activation
P08289783A1476|93 97|Oct-3
P08289783A1476|18 28|mutagenesis
P08289783A1476|190 196|EC cells
P08289783A1476|110 117|P19 cells
P08289783A1476|100 107|promoter
P08289783A1476|43 49|RAREoct
P08289784A0381|17 18|M.
P08289793A1226|122 129|enhancer
P08289793A1226|38 43|effect
P08289793A1226|105 108|stem
P08289793A1226|92 95|Oct4
P08289793A1226|81 86|effect
P08289793A1226|46 53|COUP-TFs
P08289831A0290|0 7|Analysis
P08289831A0290|10 16|mig/CAT
P08289831A0290|64 66|RAW
P08289831A0290|72 76|mouse
P08289831A0290|129 135|element
P08289831A0290|25 34|constructs
P08289831A0290|86 93|cell line
P08289831A0290|137 145|gamma RE-1
P08289834A0341|58 64|activin
P08289834A0341|68 71|bone
P08289834A0341|20 28|test cells
P08289834A0341|49 56|TGF-beta
P08289834A0341|30 34|Atr-I
P08289834A0341|85 91|protein
P08290278A0374|17 19|Mad
P08290278A0374|52 80|candidate tumor suppressor genes
P08290278A0374|10 13|Mxi1
P08290278A0374|35 45|Myc function
P08290421A0165|86 91|Alport
P08290421A0165|111 117|patient
P08290421A0165|5 13|knowledge
P08290421A0165|94 101|syndrome
P08290421A0165|33 40|acidosis
P08290421A0165|15 18|type
P08290421A0165|71 81|association
P08291233A0000|85 89|probe
P08291233A0000|117 135|Rous sarcoma virus LTR
P08291233A0000|104 111|U3 region
P08291233A0000|26 49|chicken embryo cDNA library
P08291233A0000|1 9|cDNA clone
P08291620A0372|18 34|locomotor behavior
P08291620A0372|8 15|patterns
P08291620A0372|82 92|anthropoids
P08291620A0372|51 65|torso morphology
P08291761A0416|0 8|Animal age
P08291761A0416|31 37|effects
P08291761A0416|92 94|age
P08291761A0416|12 14|sex
P08291761A0416|40 53|CSF composition
P08291761A0416|58 78|serum IgG concentration
P08291886T0024|14 22|expansion
P08293412T0000|51 62|tolerability
P08293412T0000|158 167|prevention
P08293412T0000|65 75|tropisetron
P08293412T0000|23 27|study
P08293412T0000|40 47|efficacy
P08293412T0000|145 152|cocktail
P08293412T0000|81 103|5-HT3 receptor antagonist
P08293412T0000|187 192|emesis
P08293992A0432|4 9|repeat
P08293992A0432|22 23|nt
P08293992A0432|47 54|sequence
P08293992A0432|56 61|K/NPAG
P08293993A0948|0 2|ENV
P08293993A0948|103 125|invertase signal sequence
P08293993A0948|52 84|alpha-factor prepro secretion leader
P08293993A0948|22 31|P. pastoris
P08294386A0000|0 9|BACKGROUND
P08294386A0000|73 79|authors
P08294386A0000|152 159|hospital
P08294386A0000|25 34|predictors
P08294386A0000|117 126|depression
P08294386A0000|100 107|patients
P08294386A0000|59 68|depression
P08294386A0000|174 184|desipramine
P08294386A0000|91 97|outcome
P08294386A0000|205 214|blood level
P08294429A0153|159 177|hGH promoter activity
P08294429A0153|49 50|FR
P08294429A0153|64 70|hGh cDNA
P08294429A0153|136 139|cAMP
P08294429A0153|73 104|chloramphenicol acetyltransferase
P08294429A0153|28 30|hGH
P08294429A0153|19 25|hGH gene
P08294429A0153|107 121|luciferase genes
P08294429A0153|0 7|Analysis
P08294429A0153|42 44|DNA
P08294459A0446|59 63|SAP-1
P08294459A0446|12 28|amino acid sequence
P08294459A0446|79 88|amino acids
P08294459A0446|34 42|SAP-1 cDNA
P08294459A0446|111 113|PTP
P08294459A0446|149 154|domain
P08294459A0446|171 176|region
P08294511A0639|41 47|protein
P08294511A0639|115 132|snRNP core particles
P08294511A0639|12 19|evidence
P08294511A0639|81 87|protein
P08294511A0639|150 160|interaction
P08294865A0236|43 50|mutation
P08294865A0236|24 28|cells
P08294865A0236|78 86|formation
P08294865A0236|7 14|features
P08294865A0236|89 107|peptide/DR complexes
P08294906A1315|118 126|substrate
P08294906A1315|63 71|aspartate
P08294906A1315|130 138|transport
P08294906A1315|105 114|amino acids
P08294906A1315|34 59|neurotransmitters glutamate
P08294906A1315|4 15|distribution
P08296434A1141|74 82|treatment
P08296434A1141|105 113|condition
P08296434A1141|62 70|diagnosis
P08296434A1141|50 56|adjunct
P08296434A1141|3 18|Harleco apparatus
P08297376A0236|0 14|Co-transfection
P08297376A0236|168 173|region
P08297376A0236|80 88|C/EBP beta
P08297376A0236|66 70|C/EBP
P08297376A0236|37 64|CCAAT/enhancer binding protein
P08297376A0236|144 152|sequences
P08297376A0236|107 138|rat uncoupling protein gene promoter
P08297376A0236|72 76|alpha
P08297376A0236|17 33|expression vectors
P08298129A0274|85 96|gene promoter
P08298129A0274|49 58|expression
P08298129A0274|65 68|gene
P08298129A0274|80 83|beta
P08298129A0274|26 30|basis
P08298129T0000|0 8|Isolation
P08298129T0000|40 47|promoter
P08298129T0000|12 27|characterization
P08298129T0000|64 75|integrin gene
P08298129T0000|59 62|beta
P08299181A1148|70 72|eye
P08299181A1148|38 40|eye
P08299181A1148|76 79|eyes
P08299181A1148|10 14|fluid
P08299181A1148|85 85|%
P08299181A1148|54 54|%
P08299181A1148|45 48|eyes
P08299568A1401|71 81|stimulation
P08299568A1401|21 30|activation
P08299568A1401|38 44|enzymes
P08299568A1401|5 8|data
P08299568A1401|84 99|glucose transport
P08299725A0724|98 108|readthrough
P08299725A0724|110 113|form
P08299725A0724|11 16|region
P08299725A0724|51 56|muscle
P08299725A0724|35 40|intron
P08299725A0724|122 129|residues
P08299725A0724|74 87|tumor cell lines
P08299725A0724|146 148|end
P08299725A0724|43 47|brain
P08299896A0626|0 10|Concordance
P08299896A0626|13 22|IBDQ scores
P08299896A0626|43 50|subjects
P08299896A0880|0 19|Regression line slopes
P08299896A0880|111 111|b
P08299896A0880|22 31|IBDQ scores
P08299896A0880|119 119|P
P08299896A0880|60 67|patients
P08300463A0581|15 25|Albendazole
P08300463A0581|126 130|cases
P08300463A0581|49 57|treatment
P08300463A0581|60 77|neurocysticercosis
P08300463A0581|172 176|cases
P08300463A0581|135 139|drugs
P08300463A0581|102 108|effects
P08300463A0581|0 11|Praziquantel
P08300527T0000|0 9|Inhibition
P08300527T0000|35 44|disruption
P08300527T0000|12 32|erythromycin synthesis
P08300527T0000|47 84|malonyl-coenzyme A decarboxylase gene eryM
P08300527T0000|87 112|Saccharopolyspora erythraea
P08300601A0745|70 89|E12/MyoD heterodimers
P08300601A0745|35 44|DNA binding
P08300601A0745|47 50|MyoD
P08300601A0745|23 32|activation
P08300601A0745|54 66|E12 homodimers
P08300601A0745|4 9|region
P08300605A0432|99 107|silk gland
P08300605A0432|34 48|deletion mutants
P08300605A0432|124 135|instar larvae
P08300605A0432|179 186|elements
P08300605A0432|26 31|series
P08300605A0432|147 154|presence
P08300605A0432|54 57|gene
P08300605A0432|224 237|initiation site
P08300605A0432|15 22|analysis
P08300605A0432|70 77|extracts
P08300605A0671|41 47|element
P08300605A0671|79 88|regulation
P08300605A0671|10 17|elements
P08300611A0341|43 46|gene
P08300611A0341|13 23|mutagenesis
P08300611A0341|155 171|amino acid residues
P08300611A0341|134 143|importance
P08300611A0341|50 60|application
P08300611A0341|77 88|TraI proteins
P08300611A0341|29 32|traI
P08300611A0341|99 104|assays
P08300611T0000|89 92|TraI
P08300611T0000|107 116|plasmid RP4
P08300611T0000|61 68|reaction
P08300611T0000|80 87|relaxase
P08300611T0000|9 14|action
P08300611T0000|30 36|domains
P08300611T0000|42 44|DNA
P08300625A1352|61 75|peptide sequence
P08300625A1352|110 121|slyD function
P08300625A1352|26 29|slyD
P08300625A1352|134 138|lysis
P08300625A1352|18 23|codons
P08301702A1083|86 95|microsomes
P08301702A1083|153 157|heron
P08301702A1083|115 123|cormorant
P08301702A1083|12 21|antibodies
P08301702A1083|179 192|immunoblotting
P08301702A1083|67 73|protein
P08301702A1083|35 55|rat cytochrome P-450 1A1
P08301841A0000|15 28|enzyme activity
P08301841A0000|56 65|infarction
P08301841A0000|31 35|serum
P08301841A0000|67 69|AMI
P08301841A0000|82 95|angina pectoris
P08301841A0000|97 99|UAP
P08302589A1132|14 25|cell motility
P08302589A1132|103 114|phorbol ester
P08302589A1132|128 136|ionophore
P08302589A1132|124 126|Ca2
P08302589A1132|78 90|protein kinase
P08303233A0313|2 9|addition
P08303233A0313|75 78|text
P08303233A0313|50 57|identity
P08303233A0313|18 24|priming
P08304301A0331|0 6|METHODS
P08304301A0331|47 53|nodules
P08304301A0331|67 77|examination
P08304301A0331|106 109|HCCs
P08304301A0331|18 22|cases
P08304301A0331|56 58|HCC
P08304342A0605|132 137|probes
P08304342A0605|21 43|hemochromatosis families
P08304342A0605|194 202|HLA-F loci
P08304342A0605|93 103|chromosomes
P08304342A0605|12 17|report
P08304342A0605|174 180|markers
P08304342A0605|55 80|hemochromatosis chromosomes
P08304342A0605|123 129|battery
P08304342A0605|219 220|kb
P08304342A0605|232 236|HLA-A
P08305058T0000|0 11|Pneumothorax
P08305058T0000|58 63|hiatus
P08305058T0000|30 39|dissection
P08306356A0000|44 47|rats
P08306356A0000|63 68|X-rays
P08306356A0000|57 60|dose
P08306356A0000|93 96|days
P08306356A0000|103 111|gestation
P08306356A0000|17 29|malformations
P08306356A0000|73 75|cGy
P08306834A0866|0 8|T2 cancers
P08306834A0866|35 41|benefit
P08306834A0866|56 66|irradiation
P08306959A0278|0 7|IFN alpha
P08306959A0278|11 30|IFN gamma inducibility
P08306959A0278|89 95|version
P08306959A0278|101 122|IFN gamma activation site
P08306959A0278|50 56|element
P08306959A0278|124 126|GAS
P08306959A0278|63 70|affinity
P08307338A0227|0 8|Mutations
P08307338A0227|54 59|result
P08307338A0227|62 72|degradation
P08307338A0227|109 111|cob
P08307338A0227|125 129|cells
P08307338A0227|113 115|RNA
P08307338A0227|21 28|gene CBP1
P08307338A0227|97 107|cytochrome b
P08307564A0233|57 62|contig
P08307564A0233|27 31|sites
P08307564A0233|65 71|density
P08307564A0233|94 95|kb
P08307564A0233|33 36|STSs
P08308008A0201|29 35|binding
P08308008A0201|51 57|protein
P08308008A0201|101 104|unit
P08308008A0201|133 142|activation
P08308008A0201|6 10|paper
P08308008A0201|66 82|ets sequence motifs
P08308008A0201|148 160|COXIV promoter
P08308008A0201|59 62|GABP
P08309726A0000|237 244|patients
P08309726A0000|342 345|ARDS
P08309726A0000|252 255|ARDS
P08309726A0000|108 120|relationships
P08309726A0000|187 189|PMN
P08309726A0000|213 220|severity
P08309726A0000|129 144|activation status
P08309726A0000|77 80|ARDS
P08309726A0000|268 276|pneumonia
P08309726A0000|349 357|pneumonia
P08309726A0000|323 330|patients
P08309726A0000|192 205|cytokine levels
P08309726A0000|13 19|insight
P08309726A0000|223 232|lung injury
P08309726A0000|60 75|distress syndrome
P08309726A0000|86 92|authors
P08309726A0000|175 185|neutrophils
P08309726A0000|27 38|pathogenesis
P08309726A0000|292 295|ARDS
P08309912A0306|0 9|Amiodarone
P08309912A0306|70 73|drug
P08309912A0306|33 41|treatment
P08309953A0776|120 134|characteristics
P08309953A0776|27 53|dopamine receptor stimulation
P08309953A0776|140 159|reaction time response
P08309953A0776|108 114|effects
P08309953A0776|65 80|dopamine agonists
P08309953A0776|5 11|results
P08309953A0776|99 105|pattern
P08309957A0000|3 13|experiments
P08309957A0000|114 127|agent reserpine
P08309957A0000|76 89|administration
P08309957A0000|65 68|rats
P08309957A0000|44 55|jaw movements
P08309975A0662|0 8|Depletion
P08309975A0662|134 141|increase
P08309975A0662|24 39|nucleus accumbens
P08309975A0662|11 18|dopamine
P08309975A0662|61 68|behavior
P08309975A0662|157 163|lab chow
P08309975A0662|144 154|consumption
P08309975A0662|106 110|lever
P08309975A0662|54 58|shift
P08309975A0662|96 103|decrease
P08312243A0177|86 87|Cu
P08312243A0177|21 29|influence
P08312243A0177|105 108|rats
P08312243A0177|91 102|Ca metabolism
P08312243A0177|165 169|diets
P08312243A0177|38 41|EDTA
P08312243A0177|83 84|Zn
P08312243A0177|32 36|NaFe3
P08312243A0177|65 70|levels
P08312243A0177|73 79|Na2EDTA
P08312243A0177|114 126|Zn-sufficient
P08314163T0000|0 7|Recovery
P08314163T0000|119 132|administration
P08314163T0000|110 117|rhGM-CSF
P08314163T0000|86 108|colony stimulating factor
P08314163T0000|29 43|agranulocytosis
P08314922A0941|69 80|brain surface
P08314922A0941|8 13|system
P08314922A0941|46 61|perfusion changes
P08314922A0941|92 103|tissue damage
P08316100A0586|43 47|range
P08316100A0586|12 19|Richards
P08316100A0586|50 56|factors
P08316100A0586|124 132|influence
P08316100A0586|22 27|theory
P08316100A0586|160 165|theory
P08316100A0586|3 9|neglect
P08316209A0000|144 159|sulfur catabolism
P08316209A0000|81 90|expression
P08316209A0000|55 70|Neurospora crassa
P08316209A0000|40 46|protein
P08316209A0000|135 141|enzymes
P08316209A0000|94 99|family
P08316209A0000|24 29|sulfur
P08316209A0000|48 51|CYS3
P08316209A0000|120 124|genes
P08316240A1068|204 208|yeast
P08316240A1068|70 83|hexamer element
P08316240A1068|57 64|presence
P08316240A1068|94 112|MluI restriction site
P08316240A1068|178 194|DNA synthesis genes
P08316240A1068|140 149|expression
P08316240A1068|41 45|CHL15
P08316240A1068|163 172|regulation
P08316240A1068|33 38|region
P08316240A1068|85 90|ACGCGT
P08316240A1068|0 7|Analysis
P08317092A0304|59 71|helicase motif
P08317092A0304|204 209|tobamo
P08317092A0304|89 94|region
P08317092A0304|13 18|region
P08317092A0304|98 115|RNA polymerase motif
P08317092A0304|31 37|protein
P08317092A0304|167 187|RNA replication complex
P08317092A0304|150 157|proteins
P08317092A0304|214 225|tobraviruses
P08317094A0778|97 104|promoter
P08317094A0778|18 28|transcripts
P08317094A0778|110 111|nt
P08317094A0778|73 74|nt
P08317094A0778|11 13|F3R
P08317094A0778|44 44|A
P08317094A0778|65 69|TAAAG
P08317094A0778|5 8|ends
P08317094A0778|127 141|initiation codon
P08317094A0778|54 61|sequence
P08319396A0448|230 237|peduncle
P08319396A0448|125 138|intensity areas
P08319396A0448|101 109|tegmentum
P08319396A0448|178 181|limb
P08319396A0448|90 96|capsule
P08319396A0448|12 17|images
P08319396A0448|41 48|thalamus
P08319396A0448|73 76|limb
P08319396A0448|213 216|part
P08319396A0448|22 35|intensity areas
P08319396A0448|53 60|striatum
P08319396A0448|147 164|cerebellar peduncle
P08319396A0448|195 201|capsule
P08319396A0448|2 3|T2
P08319396A0448|258 263|matter
P08319907A0754|156 164|structure
P08319907A0754|149 152|size
P08319907A0754|39 43|cells
P08319907A0754|137 143|changes
P08319907A0754|180 184|tract
P08319907A0754|8 19|rap1t alleles
P08319907A0754|94 116|telomere position effects
P08319907A0754|59 78|telomere tract lengths
P08320120A0361|75 85|capillaries
P08320120A0361|10 24|microangiopathy
P08320120A0361|49 54|fields
P08320120A0361|177 183|nodules
P08320120A0361|112 120|diffusion
P08320120A0361|168 171|area
P08320120A0361|123 139|sodium fluorescein
P08321199T0000|62 68|factors
P08321199T0000|93 101|silencing
P08321199T0000|10 18|switching
P08321199T0000|107 114|HMR locus
P08321199T0000|78 90|establishment
P08321199T0000|36 41|states
P08321199T0000|43 45|cis
P08321203A0840|0 11|NF-kappa B p65
P08321203A0840|72 81|C/EBP delta
P08321203A0840|20 22|Rel
P08321203A0840|48 57|C/EBP alpha
P08321203A0840|59 67|C/EBP beta
P08321203A0840|13 15|p50
P08321227A0854|33 45|culture medium
P08321227A0854|64 71|COS cells
P08321741A0396|257 257|%
P08321741A0396|115 122|Myelosis
P08321741A0396|8 12|group
P08321741A0396|235 246|increase-CML
P08321741A0396|187 187|%
P08321741A0396|25 27|BMB
P08321741A0396|194 201|patients
P08321741A0396|56 68|myelofibrosis
P08321741A0396|214 216|CML
P08321741A0396|166 182|Metaplasia-AMM-in
P08321741A0396|46 53|progress
P08322117A1019|28 35|patients
P08322117A1019|111 124|Sussett formula
P08322117A1019|99 103|cmH2O
P08322117A1019|80 84|cmH2O
P08322117A1019|6 12|methods
P08322117A1019|147 153|centile
P08322117A1019|155 160|cutoff
P08322117A1019|55 63|pressures
P08322823A0839|15 25|correlation
P08322823A0839|36 38|MFA
P08322823A0839|45 52|severity
P08322823A0839|58 69|UTS phenotype
P08323294T0000|0 49|Chicken sterol carrier protein 2/sterol carrier protein x
P08323294T0000|95 103|structure
P08323294T0000|116 125|expression
P08323294T0000|51 61|cDNA cloning
P08323294T0000|81 92|conservation
P08324107A0000|73 85|plasma protein
P08324107A0000|40 43|g/dl
P08324107A0000|12 31|albumin concentration
P08324107A0000|62 62|%
P08324280A0098|72 81|ulceration
P08324280A0098|5 11|lesions
P08324792T0000|17 22|period
P08324792T0000|36 41|pacing
P08324792T0000|76 86|rabbit heart
P08324792T0000|54 64|infarct size
P08325504A0226|14 30|RD21 mRNA synthesis
P08325504A0226|7 10|RD19
P08325504A0226|54 63|heat stress
P08325639A0129|203 211|ubiquitin
P08325639A0129|8 14|studies
P08325639A0129|65 67|26S
P08325639A0129|79 85|complex
P08325639A0129|175 183|breakdown
P08325639A0129|56 59|core
P08325639A0129|31 43|20S proteasome
P08325639A0129|120 137|proteinase activity
P08325639A0129|186 193|proteins
P08325720A0840|181 181|%
P08325720A0840|55 62|exercise
P08325720A0840|192 211|muscle buffer capacity
P08325720A0840|5 11|deficit
P08325720A0840|64 83|muscle enzyme activity
P08325720A0840|184 189|fibres
P08325720A0840|133 152|lactate dehydrogenase
P08325720A0840|85 99|citrate synthase
P08325720A0840|163 179|muscle capillaries
P08325720A0840|155 160|number
P08325720A0840|101 131|3-hydroxyacyl-CoA-dehydrogenase
P08325720A0840|27 38|blood lactate
P08325883A0368|56 74|RNA recognition motif
P08325883A0368|164 176|alpha-helixes
P08325883A0368|115 120|region
P08325883A0368|138 143|region
P08325883A0368|79 96|glutamine stretches
P08325883A0368|24 34|RBP1 protein
P08325883A0368|3 10|sequence
P08325883A0368|46 51|copies
P08327488A0839|195 197|p70
P08327488A0839|12 14|RNA
P08327488A0839|108 119|helper genome
P08327488A0839|38 40|p70
P08327488A0839|25 32|deletion
P08327488A0839|47 52|region
P08327488A0839|170 172|RNA
P08331064A0440|58 67|resolution
P08331064A0440|84 93|structures
P08331064A0440|22 29|pressure
P08331064A0440|43 45|way
P08331064A0440|0 6|Release
P08331067T0000|88 93|endo-N
P08331067T0000|118 124|homolog
P08331067T0000|8 25|nucleotide sequence
P08331067T0000|127 143|bacteriophage PK1E
P08331067T0000|63 86|endo-N-acylneuraminidase
P08331067T0000|98 107|comparison
P08331067T0000|31 54|bacteriophage K1F tail gene
P08331728A0686|0 6|Binding
P08331728A0686|23 39|ribonucleoprotein
P08331728A0686|9 10|U2
P08332033T0000|90 99|assessment
P08332033T0000|85 88|mice
P08332033T0000|69 82|micro-infarcts
P08332033T0000|14 27|quantification
P08332033T0000|30 39|brain edema
P08332033T0000|102 118|neurotropin effect
P08332492A0145|87 92|target
P08332492A0145|24 29|family
P08332492A0145|128 132|HIV-1
P08332492A0145|101 125|immunodeficiency virus type
P08332492A0145|146 156|replication
P08332492A0145|31 36|GATA-3
P08332492A0145|65 76|T lymphocytes
P08332492A0145|134 142|infection
P08332492A0145|3 8|member
P08332495A0408|73 78|A549-1
P08332495A0408|111 117|complex
P08332495A0408|168 176|liposomes
P08332495A0408|25 35|CAT activity
P08332495A0408|153 159|DC-chol
P08332495A0408|120 134|T7 RNA polymerase
P08332495A0408|80 84|cells
P08332495A0408|136 149|pT7-EMC-CAT DNA
P08332495A0408|18 22|level
P08332495A0408|54 71|lung adenocarcinoma
P08333643A0000|0 12|Pneumoscrotum
P08333643A0000|20 28|condition
P08333643A0000|67 71|texts
P08333643A0000|47 56|discussion
P08333643A0000|74 80|urology
P08334158A0660|40 54|cystein residues
P08334158A0660|8 16|gene codes
P08334158A0660|59 69|arrangement
P08334158A0660|21 27|protein
P08334158A0660|80 91|Fe/S proteins
P08334304A0473|16 20|cells
P08334304A0473|40 49|activation
P08334304A0473|68 87|peptide growth factors
P08334304A0473|55 61|pathway
P08334304A0473|113 123|p21 rasVal12
P08334304A0473|93 100|addition
P08334304A0473|29 36|capacity
P08334989A0070|100 107|sequence
P08334989A0070|19 27|mechanism
P08334989A0070|80 89|mouse B-myb
P08334989A0070|39 48|expression
P08334989A0070|55 58|gene
P08334989A0070|184 205|luciferase reporter gene
P08334989A0070|225 241|NIH3T3 fibroblasts
P08334989A0070|168 180|transcription
P08334989A0070|130 136|library
P08335710A0338|3 11|influence
P08335710A0338|24 31|strength
P08335710A0338|37 46|resolution
P08336012A0632|56 67|BAL fluid cell
P08336012A0632|24 27|lung
P08336012A0632|102 103|FN
P08336012A0632|11 18|bacteria
P08336012A0632|86 99|administration
P08336012A0632|44 52|blood cell
P08336012A0632|3 8|number
P08336543A0243|56 56|V
P08336543A0243|89 96|sequence
P08336543A0243|49 49|F
P08336543A0243|109 116|terminus
P08336543A0243|17 24|families
P08336543A0243|45 45|A
P08336543A0243|79 83|basis
P08336543A0243|2 5|mice
P08336543A0243|27 36|L1 elements
P08336698T0000|0 3|TFEC
P08336698T0000|40 51|heterodimers
P08336698T0000|27 33|protein
P08336698T0000|85 107|transcription activation
P08336698T0000|56 59|TFE3
P08336738A1273|3 12|equivalent
P08336738A1273|23 28|ligand
P08336738A1273|37 40|T-47
P08336738A1273|46 65|PSTAIRE sequence motif
P08336738A1273|30 33|H-87
P08337828A0895|7 13|results
P08337828A0895|24 35|Western blots
P08337828A0895|64 69|AcMNPV
P08337828A0895|38 62|Autographa californica MNPV
P08337828A0895|80 104|Spodoptera frugiperda cells
P08337841A0612|113 129|consensus sequence
P08337841A0612|152 156|G gene
P08337841A0612|217 227|nucleotides
P08337841A0612|243 268|GNS protein termination codon
P08337841A0612|131 135|AACAG
P08337841A0612|19 23|cells
P08337841A0612|176 196|polyadenylation signal
P08337841A0612|203 203|A
P08337841A0612|28 31|ARV G
P08337841A0612|82 85|mRNA
P08337841A0612|35 42|GNS genes
P08337841A0612|198 201|CATG
P08337841A0612|142 146|start
P08340400T0000|86 92|protein
P08340400T0000|50 56|pigment
P08340400T0000|9 15|cloning
P08340400T0000|19 28|expression
P08340400T0000|31 35|RPE65
P08342703A0966|15 17|mu W
P08342703A0966|119 126|pressure
P08342703A0966|73 87|outflow pressure
P08342703A0966|47 54|flow rate
P08342703A0966|7 11|power
P08342703A0966|145 150|vessel
P08342703A0966|105 112|flow rate
P08342703A0966|93 99|product
P08343041A0000|60 79|hospital laboratories
P08343041A0000|97 106|antibodies
P08343041A0000|17 26|antibodies
P08343041A0000|44 54|infertility
P08343216A0883|12 31|IgG subclass responses
P08343216A0883|52 64|IgG subclasses
P08343961A0000|0 18|Anterior body pattern
P08343961A0000|114 118|genes
P08343961A0000|53 64|distribution
P08343961A0000|76 82|protein
P08343961A0000|137 143|domains
P08343961A0000|84 86|bcd
P08344248A0910|0 4|GAP-N
P08344248A0910|53 58|growth
P08344248A0910|76 80|cells
P08345191A1140|56 65|similarity
P08345191A1140|37 46|amino acids
P08345191A1140|3 17|peptide sequence
P08345191A1140|68 72|bcl-2
P08345191A1140|111 114|gene
P08345191A1140|116 119|MCL1
P08345191A1140|27 32|region
P08347677A0308|247 252|microM
P08347677A0308|71 86|arginine residues
P08347677A0308|169 189|4-Ala-Ala-Ser-Val-Ala
P08347677A0308|242 243|Km
P08347677A0308|227 234|peptides
P08347677A0308|165 167|Arg
P08347677A0308|53 58|number
P08347677A0308|118 124|residue
P08347677A0308|3 27|phosphorylation efficiency
P08347677A0308|202 210|substrate
P08347677A0308|143 148|serine
P08347677A0308|101 114|arginyl cluster
P08348919T0000|0 13|Botulinum toxin
P08348919T0000|24 32|treatment
P08348919T0000|46 50|spasm
P08349104A0000|58 65|response
P08349104A0000|137 144|proteins
P08349104A0000|26 29|GAL1
P08349104A0000|180 183|UASG
P08349104A0000|33 42|GAL10 genes
P08349104A0000|97 103|glucose
P08349104A0000|173 177|sites
P08349104A0000|85 93|galactose
P08349104A0000|71 82|availability
P08349104A0450|87 93|factors
P08349104A0450|190 196|variety
P08349104A0450|16 22|results
P08349104A0450|125 134|expression
P08349104A0450|257 262|mating
P08349104A0450|237 243|defects
P08349104A0450|95 98|tsf1
P08349104A0450|267 277|sporulation
P08349104A0450|139 143|yeast
P08349104A0450|246 255|cell growth
P08349104A0450|101 113|tsf6 mutations
P08349104A0450|199 215|operator sequences
P08349104A0450|32 42|experiments
P08349104A0450|174 177|lacZ
P08349104A0450|57 64|TSF genes
P08349104A0450|151 165|hybrid promoters
P08349499A1169|0 2|Sex
P08349499A1169|63 66|head
P08349499A1169|47 51|width
P08349499A1169|10 16|variate
P08349499A1169|5 8|calf
P08349499A1169|54 59|muzzle
P08349632A0679|0 17|Sequence comparison
P08349632A0679|56 63|PSG12 psi
P08349632A0679|105 116|PSG12 psi gene
P08349632A0679|48 52|PSG12
P08349632A0679|39 39|L
P08349632A0679|126 134|stop codon
P08349632A0679|69 69|%
P08349632A0679|93 99|L/N exon
P08349632A0679|31 35|exons
P08349632A0679|43 45|L/N
P08350061A0209|54 60|CD8 gene
P08350061A0209|86 108|T cell development program
P08350061A0209|38 48|suppression
P08350061A0209|26 35|activation
P08350061A0209|3 12|mechanisms
P08350398A1616|140 144|class
P08350398A1616|131 137|domains
P08350398A1616|146 150|heavy
P08350398A1616|33 38|domain
P08350398A1616|158 163|chains
P08350398A1616|125 129|alpha
P08350398A1616|152 156|alpha
P08350398A1616|66 74|structure
P08350398A1616|16 17|ER
P08350398A1616|116 120|alpha
P08350398A1616|41 45|gp19K
P08352066A0000|87 99|bone formation
P08352066A0000|21 34|beta-estradiol
P08352066A0000|127 130|rats
P08352066A0000|115 118|bone
P08352066A0000|36 37|E2
P08352066A0000|56 69|bone resorption
P08352268A0000|31 37|epoetin
P08352268A0000|82 85|i.v.
P08352268A0000|105 109|route
P08352268A0000|16 29|erythropoietin
P08352268A0000|102 103|SC
P08355062A0000|29 38|tomography
P08355062A0000|145 152|patients
P08355062A0000|40 44|SPECT
P08355062A0000|13 20|emission
P08355062A0000|86 90|HMPAO
P08355062A0000|50 84|99mTc-hexamethylpropyleneamine oxime
P08355062A0000|171 180|impairment
P08355062A0000|112 118|changes
P08355062A0000|129 137|blood flow
P08355063A0456|3 11|rCBF ratio
P08355063A0456|37 41|lobes
P08355063A0456|45 45|%
P08355539A0133|0 6|METHODS
P08355539A0133|253 260|etiology
P08355539A0133|53 60|etiology
P08355539A0133|188 195|etiology
P08355539A0133|101 109|diagnosis
P08355539A0133|220 224|study
P08355539A0133|157 159|EAA
P08355539A0133|18 25|patients
P08355539A0133|71 75|study
P08355539A0133|198 200|EAT
P08355539A0133|89 98|antibodies
P08355539A0133|115 121|disease
P08355539A0133|147 154|etiology
P08355539A0133|263 265|EAI
P08355680A0824|0 3|2-AP
P08355680A0824|92 106|HIV-1 constructs
P08355680A0824|24 28|rises
P08355680A0824|137 140|gene
P08355680A0824|31 46|mRNA accumulation
P08355680A0824|112 120|increases
P08355680A0824|149 159|gamma-actin
P08355680A0824|162 192|glucose 6-phosphate dehydrogenase
P08355696A0236|3 13|UV induction
P08355696A0236|75 83|sequences
P08355696A0236|36 53|UV response elements
P08355696A0236|102 107|region
P08355696A0236|16 20|c-jun
P08355697A0000|103 116|cell activation
P08355697A0000|28 31|PTPs
P08355697A0000|91 100|regulation
P08355697A0000|46 67|protein tyrosine kinases
P08355697A0000|69 72|PTKs
P08355697A0000|128 142|differentiation
P08355697A0000|118 123|growth
P08355697A0000|0 26|Protein tyrosine phosphatases
P08355857A1293|2 10|elevation
P08355857A1293|53 59|patient
P08355857A1293|20 27|patients
P08355857A1293|37 45|subgroup A
P08355857A1293|33 33|%
P08355857A1293|65 74|subgroup B.
P08356792A1275|68 73|levels
P08356792A1275|161 170|proviruses
P08356792A1275|13 23|p21X protein
P08356792A1275|78 81|data
P08356792A1275|34 43|N-terminus
P08356792A1275|123 126|mRNA
P08356792A1275|94 97|p21X
P08356792A1275|46 49|Rex1
P08356792T0000|0 19|HTLV-1 gene expression
P08356792T0000|53 62|T-cell line
P08356792T0000|31 40|proviruses
P08356944A0589|117 139|cyanmethemoglobin method
P08356944A0589|169 174|wastes
P08356944A0589|152 161|generation
P08356944A0589|63 85|hemoglobin concentration
P08356944A0589|26 50|sodium lauryl sulfate method
P08356944A0589|101 111|alternative
P08357834A0285|258 269|counterparts
P08357834A0285|183 202|sequence conservation
P08357834A0285|225 240|PKC family members
P08357834A0285|78 80|rat
P08357834A0285|175 180|degree
P08357834A0285|124 141|sequence divergence
P08357834A0285|25 42|amino acid sequences
P08357834A0285|116 121|degree
P08357834A0285|1 10|comparison
P08357834A0285|148 156|% homology
P08357834A0285|56 70|PKC-delta clones
P08357834A0285|84 98|mouse homologues
P08360112T0036|0 2|XII
P08360180A1041|100 109|similarity
P08360180A1041|178 187|progenitor
P08360180A1041|50 62|PSI-K sequence
P08360180A1041|197 210|cyanobacterial
P08360180A1041|30 34|PSI-G
P08360180A1041|92 97|degree
P08360180A1041|143 146|gene
P08360180A1041|16 26|barley PSI-K
P08361754A0733|18 27|structures
P08361754A0733|10 13|hand
P08361754A0733|38 43|domain
P08361754A0733|81 88|proteins
P08361755A0734|117 126|Tax binding
P08361755A0734|48 59|NF-kappa B p50
P08361755A0734|10 19|conditions
P08361755A0734|103 103|s
P08361755A0734|151 157|CArG box
P08361755A0734|63 81|serum response factor
P08361755A0734|96 101|factor
P08361755A0734|38 42|cDNAs
P08361755A0734|21 33|transfections
P08361755A0734|132 144|NF-kappa B site
P08361755A0734|83 85|SRF
P08361761A0174|88 102|Sp1 binding sites
P08361761A0174|220 229|expression
P08361761A0174|389 403|Sp1 binding sites
P08361761A0174|125 148|chicken embryo fibroblasts
P08361761A0174|332 349|kappa B binding sites
P08361761A0174|311 316|repeat
P08361761A0174|150 153|CEFs
P08361761A0174|266 290|immunodeficiency virus type
P08361761A0174|196 200|sites
P08361761A0174|40 49|expression
P08361761A0174|166 170|v-Rel
P08361761A0174|14 18|v-Rel
P08361761A0174|202 206|v-Rel
P08361761A0174|55 69|reporter plasmid
P08361761A0174|318 320|LTR
P08361761A0174|293 297|HIV-1
P08361761A0174|235 249|reporter plasmid
P08363332A0365|15 23|recording
P08363332A0365|116 121|atrium
P08363332A0365|209 226|activation sequence
P08363332A0365|131 135|sinus
P08363332A0365|92 95|apex
P08363332A0365|36 43|activity
P08363332A0365|232 236|heart
P08363332A0365|157 171|mapping catheter
P08363332A0365|51 74|surface electrocardiogram
P08363332A0365|100 105|bundle
P08365944A1537|148 159|radiotherapy
P08365944A1537|184 188|boost
P08365944A1537|53 60|efficacy
P08365944A1537|28 35|analysis
P08365944A1537|100 113|5-fluorouracil
P08365944A1537|124 134|association
P08365944A1537|66 71|course
P08365944A1537|86 96|Mitomycin-C
P08365944A1537|0 9|CONCLUSION
P08366034A0637|70 78|formation
P08366034A0637|10 18|existence
P08366034A0637|40 57|carboxymethylation
P08366034A0637|23 38|cysteine residues
P08366034A0637|93 106|disulfide bonds
P08366034A0637|135 139|cells
P08367388T0035|48 55|syndrome
P08367388T0035|27 34|syndrome
P08367487A1014|216 223|extracts
P08367487A1014|164 173|antibodies
P08367487A1014|112 119|U2 snRNPs
P08367487A1014|19 26|addition
P08367487A1014|37 47|17S U2 snRNPs
P08367487A1014|190 210|mRNA-splicing activity
P08367487A1014|71 90|HeLa splicing extracts
P08367487A1014|57 67|12S U2 snRNPs
P08369887A0781|59 61|EAD
P08369887A0781|23 40|viscosity variables
P08369887A0781|64 73|RA patients
P08369887A0781|13 20|profiles
P08369887A0781|48 56|subgroups
P08369887A0781|0 10|Differences
P08370119A0642|70 78|sequences
P08370119A0642|103 114|reading frame
P08370119A0642|151 177|muscle cell AT1a receptor cDNAs
P08370119A0642|26 29|exon
P08370119A0642|44 45|bp
P08370119A0642|81 88|addition
P08370119A1521|0 7|Deletion
P08370119A1521|21 34|promoter region
P08370119A1521|128 135|elements
P08370119A1521|82 88|TATA box
P08370119A1521|111 117|ability
P08370119A1521|48 69|transcription start site
P08370119A1521|161 174|luciferase cDNA
P08370119A1521|143 155|transcription
P08370275A0290|3 12|chimpanzee
P08370275A0290|75 78|pair
P08370275A0290|52 58|testing
P08370275A0290|38 44|numeral
P08370275A0290|89 94|chimps
P08370275A0290|103 112|preference
P08371650T0000|0 10|Dissipation
P08371650T0000|13 28|claudication pain
P08371650T0000|66 73|training
P08371650T0000|42 53|implications
P08371713T0000|43 60|endothelin receptor
P08371713T0000|65 72|rat brain
P08371713T0000|11 20|transcript
P08371936T0000|45 49|study
P08371936T0000|13 31|Independence Measure
P08371936T0000|52 60|clinician
P08371936T0000|64 74|self ratings
P08373274A0546|0 9|Polymyxin B
P08373274A0546|35 46|week postburn
P08373274A0546|49 53|doses
P08373274A0546|85 95|endotoxemia
P08373972A0335|0 3|SvO2
P08374753A0335|42 61|diffusion coefficient
P08374753A0335|13 26|relaxation time
P08374753A0335|64 68|water
P08374753A0335|28 29|T2
P08375651T0000|36 51|clathrin function
P08375651T0000|26 34|chain gene
P08375651T0000|79 86|organism
P08376397A0788|58 60|E2F
P08376397A0788|81 88|E2F sites
P08376397A0788|91 101|competitors
P08376397A0788|67 72|number
P08376397A0788|3 20|binding specificity
P08376397A0788|27 33|protein
P08376796A0172|60 68|attention
P08376796A0172|125 128|IgG1
P08376796A0172|149 154|B cells
P08376796A0172|224 230|patient
P08376796A0172|305 306|Ag
P08376796A0172|176 182|patient
P08376796A0172|204 219|diabetes mellitus
P08376796A0172|116 118|IgG
P08376796A0172|140 142|mAb
P08376796A0172|291 294|self
P08376796A0172|12 20|VH regions
P08376796A0172|274 279|number
P08376796A0172|135 138|IgG3
P08376796A0172|35 44|antibodies
P08376796A0172|167 173|subject
P08376796A0172|94 99|status
P08376796A0172|235 237|SLE
P08376796A0172|261 272|efficiencies
P08377199A1432|43 54|conformation
P08377199A1432|87 97|recognition
P08377199A1432|60 63|site
P08377199A1432|19 23|patch
P08378082A1031|60 65|p21ras
P08378082A1031|31 40|cross-talk
P08378082A1031|5 12|findings
P08378082A1031|83 95|cell phenotype
P08378082A1031|123 128|states
P08378082A1031|48 56|RB protein
P08380736A0895|57 63|protein
P08380736A0895|7 10|mRNA
P08380736A0895|77 89|amino terminus
P08380736A0895|31 38|splicing
P08380896A0938|0 7|Kinetics
P08380896A0938|95 112|preinitiation stage
P08380896A0938|40 55|polymerase domain
P08380896A0938|71 81|replication
P08380896A0938|13 22|inhibition
P08381121A0773|8 27|transmembrane regions
P08381121A0773|52 57|domain
P08382296A0766|0 8|McCann III
P08382296A0766|10 11|F.
P08382300A0341|29 35|ability
P08382300A0341|124 130|mutants
P08382300A0341|83 91|VP5 mutant
P08382300A0341|48 58|replication
P08382300A0341|110 112|VP5
P08382300A0341|5 13|cell lines
P08382300A0341|116 119|VP23
P08382303A0507|3 4|E1
P08382303A0507|100 105|region
P08382303A0507|62 77|papillomaviruses
P08382303A0507|12 25|transport motif
P08382303A0507|48 53|animal
P08382303A0507|118 124|E1 genes
P08382303T0000|3 22|E1 replication protein
P08382303T0000|75 92|localization signal
P08382303T0000|106 131|p34cdc2 phosphorylation site
P08382303T0000|31 48|papillomavirus type
P08382359A0469|174 181|T antigen
P08382359A0469|83 87|virus
P08382359A0469|208 218|experiments
P08382359A0469|64 77|tumor induction
P08382359A0469|237 243|effects
P08382359A0469|36 46|interaction
P08382359A0469|267 276|activities
P08382359A0469|117 130|point mutations
P08382359A0469|26 31|extent
P08382359A0469|2 6|order
P08382359A0469|287 300|tumor induction
P08382359A0469|159 166|sequence
P08382769A0924|129 140|SRP54 protein
P08382769A0924|31 41|nucleotides
P08382769A0924|105 122|recognition element
P08382769A0924|63 73|consequence
P08382769A0924|81 84|role
P08382769A0924|17 28|conservation
P08382778A0891|114 133|transcription factors
P08382778A0891|104 108|TFIIE
P08382778A0891|63 68|region
P08382778A0891|41 48|homology
P08382778A0891|1 6|region
P08382778A0891|19 31|protein shares
P08382778A0891|83 89|feature
P08382778A0891|71 80|Raf kinases
P08383129A0776|15 36|mass polypeptide complex
P08383129A0776|167 179|T-lymphocytes
P08383129A0776|60 78|antigen presentation
P08383129A0776|90 97|peptides
P08383129A0776|185 195|cell surface
P08383129A0776|111 125|protein antigens
P08383214A0389|59 62|form
P08383214A0389|9 16|cleavage
P08383214A0389|40 42|Pol
P08383214A0389|23 37|Trp-595-Tyr-596
P08383214A0389|19 20|RT
P08383214A0389|83 94|RNase H domain
P08383217A0357|28 37|amino acids
P08383217A0357|40 44|Bel-1
P08383217A0357|127 142|activation domain
P08383217A0357|145 148|VP16
P08383217A0357|69 81|Bel-1 activity
P08383287A0611|17 23|element
P08383287A0611|104 125|hormone response element
P08383287A0611|48 75|thyroid hormone responsiveness
P08383287A0611|37 44|estrogen
P08383323A0000|43 49|signals
P08383323A0000|7 16|activation
P08383323A0000|19 24|T cells
P08383492A1205|177 193|c-type cytochromes
P08383492A1205|126 133|affinity
P08383492A1205|71 76|region
P08383492A1205|83 93|differences
P08383492A1205|108 112|terms
P08383492A1205|56 64|aa stretch
P08383492A1205|150 167|cytochrome oxidases
P08383526A0591|12 16|genes
P08383526A0591|77 80|exon
P08383526A0591|46 60|receptor protein
P08383526A0591|29 37|structure
P08383622T0000|101 118|ETS domain activator
P08383622T0000|92 95|role
P08383622T0000|37 45|activator
P08383622T0000|48 74|cytochrome oxidase expression
P08383622T0000|10 13|GABP
P08383622T0000|126 134|promoters
P08383622T0000|18 22|NRF-2
P08383622T0000|0 7|Identity
P08383850A0206|62 64|NTI
P08383850A0206|171 174|rats
P08383850A0206|12 16|study
P08383850A0206|67 82|nonequilibrium mu
P08383850A0206|38 45|beta-FNA
P08383850A0206|50 60|naltrindole
P08383850A0206|18 36|beta-funaltrexamine
P08383850A0206|138 147|withdrawal
P08384309A0000|92 97|dioxin
P08384309A0000|99 133|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08384309A0000|21 43|region/helix-loop-helix
P08384309A0000|50 63|dioxin receptor
P08384309A0000|72 89|signal transduction
P08384309A0000|206 216|target genes
P08384309A0000|228 249|dioxin response elements
P08384309A0000|166 182|DNA binding protein
P08385131A0000|30 38|alpha 2AAR
P08385131A0000|52 58|variety
P08385131A0000|21 28|receptor
P08385131A0000|108 115|proteins
P08385131A0000|61 69|effectors
P08385131A0000|3 7|alpha
P08385131A0000|73 81|pertussis
P08385337A0282|29 56|CCAAT/enhancer binding protein
P08385337A0282|127 131|bZIP1
P08385337A0282|107 120|leucine zippers
P08385337A0282|64 81|consensus sequences
P08385337A0282|135 139|bZIP2
P08385337A0282|58 62|C/EBP
P08385337A0282|152 157|region
P08385337A0282|1 18|sequence comparison
P08385337A0282|88 103|DNA binding region
P08385581A0126|128 134|mitosis
P08385581A0126|10 14|genes
P08385581A0126|118 125|function
P08385581A0126|16 21|REC114
P08385581A0126|60 65|REC114
P08385581A0126|45 48|data
P08385581A0126|85 101|recombination gene
P08386279A1621|99 112|HIV-1 infection
P08386279A1621|67 74|cell line
P08386279A1621|53 56|HeLa
P08386279A1621|120 124|cells
P08386279A1621|136 158|HIV-1 promoter activation
P08386279A1621|93 95|EBV
P08386279A1621|3 25|transactivation function
P08386279A1621|28 32|EBNA2
P08386280T0000|0 7|Mutation
P08386280T0000|63 68|repeat
P08386280T0000|35 50|Rous sarcoma virus
P08386280T0000|72 83|gag enhancers
P08386280T0000|13 29|C/EBP binding sites
P08386317T0000|43 55|protein kinase
P08386317T0000|7 26|protein phosphatase 2A
P08386317T0000|107 117|stimulation
P08386317T0000|72 75|CREB
P08386317T0000|88 91|CREB
P08386318A1102|117 118|Ca
P08386318A1102|158 162|Raf-1
P08386318A1102|23 29|JRE-IL6
P08386318A1102|10 13|IL-6
P08386318A1102|76 89|protein kinase C
P08386318A1102|51 57|pathway
P08386318A1102|154 156|Ras
P08386318A1102|110 115|kinase
P08386318A1102|166 171|NF-IL6
P08386318A1102|173 181|C/EBP beta
P08386318A1102|146 152|kinases
P08386319A1229|0 7|Mutation
P08386319A1229|49 65|threonine residues
P08386319A1229|140 152|Mpk1p function
P08386319A1229|38 45|tyrosine
P08386319A1229|68 72|Mpk1p
P08386319A1229|87 99|phenylalanine
P08386319A1229|103 109|alanine
P08386592A0089|188 189|kd
P08386592A0089|198 208|Elk-1 kinase
P08386592A0089|94 100|complex
P08386592A0089|159 164|region
P08386592A0089|144 148|Elk-1
P08386592A0089|173 182|activation
P08386592A0089|48 53|change
P08386592A0089|124 138|phosphorylation
P08386592A0089|0 22|Growth factor stimulation
P08386592A0089|74 81|mobility
P08386637A1220|126 134|receptors
P08386637A1220|50 57|exposure
P08386637A1220|35 39|cells
P08386637A1220|63 69|agonist
P08386637A1220|2 9|contrast
P08386637A1220|94 103|regulation
P08386637A1220|120 120|%
P08386637A1220|15 23|situation
P08386637A1220|73 73|h
P08387155A1248|15 20|effect
P08387155A1248|103 106|topo
P08387155A1248|66 69|topo
P08387155A1248|121 125|assay
P08387155A1248|81 85|c-Fos
P08387155A1248|42 46|c-Jun
P08387507A1015|219 241|myoblast differentiation
P08387507A1015|104 108|serum
P08387507A1015|52 58|pathway
P08387507A1015|23 34|MyoD function
P08387507A1015|191 197|factors
P08387507A1015|119 138|peptide growth factors
P08387507A1015|3 12|regulation
P08387507A1015|159 165|nucleus
P08387507A1015|15 19|Myf-5
P08387507A1015|86 92|signals
P08387519A0000|42 57|desmin expression
P08387519A0000|76 79|pair
P08387519A0000|95 102|enhancer
P08387519A0000|155 168|gene expression
P08387519A0000|128 135|myotubes
P08387519A0000|171 179|myoblasts
P08387519A0000|32 36|level
P08387662A0302|100 106|codeine
P08387662A0302|127 128|mg
P08387662A0302|115 123|ibuprofen
P08387662A0302|92 98|placebo
P08387662A0302|13 24|patients self
P08387662A0302|139 142|pain
P08387662A0302|67 77|medications
P08387662A0302|109 110|mg
P08387662A0302|167 175|intensity
P08387662A0302|5 11|surgery
P08387743A0624|0 10|Replacement
P08387743A0624|134 155|Mn-superoxide dismutase
P08387743A0624|38 43|region
P08387743A0624|116 125|expression
P08387743A0624|87 93|element
P08387743A0624|59 65|mutants
P08387994A0980|3 18|orf61 gene product
P08387994A0980|78 88|integration
P08387994A0980|105 112|attB site
P08387994A0980|48 55|promoter
P08388496A1117|0 9|Expression
P08388496A1117|51 69|virus producer status
P08388496A1117|107 113|passage
P08388496A1117|23 26|LCLs
P08388496A1117|245 253|BamHI-C/W
P08388496A1117|78 88|consequence
P08388496A1117|197 199|day
P08388496A1117|184 189|B cells
P08388496A1117|140 157|BamHI-A transcripts
P08388496A1117|303 307|mRNAs
P08388496A1117|219 227|infection
P08388510A0891|0 7|Analysis
P08388510A0891|52 59|UL28 gene
P08388510A0891|10 38|cell surface immunofluorescence
P08388510A0891|128 132|cells
P08388510A0891|76 85|expression
P08388510A0891|111 117|surface
P08388510A0891|93 105|glycoproteins
P08388543A1263|28 38|Y977F/Y989F
P08388543A1263|81 83|Ras
P08388543A1263|126 144|calcium mobilization
P08388543A1263|156 161|effect
P08388543A1263|56 60|sites
P08388543A1263|190 197|cell line
P08388543A1263|40 42|PLC
P08388543A1263|181 183|Ras
P08388543A1263|167 178|GDP/GTP state
P08388543A1263|109 122|protein kinase C
P08388543A1263|19 26|receptor
P08388543A1263|97 106|activation
P08388600A0000|0 16|Estrogen treatment
P08388600A0000|23 27|doses
P08388600A0000|83 87|girls
P08388600A0000|54 60|stature
P08389074A1227|0 8|Mutations
P08389074A1227|129 137|structure
P08389074A1227|21 30|C-terminus
P08389074A1227|65 89|activation domain functions
P08389074A1227|52 61|RNA binding
P08389074A1227|33 39|EIAV Tat
P08389074A1227|101 107|effects
P08389365A1344|45 56|repair system
P08389365A1344|4 14|observation
P08389365A1344|83 90|sequence
P08389365A1344|78 81|GATC
P08389365A1344|99 108|correction
P08389365A1344|76 76|d
P08389453A0193|102 110|duplex DNA
P08389453A0193|92 97|uracil
P08389453A0193|39 42|step
P08389453A0193|48 60|repair pathway
P08389453A0193|0 19|Uracil DNA glycosylase
P08390120A0785|15 20|trials
P08390120A0785|67 73|options
P08390120A0785|90 93|life
P08390120A0785|81 87|quality
P08390120A0785|36 43|question
P08390665A0000|0 20|Lithium phthalocyanine
P08390665A0000|48 57|generation
P08390665A0000|99 110|crystallites
P08390665A0000|170 186|resonance oximetry
P08390665A0000|22 25|LiPc
P08390665A0000|150 157|electron
P08390665A0000|30 38|prototype
P08390747A0586|25 32|genetics
P08390747A0586|83 91|syncytial
P08390747A0586|6 11|report
P08390747A0586|119 121|syn
P08390747A0586|105 114|phenotypes
P08390747A0586|51 62|hep syn gB gene
P08390747A0586|38 43|region
P08390831A0143|0 9|Recipients
P08390831A0143|106 109|risk
P08390831A0143|35 43|remission
P08390831A0143|60 68|leukaemia
P08390831A0143|83 87|phase
P08390831A0143|19 27|leukaemia
P08390831A0143|130 135|stages
P08390831A0143|143 154|risk patients
P08391534A0828|0 6|Elledge
P08391534A0828|8 9|P.
P08391748A0452|0 4|Drugs
P08391748A0452|21 21|%
P08391748A0452|52 63|contractions
P08391748A0452|100 114|QRS prolongation
P08391748A0452|157 157|%
P08391748A0452|185 199|QRS prolongation
P08391748A0452|69 76|patients
P08391748A0452|160 167|patients
P08391748A0452|210 210|%
P08391748A0452|287 301|QRS prolongation
P08391748A0452|138 151|QT prolongation
P08391748A0452|325 338|QT prolongation
P08391748A0452|262 262|%
P08391748A0452|235 248|QT prolongation
P08392221A0449|0 5|Losses
P08392221A0449|213 233|O-desmethylangolensin
P08392221A0449|166 177|matairesinol
P08392221A0449|63 80|estrogen conjugates
P08392221A0449|134 142|standards
P08392221A0449|190 202|enterolactone
P08392221A0449|235 239|equol
P08392221A0449|23 31|procedure
P08392221A0449|244 252|genistein
P08392221A0449|148 156|compounds
P08392221A0449|95 99|steps
P08392221A0449|204 211|daidzein
P08392221A0449|179 188|enterodiol
P08392623A1374|0 18|IE2-IE2 interactions
P08392623A1374|92 100|C terminus
P08392623A1374|103 105|IE2
P08392623A1374|114 123|amino acids
P08392623A1374|32 37|domain
P08392623A1374|73 77|motif
P08393143A1281|3 11|Sp1 region
P08393143A1281|53 55|TRE
P08393143A1281|66 74|tat factor
P08394019A0695|45 50|Fyn SH2
P08394019A0695|127 129|Fyn
P08394019A0695|52 54|SH3
P08394019A0695|59 72|SH2/SH3 domains
P08394019A0695|85 94|PI 3-kinase
P08394019A0695|18 34|GST fusion proteins
P08394019A0695|116 124|SH3 domain
P08394019A0695|0 12|Precipitation
P08394255A0000|84 106|polymerase chain reaction
P08394255A0000|108 110|PCR
P08394255A0000|40 51|pcDNA1 vector
P08394255A0000|163 181|hormone receptor cDNA
P08394255A0000|68 72|probe
P08394255A0000|134 143|kb fragment
P08394255A0000|149 151|rat
P08394255A0000|1 5|sheep
P08394255A0000|16 26|cDNA library
P08394464A1080|43 48|masses
P08394464A1080|11 21|Rev proteins
P08394464A1080|116 122|species
P08394464A1080|93 95|p20
P08394464A1080|76 79|p2/2
P08394464A1080|83 86|p176
P08394464A1080|58 60|kDa
P08394862A0565|40 44|group
P08394862A0565|46 52|patient
P08394862A0565|62 73|CMV hepatitis
P08394862A0565|11 18|patients
P08394862A0565|5 9|group
P08394862A0565|28 37|CMV disease
P08395004A0141|147 160|HIS4 mRNA levels
P08395004A0141|128 135|increase
P08395004A0141|53 64|interference
P08395004A0141|12 24|spt2 mutations
P08395004A0141|76 111|delta promoter insertion his-4-912 delta
P08395004A0141|3 9|ability
P08395004A0558|119 129|protein HMG1
P08395004A0558|65 80|SPT2/SIN1 protein
P08395004A0558|7 18|localization
P08395004A0558|22 48|protein sequence similarities
P08395010T0000|88 96|responses
P08395010T0000|108 118|heterodimer
P08395010T0000|35 48|thyroid hormone
P08395010T0000|27 32|heptad
P08395010T0000|125 142|homodimer formation
P08395010T0000|60 72|acid receptors
P08395014A1364|7 18|interactions
P08395014A1364|90 102|pathway branch
P08395014A1364|26 29|BCK2
P08395014A1364|38 54|pathway components
P08395014A1364|114 117|PPZ2
P08395014A1364|68 80|BCK2 functions
P08395014A1364|107 110|PPZ1
P08395654T0000|72 87|rat aromatase gene
P08395654T0000|36 43|receptor
P08395654T0000|13 18|factor
P08395654T0000|57 66|expression
P08395654T0000|97 103|tissues
P08395681A0388|171 184|binding ability
P08395681A0388|204 224|retinoblastoma protein
P08395681A0388|96 97|E7
P08395681A0388|47 50|HPV5
P08395681A0388|226 227|RB
P08395681A0388|20 30|differences
P08395681A0388|102 114|reading frames
P08395681A0388|54 60|HPV8 E7s
P08395681A0388|71 77|HPV16 E7
P08395681A0388|157 166|activities
P08395681A0388|276 294|adenovirus E1A mutant
P08395681A0388|237 259|complementation activity
P08395681A0388|192 199|products
P08396120A0690|56 60|start
P08396120A0690|63 73|translation
P08396120A0690|3 28|rhaB transcription start site
P08396261A0388|142 147|strain
P08396261A0388|14 21|evidence
P08396261A0388|185 194|growth rate
P08396261A0388|41 56|growth inhibition
P08396261A0388|97 105|phenotype
P08396261A0388|412 414|DE3
P08396261A0388|382 390|phenotype
P08396261A0388|71 81|PKA subunits
P08396261A0388|407 410|BL21
P08396261A0388|202 214|transformants
P08396261A0388|323 331|RI protein
P08396261A0388|283 288|RI cDNA
P08396261A0388|7 11|lines
P08396261A0388|236 239|cAMP
P08396261A0388|443 455|C alpha protein
P08396261A0388|416 420|cells
P08396261A0388|163 177|cyclase activity
P08396261A0388|119 122|cAMP
P08396261A0388|258 263|growth
P08396261A0388|343 353|cAMP binding
P08396261A0388|85 88|cAMP
P08396261A0388|308 313|RI cDNA
P08396657A0452|0 2|Liu
P08396657A0452|4 5|B.
P08396667T0000|0 6|BCR-ABL
P08396667T0000|54 61|lymphoma
P08396667T0000|38 45|patterns
P08396667T0000|80 96|lymphocyte subsets
P08396667T0000|15 23|oncogenes
P08396713A0305|87 91|cells
P08396713A0305|194 209|heat shock protein
P08396713A0305|103 137|2,3,7,8-tetrachlorodibenzo-p-dioxin
P08396713A0305|77 84|extracts
P08396713A0305|50 57|receptor
P08396713A0305|175 178|ARNT
P08396713A0305|139 142|TCDD
P08396713A0305|155 171|Ah receptor protein
P08396713A0305|5 15|experiments
P08396713A0305|41 44|form
P08396749A1112a|0 13|LDL cholesterol
P08396749A1112a|63 67|weeks
P08396749A1112a|51 56|mmol/l
P08396749A1112a|94 97|apo B
P08396749A1112a|82 82|P
P08396749A1112a|130 130|P
P08396749A1112a|124 128|mg/dl
P08396749A1112a|70 80|simvastatin
P08396749A1112b|0 13|LDL cholesterol
P08396749A1112b|63 67|weeks
P08396749A1112b|51 56|mmol/l
P08396749A1112b|94 97|apo B
P08396749A1112b|82 82|P
P08396749A1112b|130 130|P
P08396749A1112b|124 128|mg/dl
P08396749A1112b|70 80|simvastatin
P08396913A1379|56 59|cell
P08396913A1379|12 18|element
P08396913A1379|88 94|DGK gene
P08396913A1379|32 35|part
P08396913A1379|73 82|expression
P08397123T0000|58 91|corticotropin-releasing hormone gene
P08397123T0000|114 121|features
P08397123T0000|41 47|element
P08397123T0000|140 150|transcripts
P08397123T0000|9 16|activity
P08399970T0000|42 51|inoculants
P08399970T0000|4 29|bioencapsulation technology
P08400240A0166|85 91|A gamma*
P08400240A0166|8 27|hypersensitivity site
P08400240A0166|162 177|gamma-globin mRNA
P08400240A0166|60 62|LCR
P08400240A0166|68 83|gamma-globin gene
P08400240A0166|121 130|transcript
P08400240A0166|41 58|locus control region
P08400240A0166|30 32|HS2
P08400928A0318|138 148|combination
P08400928A0318|158 170|bromocriptine
P08400928A0318|150 152|arm
P08400928A0318|94 135|levodopa/decarboxylase inhibitor/selegiline
P08400928A0318|15 22|Patients
P08400928A0318|88 90|arm
P08400928A0318|47 81|levodopa/dopa decarboxylase inhibitor
P08400928A0318|34 42|treatment
P08400928A0318|172 174|arm
P08400928A0318|0 12|INTERVENTIONS
P08401570A0828|146 165|transcription factors
P08401570A0828|80 88|sequences
P08401570A0828|23 34|binding sites
P08401570A0828|38 59|transcription factor Sp1
P08401570A0828|138 142|sites
P08401570A0828|120 128|enhancers
P08401614A0187|45 47|PAL
P08401614A0187|74 77|PAL3
P08401614A0187|124 132|mRNA level
P08401614A0187|61 65|genes
P08401614A0187|6 9|bean
P08401614A0187|24 29|family
P08401614A0187|135 145|bean tissues
P08401614A0187|67 70|PAL2
P08401614A0187|32 36|genes
P08403245A1234|0 24|Plasma thromboxane B2 levels
P08403245A1234|35 39|group
P08403245A1234|69 75|piglets
P08403804A0754|133 147|serum creatinine
P08403804A0754|179 189|cyclosporin
P08403804A0754|158 167|transplant
P08403804A0754|24 41|regression analysis
P08403804A0754|149 152|time
P08403804A0754|114 124|cholesterol
P08403804A0754|50 58|magnesium
P08403804A0754|84 105|cyclosporin trough level
P08403804A0754|173 176|dose
P08405433A0000|58 66|promoters
P08405433A0000|68 69|P1
P08405433A0000|35 40|IGF-II
P08405433A0000|71 72|P2
P08405433A0000|20 31|growth factor
P08405433A0000|79 80|P4
P08405433A0000|42 45|gene
P08405433A0000|74 75|P3
P08406004A0691|88 100|JB cis-element
P08406004A0691|39 42|PU.1
P08406004A0691|156 163|sequence
P08406004A0691|20 37|transfection assays
P08406004A0691|183 189|portion
P08406004A0691|108 117|activation
P08406004A0691|57 74|reporter constructs
P08406004A0691|192 195|PU.1
P08406352A0172|116 123|veterans
P08406352A0172|209 215|receipt
P08406352A0172|23 34|fever vaccine
P08406352A0172|75 82|controls
P08406352A0172|142 150|carcinoma
P08406352A0172|230 236|vaccine
P08406352A0172|102 106|study
P08406352A0172|188 195|controls
P08406352A0172|51 65|hepatitis B virus
P08406352A0172|153 176|Veterans Affairs hospitals
P08406352A0172|200 206|respect
P08406352A0172|0 11|Army veterans
P08406419A0155|118 125|Westwood
P08406419A0155|127 128|MA
P08406419A0155|44 58|hepatitis C virus
P08406419A0155|78 84|testing
P08406419A0155|92 116|Ortho Diagnostic Systems Inc
P08406419A0155|32 41|antibodies
P08406419A0155|86 89|RIBA
P08406497A0000|0 6|Defects
P08406497A0000|9 17|fibrillin
P08406497A0000|26 46|glycoprotein component
P08406497A0000|65 75|microfibril
P08406497A0000|82 95|Marfan syndrome
P08406497A0000|19 22|FBN1
P08407784A0850|18 21|recJ
P08407784A0850|23 29|strains
P08407784A0850|31 43|srjA mutations
P08407784A0850|85 94|phenotypes
P08408194T0000|106 106|K
P08408194T0000|24 44|membrane-cytoskeleton
P08408194T0000|14 18|roles
P08408194T0000|141 149|epithelia
P08408194T0000|73 80|adhesion
P08408194T0000|111 129|ATPase distributions
P08408194T0000|48 55|cadherin
P08408194T0000|102 103|Na
P08408825A0000|72 73|Ro
P08408825A0000|77 86|La antigens
P08408825A0000|8 25|lupus erythematosus
P08408825A0000|51 64|autoantibodies
P08408841A0281|91 99|mutations
P08408841A0281|64 76|abnormalities
P08408841A0281|35 45|mutagenesis
P08408841A0281|7 19|abnormalities
P08408963A0048|8 9|L.
P08409284A0262|57 66|amino acids
P08409284A0262|109 118|PHE carrier
P08409284A0262|9 18|absorption
P08409284A0262|91 100|amino acids
P08409284A0262|74 79|system
P08409284A0262|187 193|cholera
P08409284A0262|160 164|stage
P08409284A0262|36 45|NBB carrier
P08409284A0262|21 30|amino acids
P08409284A0262|72 72|Y
P08409284A0262|173 181|diarrhoea
P08409593A0357|58 65|H. pylori
P08409593A0357|110 117|activity
P08409593A0357|126 129|time
P08409593A0357|81 84|AMPC
P08409593A0357|43 50|activity
P08409593A0357|7 10|AMPC
P08409593A0357|2 5|CFDN
P08409593A0357|14 16|MNZ
P08410042T0000|17 23|disease
P08410042T0000|65 69|cases
P08410042T0000|54 59|report
P08410042T0000|38 52|dura mater grafts
P08410097A0356|129 129|p
P08410097A0356|82 82|p
P08410097A0356|206 215|covariates
P08410097A0356|162 177|plasma fibrinogen
P08410097A0356|20 24|CLTPA
P08410097A0356|50 74|regression coefficient beta
P08410097A0356|105 116|oxygen uptake
P08410097A0356|5 17|mean intensity
P08410097A0356|118 121|beta
P08411024T0000|47 68|fibrosis carrier testing
P08411024T0000|9 14|people
P08411024T0000|32 37|option
P08411276A0302|83 102|Trauma Score variables
P08411276A0302|16 25|PIC patient
P08411276A0302|43 51|mechanism
P08411276A0302|265 265|C
P08411276A0302|159 162|rate
P08411276A0302|104 124|Glascow Coma Scale score
P08411276A0302|177 179|age
P08411276A0302|295 302|injuries
P08411276A0302|270 284|ASCOT components
P08411276A0302|68 73|coding
P08411276A0302|184 207|Severity Characterization
P08411276A0302|218 222|ASCOT
P08411276A0302|210 215|Trauma
P08411276A0302|54 59|injury
P08411276A0302|260 260|B
P08411276A0302|134 146|blood pressure
P08411276A0302|258 258|A
P08411276A0302|1 7|patient
P08412120A0839|0 3|Skin
P08412120A0839|7 15|bowel TPO2
P08412120A0839|42 42|P
P08412120A0839|26 28|DO2
P08412620A0688|1 6|region
P08412620A0688|23 24|bp
P08412620A0688|121 128|promoter
P08412620A0688|65 68|virB
P08412620A0688|105 114|activation
P08412620A0688|131 134|VirF
P08412620A0688|40 62|transcription start point
P08412662A0333|113 127|kb EcoRI fragment
P08412662A0333|60 78|transposon insertion
P08412662A0333|81 86|257DH4
P08412662A0333|31 33|DNA
P08412662A0333|103 105|Tn5
P08412662A0333|54 57|site
P08412662A0333|15 20|cosmid
P08412665A0000|15 20|pUR400
P08412665A0000|47 56|scr regulon
P08412665A0000|134 137|ScrR
P08412665A0000|79 85|KAY2026
P08412665A0000|124 132|repressor
P08412665A0000|3 12|scr regulon
P08412665A0000|59 68|Klebsiella
P08413186A0077|44 53|regulation
P08413186A0077|167 180|reductase genes
P08413186A0077|213 219|pathway
P08413186A0077|135 144|expression
P08413186A0077|20 29|mechanisms
P08413186A0077|119 125|factors
P08413186A0077|201 207|enzymes
P08413186A1199|3 10|Ntl1 gene
P08413186A1199|45 68|N. plumbaginifolia species
P08413186A1199|29 32|copy
P08413205A0733|131 136|copies
P08413205A0733|110 117|promoter
P08413205A0733|92 104|transcription
P08413205A0733|153 171|recognition sequence
P08413205A0733|44 56|Pax-8 isoforms
P08413205A0733|69 69|c
P08413205A0733|9 31|transfection experiments
P08413205A0733|61 61|b
P08413205A0733|73 73|d
P08413209A0159|27 33|protein
P08413209A0159|94 101|proteins
P08413209A0159|62 80|motif characteristic
P08413209A0159|17 21|third
P08413215A0327|70 82|transcription
P08413215A0327|91 102|IL-8 promoter
P08413215A0327|33 49|NF-kappa B subunits
P08413215A0327|17 23|ability
P08413223A0847|96 102|element
P08413223A0847|12 17|copies
P08413223A0847|119 130|phorbol ester
P08413223A0847|76 80|virus
P08413223A0847|23 43|IL-1 beta NF-kappa B site
P08413223A0847|162 175|gene expression
P08413223A0847|83 90|promoter
P08413239A0490|29 38|sequence CA
P08413239A0490|84 94|U snRNA genes
P08413239A0490|193 200|mutation
P08413239A0490|40 40|N
P08413239A0490|65 72|plant Pol
P08413239A0490|42 52|3-10AGTNNAA
P08413239A0490|159 168|vertebrate
P08413239A0490|171 173|box
P08413239A0490|116 127|end formation
P08413239A0490|130 142|U2 transcripts
P08413260A1437|71 74|cell
P08413260A1437|64 64|s
P08413260A1437|106 112|G2 phase
P08413260A1437|91 99|machinery
P08413260A1437|24 32|Rb protein
P08413260A1437|5 11|results
P08413260A1437|54 62|component
P08413274A0452|0 3|MDBP
P08413274A0452|123 131|MDBP sites
P08413274A0452|54 74|X-box oligonucleotides
P08413274A0452|8 11|HeLa
P08413274A0452|15 23|Raji cells
P08413274A0452|41 49|complexes
P08413291A1473|58 65|reporter
P08413291A1473|26 45|rat TnI-CAT fusion gene
P08413291A1473|91 96|muscle
P08413291A1473|10 13|mice
P08414410A0270|205 209|nerve
P08414410A0270|169 176|measures
P08414410A0270|50 53|eyes
P08414410A0270|24 27|eyes
P08414410A0270|114 125|field defects
P08414410A0270|213 227|nerve fiber layer
P08414410A0270|189 194|damage
P08414410A0270|95 98|eyes
P08414410A0270|70 75|fields
P08414410A0270|0 6|METHODS
P08414502A0244|88 90|DNA
P08414502A0244|125 133|promoters
P08414502A0244|54 62|regulator
P08414502A0244|103 115|transcription
P08414502A0244|17 26|hypothesis
P08414502A0244|73 82|p53 protein
P08415637A0000|117 125|G proteins
P08415637A0000|26 28|ARF
P08415637A0000|63 76|RAS superfamily
P08415637A0000|108 115|proteins
P08415637A0000|91 96|weight
P08415637A0000|47 57|subfamilies
P08415637A0000|3 24|ADP-ribosylation factor
P08415637A0000|30 35|family
P08415643A0555|83 89|mitosis
P08415643A0555|50 53|RCC1
P08415643A0555|43 46|gene
P08415643A0555|32 37|intron
P08415643A0555|76 80|onset
P08415643A0555|3 8|E1 gene
P08415643A0555|56 62|protein
P08415712A1153|172 193|Huntington disease locus
P08415712A1153|105 115|chromosomes
P08415712A1153|91 95|genes
P08415712A1153|196 205|chromosome
P08415712A1153|7 26|Southern blot analysis
P08415712A1153|154 157|GPRK
P08415712A1153|57 61|GPRK6
P08415712A1153|30 46|chromosome mapping
P08416952A0956|73 89|protein substrates
P08416952A0956|140 151|substitution
P08416952A0956|9 23|labeling studies
P08416952A0956|92 96|Nmt1p
P08416952A0956|129 133|Leu99
P08416952A0956|56 61|nmt72p
P08416952A0956|197 213|protein substrates
P08416952A0956|173 181|acylation
P08416952A0956|41 53|co-expression
P08416952A0956|159 167|reduction
P08416977A0892|73 78|Mono Q.
P08416977A0892|34 38|CTDK2
P08416977A0892|26 30|CTDK1
P08416977A0892|57 70|chromatography
P08416977A0892|5 14|CTD kinases
P08417117A0592|8 11|mRNA
P08417117A0592|23 24|kb
P08417117A0592|45 53|abundance
P08417330A0149|29 44|promoter fragment
P08417330A0149|109 129|CYC1-lacZ reporter gene
P08417330A0149|145 146|N.
P08417330A0149|46 55|oligo31/32
P08417330A0149|71 91|heat shock inducibility
P08417331A0745|56 62|repeats
P08417331A0745|16 23|HIR1 gene
P08417331A0745|148 151|Tup1
P08417331A0745|102 111|transducin
P08417331A0745|118 122|yeast
P08417331A0745|138 146|repressor
P08417331A0745|66 70|motif
P08417331A0745|3 10|sequence
P08417331A0745|40 46|protein
P08417331A0745|81 92|G beta subunit
P08417349A1633|115 130|mutation fixation
P08417349A1633|10 13|data
P08417349A1633|25 35|replication
P08417349A1633|48 56|templates
P08417349A1633|95 105|replication
P08418183A0000|261 261|H
P08418183A0000|135 153|Miyazaki Cohort Study
P08418183A0000|161 168|November
P08418183A0000|253 253|H
P08418183A0000|256 256|W
P08418183A0000|226 226|H
P08418183A0000|230 233|wife
P08418183A0000|115 121|couples
P08418183A0000|64 94|T cell leukemia/lymphoma virus type
P08418183A0000|276 276|W
P08418183A0000|97 102|HTLV-I
P08418183A0000|273 273|H
P08418183A0000|45 56|transmission
P08418183A0000|264 264|W
P08418183A0000|10 16|factors
P08418183A0000|247 247|W
P08418183A0000|199 205|husband
P08418183A0000|176 180|April
P08419318A1695|0 3|Biol
P08419333A0126|86 90|clone
P08419333A0126|17 26|expression
P08419333A0126|33 47|DNA repair enzyme
P08419338A0273|0 1|L.
P08419338A0273|53 54|A.
P08419338A0273|76 77|H.
P08419338A0273|26 30|Biber
P08419338A0273|10 11|G.
P08419338A0273|70 74|Murer
P08419338A0273|13 21|Markovich
P08419338A0273|42 43|X.
P08419338A0273|45 51|Zorzano
P08419338A0273|23 24|D.
P08419338A0273|56 62|Palacin
P08419338A0273|35 40|Testar
P08419338A0273|64 65|M.
P08419338A0273|32 33|J.
P08419338A0273|3 8|Stange
P08419376A0357|70 72|kDa
P08419376A0357|106 112|domains
P08419376A0357|39 49|polypeptide
P08419376A0357|26 29|gene
P08419376A0357|55 64|amino acids
P08419376A0357|3 20|nucleotide sequence
P08420230A0544|0 4|SAECG
P08420230A0544|67 71|month
P08420230A0544|25 43|thallium-201 imaging
P08420230A0544|6 21|echocardiography
P08420230A0544|86 96|angioplasty
P08420571A1880|14 18|PACE4
P08420571A1880|22 24|PC4
P08421295A0365|84 105|4ACAG consensus sequence
P08421295A0365|36 44|complexes
P08421295A0365|111 123|LexA repressor
P08421295A0365|76 79|CTGT
P08421295A0365|4 17|fusion proteins
P08421295A0365|55 63|DNA duplex
P08421687A0397|3 24|selenocysteine residues
P08421823A1041|59 66|patients
P08421823A1041|109 117|condition
P08421823A1041|77 83|absence
P08421823A1041|16 33|protein S deficiency
P08421823A1041|0 10|CONCLUSIONS
P08421897A0000|29 33|types
P08421897A0000|90 95|genome
P08421897A0000|56 64|sequences
P08421897A0000|140 148|DNA probes
P08421897A0000|108 130|stringency hybridization
P08421897A0000|172 192|animal retrovirus genes
P08421897A0000|13 18|decade
P08421910A0599|57 59|p46
P08421910A0599|22 30|complexes
P08421910A0599|122 141|uv cross-linking assay
P08421910A0599|61 63|p50
P08421910A0599|99 104|TAR RNA
P08421910A0599|43 47|TRBPs
P08421910A0599|5 14|components
P08421910A0599|49 51|p30
P08421910A0599|68 70|p56
P08421910A0599|53 55|p37
P08422975A1205|41 65|kinetoplastid mitochondria
P08422975A1205|32 38|editing
P08422975A1205|94 98|mRNAs
P08422975A1205|71 79|formation
P08422975A1205|20 28|necessity
P08423831A0523|12 16|model
P08423831A0523|83 90|diseases
P08423831A0523|127 136|parameters
P08423831A0523|64 69|issues
P08423831A0523|3 5|use
P08423831A0523|121 124|sets
P08425050A0898|117 124|sequence
P08425050A0898|38 41|rpeA
P08425050A0898|101 104|date
P08425050A0898|51 57|repeats
P08425050A0898|19 24|repeat
P08425050A0898|81 89|PE operons
P08425221A0000|127 131|cells
P08425221A0000|107 114|B lineage
P08425221A0000|48 50|BPK
P08425221A0000|52 72|B cell progenitor kinase
P08425221A0000|96 101|stages
P08425221A0000|27 40|tyrosine kinase
P08427501A0221|151 156|polyps
P08427501A0221|26 31|groups
P08427501A0221|180 185|polyps
P08427501A0221|64 77|enzyme activity
P08427501A0221|168 172|types
P08427501A0221|93 106|enzyme activity
P08427501A0221|5 15|differences
P08428722A1123|29 37|variables
P08428722A1123|78 99|blood urea nitrogen level
P08428722A1123|201 205|score
P08428722A1123|187 189|age
P08428722A1123|17 24|analysis
P08428722A1123|175 185|peritonitis
P08428722A1123|69 76|survival
P08428722A1123|101 135|serum aspartate aminotransferase level
P08428722A1123|209 213|ileus
P08428750T0000|0 11|Localization
P08428750T0000|27 30|gene
P08428750T0000|55 64|protein CLP
P08428750T0000|72 90|chromosome 10p13-ter
P08428907A0653|91 93|RNA
P08428907A0653|26 38|OBP transcript
P08428907A0653|11 21|stage larvae
P08428940A1763|41 47|hexamer
P08428940A1763|162 169|merR mRNA
P08428940A1763|86 89|MerR
P08428940A1763|50 51|PR
P08428940A1763|93 105|RNA polymerase
P08428940A1763|150 159|initiation
P08428940A1763|7 12|mutant
P08428940A1763|116 121|result
P08428940A1763|71 79|occupancy
P08428952A0399|101 110|expression
P08428952A0399|152 158|tissues
P08428952A0399|35 39|types
P08428952A0399|78 83|origin
P08428952A0399|8 16|L-plastin
P08428952A0399|56 60|cells
P08428952A0399|132 144|tumorigenesis
P08428952A1957|29 35|fimbrin
P08428952A1957|17 24|evidence
P08428952A1957|52 65|plastin isoform
P08428952A1957|116 124|intestine
P08428952A1957|100 105|levels
P08428953A1718|85 93|frequency
P08428953A1718|107 114|colonies
P08428953A1718|53 78|reporter beta-galactosidase
P08428953A1718|183 190|promoter
P08428953A1718|315 322|colonies
P08428953A1718|348 358|fibroblasts
P08428953A1718|144 152|L-plastin
P08428953A1718|38 47|expression
P08428953A1718|170 177|contrast
P08428953A1718|224 231|colonies
P08428953A1718|128 132|cells
P08428953A1718|292 301|activation
P08428953A1718|240 250|fibroblasts
P08428953A1718|377 395|L-plastin expression
P08428953A1718|269 277|frequency
P08428953A1718|4 11|promoter
P08428965A1868|30 50|CBP/tk binding activity
P08428965A1868|76 77|h.
P08428965A1868|101 105|WORDS
P08428965A1868|79 86|ABSTRACT
P08428965A1868|3 11|half-life
P08429019A0735|3 7|DNase
P08429019A0735|33 46|silencer region
P08429019A0735|9 17|footprint
P08429019A0735|89 93|motif
P08429019A0735|112 113|bp
P08429019A0735|66 71|repeat
P08429019A0735|130 134|bases
P08429019A0735|120 125|shares
P08429019A0735|95 101|epsilon
P08429019A0735|142 164|GATA-1 consensus sequence
P08429019A2022|89 98|competitor
P08429019A2022|66 80|protein B binding
P08429019A2022|35 54|YY1 consensus sequence
P08429019A2022|12 21|competitor
P08429019A2022|117 143|yeast ABF-1 consensus sequence
P08429019A2022|152 159|ABSTRACT
P08429019A2022|174 178|WORDS
P08429020A0495|58 60|DNA
P08429020A0495|78 89|reading frame
P08429020A0495|47 55|kilobases
P08429020A0495|131 134|exon
P08429020A0495|93 104|glycoprotein
P08429020A0495|20 24|exons
P08429020A0495|3 6|gene
P08429020A0495|31 37|introns
P08429568A0000|0 16|Rhizobium meliloti
P08429568A0000|131 137|ability
P08429568A0000|22 36|plasmid pRmeGR4b
P08429568A0000|97 116|nodulation efficiency
P08429568A0000|140 148|strain GR4
P08429568A0000|47 79|nodulation competitiveness locus nfe
P08429568A0000|151 162|alfalfa roots
P08430087A0467|41 51|gamma chains
P08430087A0467|90 106|beta gamma activity
P08430087A0467|11 17|ability
P08430087A0467|82 87|assays
P08430087A0467|31 34|beta
P08430087A0467|151 159|fractions
P08430087A0467|121 136|membrane extracts
P08430087A0467|172 179|Sf9 cells
P08430095A0161|4 9|report
P08430095A0161|39 42|gene
P08430095A0161|52 59|function
P08430095A0161|88 92|PRP38
P08430095A0161|61 64|SMD1
P08430095A0161|22 35|identification
P08430095A0913|85 99|snRNA maturation
P08430095A0913|103 111|stability
P08430095A0913|56 72|splicing apparatus
P08430095A0913|77 82|factor
P08430095A0913|34 42|component
P08430095A0913|5 8|data
P08430095A0913|18 22|Smd1p
P08431100A0108|155 167|children group
P08431100A0108|178 180|age
P08431100A0108|108 111|loss
P08431100A0108|139 143|hours
P08431100A0108|78 85|children
P08431100A0108|32 47|motor performance
P08431100A0108|4 8|study
P08431100A0108|95 99|years
P08431100A0108|114 126|consciousness
P08431100A0108|184 186|sex
P08432137A0000|30 47|adenosine deaminase
P08432137A0000|69 76|patients
P08432137A0000|214 216|IFN
P08432137A0000|125 132|lysozyme
P08432137A0000|82 99|PADA/serum ADA ratio
P08432137A0000|49 52|PADA
P08432137A0000|152 169|PLYS/serum LYS ratio
P08432137A0000|181 185|cases
P08432137A0000|142 146|cases
P08432137A0000|281 289|effusions
P08432137A0000|221 225|cases
P08432137A0000|13 22|parameters
P08432137A0000|101 106|P/SADA
P08432137A0000|134 137|PLYS
P08432137A0000|111 115|cases
P08432137A0000|241 247|ability
P08432137A0000|171 176|P/SLYS
P08432137A0000|198 212|interferon gamma
P08432137A0000|294 299|others
P08432526A0580|100 120|fibroblast cDNA library
P08432526A0580|61 96|polymerase chain reaction amplification
P08432526A0580|36 50|sequencing cDNAs
P08432526A0580|5 9|exons
P08432696A1117|56 66|proteinases
P08432696A1117|119 128|cell growth
P08432696A1117|81 95|aminopeptidase N
P08432696A1117|111 116|effect
P08432696A1117|41 48|deletion
P08432696A1117|13 20|apeA gene
P08432696A1117|68 75|protease
P08432696A1117|141 145|media
P08432696A1117|0 7|Deletion
P08435755A0938|72 72|h
P08435755A0938|113 115|rat
P08435755A0938|46 50|mg/kg
P08435755A0938|93 103|stimulation
P08435755A0938|125 138|stage-3 seizure
P08435755A0938|2 11|Experiment
P08435755A0938|13 35|scopolamine hydrobromide
P08435755A1078|41 52|kindling rate
P08435755A1078|147 152|values
P08435755A1078|107 113|stage-3
P08435755A1078|32 39|kindling
P08435755A1078|71 78|seizures
P08435755A1078|59 65|stage-3
P08435755A1078|10 12|BSS
P08435755A1078|80 96|seizure parameters
P08435755A1078|4 6|ADD
P08435755A1078|177 181|group
P08435755A1078|25 29|stage
P08435755A1078|0 2|PNT
P08435794A0658|0 10|CONCLUSIONS
P08435885A0787|17 27|correlation
P08435885A0787|35 63|pyridinium cross-link excretion
P08435885A0787|67 94|thyroid hormone concentrations
P08437521A0000|0 8|Mutations
P08437521A0000|198 208|areA product
P08437521A0000|186 192|ability
P08437521A0000|91 98|areA gene
P08437521A0000|245 255|areA control
P08437521A0000|40 47|residues
P08437521A0000|70 78|activator
P08437521A0000|150 157|nidulans
P08437521A0000|109 136|nitrogen metabolite repression
P08437521A0000|219 228|expression
P08437521A0000|235 239|genes
P08437737A0100|0 13|Naval personnel
P08437737A0100|62 65|duty
P08437737A0100|35 37|%BF
P08437737A0100|23 31|standards
P08438584A0524|81 88|promoter
P08438584A0524|50 51|C1
P08438584A0524|55 60|C2 ORFs
P08438584A0524|62 70|C1-C2 gene
P08438584A0524|37 44|promoter
P08438584A0524|4 19|promoter activity
P08438584A0524|94 98|V1 ORF
P08438584T0000|83 99|C1-C2 gene products
P08438584T0000|51 61|mosaic virus
P08438584T0000|16 34|coat protein promoter
P08438584T0000|3 10|activity
P08439564A0883|144 144|%
P08439564A0883|111 128|porcine haptocorrin
P08439564A0883|50 67|Cbl binding proteins
P08439564A0883|152 159|homology
P08439564A0883|3 28|amino acid sequence alignment
P08439564A0883|93 107|transcobalamin I
P08439564A0883|31 32|TC
P08439564A0883|81 86|factor
P08439564A0883|69 71|rat
P08439597A0000|76 79|FEIA
P08439597A0000|132 144|determination
P08439597A0000|109 125|fluoroimmunoassay
P08439597A0000|9 21|communication
P08439597A0000|147 157|thyrotropin
P08439597A0000|58 74|enzyme immunoassay
P08439597A0000|165 174|blood spots
P08439597A0176|87 102|screening centres
P08439597A0176|66 77|blood samples
P08439597A0176|3 12|evaluation
P08439597A0176|44 54|study design
P08440238T0000|12 21|C-terminus
P08440238T0000|124 133|modulation
P08440238T0000|60 70|association
P08440238T0000|166 178|tumorigenesis
P08440238T0000|37 46|E1a protein
P08440238T0000|24 33|adenovirus
P08440238T0000|182 191|metastasis
P08440238T0000|151 164|transformation
P08440238T0000|136 142|T24-ras
P08440238T0000|84 97|phosphoprotein
P08440238T0000|1 6|region
P08440688A1509|86 91|growth
P08440688A1509|112 125|hormone signals
P08440688A1509|5 11|studies
P08440688A1509|93 107|differentiation
P08440688A1509|38 42|genes
P08440688A1509|31 36|G alpha
P08440688A1509|68 79|LLC-PK1 cells
P08440720A1404|0 9|Constructs
P08440720A1404|84 88|level
P08440720A1404|34 42|PfCPK cDNA
P08440720A1404|117 123|protein
P08441379A0912|43 48|region
P08441379A0912|105 109|virus
P08441379A0912|112 127|enhancer elements
P08441379A0912|211 228|IL-1 beta expression
P08441379A0912|16 29|proIL-1 beta cap
P08441379A0912|170 178|HeLa cells
P08441379A0912|82 92|proIL-1 beta
P08441379A0912|155 163|monocytes
P08441394A1297|31 55|signal transduction pathway
P08441394A1297|10 15|PC-PLC
P08441394A1297|112 116|c-myc
P08441394A1297|88 91|junB
P08441394A1297|65 77|transcription
P08441394A1297|135 143|PKC-delta
P08441394A1297|80 84|c-fos
P08441394A1297|19 27|component
P08441394A1297|147 159|Ras activation
P08441411A1260|32 46|Gfi-1 expression
P08441411A1260|252 257|S phase
P08441411A1260|203 210|receptor
P08441411A1260|156 161|events
P08441411A1260|69 79|stimulation
P08441411A1260|98 103|levels
P08441411A1260|20 30|splenocytes
P08441411A1260|179 189|interaction
P08441411A1260|228 237|transition
P08441411A1260|192 195|IL-2
P08441411A1260|63 63|h
P08441411A1260|245 246|G1
P08441411A1260|111 111|h
P08441411A1260|263 271|cell cycle
P08441423A0145|40 48|GCD7 genes
P08441423A0145|94 108|GCN4 translation
P08441423A0145|127 136|conditions
P08441423A0145|33 36|GCD6
P08441423A0145|66 73|products
P08441869A0334|46 53|relation
P08441869A0334|3 17|plateau MO2 value
P08442384A0430|126 141|amino acid peptide
P08442384A0430|95 100|leader
P08442384A0430|66 77|reading frame
P08442384A0430|79 82|uORF
P08442384A0430|29 35|protein
P08442384A0430|41 50|amino acids
P08442384T0000|39 44|leader
P08442384T0000|59 70|reading frame
P08442384T0000|3 23|SCH9 protein kinase mRNA
P08443122A0657|73 75|PMA
P08443122A0657|21 50|fibroblasts PILOT gene expression
P08443122A0657|66 71|signal
P08443122A0657|12 17|T cells
P08443122A0657|95 97|CyA
P08443122A0657|2 9|contrast
P08443339A1374|103 108|cortex
P08443339A1374|38 53|promoter function
P08443339A1374|13 24|localization
P08443339A1374|27 29|GUS
P08443339A1374|133 136|root
P08443339A1374|56 68|leaf epidermis
P08443339A1374|70 78|mesophyll
P08443339A1374|120 127|cylinder
P08443339A1374|90 96|bundles
P08443340A0522|28 45|expression patterns
P08443340A0522|166 175|expression
P08443340A0522|102 114|glucanase gene
P08443340A0522|205 217|tobacco plants
P08443340A0522|139 141|GUS
P08443340A0522|183 192|constructs
P08443340A0522|68 82|promoter regions
P08443340A0522|120 137|beta-glucuronidase
P08443340A0522|2 6|order
P08443340A0522|143 154|reporter gene
P08443341A0384|97 113|MA type myrosinases
P08443341A0384|75 86|MB cDNA clones
P08443341A0384|25 30|probes
P08443341A0384|151 167|MB type myrosinases
P08443341A0384|197 203|B. napus
P08443341A0384|40 47|portions
P08443341A0384|190 194|genes
P08443341A0384|63 71|B. napus MA
P08443341A0384|140 144|genes
P08443341A0384|0 19|Southern blot analysis
P08444184A0245|0 8|Sudomoina
P08444184A0245|10 11|A.
P08444344A0000|0 10|Zinc fingers
P08444344A0000|12 13|Zf
P08444344A0000|35 39|motif
P08444344A0000|70 77|proteins
P08444345A0403|72 72|%
P08444345A0403|135 138|DbpB
P08444345A0403|47 47|%
P08444345A0403|22 30|amino acid
P08444345A0403|103 114|family member
P08444345A0403|126 133|protein B
P08444345A0403|32 33|aa
P08444345A0403|35 42|sequence
P08444345A0403|89 100|EFIA/DbpB/YB
P08444345A0403|59 65|rat EFIA
P08444345A0403|16 19|EFIA
P08445299T0000|0 5|Effect
P08445299T0000|49 61|ozone toxicity
P08445299T0000|64 67|rats
P08445299T0000|16 27|insufflation
P08445299T0000|30 41|deferoxamine
P08445655A1009|0 11|Localization
P08445655A1009|36 46|yeast genome
P08445655A1009|50 71|complementation studies
P08445655A1009|124 132|mutations
P08445655A1009|17 30|insertion locus
P08445729A0657|43 46|ARMs
P08445729A0657|59 65|stretch
P08445729A0657|68 75|sequence
P08445729A0657|87 96|RNA binding
P08445729A0657|16 29|spacer sequence
P08445729A0657|0 10|Replacement
P08445792A0469|0 3|Type
P08445792A0469|103 108|stages
P08445792A0469|118 124|species
P08445792A0469|34 38|forms
P08445792A0469|46 48|IIB
P08445792A0469|81 87|species
P08445792A0469|40 42|IIA
P08446579A0784|119 134|activating domain
P08446579A0784|76 79|cell
P08446579A0784|10 34|transcription factor Gal-ER
P08446579A0784|140 161|herpesvirus protein VP16
P08446579A0784|169 177|C terminus
P08446579A0784|93 101|variation
P08446579A1210|45 50|levels
P08446579A1210|12 18|fos gene
P08446579A1210|60 61|hr
P08446579A1210|64 79|estrogen addition
P08447005T0001|0 10|Elimination
P08447005T0001|54 65|introduction
P08447005T0001|24 48|influenzae type b meningitis
P08447005T0001|68 78|vaccination
P08449133A0578|0 13|Endosonography
P08449133A0578|51 58|T2 tumors
P08449133A0578|62 69|T3 tumors
P08449133A0578|79 86|T4 tumors
P08449133A0578|32 45|tumor extension
P08449943A0225|57 65|8-Cl-cAMP
P08449943A0225|127 139|leukemia cells
P08449943A0225|12 16|study
P08449943A0225|104 108|HL-60
P08449943A0225|88 101|kinase isozymes
P08449943A0225|38 46|mechanism
P08449943A0225|49 54|action
P08449943A0225|71 80|regulation
P08449978A0000|0 7|Analysis
P08449978A0000|10 28|cell cycle regulation
P08449978A0000|128 134|changes
P08449978A0000|113 117|Cdc28
P08449978A0000|229 233|times
P08449978A0000|155 163|cell cycle
P08449978A0000|99 111|protein kinase
P08449978A0000|197 203|cyclins
P08449978A0000|137 144|activity
P08449978A0000|41 45|yeast
P08449978A0000|189 194|groups
P08449986A0455|48 55|MMI alpha
P08449986A0455|40 44|cDNAs
P08449986A0455|11 16|clones
P08449986A0455|72 81|mouse brain
P08450015A0175|60 67|standard
P08450015A0175|127 154|n-propyl carbamate derivatives
P08450015A0175|39 48|oxiracetam
P08450015A0175|72 77|plasma
P08450015A0175|111 119|formation
P08450015A0175|80 100|solid-phase extraction
P08450015A0175|3 8|method
P08450015A0175|28 36|isolation
P08451187A0267|24 34|differences
P08451187A0267|51 62|ars sequences
P08451331T0000|0 7|Pathways
P08451331T0000|109 112|mice
P08451331T0000|27 31|bulbs
P08451331T0000|97 106|aggression
P08451331T0000|61 72|hypothalamus
P08453101A0128|0 14|Pokeweed mitogen
P08453101A0128|70 73|mRNA
P08453101A0128|83 88|T cells
P08453101A0128|52 68|c-jun messenger RNA
P08453101A0128|16 18|PWM
P08453101A0128|75 80|levels
P08453950A0498|44 47|mm Hg
P08453950A0498|26 29|MABP
P08453950A0498|51 58|brain pHi
P08453950A0498|115 115|P
P08453950A0498|104 108|level
P08453950A0498|9 24|seizure induction
P08453950A0498|113 113|h
P08453950A0498|84 86|min
P08454077A0956|2 9|contrast
P08454077A0956|107 110|GMBF
P08454077A0956|257 259|GMV
P08454077A0956|137 139|min
P08454077A0956|183 185|min
P08454077A0956|326 332|normals
P08454077A0956|24 30|U74500A
P08454077A0956|279 285|muscles
P08454077A0956|203 203|p
P08454077A0956|33 49|mg/kg i.v. infusion
P08454077A0956|263 263|%
P08454077A0956|320 321|NS
P08454077A0956|372 376|WORDS
P08454077A0956|160 162|min
P08454077A0956|212 219|controls
P08454077A0956|11 14|rats
P08454077A0956|243 255|muscle salvage
P08454077A0956|133 134|PI
P08454077A0956|72 88|revascularisation
P08454077A0956|223 229|normals
P08454077A0956|337 346|h ischaemia
P08454077A0956|350 357|ABSTRACT
P08454077A0956|296 303|controls
P08454077A0956|62 64|min
P08454077A0956|287 287|p
P08454077A0956|121 131|reperfusion
P08454591A0692|0 9|Sequencing
P08454591A0692|110 131|transcription start site
P08454591A0692|90 102|CAAT sequences
P08454591A0692|25 32|fragment
P08454591A0692|49 54|region
P08454591A0692|60 67|TSG6 gene
P08454591A1322|114 120|NF-IL-6
P08454591A1322|20 31|inducibility
P08454591A1322|80 91|binding sites
P08454591A1322|34 37|IL-1
P08454591A1322|95 99|IRF-1
P08454591A1322|44 52|positions
P08454591A1322|106 109|AP-1
P08454591A1322|3 8|region
P08454591A1322|40 42|TNF
P08454858A0285|88 96|associate
P08454858A0285|11 17|Ig-beta
P08454858A0285|160 177|signal transduction
P08454858A0285|61 70|amino acids
P08454858A0285|112 120|effectors
P08454858A0285|44 52|structure
P08454858A0285|0 7|Ig-alpha
P08455598A0000|133 145|mating ability
P08455598A0000|55 65|alpha * cells
P08455598A0000|175 184|repression
P08455598A0000|75 95|a/alpha aar1-6 genotype
P08455598A0000|149 154|result
P08455598A0000|166 173|a1-alpha
P08455598A0000|107 124|alpha mating ability
P08455598A0000|7 13|mutants
P08455598A0000|158 163|defect
P08455611A0000|143 152|globin gene
P08455611A0000|108 112|HS-40
P08455611A0000|22 32|interaction
P08455611A0000|54 57|zeta
P08455611A0000|138 141|zeta
P08455611A0000|123 124|kb
P08455611A0000|79 89|alpha globin
P08455611A0000|100 106|element
P08455611A0000|59 72|globin promoter
P08455611A0154|115 123|K562 cells
P08455611A0154|91 112|globin promoter activity
P08455611A0154|21 35|expression assay
P08455611A0154|136 143|cell line
P08455611A0154|65 72|enhancer
P08455611A0154|166 171|origin
P08455611A0154|40 44|HS-40
P08455611A0154|86 89|zeta
P08455623A0630|129 132|GAR1
P08455623A0630|114 125|proteins NOP1
P08455623A0630|151 156|strain
P08455623A0630|140 144|snr10
P08455623A0630|55 61|species
P08455623A0630|7 13|results
P08455623A0630|72 80|depletion
P08455623A0630|30 40|23S pre-rRNA
P08455629A0335|0 8|Breitbart
P08455629A0335|10 11|L.
P08456378A0134|101 105|model
P08456378A0134|83 91|technique
P08456378A0134|52 67|lymphangiography
P08456378A0134|21 31|feasibility
P08456378A0134|4 8|study
P08456879A0000|0 8|OBJECTIVE
P08456879A0000|65 77|serum cotinine
P08456879A0000|13 19|purpose
P08456879A0000|49 62|concentrations
P08456879A0000|100 104|blood
P08457205A0240|141 145|cDNAs
P08457205A0240|51 57|protein
P08457205A0240|123 128|G alpha
P08457205A0240|8 24|amino acid sequence
P08457205A0240|75 91|% sequence identity
P08457205A0240|134 139|G alpha
P08457205A0240|96 104|sequences
P08457291A0170|43 57|proto-oncogenes
P08457291A0170|119 131|c-fos oncogene
P08457291A0170|24 33|expression
P08457291A0170|99 105|regions
P08457291A0170|0 8|Estradiol
P08458660A0855|0 6|Air lead
P08458660A0855|36 43|variable
P08458849A0364|13 22|regulation
P08458849A0364|79 89|ftr elements
P08458849A0364|148 151|+120
P08458849A0364|25 41|flaN transcription
P08458849A0364|153 156|ftr3
P08458849A0364|58 62|sigma
P08458849A0364|65 72|promoter
P08458849A0364|140 143|ftr2
P08458849A0364|112 133|transcription start site
P08458906A0827|1 12|micrograms/l
P08458906A0827|26 30|urine
P08458906A0827|64 70|persons
P08459012T0000|18 27|deficiency
P08459012T0000|7 13|dimelia
P08459012T0000|33 37|tibia
P08459465A0257|221 242|energy expenditure times
P08459465A0257|246 259|activity factor
P08459465A0257|82 92|calorimetry
P08459465A0257|116 132|energy expenditure
P08459465A0257|39 56|energy expenditures
P08459465A0257|265 276|stress factor
P08459465A0257|61 68|patients
P08459465A0257|188 204|energy expenditure
P08459465A0257|15 19|study
P08459465A0257|162 169|equation
P08460270A0205|21 30|infections
P08460270A0205|42 47|larvae
P08460346A0350|62 66|study
P08460918A0252|0 4|Group
P08460918A0252|216 224|IU liter-1
P08460918A0252|126 134|bilirubin
P08460918A0252|105 114|impairment
P08460918A0252|138 149|mumol liter-1
P08460918A0252|278 285|patients
P08460918A0252|43 47|group
P08460918A0252|312 329|hyperbilirubinemia
P08460918A0252|227 231|group
P08460918A0252|184 211|gamma-glutamyltranspeptidase
P08460918A0252|82 89|patients
P08460918A0252|335 346|mumol liter-1
P08460918A0252|34 41|patients
P08460918A0252|174 182|IU liter-1
P08460918A0252|151 169|alkaline phosphatase
P08461946A0386|73 85|split function
P08461946A0386|50 57|findings
P08461946A0386|16 21|change
P08461946A0386|91 98|patients
P08461946A0386|102 102|%
P08461946A0386|26 36|improvement
P08461946A0386|59 66|t1/2 time
P08461981A0882|38 43|months
P08461981A0882|50 54|study
P08461981A0882|101 104|rats
P08461981A0882|12 15|need
P08461981A0882|21 27|animals
P08461981A0882|64 84|regeneration phenomena
P08463284A1531|13 15|PKC
P08463284A1531|7 10|beta
P08463284A1531|21 33|p34cdc2 kinase
P08463284A1531|63 68|lamina
P08463284A1531|79 87|stability
P08463284A1531|94 102|cell cycle
P08463320A1219|175 186|SSB tetramers
P08463320A1219|51 79|gel shift assembly intermediates
P08463320A1219|108 113|G4oric
P08463320A1219|6 38|copper-phenanthroline footprinting
P08463320A1219|126 137|SSB tetramers
P08463320A1219|196 204|formation
P08463320A1219|214 222|structure
P08463320A1219|161 168|addition
P08463485T0000|0 6|Effects
P08463485T0000|55 69|oxytocin release
P08463485T0000|21 37|endotoxin infusion
P08464056A0000|0 5|Finger
P08464056A0000|77 88|C2H2 type ZFPs
P08464056A0000|91 103|Xenopus laevis
P08464056A0000|39 46|FAX-ZFPs
P08464056A0000|24 37|finger proteins
P08464056A0000|59 67|subfamily
P08464056A0510|189 201|hybridization
P08464056A0510|210 220|chromosomes
P08464056A0510|113 132|restriction fragments
P08464056A0510|154 176|field gel electrophoresis
P08464056A0510|7 14|evidence
P08464056A0510|79 98|Southern blot analysis
P08464056A0510|28 39|organization
P08464056A0510|42 66|FAX-ZFP transcription units
P08464924A0243|1 7|rat cDNA
P08464924A0243|19 23|eIF-5
P08464924A0243|95 106|eIF-5 protein
P08466864A0878|145 155|binding site
P08466864A0878|229 244|promoter activity
P08466864A0878|10 17|analyses
P08466864A0878|159 166|TGF-beta
P08466864A0878|70 78|bp segment
P08466864A0878|49 57|sequences
P08466864A0878|105 107|AMP
P08466864A0878|206 220|Sp1 binding sites
P08466864A0878|199 202|PU-1
P08466864A0878|37 46|importance
P08466864A0878|140 143|CREB
P08466864A0878|171 187|PMA responsiveness
P08466864A0878|118 138|element binding protein
P08468320A0941|6 7|J.
P08468475A1280|190 210|F42A-IL-2R beta complex
P08468475A1280|259 266|affinity
P08468475A1280|57 65|YT-1 cells
P08468475A1280|272 290|F42A binding reaction
P08468475A1280|125 140|IL-2R beta subunit
P08468475A1280|155 164|IL-2R alpha
P08468475A1280|70 84|IL-2R alpha chain
P08468475A1280|224 236|alpha-subunit
P08468475A1280|17 37|internalization assays
P08469831T0001|29 43|prostaglandin E1
P08469831T0001|92 96|hyper
P08469831T0001|78 86|reactions
P08469831T0001|112 116|state
P08469831T0001|125 129|shock
P08469831T0001|50 60|nicardipine
P08469831T0001|19 26|dynamics
P08469831T0001|133 140|rat model
P08470021A0195|117 129|Ignacio Chavez
P08470021A0195|105 115|Cardiologia
P08470021A0195|25 37|IgG antibodies
P08470021A0195|133 142|Mexico City
P08470021A0195|45 60|Trypanosoma cruzi
P08470021A0195|70 80|blood donors
P08470021A0195|13 22|prevalence
P08470021A0195|86 102|Instituto Nacional
P08470895A1617|0 10|Examination
P08470895A1617|25 32|sequence
P08470895A1617|62 68|TATA box
P08470895A1617|40 52|mRNA start site
P08470895A1617|85 101|enhancer sequences
P08471241T0000|50 53|milk
P08471241T0000|13 21|synthesis
P08471241T0000|65 69|women
P08471241T0000|41 47|removal
P08471629A0816|132 138|peptide
P08471629A0816|96 107|nPKC activity
P08471629A0816|37 46|C-terminus
P08471629A0816|148 156|substrate
P08471629A0816|119 129|Histone IIIS
P08471629A0816|82 89|beta-PKC
P08471629A0816|0 14|Pseudosubstrate
P08471629A0816|61 71|PKC isotypes
P08471796A1654|70 82|A. caulinodans
P08471796A1654|24 28|model
P08471796A1654|12 18|results
P08471796A1654|35 44|regulation
P08471796A1654|54 67|gene expression
P08472750A0999|62 82|porcine endotoxin shock
P08472750A0999|116 117|pH
P08472750A0999|6 20|oxide inhalation
P08472750A0999|153 162|activation
P08472750A0999|129 139|attenuation
P08472750A0999|48 59|hypertension
P08472750A0999|102 112|oxygenation
P08473731A0149|0 0|B
P08473731A0149|77 83|complex
P08473731A0149|21 28|B29 genes
P08473731A0149|92 95|sIgM
P08473731A0149|38 57|alpha/beta components
P08473731A0149|97 102|B cells
P08473731A0149|14 17|mb-1
P08473967T0000|0 9|Bipolarity
P08473967T0000|12 28|Jungian type theory
P08473967T0000|35 59|Myers-Briggs Type Indicator
P08474438A0000|1 7|variety
P08474438A0000|76 88|RNA polymerase
P08474438A0000|235 247|mRNA transport
P08474438A0000|202 209|splicing
P08474438A0000|91 101|transcripts
P08474438A0000|144 165|RNA processing reactions
P08474438A0000|176 198|pre-mRNA polyadenylation
P08474438A0000|17 34|ribonucleoproteins
P08474439A0877|0 8|Mutations
P08474439A0877|133 141|mutations
P08474439A0877|220 228|mutations
P08474439A0877|210 215|muscle
P08474439A0877|121 131|muscle types
P08474439A0877|75 86|site mutation
P08474439A0877|101 106|effect
P08474439A0877|265 274|expression
P08474439A0877|190 199|expression
P08474439A0877|163 166|site
P08474439A0877|157 161|E-box
P08474439A0877|16 20|sites
P08474439A0877|40 45|muscle
P08474439A0877|234 241|CArG site
P08474439A0877|284 289|muscle
P08474439A0877|31 37|effects
P08474439A0877|147 150|MEF1
P08474439A0877|59 63|cells
P08474456A1041|69 74|region
P08474456A1041|9 28|transfection analysis
P08474456A1041|112 128|LyF-1 binding sites
P08474456A1041|142 151|D' activity
P08474456A1041|38 46|mutations
P08474456A1041|98 100|Ets
P08474464A0348|58 71|TR binding sites
P08474464A0348|38 44|Rev-Erb
P08474464A0348|35 36|TR
P08474464A0348|18 29|relationship
P08475104A0341|142 146|cells
P08475104A0341|166 172|cyclin A
P08475104A0341|111 113|htk
P08475104A0341|22 36|promoter element
P08475104A0341|95 109|thymidine kinase
P08475104A0341|158 163|target
P08475104A0341|179 194|p33cdk2 complexes
P08475104A0341|71 84|G1-S activation
P08475104A0341|115 122|promoter
P08476087A0814|15 24|influences
P08476087A0814|64 72|pressures
P08476087A0814|91 94|mmHg
P08476087A0814|50 54|range
P08476854A0097|0 4|DNase
P08476854A0097|76 82|domains
P08476854A0097|126 134|base pairs
P08476854A0097|37 44|extracts
P08476854A0097|6 17|footprinting
P08476854A0097|106 124|base pair DNA fragment
P08476854A0097|22 29|rat liver
P08476854A0097|98 99|P7
P08476854A0097|89 90|P1
P08479742A0985|64 80|cell proliferation
P08479742A0985|35 41|ability
P08479742A0985|24 27|part
P08479742A0985|109 117|processes
P08479742A0985|52 54|p53
P08481004A0321|29 40|endonuclease
P08481004A0321|7 11|clone
P08482539A0913|0 19|Northern blot analysis
P08482539A0913|35 37|RNA
P08482539A0913|51 54|xylP
P08482539A0913|69 78|transcript
P08482539A0913|95 99|xylan
P08483412A0000|87 95|promoters
P08483412A0000|127 137|NifA protein
P08483412A0000|10 22|nifH promoters
P08483412A0000|25 34|Klebsiella
P08483412A0000|3 6|nifJ
P08483412A0000|70 74|sigma
P08483479A1056|86 89|mice
P08483479A1056|17 19|PTH
P08483479A1056|23 26|cAMP
P08483479A1056|63 71|calvariae
P08483479A1056|108 112|alpha
P08483479A1056|237 240|bone
P08483479A1056|37 60|collagen promoter activity
P08483479A1056|191 193|PTH
P08483479A1056|213 234|collagen gene expression
P08483479A1056|146 164|elements down-stream
P08483479A1056|197 210|cAMP repression
P08483479A1056|171 179|kilobases
P08483479A1056|5 8|data
P08483479A1056|117 132|collagen promoter
P08484514A1536|44 63|baseline vein diameter
P08484514A1536|24 33|isoflurane
P08484514A1536|70 80|stimulation
P08484689T0000|0 9|Prevalence
P08484689T0000|22 30|arthritis
P08484689T0000|77 83|decline
P08484689T0000|52 56|women
P08484689T0000|58 65|evidence
P08484689T0000|44 49|factor
P08484891A0000|90 96|changes
P08484891A0000|194 201|memories
P08484891A0000|122 129|evidence
P08484891A0000|111 114|bulb
P08484891A0000|28 39|conditioning
P08484891A0000|49 52|rats
P08484891A0000|153 160|circuits
P08485317A0000|3 18|fission yeast dsk1
P08485317A0000|92 104|protein kinase
P08485317A0000|62 72|dis1 mutants
P08485317A0000|20 23|gene
P08485317A0000|35 44|suppressor
P08486035T0000|0 6|Closure
P08486035T0000|12 33|patent ductus arteriosus
P08486035T0000|39 46|Ligaclip
P08486035T0000|55 69|minithoracotomy
P08486276A0419|0 17|Sequence comparison
P08486276A0419|128 129|TM
P08486276A0419|114 126|transmembrane
P08486276A0419|131 138|proteins
P08486276A0419|45 59|protein database
P08486276A0419|162 176|chloramphenicol
P08486276A0419|231 244|symport protein
P08486276A0419|184 195|tetracycline
P08486276A0419|200 209|resistance
P08486276A0419|38 40|ORF
P08486276A0419|197 198|Tc
P08486276A0419|84 102|% aa sequence homology
P08486276A0419|178 179|Cm
P08486705A0181|115 126|eIF-5 protein
P08486705A0181|23 27|eIF-5
P08486705A0181|39 42|TIF5
P08486705A0181|3 11|yeast gene
P08488700A0283|85 96|immunization
P08488700A0283|20 29|hepatitis B
P08488700A0283|33 42|hepatitis D
P08488700A0283|195 204|hepatitis B
P08488700A0283|141 156|blood derivatives
P08488700A0283|115 122|exposure
P08488700A0283|160 168|education
P08488700A0283|227 233|disease
P08488700A0283|182 190|awareness
P08488700A0283|134 138|blood
P08488700A0283|3 12|strategies
P08490002A0620|0 5|Xylose
P08490002A0620|79 84|breads
P08490002A0620|63 71|cellulose
P08490002A0620|30 37|polymers
P08491124A0517|29 43|mouth protectors
P08491124A0517|139 153|mouth protectors
P08491124A0517|65 68|need
P08491124A0517|104 112|materials
P08491124A0517|12 23|construction
P08491124A0517|93 97|costs
P08491124A0517|72 86|instrumentation
P08491383A0154|3 15|alpha-subunit
P08491383A0154|40 42|DNA
P08491383A1291|17 29|alpha-subunit
P08491383A1291|129 146|interaction domains
P08491383A1291|67 86|transcription factors
P08491383A1291|51 57|protein
P08491683A0651|101 108|prostate
P08491683A0651|23 30|patients
P08491683A0651|50 57|patients
P08491683A0651|82 95|adenocarcinoma
P08491683A0651|5 12|patients
P08492164T0000|42 47|cortex
P08492164T0000|76 81|effect
P08492164T0000|11 21|burst firing
P08492164T0000|90 108|interaction measures
P08492164T0000|24 26|cat
P08492164T0000|49 51|age
P08492164T0000|55 69|depth dependence
P08492290A0306|43 48|medium
P08492290A0306|74 91|stability constants
P08492290A0306|109 115|log beta
P08492290A0306|27 32|method
P08492290A0306|93 99|log beta
P08492290A0306|56 65|strength mu
P08495786A0085|0 21|Cryopreservation straws
P08495786A0085|89 93|donor
P08495786A0085|67 73|surface
P08495786A0085|32 36|media
P08496157A0000|3 11|bcl-2 gene
P08496157A0000|73 85|carboxyl tails
P08496157A0000|108 124|splicing mechanism
P08496157A0000|44 51|proteins
P08496184A0772|13 24|reading frame
P08496184A0772|98 112|type counterpart
P08496184A0772|57 66|chromosome
P08496184A0772|83 90|sequence
P08496184A0772|30 34|clone
P08496184A0772|43 45|min
P08496185A0484|58 76|adenylate kinase gene
P08496185A0484|78 81|adk1
P08496185A0484|109 119|nucleotides
P08496185A0484|51 52|S.
P08496185A0484|10 16|cloning
P08496185A0484|20 45|nucleotide sequence analysis
P08496185A0484|98 103|region
P08496475T0000|60 71|Bacterionema
P08496475T0000|73 83|matruchotii
P08496475T0000|26 38|Streptococcus
P08496475T0000|0 12|Calcification
P08496475T0000|44 58|Corynebacterium
P08496599A0310|3 8|result
P08496599A0310|34 40|BGP gene
P08496599A0310|78 88|mRNA species
P08496599A0310|22 29|splicing
P08496601A1153|28 38|muMIP-1 beta
P08496601A1153|95 111|expression studies
P08496601A1153|122 132|macrophages
P08496601A1153|181 192|muMIP-1 alpha
P08496601A1153|165 175|muMIP-1 beta
P08496601A1153|42 53|muMIP-1 alpha
P08496601A1153|71 81|CK-1 element
P08496601A1153|216 260|growth hormone reporter gene link LPS-inducibility
P08496601A1153|16 24|promoters
P08496601A1153|269 284|promoter segments
P08496601A1153|1 10|comparison
P08496601A1153|195 202|promoter
P08496601A1153|114 116|RAW
P08496601A1153|315 335|consensus CK-1 sequence
P08496601A1153|145 153|fragments
P08496848A0692|17 35|contrast differences
P08496848A0692|54 65|FSE sequences
P08496848A0692|95 107|SE counterpart
P08497190T0079|0 15|Sequence analysis
P08497190T0079|38 40|hyp
P08497190T0079|51 57|mutants
P08497190T0079|19 32|identification
P08497248A0000|29 38|macrophage
P08497248A0000|159 170|trophoblasts
P08497248A0000|65 69|CSF-1
P08497248A0000|3 6|gene
P08497248A0000|57 62|factor
P08497248A0000|18 25|receptor
P08497248A0000|146 155|phagocytes
P08497248A0000|75 92|c-fms protooncogene
P08497259A0452|13 32|SUP4A53T61 transcript
P08497259A0452|56 67|tap1-1 mutant
P08497259A0452|3 7|level
P08497259A0452|81 84|type
P08497269A0999|160 166|process
P08497269A0999|169 189|translation elongation
P08497269A0999|63 71|ribosomes
P08497269A0999|116 119|GCN2
P08497269A0999|141 150|tRNA levels
P08497269A0999|90 98|functions
P08497269A0999|4 21|sequence similarity
P08497269A0999|46 49|GCN1
P08497269A0999|31 41|possibility
P08497269A0999|74 86|tRNA molecules
P08497269A0999|101 111|conjunction
P08497273T0000|0 4|NF-HB
P08497273T0000|61 73|alpha enhancer
P08497273T0000|6 9|BSAP
P08497273T0000|34 47|immunoglobulin
P08497273T0000|89 109|B-cell differentiation
P08497273T0000|81 86|stages
P08497273T0000|14 22|repressor
P08497280A0266|83 85|cis
P08497280A0266|8 17|regulation
P08497280A0266|114 130|SWI4 transcription
P08497280A0266|102 111|regulators
P08497280A0266|20 23|SWI4
P08497280A0266|43 62|cell cycle progression
P08497280A1397|86 89|SWI6
P08497280A1397|77 83|absence
P08497280A1397|55 71|SWI4 transcription
P08497280A1397|32 38|pathway
P08497280T0000|32 39|elements
P08497280T0000|47 63|SWI4 transcription
P08497280T0000|74 82|cell cycle
P08498570A1118|2 11|conclusion
P08498570A1118|101 102|Ra
P08498570A1118|13 19|changes
P08498570A1118|65 72|hindlimb
P08498570A1118|80 86|changes
P08498570A1118|22 44|carotid sinus stimulation
P08498570A1118|51 59|blood flow
P08498570A1118|93 97|Pcrit
P08499376A0000|41 54|predictability
P08499376A0000|9 11|PRK
P08499376A0000|69 79|corrections
P08499903A0883|45 52|deletion
P08499903A0883|37 42|origin
P08499903A0883|4 11|patients
P08499903A0883|16 24|deletions
P08499916A0000|3 12|COL7A1 gene
P08499916A0000|128 147|epidermolysis bullosa
P08499916A0000|62 74|candidate gene
P08499916A0000|26 40|type VII collagen
P08499916A0000|111 115|forms
P08500524A0424|28 36|gamma gene
P08500524A0424|8 12|study
P08500524A0424|87 101|splicing signals
P08500524A0424|65 68|exon
P08500524A0424|120 137|intron organization
P08500938A0408|14 18|grade
P08500938A0408|109 118|metaphysis
P08500938A0408|61 68|excision
P08500938A0408|89 96|surfaces
P08500938A0408|22 25|BGCT
P08500938A0408|100 103|part
P08501030A0456|74 77|narL
P08501030A0456|82 88|strains
P08501030A0456|90 93|M.H.
P08501030A0456|14 22|induction
P08501030A0456|31 48|.5 operon expression
P08501678A0498|59 84|immunoprophylactic strategy
P08501678A0498|7 15|knowledge
P08501678A0498|35 45|development
P08501678A0498|99 108|Hib disease
P08503348A0226|3 27|HMG CoA reductase inhibitors
P08503348A0226|67 72|agents
P08504707A0376|3 10|etiology
P08504707A0376|12 20|pathology
P08504707A0376|22 28|brain CT
P08504707A0376|67 75|treatment
P08504707A0376|50 63|manifestations
P08504707A0376|83 91|accidents
P08504707A0376|33 40|features
P08504928T0000|16 27|TFIID subunit
P08504928T0000|112 115|TATA
P08504928T0000|136 140|TFIID
P08504928T0000|40 46|homolog
P08504928T0000|127 133|subunit
P08504928T0000|57 76|cell cycle gene product
P08504928T0000|97 106|DNA binding
P08504932A0123|145 149|cells
P08504932A0123|104 118|site specificity
P08504932A0123|12 17|aspect
P08504932A0123|53 64|GATA proteins
P08504932A0123|20 39|GATA factor expression
P08504933A0000|0 4|Pit-1
P08504933A0000|107 111|gland
P08504933A0000|23 37|POU domain factor
P08504933A0000|54 63|appearance
P08504933A0000|71 84|cell phenotypes
P08505075A0236|0 12|Maximum number
P08505075A0236|27 27|%
P08505075A0236|44 61|S. bareilly serotype
P08505075A0236|91 91|%
P08505075A0236|103 109|S. typhi
P08505075A0236|15 21|strains
P08505075A0236|115 115|%
P08505312A0285|0 3|Biol
P08505340T0000|0 15|Characterization
P08505340T0000|98 111|granulosa cells
P08505340T0000|92 95|gene
P08505340T0000|27 36|regulation
P08505340T0000|55 90|rat prostaglandin endoperoxide synthase
P08505340T0000|42 49|promoter
P08505495A0253|14 21|75SeHCAT
P08505495A0253|3 11|retention
P08505605A0461|117 120|time
P08505605A0461|64 83|wound characteristics
P08505605A0461|40 45|wounds
P08505605A0461|99 104|extent
P08505605A0461|107 113|healing
P08505605A0461|54 60|patient
P08505605A0461|132 138|healing
P08505605A0461|0 21|Patient characteristics
P08506317A0000|0 6|Members
P08506317A0000|129 142|enhancer motifs
P08506317A0000|12 22|C/EBP family
P08506317A0000|45 48|bZip
P08506317A0000|50 69|transcription factors
P08506317A0000|25 43|basic-leucine zipper
P08506317A0000|98 104|CAAT box
P08506317A0000|74 85|heterodimers
P08506384A0146|99 103|eIF-2
P08506384A0146|11 15|cells
P08506384A0146|17 31|phosphorylation
P08506384A0146|65 70|eIF-2B
P08506384A0146|75 95|GDP-GTP exchange factor
P08506384A0146|34 43|eIF-2 alpha
P08506384A0146|55 62|activity
P08507921A1021|176 179|risk
P08507921A1021|46 59|stratification
P08507921A1021|67 76|MI patients
P08507921A1021|114 119|method
P08507921A1021|79 92|plasma ANF level
P08507921A1021|133 141|prognosis
P08507921A1021|2 11|conclusion
P08507921A1021|18 29|observations
P08507921A1021|159 169|individuals
P08507921A1021|189 193|death
P08508774A0242|0 7|Analysis
P08508774A0242|51 62|DNA fragments
P08508774A0242|100 102|DNA
P08508774A0242|28 30|set
P08508774A0242|22 24|Lrp
P08508774A0242|90 92|Lrp
P08508774A0242|71 76|region
P08508774A0242|13 19|binding
P08508778A0112|129 138|processing
P08508778A0112|79 89|temperature
P08508778A0112|62 72|fibrillarin
P08508778A0112|102 107|growth
P08508778A0112|30 37|NOP1 gene
P08508778A0112|0 11|Yeast mutants
P08508861A0294|72 77|change
P08508861A0294|26 34|ischaemia
P08508861A0294|51 56|groups
P08508861A0294|108 123|balloon inflation
P08508861A0294|62 66|basis
P08508861A0294|80 101|lactate extraction ratio
P08508861A0294|3 10|patients
P08509051A0316|12 19|patients
P08509051A0316|49 49|%
P08509051A0316|32 44|mortality rate
P08509333A0843|129 143|membrane protein
P08509333A0843|7 13|protein
P08509333A0843|121 124|FtsN
P08509333A0843|64 72|minicells
P08509333A0843|35 50|membrane fraction
P08509333A0843|83 90|plasmids
P08509333A0843|98 105|ftsN gene
P08509335T0000|0 3|SSG1
P08509335T0000|39 56|1,3-beta-glucanase
P08509335T0000|6 9|gene
P08509419A0785|0 9|Expression
P08509419A0785|110 122|TyrRS activity
P08509419A0785|47 54|tyrosine
P08509419A0785|76 86|suppression
P08509419A0785|94 98|yeast
P08509419A0785|16 22|protein
P08509430A0372|59 71|Chlamydomonas
P08509430A0372|184 189|medium
P08509430A0372|125 132|psaB gene
P08509430A0372|81 90|ac-u-g-2.3
P08509430A0372|51 56|mutant
P08509430A0372|16 30|complementation
P08509430A0372|73 79|CC-2341
P08509430A0372|137 145|selection
P08509430A0372|102 119|frameshift mutation
P08509430A0372|162 174|transformants
P08510320A0000|121 124|MICs
P08510320A0000|10 16|strains
P08510320A0000|106 119|concentrations
P08510320A0000|151 156|agents
P08510320A0000|176 178|ABK
P08510320A0000|129 133|total
P08510320A0000|166 174|arbekacin
P08510320A0000|61 64|MRSA
P08510320A1249|156 167|beta-lactams
P08510320A1249|52 56|Japan
P08510320A1249|139 148|resistance
P08510320A1249|36 40|MRSAs
P08510320A1249|82 91|resistance
P08510320A1249|98 102|drugs
P08510647A1347|0 3|Beg2
P08510647A1347|50 58|variation
P08510647A1347|7 10|Beg1
P08510647A1347|61 67|storage
P08510647A1347|70 90|utilization properties
P08510647A1347|99 113|barley globulins
P08510924A0490|59 71|HSP70 promoter
P08510924A0490|34 48|transactivation
P08510924A0490|74 84|Myb proteins
P08511994A0000|72 85|concentrations
P08511994A0000|30 34|carps
P08511994A0000|99 112|micrograms/dm3
P08511994A0000|58 69|ichthiomycin
P08512728A0991|0 6|RESULTS
P08512728A0991|137 146|conduction
P08512728A0991|180 183|msec
P08512728A0991|171 172|RR
P08512728A0991|152 167|accessory pathway
P08512728A0991|94 101|patients
P08512728A0991|198 198|p
P08512728A0991|121 132|fibrillation
P08512728A0991|86 91|number
P08512728A0991|32 42|differences
P08512728A0991|62 66|group
P08513025A0000|42 52|correlation
P08513025A0000|115 122|readings
P08513025A0000|12 17|effect
P08513025A0000|60 64|serum
P08513025A0000|70 83|bilirubin level
P08513025A0000|111 113|TcB
P08513025A0000|101 109|bilirubin
P08513025A0000|28 36|thickness
P08514757A1100|85 90|ligand
P08514757A1100|40 55|receptor assembly
P08514757A1100|124 138|protein function
P08514757A1100|112 121|modulators
P08514757A1100|75 82|category
P08514757A1100|4 16|immunophilins
P08514757A1100|33 37|roles
P08514766A0732|85 91|protein
P08514766A0732|19 25|CDC42Ce
P08514766A0732|105 111|p21 rac1
P08514766A0732|55 65|n-chimaerin
P08514766A0732|3 16|GTPase activity
P08515619A0184|0 16|Tl-201 uptake ratio
P08515619A0184|123 128|Tl-201
P08515619A0184|167 175|emphysema
P08515619A0184|190 210|Burrows classification
P08515619A0184|67 72|counts
P08515619A0184|94 99|counts
P08515619A0184|217 224|controls
P08515619A0184|179 187|B type COPD
P08515619A0184|27 35|ventricle
P08515619A0184|55 59|ratio
P08515619A0184|117 120|dose
P08515619A0184|83 91|ventricle
P08515619A0184|141 144|COPD
P08515776A0971|18 23|domain
P08515776A0971|49 55|regions
P08515776A0971|86 91|region
P08516301A0080|15 16|kb
P08516301A0080|48 54|introns
P08516301A0080|36 40|exons
P08516301A0080|4 7|gene
P08516308A0669|16 20|cells
P08516308A0669|37 49|microcolonies
P08516308A0669|12 14|RAD
P08516308A0669|94 98|cells
P08516308A0669|54 58|cells
P08516324A0000|224 231|FLI1 gene
P08516324A0000|52 63|Ewing sarcoma
P08516324A0000|114 121|molecule
P08516324A0000|166 172|EWS gene
P08516324A0000|154 160|portion
P08516324A0000|19 31|translocation
P08516324A0000|206 211|domain
P08516324A0000|91 95|tumor
P08517737A0889|122 129|bacteria
P08517737A0889|50 59|conditions
P08517737A0889|79 90|water systems
P08517737A0889|25 29|range
P08517737A0889|109 119|populations
P08517737A0889|5 12|findings
P08518797T0000|8 24|liver glycogenosis
P08518797T0000|53 65|candidate gene
P08518797T0000|26 37|localization
P08518797T0000|41 49|isolation
P08519621A0150|85 90|stages
P08519621A0150|194 198|tract
P08519621A0150|155 162|bacteria
P08519621A0150|125 135|association
P08519621A0150|4 13|conclusion
P08519621A0150|93 99|illness
P08519621A0150|168 174|pharynx
P08519621A0150|54 60|changes
P08519621A0150|26 37|observations
P08519862T0001|0 10|Measurement
P08519862T0001|52 54|kit
P08519862T0001|21 33|IgM antibodies
P08520646A0000|0 20|Embryo coculture system
P08520646A0000|82 90|fertility
P08520646A0000|49 58|mechanisms
P08520646A0000|95 99|aging
P08520646A0000|72 79|decrease
P08521414A1384|200 212|p16INK4A locus
P08521414A1384|23 33|methylation
P08521414A1384|181 189|cell lines
P08521414A1384|67 70|exon
P08521414A1384|155 158|exon
P08521414A1384|39 47|CpG island
P08521414A1384|160 165|E1 beta
P08521414A1384|5 13|cell lines
P08521414A1384|123 126|mRNA
P08521414A1384|73 80|p16INK4A
P08521414A1384|101 106|levels
P08521717A0126|144 151|activity
P08521717A0126|168 178|endothelium
P08521717A0126|193 201|insertion
P08521717A0126|77 84|antibody
P08521717A0126|204 213|LNG-IUD-20
P08521717A0126|27 35|PAP method
P08521717A0126|55 60|Factor
P08521717A0126|18 25|reaction
P08521717A0126|134 139|Factor
P08521717A0126|115 122|biopsies
P08521717A0126|44 52|antiserum
P08521780A0485|0 9|Umweltchem
P08522175A0306|120 122|NAC
P08522175A0306|53 63|beta subunit
P08522175A0306|24 28|BTF3b
P08522175A0306|211 216|Nature
P08522175A0306|166 179|protein sorting
P08522175A0306|112 118|complex
P08522175A0306|183 195|translocation
P08522175A0306|197 204|Wiedmann
P08522175A0306|0 4|Egd1p
P08522511A1250|8 10|PLB
P08522511A1250|24 36|lyase activity
P08522511A1250|39 40|pH
P08522511A1578|13 19|regions
P08522511A1578|33 36|pelB
P08522511A1578|126 153|beta-glucuronidase activities
P08522511A1578|113 116|f. sp
P08522511A1578|66 87|beta-glucuronidase gene
P08522511A1578|159 171|transformants
P08522511A1578|105 106|F.
P08522511A1578|118 121|pisi
P08522511A1578|26 29|pelA
P08522530A1342|155 156|bp
P08522530A1342|107 115|anaerobox
P08522530A1342|135 144|transcript
P08522530A1342|19 24|points
P08522530A1342|37 51|primer extension
P08522530A1342|175 177|box
P08522530A1342|168 172|sigma
P08522530A1342|94 95|bp
P08522530A1342|82 82|s
P08522530A1342|4 11|nifA mRNA
P08522530A1342|71 80|transcript
P08523031A0737|68 75|seizures
P08523031A0737|103 112|recurrence
P08523031A0737|19 22|data
P08523031A0737|48 51|time
P08523031A0737|94 99|stroke
P08523031A0737|54 58|onset
P08523545T0000|90 104|transactivation
P08523545T0000|144 146|ATF
P08523545T0000|107 120|adenovirus type
P08523545T0000|63 65|E1A
P08523545T0000|127 131|genes
P08523545T0000|8 25|papillomavirus type
P08523545T0000|48 61|adenovirus type
P08523545T0000|150 172|Oct-1 DNA binding activity
P08523545T0000|28 36|E7 protein
P08523566A1106|96 101|nature
P08523566A1106|53 63|interaction
P08523566A1106|11 19|detergent
P08523566A1106|107 117|interaction
P08523566A1106|24 35|% Nonidet P-40
P08524036A0747|145 149|sites
P08524036A0747|44 48|level
P08524036A0747|65 70|stripe
P08524036A0747|165 169|level
P08524036A0747|10 21|expectations
P08524036A0747|51 59|variation
P08524036A0747|200 206|regions
P08524036A0747|96 113|point substitutions
P08524036A0747|172 180|variation
P08524036A0747|117 135|insertion/deletions
P08524036A0747|72 85|enhancer region
P08524229T0000|77 80|SRS4
P08524229T0000|36 75|bisphosphate carboxylase small-subunit mRNA
P08524229T0000|110 117|cleavage
P08524229T0000|16 32|soybean ribulose-1
P08524229T0000|0 10|Degradation
P08524235A0695|115 120|region
P08524235A0695|135 140|result
P08524235A0695|90 93|loop
P08524235A0695|10 19|sequencing
P08524235A0695|154 161|splicing
P08524235A0695|164 169|max RNA
P08524235A0695|45 52|deletion
P08524235A0695|32 35|dMax
P08524235A0695|78 82|helix
P08524235A0695|69 74|region
P08524235A0695|0 6|Cloning
P08524241A0212|26 30|HSP82
P08524241A0212|59 67|IME1-IME2
P08524241A0212|83 89|cascade
P08524241A0212|15 23|induction
P08524260A0835|218 223|motifs
P08524260A0835|150 166|consensus sequence
P08524260A0835|253 258|LTBP-1
P08524260A0835|109 114|growth
P08524260A0835|126 132|repeats
P08524260A0835|26 31|LTBP-2
P08524260A0835|61 66|LTBP-2
P08524260A0835|170 183|calcium binding
P08524260A0835|80 87|examples
P08524260A0835|240 249|fibrillins
P08524260A0835|3 17|domain structure
P08524260A0835|198 205|examples
P08524267A1022|10 19|expression
P08524267A1022|181 190|myc mutants
P08524267A1022|142 144|myc
P08524267A1022|79 86|reporter
P08524267A1022|54 73|prothymosin alpha gene
P08524267A1022|104 113|repertoire
P08524267A1022|127 131|genes
P08524272T0000|58 72|Jak/Stat pathway
P08524272T0000|12 21|regulation
P08524272T0000|27 36|alpha/beta
P08524272T0000|78 80|SH2
P08524272T0000|98 122|tyrosine phosphatase SHPTP1
P08524284A0309|26 35|expression
P08524284A0309|51 58|PTF gamma
P08524284A0309|151 162|HeLa extracts
P08524284A0309|62 69|PTF delta
P08524284A0309|89 95|studies
P08524284A0309|38 42|cDNAs
P08524284A0309|139 148|PTF complex
P08524284A0309|107 116|antibodies
P08524284A0309|14 22|isolation
P08524292A1022|14 27|mechanism study
P08524292A1022|123 125|YY1
P08524292A1022|112 118|protein
P08524292A1022|62 76|transactivation
P08524292A1022|44 46|YY1
P08524292A1022|93 95|AP1
P08524292A1022|137 144|activity
P08524292A1022|147 156|DNA binding
P08524292A1022|0 6|Results
P08524294A0652|3 6|skp1
P08524294A0652|8 11|gene
P08524314A0216|70 78|N terminus
P08524314A0216|140 145|family
P08524314A0216|102 118|dimerization motif
P08524314A0216|88 98|zinc cluster
P08524314A0216|62 64|kDa
P08524314A0216|159 166|proteins
P08524314A0216|49 55|protein
P08524314A0216|8 26|Ty enhancer activator
P08524314A0216|3 6|TEA1
P08524314A0216|28 39|gene sequence
P08525186A0288|0 7|Refugees
P08525186A0288|102 113|counterparts
P08525186A0288|121 129|odds ratio
P08525186A0288|76 85|proportion
P08525186A0288|36 40|Chile
P08525186A0288|56 61|health
P08525186A0288|16 19|Lund
P08526620A1344|87 96|evaluation
P08526620A1344|76 81|marker
P08526620A1344|4 8|study
P08526620A1344|140 145|bypass
P08526620A1344|22 31|importance
P08526620A1344|42 64|SC5b-9 complement complex
P08526620A1344|99 118|complement activation
P08528479A0000|0 17|Videonystagmoscopy
P08528479A0000|120 127|deficits
P08528479A0000|77 82|system
P08528479A0000|53 61|responses
P08528479A0000|98 105|patients
P08528479A0000|86 95|population
P08528796A1470|3 5|MCA
P08528796A1470|36 44|deviation
P08528796A1470|9 18|UA PI values
P08528796A1470|64 72|parameter
P08529098A0549|88 91|SMF2
P08529098A0549|54 58|yeast
P08529098A0549|157 169|transmembrane
P08529098A0549|135 138|exon
P08529098A0549|72 79|proteins
P08529098A0549|226 229|exon
P08529098A0549|81 84|SMF1
P08529098A0549|185 188|site
P08529098A0549|127 133|domains
P08529098A0549|8 27|sequence similarities
P08529098A0549|36 36|%
P08529098A0549|250 263|transport motif
P08529098A0549|200 221|susceptibility mutation
P08529098A0549|178 183|domain
P08529630A0840|59 63|roots
P08529630A0840|26 37|P protein mRNA
P08529630A0840|52 56|level
P08529654A0589|120 124|Cyp-1
P08529654A0589|75 92|cyclophilin isoform
P08529654A0589|50 58|% identity
P08529654A0589|3 47|B. germanica cyclophilin amino acid sequence shares
P08529662A0507|42 52|ERp57/GRP58
P08529662A0507|36 39|form
P08529662A0507|55 69|Western blotting
P08529662A0507|85 92|labeling
P08530105A0308|116 118|map
P08530105A0308|93 100|patients
P08530105A0308|163 171|endpoints
P08530105A0308|10 15|region
P08530105A0308|121 128|analysis
P08530105A0308|145 153|deletions
P08530105A0308|81 88|analysis
P08530105A0308|132 139|patients
P08530105A0308|27 57|Langer-Giedion syndrome deletions
P08530107A1003|124 130|factors
P08530107A1003|48 56|histidase
P08530107A1003|62 68|finding
P08530107A1003|81 102|histidase transcription
P08530107A1003|36 45|expression
P08530149A0689|0 9|Comparison
P08530149A0689|81 83|Inr
P08530149A0689|93 95|TCA
P08530149A0689|12 20|promoters
P08530149A0689|100 104|YYYNY
P08530149A0689|32 36|c-myc
P08530149A0689|49 65|consensus sequence
P08530149A0689|85 91|element
P08530149A0689|71 79|initiator
P08530342T0000|8 19|gp39 promoter
P08530345A0880|173 178|HD PPRE
P08530345A0880|69 78|truncation
P08530345A0880|109 111|DR1
P08530345A0880|163 170|response
P08530345A0880|90 95|HD PPRE
P08530345A0880|181 203|peroxisome proliferators
P08530345A0880|55 66|TGACCT motifs
P08530345A0880|32 39|mutation
P08530345A0880|115 124|DR2 element
P08530345A0880|0 19|Transfection analyses
P08530369A0099|30 35|Tyr397
P08530369A0099|96 119|Src family tyrosine kinases
P08530369A0099|9 27|autophosphorylation
P08530369A0099|57 88|consensus autophosphorylation site
P08530369A0099|3 6|site
P08530384A0559|176 179|Oct2
P08530384A0559|157 159|BOB
P08530384A0559|170 173|Oct1
P08530384A0559|166 167|.1
P08530384A0559|19 29|interaction
P08530384A0559|210 212|DNA
P08530384A0559|81 83|DNA
P08530384A0559|126 136|interaction
P08530384A0559|195 205|interaction
P08530384A0559|68 78|Oct proteins
P08530384A0559|92 113|resolution footprinting
P08530384A0559|148 154|binding
P08530384A0559|59 65|binding
P08530418A1182|83 92|activation
P08530418A1182|101 104|HREs
P08530418A1182|12 15|data
P08530418A1182|117 123|CRBPIIp
P08530418A1182|106 113|RARE beta
P08530418A1182|146 174|acid signal transduction pathway
P08530418A1182|30 46|TR2 orphan receptor
P08530418A1182|53 67|master regulator
P08530432A0093|69 78|activation
P08530432A0093|81 90|repression
P08530432A0093|48 54|domains
P08530432A0093|6 11|series
P08530432A0093|20 27|proteins
P08530503A1004|13 31|ARP immunoreactivity
P08530503A1004|6 8|ARF
P08530503A1004|89 99|3T3-L1 cells
P08530503A1004|45 59|plasma membranes
P08530503A1004|68 74|cytosol
P08531373A0470|86 104|SS-A/SS-B antibodies
P08531373A0470|37 44|erythema
P08531373A0470|75 77|SjS
P08531373A0470|56 72|skin manifestation
P08531669A0950|0 10|Competition
P08531669A0950|77 80|kind
P08531669A0950|41 54|Central America
P08531669A0950|83 87|study
P08531669A0950|111 117|control
P08531669A0950|58 72|Caribean islands
P08531669A0950|129 135|species
P08532516A0000|55 66|fission yeast
P08532516A0000|36 49|cdc10-C4 mutant
P08532516A0000|21 30|properties
P08532516A0000|6 10|paper
P08532536A0925|101 109|induction
P08532536A0925|54 57|bone
P08532536A0925|160 182|growth factors/cytokines
P08532536A0925|121 132|growth factor
P08532536A0925|43 50|TGF-beta
P08532536A0925|81 85|BMP-2
P08532536A0925|71 79|protein-2
P08532536A0925|16 24|hFOB cells
P08532536A0925|134 136|EGF
P08532536A0925|144 152|induction
P08532536A0925|0 13|TIEG expression
P08532967A0364|62 68|therapy
P08532967A0364|12 17|origin
P08533472A0777|29 37|ORFs N2417
P08533472A0777|108 152|Candida maltosa cycloheximide-resistance protein
P08533472A0777|80 87|proteins
P08533472A0777|53 64|similarities
P08533472A0777|12 26|protein products
P08533472A0777|196 200|ILF-2
P08533472A0777|189 194|factor
P08533472A0777|69 75|domains
P08533472A0777|95 103|organisms
P08533472A0777|41 45|N2403
P08533472A0777|162 172|interleukin
P08533473A0375|58 65|database
P08533473A0375|80 91|EST sequences
P08533473A0375|31 38|ADH1 gene
P08533757A0204|14 35|Ashkenazi Jewish descent
P08533757A0204|140 144|BRCA1
P08533757A0204|136 137|kb
P08533757A0204|78 86|haplotype
P08533757A0204|105 111|markers
P08533757A0204|4 11|families
P08533757A0204|46 61|185delAG mutation
P08534217A0402|39 52|pollution level
P08534217A0402|67 76|FEV1 values
P08534217A0402|21 27|regions
P08534217A0402|61 63|FVC
P08534217A0402|93 105|Viskovo region
P08534217A0402|3 10|subjects
P08534367A0984|0 5|PTP-S3
P08534367A0984|17 22|PTP-S4
P08534367A0984|69 74|exon E1
P08534367A0984|32 39|deletion
P08534367A0984|44 53|amino acids
P08534848A0188a|32 33|cv
P08534848A0188a|8 17|NR isoforms
P08534848A0188b|32 33|cv
P08534848A0188b|8 17|NR isoforms
P08534855A0000|3 21|Arabidopsis FAD7 gene
P08534855A0000|83 94|desaturation
P08534855A0000|53 66|acid desaturase
P08534855A0000|30 47|chloroplast omega-3
P08534855A0000|121 125|acids
P08535138A0857|29 37|leaf cells
P08535138A0857|143 154|DNA synthesis
P08535138A0857|136 140|onset
P08535138A0857|71 79|treatment
P08535138A0857|57 68|cell division
P08535138A0857|98 116|cycMs4 transcription
P08535138A0857|84 96|plant hormones
P08535537A0000|1 6|survey
P08535537A0000|90 101|hypertension
P08535537A0000|34 44|backgrounds
P08535537A0000|66 78|drug treatment
P08536694A0000|0 13|Protein kinases
P08536694A0000|25 29|roles
P08536694A0000|35 41|control
P08536694A0000|56 64|processes
P08537388A0825|100 107|activity
P08537388A0825|126 134|base pairs
P08537388A0825|163 178|promoter activity
P08537388A0825|27 35|deletions
P08537388A0825|137 142|WNT-5A
P08537388A0825|56 63|promoter
P08537403A0336|120 122|VIB
P08537403A0336|138 143|insert
P08537403A0336|25 29|LIMK1
P08537403A0336|33 37|LIMK2
P08537403A0336|167 170|VIII
P08537403A0336|73 108|sequence motif Asp-Leu-Asn-Ser-His-Asn
P08537403A0336|151 163|subdomains VII
P08537403A0336|3 22|protein kinase domains
P08538052A0000|353 361|c-myc gene
P08538052A0000|331 337|element
P08538052A0000|180 205|oligodeoxynucleotide probes
P08538052A0000|254 261|peptides
P08538052A0000|287 293|protein
P08538052A0000|80 86|THZif-1
P08538052A0000|150 166|leukemia HL60 cells
P08538052A0000|227 244|amino acid sequences
P08538052A0000|40 57|amino acids residues
P08538052A0000|72 78|protein
P08538052A0000|17 25|cDNA clone
P08538052A0000|339 341|NHE
P08538052A0000|109 119|cDNA library
P08538382A1012|0 12|Erythrocyte AA
P08538382A1012|15 20|FO+EPO
P08538382A1012|70 76|placebo
P08538382A1012|34 40|infants
P08538382A1012|88 93|levels
P08538382A1012|60 65|breast
P08538483A0207|58 62|total
P08538483A0207|175 185|leiomyomata
P08538483A0207|40 46|changes
P08538483A0207|10 28|consideration weight
P08538483A0207|151 156|months
P08538483A0207|64 68|TBBMC
P08538483A0207|81 102|body bone mineral content
P08538483A0207|49 56|bone mass
P08538483A0207|135 146|GnRH agonists
P08538483A0207|160 172|endometriosis
P08538483A0207|119 123|women
P08538702A0214|71 78|gp15/400
P08538702A0214|80 85|ladder
P08538702A0214|60 66|Ascaris
P08538702A0214|10 20|polypeptide
P08538702A0214|155 161|antigen
P08538702A0214|164 181|Dirofilaria immitis
P08538702A0214|96 107|Brugia malayi
P08538702A0214|45 57|ABA-1 allergen
P08538702A0214|109 121|Brugia pahangi
P08538702A0214|32 39|sequence
P08538702A0214|87 93|protein
P08541499A0306|7 24|transcript patterns
P08541499A0306|27 42|Epifagus plastids
P08541499A0306|78 91|tobacco operons
P08541793A0796|33 35|min
P08541793A0796|39 41|hrs
P08541793A0796|11 18|recovery
P08542026A0792|0 2|DAF
P08542026A0792|101 110|regulation
P08542026A0792|8 21|kD glycoprotein
P08542026A0792|113 132|complement activation
P08542026A0792|74 77|SCRs
P08542026A0792|134 136|RCA
P08542026A0792|151 160|chromosome
P08542026A0792|178 181|size
P08542026A0792|57 72|consensus repeats
P08542026A0792|83 86|gene
P08542026A0792|138 148|gene cluster
P08542026A0792|32 41|complement
P08542026A0792|174 175|kb
P08542027A1471|41 50|expression
P08542027A1471|88 91|CD44
P08542027A1471|53 59|LU genes
P08542027A1471|76 85|expression
P08542027A1471|3 9|XS2 gene
P08542746T0000|28 37|facilities
P08542746T0000|76 84|standards
P08542746T0000|0 11|Diabetes care
P08542746T0000|14 22|guideline
P08543173A0314|71 93|primer extension analysis
P08543173A0314|52 54|tsp
P08543173A0314|9 15|TATA box
P08543173A0314|40 50|start points
P08543275A0130|101 108|presence
P08543275A0130|68 71|area
P08543275A0130|141 152|Arctic region
P08543275A0130|178 185|Japan Sea
P08543275A0130|207 214|host fish
P08543275A0130|37 41|burst
P08543275A0130|111 118|sea lions
P08543275A0130|44 61|pseudoterranovosis
P08543275A0130|14 26|investigation
P08543595A1093|58 69|radiotherapy
P08543595A1093|33 43|carboplatin
P08543595A1093|2 8|summary
P08543595A1093|13 22|efficacies
P08543810A0000|86 91|clones
P08543810A0000|142 144|set
P08543810A0000|48 59|coelomocytes
P08543810A0000|169 172|ESTs
P08543810A0000|156 167|sequence tags
P08543810A0000|19 23|genes
P08543810A0000|121 131|cDNA library
P08544820T0000|0 15|Characterization
P08544820T0000|97 105|Lsp-2 gene
P08544820T0000|20 47|EcR/USP heterodimer target site
P08544820T0000|60 81|ecdysone responsiveness
P08545502A0914|38 51|activation task
P08545502A0914|5 9|SPECT
P08545502A0914|29 31|PET
P08546707T0000|86 97|NF-kappa Bp50
P08546707T0000|15 24|activation
P08546707T0000|51 62|NF-kappa Bp65
P08546707T0000|64 67|RelA
P08546707T0000|72 76|c-Rel
P08546707T0000|30 48|chicken lysozyme gene
P08547205A1060|89 96|efficacy
P08547205A1060|104 106|SVT
P08547205A1060|36 50|agents alinidine
P08547205A1060|54 64|zatebradine
P08547205A1060|159 162|dogs
P08547205A1060|138 147|infarction
P08547205A1060|3 9|results
P08548291A1059|43 51|formation
P08548291A1059|81 85|Elk-1
P08548291A1059|64 70|complex
P08548291A1059|87 105|serum response factor
P08548291A1059|28 32|SAPKs
P08548291A1059|112 131|serum response element
P08548291A1059|16 25|activation
P08548291A1059|159 171|transcription
P08549706T0000|52 60|drug users
P08549706T0000|12 35|hepatitis B virus infection
P08549706T0000|63 69|Iceland
P08549859A1604|28 31|odds
P08549859A1604|42 53|chromosome 3p
P08549859A1604|3 6|gene
P08549859A1604|56 98|Centre d'Etude du Polymorphisme Humain pedigrees
P08550425A1401|100 108|% identity
P08550425A1401|76 96|Halobacterium halobium
P08550425A1401|12 19|subunits
P08550425A1401|49 51|POR
P08550425A1401|67 74|archaeon
P08550460A0374|85 100|protein precursor
P08550460A0374|25 28|gene
P08550460A0374|40 43|pilP
P08550460A0374|50 51|bp
P08550460A0374|121 153|membrane lipoprotein leader sequence
P08550461A0284|0 5|Cheung
P08550461A0284|9 10|S.
P08550462A0815|0 7|Upstream
P08550462A0815|43 52|amino acids
P08550462A0815|26 37|reading frame
P08550462A0815|13 19|dra gene
P08550467A0863|144 152|start site
P08550467A0863|74 81|sequence
P08550467A0863|125 128|scrB
P08550467A0863|28 31|scrB
P08550467A0863|47 54|deletion
P08550467A0863|83 84|OB
P08550467A0863|94 102|positions
P08550467A0863|58 59|bp
P08550467A0863|16 25|regulation
P08550470A1021|45 53|receptors
P08550470A1021|9 12|CheW
P08550470A1021|59 68|kinase CheA
P08550470A1021|32 39|coupling
P08550476A0610|26 29|epiF
P08550476A0610|21 24|gene
P08550476A0610|89 96|sequence
P08550476A0610|3 10|promoter
P08550476A0610|164 167|EpiQ
P08550476A0610|109 123|EpiQ binding site
P08550476A0610|45 64|activator protein EpiQ
P08550476A0610|129 140|epiA promoter
P08550564T0000|130 152|interleukin-8 receptor B.
P08550564T0000|116 122|domains
P08550564T0000|25 28|sets
P08550564T0000|31 53|selectivity determinants
P08550564T0000|0 12|CXC chemokines
P08551572A0155|0 20|Oligodeoxynucleotides
P08551572A0155|139 142|CU91
P08551572A0155|114 122|MSB1 cells
P08551572A0155|144 164|reticuloendotheliosis
P08551572A0155|129 137|MDCC-CU91
P08551572A0155|99 111|proliferation
P08551572A0155|74 77|ICP4
P08551572A0155|81 89|pp38 mRNAs
P08551572A0155|182 186|cells
P08551572A0155|44 71|translation initiation regions
P08551577A0000|154 160|src mRNA
P08551577A0000|10 20|replication
P08551577A0000|53 63|transcripts
P08551577A0000|34 40|portion
P08551577A0000|136 151|Rous sarcoma virus
P08551577A0000|106 109|mRNA
P08551577A0000|85 87|DNA
P08551577A0000|116 130|envelope protein
P08552042A1497|71 77|borders
P08552042A1497|181 187|meiosis
P08552042A1497|21 39|promoter methylation
P08552042A1497|125 128|poly
P08552042A1497|155 159|state
P08552042A1497|102 110|reduction
P08552042A1497|191 202|reactivation
P08552042A1497|216 226|generations
P08552042A1497|133 142|mRNA levels
P08552042A1497|6 9|case
P08552042A1497|130 130|A
P08552042A1497|13 18|degree
P08552045A0973|104 119|binding sequences
P08552045A0973|149 161|transcription
P08552045A0973|126 137|Cpflp protein
P08552045A0973|8 25|consensus sequences
P08552045A0973|167 171|genes
P08552045A0973|56 66|GCACGTGGG-3
P08552045A0973|202 219|centromere function
P08552045A0973|174 195|methionine biosynthesis
P08552045A0973|74 84|GCACGTTTT-3
P08552045A0973|29 49|phosphatase regulation
P08552082A0480|99 103|yeast
P08552082A0480|59 68|SH3 domains
P08552082A0480|39 41|CAP
P08552082A0480|31 36|region
P08552082A0480|78 85|proteins
P08552082A0480|120 131|protein Abp1p
P08552086A0150|67 74|promoter
P08552086A0150|57 60|VDRE
P08552086A0150|77 81|c-fos
P08552086A0150|33 55|vitamin D response element
P08552092A1678|144 156|protein factor
P08552092A1678|92 103|footprinting
P08552092A1678|59 68|regulation
P08552092A1678|12 25|protein binding
P08552092A1678|188 193|intron
P08552092A1678|71 83|transcription
P08552092A1678|2 9|addition
P08552092A1678|115 128|promoter region
P08552092A1678|199 206|rep3 gene
P08552092A1678|28 36|sequences
P08552093A0657|0 14|Differentiation
P08552093A0657|103 113|selectivity
P08552093A0657|120 127|Gq family
P08552093A0657|70 74|forms
P08552093A0657|77 83|alpha i2
P08552093A0657|86 90|alpha
P08552093A0657|42 51|expression
P08552093A0657|130 138|G proteins
P08552095A0686|43 47|Paf1p
P08552095A0686|64 70|nucleus
P08552095A0686|23 26|role
P08552095A0686|29 41|transcription
P08552095A0758|14 23|abundances
P08552095A0758|78 84|strains
P08552095A0758|112 121|expression
P08552095A0758|102 106|genes
P08552095A0758|134 137|PAF1
P08552095A0758|30 45|yeast transcripts
P08552095A0758|68 71|paf1
P08552095A1115|0 4|Paf1p
P08552095A1115|53 62|regulation
P08552095A1115|74 83|yeast genes
P08552095A1115|65 71|subsets
P08552096A0151|15 33|suppression strategy
P08552096A0151|62 65|UBS1
P08552096A0151|52 60|yeast gene
P08552096A0151|144 157|cdc34 mutations
P08552096A0151|114 129|cell cycle defects
P08552096A0151|80 89|expression
P08552387A0000|102 124|chromosome translocation
P08552387A0000|50 54|parts
P08552387A0000|36 43|melanoma
P08552387A0000|9 24|characterization
P08552387A0000|164 178|factor gene ATF-1
P08552387A0000|141 143|EWS
P08552387A0000|94 94|t
P08552387A0000|72 82|cell sarcoma
P08552387A0000|61 66|tissue
P08552387A0000|133 138|fusion
P08552643A0261|0 5|Clones
P08552643A0261|105 119|stomatitis virus
P08552643A0261|81 88|activity
P08552643A0261|138 149|IFN treatment
P08552643A0261|48 56|phenotype
P08552643A0261|19 21|DBD
P08552643A0261|125 133|infection
P08552643A0261|121 123|VSV
P08552670A0665|0 3|Abp1
P08552670A0665|55 68|DNA polymer poly
P08552670A0665|40 42|ARS
P08552670A0665|72 74|A.T
P08552670A0665|33 37|sites
P08552670A0665|70 70|d
P08552670T0000|0 13|Identification
P08552670T0000|40 46|cloning
P08552670T0000|100 111|fission yeast
P08552670T0000|88 94|protein
P08552670T0000|15 26|purification
P08553580A0102|38 45|function
P08553580A0102|10 21|reading frame
P08553580A0102|61 71|FIV isolates
P08553580A0102|23 26|ORF2
P08554069A0743|127 130|exon
P08554069A0743|39 46|mutation
P08554069A0743|66 66|G
P08554069A0743|149 159|RNA splicing
P08554069A0743|92 109|acceptor splice site
P08554069A0743|117 122|intron
P08554069A0743|3 9|patient
P08554069A0743|70 82|T transversion
P08554540A1480|5 11|regions
P08554540A1480|26 52|HIT protein similarity regions
P08554723A0187|145 145|M
P08554723A0187|71 73|PBN
P08554723A0187|55 65|acid lesions
P08554723A0187|127 129|CTA
P08554723A0187|75 78|PBNx
P08554723A0187|10 13|rats
P08554723A0187|132 140|l-alanine
P08554723A0187|184 202|furosemide treatment
P08554723A0187|161 174|sodium appetite
P08554723A0187|238 241|chow
P08554723A0187|223 228|sodium
P08554723A0187|215 220|access
P08555076A0333|60 66|mycosis
P08555076A0333|78 86|infection
P08555076A0333|110 116|Candida
P08555076A0333|9 22|Amphotericin-B
P08555076A0333|91 101|Aspergillus
P08555076A0333|118 118|n
P08555076A0333|34 41|patients
P08555076A0333|103 103|n
P08555168A0390|28 32|sites
P08555168A0390|58 65|affinity
P08555168A0390|7 9|Mn2
P08555168A0390|0 2|Mg2
P08555289A0207|70 77|purposes
P08555289A0207|8 22|storm indicators
P08555289A0207|47 56|geophysics
P08555289A0207|36 43|medicine
P08555446A0000|122 127|levels
P08555446A0000|24 28|ppa-1
P08555446A0000|10 22|tobacco plants
P08555446A0000|93 107|35S CaMV promoter
P08555446A0000|150 155|leaves
P08555446A0000|69 83|pyrophosphatase
P08555446A0000|137 142|sugars
P08555498A0427|73 82|gene family
P08555498A0427|111 129|vertebrate evolution
P08555498A0427|38 42|mouse
P08555498A0427|31 35|genes
P08555498A0427|5 9|LAF-4
P08555498A0427|46 52|chicken
P08555597A0808|0 7|Hb levels
P08555597A0808|25 26|Hb
P08555597A0808|61 66|months
P08555597A0808|40 43|g/dl
P08555753A0591|129 133|lobes
P08555753A0591|33 45|Wisconsin Card
P08555753A0591|105 116|neuroimaging
P08555753A0591|53 56|Test
P08555753A0591|16 25|comparison
P08555753A0591|78 91|activation task
P08555753A0591|0 2|CBT
P08556707A1390|87 91|yeast
P08556707A1390|48 70|transactivation activity
P08556707A1390|175 180|allele
P08556707A1390|142 152|p53 function
P08556707A1390|183 193|SNU-C5 cells
P08556707A1390|5 8|data
P08556707A1390|107 118|temperatures
P08556707A1390|158 165|presence
P08556707A1390|74 84|p53 promoter
P08556707A1390|29 34|218leu
P08558187A0403|0 5|Cycles
P08558187A0403|24 28|weeks
P08561607A1443|7 11|class
P08561607A1443|38 52|transplantation
P08561607A1443|19 28|infections
P08561893A0100|57 73|gene transcription
P08561893A0100|77 102|E-box DNA consensus sequences
P08561893A0100|139 148|eukaryotes
P08561893A0100|117 130|factor function
P08561893A0100|193 205|family members
P08561893A0100|104 110|studies
P08561893A0100|14 17|deal
P08561893A0100|175 182|presence
P08561893A0100|42 48|factors
P08561897A0604|0 7|Mobility
P08561897A0604|105 126|competition experiments
P08561897A0604|164 177|CRE/TRE element
P08561897A0604|11 26|supershift assays
P08561897A0604|94 101|elements
P08561897A0604|140 147|CREB/ATF
P08561897A0604|69 71|USF
P08561897A0604|62 67|factor
P08561897A0604|151 154|AP-1
P08561897A0604|76 78|Sp1
P08562688A0968|0 7|Upstream
P08562688A0968|74 81|sequence
P08562688A0968|31 39|sequences
P08562688A0968|65 70|length
P08562688A0968|45 52|isolates
P08563483A0094|60 65|levels
P08563483A0094|7 11|cases
P08563483A0094|116 123|activity
P08563483A0094|79 87|TSH levels
P08563483A0094|99 101|hCG
P08563483A0094|56 58|hCG
P08563483A0094|43 54|gonadotropin
P08564488A1359|32 35|risk
P08564488A1359|52 61|thrombosis
P08564488A1359|4 19|fibrinogen levels
P08564588A1318|0 18|Strontium chloride Sr
P08564588A1318|76 97|management expenditures
P08564588A1318|107 114|ABSTRACT
P08564588A1318|129 133|WORDS
P08564588A1318|44 51|analysis
P08565330A1783|48 54|control
P08565330A1783|23 30|features
P08565330A1783|63 69|control
P08565330A1783|79 88|expression
P08565548A0196|129 134|DA rats
P08565548A0196|94 96|BII
P08565548A0196|35 43|potential
P08565548A0196|111 121|silicone gel
P08565548A0196|4 8|study
P08565548A0196|46 56|silicone gel
P08565548A0196|83 90|collagen
P08566747A0756|13 20|promoter
P08566747A0756|79 93|Cln/Cdc28 kinase
P08566747A0756|62 63|G1
P08566747A0756|31 40|activation
P08566747A0756|43 55|transcription
P08566747A0756|106 112|ability
P08566747A0756|143 155|transcription
P08566747A0756|130 132|SBF
P08566747A0756|0 2|SBF
P08566751A0455|147 154|Hox genes
P08566751A0455|23 30|question
P08566751A0455|38 55|vertebrate Hox genes
P08566751A0455|73 79|control
P08566751A0455|127 134|function
P08566751A0455|102 110|sequences
P08566751A0788|75 77|lab
P08566751A0788|18 24|gHoxb-1
P08566751A0788|4 11|approach
P08566751A0788|61 67|context
P08566754A0783|97 114|ribonucleoproteins
P08566754A0783|6 23|splice site sequence
P08566754A0783|116 121|snRNPs
P08566754A0783|168 174|ASF/SF2
P08566754A0783|46 60|polyadenylation
P08566754A0783|137 165|splicing factor/splicing factor
P08566754A0783|83 84|U1
P08566756A0752|85 92|pre-mRNA
P08566756A0752|52 68|SF3a/SF3b subunits
P08566756A0752|24 26|SAP
P08566756A0752|128 130|BPS
P08566756A0752|70 82|UV cross-links
P08566756A0752|109 114|region
P08566756A0752|4 11|analysis
P08566773A1023|13 16|CTS1
P08566773A1023|31 37|members
P08566773A1023|66 75|chitinases
P08566773A1023|20 23|CTS2
P08566773A1023|121 126|fungus
P08566773A1023|51 57|classes
P08566773A1023|79 89|observation
P08566773A1023|26 27|Ci
P08567556A0000|87 97|seal muscles
P08567556A0000|127 132|diving
P08567556A0000|104 124|laboratory simulations
P08567556A0000|11 21|consumption
P08567556A0000|162 172|field diving
P08567556A0000|42 45|MbO2
P08567556A0000|47 52|stores
P08567556A0000|180 191|measurements
P08567556A0000|206 222|lactate production
P08567556A0000|147 153|feature
P08567556A0000|233 243|differences
P08567556A0000|194 202|heart rate
P08567556A0000|259 272|diving response
P08567556A0000|55 65|seal muscles
P08567556A0000|288 296|immersion
P08567683A0401|33 38|length
P08567683A0401|60 73|acid polypeptic
P08567683A0401|22 30|base pairs
P08567683A0401|75 76|Mr
P08567683A0401|8 15|purH cDNA
P08567717T0000|62 65|part
P08567717T0000|76 85|checkpoint
P08567717T0000|26 59|spindle pole body duplication gene MPS1
P08567847A1005|42 53|shortcomings
P08567847A1005|106 116|examination
P08567847A1005|93 102|instrument
P08567847A1005|150 157|features
P08567847A1005|124 135|semen samples
P08567847A1005|16 27|SM-CMA system
P08567847A1005|5 11|opinion
P08567847A1005|59 72|user-interface
P08569443A0123|98 108|consequence
P08569443A0123|73 74|T2
P08569443A0123|137 142|volume
P08569443A0123|111 121|differences
P08569443A0123|82 87|tumors
P08569443A0123|55 65|differences
P08569443A0123|161 171|compartment
P08569443A0123|68 69|T1
P08569443A0123|3 9|purpose
P08569443A0123|15 19|study
P08569680A0636|94 99|domain
P08569680A0636|77 80|GATA
P08569680A0636|7 17|areA product
P08569680A0636|114 121|function
P08569680A0636|50 56|residue
P08569684A0000|30 34|basis
P08569684A0000|115 128|protein kinase C
P08569684A0000|54 78|amino acid sequence segments
P08569684A0000|243 265|fungus Trichoderma reesei
P08569684A0000|130 132|PKC
P08569684A0000|163 186|polymerase chain reactions
P08569684A0000|97 102|domain
P08569684A0000|153 159|primers
P08569684A0000|214 224|DNA fragment
P08569684A0000|134 141|proteins
P08569684A0000|0 15|Oligonucleotides
P08570615T0000|0 9|Disruption
P08570615T0000|68 79|S-phase entry
P08570615T0000|12 17|RB/E2F
P08570615T0000|39 52|point mutations
P08570615T0000|20 30|interaction
P08570615T0000|83 91|apoptosis
P08570615T0000|55 59|E2F-1
P08572616A0000|14 35|differentiation markers
P08572616A0000|66 74|neoplasms
P08572616A0000|8 11|loss
P08573083A0645|4 9|region
P08573083A0645|50 60|binding site
P08573083A0645|35 42|identity
P08573083A0645|77 95|transcription factor
P08573083A0645|115 120|factor
P08573083A0645|19 23|motif
P08573083A0645|122 124|USF
P08573083A0645|147 161|insulin promoter
P08573637A0434|42 54|determination
P08573637A0434|109 114|fluids
P08573637A0434|84 95|formulations
P08573637A0434|57 67|paracetamol
P08573637A0434|3 8|method
P08574414A1037|84 92|pathovars
P08574414A1037|63 80|Xanthomonas species
P08574414A1037|20 29|PCR product
P08574414A1037|47 52|length
P08574414A1037|5 11|primers
P08574583A0658|128 137|sim mutants
P08574583A0658|64 69|arrest
P08574583A0658|90 95|strain
P08574583A0658|103 110|activity
P08574583A0658|72 76|cells
P08574583A0658|3 12|Clb5 kinase
P08574583A0658|27 32|S phase
P08575609A0526|53 58|values
P08575609A0526|100 107|patients
P08575609A0526|86 89|eyes
P08575609A0526|33 37|cases
P08575609A0526|3 10|C/D ratio
P08575609A0526|41 44|eyes
P08575609A0526|94 94|%
P08575614A0264|0 10|Rad6 mutants
P08575614A0264|40 48|phenotype
P08575614A0264|64 70|protein
P08575614A0264|102 122|postreplication repair
P08575614A0264|124 133|repression
P08575614A0264|158 168|sporulation
P08575614A0264|73 75|DNA
P08575614A0264|136 153|retrotransposition
P08575614A0264|90 100|mutagenesis
P08575618A1138|0 20|RNase protection assays
P08575618A1138|93 127|pigmentation/phaeomelanin phenotypes
P08575618A1138|75 88|skin expression
P08575618A1138|30 40|correlation
P08575618A1138|51 56|levels
P08575618A1138|59 64|dorsal
P08575754T0000|17 33|expression pattern
P08575754T0000|9 15|cloning
P08575754T0000|83 91|inhibitor
P08575754T0000|94 99|cyclin
P08575754T0000|111 117|kinases
P08575754T0000|68 79|CDKN2D/INK4d
P08575754T0000|49 60|localization
P08576042A0765|0 13|Overproduction
P08576042A0765|177 189|transcription
P08576042A0765|124 141|heat shock induction
P08576042A0765|227 233|amounts
P08576042A0765|154 164|groE operons
P08576042A0765|44 47|hrcA
P08576042A0765|68 72|phrcA
P08576042A0765|246 256|temperature
P08576042A0765|77 86|B. subtilis
P08576042A0765|147 150|dnaK
P08576042A0765|38 41|copy
P08576042A0765|99 114|delta hrcA strains
P08576042A0765|16 26|HrcA protein
P08576042A0765|236 239|mRNA
P08576042A0765|60 66|plasmid
P08576042A0765|170 174|level
P08576131A0151|101 105|USF2a
P08576131A0151|128 132|USF2b
P08576131A0151|93 99|subunit
P08576131A0151|157 164|splicing
P08576131A0151|40 55|characterization
P08576131A0151|58 69|USF2 isoforms
P08576131A0151|20 26|cloning
P08576131A0151|120 126|subunit
P08576131A0685|15 32|heterodimerization
P08576131A0685|106 113|subunits
P08576131A0685|81 91|association
P08576131A0685|128 138|USF proteins
P08576131A0685|35 45|USF subunits
P08576179A0126|58 84|translation initiation factor
P08576179A0126|9 11|PKR
P08576179A0126|23 27|dimer
P08576179A0126|86 97|alpha subunit
P08576179A0126|119 144|polypeptide chain initiation
P08576179A0126|99 108|cIF-2 alpha
P08576245A0000|0 4|GRP78
P08576245A0000|172 194|glycoprotein trafficking
P08576245A0000|98 112|stress responses
P08576245A0000|81 87|protein
P08576245A0000|50 58|reticulum
P08576245A0000|16 24|chaperone
P08576245A0000|124 130|glucose
P08576245A0000|147 153|calcium
P08576262A0160|102 103|Gi
P08576262A0160|107 109|G16
P08576262A0160|84 92|G proteins
P08576262A0160|18 52|seven-transmembrane spanning receptor
P08576262A0160|3 14|IL-8 receptor
P08576546A0975|42 50|PDC/HDC Ac
P08576546A0975|86 98|dose regiments
P08576546A0975|17 27|experiments
P08576546A0975|9 14|series
P08576546A0975|32 39|efficacy
P08580083A0259|87 106|Fyn-expression vector
P08580083A0259|24 35|significance
P08580083A0259|38 40|Fyn
P08580083A0259|63 71|promoters
P08580083A0259|46 55|expression
P08580083A0259|148 183|chloramphenicol acetyltransferase gene
P08580083A0259|208 216|T cell line
P08580083A0259|192 197|HIV LTR
P08580083A0259|120 134|reporter plasmid
P08580083A0259|218 223|Jurkat
P08580671A0137|133 144|hypertension
P08580671A0137|173 184|liver disease
P08580671A0137|212 219|bleeding
P08580671A0137|72 83|beta-blocker
P08580671A0137|51 60|metoprolol
P08580671A0137|115 122|bleeding
P08580671A0137|161 168|patients
P08580671A0137|87 96|prevention
P08580671A0137|44 48|trial
P08581174A0472|43 53|qutA mutants
P08581174A0472|20 27|analysis
P08581174A0472|124 134|QUTA protein
P08581174A0472|69 77|mutations
P08581174A0472|108 111|half
P08581174A0472|86 88|map
P08582143A0614|143 166|beta-lactamase production
P08582143A0614|76 98|cephalosporin substrates
P08582143A0614|38 41|test
P08582143A0614|180 186|species
P08582143A0614|5 11|studies
P08582143A0614|106 115|nitrocefin
P08582143A0614|119 120|S1
P08582633T0000|0 10|Suppressors
P08582633T0000|39 45|effects
P08582633T0000|22 30|silencing
P08582633T0000|63 72|repression
P08582633T0000|78 85|HMR locus
P08582633T0000|87 96|cell growth
P08582633T0000|33 37|yeast
P08582633T0000|100 116|telomere structure
P08583783A0870|56 65|filtration
P08583783A0870|35 44|filtration
P08583783A0870|51 54|calf
P08583783A0870|8 10|ANP
P08583783A0870|80 82|ANP
P08583846A0121|73 78|marker
P08583846A0121|32 48|beta-2 transferrin
P08583846A0121|6 15|literature
P08583846A0121|82 90|perilymph
P08583846A0807|73 78|marker
P08583846A0807|105 111|setting
P08583846A0807|11 38|methodology beta-2 transferrin
P08583846A0807|82 90|perilymph
P08584026A0115|29 30|P1
P08584026A0115|34 35|P2
P08584026A0115|19 27|promoters
P08584026A0115|3 12|hIGF-I gene
P08584035A0740|87 103|binding properties
P08584035A0740|179 180|R1
P08584035A0740|169 177|complexes
P08584035A0740|114 120|ability
P08584035A0740|53 60|proteins
P08584035A0740|131 144|beta I-A element
P08584035A0740|183 184|R4
P08584035A0740|0 21|Gel mobility shift assays
P08584074A0000|129 134|period
P08584074A0000|139 144|months
P08584074A0000|37 42|months
P08584074A0000|106 108|TLE
P08584074A0000|93 104|lobe epilepsy
P08584074A0000|10 17|patients
P08584074A0000|48 52|years
P08584074A0000|147 166|Bethel Epilepsy Center
P08584074A0000|31 35|years
P08584530A0545|60 65|values
P08584530A0545|143 153|test results
P08584530A0545|68 70|Raw
P08584530A0545|37 40|FEV1
P08584530A0545|11 22|correlations
P08584530A0545|125 135|differences
P08584530A0545|80 84|MEF25
P08584530A0545|72 76|MEF50
P08585324A0467|28 35|SSC1 gene
P08585324A0467|37 41|Smith
P08585324A0823|69 78|tau element
P08585324A0823|23 26|gene
P08585324A0823|46 54|precursor
P08585324A0823|4 9|region
P08585324A0823|59 65|remnant
P08585639T0000|45 65|immunodeficiency virus
P08585639T0000|12 19|exposure
P08585639T0000|79 90|risk analysis
P08585639T0000|22 36|hepatitis B virus
P08585883A0381|0 5|Hybrid
P08585883A0381|105 119|copulation plugs
P08585883A0381|12 15|mice
P08585883A0381|134 136|day
P08585883A0381|87 89|day
P08585883A0381|62 71|LNG pellets
P08585883A0381|17 25|C57BL x CBA
P08585883A0381|140 142|day
P08585883A0381|159 164|period
P08585883A0381|95 97|day
P08585883A0381|54 57|CD-1
P08585883A0381|41 52|breeder males
P08585957A0101|117 123|domains
P08585957A0101|197 217|mobility group proteins
P08585957A0101|167 173|AT-hook
P08585957A0101|78 85|proteins
P08585957A0101|24 42|transcription factor
P08585957A0101|4 7|gene
P08585957A0101|186 190|motif
P08585957A0101|56 63|homology
P08585957A0101|47 53|regions
P08585957A0101|148 158|gene product
P08585957A0101|98 108|zinc fingers
P08585994A0567|218 223|embryo
P08585994A0567|102 117|band interval 89A1
P08585994A0567|5 19|reference probes
P08585994A0567|179 212|segmentation gene expression patterns
P08585994A0567|53 72|ost transcription unit
P08585994A0567|30 38|standards
P08585994A0567|130 132|arm
P08585994A0567|143 152|chromosome
P08586643A0951|45 62|phosphoryl transfer
P08586643A0951|78 80|CMP
P08586643A0951|67 69|ATP
P08586643A0951|22 27|enzyme
P08586643A0951|72 74|UMP
P08586874T0000|0 6|Studies
P08586874T0000|23 39|Haplorchis pumilio
P08586874T0000|52 56|Looss
P08586874T0000|12 20|life cycle
P08586874T0000|108 113|stages
P08586874T0000|79 91|redescription
P08586874T0000|41 45|Looss
P08587075T0000|56 74|polyarteritis nodosa
P08587075T0000|10 23|microaneurysms
P08587075T0000|27 31|cases
P08587075T0000|34 48|hepatitis B virus
P08588852A0236|59 63|fetus
P08588852A0236|153 158|tibiae
P08588852A0236|102 113|micrognathia
P08588852A0236|79 87|gestation
P08588852A0236|127 132|thumbs
P08588852A0236|140 143|toes
P08588852A0236|43 49|studies
P08588852A0236|18 26|pregnancy
P08588852A0236|73 76|week
P08589315A1029|187 194|syndrome
P08589315A1029|210 210|%
P08589315A1029|169 169|%
P08589315A1029|34 41|survival
P08589315A1029|102 119|tumor lysis syndrome
P08589315A1029|153 160|patients
P08589315A1029|32 32|%
P08589315A1029|199 206|patients
P08589315A1029|95 100|groups
P08589315A1029|16 27|survival rate
P08589315A1029|131 148|lupus erythematosus
P08589315A1029|73 73|%
P08589358A0235|86 89|week
P08589358A0235|51 55|rhEPO
P08589358A0235|10 17|units/kg
P08589358A0235|94 98|weeks
P08589358A0235|80 84|times
P08589358A0235|36 49|erythropoietin
P08589358A0841|128 137|milligrams
P08589358A0841|7 13|regimen
P08589358A0841|47 51|donor
P08589358A0841|77 92|blood transfusion
P08589358A0841|16 29|erythropoietin
P08589358A0841|108 115|Hb levels
P08589358A0841|54 57|need
P08589735A0577|103 106|Adh1
P08589735A0577|109 122|maize ubiquitin
P08589735A0577|7 16|constructs
P08589735A0577|130 138|rice actin
P08589735A0577|124 127|Ubi1
P08589735A0577|148 159|CaMV 35S genes
P08589735A0577|140 143|Act1
P08589735A0577|42 56|promoter regions
P08589735A0577|18 30|GUS expression
P08589735A0577|71 101|Arabidopsis alcohol dehydrogenase
P08590465A0773|100 114|URA2 gene product
P08590465A0773|50 64|URA1 gene product
P08590465A0773|18 27|regulation
P08590465A0773|3 14|organization
P08590465A0773|43 44|S.
P08591700A0972|56 60|kg/m2
P08591700A0972|21 23|BMI
P08591700A0972|71 73|men
P08591700A0972|3 19|mean body mass index
P08591700A0972|63 67|women
P08591700A0972|38 42|kg/m2
P08592590A0822|60 69|hepatitis C
P08592590A0822|83 101|interferon treatment
P08592590A0822|5 12|findings
P08592590A0822|156 163|patients
P08592590A0822|28 48|haemodialysis patients
P08592590A0822|119 126|response
P08592590A0822|144 153|proportion
P08592713T0001|22 26|drugs
P08592713T0001|9 19|enantiomers
P08593813A0967|120 129|transcript
P08593813A0967|41 44|germ
P08593813A0967|96 105|efficiency
P08593813A0967|8 15|analysis
P08593813A0967|58 65|Sp1 mRNAs
P08595012A0817|69 72|rest
P08595012A0817|17 24|response
P08595012A0817|61 66|values
P08595012A0817|27 31|tcPO2
P08595012A0817|2 13|nondiabetics
P08595012A0817|40 42|LDF
P08595184A0407|74 85|correlations
P08595184A0407|54 60|effects
P08595184A0407|114 117|LFPs
P08595184A0407|4 8|study
P08595184A0407|19 27|estimator
P08595184A0407|98 112|field potentials
P08595414A0000|220 230|orientation
P08595414A0000|50 53|maps
P08595414A0000|193 198|clones
P08595414A0000|91 97|contigs
P08595414A0000|163 168|extent
P08595414A0000|3 10|assembly
P08595414A0000|57 68|construction
P08595414A0000|13 20|sequence
P08595414A0000|145 157|determination
P08595414A0000|117 128|model genomes
P08595627A1513|43 49|channel
P08595627A1513|183 184|VF
P08595627A1513|93 101|occlusion
P08595627A1513|151 152|VF
P08595627A1513|71 82|consequences
P08595627A1513|111 121|KATP opening
P08595627A1513|28 37|inhibition
P08595627A1513|4 10|opening
P08595627A1513|13 16|KATP
P08595658A0961|54 87|plant mitochondrial-processing sites
P08595658A0961|111 114|ends
P08595658A0961|141 153|RNA processing
P08595658A0961|30 36|termini
P08595658A0961|44 51|homology
P08595658A0961|3 14|DNA sequences
P08595836T0000|74 82|materials
P08595836T0000|6 14|shrinkage
P08595836T0000|51 62|glass ionomer
P08595836T0000|28 34|changes
P08595878A0201|85 106|receptor tyrosine kinase
P08595878A0201|67 70|Ras1
P08595878A0201|108 110|RTK
P08595878A0201|20 27|evidence
P08595878A0201|112 136|signal transduction pathway
P08595878A0201|150 172|R7 photoreceptor cell fate
P08595878A0201|188 200|Drosophila eye
P08595878A0201|42 54|PP2A functions
P08597108A0642|0 4|QBMDs
P08597108A0642|19 26|response
P08597108A0642|10 16|% change
P08597108A0642|53 59|average
P08597108A0642|81 85|NOAEL
P08597108A0642|28 33|QBMD05
P08597177T0000|0 6|Effects
P08597177T0000|17 25|exposures
P08597177T0000|28 43|hydrogen sulphide
P08597177T0000|46 48|rat
P08597177T0000|60 62|EEG
P08597596A0135|27 34|cassette
P08597596A0135|36 49|ABC transporter
P08597596A0135|3 6|gene
P08597636A0000|25 30|family
P08597636A0000|33 37|genes
P08597636A0000|64 81|expression patterns
P08597636A0000|8 12|motif
P08597636A0000|53 60|features
P08597636A0000|94 104|involvement
P08597636A0000|120 133|gene regulation
P08598051T0000|66 86|RNP consensus-sequence
P08598051T0000|25 43|schizosaccharomyces
P08598051T0000|9 16|analysis
P08598051T0000|49 52|gene
P08598051T0000|98 104|domains
P08598359X0000|87 100|cell carcinomas
P08598359X0000|225 229|T1-T2
P08598359X0000|23 31|field size
P08598359X0000|150 156|patient
P08598359X0000|36 59|treatment energy influence
P08598359X0000|138 146|treatment
P08598359X0000|9 21|treatment time
P08598359X0000|113 118|larynx
P08598359X0000|74 78|T1-T2
P08598359X0000|214 222|treatment
P08598359X0000|120 126|PURPOSE
P08598359X0000|174 180|factors
P08598359X0000|65 71|control
P08598359X0000|263 268|larynx
P08598359X0000|238 250|cell carcinoma
P08598359X0000|202 208|control
P08598449A0784|260 273|concentrations
P08598449A0784|256 258|CA2
P08598449A0784|163 165|fyn
P08598449A0784|15 23|signaling
P08598449A0784|69 80|CD38 ligation
P08598449A0784|178 180|vav
P08598449A0784|206 212|protein
P08598449A0784|101 123|tyrosine phosphorylation
P08598449A0784|35 53|surface Ig engagement
P08598449A0784|137 161|protein tyrosine kinases lyn
P08598449A0784|238 244|changes
P08598449A0784|170 172|btk
P08598449A0784|56 67|B lymphocytes
P08598449A0784|2 9|contrast
P08599945T0000|14 27|alpha-amanitin
P08599945T0000|37 42|domain
P08599945T0000|128 138|transitions
P08599945T0000|64 81|yeast RNA polymerase
P08599945T0000|99 109|RNA cleavage
P08599945T0000|55 61|subunit
P08599945T0000|0 8|Mutations
P08599946A0999|148 157|structures
P08599946A0999|52 75|ribonucleoprotein complex
P08599946A0999|39 48|p40 complex
P08599946A0999|3 10|evidence
P08599946A0999|173 191|example coiled-coils
P08599946A0999|94 94|s
P08599946A0999|206 212|complex
P08599946A0999|86 92|L1Hs RNA
P08599946A0999|118 129|interactions
P08600028A1129|119 128|Myc protein
P08600028A1129|77 86|reflection
P08600028A1129|52 65|intron enhancer
P08600028A1129|18 33|trans-activation
P08600028A1129|104 113|properties
P08600028A1129|3 6|data
P08600048T0000|16 29|conjunctivitis
P08600048T0000|39 63|bone marrow transplantation
P08600048T0000|111 114|case
P08600048T0000|101 105|study
P08601283A0875|199 211|SECIS function
P08601283A0875|73 86|selenoproteins
P08601283A0875|151 162|SECIS element
P08601283A0875|112 115|type
P08601283A0875|100 106|effects
P08601283A0875|11 18|presence
P08601283A0875|43 55|reading frames
P08601283A0875|117 126|deiodinase
P08601283A0875|21 33|SECIS elements
P08601283A0875|57 60|ORFs
P08601283A0875|2 5|view
P08601283A0875|141 143|ORF
P08601284A0000|88 95|sequence
P08601284A0000|102 103|bp
P08601284A0000|35 40|region
P08601284A0000|24 29|spacer
P08601284A0000|113 127|complementarity
P08601284A0000|133 140|U3 snoRNA
P08601284A0000|31 33|ETS
P08601284A0000|46 53|pre-rRNA
P08601490A0659|5 11|animals
P08601616A0726|86 97|G1/S boundary
P08601616A0726|112 126|spindle assembly
P08601616A0726|63 66|step
P08601616A0726|19 29|pds1 mutants
P08601616A0726|106 109|time
P08601616A0726|4 16|spindle defect
P08601806A0875|52 56|steps
P08601806A0875|20 24|RPF-1
P08601806A0875|90 102|ganglion cells
P08601806A0875|5 8|data
P08601806A0875|62 76|differentiation
P08601806A0875|79 86|amacrine
P08602169A0484|70 73|type
P08602169A0484|90 93|CPDs
P08602169A0484|99 106|MAT alpha
P08602169A0484|32 37|repair
P08602169A0484|55 58|site
P08602169A0484|5 15|point mutant
P08602169A0484|40 51|endonuclease
P08602169A0484|81 87|removal
P08602169A0484|110 121|HML alpha loci
P08602608A1056|32 43|performances
P08602608A1056|61 64|STKS
P08602608A1056|49 54|CD3500
P08602608A1056|23 27|cases
P08602608A1056|122 139|reference procedure
P08603921A1346|75 80|growth
P08603921A1346|108 111|cell
P08603921A1346|44 64|calmodulin binding site
P08603921A1346|126 131|manner
P08603921A1346|16 33|Spc110p truncations
P08604338A0198|16 28|FLI-1 proteins
P08604338A0198|39 58|transcription factors
P08604338A0198|115 130|promoter elements
P08604338A0198|97 104|ets boxes
P08604338A0198|81 92|ets sequences
P08604338A0198|4 12|EWS-FLI-1
P08604338A0885|129 139|interaction
P08604338A0885|50 52|SRE
P08604338A0885|79 81|SRF
P08604338A0885|174 189|complex formation
P08604338A0885|152 155|step
P08604338A0885|101 105|FLI-1
P08604338A0885|144 146|DNA
P08604338A0885|92 98|binding
P08604338A0885|192 196|FLI-1
P08604338A0885|2 27|electromobility shift assays
P08604338A0885|70 76|absence
P08604338A0885|29 44|EWS-FLI-1 binding
P08604708A1086|132 134|BTG
P08604708A1086|10 16|studies
P08604708A1086|91 104|blood flow rates
P08604708A1086|124 129|change
P08604708A1086|49 66|cellulose dialyzers
P08604708A1086|109 115|minutes
P08605302A1770|0 13|DNA methylation
P08605302A1770|130 141|rice CatA gene
P08605302A1770|173 192|CatA promoter activity
P08605302A1770|119 124|intron
P08605302A1770|47 61|deoxyadenosines
P08605302A1770|217 221|assay
P08605302A1770|94 97|exon
P08605302A1770|70 79|GATC motifs
P08605324A0434|8 10|LTR
P08605324A0434|23 30|promoter
P08605326A0772|11 20|cDNA clones
P08605705A0676|40 42|CIC
P08605705A0676|13 23|IgM class CIC
P08605705A0676|77 91|disease activity
P08605705A0676|50 59|hepatitis A
P08605705A0676|2 11|conclusion
P08605931A0777|0 13|Epitope mapping
P08605931A0777|105 112|RNP motif
P08605931A0777|70 82|epitope domain
P08605931A0777|36 41|clones
P08605931A0777|118 127|U1A protein
P08606267A0740|0 8|Variables
P08606267A0740|148 157|evaluation
P08606267A0740|160 192|Tc-99m 2-methoxy isobutyl isonitrile
P08606267A0740|119 130|registration
P08606267A0740|199 203|scans
P08606267A0740|50 53|data
P08606267A0740|216 224|variables
P08606267A0740|68 82|exercise testing
P08606267A0740|194 197|MIBI
P08606267A0740|22 27|number
P08606267A0740|43 48|events
P08608126A0811|72 75|acid
P08608126A0811|148 158|short-chain
P08608126A0811|92 92|K
P08608126A0811|21 24|acid
P08608126A0811|108 109|nM
P08608126A0811|38 52|binding affinity
P08608126A0811|5 10|length
P08608126A0811|177 182|lipids
P08608126A0811|135 138|acid
P08608126A0811|114 125|medium-chain
P08608126A0811|94 94|d
P08608126A0811|168 171|acid
P08608222T0000|29 34|region
P08608222T0000|71 84|factor receptor
P08608222T0000|98 102|STAT3
P08608222T0000|109 131|STAT1 homodimer formation
P08608222T0000|42 52|granulocyte
P08608447A0806|28 43|codon recognition
P08608447A0806|50 63|TPI transcripts
P08608447A0806|88 95|splicing
P08608447A0806|69 73|place
P08608448A0353|202 206|loops
P08608448A0353|144 147|S RNA
P08608448A0353|12 19|residues
P08608448A0353|161 170|reactivity
P08608448A0353|71 77|regions
P08608448A0353|125 138|structure model
P08608448A0353|42 57|dimethylsulphate
P08608448A0353|184 191|residues
P08608448A0353|61 68|kethoxal
P08610272A0265|205 211|outcome
P08610272A0265|171 183|growth factors
P08610272A0265|151 167|response modifiers
P08610272A0265|231 237|disease
P08610272A0265|89 96|duration
P08610272A0265|215 222|patients
P08610272A0265|71 77|control
P08610272A0265|137 140|role
P08610272A0265|99 121|maintenance chemotherapy
P08610272A0265|55 62|approach
P08610272A0265|16 29|investigations
P08610328A0228|28 35|criteria
P08610328A0228|78 88|experiences
P08610328A0228|48 54|studies
P08610328A0228|9 14|REVIEW
P08610328A0228|97 103|studies
P08610328A0228|122 126|world
P08610328A0228|0 6|SUMMARY
P08610582A0150|29 35|lesions
P08610582A0150|10 17|patients
P08610582A0150|95 96|T.
P08610582A0150|81 89|MR imaging
P08610582A0150|48 54|CT scans
P08611280A0820|188 193|cm3/m2
P08611280A0820|152 152|p
P08611280A0820|195 195|p
P08611280A0820|117 123|systole
P08611280A0820|74 79|cm3/m2
P08611280A0820|145 150|cm3/m2
P08611280A0820|50 57|subjects
P08611280A0820|10 16|volumes
P08611280A0820|175 180|cm3/m2
P08611280A0820|95 95|p
P08611280A0820|131 136|cm3/m2
P08611280A0820|88 93|cm3/m2
P08611280A0820|104 108|onset
P08612852A0553|99 106|controls
P08612852A0553|38 50|body mass index
P08612852A0553|13 29|plasma IGF-I levels
P08612852A0553|78 85|patients
P08612852A0553|52 54|BMI
P08612852A0553|0 6|RESULTS
P08614403A0557|18 23|levels
P08614403A0557|142 149|myotubes
P08614403A0557|53 66|C2C12 myoblasts
P08614403A0557|26 42|Rev-erbA alpha mRNA
P08614403A0557|94 98|cells
P08614403A0989|142 149|presence
P08614403A0989|24 49|GAL4-REV-erbA alpha chimeras
P08614403A0989|152 160|8-Br-cAMP
P08614403A0989|102 114|transcription
P08614403A0989|87 92|region
P08614403A0989|190 192|LBD
P08614403A0989|68 73|region
P08614403A0989|65 66|AB
P08614403A0989|225 232|silencer
P08614403A0989|85 85|E
P08614403A0989|183 188|domain
P08614403A0989|117 136|GAL4 response elements
P08614410A0000|117 126|regulation
P08614410A0000|75 85|oncogenesis
P08614410A0000|37 55|gonadotroph cell line
P08614410A0000|166 172|activin
P08614410A0000|3 19|alpha T3-1 cell line
P08614410A0000|98 101|mice
P08614410A0000|132 163|glycoprotein hormone alpha-subunit
P08615012A0627|0 13|Cotransfection
P08615012A0627|60 65|amount
P08615012A0627|74 80|enzymes
P08615012A0627|21 27|ie1 gene
P08615012A0627|47 54|increase
P08615012A0627|106 110|cells
P08615025A1214|346 350|cells
P08615025A1214|125 127|Env
P08615025A1214|252 263|cell membrane
P08615025A1214|151 166|immunoreactivity
P08615025A1214|324 337|membrane fusion
P08615025A1214|80 101|glycosylation phenotype
P08615025A1214|26 28|Env
P08615025A1214|342 344|CD4
P08615025A1214|276 280|gp120
P08615025A1214|41 47|mutants
P08615025A1214|217 221|gp120
P08615025A1214|225 228|gp41
P08615025A1214|187 191|gp160
P08615025A1214|169 170|V3
P08615025A1214|113 122|quantities
P08615025A1214|11 23|glycosylation
P08615025A1214|286 288|CD4
P08615025A1214|297 308|membrane gp41
P08615025A1214|234 236|Env
P08615183T0000|0 6|Effects
P08615183T0000|36 44|Parkinson
P08615183T0000|23 33|pallidotomy
P08615183T0000|47 53|disease
P08616743T0000|12 14|Dr.
P08616743T0000|5 9|trail
P08617216A0584|53 59|protein
P08617216A0584|61 64|GrpE
P08617216A0584|40 43|DnaK
P08617216A0584|68 76|refolding
P08617216A0584|93 102|luciferase
P08617216A0584|20 23|DnaJ
P08617237A0489|29 33|STAT5
P08617237A0489|78 87|reactivity
P08617237A0489|92 114|tyrosine phosphopeptides
P08617237A0489|54 74|DNA binding specificity
P08617237A0489|140 151|localization
P08617237A0489|15 26|phosphoforms
P08617238A0334|71 85|phosphorylation
P08617238A0334|122 151|substrate protein MAPKAP kinase-2
P08617238A0334|192 207|heat shock protein
P08617238A0334|88 99|p38 MAP kinase
P08617238A0334|30 48|p38 MAP kinase pathway
P08617238A0334|211 215|hsp27
P08617238A0334|107 116|activation
P08617238A0334|0 11|TNF Treatment
P08617238A0334|172 186|phosphorylation
P08617238A0334|14 17|cell
P08617243A0336|97 102|region
P08617243A0336|20 26|protein
P08617243A0336|48 55|extracts
P08617243A0336|81 84|site
P08617311A0979|44 56|membrane exons
P08617311A0979|125 135|Xenopus mIgY
P08617311A0979|111 120|similarity
P08617311A0979|64 67|mIgY
P08617311A0979|16 33|sequence similarity
P08617311A0979|80 83|mIgG
P08617311A0979|87 89|IgE
P08617800A0150|0 6|Control
P08617800A0150|50 60|determinant
P08617800A0150|9 21|transcription
P08617800A0150|63 80|receptor expression
P08617800A0150|27 36|erbB-2 gene
P08617800A0675|0 4|DNase
P08617800A0675|80 88|half-site
P08617800A0675|36 54|mobility shift assays
P08617800A0675|112 140|core recognition sequence TGGGAG
P08617800A0675|6 17|footprinting
P08617800A0675|67 69|PBP
P08617800A0675|95 104|palindrome
P08617802A0993|60 66|p120 GAP
P08617802A0993|94 101|activity
P08617802A0993|27 35|sequences
P08617802A0993|5 11|results
P08617802A0993|108 110|Ras
P08617802A0993|41 57|SH2/SH3/SH2 region
P08618433A0000|71 74|FLT3
P08618433A0000|126 130|STK-1
P08618433A0000|118 122|FLK-2
P08618433A0000|21 42|growth factor FLT3 ligand
P08618433A0000|76 97|tyrosine kinase receptor
P08618433A0000|99 99|R
P08618433A0000|59 64|ligand
P08618433A0000|44 45|FL
P08618433A1720|2 9|contrast
P08618433A1720|39 46|receptor
P08618433A1720|103 119|leukemia cell lines
P08618433A1720|140 151|cell lineages
P08618433A1720|24 33|expression
P08618433A1720|79 79|%
P08618433A1720|48 59|FL expression
P08618433A1720|92 100|cell types
P08618864A0754|57 60|core
P08618864A0754|7 14|analysis
P08618864A0754|36 46|mutagenesis
P08618864A0754|107 114|activity
P08618864A0754|21 26|domain
P08618864A0754|83 90|residues
P08618882A0343|0 7|Analysis
P08618882A0343|10 24|RAR alpha mutants
P08618882A0343|103 115|BZLF1 activity
P08618882A0343|27 45|transfection studies
P08618882A0343|91 100|inhibition
P08618882A0343|60 75|DNA binding domain
P08619866A0000|71 80|infarction
P08619866A0000|105 117|heart diseases
P08619866A0000|38 40|HGF
P08619866A0000|82 95|angina pectoris
P08619866A0000|10 36|serum hepatocyte growth factor
P08619866A0000|44 51|patients
P08619910A0000|60 65|tremor
P08619910A0000|259 266|findings
P08619910A0000|286 302|nigra zona compacta
P08619910A0000|220 226|disease
P08619910A0000|304 306|SNc
P08619910A0000|69 76|akinesia
P08619910A0000|51 58|rigidity
P08619910A0000|229 236|relation
P08619910A0000|155 166|observations
P08619910A0000|172 177|effect
P08619910A0000|9 17|mechanism
P08619910A0000|89 94|result
P08619910A0000|32 44|motor symptoms
P08619910A0000|110 127|dopamine deficiency
P08619910A0000|206 214|treatment
P08620003T0000|29 48|N-O acyl rearrangement
P08620003T0000|61 64|step
P08620003T0000|70 84|splicing process
P08620003T0000|16 23|evidence
P08620003T0000|0 14|Protein splicing
P08620856A1172|175 186|reading frame
P08620856A1172|20 23|data
P08620856A1172|108 124|mouse c-kit protein
P08620856A1172|210 218|c-kit cDNA
P08620856A1172|153 156|size
P08620856A1172|25 46|western blot experiments
P08620856A1172|280 290|spermatozoa
P08620856A1172|136 146|polypeptide
P08620856A1172|242 247|stages
P08620856A1172|250 264|spermatogenesis
P08620856A1172|54 61|antibody
P08620856A1172|96 102|portion
P08620856A1172|2 10|agreement
P08620889A0771|26 32|element
P08620889A0771|62 74|transcription
P08620889A0771|106 110|cells
P08620889A0771|38 54|aldolase C promoter
P08620889A0771|17 19|G+C
P08621017A1186|0 7|LY290181
P08621017A1186|24 44|uPA promoter activation
P08621017A1186|160 166|element
P08621017A1186|94 101|proteins
P08621017A1186|107 116|uPA PEA3/12
P08621017A1186|78 84|binding
P08621017A1186|168 170|TRE
P08621017A1186|55 61|phorbol
P08621017A1186|120 149|tetradecanoylphorbol 13-acetate
P08621384A0935|0 8|Treatment
P08621384A0935|115 117|min
P08621384A0935|125 155|PKCdelta tyrosine phosphorylation
P08621384A0935|50 69|growth factor receptor
P08621384A0935|11 23|keratinocytes
P08621384A0935|99 110|growth factor
P08621384A0935|80 87|TGFalpha
P08621384A0935|71 74|EGFR
P08621420A1166|57 66|antibodies
P08621420A1166|46 48|p50
P08621420A1166|101 106|effect
P08621420A1166|36 43|antibody
P08621420A1166|79 95|NF-kappaB proteins
P08621420A1166|69 71|p65
P08621420A1166|14 18|bands
P08621448A0862|28 31|cDNA
P08621448A0862|95 101|protein
P08621448A0862|24 26|DNA
P08621448A0862|81 82|C1
P08621448A0862|44 66|RL95-2 expression library
P08621448A0862|33 37|clone
P08621451A0552|0 3|Biol
P08621453A0815|31 40|antibodies
P08621453A0815|68 78|cell lysates
P08621453A0815|59 63|80K-H
P08621453A0815|112 122|fibroblasts
P08621453A0815|2 9|addition
P08621542A0535|103 111|TNF-alpha
P08621542A0535|40 46|kinases
P08621542A0535|70 83|protein kinases
P08621542A0535|23 27|c-Jun
P08621542A0535|8 21|protein kinases
P08621542A0535|48 51|JNKs
P08621542A0535|113 116|IL-1
P08621542A0535|121 137|CD28 costimulation
P08621628A1233|5 11|hGRbeta
P08621628A1233|62 77|hGRalpha activity
P08621628A1233|51 59|inhibitor
P08621659A0189|102 108|domains
P08621659A0189|100 100|G
P08621659A0189|26 34|Gla domain
P08621659A0189|0 3|Gas6
P08621659A0189|75 81|repeats
P08621659A0189|58 63|growth
P08621661A1035|4 18|P5CDh cDNA clones
P08621661A1035|165 174|transcript
P08621661A1035|103 106|cDNA
P08621661A1035|50 62|Northern blots
P08621661A1035|78 84|tissues
P08621661A1035|38 47|transcript
P08621661A1035|135 140|intron
P08621664A1430|58 72|phosphorylation
P08621664A1430|98 100|PKN
P08621664A1430|75 95|neurofilament L protein
P08621664A1430|16 36|neurofilament L protein
P08621664A1430|0 13|Polymerization
P08621714A0361|53 62|thiol group
P08621714A0361|31 44|disulfide bonds
P08621714A0361|65 69|Cys25
P08621714A0361|3 9|protein
P08621719A0000|5 10|others
P08621719A0000|114 137|T cell receptor stimulation
P08621719A0000|34 59|c-cbl proto-oncogene product
P08621719A0000|87 109|tyrosine phosphorylation
P08621719A0000|78 84|targets
P08621719A0568|56 59|Grb2
P08621719A0568|12 19|fraction
P08621719A0568|22 24|Cbl
P08621719A0568|91 104|Grb2 SH3 domains
P08621719A0568|67 77|interaction
P08621730T0000|73 78|COL1A2
P08621730T0000|62 62|I
P08621730T0000|35 44|regulation
P08621730T0000|110 126|growth factor-beta
P08621730T0000|80 95|promoter activity
P08621730T0000|55 60|alpha2
P08621730T0000|64 71|collagen
P08621730T0000|2 20|AP-1 binding sequence
P08622030A0667|44 52|age groups
P08622030A0667|13 23|differences
P08622030A0667|157 161|level
P08622030A0667|127 151|serum lactate dehydrogenase
P08622030A0667|106 122|performance status
P08622030A0667|153 155|LDH
P08622030A0667|55 77|baseline characteristics
P08622030A0667|88 104|treatment protocol
P08622070A0889|57 67|progression
P08622070A0889|7 14|patients
P08622070A0889|25 26|CA
P08622070A0889|43 46|time
P08622070A0889|19 19|%
P08622070A0889|30 37|response
P08622596A0189|30 33|diet
P08622596A0189|36 39|home
P08622596A0189|75 77|fat
P08622596A0189|3 5|men
P08622596A0189|82 85|week
P08622596A0189|60 62|fat
P08622645A1026|15 17|VDR
P08622645A1026|34 42|vitamin D3
P08622645A1026|58 68|RA induction
P08622645A1026|89 95|element
P08622668A1155|147 161|binding affinity
P08622668A1155|63 72|modulation
P08622668A1155|76 113|phosphorylation-dephosphorylation cycle
P08622668A1155|116 129|C1 hnRNP protein
P08622668A1155|54 58|U6 RNA
P08622668A1155|168 174|protein
P08622668A1155|178 185|pre-mRNA
P08622668A1155|5 11|results
P08622668A1155|44 51|function
P08622675A0587|0 8|Inclusion
P08622675A0587|22 30|N terminus
P08622675A0587|82 91|similarity
P08622675A0587|105 115|factor Lef-1
P08622675A0587|56 62|protein
P08622698T0000|61 69|mechanism
P08622698T0000|98 107|virus EBNA2
P08622698T0000|53 57|genes
P08622698T0000|18 23|Notch1
P08622887A1026|15 33|mobility shift assays
P08622887A1026|234 236|DBD
P08622887A1026|54 91|glucocorticoid receptor DNA binding domain
P08622887A1026|93 95|DBD
P08622887A1026|127 132|motifs
P08622887A1026|145 147|DBD
P08622887A1026|117 121|GRE-2
P08622887A1026|151 187|oligonucleotide competition experiments
P08622887A1026|35 39|EMSAs
P08622887A1026|221 230|affinities
P08622893A0000|43 46|RTKs
P08622893A0000|137 147|development
P08622893A0000|166 183|signalling pathways
P08622893A0000|103 115|communication
P08622893A0000|198 203|family
P08622893A0000|64 72|prototype
P08622893A0000|8 16|subfamily
P08622893A0000|56 58|EPH
P08622893A0000|19 41|receptor tyrosine kinases
P08622893A0000|83 87|roles
P08623554A1058|40 48|infection
P08623554A1058|51 56|plants
P08623554A1058|9 15|protein
P08624445A0257|128 132|wx-m9
P08624445A0257|149 150|Ac
P08624445A0257|52 78|cytosine methylation patterns
P08624445A0257|168 176|tenth exon
P08624445A0257|84 106|transposase binding sites
P08624445A0257|135 142|Ac allele
P08624445A0257|29 46|sequencing analysis
P08624445A0257|186 189|gene
P08624445A0257|117 118|Ac
P08625806A0263|0 6|Krox-20
P08625806A0263|52 61|expression
P08625806A0263|104 114|maintenance
P08625806A0263|64 65|r3
P08625806A0263|9 22|zinc finger gene
P08625806A0263|117 128|mouse embryos
P08625806A0263|43 49|pattern
P08625806A0263|69 70|r5
P08625900T0000|36 46|polypeptide
P08625900T0000|9 17|adenylate
P08625900T0000|108 114|pathway
P08625900T0000|56 80|prolactin promoter activity
P08625900T0000|190 196|hormone
P08625900T0000|85 97|protein kinase
P08625900T0000|152 158|pathway
P08625924A0411|0 8|Clones 33F
P08625924A0411|142 146|mRNAs
P08625924A0411|53 62|amino acids
P08625924A0411|12 14|34B
P08625924A0411|31 47|aromatase proteins
P08625924A0411|77 80|size
P08625924A0411|97 122|polyadenylation signal usage
P08625987A1086|179 184|B cells
P08625987A1086|39 48|VpreB genes
P08625987A1086|112 122|state levels
P08625987A1086|62 73|pro-B/pre-BI
P08625987A1086|103 105|RNA
P08625987A1086|89 93|cells
P08625987A1086|8 32|bone marrow cells expression
P08626065A0000|32 47|Bacillus subtilis
P08626065A0000|80 83|nrdA
P08626065A0000|52 62|DNA fragment
P08626065A0000|87 95|citB genes
P08626065A0000|106 112|degrees
P08626065A0000|49 50|Bs
P08626065A0000|118 127|chromosome
P08626290T0000|45 52|homologs
P08626290T0000|68 82|membrane protein
P08626290T0000|32 36|genes
P08626290T0000|84 87|OmpA
P08626290T0000|0 19|Aeromonas salmonicida
P08626313A1037|0 9|Expression
P08626313A1037|12 14|Msp
P08626313A1037|44 50|msp gene
P08626325A0543|57 60|UmuD
P08626325A0543|108 111|UmuD
P08626325A0543|102 105|UmuD
P08626325A0543|50 53|UmuD
P08626325A0543|118 128|heterodimer
P08626325A0543|30 33|data
P08626325A0543|90 98|UmuD-UmuD
P08626325A0543|130 138|UmuD-UmuD
P08626325A0543|79 88|homodimers
P08626325A0543|2 10|agreement
P08626437A0332|0 8|Lyn kinase
P08626437A0332|159 166|tyrosine
P08626437A0332|73 96|glutathione S-transferase
P08626437A0332|98 100|GST
P08626437A0332|50 52|BCP
P08626437A0332|103 111|Lyn fusion
P08626437A0332|31 37|lysates
P08626437A0332|150 156|p34cdc2
P08626493A1468|0 8|Mutations
P08626493A1468|24 29|region
P08626493A1468|191 197|type E1A
P08626493A1468|72 96|retinoblastoma gene product
P08626493A1468|153 165|PEPCK promoter
P08626493A1468|38 40|E1A
P08626493A1468|55 61|binding
P08626493A1468|32 34|CR2
P08626493A1468|64 66|E1A
P08626493A1468|133 145|transcription
P08626493A1468|120 130|stimulation
P08626493A1468|98 100|pRb
P08626529A0000|134 137|face
P08626529A0000|24 30|Sjogren
P08626529A0000|167 168|B.
P08626529A0000|163 165|Toh
P08626529A0000|155 158|Kooy
P08626529A0000|93 107|membrane protein
P08626529A0000|33 47|syndrome patient
P08626529A0000|5 18|autoantibodies
P08626529A0000|160 161|J.
P08626529A0799|59 62|p230
P08626529A0799|105 118|characteristic
P08626529A0799|209 218|amino acids
P08626529A0799|24 30|regions
P08626529A0799|171 174|p230
P08626529A0799|244 255|granin family
P08626529A0799|160 169|structures
P08626529A0799|190 207|sequence ESLALEELEL
P08626529A0799|229 233|motif
P08626529A0799|80 88|frequency
P08626529A0799|121 133|alpha-helices
P08626529A0799|300 318|neuroendocrine cells
P08626529A0799|91 103|heptad repeats
P08626529A0799|264 271|proteins
P08626529A0799|32 41|amino acids
P08626529A0799|290 297|granules
P08626539T0000|0 17|Binding specificity
P08626539T0000|21 30|modulation
P08626539T0000|89 97|receptors
P08626539T0000|68 79|heterodimers
P08626539T0000|36 57|ApoA-I promoter activity
P08626539T0000|60 63|homo
P08626540A1007|85 92|ceramide
P08626540A1007|52 59|turnover
P08626540A1007|94 109|glucosylceramide
P08626540A1007|114 129|lactosylceramide
P08626540A1007|35 48|concentrations
P08626596A0000|73 76|role
P08626596A0000|89 93|cells
P08626596A0000|48 60|protein kinase
P08626596A0000|166 173|pathways
P08626596A0000|115 126|ATP depletion
P08626596A0000|62 65|AMPK
P08626596A0000|98 105|stresses
P08626596A0000|14 21|evidence
P08626610A0931|144 148|forms
P08626610A0931|152 157|result
P08626610A0931|114 125|COOH terminus
P08626610A0931|38 44|SREBP-1
P08626610A0931|91 96|region
P08626610A0931|28 35|cleavage
P08626610A0931|98 104|residue
P08626610A0931|171 178|splicing
P08626610A0931|15 25|suppression
P08626612A1040|0 1|Am
P08626667A1372|0 25|EMSA competition experiments
P08626667A1372|36 44|mutations
P08626667A1372|104 111|proteins
P08626667A1372|85 91|binding
P08626667A1372|125 143|type oligonucleotide
P08626667A1372|60 66|repeats
P08626667A1517|147 163|GPT gene expression
P08626667A1517|54 60|repeats
P08626667A1517|117 131|motifs functions
P08626667A1517|98 107|conclusion
P08626667A1517|20 27|promoter
P08626667A1517|0 12|Transcription
P08626698A0989|146 163|complex kinase assay
P08626698A0989|45 63|PKC beta transfectant
P08626698A0989|17 24|increase
P08626698A0989|74 92|immunoprecipitation
P08626698A0989|27 38|ERK3 activity
P08626698A0989|170 183|gel kinase assay
P08626698A0989|116 123|antibody
P08626777A0537|146 158|cartilage gene
P08626777A0537|123 137|link protein gene
P08626777A0537|80 85|motifs
P08626777A0537|112 117|region
P08626777A0537|28 41|Col2a1 enhancer
P08626777A0537|57 70|sequence motifs
P08626777A0537|0 15|Sequence analysis
P08626785A0674|265 271|mTGRRE1
P08626785A0674|285 308|hexanucleotide half-sites
P08626785A0674|345 356|DR7/DR5 motif
P08626785A0674|256 262|mTGRRE1
P08626785A0674|373 387|RXR heterodimers
P08626785A0674|111 119|sequences
P08626785A0674|156 191|mouse tissue transglutaminase promoters
P08626785A0674|391 403|RXR homodimers
P08626785A0674|18 27|activation
P08626785A0674|369 371|RAR
P08626785A0674|228 254|pair retinoid response element
P08626785A0674|202 207|region
P08626785A0674|95 100|region
P08626785A0674|33 62|tissue transglutaminase promoter
P08626809A0729|73 89|eIF-2alpha peptide
P08626809A0729|14 17|pPKR
P08626809A0729|56 60|Ser51
P08626809A0729|114 135|eIF-2alpha kinase family
P08626809A0729|95 108|characteristic
P08627354A0000|30 35|family
P08627354A0000|10 18|synapsins
P08627354A0000|74 83|regulation
P08627354A0000|46 53|proteins
P08627354A0000|86 108|neurotransmitter release
P08627649A0734|198 200|Sp3
P08627649A0734|182 190|Sp1 family
P08627649A0734|77 83|binding
P08627649A0734|112 131|transcription factors
P08627649A0734|101 109|Ets family
P08627649A0734|15 33|mobility shift assays
P08627649A0734|44 51|extracts
P08627649A0734|154 164|interaction
P08627649A0734|217 221|GC box
P08627649A0734|192 194|Sp1
P08627649A0734|137 141|P4 EBS
P08627649A0734|94 94|s
P08627649A0734|170 176|members
P08627649A0734|56 65|FREJ4 cells
P08627649A0734|87 92|member
P08627667A0132|0 4|ZEBRA
P08627667A0132|99 111|specificities
P08627667A0132|41 45|c-Fos
P08627667A0132|16 33|AP-1 bZip activators
P08627667A0132|72 78|domains
P08627688A1520|29 32|I299
P08627688A1520|57 64|activity
P08627688A1520|4 9|result
P08627719A0784|0 25|UV cross-linking experiments
P08627719A0784|77 90|protein factors
P08627719A0784|160 160|A
P08627719A0784|42 53|HSV infection
P08627719A0784|162 169|site RNAs
P08627719A0784|250 253|IE63
P08627719A0784|223 229|binding
P08627719A0784|155 158|poly
P08627719A0784|110 118|component
P08627719A0784|238 247|expression
P08627719A0784|68 74|binding
P08627719A0784|197 203|classes
P08627719A0784|147 150|CstF
P08627719A0784|174 183|virus genes
P08627719A0784|121 145|cleavage stimulation factor
P08628251A1455|0 6|CM-ACO3
P08628251A1455|20 26|flowers
P08628251A1455|52 58|stimuli
P08628254A0665|60 67|AP1 sites
P08628254A0665|111 114|foci
P08628254A0665|43 57|transactivators
P08628254A0665|19 33|Jun/eb1 chimeras
P08628254A0665|95 102|c-Ha-Ras
P08628255A0932|14 22|HeLa cells
P08628255A0932|24 33|expression
P08628255A0932|135 138|site
P08628255A0932|80 91|DNA synthesis
P08628255A0932|112 119|presence
P08628255A0932|144 156|H2A.1 promoter
P08628255A0932|36 53|luciferase activity
P08628255A0932|69 77|beginning
P08628260A0895|18 36|transfection studies
P08628260A0895|88 104|promoter sequences
P08628260A0895|39 48|HepG2 cells
P08628260A0895|113 122|nucleotide
P08628260A0895|155 162|increase
P08628260A0895|165 180|promoter activity
P08628260A0895|78 83|factor
P08628260A0895|126 132|results
P08628260A0895|65 72|deletion
P08628284A0181|14 32|yeast reporter strain
P08628284A0181|113 117|TRE-1
P08628284A0181|62 68|control
P08628284A0181|105 110|copies
P08628284A0181|74 85|CYC1 promoter
P08628284A0181|46 53|lacZ gene
P08628302A0683|11 29|transcription factor
P08628302A0683|35 46|interactions
P08628302A0683|54 66|RNA polymerase
P08628302A0683|69 90|transcription apparatus
P08628302A0683|2 7|hnRNP K
P08628681A0364|28 33|kb mRNA
P08628681A0364|48 60|Northern blots
P08628681A0364|63 71|oocyte RNA
P08628681A0364|80 91|X.laevis cDNA
P08628681A0821|0 19|Sequence conservation
P08628681A0821|79 88|pol domains
P08628681A0821|100 112|DNA polymerase
P08628681A0821|61 67|centers
P08628681A0821|33 40|residues
P08628681A0821|73 75|exo
P08629348A0237|160 164|cysts
P08629348A0237|80 86|changes
P08629348A0237|214 226|hydrocephalus
P08629348A0237|27 33|history
P08629348A0237|205 212|epilepsy
P08629348A0237|137 145|processes
P08629348A0237|41 42|BI
P08630542A1421|68 75|increase
P08630542A1421|37 37|V
P08630542A1421|78 78|Q
P08630542A1421|5 12|findings
P08630542A1421|105 113|procedure
P08630542A1421|92 99|response
P08630542A1421|52 62|consequence
P08630542A1421|27 34|increase
P08630548A0000|72 78|potency
P08630548A0000|131 139|TNF-alpha
P08630548A0000|44 53|regulation
P08630548A0000|7 15|cytokines
P08630548A0000|105 129|tumor necrosis factor-alpha
P08630548A0000|28 33|degree
P08630548A0000|99 102|IL-1
P08630548A0000|85 97|interleukin-1
P08630583A1056|55 55|Q
P08630583A1056|7 8|Hb
P08630583A1056|47 52|effect
P08630583A1056|33 42|CO2 content
P08630583A1056|2 3|pH
P08630599A0534|175 183|policemen
P08630599A0534|160 172|micrograms/ml
P08630599A0534|135 142|patients
P08630599A0534|99 102|mean
P08630599A0534|72 79|patients
P08630599A0534|106 107|SD
P08630599A0534|213 222|coal miners
P08630599A0534|120 132|micrograms/ml
P08630599A0534|198 210|micrograms/ml
P08630599A0534|90 97|subjects
P08630599A0534|2 11|difference
P08630599A0534|14 40|elastin peptide concentration
P08631667A0851|0 13|Identification
P08631667A0851|167 180|kinase activity
P08631667A0851|227 234|plasmids
P08631667A0851|140 150|enzyme assay
P08631667A0851|37 43|tmk gene
P08631667A0851|20 25|region
P08631667A0851|68 82|complementation
P08631667A0851|205 207|use
P08631667A0851|183 194|cell extracts
P08631667A0851|122 127|mutant
P08631667A0851|86 100|yeast dTMP kinase
P08631685A0000|86 101|amine oxidase gene
P08631685A0000|69 72|maoA
P08631685A0000|52 67|monoamine oxidase
P08631685A0000|13 16|gene
P08631685A0000|123 125|min
P08631685A0000|20 25|copper
P08631685A0000|146 155|chromosome
P08631760A0609|41 43|Crk
P08631760A0609|66 79|phosphopeptide
P08631760A0609|30 38|SH2 domain
P08631760A0609|93 111|Crk-SH2 binding motif
P08631760A0609|4 14|interaction
P08631797A0982|14 19|ErbB-2
P08631797A0982|154 163|EGF binding
P08631797A0982|104 110|ligands
P08631797A0982|51 73|tyrosine phosphorylation
P08631797A0982|149 151|NDF
P08631797A0982|141 146|effect
P08631797A0982|32 46|receptor subunit
P08631817T0000|0 13|Identification
P08631817T0000|42 66|kinase phosphorylation site
P08631817T0000|85 88|form
P08631817T0000|96 138|deoxyuridine triphosphate nucleotidohydrolase
P08631817T0000|17 25|consensus
P08631820A0755|3 6|cDNA
P08631820A0755|126 133|Lacroute
P08631820A0755|114 121|Delourme
P08631820A0755|102 112|FPS activity
P08631820A0755|25 32|FPS1 gene
P08631820A0755|123 124|D.
P08631820A0755|80 90|yeast strain
P08631820A0755|141 145|Karst
P08631820A0755|135 136|F.
P08631820A0755|56 70|complementation
P08631820A0755|147 148|F.
P08631822A0677|29 32|VEGF
P08631822A0677|11 26|plasmin fragments
P08631822A0677|95 107|VEGF receptors
P08631822A0677|49 55|respect
P08631822A0677|112 118|ability
P08631822A0677|73 83|interaction
P08631822A0677|139 153|cell mitogenesis
P08631822A0677|58 71|heparin binding
P08631908A0224|0 6|VDR/RXR
P08631908A0224|37 39|DR5
P08631908A0224|63 80|mobility shift assay
P08631908A0224|21 25|VDREs
P08631908A0224|31 33|DR4
P08631934A0000|147 149|G/A
P08631934A0000|135 135|C
P08631934A0000|110 113|site
P08631934A0000|137 141|A/C/G
P08631934A0000|143 145|GTT
P08631934A0000|128 129|YG
P08631934A0000|15 23|Myb family
P08631934A0000|131 133|A/G
P08631934A0000|3 9|members
P08631934A0000|82 87|domain
P08631934A0000|119 126|sequence
P08631934A0000|58 65|homology
P08631934A0000|26 45|transcription factors
P08631934A0000|115 117|MBS
P08631944A0663|188 196|secretion
P08631944A0663|176 185|regulation
P08631944A0663|38 52|C epsilon4 domain
P08631944A0663|18 24|isoform
P08631944A0663|105 117|J558L cell line
P08631944A0663|79 87|IgE grande
P08631944A0663|2 9|contrast
P08631944A0663|158 161|cell
P08631944A0663|72 77|M2 exon
P08631958T0000|35 51|protein IE2 tethers
P08631958T0000|86 88|p53
P08631958T0000|68 83|repression domain
P08631958T0000|5 19|cytomegalovirus
P08632009A1067|16 21|action
P08632009A1067|24 41|C/EBP family members
P08632009A1067|61 75|characteristics
P08632009A1067|101 118|expression profiles
P08632009A1067|123 142|DNA binding affinities
P08632009A1067|180 202|DNA binding specificities
P08632009A1067|167 174|addition
P08632009A1067|3 13|specificity
P08632009A1067|147 155|cofactors
P08632009A1067|82 87|factor
P08632015A0879|3 12|antibodies
P08632015A0879|37 49|transcription
P08632015A0879|52 77|DNA polymerase alpha promoter
P08632015A1226|18 25|analysis
P08632015A1226|182 191|expression
P08632015A1226|144 147|DREF
P08632015A1226|194 196|DNA
P08632015A1226|41 48|presence
P08632015A1226|51 65|DREF polypeptide
P08632015A1226|95 107|division cycle
P08632015A1226|130 141|accumulation
P08632015A1226|216 220|genes
P08632015A1226|68 73|nuclei
P08632015A1226|229 240|DRE sequences
P08632018A0587|72 81|UGT1A1 gene
P08632018A0587|25 35|nucleotides
P08632018A0587|61 66|region
P08632018A0587|94 104|MC induction
P08632018A0587|1 11|DNA fragment
P08632463A1508|84 91|progress
P08632463A1508|64 67|role
P08632463A1508|21 28|argument
P08632463A1508|36 39|beta
P08632463A1508|4 9|result
P08632463A1508|94 116|transcription elongation
P08632463A1508|41 47|subunit
P08632779A0351|172 180|HeLa cells
P08632779A0351|163 169|nucleus
P08632779A0351|75 79|NLS-C
P08632779A0351|156 156|%
P08632779A0351|39 40|AA
P08632779A0351|25 27|NLS
P08632779A0351|3 12|XPG regions
P08632779A0351|133 140|beta-gal
P08632779A0351|81 82|AA
P08632779A0351|60 61|AA
P08632779A0351|54 58|NLS-B
P08632779A0351|29 37|amino acid
P08633855A1064|3 10|lacS gene
P08633855A1064|103 116|S. thermophilus
P08633855A1064|24 56|E. coli-Streptococcus shuttle vector
P08633855A1064|149 154|NZ6091
P08633855A1064|134 139|strain
P08633855A1064|79 100|lacS deletion derivative
P08634290A0000|14 25|retroviruses
P08634290A0000|82 84|end
P08634290A0000|48 51|RNAs
P08634290A0000|3 8|genome
P08634357A0527|3 20|extraction recovery
P08634357A0527|75 75|%
P08634357A0527|95 99|range
P08634357A0527|23 35|Amphotericin B
P08634357A0527|56 60|fluid
P08634420A1784|71 75|clone
P08634420A1784|37 50|UT-7 cell growth
P08634420A1784|122 142|UT-7 cell proliferation
P08634420A1784|96 102|muEpo-R
P08634420A1784|64 68|cells
P08634420A1784|0 8|HuEpo-R Ab
P08634423A0498|14 25|integrations
P08634423A0498|108 108|%
P08634423A0498|53 60|lacZ gene
P08634423A0498|86 97|integrations
P08634423A0498|145 152|32D cells
P08634423A0498|80 80|%
P08634423A0498|35 47|transcription
P08634423A0498|3 11|frequency
P08634423A0498|160 170|neutrophils
P08634423A0498|128 142|differentiation
P08634697A1155|148 154|domains
P08634697A1155|88 92|mouse
P08634697A1155|66 75|expression
P08634697A1155|22 26|cDNAs
P08634697A1155|110 119|importance
P08634697A1155|44 51|reagents
P08634697A1155|78 82|Brca1
P08634697A1155|3 10|sequence
P08635771A0000|1 5|study
P08635771A0000|114 136|methaqualone metabolites
P08635771A0000|104 111|analysis
P08635771A0000|61 96|gas chromatographic/mass spectrometric
P08635771A0000|149 155|samples
P08635771A0000|30 35|ONLINE
P08635771A0000|139 143|urine
P08635771A0000|39 56|EMIT II immunoassays
P08635771A0000|98 102|GC/MS
P08635771A0000|177 181|study
P08636031A1413|100 116|Fur titration assay
P08636031A1413|62 73|pvdS promoter
P08636031A1413|39 46|fragment
P08636031A1413|138 162|gel retardation experiments
P08636031A1413|16 27|Fur repressor
P08636031A1413|185 198|Fur preparation
P08636031A1413|0 10|Interaction
P08636124A0410|4 10|protein
P08636124A0410|24 27|cDNA
P08636124A0410|155 163|evolution
P08636124A0410|126 132|nucleus
P08636124A0410|46 52|p150TSP
P08636124A0410|83 96|phosphoprotein
P08636149A0220|118 125|response
P08636149A0220|128 134|insulin
P08636149A0220|37 47|cell surface
P08636149A0220|56 62|insulin
P08636149A0220|10 18|receptors
P08636149A0220|97 115|autophosphorylation
P08636211A0983|0 5|EMBO J.
P08636428A1363|147 154|mitogens
P08636428A1363|17 23|results
P08636428A1363|117 126|expression
P08636428A1363|63 87|smooth muscle proliferation
P08637006A0000|0 12|Transcription
P08637006A0000|153 163|orientation
P08637006A0000|115 121|TBP site
P08637006A0000|126 133|E2F sites
P08637006A0000|64 68|array
P08637006A0000|189 195|ATF site
P08637006A0000|85 92|elements
P08637006A0000|35 42|promoter
P08637006A0000|17 26|adenovirus
P08637711A1121|178 193|binding complexes
P08637711A1121|127 130|site
P08637711A1121|91 96|IR/IRF
P08637711A1121|77 89|IRF-1 promoter
P08637711A1121|57 71|response element
P08637711A1121|32 46|interferon gamma
P08637711A1121|152 155|site
P08637711A1121|203 213|JRE-IL6-BCs
P08637711A1121|48 55|IFN gamma
P08637711A1121|27 30|IL-6
P08637717A0817|114 125|cyclin E/Cdk2
P08637717A0817|66 72|peptide
P08637717A0817|7 13|peptide
P08637717A0817|88 94|ability
P08637717A0817|97 99|p21
P08637717A0817|46 57|p21-activity
P08637717A0817|15 24|amino acids
P08637717A1231|1 10|p21 peptide
P08637717A1231|110 128|p21-PCNA interaction
P08637717A1231|50 53|PCNA
P08637717A1231|57 74|filter binding assay
P08637717A1231|19 28|amino acids
P08637717A1231|82 88|peptide
P08638435A0522|0 6|Results
P08638435A0522|25 43|agar diffusion method
P08638435A0522|47 62|Y. enterocolitica
P08638435A0522|103 114|A. hydrophila
P08638435A0522|71 88|inhibition activity
P08639310A0548|0 2|OND
P08639310A0548|21 32|mg tid prn days
P08639310A0548|118 120|MCP
P08639310A0548|57 65|mg qds days
P08639310A0548|113 114|CT
P08639310A0548|139 139|h
P08639310A0548|101 106|mg i.v.
P08639310A0548|74 76|MCP
P08639310A0548|4 12|mg tid days
P08639310A0548|123 128|mg p.r.
P08639521A1032|96 101|models
P08639521A1032|113 118|motion
P08639521A1032|26 40|protein fragment
P08639521A1032|10 19|properties
P08639561T0000|0 8|Adduction
P08639561T0000|235 253|deoxyadenosyl adduct
P08639561T0000|173 174|7S
P08639561T0000|19 28|N-ras codon
P08639561T0000|48 49|7S
P08639561T0000|114 119|pyrene
P08639561T0000|222 228|pyrenyl
P08639561T0000|52 52|R
P08639561T0000|81 87|epoxy-7
P08639561T0000|131 140|refinement
P08639561T0000|180 180|S
P08639561T0000|177 177|R
P08639561T0000|66 76|dihydroxy-9
P08639561T0000|96 110|tetrahydrobenzo
P08639561T0000|204 218|tetrahydrobenzo
P08639561T0000|31 38|sequence
P08639561T0000|55 55|R
P08639561T0000|158 161|SRSR
P08639561T0000|258 262|1H NMR
P08639561T0000|184 184|R
P08639561T0000|59 59|S
P08639742T0000|55 61|petunia
P08639742T0000|43 52|similarity
P08639742T0000|17 25|cDNA clone
P08639742T0000|11 13|PCR
P08639742T0000|30 38|pea petals
P08639742T0000|65 87|wheat zinc finger proteins
P08639742T0000|0 8|Isolation
P08639837A0268|83 91|Ets family
P08639837A0268|38 44|factors
P08639837A0268|71 77|members
P08639837A0268|62 67|GATA-1
P08639837A0268|4 11|fragment
P08640866A0473|0 7|Exposure
P08640866A0473|140 147|activity
P08640866A0473|50 52|PHA
P08640866A0473|20 30|blood T cells
P08640866A0473|110 118|increases
P08640866A0473|128 130|MEK
P08640866A0473|40 47|subjects
P08640866A0473|121 124|MAPK
P08640866A0473|85 94|antibodies
P08641705A0986|14 25|observations
P08641705A0986|89 96|deletion
P08641705A0986|187 197|inheritance
P08641705A0986|135 160|beta-globin gene duplication
P08641705A0986|53 53|A
P08641705A0986|200 210|Hb Costa Rica
P08641705A0986|115 123|Hbs Lepore
P08641705A0986|34 47|heterozygosity
P08641705A0986|57 65|G mutation
P08641705A0986|68 76|codon beta
P08641705A0986|165 169|point
P08641705A0986|126 130|Kenya
P08642282A1009|72 81|expression
P08642282A1009|31 39|knowledge
P08642282A1009|53 60|elements
P08642282A1009|113 120|molecule
P08642282A1009|85 88|gene
P08642282A1009|14 24|description
P08642282A1009|98 99|B7
P08642285A1548|0 16|DNA-STAT complexes
P08642285A1548|53 61|cell lines
P08642285A1548|112 116|STAT5
P08642285A1548|104 108|STAT1
P08642285A1548|87 96|antibodies
P08642313A0770|119 125|fashion
P08642313A0770|157 163|protein
P08642313A0770|72 86|transactivation
P08642313A0770|98 115|reporter gene assays
P08642313A0770|32 39|cell line
P08642313A0770|165 169|Bcl-3
P08642313A0770|56 60|kappa
P08642313A0770|41 46|TAN-1C
P08642313T0000|0 4|T cell
P08642313T0000|152 157|T cells
P08642313T0000|129 149|factor-kappa B proteins
P08642313T0000|59 72|Notch homologue
P08642313T0000|88 95|activity
P08642313T0000|76 81|I kappa
P08642693T0000|0 20|Polyprotein processing
P08642693T0000|40 53|identification
P08642693T0000|23 38|Southampton virus
P08642693T0000|93 103|mutagenesis
P08642693T0000|63 83|protease cleavage sites
P08643111A0855|250 265|oligosaccharides
P08643111A0855|273 276|mLL2
P08643111A0855|128 130|LL2
P08643111A0855|210 220|counterpart
P08643111A0855|182 191|properties
P08643111A0855|12 14|LL2
P08643111A0855|16 19|hLL2
P08643111A0855|47 65|region glycosylation
P08643111A0855|34 38|chain
P08643111A0855|295 308|antigen binding
P08643111A0855|76 93|immunoreactivities
P08643111A0855|132 135|cLL2
P08643382A0752|57 60|poly
P08643382A0752|64 67|tail
P08643382A0752|78 86|cDNA clone
P08643382A0752|62 62|A
P08643382A0752|20 33|transit peptide
P08643382A0752|104 121|chloroplast protein
P08643382A0752|45 50|region
P08643513A0361|178 202|osteocalcin gene expression
P08643513A0361|171 175|level
P08643513A0361|147 148|nt
P08643513A0361|18 20|rOC
P08643513A0361|103 110|sequence
P08643513A0361|128 135|promoter
P08643513A0361|165 165|%
P08643513A0361|45 71|acetyltransferase constructs
P08643513A0361|0 15|Deletion analysis
P08643557A0259|14 21|question
P08643557A0259|54 57|sets
P08643557A0259|60 70|target genes
P08643557A0259|27 37|HOX proteins
P08643578A0000|0 8|RAS2val19
P08643578A0000|124 133|reporter FG
P08643578A0000|96 105|expression
P08643578A0000|141 144|lacZ
P08643578A0000|57 60|Ras2
P08643578A0000|191 194|lacZ
P08643578A0000|164 188|mating pathway reporter FUS1
P08643578A0000|28 31|form
P08643578A0000|87 92|growth
P08643578A0000|135 137|TyA
P08643578A0532|101 106|growth
P08643578A0532|79 87|regulator
P08643578A0532|113 115|TyA
P08643578A0532|12 32|Rho family protein Cdc42
P08643578A0532|57 64|G protein
P08643578A0532|110 111|FG
P08643578A0532|119 132|lacZ expression
P08643633A1187|31 37|complex
P08643633A1187|54 57|CBF1
P08643633A1187|4 20|immunoprecipitate
P08643633A1187|40 41|N1
P08643633A1187|43 49|deltaEC
P08643646A0479|70 81|biosynthesis
P08643646A0479|34 37|gene
P08643646A0479|4 9|region
P08643646A0479|196 205|conditions
P08643646A0479|111 121|transcripts
P08643646A0479|147 148|kb
P08643646A0479|18 21|verA
P08643646A0479|131 134|size
P08643682A0268|150 162|fusion protein
P08643682A0268|11 23|localizations
P08643682A0268|93 110|immunofluorescence
P08643682A0268|51 76|CBFbeta-SMMHC fusion protein
P08643682A0268|38 44|CBFbeta
P08643682A0268|113 123|NIH 3T3 cells
P08643759A0338|45 64|personality variables
P08643759A0338|73 77|group
P08643759A0338|15 19|phase
P08644734A0404|73 92|segment-polarity gene
P08644734A0404|11 19|isolation
P08644734A0404|27 31|cDNAs
P08645214A1052|15 18|BL21
P08645214A1052|118 125|proteins
P08645214A1052|143 150|SDS/PAGE
P08645214A1052|52 58|plasmid
P08645214A1052|110 115|amount
P08645214A1052|24 28|plysS
P08645214A1052|164 169|enzyme
P08645214A1052|72 94|catalase-peroxidase gene
P08645214A1052|20 22|DE3
P08645219A1377|0 2|Ca2
P08645219A1377|26 33|S100 beta
P08645219A1377|13 15|Zn2
P08645219A1377|90 100|binding site
P08645219A1377|138 140|Ca2
P08645219A1377|86 88|Zn2
P08645219A1377|142 155|binding domains
P08645219A1377|63 67|MRP14
P08645219A1377|17 23|binding
P08647086A0622|0 3|Cdk2
P08647086A0622|11 17|complex
P08647086A0622|36 41|system
P08647086A0622|22 29|cyclin D1
P08647086A0720|3 23|Cdk2-cyclin-D1 complex
P08647086A0720|105 109|E2F-1
P08647086A0720|52 61|substrates
P08647086A0720|157 164|contrast
P08647086A0720|214 221|proteins
P08647086A0720|69 77|H1 histone
P08647086A0720|133 140|proteins
P08647086A0720|79 81|pRB
P08647086A0720|182 194|Cdk2-cyclin-A
P08647086A0720|92 99|T antigen
P08647086A0720|113 123|preparation
P08647086A0720|101 103|p53
P08647086A0720|145 153|HeLa cells
P08647086A0720|166 178|Cdk2-cyclin-E
P08647086A0720|83 86|SV40
P08647086T0000|45 51|complex
P08647086T0000|56 63|cyclin D1
P08647086T0000|69 72|Cdk2
P08647086T0000|25 28|Cdk2
P08647086T0000|116 128|Cdk7-cyclin-H
P08647086T0000|87 94|cyclin D1
P08647086T0000|16 23|kinase-2
P08647091A0592|144 151|ADH genes
P08647091A0592|101 107|introns
P08647091A0592|76 81|region
P08647091A0592|63 67|exons
P08647091A0592|90 98|placement
P08647091A0592|40 48|Adh-2 gene
P08647091A0592|14 19|clones
P08647264T0000|162 169|cleavage
P08647264T0000|10 13|CD40
P08647264T0000|118 127|activation
P08647264T0000|52 67|calcium ionophore
P08647264T0000|34 47|lymphoma B cells
P08647264T0000|175 187|substrate PARP
P08647264T0000|97 105|apoptosis
P08647264T0000|133 158|cysteine protease CPP32/Yama
P08647264T0000|72 78|antigen
P08647264T0000|0 7|Ligation
P08647434A1124|126 135|conditions
P08647434A1124|64 66|TBP
P08647434A1124|38 47|antibodies
P08647434A1124|82 85|hTAF
P08647434A1124|78 80|TBP
P08647434A1124|94 97|hTAF
P08647434A1124|141 150|holo-TFIID
P08647434A1124|109 112|hTAF
P08647434A1124|5 12|T antigen
P08647451A0663|0 24|Northern blot hybridization
P08647451A0663|92 98|tissues
P08647451A0663|41 47|HEP-COP
P08647451A0663|67 71|range
P08647802A0000|17 32|signaling protein
P08647802A0000|76 86|arrangement
P08647802A0000|89 106|SH3-SH2-SH3 domains
P08647802A0000|109 112|Grb2
P08647822T0000|14 19|sterol
P08647822T0000|53 62|activation
P08647822T0000|91 98|coenzyme
P08647822T0000|30 50|element binding protein
P08647822T0000|7 10|role
P08647822T0000|100 112|reductase gene
P08647884A0547|29 37|reticulum
P08647884A0547|61 69|molecules
P08647884A0547|93 101|transport
P08647884A0547|52 59|MHC class
P08647884A0547|107 117|cell surface
P08648408A0792|13 21|CSA groups
P08648408A0792|7 9|PHT
P08648408A0792|79 83|group
P08648408A0792|100 104|group
P08648408A0792|93 98|CSA-GO
P08648408A0792|35 43|Hyp levels
P08648408A0792|72 77|PHT-GO
P08648665A0956|39 62|transformation efficiency
P08648665A0956|121 123|LE6
P08648665A0956|8 19|LE6 deletions
P08648665A0956|85 89|cells
P08648665A1320|0 12|ORF E8 colinear
P08648665A1320|123 135|pZipNeo vector
P08648665A1320|101 105|cells
P08648665A1320|55 61|protein
P08648665A1320|78 84|segment
P08648665A1320|17 21|ORF E6
P08648726A0713|0 6|Cloning
P08648726A0713|77 79|ZIC
P08648726A0713|46 53|promoter
P08648726A0713|19 27|ZI domains
P08648726A0713|104 112|ZIB domain
P08648726A0713|73 75|ZIA
P08648726A0713|117 119|TPA
P08648726A0713|84 93|ZID domains
P08649372A0501|58 63|factor
P08649372A0501|35 44|repression
P08649372A0501|79 86|activity
P08649372A0501|89 90|G2
P08649372A0501|94 99|M phase
P08649372A0501|0 15|Clb2/Cdc28 kinase
P08649372A0755|99 109|interaction
P08649372A0755|39 49|interaction
P08649372A0755|3 17|carboxy terminus
P08649372A0755|20 23|Mbp1
P08649372A0755|65 79|carboxy terminus
P08649372A0755|82 85|Swi6
P08649372A0755|54 57|Swi6
P08649372A0755|114 117|Mbp1
P08649373T0000|60 68|chromatin
P08649373T0000|79 87|c-myc gene
P08649373T0000|23 33|cis elements
P08649386A1032|73 85|consensus Abf1
P08649386A1032|50 57|analysis
P08649386A1032|93 96|site
P08649386A1032|4 24|UASH consensus sequence
P08649389A0000|158 166|% identity
P08649389A0000|139 145|protein
P08649389A0000|30 43|CTCF cDNA clones
P08649389A0000|187 204|amino acid sequences
P08649389A0000|97 106|factor CTCF
P08649389A0692|124 132|repressor
P08649389A0692|52 86|transient-cotransfection experiments
P08649389A0692|143 151|c-myc gene
P08649389A0692|34 48|CTCF binding site
P08649389A0692|10 17|analysis
P08649389A0692|102 105|CTCF
P08649393A0000|102 104|CEN
P08649393A0000|91 100|centromere
P08649393A0000|32 34|ctf
P08649393A0000|36 41|mutant
P08649393A0000|161 180|kinetochore integrity
P08649393A0000|1 30|chromosome transmission fidelity
P08649393A0000|121 140|readthrough phenotype
P08649393A0000|43 46|s138
P08649403A0963|3 14|growth defect
P08649403A0963|32 37|mutant
P08649403A0963|18 25|reg1 reg2
P08649403A0963|94 106|protein kinase
P08649403A0963|69 76|mutation
P08649405T0000|0 2|Sp1
P08649405T0000|61 65|cells
P08649405T0000|11 15|sites
P08649405T0000|96 108|transcription
P08649405T0000|21 33|CD11c promoter
P08649405T0000|83 85|AP1
P08649424A0000|0 9|Expression
P08649424A0000|102 116|glucocorticoids
P08649424A0000|63 69|rodents
P08649424A0000|134 138|liver
P08649424A0000|54 60|kidneys
P08649424A0000|126 128|AMP
P08649424A0000|83 87|birth
P08649424A0000|45 50|livers
P08649424A0000|15 42|phenylalanine hydroxylase gene
P08649425A0373|57 61|DNase
P08649425A0373|21 28|enhancer
P08649425A0373|14 15|bp
P08649425A0373|46 49|core
P08649425A0373|84 100|B-cell development
P08649425T0000|74 81|enhancer
P08649425T0000|25 42|chromatin structure
P08649425T0000|48 71|mouse immunoglobulin kappa
P08649427A0689|99 114|GTPase regulators
P08649427A0689|91 96|family
P08649427A0689|51 56|member
P08649427A0689|87 89|GAP
P08649427A0689|32 35|cDNA
P08649427A0689|79 85|protein
P08649427A0689|15 28|identification
P08649428A1227|120 123|Cdc2
P08649428A1227|65 84|c-mos oncogene product
P08649428A1227|51 59|synthesis
P08649428A1227|6 10|study
P08649428A1227|36 45|regulation
P08649428A1227|108 117|activation
P08649440T0000|30 33|VIII
P08649440T0000|24 27|IgG2
P08649440T0000|3 15|heterogeneity
P08649773A1374|116 127|cell lymphoma
P08649773A1374|90 101|B lymphocytes
P08649773A1374|12 16|BCL-6
P08649773A1374|3 9|ability
P08649773A1374|45 53|repressor
P08649773A1374|72 78|ability
P08649841A0956|102 116|CAT reporter gene
P08649841A0956|183 189|CAT mRNA
P08649841A0956|82 89|promoter
P08649841A0956|47 60|Kozak sequences
P08649841A0956|173 180|decrease
P08649841A0956|94 97|SV40
P08649841A0956|145 164|CAT protein production
P08649841A0956|133 142|inhibition
P08649841A0956|15 18|uORF
P08650818A0000|76 79|MRSA
P08650818A0000|10 15|spread
P08650818A0000|141 149|isolation
P08650818A0000|91 98|patients
P08650818A0000|198 204|arrival
P08650818A0000|69 74|strain
P08650818A0000|128 131|ward
P08650818A0000|223 239|Mediterranean area
P08650818A0000|210 217|hospital
P08650818A0000|134 138|spite
P08651853A0607|188 195|patients
P08651853A0607|112 119|patients
P08651853A0607|154 161|patients
P08651853A0607|139 150|dentate gyrus
P08651853A0607|93 108|CA1/prosubiculum
P08651853A0607|55 58|loss
P08651853A0607|199 199|%
P08651853A0607|72 78|gliosis
P08651853A0607|124 124|%
P08651853A0607|176 184|CA4 region
P08651853A0607|165 165|%
P08651853A0607|14 22|sclerosis
P08651853T0000|14 22|sclerosis
P08652081A1953|119 126|skin rash
P08652081A1953|182 185|IL-4
P08652081A1953|65 74|toxicities
P08652081A1953|131 134|IL-3
P08652081A1953|109 116|headache
P08652081A1953|83 93|hypotension
P08652081A1953|144 153|congestion
P08652081A1953|171 177|lesions
P08652081A1953|98 101|IL-1
P08652081A1953|19 24|events
P08654200A0274|176 180|mg/kg
P08654200A0274|210 214|mg/kg
P08654200A0274|126 140|model substrates
P08654200A0274|142 150|lorazepam
P08654200A0274|156 160|mg/kg
P08654200A0274|52 62|liver volume
P08654200A0274|18 33|resonance imaging
P08654200A0274|163 172|antipyrine
P08654200A0274|110 118|clearance
P08654200A0274|203 205|ICG
P08654200A0274|186 196|indocyanine
P08654200A0274|87 94|patients
P08654375A0544|152 156|Oct-2
P08654375A0544|124 142|DNA binding POU domain
P08654375A0544|11 18|analysis
P08654375A0544|31 36|region
P08654375A0544|76 85|N-terminus
P08654375A0544|88 91|Bob1
P08654375A0544|55 64|amino acids
P08654375A0544|44 53|amino acids
P08654375A0544|145 149|Oct-1
P08654390A0000|70 79|biliverdin
P08654390A0000|35 48|heme catabolism
P08654390A0000|60 63|heme
P08654390A0000|89 102|carbon monoxide
P08654390A0000|27 32|enzyme
P08654390A0000|81 84|iron
P08654390A0000|0 12|Heme oxygenase
P08654435A0540|29 32|WM12
P08654435A0540|105 112|activity
P08654435A0540|10 15|analog
P08654435A0540|94 99|effect
P08654435A0540|79 88|wortmannin
P08654435A0540|148 153|assays
P08654435A0540|61 74|Erk2 activation
P08654435A0540|18 27|wortmannin
P08654435A0540|115 118|Erk2
P08654946A0475|14 22|% identity
P08654946A0475|39 44|region
P08654946A0475|6 11|shares
P08654946A0475|47 63|Xenopus laevis FGF3
P08654946A0475|122 125|gene
P08654946A0475|3 4|aa
P08654946A0475|69 77|% identity
P08654946A0475|85 91|product
P08654946A0986|99 104|region
P08654946A0986|61 75|mouse promoter P3
P08654946A0986|107 114|sequence
P08654946A0986|39 46|promoter
P08654946A0986|3 25|transcription start point
P08654972A0000|0 6|Defects
P08654972A0000|40 43|cell
P08654972A0000|76 95|cell cycle progression
P08654972A0000|37 38|Sp
P08654972A0000|61 65|genes
P08654983A0000|45 55|SRP receptor
P08654983A0000|69 84|Bacillus subtilis
P08654983A0000|57 59|Srb
P08654983A0000|172 176|Oguro
P08654983A0000|124 132|homologue
P08654983A0000|40 42|SRP
P08654983A0000|183 188|DNA Res
P08654983A0000|147 170|SRP receptor alpha-subunit
P08654983A0000|86 87|Bs
P08654983A0000|101 109|Bs srb gene
P08654983A0000|61 66|system
P08654983A0000|14 38|signal recognition particle
P08655497A0000|41 43|min
P08655497A0000|20 22|cmr
P08655497A0000|64 73|K-12 genome
P08655497A0000|151 156|vector
P08655497A0000|6 9|gene
P08655497A0000|104 118|chloramphenicol
P08655497A0000|92 101|resistance
P08655555A0772|13 21|deletions
P08655555A0772|53 75|transcription start point
P08655555A0772|135 141|hexamer
P08655555A0772|38 39|bp
P08655555A0772|160 175|promoter activity
P08655555A0772|97 113|% promoter activity
P08655555A0772|2 9|addition
P08655555A1368|3 13|DNA sequence
P08655555A1368|62 69|TGn motif
P08655555A1368|43 49|hexamer
P08655555A1368|113 121|promoters
P08655555A1368|94 99|region
P08656672A0678|127 153|cervix carcinoma cell line HeLa
P08656672A0678|60 76|leukemia cell lines
P08656672A0678|113 121|subclones
P08656672A0678|10 30|ufo mRNA overexpression
P08657135A1444|115 124|muscle gene
P08657135A1444|62 71|myogenesis
P08657135A1444|135 142|elements
P08657135A1444|51 59|regulator
P08657135A1444|30 33|CKII
P08657135A1444|19 25|studies
P08657135A1444|84 101|E protein homodimers
P08657150A1049|17 26|regulators
P08657150A1049|33 36|NCE3
P08657150A1049|124 133|activators
P08657150A1049|93 111|promoter specificity
P08657150A1049|68 75|SIN5 gene
P08657150A1049|3 6|role
P08657157A0000|146 156|recognition
P08657157A0000|37 45|POU domain
P08657157A0000|166 188|octamer sequence elements
P08657157A0000|117 125|POU domain
P08657157A0000|57 61|motif
P08657157A0000|94 102|complexes
P08657157A0000|15 24|regulators
P08657183A0145|57 61|genes
P08657183A0145|79 82|gene
P08657183A0145|22 27|repair
P08657183A0145|63 66|DHFR
P08657183A0145|93 96|DHFR
P08657183A0145|7 12|strand
P08657183A0145|30 41|DNA fragments
P08657918A0360|0 8|MATERIALS
P08657918A0360|188 197|dissection
P08657918A0360|12 18|METHODS
P08657918A0360|98 105|patients
P08657918A0360|175 177|SLL
P08657918A0360|91 93|SLL
P08657918A0360|134 136|SLL
P08657918A0360|72 85|dorsal portions
P08657918A0360|20 38|Coronal 3D GRE imaging
P08657918A0360|155 160|wrists
P08659545A0000|142 150|fragments
P08659545A0000|47 56|chromosome
P08659545A0000|165 169|genes
P08659545A0000|100 106|trisomy
P08659545A0000|65 77|understanding
P08659545A0000|4 9|effort
P08659545A0000|120 131|exon trapping
P08659545A0000|153 162|chromosome
P08659545A0000|83 97|pathophysiology
P08659545A0000|27 39|transcript map
P08660733X0000|28 32|aphid
P08660733X0000|11 21|populations
P08660733X0000|52 61|Puerto Rico
P08660733X0000|64 68|April
P08660748X0000|41 48|dynamics
P08660748X0000|68 78|predictions
P08660748X0000|19 25|essence
P08660748X0000|81 98|population patterns
P08660748X0000|3 7|model
P08660866A0504|203 207|cells
P08660866A0504|178 182|shaft
P08660866A0504|43 55|loss phenotype
P08660866A0504|187 194|tormogen
P08660866A0504|97 100|SOPs
P08660866A0504|151 155|cells
P08660866A0504|75 81|progeny
P08660866A0504|125 131|neurons
P08660866A0504|168 176|trichogen
P08660866A0504|135 142|thecogen
P08660866A0504|11 19|positions
P08660866A0504|33 35|Brd
P08660866A0504|196 201|socket
P08660866A0504|144 149|sheath
P08660892A1044|130 136|factors
P08660892A1044|36 51|co-transfections
P08660892A1044|105 114|expression
P08660892A1044|64 82|SRF expression vector
P08660892A1044|144 147|MyoD
P08660892A1044|151 156|Mef-2C
P08660892A1044|15 22|blockade
P08660998A0851|146 151|mMIWC1
P08660998A0851|165 178|initiation site
P08660998A0851|129 130|bp
P08660998A0851|52 55|GATA
P08660998A0851|47 50|CAAT
P08660998A0851|3 16|mMIWC1 promoter
P08660998A0851|96 123|mMIWC transcription initiation
P08660998A0851|73 87|primer extension
P08660998A0851|60 71|AP-2 elements
P08660998A0851|42 45|TATA
P08661007T0000|57 65|structure
P08661007T0000|22 27|member
P08661007T0000|75 100|protein domain relationships
P08661007T0000|5 14|MN/CA9 gene
P08661007T0000|69 72|exon
P08661007T0000|41 55|anhydrase family
P08661100A0285|129 137|structure
P08661100A0285|80 86|regions
P08661100A0285|107 113|domains
P08661100A0285|148 152|parts
P08661100A0285|28 32|Cdebp
P08661100A0285|68 74|App gene
P08661100A0285|14 25|distribution
P08661101A0396|0 18|DNA sequence analysis
P08661101A0396|33 36|gene
P08661101A0396|70 76|rat CRP1
P08661101A0396|45 51|protein
P08661104A0687|42 45|mRNA
P08661104A0687|113 117|colon
P08661104A0687|104 108|liver
P08661104A0687|90 97|prostate
P08661104A0687|68 80|cells/tissues
P08661104A0687|3 6|gene
P08661104A0687|99 102|lung
P08661114A0564|55 57|SIM
P08661114A0564|74 81|proteins
P08661114A0564|11 17|domains
P08661114A0564|30 45|sequence homology
P08661116A0963|0 15|Promoter activity
P08661116A0963|89 108|Northern blot analyses
P08661116A0963|51 56|levels
P08661116A0963|25 33|cell lines
P08661116A0963|169 170|bp
P08661116A0963|69 74|D3 mRNA
P08661116A0963|143 150|promoter
P08661119A0085|80 87|EP4R cDNA
P08661119A0085|113 128|blood lymphocytes
P08661119A0085|61 69|structure
P08661119A0085|22 44|EP4 receptor gene sequence
P08661613A0691|73 80|response
P08661613A0691|4 8|users
P08661613A0691|139 159|enforcement activities
P08661613A0691|114 118|group
P08661613A0691|32 49|management measures
P08661613A0691|56 60|users
P08661613A0691|83 91|education
P08662193A0404|123 126|NIT4
P08662193A0404|13 32|activation subdomains
P08662193A0404|77 81|yeast
P08662193A0404|55 60|region
P08662193A0404|115 120|region
P08662499A0484|3 7|front
P08662499A0484|11 21|interaction
P08662499A0484|9 9|F
P08662499A0484|50 52|RNA
P08662499A0484|45 47|end
P08662617A2051|146 154|cell lines
P08662617A2051|69 75|protein
P08662617A2051|90 96|surface
P08662617A2051|18 21|data
P08662617A2051|110 125|uterine epithelia
P08662617A2051|34 36|HIP
P08662789A0673|57 73|sequence alignment
P08662789A0673|83 88|RPS30A
P08662789A0673|38 54|GenBankTM data base
P08662789A0673|16 19|gene
P08662852A1297|28 51|GRK5 phosphoacceptor sites
P08662852A1297|21 24|GRK2
P08662852A1297|143 151|rhodopsin
P08662852A1297|126 140|phosphorylation
P08662852A1297|3 10|location
P08662852A1297|64 79|carboxyl terminus
P08662852A1297|85 91|beta2AR
P08662928A1153|4 13|regulation
P08662928A1153|53 62|expression
P08662928A1153|65 76|STAT proteins
P08662928T0000|0 8|Receptors
P08662928T0000|24 25|IL
P08662928T0000|91 103|transcription
P08662928T0000|12 22|interleukin
P08662928T0000|42 50|cytokines
P08662928T0000|111 130|IL-6 response elements
P08662928T0000|61 79|signaling mechanisms
P08662936A0428|132 134|TEA
P08662936A0428|90 102|chicken TEF-1A
P08662936A0428|152 157|factor
P08662936A0428|23 44|FR-19 amino acid sequence
P08662936A0428|104 113|mouse TEF-1
P08662936A0428|72 72|%
P08662936A0428|80 87|identity
P08662936A0428|118 122|mouse
P08662980A0762|188 193|effect
P08662980A0762|4 13|phenomenon
P08662980A0762|152 159|receptor
P08662980A0762|27 36|DNA binding
P08662980A0762|55 62|receptor
P08662980A0762|132 135|form
P08663000A0000|14 23|hyaluronan
P08663000A0000|41 45|RHAMM
P08663000A0000|32 39|motility
P08663000A0000|81 93|fibrosarcomas
P08663000A0000|115 132|growth factor-beta1
P08663000A0000|3 10|receptor
P08663000A0000|47 60|gene expression
P08663000A0000|134 142|TGF-beta1
P08663120T0000|55 61|protein
P08663120T0000|23 33|p70 S6 kinase
P08663120T0000|80 86|pathway
P08663120T0000|9 13|Raf-1
P08663127A0697|134 151|glycosylation sites
P08663127A0697|182 188|regions
P08663127A0697|53 56|NKCC
P08663127A0697|109 112|loop
P08663127A0697|82 88|domains
P08663127A0697|10 17|analysis
P08663127A0697|167 167|N
P08663127A0697|20 23|KCC1
P08663127A0697|43 50|homology
P08663141T0000|120 138|angiotensinogen gene
P08663141T0000|104 112|sequences
P08663141T0000|11 20|DNA element
P08663141T0000|45 71|transcription initiation site
P08663141T0000|35 41|TATA box
P08663141T0000|84 91|response
P08663172A0311|27 39|amino terminus
P08663172A0311|60 66|protein
P08663172A0311|4 10|protein
P08663219A0246|100 118|hormone inducibility
P08663219A0246|161 171|E-box region
P08663219A0246|128 142|CAT reporter gene
P08663219A0246|122 126|PGS-2
P08663219A0246|78 84|CAAT box
P08663219A0246|37 40|CAAT
P08663219A0246|3 10|promoter
P08663219A0246|16 27|rat PGS-2 gene
P08663219A0246|57 76|protein consensus site
P08663310A0157|67 79|response genes
P08663310A0157|159 168|cell growth
P08663310A0157|101 105|genes
P08663310A0157|8 10|SRF
P08663310A0157|31 39|regulator
P08663310A0157|172 186|differentiation
P08663310A0157|42 48|members
P08663310A0157|107 110|IEGs
P08663310A0157|52 56|class
P08663326A0000|88 94|enzymes
P08663326A0000|111 116|methyl
P08663326A0000|25 37|DmpR activator
P08663326A0000|65 73|dmp operon
P08663326A0000|98 107|catabolism
P08663326A0000|47 59|transcription
P08663326A0000|118 124|phenols
P08663392A0215|84 93|expression
P08663392A0215|6 10|study
P08663392A0215|32 39|DSG3 gene
P08663392A0215|69 78|regulation
P08664229T0000|42 54|autorefractor
P08664229T0000|8 17|evaluation
P08664229T0000|23 38|Allergan Humphrey
P08664229T0000|61 85|Nidek AR-1000 autorefractor
P08664347A0923|13 41|proprotein processing proteases
P08664347A0923|127 136|maturation
P08664347A0923|143 148|enzyme
P08664347A0923|74 80|pro-LPH
P08664347A0923|0 3|None
P08664462A1404|187 197|hypothermia
P08664462A1404|20 25|result
P08664462A1404|166 180|plasma clearance
P08664462A1404|37 40|hand
P08664462A1404|5 11|changes
P08664462A1404|150 155|result
P08664462A1404|109 127|muscle contractility
P08664462A1404|82 93|transmission
P08664462A1404|53 63|sensitivity
P08664462A1404|142 145|hand
P08664667A0093|20 24|India
P08664667A0093|9 13|Delhi
P08665853A0228|30 34|cells
P08665853A0228|65 76|ErbB proteins
P08665853A0228|209 216|activity
P08665853A0228|108 113|ErbB-3
P08665853A0228|137 144|activity
P08665853A0228|84 95|combinations
P08665853A0228|152 157|ErbB-1
P08665853A0228|161 166|ErbB-2
P08666102A0820|0 3|ZIOS
P08666102A0820|61 63|Ptc
P08666102A0820|50 56|methods
P08666102A0820|100 103|FEV1
P08666238T0000|32 39|ribosome
P08666238T0000|9 29|translation initiation
P08666238T0000|83 87|cells
P08666241A0930|71 87|Dex responsiveness
P08666241A0930|34 39|region
P08666241A0930|45 56|24p3 promoter
P08666383A1252|116 125|definition
P08666383A1252|64 76|hybridization
P08666383A1252|153 158|genome
P08666383A1252|140 142|map
P08666383A1252|103 110|approach
P08666383A1252|46 57|fluorescence
P08666383A1252|5 12|findings
P08666383A1252|30 40|cDNA mapping
P08666398T0000|57 69|16p12.1-p11.2
P08666398T0000|6 18|cosmid contigs
P08666398T0000|49 54|region
P08666398T0000|30 42|Batten disease
P08666398T0000|44 47|CLN3
P08666398T0000|0 2|YAC
P08666404A0311|0 8|Isolation
P08666404A0311|155 159|PPP5C
P08666404A0311|161 163|PP5
P08666404A0311|110 131|tetratricopeptide motif
P08666404A0311|46 61|brain cDNA library
P08666404A0311|71 104|protein serine-threonine phosphatase
P08666404A0311|186 191|rat PPT
P08666404A0311|27 30|cDNA
P08666913A0000|70 79|chromosome
P08666913A0000|51 61|gene cluster
P08666913A0000|20 40|transmembrane proteins
P08666913A0000|8 17|family type
P08666913A0000|0 4|Ly-49
P08668124A0744|3 11|Dox-A2 ORF
P08668124A0744|50 58|phenotype
P08668124A0744|23 34|TDH3 promoter
P08668124A0744|62 67|strain
P08668124A0744|78 81|sun2
P08668142A1048|27 31|cells
P08668142A1048|90 99|Sec7p pools
P08668142A1048|45 51|balance
P08668142A1048|17 21|hARF4
P08668142A1048|3 14|introduction
P08668158A0765|30 34|Rpm1r
P08668158A0765|211 214|gene
P08668158A0765|77 83|tRNAPro
P08668158A0765|145 151|portion
P08668158A0765|177 184|promoter
P08668158A0765|203 206|tRNA
P08668158A0765|218 221|RPM1
P08668158A0765|66 69|tRNA
P08668158A0765|90 97|promoter
P08668158A0765|126 129|gene
P08668158A0765|118 121|tRNA
P08668158A0765|55 64|substrates
P08668158A0765|3 6|data
P08668158A1252|118 134|biogenesis defects
P08668158A1252|12 18|strains
P08668158A1252|52 65|precursor Rpm1r
P08668158A1252|98 101|gene
P08668158A1252|81 89|mutations
P08668158A1252|29 37|RPM1 genes
P08668190A1364|145 152|membrane
P08668190A1364|8 23|membrane vesicles
P08668190A1364|114 116|Ca2
P08668190A1364|53 68|antiport activity
P08668190A1364|104 111|exchange
P08668190A1364|121 121|H
P08668190A1364|46 48|Ca2
P08668190A1364|51 51|H
P08668190A1364|28 38|hum1 mutants
P08668190A1364|132 136|yeast
P08668190A1364|87 91|Hum1p
P08668201A1059|173 180|interval
P08668201A1059|24 30|element
P08668201A1059|108 118|MATalpha1 IE
P08668201A1059|144 148|codon
P08668201A1059|95 102|activity
P08668201A1059|8 18|mutagenesis
P08668201A1059|51 66|sequence boundary
P08668201A1059|154 160|element
P08668203A1230|0 2|FTF
P08668203A1230|52 75|differentiation functions
P08668203A1230|128 134|tissues
P08668203A1230|109 112|SF-1
P08668203A1230|33 40|pancreas
P08668203A1230|88 98|sublineages
P08668209A0406|0 5|Merlie
P08668209A0406|7 26|Cold Spring Harbor Symp
P08668210A0000|88 107|protein kinase pathway
P08668210A0000|11 18|evidence
P08668210A0000|131 144|transformation
P08668210A0000|36 39|role
P08668210A0000|61 65|Raf-1
P08668210A0000|46 55|activation
P08669274T0000|47 54|approach
P08669274T0000|28 33|choice
P08669274T0000|10 26|chain ossification
P08669676A1644|57 57|n
P08669676A1644|48 55|propofol
P08669676A1644|75 75|P
P08669676A1644|96 103|propofol
P08669676A1644|105 105|n
P08669676A1644|120 120|n
P08669676A1644|71 71|n
P08669676A1644|40 46|Q wave MI
P08669676A1644|88 94|Q wave MI
P08669676A1644|21 25|death
P08669676A1644|33 37|group
P08669676A1644|125 125|P
P08669676A1644|151 165|treatment groups
P08669676A1644|110 118|midazolam
P08669676A1644|61 69|midazolam
P08669676A1644|3 11|incidence
P08670556A0425|15 15|p
P08670556A0425|93 102|0-infinity
P08670556A0425|37 65|plasma concentration-time curve
P08670556A0425|80 90|infinity AUC
P08670556A0425|25 28|area
P08670556A0425|4 13|micromol/1
P08670853A0000|0 15|Cluster formation
P08670853A0000|87 94|adhesion
P08670853A0000|33 43|cell surface
P08670853A0000|65 74|importance
P08670853A0000|18 27|E-cadherin
P08670910A0156|0 13|DNA polymerase E
P08670910A0156|52 72|endonuclease co-purify
P08670910A0156|84 101|polypeptide complex
P08670910A0156|31 33|DNA
P08670910A0156|15 23|DNA ligase
P08672242A0517|7 28|reporter gene constructs
P08672242A0517|51 59|sequences
P08672242A0517|89 95|regions
P08672242A0517|111 120|expression
P08672242A0517|65 74|P1 promoter
P08673026T0000|33 38|traits
P08673026T0000|46 61|replication study
P08673026T0000|21 31|schizotypal
P08673026T0000|3 17|factor structure
P08675026A0420|80 87|function
P08675026A0420|92 112|Caenorhabditis elegans
P08675026A0420|54 65|sequence tags
P08675026A0420|114 124|Oryza sativa
P08675026A0420|128 131|Homo
P08675026A0420|67 69|EST
P08675395A0751|0 6|RESULTS
P08675395A0751|19 23|model
P08675395A0751|52 54|fit
P08675395A0751|60 76|acuity outcome data
P08675608T0000|0 6|Outcome
P08675608T0000|25 38|hypothyroidism
P08675763A0788|14 29|milk protein yield
P08675763A0788|49 51|Lys
P08675763A0788|60 67|increase
P08675763A0788|74 87|protein content
P08675763A0788|35 37|g/d
P08675763A0788|100 103|milk
P08675763A0788|94 97|g/kg
P08675763A0788|42 44|Met
P08675763A0788|0 11|Mean increase
P08675769A0158|215 225|performance
P08675769A0158|194 202|fertility
P08675769A0158|206 209|bull
P08675769A0158|78 87|efficiency
P08675769A0158|95 108|conception rate
P08675769A0158|112 122|calving rate
P08675769A0158|9 13|rates
P08675769A0158|171 174|rate
P08675769A0158|55 62|measures
P08675769A0158|230 241|AI technician
P08675821A0657|45 48|area
P08675821A0657|25 34|glans penis
P08675821A0657|10 13|EMPD
P08675821A0657|51 56|search
P08675821A0657|68 77|malignancy
P08676266A0838|59 68|test groups
P08676266A0838|78 89|control group
P08676266A0838|3 12|mean values
P08676266A0838|92 99|baseline
P08676266A0838|15 30|protease activity
P08676383A0518|28 44|disulfide linkages
P08676383A0518|52 62|cis peptides
P08676383A0518|4 15|half molecule
P08676454A0731|39 43|ICP35
P08676454A0731|60 67|B capsids
P08676454A0731|107 113|virions
P08676454A0731|33 37|ICP35
P08676454A0731|22 23|N0
P08676454A0731|18 20|Pra
P08676454A0731|89 98|precursors
P08676454A0731|27 28|Nb
P08676456A0879|72 89|AP-1 responsiveness
P08676456A0879|39 54|leucine mutations
P08676456A0879|92 101|comparison
P08676456A0879|115 134|VP16 activation domain
P08676456A0879|9 25|VP16-Tat construct
P08676495A0129|173 177|warts
P08676495A0129|113 121|C127 cells
P08676495A0129|44 45|nt
P08676495A0129|64 73|processing
P08676495A0129|33 42|nucleotide
P08676495A0129|146 150|times
P08676495A0129|80 93|BPV-1 pre-mRNAs
P08676495A0129|13 22|splice site
P08676858A0309|187 192|RNases
P08676858A0309|36 47|S-RNase genes
P08676858A0309|111 123|Pyrus serotina
P08676858A0309|106 109|pear
P08676858A0309|8 14|cloning
P08676858A0309|18 33|characterization
P08676858A0309|79 93|Malus x domestica
P08676858A0309|64 71|Rosaceae
P08676858A0309|73 77|apple
P08676858A0309|55 61|species
P08676858A0309|144 152|sequences
P08676858A1084|54 59|plants
P08676858A1084|19 25|members
P08676858A1084|13 16|tree
P08676858A1084|31 51|T2/S-RNase superfamily
P08677443A0238|231 231|%
P08677443A0238|228 228|%
P08677443A0238|155 160|months
P08677443A0238|239 239|%
P08677443A0238|190 195|months
P08677443A0238|212 224|survival rates
P08677443A0238|136 146|progression
P08677443A0238|77 79|VIP
P08677443A0238|130 133|time
P08677443A0238|236 236|%
P08677443A0238|116 121|regard
P08677443A0238|64 75|SCLC patients
P08677443A0238|33 37|study
P08677443A0238|169 181|survival times
P08677443A0238|3 22|Hoosier Oncology Group
P08677678A0258|117 133|avoidance behavior
P08677678A0258|96 104|retention
P08677678A0258|107 113|feeding
P08677678A0258|176 184|phenomena
P08677678A0258|30 55|immunomodulator neurotropin
P08677678A0258|80 92|consolidation
P08677678A0258|14 27|administration
P08677678A0258|57 59|NSP
P08677678A0258|160 169|mechanisms
P08678959A0640|0 20|Sestamibi scintigraphy
P08678959A0640|35 42|patients
P08678959A0640|64 78|ultrasonography
P08678959A0640|82 82|%
P08679131T0000|6 12|allergy
P08679131T0000|21 38|hypersensitivities
P08680702A0548|202 202|p
P08680702A0548|182 184|Day
P08680702A0548|350 350|p
P08680702A0548|284 291|Vo2INDIR
P08680702A0548|209 211|Day
P08680702A0548|330 332|Day
P08680702A0548|126 136|differences
P08680702A0548|103 109|animals
P08680702A0548|293 301|ml/kg/min
P08680702A0548|303 305|Day
P08680702A0548|74 77|Days
P08680702A0548|44 54|dysfunction
P08680702A0548|18 26|lethality
P08680702A0548|152 155|cart
P08680702A0548|67 71|group
P08680702A0548|265 272|catheter
P08680702A0548|165 170|Vo2DIR
P08680702A0548|172 180|ml/kg/min
P08680702A0548|323 323|p
P08680702A0548|229 229|p
P08680706A0889|126 129|mm Hg
P08680706A0889|177 182|values
P08680706A0889|21 33|PO2/FlO2 ratio
P08680706A0889|9 19|reperfusion
P08680706A0889|185 200|Donor Aerosol dogs
P08680706A0889|99 116|Recipient Instilled
P08680706A0889|155 158|mm Hg
P08680706A0889|134 146|Control groups
P08680706A0889|6 6|h
P08680706A0889|85 88|mm Hg
P08680706A0889|69 75|Therapy
P08680706A0889|210 213|mm Hg
P08682155A0902|114 124|differences
P08682155A0902|64 74|non-smokers
P08682155A0902|3 25|euglobulin clot lysis time
P08682155A0902|48 54|smokers
P08682155A0902|97 106|situations
P08682317A0900|102 106|cells
P08682317A0900|43 65|HS transcription factor-1
P08682317A0900|67 71|HSF-1
P08682317A0900|25 27|HSE
P08682317A0900|116 117|HS
P08682317A0900|82 89|extracts
P08682317A0900|0 13|HS inducibility
P08682868A0738|72 77|domain
P08682868A0738|11 24|DSK2-1 mutation
P08682868A0738|102 106|Dsk2p
P08682868A0738|89 99|differences
P08682868A0738|109 123|Cdc31p stability
P08682868A0738|53 57|Dsk2p
P08682868A0738|41 47|residue
P08683106A0374|120 129|STAT1 alpha
P08683106A0374|78 82|STAT5
P08683106A0374|46 50|STAT5
P08683106A0374|8 11|IL-2
P08683106A0374|52 55|IL-2
P08683106A0374|15 23|IFN-alpha
P08683106A0374|33 42|STAT1 alpha
P08683106A0374|89 97|IFN-alpha
P08683108A0965|61 87|transcription factor proteins
P08683108A0965|96 99|junB
P08683108A0965|108 111|site
P08683108A0965|18 31|interpretation
P08683108A0965|149 152|site
P08683108A0965|44 47|CREB
P08683108A1501|18 24|results
P08683108A1501|36 45|components
P08683108A1501|95 97|mIg
P08683108A1501|106 122|junB transcription
P08683108A1501|51 80|protein kinase A signaling pathway
P08683983A0785|3 9|complex
P08683983A0785|23 30|D protein
P08683983A0785|92 104|leukemia cells
P08683983A1163|86 90|mouse
P08683983A1163|35 40|intron
P08683983A1163|140 149|mechanisms
P08683983A1163|208 224|cell growth control
P08683983A1163|182 196|differentiation
P08683983A1163|152 161|activation
P08683983A1163|20 32|participation
P08683983A1163|74 82|c-myb gene
P08683983A1163|3 9|results
P08683983A1163|59 68|regulation
P08684522A0415|90 97|collagen
P08684522A0415|101 107|laminin
P08684522A0415|74 81|matrices
P08684522A0415|84 87|type
P08684522A0415|121 124|wall
P08684522A0415|45 54|deposition
P08684522A0415|0 27|Immunofluorescence microscopy
P08684742A0000|0 8|OBJECTIVE
P08684742A0000|107 119|amniocentesis
P08684742A0000|19 40|pregnancy complications
P08684742A0000|81 85|weeks
P08684742A0000|127 131|weeks
P08684742A0000|61 73|amniocentesis
P08684742A0000|43 47|women
P08684742A0000|133 141|gestation
P08686381A0527|179 184|region
P08686381A0527|212 222|protein Swi3
P08686381A0527|10 20|9765orfR002
P08686381A0527|162 168|protein
P08686381A0527|22 32|9765orfR011
P08686381A0527|174 176|BCR
P08686381A0527|36 46|9765orfR013
P08686381A0527|99 125|polyadenylate binding protein
P08686381A0527|5 8|ORFs
P08686381A0527|189 201|transcription
P08688190A0000|139 143|parts
P08688190A0000|6 22|flavone glucosides
P08688190A0000|24 53|nevadensin 5-O-beta-D-glucoside
P08688190A0000|57 85|nevadensin 5-O-beta-D-glucosyl
P08688190A0000|146 166|Lysionotus pauciflorus
P08688190A0000|93 108|beta-D-glucoside
P08688556A0242|132 136|yeast
P08688556A0242|12 21|laboratory
P08688556A0242|65 75|suppressors
P08688556A0242|151 159|viability
P08688556A0242|142 147|scd1-i
P08688556A0242|104 111|clathrin
P08688556A0242|32 37|screen
P08688556A0242|95 101|strains
P08688556A0242|138 140|Chc
P08689520T0000|0 17|Reproductive period
P08689520T0000|25 35|water intake
P08689520T0000|61 65|goats
P08690118A0845|102 111|predictors
P08690118A0845|77 80|IVOS
P08690118A0845|63 72|morphology
P08690118A0845|11 28|regression analysis
P08690118A0845|34 45|manual method
P08690118A0845|114 126|fertilization
P08690118A0845|47 56|percentage
P08690198A0346|0 6|METHODS
P08690198A0346|96 119|Lactobacillus reuteri R2LC
P08690198A0346|8 11|Rats
P08690198A0346|168 179|fermentation
P08690198A0346|42 49|infusion
P08690198A0346|202 206|study
P08690198A0346|124 148|Lactobacillus plantarum DSM
P08690198A0346|71 85|supplementation
P08690198A0346|88 94|oatbase
P08690198A0346|188 196|beginning
P08690198A0346|61 64|diet
P08691106A0733|87 90|cell
P08691106A0733|52 61|lactotroph
P08691106A0733|30 47|nuclease protection
P08691106A0733|8 16|D8 binding
P08691106A0733|98 104|protein
P08691962T0000|43 49|disease
P08691962T0000|23 31|diagnosis
P08691962T0000|64 68|blood
P08691962T0000|80 84|cells
P08691962T0000|34 40|Whipple
P08691962T0000|7 10|role
P08692885A0663|3 9|ability
P08692885A0663|22 40|NF-kappaB activation
P08692885A0663|12 14|A20
P08692885A0663|65 80|zinc finger domain
P08692892A0330|17 21|P258L
P08692892A0330|13 15|Leu
P08692892A0330|92 92|%
P08692892A0330|148 159|alpha-factor
P08692892A0330|23 30|mutation
P08692892A0330|129 133|cells
P08692892A0330|3 9|Pro-258
P08692892A0330|98 109|maximum level
P08692892A0330|49 65|receptor signaling
P08692924A0328|84 88|BCL-6
P08692924A0328|33 39|ability
P08692924A0328|8 18|DNA sequence
P08692924A0328|111 119|complexes
P08692924A0328|129 136|extracts
P08692924A0328|148 158|B-cell lines
P08692924A0328|57 61|BCL-6
P08697728A1199|29 32|flag
P08697728A1199|13 17|value
P08697728A1199|40 40|%
P08698756A1240|15 22|findings
P08698756A1240|105 114|procedures
P08698756A1240|168 173|degree
P08698756A1240|80 83|role
P08698756A1240|51 61|coenzyme Q10
P08698756A1240|139 143|cross
P08698756A1240|188 193|damage
P08698756A1240|34 46|pre-treatment
P08698756A1240|0 10|CONCLUSIONS
P08700531A1420|146 157|localization
P08700531A1420|163 170|cph locus
P08700531A1420|211 221|cph oncogene
P08700531A1420|50 60|alterations
P08700531A1420|228 231|role
P08700531A1420|79 90|hamster cells
P08700531A1420|104 122|chemical carcinogens
P08700531A1420|279 296|hamster fibroblasts
P08700531A1420|246 255|conversion
P08700531A1420|135 141|viruses
P08700531A1420|7 17|chromosome X
P08700531A1420|198 203|notion
P08700531A1420|177 186|chromosome
P08702517A0000|12 16|genes
P08702517A0000|59 65|B6SUtA1
P08702517A0000|3 8|screen
P08702517A0000|73 90|progenitor cell line
P08702543A0000|0 3|Gap1
P08702543A0000|18 23|member
P08702543A0000|144 145|P.
P08702543A0000|117 119|IP4
P08702543A0000|83 115|inositol 1,3,4,5-tetrakisphosphate
P08702543A0000|46 53|proteins
P08702543A0000|5 9|IP4BP
P08702543A0000|26 28|Ras
P08702543A0000|137 142|Cullen
P08702543A0000|122 135|binding protein
P08702556A0000|117 120|Imai
P08702556A0000|74 76|PAP
P08702556A0000|135 136|K.
P08702556A0000|108 112|Kanoh
P08702556A0000|24 35|purification
P08702556A0000|128 133|Yamada
P08702556A0000|155 156|J.
P08702556A0000|147 148|F.
P08702556A0000|114 115|H.
P08702556A0000|140 145|Sakane
P08702556A0000|58 72|acid phosphatase
P08702556A0000|122 126|S.-i.
P08702556A0000|85 106|porcine thymus membranes
P08702633A0164|46 54|increases
P08702633A0164|107 126|Grb2 complex formation
P08702633A0164|144 185|Ras guanine nucleotide exchange factor activity
P08702633A0164|85 101|Shc adapter protein
P08702633A0164|20 29|Gbetagamma
P08702633A0164|131 141|recruitment
P08702633A0164|57 79|tyrosine phosphorylation
P08702633A0164|3 11|mechanism
P08702633A0164|103 105|Shc
P08702644A0499|1 4|cDNA
P08702644A0499|147 190|glycosylphosphatidylinositol anchor attachment
P08702644A0499|110 115|factor
P08702644A0499|138 143|signal
P08702644A0499|80 89|amino acids
P08702644A0499|32 32|%
P08702644A0499|35 38|apoB
P08702644A0499|40 45|apoB17
P08702644A0499|117 119|DAF
P08702644A0499|58 61|cDNA
P08702728A1325|58 66|HIRc cells
P08702728A1325|40 44|Y317F
P08702728A1325|51 53|Shc
P08702728A1325|35 37|Shc
P08702756A0000|44 52|functions
P08702756A0000|128 144|muscle contraction
P08702756A0000|106 117|cell motility
P08702756A0000|8 16|GTPase Rho
P08702756A0000|94 104|cytokinesis
P08702756A0000|67 87|actin-myosin filaments
P08702807A0964|136 160|cyclin D1 protein expression
P08702807A0964|78 81|MKK1
P08702807A0964|11 20|activation
P08702807A0964|165 170|growth
P08702807A0964|27 42|signaling pathway
P08702807A0964|45 54|expression
P08702807A0964|109 132|cyclin D1 promoter activity
P08702807A0964|189 194|manner
P08702826A0870|102 110|MCF7 cells
P08702826A0870|92 99|promoter
P08702826A0870|34 53|GSTP1 silencer element
P08702826A0870|20 28|insertion
P08702826A0870|69 76|activity
P08702845A0000|86 104|dopamine transporter
P08702845A0000|125 146|dopamine uptake kinetics
P08702845A0000|154 178|CFT binding characteristics
P08702845A0000|181 190|COS-7 cells
P08702845A0000|106 108|DAT
P08702845A0000|53 60|affinity
P08702845A0000|232 243|COOH terminus
P08702845A0000|151 152|3H
P08702845A0000|64 74|recognition
P08702845A0000|218 221|DATs
P08702845A0000|28 33|motifs
P08702845A0000|122 123|3H
P08702845A0000|2 6|order
P08702936A0168|62 66|cDNAs
P08702936A0168|167 173|CD4 cDNA
P08702936A0168|110 114|blood
P08702936A0168|145 150|signal
P08702936A0168|190 207|virus shuttle vector
P08702936A0168|126 130|cells
P08702936A0168|2 18|expression library
P08702936A0984|83 91|monocytes
P08702936A0984|23 26|TARC
P08702936A0984|94 105|granulocytes
P08702936A0984|46 55|T cell lines
P08702936A0984|69 74|T cells
P08703005A0645|62 66|sites
P08703005A0645|112 116|CCAAT
P08703005A0645|128 134|protein
P08703005A0645|13 20|elements
P08703005A0645|32 47|promoter activity
P08703005A0645|96 103|alphaCbf
P08703005A0645|70 92|transcription factors Sp1
P08703010A0905|204 207|site
P08703010A0905|147 156|GAP-43 gene
P08703010A0905|37 43|element
P08703010A0905|48 54|E1 E-box
P08703010A0905|68 87|GAP-43 promoter region
P08703010A0905|186 193|proteins
P08703010A0905|132 141|expression
P08703908A1814|16 23|findings
P08703908A1814|39 42|SF-1
P08703908A1814|95 104|expression
P08703908A1814|52 55|role
P08703908A1814|110 117|StAR gene
P08703959A0659|87 96|lesion site
P08703959A0659|64 70|segment
P08703959A0659|169 176|spectrum
P08703959A0659|138 149|sugar protons
P08703959A0659|122 131|assignment
P08703959A0659|155 163|C7 residue
P08703959A0659|182 193|adduct duplex
P08703959A0659|28 43|proton resonances
P08704124A0420|56 63|VrCDPK-1
P08704124A0420|49 54|bp cDNA
P08704124A0420|70 98|Vigna radiata lambda gt11 library
P08704124A0420|16 24|fragments
P08704124A0420|26 31|CPK3-8
P08704240A1111|26 31|GM-CSF
P08704240A1111|38 47|starvation
P08704240A1111|10 18|TF-1 cells
P08704240A1111|81 87|minutes
P08704240A1111|93 110|PIXY321 stimulation
P08704240A1111|49 67|CREB phosphorylation
P08705056T0000|0 16|Workplace violence
P08705056T0000|27 30|risk
P08705056T0000|19 24|nurses
P08706368A1024|88 88|p
P08706368A1024|124 133|brightness
P08706368A1024|75 86|correlations
P08706368A1024|11 29|LV maximum brightness
P08706368A1024|172 172|p
P08706368A1024|160 170|correlation
P08706368A1024|104 107|FIO2
P08706368A1024|45 49|curve
P08706368A1024|33 36|area
P08706368A1024|0 6|RESULTS
P08706662A1125|26 32|absence
P08706662A1125|35 52|perforin expression
P08706662A1125|102 110|induction
P08706662A1125|86 96|suppression
P08706662A1125|148 158|factor NF-P2
P08706662A1125|68 72|cells
P08706662A1125|3 9|results
P08706731A1303|64 81|expression patterns
P08706731A1303|37 48|similarities
P08706731A1303|236 248|PR-10 proteins
P08706731A1303|147 164|sequence similarity
P08706731A1303|170 188|ginseng ribonuclease
P08706731A1303|260 269|prediction
P08706731A1303|200 209|hypothesis
P08706731A1303|84 93|Ypr10 genes
P08706731A1303|213 232|ribonuclease function
P08706731A1303|290 294|roles
P08706731A1303|97 113|ribonuclease genes
P08707424A0709|100 105|stages
P08707424A0709|3 12|expression
P08707424A0709|73 82|expression
P08707424A0709|15 25|ERV3 env mRNA
P08707424A0709|117 127|development
P08707516A0194|34 39|people
P08707516A0194|51 57|receipt
P08707516A0194|76 91|handicap services
P08707516A0194|64 67|need
P08707516A0194|7 15|estimates
P08707825A0063|216 222|protein
P08707825A0063|182 192|antibody R4A
P08707825A0063|82 89|analysis
P08707825A0063|113 122|smoothelin
P08707825A0063|207 210|cDNA
P08707825A0063|44 59|Northern blotting
P08707825A0063|31 41|muscle cells
P08707825A0063|137 153|muscle cDNA library
P08707840A0753|15 32|electron microscopy
P08707840A0753|109 111|p62
P08707840A0753|76 80|sides
P08707840A0753|45 51|p58/p45
P08707840A0753|93 103|pore complex
P08707840A0753|55 57|p54
P08707846A2308|224 234|endocytosis
P08707846A2308|113 134|receptor ubiquitination
P08707846A2308|183 198|a-factor receptor
P08707846A2308|53 60|receptor
P08707846A2308|84 97|ubiquitination
P08707846A2308|167 177|endocytosis
P08707846A2308|30 35|uptake
P08707922A0334|0 27|Transcription initiation sites
P08707922A0334|121 146|translation initiation codon
P08707922A0334|165 187|primer extension analysis
P08707922A0334|102 103|bp
P08707922A0334|38 41|beta
P08707922A0334|44 50|III beta
P08707922A0334|92 100|base pairs
P08707922A0334|148 150|ATG
P08707922A0334|33 35|rat
P08707922A0334|55 71|O beta-globin genes
P08707922A0334|159 162|gene
P08708984T0000|55 60|lesion
P08708984T0000|63 65|rat
P08708984T0000|27 38|indomethacin
P08708984T0000|11 17|process
P08709224T0000|33 37|EBNA2
P08709224T0000|47 55|component
P08709224T0000|12 16|virus
P08709224T0000|24 30|protein
P08709224T0000|66 79|SNF-SWI complex
P08709224T0000|81 90|hSNF5/Ini1
P08709245A1521|87 91|roles
P08709245A1521|43 57|phosphorylation
P08709245A1521|132 135|HDAg
P08709245A1521|97 121|trans-suppression activity
P08709245A1521|206 210|HDAgs
P08709245A1521|76 82|Ser-210
P08709245A1521|25 35|possibility
P08709245A1521|167 178|HDAg particle
P08709245A1521|195 203|transport
P08709245A1521|66 72|Ser-123
P08709245A1521|142 149|assembly
P08709245A1521|3 9|studies
P08709245A1521|60 64|Ser-2
P08709251A0000|61 77|polyhedrosis virus
P08709251A0000|140 154|DNA helicase gene
P08709251A0000|10 22|recombination
P08709251A0000|79 83|AcNPV
P08709251A0000|107 117|DNA fragment
P08709251A0000|157 162|Bombyx
P08709251A0000|200 208|eh2-AcNPV
P08709251A0000|231 241|AcNPV mutant
P08709251A0000|85 90|genome
P08709251A0000|243 244|S.
P08709251A0000|33 53|Autographa californica
P08709251A0000|174 190|polyhedrosis virus
P08709637A1471|29 44|IL-7R alpha chains
P08709637A1471|125 133|signaling
P08709637A1471|106 109|role
P08709637A1471|88 92|STATs
P08709637A1471|136 150|precursor B cells
P08709637A1471|69 78|activation
P08709637A1471|81 84|JAKs
P08709637A1471|3 6|data
P08709831A0599|15 21|potency
P08709831A0599|40 48|treatment
P08709831A0599|24 34|Dacarbacine
P08709831A0599|60 65|tumors
P08710151A0782|107 113|patient
P08710151A0782|116 121|class A
P08710151A0782|58 63|class A
P08710151A0782|35 38|cost
P08710151A0782|25 29|value
P08710151A0782|88 93|class B
P08710151A0782|100 103|cost
P08710151A0782|143 149|class B.
P08710151A0782|51 55|pnx s.
P08710151A0782|42 48|episode
P08710151A0782|77 77|%
P08710371A0000|118 124|biology
P08710371A0000|51 64|polyomavirus BK
P08710371A0000|93 102|protein p53
P08710371A0000|21 31|interaction
P08710371A0000|176 193|p53 transactivation
P08710371A0000|164 173|mechanisms
P08710371A0000|66 68|BKV
P08710371A0000|131 135|virus
P08710371A0499|0 7|Site S-II
P08710371A0499|49 69|consensus binding sites
P08710371A0499|20 29|bp sequence
P08710371A0499|110 125|base pair deletion
P08710371A0499|79 96|base pair mismatches
P08710377A0577|0 2|Cbl
P08710377A0577|124 137|BCR stimulation
P08710377A0577|55 64|preference
P08710377A0577|45 48|Grb2
P08710377A0577|103 105|way
P08710377A0577|33 42|SH3 domains
P08710377A0577|117 119|Shc
P08710377A0577|85 90|domain
P08710504A0995|0 9|Activation
P08710504A0995|49 58|cat1 mutant
P08710504A0995|20 24|Cat8p
P08711631A0989|0 8|Treatment
P08711631A0989|38 53|cyclophosphamide
P08711631A0989|25 34|prednisone
P08712799A0123|21 27|smoking
P08712799A0123|7 14|attempts
P08713933A0606|0 19|Laboratory evaluation
P08713933A0606|33 44|neuroimaging
P08713933A0606|90 97|drainage
P08713933A0606|60 70|obstruction
P08716757T0001|0 22|Microcomputer management
P08716757T0001|59 66|patients
P08716757T0001|32 46|hepatitis B virus
P08717391A0466|71 76|fusion
P08717391A0466|179 192|immunogenicity
P08717391A0466|164 175|antigenicity
P08717391A0466|127 142|particle assembly
P08717391A0466|100 109|C-terminus
P08717391A0466|49 55|surface
P08717391A0466|35 40|linker
P08717391A0466|195 199|HBcAg
P08717391A0466|16 25|N-terminus
P08717391A0466|5 10|fusion
P08717391A0466|82 91|N-terminus
P08717559A0223|82 91|micrograms
P08717559A0223|11 16|dosage
P08717559A0223|62 68|ampoule
P08717559A0223|55 58|ages
P08719155A0105|262 263|CS
P08719155A0105|88 95|sequence
P08719155A0105|213 216|TRAP
P08719155A0105|24 30|cloning
P08719155A0105|155 164|Plasmodium
P08719155A0105|50 57|molecule
P08719155A0105|231 236|extent
P08719155A0105|136 150|surface molecule
P08719155A0105|245 260|circumsporozoite
P08719155A0105|62 73|P. falciparum
P08719155A0105|265 271|protein
P08719155A0105|109 120|similarities
P08719155A0105|205 211|protein
P08719156A0953|56 67|reading frame
P08719156A0953|10 16|introns
P08719156A0953|86 92|protein
P08719156A0953|26 29|gene
P08719697A0221|28 30|eye
P08719697A0221|8 10|DSF
P08719697A0221|61 63|eye
P08719697A0221|48 49|CF
P08719697A0221|101 103|KCS
P08719697A0221|89 96|patients
P08719697A0221|74 81|subjects
P08719697A0221|0 6|METHODS
P08719832A0397|59 65|surgery
P08719832A0397|68 77|acromegaly
P08719832A0397|25 41|rhinotomy approach
P08719832A0397|3 12|experience
P08720407A1386|0 9|CONCLUSION
P08720407A1386|95 112|interleukin-1 alpha
P08720407A1386|139 163|prostaglandin E2 production
P08720407A1386|53 66|disc herniation
P08720407A1386|41 44|site
P08720407A1386|80 88|cytokines
P08720407A1386|14 20|results
P08721526A0000|52 59|children
P08721526A0000|25 33|allergens
P08721526A0000|69 78|pet animals
P08721989A1012|44 50|domains
P08721989A1012|166 181|signal transducer
P08721989A1012|130 134|beta c
P08721989A1012|118 125|evidence
P08721989A1012|91 107|signaling pathways
P08721989A1012|58 74|cytokine receptors
P08721989A1012|138 154|IL-2R beta function
P08721989A1012|3 9|results
P08721999A0432|28 35|features
P08721999A0432|67 75|snoRNA U14
P08721999A0432|2 9|addition
P08721999A0727|0 2|U24
P08721999A0727|60 64|tract
P08721999A0727|67 73|28S rRNA
P08721999A0727|19 20|nt
P08721999A0727|25 41|complementarities
P08722011A0103|73 83|binding site
P08722011A0103|25 36|GTPase domain
P08722011A0103|47 57|subunit rRNA
P08722011A0103|89 95|protein
P08722011A0103|114 124|counterpart
P08722011A0103|149 158|protein L15
P08722011A0103|171 180|protein L12
P08722011A0103|4 10|complex
P08722568A1001|103 127|replacement H3 histone genes
P08722568A1001|26 41|replacement genes
P08722568A1001|130 135|plants
P08722568A1001|91 100|expression
P08722568A1001|0 18|Chromatin repression
P08723352A0084|72 75|cdks
P08723352A0084|95 101|product
P08723352A0084|64 70|kinases
P08723352A0084|142 144|pRb
P08723352A0084|107 140|retinoblastoma tumour suppressor gene
P08723352A0084|4 13|transition
P08723365T0000|69 83|nephrosclerosis
P08723365T0000|56 66|hypertrophy
P08723365T0000|27 42|hyperinsulinemia
P08723365T0000|8 19|relationship
P08723883A0823|0 18|Blood GSH-Px activity
P08723883A0823|35 51|spectrophotometer
P08723883A0823|93 97|assay
P08723883A0823|59 70|modification
P08723883A1684|157 164|vitamins
P08723883A1684|92 97|levels
P08723883A1684|111 120|alfalfa hay
P08723883A1684|40 47|vitamin E
P08723883A1684|101 106|llamas
P08723883A1684|19 36|vitamin A precursors
P08723883A1684|176 182|species
P08723883A1684|149 154|source
P08723883A1684|3 16|concentrations
P08723883A1684|169 169|E
P08723883A1684|53 55|hay
P08726024A0244|5 8|cats
P08726024A0244|21 28|H. pylori
P08726024A0244|42 46|study
P08726024A0532|29 35|primers
P08726024A0532|107 118|fluid samples
P08726024A0532|88 96|weeks p.t.
P08726024A0532|162 165|cats
P08726024A0532|22 24|PCR
P08726024A0532|169 177|weeks p.t.
P08726024A0532|56 62|product
P08726024A0532|187 192|plaque
P08726024A0532|77 80|cats
P08726024A0532|67 74|majority
P08726024A0532|212 219|H. pylori
P08726024A0532|139 146|H. pylori
P08726247A0175|44 55|measurements
P08726247A0175|85 94|path length
P08726247A0175|63 73|attenuation
P08726247A0175|20 39|concentration changes
P08727192A0000|0 10|STUDY DESIGN
P08727992A0570|33 39|heifers
P08727992A0570|63 67|signs
P08727992A0570|12 20|injection
P08727992A0570|92 94|min
P08727992A0570|23 31|PGF2 alpha
P08727992A0570|70 75|estrus
P08728040T0000|75 98|Janus kinase-Stat pathways
P08728040T0000|12 21|activation
P08728040T0000|164 175|sarcoma cells
P08728040T0000|156 161|Kaposi
P08728040T0000|56 61|kinase
P08728040T0000|120 141|fibroblast growth factor
P08728040T0000|101 111|oncostatin M
P08728040T0000|63 71|Jun kinase
P08730470A0000|14 22|agreement
P08730470A0000|151 166|household contact
P08730470A0000|123 128|babies
P08730470A0000|114 120|mothers
P08730470A0000|98 109|transmission
P08730470A0000|30 44|hepatitis C virus
P08730470A0000|87 90|data
P08731155A0499|13 26|reconstruction
P08731155A0499|71 76|nerves
P08731155A0499|3 7|weeks
P08731155A0499|43 48|nerves
P08731222A0000|147 150|area
P08731222A0000|107 109|SRD
P08731222A0000|261 267|C7 level
P08731222A0000|144 145|Cu
P08731222A0000|193 224|Phaseolus vulgaris leucoagglutinin
P08731222A0000|18 29|organization
P08731222A0000|226 230|PHA-L
P08731222A0000|77 105|subnucleus reticularis dorsalis
P08731222A0000|129 142|Cuneate nucleus
P08731222A0000|245 251|laminae
P08731222A0000|166 168|rat
P08731222A0000|64 74|enlargement
P08731222A0000|3 14|distribution
P08731222A0000|32 42|projections
P08731222A0000|176 190|microinjections
P08731511A0625|72 75|HCII
P08731511A0625|11 20|fibrinogen
P08731511A0625|122 128|animals
P08731511A0625|29 40|antithrombin
P08731511A0625|77 86|activities
P08731511A0625|54 68|heparin cofactor
P08731511A0625|45 49|ATIII
P08731511A0625|3 8|levels
P08732665A0000|0 12|Amplification
P08732665A0000|288 294|culture
P08732665A0000|16 29|overexpression
P08732665A0000|69 88|breast carcinoma cells
P08732665A0000|257 268|growth factor
P08732665A0000|229 231|IGF
P08732665A0000|216 227|growth factor
P08732665A0000|49 54|21MT-2
P08732665A0000|274 285|independence
P08732665A0000|35 46|c-erbB-2 gene
P08732665A0000|164 173|p185erbB-2
P08732665A0000|119 124|levels
P08732665A0000|270 272|EGF
P08732665A0000|58 63|21MT-1
P08733123A0000|121 127|muscles
P08733123A0000|133 136|face
P08733123A0000|37 40|FSHD
P08733123A0000|111 118|weakness
P08733123A0000|27 35|dystrophy
P08733123A0000|138 145|shoulder
P08733123A0000|154 156|arm
P08733123A0000|77 84|disorder
P08733123A0951|40 41|bp
P08733123A0951|90 96|protein
P08733123A0951|65 69|exons
P08733123A0951|9 18|chromosome
P08733123A0951|20 33|FRG1 transcript
P08733123A0951|102 118|amino acid residues
P08733123A0951|44 49|length
P08733874A0000|132 135|131I
P08733874A0000|40 55|thyroid carcinoma
P08733874A0000|24 36|thyroidectomy
P08733874A0000|156 166|measurement
P08733874A0000|141 152|body scanning
P08733874A0000|169 175|serum TG
P08733874A0000|80 86|periods
P08733874A0000|118 128|preparation
P08733874A0000|102 115|hypothyroidism
P08733874A0000|0 7|Patients
P08733881A0343|59 65|samples
P08733881A0343|114 122|TSH levels
P08733881A0343|94 101|subjects
P08733881A0343|76 84|TSH values
P08733881A0343|4 25|thyroid function testing
P08734538A0613|47 54|textures
P08734538A0613|102 109|textures
P08734538A0613|120 121|AM
P08734538A0613|8 17|experiment
P08734538A0613|19 27|crossover
P08738510A0254|67 77|meningiomas
P08738510A0254|55 60|cortex
P08738510A0254|27 33|Q-MRGlu
P08738510A0254|11 25|tumor FDG-uptake
P08739209A0700|0 10|Zatebradine
P08739209A0700|166 169|dogs
P08739209A0700|138 138|h
P08739209A0700|128 135|ligation
P08739209A0700|91 101|arrhythmias
P08739209A0700|47 50|rate
P08739209A0700|147 154|ligation
P08739209A0700|70 74|ratio
P08739260T0000|0 4|Catha
P08739260T0000|25 42|amphetamine effects
P08739260T0000|13 17|plant
P08740416A0239|88 93|region
P08740416A0239|12 18|protein
P08740416A0239|38 47|amino acids
P08740416A0239|20 24|Seb1p
P08740416A0239|124 137|signal sequence
P08740416A0239|99 108|C-terminus
P08740416A0919|29 32|SEB2
P08740416A0919|51 51|%
P08740416A0919|3 15|SEB1 homologue
P08740416A0919|63 67|Seb1p
P08740416A0919|42 48|protein
P08741206A1551|107 117|hypotension
P08741206A1551|53 60|settings
P08741206A1551|27 35|afferents
P08741206A1551|92 103|vasodilation
P08741280A0374|91 94|lobe
P08741280A0374|76 81|length
P08741280A0374|35 38|lobe
P08741280A0374|47 50|ones
P08741280A0374|22 25|size
P08741280A0374|5 8|ones
P08742135A0000|0 8|Fragments
P08742135A0000|24 34|hormone ACTH
P08742135A0000|12 18|analogs
P08742135A0000|137 138|CS
P08742135A0000|122 135|corticosterone
P08742135A0000|90 99|head injury
P08742135A0000|70 75|effect
P08742135A0000|81 87|outcome
P08742135A0000|114 119|levels
P08742385A0211|121 121|%
P08742385A0211|99 99|%
P08742385A0211|61 68|drainage
P08742385A0211|104 113|head injury
P08742385A0211|74 74|%
P08742385A0211|15 20|causes
P08742385A0211|26 35|meningitis
P08745669A0000|178 187|bleomocyin
P08745669A0000|9 16|patients
P08745669A0000|168 176|methyl GAG
P08745669A0000|105 111|disease
P08745669A0000|96 102|Hodgkin
P08745669A0000|156 166|cisplatinum
P08745669A0000|81 88|lymphoma
P08745669A0000|189 205|methyl prednisolon
P08745669A0000|57 64|lymphoma
P08745669A0000|148 154|regimen
P08746605A0377|17 19|use
P08746605A0377|39 47|incidence
P08746605A0377|22 34|ACE inhibitors
P08746605A0377|61 67|effects
P08746605A0377|91 102|pancreatitis
P08746981A0154|16 19|diet
P08746981A0154|50 67|mg probiotic/kg food
P08746981A0154|3 12|treatments
P08747078T0000|8 14|aspirin
P08747078T0000|27 37|miscarriage
P08747343A0790|0 11|Protein films
P08747343A0790|79 87|materials
P08747343A0790|63 67|films
P08747343A0790|46 53|profiles
P08748033A0874|59 80|LamB-LacZ hybrid protein
P08748033A0874|108 116|cytoplasm
P08748033A0874|96 102|effects
P08748033A0874|12 15|cpxA
P08748033A0874|17 25|mutations
P08748033A0874|37 44|toxicity
P08748033A0874|133 136|DegP
P08749393A0783|3 14|PI3K_68D cDNA
P08749393A0783|23 29|protein
P08749393A0783|49 57|sequences
P08749393A0783|35 37|kDa
P08749393A0783|208 215|C2 domain
P08749393A0783|177 186|SH3 domains
P08749393A0783|152 159|sequence
P08749393A0783|77 91|p110 PI 3-kinases
P08749393A0783|94 111|p85 adaptor proteins
P08749394A0874|145 159|Drosophila Notch
P08749394A0874|7 24|interaction studies
P08749394A0874|95 96|Su
P08749394A0874|31 38|proteins
P08749394A0874|98 98|H
P08749394A0874|82 91|RBP-J kappa
P08749394A0874|117 128|RAM23 regions
P08749394A0874|46 70|glutathione-S-transferase
P08749394A0874|131 141|mouse Notch1
P08750173A0000|32 45|system function
P08750173A0000|131 145|D-galactosamine
P08750173A0000|59 67|clearance
P08750173A0000|83 90|bacteria
P08750173A0000|111 121|liver injury
P08750173A0000|148 151|rats
P08750173A0000|179 198|% liver resection model
P08750173A0000|0 11|AIMS/METHODS
P08750190A0000|42 49|splicing
P08750190A0000|152 159|isoforms
P08750190A0000|88 91|site
P08750190A0000|146 150|CD44v
P08750190A0000|122 131|generation
P08750190A0000|134 144|CD44 variant
P08750190A0000|59 63|exons
P08750190A0000|3 12|laboratory
P08750190A0000|16 21|others
P08750702A0183|0 10|Study groups
P08750702A0183|72 85|blockers WB4101
P08750702A0183|126 134|mg/kg i.v.
P08750702A0183|90 98|mg/kg i.v.
P08750702A0183|15 21|control
P08750702A0183|102 121|chloroethylclonidine
P08751635A0135|41 44|loss
P08751635A0135|24 29|damage
P08751635A0135|78 82|hilus
P08751635A0135|47 69|hippocampus subfields CA1
P08751635A0135|71 73|CA3
P08752714A0000|129 133|years
P08752714A0000|23 32|malignancy
P08752714A0000|104 113|department
P08752714A0000|71 82|malignancies
P08752714A0000|48 55|patients
P08752714A0000|3 12|occurrence
P08754777A1214|72 73|T3
P08754777A1214|37 55|T3R-RXR heterodimers
P08754777A1214|131 135|upTRE
P08754777A1214|96 113|heterodimer binding
P08754777A1214|63 67|dnTRE
P08754777A1214|17 29|T3R homodimers
P08754777A1214|3 7|upTRE
P08754777A1214|119 120|dn
P08754802T0000|15 21|control
P08754802T0000|94 97|mice
P08754802T0000|113 121|receptors
P08754802T0000|63 81|acid oxidation enzyme
P08754802T0000|32 35|gene
P08754802T0000|139 155|adipose expression
P08754802T0000|99 102|role
P08754827A0231|0 5|Hoeben
P08754827A0231|7 10|F.J.
P08754834A1097|72 88|transcription unit
P08754834A1097|13 21|fragments
P08754834A1097|139 144|detail
P08754834A1097|113 119|NN-84AG
P08754834A1097|37 52|response elements
P08754840A0793|84 98|deltabem4 mutant
P08754840A0793|9 30|glucan synthase activity
P08754840A0793|50 54|Rho1p
P08754852A0960|72 78|protein
P08754852A0960|25 27|RCS
P08754852A0960|137 144|sequence
P08754852A0960|154 159|18-mer
P08754852A0960|112 123|chondrocytes
P08754852A0960|2 21|gel retardation assays
P08754852A0960|94 101|RCS cells
P08754852A0960|41 47|protein
P08755898A0339|117 122|avrBs2
P08755898A0339|39 55|Bs2 host resistance
P08755898A0339|23 31|pathogens
P08755898A0339|76 82|fitness
P08755898A0339|3 9|classes
P08756332A0000|0 6|Members
P08756332A0000|12 23|Ras subfamily
P08756332A0000|197 203|Ral-GEF
P08756332A0000|165 195|guanine nucleotide exchange factor
P08756332A0000|103 119|effector molecules
P08756332A0000|42 49|proteins
P08756332A0000|129 146|protein kinase c-Raf
P08756332A0000|86 92|variety
P08756433A0282|29 42|promoter region
P08756433A0282|8 23|characterization
P08756433A0282|136 144|MAP1B gene
P08756433A0282|71 78|elements
P08756433A0282|121 130|expression
P08756556A0406|3 6|cDNA
P08756556A0406|21 27|protein
P08756556A0406|62 79|acid signal sequence
P08756556A0406|33 42|amino acids
P08756597A0854|0 6|Mutants
P08756597A0854|40 49|% reduction
P08756597A0854|62 69|psaB mRNA
P08756597A0854|55 59|level
P08756609A0498|117 124|protozoa
P08756609A0498|10 26|amino acid sequence
P08756609A0498|76 86|vertebrates
P08756609A0498|108 113|plants
P08756609A0498|65 74|eukaryotes
P08756609A0498|137 140|gene
P08756609A0498|88 100|invertebrates
P08756609A0498|58 62|range
P08756609A0498|102 106|fungi
P08756617A1204|0 3|Biol
P08756636T0000|71 82|Srs2 helicase
P08756636T0000|51 63|relationships
P08756636T0000|26 42|yeast Rad51 protein
P08756636T0000|12 20|mutations
P08756642A0230|0 10|Alterations
P08756642A0230|24 31|interval
P08756642A0230|79 86|leukemia
P08756642A0230|55 68|myelodysplasia
P08756712A0227|54 60|subunit
P08756712A0227|63 65|RPA
P08756712A0227|38 46|amino acid
P08756712A0227|8 14|studies
P08756712A0227|114 120|domains
P08756712A0227|67 69|RPA
P08757265A0466|0 6|Neurons
P08757265A0466|47 53|effects
P08757265A0466|20 21|mV
P08757943A0876|4 7|site
P08757943A0876|23 29|element
P08757943A0876|50 72|thymidine kinase promoter
P08757943A0876|90 101|inducibility
P08759870A1128|55 74|footprinting analysis
P08759870A1128|91 97|binding
P08759870A1128|37 38|bp
P08759870A1128|3 8|extent
P08759870A1128|103 120|Fur repressor dimers
P08759870A1128|14 33|fbpA operator sequence
P08760286A0696|30 32|Vav
P08760286A0696|229 232|MAPK
P08760286A0696|92 99|proteins
P08760286A0696|13 22|similarity
P08760286A0696|41 72|guanine nucleotide exchange factors
P08760286A0696|166 172|members
P08760286A0696|251 260|components
P08760286A0696|184 192|Rho family
P08760286A0696|235 237|JNK
P08760286A0696|266 285|Vav signaling pathways
P08760286A0696|195 201|GTPases
P08760286A0696|178 180|Ras
P08760286A0696|122 135|identification
P08760286A0696|149 154|routes
P08760776A1559|0 9|CONCLUSION
P08760776A1559|79 88|micrograms
P08760776A1559|139 147|treatment
P08760776A1559|64 73|micrograms
P08760776A1559|41 61|fluticasone propionate
P08760776A1559|122 133|theophylline
P08760776A1559|21 29|treatment
P08760776A1559|166 171|asthma
P08760872A0696|131 141|CHR elements
P08760872A0696|79 84|stages
P08760872A0696|90 98|cell cycle
P08760872A0696|51 60|repression
P08760872A0696|32 34|E2F
P08760872A0696|18 22|model
P08760872A0696|3 9|results
P08760889A0170|3 11|cDNA clone
P08760889A0170|63 67|clone
P08760889A0170|32 36|probe
P08760889A0170|76 79|H2A1
P08760889A0531|0 9|Comparison
P08760889A0531|213 222|divergence
P08760889A0531|44 59|protein sequences
P08760889A0531|149 152|H2A1
P08760889A0531|22 39|amino acid sequences
P08760889A0531|173 176|H2A2
P08760889A0531|126 130|total
P08760889A0531|160 169|amino acids
P08760889A0531|99 109|differences
P08760889A0531|74 77|H2As
P08760889A0531|136 145|amino acids
P08760889A0531|233 239|species
P08760889A0531|194 198|genes
P08761169T0000|29 33|child
P08761169T0000|46 51|damage
P08761169T0000|15 25|dysfunction
P08761480A0331|0 10|Interaction
P08761480A0331|191 193|RD1
P08761480A0331|337 349|fusion protein
P08761480A0331|135 144|N-terminus
P08761480A0331|210 212|PDE
P08761480A0331|49 60|splice region
P08761480A0331|75 85|PDE4A splice
P08761480A0331|93 99|RPDE-39
P08761480A0331|63 68|RPDE-6
P08761480A0331|373 384|splice region
P08761480A0331|293 303|association
P08761480A0331|306 311|RPDE-6
P08761480A0331|277 285|v-Src-SH3
P08761480A0331|315 323|v-Src-SH3
P08761480A0331|167 175|v-Src-SH3
P08761480A0331|196 198|rat
P08761480A0331|177 184|met26RD1
P08761480A0331|236 247|splice region
P08761480A0331|117 122|RPDE-6
P08762021A0156|48 58|performance
P08762021A0156|120 126|rabbits
P08762021A0156|27 34|measures
P08762172A0178|170 174|boxes
P08762172A0178|63 72|proportion
P08762172A0178|37 45|variables
P08762172A0178|5 21|strain differences
P08762172A0178|136 146|transitions
P08762172A0178|93 96|time
P08762172A0178|84 88|males
P08762172A0178|118 120|box
P08762172A0178|128 133|number
P08762472A0000|101 107|studies
P08762472A0000|11 35|ligustrazine hydrochloride
P08762472A0000|3 8|effect
P08762472A0000|37 39|LTH
P08762472A0000|62 79|artery hypertension
P08763207A0402|83 85|DPV
P08763207A0402|49 53|media
P08763207A0402|104 115|accumulation
P08763207A0402|7 19|oxidation peak
P08763207A0402|60 60|V
P08763207A0402|118 128|clenbuterol
P08763207A0402|149 151|CPE
P08763207A0402|26 32|product
P08763311A0189|0 12|Phenylephrine
P08763311A0189|105 116|hypertension
P08763311A0189|76 91|vasoconstriction
P08763311A0189|145 155|bradycardia
P08763311A0189|20 47|alpha-1 adrenoreceptor agonist
P08763925A0588|26 30|genes
P08763925A0588|119 126|antisera
P08763925A0588|106 113|analyses
P08763925A0588|49 54|c-gvpD
P08763925A0588|3 12|expression
P08763925A0588|44 47|unit
P08763925A0588|145 152|proteins
P08763925A0588|58 63|c-gvpE
P08763925A0588|95 104|immunoblot
P08763925A0588|83 93|Western blot
P08763953A0805|14 17|traA
P08763953A0805|3 6|unit
P08763953A0805|66 69|traG
P08763953A0805|19 22|traF
P08763953A0805|27 30|traB
P08763953A0805|53 56|traC
P08763953A0805|58 61|traD
P08764015A0284|0 1|A.
P08764136A0000|239 244|76R-30
P08764136A0000|153 165|hybridization
P08764136A0000|19 23|genes
P08764136A0000|125 128|MECs
P08764136A0000|119 123|cells
P08764136A0000|81 94|transformation
P08764136A0000|4 9|effort
P08764136A0000|42 51|expression
P08764136A0000|179 190|MEC strain 76N
P08764136A0000|57 65|mRNA level
P08766049A0000|183 192|Vancomycin
P08766049A0000|155 156|ml
P08766049A0000|141 149|injection
P08766049A0000|91 97|patient
P08766049A0000|176 177|ml
P08766049A0000|64 71|reaction
P08766049A0000|159 160|mg
P08766049A0000|34 51|corneal perforation
P08766049A0000|162 169|Amikacin
P08766049A0000|180 181|mg
P08766049A0000|82 88|chamber
P08766049A0000|0 9|CASE REPORT
P08766781A0322|56 56|%
P08766781A0322|71 72|Hb
P08766781A0322|9 14|period
P08766781A0322|61 61|%
P08766781A0322|29 36|increase
P08766781A0322|87 90|g/dl
P08766781A0322|39 48|hematocrit
P08768374A0765|3 6|P-wr
P08768374A0765|10 26|P-rr cDNA sequences
P08768374A0765|50 56|regions
P08768377A1387|121 127|cloning
P08768377A1387|33 40|distance
P08768377A1387|10 20|hcf109 locus
P08768377A1387|64 79|phytochrome C gene
P08768377A1387|45 56|centimorgans
P08768377A1387|93 108|characterization
P08769132A0000|27 32|member
P08769132A0000|362 367|cancer
P08769132A0000|159 162|MutS
P08769132A0000|410 423|chromosome 2p16
P08769132A0000|303 311|base pairs
P08769132A0000|51 56|family
P08769132A0000|101 114|mismatch repair
P08769132A0000|277 285|deletions
P08769132A0000|196 208|MSH-2 proteins
P08769132A0000|8 23|MSH-2 gene product
P08769132A0000|369 373|HNPCC
P08769132A0000|59 66|proteins
P08769132A0000|244 248|sites
P08769132A0000|188 192|MSH-1
P08769132A0000|375 394|tumor suppressor genes
P08769132A0000|260 273|base mismatches
P08769132A0000|236 238|DNA
P08769132A0000|288 297|insertions
P08769132A0000|116 121|hMSH-2
P08769132A0000|313 318|hMSH-2
P08769409A0114|70 81|mouse embryos
P08769409A0114|192 195|A.M.
P08769409A0114|175 180|region
P08769409A0114|111 115|level
P08769409A0114|189 190|A.
P08769409A0114|149 153|uORFs
P08769409A0114|135 147|reading frames
P08769409A0114|64 67|gene
P08769409A0114|182 187|Zimmer
P08769409A0114|56 62|RAR beta
P08769409A0114|41 50|expression
P08769566A0000|160 162|ZD2
P08769566A0000|107 113|protein
P08769566A0000|33 51|transcription factor
P08769566A0000|25 28|cDNA
P08769566A0000|180 182|DNA
P08769566A0000|154 156|ZD1
P08769566A0000|64 68|Zfhep
P08769566A0000|188 198|homeodomain
P08769566A0000|136 152|zinc finger domains
P08769566A0000|70 90|zinc finger homeodomain
P08769568A0949|3 11|structure
P08769568A0949|60 68|PLA2 genes
P08769568A0949|39 46|ancestor
P08769568A0949|19 23|genes
P08770021T0000|27 48|tyrosine kinase oncogene
P08770021T0000|67 85|Ras signaling pathway
P08770021T0000|50 56|Tpr-Met
P08770021T0000|9 23|PTHRP production
P08770021T0000|58 61|role
P08770896A1121|115 121|species
P08770896A1121|126 130|appMr
P08770896A1121|38 41|xz97
P08770896A1121|134 136|17K
P08770896A1121|80 85|medium
P08770896A1121|140 142|14K
P08770896A1121|45 52|G11 cells
P08770896A1121|17 25|secretion
P08770896A1121|30 35|IGF-II
P08770920A1220|122 126|IDX-1
P08770920A1220|160 170|enhancement
P08770920A1220|80 84|IDX-1
P08770920A1220|14 25|coexpression
P08770920A1220|91 98|proteins
P08770920A1220|173 187|transactivation
P08770920A1220|208 228|TAAT-1 element reporter
P08770981A0328|42 44|vWF
P08770981A0328|124 141|weight vWF multimers
P08770981A0328|94 99|weight
P08770981A0328|22 40|von Willebrand factor
P08770981A0328|46 58|fragmentation
P08770981A0328|147 157|circulation
P08770981A0328|3 10|patients
P08771781A0103|214 228|leaf cDNA library
P08771781A0103|81 92|reading frame
P08771781A0103|44 49|region
P08771781A0103|164 168|ORFII
P08771781A0103|102 114|Brassica napus
P08771781A0103|170 179|cDNA clones
P08771781A0103|4 10|attempt
P08771781A0103|94 98|ORFII
P08771781A0103|60 66|oleosin
P08771781A0103|131 138|promoter
P08771781A0103|116 117|L.
P08771781A1103|3 18|ORFII gene product
P08771781A1103|75 78|data
P08771781A1103|102 113|PMSR activity
P08771781A1103|34 44|chloroplast
P08771781A1103|92 99|presence
P08771781A1103|119 129|chloroplast
P08771787T0000|0 15|Characterization
P08771787T0000|46 52|protein
P08771787T0000|35 40|repeat
P08771787T0000|90 101|pathogenesis
P08771787T0000|18 20|LRP
P08771787T0000|57 68|tomato plants
P08771787T0000|42 44|LRR
P08774732A0271|13 15|Sp1
P08774732A0271|47 51|motif
P08774732A0271|53 72|gel retardation assays
P08774732A0271|19 28|zif268/egr
P08775674A0000|0 9|OBJECTIVES
P08775674A0000|50 64|characteristics
P08775674A0000|22 26|study
P08775674A0000|90 97|patients
P08775674A0000|102 117|hydatidiform mole
P08775674A0000|78 84|outcome
P08775674A0000|66 74|treatment
P08775674A0000|14 16|aim
P08776735A0000|175 183|rLHR-t628
P08776735A0000|104 108|tails
P08776735A0000|74 77|rLHR
P08776735A0000|162 170|rLHR-t631
P08776735A0000|250 263|responsiveness
P08776735A0000|22 27|kidney
P08776735A0000|152 160|rLHR-t653
P08776735A0000|53 72|type rat LH/CG receptor
P08776735A0000|31 35|cells
P08776735A0000|81 89|receptors
P08776735A0000|219 224|region
P08776735A0000|230 239|regulation
P08776735A0000|120 127|residues
P08776735A0000|203 212|importance
P08776748T0000|30 42|schizophrenia
P08776748T0000|21 26|marker
P08776748T0000|6 19|P300 amplitudes
P08776792A0626|0 4|Sleep
P08776792A0626|39 42|days
P08776792A0626|47 51|hours
P08776793A0811|29 33|males
P08776793A0811|3 10|patients
P08776901A0000|0 17|Chloroplast mutator
P08776901A0000|19 21|chm
P08776901A0000|135 141|fashion
P08776901A0000|25 35|Arabidopsis
P08776901A0000|86 96|variegation
P08776901A0000|55 62|mutation
P08776901A0000|99 104|leaves
P08777374A1471|89 97|exposures
P08777374A1471|6 19|concentrations
P08777374A1471|55 68|concentrations
P08777374A1471|137 150|concentrations
P08778265A0422|73 76|test
P08778265A0422|78 97|Street completion test
P08778265A0422|99 108|Stroop test
P08778265A0422|19 29|test battery
P08778265A0422|53 65|Wisconsin card
P08778265A0422|149 163|recognition test
P08778265A0422|134 137|test
P08778265A0422|119 124|memory
P08778700A0476|13 16|case
P08778700A0476|52 62|involvement
P08778700A0476|77 80|ARVD
P08778700A0476|29 34|rarity
P08780339A0142|28 44|Latin-square study
P08780339A0142|26 26|x
P08780339A0142|189 191|RS2
P08780339A0142|131 137|glucose
P08780339A0142|95 101|females
P08780339A0142|49 59|corrections
P08780339A0142|233 235|RS3
P08780339A0142|156 157|RS
P08780339A0142|178 187|cornstarch
P08780339A0142|66 81|carryover effects
P08780339A0142|222 231|cornstarch
P08780339A0142|13 24|single-blind
P08780339A0142|149 154|starch
P08780339A0142|110 120|supplements
P08780339A0142|85 89|males
P08781119A0723|13 18|region
P08781119A0723|109 124|rat Met-ase-1 gene
P08781119A0723|24 41|mouse Met-ase-1 gene
P08781119A0723|73 80|identity
P08781119A0723|64 70|regions
P08781119A0723|98 103|region
P08781144A1520|45 49|index
P08781144A1520|62 74|tumour hypoxia
P08781144A1520|77 79|NPC
P08781144A1520|8 16|FMISO TMRR
P08781144A1520|4 6|18F
P08783180A0000|8 14|methods
P08783180A0000|92 112|Carollia perspicillata
P08783180A0000|146 152|setting
P08783180A0000|83 90|fruit bat
P08783666A0957|14 17|time
P08783666A0957|20 30|engraftment
P08783666A0957|2 9|addition
P08783666A0957|78 84|cohorts
P08783666A0957|59 71|amifostine arm
P08784787A0383|28 31|PAR2
P08784787A0383|11 26|thrombin receptor
P08784787A0383|115 130|receptor cleavage
P08784787A0383|88 101|ligand sequence
P08784787A0383|51 61|hexapeptide
P08787110A0981|27 39|investigation
P08787110A0981|45 54|management
P08787110A0981|84 90|disease
P08787110A0981|153 170|function laboratory
P08787110A0981|57 64|patients
P08787110A0981|120 133|investigations
P08787110A0981|14 17|CPET
P08789441A0339|146 146|t
P08789441A0339|210 215|region
P08789441A0339|154 166|translocation
P08789441A0339|103 113|sex reversal
P08789441A0339|183 195|cosmid markers
P08789441A0339|96 99|CMPD
P08789441A0339|23 35|hybridization
P08789441A0339|74 80|patient
P08789441A0339|5 16|fluorescence
P08789441A0339|61 70|breakpoint
P08790288A0068|42 48|spinach
P08790288A0068|77 92|Hordeum vulgare cv
P08790288A0068|50 65|Spinacia oleracea
P08790288A0068|33 37|cDNAs
P08790288A0068|22 30|isolation
P08790288A0068|70 75|barley
P08790291A1022|3 6|data
P08790291A1022|61 78|DNA damage tolerance
P08790291A1022|22 25|work
P08790291A1022|38 41|thi1
P08790291A1022|81 90|plant cells
P08790387A0299|5 16|rat rnu allele
P08790387A0299|50 53|exon
P08790387A0299|60 66|whn gene
P08790387A0299|32 47|nonsense mutation
P08792217A1407|115 123|germ cells
P08792217A1407|166 173|increase
P08792217A1407|74 79|result
P08792217A1407|202 216|TIMP-2 mRNA level
P08792217A1407|41 55|TIMP-2 mRNA level
P08792217A1407|145 149|cells
P08792217A1407|6 13|increase
P08792217A1407|186 189|cell
P08792217A1407|84 96|up-regulation
P08792217A1407|99 107|germ cells
P08793029A0246|0 6|Control
P08793029A0246|13 16|rats
P08793029A0246|53 58|groups
P08793693A0237|0 5|DESIGN
P08793693A0237|23 27|study
P08794254A2957|70 78|graft loss
P08794254A2957|11 21|PTA category
P08794254A2957|34 40|therapy
P08794254A2957|64 67|risk
P08794254A2957|5 7|SPK
P08794326A0405|72 74|end
P08794326A0405|102 108|pol gene
P08794326A0405|55 57|TRE
P08794326A0405|111 115|SFV-1
P08794326A0405|80 86|gag gene
P08794326A0405|37 43|element
P08794326A0405|59 60|GP
P08794339A1162|55 58|CREB
P08794339A1162|158 161|CREB
P08794339A1162|20 22|IE2
P08794339A1162|106 109|p300
P08794339A1162|148 151|turn
P08794339A1162|80 82|IE2
P08794339A1162|175 189|adaptor proteins
P08794339A1162|61 69|deltaCREB
P08794339A1162|11 17|binding
P08794339A1162|128 134|protein
P08794339A1162|93 101|complexes
P08794339A1162|136 138|CBP
P08794339A1162|193 204|CREB function
P08794348A1067|64 68|trans
P08794348A1067|51 53|NIa
P08794348A1067|11 30|complementation assay
P08794348A1067|130 140|NIa proteins
P08794348A1067|108 114|genomes
P08794363A0259|68 84|jun-fos gene family
P08794363A0259|5 9|basis
P08794363A0259|102 107|origin
P08794363A0259|38 40|meq
P08794363A0259|15 18|bZIP
P08794363A0259|29 36|homology
P08794363A0259|57 62|member
P08794547A0648|3 6|rCBF
P08794547A0648|10 19|vasomotion
P08794547A0648|34 55|laser-doppler fluxmetry
P08794547A1403|73 75|SAH
P08794547A1403|13 19|vessels
P08794547A1403|49 55|vessels
P08794601A0000|100 100|%
P08794601A0000|9 19|combination
P08794601A0000|51 67|bismuth subcitrate
P08794601A0000|106 128|H. pylori eradication rate
P08794601A0000|22 31|nizatidine
P08794601A0000|133 133|%
P08794601A0000|80 95|ulcer healing rate
P08794601A0000|33 46|clarithromycin
P08794869A0274|14 21|evidence
P08794869A0274|7 11|lines
P08794869A0274|66 70|alpha
P08794869A0274|60 63|role
P08794869A0274|46 53|PKC-zeta
P08794869A0274|72 93|integrin gene expression
P08795304T0000|0 19|Plasma thrombomodulin
P08795304T0000|59 74|diabetes mellitus
P08795304T0000|22 27|marker
P08795304T0000|44 56|complications
P08797362T0037|0 5|Update
P08797362T0037|63 66|USSR
P08797362T0037|46 51|states
P08797362T0037|7 16|diphtheria
P08797362T0037|68 74|January
P08798420A0207|146 152|CAAT box
P08798420A0207|123 140|PRDII/kappaB domain
P08798420A0207|181 184|pp60
P08798420A0207|24 37|promoter region
P08798420A0207|3 18|characterization
P08798420A0207|169 178|activation
P08798420A0207|99 113|AP-1 binding site
P08798420A0207|117 119|TRE
P08798420A0207|189 191|src
P08798420A0207|74 81|elements
P08798443A0660|0 5|Serine
P08798443A0660|67 72|serine
P08798443A0660|183 188|mim-1A
P08798443A0660|150 157|promoter
P08798443A0660|122 124|Myb
P08798443A0660|78 84|alanine
P08798443A0660|203 209|element
P08798443A0660|113 119|ability
P08798443A0660|40 48|cell lines
P08798443A0660|221 236|herpes tk promoter
P08798443A0660|172 177|copies
P08798443A0660|53 64|substitution
P08798443A0660|86 90|S528A
P08798443A1218|43 47|c-Myb
P08798443A1218|105 119|phosphorylation
P08798443A1218|155 190|transcription transactivating activity
P08798443A1218|193 197|c-Myb
P08798443A1218|231 238|proteins
P08798443A1218|16 40|multimerization activities
P08798443A1218|122 127|serine
P08798443A1218|210 221|interactions
P08798443A1218|73 89|S528A substitution
P08798443A1218|3 12|DNA binding
P08798443A1218|144 149|effect
P08798512A1197|3 8|amount
P08798512A1197|53 61|u-PAR gene
P08798512A1197|35 42|GEO cells
P08798512A1197|16 22|factors
P08798610A0843|0 3|PIP2
P08798610A0843|77 83|guanine
P08798610A0843|229 242|Dbl oncoprotein
P08798610A0843|139 142|form
P08798610A0843|109 115|Cdc42Hs
P08798610A0843|25 58|phosphatidylcholine carrier vesicles
P08798610A0843|191 197|Cdc42Hs
P08798610A0843|103 106|form
P08798610A0843|159 165|protein
P08798635A0870|86 91|effect
P08798635A0870|106 119|myristoylation
P08798635A0870|40 42|GTP
P08798635A0870|79 82|ARF6
P08798635A0870|66 69|ARF3
P08798635A0870|8 16|spleen GAP
P08798635A0870|61 64|ARF1
P08798635A0870|71 74|ARF5
P08798635A0870|28 37|hydrolysis
P08798641A0400|0 3|Biol
P08798643T0000|29 34|domain
P08798643T0000|116 121|T cells
P08798643T0000|50 67|transforming region
P08798643T0000|108 113|ZAP-70
P08798643T0000|70 72|Cbl
P08798648A1816|0 6|Cys-757
P08798648A1816|67 80|enzyme activity
P08798648A1816|40 45|domain
P08798648A1816|17 21|Fe4S4
P08798700A0134|170 187|activation sequence
P08798700A0134|134 137|part
P08798700A0134|124 128|Rox1p
P08798700A0134|61 66|oxygen
P08798700A0134|189 191|UAS
P08798700A0134|51 58|response
P08798700A0134|3 15|transcription
P08798700A0134|69 82|heme deficiency
P08798700A0134|105 114|repression
P08798700A0134|140 149|activation
P08798700A0134|97 102|relief
P08798700A0134|86 89|part
P08798762A1279|14 20|results
P08798762A1279|85 87|PKC
P08798762A1279|51 58|activity
P08798762A1279|61 71|Cut proteins
P08798782A0976|0 2|Lck
P08798782A0976|46 55|SH3 domains
P08798782A0976|40 42|SH2
P08798893A0611|41 51|lactalbumin
P08798893A0611|127 133|respect
P08798893A0611|25 32|presence
P08798893A0611|91 99|viability
P08798893A0611|12 19|freezing
P08798893A0611|67 77|maintenance
P08798893A0611|141 145|cells
P08798893A0611|108 124|CCCD heterogeneity
P08801403T0001|28 43|presentation form
P08801403T0001|54 60|myeloma
P08801403T0001|18 25|effusion
P08803710A0701|31 31|%
P08803710A0701|49 49|%
P08803710A0701|75 77|IVA
P08803710A0701|56 56|%
P08803710A0701|37 37|%
P08803710A0701|9 17|survivals
P08803710A0701|60 65|stages
P08803710A0701|81 83|IVB
P08803710A0701|43 43|%
P08803845A0665|169 176|excision
P08803845A0665|114 122|insertion
P08803845A0665|69 73|cells
P08803845A0665|49 56|clusters
P08803845A0665|125 130|lesion
P08803845A0665|146 152|attempt
P08803845A0665|108 111|line
P08803845A0665|3 10|presence
P08804012A0662|70 77|pastimes
P08804012A0662|25 27|SIP
P08804012A0662|79 92|home management
P08804012A0662|52 55|work
P08804012A0662|10 19|categories
P08804012A0662|97 101|sleep
P08804012A0662|105 108|rest
P08804012A0662|57 66|recreation
P08804389A0893|0 19|Northern blot analysis
P08804389A0893|181 188|decrease
P08804389A0893|130 137|Ltp4 mRNA
P08804389A0893|105 112|increase
P08804389A0893|163 164|pv
P08804389A0893|85 95|translucens
P08804389A0893|166 173|japonica
P08804389A0893|42 46|probe
P08804389A0893|122 127|levels
P08804389A0893|61 83|Xanthomonas campestris pv
P08805338A1061|117 120|Ogg1
P08805338A1061|23 30|OGG1 gene
P08805338A1061|8 17|disruption
P08805338A1061|149 150|OG
P08805338A1061|33 37|yeast
P08805338A1061|96 99|Ogg2
P08805338A1061|152 153|G.
P08805338A1061|53 78|OG glycosylase/lyase protein
P08805824A1155|15 17|use
P08805824A1155|158 167|scattering
P08805824A1155|40 50|combination
P08805824A1155|190 204|lens aberrations
P08805824A1155|20 28|zero-loss
P08805824A1155|171 180|microscope
P08805824A1155|55 81|exit wavefront reconstruction
P08805824A1155|215 223|technique
P08805824A1155|122 128|effects
P08806491A0542|0 10|Transcripts
P08806491A0542|57 66|TAAG motifs
P08806491A0542|108 113|hr p.i.
P08806491A0542|18 24|ODV-E18
P08806491A0542|71 81|transcripts
P08806491A0542|28 35|ODV-EC27
P08806693A0584|140 165|luciferase expression vector
P08806693A0584|190 205|mouse fibroblasts
P08806693A0584|102 110|deletions
P08806693A0584|88 94|protein
P08806693A0584|23 31|sequences
P08806693A0584|37 50|GATA-1 promoter
P08806693A0584|64 73|activation
P08806693A0584|79 82|ME26
P08806693A0584|180 187|activity
P08806693A0584|116 123|promoter
P08806693A0584|224 229|GATA-1
P08806693A0584|2 6|order
P08806817A0244|0 15|Sequence analysis
P08806817A0244|36 40|clone
P08806817A0244|56 71|DNA binding domain
P08806817A0244|78 91|orphan receptor
P08806817A0244|118 128|TR2 receptor
P08806817A0716|55 58|gene
P08806817A0716|7 22|DNA hybridization
P08806817A0716|35 40|SpSHR2
P08806817A0716|64 81|S. purpuratus genome
P08807245A0843|53 62|undercalls
P08807245A0843|5 23|retrospective review
P08807245A0843|47 47|%
P08807288T0000|0 8|Isolation
P08807288T0000|57 70|ADH2 expression
P08807288T0000|12 25|identification
P08807288T0000|28 32|genes
P08807408A0524|0 6|METHODS
P08807408A0524|64 74|tachycardia
P08807408A0524|108 121|AV modification
P08807408A0524|48 49|AV
P08807408A0524|10 16|RESULTS
P08807408A0524|133 157|radiofrequency application
P08807408A0524|100 106|pathway
P08807408A0524|30 34|woman
P08808120A0774|0 7|Patients
P08808120A0774|226 236|probability
P08808120A0774|209 216|patients
P08808120A0774|126 131|values
P08808120A0774|306 317|micrograms/L
P08808120A0774|91 102|micrograms/L
P08808120A0774|245 260|aluminum overload
P08808120A0774|15 25|probability
P08808120A0774|134 142|serum iron
P08808120A0774|69 80|micrograms/L
P08808120A0774|284 295|micrograms/L
P08808120A0774|51 65|serum iron levels
P08808120A0774|173 191|serum ferritin levels
P08808120A0774|299 301|DAI
P08808120A0774|34 49|aluminum overload
P08808120A0774|262 280|serum aluminum levels
P08808120A0774|84 86|DAI
P08808120A0774|144 168|iron transferrin saturation
P08808275A1193|120 135|yeast counterpart
P08808275A1193|104 112|phenotype
P08808275A1193|49 57|evolution
P08808275A1193|11 26|RAD23 equivalents
P08808275A1193|71 75|genes
P08808707A0631|0 8|Ha-RasV12
P08808707A0631|108 111|SAPK
P08808707A0631|128 133|kinase
P08808707A0631|115 117|Jun
P08808707A0631|183 196|gene expression
P08808707A0631|139 146|cascades
P08808707A0631|94 106|protein kinase
P08808707A0631|68 70|ERK
P08808707A0631|135 137|JNK
P08808707A0631|21 28|proteins
P08808707A0631|61 66|kinase
P08808756A0587|0 15|Sequence analysis
P08808756A0587|68 70|RNA
P08808756A0587|192 203|accumulation
P08808756A0587|141 148|products
P08808756A0587|114 121|presence
P08808756A0587|94 98|cells
P08808756A0587|176 180|bases
P08808756A0587|46 49|cDNA
P08808756A0587|215 218|mRNA
P08808924A0326|175 183|proximity
P08808924A0326|46 50|spans
P08808924A0326|66 78|amino terminus
P08808924A0326|157 160|L-61
P08808924A0326|213 219|segment
P08808924A0326|122 129|presence
P08808924A0326|97 104|residues
P08808924A0326|3 19|hydropathy profile
P08808924A0326|222 225|ProW
P08808924A0326|163 166|F-97
P08808927A0417|21 28|fragment
P08808927A0417|52 62|M. bovis PG45
P08808927A0417|40 47|vspA gene
P08808927A0417|7 13|HindIII
P08808939A0000|0 25|Carbon catabolite repression
P08808939A0000|137 160|phosphotransferase system
P08808939A0000|106 108|HPr
P08808939A0000|111 131|phosphocarrier protein
P08808939A0000|73 100|catabolite control protein CcpA
P08808939A0000|31 39|gnt operon
P08808939A0000|42 57|Bacillus subtilis
P08809680T0000|0 8|Melatonin
P08809680T0000|12 22|seasonality
P08809680T0000|34 36|gap
P08810040A0955|86 96|replacement
P08810040A0955|23 26|loss
P08810040A0955|11 16|screen
P08810040A0955|105 113|frequency
P08810040A0955|52 68|target locus marker
P08810040A0955|117 117|%
P08810278A0682|115 122|tyrosine
P08810278A0682|51 57|BCR/ABL
P08810278A0682|216 226|ALL patients
P08810278A0682|99 101|CAS
P08810278A0682|247 254|controls
P08810278A0682|68 81|CRKL-SH2 domain
P08810278A0682|160 185|BCR/ABL expressing cell lines
P08810278A0682|210 212|CML
P08810278A0682|154 157|CRKL
P08810278A0682|236 242|samples
P08810278A0682|89 91|CAS
P08810278A0682|191 197|samples
P08810278A0682|36 42|protein
P08810278A0682|94 97|p130
P08810278A0682|84 87|p130
P08810323A0735|61 67|regions
P08810323A0735|12 30|polyglutamine motifs
P08812012T0000|3 9|effects
P08812012T0000|22 31|variations
P08812012T0000|45 57|Stroop effects
P08812020A0597|60 65|boards
P08812020A0597|8 17|experiment
P08812020A0597|139 144|pieces
P08812020A0597|52 57|number
P08812020A0597|20 30|Chessmaster
P08812020A0597|104 111|accuracy
P08812020A0597|96 96|%
P08812106T0000|0 7|PCNA mRNA
P08812106T0000|34 44|crescent RNA
P08812106T0000|14 16|UTR
P08812106T0000|76 82|embryos
P08812106T0000|69 72|eggs
P08812490A0000|94 110|kidney cDNA library
P08812490A0000|50 57|homology
P08812490A0000|25 28|hKID
P08812490A0000|63 72|aquaporins
P08812490A0000|7 15|cDNA clone
P08812490A0000|30 44|gene symbol AQP2L
P08812490A0542|0 23|PCR/Southern blot analysis
P08812490A0542|114 117|mRNA
P08812490A0542|163 166|exon
P08812490A0542|90 99|expression
P08812490A0542|64 67|hKID
P08812490A0542|31 40|kidney cDNA
P08812490A0542|168 176|deletions
P08812490A0542|126 136|transcripts
P08812490A0542|46 52|primers
P08812490A0542|148 151|exon
P08812490A0542|74 81|sequence
P08812490A1509|71 74|loci
P08812490A1509|102 121|MIP family gene cluster
P08812490A1509|77 80|hKID
P08812490A1509|89 93|AQP-2
P08812490A1509|38 46|structure
P08812490A1509|82 84|MIP
P08812490A1509|124 143|chromosome locus 12q13
P08812490A1509|7 22|sequence homology
P08813766A0605|164 173|yeast Mig1p
P08813766A0605|152 159|homology
P08813766A0605|96 112|consensus sequence
P08813766A0605|177 181|Cre-A
P08813766A0605|21 30|transcript
P08813766A0605|49 55|protein
P08813766A0605|198 207|Emericella
P08813766A0605|186 196|Aspergillus
P08813766A0605|36 37|kb
P08813766A0605|86 90|match
P08813766A0605|61 68|residues
P08813766A0605|8 10|ORF
P08813766A0605|116 135|C2H2 zinc finger domain
P08813900A1088|131 141|P deficiency
P08813900A1088|6 12|phytase
P08813900A1088|181 186|tibias
P08813900A1088|167 175|structure
P08813900A1088|96 104|bone cells
P08813900A1088|54 67|mineralization
P08813900A1088|122 128|effects
P08813900A1088|84 92|cartilage
P08813900A1088|71 81|arrangement
P08813900A1088|29 39|orderliness
P08813900A1088|16 17|nP
P08813900A1088|42 52|development
P08814651A0000|116 121|tremor
P08814651A0000|104 114|rating scale
P08814651A0000|141 149|paradigms
P08814651A0000|56 77|ethanol withdrawal signs
P08814651A0000|35 42|presence
P08814651A0000|23 29|factors
P08814651A0000|3 12|importance
P08814651A0000|83 85|rat
P08814651A0000|46 53|severity
P08816052A0238|147 152|K-SNAP
P08816052A0238|68 75|validity
P08816052A0238|16 22|brevity
P08816052A0238|97 145|Kaufman Short Neuropsychological Assessment Procedure
P08816052A0238|85 90|K-FAST
P08816052A0238|0 3|Data
P08816052A0238|41 44|form
P08816052A0238|28 35|WISC-III
P08816438A0316|132 145|DNA replication
P08816438A0316|12 19|analysis
P08816438A0316|114 119|defect
P08816438A0316|63 70|plasmids
P08816438A0316|40 54|cdc28-1N strains
P08816438A0316|83 100|replication origins
P08816438A0316|22 37|plasmid loss rates
P08816438A0316|164 183|plasmid loss phenotype
P08816443A1674|157 168|kinase domain
P08816443A1674|21 28|ROK alpha
P08816443A1674|205 216|stress fibers
P08816443A1674|89 89|N
P08816443A1674|50 63|reorganization
P08816443A1674|225 241|adhesion complexes
P08816443A1674|194 202|formation
P08816443A1674|93 100|C termini
P08816443A1674|174 181|activity
P08816443A1674|69 80|cytoskeleton
P08816443A1674|128 137|regulators
P08816452A0936|99 108|regulation
P08816452A0936|76 82|protein
P08816452A0936|5 12|findings
P08816452A0936|162 167|manner
P08816452A0936|51 53|p54
P08816452A0936|122 129|splicing
P08816452A0936|31 48|tissue distribution
P08816452A0936|133 138|tissue
P08816453A0000|29 34|levels
P08816453A0000|60 67|activity
P08816453A0000|24 27|cAMP
P08816453A0000|73 83|Raf-1 kinase
P08816453A0000|3 11|elevation
P08816453A0000|20 22|AMP
P08816453A0000|40 43|cell
P08816459A0090|100 121|thyroid hormone receptor
P08816459A0090|26 41|repression domain
P08816459A0090|77 81|N-CoR
P08816459A0090|123 124|TR
P08816459A0090|137 148|acid receptor
P08816459A0090|47 66|orphan receptor RevErb
P08816459A0090|2 18|interaction screen
P08816459A0090|150 152|RAR
P08816459A0090|86 96|corepressor
P08816460A1769|122 126|Erk-2
P08816460A1769|103 110|presence
P08816460A1769|77 93|Ras transformation
P08816460A1769|36 54|Jun kinase activation
P08816460A1769|24 33|inhibition
P08816460A1769|5 11|results
P08816461A0892|3 10|analysis
P08816461A0892|104 122|nonsense suppression
P08816461A0892|89 100|mRNA turnover
P08816461A0892|66 75|activities
P08816461A0892|23 27|Upf1p
P08816461A0892|46 52|protein
P08816472T0000|43 46|Byr2
P08816472T0000|32 40|regulator
P08816472T0000|58 72|response pathway
P08816472T0000|16 19|Ste4
P08816472T0000|0 13|Identification
P08816482A0234|42 47|Stat5b
P08816482A0234|69 73|genes
P08816482A0234|33 38|Stat5a
P08816482A0234|17 24|variants
P08816482A0234|27 31|Stat5
P08816483A0869|0 8|Mutations
P08816483A0869|26 29|SWI5
P08816483A0869|21 24|SIC1
P08816483A0869|34 37|RIC3
P08816483A0869|16 19|loci
P08816498A0000|58 82|signal transduction cascade
P08816498A0000|51 54|Rats
P08816498A0000|106 112|stimuli
P08816498A0000|3 29|serine/threonine kinase Raf-1
P08816498A0000|139 145|nucleus
P08816498A0000|120 133|plasma membrane
P08816504T0000|16 21|growth
P08816504T0000|129 136|proteins
P08816504T0000|38 47|activation
P08816504T0000|91 105|receptor binding
P08816504T0000|50 77|phosphatidylinositol 3-kinase
P08816504T0000|151 161|Ras activity
P08816507A1125|43 50|activity
P08816507A1125|11 28|cotransfections E1A
P08816507A1125|123 130|activity
P08816507A1125|135 137|YY1
P08816507A1125|111 116|13S E1A
P08816507A1125|56 66|p53 promoter
P08816507A1125|190 198|induction
P08816507A1125|74 78|level
P08816507A1125|157 163|element
P08816507A1125|80 85|12S E1A
P08816507A1125|183 183|%
P08816759A0000|117 125|subfamily
P08816759A0000|86 88|RAR
P08816759A0000|36 49|orphan receptor
P08816759A0000|25 31|RZR beta
P08816759A0000|91 112|thyroid hormone receptor
P08816759A0000|73 84|acid receptor
P08816759A0000|114 115|TR
P08816759A0000|54 59|member
P08816759A0000|135 143|receptors
P08816759A0000|3 23|retinoid Z receptor beta
P08816792A0000|87 93|subunit
P08816792A0000|66 67|Ku
P08816792A0000|27 32|DNA-PK
P08816792A0000|95 102|DNA-PKcs
P08816792A0000|13 25|protein kinase
P08816792A0000|58 64|protein
P08817323A0714|85 96|sequence tags
P08817323A0714|147 150|EST.
P08817323A0714|58 69|DXS6673E gene
P08817323A0714|118 120|end
P08817323A0714|50 52|end
P08817323A0714|14 29|sequence identity
P08817323A0714|98 101|ESTs
P08817323A0714|126 137|DXS6673E gene
P08817324A1070|0 9|Sequencing
P08817324A1070|23 48|Xq28 duplication breakpoints
P08817324A1070|63 70|presence
P08817324A1070|15 17|16p
P08817324A1070|135 152|paralogy boundaries
P08817324A1070|102 123|CAGGG pentamer sequences
P08818436A0557|103 108|gender
P08818436A0557|65 71|history
P08818436A0557|23 30|analysis
P08818436A0557|142 146|death
P08818436A0557|42 44|age
P08818436A0557|46 51|gender
P08818436A0557|88 95|diseases
P08818718A1229|156 161|organs
P08818718A1229|130 136|GC cDNAs
P08818718A1229|113 120|delivery
P08818718A1229|108 111|mice
P08818718A1229|36 44|injection
P08818718A1229|86 94|liposomes
P08818718A1229|123 126|MDR1
P08818718A1229|61 66|vector
P08820324A1699|27 29|DBS
P08820324A1699|33 44|TOF responses
P08820324A1699|11 19|agreement
P08820324A1699|3 8|limits
P08820642A0173|173 180|bacteria
P08820642A0173|39 44|operon
P08820642A0173|240 246|tobacco
P08820642A0173|113 119|cluster
P08820642A0173|122 129|hrp genes
P08820642A0173|139 150|cosmid pHIR11
P08820642A0173|60 88|Hrp secretion pathway components
P08820642A0173|18 25|hrpZ gene
P08820642A0173|94 97|part
P08820642A0173|236 237|HR
P08820648A0123|102 107|growth
P08820648A0123|10 17|presence
P08820648A0123|113 116|cell
P08820648A0123|186 191|oxygen
P08820648A0123|139 145|mutants
P08820648A0123|152 158|species
P08820648A0123|33 55|ribonucleotide reductase
P08820648A0123|73 78|enzyme
P08820648A0123|176 183|presence
P08822208A1364|14 20|results
P08822208A1364|103 112|regulation
P08822208A1364|85 95|differences
P08822208A1364|63 71|responses
P08822208A1364|42 49|isoforms
P08822399A0518|29 37|attitudes
P08822399A0518|12 18|factors
P08822399A0518|86 92|factors
P08822399A0518|64 72|pregnancy
P08822399A0518|48 61|susceptibility
P08823163T0000|132 135|role
P08823163T0000|66 71|cobalt
P08823163T0000|149 162|co-corepressor
P08823163T0000|138 146|phosphate
P08823163T0000|106 111|domain
P08823163T0000|75 83|manganese
P08823163T0000|29 52|diphtheria toxin repressor
P08823163T0000|15 23|structure
P08823187A1020|0 8|Titration
P08823187A1020|22 36|porcine proteins
P08823187A1020|134 147|disulfide bonds
P08823187A1020|81 99|membrane dipeptidase
P08823260A1161|0 3|FEV1
P08823260A1161|87 94|patients
P08823260A1161|29 36|patients
P08823260A1161|125 133|infection
P08823260A1161|58 61|GVHD
P08823646A1012|0 13|Administration
P08823646A1012|74 85|measurements
P08823646A1012|61 64|SaO2
P08823646A1012|16 25|adrenaline
P08823646A1012|42 55|overestimation
P08823709A0220|0 6|Therapy
P08823709A0220|80 87|symptoms
P08823709A0220|68 77|resolution
P08823709A0220|91 97|parotid
P08823709A0220|18 29|modification
P08823709A0220|111 117|patient
P08823709A0220|33 57|triglyceride lowering drugs
P08824201A0270|0 7|Chernoff
P08824201A0270|21 31|publication
P08824585A0260|118 122|cells
P08824585A0260|51 66|progenitor kinase
P08824585A0260|18 30|protein kinase
P08824585A0260|138 152|progenitor cells
P08824585A0260|69 72|HPK1
P08824798A0761|27 36|LIM domains
P08824798A0761|75 82|residues
P08824798A0761|113 115|CRP
P08824798A0761|5 20|ESP1/CRP2 protein
P08824798A0761|105 111|protein
P08824798A0761|65 65|%
P08824798A0761|45 50|shares
P08824798A0761|120 126|rat CRIP
P08824798A0761|55 55|%
P08824800A0808|42 66|agarose gel electrophoresis
P08824800A0808|3 11|fragments
P08824805A0832|41 50|boundaries
P08824805A0832|63 69|domains
P08824805A0832|12 25|exon boundaries
P08824805A0832|75 84|p55 protein
P08824881A0133|0 13|Linkage studies
P08824881A0133|63 76|chromosome 9q34
P08824881A0133|48 54|TSC gene
P08824881A0133|89 95|16p13.3
P08824881A0133|23 40|locus heterogeneity
P08824884A0000|29 34|folate
P08824884A0000|117 127|X chromosome
P08824884A0000|51 54|site
P08824884A0000|103 106|Xq28
P08824884A0000|72 80|expansion
P08824884A0000|164 171|handicap
P08824884A0000|56 60|FRAXE
P08824884A0000|152 155|form
P08824884A0000|84 92|GCC repeat
P08824884A0000|14 23|expression
P08825087A0213|0 18|DNA sequence analysis
P08825087A0213|106 116|orientation
P08825087A0213|67 79|reading frames
P08825087A0213|81 84|ORFs
P08825087A0213|26 45|bp BamHI-ClaI fragment
P08825178A0071|58 59|TB
P08825178A0071|77 86|acceptance
P08825178A0071|114 119|TB care
P08825178A0071|92 104|participation
P08825178A0071|10 28|inpatient experience
P08825178A0071|32 42|individuals
P08825554A0000|16 18|TTP
P08825554A0000|25 33|prototype
P08825554A0000|37 41|group
P08825554A0000|100 114|CCCH zinc fingers
P08825554A0000|53 72|transcription factors
P08825554A0000|0 14|Tristetraprolin
P08825556A0522|74 76|CRE
P08825556A0522|78 83|CREpal
P08825556A0522|26 33|TGACCTCA
P08825556A0522|120 128|homodimer
P08825556A0522|48 57|nucleotide
P08825556A0522|113 116|CREB
P08825556A0522|85 92|TGACGTCA
P08825556A0522|4 10|element
P08825556A0522|18 24|CREsp-a
P08825633A0304|0 7|Analysis
P08825633A0304|62 69|homology
P08825633A0304|77 82|G alpha
P08825633A0304|44 51|sequence
P08825633A0304|22 24|DNA
P08825633A0304|84 87|cDNA
P08825636T0000|72 75|p105
P08825636T0000|153 160|NF-kappa
P08825636T0000|138 149|implications
P08825636T0000|22 30|structure
P08825636T0000|124 136|I kappa B-gamma
P08825636T0000|79 89|p50 proteins
P08825636T0000|47 55|gene NFKB1
P08825636T0000|92 120|transcription factors NF-kappa B
P08825636T0000|171 188|signal transduction
P08825639A0827|108 114|cap site
P08825639A0827|49 55|repeats
P08825639A0827|10 25|Alu repeat element
P08825639A0827|79 84|region
P08827783A0499|59 60|h.
P08827783A0499|33 42|monitoring
P08827783A0499|21 28|normoxia
P08827783A0499|3 6|ewes
P08828142A0000|87 96|cat species
P08828142A0000|133 144|environments
P08828142A0000|6 20|leukemia viruses
P08828142A0000|22 26|FeLVs
P08828142A0000|58 73|oncoretroviruses
P08828152A1238|0 9|Comparison
P08828152A1238|61 64|LCDV
P08828152A1238|154 172|amino acid similarity
P08828152A1238|141 151|differences
P08828152A1238|56 59|IIV6
P08828152A1238|125 132|proteins
P08828152A1238|38 53|RPO1 polypeptides
P08828152A1238|69 73|MCV-1
P08828152A1238|188 200|relationships
P08828152A1238|15 32|amino acid sequences
P08828152A1825|28 37|similarity
P08828152A1825|49 52|IIV6
P08828152A1825|43 46|RPO1
P08828152A1825|9 12|LCDV
P08828152A1825|72 81|similarity
P08828152A1825|3 6|RPO1
P08828152A1825|143 149|subunit
P08828152A1825|97 107|polymerases
P08828857A2423|158 166|pregnancy
P08828857A2423|110 116|factors
P08828857A2423|88 96|paracrine
P08828857A2423|78 86|endocrine
P08828857A2423|68 72|study
P08828857A2423|138 151|gene expression
P08828857A2423|52 57|system
P08828857A2423|3 5|use
P08828857A2423|15 21|GE cells
P08829393A0083|29 34|spikes
P08829393A0083|11 26|dipole estimation
P08829393A0083|38 50|SEP components
P08829393A0083|62 69|patients
P08831364A1252|132 135|dose
P08831364A1252|111 119|verapamil
P08831364A1252|138 146|adenosine
P08831364A1252|77 78|AV
P08831364A1252|164 165|AV
P08831364A1252|56 64|adenosine
P08831364A1252|4 12|verapamil
P08831364A1252|45 51|effects
P08831364A1252|171 175|block
P08831364A1252|84 97|conduction time
P08831364A1252|16 26|propranolol
P08832146A0959|85 87|PTH
P08832146A0959|37 59|bone alkaline phosphatase
P08832146A0959|8 10|CBD
P08832146A0959|89 89|r
P08832146A0959|61 61|r
P08832146A0959|69 69|p
P08832146A0959|97 97|p
P08833153A0628|86 92|portion
P08833153A0628|268 278|chromosomes
P08833153A0628|141 147|domains
P08833153A0628|12 21|comparison
P08833153A0628|100 104|genes
P08833153A0628|211 214|part
P08833153A0628|183 190|proteins
P08833153A0628|27 44|hCHLR gene sequences
P08833153A0628|170 175|region
P08833153A0628|238 251|repeat sequence
P08833153A0628|115 119|exons
P08833153A0628|2 9|addition
P08833153A0628|58 66|databases
P08833653A0304|58 74|rat amylin promoter
P08833653A0304|94 107|islet cell lines
P08833653A0304|17 45|LIM domain homeobox protein isl-1
P08833653A0304|81 90|fibroblast
P08833653A0783|98 108|differences
P08833653A0783|76 84|sequences
P08833653A0783|37 62|amylin gene promoter elements
P08833653A0783|139 148|properties
P08833653A0783|8 12|isl-1
P08833653A0783|209 212|InR1
P08833653A0783|214 225|G9 islet cells
P08833653A0783|183 190|promoter
P08833653A0783|27 33|insulin
P08835393A2829|73 91|calcium mobilization
P08835393A2829|19 26|pathways
P08835393A2829|126 128|SRE
P08835393A2829|96 119|promoter response elements
P08835393A2829|43 66|signal transduction events
P08835895A1292|73 76|risk
P08835895A1292|92 100|infection
P08835895A1292|18 26|remission
P08835895A1292|49 64|immunodeficiency
P08835895A1292|3 10|CD4 count
P08835969A0000|89 97|pregnancy
P08835969A0000|134 143|sonography
P08835969A0000|216 227|gonadotropin
P08835969A0000|18 28|laparoscopy
P08835969A0000|99 100|EP
P08835969A0000|189 199|beta subunit
P08835969A0000|71 79|diagnosis
P08835969A0000|229 236|beta-hCG
P08835969A0000|273 275|EPs
P08835969A0000|173 183|serum assays
P08835969A0000|103 105|use
P08835969A0000|57 65|reference
P08835969A0000|245 253|detection
P08835969A0000|147 157|conjunction
P08836032T0000|0 14|Bifunctionality
P08836032T0000|51 53|hr1
P08836032T0000|36 49|region sequence
P08836032T0000|92 111|sequence requirements
P08836032T0000|20 25|AcMNPV
P08836032T0000|67 78|ori functions
P08836032T0000|56 63|enhancer
P08836172A1382|0 2|RVR
P08836172A1382|40 54|over-expression
P08836172A1382|10 17|function
P08836172A1382|102 107|levels
P08836172A1382|19 25|studies
P08836172A1382|125 137|myogenin mRNAs
P08836172A1382|110 121|p21Cip1/Waf1
P08836172A1382|74 82|RVR delta E
P08836172A1382|4 7|loss
P08836172A1382|143 157|serum withdrawal
P08836740A1025|14 17|CES4
P08836740A1025|32 41|cell growth
P08836740A1025|7 10|CES1
P08836740A1025|53 66|deletion mutant
P08837503A0392|171 184|dicot extensins
P08837503A0392|163 168|groups
P08837503A0392|138 149|repeat motifs
P08837503A0392|121 128|proteins
P08837503A0392|94 100|SbHRGP3
P08837503A0392|8 19|repeat motifs
P08837503A0392|70 75|domain
P08837503A0392|57 63|pattern
P08837503A0392|114 118|group
P08837746A0951|68 88|postglutamate cleavage
P08837746A0951|26 38|BrAAP activity
P08837746A0951|53 63|postproline
P08837746A0951|112 122|specificity
P08837746A0951|5 7|use
P08838144A0107|102 121|S1 or/and S2 subdomains
P08838144A0107|22 33|significance
P08838144A0107|53 62|PRL binding
P08838144A0107|85 99|deletion mutants
P08838144A0107|66 83|signal transduction
P08838144A0107|41 50|subdomains
P08838148A1218|72 83|transfection
P08838148A1218|40 55|mouse TRH receptor
P08838148A1218|101 105|cells
P08838148A1218|19 26|cell line
P08838148A1218|116 131|L channel activity
P08838314A0129|146 152|mapping
P08838314A0129|35 44|regulation
P08838314A0129|22 31|expression
P08838314A0129|94 109|tissue expression
P08838314A0129|78 92|characteristics
P08838314A0129|50 53|V1aR
P08838314A0129|172 177|AVPR1A
P08838314A0129|163 170|V1aR gene
P08838314A0129|122 133|localization
P08838585A0968|71 77|ras-p21
P08838585A0968|38 54|backbone deviation
P08838585A0968|17 25|structure
P08838805T0000|29 44|beta-catenin gene
P08838805T0000|7 18|organization
P08838805T0000|46 51|CTNNB1
P08839498A0507|117 122|stages
P08839498A0507|135 146|distribution
P08839498A0507|49 58|tissue mass
P08839498A0507|64 68|trunk
P08839498A0507|31 42|distribution
P08839498A0507|149 151|fat
P08839498A0507|72 75|legs
P08839832A0729|17 28|CD30v protein
P08839832A0729|103 109|domains
P08839832A0729|56 61|region
P08839832A1220|32 43|CD30v protein
P08839832A1220|68 75|labeling
P08839832A1220|12 26|phosphorylation
P08839832A1220|81 83|32P
P08839911A0716|4 4|%
P08839911A0716|7 12|cycles
P08840501A0345|15 23|discovery
P08840501A0345|43 46|gene
P08840501A0345|78 81|ACT4
P08840501A0345|53 60|organism
P08840506A0544|41 44|ones
P08840506A0544|8 11|ORFs
P08840506A0544|75 79|G2850
P08840997A0765|0 8|MVR typing
P08840997A0765|22 28|alleles
P08840997A0765|133 139|alleles
P08840997A0765|106 116|resemblance
P08840997A0765|72 80|sequences
P08842143A0000|88 93|viciae
P08842143A0000|105 111|cluster
P08842143A0000|55 57|hup
P08842143A0000|46 53|H2 uptake
P08842143A0000|31 42|determinants
P08842143A0000|116 120|genes
P08842143A0000|85 86|bv
P08842143A0000|0 12|Plasmid pAL618
P08843411A0801|73 82|activation
P08843411A0801|20 28|receptors
P08843411A0801|3 9|classes
P08843411A0801|149 158|activation
P08843411A0801|86 97|dimerization
P08843412A0543|98 124|promoter transcription factor
P08843412A0543|179 189|interaction
P08843412A0543|153 160|identity
P08843412A0543|74 89|chicken ovalbumin
P08843412A0543|64 66|RAR
P08843412A0543|209 218|DNA binding
P08843412A0543|60 62|RXR
P08843412A0543|54 57|LBDs
P08843412A0543|68 69|TR
P08843412A0543|27 44|40-amino acid region
P08843419A1290|0 2|OKA
P08843419A1290|6 15|calyculin A
P08843419A1290|29 33|OCFRE
P08843419A1290|96 107|interactions
P08843419A1290|45 56|interactions
P08844448A0000|204 213|absorption
P08844448A0000|168 182|lipase inhibitor
P08844448A0000|142 149|orlistat
P08844448A0000|276 283|vitamins
P08844448A0000|50 63|crossover study
P08844448A0000|134 139|effect
P08844448A0000|251 257|obesity
P08844448A0000|236 248|weight control
P08844448A0000|264 273|absorption
P08844448A0000|112 116|years
P08844448A0000|288 289|E.
P08844448A0000|87 96|volunteers
P08844448A0000|119 121|age
P08844577A0000|73 80|medicine
P08844577A0000|58 60|use
P08844577A0000|18 26|macrolide
P08844577A0000|0 9|Tilmicosin
P08844712A0000|0 5|Effect
P08844712A0000|104 107|rats
P08844712A0000|21 23|N2O
P08844712A0000|52 61|C-reflexes
P08844712A0000|143 150|urethane
P08844712A0000|47 47|A
P08844712A0000|124 139|alpha-chloralose
P08844712A0000|15 19|oxide
P08845378A0368|0 23|Restriction enzyme mapping
P08845378A0368|94 97|gene
P08845378A0368|27 42|Southern analysis
P08845378A0368|71 79|MZF-1 gene
P08846775A0110|113 116|CLN2
P08846775A0110|85 92|G1 cyclin
P08846775A0110|107 110|CLN1
P08846775A0110|21 37|Swi6 cell viability
P08846775A0110|101 105|genes
P08846775A0110|14 17|Swi4
P08846775A0110|5 11|absence
P08846775A0110|70 79|expression
P08847138A0609|69 73|years
P08847138A0609|76 78|age
P08847138A0609|25 28|ages
P08847138A0609|3 16|detection ratio
P08847403T0000|26 33|patients
P08847403T0000|7 13|embryos
P08847403T0000|44 46|IVF
P08847723A2351|0 11|IMPLICATIONS
P08847723A2351|62 68|results
P08847723A2351|165 172|findings
P08847723A2351|26 29|size
P08847723A2351|36 40|study
P08847723A2351|91 97|studies
P08847723A2351|47 59|inconsistency
P08847723A2351|146 157|replications
P08847723A2351|107 112|cancer
P08847723A2351|133 144|associations
P08848013A1469|15 21|TATA box
P08848013A1469|52 55|role
P08848013A1469|24 32|promoter B
P08848013A1469|81 87|TATA box
P08848013A1469|90 99|promoter A.
P08848013A1469|58 73|promoter activity
P08848052A0733|99 106|function
P08848052A0733|109 112|Gle1
P08848052A0733|76 84|RNA export
P08848052A0733|27 30|Gle1
P08848052A0733|5 14|properties
P08848052A0733|35 50|RNA-export factor
P08848052A0733|58 60|Rev
P08849208A1022|43 49|stature
P08849208A1022|34 40|measure
P08849208A1022|0 7|Demispan
P08849569A0615|99 106|cortisol
P08849569A0615|90 96|pattern
P08849569A0615|20 36|assay coefficients
P08849569A0615|39 47|variation
P08849569A0615|3 12|techniques
P08849778A0226|69 74|duplex
P08849778A0226|91 93|RNA
P08849778A0226|36 43|repA mRNA
P08849778A0226|95 98|CopA
P08849778A0226|46 54|plasmid R1
P08849778A0226|15 33|toeprinting analyses
P08849778A0598|44 53|expression
P08849778A0598|80 90|translation
P08849778A0598|8 11|work
P08849778A0598|22 25|repA
P08849778A0598|62 64|tap
P08849778A0598|66 78|leader peptide
P08849778A0598|27 42|initiator protein
P08849834A0000|28 41|volume flow rate
P08849834A0000|85 114|colour Doppler ultrasound imaging
P08849834A0000|44 48|blood
P08849834A0000|52 57|vessel
P08849834A0000|1 6|system
P08850585A0602|74 79|caries
P08850585A0602|51 65|pathophysiology
P08850585A0602|103 118|virulence factors
P08850585A0602|38 45|elements
P08850585A0602|3 18|enzyme activities
P08851337A1092|0 12|Tonsillectomy
P08851337A1092|26 30|means
P08851337A1092|82 95|angina patients
P08851337A1092|63 71|infection
P08851337A1092|33 43|prophylaxis
P08851434A0383|70 73|mice
P08851434A0383|54 57|half
P08851434A0383|6 9|mice
P08851434A0383|14 36|fat/water intensity ratio
P08853303A0431|120 123|Tmax
P08853303A0431|54 63|literature
P08853303A0431|225 227|min
P08853303A0431|128 130|min
P08853303A0431|154 164|MMC infusion
P08853303A0431|212 219|T1/2 beta
P08853303A0431|15 24|parameters
P08853303A0431|185 190|ml/min
P08853303A0431|101 118|bolus MMC injections
P08853303A0431|98 99|IA
P08853303A0431|208 210|min
P08853303A0431|179 180|C1
P08853303A0431|38 43|values
P08853303A0431|192 193|kg
P08853303A0431|166 168|Vss
P08853303A0431|174 177|1/kg
P08853303A0431|195 203|T1/2 alpha
P08853303A0431|143 151|beginning
P08853893A0158|6 10|study
P08853893A0158|92 102|fibroblasts
P08853893A0158|36 47|E2F complexes
P08854459A0000|56 66|earthquakes
P08854459A0000|125 132|February
P08854459A0000|4 8|paper
P08854459A0000|108 116|September
P08854459A0000|35 41|pattern
P08854459A0000|44 53|casualties
P08854459A0000|16 23|overview
P08854459A0000|97 102|period
P08854844A0637|82 90|diagnosis
P08854844A0637|109 116|accuracy
P08854844A0637|48 61|h post injection
P08854844A0637|93 94|AC
P08854844A0637|43 44|GB
P08854844A0637|21 37|non-visualization
P08854844A0637|12 18|finding
P08854844A0637|128 128|%
P08854844A0637|67 75|criterion
P08855804A1528|114 119|months
P08855804A1528|66 68|men
P08855804A1528|100 104|times
P08855804A1528|89 91|SLT
P08855804A1528|5 11|results
P08855804A1528|93 94|mg
P08855804A1528|41 45|study
P08856077T0000|84 88|cells
P08856077T0000|26 56|tryptophanyl-tRNA synthetase mRNA
P08856077T0000|11 20|processing
P08856132T0000|0 7|Evidence
P08856132T0000|103 110|abortion
P08856132T0000|23 26|role
P08856132T0000|62 72|development
P08856132T0000|45 56|kinin release
P08858211A0694|28 49|3T3-L1 adipocyte lysates
P08858211A0694|102 104|GTP
P08858211A0694|125 133|alpha-32P
P08858211A0694|112 119|GST-Rab4
P08858211A0694|76 85|hydrolysis
P08858211A0694|135 137|GDP
P08858211A0694|92 100|alpha-32P
P08858211A0694|4 14|GAP activity
P08858268A1307|0 9|CONCLUSION
P08858268A1307|131 138|patients
P08858268A1307|118 128|improvement
P08858268A1307|143 145|CHF
P08858268A1307|24 32|treatment
P08858268A1307|63 72|cilazapril
P08858268A1307|49 56|response
P08858268A1307|188 194|effects
P08858268A1307|148 150|CLZ
P08858463A0853|184 197|nephrotoxicity
P08858463A0853|33 46|cryptococcosis
P08858463A0853|48 56|tolerance
P08858463A0853|91 96|dosage
P08858463A0853|131 135|mg/kg
P08858463A0853|178 181|rate
P08858463A0853|110 114|mg/kg
P08858463A0853|141 146|dosage
P08858463A0853|17 28|AIDS patients
P08858463A0853|59 65|ILd-AmB
P08861955A0927|129 139|Rab proteins
P08861955A0927|44 57|amino-terminus
P08861955A0927|110 116|members
P08861955A0927|188 193|R-Ras2
P08861955A0927|27 31|motif
P08861955A0927|183 185|Ran
P08861955A0927|195 198|TC21
P08861955A0927|159 176|GTP binding proteins
P08861955A0927|60 63|p619
P08861955A0927|74 98|guanine nucleotide exchange
P08861955A0927|101 104|ARF1
P08861963A0375b|131 145|rrnBP1 UP element
P08861963A0375b|92 114|transcription activation
P08861963A0375b|117 124|cAMP-CRP
P08861963A0375b|16 29|RNA polymerases
P08861963A0375b|82 89|response
P08861963A0375b|43 61|mutant alpha subunits
P08861963T0000|0 36|Transcription factor recognition surface
P08861963T0000|79 85|contact
P08861963T0000|93 110|DNA enhancer element
P08861963T0000|42 66|RNA polymerase alpha subunit
P08862522A0690|18 27|similarity
P08862522A0690|92 102|temperature
P08862522A0690|66 75|precursors
P08862522A0690|32 39|cdc28-P8
P08862743A0603|28 30|age
P08862743A0603|11 23|erythrocyte Mn
P08862743A0603|59 59|p
P08862743A0603|43 48|nmol/L
P08862743A0603|1 8|decrease
P08863824A0509|0 6|Cloning
P08863824A0509|113 116|loop
P08863824A0509|68 73|region
P08863824A0509|153 160|5-HT2C-R
P08863824A0509|10 25|sequence analyses
P08863824A0509|41 44|cDNA
P08863824A0509|55 62|deletion
P08863824A0509|129 147|transmembrane domain
P08864061A0000|0 9|Expression
P08864061A0000|12 30|thymidine kinase gene
P08864061A0000|51 55|cells
P08864061A0000|62 70|cell cycle
P08864219A0178|42 53|ketoconazole
P08864219A0178|66 77|itraconazole
P08864219A0178|94 106|amphotericin B
P08864219A0178|20 33|concentrations
P08864219A0178|79 89|fluconazole
P08864219A0178|55 64|miconazole
P08864219A0178|139 150|inoculum size
P08864219A0178|35 38|MICs
P08864219A0178|167 176|techniques
P08866485A0125|143 147|cells
P08866485A0125|129 137|functions
P08866485A0125|23 36|export proteins
P08866485A0125|107 111|order
P08866485A0125|54 65|interactions
P08866485A0125|96 104|molecules
P08866485A0125|82 85|cell
P08866485A0125|5 12|bacteria
P08867519A0557|72 85|administration
P08867519A0557|104 110|periods
P08867519A0557|3 12|elevations
P08867519A0557|23 26|LDEE
P08867519A0557|32 35|s.c.
P08868473A1287|128 136|cell cycle
P08868473A1287|62 70|cleavages
P08868473A1287|13 15|p28
P08868473A1287|35 38|role
P08868473A1287|122 125|type
P08868473A1287|92 102|development
P08868660A0087|116 123|research
P08868660A0087|75 84|Infermiere
P08868660A0087|40 44|arena
P08868660A0087|15 26|contribution
P08868660A0087|212 222|instruments
P08868660A0087|48 57|discussion
P08868660A0087|228 237|discussion
P08868660A0087|180 200|hypothesis formulation
P08868660A0087|155 161|novelty
P08868660A0087|63 73|Rivista dell
P08868660A0087|240 246|results
P08868660A0087|165 174|weaknesses
P08868660A0087|202 208|methods
P08868660A0087|7 9|aim
P08868660A0087|143 151|strengths
P08868954A0648|27 33|effects
P08868954A0648|173 184|hemodynamics
P08868954A0648|144 159|enzyme inhibitors
P08868954A0648|52 56|drugs
P08868954A0648|99 116|calcium antagonists
P08868954A0648|123 133|angiotensin
P08868954A0648|88 93|agents
P08869358A0121|87 91|cells
P08869358A0121|62 70|apoptosis
P08869358A0121|109 114|T cells
P08869358A0121|9 15|viruses
P08869358A0121|40 49|strategies
P08869763A0378|57 64|morphine
P08869763A0378|47 54|response
P08869763A0378|81 91|differences
P08869763A0378|107 117|sensitivity
P08869763A0378|36 44|phenomena
P08869763A0378|148 155|migraine
P08869763A0378|94 103|expression
P08869763A0378|130 145|receptor subtypes
P08869825A0000|100 105|manner
P08869825A0000|51 64|monooxygenases
P08869825A0000|66 68|FMO
P08869825A0000|8 14|studies
P08870266A0651|149 167|secretion efficiency
P08870266A0651|108 113|region
P08870266A0651|128 133|domain
P08870266A0651|58 67|amino acids
P08870266A0651|19 30|observations
P08870266A0651|84 96|NodO secretion
P08871542A1352|43 52|mechanisms
P08871542A1352|66 73|evidence
P08871542A1352|90 92|Mtx
P08871542A1352|100 107|promoter
P08871542A1352|15 23|potential
P08871542A1352|134 152|Thbs3 gene expression
P08871567A0000|0 11|MSSP proteins
P08871567A0000|65 69|c-myc
P08871567A0000|37 43|binding
P08871567A0000|56 62|element
P08871567A0629|0 3|Gene
P08871635A0000|0 19|B cell antigen receptor
P08871635A0000|21 23|BCR
P08871635A0000|33 41|apoptosis
P08871635A0000|96 99|CD40
P08871635A0000|47 71|WEHI-231 B lymphoma cell line
P08872162A0884|4 10|alleles
P08872162A0884|67 78|T cell subsets
P08872162A0884|63 65|CD8
P08872162A0884|58 60|CD4
P08872671A0573|3 7|model
P08872671A0573|75 80|oxygen
P08872671A0573|24 45|blood flow shunt fraction
P08872671A0573|165 169|blood
P08872671A0573|90 111|amplitude perturbations
P08872671A0573|136 138|air
P08872671A0573|47 51|Qs/QT
P08872671A0573|186 194|equations
P08873063A0493|29 34|LvUSF2
P08873063A0493|54 59|LvUSF1
P08873063A0493|10 26|amino acid sequence
P08873063A0493|71 78|amino end
P08873063A0875|0 12|ECM disruption
P08873063A0875|53 76|USF RNA accumulation levels
P08873063A0875|47 50|drop
P08873063A0875|160 160|%
P08873063A0875|94 94|%
P08873063A0875|15 31|Lytechinus embryos
P08873063A0875|97 110|control embryos
P08873063A0875|117 141|LpS1 RNA accumulation levels
P08873159A0791|26 30|group
P08873159A0791|51 62|chemotherapy
P08873159A0791|16 23|patients
P08874399A0277|131 132|B.
P08874399A0277|110 111|Ca
P08874399A0277|91 93|Ca2
P08874399A0277|5 8|days
P08874399A0277|113 113|o
P08874399A0277|95 107|concentration
P08874399A0277|121 126|groups
P08874399A0277|46 53|tensions
P08874399A0277|17 28|intervention
P08874631A1133|0 13|Discrimination
P08874631A1133|40 47|evidence
P08874631A1133|64 68|HIV-1
P08874631A1133|21 25|HIV-1
P08874631A1133|54 61|presence
P08874631A1133|29 33|HIV-2
P08876167A0322|30 36|subunit
P08876167A0322|40 45|HiNF-D
P08876167A0717|142 149|promoter
P08876167A0717|89 91|pRB
P08876167A0717|98 101|p107
P08876167A0717|18 24|complex
P08876167A0717|151 159|gp91-phox
P08876167A0717|79 85|CDP/cut
P08876167A0717|181 194|p107 antibodies
P08876167A0717|120 126|complex
P08876167A0717|10 16|CDP/cut
P08876167A0717|62 71|antibodies
P08876167A0717|3 8|HiNF-D
P08876167A0717|32 41|H4 promoter
P08876167A0717|175 177|CDP
P08876701A0177|39 42|DinB
P08876701A0177|26 37|UmuC-homolog
P08877103A0081|117 123|J7.V2-1
P08877103A0081|22 35|mdr2 expression
P08877103A0081|10 19|regulation
P08877103A0081|53 60|mdr2 gene
P08877103A0081|108 115|cell line
P08877103A0081|40 47|promoter
P08877818A0184|59 79|TRH progenitor sequence
P08877818A0184|81 95|Lys/Arg-Arg-Gln
P08877818A0184|35 41|primers
P08877818A0184|97 111|His-Pro-Gly-Lys
P08877818A0184|113 119|Arg-Arg
P08877818A0184|3 15|amplification
P08878019A0357|131 134|case
P08878019A0357|40 48|sinusoids
P08878019A0357|24 28|cells
P08878019A0357|54 63|lymph nodes
P08878019A0357|120 124|tumor
P08878037A0000|3 10|gene ccpA
P08878037A0000|22 49|catabolite control protein CcpA
P08878044A1390|117 122|Caco-2
P08878044A1390|126 134|J774 cells
P08878044A1390|109 114|mutant
P08878044A1390|66 75|mouse model
P08878044A1390|93 103|replication
P08878044A1390|32 40|virulence
P08878044A1390|178 183|strain
P08878044A1390|2 19|InlC deletion mutant
P08878045A0606|96 100|group
P08878045A0606|147 159|transcription
P08878045A0606|77 89|RNA polymerase
P08878045A0606|135 144|initiation
P08878045A0606|63 74|alpha subunit
P08878045A0606|8 19|N-Nus complex
P08878045A0606|40 47|contacts
P08878045A0606|55 57|CTD
P08878045A0606|113 120|proteins
P08878573A1370|85 96|prolongation
P08878573A1370|147 150|RIFA
P08878573A1370|126 129|mice
P08878573A1370|51 53|ATO
P08878573A1370|25 33|mg/kg/day
P08878573A1370|59 67|mg/kg/day
P08878573A1370|16 19|RIFA
P08878573A1370|36 46|combination
P08878573A1370|99 106|survival
P08878573A1370|142 144|ATO
P08878573A1370|0 13|Administration
P08879080A0265|68 79|path analysis
P08879080A0265|62 65|data
P08879080A0265|10 14|ACOAs
P08879080A0265|84 92|LISREL VII
P08879080A0265|52 56|model
P08879080A0265|44 46|fit
P08879080A0265|27 31|order
P08879237A0744|114 114|R
P08879237A0744|120 120|G
P08879237A0744|10 24|initiation sites
P08879237A0744|62 83|consensus promoter motif
P08879237A0744|39 46|sequence
P08879237A0744|127 143|rice mitochondrion
P08879237A0744|99 107|CRTA motif
P08880405A1170|0 8|Selection
P08880405A1170|68 70|age
P08880405A1170|49 57|selection
P08880405A1170|73 79|puberty
P08880405A1170|82 90|daughters
P08880405A1170|14 18|SC EPD
P08881036A0351|18 26|VL element
P08881036A0351|13 15|PCR
P08881036A0351|39 41|CL2
P08881542T0000|0 34|Sodium polystyrene sulfonate treatment
P08881542T0000|63 90|serum potassium concentrations
P08881542T0000|54 60|effects
P08881542T0000|38 52|lithium toxicity
P08882492A0000|189 197|organisms
P08882492A0000|12 30|homeodomain proteins
P08882492A0000|173 176|axis
P08882492A0000|40 47|Hox genes
P08882492A0000|63 66|role
P08882492A0000|110 115|queues
P08882492A0000|78 88|development
P08882492A0000|140 149|identities
P08882710A0000|118 121|beta
P08882710A0000|49 67|transcription factor
P08882710A0000|128 131|IFNs
P08882710A0000|90 94|cells
P08882710A0000|32 36|ISGF3
P08882710A0000|20 29|gene factor
P08882710A0000|79 87|treatment
P08882710A0000|99 114|interferon-alpha
P08882710A0000|123 126|type
P08882710A0000|0 9|Interferon
P08884273A1413|87 93|studies
P08884273A1413|128 132|means
P08884273A1413|154 167|map integration
P08884273A1413|116 123|function
P08884273A1413|70 77|resource
P08884273A1413|96 112|telomere structure
P08884273A1413|37 49|polymorphisms
P08884273A1413|3 17|TYAC/P1 resource
P08884273A1413|171 177|closure
P08884273A1413|29 32|STSs
P08884757A0653|237 239|BGP
P08884757A0653|152 155|help
P08884757A0653|54 63|Impression
P08884757A0653|127 131|scale
P08884757A0653|78 82|score
P08884757A0653|102 120|Assessment Geriatric
P08884757A0653|88 93|Sandoz
P08884757A0653|65 67|CGI
P08884757A0653|309 311|SKT
P08884757A0653|276 290|Performance Test
P08884757A0653|162 166|nurse
P08884757A0653|252 256|score
P08884757A0653|186 193|patients
P08884757A0653|195 235|Beurteilungsskala fur geriatrische Patienten
P08884757A0653|169 174|rating
P08884757A0653|12 21|statistics
P08884757A0653|30 33|item
P08884757A0653|122 125|SCAG
P08884757A0653|292 307|Syndrom-Kurztest
P08885270A0428|41 46|strain
P08885270A0428|48 51|PAO1
P08885270A0428|5 11|mutants
P08886845A1274|184 192|myoblasts
P08886845A1274|45 52|presence
P08886845A1274|121 128|myotubes
P08886845A1274|101 118|expression activity
P08886845A1274|28 43|myogenin promoter
P08886845A1274|68 73|copies
P08886845A1274|83 89|vectors
P08887643A1167|58 61|TC21
P08887643A1167|40 49|activation
P08887643A1167|52 54|Ras
P08887643A1167|28 34|signals
P08887643A1167|75 96|TC21 controls cell growth
P08887643A1167|133 149|signaling pathways
P08887647T0000|0 15|Fission yeast mal2
P08887647T0000|30 50|chromosome segregation
P08887652A0341|118 124|segment
P08887652A0341|180 208|hygromycin B phosphotransferase
P08887652A0341|92 97|region
P08887652A0341|232 234|hph
P08887652A0341|140 151|reading frame
P08887652A0341|159 163|frame
P08887652A0341|19 28|expression
P08887652A0341|224 228|con10
P08887652A0341|0 8|Selection
P08887652A0341|219 222|gene
P08887652A0341|43 53|DNA fragment
P08887659A0753|43 51|threonine
P08887659A0753|25 29|sites
P08887659A0753|31 36|serine
P08887659A0753|70 75|effect
P08887659A0753|0 8|Mutations
P08887661A0138|0 4|IRF-1
P08887661A0138|27 35|activator
P08887661A0138|54 62|repressor
P08887661A0138|42 46|IRF-2
P08887661A1061|2 9|contrast
P08887661A1061|140 145|manner
P08887661A1061|35 39|IRF-1
P08887661A1061|11 24|cotransfection
P08887661A1061|27 31|TFIIB
P08887661A1061|80 89|repression
P08887661A1061|92 109|promoter activation
P08887661A1061|44 54|NIH 3T3 cells
P08887667A0992|16 38|Tyr-19 dephosphorylation
P08887667A0992|179 191|SPB separation
P08887667A0992|76 85|conditions
P08887667A0992|149 159|involvement
P08887667A0992|124 130|mitosis
P08887667A0992|93 108|spindle formation
P08887667A0992|3 13|requirement
P08887667A0992|162 176|Cdc28/Clb kinase
P08887667A0992|42 56|spindle assembly
P08887674A0630|100 107|elements
P08887674A0630|14 37|DMP1 recognition sequences
P08887674A0630|49 68|GGA trinucleotide core
P08887674A0630|1 6|subset
P08887674A0920|55 61|kinases
P08887674A0920|38 43|cyclin
P08887674A0920|95 102|activity
P08887674A0920|6 13|settings
P08887674A0920|136 145|mechanisms
P08887678A0000|0 9|Expression
P08887678A0000|27 36|protein Bax
P08887678A0000|55 67|GAL10 promoter
P08887678A0000|45 51|control
P08887678A0000|122 130|cell death
P08890537A0355|28 35|patients
P08890537A0355|51 58|bone cyst
P08890537A0355|4 12|technique
P08891131A0000|0 25|Enterococcus faecium strains
P08891131A0000|43 64|glycopeptide resistance
P08891131A0000|136 142|species
P08891131A0000|165 165|%
P08891131A0000|186 186|%
P08891131A0000|79 95|enrichment culture
P08891131A0000|159 162|dogs
P08891131A0000|200 203|pigs
P08891131A0000|116 120|feces
P08891131A0000|103 112|intestines
P08891131A0000|176 183|chickens
P08891131A0000|150 155|horses
P08891131A0000|206 206|%
P08891337A0614|162 175|binding protein
P08891337A0614|117 120|p300
P08891337A0614|157 159|CRE
P08891337A0614|25 27|E1A
P08891337A0614|53 66|weight proteins
P08891337A0614|137 155|cAMP response element
P08891337A0614|96 114|coactivator function
P08891337A0614|17 22|region
P08891341A0724|146 147|bp
P08891341A0724|114 121|sequence
P08891341A0724|90 98|sequences
P08891341A0724|166 175|expression
P08891341A0724|208 216|cell lines
P08891341A0724|9 26|transfection assays
P08891341A0724|129 139|between-247
P08891341A0724|32 53|reporter gene constructs
P08891341A0724|181 192|reporter gene
P08891341A0724|71 77|lengths
P08891345A0684|75 85|translation
P08891345A0684|112 122|transcripts
P08891345A0684|194 198|uORFs
P08891345A0684|151 165|beta-globin mRNA
P08891345A0684|49 57|c-mos mRNA
P08891345A0684|99 109|translation
P08891345A0684|137 139|UTR
P08891345A0684|15 31|UTR characteristic
P08891346A1217|144 148|FGF8e
P08891346A1217|38 54|isoform expression
P08891346A1217|123 126|cDNA
P08891346A1217|22 27|effect
P08891346A1217|130 134|FGF8a
P08891346A1217|136 140|FGF8b
P08891346A1217|97 112|expression vector
P08891346A1217|56 66|NIH3T3 cells
P08891474A0667|143 151|threshold
P08891474A0667|69 91|depolarization threshold
P08891474A0667|48 57|motoneuron
P08891474A0667|154 167|depolarization
P08891474A0667|5 12|findings
P08891474A0667|121 131|nerve fibers
P08891474A0667|27 32|F-wave
P08892755A0186|100 106|domains
P08892755A0186|89 94|kinase
P08892755A0186|11 18|carp JAK1
P08892755A0186|82 84|JH2
P08892755A0186|57 60|JAK1
P08892755A0186|123 131|% identity
P08892755A0186|96 98|JH1
P08892755A0186|30 45|sequence homology
P08892755A0186|2 9|addition
P08892755A0981|74 76|CAT
P08892755A0981|139 147|synthesis
P08892755A0981|78 89|reporter gene
P08892755A0981|109 122|carp CF cell line
P08892755A0981|8 18|DNA fragment
P08892755A0981|161 165|times
P08892755A0981|200 209|pCAT-Basic
P08892755A0981|150 158|CAT enzyme
P08892755A0981|41 72|chloramphenicol acetyltransferase
P08892757T0000|28 33|member
P08892757T0000|63 80|mouse embryogenesis
P08892757T0000|9 15|cloning
P08892757T0000|112 129|repression activity
P08892757T0000|39 47|Ets family
P08892757T0000|18 22|Elk-3
P08892757T0000|84 91|analysis
P08892859A0563|142 152|c-myb allele
P08892859A0563|52 59|cell line
P08892859A0563|111 116|result
P08892859A0563|10 16|example
P08892859A0563|78 83|levels
P08892859A0563|96 107|C-MYB protein
P08892859A0563|119 132|RAV integration
P08892859A0563|61 62|T9
P08893779A0229|89 95|failure
P08893779A0229|105 110|energy
P08893779A0229|129 129|p
P08893779A0229|156 156|p
P08893779A0229|245 253|interface
P08893779A0229|21 52|digitorum longus muscle tendon units
P08893779A0229|97 97|p
P08893779A0229|83 86|load
P08893779A0229|148 154|failure
P08893779A0229|203 210|location
P08893779A0229|212 212|p
P08893779A0229|74 79|values
P08893779A0229|301 308|junction
P08893779A0229|140 145|strain
P08893779A0229|319 323|units
P08893779A0229|121 127|failure
P08893822A0560|0 15|Northern analysis
P08893822A0560|105 111|tissues
P08893822A0560|60 69|transcript
P08893822A0560|27 35|PWP2H cDNA
P08894144A0330|89 102|CsA vehicle p.o.
P08894144A0330|107 117|FB vehicle sc
P08894144A0330|202 206|mg/kg
P08894144A0330|222 226|mg/kg
P08894144A0330|175 176|FB
P08894144A0330|208 211|p.o.
P08894144A0330|216 217|FB
P08894144A0330|157 170|CsA vehicle p.o.
P08894144A0330|181 185|mg/kg
P08894144A0330|134 137|p.o.
P08894144A0330|81 84|days
P08894144A0330|122 124|CsA
P08894144A0330|43 46|rats
P08894144A0330|187 188|sc
P08894144A0330|128 132|mg/kg
P08894144A0330|196 198|CsA
P08894144A0330|228 229|sc
P08894144A0330|142 152|FB vehicle sc
P08894144A1173|0 2|CsA
P08894144A1173|26 37|bone turnover
P08894826A0228|0 10|Individuals
P08894826A0228|215 219|study
P08894826A0228|161 169|infection
P08894826A0228|135 140|herpes
P08894826A0228|122 126|warts
P08894826A0228|23 35|GUM Department
P08894826A0228|102 113|HIV infection
P08894826A0228|171 174|NSGI
P08894826A0228|190 197|syphilis
P08894826A0228|41 54|Royal Infirmary
P08894826A0228|57 65|Edinburgh
P08894826A0228|91 99|diagnosis
P08894826A0228|177 186|gonorrhoea
P08895522T0000|73 78|fusion
P08895522T0000|24 43|tyrosine kinase domain
P08895522T0000|54 70|trk proto-oncogene
P08895522T0000|9 18|activation
P08895522T0000|82 101|cell adhesion molecule
P08895579A0583|0 15|Northern blotting
P08895579A0583|35 38|MDM2
P08895579A0583|26 29|MDMX
P08895579A0583|56 62|tissues
P08895579A0583|92 95|MDMX
P08895579A0583|84 88|mRNAs
P08895997A0336|0 6|Physiol
P08896272A0000|29 30|bp
P08896272A0000|3 20|nucleotide sequence
P08896272A0000|45 54|chromosome
P08896272A0000|40 42|arm
P08896280A0860|44 47|IME1
P08896280A0860|75 80|result
P08896280A0860|51 58|IME2 mRNA
P08896280A0860|118 131|acid metabolism
P08896280A0860|36 41|levels
P08896280A0860|143 156|yvh1 disruption
P08896402A0587|98 109|glycoprotein
P08896402A0587|123 132|kD subunits
P08896402A0587|43 50|cell line
P08896402A0587|7 15|FL protein
P08896402A0587|150 151|kD
P08896402A0587|167 172|sugars
P08896402A0587|66 67|kD
P08896402A0587|154 154|N
P08896473A0282|99 101|VGS
P08896473A0282|38 46|influence
P08896473A0282|86 96|development
P08896473A0282|49 52|HHCA
P08896473A0282|3 11|objective
P08896473A0282|18 22|study
P08896473A0282|72 78|factors
P08896590T0000|14 23|adenovirus
P08896590T0000|7 11|exons
P08896590T0000|46 50|snRNP
P08896590T0000|69 74|domain
P08896590T0000|28 31|RNAs
P08896795A0166|28 33|medium
P08896795A0166|88 91|lens
P08896795A0166|12 16|resin
P08896795A0166|127 136|air bubbles
P08896795A0166|144 151|specimen
P08896795A0166|107 116|coverslips
P08896795A0166|102 104|use
P08896795A0166|54 62|specimens
P08896795A0166|5 9|Spurr
P08896795A0166|67 78|oil immersion
P08896804A0000|206 208|CGS
P08896804A0000|127 131|mg/kg
P08896804A0000|316 319|% v/v
P08896804A0000|258 258|P
P08896804A0000|81 83|BDZ
P08896804A0000|107 115|RO19-4603
P08896804A0000|335 343|saccharin
P08896804A0000|260 263|rats
P08896804A0000|27 40|dose dependence
P08896804A0000|283 292|choice test
P08896804A0000|144 154|combination
P08896804A0000|195 196|ZK
P08896804A0000|44 60|time course effects
P08896804A0000|308 311|EtOH
P08896804A0000|216 220|mg/kg
P08896804A0000|99 105|agonist
P08896804A0000|162 193|BDZ receptor antagonists flumazenil
P08896804A0000|300 306|ethanol
P08896804A0000|66 79|benzodiazepine
P08896804A0000|10 14|study
P08896804A0000|239 256|alcohol-preferring
P08896804A0000|356 363|solution
P08896804A0000|351 354|% g/v
P08897663T0000|16 20|Babel
P08897663T0000|38 48|suicidology
P08897663T0000|23 34|nomenclature
P08897663T0000|9 13|Tower
P08897721A0000|0 8|Infection
P08897721A0000|91 95|group
P08897721A0000|13 21|Neisseria
P08897721A0000|34 39|group B
P08897721A0000|98 111|polysaccharide
P08897721A0000|119 127|immunogen
P08898336A0268|0 22|RNase protection analysis
P08898336A0268|95 104|transcript
P08898336A0268|115 123|sequences
P08898336A0268|154 157|RNAs
P08898336A0268|46 50|genes
P08898336A0268|70 77|evidence
P08898336A0268|28 40|rRNA fragments
P08898365A0274|0 4|Rss1p
P08898365A0274|93 98|domain
P08898365A0274|39 48|amino acids
P08898365A0274|151 159|cytoplasm
P08898365A0274|138 141|NPCs
P08898365A0274|124 136|pore complexes
P08898365A0274|27 33|protein
P08898866A0458|104 110|annexin
P08898866A0458|137 143|mutants
P08898866A0458|128 134|annexin
P08898866A0458|120 125|series
P08898866A0458|19 43|serine phosphorylation site
P08898866A0458|182 195|serine residues
P08898866A0458|76 91|expression system
P08898866A0458|158 170|substitutions
P08898866A0458|218 223|domain
P08898893A0202|157 160|acid
P08898893A0202|206 210|cells
P08898893A0202|190 194|U-937
P08898893A0202|168 186|HT-1080 fibrosarcoma
P08898893A0202|119 121|PMA
P08898893A0202|77 117|phorbol ester phorbol 12-myristate 13-acetate
P08898893A0202|129 148|phosphatase inhibitor
P08898893A0202|3 11|PAI-2 gene
P08898893A0202|40 44|genes
P08899719A0318|116 124|certainty
P08899719A0318|37 49|reading frames
P08899719A0318|51 54|ORFs
P08899719A0318|23 27|total
P08899719A0318|81 84|ORFs
P08899719A0318|8 14|contigs
P08899719A0318|71 77|operons
P08900164A0188|0 1|T.
P08900164A0188|9 10|S.
P08900164A0188|3 7|Patel
P08900190A0430|0 12|Growth factors
P08900190A0430|22 31|expression
P08900190A0430|51 84|gene products MAP kinase phosphatase-1
P08900190A0430|86 90|MKP-1
P08900190A0430|93 97|c-Fos
P08900190A0430|101 105|c-Jun
P08900296A0000|59 69|endothelium
P08900296A0000|120 127|response
P08900296A0000|94 102|mediation
P08900296A0000|37 53|adhesion molecules
P08900296A0000|3 15|up-regulation
P08900296A0000|84 88|event
P08900296A0000|18 27|E-selectin
P08901135A1132|70 77|fraction
P08901135A1132|80 84|cells
P08901135A1132|118 135|nitrogen repression
P08901135A1132|3 13|NIT2 protein
P08901135A1132|169 172|NIT2
P08901135A1132|27 32|nuclei
P08901135A1132|161 166|import
P08901135A1132|96 115|nitrogen derepression
P08901635A0000|13 18|effort
P08901635A0000|22 24|one
P08901635A0000|102 110|cellulose
P08901635A0000|137 142|plants
P08901635A0000|91 99|synthesis
P08901635A0000|75 75|s
P08901635A0000|120 134|cell wall polymer
P08901635A0000|68 73|enzyme
P08901635A0000|2 6|spite
P08901658A0498|126 128|GTN
P08901658A0498|107 124|glyceryl trinitrate
P08901658A0498|41 52|flow increase
P08901658A0498|27 35|hyperemia
P08901658A0498|8 16|responses
P08901658A0498|83 90|dilation
P08901658A0498|153 160|dilation
P08902214A1486|101 111|Stat factors
P08902214A1486|77 86|activation
P08902214A1486|10 15|period
P08902214A1486|17 30|administration
P08902214A1486|52 54|PRL
P08902214A1486|88 94|binding
P08902548A0144|31 51|L-5-hydroxytryptophan
P08902548A0144|53 59|L-5-HTP
P08902548A0144|114 117|mice
P08902548A0144|77 81|mg/kg
P08902548A0144|15 28|administration
P08902548A0144|102 111|defecation
P08902548A0144|63 67|doses
P08902641A0930|95 101|outflow
P08902641A0930|46 53|conduits
P08902641A0930|120 120|n
P08902641A0930|61 66|LV apex
P08902641A0930|19 28|connection
P08902641A0930|104 104|n
P08902641A0930|89 93|aorta
P08902641A0930|68 73|inflow
P08902641A0930|5 14|VA-SMV mode
P08902641A0930|116 118|DAo
P08902847A1946|191 198|degrees C
P08902847A1946|147 154|hCG alpha
P08902847A1946|174 178|min-1
P08902847A1946|242 246|rehCG
P08902847A1946|216 224|magnitude
P08902847A1946|182 183|pH
P08902847A1946|13 19|support
P08902847A1946|261 265|min-1
P08902847A1946|128 144|order rate constant
P08902847A1946|156 159|beta
P08902847A1946|209 213|order
P08902847A1946|43 46|fact
P08902847A1946|161 162|km
P08902847A1946|64 74|interaction
P08902847A1946|88 95|subunits
P08902847A1946|3 10|evidence
P08902847A1946|54 61|affinity
P08902847A1946|248 249|kw
P08902988A0258|0 12|Factor V Leiden
P08902988A0258|56 59|risk
P08902988A0258|23 30|disorder
P08902988A0258|68 77|thrombosis
P08903339A0264|14 26|determination
P08903339A0264|75 85|spliceosome
P08903339A0264|62 64|RNA
P08903339A0264|49 57|structure
P08905819A0531|52 57|cancer
P08905819A0531|25 27|0-I
P08905819A0531|49 50|sm
P08905819A0531|3 10|majority
P08905819A0531|16 20|cases
P08905819A0531|30 44|0-III components
P08906056A1290|70 75|status
P08906056A1290|102 107|degree
P08906056A1290|110 130|health care utilization
P08906056A1290|48 55|function
P08906056A1290|5 12|patients
P08906139A2935|88 98|adjustments
P08906139A2935|52 76|alkaline phosphatase values
P08906139A2935|42 48|calcium
P08906139A2935|4 14|observation
P08906139A2935|147 153|periods
P08906139A2935|119 128|fortifiers
P08906139A2935|101 114|vitamin D intake
P08906139A2935|30 39|monitoring
P08909546A0810|15 18|PEA2
P08909546A0810|82 88|protein
P08909546A0810|53 59|pattern
P08909546A0810|114 119|domain
P08910292T0000|57 61|c-Jun
P08910292T0000|95 114|protein kinase pathway
P08910292T0000|47 51|Cdc42
P08910292T0000|32 43|proteins Rac1
P08910292T0000|0 8|Signaling
P08910373A0315|0 16|Percent identities
P08910373A0315|59 69|Y2 receptors
P08910373A0315|32 38|mouse Y1
P08910373A0315|22 29|mouse PP2
P08910373A0315|40 50|mouse Y4/PP1
P08910550A0501|83 86|EDTA
P08910550A0501|101 115|cation chelators
P08910550A0501|76 79|EGTA
P08910550A0501|26 36|observation
P08910550A0501|56 63|78C1 site
P08910550A0501|41 50|CBF binding
P08910550A0501|150 162|transcription
P08910567A2269|84 91|enhancer
P08910567A2269|8 19|gene fragment
P08910567A2269|39 65|rat liver glucokinase promoter
P08910567A2269|97 124|hepatocyte transfection system
P08912232A0260|15 16|ML
P08912232A0260|71 75|girls
P08912232A0260|36 39|axis
P08912232A0260|51 58|children
P08912232A0260|9 12|role
P08912232A0260|62 65|boys
P08912807A0411|87 92|domain
P08912807A0411|139 157|beta-casein promoter
P08912807A0411|124 133|activation
P08912807A0411|54 68|tyrosine residue
P08912807A0411|20 31|deer receptor
P08913186A0431|99 109|development
P08913186A0431|25 32|evidence
P08913186A0431|4 9|report
P08913186A0431|49 55|control
P08913186A0431|39 43|riMLF
P08913186A0431|115 144|convergence retraction nystagmus
P08913186A0431|71 80|synkinesis
P08913186A0431|58 65|downgaze
P08913387A1010|0 8|Rifabutin
P08913387A1010|52 57|agents
P08913387A1010|23 30|efficacy
P08913974A0533|130 140|salpingitis
P08913974A0533|11 17|percent
P08913974A0533|115 115|%
P08913974A0533|75 81|changes
P08913974A0533|23 25|EPs
P08913974A0533|152 157|others
P08913974A0533|144 144|%
P08913974A0533|41 41|%
P08913974A0533|47 51|tubes
P08913974A0533|99 109|salpingitis
P08914388A1645|27 32|medium
P08914388A1645|155 166|levofloxacin
P08914388A1645|126 133|AM-1155*
P08914388A1645|194 201|sequence
P08914388A1645|87 93|CS-940*
P08914388A1645|97 108|sparfloxacin
P08914388A1645|71 80|activities
P08914388A1645|44 49|author
P08914388A1645|19 19|H
P08914388A1645|185 190|NM-394
P08914388A1645|168 171|LVFX
P08914388A1645|110 113|SPFX
P08914388A1645|135 147|ciprofloxacin
P08914388A1645|149 152|CPFX
P08914388A1645|174 183|OPC-17116*
P08914388A1645|3 12|assessment
P08914522A0118|163 175|G beta mutation
P08914522A0118|109 114|screen
P08914522A0118|22 34|protein kinase
P08914522A0118|46 72|pheromone signal transduction
P08914522A0118|3 11|STE20 gene
P08914522A0118|134 144|suppressors
P08914532A0598|4 9|enzyme
P08914532A0598|40 64|endohydrolase isoenzyme X-I
P08915051T0000|38 46|arthritis
P08915051T0000|8 23|resonance imaging
P08915508A0000|0 6|Moloney
P08915508A0000|366 368|RNA
P08915508A0000|111 125|trans-activator
P08915508A0000|128 140|transcription
P08915508A0000|217 225|sequences
P08915508A0000|235 246|group antigen
P08915508A0000|292 294|tat
P08915508A0000|27 30|MMLV
P08915508A0000|107 109|Tat
P08915508A0000|248 250|Gag
P08915508A0000|253 260|protease
P08915508A0000|332 358|immunodeficiency virus type-1
P08915508A0000|13 25|leukemia virus
P08915508A0000|288 289|RT
P08915508A0000|312 324|coding regions
P08915508A0000|168 186|hammerhead ribozymes
P08915508A0000|299 306|envelope
P08915508A0000|274 286|transcriptase
P08915508A0000|308 310|Env
P08915508A0000|360 364|HIV-1
P08915508A0000|64 70|vectors
P08915508A0000|152 161|expression
P08915559A0366|0 18|REM sleep deprivation
P08915559A0366|39 55|platform technique
P08916928A0950|43 48|effect
P08916928A0950|7 13|ligands
P08916928A0950|117 134|PDGF beta-receptors
P08916928A0950|72 93|thymidine incorporation
P08916928A0950|96 103|PAE cells
P08916928A0950|69 70|3H
P08916960A0350|16 30|biopsy specimens
P08916960A0350|40 47|patients
P08916960A0350|52 53|FL
P08916960A0350|92 100|bcl-2 gene
P08916960A0350|66 76|alterations
P08916960A0350|140 146|regions
P08916960A0350|136 138|ORF
P08916960A0350|123 134|reading frame
P08916960A0350|106 115|breakpoint
P08916960A1331|28 35|DLL cells
P08916960A1331|109 120|conservation
P08916960A1331|153 165|translocation
P08916960A1331|23 24|FL
P08916960A1331|10 14|cases
P08916960A1331|126 134|bcl-2 gene
P08916960A1331|42 52|alterations
P08916960A1331|180 193|transformation
P08916960A1331|78 93|breakpoint region
P08916960A1331|145 145|t
P08916960A1331|55 72|bcl-2 gene sequences
P08916960A1331|199 205|FL cells
P08917270A0229|0 9|BACKGROUND
P08917270A0229|112 120|substrate
P08917270A0229|90 96|disease
P08917270A0229|33 35|QTc
P08917270A0229|37 44|interval
P08917270A0229|51 58|exercise
P08917270A0229|73 78|marker
P08917270A0229|30 31|QT
P08917270A0229|131 140|QT syndrome
P08917435A0481|128 153|c-fos oligodeoxynucleotides
P08917435A0481|25 29|c-Fos
P08917435A0481|100 106|finding
P08917435A0481|120 124|c-jun
P08917435A0481|195 208|PAI-1 synthesis
P08917435A0481|11 14|role
P08917435A0481|17 21|c-Jun
P08917435A0481|54 66|transcription
P08917435A0481|72 80|PAI-1 gene
P08917449A0000|131 141|populations
P08917449A0000|83 90|survival
P08917449A0000|62 76|differentiation
P08917449A0000|26 28|LIF
P08917449A0000|19 24|factor
P08917449A0000|97 105|cell types
P08917449A0000|33 44|neuropoietin
P08917696A0485|296 309|luciferase gene
P08917696A0485|224 226|CRE
P08917696A0485|219 222|cAMP
P08917696A0485|341 348|promoter
P08917696A0485|96 111|expression assays
P08917696A0485|214 216|SRE
P08917696A0485|330 333|SV40
P08917696A0485|23 39|fos/jun activation
P08917696A0485|271 278|jun genes
P08917696A0485|165 201|12-O-tetradecanoyl-phorbol-13-acetate
P08917696A0485|12 20|mechanism
P08917696A0485|114 135|reporter gene constructs
P08917696A0485|253 256|AhRE
P08917696A0485|42 45|TCDD
P08917696A0485|71 83|mobility shift
P08917696A0485|208 212|serum
P08917696A0485|318 324|control
P08917696A0485|203 205|TRE
P08917696A0485|265 267|fos
P08917696A0485|146 161|response elements
P08917696A0485|240 251|hydrocarbons
P08918456A0455|114 122|position Y
P08918456A0455|105 111|leucine
P08918456A0455|46 49|AP-2
P08918456A0455|10 17|sequence
P08918456A0455|36 37|mu
P08918456A0455|21 31|interaction
P08918456A0455|91 99|position Y
P08918456A0455|65 70|anchor
P08918456A0455|53 60|tyrosine
P08918456A0455|81 88|arginine
P08918464A0225|123 125|MEL
P08918464A0225|96 121|mouse erythroleukaemia cells
P08918464A0225|28 32|cells
P08918464A0225|64 69|growth
P08918464A0225|34 40|BaF/STK
P08918464A0225|127 129|STK
P08918464A0225|78 80|STK
P08918464A0225|18 22|Ba/F3
P08918464A0225|151 159|apoptosis
P08918810A0967|13 24|footprinting
P08918810A0967|35 44|OxyR-C199S
P08918810A0967|7 11|DNase
P08918810A0967|54 57|Pmom
P08918810A0967|146 149|OxyR
P08918810A0967|79 84|strand
P08918810A0967|97 127|protection pattern characteristic
P08918885A0811|0 3|Kss1
P08918885A0811|24 37|GST-Dig1 fusion
P08918885A0811|60 71|yeast protein
P08918885A0811|43 49|absence
P08918885A1087|127 130|role
P08918885A1087|164 176|growth pathway
P08918885A1087|63 75|dig1 dig2 ste12
P08918885A1087|82 87|mutant
P08918885A1087|110 113|Dig1
P08918885A1087|11 23|dig1 dig2 cells
P08918885A1087|117 120|Dig2
P08918885A1087|2 9|contrast
P08918885A1087|44 53|agar medium
P08918918T0000|86 101|trans-activation
P08918918T0000|50 59|Tat protein
P08918918T0000|9 18|activation
P08918918T0000|24 39|HIV-1 LTR promoter
P08918918T0000|109 112|cell
P08918934A0424|130 133|core
P08918934A0424|73 76|NTF2
P08918934A0424|179 185|linkers
P08918934A0424|55 59|Nsplp
P08918934A0424|49 51|p62
P08918934A0424|141 147|repeats
P08918934A0424|29 46|xFxFG repeat regions
P08918934A0424|15 23|sequences
P08918934A0424|0 9|Comparison
P08919289A0402|14 19|report
P08919289A0402|112 119|vena cava
P08919289A0402|47 49|MFH
P08919289A0402|35 43|resection
P08919289A0402|79 84|tissue
P08919907A0763|62 71|activation
P08919907A0763|9 18|expression
P08919907A0763|49 52|vs-1
P08919907A0763|21 25|VSF-1
P08919907A0763|94 101|promoter
P08919907A0763|28 38|protoplasts
P08919986A1262|116 122|results
P08919986A1262|75 78|drug
P08919986A1262|36 42|dosages
P08919986A1262|30 32|age
P08919986A1262|9 12|mind
P08919986A1262|23 27|range
P08919986A1262|44 53|advantages
P08919986A1262|146 155|literature
P08919986A1262|57 69|disadvantages
P08920499A0164|0 22|Blood sampling procedures
P08921387A1182|0 7|Analysis
P08921387A1182|34 46|splicing event
P08921387A1182|166 171|domain
P08921387A1182|78 85|gene GPR2
P08921387A1182|107 115|mechanism
P08921387A1182|131 141|EZH1 protein
P08921387A1182|56 59|EZH1
P08921387A1182|13 16|cDNA
P08921667A0294|14 26|input function
P08921667A0294|36 40|value
P08921667A0294|146 155|volunteers
P08921667A0294|75 89|rCBF measurement
P08921667A0294|62 63|Vd
P08921667A0294|130 134|study
P08921667A0294|43 60|distribution volume
P08921667A0294|96 101|method
P08921865A1293|173 177|T4DNA
P08921865A1293|134 145|ssDNA regions
P08921865A1293|90 95|T4 gp17
P08921865A1293|33 34|ss
P08921865A1293|36 50|DNA binding motif
P08921865A1293|71 87|terminase proteins
P08922344A1539|99 111|blood pressure
P08922344A1539|34 41|subjects
P08922344A1539|162 166|cause
P08922344A1539|177 188|hypertension
P08922344A1539|134 140|factors
P08922344A1539|47 50|acid
P08922344A1539|54 68|xanthine oxidase
P08922344A1539|169 174|effect
P08922344A1539|84 94|association
P08922384A0466|0 13|Immunoblotting
P08922384A0466|36 43|proteins
P08922384A0466|115 121|protein
P08922384A0466|99 109|carboxyl end
P08922384A0466|84 93|08L epitope
P08922384A0466|61 71|08L antibody
P08922385A0622|148 155|lysosome
P08922385A0622|108 120|fusion subunit
P08922385A0622|61 71|proteolysis
P08922385A0622|77 102|beta-galactosidase tetramer
P08922385A0622|135 142|tetramer
P08922385A0622|124 129|detour
P08922385A0622|30 39|inhibition
P08922390A0361|61 68|paxillin
P08922390A0361|10 14|study
P08922390A0361|52 58|domains
P08922390A0361|25 32|vinculin
P08922390A0361|107 114|adhesion
P08922390A0361|94 101|paxillin
P08922390A0361|124 128|motif
P08922390A0793|83 87|sites
P08922390A0793|125 131|stretch
P08922390A0793|91 93|FAK
P08922390A0793|23 30|presence
P08922390A0793|137 146|amino acids
P08922390A0793|54 61|vinculin
P08922390A0793|5 8|data
P08922390A0793|40 50|binding site
P08922390A2076|135 147|demonstration
P08922390A2076|212 223|localization
P08922390A2076|48 56|adhesions
P08922390A2076|24 31|paxillin
P08922390A2076|194 200|protein
P08922390A2076|181 191|determinant
P08922390A2076|150 159|LIM domains
P08922390A2076|5 8|data
P08922390A2076|231 239|adhesions
P08922390A2076|70 81|interactions
P08922390A2076|86 93|vinculin
P08922390A2076|100 102|FAK
P08922391A0304|59 68|PDZ repeats
P08922391A0304|25 33|structure
P08922391A0304|75 80|PDZ1-2
P08922391A0304|93 99|protein
P08922391A0304|111 114|site
P08922391A0304|45 52|entirety
P08922488A0187|29 37|treatment
P08922488A0187|62 68|effects
P08922488A0187|7 12|agents
P08923258A0353|0 6|Jerseys
P08923258A0353|57 57|d
P08923258A0353|23 38|Cu concentrations
P08923258A0353|46 54|Holsteins
P08923460A0565|114 120|cloning
P08923460A0565|74 81|splicing
P08923460A0565|37 47|RUSH-1 alpha
P08923460A0565|0 9|RUSH-1 beta
P08923460A0565|90 93|exon
P08923460A0565|28 34|version
P08923469A1391|47 54|polarity
P08923469A1391|140 151|half-element
P08923469A1391|89 111|hormone response elements
P08923469A1391|5 11|results
P08923469A1391|57 77|RXR heterodimer binding
P08923469A1391|120 122|VDR
P08923470A0458|0 18|PPAR gamma mRNA levels
P08923470A0458|64 65|h.
P08923470A0458|34 34|%
P08923470A0458|40 58|nM TNF alpha treatment
P08924211A0941|0 4|Exons
P08924211A0941|90 94|types
P08924211A0941|60 65|region
P08924211A0941|34 39|region
P08924211A0941|102 109|AST cDNAs
P08924211A0941|97 99|PST
P08924381T0000|0 11|Growth factor
P08924381T0000|41 47|regimen
P08924381T0000|58 77|breast cancer patients
P08925545T0001|66 72|myeloma
P08925545T0001|39 47|treatment
P08925545T0001|11 24|erythropoietin
P08925545T0001|26 32|r-HuEPO
P08925545T0001|50 55|anemia
P08927169A0178|96 117|Community Health Service
P08927169A0178|120 126|Utrecht
P08927169A0178|29 36|body lice
P08927169A0178|61 68|patients
P08927169A0178|74 79|clinic
P08927169A0178|52 56|times
P08927169A0178|16 24|infection
P08927169A0178|83 90|homeless
P08927612T0000|9 20|p53 mutations
P08927612T0000|39 52|adenocarcinoma
P08927841A0053|15 18|data
P08927841A0053|77 84|activity
P08927841A0053|103 112|occurrence
P08927841A0053|49 53|death
P08929089A0231|35 39|index
P08929089A0231|11 19|ratio M/Pc
P08929089A0231|78 83|demand
P08929563T0000|0 15|Rat liver catalase
P08929563T0000|90 105|Ser-Lys-Leu motif
P08929563T0000|52 72|tripeptide Ala-Asn-Leu
P08929563T0000|26 36|peroxisomes
P08931388A0806|41 48|fragment
P08931388A0806|110 113|band
P08931388A0806|140 145|sample
P08931388A0806|60 66|extract
P08931388A0806|28 29|bp
P08931388A0806|3 20|mobility shift assay
P08931388A0806|86 91|sample
P08931991A1026|86 95|regulation
P08931991A1026|22 29|evidence
P08931991A1026|52 70|transcription factor
P08931991A1026|107 122|myosin expression
P08931991A1026|34 36|E2F
P08931991A1026|5 8|data
P08932363A0807|41 61|squelshing experiments
P08932363A0807|29 38|competitor
P08932363A0807|7 19|E1A N-terminus
P08932363A0807|114 122|E1A mutant
P08932363A0807|84 93|activation
P08932363A0807|96 103|E2F1/DP1
P08932363A0807|130 146|CBP binding ability
P08932385T0000|5 15|Maf proteins
P08932385T0000|36 70|transcription factor TCF11/Nrf1/LCR-F
P08933487A0325|24 24|W
P08933487A0325|50 52|run
P08933487A0325|10 22|occasion water
P08933640A0000|102 108|rabbits
P08933640A0000|82 84|KBL
P08933640A0000|19 27|ingestion
P08933640A0000|40 64|energy sweetener erythritol
P08933640A0000|3 8|effect
P08933640A0000|86 93|JW strain
P08934533A0784|58 60|DNA
P08934533A0784|44 47|junB
P08934533A0784|67 75|chromatin
P08934533A0784|33 41|structure
P08934533A0784|16 24|mutations
P08934540A0673|3 9|nm23-H1
P08934540A0673|37 49|activity ratio
P08934540A0673|11 21|nm23-H2 gene
P08934540A0673|70 77|cell line
P08935931A0787|0 9|CONCLUSION
P08935931A0787|167 169|EGD
P08935931A0787|79 82|SpO2
P08935931A0787|73 76|fall
P08935931A0787|22 43|diazepam administration
P08935931A0787|92 100|procedure
P08935931A0787|145 148|SpO2
P08935931A0787|50 52|EGD
P08935931A0787|133 142|monitoring
P08935991A0844|140 144|sizes
P08935991A0844|61 69|% identity
P08935991A0844|150 156|introns
P08935991A0844|37 41|mouse
P08935991A0844|50 51|CA
P08935991A0844|109 118|boundaries
P08935991A0844|3 29|nucleotide sequence alignment
P08935991A0844|81 86|region
P08935991A0844|54 58|shows
P08936128A0611|0 10|Discordance
P08936128A0611|53 55|G Hb
P08936128A0611|99 110|disagreement
P08936128A0611|81 87|control
P08936128A0611|16 28|cost dimension
P08936640A0105|0 10|DATA SOURCES
P08936640A0105|110 119|lung cancer
P08936640A0105|96 107|epidemiology
P08936640A0105|25 31|studies
P08936640A0105|33 47|research studies
P08936640A0105|67 83|government reports
P08936640A0105|49 62|review articles
P08937112A0561|55 59|years
P08937112A0561|11 25|age distribution
P08937112A0561|44 47|mean
P08937112A0561|35 39|years
P08937112A0561|0 6|RESULTS
P08937631A1223|119 127|relevance
P08937631A1223|12 18|changes
P08937631A1223|155 165|vasculature
P08937631A1223|54 63|hemorrhage
P08937631A1223|133 142|remodeling
P08937631A1223|37 50|cell involution
P08937631A1223|90 95|period
P08937981A0840|131 137|nucleus
P08937981A0840|91 93|p46
P08937981A0840|107 109|p46
P08937981A0840|77 88|distribution
P08937981A0840|12 24|co-expression
P08937981A0840|153 155|p54
P08937981A0840|37 47|p54 subunits
P08937981A0840|31 33|p46
P08937989A1365|99 105|regions
P08937989A1365|111 117|protein
P08937989A1365|61 65|talin
P08937989A1365|52 58|regions
P08937989A1365|37 37|N
P08937989A1365|3 9|results
P08937989A1365|79 88|properties
P08937989A1365|70 74|actin
P08938418A0099|0 3|Merr
P08938418A0099|6 18|embryo library
P08938420A0862|70 75|sugars
P08938420A0862|3 14|accumulation
P08938420A0862|157 173|3-O-methylglucose
P08938420A0862|21 24|LHA4
P08938420A0862|51 58|addition
P08938420A0862|114 124|sugar uptake
P08938420A0862|83 91|induction
P08938420A0862|146 153|mannitol
P08938420A0862|188 203|mRNA accumulation
P08938420A0862|128 137|metabolism
P08938420A0862|28 36|LHA2 mRNAs
P08939891A0285|43 45|NRE
P08939891A0285|8 12|yeast
P08939891A0285|103 105|Nrl
P08939891A0285|62 65|bait
P08939891A0285|57 59|DNA
P08939891A0285|23 28|screen
P08939891A0285|81 85|clone
P08939966A0816|86 96|mRNA decline
P08939966A0816|5 8|rate
P08939966A0816|11 26|protein synthesis
P08939966A0816|46 58|embryogenesis
P08939966A0816|68 72|SEC-1
P08939966A0816|60 65|levels
P08940132A1120|205 209|CPP32
P08940132A1120|5 12|findings
P08940132A1120|108 118|sensitivity
P08940132A1120|24 40|fodrin proteolysis
P08940132A1120|180 187|protease
P08940132A1120|60 67|activity
P08940132A1120|121 128|DEVD-CHO
P08940132A1120|212 229|DEVD-CHO inhibition
P08940132A1120|161 165|CPP32
P08940132A1120|145 156|contribution
P08940132A1120|87 95|proteases
P08940134A0705|145 153|reticulum
P08940134A0705|8 10|3Y1
P08940134A0705|74 74|%
P08940134A0705|87 89|Cas
P08940134A0705|82 85|p130
P08940134A0705|106 114|membranes
P08940134A0705|91 101|co-sediment
P08940134A0705|28 38|fibroblasts
P08940134A0705|2 4|3Y1
P08940134A0705|59 63|PTP1B
P08940298A0962|115 122|receptor
P08940298A0962|67 83|vitamin D3 receptor
P08940298A0962|89 104|estrogen receptor
P08940298A0962|26 33|delta419
P08940298A0962|50 59|AF-2 domain
P08940298A0962|9 16|residues
P08940298A0962|156 163|activity
P08942999T0000|43 47|SREBP
P08942999T0000|9 26|G-to-A substitution
P08942999T0000|116 136|hamster ovary cell lines
P08942999T0000|36 40|codon
P08942999T0000|67 73|protein
P08942999T0000|86 95|resistance
P08943032A0000|175 183|selection
P08943032A0000|37 50|operator system
P08943032A0000|137 148|interactions
P08943032A0000|32 35|TetR
P08943032A0000|82 86|yeast
P08943032A0000|109 119|disruptions
P08943032A0000|97 101|assay
P08943032A0000|68 76|variation
P08943032A0000|18 30|tet-repressor
P08943354A0295|30 34|SHP-1
P08943354A0295|106 116|association
P08943354A0295|177 190|motheaten cells
P08943354A0295|140 159|hyperphosphorylation
P08943354A0295|6 12|studies
P08943354A0295|209 213|SHP-1
P08943354A0295|124 133|Tyk2 kinase
P08943354A0295|47 54|function
P08943354A0295|57 80|Jak family tyrosine kinases
P08943354A0295|162 171|Jak kinases
P08943928A1137|0 13|Administration
P08943928A1137|45 52|outbreak
P08943928A1137|23 26|dose
P08943928A1137|29 35|vaccine
P08943934A0604|47 54|exposure
P08943934A0604|6 14|Theriault
P08943934A0604|24 35|improvements
P08943934A0604|97 104|findings
P08944755A0211|0 3|Biol
P08945479T0000|58 80|tyrosine phosphorylation
P08945479T0000|35 53|lymphocyte kinase Lck
P08945479T0000|10 14|basis
P08945479T0000|18 27|activation
P08945810T0001|33 36|bulb
P08945810T0001|61 67|mammals
P08945810T0001|39 41|man
P08945810T0001|9 18|morphology
P08946166A0568|44 51|FRDS gene
P08946166A0568|9 15|results
P08946166A0568|36 38|ORF
P08946668A0077|0 4|FK506
P08946668A0077|77 84|toxicity
P08946668A0077|34 45|cyclosporin A
P08946668A0077|58 71|organ rejection
P08947028A0992|85 89|Pkc1p
P08947028A0992|77 81|Bni1p
P08947028A0992|23 27|Rho1p
P08947028A0992|49 62|reorganization
P08947028A0992|5 11|results
P08948440A0628|41 43|An3
P08948440A0628|64 79|animal hemisphere
P08948440A0628|82 88|oocytes
P08948440A0628|118 123|embryo
P08948440A0628|3 22|ERH expression profile
P08950144A0172|13 15|CNV
P08950144A0172|35 45|CNV paradigm
P08950144A0172|113 115|sec
P08950144A0172|106 108|ISI
P08950144A0172|8 9|P3
P08950144A0172|97 104|interval
P08950144A0172|55 70|reaction time task
P08950144A0172|0 6|Waves N1
P08950352A0525|147 158|significance
P08950352A0525|38 44|samples
P08950352A0525|91 95|rates
P08950352A0525|126 129|area
P08950352A0525|179 182|test
P08950352A0525|65 69|areas
P08950352A0525|111 114|ones
P08950352A0525|160 160|p
P08951815A0465|0 9|Regulation
P08951815A0465|12 15|ASN1
P08951815A0465|91 95|times
P08951815A0465|48 58|lacZ fusions
P08951815A0465|66 70|genes
P08951815A0465|114 120|absence
P08951815A0465|19 32|ASN2 expression
P08951815A0465|126 152|transcription activator Gcn4p
P08952483A0207|17 24|features
P08952483A0207|114 121|assembly
P08952483A0207|128 133|enzyme
P08952483A0207|57 83|hamster lysyl-tRNA synthetase
P08952483A0207|31 49|polypeptide fragment
P08952483A0207|143 164|multisynthetase complex
P08952796A0743|13 17|years
P08952796A0743|23 29|relapse
P08952965A1182|0 9|Comparison
P08952965A1182|181 182|pN
P08952965A1182|196 212|MHC contact regions
P08952965A1182|41 42|pN
P08952965A1182|15 24|proportion
P08952965A1182|135 143|reduction
P08952965A1182|214 217|CDR1
P08952965A1182|221 224|CDR2
P08952965A1182|153 168|framework regions
P08952965A1182|58 59|pS
P08952965A1182|96 102|tamarin
P08952965A1182|111 121|region genes
P08952965A1182|61 73|substitutions
P08952965A1182|86 89|site
P08952965A1182|146 147|pN
P08953340A0000|86 96|performance
P08953340A0000|169 193|weight-training volunteers
P08953340A0000|53 65|anthropometry
P08953340A0000|31 35|VOSO4
P08953340A0000|67 81|body composition
P08953340A0000|155 159|trial
P08953340A0000|3 9|effects
P08953340A0000|16 29|vanadyl sulfate
P08953340A0000|41 49|mg/kg/day
P08954725A1175|117 122|source
P08954725A1175|7 17|development
P08954725A1175|106 111|streak
P08954725A1175|125 132|mesoderm
P08954725A1175|19 32|Tbx6 expression
P08954725A1175|66 73|mesoderm
P08954725A1175|82 88|tail bud
P08955071T0000|0 9|Disruption
P08955071T0000|12 32|re-replication control
P08955071T0000|35 48|overexpression
P08955071T0000|62 73|fission yeast
P08955071T0000|56 59|ORC1
P08955111A0989|132 154|activin betaA subunit gene
P08955111A0989|39 53|enhancer regions
P08955111A0989|3 9|results
P08955111A0989|106 121|promoter activity
P08955111A0989|28 35|promoter
P08955136A0606|32 42|PIP5KIalpha
P08955136A0606|52 64|PIP5K activity
P08955136A0606|98 113|PIP5KI antibodies
P08955159A0000|5 18|acid ceramidase
P08955159A0000|56 57|EC
P08955159A0000|24 54|N-acylsphingosine amidohydrolase
P08955159A0000|21 22|AC
P08955189A1198|118 142|EGR-1 transcription factors
P08955189A1198|10 27|NheI/BglII promoter
P08955189A1198|93 99|element
P08955189A1198|112 114|Sp1
P08955189A1198|37 51|PMA inducibility
P08955189A1198|61 65|cells
P08955306A0224|0 7|Northern
P08955306A0224|9 11|RNA
P08955306A0224|140 145|growth
P08955306A0224|13 24|blot analyses
P08955306A0224|81 92|reading frame
P08955306A0224|64 71|subunits
P08955306A0224|110 117|function
P08955306A0224|148 154|acetate
P08955306A0224|94 97|ORF1
P08955306A0224|41 48|cdh genes
P08955402A0288|70 73|HOL1
P08955402A0288|62 67|region
P08955402A0288|88 94|ability
P08955402A0288|12 20|mutations
P08955402A0288|158 173|HOL1-1 background
P08955402A0288|103 112|histidinol
P08955402A0288|203 213|Hol1 protein
P08955402A0288|131 139|mutations
P08955402A0288|3 9|classes
P08955402A0288|188 197|expression
P08955928A0390|0 5|Damage
P08955928A0390|11 13|BBB
P08955928A0390|99 103|onset
P08955928A0390|106 109|MCAo
P08955928A0390|50 51|EB
P08955928A0390|25 37|extravasation
P08955928A0390|93 93|h
P08955928A0390|40 48|Evans Blue
P08958137A0534|0 23|Lipid hydroperoxide levels
P08958137A0534|35 37|LDL
P08958137A0534|26 31|plasma
P08958137A0534|68 72|study
P08958720A1204|15 22|exercise
P08958720A1204|34 37|mPAP
P08958720A1204|88 90|VO2
P08958720A1204|52 54|SVI
P08958720A1204|65 66|HR
P08958720A1204|7 12|degree
P08958720A1204|83 84|CO
P08959062A0372|83 95|immunodeficit
P08959062A0372|9 12|case
P08959062A0372|103 105|EBV
P08959062A0372|62 70|discovery
P08959062A0372|15 24|vasculitis
P08959062A0372|125 132|syndrome
P08959062A0372|116 122|Purtilo
P08959117A0708|89 95|disease
P08959117A0708|109 118|influences
P08959117A0708|36 42|changes
P08959117A0708|215 217|REF
P08959117A0708|200 213|reference group
P08959117A0708|149 160|measurements
P08959117A0708|60 69|hypoxaemia
P08959117A0708|135 144|ICU setting
P08959117A0708|250 259|hypoxaemia
P08959778A0292|84 86|EGF
P08959778A0292|91 93|DGF
P08959778A0292|35 47|graft survival
P08959778A0292|22 32|differences
P08959778A0292|126 143|retransplantations
P08959778A0292|70 82|graft function
P08959778A0292|108 123|transplantations
P08959778A0292|55 60|groups
P08960827A1169|101 111|association
P08960827A1169|5 11|results
P08960827A1169|65 77|transcription
P08960827A1169|155 160|factor
P08960827A1169|28 35|GG motifs
P08960827A1169|119 125|binding
P08960827A1169|88 98|insulin gene
P08961873T0000|15 34|coproporphyrin levels
P08961873T0000|37 44|patients
P08961873T0000|55 69|hepatitis C virus
P08961873T0000|88 108|immunodeficiency virus
P08962614A0000|159 169|individuals
P08962614A0000|80 94|skin-prick tests
P08962614A0000|62 76|laboratory tests
P08962614A0000|38 47|antibodies
P08962614A0000|34 36|IgE
P08962614A0000|199 206|children
P08962614A0000|110 128|challenge procedures
P08962614A0000|18 32|immunoglobulin E
P08962614A0000|3 15|determination
P08962614A0000|174 190|outcome predictors
P08964067A0188|0 9|Thrombosis
P08964067A0188|52 58|failure
P08964067A0188|20 23|vein
P08964172A0221|0 5|Filter
P08964172A0221|9 34|cytocentrifuge preparations
P08964172A0221|40 44|urine
P08964172A0221|62 66|cases
P08964172A0221|93 102|aggregates
P08964172A0221|137 146|background
P08964172A0221|111 120|tumor cells
P08967870A0000|46 61|Moscow hospitals N
P08967870A0000|9 17|protocols
P08967870A0000|20 41|postmortem examinations
P08967963A1735|3 17|promoter segment
P08967963A1735|126 144|beta cell line RIN-5AH
P08967963A1735|113 115|rat
P08967963A1735|75 77|rat
P08967963A1735|50 70|rat glioma cell line C6B4
P08967963A1735|91 105|cell line RSMT-A5
P08967963A1735|181 194|alpha2c-AR gene
P08969495A0256|188 192|locus
P08969495A0256|178 181|role
P08969495A0256|104 112|mutations
P08969495A0256|64 74|nrdE cistron
P08969495A0256|149 152|nrdF
P08969495A0256|35 48|mutation ts-A13
P08969495A0256|142 145|nrdE
P08969495A0256|134 139|region
P08969495A0256|82 90|lethality
P08969495A0256|3 12|sequencing
P08969777A0771|60 67|patients
P08969777A0771|139 144|degree
P08969777A0771|95 118|serum 25-OHD concentration
P08969777A0771|47 57|differences
P08969777A0771|21 26|scores
P08969777A0771|147 155|paralysis
P08970352A0880|40 43|risk
P08970352A0880|46 56|progression
P08970352A0880|59 62|MSOF
P08970352A0880|24 26|use
P08970352A0880|65 70|sepsis
P08970352A0880|29 31|LDD
P08970352A0880|5 8|data
P08970951A0823|99 109|Pol proteins
P08970951A0823|92 95|core
P08970951A0823|25 30|levels
P08970951A0823|52 58|antigen
P08970951A0823|84 89|levels
P08970951A0823|124 142|HBV DNA intermediates
P08970951A0823|41 50|hepatitis B
P08970979A1246|117 124|promoter
P08970979A1246|64 76|transcription
P08970979A1246|92 99|template
P08970979A1246|11 18|extracts
P08970979A1246|30 36|virions
P08970979A1246|57 61|level
P08970979A1246|2 9|contrast
P08970984A0765|73 75|SRF
P08970984A0765|77 88|Rel/NFkappaB
P08970984A0765|3 14|SCMV SNE sites
P08970984A0765|97 124|YY1 class transcription factors
P08970984A0765|90 92|ETS
P08970984A0765|42 69|core recognition binding motifs
P08970984A0765|149 153|serum
P08970984A0765|156 179|tumor necrosis factor alpha
P08970991A0747|85 85|%
P08970991A0747|34 44|temperature
P08970991A0747|58 66|apoptosis
P08970991A0747|91 95|cells
P08970991A0747|4 18|serum withdrawal
P08971009A0860|16 22|problem
P08971009A0860|39 46|strategy
P08971009A0860|139 142|loci
P08971009A0860|96 103|sequence
P08971009A0860|83 87|sites
P08971009A0860|155 164|DNA genomes
P08971721A1314|58 61|HspA
P08971721A1314|50 55|domain
P08971721A1314|91 96|domain
P08971721A1314|23 29|studies
P08971721A1314|5 9|basis
P08971835A1057|2 6|Group
P08971835A1057|25 33|alpha-MSH
P08971835A1057|93 93|%
P08971835A1057|9 12|dogs
P08971835A1057|124 140|reperfusion period
P08971835A1057|44 54|reperfusion
P08971835A1057|104 110|Group II
P08971835A1057|56 60|BAEPs
P08972182A0000|87 91|hours
P08972182A0000|94 114|receptor cross-linking
P08972182A0000|23 39|signalling cascade
P08972182A0000|3 13|Fas receptor
P08972182A0000|71 79|apoptosis
P08972182A0000|61 69|cell death
P08972182A0527|160 191|tetrapeptide ICE inhibitor YVAD-CMK
P08972182A0527|199 233|tripeptide pan-ICE inhibitor Z-VAD-FMK
P08972182A0527|63 77|family proteases
P08972182A0527|24 26|ICE
P08972182A0527|86 94|apoptosis
P08972182A0527|99 105|studies
P08972182A0527|56 61|enzyme
P08972182A0527|0 2|Fas
P08972182A0527|28 40|interleukin-1
P08972182A0527|118 146|cowpox ICE inhibitor protein CrmA
P08972211A0059|115 122|sequence
P08972211A0059|61 64|mice
P08972211A0059|125 126|kb
P08972211A0059|12 21|expression
P08972211A0059|37 40|gene
P08972211A0059|78 86|transgene
P08972211A0059|140 147|sequence
P08972211A0059|185 193|enhancers
P08972211A0059|227 230|gene
P08972211A0059|100 101|kb
P08972232A0365|81 85|yGCN5
P08972232A0365|59 78|substrate specificity
P08972232A0365|30 34|hGCN5
P08972232A0365|6 11|report
P08972232A0365|43 45|HAT
P08973185T0061|42 56|phosphorylation
P08973185T0061|14 30|arginine mutations
P08973185T0061|3 8|effect
P08973185T0061|60 72|AAC expression
P08973527A0000|117 120|HoMV
P08973527A0000|32 42|coat protein
P08973527A0000|90 93|AgMV
P08973527A0000|13 16|DNAs
P08973527A0000|98 115|Hordeum mosaic virus
P08973527A0000|69 88|Agropyron mosaic virus
P08973527A0000|60 66|regions
P08973630A0923|101 113|Rac activation
P08973630A0923|79 93|Cdc42 activation
P08973630A0923|26 38|Rac activation
P08973630A0923|6 10|cases
P08973630A0923|48 60|Rho activation
P08973630A0923|150 156|changes
P08973917A0632|7 11|cDNAs
P08973917A0632|35 42|PWP2 gene
P08973917T0000|0 8|Isolation
P08973917T0000|61 77|tryptophan protein
P08973917T0000|48 52|yeast
P08973917T0000|36 42|homolog
P08973917T0000|80 83|PWP2
P08973917T0000|85 95|gene mapping
P08973917T0000|19 27|structure
P08973917T0000|98 104|21q22.3
P08974103A0451|101 105|all-2
P08974103A0451|48 64|laboratory results
P08974103A0451|92 94|PEM
P08974103A0451|113 119|pattern
P08974103A0451|17 28|combinations
P08974103A0451|80 89|likelihood
P08974103A0451|0 7|Patterns
P08974135A0052|117 124|patients
P08974135A0052|25 33|vitamin B1
P08974135A0052|78 87|stomatitis
P08974135A0052|163 169|members
P08974135A0052|98 112|vitamin B1 levels
P08974135A0052|35 44|deficiency
P08974135A0052|146 155|stomatitis
P08974135A0052|16 23|thiamine
P08974135A0052|173 184|control group
P08975532T0001|0 12|Liver injuries
P08975713A0454|28 32|probe
P08975713A0454|172 184|p53p2 promoter
P08975713A0454|112 115|cDNA
P08975713A0454|12 22|cDNA library
P08975713A0454|131 134|mRNA
P08975713A0454|68 81|p53p2 start site
P08975713A0454|44 52|sequences
P08976253A0637|57 71|plasma PSA levels
P08976253A0637|24 34|correlation
P08976253A0637|42 46|serum
P08977013A0788|61 71|differences
P08977013A0788|94 99|foveal
P08977013A0788|113 118|vision
P08977013A0788|77 91|specializations
P08977013A0788|3 14|implications
P08977013A0788|37 49|magnification
P08977013A0788|18 26|estimates
P08977235A0134|0 4|G-CSF
P08977235A0134|53 56|JAK1
P08977235A0134|31 39|molecules
P08977235A0134|77 100|STAT transcription factors
P08977235A0134|60 70|JAK2 kinases
P08977235A0588|0 6|Mutants
P08977235A0588|68 74|ability
P08977235A0588|141 155|STAT1 activation
P08977235A0588|115 119|STAT3
P08977235A0588|17 32|tyrosine residues
P08977235A0588|49 54|domain
P08977235A0588|93 97|STAT1
P08977235A0588|170 200|receptor tyrosine phosphorylation
P08977235A0588|85 89|STAT5
P08977235A0588|133 137|STAT5
P08977401A0227|283 293|leader exons
P08977401A0227|300 303|rise
P08977401A0227|50 56|lengths
P08977401A0227|324 336|messenger RNAs
P08977401A0227|36 40|exons
P08977401A0227|69 75|introns
P08977401A0227|96 101|length
P08977401A0227|125 131|cloning
P08977401A0227|178 183|region
P08977401A0227|218 224|RI alpha
P08977401A0227|144 160|RI alpha pseudogene
P08977401A0227|238 240|RNA
P08977401A0227|86 89|gene
P08977401A0227|338 342|mRNAs
P08977401A0227|3 13|RI alpha gene
P08977401A0227|257 267|RI alpha gene
P08977401A0227|113 114|kb
P08978690A0262|15 23|Rad3/Mec1
P08978690A0262|42 48|protein
P08978690A0262|102 118|yeast model systems
P08978690A0262|73 95|DNA structure checkpoints
P08978817A0620|58 81|endocytosis mutants end4-1
P08978817A0620|108 120|growth defects
P08978817A0620|34 43|dim1-delta
P08978817A0620|46 51|dim2-1
P08978817A0620|17 23|mutants
P08978817A0620|139 153|DIM gene products
P08978817A0620|2 9|addition
P08978817A0620|84 89|act1-1
P08978817A0620|190 196|pathway
P08978996A0000|171 179|infection
P08978996A0000|47 51|cause
P08978996A0000|22 36|hepatitis C virus
P08978996A0000|153 158|impact
P08978996A0000|72 87|dialysis patients
P08978996A0000|54 65|liver disease
P08978996A0000|135 146|epidemiology
P08978996A0000|121 129|attention
P08978996A0000|3 16|identification
P08978996A0000|93 110|transplant patients
P08978996A0000|187 199|patient groups
P08979089A1197|171 186|Ig kappa enhancers
P08979089A1197|106 112|Sp1 site
P08979089A1197|61 81|core promoter mutations
P08979089A1197|144 153|activation
P08979089A1197|6 17|transfection
P08979089A1197|23 36|BL cell line Raji
P08979089A1197|41 50|constructs
P08979089A1197|119 125|TATA box
P08979089A1197|156 165|promoter P1
P08979828A1561|16 27|interactions
P08979828A1561|47 54|behavior
P08980413A0500|14 19|ppSEPs
P08980413A0500|9 11|N22
P08980413A0500|60 61|N2
P08980413A0500|23 47|phase reversal relationship
P08980413A0500|55 56|P2
P08980413A0500|77 79|PES
P08980413A0500|3 5|P13
P08980522A0280|3 6|cDNA
P08980522A0280|35 41|protein
P08980522A0280|9 12|cpm7
P08980522A0280|48 50|kDa
P08980533A1160|29 33|ENBP1
P08980533A1160|56 62|protein
P08980533A1160|21 26|region
P08980533A1160|67 69|rat
P08980533A1160|45 52|homology
P08980533A1160|99 110|testis tissue
P08980536A1196|3 14|conservation
P08980536A1196|75 84|importance
P08980536A1196|24 28|G-box
P08980536A1196|32 36|H-box
P08980536A1196|48 59|CHS promoters
P08980536A1196|97 102|motifs
P08980819A0193|0 8|Mortality
P08980819A0193|105 109|birds
P08980819A0193|114 118|birds
P08980819A0193|139 143|event
P08980819A0193|66 71|groups
P08980819A0193|93 96|toms
P08980819A0193|160 171|insemination
P08980819A0193|18 22|ranch
P08980819A0193|74 80|turkeys
P08981371A2049a|32 41|kDa protein
P08981371A2049a|11 21|PIP2 content
P08981371A2049a|64 77|CSF-1 treatment
P08981371A2049b|32 41|kDa protein
P08981371A2049b|11 21|PIP2 content
P08981371A2049b|64 77|CSF-1 treatment
P08985109A1285|41 44|apex
P08985109A1285|55 59|crest
P08985109A1285|32 37|margin
P08985109A1285|80 85|aspect
P08985109A1285|94 97|cone
P08985115A1571|232 241|metastasis
P08985115A1571|122 125|gene
P08985115A1571|77 80|step
P08985115A1571|90 98|isolation
P08985115A1571|8 21|identification
P08985115A1571|61 65|study
P08985115A1571|33 45|37LRP/p40 gene
P08985115A1571|132 144|understanding
P08985115A1571|159 168|mechanisms
P08985115A1571|200 209|expression
P08985115A1571|182 194|up-regulation
P08985115A1571|216 228|tumor invasion
P08985122A0501|196 204|CpG island
P08985122A0501|43 47|group
P08985122A0501|271 275|genes
P08985122A0501|18 19|P1
P08985122A0501|95 103|CAAT boxes
P08985122A0501|179 179|G
P08985122A0501|50 77|transcription initiation sites
P08985122A0501|136 157|transcription factor SP1
P08985122A0501|187 192|domain
P08985122A0501|88 91|TATA
P08985122A0501|3 16|promoter region
P08985122A0501|118 129|binding sites
P08985122A0501|225 233|promoters
P08985415A1096|43 51|mechanism
P08985415A1096|90 98|monocytes
P08985415A1096|79 87|IFN-gamma
P08985415A1096|55 64|activation
P08985415A1096|70 76|CAEV LTR
P08985415A1096|3 24|STAT-1 signaling pathway
P08986190A0927|0 10|Reperfusion
P08986190A0927|27 35|reduction
P08986190A0927|80 89|LDH release
P08986190A0927|38 54|lactate production
P08986190A0927|70 77|increase
P08986214A0000|87 94|patients
P08986214A0000|114 122|hepatitis
P08986214A0000|76 79|sera
P08986214A0000|63 74|liver disease
P08986214A0000|129 137|cirrhosis
P08986214A0000|32 39|response
P08986214A0000|153 174|hepatocyte growth factor
P08986214A0000|183 199|alpha-fetoprotein
P08986214A0000|42 49|patients
P08986214A0000|201 203|AFP
P08986214A0000|176 178|HGF
P08986228A0000|0 7|Children
P08986228A0000|69 75|effects
P08986228A0000|107 119|malformations
P08986228A0000|32 38|mothers
P08986692A0306|0 11|INTERVENTION
P08986692A0306|67 74|patients
P08986692A0306|26 45|hemostasis parameters
P08986692A0306|13 13|S
P08986692A0306|85 90|IVF-ET
P08986770A0268|128 140|splice variant
P08986770A0268|109 113|I-POU
P08986770A0268|77 81|phase
P08986770A0268|16 25|expression
P08986770A0268|94 104|development
P08986770A0268|31 49|I-POU/tI-POU message
P08986812A1214|15 17|p53
P08986812A1214|76 84|cell lines
P08986812A1214|38 41|cDNA
P08986812A1214|22 31|delta proAE
P08986812A1214|112 118|effects
P08986812A1214|64 68|tumor
P08987009A0400|85 97|psychoanalyst
P08987009A0400|12 15|role
P08987009A0400|56 62|freedom
P08987009A0400|31 43|prerequisites
P08987009A0400|3 9|patient
P08987225A0675|13 22|risk factor
P08987225A0675|136 142|history
P08987225A0675|111 120|proportion
P08987225A0675|74 80|history
P08987225A0675|55 69|hepatitis C cases
P08987225A0675|163 165|ACT
P08987225A0675|123 127|cases
P08987225A0675|157 158|NT
P08987225A0675|92 98|drug use
P08987225A0675|169 178|Queensland
P08988257A1256|96 100|yeast
P08988257A1256|47 48|kb
P08988257A1256|35 42|telomere
P08988257A1256|24 31|creation
P08988257A1256|110 123|repeat sequence
P08988257A1256|92 93|bp
P08988257A1256|78 86|insertion
P08988257A1256|130 133|site
P08988257A1256|152 161|truncation
P08988257A1256|56 72|reporter construct
P08988257A1256|0 8|Silencing
P08988913A0821|30 35|models
P08988913A0821|37 46|provisions
P08988913A0821|81 95|folate excretion
P08988913A0821|64 71|turnover
P08988913A0821|2 9|contrast
P08988913A0821|122 130|excretion
P08988913A0821|143 151|processes
P08989025A0359|131 139|responses
P08989025A0359|24 31|channels
P08989025A0359|20 22|Ca2
P08989025A0359|96 101|microM
P08989025A0359|50 59|nifedipine
P08989025A0359|61 69|midazolam
P08989025A0359|33 35|VOC
P08989025A0359|73 86|concentrations
P08989763A0605|60 68|diaphragm
P08989763A0605|7 15|artifacts
P08989763A0605|42 54|visualization
P08990168A0688|59 63|STAT1
P08990168A0688|37 41|STAT1
P08990168A0688|77 80|GATE
P08990168A0688|8 23|p48 gene induction
P08990168A0688|45 48|JAK1
P08990194A0000|13 22|resistance
P08990194A0000|64 68|serum
P08990194A0000|25 38|thyroid hormone
P08990194A0000|89 95|failure
P08990194A0000|157 170|refractoriness
P08990194A0000|115 134|thyrotropin secretion
P08990194A0000|3 10|syndrome
P08990194A0000|173 185|hormone action
P08990194A0000|73 87|thyroid hormones
P08990397A1437|76 78|H13
P08990397A1437|116 128|RNA processing
P08990397A1437|25 31|mutants
P08990397A1437|57 67|photosystem
P08990397A1437|90 97|evidence
P08992115A0199|190 192|air
P08992115A0199|126 134|serotonin
P08992115A0199|114 118|blood
P08992115A0199|76 94|acute-phase proteins
P08992115A0199|96 108|KKS activation
P08992115A0199|21 30|bronchitis
P08992115A0199|138 154|lactic acid content
P08992115A0199|3 13|progression
P08992115A0199|160 164|humor
P08992115A0199|55 73|blood concentrations
P08993393A0498|55 64|physiology
P08993393A0498|40 47|findings
P08993393A0498|77 88|hPACAP-R gene
P08993393A0498|21 32|implications
P08993393T0000|139 146|hPACAP-R
P08993393T0000|12 20|signaling
P08993393T0000|119 137|polypeptide receptor
P08993393T0000|39 52|gene activation
P08993393T0000|92 100|adenylate
P08993393T0000|59 72|splice variants
P08993831A0000|14 30|muscle development
P08993831A0000|41 45|types
P08993831A0000|123 134|gene products
P08993831A0000|94 105|combinations
P08993831A0000|48 59|muscle fibers
P08993836A0699|14 20|results
P08993836A0699|52 60|induction
P08993836A0699|25 31|respect
P08993836A0699|109 121|embryogenesis
P08993836A0699|66 79|HNF-3 alpha gene
P08993836A0699|93 102|epithelium
P08994825A0000|0 9|BACKGROUND
P08994825A0000|11 17|Mitosis
P08994825A0000|54 59|factor
P08994825A0000|77 100|Cdc2/28-cyclin B complexes
P08994825A0000|71 74|form
P08994825A0000|35 44|maturation
P08994825A0000|31 33|MPF
P08994832A0782|56 64|apoptosis
P08994832A0782|26 31|HEK293
P08994832A0782|7 16|expression
P08994832A0782|34 42|HeLa cells
P08994832A0782|19 23|Apo-3
P08994968A0926|82 88|subunit
P08994968A0926|12 14|arm
P08994968A0926|114 117|NADP
P08994968A0926|23 29|subunit
P08994968A0926|64 69|domain
P08994968A0926|108 111|ring
P08995054A0618|0 9|Similarity
P08995054A0618|105 117|retroelements
P08995054A0618|70 77|gag genes
P08995054A0618|48 53|region
P08995054A0618|29 45|zinc knuckle region
P08995054A1368|0 1|D.
P08995054A1368|86 91|codons
P08995054A1368|50 55|region
P08995054A1368|25 33|sequences
P08995054A1368|60 79|insertions/deletions
P08995054A1368|99 115|nucleotide changes
P08995054A1368|14 18|HeT-A
P08995410A0000|28 31|eIF3
P08995410A0000|150 156|subunit
P08995410A0000|178 192|ribosome subunit
P08995410A0000|209 214|factor
P08995410A0000|106 108|Met
P08995410A0000|53 59|complex
P08995410A0000|101 104|tRNA
P08995410A0000|92 99|eIF2 x GTP
P08995410A0000|158 161|eIF3
P08995410A0000|122 132|mRNA binding
P08995410A0000|10 25|initiation factor
P08995410A0000|140 140|S
P08995410A0000|84 90|complex
P08995410A1109|140 142|p40
P08995410A1109|124 126|p66
P08995410A1109|102 105|p170
P08995410A1109|37 46|co-workers
P08995410A1109|112 116|hPrt1
P08995410A1109|128 130|p48
P08995410A1109|68 71|eIF3
P08995410A1109|132 134|p47
P08995410A1109|93 100|subunits
P08995410A1109|151 153|p35
P08995410A1109|119 122|p110
P08995410A1109|136 138|p44
P08995410A1109|107 110|p116
P08995410A1109|3 6|data
P08995410A1109|144 146|p36
P08995410A1109|27 33|Hershey
P08995614T0000|0 13|Identification
P08995614T0000|27 33|element
P08995614T0000|50 86|histocompatibility complex gene promoter
P08995614T0000|121 129|sequences
P08995614T0000|39 43|class
P08995614T0000|99 108|activation
P08995652A0812|401 410|amino acids
P08995652A0812|382 389|sequence
P08995652A0812|225 234|amino acids
P08995652A0812|578 583|UL26.5
P08995652A0812|546 567|maturation cleavage site
P08995652A0812|260 266|capsids
P08995652A0812|36 42|capsids
P08995652A0812|416 428|UL80.5 protein
P08995652A0812|495 510|scaffold proteins
P08995652A0812|317 319|VP5
P08995652A0812|300 312|UL80.5 protein
P08995652A0812|443 454|RRIFVA ALNKLE
P08995652A0812|353 359|capsids
P08995652A0812|109 118|amino acids
P08995652A0812|240 252|UL26.5 protein
P08995652A0812|523 532|sequences N
P08995652A0812|622 639|scaffold structures
P08995652A0812|474 489|self-interaction
P08995652A0812|587 600|UL80.5 proteins
P08995652A0812|181 193|UL80.5 protein
P08995652A0812|120 132|UL80.5 protein
P08995652A0812|337 344|assembly
P08995652A0812|166 175|amino acids
P08995652A0812|3 9|results
P08995652A0812|457 468|RRIFVAAMMKLE
P08995652A0812|284 294|interaction
P08995659A0563|131 137|primers
P08995659A0563|39 42|MSRs
P08995659A0563|13 33|region splice junctions
P08995659A0563|152 163|splice region
P08995659A0563|93 117|sequencing RNA-PCR products
P08995659A0563|68 76|infection
P08995681A0518|42 46|forms
P08995681A0518|55 61|protein
P08995681A0518|49 52|ICP4
P08995681A0518|4 8|ICP27
P08996730A1146|159 169|measurement
P08996730A1146|46 64|employment durations
P08996730A1146|22 42|vibration measurements
P08996730A1146|89 98|variations
P08996730A1146|116 128|grinder wheels
P08996730A1146|16 19|data
P08996730A1146|73 83|uncertainty
P08996730A1146|0 3|Lack
P08996730A1146|145 156|difficulties
P08996730A1146|101 114|tool conditions
P08997490A1127|0 9|C/EBP beta V
P08997490A1127|35 40|subset
P08997490A1127|64 71|DBP sites
P08997490A1127|43 52|C/EBP sites
P08997490A1127|137 167|cholesterol hydroxylase promoters
P08997490A1127|127 133|albumin
P08997490A1127|79 94|oligonucleotides
P08997490A1127|114 121|contexts
P08997532A0116|88 95|antigens
P08997532A0116|31 48|IgE immunoglobulins
P08997532A0116|97 99|TES
P08997532A0116|8 10|IgG
P08997532A0116|56 63|Toxocara
P08997532A0116|20 22|IgE
P08997532A0116|120 133|ELISA technique
P08998115A0114|0 20|SUMMARY BACKGROUND DATA
P08998115A0114|22 33|Melanoma care
P08998115A0114|104 123|lymph node dissections
P08998115A0114|130 136|disease
P08998115A0114|83 93|controversy
P08998115A0114|71 75|years
P08999414A0819|3 13|differences
P08999414A0819|19 27|subgenera
P08999414A0819|33 48|genus Dermacentor
P08999857A0801|131 150|collagen gene promoter
P08999857A0801|129 129|I
P08999857A0801|109 116|activity
P08999857A0801|21 27|context
P08999857A0801|11 15|E-box
P08999857A0801|81 91|enhancement
P08999857A0801|122 127|alpha1
P08999857A0801|44 49|region
P08999882T0000|0 9|Expression
P08999882T0000|38 46|beta cells
P08999882T0000|20 25|traits
P09000049A1341|60 62|Myc
P09000049A1341|64 76|Max activities
P09000049A1341|91 107|cell proliferation
P09000049A1341|17 19|Max
P09000049A1341|25 33|complexes
P09000049A1341|13 15|Mnt
P09000108A0330|87 108|polyadenylation signals
P09000108A0330|138 164|translation termination codon
P09000108A0330|3 22|transcription product
P09000108A0330|54 57|site
P09000108A0330|168 171|CG30
P09000108A0330|121 122|bp
P09000108A0330|68 76|consensus
P09000108A0330|28 33|kb mRNA
P09000146T0000|72 90|sequence alterations
P09000146T0000|44 53|c-src genes
P09000146T0000|10 16|changes
P09000146T0000|30 33|type
P09000589A0000|29 35|malaria
P09000589A0000|50 59|evaluation
P09000589A0000|77 82|agents
P09000589A0000|3 12|resurgence
P09000632A2341|99 105|complex
P09000632A2341|19 34|Cys181 side-chain
P09000632A2341|55 63|direction
P09000632A2341|5 14|p51 subunit
P09000632A2341|69 84|Tyr181 side-chain
P09001213A1111|159 173|expression sites
P09001213A1111|70 83|chromosome ends
P09001213A1111|177 184|var genes
P09001213A1111|86 97|P. falciparum
P09001213A1111|17 34|level transcription
P09001213A1111|43 46|gene
P09001245A0187|0 5|NUP145
P09001245A0187|59 64|screen
P09001313A0000|74 78|women
P09001313A0000|38 40|SDB
P09001313A0000|28 36|breathing
P09001313A0000|0 9|Prevalence
P09001667A0312|13 23|antigenemia
P09001667A0312|52 70|day post-vaccination
P09001667A0312|5 9|cases
P09001828A0222|138 142|study
P09001828A0222|58 61|time
P09001828A0222|1 5|total
P09001828A0222|111 119|treatment
P09001828A0222|64 73|physicians
P09001828A0222|82 84|BPH
P09001828A0222|12 14|men
P09001828A0222|25 29|years
P09002648A0202|0 4|BCL-2
P09002648A0202|8 16|inhibitor
P09002648A0202|101 109|cell death
P09002648A0202|19 27|apoptosis
P09002648A0202|35 41|variety
P09002648A0202|44 52|cell types
P09002672A0439|143 148|arrays
P09002672A0439|72 83|repeat arrays
P09002672A0439|23 31|mTRF1 cDNA
P09002672A0439|85 89|mTRF1
P09002672A0439|187 192|TTAGGC
P09002672A0439|151 163|TTAGGG repeats
P09002672A0439|106 124|sequence specificity
P09002672A0439|7 17|translation
P09002672A0439|45 54|kDa protein
P09002672A0439|196 208|TTGGGG repeats
P09002672A0439|167 182|binding substrate
P09002672A0439|127 131|hTRF1
P09003001A1593|76 82|factors
P09003001A1593|24 26|E12
P09003001A1593|31 37|protein
P09003001A1909|59 64|CATCTG
P09003001A1909|80 88|gel shifts
P09003001A1909|21 31|SE2 fragment
P09003001A1909|37 55|transferrin promoter
P09003001A1909|94 115|consensus E-box elements
P09003001A1909|3 15|E-box sequence
P09003001A1909|117 122|CANNTG
P09003311A0478|86 92|regions
P09003311A0478|66 70|porCa
P09003311A0478|51 59|porin gene
P09003311A0478|7 17|DNA fragment
P09003312A0740|176 182|mutants
P09003312A0740|11 17|AT-PHH1
P09003312A0740|26 32|AT-PHH1
P09003312A0740|153 157|yeast
P09003312A0740|210 214|light
P09003312A0740|114 118|cDNAs
P09003312A0740|83 86|size
P09003312A0740|36 52|AT-PHH1 delta C-513
P09003312A0740|98 112|photolyase genes
P09003410A0000|71 75|virus
P09003410A0000|43 53|coactivator
P09003410A0000|8 18|p100 protein
P09003410A0000|83 89|antigen
P09003462A0792|29 31|S61
P09003462A0792|37 39|S29
P09003462A0792|74 83|nrdB intron
P09003462A0792|94 106|self-splicing
P09003462A0792|54 58|SL126
P09003462A0792|33 35|SL1
P09003462A0792|15 27|mutation sites
P09003462A0792|46 50|SL196
P09003462A0792|41 44|SL11
P09003463A0198|75 76|kb
P09003463A0198|21 29|isolation
P09003463A0198|81 84|exon
P09003463A0198|65 70|region
P09003463A0198|33 48|characterization
P09003463A0198|4 9|report
P09003463A0198|96 107|RII alpha gene
P09003617A0000|41 46|months
P09003617A0000|51 55|years
P09003617A0000|16 23|children
P09003617A0000|58 60|age
P09003617A0000|1 6|cohort
P09004304A0000|130 138|51Cr-EDTA
P09004304A0000|88 113|chromium-51 ethylenediamine
P09004304A0000|49 54|number
P09004304A0000|67 82|clearance methods
P09004304A0000|125 128|acid
P09004304A0000|31 45|reproducibility
P09004304A0000|3 5|aim
P09004304A0000|172 191|blood sample technique
P09004304A0000|12 16|study
P09004504A0000|26 38|bp DNA fragment
P09004504A0000|125 151|Yersinia pestis plasmid pYP358
P09004504A0000|100 110|replication
P09004504A0000|49 55|pla gene
P09004504A0000|65 84|plasminogen activator
P09004504A0000|10 18|structure
P09004504A0000|92 97|origin
P09004987T0001|0 21|Serotonin concentration
P09004987T0001|27 31|blood
P09004987T0001|57 61|fever
P09004987T0001|34 41|patients
P09004987T0001|71 78|syndrome
P09005273A0322|0 18|MAIN OUTCOME MEASURES
P09005273A0322|56 64|syndromes
P09005273A0322|83 102|chemical interactions
P09005273A0322|69 79|risk factors
P09005273A0322|114 134|butyrylcholinesterase
P09005273A0322|34 39|factor
P09005273A0322|20 31|Associations
P09005273A0322|138 161|neuropathy target esterase
P09005273A1558|15 29|Gulf War veterans
P09005273A1558|92 103|combinations
P09005273A1558|82 89|exposure
P09005273A1558|106 114|chemicals
P09005273A1558|62 70|syndromes
P09005273A1558|150 173|neuropathy target esterase
P09005273A1558|126 146|butyrylcholinesterase
P09005273A1558|0 9|CONCLUSION
P09005609A0299|0 17|Control examination
P09005609A0299|35 37|end
P09005609A0299|44 49|period
P09005836A0977|2 12|correlation
P09005836A0977|43 55|antibody level
P09005836A0977|23 25|age
P09005836A0977|31 36|horses
P09005979A0841|3 9|GHR mRNA
P09005979A0841|11 23|GHBP mRNA ratio
P09005979A0841|63 77|differentiation
P09006007A0997|204 216|compatibility
P09006007A0997|156 166|specificity
P09006007A0997|54 61|UGA codon
P09006007A0997|114 124|SelB protein
P09006007A0997|246 253|ribosome
P09006007A0997|232 238|complex
P09006007A0997|86 95|conditions
P09006007A0997|181 191|interaction
P09006007A0997|3 9|results
P09006010A0527|174 188|secretion signal
P09006010A0527|71 87|S-layer biogenesis
P09006010A0527|45 53|amino acid
P09006010A0527|160 163|RsaA
P09006010A0527|124 132|secretion
P09006010A0527|205 213|amino acid
P09006010A0527|102 110|amino acid
P09006010A0527|63 68|effect
P09006010A0527|194 194|C
P09006010A0527|138 144|protein
P09006010A0527|31 43|RsaA C terminus
P09006010A0527|233 241|amino acid
P09006010A0527|3 25|linker-peptide insertion
P09006022A0252|73 79|control
P09006022A0252|33 40|cvaA gene
P09006022A0252|17 28|gene products
P09006022A0252|82 104|T7 RNA polymerase promoter
P09006051A1162|0 3|PrpB
P09006051A1162|183 198|citrate synthases
P09006051A1162|210 217|homology
P09006051A1162|280 287|homology
P09006051A1162|228 251|Bacillus subtilis proteins
P09006051A1162|140 143|PrpC
P09006051A1162|290 315|acetyl coenzyme A synthetases
P09006051A1162|20 62|carboxyphosphonoenolpyruvate phosphonomutase
P09006051A1162|110 138|carnation Dianthus caryophyllus
P09006051A1162|261 268|function
P09006051A1162|10 17|homology
P09006051A1162|163 170|archaeal
P09006051A1162|220 224|yeast
P09006051A1162|98 104|homolog
P09006051A1162|200 203|PrpD
P09006051A1162|270 273|PrpE
P09006555A0738|0 18|MAIN OUTCOME MEASURES
P09006555A0738|132 153|neutrophil oxidant burst
P09006555A0738|213 219|studies
P09006555A0738|98 110|lavage protein
P09006555A0738|40 51|hemodynamics
P09006555A0738|185 200|scanning electron
P09006555A0738|155 180|lung myeloperoxidase content
P09006555A0738|114 130|neutrophil content
P09006555A0738|61 81|blood gas determination
P09006902A0370|15 18|cDNA
P09006902A0370|32 36|MEKK3
P09006910A0000|130 145|RXRgamma2 isoform
P09006910A0000|114 119|region
P09006910A0000|63 79|retinoid X receptor
P09006910A0000|54 60|control
P09006910A0000|85 98|gene expression
P09006910A0000|81 83|RXR
P09006910A0000|16 25|mechanisms
P09006914A0812|0 2|JNK
P09006914A0812|91 93|JNK
P09006914A0812|66 70|ATF-2
P09006914A0812|38 44|nucleus
P09006914A0812|97 99|p38
P09006914A0812|6 8|p38
P09006914A0812|58 62|c-JUN
P09006914A1127|132 155|E-selectin gene expression
P09006914A1127|96 102|kinases
P09006914A1127|79 88|activation
P09006914A1127|3 9|effects
P09006914A1127|31 35|forms
P09006914A1127|41 63|JNK/p38 signaling pathway
P09006935A0590|0 2|Sp1
P09006935A0590|35 36|KD
P09006935A0590|11 19|CTC repeat
P09006935A0590|63 76|consensus GC box
P09006935A0590|42 43|nM
P09006935A0590|26 33|affinity
P09006936T0000|0 13|Identification
P09006936T0000|40 46|protein
P09006936T0000|19 24|region
P09006936T0000|80 98|glycoprotein IBalpha
P09006936T0000|72 77|domain
P09008301A0193|99 105|protein
P09008301A0193|50 67|autoprocessing site
P09008301A0193|127 133|studies
P09008301A0193|6 16|enzyme forms
P09009208A0337|65 71|Tf1 mRNA
P09009208A0337|48 52|bases
P09009208A0337|23 30|cleavage
P09009208A0337|3 8|primer
P09010223A0667|72 83|PU.1 proteins
P09010223A0667|119 126|Egr1 SREI
P09010223A0667|65 68|PEA3
P09010223A0667|111 113|SRF
P09010223A0667|35 39|SAP1a
P09010223A0667|41 44|FLI1
P09010223A0667|55 58|ETS1
P09010223A0667|46 53|EWS-FLI1
P09010223A0667|60 63|ETS2
P09010223A0667|98 106|complexes
P09010223A0667|30 33|ELK1
P09010223A1850|41 43|SRF
P09010223A1850|90 97|EWS-FLI1
P09010223A1850|164 173|regulation
P09010223A1850|26 36|interaction
P09010223A1850|120 127|function
P09010223A1850|179 186|Egr1 gene
P09010223A1850|136 158|ETS transcription factors
P09010223A1850|55 63|mechanism
P09010223A1850|4 11|R-domain
P09010223A1850|83 86|FLI1
P09011591A0309|52 58|smokers
P09011591A0309|8 13|number
P09011591A0309|37 46|nonsmokers
P09011591A0309|16 24|specimens
P09011744A0790|86 92|epsilon
P09011744A0790|78 83|Grin2a
P09011744A0790|151 158|subunits
P09011744A0790|256 266|F1xC57BL/6J
P09011744A0790|226 232|crosses
P09011744A0790|103 109|epsilon
P09011744A0790|38 64|NMDA receptor channel subunits
P09011744A0790|139 142|zeta
P09011744A0790|129 134|Grin2d
P09011744A0790|248 254|spretus
P09011744A0790|69 75|epsilon
P09011744A0790|20 28|locations
P09011744A0790|95 100|Grin2b
P09011744A0790|268 271|mice
P09011744A0790|194 214|backcross mapping panel
P09011744A0790|112 117|Grin2c
P09011744A0790|237 246|C57BL/6JxM
P09011744A0790|145 149|Grinl
P09011744A0790|120 126|epsilon
P09011745T0000|108 116|structure
P09011745T0000|149 157|processes
P09011745T0000|4 10|cloning
P09011745T0000|171 179|receptors
P09011745T0000|118 125|function
P09011745T0000|13 22|chick brain
P09011745T0000|74 86|acid receptors
P09011745T0000|94 105|conservation
P09012405A0785|15 19|TTD-A
P09012405A0785|103 110|function
P09012405A0785|113 121|DNA repair
P09012405A0785|51 58|subunits
P09012405A0785|23 33|XP-D defects
P09012405A0785|61 65|TFIIH
P09012405A0785|73 91|transcription factor
P09012636A0723|0 9|Adjustment
P09012636A0723|146 160|atherosclerosis
P09012636A0723|133 142|fibrinogen
P09012636A0723|13 15|age
P09012636A0723|70 76|smoking
P09012636A0723|49 61|triglycerides
P09012636A0723|22 32|cholesterol
P09012636A0723|34 47|HDL cholesterol
P09012636A0723|115 125|association
P09012636A0723|89 96|pressure
P09013499A0198|222 229|controls
P09013499A0198|157 168|conditioning
P09013499A0198|130 132|min
P09013499A0198|63 106|N-methyl-D-aspartate receptor antagonist MK-801
P09013499A0198|200 203|odor
P09013499A0198|111 115|mg/kg
P09013499A0198|35 43|injection
P09013499A0198|178 181|time
P09013499A0198|2 11|Experiment
P09013499A0198|14 17|pups
P09013760A0000|0 10|Cholesterol
P09013760A0000|21 42|cleavage cytochrome P450
P09013760A0000|111 115|ovary
P09013760A0000|51 57|P450scc
P09013760A0000|128 131|cAMP
P09013760A0000|121 124|ACTH
P09013760A0000|86 98|gonadotropins
P09013760A0000|59 72|gene expression
P09013760A0000|102 105|cAMP
P09013760A0000|149 153|cells
P09013760A0000|44 49|CYP11A
P09015543A0210|32 38|forearm
P09015543A0210|11 18|solution
P09015543A0210|43 46|flap
P09015757T0000|103 105|BSP
P09015757T0000|107 110|gene
P09015757T0000|39 44|tissue
P09015757T0000|66 75|expression
P09015757T0000|21 36|characterization
P09015757T0000|10 17|analysis
P09015757T0000|86 101|bone sialoprotein
P09015799T0000|0 17|Serotonin receptors
P09015799T0000|20 33|suicide victims
P09015799T0000|43 52|depression
P09016566A0655|45 50|number
P09016566A0655|62 69|BiP mRNAs
P09016566A0655|19 23|motif
P09017443A0734|86 91|effect
P09017443A0734|133 133|p
P09017443A0734|94 100|regimen
P09017443A0734|67 74|syndrome
P09017443A0734|118 131|stratification
P09017443A0734|46 55|occurrence
P09017443A0734|14 25|marker screen
P09018122A1389|14 27|ORF-1 sequences
P09018122A1389|64 75|prerequisite
P09018122A1389|100 115|tumor development
P09018122A1389|50 54|proof
P09018122A1389|94 97|role
P09018122A1389|35 40|tumors
P09018122A1389|3 11|detection
P09018133A0244|117 135|alpha-Herpesvirinae
P09018133A0244|53 64|relationship
P09018133A0244|24 31|evidence
P09018133A0244|144 154|herpesvirus
P09018133A0244|12 19|analysis
P09018133A0244|81 87|members
P09018133A0244|93 111|Varicellovirus genus
P09018133A0244|72 77|PhHV-1
P09019302A0600|13 15|PLP
P09019302A0600|63 76|derivatization
P09019302A0600|6 11|method
P09019302A0600|47 57|sensitivity
P09019302A0600|18 23|plasma
P09019302A0600|107 111|phase
P09019302A0600|81 95|sodium bisulfite
P09020138A0833|25 31|complex
P09020138A0833|11 13|Cas
P09020138A0833|88 95|tyrosine
P09020138A0833|74 78|RAFTK
P09020138A0833|59 72|tyrosine kinase
P09020138A0833|4 7|HEF1
P09020138A0833|46 53|adhesion
P09020138A0833|118 136|adapter molecule CrkL
P09020169A0552|55 57|AHR
P09020169A0552|7 10|SIM2
P09020169A0552|20 29|homodimers
P09020169A0552|0 3|SIM1
P09020172A0964|0 8|Complexes
P09020172A0964|75 79|forms
P09020172A0964|11 16|qTBP42
P09020172A0964|38 43|strand
P09020172A0964|114 136|nM dissociation constants
P09020172A0964|209 216|Kd values
P09020172A0964|185 187|DNA
P09020172A0964|138 139|Kd
P09020172A0964|97 102|strand
P09020172A0964|148 156|complexes
P09020172A0964|55 57|DNA
P09020856A0560|58 68|MCK promoter
P09020856A0560|12 17|effect
P09020856A0560|27 30|TIS1
P09021684A1418|175 197|transactivation activity
P09021684A1418|78 84|nucleus
P09021684A1418|39 46|proteins
P09021684A1418|145 157|NF-kappa B2p52
P09021684A1418|12 15|data
P09021684A1418|112 129|repressor functions
P09022040A0263|204 211|function
P09022040A0263|127 140|gene expression
P09022040A0263|157 161|cells
P09022040A0263|71 77|rodents
P09022040A0263|7 25|L-plastin expression
P09022040A0263|253 274|L-plastin gene promoters
P09022040A0263|62 67|humans
P09022040A0263|100 109|mechanisms
P09022040A0263|215 233|nucleotide sequences
P09022632T0000|36 42|surgery
P09023197T0000|15 30|Bacillus subtilis
P09023197T0000|3 12|dnaK operon
P09023378A0959|144 151|versions
P09023378A0959|115 131|activator sequence
P09023378A0959|50 62|transcription
P09023378A0959|21 24|CBF1
P09023378A0959|9 18|expression
P09023378A0959|91 102|C-repeat/DRE
P09023378A0959|157 166|DNA element
P09023378A0959|65 77|reporter genes
P09023378A0959|27 31|yeast
P09024039A0247|118 120|CCA
P09024039A0247|78 87|procedures
P09024039A0247|125 134|desflurane
P09024039A0247|36 43|patients
P09024039A0247|137 146|isoflurane
P09024039A0247|151 161|ventilation
P09024039A0247|9 11|ASA
P09024039A0247|55 61|variety
P09024039A0247|20 25|status
P09024039A0247|69 69|h
P09024097A0000|118 125|ligation
P09024097A0000|56 60|women
P09024097A0000|103 112|postpartum
P09024097A0000|13 16|goal
P09024097A0000|72 75|rate
P09024097A0000|85 97|complications
P09024097A0000|0 8|OBJECTIVE
P09024793A1325|152 159|presence
P09024793A1325|162 166|BMP-2
P09024793A1325|50 57|extracts
P09024793A1325|77 80|MyoD
P09024793A1325|5 37|electrophoresis mobility shift assay
P09024793A1325|136 142|MCK gene
P09024793A1325|107 111|E-box
P09024793A1325|84 91|myogenin
P09024793A1325|71 75|cells
P09024793A1325|117 130|enhancer region
P09024805A0905b|155 172|beta-globin TATA box
P09024805A0905b|108 111|CREB
P09024805A0905b|104 106|ZII
P09024805A0905b|113 115|AP1
P09024805A0905b|13 29|promoter construct
P09024805A0905b|117 123|element
P09024805A0905b|183 206|phorbol ester inducibility
P09024805A0905b|95 98|copy
P09024805A0905b|55 70|consensus Sp1 site
P09024805A0905b|131 143|BZLF1 promoter
P09024805A0905b|45 51|repeats
P09025122A0374|74 81|COWA task
P09025122A0374|10 20|experiments
P09025122A0374|122 132|performance
P09025122A0374|38 42|tasks
P09025122A0374|62 68|aspects
P09025549A0000|41 50|competence
P09025549A0000|34 38|level
P09025549A0000|76 88|practitioners
P09025549A0000|8 12|nurse
P09025549A0000|222 230|continent
P09025549A0000|100 132|Vancouver sex therapist Bianca Rucker
P09025549A0000|178 184|mentors
P09025549A0000|165 174|colleagues
P09025549A0000|156 162|network
P09025549A0000|206 209|home
P09025549A0000|194 199|fields
P09025549A0000|94 98|field
P09027346A1957|134 137|exon
P09027346A1957|139 141|pE x
P09027346A1957|38 58|hCG-ectodomain complex
P09027346A1957|25 32|site IIIa
P09027346A1957|149 151|LHR
P09027346A1957|8 22|antibody binding
P09027346A1957|90 92|mAb
P09027346A1957|109 115|peptide
P09027506T0000|45 56|localization
P09027506T0000|92 94|iso
P09027506T0000|12 29|expression analysis
P09027506T0000|82 89|wheat eIF
P09027506T0000|110 115|eIF-4G
P09027506T0000|96 97|4F
P09027506T0000|72 79|homology
P09027506T0000|60 63|gene
P09027506T0000|0 10|cDNA cloning
P09028089A0183|32 43|hypertension
P09028089A0183|93 114|transplantation surgery
P09028089A0183|67 75|blood flow
P09028308A0590|29 31|AZQ
P09028308A0590|196 200|cycle
P09028308A0590|168 170|day
P09028308A0590|10 17|patients
P09028308A0590|142 154|micrograms/kg
P09028308A0590|113 119|cohorts
P09028308A0590|35 47|mitroxantrone
P09028308A0590|68 88|bone marrow suppression
P09028308A0590|135 139|G-CSF
P09028308A0590|176 185|completion
P09028308A0590|203 214|chemotherapy
P09028942A0000|75 79|genes
P09028942A0000|128 132|egr-1
P09028942A0000|92 94|jun
P09028942A0000|70 72|set
P09028942A0000|108 125|growth response gene
P09028942A0000|52 58|hGM-CSF
P09028942A0000|86 90|c-fos
P09028942A0000|96 98|myc
P09028942A0000|45 50|factor
P09028998A0143|29 35|control
P09028998A0143|63 69|outcome
P09028998A0143|113 115|BCT
P09028998A0143|2 6|order
P09028998A0143|82 93|breast tissue
P09028998A0143|74 79|amount
P09029091A0881|120 132|A2/HCP chimera
P09029091A0881|33 55|tyrosine phosphorylation
P09029091A0881|96 106|Jurkat cells
P09029091A0881|58 76|phospholipase C gamma
P09029104A0226|59 64|manner
P09029104A0226|32 38|lineage
P09029104A0226|8 12|IGLL1
P09029104A0226|14 17|gene
P09029159A0000|45 49|dsRNA
P09029159A0000|82 84|PKR
P09029159A0000|41 43|RNA
P09029159A0000|61 80|Ser/Thr protein kinase
P09029159A0000|130 136|effects
P09029159A0000|92 95|role
P09029159A0000|3 12|interferon
P09029159A0000|139 141|IFN
P09029159A0000|14 16|IFN
P09029713A1120|84 99|repressor COUP-TF
P09029713A1120|41 47|control
P09029713A1120|12 15|data
P09029713A1120|128 140|transcription
P09029713A1120|53 59|amounts
P09029713A1120|65 77|activator SF-1
P09029956T0000|43 60|structure formation
P09029956T0000|22 31|management
P09029956T0000|6 14|relations
P09030581A0990|85 92|JNK/SAPK
P09030581A0990|66 79|selectivity ERK
P09030581A0990|37 46|activation
P09030581A0990|26 30|MKP-4
P09030581A0990|81 83|p38
P09030581A0990|49 58|MAP kinases
P09030581A0990|15 24|COS-7 cells
P09030688A0435|74 90|Rap1p localization
P09030688A0435|23 31|chromatin
P09030688A0435|53 61|silencing
P09030688A0435|2 12|rlf2 mutants
P09030781A0734|4 10|kinases
P09030781A0734|41 51|roscovitine
P09030781A0734|162 167|microM
P09030781A0734|183 195|cdk4/cyclin D1
P09030781A0734|256 261|microM
P09030781A0734|53 64|cdc2/cyclin B
P09030781A0734|79 90|cdk2/cyclin E
P09030781A0734|94 101|cdk5/p35
P09030781A0734|132 141|IC50 values
P09030781A0734|248 251|IC50
P09030781A0734|236 246|roscovitine
P09030781A0734|66 77|cdk2/cyclin A
P09030781A0734|199 211|cdk6/cyclin D2
P09031639A0474|41 43|ORF
P09031639A0474|8 13|kb cDNA
P09031639A0474|121 128|position
P09031639A0474|50 51|bp
P09031639A0474|144 154|U1-C protein
P09031639A0474|88 89|aa
P09031639A0474|77 86|amino acids
P09031639A0474|112 119|position
P09031639A0474|61 71|polypeptide
P09031639A0474|28 39|reading frame
P09032233T0000|0 10|Interaction
P09032233T0000|13 17|Ets-1
P09032233T0000|52 56|Pit-1
P09032233T0000|24 50|POU-homeodomain protein GHF-1
P09032233T0000|88 101|gene expression
P09032248A0239|85 89|Start
P09032248A0239|104 122|Cln1,2-Cdc28 kinases
P09032248A0239|40 66|Pcl1,2-Pho85 kinase complexes
P09032248A0239|95 101|absence
P09032248A0239|8 12|Pho85
P09032248A0239|30 38|viability
P09032250A0257|96 118|CCAAT binding protein NF-Y
P09032250A0257|124 138|HeLa cDNA library
P09032250A0257|65 68|Tax1
P09032250A0257|23 28|system
P09032250A0257|8 12|yeast
P09032250A0257|83 90|B subunit
P09032250A0257|31 36|screen
P09032250A0257|40 47|proteins
P09032254A0724|0 15|Enhancer activity
P09032254A0724|31 38|AP-1 site
P09032254A0724|55 63|sequences
P09032258A0395|0 6|Studies
P09032258A0395|12 28|HLA-DR-B7-1-LFA-3
P09032258A0395|35 47|transfectants
P09032258A0395|74 96|NF-AT DNA binding activity
P09032258A0395|121 137|B7-1 costimulation
P09032259A0150|88 96|functions
P09032259A0150|24 27|Rac1
P09032259A0150|12 21|activation
P09032259A0150|52 65|transformation
P09032259A0150|31 34|RhoA
P09032259A0150|68 78|NIH 3T3 cells
P09032259A0150|117 133|Ras transformation
P09032259A0972|28 30|JNK
P09032259A0972|12 25|Rac1 activation
P09032259A0972|50 61|lamellipodia
P09032259A0972|33 35|SRF
P09032259A0972|39 47|induction
P09032259A0972|98 121|Rac1 transforming activity
P09032267A0850|0 13|Overexpression
P09032267A0850|93 94|TR
P09032267A0850|77 85|cross talk
P09032267A0850|98 105|p45/NF-E
P09032267A0850|19 39|bZip interaction domain
P09032267A0850|42 44|CBP
P09032275A1133|14 19|domain
P09032275A1133|57 74|AHC deletion mutants
P09032275A1133|86 89|date
P09032304T0000|60 77|herpes simplex virus
P09032304T0000|88 98|protein ICP4
P09032304T0000|34 54|transactivation domain
P09032304T0000|0 13|Identification
P09032328A0650|0 12|DNA sequencing
P09032328A0650|108 115|presence
P09032328A0650|21 27|segment
P09032328A0650|127 130|ORFs
P09032328A0650|92 96|ORF17
P09032328A0650|72 75|DL-B
P09032328A0650|84 88|ORF11
P09032328A0650|66 70|locus
P09032328A0650|41 56|gammaherpesvirus
P09032328A0650|173 180|proteins
P09032328A0650|144 155|gene products
P09034337A0251|73 87|phosphorylation
P09034337A0251|104 111|response
P09034337A0251|90 96|p34cdc2
P09034337A0251|58 65|tyrosine
P09034337A0251|37 45|induction
P09034337A0251|114 122|DNA damage
P09034337A0251|18 22|cells
P09034337A0251|69 71|Y15
P09034337A0251|0 6|Studies
P09035307A0000|73 79|adenoma
P09035307A0000|35 37|man
P09035307A0000|137 146|99mTc-MIBI
P09035307A0000|93 135|99mTc-methoxyisobutylisonitrile scintigraphy
P09035307A0000|17 20|case
P09035612T0000|102 112|reperfusion
P09035612T0000|49 57|blood flow
P09035612T0000|27 37|infarct size
P09035612T0000|73 80|function
P09035612T0000|7 23|endothelin release
P09035612T0000|89 98|infarction
P09036529A0343|145 157|Apis mellifera
P09036529A0343|180 184|venom
P09036529A0343|77 84|serum IgE
P09036529A0343|89 96|RAST-CAP
P09036529A0343|98 106|Pharmacia
P09036529A0343|162 165|wasp
P09036529A0343|17 25|skin tests
P09036529A0343|45 53|Pharmacia
P09036529A0343|186 195|Aquagen ALK
P09036529A0343|125 138|concentrations
P09036529A0343|32 43|microgram/ml
P09036529A0343|112 115|CAST
P09036529A0343|141 143|bee
P09036529A0343|56 66|measurement
P09036529A0343|167 177|Vespula spec
P09036529A0343|3 8|workup
P09037032T0000|90 117|ribonucleoprotein association
P09037032T0000|41 45|P2P-R
P09037032T0000|145 154|expression
P09037032T0000|55 61|domains
P09037032T0000|121 130|Rb1 binding
P09037032T0000|3 15|proliferation
P09037032T0000|47 50|gene
P09037032T0000|169 183|differentiation
P09037064A0183|30 47|canarypox ALVAC/HIV
P09037064A0183|78 82|HIV-1
P09037064A0183|117 128|CTL responses
P09037064A0183|143 148|number
P09037064A0183|96 105|volunteers
P09037064A0183|50 56|vectors
P09037064A0183|59 75|vaccine immunogens
P09037064A0183|6 16|application
P09037064A0183|151 159|vaccinees
P09037163A1652|59 76|gpc4 gene expression
P09037163A1652|19 26|elements
P09037163A1652|48 56|induction
P09037163A1652|3 11|relevance
P09038166A0818|56 61|intron
P09038166A0818|11 13|A1b
P09038166A0818|0 7|Exons A1a
P09038192A0846|33 38|Dudley
P09038192A0846|40 41|D.
P09038192A0846|13 21|inhibitor
P09038192A0846|23 30|PD098059
P09038202A1951|140 148|promoters
P09038202A1951|5 8|data
P09038202A1951|117 124|proteins
P09038202A1951|30 47|repression activity
P09038202A1951|50 58|NRSF/REST
P09038202A1951|82 89|promoter
P09038202A1951|19 22|idea
P09038202A1951|73 79|species
P09039744T0000|61 72|sinc function
P09039744T0000|19 26|analysis
P09039744T0000|29 50|electro-encephalograms
P09040011A1316|60 70|thymoblasts
P09040011A1316|36 49|G1/S transition
P09040011A1316|10 12|p56
P09040011A1316|169 187|Ras/Raf/MAPK pathway
P09040011A1316|99 110|transduction
P09040011A1316|125 141|activation signals
P09040011A1316|154 163|components
P09040011A1316|83 95|cell viability
P09040011A1316|2 8|summary
P09040011A1316|18 25|activity
P09040011A1316|14 16|lck
P09041123A0195|59 65|factors
P09041123A0195|11 16|action
P09041123A0195|140 146|complex
P09041123A0195|113 121|responses
P09041123A0195|30 35|ligand
P09042078A0202|52 61|dimensions
P09042078A0202|22 29|incisors
P09042078A0202|36 44|direction
P09042078A0202|90 97|subjects
P09042078A0202|74 84|jaw openings
P09042078A0202|17 19|MBF
P09042269A1007|48 59|chemotherapy
P09042269A1007|95 100|cancer
P09042269A1007|5 12|findings
P09042683A0492|3 18|FBF questionnaire
P09042683A0492|54 68|symptoms profile
P09042683A0492|138 150|schizophrenia
P09042683A0492|127 134|disorder
P09042683A0492|86 93|disorder
P09042755T0000|14 30|sigma factor sigmaB
P09042755T0000|91 101|growth phase
P09042755T0000|54 63|regulation
P09042755T0000|81 88|response
P09042755T0000|105 113|heat shock
P09042755T0000|69 78|sigB operon
P09042911A0626|163 170|sequence
P09042911A0626|35 48|glucocorticoid
P09042911A0626|66 75|regulation
P09042911A0626|86 90|liver
P09042911A0626|7 22|promoter elements
P09042911A0626|124 133|expression
P09043534A1600|61 67|minutes
P09043534A1600|20 28|decreases
P09043534A1600|34 47|alkalinization
P09043768A0139|29 31|BLM
P09043768A0139|16 26|biokinetics
P09043768A0139|43 52|indium-111
P09043768A0139|54 59|In-111
P09045636A0789|0 15|CD3 cross-linking
P09045636A0789|23 45|tyrosine phosphorylation
P09045636A0789|65 70|T cells
P09045636A0789|48 52|Sam68
P09045805A0945|71 81|acoK mutants
P09045805A0945|133 155|transactivating function
P09045805A0945|32 44|acoABCD operon
P09045805A0945|94 100|plasmid
P09045805A0945|17 26|expression
P09045805A0945|161 171|gene product
P09045805A0945|117 120|acoK
P09045842T0000|14 18|alpha
P09045842T0000|30 37|subunits
P09045842T0000|74 82|mer operon
P09045842T0000|59 68|expression
P09045842T0000|40 52|RNA polymerase
P09045842T0000|0 8|Mutations
P09045919A1250|60 62|NFE
P09045919A1250|217 238|B lymphocyte development
P09045919A1250|23 30|evidence
P09045919A1250|121 148|transcription factor machinery
P09045919A1250|203 210|IgH locus
P09045919A1250|50 58|activator
P09045919A1250|164 179|enhancer activity
P09045919A1250|112 115|part
P09045919A1250|71 81|combination
P09045919A1250|95 107|c-Rel proteins
P09045919A1250|191 197|control
P09045919A1250|37 45|existence
P09045919A1250|89 91|p50
P09046013A0000|149 151|min
P09046013A0000|167 174|ischemia
P09046013A0000|132 135|rats
P09046013A0000|268 273|artery
P09046013A0000|85 91|SNX-111
P09046013A0000|186 193|ligation
P09046013A0000|210 222|carotid artery
P09046013A0000|63 83|calcium channel blocker
P09046013A0000|18 25|efficacy
P09046013A0000|235 243|occlusion
P09046090T0000|73 90|glucose transporter
P09046090T0000|19 45|transcription factor yTAFII60
P09046090T0000|50 60|G4p1 protein
P09046090T0000|110 122|kb DNA fragment
P09046090T0000|3 7|genes
P09046090T0000|132 134|arm
P09046090T0000|160 172|chromosome VII
P09046186A0189|59 68|trochanter
P09046186A0189|46 53|fracture
P09046186A0189|31 42|fall distance
P09046186A0189|3 11|protector
P09046384A0403|0 21|Marinol/marijuana usage
P09046384A0403|91 101|DDI subgroup
P09046384A0403|52 57|counts
P09046384A0403|69 81|amylase levels
P09046384A0403|48 50|CD4
P09047252A0209|0 6|METHODS
P09047252A0209|107 111|ng/ml
P09047252A0209|55 63|resection
P09047252A0209|90 98|AFP levels
P09047252A0209|19 26|patients
P09047252A0209|67 69|HCC
P09047252A0209|132 136|study
P09047344A0000|43 52|amino acids
P09047344A0000|64 75|muscle myosin
P09047344A0000|81 91|chain kinase
P09047344A0000|93 96|MLCK
P09047344A0000|26 28|CBP
P09047344A0000|129 136|affinity
P09047344A0000|32 38|peptide
P09047344A0000|106 115|calmodulin
P09047344A0000|18 24|peptide
P09048617A0648|17 20|type
P09048617A0648|87 96|cAMP effect
P09048617A0648|23 44|tyrosine kinase receptor
P09048617A0648|76 81|nature
P09049198A0289|28 38|involvement
P09049198A0289|78 87|regulation
P09049198A0289|65 74|expression
P09049198A0289|46 60|liver cell growth
P09049198A0289|164 176|liver diseases
P09049198A0289|148 156|specimens
P09049198A0289|6 12|insight
P09049198A0289|120 125|models
P09049198A0289|128 144|liver regeneration
P09049198A0289|93 99|p21 gene
P09049198A0289|41 43|p21
P09049270A0488|0 19|Northern blot analysis
P09049270A0488|96 101|leaves
P09049270A0488|179 182|type
P09049270A0488|49 59|transcripts
P09049270A0488|106 110|roots
P09049270A0488|22 25|LeMT
P09049270A0488|27 27|A
P09049270A0488|152 160|metal ions
P09049270A0488|113 124|tomato plants
P09049270A0488|163 176|characteristic
P09049270A0488|185 187|MTs
P09049270A0488|73 77|genes
P09049270A0488|137 144|addition
P09049270A0488|37 37|B
P09049270A0488|32 35|LeMT
P09049304A1193|161 182|VPF/VEGF gene expression
P09049304A1193|109 119|AP-2 protein
P09049304A1193|39 59|Egr-1 expression vector
P09049304A1193|27 30|AP-2
P09049304A1193|2 23|co-transfection studies
P09049304A1193|69 89|VPF/VEGF transcription
P09049304A1193|145 147|TGF
P09049306A0830|27 31|exons
P09049306A0830|61 70|chromosome
P09049306A0830|3 9|HBP gene
P09049306A0830|44 45|kb
P09049306A0830|56 58|arm
P09049313A0116|41 50|expression
P09049313A0116|100 120|initiation factor eIF4G
P09049313A0116|6 14|instances
P09049313A0116|90 97|cleavage
P09049313A0116|67 75|proteases
P09050689A0685|101 104|J/cm
P09050689A0685|64 77|administration
P09050689A0685|37 41|SnET2
P09050689A0685|18 25|ablation
P09050689A0685|107 111|hours
P09050689A0685|87 95|treatment
P09050847A0180|29 44|TBP-TAF complexes
P09050847A0180|6 10|class
P09050847A0180|76 80|class
P09050847A0180|91 129|transcription initiation factor TIF-IB/SL1
P09050847A0180|62 67|murine
P09050847A0180|176 183|promoter
P09050847A0180|149 159|selectivity
P09050849A0000|0 10|Cytohesin-1
P09050849A0000|78 84|homolog
P09050849A0000|113 127|Sec7 gene product
P09050849A0000|13 19|protein
P09050849A0000|46 51|system
P09050849A0000|145 160|protein transport
P09050849A0000|30 34|cells
P09050849A1459|56 62|ARF-GEP
P09050849A1459|80 85|domain
P09050849A1459|6 11|regard
P09050861A0903|32 34|DEK
P09050861A0903|47 56|pets factor
P09050861A0903|16 29|identification
P09050867A0542|72 83|octamer motif
P09050867A0542|22 32|binding site
P09050867A0542|126 141|TN control element
P09050867A0542|62 67|factor
P09050867A0542|93 115|POU-homeodomain proteins
P09050867A0542|36 47|Krox proteins
P09050867A0542|5 12|elements
P09051656A0390|0 12|Tissue samples
P09051656A0390|111 114|sham
P09051656A0390|90 108|day morphine infusion
P09051656A0390|65 74|withdrawal
P09051656A0390|35 38|rats
P09051656A0390|129 136|subjects
P09053309A1103|44 53|oep mutants
P09053309A1103|82 101|floor plate inducer shh
P09053309A1103|21 41|floor plate development
P09053309A1103|70 76|absence
P09053494A0612|0 6|RESULTS
P09053494A0612|50 57|patients
P09053494A0612|37 46|cell yields
P09053494A0612|99 103|G-CSF
P09053494A0612|211 215|G-CSF
P09053494A0612|217 217|P
P09053494A0612|69 78|paclitaxel
P09053494A0612|205 206|CY
P09053494A0612|179 192|reference group
P09053494A0612|83 84|CY
P09053494A0612|92 94|CEP
P09053494A0612|133 134|kg
P09053494A0612|11 17|medians
P09053494A0612|172 173|kg
P09053494A0612|32 35|CD34
P09053494A0612|86 87|CE
P09053835A0865|29 30|OP
P09053835A0865|9 19|p53 activity
P09053835A0865|49 55|p53 mRNA
P09053835A0865|61 73|protein levels
P09053973A1252|0 9|CONCLUSION
P09053973A1252|107 113|ascites
P09053973A1252|78 83|effect
P09053973A1252|18 31|administration
P09053973A1252|95 102|patients
P09053973A1252|34 44|misoprostol
P09055221A0288|81 94|signal contrast
P09055221A0288|61 64|MSEs
P09055221A0288|33 41|magnitude
P09055221A0288|101 107|effects
P09055221A0288|17 21|SSTEs
P09055221A0288|3 11|intensity
P09055221A0288|26 30|order
P09056761A0000|174 180|nucleus
P09056761A0000|40 50|translation
P09056761A0000|89 93|cause
P09056761A0000|27 37|termination
P09056761A0000|12 16|cells
P09056761A0000|97 103|variety
P09056761A0000|160 168|cytoplasm
P09056761A0000|212 215|exon
P09056761A0000|125 130|events
P09056761A0000|189 207|splice site selection
P09056761A0000|61 66|codons
P09056761A0000|146 154|mRNA decay
P09057325A0177|86 107|complementation studies
P09057325A0177|33 55|pathogenicity locus pat-1
P09057325A0177|11 21|plasmid pCM2
P09057325A0177|3 8|region
P09057325A0177|67 82|deletion analysis
P09057325A0177|117 137|Bg/II/SmaI DNA fragment
P09057648A0422|144 175|chloramphenicol acetyltransferase
P09057648A0422|51 55|tat/S
P09057648A0422|356 364|U937 cells
P09057648A0422|256 256|%
P09057648A0422|125 129|front
P09057648A0422|25 31|tat cDNA
P09057648A0422|105 107|FC3
P09057648A0422|279 309|micrograms/mL phytohemagglutinin
P09057648A0422|181 184|gene
P09057648A0422|91 103|c-fos promoter
P09057648A0422|349 351|PMA
P09057648A0422|272 274|FCS
P09057648A0422|244 251|addition
P09057648A0422|219 229|Jurkat cells
P09057648A0422|390 397|mol/L PMA
P09057648A0422|71 77|plasmid
P09057648A0422|320 347|mol/L phorbol myristate acetate
P09057648A0422|177 179|CAT
P09057648A0422|9 22|cotransfection
P09057648A0422|34 49|sense orientation
P09057648A0422|378 381|% FCS
P09057648A0422|262 270|calf serum
P09057648A0422|206 216|CAT activity
P09057703A1389|0 13|Snail mortality
P09057703A1389|41 59|treatment conditions
P09057840A0946|14 20|protein
P09057840A0946|48 50|NH4
P09057840A0946|52 69|2SO4-precipitation
P09057840A0946|73 94|affinity chromatography
P09057840A0946|34 44|homogeneity
P09057840A0946|99 111|AMP-Sepharose
P09057841T0000|0 11|Derepression
P09057841T0000|62 80|isocitrate lyase gene
P09057841T0000|51 56|region
P09057841T0000|83 99|Candida tropicalis
P09057841T0000|135 142|pathways
P09057841T0000|14 27|gene expression
P09058002T0000|43 52|lobe damage
P09058002T0000|17 20|task
P09058250A0128|56 58|NO2
P09058250A0128|41 48|analysis
P09058250A0128|7 19|complications
P09058250A0128|80 86|therapy
P09058250A0128|51 52|NO
P09058323A1287|129 139|CNS patterns
P09058323A1287|110 113|part
P09058323A1287|25 35|cis elements
P09058323A1287|76 82|regions
P09058323A1287|56 60|alpha
P09058323A1287|65 68|beta
P09058323A1287|164 180|gene transcription
P09058323A1287|148 152|alpha
P09058323A1287|158 162|alpha
P09058323A1287|3 9|results
P09058323A1287|142 145|beta
P09058373A0670|0 25|RNase protection experiments
P09058373A0670|68 76|IM-9 cells
P09058373A0670|51 65|GHR1-279 variant
P09058373A0670|38 45|presence
P09058373A0670|85 89|liver
P09058373A1620|159 166|receptor
P09058373A1620|94 97|form
P09058373A1620|10 14|tests
P09058373A1620|135 142|function
P09058373A1620|21 32|reporter gene
P09058373A1620|57 64|elements
P09058378A1134|90 104|transrepression
P09058378A1134|81 83|p53
P09058378A1134|56 78|transactivation function
P09058378A1134|107 109|p53
P09058378A1134|20 42|glucocorticoid receptors
P09059039A0850|0 10|99mTc-HMPAO
P09059039A0850|237 246|papaverine
P09059039A0850|129 137|C4 segment
P09059039A0850|46 48|ACA
P09059039A0850|266 271|ml/min
P09059039A0850|179 181|ACA
P09059039A0850|52 54|MCA
P09059039A0850|102 109|infusion
P09059039A0850|63 70|patients
P09059039A0850|165 173|territory
P09059039A0850|188 195|patients
P09059039A0850|112 121|papaverine
P09059039A0850|30 40|territories
P09059039A0850|227 234|infusion
P09059039A0850|254 262|C1 segment
P09060045A0576|89 104|endotoxin release
P09060045A0576|58 65|settings
P09060045A0576|9 22|review analyses
P09060045A0576|28 39|interactions
P09060444A0557|29 38|expression
P09060444A0557|185 188|gene
P09060444A0557|138 155|EGF-responsiveness
P09060444A0557|113 120|reporter
P09060444A0557|4 18|promoter segment
P09060444A0557|98 107|initiation
P09060444A0557|42 63|luciferase reporter gene
P09060622A1679|71 71|A
P09060622A1679|66 69|poly
P09060622A1679|128 133|genome
P09060622A1679|88 96|infection
P09060622A1679|14 19|report
P09060622A1679|45 57|alphavirus RNA
P09060622A1679|73 76|tail
P09060623A0961|43 50|SIV entry
P09060623A0961|8 17|coreceptor
P09060676A1634|14 31|virus entry features
P09060676A1634|43 55|coronaviruses
P09060676A1634|75 84|properties
P09060676A1634|5 11|changes
P09060971A0982|0 6|RESULTS
P09060971A0982|42 44|BMD
P09060971A0982|162 162|p
P09060971A0982|221 221|p
P09060971A0982|154 160|g/cm2/y
P09060971A0982|203 205|hip
P09060971A0982|67 71|sites
P09060971A0982|188 197|trochanter
P09060971A0982|13 17|women
P09060971A0982|213 219|g/cm2/y
P09060971A0982|33 39|decline
P09060971A0982|120 126|decline
P09060971A0982|143 146|neck
P09061697A0629|199 202|days
P09061697A0629|217 219|MBq
P09061697A0629|94 96|MBq
P09061697A0629|148 155|patients
P09061697A0629|121 131|day protocol
P09061697A0629|223 225|mCi
P09061697A0629|51 67|99Tcm-tetrofosmin
P09061697A0629|100 102|mCi
P09061697A0629|13 13|%
P09061697A0629|15 22|patients
P09061697A0629|269 279|day protocol
P09061697A0629|42 44|MBq
P09061697A0629|47 49|mCi
P09061697A0629|70 73|rest
P09061697A0629|159 162|rest
P09061697A0629|166 185|stress imaging studies
P09061697A0629|83 83|h
P09061697A0629|233 249|99Tcm-tetrofosmin
P09061697A0629|110 115|stress
P09061697A0629|146 146|%
P09061697A0629|256 263|occasion
P09061697A0629|227 230|dose
P09061697T0000|61 70|comparison
P09061697T0000|10 20|SPET imaging
P09061697T0000|25 41|99Tcm-tetrofosmin
P09061697T0000|83 100|day imaging protocol
P09061697T0000|52 59|practice
P09061697T0000|75 77|day
P09061698A0177|0 12|99Tcm-DMP-HSA
P09061698A0177|36 44|behaviour
P09061698A0177|76 79|RBCs
P09061698A0177|65 74|blood cells
P09061698A0177|112 128|reference standard
P09061698A0177|132 146|blood pool agents
P09062130A0116|0 5|Relief
P09062130A0116|10 23|autoinhibition
P09062130A0116|142 149|deletion
P09062130A0116|48 55|increase
P09062130A0116|184 195|PTPase domain
P09062130A0116|58 58|V
P09062130A0116|155 164|SH2 domains
P09062130A0116|60 62|max
P09062130A0116|84 104|N-SH2 domain engagement
P09062130A0116|116 135|phosphotyrosyl ligand
P09064659A1055|85 96|nonsense mRNA
P09064659A1055|37 43|homolog
P09064659A1055|77 82|levels
P09064659A1055|122 128|protein
P09064659A1055|148 154|homolog
P09064659A1055|134 138|HUPF1
P09064659A1055|46 54|yeast UPF1
P09064659A1055|157 160|UPF1
P09064659A1055|57 63|protein
P09064868T0001|1 11|miracle cure
P09064868T0001|18 25|solution
P09065170A0853|42 49|transfer
P09065170A0853|3 10|addition
P09065170A0853|13 22|zidovudine
P09065463A1012|0 16|DNA strand exchange
P09065463A1012|65 67|RPA
P09065463A1012|28 39|Rad51 protein
P09065690A0463|87 94|sequence
P09065690A0463|65 78|CAR1 expression
P09065690A0463|50 54|genes
P09065690A0463|108 115|function
P09065690A0463|26 35|expression
P09065690A0463|101 103|URS
P09065690A0463|118 137|nitrogen availability
P09065690A0463|0 4|Ume6p
P09065768A0862|95 105|lactase mRNA
P09065768A0862|9 13|class
P09065768A0862|35 46|kb transcript
P09065768A0862|16 19|cDNA
P09067577A0307|2 10|cell lines
P09067577A0307|39 46|tyrosine
P09067577A0307|67 69|CRK
P09067577A0307|24 30|BCR/ABL
P09067577A0307|32 35|CRKL
P09067577A0721|74 76|C3G
P09067577A0721|31 38|proteins
P09067577A0721|78 80|SOS
P09067577A0721|84 88|c-ABL
P09067577A0721|57 60|CRKL
P09067577A0721|15 19|cells
P09068989T0000|0 5|Effect
P09068989T0000|69 74|system
P09068989T0000|39 49|leaf extract
P09068989T0000|8 24|Azadirachta indica
P09071308A0376|15 23|opacities
P09071308A0376|127 130|NTMB
P09071308A0376|46 57|distribution
P09071308A0376|109 116|patients
P09071308A0376|95 95|%
P09071308A0376|105 105|%
P09071308A0376|76 82|finding
P09071308A0376|121 123|MTB
P09071308A0376|0 6|RESULTS
P09071407T0000|54 65|cohabitation
P09071407T0000|25 34|guinea pigs
P09071407T0000|11 18|oxytocin
P09071407T0000|81 89|condition
P09072361A0357|30 34|SHRSP
P09072361A0357|102 115|magnesium ratio
P09072361A0357|52 60|magnesium
P09072361A0357|21 28|fraction
P09072361A0357|79 87|elevation
P09072361A0357|67 73|tissues
P09072361A0357|141 143|WKY
P09072361A0357|147 151|SHRSR
P09072361A0357|93 99|calcium
P09072361A0357|42 49|decrease
P09073074T0000|31 46|FGFR-3 psuedogene
P09073074T0000|9 21|transcription
P09073074T0000|58 69|developement
P09073582A0444|58 68|SSO activity
P09073582A0444|75 81|Kataoka
P09073582A0444|88 90|Mol
P09073582A0444|35 52|BglII-SmaI fragment
P09073582A0444|9 14|report
P09073582A0444|70 73|ori2
P09074508A0397|27 31|exons
P09074508A0397|52 53|kb
P09074508A0397|8 15|CD38 gene
P09074508A0397|64 69|genome
P09075739A0827|0 3|Type
P09075739A0827|63 67|ovary
P09075739A0827|39 39|S
P09075739A0827|54 59|kidney
P09075739A0827|6 18|splice pattern
P09075739A0827|30 35|exon U3
P09076336A0281|170 180|GH secretion
P09076336A0281|45 53|diagnosis
P09076336A0281|149 161|GH sufficiency
P09076336A0281|73 85|constellation
P09076336A0281|128 135|spectrum
P09076336A0281|107 114|findings
P09076336A0281|0 11|GH deficiency
P09077076A0219|8 14|CRP test
P09077108A0458|72 80|TNF-alpha
P09077108A0458|107 111|fluid
P09077108A0458|23 33|pleocytosis
P09077108A0458|67 70|IL-6
P09077108A0458|63 65|IgG
P09077108A0458|16 21|period
P09077108A0458|55 60|levels
P09077108A0458|85 88|PGE2
P09077437T0000|0 20|Recognition mechanisms
P09077437T0000|70 82|RNA polymerase
P09077437T0000|38 43|origin
P09077437T0000|46 52|phage f1
P09077438A0076|3 9|minimum
P09077438A0076|22 29|subunits
P09077438A0076|33 44|RNA synthesis
P09079625A0935|43 53|interaction
P09079625A0935|95 99|sites
P09079625A0935|18 34|adhesion component
P09079625A0935|109 117|adhesions
P09079625A0935|85 92|activity
P09079625A0935|69 71|PKC
P09079625A0935|0 9|Syndecan-4
P09079638A0883|43 49|Ser-346
P09079638A0883|79 86|mutation
P09079638A0883|65 71|alanine
P09079638A0883|24 28|CXCR2
P09079638A0883|202 216|ligand challenge
P09079638A0883|3 13|3ASubE cells
P09079638A0883|33 40|mutation
P09079638A0883|143 150|response
P09079638A0883|108 113|domain
P09079638A0883|153 158|ligand
P09079638A0883|96 101|serine
P09079638A0883|170 170|%
P09079650A0136|103 109|kinases
P09079650A0136|111 114|JNKs
P09079650A0136|67 72|p42/44
P09079650A0136|12 21|MAPK family
P09079650A0136|61 64|ERKs
P09079650A0136|84 88|c-Jun
P09079650A0136|123 129|p38/Hog
P09079650A0136|45 59|response kinases
P09079650A0136|131 144|protein kinases
P09079650A0136|74 77|MAPK
P09079650A0136|0 6|Members
P09079689A0472|30 38|PAS domain
P09079689A0472|120 131|reading frame
P09079689A0472|51 59|C terminus
P09079689A0472|97 102|domain
P09079689A0472|80 83|cDNA
P09079689A0472|0 3|MOP5
P09079817A0928|29 33|cells
P09079817A0928|62 65|mRNA
P09079817A0928|77 88|NO synthetase
P09079817A0928|10 21|NO production
P09079817A0928|54 59|levels
P09079878A0000|14 42|Lactobacillus sake plasmid pCIM1
P09079878A0000|90 102|reading frames
P09079878A0000|104 107|ORFs
P09079878A0000|7 8|kb
P09079878A0000|152 153|S.
P09079878A0000|123 126|lasA
P09079902A0713|82 88|complex
P09079902A0713|62 63|Pk
P09079902A0713|110 111|Pk
P09079902A0713|71 73|Pra
P09079902A0713|145 152|affinity
P09079902A0713|47 60|pyruvate kinase
P09079902A0713|171 177|complex
P09079902A0713|133 134|Pk
P09079902A0713|8 10|Pra
P09079902A0713|66 67|Pk
P09079902A0713|157 159|Pra
P09079902A0713|116 118|Pra
P09079902A0713|106 108|Ndk
P09079902A0713|191 193|Ndk
P09079904A0995|128 136|Bvg system
P09079904A0995|9 22|iron regulation
P09079904A0995|24 37|sodA expression
P09079904A0995|51 57|changes
P09079904A0995|109 117|virulence
P09079904A0995|80 91|coumermycin A
P09079904A0995|60 70|DNA topology
P09079915T0000|85 108|consensus sigma70 promoter
P09079915T0000|9 24|characterization
P09079915T0000|52 65|motility operon
P09079928A0525|0 11|M. leprae OxyR
P09079928A0525|76 81|region
P09079928A0525|84 91|M. leprae
P09079928A0525|45 51|binding
P09079928A0525|57 65|oxyR-ahpC
P09079928A1319|17 20|OxyR
P09079928A1319|68 72|loops
P09079928A1319|31 36|P1oxyR
P09079928A1319|109 116|bacteria
P09079928A1319|139 153|LysR superfamily
P09079928A1319|96 99|oxyR
P09079928A1319|120 133|characteristic
P09079928A1319|84 93|expression
P09079928A1319|3 13|binding site
P09080250A0212|131 134|P815
P09080250A0212|90 112|polymerase chain reaction
P09080250A0212|114 116|PCR
P09080250A0212|51 71|p15E cDNA gene fragments
P09080250A0212|12 16|study
P09080250A0212|161 171|tumour cells
P09080250A0212|151 159|P815/DTIC
P09080250A0212|83 87|means
P09080517A0215|11 18|patients
P09081389A1088|0 4|Grade
P09081389A1088|8 16|mucositis
P09081389A1088|37 42|cycles
P09081389A1088|31 31|%
P09081392A0174|31 45|salvage regimens
P09082335A0730|0 3|None
P09082335A0730|18 31|manifestations
P09082335A0730|60 64|means
P09083291A1378|86 89|cdks
P09083291A1378|44 53|expression
P09083291A1378|97 99|MCs
P09083291A1378|221 226|S phase
P09083291A1378|209 218|transition
P09083291A1378|180 191|inactivation
P09083291A1378|123 130|activity
P09083291A1378|194 196|pRb
P09083291A1378|68 82|G1 phase cyclin D1
P09083291A1378|162 176|phosphorylation
P09083291A1378|111 121|cyclin E-cdk
P09083291A1378|5 13|TGF-beta1
P09083291A1378|57 65|abundance
P09083291A1378|199 205|G1 phase
P09083345A0851|177 184|duration
P09083345A0851|98 102|SYPLR
P09083345A0851|187 194|symptoms
P09083345A0851|18 23|values
P09083345A0851|49 52|need
P09083345A0851|107 113|respect
P09083345A0851|90 95|values
P09083345A0851|11 15|range
P09083345A0851|161 175|characteristics
P09083345A0851|219 235|treatment efficacy
P09083345A0851|119 137|inter-relationships
P09083345A0851|66 74|districts
P09083345A0851|204 215|presentation
P09083563A0971|217 224|B. cereus
P09083563A0971|207 211|fluid
P09083563A0971|179 184|toxins
P09083563A0971|91 106|arachnoid vessels
P09083563A0971|12 18|lesions
P09083563A0971|144 148|fluid
P09083563A0971|44 55|surface layer
P09083563A0971|59 78|leptomeningeal tissue
P09084174A0667|105 144|aspartate-beta-semialdehyde dehydrogenase
P09084174A0667|177 186|similarity
P09084174A0667|49 52|leuB
P09084174A0667|93 95|asd
P09084174A0667|79 91|dehydrogenase
P09084174A0667|4 11|fragment
P09084174A0667|154 157|orfA
P09084174A0667|36 46|nucleotides
P09084174A0667|146 148|Asd
P09084174A0667|207 215|Vibrio spp
P09084174A0667|192 202|Asd proteins
P09084174A0667|164 170|product
P09084176A0601|15 22|activity
P09084176A0601|94 110|M. smegmatis clones
P09084176A0601|74 76|RNA
P09084176A0601|36 57|slot-blot hybridization
P09084176A0601|89 92|lacZ
P09084227A0833|0 9|Hovenitin I
P09084227A0833|17 26|ampelopsin
P09084227A0833|134 141|activity
P09084227A0833|52 62|ingredients
P09084227A0833|180 183|rats
P09084227A0833|162 177|muscle relaxation
P09084227A0833|98 105|medicine
P09084227A0833|74 82|fractions
P09084621A0374|146 162|movement variables
P09084621A0374|139 142|task
P09084621A0374|111 136|brain activity proportionate
P09084621A0374|24 38|characteristics
P09084621A0374|104 108|areas
P09084621A0374|85 93|blood flow
P09084621A0374|66 74|magnitude
P09084621A0374|0 11|Movement time
P09084621A2567|0 4|Areas
P09084621A2567|56 66|motor cortex
P09084621A2567|29 32|rCBF
P09084621A2567|85 90|sulcus
P09084621A2567|99 105|caudate
P09085842A0181|142 148|SF2/ASF
P09085842A0181|126 138|U1-70K protein
P09085842A0181|114 120|domains
P09085842A0181|61 70|splice site
P09085842A0181|36 42|U1 snRNP
P09085842A0181|73 99|protein/protein interactions
P09085842A0181|6 12|studies
P09085842A1559|129 148|phosphorylation state
P09085842A1559|26 35|27K protein
P09085842A1559|162 177|pre-mRNA splicing
P09085842A1559|82 108|protein/protein interactions
P09086268A0611|71 72|P2
P09086268A0611|91 92|P7
P09086268A0611|74 86|RNA polymerase
P09086268A0611|51 59|particles
P09086268A0611|30 38|particles
P09086268A0611|8 9|P7
P09086268A0611|46 47|P7
P09087430A1046|42 44|BSA
P09087430A1046|64 66|PAP
P09087430A1046|15 24|U1A peptide
P09088371T0000|14 21|protein C
P09088371T0000|23 30|protein S
P09088371T0000|76 86|haemorrhage
P09088371T0000|35 46|antithrombin
P09088371T0000|52 59|patients
P09088371T0000|0 11|Plasma levels
P09088416A0000|74 81|syndrome
P09088416A0000|169 183|artery occlusion
P09088416A0000|132 142|hearing loss
P09088416A0000|28 33|branch
P09088416A0000|59 65|IBRBRAO
P09088416A0000|156 161|branch
P09088416A0000|97 113|migraine headaches
P09088416A0000|115 122|tinnitus
P09088416A0000|124 130|vertigo
P09088416A0000|49 57|occlusion
P09088416A0000|193 200|etiology
P09088737T0000|57 66|microscopy
P09088737T0000|83 86|CMTF
P09088737T0000|20 40|thickness measurements
P09089093A0373|0 8|Sequences
P09089093A0373|68 83|enhancer elements
P09089093A0373|32 38|CA genes
P09089653A0615|156 169|control plasmid
P09089653A0615|50 53|exon
P09089653A0615|102 119|luciferase activity
P09089653A0615|11 18|plasmids
P09089653A0615|41 42|nt
P09089653A0615|84 91|sequence
P09089653A0615|45 47|UTR
P09089653A0615|63 71|nt segment
P09089653A0615|128 132|times
P09089653A1112|0 7|Analysis
P09089653A1112|109 110|nt
P09089653A1112|78 83|region
P09089653A1112|86 95|protection
P09089653A1112|22 33|interactions
P09089653A1112|43 61|DNase-I footprinting
P09090050A0419|48 52|mouse
P09090050A0419|25 37|sugar carriers
P09090054A0186|186 192|cluster
P09090054A0186|60 68|regulator
P09090054A0186|51 55|genes
P09090054A0186|81 97|alpha-glucosidase
P09090054A0186|20 23|loci
P09090054A0186|110 113|gene
P09090054A0186|164 167|MAL1
P09090054A0186|200 204|genes
P09090054A0186|132 152|alpha-glucosidase gene
P09090054A0186|70 77|permease
P09090592A0175|85 89|error
P09090592A0175|25 31|control
P09090592A0175|8 14|methods
P09090592A0175|150 160|orientation
P09090592A0175|35 53|activation fMR images
P09091010A1003|73 79|disease
P09091010A1003|5 9|women
P09091010A1003|45 52|cytology
P09091125A0161|47 54|activity
P09091125A0161|90 103|NBT-test values
P09091125A0161|57 64|alkaline
P09091125A0161|68 83|acid phosphatases
P09091125A0161|19 23|cells
P09091403T0001|57 61|mouse
P09091403T0001|94 110|microsatellite DNA
P09091403T0001|20 31|DNA sequences
P09091403T0001|87 90|site
P09091403T0001|70 78|mts1 genes
P09091403T0001|46 51|intron
P09091403T0001|0 7|Analysis
P09092493A0861|146 154|signaling
P09092493A0861|121 124|cell
P09092493A0861|19 25|VIP CyRE
P09092493A0861|42 62|AP-1 signaling pathways
P09092493A0861|109 117|mechanism
P09092493A0861|3 13|integration
P09092493A0861|31 38|Jak-Stat
P09092493A0861|84 91|proteins
P09092580A1354|119 123|sites
P09092580A1354|91 104|transmigration
P09092580A1354|59 68|activation
P09092580A1354|38 53|MAP kinase pathway
P09092580A1354|5 11|studies
P09092580A1354|22 32|involvement
P09092580A1354|80 84|cells
P09092636A0802|104 125|DYZ3 satellite sequences
P09092636A0802|68 80|recombination
P09092636A0802|158 161|DYZ5
P09092636A0802|42 54|rad54-3 allele
P09092636A0802|3 9|results
P09092636A0802|182 189|YAC clone
P09092675A0283|40 40|A
P09092675A0283|33 38|P22 R17
P09092675A0283|75 83|infection
P09092675A0283|23 31|OcRNA site
P09092675A0283|91 97|strains
P09092675A0283|46 46|U
P09092675A0283|1 16|P22 R17 derivative
P09093867T0000|29 37|formation
P09093867T0000|51 54|fate
P09093867T0000|12 27|Ac/Ds transposons
P09093867T0000|39 47|structure
P09094093A0578|4 7|site
P09094093A0578|25 31|TATA box
P09094093A0578|45 49|cells
P09094315A0541|56 66|cyclin-Cdks
P09094315A0541|6 10|study
P09094315A0541|46 53|activity
P09094315A0541|29 38|regulation
P09094671A1192|30 33|Mts1
P09094671A1192|52 59|p15INK4b
P09094671A1192|94 113|Southern blot analysis
P09094671A1192|35 42|p16INK4a
P09094671A1192|156 159|gene
P09094671A1192|127 135|deletions
P09094671A1192|47 50|Mts2
P09094671A1192|82 87|region
P09094671A1192|0 28|Candidate tumor suppressor genes
P09096229T0000|0 13|Excision repair
P09096229T0000|203 218|control sequences
P09096229T0000|76 82|mapping
P09096229T0000|29 38|nucleotide
P09096229T0000|19 23|level
P09096229T0000|120 125|strand
P09096229T0000|67 74|MFA2 gene
P09096229T0000|98 103|repair
P09096229T0000|169 173|rad16
P09096229T0000|141 154|identification
P09096234T0000|56 77|DNA sequence specificity
P09096234T0000|79 104|operator site discrimination
P09096234T0000|36 43|subunits
P09096234T0000|107 128|phage lambda cI repressor
P09096234T0000|18 28|interaction
P09096958A0000|205 213|adhesions
P09096958A0000|66 78|platelet talin
P09096958A0000|38 47|antibodies
P09096958A0000|180 196|actin stress fibers
P09096958A0000|103 115|precipitation
P09096958A0000|120 137|immunofluorescence
P09096958A0000|81 95|Western blotting
P09096958A0000|169 172|TD77
P09096958A0000|20 24|panel
P09096958A0000|225 236|cell motility
P09096958A0000|151 165|antibodies TA205
P09096958A0000|263 273|fibroblasts
P09098066A0119|176 184|phenotype
P09098066A0119|137 144|proteins
P09098066A0119|126 129|loss
P09098066A0119|39 43|genes
P09098066A0119|90 93|HMW3
P09098066A0119|75 86|proteins HMW1
P09098066A0119|4 8|locus
P09098066A0119|232 236|locus
P09098066A0119|198 208|designation
P09098066A0119|101 110|insertions
P09098066A0119|238 240|crl
P09098066A0119|29 31|kbp
P09098899A0000|160 175|zinc-finger motif
P09098899A0000|12 12|B
P09098899A0000|49 57|Ogr family
P09098899A0000|24 34|acid protein
P09098899A0000|69 88|transcription factors
P09098899A0000|105 109|phage
P09098899A0000|0 8|Coliphage
P09098899A0435|3 22|UV absorption spectrum
P09098899A0435|191 198|mM-1 cm-1
P09098899A0435|226 230|Cys-S
P09098899A0435|48 61|characteristic
P09098899A0435|212 219|presence
P09098899A0435|233 238|center
P09098899A0435|159 171|acidification
P09098899A0435|173 184|delta epsilon
P09098899A0435|90 115|charge-transfer transitions
P09098899A0435|223 224|Cd
P09098899A0435|45 46|nm
P09098899A0435|123 153|difference absorption coefficient
P09098899A0435|64 70|CysS-Cd
P09098899A0435|32 39|shoulder
P09099683A0000|0 19|Diacylglycerol kinase
P09099683A0000|129 132|acid
P09099683A0000|49 71|messenger diacylglycerol
P09099683A0000|107 115|messenger
P09099683A0000|35 40|levels
P09099683A0000|21 23|DGK
P09099683A0000|74 78|cells
P09099702A0000|99 102|GCNF
P09099702A0000|63 84|orphan receptor germ cell
P09099702A0000|26 32|cloning
P09099702A0000|38 41|germ
P09099702A0000|105 107|RTR
P09099702A0000|92 97|factor
P09099702A0692|154 158|stage
P09099702A0692|10 17|sequence
P09099702A0692|49 52|RTRE
P09099702A0692|178 180|RTR
P09099702A0692|107 120|mouse protamine
P09099702A0692|122 125|gene
P09099702A0692|23 29|conRTRE
P09099702A0692|66 70|P2-RE
P09099702A0692|161 175|spermatogenesis
P09099702A0692|96 101|region
P09099743A0585|173 179|doublet
P09099743A0585|39 42|form
P09099743A0585|166 168|kDa
P09099743A0585|145 156|polypeptides
P09099743A0585|67 74|particle
P09099743A0585|111 122|polypeptides
P09099743A0585|206 214|nucleolin
P09099743A0585|15 26|purification
P09099743A0585|189 191|kDa
P09099743A0585|87 93|mRNP3+4
P09099745A1446|118 121|Cdk2
P09099745A1446|305 308|Cdk2
P09099745A1446|96 98|p21
P09099745A1446|135 143|threonine
P09099745A1446|288 302|phosphorylation
P09099745A1446|178 186|mechanism
P09099745A1446|102 104|p27
P09099745A1446|6 14|complexes
P09099745A1446|57 65|complexes
P09099745A1446|39 44|weight
P09099745A1446|189 198|activation
P09099745A1446|201 212|cyclin E-Cdk2
P09099745A1446|147 161|phosphorylation
P09099745A1446|233 255|CDK inhibitor association
P09100202A0000|15 31|Class II recessions
P09100202A0000|91 110|tissue graft procedure
P09100202A0000|36 43|patients
P09100202A0000|6 10|Class
P09101085A0686|28 36|cell lines
P09101085A0686|67 80|p27Kip1 protein
P09101085A0686|52 61|expression
P09101085A0686|3 13|derivatives
P09101085A0686|96 105|cell growth
P09101085A0686|84 93|inhibition
P09101910A0394|44 44|%
P09101910A0394|49 57|mortality
P09101910A0394|79 83|years
P09101910A0394|90 90|%
P09101910A0394|60 67|patients
P09101910A0394|16 24|mortality
P09101910A0394|30 37|patients
P09102113A0739|135 135|%
P09102113A0739|92 98|disease
P09102113A0739|12 26|failure patients
P09102113A0739|59 64|causes
P09102113A0739|113 117|death
P09102113A0739|72 80|frequency
P09103382T0000|45 52|critique
P09103382T0000|6 19|FIGO definition
P09103382T0000|30 42|cancer stage IA
P09104816A0610|100 101|VV
P09104816A0610|22 31|biogenesis
P09104816A0610|49 54|detail
P09104816A0610|11 13|Vpu
P09104816A0610|16 20|class
P09104816A0610|3 8|effect
P09104816A0610|86 98|vaccinia virus
P09105042A1497|100 108|mutations
P09105042A1497|151 156|myosin
P09105042A1497|62 72|HCM patients
P09105042A1497|162 173|chain protein
P09105042A1497|25 33|phenotype
P09105042A1497|232 237|effect
P09105042A1497|4 8|study
P09105042A1497|36 55|myofibrillar disarray
P09105042A1497|133 139|failure
P09105042A1497|197 206|sarcomeres
P09105042A1497|269 274|stress
P09105042A1497|286 300|beta MHC function
P09105363A0636|30 49|emission spectroscopy
P09105363A0636|72 96|tissue silicon measurements
P09105363A0636|18 23|plasma
P09105530A0000|13 20|lysozyme
P09105530A0000|62 78|cheese preparation
P09105530A0000|2 11|egg protein
P09106057A0000|209 212|HPLC
P09106057A0000|194 207|chromatography
P09106057A0000|137 142|plasma
P09106057A0000|218 234|chemiluminescence
P09106057A0000|236 237|CL
P09106057A0000|25 37|determination
P09106057A0000|53 61|N-ethyl-8
P09106057A0000|146 150|urine
P09106057A0000|65 83|anhydroerythromycin
P09106057A0000|119 129|metabolites
P09106057A0000|43 50|N-methyl
P09106057A0000|239 247|detection
P09106057A0000|100 104|EM523
P09106057A0000|1 6|method
P09108029A0399|86 96|redox factor
P09108029A0399|70 84|DNA repair enzyme
P09108029A0399|24 31|activity
P09108029A0399|125 139|DNA repair enzyme
P09108029A0399|52 55|AP-1
P09108029A0399|141 154|AP endonuclease
P09108029A0399|34 49|activator protein
P09108029A0399|99 103|Ref-1
P09108038A1128|83 88|family
P09108038A1128|8 16|LRR domain
P09108038A1128|103 117|binding proteins
P09108038A1128|53 70|C. elegans homologue
P09108038A1128|33 38|domain
P09108038A1128|40 46|Acan125
P09108207A0306|42 64|oropharyngeal irritation
P09108207A0306|11 23|participation
P09108279A0431|156 163|8-OxoG/C
P09108279A0431|51 58|extracts
P09108279A0431|19 24|8-OxoG
P09108279A0431|147 154|cytosine
P09108279A0431|90 105|34mer DNA fragment
P09108279A0431|123 135|8-OxoG residue
P09108279A0431|168 176|substrate
P09108279A0431|3 10|capacity
P09108279A0431|73 83|ogg1 strains
P09108451A0160|0 6|Results
P09108451A0160|51 56|UCN-01
P09108451A0160|22 33|laboratories
P09108451A0160|76 95|G1-phase accumulation
P09108451A0160|110 123|tumor cell lines
P09110176A0890|0 7|Northern
P09110176A0890|230 239|expression
P09110176A0890|248 252|locus
P09110176A0890|11 24|RT-PCR analysis
P09110176A0890|202 209|evidence
P09110176A0890|175 181|animals
P09110176A0890|148 157|expression
P09110176A0890|44 55|mouse tissues
P09110176A0890|100 105|disomy
P09110176A0890|60 66|animals
P09110176A0890|27 41|Ube3a expression
P09111004A0732|56 86|phosphorylation motif Thr-Xaa-Tyr
P09111004A0732|152 157|length
P09111004A0732|106 140|L12 influence p38 substrate specificity
P09111004A0732|191 209|autophosphorylation
P09111004A0732|174 177|role
P09111004A0732|37 46|Xaa residue
P09111004A0732|98 103|length
P09111004A0732|160 162|L12
P09111004A0732|14 20|effects
P09111048X0000|181 193|cells/tissues
P09111048X0000|22 35|mRNA transcript
P09111048X0000|117 121|theme
P09111048X0000|158 171|gene expression
P09111048X0000|132 151|nitric-oxide synthase
P09111048X0000|88 100|mRNA diversity
P09111048X0000|67 86|nitric-oxide synthase
P09111048X0000|153 156|nNOS
P09111059A0327|87 89|DNA
P09111059A0327|74 84|specificity
P09111059A0327|20 25|domain
P09111059A0327|30 40|homeodomain
P09111309A0674|0 13|Cotransfection
P09111309A0674|24 26|p44
P09111309A0674|145 146|ER
P09111309A0674|124 131|response
P09111309A0674|56 78|kinase expression vectors
P09111309A0674|52 54|MAP
P09111309A0674|98 121|HB-EGF promoter activation
P09111309A0674|44 50|protein
P09111309A0674|16 20|Ets-2
P09111309A0674|134 143|deltaRaf-1
P09111314A0970|0 7|Cyclin D1
P09111314A0970|49 67|184A1L5R cell lysates
P09111314A0970|31 34|cdk4
P09111314A1243|237 252|kinase activation
P09111314A1243|54 61|TGF-beta
P09111314A1243|157 171|p15INK4B protein
P09111314A1243|32 41|regulation
P09111314A1243|79 89|observation
P09111314A1243|211 233|cyclin D1-cdk association
P09111314A1243|114 121|184A1L5R
P09111314A1243|134 146|p15 transcript
P09111314A1243|3 12|importance
P09111314A1243|44 51|p15INK4B
P09111331A0119|27 39|MADS box family
P09111331A0119|42 61|transcription factors
P09111331A0119|93 99|pathway
P09111331A0119|63 71|functions
P09111331A0119|3 13|Rlm1 protein
P09111331A0119|16 21|member
P09111331A0119|84 87|Mpk1
P09111340A0240|219 250|chloramphenicol acetyltransferase
P09111340A0240|50 63|downregulation
P09111340A0240|138 142|genes
P09111340A0240|256 259|gene
P09111340A0240|38 46|c-myc mRNA
P09111340A0240|100 109|C2C12 cells
P09111340A0240|70 79|myogenesis
P09111340A0240|252 254|CAT
P09111340A0240|20 27|elements
P09111340A0240|157 168|myc sequences
P09111340A0240|120 127|myc genes
P09111340A0240|188 202|beta-globin gene
P09111367A1098|352 363|tal-1 effects
P09111367A1098|497 501|cells
P09111367A1098|322 332|experiments
P09111367A1098|266 273|host cell
P09111367A1098|435 446|N-terminally
P09111367A1098|146 151|effect
P09111367A1098|511 517|effects
P09111367A1098|456 467|tal-1 variant
P09111367A1098|109 119|temperature
P09111367A1098|51 58|p53 cells
P09111367A1098|311 315|tal-1
P09111367A1098|483 487|T-ALL
P09111367A1098|227 235|integrity
P09111367A1098|191 195|tal-1
P09111367A1098|288 292|c-myc
P09111367A1098|79 93|tal-1 expression
P09111367A1098|27 29|32D
P09111367A1098|209 214|effect
P09111367A1098|532 538|protein
P09111367A1098|401 425|heterodimerization domains
P09111367A1098|173 181|apoptosis
P09111367A1098|12 22|experiments
P09111367A1098|469 470|M3
P09111367A1098|301 309|oncogenes
P09111367A1098|241 260|cell cycle checkpoints
P09111863A0743|3 12|likelihood
P09111863A0743|24 29|region
P09111863A0743|164 175|introduction
P09111863A0743|146 159|tumorigenicity
P09111863A0743|106 111|region
P09111863A0743|178 187|tumor cells
P09111863A0743|89 99|coincidence
P09111863A0743|54 68|tumor suppressor
P09111863A0743|32 40|deletions
P09111863A0743|117 134|chromosome fragment
P09112400A1155|49 57|forskolin
P09112400A1155|11 18|activity
P09112400A1155|74 78|cells
P09112400A1155|39 46|addition
P09112589A0078|26 32|pattern
P09114972A1366|15 17|SOS
P09114972A1366|19 27|viability
P09114972A1366|4 12|induction
P09115242A0934|180 192|collagenase-1
P09115242A0934|69 72|role
P09115242A0934|98 109|protein-beta
P09115242A0934|21 30|supershift
P09115242A0934|111 120|C/EBP-beta
P09115242A0934|35 58|promoter deletion analyses
P09115242A0934|165 177|transcription
P09115242A0934|204 208|cells
P09115242A0934|122 132|binding site
P09115247A2069|0 24|11-Aminoundecanoyl-SK-NH2
P09115247A2069|110 117|distance
P09115247A2069|251 268|epsilon-amino group
P09115247A2069|171 176|enzyme
P09115247A2069|28 52|11-aminoundecanoyl-SH-NH2
P09115247A2069|194 197|site
P09115247A2069|273 281|imidazole
P09115247A2069|232 244|beta-hydroxyl
P09115247A2069|130 137|elements
P09115247A2069|73 85|alkyl backbone
P09115247A2069|220 229|amino group
P09115247A2069|149 159|recognition
P09115265A1160|87 111|transcription factor GATA-1
P09115265A1160|67 72|domain
P09115265A1160|20 29|CCCC module
P09115279A0345|85 91|partner
P09115279A0345|56 59|Cdc2
P09115279A0345|36 46|cell lysates
P09115279A0345|23 26|Pch1
P09115279A0345|0 18|Cdc2 co-precipitates
P09115279A0345|95 104|Pch1 kinase
P09115279A0345|29 30|S.
P09115357A0073|223 229|process
P09115357A0073|62 67|assays
P09115357A0073|37 48|availability
P09115357A0073|139 152|culture systems
P09115357A0073|126 136|development
P09115357A0073|21 29|mechanism
P09115357A0073|156 174|hypermutating B cells
P09115357A0073|81 107|immunoglobulin hypermutation
P09115357A0073|186 194|screening
P09115357A0073|198 208|individuals
P09115365A0000|0 9|Expression
P09115365A0000|38 41|gene
P09115365A0000|85 93|oncogenes
P09115365A0000|74 79|stress
P09115365A0000|43 47|hsp70
P09115365A0000|20 35|heat shock protein
P09115365A0000|67 71|kinds
P09115395A0478|300 303|Cdc5
P09115395A0478|452 456|Vent2
P09115395A0478|148 151|BRG1
P09115395A0478|447 450|Sox3
P09115395A0478|441 445|HoxD1
P09115395A0478|436 439|Cdc5
P09115395A0478|164 174|protein L18A
P09115395A0478|464 471|isoforms
P09115395A0478|217 221|roles
P09115395A0478|373 392|transcription factors
P09115395A0478|429 430|S.
P09115395A0478|423 427|Oct91
P09115395A0478|107 117|protein-115
P09115395A0478|264 274|protein-115
P09115395A0478|224 230|mitosis
P09115395A0478|193 200|proteins
P09115395A0478|338 351|RNA helicase WM6
P09115395A0478|394 397|BRG1
P09115395A0478|75 96|epithelial-microtubule
P09115395A0478|232 253|epithelial-microtubule
P09115395A0478|328 331|BRG1
P09115395A0478|67 73|mitosis
P09115395A0478|305 326|innercentrosome protein
P09115395A0478|407 421|co-factor 2alpha
P09115395A0478|119 123|Oct91
P09115395A0478|125 146|Elongation factor 1gamma
P09115395A0478|7 14|proteins
P09115395A0478|474 478|Xbr1b
P09115989A0993|30 48|psoralen cross-links
P09115989A0993|76 92|initiation process
P09115989A0993|66 70|steps
P09115989A0993|21 28|location
P09117345A0945|27 32|TS2/16
P09117345A0945|18 21|beta
P09117345A0945|110 124|phosphorylation
P09117345A0945|101 107|pattern
P09117345A0945|12 16|alpha
P09117345A0945|70 82|cell migration
P09117345A0945|56 66|protrusions
P09117345A0945|0 9|Activation
P09118196A0281|0 10|Performance
P09118196A0281|104 141|Wechsler Adult Intelligence Scale-Revised
P09118196A0281|186 194|education
P09118196A0281|143 148|WAIS-R
P09118196A0281|67 72|NART-R
P09118196A0281|80 96|Vocabulary subtest
P09118196A0281|34 46|National Adult
P09118196A0281|179 183|level
P09118196A0281|163 174|correlations
P09118664A1734|0 11|L-canavanine
P09118664A1734|90 104|filling pressure
P09118664A1734|52 64|oxide synthase
P09118664A1734|23 31|inhibitor
P09118664A1734|145 154|conditions
P09118664A1734|128 133|return
P09118704A0771|0 6|RESULTS
P09118704A0771|75 93|% confidence interval
P09118704A0771|44 55|chemotherapy
P09118704A0771|109 109|%
P09118704A0771|95 96|CI
P09118704A0771|150 166|bleomycin toxicity
P09118704A0771|15 22|patients
P09118704A0771|71 71|%
P09118704A0771|59 63|G-CSF
P09119031A1036|207 217|sigma factor
P09119031A1036|110 123|alpha2beta beta
P09119031A1036|182 187|enzyme
P09119031A1036|92 108|core RNA polymerase
P09119031A1036|12 35|holoenzyme RNA polymerases
P09119031A1036|157 164|activity
P09119031A1036|68 74|mutants
P09119031A1036|167 176|comparison
P09119112A1350|39 44|GATA-5
P09119112A1350|92 99|function
P09119112A1350|114 118|heart
P09119112A1350|5 8|data
P09119112A1350|122 125|lung
P09119112A1350|27 31|model
P09119391A0870|91 105|protein sequence
P09119391A0870|25 31|protein
P09119391A0870|113 117|GPT-1
P09119391A0870|37 46|amino acids
P09119391A0870|9 16|sequence
P09121424A0296|86 92|complex
P09121424A0296|102 108|homolog
P09121424A0296|110 113|Sthl
P09121424A0296|32 42|Swi3 homolog
P09121424A0296|44 47|Swh3
P09121424A0296|59 66|evidence
P09121430A0132|0 2|Shc
P09121430A0132|111 111|Y
P09121430A0132|68 74|complex
P09121430A0132|113 119|residue
P09121430A0132|79 82|Grb2
P09121430A0132|48 51|MAPK
P09121430A0132|34 46|protein kinase
P09121430A0132|102 109|tyrosine
P09121430A1075|60 71|c-myc message
P09121430A1075|30 37|Y317F Shc
P09121430A1075|11 22|Y239/240F Shc
P09121430A1075|2 9|contrast
P09121432A0000|59 64|switch
P09121432A0000|105 111|kinases
P09121432A0000|3 12|Ras guanine
P09121432A0000|67 76|signalling
P09121432A0000|31 37|protein
P09121433A0463|118 121|SMP1
P09121433A0463|158 164|ACTACTA
P09121433A0463|17 20|Smp1
P09121433A0463|95 98|MEF2
P09121433A0463|108 111|4TAG
P09121433A0463|48 60|specificities
P09121433A0463|104 106|T/A
P09121433A0463|166 168|T/A
P09121433A0463|10 13|Rlm1
P09121433A0463|140 156|consensus sequence
P09121433A0463|100 102|CTA
P09121433A0463|170 173|4TAG
P09121433A0463|62 65|Rlm1
P09121433A0463|82 92|specificity
P09121435A1183|0 6|Domains
P09121435A1183|75 93|protein footprinting
P09121435A1183|30 37|assembly
P09121435A1183|15 15|B
P09121435A1183|43 59|TFIIIB-DNA complex
P09121452A0538|87 102|activation domain
P09121452A0538|196 203|promoter
P09121452A0538|138 148|2D5 promoter
P09121452A0538|225 233|C/EBP site
P09121452A0538|105 114|C/EBP alpha
P09121452A0538|33 49|C/EBP beta proteins
P09121452A0538|69 81|leucine zipper
P09121452A0538|0 22|Domain switch experiments
P09121454A1328|144 165|transcription machinery
P09121454A1328|10 19|phenotypes
P09121454A1328|39 47|mutations
P09121454A1328|67 71|Mot1p
P09121454A1328|124 131|activity
P09121454A1328|34 37|mot1
P09121454A1328|22 25|bur6
P09121454A1328|29 32|bur3
P09121454A1328|59 63|Bur6p
P09121454A1328|100 108|functions
P09121476T0000|0 4|PRH75
P09121476T0000|27 32|member
P09121476T0000|38 58|DEAD-box protein family
P09121476T0000|69 74|plants
P09121774A0611|32 42|stimulation
P09121774A0611|76 82|members
P09121774A0611|5 14|activities
P09121774A0611|88 102|MAP kinase family
P09121774A0611|45 54|cell growth
P09121774T0000|27 38|polyomavirus
P09121774T0000|103 120|cell transformation
P09121774T0000|63 72|activation
P09121774T0000|16 24|GTPase Rac
P09121774T0000|78 97|serum response element
P09121774T0000|1 4|role
P09121998A0663|33 38|region
P09121998A0663|132 142|transit time
P09121998A0663|41 48|interest
P09121998A0663|208 210|F90
P09121998A0663|204 206|min
P09121998A0663|156 163|fraction
P09121998A0663|144 146|MTT
P09121998A0663|13 18|curves
P09121998A0663|63 72|subjection
P09121998A0663|190 196|stomach
P09121998A0663|96 105|procedures
P09121998A0663|169 176|test meal
P09121998A0663|121 124|mean
P09122168A1427|40 43|role
P09122168A1427|177 187|interaction
P09122168A1427|104 107|GRK2
P09122168A1427|89 101|translocation
P09122168A1427|111 114|GRK3
P09122168A1427|47 56|G betagamma
P09122168A1427|154 171|isoform specificity
P09122168A1427|24 36|demonstration
P09122168A1427|133 138|system
P09122168A1427|195 204|components
P09122168A1427|4 8|study
P09122176A0970|33 42|repression
P09122176A0970|103 119|RA response element
P09122176A0970|48 55|hMGP gene
P09122176A0970|80 86|RAR/RXR
P09122176A0970|63 69|binding
P09122176A0970|3 9|results
P09122198A0478|0 13|Point mutations
P09122198A0478|23 38|tyrosine residues
P09122198A0478|106 116|conclusions
P09122198A0478|66 73|receptor
P09122198A0478|55 60|domain
P09122215A0335|100 107|interest
P09122215A0335|94 97|gene
P09122215A0335|80 88|mutations
P09122215A0335|16 21|method
P09123055T0000|45 50|livers
P09123055T0000|14 19|injury
P09123055T0000|55 56|UW
P09123055T0000|26 37|preservation
P09123055T0000|60 70|HTK solution
P09123787A0486|32 40|responses
P09123787A0486|112 115|side
P09123787A0486|182 183|Rc
P09123787A0486|164 165|R2
P09123787A0486|222 243|orbicularis oculi muscle
P09123787A0486|59 68|R1 response
P09123787A0486|195 204|R3 response
P09123787A0486|118 128|stimulation
P09123787A0486|74 106|orbicularis oculi muscle ipsilateral
P09123787A0486|144 151|response
P09124054A1164|3 11|prognosis
P09124054A1164|38 42|ABSCT
P09124054A1164|108 114|therapy
P09124054A1164|77 84|patients
P09124054A1164|19 26|patients
P09126487A1399|6 8|Hum
P09126622A0466|100 103|type
P09126622A0466|34 41|colonies
P09126622A0466|3 18|pigment intensity
P09126622A0466|45 55|appressoria
P09126622A0466|58 73|CAL transformants
P09128730A0000|208 216|delta mu Na
P09128730A0000|52 60|formation
P09128730A0000|159 171|biotin protein
P09128730A0000|131 138|malonate
P09128730A0000|25 40|Malonomonas rubra
P09128730A0000|108 126|acyl-carrier protein
P09128730A0000|63 71|malonyl-S
P09128730A0000|140 155|carboxyltransfer
P09128730A0000|74 92|acyl-carrier protein
P09128730A0000|218 227|generation
P09128730A0000|98 105|acetyl-S
P09128730A0000|8 22|decarboxylation
P09128730A0000|178 192|decarboxylation
P09129147A0644|28 41|leucine-zipper
P09129147A0644|81 87|Fos/Jun
P09129147A0644|91 106|ATF/CREB proteins
P09129147A0644|55 59|motif
P09129147A0644|71 78|homology
P09129147A0644|125 144|phosphorylation sites
P09129147A0644|3 20|Jem peptide sequence
P09130595A0478|27 33|protein
P09130595A0478|45 56|enhancer site
P09130595A0478|15 21|cloning
P09130700A0676|43 48|Spc98p
P09130700A0676|52 57|Spc97p
P09130700A0676|37 41|Tub4p
P09130700A0676|7 13|support
P09130700A0676|149 153|SPC98
P09130700A0676|124 140|co-overexpression
P09130700A0676|24 34|interaction
P09130700A0676|70 77|toxicity
P09130700A0676|143 146|TUB4
P09130700A0676|86 104|SPC97 overexpression
P09130718A0497|0 8|Sequences
P09130718A0497|91 92|kb
P09130718A0497|67 74|bp region
P09130718A0497|32 41|expression
P09130718A0497|106 108|ATG
P09130718A0497|44 47|sid1
P09130720A0417|116 132|intron recognition
P09130720A0417|23 29|mutants
P09130720A0417|86 100|TACTAAC sequence
P09130720A0417|35 50|branch site region
P09130720A0417|8 13|screen
P09130720A0417|63 71|positions
P09131139T0000|0 10|Implication
P09131139T0000|63 69|disease
P09131139T0000|13 15|PAF
P09131139T0000|19 33|acetylhydrolase
P09131139T0000|35 40|PAF-AH
P09131139T0000|42 49|activity
P09132011A0298|0 9|Comparison
P09132011A0298|96 102|protein
P09132011A0298|108 116|% homology
P09132011A0298|39 46|proteins
P09132011A0298|155 157|cdc
P09132011A0298|121 153|Drosophila cell cycle control protein
P09132011A0298|57 65|% homology
P09132011A0298|15 25|p50 sequence
P09132057A0559|232 237|tomato
P09132057A0559|272 279|pathogen
P09132057A0559|95 116|receptor protein kinases
P09132057A0559|250 259|resistance
P09132057A0559|48 65|sequence similarity
P09132057A0559|121 126|plants
P09132057A0559|182 192|self-pollen
P09132057A0559|24 26|NTS
P09132057A0559|195 209|Brassica species
P09132057A0559|33 44|reading frame
P09132057A0559|139 155|S-receptor kinases
P09132057A0559|216 229|Pto gene product
P09132057A0559|80 85|domain
P09132057A0559|171 179|rejection
P09132057A0559|1 11|polypeptide
P09132061A0828|128 131|ESTs
P09132061A0828|21 33|cDNA sequences
P09132061A0828|73 86|isoperoxidases
P09132061A0828|10 12|atp
P09132061A0828|14 18|types
P09132061A0828|110 119|peroxidase
P09132061A0828|3 5|atp
P09133122A0656|47 55|sequences
P09133122A0656|10 20|information
P09133122A0656|132 138|program
P09133122A0656|70 83|video sequences
P09133122A0656|99 108|angiograms
P09133122A0656|85 97|x-ray analysis
P09135066A0653|83 85|Ras
P09135066A0653|65 71|absence
P09135066A0653|53 59|p96h2bk
P09135066A0653|36 39|Mek1
P09135149A0000|30 37|activity
P09135149A0000|85 90|kinase
P09135149A0000|153 176|Pyp3 tyrosine phosphatases
P09135149A0000|145 149|Cdc25
P09135149A0000|59 68|Cdc2/Cdc13
P09135149A0000|111 129|Mik1 tyrosine kinases
P09135149A0000|104 107|Wee1
P09135772T0000|8 15|response
P09135772T0000|62 66|foods
P09135772T0000|75 82|subjects
P09135772T0000|34 39|roller
P09135928A0912|116 128|glibenclamide
P09135928A0912|11 16|mmol/l
P09135928A0912|78 88|angiotensin
P09135928A0912|37 47|BP responses
P09135928A0912|154 154|P
P09135928A0912|61 74|norepinephrine
P09135928A0912|135 143|metformin
P09135928A0912|18 18|P
P09135928A0912|145 145|P
P09136015A0529|3 12|sequencing
P09136015A0529|89 103|diversification
P09136015A0529|80 86|pattern
P09136015A0529|23 28|copies
P09136015A0529|57 63|cluster
P09136080A1469|161 164|gene
P09136080A1469|37 54|chromatin structure
P09136080A1469|22 35|DNA methylation
P09136080A1469|116 125|expression
P09136080A1469|78 84|Sp1 site
P09136080A1469|146 152|lineage
P09136080A1469|3 9|results
P09136080A1469|59 73|transactivation
P09138076A1099|132 136|E-box
P09138076A1099|48 55|extracts
P09138076A1099|81 90|osteoblast
P09138076A1099|141 145|E-box
P09138076A1099|25 31|factors
P09138076A1099|98 118|oligonucleotide probes
P09138076A1099|147 154|elements
P09138076A1099|2 23|gel mobility shift assays
P09138492A0806|15 17|IDR
P09138492A0806|49 64|chest radiography
P09138492A0806|112 116|tumor
P09138492A0806|23 32|tuberculin
P09138492A0806|84 97|calcifications
P09138492A0806|163 166|exam
P09138492A0806|99 105|ORL exam
P09138492A0806|122 125|foot
P09138492A0806|189 207|epidermoid carcinoma
P09138492A0806|131 140|epiglottis
P09138492A0806|0 13|Laboratory exam
P09139665A0784|18 30|PhLP complexes
P09139665A0784|53 62|Gbetagamma
P09139694A0789|174 183|palindrome
P09139694A0789|154 160|binding
P09139694A0789|123 134|DNA fragments
P09139694A0789|112 121|palindrome
P09139694A0789|163 171|CTF1alpha
P09139694A0789|63 72|palindrome
P09139694A0789|74 84|DNA fragment
P09139694A0789|93 102|palindrome
P09139694A0789|0 8|CTF1alpha
P09139721A0183|88 98|lymphocytes
P09139721A0183|138 146|apoptosis
P09139721A0183|127 134|deletion
P09139721A0183|36 41|system
P09139721A0183|58 74|tolerance subjects
P09139721A0183|109 117|selection
P09139721A0183|0 7|Cyclin G2
P09139737A0000|236 246|cholesterol
P09139737A0000|216 221|uptake
P09139737A0000|99 106|proteins
P09139737A0000|225 233|synthesis
P09139737A0000|255 259|acids
P09139737A0000|108 113|SREBPs
P09139737A0000|183 195|transcription
P09139737A0000|198 202|genes
P09139737A0000|119 131|cell membranes
P09139737A0000|162 168|nucleus
P09139737A0000|17 24|protease
P09139737A0000|58 65|segments
P09139737A0000|68 73|sterol
P09139737A0000|34 40|release
P09139892A1150|101 111|orientation
P09139892A1150|65 75|orientation
P09139892A1150|124 135|crp promoters
P09139892A1150|27 38|vfr promoters
P09139892A1150|20 23|orfX
P09139892A1150|117 120|dorf
P09139910A0350|188 192|pOST4
P09139910A0350|24 34|PCR products
P09139910A0350|204 208|pOST2
P09139910A0350|78 89|DNA fragments
P09139910A0350|200 202|kbp
P09139910A0350|47 54|presence
P09139910A0350|139 144|probes
P09139910A0350|184 186|kbp
P09139910A0350|161 178|clone XbaI fragments
P09139910A0350|118 121|nifV
P09139910A0350|0 15|Sequence analysis
P09139910A1572|14 27|Anabaena strain
P09139910A1572|73 77|R229I
P09139910A1572|2 9|contrast
P09139910A1572|32 39|leuA gene
P09139910A1572|59 70|nifV mutation
P09140079A2528|44 46|TRE
P09140079A2528|34 36|TRs
P09140079A2528|7 12|effect
P09140474T0000|43 47|Spain
P09140474T0000|64 67|case
P09140474T0000|35 41|Minorca
P09140474T0000|88 94|Minorca
P09140474T0000|2 14|leishmaniasis
P09140474T0000|81 85|years
P09140474T0000|27 32|island
P09142146A0887|155 159|hours
P09142146A0887|161 161|p
P09142146A0887|41 49|mortality
P09142146A0887|55 60|trauma
P09142146A0887|21 31|PAF blockade
P09142146A0887|107 107|p
P09142146A0887|67 81|WEB-2086 animals
P09142146A0887|92 105|vehicle animals
P09142146A0887|0 6|RESULTS
P09142146A0887|133 137|index
P09142146A0887|143 150|delivery
P09143328A1002|59 76|dinucleotide primer
P09143328A1002|21 27|example
P09143328A1002|30 40|utilization
P09143328A1002|81 93|RNA polymerase
P09143328A1002|4 10|finding
P09143465A0838|59 60|IQ
P09143465A0838|75 79|scale
P09143465A0838|4 5|T1
P09143465A0838|9 21|dual-T1 images
P09143465A0838|46 57|image quality
P09144165A0614|82 88|feature
P09144165A0614|126 129|size
P09144165A0614|20 26|complex
P09144165A0614|76 78|RIR
P09144165A0614|51 54|AP-1
P09144165A0614|150 156|members
P09144165A0614|135 142|sequence
P09144165A0614|60 74|Rel insert region
P09144165A0614|108 123|hypervariability
P09144165A0614|40 43|NFAT
P09144165A0614|31 37|segment
P09144165A0614|162 189|Rel transcription factor family
P09144165A0614|3 7|model
P09144165A1275|82 88|binding
P09144165A1275|21 27|NFAT RIR
P09144165A1275|91 120|AP-1 family transcription factors
P09144165A1275|48 51|role
P09144165A1275|54 67|DNA recognition
P09144195A1051|100 105|PS1 CTF
P09144195A1051|62 94|phosphorylation/dephosphorylation
P09144195A1051|21 32|PS1 fragments
P09144195A1051|8 18|association
P09144195A1051|54 59|cycles
P09144770A0906|27 35|beta-turn
P09144770A0906|77 96|FKBP12 binding surface
P09144770A0906|22 25|Type
P09144770A0906|62 69|contacts
P09144770A0906|4 12|conformer
P09144958A0047|71 95|chlorophyll a/b protein gene
P09144958A0047|44 54|Arabidopsis
P09144958A0047|32 39|promoter
P09144958A0047|139 149|phytochrome
P09144958A0047|127 136|regulation
P09144958A0047|4 10|protein
P09144958A0047|21 26|region
P09144958A0047|97 101|Lhcb1
P09146027A0809|71 75|trunk
P09146027A0809|79 82|neck
P09146027A0809|10 15|Group B
P09146027A0809|25 34|athetoid CP
P09146027A0809|1 7|patient
P09146027A0809|39 48|spasticity
P09146071T0001|51 67|pontine hemorrhage
P09146071T0001|8 15|movement
P09146071T0001|37 40|case
P09146071T0001|30 33|limb
P09147420A0623|28 38|HCMV IE1/IE2
P09147420A0623|68 75|HIV-1 LTR
P09147420T0000|0 2|TAR
P09147420T0000|79 86|presence
P09147420T0000|53 58|repeat
P09147420T0000|64 73|Tat protein
P09147420T0000|38 40|HIV
P09147420T0000|21 35|transactivation
P09147420T0000|94 115|cytomegalovirus IE1/IE2
P09147788A0458|11 29|chain enzyme activity
P09147832A0174|86 95|predictors
P09147832A0174|53 53|n
P09147832A0174|66 70|years
P09147832A0174|10 20|temperament
P09147832A0174|156 163|measures
P09147832A0174|104 113|conscience
P09147832A0174|47 50|Time
P09147832A0174|32 44|socialization
P09147832A0174|0 7|Children
P09148770A0977|84 95|Csk SH2 domain
P09148770A0977|35 49|phosphoproteins
P09148770A0977|8 10|Csk
P09148903A1715|189 199|degradation
P09148903A1715|49 64|HIV-1 LTR activity
P09148903A1715|8 14|studies
P09148903A1715|246 252|pathway
P09148903A1715|89 101|translocation
P09148903A1715|107 134|NF-kappaB transcription factor
P09148903A1715|37 46|activation
P09148903A1715|153 185|IkappaBalpha serine phosphorylation
P09148929A0372|3 4|P1
P09148929A0372|12 16|clone
P09148929A0372|33 48|plasmid subclones
P09148929A0372|89 100|organization
P09148929A0372|106 114|Ctpct gene
P09148935A0805|158 160|FAK
P09148935A0805|112 121|expression
P09148935A0805|127 155|c-Src binding site Phe-397 mutant
P09148935A0805|13 28|c-Src PTK activity
P09148935A0805|84 93|activation
P09148935A0805|96 99|ERK2
P09148935A0805|46 62|type FAK expression
P09149825A0151|13 18|cement
P09149825A0151|40 44|resin
P09149825A0151|72 81|properties
P09149825A0151|20 33|4-META/MMA-TBB
P09149825A0151|85 94|bone cement
P09149929A0750|22 32|predictions
P09149929A0750|49 56|children
P09149929A0750|129 135|control
P09149929A0750|95 104|separation
P09149929A0750|69 75|control
P09149929A0750|80 91|homesickness
P09150334A0559|4 9|sample
P09150334A0559|71 78|sampling
P09150334A0559|63 65|min
P09150566A0316|15 18|role
P09150566A0316|32 40|formation
P09150566A0316|43 58|complex molecules
P09150566A0316|21 26|grains
P09150566A0316|82 87|clouds
P09150595A0225|44 45|HR
P09150595A0225|35 42|reaction
P09150595A0225|206 211|domain
P09150595A0225|97 104|HarpinEa
P09150595A0225|57 70|E. chrysanthemi
P09150595A0225|152 165|signal sequence
P09150595A0225|7 15|elicitors
P09150595A0225|85 95|E. amylovora
P09150595A0225|123 129|protein
P09150595A0225|72 80|HarpinEch
P09150595T0000|43 70|Erwinia carotovora hrpNEcc gene
P09150595T0000|28 37|expression
P09150595T0000|9 24|characterization
P09150595T0000|113 120|reaction
P09150595T0000|86 93|elicitor
P09150728A0596|86 91|muscle
P09150728A0596|3 6|mRNA
P09150728A0596|26 29|HES1
P09150728A0596|15 18|gene
P09150728A0596|70 74|heart
P09150774A0616|0 9|Anesthesia
P09150774A0616|27 36|isoflurane
P09150774A0616|38 40|ISO
P09150774A0616|49 58|inhalation
P09150774A0616|43 45|N2O
P09151152A0174|130 138|factor VII
P09151152A0174|204 219|serum lipoprotein
P09151152A0174|103 114|hemodialysis
P09151152A0174|170 183|heparinization
P09151152A0174|196 201|amount
P09151152A0174|21 36|protein C activity
P09151152A0174|55 55|p
P09151152A0174|120 126|factor X
P09151152A0174|149 149|p
P09151152A0174|156 156|p
P09151376A0000|16 19|type
P09151376A0000|61 69|diagnosis
P09151376A0000|10 13|case
P09151376A0000|166 169|gout
P09151376A0000|49 55|patient
P09151376A0000|22 45|hyperbetalipoproteinemia
P09151376A0000|149 157|arthritis
P09151806A1125|55 66|mLAT pre-mRNA
P09151806A1125|5 8|data
P09151806A1125|37 39|LAT
P09151806A1125|44 49|intron
P09151806A1125|78 88|branch point
P09151806A1125|16 23|evidence
P09151828A0919|115 122|residues
P09151828A0919|10 26|amino acid residues
P09151828A0919|43 59|9ORF1 polypeptides
P09151828A0919|107 112|region
P09151828A0919|179 186|residues
P09151828A0919|140 147|residues
P09151828A0919|131 136|region
P09151828A0919|169 174|region
P09151828A0919|88 94|regions
P09151837A0723|136 148|fusion protein
P09151837A0723|51 82|coimmunoprecipitation experiments
P09151837A0723|7 24|protein interaction
P09151837A0723|189 193|Rep78
P09151837A0723|222 252|transcription-translation system
P09151837A0723|167 169|35S
P09151837A0723|151 161|combination
P09151925A0479|59 61|TAE
P09151925A0479|107 129|ethanol injection therapy
P09151925A0479|63 67|C-LIP
P09151925A0479|78 90|gelatin sponge
P09151925A0479|131 134|PEIT
P09151925A0479|3 7|C-LIP
P09151925A0479|46 57|embolization
P09151925A0479|27 37|transcather
P09152656A0149|60 71|heart failure
P09152656A0149|110 114|study
P09152656A0149|8 15|patients
P09152656A0149|20 47|New York Heart Association class
P09153010A0499|85 94|collection
P09153010A0499|201 204|MUPs
P09153010A0499|130 140|possibility
P09153010A0499|214 228|reproducibility
P09153010A0499|160 172|threshold MUPs
P09153010A0499|122 125|site
P09153010A0499|48 58|acquisition
P09153010A0499|181 184|bias
P09153010A0499|104 107|MUPs
P09153010A0499|65 68|MUPs
P09153010A0499|291 302|laboratories
P09153010A0499|234 240|results
P09153010A0499|190 198|selection
P09153010A0499|257 271|reference values
P09153010A0499|7 16|advantages
P09153010A0499|28 35|analysis
P09153319A0844|73 79|ethanol
P09153319A0844|96 100|water
P09153319A0844|30 38|triplexes
P09153319A1332|0 22|Transfection experiments
P09153319A1332|37 45|triplexes
P09153319A1332|132 144|transcription
P09153319A1332|79 102|collagen promoter sequence
P09153319A1332|162 187|control phosphorothioate ODN
P09153319A1332|51 65|reporter plasmid
P09153319A1332|120 129|inhibition
P09153348A0647|57 89|mineralocorticoid steroid secretion
P09153348A0647|163 170|patients
P09153348A0647|128 134|markers
P09153348A0647|154 160|disease
P09153348A0647|97 113|cortisol secretion
P09153348A0647|138 148|progression
P09153348A0647|7 14|increase
P09153348A0647|46 53|androgen
P09153348A0647|30 34|shift
P09153348A0647|17 25|plasma TBG
P09153348A0647|175 187|HIV-infection
P09153795A0298|41 51|reliability
P09153795A0298|9 15|studies
P09153795A0298|55 62|validity
P09153795A0298|19 22|RDFS
P09153795A0298|31 38|evidence
P09154283A0307|0 10|Latanoprost
P09154283A0307|53 60|pressure
P09154283A0307|111 123|acetazolamide
P09154283A0307|127 136|dipivefrin
P09154283A0307|76 86|combination
P09154283A0307|91 97|timolol
P09154283A0307|62 64|IOP
P09154283A0307|99 109|pilocarpine
P09154283A0307|31 39|reduction
P09154621A1475|30 51|safflower phospholipids
P09154621A1475|66 75|ingredient
P09154621A1475|116 131|serum cholesterol
P09154621A1475|78 83|layers
P09154621A1475|5 11|results
P09154621A1475|95 112|liver triglycerides
P09154621A1475|149 155|effects
P09154795A0628|102 109|beta-pol
P09154795A0628|12 21|techniques
P09154795A0628|111 122|gene promoter
P09154795A0628|50 57|analysis
P09154795A0628|84 100|DNA polymerase beta
P09154797A0777|30 33|stk2
P09154797A0777|9 27|spermidine transport
P09154797A0777|79 86|affinity
P09154797A0777|124 129|strain
P09154797A0777|36 46|lacZ mutants
P09154797A0777|103 106|Vmax
P09154819A0501|74 78|FR3T3
P09154819A0501|25 29|c-Jun
P09154819A0501|66 68|REF
P09154819A0501|93 110|fibroblast cell line
P09154819A0501|9 22|overexpression
P09154819A0501|37 56|tenascin-C expression
P09154822T0000|0 9|Inhibition
P09154822T0000|51 59|apoptosis
P09154822T0000|79 83|cells
P09154822T0000|34 44|AMP agonists
P09154822T0000|15 25|Raf-1 kinase
P09154827A0158|147 152|subset
P09154827A0158|163 169|arrests
P09154827A0158|184 192|degrees C.
P09154827A0158|77 79|TAF
P09154827A0158|49 52|ts13
P09154827A0158|104 107|gene
P09154827A0158|155 159|genes
P09154827A0158|33 47|hamster cell line
P09154827A0158|93 95|TAF
P09154827A0158|8 14|studies
P09154827A0158|134 143|expression
P09154827A0158|176 177|G1
P09154827A0158|59 71|point mutation
P09154827A0158|84 91|250/CCG1
P09155015A0140|97 99|ANF
P09155015A0140|90 95|factor
P09155015A0140|151 161|hypertrophy
P09155015A0140|101 108|promoter
P09155015A0140|44 65|reporter gene expression
P09155015A0140|17 34|protein kinase MEKK1
P09155015A0140|118 123|marker
P09155024A0955|58 63|growth
P09155024A0955|83 94|pseudohyphae
P09155024A0955|69 72|form
P09155024A0955|22 31|C. albicans
P09155024A0955|113 117|media
P09155024A0955|16 19|EFG1
P09155024A0955|97 102|liquid
P09155024A0955|0 13|Overexpression
P09156883A0294|132 140|procedure
P09156883A0294|41 53|blood pressure
P09156883A0294|19 27|heart rate
P09156883A0294|83 86|SaO2
P09156883A0294|8 17|parameters
P09156883A0294|55 57|ABP
P09156883A0294|29 30|HR
P09156883A0294|99 110|pulsoximetry
P09156883A0294|72 81|saturation
P09157100A0583|13 19|signing
P09157100A0583|53 55|SIB
P09157100A0583|79 88|extinction
P09157337A0545|27 33|couples
P09157337A0545|107 111|years
P09157337A0545|47 55|hepatitis
P09157337A0545|3 9|husband
P09157337A0545|82 102|Infectology Department
P09157337A0545|70 77|etiology
P09157760A0000|91 97|nucleus
P09157760A0000|82 88|Meynart
P09157760A0000|116 119|part
P09157760A0000|142 149|thalamus
P09157760A0000|67 79|peculiarities
P09157760A0000|133 139|nucleus
P09157760A0000|178 188|individuals
P09157760A0000|30 37|analysis
P09159111A0437|55 56|CD
P09159111A0437|105 112|proteins
P09159111A0437|61 74|NMR experiments
P09159111A0437|16 23|proposal
P09159111A0437|80 88|Skn domain
P09159111A0437|45 53|dichroism
P09159160A0000|64 68|genes
P09159160A0000|91 98|diseases
P09159160A0000|38 46|sequences
P09159160A0000|10 16|cloning
P09159183A0119|145 150|plants
P09159183A0119|66 90|basic-region leucine zipper
P09159183A0119|33 36|OBFs
P09159183A0119|137 142|number
P09159183A0119|92 95|bZIP
P09159183A0119|8 31|ocs element binding factors
P09159183A0119|59 63|class
P09159183A0119|97 116|transcription factors
P09159183A0119|0 4|Genes
P09160361A0858|44 48|group
P09160361A0858|112 112|p
P09160361A0858|23 30|CPB group
P09160361A0858|62 62|%
P09160361A0858|9 17|mortality
P09160361A0858|55 55|%
P09160881A0491|60 65|screen
P09160881A0491|18 40|co-precipitation studies
P09160881A0491|94 105|interactions
P09160881A0491|45 49|yeast
P09162084A0956|84 108|GST-Src-SH2 affinity matrix
P09162084A0956|57 63|PECAM-1
P09162084A0956|36 48|Src-SH2 domain
P09162084A0956|4 14|association
P09162092A0675|0 22|MKK3 autophosphorylation
P09162092A0675|103 107|MEKK2
P09162092A0675|79 82|MKK3
P09162092A0675|65 76|coexpression
P09162092A0675|38 40|p38
P09162092A0675|26 35|activation
P09162092A0675|87 91|MEKK3
P09162097A0776|59 62|exon
P09162097A0776|119 124|LPAM-1
P09162097A0776|22 36|MAdCAM-1 variant
P09162097A0776|75 85|mucin domain
P09162097A0776|154 161|receptor
P09162097A0776|132 139|adhesion
P09162097A0776|163 172|L-selectin
P09162097A0776|100 116|leukocyte adhesion
P09162097A1258|129 143|dissimilarities
P09162097A1258|56 67|MAdCAM-1 cDNA
P09162097A1258|92 100|homologue
P09162097A1258|103 115|mouse MAdCAM-1
P09162097A1258|167 176|structures
P09162097A1258|2 8|summary
P09162097A1258|149 156|MAdCAM-1
P09162097A1258|13 16|data
P09163332A0275|99 105|sequons
P09163332A0275|64 70|hydroxy
P09163332A0275|80 96|amino acid residues
P09163332A0275|24 42|mutagenesis approach
P09163332A0275|133 142|efficiency
P09163332A0275|72 78|Ser/Thr
P09163332A0275|58 60|Xaa
P09164543A0219|0 7|MATERIAL
P09164543A0219|39 45|persons
P09164543A0219|11 17|METHODS
P09164543A0219|88 93|months
P09164543A0219|79 83|years
P09164543A0219|65 71|surgery
P09164543A0219|22 28|authors
P09164543A0219|123 130|vagotomy
P09164543A0219|183 190|drainage
P09164543A0219|157 164|vagotomy
P09164543A0219|98 101|mean
P09164856A0980|117 124|promoter
P09164856A0980|38 48|TATA element
P09164856A0980|82 96|glutaminase gene
P09164856A0980|64 76|transcription
P09164856A0980|4 9|region
P09165004A1700|0 10|SRE activity
P09165004A1700|66 78|complex factor
P09165004A1700|103 116|complex factors
P09165004A1700|41 55|phosphorylation
P09165004A1700|119 123|Elk-1
P09165004A1700|29 38|activation
P09165035A0842|0 31|Serum alkaline phosphatase activity
P09165035A0842|33 52|bone mass measurements
P09165035A0842|83 90|analysis
P09165035A0842|93 106|mineral density
P09165035A0842|208 208|D
P09165035A0842|136 144|vertebrae
P09165035A0842|164 170|animals
P09165035A0842|58 68|energy x-ray
P09165035A0842|212 218|animals
P09165035A0842|160 160|D
P09165035A0842|121 133|testing values
P09165035A0842|148 153|femora
P09165039A0728|30 30|%
P09165039A0728|75 82|LHR cDNAs
P09165039A0728|38 53|sequence homology
P09165039A0728|3 15|monkey LHR cDNA
P09165039A1372|2 11|conclusion
P09165039A1372|101 107|species
P09165039A1372|13 29|marmoset monkey LHR
P09165039A1372|78 84|LHR gene
P09165039A1372|67 70|exon
P09165039A1372|44 51|sequence
P09165118A0311|15 28|VA motor neurons
P09165118A0311|90 100|sister cells
P09165118A0311|176 189|movement defect
P09165118A0311|7 13|mutants
P09165118A0311|105 118|VB motor neurons
P09165118A0311|123 126|loss
P09165118A0311|38 44|pattern
P09165118A0311|55 59|input
P09165118A0311|135 139|input
P09165118A0311|145 147|VAs
P09167421A0234|42 58|microSelectron HDR
P09167421A0234|91 92|Gy
P09167421A0234|108 116|fractions
P09167421A0234|13 23|irradiation
P09167421A0234|71 76|device
P09168083A0987|26 28|HAT
P09168083A0987|11 15|group
P09168083A0987|43 47|group
P09168083A0987|30 30|P
P09168083A0987|2 8|patient
P09168134A0858|0 17|Sequence comparison
P09168134A0858|151 165|snRNP components
P09168134A0858|135 139|genes
P09168134A0858|66 73|Sm-E gene
P09168134A0858|52 60|promoters
P09168134A0858|27 44|kb promoter sequence
P09168134A0858|77 88|U1 snRNA genes
P09168134A0858|114 119|motifs
P09168218A0216|58 73|pain syndrome type
P09168218A0216|113 117|grill
P09168218A0216|11 19|responses
P09168218A0216|153 165|ganglion block
P09168218A0216|34 38|woman
P09168218A0216|93 101|dystrophy
P09168218A0216|0 6|METHODS
P09168511A0640|100 112|dexamethasone
P09168511A0640|22 27|number
P09168511A0640|61 63|use
P09168511A0640|76 92|steroid budesonide
P09168511A0640|30 41|developments
P09168511A0640|146 153|steroids
P09168511A0640|130 137|argument
P09168623A0614|1 4|xylE
P09168623A0614|137 146|expression
P09168623A0614|39 50|mxbD promoter
P09168623A0614|113 121|compounds
P09168623A0614|20 25|fusion
P09168623A0614|161 169|succinate
P09168623A0614|110 111|C1
P09168623A0614|66 75|expression
P09168623A0614|87 91|cells
P09168623A0614|149 153|cells
P09168623A0614|99 108|one-carbon
P09168879A0219|116 124|TAAG sites
P09168879A0219|17 24|Sf9 cells
P09168879A0219|82 90|TAAG sites
P09168879A0219|30 52|transcription initiation
P09168892A1016|0 7|Mutation
P09168892A1016|10 20|nucleotides
P09168892A1016|63 68|effect
P09168892A1016|50 57|elements
P09168892A1016|34 37|AP-1
P09168892A1016|71 86|trans-activation
P09169127A0371|242 249|sequence
P09169127A0371|8 16|proximity
P09169127A0371|190 197|sequence
P09169127A0371|25 50|neuropeptide Y receptor genes
P09169127A0371|155 160|y1 gene
P09169127A0371|115 120|intron
P09169127A0371|297 302|y1 gene
P09169127A0371|207 212|y5 gene
P09169127A0371|142 149|sequence
P09169127A0371|83 102|gene duplication event
P09169127A0371|287 290|exon
P09169420A0000|149 151|PIK
P09169420A0000|145 147|p55
P09169420A0000|12 36|phosphoinositide 3-kinases
P09169420A0000|54 57|beta
P09169420A0000|121 128|adaptors
P09169420A0000|100 102|SH2
P09169420A0000|87 97|Src homology
P09169420A0000|38 42|PI3Ks
P09169420A0000|44 52|p110alpha
P09169420A0000|135 142|p85alpha
P09169420A0000|62 82|delta form heterodimers
P09169475A0272|81 108|transcription initiation sites
P09169475A0272|5 11|studies
P09169475A0272|39 44|region
P09169475A0272|55 63|gp130 gene
P09169475A0772|0 11|Localization
P09169475A0772|107 117|binding site
P09169475A0772|77 87|mutagenesis
P09169475A0772|45 60|deletion analysis
P09169475A0772|130 142|STAT complexes
P09169475A0772|17 39|cytokine response element
P09169593T0000|132 135|role
P09169593T0000|141 150|regulation
P09169593T0000|111 121|cell nucleus
P09169593T0000|36 54|protein kinase kinase
P09169593T0000|94 105|casein kinase
P09169593T0000|56 58|MEK
P09169593T0000|78 90|protein kinase
P09169593T0000|153 166|gene expression
P09169593T0000|0 16|Insulin regulation
P09169852A0235|184 191|tyrosine
P09169852A0235|138 147|zinc finger
P09169852A0235|0 9|Sequencing
P09169852A0235|96 106|zinc fingers
P09169852A0235|20 31|pag-3 alleles
P09169852A0235|111 126|missense mutation
P09169852A0235|71 86|nonsense mutation
P09169852A0235|57 63|alleles
P09169852A0235|172 180|histidine
P09169853A0000|0 4|Pax-3
P09169853A0000|19 30|homeobox gene
P09169853A0000|63 68|dorsal
P09169853A0000|87 90|tube
P09170159A0348|30 34|cells
P09170159A0348|108 114|protein
P09170159A0348|77 86|tyrosinase
P09170159A0348|57 70|marker proteins
P09170159A0721|98 104|HLH-Zip
P09170159A0721|107 118|Zip structure
P09170159A0721|24 29|codons
P09170159A0721|83 90|proteins
P09170159A0721|5 13|mutations
P09170159A0721|32 35|exon
P09171038A0219|12 18|Sjogren
P09171038A0219|21 28|syndrome
P09171038A0219|103 111|treatment
P09171038A0219|114 120|Sjogren
P09171038A0219|6 9|case
P09171038A0219|80 89|complaints
P09171038A0219|123 130|patients
P09171081T0000|29 32|cDNA
P09171081T0000|10 25|characterization
P09171081T0000|60 72|RNA polymerase
P09171081T0000|86 106|plant Chenopodium album
P09171081T0000|0 6|Cloning
P09171235A0851|127 132|TRbeta
P09171235A0851|10 23|overexpression
P09171235A0851|66 80|COUP-TFI delta35
P09171235A0851|36 48|concentration
P09171235A0851|95 111|silencing activity
P09171235A0851|51 58|COUP-TFI
P09171239A1118|40 44|helix
P09171239A1118|78 93|hormone receptors
P09171239A1118|21 24|part
P09171239A1118|139 161|transactivation function
P09171239A1118|108 117|core domain
P09171239A1118|8 17|amino acids
P09171239A1118|163 166|AF-2
P09171239A2146|59 65|binding
P09171239A2146|28 33|ligand
P09171239A2146|78 89|RXR component
P09171239A2146|68 72|SRC-1
P09171239A2146|104 114|heterodimer
P09171239A2146|48 51|acid
P09171363A0149|15 24|mechanisms
P09171363A0149|2 9|ciliates
P09171389A0549|261 277|pyr gene expression
P09171389A0549|241 251|attenuation
P09171389A0549|176 186|Bacillus sp.
P09171389A0549|10 19|occurrence
P09171389A0549|280 286|Thermus
P09171389A0549|148 170|PyrR attenuation proteins
P09171389A0549|54 77|Thermus pyr promoter region
P09171389A0549|122 122|%
P09171389A0549|208 216|mechanism
P09171389A0549|29 48|transcription signals
P09171389A0549|131 141|Thermus PyrR
P09171389A0549|87 113|amino acid sequence identities
P09171468T0000|0 4|Diver
P09171468T0000|49 66|breathing apparatus
P09171468T0000|16 24|responses
P09171969A1165|0 10|Measurement
P09171969A1165|36 46|oxygen pulse
P09171969A1165|30 32|VO2
P09171969A1165|144 147|COPD
P09171969A1165|61 76|work rate exercise
P09171969A1165|101 110|evaluation
P09171969A1165|16 19|time
P09171969A1165|132 139|patients
P09171969A1165|116 129|training effect
P09172312T0000|0 15|Characterization
P09172312T0000|18 26|CR1 repeat
P09172312T0000|56 68|chicken genome
P09172312T0000|33 42|PCR markers
P09172414A0000|120 124|serum
P09172414A0000|128 141|liver esterases
P09172414A0000|70 82|determination
P09172414A0000|85 102|cocaine metabolites
P09172414A0000|53 56|HPLC
P09172414A0000|58 63|method
P09172641A0181|71 79|subdomain
P09172641A0181|24 31|evidence
P09172641A0181|10 16|studies
P09172641A0181|38 40|end
P09172641A0181|95 102|contacts
P09172641A0181|110 120|nucleotides
P09172641A0181|59 68|side chains
P09172812A0660|17 27|fludarabine
P09172812A0660|50 52|CLL
P09172812A0660|43 47|agent
P09173733A0404|232 240|densities
P09173733A0404|49 53|study
P09173733A0404|222 223|EA
P09173733A0404|203 216|factor analysis
P09173733A0404|150 158|expansion
P09173733A0404|26 35|EA analysis
P09173733A0404|99 102|band
P09173733A0404|89 90|EA
P09173733A0404|61 81|Fourier transformation
P09173733A0404|14 23|techniques
P09173733A0404|130 135|method
P09173733A0404|195 199|shape
P09173733A0404|164 172|EEG curves
P09173733A0404|83 85|FFT
P09174049A1788|145 153|cell death
P09174049A1788|14 43|p34CDC2 histone H1 kinase activity
P09174049A1788|82 90|cell lines
P09174049A1788|108 111|role
P09174049A1788|119 125|protein
P09175708A1526|158 164|nucleus
P09175708A1526|65 72|receptor
P09175708A1526|47 53|regions
P09175708A1526|5 9|PRL-R
P09175708A1526|105 112|fragment
P09175708A1526|84 94|possibility
P09175858A1449|250 254|GAPDH
P09175858A1449|189 195|account
P09175858A1449|8 16|B-S mutant
P09175858A1449|94 100|effects
P09175858A1449|233 238|mutant
P09175858A1449|161 170|structures
P09175858A1449|56 61|GAPDHs
P09175858A1449|132 141|inspection
P09176340A1194|0 12|Transcription
P09176340A1194|20 24|genes
P09176340A1194|48 51|lung
P09176340A1194|109 113|liver
P09176340A1194|87 93|tissues
P09176340A1194|42 44|gut
P09176340A1194|58 65|freezing
P09176340A1194|70 79|mRNA levels
P09176837A0211|117 131|P administration
P09176837A0211|33 36|CSAO
P09176837A0211|66 76|P solubility
P09176837A0211|112 113|Ca
P09176837A0211|89 92|data
P09176837A0211|61 64|PN Ca
P09176837A0211|0 15|Computer software
P09177169A0935|86 93|bacteria
P09177169A0935|8 14|chimera
P09177169A0935|37 42|halves
P09177169A0935|48 55|molecule
P09177857A0000|132 135|type
P09177857A0000|145 150|plasma
P09177857A0000|122 126|steel
P09177857A0000|81 86|oxygen
P09177857A0000|25 39|titanium dioxide
P09177857A0000|3 12|conditions
P09177857A0000|159 188|chemical vapour deposition method
P09177857A0000|47 77|substrates titanium tetrachloride
P09178269A0107|6 10|genes
P09178491A0262|13 19|regions
P09178491A0262|103 118|initiator element
P09178491A0262|59 71|HBV adw subtype
P09178491A0262|30 53|preS2/S gene transcription
P09178491A0262|84 90|TATA box
P09178494A1123|188 190|RNA
P09178494A1123|165 176|preservation
P09178494A1123|75 78|stem
P09178494A1123|245 251|control
P09178494A1123|255 265|replication
P09178494A1123|153 161|selection
P09178494A1123|65 72|patterns
P09178494A1123|50 56|regions
P09178494A1123|121 132|flaviviruses
P09178494A1123|82 95|loop structures
P09178494A1123|200 209|structures
P09178752A0574|58 61|cAMP
P09178752A0574|18 22|means
P09178752A0574|25 49|transactivation domain AF-1
P09178752A0574|99 100|ER
P09178752A0574|69 93|transactivation domain AF-2
P09178752A0574|0 2|EGF
P09180687A0096|142 167|alanine substitution mutants
P09180687A0096|126 129|SulA
P09180687A0096|84 89|series
P09180687A0096|45 54|inhibition
P09180687A0096|134 139|series
P09180687A0096|24 27|SulA
P09180687A0096|57 68|cell division
P09180687A0096|16 21|region
P09180687A0096|115 123|deletions
P09181130A1067|98 105|deletion
P09181130A1067|108 109|r3
P09181130A1067|80 87|mutation
P09181130A1067|113 114|r5
P09181130A1067|51 57|ES cells
P09181130A1067|36 48|recombination
P09181130A1067|17 23|Krox-20
P09181130A1587a|58 68|populations
P09181130A1587a|102 106|light
P09181130A1587a|82 89|mutation
P09181130A1587a|180 191|inactivation
P09181130A1587a|112 115|role
P09181130A1587a|163 174|consequences
P09181130A1587a|118 124|Krox-20
P09181130A1587a|32 39|analysis
P09181130A1587a|130 141|segmentation
P09182281A0197|30 41|Cyclosporin A
P09182281A0197|77 80|drug
P09182527A0443|41 46|mE6-AP
P09182527A0443|74 80|cytosol
P09182527A0443|23 39|p53 ubiquitination
P09182527A0443|87 92|Nedd-4
P09182527A0443|64 70|nucleus
P09182527A0443|110 116|cytosol
P09182527A0443|17 20|role
P09182707A0254|89 102|tyrosine kinase
P09182707A0254|123 131|adhesions
P09182707A0254|68 71|p125
P09182707A0254|23 45|tyrosine phosphorylation
P09182707A0254|53 66|adhesion kinase
P09182707A0254|164 178|protein paxillin
P09182707A0254|73 75|FAK
P09182707A0254|0 2|SPP
P09182990A0245|154 159|factor
P09182990A0245|195 199|yeast
P09182990A0245|56 66|combination
P09182990A0245|138 143|Sup45p
P09182990A0245|38 42|SUP45
P09182990A0245|128 136|SUP45 gene
P09182990A0245|171 192|translation termination
P09182990A0245|116 122|product
P09182990A0245|146 149|eRF1
P09182990A0245|44 50|sup45-2
P09182990A0245|30 35|allele
P09182990A0245|85 94|approaches
P09183145T0001|0 9|Evaluation
P09183145T0001|109 119|angioplasty
P09183145T0001|22 30|perfusion
P09183145T0001|50 54|SPECT
P09183145T0001|138 147|infarction
P09183406A0637|48 51|Baka
P09183406A0637|41 46|HPA-3a
P09183406A0637|53 67|incompatibility
P09183406A0637|19 34|thrombocytopenia
P09185183A0089|27 31|years
P09185183A0089|67 80|motor abilities
P09185183A0089|34 36|age
P09185183A0089|56 64|worsening
P09185183T0000|0 6|Merosin
P09185183T0000|33 41|dystrophy
P09185183T0000|52 61|deficiency
P09185183T0000|74 83|MRI changes
P09185183T0000|63 70|epilepsy
P09185183T0000|102 107|matter
P09185586A0000|14 18|mRNAs
P09185586A0000|53 61|mechanism
P09185586A0000|36 51|scanning ribosome
P09185645T0000|0 9|Comparison
P09185645T0000|93 101|detection
P09185645T0000|12 42|Tc-99m sestamibi perfusion imaging
P09185645T0000|112 124|artery disease
P09185645T0000|69 86|arbutamine infusion
P09185645T0000|46 61|echocardiography
P09186056A0514|43 52|C2C12 cells
P09186056A0514|79 90|CAT-reporter
P09186056A0514|104 111|E12/MyoD
P09186056A0514|63 75|transcription
P09186056A0514|118 125|enhancer
P09186056A0514|34 40|protein
P09186056A0514|14 27|overexpression
P09186430A0341|37 44|albinism
P09186507A0882|189 204|CpG dinucleotides
P09186507A0882|131 134|TATA
P09186507A0882|138 146|CAAT boxes
P09186507A0882|116 124|CpG island
P09186507A0882|284 287|gene
P09186507A0882|164 173|G+C content
P09186507A0882|84 95|cDNA sequence
P09186507A0882|47 54|sequence
P09186507A0882|239 242|site
P09187136A0000|0 5|SSeCKS
P09187136A0000|36 58|protein kinase C substrate
P09187136A0000|126 136|fibroblasts
P09187136A0000|166 176|fibroblasts
P09187136A0000|63 72|expression
P09187136A0000|178 179|X.
P09187136A0000|98 100|src
P09187136A0000|17 21|essex
P09187277A0118|128 134|neurons
P09187277A0118|55 56|V I
P09187277A0118|82 87|number
P09187277A0118|58 64|neurons
P09187277A0118|5 29|position-vestibular-pause
P09187277A0118|103 106|type
P09187277A0118|0 3|Type
P09187277A0118|95 98|type
P09187277A0118|31 34|PVP I
P09187371A0450|83 87|heart
P09187371A0450|63 69|species
P09187371A0450|45 49|heart
P09187371A0450|120 125|muscle
P09187371A0450|98 102|brain
P09187371A0450|128 132|liver
P09187371A0450|89 94|kidney
P09187371A0450|16 26|mRNA species
P09187637A1199|59 61|OP4
P09187637A1199|42 50|amplitude
P09187637A1199|53 55|OP1
P09187637A1199|0 16|Taurine deficiency
P09188094A0934|57 64|response
P09188094A0934|20 24|cells
P09188094A0934|51 54|Spc1
P09188094A0934|74 78|forms
P09188094A0934|39 48|activation
P09188094A0934|81 86|stress
P09188094A0934|15 18|mcs4
P09188699A1388|99 110|SDS-PAGE gels
P09188699A1388|77 87|SP-A species
P09188699A1388|11 25|rat SP-A isoforms
P09188863A0954|21 26|CDC25B
P09188863A0954|11 18|splicing
P09188863A0954|63 79|cell proliferation
P09188863A0954|54 60|control
P09189783A0000|90 101|carbohydrate
P09189783A0000|142 153|blood glucose
P09189783A0000|4 16|investigation
P09189783A0000|125 129|bolus
P09189783A0000|69 76|feedings
P09189783A0000|157 172|insulin responses
P09189783A0000|103 105|CHO
P09189783A0000|186 193|exercise
P09189783A0000|179 182|rest
P09189896A0611|42 56|memory processes
P09189896A0611|97 108|instructions
P09189896A0611|22 31|ERP effects
P09189896A0611|3 10|findings
P09190202A0166|86 105|Sec13p protein complex
P09190202A0166|25 29|Sar1p
P09190202A0166|146 149|p150
P09190202A0166|138 144|protein
P09190202A0166|34 53|Sec23p protein complex
P09190202A0166|64 69|Sec23p
P09190202A0166|73 78|Sec24p
P09190202A0166|4 14|coat protein
P09190202A0166|116 121|Sec13p
P09190821A0707|70 74|P243L
P09190821A0707|50 55|change
P09190821A0707|58 65|position
P09190940A0127|0 8|Induction
P09190940A0127|27 45|germline transcripts
P09190940A0127|66 77|switch region
P09190940A0127|81 93|recombination
P09190940A0127|97 105|switching
P09191052A0850|55 65|Hox proteins
P09191052A0850|8 10|PCE
P09191052A0850|49 53|Class
P09191052A0850|17 31|Pbx dimer partner
P09192732A1384|109 112|part
P09192732A1384|39 47|homologue
P09192732A1384|27 33|portion
P09192732A1384|78 85|membrane
P09192769T0000|59 75|chemokine receptor
P09192769T0000|19 34|characterization
P09192769T0000|81 88|homology
P09192769T0000|9 15|cloning
P09192769T0000|38 41|cDNA
P09192769T0000|99 118|C-C chemokine receptor
P09192769T0000|120 124|CCR-4
P09192769T0000|43 48|CHEMR1
P09192786T0000|0 11|Organization
P09192786T0000|22 27|LU gene
P09192786T0000|61 82|blood group polymorphism
P09192786T0000|50 51|Lu
P09192786T0000|40 44|basis
P09192786T0000|56 57|Lu
P09192786T0000|59 59|b
P09192842A0988|215 228|carcinogenesis
P09192842A0988|23 29|hybrids
P09192842A0988|75 91|chromosome 19q13.2
P09192842A0988|127 135|deletions
P09192842A0988|192 200|ETS factor
P09192842A0988|138 146|leukemias
P09192842A0988|94 99|region
P09192842A0988|49 56|PE-2 gene
P09192842A0988|110 123|translocations
P09192842A0988|33 44|FISH analysis
P09192842A0988|209 212|role
P09192842A0988|162 167|tumors
P09192998A0356|169 177|CJ signals
P09192998A0356|163 165|PTH
P09192998A0356|61 65|T7 DNA
P09192998A0356|131 136|rrnB T1
P09192998A0356|69 71|phi
P09192998A0356|77 82|rrnB T2
P09192998A0356|49 58|terminator
P09192998A0356|113 128|termination sites
P09192998A0356|67 67|T
P09192998A0356|16 22|enzymes
P09193072A0199|29 38|transgenes
P09193072A0199|53 61|nucleolus
P09193072A0199|11 14|data
P09193077A0000|130 148|Petroselinum crispum
P09193077A0000|21 24|LRU1
P09193077A0000|92 107|chalcone synthase
P09193077A0000|77 86|activation
P09193077A0000|120 127|promoter
P09193077A0000|109 111|CHS
P09193077A0000|15 18|unit
P09193080A0904|0 17|Sequence divergence
P09193080A0904|42 48|regions
P09193080A0904|63 72|definition
P09193080A0904|88 93|probes
P09193671A0347|28 37|hydrolysis
P09193671A0347|66 72|ARF-GDP
P09193671A0347|9 13|state
P09193671A0347|45 47|GTP
P09194250A0708|59 73|mortality target
P09194250A0708|25 35|World Summit
P09194250A0708|129 140|inequalities
P09194250A0708|102 108|targets
P09194250A0708|153 161|mortality
P09194250A0708|80 83|year
P09194250A0708|39 46|Children
P09195923A0125|176 187|immunophilin
P09195923A0125|107 109|TPR
P09195923A0125|111 116|domain
P09195923A0125|210 215|region
P09195923A0125|72 76|hsp90
P09195923A0125|39 63|cyclosporin A-binding class
P09195923A0125|31 35|FK506
P09195923A0125|3 14|immunophilin
P09195923A0125|83 105|tetratricopeptide repeat
P09195923A0125|218 222|hsp90
P09195923A0125|130 152|receptor heterocomplexes
P09197241A0770|104 106|lyn
P09197241A0770|22 28|absence
P09197241A0770|66 80|hyperactivation
P09197241A0770|10 20|macrophages
P09197241A0770|83 88|p56/59
P09197241A0770|31 34|CD45
P09197241A0770|97 102|p53/56
P09197241A0770|43 62|hyperphosphorylation
P09197241A0770|90 92|hck
P09197241A0770|121 125|c-fgr
P09197241A0770|117 119|p58
P09197342T0000|0 8|Secretion
P09197342T0000|80 86|rabbits
P09197342T0000|11 14|milk
P09197342T0000|52 55|oils
P09197342T0000|57 66|Lipiodol UF
P09197342T0000|32 39|transfer
P09197342T0000|70 76|Oriodol
P09197408A0126|0 9|Sequencing
P09197408A0126|15 22|facB gene
P09197408A0126|45 51|protein
P09197408A0126|214 220|regions
P09197408A0126|125 134|DNA binding
P09197408A0126|154 171|heptad repeat motifs
P09197408A0126|136 142|leucine
P09197408A0126|91 95|2Cys6
P09197408A0126|274 282|activator
P09197408A0126|99 104|C6 zinc
P09197408A0126|85 86|Zn
P09197408A0126|237 244|function
P09197408A0126|115 121|cluster
P09199167A0942|0 13|Overexpression
P09199167A0942|39 45|absence
P09199167A0942|16 20|Sed5p
P09199167A0942|48 52|Vti1p
P09199167A0942|28 33|growth
P09199286A0086|45 48|exon
P09199286A0086|9 14|region
P09199286A0086|74 80|protein
P09199286A0086|17 20|mkh1
P09199292A0536|72 83|cyclin A-cdk2
P09199292A0536|38 41|p107
P09199292A0536|25 35|association
P09199292A0536|111 117|kinases
P09199292A0536|58 69|cyclin E-cdk2
P09199292A0536|94 103|activities
P09199292A0536|44 47|p130
P09199318A1147|62 80|muscle alpha-actinin
P09199318A1147|12 15|p150
P09199318A1147|26 38|actin gelation
P09199322T0000|0 11|Denaturation
P09199322T0000|38 48|replication
P09199322T0000|64 83|replication protein A.
P09199322T0000|23 27|virus
P09199322T0000|30 35|origin
P09199327A1250|58 66|construct
P09199327A1250|182 188|binding
P09199327A1250|138 146|TEF-1-Max
P09199327A1250|194 200|complex
P09199327A1250|158 164|complex
P09199327A1250|206 212|EM motif
P09199327A1250|4 9|effect
P09199327A1250|110 132|transactivation function
P09199327A1250|29 35|EM motif
P09199328T0000|58 62|Oct-1
P09199328T0000|64 66|HCF
P09199328T0000|14 21|residues
P09199328T0000|42 45|VP16
P09199328T0000|34 39|region
P09199328T0000|71 73|DNA
P09199348A0156|5 8|view
P09199348A0156|36 50|U14 interactions
P09199348A0156|112 118|U14 RNAs
P09199348A0156|62 67|domain
P09199348A0156|123 129|Y domain
P09199348A0156|79 86|activity
P09199348A0156|168 175|analysis
P09199353A1924|171 177|origins
P09199353A1924|65 82|chromatin structure
P09199353A1924|12 18|results
P09199353A1924|159 166|template
P09199353A1924|54 62|regulator
P09199353A1924|134 141|proteins
P09199353A1924|148 153|access
P09199353A1924|29 33|Cdc68
P09199353A1924|180 190|replication
P09199353A1924|99 113|polymerase alpha
P09199413A0518|53 61|CFU/mouse
P09199413A0518|11 22|inoculum size
P09199413A0518|66 66|%
P09199413A0518|87 93|animals
P09199413A0518|105 108|days
P09199626A0613|13 13|%
P09199626A0613|4 8|cases
P09199626A0613|17 22|change
P09199626A0613|25 29|stage
P09199932A1357|0 28|Promoter recognition algorithms
P09199932A1357|108 120|E14/NPAT genes
P09199932A1357|225 228|exon
P09199932A1357|48 63|promoter elements
P09199932A1357|73 81|CpG island
P09199932A1357|182 187|intron
P09199932A1357|158 168|ATM promoter
P09199932A1357|102 104|ATM
P09199932A1357|132 139|evidence
P09199970A1101|18 21|pMCP
P09199970A1101|94 104|C3b cleavage
P09199970A1101|69 74|factor
P09199970A1101|76 91|cofactor activity
P09199970A1101|32 44|transmembrane
P09199970A1101|169 171|MCP
P09199970A1101|59 65|domains
P09200029A0211|64 72|diagnosis
P09200029A0211|25 29|signs
P09200029A0211|108 128|bone marrow examination
P09200029A0211|93 100|features
P09200029A0211|50 56|setting
P09200498T0000|15 32|muscle coactivation
P09200498T0000|7 11|zones
P09200498T0000|39 45|control
P09200498T0000|56 64|stability
P09200530A0411|0 5|Liquid
P09200530A0411|76 90|gradient elution
P09200530A0411|45 54|Zorbax RX C8
P09200530A0411|65 70|column
P09200530A0411|21 30|separation
P09200811T0000|81 106|pGKL1-plasmid DNA polymerase
P09200811T0000|53 59|protein
P09200811T0000|9 20|plasmid pDHL1
P09201946A0000|175 180|length
P09201946A0000|62 94|transcription termination factor rho
P09201946A0000|24 41|helicase activities
P09201946A0000|155 172|nucleotide residues
P09201946A0000|198 201|trp t
P09201946A0000|127 138|RNA molecules
P09201946A0000|216 234|termination sequence
P09201980A0910|73 79|species
P09201980A0910|3 15|p20-CGGBP gene
P09201980A0910|49 56|homology
P09201980A0910|32 38|mammals
P09202147A0866|98 108|degradation
P09202147A0866|24 28|yeast
P09202147A0866|119 126|proteins
P09202147A0866|46 54|subfamily
P09202147A0866|32 37|plants
P09202147A0866|137 142|stress
P09202147A0866|57 59|UBC
P09202147A0866|3 6|data
P09202147A0866|129 134|result
P09202669A0614|131 148|neomycin resistance
P09202669A0614|23 25|AAV
P09202669A0614|150 153|neoR
P09202669A0614|124 127|gene
P09202669A0614|66 76|replication
P09202669A0614|52 62|integration
P09202669A0614|83 108|herpes virus thymidine kinase
P09202669A0614|3 8|pWP-19
P09202669A0614|42 48|repeats
P09202669A1530|29 46|gene transfer system
P09202669A1530|53 68|rat preproinsulin
P09202669A1530|71 74|gene
P09202859A0091|48 50|HCG
P09202859A0091|35 46|gonadotropin
P09202859A0091|64 82|alkaline phosphatase
P09202859A0091|16 25|beta-human
P09202859A0091|84 87|PLAP
P09202859A0091|3 13|serum levels
P09203585A0660|82 103|neo replacement cassette
P09203585A0660|9 15|feature
P09203585A0660|32 40|H19 allele
P09203585A0660|46 55|occurrence
P09203585A0660|67 73|imprint
P09203586A1197|84 87|step
P09203586A1197|35 42|T antigen
P09203586A1197|62 64|SL1
P09203586A1197|93 109|activation process
P09203586A1197|48 59|rRNA promoter
P09203586A1197|17 27|recruitment
P09203731A0497|66 89|Poliomyelitis Eradication
P09203731A0497|168 179|transmission
P09203731A0497|116 144|Pan American Health Organization
P09203731A0497|38 50|Certification
P09203731A0497|53 63|Eradication
P09203731A0497|91 95|ICCPE
P09203731A0497|9 31|International Commission
P09204566T0000|65 96|Rhizobium leguminosarum strain VF39
P09204566T0000|39 44|copies
P09204566T0000|50 62|fixNOQP operon
P09204566T0000|23 30|analysis
P09204570A0110|4 8|study
P09204570A0110|59 60|J.
P09204570A0110|34 38|nmhC5
P09204570A0110|22 32|MADS box gene
P09204570A0110|54 57|nmh7
P09205113A0587|4 6|E14
P09205113A0587|134 146|mouse germ line
P09205113A0587|118 126|frequency
P09205113A0587|9 13|TG3B1
P09205113A0587|99 110|transmission
P09205113A0587|23 32|ES cell line
P09205113A0587|67 74|HPRT gene
P09205113A0587|48 58|mouse genome
P09205113A0587|78 92|selection marker
P09205677A0577|0 3|Lung
P09205677A0577|34 43|indicators
P09205677A0577|19 24|damage
P09205677A0577|50 56|outcome
P09205677A0577|74 80|disease
P09205965A1249|102 108|pathway
P09205965A1249|35 45|micturition
P09205965A1249|114 125|transmission
P09205965A1249|77 82|L-dopa
P09205965A1249|144 169|spinal alpha 1-adrenoceptors
P09205965A1249|3 9|results
P09205965A1249|60 73|bladder filling
P09206230A0000|0 8|OBJECTIVE
P09206230A0000|48 52|cause
P09206230A0000|14 18|study
P09206230A0000|55 64|asthenopia
P09206230A0000|71 81|astigmatism
P09206968A0000|0 10|Disturbance
P09206968A0000|13 24|regeneration
P09206968A0000|94 97|loss
P09206968A0000|136 146|homeostasis
P09206968A0000|103 110|function
P09206968A0000|78 90|tunica propria
P09206968A0000|70 75|damage
P09206968A0000|47 55|condition
P09206968A0000|117 123|support
P09208214A0572|0 18|Sternocleidomastoid
P09208214A0572|32 38|muscles
P09208214A0572|66 70|cases
P09208214A0572|20 23|neck
P09208930T0000|0 13|Identification
P09208930T0000|23 27|genes
P09208930T0000|111 119|proteases
P09208930T0000|48 64|interleukin-1beta
P09208930T0000|75 84|enzyme gene
P09209031A0350|19 24|region
P09209031A0350|49 71|serine carboxypeptidases
P09209312A0968|85 91|complex
P09209312A0968|136 137|nt
P09209312A0968|99 101|RNA
P09209312A0968|121 131|nucleotides
P09209312A0968|34 44|nucleotides
P09209312A0968|53 54|nt
P09209312A0968|60 61|nt
P09209312A0968|143 144|nt
P09209312A0968|46 47|nt
P09209312A0968|3 14|RNA construct
P09209372A0345|160 167|affinity
P09209372A0345|125 129|AML1b
P09209372A0345|21 25|AML1a
P09209372A0345|138 142|AML1a
P09209372A0345|113 122|activation
P09209372A0345|68 76|regulator
P09209372A0345|43 49|effects
P09209372A0345|186 190|AML1b
P09209406A1021|46 77|guanine nucleotide exchange factors
P09209406A1021|35 41|regions
P09209406A1021|110 118|c-cbl gene
P09209406A1021|97 104|proteins
P09209438A0994|132 139|GATA site
P09209438A0994|27 33|extract
P09209438A0994|13 19|ATL-16T
P09209438A0994|115 121|complex
P09209438A0994|53 58|GATA-4
P09209438A0994|80 86|protein
P09210012A0000|17 23|support
P09210012A0000|29 41|relationships
P09210012A0000|51 57|couples
P09210012A0000|3 8|impact
P09210478A0000|50 54|HIF-1
P09210478A0000|41 48|factor-1
P09210478A0000|110 114|genes
P09210478A0000|68 77|expression
P09210478A0000|86 91|number
P09211354A0000|0 12|Stromelysin-1
P09211354A0000|109 120|organ tissues
P09211354A0000|14 38|matrix metalloproteinase-3
P09211354A0000|60 72|endopeptidase
P09211354A0000|40 44|MMP-3
P09211354A0000|102 106|cells
P09211605A0478|0 5|Tendon
P09211605A0478|24 36|extensibility
P09211605A0478|16 21|degree
P09211675A0392|0 11|Surveillance
P09211675A0392|184 189|visits
P09211675A0392|74 84|assignments
P09211675A0392|285 291|records
P09211675A0392|103 114|measurements
P09211675A0392|257 264|delivery
P09211675A0392|191 199|protocols
P09211675A0392|218 229|measurements
P09211675A0392|140 155|protein excretion
P09211675A0392|305 320|outpatient visits
P09211675A0392|41 49|personnel
P09211675A0392|117 129|blood pressure
P09211675A0392|15 26|preeclampsia
P09211675A0392|239 253|hospitalization
P09211675A0392|269 275|reviews
P09211675A0392|327 342|hospitalizations
P09211913A0000|0 22|Aryl hydrocarbon receptor
P09211913A0000|165 175|target genes
P09211913A0000|51 59|component
P09211913A0000|110 112|AhR
P09211913A0000|259 271|concentration
P09211913A0000|183 188|CYP1A1
P09211913A0000|209 216|response
P09211913A0000|65 84|transcription factors
P09211913A0000|134 139|factor
P09211913A0000|192 205|erythropoietin
P09211913A0000|43 46|ARNT
P09211913A0000|237 248|hydrocarbons
P09211913A0000|86 108|aryl hydrocarbon receptor
P09211913A0000|30 41|translocator
P09211934A0722|0 4|DNase
P09211934A0722|6 22|footprint analysis
P09211934A0722|43 48|region
P09211981A0526|13 20|evidence
P09211981A0526|114 121|extracts
P09211981A0526|183 186|cdc2
P09211981A0526|25 28|gar2
P09211981A0526|188 193|kinase
P09211981A0526|153 160|activity
P09211981A0526|55 57|p13
P09211981A0526|80 85|kinase
P09211981A0526|134 137|cell
P09211981A0526|59 62|suc1
P09211981A0526|179 181|p34
P09212059A1356|119 123|DhLBD
P09212059A1356|54 69|self-association
P09212059A1356|21 52|metal affinity chromatography assay
P09212059A1356|126 139|hLBD constructs
P09212059A1356|72 75|PR-A
P09212059A1856|249 250|PR
P09212059A1856|23 27|paper
P09212059A1856|231 246|homodimerization
P09212059A1856|183 191|sequences
P09212059A1856|10 16|results
P09212059A1856|141 147|regions
P09212059A1856|112 125|PR dimerization
P09212059A1856|161 165|hinge
P09212059A1856|48 57|conclusion
P09212059A1856|82 84|LBD
P09212063A0425|28 34|A-phage
P09212063A0425|38 49|cosmid clones
P09212063A0425|79 81|DNA
P09212063A0425|103 109|VDR gene
P09212063A0425|70 71|kb
P09214274T0001|31 38|approach
P09214274T0001|10 18|carcinoma
P09214274T0001|41 48|patients
P09214274T0001|67 85|metastasis resection
P09215525A0581|28 36|cell cycle
P09215525A0581|93 105|C2C12 myocytes
P09215525A0581|50 64|E2F/DP complexes
P09215525A0581|19 25|effects
P09215525A0581|68 75|activity
P09215525A0581|41 47|changes
P09215891A0000|44 47|CIN2
P09215891A0000|51 59|CIN4 genes
P09215891A0000|39 42|CIN1
P09215891A0000|3 10|products
P09215891A0000|110 128|microtubule function
P09215891A0000|86 92|pathway
P09216017A0621|0 9|Vitrectomy
P09216017A0621|51 55|holes
P09216017A0621|30 39|risk factor
P09216936T0000|43 50|exercise
P09216936T0000|53 64|leptin levels
P09216936T0000|7 15|editorial
P09216936T0000|34 40|effects
P09216936T0000|67 72|humans
P09218436A0443|57 65|promoters
P09218436A0443|18 24|TATA box
P09218436A0443|45 54|MED-1 class
P09218436A0443|103 107|sites
P09218436A0443|29 32|Pint
P09218436A0443|80 92|transcription
P09218436A0443|4 12|promoters
P09218459A0000|0 18|Serum response factor
P09218459A0000|104 122|transcription factor
P09218459A0000|166 170|genes
P09218459A0000|62 69|proteins
P09218459A0000|26 31|member
P09218459A0000|20 22|SRF
P09218459A0000|43 48|family
P09218459A0000|143 148|growth
P09218520A0075|87 92|domain
P09218520A0075|102 106|IL-1R
P09218520A0075|32 57|candidate signal transducers
P09218520A0075|94 95|cd
P09218520A0075|15 21|studies
P09218599A0184|84 87|IL-4
P09218599A0184|6 10|study
P09218599A0184|75 81|effects
P09218599A0184|30 39|mechanisms
P09218775A0000|21 27|strains
P09218775A0000|37 44|patients
P09218775A0000|64 65|CF
P09218775A0000|55 62|fibrosis
P09218775A0000|81 89|phenotype
P09218775A0000|111 118|alginate
P09218775A0000|95 108|overproduction
P09218775A1229|0 7|Activity
P09218775A1229|33 35|CHA
P09218775A1229|100 114|algD-xylE fusion
P09218775A1229|10 14|palgD
P09218775A1229|54 62|strain PAO
P09218775A1229|20 29|cysB mutant
P09218775A1229|79 81|use
P09219526A0383|186 191|region
P09219526A0383|35 47|cDNA construct
P09219526A0383|64 74|observation
P09219526A0383|82 97|peptide sequences
P09219526A0383|154 161|fragment
P09219526A0383|19 29|specificity
P09220158A0537|185 192|Sf9 cells
P09220158A0537|121 147|baculovirus expression vector
P09220158A0537|93 102|amino acids
P09220158A0537|53 62|processing
P09220158A0537|113 117|ORF-2
P09220158A0537|172 176|virus
P09220158A0537|83 90|sequence
P09220158A0537|14 20|protein
P09220177A0564|96 100|shock
P09220177A0564|51 53|CPK
P09220177A0564|65 65|%
P09220177A0564|87 87|h
P09220177A0564|136 148|cardioversion
P09220177A0564|26 43|percentage increase
P09220177A0564|3 17|CPK-MB isoenzyme
P09220177A0564|118 123|number
P09220177A0564|126 133|attempts
P09222057A0176|0 4|Serum
P09222057A0176|70 75|course
P09222057A0176|32 34|PDF
P09222057A0176|52 56|assay
P09222057A0176|81 85|study
P09222057A0176|93 96|days
P09222057A0176|18 30|dialysis fluid
P09222115A0545|0 6|Results
P09222115A0545|187 195|isolation
P09222115A0545|203 214|surroundings
P09222115A0545|138 159|response characteristic
P09222115A0545|17 26|hypothesis
P09222115A0545|97 107|binding site
P09222115A0545|180 184|phase
P09222115A0545|64 69|factor
P09222115A0545|162 165|pups
P09223042A0000|0 4|Liver
P09223042A0000|13 23|blood volume
P09223042A0000|48 60|disease states
P09223042A0000|25 28|LRBV
P09223042A0000|71 75|drugs
P09223122A0774|46 51|groups
P09223122A0774|7 23|matter NAA/mI ratio
P09223229A0565|55 62|mb-1 gene
P09223229A0565|23 31|mb-1 genes
P09223229A0565|70 76|TATA box
P09223229A0565|38 43|region
P09223475A0898|0 37|Chloramphenicol acetyltransferase assays
P09223475A0898|59 62|IE86
P09223475A0898|72 79|activity
P09223475A0898|155 158|RNAs
P09223475A0898|128 135|promoter
P09223475A0898|50 56|ability
P09223475A0898|148 152|class
P09223475A0898|98 105|promoter
P09223475A0898|198 208|IE86 protein
P09223475A0898|87 90|HCMV
P09223475A0898|184 192|integrity
P09223475A0898|119 122|HCMV
P09223479A1193|0 4|ORF M1
P09223479A1193|47 52|ORF M11
P09223479A1193|112 129|gammaherpesviruses
P09223479A1193|89 97|molecules
P09223479A1193|139 141|HVS
P09223479A1193|155 163|BHRF1 gene
P09223479A1193|16 23|homology
P09223479A1193|145 148|KSHV
P09223479A1193|166 168|EBV
P09223479A1193|70 76|homolog
P09223479A1193|26 40|poxvirus serpins
P09223479A1193|131 134|gene
P09223506T0000|0 30|Transcription factor binding sites
P09223506T0000|77 98|transcription start site
P09223506T0000|114 129|virus infectivity
P09223506T0000|51 75|immunodeficiency virus type
P09223647T0000|0 15|Crystal structure
P09223647T0000|20 27|oligomer
P09223647T0000|108 119|implications
P09223647T0000|128 137|activation
P09223647T0000|98 104|complex
P09223647T0000|72 79|analysis
P09223647T0000|41 48|zymogens
P09223667A0139|30 50|NIH3T3 fibroblast cells
P09223667A0139|138 139|bp
P09223667A0139|179 191|CTCCC sequence
P09223667A0139|54 75|gel mobility shift assays
P09223667A0139|90 100|binding site
P09223667A0139|147 168|transcription start site
P09223667A0139|121 126|region
P09223667A0139|16 27|transfection
P09223880A1147|17 30|injection speed
P09223880A1147|37 44|.2 ml.s-1
P09223880A1147|65 74|anesthesia
P09224655T0000|118 123|ClC-6c
P09224655T0000|21 25|ClC-6
P09224655T0000|11 18|splicing
P09224655T0000|39 63|CIC chloride-channel family
P09224655T0000|99 106|isoforms
P09224655T0000|65 75|transcripts
P09224655T0000|28 33|member
P09224811A0000|148 153|animal
P09224811A0000|201 208|pathways
P09224811A0000|96 100|P450R
P09224811A0000|10 14|study
P09224811A0000|137 142|status
P09224811A0000|122 128|thyroid
P09224811A0000|67 94|cytochrome P450 oxidoreductase
P09224811A0000|246 259|P450R mRNA level
P09224811A0000|43 55|transcription
P09224811A0000|102 105|gene
P09224811A0000|61 65|NADPH
P09225151T0000|29 51|polytetrafluoroethylene
P09225151T0000|83 97|scarring process
P09225151T0000|22 26|types
P09225151T0000|53 56|PTFE
P09225151T0000|58 67|prostheses
P09225151T0000|109 119|wall defects
P09225151T0000|3 10|behavior
P09225506A0462|42 47|levels
P09225506A0462|50 67|coagulation factors
P09225506A0462|75 78|VIII
P09225506A0462|71 71|V
P09225506A0462|93 102|index group
P09225506A0462|3 14|control group
P09225682A0579|88 95|isolates
P09225682A0579|63 78|syndrome patients
P09225682A0579|179 186|isolates
P09225682A0579|3 11|frequency
P09225682A0579|174 176|PEN
P09225682A0579|83 85|PEN
P09225682A0579|151 166|syndrome patients
P09225682A0579|143 148|Fisher
P09225682A0579|132 139|syndrome
P09225682A0579|30 43|antibody titers
P09225686A0683|59 74|seizure remission
P09225686A0683|12 34|radiofrequency lesioning
P09225686A0683|40 48|hamartoma
P09225686A0683|82 94|complications
P09225686A0683|108 114|surgery
P09225686A0683|97 102|months
P09225998A0000|0 32|NF-kappa B/Rel transcription factors
P09225998A0000|69 73|genes
P09225998A0000|49 58|activation
P09225998A0000|132 151|cell surface receptors
P09225998A0000|90 112|regulation/inflammation
P09225998A0000|179 191|phase proteins
P09225998A0000|153 169|adhesion molecules
P09225998A0000|122 130|cytokines
P09226113A0857|43 50|borehole
P09226113A0857|74 81|borehole
P09226113A0857|22 38|source water sample
P09226345A0436|29 34|% group
P09226345A0436|60 60|p
P09226345A0436|103 110|SEP group
P09226345A0436|89 89|p
P09226345A0436|146 146|%
P09226345A0436|12 21|food intake
P09226345A0436|154 164|requirement
P09226345A0436|51 58|ACT group
P09226345A0436|125 131|amounts
P09227099A0106|102 109|security
P09227099A0106|90 100|convenience
P09227099A0106|195 202|accuracy
P09227099A0106|180 187|implants
P09227099A0106|78 87|advantages
P09227099A0106|12 20|technique
P09227099A0106|31 42|modification
P09227099A0106|168 177|angulation
P09227099A0106|46 62|bar superstructure
P09227332A1798|71 79|cytokines
P09227332A1798|10 12|DDC
P09227332A1798|45 53|cytokines
P09227332A1798|94 95|DC
P09227332A1798|20 28|receptors
P09227332A1798|38 42|panel
P09227332A1798|59 67|receptors
P09227332A1798|2 8|summary
P09227332A1798|85 91|effects
P09227799A0254|176 189|precipitin test
P09227799A0254|156 158|SEA
P09227799A0254|25 28|tool
P09227799A0254|47 58|surveillance
P09227799A0254|112 127|stool examination
P09227799A0254|106 110|tests
P09227799A0254|129 133|ELISA
P09227799A0254|191 194|COPT
P09227799A0254|145 154|egg antigen
P09227799A0254|72 81|comparison
P09228042A0109|226 230|steps
P09228042A0109|200 202|Zn2
P09228042A0109|68 75|biglycan
P09228042A0109|158 169|ion-exchange
P09228042A0109|16 42|dermatan sulfate proteoglycan
P09228042A0109|58 64|decorin
P09228042A0109|95 104|extraction
P09228042A0109|171 183|gel permeation
P09228042A0109|44 52|epiphycan
P09228042A0109|204 210|chelate
P09228042A0109|118 136|epiphyseal cartilage
P09228092A1779|117 119|use
P09228092A1779|65 68|gene
P09228092A1779|89 99|transcripts
P09228092A1779|31 45|dUTPase isoforms
P09228092A1779|5 12|analyses
P09228092A1779|135 139|exons
P09228202A0581|60 66|KAE-393
P09228202A0581|47 51|YM060
P09228202A0581|112 121|benzamides
P09228202A0581|190 197|SC-53116
P09228202A0581|83 93|ondansetron
P09228202A0581|54 58|YM114
P09228202A0581|69 79|granisetron
P09228202A0581|12 45|5-HT3 receptor antagonists ramosetron
P09228202A0581|229 236|emptying
P09228202A0581|169 186|cisapride mosapride
P09228202A0581|149 167|receptor antagonists
P09228202A0581|245 248|rats
P09228202A0581|123 147|5-HT4 receptor agonist/5-HT
P09229420A0158|0 12|Re-evaluation
P09229420A0158|73 81|operation
P09229420A0158|18 31|biopsy specimen
P09229420A0158|44 46|hip
P09229420A0158|121 130|background
P09229420A0158|88 92|areas
P09229420A0158|141 154|chondromatosis
P09229420A0158|95 108|chondrosarcoma
P09229420A0158|57 60|time
P09229595A0618|3 16|corneal buttons
P09229595A0618|51 58|electron
P09229595A0618|70 76|studies
P09230129A0039|205 212|antibody
P09230129A0039|223 228|enzyme
P09230129A0039|19 29|homogeneity
P09230129A0039|109 119|preparation
P09230129A0039|76 88|DNA-cellulose
P09230129A0039|180 189|production
P09230129A0039|93 98|purity
P09230129A0039|142 145|lack
P09230129A0039|133 140|SDS/PAGE
P09230129A0039|45 66|affinity chromatography
P09230129A0039|37 42|% yield
P09230129A0039|168 176|nucleases
P09230129A0039|148 160|contamination
P09230216T0000|74 87|heterozygosity
P09230216T0000|97 102|cancer
P09230216T0000|68 71|loss
P09230216T0000|56 61|region
P09230216T0000|33 51|chromosome 12q22-q24
P09230216T0000|16 30|glycosylase maps
P09230307A0329|0 2|FOG
P09230307A0329|83 87|cells
P09230307A0329|20 25|GATA-1
P09230307A0329|41 51|development
P09230384A0725|28 39|mycobacteria
P09230384A0725|68 69|TB
P09230384A0725|44 49|BACTEC
P09230384A0725|7 11|times
P09230384A0725|59 64|BACTEC
P09230384A0725|93 96|days
P09230384A0725|54 55|MB
P09230384A0725|14 22|detection
P09230384A1056|54 62|specimens
P09230384A1056|9 14|BACTEC
P09230384A1056|112 119|recovery
P09230384A1056|180 184|sites
P09230384A1056|146 154|specimens
P09230384A1056|122 133|mycobacteria
P09230384A1056|19 26|MB system
P09230894A0422|18 24|KmMig1p
P09230945A0089|16 24|deformity
P09230945A0089|57 60|slip
P09230986A0000|0 20|Autoimmune neutropenia
P09230986A0000|51 61|neutropenia
P09230986A0000|22 24|AIN
P09230986A0000|82 89|children
P09230986A0000|37 41|cause
P09232593A0946|29 45|expression pattern
P09232593A0946|103 107|roles
P09232593A0946|4 9|regard
P09232593A0946|48 56|DJ protein
P09232593A0946|74 84|repeat units
P09233487A1386|99 110|ear selection
P09233487A1386|90 96|benefit
P09233487A1386|25 39|outcome measures
P09233487A1386|119 127|Prom-EABR
P09233487A1386|6 13|analysis
P09233487A1386|42 52|performance
P09233772A0136|437 462|E3 ubiquitin-protein ligases
P09233772A0136|329 337|G proteins
P09233772A0136|54 59|weight
P09233772A0136|196 226|guanine nucleotide exchange factor
P09233772A0136|249 258|protein Ran
P09233772A0136|276 282|domains
P09233772A0136|302 312|beta subunit
P09233772A0136|22 25|p532
P09233772A0136|125 131|regions
P09233772A0136|106 112|domains
P09233772A0136|61 65|EMBO J
P09233772A0136|4 10|protein
P09233772A0136|147 153|repeats
P09233772A0136|172 193|cell cycle regulator RCC1
P09233772A0136|377 390|leucine-zipper
P09233772A0136|352 366|SH3 binding sites
P09233772A0136|411 434|HECT domain characteristic
P09233801A1180|57 78|TGF-beta responsiveness
P09233801A1180|89 96|receptor
P09233801A1180|26 41|kinase subdomains
P09233801A1180|8 18|L45 sequence
P09233801A1180|47 47|V
P09233801A1180|84 87|type
P09233809A0381|149 158|Hnf3g locus
P09233809A0381|169 176|elements
P09233809A0381|6 15|mouse lines
P09233809A0381|142 143|kb
P09233809A0381|39 51|Hnf3g-lacZ YAC
P09233809A0381|117 126|expression
P09233809A0381|191 200|regulation
P09233809A0381|203 207|Hnf3g
P09233809A0381|74 77|copy
P09233809A0815|187 191|liver
P09233809A0815|127 130|gene
P09233809A0815|116 121|region
P09233809A0815|22 31|transgenes
P09233809A0815|193 200|pancreas
P09233809A0815|63 76|Hnf3g gene locus
P09233809A0815|163 184|reporter gene expression
P09233809A0815|202 208|stomach
P09233809A0815|35 47|gene targeting
P09233809A0815|217 225|intestine
P09233811A0072|101 114|protein Mat1-Mc
P09233811A0072|54 77|Ste11 transcription factor
P09233811A0072|84 84|M
P09233811A0072|25 39|HMG-box proteins
P09233811A0072|4 13|regulation
P09234677A0770|115 125|respiration
P09234677A0770|19 28|hypothesis
P09234677A0770|85 95|transcripts
P09234677A0770|55 62|proteins
P09234677A0770|41 51|transcripts
P09234690A0242|0 7|Upstream
P09234690A0242|18 26|sequences
P09234690A0242|137 139|PRE
P09234690A0242|65 69|genes
P09234690A0242|28 31|UASs
P09234690A0242|150 160|binding site
P09234690A0242|124 127|PREs
P09234690A0242|171 177|protein
P09234696A0238|75 77|MAP
P09234696A0238|9 29|protein kinase cascades
P09234696A0238|79 85|kinases
P09234696A0238|67 73|protein
P09234703A0192|57 61|Cdc42
P09234703A0192|42 53|G proteins Rac
P09234703A0192|0 2|JNK
P09234713A0754|171 177|Jdelta1
P09234713A0754|157 163|Ddelta3
P09234713A0754|103 106|gene
P09234713A0754|24 29|notion
P09234713A0754|68 76|formation
P09234713A0754|142 145|DSBs
P09234713A0754|6 10|study
P09234713A0754|108 110|RAG
P09234713A0754|54 56|PCR
P09234713A0754|149 152|RSSs
P09234713A0754|122 140|double-strand breaks
P09234717A0000|173 175|SH2
P09234717A0000|215 218|role
P09234717A0000|47 60|protein product
P09234717A0000|221 238|signal transduction
P09234717A0000|95 103|substrate
P09234717A0000|107 112|number
P09234717A0000|167 169|SH3
P09234717A0000|66 84|c-cbl proto-oncogene
P09234717A0000|193 200|proteins
P09234717A0000|131 145|tyrosine kinases
P09234717A0000|149 162|forms complexes
P09234717A0000|6 12|studies
P09234717A0000|33 35|Cbl
P09234720A1015|148 150|MEK
P09234720A1015|52 56|v-Src
P09234720A1015|38 40|MEK
P09234720A1015|154 158|v-Src
P09234720A1015|42 47|MEK-2E
P09234720A1015|100 109|H19-7 cells
P09234720A1015|111 122|coexpression
P09234720A1015|166 181|neurite outgrowth
P09234723A0846|59 61|PTB
P09234723A0846|4 12|mechanism
P09234723A0846|92 101|splice site
P09234723A0846|73 79|protein
P09234723A0846|17 24|contrast
P09234723A0846|32 36|cases
P09234723A0846|39 56|splicing regulation
P09234725A1892|33 47|transactivation
P09234725A1892|111 122|AP-1 activity
P09234725A1892|94 108|transrepression
P09234725A1892|53 70|interaction surface
P09234727A0770|30 42|transcription
P09234727A0770|67 74|promoter
P09234727A0770|46 57|reporter gene
P09234727A0770|8 20|fusion protein
P09234727A0770|99 109|DNA elements
P09234736A0999|202 212|goblet cells
P09234736A0999|34 42|rat tissue
P09234736A0999|164 168|cells
P09234736A0999|184 187|type
P09234736A0999|54 64|correlation
P09234736A0999|96 102|drm mRNA
P09234736A0999|6 26|hybridization analysis
P09234736A0999|189 197|lung cells
P09234736A0999|73 79|pattern
P09234736A0999|176 182|neurons
P09234743A0475|14 21|proteins
P09234743A0475|69 71|UTR
P09234743A0475|55 66|alpha-globin
P09234743A0475|141 153|alpha-complex
P09234743A0475|119 119|C
P09234743A0475|121 135|binding proteins
P09234743A0475|40 43|pair
P09235073A0000|26 32|patient
P09235073A0000|41 49|diagnosis
P09235073A0000|2 6|years
P09235073A0000|52 65|Weaver syndrome
P09235073A0000|11 16|months
P09235424A1200|46 49|ABPM
P09235424A1200|24 29|nurses
P09235424A1200|75 80|effect
P09235424A1200|53 57|women
P09235424A1200|10 17|measures
P09235618A0000|207 213|factors
P09235618A0000|223 234|thrombocytes
P09235618A0000|255 266|erythrocytes
P09235618A0000|50 70|Guillain Barre syndrome
P09235618A0000|215 220|member
P09235618A0000|109 116|epilepsy
P09235618A0000|236 252|sedimentation rate
P09235618A0000|23 36|neuroinfection
P09235618A0000|11 18|patients
P09235618A0000|38 48|Lyme disease
P09235618A0000|72 86|demyelinization
P09235618A0000|164 166|IgG
P09235618A0000|152 161|antibodies
P09235618A0000|170 180|IgM subtypes
P09235618A0000|3 8|series
P09235995A0339|1 5|1996a
P09235995A0339|7 18|Biochemistry
P09235998A0788|30 34|alpha
P09235998A0788|63 73|cholesterol
P09235998A0788|38 49|beta subunits
P09235998A0788|10 27|membrane expression
P09235998A0788|77 94|17-ketocholesterol
P09235998A0788|114 129|HMG-CoA reductase
P09236118A1455|100 108|DNA target
P09236118A1455|21 23|Lrp
P09236118A1455|48 51|site
P09236118A1455|127 132|dimers
P09236118A1455|89 94|groove
P09236118A1455|3 9|results
P09236118A1455|147 151|sites
P09236118A1455|159 188|nucleoprotein activation complex
P09236224A0939|85 87|NGF
P09236224A0939|75 82|activity
P09236224A0939|63 69|feature
P09236224A0939|127 141|differentiation
P09236224A0939|105 120|PC12 growth arrest
P09236224A0939|9 18|activation
P09236224A0939|21 33|p21 expression
P09236441A0639|14 21|patients
P09236441A0639|31 40|recordings
P09236441A0639|67 82|oxygen saturation
P09236441A0639|93 103|respiration
P09236441A0639|138 146|breathing
P09236441A0639|84 87|SaO2
P09236441A0639|43 45|ECG
P09236656A0124|40 47|baseline
P09236656A0124|63 64|SD
P09236656A0124|84 85|SD
P09236656A0124|61 61|L
P09236656A0124|92 94|day
P09236656A0124|17 25|cell count
P09236656A0124|82 82|L
P09237695A0000|57 66|indicators
P09237695A0000|25 29|study
P09237695A0000|80 93|virus infection
P09237862A0782|83 88|nerves
P09237862A0782|37 45|reduction
P09237862A0782|94 97|iris
P09237862A0782|64 70|absence
P09237862A0782|17 20|eyes
P09238467A0763|26 36|propranolol
P09238467A0763|39 50|phentolamine
P09238467A0763|5 11|lesions
P09238850A0785|77 88|feedback loop
P09238850A0785|12 15|ICER
P09238850A0785|53 60|promoter
P09238850A2042|88 90|SCN
P09238850A2042|80 86|nucleus
P09238850A2042|13 23|oscillation
P09238850A2042|47 51|clock
P09238860A0175|16 22|nucleus
P09238860A0175|132 138|CREM tau
P09238860A0175|159 173|protein kinase A.
P09238860A0175|92 128|AMP response element binding proteins CREB
P09238860A0175|28 32|cells
P09238860A0175|142 147|manner
P09238860A1974|85 105|cytokine Interleukin-2
P09238860A1974|140 147|increase
P09238860A1974|114 121|response
P09238860A1974|49 52|CREB
P09238860A1974|124 129|agents
P09238860A1974|107 110|IL-2
P09238860A1974|179 193|protein kinase C.
P09238860A1974|161 163|Ca2
P09238860A1974|5 9|cells
P09238860A1974|27 33|signals
P09239635A0477|38 42|mg/ml
P09239635A0477|99 103|mg/ml
P09239635A0477|11 14|dogs
P09239635A0477|80 87|serum IgA
P09239635A0477|21 28|serum IgG
P09239635A0477|56 65|littermate
P09241092A1108|77 86|trans-diol
P09241092A1108|40 54|glucuronidation
P09241092A1108|12 20|Valproate
P09241092A1108|159 178|trans-diol derivative
P09241092A1108|146 152|epoxide
P09241092A1108|114 123|conversion
P09241092A1108|215 222|reaction
P09241092A1108|57 72|carbamazepine-10
P09241092A1108|126 141|carbamazepine-10
P09241092A1108|0 10|CONCLUSIONS
P09241232A0653|57 62|AP site
P09241232A0653|89 92|AP/C
P09241232A0653|33 41|DNA duplex
P09241232A0653|80 87|cytosine
P09241232A0653|3 13|Ogg1 protein
P09241232A1154|86 89|Ogg1
P09241232A1154|80 83|K241
P09241232A1154|63 74|endonuclease
P09241232A1154|1 17|consensus sequence
P09241232A1154|57 60|K120
P09241232A1154|43 55|lysine residue
P09242375A1313|203 207|MEN2A
P09242375A1313|53 57|V804L
P09242375A1313|13 20|findings
P09242375A1313|211 224|MEN2B mutations
P09242375A1313|36 49|mutations E768D
P09242375A1313|164 172|mutations
P09242375A1313|105 114|RET isoform
P09242375A1313|118 125|capacity
P09242375A1313|61 85|gain-of-function mutations
P09242375A1313|144 149|effect
P09242499A0505|85 94|sunscreens
P09242499A0505|124 128|sites
P09242499A0505|103 112|base lotion
P09242499A0505|63 63|d
P09242499A0505|52 53|UV
P09242499A0505|69 79|application
P09242499A0505|31 35|backs
P09242499A0505|0 9|Volunteers
P09242506A1033|0 2|E2F
P09242506A1033|62 71|DP proteins
P09242506A1033|38 53|E2F family members
P09242506A1033|19 25|complex
P09242551A0653|0 8|EBER1 mRNA
P09242551A0653|34 40|latency
P09242551A0653|117 131|EBER1 expression
P09242551A0653|147 152|subset
P09242551A0653|21 26|marker
P09242551A0653|104 111|controls
P09242551A0653|82 87|levels
P09242551A0653|155 167|lymphoma cells
P09242551A0653|58 65|PEL cases
P09243267A0401|58 70|cell carcinoma
P09243267A0401|80 85|cavity
P09243267A0401|39 47|diagnosis
P09243267A0401|141 144|RPCI
P09243267A0401|24 31|patients
P09243267A0401|117 139|Roswell Park Cancer Center
P09243267A0401|106 114|treatment
P09243267A0401|0 6|METHODS
P09243385A1314|15 27|presaturation
P09243385A1314|76 89|PC velocity data
P09243385A1314|54 66|motion studies
P09243385A1314|10 12|use
P09243505A1194|256 266|specificity
P09243505A1194|61 71|MADS domains
P09243505A1194|224 228|cases
P09243505A1194|125 135|specificity
P09243505A1194|75 79|dimer
P09243505A1194|2 9|addition
P09243505A1194|193 198|region
P09243505A1194|25 35|experiments
P09243505A1194|204 213|MADS domain
P09243505A1194|272 279|proteins
P09243505A1194|141 147|complex
P09243505A1194|155 163|sequences
P09243587A0000|160 192|abortion increases breast cancer risk
P09243587A0000|99 110|breast cancer
P09243587A0000|69 77|pregnancy
P09243587A0000|138 146|pregnancy
P09243587A0000|79 82|FFTP
P09243587A0000|31 38|question
P09243587A0000|121 132|interruption
P09243587A0000|0 17|PURPOSE/OBJECTIVES
P09243840A0663|84 86|DNA
P09243840A0663|111 133|DNA Laboratory structures
P09243840A0663|61 68|HLA-DQA1
P09243840A0663|89 99|autopsy room
P09243840A0663|10 16|studies
P09243840A0663|35 44|week period
P09244100A0194|33 38|groups
P09244100A0194|10 13|rats
P09244282A1371|0 10|Mutagenesis
P09244282A1371|60 64|sites
P09244282A1371|47 54|presence
P09244282A1371|95 108|pec-1 phenotype
P09244282A1371|16 19|pecT
P09244282A1371|72 81|insertions
P09244282A1371|30 35|region
P09244350A0000|0 4|BRCA1
P09244350A0000|98 113|tumor suppressors
P09244350A0000|31 54|cancer susceptibility gene
P09244350A0000|121 137|breast cancer cells
P09244350A0000|69 83|phosphoproteins
P09244350A0000|15 20|breast
P09244430A0693|102 106|exons
P09244430A0693|54 59|beta-3
P09244430A0693|39 52|adducin isoform
P09244430A0693|75 79|donor
P09244430A0693|83 95|acceptor sites
P09244430A0693|14 24|splice sites
P09246343T0000|0 10|Proteinuria
P09246343T0000|19 21|man
P09246585T0000|6 13|blockade
P09246585T0000|26 35|cancer pain
P09247645A0000|87 92|fusion
P09247645A0000|27 33|alleles
P09247645A0000|36 39|SEC3
P09247645A0000|258 263|sec4-8
P09247645A0000|127 140|plasma membrane
P09247645A0000|114 121|vesicles
P09247645A0000|57 64|SEC genes
P09247645A0000|182 187|screen
P09247645A0000|221 227|mutants
P09248639A0152|28 38|fibroblasts
P09248639A0152|76 87|blister fluid
P09248639A0152|63 69|samples
P09248639A0152|94 99|effect
P09248639A0152|165 180|collagen lattices
P09248639A0152|121 131|contraction
P09248639A0152|182 185|FPCL
P09248639A0152|146 155|fibroblast
P09248639A0152|4 14|cell strains
P09248639A0152|115 118|rate
P09249039A0124|73 78|growth
P09249039A0124|115 125|vertebrates
P09249039A0124|103 112|metabolism
P09249039A0124|80 94|differentiation
P09249039A0124|19 25|enzymes
P09249039A0124|64 70|control
P09249070A0989|0 3|Cell
P09249710A0331|60 95|plaque reduction neutralization testing
P09249710A0331|24 27|sera
P09250554A0402|57 67|combination
P09250554A0402|22 32|diltiazem CD
P09250554A0402|91 97|therapy
P09250554A0402|40 54|placebo once/day
P09250554A0402|36 37|mg
P09250554A0402|0 7|Patients
P09251843A0189|179 183|cases
P09251843A0189|157 164|lymphoma
P09251843A0189|90 98|Castleman
P09251843A0189|77 87|hyperplasia
P09251843A0189|125 135|hyperplasia
P09251843A0189|197 204|lymphoma
P09251843A0189|232 236|cases
P09251843A0189|39 43|cases
P09251843A0189|16 26|hyperplasia
P09251843A0189|46 50|cases
P09251843A0189|101 107|disease
P09252397A0081|217 224|promoter
P09252397A0081|113 123|fibroblasts
P09252397A0081|153 161|sequences
P09252397A0081|65 84|nucleotide resolution
P09252397A0081|36 62|cyclobutane pyrimidine dimers
P09252397A0081|169 195|transcription initiation site
P09252397A0081|23 33|repair rates
P09252397A0081|145 150|repair
P09252397A0081|98 104|JUN gene
P09252397A0081|203 208|repair
P09252406A0511|0 7|Tyrosine
P09252406A0511|113 118|kinase
P09252406A0511|156 159|SHP2
P09252406A0511|32 42|binding site
P09252406A0511|78 87|p85 subunit
P09252406A0511|49 52|Grb2
P09252406A0511|90 109|phosphatidylinositol
P09252406A0511|120 138|phospholipase Cgamma
P09252406A0511|56 73|Shc adaptor proteins
P09252406A0511|144 154|phosphatase
P09252879A0470|73 88|methacholine PC20
P09252879A0470|61 69|functions
P09252879A0470|90 94|PC20M
P09252879A0470|16 27|HRCT findings
P09252879A0470|119 130|significance
P09252879A0470|43 50|features
P09254678A0106|0 6|Gtx mRNA
P09254678A0106|252 264|point mutation
P09254678A0106|128 130|PLP
P09254678A0106|194 196|MBP
P09254678A0106|101 103|MBP
P09254678A0106|213 218|brains
P09254678A0106|164 170|Gtx mRNA
P09254678A0106|270 276|PLP gene
P09254678A0106|20 27|parallel
P09254678A0106|182 189|parallel
P09254678A0106|35 38|RNAs
P09254678A0106|93 99|protein
P09254678A0106|109 126|proteolipid protein
P09254678A0106|65 72|proteins
P09254678A0106|200 207|PLP mRNAs
P09254678A0106|147 162|brain development
P09254678A0106|237 240|rats
P09254709T0000|15 40|Bacillus subtilis catabolite
P09254709T0000|51 61|protein CcpA
P09254709T0000|65 78|amyO target site
P09254709T0000|0 7|Contacts
P09255349A0836|60 63|IRA2
P09255349A0836|20 25|GTPase
P09255349A0836|53 56|IRA1
P09255349A0836|36 43|proteins
P09256973A0455|67 74|capsules
P09256973A0455|35 35|G
P09256973A0455|29 33|group
P09256973A0455|44 45|G2
P09256973A0455|10 12|cat
P09256973A0455|47 48|mg
P09256973A0455|90 94|weeks
P09256973A0455|51 65|itraconazole/kg
P09256973A0455|3 4|E2
P09256973A0673|14 48|itraconazole plasma drug concentration
P09256973A0673|11 12|E1
P09256973A0673|140 144|hours
P09256973A0673|126 128|MRT
P09256973A0673|63 66|time
P09256973A0673|112 124|residence time
P09256973A0673|74 77|dose
P09256973A0673|91 103|micrograms/ml
P09256973A0673|0 6|RESULTS
P09257651T0000|31 42|90kD proteins
P09257651T0000|105 109|Prp3p
P09257651T0000|8 17|U4/U6 snRNP
P09257651T0000|77 101|yeast splicing factors Prp4p
P09257887A0457|0 4|G-CSF
P09257887A0457|103 117|neutrophil count
P09257887A0457|64 66|day
P09257887A0457|34 46|microg/kg/day
P09257887A0457|17 19|day
P09257887A0457|80 88|apheresis
P09257887A0457|27 31|cycle
P09258439A1001|101 104|gene
P09258439A1001|7 22|expression system
P09258439A1001|56 61|SsEF-2
P09258439A1001|49 53|forms
P09258439A1001|72 82|mutagenesis
P09258606A0822|0 8|Crosstalk
P09258606A0822|73 83|development
P09258606A0822|87 96|malignancy
P09258606A0822|17 24|pathways
P09258606A0822|49 54|stress
P09258606A0822|42 46|forms
P09259052A0568|0 15|Supershift assays
P09259052A0568|177 180|JunD
P09259052A0568|114 121|extracts
P09259052A0568|190 193|cJun
P09259052A0568|52 61|antibodies
P09259052A0568|160 175|Jun family members
P09259052A0568|97 106|AtT-20 cell
P09259052A0568|22 24|Jun
P09259052A0568|182 185|JunB
P09259052A0568|132 144|c-jun AP-1 site
P09259052A0568|28 36|Fos family
P09259052A0568|73 88|protein complexes
P09259313A0950|13 28|PI kinase activity
P09259313A0950|3 10|majority
P09259313A0950|60 73|PRL stimulation
P09259315A0809|147 177|CSEn enhancer/silencer activities
P09259315A0809|180 183|BeWo
P09259315A0809|10 13|Enh4
P09259315A0809|68 75|enhancer
P09259315A0809|187 193|GC cells
P09259315A0809|50 56|context
P09259315A0809|37 44|enhanson
P09259315A0809|0 7|Mutation
P09259315A0809|86 101|silencer activity
P09259315A0809|118 132|GT-IIC enhansons
P09259320A0830|89 92|DSBP
P09259320A0830|65 79|O-glycosylation
P09259320A0830|56 62|pattern
P09259320A0830|20 33|chromatography
P09259320A0830|82 85|SSBP
P09259320A0830|35 45|discordance
P09259328A0440|0 25|Deletion mapping experiments
P09259328A0440|43 51|sequences
P09259328A0440|217 218|bp
P09259328A0440|108 109|bp
P09259328A0440|210 211|bp
P09259328A0440|225 226|bp
P09259328A0440|77 86|MSC-1 cells
P09259328A0440|202 203|bp
P09259328A0440|67 74|activity
P09259328A0440|235 236|bp
P09259328A0440|242 248|regions
P09259328A0440|144 150|regions
P09259328A0440|176 193|luciferase activity
P09259328A0440|115 123|start site
P09261155A0833|15 16|PH
P09261155A0833|20 29|PTB domains
P09261155A0833|133 137|IRS-3
P09261155A0833|124 128|IRS-2
P09261155A0833|84 108|insulin receptor substrates
P09261155A0833|118 122|IRS-1
P09261155A0833|59 59|%
P09261178T0000|44 47|gene
P09261178T0000|37 42|kinase
P09261178T0000|3 7|mouse
P09261184A0170|43 63|supershift experiments
P09261184A0170|120 123|NF-Y
P09261184A0170|65 69|FIRE1
P09261184A0170|16 39|gel mobility shift analysis
P09261200T0001|0 8|MR imaging
P09261200T0001|37 50|FLAIR technique
P09261200T0001|20 31|head injuries
P09261397A0509|0 23|Gag protein sequence motifs
P09261397A0509|51 57|viruses
P09261397A0509|115 118|FeFV
P09261397A0509|79 97|genome encapsidation
P09261397A0509|29 36|NC domain
P09263010T0000|0 8|Induction
P09263010T0000|81 85|c-myc
P09263010T0000|11 24|B cell apoptosis
P09263010T0000|102 106|bcl-2
P09263010T0000|69 78|regulation
P09263010T0000|50 52|sIg
P09263010T0000|43 46|CD23
P09263094A0799|0 11|MEASUREMENTS
P09263094A0799|79 90|measurements
P09263094A0799|280 288|intervals
P09263094A0799|27 39|Lung elastance
P09263094A0799|130 139|airway flow
P09263094A0799|15 25|MAIN RESULTS
P09263094A0799|330 331|mL
P09263094A0799|303 309|volumes
P09263094A0799|276 277|Hz
P09263094A0799|247 266|breathing frequencies
P09263094A0799|47 56|resistance
P09263094A0799|228 232|cmH2O
P09263094A0799|240 244|range
P09263094A0799|93 106|airway pressure
P09263094A0799|41 42|EL
P09263094A0799|168 171|dogs
P09263094A0799|118 125|pressure
P09263094A0799|58 59|RL
P09263094A0799|206 223|mean airway pressure
P09263856A0563|42 53|EGF-1 modules
P09263856A0563|112 121|structures
P09263856A0563|24 29|models
P09263856A0563|61 62|PS
P09263856A0563|36 38|Gla
P09263856A0563|79 89|prothrombin
P09263856A0563|93 99|factor X
P09264466A0947|27 32|target
P09264466A0947|104 118|phosphorylation
P09264466A0947|89 100|interactions
P09264466A0947|46 48|APC
P09264466A0947|59 66|function
P09264466A0947|3 13|Cut9 subunit
P09265534A0455|12 32|Gy/20 fractions/5 weeks
P09265534A0455|3 6|dose
P09265642A0668|75 89|internalization
P09265642A0668|34 40|vacuole
P09265642A0668|141 150|sop mutants
P09265642A0668|114 121|marker FM
P09265642A0668|22 28|pathway
P09265642A0668|67 73|pathway
P09265642A0668|97 104|membrane
P09265932A0575|70 83|L2-3 interspace
P09265932A0575|23 24|mg
P09265932A0575|30 40|bupivacaine
P09265932A0575|6 10|women
P09265932A0575|56 64|injection
P09267306A0381|158 169|laboratories
P09267306A0381|48 51|apo B
P09267306A0381|35 45|measurement
P09267306A0381|19 22|case
P09267306A0381|73 80|standard
P09267306A0381|136 147|introduction
P09267306A0381|105 115|reliability
P09267306A0381|83 101|laboratory precision
P09267431A0000|29 33|SPK-4
P09267431A0000|21 25|SPK-3
P09267431A0000|51 64|protein kinases
P09267431A0000|3 19|soybean cDNA clones
P09267439A0000|119 127|organisms
P09267439A0000|110 116|variety
P09267439A0000|74 81|proteins
P09267439A0000|19 32|ras superfamily
P09267439A0000|0 4|Genes
P09267542A0126|0 9|Naltrexone
P09267542A0126|38 41|Food
P09267542A0126|69 77|treatment
P09267542A0126|80 96|alcohol dependence
P09267542A0126|45 62|Drug Administration
P09268298T0000|0 18|Ent-kaurene synthase
P09268298T0000|26 46|fungus Phaeosphaeria sp
P09268387A0293|100 112|RNA polymerase
P09268387A0293|52 54|ELL
P09268387A0293|128 144|elongation complex
P09268387A0293|65 71|domains
P09268387A0293|6 11|report
P09268387A0293|85 95|interaction
P09268578A0225|83 85|mud
P09268578A0225|12 24|cDNA sequences
P09268578A0225|52 58|message
P09268578A0225|77 81|death
P09268631A0316|60 64|genes
P09268631A0316|12 35|transcription orientation
P09268631A0316|3 10|position
P09268631A0316|84 88|Igf2r
P09268631A0316|49 54|status
P09268638A0332|62 67|D8S260
P09268638A0332|26 49|chromosome walking studies
P09268638A0332|76 81|D8S285
P09268652A0116|86 90|dsRNA
P09268652A0116|65 81|expression library
P09268652A0116|34 42|dsRBP-ZFa
P09268652A0116|16 32|zinc finger protein
P09268661A1405|44 56|transcriptase
P09268661A1405|25 36|retroplasmid
P09268661A1405|84 96|cDNA synthesis
P09268661A1405|113 123|CCA sequence
P09268661A1405|3 9|results
P09269879A0266|29 43|bioavailability
P09269879A0266|49 49|%
P09269879A0266|5 14|absorption
P09269879A0266|57 58|iv
P09269879A0266|67 85|elimination profiles
P09269900A1035|74 83|activation
P09269900A1035|113 118|factor
P09269900A1035|153 160|response
P09269900A1035|138 146|repressor
P09269900A1035|127 130|JunD
P09269900A1035|50 62|transcription
P09269900A1035|86 95|ATF3/c-Jun
P09269900A1035|32 42|EGF/Ras/Raf
P09269900A1035|14 20|results
P09271393A1333|56 69|HTLV-1 promoter
P09271393A1333|26 30|model
P09271393A1333|136 145|activities
P09271393A1333|171 181|recruitment
P09271393A1333|38 50|Tax anchors CBP
P09271393A1333|194 215|transcription machinery
P09271393A1333|158 167|remodeling
P09271393A1333|96 105|activation
P09271393A1333|14 17|data
P09271394A0558|131 133|TIR
P09271394A0558|35 46|footprinting
P09271394A0558|136 138|Mu1
P09271394A0558|81 84|MURA
P09271394A0558|120 125|region
P09271394A0558|49 68|MURA-Mu1 TIR complexes
P09271394A0558|0 4|DNase
P09271397A1596|116 122|Sp1 site
P09271397A1596|177 183|fashion
P09271397A1596|64 69|copies
P09271397A1596|81 100|LDL receptor SREBP site
P09271397A1596|34 42|construct
P09271397A1596|18 22|model
P09271400A0475|86 99|E2F2 expression
P09271400A0475|24 39|promoter activity
P09271400A0475|77 83|control
P09271400A0475|7 12|assays
P09271400A0475|107 123|growth stimulation
P09271400A0475|46 53|sequence
P09271417A0585|120 124|acids
P09271417A0585|47 52|kidney
P09271417A0585|79 85|tissues
P09271417A0585|10 14|mouse
P09271417A0585|68 77|adipocytes
P09271417A0585|54 58|heart
P09271417A0585|16 23|ERR alpha
P09271417A1011|14 36|receptor response element
P09271417A1011|39 44|NRRE-1
P09271417A1011|3 6|MCAD
P09271417A1011|66 73|ERR alpha
P09271417A1011|85 94|COS-7 cells
P09271496T0000|0 14|Mapping features
P09271496T0000|17 30|HIV-1 integrase
P09271496T0000|105 123|photo-cross-linking
P09271496T0000|43 47|sites
P09271496T0000|96 102|complex
P09271496T0000|58 75|target DNA molecules
P09272108A1295a|0 7|Analysis
P09272108A1295a|78 90|CAAT sequences
P09272108A1295a|23 28|region
P09272108A1295a|53 60|presence
P09272108A1295a|34 37|gene
P09272108A1295a|71 74|TATA
P09272108A1295b|0 7|Analysis
P09272108A1295b|78 90|CAAT sequences
P09272108A1295b|23 28|region
P09272108A1295b|53 60|presence
P09272108A1295b|34 37|gene
P09272108A1295b|71 74|TATA
P09272138A1153|111 115|weeks
P09272138A1153|93 100|survival
P09272138A1153|20 21|CR
P09272138A1153|23 26|rate
P09272138A1153|46 57|rhG-CSF group
P09272138A1153|144 144|P
P09272138A1153|63 63|%
P09272138A1153|11 18|response
P09272138A1153|38 41|CODE
P09272138A1153|69 72|CODE
P09272138A1153|32 32|%
P09272138A1153|78 82|group
P09272138A1153|137 142|groups
P09275159T0000|73 78|region
P09275159T0000|81 102|mouse hepatitis virus RNA
P09275159T0000|20 38|ribonucleoprotein A1
P09275164A0000|101 117|RNA triphosphatase
P09275164A0000|160 176|methyltransferase
P09275164A0000|80 85|action
P09275164A0000|34 37|mRNA
P09275164A0000|93 99|enzymes
P09275164A0000|145 147|RNA
P09275164A0000|3 21|m7GpppN cap structure
P09275164A0000|149 157|guanine-7
P09275164A0000|119 140|RNA guanylyltransferase
P09275990A0938|86 95|activation
P09275990A0938|60 69|TA98 strain
P09275990A0938|10 13|part
P09275990A0938|35 46|mutagenicity
P09275990A0938|121 142|mutagenicity prevalence
P09275990A0938|19 23|study
P09275990A0938|145 150|diesel
P09276882A0479|170 182|% carbohydrate
P09276882A0479|116 137|% carbohydrate treatment
P09276882A0479|102 104|Day
P09276882A0479|33 45|SW by-products
P09276882A0479|25 26|CC
P09276882A0479|158 159|pH
P09276882A0479|30 31|CC
P09276882A0479|3 10|addition
P09276882A0479|93 99|culture
P09276882A0479|56 63|pH values
P09276882A0479|13 19|culture
P09276882A0479|70 70|P
P09277472A1070|85 92|DC shocks
P09277472A1070|22 26|edema
P09277472A1070|49 57|mechanism
P09277472A1070|69 79|dysfunction
P09277629A0268|15 15|N
P09277629A0268|88 97|memory task
P09277629A0268|50 55|nature
P09277629A0268|120 129|memory task
P09277629A0268|58 72|ERP negativities
P09277629A0268|3 13|experiments
P09278441A0163|0 3|Biol
P09278441A1160|174 177|gene
P09278441A1160|133 139|homolog
P09278441A1160|120 122|Csx
P09278441A1160|21 38|CARP mRNA expression
P09278441A1160|113 116|Nkx2
P09278441A1160|85 88|days
P09278441A1160|73 78|tongue
P09278441A1160|3 9|pattern
P09278441A1160|199 209|development
P09278441A1160|13 18|timing
P09278441A1160|142 147|tinman
P09278441A1160|58 67|expression
P09278441A1777|0 13|Overexpression
P09278441A1777|53 61|troponin C
P09278441A1777|82 100|factor transcription
P09278441A1777|22 35|cardiomyocytes
P09278441A1777|16 19|CARP
P09278445T0000|0 19|Substrate specificity
P09278445T0000|40 57|yeast RNA polymerase
P09278445T0000|25 37|RNase activity
P09278450A1338|15 33|mobility shift assays
P09278450A1338|69 73|site A
P09278450A1338|90 99|NF1 protein
P09278450A1338|37 58|competition experiments
P09278454A1261|0 10|Examination
P09278454A1261|128 160|DMS protection footprinting analysis
P09278454A1261|52 64|Y-box sequence
P09278454A1261|16 31|MMP-2 RE1 sequence
P09278454A1261|66 77|CTGCTGGGCAAG
P09278454A1261|122 125|YB-1
P09278475A0465|73 85|Ino-phenotype
P09278475A0465|37 47|ts phenotype
P09278475A0465|88 95|rpo26-31
P09278475A0465|6 10|scs32
P09278494A0762|15 17|Sp1
P09278494A0762|59 74|promoter activity
P09278494A0762|80 94|Surf-1 direction
P09278494A0762|21 31|ETS proteins
P09278494A0762|2 9|contrast
P09278758A1636|0 9|CONCLUSION
P09278758A1636|11 21|Patients wit
P09278758A1636|145 154|lymph nodes
P09278758A1636|40 50|neck disease
P09278758A1636|116 121|spread
P09278758A1636|95 101|disease
P09278758A1636|70 77|evidence
P09278758A1636|167 170|risk
P09278758A1636|183 189|failure
P09278758A1636|52 55|N1-3
P09278758A1636|199 203|sites
P09279379A0310|46 48|DNA
P09279379A0310|120 133|H2B histone gene
P09279379A0310|50 58|sequences
P09279379A0310|109 114|spacer
P09279379A0310|41 44|acid
P09279379A0310|95 100|spacer
P09279379A0310|83 88|region
P09279379A0310|19 24|pBR322
P09279889A1124|0 3|Area
P09279889A1124|41 49|AUC0-24 hr
P09279889A1124|12 15|drug
P09279889A1124|34 39|curves
P09279889A1124|105 117|% Azone systems
P09279889A1124|90 95|% Azone
P09279889A1124|54 56|MTX
P09279889A1124|84 87|PG-2
P09279889A1124|72 73|ng
P09279889A1124|99 102|PG-7
P09280747A0195|74 81|survival
P09280747A0195|92 101|comparison
P09280747A0195|150 155|effect
P09280747A0195|124 131|evidence
P09280747A0195|169 181|ACE inhibitors
P09280747A0195|108 115|regimens
P09280747A0195|16 39|hydralazine hydrochloride
P09280747A0195|3 13|combination
P09280747A0195|43 61|isosorbide dinitrate
P09282329A0527|29 40|interactions
P09282329A0527|9 18|mechanisms
P09282329A0527|165 183|G1/S phase transition
P09282329A0527|74 96|cell cycle control element
P09282329A0527|186 191|FDC-P1
P09282329A0527|150 159|regulation
P09282329A0527|121 132|determinants
P09282329A0527|59 65|factors
P09282329A0527|43 46|Site
P09282329A0527|205 219|progenitor cells
P09282911A0277|13 17|study
P09282911A0277|110 111|T3
P09282911A0277|139 148|regulation
P09282911A0277|62 76|RC3/neurogranin
P09282911A0277|39 50|cell cultures
P09282911A0277|3 6|goal
P09282911A0277|128 136|mechanism
P09282985A0961|52 66|characteristics
P09282985A0961|9 19|differences
P09282985A0961|27 31|males
P09282985A0961|33 33|p
P09283828A0484|14 22|responses
P09283828A0484|48 51|cues
P09285715A1257|114 116|CTE
P09285715A1257|89 92|RNAs
P09285715A1257|107 109|RNA
P09285715A1257|37 39|Rev
P09285715A1257|193 202|mRNA export
P09285715A1257|51 63|export pathway
P09285715A1257|96 97|5S
P09285715A1257|159 165|factors
P09285715A1257|16 19|data
P09285789A0712|17 47|guanine nucleotide exchange factor
P09285789A0712|49 51|GEF
P09285789A0712|112 117|domain
P09285789A0712|90 107|pleckstrin homology
P09285789A0712|53 58|domain
P09285789A0712|5 7|Duo
P09285789A0712|109 110|PH
P09285789A0712|134 144|repeat units
P09286115T0000|30 35|factor
P09286115T0000|60 66|element
P09286115T0000|96 104|RPL21 gene
P09286115T0000|0 2|S2F
P09286981A0147|0 3|ArgR
P09286981A0147|59 62|mass
P09286981A0147|32 39|subunits
P09286981A0147|71 72|Da
P09286981A0147|17 21|dimer
P09287036A0457|0 25|Plasma leptin concentrations
P09287036A0457|38 42|women
P09287036A0457|111 115|women
P09287036A0457|76 86|differences
P09287036A0457|63 72|adjustment
P09287036A0457|103 107|ng/ml
P09287036A0457|92 95|mass
P09287036A0457|47 49|men
P09287352A0930|148 152|SHP-1
P09287352A0930|256 264|% increase
P09287352A0930|45 59|SHP-1 expression
P09287352A0930|23 36|STAT activation
P09287352A0930|83 92|activation
P09287352A0930|155 157|Cys
P09287352A0930|213 222|expression
P09287352A0930|184 186|MEK
P09287352A0930|225 229|SHP-1
P09287352A0930|14 20|effects
P09287352A0930|161 163|Ser
P09287352A0930|136 145|expression
P09287352A0930|115 134|protein kinase pathway
P09287352A0930|174 181|activity
P09287352A0930|204 204|%
P09287362A0589|41 43|csk
P09287362A0589|61 66|region
P09287362A0589|105 110|region
P09287362A0589|37 39|p50
P09287362A0589|26 34|SH3 region
P09287362A0589|4 14|interaction
P09287362A0589|113 120|PTP-PEST
P09287362A0589|68 84|PPPLPERTPESFVLADM
P09288848A0780|15 25|HbO2 changes
P09288848A0780|12 13|Gy
P09288916T0000|135 145|kidney cells
P09288916T0000|9 18|expression
P09288916T0000|118 128|Madin-Darby
P09288916T0000|96 100|alpha
P09288916T0000|89 94|meprin
P09288916T0000|70 82|acid hydrolase
P09288916T0000|104 115|beta subunits
P09290207A0731|45 58|mating type loci
P09290207A0731|22 33|derepression
P09290571A0420|76 78|EPS
P09290571A0420|7 14|patients
P09290571A0420|91 98|patients
P09290571A0420|83 85|VTs
P09290571A0420|37 39|VTs
P09290571A0420|70 74|study
P09290571A0799|26 26|n
P09290571A0799|23 24|VT
P09290571A0799|30 32|VTs
P09290571A0799|45 48|msec
P09290571A0799|3 13|cycle length
P09291077T0000|9 23|hyperammonaemia
P09291077T0000|39 49|shepherd dog
P09291098A0452|92 101|transcript
P09291098A0452|71 78|splicing
P09291098A0452|23 31|kb mRNA V-1
P09291098A0452|133 142|rat GGT gene
P09291098A0452|120 127|promoter
P09291098A0452|41 52|kb GGT mRNA V-2
P09291098T0000|91 93|rat
P09291098T0000|15 22|promoter
P09291098T0000|31 72|gamma-glutamyl transpeptidase gene expression
P09291098T0000|105 114|liver cells
P09292499A0887|88 90|PTB
P09292499A0887|105 112|extracts
P09292499A0887|22 31|pyrimidine
P09292499A0887|127 158|UV crosslinking/competition assays
P09292499A0887|5 18|repressor sites
P09292499A0887|94 97|HeLa
P09292499A0887|54 86|polypyrimidine tract binding protein
P09293006A1412|69 81|aphII promoter
P09293006A1412|9 18|expression
P09293006A1412|27 36|S. lividans
P09293006A1412|21 24|lipA
P09293006A1412|41 44|gene
P09294139A0729|116 121|motifs
P09294139A0729|287 292|motifs
P09294139A0729|92 98|homolog
P09294139A0729|179 186|enhancer
P09294139A0729|71 71|%
P09294139A0729|212 231|sequence conservation
P09294139A0729|198 205|segments
P09294139A0729|242 252|possibility
P09294139A0729|40 52|HS12 enhancers
P09294139A0729|160 167|function
P09294139A0729|13 30|core homology region
P09294161A0650|2 9|contrast
P09294161A0650|63 78|activation domain
P09294161A0650|44 51|p45 NF-E2
P09294161A0650|92 99|cell line
P09294161A0650|24 30|protein
P09294161A0650|156 161|assays
P09294161A0650|32 41|expression
P09294161A0650|83 87|NF-E2
P09294161A0650|132 144|transcription
P09294161A1103|116 124|promoters
P09294161A1103|91 100|globin loci
P09294161A1103|79 85|regions
P09294161A1103|32 40|mechanism
P09294161A1103|50 60|recruitment
P09294161A1103|5 12|findings
P09294262A0885|94 99|stress
P09294262A0885|138 146|promoters
P09294262A0885|62 70|CreA boxes
P09294262A0885|25 40|consensus TATA box
P09294262A0885|54 58|CCAAT
P09294262A0885|120 129|regulation
P09294262A0885|3 16|promoter region
P09294422A1223|144 151|activity
P09294422A1223|6 21|cysteine residues
P09294422A1223|113 129|activation process
P09294422A1223|69 77|formation
P09294422A1223|45 50|region
P09294422A1223|81 95|disulfide bridge
P09294422A1376|135 145|tac promoter
P09294422A1376|173 175|POR
P09294422A1376|38 41|time
P09294422A1376|187 190|form
P09294422A1376|3 9|por gene
P09294422A1376|161 170|production
P09294452A2107|17 24|operator
P09294452A2107|53 61|reduction
P09294452A2107|64 83|reporter enzyme levels
P09294453A0949|71 74|role
P09294453A0949|77 94|T beta L biosynthesis
P09294453A0949|36 43|tabtoxin
P09294453A0949|28 33|levels
P09294453A0949|3 12|ORF3 mutant
P09294453A0949|59 62|ORF3
P09294471A1198|115 117|fit
P09294471A1198|100 104|model
P09294471A1198|32 41|150/microL
P09294471A1198|22 29|CD4 count
P09294471A1198|75 76|I0
P09294471A1198|52 61|200/microL
P09294471A1198|80 81|I1
P09294471A1198|7 15|Cox models
P09294471A1198|131 134|data
P09296251A0163|42 47|number
P09296251A0163|20 26|reports
P09296251A0163|50 57|patients
P09296251A0163|68 71|data
P09297698A0933|130 140|enolase gene
P09297698A0933|65 70|UbCRBP
P09297698A0933|113 120|distance
P09297698A0933|91 96|region
P09297698A0933|28 31|ends
P09297698A0933|5 15|transcripts
P09297698A0933|40 50|UbCRBP mRNAs
P09299696A1074|158 161|kids
P09299696A1074|48 53|number
P09299696A1074|126 141|characterization
P09299696A1074|165 169|model
P09299696A1074|78 83|villus
P09299696A1074|56 69|cryptosporidia
P09299696A1074|147 155|infection
P09299696A1074|36 44|intestine
P09299696A1074|95 97|DPI
P09299696A1074|17 30|cryptosporidia
P09299696A1074|185 201|cryptosporidiosis
P09299696A1074|3 14|distribution
P09300323A1182|56 63|ENDO/EPI
P09300323A1182|41 54|blood flow ratio
P09300323A1182|128 130|ITF
P09300323A1182|155 158|i.v.
P09300323A1182|95 109|control stenosis
P09300323A1182|181 183|NTG
P09300323A1182|3 8|result
P09300697A0000|0 10|Proteasomes
P09300697A0000|90 98|molecules
P09300697A0000|62 69|peptides
P09300697A0000|50 59|generation
P09300697A0000|81 88|MHC class
P09300697A0000|29 36|protease
P09300698A1219|15 28|interpretation
P09300698A1219|46 49|MQ9b
P09300698A1219|108 115|peptides
P09300698A1219|2 8|support
P09301114A0573|0 8|Takahashi
P09301114A0573|10 11|H.
P09301350A0946|199 206|capacity
P09301350A0946|75 79|pg/ml
P09301350A0946|273 274|pp
P09301350A0946|177 177|%
P09301350A0946|103 104|CI
P09301350A0946|152 165|expiratory flow
P09301350A0946|242 257|percentage points
P09301350A0946|219 221|sex
P09301350A0946|129 135|placebo
P09301350A0946|45 69|treatment median difference
P09301350A0946|121 126|favour
P09301350A0946|225 230|height
P09301350A0946|276 298|mean treatment difference
P09301350A0946|301 306|favour
P09301350A0946|83 101|% confidence interval
P09301350A0946|170 170|%
P09301350A0946|265 267|% CI
P09301350A0946|113 117|pg/ml
P09301350A0946|259 260|pp
P09301350A0946|309 315|placebo
P09301350A0946|3 21|sputum interleukin-8
P09303437A0875|217 233|CAT gene expression
P09303437A0875|105 112|function
P09303437A0875|204 214|stimulation
P09303437A0875|26 28|Fp1
P09303437A0875|167 174|promoter
P09303437A0875|137 145|insertion
P09303437A0875|34 43|hCRBP1 gene
P09303437A0875|126 132|element
P09303437A0875|60 70|CAT activity
P09303437A0875|16 23|deletion
P09303437A0875|159 161|p12
P09303635A0000|58 61|lack
P09303635A0000|9 15|disease
P09303635A0000|87 92|enzyme
P09303635A0000|32 39|disorder
P09303635A0000|0 6|Gaucher
P09304123A0079|58 71|tooth structure
P09304123A0079|134 137|bulk
P09304123A0079|110 114|order
P09304123A0079|102 107|manner
P09304123A0079|158 165|material
P09304123A0079|5 17|discoloration
P09304123A0079|41 44|ways
P09305592A0000|18 44|translocation characteristic
P09305592A0000|89 101|fusion protein
P09305592A0000|65 75|bcr/abl gene
P09305592A0000|103 113|p210bcr/abl
P09305592A0000|47 49|CML
P09305631A0770|0 13|Overexpression
P09305631A0770|41 49|cell lines
P09305631A0770|71 79|cell death
P09305631A0770|54 57|heat
P09305631A0770|16 20|BAG-1
P09305755A0540|118 122|C/EBP
P09305755A0540|142 148|factors
P09305755A0540|13 18|region
P09305755A0540|160 163|HNF5
P09305755A0540|71 73|Sp1
P09305755A0540|125 134|hepatocyte
P09305755A0540|82 87|factor
P09305755A0540|155 158|HNF1
P09305755A0540|95 116|CAAT-box binding protein
P09305755A0540|63 69|protein
P09305755A0540|191 193|AP1
P09305755A0540|90 92|NF1
P09305755A0540|168 184|activator proteins
P09305755A0540|195 197|AP2
P09305755A0540|36 47|binding sites
P09305870A0894|85 88|hDlg
P09305870A0894|73 82|PDZ domains
P09305870A0894|95 113|lymphocyte homologue
P09305870A0894|3 24|recognition specificity
P09305870A0894|178 183|domain
P09305870A0894|139 153|tumor suppressor
P09305870A0894|186 198|glycophorin C.
P09305870A0894|129 133|discs
P09305870A0894|30 41|p55 PDZ domain
P09305944A0621|144 156|yeast proteins
P09305944A0621|197 209|GTP hydrolysis
P09305944A0621|109 116|sequence
P09305944A0621|61 82|rna1p mutant derivatives
P09305944A0621|132 137|domain
P09305944A0621|31 36|series
P09305944A0621|14 27|RanGAP activity
P09307065A0553|217 222|microM
P09307065A0553|73 85|enterotoxin C2
P09307065A0553|126 126|M
P09307065A0553|177 179|sec
P09307065A0553|131 133|sec
P09307065A0553|5 11|absence
P09307065A0553|92 106|association rate
P09307065A0553|192 211|dissociation constant
P09307065A0553|40 45|D10 TCR
P09307065A0553|14 21|MHC class
P09307065A0553|142 157|dissociation rate
P09307312A0172|233 236|data
P09307312A0172|173 201|membrane vibration measurements
P09307312A0172|61 71|nerve fibers
P09307312A0172|138 142|cells
P09307312A0172|19 24|shifts
P09307312A0172|81 92|microphonics
P09307312A0172|42 50|responses
P09307312A0172|148 154|cochlea
P09307312A0172|0 7|Evidence
P09307312A0172|116 124|hair cells
P09307312A0172|100 108|responses
P09308234A0225|0 2|Mnt
P09308234A0225|73 80|promoter
P09308234A0225|52 61|activation
P09308234A0225|4 15|Max complexes
P09308738A1216|125 160|factor VIII/von Willebrand factor levels
P09308738A1216|24 26|HES
P09308738A1216|5 16|United States
P09308738A1216|100 101|MW
P09308738A1216|115 122|decrease
P09309457A0680|0 5|Assays
P09309457A0680|158 163|months
P09309457A0680|39 42|HDL2
P09309457A0680|44 46|LDL
P09309457A0680|48 60|triglycerides
P09309457A0680|123 130|baseline
P09309457A0680|75 85|lipoprotein
P09309457A0680|62 73|endothelin-1
P09309457A0680|90 98|estradiol
P09309457A0680|102 104|FSH
P09309457A0680|13 23|cholesterol
P09309457A0680|166 168|ERT
P09309457A0680|35 37|HDL
P09309457A0680|146 148|ERT
P09310836A1019|40 51|SV40 promoter
P09310836A1019|9 15|repeats
P09310836A1019|109 116|elements
P09310836A1019|21 28|P element
P09310836A1019|63 91|phorbol 12-myristate 13-acetate
P09311164A0245|68 76|motor unit
P09311164A0245|21 28|density J
P09311164A0245|50 55|volume
P09311568A0595|42 42|Q
P09311568A0595|51 51|G
P09311568A0595|49 49|A
P09311568A0595|23 38|C1YVV NIa protease
P09311568A0595|3 20|cleavage dipeptides
P09311568A0595|44 44|E
P09311568A0595|47 47|S
P09311796A0218|13 19|studies
P09311796A0218|90 111|TATA-box binding protein
P09311796A0218|113 115|TBP
P09311796A0218|123 141|transcription factor
P09311796A0218|36 45|activation
P09311796A0218|69 80|IEP86 binding
P09311808A0341|31 40|p4 molecule
P09311810A0814|133 137|virus
P09311810A0814|152 156|virus
P09311810A0814|38 46|Vero cells
P09311810A0814|174 188|alpha0 sequences
P09311810A0814|61 80|alpha0 deletion mutant
P09311810A0814|21 35|cyclin D3 protein
P09311810A0814|7 18|accumulation
P09311810A0814|107 111|cells
P09311835A0147|129 136|residues
P09311835A0147|77 87|SV40 mutants
P09311835A0147|54 62|T antigens
P09311835A0147|152 167|ATP binding pocket
P09311835A0147|33 48|characterization
P09312025A0373|134 141|LY294002
P09312025A0373|171 178|p85alpha
P09312025A0373|58 64|PKC zeta
P09312025A0373|5 11|effects
P09312025A0373|80 120|phosphatidylinositol 3-kinase p85alpha-p110
P09312025A0373|68 77|inhibition
P09312025A0373|163 168|mutant
P09312025A0373|123 132|wortmannin
P09312025A0373|27 39|co-expression
P09312025T0000|0 19|Protein phosphatase 2A
P09312025T0000|79 82|SV40
P09312025T0000|111 129|NF-kappaB activation
P09312025T0000|88 88|t
P09312025T0000|42 68|protein kinase C zeta signaling
P09312025T0000|31 39|regulator
P09312025T0000|98 107|cell growth
P09312028A0975|17 29|RXRalphaF318A
P09312028A0975|65 76|heterodimers
P09312028A0975|42 49|activity
P09312028A0975|130 143|RAR AF-2 domains
P09312028A0975|92 97|BMS614
P09312028A0975|82 89|presence
P09312028A0975|109 117|integrity
P09312028A0975|124 126|RXR
P09312032A0165|29 39|snoRNA genes
P09312032A0165|112 124|intron lariats
P09312032A0165|92 97|snoRNA
P09312032A0165|80 86|release
P09312032A0165|48 57|processing
P09312032A0165|5 11|introns
P09312087A0000|29 41|Src homology-2
P09312087A0000|344 350|Tyr-686
P09312087A0000|43 45|SH2
P09312087A0000|134 140|PECAM-1
P09312087A0000|228 231|part
P09312087A0000|292 297|domain
P09312087A0000|319 341|tyrosine residues Tyr-663
P09312087A0000|80 90|phosphatase
P09312087A0000|202 208|process
P09312087A0000|248 262|phosphopeptides
P09312087A0000|92 96|SHP-2
P09312087A0000|300 306|PECAM-1
P09312087A0000|126 131|domain
P09312087A0000|6 12|studies
P09312087A0000|181 199|platelet aggregation
P09313755A0816|30 42|risk variables
P09313755A0816|13 22|clustering
P09313755A0816|52 58|factors
P09314306A0571|0 14|Supplementation
P09314306A0571|45 48|g/dL
P09314306A0571|29 34|pl-ALB
P09314487T0000|0 8|Detection
P09314487T0000|46 58|air filtration
P09314487T0000|19 43|Mycobacterium tuberculosis
P09314487T0000|62 84|polymerase chain reaction
P09314537A1600|5 12|findings
P09314537A1600|52 70|ezrin binding protein
P09314537A1600|21 25|EBP50
P09314554A0149|199 232|influenza A PR/8/34 nucleoprotein gene
P09314554A0149|177 189|reading frames
P09314554A0149|154 161|epitopes
P09314554A0149|66 68|AUG
P09314554A0149|83 94|reading frame
P09314554A0149|36 46|translation
P09314554A0149|133 144|presentation
P09314570A0153|102 111|repression
P09314570A0153|129 138|activities
P09314570A0153|90 99|activation
P09314570A0153|12 19|proteins
P09314570A0153|4 9|family
P09314570A0153|57 69|gene promoters
P09314570A0153|32 37|motifs
P09315631A1064|0 7|Deletion
P09315631A1064|56 61|yeasts
P09315631A1064|91 99|POR2 genes
P09315631A1064|66 74|deletions
P09315631A1064|13 20|POR2 gene
P09315631A1064|137 144|degrees C
P09315631A1064|84 87|POR1
P09315631A1064|166 174|delta por1
P09315631A1064|125 132|glycerol
P09315631A1064|41 49|phenotype
P09315631A1064|181 187|mutants
P09315632A1137|188 196|neoplasia
P09315632A1137|20 30|observation
P09315632A1137|35 44|expression
P09315632A1137|112 122|fibroblasts
P09315632A1137|63 79|FGFR3 kinase domain
P09315632A1137|135 147|dysregulation
P09315632A1137|150 154|FGFR3
P09315632A1137|177 180|role
P09315633A0333|83 89|factors
P09315633A0333|91 94|IRFs
P09315633A0333|50 57|homology
P09315633A0333|63 72|interferon
P09315633A0333|10 26|amino acid sequence
P09315633A0333|32 35|gene
P09315651T0000|0 10|Involvement
P09315651T0000|13 16|AP-2
P09315651T0000|19 28|regulation
P09315651T0000|34 43|R-FABP gene
P09315651T0000|59 69|chick retina
P09315678A0278|72 83|protein NAP57
P09315678A0278|60 62|rat
P09315678A0278|114 120|Nopp140
P09315678A0278|186 187|U.
P09315678A0278|8 12|Cbf5p
P09315678A0278|176 184|shuttling
P09316937A0133|18 25|organism
P09316937A0133|76 80|Vitek
P09316937A0133|53 65|discrepancies
P09316937A0133|84 110|API 20E identification systems
P09317131A0000|0 1|Ig
P09317131A0000|38 46|cytokines
P09317131A0000|84 90|CH genes
P09317131A0000|7 25|chain class switching
P09317131A0000|55 67|transcription
P09317131A1332|132 146|IgE germline gene
P09317131A1332|12 15|data
P09317131A1332|30 58|NF kappa B2 nucleoprotein complex
P09317131A1332|112 121|activation
P09317131A1332|84 88|STAT6
P09317757T0000|0 7|EXERCISE
P09317757T0000|24 63|CHRISTMAS ISLAND RED CRAB GECARCOIDEA NATALIS
P09317757T0000|77 86|LOCOMOTION
P09317757T0000|65 74|ENERGETICS
P09317830T0000|27 33|CICADAS
P09317830T0000|12 24|SONG FREQUENCY
P09321406T0000|89 97|chromatin
P09321406T0000|51 69|Ty5 retrotransposons
P09321406T0000|36 48|transcription
P09321406T0000|3 26|pheromone response pathway
P09321657A0439|185 190|effect
P09321657A0439|69 81|cox3 promoters
P09321657A0439|6 10|study
P09321657A0439|101 111|core element
P09321657A0439|126 145|cox3 promoter activity
P09321657A0439|27 35|mutations
P09321657A0439|56 63|elements
P09321657A0439|155 170|element mutations
P09321930A0567|175 184|expression
P09321930A0567|53 55|APC
P09321930A0567|127 136|mechanisms
P09321930A0567|191 198|mutation
P09321930A0567|225 238|binding protein
P09321930A0567|186 188|LOE
P09321930A0567|164 166|LOH
P09321930A0567|19 38|tumor suppressor genes
P09321930A0567|45 47|p53
P09321930A0567|49 51|DCC
P09321930A0567|106 116|frequencies
P09321930A0567|169 172|loss
P09321930A0567|143 146|loss
P09321930A0567|61 65|BRCA1
P09321930A0567|70 78|WAF1/CIP1
P09321930A0567|203 214|inactivation
P09321930A0567|149 162|heterozygosity
P09321930A0567|57 59|MCC
P09322738A0510|71 80|chromosome
P09322738A0510|19 22|gene
P09322738A0510|24 30|rpoCHIS
P09322738A0510|98 107|S. lividans
P09322738A0510|83 94|S. coelicolor
P09322738A0510|60 65|allele
P09322872A0745|29 34|TK gene
P09322872A0745|10 17|deletion
P09322872A0745|90 102|recombination
P09322872A0745|36 44|selection
P09322872A0745|67 71|cells
P09322872A0745|49 59|gancyclovir
P09323366A0000|3 20|malate synthase gene
P09323366A0000|22 25|MLS1
P09323366A0000|110 121|growth medium
P09323366A0000|93 104|carbon source
P09323366A0000|32 36|yeast
P09323366A0299|114 117|gene
P09323366A0299|56 60|sites
P09323366A0299|23 39|MLS1 control region
P09323366A0299|62 65|UAS1
P09323366A0299|2 17|deletion analysis
P09323366A0299|69 72|UAS2
P09323366A0299|97 108|derepression
P09323612A0374|74 76|use
P09323612A0374|197 202|speech
P09323612A0374|92 99|children
P09323612A0374|117 125|dysphasia
P09323612A0374|27 33|studies
P09323612A0374|166 173|children
P09323612A0374|36 61|sleep electroencephalograms
P09323612A0374|79 88|medication
P09323612A0374|145 163|treatment strategies
P09323612A0374|206 222|language disorders
P09323612A0374|63 65|EEG
P09323612A0374|0 3|Lack
P09324720A0317|43 48|Alzoon
P09324720A0317|16 20|times
P09324720A0317|7 11|meals
P09324720A0317|30 40|tablespoons
P09324878A0952|28 31|wall
P09324878A0952|114 128|type B dissection
P09324878A0952|36 56|ultrasound examination
P09324878A0952|81 89|diagnosis
P09324922T0065|0 18|Fermentation process
P09324922T0065|84 87|acid
P09324922T0065|24 38|supplementation
P09324922T0065|63 74|acid bacteria
P09324988X0000|44 49|lamins
P09324988X0000|70 77|proteins
P09324988X0000|20 22|p21
P09324988X0000|24 26|ras
P09324988X0000|28 35|proteins
P09324988X0000|55 60|series
P09324988X0000|0 9|Substrates
P09325022A0192|41 48|CD-1 mice
P09325022A0192|11 17|animals
P09325022A0192|105 110|microm
P09325022A0192|32 38|studies
P09325022A0192|21 25|group
P09325022A0192|70 80|C57BL/6 mice
P09325022A0192|64 66|C3H
P09325022A0192|53 57|study
P09325022A0192|0 6|Ovaries
P09325135A0737|74 80|protein
P09325135A0737|9 21|fusion protein
P09325135A0737|51 51|%
P09325273A1240|291 313|ubiquitin fusion proteins
P09325273A1240|46 49|role
P09325273A1240|66 74|ubiquitin
P09325273A1240|219 227|ubiquitin
P09325273A1240|77 86|hydrolysis
P09325273A1240|23 27|UBP41
P09325273A1240|279 286|proteins
P09325273A1240|203 212|production
P09325273A1240|55 63|recycling
P09325273A1240|238 257|poly-ubiquitin chains
P09325273A1240|97 116|poly-ubiquitin chains
P09325273A1240|131 136|action
P09325273A1240|5 11|results
P09325273A1240|172 188|protein substrates
P09325273A1240|141 151|S proteasome
P09325278A0458|172 178|regions
P09325278A0458|104 106|rat
P09325278A0458|47 66|ER1 amino acid sequence
P09325278A0458|89 98|similarity
P09325278A0458|240 243|mta1
P09325278A0458|161 164|mta1
P09325278A0458|196 224|Caenorhabditis elegans sequence
P09325278A0458|80 86|regions
P09325278A0458|181 190|similarity
P09325278A0458|1 22|data base homology search
P09325278A0458|115 122|proteins
P09325278A0458|156 159|gene
P09325284A0469|47 47|%
P09325284A0469|34 44|acid protein
P09325284A0469|12 15|cDNA
P09325284A0469|64 78|progelatinase B.
P09325322A1293|69 73|shift
P09325322A1293|76 79|EC50
P09325322A1293|24 26|Ca2
P09325322A1293|50 62|cooperativity
P09325322A1293|3 12|inhibition
P09325322A1293|92 110|InsP3 concentrations
P09325322A1293|40 47|decrease
P09326163A0942|0 6|RESULTS
P09326163A0942|23 36|mortality ratio
P09326163A0942|57 65|neoplasms
P09326163A0942|38 40|SMR
P09326163A0942|74 76|% CI
P09326246A0567|103 108|levels
P09326246A0567|111 128|luciferase activity
P09326246A0567|139 155|bp reporter plasmid
P09326246A0567|22 27|region
P09326246A0567|0 15|Sequence analysis
P09326246A0567|71 78|deletion
P09326246A0567|59 66|elements
P09326263A0410|86 90|brain
P09326263A0410|73 81|sequences
P09326263A0410|46 58|methodologies
P09326263A0410|21 37|transcription-PCR
P09326263A0410|156 160|exons
P09326263A0410|230 231|1B
P09326263A0410|114 121|material
P09326263A0410|39 44|RT-PCR
P09326263A0410|194 197|exon
P09326263A0410|225 228|exon
P09326263A0410|199 200|1A
P09326263A0410|94 101|placenta
P09326263A0410|7 10|RACE
P09326317A0372|69 72|EXT1
P09326317A0372|76 84|EXT2 genes
P09326317A0372|26 42|mutation screening
P09326317A0372|14 18|study
P09326317A0372|95 109|linkage analysis
P09326727T0000|3 15|regurgitation
P09326727T0000|31 40|injections
P09327881T0000|89 96|primates
P09327881T0000|64 70|studies
P09327881T0000|41 60|dopamine transporters
P09327881T0000|0 37|Positron emission tomography radioligands
P09328341A1449|0 10|Attenuation
P09328341A1449|62 71|DNA binding
P09328341A1449|132 146|transactivation
P09328341A1449|77 99|TR alpha DNA binding mutant
P09328341A1449|18 34|vit A2 consensus ERE
P09328343A0181|0 9|Expression
P09328343A0181|110 117|proteins
P09328343A0181|152 157|family
P09328343A0181|92 94|E2A
P09328343A0181|136 142|members
P09328343A0181|50 63|protein complex
P09328343A0181|18 24|element
P09328349A1679|74 83|expression
P09328349A1679|38 52|characteristics
P09328349A1679|8 15|CCAAT box
P09328349A1679|89 105|alpha-subunit gene
P09328349A1679|108 119|trophoblasts
P09328476A0068|42 58|ribonucleoprotein
P09328476A0068|76 77|U1
P09328476A0068|82 83|U5
P09328476A0068|79 80|U2
P09328476A0068|66 74|particles
P09328476A0068|105 115|spliceosome
P09328476A0068|87 91|U4/U6
P09328476A0068|60 64|snRNP
P09328476A0068|0 9|U4/U6 snRNP
P09328476A0374|0 5|Hprp3p
P09328476A0374|11 20|kDa protein
P09328476A0374|67 85|splicing factor Prp3p
P09328824A0000|118 122|alpha
P09328824A0000|164 173|repression
P09328824A0000|192 196|roles
P09328824A0000|85 113|chicken thyroid hormone receptor
P09328824A0000|199 200|TR
P09328824A0000|212 224|acid receptors
P09328824A0000|115 116|TR
P09328824A0000|44 57|v-erbA oncogene
P09328824A0000|19 28|properties
P09328824A0000|73 79|version
P09328833A0588|40 55|MCF-7 cDNA library
P09328833A0588|31 33|HET
P09328833A0588|25 26|kb
P09328833A0588|17 20|cDNA
P09331119A0659|42 57|thrombocytopenia
P09331119A0659|19 26|toxicity
P09331119A0659|91 96|cycles
P09331119A0659|62 73|parasthesias
P09331119A0659|88 88|%
P09331119A0659|30 40|neutropenia
P09331119A0659|13 17|grade
P09331864A0230|0 18|Serum concentrations
P09331864A0230|26 29|TBOH
P09331864A0230|94 100|heifers
P09331864A0230|194 197|mg E2
P09331864A0230|202 210|Revalor-H
P09331864A0230|125 134|treatments
P09331864A0230|154 155|mg
P09331864A0230|44 44|d
P09331864A0230|21 22|E2
P09331864A0230|212 214|MGA
P09331864A0230|173 181|Revalor-H
P09331864A0230|148 150|MGA
P09331864A0230|159 164|heifer
P09331864A0230|186 190|mg TBA
P09331864A0230|255 257|MGA
P09331864A0230|232 236|mg TBA
P09331864A0230|138 144|control
P09331864A0230|218 227|Finaplix-H
P09331864A0230|244 253|Finaplix-H
P09331864A0848|0 20|Serum E2 concentrations
P09331864A0848|81 83|MGA
P09331864A0848|111 113|MGA
P09331864A0848|60 60|d
P09331864A0848|97 104|controls
P09331864A0848|70 77|controls
P09333018A0000|0 9|Interferon
P09333018A0000|27 29|IRF
P09333018A0000|20 25|Factor
P09333018A0000|66 71|growth
P09333018A0000|101 119|transcription factor
P09333026A0397|144 153|divergence
P09333026A0397|10 18|structure
P09333026A0397|88 103|PTK family members
P09333026A0397|35 39|exons
P09333026A0397|46 55|boundaries
P09333026A0397|21 23|brk
P09333026A0851|146 151|growth
P09333026A0851|126 134|anchorage
P09333026A0851|113 117|cells
P09333026A0851|54 60|brk cDNA
P09333026A0851|63 67|mouse
P09333026A0851|77 87|fibroblasts
P09333026A0851|209 220|growth factor
P09333026A0851|41 46|tumour
P09333026A0851|28 37|expression
P09333026A0851|190 197|response
P09333168A0310|0 19|Anti-hepatitis A virus
P09333168A0310|90 92|men
P09333168A0310|35 45|vaccination
P09333168A0310|25 29|titer
P09333168A0310|21 23|HAV
P09333231T0018|16 22|species
P09333231T0018|3 7|skull
P09334264A0540|98 100|kDa
P09334264A0540|13 26|calf thymus CstF
P09334264A0540|90 93|mass
P09334264A0540|54 57|form
P09334264A0540|69 75|subunit
P09334330A0252|28 36|mutations
P09334330A0252|15 19|daf-3
P09334330A0252|216 226|development
P09334330A0252|97 126|Smad signal transduction proteins
P09334330A0252|187 190|DPC4
P09334330A0252|128 132|daf-3
P09334330A0252|267 282|dauer development
P09334330A0252|39 43|genes
P09334330A0252|141 151|Smad protein
P09334330A0252|74 82|receptors
P09334330A0252|56 69|TGF-beta signal
P09334330A0252|238 244|tissues
P09334330A0252|4 12|mutations
P09334331A0910|99 106|receptor
P09334331A0910|79 86|EMA cells
P09334331A0910|110 113|Vein
P09334331A0910|46 64|EGF receptor DER/Egfr
P09334331A0910|18 28|possibility
P09334331A0910|3 9|results
P09334475A0327|0 7|PATIENTS
P09334475A0327|178 180|min
P09334475A0327|139 154|segment elevation
P09334475A0327|188 193|CK rise
P09334475A0327|265 276|thrombolysis
P09334475A0327|161 161|%
P09334475A0327|221 227|infarct
P09334475A0327|205 218|T wave inversion
P09334475A0327|125 133|chest pain
P09334475A0327|201 201|h
P09334475A0327|35 42|patients
P09334475A0327|11 17|METHODS
P09334475A0327|113 122|resolution
P09334475A0327|90 99|Infarction
P09334475A0327|259 259|h
P09334475A0327|235 237|EKG
P09334475A0327|57 72|National Registry
P09335267A0142|159 167|mutations
P09335267A0142|12 26|operon structure
P09335267A0142|182 187|genome
P09335267A0142|33 40|organism
P09335267A0142|53 59|methods
P09335267A0142|77 87|mutagenesis
P09335267A0142|135 139|genes
P09335267A0142|94 97|risk
P09335267A0142|116 122|effects
P09335298A0529|44 68|plasmid partitioning system
P09335298A0529|24 35|parCBA operon
P09335298A0529|70 71|M.
P09335298A1227|29 40|ColE1 cer site
P09335298A1227|100 106|plasmid
P09335298A1227|74 79|region
P09335298A1227|143 168|multimer resolution activity
P09335298A1227|178 183|parCBA
P09335298A1227|250 255|operon
P09335298A1227|48 57|RK2 plasmid
P09335298A1227|112 124|MC1061K strain
P09335298A1227|214 234|stabilization activity
P09335298A1227|15 23|insertion
P09335298A2129|87 93|strains
P09335298A2129|181 196|ParE toxin protein
P09335298A2129|169 175|strains
P09335298A2129|151 163|sensitivities
P09335298A2129|12 16|basis
P09335298A2129|31 41|differences
P09335298A2129|95 114|transformation assays
P09335298A2129|61 67|killing
P09335608T0000|62 69|splicing
P09335608T0000|96 114|chain gene transcript
P09335608T0000|34 42|sequences
P09335608T0000|85 90|myosin
P09335608T0000|15 22|elements
P09335619A0583|0 25|Nucleotide sequence analysis
P09335619A0583|90 99|maize races
P09335619A0583|211 218|sequence
P09335619A0583|243 252|orf221 gene
P09335619A0583|121 129|M1 plasmid
P09335619A0583|148 150|Zea
P09335619A0583|104 114|RU cytoplasm
P09335619A0583|174 177|atp9
P09335619A0583|57 65|R1 plasmid
P09335619A0583|191 194|gene
P09335619A0583|160 167|teosinte
P09335619A0583|40 51|similarities
P09335619A0583|140 145|source
P09335619A0583|230 235|region
P09335619A0583|28 28|R
P09336455A0000|126 134|radiation
P09336455A0000|75 83|RNR3 genes
P09336455A0000|99 108|yeast cells
P09336455A0000|30 37|recovery
P09336455A0000|89 96|exposure
P09336455A0000|123 124|UV
P09336455A0000|111 121|ultraviolet
P09336455A0000|67 71|GAL10
P09336455A0000|17 24|kinetics
P09336455A0000|40 52|mRNA synthesis
P09337861T0000|0 6|Cloning
P09337861T0000|44 51|C2 domain
P09337861T0000|71 81|sensitivity
P09337861T0000|15 38|phosphoinositide 3-kinase
P09337861T0000|87 105|inhibitor wortmannin
P09338414A0430|0 6|Ea value
P09338414A0430|65 72|pressure
P09338414A0430|25 29|ratio
P09338414A0430|81 92|stroke volume
P09338414A0430|94 107|thermodilution
P09338414A0430|74 77|ESAP
P09339900A0939|60 67|cyclin D2
P09339900A0939|131 135|c-Myc
P09339900A0939|20 35|promoter activity
P09339900A0939|122 124|AP2
P09339900A0939|174 181|activity
P09339900A0939|52 57|region
P09339900A0939|126 129|NF-Y
P09339900A0939|117 120|PEA3
P09339900A0939|10 17|analysis
P09339900A0939|111 115|C/EBP
P09339900A0939|185 194|expression
P09339900A0939|140 142|Sp1
P09339900A0939|84 89|region
P09339900A0939|197 204|cyclin D2
P09340641T0001|0 5|Effect
P09340641T0001|8 14|alcohol
P09340641T0001|33 45|nCPAP pressure
P09341139A0690|121 124|GRK2
P09341139A0690|51 63|beta2AR mutant
P09341139A0690|65 69|Y326A
P09341139A0690|11 25|resensitization
P09341139A0690|99 112|overexpression
P09341139A0690|127 139|beta-arrestin
P09341139A0690|2 9|contrast
P09341158A0167|99 103|beta1
P09341158A0167|148 158|recognition
P09341158A0167|65 69|types
P09341158A0167|38 40|mu2
P09341158A0167|72 82|interaction
P09341158A0167|3 14|medium chains
P09341158A0167|136 144|complexes
P09341158A0167|107 117|beta2 chains
P09341158A0167|22 30|complexes
P09341158A0167|84 91|assembly
P09341158A0167|32 34|mu1
P09341158A0167|175 188|sorting signals
P09341182A0605|61 73|BTB/POZ domain
P09341182A0605|78 81|PLZF
P09341182A0605|83 94|PLZF-BTB/POZ
P09341192T0000|42 56|3T3L1 adipocytes
P09341192T0000|22 39|GLUT4 translocation
P09341192T0000|7 11|shock
P09341192T0000|65 85|tyrosine kinase pathway
P09341193A0362|87 90|TRE1
P09341193A0362|20 22|Sp3
P09341193A0362|103 119|Tax responsiveness
P09341193A0362|16 18|Sp1
P09341193A0362|27 36|NGFI-A/Egr
P09341193A0362|58 77|transcription factors
P09343208A1405|120 131|organization
P09343208A1405|54 63|copy number
P09343208A1405|14 20|segment
P09343208A1405|168 176|functions
P09343208A1405|80 87|segment W
P09343208A1405|183 187|virus
P09343208A1405|66 70|genes
P09343208A1405|236 240|wasps
P09343208A1405|212 222|association
P09343208A1405|134 137|PDVs
P09343210A1112|44 57|VCAM-1 promoter
P09343210A1112|12 19|deletion
P09343210A1112|271 280|expression
P09343210A1112|169 182|NF-kappaB sites
P09343210A1112|287 302|adhesion molecule
P09343210A1112|71 112|chloramphenicol acetyltransferase constructs
P09343210A1112|23 38|mutation analyses
P09343210A1112|208 225|VCAM-1 gene promoter
P09343210A1112|149 162|VCAM-1 promoter
P09343210A1112|125 127|Tax
P09343210A1112|192 193|bp
P09343222A0415|56 56|%
P09343222A0415|9 34|NIH/Swiss mouse CCR5 proteins
P09343222A0415|76 82|protein
P09343222A0415|48 48|%
P09343222A0415|3 5|AGM
P09343398A1193|0 11|Processivity
P09343398A1193|37 46|holoenzyme
P09343398A1193|84 85|dA
P09343398A1193|153 161|structure
P09343398A1193|79 82|poly
P09343398A1193|94 95|dT
P09343398A1193|132 139|template
P09343398A1193|57 63|pcna-79
P09343398A1193|14 25|DNA synthesis
P09343426A0456|0 27|Alanine substitution mutations
P09343426A0456|78 80|Zta
P09343426A0456|69 75|ability
P09343426A0456|95 104|D-A complex
P09343426A0456|33 51|Zta activation domain
P09343432A0209|25 38|homology domain
P09343432A0209|129 136|C termini
P09343432A0209|89 97|SPM domain
P09343432A0209|9 18|ph proteins
P09343432A0209|59 64|length
P09343432A0209|45 53|% identity
P09343432A0209|3 5|Scm
P09343432A0209|69 78|amino acids
P09343433A0000|28 32|genes
P09343433A0000|62 65|RNAP
P09343433A0000|121 134|yeast telomeres
P09343433A0000|89 105|effect variegation
P09343433A0000|46 58|RNA polymerase
P09343433A0360|86 89|ADE2
P09343433A0360|26 34|silencing
P09343433A0360|9 18|rad6-delta
P09343433A0360|56 59|RNAP
P09343433A0360|74 82|genes URA3
P09343982A0890|14 33|detrusor contractions
P09343982A0890|46 50|hours
P09343982A0890|3 11|amplitude
P09343982A0890|93 100|controls
P09343982A0890|70 79|difference
P09344650A0967|14 32|transmembrane domain
P09344650A0967|45 52|Casr-rs3
P09344650A0967|70 77|Casr-rs1
P09344650A0967|58 58|%
P09344650A0967|34 41|Casr-rs2
P09345037A0886|48 65|trans-factor GATA-1
P09345037A0886|78 104|progenitor cell proliferation
P09345037A0886|9 13|roles
P09345495A0000|0 19|PET activation studies
P09345495A0000|50 62|brain function
P09346238T0000|16 24|receptors
P09346238T0000|50 59|substrates
P09346238T0000|65 90|SCF ubiquitin-ligase complex
P09346238T0000|5 12|proteins
P09346621A1181|85 92|patients
P09346621A1181|5 11|context
P09346621A1181|104 110|failure
P09346621A1181|123 125|OSF
P09346621A1181|60 62|ELT
P09346621A1181|14 35|liver allograft shortage
P09346621A1181|131 138|APACHE II
P09346621A1181|40 46|results
P09346925A0660|15 18|Grb2
P09346925A0660|132 135|HPK1
P09346925A0660|149 157|Cos1 cells
P09346925A0660|64 71|HPK1 tail
P09346925A0660|126 129|Grb2
P09346925A0660|3 12|SH3 domains
P09346925A0660|117 123|binding
P09346925A0660|53 58|motifs
P09346935A0459|204 207|form
P09346935A0459|70 74|ZNF74
P09346935A0459|24 51|coimmunoprecipitation studies
P09346935A0459|91 106|zinc finger domain
P09346935A0459|13 20|analysis
P09346935A0459|150 162|RNA polymerase
P09346935A0459|141 147|subunit
P09346935A0459|166 171|pol IIo
P09346935A0927|205 218|mRNA processing
P09346935A0927|153 156|form
P09346935A0927|228 231|role
P09346935A0927|80 97|RNA binding activity
P09346935A0927|127 137|interaction
P09346935A0927|280 292|RNA processing
P09346935A0927|145 150|pol IIo
P09346935A0927|162 174|RNA polymerase
P09346935A0927|250 277|KRAB multifinger protein family
P09346935A0927|51 75|pre-mRNA maturating factors
P09346935A0927|5 24|ZNF74 sublocalization
P09346935A0927|239 244|member
P09346935A0927|34 40|domains
P09346938A1680|0 30|Ki-ras4BVal-12 transfectant cells
P09346938A1680|127 150|cathepsin B mRNA expression
P09346938A1680|54 66|protein levels
P09346938A1680|81 106|cysteine protease cathepsin B
P09346953A0000|30 55|heparan sulfate proteoglycan
P09346953A0000|129 136|activity
P09346953A0000|11 14|rate
P09346953A0000|65 74|generation
P09346953A0000|57 63|HSPGact
P09346953A0000|138 160|HSact conversion activity
P09346953A0000|261 267|Shworak
P09346953A0000|92 96|level
P09346953A0000|254 258|3-OST
P09346953A0000|205 252|heparan sulfate D-glucosaminyl 3-O-sulfotransferase
P09346953A0000|269 270|N.
P09348226A0852|42 64|tyrosine phosphorylation
P09348226A0852|78 88|association
P09348226A0852|14 16|EGF
P09348226A0852|93 98|Crk-II
P09348226A0852|24 30|insulin
P09348226A0852|67 71|c-cbl
P09348931T0000|2 4|end
P09348931T0000|10 16|lottery
P09349501A0196|98 106|MLL-LTG19
P09349501A0196|35 41|portion
P09349501A0196|176 179|role
P09349501A0196|87 94|MLL-LTG9
P09349501A0196|65 75|MLL products
P09349501A0196|122 127|nuclei
P09349501A0196|182 195|leukemogenesis
P09349967A0653|3 9|results
P09349967A0653|24 30|pattern
P09349967A0653|33 43|blood supply
P09349967A0653|89 100|lamellar bone
P09349967A0653|69 80|organisation
P09351242A0719|148 160|cycloheximide
P09351242A0719|11 33|AtP5CS1 mRNA accumulation
P09351242A0719|48 56|seedlings
P09351242A0719|115 127|ABA signalling
P09351242A0719|211 231|aba1 Arabidopsis mutant
P09351242A0719|96 103|response
P09351242A0719|191 205|ABA biosynthesis
P09351242A0719|179 188|deficiency
P09351242A0719|0 8|Induction
P09351823A0414|73 76|eggs
P09351823A0414|110 120|development
P09351823A0414|39 48|maturation
P09351823A0414|17 29|MAPK functions
P09352016A1110|26 27|ml
P09352016A1110|23 24|pg
P09352016A1110|6 17|AF G-CSF level
P09352016A1110|45 53|predictor
P09352016A1110|56 58|CAM
P09352127A0953|44 62|CA III concentrations
P09352127A0953|9 19|correlation
P09352127A0953|64 65|rs
P09352127A0953|27 40|serum myoglobin
P09352127A0953|73 73|P
P09352127A0953|106 113|patients
P09352127A0953|130 136|failure
P09353247A0922|60 67|p65cdc18
P09353247A0922|97 114|cyclin/CDK activity
P09353247A0922|133 148|over-replication
P09353247A0922|122 130|inhibitor
P09353247A0922|15 39|over-replication phenotype
P09353255A0159|103 114|pore proteins
P09353255A0159|81 100|FG-nucleoporin family
P09353255A0159|40 52|pore complexes
P09353255A0159|0 4|Rip1p
P09353296A0510|27 40|amino acid level
P09353296A0510|106 116|moaC product
P09353296A0510|158 165|cistrons
P09353296A0510|61 75|moaA gene product
P09353296A0510|3 12|CNXA domain
P09353296A0510|132 139|products
P09353296A0510|82 85|CNXC
P09353304A0732|58 62|Tiam1
P09353304A0732|22 28|regions
P09353304A0732|36 55|membrane localization
P09353304A0732|66 81|membrane ruffling
P09353304A0732|0 8|Deletions
P09353328A0736|33 38|domain
P09353328A0736|66 72|zippers
P09353328A0736|112 119|proteins
P09353328A0736|95 102|homology
P09353328A0736|18 23|kinase
P09353343A0919|0 12|RNA polymerase
P09353343A0919|116 129|hnRNP A1 binding
P09353343A0919|50 61|AUBP activity
P09353343A0919|96 102|hnRNP A1
P09353343A0919|37 43|binding
P09353343A0919|66 69|poly
P09353343A0919|15 24|inhibition
P09353343A0919|71 71|U
P09353343A0919|74 82|Sepharose
P09353343T0000|0 9|Modulation
P09353343T0000|61 79|ribonucleoprotein A1
P09353343T0000|12 38|AUUUA response element binding
P09353343T0000|87 98|T lymphocytes
P09354349A0338|102 107|Giemsa
P09354349A0338|12 17|slides
P09354349A0338|116 129|Warthin-Starry
P09354349A0338|131 132|WS
P09354349A0338|109 110|MG
P09354349A0338|23 28|biopsy
P09354349A0338|211 218|DAKO B471
P09354349A0338|159 164|method
P09354349A0338|166 168|IMM
P09354349A0338|35 41|patient
P09354349A0338|193 209|H. pylori antiserum
P09354644A0124|91 95|IGnT6
P09354644A0124|64 89|beta1,6-GlcNAc transferases
P09354644A0124|105 107|Gal
P09354644A0124|5 16|biosynthesis
P09354644A0124|97 102|GlcNAc
P09354644A0124|34 43|precursors
P09354676A1714|42 44|q32
P09354676A1714|135 140|target
P09354676A1714|192 193|MM
P09354676A1714|177 189|tumorigenesis
P09354676A1714|98 99|MM
P09354676A1714|83 95|translocation
P09354676A1714|5 12|findings
P09354676A1714|36 40|p16.3
P09354676A1714|28 28|t
P09354676A1714|147 157|abnormality
P09354676A1714|118 126|FGFR3 gene
P09354684A1158|2 9|addition
P09354684A1158|24 30|Sp1 site
P09354684A1158|11 18|mutation
P09354684A1158|55 70|promoter activity
P09354757A1444|0 16|Amino acid residues
P09354757A1444|48 51|loop
P09354757A1444|62 67|His539
P09354757A1444|34 39|alpha B
P09354757A1444|100 111|primer strand
P09354757A1444|73 84|RNase H domain
P09354757A1444|19 22|beta
P09354757A1444|117 121|dsDNA
P09354757A1444|26 31|alpha A
P09356645A0672|57 65|procedure
P09356645A0672|26 32|sarcoma
P09356645A0672|76 91|nerve enlargement
P09356645A0672|14 20|patient
P09358045A0000|72 79|receptor
P09358045A0000|7 24|length cDNA sequence
P09358045A0000|63 70|TGF-beta
P09358045A0000|45 61|growth factor-beta
P09358045A0000|119 139|nematode Brugia pahangi
P09358045A0000|28 31|Type
P09358055A0590|88 90|LTR
P09358055A0590|93 97|mouse
P09358055A0590|113 123|A-particles
P09358055A0590|55 69|promoter element
P09358055A0590|4 11|sequence
P09358055A0590|21 28|homology
P09358055A0590|71 74|Enh2
P09358069T0000|30 39|expression
P09358069T0000|77 81|cells
P09358069T0000|62 64|EPO
P09358069T0000|47 60|erythropoietin
P09358069T0000|0 16|Codon optimization
P09358837T0000|42 50|treatment
P09358837T0000|11 14|rise
P09358837T0000|24 36|albumin levels
P09358837T0000|62 73|hypertension
P09359844A0674|43 52|adipocytes
P09359844A0674|10 23|HSL transcripts
P09359844A0674|2 2|%
P09359887A1168|88 93|region
P09359887A1168|64 66|NPC
P09359887A1168|17 20|data
P09359887A1168|105 113|sequences
P09359887A1168|32 44|Rat7p/Nup159p
P09360422A0135|237 246|volunteers
P09360422A0135|36 49|arteriopathies
P09360422A0135|12 19|patients
P09360422A0135|97 98|TM
P09360422A0135|68 79|plasma levels
P09360422A0135|210 215|values
P09360422A0135|101 119|betathromboglobulin
P09360422A0135|130 136|D-dimer
P09360422A0135|3 7|group
P09360422A0135|82 95|thrombomodulin
P09360422A0135|138 139|DD
P09360422A0135|60 64|limbs
P09360422A0135|121 127|beta-TG
P09360422A0135|175 179|pAI-1
P09360422A0135|144 173|plasminogen activator-inhibitor
P09360953A1057|14 19|Ile244
P09360953A1057|90 96|portion
P09360953A1057|38 40|end
P09360953A1057|5 12|residues
P09360953A1057|137 139|Ile
P09360953A1057|112 115|loop
P09360953A1057|66 71|Tyr318
P09360953A1057|145 157|PTH-1 receptor
P09360953A1057|56 60|helix
P09360953A1057|131 133|Leu
P09360956A0840|99 105|binding
P09360956A0840|108 112|c-Raf
P09360956A0840|47 50|zeta
P09360956A0840|24 38|phosphorylation
P09360956A0840|56 67|CKIalpha site
P09360956A0840|145 162|signal transduction
P09360956A0840|69 75|Thr-233
P09360993T0000|0 20|Mouse mast cell protease
P09360993T0000|110 118|mast cells
P09360993T0000|60 74|serine proteases
P09360993T0000|52 57|family
P09360993T0000|29 34|member
P09360993T0000|40 49|chromosome
P09361007A0922|1 5|DNase
P09361007A0922|22 25|site
P09361007A0922|56 73|pair enhancer region
P09362105X0422|29 31|PVR
P09362105X0422|123 125|HPV
P09362105X0422|106 121|vasoconstriction
P09362105X0422|41 47|% O2-PVR
P09362105X0422|18 27|resistance
P09362105X0422|71 71|%
P09362105X0422|56 62|% O2/PVR
P09362473A1540|234 246|twist activity
P09362473A1540|12 18|results
P09362473A1540|271 291|twist expression domain
P09362473A1540|129 134|inputs
P09362473A1540|171 191|repressor binding sites
P09362473A1540|49 53|array
P09362473A1540|64 79|enhancer elements
P09362473A1540|257 261|areas
P09362473A1540|159 167|activator
P09362473A1540|212 219|enhancer
P09362473A1540|27 32|tinman
P09362480A0452|85 88|core
P09362480A0452|38 46|sequences
P09362480A0452|49 57|TB domains
P09362480A0452|9 23|cysteine triplet
P09362480A0452|95 104|C-terminus
P09362499A0000|117 124|enhancer
P09362499A0000|67 79|DNA invertases
P09362499A0000|3 12|Fis protein
P09362499A0000|35 46|DNA inversion
P09362499A0000|59 64|family
P09363759A0000|0 18|Protein phosphatases
P09363759A0000|66 74|cell cycle
P09363759A0000|32 35|role
P09363759A0000|78 95|signal transduction
P09363759A0000|41 50|regulation
P09364211A0319|68 74|binding
P09364211A0319|22 43|transcription factor E2F
P09364211A0319|61 63|DNA
P09364211A0319|3 6|cell
P09364440A2206|29 37|structure
P09364440A2206|43 57|FSH receptor gene
P09364440A2206|102 110|effectors
P09364440A2206|83 90|coupling
P09364440A2206|67 72|motifs
P09364440A2206|3 7|study
P09364750T0000|15 24|regulation
P09364750T0000|27 31|SUP35
P09364750T0000|35 39|SUP45
P09365201A2018|71 79|mechanism
P09365201A2018|108 119|breast cancer
P09365201A2018|123 126|ASCs
P09365201A2018|22 26|basis
P09365201A2018|5 11|studies
P09365201A2018|82 100|aromatase expression
P09365201A2018|40 55|characterization
P09365272T0000|0 6|Xenopus
P09365272T0000|36 47|interactions
P09365272T0000|77 94|Xenopus egg extracts
P09365272T0000|67 74|assembly
P09365272T0000|51 57|effects
P09365272T0000|18 24|protein
P09365431A0314|29 43|benzodiazepines
P09365431A0314|50 91|acetylcholinesterase inhibitor physostigmine
P09365431A0314|16 26|combination
P09366456A0234|0 6|METHODS
P09366456A0234|87 99|body mass index
P09366456A0234|50 59|anesthesia
P09366456A0234|75 81|persons
P09366456A0234|120 124|group
P09366456A0234|147 158|body mas index
P09366456A0234|107 108|kg
P09366456A0234|135 141|persons
P09366456A0234|63 67|group
P09366456A0234|13 27|muscle paralysis
P09366456A0234|83 83|n
P09366456A0234|143 143|n
P09366456A0234|166 167|kg
P09366517A0835|0 2|PKA
P09366517A0835|32 38|Ser-393
P09366517A0835|80 94|phosphorylation
P09366517A0835|22 28|Ser-365
P09366517A0835|128 130|WT1
P09366517A0835|17 19|WT1
P09366517A0835|67 71|sites
P09366517A0835|118 125|activity
P09366517A1828|41 48|function
P09366517A1828|26 33|evidence
P09366517A1828|73 87|phosphorylation
P09366517A1828|51 53|WT1
P09366517A1828|3 10|findings
P09366628T0000|0 1|Re
P09366628T0000|16 24|direction
P09366628T0000|53 59|studies
P09366628T0000|27 35|causality
P09367288A0115|145 155|adaptations
P09367288A0115|169 174|tendon
P09367288A0115|34 41|decrease
P09367288A0115|7 9|aim
P09367288A0115|90 103|immobilisation
P09367288A0115|57 70|unit rest length
P09367288A0115|161 166|muscle
P09367288A0115|116 123|position
P09367392A0567|114 125|accumulation
P09367392A0567|62 64|end
P09367392A0567|25 32|sequence
P09367392A0567|3 10|presence
P09367392A0567|35 45|nucleotides
P09367392A0567|149 154|levels
P09367392A0567|79 97|template recognition
P09367392A0567|128 131|RNA3
P09367392A0567|67 70|RNA3
P09367392A0567|100 103|RdRp
P09367426A1354|27 28|hh
P09367426A1354|42 49|polarity
P09367426A1354|21 24|role
P09367426A1354|134 145|polarization
P09367426A1354|67 82|compartment cells
P09367426A1354|97 110|interpretation
P09367676A0275|0 23|Restriction enzyme mapping
P09367676A0275|39 59|DNA sequencing analysis
P09367676A0275|169 171|DNA
P09367676A0275|107 111|exons
P09367676A0275|25 34|subcloning
P09367676A0275|129 139|mouse TS mRNA
P09367676A0275|160 161|kb
P09367676A0275|73 83|phage lambda
P09367676A0275|87 94|P1 clones
P09367676A1115|0 19|Transfection analyses
P09367676A1115|36 45|expression
P09367676A1115|99 106|sequence
P09367676A1115|48 53|Tbxas1
P09367676A1115|135 142|elements
P09368006A1332|86 94|cell cycle
P09368006A1332|68 78|interaction
P09368006A1332|105 111|protein
P09368006A1332|113 117|E2F-1
P09368006A1332|32 48|NF-kappaB activity
P09368006A1332|16 20|study
P09368006A1332|3 9|results
P09368014A0740|3 17|lysozyme FEF site
P09368014A0740|36 37|PU
P09368026A0000|0 10|Osteocalcin
P09368026A0000|93 106|mineralization
P09368026A0000|12 13|OC
P09368026A0000|39 45|protein
P09368026A0000|71 82|odontoblasts
P09368026A0000|18 23|matrix
P09368026A0000|57 67|osteoblasts
P09368026A0435|70 87|luciferase reporter
P09368026A0435|114 132|MC3T3-E1 osteoblasts
P09368026A0435|102 111|calcitriol
P09368026A0435|49 68|OC promoter activation
P09368026A0435|24 30|effects
P09368026A0435|91 98|FGF2/FSK
P09368026A0435|33 46|Msx2 expression
P09368026A0435|6 10|study
P09368057A1083|16 23|proteins
P09368057A1083|152 161|SRF binding
P09368057A1083|140 149|inhibition
P09368057A1083|97 103|element
P09368057A1083|56 72|repressor activity
P09368057A1083|41 51|SRF activity
P09368058A0969|77 90|phosphopeptide
P09368058A0969|150 152|CAK
P09368058A0969|184 187|site
P09368058A0969|29 52|phosphopeptide comigrates
P09368097T0000|3 5|pen
P09368100A1354|42 46|exons
P09368100A1354|24 27|gene
P09368100A1354|3 13|mHIF-1 alpha
P09368190A1053|58 61|EMSA
P09368190A1053|64 80|DNA binding pattern
P09368190A1053|36 43|sequence
P09368190A1053|110 117|exposure
P09368190A1053|178 186|IFN-alpha
P09368190A1053|190 198|IFN-gamma
P09368190A1053|120 128|IFN-gamma
P09368190A1053|159 169|stimulation
P09368419A0000|101 119|protein biosynthesis
P09368419A0000|136 149|gene expression
P09368419A0000|17 25|induction
P09368419A0000|51 54|gene
P09368419A0000|81 84|acid
P09368419A0000|2 12|Arabidopsis
P09368419A0000|56 59|rd22
P09368419A0000|86 88|ABA
P09368419A0628|1 4|cDNA
P09368419A0628|104 108|probe
P09368419A0628|25 41|DNA binding protein
P09368419A0628|95 100|region
P09368419A0628|123 129|rd22BP1
P09368419A0628|55 80|DNA-ligand binding screening
P09368760A0665|84 93|regulation
P09368760A0665|127 141|spermatogenesis
P09368760A0665|115 123|oogenesis
P09368760A0665|96 113|sex differentiation
P09368760A0665|5 8|PDK1
P09368760A0665|26 55|Drosophila protein kinase DSTPK61
P09369450A1358|175 186|interactions
P09369450A1358|197 216|transcription factors
P09369450A1358|115 123|HNF-1 site
P09369450A1358|71 86|promoter activity
P09369450A1358|19 25|effects
P09369450A1358|242 263|transcription machinery
P09369450A1358|267 292|steroid receptor coactivator
P09369450A1358|130 132|GRE
P09369450A1358|28 36|HNF-1beta
P09369450A1358|43 44|GR
P09369451A0693|159 164|region
P09369451A0693|106 108|MEF
P09369451A0693|116 123|sequence
P09369451A0693|84 104|myocyte enhancer factor
P09369451A0693|33 36|AP-1
P09369451A0693|183 192|OP-1 effect
P09369451A0693|10 17|analysis
P09369451A0693|41 48|sequence
P09369451A0693|135 147|TTAAAAATAAAAA
P09369451A0693|60 69|TGAATCATCA
P09369453A0273|27 37|Bcl-2 family
P09369453A0273|39 41|BAD
P09369453A0273|182 189|envelope
P09369453A0273|110 128|transmembrane domain
P09369453A0273|65 77|death promoter
P09369453A0273|81 93|death enhancer
P09369453A0273|164 171|membrane
P09369453A0273|43 52|Bcl-xL/Bcl
P09369453A0273|15 21|members
P09369482A0690|75 78|HNF4
P09369482A0690|97 100|site
P09369482A0690|23 42|cotransfection assays
P09369482A0690|118 137|G6Pase gene expression
P09369482A0690|59 67|HNF1alpha
P09369482A0690|0 19|Electromobility shift
P09370276A0781|38 53|amino acid protein
P09370276A0781|24 25|bp
P09370276A0781|6 17|reading frame
P09370307A0093|96 112|barley gibberellin
P09370307A0093|123 129|element
P09370307A0093|150 167|DNA binding proteins
P09370307A0093|48 56|regulator
P09370307A0093|81 90|similarity
P09370307A0093|67 73|tissues
P09370307A0093|13 21|AACA motif
P09371431A1172|83 100|thiCOGE gene cluster
P09371431A1172|64 77|promoter region
P09371431A1172|44 58|Tn5mob insertion
P09371431A1172|16 27|R. etli mutant
P09371431A1172|0 11|Strain CFN037
P09371431T0000|0 9|Expression
P09371431T0000|69 87|terminal oxidase cbb3
P09371431T0000|90 102|Rhizobium etli
P09371431T0000|48 57|production
P09371431T0000|37 43|thiCOGE
P09371431T0000|31 35|genes
P09371455A0000|40 51|lipase operon
P09371455A0000|90 104|metalloprotease
P09371455A0000|25 30|region
P09371455A0000|107 122|Vibrio cholerae O1
P09371564A0713|15 20|amount
P09371564A0713|122 126|virus
P09371564A0713|23 26|tRNA
P09371564A0713|67 73|viruses
P09371564A0713|55 57|RNA
P09371564A0713|28 31|3Lys
P09371566A1384|128 134|protein
P09371566A1384|75 93|protein preparations
P09371566A1384|37 44|extracts
P09371566A1384|4 10|protein
P09371566A1384|48 59|S100 extracts
P09371566A1384|26 29|HeLa
P09371596T0000|61 75|hepatitis B virus
P09371596T0000|12 21|regulation
P09371596T0000|27 31|pre-C
P09371596T0000|45 53|promoters
P09371596T0000|78 84|members
P09371596T0000|97 115|receptor superfamily
P09371612A1964|0 3|Acad
P09371622A0779|89 108|lac operator sequences
P09371622A0779|50 62|transcription
P09371622A0779|18 28|IE1 peptides
P09371622A0779|73 80|promoter
P09371622A0779|0 7|Chimeras
P09371626A1345|60 67|deletion
P09371626A1345|202 210|synthesis
P09371626A1345|126 136|replication
P09371626A1345|114 117|role
P09371626A1345|12 26|replicase assays
P09371626A1345|121 123|VP2
P09371626A1345|159 165|ability
P09371626A1345|150 156|protein
P09371626A1345|175 186|mRNA template
P09371626A1345|84 89|domain
P09371626A1345|46 48|VP2
P09371626A1345|3 9|results
P09371657A0165|61 64|K79A
P09371657A0165|110 132|triphosphatase component
P09371657A0165|53 53|A
P09371657A0165|24 46|alanine cluster mutations
P09371657A0165|68 78|E192A-E194A
P09371657A0165|55 58|R77A
P09371657A0165|48 50|R77
P09371698A1254|0 11|Transfection
P09371698A1254|38 47|constructs
P09371698A1254|122 139|bp promoter fragment
P09371698A1254|153 166|pseudo-TATA box
P09371698A1254|22 33|SK-N-MC cells
P09371698A1254|78 86|fragments
P09371698A1254|192 196|sites
P09371698A1254|99 108|definition
P09371698A1254|14 18|HepG2
P09371731A0627|29 38|homologues
P09371731A0627|4 10|inserts
P09371731A0627|41 57|eIF-2alpha kinases
P09372287A0296|118 121|MVST
P09372287A0296|152 158|pathway
P09372287A0296|112 116|tract
P09372287A0296|77 81|tract
P09372287A0296|128 136|C1 segment
P09372287A0296|83 86|LVST
P09372287A0296|161 165|axons
P09372287A0296|14 23|electrodes
P09372451T0000|0 7|Epitopes
P09372451T0000|92 103|integrin beta
P09372451T0000|105 111|subunit
P09372451T0000|81 86|domain
P09372451T0000|39 48|antibodies
P09372908A1068|103 116|gene repression
P09372908A1068|168 171|PREs
P09372908A1068|139 153|Polycomb protein
P09372908A1068|24 31|Sex Combs
P09372908A1068|128 136|inclusion
P09372908A1068|159 165|complex
P09372908A1068|185 193|silencing
P09372908A1068|75 83|mechanism
P09372924A0758|158 168|interaction
P09372924A0758|82 89|proteins
P09372924A0758|138 154|DNA repair reaction
P09372924A0758|48 56|NER system
P09372924A0758|107 117|involvement
P09372924A0758|16 29|rhHR23 proteins
P09372924A0758|173 175|XPC
P09372924A0758|120 132|hHR23 proteins
P09372937T0000|14 45|information regulator Sir4p anchors
P09372937T0000|49 66|partitions plasmids
P09372937T0000|3 7|yeast
P09372950A1283|119 128|processing
P09372950A1283|69 77|sequences
P09372950A1283|84 88|sides
P09372950A1283|51 59|structure
P09372950A1283|5 11|results
P09372950A1283|136 140|U2 RNA
P09372950A1283|100 111|cleavage site
P09372960A0456|0 15|Polysome analyses
P09372960A0456|96 101|number
P09372960A0456|104 106|40S
P09372960A0456|40 51|fal1-1 mutant
P09372960A0456|70 75|strain
P09372960A0456|83 90|decrease
P09372960A0456|116 123|subunits
P09372968A0532|0 15|Sequence analysis
P09372968A0532|110 115|dynein
P09372968A0532|89 95|homolog
P09372968A0532|127 133|protein
P09372968A0532|49 53|Dlc-1
P09372968A0532|37 46|cDNA clones
P09372968A0532|56 63|sequence
P09372968A0996|14 17|HeLa
P09372968A0996|112 116|Dlc-1
P09372968A0996|24 28|cells
P09372968A0996|55 65|kappaB alpha
P09373140A0000|28 35|enhancer
P09373140A0000|3 17|mouse M-lysozyme
P09373140A0000|83 96|gene regulation
P09373140A0000|75 80|levels
P09373155T0000|0 13|Identification
P09373155T0000|27 36|chain genes
P09373155T0000|103 112|dynein gene
P09373155T0000|56 66|mouse testis
P09373155T0000|79 90|localization
P09373155T0000|16 21|dynein
P09373651A0255|89 103|hydrogen cyanide
P09373651A0255|42 51|processing
P09373651A0255|6 12|cassava
P09373651A0255|68 85|acetone cyanohydrin
P09373651A0255|31 40|glycosides
P09374082A0504|239 250|inflammation
P09374082A0504|288 293|asthma
P09374082A0504|22 33|effect states
P09374082A0504|82 98|hydrolysis product
P09374082A0504|182 193|thromboxanes
P09374082A0504|11 19|mechanism
P09374082A0504|66 69|MEHP
P09374082A0504|225 228|risk
P09374082A0504|43 54|2-ethylhexyl
P09374082A0504|101 104|DEHP
P09374082A0504|138 139|PG
P09374082A0504|256 262|airways
P09374082A0504|157 164|betaPGF2
P09374082A0504|141 143|PGD
P09374082A0504|272 285|characteristic
P09374082A0504|199 203|lungs
P09374082A0504|169 177|PGF2alpha
P09374082A0504|56 64|phthalate
P09374082A0504|123 136|prostaglandins
P09374082A0504|148 153|9alpha
P09374541A0277|9 27|protein binding sites
P09374541T0000|86 105|cell cycle progression
P09374541T0000|24 46|E2F recognition sequences
P09374541T0000|12 21|protection
P09374541T0000|57 79|thymidine kinase promoter
P09376325A0167|0 9|Comparison
P09376325A0167|19 26|sequence
P09376325A0167|39 45|ph locus
P09376325A0167|98 115|transcription units
P09376626A0737|29 30|T4
P09376626A0737|55 60|group A
P09376626A0737|37 37|h
P09376626A0737|46 51|group C
P09376626A0737|69 74|group B
P09376626A0737|21 26|levels
P09376626A0737|34 35|T3
P09376626A0737|79 91|h postexposure
P09376626A0737|65 65|h
P09376626A0737|43 43|h
P09376626A0737|0 8|Radiation
P09376782A0328|57 71|hepatitis C virus
P09376782A0328|35 37|MMT
P09376782A0328|73 75|HCV
P09376782A0328|17 26|experience
P09376782A0328|77 85|infection
P09376782A0328|45 52|practice
P09377355A0362|29 32|data
P09377355A0362|148 152|tools
P09377355A0362|83 91|disorders
P09377355A0362|106 116|impairement
P09377355A0362|127 129|use
P09377355A0362|40 44|study
P09377355A0362|3 8|author
P09377355A0362|59 66|features
P09377374A0000|100 109|narcomania
P09377374A0000|88 97|background
P09377374A0000|12 27|characterization
P09377374A0000|69 77|VH B course
P09377374A0000|6 10|paper
P09377374A0000|59 66|features
P09379301A2036|70 79|proglottis
P09379301A2036|34 40|microns
P09379301A2036|61 66|testes
P09379301A2036|3 9|microns
P09379301A2036|44 50|A. wedli
P09379301A2036|13 27|A. microcephalum
P09380504A1255|140 147|addition
P09380504A1255|79 80|kb
P09380504A1255|134 134|h
P09380504A1255|150 162|actinomycin D.
P09380504A1255|100 121|cycloheximide treatment
P09380504A1255|32 42|transcripts
P09380504A1255|3 11|ZnF20 cDNA
P09380504A1255|46 66|thyroid cancer cell line
P09380507A0514|0 23|Glutathione S-transferase
P09380507A0514|36 55|GST-DP fusion proteins
P09380507A0514|25 27|GST
P09380507A0514|108 137|DNA polymerase alpha gene promoter
P09380507A0514|95 102|E2F sites
P09380507A0514|30 32|E2F
P09380697T0000|31 39|sequences
P09380697T0000|3 8|sterol
P09380697T0000|47 59|up-regulation
P09380697T0000|124 134|cholesterol
P09380697T0000|62 86|caveolin gene transcription
P09380697T0000|89 96|response
P09380697T0000|102 119|density lipoprotein
P09380707A0714|21 29|LAZ3/BCL6
P09380707A0714|69 76|proteins
P09380707A0714|106 109|dots
P09380707A0714|38 41|SMRT
P09381261A0970|0 10|CONCLUSIONS
P09381261A0970|40 46|mothers
P09381261A0970|102 105|ones
P09381261A0970|64 67|area
P09381261A0970|50 57|newborns
P09381261A0970|28 36|EPO levels
P09381950A0209|0 8|Ischaemia
P09381950A0209|25 32|flow rate
P09381950A0209|38 44|mL min-1
P09381950A0209|50 52|min
P09381950A0209|80 90|reperfusion
P09382498A0618|68 71|area
P09382498A0618|9 12|MCTs
P09382498A0618|118 121|size
P09382498A0618|23 31|electrode
P09382498A0618|169 173|tumor
P09382498A0618|114 115|cm
P09382498A0618|103 111|electrode
P09382498A0618|34 35|cm
P09382498A0618|160 163|area
P09382498A0618|91 94|MCTs
P09382498A0618|77 81|tumor
P09382498A0618|38 41|size
P09382850A0000|46 56|progression
P09382850A0000|11 28|Checkpoint pathways
P09382850A0000|62 66|event
P09382850A0000|69 78|DNA lesions
P09382850A0000|0 9|BACKGROUND
P09382886A1061|116 118|SBM
P09382886A1061|122 124|p53
P09382886A1061|102 108|matings
P09382886A1061|52 54|PKD
P09382886A1061|76 78|p53
P09382886A1061|41 49|apoptosis
P09382886A1061|6 10|proof
P09382886A1061|130 133|mice
P09382924A0131|126 131|PSMB10
P09382924A0131|222 226|PSMB6
P09382924A0131|52 67|interferon-gamma
P09382924A0131|113 116|LMP2
P09382924A0131|155 167|20S proteasome
P09382924A0131|237 241|PSMB7
P09382924A0131|11 18|evidence
P09382924A0131|118 121|LMP7
P09382924A0131|94 101|subunits
P09382924A0131|228 232|PSMB5
P09382924A0131|37 47|stimulation
P09382924A0131|69 77|IFN-gamma
P09382924A0131|204 211|subunits
P09383156A0691|8 28|RNase E cleavage product
P09383156A0691|91 96|PNPase
P09383156A0691|63 89|polynucleotide phosphorylase
P09383156A0691|37 42|pSok-6
P09383188A0654|45 59|ARG box consensus
P09383188A0654|35 39|match
P09383188A0654|72 75|site
P09383188A0654|4 13|difference
P09383188A0654|67 70|rocD
P09383188A0654|65 65|O
P09385169T0000|3 6|AONE
P09385169T0000|24 45|productivity indicators
P09385169T0000|9 15|experts
P09386074A0694|29 41|LV dysfunction
P09386074A0694|52 69|LV ejection fraction
P09386074A0694|78 78|%
P09386074A0694|3 6|pigs
P09387333T0001|3 10|progress
P09387333T0001|26 33|research
P09387333T0001|51 57|nucleus
P09387999A1053|57 70|hair cell losses
P09387999A1053|103 106|ears
P09387999A1053|3 12|amplitudes
P09387999A1053|43 48|extent
P09387999A1053|15 19|DPOAE
P09388198A1396|72 74|ERK
P09388198A1396|180 183|rhoB
P09388198A1396|108 116|induction
P09388198A1396|79 90|p38 MAP kinase
P09388198A1396|30 54|signal transduction pathway
P09388198A1396|119 122|rhoB
P09388198A1396|164 177|autoregulation
P09388198A1396|134 139|stress
P09388198A1396|3 6|data
P09388198A1396|68 70|JNK
P09388198A1396|14 21|evidence
P09388199A0948|71 83|ligand binding
P09388199A0948|20 26|domains
P09388199A0948|151 157|regions
P09388199A0948|135 138|LexA
P09388199A0948|29 32|FadR
P09388199A0948|4 9|effort
P09388199A0948|55 66|dimerization
P09388199A0948|93 106|protein fusions
P09388199A0948|160 163|FadR
P09388199A0948|44 53|DNA binding
P09388199A0948|117 132|DNA binding domain
P09388200A0639|118 126|promoters
P09388200A0639|47 66|transcription factors
P09388200A0639|100 104|c-fos
P09388200A0639|141 153|transcription
P09388200A0639|29 37|titration
P09388200A0639|0 9|Inhibition
P09388200A0639|74 91|MDM2 overexpression
P09388201A1027|27 30|TATA
P09388201A1027|33 42|CAAT motifs
P09388201A1027|7 8|PD
P09388201A1027|2 3|PU
P09388246A0903|151 163|intermediates
P09388246A0903|104 113|cytomatrix
P09388246A0903|91 95|nerve
P09388246A0903|63 73|amphiphysin
P09388246A0903|22 58|electron microscopy immunocytochemistry
P09388271A1243|97 103|protein
P09388271A1243|63 72|inhibitors
P09388271A1243|50 58|treatment
P09388271A1243|75 77|PKC
P09388271A1243|29 36|proteins
P09388271A1243|138 149|kinase kinase
P09388271A1243|3 15|mobility shift
P09389137A0763|18 25|apoplexy
P09389137A0763|39 42|T1-9
P09389137A0763|46 49|L2-4
P09389137A0763|34 37|C1-7
P09389137A0763|3 14|prescription
P09389198A0363|79 89|A delta units
P09389198A0363|9 17|aftermath
P09389198A0363|111 115|state
P09389198A0363|139 147|threshold
P09389198A0363|63 73|arithmetics
P09389198A0363|35 38|skin
P09389198A0363|20 29|excitation
P09389198A0363|50 54|nerve
P09389492A0520|58 65|response
P09389492A0520|33 37|cells
P09389492A0520|89 94|effect
P09389492A0520|39 43|serum
P09389492A0520|10 16|fashion
P09389492A0520|120 127|activity
P09389492A0520|68 80|dexamethasone
P09389492A0520|97 103|phorbol
P09389666A0538|5 17|Hex expression
P09389666A0538|128 131|axis
P09389666A0538|54 77|anteroposterior asymmetry
P09389666A0538|181 189|asymmetry
P09389666A0538|155 164|conversion
P09389666A0538|137 142|embryo
P09389666A0538|83 93|mouse embryo
P09389666A0538|215 229|endoderm lineage
P09389669A1009|5 7|dpp
P09389669A1009|25 41|dorsal leg cell fate
P09389669A1009|11 13|omb
P09389669A1009|78 89|leg disc cells
P09389982A1383|0 10|CONCLUSIONS
P09389982A1383|101 115|prothrombin time
P09389982A1383|76 90|log reference INR
P09389982A1383|56 62|methods
P09389982A1383|124 141|regression analysis
P09389982A1383|17 29|INR correction
P09390125A0379|0 6|RESULTS
P09390125A0379|78 85|quarters
P09390125A0379|64 64|%
P09390125A0379|46 46|%
P09390125A0379|52 52|%
P09390125A0379|18 20|FNF
P09390125A0379|35 35|%
P09390125A0379|57 57|%
P09390183A1027|0 18|Western blot analysis
P09390183A1027|34 40|tissues
P09390183A1027|107 110|band
P09390183A1027|155 161|tissues
P09390183A1027|147 149|kDa
P09390183A1027|50 67|NMT peptide antibody
P09390183A1027|134 137|mass
P09391173A0811|0 22|Transcription start sites
P09391173A0811|121 128|cDNA ends
P09391173A0811|106 118|amplification
P09391173A0811|28 45|plastid ACCase genes
P09391173A0811|96 99|RACE
P09391173A0811|73 82|cDNA clones
P09392979T0000|53 62|California
P09392979T0000|40 51|San Francisco
P09392979T0000|24 37|histoplasmosis
P09393706A1171|57 64|promoter
P09393706A1171|40 48|activator
P09393706A1171|5 7|Fis
P09393717A1517|147 150|mutA
P09393717A1517|51 60|expression
P09393717A1517|83 98|mutator phenotype
P09393717A1517|5 16|observations
P09393717A1517|128 136|phenotype
P09393717A1517|154 162|mutC cells
P09393717A1517|43 46|idea
P09393717A1517|69 72|tRNA
P09393717A1517|30 36|support
P09393771A1659|0 16|TNF-alpha exposure
P09393771A1659|113 119|protein
P09393771A1659|34 41|activity
P09393771A1659|87 88|Mr
P09393771A1659|62 69|proteins
P09393875A0873|73 78|copies
P09393875A0873|23 36|papillomavirus
P09393875A0873|166 172|factors
P09393875A0873|132 141|c-fos mRNAs
P09393875A0873|84 94|virus genome
P09393875A0873|224 237|papillomavirus
P09393875A0873|112 116|cells
P09393875A0873|246 250|cells
P09393875A0873|41 45|mRNAs
P09393875A0873|201 216|Fos protein levels
P09393966A0190|28 38|region genes
P09393966A0190|17 19|IgH
P09393966A0190|40 42|CHA
P09393966A0190|46 48|CHB
P09394650A0121|12 16|study
P09394650A0121|63 72|lymph nodes
P09394650A0121|101 102|US
P09394650A0121|3 5|aim
P09395456A0424|161 173|signal peptide
P09395456A0424|90 107|proenteropeptidase
P09395456A0424|10 13|role
P09395456A0424|63 70|variants
P09395456A0424|34 53|substrate recognition
P09395456A0424|21 31|chain motifs
P09395456A0424|137 155|transmembrane domain
P09395470A0294|0 11|CKbeta4GT-II
P09395470A0294|38 62|transmembrane glycoprotein
P09395470A0294|95 112|glycosylation sites
P09395470A0294|67 69|kDa
P09395470A0294|32 35|type
P09395525A0395|162 174|IGF-I promoter
P09395525A0395|42 48|protein
P09395525A0395|138 147|C/EBPdelta
P09395525A0395|50 54|C/EBP
P09395525A0395|107 113|complex
P09395525A0395|56 60|delta
P09395525A0395|123 126|HS3D
P09395525A0395|69 77|component
P09395525A0395|187 190|site
P09396402A0264|72 73|HD
P09396402A0264|163 174|radiotherapy
P09396402A0264|61 66|stages
P09396402A0264|11 17|METHODS
P09396402A0264|145 151|effects
P09396402A0264|19 31|Semen analyses
P09396402A0264|49 56|patients
P09396402A0264|192 203|chemotherapy
P09396402A0264|119 128|sperm count
P09396402A0264|96 107|chemotherapy
P09396402A0264|0 7|PATIENTS
P09396427A1488|103 110|dilation
P09396427A1488|170 177|geometry
P09396427A1488|25 45|infarct-zone viability
P09396427A1488|59 66|patients
P09396427A1488|8 14|absence
P09396427A1488|126 128|AMI
P09396437A0878|93 100|subjects
P09396437A0878|62 69|subjects
P09396437A0878|46 46|%
P09396437A0878|5 13|BMI cutoff
P09396437A0878|102 102|P
P09396437A0878|30 40|NE spillover
P09396722A0185|102 105|gene
P09396722A0185|39 67|ascorbate peroxidase isoenzymes
P09396722A0185|3 6|gene
P09396722A0185|8 12|ApxII
P09396722A0185|85 96|organization
P09396796A1173|114 118|CDF-1
P09396796A1173|43 57|E2F family member
P09396796A1173|77 87|differences
P09396796A1173|122 124|E2F
P09396796A1173|61 66|points
P09396796A1173|31 35|CDF-1
P09396796A1173|93 111|cell cycle regulation
P09396796A1173|17 26|conclusion
P09396823T0000|15 20|domain
P09396823T0000|69 89|RNA exonuclease domains
P09396823T0000|38 50|DNA polymerase
P09396823T0000|60 62|DNA
P09397261A0940|0 18|Interleukin-1 levels
P09397261A0940|43 48|course
P09397723T0001|0 20|Responsibility matters
P09397723T0001|40 46|council
P09398267A0440|104 107|MEK2
P09398267A0440|50 52|DNA
P09398267A0440|64 85|chick embryo fibroblasts
P09398267A0440|142 148|species
P09398267A0440|122 125|gene
P09398267A0440|87 89|CEF
P09398267A0440|0 19|Southern blot analysis
P09398332A0732|0 8|Sequences
P09398332A0732|90 97|sequence
P09398332A0732|39 44|CTLA-4
P09398332A0732|166 172|165YVKM
P09398332A0732|33 35|mu2
P09398332A0732|20 30|interaction
P09398332A0732|79 84|CTLA-4
P09398332A0732|150 164|SH2 binding motif
P09398332A0732|184 198|CTLA-4 signaling
P09398332A0732|69 76|161TTGVY
P09398332A0732|60 67|residues
P09398598A0256|176 184|multimers
P09398598A0256|49 51|CHO
P09398598A0256|36 47|hamster ovary
P09398598A0256|53 60|cell line
P09398598A0256|120 126|domains
P09398598A0256|78 88|CD4 fragment
P09398598A0256|148 156|molecules
P09398855A0438|0 4|SCID V
P09398855A0438|75 80|agents
P09398855A0438|102 110|bieomycin
P09398855A0438|132 138|p53 gene
P09398855A0438|248 250|p53
P09398855A0438|82 98|gamma-irradiation
P09398855A0438|225 233|apoptosis
P09398855A0438|205 213|DNA damage
P09398855A0438|239 245|absence
P09398855A0438|8 21|J recombination
P09398855A0438|195 202|response
P09398855A0438|42 54|T-lymphocytes
P09398855A0438|119 126|mutation
P09398855A0438|6 6|D
P09398855A0438|176 192|DNA repair activity
P09400613A0594|0 11|Coexpression
P09400613A0594|193 200|mouse PKR
P09400613A0594|49 60|domain fusion
P09400613A0594|108 118|K296R mutant
P09400613A0594|264 273|activation
P09400613A0594|159 168|K64E/K296R
P09400613A0594|14 21|mouse PKR
P09400613A0594|286 298|lacZ reporters
P09400613A0594|223 253|PKR-Gal4 activation domain fusions
P09400613A0594|98 100|PKR
P09400613A0594|34 37|Gal4
P09400613A0594|279 282|HIS3
P09400613A0594|149 151|PKR
P09400613A1209|47 57|interaction
P09400613A1209|81 91|PKR homologs
P09400613A1209|68 72|mouse
P09400613A1209|5 31|GST-PKR fusion chromatography
P09400738A1046|76 79|ufCB
P09400738A1046|25 32|response
P09400738A1046|92 105|CB instillation
P09400738A1046|62 73|instillation
P09402029A1632|47 59|hybridization
P09402029A1632|204 214|strain H37Rv
P09402029A1632|164 174|copy numbers
P09402029A1632|26 36|strain H37Ra
P09402029A1632|72 77|probes
P09402029A1632|137 142|strain
P09402029A1632|98 102|genes
P09402088A2250|14 18|doubt
P09402088A2250|38 50|configuration
P09402088A2250|84 99|AVP gene precursor
P09402088A2250|5 11|defects
P09402088A2250|69 78|processing
P09402139A1121|0 11|Similarities
P09402139A1121|101 107|insulin
P09402139A1121|22 29|hIGFBP-1
P09402139A1121|84 90|regions
P09402139A1121|239 255|glucose metabolism
P09402139A1121|109 122|glucocorticoid
P09402139A1121|208 214|IGFBP-1
P09402139A1121|65 73|promoters
P09402139A1121|227 236|regulation
P09402139A1121|194 203|hypothesis
P09402139A1121|59 63|PEPCK
P09402139A1121|156 164|responses
P09402139A1121|33 57|phosphoenolpyruvate kinase
P09403059A0209|121 127|element
P09403059A0209|62 66|SINES
P09403059A0209|10 15|repeat
P09403059A0209|34 44|DNA elements
P09403059A0209|68 100|medium reiteration frequency repeats
P09403059A0209|56 60|LINES
P09404725A0644|83 91|exception
P09404725A0644|50 56|females
P09404725A0644|11 16|amount
P09404725A0644|19 30|gangliosides
P09404725A0644|63 67|males
P09404725A0644|4 7|days
P09405195A0320|46 50|locus
P09405195A0320|92 100|sequences
P09405195A0320|140 142|DNA
P09405195A0320|197 199|DNA
P09405195A0320|63 75|recombination
P09405195A0320|12 21|constructs
P09405195A0320|215 227|recombination
P09405195A0320|112 120|stretches
P09405195A0320|149 162|intron excision
P09405380A0800|58 63|system
P09405380A0800|34 40|strains
P09405380A0800|74 83|properties
P09405380A0800|108 117|retrovirus
P09405380A0800|22 31|categories
P09405380A0800|3 11|existence
P09405536A0777|161 179|conditioning stimuli
P09405536A0777|195 203|magnitude
P09405536A0777|226 232|plateau
P09405536A0777|9 29|conditioning procedure
P09405536A0777|91 97|fashion
P09405536A0777|209 217|responses
P09405536A0777|135 145|application
P09405536A0777|34 40|C-fiber
P09405536A0777|119 125|animals
P09405685A0113|136 144|GPyPyPy-3
P09405685A0113|132 134|T/A
P09405685A0113|78 91|consensus motif
P09405685A0113|95 101|PuPuPuC
P09405685A0113|112 125|GPyPyPyPuPuPuC
P09405685A0113|50 52|p53
P09405685A0113|108 110|T/A
P09405685A0113|127 129|A/T
P09405685A0113|20 48|DNA binding transcription factor
P09405685A0113|103 105|A/T
P09407026A0426|0 11|TSA treatment
P09407026A0426|68 78|positioning
P09407026A0426|251 260|remodeling
P09407026A0426|81 85|nuc-1
P09407026A0426|104 121|chromatin templates
P09407026A0426|286 292|factors
P09407026A0426|136 153|protein acetylation
P09407026A0426|189 193|steps
P09407026A0426|42 62|enhancer factor binding
P09407026A0426|157 175|chromatin remodeling
P09407026A0426|263 267|nuc-1
P09407026A0426|91 98|majority
P09407026A0426|235 243|templates
P09407031A0557|13 16|Crb2
P09407031A0557|135 148|Cdc2 activation
P09407031A0557|82 96|phosphorylation
P09407031A0557|99 108|Chk1 kinase
P09407031A0557|4 11|UV damage
P09407031A0557|74 79|timing
P09407031A0974|17 30|overexpression
P09407031A0974|50 59|phenotypes
P09407031A0974|69 79|crb2 mutants
P09407031A0974|33 36|Chk1
P09407031A0974|62 65|cut5
P09407036T0000|0 10|Tcn1p/Crz1p
P09407036T0000|80 93|gene expression
P09407036T0000|34 52|transcription factor
P09407090T0000|0 8|Structure
P09407090T0000|34 37|gene
P09407090T0000|12 23|localization
P09407090T0000|46 54|SR-BI/CLA
P09407642A0305|15 26|gel technique
P09407642A0305|65 78|identification
P09407642A0305|37 41|assay
P09407642A0305|45 61|antibody detection
P09408516T0000|0 8|Stability
P09408516T0000|11 23|pyrimethamine
P09408516T0000|64 69|months
P09408516T0000|33 49|dosage formulation
P09408796A0648|146 156|CVLT indices
P09408796A0648|8 25|regression analyses
P09408796A0648|138 142|WMS-R
P09408796A0648|78 84|Freedom
P09408796A0648|128 135|variance
P09408796A0648|122 122|%
P09408796A0648|38 74|WAIS-R factor scores Verbal Comprehension
P09408796A0648|89 103|Distractibility
P09409416A0111|14 21|arteries
P09409416A0111|52 59|approach
P09409416A0111|93 102|TC-2 64B EME
P09409416A0111|75 91|Doppler instrument
P09409416A0111|66 68|MHz
P09409774A0214|183 193|polypeptide
P09409774A0214|12 16|level
P09409774A0214|35 41|members
P09409774A0214|148 156|VCSB1 gene
P09409774A0214|21 29|sequences
P09409774A0214|126 140|polypeptide SMR1
P09409774A0214|90 98|VCSA1 gene
P09409774A0214|48 53|family
P09409774A0214|67 85|rat Rattus norvegicus
P09409821T0000|98 106|functions
P09409821T0000|26 34|RAD30 gene
P09409821T0000|63 66|dinB
P09409821T0000|77 85|DNA damage
P09409821T0000|37 45|homologue
P09409821T0000|125 154|postreplication repair mechanism
P09409821T0000|70 73|umuC
P09411459A0729|14 23|experiment
P09411459A0729|138 142|level
P09411459A0729|61 70|puppet game
P09411459A0729|79 89|pretraining
P09411459A0729|34 45|deletion task
P09411459A0729|104 116|vowel deletion
P09411459A0729|190 201|CVCC material
P09411459A0729|93 101|selection
P09411459A0729|168 175|children
P09411459A0729|145 151|success
P09412079T0001|0 10|Diet therapy
P09412079T0001|36 48|stomach ulcers
P09412079T0001|15 25|soy proteins
P09413375A1486|84 103|plasma concentrations
P09413375A1486|106 114|cytokines
P09413375A1486|78 81|rise
P09413375A1486|51 59|IL-6 level
P09413375A1486|17 19|LIS
P09413375A1486|45 48|rise
P09413375A1486|2 12|ICU patients
P09414074A0827|0 17|Resistance training
P09414074A0827|64 75|measurements
P09414074A0827|180 182|SSP
P09414074A0827|48 56|direction
P09414074A0827|27 36|power curve
P09414074A0827|101 105|loads
P09414074A0827|122 126|power
P09414074A0827|158 172|performance task
P09414287A0637|0 14|Gel-shift assays
P09414287A0637|53 59|element
P09414287A0637|28 42|Sp1 binding sites
P09414319A1442|0 5|Y15170
P09414319A1442|54 59|Y15172
P09414319A1442|29 34|Surf-3
P09414319A1442|22 27|Y15171
P09414319A1442|7 12|Surf-2
P09414319A1442|36 41|Surf-1
P09414319A1442|61 66|Surf-5
P09414319A1442|43 48|Surf-6
P09414319A1442|14 19|Surf-4
P09415711A1348|0 15|Gel mobility shift
P09415711A1348|53 60|extracts
P09415711A1348|71 78|rat liver
P09415711A1348|121 134|alpha 1B-AR gene
P09415711A1348|140 156|CRE binding protein
P09415711A1348|113 115|CRE
P09415711A1348|41 45|liver
P09415711A1348|81 93|DDT1MF-2 cells
P09415711A1348|30 35|assays
P09416467A0959|89 108|ischemia-reperfusion
P09416467A0959|180 183|role
P09416467A0959|69 79|arrhythmias
P09416467A0959|201 206|effect
P09416467A0959|5 11|results
P09416467A0959|48 60|ACE inhibitors
P09416467A0959|146 150|drugs
P09416467A0959|123 138|scavenging action
P09416467A0959|42 46|model
P09416898A1798|28 37|components
P09416898A1798|69 80|ARVD patients
P09416898A1798|91 98|subjects
P09416898A1798|3 12|mean values
P09417082A0127|40 56|urokinase receptor
P09417082A0127|11 26|signaling cascade
P09417108A0000|81 88|promoter
P09417108A0000|25 35|Htf9-c genes
P09417108A0000|9 21|Htf9-a/RanBP1
P09417493A0823|43 50|decrease
P09417493A0823|53 72|laboratory indicators
P09417493A0823|106 121|alpha 2-globuline
P09417493A0823|75 86|inflammation
P09417493A0823|24 34|improvement
P09417493A0823|123 137|prostaglandin E2
P09417493A0823|98 104|protein
P09417493A0823|2 11|accordance
P09417870A0105|100 116|phorbol dibutyrate
P09417870A0105|153 165|melanogenesis
P09417870A0105|64 72|treatment
P09417870A0105|75 95|B16 mouse melanoma cells
P09417870A0105|39 52|protein kinase C
P09417870A0105|132 135|cell
P09417870A0105|28 36|depletion
P09417870A0105|118 121|PDBu
P09417928A0980|0 10|Replacement
P09417928A0980|13 20|residues
P09417928A0980|23 31|positions
P09417928A0980|48 49|+2
P09417928A0980|35 43|His128Asn
P09417928A0980|51 59|Gln155Lys
P09417928A0980|82 88|fingers
P09417928A0980|66 79|reading helices
P09417928A0980|117 123|binding
P09417941A1287|43 63|spermadhesin molecules
P09417941A1287|173 178|domain
P09417941A1287|124 125|LG
P09417941A1287|71 80|CUB domains
P09417941A1287|164 167|face
P09417941A1287|150 154|edges
P09417941A1287|91 96|loop LA
P09417941A1287|100 109|strand beta
P09417941A1287|3 19|disulphide bridges
P09417941A1287|114 120|loops LE
P09418040T0000|0 11|Mg-chelatase
P09418040T0000|217 220|CHL H
P09418040T0000|212 215|CHL D
P09418040T0000|69 75|subunit
P09418040T0000|224 228|CHL I.
P09418040T0000|22 35|identification
P09418040T0000|151 164|reconstitution
P09418040T0000|77 84|analysis
P09418040T0000|126 130|yeast
P09418040T0000|111 118|subunits
P09418040T0000|39 54|Chl D cDNA sequence
P09418040T0000|186 198|co-expression
P09418040T0000|14 20|tobacco
P09418040T0000|141 146|system
P09418040T0000|90 100|interaction
P09418040T0000|170 183|enzyme activity
P09418057A0684|45 53|locations
P09418057A0684|22 29|sequence
P09418057A0684|3 7|R-EST
P09418861A0623|45 49|motif
P09418861A0623|107 130|pleckstrin homology domain
P09418861A0623|84 94|n-chimaerin
P09418861A0623|67 80|protein kinase C
P09418861A0623|14 22|structure
P09418871A0620|27 30|E2F1
P09418871A0620|21 23|DDB
P09418871A0620|50 81|coimmunoprecipitation experiments
P09418871A0620|3 13|interaction
P09418882A0760|92 98|U1 snRNA
P09418882A0760|54 60|version
P09418882A0760|63 68|Prp42p
P09418882A0760|13 22|antibodies
P09418882A0760|103 115|yeast extracts
P09418905A1396|61 63|Ras
P09418905A1396|129 140|S-phase entry
P09418905A1396|26 33|addition
P09418905A1396|110 112|EGF
P09418905A1396|49 58|activation
P09418905A1396|186 188|PKC
P09418905A1396|144 157|gene expression
P09418905A1396|84 96|DAG production
P09418905A1396|5 11|results
P09418905A1396|174 183|activation
P09419415A0236|56 74|fibroblast cell lines
P09419415A0236|26 39|STAT activation
P09419415A0236|6 10|study
P09419415A0236|106 117|oncoproteins
P09419415A0236|43 47|panel
P09419421A0385|46 49|TKC1
P09419421A0385|78 84|plateau
P09419421A0385|27 33|binding
P09419421A0385|36 43|NF-Y/CBF
P09419421A0385|90 95|S phase
P09419421A0385|18 22|cells
P09419680A1112|0 9|CONCLUSION
P09419680A1112|90 104|single-fraction
P09419680A1112|39 55|barrier disruption
P09419680A1112|81 87|finding
P09419680A1112|115 131|irradiation injury
P09419680A1112|16 26|animal model
P09420219A0284|59 64|export
P09420219A0284|274 279|genome
P09420219A0284|246 248|end
P09420219A0284|15 27|investigation
P09420219A0284|254 267|adenovirus type
P09420219A0284|210 219|tumor virus
P09420219A0284|270 272|Ad5
P09420219A0284|198 202|mouse
P09420219A0284|117 134|beta-actin minigene
P09420219A0284|143 149|control
P09420219A0284|30 39|parameters
P09420219A0284|86 90|cells
P09420219A0284|179 195|enhancer-promoter
P09420220A0070|120 123|gene
P09420220A0070|125 126|J.
P09420220A0070|92 95|HCMV
P09420220A0070|77 86|expression
P09420220A0070|29 40|interactions
P09420220A0070|0 3|Cell
P09420234A0654|0 7|MpB GroEL
P09420234A0654|75 81|members
P09420234A0654|41 41|%
P09420234A0654|20 37|sequence similarity
P09420234A0654|62 66|GroEL
P09420234A0654|87 105|chaperonin-60 family
P09420239A1937|85 86|TM
P09420239A1937|11 19|mutations
P09420239A1937|90 107|Nef coding sequences
P09420239A1937|182 188|changes
P09420239A1937|70 79|elongation
P09420239A1937|217 246|consensus neutralization epitope
P09420239A1937|149 160|TATA box sites
P09420239A1937|204 205|SU
P09420239A1937|109 115|changes
P09420239A1937|165 172|Sp1 sites
P09420239A1937|135 147|acceptor sites
P09420239A1937|266 283|glycosylation sites
P09420239A1937|118 131|RNA splice donor
P09420239A1937|194 201|V2 region
P09420239A1937|286 287|SU
P09420251A1363|0 1|C.
P09420252A0092|87 94|proteins
P09420252A0092|189 205|auxiliary proteins
P09420252A0092|114 121|promoter
P09420252A0092|150 156|env gene
P09420252A0092|34 41|promoter
P09420252A0092|142 144|end
P09420252A0092|23 28|repeat
P09420252A0092|30 32|LTR
P09420252A0092|57 66|expression
P09420252A0092|169 178|expression
P09420269A0000|200 202|RNA
P09420269A0000|251 259|synthesis
P09420269A0000|240 247|promoter
P09420269A0000|273 279|strands
P09420269A0000|38 40|RUB
P09420269A0000|156 165|complement
P09420269A0000|209 210|SL
P09420269A0000|124 132|structure
P09420269A0000|20 22|RNA
P09420269A0000|180 182|end
P09420269A0000|139 140|SL
P09420269A0000|65 66|nt
P09420269A0000|143 144|nt
P09420269A0000|90 98|ss-leader
P09420269A0000|83 88|leader
P09420269A0000|5 7|end
P09420269A0000|25 36|rubella virus
P09420275A0682|16 27|requirements
P09420275A0682|170 178|sequences
P09420275A0682|65 80|oligonucleotides
P09420275A0682|140 151|core sequence
P09420275A0682|57 62|series
P09420275A0682|95 115|transversion mutations
P09420275A0682|31 41|CBF2 binding
P09420275A1111|14 23|affinities
P09420275A1111|51 55|LMP-2
P09420275A1111|26 29|CBF2
P09420275A1111|45 49|LMP-1
P09420275A1111|60 72|CD23 promoters
P09420275A1111|2 9|addition
P09420671A1190|0 10|CONCLUSIONS
P09420671A1190|116 123|exercise
P09420671A1190|141 155|adenosine stress
P09420671A1190|125 136|dipyridamole
P09420671A1190|66 73|patients
P09420671A1190|25 30|uptake
P09420671A1190|55 62|subjects
P09420671A1190|33 46|99mTc sestamibi
P09420671A1190|86 98|artery disease
P09421507A0000|54 69|pre-mRNA splicing
P09421507A0000|122 130|organisms
P09421507A0000|5 17|protein family
P09421508A0696|72 79|presence
P09421508A0696|107 123|transfection assay
P09421508A0696|26 30|TCF11
P09421508A0696|82 85|MafG
P09421508A0696|50 53|site
P09421508A0696|16 23|activity
P09421511A0827|133 140|position
P09421511A0827|42 50|evolution
P09421511A0827|86 112|telomerase RNA-gene promoters
P09421511A0827|167 179|telomerase RNA
P09421511A0827|13 23|comparisons
P09421511A0827|146 161|template sequence
P09421511A0827|59 83|RNA-polymerase specificity
P09421516A1516|186 202|deadenylation step
P09421516A1516|154 162|K562 cells
P09421516A1516|82 92|NIH 3T3 cells
P09421516A1516|137 151|beta-globin mRNA
P09421516A1516|23 37|beta-globin mRNA
P09421516A1516|40 48|K562 cells
P09421516A1516|16 20|decay
P09421516A1516|120 128|stability
P09421516A1516|0 12|Deadenylation
P09421521T0000|0 24|Holliday junction resolvase
P09421521T0000|63 82|endonuclease activity
P09421521T0000|88 104|CCE1 homologue YDC2
P09422351A0000|0 2|Ca2
P09422351A0000|25 37|protein kinase
P09422351A0000|108 118|ion channels
P09422351A0000|66 94|serine/threonine protein kinase
P09422351A0000|41 44|CaMK
P09422351A0000|169 188|transcription factors
P09422351A0000|129 135|enzymes
P09422351A0000|149 156|proteins
P09422727A0196|161 164|CREB
P09422727A0196|143 159|CRE binding protein
P09422727A0196|114 122|induction
P09422727A0196|38 45|TGACGTGA
P09422727A0196|227 233|process
P09422727A0196|127 136|activation
P09422727A0196|179 199|transcription factor-2
P09422727A0196|47 62|promoter sequence
P09422727A0196|67 96|protein kinase A signaling pathway
P09422727A0196|201 205|ATF-2
P09423123A0000|0 3|IVOX
P09423123A0000|39 48|oxygenator
P09423123A0000|16 22|acronym
P09423310A0251|0 18|Histopathologically
P09423310A0251|144 150|antigen
P09423310A0251|27 38|lymphangioma
P09423310A0251|127 132|Factor
P09423310A0251|198 202|cells
P09423310A0251|109 117|stainings
P09423310A0251|208 212|cysts
P09423310A0251|76 83|features
P09423310A0251|176 184|reactions
P09423310A0251|120 123|CD34
P09423856A1098|0 17|Protease activities
P09423856A1098|154 163|processing
P09423856A1098|123 125|kDa
P09423856A1098|183 197|autoproteolysis
P09423856A1098|212 223|peptide bonds
P09423856A1098|98 103|masses
P09423856A1098|46 52|strains
P09423856A1098|20 27|cultures
P09423856A1098|71 77|species
P09423856A1098|239 243|parts
P09423856A1098|175 180|result
P09423856A1098|249 257|molecules
P09423968A0039|132 138|defense
P09423968A0039|195 205|nociception
P09423968A0039|144 147|pain
P09423968A0039|63 73|interaction
P09423968A0039|26 34|analgesia
P09423968A0039|124 130|systems
P09423968A0039|244 251|ontogeny
P09423968A0039|185 191|defense
P09423968A0039|212 220|processes
P09423968A0039|3 11|mechanism
P09423968A0039|254 257|rats
P09423968A0039|177 182|course
P09424012A1774|57 67|mm distances
P09424012A1774|34 41|patients
P09424012A1774|10 29|field placement errors
P09424012A1774|190 195|errors
P09424012A1774|152 156|error
P09424012A1774|136 141|degree
P09424012A1774|123 129|patient
P09424012A1774|95 103|isocenter
P09425036A0649|73 82|cell kinase
P09425036A0649|122 133|Csk substrate
P09425036A0649|61 63|Lck
P09425036A0649|33 39|version
P09425036A0649|45 59|Src family member
P09425036A0649|2 9|addition
P09425038A0752|0 1|A.
P09425038A0752|9 10|A.
P09425038A0752|3 7|Swift
P09425676A0000|46 48|S-R
P09425676A0000|8 17|mechanisms
P09425676A0000|117 123|monkeys
P09425676A0000|28 44|stimulus-response
P09425676A0000|64 84|S-R compatibility tasks
P09425676A0000|50 61|associations
P09425676A0000|102 112|experiments
P09426068A0826|3 21|c-myc/TGF-alpha HCCs
P09426068A0826|64 73|expression
P09426068A0826|156 162|tissues
P09426068A0826|76 84|TGF-alpha
P09426068A0826|166 174|c-myc HCCs
P09426068A0826|104 108|index
P09426068A0826|125 130|levels
P09426068A0826|111 118|contrast
P09426068A0826|133 141|apoptosis
P09426143A1358|145 155|competition
P09426143A1358|241 249|DNA region
P09426143A1358|71 80|expression
P09426143A1358|47 53|effects
P09426143A1358|222 231|occupation
P09426143A1358|17 20|data
P09426143A1358|255 265|target genes
P09426143A1358|169 178|regulators
P09426143A1358|62 65|KdgR
P09426143A1358|86 102|pectinolysis genes
P09426143A1358|191 199|repressor
P09426143A1358|56 58|CRP
P09426143A1358|119 128|mechanisms
P09426143A1358|203 215|RNA polymerase
P09426183A0000|148 155|activity
P09426183A0000|113 120|proteins
P09426183A0000|129 131|DNA
P09426183A0000|180 187|location
P09426183A0000|13 31|Rel/NF-kappaB family
P09426183A0000|134 139|dimers
P09426183A0000|34 63|vertebrate transcription factors
P09426183A0000|74 79|number
P09426239A0386|56 63|addition
P09426239A0386|34 39|operon
P09426239A0386|97 114|restriction enzymes
P09426239A0386|68 72|genes
P09426239A0386|3 11|cglIM gene
P09426595T0000|32 56|saccharopine dehydrogenase
P09426595T0000|81 98|nucleotide sequence
P09426595T0000|102 117|characterization
P09426595T0000|61 79|Arabidopsis thaliana
P09426595T0000|20 28|reductase
P09426907A0391|59 76|silver sulfadiazine
P09426907A0391|80 84|water
P09426907A0391|92 94|gel
P09426907A0391|46 56|formulation
P09426907A0391|3 9|purpose
P09426907A0391|16 28|investigation
P09426907A0391|96 104|poloxamer
P09426958A0110|67 84|corneal cDNA library
P09426958A0110|51 55|CO-Ag
P09426958A0110|38 42|clone
P09426958A0110|101 105|clone
P09426958A0110|3 12|study goals
P09427544A0000|98 107|DNA library
P09427544A0000|73 80|activity
P09427544A0000|37 48|pectate lyase
P09427544A0000|50 51|EC
P09427544A0000|16 26|Amycolata sp
P09427544A0000|3 9|pel gene
P09427544A0000|130 133|TK24
P09427551A0501|41 49|kb introns
P09427551A0501|18 22|exons
P09427551A0501|93 107|linkage analysis
P09427551A0501|80 89|chromosome
P09427551A0501|3 6|gene
P09427627A0802|59 67|formation
P09427627A0802|70 77|mesoderm
P09427627A0802|93 100|explants
P09427627A0802|2 15|Xenopus embryos
P09427627A0802|121 126|manner
P09427627A0802|30 48|PDGF receptor protein
P09427627A0930|132 140|treatment
P09427627A0930|22 28|protein
P09427627A0930|145 150|FK1012
P09427627A0930|108 110|S6k
P09427627A0930|10 16|variant
P09427627A0930|47 66|transphosphorylation
P09427627A0930|114 122|MAP kinase
P09427627A0930|104 106|p70
P09427627T0000|60 63|role
P09427627T0000|14 20|control
P09427627T0000|66 83|membrane attachment
P09427627T0000|23 29|insulin
P09427627T0000|33 53|PDGF receptor signaling
P09427844A0739|60 70|association
P09427844A0739|81 90|dCK subunit
P09427844A0739|22 31|dAK subunit
P09427844A0739|76 78|dGK
P09427844A0739|141 144|dGuo
P09427844A0739|133 138|affect
P09427844A0739|147 150|dCyd
P09427844A0739|169 175|subunit
P09428389A1805|0 10|CONCLUSIONS
P09428389A1805|188 198|monotherapy
P09428389A1805|175 178|drug
P09428389A1805|138 142|doses
P09428389A1805|81 85|agent
P09428389A1805|64 74|combination
P09428389A1805|23 26|dose
P09428389A1805|111 127|serum testosterone
P09428389A1805|145 156|bicalutamide
P09428389A1805|94 99|LHRH-A
P09428389A1805|29 40|bicalutamide
P09428787A0138|41 42|kb
P09428787A0138|85 108|p69/71 2-5A synthetase gene
P09428787A0138|76 79|exon
P09428787A0138|8 12|clone
P09428787A0138|59 64|region
P09428799A0897|86 108|intron/exon organization
P09428799A0897|141 147|P450scc
P09428799A0897|75 81|enzymes
P09428799A0897|11 14|gene
P09428799A0897|49 53|genes
P09429913A0528|127 135|disorders
P09429913A0528|161 168|disorder
P09429913A0528|20 27|question
P09429913A0528|33 40|benefits
P09429913A0528|104 111|efficacy
P09429913A0528|0 6|RESULTS
P09429913A0528|84 90|studies
P09429913A0528|115 118|EMDR
P09430461A0742|85 92|infarcts
P09430461A0742|94 94|p
P09430461A0742|176 176|p
P09430461A0742|247 254|patients
P09430461A0742|324 333|defect size
P09430461A0742|278 289|BMIPP imaging
P09430461A0742|22 31|defect size
P09430461A0742|350 367|threshold technique
P09430461A0742|308 321|quantification
P09430461A0742|185 194|CONCLUSION
P09430461A0742|215 218|data
P09430461A0742|240 244|group
P09430461A0742|13 17|study
P09430461A0742|126 133|risk area
P09430461A0742|416 421|amount
P09430461A0742|39 50|BMIPP imaging
P09430461A0742|385 389|phase
P09430461A0742|460 469|infarction
P09430461A0742|424 433|myocardium
P09430461A0742|169 169|r
P09430461A0742|336 340|means
P09430461A0742|398 410|determination
P09430461A0742|144 167|contrast ventriculography
P09430461A0742|436 439|risk
P09430661A0796|31 44|EphB1 receptors
P09430661A0796|59 72|Nck recruitment
P09430661A0796|46 50|Y594F
P09430661A0796|9 22|overexpression
P09430661A0796|101 113|JNK activation
P09430661A0796|125 147|cell attachment responses
P09430661A0796|75 79|EphB1
P09430668A0172a|14 28|HMG-CoA synthase
P09430668A0172a|3 10|promoter
P09430668A0172a|98 103|SREBPs
P09430668A0172a|58 63|sterol
P09430668A0172a|47 51|sites
P09430668A0172a|89 96|proteins
P09430730A0374|0 1|S.
P09430730A0374|6 11|Walter
P09430730A0374|13 14|P.
P09431812A0576|26 32|Patched
P09431812A0576|34 36|Ptc
P09431812A0576|126 132|S2 cells
P09431812A0576|114 123|activation
P09431812A0576|80 84|level
P09431812A0576|21 22|Hh
P09431812A0576|53 66|Ci binding sites
P09431828A1472|30 45|cyclosporine DR/C
P09431828A1472|94 98|range
P09431828A1472|76 79|l h-1
P09431828A1472|47 54|SS trough
P09431828A1472|20 27|increase
P09431828A1472|61 64|l h-1
P09432752A0109|117 127|application
P09432752A0109|142 148|patient
P09432752A0109|103 108|moment
P09432752A0109|16 24|relatives
P09432752A0109|65 86|treatment possibilities
P09432752A0109|0 7|Patients
P09434160A0767|7 13|PTPases
P09434160A0767|54 72|bone marrow stem cells
P09434160A2078|0 9|Expression
P09434160A2078|89 97|stem cells
P09434160A2078|39 42|CD34
P09434160A2078|12 16|PTPRO
P09434160A2078|44 58|bone marrow cells
P09434185A0902|130 136|regions
P09434185A0902|51 62|DNA packaging
P09434185A0902|169 177|DNA phages
P09434185A0902|66 86|phage assembly proteins
P09434185A0902|113 117|genes
P09434185A0902|39 49|replication
P09434185A0902|3 14|organization
P09434185A0902|17 25|SPP1 genes
P09434185A0902|99 110|organization
P09434979A0790|142 150|isocenter
P09434979A0790|194 199|filter
P09434979A0790|164 164|%
P09434979A0790|68 80|photon fluence
P09434979A0790|136 136|%
P09434979A0790|121 126|filter
P09434979A0790|95 104|collimator
P09434979A0790|40 52|photon fluence
P09434979A0790|3 9|results
P09434979A0790|132 132|%
P09435056A0128|27 37|pediocin AcH
P09435056A0128|202 204|MBP
P09435056A0128|39 41|Lys
P09435056A0128|172 178|protein
P09435056A0128|136 140|frame
P09435056A0128|19 24|domain
P09435056A0128|146 157|COOH terminus
P09435056A0128|104 112|periplasm
P09435056A0128|121 124|form
P09435056A0128|194 200|protein
P09435056A0128|79 87|machinery
P09435056A0128|46 48|Cys
P09435116A0437|0 6|Isomers
P09435116A0437|35 43|MS-MS data
P09435116A0437|49 85|trofluoroacetyl-biphenylol derivatives
P09435789A0961a|81 91|hydroxyurea
P09435789A0961a|93 94|HU
P09435789A0961a|216 224|DNA damage
P09435789A0961a|22 25|MEC3
P09435789A0961a|198 203|repair
P09435789A0961a|149 156|presence
P09435789A0961a|62 67|S phase
P09435789A0961a|14 18|RAD24
P09435789A0961a|129 138|yeast cells
P09435789A0961a|43 57|cell cycle arrest
P09435789A0961a|8 12|RAD17
P09435789A0961a|159 160|HU
P09435789A0961a|118 126|viability
P09435806T0001|60 76|cancer recurrences
P09435806T0001|8 12|value
P09435806T0001|92 95|time
P09435806T0001|18 27|estimation
P09435806T0001|79 83|CA125
P09435806T0001|30 43|growth kinetics
P09436657A0303|156 164|knowledge
P09436657A0303|4 9|review
P09436657A0303|82 85|ways
P09436657A0303|56 69|carcinogenesis
P09436657A0303|109 119|risk factors
P09436657A0303|141 145|basis
P09436657A0303|46 53|pathways
P09436657A0303|29 35|disease
P09436706A0168|239 252|gonadotrophins
P09436706A0168|131 141|stimulation
P09436706A0168|116 122|mistake
P09436706A0168|38 57|sperm injection cycles
P09436706A0168|78 88|spermatozoa
P09436706A0168|104 113|pharmacist
P09436706A0168|182 218|gonadotrophin-releasing hormone agonist
P09436706A0168|158 168|combination
P09436706A0168|3 9|patient
P09436706A0168|220 234|leuprolide depot
P09436795A0350|0 17|Protein C deficiency
P09436795A0350|77 84|patients
P09436795A0350|93 93|%
P09436795A0350|20 37|protein S deficiency
P09436795A0350|74 74|%
P09436795A0350|58 67|risk factor
P09436795A0350|96 103|patients
P09436795A0350|128 135|children
P09436989A1011|83 104|cell cycle reset function
P09436989A1011|65 68|MOB1
P09436989A1011|9 16|addition
P09436989A1011|135 160|spindle pole body duplication
P09436989A1011|24 27|part
P09436989A1011|43 50|function
P09436989A1011|120 129|initiation
P09436989A1011|57 63|mitosis
P09437001A0769|71 81|temperature
P09437001A0769|11 24|overproduction
P09437001A0769|27 31|Der3p
P09437001A0769|2 9|contrast
P09437001A0769|43 55|sec61-2 strain
P09437001A0769|86 94|degrees C.
P09438165A0405|15 19|day-8
P09438165A0405|37 37|%
P09438165A0405|64 71|patients
P09438165A0405|21 28|PC levels
P09438165A0405|132 132|%
P09438165A0405|101 103|day
P09438165A0405|6 13|baseline
P09438165A0405|77 80|time
P09438165A0405|83 98|VOD manifestation
P09438427A0727|44 58|Hoxa1 expression
P09438427A0727|22 31|CE2 element
P09438427A0727|76 79|mice
P09438427A0727|12 15|role
P09438427A0727|167 176|CE2 element
P09438427A0727|154 161|mutation
P09438427A0727|106 140|Hoxa1 beta-galactosidase reporter gene
P09438427T0000|44 49|somite
P09438427T0000|72 81|expression
P09438427T0000|23 29|element
P09438427T0000|87 95|Hoxa1 gene
P09440166A0857|0 6|RESULTS
P09440166A0857|17 34|cDNA insert sequence
P09440166A0857|161 166|region
P09440166A0857|178 181|tail
P09440166A0857|122 127|region
P09440166A0857|176 176|A
P09440166A0857|92 102|nucleotides
P09440166A0857|41 51|nucleotides
P09440166A0857|72 75|mRNA
P09440166A0857|131 141|nucleotides
P09440166A0857|54 59|length
P09440166A0857|82 87|region
P09440166A0857|171 174|poly
P09440616A0422|20 29|activities
P09440616A0422|12 16|phase
P09441664A0377|61 65|HNF-6
P09441664A0377|41 59|transcription factor
P09441664A0377|85 109|HNF-3 beta promoter activity
P09441664A0377|140 145|region
P09441664A0377|175 179|genes
P09441746A0546|1 9|cDNA clone
P09441746A0546|51 54|gene
P09441746A0546|56 60|GPR39
P09442017A0435|6 12|Science
P09442024A0236|0 1|P.
P09442024A0236|10 11|J.
P09442024A0236|3 8|Peyron
P09442024A0708|144 156|Jacalin lectin
P09442024A0708|75 94|fibroblasts MRC5 cells
P09442024A0708|49 57|CEMLAI/NP
P09442024A0708|36 41|fusion
P09442024A0708|169 177|O-glycans
P09442024A0708|112 118|amounts
P09442024A0708|1 14|hybridoma clone
P09442024A0708|121 123|P47
P09442024A0708|16 18|7H1
P09442031A0586|43 46|size
P09442031A0586|190 196|residue
P09442031A0586|159 166|vicinity
P09442031A0586|135 152|places cleavage Site
P09442031A0586|67 73|subunit
P09442031A0586|112 133|TSHR ectodomain variants
P09442031A0586|85 90|series
P09442031A0586|4 14|information
P09442031A0586|28 37|estimation
P09442072A0716|113 121|footprint
P09442072A0716|125 130|region
P09442072A0716|154 155|bp
P09442072A0716|44 49|region
P09442072A0716|92 98|extract
P09442072A0716|218 223|region
P09442072A0716|74 77|Hepa
P09442072A0716|55 62|promoter
P09442072A0716|190 201|liver factors
P09442072A0716|7 11|DNase
P09442072A0716|13 24|footprinting
P09442072A0716|229 231|DNA
P09442072A0716|81 84|cell
P09442072A0716|167 174|fVII gene
P09442080A0856|113 142|glutathione S-transferase fusion
P09442080A0856|90 94|SHP-2
P09442080A0856|102 106|SHP-1
P09442080A0856|11 22|binding assay
P09442080A0856|204 209|fusion
P09442080A0856|28 36|IM-9 cells
P09442080A0856|170 183|domain residues
P09442080A0856|77 87|association
P09442080A0856|48 52|SHP-1
P09442080A0856|156 158|GHR
P09442080A0856|40 45|source
P09442080A0856|56 60|SHP-2
P09442172A0908|73 89|gonadotrophin dose
P09442172A0908|128 140|pregnancy rate
P09442172A0908|25 27|age
P09442172A0908|19 21|FSH
P09442172A0908|109 115|oocytes
P09442172A0908|101 106|number
P09443948A0000|163 165|IIF
P09443948A0000|67 75|technique
P09443948A0000|140 161|immunofluorescence test
P09443948A0000|12 16|study
P09443948A0000|201 214|trichinellosis
P09443948A0000|185 193|outbreaks
P09443948A0000|112 125|trichinellosis
P09443948A0000|96 104|diagnosis
P09443948A0000|217 225|Argentina
P09443948A0000|177 180|sera
P09443948A0000|77 79|EIT
P09443972A1145|43 61|transcription factor
P09443972A1145|90 99|expression
P09443972A1145|78 87|regulation
P09443972A1145|19 22|GKLF
P09443972A1145|112 116|genes
P09443972A1145|3 9|results
P09443973A1028|42 50|tif1-A79V
P09443973A1028|16 22|plasmid
P09443973A1028|0 3|CES4
P09443978A0262|26 30|cells
P09443978A0262|85 97|transcription
P09443978A0262|111 119|promoters
P09443978A0262|130 138|TATA boxes
P09443978A0262|62 64|Sp1
P09443978A0262|172 180|initiator
P09443978A0262|150 158|promoters
P09443978A0262|191 197|TATA box
P09444316A0388|43 50|toxicity
P09444316A0388|90 92|sex
P09444316A0388|18 22|signs
P09444316A0388|68 69|F0
P09444316A0388|73 81|F1 animals
P09445056A0215|103 114|architecture
P09445056A0215|120 131|gp41 oligomer
P09445056A0215|83 85|BS3
P09445056A0215|27 47|chemical cross-linking
P09445056A0215|52 54|bis
P09445056A0215|56 72|sulfosuccinimidyl
P09445056A0215|74 81|suberate
P09445488A0230|98 108|chromosomes
P09445488A0230|23 38|USH1C disease gene
P09445488A0230|74 80|markers
P09445488A0230|4 9|effort
P09445488A0230|121 131|combination
P09445488A0230|110 113|YACs
P09445488A0230|134 150|STS content mapping
P09445488A0230|154 173|Alu-PCR hybridization
P09445488A0230|83 87|yeast
P09445488A0230|56 61|region
P09445488A1169|0 17|PowerBLAST analysis
P09445488A1169|77 81|genes
P09445488A1169|63 66|ESTs
P09445488A1169|83 85|BIR
P09445488A1169|168 180|DNA binding/EF
P09445488A1169|50 61|sequence tags
P09445488A1169|114 119|region
P09445488A1169|159 166|gene NEFA
P09445488A1169|87 90|SUR1
P09445488A1169|31 38|clusters
P09446600A0260|118 123|manner
P09446600A0260|92 98|nucleus
P09446600A0260|78 86|cytoplasm
P09446600A0260|56 58|Ahr
P09446600A0260|24 41|beta-galactosidase
P09446600A0260|1 13|fusion protein
P09446616A0780|0 13|Reconstitution
P09446616A0780|48 53|kinase
P09446616A0780|16 28|Raf-1 activity
P09446616A0780|70 78|cell lines
P09446616A0780|60 63|Jak1
P09446815A1021|31 36|region
P09446815A1021|61 62|bp
P09446815A1021|2 9|addition
P09447917A0000|15 21|Geisler
P09447917A0000|23 30|Brain Res
P09447917A0000|3 12|hypothesis
P09447962A0452|20 25|rhis4l
P09447962A0452|9 18|transcript
P09447962A1027|145 153|rhis4 mRNA
P09447962A1027|194 203|mRNA levels
P09447962A1027|40 43|form
P09447962A1027|172 179|increase
P09447962A1027|69 79|exonuclease
P09447962A1027|226 238|HIS4 mRNA level
P09447962A1027|108 117|suppressor
P09447962A1027|134 142|half-life
P09447962A1027|46 49|XRN1
P09447962A1027|18 31|interpretation
P09447963A0223|0 3|Sip1
P09447963A0223|60 73|splicing factor
P09447963A0223|39 49|interaction
P09447963A0223|81 86|family
P09447963A0223|54 57|SC35
P09447963A0223|28 33|virtue
P09447973A0168|129 141|mSos C terminus
P09447973A0168|181 188|activity
P09447973A0168|63 67|mSos1
P09447973A0168|143 156|MyrSos1-deltaC
P09447973A0168|41 60|myristoylation signal
P09447973A0168|69 75|MyrSos1
P09447973A0168|22 28|reports
P09447973A0168|116 123|deletion
P09447973A0168|102 112|NIH 3T3 cells
P09447973A0168|30 37|addition
P09447979A1430|72 102|guanine nucleotide exchange factor
P09447979A1430|104 107|GNEF
P09447979A1430|54 66|sequestration
P09447979A1430|4 12|mutations
P09447979A1430|43 51|phenotype
P09447994A0000|89 96|elements
P09447994A0000|7 13|studies
P09447994A0000|181 188|response
P09447994A0000|192 198|variety
P09447994A0000|116 119|cAMP
P09447994A0000|214 220|stimuli
P09447994A0000|138 141|CREs
P09447994A0000|112 114|AMP
P09447994A0000|52 57|region
P09447994A0000|60 64|c-fos
P09447994A0000|121 136|response elements
P09447994A0000|161 178|c-fos transcription
P09448268A0186|13 18|kinase
P09448268A0186|37 43|homolog
P09448268A0186|20 22|Nlk
P09448268A0186|64 66|nmo
P09448268A0186|68 71|gene
P09448574A0964|147 159|system atrophy
P09448574A0964|48 52|RACLO
P09448574A0964|127 134|patients
P09448574A0964|77 84|measures
P09448574A0964|3 10|findings
P09448574A0964|95 102|function
P09448574A0964|30 32|FDG
P09449018T0000|0 19|Childhood misbehavior
P09449018T0000|26 29|risk
P09449018T0000|41 47|drug use
P09450932A0142|102 107|arrest
P09450932A0142|40 50|subpathways
P09450932A0142|7 14|analysis
P09450932A0142|110 121|DNA synthesis
P09450932A0142|56 78|DNA structure checkpoints
P09451003A0894|42 48|protein
P09451003A0894|140 147|Esigma54
P09451003A0894|122 132|interaction
P09451003A0894|37 39|CRP
P09451003A0894|154 168|CRP-cAMP complex
P09451003A0894|112 117|result
P09451003A0894|84 93|repression
P09451003A0894|5 21|Esigma54 promoters
P09451003A0894|60 76|sigma54 activators
P09451016A1037|90 94|cells
P09451016A1037|185 188|gene
P09451016A1037|10 40|GlcNAc2-PP-Dolichol biosynthesis
P09451016A1037|157 169|transcription
P09451016A1037|118 124|plasmid
P09451016A1037|77 85|membranes
P09451016A1037|135 141|glucose
P09451016A1037|0 5|GlcNAc
P09451857T0001|15 27|tissue lesions
P09451857T0001|72 85|creatine kinase
P09451857T0001|46 54|injection
P09451857T0001|88 92|blood
P09451857T0001|57 69|determination
P09451857T0001|0 12|Demonstration
P09452421A1042|0 9|Antibodies
P09452421A1042|100 102|Tyr
P09452421A1042|23 31|GST mSH2-B
P09452421A1042|62 64|kDa
P09452421A1042|51 57|protein
P09452444A0000|0 12|Interleukin-6
P09452444A0000|113 125|hematopoiesis
P09452444A0000|14 17|IL-6
P09452444A0000|95 108|phase reactions
P09452444A0000|80 88|responses
P09452444A0000|33 40|cytokine
P09452444A0450|4 11|analysis
P09452444A0450|89 100|reporter gene
P09452444A0450|63 78|IL-6 gene promoter
P09452444A0450|45 52|variants
P09452444A0450|21 28|deletion
P09452444A0450|134 153|transcription factors
P09453537A0863|83 98|recognition sites
P09453537A0863|49 58|complement
P09453537A0863|102 104|SP1
P09453537A0863|4 9|region
P09453537A0863|69 75|GC boxes
P09453537A0863|28 36|CCAATC box
P09453689A0000|116 125|cord injury
P09453689A0000|66 80|bulbocavernosus
P09453689A0000|127 129|SCI
P09453689A0000|3 9|purpose
P09453689A0000|82 85|S2-4
P09453689A0000|146 168|bladder function recovery
P09453689A0000|94 96|BCR
P09453689A0000|41 44|S4-5
P09453689A0000|46 57|pin sensation
P09453689A0000|59 61|PPS
P09454719A0181|100 126|AAUAAA polyadenylation signal
P09454719A0181|166 195|polyadenylation signal sequences
P09454719A0181|240 245|vector
P09454719A0181|10 20|termination
P09454719A0181|51 65|LTR R/U5 junction
P09454719A0181|33 43|transcripts
P09454719A0181|147 152|effect
P09454719A0181|201 210|properties
P09454735A1782|0 5|Levels
P09454735A1782|116 134|adhesion disassembly
P09454735A1782|64 87|MAP kinase phosphorylation
P09454735A1782|50 60|mitogenesis
P09454735A1782|11 29|MEK inhibitor PD98059
P09454735A1782|138 149|cell motility
P09455695A0762|0 8|ALT levels
P09455695A0762|64 64|%
P09455695A0762|72 76|weeks
P09455695A0762|11 20|responders
P09455695A0762|79 95|vitamin E treatment
P09455695A0762|36 36|%
P09455695A0762|40 48|AST levels
P09456312A1064|72 89|localization signal
P09456312A1064|37 43|RanGAP1
P09456312A1064|29 34|domain
P09458021A1373|4 4|%
P09458021A1373|6 6|P
P09458021A1373|20 22|MMF
P09458021A1373|32 40|AZA groups
P09458030A0192|3 7|study
P09458030A0192|43 45|MMF
P09458030A0192|35 40|effect
P09458030A0192|54 74|bone mineral metabolism
P09459241A0707|0 3|Pao2
P09459241A0707|56 58|kPa
P09459241A0707|68 71|mm Hg
P09459241A0707|27 29|kPa
P09459241A0707|74 74|P
P09459241A0707|39 42|mm Hg
P09459685T0001|76 83|children
P09459685T0001|35 47|stress factors
P09459685T0001|7 20|configurations
P09459685T0001|87 97|adolescents
P09459835A0297|16 19|PMEA
P09459835A0297|33 47|mg/kg body weight
P09459835A0297|23 28|dosage
P09459835A0297|83 97|mg/kg body weight
P09459835A0297|73 78|dosage
P09459835A0297|4 7|cats
P09459835A0297|53 56|cats
P09459835A0297|65 69|FPMPA
P09460171T0000|0 9|Resistance
P09460171T0000|27 38|implications
P09460171T0000|12 25|thyroid hormone
P09460171T0000|60 67|research
P09460171T0000|82 105|thyroid hormone disruptors
P09460171T0000|73 79|effects
P09461594A0000|86 88|EMF
P09461594A0000|157 166|PLC-gamma2
P09461594A0000|26 33|exposure
P09461594A0000|100 107|tyrosine
P09461594A0000|124 133|activation
P09461594A0000|80 84|field
P09461594A0000|136 155|phospholipase Cgamma2
P09461594A0000|59 64|energy
P09461594A0000|186 213|inositol phospholipid turnover
P09461594A0000|36 53|DT40 lymphoma B cells
P09461594A0000|14 21|evidence
P09463174A0670|85 90|months
P09463174A0670|23 29|results
P09463174A0670|75 80|period
P09463174A0670|42 49|patients
P09463380A1050|29 38|expression
P09463380A1050|48 66|mesoderm marker genes
P09463380A1050|76 80|Smad1
P09463380A1050|9 15|xTAK1KN
P09463560A0124|0 7|PATIENTS
P09463560A0124|11 16|METHOD
P09463560A0124|30 37|patients
P09463964A0243|3 7|assay
P09463964A0243|38 50|micrograms l-1
P09463964A0243|24 28|range
P09463964A0243|140 148|antiserum
P09463964A0243|109 113|mg l-1
P09463964A0243|92 104|micrograms l-1
P09463964A0243|67 74|antibody
P09463991T0000|11 15|audit
P09464248A0289|10 16|TATA box
P09464525T0000|0 9|Expression
P09464525T0000|54 55|Fv
P09464525T0000|13 28|characterization
P09464525T0000|59 69|Fv fragments
P09464525T0000|82 84|set
P09464525T0000|96 105|antibodies
P09465035A1032|73 73|L
P09465035A1032|75 79|alpha
P09465035A1032|51 58|fraction
P09465035A1032|81 88|activity
P09465035A1032|9 17|inhibitor
P09465035A1032|19 19|s
P09465783A0449|0 18|Platelet aggregation
P09465783A0449|81 89|treatment
P09465783A0449|68 75|parallel
P09465783A0449|21 28|response
P09465783A0449|94 96|ASA
P09465783A0449|33 53|micrograms collagen/ml
P09466267A1192|41 44|role
P09466267A1192|69 78|regulation
P09466267A1192|81 99|dmsA-lacZ expression
P09466267A1192|5 15|himA mutants
P09466267A1192|32 34|IHF
P09466931T0000|60 74|response element
P09466931T0000|80 83|ng-1
P09466931T0000|87 104|ng-2 intermolt genes
P09466931T0000|35 43|receptors
P09466931T0000|0 12|Cross-talking
P09467044A0973|14 35|breast tumor relapse rate
P09467044A0973|63 73|MGDET groups
P09467044A0973|56 59|PALP
P09467707T0000|0 17|Sibling aggregation
P09467707T0000|64 79|apolipoproteins B
P09467707T0000|39 60|lipoprotein cholesterol
P09467707T0000|107 114|children
P09467707T0000|83 91|A-I levels
P09467707T0000|119 136|Bogalusa Heart Study
P09467900A0701|172 180|EF-hand Ca
P09467900A0701|186 198|binding domain
P09467900A0701|66 72|stretch
P09467900A0701|106 112|X domain
P09467900A0701|80 96|amino acid residues
P09467900A0701|131 140|N-terminus
P09467900A0701|3 15|CAPLC1 protein
P09467900A0701|42 49|features
P09467955A0468|97 100|PEA3
P09467955A0468|120 127|promoter
P09467955A0468|66 77|PEA3 promoter
P09467955A0468|88 94|ability
P09467955A0468|4 13|hypothesis
P09467955A0468|45 60|PEA3 binding sites
P09467955A0468|33 42|occurrence
P09468386A0594|0 4|Pet-1
P09468386A0594|126 131|manner
P09468386A0594|88 105|promoter constructs
P09468386A0594|45 49|motif
P09468386A0594|64 76|transcription
P09468386A0594|27 33|PEA3 ETS
P09468509A0463|43 50|COS cells
P09468509A0463|3 9|protein
P09468509A0463|21 29|F2771 cDNA
P09468509A0463|67 75|cytoplasm
P09468514A1065|0 15|Northern analysis
P09468514A1065|66 75|expression
P09468514A1065|81 85|heart
P09468514A1065|37 46|expression
P09468514A1065|49 54|tissue
P09468515A0621|14 21|deletion
P09468515A0621|78 92|SF-1 binding site
P09468515A0621|110 116|ability
P09468515A0621|43 52|nucleotide
P09468515A0621|137 140|SF-1
P09468515A0621|27 40|promoter region
P09469415A1337|73 91|CTL target structures
P09469415A1337|108 120|possibilities
P09469415A1337|180 194|DNA immunization
P09469415A1337|3 13|observation
P09469415A1337|133 141|induction
P09469415A1337|46 52|peptide
P09469415A1337|197 205|injection
P09469415A1337|233 238|beta 2m
P09469415A1337|18 23|beta 2m
P09469415A1337|160 171|CTL responses
P09469820A0151|116 125|modulation
P09469820A0151|43 50|YAP1 uORF
P09469820A0151|219 229|translation
P09469820A0151|15 19|genes
P09469820A0151|71 75|uORF2
P09469820A0151|180 182|UTR
P09469820A0151|203 209|control
P09469820A0151|239 247|mRNA decay
P09469820A0151|170 175|region
P09469820A0151|89 101|reading frames
P09469820A0151|144 149|events
P09469820A0151|3 7|mRNAs
P09469820A0151|59 67|YAP2 uORF1
P09469833A0533|55 69|deletion mutants
P09469833A0533|50 52|set
P09469833A0533|23 28|nature
P09469833A0533|34 48|site specificity
P09469833A0533|78 87|bp sequence
P09469933A1060|44 51|CLIP-170
P09469933A1060|25 29|brain
P09469933A1060|78 83|Restin
P09469933A1060|34 40|message
P09469933A1060|5 11|tissues
P09471984A0000|74 90|contact dermatitis
P09471984A0000|52 58|ability
P09471984A0000|11 19|Chemicals
P09471984A0000|0 9|BACKGROUND
P09472038T0000|75 84|activation
P09472038T0000|12 23|polarization
P09472038T0000|47 60|immunoreceptor
P09472038T0000|26 31|T cells
P09472038T0000|100 108|mechanism
P09472608A0253|171 176|Jurkat
P09472608A0253|111 118|cell line
P09472608A0253|137 144|cell line
P09472608A0253|62 74|transcription
P09472608A0253|165 169|cells
P09472608A0253|120 125|U-87MG
P09472608A0253|180 196|transfection assay
P09472608A0253|21 27|ability
P09472608A0253|146 152|SK-N-MC
P09472608A0253|80 92|HIV-1 promoter
P09472608A0253|41 51|protein YB-1
P09472616A1004|98 105|lineages
P09472616A1004|48 48|B
P09472616A1004|39 45|regions
P09472616A1004|15 24|amino acids
P09472616A1004|52 52|C
P09472616A1004|55 57|VP7
P09473040A1303a|45 71|siderophore system activities
P09473040A1303a|77 83|mutants
P09473040A1303a|9 16|alcR gene
P09473040A1303b|45 71|siderophore system activities
P09473040A1303b|77 83|mutants
P09473040A1303b|9 16|alcR gene
P09473317X2131|0 8|Copyright
P09473317X2131|13 25|Academic Press
P09473483A0953|171 175|HIV-I
P09473483A0953|179 184|HTLV-1
P09473483A0953|34 37|care
P09473483A0953|74 82|Rev mutant
P09473483A0953|113 119|therapy
P09473483A0953|144 154|individuals
P09473483A0953|127 140|HIV-I infection
P09473755A0318|0 7|PATIENTS
P09473755A0318|26 32|January
P09473755A0318|11 17|METHODS
P09473755A0318|50 52|St.
P09473755A0318|40 43|June
P09474001A0825|14 16|SPs
P09474001A0825|134 138|MMFCV
P09474001A0825|147 147|%
P09474001A0825|44 49|groups
P09474001A0825|107 107|p
P09474001A0825|119 122|arms
P09474001A0825|101 105|MMFCV
P09474001A0825|154 155|SP
P09474001A0825|82 89|patients
P09474001A0825|3 11|frequency
P09474648A0298|13 19|P-SAECG
P09474648A0298|71 78|controls
P09474648A0298|25 28|time
P09474648A0298|32 46|frequency domain
P09474648A0298|51 58|patients
P09474648A0298|63 65|Paf
P09475378A1449|58 69|HPLC analysis
P09475378A1449|118 130|splice variant
P09475378A1449|80 90|RUSH-1alpha
P09475378A1449|18 54|transcription-polymerase chain reaction
P09475724T0000|0 3|TOR2
P09475724T0000|22 38|signaling pathways
P09475724T0000|51 60|cell growth
P09475724T0000|6 9|part
P09475898T0000|13 25|amnioinfusion
P09476399A0141|40 44|Kandy
P09476399A0141|25 37|tea plantation
P09476399A0141|9 16|division
P09476520A1326|129 138|complexity
P09476520A1326|114 120|hybrids
P09476520A1326|197 205|molecules
P09476520A1326|151 159|existence
P09476520A1326|67 74|profiles
P09476520A1326|25 35|interaction
P09476520A1326|98 107|antibodies
P09476520A1326|6 11|models
P09476520A1326|177 189|heterogeneity
P09477316A0140|2 6|order
P09477316A0140|101 139|leucine zipper transcription factor MafB/Kr
P09477316A0140|38 53|Hox gene induction
P09477316A0140|20 26|pathway
P09477316A0140|193 199|signals
P09477316A0140|81 96|Hox gene regulator
P09478921A0126|0 9|Substrates
P09478921A0126|13 16|p210
P09478921A0126|66 68|CML
P09478921A0126|52 63|pathogenesis
P09478921A0126|18 24|bcr-abl
P09478971A1896|72 74|AhR
P09478971A1896|109 118|expression
P09478971A1896|37 42|manner
P09478971A1896|63 66|role
P09478971A1896|129 150|mouse embryo fibroblasts
P09478971A1896|121 126|Cyp1B1
P09478971A1896|0 17|Reporter constructs
P09478976A0718|0 18|Transfection studies
P09478976A0718|36 43|deletion
P09478976A0718|117 119|OSM
P09478976A0718|85 93|start site
P09478976A0718|125 133|induction
P09478976A0718|46 54|sequences
P09478976T0000|0 10|Oncostatin M
P09478976T0000|21 25|c-Fos
P09478976T0000|97 123|metalloproteinase-1 promoter
P09478976T0000|80 94|tissue inhibitor
P09478976T0000|60 70|AP-1 element
P09479498A0000|70 76|protein
P09479498A0000|39 42|RNF4
P09479498A0000|23 37|RING-finger gene
P09480831A0272|88 93|region
P09480831A0272|137 141|cells
P09480831A0272|67 74|elements
P09480831A0272|24 32|mechanism
P09480831A0272|143 146|HAEC
P09480831A0272|96 101|AM gene
P09480831A0272|42 55|gene expression
P09480843A0848|73 79|alanine
P09480843A0848|69 71|GCT
P09480843A0848|143 149|rat RL14
P09480843A0848|54 67|triplet repeats
P09480843A0848|16 21|region
P09480843A0848|83 92|nucleotide
P09480843A0848|27 37|transcripts
P09480929T0000|90 97|proteins
P09480929T0000|25 30|domain
P09480929T0000|106 133|baculovirus/insect cell system
P09480929T0000|7 10|FasR
P09480929T0000|42 51|production
P09480929T0000|60 65|fusion
P09481826T0000|14 26|liver syndrome
P09481826T0000|43 48|change
P09481826T0000|30 39|Jersey herd
P09481826T0000|61 63|use
P09481826T0000|83 95|somatotrophin
P09481826T0000|51 54|diet
P09481826T0000|0 6|Control
P09482107A0551|184 188|cells
P09482107A0551|134 141|survival
P09482107A0551|204 216|plasmid vector
P09482107A0551|110 117|C3G cells
P09482107A0551|52 54|C3G
P09482107A0551|15 28|focus formation
P09482107A0551|80 92|cell viability
P09482107A0551|3 12|inhibition
P09482107A0551|145 155|growth rates
P09482107A0551|42 49|presence
P09482107A0551|71 77|effects
P09482107A0551|171 181|NIH3T3 cells
P09482902A0423|0 7|C.D2-Chr
P09482902A0423|97 103|alleles
P09482902A0423|109 130|CDK4/CDK6 inhibitors p16
P09482902A0423|81 85|DBA/2
P09482902A0423|62 71|Pctr1 locus
P09482902A0423|33 44|DBA/2 alleles
P09482902A0423|17 23|strains
P09482902A0423|134 136|p15
P09482902A0942|30 32|p16
P09482902A0942|283 303|plasmacytoma induction
P09482902A0942|254 267|susceptibility
P09482902A0942|76 78|p16
P09482902A0942|24 28|DBA/2
P09482902A0942|38 42|A134C
P09482902A0942|101 107|ability
P09482902A0942|130 142|cyclin D2/CDK4
P09482902A0942|216 221|allele
P09482902A0942|46 50|G232A
P09482902A0942|161 181|retinoblastoma protein
P09482902A0942|330 338|candidate
P09482902A0942|311 313|p16
P09482902A0942|145 156|kinase assays
P09482902A0942|66 73|variants
P09482902A0942|270 279|BALB/c mice
P09482902A0942|345 354|Pctr1 locus
P09482902A0942|238 241|role
P09482902A0942|120 127|activity
P09482902A0942|315 319|INK4a
P09483596A0626|116 126|excellent/3
P09483596A0626|21 30|difference
P09483596A0626|73 83|excellent/5
P09483596A0626|61 66|minute
P09483596A0626|93 110|suxamethonium group
P09483596A0626|136 150|rocuronium group
P09483596A0626|46 55|conditions
P09484463T0000|0 6|Cloning
P09484463T0000|25 29|genes
P09484463T0000|10 19|expression
P09484463T0000|63 69|tobacco
P09484463T0000|51 58|proteins
P09484781A1233|90 96|PKB/Akt
P09484781A1233|33 56|D3 phosphatidylinositides
P09484781A1233|78 87|activation
P09484781A1233|18 28|association
P09485308A1165|41 47|subunit
P09485308A1165|74 81|reaction
P09485308A1165|29 35|cluster
P09485308A1165|22 27|3Fe-4S
P09485308A1165|3 11|FMN moiety
P09485790T0000|0 22|Alison Bell Memorial Award
P09486035A0051|101 109|blindness
P09486035A0051|93 98|causes
P09486035A0051|9 24|population survey
P09486035A0051|112 118|Lebanon
P09486035A0051|69 78|prevalence
P09486035A0051|46 56|individuals
P09486035A0051|0 6|METHODS
P09486531A0638|87 97|gut endoderm
P09486531A0638|156 171|gut morphogenesis
P09486531A0638|20 34|HFH-8 expression
P09486531A0638|6 18|organogenesis
P09486531A0638|110 113|role
P09486531A0638|138 146|induction
P09486531A0638|149 152|lung
P09486531A0638|57 64|mesoderm
P09486531A0638|72 81|apposition
P09486890A0234|61 75|carcinoma spread
P09486890A0234|54 58|cases
P09486890A0234|78 82|areas
P09486890A0234|8 18|laparoscopy
P09486890A0234|36 48|inoperability
P09486890A0234|110 122|visualization
P09487130A0383|14 27|telomere length
P09487130A0383|131 139|telomeres
P09487130A0383|69 72|Cdc2
P09487130A0383|90 105|DNA repair mutants
P09487130A0383|37 43|mutants
P09487130A0383|154 157|type
P09487130A0383|2 11|difference
P09487130A0383|57 66|regulation
P09487590A0657|17 26|pain relief
P09487590A0657|33 37|weeks
P09487590A0657|3 14|mean duration
P09487841A0132|41 57|sample preparation
P09487841A0132|3 6|ESEM
P09487841A0132|89 95|changes
P09487841A0132|30 32|SEM
P09488441A0615|0 2|Sp1
P09488441A0615|102 114|p50 homodimers
P09488441A0615|227 233|concert
P09488441A0615|159 173|site competition
P09488441A0615|212 221|expression
P09488441A0615|132 149|P-selectin promoter
P09488441A0615|59 66|enhancer
P09488441A0615|69 100|P-selectin promoter NF-kappaB sites
P09488441A0615|14 26|transcription
P09488441A0615|253 262|expression
P09488441A0615|122 124|Sp1
P09488441A0615|34 47|immunoglobulin
P09488441A0615|238 242|Bcl-3
P09488466A0695|100 128|precursor-product relationship
P09488466A0695|63 73|actinomycin
P09488466A0695|83 87|cells
P09488466A0695|5 12|fragment
P09488466A0695|46 49|mRNA
P09488486A0000|131 133|III
P09488486A0000|26 28|TBP
P09488486A0000|46 49|role
P09488486A0000|107 117|polymerases
P09488486A0000|92 105|RNA polymerases
P09488486A0000|52 64|transcription
P09488486A0000|18 24|protein
P09488486A0000|3 6|TATA
P09488486A0000|119 121|Pol
P09488486A0906|14 16|TBP
P09488486A0906|30 34|R239S
P09488486A0906|64 92|yeast U6 snRNA gene transcription
P09488486A0906|24 28|R235E
P09488486A0906|126 138|transcription
P09488486A0906|53 60|activity
P09488486A0906|18 22|R231E
P09488486A0906|116 118|Pol
P09488491A0000|0 10|E2F activity
P09488491A0000|33 52|retinoblastoma family
P09488491A0000|24 27|part
P09488491A0000|55 77|tumor suppressor proteins
P09488713A0886|35 48|Site-1 cleavage
P09488713A0886|104 107|SCAP
P09488713A0886|77 90|overexpression
P09488713A0886|23 32|inhibition
P09488725A0904|27 34|identity
P09488725A0904|37 39|SFD
P09488725A0904|60 71|polypeptides
P09488725T0000|42 49|subunits
P09488725T0000|9 24|characterization
P09488725T0000|69 78|proton pump
P09489670A1157|86 90|yeast
P09489670A1157|48 53|levels
P09489670A1157|92 97|hyphae
P09489670A1157|271 280|C. albicans
P09489670A1157|2 11|C. albicans
P09489670A1157|68 76|cell types
P09489670A1157|253 268|Hst6p transporter
P09489670A1157|239 246|function
P09489670A1157|176 180|yeast
P09489670A1157|132 148|HST6 transcription
P09489670A1157|13 16|HST6
P09490676A0800|87 92|excess
P09490676A0800|109 129|oligodeoxynucleotides
P09490676A0800|12 18|binding
P09490676A0800|181 185|sites
P09490676A0800|38 49|Ets-2 protein
P09490676A0800|32 34|Myb
P09490676A0800|57 65|fragments
P09490676A0800|164 166|Myb
P09490727A1041|34 41|triplets
P09490727A1041|52 57|bodies
P09490727A1041|106 114|apparatus
P09490727A1041|77 83|bundles
P09490727A1041|4 25|structure interconnects
P09491074A0104|48 57|expression
P09491074A0104|63 73|temperature
P09491074A0104|78 91|promoter region
P09491074A0104|25 33|mechanism
P09492038A0352|126 136|mutagenesis
P09492038A0352|21 25|roles
P09492038A0352|87 90|exon
P09492038A0352|74 79|region
P09492038A0352|12 16|study
P09492038A0352|92 107|promoter activity
P09492038A0352|49 56|elements
P09492038A0352|158 170|binding assays
P09494078A1362|32 40|yohimbine
P09494078A1362|6 18|5HT5A receptor
P09494078A1362|22 29|addition
P09494078A1362|69 74|effect
P09495283A0000|14 25|reporter gene
P09495283A0000|36 45|expression
P09495283A0000|110 118|HeLa cells
P09495283A0000|124 128|yeast
P09495283A0000|103 106|HSF2
P09495283A0000|61 89|heat shock transcription factors
P09495283A0000|96 99|HSF1
P09495283A0000|27 34|beta-gal
P09495771A0379|135 139|stage
P09495771A0379|142 150|septation
P09495771A0379|63 81|midcell constriction
P09495771A0379|9 20|fluorescence
P09495771A0379|40 44|cells
P09495771A0379|97 100|FtsK
P09498553A0702|56 62|GC boxes
P09498553A0702|30 43|promoter region
P09498553A0702|81 88|cap sites
P09498553A0702|133 138|nature
P09498553A0702|178 205|transcription initiation sites
P09498553A0702|141 149|CYP51 gene
P09498553A0702|2 8|TATA box
P09498553A0702|156 164|existence
P09498553T0000|100 101|I.
P09498553T0000|25 31|studies
P09498553T0000|54 57|P450
P09498553T0000|59 63|CYP51
P09498553T0000|82 98|P450 monooxygenase
P09498553T0000|34 39|sterol
P09498769A0095|42 42|B
P09498769A0095|175 185|plasma cells
P09498769A0095|139 144|B cells
P09498769A0095|22 35|representative
P09498769A0095|104 113|activation
P09498769A0095|85 100|B cell development
P09498769A0095|56 63|proteins
P09498769A0095|3 19|expression pattern
P09499031A0000|164 173|transcript
P09499031A0000|41 55|stomatitis virus
P09499031A0000|196 208|transcription
P09499031A0000|112 126|polyadenylation
P09499031A0000|182 193|reinitiation
P09499031A0000|130 153|transcription termination
P09499031A0000|77 92|sequence elements
P09499031A0000|221 230|transcript
P09499031A0000|57 59|VSV
P09499031A0000|17 29|gene junctions
P09499048A1003|16 27|virus progeny
P09499048A1003|91 92|gK
P09499048A1003|120 135|replication cycle
P09499048A1003|107 114|function
P09499048A1003|71 75|cells
P09499061A0000|0 7|Cleavage
P09499061A0000|11 13|DNA
P09499061A0000|21 29|reactions
P09499061A0000|81 89|integrase
P09499061A0000|48 72|immunodeficiency virus type
P09499061A0000|75 79|HIV-1
P09499061A0000|133 140|HIV-1 DNA
P09499061A0000|122 130|insertion
P09499061A0000|148 157|host genome
P09499254A1309|3 12|DSF regimen
P09499254A1309|166 178|investigation
P09499254A1309|105 120|patient tolerance
P09499254A1309|37 44|activity
P09499254A1309|126 132|regimen
P09499254A1309|47 54|patients
P09499254A1309|82 100|islet-cell carcinoma
P09501093A0071|72 84|Ras activation
P09501093A0071|39 41|MAP
P09501093A0071|97 100|role
P09501093A0071|15 21|mitogen
P09501093A0071|31 37|protein
P09501093A0071|112 132|Ras signal transduction
P09501093A0071|43 48|kinase
P09501093A0071|59 69|consequence
P09501093A0071|0 9|Activation
P09501169A0000|0 23|Histone acetylation levels
P09501169A0000|26 30|cells
P09501169A0000|49 59|equilibrium
P09501169A0000|76 92|histone acetylases
P09501169A0000|96 107|deacetylases
P09501982A1178|0 10|CONCLUSIONS
P09501982A1178|285 294|commitment
P09501982A1178|92 105|Xenopus embryos
P09501982A1178|172 180|potential
P09501982A1178|330 344|differentiation
P09501982A1178|12 16|XCoe2
P09501982A1178|142 146|XCoe2
P09501982A1178|191 205|progenitor cells
P09501982A1178|217 224|X-ngnr-1
P09501982A1178|260 269|competence
P09501982A1178|357 373|XNeuroD expression
P09501982A1178|56 62|cascade
P09501982A1178|83 89|neurons
P09501982A1178|304 307|fate
P09501982A1178|32 35|role
P09501982A1178|120 140|Delta-Notch signalling
P09501982A1178|237 246|transition
P09502627A0705|259 259|p
P09502627A0705|217 232|ejection fraction
P09502627A0705|18 23|Group A
P09502627A0705|160 183|peak creatine kinase levels
P09502627A0705|186 186|p
P09502627A0705|105 120|ventriculography
P09502627A0705|278 284|Group B.
P09502627A0705|129 139|infarct area
P09502627A0705|234 237|LVEF
P09502627A0705|34 42|incidence
P09502627A0705|8 15|Patients
P09502627A0705|241 257|hospital discharge
P09502627A0705|59 81|wall motion abnormalities
P09502627A0705|83 83|p
P09502627A0705|0 6|RESULTS
P09502720A0214|0 17|CyIIa transcription
P09502720A0214|63 75|specification
P09502720A0214|92 98|domains
P09502720T0000|102 110|CyIIa gene
P09502720T0000|113 128|sea urchin embryos
P09502720T0000|80 96|complex expression
P09502720T0000|26 46|cell type specification
P09502720T0000|62 68|element
P09503017A1021|159 180|lung carcinoma cell lines
P09503017A1021|65 68|gene
P09503017A1021|89 94|others
P09503017A1021|99 114|chromosome 3p21.3
P09503017A1021|30 34|HYAL1
P09503017A1021|13 20|evidence
P09503526A0614|14 20|myalgia
P09503526A0614|22 28|Raynaud
P09503526A0614|40 53|skin vasculitis
P09503526A0614|65 90|diseases WFAg concentrations
P09503526A0614|31 38|syndrome
P09503526A0614|107 114|patients
P09503526A0614|2 9|patients
P09504423A0114|202 210|pGEX-4T-2
P09504423A0114|160 162|GST
P09504423A0114|185 200|gene fusion vector
P09504423A0114|272 279|protease
P09504423A0114|227 238|gene sequence
P09504423A0114|104 107|BL21
P09504423A0114|281 294|alpha-thrombin
P09504423A0114|26 35|4E-BP1 gene
P09504423A0114|164 167|gene
P09504423A0114|11 20|expression
P09504423A0114|70 73|gene
P09504423A0114|248 259|cleavage site
P09504423A0114|109 111|DE3
P09504423A0114|134 158|glutathione-S-transferase
P09504423A0114|117 126|fusion gene
P09504514T0000|122 130|remission
P09504514T0000|106 114|leukaemia
P09504514T0000|141 146|MRC AML
P09504514T0000|10 19|comparison
P09504514T0000|79 90|chemotherapy
P09504514T0000|132 138|results
P09504514T0000|149 153|trial
P09504514T0000|22 29|addition
P09504514T0000|42 67|bone-marrow transplantation
P09504553T0000|16 23|cannabis
P09504553T0000|11 13|use
P09504906A0099|0 7|Analysis
P09504906A0099|63 71|amino acid
P09504906A0099|128 132|Hap1p
P09504906A0099|89 103|cysteine residue
P09504906A0099|120 125|domain
P09504906A0099|20 29|revertants
P09504906A0099|43 50|function
P09505135A0182|60 66|targets
P09505135A0182|16 22|stimuli
P09505135A0182|43 49|stimuli
P09505733A0246|70 76|factors
P09505733A0246|43 47|shows
P09505733A0246|9 15|studies
P09505733A0246|154 161|patients
P09505733A0246|102 109|distress
P09505733A0246|147 151|group
P09505733A0246|132 142|limitations
P09505733A0246|1 6|review
P09506439A2179|0 8|PKC-gamma
P09506439A2179|64 77|gene expression
P09506439A2179|121 129|SVHK cells
P09506439A2179|96 101|manner
P09506439A2179|29 41|keratinocytes
P09506959T0000|0 13|Identification
P09506959T0000|120 129|regulators
P09506959T0000|54 62|complexes
P09506959T0000|73 79|members
P09506959T0000|85 102|Myc/Max/Mad network
P09506959T0000|17 32|characterization
P09506962A1000|101 103|YY1
P09506962A1000|39 45|calpain
P09506962A1000|54 63|proteasome
P09506962A1000|91 98|elements
P09506962A1000|28 36|targeting
P09506983A0304|0 6|Primers
P09506983A0304|69 80|RACE products
P09506983A0304|54 57|ends
P09506983A0304|20 25|rounds
P09506983A0304|28 31|RACE
P09506990T0000|5 15|ZFM1 protein
P09506990T0000|108 123|activator protein
P09506990T0000|63 91|transcription activation domain
P09506990T0000|34 42|repressor
P09507032A1144|87 91|cells
P09507032A1144|117 125|apoptosis
P09507032A1144|70 84|CSF-1 protection
P09507032A1144|51 58|CSF1R/IR
P09507032A1144|16 31|CSF1R/IRDelta960
P09508119A0498|30 41|presentation
P09508119A0498|47 50|case
P09508119A0498|61 67|Gardner
P09508119A0498|70 77|syndrome
P09508119A0498|0 10|CONCLUSIONS
P09508377A0863|230 237|melanoma
P09508377A0863|66 77|phaeomelanin
P09508377A0863|103 107|point
P09508377A0863|113 139|eumelanin/phaeomelanin ratio
P09508377A0863|210 213|risk
P09508377A0863|5 11|results
P09508377A0863|33 45|UV sensitivity
P09508377A0863|193 203|individuals
P09508377A0863|217 226|skin cancer
P09508377A0863|148 164|chemical parameter
P09508377A0863|84 98|eumelanin levels
P09508511A0588|69 80|fluorofamide
P09508511A0588|109 114|urease
P09508511A0588|64 65|os
P09508511A0588|48 51|dose
P09508511A0588|2 8|ferrets
P09508511A0588|55 59|mg/kg
P09508511A0588|30 39|H. mustelae
P09508775A0293|178 212|protooncogenes/transcription factors
P09508775A0293|77 99|protein kinase activation
P09508775A0293|26 32|pathway
P09508775A0293|114 119|growth
P09508775A0293|136 143|pathways
P09508775A0293|149 153|level
P09508775A0293|159 168|expression
P09509226A1235|114 117|unit
P09509226A1235|88 90|ICU
P09509226A1235|151 157|methods
P09509226A1235|12 14|Use
P09509226A1235|25 30|method
P09509226A1235|63 74|time patients
P09509226A1235|49 57|reduction
P09509226A1235|121 127|savings
P09509226A1235|189 196|outcomes
P09509226A1235|97 104|transfer
P09509226A1235|130 140|nursing time
P09509226A1235|0 10|CONCLUSIONS
P09510189A0192|118 120|DNA
P09510189A0192|92 100|kilobases
P09510189A0192|102 103|kb
P09510189A0192|30 41|organization
P09510189A0192|58 65|CD58 gene
P09510398A1138|28 35|patients
P09510398A1138|63 71|elevation
P09510398A1138|45 56|hypouricemia
P09510398A1138|81 98|urate concentration
P09510398A1138|122 130|Secretion
P09510398A1138|105 112|subtypes
P09510398A1138|17 25|hematuria
P09510398A1138|3 13|risk factors
P09510398A1138|115 118|Post
P09510582A0157|100 102|geG
P09510582A0157|137 141|agent
P09510582A0157|90 95|geG-25
P09510582A0157|109 114|geG-50
P09510582A0157|106 107|mg
P09510582A0157|124 125|mg
P09510582A0157|40 43|DCBM
P09510582A0157|119 121|HBB
P09510582A0157|20 27|patients
P09510582A0157|87 88|mg
P09510925A0389|69 78|week course
P09510925A0389|88 95|sulphate
P09510925A0389|46 50|g dL-1
P09510925A0389|5 28|haemoglobin concentration
P09510925A0389|30 31|Hb
P09511724A0483|85 91|calcium
P09511724A0483|5 9|cells
P09511724A0483|102 103|mM
P09511724A0483|105 109|media
P09511724A0483|32 47|Dsg protein levels
P09511724A0483|56 62|calcium
P09511724A0483|14 25|accumulation
P09511760A0221|160 168|cHO-1 gene
P09511760A0221|81 93|DNA sequencing
P09511760A0221|7 31|restriction enzyme analysis
P09511760A0221|208 214|regions
P09511760A0221|193 194|kb
P09511760A0221|47 77|polymerase chain reaction analysis
P09511760A0221|221 224|ends
P09511760A0221|33 45|Southern blots
P09511760A0221|132 137|clones
P09512416A0460|176 183|features
P09512416A0460|13 23|information
P09512416A0460|119 125|protein
P09512416A0460|200 211|7TM receptors
P09512416A0460|78 100|Arabidopsis thaliana gene
P09512416A0460|53 64|sequence tags
P09512416A0460|0 6|RESULTS
P09512416A0460|161 167|domains
P09512416A0460|29 41|dbEST database
P09512416A0460|102 105|GCR1
P09512550T0000|0 2|E1A
P09512550T0000|12 43|apolipoprotein AI enhancer activity
P09512550T0000|64 66|pRb
P09512550T0000|46 55|liver cells
P09512550T0000|86 92|pathway
P09512559T0000|102 117|chromosome vector
P09512559T0000|38 77|nerve growth factor-luciferase reporter gene
P09512559T0000|20 29|expression
P09512559T0000|87 91|yeast
P09513759A0716|0 16|Calcitriol therapy
P09513759A0716|35 42|decrease
P09513759A0716|45 59|serum iPTH levels
P09514156A1147|0 10|Alterations
P09514156A1147|45 57|element region
P09514156A1147|19 28|reactivity
P09514156A1147|170 174|state
P09514156A1147|13 17|DNase
P09514156A1147|69 70|GC
P09514156A1147|82 90|complexes
P09514156A1147|116 121|manner
P09514156A1147|130 137|promoter
P09514159A0562|54 57|Ptx1
P09514159A0562|13 39|hormone-coding gene promoters
P09514260A1083|115 120|origin
P09514260A1083|186 193|findings
P09514260A1083|209 213|roles
P09514260A1083|224 224|C
P09514260A1083|124 135|relationship
P09514260A1083|41 52|pseudo intein
P09514260A1083|216 222|intein N
P09514260A1083|15 21|inteins
P09514260A1083|95 101|inteins
P09514260A1083|229 236|EN motifs
P09514260A1083|80 91|architecture
P09514260A1083|58 64|results
P09514260A1083|143 157|protein families
P09514272A0482|100 102|P16
P09514272A0482|66 69|mass
P09514272A0482|94 96|P15
P09514272A0482|80 82|kDa
P09514272A0482|14 17|MvaT
P09514272A0482|32 43|polypeptides
P09514272A0482|72 74|kDa
P09514272A0482|0 11|Purification
P09514962A0841|0 3|M-66
P09514962A0841|23 29|protein
P09514962A0841|39 42|MMTV
P09514962A0841|50 63|T-cell lymphoma
P09514962A0841|65 68|EL-4
P09515031A1020|47 54|c-fos SRE
P09515031A1020|66 68|PKC
P09515031A1020|24 32|TGF-betaf
P09515031A1020|79 92|SRF binding site
P09515031A1020|5 11|results
P09515032A1230|0 5|RT-PCR
P09515032A1230|19 25|p21 mRNA
P09515032A1230|142 146|stage
P09515032A1230|98 103|stages
P09515665T0000|45 64|CMV polyradiculopathy
P09515665T0000|14 30|foscarnet efficacy
P09515665T0000|0 10|Ganciclovir
P09515858A0000|0 9|BACKGROUND
P09515858A0000|11 19|Defensins
P09515858A0000|37 54|neutrophil peptides
P09515858A0000|92 108|azurophil granules
P09515858A0000|111 121|neutrophils
P09515858A0000|72 79|peptides
P09515921A1662|30 46|pca gene expression
P09515921A1662|76 84|pca operon
P09515921A1662|62 69|promoter
P09515921A1662|14 21|mutation
P09515924A0104|54 61|activity
P09515924A0104|31 40|PDH complex
P09515924A0104|10 14|cells
P09515924A0104|7 7|g
P09515924A0104|74 80|protein
P09515924A0104|68 71|U/mg
P09515924A0104|27 28|mg
P09515924A0553|43 66|hybridization experiments
P09515924A0553|22 26|genes
P09515924A0553|115 120|genome
P09515924A0553|70 85|sequence analysis
P09515924A0553|123 131|Z. mobilis
P09515924A0553|99 109|gene regions
P09515924A0553|3 5|PDH
P09516472A0292|87 105|Id4 promoter activity
P09516472A0292|66 74|TATA motif
P09516472A0292|29 36|elements
P09517646A0149|0 11|Azithromycin
P09517646A0149|138 151|pylori regimens
P09517646A0149|113 117|agent
P09517646A0149|18 36|generation macrolide
P09517646A0149|70 85|pharmacokinetics
P09517989A0476|46 48|HIV
P09517989A0476|40 42|CMV
P09517989A0476|90 96|cells/l
P09517989A0476|64 71|CD4 count
P09517989A0476|19 24|people
P09517989A0476|3 7|study
P09518383A0000|0 9|BACKGROUND
P09518383A0000|188 197|medication
P09518383A0000|46 53|diseases
P09518383A0000|163 168|smears
P09518383A0000|82 91|sex workers
P09518383A0000|55 57|STD
P09518383A0000|104 107|Peru
P09518383A0000|206 212|condoms
P09518383A0000|93 95|FSW
P09518383A0000|13 22|OBJECTIVES
P09518383A0000|99 102|Lima
P09518383A0000|136 140|tests
P09518383A0000|59 72|control program
P09518383A0000|144 151|syphilis
P09518383A0000|172 180|gonococci
P09518383A0000|201 203|STD
P09518808T0000|0 20|National certification
P09518808T0000|39 54|quality assurance
P09518808T0000|28 36|component
P09519757A0482|99 101|NBF
P09519757A0482|126 131|region
P09519757A0482|12 20|mutations
P09519757A0482|45 48|exon
P09519757A0482|22 26|D811N
P09519757A0482|160 172|heterozygotes
P09519757A0482|38 42|R835C
P09519757A0482|94 97|fold
P09519757A0482|134 137|SUR1
P09519757A0482|144 150|patient
P09519757A0482|29 32|exon
P09519828A0809|118 140|E2 transactivation domain
P09519828A0809|9 24|VP16-E2 molecules
P09519828A0809|87 102|BPV-4 LCR promoter
P09519828A0809|72 81|activation
P09519830A0282|250 268|thymidine kinase gene
P09519830A0282|49 57|silencing
P09519830A0282|144 148|ICP34
P09519830A0282|151 159|promoters
P09519830A0282|100 106|viruses
P09519830A0282|279 284|genome
P09519830A0282|187 230|chloramphenicol acetyltransferase reporter gene
P09519830A0282|2 6|order
P09519830A0282|174 183|expression
P09519830A0282|74 87|HSV-1 infection
P09519830A0282|28 31|role
P09520398A0124|5 11|changes
P09520398A0124|74 85|core histones
P09520398A0124|35 42|increase
P09520398A0124|48 64|acetylation levels
P09521907A0190|72 89|expression patterns
P09521907A0190|37 44|Otx genes
P09521907A0190|24 26|otd
P09521907A0190|65 69|terms
P09521907A0190|99 108|phenotypes
P09521909A0081|85 99|stamen primordia
P09521909A0081|50 55|region
P09521909A0081|104 113|expression
P09521909A0081|154 164|development
P09521909A0081|172 177|organs
P09521909A0081|77 81|petal
P09521909A0081|132 137|region
P09521909A0081|0 18|APETALA3 transcripts
P09521913A0400|29 35|60A gene
P09521913A0400|71 76|factor
P09521913A0400|15 23|mutations
P09522297A0744|0 8|Cell lines
P09522297A0744|87 95|karyotype
P09522297A0744|74 81|analysis
P09522297A0744|46 51|tumors
P09522297A0744|58 61|mice
P09522979T0000|72 81|population
P09522979T0000|36 45|prediction
P09522979T0000|20 30|fibronectin
P09522979T0000|48 60|preterm labour
P09523478A0572|27 34|children
P09523478A0572|11 13|IgM
P09523478A0572|64 71|subjects
P09523478A0572|49 61|toxoplasmosis
P09523478A0572|2 9|addition
P09523478A0572|85 96|reactivation
P09523551A0367|4 11|variants
P09523551A0367|65 65|G
P09523551A0367|41 48|topology
P09523551A0367|81 89|receptors
P09524122A0336|21 24|GPA2
P09524122A0336|39 44|growth
P09524122A0336|13 18|allele
P09524122A0336|65 72|RAS genes
P09524122A0336|48 53|strain
P09524222A0769|83 90|sequence
P09524222A0769|186 191|MARCKS
P09524222A0769|49 52|beta
P09524222A0769|178 183|region
P09524222A0769|205 215|actin-cross
P09524222A0769|223 229|protein
P09524222A0769|25 31|isoform
P09524222A0769|139 146|subunits
P09524222A0769|320 342|calmodulin binding domain
P09524222A0769|241 254|protein kinase C
P09524222A0769|277 289|beta 4-adducin
P09524222A0769|3 15|COOH-terminus
P09524222A0769|63 71|amino acid
P09524222A0769|114 122|cell alpha
P09524222A0769|258 275|calcium/calmodulin
P09524222A1113|117 121|cells
P09524222A1113|31 49|beta-adducin isoform
P09524222A1113|153 159|tissues
P09524222A1113|76 80|liver
P09524222A1113|68 72|brain
P09524222A1113|82 91|bone marrow
P09524222A1113|96 99|NT-2
P09524222A1113|0 10|PCR analysis
P09524229A0000|144 154|hypoviruses
P09524229A0000|185 195|mycoviruses
P09524229A0000|253 266|concentrations
P09524229A0000|285 306|inhibitor cycloheximide
P09524229A0000|24 36|enzyme laccase
P09524229A0000|102 124|Cryphonectria parasitica
P09524229A0000|157 161|group
P09524229A0000|308 310|CHX
P09524229A0000|337 349|cyclosporin A.
P09524229A0000|71 75|genes
P09524229A0000|63 68|number
P09524229A0000|197 201|lac-1
P09524229A0000|81 100|chestnut blight fungus
P09524229A0000|3 11|gene lac-1
P09524250A0767|40 42|AP1
P09524250A0767|12 19|elements
P09524259A0301|129 143|insulin receptor
P09524259A0301|168 173|system
P09524259A0301|52 56|IGFIR
P09524259A0301|153 157|yeast
P09524259A0301|85 98|mutant receptor
P09524259A0301|3 18|hp55 gamma protein
P09524259A0301|100 108|hp55 gamma
P09524259A0301|145 146|IR
P09524267A1023|87 104|localization signal
P09524267A1023|62 69|proteins
P09524267A1023|240 249|plant cells
P09524267A1023|126 139|helicase motifs
P09524267A1023|40 46|domains
P09524267A1023|117 122|domain
P09524267A1023|171 174|part
P09524267A1023|180 204|RNA transcription apparatus
P09524267A1023|3 14|plant protein
P09524267A1023|214 237|nucleotide excision repair
P09524273A0205|59 74|characterization
P09524273A0205|4 8|paper
P09524273A0205|90 95|region
P09524273A0205|28 39|organization
P09524273A0205|42 52|mouse gC1qBP
P09524276A0939|130 148|bacterium protection
P09524276A0939|35 40|urease
P09524276A0939|166 171|damage
P09524276A0939|63 65|NAC
P09524276A0939|97 100|OxyR
P09524276A0939|43 61|Klebsiella aerogenes
P09524276A0939|71 78|catalase
P09524276A0939|0 11|LysR proteins
P09525105A0298|55 69|Buddleia cordata
P09525105A0298|25 34|activities
P09525105A0298|46 52|extract
P09525105A0298|85 100|glycoside linarin
P09525598A0325|126 133|activity
P09525598A0325|102 104|Raf
P09525598A0325|98 100|Raf
P09525598A0325|65 73|cell lines
P09525598A0325|43 50|findings
P09525598A0325|106 116|delta26-303
P09525598A0325|90 95|domain
P09525598A0325|26 31|T cells
P09525598A0325|15 23|Raf kinase
P09525598A0325|56 62|variety
P09525598A0325|0 9|Regulation
P09525888A1482|11 20|FLAP clones
P09525888A1482|38 42|mouse
P09525888A1482|51 67|muscle cDNA library
P09525891T0000|0 6|Members
P09525891T0000|12 16|meis1
P09525891T0000|106 110|CYP17
P09525891T0000|91 94|CRS1
P09525891T0000|82 89|sequence
P09525891T0000|20 48|pbx homeodomain protein families
P09527921A1178|172 185|initiation site
P09527921A1178|228 240|transcription
P09527921A1178|108 118|core element
P09527921A1178|80 83|site
P09527921A1178|38 55|electron microscopy
P09527921A1178|27 35|complexes
P09527921A1178|247 253|TATA box
P09527921A1178|197 205|start site
P09527921A1178|86 98|WDV Rep protein
P09527921A1178|155 156|bp
P09528758T0000|0 4|Rex-1
P09528758T0000|125 131|protein
P09528758T0000|7 10|gene
P09528758T0000|133 137|Rox-1
P09528758T0000|79 83|Oct-3
P09528758T0000|89 100|Oct-6 binding
P09528758T0000|20 38|transcription factor
P09528758T0000|105 115|octamer site
P09528758T0000|158 161|site
P09528758T0000|58 63|embryo
P09528766A0915|57 64|pathways
P09528766A0915|95 120|CREB Ser-133 phosphorylation
P09528766A0915|8 17|inhibition
P09528766A0915|40 55|p38/MAPKAP kinase
P09528766A0915|27 33|ERK/RSK
P09528768A0000|73 74|ER
P09528768A0000|39 46|proteins
P09528768A0000|91 103|transcription
P09528768A0000|63 71|reticulum
P09528768A0000|17 28|accumulation
P09528768A0000|109 113|genes
P09528768A0000|133 149|chaperone proteins
P09528768A0000|0 4|Cells
P09528770A1379|145 159|activators Msn2p
P09528770A1379|26 49|protein kinase cAPK pathway
P09528770A1379|163 167|Msn4p
P09528770A1379|178 188|UAS activity
P09528770A1379|195 200|repeat
P09528770A1379|93 99|glucose
P09528770A1379|206 213|presence
P09528770A1379|109 120|carbon source
P09528770A1379|74 77|IREu
P09528770A1379|83 90|presence
P09528770A1379|216 222|acetate
P09528770A1379|61 71|UAS activity
P09528784A0000|74 88|complementation
P09528784A0000|8 11|gene
P09528784A0000|17 28|fission yeast
P09528784A0000|3 6|mei4
P09528792A0000|161 166|manner
P09528792A0000|11 18|splicing
P09528792A0000|178 186|cell types
P09528792A0000|53 58|FGF-R2
P09528792A0000|64 70|example
P09528792A0000|126 129|IIIc
P09528792A0000|114 122|exons IIIb
P09528792A0000|21 50|fibroblast growth factor receptor
P09528792A0000|99 106|splicing
P09528858A0205|86 97|gene activity
P09528858A0205|23 33|methylation
P09528858A0205|36 39|CpGs
P09528858A0205|73 83|suppression
P09528858A0205|6 10|cases
P09528858A0205|58 64|regions
P09528950A0716|41 62|luciferase reporter gene
P09528950A0716|10 18|fragments
P09528987A1348|0 21|Cotransfection analyses
P09528987A1348|64 84|T/EBP expression vector
P09528987A1348|27 58|T/EBP promoter-reporter constructs
P09528987A1348|141 154|autoregulation
P09528987A1348|94 103|HepG2 cells
P09528987A1348|185 187|rat
P09528987A1348|196 214|T/EBP gene expression
P09528987A1348|122 126|T/EBP
P09529156A1238|0 7|Deletion
P09529156A1238|65 76|receptor tail
P09529156A1238|128 142|desensitization
P09529156A1238|20 30|Ser residues
P09529156A1238|91 109|phorbol 12-myristate
P09529156A1238|44 59|PKC consensus site
P09529156A1238|147 147|%
P09529216A0644|0 11|Flap survival
P09529216A0644|24 34|development
P09529216A0644|77 83|vessels
P09529216A0644|43 48|number
P09529216A0644|125 131|vessels
P09529216A0644|59 69|connections
P09529216A0644|98 104|pedicle
P09529649A0307|0 7|Jean Klig
P09529649A0307|52 65|tract infection
P09529649A0307|68 75|children
P09529649A0307|21 30|literature
P09529721A0000|237 246|assessment
P09529721A0000|191 198|hospital
P09529721A0000|111 120|management
P09529721A0000|259 269|counselling
P09529721A0000|210 215|weight
P09529721A0000|9 18|indicators
P09529721A0000|146 157|malnutrition
P09529721A0000|40 54|classifications
P09529721A0000|71 82|malnutrition
P09529721A0000|123 138|childhood illness
P09529721A0000|273 281|follow-up
P09529721A0000|181 188|referral
P09529721A0000|88 97|guidelines
P09530251A0766|0 3|SNAC
P09530251A0766|47 54|ischemia
P09530251A0766|6 8|PBS
P09530251A0766|81 88|duration
P09530251A0766|91 101|reperfusion
P09530251A0766|38 40|min
P09530251A0766|25 25|h
P09531538A0983|69 83|dU2AF38 RS domain
P09531538A0983|42 57|splicing activity
P09531538A0983|10 20|requirement
P09531549A0658|115 128|yAP180 proteins
P09531549A0658|168 174|patches
P09531549A0658|88 94|yAP180A
P09531549A0658|26 42|GST fusion proteins
P09531549A0658|46 58|yeast extracts
P09531549A0658|106 113|clathrin
P09531549A0658|7 20|binding studies
P09531549A0658|81 85|sites
P09531549A0658|183 196|plasma membrane
P09531549A0658|132 136|Pan1p
P09531549A0658|98 102|Pan1p
P09531549A0658|142 146|actin
P09531559A1153|132 135|ZO-2
P09531559A1153|105 110|domain
P09531559A1153|7 22|affinity analyses
P09531559A1153|113 120|occludin
P09531559A1153|84 87|ZO-1
P09531559A1153|56 62|protein
P09533030T0000|0 10|Cytochrome b
P09533030T0000|18 24|complex
P09533030T0000|80 89|components
P09533030T0000|154 157|SDHC
P09533030T0000|183 186|1q21
P09533030T0000|92 108|liver mitochondria
P09533030T0000|190 194|11q23
P09533030T0000|48 61|oxidoreductase
P09533030T0000|137 141|genes
P09533030T0000|168 171|SDHD
P09533030T0000|64 74|cDNA cloning
P09533030T0000|112 131|chromosome assignment
P09533030T0000|173 180|subunits
P09533109A0449|179 179|p
P09533109A0449|56 59|days
P09533109A0449|19 30|theophylline
P09533109A0449|9 16|decrease
P09533109A0449|166 177|significance
P09533109A0449|33 38|volume
P09533109A0449|84 97|administration
P09533109A0449|41 52|distribution
P09533109A0449|100 110|chloroquine
P09535082A0537|86 100|target sequences
P09535082A0537|217 223|complex
P09535082A0537|106 112|absence
P09535082A0537|176 186|DNA fragment
P09535082A0537|225 226|CI
P09535082A0537|171 172|bp
P09535082A0537|3 10|addition
P09535082A0537|133 139|complex
P09535082A0537|158 161|PrfA
P09535082A0537|28 34|extract
P09535082A0537|115 118|PrfA
P09535082A0537|141 144|CIII
P09535082A0537|59 72|protein binding
P09535579A1105|130 131|kJ
P09535579A1105|113 116|EPOC
P09535579A1105|74 87|interpretation
P09535579A1105|16 26|assumptions
P09535579A1105|90 106|energy expenditure
P09535579A1105|119 119|l
P09535579A1105|47 52|uptake
P09535833A0228|120 125|factor
P09535833A0228|75 109|selenocysteine tRNA gene transcription
P09535833A0228|128 140|Xenopus laevis
P09535833A0228|12 28|amino acid sequence
P09535833A0228|63 66|Staf
P09535833A0228|31 36|m-Staf
P09535835A0279|0 5|ROCK-I
P09535835A0279|38 46|type forms
P09535835A0279|60 64|Cdc42
P09535835A0279|19 23|mDia2
P09535835A0279|7 14|Kinectin
P09535835A0279|53 56|RhoA
P09535835A0279|81 86|manner
P09535851A0591|71 85|P kinase activity
P09535851A0591|10 17|isoforms
P09535851A0591|62 67|PtdIns
P09535851A0591|47 55|Vmax value
P09535851A0591|22 32|beta isoform
P09535851A0591|92 103|gamma isoform
P09535851A0591|142 145|acid
P09535892A0000|71 84|plasma membrane
P09535892A0000|166 167|WD
P09535892A0000|169 175|Trp-Asp
P09535892A0000|124 130|segment
P09535892A0000|177 183|repeats
P09535892A0000|155 159|units
P09535892A0000|55 61|signals
P09535892A0000|33 41|G proteins
P09535892A0000|3 13|beta subunit
P09535892A0000|212 219|proteins
P09535908A0321|98 100|LNX
P09535908A0321|26 36|LNX messages
P09535908A0321|54 61|proteins
P09535908A0321|84 89|masses
P09535908A0321|111 115|LNX-b
P09535908A0321|94 96|kDa
P09535908A0321|107 109|kDa
P09536028A0945|44 47|acid
P09536028A0945|126 128|EGF
P09536028A0945|61 81|cyclooxygenase product
P09536028A0945|153 180|signal pathway probe inhibitors
P09536028A0945|121 122|TF
P09536028A0945|97 108|contractions
P09536028A0945|2 9|contrast
P09536028A0945|14 30|contractile action
P09536440A0000|6 12|studies
P09536440A0000|39 45|myosin V
P09536440A0000|105 112|movement
P09536440A0000|81 85|motor
P09536901A0362|99 106|relation
P09536901A0362|35 36|T2
P09536901A0362|22 23|T1
P09536901A0362|11 18|occasion
P09536901A0362|45 52|sagittal
P09536901A0362|119 128|assessment
P09536901A0362|71 79|sequences
P09536901A0362|56 57|T2
P09537295A0951|42 43|bp
P09537295A0951|126 134|P1 primers
P09537295A0951|78 114|transcriptase-polymerase chain reaction
P09537295A0951|62 65|site
P09537295A0951|151 165|primer extension
P09537295A0951|170 180|cDNA cloning
P09537295A0951|136 148|primer walking
P09537295A0951|18 26|start site
P09537295T0000|0 7|Analysis
P09537295T0000|10 17|promoter
P09537295T0000|39 47|sequences
P09537295T0000|66 78|transcription
P09537295T0000|21 28|androgen
P09537295T0000|84 86|rat
P09537295T0000|103 113|protein gene
P09537361A0149|175 183|depletion
P09537361A0149|35 44|expression
P09537361A0149|96 98|cvi
P09537361A0149|65 91|transporter accessory protein
P09537361A0149|151 160|conditions
P09537361A0149|111 133|colicin V immunity protein
P09537361A0149|163 172|iron excess
P09537361A0149|19 31|transcription
P09537361A0149|3 16|iron dependence
P09537361A0149|47 50|cvaA
P09537375A0198|55 64|lacZ fusion
P09537375A0198|105 108|GntR
P09537375A0198|25 34|expression
P09537375A0198|49 52|gntT
P09537375A0198|122 130|regulator
P09537375A0198|133 136|gntT
P09537375A0198|3 20|gntR deletion mutant
P09537378A1227|15 22|deletion
P09537378A1227|25 27|bcp
P09537378A1227|50 55|effect
P09537378A1227|35 44|chromosome
P09537378A1227|58 75|gcv-lacZ expression
P09537651A0366|13 16|PEA3
P09537651A0366|49 57|induction
P09537651A0366|7 11|sites
P09537651A0366|111 119|induction
P09537651A0366|125 159|phorbol ester phorbol myristate acetate
P09537651A0366|161 163|PMA
P09537651A0366|20 23|STAT
P09537651A0366|60 64|v-src
P09537651A0366|85 92|elements
P09538156A0130|0 11|BRCA1 protein
P09538156A0130|77 82|region
P09538156A0130|36 50|zinc finger motif
P09538220A0000|33 35|mrr
P09538220A0000|91 93|DNA
P09538220A0000|54 60|tRNAPhe
P09538220A0000|64 75|tRNAPro genes
P09538220A0000|141 153|transcription
P09538220A0000|115 124|regulation
P09538220A0000|127 137|replication
P09538220A0000|26 31|region
P09538220A0000|172 177|genome
P09538220A0000|95 99|mtDNA
P09538258A0200|117 121|cells
P09538258A0200|6 11|report
P09538258A0200|48 60|Ras activation
P09538258A0200|93 101|receptors
P09538258A0200|65 75|stimulation
P09538258A0200|86 90|types
P09538258A0200|29 37|mechanism
P09539421A0970|32 36|roles
P09539421A0970|20 27|K. lactis
P09539421A0970|55 79|telomere length maintenance
P09539421A0970|110 115|themes
P09539421A0970|5 15|Sir proteins
P09539421A0970|43 51|silencing
P09539721A0599|73 82|activation
P09539721A0599|24 27|DnaA
P09539721A0599|88 97|pR promoter
P09539721A0599|54 66|RNA polymerase
P09539721A0599|41 51|beta subunit
P09539746A0781|73 77|cells
P09539746A0781|12 17|Bcl-XL
P09539746A0781|30 40|association
P09539746A0781|53 61|caspase-9
P09539746A0781|43 48|Apaf-1
P09539746A0781|0 9|Expression
P09539779A0621|130 139|expression
P09539779A0621|142 145|All1
P09539779A0621|89 102|Arp1 expression
P09539779A0621|37 48|mouse embryos
P09539779A0621|80 86|pattern
P09539779A0621|17 29|hybridization
P09539779A0621|59 62|days
P09540062A0755|128 135|activity
P09540062A0755|149 178|H4 promoter/CAT fusion constructs
P09540062A0755|111 112|H4
P09540062A0755|60 67|proteins
P09540062A0755|25 31|ability
P09540062A0755|5 11|mutants
P09540062A0755|47 50|Site
P09540062A0755|96 102|ability
P09540062A0755|190 198|cell types
P09541280A0404|85 98|plasma IgE level
P09541280A0404|62 74|FK506 ointment
P09541280A0404|49 57|treatment
P09541280A0404|39 44|NC mice
P09541280A0404|9 17|plasma IgE
P09541636T0000|74 79|tumors
P09541636T0000|53 60|patients
P09541636T0000|33 50|artery embolization
P09541636T0000|0 20|Creatine kinase release
P09541721A0894|106 110|LVEDP
P09541721A0894|48 55|AHF model
P09541721A0894|97 104|pressure
P09541721A0894|17 37|ischemia/angiotension
P09541721A0894|57 59|NIC
P09543227A0815|0 5|Group A
P09543227A0815|62 62|B
P09543227A0815|34 41|patients
P09543227A0815|90 100|risk factors
P09543227A0815|74 78|years
P09543227A0815|50 60|risk factors
P09543227A0815|17 21|years
P09543227A0815|105 105|C
P09543227A0815|117 121|years
P09543227A0815|139 149|risk factors
P09544987A1583|57 60|NCoR
P09544987A1583|24 33|RU486-PR-B
P09544991A0483|0 10|PRL receptor
P09544991A0483|24 28|SHP-2
P09544991A0483|40 58|tyrosine phosphatase
P09544991A0750|220 227|m-Stat5a
P09544991A0750|52 60|induction
P09544991A0750|166 181|m-Stat5adelta749
P09544991A0750|194 217|transactivation potential
P09544991A0750|19 24|mutant
P09544991A0750|110 117|m-Stat5a
P09544991A0750|63 85|tyrosine phosphorylation
P09544991A0750|231 238|m-Stat5b
P09544991A0750|27 31|SHP-2
P09544991A0750|151 158|deletion
P09544991A0750|100 107|activity
P09544991A0750|119 126|m-Stat5b
P09545146A0884|0 10|CONCLUSIONS
P09545146A0884|129 132|Cl/F
P09545146A0884|79 85|CBZ Cl/F
P09545146A0884|70 76|changes
P09545146A0884|143 161|regression equations
P09545146A0884|91 102|comedication
P09545146A0884|181 194|concentrations
P09545146A0884|35 38|data
P09545146A0884|59 67|estimates
P09545146A0884|119 126|decrease
P09545146A0884|206 218|validation set
P09545293A0590|12 18|lumican
P09545293A0590|22 30|keratocan
P09545293A0590|47 54|location
P09545293A0590|0 4|Sites
P09545312A1197|83 95|transcription
P09545312A1197|38 48|HMG-I family
P09545312A1197|26 32|members
P09545312A1197|64 67|role
P09545312A1197|151 161|interaction
P09545312A1197|108 113|effect
P09545312A1197|3 14|observations
P09545323T0000|85 109|MLH1-PMS1 protein complexes
P09545323T0000|13 20|assembly
P09545323T0000|51 61|DNA mismatch
P09545323T0000|31 37|complex
P09545323T0000|68 81|yeast MSH2-MSH6
P09545332A0137|28 30|Phe
P09545332A0137|20 25|Tyr497
P09545332A0137|137 140|IL-4
P09545332A0137|127 134|response
P09545332A0137|112 124|proliferation
P09545332A0137|68 91|insulin receptor substrate
P09545332A0137|94 97|IRS1
P09545332A0137|40 62|tyrosine phosphorylation
P09545332A0137|0 7|Mutation
P09545353A1071|28 41|kappaB elements
P09545353A1071|195 204|expression
P09545353A1071|128 132|sites
P09545353A1071|53 105|activating transcription factor/cAMP response element site
P09545353A1071|138 151|E-selectin gene
P09545353A1071|170 178|TNF-alpha
P09545638A0330a|30 56|yeast hnRNP methyltransferase
P09545638A0330a|58 61|HMT1
P09545638A0330b|30 56|yeast hnRNP methyltransferase
P09545638A0330b|58 61|HMT1
P09545638A0836|66 90|methyltransferase activity
P09545638A0836|11 24|HRMT1L2 protein
P09545638A1181|42 48|disease
P09545638A1181|11 15|roles
P09545638A1181|18 24|HRMT1L1
P09545638A1181|28 34|HRMT1L2
P09545638T0000|0 13|Identification
P09545638T0000|88 94|HRMT1L2
P09545638T0000|51 76|arginine methyltransferases
P09545638T0000|17 32|characterization
P09545638T0000|78 84|HRMT1L1
P09546424A1550|60 70|Crk proteins
P09546424A1550|26 42|PDGF beta-receptor
P09547311A1394|150 155|domain
P09547311A1394|171 178|evidence
P09547311A1394|55 64|E-cadherin
P09547311A1394|71 77|chimera
P09547311A1394|126 135|desmoglein
P09547311A1394|114 119|domain
P09547311A1394|12 23|interactions
P09547311A1394|222 231|E-cadherin
P09547311A1394|245 251|domains
P09547311A1394|208 219|interactions
P09547311A1394|91 100|E-cadherin
P09547349A0000|3 72|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09547349A0000|85 94|edelfosine
P09547349A0000|114 122|apoptosis
P09547349A0000|74 83|ET-18-OCH3
P09547349A0000|130 139|tumor cells
P09547349A0000|105 111|inducer
P09548481A0000|98 111|IL-5Ralpha gene
P09548481A0000|61 69|existence
P09548481A0000|36 43|promoter
P09548481A0000|79 86|promoter
P09548481A0000|45 46|P1
P09548481A0000|2 9|addition
P09549179A0774|0 10|Serum levels
P09549179A0774|69 69|p
P09549179A0774|57 64|exposure
P09549179A0774|67 67|p
P09549179A0774|48 54|changes
P09549179A0774|99 103|study
P09549179A0774|83 92|conditions
P09549179A0774|13 24|testosterone
P09549179A0774|72 74|DDE
P09549398A1463|198 198|%
P09549398A1463|70 80|SPET studies
P09549398A1463|7 15|agreement
P09549398A1463|192 192|%
P09549398A1463|23 58|rest/postnitroglycerin technetium-99m
P09549398A1463|177 185|viability
P09549398A1463|84 102|rest/redistribution
P09549398A1463|157 164|presence
P09549398A1463|105 143|rest/reinjection thallium-201 SPET studies
P09549632A1189|39 49|specificity
P09549632A1189|19 29|sensitivity
P09549632A1189|34 34|%
P09549632A1189|59 64|regard
P09549632A1189|111 115|trial
P09549632A1189|54 54|%
P09549632A1189|5 7|use
P09549632A1189|67 80|predictability
P09549632A1189|83 91|ALT levels
P09549660A0782|71 82|data scenario
P09549660A0782|19 26|data sets
P09549660A0782|32 39|subjects
P09549783T0000|72 79|patients
P09549783T0000|49 56|saccades
P09549783T0000|7 14|accuracy
P09550591A0454|116 128|blood pressure
P09550591A0454|10 18|treatment
P09550591A0454|102 109|decrease
P09550591A0454|46 59|airway pressure
P09550591A0454|80 83|days
P09550591A0454|70 74|cmH2O
P09550591A0454|131 134|OSAS
P09550919A0365|109 112|PSVT
P09550919A0365|118 125|episodes
P09550919A0365|179 179|%
P09550919A0365|150 157|episodes
P09550919A0365|44 51|response
P09550919A0365|145 145|%
P09550919A0365|79 80|mg
P09550919A0365|99 106|episodes
P09550919A0365|168 175|episodes
P09550919A0365|75 76|mg
P09550919A0365|161 161|%
P09550919A0365|34 39|manner
P09550919A0365|129 129|%
P09550919A0365|134 141|episodes
P09550919A0365|65 73|adenosine
P09550919A0365|90 91|mg
P09550919A0365|4 7|data
P09550919A0365|83 84|mg
P09551096A0108|0 3|RNAs
P09551096A0108|48 55|subunits
P09551096A0108|23 32|components
P09551096A0108|85 91|factors
P09551096A0108|98 114|particle formation
P09551182A0212|85 93|retinoids
P09551182A0212|102 108|embryos
P09551182A0212|181 192|acid receptor
P09551182A0212|149 169|transactivation domain
P09551182A0212|134 139|ligand
P09551182A0212|61 66|method
P09551182A0212|209 224|DNA binding domain
P09551182A0212|7 24|retinoid signalling
P09551182A0212|116 128|fusion protein
P09551182A0212|27 42|zebrafish embryos
P09551938A0318|79 94|CCR5 gene promoter
P09551938A0318|27 33|factors
P09551972A1033|0 11|Fluorescence
P09551972A1033|111 122|cosmid c101F1
P09551972A1033|161 166|8q24.3
P09551972A1033|51 60|chromosome
P09551972A1033|151 158|telomere
P09551972A1033|137 145|gene close
P09551972A1033|33 48|metaphase spreads
P09551972A1033|18 30|hybridization
P09551972A1033|73 97|hybrid cell line 706-B6 clone
P09551972A1033|101 105|CL-17
P09552469A0225|148 157|dispersion
P09552469A0225|183 189|mixture
P09552469A0225|91 102|spectroscopy
P09552469A0225|3 13|interaction
P09552469A0225|125 132|analysis
P09552469A0225|21 29|piroxicam
P09552469A0225|54 72|x-ray diffractometry
P09552469A0225|88 89|IR
P09552469A0225|33 41|poloxamer
P09552469A0225|134 136|DTA
P09552469A0225|74 76|XRD
P09553040A0651|14 16|Epo
P09553040A0651|104 108|Stats
P09553040A0651|52 68|signaling pathways
P09553040A0651|89 97|PLC-gamma
P09553040A0651|30 39|activation
P09553040A0651|78 87|PI-3 kinase
P09553040A0651|99 101|Ras
P09553040A0651|0 11|Cell survival
P09553134A0596|23 38|neurite outgrowth
P09553134A0596|93 95|PP1
P09553134A0596|55 89|tyrosine kinase inhibitors herbimycin A
P09553143A0729|146 149|H2O2
P09553143A0729|8 22|ZAP-70 substrate
P09553143A0729|24 29|SLP-76
P09553143A0729|133 141|treatment
P09553143A0729|99 109|Jurkat cells
P09553143A0729|119 127|P116 cells
P09553143A0729|43 55|Erk activation
P09553686A0000|203 221|absorption enhancers
P09553686A0000|187 192|matrix
P09553686A0000|18 25|patterns
P09553686A0000|135 145|application
P09553686A0000|283 289|patch 7D
P09553686A0000|54 60|estrone
P09553686A0000|152 160|estradiol
P09553686A0000|38 40|CAS
P09553686A0000|93 97|women
P09553686A0000|62 64|CAS
P09553686A0000|245 256|applications
P09553686A0000|117 125|menopause
P09553686A0000|172 176|patch
P09553686A0000|28 36|estradiol
P09553686A0000|260 263|days
P09555046A1617|28 37|base change
P09555046A1617|113 120|sequence
P09555046A1617|75 80|intron
P09555046A1617|43 70|branchpoint consensus sequence
P09555046A1617|140 146|mammals
P09555046A1617|94 100|disease
P09555046A1617|3 9|results
P09556557A1238|21 27|regions
P09556561A0671|113 118|guides
P09556561A0671|8 19|H/ACA snoRNAs
P09556561A0671|122 143|pseudouridine synthesis
P09556561A0671|63 67|group
P09556561A0671|159 166|molecule
P09556561A0671|34 38|Gar1p
P09556561A0671|70 76|snoRNAs
P09556561A0671|98 102|yeast
P09556566A0174|26 28|VDR
P09556566A0174|63 70|RXRalpha
P09556566A0174|9 24|vitamin D receptor
P09556566A0174|44 61|acid Xalpha receptor
P09556566A0174|82 98|T cell line MT2 cells
P09556573A1062|76 79|acid
P09556573A1062|50 50|S
P09556573A1062|128 146|co-activator RIP-140
P09556573A1062|112 120|PPARalpha
P09556573A1062|99 109|interaction
P09556573A1062|175 183|PPARalpha
P09556573A1062|203 206|SMRT
P09556573A1062|7 13|studies
P09556573A1062|33 47|PPARalpha ligand
P09556573A1062|162 172|interaction
P09556861A1018|146 154|depletion
P09556861A1018|157 159|ATP
P09556861A1018|17 26|literature
P09556861A1018|95 104|inhibition
P09556861A1018|212 227|protein synthesis
P09556861A1018|31 40|mechanisms
P09556861A1018|64 65|OA
P09556861A1018|164 173|inhibition
P09556861A1018|243 259|lipid peroxidation
P09556861A1018|54 61|toxicity
P09556861A1018|120 130|respiration
P09556861A1018|176 190|tRNA-synthetase
P09556861A1018|84 90|effects
P09557678A0140|74 77|BPV1
P09557678A0140|109 126|carcinoma cell lines
P09557678A0140|79 87|E2 protein
P09557678A0140|90 93|HeLa
P09557678A0140|54 71|papillomavirus type
P09557678A0140|33 42|expression
P09557678A0140|181 201|G1/S phase growth arrest
P09557678A0140|97 100|HT-3
P09557678A0140|149 161|proliferation
P09557682A0490|102 110|splicings
P09557682A0490|12 19|isoforms
P09557682A0490|63 74|combinations
P09557682A0490|37 41|gamma
P09557682A0490|21 30|hGli2 alpha
P09557682A0490|141 148|DNA motif
P09557682A0490|161 163|LTR
P09557682A0490|32 35|beta
P09557682A0490|150 154|TRE2S
P09557682A0490|121 128|isoforms
P09557682A0490|46 50|delta
P09557708A1426|131 135|cells
P09557708A1426|48 56|periphery
P09557708A1426|113 117|cells
P09557708A1426|31 42|IEV particles
P09557708A1426|148 156|vA33delta
P09557708A1426|72 81|microvilli
P09557708A1426|0 20|Specialized actin tails
P09557912A0699|26 29|mmHg
P09557912A0699|211 212|SD
P09557912A0699|20 21|SD
P09557912A0699|304 314|respiration
P09557912A0699|152 160|cessation
P09557912A0699|255 256|SD
P09557912A0699|226 234|cessation
P09557912A0699|48 57|anesthesia
P09557912A0699|9 11|IOP
P09557912A0699|107 115|injection
P09557912A0699|37 45|induction
P09557912A0699|85 91|eyelash
P09557912A0699|137 138|SD
P09557912A0699|274 283|resumption
P09557912A0699|217 220|mmHg
P09557912A0699|70 73|mmHg
P09557912A0699|237 246|convulsion
P09557912A0699|163 182|muscle fasciculations
P09557912A0699|192 204|suxamethonium
P09557912A0699|64 65|SD
P09557912A0699|79 82|loss
P09557912A0699|143 146|mmHg
P09557912A0699|118 130|methohexitone
P09557912A0699|261 264|mmHg
P09560221A0282|141 150|animal CAKs
P09560221A0282|89 109|fission yeast CAK mutant
P09560221A0282|61 65|yeast
P09560221A0282|125 131|protein
P09560221A0282|6 11|cak1At
P09560221A0282|111 116|cak1At
P09560221A0282|1 4|cDNA
P09560221A0282|41 51|CAK mutation
P09560325A1285|18 30|modifications
P09560325A1285|37 49|glycosylation
P09560325A1285|94 105|explanations
P09560325A1285|53 67|phosphorylation
P09560325A1285|112 131|protein heterogeneity
P09560390A0771|2 9|addition
P09560390A0771|39 52|overexpression
P09560390A0771|55 58|sum1
P09560390A0771|103 108|stress
P09560390A0771|77 93|cell cycle response
P09560390A0771|21 37|checkpoint control
P09560430A0000|0 3|Ime1
P09560430A0000|61 65|cells
P09560430A0000|47 53|a/alpha
P09560430A0000|38 44|meiosis
P09560430A0000|17 20|role
P09560430A0000|26 35|initiation
P09561560A0579|0 13|Rhesus macaques
P09561560A0579|106 120|SIV gene products
P09561560A0579|44 68|Mengo virus SIV recombinants
P09561560A0579|166 176|CTL response
P09561560A0579|179 182|mice
P09561560A0579|135 153|HIV-Nef recombinants
P09561560A0579|17 26|BALB/c mice
P09561560A0579|195 208|HIV1 Nef peptide
P09561560A0579|84 95|CTL responses
P09561560A0579|217 225|positions
P09561616A0142|0 11|Deltamethrin
P09561616A0142|77 94|culicifacies adults
P09561616A0142|101 105|weeks
P09561616A0142|133 136|dose
P09561616A0142|62 71|% mortality
P09561616A0142|41 47|surface
P09561616A0142|142 146|mg/m2
P09562398A0848|120 125|values
P09562398A0848|37 39|AUC
P09562398A0848|80 81|.4
P09562398A0848|50 51|.4
P09562398A0848|129 136|n-hexane
P09562398A0848|150 151|.1
P09562398A0848|20 23|turn
P09562398A0848|179 180|.9
P09562398A0848|0 16|Trichloroethylene
P09562558T0000|0 16|Solution structure
P09562558T0000|38 43|domain
P09562558T0000|51 58|subgroup
P09562558T0000|22 26|IRF-2
P09562558T0000|86 91|family
P09564860A2139|119 126|proteins
P09564860A2139|68 80|loop 3i domains
P09564860A2139|113 113|G
P09564860A2139|11 35|receptor/G protein coupling
P09564860A2139|115 117|i/o
P09564860A2139|165 173|receptors
P09564860A2139|95 103|receptors
P09564860A2139|56 65|expression
P09564860A2139|2 9|contrast
P09564860A2315|128 130|GGH
P09564860A2315|205 220|Gs protein pathway
P09564860A2315|87 101|protein coupling
P09564860A2315|51 59|rat GnRH-R
P09564860A2315|169 186|signal transduction
P09564860A2315|108 118|selectivity
P09564860A2315|136 143|cell line
P09564860A2315|149 152|loop
P09564860A2315|82 85|q/11
P09564860A2315|5 8|data
P09564860A2315|42 45|loop
P09564860A2315|72 80|receptor G
P09564917A0900|87 87|p
P09564917A0900|82 85|U/mL
P09564917A0900|9 14|levels
P09564917A0900|17 34|alpha2-antiplasmin
P09564917A0900|56 66|mediastinum
P09565576T0000|28 45|DNA topoisomerase I.
P09565576T0000|10 15|domain
P09565584A0770|155 155|H
P09565584A0770|1 7|cluster
P09565584A0770|54 62|sequences
P09565584A0770|110 113|exon
P09565584A0770|87 90|exon
P09565584A0770|26 29|KKKR
P09565584A0770|15 24|amino acids
P09565584A0770|186 204|mutagenesis analysis
P09565584A0770|141 149|targeting
P09565606A0520|44 46|end
P09565606A0520|81 88|sequence
P09565606A0520|115 118|site
P09565606A0520|22 30|structure
P09565606A0520|49 52|repY
P09565606A0520|95 98|repZ
P09565606A0520|73 79|rCGCC-3
P09566731A0458|143 148|clones
P09566731A0458|8 12|genes
P09566731A0458|93 107|mouse chromosome
P09566731A0458|123 133|cell hybrids
P09566731A0458|44 49|region
P09566731A0458|57 79|chromosome 16p12.1-p11.2
P09566871A0343|142 150|integrase
P09566871A0343|138 140|TyA
P09566871A0343|63 72|processing
P09566871A0343|32 47|protein synthesis
P09566871A0343|104 114|FUS3 strains
P09566871A0343|162 182|transcriptase proteins
P09566871A0343|25 30|Ty1 RNA
P09566871A0343|17 22|levels
P09566871A0343|186 192|Ty1 cDNA
P09566871A0343|2 12|fus3 mutants
P09566871A0343|130 135|levels
P09566871T0000|29 49|Ty1 retrotransposition
P09566871T0000|69 85|protein kinase Fus3
P09566871T0000|17 26|regulation
P09566876A0000|101 123|transcription activation
P09566876A0000|10 31|transcription factor IIA
P09566876A0000|33 37|TFIIA
P09566876A0000|81 91|promoter DNA
P09566876A0000|55 72|TATA binding protein
P09566876A0000|74 76|TBP
P09566882A0693|69 75|binding
P09566882A0693|78 81|Pho4
P09566882A0693|94 97|Pho2
P09566882A0693|5 12|function
P09566882A0693|31 34|Pho2
P09566882A0693|40 47|promoter
P09566918A1115|0 11|Substitution
P09566918A1115|89 93|IRF-3
P09566918A1115|50 52|Asp
P09566918A1115|151 161|PRDI-PRDIII
P09566918A1115|178 185|elements
P09566918A1115|164 167|ISRE
P09566918A1115|121 129|activator
P09566918A1115|83 86|form
P09566918A1115|17 28|Ser-Thr sites
P09566918A1115|132 140|promoters
P09568445T0000|73 91|contractile recovery
P09568445T0000|39 48|infarction
P09568445T0000|9 14|angina
P09568445T0000|97 108|thrombolysis
P09568549A0188|98 101|rats
P09568549A0188|51 55|doses
P09568549A0188|117 125|histamine
P09568549A0188|104 114|serum levels
P09568549A0188|91 94|mice
P09568549A0188|6 10|study
P09568549A0188|58 66|malathion
P09568549A0188|15 20|effect
P09568549A0188|83 88|routes
P09568549A0188|28 41|administration
P09570030T0000|5 21|growth retardation
P09570030T0000|25 29|cause
P09570030T0000|47 57|development
P09570107A0355|28 30|ESP
P09570107A0355|52 57|boiler
P09570107A0355|10 25|PCDFs/PCDDs ratio
P09570133A0474|122 129|proteins
P09570133A0474|96 100|roles
P09570133A0474|67 81|partner proteins
P09570133A0474|23 34|interactions
P09570133A0474|140 148|promoters
P09570133A0474|51 62|interactions
P09570133A0474|2 9|addition
P09570944T0000|0 11|Localization
P09570944T0000|24 32|YAC contig
P09570944T0000|91 106|chromosome 7q21.1
P09570944T0000|64 83|resistance gene region
P09570944T0000|44 45|Mb
P09570944T0000|16 20|exons
P09570952A0000|57 65|M-protein
P09570952A0000|22 33|organization
P09570952A0000|78 84|protein
P09570952A0000|45 48|gene
P09570952A0000|97 106|myofibrils
P09571563A0000|0 6|PURPOSE
P09571563A0000|62 72|keratectomy
P09571563A0000|39 44|cornea
P09571563A0000|155 160|cornea
P09571563A0000|141 149|condition
P09571563A0000|129 135|changes
P09571563A0000|114 126|determination
P09571563A0000|21 33|image analysis
P09571563A0000|74 76|PRK
P09572428A0526|0 3|Mean
P09572428A0526|75 77|PCO
P09572428A0526|66 70|women
P09572428A0526|138 142|women
P09572428A0526|170 174|ng/ml
P09572428A0526|56 56|P
P09572428A0526|108 112|ng/ml
P09572428A0526|153 159|ovaries
P09572428A0526|7 31|SD serum VEGF concentrations
P09572428A0526|81 84|PCOS
P09572491A1044|29 44|missense mutation
P09572491A1044|94 100|alanine
P09572491A1044|104 110|glycine
P09572491A1044|68 70|p53
P09572491A1044|50 56|p53 gene
P09572491A1044|16 20|cells
P09572491A1044|59 63|codon
P09572511A0148|67 72|RBI-EM
P09572511A0148|50 54|block
P09572511A0148|22 28|RBI-MAP
P09572511A0148|74 82|algorithm
P09572511A0148|6 14|algorithm
P09572511A0148|64 65|EM
P09572965A1235|85 93|mechanism
P09572965A1235|135 141|species
P09572965A1235|111 128|virulence phenotype
P09572965A1235|10 13|ORF5
P09572965A1235|20 27|homology
P09572965A1235|6 8|ORF
P09572965A1235|32 39|gene agrB
P09572965A1235|96 105|regulation
P09572990A0630|89 94|Stat-3
P09572990A0630|156 162|agarose
P09572990A0630|130 138|hSIE probe
P09572990A0630|38 50|MHC-I ligation
P09572990A0630|20 23|hSIE
P09572990A0630|106 113|extracts
P09572990A0630|2 12|association
P09572990A0630|27 32|Stat-3
P09573187T0000|15 24|repression
P09573187T0000|72 83|binding sites
P09573187T0000|44 56|regulator CatR
P09573202A0900|141 146|domain
P09573202A0900|80 86|glycine
P09573202A0900|101 111|acid residue
P09573202A0900|114 121|position
P09573202A0900|66 77|substitution
P09573202A0900|40 51|alpha subunit
P09573202A0900|29 34|levels
P09573244A0523|44 67|polyadenylation site usage
P09573244A0523|8 18|mRNA species
P09573374A0687|88 99|cosmid clones
P09573374A0687|182 190|structure
P09573374A0687|28 45|restriction mapping
P09573374A0687|148 155|IRF1 gene
P09573374A0687|55 57|YAC
P09573374A0687|5 24|Southern blot analysis
P09573374A0687|118 124|RIL gene
P09573374A0687|74 83|chromosome
P09573374A0687|132 133|kb
P09573374A0687|59 63|yeast
P09573378A0761|0 2|U73
P09573378A0761|50 64|complementarity
P09573378A0761|17 23|D' boxes
P09573378A0761|11 11|C
P09573378A0761|82 84|RNA
P09573378A0761|13 13|D
P09573884A0392|72 80|retrusive
P09573884A0392|112 119|subjects
P09573884A0392|27 31|S-N-B
P09573884A0392|106 110|Class
P09573884A0392|35 41|S-N-Pog
P09573884A0392|83 87|Class
P09573884A0392|18 25|position
P09574799A1072|162 171|sanitation
P09574799A1072|42 48|factors
P09574799A1072|212 221|conditions
P09574799A1072|129 142|food inspection
P09574799A1072|63 74|malnutrition
P09574799A1072|55 61|poverty
P09574799A1072|178 190|helminthiases
P09574799A1072|113 116|lack
P09574799A1072|0 14|Echinostomiasis
P09574799A1072|105 110|market
P09575143A1189|28 37|cell cortex
P09575143A1189|184 186|TCR
P09575143A1189|65 72|activity
P09575143A1189|113 119|ability
P09575143A1189|75 91|SRC-family kinases
P09575143A1189|163 178|activation motifs
P09575143A1189|135 148|immunoreceptor
P09575143A1189|17 22|ZAP-70
P09575143A1189|3 14|localization
P09575187A1558|55 70|ER calcium release
P09575187A1558|103 111|sAPPalpha
P09575187A1558|88 91|data
P09575187A1558|37 45|apoptosis
P09575187A1558|167 180|kappaB decoy DNA
P09575187A1558|152 157|effect
P09575187A1558|9 12|role
P09575187A1558|140 148|apoptosis
P09575187A1558|16 24|NF-kappaB
P09575217A0000|4 20|cytokine receptors
P09575217A0000|55 58|Jaks
P09575217A0000|63 79|signal transducers
P09575217A0000|27 53|Janus protein tyrosine kinases
P09575217A0000|95 107|transcription
P09575217A0000|109 113|Stats
P09575217A0000|125 133|signaling
P09575217A0000|83 92|activators
P09575217A0971|58 72|phosphorylation
P09575217A0971|75 78|Jak2
P09575217A0971|112 136|Stat5 hyperphosphorylation
P09575217A0971|98 106|C terminus
P09575217A0971|32 45|Stat5 SH2 domain
P09575217A0971|85 92|deletion
P09575217A0971|14 26|R618K mutation
P09576230T0000|41 57|reperfusion injury
P09576230T0000|95 100|arrest
P09576230T0000|63 67|brain
P09576230T0000|3 8|effect
P09576230T0000|17 38|oxide synthase inhibitor
P09576915A0269|70 78|silencers
P09576915A0269|28 30|HMR
P09576915A0269|13 25|recombination
P09576915A0269|65 65|E
P09576915A0269|47 51|rings
P09577365A0747|186 202|muscularis mucosae
P09577365A0747|176 180|level
P09577365A0747|63 74|collagen type
P09577365A0747|36 41|mucosa
P09577365A0747|152 156|cases
P09577365A0747|24 30|vessels
P09577365A0747|163 170|staining
P09577365A0747|95 101|vessels
P09577365A0747|107 115|submucosa
P09577365A0747|2 15|angiodysplasia
P09577365A0747|131 137|vessels
P09577395A0000|137 149|low-amplitude
P09577395A0000|61 68|impulses
P09577395A0000|40 42|VOR
P09577395A0000|168 176|rotations
P09577395A0000|156 162|degrees
P09577395A0000|125 134|degrees/s2
P09577395A0000|71 75|brief
P09577395A0000|46 53|response
P09578042A0363|30 37|patterns
P09578042A0363|111 118|patients
P09578042A0363|104 108|group
P09578042A0363|144 146|TLE
P09578042A0363|85 93|SEEG/ECoG
P09578042A0363|61 74|seizure outcome
P09578042A0363|131 142|lobe epilepsy
P09578570A0200|29 32|gene
P09578570A0200|89 99|combination
P09578570A0200|36 43|protein Z
P09578570A0200|6 10|study
P09578570A0200|135 143|isolation
P09578570A0200|174 180|library
P09578570A0200|102 117|PCR amplification
P09578570A0200|63 71|structure
P09578570A0200|48 59|organization
P09578570A0200|120 131|leukocyte DNA
P09578570A0200|146 156|phage clones
P09579602A1720|89 97|reduction
P09579602A1720|130 136|results
P09579602A1720|117 127|calculation
P09579602A1720|5 17|modifications
P09579602A1720|46 60|reproducibility
P09579602A1720|100 113|sample handling
P09579602A1720|63 80|CD34 determinations
P09579789A0974|117 135|discrimination tasks
P09579789A0974|10 16|results
P09579789A0974|101 113|odor detection
P09579789A0974|77 80|bulb
P09579789A0974|32 35|rats
P09579789A0974|92 98|variety
P09579789A0974|158 165|controls
P09579789A0974|55 62|remnants
P09579808A0000|0 9|UDP-GlcNAc
P09579808A0000|39 69|N-acetylglucosaminyltransferase
P09579808A0000|11 35|alpha-6-D-mannoside beta-1
P09579808A0000|73 75|GnT
P09579808A0000|114 121|assembly
P09579808A0000|141 147|glycans
P09579808A0000|79 80|EC
P09580062A0100|116 119|dose
P09580062A0100|123 131|mg/kg/day
P09580062A0100|41 56|cyclophosphamide
P09580062A0100|5 12|patients
P09580062A0100|99 111|cyclosporine A
P09580062A0100|60 67|steroids
P09580563A0331|129 136|nidulans
P09580563A0331|35 35|%
P09580563A0331|61 66|dynein
P09580563A0331|12 28|amino acid sequence
P09580563A0331|100 100|%
P09580563A0331|79 94|Neurospora crassa
P09580563A0331|144 144|%
P09580563A0331|72 76|chain
P09580700A0841|89 92|CIRs
P09580700A0841|125 130|region
P09580700A0841|33 53|repressor preparations
P09580700A0841|151 162|footprinting
P09580700A0841|94 102|CIR3-CIR6
P09580700A0841|3 22|DNA binding activities
P09580700A0841|70 78|fragments
P09580700A0841|133 141|templates
P09580700A0841|145 149|DNase
P09581552A1323|88 99|interactions
P09581552A1323|9 17|modelling
P09581552A1323|69 74|bundle
P09581552A1323|124 133|amino acids
P09581552A1323|34 54|tetramerization domain
P09581775A0185|180 188|signaling
P09581775A0185|114 117|U937
P09581775A0185|159 163|cells
P09581775A0185|12 16|study
P09581775A0185|119 125|U9-IIIB
P09581775A0185|142 148|PLB-985
P09581775A0185|58 74|NF-kappaB activity
P09581775A0185|150 157|PLB-IIIB
P09581834A2578|204 211|G1 arrest
P09581834A2578|90 92|PCA
P09581834A2578|77 82|effect
P09581834A2578|157 172|signaling pathway
P09581834A2578|104 109|effect
P09581834A2578|127 136|impairment
P09581834A2578|37 45|silymarin
P09581834A2578|185 189|CDKIs
P09581834A2578|19 25|results
P09581834A2578|174 182|induction
P09581872A0000|45 48|type
P09581872A0000|12 17|tissue
P09581872A0000|50 67|collagen expression
P09581872A0000|19 31|cell structure
P09582267A0326|133 137|cells
P09582267A0326|12 19|function
P09582267A0326|141 160|GM701 fibroblast cells
P09582267A0326|173 184|growth arrest
P09582267A0326|83 89|Siah-1A
P09582267A0326|48 55|proteins
P09582267A0326|203 211|apoptosis
P09582267A0326|57 74|expression plasmids
P09582267A0326|43 46|Siah
P09582267A0326|192 200|induction
P09582306T0000|26 33|Galphai1
P09582306T0000|66 90|G protein signaling proteins
P09582306T0000|55 63|regulator
P09582306T0000|16 22|Galphao
P09582306T0000|40 50|interaction
P09582306T0000|1 13|point mutation
P09582308A1165|99 110|heterodimers
P09582308A1165|80 88|formation
P09582308A1165|33 41|formation
P09582308A1165|91 94|homo
P09582308A1165|60 69|homodimers
P09582326A0151|14 15|E.
P09582326A0151|6 12|Fanning
P09582326A0151|0 1|N.
P09582327A0295|313 323|stimulation
P09582327A0295|94 103|expression
P09582327A0295|78 82|cells
P09582327A0295|178 185|sequence
P09582327A0295|227 232|region
P09582327A0295|51 69|rat GnRH receptor cDNA
P09582327A0295|326 333|activity
P09582327A0295|25 32|GH3 cells
P09582327A0295|290 300|GnRH agonist
P09582327A0295|71 76|GGH3-1
P09582327A0295|241 258|luciferase reporter
P09582327A0295|154 166|rat LHbeta gene
P09582327A0295|120 129|fusion gene
P09582327A0295|267 275|LHbetaLUC
P09582327A0295|198 206|base pairs
P09582327A0295|143 151|base pairs
P09582331A0506|86 91|GATA-1
P09582331A0506|54 57|TATA
P09582331A0506|25 34|nucleotide
P09582331A0506|69 77|CAAT boxes
P09582331A0506|93 95|SP1
P09582331A0506|134 141|elements
P09582331A0506|14 19|region
P09582343A0000|30 40|cell line SX9
P09582343A0000|52 72|carcinoma cell line FM3A
P09582350A0165|85 88|loss
P09582350A0165|110 130|ketoacid dehydrogenase
P09582350A0165|140 149|activities
P09582350A0165|91 92|E1
P09582350A0165|46 59|E1alpha subunit
P09582350A0165|2 9|patients
P09582350A0165|14 41|type IA maple syrup urine disease
P09582635A0523|0 6|Results
P09582635A0523|38 52|H.T.V. specimens
P09582635A0523|73 78|kg/cm2
P09582635A0523|20 35|mean bond strength
P09582635A0523|88 103|mean bond strength
P09582635A0523|106 120|R.T.V. specimens
P09582635A0523|141 146|kg/cm2
P09582953A0000|0 9|OBJECTIVES
P09582953A0000|185 185|X
P09582953A0000|340 346|changes
P09582953A0000|187 189|F.X
P09582953A0000|280 284|colic
P09582953A0000|258 267|population
P09582953A0000|229 247|acute-phase response
P09582953A0000|20 40|coagulation factor VIII
P09582953A0000|52 57|F.VIII
P09582953A0000|114 140|acute-phase reactant proteins
P09582953A0000|85 90|C1-INH
P09582953A0000|288 310|hemostasis abnormalities
P09582953A0000|64 83|C1-esterase inhibitor
P09582953A0000|42 50|coagulant
P09582953A0000|166 170|F.VII
P09582953A0000|192 209|hemostasis proteins
P09582953A0000|176 177|F.
P09582953A0000|144 164|coagulation factors VII
P09582953A0000|59 59|C
P09582953A0000|270 275|horses
P09582953A1097|0 6|RESULTS
P09582953A1097|45 67|fibrinogen concentration
P09582953A1097|138 143|horses
P09582953A1097|8 13|Horses
P09582953A1097|115 116|PT
P09582953A1097|18 22|colic
P09582953A1097|120 123|APTT
P09582953A1097|76 83|alpha 2AP
P09582953A1097|87 104|protein C activities
P09582953A1670|42 47|C1-INH
P09582953A1670|3 6|data
P09582953A1670|18 28|plasminogen
P09582953A1670|73 91|acute-phase proteins
P09582953A1670|30 37|alpha 2AP
P09583201A0759|0 3|None
P09583201A0759|9 16|patients
P09583208A0171|60 73|immunoglobulin
P09583208A0171|6 14|elevation
P09583208A0171|78 87|complement
P09583208A0171|17 30|creatine kinase
P09583208A0171|47 58|serum albumin
P09583592A0263|0 5|DESIGN
P09583592A0263|9 15|METHODS
P09583592A0263|17 25|Case study
P09583823A0238|0 6|METHODS
P09583823A0238|122 128|holmium
P09583823A0238|154 155|Ho
P09583823A0238|215 215|n
P09583823A0238|209 213|group
P09583823A0238|18 21|pigs
P09583823A0238|69 83|infarction group
P09583823A0238|130 152|yttrium-aluminium garnet
P09583823A0238|92 95|TMLR
P09583823A0238|178 178|n
P09583823A0238|161 165|laser
P09583823A0238|38 45|ligation
P09583823A0238|60 67|arteries
P09583823A0238|157 159|YAG
P09583823A0238|167 176|laser group
P09583823A0238|9 13|total
P09583823A0238|85 85|n
P09583823A0238|112 115|wall
P09584165T0000|0 4|RACK1
P09584165T0000|38 44|homolog
P09584165T0000|7 14|receptor
P09584165T0000|120 130|NIH 3T3 cells
P09584165T0000|63 71|G proteins
P09584165T0000|50 60|beta subunit
P09584165T0000|81 88|activity
P09584165T0000|91 108|src tyrosine kinases
P09584165T0000|27 33|C kinase
P09584165T0000|112 117|growth
P09584179A0673|0 15|Peptide sequences
P09584179A0673|47 70|transcription factor Adf-1
P09584179A0673|21 40|zinc finger protein Ttk
P09584180A0701|86 102|NF-kappaB proteins
P09584180A0701|78 82|Stat6
P09584180A0701|21 32|reporter gene
P09584180A0701|120 139|I.29mu B lymphoma cells
P09584194A0000|0 3|HEF1
P09584194A0000|109 118|regulation
P09584194A0000|36 41|family
P09584194A0000|10 12|Cas
P09584194A0000|18 24|Efs/Sin
P09584194A0000|5 8|p130
P09584194A0000|55 69|docking proteins
P09584194A0000|121 132|cell adhesion
P09584194A1305|115 126|protein Dim1p
P09584194A1305|93 96|G2/M
P09584194A1305|178 180|p55
P09584194A1305|153 158|region
P09584194A1305|21 27|spindle
P09584194A1305|138 147|interactor
P09584194A1305|12 15|role
P09584194A1305|39 54|library screening
P09584194A1305|182 185|HEF1
P09584194A1305|81 87|homolog
P09584194A1305|161 164|HEF1
P09584194A1305|59 62|HEF1
P09584194A1305|2 8|support
P09585253A1147|173 187|MDA-MB-231 cells
P09585253A1147|51 60|activation
P09585253A1147|77 96|breast carcinoma cells
P09585253A1147|63 74|TF expression
P09585253A1147|141 147|pathway
P09585253A1147|125 134|activation
P09585253A1147|32 45|raf-ERK pathway
P09585253A1147|159 170|TF expression
P09585253A1147|3 6|data
P09585253A1147|17 26|activation
P09585540A0440|88 111|agent 1,10-phenanthroline
P09585540A0440|53 60|dialysis
P09585540A0440|22 27|enzyme
P09586285A0551|3 10|patients
P09586285A0551|61 65|years
P09586285A0551|22 47|H. influenza type b meningitis
P09586832A0229|59 67|receptors
P09586832A0229|3 7|lines
P09587549T0001|37 51|interferon alpha
P09587549T0001|24 32|treatment
P09587549T0001|10 16|seizure
P09587549T0001|67 76|hepatitis C
P09588228A0370|22 36|anticytokeratin
P09588228A0370|99 108|MPM tissues
P09588228A0370|39 46|antibody
P09588228A0370|61 68|staining
P09590294A0453|7 13|studies
P09590294A0453|76 87|Notch pathway
P09590294A0453|38 51|identification
P09590294A0453|61 70|components
P09590540A0513|26 27|kb
P09590540A0513|20 21|nt
P09590540A0513|155 162|fragment
P09590540A0513|209 226|lac operator control
P09590540A0513|230 241|pQE-30 vector
P09590540A0513|171 175|frame
P09590540A0513|39 47|sequences
P09590540A0513|191 200|T5 promoter
P09590540A0513|136 144|Sac1-Sal1
P09590540A0513|111 116|domain
P09590540A0513|67 80|signal sequence
P09590540A0513|121 123|PCR
P09590540A0513|3 10|bZP2 cDNA
P09591221A0137|0 14|Control subjects
P09591221A0137|22 31|potentials
P09591221A0137|65 74|positivity
P09591221A0137|33 35|EPs
P09591221A0137|94 95|P1
P09591221A0137|86 92|ms range
P09591221A0137|119 122|site
P09592125A0000|0 4|Class
P09592125A0000|6 26|alpha1,2-mannosidases
P09592125A0000|64 70|complex
P09592125A0000|51 61|elaboration
P09592125A0000|42 45|role
P09592125A0000|82 88|glycans
P09592125A0000|74 80|hybrid N
P09592125A0000|100 104|cells
P09592168T0000|30 45|DNA binding domain
P09592168T0000|63 96|nucleotide excision repair protein XPA
P09592168T0000|10 17|features
P09592168T0000|47 54|M98-F219
P09592208A0470|120 123|data
P09592208A0470|25 28|book
P09592208A0470|141 153|possibilities
P09592208A0470|12 20|qualities
P09592208A0470|92 103|construction
P09592208A0470|185 194|statistics
P09592208A0470|50 53|fact
P09592208A0470|31 40|importance
P09592219A0652|3 9|results
P09592219A0652|49 60|intervention
P09592219A0652|20 32|effectiveness
P09593302A1165|121 126|phenol
P09593302A1165|36 53|non-responsiveness
P09593302A1165|108 114|ability
P09593302A1165|77 84|A-domain
P09593302A1165|14 25|implications
P09594299A0468|100 108|reduction
P09594299A0468|140 142|hip
P09594299A0468|88 91|year
P09594299A0468|124 134|dislocation
P09594299A0468|53 56|time
P09594299A0468|18 22|index
P09594299A0468|0 6|RESULTS
P09595496A0000|30 41|endothelin-1
P09595496A0000|76 80|fluid
P09595496A0000|22 27|levels
P09595496A0000|108 114|surgery
P09595496A0000|83 90|patients
P09595496A0000|43 46|ET-1
P09596536A0219|28 45|knee loading changes
P09596536A0219|91 111|cartilage degeneration
P09596536A0219|55 68|ACL transection
P09596542A0542|13 20|surfaces
P09596542A0542|91 94|core
P09596542A0542|31 45|cartilage matrix
P09596638T0000|59 69|Arabidopsis
P09596638T0000|11 17|mapping
P09596638T0000|23 42|Brassica S locus region
P09596638T0000|49 56|homeolog
P09596738T0000|0 4|Roles
P09596738T0000|10 24|Candida albicans
P09596738T0000|77 87|development
P09596738T0000|63 67|Cek1p
P09596738T0000|99 109|candidiasis
P09596738T0000|42 61|protein kinase homolog
P09598205A0430|41 53|disaccharides
P09598205A0430|10 17|reaction
P09598205A0430|20 34|monosaccharides
P09598205A0430|94 99|maltol
P09598205A0430|58 69|beta-alanine
P09598205A0430|83 91|formation
P09598894A0732|40 49|resorption
P09598894A0732|24 36|bone formation
P09598894A0732|6 13|subjects
P09598894A0732|15 21|markers
P09599102A1191|0 7|Analysis
P09599102A1191|52 61|repression
P09599102A1191|23 32|refractile
P09599102A1191|11 21|Mac1p mutant
P09599102A1191|129 145|copper sensitivity
P09599102A1191|103 109|pattern
P09599102A1191|112 125|CUP1 expression
P09599102A1191|67 68|Cu
P09599102A1191|70 70|I
P09599102A1191|72 85|transport genes
P09599664A0881|72 78|RXR beta
P09599664A0881|49 58|expression
P09599664A0881|61 68|RXR alpha
P09599664A0881|3 15|DNA sequencing
P09599664A0881|32 37|clones
P09599724A0193|116 128|PCDF congeners
P09599724A0193|17 22|sample
P09599724A0193|131 141|blood lipids
P09599724A0193|267 272|cohort
P09599724A0193|47 52|cohort
P09599724A0193|172 183|PCDF exposure
P09599724A0193|109 112|PCDD
P09599724A0193|210 217|exposure
P09599724A0193|153 158|extent
P09599724A0193|243 256|cancer findings
P09599724A0193|33 41|employees
P09599724A0193|165 168|PCDD
P09599724A0193|190 195|cohort
P09599724A0193|55 77|phenoxy herbicide workers
P09599897A0000|175 177|WBC
P09599897A0000|255 268|manifestations
P09599897A0000|72 74|HSP
P09599897A0000|213 218|levels
P09599897A0000|229 231|PLT
P09599897A0000|48 70|Henoch-Schonlein purpura
P09599897A0000|186 190|serum
P09599897A0000|209 211|CRP
P09599897A0000|14 31|laboratory features
P09599897A0000|220 227|platelet
P09599897A0000|132 148|laboratory indices
P09599897A0000|165 173|blood cell
P09599897A0000|36 43|children
P09599897A0000|276 278|HSP
P09599897A0000|110 121|associations
P09599897A0000|201 207|protein
P09601007A0223|87 101|coral reef waters
P09601007A0223|27 30|data
P09601007A0223|180 192|calcification
P09601007A0223|61 76|CO2 concentration
P09601007A0223|168 178|respiration
P09601007A0223|52 58|changes
P09601007A0223|9 17|community
P09601007A0223|197 212|CaCO3 dissolution
P09601007A0223|153 166|photosynthesis
P09601007A0223|119 127|processes
P09601510A0215|70 80|transcripts
P09601510A0215|38 47|FV pol genes
P09601510A0215|22 33|retroviruses
P09601510A0215|2 9|contrast
P09601516A0695|30 37|residues
P09601516A0695|49 56|residues
P09601516A0695|77 90|fusion activity
P09601516A0695|63 66|PEP1
P09601516A0695|120 129|processing
P09601516A0695|96 103|S protein
P09601516A0695|133 149|surface expression
P09601516A0695|0 11|Substitution
P09601921A0000|0 10|Tributyltin
P09601921A0000|178 183|Canada
P09601921A0000|71 80|water birds
P09601921A0000|107 116|Great Lakes
P09601921A0000|151 159|west coast
P09601921A0000|94 102|Lake Huron
P09601921A0000|162 176|British Columbia
P09601921A0000|17 33|breakdown products
P09601921A0000|132 143|United States
P09601921A0000|43 53|di-butyltin
P09601940A0280|101 108|NF-IL2-A
P09601940A0280|24 30|CD1 gene
P09601940A0280|112 117|NF-IL6
P09601940A0280|80 99|transcription factors
P09601940A0280|43 55|binding motifs
P09601940A0280|13 18|region
P09602124A0127|0 6|Fregnac
P09602124A0127|8 9|M.
P09603345A1257|0 6|GLRaV-2
P09603345A1257|157 174|genus Closterovirus
P09603345A1257|88 92|group
P09603345A1257|50 67|genome organization
P09603345A1257|16 28|closterovirus
P09603345A1257|94 96|BYV
P09603345A1257|146 151|member
P09603345A1257|73 82|type member
P09604052A0166|43 54|control group
P09604052A0166|111 123|wrist fracture
P09604052A0166|91 96|sample
P09604052A0166|102 106|women
P09604052A0166|78 82|women
P09604052A0166|22 25|data
P09605137A0677|61 72|IL-2 promoter
P09605137A0677|140 150|Jurkat cells
P09605137A0677|114 118|LFA-3
P09605137A0677|90 107|reporter constructs
P09605137A0677|20 24|c-Jun
P09605137A0677|8 17|expression
P09605137A0677|46 58|transcription
P09605137A0677|28 30|p65
P09605930A1428|89 102|rat hepatocytes
P09605930A1428|32 44|transfections
P09605930A1428|9 15|results
P09605930A1428|123 129|ALS gene
P09605930A1428|48 66|mobility shift assays
P09605934A0801|116 121|family
P09605934A0801|80 85|factor
P09605934A0801|124 143|transcription factors
P09605934A0801|89 94|member
P09605934A0801|17 22|CACGTG
P09605934A0801|4 15|E box sequence
P09605934A0801|40 53|binding element
P09605934A0801|57 59|USF
P09606633A0523|0 20|Interferon beta therapy
P09606633A0523|40 44|weeks
P09606924T0000|30 37|analysis
P09606924T0000|21 26|method
P09606924T0000|40 70|all-rac-alpha-tocopheryl acetate
P09606924T0000|102 114|infant formula
P09606924T0000|74 89|retinyl palmitate
P09606924T0000|120 146|matrix solid-phase dispersion
P09606924T0000|0 5|Liquid
P09609342A0000|126 136|performance
P09609342A0000|89 96|flow pump
P09609342A0000|65 72|flow pump
P09609342A0000|98 100|AFP
P09609342A0000|74 76|MFP
P09609342A0000|19 23|types
P09609342A0000|49 52|pump
P09609342A0000|54 56|CFP
P09609342A0000|26 35|turbo pumps
P09609705A0895|0 10|Examination
P09609705A0895|86 87|V.
P09609705A0895|71 72|L.
P09609705A0895|65 69|Huang
P09609705A0895|29 54|bc1 complex crystal structure
P09609705A0895|56 60|Zhang
P09609705A0895|62 63|Z.
P09609705A0895|74 84|Shulmeister
P09609720A0357|103 111|proteases
P09609720A0357|41 41|N
P09609720A0357|142 147|region
P09609720A0357|126 132|protein
P09609720A0357|67 74|nuclease
P09609720A0357|21 29|fragments
P09609720A0357|56 61|halves
P09610755A1731|73 81|degrees/s
P09610755A1731|83 83|p
P09610755A1731|54 56|EXT
P09610755A1731|3 24|side-to-side difference
P09610755A1731|59 67|degrees/s
P09611016A0652|99 105|pessary
P09611016A0652|124 132|pessaries
P09611016A0652|110 118|placement
P09611016A0652|13 17|women
P09611016A0652|46 55|management
P09611016A0652|64 71|prolapse
P09611016A0652|0 9|CONCLUSION
P09611016A0652|58 62|grade
P09611229A1664|72 80|existence
P09611229A1664|38 60|nmt1-451Dino2 Delta cells
P09611229A1664|125 143|expression/activity
P09611229A1664|112 118|factors
P09611229A1664|171 176|levels
P09611229A1664|90 108|transcription factor
P09611229A1664|187 210|protein N-myristoy-lation
P09611229A1664|20 29|expression
P09611229A1664|3 9|ability
P09611229A1664|32 35|FAS1
P09611234A0098|0 17|Rev-erbAalpha/beta
P09611234A0098|53 68|oncoproteins PLZF
P09611234A0098|28 46|Mad bHLH-zip proteins
P09611234A0098|96 112|corepressors N-CoR
P09611234A0098|116 119|SMRT
P09611234A0098|72 80|LAZ3/BCL6
P09611234A0098|20 24|Mxi-1
P09611877A0455|23 25|CSF
P09611877A0455|49 52|ECHO
P09611877A0455|13 20|isolates
P09611877A0455|59 62|ECHO
P09611877A0455|70 73|ECHO
P09612351A0386|33 43|oscillation
P09612351A0386|10 17|evidence
P09612351A0386|53 59|ULF band
P09612775A0726|3 17|ParaSight-F test
P09612775A0726|75 82|patients
P09612775A0726|62 70|treatment
P09612775A0726|39 56|serum antigen levels
P09613574A0905|85 96|methyl groups
P09613574A0905|186 188|min
P09613574A0905|22 28|protein
P09613574A0905|166 173|degrees C
P09613574A0905|136 143|activity
P09613574A0905|104 115|substrate DNA
P09613574A0905|71 78|transfer
P09613574A0905|45 58|enzyme activity
P09613574A0905|82 83|3H
P09613574A0905|121 131|MGMT protein
P09613946A0194|1 25|deproteinization procedure
P09613946A0194|55 68|HPLC separation
P09613946A0194|82 87|mm I.D.
P09614065A0966|145 153|induction
P09614065A0966|25 32|response
P09614065A0966|90 97|presence
P09614065A0966|53 60|mutation
P09614065A0966|108 111|EpRE
P09614065A0966|67 75|sequences
P09614065A0966|123 130|AP-1 site
P09614065A0966|0 10|Elimination
P09614106T0000|109 118|expression
P09614106T0000|9 16|mobility
P09614106T0000|27 35|sequences
P09614106T0000|67 76|Col2a1 gene
P09614106T0000|50 61|pair enhancer
P09617765A0174|83 88|region
P09617765A0174|108 108|A
P09617765A0174|110 113|tail
P09617765A0174|61 66|strand
P09617765A0174|25 36|reading frame
P09617765A0174|43 44|nt
P09617765A0174|103 106|poly
P09617765A0174|3 10|sequence
P09617765A0174|95 96|nt
P09617807A0929|118 124|element
P09617807A0929|185 192|elements
P09617807A0929|82 91|assessment
P09617807A0929|107 109|pea
P09617807A0929|13 20|analysis
P09617807A0929|96 102|Cyclops
P09617807A0929|197 202|plants
P09617807A0929|139 150|relationship
P09617807A0929|33 51|transcriptase domain
P09618150A0127|231 239|treatment
P09618150A0127|211 218|increase
P09618150A0127|151 151|h
P09618150A0127|105 110|dbcAMP
P09618150A0127|124 148|UCP1 gene transcription rate
P09618150A0127|53 57|IGF-I
P09618150A0127|15 19|doses
P09618150A0127|245 246|h.
P09618150A0127|160 179|UCP1 mRNA accumulation
P09618150A0127|182 182|h
P09618150A0127|91 103|dibutyryl cAMP
P09618150A0127|39 51|growth factor I
P09618150A0127|197 202|effect
P09618150A0127|61 67|insulin
P09618150A1464|2 9|addition
P09618150A1464|52 57|effect
P09618150A1464|25 46|AP-1 DNA binding activity
P09618150A1464|11 17|insulin
P09618150A1464|94 107|MEK-1 inhibitor
P09618150A1464|84 91|presence
P09618164A0709|46 51|OMeRNA
P09618164A0709|17 42|methyl oligoribonucleotides
P09618164A0709|71 76|nuclei
P09618164A0709|86 97|mdx myoblasts
P09618164A0709|100 106|culture
P09618164A0709|15 15|O
P09618475A0747|41 55|down-regulation
P09618475A0747|6 13|deletion
P09618475A0747|94 97|Nrd1
P09618475A0747|30 34|motif
P09618475A0747|84 91|function
P09618481T0000|0 9|Regulation
P09618481T0000|92 108|Smad family members
P09618481T0000|20 40|p21/WAF1/Cip1 promoter
P09618481T0000|67 78|interactions
P09618481T0000|50 54|cells
P09618481T0000|86 88|Sp1
P09619631A0344|0 6|RESULTS
P09619631A0344|105 115|p120 Ras-GAP
P09619631A0344|19 31|C. elegans cDNA
P09619631A0344|44 50|protein
P09619777A1583|88 92|Fluid
P09619777A1583|159 163|state
P09619777A1583|100 105|pepsin
P09619777A1583|218 222|hours
P09619777A1583|185 194|conditions
P09619777A1583|107 111|SGFsp
P09619777A1583|234 248|state conditions
P09619777A1583|7 22|base ketoconazole
P09619777A1583|37 47|dissolution
P09619777A1583|131 142|% dissolution
P09619777A1583|203 214|% dissolution
P09619777A1583|121 127|minutes
P09619777A1583|59 69|formulation
P09619777A1583|146 150|hours
P09620273A0189|72 88|cell proliferation
P09620273A0189|53 59|cyclins
P09620273A0189|111 133|E2F transcription factors
P09620273A0189|91 97|binding
P09620273A0189|2 8|mammals
P09620273A0189|13 21|Rb protein
P09620606A0000|84 90|signals
P09620606A0000|49 54|T cells
P09620606A0000|45 47|TCR
P09620606A0000|32 39|ligation
P09620606A0000|2 9|addition
P09620606A0000|15 21|signals
P09620873A1710|73 81|pregnancy
P09620873A1710|12 22|observation
P09620873A1710|33 59|luteal HSP-27 phosphorylation
P09620873A1710|162 186|sHSP phosphorylation events
P09620873A1710|134 149|PKC family members
P09620873A1710|87 95|PKC-delta
P09620955A0370|145 153|lac operon
P09620955A0370|33 42|leader mRNA
P09620955A0370|53 64|program Mfold
P09620955A0370|18 26|structure
P09620955A0370|69 79|combination
P09620955A0370|99 107|deletions
P09621062A0810|43 52|activation
P09621062A0810|128 134|mutants
P09621062A0810|78 88|mutagenesis
P09621062A0810|140 185|chloramphenicol acetyltransferase reporter system
P09621062A0810|20 24|sites
P09621062A0810|99 122|promoter function analysis
P09621062A0810|3 12|importance
P09621372A0369|92 98|enzymes
P09621372A0369|42 57|thrombocytopenia
P09621372A0369|67 69|CRP
P09621372A0369|7 22|blood examination
P09621372A0369|29 40|leukocytosis
P09621893A0000|59 72|responsiveness
P09621893A0000|83 102|alpha2-adrenoceptors
P09621893A0000|8 14|studies
P09621893A0000|47 55|increases
P09622055A0207|84 88|Sli-1
P09622055A0207|46 52|mammals
P09622055A0207|109 113|D-Cbl
P09622055A0207|74 82|C. elegans
P09622055A0207|54 58|c-Cbl
P09622055A0207|62 66|Cbl-b
P09622055A0207|3 9|members
P09622055A0207|15 23|Cbl family
P09622121A0525|43 45|PTB
P09622121A0525|34 40|binding
P09622121A0525|72 97|supershift RNA-PTB complexes
P09622121A0525|8 17|antibodies
P09622121A0525|48 50|RNA
P09622121T0000|73 89|protein components
P09622121T0000|8 17|antibodies
P09622121T0000|23 55|polypyrimidine tract binding protein
P09622121T0000|57 59|PTB
P09622121T0000|124 132|pre-mRNAs
P09622121T0000|147 158|branch points
P09622121T0000|3 5|use
P09623830A0000|14 16|use
P09623830A0000|34 38|Botox
P09623830A0000|19 32|botulinum toxin
P09623830A0000|54 63|popularity
P09625762A0426|44 58|transactivation
P09625762A0426|8 21|oncoprotein E1A
P09625762A0426|76 81|manner
P09625807A0000|32 44|display method
P09625807A0000|64 68|mRNAs
P09625807A0000|115 126|cell cultures
P09625807A0000|148 165|carcinoma cell lines
P09625807A0000|16 19|mRNA
P09626662A1076|59 68|RXR subunit
P09626662A1076|7 17|experiments
P09626662A1076|48 53|RIP140
P09626662A1076|38 45|affinity
P09626662A1076|105 121|TR/RXR heterodimer
P09626662A1076|22 23|TR
P09626662A1076|93 99|partner
P09626662A1076|147 152|ligand
P09627285A0160|0 6|SETTING
P09627285A0160|41 61|care infertility center
P09627285A0160|8 17|University
P09627285A0554|43 50|cycle day
P09627285A0554|7 7|S
P09627285A0554|106 112|ampules
P09627285A0554|98 103|number
P09627285A0554|12 19|patients
P09627285A0554|115 117|hMG
P09627285A0554|32 40|FSH levels
P09627285A0554|57 67|oocyte yield
P09627285A0554|0 5|RESULT
P09627598A0384|0 6|RESULTS
P09627598A0384|152 159|subjects
P09627598A0384|110 131|otolith system imbalance
P09627598A0384|91 98|OVAR test
P09627598A0384|101 107|measure
P09627598A0384|54 59|values
P09627598A0384|30 30|%
P09627598A0384|73 85|preponderance
P09627598A0384|13 20|patients
P09628375A0700|5 18|ePTFE specimens
P09628375A0700|20 33|tissue coverage
P09628419A0812|45 53|durations
P09628419A0812|23 40|Kristofferson model
P09628419A0812|66 69|ISIs
P09628419A0812|16 19|Wing
P09628821A1194|56 60|genes
P09628821A1194|72 76|roles
P09628821A1194|107 117|progression
P09628821A1194|35 44|candidates
P09628821A1194|18 31|KG1a EST dataset
P09628821A1194|121 137|lineage commitment
P09628890A0455|28 36|mutations
P09628890A0455|10 18|following
P09628890A0455|91 98|HA trimer
P09628890A0455|55 75|carbohydrate structure
P09629449A0540|3 9|results
P09629449A0540|75 87|concentration
P09629449A0540|39 49|spermatozoa
P09629449A0540|107 112|number
P09629449A0540|90 100|PMN elastase
P09629449A0540|18 30|ROS production
P09629449A0540|146 150|cells
P09630245A0102|103 107|yeast
P09630245A0102|52 62|counterpart
P09630245A0102|111 117|metazoa
P09630245A0102|125 138|splicing events
P09630245A0102|85 95|differences
P09630245A0102|0 11|Yeast U1 snRNP
P09630245A0903|0 11|Yeast U1 snRNP
P09630245A0903|63 79|snRNP core proteins
P09630245A0903|40 47|proteins
P09630245A0903|154 168|U1 snRNP proteins
P09630245A0903|125 132|proteins
P09630245A0903|86 95|homologues
P09630245A0903|101 110|metazoan U1
P09631366A0951|13 17|cycle
P09631366A0951|21 25|cases
P09631366A0951|62 66|cycle
P09631366A0951|88 96|dose level
P09631366A0951|39 47|dose level
P09631366A0951|70 74|cases
P09632217A0477|174 180|cocaine
P09632217A0477|9 28|antagonist naltrexone
P09632217A0477|99 108|naltrexone
P09632217A0477|122 126|mg/kg
P09632217A0477|111 115|doses
P09632217A0477|38 42|mg/kg
P09632217A0477|89 94|heroin
P09632217A0477|72 86|stimulus effects
P09632217A0477|132 137|effect
P09632217A0477|157 171|stimulus effects
P09632637A0361|175 178|CCl4
P09632637A0361|36 49|cell regulation
P09632637A0361|155 173|carbon tetrachloride
P09632637A0361|142 145|rats
P09632637A0361|52 71|M6P/IGFIIR expression
P09632637A0361|198 206|stimulant
P09632637A0361|6 10|study
P09632637A0361|84 113|M6P/IGFIIR mRNA transcript levels
P09632637A0361|133 137|cells
P09632709A0464|146 159|gene expression
P09632709A0464|75 78|BX42
P09632709A0464|47 53|protein
P09632709A0464|22 28|NCoA-62
P09632709A0464|110 116|protein
P09632709A0464|3 11|cDNA clone
P09632734A0081|44 49|region
P09632734A0081|125 134|Rab3 family
P09632734A0081|89 93|group
P09632734A0081|96 118|GDP/GTP exchange proteins
P09632734A0081|20 27|proteins
P09632734A0081|70 85|sequence homology
P09632734A0081|142 159|GTP binding proteins
P09632734A0943|54 56|p70
P09632734A0943|25 30|effect
P09632734A0943|80 87|activity
P09632734A0943|33 46|ERK2 activation
P09632734A0943|7 19|p82 expression
P09632734A0943|49 52|p126
P09632785A0000|30 31|U2
P09632785A0000|114 132|splice site selection
P09632785A0000|106 109|role
P09632785A0000|85 90|factor
P09632785A0000|44 68|ribonucleoprotein particle
P09632785A0000|70 74|snRNP
P09632785A0000|3 28|pre-mRNA splicing factor U2AF
P09633171A0321|85 99|room temperature
P09633171A0321|66 72|storage
P09633171A0321|48 55|incisors
P09633171A0321|75 82|tap water
P09633171A0321|164 177|testing machine
P09633171A0321|105 109|hours
P09633171A0321|3 10|brackets
P09633171A0321|140 148|shear mode
P09633274A0000|0 15|Exercise training
P09633274A0000|62 81|heart failure patients
P09633274A0000|51 59|treatment
P09633630A0740|44 57|lettuce extract
P09633630A0740|91 93|BMC
P09633630A0740|153 155|v/v
P09633630A0740|11 13|Aer
P09633630A0740|3 8|growth
P09633630A0740|107 108|Ps
P09633630A0740|151 151|%
P09633630A0740|110 120|fluorescens
P09633630A0740|87 89|v/v
P09633630A0740|85 85|%
P09633630A0740|157 159|BMC
P09633630A0740|15 24|hydrophila
P09633879A0246|118 122|years
P09633879A0246|83 90|patients
P09633879A0246|51 69|serum ferritin levels
P09633879A0246|105 109|group
P09633879A0246|39 48|resurgence
P09633879A0246|125 126|L1
P09633879A0246|97 103|veteran
P09633879A0246|17 26|compliance
P09635149A1148|0 9|Hematocrit
P09635149A1148|13 16|PaO2
P09635276A1608|45 51|changes
P09635276A1608|54 72|subunit interactions
P09635276A1608|12 36|myosin phosphatase activity
P09635276A1608|91 100|mechanisms
P09635276A1608|0 9|Regulation
P09636119T0000|59 63|plant
P09636119T0000|68 74|pulleys
P09636119T0000|19 27|generator
P09636358A0000|143 151|infection
P09636358A0000|93 103|translation
P09636358A0000|61 63|RNA
P09636358A0000|133 137|times
P09636358A0000|122 126|mRNAs
P09636358A0000|19 24|VAI RNA
P09636358A0000|27 36|adenovirus
P09636670T0000|14 17|gene
P09636670T0000|81 88|analysis
P09636670T0000|91 102|breast cancer
P09636670T0000|50 67|kinase inhibitor p18
P09636670T0000|0 8|Structure
P09636708A0460|97 103|protein
P09636708A0460|52 57|manner
P09636708A0460|85 90|YccA11
P09636708A0460|193 203|degradation
P09636708A0460|168 173|domain
P09636708A0460|3 13|YccA protein
P09636708A0460|117 133|amino acid residues
P09637689A0150|82 85|RNAP
P09637689A0150|20 36|activator proteins
P09637689A0150|8 11|type
P09637689A0150|47 49|DNA
P09637689A0150|87 96|holoenzyme
P09637689A0150|68 80|RNA polymerase
P09637689A0150|137 140|RNAP
P09637689A0150|121 131|recruitment
P09637689A0150|146 153|promoter
P09638342T0000|17 18|L1
P09638342T0000|65 92|membrane cytoskeleton assembly
P09638342T0000|10 13|role
P09638342T0000|35 38|link
P09638342T0000|54 61|adhesion
P09638485A0111|47 82|leukocyte alkaline phosphatase activity
P09638485A0111|84 87|LAPA
P09638485A0111|157 163|workers
P09638485A0111|11 17|benzene
P09638485A0111|38 42|tt-MA
P09638485A0111|109 120|car mechanics
P09638485A0111|33 36|acid
P09638485A0111|124 140|road tanker drivers
P09638650A0169|30 32|NCR
P09638650A0169|248 251|OFR5
P09638650A0169|23 28|region
P09638650A0169|104 104|M
P09638650A0169|225 228|ORF4
P09638650A0169|111 113|kDa
P09638650A0169|72 75|ORFs
P09638650A0169|127 139|RNA polymerase
P09638650A0169|267 277|nucleotides
P09638650A0169|205 222|kDa movement protein
P09638650A0169|177 194|kDa movement protein
P09638650A0169|106 106|r
P09638650A0169|149 166|kDa movement protein
P09638650A0169|92 99|proteins
P09638650A0169|260 262|NCR
P09638650A0169|233 246|kDa coat protein
P09638650A0169|38 48|nucleotides
P09638650A0169|141 144|ORF1
P09638650A0169|169 172|ORF2
P09638650A0169|197 200|ORF3
P09638650A0169|58 70|reading frames
P09638793A1446|44 54|superiority
P09638793A1446|64 65|LV
P09638793A1446|108 118|oxygenation
P09638793A1446|75 84|properties
P09638793A1446|42 42|%
P09638793A1446|25 36|hemodilution
P09638793A1446|38 40|Hct
P09638793A1446|168 174|carrier
P09638793A1446|57 60|LV MC
P09638793A1446|133 154|i.v. perflubron emulsion
P09639074A0707|0 2|Sp1
P09639074A0707|9 19|Sp3 isoforms
P09639074A0707|77 85|complexes
P09639074A0707|52 63|constituents
P09639074A0707|117 120|site
P09639410A3282|33 39|targets
P09639410A3282|5 9|genes
P09639410A3282|57 66|strategies
P09639558A0957|47 49|IgG
P09639558A0957|68 79|erythrocytes
P09639558A0957|31 40|haemolysis
P09639565A0225|94 105|SV40 promoter
P09639565A0225|39 54|enhancer activity
P09639565A0225|66 70|cells
P09640162A0242|60 68|treatment
P09640162A0242|9 15|patient
P09640162A0242|138 139|yr
P09640162A0242|112 128|ventricle teratoma
P09640162A0242|71 93|growth hormone deficiency
P09640162A0242|44 56|growth hormone
P09640802A0467|98 107|flap choice
P09640802A0467|80 92|possibilities
P09640802A0467|36 47|consequences
P09640802A0467|60 63|flap
P09641167A1359|0 9|CONCLUSION
P09641167A1359|11 18|TNF alpha
P09641167A1359|52 69|LDLr gene expression
P09641167A1359|20 26|TGF beta
P09641167A1359|35 42|IL-1beta
P09641167A1359|126 142|gene transcription
P09641167A1359|28 31|PDGF
P09642042A0646|104 123|beta-phosphate moiety
P09642042A0646|50 62|triphosphates
P09642042A0646|137 152|substrate binding
P09642042A0646|82 88|analogs
P09642042A0646|28 41|nucleotide mono
P09642042A0646|0 16|Binding affinities
P09642200A0956|248 255|bacteria
P09642200A0956|88 99|M. jannaschii
P09642200A0956|211 225|chemical natures
P09642200A0956|64 84|M. thermoautotrophicum
P09642200A0956|114 117|ahaK
P09642200A0956|39 42|size
P09642200A0956|48 59|proteolipids
P09642200A0956|228 233|lipids
P09642200A0956|184 191|membrane
P09642200A0956|238 244|archaea
P09642214A0244|120 123|MAPK
P09642214A0244|106 118|protein kinase
P09642214A0244|77 86|activation
P09642214A0244|24 27|role
P09642214A0244|155 164|COS-7 cells
P09642214A0244|141 152|SHP-2 mutants
P09642214A0244|6 11|report
P09642214A0244|46 61|phosphatase SHP-2
P09642227A0000|0 11|Osteoadherin
P09642227A0000|32 47|bone proteoglycan
P09642227A0000|58 71|keratan sulfate
P09642238A0532|0 5|Intron
P09642238A0532|40 55|enhancer activity
P09642238A1285|115 125|involvement
P09642238A1285|64 89|transactivation experiments
P09642238A1285|92 101|COS-1 cells
P09642238A1285|10 23|enhancer region
P09642238A1285|178 183|factor
P09642238A1285|3 8|intron
P09642238A1285|136 145|Sp1 protein
P09642238A1285|59 61|Sp1
P09642238A1285|41 46|GATA-1
P09642276A0881|113 120|function
P09642276A0881|48 51|role
P09642276A0881|123 125|Fak
P09642276A0881|71 84|suicide program
P09642276A0881|3 10|cleavage
P09642276A0881|18 25|caspases
P09642276A0881|57 65|execution
P09642276A0881|13 15|Fak
P09642764A0469|216 218|QCM
P09642764A0469|76 79|mass
P09642764A0469|121 130|techniques
P09642764A0469|53 69|Sauerbrey equation
P09642764A0469|12 15|mass
P09642764A0469|152 156|assay
P09642764A0469|183 186|mass
P09642764A0469|137 140|case
P09642764A0469|32 42|QCM response
P09642764A0469|98 103|thanks
P09643153T0000|1 9|Treatment
P09643153T0000|24 39|T2N breast cancers
P09643153T0000|17 18|T1
P09643546A0436|0 22|Transcription initiation
P09643546A0436|126 141|stress conditions
P09643546A0436|73 80|promoter
P09643546A0436|103 107|cells
P09643548A0000|3 7|genes
P09643548A0000|71 104|cyanobacterium Synechocystis PCC6803
P09643548A0000|17 22|2Fe-2S
P09643548A0000|34 44|ferredoxins
P09645576A0148|0 2|RNA
P09645576A0148|44 46|BMT
P09645576A0148|5 9|GBV-C
P09645576A0148|30 37|patients
P09645576A0148|28 28|%
P09645942A1164|12 35|Dsg-plakoglobin complexes
P09645942A1164|48 49|8S
P09645942A1164|66 78|stoichiometry
P09645942A1164|6 9|pool
P09645961A1158|3 9|results
P09645961A1158|25 31|binding
P09645961A1158|94 103|activation
P09645961A1158|34 41|CBF/NF-Y
P09645961A1158|109 116|nTPH gene
P09645961A1158|55 62|CCAAT box
P09647233A0336|99 110|binding sites
P09647233A0336|139 144|repeat
P09647233A0336|64 70|binding
P09647233A0336|27 45|HIV-1 gene expression
P09647233A0336|146 148|LTR
P09647233A0336|58 61|part
P09647233A0336|2 12|macrophages
P09647233A0336|73 81|NF-kappa B
P09647240A0000|163 174|Val135 mutant
P09647240A0000|37 61|Janus kinase-STAT signaling
P09647240A0000|177 179|p53
P09647240A0000|84 105|hepatoma Hep3B cell lines
P09647240A0000|3 11|influence
P09647240A0000|14 16|p53
P09649069A0490|31 49|laryngeal parameters
P09649069A0490|97 108|examinations
P09649265A1575|0 10|CONCLUSIONS
P09649265A1575|66 73|biopsies
P09649265A1575|157 159|men
P09649265A1575|26 29|sets
P09649265A1575|105 115|office visit
P09649265A1575|79 86|prostate
P09649265A1575|140 153|biopsy strategy
P09649265A1575|197 207|examination
P09649265A1575|222 229|serum PSA
P09649265A1575|43 52|ultrasound
P09649315A0943|130 134|range
P09649315A0943|137 143|ability
P09649315A0943|81 97|MIP-1 beta variants
P09649315A0943|114 121|proteins
P09649315A0943|52 57|series
P09649315A0943|42 48|spectra
P09649315A0943|38 40|NMR
P09649315A0943|28 36|resonance
P09649315A0943|0 10|Examination
P09649426A0636|41 46|strain
P09649426A0636|14 24|PKA activity
P09649426A0636|62 74|Msn4p activity
P09649426A0636|54 58|Msn2p
P09649437A1140|45 50|C/EBPs
P09649437A1140|113 142|eosinophil lineage determination
P09649437A1140|26 37|interactions
P09649437A1140|62 77|Ets family members
P09649437A1140|91 96|GATA-1
P09649438A0182|145 157|Tat activation
P09649438A0182|99 105|factors
P09649438A0182|171 177|extract
P09649438A0182|160 163|HeLa
P09649438A0182|63 72|CDK9 kinase
P09649438A0182|15 49|transcription elongation factor P-TEFb
P09649438A0182|133 135|Tat
P09649438A0182|188 193|P-TEFb
P09649438A0182|74 80|cyclin T
P09649501A0358|143 147|HSBP1
P09649501A0358|180 186|protein
P09649501A0358|24 30|repeats
P09649501A0358|112 140|heat shock factor binding protein
P09649501A0358|229 235|repeats
P09649501A0358|36 58|HSF1 trimerization domain
P09649501A0358|255 271|HSF1 heptad repeats
P09649501A0358|79 101|protein interaction assay
P09649501A0358|64 68|yeast
P09649501A0358|210 215|arrays
P09649537A0000|35 59|yeast GCN2 eIF-2alpha kinase
P09649537A0000|10 19|cDNA clones
P09649537A0000|61 65|yGCN2
P09650180A1130|36 42|voltage
P09650180A1130|60 60|%
P09650180A1130|86 93|mGy min-1
P09650180A1130|10 22|recombination
P09650180A1130|64 73|dose-rates
P09650180A1130|48 48|V
P09650186A1043|97 103|regions
P09650186A1043|6 11|number
P09650186A1043|19 27|positives
P09650186A1043|68 78|radiologist
P09650186A1043|44 49|scheme
P09650275T0000|46 57|implications
P09650275T0000|80 100|biotechnology industry
P09650275T0000|26 42|weapons convention
P09650299A0000|0 4|VirD2
P09650299A0000|18 49|Agrobacterium tumefaciens proteins
P09650299A0000|65 74|processing
P09650299A0000|78 85|transfer
P09650299A1334|82 92|integration
P09650299A1334|38 42|VirD2
P09650299A1334|48 53|domain
P09650299A1334|19 22|data
P09650403A0868|3 13|DHEAS levels
P09650403A0868|75 79|group
P09650403A0868|36 38|BMD
P09650403A0868|90 92|BMD
P09650403A0868|19 24|stages
P09650789A0185|86 97|energy levels
P09650789A0185|23 32|spin system
P09650789A0185|115 120|degree
P09650789A0185|130 140|orientation
P09650789A0185|0 10|Orientation
P09650789A0185|57 71|Overhauser shift
P09651321A0000|0 8|Cystatin A
P09651321A0000|11 37|cysteine proteinase inhibitor
P09651321A0000|138 164|keratinocyte differentiation
P09651321A0000|91 103|keratinocytes
P09651321A0000|77 88|cell envelope
P09651321A0000|49 65|precursor proteins
P09651321A0000|131 135|stage
P09651367T0000|1 4|role
P09651367T0000|51 60|inhibition
P09651367T0000|23 33|Ras effector
P09651367T0000|8 13|RalGDS
P09651367T0000|71 80|myogenesis
P09651375T0000|0 5|GTPase
P09651375T0000|83 88|PSD-95
P09651375T0000|37 54|binding specificity
P09651375T0000|79 81|PDZ
P09651375T0000|16 26|specificity
P09651375T0000|99 104|domain
P09651375T0000|29 33|RGS12
P09651375T0000|90 95|Dlg/ZO
P09651383A0967|82 91|HepG2 cells
P09651383A0967|40 50|element CIIB
P09651383A0967|22 37|HNF-4 binding site
P09651383A0967|103 117|HNF-4 constructs
P09651383A0967|203 211|regulator
P09651383A0967|217 226|apoCII gene
P09651383A0967|159 159|%
P09651383A0967|187 191|HNF-4
P09651383A0967|130 151|apoCII promoter activity
P09651383A0967|165 171|control
P09651383A0967|66 79|HNF-4 synthesis
P09651383A0967|8 16|mutations
P09651383A0967|54 63|inhibition
P09652736A1205|98 109|co-activator
P09652736A1205|164 168|E2F-1
P09652736A1205|34 42|apoptosis
P09652736A1205|21 25|E2F-1
P09652736A1205|154 161|activity
P09652736A1205|51 61|tumour cells
P09652736A1205|45 47|p53
P09652736A1205|116 132|E2F/DP heterodimer
P09652736A1205|2 9|addition
P09652736A1205|72 75|p300
P09652737A1244|118 124|changes
P09652737A1244|185 188|AP-1
P09652737A1244|135 157|Jun family member proteins
P09652737A1244|85 89|Fra-2
P09652737A1244|23 30|analysis
P09652737A1244|44 66|Fos family member proteins
P09652737A1244|190 206|DNA binding complex
P09652737A1244|77 81|Fra-1
P09652737A1244|102 112|progression
P09652742A0455|33 35|p53
P09652742A0455|76 81|glands
P09652742A0455|124 129|strain
P09652742A0455|94 99|tumors
P09653182A1298|29 37|virus RNAs
P09653182A1298|93 105|transcription
P09653182A1298|39 42|BSMV
P09653182A1298|5 8|data
P09653182A1298|122 127|plants
P09653182A1298|69 76|MStV mRNA
P09653182A1298|54 65|primer donors
P09653641A0471|53 62|start codon
P09653641A0471|5 12|isoforms
P09653648A0445|0 9|Comparison
P09653648A0445|125 131|end exon
P09653648A0445|77 78|kb
P09653648A0445|26 34|sequences
P09653648A0445|12 15|cDNA
P09653648A0445|188 193|region
P09653648A0445|152 167|zinc finger domain
P09653648A0445|47 56|ZNF189 gene
P09653648A0445|108 112|exons
P09653745A0180|0 6|Malaria
P09653745A0180|165 169|model
P09653745A0180|148 155|projects
P09653745A0180|193 197|world
P09653745A0180|79 87|reduction
P09653745A0180|204 210|malaria
P09653745A0180|221 232|problem today
P09653745A0180|56 67|paper queries
P09653745A0180|119 126|thirties
P09653745A0180|43 47|1940s
P09653745A0180|99 113|control projects
P09655248A0000|131 136|uptake
P09655248A0000|52 80|lipoprotein receptor gene family
P09655248A0000|22 28|protein
P09655248A0000|163 169|ligands
P09655248A0000|139 150|lipoproteins
P09655248A0000|3 19|gp330/Megalin/LRP
P09655248A0000|117 124|receptor
P09655916A0415|127 129|Leu
P09655916A0415|47 49|Arg
P09655916A0415|104 112|histidine
P09655916A0415|73 76|side
P09655916A0415|132 134|Gln
P09655916A0415|5 23|DNA recognition helix
P09655916A0415|52 59|position
P09655916A0415|26 31|finger
P09656414A0220|0 5|Dosage
P09656414A0220|12 16|cases
P09656414A0220|23 26|g/m2
P09656485A0351|14 19|copies
P09656485A0351|26 33|elements
P09656485A0351|55 74|restriction digestion
P09657003T0000|175 178|RNAs
P09657003T0000|128 146|Ophiostoma novo-ulmi
P09657003T0000|51 64|RNA polymerases
P09657003T0000|211 216|genome
P09657003T0000|12 24|relationships
P09657003T0000|111 126|elm disease fungus
P09657003T0000|98 100|RNA
P09657003T0000|155 161|viruses
P09657003T0000|187 197|Arabidopsis
P09658104T0000|0 3|Role
P09658104T0000|44 65|transcription factor YY1
P09658104T0000|9 40|transcription start site core region
P09658104T0000|96 117|repeat promoter activity
P09658104T0000|68 83|Rous sarcoma virus
P09658122T0000|60 63|PC-1
P09658122T0000|49 58|alpha-SNAP
P09658122T0000|99 113|nematode protein
P09658122T0000|81 87|homolog
P09658122T0000|31 38|homologs
P09658122T0000|0 11|Fowlpox virus
P09658403A1207|41 62|progesterone agonist Org
P09658403A1207|91 101|CAT activity
P09658403A1207|10 12|Rap
P09658403A1207|72 77|effect
P09658403A1207|24 31|exposure
P09658403A1207|80 88|induction
P09658403A1207|34 38|cells
P09658403A1207|15 18|KN62
P09658403A1207|0 7|Addition
P09658405A0000|3 11|Dax-1 gene
P09658405A0000|20 26|protein
P09658405A0000|79 97|receptor superfamily
P09658405A0000|54 60|members
P09658405A0000|66 71|orphan
P09658769A0058|28 38|IFN alpha-2b
P09658769A0058|65 75|hepatitis C.
P09658769A0058|47 55|diagnosis
P09660823A0934|57 67|p70 S6 kinase
P09660823A0934|42 53|molecules Akt
P09660823A0934|8 29|Ser/Thr phosphorylation
P09660836A0983|148 155|S222D MEK
P09660836A0983|68 76|compounds
P09660836A0983|123 130|affinity
P09660836A0983|48 60|MEK inhibition
P09660836A0983|12 21|evaluation
P09660836A0983|134 146|deltaN3-S218E
P09660836A0983|33 45|state kinetics
P09660836A0983|164 171|PD098059
P09660836A0983|88 92|U0126
P09660838A0920|117 130|serine residues
P09660838A0920|100 114|phosphorylation
P09660838A0920|44 49|action
P09660838A0920|180 196|heat shock response
P09660838A0920|89 92|HSF1
P09660838A0920|0 9|Regulation
P09660838A0920|158 163|growth
P09660838A0920|14 21|degrees C
P09660838A0920|57 77|protein kinase cascades
P09661676T0000|36 39|IL-5
P09661676T0000|8 18|implication
P09661676T0000|66 73|patients
P09661676T0000|21 33|protein levels
P09661676T0000|49 54|sputum
P09662339A0744|117 124|CD44 mRNA
P09662339A0744|24 33|transition
P09662339A0744|128 134|protein
P09662339A0744|7 11|cells
P09662339A0744|105 114|expression
P09662339A0744|79 86|activity
P09662339A0744|56 64|induction
P09662443A0402|83 100|caveolin gene family
P09662443A0402|40 51|organization
P09662443A0402|68 77|expression
P09663062A0175|0 19|Tensile bond strengths
P09663062A0175|50 55|dentin
P09663062A0175|184 191|dentists
P09663062A0175|27 31|resin
P09663062A0175|103 104|LB
P09663062A0175|75 81|systems
P09663062A0175|135 148|bonding systems
P09663062A0175|161 167|scatter
P09663062A0175|108 130|Scotchbond Multi-Purpose
P09663062A0175|173 180|students
P09663062A0175|132 133|MP
P09663062A0175|83 101|Clearfil Liner Bond II
P09663062A0175|61 66|dentin
P09664033A1204|159 164|bodies
P09664033A1204|4 15|distribution
P09664033A1204|128 144|processing pathway
P09664033A1204|120 125|import
P09664033A1204|69 77|nucleolus
P09664033A1204|43 51|precursor
P09664033A1204|102 108|snoRNAs
P09665361T0000|21 34|thyroid nodules
P09665361T0000|11 17|therapy
P09665503A0526|19 28|volunteers
P09665503A0526|41 45|study
P09665720A0325|14 16|Mg2
P09665720A0325|62 75|polymerase site
P09665720A0325|5 11|absence
P09665720A0325|79 88|possession
P09665720A0325|94 107|primer terminus
P09665720A0325|31 45|exonuclease site
P09665720A1145|18 20|Mg2
P09665720A1145|76 90|exonuclease site
P09665720A1145|112 121|polymerase
P09665720A1145|128 131|site
P09665720A1145|22 33|binding sites
P09665720A1145|47 60|primer terminus
P09666103A0496|145 153|phenotype
P09666103A0496|105 109|E274K
P09666103A0496|91 95|E225K
P09666103A0496|125 135|temperature
P09666103A0496|3 16|missense allele
P09666103A0496|54 61|degreesC
P09666103A0496|69 83|missense alleles
P09666103A0496|36 39|loss
P09666103A0496|97 101|S269L
P09666103A0496|18 22|P236S
P09666103A0496|85 89|L173F
P09666103A0496|42 49|function
P09666114A0389|74 77|TATA
P09666114A0389|10 17|analysis
P09666114A0389|113 122|G-C content
P09666114A0389|80 91|CAAT elements
P09666114A0389|36 41|region
P09666114A0389|134 148|Sp1 binding sites
P09666114A0389|56 68|c-met promoter
P09667482A0978|44 56|stress factors
P09667482A0978|160 190|stress system disorder perspective
P09667482A0978|150 156|context
P09667482A0978|112 118|results
P09667482A0978|62 68|context
P09667482A0978|3 8|report
P09667482A0978|98 104|disease
P09667482A0978|30 41|contribution
P09667482A0978|71 77|therapy
P09667795A0000|41 48|disorder
P09667795A0000|5 16|pancreatitis
P09668063A0274|144 149|NIH3T3
P09668063A0274|151 152|DT
P09668063A0274|104 110|variety
P09668063A0274|78 84|effects
P09668063A0274|154 158|cells
P09668063A0274|27 37|Ets proteins
P09668063A0274|21 24|role
P09668063A0274|40 56|Ras transformation
P09668063A0274|113 126|Ets2 constructs
P09668096A0806|41 50|preference
P09668096A0806|11 14|site
P09668096A0806|61 68|partners
P09668098A0868|117 125|base pairs
P09668098A0868|139 160|transcription start site
P09668098A0868|67 69|TPA
P09668098A0868|47 62|deletion analysis
P09668098A0868|80 87|elements
P09668098A0868|18 31|FGF-BP promoter
P09668108A1017|0 11|Manipulation
P09668108A1017|104 116|cancer therapy
P09668108A1017|65 73|apoptosis
P09668108A1017|94 101|strategy
P09668108A1017|17 36|checkpoint regulators
P09668108A1017|47 61|cell cycle arrest
P09668119A0496|61 74|protein binding
P09668119A0496|197 203|CTCCT-3
P09668119A0496|174 178|bases
P09668119A0496|94 107|point mutations
P09668119A0496|126 143|binding nucleotides
P09668119A0496|15 33|mobility shift assays
P09669641A0425|23 31|serum PE-1
P09669641A0425|13 20|accuracy
P09669641A0425|49 55|amylase
P09670034A0340|17 21|Ddc1p
P09670034A0340|51 55|Mec3p
P09670034A0340|64 74|interaction
P09670034A0340|83 88|Rad17p
P09670912T0000|16 23|seizures
P09670943T0000|0 19|B cell antigen receptor
P09670943T0000|21 23|BCR
P09670943T0000|82 107|Fc gamma RIIB1-BCR coligation
P09670943T0000|70 79|inhibition
P09670943T0000|34 42|formation
P09670943T0000|46 63|SHP-2-pp120 complex
P09671313A0334|0 4|Chem.
P09671313A0334|45 46|J.
P09671313A0334|28 38|MT Hartsough
P09671464A0316|101 107|meiosis
P09671464A0316|66 72|glucose
P09671464A0316|88 94|glucose
P09671464A0316|21 27|meiosis
P09671464A0316|8 11|SNF1
P09671464A0316|120 123|Snf1
P09671464A0316|42 46|steps
P09671496A0557|158 167|appearance
P09671496A0557|33 43|development
P09671496A0557|74 83|disruption
P09671496A0557|60 63|mice
P09671496A0557|89 98|c-Cbl locus
P09671496A0557|20 23|role
P09671496A0557|47 57|homeostasis
P09671496A0557|26 30|c-Cbl
P09671496A0557|115 118|mice
P09671576A0900|27 34|endoderm
P09671576A0900|50 68|streak morphogenesis
P09671579A1168|13 20|noi/pax2
P09671579A1168|71 80|integrator
P09671579A1168|47 64|signaling processes
P09671579A1168|101 119|boundary development
P09671791T0000|46 65|growth factor receptor
P09671791T0000|133 140|activity
P09671791T0000|78 89|intermediate
P09671791T0000|143 148|L cells
P09671791T0000|18 27|activation
P09673037A0358|0 6|METHODS
P09673037A0358|119 124|method
P09673037A0358|127 132|Gomori
P09673037A0358|32 41|bone marrow
P09673037A0358|16 22|changes
P09673037A0358|92 117|reticulin fiber impregnation
P09673436A0898|60 74|sodium excretion
P09673436A0898|174 174|n
P09673436A0898|49 57|increases
P09673436A0898|25 35|ANP infusion
P09673436A0898|172 172|%
P09673436A0898|76 79|FENA
P09673436A0898|20 23|rats
P09673436A0898|131 138|infusion
P09673436A0898|108 108|%
P09673436A0898|189 198|hypocapnia
P09673436A0898|110 110|P
P09673436A0898|117 117|n
P09673436A0898|140 143|FENA
P09675154A0690|71 79|mutations
P09675154A0690|170 185|missense mutation
P09675154A0690|108 116|insertion
P09675154A0690|34 41|families
P09675154A0690|187 191|W118R
P09675154A0690|139 164|consensus splicing donor site
P09675154A0690|46 51|GSD-Ib
P09675154A0690|119 131|point mutation
P09675896A0959|0 6|Removal
P09675896A0959|12 25|carboxyl region
P09675896A0959|56 65|activation
P09676349A0000|2 7|Level A
P09676349A0000|61 79|release theophylline
P09676349A0000|104 116|Bronchoretard
P09676349A0000|81 83|CAS
P09676349A0000|23 33|correlation
P09676349A0000|92 102|preparation
P09676349A0000|123 135|investigation
P09676419A0158|0 5|METHOD
P09676419A0158|71 75|study
P09676419A0158|273 295|solid-phase immunoassays
P09676419A0158|20 27|children
P09676419A0158|188 193|CAP SX1
P09676419A0158|106 112|patient
P09676419A0158|47 51|years
P09676419A0158|178 186|allergens
P09676419A0158|90 103|questionnaires
P09676419A0158|240 242|IgE
P09676419A0158|37 42|months
P09676419A0158|219 238|serum immunoglobulin E
P09676419A0158|143 156|screening tests
P09676419A0158|199 211|determination
P09676419A0158|116 130|family histories
P09676419A0158|263 270|serum IgE
P09677330A0584|60 63|UCR2
P09677330A0584|124 127|unit
P09677330A0584|27 41|linker region LR1
P09677330A0584|53 56|UCR1
P09677330A0584|106 109|UCR2
P09677330A0584|92 94|LR2
P09677330A0584|147 150|exon
P09677330A0584|79 83|exons
P09677405A0856|0 16|Pol32Delta strains
P09677405A0856|24 35|antimutators
P09677405A0856|68 78|mutagenesis
P09677410A1059|100 114|HBV core promoter
P09677410A1059|36 38|p53
P09677410A1059|149 151|HBx
P09677410A1059|136 143|enhancer
P09677410A1059|65 67|HBV
P09677410A1059|9 12|time
P09677410A1059|54 57|role
P09677410A1059|17 23|results
P09677410A1059|198 200|p53
P09677410A1059|188 195|function
P09678579A0768|53 64|blot analysis
P09678579A0768|35 43|AtCP1 gene
P09678579A0768|6 12|insight
P09678579A0768|20 29|expression
P09678837A0736|71 82|methacholine
P09678837A0736|11 15|study
P09678837A0736|106 113|rhinitis
P09678837A0736|163 178|blood eosinophils
P09678837A0736|152 159|serum IgE
P09678837A0736|49 66|bronchoprovocation
P09678837A0736|3 5|aim
P09678837A0736|33 46|responsiveness
P09678837A0736|131 142|pollen season
P09678837A0736|85 92|subjects
P09679066A1352|85 93|pre-mRNAs
P09679066A1352|48 54|protein
P09679066A1352|67 74|splicing
P09679066A1352|5 11|results
P09679066A1352|27 39|demonstration
P09679750A0304|123 128|NSAIDs
P09679750A0304|147 155|attention
P09679750A0304|28 56|prostate cancer chemoprevention
P09679750A0304|97 121|cyclo-oxygenase inhibitors
P09679750A0304|16 24|potential
P09679750A0304|91 95|drugs
P09680994A0169|158 176|P. hybrida orthologue
P09680994A0169|124 143|intron/exon structure
P09680994A0169|81 87|protein
P09680994A0169|19 27|isolation
P09680994A0169|105 120|sequence homology
P09680994A0169|182 193|Z. mays r genes
P09680994A0169|31 43|P. hybrida gene
P09680994A0169|4 8|study
P09680994A0169|45 49|jaf13
P09680994A0169|98 102|basis
P09681822A0520|61 67|tissues
P09681822A0520|9 26|c-erbB3 transcripts
P09682897A0218|14 18|years
P09682897A0218|47 64|electrocardiograms
P09682897A0218|89 98|QRS changes
P09682897A0218|121 133|injury pattern
P09682897A0218|31 36|search
P09683576A0542|18 29|cleavage site
P09683576A0542|52 65|protease domain
P09683576A0542|93 102|processing
P09683576A0542|67 81|Gln2526-Asp2527
P09685021A0127|0 6|METHODS
P09685021A0127|208 216|membranes
P09685021A0127|156 161|microm
P09685021A0127|76 98|model lenticule materials
P09685021A0127|294 299|cornea
P09685021A0127|243 251|collagen I
P09685021A0127|166 181|surface roughness
P09685021A0127|275 280|pocket
P09685021A0127|134 139|microm
P09685021A0127|307 310|cats
P09685021A0127|110 126|membrane pore sizes
P09685021A0127|352 368|epithelialization
P09685021A0127|200 204|order
P09685021A0127|236 240|layer
P09685021A0127|398 407|attachment
P09685021A0127|8 40|Millipore ultrafiltration membranes
P09685021A0127|57 65|pore sizes
P09685021A0127|375 385|persistence
P09685021A0127|145 150|microm
P09685021A0127|344 349|extent
P09685226A0000|28 35|agonists
P09685226A0000|76 88|transcription
P09685226A0000|139 142|gene
P09685226A0000|9 18|calcitonin
P09685226A0000|52 62|cAMP pathway
P09685226A0000|166 183|lung cancer cell line
P09685226A0000|185 187|BEN
P09685226A0000|125 131|protein
P09685226A0000|3 6|role
P09685226A0000|133 137|PTHrP
P09685346A0419|16 20|Pitx2
P09685346A0419|82 91|activation
P09685346A0419|116 133|transfection assays
P09685346A0419|31 48|homeodomain protein
P09685346A0419|50 54|Pit-1
P09685346A0419|97 113|prolactin promoter
P09685346A0419|3 13|combination
P09686344T0000|36 70|ornithine transcarbamylase deficiency
P09686344T0000|26 33|spectrum
P09686603A0124|147 165|TCR beta gene segments
P09686603A0124|38 45|elements
P09686603A0124|22 25|role
P09686603A0124|63 72|mechanisms
P09686603A0124|127 144|germline expression
P09686603A0124|109 116|promoter
P09687498A1173|59 64|v-erbA
P09687498A1173|3 9|results
P09687498A1173|69 76|oncogene
P09687498A1173|31 34|role
P09687498A1173|89 94|c-ErbA
P09687498A1173|161 174|overexpression
P09687498A1173|96 102|TRalpha
P09687498A1173|131 142|conformation
P09687498A1173|40 48|mutations
P09687511A1091|0 13|Downregulation
P09687511A1091|114 128|colony formation
P09687511A1091|204 212|potential
P09687511A1091|130 140|restoration
P09687511A1091|77 87|suppression
P09687511A1091|49 59|32Dcl3 cells
P09687511A1091|168 182|differentiation
P09687511A1091|16 28|FUS expression
P09687511A1091|90 95|growth
P09687514A0521|41 59|transcription system
P09687514A0521|92 99|proteins
P09687514A0521|129 137|complexes
P09687514A0521|6 10|study
P09688264A1029|4 12|repressor
P09688264A1029|39 41|spi
P09688264A1029|87 100|rat hepatocytes
P09688264A1029|47 63|UTR silencer action
P09689047A0253|1 12|prerequisite
P09689047A0253|96 108|monophosphate
P09689047A0253|132 141|CMP-Neu5Ac
P09689047A0253|170 192|Golgi sialyltransferases
P09689047A0253|40 54|glycoconjugates
P09689047A0253|127 130|acid
P09689047A0253|158 166|substrate
P09689047A0253|19 27|synthesis
P09689047A0253|69 92|sugar-nucleotide cytidine
P09689919A1192|14 21|PEDF cDNA
P09689919A1192|68 83|PEDF glycoprotein
P09691031A1050|93 100|pathways
P09691031A1050|10 14|model
P09691031A1050|49 57|targeting
P09691031A1050|22 33|Sro7 function
P09691031A1050|63 76|myosin proteins
P09691037A0355|58 65|N. crassa
P09691037A0355|7 15|sequences
P09691037A0355|74 90|Neurospora species
P09691037A0355|49 55|strains
P09691037A0355|29 37|insertion
P09692965A0904|62 69|patterns
P09692965A0904|90 95|burial
P09692965A0904|79 86|exposure
P09692965A0904|31 37|helices
P09692965A0904|4 11|cysteine
P09693035T0000|120 129|assignment
P09693035T0000|95 104|expression
P09693035T0000|61 81|Caenorhabditis elegans
P09693035T0000|83 93|cDNA cloning
P09693035T0000|5 8|ULK1
P09693035T0000|16 37|serine/threonine kinase
P09693035T0000|47 58|UNC-51 kinase
P09693134A0782|224 233|identities
P09693134A0782|159 175|column neuroblasts
P09693134A0782|26 32|markers
P09693134A0782|81 91|neuroblasts
P09693134A0782|128 130|DER
P09693134A0782|70 76|domains
P09693134A0782|195 211|column neuroblasts
P09693134A0782|255 262|position
P09693134A0782|137 143|embryos
P09693134A0782|279 289|neuroblasts
P09693134A0782|104 114|neuroblasts
P09693306T0000|31 38|patients
P09693306T0000|53 63|schwannomas
P09693306T0000|19 28|potentials
P09694034A0713|16 24|clozapine
P09694034A0713|189 193|drugs
P09694034A0713|39 40|LI
P09694034A0713|5 11|results
P09694034A0713|136 144|test model
P09694034A0713|124 128|value
P09694034A0713|92 97|action
P09694034A0713|86 89|mode
P09694034A0713|54 67|antipsychotics
P09694034A0713|131 132|LI
P09694034A0713|173 181|potential
P09694514A0000|120 135|C3a peptide ligand
P09694514A0000|160 168|responses
P09694514A0000|65 73|G-protein
P09694514A0000|215 231|muscle contraction
P09694514A0000|81 103|chemoattractant receptor
P09694514A0000|38 41|C3aR
P09694514A0000|199 207|mast cells
P09694514A0000|258 268|eosinophils
P09694514A0000|247 255|migration
P09694514A0000|3 36|complement C3a anaphylatoxin receptor
P09694514A0000|179 194|histamine release
P09694599A1355|0 10|CONCLUSIONS
P09694599A1355|83 90|cystitis
P09694599A1355|105 113|hematuria
P09694599A1355|47 54|IL-1beta
P09694599A1355|23 32|elevations
P09694599A1355|35 43|IL-1alpha
P09694599A1355|62 69|patients
P09694725A0500|90 114|gamma interferon activation
P09694725A0500|67 71|LILRE
P09694725A0500|10 15|assays
P09694725A0500|73 87|oligonucleotide
P09694725A0500|59 65|element
P09694725A0500|124 127|site
P09694725A0500|151 166|IL-1beta promoter
P09694860A0498|105 111|protein
P09694860A0498|65 70|region
P09694860A0498|13 18|region
P09694860A0498|38 43|domain
P09694860A0498|78 85|homology
P09694869A0932|113 126|cytokine effect
P09694869A0932|16 22|support
P09694869A0932|94 98|Stat3
P09694869A0932|246 259|cytokine effect
P09694869A0932|66 76|p21 promoter
P09694869A0932|132 142|p21 promoter
P09694869A0932|177 184|mutation
P09694869A0932|35 38|role
P09694869A0932|190 208|STAT response element
P09694869A0932|214 221|promoter
P09694869A0932|41 45|STATs
P09694869A0932|168 172|Stat3
P09694869A0932|78 91|overexpression
P09694869A0932|51 60|activation
P09694869A0932|2 9|addition
P09694897T0000|61 62|U1
P09694897T0000|129 133|motif
P09694897T0000|23 55|ribonucleoprotein C protein tetramer
P09694897T0000|64 65|U2
P09694897T0000|92 115|affinity RNA binding domain
P09694897T0000|70 77|U6 snRNAs
P09695194T0000|27 37|proportions
P09695194T0000|50 53|data
P09695194T0000|5 14|comparison
P09696164A0000|26 34|detection
P09696164A0000|63 66|SIDS
P09696164A0000|43 61|infant death syndrome
P09696164A0000|14 19|system
P09696819A0450|83 91|formation
P09696819A0450|116 117|ER
P09696819A0450|38 39|gE
P09696819A0450|12 18|mutants
P09696819A0450|64 75|vTF7-3 system
P09696819A0450|128 136|transport
P09696819A0450|159 165|complex
P09696819A0450|106 114|reticulum
P09696819A0450|45 52|vaccinia
P09698457A0778|31 45|Cux/CDPDeltaCR1
P09698457A0778|84 92|vibrissae
P09698457A0778|55 63|phenotype
P09698457A0778|100 103|hair
P09698457A0778|16 19|mice
P09698457A0976|204 207|date
P09698457A0976|142 149|affinity
P09698457A0976|182 184|DNA
P09698457A0976|109 115|protein
P09698457A0976|80 97|tissue distribution
P09698457A0976|9 15|protein
P09698457A0976|223 231|cut repeat
P09698457A0976|235 241|binding
P09698457A0976|27 32|levels
P09698457A0976|158 172|target sequences
P09698512A0296|0 6|METHODS
P09698512A0296|55 74|transplant recipients
P09700644T0000|3 10|spectrum
P09700644T0000|27 44|brain abnormalities
P09700644T0000|51 61|measurement
P09700644T0000|82 91|correlates
P09701609A0116|75 80|PhLOP2
P09701609A0116|66 71|PhLOP1
P09701609A0116|93 99|ability
P09701609A0116|114 123|Gbetagamma
P09701609A0116|51 64|orphan proteins
P09701609A0116|3 12|laboratory
P09701616A0108|90 92|DNA
P09701616A0108|98 123|sand shrimp Metapenaeus ensis
P09701616A0108|69 76|eyestalk
P09701616A0108|7 43|transcriptase-polymerase chain reaction
P09701616A0108|45 50|RT-PCR
P09701821A1108|59 68|proportion
P09701821A1108|11 23|transcription
P09701821A1108|114 119|levels
P09701821A1108|82 91|osmolarity
P09701821A1108|38 44|opuE P-1
P09701821A1108|46 51|sigma A
P09701821A1108|2 9|contrast
P09701895A0119|70 73|year
P09701895A0119|87 96|prevalence
P09701895A0119|19 26|children
P09701895A0119|110 116|anaemia
P09701895A0119|32 41|months-3 yr
P09701895A0119|59 64|period
P09703021A0000|230 233|step
P09703021A0000|111 124|sclerotization
P09703021A0000|10 43|arylalkylamine N-acetyltransferases
P09703021A0000|147 163|neurotransmitters
P09703021A0000|181 188|function
P09703021A0000|236 256|melatonin biosynthesis
P09703021A0000|203 211|catalysis
P09703021A0000|191 201|vertebrates
P09703021A0000|2 8|insects
P09703021A0000|126 137|inactivation
P09703021A0000|45 50|AANATs
P09703021A0000|92 100|processes
P09703213A0280|62 71|depression
P09703213A0280|20 34|D1 antagonist SCH
P09703213A0280|98 109|facilitation
P09703213A0280|2 12|experiments
P09703276A2346|59 73|carcinogenicity
P09703276A2346|25 37|hydroquinones
P09703276A2346|5 11|results
P09703276A2346|44 55|mutagenicity
P09703816A0139|0 4|IA-CT
P09703816A0139|60 69|shot method
P09703816A0139|25 35|doxorubicin
P09703816A0139|38 39|mg
P09703816A0139|89 101|iliac arteries
P09703816A0139|9 17|cisplatin
P09703816A0139|20 21|mg
P09704006A0224|0 8|Arnt3 mRNA
P09704006A0224|37 42|muscle
P09704006A0224|63 70|P19 cells
P09704006A0224|52 58|embryos
P09704006A0224|23 27|brain
P09704006A0224|90 93|acid
P09704296T0000|31 37|purpura
P09704296T0000|65 79|immunoglobulin E
P09704296T0000|53 62|serum level
P09704296T0000|106 112|patient
P09704296T0000|83 94|eosinophilia
P09704569T0000|33 40|location
P09704569T0000|10 18|structure
P09704569T0000|51 67|TR2 orphan receptor
P09704569T0000|81 106|steroid receptor superfamily
P09704569T0000|70 75|member
P09704857T0000|0 10|Correlation
P09704857T0000|51 58|patients
P09704857T0000|13 25|skin disorders
P09704857T0000|63 70|HIV/AIDS
P09704857T0000|30 42|CD4 lymphocyte
P09704927A0479|72 89|heterodimerization
P09704927A0479|22 29|homology
P09704927A0479|34 37|E2Fs
P09704927A0479|5 10|shares
P09704927A0479|99 108|box domains
P09704927A0479|61 70|DNA binding
P09705258A0837|95 103|insertion
P09705258A0837|124 131|lacZ gene
P09705258A0837|77 80|gene
P09705258A0837|64 69|copies
P09705258A0837|48 52|virus
P09705258A0837|3 16|IE13.1 cell line
P09705324A0213|0 4|DNase
P09705324A0213|251 256|rat Std
P09705324A0213|225 226|bp
P09705324A0213|168 197|thyroid hormone response elements
P09705324A0213|215 223|base pairs
P09705324A0213|233 248|promoter sequence
P09705324A0213|68 77|hepatocyte
P09705324A0213|36 56|mobility shift analyses
P09705324A0213|94 97|HNF1
P09705324A0213|135 139|C/EBP
P09705324A0213|85 92|factor-1
P09705324A0213|6 17|footprinting
P09705324A0213|127 133|protein
P09705324A0213|148 156|consensus
P09705324A1602|85 100|liver specificity
P09705324A1602|305 316|interference
P09705324A1602|356 372|DNA-AR interaction
P09705324A1602|179 183|OCT-1
P09705324A1602|131 140|repression
P09705324A1602|19 40|rat Std promoter function
P09705324A1602|267 272|effect
P09705324A1602|207 215|positions
P09705324A1602|106 115|rat Std gene
P09705324A1602|327 331|C/EBP
P09705324A1602|161 168|presence
P09705324A1602|187 199|C/EBP elements
P09705324A1602|319 323|OCT-1
P09705324A1602|236 237|AR
P09705324A1602|63 67|C/EBP
P09705324A1602|10 16|studies
P09705324A1602|56 59|HNF1
P09705324A1602|146 149|gene
P09705352A0879|29 33|Cdc19
P09705352A0879|40 46|subunit
P09705352A0879|35 38|Mcm2
P09705352A0879|62 100|minichromosome maintenance protein complex
P09705352A0879|8 11|Hsk1
P09705352A0879|113 124|fission yeast
P09705497A0227|52 84|methyl methanesulfonate sensitivity
P09705497A0227|132 156|DNA post-replication repair
P09705497A0227|90 101|mms2-1 mutant
P09705497A0227|3 15|yeast MMS2 gene
P09705497A0227|30 36|ability
P09705564T0000|57 60|E1E4
P09705564T0000|62 73|E5 transcript
P09705564T0000|40 49|E5A protein
P09705564T0000|20 37|papillomavirus type
P09705564T0000|0 9|Expression
P09706565A1072|42 55|immobilization
P09706565A1072|60 70|atipamezole
P09706565A1072|37 39|min
P09706565A1072|14 16|M/K
P09706565A1072|0 9|Anesthesia
P09706643A0206|35 41|disease
P09706643A0206|25 29|agent
P09707498A0262|0 19|MK-801 administration
P09707498A0262|39 46|response
P09707498A0262|49 62|seizure latency
P09707577A1047|14 25|distribution
P09707577A1047|37 43|markers
P09707577A1047|2 9|contrast
P09708450A0648|0 7|Toxicity
P09708450A0648|91 97|control
P09708450A0648|117 123|regimen
P09708450A0648|56 65|study group
P09708450A0648|28 33|period
P09708450A0648|131 135|G-CSF
P09708565A0000|235 251|commercialization
P09708565A0000|128 145|radioimmunotherapy
P09708565A0000|215 231|multicenter trials
P09708565A0000|16 22|article
P09708565A0000|68 77|antibodies
P09708565A0000|79 91|radionuclides
P09708565A0000|103 109|methods
P09708565A0000|199 207|study site
P09708565A0000|147 149|RIT
P09708565A0000|37 43|factors
P09708565A0000|167 174|lymphoma
P09708565A0000|57 65|selection
P09708565A0000|3 9|purpose
P09708565A0000|176 178|NHL
P09708565A0000|115 125|development
P09710131A0374|43 51|distances
P09710131A0374|53 77|image intensifier tube modes
P09710131A0374|81 99|laser printer formats
P09710131A0374|4 10|methods
P09710582A0535|116 122|PD98059
P09710582A0535|55 74|protein kinase pathway
P09710582A0535|103 114|MEK inhibitor
P09710582A0535|11 13|Rho
P09710582A0535|147 158|AP-1 activity
P09710582A0535|96 98|MEK
P09710582A0535|3 8|effect
P09710582A0535|16 19|AP-1
P09710589A1111|47 50|R82A
P09710589A1111|40 45|domain
P09710589A1111|26 33|residues
P09710589A1111|13 23|mutagenesis
P09710589A1111|52 55|K85A
P09710589A1111|65 68|V89A
P09710589A1111|80 87|proteins
P09710589A1111|121 129|HTLV-1 LTR
P09710589A1111|57 60|K88A
P09710591A0981|0 8|Mutations
P09710591A0981|36 49|serine residues
P09710591A0981|162 170|MAP kinase
P09710591A0981|82 94|growth factors
P09710591A0981|125 139|transactivation
P09710591A0981|143 159|block potentiation
P09710591A0981|98 106|MAP kinase
P09710591A0981|18 26|C terminus
P09710591A0981|29 33|c-fos
P09710591A0981|57 78|phosphorylation targets
P09710599A0310|129 140|ets-2 protein
P09710599A0310|76 80|ets-2
P09710599A0310|101 101|h
P09710599A0310|11 15|cells
P09710599A0310|17 21|ets-2
P09710599A0310|117 126|expression
P09710599A0310|46 57|response gene
P09710599A0310|26 30|CSF-1
P09710599T0000|87 94|response
P09710599T0000|10 19|activation
P09710599T0000|65 84|ets-2 phosphorylation
P09710599T0000|128 136|signaling
P09710599T0000|115 120|factor
P09710599T0000|39 55|protein kinases p42
P09710599T0000|59 61|p44
P09710614T0000|73 82|regulation
P09710614T0000|56 61|domain
P09710614T0000|125 148|phosphoinositide 3-kinase
P09710614T0000|113 122|activation
P09710614T0000|42 44|CD2
P09710614T0000|29 36|sequence
P09710614T0000|102 109|adhesion
P09710614T0000|0 13|Identification
P09710615T0000|0 4|Vam7p
P09710615T0000|54 61|function
P09710615T0000|38 52|syntaxin homolog
P09710615T0000|31 35|Vam3p
P09710615T0000|19 26|molecule
P09710615T0000|85 102|protein trafficking
P09710615T0000|72 76|yeast
P09710621A0598|87 108|Neu juxtamembrane domain
P09710621A0598|61 81|cysteine substitutions
P09710621A0598|141 146|series
P09710621A0598|53 58|series
P09710621A0598|149 161|interreceptor
P09710621A0598|111 115|order
P09710621A0598|123 134|dimerization
P09710621A0598|16 26|possibility
P09710641A0000|177 196|zeta-crystallin genes
P09710641A0000|71 72|HD
P09710641A0000|48 53|domain
P09710641A0000|158 163|alphaA
P09710641A0000|104 117|eye development
P09710641A0000|35 39|Pax-6
P09710641A0000|166 171|delta1
P09710641A0000|74 92|transcription factor
P09710641A0000|135 144|activation
P09710641A0000|150 155|alphaB
P09710641A0000|202 205|lens
P09710641A0000|55 56|PD
P09710641A0000|59 69|homeodomain
P09712037A0470|0 13|Tctex-1 binding
P09712037A0470|88 95|sequence
P09712037A0470|50 58|integrity
P09712037A0470|44 46|Fyn
P09712037A0470|210 230|lymphocyte Ag receptors
P09712037A0470|135 149|Fyn interactions
P09712037A0470|64 77|lysine residues
P09712037A0470|185 200|activation motifs
P09712037A0470|157 170|immunoreceptor
P09712037A0470|32 41|amino acids
P09712037A0470|202 206|ITAMs
P09712297T0000|72 85|vein thrombosis
P09712297T0000|56 63|patients
P09712297T0000|96 106|individuals
P09712297T0000|3 32|prothrombin gene G20210A mutation
P09712644T0000|30 38|GluR2 gene
P09712644T0000|97 104|elements
P09712644T0000|55 64|expression
P09712644T0000|74 82|promoters
P09712644T0000|15 24|regulation
P09712859A1110|85 93|infection
P09712859A1110|12 17|NF-ATp
P09712859A1110|43 50|enhancer
P09712859A1110|111 122|blood T-cells
P09712859A1110|30 35|NF-AT4
P09712859A1110|3 9|binding
P09712898A0911|74 76|GCK
P09712898A0911|26 38|p38 activation
P09712898A0911|19 22|SAPK
P09712898A0911|80 82|RIP
P09712898A0911|5 9|TRAF2
P09712898A0911|59 72|protein kinases
P09712898T0000|60 63|SAPK
P09712898T0000|81 86|kinase
P09712898T0000|66 68|Jun
P09712898T0000|46 58|protein kinase
P09712898T0000|95 97|p38
P09712898T0000|88 90|JNK
P09712898T0000|0 27|Tumor necrosis factor signaling
P09712915A0672|56 66|combination
P09712915A0672|72 81|activities
P09712915A0672|23 30|promoter
P09712915A0672|111 113|Sp3
P09712915A0672|87 109|transcription factors Sp1
P09712915A0672|118 121|NF-Y
P09712915A0672|3 10|activity
P09712919A0307|72 72|s
P09712919A0307|5 11|studies
P09712919A0307|55 70|signaling pathway
P09712919A0307|95 108|CREB activation
P09712919A0307|27 32|report
P09712919A0307|117 122|T cells
P09713584A1193|0 10|Respondents
P09713584A1193|24 37|spouse/partner
P09713584A1193|88 93|people
P09713584A1193|75 83|BMI status
P09713584A1193|107 112|groups
P09713990T0000|0 8|Isolation
P09713990T0000|36 54|colon cancer cell line
P09713990T0000|88 107|TP53 expression system
P09713990T0000|17 30|TP53 target gene
P09713996A0262|99 105|variety
P09713996A0262|77 85|cell lines
P09713996A0262|124 129|agents
P09713996A0262|16 19|MDR1
P09713996A0262|45 51|cancers
P09713996A0262|59 71|patient tumors
P09713996A0262|0 13|Overexpression
P09713996T0000|151 158|patients
P09713996T0000|58 71|rearrangements
P09713996T0000|85 102|drug resistance gene
P09713996T0000|23 38|characterization
P09713996T0000|139 147|cell lines
P09713996T0000|177 179|ALL
P09713996T0000|104 122|MDR1/P-glycoprotein
P09713996T0000|163 166|drug
P09714109A0000|0 9|BACKGROUND
P09714109A0000|52 64|blood pressure
P09714109A0000|93 105|nerve activity
P09714109A0000|76 81|muscle
P09714109A0000|107 109|SNA
P09714109A0000|36 42|smoking
P09714109A0785|72 79|infusion
P09714109A0785|7 27|blood pressure increase
P09714109A0785|30 37|response
P09714109A0785|108 116|muscle SNA
P09714109A0785|40 46|smoking
P09714109A0785|98 105|increase
P09714835A0345|191 197|Fricker
P09714835A0345|9 14|report
P09714835A0345|104 120|carboxypeptidase E
P09714835A0345|131 136|enzyme
P09714835A0345|34 36|CPD
P09714835A0345|188 189|L.
P09714835A0345|199 202|L.D.
P09714835A0345|183 186|Song
P09714835A0345|122 124|CPE
P09714835A0345|173 181|duck gp180
P09714835A0345|16 32|carboxypeptidase D
P09714835A0345|146 160|characteristics
P09715278A1079|131 136|manner
P09715278A1079|111 127|G1 cell cycle arrest
P09715278A1079|69 78|maturation
P09715278A1079|80 86|changes
P09715278A1079|19 31|transfectants
P09715278A1079|154 164|NT2/D1 cells
P09715278A1079|101 105|genes
P09715278A1079|0 11|RA-treatment
P09715278A1526|3 16|histopathology
P09715278A1526|94 112|FGF4 over-expressing
P09715278A1526|119 138|control transfectants
P09715278A1526|68 82|xenograft tumors
P09715278A1526|20 37|neovascularization
P09715384A0235|38 47|treatments
P09715384A0235|72 78|results
P09715384A0235|57 61|J/cm2
P09715384A0235|10 16|vessels
P09715384A0235|22 29|diameter
P09715384A0235|35 36|mm
P09715384A0235|117 118|mm
P09715384A0235|105 111|vessels
P09715384A0235|128 128|%
P09715384A0235|88 88|%
P09716095T0000|0 13|Pressure ulcers
P09716179A0974|0 18|RXR-gamma expression
P09716179A0974|70 74|genes
P09716179A0974|169 186|cdk2 kinase activity
P09716179A0974|162 165|cdc2
P09716179A0974|134 140|p27Kip1
P09716179A0974|190 206|RB phosphorylation
P09716179A0974|38 46|reduction
P09716179A0974|49 54|levels
P09716179A0974|103 130|kinase inhibitors p21Cip1/WAF1
P09716183A1036|0 2|TBP
P09716183A1036|123 145|ERK kinase consensus sites
P09716183A1036|91 110|phosphorylation sites
P09716183A1036|151 153|TBP
P09716183A1036|83 86|ERK2
P09716183A1036|168 173|domain
P09716183A1036|31 38|extracts
P09716183A1036|41 49|U937 cells
P09716435A1004|97 113|cortisol elevation
P09716435A1004|88 93|vigour
P09716435A1004|25 34|HS subjects
P09716435A1004|62 65|rise
P09716435A1004|79 85|decline
P09716435A1004|9 17|CR/PP diet
P09716435A1004|136 144|PR/CP diet
P09716435A1004|68 77|depression
P09717246A0526|141 145|day-1
P09717246A0526|48 59|exposure time
P09717246A0526|125 127|ILC
P09717246A0526|149 152|ILVF
P09717246A0526|64 76|rate constants
P09717246A0526|110 120|lipid weight
P09717246A0526|9 11|ILC
P09717246A0526|15 24|ILVF values
P09717246A0526|98 102|day-1
P09717835A0941|57 65|IRS family
P09717835A0941|77 90|Xenopus homolog
P09717835A0941|32 37|xIRS-u
P09717835A0941|103 108|member
P09717835A0941|5 20|sequence analyses
P09717835A0941|46 51|member
P09717887A0239|160 169|predictors
P09717887A0239|50 56|VO2peak
P09717887A0239|172 178|VO2peak
P09717887A0239|185 194|population
P09717887A0239|10 14|study
P09717887A0239|77 92|occlusive disease
P09717887A0239|123 134|claudication
P09717887A0239|94 97|PAOD
P09717887A0239|32 39|equation
P09717887A0239|99 106|patients
P09718372T0000|0 7|Evidence
P09718372T0000|35 41|pathway
P09718372T0000|91 102|fission yeast
P09718372T0000|56 61|stress
P09718372T0000|71 88|Sty1/Spc1 MAP kinase
P09718671A0000|14 24|Injury Scale
P09718671A0000|137 144|patients
P09718671A0000|53 68|TRISS methodology
P09718671A0000|26 28|AIS
P09718671A0000|97 102|system
P09718671A0000|109 116|analysis
P09718671A0000|31 49|Injury Severity Scale
P09718671A0000|119 126|injuries
P09719636A1134|99 114|H411-X2-H414 pair
P09719636A1134|194 197|gp17
P09719636A1134|170 175|region
P09719636A1134|79 94|H382-X2-H385 pair
P09719636A1134|61 74|histidine pairs
P09719636A1134|36 44|mutations
P09719636A1134|183 191|C terminus
P09719636A1134|121 136|H430-X5-H436 pair
P09719636A1134|4 13|hypothesis
P09721207A0637|14 21|analysis
P09721207A0637|103 115|vacillans gene
P09721207A0637|27 31|exons
P09721207A0637|54 59|region
P09721207A0637|68 77|Chromosome
P09721798A1734|60 71|HCV hepatitis
P09721798A1734|12 18|percent
P09721798A1734|90 99|recurrence
P09721798A1734|21 28|children
P09721798A1734|124 128|death
P09721798A1734|109 120|liver failure
P09721798A1734|47 56|transplant
P09722043A2070|70 76|enzymes
P09722043A2070|34 41|increase
P09722043A2070|12 20|TPN groups
P09722043A2070|56 60|liver
P09722043A2070|44 53|activities
P09722161A3065|0 9|Regulation
P09722161A3065|39 47|targeting
P09722161A3065|62 73|Igf2/Mpr gene
P09722161A3065|21 26|growth
P09722508A0953|30 42|Galpha11 Q209L
P09722508A0953|118 125|proteins
P09722508A0953|53 75|Src family kinase activity
P09722508A0953|128 139|HEK-293 cells
P09722508A0953|86 108|tyrosine phosphorylation
P09722766A0706|99 102|rats
P09722766A0706|69 73|BUP-4
P09722766A0706|3 21|micturition pressure
P09722766A0706|56 64|injection
P09723896A0000|32 40|receptors
P09723896A0000|42 45|PPAR
P09723896A0000|190 192|RXR
P09723896A0000|177 188|acid receptor
P09723896A0000|118 125|elements
P09723896A0000|55 67|transcription
P09723896A0000|127 130|PPRE
P09723896A0000|87 96|peroxisome
P09723896A0000|139 156|heterodimerization
P09723896A0000|0 9|Peroxisome
P09724654A0761|113 123|recruitment
P09724654A0761|53 58|timing
P09724654A0761|100 105|timing
P09724654A0761|66 76|recruitment
P09724654A0761|108 110|RPA
P09724654A0761|32 38|origins
P09724654A0761|81 90|Mcm protein
P09724654A1120|56 62|origins
P09724654A1120|35 43|Dbf4/Cdc7
P09724654A1120|10 17|presence
P09724654A1120|95 97|RPA
P09724654A1120|45 48|Mcms
P09724654A1120|26 31|S-CDKs
P09724654A1120|86 92|loading
P09724754A0173|0 7|Tyrosine
P09724754A0173|22 26|STATs
P09724754A0173|81 85|genes
P09724754A0173|56 62|nucleus
P09724763T0000|101 103|DNA
P09724763T0000|13 24|substitution
P09724763T0000|27 56|abalone sperm fertilization genes
P09724763T0000|78 84|introns
P09724763T0000|64 75|substitution
P09724772A0840|0 19|Gel retardation assays
P09724772A0840|65 84|zia operator-promoter
P09724772A0840|42 50|complexes
P09724772A0840|130 143|metal-chelator
P09724772A0840|116 124|treatment
P09724772A0840|88 102|ZiaR-DNA binding
P09725292A1473|0 9|CONCLUSION
P09725292A1473|85 86|CT
P09725292A1473|71 75|liver
P09725292A1473|45 52|criteria
P09725651A0077|114 130|Pentium processors
P09725651A0077|75 82|versions
P09725651A0077|35 50|Microsoft Windows
P09725651A0077|88 96|computers
P09725651A0077|11 14|RTPS
P09725651A0077|55 65|environment
P09725854A1060|131 137|alleles
P09725854A1060|140 154|maintainer lines
P09725854A1060|47 52|action
P09725854A1060|58 62|genes
P09725854A1060|81 91|differences
P09725854A1060|193 218|urf209 processing activities
P09725854A1060|184 189|orf107
P09725854A1060|160 169|capability
P09725854A1060|17 26|similarity
P09725854A1060|102 117|IS1112C Rf3 allele
P09726201T0000|0 4|JCAHO
P09726201T0000|12 25|interpretation
P09726979T0000|29 44|characterization
P09726979T0000|53 69|sphingosine kinase
P09726979T0000|9 15|cloning
P09726987T0000|6 40|SPT3-TAFII31-GCN5-L acetylase complex
P09726987T0000|53 74|transcription factor IID
P09726988A0275|0 5|Oleate
P09726988A0275|25 30|levels
P09726988A0275|33 42|M-CPT I mRNA
P09726991T0000|0 6|Mapping
P09726991T0000|12 27|DNA binding domain
P09726991T0000|50 72|transcription factor Mac1
P09727045A0817|116 123|presence
P09727045A0817|133 143|AR N terminus
P09727045A0817|35 44|activation
P09727045A0817|8 16|mechanism
P09727045A0817|147 165|ligand binding domain
P09727045A0817|48 58|cooperation
P09727045A0817|87 90|HREs
P09727045A0817|61 69|receptors
P09727046A0000|162 164|Lam
P09727046A0000|107 110|site
P09727046A0000|157 159|LCR
P09727046A0000|127 155|beta-globin locus control region
P09727046A0000|166 167|L.
P09727046A0000|113 115|HS2
P09727046A0000|81 86|region
P09727046A0000|38 44|protein
P09727046A0000|46 51|HS2NF5
P09727046A0784|84 87|TAL1
P09727046A0784|75 79|NF-E2
P09727046A0784|52 61|regulators
P09727046A0784|17 19|HS2
P09727046A0784|3 10|CBF1 site
P09727046A0784|31 35|sites
P09727046A0784|68 73|GATA-1
P09729481A0000|132 146|Sp1 binding sites
P09729481A0000|154 175|transcription start site
P09729481A0000|109 117|sequences
P09729481A0000|3 43|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A0000|87 94|promoter
P09729481A0000|50 59|kinase mRNA
P09729481A0000|45 48|BCOD
P09729481A1177|0 14|Co-transfection
P09729481A1177|125 130|kinase
P09729481A1177|106 108|Sp1
P09729481A1177|179 182|site
P09729481A1177|191 196|region
P09729481A1177|80 93|Schneider cells
P09729481A1177|49 65|promoter construct
P09729481A1177|136 151|promoter activity
P09729481A1177|20 39|Sp1 expression plasmid
P09730413A0642|158 164|cancers
P09730413A0642|9 22|investigations
P09730413A0642|53 56|role
P09730413A0642|68 76|treatment
P09730413A0642|124 138|treatment option
P09730413A0642|98 107|TME surgery
P09730413A0642|142 151|Stage T1-T3
P09731354A0963|14 21|degrees C
P09731354A0963|34 47|surface density
P09731354A0963|50 58|NH2 groups
P09731354A0963|115 116|hr
P09731354A0963|78 79|hr
P09731354A0963|67 73|maximum
P09731354A0963|27 27|%
P09731513A1090|130 138|HTLV-I Tax
P09731513A1090|40 50|cooperation
P09731513A1090|103 117|transactivation
P09731513A1090|19 25|results
P09731513A1090|53 81|transcription factors NF-kappaB
P09731513A1090|85 88|AP-1
P09731513A1090|120 127|IL-8 gene
P09731704A0000|86 93|estrogen
P09731704A0000|123 144|U2-OS osteosarcoma cells
P09731704A0000|95 96|E2
P09731704A0000|107 120|gene activation
P09731704A0000|77 83|isoform
P09731704A0000|4 8|study
P09731704A0000|31 37|effects
P09731704A0000|69 75|ERalpha
P09731704A0000|46 67|estrogen receptor-alpha
P09731704A1472|76 82|OS cells
P09731704A1472|67 73|ERalpha
P09731704A1472|24 30|amounts
P09731704A1472|93 104|potentiation
P09731704A1472|163 168|manner
P09731704A1472|33 61|delta5ERalpha expression vector
P09731704A1472|120 133|ERELuc activity
P09731704A1472|0 11|Transfection
P09731705A2126|0 6|Studies
P09731705A2126|79 84|VDR-TR
P09731705A2126|53 60|evidence
P09731705A2126|15 19|yeast
P09731705A2126|67 75|formation
P09731705A2126|30 35|system
P09731705A2126|100 110|interaction
P09733493A0493|118 125|solution
P09733493A0493|78 93|hydroxyl radicals
P09733493A0493|50 58|melatonin
P09733493A0493|39 48|standpoint
P09733493A0493|3 9|results
P09733493A0493|100 105|vacuum
P09733647A1960|63 68|B-loop
P09733647A1960|54 57|part
P09733647A1960|128 132|algae
P09733647A1960|90 96|variety
P09733647A1960|13 47|Thr-Gly-X-X-Gly-Asp-Gly-Lys-Ile-Phe
P09733647A1960|4 11|sequence
P09733647A1960|136 149|archeabacteria
P09733647A1960|99 107|organisms
P09733647A1960|119 126|bacteria
P09733794A1323|27 31|Bcl-2
P09733794A1323|47 54|proteins
P09733794A1323|75 81|control
P09733794A1323|62 64|Bax
P09733794A1323|101 105|cells
P09733794A1323|119 127|treatment
P09733794A1323|56 60|Bcl-x
P09733794A1323|18 24|changes
P09733794A1323|132 133|Tg
P09733815T0000|0 7|Tyrosine
P09733815T0000|105 116|virus latency
P09733815T0000|50 77|protein tyrosine kinase loading
P09733815T0000|19 35|membrane protein 2A
P09733815T0000|81 90|regulation
P09733854A0198|73 74|LR
P09733854A0198|76 78|RNA
P09733854A0198|20 29|transcript
P09733854A0198|45 51|latency
P09734808A0000|159 164|phases
P09734808A0000|9 22|test efficiency
P09734808A0000|57 78|contrast/color card test
P09734808A0000|126 131|number
P09734808A0000|134 140|stimuli
P09734808A0000|100 111|test stimulus
P09735286A0599|83 90|presence
P09735286A0599|68 77|Mu B protein
P09735286A0599|99 107|target DNA
P09735286A0599|93 95|ATP
P09735286A0599|16 23|proteins
P09735286A0599|3 8|defect
P09735286A0599|58 60|Mn2
P09735366A1180|100 103|EPL1
P09735366A1180|163 168|humans
P09735366A1180|126 129|ESTs
P09735366A1180|5 29|homology cloning techniques
P09735366A1180|78 89|yeast protein
P09735366A1180|134 154|Caenorhabditis elegans
P09735366A1180|62 63|Pc
P09735366A1180|60 60|E
P09735366A1180|156 159|mice
P09735366A1180|72 75|Epc1
P09735366A1180|44 57|mouse homologue
P09735368A0636|87 94|activity
P09735368A0636|23 25|UTR
P09735368A0636|110 122|K box sequences
P09735368A0636|67 77|transcripts
P09735368A0636|19 20|m8
P09735368A0636|41 52|accumulation
P09735371A0227|117 134|homeodomain protein
P09735371A0227|80 89|touch cells
P09735371A0227|35 52|homeodomain protein
P09735371A0227|65 74|production
P09735371A0227|167 176|touch cells
P09735371A0227|96 100|mec-3
P09735371A0227|147 161|differentiation
P09736239A0436|236 247|accumulation
P09736239A0436|256 267|excitotoxins
P09736239A0436|208 208|%
P09736239A0436|181 193|resuscitation
P09736239A0436|284 296|resuscitation
P09736239A0436|92 99|striatum
P09736239A0436|44 52|aspartate
P09736239A0436|140 140|p
P09736239A0436|126 138|resuscitation
P09736239A0436|200 200|%
P09736239A0436|11 29|resuscitation period
P09736239A0436|150 150|p
P09736239A0436|56 78|glutamate concentrations
P09736697A0783|59 62|ERKs
P09736697A0783|82 85|ERK2
P09736697A0783|93 96|JNK1
P09736697A0783|40 45|kinase
P09736697A0783|66 79|overexpression
P09736697A0783|107 121|Stat3 activation
P09736697A0783|32 35|MEK1
P09736697A0783|0 9|Expression
P09736697A1107|0 3|MEKs
P09736697A1107|218 224|pathway
P09736697A1107|157 172|Janus kinases Jak1
P09736697A1107|20 33|IL-6 activation
P09736697A1107|80 83|site
P09736697A1107|51 58|mutation
P09736697A1107|36 40|Stat3
P09736697A1107|61 70|serine-727
P09736697A1107|87 107|serine phosphorylation
P09736697A1107|190 194|Stat3
P09736697A1107|139 143|Stat3
P09736697A1107|7 10|ERKs
P09736697A1107|176 179|Jak2
P09736697A1107|118 127|inhibition
P09736715A0729|154 154|K
P09736715A0729|87 89|ILK
P09736715A0729|164 166|ILK
P09736715A0729|149 150|Pi
P09736715A0729|12 31|phosphatidylinositol
P09736715A0729|112 119|membrane
P09736715A0729|39 51|trisphosphate
P09736715A0729|77 84|activity
P09736715A0729|103 110|addition
P09736770A0351|58 65|promoter
P09736770A0351|22 35|binding studies
P09736770A0351|76 83|activity
P09736770A0351|52 56|HEFT1
P09736770A0351|109 111|Sp1
P09736770A0351|93 97|GC box
P09736770A0351|114 116|Sp3
P09736770A0351|0 11|Transfection
P09737453A0557|0 5|Plasma
P09737453A0557|168 172|ELISA
P09737453A0557|75 81|complex
P09737453A0557|47 53|surgery
P09737453A0557|100 105|factor
P09737453A0557|162 166|assay
P09737453A0557|42 45|days
P09737453A0557|39 40|SD
P09737453A0557|57 69|IgG antibodies
P09737921T0000|0 15|Genome plasticity
P09737921T0000|52 64|bacteriophage
P09737921T0000|113 123|specificity
P09737921T0000|66 78|recombination
P09737921T0000|95 105|motifs swaps
P09737921T0000|27 40|tail fiber locus
P09738010A0305|3 13|FAS promoter
P09738010A0305|110 125|base pair position
P09738010A0305|91 100|E-box motif
P09738010A0305|31 37|insulin
P09738010A0305|56 78|insulin response sequence
P09738087A0583|99 107|illnesses
P09738087A0583|22 31|predictors
P09738087A0583|78 87|adjustment
P09738087A0583|34 41|survival
P09738087A0583|56 73|Cox regression model
P09738087A0583|3 8|effect
P09738693T0000|0 6|Effects
P09738693T0000|40 47|survival
P09738693T0000|50 55|sepsis
P09738693T0000|9 15|rhG-CSF
P09738693T0000|18 36|neutrophil functions
P09738693T0000|71 74|rats
P09739401A0000|0 8|OBJECTIVE
P09739401A0000|26 32|article
P09739401A0000|13 19|purpose
P09739401A0000|43 60|balance instruments
P09739401A0000|108 113|clinic
P09739401A0000|116 130|home environment
P09739401A0000|85 89|years
P09739913A0194|0 9|CASE REPORT
P09739913A0194|65 69|trunk
P09739913A0194|32 41|skin defect
P09741391A0581|29 35|body box
P09741391A0581|107 111|pause
P09741391A0581|37 45|PenH units
P09741391A0581|77 85|breathing
P09741391A0581|119 129|inspiration
P09741391A0581|69 74|effort
P09741391A0581|55 59|Pause
P09741391A0581|133 142|expiration
P09741783A0000|0 10|Anastrozole
P09741783A0000|128 139|breast cancer
P09741783A0000|21 38|aromatase inhibitor
P09741783A0000|111 115|women
P09741783A0000|57 73|survival advantage
P09741783A0000|87 93|acetate
P09742129A0491|0 1|W.
P09743128A0969|0 6|Moritta
P09743128A0969|19 25|Bis-GMA
P09743233A0526|0 7|Mutation
P09743233A0526|46 49|site
P09743233A0526|19 22|AP-1
P09743233A0526|63 78|promoter activity
P09743233A0526|81 84|SMCs
P09743233A0526|28 39|ets component
P09743720A0268|0 6|ANIMALS
P09743720A0268|13 16|dogs
P09743720A0268|40 41|DM
P09744095A1016|262 267|mutant
P09744095A1016|19 25|mutants
P09744095A1016|72 81|mutants hy2
P09744095A1016|215 229|level expression
P09744095A1016|83 85|hy3
P09744095A1016|188 204|inflorescence stem
P09744095A1016|235 241|CAB gene
P09744095A1016|142 149|response
P09744095A1016|171 179|hypocotyl
P09744095A1016|249 255|shy2-1D
P09744095A1016|104 111|phyA-201
P09744095A1016|152 159|darkness
P09744095A1016|97 102|fre1-1
P09744095A1016|31 43|shy2-1D mutant
P09744095A1016|87 92|phyB-1
P09745797A0943|57 66|disruption
P09745797A0943|76 80|tasks
P09745797A0943|39 42|pain
P09745797A0943|21 36|underpredictions
P09745797A0943|97 102|impact
P09747651A0000|0 12|Laser ablation
P09747651A0000|68 76|emphysema
P09747651A0000|42 48|measure
P09747873T0000|17 35|adapter protein GRB10
P09747873T0000|49 55|BCR-ABL
P09748261A0000|88 92|Faaps
P09748261A0000|40 58|acyl-CoA synthetases
P09748261A0000|65 86|acid activation proteins
P09748286A0000|87 90|LIFR
P09748286A0000|92 95|gene
P09748286A0000|54 61|leukemia
P09748286A0000|143 154|pair enhancer
P09748286A0000|167 177|nucleotides
P09748286A0000|114 129|characterization
P09748286A0000|36 43|enhancer
P09748286A0000|72 85|factor receptor
P09748513X1360|0 8|Copyright
P09748513X1360|13 31|Elsevier Science B.V.
P09748669A0414|42 43|AD
P09748669A0414|7 10|time
P09748669A0414|47 49|VaD
P09748669A0414|26 34|dichotomy
P09749533A0764|0 4|Clone
P09749533A0764|11 17|homolog
P09749533A0764|20 27|CONSTANS
P09749533A0764|37 40|gene
P09749533A0764|65 77|flowering time
P09749533A0764|80 90|Arabidopsis
P09749988A0000|0 6|Badcock
P09749988A0000|72 75|line
P09749988A0000|96 105|attraction
P09749988A0000|123 127|study
P09749988A0000|253 261|repulsion
P09749988A0000|205 217|repulsion zone
P09749988A0000|10 19|Westheimer
P09749988A0000|39 42|3-11
P09749988A0000|89 93|zones
P09749988A0000|140 146|results
P09749988A0000|109 117|repulsion
P09749988A0000|193 199|extents
P09749988A0000|238 244|contour
P09749988A0000|28 33|Vision
P09750325A0000|178 179|H7
P09750325A0000|62 87|power energization technique
P09750325A0000|119 129|populations
P09750325A0000|16 38|intensity light emissions
P09750325A0000|184 204|Listeria monocytogenes
P09750325A0000|89 92|PPET
P09750325A0000|3 9|effects
P09750325A0000|165 172|serotype
P09750325A0000|206 215|serotype 4b
P09750325A0000|100 107|survival
P09750540A0000|58 65|symptoms
P09750540A0000|35 42|syndrome
P09750540A0000|28 30|MCS
P09750540A0000|94 109|chemical exposure
P09750540A0000|8 26|chemical sensitivity
P09751061A0000|73 89|homeodomain family
P09751061A0000|234 243|expression
P09751061A0000|92 99|proteins
P09751061A0000|254 258|genes
P09751061A0000|46 56|factor Pit-1
P09751061A0000|169 176|response
P09751061A0000|179 205|signal-transduction pathways
P09751061A0000|61 67|members
P09751061A0000|133 143|homeostasis
P09751061A0000|119 129|development
P09751061A0000|0 17|POU-domain proteins
P09751114A0967|18 21|MyoD
P09751114A0967|40 44|cells
P09751114A0967|52 53|E1
P09751114A0967|75 80|vector
P09751114A1987|85 94|conditions
P09751114A1987|47 50|role
P09751114A1987|101 111|mitogenesis
P09751114A1987|68 79|MyoD function
P09751114A1987|23 28|Thr115
P09751114A1987|5 11|results
P09751114A1987|56 65|regulation
P09751166A1460|42 48|Sp1 site
P09751166A1460|75 89|TH transcription
P09751166A1460|93 100|promoter
P09751166A1460|36 38|CRE
P09751166A1460|15 21|results
P09751166A1460|118 123|manner
P09751458A0845|0 19|desmethyltrimebutine
P09753241A0524|176 184|% DSS model
P09753241A0524|113 123|colon mucosa
P09753241A0524|10 21|examinations
P09753241A0524|94 96|MPO
P09753241A0524|70 92|myeloperoxidase activity
P09753241A0524|48 50|WBC
P09753241A0524|38 46|blood cell
P09753241A0524|169 173|weeks
P09753241A0524|151 159|% DSS model
P09753241A0524|100 110|homogenates
P09753241A0524|62 67|assays
P09753241A0524|145 148|week
P09753730A0881|0 14|T7 transcription
P09753730A0881|51 56|levels
P09753730A0881|92 94|use
P09753730A0881|71 80|expression
P09753730A0881|97 113|promoter mutations
P09753769A0362|85 97|PBAN precursor
P09753769A0362|62 79|amino acid sequences
P09753769A0362|24 27|sets
P09753769A0362|30 45|oligonucleotides
P09753769A0362|3 9|primers
P09753774A1642|0 5|Plants
P09753774A1642|96 98|GF3
P09753774A1642|84 94|1,1-nystose
P09753774A1642|79 81|GF2
P09753774A1642|56 77|oligofructans 1-kestose
P09753774A1642|33 41|construct
P09753774A1642|126 128|GF4
P09753774A1642|103 124|1,1,1-fructosylnystose
P09753774A2246|83 112|plant fructosyl transferase genes
P09753774A2246|10 19|comparison
P09753774A2246|62 66|1-fft
P09753774A2246|165 183|plant invertase genes
P09753774A2246|34 51|amino acid sequences
P09753774A2246|133 149|plant fructan genes
P09753774A2246|54 58|1-sst
P09753775A0734|40 52|ICK1 induction
P09753775A0734|8 11|ICK1
P09753775A0734|24 26|ABA
P09753775A0734|62 69|decrease
P09753775A0734|81 103|histone H1 kinase activity
P09754571A0169|42 59|display amplicon 3G1
P09754571A0169|91 108|RAG1 mRNA expression
P09754571A0169|7 16|transcript
P09754571A0169|123 131|cell lines
P09754571A1257|38 47|chromosome
P09754571A1257|51 55|10q26
P09754571A1257|33 35|arm
P09754571A1257|3 11|hBRAG gene
P09755191A0553|84 89|chc1-5
P09755191A0553|50 55|allele
P09755191A0553|105 122|frameshift mutation
P09755191A0553|74 82|chain gene
P09755191A0553|61 68|clathrin
P09755191A0553|132 134|end
P09755191A0553|148 159|reading frame
P09755191A0553|17 22|swa5-1
P09755191A0553|140 143|CHC1
P09755199A0373|41 43|Scm
P09755199A0373|104 110|domains
P09755199A0373|50 56|alleles
P09755199A0373|81 92|requirements
P09755199A0373|28 34|lesions
P09755199A0559|29 40|Scm mutations
P09755199A0559|110 112|Scm
P09755199A0559|80 91|PcG mutations
P09755199A0559|58 66|mbt repeat
P09755199A0559|117 123|alleles
P09755478A0366|105 110|larvae
P09755478A0366|36 45|expression
P09755478A0366|63 70|diapause
P09755478A0366|119 133|trace expression
P09755478A0366|51 60|transcript
P09755478A0366|149 153|pupae
P09755478A0366|0 15|Northern analysis
P09756687A0981|29 38|discussion
P09756687A0981|126 131|values
P09756687A0981|10 25|characterization
P09756687A0981|69 81|rate constants
P09756687A0981|56 60|setup
P09756895A0322|14 19|chCTCF
P09756895A0322|76 80|exons
P09756895A0322|88 93|intron
P09756895A0322|48 51|exon
P09756895A0322|7 11|locus
P09757012A0942|13 15|PDZ
P09757012A0942|19 28|SAM domains
P09757012A0942|76 82|adaptor
P09757012A0942|104 114|information
P09757012A0942|34 43|KS5 protein
P09757012A0942|118 142|signal transduction pathway
P09757012A0942|3 10|presence
P09759180A0000|0 9|BACKGROUND
P09759180A0000|28 29|FQ
P09759180A0000|77 91|cartilage damage
P09759180A0000|11 26|Fluoroquinolones
P09759180A0000|51 58|children
P09759180A0000|71 74|risk
P09759691A1051|174 175|SD
P09759691A1051|313 322|nonsmokers
P09759691A1051|228 235|1.0-mmol
P09759691A1051|304 310|smokers
P09759691A1051|14 20|control
P09759691A1051|104 113|microg/min
P09759691A1051|185 197|blood pressure
P09759691A1051|162 165|mm Hg
P09759691A1051|81 96|albumin excretion
P09759691A1051|253 274|plasma cholesterol level
P09759691A1051|50 53|risk
P09759691A1051|357 361|kg/m2
P09759691A1051|123 127|women
P09759691A1051|368 380|body mass index
P09759691A1051|241 245|mg/dL
P09759691A1051|117 119|men
P09759691A1051|237 237|L
P09759691A1051|57 72|microalbuminuria
P09759691A1051|32 40|variables
P09759691A1051|2 9|analyses
P09759865A0673|262 272|PDGF-Ralpha
P09759865A0673|51 57|binding
P09759865A0673|122 135|gel shift assays
P09759865A0673|80 82|p65
P09759865A0673|154 164|degradation
P09759865A0673|24 32|TNF-alpha
P09759865A0673|178 192|NF-kappaB-alpha
P09759865A0673|13 20|IL-1beta
P09759865A0673|87 119|NF-kappaB consensus oligonucleotide
P09759865A0673|224 237|myofibroblasts
P09759865A0673|213 221|cytoplasm
P09759865A0673|194 206|IkappaB-alpha
P09759865A0673|63 76|Rel proteins p50
P09759865A0673|167 175|inhibitor
P09759865A0673|243 250|IL-1beta
P09760243A0970|0 14|Cotransfections
P09760243A0970|68 82|transactivation
P09760243A0970|27 49|HNF-4 expression plasmids
P09760243A0970|19 23|ATF-2
P09760243A0970|88 102|apoCIII promoter
P09760341T0000|0 24|Phosphocreatine hydrolysis
P09760341T0000|41 48|exercise
P09760341T0000|53 58|effect
P09760341T0000|61 64|FIO2
P09761711A0000|74 81|coupling
P09761711A0000|108 113|nuclei
P09761711A0000|55 61|average
P09761711A0000|97 104|electron
P09761711A0000|138 161|susceptibility anisotropy
P09761711A0000|120 127|presence
P09761711A0000|0 18|Pseudocontact shifts
P09761723A0226|0 5|GETS-1
P09761723A0226|23 29|tissues
P09761723A0226|46 51|retina
P09761723A0226|55 59|brain
P09761791A0489|29 39|SRZ proteins
P09761791A0489|3 13|interaction
P09761791A0489|71 86|blot overlay assay
P09761791A0489|16 21|U1-70K
P09763421A1199|31 53|Fab1p kinase inactivation
P09763421A1199|148 151|size
P09763421A1199|8 17|phenotypes
P09763421A1199|97 116|acidification defects
P09763421A1199|82 87|growth
P09763421A1199|129 137|increases
P09763446A0000|17 29|Ypt/Rab family
P09763446A0000|46 55|regulation
P09763446A0000|5 11|GTPases
P09763446A0000|67 75|transport
P09763446A1234|59 67|fractions
P09763446A1234|25 29|Ypt1p
P09763446A1234|9 21|GAP activities
P09763446A1234|3 5|GEF
P09763470A0000|0 23|Dopamine beta-hydroxylase
P09763470A0000|41 50|conversion
P09763470A0000|53 60|dopamine
P09763470A0000|129 135|neurons
P09763470A0000|63 75|noradrenaline
P09763470A0000|25 27|DBH
P09763470A0000|139 157|neuroendocrine cells
P09763470A1756|130 132|Sp1
P09763470A1756|166 172|DBH gene
P09763470A1756|151 160|activation
P09763470A1756|92 111|transcription factors
P09763470A1756|74 82|synergism
P09763470A1756|41 44|role
P09763470A1756|47 52|Phox2a
P09763470A1756|123 125|AP2
P09763470A1756|118 121|CREB
P09763470A1756|17 21|study
P09763522A2545|117 123|studies
P09763522A2545|126 134|apoptosis
P09763522A2545|49 54|Ox-LDL
P09763522A2545|16 23|antibody
P09763522A2545|149 155|animals
P09763522A2545|76 84|apoptosis
P09763522A2545|31 37|N-SMase
P09763607A0521|19 28|Ngo strains
P09763607A0521|53 62|activation
P09763607A0521|76 84|p38 kinase
P09763607A0521|35 49|phosphorylation
P09763607A0521|65 67|JNK
P09764741A0092|106 110|basis
P09764741A0092|89 94|hearts
P09764741A0092|34 41|elements
P09764741A0092|47 67|cell division machinery
P09764741A0092|80 86|beating
P09764741A0092|7 11|beams
P09765261A0000|267 289|cAMP response element core
P09765261A0000|137 169|cAMP response element binding protein
P09765261A0000|307 315|sequences
P09765261A0000|48 62|trans-activator
P09765261A0000|129 135|protein
P09765261A0000|25 38|retrovirus type
P09765261A0000|246 256|pair repeats
P09765261A0000|64 66|Tax
P09765261A0000|171 174|CREB
P09765261A0000|41 46|HTLV-I
P09765261A0000|96 122|basic-domain/leucine-zipper
P09765261A0000|8 12|T cell
P09765261A0000|124 127|bZip
P09765261A0000|206 212|element
P09765271A1108|86 90|genes
P09765271A1108|231 237|protein
P09765271A1108|112 118|insulin
P09765271A1108|211 216|growth
P09765271A1108|138 169|phosphoenolpyruvate carboxykinase
P09765271A1108|30 52|insulin response sequence
P09765271A1108|171 194|tyrosine aminotransferase
P09765271A1108|4 11|sequence
P09765271A1108|73 78|region
P09765277A0000|119 130|trophoblasts
P09765277A0000|21 45|glucose transporter isoform
P09765277A0000|109 115|neurons
P09765277A0000|48 51|Glut
P09765285A0998|89 93|AaUSP
P09765285A0998|125 128|time
P09765285A0998|183 189|IRper-0
P09765285A0998|155 177|spacer length requirement
P09765285A0998|105 111|IRhsp-1
P09765285A0998|140 149|stringency
P09765285A0998|74 80|binding
P09765285A0998|216 222|binding
P09765285A0998|19 27|half-site
P09765285A0998|83 87|AaEcR
P09765285A0998|192 198|IRper-5
P09765285A0998|57 63|IRper-1
P09765285A0998|33 55|consensus sequence AGGTCA
P09765285A1763|3 8|levels
P09765285A1763|11 25|transactivation
P09765285A1763|103 106|DR-4
P09765285A1763|95 101|IRper-1
P09765285A1763|78 93|response elements
P09765285A1763|108 114|IRhsp-1
P09765285A1763|56 72|binding affinities
P09765372A0669|43 46|half
P09765372A0669|7 13|density
P09765372A0669|52 55|body
P09765372A0669|138 146|C. armatus
P09765372A0669|26 31|spines
P09765372A0669|62 73|distribution
P09765372A0669|76 79|type
P09765372A0669|92 104|dorsal surface
P09765372A0669|82 89|papillae
P09765388T0000|0 11|Inactivation
P09765388T0000|23 25|p73
P09765388T0000|62 63|E4
P09765388T0000|43 45|E1B
P09765388T0000|77 88|oncoproteins
P09765388T0000|14 16|p53
P09765388T0000|28 41|adenovirus type
P09765394A0000|102 107|origin
P09765394A0000|50 63|gene expression
P09765394A0000|81 91|replication
P09765394A0000|109 114|oriLyt
P09765394A0000|15 36|virus transactivator Zta
P09765394A1590|0 13|Cotransfection
P09765394A1590|129 141|CAT expression
P09765394A1590|77 92|activation domain
P09765394A1590|112 126|superactivation
P09765394A1590|35 42|proteins
P09765411A0991|0 18|Sequence comparisons
P09765411A0991|124 127|mRNA
P09765411A0991|41 44|S27a
P09765411A0991|137 149|hybrid protein
P09765411A0991|51 59|ubiquitin
P09765411A0991|93 97|CP Rit
P09765411A0991|66 74|sequences
P09765411A0991|157 188|structure NH2-ubiquitin-S27a-COOH
P09765411A0991|85 90|genome
P09765466A0231|0 1|J.
P09765754A1727|19 25|studies
P09765754A1727|9 13|trend
P09765754A1727|35 37|PVI
P09767504A1371|68 81|administration
P09767504A1371|45 57|concentration
P09767504A1371|21 25|mg/kg
P09767504A1371|65 65|h
P09767504A1371|103 104|h.
P09767504A1371|13 16|dose
P09767575A0657|117 122|domain
P09767575A0657|34 37|edge
P09767575A0657|43 52|SD sequence
P09767575A0657|109 114|region
P09767575A0657|68 82|ribosome binding
P09767575A0657|4 9|domain
P09767593A0130|86 93|proteins
P09767593A0130|115 121|p130Cas
P09767593A0130|96 104|host cells
P09767593A0130|8 11|YopH
P09767593A0130|55 60|subset
P09767593A0130|27 29|PTP
P09767687T0000|72 79|analysis
P09767687T0000|12 19|position
P09767687T0000|25 35|Phacotaceae
P09767687T0000|92 104|rbcL sequences
P09767687T0000|82 88|18S rDNA
P09767687T0000|45 61|Chlamydophyceaeas
P09769209A0100|72 91|nasF operon expression
P09769209A0100|30 39|conclusion
P09769209A0100|61 69|induction
P09769209A0100|122 145|antitermination mechanism
P09769209A0100|15 21|studies
P09769910A1700|16 21|injury
P09769910A1700|75 83|cytokines
P09769910A1700|103 109|effects
P09769910A1700|49 51|TNF
P09769910A1700|35 39|cells
P09769910A1700|3 12|activation
P09769910A1700|117 125|mediators
P09770241A0000|1 9|technique
P09770241A0000|79 84|system
P09770241A0000|46 56|brain cortex
P09770241A0000|20 26|imaging
P09770241A0000|32 37|animal
P09770378A0641|0 9|EGFR levels
P09770415A0139|42 56|KRxxxxxxxxxKTKK
P09770415A0139|36 40|motif
P09770415A0139|125 142|localization signal
P09770415A0139|144 146|NLS
P09770415A0139|21 26|THOV NP
P09770415A0139|60 77|amino acid positions
P09770493A0499|13 17|range
P09770493A0499|147 162|postimplantation
P09770493A0499|120 126|embryos
P09770493A0499|179 181|day
P09770493A0499|68 88|cell fate determination
P09770493A0499|46 64|cell cycle regulation
P09770493A0499|2 5|PP2A
P09770493A0499|28 36|functions
P09770686A0484|40 51|hypertension
P09770686A0484|15 24|risk factor
P09771555A0499|3 9|results
P09771555A0499|22 44|anthraquinone sennoside B
P09771555A0499|48 52|rhein
P09771967A1052|27 41|chromosome 13q14
P09771967A1052|44 49|region
P09771967A1052|12 18|LB1 gene
P09771967A1052|95 98|DLBL
P09771967A1052|83 92|breakpoint
P09771985A0238|14 20|repatch
P09771985A0238|50 55|EtHgCl
P09771985A0238|81 86|EtHgCl
P09771985A0238|62 70|solutions
P09771985A0238|96 105|L-cysteine
P09771985A0238|109 119|glutathione
P09771985A0238|2 9|subjects
P09771985A0238|29 48|ethylmercury chloride
P09773975A1873|118 122|level
P09773975A1873|267 270|t1/2
P09773975A1873|41 57|hamster ovary cells
P09773975A1873|193 205|substitutions
P09773975A1873|247 249|min
P09773975A1873|220 222|min
P09773975A1873|305 308|Ymax
P09773975A1873|100 103|t1/2
P09773975A1873|164 172|receptors
P09773975A1873|251 254|Ymax
P09773975A1873|301 303|min
P09773975A1873|213 216|t1/2
P09773975A1873|107 109|min
P09773975A1873|259 259|%
P09773975A1873|286 286|%
P09773975A1873|125 139|internalization
P09773975A1873|83 98|Ang II stimulation
P09773975A1873|232 232|%
P09773975A1873|207 211|T332E
P09773975A1873|261 265|T336E
P09773975A1873|313 313|%
P09773975A1873|150 150|%
P09773975A1873|141 144|Ymax
P09773975A1873|294 297|t1/2
P09773975A1873|278 281|Ymax
P09773975A1873|224 227|Ymax
P09773975A1873|274 276|min
P09773975A1873|288 292|S338D
P09773975A1873|9 21|AT1A receptors
P09773975A1873|240 243|t1/2
P09773975A1873|234 238|S335D
P09773981A0415b|51 55|Stat5
P09773981A0415b|12 33|glucocorticoid receptor
P09773981A0415b|40 46|complex
P09773981A0415b|96 104|induction
P09774403A0107|0 1|T.
P09774403A0107|23 24|G.
P09774403A0107|12 13|A.
P09774403A0107|18 21|Cote
P09774403A0107|3 10|Mahasneh
P09774444A0351|29 32|UKLF
P09774444A0351|62 74|Cys2-His2 type
P09774444A0351|137 158|Sp1 recognition sequence
P09774444A0351|20 26|portion
P09774444A0351|110 128|beta-globin promoter
P09774444A0351|46 56|zinc fingers
P09774444A0351|95 104|CACCC motif
P09774450A0000|42 68|gamma-glutamyl leukotrienase
P09774450A0000|107 119|leukotriene D4
P09774450A0000|25 35|mouse enzyme
P09774450A0000|86 98|leukotriene C4
P09774450A0000|70 72|GGL
P09774450A0000|121 124|LTD4
P09774450A0000|100 103|LTC4
P09774484T0000|0 15|UGA codon position
P09774484T0000|38 64|selenocysteine incorporation
P09774484T0000|26 35|efficiency
P09774484T0000|69 91|glutathione peroxidase-1
P09774641A0824|62 68|cyclin D
P09774641A0824|50 59|expression
P09774641A0824|92 116|retinoblastoma gene product
P09774641A0824|72 86|phosphorylation
P09774641A0824|0 8|Forskolin
P09774662A0958|96 103|RNA level
P09774662A0958|48 61|E2F1 expression
P09774662A0958|3 13|ARF promoter
P09774662A0958|84 90|results
P09776293A0777|84 84|%
P09776293A0777|11 17|binding
P09776293A0777|63 63|%
P09776293A0777|89 90|ml
P09776293A0777|77 77|%
P09776293A0777|20 25|99mTc d
P09776293A0777|99 106|solution
P09776293A0777|41 48|placenta
P09776293A0777|27 33|1-HMPAO
P09776293A0777|70 70|%
P09776293A0777|0 6|RESULTS
P09776360A0620|0 1|CM
P09776360A0620|36 58|transcription factor AP-1
P09776360A0620|19 33|binding activity
P09776360A1781|0 8|NF-kappaB
P09776360A1781|102 109|effector
P09776360A1781|112 113|CM
P09776360A1781|116 125|DLD-1 cells
P09776360A1781|65 72|promoter
P09776360A1781|60 62|NOS
P09776360A1781|42 49|activity
P09777477A0000|0 8|Observers
P09777477A0000|122 124|air
P09777477A0000|136 145|peppermint
P09777477A0000|13 23|brain injury
P09777477A0000|100 105|whiffs
P09777477A0000|56 68|vigilance task
P09777477A0000|27 45|control participants
P09777477A0000|117 119|air
P09777600A0000|59 72|chromatography
P09777600A0000|26 34|l-menthol
P09777600A0000|98 105|detector
P09777600A0000|17 22|method
P09777999A0796|0 6|RESULTS
P09777999A0796|54 64|PaCO2 levels
P09777999A0796|79 79|%
P09777999A0796|95 95|%
P09777999A0796|81 91|hypercapnia
P09777999A0796|66 75|hypocapnia
P09777999A0796|18 22|index
P09778006A0718|227 231|value
P09778006A0718|75 79|PaCO2
P09778006A0718|98 101|mean
P09778006A0718|152 155|mmHg
P09778006A0718|46 58|carbon dioxide
P09778006A0718|245 261|baseline Vmca/mmHg
P09778006A0718|69 73|blood
P09778006A0718|93 96|mmHg
P09778006A0718|105 106|SD
P09778006A0718|204 204|s
P09778006A0718|201 202|cm
P09778006A0718|109 120|measurements
P09778006A0718|136 139|PaCO
P09778006A0718|210 213|mmHg
P09778006A0718|14 25|baseline Vmca
P09778006A0718|233 242|percentage
P09778006A0718|163 185|carbon dioxide reactivity
P09778006A0718|36 43|pressure
P09778006A0718|195 199|value
P09778068A1129|217 221|death
P09778068A1129|12 30|Cox survival analysis
P09778068A1129|205 214|predictors
P09778068A1129|167 171|month
P09778068A1129|57 57|%
P09778068A1129|153 163|performance
P09778068A1129|110 117|ablation
P09778068A1129|41 50|baseline EF
P09778068A1129|86 98|regurgitation
P09778068A1129|122 128|failure
P09778068A1129|59 66|presence
P09778068A1129|177 184|ablation
P09778191A0000|28 37|estimation
P09778191A0000|75 89|reserve capacity
P09778191A0000|52 55|rCBF
P09778191A0000|153 155|MRI
P09778191A0000|114 118|means
P09778191A0000|19 24|method
P09778191A0000|136 151|resonance imaging
P09778191A0000|48 50|CBF
P09778191A0000|107 111|basis
P09778197A0415|0 25|Cost-effectiveness analysis
P09778197A0415|99 108|comparison
P09778197A0415|257 271|atherosclerosis
P09778197A0415|234 240|statins
P09778197A0415|214 232|reductase inhibitors
P09778197A0415|156 162|therapy
P09778197A0415|302 312|cholesterol
P09778197A0415|250 254|costs
P09778197A0415|43 47|means
P09778197A0415|135 141|therapy
P09778197A0415|167 202|beta-hydroxy-beta-methylglutaryl-CoA
P09778197A0415|114 118|costs
P09778197A0415|204 212|coenzyme A
P09778197A0415|67 85|health care resources
P09780002A0996|103 107|E2F-1
P09780002A0996|22 42|transactivation domain
P09780002A0996|73 85|transcription
P09780002A0996|8 13|E2FBP1
P09780002A0996|56 58|E2F
P09780002A0996|88 98|cooperation
P09780228A0122|0 9|Sequencing
P09780228A0122|33 48|FK506 gene cluster
P09780228A0122|18 27|DNA segment
P09780228A0613|30 33|FkbB
P09780228A0613|61 64|FkbA
P09780228A0613|37 40|FkbC
P09780228A0613|12 27|domain structures
P09780228A0613|78 96|fatty-acid-synthase
P09780228A0613|125 131|modules
P09780228A0613|107 113|domains
P09780228A0613|98 100|FAS
P09780336A0771|0 7|Analysis
P09780336A0771|74 84|populations
P09780336A0771|49 59|mouse testes
P09780336A0771|111 120|expression
P09780336A0771|151 158|cell type
P09780336A0771|10 27|Msy2 mRNA expression
P09780336A0771|134 148|round spermatids
P09780336A0771|186 212|messenger ribonucleoproteins
P09780336A0771|171 177|amounts
P09780336A0771|87 95|germ cells
P09781761A0384|98 102|fluid
P09781761A0384|77 81|fluid
P09781761A0384|58 62|blood
P09781761A0384|3 15|Ho Chi Minh City
P09781761A0384|28 34|culture
P09781761A0384|38 55|latex agglutination
P09781761A0384|83 87|urine
P09781871A0404|0 16|Glycogen synthesis
P09781871A0404|231 233|Ecc
P09781871A0404|20 29|catabolism
P09781871A0404|47 56|glycolysis
P09781871A0404|191 195|plant
P09781871A0404|290 293|rsmA
P09781871A0404|265 275|metabolites
P09781871A0404|210 229|response elicitor HrpN
P09781871A0404|114 117|csrA
P09781871A0404|171 186|virulence factors
P09781871A0404|67 87|cell surface properties
P09781871A0404|144 153|production
P09781871A0404|296 312|Erwinia carotovora
P09781871A0404|58 65|motility
P09781871A0404|31 45|gluconeogenesis
P09781871A0404|91 99|adherence
P09781874A1061|42 60|adenine substitution
P09781874A1061|87 92|region
P09781874A1061|63 72|nucleotide
P09781874A1061|33 39|guanine
P09781874A1061|124 128|cwg2p
P09781874A1061|108 118|change A202T
P09781874A1061|3 16|cwg2-1 mutation
P09784063A0621|0 15|Deletion analysis
P09784063A0621|40 45|domain
P09784063A0621|52 59|promoter
P09784063A0621|108 118|nucleotides
P09784063A0621|70 98|ORF5/deltaX transcript promoter
P09784192A1027|17 26|MBP fusions
P09784192A1027|9 15|peptide
P09784192A1027|48 70|surface plasmon resonance
P09784245T0000|30 35|MyBP-C
P09784245T0000|38 51|identification
P09784245T0000|54 67|protein kinase A
P09784245T0000|71 104|protein kinase C phosphorylation sites
P09784245T0000|21 28|protein C
P09785114A1026|56 61|groups
P09785114A1026|36 45|CORT levels
P09785114A1026|10 12|PND
P09786197A0322|0 7|Analysis
P09786197A0322|144 161|sequence similarity
P09786197A0322|118 121|csrR
P09786197A0322|196 202|systems
P09786197A0322|21 31|DNA sequence
P09786197A0322|94 106|reading frames
P09786197A0322|125 128|csrS
P09786197A0322|58 76|transposon insertion
P09786404A0541|29 29|P
P09786404A0541|25 27|rpm
P09786404A0541|9 21|aggregates/ml
P09786926A0095|218 220|rat
P09786926A0095|117 134|fatty-acid synthase
P09786926A0095|170 177|activity
P09786926A0095|140 143|gene
P09786926A0095|23 28|region
P09786926A0095|34 59|fatty-acid synthase promoter
P09786926A0095|136 138|FAS
P09786926A0095|98 111|overexpression
P09786926A0095|224 228|cells
P09786926A0095|193 200|promoter
P09786926A1372|70 87|ADD1/SREBP1 binding
P09786926A1372|111 117|element
P09786926A1372|47 52|SREBP2
P09786926A1372|123 126|site
P09786926A1372|20 33|binding studies
P09786926A1372|95 100|sterol
P09786926A1372|119 121|SRE
P09786932A1042|28 37|similarity
P09786932A1042|40 44|IRF-3
P09786932A1042|105 112|cell type
P09786932A1042|126 129|IFNA
P09786932A1042|69 78|expression
P09786932A1042|164 167|role
P09786932A1042|143 147|IRF-7
P09786932A1042|81 85|IRF-7
P09786932A1042|96 100|cells
P09786932A1042|5 9|IRF-7
P09786932A1042|183 200|IFNA gene expression
P09786949A0114|0 1|J.
P09787323A0000|0 6|PURPOSE
P09787323A0000|39 47|treatment
P09787323A0000|11 27|role interleukin-6
P09787323A0000|29 32|IL-6
P09787323A0000|60 76|thrombocytopenias
P09788739A1096|132 154|MDA231 breast cancer cells
P09788739A1096|75 90|signaling cascade
P09788739A1096|104 110|variety
P09788739A1096|22 33|serine kinase
P09788739A1096|64 71|molecule
P09788739A1096|121 129|responses
P09789025A0149|0 6|Galphaq
P09789025A0149|35 41|Galphai
P09789025A0149|51 53|SRF
P09789025A0149|8 15|Galpha12
P09789025A0149|20 27|Galpha13
P09789025A0149|61 64|RhoA
P09789795A0607|60 73|concentrations
P09789795A0607|19 26|subjects
P09789795A0607|38 38|A
P09789795A0607|57 58|NA
P09789795A0607|43 55|noradrenaline
P09790499A0545|0 19|Northern blot analyses
P09790499A0545|31 44|hBub1 mRNA level
P09790499A0545|77 81|cells
P09790499A0545|68 74|tissues
P09790499A0545|98 102|index
P09790767A0372|87 93|band q31
P09790767A0372|62 67|contig
P09790767A0372|75 84|chromosome
P09790767A0372|31 47|sequence tag clones
P09790768A0621|0 10|Htra2-beta3
P09790768A0621|93 98|kidney
P09790768A0621|64 68|brain
P09790768A0621|70 80|liver testis
P09790771A0956|0 16|Gng3lg transcripts
P09790771A0956|69 74|testes
P09790771A0956|61 65|brain
P09790771A0956|32 38|variety
P09790771A0956|41 47|tissues
P09790771A1032|72 76|locus
P09790771A1032|50 53|Gng3
P09790771A1032|79 88|chromosome
P09790771A1032|57 62|Gng3lg
P09790771A1032|20 33|backcross panel
P09790986A0689|41 77|glutathione S-transferase fusion protein
P09790986A0689|105 114|amino acids
P09790986A0689|23 30|antibody
P09790986A0689|122 127|NRAMP2
P09792439T0000|0 9|Inhibition
P09792439T0000|57 70|hnRNP C1 protein
P09792439T0000|15 40|apolipoprotein B mRNA editing
P09792439T0000|74 90|40S hnRNP complexes
P09792627A0441|0 4|SRC-1
P09792627A0441|36 45|repression
P09792627A0441|48 57|GR activity
P09792630A1127|62 65|TTCC
P09792630A1127|109 118|nucleoside
P09792630A1127|125 140|initiator element
P09792630A1127|81 93|consensus CTCA
P09792630A1127|156 182|deoxynucleotidyltransferase
P09792630A1127|103 103|N
P09792630A1127|187 192|number
P09792630A1127|98 101|NTCT
P09792630A1127|215 219|genes
P09792630A1127|95 96|+1
P09792630A1127|10 17|sequence
P09792630A1127|59 60|+1
P09792630A1127|32 57|transcription start site CTCA
P09792682A0713|40 47|subunit c
P09792682A0713|50 51|F0
P09792682A0713|5 11|results
P09792682A0713|32 37|number
P09792702A0754|30 35|mutant
P09792702A0754|104 122|HSP70 gene expression
P09792702A0754|82 95|JNK1 activation
P09792702A0754|38 41|JNK1
P09792702A0754|56 62|glucose
P09792702A0754|0 9|Expression
P09792714A1408|59 71|transcription
P09792714A1408|134 137|AF-1
P09792714A1408|106 115|activation
P09792714A1408|24 31|proteins
P09792714A1408|52 56|steps
P09792714A1408|83 91|mechanism
P09792714A1408|3 13|interaction
P09792714A1408|118 131|gene expression
P09792714A1408|16 19|AF-1
P09794414T0000|3 6|role
P09794414T0000|9 31|protein kinase C signaling
P09794414T0000|43 58|DRA transcription
P09794795A0183|0 12|Ligand binding
P09794795A0183|220 244|transcription factors STAT3
P09794795A0183|40 62|tyrosine phosphorylation
P09794795A0183|277 279|SH2
P09794795A0183|18 32|receptor complex
P09794795A0183|96 110|phosphorylation
P09794795A0183|209 217|activator
P09794795A0183|259 275|src homology domain
P09794795A0183|78 89|Janus kinases
P09794795A0183|156 166|recruitment
P09794795A0183|248 252|STAT1
P09794795A0183|91 93|Jak
P09794795A0183|116 144|signal transducing subunit gp130
P09794795A0183|190 205|signal transducer
P09794795A0183|170 184|phosphorylation
P09794795A0183|66 75|activation
P09794795A0183|292 317|protein tyrosine phosphatase
P09794795A0183|319 322|SHP2
P09795130A0742|16 23|increase
P09795130A0742|26 33|distance
P09795130A0742|61 66|effect
P09795130A0742|69 89|translation efficiency
P09795170A0774|55 57|TGA
P09795170A0774|62 66|codon
P09795170A0774|88 103|kb transcript size
P09795170A0774|16 34|polyadenylation site
P09795213A0129|0 11|RBP56 protein
P09795213A0129|149 153|Heard
P09795213A0129|176 177|L.
P09795213A0129|155 158|D.J.
P09795213A0129|25 32|hTAFII68
P09795213A0129|128 139|Bertolotti A.
P09795213A0129|141 144|Lutz
P09795213A0129|88 90|TAF
P09795213A0129|113 126|TFIID complexes
P09795213A0129|216 222|protein
P09795213A0129|97 110|sub-population
P09795213A0129|299 311|RNA polymerase
P09795213A0129|184 191|hTAFII68
P09795213A0129|160 166|Chambon
P09795213A0129|227 234|homology
P09795213A0129|240 264|proto-oncoproteins TLS/FUS
P09795213A0129|64 70|protein
P09795213A0129|268 270|EWS
P09795213A0129|168 169|P.
P09795213A0129|171 174|Tora
P09795213A0129|146 147|Y.
P09795213A0129|81 86|factor
P09795213A0129|291 295|TFIID
P09795341A0806|17 34|mobility shift assay
P09795341A0806|64 78|binding property
P09795341A0806|81 83|TR2
P09795341A0806|99 105|isoform
P09797189A0559|47 56|CCAAT motif
P09797189A0559|12 24|shift analysis
P09797456A0000|58 62|roles
P09797456A0000|65 81|cell proliferation
P09797456A0000|116 124|apoptosis
P09797456A0000|99 112|transformation
P09797456A0000|83 97|differentiation
P09797456A0000|14 32|c-myc proto-oncogene
P09797456A0000|0 9|BACKGROUND
P09797456A0883|0 4|AMY-1
P09797456A0883|73 79|nucleus
P09797456A0883|85 89|cells
P09797456A0883|136 140|cells
P09797456A0883|97 111|c-myc expression
P09797456A0883|33 37|cells
P09797456A0883|22 30|cytoplasm
P09797456A0883|48 52|c-myc
P09797456A0883|58 63|levels
P09798068A0290|0 6|RESULTS
P09798068A0290|91 97|protein
P09798068A0290|152 154|rat
P09798068A0290|136 144|% homology
P09798068A0290|64 65|bp
P09798068A0290|179 183|GABAB
P09798068A0290|103 112|amino acids
P09798068A0290|46 57|reading frame
P09798068A0290|32 35|cDNA
P09798068A0290|173 177|acid B
P09798068A0290|185 192|receptor
P09798100A0705|2 4|Day
P09798100A0705|63 64|IM
P09798100A0705|10 15|CIDR-B
P09798100A0705|32 53|micrograms cloprostenol
P09798263T0000|62 86|calcium channel antagonists
P09798263T0000|19 28|properties
P09798263T0000|108 119|swimming test
P09798263T0000|35 58|serotonin receptor ligands
P09798263T0000|122 125|mice
P09799086A0725|113 114|Gs
P09799086A0725|50 59|frame shift
P09799086A0725|164 173|LN patients
P09799086A0725|102 107|repeat
P09799086A0725|69 88|G nucleotide insertion
P09799086A0725|117 124|HPRT exon
P09799086A0725|16 30|hotspot mutation
P09799086A0725|41 47|patient
P09799237A0624|39 56|gastrulation defect
P09799237A0624|13 19|embryos
P09799237A0624|74 77|term
P09799362A0507|88 104|Zinc Finger protein
P09799362A0507|56 71|abbreviation AZF1
P09799362A0507|29 36|features
P09799362A1463|130 138|influence
P09799362A1463|187 205|RNA polymerase mutant
P09799362A1463|151 161|suppression
P09799362A1463|141 145|Azf1p
P09799362A1463|88 111|transcription factor Mtf1p
P09799362A1463|17 21|Azf1p
P09799362A1463|55 69|expression level
P09799362A1463|27 35|yeast cell
P09799362A1463|0 14|Over-expression
P09799634A0161|113 119|protein
P09799634A0161|77 92|crystal structure
P09799634A0161|44 49|domain
P09799634A0161|108 111|UmuD
P09799634A0161|16 28|computer model
P09799634A0161|58 66|repressor
P09799793T0000|55 62|analysis
P09799793T0000|11 20|sequencing
P09799793T0000|102 110|CUTL1 loci
P09799793T0000|40 53|chromosome 7q22
P09799793T0000|26 32|regions
P09799793T0000|120 124|genes
P09799793T0000|79 86|sequence
P09799793T0000|68 69|kb
P09799793T0000|96 98|EPO
P09800187A0100|199 207|mutations
P09800187A0100|103 111|responses
P09800187A0100|175 192|mouse lymphoma cells
P09800187A0100|53 55|Tk1
P09800187A0100|121 128|exposure
P09800187A0100|35 38|TP53
P09800187A0100|7 11|Trp53
P09800187A0100|210 214|Trp53
P09800187A0100|131 147|DNA damaging agents
P09800187A0100|58 67|chromosome
P09800187A0100|16 27|mouse homolog
P09801156A0220|87 93|gene E75
P09801156A0220|10 18|fragments
P09801156A0220|34 58|amino acid sequence homology
P09801156A0220|70 77|ecdysone
P09801333A0174|14 18|N gene
P09801333A0174|33 44|reading frame
P09801333A0174|81 84|PA-8
P09801333A0174|71 79|PRRS virus
P09802206A1058|27 31|genes
P09802206A1058|48 50|TEF
P09802206A1058|97 100|RPS7
P09802206A1058|7 22|sequence homology
P09802206A1058|60 93|translation elongation factor-1 alpha
P09802206A1058|119 127|protein S7
P09802902A0225|86 107|ARF6 nucleotide exchange
P09802902A0225|25 28|ARNO
P09802902A0225|43 56|plasma membrane
P09803081T0000|5 13|pathology
P09803081T0000|26 32|outcome
P09803081T0000|35 46|childhood SLE
P09804779A0000|0 19|Transcription factors
P09804779A0000|25 34|Stat family
P09804779A0000|50 63|protein kinases
P09804779A1163|32 57|Stat5 serine phosphorylation
P09804779A1163|183 188|Stat5a
P09804779A1163|16 23|pathways
P09804836A0000|86 109|mouse BAC1.2F5 macrophages
P09804836A0000|76 83|response
P09804836A0000|195 195|P
P09804836A0000|138 142|CSF-1
P09804836A0000|220 246|size exclusion chromatography
P09804836A0000|260 264|phase
P09804836A0000|197 218|affinity chromatography
P09804836A0000|251 252|C4
P09804836A0000|145 148|pp37
P09804836A0000|283 296|chromatography
P09804836A0000|176 183|fraction
P09804836A0000|112 136|colony stimulating factor-1
P09804836A0000|32 38|protein
P09804836A0000|269 276|pressure
P09805052A0119|0 3|Dose
P09805052A0119|134 137|dose
P09805052A0119|49 54|months
P09805052A0119|72 85|immunogenicity
P09805052A0119|8 9|ig
P09805052A0119|57 61|order
P09805052A0119|33 38|scheme
P09805052A0119|115 120|months
P09805977A0143|61 66|origin
P09805977A0143|140 149|substances
P09805977A0143|19 22|data
P09805977A0143|154 166|xenoestrogens
P09805977A0143|133 137|class
P09805977A0143|74 82|sperm fall
P09806516A1212|45 52|patients
P09806516A1212|4 14|association
P09806516A1212|76 85|recurrence
P09806516A1689|0 9|CONCLUSION
P09806516A1689|95 100|Postop
P09806516A1689|37 41|Preop
P09806516A1689|103 110|patients
P09806516A1689|44 51|patients
P09806516A1689|80 86|disease
P09806516A1689|149 156|excision
P09806516A1689|16 22|control
P09806546A1270|56 65|RFX complex
P09806546A1270|25 29|RFXAP
P09806546A1270|68 82|MHC-II promoters
P09806546A1270|44 50|binding
P09806546A1270|3 13|interaction
P09806546A1270|18 21|RFX5
P09806826A0244|84 86|Chr
P09806826A0244|74 81|Vwf locus
P09806826A0244|25 30|defect
P09806826A0244|33 39|RIIIS/J
P09806826A0244|48 55|mouse Chr
P09806826A1773|85 88|gene
P09806826A1773|5 8|data
P09806826A1773|112 119|syndrome
P09806826A1773|138 151|susceptibility
P09806826A1773|24 35|localization
P09806826A1773|172 181|lung injury
P09806826A1773|43 53|disease loci
P09806826A1773|66 71|region
P09806826A1773|130 134|locus
P09806830X1174|0 8|Copyright
P09806830X1174|13 25|Academic Press
P09806857A0854|27 33|protein
P09806857A0854|67 76|invertases
P09806857A0854|124 138|Pac25I R-M operon
P09806857A0854|80 89|resolvases
P09806857A0854|6 17|reading frame
P09806857A0854|55 64|similarity
P09806858T0000|57 64|rnaI gene
P09806858T0000|20 23|gene
P09806858T0000|42 52|plasmid pLS1
P09806858T0000|0 13|Identification
P09806919A0447|102 114|ecdysone pulse
P09806919A0447|7 9|usp
P09806919A0447|127 143|puparium formation
P09806919A0447|31 42|instar larvae
P09806919A0447|88 96|responses
P09807755A0146|56 65|muscle flap
P09807755A0146|21 26|supply
P09807755A0146|44 52|viability
P09808155A0813|0 10|Examination
P09808155A0813|168 169|bp
P09808155A0813|79 85|factors
P09808155A0813|13 15|DNA
P09808155A0813|51 58|analysis
P09808155A0813|140 150|DNA fragment
P09808155A0813|125 129|cells
P09808155A0813|17 39|protein binding complexes
P09808216A0000|71 72|FB
P09808216A0000|101 106|ratios
P09808216A0000|35 44|regulation
P09808216A0000|47 52|energy
P09808216A0000|11 17|Studies
P09808216A0000|24 26|men
P09808216A0000|80 91|manipulation
P09808216A0000|63 69|balance
P09808216A0000|54 55|EB
P09808216A0000|0 9|BACKGROUND
P09808366A0828|129 135|animals
P09808366A0828|38 47|conditions
P09808366A0828|90 105|KA microinjection
P09808366A0828|120 126|VRG-Apa
P09808366A0828|111 114|side
P09808366A0828|5 12|apneusis
P09808366A0828|62 66|apnea
P09808441A0320|159 169|coexistence
P09808441A0320|128 135|melanoma
P09808441A0320|114 122|character
P09808441A0320|12 19|analysis
P09808441A0320|79 89|singularity
P09808441A0320|140 152|lymphotropism
P09808441A0320|95 98|case
P09808441A0320|188 200|cell carcinoma
P09808441A0320|57 65|melanomas
P09810087A0379|0 6|RESULTS
P09810087A0379|92 96|acids
P09810087A0379|80 83|HSV I
P09810087A0379|61 78|herpes simplex virus
P09810087A0379|46 53|presence
P09810087A0379|120 124|humor
P09810087A0379|56 59|type
P09810087A0379|18 31|seroconversion
P09811695A1146|87 105|MuLV TM Env protein p15
P09811695A1146|107 107|E
P09811695A1146|24 40|HIV-1 Gag sequences
P09811695A1146|5 11|results
P09811695A1146|72 81|processing
P09811718A0979a|5 11|results
P09811718A0979a|51 58|HIV-2 nef
P09811718A0979a|79 85|TCRzeta
P09811718A0979a|66 73|HIV-1 nef
P09811718A0979a|32 42|association
P09811718A0979a|45 47|SIV
P09811730A1396|0 14|Competition EMSA
P09811730A1396|98 122|KCS protein binding activity
P09811730A1396|167 191|transfection reporter assay
P09811730A1396|60 67|proteins
P09811730A1396|137 152|promoter activity
P09811730A1396|76 85|KCS element
P09811730T0000|0 8|Mechanism
P09811730T0000|11 26|interferon action
P09811730T0000|53 61|positions
P09811730T0000|124 133|activation
P09811730T0000|152 171|protein kinase pkr gene
P09811730T0000|28 41|identification
P09811730T0000|88 97|KCS element
P09813041A1122|0 1|GH
P09813041A1122|75 84|conditions
P09813041A1122|36 45|activation
P09813041A1122|48 50|Jun
P09813041A1122|19 33|phosphorylation
P09813041A1122|61 66|kinase
P09813063T0000|0 9|Expression
P09813063T0000|24 44|phospholipase D homolog
P09813063T0000|70 80|development
P09813063T0000|86 94|forebrain
P09813093A0624|28 34|YCL024W
P09813093A0624|76 79|GIN4
P09813093A0624|12 17|effect
P09813093A0624|51 61|combination
P09813093A0624|66 73|deletion
P09813098A0521|0 9|Paralemmin
P09813098A0521|109 114|manner
P09813098A0521|37 40|mRNA
P09813110A0982|99 104|domain
P09813110A0982|50 59|similarity
P09813110A0982|120 125|region
P09813110A0982|10 26|amino acid sequence
P09813110A0982|29 33|CBP90
P09813110A0982|70 76|protein
P09813203T0000|96 110|envelope protein
P09813203T0000|22 40|serine substitutions
P09813203T0000|46 51|V3 loop
P09813203T0000|77 90|immunogenicity
P09813203T0000|54 71|HIV-1 gp120 IIIB/LAI
P09813203T0000|3 8|effect
P09813207A0434|0 28|Transcription start site mapping
P09813207A0434|278 280|ATG
P09813207A0434|211 221|nucleotides
P09813207A0434|283 286|lef2
P09813207A0434|79 88|transcript
P09813207A0434|248 258|nucleotides
P09813207A0434|193 201|TTGT motif
P09813207A0434|42 49|presence
P09813207A0434|101 109|TAAG motif
P09813207A0434|123 133|nucleotides
P09813207A0434|167 176|transcript
P09813207A0434|235 241|TATA box
P09813207A0434|264 270|respect
P09813254A0000|58 73|family interferon
P09813254A0000|34 44|synthetases
P09813254A0000|99 106|proteins
P09813254A0000|29 32|2-5A
P09813254A0000|48 54|members
P09813254A0000|75 77|IFN
P09813254A0000|14 27|oligoadenylate
P09813259A1097|60 70|sensitivity
P09813259A1097|103 105|GBP
P09813259A1097|37 44|blockade
P09813259A1097|91 96|injury
P09813259A1097|109 111|IBG
P09813259A1097|3 10|findings
P09813635A0678|27 33|contact
P09813635A0678|75 76|P3
P09813635A0678|49 52|edge
P09813635A0678|105 111|complex
P09813635A0678|63 68|canine
P09813635A0678|5 14|striations
P09814637A1214|3 15|PbrO2 readings
P09814637A1214|76 77|CT
P09814637A1214|80 82|MRI
P09814637A1214|45 60|microhemorrhages
P09814905A0598|86 94|nutrition
P09814905A0598|26 40|swine production
P09814905A0598|79 83|means
P09814905A0598|68 76|solutions
P09814905A0598|46 56|environment
P09814905A0598|3 14|consequences
P09815578A1245|86 99|prostate cancer
P09815578A1245|25 34|alteration
P09815578A1245|4 8|study
P09815578A1245|37 41|CDKN2
P09815578A1245|118 139|prostate carcinogenesis
P09815578A1245|71 83|abnormalities
P09815948A1065|89 103|peak plasma level
P09815948A1065|51 60|toxicities
P09815948A1065|69 72|area
P09815948A1065|81 85|curve
P09815948A1065|18 27|parameters
P09817131A0296|52 69|translation process
P09817131A0296|12 26|SF-36 survey form
P09817190A0074|67 78|hypertension
P09817190A0074|55 64|prevalence
P09817190A0074|11 13|use
P09817190A0074|81 106|kidney transplant recipients
P09817190A0074|16 27|cyclosporin A
P09817373A0000|0 6|PURPOSE
P09817373A0000|133 142|muscle tone
P09817373A0000|102 114|insufficiency
P09817373A0000|31 50|hypercholesterolemia
P09817373A0000|189 203|tissue synthesis
P09817373A0000|22 28|effects
P09817373A0000|168 175|activity
P09817373A0000|206 227|constrictor eicosanoids
P09817373A0000|164 166|NOS
P09817373A0000|150 162|oxide synthase
P09817601T0000|0 15|Characterization
P09817601T0000|48 56|aromatase
P09817601T0000|58 65|P450arom
P09817601T0000|67 70|gene
P09817601T0000|98 107|expression
P09817601T0000|31 37|regions
P09819038A0448|84 98|body temperature
P09819038A0448|52 55|days
P09819038A0448|30 41|infusion pump
P09819038A0448|11 15|FVIIa
P09819038A0448|81 81|h
P09819038A0448|58 72|room temperature
P09819110A0703|0 12|CD4 lymphocyte
P09819110A0703|49 56|response
P09819110A0703|74 79|time LD
P09819110A0703|21 30|load levels
P09819110A0703|59 68|ARV therapy
P09819216A0220|6 17|Biochemistry
P09819288A0578|0 5|Levels
P09819288A0578|72 74|end
P09819288A0578|63 68|height
P09819288A0578|8 15|serum IgE
P09819288A0578|44 46|IgE
P09819288A0578|80 85|season
P09819377A1209|99 110|accumulation
P09819377A1209|65 73|mutations
P09819377A1209|32 48|underaccumulation
P09819377A1209|147 151|range
P09819377A1209|51 56|snR13F
P09819377A1209|81 90|C2U4 repeat
P09819377A1209|121 124|RNAs
P09819377A1209|16 25|C2U4 repeat
P09819377A1209|1 8|mutation
P09819391A1123|29 32|Arfs
P09819391A1123|36 50|tyrosine kinases
P09819391A1123|129 152|membrane remodeling events
P09819391A1123|96 107|organization
P09819391A1123|109 113|ASAP1
P09819391A1123|71 80|cell growth
P09819391A1123|162 170|processes
P09819411A0897|87 98|CTTCCCTGGAAG
P09819411A0897|8 24|footprint analysis
P09819411A0897|42 51|palindrome
P09819411A0897|30 39|PNR element
P09819411A0897|81 85|sites
P09819411A0897|2 6|DNase
P09819414A1103|43 49|isoform
P09819414A1103|12 17|nexins
P09819414A1103|90 103|medium isoforms
P09819414A1103|55 68|leptin receptor
P09819421A0000|0 11|Cyclophilins
P09819421A0000|110 112|CsA
P09819421A0000|40 49|isomerases
P09819421A0000|97 108|cyclosporin A
P09819422A0768|104 107|Cns1
P09819422A0768|7 33|protein retention experiments
P09819422A0768|41 60|Hsp90 heterocomplexes
P09819422A0768|87 101|coprecipitation
P09819430A0000|14 20|GTPases
P09819430A0000|54 58|cycle
P09819430A0000|109 113|state
P09819430A0000|41 48|proteins
P09819430A0000|85 88|form
P09819440A0000|104 110|variety
P09819440A0000|10 22|transcription
P09819440A0000|34 40|factors
P09819440A0000|113 116|ways
P09819440A0000|87 100|RNA polymerases
P09819440A0000|61 80|transcription factors
P09819440A0783|63 66|RPB5
P09819440A0783|93 97|cells
P09819440A0783|10 12|RMP
P09819440A0783|69 81|RNA polymerase
P09819507A0000|110 113|days
P09819507A0000|12 18|rabbits
P09819507A0000|6 10|study
P09819507A0000|64 68|Dexon
P09819507A0000|47 59|wound reaction
P09819507A0000|119 139|trabeculectomy surgery
P09819507A0000|93 96|flap
P09819507A0000|161 171|mitomycin-C
P09819507A0000|156 158|use
P09819507A0000|71 75|nylon
P09820163A0565|3 9|mapping
P09820163A0565|26 41|Southern blotting
P09820163A0565|45 63|restriction analysis
P09820205A0000|100 116|gamete interaction
P09820205A0000|37 46|glycocalyx
P09820205A0000|63 68|oocyte
P09820205A0000|17 18|ZP
P09820205A0000|3 15|zona pellucida
P09820611T0000|38 45|infusion
P09820611T0000|92 102|predialysis
P09820611T0000|11 13|use
P09820611T0000|64 77|erythropoietin
P09820611T0000|109 116|patients
P09820611T0000|129 139|nephropathy
P09820621A0067|102 110|influence
P09820621A0067|113 124|leptin levels
P09820621A0067|46 52|changes
P09820621A0067|20 34|thyroid function
P09820621A0067|55 71|energy expenditure
P09820621A0067|75 89|body composition
P09821978A1255|14 21|deficits
P09821978A1255|67 68|SE
P09821978A1255|37 43|animals
P09821978A1255|55 60|MK-801
P09822602A0237|221 223|CBP
P09822602A0237|47 56|HIF-1alpha
P09822602A0237|24 32|mechanism
P09822602A0237|114 119|import
P09822602A0237|35 44|activation
P09822602A0237|185 195|recruitment
P09822602A0237|152 172|transactivation domain
P09822602A0237|213 219|protein
P09822602A0237|123 132|activation
P09822602A0237|70 76|process
P09822602A0237|134 145|derepression
P09822602A0237|226 240|p300 coactivator
P09822602A1172|29 34|import
P09822602A1172|126 130|roles
P09822602A1172|55 65|recruitment
P09822602A1172|68 70|CBP
P09822602A1172|38 52|transactivation
P09822602A1172|153 162|HIF-1alpha
P09822602A1172|133 150|signal transduction
P09822647A0000|3 18|rat aldolase C gene
P09822647A0000|37 42|enzyme
P09822647A0000|67 71|brain
P09822652A1118|72 74|Sp1
P09822652A1118|12 17|effect
P09822652A1118|20 38|HCK promoter activity
P09822652A1118|56 69|concentrations
P09822661T0073|15 20|domain
P09822661T0073|24 40|amino acid residues
P09822661T0073|51 64|quinone binding
P09822685A0596|102 113|reading frame
P09822685A0596|78 83|region
P09822685A0596|7 14|analyses
P09822685A0596|40 56|Lu-ECAM-1 peptides
P09822685A0596|138 149|size proteins
P09822685A0596|19 26|antisera
P09822690A0000|59 86|protein phosphorylation events
P09822690A0000|9 21|sperm motility
P09822690A0000|36 42|cascade
P09822690A0000|97 111|protein kinase A.
P09822825A0141|27 30|BAP2
P09822825A0141|35 44|expression
P09822825A0141|110 119|amino acids
P09822825A0141|86 93|addition
P09822825A0141|50 57|BAP3 gene
P09822825A0141|6 10|paper
P09822825A0141|125 130|medium
P09823014T0000|0 5|Effect
P09823014T0000|65 71|indices
P09823014T0000|106 113|patients
P09823014T0000|89 103|lipid metabolism
P09823014T0000|26 33|products
P09823014T0000|118 122|NIDDM
P09823014T0000|45 56|carbohydrate
P09823014T0000|74 85|carbohydrate
P09823014T0000|60 62|fat
P09823561T0001|16 27|MALT lymphoma
P09823561T0001|54 75|Gastrospirillum hominis
P09823561T0001|31 52|helicobacter heilmannii
P09823775A1122|115 123|mechanism
P09823775A1122|100 107|insights
P09823775A1122|22 25|view
P09823775A1122|61 81|HLA-DRA gene activation
P09823775A1122|50 57|cofactor
P09823775A1122|126 131|action
P09823775A1122|5 11|studies
P09823775A1122|35 35|Y
P09823775A1122|30 33|HMG I
P09823775A1122|84 89|Oct-2A
P09824001A1665|43 52|predictors
P09824001A1665|64 66|vWF
P09824001A1665|92 101|techniques
P09824001A1665|55 62|survival
P09824001A1665|68 69|Ag
P09824001A1665|2 9|contrast
P09824021A1263|43 49|disease
P09824021A1263|125 134|parameters
P09824021A1263|108 116|NO therapy
P09824021A1263|91 98|response
P09824021A1263|33 40|features
P09824021A1263|0 9|CONCLUSION
P09824158A1336|70 73|SMRT
P09824158A1336|10 32|BCL-6 POZ domain mutations
P09824158A1336|62 66|N-CoR
P09824158A1336|89 101|transcription
P09824158A1336|47 57|interaction
P09826434T0000|43 71|platelet cAMP phosphodiesterase
P09826434T0000|7 22|characterization
P09826434T0000|94 104|mutagenesis
P09826434T0000|73 77|PDE3A
P09826434T0000|34 37|site
P09826658A0691|136 149|BPV-1 pre-mRNAs
P09826658A0691|91 101|suppression
P09826658A0691|126 133|splicing
P09826658A0691|115 122|assembly
P09826658A0691|4 15|core sequence
P09826658A0691|57 67|nucleotides
P09826778A0943|0 14|Over-expression
P09826778A0943|76 88|transcription
P09826778A0943|50 60|coactivator
P09826778A0943|112 118|COUP-TF
P09826778A0943|20 31|cofactor p300
P09826778A0943|100 109|repression
P09827446T0001|30 41|C4 deficiency
P09827446T0001|18 26|hepatitis
P09827724A1362|2 10|mutations
P09827724A1362|32 39|adenomas
P09827878A0091|104 110|defence
P09827878A0091|5 25|glutathione peroxidase
P09827878A0091|80 90|erythrocyte
P09827878A0091|54 56|SOD
P09827878A0091|27 29|GPX
P09827878A0091|34 52|superoxide dismutase
P09827878A0091|176 182|workers
P09827878A0091|145 152|activity
P09827878A0091|74 77|role
P09827993A0000|31 34|NCPs
P09827993A0000|117 134|retrovirus assembly
P09827993A0000|145 160|RNA encapsidation
P09827993A0000|77 102|virion RNA binding activities
P09827993A0000|10 29|nucleocapsid proteins
P09827993A0000|48 65|zinc finger proteins
P09828137A0000|75 81|S-phase
P09828137A0000|111 119|DNA damage
P09828137A0000|27 30|rad1
P09828137A0000|85 94|G2/M arrest
P09828137A0000|32 61|cell cycle checkpoint control gene
P09828137A0000|97 104|response
P09828137A0000|133 146|DNA replication
P09829836A0000|131 134|CDKs
P09829836A0000|123 129|kinases
P09829836A0000|80 91|oscillations
P09829836A0000|57 65|cell cycle
P09829836A0000|107 112|cyclin
P09829836A0000|97 104|activity
P09829836A0000|26 36|progression
P09829836A0815|15 24|selections
P09829836A0815|40 57|cyclin/CDK function
P09829836A0815|95 108|yeast LEU2 genes
P09829836A0815|28 37|inhibition
P09829843A0119|178 183|cancer
P09829843A0119|187 197|neutropenia
P09829843A0119|42 44|CSF
P09829843A0119|130 138|incidence
P09829843A0119|106 113|measures
P09829843A0119|151 163|complications
P09829843A0119|34 40|factors
P09829843A0119|166 173|patients
P09829843A0119|76 83|practice
P09829843A0819|312 334|chemiluminescence system
P09829843A0819|210 214|level
P09829843A0819|270 287|neutrophil function
P09829843A0819|78 87|occurrence
P09829843A0819|47 57|neutropenia
P09829843A0819|180 182|day
P09829843A0819|252 266|neutrophil count
P09829843A0819|203 205|day
P09829843A0819|191 198|microg kg
P09829843A0819|100 117|neutrophil recovery
P09829843A0819|15 17|CSF
P09829843A0819|131 138|rHu G-CSF
P09829843A0819|119 127|rHu GM-CSF
P09829843A0819|35 44|initiation
P09829843A0819|169 175|microg m
P09829843A0819|3 12|injections
P09829916T0000|0 9|Expression
P09829916T0000|12 15|lacZ
P09829916T0000|88 91|W205
P09829916T0000|54 59|operon
P09829916T0000|23 30|promoter
P09829916T0000|70 76|vectors
P09829916T0000|99 104|fusion
P09832099A0000|117 135|color kinesis imaging
P09832099A0000|35 44|wall motion
P09832099A0000|90 98|tetralogy
P09832099A0000|51 57|systole
P09832099A0000|108 110|TOF
P09832099A0000|60 67|patients
P09832099A0000|101 106|Fallot
P09832436A0738|0 13|RT-PCR analysis
P09832436A0738|100 111|PLP diversity
P09832436A0738|37 41|PLP-C
P09832436A0738|67 76|rat strains
P09832436A0738|24 28|PLP-H
P09832436A0738|45 49|PLP-D
P09832436A0738|128 138|differences
P09832436T0000|74 76|PRL
P09832436T0000|9 15|cloning
P09832436T0000|93 101|protein H.
P09832436T0000|52 54|rat
P09832436T0000|64 72|prolactin
P09832436T0000|78 83|family
P09832436T0000|19 34|characterization
P09832436T0000|41 46|member
P09832504A0596|86 101|cysteine residues
P09832504A0596|51 56|hCycT1
P09832504A0596|65 68|zinc
P09832504A0596|108 115|proteins
P09832504A0596|45 47|Tat
P09832504A0596|27 37|interaction
P09832505A0903|57 61|Oct-1
P09832505A0903|23 38|activation target
P09832505A0903|47 55|activator
P09832505A0903|84 103|transcription complex
P09832511A0269|116 122|pattern
P09832511A0269|11 22|neurogenesis
P09832511A0269|125 131|neurons
P09832511A0269|77 87|neuroblasts
P09832511A0269|24 33|Vnd protein
P09832511A0269|55 73|column neuroectoderm
P09832518A0615|3 18|repression domain
P09832518A0615|141 146|lactis
P09832518A0615|152 167|database searches
P09832518A0615|38 49|Cdc68 protein
P09832518A0615|123 127|yeast
P09832518A0615|109 115|homolog
P09832518A0615|81 88|sequence
P09832518A0615|94 98|Cdc68
P09833610A0626|27 41|affinity hormone
P09833610A0626|88 93|signal
P09833610A0626|49 52|site
P09833610A0626|3 11|exodomain
P09833740A1112|0 25|Pyrrolidine dithiocarbamate
P09833740A1112|107 108|U1
P09833740A1112|226 240|provirus latency
P09833740A1112|68 70|LTR
P09833740A1112|173 181|mechanism
P09833740A1112|112 121|ACH-2 cells
P09833740A1112|49 57|inhibitor
P09833740A1112|84 100|cytokine responses
P09833740A1112|189 197|cell types
P09833740A1112|219 223|modes
P09834070A0793|118 139|protein kinase C activity
P09834070A0793|52 58|absence
P09834070A0793|83 85|Ca2
P09834070A0793|23 32|activation
P09834070A0793|106 115|inhibition
P09834070A0793|176 179|CD19
P09834070A0793|162 168|pathway
P09834070A0793|35 38|ERK2
P09834070A0793|61 67|changes
P09834070A0793|189 201|B cell function
P09834521A0000|15 25|hydatid cyst
P09834521A0000|37 40|site
P09835615A0574|43 49|protein
P09835615A0574|78 93|repressor domains
P09835615A0574|95 96|R1
P09835615A0574|11 18|analysis
P09835615A0574|100 101|R2
P09835615A0574|30 32|KS1
P09836881A0441|101 109|Bruininks
P09836881A0441|11 18|BCH group
P09836881A0441|38 53|motor performance
P09836881A0441|84 99|Motor Proficiency
P09836881A0441|59 81|Bruininks-Oseretsky Test
P09837714A1068|60 72|modifications
P09837714A1068|33 34|pH
P09837714A1068|18 28|possibility
P09837714A1068|107 123|cell proliferation
P09837714A1068|93 98|events
P09837714A1068|3 9|results
P09837714A1068|150 162|Dictyostelium
P09837714A1068|75 79|DdRPA
P09837714A1068|133 147|differentiation
P09837715A0581|174 176|MLV
P09837715A0581|48 50|DNA
P09837715A0581|178 206|SL3-3 LTR-CAT reporter construct
P09837715A0581|160 172|leukemia virus
P09837715A0581|55 59|level
P09837715A0581|62 93|chloramphenicol acetyltransferase
P09837715A0581|95 97|CAT
P09837715A0581|99 102|mRNA
P09837715A0581|29 34|amount
P09837715A0581|130 134|cells
P09837715A0581|146 150|HIV-1
P09837824A0419|175 177|A2G
P09837824A0419|87 92|telSMN
P09837824A0419|12 26|telSMN mutations
P09837824A0419|81 84|copy
P09837824A0419|109 127|frameshift mutations
P09837824A0419|179 183|S262I
P09837824A0419|140 147|542delGT
P09837824A0419|157 173|missense mutations
P09837824A0419|55 65|individuals
P09837824A0419|188 192|T274I
P09837824A0419|129 136|800ins11
P09837907A0857|13 24|TNF receptors
P09837907A0857|75 84|activities
P09837907A0857|158 162|c-Jun
P09837907A0857|47 61|down-regulation
P09837907A0857|173 187|kinase induction
P09837907A0857|140 153|AP-1 activation
P09837907A0857|108 126|caspase-3 activation
P09837907A0857|95 106|cytotoxicity
P09837907A0857|128 136|NF-kappaB
P09837907A0857|3 10|decrease
P09837907A0857|27 30|IL-4
P09837913A0000|0 3|Type
P09837913A0000|48 56|thyroxine
P09837913A0000|5 14|deiodinase
P09837913A0000|34 45|deiodination
P09837913A0000|70 85|triiodothyronine
P09837913A0000|16 17|D2
P09837913A0419|101 102|D2
P09837913A0419|104 106|hD2
P09837913A0419|39 55|sequence tag clones
P09837913A0419|108 111|cDNA
P09837913A0419|88 90|UTR
P09837914A0844|0 3|Biol
P09837920A0222|74 88|phosphorylation
P09837920A0222|35 46|requirements
P09837920A0222|50 61|consequences
P09837920A0222|95 105|interaction
P09837920A0222|113 117|c-Jun
P09837920A0222|121 123|JNK
P09837933T0000|57 71|peptidylglycine
P09837933T0000|117 125|endosomes
P09837933T0000|87 99|monooxygenase
P09837933T0000|49 54|domain
P09837933T0000|13 19|protein
P09837933T0000|0 5|P-CIP1
P09837945A0820|148 155|fraction
P09837945A0820|170 177|material
P09837945A0820|116 120|Sop1p
P09837945A0820|106 113|fraction
P09837945A0820|0 17|Immunolocalization
P09837945A0820|20 24|Sop1p
P09837945A0820|45 56|distribution
P09837945A0820|60 83|cell fractionation studies
P09837978T0093|73 80|JNK/SAPK
P09837978T0093|9 18|activation
P09837978T0093|21 25|c-Jun
P09837978T0093|59 71|protein kinase
P09838122A0489|49 62|mouse homologue
P09838122A0489|26 43|coding cDNA sequence
P09838122A0489|65 68|MPP3
P09840822A0462|46 52|concern
P09840822A0462|23 29|tagging
P09840822A0462|68 95|magnetization transfer effects
P09840822A0462|3 8|method
P09840928A0884|59 61|H2A
P09840928A0884|78 87|substrates
P09840928A0884|112 123|kinase assays
P09840928A0884|27 29|Dlk
P09840928A0884|135 142|extracts
P09840928A0884|65 66|H4
P09840928A0884|44 57|core histones H3
P09840928A0884|101 109|histone H3
P09840932A0365|59 64|target
P09840932A0365|20 27|evidence
P09840932A0365|6 10|study
P09840932A0365|68 79|cyclin A/Cdk2
P09840932A0365|32 36|B-Myb
P09840934A0435|209 213|cells
P09840934A0435|165 171|effects
P09840934A0435|80 85|Ha-Ras
P09840934A0435|25 36|Ha-RasV12S35
P09840934A0435|130 142|RalGDS pathway
P09840934A0435|14 17|G12V
P09840934A0435|191 199|apoptosis
P09840934A0435|19 22|T35S
P09840934A0435|98 109|Ha-RasV12G37
P09840934A0435|7 12|Ha-Ras
P09840934A0435|92 95|E37G
P09840934A0435|87 90|G12V
P09840934A0435|56 75|Rafl signaling pathway
P09840943A0144|32 39|cyclin E2
P09840943A0144|25 30|cyclin
P09840943A0144|74 81|cyclin E.
P09840943A0144|64 71|homology
P09842517A0497|98 100|MRI
P09842517A0497|80 86|methods
P09842517A0497|7 16|experience
P09842517A0497|50 57|SieScape
P09842517A0497|93 94|CT
P09842517A0497|27 36|technology
P09843378A0187|86 102|SH3 binding domains
P09843378A0187|55 63|receptors
P09843378A0187|3 20|dopamine D4 receptor
P09843412A0130|44 50|Abeta42
P09843412A0130|62 68|species
P09843412A0130|38 42|Abeta
P09843412A0130|107 108|AD
P09843412A0130|32 35|form
P09843572A0944|99 109|cell lysates
P09843572A0944|93 96|Wee1
P09843572A0944|127 130|Wee1
P09843572A0944|44 57|Cdr2 associates
P09843572A0944|22 32|experiments
P09843572A0944|4 8|model
P09843572A0944|85 90|domain
P09843577A0000|46 56|deprivation
P09843577A0000|24 28|cells
P09843577A0000|67 85|G2/M cell size control
P09843944A0976|129 145|UP element function
P09843944A0976|76 79|turn
P09843944A0976|49 55|hexamer
P09843944A0976|0 7|A-tracts
P09844106A0835|43 45|FLG
P09844106A0835|57 67|fibronectin
P09844106A0835|50 54|cells
P09844106A0835|4 18|phosphorylation
P09844106A0835|32 40|adherence
P09844106A0835|83 87|cells
P09844106A0835|73 75|ST2
P09844921A0000|0 2|Raf
P09844921A0000|98 120|differentiation messages
P09844921A0000|9 37|serine-threonine protein kinase
P09844921A0000|60 71|transmission
P09844921A0000|74 79|growth
P09845043A0000|87 94|drinking
P09845043A0000|104 115|alcohol abuse
P09845043A0000|130 136|problem
P09845043A0000|50 54|NIAAA
P09845043A0000|24 35|Alcohol Abuse
P09845043A0000|39 48|Alcoholism
P09845043A0000|142 158|alcohol dependence
P09845043A0000|69 73|forms
P09845043A0000|3 21|US National Institute
P09845043A0000|173 180|disorder
P09845043A0000|203 211|component
P09845662A0085|116 133|gel electrophoresis
P09845662A0085|135 142|SDS-PAGE
P09845662A0085|51 58|collagen
P09845662A0085|38 41|lack
P09845662A0085|74 78|means
P09845662A0085|81 93|sodium dodecyl
P09845662A0085|44 47|type
P09845662A0085|27 30|skin
P09845662A0085|0 7|Collagen
P09845856A0560|0 6|RESULTS
P09845856A0560|55 67|ulcer diseases
P09845856A0560|23 28|period
P09846033A0488|30 41|pretreatment
P09846033A0488|19 25|changes
P09846033A0488|70 70|p
P09846033A0488|44 56|posttreatment
P09846033A0488|0 6|RESULTS
P09846482A0441|2 5|turn
P09846482A0441|104 122|actin polymerization
P09846482A0441|21 27|complex
P09846482A0441|76 88|protein kinase
P09846482A0441|48 57|activation
P09846482A0441|7 14|assembly
P09846927A0227|70 74|death
P09846927A0227|49 59|stomach wall
P09846927A0227|11 16|button
P09846927A0227|24 34|perforation
P09846927A0227|3 5|tip
P09847371A0000|0 19|Jembrana disease virus
P09847371A0000|112 114|BIV
P09847371A0000|90 110|immunodeficiency virus
P09847371A0000|21 23|JDV
P09847371A0000|49 58|lentivirus
P09847397A0935|15 15|%
P09847397A0935|153 162|CCAAT boxes
P09847397A0935|113 127|glucocorticoids
P09847397A0935|75 81|viruses
P09847397A0935|21 28|residues
P09847397A0935|94 109|response elements
P09847397A0935|188 196|TATA boxes
P09847397A0935|54 62|sequences
P09848653A0597|0 4|Nhp2p
P09848653A0597|19 25|protein
P09848653A0597|67 74|proteins
P09848653A0597|40 45|family
P09849421A0332|87 98|Organization
P09849421A0332|179 182|mail
P09849421A0332|102 109|Research
P09849421A0332|124 140|Cancer Core Quality
P09849421A0332|113 121|Treatment
P09849421A0332|62 64|age
P09849421A0332|38 47|Norwegians
P09849421A0332|4 9|survey
P09849421A0332|161 172|EORTC QLQ-C30
P09849421A0332|55 59|years
P09849421A0332|143 159|Life Questionnaire
P09849722A0797|191 202|brain regions
P09849722A0797|185 189|gyrus
P09849722A0797|158 163|cortex
P09849722A0797|54 67|signal increase
P09849722A0797|131 143|cingulate gyri
P09849722A0797|240 261|emotion processing tasks
P09849722A0797|6 17|presentation
P09849722A0797|31 41|expressions
P09849722A0797|98 111|cingulate gyrus
P09849961A0387|0 14|Down-regulation
P09849961A0387|106 120|differentiation
P09849961A0387|194 209|myoblast cell line
P09849961A0387|35 55|serine phosphorylation
P09849961A0387|67 84|PI 3-kinase activity
P09849961A0387|17 21|IRS-1
P09849961A0387|131 135|IRS-1
P09849965A0000|4 8|study
P09849965A0000|63 68|ligand
P09849965A0000|39 44|system
P09849965A0000|74 85|dimerization
P09849965A0000|114 116|hPR
P09849965A0000|93 112|progesterone receptor
P09849965A0000|57 60|role
P09851614A0109|144 148|mRNAs
P09851614A0109|124 136|cap structures
P09851614A0109|93 95|nts
P09851614A0109|112 118|absence
P09851614A0109|81 91|nucleotides
P09851614A0109|65 71|regions
P09851614A0109|14 21|features
P09851614A0109|73 75|UTR
P09851700A0000|89 94|manner
P09851700A0000|20 50|tissue-type plasminogen activator
P09851700A0000|52 55|t-PA
P09851700A0000|3 6|gene
P09851988A0085|28 39|anaerobiosis
P09851988A0085|17 24|arginine
P09851988A0085|7 14|presence
P09851988A0085|72 78|pathway
P09851988A0085|58 66|induction
P09852005A1287|216 224|complexes
P09852005A1287|168 186|serum response factor
P09852005A1287|138 164|MADS box consensus binding site
P09852005A1287|113 120|gene PEP1
P09852005A1287|24 50|MADS box consensus binding site
P09852005A1287|247 257|OP4 sequence
P09852005A1287|122 125|SAP1
P09852005A1287|58 65|promoter
P09852005A1287|0 10|Competition
P09852068A0150b|41 45|DNase
P09852068A0150b|47 58|footprinting
P09852068A0150b|8 11|SHBG
P09852068A0150b|102 108|regions
P09852068A0150b|76 87|significance
P09852068A0150b|110 116|FP1-FP6
P09852068A0150b|20 27|promoter
P09852068A0150b|135 142|promoter
P09852068A0150b|160 183|HepG2 hepatoblastoma cells
P09852109A1475|117 128|efficiencies
P09852109A1475|7 17|translation
P09852109A1475|207 213|regions
P09852109A1475|63 74|transcripts C
P09852109A1475|166 176|transcript D
P09852109A1475|35 49|profile analysis
P09852109A1475|78 78|E
P09852109A1475|238 244|control
P09852109A1475|219 222|role
P09852136A0174|144 150|protein
P09852136A0174|26 30|Ser36
P09852136A0174|74 80|ability
P09852136A0174|46 51|domain
P09852136A0174|34 36|Asn
P09852136A0174|153 160|COS cells
P09852136A0174|87 103|guanine nucleotide
P09852136A0174|120 132|hemagglutinin
P09852136A0174|134 135|HA
P09852136A0174|54 57|p190
P09852136A0174|17 24|mutation
P09852136A0507|0 14|Wild type HA-p190
P09852136A0507|23 31|phenotype
P09852136A0507|92 102|Rho function
P09852136A0507|61 70|extensions
P09852136A0507|41 45|cells
P09852136A0507|116 131|ADP-ribosylation
P09852752A0950|30 39|vasculitis
P09852752A0950|72 73|RA
P09852752A0950|58 69|complication
P09854034A0536|94 104|mRNA species
P09854034A0536|38 47|G+C content
P09854034A0536|52 57|exon 1b
P09854034A0536|23 30|promoter
P09855111A0905|266 273|synthase
P09855111A0905|259 264|HMG CoA
P09855111A0905|55 61|domains
P09855111A0905|284 292|cell lines
P09855111A0905|182 191|regulation
P09855111A0905|96 105|regulation
P09855111A0905|108 122|SREBP processing
P09855111A0905|23 36|overexpression
P09855111A0905|210 219|mRNA levels
P09855111A0905|249 257|coenzyme A
P09855111A0905|325 330|manner
P09855111A0905|137 146|disruption
P09855111A0905|201 205|genes
P09856397A0099|0 14|Dry matter intake
P09856397A0099|24 46|nutrient digestibilities
P09856397A0099|119 125|tissues
P09856397A0099|101 111|persistency
P09856397A0099|114 116|FB1
P09856397A0099|48 69|serum chemistry profiles
P09856397A0099|71 96|sphingolipid concentrations
P09856732A0114|86 94|lidocaine
P09856732A0114|78 83|effect
P09856732A0114|10 16|studies
P09857038A1374|0 1|E.
P09857038A1374|9 10|J.
P09857038A1374|3 7|Scott
P09857197A0289|0 4|Yap1p
P09857197A0289|31 40|crm1 mutant
P09857197A0289|109 116|presence
P09857197A0289|65 78|export sequence
P09857197A0289|89 96|sequence
P09857197A0289|119 124|RanGTP
P09857197A0289|80 82|NES
P09857197A0289|45 49|Crm1p
P09857197A0289|99 103|Yap1p
P09857265A0669|0 9|Mean intake
P09857265A0669|110 119|vegetables
P09857265A0669|98 101|fats
P09857265A0669|155 155|%
P09857265A0669|39 46|mg RE/day
P09857265A0669|93 96|meat
P09857265A0669|50 52|men
P09857265A0669|123 135|dairy products
P09857265A0669|163 163|%
P09857265A0669|105 108|oils
P09857265A0669|159 159|%
P09857265A0669|12 19|vitamin A
P09857265A0669|78 90|contributions
P09857265A0669|143 148|intake
P09857265A0669|56 60|women
P09857265A0669|170 170|%
P09858094A0583|44 45|O1
P09858094A0583|53 54|O4
P09858094A0583|50 51|O3
P09858094A0583|8 16|amplitude
P09858094A0583|33 42|potentials
P09858094A0583|102 107|period
P09858531A1017|86 90|c-fos
P09858531A1017|12 30|RING1 overexpression
P09858531A1017|63 82|proto-oncogenes c-jun
P09858531A1017|48 57|expression
P09858571T0000|119 135|dolichol synthesis
P09858571T0000|111 116|enzyme
P09858571T0000|40 76|reticulum protein localization mutations
P09858571T0000|85 105|cis-prenyltransferase
P09858571T0000|3 15|yeast RER2 gene
P09858572A0000|3 25|yeast retrotransposon Ty5
P09858572A0000|54 60|regions
P09858572A0000|69 77|chromatin
P09858577A1186|118 122|Sko1p
P09858577A1186|136 143|effector
P09858577A1186|9 12|SKO1
P09858577A1186|90 106|stress sensitivity
P09858577A1186|48 57|hog1 mutant
P09858577A1186|149 158|HOG pathway
P09858577A1186|31 44|ENA1 expression
P09858577A1186|3 6|loss
P09858581A0183|46 49|gene
P09858581A0183|131 132|Ts
P09858581A0183|91 105|splicing defects
P09858581A0183|8 17|expression
P09858581A0183|140 146|prp38-1
P09858581A0183|51 56|SPP381
P09858581A0183|82 87|growth
P09858588A1046|86 90|cells
P09858588A1046|40 42|p68
P09858588A1046|34 37|form
P09858588A1046|66 69|G1/S
P09858588A1046|98 101|G2/M
P09858588A1046|59 63|cells
P09858593A0334|87 107|insulin gene expression
P09858593A0334|48 67|Xenopus NeuroD1/BETA2
P09858593A0334|118 129|neurogenesis
P09858593A0334|16 33|amino acid sequences
P09858599A0392|59 72|transformation
P09858599A0392|112 125|PBX interaction
P09858599A0392|4 22|NUP98-HOXA9 chimeras
P09858599A0392|84 95|HOXA9 domains
P09858599A0392|99 108|DNA binding
P09858599A0392|34 50|NIH 3T3 fibroblasts
P09858619A0356|30 33|Y319
P09858619A0356|6 12|studies
P09858619A0356|56 69|ZAP-70 function
P09858713A1174|44 46|Pan
P09858713A1174|136 138|ciD
P09858713A1174|204 206|CiD
P09858713A1174|162 172|enhancement
P09858713A1174|219 225|mutants
P09858713A1174|19 22|data
P09858713A1174|50 52|CiD
P09858713A1174|178 201|gain-of-function activity
P09858713A1174|97 108|transduction
P09858713A1174|72 74|Arm
P09858713A1174|141 147|animals
P09858713A1174|114 121|Wg signal
P09858714A1171|30 33|modA
P09858714A1171|37 39|dda
P09858714A1171|88 90|srd
P09858714A1171|7 9|ORF
P09858714A1171|11 15|dda.2
P09858714A1171|69 75|sigma70
P09858714A1171|41 64|shares sequence similarity
P09858745A1350|42 45|gene
P09858745A1350|123 125|IBS
P09858745A1350|50 62|cooperativity
P09858745A1350|102 108|studies
P09858745A1350|143 153|interaction
P09858745A1350|73 91|footprinting studies
P09858745A1350|3 10|location
P09858745A1350|16 18|IBS
P09858745A1350|175 186|binding sites
P09858745A1350|156 159|CatR
P09858745A1350|213 215|DNA
P09858745A1350|28 31|catB
P09858745A2033|123 136|clcA transcript
P09858745A2033|53 64|intermediate
P09858745A2033|66 73|fumarate
P09858745A2033|109 117|formation
P09858745A2033|7 25|transcription assays
P09858883A1106|54 57|N-A3
P09858883A1106|36 38|M-1
P09858883A1106|20 23|Kaff
P09858883A1106|45 51|binding
P09858883A1106|102 104|T84
P09858883A1106|96 99|N-A3
P09858883A1106|60 64|T84.1
P09858883A1106|87 93|binding
P09858883A1106|78 80|M-1
P09858883A1106|0 14|BIAcore analysis
P09860979A0521|0 9|Expression
P09860979A0521|124 126|Crk
P09860979A0521|53 65|Crk SH2-domain
P09860979A0521|12 15|p130
P09860979A0521|22 24|Cas
P09860979A0521|78 90|JNK activation
P09860979A0521|33 46|binding protein
P09860979A0521|17 19|Cas
P09861099A1011|118 128|differences
P09861099A1011|135 140|g/kg/d
P09861099A1011|152 162|kcal/kg/day
P09861099A1011|81 92|energy intake
P09861099A1011|53 65|protein intake
P09861099A1011|164 165|SD
P09861099A1011|38 49|measurements
P09861099A1011|73 73|P
P09861099A1011|100 100|P
P09861099A1011|67 67|r
P09861099A1011|142 143|SD
P09861099A1011|8 19|correlations
P09861099A1011|94 94|r
P09861365A0000|34 38|assay
P09861365A0000|40 44|ELISA
P09861365A0000|84 90|antigen
P09861365A0000|105 109|serum
P09861365A0000|97 102|microL
P09861365A0000|3 7|Og4C3
P09862343A0225|42 45|IL-4
P09862343A0225|156 164|molecules
P09862343A0225|89 97|influence
P09862343A0225|127 139|up-regulation
P09862343A0225|113 118|system
P09862343A0225|167 178|B lymphocytes
P09862343A0225|13 29|gp200-MR6 ligation
P09862481A0000|3 15|Mig1 repressor
P09862481A0000|19 35|zinc finger protein
P09862481A0000|48 64|glucose repression
P09862481A0000|67 71|yeast
P09862496A0187|0 7|Ethylene
P09862496A0187|20 35|endosperm rupture
P09862496A0187|49 66|betaGLU I expression
P09862496A0187|108 114|pattern
P09862496A0187|117 134|betaGLU I expression
P09863624A0629|41 49|sheep CRF1
P09863624A0629|113 117|amino
P09863624A0629|70 74|CRF1s
P09863624A0629|137 144|receptor
P09863624A0629|22 30|structure
P09863624A0629|126 131|domain
P09863624A0629|3 12|divergence
P09863624A0629|161 168|residues
P09863624A0629|170 174|ovine
P09863624A0629|182 185|CRF1
P09863624A2301|74 82|Tyr0-oCRF
P09863624A2301|167 169|min
P09863624A2301|158 161|time
P09863624A2301|54 60|percent
P09863624A2301|69 72|125I
P09863624A2301|209 213|oCRF1
P09863624A2301|139 143|cells
P09863624A2301|114 121|fraction
P09863624A2301|63 67|total
P09863624A2301|174 181|degrees C
P09863624A2301|135 137|Cos
P09863624A2301|15 37|receptor internalization
P09863720T0000|49 66|protein S deficiency
P09863720T0000|27 33|disease
P09863720T0000|41 45|onset
P09864141A0528|86 89|Y744
P09864141A0528|12 16|Stat3
P09864141A0528|33 40|affinity
P09864141A0528|79 82|Y704
P09864141A0528|167 170|Y764
P09864141A0528|115 130|peptide analogues
P09864141A0528|135 149|phosphopeptides
P09864141A0528|20 28|Stat3beta
P09864141A0528|54 68|phosphopeptides
P09864141A0528|160 163|Y729
P09864335A1226|17 23|results
P09864335A1226|76 89|drug resistance
P09864335A1226|123 130|evidence
P09864335A1226|39 46|FCR1 gene
P09864335A1226|201 205|Fcr1p
P09864335A1226|189 194|factor
P09864335A1226|135 147|FCZ resistance
P09864335A1226|65 73|regulator
P09864335A1226|164 175|inactivation
P09864335A1226|92 101|C. albicans
P09864689A1408|71 76|effect
P09864689A1408|107 109|DCM
P09864689A1408|90 101|heart failure
P09864689A1408|5 12|findings
P09864689A1408|49 59|washout rate
P09864689A1408|79 87|treatment
P09864689A1408|28 32|MYO/M
P09865775A0162|87 96|properties
P09865775A0162|35 42|couplers
P09865775A0162|51 59|placement
P09865775A0162|69 73|ALGO2
P09865775A0162|4 8|study
P09866068A1058|0 10|CONCLUSIONS
P09866068A1058|12 23|Pretreatment
P09866068A1058|130 135|effect
P09866068A1058|28 30|OCs
P09866068A1058|78 82|phase
P09866068A1058|171 184|pregnancy rates
P09866068A1058|158 168|recruitment
P09866068A1058|47 57|suppression
P09866068A1058|99 111|cyst formation
P09867159A1444|118 118|%
P09867159A1444|80 80|%
P09867159A1444|108 108|%
P09867159A1444|22 36|threshold values
P09867159A1444|52 62|specificity
P09867159A1444|89 94|FDG PET
P09867159A1444|38 48|sensitivity
P09867159A1444|74 74|%
P09867159A1444|70 70|%
P09867159A1444|84 84|%
P09867159A1444|112 112|%
P09867159A1444|122 122|%
P09867159A1444|4 9|regard
P09867253A0229|43 58|protooncoprotein
P09867253A0229|92 114|transcription factor AP-1
P09867253A0229|78 82|c-Jun
P09867253A0229|30 34|c-Fos
P09867253A0229|4 16|c-Jun activity
P09867855T0000|0 16|Dorsal root ganglia
P09867855T0000|53 105|rabbit beta-galactoside alpha1,2-fucosyltransferase gene
P09867855T0000|32 47|promoter activity
P09868412A1628|0 9|CONCLUSION
P09868412A1628|188 190|BMD
P09868412A1628|159 174|swimming exercise
P09868412A1628|180 185|effect
P09868412A1628|206 213|swimming
P09868412A1628|125 133|exercises
P09868412A1628|36 42|body BMD
P09868412A1628|88 97|study group
P09868412A1628|267 274|shoulder
P09868412A1628|14 18|study
P09868412A1628|233 240|exercise
P09868412A1628|284 301|grip muscle strength
P09868412A1628|147 154|subjects
P09868412A1628|53 59|neck BMD
P09869297A1807|56 74|Hoxb1 gene expression
P09869297A1807|33 43|CE2 elements
P09869297A1807|12 16|roles
P09869297A1807|81 91|development
P09869297A1807|27 29|CE1
P09869356A0926|0 6|CAL gain
P09869356A0926|26 27|mm
P09869356A0926|37 43|defects
P09869356A0926|51 57|CAL gain
P09869356A0926|63 64|mm
P09869356A0926|31 31|%
P09869400A0203|0 10|Comparisons
P09869400A0203|109 119|wheat germin
P09869400A0203|25 31|germins
P09869400A0203|71 95|Arabidopsis GLP subfamilies
P09869400A0203|46 53|proteins
P09869528T0000|14 17|dogs
P09869528T0000|30 37|RF energy
P09869528T0000|4 11|fixation
P09871353A0174|102 105|fish
P09871353A0174|112 115|loch
P09871353A0174|36 58|A. salmonicida infections
P09871353A0174|26 33|evidence
P09871353A0174|72 83|furunculosis
P09872326A0566|57 59|CBF
P09872326A0566|86 101|heat shock protein
P09872326A0566|35 42|CBF/cdc2
P09872326A0566|104 111|promoter
P09872337A0000|150 174|clindamycin phosphate ester
P09872337A0000|258 265|Dalacin T
P09872337A0000|109 112|% w/v
P09872337A0000|130 133|% w/v
P09872337A0000|27 37|clindamycin
P09872337A0000|115 123|tretinoin
P09872337A0000|15 24|absorption
P09872337A0000|135 138|gels
P09872337A0000|217 242|clindamycin phosphate lotion
P09872337A0000|178 191|clindamycin HCl
P09872337A0000|97 107|clindamycin
P09872337A0000|245 256|% clindamycin
P09872337A0000|61 70|volunteers
P09872832A1262|147 155|TNF-alpha
P09872832A1262|161 175|interferon gamma
P09872832A1262|72 76|lungs
P09872832A1262|216 216|p
P09872832A1262|104 107|IL-6
P09872832A1262|121 145|tumor necrosis factor-alpha
P09872832A1262|110 113|IL-8
P09872832A1262|90 102|interleukin-6
P09872832A1262|115 119|IL-12
P09872832A1262|3 19|BAL concentrations
P09872832A1262|204 214|differences
P09872832A1262|29 37|cytokines
P09872832A1262|177 185|IFN-gamma
P09873060A0901|0 22|Phosphorylation analyses
P09873060A0901|108 111|FosB
P09873060A0901|36 45|inhibition
P09873060A0901|84 98|phosphorylation
P09873060A0901|101 104|JunD
P09873060A0901|48 52|ERK-1
P09873291A0620|59 72|knowledge score
P09873291A0620|7 14|analysis
P09873291A0620|17 24|variance
P09873291A0620|86 98|patient groups
P09874803A0000|165 179|disease episodes
P09874803A0000|118 121|SpeB
P09874803A0000|69 84|cysteine protease
P09874803A0000|108 116|exotoxin B
P09874803A0000|139 153|virulence factor
P09874803A0000|18 45|bacterium group A Streptococcus
P09875541A0210|133 136|SELF
P09875541A0210|116 131|hand movement task
P09875541A0210|42 45|part
P09875541A0210|51 69|dorsal premotor areas
P09875541A0210|3 15|orbitofrontal
P09876794T0000|0 8|Improving
P09876794T0000|12 23|evidence base
P09876794T0000|27 37|anaesthesia
P09877417A0704|0 14|Plasma CCK levels
P09877417A0704|38 46|intervals
P09878256A0000|103 114|deficiencies
P09878256A0000|127 139|abnormalities
P09878256A0000|147 157|retardation
P09878256A0000|171 175|death
P09878256A0000|3 31|peroxisome biogenesis disorders
P09878256A0000|33 36|PBDs
P09878256A0000|60 67|diseases
P09878256A0000|42 44|set
P09878437A0967|44 47|site
P09878437A0967|50 64|phosphorylation
P09878437A0967|9 12|site
P09878437A0967|75 78|Glu9
P09878437A0967|67 71|Asp10
P09878437A0967|30 39|triad Asp53
P09878542A1151|99 113|osteopontin VDRE
P09878542A1151|77 79|VDR
P09878542A1151|19 26|findings
P09878542A1151|57 65|silencing
P09879766A0402|2 6|PAV-3
P09879766A0402|11 19|E1A region
P09879766A0402|45 52|map units
P09880029A0703|87 103|amino acid identity
P09880029A0703|183 184|C3
P09880029A0703|125 137|FBNYV proteins
P09880029A0703|154 164|Rep proteins
P09880029A0703|226 232|SCSV-C2
P09880029A0703|236 237|C6
P09880029A0703|192 192|%
P09880029A0703|11 27|MDV genome products
P09880029A0703|41 43|Rep
P09880029A0703|200 200|%
P09880029A0703|85 85|%
P09880029A0703|58 65|proteins
P09880029A0703|174 179|MDV-C2
P09880103A0387|0 2|MPO
P09880103A0387|73 89|M hydrogen peroxide
P09880103A0387|18 24|mCi 125I
P09880103A0387|28 36|technique
P09880103A0387|57 64|presence
P09880103A0387|39 51|self-labeling
P09880327A0322|86 92|protein
P09880327A0322|140 147|vesicles
P09880327A0322|48 55|proteins
P09880327A0322|103 109|docking
P09880327A0322|64 73|yeast Uso1p
P09880327A0322|14 20|variety
P09880512A1251|74 76|Sp1
P09880512A1251|62 70|receptors
P09880512A1251|19 22|Bmp2
P09880512A1251|3 6|data
P09880513A1013|4 11|proteins
P09880513A1013|53 59|tubulin
P09880543A0570|0 3|HEED
P09880543A0570|20 28|MA protein
P09880543A0570|60 69|yeast cells
P09880544A0693|103 123|recombination knockout
P09880544A0693|171 180|DT-40 cells
P09880544A0693|13 32|DT-40 lymphoma B-cells
P09880544A0693|196 205|DT-40 cells
P09880544A0693|133 141|apoptosis
P09880544A0693|147 157|Fas ligation
P09880544A0693|237 243|btk gene
P09880544A0693|84 90|btk gene
P09880544A0693|69 78|disruption
P09881666A0535|29 36|CREB site
P09881666A0535|7 14|TGATGTCA
P09881666A0535|77 79|ER2
P09881666A0535|53 60|AP-1 site
P09881666A0535|1 5|motif
P09881692A0094|44 45|b4
P09881692A0094|101 116|Ckappa1 gene locus
P09881692A0094|47 48|b5
P09881692A0094|50 51|b6
P09881692A0094|35 42|variants
P09881692A0094|55 56|b9
P09881692A1109|88 89|b6
P09881692A1109|37 41|genes
P09881692A1109|66 81|oligonucleotides
P09881692A1109|140 146|rabbits
P09881692A1109|123 124|T.
P09881692A1109|12 16|order
P09881692A1109|149 164|Southern blotting
P09881692A1109|93 94|b9
P09881692A1109|85 86|b5
P09881692A1109|97 105|probe DNAs
P09882303A1413|0 4|TRAF2
P09882303A1413|36 45|expression
P09882303A1413|151 155|cells
P09882303A1413|76 94|deletion TRAF2 mutant
P09882303A1413|27 31|TRADD
P09882303A1413|133 145|JNK activation
P09882303A1984|84 103|signalling mechanisms
P09882303A1984|45 57|JNK activation
P09882303A1984|72 75|LMP1
P09882303A1984|38 42|TRAF2
P09882303A1984|23 26|role
P09882303A1984|5 8|data
P09882303A1984|30 34|TRADD
P09882303A1984|113 134|TNF receptor/CD40 family
P09882303A1984|157 166|activities
P09882303T0000|31 45|membrane protein
P09882303T0000|125 129|TRAF2
P09882303T0000|86 94|C terminus
P09882303T0000|59 68|JNK pathway
P09882303T0000|99 107|mechanism
P09882303T0000|117 121|TRADD
P09882321A0948|2 9|contrast
P09882321A0948|80 102|EBNA-3 protein expression
P09882321A0948|117 126|EBNA-3 gene
P09882321A0948|137 146|EBNA-3 cDNA
P09882321A0948|33 37|cells
P09882321A0948|48 53|EBNA-3
P09882321A0948|70 77|increase
P09882334A0822|29 38|lamb kidney
P09882334A0822|124 131|mutation
P09882334A0822|141 155|tyrosine residue
P09882334A0822|40 42|FLK
P09882334A0822|198 208|propagation
P09882334A0822|82 84|BLV
P09882334A0822|69 77|infection
P09882334A0822|44 48|cells
P09882334A0822|171 175|motif
P09882334A0822|214 218|virus
P09882334A0822|14 21|passages
P09882334A0822|100 111|transfection
P09882337A0000|0 20|Varicella-zoster virus
P09882337A0000|113 131|gI Fc receptor complex
P09882337A0000|48 72|transmembrane glycoprotein
P09882337A0000|26 39|glycoprotein gI
P09882337A0000|110 111|gE
P09882337A0000|22 24|VZV
P09882337A0000|83 91|component
P09882337A0000|43 46|type
P09882348A0611|144 151|oncogene
P09882348A0611|115 125|fibroblasts
P09882348A0611|95 111|Shc adapter protein
P09882348A0611|23 43|phosphorylation status
P09882348A0611|6 8|end
P09882348A0611|56 78|tyrosine kinase substrate
P09882451A0195|5 9|genes
P09882451A0195|75 92|ferrochelatase gene
P09882451A0195|136 148|transformants
P09882451A0195|94 98|HEM15
P09882451A0195|49 54|mutant
P09882451A0195|121 130|phenotypes
P09882489A0451|101 105|array
P09882489A0451|12 19|evidence
P09882489A0451|170 176|signals
P09882489A0451|128 134|modules
P09882489A0451|6 10|study
P09882489A0451|65 78|mef2 expression
P09882499A0231|78 85|elements
P09882499A0231|27 41|mouse technology
P09882499A0231|115 124|expression
P09882499A0231|127 130|Pax6
P09882593A0996|43 46|61Ni
P09882593A0996|162 174|pompholyx type
P09882593A0996|126 131|groups
P09882593A0996|11 20|experiment
P09882593A0996|113 120|controls
P09882593A0996|147 156|hand eczema
P09882593A0996|92 96|women
P09882593A0996|58 70|drinking water
P09882593A0996|29 41|nickel isotope
P09882638A0235|41 55|tunica albuginea
P09882638A0235|80 87|erection
P09882638A0235|22 35|collagen fibers
P09882638A0235|65 73|expansion
P09882638A0235|6 11|tissue
P09883639A0000|89 93|years
P09883639A0000|8 15|patients
P09883639A0000|55 57|NTM
P09883639A0000|42 53|mycobacteria
P09883639A0000|0 5|Number
P09884232A0286|0 9|Comparison
P09884232A0286|26 29|attP
P09884232A0286|151 163|integrase gene
P09884232A0286|128 132|place
P09884232A0286|71 74|attR
P09884232A0286|31 34|attB
P09884232A0286|92 103|core sequence
P09884232A0286|110 122|recombination
P09884232A0286|15 23|sequences
P09884232A0286|55 67|junctions attL
P09884232A0286|84 85|bp
P09884232A0286|143 145|end
P09884275T0000|0 24|Interferon-alpha treatment
P09884275T0000|70 79|recipients
P09884275T0000|87 102|organ transplants
P09884275T0000|60 67|disorder
P09884747A0477|58 74|control volunteers
P09884747A0477|156 164|allergens
P09884747A0477|115 127|yeast antigens
P09884747A0477|13 19|testing
P09884747A0477|37 50|brewery workers
P09884747A0477|105 110|barley
P09884747A0477|80 95|skin prick testing
P09884747A0477|187 200|serum IgE levels
P09885431A0000|86 88|mix
P09885431A0000|151 155|types
P09885431A0000|56 73|bridge restorations
P09885431A0000|48 52|crown
P09885431A0000|23 30|accuracy
P09885431A0000|99 106|silicone
P09885431A0000|118 136|impression materials
P09885431A0000|158 166|stock tray
P09885431A0000|0 8|OBJECTIVE
P09886602A0000|0 9|OBJECTIVES
P09886602A0000|180 189|recurrence
P09886602A0000|132 141|Gleason sum
P09886602A0000|244 246|XRT
P09886602A0000|192 205|prostate cancer
P09886602A0000|77 83|antigen
P09886602A0000|223 242|beam radiation therapy
P09886602A0000|276 286|tumor marker
P09886602A0000|256 267|introduction
P09886602A0000|155 167|radiation dose
P09886602A0000|22 28|ability
P09886602A0000|110 119|tumor stage
P09886602A0000|31 42|pretreatment
P09886602A0000|143 146|race
P09886602A0000|300 309|care center
P09886602A0000|270 272|PSA
P09886602A0000|89 100|measurements
P09886602A0000|85 87|PSA
P09886602A0000|148 150|age
P09886602A0000|121 130|tumor grade
P09886843A0339|98 101|NRGN
P09886843A0339|36 41|target
P09886843A0339|25 28|gene
P09886843A0339|140 143|gene
P09886843A0339|88 95|elements
P09886843A0339|44 57|thyroid hormone
P09886843A0339|115 123|fragments
P09886850A0145|60 72|ligand binding
P09886850A0145|97 111|phosphorylation
P09886850A0145|125 147|MEK/ERK signaling pathway
P09886850A0145|18 25|activity
P09886850A0145|28 36|PPARgamma
P09887544A0000|0 9|BACKGROUND
P09887544A0000|11 18|Diazepam
P09887544A0000|124 132|treatment
P09887544A0000|112 118|anxiety
P09887544A0000|104 109|relief
P09887544A0000|90 97|sedation
P09887544A0000|135 142|epilepsy
P09887544A0000|49 61|tranquilizers
P09887544A0000|83 86|drug
P09887544A0000|28 46|benzodiazepine group
P09888711A0781|0 20|Bioplastique granuloma
P09888711A0781|199 202|size
P09888711A0781|139 155|Artecoll granuloma
P09888711A0781|283 288|bodies
P09888711A0781|126 131|bodies
P09888711A0781|56 61|spaces
P09888711A0781|220 224|round
P09888711A0781|169 181|round vacuoles
P09888711A0781|71 74|size
P09888711A0781|206 210|shape
P09888994A0858|73 85|somitogenesis
P09888994A0858|53 69|mesoderm formation
P09888994A0858|93 98|embryo
P09888994A0858|18 21|gene
P09889202T0000|44 55|domain Zalpha
P09889202T0000|144 151|proteins
P09889202T0000|93 102|similarity
P09889202T0000|115 118|beta
P09889202T0000|58 84|dsRNA adenosine deaminase type
P09889202T0000|109 113|alpha
P09889202T0000|120 125|family
P09889202T0000|18 25|analysis
P09889306A0321|14 23|regulation
P09889306A0321|62 73|applications
P09889306A0321|26 45|Glvr-1 gene expression
P09889306A0321|166 177|gene delivery
P09889306A0321|103 109|vectors
P09889306A0321|124 155|ape leukemia virus envelope proteins
P09889306A0321|76 86|gene therapy
P09889306A0321|2 9|addition
P09889306A0321|191 199|cell types
P09890778T0000|0 12|Carbohydrates
P09890778T0000|42 48|methods
P09890778T0000|16 30|glycoconjugates
P09891009T0000|18 38|mouse glycolate oxidase
P09891009T0000|9 15|cloning
P09891046A0269|71 80|disruption
P09891046A0269|23 25|PKR
P09891046A0269|89 100|PKR signaling
P09891046A0269|7 12|manner
P09891046A0269|34 43|cell growth
P09891046A0269|121 130|cell growth
P09891046A0269|54 62|apoptosis
P09891046A0554|32 42|interaction
P09891046A0554|47 49|PKR
P09891046A0554|20 29|protein L18
P09891049A0761|45 53|nucleases
P09891049A0761|68 81|rRNA processing
P09891049A0761|88 92|Rnt1p
P09891049A0761|96 100|Rat1p
P09891049A0761|28 36|precursor
P09891049A0761|0 9|Processing
P09891061A0373|57 68|SpHE promoter
P09891061A0373|26 35|regulators
P09891061A0373|157 166|cis element
P09891061A0373|128 131|bait
P09891061A0373|44 51|fragment
P09891061A0373|96 103|elements
P09891061A1240|102 111|expression
P09891061A1240|54 59|timing
P09891061A1240|62 81|SpEts4 gene expression
P09891061A1240|22 25|SpHE
P09891061A1240|114 117|SpHE
P09891061A1240|132 148|sea urchin blastula
P09891061A1240|41 49|regulator
P09891065A1493|75 83|PKC-alpha
P09891065A1493|66 72|mutants
P09891065A1493|25 37|SRE activation
P09891065A1493|86 96|PKC-epsilon
P09891085A0815|89 101|27S precursors
P09891085A0815|14 18|cells
P09891085A0815|35 41|defects
P09891085A0815|58 62|cells
P09891092A1000|42 51|structures
P09891092A1000|77 88|end formation
P09891092A1000|23 26|site
P09891092A1000|30 38|stem-loop
P09891707A0000|43 45|SpA
P09891707A0000|13 20|subtypes
P09891707A0000|23 41|spondyloarthropathy
P09892017A2151|58 61|ELE1
P09892017A2151|52 55|role
P09892017A2151|7 17|experiments
P09892017A2151|71 89|receptor functioning
P09892021A0712|87 108|fibroblast growth factor
P09892021A0712|33 43|NIH 3T3 cells
P09892021A0712|71 79|secretion
P09892021A0712|125 129|tumor
P09892021A0712|147 152|factor
P09892021A0712|16 19|PTTG
P09892021A0712|0 13|Overexpression
P09892021A0712|58 67|expression
P09892422A1096|160 166|impulse
P09892422A1096|143 154|transmission
P09892422A1096|192 204|purkinje fibre
P09892422A1096|65 75|contraction
P09892422A1096|27 38|tissue sheath
P09892422A1096|110 115|spread
P09892422A1096|81 90|myocardium
P09892422A1096|176 186|termination
P09892422A1096|118 127|conduction
P09892642A0172|0 1|E1
P09892642A0172|62 72|replication
P09892642A0172|35 46|HPV E2 protein
P09892642A0172|4 14|DNA helicase
P09892662A0334|75 84|activation
P09892662A0334|123 129|cyclase
P09892662A0334|104 112|regulator
P09892662A0334|87 88|Gs
P09892662A0334|15 32|mutant alpha subunit
P09892736A0343|98 115|signal transduction
P09892736A0343|7 12|search
P09892736A0343|61 71|% similarity
P09892736A0343|38 46|CDED/LIOR
P09892736A0343|141 144|ORC1
P09892736A0343|81 88|proteins
P09892736A0343|30 35|region
P09892736A0343|119 133|cell replication
P09892736A0343|148 150|KSR
P09893060A0767|45 54|expression
P09893060A0767|60 61|kb
P09893060A0767|0 19|Northern blot analysis
P09893262A1272|14 20|variety
P09893262A1272|84 100|TGF-beta responses
P09893262A1272|33 39|schemes
P09893262A1272|71 81|restriction
P09893913A0656|0 8|Induction
P09893913A0656|38 45|fentanyl
P09893913A0656|83 92|atracurium
P09893913A0656|11 21|anaesthesia
P09893913A0656|48 60|micrograms/kg
P09893913A0656|97 101|mg/kg
P09893913A0656|63 73|thiopentone
P09893913A0656|76 80|mg/kg
P09894962T0000|42 54|malformations
P09894962T0000|24 30|profile
P09894962T0000|85 97|malformations
P09894962T0000|1 10|comparison
P09895323T0000|27 34|kreisler
P09895323T0000|62 66|Hoxa3
P09895323T0000|37 46|regulation
P09895323T0000|20 24|roles
P09895323T0000|70 79|Hoxb3 genes
P09897032T0000|50 58|resonator
P09897032T0000|26 37|self-pulsing
P09900679T0000|0 14|Wave cybernetics
P09900679T0000|23 27|model
P09900679T0000|76 84|phenomena
P09903722T0000|0 18|Autoionization rates
P09903722T0000|22 33|energy levels
P09903722T0000|49 61|Rydberg states
P09903722T0000|36 44|triplet nf
P09903722T0000|64 65|H2
P09904139T0000|37 45|operators
P09904139T0000|13 20|approach
P09911328T0000|18 27|scattering
P09911328T0000|8 15|approach
P09911328T0000|46 52|problem
P09913308T0000|52 57|energy
P09913308T0000|49 49|J
P09913308T0000|10 15|lasing
P09913308T0000|71 81|laser pulses
P09913308T0000|22 23|nm
P09913308T0000|33 38|Ti ions
P09914156A1496|146 161|promoter activity
P09914156A1496|212 213|bp
P09914156A1496|63 90|tenascin-C promoter constructs
P09914156A1496|184 194|pair element
P09914156A1496|227 238|RNA start site
P09914156A1496|97 105|deletions
P09914156A1496|55 60|series
P09914156A1496|15 21|regions
P09914156A1496|27 34|promoter
P09914500A0000|43 61|transcription factor
P09914500A0000|155 173|tumor necrosis factor
P09914500A0000|95 102|proteins
P09914500A0000|20 28|NF-kappaB
P09914500A0000|179 183|alpha
P09914500A0000|208 217|conditions
P09914500A0000|68 72|genes
P09914500A0000|7 18|factor kappa B
P09914500A0000|130 151|cytokines interleukin-1
P09914500A0000|175 177|TNF
P09914518A1217|146 147|E2
P09914518A1217|84 110|AF-1 transactivation function
P09914518A1217|41 50|activation
P09914518A1217|53 60|COUP-TFI
P09914518A1217|13 23|enhancement
P09914518A1217|113 114|ER
P09914518A1217|150 167|4-hydroxytamoxifen
P09914518A1217|136 143|presence
P09914518A1217|174 176|ICI
P09914525A0890|32 33|tm
P09914525A0890|25 29|point
P09914525A0890|37 44|degreesC
P09914525A0890|11 13|Ffh
P09915118T0000|30 41|rat accessory
P09915118T0000|10 23|naris occlusion
P09915118T0000|51 54|bulb
P09915798A1077|134 159|steroid receptor interaction
P09915798A1077|12 16|hsp90
P09915798A1077|69 91|hsp90 dimerization domain
P09915798A1077|40 56|chaperone activity
P09915798A1077|114 121|elements
P09915798A1077|4 9|region
P09915860A0000|81 88|mdr genes
P09915860A0000|51 56|pgp2GC
P09915860A0000|16 32|rat pgp2/mdr1b gene
P09915860A0000|102 117|consensus Sp1 site
P09915860A0000|44 49|region
P09915860A0000|3 10|promoter
P09915860A0119|0 2|Sp1
P09915860A0119|31 48|pgp2/mdr1b promoter
P09915860A0119|11 25|transactivation
P09915860A0119|70 83|Schneider cells
P09915860A0119|5 8|role
P09916786A0811|0 11|Measurements
P09916786A0811|181 191|immunoassay
P09916786A0811|195 216|urine deoxypyridinoline
P09916786A0811|142 146|serum
P09916786A0811|20 37|bone mineral density
P09916786A0811|65 69|femur
P09916786A0811|49 53|spine
P09916786A0811|127 140|bone remodeling
P09916786A0811|238 251|chromatography
P09916786A0811|84 102|X-ray absorptiometry
P09916786A0811|160 178|alkaline phosphatase
P09916786A0811|118 124|markers
P09916809A0405|98 123|transmembrane signal peptide
P09916809A0405|37 42|matrix
P09916809A0405|44 46|ECM
P09916809A0405|48 54|protein
P09916809A0405|5 7|MGP
P09916809A0405|82 88|protein
P09917064T0000|4 8|roles
P09917064T0000|78 84|masking
P09917064T0000|11 13|p82
P09917064T0000|47 61|polyadenylation
P09917064T0000|18 32|clam CPEB homolog
P09917387T0000|30 41|factor TFIIIB
P09917387T0000|50 56|DNA bend
P09917387T0000|67 73|TATA box
P09917387T0000|95 103|start site
P09917387T0000|3 15|RNA polymerase
P09917389A1239|3 9|pattern
P09917389A1239|51 54|FinP
P09917389A1239|12 26|RNase E digestion
P09917389A1239|80 89|finP305 RNA
P09917389A1239|59 66|GST-FinO
P09917389A1239|29 38|finP305 RNA
P09917389A1239|94 101|cleavage
P09917391A0380|0 23|Transcription readthrough
P09917391A0380|39 45|repeats
P09917391A0380|55 60|effect
P09917391A0380|67 71|event
P09917555T0001|0 7|Analysis
P09917555T0001|23 47|growth factor prescriptions
P09917555T0001|58 70|cancer centers
P09918096A0520|27 30|cyst
P09918096A0520|11 14|case
P09918715A0304|27 33|MotA box
P09918715A0304|46 53|position
P09918715A0304|14 24|DNA sequence
P09918715A0304|0 3|MotA
P09918715A1158|128 140|transcription
P09918715A1158|61 78|TATA binding protein
P09918715A1158|20 23|AsiA
P09918715A1158|107 113|binding
P09918715A1158|94 100|factors
P09918715A1158|80 82|TBP
P09918715A1158|148 168|core promoter sequences
P09918715A1158|56 59|TAFs
P09918715A1158|13 16|MotA
P09918715A1158|116 125|TBP results
P09918720A0998|154 160|adenine
P09918720A0998|36 40|bases
P09918720A0998|135 141|contact
P09918720A0998|119 124|Ser229
P09918720A0998|3 14|S229A variant
P09918720A0998|72 75|base
P09918720A0998|98 103|pocket
P09918842A0184|98 107|initiation
P09918842A0184|76 83|proteins
P09918842A0184|50 55|region
P09918842A0184|110 123|RNA replication
P09918842A0184|66 73|assembly
P09918842A0184|7 18|conservation
P09918842A0184|26 33|terminus
P09920539A0272|3 14|stimulations
P09920539A0272|66 73|protocol
P09920539A0272|54 56|day
P09920539A0272|80 102|gonadotropin stimulation
P09920539A0272|37 42|GnRH-a
P09920775A0075|3 10|sequence
P09920775A0075|141 148|P19 cells
P09920775A0075|124 138|differentiation
P09920775A0075|78 99|reporter gene expression
P09920775A0075|19 20|bp
P09920775A0075|34 55|transcription start site
P09920882A0287|0 3|Chem
P09920896A1230|118 124|protein
P09920896A1230|13 23|differences
P09920896A1230|166 175|structures
P09920896A1230|52 63|type peptides
P09920896A1230|95 106|substitution
P09920896A1230|133 142|disruption
P09920903A1045|5 11|results
P09920903A1045|26 34|c-met gene
P09920903A1045|50 66|p53 gene regulation
P09920903A1045|42 47|target
P09920930A0521|103 117|c-Fos expression
P09920930A0521|26 37|RhoA function
P09920930A0521|57 59|SRE
P09920930A0521|81 86|effect
P09920930A0521|61 71|Luc activity
P09920930A0521|0 6|C3 toxin
P09920930A0959|159 172|co-stimulation
P09920930A0959|39 51|growth factors
P09920930A0959|193 202|Ro-31-8220
P09920930A0959|24 34|combination
P09920930A0959|149 156|response
P09920930A0959|67 70|AP-1
P09920930A0959|136 138|Luc
P09920930A0959|8 14|C3 toxin
P09920930A0959|119 128|activation
P09920930A0959|177 189|growth factors
P09920930A0959|131 134|AP-1
P09920930A0959|72 82|Luc activity
P09920982A0253|114 115|P.
P09920982A0253|105 111|strains
P09920982A0253|51 64|susceptibility
P09920982A0253|163 177|Rap ID ANA II panel
P09920982A0253|133 143|acne lesions
P09920982A0253|95 100|agents
P09920982A0253|18 22|study
P09920982A0253|3 5|aim
P09921179T0001|3 6|role
P09921179T0001|53 57|heart
P09921179T0001|41 47|surgery
P09921179T0001|23 38|echocardiography
P09921179T0001|66 72|vessels
P09922230A1482|102 111|C. albicans
P09922230A1482|64 73|resistance
P09922230A1482|39 42|CAP1
P09922230A1482|17 23|results
P09922230A1482|86 99|stress response
P09922856A0459|0 9|Trinipatch
P09922856A0459|93 106|dose-strengths
P09922856A0459|50 54|patch
P09922856A0459|120 125|mg/24 h
P09922856A0459|109 114|mg/24 h
P09922856A0459|61 78|absorption promoter
P09922856A0459|129 150|Laboratoires Synthelabo
P09923245A0482|3 6|RMRI
P09923245A0482|19 39|interrater reliability
P09923245A0482|70 77|patients
P09924675A0412|202 208|process
P09924675A0412|21 33|consideration
P09924675A0412|227 238|intervention
P09924675A0412|11 15|point
P09924675A0412|219 223|basis
P09924675A0412|94 101|mainstay
P09924675A0412|105 109|model
P09924675A0412|65 69|ICIDH
P09924675A0412|113 123|diagnostics
P09924675A0412|41 51|conceptions
P09924675A0412|126 139|rehabilitation
P09924675A0412|172 186|characteristics
P09924987A0000|0 7|Pokeweed
P09924987A0000|17 23|protein
P09924987A0000|69 81|N-glycosidase
P09924987A0000|25 27|PAP
P09924987A0000|106 110|A4324
P09924987A0000|123 127|A2660
P09924987A0000|113 119|28S rRNA
P09924987A0000|163 172|eukaryotes
P09924987A0000|130 136|23S rRNA
P09924987A0000|33 51|Phytolacca americana
P09924987A0000|148 156|ribosomes
P09924987A0000|176 186|prokaryotes
P09924987A0000|90 104|adenine residues
P09925120A0074|0 8|OBJECTIVE
P09925120A0074|41 46|trials
P09925120A0074|92 97|effect
P09925120A0074|112 117|fibers
P09925120A0074|14 26|meta-analysis
P09925372A0458|13 16|ZFPs
P09925372A0458|36 39|HFHZ
P09925372A0458|24 30|ZFP cDNA
P09925372A0458|51 58|heart ZFP
P09925372A0458|101 103|box
P09925372A0458|64 79|sequence homology
P09925372A0458|105 108|KRAB
P09925372A1063|56 60|heart
P09925372A1063|37 41|heart
P09925372A1063|101 107|process
P09925372A1063|73 80|HFHZ mRNA
P09925372A1063|110 120|development
P09925372A1063|17 26|expression
P09925777A1195|55 73|beta-globin reporter
P09925777A1195|126 130|mRNAs
P09925777A1195|11 25|affinity hnRNP A1
P09925777A1195|109 114|levels
P09925777A1195|75 77|Rev
P09925777A1195|33 36|site
P09925777A1195|135 135|%
P09927193A0107|14 21|proteins
P09927193A0107|62 72|oncogenesis
P09927193A0107|36 40|BCL-6
P09927193A0107|23 26|PLZF
P09927193A0107|30 34|LAZ-3
P09927193A0107|2 5|date
P09927449A0421|0 13|Overexpression
P09927449A0421|96 104|CLN2 genes
P09927449A0421|74 83|repression
P09927449A0421|48 55|G1 arrest
P09927449A0421|16 19|POG1
P09927449A0421|89 92|CLN1
P09927570A0507|13 25|RNU2 fragility
P09927570A0507|168 170|kDa
P09927570A0507|109 116|E1 vector
P09927570A0507|128 137|E1 products
P09927570A0507|176 186|kDa proteins
P09927570A0507|140 150|E1A proteins
P09927570A0507|91 93|kDa
P09927570A0507|163 165|E1B
P09927570A0507|82 88|Ad12 E1B
P09927570A0507|58 73|expression vector
P09927570A0507|40 51|transfection
P09927585A0796|131 139|factor Sp1
P09927585A0796|73 97|bandshift complex formation
P09927585A0796|51 58|proteins
P09927585A0796|102 104|KCS
P09927585A0796|0 30|Competitionsupershift EMSA assays
P09927589T0000|0 9|Similarity
P09927589T0000|40 49|regulation
P09927589T0000|12 21|DNA binding
P09927589T0000|52 77|Caenorhabditis elegans MAB-3
P09927589T0000|128 130|sex
P09927589T0000|114 125|conservation
P09927589T0000|142 151|mechanisms
P09927589T0000|103 105|DSX
P09929088A0000|0 6|CONTEXT
P09929088A0000|96 110|cancer screening
P09929088A0000|82 85|cost
P09929088A0000|8 15|ThinPrep
P09929088A0000|17 23|AutoPap
P09929088A0000|68 78|sensitivity
P09929088A0000|28 33|Papnet
P09929088A0000|41 52|technologies
P09929811A0000|0 10|Experiments
P09929811A0000|278 283|branch
P09929811A0000|46 56|derivatives
P09929811A0000|224 234|electrogram
P09929811A0000|185 191|segment
P09929811A0000|23 26|cats
P09929811A0000|159 164|CM-345
P09929811A0000|301 306|artery
P09929811A0000|142 147|CM-251
P09929811A0000|95 104|properties
P09929811A0000|246 254|occlusion
P09929811A0000|175 182|mean rise
P09929811A0000|126 131|agents
P09929811A0000|204 208|leads
P09929811A0000|149 154|CM-266
P09931118A1072|56 63|IL-1beta
P09931118A1072|10 15|p42/44
P09931118A1072|22 31|JNK pathway
P09931118A1072|48 53|action
P09931191A0434|43 45|Con
P09931191A0434|92 105|muscle ischemia
P09931191A0434|26 33|subjects
P09931191A0434|62 68|fatigue
P09931191A0434|49 59|Ecc arm curls
P09931191A0434|135 142|protocol
P09931191A0434|121 130|resistance
P09931191A0434|2 9|protocol
P09931216A0566|0 6|Airflow
P09931216A0566|91 96|module
P09931216A0566|38 44|turbine
P09931216A0566|49 53|45-ft
P09931216A0566|60 64|cable
P09931252A1055|86 94|abilities
P09931252A1055|114 131|scaffolding protein
P09931252A1055|51 61|coat protein
P09931252A1055|19 40|amino acid substitutions
P09931252A1055|4 12|mutations
P09931391A0944|18 30|liver function
P09931391A0944|40 46|surgery
P09931391A0944|8 15|recovery
P09931435A0357|98 101|exon
P09931435A0357|87 90|exon
P09931435A0357|105 109|ZIS-1
P09931435A0357|120 123|size
P09931435A0357|40 44|exons
P09931435A0357|12 22|transcripts
P09931435A0357|46 49|exon
P09931435A0357|146 148|UTR
P09931435A0357|54 58|ZIS-2
P09931435A0357|70 74|ZIS-1
P09932288A0378|0 9|Expression
P09932288A0378|26 28|XT3
P09932288A0378|104 114|cDNA library
P09932288A0378|75 82|sequence
P09932288A0378|21 24|gene
P09932288A0378|58 63|kidney
P09933428A0351|0 8|IFN-gamma
P09933428A0351|89 97|treatment
P09933428A0351|32 33|TB
P09933428A0351|57 64|controls
P09933641A0241|71 78|analysis
P09933641A0241|146 158|amplification
P09933641A0241|94 98|clone
P09933641A0241|161 168|cDNA ends
P09933641A0241|12 20|sequences
P09933641A0241|115 123|sequences
P09933641A0241|83 86|NHE5
P09933641A0241|43 55|amplification
P09933641A0241|58 65|cDNA ends
P09933848A1008|54 57|role
P09933848A1008|74 87|autoantibodies
P09933848A1008|60 63|drug
P09933848A1008|37 44|analysis
P09933848A1008|4 17|alloantibodies
P09934611A1054|72 75|mean
P09934611A1054|44 49|extent
P09934611A1054|60 69|min LVdP/dt
P09934611A1054|4 13|dependence
P09934611A1054|82 89|pressure
P09935377T0108|0 4|Genoa
P09935377T0108|6 10|Italy
P09935377T0108|17 22|August
P09936001T0000|70 74|delta
P09936001T0000|10 18|structure
P09936001T0000|76 84|plutonium
P09936001T0000|27 35|plutonium
P09936001T0000|50 51|Ga
P09936001T0000|21 25|delta
P09936001T0000|56 67|Sc impurities
P09936001T0000|47 48|Al
P09938097T0000|61 69|acceptors
P09938097T0000|13 20|transfer
P09938097T0000|24 57|photoluminescence undulation spectra
P09938097T0000|72 75|ZnTe
P09940132T0000|68 77|properties
P09940132T0000|38 58|charge-transfer solids
P09940132T0000|7 12|theory
P09943651T0000|16 22|soliton
P09943651T0000|8 12|modes
P09944066T0073|0 1|II
P09945838T0000|47 48|Ga
P09945838T0000|38 41|GaAs
P09945838T0000|52 66|heterojunctions
P09945838T0000|17 34|matching conditions
P09945838T0000|44 45|Al
P09947191T0000|59 60|Z2
P09947191T0000|67 81|antiferromagnet
P09947191T0000|39 47|exponents
P09947191T0000|50 56|CsMnBr3
P09947191T0000|0 28|Neutron scattering measurements
P09949160A0600|199 201|Epo
P09949160A0600|43 49|bulk PKC
P09949160A0600|77 86|expression
P09949160A0600|177 181|betaI
P09949160A0600|224 228|cells
P09949160A0600|204 209|growth
P09949160A0600|136 147|upregulation
P09949160A0600|162 169|isoforms
P09949160A0600|187 196|readdition
P09949160A0600|99 112|eta PKC isoforms
P09949160A0600|12 23|32D Epo1 cells
P09949160A0600|36 40|level
P09949160A0600|89 95|epsilon
P09949160A0600|59 66|activity
P09949178A0264|86 95|pre-B-cell
P09949178A0264|6 15|expression
P09949178A0264|103 106|line
P09949178A0264|77 82|growth
P09949178A0264|57 62|factor
P09949178A0264|108 112|1A9-M
P09949178A0264|33 45|interleukin-6
P09949178A0264|47 50|IL-6
P09949312A0524|0 6|Airflow
P09949312A0524|43 52|vacuum pump
P09949312A0524|17 24|dust trap
P09950213A1660|117 129|participation
P09950213A1660|45 51|TbetaRI
P09950213A1660|55 62|TbetaRII
P09950213A1660|33 43|goblet cells
P09950213A1660|99 106|TGF-beta
P09950213A1660|132 140|TbetaRIII
P09950394A0336|60 68|physician
P09950394A0336|23 45|carboxyhemoglobin levels
P09950394A0336|12 19|exposure
P09950394A0336|75 83|diagnosis
P09950394A0336|3 9|history
P09952378A0529|28 46|% confidence interval
P09952378A0529|110 119|adjustment
P09952378A0529|92 104|IgG antibodies
P09952378A0529|3 11|odds ratio
P09952378A0529|123 132|covariates
P09952378A0529|72 81|serostatus
P09952378A0529|15 17|CHD
P09952425A0893|219 224|degree
P09952425A0893|53 57|tasks
P09952425A0893|193 196|role
P09952425A0893|101 104|type
P09952425A0893|150 159|structures
P09952425A0893|7 11|group
P09952425A0893|34 40|animals
P09952425A0893|66 71|lesion
P09952425A0893|175 180|lesion
P09952425A0893|85 95|impairments
P09952425A0893|202 212|hippocampus
P09952425A0893|14 17|HIPP
P09959737T0000|3 6|case
P09959737T0000|10 18|neutrinos
P09959737T0000|23 29|SN 1987A
P09961326T0000|57 62|models
P09961326T0000|9 20|fluctuations
P09961326T0000|38 46|interface
P09961682T0000|0 4|Model
P09961682T0000|21 28|dynamics
P09961682T0000|31 46|stick-slip motion
P09964171T0000|14 18|atoms
P09964171T0000|47 54|presence
P09964171T0000|36 41|medium
P09964171T0000|76 80|field
P09964171T0000|0 2|NMR
P09964770T0000|0 13|Microstructure
P09964770T0000|43 60|laminate composites
P09964770T0000|17 28|conductivity
P09965234T0000|29 46|octylcyanobiphenyl
P09965234T0000|11 23|heat transport
P09965234T0000|52 64|liquid crystal
P09965234T0000|48 50|8CB
P09965909T0000|26 45|soliton perturbations
P09965909T0000|6 13|approach
P09965909T0000|19 23|study
P09971776A0838|87 89|Nef
P09971776A0838|173 181|dipeptide
P09971776A0838|111 113|W57
P09971776A0838|78 84|binding
P09971776A0838|117 119|L58
P09971776A0838|96 103|receptor
P09971776A0838|22 34|CD4 regulation
P09971776A0838|146 159|dileucine motif
P09971776A0838|197 202|region
P09971776A0838|208 214|protein
P09971776A0838|43 50|residues
P09971776A0838|0 8|Mutations
P09971790A0856|43 60|helicase activities
P09971790A0856|77 104|amino-terminal-charge cluster
P09971790A0856|119 132|D40A-D42A-D44A
P09971790A0856|111 117|protein
P09971790A0856|148 175|AAV hairpin DNA binding activity
P09971790A0856|7 15|mutations
P09971790A0856|28 39|endonuclease
P09971806A1585|15 18|KSHV
P09971806A1585|8 12|cycle
P09971806A1585|91 107|tumor pathogenesis
P09971806A1585|43 49|control
P09971806A1585|55 66|KSHV/Rta gene
P09971815A2094|204 208|sites
P09971815A2094|40 60|candidate latency genes
P09971815A2094|337 354|gammaherpesviruses
P09971815A2094|69 77|gammaHV68
P09971815A2094|95 99|genes
P09971815A2094|251 261|v-bcl-2 gene
P09971815A2094|227 233|regions
P09971815A2094|211 217|latency
P09971815A2094|106 112|latency
P09971815A2094|167 181|latency programs
P09971815A2094|244 249|genome
P09971815A2094|303 309|latency
P09971815A2094|276 279|gene
P09971815A2094|263 271|v-GCR gene
P09971815A2094|138 143|organs
P09971815A2094|83 92|expression
P09971815A2094|318 326|gammaHV68
P09971822A1542|28 31|role
P09971822A1542|51 68|splicing inhibition
P09971822A1542|35 36|U1
P09971822A1542|5 8|data
P09973351A1522|19 33|DcuS-DcuR system
P09973351A1522|52 61|substrates
P09973607A0254|59 69|Sp100 splice
P09973607A0254|34 49|characterization
P09973607A0254|77 84|proteins
P09973607A0254|130 132|end
P09973607A0254|111 121|elucidation
P09973607A0254|138 146|Sp100 gene
P09973607A0254|17 30|identification
P09973607A0254|100 108|existence
P09974642T0000|0 8|Crossover
P09974642T0000|22 25|heat
P09974642T0000|34 40|magnets
P09974642T0000|67 74|dynamics
P09976626T0000|0 6|Erratum
P09976626T0000|52 65|transformation
P09976626T0000|17 32|precursor effects
P09976626T0000|8 14|Absence
P09976626T0000|84 90|Li metal
P09976626T0000|75 81|crystal
P09980944T0000|0 17|Interplane coupling
P09980944T0000|78 86|resonance
P09980944T0000|23 47|superconductor Y2Ba4Cu7O15
P09980944T0000|60 71|NQR spin-echo
P09982923T0000|28 32|NiSi2
P09982923T0000|10 18|structure
P09982923T0000|47 52|bulk Si
P09982923T0000|35 44|CoSi2 layer
P09983871T0000|0 17|Raman investigation
P09983871T0000|20 41|YBa2-xLaxCu3O7 ceramics
P09984526T0000|0 6|Effects
P09984526T0000|23 39|lattice parameters
P09984526T0000|9 20|point defects
P09984526T0000|42 55|semiconductors
P09985302T0000|7 22|electron dynamics
P09985302T0000|54 60|antidot
P09986796A1761|8 16|deletions
P09986796A1761|37 46|amino acids
P09986796A1761|22 22|C
P09986796A1761|65 71|effects
P09987176A0260|102 109|anti-HAV
P09987176A0260|26 36|vaccination
P09987176A0260|67 75|follow-up
P09987176A0260|94 99|levels
P09987176A0260|5 10|months
P09987176A0260|41 49|vaccinees
P09987634A1265|82 90|PRK effect
P09987634A1265|13 15|PRK
P09987634A1265|19 23|weeks
P09987634A1265|37 47|retreatment
P09987634A1265|67 76|regression
P09987634A1265|26 28|age
P09987961A0093|47 58|vasculopathy
P09987961A0093|63 75|proliferation
P09987961A0093|93 103|fibroblasts
P09987961A0093|78 89|synoviocytes
P09987961A0093|8 14|lesions
P09987961A0093|34 45|angiomatosis
P09988682T0033|41 79|beta1,6-N-acetylglucosaminyltransferase
P09988682T0033|23 26|cDNA
P09988682T0033|9 15|cloning
P09988682T0033|95 98|core
P09988682T0033|87 90|core
P09988767A1496|56 69|mouse 3Ost genes
P09988767A1496|81 91|assignments
P09988767A1496|13 35|mouse back-cross analysis
P09988767A1496|137 150|identification
P09988767A1496|112 118|isologs
P09988767A1496|174 184|site markers
P09988767A1496|49 52|loci
P09988850A0000|60 66|SCIRFIR
P09988850A0000|257 262|course
P09988850A0000|20 29|Impairment
P09988850A0000|211 217|purpose
P09988850A0000|52 58|Records
P09988850A0000|70 76|battery
P09988850A0000|96 120|dementia rating instruments
P09988850A0000|136 142|records
P09988850A0000|183 203|schizophrenia patients
P09988850A0000|274 279|change
P09988850A0000|282 294|schizophrenia
P09988850A0000|319 334|autopsy materials
P09988850A0000|3 8|Scales
P09989334A0964|133 138|intron
P09989334A0964|24 40|processing signals
P09989334A0964|87 105|polyadenylation site
P09989334A0964|65 80|donor splice sites
P09989334A0964|46 55|transcript
P09989339A0968|16 18|use
P09989339A0968|24 30|product
P09989339A0968|33 43|brain weight
P09989339A0968|47 55|clearance
P09990057T0000|0 12|Recombination
P09990057T0000|83 87|chain
P09990057T0000|119 125|absence
P09990057T0000|51 60|chain locus
P09990057T0000|76 77|Ig
P09990057T0000|131 153|matrix attachment regions
P09990057T0000|96 113|enhancer core region
P09990057T0000|16 28|transcription
P09990057T0000|44 45|Ig
P09990060A0803|53 71|dyad symmetry element
P09990060A0803|103 114|IL-2 enhancer
P09990060A0803|10 15|motifs
P09990060A0803|121 132|CD18 promoter
P09990060A0803|19 22|part
P09990060A0937|143 151|induction
P09990060A0937|154 166|IL-16 promoter
P09990060A0937|82 88|binding
P09990060A0937|113 131|dyad symmetry element
P09990060A0937|91 99|GABPalpha
P09990060A0937|104 107|beta
P09990060A0937|16 49|coactivator CREB binding protein/p300
P09990060A0937|169 174|T cells
P09990060A0937|69 77|GABPalpha
P09990060A0937|2 8|concert
P09990315A0205|0 2|TPO
P09990315A0205|99 108|activation
P09990315A0205|129 136|agonists
P09990315A0205|210 217|agonists
P09990315A0205|25 28|ERK1
P09990315A0205|37 50|protein kinase C
P09990315A0205|111 114|ERKs
P09990315A0205|190 202|PKC activation
P09990315A0205|157 169|phorbol esters
P09990315A0205|30 33|ERK2
P09990315A0205|64 66|TPO
P09990315A0205|146 153|thrombin
P09990315A0205|52 54|PKC
P09990507A0000|0 9|BACKGROUND
P09990507A0000|113 118|timing
P09990507A0000|55 69|ubiquitin ligase
P09990507A0000|35 52|proteolysis pathway
P09990507A0000|99 109|selectivity
P09990507A0000|71 72|E3
P09990507A0000|121 131|degradation
P09990507A0763|0 10|CONCLUSIONS
P09990507A0763|39 42|Pop1
P09990507A0763|12 26|Fission yeast SCF
P09990507A0763|46 49|Pop2
P09990507A0763|99 121|F-box/WD-repeat proteins
P09994942T0000|3 12|NMR studies
P09994942T0000|31 46|antiferromagnets
P09995847T0000|0 24|Optical-absorption spectra
P09995847T0000|55 77|transition line strengths
P09995847T0000|80 86|holmium
P09995847T0000|39 50|energy levels
P09995847T0000|97 99|Na3
P09995897T0000|0 10|Observation
P09995897T0000|39 48|Pb0 defects
P09995897T0000|20 31|interactions
P09995897T0000|59 74|Si/SiO2 interface
P09999256T0000|19 24|theory
P09999256T0000|37 54|transport phenomena
P09999742T0000|0 2|NH3
P09999742T0000|36 43|surfaces
P09999742T0000|23 24|Si
P09999742T0000|6 18|NO interaction
P10000253T0000|0 14|Chirality-glass
P10000253T0000|71 77|XY model
P10000253T0000|18 39|spin-glass correlations
P10001333T0038|0 13|Echo modulation
P10001333T0038|21 25|YAlO3
P10001333T0038|16 18|Pr3
P10001541T0000|0 9|Mechanisms
P10001541T0000|25 32|emission
P10001541T0000|59 65|silicon
P10002245T0000|61 69|YBa2Cu3O7
P10002245T0000|36 44|CuO chains
P10002245T0000|71 82|delta crystal
P10002245T0000|19 30|conductivity
P10006319T0000|0 15|Surface spin waves
P10006319T0000|19 39|Heisenberg ferrimagnet
P10006319T0000|55 64|anisotropy
P10007469T0000|17 23|librons
P10007469T0000|27 33|phonons
P10007469T0000|47 49|C60
P10007564T0000|60 66|surface
P10007564T0000|54 54|W
P10007564T0000|42 50|structure
P10007564T0000|21 28|geometry
P10008261T0000|0 20|Temperature dependence
P10008261T0000|26 35|sublattice
P10008261T0000|47 59|magnetization
P10008261T0000|62 70|YBa2Cu3O6
P10009565T0000|0 19|GW Gamma approximation
P10009565T0000|63 72|insulators
P10009565T0000|23 43|electron self-energies
P10009565T0000|46 59|semiconductors
P10013227T0000|0 19|Precision measurement
P10013227T0000|25 45|pion mass difference m pi
P10013227T0000|48 50|m pi
P10019841T0000|7 13|gravity
P10019841T0000|55 62|approach
P10019841T0000|36 40|order
P10021333A0674|73 83|interaction
P10021333A0674|96 100|genes
P10021333A0674|23 29|mutants
P10021333A0674|7 17|experiments
P10021333A0674|51 55|bruno
P10021350A0093|91 96|nuclei
P10021350A0093|143 162|transcription factors
P10021350A0093|213 217|genes
P10021350A0093|105 125|TCF/LEF family proteins
P10021350A0093|12 16|model
P10021350A0093|176 188|transcription
P10021350A0093|46 67|Armadillo/beta-catenin
P10021350A0093|191 202|Wingless/Wnt
P10021350A0093|30 35|signal
P10022032A0000|161 190|calcium channel blocker diltiazem
P10022032A0000|63 65|NIC
P10022032A0000|2 8|support
P10022032A0000|100 129|receptor antagonists propranolol
P10022032A0000|138 145|atenolol
P10022032A0000|244 255|interactions
P10022032A0000|147 149|ATN
P10022032A0000|41 61|vasodilator nicorandil
P10022032A0000|30 36|studies
P10022032A0000|192 194|DTZ
P10022210A0620|0 6|Factors
P10022210A0620|39 49|SPME process
P10022210A0620|18 33|direct-immersion
P10022210A0620|35 36|DI
P10022850A0929|88 103|Zta transcription
P10022850A0929|27 34|fragment
P10022850A0929|48 57|C/H1 domain
P10022850A0929|112 131|reactivation function
P10022850A0929|2 9|contrast
P10022850A0929|74 85|coactivation
P10022858A0985|2 9|addition
P10022858A0985|90 96|protein
P10022858A0985|18 41|splicing enhancer sequence
P10022858A0985|55 63|selection
P10022867A1069a|0 10|Elimination
P10022867A1069a|54 66|mutation rates
P10022867A1069a|113 121|reversion
P10022867A1069a|13 16|ETH1
P10022867A1069a|133 149|lysine prototrophy
P10022867A1069a|124 130|adenine
P10022867A1069a|19 29|apn1 strains
P10022867A1069a|95 98|type
P10022867A1069b|0 10|Elimination
P10022867A1069b|54 66|mutation rates
P10022867A1069b|113 121|reversion
P10022867A1069b|13 16|ETH1
P10022867A1069b|133 149|lysine prototrophy
P10022867A1069b|124 130|adenine
P10022867A1069b|19 29|apn1 strains
P10022867A1069b|95 98|type
P10022875A1265|55 64|PI 3-kinase
P10022875A1265|25 36|Ras effectors
P10022875A1265|91 93|Pak
P10022875A1265|5 8|data
P10022880A0000|147 172|signal transduction pathways
P10022880A0000|104 114|Ras proteins
P10022880A0000|78 90|downregulator
P10022880A0000|129 132|role
P10022880A0000|37 39|GAP
P10022880A0000|42 52|p120 Ras-GAP
P10022880A0000|94 101|effector
P10022880A0000|9 35|Ras GTPase-activating protein
P10022905A0446|80 95|missense mutation
P10022905A0446|63 69|alleles
P10022905A0446|176 182|tissues
P10022905A0446|123 130|activity
P10022905A0446|5 16|mog-1 alleles
P10022905A0446|132 140|mog-1 mRNA
P10022905A0446|158 165|germ line
P10022905A0446|33 42|stop codons
P10022921A0608|72 84|cell viability
P10022921A0608|51 54|pst1
P10022921A0608|17 24|SIN3 gene
P10022925A0870|55 60|motifs
P10022925A0870|68 75|function
P10022925A0870|3 21|Nmd3 protein sequence
P10022978A1261|27 33|repeats
P10022978A1261|91 97|regions
P10022978A1261|45 56|organization
P10022978A1261|105 108|base
P10022978A1261|119 132|chromosome arms
P10022978A1261|3 14|distribution
P10024383T0000|0 9|Calcitonin
P10024383T0000|47 58|hyperostosis
P10024383T0000|111 117|twy/twy
P10024383T0000|72 81|osteopenia
P10024383T0000|105 109|mouse
P10024498A0783|60 65|Y sites
P10024498A0783|29 34|assays
P10024498A0783|110 119|HNF-3alpha
P10024498A0783|51 56|HNF-3 X
P10024498A0783|123 131|HNF-3beta
P10024498A0783|86 90|sites
P10024882A0541|2 9|addition
P10024882A0541|99 113|promoter opening
P10024882A0541|64 69|domain
P10024882A0541|77 82|RNA pol
P10024882A0541|25 28|cdk7
P10024882A0541|90 96|absence
P10024882A0541|71 73|CTD
P10025050A1052|3 9|therapy
P10025050A1052|26 35|antagonist
P10025050A1052|89 100|lansoprazole
P10025050A1052|77 86|omeprazole
P10025050A1052|64 72|therapies
P10025506A0079|29 43|plastin isoforms
P10025506A0079|2 7|humans
P10025506A1078|2 5|TATA
P10025506A1078|8 18|Inr sequence
P10026146A0680|114 117|PrKX
P10026146A0680|18 31|RIalpha subunit
P10026146A0680|79 82|cAMP
P10026146A0680|206 215|holoenzyme
P10026146A0680|223 235|Calpha subunit
P10026146A0680|252 264|protein kinase
P10026146A0680|63 76|concentrations
P10026146A0680|127 130|type
P10026146A0680|181 198|cAMP concentrations
P10026146A0680|44 51|addition
P10026146A0680|84 85|Ka
P10026146A0680|89 90|nM
P10026146A0680|146 158|protein kinase
P10026146A0680|3 12|inhibition
P10026211A0136|0 7|Proteins
P10026211A0136|22 29|PEPCK CRE
P10026211A0136|51 57|protein
P10026211A0136|115 120|family
P10026211A0136|67 73|members
P10026211A0136|109 113|C/EBP
P10026211A0136|59 62|CREB
P10026211A0136|101 107|protein
P10026211A0543|147 167|H4IIE rat hepatoma cells
P10026211A0543|53 56|beta
P10026211A0543|40 49|C/EBPalpha
P10026211A0543|95 116|glucocorticoid response
P10026211A0543|63 66|CREB
P10026211A0543|20 33|pDeltaCREC/EBP
P10026211A0543|4 12|construct
P10026229A0950|160 167|fragment
P10026229A0950|126 136|enhancement
P10026229A0950|47 55|Pbx1 sites
P10026229A0950|18 28|mutagenesis
P10026229A0950|35 43|Engrailed
P10026229A0950|2 9|addition
P10026229A0950|86 90|sites
P10026275A0549|16 32|structure elements
P10026784A0331|57 76|transcription factors
P10026784A0331|7 14|evidence
P10026784A0331|35 43|functions
P10026784A0331|95 112|POU DNA binding motif
P10026784A0331|49 54|family
P10026784A0331|135 145|development
P10026784A0331|119 123|roles
P10026784A0929|100 114|POU-homeodomain
P10026784A0929|26 35|DNA binding
P10026784A0929|38 66|POU domain transcription factors
P10026784A2166|132 135|GTAT
P10026784A2166|50 62|GCAT half-site
P10026784A2166|125 130|domain
P10026784A2166|108 112|Pit-1
P10026784A2166|5 16|Oct-1 crystal
P10026784A2166|152 157|strand
P10026784A2166|33 38|domain
P10026784A2166|85 92|sequence
P10026824A0309|30 50|V1a/V2 hybrid receptors
P10026824A0309|191 200|V2 receptor
P10026824A0309|227 234|coupling
P10026824A0309|138 145|coupling
P10026824A0309|83 86|loop
P10026824A0309|92 102|V1a receptor
P10026824A0309|20 27|analysis
P10026824A0309|182 185|loop
P10026824A0309|148 152|Gq/11
P10026824A0309|237 238|Gs
P10027498A0536|43 47|death
P10027498A0536|103 103|p
P10027498A0536|75 85|U.S. program
P10027498A0536|9 17|end points
P10027904A0768|51 56|region
P10029337A0406|142 145|days
P10029337A0406|80 80|l
P10029337A0406|124 131|activity
P10029337A0406|151 152|SD
P10029337A0406|101 119|serum creatine kinase
P10029337A0406|159 159|l
P10029337A0406|38 62|blood lactate concentration
P10029337A0406|75 78|mmol
P10029337A0406|157 157|U
P10029337A0406|91 98|increase
P10029337A0406|69 70|SD
P10029337A0406|121 122|CK
P10029337A0406|3 17|fatigue exercise
P10029860A0605|44 53|categories
P10029860A0605|91 97|filling
P10029860A0605|57 60|type
P10029860A0605|17 23|aspects
P10029917A0366|0 6|Results
P10029917A0366|78 81|case
P10029917A0366|26 33|presence
P10029917A0366|109 128|muscle cell dispersion
P10029917A0366|168 185|portal vein branches
P10029917A0366|36 49|myofibroblasts
P10029917A0366|72 75|case
P10031854T0000|0 19|New Langevin equations
P10031854T0000|70 72|top
P10032519T0000|57 66|generation
P10032519T0000|37 47|possibility
P10032519T0000|9 19|corrections
P10032519T0000|22 30|beta decay
P10032581T0000|16 43|grazing-incidence diffraction
P10032581T0000|58 66|radiation
P10032581T0000|46 56|synchrotron
P10033973T0000|48 62|Bose condensates
P10033973T0000|11 18|exchange
P10033973T0000|21 25|atoms
P10033973T0000|33 37|traps
P10034615T0000|0 21|Structure determination
P10034615T0000|70 70|x
P10034615T0000|53 66|reconstruction
P10034615T0000|74 77|H/Ni
P10035841T0000|38 45|hydrogen
P10035841T0000|8 15|trapping
P10036181A0603|87 101|rat brain regions
P10036181A0603|21 41|hybridization analyses
P10036181A0603|50 69|GPR34 mRNA transcripts
P10036181A0603|0 11|Northern blot
P10036191A0000|121 124|TFEC
P10036191A0000|111 114|TFE3
P10036191A0000|26 34|subfamily
P10036191A0000|183 196|gene expression
P10036191A0000|81 100|transcription factors
P10036191A0000|72 79|bHLH-ZIP
P10036191A0000|22 24|MiT
P10036191A0000|156 165|regulation
P10036191A0000|129 132|Mitf
P10036191A0000|58 70|leucine zipper
P10036191A0000|116 119|TFEB
P10036191A0000|3 20|microphthalmia-TFE
P10036191A0000|206 217|cell lineages
P10037004A0000|95 101|relapse
P10037004A0000|11 18|patients
P10037004A0000|126 132|therapy
P10037004A0000|53 60|leukemia
P10037004A0000|26 30|years
P10037004A0000|92 93|BM
P10037004A0000|62 64|ALL
P10037004A0000|167 171|study
P10037004A0000|81 90|bone marrow
P10037378A0176|3 14|dorsal nerves
P10037378A0176|20 24|penis
P10037378A0176|56 64|lidocaine
P10037460A0221|45 58|memory function
P10037460A0221|61 71|interaction
P10037460A0221|37 41|motor
P10037460A0221|81 99|ligand acetylcholine
P10037460A0221|21 29|receptors
P10037460A0221|5 9|brain
P10037576T0000|31 36|iodine
P10037576T0000|18 25|necrosis
P10037576T0000|41 58|plaque radiotherapy
P10037576T0000|76 83|melanoma
P10037681A0494|29 37|PKC-alpha
P10037681A0494|138 141|RhoA
P10037681A0494|10 20|interaction
P10037681A0494|75 82|fragment
P10037681A0494|103 104|D4
P10037681A0494|90 93|PLD1
P10037681A0494|42 45|PLD1
P10037681A0494|23 25|ARF
P10037681A0494|130 135|mutant
P10037681A0494|143 152|RhoAVal-14
P10037774A0366|29 54|signal transduction pathways
P10037774A0366|6 10|study
P10037774A0366|82 98|LDLR transcription
P10041728T0000|0 18|Vacuum Rabi splitting
P10041728T0000|22 28|feature
P10041728T0000|78 89|observations
P10041728T0000|31 53|linear-dispersion theory
P10041728T0000|55 62|Analysis
P10043466T0000|62 81|polydiacetylene 4BCMU
P10043466T0000|13 19|effects
P10043466T0000|42 49|kinetics
P10043466T0000|52 59|excitons
P10044519T0000|4 12|reduction
P10044519T0000|24 28|flows
P10044519T0000|31 38|polymers
P10046849T0000|20 40|structure calculations
P10046849T0000|5 9|scale
P10047970T0013|7 21|world literature
P10049357A0608|40 50|HDAC complex
P10049357A0608|20 22|Ski
P10049357A0608|58 60|Ski
P10049357A0608|5 11|results
P10049357A0608|92 101|repression
P10049357A0608|116 122|complex
P10049357A0608|26 34|component
P10049359A1073|87 100|rhinovirus IRES
P10049359A1073|11 13|unr
P10049359A1073|48 50|PTB
P10049359A1073|62 72|translation
P10049742T0000|0 7|Analysis
P10049742T0000|62 64|ZF5
P10049742T0000|54 59|domain
P10049742T0000|13 36|consensus binding sequence
P10049775T0000|0 6|Mapping
P10049775T0000|34 53|Anion Channel isoforms
P10049912T0000|0 13|Identification
P10049912T0000|34 43|suppressor
P10049912T0000|89 112|DNA exonuclease deficiency
P10049912T0000|49 61|UV sensitivity
P10049912T0000|16 21|RNase T
P10050883A0967|0 9|Inhibition
P10050883A0967|114 119|effect
P10050883A0967|134 142|viability
P10050883A0967|12 39|phosphatidylinositol-3 kinase
P10050883A0967|70 84|p53 conformation
P10050883A0967|62 67|effect
P10051030A1080|14 23|percentage
P10051030A1080|26 30|males
P10051030A1080|63 69|strains
P10051030A1080|33 47|semen production
P10051030A1080|89 96|regimens
P10051030A1080|2 11|difference
P10051030A1080|71 78|CP levels
P10051400A0000|69 87|cranio-rachischisis
P10051400A0000|64 66|NTD
P10051400A0000|25 29|model
P10051400A0000|53 62|tube defect
P10051400A0000|3 9|Lp mouse
P10051488A1293|96 116|mobility AP-1 complexes
P10051488A1293|69 72|HSCs
P10051488A1293|7 14|analysis
P10051488A1293|53 59|culture
P10051488A1293|17 40|AP-1 DNA binding activities
P10051488A1293|81 89|discovery
P10051488A1293|118 123|HMAP-1
P10051488A1610|27 40|TIMP-1 promoter
P10051488A1610|80 84|% loss
P10051488A1610|65 70|HMAP-1
P10051488A1610|87 94|activity
P10051488A1610|117 120|HSCs
P10051488A1610|54 62|formation
P10051488A1610|0 8|Mutations
P10051488A1610|14 21|AP-1 site
P10052371A0171|115 121|smoking
P10052371A0171|76 84|occasions
P10052371A0171|51 58|subjects
P10052371A0171|20 40|immunoglobulin A levels
P10052371A0171|174 176|day
P10052371A0171|140 148|cessation
P10052371A0171|151 157|smoking
P10052371A0171|131 134|days
P10052371A0171|182 190|cessation
P10052371A0171|0 10|STUDY DESIGN
P10052371A0171|100 106|subject
P10052878A0135|14 27|set-up accuracy
P10052878A0135|31 45|reproducibility
P10053852T0000|0 3|Role
P10053852T0000|33 61|Gerasimov-Drell-Hearn sum rules
P10053852T0000|21 29|Schwinger
P10053852T0000|6 7|g2
P10054976T0000|59 77|Raman coupling regime
P10054976T0000|22 25|ions
P10054976T0000|46 55|detachment
P10054976T0000|0 11|Spectroscopy
P10055173T0000|0 19|Band structure effects
P10055173T0000|54 66|quasicrystals
P10055173T0000|22 40|transport properties
P10059496T0000|32 45|Penrose lattice
P10059496T0000|8 26|transmission spectra
P10063122T0000|0 22|Two-Channel Kondo Lattice
P10063122T0000|36 40|Metal
P10063739A0601|101 108|controls
P10063739A0601|65 74|study group
P10063739A0601|23 49|esophageal sphincter pressure
P10063739A0601|162 164|EVL
P10063739A0601|76 79|mean
P10063739A0601|128 135|pressure
P10063739A0601|93 96|mmHg
P10063739A0601|81 82|SD
P10063739A0601|119 122|mmHg
P10063739A0601|157 159|EVS
P10064604A0824|0 3|CPDs
P10064604A0824|16 20|sites
P10064604A0824|68 73|repair
P10064604A0824|41 46|TFIIIA
P10065176A0657|129 143|macrometastases
P10065176A0657|25 45|hormone receptor status
P10065176A0657|56 60|cases
P10065176A0657|10 19|difference
P10065176A0657|94 112|lymph node metastases
P10065176A0657|68 86|lymph node metastases
P10065684A0916|174 183|sarcomeres
P10065684A0916|261 266|microm
P10065684A0916|10 13|hand
P10065684A0916|63 74|lung capacity
P10065684A0916|15 22|subjects
P10065684A0916|157 157|p
P10065684A0916|225 235|abnormality
P10065684A0916|185 185|L
P10065684A0916|187 189|sar
P10065684A0916|47 52|volume
P10065684A0916|76 78|TLC
P10065684A0916|108 108|n
P10065684A0916|196 203|subjects
P10065684A0916|110 112|mit
P10065684A0916|143 151|mt x microm
P10065684A0916|268 268|p
P10065684A0916|83 83|%
P10065684A0916|54 55|RV
P10065684A0916|27 37|air trapping
P10066790A0497|220 226|epsilon
P10066790A0497|39 68|immunoprecipitation experiments
P10066790A0497|209 215|mu-ARP2
P10066790A0497|81 85|beta4
P10066790A0497|121 124|AP-4
P10066790A0497|89 97|component
P10066790A0497|113 119|complex
P10066790A0497|145 161|sigma4 polypeptide
P10066790A0497|14 34|sedimentation velocity
P10066790A0497|205 207|mu4
P10066790A0497|0 12|Gel filtration
P10066790A0497|178 199|adaptor subunit homologs
P10066798A0391|0 5|Cyclin
P10066798A0391|36 48|protein levels
P10066798A0391|130 133|mice
P10066798A0391|110 118|c-src527F
P10066798A0391|94 108|tumor virus-pp60
P10066798A0391|71 76|tumors
P10066798A0391|19 32|kinase activity
P10066815T0000|74 97|phosphoinositide 3-kinase
P10066815T0000|3 5|SH2
P10066815T0000|125 134|inhibition
P10066815T0000|23 30|inositol
P10066815T0000|62 71|p85 subunit
P10066815T0000|34 44|phosphatase
P10066815T0000|137 158|B cell receptor signaling
P10066815T0000|46 49|SHIP
P10068040A0136|13 23|mouse genome
P10068040A0136|36 41|copies
P10068040A0136|47 55|ubc-9 gene
P10068418A1194|58 61|body
P10068418A1194|46 48|hip
P10068418A1194|123 130|estrogen
P10068418A1194|12 29|bone mineral density
P10068418A1194|133 150|alendronate therapy
P10068418A1194|35 39|spine
P10068418A1194|81 90|raloxifene
P10068418A1194|2 9|increase
P10068446A0124|56 70|PKC preparations
P10068446A0124|94 96|BPO
P10068446A0124|30 37|presence
P10068446A0124|113 128|cysteine residues
P10068446A0124|15 21|studies
P10068446A0124|131 133|PKC
P10068446A0124|84 91|reaction
P10068446A0124|40 50|thiol agents
P10068637A1320|14 21|Csx/Nkx2
P10068674A0644|42 47|Lyp RNA
P10068674A0644|36 39|form
P10068674A0644|49 52|Lyp2
P10068834A0713|39 40|VR
P10068834A0713|24 25|PE
P10068834A0713|12 13|DM
P10068834A0713|44 45|DM
P10068834A0713|55 57|MR.
P10068834A0713|3 7|costs
P10068834A0713|27 28|DM
P10069815A0285|72 81|proteasome
P10069815A0285|12 19|evidence
P10069815A0285|62 65|Doa4
P10069815A0285|44 54|interaction
P10070158A0573|110 128|transmembrane domain
P10070158A0573|11 24|splicing events
P10070158A0573|56 68|cassette exons
P10071205A0833|41 43|ORF
P10071205A0833|99 105|cistron
P10071205A0833|50 53|STA2
P10071205A0833|11 15|genes
P10071205A0833|78 86|AUG codons
P10071212A0399|18 32|O. australiensis
P10071761A2374|133 142|regulation
P10071761A2374|11 17|mapping
P10071761A2374|104 110|insight
P10071761A2374|175 180|anyone
P10071761A2374|43 56|identification
P10071761A2374|67 74|promoter
P10071761A2374|23 36|promoter region
P10071761A2374|85 93|sequences
P10071761A2374|200 206|factors
P10071761A2374|2 9|addition
P10071761A2374|145 158|UCP2 expression
P10071806A0377|3 6|rate
P10071806A0377|36 43|survival
P10071806A0377|9 21|resectability
P10072205A0167|71 80|conditions
P10072205A0167|49 60|MAP estimates
P10072205A0167|91 108|point approximation
P10072205A0167|140 151|distribution
P10072205A0167|111 123|density values
P10072205A0167|30 41|distribution
P10072205A0167|44 45|ML
P10072205A0167|2 6|order
P10072205A0167|158 166|estimates
P10072774A0537|0 5|RT-PCR
P10072774A0537|78 96|ligand binding domain
P10072774A0537|109 128|beta integrin subunits
P10072774A0537|51 72|oligonucleotide primers
P10072774A0537|98 100|LBD
P10072774A0537|132 138|Bge cDNA
P10073899A0740|82 84|CVS
P10073899A0740|9 26|culture failure rate
P10073899A0740|73 76|cent
P10073899A0740|35 38|cent
P10073899A0740|52 54|EAF
P10073940A0335|42 50|signaling
P10073940A0335|7 16|expression
P10073940A0335|19 24|d-axin
P10073947A1110|29 33|FVIIa
P10073947A1110|37 41|PAI-1
P10073947A1110|16 26|differences
P10074135T0000|59 64|barley
P10074135T0000|71 80|dwarf virus
P10074135T0000|91 94|RNA1
P10074135T0000|48 56|synthesis
P10074135T0000|29 36|elements
P10074282A0236|28 31|ring
P10074282A0236|47 51|L-NNA
P10074282A0236|10 13|side
P10074282A0236|53 73|NO-synthesis inhibitor
P10074282A0236|77 89|methylene blue
P10074282A0236|119 125|changes
P10074282A0236|98 113|cGMPase inhibitor
P10074425A0729|117 124|deletion
P10074425A0729|94 97|MEFs
P10074425A0729|13 24|inactivation
P10074425A0729|61 77|mitogen starvation
P10074425A0729|51 58|response
P10074425A0729|130 136|p27 gene
P10074425A0729|30 48|cyclin E-Cdk2 complex
P10074520T0000|0 13|Identification
P10074520T0000|82 90|detection
P10074520T0000|116 118|PCR
P10074520T0000|93 113|Mycobacterium ulcerans
P10074520T0000|70 78|sequences
P10074520T0000|35 40|IS2404
P10074520T0000|17 32|characterization
P10074520T0000|44 49|IS2606
P10074903A0915|88 116|cell growth retardation activity
P10074903A0915|136 139|part
P10074903A0915|153 168|p21 protein levels
P10074903A0915|122 125|IFNs
P10074903A0915|19 25|results
P10074903A0915|46 56|possibility
P10074903A0915|61 71|p202 protein
P10074921A1169|72 74|p53
P10074921A1169|7 13|results
P10074921A1169|35 61|HepG2 hepatoblastoma cell line
P10075415A1178|55 62|homology
P10075415A1178|40 46|ORF-Pto
P10075415A1178|89 100|UV resistance
P10075415A1178|106 117|plasmid pPSR1
P10075415A1178|22 27|region
P10075415A1178|7 16|sequencing
P10075415A1178|68 77|ru/AB genes
P10076007A0656|28 39|casein kinase
P10076007A0656|110 115|kinase
P10076007A0656|74 80|mRNP3+4
P10076007A0656|83 89|oocytes
P10076007A0656|17 22|kinase
P10076007A0656|3 6|MSY2
P10076007A0656|45 50|kinase
P10077188A1172|100 104|genes
P10077188A1172|185 188|mRNA
P10077188A1172|138 146|heat shock
P10077188A1172|192 198|protein
P10077188A1172|52 63|biosynthesis
P10077188A1172|29 33|genes
P10077188A1172|81 88|proteins
P10077188A1172|73 77|acids
P10077188A1172|174 182|synthesis
P10077533A0976|72 79|MUL genes
P10077533A0976|5 8|data
P10077533A0976|63 65|MKS
P10077533A0976|44 57|identification
P10077533A0976|28 32|tools
P10078734A0480|72 76|elbow
P10078734A0480|11 23|recovery curve
P10078734A0480|62 66|nerve
P10078734A0480|40 50|stimulation
P10078734A0480|80 88|recording
P10078734A0480|96 114|flexor carpi radialis
P10078876A0000|177 185|flowmetry
P10078876A0000|211 233|hemoglobin concentration
P10078876A0000|197 203|changes
P10078876A0000|71 77|signals
P10078876A0000|237 247|oxygenation
P10078876A0000|130 136|imaging
P10078876A0000|26 32|changes
P10078876A0000|138 159|microspectrophotometry
P10078876A0000|97 118|rat somatosensory cortex
P10078876A0000|3 9|origins
P10078876A0000|55 62|activity
P10079173A0000|71 74|RRMs
P10079173A0000|50 69|RNA recognition motifs
P10079173A0000|22 29|proteins
P10080436T0000|0 9|Comparison
P10080436T0000|12 22|frequencies
P10080436T0000|113 118|bypass
P10080436T0000|93 95|use
P10080436T0000|31 42|fibrillation
P10080436T0000|56 67|artery bypass
P10080875A0772|60 79|transcription factors
P10080875A0772|12 29|supershift analysis
P10080875A0772|104 112|complexes
P10080875A0772|222 226|c-Fos
P10080875A0772|43 52|antibodies
P10080875A0772|193 195|p52
P10080875A0772|251 256|NF-IL6
P10080875A0772|228 232|C-Jun
P10080875A0772|209 220|AP-1 proteins
P10080875A0772|175 191|NF-kappaB proteins
P10080875A0772|150 152|p65
P10080875A0772|241 249|C/EBPbeta
P10080875A0772|197 201|c-Rel
P10080875A0772|203 206|Rel B
P10080875A0772|125 146|NF-kappaB components p50
P10080875A0772|3 9|results
P10080875A0772|235 238|CREB
P10080901A0271|42 49|elements
P10080901A0271|114 122|protein L9
P10080901A0271|6 13|peptides
P10080901A0271|61 69|structure
P10080901A0271|94 99|domain
P10080901A0271|1 3|set
P10082137A0262|87 89|IRF
P10082137A0262|154 178|procollagen mRNA expression
P10082137A0262|20 28|IFN-gamma
P10082137A0262|80 85|factor
P10082137A0262|181 195|skin fibroblasts
P10082137A0262|93 96|mRNA
P10082137A0262|133 142|inhibition
P10082137A0262|47 58|accumulation
P10082137A0262|216 221|donors
P10082137A0262|3 9|results
P10082137A0262|152 152|I
P10082137A0262|145 150|alpha1
P10082137A0262|61 70|interferon
P10082554T0000|85 104|cell growth regulation
P10082554T0000|10 16|domains
P10082554T0000|19 45|c-myc promoter binding protein
P10082554T0000|72 81|repression
P10082570A0440|25 33|gene UBP43
P10082573A1015|126 136|holocomplex
P10082573A1015|186 190|DNase
P10082573A1015|174 182|formation
P10082573A1015|100 122|globin gene transcription
P10082573A1015|46 48|HS2
P10082573A1015|206 216|holocomplex
P10082573A1015|5 11|results
P10082573A1015|50 52|HS3
P10082573A1015|81 84|unit
P10082573A1015|32 41|hypothesis
P10082573A1015|259 281|globin gene transcription
P10082573A1015|57 59|HS4
P10082585A0512|44 56|rDNA silencing
P10082585A0512|166 169|rDNA
P10082585A0512|77 82|screen
P10082585A0512|122 131|expression
P10082585A0512|27 33|factors
P10082585A0512|134 146|reporter genes
P10082585A0512|100 108|mutations
P10084294A0219|87 99|serum ferritin
P10084294A0219|155 166|microg/liter
P10084294A0219|103 129|transferrin saturation levels
P10084294A0219|172 172|%
P10084294A0219|19 22|need
P10084294A0219|26 29|iron
P10084294A0219|58 68|progenitors
P10085088A0918|85 100|protein synthesis
P10085088A0918|122 127|domain
P10085088A0918|148 155|activity
P10085088A0918|39 42|eIF3
P10085088A0918|68 82|initiation phase
P10085088A0918|5 11|results
P10085088A0918|59 62|role
P10085088A0918|27 36|p33 subunit
P10085120A0000|61 67|therapy
P10085120A0000|23 39|signaling pathways
P10085120A0000|77 85|hypericin
P10085120A0000|6 10|study
P10085120A0000|69 71|PDT
P10085140A1004|42 45|role
P10085140A1004|89 94|target
P10085140A1004|24 28|ATF-2
P10085140A1004|108 119|TAK1 pathways
P10085140A1004|101 104|Smad
P10085140A1004|48 64|TGF-beta signaling
P10085140A1004|5 11|results
P10085383A1367|3 7|WORDS
P10085383A1367|9 17|Melaleuca
P10085383A1367|58 75|Regulation schedule
P10085383A1367|19 32|Lake Okeechobee
P10085383A1367|34 45|Littoral zone
P10085383A1367|47 56|Water level
P10085505A1184|70 74|cases
P10085505A1184|26 29|vein
P10085505A1184|11 14|peak
P10085505A1184|55 58|peak
P10085605A0239|0 8|Specimens
P10085605A0239|82 84|hCG
P10085605A0239|65 72|alpha hCG
P10085605A0239|23 39|alpha-fetoprotein
P10085605A0239|53 59|estriol
P10085697T0000|0 39|FASEB Federal Funding Consensus Conference FY
P10086544A0504|416 429|catecholamines
P10086544A0504|457 466|furosemide
P10086544A0504|431 441|epinephrine
P10086544A0504|95 97|CPB
P10086544A0504|160 180|temperature difference
P10086544A0504|259 265|lactate
P10086544A0504|99 107|heart rate
P10086544A0504|51 58|care unit
P10086544A0504|338 345|fraction
P10086544A0504|204 229|oxygen saturation difference
P10086544A0504|82 92|termination
P10086544A0504|30 36|arrival
P10086544A0504|321 327|factors
P10086544A0504|444 452|enoximone
P10086544A0504|269 292|neutrophil elastase levels
P10086544A0504|133 140|pressure
P10086544A0504|383 394|ejection time
P10086544A0504|12 15|data
P10086544A0504|297 303|Doppler
P10086544A0504|72 76|hours
P10086544A0504|231 241|urine output
P10086544A0504|409 413|doses
P10086544A0504|109 121|blood pressure
P10086544A0504|243 257|serum creatinine
P10086544A0504|349 359|preejection
P10086725A0000|0 8|MDS1/EVI1
P10086725A0000|68 89|transcription activator
P10086725A0000|19 28|chromosome
P10086725A0000|154 160|tissues
P10086725A0000|122 126|cells
P10086725A0000|30 36|band q26
P10087213A0878|0 7|Analysis
P10087213A0878|39 48|replicases
P10087213A0878|131 139|formation
P10087213A0878|151 155|class
P10087213A0878|85 118|H. pylori plasmid replication proteins
P10087213A0878|158 180|H. pylori plasmid proteins
P10087213A0878|13 28|protein sequences
P10087549A0720|3 10|JTc delta
P10087549A0720|113 116|msec
P10087549A0720|74 75|ms
P10087549A0720|49 56|JTc delta
P10087549A0720|163 164|ms
P10087549A0720|24 29|groups
P10087549A0720|170 172|ms.
P10087549A0720|122 125|msec
P10087549A0720|87 94|JTc delta
P10087549A0720|146 157|control group
P10087549A0720|62 68|VT group
P10087549A0720|81 82|ms
P10087549A0720|100 107|PVC group
P10087549A0720|133 140|JTc delta
P10087993A0782|69 76|decrease
P10087993A0782|11 18|deletion
P10087993A0782|44 56|delta promoter
P10087993A0782|79 88|expression
P10087993A0782|32 38|portion
P10087993A0782|2 9|contrast
P10087993A1352|44 63|repressor proteins BP1
P10087993A1352|146 161|promoter activity
P10087993A1352|67 69|BP2
P10087993A1352|13 23|mutagenesis
P10087993A1352|136 143|increase
P10087993A1352|95 108|beta globin gene
P10087993A1352|33 37|sites
P10087993A1352|83 89|portion
P10087993A1352|117 122|region
P10090125A0750|57 57|M
P10090125A0750|62 71|relaxation
P10090125A0750|15 38|alpha1 antagonist prazosin
P10090146T0000|59 69|chick retina
P10090146T0000|36 43|AP-2beta
P10090146T0000|12 21|expression
P10090146T0000|24 32|AP-2alpha
P10090146T0000|107 110|AP-2
P10090146T0000|71 80|repression
P10090146T0000|83 104|R-FABP promoter activity
P10090535A1194|53 54|Lp
P10090535A1194|23 24|TG
P10090535A1194|48 48|%
P10090535A1194|36 39|apoB
P10090535A1194|34 34|%
P10090535A1194|87 92|groups
P10090535A1194|3 11|algorithm
P10090535A1194|67 67|%
P10090943A1426|68 69|SD
P10090943A1426|7 11|value
P10090943A1426|98 99|SD
P10090943A1426|108 108|P
P10090943A1426|49 53|ratio
P10090943A1426|17 21|CD79b
P10090943A1426|102 106|B-CLL
P10090943A1426|78 83|donors
P10090943A1426|27 31|CD79b
P10090943A1976|100 114|activation stage
P10090943A1976|140 144|B-CLL
P10090943A1976|75 84|regulation
P10090943A1976|51 55|CD79b
P10090943A1976|8 13|B cells
P10090943A1976|126 130|B cell
P10090943A1976|29 35|variant
P10090943A1976|40 48|mechanism
P10091594A0284|60 61|CD
P10091594A0284|144 150|epitope
P10091594A0284|129 138|propensity
P10091594A0284|65 79|NMR spectroscopy
P10091594A0284|92 102|ELISA assays
P10091594A0284|14 20|studies
P10091594A0284|39 58|structure predictions
P10091594A0284|195 203|anti-K159
P10091594A0284|154 167|helix formation
P10091594A0284|182 192|recognition
P10091619A0104|56 56|%
P10091619A0104|35 39|state
P10091619A0104|9 24|England ADL scores
P10091619A0104|69 73|state
P10091619A0104|77 82|scores
P10091619A0104|94 94|%
P10091619A0104|0 5|Schwab
P10092132A0285|159 163|13q34
P10092132A0285|77 81|cases
P10092132A0285|67 71|11q13
P10092132A0285|137 143|11p11.2
P10092132A0285|91 94|case
P10092132A0285|10 14|gains
P10092132A0285|126 127|.2
P10092132A0285|16 19|HLGs
P10092132A0285|33 50|gene amplifications
P10092132A0285|145 154|12p11.2-12
P10092132A0285|129 135|7q21-22
P10092847A0455|16 27|distribution
P10092847A0455|65 75|hMT-IIA gene
P10092847A0455|47 60|promoter region
P10092847A0455|142 155|MRE arrangement
P10092847A0455|101 126|mouse metallothionein-I gene
P10092847A0455|36 39|MREs
P10092847A0455|181 195|metal regulation
P10092847A0455|172 177|factor
P10092847A0455|4 10|respect
P10092856A0798|3 6|cDNA
P10092856A0798|52 58|control
P10092856A0798|75 100|phosphate isomerase promoter
P10092856A0798|64 68|yeast
P10094314A0935|142 146|SRp20
P10094314A0935|136 138|9G8
P10094314A0935|49 69|zinc knuckle 9G8 variant
P10094314A0935|104 112|agreement
P10094314A0935|120 123|fact
P10094314A0935|96 100|SRp20
P10094314A0935|131 133|RBD
P10094314A0935|17 28|RNA sequences
P10094396A0000|0 14|Topoisomerase II
P10094396A0000|61 65|PK CK2
P10094396A0000|23 28|target
P10094396A0000|34 58|protein kinase casein kinase
P10094701A0000|41 44|gene
P10094701A0000|122 140|phosphate limitation
P10094701A0000|112 119|response
P10094701A0000|75 95|Sinorhizobium meliloti
P10094701A0000|68 71|ackA
P10094701A0000|6 9|work
P10094701A0000|54 66|acetate kinase
P10094701A0000|16 25|laboratory
P10095059A1003|17 35|nucleotide positions
P10095059A1003|50 64|HIV-1 transcript
P10095059A1003|3 9|numbers
P10095061A0592|158 167|structures
P10095061A0592|31 41|MEMA protein
P10095061A0592|93 95|DRS
P10095061A0592|122 132|nucleoplasm
P10095061A0592|61 63|kDa
P10095061A0592|84 90|serines
P10095061A0592|72 77|domain
P10095061A0592|97 103|protein
P10095061A0592|0 15|Sequence analysis
P10095062A0558|85 89|exons
P10095062A0558|102 103|kb
P10095062A0558|24 32|structure
P10095062A0558|43 66|topoisomerase IIalpha gene
P10096469T0000|47 54|cat motor
P10096469T0000|12 21|modulation
P10096469T0000|63 69|neurons
P10096469T0000|37 44|activity
P10096573A0207|76 97|kappaB consensus element
P10096573A0207|65 70|factor
P10096573A0207|158 159|bp
P10096573A0207|72 73|NF
P10096573A0207|8 14|studies
P10096573A0207|124 129|region
P10096573A0207|135 152|MGSA/GRO-alpha gene
P10097120T0000|2 5|exon
P10097120T0000|36 39|mRNA
P10097120T0000|18 26|transport
P10097932A0915|59 64|mg/24 h
P10097932A0915|138 141|UAER
P10097932A0915|66 66|n
P10097932A0915|52 55|UAER
P10097932A0915|166 174|follow-up
P10097932A0915|73 88|microalbuminuria
P10097932A0915|146 151|mg/24 h
P10097932A0915|121 128|patients
P10097932A0915|159 163|years
P10097932A0915|15 22|patients
P10098601A1320|71 74|site
P10098601A1320|10 17|analysis
P10098601A1320|55 62|proteins
P10098601A1320|107 118|SF-1 sequence
P10098601A1320|30 32|DNA
P10098601A1320|43 47|JEG-3
P10098744A0630|58 63|clones
P10098744A0630|135 150|serum-dependence
P10098744A0630|106 122|proliferation rate
P10098744A0630|125 133|monolayer
P10098744A0630|154 166|proliferation
P10098744A0630|35 43|phenotype
P10098744A0630|13 18|change
P10098744A0630|229 250|differentiation markers
P10098744A0630|95 104|parameters
P10098744A0630|69 75|respect
P10098744A0630|201 210|morphology
P10098744A0630|169 176|survival
P10098744A0630|2 9|contrast
P10098744A0630|178 191|tumorigenicity
P10099247A1051|84 96|SRB population
P10099247A1051|32 44|retention time
P10099247A1051|181 182|MB
P10099247A1051|102 109|inoculum
P10099247A1051|50 53|days
P10099247A1051|62 69|presence
P10099247A1051|134 137|time
P10099247A1051|166 168|SRB
P10099247A1051|5 13|reactor pH
P10099576A0666|83 90|geometry
P10099576A0666|22 24|aim
P10099576A0666|12 17|valves
P10099576A0666|49 53|shear
P10099576A0666|57 65|parameter
P10099576A0666|115 124|conditions
P10099576A0666|41 46|effect
P10099576A0666|96 100|valve
P10100605A0392|122 130|rhodamine
P10100605A0392|21 25|burst
P10100605A0392|68 81|transformation
P10100605A0392|84 99|dihydrorhodamine
P10100605A0392|137 149|flow cytometry
P10101159A0742|57 65|mutations
P10101159A0742|20 27|SOC1 gene
P10101159A0742|78 90|cbp1 ts alleles
P10101159A0742|120 124|mRNAs
P10101159A0742|1 8|mutation
P10101198A0632|1 24|deletion mutation analysis
P10101198A0632|120 126|binding
P10101198A0632|88 101|leucine zippers
P10101198A0632|41 47|protein
P10101198A0632|73 78|region
P10101198A0946|146 148|DNA
P10101198A0946|1 14|database search
P10101198A0946|210 221|interactions
P10101198A0946|48 55|homology
P10101198A0946|126 132|protein
P10101198A0946|152 158|monomer
P10101198A0946|87 116|transcription termination factor
P10101198A0946|175 188|leucine zippers
P10101198A0946|57 61|match
P10101198A0946|118 122|mTERF
P10101744A0917|5 10|trials
P10101744A0917|12 27|antigen challenge
P10101744A0917|37 37|h
P10101744A0917|50 58|treatment
P10102000A1206|53 64|ERA-III group
P10102000A1206|33 43|ERA-II group
P10102000A1206|10 17|patients
P10102000A1206|76 88|mortality rate
P10102000A1206|94 94|%
P10102136A0220|68 71|sera
P10102136A0220|59 59|%
P10102136A0220|37 46|cyst fluids
P10102136A0220|16 18|PSA
P10102136A0646|26 30|ratio
P10102136A0646|60 63|Type
P10102136A0646|20 20|K
P10102136A0646|23 24|Na
P10102136A0646|53 55|PSA
P10102136A0646|5 9|cysts
P10102136A0646|66 70|cysts
P10102136A0646|0 3|Type
P10102627A0217|30 49|AP-1 reporter activity
P10102627A0217|11 28|DNA binding activity
P10102627A0217|70 74|cells
P10103002A0705|85 104|carbohydrate analysis
P10103002A0705|161 164|site
P10103002A0705|140 154|type glycan chain
P10103002A0705|76 83|proteins
P10103002A0705|7 25|N-glycosylation site
P10103002A0705|35 45|chicken gp42
P10103002A0705|107 110|gp42
P10103002A0705|122 129|presence
P10103057A0251|32 47|characterization
P10103057A0251|129 135|studies
P10103057A0251|84 93|Runt domain
P10103057A0251|62 69|fragment
P10103057A0251|96 99|AML1
P10103057A0251|17 28|optimization
P10119827T0000|0 11|Judge OKs docs
P10119827T0000|19 33|Chicago hospital
P10119827T0000|13 15|bid
P10120952T0000|0 4|HANYS
P10120952T0000|27 47|gall bladder guidelines
P10125354T0000|0 11|Groups dicker
P10125354T0000|38 40|gas
P10125354T0000|15 25|price breaks
P10132730T0000|8 18|CareNetwork
P10132730T0000|38 49|teacher union
P10132730T0000|52 55|Wis.
P10132730T0000|23 26|pact
P10134977T0000|0 4|JCAHO
P10134977T0000|12 20|hospitals
P10134977T0000|22 29|patience
P10146207A0223|0 14|Ultrasonography
P10146207A0223|64 73|cord injury
P10146207A0223|46 55|evaluation
P10153759A0360|0 3|UPMC
P10153759A0360|46 65|NHBC organ procurement
P10153759A0360|16 27|organization
P10171173A0955|62 68|disease
P10171173A0955|9 16|concerns
P10171173A0955|183 192|hemorrhage
P10171173A0955|108 112|non-A
P10171173A0955|119 127|hepatitis
P10171173A0955|26 30|blood
P10171173A0955|152 165|research effort
P10171173A0955|217 222|bypass
P10171173A0955|87 104|deficiency syndrome
P10171173A0955|241 251|circulation
P10181397A0641|117 128|United States
P10181397A0641|78 86|countries
P10181397A0641|12 17|trends
P10181397A0641|20 28|fertility
P10181397A0641|54 70|gender differences
P10181397A0641|30 49|life expectancy ratios
P10181397A0641|102 111|population
P10184191T0045|0 5|Holger
P10187317T0000|0 7|Hospital
P10187317T0000|20 34|AHERF physicians
P10187798A1098|131 134|U2OS
P10187798A1098|22 26|DAP-1
P10187798A1098|110 129|osteosarcoma cell line
P10187798A1098|42 50|apoptosis
P10187798A1098|66 87|L929 fibroblast cell line
P10187798A1098|0 13|Overexpression
P10187798A1098|29 35|sentrin
P10187842A1155|115 119|sites
P10187842A1155|86 90|motif
P10187842A1155|8 15|contrast
P10187842A1155|134 142|PPARalpha
P10187842A1155|79 82|site
P10187842A1155|18 27|PPARgamma2
P10187864A1372|68 77|regulation
P10187864A1372|19 22|KCC3
P10187864A1372|29 34|member
P10187864A1372|5 11|results
P10187864A1372|82 85|KCC1
P10187864A1372|40 48|KCC family
P10190324A0000|73 80|stenosis
P10190324A0000|154 157|SVAS
P10190324A0000|17 27|elastin gene
P10190324A0000|82 85|SVAS
P10190324A0000|31 39|mutations
P10190324A0000|120 127|families
P10191090A0000|61 71|development
P10191090A0000|14 23|expression
P10191090A0000|29 36|PAX3 gene
P10192134A1088|0 7|25-OH-D3
P10192134A1088|35 40|health
P10192134A1088|66 82|micrograms/kg feed
P10192134A1088|107 119|turkey rations
P10192134A1088|96 104|vitamin D3
P10192134A1088|54 61|use level
P10192432A0214|1 4|list
P10192432A0214|141 148|criteria
P10192432A0214|20 26|disease
P10192432A0214|9 13|names
P10192432A0214|132 138|core set
P10192432A0214|42 49|criteria
P10192432A0214|90 96|experts
P10192432A0214|65 78|Consensus Panel
P10192432A0214|112 116|order
P10192638T0000|0 22|Methanesulfonyl fluoride
P10192638T0000|68 73|safety
P10192638T0000|24 26|MSF
P10192638T0000|107 114|dementia
P10192638T0000|77 84|efficacy
P10192638T0000|61 65|study
P10192638T0000|120 132|Alzheimer type
P10192638T0000|90 98|treatment
P10193950A0478|0 6|METHODS
P10193950A0478|94 97|bone
P10193950A0478|76 92|prostate carcinoma
P10193950A0478|124 127|risk
P10193950A0478|59 60|T3
P10193950A0478|15 20|August
P10193950A0478|72 74|TNM
P10193950A0478|40 42|men
P10193950A0478|130 149|lymph node involvement
P10193950A0478|55 56|T2
P10193950A0478|194 215|staging lymphadenectomy
P10193950A0478|28 31|June
P10193950A0478|174 182|pendetide
P10194225A1132|88 97|glycerol Ra
P10194225A1132|9 13|wheel
P10194225A1132|66 77|pyruvate Gneo
P10194225A1132|57 63|alanine
P10194230A0817|16 22|surgery
P10194230A0817|88 89|nM
P10194230A0817|40 62|adenosine concentrations
P10194230A0817|24 36|dialysate PGE2
P10194451A0000|208 221|p210 substrates
P10194451A0000|184 187|goal
P10194451A0000|26 37|relationship
P10194451A0000|57 60|p210
P10194451A0000|158 160|CML
P10194451A0000|260 274|progenitor cells
P10194451A0000|231 246|chronic-phase CML
P10194451A0000|70 98|protein tyrosine kinase activity
P10194451A0000|102 115|manifestations
P10194451A0000|169 177|expansion
P10194451A0000|149 156|leukemia
P10194451A0000|62 68|bcr/abl
P10194762A0648|226 232|alanine
P10194762A0648|208 213|STAT5a
P10194762A0648|147 152|ERK1/2
P10194762A0648|134 144|association
P10194762A0648|160 172|fusion protein
P10194762A0648|25 63|glutathione-S-transferase-fusion protein
P10194762A0648|110 115|STAT5a
P10194762A0648|197 202|serine
P10194762A0648|7 19|precipitation
P10194762A0648|87 107|transactivation domain
P10194769A0146|41 43|rat
P10194769A0146|53 73|cDNA expression library
P10194769A0146|146 152|protein
P10194769A0146|80 101|417-amino acid WD protein
P10194769A0146|7 13|element
P10194769A0146|113 116|PREB
P10194769A0146|118 120|PRL
P10194769A0146|31 35|clone
P10194769A0146|131 144|element binding
P10194769A0146|15 16|1P
P10195425T0000|0 15|Characterization
P10195425T0000|21 44|transcription factor MTF-1
P10195425T0000|103 114|conservation
P10195425T0000|71 82|Fugu rubripes
P10195425T0000|122 140|metal stress response
P10195425T0000|60 69|pufferfish
P10195690A0000|45 49|PPARs
P10195690A0000|73 98|hormone receptor superfamily
P10195690A0000|54 60|members
P10195690A0000|3 12|peroxisome
P10195690A0000|35 43|receptors
P10195697A0456|63 79|enhancing activity
P10195697A0456|8 20|F-SRC-1 mutant
P10195697A0456|43 48|domain
P10196127A1059|58 65|residues
P10196127A1059|12 15|site
P10196127A1059|21 28|S1 pocket
P10196127A1059|82 100|pyroglutamyl residue
P10196248A0482|43 50|sequence
P10196248A0482|56 57|nt
P10196248A0482|19 27|TTV genome
P10196248A0482|105 108|arms
P10196248A0482|131 137|stretch
P10196248A0482|59 60|nt
P10196248A0482|156 157|nt
P10196248A0482|153 153|%
P10196248A0482|139 147|GC content
P10196266A0000|85 87|MCF
P10196266A0000|62 83|mink cell focus-inducing
P10196266A0000|89 96|subgroup
P10196266A0000|105 119|leukemia viruses
P10196266A0000|38 46|infection
P10196266A0000|8 24|mouse Mus castaneus
P10196266A0000|121 125|MuLVs
P10196316A0715|14 21|function
P10196316A0715|31 41|virus growth
P10196316A0715|24 28|VZV gK
P10196316A0715|88 90|VZV
P10196316A0715|44 49|series
P10196316A0715|52 68|gK deletion mutants
P10196316A0715|114 122|Oka strain
P10196316A0715|97 99|DNA
P10196318T0000|0 23|CCAAT displacement protein
P10196318T0000|80 81|E7
P10196318T0000|77 78|E6
P10196318T0000|58 75|papillomavirus type
P10196318T0000|86 96|E1 promoters
P10196597A0510|32 38|studies
P10196597A0510|9 16|findings
P10196597A0510|68 82|characteristics
P10196597A0510|85 96|drink drivers
P10197763A0580|47 64|AMP response element
P10197763A0580|27 35|mutations
P10197763A0580|107 107|%
P10197763A0580|79 101|nerve growth factor effect
P10197985A0145|146 148|U11
P10197985A0145|226 242|pre-mRNA substrate
P10197985A0145|47 62|oligonucleotides
P10197985A0145|106 107|ss
P10197985A0145|132 134|BPS
P10197985A0145|216 220|sites
P10197985A0145|136 143|elements
P10197985A0145|152 160|U12 snRNPs
P10197985A0145|255 270|complex formation
P10197985A0145|189 201|cooperativity
P10197985A0145|74 84|recognition
P10197985A0145|112 130|branchpoint sequence
P10197985A0145|7 27|RNase H protection assay
P10198003A1505|0 7|Analysis
P10198003A1505|10 13|lacZ
P10198003A1505|84 93|expression
P10198003A1505|96 99|rsmB
P10198003A1505|29 35|fusions
P10198003A1505|60 64|sites
P10198056A0000|14 32|cell surface proteins
P10198056A0000|49 60|lipid bilayer
P10198056A0000|97 99|GPI
P10198056A0000|68 95|glycosylphosphatidylinositol
P10198061A0339|14 24|import assay
P10198061A0339|104 106|Ran
P10198061A0339|26 37|beta-catenin
P10198061A0339|96 102|cytosol
P10198061A0339|110 116|ATP/GTP
P10198061A0339|60 66|nucleus
P10198061A0339|86 93|addition
P10199539A1353|85 87|VO2
P10199539A1353|61 63|cyt
P10199539A1353|112 118|hypoxia
P10199539A1353|20 26|hypoxia
P10199539A1353|66 81|a3 oxidation level
P10199539A1353|35 45|correlation
P10199539A1353|120 121|r2
P10200473A0171|117 123|FLAME-1
P10200473A0171|104 109|Casper
P10200473A0171|130 136|I-FLICE
P10200473A0171|111 115|CLARP
P10200473A0171|36 42|process
P10200473A0171|125 128|FLIP
P10200473A0171|21 29|regulator
P10200473A0171|49 55|Usurpin
P10200473A0171|85 91|Usurpin
P10200473A0171|140 143|MRIT
P10200473A0171|99 102|CASH
P10200473A0171|75 81|aliases
P10201468A0297|0 12|Plasma glucose
P10201468A0297|36 38|IRI
P10201468A0297|41 49|C-peptide
P10201468A0297|28 34|insulin
P10201468A0297|80 88|time point
P10201468A0297|51 58|glucagon
P10201468A0297|95 98|OGTT
P10201468A0297|63 73|GLP-1 levels
P10202006A0546|15 21|product
P10202006A0546|76 78|SPA
P10202006A0546|26 38|fusion protein
P10202006A0546|44 50|B domain
P10202006A0546|67 74|protein A
P10202006A1266|0 13|Polypyrimidine
P10202006A1266|154 160|binding
P10202006A1266|180 194|polypyrimidines
P10202006A1266|229 240|immunization
P10202006A1266|17 28|ssDNA binding
P10202006A1266|42 49|VH domain
P10202006A1266|164 169|ligand
P10202006A1266|209 222|B cell selection
P10202006A1266|82 83|Ab
P10202006A1266|113 126|autoantibodies
P10202006A1266|245 249|Z-DNA
P10202006A1266|96 103|activity
P10202006A1266|203 206|role
P10203611T0000|0 52|Technetium-99m methylene diphosphonate scintimammography
P10203611T0000|56 65|evaluation
P10203611T0000|76 87|breast masses
P10205099A0377|0 12|INTERVENTIONS
P10205099A0377|154 156|day
P10205099A0377|204 205|I4
P10205099A0377|100 102|day
P10205099A0377|130 132|T16
P10205099A0377|97 98|mg
P10205099A0377|173 177|weeks
P10205099A0377|151 152|mg
P10205099A0377|187 191|weeks
P10205099A0377|161 164|week
P10205099A0377|14 26|Study patients
P10205099A0377|112 116|weeks
P10205099A0377|136 147|itraconazole
P10205099A0377|118 126|groups T12
P10205099A0377|83 93|terbinafine
P10205099A0377|62 67|groups
P10205099A0377|193 200|groups I3
P10205176A0000|17 19|NRs
P10205176A0000|49 63|transregulators
P10205176A0000|116 123|features
P10205176A0000|141 147|control
P10205176A0000|82 91|yeast cells
P10205176A0000|7 15|receptors
P10205176A0000|175 183|evolution
P10205176A0704|60 72|transcription
P10205176A0704|38 43|domain
P10205176A0704|45 48|PSU1
P10205588A0000|60 68|infection
P10205588A0000|88 99|streptococci
P10205588A0000|150 164|characteristics
P10205588A0000|46 54|arthritis
P10205588A0000|119 125|beta HSA
P10205588A0000|132 139|emphasis
P10205588A0000|102 117|Lancefield group A
P10205588A0000|34 41|patients
P10205588A0000|179 186|features
P10205588A0000|0 8|OBJECTIVE
P10205933A0699|0 7|Bacteria
P10205933A0699|168 178|Lyme Disease
P10205933A0699|21 33|labyrinthitis
P10205933A0699|115 122|syphilis
P10205933A0699|147 157|spirochaete
P10205933A0699|93 103|spirochaete
P10205933A0699|73 90|Treponemas Pallidum
P10205933A0699|58 60|ear
P10206152A1024|58 64|minimum
P10206152A1024|67 68|G1
P10206152A1024|48 54|mitosis
P10206152A1024|107 118|messenger RNA
P10206152A1024|29 35|protein
P10206152A1024|92 101|expression
P10206152A1024|14 23|expression
P10206152A1024|39 45|maximum
P10206698A2041|44 54|mutagenesis
P10206698A2041|91 95|genes
P10206698A2041|113 119|ability
P10206698A2041|64 71|approach
P10206698A2041|138 142|tract
P10206698A2041|5 12|findings
P10206959A0368|0 5|Pathol
P10207041A0065|83 97|protein products
P10207041A0065|13 21|cell cycle
P10207041A0065|34 37|part
P10207041A0065|51 63|transcription
P10207041A0065|66 76|cyclin genes
P10207041A0065|151 157|kinases
P10207049A0693|42 45|type
P10207049A0693|31 37|subunit
P10207049A0693|47 87|serine/threonine phosphoprotein phosphatase
P10207049A0693|3 10|GAC1 gene
P10207049A0693|89 92|Glc7
P10207049A1001|28 42|Glc7 phosphatase
P10207049A1001|63 73|subunit play
P10207049A1001|89 101|HSF activation
P10207049A1001|49 52|Gac1
P10207049A1001|104 120|CUP1 transcription
P10207049A1001|82 86|roles
P10207049A1001|3 9|results
P10207087A0956|0 2|MEF
P10207087A0956|54 82|promoter reporter gene construct
P10207087A0956|129 131|MEF
P10207087A0956|90 107|activating activity
P10207087A0956|110 112|MEF
P10207087A0956|6 10|AML1B
P10207087A0956|150 157|AML1/ETO
P10207087A0956|42 52|interleukin
P10207090A0801|19 26|presence
P10207090A0801|32 34|GRR
P10207090A0801|88 95|molecule
P10207090A0801|55 65|degradation
P10207090A0801|68 70|p50
P10207092A0924|75 95|protein kinase activity
P10207092A0924|4 18|phosphorylation
P10207092A0924|103 118|sea urchin nucleus
P10207115A0389|30 34|level
P10207115A0389|83 91|mechanism
P10207115A0389|37 39|p21
P10208865A1246|42 48|mrIhh-N
P10208865A1246|81 94|resorption pits
P10208865A1246|23 40|osteoclast cultures
P10208865A1246|97 109|dentine slices
P10208865A1246|70 78|formation
P10208893A0839|60 76|WAD goat population
P10208893A0839|38 46|genotypes
P10208893A0839|11 17|results
P10209021A0212|73 82|mRNA export
P10209021A0212|12 20|mechanism
P10209021A0212|52 70|interaction function
P10209021A0212|28 32|Gle2p
P10209031A0832|118 132|phosphorylation
P10209031A0832|164 187|zeta ITAM phosphotyrosines
P10209031A0832|86 95|SH2 domains
P10209031A0832|63 66|zeta
P10209031A0832|135 151|zeta ITAM tyrosines
P10209031A0832|74 82|Fyn kinase
P10209031A0832|48 58|interaction
P10209031A0832|3 16|Fyn NH2 terminus
P10209119A0076|190 200|proteolysis
P10209119A0076|18 29|protein Skp1p
P10209119A0076|66 92|F-box/WD-repeat protein Cdc4p
P10209119A0076|9 13|yeast
P10209119A0076|169 171|Cdk
P10209119A0076|47 58|member Cdc53p
P10209119A0076|173 186|inhibitor Sic1p
P10209119A0076|100 129|SCFCdc4p ubiquitin ligase complex
P10209119A0076|162 167|kinase
P10209119A0594|207 217|proteolysis
P10209119A0594|196 204|functions
P10209119A0594|50 61|similarities
P10209119A0594|66 69|pop1
P10209119A0594|109 126|deletion phenotypes
P10209119A0594|73 81|pop2 genes
P10209759T0000|0 14|Antithrombin III
P10209759T0000|25 27|min
P10209759T0000|69 72|rats
P10209759T0000|42 66|ischemia reperfusion injury
P10210952A0261|16 24|diagnoses
P10210952A0261|55 62|criteria
P10210952A0261|2 11|retrospect
P10211329A0457|118 128|involvement
P10211329A0457|78 85|evidence
P10211329A0457|88 97|malignancy
P10211329A0457|27 37|serum lipase
P10211329A0457|63 70|syndrome
P10211329A0457|135 142|disorder
P10211329A0457|5 16|observations
P10211329A0457|54 60|Sjogren
P10211329A0457|41 47|serum CA
P10211422T0000|5 16|pancreatitis
P10211422T0000|34 52|polyarteritis nodosa
P10211422T0000|20 31|complication
P10211919A0846|179 194|CGI Severity scale
P10211919A0846|88 91|week
P10211919A0846|83 85|end
P10211919A0846|44 58|sertraline group
P10211919A0846|20 30|improvement
P10211919A0846|172 175|NIMH
P10211919A0846|110 128|CGI Improvement scale
P10211919A0846|138 140|end
P10211919A0846|143 147|weeks
P10211919A0846|32 32|p
P10211919A0846|98 103|Y-BOCS
P10212278A0387|16 29|protein kinases
P10212278A0387|188 191|MAPK
P10212278A0387|116 128|protein kinase
P10212278A0387|174 186|protein kinase
P10212278A0387|130 137|SAPK/JNK
P10212278A0387|215 223|molecules
P10212278A0387|142 151|p38 members
P10212278A0387|87 105|protein kinase/c-Jun
P10212278A0387|193 203|superfamily
P10212278A0387|49 63|c-jun expression
P10212284A0000|30 34|beta1
P10212284A0000|55 70|matrix deposition
P10212284A0000|25 27|TGF
P10212284A0000|12 23|growth factor
P10212284A0000|100 104|cells
P10212284A0000|74 86|proliferation
P10212332T0000|0 17|Chronotherapeutics
P10212332T0000|34 40|disease
P10212426A1067|0 4|Group
P10212426A1067|96 101|values
P10212426A1067|104 108|delta
P10212426A1067|124 128|study
P10212426A1067|63 70|decrease
P10212426A1067|42 52|hearing loss
P10212426A1067|29 37|listeners
P10212426A1067|17 25|functions
P10212426A1067|73 83|performance
P10212969A0470|0 11|Uroflowmetry
P10212969A0470|21 27|dysuria
P10212969A0470|72 79|subjects
P10214610A0900|34 44|percentiles
P10214610A0900|12 20|variation
P10214610A0900|58 60|age
P10215485A0837|101 102|NA
P10215485A0837|93 97|mI/Cr
P10215485A0837|36 41|status
P10215485A0837|11 22|correlations
P10215485A0837|68 83|State Examination
P10215485A0837|87 91|NA/mI
P10215594A1728|0 7|Glucagon
P10215594A1728|93 96|CRE1
P10215594A1728|49 52|CRE1
P10215594A1728|151 153|pO2
P10215594A1728|105 123|2SV40-LUC constructs
P10215594A1728|19 29|LUC activity
P10215594A1728|78 86|induction
P10215594A1728|56 64|CRE2 sites
P10215594A1728|100 103|CRE2
P10215608A0161|71 77|rGST Yc1
P10215608A0161|62 69|rat GSTA3
P10215608A0161|79 89|subunit gene
P10215608A0161|23 31|isolation
P10215608A0161|35 50|characterization
P10215608A0161|6 10|study
P10215803T0000|45 60|calcium gluconate
P10215803T0000|35 42|infusion
P10215811A0635|16 23|bleeding
P10215811A0635|77 79|EVL
P10215811A0635|37 47|eradication
P10215811A0635|65 72|sessions
P10215811A0635|7 13|control
P10215850A0754|99 100|kb
P10215850A0754|52 60|TrxR2 gene
P10215850A0754|119 130|localization
P10215850A0754|79 83|exons
P10215850A0754|133 147|position 22q11.2
P10215850A0754|30 41|organization
P10216052A0105|314 322|questions
P10216052A0105|304 311|subgroup
P10216052A0105|72 81|disability
P10216052A0105|154 165|disabilities
P10216052A0105|89 93|tasks
P10216052A0105|134 146|interrelation
P10216052A0105|268 276|field loss
P10216052A0105|13 17|study
P10216052A0105|337 344|validity
P10216052A0105|43 51|frequency
P10216052A0105|105 120|glaucoma patients
P10216052A0105|226 235|difficulty
P10216052A0105|252 259|severity
P10216052A0105|54 57|self
P10216052A0105|171 184|factor analysis
P10216052A0105|196 203|relation
P10216052A0105|365 372|subgroup
P10216052A0105|240 246|measure
P10216052A0105|3 6|aims
P10216052A0105|348 358|reliability
P10216052A0105|375 383|questions
P10216052A0105|288 295|glaucoma
P10216052A1682|197 204|glaucoma
P10216052A1682|150 158|field loss
P10216052A1682|223 231|questions
P10216052A1682|179 187|variables
P10216052A1682|125 132|severity
P10216052A1682|15 22|validity
P10216052A1682|213 220|subgroup
P10216052A1682|73 73|r
P10216052A1682|40 48|questions
P10216052A1682|94 104|correlation
P10216052A1682|169 173|score
P10216052A1682|113 119|measure
P10216052A1682|81 81|p
P10216052A1682|32 37|subset
P10216161A1530|88 95|proteins
P10216161A1530|192 195|type
P10216161A1530|41 48|homologs
P10216161A1530|20 32|cytochromes bd
P10216161A1530|208 233|B. stearothermophilus enzyme
P10216161A1530|258 261|type
P10216161A1530|165 166|bd
P10216161A1530|60 68|organisms
P10216161A1530|118 128|subfamilies
P10216161A1530|146 149|type
P10216161A1530|0 17|Sequence comparison
P10217683A0509|0 20|Canalith repositioning
P10217683A0509|26 33|mainstay
P10217683A0509|36 44|treatment
P10218109T0000|0 16|Solution structure
P10218109T0000|34 57|MutT pyrophosphohydrolase
P10218109T0000|20 28|mechanism
P10218200A0534|4 7|eyes
P10218200A0534|37 46|micrograms
P10218200A0534|60 85|tissue plasminogen activator
P10218200A0534|112 114|hrs
P10218357A0486|89 101|cuff-pressure
P10218357A0486|36 45|cuff-tubes
P10218357A0486|108 118|anaesthesia
P10218357A0486|10 20|CONCLUSIONS
P10218357A0486|79 86|increase
P10218357A0486|47 48|G2
P10218357A0486|22 27|Brandt
P10218357A0486|123 125|N2O
P10218357A0486|0 6|RESULTS
P10219091A0246|44 49|enzyme
P10219091A0246|28 35|gene CTL1
P10220275A0694|3 9|binding
P10220275A0694|112 118|Gialpha
P10220275A0694|12 20|PH domains
P10220275A0694|23 32|Gbetagamma
P10220275A0694|62 71|Gbetagamma
P10220275A0694|47 59|preincubation
P10220275A0694|106 109|form
P10220364A0087|30 39|supernovae
P10220364A0087|5 14|afterglows
P10220364A0087|61 70|hypernovae
P10221467T0000|62 83|dopamine agonist therapy
P10221467T0000|12 23|pericarditis
P10221467T0000|111 117|disease
P10221467T0000|42 48|disease
P10221467T0000|85 95|cabergoline
P10221467T0000|100 108|Parkinson
P10221820A0902|17 20|APBD
P10221820A0902|111 121|coexistence
P10221820A0902|11 14|type
P10221820A0902|47 49|AMT
P10221820A0902|124 127|APBD
P10221820A0902|77 86|clinicians
P10221820A0902|131 133|AMT
P10223338A1601|73 80|HIV-2 gag
P10223338A1601|125 131|HIV-1RF
P10223338A1601|48 60|fusion protein
P10223338A1601|114 121|HIV-1SF2
P10223338A1601|96 104|HIV-1IIIB
P10223338A1601|106 112|HIV-1MN
P10223338A1601|2 9|addition
P10223338A1601|85 93|V3 domains
P10223338A2186|95 109|HIV/AIDS vaccine
P10223338A2186|52 56|HIV-1
P10223338A2186|44 49|clades
P10223338A2186|22 31|V3 peptides
P10223338A2186|66 73|HIV-2 gag
P10223338A2186|3 9|results
P10223498A0479|144 159|Erectile Function
P10223498A0479|44 50|ability
P10223498A0479|23 31|responses
P10223498A0479|103 110|erection
P10223498A0479|74 81|question
P10223498A0479|62 69|erection
P10223498A0479|161 164|IIEF
P10223498A0479|117 141|15-item International Index
P10223498A0479|84 90|ability
P10223498A0479|0 7|Efficacy
P10224244T0000|14 24|involvement
P10224244T0000|76 85|regulation
P10224244T0000|30 49|Glc7-Reg1 phosphatase
P10224244T0000|88 104|INO1 transcription
P10224244T0000|56 70|Snf1-Snf4 kinase
P10224244T0000|0 7|Evidence
P10224257A0079|115 116|P2
P10224257A0079|105 110|region
P10224257A0079|79 80|P1
P10224257A0079|33 38|her-1b
P10224257A0079|24 29|her-1a
P10224257A0079|2 8|XO males
P10224257A0079|69 77|promoters
P10224257A0079|141 146|intron
P10224257A0079|13 22|her-1 mRNAs
P10224289T0000|0 8|Induction
P10224289T0000|11 29|Fas ligand expression
P10224289T0000|32 34|HIV
P10224289T0000|69 90|T cell receptor zeta chain
P10224289T0000|46 56|interaction
P10224289T0000|59 61|Nef
P10224293A0000|150 155|motifs
P10224293A0000|36 40|RPTPs
P10224293A0000|91 108|phosphatase domains
P10224293A0000|51 56|family
P10224293A0000|114 123|ectodomain
P10224293A0000|0 34|Receptor protein tyrosine phosphatases
P10224293A0000|59 66|proteins
P10224293A2021|60 66|studies
P10224293A2021|23 34|brain regions
P10224293A2021|46 50|basis
P10224293A2021|69 86|RPTP-kappa function
P10224513A0240|30 40|arithmetics
P10224513A0240|105 114|interviews
P10224513A0240|92 101|videotapes
P10224513A0240|12 20|stressors
P10224513A0240|57 66|Stroop test
P10224513A0240|68 83|videogame playing
P10224513A0240|85 89|films
P10224513A0240|42 52|speech tasks
P10224758A0202|3 14|control group
P10224758A0202|24 40|afterbirth samples
P10224758A0202|67 77|pregnancies
P10225279A0450|127 130|gene
P10225279A0450|21 24|gene
P10225279A0450|77 79|ORF
P10225279A0450|46 54|UL55 genes
P10225279A0450|59 66|homology
P10225279A0450|143 159|pseudorabies virus
P10225279A0450|35 42|MDV2 UL54
P10225279A0450|81 85|ORF-1
P10225279A0450|95 109|herpesvirus type
P10225945A0436|14 17|loss
P10225945A0436|34 40|meiosis
P10225945A0436|20 31|MAD2 staining
P10225945A0436|110 116|measure
P10225945A0436|163 174|kinetochores
P10225945A0436|178 184|meiosis
P10225945A0436|119 125|tension
P10225945A0436|68 88|microtubule attachment
P10225945A0436|2 9|contrast
P10225945A0436|130 137|distance
P10226029A0905|131 135|serum
P10226029A0905|79 85|contact
P10226029A0905|104 111|contacts
P10226029A0905|12 16|cells
P10226029A0905|21 28|PH domain
P10226029A0905|122 128|absence
P10226029A0905|49 53|sites
P10226029A0905|31 37|Akt/PKB
P10226074A0637|107 110|exon
P10226074A0637|26 32|regions
P10226074A0637|53 57|exons
P10226074A0637|66 85|translation start site
P10226838A1011|115 120|energy
P10226838A1011|75 85|stimulation
P10226838A1011|47 56|electrodes
P10226838A1011|89 91|60s
P10226838A1011|3 10|motility
P10226838A1011|13 17|sperm
P10228009A0600|28 32|IL-17
P10228009A0600|48 50|TNF
P10228009A0600|35 44|IEC-6 cells
P10228009A0600|92 96|TRAF2
P10228009A0600|70 77|factor-6
P10228009A0600|79 83|TRAF6
P10228009A0600|0 8|Induction
P10228009A0600|14 25|CINC promoter
P10228155A1293|0 6|SCFFWD1
P10228155A1293|60 69|regulation
P10228155A1293|23 38|tumor development
P10228155A1293|42 52|suppression
P10228155A1293|72 99|beta-catenin protein stability
P10228157T0000|16 39|spindle checkpoint pathway
P10228157T0000|52 62|Dbf2p kinase
P10228157T0000|72 76|yeast
P10228561A0539|120 126|modules
P10228561A0539|63 70|residues
P10228561A0539|88 100|DNA phosphates
P10228561A0539|77 83|contact
P10228561A0539|34 50|DNA polymerase beta
P10228561A0539|20 31|organization
P10228795A0842|0 6|RESULTS
P10228795A0842|66 79|nerve responses
P10228795A0842|96 98|IAS
P10228795A0842|82 84|EFS
P10228795A0842|19 24|nerves
P10228795A0842|47 56|regulation
P10229084A0000|243 246|pp43
P10229084A0000|261 285|protein tyrosine kinase Pyk2
P10229084A0000|156 169|protein complex
P10229084A0000|340 347|SLAP-130
P10229084A0000|315 329|adaptor proteins
P10229084A0000|46 63|immunoprecipitates
P10229084A0000|227 241|phosphoproteins
P10229084A0000|15 32|gel electrophoresis
P10229084A0000|103 114|T lymphocytes
P10229084A0000|128 141|identification
P10229084A0000|248 251|pp72
P10229084A0000|253 256|pp85
P10229084A0000|331 336|SKAP55
P10229084A0000|204 206|Fyn
P10229668A0190|15 26|cdc33 mutants
P10229668A0190|39 40|G1
P10229668A0560|42 48|Cln3-1p
P10229668A0560|108 117|dependence
P10229668A0560|80 90|translation
P10229668A0560|66 73|CLN3 mRNA
P10229668A0560|53 62|hybrid UBI4
P10229668A0560|147 155|cell cycle
P10229668A0560|36 40|Cln3p
P10229668A0560|120 124|eIF4E
P10229668A0560|1 13|cdc33-1 strain
P10229682A1151|156 166|NF-IL-6 site
P10229682A1151|10 15|motifs
P10229682A1151|203 208|region
P10229682A1151|19 32|gene expression
P10229682A1151|147 154|sequence
P10229682A1151|87 96|kappaB site
P10229682A1151|78 85|sequence
P10231026A0253|31 32|kb
P10231026A0253|62 68|introns
P10231026A0253|51 55|exons
P10231026A0253|18 21|Elk1
P10231026A0253|3 15|gene structure
P10231454A0731|131 137|U/liter
P10231454A0731|49 55|calcium
P10231454A0731|102 120|alkaline phosphatase
P10231454A0731|74 83|phosphorus
P10231454A0731|29 33|mg/dl
P10231454A0731|5 16|serum calcium
P10231454A0731|68 72|mg/dl
P10231454A0731|93 97|mg/dl
P10231485A0342|0 15|Sequence analysis
P10231485A0342|105 108|TtrB
P10231485A0342|86 91|4Fe-4S
P10231485A0342|126 133|clusters
P10231485A0342|184 202|quinol oxidation site
P10231485A0342|93 99|cluster
P10231485A0342|142 145|TtrC
P10231485A0342|119 124|4Fe-4S
P10231485A0342|41 80|molybdopterin guanine dinucleotide cofactor
P10231485A0342|158 172|membrane protein
P10231485A0342|28 31|TtrA
P10231513T0000|26 51|granulation tissue formation
P10231513T0000|67 71|study
P10231513T0000|13 23|differences
P10231513T0000|77 79|rat
P10231581A1125|45 52|SP1 sites
P10231581A1125|13 23|mutagenesis
P10231581A1125|63 66|exon
P10231581A1125|105 120|promoter activity
P10231862A1117|17 23|infants
P10231862A1117|110 121|contribution
P10231862A1117|93 96|week
P10231862A1117|67 71|acids
P10231862A1117|184 187|pool
P10231862A1117|153 158|plasma
P10231862A1117|99 102|life
P10231862A1117|134 142|synthesis
P10232078A0552|0 7|Ischemia
P10232078A0552|51 66|6-keto-PGF1 alpha
P10232078A0552|11 21|reperfusion
P10232078A0552|70 73|TXB2
P10232078A0552|42 48|release
P10232600T0000|17 23|antigen
P10232600T0000|97 119|prostate cancer cell lines
P10232600T0000|25 27|PSA
P10232600T0000|62 71|expression
P10232600T0000|74 94|sodium iodide symporter
P10232872A0081|67 76|population
P10232872A0081|48 55|subgroup
P10232872A0081|33 34|CD
P10233147A0218|0 4|Ras2p
P10233147A0218|112 118|cascade
P10233147A0218|22 27|growth
P10233147A0218|54 70|signaling pathways
P10233147A0218|93 110|Cdc42p/Ste20p/MAPK
P10233147A0218|152 165|Cyr1p/cAMP/PKA
P10233147A0218|167 173|pathway
P10233147A0218|138 150|protein kinase
P10233147A0218|75 91|filamentation MAPK
P10233885A0899|131 133|p32
P10233885A0899|137 147|p30 isoforms
P10233885A0899|113 125|mim-1 promoter
P10233885A0899|18 27|prediction
P10233885A0899|98 107|activation
P10233885A0899|29 41|transfections
P10233885A0899|62 75|cell line Jurkat
P10233946A0000|60 66|repeats
P10233946A0000|145 160|leukemia virus RNA
P10233946A0000|175 184|hypothesis
P10233946A0000|44 46|SNV
P10233946A0000|127 136|expression
P10233946A0000|8 11|work
P10233946A0000|24 42|spleen necrosis virus
P10233946A0000|214 220|element
P10233946A0000|189 194|SNV RNA
P10233946A0000|254 261|proteins
P10233946A0000|68 71|LTRs
P10234698A0728|29 35|effects
P10234698A0728|62 74|animal studies
P10234698A0728|88 99|pretreatment
P10234698A0728|38 51|CNS development
P10234698A0728|195 203|treatment
P10234698A0728|54 59|number
P10234698A0728|104 118|corticosteroids
P10234698A0728|141 145|brain
P10234698A0728|166 171|injury
P10235265A0197|57 62|system
P10235265A0197|5 13|mechanism
P10235265A0197|130 142|cyclin subunit
P10235265A0197|86 105|proteolysis machinery
P10235265A0197|126 128|Clb
P10236651T0000|0 9|Predictors
P10236651T0000|48 64|admission criteria
P10236651T0000|12 18|success
P10236651T0000|21 34|pharmacy school
P10236651T0000|36 39|PCAT
P10240361T0000|31 45|dissatisfaction
P10240361T0000|51 60|physicians
P10240361T0000|8 13|survey
P10243927A0000|154 159|spread
P10243927A0000|33 45|investigators
P10243927A0000|23 31|fire tests
P10243927A0000|51 70|IIT Research Institute
P10243927A0000|175 179|gases
P10243927A0000|113 116|room
P10243927A0000|3 8|series
P10243927A0000|119 128|fire origin
P10243927A0000|167 171|smoke
P10243927A0000|97 107|door control
P10271171A0458|69 72|unit
P10271171A0458|88 101|resource center
P10271171A0458|50 56|library
P10271171A0458|24 28|shift
P10271171A0458|6 10|LATCH
P10271171A0458|31 44|identification
P10281637A0000|0 8|Reporting
P10281637A0000|78 84|complex
P10281637A0000|70 74|drugs
P10281637A0000|47 52|trials
P10281637A0000|18 23|events
P10281637A0000|101 105|issue
P10304090T0000|0 18|Medicare SNF benefits
P10308312A0203|145 151|effects
P10308312A0203|33 45|understanding
P10308312A0203|74 83|ultrasound
P10308312A0203|51 71|interaction mechanisms
P10308312A0203|6 10|paper
P10308312A0203|22 27|status
P10308312A0203|109 115|factors
P10308312A0203|98 102|media
P10318806A0000|0 6|Members
P10318806A0000|138 143|kinase
P10318806A0000|82 87|kinase
P10318806A0000|217 225|cytokines
P10318806A0000|162 169|elements
P10318806A0000|186 191|signal
P10318806A0000|40 51|kinase family
P10318806A0000|148 150|p38
P10318806A0000|121 125|c-Jun
P10318806A0000|12 18|mitogen
P10318806A0000|105 119|protein kinase-1
P10318806A0000|36 38|MAP
P10318806A0000|203 215|growth factors
P10318806A0000|28 34|protein
P10318806A0000|239 244|agents
P10318806A0476|96 104|responses
P10318806A0476|12 16|study
P10318806A0476|49 52|role
P10318806A0476|63 72|MAP kinases
P10318806A0918|0 7|Analyses
P10318806A0918|228 247|phospholipase C-gamma
P10318806A0918|312 314|p38
P10318806A0918|100 115|Src family kinases
P10318806A0918|83 90|proteins
P10318806A0918|54 64|Src homology
P10318806A0918|211 226|phosphatase SHP-2
P10318806A0918|10 17|tyrosine
P10318806A0918|252 254|Crk
P10318806A0918|300 309|activation
P10318806A0918|117 144|phosphatidylinositol 3-kinase
P10318806A0918|166 172|protein
P10318806A0918|33 45|PDGF receptors
P10318806A0918|175 177|Ras
P10318806A0918|270 273|role
P10318806A0918|182 192|Src homology
P10318859A0535|61 83|tyrosine phosphorylation
P10318859A0535|98 105|paxillin
P10318859A0535|31 50|tyrosine phosphatases
P10318859A0535|14 22|calpeptin
P10318900A0637|203 210|particle
P10318900A0637|113 124|conformation
P10318900A0637|143 152|efficiency
P10318900A0637|27 33|studies
P10318900A0637|155 168|mRNA production
P10318900A0637|130 135|capsid
P10318900A0637|74 80|binding
P10318900A0637|39 60|electron cryomicroscopy
P10318900A0637|86 88|Fab
P10318900A0637|90 95|8H2/G5
P10318918A0824|75 79|motif
P10318918A0824|106 117|HCV genotypes
P10318918A0824|54 59|region
P10318918A0824|18 25|analysis
P10318918A0824|28 31|NS5A
P10319320A1022|147 153|control
P10319320A1022|35 41|16K hPRL
P10319320A1022|156 167|angiogenesis
P10319320A1022|19 26|findings
P10319320A1022|65 77|Ras activation
P10319320A1022|83 92|antagonism
P10319320A1022|132 140|mechanism
P10319327A1237|117 119|SRF
P10319327A1237|151 164|protein E12/E47
P10319327A1237|10 49|SRE oligonucleotide gel mobility shift assays
P10319327A1237|61 68|extracts
P10319327A1237|80 84|cells
P10319327A1237|100 107|presence
P10319327A1237|0 7|Analysis
P10319955A0941|29 42|occlusion rates
P10319955A0941|12 22|differences
P10319955A0941|64 67|test
P10319955A0941|48 51|chi2
P10319955A0941|53 62|chi-square
P10319955A0941|109 109|P
P10319955A0941|82 92|differences
P10320177A0487|0 27|Baseline electrocorticography
P10320177A0487|227 235|microg/kg
P10320177A0487|55 58|lobe
P10320177A0487|205 213|microg/kg
P10320177A0487|62 85|depth electrode recordings
P10320177A0487|91 98|amygdala
P10320177A0487|193 202|alfentanil
P10320177A0487|102 112|hippocampus
P10320177A0487|217 224|fentanyl
P10320177A0487|138 140|min
P10320177A0487|169 186|i.v. administration
P10320177A0487|35 41|surface
P10320177A0487|143 151|recording
P10320480A0451|82 92|beta subunit
P10320480A0451|101 113|RNA polymerase
P10320480A0451|51 54|role
P10320480A0451|18 23|system
P10320480A0451|67 76|C-terminus
P10320579A1831|13 16|FlgN
P10320579A1831|95 98|HAPs
P10320579A1831|20 23|FliT
P10320579A1831|122 128|domains
P10320579A1831|45 63|flagellar chaperones
P10320579A1831|135 140|export
P10320579A1831|75 89|oligomerization
P10321158T0000|56 59|core
P10321158T0000|34 39|canals
P10321158T0000|77 81|dowel
P10321158T0000|7 21|core fabrication
P10321158T0000|45 52|cast post
P10321158T0000|0 3|Post
P10322022A0263|0 5|Rep63A
P10322022A0263|45 47|ORF
P10322022A0263|21 22|aa
P10322022A0263|77 85|% identity
P10322022A0263|10 19|amino acids
P10322022A0263|142 149|pSM19035
P10322022A0263|193 206|pAMbeta1 family
P10322022A0263|115 130|plasmids pAMbeta1
P10322022A0263|132 137|pIP501
P10322022A0263|168 180|pAW63 replicon
P10322022A0263|92 110|replication proteins
P10322022A0263|64 73|similarity
P10322022A0263|239 246|plasmids
P10322629A0198|43 54|Xenopus Pax-5
P10322629A0198|92 101|gene family
P10322629A0198|25 40|characterization
P10322629A0198|83 87|Pax-2
P10322629A0198|67 77|orthologues
P10322629A0198|15 21|cloning
P10322629A0198|58 62|Pax-8
P10323225A0244|0 7|Km values
P10323225A0244|11 18|ammonium
P10323225A0244|52 54|NAD
P10323225A0244|35 38|NADH
P10323225A0244|40 48|glutamate
P10323225A0244|20 33|2-oxoglutarate
P10323225A0244|85 86|mM
P10323463T0000a|0 15|Interferon-alpha
P10323463T0000a|85 90|effect
P10323463T0000a|61 74|manifestations
P10323463T0000a|129 136|activity
P10323463T0000b|0 15|Interferon-alpha
P10323463T0000b|85 90|effect
P10323463T0000b|61 74|manifestations
P10323463T0000b|129 136|activity
P10323863A0852|87 110|rabbit reticulocyte lysate
P10323863A0852|79 84|factor
P10323863A0852|123 147|ribonucleoprotein assembly
P10323863A0852|31 40|production
P10323863A0852|2 9|addition
P10323863A0852|60 69|telomerase
P10325413A1211|88 97|propensity
P10325413A1211|109 113|helix
P10325413A1211|20 24|c-Abl
P10325413A1211|11 17|binding
P10325413A1211|184 194|interaction
P10325413A1211|172 175|base
P10325413A1211|27 63|DNA containing 5-methylcytosine residues
P10325413A1211|158 166|reduction
P10326221A0531|64 72|fulminans
P10326221A0531|23 30|children
P10326221A0531|10 17|mutation
P10326221A0531|48 51|legs
P10326221A0531|36 45|amputation
P10326654A0351|310 319|difference
P10326654A0351|157 161|group
P10326654A0351|98 104|minutes
P10326654A0351|183 194|fibrillation
P10326654A0351|222 232|arrhythmias
P10326654A0351|335 342|ischemia
P10326654A0351|325 332|duration
P10326654A0351|149 155|minutes
P10326654A0351|49 57|durations
P10326654A0351|277 278|VF
P10326654A0351|11 26|pilot experiments
P10326654A0351|141 145|study
P10326654A0351|216 219|form
P10326654A0351|73 80|ischemia
P10326654A0351|247 251|group
P10326654A0351|239 245|minutes
P10326654A0351|265 274|prevalence
P10326654A0351|196 197|VF
P10326654A0351|109 117|durations
P10326856T0000|50 67|purse-string device
P10326856T0000|12 33|pancreaticojejunostomy
P10327051A0688|90 94|Thr71
P10327051A0688|154 160|complex
P10327051A0688|82 86|Thr69
P10327051A0688|129 140|p300/CBP-ATF
P10327051A0688|115 123|formation
P10327051A0688|64 74|target sites
P10327051A0688|59 62|SAPK
P10327051A0688|27 57|Stress-Activated-Protein-Kinase
P10327051A0688|77 80|ATF2
P10328351A0443|0 11|Blood samples
P10328351A0443|64 64|d
P10328351A0443|39 59|supplementation period
P10328351A0443|76 76|d
P10329135A1326|5 11|results
P10329135A1326|63 70|mt-hsp70
P10329135A1326|36 47|presequences
P10329135A1326|97 109|protein import
P10329566A0610|58 66|structure
P10329566A0610|148 154|feature
P10329566A0610|75 89|valine anticodon
P10329566A0610|133 145|aminoacyl stem
P10329566A0610|103 111|structure
P10329566A0610|175 186|tetraviruses
P10329566A0610|118 127|pseudoknot
P10329566A0610|5 12|terminus
P10329566A0610|18 23|genome
P10329566A0610|167 172|genera
P10329574A1733|0 1|O.
P10329574A1733|11 15|RNA-7
P10329574A1733|124 132|deletions
P10329574A1733|54 56|RNA
P10329574A1733|79 81|RNA
P10329574A1733|94 105|OnuMV4-Ld RNA
P10329586A0414|123 124|FN
P10329586A0414|24 25|FN
P10329586A0414|12 22|fibronectin
P10329586A0414|107 120|overexpression
P10329586A0414|62 73|LNCaP-r cells
P10329586A0414|127 140|prostate cancer
P10329586A0414|7 10|gene
P10329625A0715|134 138|cells
P10329625A0715|143 146|FTOC
P10329625A0715|41 43|CD3
P10329625A0715|66 73|TCR genes
P10329625A0715|35 37|CD8
P10329625A0715|18 31|cell surface CD4
P10329625A0715|47 51|cells
P10329736A0681|68 77|p85 subunit
P10329736A0681|23 27|yeast
P10329736A0681|38 43|system
P10329736A0681|45 49|mIRS3
P10329736A0681|80 107|phosphatidylinositol 3-kinase
P10329736A1106|0 17|Insulin stimulation
P10329736A1106|51 53|p85
P10329736A1106|67 69|Shc
P10329736A1106|29 39|association
P10329736A1106|55 58|SHP2
P10329736A1106|42 46|mIRS3
P10329736A1106|60 62|Nck
P10330134A0765|3 16|mRNA expression
P10330134A0765|65 92|transient-transfection assays
P10330134A0765|136 143|promoter
P10330134A0765|24 27|RFX2
P10330134A0765|194 199|manner
P10330134A0765|106 120|RFX binding sites
P10330134A0765|19 22|RFX1
P10330134A0765|168 173|tissue
P10330134A0765|123 127|front
P10330134A0765|32 35|RFX3
P10330146A0730|26 31|intron
P10330146A0730|94 102|sequences
P10330146A0730|158 162|sites
P10330146A0730|143 150|deletion
P10330146A0730|109 128|luciferase expression
P10330146A0730|33 42|repression
P10330146A0730|5 8|case
P10330146A0730|45 64|luciferase expression
P10330159A1258|129 132|site
P10330159A1258|5 7|VDR
P10330159A1258|161 167|Jun-Fos
P10330159A1258|52 61|activation
P10330159A1258|68 84|promoter/enhancer
P10330159A1258|31 40|components
P10330159A1258|100 104|NFAT1
P10330159A1258|173 175|DNA
P10330168A0135|87 91|Cdc7p
P10330168A0135|26 32|kinases
P10330168A0135|144 145|G1
P10330168A0135|66 71|kinase
P10330168A0135|156 169|DNA replication
P10330168A0135|37 43|cyclin B
P10330168A0135|115 125|factor Dbf4p
P10330168A0135|45 47|Clb
P10330168A0135|73 82|Cdk/Cdc28p
P10330396A0387|44 47|CRM1
P10330396A0387|121 130|p62 complex
P10330396A0387|134 143|Can/Nup214
P10330396A0387|103 113|association
P10330396A0387|64 72|periphery
P10330396A0387|3 22|RanQ69L preincubation
P10330396A0387|97 99|NPC
P10330396A0387|85 95|pore complex
P10330396A0387|30 41|accumulation
P10331276A0298|33 41|structure
P10331276A0298|8 15|elements
P10331646A0595|2 9|contrast
P10331646A0595|159 171|amino terminus
P10331646A0595|21 37|amino acid sequence
P10331646A0595|121 129|abundance
P10331646A0595|47 52|family
P10331646A0595|61 72|transferases
P10331646A0595|188 201|signal sequence
P10331646A0595|276 282|protein
P10331646A0595|132 137|testis
P10331646A0595|223 236|signal sequence
P10331646A0595|90 102|lymphoma cells
P10331646A0595|242 257|carboxyl terminus
P10331646A0595|296 301|export
P10331646A0595|54 57|ART5
P10331730A0504|0 6|RESULTS
P10331730A0504|68 68|%
P10331730A0504|42 49|Sardinia
P10331730A0504|104 114|study period
P10331730A0504|12 15|year
P10331730A0504|31 35|cases
P10331730A0504|79 86|patients
P10331730A0504|145 151|centres
P10331730A0504|28 28|%
P10331875A0523|128 140|cooperativity
P10331875A0523|76 83|affinity
P10331875A0523|103 105|HSF
P10331875A0523|62 72|specificity
P10331875A0523|156 162|trimers
P10331875A0523|97 100|form
P10331875A0523|4 17|dimer interface
P10332733A0000|3 21|paramyxovirus fusion
P10332733A0000|25 31|protein
P10332733A0000|40 53|membrane fusion
P10332733A0000|23 23|F
P10333481A1102|103 118|promoter activity
P10333481A1102|34 37|UCP2
P10333481A1102|84 89|region
P10333481A1102|51 60|constructs
P10333481A1102|13 28|deletion analysis
P10333481A1102|136 137|nt
P10333481A1102|163 170|enhancer
P10333481A1102|190 191|bp
P10333481A1102|200 213|promoter region
P10333526A0459|3 11|hTERT gene
P10333526A0459|50 54|exons
P10333529A0277|4 14|betaAPP mRNA
P10333529A0277|18 28|Abeta levels
P10333529A0277|43 49|trisomy
P10334888A0960|59 66|increase
P10334888A0960|108 119|nondiabetics
P10334888A0960|95 97|min
P10334888A0960|30 34|group
P10334888A0960|69 86|IL-8 concentrations
P10334888A0960|2 13|reperfusion B
P10336495A0547|73 83|interaction
P10336495A0547|129 137|complexes
P10336495A0547|108 115|RXRalpha
P10336495A0547|25 32|agonists
P10336495A0547|91 94|NCoR
P10336495A0547|4 13|repression
P10336495A0547|98 106|PPARalpha
P10336495A0547|41 48|receptor
P10336495A0547|149 153|cells
P10339552A0361|28 37|SRm160/300
P10339552A0361|12 16|study
P10339552A0361|78 85|splicing
P10339552A0361|89 96|pre-mRNA
P10339552A0361|63 65|ESE
P10339552A0361|130 133|gene
P10339566A0602|72 83|Spc94p/Nud1p
P10339566A0602|95 100|Spc42p
P10339566A0602|85 90|Cnm67p
P10339566A0602|49 61|SPB subcomplex
P10339566A0602|26 34|component
P10339566A0602|0 5|Spc42p
P10340447A0424|60 62|QMF
P10340447A0424|24 34|correlation
P10340447A0424|10 21|coefficients
P10340447A0424|69 77|QIT system
P10340883A1266|14 22|stage IIIB
P10340883A1266|9 10|OS
P10340883A1266|49 53|stage
P10340883A1266|30 30|%
P10340883A1266|45 45|%
P10341219A0481|123 136|mass aggregates
P10341219A0481|12 32|heparin lyase treatment
P10341219A0481|45 49|cells
P10341219A0481|35 42|extracts
P10341219A0481|99 105|protein
P10341219A0481|71 86|YD-repeat protein
P10342511A0909|43 48|scores
P10342511A0909|3 13|coefficient
P10342511A0909|16 28|determination
P10342511A0909|30 31|r2
P10342536A0954|42 49|formulae
P10342536A0954|61 71|information
P10342536A0954|147 157|whey formula
P10342536A0954|110 113|milk
P10342536A0954|23 36|protein content
P10342536A0954|197 219|soy/pork collagen formula
P10342536A0954|105 107|cow
P10342536A0954|227 242|amino acid formula
P10342536A0954|5 17|determination
P10342536A0954|73 91|RAST/EAST inhibition
P10342536A0954|178 195|whey/casein formula
P10342829A0236|42 51|mechanisms
P10342829A0236|152 163|reproduction
P10342829A0236|106 111|hGnRHR
P10342829A0236|113 116|gene
P10342829A0236|127 131|issue
P10342829A0236|24 28|GnRHR
P10342829A0236|2 6|light
P10342829A0236|80 89|regulation
P10342829A0236|100 104|GnRHR
P10342829A0236|12 21|importance
P10342829A1370|57 63|extract
P10342829A1370|41 49|alphaT3-1
P10342829A1370|11 29|mobility shift assays
P10342829A1370|77 87|SF-1 protein
P10342829A1370|108 111|SF-1
P10342829A1370|148 157|GSE element
P10343189A0911|0 4|Grade
P10343189A0911|6 14|mucositis
P10343189A0911|29 35|patient
P10344736A0796|0 19|CDK4 kinase activities
P10344736A0796|44 49|levels
P10344736A0796|55 73|CDK inhibitor p21Cip1
P10344736A0796|83 104|cyclin E immunocomplexes
P10347144A0516|43 59|baculovirus system
P10347144A0516|91 93|kDa
P10347144A0516|22 28|protein
P10347144A0516|112 119|sequence
P10347144A0516|122 126|AVQGP
P10347144A0516|85 88|size
P10347197A0502|101 104|Grb2
P10347197A0502|68 80|co-expression
P10347197A0502|108 130|Sos1 expression construct
P10347197A0502|45 55|Met receptor
P10347197A0502|33 38|HGF/SF
P10347197A0502|0 8|Induction
P10347197A0502|14 30|urokinase promoter
P10347203A0832|146 158|proliferation
P10347203A0832|48 68|somatostatin treatment
P10347203A0832|23 27|STAT3
P10347203A0832|86 99|pertussis toxin
P10347203A0832|135 143|increases
P10347203A0832|0 20|Serine phosphorylation
P10347203A0832|102 103|PD
P10347220A1477|88 90|RNA
P10347220A1477|54 58|yeast
P10347220A1477|66 74|apparatus
P10347220A1477|116 137|RNA guanylyltransferase
P10347220A1477|236 274|triphosphatase-guanylyltransferase Mce1p
P10347220A1477|109 113|Cet1p
P10347220A1477|94 107|triphosphatase
P10347220A1477|281 301|methyltransferase Hcm1
P10347220A1477|202 210|apparatus
P10347220A1477|311 312|p.
P10347220A1477|139 143|Ceg1p
P10347220A1477|149 153|Abd1p
P10347839A0434|67 67|M
P10347839A0434|22 24|dog
P10347839A0434|53 53|M
P10347839A0434|32 38|bladder
P10347839A0434|16 18|rat
P10347839A0434|3 12|IC50 values
P10348859A0292|115 120|Cys117
P10348859A0292|124 129|Cys126
P10348859A0292|74 75|Hg
P10348859A0292|25 36|binding sites
P10348859A0292|105 111|monomer
P10348859A0292|80 82|ion
P10348859A0292|49 61|MerR homodimer
P10348859A0292|93 97|Cys82
P10349084T0000|121 127|purpura
P10349084T0000|26 44|virus seropositivity
P10349084T0000|50 57|efficacy
P10349084T0000|77 84|globulin
P10349084T0000|3 11|influence
P10349084T0000|87 94|children
P10349443A0358|111 111|%
P10349443A0358|63 68|larvae
P10349443A0358|21 30|field tests
P10349443A0358|73 78|values
P10349443A0358|50 60|infestation
P10349443A0358|3 9|results
P10349443A0358|42 47|levels
P10349443A0358|15 17|lab
P10349443A0358|97 97|%
P10350027A0942|87 97|performance
P10350027A0942|108 110|day
P10350027A0942|14 15|mg
P10350027A0942|33 39|effects
P10350027A0942|42 52|psychomotor
P10350027A0942|0 10|Amisulpride
P10350454A0000|0 3|MutY
P10350454A0000|95 97|G.A
P10350454A0000|48 57|mismatches
P10350454A0000|80 81|oG
P10350454A0000|67 78|8-oxoguanine
P10350454A0000|34 44|specificity
P10350454A0000|19 29|glycosylase
P10350454A0000|87 93|guanine
P10350484A0346|13 26|kinase activity
P10350484A0346|124 131|increase
P10350484A0346|137 140|Vmax
P10350484A0346|90 98|% decrease
P10350484A0346|38 46|complexes
P10350484A0346|109 111|ATP
P10350484A0346|104 105|KM
P10350484A0346|57 60|CheA
P10350484A0346|3 10|kinetics
P10350638A0000|0 6|Latexin
P10350638A0000|9 34|carboxypeptidase A inhibitor
P10350638A0000|67 72|manner
P10350638A0000|106 112|systems
P10350638A0000|50 53|cell
P10350638A0000|118 120|rat
P10353073A0118|0 17|Regression analyses
P10353073A0118|47 53|factors
P10353073A0118|29 32|risk
P10353880A0257|85 93|diagnosis
P10353880A0257|75 80|births
P10353880A0257|100 100|P
P10353880A0257|54 60|infants
P10353880A0257|96 98|HSV
P10355085A1119|0 6|Subsets
P10355085A1119|102 114|injury pattern
P10355085A1119|9 16|patients
P10355085A1119|61 63|ISS
P10355085A1119|119 127|survivors
P10355085A1119|134 145|nonsurvivors
P10355085A1119|44 51|severity
P10355085A1119|54 59|trauma
P10355536A0172|17 21|years
P10355536A0172|23 27|range
P10355536A0172|9 11|age
P10355536A0172|33 37|years
P10355910A0369|28 32|years
P10355910A0369|13 21|follow-up
P10355910A0369|24 26|age
P10357751A0866|116 119|risk
P10357751A0866|201 208|children
P10357751A0866|250 254|score
P10357751A0866|25 32|children
P10357751A0866|223 229|disease
P10357751A0866|136 139|risk
P10357751A0866|49 53|score
P10357751A0866|305 308|risk
P10357751A0866|72 74|FFM
P10357751A0866|122 126|death
P10357751A0866|10 14|group
P10357751A0866|60 65|weight
P10357751A0866|143 145|% CI
P10357751A0866|258 263|weight
P10358031A0303|85 92|division
P10358031A0303|109 119|cytokinesis
P10358031A0303|101 106|defect
P10358031A0303|126 139|cell separation
P10358031A0303|67 75|G2/M delay
P10358031A0303|48 53|nuclei
P10358031A0303|2 9|addition
P10358031A0303|16 20|cells
P10358075A0984|0 4|DAF16
P10358075A0984|150 152|PKB
P10358075A0984|124 131|receptor
P10358075A0984|111 121|insulin/IGF
P10358075A0984|133 146|PtdIns 3-kinase
P10358075A0984|17 25|component
P10358075A0984|29 44|signaling pathway
P10358075A0984|96 105|homologues
P10358079A0391|62 66|ErbB4
P10358079A0391|40 51|heterodimers
P10358079A0391|54 58|ErbB2
P10358079A0391|8 25|neu differentiation
P10358079A0391|76 80|Stat5
P10358080A1114|129 132|role
P10358080A1114|146 167|HSF1 binding preferences
P10358080A1114|8 20|linker regions
P10358080A1114|112 121|HSF1 linker
P10358080A1114|23 42|transcription factors
P10358080A1114|188 198|determinant
P10358080A1114|61 81|DNA binding specificity
P10358080A1114|214 242|HSF1 monomer-trimer equilibrium
P10358080A1114|86 92|studies
P10358080T0000|0 9|Modulation
P10358080T0000|50 61|linker domain
P10358080T0000|17 44|heat shock factor trimerization
P10358083A0263|162 165|GATA
P10358083A0263|174 192|transcription factor
P10358083A0263|200 204|sites
P10358083A0263|67 82|characterization
P10358083A0263|96 104|complexes
P10358083A0263|129 148|sequence motifs GTGACT
P10358083A0263|153 157|ATTGT
P10358083A0263|57 63|F9 cells
P10358083A0263|14 21|analyses
P10358083A0263|150 150|C
P10358138A0672|85 88|SLAM
P10358138A0672|62 70|signaling
P10358138A0672|37 39|XLP
P10358138A0672|26 34|phenotype
P10358138A0672|139 161|signaling adaptor protein
P10358138A0672|102 121|cell surface molecules
P10358138A0672|5 11|results
P10358138A0672|133 135|SAP
P10359014A1077|73 86|serine residues
P10359014A1077|56 64|threonine
P10359014A1077|18 42|Fra-2 phosphorylation sites
P10359014A1077|105 110|region
P10359014A1077|113 117|means
P10359014A1077|45 48|MAPK
P10359014A1077|160 176|threonine residues
P10359014A1077|198 201|MAPK
P10359014A1077|133 143|mutagenesis
P10359575A0317|131 134|hIgA
P10359575A0317|105 114|bFcgamma2R
P10359575A0317|91 95|bIgG2
P10359575A0317|65 67|IgA
P10359575A0317|69 72|hIgA
P10359575A0317|46 54|FcalphaRI
P10359575A0317|120 124|bIgG2
P10359575A0317|86 89|IgG2
P10359603A0430|0 4|Vac1p
P10359603A0430|22 41|Sec1p homologue Vps45p
P10359663A0425|201 231|oIFNtau-SV40-CAT transactivation
P10359663A0425|63 69|oIFNtau
P10359663A0425|136 140|bases
P10359663A0425|110 117|promoter
P10359663A0425|105 108|SV40
P10359663A0425|54 60|regions
P10359663A0425|176 189|enhancer region
P10359663A0425|84 88|front
P10359663A0425|122 128|regions
P10359663A0425|97 101|virus
P10359663A0425|30 35|system
P10359663A1280|118 123|GATA-2
P10359663A1280|65 79|transactivation
P10359663A1280|82 92|oIFNtau-CAT
P10359663A1280|49 53|c-Fos
P10359663A1280|126 131|GATA-3
P10359663A1280|40 44|c-Jun
P10359663A1280|99 108|expression
P10359663A1280|111 116|GATA-1
P10359663A1280|2 23|co-transfection studies
P10359663A1280|28 37|expression
P10359664A0579|61 77|lysyl endoprotease
P10359664A0579|40 45|MARCKS
P10359664A0579|91 105|electrospray MS.
P10359664A0579|15 19|sites
P10359673A0000|3 15|yeast LPD1 gene
P10359673A0000|24 45|lipoamide dehydrogenase
P10359673A0000|76 96|amino acid biosynthesis
P10359673A0000|67 73|control
P10359673A0000|110 132|GCN4 transcription factor
P10359792A0610|87 110|dCtBP corepressor proteins
P10359792A0610|77 83|Groucho
P10359792A0610|34 44|Rpd3 mutants
P10359792A0610|140 150|recruitment
P10359792A0610|153 171|histone deacetylases
P10359792A0610|17 23|defects
P10360454A0916|75 88|pentoxifylline
P10360454A0916|152 163|control group
P10360454A0916|11 33|serum TNF-a concentration
P10360454A0916|133 133|p
P10360454A0916|127 131|pg/ml
P10360454A0916|113 117|month
P10360454A0916|58 65|patients
P10360454A0916|104 108|pg/ml
P10360839A1338|58 66|subfamily
P10360839A1338|24 33|expression
P10360839A1338|69 87|KRAB zinc finger genes
P10360839A1338|123 134|cell lineages
P10360839A1338|46 52|members
P10360839A1338|2 9|addition
P10360947A1113|121 127|changes
P10360947A1113|9 32|fluorescence spectroscopy
P10360947A1113|69 75|binding
P10360947A1113|78 80|Ca2
P10360947A1113|84 88|ALG-2
P10360947A1113|172 178|protein
P10360947A1113|160 166|domains
P10360947A1113|44 52|dichroism
P10361038A0281|68 79|protein genes
P10361038A0281|36 44|promoters
P10361038A0281|22 30|locations
P10362652A0350|27 29|EGF
P10362652A0350|43 55|Ras activation
P10362652A0350|33 34|nM
P10362652A0350|4 12|carbachol
P10362652A0350|17 22|microM
P10362652A1456|101 101|%
P10362652A1456|53 59|HA-ERK2
P10362652A1456|31 50|carbachol stimulation
P10362652A1456|94 96|EGF
P10362652A1456|16 18|Sos
P10362652A1456|86 91|effect
P10362897A0545|0 6|RESULTS
P10362897A0545|22 28|passage
P10362897A0545|92 104|Doppler signal
P10362897A0545|78 86|intensity
P10362897A0545|139 144|effect
P10362897A0545|125 132|duration
P10362897A0545|59 65|amounts
P10362897A0545|31 38|contrast
P10363517A0401|28 32|cases
P10363517A0401|6 10|paper
P10363517A0401|48 62|ultrasonography
P10363517A0401|16 22|lesions
P10364076A0429|5 11|regions
P10364076A0429|27 31|E-box
P10364076A0429|90 99|affinities
P10364076A0429|51 62|repeat motifs
P10364076A0429|70 76|SREBP-1
P10364159A0813|14 22|questions
P10364159A0813|130 135|4E-BP1
P10364159A0813|103 114|kinase assays
P10364159A0813|36 51|FRAP/mTOR protein
P10364159A0813|56 81|FRAP/mTOR immunoprecipitate
P10364163A0092|0 2|Hrs
P10364163A0092|139 145|traffic
P10364163A0092|80 88|phosphate
P10364163A0092|112 119|proteins
P10364163A0092|7 10|FYVE
P10364163A0092|17 32|zinc finger domain
P10364163A0092|56 75|phosphatidylinositol
P10364202A0646|101 108|increase
P10364202A0646|170 180|involvement
P10364202A0646|111 120|activation
P10364202A0646|68 81|leukemia factor
P10364202A0646|55 57|DBP
P10364202A0646|193 203|coactivator
P10364202A0646|134 155|GAL4-DBP fusion proteins
P10364202A0646|210 216|process
P10364202A0646|3 14|coexpression
P10364202A0646|28 47|expression constructs
P10364314A0919|70 76|NS2 gene
P10364314A0919|61 64|part
P10364314A0919|34 44|nucleotides
P10364314A0919|5 14|subgenomes
P10364319A0109|0 1|Cp
P10364319A0109|19 26|promoter
P10364319A0109|64 69|EBNA3C
P10364319A0109|106 116|control loop
P10364319A0109|30 47|EBNA mRNA initiation
P10364425A0610|44 50|absence
P10364425A0610|104 108|STAT3
P10364425A0610|92 101|activation
P10364425A0610|53 60|tyrosine
P10364425A0610|5 15|indications
P10364425A0610|29 38|signalling
P10364523A0826|124 131|vicinity
P10364523A0826|44 48|exons
P10364523A0826|77 82|region
P10364523A0826|4 15|exon trapping
P10364523A0826|56 64|YAC 946E12
P10364523A0826|113 118|contig
P10364523A0826|137 147|breakpoints
P10364523T0000|60 61|Mb
P10364523T0000|10 42|dysplasia translocation breakpoints
P10364523T0000|77 84|evidence
P10364523T0000|72 75|SOX9
P10364523T0000|98 110|control region
P10365883A1355|30 40|VRE patients
P10365883A1355|143 151|pathogens
P10365883A1355|104 112|infection
P10365883A1355|172 180|infection
P10365883A1355|114 124|coinfection
P10365883A1355|56 68|vancomycin use
P10365883A1355|13 27|characteristics
P10366446A0893|71 86|interaction motif
P10366446A0893|90 95|FLI LRR
P10366446A0893|12 17|domain
P10366446A0893|45 51|protein
P10366503A0812|101 110|gp17 column
P10366503A0812|180 185|nature
P10366503A0812|83 89|His-tag
P10366503A0812|197 203|protein
P10366503A0812|151 159|terminase
P10366503A0812|35 40|phages
P10366503A0812|207 231|terminase interaction sites
P10366503A0812|117 138|co-immunoprecipitation
P10366503A0812|74 79|phages
P10366503A0812|0 16|Binding affinities
P10366503A0812|58 66|retention
P10366503A1506|237 242|portal
P10366503A1506|188 191|gp17
P10366503A1506|212 227|terminase regions
P10366503A1506|181 184|gp20
P10366503A1506|140 148|structure
P10366503A1506|248 263|packasome complex
P10366503A1506|75 82|antibody
P10366503A1506|47 50|gp20
P10366503A1506|99 105|peptide
P10366503A1506|11 19|terminase
P10366503A1506|168 178|association
P10366503A1506|57 63|peptide
P10366503A1506|121 126|access
P10366559A0605|59 64|plants
P10366559A0605|78 84|virions
P10366559A0605|43 48|levels
P10366559A0605|3 15|hybrid viruses
P10366722T0000|0 3|cDNA
P10366722T0000|49 73|mouse DNA polymerase epsilon
P10366722T0000|34 42|gene Pole1
P10366722T0000|17 28|organization
P10366722T0000|83 89|subunit
P10367240A1354|44 49|medium
P10367240A1354|82 91|substances
P10367240A1354|212 225|sperm injection
P10367240A1354|130 140|spermatozoa
P10367240A1354|12 27|cryopreservation
P10367240A1354|67 68|SP
P10367240A1354|114 127|cryoprotection
P10367240A1354|30 40|spermatozoa
P10367240A1354|159 181|fertilization procedures
P10367385A0000|42 49|analysis
P10367385A0000|52 64|beta-carotene
P10367385A0000|22 27|method
P10367385A0000|74 77|food
P10367460A0191|71 94|V maximum capacitor voltage
P10367460A0191|154 164|Hz frequency
P10367460A0191|51 66|power consumption
P10367460A0191|141 144|time
P10367460A0191|32 40|kW maximum
P10367460A0191|125 136|microseconds
P10367460A0191|3 16|FCMS conditions
P10367460A0191|99 110|microseconds
P10367646A0569|147 153|calcium
P10367646A0569|184 190|albumin
P10367646A0569|207 207|P
P10367646A0569|158 171|serum globulins
P10367646A0569|113 121|increases
P10367646A0569|91 98|addition
P10367646A0569|49 55|changes
P10367646A0569|123 145|alanine aminotransferase
P10367646A0569|81 88|analytes
P10367646A0569|199 205|protein
P10367646A0569|6 14|hemolysis
P10367646A0569|173 173|P
P10367646A0569|61 70|mean values
P10369418A0644|87 104|NF-kappaB complexes
P10369418A0644|76 84|induction
P10369418A0644|129 142|NF-kappaB sites
P10369418A0644|198 200|p65
P10369418A0644|165 167|p50
P10369418A0644|20 27|extracts
P10369418A0644|190 194|c-Rel
P10369418A0644|0 3|EMSA
P10369418A0644|171 174|RelB
P10369418A0644|44 54|stimulation
P10369418A0644|59 63|CD40L
P10369625A0942|19 21|ODA
P10369625A0942|7 16|monitoring
P10369757A0000|269 281|transcription
P10369757A0000|189 197|complexes
P10369757A0000|293 297|genes
P10369757A0000|77 92|Bacillus subtilis
P10369757A0000|158 158|l
P10369757A0000|94 97|ArgR
P10369757A0000|39 56|arginine metabolism
P10369757A0000|101 104|AhrC
P10369757A0000|217 229|transcription
P10369757A0000|322 343|plasmid dimer resolution
P10369757A0000|8 27|transcription factors
P10369757A0000|247 251|genes
P10369757A0000|142 149|proteins
P10369757A0000|299 302|AhrC
P10369775A0178|71 91|residues Lys438-Gln520
P10369775A0178|35 55|residues Arg183-His267
P10369775A0178|10 25|protein fragments
P10369775A0178|66 67|ER
P10369775A0178|97 101|rat GR
P10369926A0251|115 131|CXC chemokine genes
P10369926A0251|8 22|intron structure
P10369926A0251|25 34|chicken IL8
P10369926A0251|3 6|exon
P10369926A0251|72 74|IL8
P10369965A0000|42 67|basidiocarp differentiation
P10369965A0000|73 96|mushroom Agrocybe aegerita
P10369965A0000|3 13|Aa-Pri2 gene
P10370675A0649|114 116|HCV
P10370675A0649|51 65|hepatitis C virus
P10370675A0649|101 111|combination
P10370675A0649|74 74|%
P10370675A0649|15 26|liver disease
P10370675A0649|44 46|HCC
P10370675A0649|67 69|HCV
P10370675A0649|120 131|alcohol abuse
P10370675A0649|77 88|alcohol abuse
P10370675A0649|92 92|%
P10370675A0649|32 39|patients
P10370675A0649|7 12|causes
P10370675A0649|135 135|%
P10370778A0000|89 100|breast cancer
P10370778A0000|48 52|phase
P10370778A0000|230 237|vorozole
P10370778A0000|218 225|Novartis
P10370778A0000|155 170|tamoxifen therapy
P10370778A0000|128 134|disease
P10370778A0000|184 191|ARIMIDEX
P10370778A0000|211 216|FEMARA
P10370778A0000|201 209|letrozole
P10370778A0000|8 26|aromatase inhibitors
P10370778A0000|68 76|treatment
P10370778A0000|172 182|anastrozole
P10370778A0000|193 198|Zeneca
P10370778A0000|56 65|evaluation
P10370778A0000|247 253|Janssen
P10370778A0000|239 245|RIVIZOR
P10370778A0000|118 122|women
P10371097A0963|0 10|CONCLUSIONS
P10371097A0963|138 147|Turbuhaler
P10371097A0963|32 35|tool
P10371097A0963|115 133|inhalation technique
P10371097A0963|12 20|Turbutest
P10371097A0963|47 54|patients
P10371097A0963|56 63|training
P10371097A0963|73 86|identification
P10371097A0963|90 100|improvement
P10372627A0530|28 36|snowboard
P10372627A0530|50 54|cases
P10372627A0530|7 14|injuries
P10372627A0530|19 23|cases
P10373029A0204|27 32|soleus
P10373029A0204|10 20|artery/vein
P10373029A0204|36 55|gastrocnemius muscles
P10373029A0204|86 95|volunteers
P10373507A0680|134 144|alpha-actin
P10373507A0680|159 198|SRF promoter-luciferase reporter activities
P10373507A0680|146 154|SM22alpha
P10373507A0680|97 107|alpha-actin
P10373507A0680|116 126|alpha-actin
P10373507A0680|60 65|mutant
P10373507A0680|0 8|SRFDelta5
P10373523A0924|18 23|p50E4F
P10373523A0924|12 16|media
P10373523A0924|46 54|apoptosis
P10374632A0818|15 20|effect
P10374632A0818|60 62|NBP
P10374632A0818|66 72|mg.kg-1
P10374632A0818|23 25|Nim
P10374632A0818|3 9|potency
P10374632A0818|30 36|mg.kg-1
P10374632A0897|0 9|CONCLUSION
P10374632A0897|11 26|NBP pre-treatment
P10374632A0897|78 86|RMCAO rats
P10374632A0897|68 75|striatum
P10374632A0897|62 65|rCBF
P10375107A1138|0 10|Progression
P10375107A1138|96 105|metastasis
P10375107A1138|26 37|chemotherapy
P10375107A1138|84 91|patients
P10375107A1138|73 80|survival
P10375638A0859|104 108|cells
P10375638A0859|81 90|efficiency
P10375638A0859|64 67|mRNA
P10375638A0859|32 46|NRF-1 expression
P10375638A0859|123 139|translation system
P10375638A0859|20 23|UTR1
P10375638A0859|0 8|Mutations
P10375640A0153|41 44|cDNA
P10375640A0153|65 76|reading frame
P10375640A0153|46 50|CBS-1
P10375640A0153|18 35|nucleotide sequence
P10375640A0153|92 101|amino acids
P10375640A0153|117 122|weight
P10375640A0153|129 131|kDa
P10375694T0000|90 95|monkey
P10375694T0000|144 152|motor area
P10375694T0000|69 77|motor area
P10375694T0000|114 123|input zones
P10375694T0000|97 106|comparison
P10375694T0000|36 45|input zones
P10375718A0000|74 85|animal models
P10375718A0000|102 115|administration
P10375718A0000|93 99|methods
P10375718A0000|53 64|angiogenesis
P10375718A0000|5 26|fibroblast growth factor
P10375718A0000|28 31|bFGF
P10376065A0881|94 105|spring filter
P10376065A0881|109 118|RF02 filter
P10376065A0881|62 67|median
P10376065A0881|53 60|pressure
P10376065A0881|31 39|elevation
P10376065A0881|78 81|mm Hg
P10376065A0881|4 10|filters
P10376065A0881|83 83|n
P10376446A0000|57 62|method
P10376446A0000|138 142|cycle
P10376446A0000|112 113|LP
P10376446A0000|82 84|PLR
P10376446A0000|49 54|2-hour
P10376446A0000|105 110|luteal
P10376446A0000|9 13|women
P10376446A0000|23 27|years
P10376446A0000|72 74|leg
P10376446A0000|15 17|age
P10376446A0000|115 120|phases
P10376446A0000|99 100|FP
P10376873A0706|28 30|UTR
P10376873A0706|5 10|sgRNA2
P10376874A0759|177 183|support
P10376874A0759|211 221|interaction
P10376874A0759|153 159|protein
P10376874A0759|21 27|defects
P10376874A0759|85 96|protein eRF3C
P10376874A0759|33 52|eRF1-eRF3 interaction
P10376874A0759|118 129|eRF1 proteins
P10376874A0759|190 197|presence
P10376877A0611|0 6|Removal
P10376877A0611|30 37|segments
P10376877A0611|96 101|Ss rRNA
P10376877A0611|180 186|18S rRNA
P10376877A0611|168 177|production
P10376877A0611|137 142|region
P10376877A0611|55 58|half
P10376877A0611|82 90|formation
P10376877A0611|148 154|protein
P10376877A0611|118 121|part
P10376991A0977|0 2|Ras
P10376991A0977|25 32|tegument
P10377345A0740|0 4|Green
P10377345A0740|109 115|regions
P10377345A0740|40 54|UNC-49C subunits
P10377345A0740|71 81|muscle cells
P10377345A0740|30 36|UNC-49B
P10377438A0647|49 51|TEL
P10377438A0647|11 17|protein
P10377438A0647|19 22|UBC9
P10378989A0000|12 16|study
P10378989A0000|103 110|patients
P10378989A0000|138 142|Italy
P10378989A0000|118 122|years
P10378989A0000|164 170|January
P10378989A0000|47 53|reports
P10378989A0000|153 158|period
P10378989A0000|125 127|age
P10378989A0000|3 5|aim
P10378989A0000|131 136|Sicily
P10378989A0000|179 186|December
P10378989A0000|72 84|drug reactions
P10379547A0000|0 8|Molecules
P10379547A0000|11 13|NH3
P10379547A0000|54 58|MASER
P10379547A0000|44 52|radiation
P10379899A0446|63 69|signals
P10379899A0446|110 130|theca cell layer markers
P10379899A0446|21 27|studies
P10379899A0446|8 15|findings
P10379899A0446|91 99|follicles
P10379942A0956|88 102|MDV2 UL10 protein
P10379942A0956|27 34|residues
P10379942A0956|79 82|part
P10379942T0000|0 13|Identification
P10379942T0000|91 108|glycoprotein M genes
P10379942T0000|38 57|disease virus serotype
P10379942T0000|77 86|comparison
P10379942T0000|31 35|Marek
P10379942T0000|111 129|Herpesviridae family
P10379942T0000|17 25|structure
P10379942T0000|59 75|glycoprotein M gene
P10380232A0000|0 8|OBJECTIVE
P10380232A0000|189 194|emesis
P10380232A0000|77 98|regimen-chlorpromazine
P10380232A0000|163 166|TROP
P10380232A0000|265 276|perspectives
P10380232A0000|289 296|patients
P10380232A0000|47 49|CEA
P10380232A0000|100 112|dexamethasone
P10380232A0000|127 161|5-HT3 receptor antagonist-tropisetron
P10380232A0000|234 241|children
P10380232A0000|20 45|cost-effectiveness analysis
P10380232A0000|278 285|hospital
P10380232A0000|220 231|chemotherapy
P10380232A0000|114 120|CPM-DEX
P10380232A0000|175 181|control
P10380659A0545|0 11|Baseline data
P10380659A0545|30 35|adults
P10380800A0194|213 220|ancestor
P10380800A0194|149 154|dsRNAs
P10380800A0194|193 201|host plant
P10380800A0194|125 130|dsRNAs
P10380800A0194|88 107|RNA polymerase domains
P10380800A0194|16 25|nucleotide
P10380800A0194|36 53|amino acid sequences
P10380800A0194|59 69|core regions
P10380800A0194|1 10|comparison
P10380878A0542|114 131|histone deacetylase
P10380878A0542|38 43|region
P10380878A0542|46 49|Bin1
P10380878A0542|93 95|DNA
P10380878A0542|18 28|possibility
P10380878A0542|73 90|repression function
P10380890A0619|90 91|IR
P10380890A0619|11 19|sequences
P10381257A0000|56 78|preprotein import complex
P10381257A0000|26 32|metaxin
P10381257A0000|111 123|mitochondrion
P10381257A0000|89 96|membrane
P10381257A0000|44 52|component
P10381257A0000|18 24|protein
P10381377T0000|56 60|SHIP2
P10381377T0000|77 86|regulation
P10381377T0000|89 104|insulin signaling
P10381377T0000|9 15|cloning
P10381377T0000|68 71|role
P10381377T0000|35 53|inositol phosphatase
P10381377T0000|18 20|rat
P10381570A1355|0 3|Slp1
P10381570A1355|46 55|yeast cells
P10381570A1355|110 127|interstripe regions
P10381570A1355|87 95|repressor
P10381570A1355|138 143|stages
P10381570A1355|13 25|transcription
P10381570A1355|33 43|binding site
P10381570A1355|146 158|embryogenesis
P10381570A1355|74 77|role
P10381570A1355|98 107|ftz stripes
P10383764A1809|57 69|homomultimers
P10383764A1809|90 100|information
P10383764A1809|233 239|channel
P10383764A1809|44 54|VirB4 dimers
P10383764A1809|32 36|model
P10383764A1809|252 264|export machine
P10383764A1809|107 114|assembly
P10383764A1809|197 204|activity
P10383764A1809|3 9|results
P10383764A1809|118 137|transenvelope channel
P10383764A1809|17 23|studies
P10383764A1809|163 173|DNA transfer
P10383966A0000|104 111|cell wall
P10383966A0000|81 89|component
P10383966A0000|54 66|peptidoglycan
P10383966A0000|3 27|penicillin binding proteins
P10383966A0000|29 32|PBPs
P10384129A0000|113 123|individuals
P10384129A0000|79 81|CD4
P10384129A0000|66 76|populations
P10384129A0000|9 12|TCRA
P10384129A0000|51 54|PBMC
P10384129A0000|37 46|RNA samples
P10384129A0000|84 86|CD8
P10384129A0000|94 99|T cells
P10384129A0000|0 7|TCR alpha
P10384129A0000|14 23|expression
P10385384A0654|30 36|xylitol
P10385384A0654|40 48|activator
P10385384A0654|7 13|results
P10385384A0654|54 76|pentose phosphate pathway
P10385395A0000|147 151|gland
P10385395A0000|26 28|HDL
P10385395A0000|71 87|cholesteryl esters
P10385395A0000|57 67|cholesterol
P10385395A0000|7 24|density lipoprotein
P10385395A0000|49 54|uptake
P10385395A0000|155 160|gonads
P10385395A0000|30 37|receptor
P10385395A0000|124 134|HDL particle
P10385395A0000|89 98|substrates
P10385395A0000|102 116|steroidogenesis
P10385915A1341|0 6|D3S1261
P10385915A1341|99 100|cM
P10385915A1341|62 68|D3S1766
P10385915A1341|37 45|MITF locus
P10385915A1341|108 115|distance
P10385915A1341|52 58|D3S2465
P10385915A1341|120 123|side
P10385915A1341|83 87|locus
P10388670A1976|133 140|adhesion
P10388670A1976|70 79|dispersant
P10388670A1976|37 47|storage time
P10388670A1976|100 106|storage
P10388670A1976|3 13|percentages
P10388670A1976|16 23|recovery
P10388670A1976|60 67|addition
P10390158A1150|0 13|Point mutations
P10390158A1150|37 48|Pit-1 binding
P10390158A1150|19 22|site
P10390158A1150|68 87|tiGH promoter activity
P10390538T0000|20 37|zinc-finger protein
P10390538T0000|58 66|sequences
P10391075A0000|98 107|brain tumor
P10391075A0000|52 60|sclerosis
P10391075A0000|110 120|MRI findings
P10391075A0000|16 26|autopsy case
P10391246A0756|59 74|kinase activities
P10391246A0756|12 16|MOM-4
P10391246A0756|35 42|proteins
P10391246A0756|20 23|TAK1
P10391277A0000|0 9|BACKGROUND
P10391277A0000|80 91|fibrillation
P10391277A0000|35 43|treatment
P10391277A0000|46 51|choice
P10391277A0000|14 21|MAZE-III
P10391903T0000|0 3|Gab2
P10391903T0000|9 26|pleckstrin homology
P10391903T0000|86 94|ERK kinase
P10391903T0000|97 101|Elk-1
P10391903T0000|44 57|adapter protein
P10391903T0000|73 81|signaling
P10392266A0111|86 93|activity
P10392266A0111|109 122|immunoglobulin
P10392266A0111|22 30|xanthomas
P10392266A0111|3 10|presence
P10392266A0111|41 56|serum lipid levels
P10392669A0935|120 151|prostaglandin analogue misoprostol
P10392669A0935|504 513|prevention
P10392669A0935|269 277|reduction
P10392669A0935|376 385|ranitidine
P10392669A0935|213 222|prevention
P10392669A0935|572 581|omeprazole
P10392669A0935|357 369|H2 antagonists
P10392669A0935|776 786|gastropathy
P10392669A0935|256 261|ulcers
P10392669A0935|308 320|complications
P10392669A0935|463 468|ulcers
P10392669A0935|536 541|ulcers
P10392669A0935|82 91|approaches
P10392669A0935|387 396|cimetidine
P10392669A0935|548 567|proton pump inhibitors
P10392669A0935|22 30|incidence
P10392669A0935|681 693|barrier agents
P10392669A0935|736 753|prophylactic agents
P10392669A0935|430 439|prevention
P10392669A0935|326 355|histamine H2 receptor antagonists
P10392669A0935|112 114|use
P10392669A0935|640 645|ulcers
P10392669A0935|62 68|lesions
P10392669A0935|400 409|famotidine
P10392669A0935|604 611|efficacy
P10392669A0935|479 491|term treatment
P10392669A0935|171 174|drug
P10392669A0935|4 10|attempt
P10392669A0935|586 597|pantoprazole
P10392710A1000|0 13|Lung mesenchyme
P10392710A1000|24 31|compleat
P10392710A1000|77 96|peptide growth factors
P10392710A1000|33 39|inducer
P10392710A1000|42 58|lung morphogenesis
P10392900A1020|99 121|tyrosine phosphorylation
P10392900A1020|61 65|c-Abl
P10392900A1020|124 136|RNA polymerase
P10392900A1020|47 58|localization
P10392900A1020|18 28|HIV promoter
P10392900A1020|3 12|activation
P10392903A0000|133 150|papillomavirus type
P10392903A0000|91 107|carcinoma cell line
P10392903A0000|153 155|DNA
P10392903A0000|9 31|papillomavirus E2 protein
P10392903A0000|45 57|proliferation
P10392903A0000|60 68|HT-3 cells
P10392903A0889|0 13|E2 point mutants
P10392903A0889|87 116|cell cycle inhibitors hydroxyurea
P10392903A0889|52 57|cdc25A
P10392903A0889|61 76|cdc25B expression
P10392903A0889|120 127|mimosine
P10392903A0889|29 38|cell growth
P10392914A0000|62 65|duct
P10392914A0000|28 38|arrangement
P10392914A0000|108 117|dilatation
P10392914A0000|67 71|AAPBD
P10392914A0000|152 166|tract malignancy
P10392914A0000|0 17|BACKGROUND/PURPOSE
P10393192A0792|0 21|Neurospora crassa CYT-18
P10393192A0792|48 60|intron mutants
P10393192A0792|82 87|defect
P10393192A0792|41 44|trap
P10393197A0543|0 3|DDP1
P10393197A0543|36 51|interphase nuclei
P10393197A0543|19 33|heterochromatin
P10393197A0543|60 70|neuroblasts
P10393201A0654|144 148|break
P10393201A0654|175 185|exonuclease
P10393201A0654|162 169|addition
P10393201A0654|21 35|DNA repair system
P10393201A0654|66 83|DNA ligase III-XRCC1
P10393201A0654|46 62|DNA polymerase beta
P10393201A0654|117 127|base residue
P10393251A0283|56 74|restriction analysis
P10393251A0283|17 26|insert size
P10393251A0283|29 33|120kb
P10393251A0283|3 10|PAC clone
P10393251T0000|0 7|Sequence
P10393251T0000|78 90|T-ALL cell line
P10393251T0000|10 19|10q24 locus
P10393251T0000|34 46|HOX11 oncogene
P10393251T0000|58 65|gene HUG1
P10393422A0476|19 23|LAMB2
P10393422A0476|32 35|gene
P10393422A0476|91 96|LAMB2L
P10393422A0476|80 89|pseudogene
P10393422A0476|7 8|kb
P10393910A0705|96 99|site
P10393910A0705|81 84|part
P10393910A0705|105 116|endonuclease
P10393910A0705|13 23|mutagenesis
P10393910A0705|130 136|element
P10393910A0705|70 74|motif
P10393910A0705|54 61|evidence
P10393910A0705|29 37|R2 protein
P10393969A0000|98 107|expression
P10393969A0000|148 159|transfection
P10393969A0000|110 114|genes
P10393969A0000|11 24|cell protein no.
P10393969A0000|137 145|infection
P10393969A0000|67 80|transactivator
P10393969A0000|34 51|herpes simplex virus
P10393969A0000|27 30|ICP0
P10393969A0000|130 134|cells
P10394116T0000|44 50|remarks
P10394116T0000|53 64|oscillometry
P10394116T0000|18 30|blood pressure
P10394116T0000|0 15|Wrist measurement
P10394900A1166|43 50|presence
P10394900A1166|104 114|35S promoter
P10394900A1166|14 23|expression
P10394900A1166|76 97|cauliflower mosaic virus
P10394900A1166|26 31|leaves
P10394900A1166|55 68|enhancer region
P10394900A1166|99 102|CaMV
P10394919A1058|7 13|element
P10394919A1058|39 47|amplitude
P10394919A1058|53 63|oscillation
P10395199A0792|229 240|Virone-Oddos
P10395199A0792|265 268|W.H.
P10395199A0792|214 215|M.
P10395199A0792|245 250|Multon
P10395199A0792|160 174|tumor regression
P10395199A0792|301 306|Tocque
P10395199A0792|252 255|M.C.
P10395199A0792|203 212|Kenigsberg
P10395199A0792|308 309|B.
P10395199A0792|270 282|Schweighoffer
P10395199A0792|135 144|Ras pathway
P10395199A0792|284 285|F.
P10395199A0792|226 227|I.
P10395199A0792|200 201|O.
P10395199A0792|257 263|Fridman
P10395199A0792|26 32|control
P10395199A0792|193 198|Cochet
P10395199A0792|35 45|experiments
P10395199A0792|242 243|A.
P10395199A0792|114 123|mAb Y13-259
P10395199A0792|71 78|Y259 scFv
P10395199A0792|217 224|Delumeau
P10395199A0792|182 191|mouse model
P10395199A0792|66 69|scFv
P10395199A0792|296 299|J.L.
P10395199A0792|4 7|scFv
P10395199A0792|287 294|Teillaud
P10395283A0960|28 35|activin A
P10395283A0960|60 64|Smad4
P10395283A0960|39 42|OP-1
P10395283A0960|10 20|competition
P10395283A0960|108 123|signal transducer
P10395283A0960|46 57|availability
P10395283A0960|83 95|concentration
P10395283A0960|171 179|responses
P10395378A1198|131 144|fusion activity
P10395378A1198|83 89|ligands
P10395378A1198|109 111|end
P10395378A1198|3 6|data
P10395378A1198|53 74|HA envelope glycoprotein
P10395827A1297|98 114|parallel beta sheet
P10395827A1297|51 54|coil
P10395827A1297|77 87|beta strands
P10395827A1297|19 40|parallel beta helix model
P10395908A0236|75 81|regions
P10395908A0236|88 115|amino acid motif characteristic
P10395908A0236|121 129|R7G family
P10395908A0236|35 41|protein
P10395908A0236|132 140|G-protein
P10395908A0236|162 170|receptors
P10395911A0288|60 65|region
P10395911A0288|21 48|chicken apolipoprotein A-I gene
P10395911A0288|0 15|Characterisation
P10395920A1424|99 105|KGF gene
P10395920A1424|5 11|results
P10395920A1424|108 115|response
P10395920A1424|35 43|ATF family
P10395920A1424|23 29|members
P10395920A1424|147 149|CRE
P10395920A1424|84 93|regulation
P10395920A1424|160 166|element
P10395920A1424|131 137|stimuli
P10396343A0754|69 76|suspects
P10396343A0754|127 127|%
P10396343A0754|49 54|sample
P10396343A0754|60 63|rest
P10396343A0754|114 116|DNA
P10396343A0754|26 37|blood samples
P10396343A0754|151 151|%
P10396343A0754|131 143|T. b. gambiense
P10396343A0754|119 121|PCR
P10396343A0754|155 169|T. b. rhodesiense
P10396343A0754|14 23|proportion
P10396343T0000|76 88|TrypTect CIATT
P10396343T0000|40 56|agglutination test
P10396343T0000|13 22|evaluation
P10396343T0000|28 31|card
P10396343T0000|60 74|trypanosomiasis
P10396793A0815|0 6|Results
P10396793A0815|86 95|reductions
P10396793A0815|121 130|indicators
P10396793A0815|133 149|alcohol dependence
P10396793A0815|101 110|prevalence
P10396793A0815|10 12|men
P10396793A0815|37 39|day
P10396793A0815|28 33|drinks
P10396793A0815|167 167|%
P10396793A0815|56 73|dependence criteria
P10396793A0815|173 173|%
P10397257A1142|0 10|Mutagenesis
P10397257A1142|34 41|Sp1 sites
P10397257A1142|137 141|cells
P10397257A1142|113 113|%
P10397257A1142|154 173|cell cycle periodicity
P10397257A1142|193 197|cells
P10397257A1142|48 53|region
P10397257A1142|64 74|combination
P10397257A1142|98 105|activity
P10397257A1142|16 30|CDE/CHR elements
P10398286A0678|14 22|procedure
P10398286A0678|40 50|comparisons
P10398286A0678|116 121|nature
P10398286A0678|65 81|sample size methods
P10398286A0678|124 126|S2p
P10398286A0678|5 11|Scheffe
P10398286A0678|27 38|illustration
P10398682A0365|55 64|resolution
P10398682A0365|24 31|VP16 core
P10398682A0365|3 18|crystal structure
P10399136A0389|0 6|Ozagrel
P10399136A0389|96 98|HPC
P10399136A0389|8 17|ifenprodil
P10399136A0389|87 90|rCBF
P10399136A0389|33 39|dilazep
P10399136A0389|19 29|cinnarizine
P10399136A0389|61 74|pentoxifylline
P10400032A0304|102 111|management
P10400032A0304|9 14|method
P10400032A0304|63 73|hypotension
P10400032A0304|40 47|vena cava
P10400593A1084|2 9|contrast
P10400593A1084|11 15|PvirE
P10400593A1084|18 39|Plac promoter constructs
P10400593A1084|91 95|virE2
P10400593A1084|57 61|VirE2
P10400593A1084|68 72|virE1
P10400712A0000|6 23|parainfluenza virus
P10400712A0000|33 41|prototype
P10400712A0000|26 28|SV5
P10400712A0000|47 67|Paramyxoviridae family
P10400712A0000|96 105|RNA viruses
P10400712A0577|27 28|GE
P10400712A0577|115 123|SV5 genome
P10400712A0577|222 223|HN
P10400712A0577|16 24|functions
P10400712A0577|156 157|GE
P10400712A0577|159 160|IG
P10400712A0577|134 154|gene junction sequences
P10400712A0577|231 240|polymerase
P10400712A0577|49 61|transcription
P10400712A0577|76 83|plasmids
P10400712A0577|194 220|hemagglutinin-neuraminidase
P10400712A0577|268 287|counterpart sequences
P10400712A0577|297 309|gene junctions
P10400712A0577|244 248|genes
P10400712A0577|36 46|GS sequences
P10400712A0577|94 98|cDNAs
P10400712A0577|165 175|GS sequences
P10400712A0577|242 242|L
P10400712A0577|30 31|IG
P10400757A0000|0 4|CXCR4
P10400757A0000|8 24|chemokine receptor
P10400757A0000|116 120|HIV-1
P10400757A0000|89 113|immunodeficiency virus type
P10400757A0000|122 129|isolates
P10400757A0000|79 82|R5X4
P10400757A0000|29 38|coreceptor
P10400757A0000|61 62|X4
P10400757A1498|27 32|detail
P10400757A1498|184 188|HIV-1
P10400757A1498|5 8|data
P10400757A1498|166 170|CXCR4
P10400757A1498|51 62|requirements
P10400757A1498|36 40|CXCR4
P10400757A1498|157 163|domains
P10400757A1498|83 94|HIV-1 strains
P10400757A1498|201 213|fusion process
P10400757A1498|115 132|mutagenesis efforts
P10400760A0663|59 84|amino acid residues E960-A961
P10400760A0663|136 153|cleavage efficiency
P10400760A0663|98 108|E1345-T1346
P10400760A0663|113 123|E1419-G1420
P10400760A0663|17 24|analyses
P10400760A0663|3 9|results
P10400760A0663|40 49|proteinase
P10400760A0663|86 96|E1071-S1072
P10400774A0240|0 1|y.
P10400785A0912|0 1|SM
P10400785A0912|107 127|nucleoporin CAN/Nup214
P10400785A0912|42 51|components
P10400785A0912|61 73|export pathway
P10400785A0912|92 100|GTPase Ran
P10400785A0912|57 59|CRM
P10400794T0000|89 100|similarities
P10400794T0000|109 124|membrane proteins
P10400794T0000|78 84|protein
P10400794T0000|129 130|2A
P10400794T0000|24 27|gene
P10400794T0000|32 37|Kaposi
P10400794T0000|58 68|herpesvirus
P10400794T0000|145 149|virus
P10400794T0000|0 13|Identification
P10402022A0432|26 29|rate
P10402022A0432|8 13|clicks
P10402022A0432|34 34|s
P10402467T0000|0 5|Myosin
P10402467T0000|115 119|cells
P10402467T0000|11 21|chain kinase
P10402467T0000|84 94|plasminogen
P10402467T0000|142 147|manner
P10402467T0000|43 49|Ras/ERK
P10402467T0000|59 67|migration
P10403575A1401|87 99|control levels
P10403575A1401|38 42|DAX-1
P10403575A1401|84 84|%
P10403575A1401|68 80|transcription
P10403575A1401|3 12|inhibition
P10403575A1401|15 35|StAR gene transcription
P10403690A0000|233 242|IEP regimen
P10403690A0000|83 91|stage IIIb
P10403690A0000|416 419|days
P10403690A0000|266 283|mesna uroprotection
P10403690A0000|363 367|mg/m2
P10403690A0000|244 253|ifosfamide
P10403690A0000|100 120|ECOG performance status
P10403690A0000|407 411|mg/m2
P10403690A0000|209 231|combination chemotherapy
P10403690A0000|255 259|gm/m2
P10403690A0000|351 361|mitomycin-C
P10403690A0000|306 308|day
P10403690A0000|122 123|PS
P10403690A0000|180 183|care
P10403690A0000|324 328|mg/m2
P10403690A0000|24 28|study
P10403690A0000|77 81|NSCLC
P10403690A0000|201 204|care
P10403690A0000|313 321|cisplatin
P10403690A0000|369 377|cisplatin
P10403690A0000|33 40|patients
P10403690A0000|390 392|day
P10403690A0000|340 349|MVP regimen
P10403690A0000|185 187|BSC
P10403690A0000|333 335|day
P10403690A0000|381 385|mg/m2
P10403690A0000|297 301|mg/m2
P10403690A0000|62 75|cell lung cancer
P10403690A0000|285 294|epirubicin
P10403690A0000|395 405|vinblastine
P10403839A0140|133 146|splice variants
P10403839A0140|5 23|sequence information
P10403839A0140|170 173|gene
P10403839A0140|152 161|mouse BMAL1
P10403839A0140|115 119|cDNAs
P10403839A0140|39 44|hBMAL1
P10403839A0140|33 37|BMAL1
P10403839A0140|46 50|cDNAs
P10403839A0140|163 168|mBMAL1
P10403839A0140|74 83|laboratory
P10403839A1459|0 9|Comparison
P10403839A1459|202 205|gene
P10403839A1459|140 142|Ahr
P10403839A1459|77 82|mBMAL1
P10403839A1459|51 74|intron/exon splice pattern
P10403839A1459|158 165|subclass
P10403839A1459|110 113|mAhr
P10403839A1459|17 35|bHLH/PAS family genes
P10403839A1459|132 136|BMAL1
P10405635A0374|44 51|promoter
P10405635A0374|155 159|cells
P10405635A0374|18 27|activities
P10405635A0374|73 90|deletion constructs
P10406047A1244|87 92|height
P10406047A1244|97 106|compliance
P10406047A1244|282 293|lung function
P10406047A1244|123 128|system
P10406047A1244|79 84|weight
P10406047A1244|203 209|infants
P10406047A1244|163 172|ILD infants
P10406047A1244|240 243|PFTs
P10406047A1244|140 145|weight
P10406047A1244|300 307|age group
P10406047A1244|216 219|PPHN
P10406047A1244|148 157|lung volume
P10406047A1244|193 200|controls
P10406047A1244|60 67|capacity
P10406047A1244|29 39|differences
P10406122T0000|86 99|responsiveness
P10406122T0000|125 139|methyl jasmonate
P10406122T0000|102 114|tissue culture
P10406122T0000|20 26|element
P10406122T0000|48 73|tobacco retrotransposon Tto1
P10406122T0000|149 157|elicitors
P10406122T0000|32 42|LTR promoter
P10406459A0000|198 206|magnitude
P10406459A0000|162 183|Ser-133 phosphorylation
P10406459A0000|119 122|CREB
P10406459A0000|154 160|protein
P10406459A0000|6 10|study
P10406459A0000|220 230|NIH 3T3 cells
P10406459A0000|95 97|TPA
P10406459A0000|54 57|PDGF
P10406459A0000|41 52|growth factor
P10406459A0000|210 217|kinetics
P10406459A0000|103 111|forskolin
P10406459A0000|60 93|12-O-tetradecanoyl-phorbol-acetate
P10406462A1127|15 22|evidence
P10406462A1127|67 76|activation
P10406462A1127|34 37|role
P10406462A1127|79 90|OR1/RXRalpha
P10406462A1127|40 44|SRC-1
P10406464A0687|2 9|contrast
P10406464A0687|11 32|mTRAP100 coprecipitates
P10406464A0687|114 129|vitamin D receptor
P10406464A0687|64 74|TRAP complex
P10406464A0687|50 58|component
P10406464A0687|76 82|TRAP220
P10406464A0687|98 107|contacts TR
P10406464A0687|149 154|manner
P10406465A0589|29 50|vitamin D responsiveness
P10406465A0589|23 25|VDR
P10406465A0589|66 73|promoter
P10406465A0589|4 11|sequence
P10406466A0000|46 67|thyroid hormone receptor
P10406466A0000|77 88|acid receptor
P10406466A0000|104 112|receptors
P10406466A0000|32 40|receptors
P10406843A1265|0 9|Expression
P10406843A1265|12 24|GlcNAc-TI mRNA
P10406843A1265|56 61|RT-PCR
P10406843A1265|27 33|tobacco
P10406954A0715|0 21|Chemical stability tests
P10406954A0715|38 48|mutagenesis
P10406954A0715|81 84|RegS
P10406954A0715|59 72|amino acids H219
P10406954A0715|125 132|residues
P10406954A0715|76 78|D63
P10406954A0715|88 91|RegR
P10407184A0149|41 45|areas
P10407184A0149|100 113|neuropathology
P10407184A0149|51 57|AD brain
P10407184A0149|21 31|betaAPP gene
P10407184A0149|89 94|factor
P10407184A0149|116 117|AD
P10407184A0149|2 15|overexpression
P10407184A0520|195 197|URE
P10407184A0520|252 265|promoter region
P10407184A0520|108 110|CAT
P10407184A0520|206 215|prhbetaE-B
P10407184A0520|24 38|promoter regions
P10407184A0520|75 106|chloramphenicol acetyl transferase
P10407184A0520|157 157|h
P10407184A0520|304 319|hbetaAPP promoter
P10407184A0520|129 135|plasmid
P10407184A0520|116 124|phbetaE-B
P10407184A0520|159 172|promoter region
P10407184A0520|220 226|plasmid
P10407184A0520|275 277|URE
P10407184A0520|249 250|rh
P10407184A0520|242 247|rhesus
P10407184A0520|13 19|studies
P10407184A0520|291 298|bp region
P10407184A0520|62 73|reporter gene
P10407269A0000a|113 116|part
P10407269A0000a|71 92|fission yeast chromosome
P10407269A0000a|51 55|cdc14
P10407269A0000a|122 134|European Union
P10407269A0000a|36 47|markers cdc18
P10407269A0000a|5 6|bp
P10407269A0000a|19 21|DNA
P10407269A0000a|159 181|genome sequencing project
P10407269A0000a|66 68|arm
P10407269A0000b|113 116|part
P10407269A0000b|71 92|fission yeast chromosome
P10407269A0000b|51 55|cdc14
P10407269A0000b|122 134|European Union
P10407269A0000b|36 47|markers cdc18
P10407269A0000b|5 6|bp
P10407269A0000b|19 21|DNA
P10407269A0000b|159 181|genome sequencing project
P10407269A0000b|66 68|arm
P10407985A0574|0 4|G-CSF
P10407985A0574|9 18|micrograms
P10407985A0574|55 60|GM-CSF
P10407985A0574|65 78|micrograms s.c.
P10407985A0574|34 37|s.c.
P10407985A0574|100 105|cycles
P10409656A1016|0 13|Overexpression
P10409656A1016|111 114|H411
P10409656A1016|153 155|LPS
P10409656A1016|74 83|growth rate
P10409656A1016|139 150|cell response
P10409656A1016|37 54|macrophage cell line
P10409656A1016|99 108|expression
P10409656A1016|16 23|H411 cDNA
P10409656A1016|117 120|part
P10409656A1016|29 31|RAW
P10409699A0292|250 272|polymerase chain reaction
P10409699A0292|233 240|cDNA ends
P10409699A0292|165 182|mannosidase homolog
P10409699A0292|140 151|coding region
P10409699A0292|79 83|yeast
P10409699A0292|110 121|mannosidases
P10409699A0292|197 207|combination
P10409699A0292|218 230|amplification
P10409699A0292|291 294|cDNA
P10409699A0292|47 64|sequence similarity
P10409699A0292|14 30|sequence tag clones
P10409724A1021|0 9|Activation
P10409724A1021|12 17|ERK1/2
P10409724A1021|63 75|response genes
P10409724A1021|34 42|induction
P10409730A0597|71 72|bp
P10409730A0597|100 112|transcription
P10409730A0597|88 97|initiation
P10409730A0597|22 28|RP genes
P10409730A0597|3 15|transcription
P10409730A0597|45 61|Rap1p binding sites
P10409741A0382|58 64|cdc4-16
P10409741A0382|89 102|division defect
P10409741A0382|25 31|alleles
P10409741A0382|34 37|CDC4
P10409741A0382|39 45|cdc4-10
P10409741A0382|47 53|cdc4-11
P10409741A0382|105 116|cdc20-1 cells
P10409749T0000|0 3|Role
P10409749T0000|26 39|discrimination
P10409749T0000|71 80|activators
P10409749T0000|15 23|structure
P10409755A1846|2 8|summary
P10409755A1846|26 35|activation
P10409755A1846|10 11|Ca
P10409755A1846|72 81|TG exposure
P10409755A1846|38 49|NO production
P10409755A1846|84 94|JT/Neo cells
P10409755A1846|58 66|apoptosis
P10411139A0887|0 11|Accumulation
P10411139A0887|66 71|Prp44p
P10411139A0887|17 27|U4/U6 duplex
P10411139A0887|41 54|overexpression
P10411139A1344|3 9|results
P10411139A1344|75 78|role
P10411139A1344|53 59|results
P10411139A1344|104 113|U4/U6 helix
P10411139A1344|82 87|Prp44p
P10411140A0499|85 89|mRNAs
P10411140A0499|74 79|region
P10411140A0499|100 109|terminator
P10411140A0499|23 25|RNA
P10411140A0499|42 55|RNase E cleavage
P10411160T0000|48 66|skin cancer incidence
P10411160T0000|24 34|variability
P10411160T0000|3 11|mysteries
P10413604A0063|138 149|DNA synthesis
P10413604A0063|109 117|mechanism
P10413604A0063|42 48|kinases
P10413604A0063|50 53|PKAs
P10413604A0063|73 78|growth
P10413607A0085|147 155|cell types
P10413607A0085|115 126|DNA synthesis
P10413607A0085|197 214|signal transduction
P10413607A0085|99 101|CVI
P10413607A0085|55 69|matrix molecules
P10413607A0085|27 34|contrast
P10413607A0085|88 97|collagen VI
P10413662A0193|87 93|plasmid
P10413662A0193|107 127|iron acquisition system
P10413662A0193|81 84|pJM1
P10413662A0193|142 150|virulence
P10413662A0193|34 56|pMJ101 replication region
P10413662A0193|153 165|V. anguillarum
P10413662A0193|186 193|pathogen
P10413662A0193|204 212|vibriosis
P10413676A0000|14 18|sites
P10413676A0000|21 59|transmembrane integrin receptor clustering
P10413676A0000|87 101|signaling events
P10413676A0000|0 2|FAK
P10413676A0595|0 9|Expression
P10413676A0595|247 261|paxillin binding
P10413676A0595|160 165|domain
P10413676A0595|213 215|FAK
P10413676A0595|19 28|FAK mutants
P10413676A0595|74 80|Tyr-397
P10413676A0595|126 141|SH3 binding region
P10413676A0595|264 266|FAK
P10413676A0595|34 36|FAK
P10413676A0595|38 42|cells
P10413676A0595|217 229|cell migration
P10413676A0595|98 101|site
P10413676A0595|147 149|FAK
P10413676A0595|82 90|SH2 domain
P10413676A0595|53 69|FAK kinase activity
P10413676A0595|232 233|FN
P10413676A1193|71 73|Ser
P10413676A1193|112 123|contact sites
P10413676A1193|89 104|FRNK localization
P10413676A1193|47 59|point mutation
P10413676A1193|61 68|Leu-1034
P10413676A1193|21 26|effect
P10413676A1193|29 32|FRNK
P10414451A0093|28 29|yr
P10414451A0093|186 193|protein C
P10414451A0093|49 51|DVT
P10414451A0093|22 24|age
P10414451A0093|105 112|protein C
P10414451A0093|74 81|presence
P10414451A0093|195 202|protein S
P10414451A0093|114 118|APC-R
P10414451A0093|140 141|LA
P10414451A0093|13 20|patients
P10414451A0093|159 168|antibodies
P10414451A0093|172 183|deficiencies
P10414451A0093|121 138|lupus anticoagulant
P10414451A0093|84 93|resistance
P10414451A0093|204 218|ATIII activities
P10416429A0221|0 5|DESIGN
P10416429A0221|19 24|number
P10416429A0221|7 16|Comparison
P10416429A0221|48 52|years
P10416429A0221|36 38|PKU
P10416429A0221|100 105|number
P10416429A0221|81 86|number
P10416429A0221|117 130|population data
P10416429A0221|58 71|NSW PKU database
P10416429A0221|27 31|women
P10416558A0000|0 6|PURPOSE
P10416558A0000|163 174|health status
P10416558A0000|211 221|individuals
P10416558A0000|281 295|exercise relapse
P10416558A0000|51 57|effects
P10416558A0000|11 18|purposes
P10416558A0000|242 247|degree
P10416558A0000|129 140|CD4 cell count
P10416558A0000|223 223|N
P10416558A0000|66 75|laboratory
P10416558A0000|120 127|function
P10416558A0000|88 102|exercise program
P10416558A0000|31 35|study
P10416558A0000|258 263|health
P10417331A1008|42 51|mM pantoate
P10417331A1008|24 31|activity
P10417331A1008|63 63|s
P10417331A1008|74 75|pH
P10417331A1008|53 53|k
P10417331A1008|55 57|cat
P10417331A1008|3 8|enzyme
P10417703A1326|44 45|RP
P10417703A1326|139 154|plant RPT subunits
P10417703A1326|165 181|yeast counterparts
P10417703A1326|19 25|results
P10417703A1326|111 120|eukaryotes
P10417703A1326|200 208|functions
P10417703A1326|54 66|20S proteasome
P10419006A0378|34 59|estrogen replacement therapy
P10419006A0378|13 20|evidence
P10419006A0378|65 73|menopause
P10419006A0378|83 98|breast cancer risk
P10419521A0136|114 131|polymerase activity
P10419521A0136|34 36|ELL
P10419521A0136|151 163|transcription
P10419521A0136|51 54|type
P10419521A0136|15 32|elongation activity
P10419521A0136|2 9|addition
P10419521A0136|72 88|interaction domain
P10419521A0136|57 69|RNA polymerase
P10422291A0572|29 35|myeloma
P10422291A0572|12 20|IgA lambda
P10422291A0572|50 60|involvement
P10422291A0572|1 9|diagnosis
P10422342A0535|206 209|131I
P10422342A0535|224 228|111In
P10422342A0535|211 215|201Tl
P10422342A0535|152 163|examinations
P10422342A0535|35 42|majority
P10422342A0535|190 201|preparations
P10422342A0535|217 220|67Ga
P10422342A0535|45 56|examinations
P10422342A0535|97 100|dose
P10422342A0535|174 187|administration
P10422342A0535|66 73|medicine
P10422342A0535|120 134|radiation burden
P10422342A0535|3 17|radiation burden
P10422468A0524|197 200|case
P10422468A0524|180 190|Y chromosome
P10422468A0524|216 224|mutations
P10422468A0524|105 117|abnormalities
P10422468A0524|48 51|ICSI
P10422468A0524|145 157|sex chromosome
P10422468A0524|126 128|NOA
P10422468A0524|11 14|risk
P10422468A0524|236 247|fibrosis gene
P10422468A0524|161 174|microdeletions
P10422468A0524|213 214|OA
P10422468A0524|17 28|malformation
P10422468A0524|120 123|case
P10422468A0524|31 38|children
P10422468A0524|139 142|rate
P10422468A0524|84 87|risk
P10423156A0265|0 11|TaV particles
P10423156A0265|86 88|kDa
P10423156A0265|38 42|g/cm3
P10423156A0265|24 30|density
P10423156A0265|64 77|capsid proteins
P10423156A0265|45 48|CsCl
P10423193A1309|0 9|CONCLUSION
P10423193A1309|57 67|involvement
P10423193A1309|123 125|CTS
P10423193A1309|101 110|neuropathy
P10423193A1309|16 22|results
P10423292A0782|28 32|Spam1
P10423292A0782|112 114|CRE
P10423292A0782|10 11|bp
P10423292A0782|97 101|sites
P10423292A0782|20 25|region
P10423292A0782|71 89|transcription factor
P10423292A0782|131 137|element
P10425094A1006|39 39|s
P10425094A1006|25 31|complex
P10425094A1006|10 19|relaxivity
P10425094A1006|44 45|mM
P10425445T0000|0 8|Structure
P10425445T0000|12 21|expression
P10425445T0000|27 84|mouse growth hormone receptor/growth hormone binding protein gene
P10426450A1458|28 39|liver/spleen
P10426450A1458|19 20|SA
P10426450A1458|105 107|ILK
P10426450A1458|9 16|recovery
P10426450A1458|51 56|tonsil
P10426450A1458|75 76|SG
P10426450A1458|81 93|contact chicks
P10426450A1458|171 176|chicks
P10426450A1458|59 71|contact poults
P10426450A1458|155 167|contact poults
P10426878A0367|15 25|ISIS-2 trial
P10426878A0367|111 118|patients
P10426878A0367|65 77|Collaboration
P10426878A0367|32 35|data
P10426878A0367|91 97|aspirin
P10426878A0367|55 63|Trialists
P10426878A0367|138 147|infarction
P10426878A0367|163 172|prevention
P10426878A0367|3 9|results
P10427654A0000|58 68|laparoscopy
P10427654A0000|162 167|cancer
P10427654A0000|95 102|patients
P10427654A0000|107 120|adenocarcinoma
P10427654A0000|143 148|cancer
P10427654A0000|126 134|esophagus
P10427654A0000|32 35|role
P10427654A0000|4 8|study
P10427654A0000|86 92|staging
P10427654A0000|191 197|surgery
P10428091A0322|119 123|women
P10428091A0322|32 35|MMRs
P10428091A0322|69 79|disparities
P10428091A0322|4 9|report
P10428091A0322|90 98|mortality
P10428294A0227|0 21|Preheparin LPL mass level
P10428294A0227|49 59|individuals
P10428294A0227|86 88|men
P10428294A0227|92 96|women
P10428294A0227|70 74|years
P10428759A0743|1 8|decrease
P10428759A0743|26 47|receptor kinase activity
P10428759A0743|81 89|receptors
P10428811A0628|0 4|Cat-1
P10428811A0628|39 52|binding partner
P10428811A0628|74 87|receptor kinase
P10428811A0628|98 102|GRK-2
P10428811A0628|131 138|activity
P10428811A0628|89 95|betaARK
P10428811A1067|0 10|Cat proteins
P10428811A1067|55 59|cells
P10428811A1067|92 94|Src
P10428811A1067|72 88|adhesion kinase Fak
P10428862A0834|0 29|Immunoprecipitation experiments
P10428862A0834|68 78|interaction
P10428862A0834|96 99|DokR
P10428862A0834|163 172|BaF/3 cells
P10428862A0834|111 117|protein
P10428862A0834|48 57|antibodies
P10429184A0000|0 8|Expansins
P10429184A0000|113 121|mechanism
P10429184A0000|50 58|extension
P10429184A0000|21 28|proteins
P10429184A0000|69 82|plant cell walls
P10429184A0000|13 18|family
P10429740A0000|89 91|IBS
P10429740A0000|4 9|review
P10429740A0000|31 38|evidence
P10429740A0000|55 63|therapies
P10429740A0000|75 87|bowel syndrome
P10429946A0473|112 120|sequences
P10429946A0473|13 18|region
P10429946A0473|103 104|bp
P10429946A0473|89 96|promoter
P10429946A0473|33 44|collagen gene
P10429946A0473|24 28|alpha
P10429946A0473|60 67|fragment
P10429946A0473|147 154|elements
P10429946A0473|107 110|exon
P10429946A0473|31 31|V
P10429946A0473|80 81|bp
P10429946A0988|76 91|complex formation
P10429946A0988|12 19|addition
P10429946A0988|22 66|B-Myb-glutathionine S-transferase fusion protein
P10430421T0000|73 88|Cache County Study
P10430421T0000|45 55|AD increases
P10430421T0000|26 28|age
P10430421T0000|33 42|prevalence
P10430421T0000|0 17|APOE-epsilon4 count
P10430580A0000|0 5|Repair
P10430580A0000|8 26|double-strand breaks
P10430580A0000|64 74|end-joining
P10430580A0000|46 48|DNA
P10430580A0000|108 112|yeast
P10430580A0000|28 31|DSBs
P10430580A0000|76 79|NHEJ
P10430583A0000|59 62|RecA
P10430583A0000|49 56|homology
P10430583A0000|4 16|DNA repair gene
P10430883A0000|62 67|glands
P10430883A0000|189 193|mucin
P10430883A0000|20 24|cells
P10430883A0000|258 283|sodium borohydride reduction
P10430883A0000|78 83|glands
P10430883A0000|181 185|class
P10430883A0000|285 288|Con A
P10430883A0000|53 59|Brunner
P10430883A0000|145 154|metaplasia
P10430883A0000|104 108|tract
P10430883A0000|221 228|staining
P10430883A0000|217 219|Con
P10430883A0000|47 51|cells
P10430883A0000|36 40|gland
P10430883A0000|248 256|oxidation
P10430883A0000|123 127|ducts
P10430883A0000|293 321|horseradish peroxidase reaction
P10430886A0838|44 47|TraR
P10430886A0838|13 19|mutants
P10430886A0838|105 113|activator
P10430886A0838|74 88|heteromultimers
P10430890A1059|5 12|elongin C
P10430890A1059|115 129|partner proteins
P10430890A1059|76 89|rearrangements
P10430890A1059|35 42|solution
P10430890A1059|94 100|binding
P10430944A1298|57 68|malignancies
P10430944A1298|37 40|role
P10430944A1298|16 32|JAK/STAT signaling
P10430944A1298|3 6|data
P10430980A0465|20 24|women
P10430980A0465|11 13|men
P10433729A1559|0 1|A.
P10433729A1559|10 12|K.E
P10433729A1559|26 27|C.
P10433729A1559|3 8|Bowers
P10433729A1559|17 24|Matthews
P10433970A0279|28 39|reading frame
P10433970A0279|55 70|DNA binding domain
P10433970A0279|79 96|localization signal
P10433970A0279|100 120|transactivation domain
P10433970A0279|0 5|Spfkh1
P10435595A0203|35 50|trans-activation
P10435595A0203|12 20|mechanism
P10436016A0337|0 12|Gel filtration
P10436016A0337|116 120|Mad1p
P10436016A0337|56 60|Mad2p
P10436016A0337|89 114|spindle checkpoint component
P10436016A0337|16 45|co-immunoprecipitation analyses
P10437043A0164|43 50|biopsies
P10437043A0164|20 24|cases
P10437043A0164|0 6|METHODS
P10437043A0164|29 30|SS
P10438540A1185|86 102|transport activity
P10438540A1185|51 52|Cd
P10438540A1185|108 114|protein
P10438540A1185|77 82|strain
P10438540A1185|57 65|tolerance
P10438540A1185|31 43|domain mutants
P10438593A0000|61 73|transcription
P10438593A0000|8 34|immunodeficiency virus type-1
P10438593A0000|36 40|HIV-1
P10438593A0000|87 111|RNA polymerase processivity
P10438593A0000|42 51|Tat protein
P10438607A0330|57 68|gene fork head
P10438607A0330|10 14|SEBPs
P10438607A0330|37 43|product
P10438607A0330|16 20|SEBP2
P10438627A0885|0 15|Identity elements
P10438627A0885|104 116|T7 transcripts
P10438627A0885|25 28|mono
P10438627A0885|148 150|Phe
P10438627A0885|121 128|variants
P10438627A0885|71 77|pfTrm1p
P10438627A0885|136 138|Asp
P10438627A0885|156 160|yeast
P10438627A0885|18 21|tRNA
P10438627A0885|46 54|reactions
P10438627A0885|131 134|tRNA
P10438627A0885|143 146|tRNA
P10438924A1009|60 105|serine/threonine kinase glycogen synthase kinase-3
P10438924A1009|107 111|GSK-3
P10438924A1009|26 28|Akt
P10438924A1009|20 24|cells
P10438924T0000|3 22|B cell antigen receptor
P10438924T0000|35 37|Akt
P10438924T0000|39 52|protein kinase B
P10438924T0000|55 94|glycogen synthase kinase-3 signaling pathway
P10438924T0000|98 125|phosphatidylinositol 3-kinase
P10438941A1197|116 120|genes
P10438941A1197|80 98|switch recombination
P10438941A1197|50 50|B
P10438941A1197|5 23|recombination events
P10438941A1197|54 63|T cell lines
P10438950A0580|0 3|IL-1
P10438950A0580|81 99|fibroblast cell lines
P10438950A0580|7 39|TNF increase AND-34 transcript levels
P10438950A0580|72 76|nurse
P10439040A0658|73 78|region
P10439040A0658|102 113|CAT reporters
P10439040A0658|139 148|constructs
P10439040A0658|35 49|c-myc expression
P10439040A0658|80 82|UTR
P10439040A0658|54 58|c-myc
P10439040A0658|15 23|role eIF4E
P10440923A0684|0 7|Analysis
P10440923A0684|223 228|levels
P10440923A0684|66 77|control cells
P10440923A0684|42 60|lovastatin treatment
P10440923A0684|179 184|cyclin
P10440923A0684|100 105|levels
P10440923A0684|152 161|inhibition
P10440923A0684|10 26|cell cycle proteins
P10440923A0684|39 39|h
P10440923A0684|86 94|elevation
P10440923A0684|127 144|kinase inhibitor p27
P10440923A0684|250 270|retinoblastoma protein
P10440923A0684|168 174|cyclin E
P10440923A0684|272 274|pRb
P10440923A0684|196 209|kinase activity
P10440923A0684|146 149|kip1
P10441243A0443|0 6|RESULTS
P10441243A0443|19 38|leptin concentrations
P10441243A0443|71 75|ng/ml
P10441243A0443|85 92|subjects
P10441449X1212|0 8|Copyright
P10441449X1212|13 25|Academic Press
P10441483A0454|0 20|Oligonucleotide probes
P10441483A0454|54 66|EpRE sequences
P10441483A0454|100 107|analyses
P10441483A0454|118 125|proteins
P10441506A0098|0 6|PKNbeta
P10441506A0098|14 29|sequence homology
P10441506A0098|221 236|amino acid stretch
P10441506A0098|193 198|domain
P10441506A0098|96 100|amino
P10441506A0098|80 86|repeats
P10441506A0098|292 297|domain
P10441506A0098|120 133|leucine-zipper
P10441506A0098|110 115|region
P10441506A0098|34 41|PKNalpha
P10441506A0098|138 146|sequences
P10441506A0098|61 63|PKN
P10441506A0098|265 276|CZ region/HR1
P10441506A0098|238 248|D region/HR2
P10441506A0098|148 159|CZ region/HR1
P10442493A0815|99 122|plasma cyclosporine levels
P10442493A0815|60 68|serum FLOP
P10442493A0815|24 31|lycopene
P10442493A0815|11 21|serum levels
P10442493A0815|35 38|FLOP
P10442493A0815|124 124|r
P10442493A0815|132 132|p
P10442493A0815|2 9|baseline
P10443990A0000|0 9|BACKGROUND
P10443990A0000|72 81|bone health
P10443990A0000|18 35|alcohol consumption
P10444597A0586|142 148|nucleus
P10444597A0586|23 31|induction
P10444597A0586|95 104|mRNA export
P10444597A0586|115 119|Npl3p
P10444597A0586|63 69|ethanol
P10444597A0586|56 59|salt
P10444597A0586|71 80|conditions
P10444597A0586|34 39|stress
P10444597A0586|42 50|heat shock
P10444813A0448|14 19|relief
P10444813A0448|23 32|inhibition
P10444813A0448|38 43|growth
P10444813A0448|49 70|metastases interferon-a
P10444813A0448|74 94|somatostatin analogues
P10445161A1565|43 47|study
P10445161A1565|147 151|sexes
P10445161A1565|123 140|organ weight changes
P10445161A1565|89 98|weight gain
P10445161A1565|69 71|ppm
P10445161A1565|107 110|rats
P10445161A1565|158 160|ppm
P10445161A1565|2 8|summary
P10445506A0073|54 63|body length
P10445506A0073|25 29|sperm
P10445506A0073|37 41|times
P10445945T0000|0 16|John leonard dawson
P10446131A0132|0 16|PDGF A-chain levels
P10446131A0132|75 78|ATII
P10446131A0132|61 64|SMCs
P10446131A0132|43 59|smooth muscle cells
P10446149A0809|86 90|A-Raf
P10446149A0809|39 43|assay
P10446149A0809|24 28|yeast
P10446149A0809|92 96|B-Raf
P10446149A0809|78 84|c-Raf-1
P10446149A0809|56 67|Ras effectors
P10446149A0809|127 132|RalGDS
P10446149A0809|137 140|Rin1
P10446149A0809|98 125|phosphoinositol-3 kinase delta
P10446206A0000|144 148|study
P10446206A0000|184 201|hepatoma HepG2 cells
P10446206A0000|110 131|transcription start site
P10446206A0000|161 180|neuroblastoma SK-N-SH
P10446206A0000|38 40|PS1
P10446206A0000|25 36|presenilin-1
P10446206A0000|42 49|promoter
P10446206A0000|97 104|relation
P10446206A0000|0 14|Deletion mapping
P10446206A0000|73 80|fragment
P10446833T0000|16 26|oxygenation
P10446833T0000|40 45|sepsis
P10446833T0000|49 53|shock
P10446833T0000|30 37|shunting
P10446910A0147|0 7|Analysis
P10446910A0147|71 87|E2-responsiveness
P10446910A0147|254 255|E2
P10446910A0147|237 251|transactivation
P10446910A0147|51 56|region
P10446910A0147|217 221|sites
P10446910A0147|131 155|deletion/mutation analysis
P10446910A0147|13 28|E2F1 gene promoter
P10446910A0147|99 116|transfection assays
P10446912A0883|29 38|mechanisms
P10446912A0883|64 83|CYP11A1 transcription
P10446912A0883|121 130|JEG-3 cells
P10446912A0883|52 54|OF3
P10446912A0883|110 112|Sp1
P10446912A0883|102 104|OF3
P10446912A0883|96 98|OF5
P10446912A0883|5 10|course
P10446912A0883|116 118|Sp3
P10446912A0883|46 48|OF5
P10446998A0375|14 28|differentiation
P10446998A0375|106 122|c-fos inducibility
P10446998A0375|84 97|responsiveness
P10446998A0375|56 60|cells
P10446998A0375|100 103|junB
P10446998A0375|2 9|contrast
P10446998A0955|0 23|Adipocyte differentiation
P10446998A0955|40 44|cells
P10446998A0955|92 98|junB SRE
P10446998A0955|69 75|ability
P10446998A0955|78 80|SRF
P10446998A0955|139 151|mobility shift
P10446998A0955|103 110|c-fos SRE
P10446998A0955|120 123|SREs
P10446998A0955|194 218|DNA binding characteristics
P10446998A0955|155 173|gel supershift assays
P10446998A0955|231 241|protein SP-1
P10446998T0000|0 13|Transformation
P10446998T0000|55 85|serum response factor interactions
P10446998T0000|43 52|inhibition
P10446998T0000|90 110|serum response elements
P10447593A0144|116 127|sigma factors
P10447593A0144|91 102|similarities
P10447593A0144|51 52|T7
P10447593A0144|3 12|core enzyme
P10447593A0144|34 49|bacteriophages T3
P10447593A0144|69 85|specificity factor
P10447593A0144|56 58|SP6
P10447597A1004|3 14|Cr.psbA-4 ORF
P10447597A1004|48 59|GIY-YIG motif
P10447597A1004|30 34|motif
P10448036A0748|144 149|finger
P10448036A0748|37 40|S RNA
P10448036A0748|172 179|affinity
P10448036A0748|107 111|zf4-7
P10448036A0748|208 221|RNA interaction
P10448036A0748|74 96|competitor concentration
P10448036A0748|114 128|S RNA interaction
P10448036A0748|183 193|specificity
P10448036A0748|3 13|interaction
P10448036A0748|200 206|protein
P10448036A0748|16 20|zf4-6
P10448095A0865|89 98|conversion
P10448095A0865|114 123|adipocytes
P10448095A0865|39 53|C/EBP expression
P10448095A0865|188 197|adipocytes
P10448095A0865|139 155|expression profile
P10448095A0865|3 25|STAT protein accumulation
P10448095A0865|101 111|fibroblasts
P10448285A1035|84 89|months
P10448285A1035|72 77|months
P10448285A1035|60 64|trial
P10448285A1035|21 28|response
P10448285A1035|9 17|durations
P10448285A1035|32 43|survival time
P10448285A1035|53 57|phase
P10448440T0020|3 6|role
P10448440T0020|20 29|psychiatry
P10448440T0020|65 77|schizophrenia
P10448440T0020|33 53|understanding patients
P10448440T0020|86 104|personality disorder
P10448902A0921|62 80|superoxide dismutase
P10448902A0921|38 58|glutathione peroxidase
P10448902A0921|21 27|enzymes
P10448902A0921|98 101|rats
P10448902A0921|29 36|catalase
P10448902A0921|135 138|rats
P10449072A0560|57 59|GPi
P10449072A0560|62 63|PD
P10449072A0560|9 12|goal
P10449072A0560|41 51|arrangement
P10449899A0881|50 57|PERV copy
P10449899A0881|12 18|results
P10449899A0881|61 75|integration site
P10450815A0180|235 240|gender
P10450815A0180|218 224|factors
P10450815A0180|79 86|age range
P10450815A0180|124 135|relationship
P10450815A0180|231 233|age
P10450815A0180|92 96|years
P10450815A0180|10 22|investigation
P10450815A0180|246 252|hygiene
P10450815A0180|63 73|individuals
P10450815A0180|192 198|account
P10450815A0180|173 180|calculus
P10450815A0180|35 44|population
P10450815A0180|264 275|inflammation
P10450815A0180|143 156|tobacco smoking
P10451209A0000|0 8|OBJECTIVE
P10451209A0000|108 112|doses
P10451209A0000|70 79|hemorrhage
P10451209A0000|115 147|methylprednisolone sodium succinate
P10451209A0000|28 41|administration
P10451209A0000|89 92|dogs
P10451209A0000|44 54|misoprostol
P10451209A0000|149 152|MPSS
P10452306A0502|0 7|Patients
P10452306A0502|93 97|x-ray
P10452306A0502|170 199|heart catheterization parameters
P10452306A0502|118 123|M-mode
P10452306A0502|80 83|LVEF
P10452306A0502|52 78|norepinephrine concentration
P10452306A0502|112 116|ratio
P10452306A0502|148 155|diameter
P10452306A0502|85 91|peak Vo2
P10452306A0502|30 39|MIBG uptake
P10452951A0000|101 107|species
P10452951A0000|7 22|hormone receptors
P10452951A0000|24 26|NRs
P10452951A0000|86 94|functions
P10452951A0000|47 66|transcription factors
P10452991A0331|27 49|influenza virus particles
P10452991A0331|5 9|cells
P10452991A0331|70 80|T cell clones
P10453006A0000|0 9|Sequencing
P10453006A0000|22 31|Danio rerio
P10453006A0000|52 61|chromosome
P10453006A0000|77 86|chromosome
P10453006A0000|12 20|zebrafish
P10453006A0000|65 66|P1
P10453006A0000|157 160|loci
P10453006A0000|134 147|identification
P10453006A0000|184 194|proteasomes
P10453006A0000|113 122|cDNA clones
P10453006A0000|94 107|clone fragments
P10453006A0000|196 199|PSMB
P10453006A0000|170 181|beta subunits
P10453006A0478|139 144|humans
P10453006A0478|49 53|PSMB9
P10453006A0478|76 81|PSMB12
P10453006A0478|61 65|genes
P10453006A0478|12 21|homologues
P10453006A0478|32 41|genes PSMB5
P10453006A0478|132 136|genes
P10453006A0478|67 72|PSMB11
P10453006A0478|2 9|addition
P10453248A0094|88 93|models
P10453248A0094|24 34|perspective
P10453248A0094|9 12|Udry
P10453248A0094|127 135|behaviour
P10453371A0640|0 5|Weight
P10453371A0640|54 64|BMD z-scores
P10453371A0640|9 22|height z-scores
P10453721A0445|81 84|part
P10453721A0445|8 23|sampling strategy
P10453721A0445|47 74|parameter estimation algorithm
P10453721A0445|90 111|ADAPT II software package
P10454533A0859|42 55|transformation
P10454533A0859|20 24|Hsc70
P10454533A0859|91 94|acid
P10454533A0859|140 151|conformation
P10454533A0859|13 15|HRI
P10454533A0859|116 118|HRI
P10454533A0859|67 81|Hsc70 antagonist
P10454533A0859|58 60|HRI
P10454533A0859|0 10|Interaction
P10454540A0392|27 31|D208A
P10454540A0392|49 59|combination
P10454540A0392|63 81|exonuclease activity
P10454540A0392|3 23|amino acid changes D206A
P10454550A0960|59 62|Glc7
P10454550A0960|20 27|evidence
P10454550A0960|91 107|Snf1 kinase complex
P10454550A0960|44 47|Reg1
P10454550A0960|72 81|substrates
P10454557A0000|74 83|chromosome
P10454557A0000|200 211|HML locus show
P10454557A0000|109 116|sequence
P10454557A0000|145 154|chromosome
P10454557A0000|118 120|ARS
P10454557A0000|12 16|yeast
P10454557A0000|166 169|ARSs
P10454557A0000|214 238|replication origin activity
P10454557A0000|42 52|replicators
P10454557A0000|122 129|elements
P10454557A0975|189 198|components
P10454557A0975|61 66|ARS302
P10454557A0975|51 56|ARS320
P10454557A0975|69 78|inactivity
P10454557A0975|123 131|silencing
P10454557A0975|153 161|silencers
P10454557A0975|170 172|cis
P10454557A0975|143 149|origins
P10454557A0975|30 42|HML ARS cluster
P10454557A0975|5 11|results
P10454557A0975|44 49|ARS303
P10454557A0975|81 87|origins
P10454561A0594|268 282|TD-IkappaBalpha
P10454561A0594|12 16|study
P10454561A0594|262 264|p65
P10454561A0594|113 131|tumor necrosis factor
P10454561A0594|47 61|TD-IkappaBalpha
P10454561A0594|186 212|NF-kappaB DNA binding activity
P10454561A0594|145 173|IkappaBalpha gene transcription
P10454561A0594|69 110|phorbol myristate acetate-phytohemagglutinin
P10454561A0594|35 44|expression
P10454561A0594|257 260|RelA
P10454561A0594|242 254|sequestration
P10454568A0815|30 33|cDNA
P10454568A0815|11 25|Grb10 expression
P10454568A0815|111 117|insulin
P10454568A0815|67 82|expression system
P10454568A0815|198 204|fashion
P10454568A0815|159 170|DNA synthesis
P10454568A0815|93 99|PDGF-BB
P10454568A0815|102 106|IGF-I
P10454568A0815|175 182|ecdysone
P10454568A0815|134 145|growth factor
P10454568A0815|147 149|EGF
P10454570A0846|236 244|induction
P10454570A0846|298 312|ERK-2 activation
P10454570A0846|162 166|ATF-2
P10454570A0846|281 286|kinase
P10454570A0846|168 172|c-Jun
P10454570A0846|289 293|ERK-1
P10454570A0846|357 367|stimulation
P10454570A0846|328 330|TPA
P10454570A0846|114 129|kinase activation
P10454570A0846|373 383|uPA enhancer
P10454570A0846|41 61|protein kinase pathways
P10454570A0846|145 159|phosphorylation
P10454570A0846|87 103|protein kinase-Jun
P10454570A0846|177 180|JunD
P10454570A0846|3 10|analysis
P10454570A0846|205 208|IL-1
P10455087A1400|0 10|CONCLUSIONS
P10455087A1400|21 31|individuals
P10455087A1400|38 59|body insulin sensitivity
P10455087A1400|96 104|threshold
P10455143T0000|0 19|Interdomain signaling
P10455143T0000|51 72|glucocorticoid receptor
P10455143T0000|33 40|fragment
P10455183A0530|14 18|xtRNA
P10455183A0530|36 42|binding
P10455183A0530|24 27|gene
P10455183A0530|75 79|Oct-1
P10455183A0530|20 22|Sec
P10455183A0530|106 113|capacity
P10455183A0530|53 67|Staf zinc fingers
P10455183A0530|2 9|contrast
P10455183A0930|61 74|Staf zinc finger
P10455183A0930|167 169|Sec
P10455183A0930|155 165|Xenopus tRNA
P10455183A0930|130 148|activation mechanism
P10455183A0930|18 24|results
P10455183A0930|179 190|U6 snRNA genes
P10455183A0930|48 58|utilization
P10455183A0930|99 109|determinant
P10455189A0104|2 7|B cells
P10455189A0104|9 12|HEF1
P10455189A0104|54 62|mechanism
P10455189A0104|80 95|integrin ligation
P10455189A0427|46 49|HEF1
P10455189A0427|21 43|tyrosine phosphorylation
P10455189A0427|84 89|manner
P10455189A0427|62 65|time
P10457075A1198|46 47|VI
P10457075A1198|89 93|Pcrit
P10457075A1198|67 67|%
P10457075A1198|107 108|Rn
P10457075A1198|110 121|peak decrease
P10457075A1198|69 69|P
P10457075A1198|126 126|%
P10457075A1198|57 64|increase
P10457075A1198|49 51|max
P10457075A1198|128 128|P
P10457075A1198|0 36|Independent protrudor muscle stimulation
P10458905A0000|60 77|YAC/BAC clone contig
P10458905A0000|11 22|construction
P10458905A0000|80 87|8p22-p23
P10458907A0543|17 42|mouse Rad30b mRNA transcripts
P10458907A0543|52 65|repair proteins
P10458907A0543|90 95|testis
P10458907A0543|8 13|RAD30B
P10458914A0674|84 89|region
P10458914A0674|48 54|library
P10458914A0674|98 99|kb
P10458914A0674|13 25|mouse STAP gene
P10458914A0674|117 121|exons
P10458914A0674|70 77|STAP gene
P10458914A0674|0 7|Analysis
P10459809A1262|65 71|biofilm
P10459809A1262|8 25|matrix distribution
P10459809A1262|37 47|cell density
P10460015A0465|57 62|height
P10460015A0465|78 88|improvement
P10460015A0465|7 12|months
P10460015A0465|66 71|weight
P10460015A0465|98 115|bone mineral density
P10460015A0465|119 125|bone age
P10460015A0465|15 23|treatment
P10460015A0465|41 48|estrogen
P10460171A0842|0 19|Viscosity experiments
P10460171A0842|84 101|phosphoryl transfer
P10460171A0842|75 82|chemical
P10460171A0842|34 55|fragment kinase reaction
P10460171A0842|103 106|step
P10460171A0842|118 121|rate
P10460172A0823|0 20|Velocity sedimentation
P10460172A0823|119 133|kDa polypeptides
P10460172A0823|22 34|cross-linking
P10460172A0823|146 160|heterotetramers
P10460172A0823|39 65|immunoprecipitation analyses
P10460172A0823|89 96|rat brain
P10463057A0534|7 22|expression levels
P10463057A0534|37 44|plasmids
P10463242A0316|41 46|region
P10463242A0316|19 23|waves
P10463242A0316|2 4|EEG
P10464185T0000|48 78|polysaccharide biosynthesis genes
P10464185T0000|81 109|Streptococcus agalactiae type Ia
P10464185T0000|9 24|characterization
P10464250A0275|6 12|FASEB J.
P10464291A0597|76 87|protein delta
P10464291A0597|113 116|time
P10464291A0597|41 50|PDGFalphaR
P10464291A0597|11 15|ng/ml
P10464291A0597|100 109|mRNA levels
P10464291A0597|126 131|manner
P10464291A0597|89 98|C/EBPdelta
P10464291A0597|0 7|IL-1beta
P10464302A1109b|77 91|pathway proteins
P10464302A1109b|196 202|pathway
P10464302A1109b|152 156|model
P10464302A1109b|174 181|assembly
P10464302A1109b|247 258|cytoskeleton
P10464302A1109b|120 134|interaction site
P10464302A1109b|210 221|transmission
P10464302A1109b|3 13|recruitment
P10464302A1109b|49 51|neu
P10464302A1109b|224 241|growth factor signal
P10464302A1109b|44 47|p185
P10464310A0218|251 256|FGFR-1
P10464310A0218|107 134|juxtamembrane tyrosine residue
P10464310A0218|39 54|fibroblast growth
P10464310A0218|245 247|Crk
P10464310A0218|85 89|cells
P10464310A0218|9 31|tyrosine phosphorylation
P10464310A0218|198 204|Tyr-463
P10464310A0218|140 145|FGFR-1
P10464310A0218|151 162|Crk SH2 domain
P10464310A0218|175 180|FGFR-1
P10464310A0218|34 36|Crk
P10464310A0218|222 237|complex formation
P10466306A0000|56 64|technique
P10466306A0000|96 103|function
P10466306A0000|84 92|perfusion
P10466306A0000|19 46|Technetium-99m sestamibi SPECT
P10466825T0000|0 3|Role
P10466825T0000|61 70|expression
P10466825T0000|23 28|region
P10466825T0000|80 84|genes
P10466825T0000|31 48|baculovirus p10 mRNA
P10467004A0116|26 36|nucleotides
P10467004A0116|123 129|introns
P10467004A0116|3 11|intron RNA
P10467004A0116|94 107|sequence motifs
P10467004A0116|67 75|structure
P10467004A0116|131 136|Michel
P10467004A0683|3 8|intron
P10467004A0683|38 41|fact
P10467004A0683|152 153|bp
P10467004A0683|20 27|splicing
P10467004A0683|122 129|splicing
P10467004A0683|68 90|EBS2/IBS2 sequence motifs
P10467004A0683|53 61|EBS1/IBS1
P10467403A0000|3 31|Trk/Nerve Growth Factor receptor
P10467403A0000|61 66|number
P10467403A0000|109 136|phosphatidylinositol 3-kinase
P10467403A0000|48 57|activation
P10467403A0000|82 98|signaling proteins
P10467403A0000|138 147|PI 3-kinase
P10467465T0000|16 34|significance testing
P10467465T0000|53 64|alternatives
P10467465T0000|36 49|misconceptions
P10467465T0000|3 13|controversy
P10468033T0000|0 13|Chemical uptake
P10468033T0000|23 36|stratum corneum
P10468033T0000|70 77|solvents
P10468585A0980|30 40|enhancement
P10468585A0980|129 133|Hap46
P10468585A0980|4 13|DNA binding
P10468585A0980|154 169|hsp70 interaction
P10468585A0980|77 93|amino acid residues
P10468585A0980|120 126|portion
P10469140A0336|176 191|mutation analyses
P10469140A0336|108 115|TNFalpha
P10469140A0336|92 105|responsiveness
P10469140A0336|51 55|sites
P10469140A0336|81 88|promoter
P10469140A0336|121 172|chloramphenicol acetyl transferase reporter gene deletion
P10469140A0336|68 72|PAI-2
P10469140A0336|15 22|function
P10469174A0678|60 67|fragment
P10469174A0678|10 25|sequence analysis
P10469174A0678|143 148|domain
P10469174A0678|156 162|MBF1CTD
P10469174A0678|151 154|MBF1
P10469174A0678|107 110|MBF1
P10469174A0678|97 104|residues
P10469174A0678|29 43|NMR measurements
P10469656T0000|14 21|response
P10469656T0000|106 109|MSK1
P10469656T0000|138 143|kinase
P10469656T0000|51 63|gene induction
P10469656T0000|122 134|histone H3/HMG
P10469656T0000|88 104|MAP kinase cascades
P10470220A1011|3 13|arrangement
P10470220A1011|105 107|RIA
P10470220A1011|149 149|%
P10470220A1011|76 76|%
P10470220A1011|61 71|specificity
P10470220A1011|134 144|specificity
P10470220A1011|42 52|sensitivity
P10470220A1011|130 130|%
P10470220A1011|21 33|cutoff-levels
P10470220A1011|57 57|%
P10470220A1011|80 90|Protein S100
P10470220A1011|164 166|LIA
P10470220A1011|115 125|sensitivity
P10471587A0239|249 259|amoxicillin
P10471587A0239|134 147|antimicrobials
P10471587A0239|168 171|MICs
P10471587A0239|7 13|strains
P10471587A0239|184 189|RT-PCR
P10471587A0239|114 122|technique
P10471587A0239|31 46|triplicate assays
P10471587A0239|16 28|C. trachomatis
P10471587A0239|58 69|RT-PCR method
P10471587A0239|216 227|erythromycin
P10471696A0734|13 16|SAS4
P10471696A0734|20 23|SAS5
P10471696A0734|35 38|role
P10471696A0734|87 90|role
P10471696A0734|96 98|ACS
P10471696A0734|4 10|alleles
P10471696A0734|101 116|Rap1p binding site
P10471696A0734|44 59|Abf1p binding site
P10471696A0734|65 77|HMR-E silencer
P10471721A0141|15 22|analysis
P10471721A0141|125 135|pollen S gene
P10471721A0141|137 137|s
P10471721A0141|154 158|genes
P10471721A0141|84 88|genes
P10471721A0141|95 97|SLG
P10471721A0141|41 46|S locus
P10471721A0141|99 101|SRK
P10471743A0000|1 4|cDNA
P10471743A0000|61 92|Arabidopsis thaliana cDNA libraries
P10471743A0000|22 24|RNA
P10471743A0000|31 41|DNA helicase
P10471746A1102|98 118|Myogenin transcription
P10471746A1102|7 10|MyoD
P10471746A1102|23 37|tryptophan motif
P10471746A1102|69 84|Myogenin promoter
P10471746A1102|45 63|chromatin remodeling
P10472314A0717|54 58|women
P10472314A0717|25 28|PUNP
P10472314A0717|20 22|TTP
P10472314A0717|11 17|Periods
P10472314A0717|43 45|men
P10472314A0717|0 6|RESULTS
P10472836A0189|0 9|Feed intake
P10472836A0189|34 34|P
P10472836A0189|50 59|treatments
P10472836A0189|13 19|BW gains
P10472836A0189|70 71|M.
P10473589A0189|14 17|beta
P10473589A0189|50 64|integrase domain
P10473589A0189|38 42|alpha
P10473589A0189|78 86|C terminus
P10473589A0189|21 23|kDa
P10473589A0189|90 92|kDa
P10473589A0189|3 11|N terminus
P10473598A0691|118 132|transactivation
P10473598A0691|141 146|Skn-1a
P10473598A0691|26 31|region
P10473598A0691|149 165|competition assays
P10473598A0691|46 67|transactivation ability
P10473598A0691|86 93|promoter
P10473598A0691|0 5|Skn-1a
P10473623A0081|102 110|formation
P10473623A0081|77 85|gene Mix.2
P10473623A0081|159 161|ARF
P10473623A0081|7 20|Xenopus embryos
P10473623A0081|126 132|complex
P10473623A0081|37 66|growth factor-beta member activin
P10473623A0081|152 157|factor
P10474898A0629|178 185|primates
P10474898A0629|109 112|FISH
P10474898A0629|146 151|assays
P10474898A0629|62 76|CMT1A-REP repeat
P10474898A0629|24 32|structure
P10474898A0629|95 107|hybridization
P10474898A0629|114 121|analysis
P10474898A0629|170 175|series
P10474898A0629|48 56|synthesis
P10475610A1289|0 4|Natl.
P10475972A0269|14 21|outbreak
P10475972A0269|5 8|face
P10475972A0269|32 36|delay
P10475972A0269|67 72|deaths
P10475972A0269|43 53|vaccination
P10476970A0542|119 124|family
P10476970A0542|141 150|G-proteins
P10476970A0542|115 115|G
P10476970A0542|50 56|protein
P10476970A0542|64 72|rap1GAPII
P10476970A0542|20 26|isoform
P10476970A0542|29 32|Rapl
P10476970A0542|96 109|alpha-subunits
P10477545T0000|15 28|pertussis toxin
P10477545T0000|84 95|HIV-1 strains
P10477545T0000|40 58|CC chemokine receptor
P10477545T0000|3 12|B-oligomer
P10477545T0000|69 73|entry
P10477583A0000a|59 61|IgG
P10477583A0000a|102 110|mechanism
P10477583A0000a|87 97|progression
P10477583A0000a|45 55|Fc receptors
P10477583A0000a|63 70|Fc gamma R
P10477583A0000a|32 34|BCR
P10477583A0000a|16 30|B cell Ag receptor
P10477583A0000b|59 61|IgG
P10477583A0000b|102 110|mechanism
P10477583A0000b|87 97|progression
P10477583A0000b|45 55|Fc receptors
P10477583A0000b|63 70|Fc gamma R
P10477583A0000b|32 34|BCR
P10477583A0000b|16 30|B cell Ag receptor
P10477597A0126|0 4|TRAF2
P10477597A0126|109 112|KHS1
P10477597A0126|32 53|serine/threonine kinase
P10477597A0126|127 136|activation
P10477597A0126|14 22|activator
P10477597A0126|68 79|center kinase
P10477597A0126|142 152|SAPK pathway
P10477597A0126|88 91|GCKR
P10477599T0000|70 73|site
P10477599T0000|23 29|element
P10477599T0000|38 45|C motif-1
P10477599T0000|156 160|T cell
P10477599T0000|111 122|interactions
P10477599T0000|47 66|lymphotactin promoter
P10477599T0000|139 144|factor
P10477620A0580|145 152|activity
P10477620A0580|69 91|I kappa B alpha degradation
P10477620A0580|127 139|I kappa B kinase
P10477620A0580|55 67|translocation
P10477620A0580|141 143|IKK
P10477620A0580|93 105|I kappa B serine
P10477620A0580|108 122|phosphorylation
P10477620A0580|166 182|curcumin treatment
P10477620A0580|44 47|RelA
P10477620A0580|16 42|NF-kappa B DNA binding activity
P10477748A1076|1 7|portion
P10477748A1076|10 13|p193
P10477748A1076|47 53|spindle
P10478275A1230|185 192|contrast
P10478275A1230|19 22|need
P10478275A1230|7 12|issues
P10478275A1230|88 91|diet
P10478275A1230|137 141|foods
P10478275A1230|158 167|technology
P10478275A1230|33 38|number
P10478275A1230|53 62|mechanisms
P10478275A1230|118 121|risk
P10478844A1604|0 13|Cotransfection
P10478844A1604|100 110|PPARalphatr
P10478844A1604|204 215|coactivators
P10478844A1604|19 29|coactivator
P10478844A1604|42 48|protein
P10478844A1604|145 150|effect
P10478844A1604|87 97|PPARalphawt
P10478844A1604|153 163|PPARalphatr
P10478844A1604|181 191|competition
P10478844A1604|75 84|repression
P10478848A0331|0 3|SF-1
P10478848A0331|27 35|AF1 domain
P10479025A0528|115 123|responses
P10479025A0528|86 96|spectrogram
P10479025A0528|38 54|TF-MUSIC algorithm
P10479025A0528|24 30|sources
P10479025A0528|69 80|target region
P10479025A0528|13 21|locations
P10479382A1098|14 20|results
P10479382A1098|23 27|terms
P10479382A1098|88 106|development patterns
P10479382A1098|46 49|time
P10479382A1098|33 41|influence
P10479382A1098|110 116|fitness
P10479382A1098|64 74|constraints
P10479492A0000|0 8|OBJECTIVE
P10479492A0000|59 62|data
P10479492A0000|77 77|%
P10479492A0000|54 57|SEER
P10479492A0000|27 38|Epidemiology
P10479492A0000|99 132|corpus uteri adenocarcinoma FIGO stage
P10479492A0000|84 95|survival rate
P10479492A0000|43 52|End Results
P10479492A0000|14 25|Surveillance
P10480937A0000|159 160|Ca
P10480937A0000|154 157|cAMP
P10480937A0000|6 35|Drosophila A kinase anchor protein
P10480937A0000|196 197|E.
P10480937A0000|138 144|signals
P10480937A0000|169 182|diacylglycerol
P10480937A0000|184 185|Li
P10480937A0000|47 66|A kinase anchor protein
P10480937A0000|187 188|Z.
P10480937A0000|190 194|Rossi
P10480937A0000|71 78|DAKAP200
P10482516A1158|134 157|transcription readthrough
P10482516A1158|107 115|stem-loop
P10482516A1158|94 101|deletion
P10482516A1158|124 131|increase
P10482516A1158|7 26|transcription results
P10482516A1158|45 62|structure functions
P10482516A1158|68 87|attenuation mechanism
P10482516T0000|32 64|transcription attenuation mechanism
P10482516T0000|92 122|Bacillus subtilis trpEDCFBA operon
P10482516T0000|77 86|expression
P10482516T0000|3 14|RNA stem-loop
P10482565A0469|83 88|fusion
P10482565A0469|27 35|mutations
P10482565A0469|53 59|effects
P10482620A1009|86 91|Stat5a
P10482620A1009|94 112|transcription factor
P10482620A1009|77 83|absence
P10482620A1009|49 52|MMTV
P10482620A1009|29 41|transcription
P10482620A1009|55 57|LTR
P10482620A1009|154 166|transcription
P10482620A1009|174 180|MMTV LTR
P10483124T0000|0 7|Regional
P10483124T0000|126 136|combination
P10483124T0000|144 161|cDNA scanning method
P10483124T0000|40 44|genes
P10483124T0000|109 123|Ac/Ds transposon
P10483124T0000|50 68|CIC5F11/CIC2B9 locus
P10483124T0000|71 99|Arabidopsis thaliana chromosome
P10483124T0000|19 29|mutagenesis
P10483945A0641|58 61|1-3x
P10483945A0641|38 45|patients
P10483945A0641|70 73|3-5x
P10483945A0641|51 51|%
P10483945A0641|8 21|CK-MB elevation
P10483945A0641|79 79|%
P10483945A0641|100 107|patients
P10483945A0641|84 85|5x
P10483945A0641|68 68|%
P10483945A0641|97 97|%
P10483945A0641|0 6|RESULTS
P10484695A0791|5 21|NART-R performance
P10484695A0791|36 43|estimate
P10484695A0791|59 66|patients
P10484695A0791|103 120|language impairment
P10484695A0791|46 55|baseline IQ
P10484695A0791|81 89|disorders
P10484818A0292|41 65|cross-correlation analysis
P10484818A0292|9 13|areas
P10484818A0292|34 38|means
P10485353T0000|119 124|France
P10485353T0000|80 87|children
P10485353T0000|92 101|West Africa
P10485353T0000|41 64|polysaccharide antibodies
P10485353T0000|142 151|serosurvey
P10485353T0000|7 32|Haemophilus influenzae type b
P10485353T0000|70 76|infants
P10485353T0000|103 114|Burkina-Faso
P10485470A0242|40 46|factors
P10485470A0242|24 26|Sp1
P10485470A0242|59 66|Sp1 sites
P10485470A0242|187 203|binding activities
P10485470A0242|126 144|mobility shift assays
P10485470A0242|72 92|p21/WAF1/Cip1 promoter
P10485470A0242|30 32|Sp3
P10485470A0242|6 10|study
P10485470A0242|158 169|TSA treatment
P10485470A0242|95 103|MG63 cells
P10485585A0175|58 70|neurohormones
P10485585A0175|23 29|results
P10485585A0175|35 43|discovery
P10485585A0175|0 6|Galoyan
P10486210A0126|68 75|promoter
P10486210A0126|25 34|expression
P10486210A0126|10 19|regulation
P10486210A0126|44 64|aldehyde reductase gene
P10487040A0453|31 35|MIB-1
P10487040A0453|39 51|p53 antibodies
P10487040A0453|77 84|reaction
P10487040A0453|64 64|%
P10487040A0453|19 26|staining
P10487217A0735|87 92|signal
P10487217A0735|112 121|N-terminus
P10487217A0735|37 46|amino acids
P10487217A0735|22 31|preprotein
P10487217A0735|3 9|C2C-Prx
P10487217A0735|97 106|amino acids
P10487307A0768|17 31|surgery patients
P10487307A0768|78 84|placebo
P10487307A0768|106 110|order
P10487307A0768|74 75|mg
P10487307A0768|57 70|hydrocortisone
P10487744T0000|15 27|sorting signal
P10487744T0000|57 62|domain
P10487744T0000|134 142|migration
P10487744T0000|33 45|beta2 integrin
P10487744T0000|74 82|recycling
P10487744T0000|88 101|plasma membrane
P10487753A0788|14 25|XDRP1 protein
P10487753A0788|40 50|Xenopus eggs
P10487753A0788|67 78|cell division
P10487753A0788|3 11|injection
P10487759A0630|15 28|Xenopus embryos
P10487759A0630|106 115|expression
P10487759A0630|139 150|reporter gene
P10487759A0630|50 58|integrity
P10487759A0630|119 123|Xbra2
P10487759A0630|69 77|sequences
P10487760A0336|2 6|order
P10487760A0336|22 30|cofactors
P10487760A0336|76 87|Xenopus MEF2D
P10487760A0336|91 95|yeast
P10487760A0336|9 14|screen
P10487760A0336|106 111|screen
P10487760A0336|68 73|mutant
P10487762A0252|0 3|NuA4
P10487762A0252|26 29|mass
P10487762A0252|35 37|MDa
P10487921A0132|0 16|ATF1 transcription
P10487921A0132|64 69|oxygen
P10487921A0132|56 60|acids
P10487953A0765|3 10|patients
P10487953A0765|37 52|S-phase fractions
P10487953A0765|75 83|specimens
P10487953A0765|24 29|tumors
P10487953A0765|92 95|time
P10487953A0765|107 115|operation
P10488087A0340|0 7|Mutation
P10488087A0340|96 99|SP-A
P10488087A0340|23 27|sites
P10488087A0340|161 177|SP-A gene sequences
P10488087A0340|43 53|combination
P10488087A0340|124 150|acetyltransferase constructs
P10488087A0340|29 31|TBE
P10488087A0340|86 93|activity
P10488088T0000|103 109|protein
P10488088T0000|12 25|growth factor-I
P10488088T0000|33 45|bcl-2 promoter
P10488088T0000|56 74|transcription factor
P10488129T0058|0 8|Synthesis
P10488129T0058|51 62|E2F complexes
P10488129T0058|65 70|intron
P10488129T0058|26 26|S
P10488129T0058|20 22|RNA
P10488129T0058|42 48|binding
P10488147A1176|73 93|eosinophil trafficking
P10488147A1176|64 70|control
P10488147A1176|125 133|phenomena
P10488147A1176|46 58|understanding
P10488147A1176|16 24|eotaxin-3
P10488147A1176|0 13|Identification
P10488148A0111|0 8|NF-kappaB
P10488148A0111|93 118|signal transduction pathways
P10488148A0111|23 26|role
P10488148A0111|79 85|stimuli
P10488148A0111|62 70|cytokines
P10488148A0111|162 170|infection
P10488148A0111|134 139|switch
P10488148A0111|41 59|HIV-1 gene expression
P10488148A0111|29 38|activation
P10488148A1267|83 93|interaction
P10488148A1267|23 26|MAPK
P10488148A1267|104 112|NF-kappaB
P10488148A1267|126 132|complex
P10488148A1267|44 47|AP-1
P10488148A1267|169 176|HIV-1 LTR
P10488148A1267|5 11|studies
P10488148A1267|96 99|AP-1
P10488148T0000|0 31|ERK MAP kinase links cytokine signals
P10488148T0000|52 65|HIV-1 infection
P10488148T0000|104 107|AP-1
P10488148T0000|91 101|interaction
P10488148T0000|34 43|activation
P10488148T0000|111 119|NF-kappaB
P10488337T0000|45 56|dimerization
P10488337T0000|97 108|bZIP proteins
P10488337T0000|23 31|chaperone
P10488337T0000|58 67|DNA binding
P10488337T0000|87 94|activity
P10488875A0000|57 61|palsy
P10488875A0000|79 88|toe walking
P10488875A0000|25 32|patients
P10488875A0000|90 92|ITW
P10488875A0000|63 64|CP
P10488875A0000|8 22|differentiation
P10489680A0927|0 9|Sputum IL-8
P10489680A0927|80 80|P
P10489680A0927|56 58|TDI
P10489680A0927|63 78|grain dust-asthma
P10489680A0927|47 49|BPT
P10489680A0927|13 15|MPO
P10489822T0000|0 10|Montelukast
P10489822T0000|50 55|asthma
P10489822T0000|79 83|trial
P10489822T0000|36 47|inflammation
P10489822T0000|18 23|airway
P10490065T0000|0 8|Treatment
P10490065T0000|26 29|role
P10490065T0000|19 24|angina
P10490065T0000|46 52|therapy
P10490604A0601|59 61|Lck
P10490604A0601|22 32|kinase-dead
P10490604A0601|66 79|ZAP-70 block 70Z
P10490604A0601|48 52|forms
P10490604A0601|92 105|NFAT activation
P10490604A0601|55 57|Fyn
P10490609A0413|187 197|ARS activity
P10490609A0413|64 71|sequence
P10490609A0413|122 129|thymines
P10490609A0413|138 149|interruption
P10490609A0413|81 87|repeats
P10490609A0413|35 43|sequences
P10490609A0413|112 119|adenines
P10490609A0413|161 168|cytosine
P10490609A0413|152 158|guanine
P10490609A0413|0 12|Substitutions
P10490609A0413|15 20|region
P10490639A0000|162 175|cyclin partners
P10490639A0000|69 71|Cdk
P10490639A0000|26 30|PHO85
P10490639A0000|55 67|protein kinase
P10490639A0000|82 88|subunit
P10490639A0000|111 115|roles
P10490639A0000|138 148|association
P10490639A0000|177 180|Pcls
P10490662A0431|0 6|Mutants
P10490662A0431|38 43|adults
P10490662A0431|64 75|morphologies
P10490662A0431|92 102|compound eye
P10490662A0431|81 90|appendages
P10490662A0431|15 25|lace alleles
P10490662A0819|2 5|fact
P10490662A0819|7 17|SPT activity
P10490662A0819|23 25|fly
P10490662A0819|50 53|Lace
P10490662A0819|83 90|antibody
P10490816A0000|14 20|RET gene
P10490816A0000|111 115|MEN 2B
P10490816A0000|88 107|cancer syndromes MEN 2A
P10490816A0000|31 52|receptor tyrosine kinase
P10490816A0000|0 8|Mutations
P10490822A1167|68 75|approach
P10490822A1167|20 28|targeting
P10490822A1167|31 37|Ras-GAP
P10490822A1167|5 11|results
P10490826T0000|0 3|EB-1
P10490826T0000|76 76|t
P10490826T0000|6 41|tyrosine kinase signal transduction gene
P10490826T0000|112 130|oncoprotein E2a-Pbx1
P10490826T0000|96 98|ALL
P10490826T0000|83 88|subset
P10490835T0000|46 55|inhibition
P10490835T0000|95 124|tyrosine kinase signaling pathway
P10490835T0000|65 80|cancer cell growth
P10490835T0000|82 90|crosstalk
P10490835T0000|0 20|Protein kinase A-Ialpha
P10490843A0159|0 3|BCL6
P10490843A0159|142 151|malignancy
P10490843A0159|12 30|POZ/Zn finger protein
P10490843A0159|106 112|protein
P10490843A0159|33 41|structure
P10490843A0159|153 156|PLZF
P10490843A0159|84 93|regulators
P10490955T0000|0 3|Beta
P10490955T0000|116 131|thrombospondin-1
P10490955T0000|92 113|protein kinase signaling
P10490955T0000|51 71|T lymphoma cell adhesion
P10490955T0000|38 48|stimulation
P10490955T0000|5 12|integrin
P10490955T0000|135 158|thrombospondin-1 peptides
P10491133A0365|57 66|reactivity
P10491133A0365|102 109|NO donors
P10491133A0365|69 78|HO isozymes
P10491133A0365|24 39|activity analyses
P10491133A0365|83 91|NO species
P10491133A0365|0 8|Optical CD
P10491187T0000|3 26|phosphotransferase system
P10491187T0000|28 30|PTS
P10491187T0000|84 91|analysis
P10491187T0000|56 69|identification
P10491187T0000|140 147|gene ptsH
P10491187T0000|95 127|histidine phosphocarrier protein HPr
P10491213A0263|0 18|Serum concentrations
P10491213A0263|146 149|Dpyr
P10491213A0263|162 171|tomography
P10491213A0263|251 257|density
P10491213A0263|307 321|material density
P10491213A0263|366 369|boys
P10491213A0263|100 105|levels
P10491213A0263|218 226|vertebrae
P10491213A0263|108 119|pyridinoline
P10491213A0263|53 56|BALP
P10491213A0263|332 335|bone
P10491213A0263|21 24|bone
P10491213A0263|128 144|deoxypyridinoline
P10491213A0263|382 385|ages
P10491213A0263|233 238|femurs
P10491213A0263|208 212|areas
P10491213A0263|376 380|girls
P10491213A0263|88 90|BGP
P10491213A0263|33 51|alkaline phosphatase
P10491213A0263|270 273|bone
P10491213A0263|173 174|CT
P10491213A0263|279 287|vertebrae
P10491213A0263|390 394|years
P10491213A0263|341 346|femurs
P10491213A0263|73 86|bone Gla protein
P10491213A0263|61 71|osteocalcin
P10491213A0263|176 187|measurements
P10491213A0263|121 123|Pyr
P10491213A0263|295 300|volume
P10492127A0914|177 178|hr
P10492127A0914|110 117|mg/kg/hr
P10492127A0914|9 13|study
P10492127A0914|128 130|min
P10492127A0914|26 39|administration
P10492127A0914|101 104|dose
P10492127A0914|149 160|saline intake
P10492127A0914|42 51|devazepide
P10492127A0914|62 96|cholecystokinin-A receptor antagonist
P10492169A0939|134 140|EST-YD1
P10492169A0939|97 102|PAPP-A
P10492169A0939|113 116|gene
P10492169A0939|45 48|ESTs
P10492169A0939|81 95|plasma protein-A
P10492169A0939|4 10|cluster
P10492169A0939|55 59|genes
P10493203T0000|102 104|ECG
P10493203T0000|10 14|value
P10493203T0000|53 60|patients
P10493203T0000|80 92|abnormalities
P10493203T0000|18 39|treadmill exercise score
P10493575T0000|44 51|rat S100B
P10493575T0000|125 127|p53
P10493575T0000|53 60|beta beta
P10493575T0000|76 82|peptide
P10493575T0000|22 31|C-terminus
P10493575T0000|10 16|changes
P10493575T0000|34 36|Ca2
P10493575T0000|117 122|domain
P10493580A1126|13 17|Gly84
P10493580A1126|20 23|part
P10493580A1126|36 47|oxyanion hole
P10493580A1126|107 112|C group
P10493580A1126|62 74|stabilization
P10493580A1126|118 138|esterase/lipase family
P10493580A1126|80 94|transition state
P10493876A0000|240 249|residue dA6
P10493876A0000|531 537|NMR data
P10493876A0000|472 477|duplex
P10493876A0000|218 227|amino group
P10493876A0000|367 367|B
P10493876A0000|214 214|N
P10493876A0000|369 369|g
P10493876A0000|53 59|bonding
P10493876A0000|371 371|C
P10493876A0000|576 587|calculations
P10493876A0000|461 462|dA
P10493876A0000|455 455|B
P10493876A0000|85 87|12R
P10493876A0000|573 574|MD
P10493876A0000|457 457|g
P10493876A0000|81 83|11S
P10493876A0000|459 459|C
P10493876A0000|394 394|d
P10493876A0000|331 349|DNA sequence context d
P10493876A0000|93 95|14S
P10493876A0000|138 145|epoxy-11
P10493876A0000|89 91|13R
P10493876A0000|464 465|dT
P10493876A0000|278 278|B
P10493876A0000|373 391|A6-C7-T8-T9-C10-C11
P10493876A0000|97 108|stereoisomer
P10493876A0000|435 441|A21-G22
P10493876A0000|308 325|thymine residue dT17
P10493876A0000|284 286|dA6
P10493876A0000|282 282|C
P10493876A0000|192 192|B
P10493876A0000|280 280|g
P10493876A0000|122 133|dihydroxy-13
P10493876A0000|509 519|information
P10493876A0000|564 571|dynamics
P10493876A0000|396 430|G12-G13-A14-A15-G16-T17-G18-A19-G20
P10493876A0000|25 30|adduct
P10493876A0000|266 275|trans-anti
P10493876A0000|351 364|C1-T2-C3-T4-C5
P10493876A0000|65 75|fjord region
P10493876A0000|172 172|g
P10493876A0000|194 194|g
P10493876A0000|196 198|CDE
P10493876A0000|3 19|solution structure
P10493876A0000|174 181|chrysene
P10493876A0000|299 306|opposite
P10493876A0000|540 550|combination
P10495573A0365|83 89|studies
P10495573A0365|160 169|acceptance
P10495573A0365|100 106|results
P10495573A0365|5 14|sildenafil
P10495573A0365|136 136|%
P10495573A0365|124 127|MUSE
P10495573A0365|24 29|market
P10495573A0365|110 119|sildenafil
P10495573A0365|45 49|place
P10495573A0365|143 148|course
P10495573A0365|52 55|MUSE
P10495573A0365|131 131|%
P10496161A0503|0 14|Serum antibodies
P10496161A0503|38 38|%
P10496161A0503|52 61|guinea pigs
P10496161A0503|73 75|WPI
P10496161A0503|79 82|rats
P10496161A0503|94 96|WPI
P10496284A0115|102 109|IgG index
P10496284A0115|112 127|IgG synthesis rate
P10496284A0115|24 31|episodes
P10496284A0115|33 42|CSF protein
P10496284A0115|66 71|levels
P10496284A0115|46 60|immunoglobulin G
P10496284A0115|62 64|IgG
P10496303A1968|149 153|mg/kg
P10496303A1968|45 58|valganciclovir
P10496303A1968|80 90|ganciclovir
P10496303A1968|92 96|AUC24
P10496303A1968|136 146|ganciclovir
P10496303A1968|69 77|exposures
P10496303A1968|17 23|results
P10496303A1968|0 10|CONCLUSIONS
P10496388A1956a|98 104|concern
P10496388A1956a|9 20|nonperfusion
P10496388A1956a|57 60|dose
P10496388A1956a|66 70|J/cm2
P10496388A1956a|42 48|vessels
P10496388A1956a|86 91|events
P10496388A1956b|98 104|concern
P10496388A1956b|9 20|nonperfusion
P10496388A1956b|57 60|dose
P10496388A1956b|66 70|J/cm2
P10496388A1956b|42 48|vessels
P10496388A1956b|86 91|events
P10496553A1004|41 47|percent
P10496553A1004|55 59|weeks
P10496553A1004|80 84|weeks
P10496553A1004|166 172|percent
P10496553A1004|102 108|figures
P10496553A1004|112 119|patients
P10496553A1004|132 155|immunodeficiency syndrome
P10496553A1004|66 72|percent
P10496553A1004|3 13|healing rate
P10496553A1004|28 35|patients
P10497117A0358|26 28|ORF
P10497117A0358|35 42|V protein
P10497117A0358|79 81|ORF
P10497117A0358|3 7|P mRNA
P10497199A0559|149 157|COUP-TFII
P10497199A0559|8 13|screen
P10497199A0559|140 145|factor
P10497199A0559|16 20|yeast
P10497199A0559|64 76|factor binding
P10497199A0559|82 85|GlRE
P10497199A0559|94 109|chicken ovalbumin
P10497262A0000|54 60|U5 snRNA
P10497262A0000|26 29|gene
P10497262A0000|113 134|U5 RNA affinity selection
P10497262A0000|36 40|trans
P10497262A0000|138 148|cDNA cloning
P10497262A0000|68 106|trypanosomatid species Leptomonas seymouri
P10497800A0000|101 107|bulimia
P10497800A0000|90 97|anorexia
P10497800A0000|10 16|Butcher
P10497800A0000|55 62|McKinley
P10497800A0000|46 53|Hathaway
P10497800A0000|3 8|MMPI-A
P10497800A0000|41 44|MMPI
P10497874A0925|15 34|phosphatidyl inositol
P10497874A0925|10 13|hand
P10497874A0925|117 133|PLC-gamma1 isozyme
P10497874A0925|38 49|bisphosphate
P10497874A0925|97 111|tyrosine residue
P10497874A0925|80 94|phosphorylation
P10497874A0925|51 54|PIP2
P10497874A0925|56 65|hydrolysis
P10498616A0157|175 180|growth
P10498616A0157|183 186|IL-4
P10498616A0157|152 158|absence
P10498616A0157|75 78|IL-3
P10498616A0157|61 73|interleukin-3
P10498616A0157|90 119|mast cell/megakaryocyte cell line
P10498616A0157|13 17|M-Ras
P10498616A0157|161 164|IL-3
P10498616A0157|47 56|expression
P10498616A0157|198 213|expression levels
P10498616A0157|139 146|survival
P10498616A0157|1 10|G22V mutant
P10498616A0157|235 240|growth
P10498616A1280|161 168|parallel
P10498616A1280|110 119|activation
P10498616A1280|9 13|M-Ras
P10498616A1280|49 55|exhibit
P10498616A1280|188 193|p21 Ras
P10498616A1280|18 38|Caenorhabditis elegans
P10498616A1280|133 146|signaling paths
P10498616A1280|75 82|features
P10498706A1219|32 35|PecS
P10498706A1219|53 66|pelE expression
P10498706A1219|90 98|repressor
P10498706A1219|103 106|KdgR
P10498706A1219|17 20|data
P10498706A1219|46 49|pelD
P10498717A1048|90 103|RsmA production
P10498717A1048|53 69|rsmB transcription
P10498717A1048|5 16|observations
P10498717A1048|30 33|RsmC
P10499121A0542|46 62|Class D instruments
P10499121A0542|123 127|study
P10499121A0542|67 82|input compression
P10499121A0542|107 116|enrollment
P10499121A0542|96 99|time
P10499121A0542|18 32|hearing aid users
P10499357A0439|0 10|SCOB testing
P10499357A0439|154 161|behavior
P10499357A0439|82 89|schedule
P10499357A0439|126 133|exposure
P10499357A0439|207 214|evidence
P10499357A0439|79 80|FI
P10499357A0439|96 100|FI120
P10499357A0439|166 169|data
P10499357A0439|91 94|FR20
P10499357A0439|217 229|neurotoxicity
P10499357A0439|70 77|interval
P10499357A0439|55 59|ratio
P10499357A0439|174 178|Weeks
P10499357A0439|61 62|FR
P10499357A0439|28 34|animals
P10501034A0839|0 27|Ribonuclease protection assays
P10501034A0839|118 123|manner
P10501034A0839|40 43|hmg1
P10501034A0839|176 188|pigment glands
P10501034A0839|130 142|morphogenesis
P10501034A0839|47 50|hmg2
P10501034A0839|191 197|embryos
P10501656A1415|82 95|tumor cell lines
P10501656A1415|12 21|expression
P10501656A1415|36 55|Northern blot analysis
P10501936T0000|149 158|morphology
P10501936T0000|17 32|Neurospora crassa
P10501936T0000|111 117|defects
P10501936T0000|51 70|membrane protein TOM70
P10501936T0000|101 103|RIP
P10501936T0000|87 99|point mutation
P10501936T0000|0 11|Inactivation
P10501936T0000|133 145|protein import
P10501965A0879|178 185|receptor
P10501965A0879|7 11|genes
P10501965A0879|126 130|genes
P10501965A0879|63 65|end
P10501965A0879|77 84|s6 kinase
P10501965A0879|135 139|Gpr31
P10501965A0879|162 170|G-protein
P10501965A0879|29 33|units
P10501965A0879|86 89|Rsk3
P10501969A1329|3 9|results
P10501969A1329|66 71|GATA-4
P10501969A1329|52 58|targets
P10501969A1329|121 133|cardiogenesis
P10501969A1329|21 26|GATA-5
P10502216A0289|42 50|efegatran
P10502216A0289|137 147|reperfusion
P10502216A0289|123 125|TPA
P10502216A0289|96 121|tissue plasminogen activator
P10502216A0289|155 156|MI
P10502216A0289|4 8|study
P10502216A0289|55 67|streptokinase
P10502216A0289|32 39|efficacy
P10502216A0289|74 80|heparin
P10502402A0129|98 108|possibility
P10502402A0129|135 135|T
P10502402A0129|113 117|TRAIL
P10502402A0129|21 25|TRAIL
P10502402A0129|149 160|cytotoxicity
P10502402A0129|70 86|mouse T lymphocytes
P10502402A0129|173 182|regulation
P10502402A0533|117 137|T lymphocyte activation
P10502402A0533|21 30|inhibitors
P10502402A0533|90 107|TRAIL gene induction
P10502402A0533|54 79|signal transduction pathways
P10502402A0533|1 5|panel
P10502434A0367|55 63|carcinoma
P10502434A0367|115 132|vault brachytherapy
P10502434A0367|150 158|treatment
P10502434A0367|18 23|August
P10502434A0367|4 11|February
P10502434A0367|32 39|patients
P10502434A0604|41 44|ICG2
P10502434A0604|53 63|ICG3 disease
P10502434A0604|6 13|patients
P10502434A0604|17 25|stage IBG3
P10502434A0604|32 35|ICG1
P10502522A0000|101 111|individuals
P10502522A0000|125 133|cell lines
P10502522A0000|9 23|provirus genomes
P10502522A0000|78 88|lymphocytes
P10502522A0000|31 53|T-cell leukemia virus type
P10503540A0602|1 5|total
P10503540A0602|11 21|primer pairs
P10503540A0602|61 61|%
P10503540A0602|39 53|banding patterns
P10503540A0602|88 94|alleles
P10503540A0602|103 120|polyacrylamide gels
P10503812A1450|118 120|age
P10503812A1450|46 68|organ transplant patients
P10503812A1450|136 138|age
P10503812A1450|111 115|years
P10503812A1450|26 30|study
P10503812A1450|33 43|cyclosporin
P10503812A1450|163 189|cyclosporin pharmacokinetics
P10503812A1450|86 104|allograft recipients
P10503812A1450|1 10|population
P10504332A0701|0 20|Immunofluoresence data
P10504332A0701|216 222|markers
P10504332A0701|140 144|cells
P10504332A0701|54 61|receptor
P10504332A0701|167 174|receptor
P10504332A0701|176 190|RAP fluorescence
P10504332A0701|82 84|RAP
P10504332A0701|122 128|pathway
P10504332A0701|101 107|markers
P10505694A0000|74 77|PBMC
P10505694A0000|52 56|blood
P10505694A0000|68 72|cells
P10505694A0000|129 139|enhancement
P10505694A0000|116 125|production
P10505694A0000|24 31|cytokine
P10505694A0000|106 114|IFN-gamma
P10505694A0000|15 19|IL-12
P10505694A0000|155 166|cytotoxicity
P10505694A0000|89 104|interferon-gamma
P10505694A0000|0 13|Interleukin-12
P10505694A0739|0 14|IL-12 production
P10505694A0739|93 100|dialysis
P10505694A0739|109 109|P
P10505694A0739|102 102|r
P10505694A0739|69 80|hemodialyzer
P10505694A0739|32 47|C3a concentration
P10505694A0739|61 66|outlet
P10505694A0739|88 90|min
P10506143A0610|144 146|EGF
P10506143A0610|95 98|JNK1
P10506143A0610|183 187|MEKK1
P10506143A0610|124 133|activators
P10506143A0610|197 218|GTP binding proteins Rac1
P10506143A0610|114 120|stimuli
P10506143A0610|15 37|JNKK2-JNK1 fusion protein
P10506143A0610|158 167|anisomycin
P10506143A0610|222 228|Cdc42Hs
P10506143A0610|148 156|TNF-alpha
P10506143A0610|169 181|UV irradiation
P10506143A0610|55 65|JNK activity
P10506143A0610|2 10|HeLa cells
P10506160A0297|0 1|J.
P10508522A1598|3 9|results
P10508522A1598|39 44|target
P10508522A1598|47 54|EWS-FLI1
P10508522A1598|19 29|TGF-beta RII
P10509768A1118|56 60|group
P10509768A1118|78 83|mmol/l
P10509768A1118|88 88|%
P10509768A1118|106 126|serum cholesterol level
P10509768A1118|90 98|reduction
P10509768A1118|3 11|reduction
P10509768A1118|28 38|acids intake
P10510295A0606|43 45|ERA
P10510295A0606|129 136|GLK1 gene
P10510295A0606|11 41|ethanol repression autoregulation
P10510295A0606|68 70|TAB
P10510295A0606|110 123|promoter region
P10510295A0606|59 66|TA repeat
P10510295A0606|72 87|repressor element
P10510379A0105|42 46|STAT6
P10510379A0105|69 78|DNA element
P10510379A0105|8 26|transcription factor
P10510379A0105|33 39|process
P10510379A0105|83 100|cytokine activation
P10511216A0654|0 10|CONCLUSIONS
P10511216A0654|54 58|cause
P10511216A0654|38 41|kink
P10511554T0000|58 88|clone Caenorhabditis elegans cdf-1
P10511554T0000|37 51|polymorphism map
P10512699A0364|135 138|opal
P10512699A0364|41 52|SECIS element
P10512699A0364|140 142|UGA
P10512699A0364|95 117|selenocysteine insertion
P10512699A0364|181 191|translation
P10512699A0364|168 178|termination
P10512699A0364|144 148|codon
P10512699A0364|31 39|structure
P10512699A0364|81 84|mRNA
P10512699A0364|4 12|machinery
P10512699A0364|123 130|position
P10512699T0000|151 163|co-expression
P10512699T0000|171 174|selA
P10512699T0000|96 106|gene fusions
P10512699T0000|135 147|SECIS elements
P10512699T0000|10 19|expression
P10512699T0000|183 191|selC genes
P10512699T0000|176 179|selB
P10512699T0000|64 86|rat thioredoxin reductase
P10512857A0000|30 40|plakoglobin
P10512857A0000|62 68|nucleus
P10512857A0000|76 87|interactions
P10512857A0000|100 119|transcription factors
P10512857A0000|50 56|signals
P10512857A0000|2 13|Wnt signaling
P10512857A0000|15 26|beta-catenin
P10512882A0137|100 107|activity
P10512882A0137|133 139|kinases
P10512882A0137|73 84|localization
P10512882A0137|11 17|complex
P10512882A0137|25 27|FAK
P10512882A0137|122 130|Src family
P10512882A0137|110 116|members
P10512882A0137|31 40|Src kinases
P10512882A0137|0 7|Assembly
P10513756A0584|96 113|selection criterion
P10513756A0584|122 126|alpha
P10513756A0584|33 33|%
P10513756A0584|19 22|bias
P10513756A0584|50 65|8-predictor model
P10513756A0584|3 5|EPV
P10513922A1237|73 78|fibers
P10513922A1237|142 142|p
P10513922A1237|102 111|comparison
P10513922A1237|90 99|repair site
P10513922A1237|49 54|number
P10513922A1237|35 43|increases
P10513922A1237|135 140|groups
P10513922A1237|3 7|study
P10514493A0199|23 37|differentiation
P10514493A0199|106 114|Ntr-1 gene
P10514493A0199|81 90|expression
P10514493A0199|40 64|N1E-115 neuroblastoma cells
P10514493A0199|118 130|reporter genes
P10514493A0199|139 160|NTR-1 promoter sequences
P10514808T0000|31 45|epileptogenesis
P10514808T0000|8 17|dysplasias
P10514808T0000|19 26|genetics
P10516011A0471|28 41|peptide mapping
P10516011A0471|76 86|mutagenesis
P10516011A0471|5 8|work
P10516011A0471|106 128|pAP phosphorylation sites
P10516011A0471|43 58|mass spectrometry
P10516011A0471|100 103|sets
P10516026A0270|4 13|HERV-K type
P10516026A0270|19 24|clones
P10516072A0146|0 3|Duch
P10516072A0146|8 9|F.
P10516738A0925|5 15|time-points
P10516738A0925|35 35|%
P10516738A0925|50 64|irbesartan/HCTZ
P10516738A0925|21 28|patients
P10516878T0000|0 11|Modification
P10516878T0000|53 61|Parkinson
P10516878T0000|64 70|disease
P10516878T0000|42 50|pergolide
P10516878T0000|80 84|study
P10516878T0000|14 39|dopamine D2 receptor activity
P10516878T0000|87 89|PET
P10517666A1069|96 99|nGRE
P10517666A1069|37 54|AP-1 nucleoproteins
P10517666A1069|13 24|binding sites
P10517666A1069|79 86|elements
P10517666A1069|32 33|GR
P10517672A1417|176 183|proteins
P10517672A1417|185 200|trans-activation
P10517672A1417|32 65|alpha1-globin promoter-CAT construct
P10517672A1417|112 115|CTF1
P10517672A1417|12 19|fragment
P10517672A1417|203 213|CAT activity
P10517672A1417|125 157|Drosophila Schneider SL2 insect cells
P10517672A1417|86 109|CCAAT transcription factor
P10517672A1417|118 120|NF1
P10517675A0809|103 108|member
P10517675A0809|54 72|p21WAF1/CIP1 protein
P10517675A0809|130 150|kinase inhibitor family
P10517675A0809|152 158|p27kip1
P10517675A0809|81 93|protein levels
P10517675A0809|0 18|Western blot analysis
P10517675A0809|44 51|increase
P10518496A0952|0 10|Aggregation
P10518496A0952|134 158|periimplantation lethality
P10518496A0952|119 125|tissues
P10518496A0952|69 75|embryos
P10518496A0952|37 45|stem cells
P10518496A0952|168 178|development
P10518496A0952|196 208|organogenesis
P10518502T0000|87 94|survival
P10518502T0000|8 12|nos-2
P10518502T0000|97 117|Caenorhabditis elegans
P10518502T0000|65 83|germ cell development
P10518502T0000|17 21|genes
P10518502T0000|0 4|nos-1
P10518561A0261|119 125|enzymes
P10518561A0261|103 111|effectors
P10518561A0261|16 25|regulators
P10518561A0261|28 43|Tec family kinases
P10518561A0885|47 48|PH
P10518561A0885|52 61|SH2 domains
P10518561A0885|73 84|kinase domain
P10518561A0885|26 30|BRDG1
P10518561A0885|9 23|phosphorylation
P10518561A0885|33 35|Tec
P10518822A1037|0 9|CONCLUSION
P10518822A1037|95 103|biomarker
P10518822A1037|107 114|activity
P10518822A1037|78 83|asthma
P10518822A1037|172 177|asthma
P10518822A1037|120 143|CCR3 receptor ligand system
P10518822A1037|33 39|eotaxin
P10518822A1037|16 23|findings
P10518937A0572|169 176|K. lactis
P10518937A0572|108 111|Bas2
P10518937A0572|66 78|adenine supply
P10518937A0572|102 105|Bas1
P10518937A0572|88 94|factors
P10518937A0572|26 35|KlHIS4 gene
P10518937A0572|131 137|control
P10518937A0572|164 166|way
P10518937A0572|3 20|expression analysis
P10518937A0572|41 59|phosphate starvation
P10518956A0137|130 134|gland
P10518956A0137|165 180|deiodinase system
P10518956A0137|47 55|cytokines
P10518956A0137|75 83|mediators
P10518956A0137|139 150|thyroid gland
P10518956A0137|5 25|thyroid hormone changes
P10518956A0137|106 117|hypothalamus
P10518956A0137|96 100|level
P10518956A0137|41 44|part
P10518956A1212|13 15|FT3
P10518956A1212|28 30|TSH
P10518956A1212|22 24|FT4
P10518956A1212|55 58|form
P10518956A1212|0 6|ESS type
P10520800A0307|0 6|METHODS
P10520800A0307|94 102|reduction
P10520800A0307|68 72|years
P10520800A0307|49 51|men
P10520800A0307|108 123|echocardiography
P10520800A0307|127 143|electrocardiogram
P10520800A0307|30 37|patients
P10520800A0307|42 45|HOCM
P10520800A0307|58 60|age
P10520800A0307|145 147|ECG
P10521345A0202|230 235|system
P10521345A0202|181 189|centuries
P10521345A0202|160 165|Ice Age
P10521345A0202|49 53|proxy
P10521345A0202|203 208|notion
P10521345A0202|89 111|surface slope waters north
P10521345A0202|28 40|Laurentian Fan
P10521345A0202|17 20|data
P10521345A0202|117 126|Gulf Stream
P10521345A0202|57 77|sea surface temperature
P10521443A0486|219 239|NF-kappaB c-Rel subunit
P10521443A0486|93 111|NF-kappaB activation
P10521443A0486|21 32|IR activation
P10521443A0486|166 178|IkappaB-alpha
P10521443A0486|133 146|overexpression
P10521443A0486|180 185|A32/36
P10521443A0486|54 63|IR mutation
P10521443A0486|4 9|effect
P10521443A0486|66 74|tyrosines
P10521443A0486|200 213|overexpression
P10521447A0606|96 132|AML/CBFalpha transcription factor family
P10521447A0606|47 60|sequence TGTGGT
P10521447A0606|19 19|B
P10521447A0606|63 71|core motif
P10521447A0606|3 8|factor
P10521447A0606|84 90|members
P10521447A1190|56 73|AML1-ETO repression
P10521447A1190|28 41|AML3/CBFalpha1
P10521447A1190|12 25|overexpression
P10521450A0437|72 74|Lyn
P10521450A0437|62 67|B cells
P10521450A0437|25 27|Lyn
P10521450A0437|50 58|DT40 cells
P10521450A0437|10 22|Akt activation
P10521450A0437|30 32|Syk
P10521450A0437|80 83|mice
P10521509A0000|0 9|Regulators
P10521509A0000|75 84|pleckstrin
P10521509A0000|185 188|RGS9
P10521509A0000|164 178|RGS proteins RGS6
P10521509A0000|53 55|DEP
P10521509A0000|180 183|RGS7
P10521509A0000|93 105|G protein gamma
P10521509A0000|68 73|EGL-10
P10521509A0000|193 197|RGS11
P10521509A0000|12 28|G protein signaling
P10521509A0000|131 139|subfamily
P10521509A0000|119 125|domains
P10521509A0000|34 41|proteins
P10521509A0000|89 91|GGL
P10521509A0000|30 32|RGS
P10521544T0000|0 6|Cloning
P10521544T0000|78 95|Man8GlcNAc2 isomer B
P10521544T0000|36 55|alpha 1,2-mannosidase
P10521544T0000|10 19|expression
P10521544T0000|110 121|biosynthesis
P10521544T0000|65 75|Man9GlcNAc2
P10521796A0872|256 263|subjects
P10521796A0872|137 138|IM
P10521796A0872|161 162|IM
P10521796A0872|186 200|neck hyperplasia
P10521796A0872|99 108|metaplasia
P10521796A0872|155 157|DYS
P10521796A0872|279 287|gastritis
P10521796A0872|176 182|atrophy
P10521796A0872|145 153|dysplasia
P10521796A0872|22 24|age
P10521796A0872|325 332|baseline
P10521796A0872|110 111|IM
P10521796A0872|8 9|GC
P10521796A0872|238 240|DYS
P10521796A0872|289 290|SG
P10521796A0872|59 75|baseline diagnoses
P10521796A0872|309 317|gastritis
P10521796A0872|319 321|CAG
P10521796A0872|28 30|sex
P10521796A0872|3 5|ORs
P10523319A0209|58 64|domains
P10523319A0209|24 28|Rat7p
P10523319A0209|16 20|Dbp5p
P10523520A0986|41 51|Hh molecules
P10523520A0986|59 63|phyla
P10523520A0986|8 20|nematode genes
P10523520A0986|31 38|homologs
P10523634A1404|70 82|Cbf5p proteins
P10523634A1404|47 57|association
P10523634A1404|23 39|Psi synthase domain
P10523634A1404|9 17|mutations
P10523634A1404|95 109|box H/ACA snoRNAs
P10523634A1404|171 181|interaction
P10523634A1404|147 152|domain
P10523634A1404|1 6|subset
P10523640A0367|164 168|Stat3
P10523640A0367|130 137|tyrosine
P10523640A0367|78 87|activation
P10523640A0367|11 27|Src tyrosine kinase
P10523640A0367|141 161|serine phosphorylation
P10523640A0367|69 76|tyrosine
P10523640A0367|47 66|Stat3 phosphorylation
P10523640A0367|104 117|gene regulation
P10523647A0000|85 91|stimuli
P10523647A0000|147 156|cell growth
P10523647A0000|109 123|stress responses
P10523647A0000|76 82|variety
P10523647A0000|27 31|C/EBP
P10523647A0000|55 65|bZIP protein
P10523647A0000|179 187|cell death
P10523647A0000|3 25|transcription factor CHOP
P10523647A0000|42 48|protein
P10523647A1001|38 46|regulator
P10523647A1001|49 64|C/EBP target genes
P10523647A1001|110 124|AP-1 target genes
P10523647A1001|87 97|AP-1 factors
P10523647A1001|5 8|CHOP
P10523663A0404|4 8|motif
P10523663A0404|40 62|homeobox activator DEAF-1
P10523663A0404|114 123|modulators
P10523663A0404|84 88|group
P10523674A0000|117 131|S rRNA processing
P10523674A0000|90 103|DNA replication
P10523674A0000|11 43|ribonucleoprotein endoribonuclease
P10523674A0000|66 70|roles
P10523674A0000|0 7|RNase MRP
P10524258A0286|17 26|regulation
P10524258A0286|74 92|immunocytochemistry
P10524258A0286|43 47|cek-1
P10524258A0286|64 71|cultures
P10524258A0286|96 115|Northern blot analysis
P10524258A0286|32 41|FGFR-1 gene
P10524258T0000|0 9|Regulation
P10524258T0000|84 104|muscle differentiation
P10524258T0000|49 54|FGFR-1
P10524258T0000|17 46|fibroblast growth factor receptor
P10524258T0000|56 69|gene expression
P10525413A1408|58 61|LIM2
P10525413A1408|47 50|part
P10525413A1408|63 67|R122A
P10525413A1408|21 28|residues
P10525413A1408|110 125|N NMR spectroscopy
P10525413A1408|3 18|backbone dynamics
P10525413A1408|53 56|CRP2
P10526670A0236|0 2|Rac
P10526670A0236|20 33|actin filaments
P10526670A0236|48 56|plus-ends
P10526670A0236|35 41|F-actin
P10526670A0236|9 17|uncapping
P10526670A0236|65 84|phosphatidylinositol
P10526670A0236|127 142|membrane ruffling
P10526670A0236|101 104|PIP2
P10526670A0236|88 99|bisphosphate
P10526670A1828|105 107|PKB
P10526670A1828|154 170|Ras transformation
P10526670A1828|141 151|suppression
P10526670A1828|17 27|ICE/caspase
P10526670A1828|82 90|apoptosis
P10526670A1828|30 38|inhibitor
P10526670A1828|45 49|N1445
P10527106A0384|0 8|OBJECTIVE
P10527106A0384|111 117|deficit
P10527106A0384|49 55|support
P10527106A0384|36 43|findings
P10527106A0384|120 123|need
P10527106A0384|21 33|preponderance
P10527106A0384|142 150|depiction
P10527106A0384|156 162|deficit
P10527158T0000|3 9|AL-R8 SI
P10527158T0000|47 59|plutonium pits
P10527158T0000|65 80|USDOE Pantex Plant
P10527158T0000|18 43|generation staging container
P10527180A0869|523 525|% CI
P10527180A0869|259 274|hormone receptors
P10527180A0869|156 174|% confidence interval
P10527180A0869|610 616|disease
P10527180A0869|316 327|chemotherapy
P10527180A0869|671 678|response
P10527180A0869|83 85|Cox
P10527180A0869|436 438|% CI
P10527180A0869|451 460|metastases
P10527180A0869|142 147|hazard
P10527180A0869|574 577|bone
P10527180A0869|250 256|absence
P10527180A0869|714 716|% CI
P10527180A0869|625 627|% CI
P10527180A0869|509 514|system
P10527180A0869|43 43|P
P10527180A0869|303 305|use
P10527180A0869|370 385|survival interval
P10527180A0869|98 105|analysis
P10527180A0869|422 427|months
P10527180A0869|567 572|tissue
P10527180A0869|466 470|liver
P10527180A0869|537 558|approaches significance
P10527180A0869|191 215|Karnofsky performance score
P10527180A0869|399 407|treatment
P10527180A0869|653 660|response
P10527180A0869|226 226|%
P10527180A0869|593 597|sites
P10527180A0869|128 132|years
P10527180A0869|336 338|% CI
P10527180A0869|283 285|% CI
P10527180A0869|694 705|chemotherapy
P10527180A0869|479 481|% CI
P10527180A0869|581 584|lung
P10527180A0869|8 14|Factors
P10527180A0869|114 116|age
P10527180A0869|64 79|treatment failure
P10527180A0869|235 237|% CI
P10527180A0869|58 61|risk
P10527180A0869|176 177|CI
P10527180A0869|0 6|RESULTS
P10527426A0521|141 149|exclusion
P10527426A0521|60 82|exon I+II+III combination
P10527426A0521|132 137|intron
P10527426A0521|106 110|forms
P10527426A0521|121 129|inclusion
P10527426A0521|90 92|end
P10527426A0521|158 166|sequences
P10527426A0521|152 155|exon
P10527426A0521|3 6|form
P10527426A0521|12 29|SBEI gene transcript
P10527426A0521|41 47|kernels
P10527475A0643|42 48|grooves
P10527475A0643|9 13|MNGCs
P10527475A0643|2 3|PC
P10527475A0643|29 38|inclusions
P10528035A1102|2 8|percent
P10528035A1102|83 89|percent
P10528035A1102|10 10|P
P10528035A1102|31 43|normalization
P10528035A1102|46 79|serum alanine aminotransferase levels
P10529198A0068|86 88|Sos
P10529198A0068|75 81|ras-GRF
P10529198A0068|60 73|homologues p140
P10529198A0068|22 27|domain
P10529354A0375|87 98|P28 complexes
P10529354A0375|79 83|PA700
P10529354A0375|21 27|complex
P10529354A0375|75 77|19S
P10529354A0375|55 64|structures
P10529354A0375|120 131|26S particles
P10529354A0375|3 12|proteasome
P10529354A0375|69 71|20S
P10531334A0525|43 51|PTPS-S19A
P10531334A0525|111 114|type
P10531334A0525|93 105|protein kinase
P10531334A0525|20 26|enzymes
P10531334A0525|107 109|cGK
P10531334A0525|64 72|substrate
P10531334A0525|2 7|assays
P10531340A1275|15 16|R.
P10531340A1275|3 13|Fleischmann
P10531340A1275|25 26|J.
P10531340A1275|18 23|Venter
P10531340A1275|0 1|R.
P10531342A0348|86 93|homology
P10531342A0348|13 18|domain
P10531342A0348|96 127|promastigote surface glycoproteins
P10531342A0348|36 38|kDa
P10531342A0348|133 148|psa2/gp46 complex
P10531342A0348|58 73|amino acid repeats
P10531342A1111|2 9|contrast
P10531342A1111|129 151|promastigote cell surface
P10531342A1111|35 54|proteophosphoglycans
P10531342A1111|59 73|ppg1 gene product
P10531360A0958|101 108|VEGF mRNA
P10531360A0958|114 123|conditions
P10531360A0958|90 98|induction
P10531360A0958|133 139|hypoxia
P10531360A0958|49 57|construct
P10531360A0958|28 32|cells
P10531360A0958|14 22|infection
P10531446A0203|0 9|Neuregulin
P10531446A0203|53 62|ErbB family
P10531446A0203|41 47|members
P10531446A0203|35 39|ErbB4
P10531446A0203|26 30|ErbB3
P10531446A0203|65 87|receptor tyrosine kinases
P10531446A0203|20 24|ErbB2
P10532354A1374|115 122|blockage
P10532354A1374|163 172|alteration
P10532354A1374|56 66|epsilon-COP
P10532354A1374|21 25|Anu2p
P10532354A1374|133 155|protein transport pathway
P10532354A1374|79 90|accumulation
P10532354A1374|204 213|yeast cells
P10532354A1374|182 191|morphology
P10532354A1374|96 105|ER membrane
P10532354A1374|3 9|results
P10532354A1374|31 44|yeast homologue
P10532805A0792|2 10|PC12 cells
P10532805A0792|44 58|differentiation
P10532805A0792|12 28|nerve growth factor
P10532805A0792|71 80|expression
P10532805A0792|83 87|nrg-1
P10532805A1084|57 58|AB
P10532805A1084|34 55|protein kinase A activity
P10532805A1084|87 92|agents
P10532805A1084|3 16|PC12 cell mutant
P10532805A1084|118 126|nrg-1 mRNA
P10533066A0758|0 12|TSC1 mutations
P10533066A0758|64 78|splice mutations
P10533066A0758|45 54|insertions
P10533066A0758|31 39|mutations
P10533066A1197|88 91|TSC2
P10533066A1197|21 33|abnormalities
P10533066A1197|39 41|PTT
P10533066A1197|6 13|patients
P10533066A1197|60 76|missense mutations
P10534048A0297|119 121|ACF
P10534048A0297|8 16|algorithm
P10534048A0297|158 169|transmission
P10534048A0297|246 255|projection
P10534048A0297|90 117|attenuation correction factors
P10534048A0297|204 217|attenuation map
P10534048A0297|71 81|calculation
P10534048A0297|18 25|FOREPROJ
P10534048A0297|42 60|projection algorithm
P10534402A0126|116 123|proteins
P10534402A0126|73 90|sequence similarity
P10534402A0126|102 108|domains
P10534402A0126|12 15|cDNA
P10534402A0126|51 57|protein
P10534402A0126|33 41|mouse gene
P10534402A0126|129 140|Spo11p family
P10534402A0126|26 28|DNA
P10534402A0659|0 5|RT-PCR
P10534402A0659|172 183|accumulation
P10534402A0659|186 189|mRNA
P10534402A0659|123 130|Prophase
P10534402A0659|39 48|time course
P10534402A0659|88 102|Spo11 expression
P10534402A0659|200 213|pachytene stage
P10534402A0659|59 75|testis development
P10534402A0659|15 35|hybridization analyses
P10534402A0659|143 156|pachytene stage
P10534691A0542|0 6|Animals
P10534691A0542|121 130|procedures
P10534691A0542|93 99|culture
P10534691A0542|22 26|weeks
P10534691A0542|16 20|death
P10534691A0542|134 141|evidence
P10534691A0542|38 43|grafts
P10534691A0542|144 152|infection
P10535715A0268|28 32|phase
P10535715A0268|91 96|kJ/24 h
P10535715A0268|122 127|phases
P10535715A0268|53 53|F
P10535715A0268|104 109|luteal
P10535715A0268|3 5|RMR
P10535715A0268|115 120|kJ/24 h
P10536125A0093|0 10|Oseltamivir
P10536125A0093|89 97|inhibitor
P10536125A0093|12 17|GS4104
P10536125A0093|63 68|GS4071
P10536125A0093|54 60|prodrug
P10536125A0093|100 127|influenzavirus neuraminidases
P10536369A0662|86 92|element
P10536369A0662|34 41|evidence
P10536369A0662|45 72|VDR-TR heterodimer interaction
P10536369A0662|2 23|gel mobility shift assays
P10536369A1280|31 40|mechanisms
P10536369A1280|11 20|importance
P10536369A1280|52 59|response
P10536369A1280|76 81|manner
P10536788A0931|84 96|control livers
P10536788A0931|7 7|d
P10536788A0931|60 65|breeds
P10536788A0931|10 20|overfeeding
P10536788A0931|116 117|PL
P10536788A0931|132 132|%
P10536788A0931|140 141|PL
P10536788A0931|29 38|PL profiles
P10540015A0664|58 65|controls
P10540015A0664|37 47|ALS patients
P10540015A0664|133 133|%
P10540015A0664|108 119|MEP threshold
P10540015A0664|71 90|stimulation intensity
P10540015A0664|0 11|C-SP duration
P10540292A1179|170 175|inputs
P10540292A1179|66 73|regulons
P10540292A1179|79 82|cell
P10540292A1179|139 146|response
P10540292A1179|109 121|spv expression
P10540292A1179|20 36|spv virulence genes
P10540292A1179|94 104|possibility
P10540292A1179|5 8|data
P10540553A0980|28 32|cells
P10540553A0980|138 150|proliferation
P10540553A0980|82 89|activity
P10540553A0980|108 110|DNA
P10540553A0980|48 51|wall
P10540553A0980|9 17|synthesis
P10540553A0980|152 155|i.g.
P10540553A0980|97 105|synthesis
P10540553A0980|20 22|PNA
P10540553A0980|161 166|growth
P10540553A0980|128 134|ability
P10540915A0697|76 76|%
P10540915A0697|78 81|n.s.
P10540915A0697|37 44|ligation
P10540915A0697|8 19|transsection
P10540915A0697|46 50|TL&PL
P10540915A0697|61 69|reduction
P10541432A0185|16 27|erbB proteins
P10541432A0185|69 91|tyrosine phosphorylation
P10541432A0185|161 177|ERK MAPK activities
P10541432A0185|185 201|glioblastoma cells
P10541432A0185|57 59|EGF
P10541432A0185|216 232|ERK MAPK activities
P10541432A0185|104 114|Shc proteins
P10541432A0185|44 55|growth factor
P10541550A0487|103 115|amplification
P10541550A0487|49 62|chorion element
P10541550A0487|143 155|follicle cells
P10541550A0487|124 140|DmORC localization
P10541550A0487|37 40|ACE3
P10541550A0487|5 22|immunolocalization
P10541550A0487|75 85|information
P10541865A1301|59 67|mutations
P10541865A1301|129 134|tumors
P10541865A1301|87 97|transcripts
P10541865A1301|20 31|co-deletions
P10541865A1301|34 39|CDKN2A
P10541865A1301|43 48|CDKN2B
P10542237A0357|134 136|LPS
P10542237A0357|21 28|explants
P10542237A0357|115 132|lipopolysaccharide
P10542237A0357|164 176|IL-6 secretion
P10542237A0357|79 86|response
P10542237A0357|55 58|mice
P10542237A0357|101 107|stimuli
P10542249A0415|42 52|combination
P10542249A0415|95 98|CAAT
P10542249A0415|34 38|liver
P10542249A0415|129 133|alpha
P10542249A0415|115 121|protein
P10542249A0415|137 145|C/EBPbeta
P10542249A0415|123 127|C/EBP
P10542249A0415|69 88|transcription factors
P10542249A0415|0 16|Albumin expression
P10542260A0832|42 46|FVIIa
P10542260A0832|83 91|receptors
P10542260A0832|50 52|FXa
P10542260A0832|3 13|requirement
P10542260A0832|28 35|activity
P10542269A0000|0 18|Amyloid beta-protein
P10542269A0000|75 81|plaques
P10542269A0000|102 110|Alzheimer
P10542269A0000|138 148|proteolysis
P10542269A0000|93 99|vessels
P10542269A0000|48 61|amyloid fibrils
P10542269A0000|35 45|constituent
P10542269A0000|113 119|disease
P10542269A0000|121 122|AD
P10542269A0000|20 24|Abeta
P10542269A0000|185 187|APP
P10542269A0000|156 183|beta-amyloid precursor protein
P10542274A1376|41 43|PKA
P10542274A1376|111 126|promoter activity
P10542274A1376|45 53|signaling
P10542274A1376|81 107|caveolin-1 protein expression
P10542274A1376|14 23|activation
P10542274A1376|26 39|protein kinase A
P10542277A0000|17 31|beta heterodimer
P10542277A0000|47 52|import
P10542277A0000|55 62|proteins
P10542277A0000|3 15|importin alpha
P10542277A0000|89 107|localization signals
P10542281A0382|130 137|G1 domain
P10542281A0382|114 124|repeat loops
P10542281A0382|12 16|G1-G2
P10542281A0382|41 51|link protein
P10542281A0382|96 107|proteoglycan
P10542281A0382|28 37|hyaluronan
P10542281A0382|88 92|motif
P10542281A2021|70 74|G1-G2
P10542281A2021|101 110|atrolysin C
P10542281A2021|24 31|presence
P10542281A2021|123 127|sites
P10542281A2021|91 98|activity
P10542281A2021|34 40|absence
P10542281A2021|48 61|keratan sulfate
P10542281A2021|3 9|results
P10543270A1054|59 66|recovery
P10543270A1054|78 80|ppb
P10543270A1054|119 119|p
P10543270A1054|27 31|NOexh
P10543270A1054|95 103|discharge
P10543270A1054|115 117|ppb
P10543270A1054|7 24|i.v. steroid therapy
P10543270A1054|82 82|p
P10543727A0282|148 152|H2TF1
P10543727A0282|362 368|EnA-TRE
P10543727A0282|17 21|sites
P10543727A0282|252 263|H2TF1 element
P10543727A0282|182 191|kappaB site
P10543727A0282|358 360|end
P10543727A0282|155 168|kappaB1 element
P10543727A0282|329 350|ATF recognition sequence
P10543727A0282|141 143|end
P10543727A0282|324 327|AP-1
P10543727A0282|196 209|kappaB2 element
P10543727A0282|304 312|HLA system
P10543727A0282|100 132|rel/NF-kappaB transcription factors
P10543727A0282|86 96|binding site
P10543727A0282|286 293|p65/relA
P10543727A0282|56 62|example
P10543727A0282|32 51|transcription factors
P10543728A0358|14 16|E1A
P10543728A0358|67 86|DNA binding activities
P10543728A0358|89 92|AP-1
P10543728A0358|96 103|contrast
P10543728A0358|18 29|cHa-ras cells
P10543728A0358|120 124|cells
P10543728A0358|131 138|E1A cells
P10543730A0000|14 31|cyclin Ume3p/Srb11p
P10543730A0000|91 100|repression
P10543730A0000|54 59|kinase
P10543730A0000|103 107|genes
P10543730A0000|65 69|Ume5p
P10543730A0000|121 134|stress response
P10543730A0000|137 143|meiosis
P10543730A0000|3 7|yeast
P10543730A0000|61 63|Cdk
P10543949A0686|16 17|S1
P10543949A0686|61 66|cavity
P10543949A0686|19 33|specificity site
P10544037A0617|0 3|FZD4
P10544037A0617|103 103|%
P10544037A0617|121 121|%
P10544037A0617|25 29|FZD10
P10544037A0617|70 73|FZD4
P10544037A0617|41 57|amino acid identity
P10544037A0617|93 97|FZD10
P10544037A0617|18 21|FZD9
P10544037A0617|76 79|FZD9
P10544037A0617|105 108|FZD9
P10544037A0617|87 90|FZD4
P10544037A0617|111 115|FZD10
P10544037A0617|85 85|%
P10544088A0308|71 83|transcription
P10544088A0308|117 119|Tat
P10544088A0308|41 45|PRDII
P10544088A0308|22 38|reporter construct
P10544088A0308|51 53|CAT
P10544088A0308|97 105|NF-kappaB
P10544088A0308|3 11|NF-kappaB
P10544089A1208|181 187|MP-CP-3
P10544089A1208|98 98|H
P10544089A1208|45 50|sgRNAs
P10544089A1208|189 191|UTR
P10544089A1208|152 158|MP-CP-3
P10544089A1208|214 219|MP gene
P10544089A1208|126 127|MP
P10544089A1208|53 57|TMV U1
P10544089A1208|148 149|CR
P10544089A1208|139 140|MP
P10544089A1208|61 65|crTMV
P10544089A1208|170 171|MP
P10544089A1208|160 162|UTR
P10544089A1208|177 178|U1
P10544089A1208|81 96|hairpin structure
P10544089A1208|121 124|IRES
P10544089A1208|3 16|RNA transcripts
P10544113A0293|0 25|EIAV LTR sequence variability
P10544113A0293|62 69|enhancer
P10544113A0293|50 56|portion
P10544113A0293|79 87|U3 segment
P10544113A0293|93 95|LTR
P10545192T0000|122 140|agent vanadyl sulfate
P10545192T0000|82 84|s6k
P10545192T0000|68 74|MEK/ERK
P10545192T0000|41 50|activation
P10545192T0000|86 101|signaling cascade
P10545192T0000|56 64|ras/C-raf
P10545192T0000|78 80|p70
P10545192T0000|0 38|Phosphatidylinositol 3-kinase requirement
P10545248A0567|13 20|enhancer
P10545248A0567|98 100|Tin
P10545248A0567|55 66|binding sites
P10545248A0567|3 6|core
P10545248A0567|151 164|muscle lineages
P10545248A0567|73 96|homeodomain protein Tinman
P10545281A0836|3 9|example
P10545281A0836|39 62|purification tag sequences
P10545281A0836|128 146|protein accumulation
P10545281A0836|11 22|introduction
P10545281A0836|114 124|bop gene mRNA
P10545281A0836|80 91|coding region
P10548434A1549|133 144|p38 signaling
P10548434A1549|114 116|ERK
P10548434A1549|23 29|ability
P10548434A1549|32 38|polyoma
P10548434A1549|124 130|JNK/SPK
P10548434A1549|45 53|T antigens
P10548434A1549|83 97|differentiation
P10548622A0906|103 115|egg collection
P10548622A0906|176 180|TUGOR
P10548622A0906|36 45|lignocaine
P10548622A0906|75 96|i.v. sedation/analgesia
P10548622A0906|27 31|block
P10548622A0906|157 174|ultrasound guidance
P10548622A0906|60 70|conjunction
P10548622A0906|202 210|procedure
P10548622A0906|193 196|pain
P10548622A0906|147 151|route
P10548722A0099|41 44|H1.8
P10548722A0099|19 30|organization
P10548722A0099|207 210|gene
P10548722A0099|164 170|element
P10548722A0099|3 6|loci
P10548722A0099|132 135|SIRE
P10548722A0099|118 125|sequence
P10548722A0099|59 71|TcP2beta genes
P10549354A1782|89 109|beta-catenin complexes
P10549354A1782|129 137|mutations
P10549354A1782|154 165|beta-catenin
P10549354A1782|25 39|colon carcinomas
P10549354A1782|207 209|APC
P10549354A1782|43 51|melanomas
P10549354A1782|13 15|APC
P10549354A1782|191 204|downregulation
P10549354A1782|223 236|Axin/Conductin
P10549354A1782|211 218|GSK3 beta
P10549354A1782|113 118|result
P10549354A1782|143 151|N terminus
P10549354A1782|83 87|Tcf-4
P10549354A1782|1 10|proportion
P10549354A2371|100 104|forms
P10549354A2371|26 37|deregulation
P10549354A2371|107 112|cancer
P10549354A2371|40 60|Tcf target gene activity
P10549354A2371|7 16|mechanisms
P10549354A2371|84 91|melanoma
P10549912A0136|204 211|branches
P10549912A0136|157 161|V1-V4
P10549912A0136|140 155|segment elevation
P10549912A0136|20 26|patient
P10549912A0136|256 261|artery
P10549912A0136|227 237|angioplasty
P10549912A0136|63 72|infarction
P10549912A0136|4 9|report
P10549912A0136|174 177|loss
P10549912A0136|101 110|infarction
P10549912A0136|134 137|lead
P10550139A0191|0 7|PATIENTS
P10550139A0191|84 88|sides
P10550139A0191|11 17|METHODS
P10550139A0191|99 103|crest
P10550139A0191|57 75|bone marrow aspirates
P10550139A0191|120 127|patients
P10550139A0191|43 55|prostatectomy
P10550571A0000|0 6|PURPOSE
P10550571A0000|164 169|thiols
P10550571A0000|145 151|WR-2721
P10550571A0000|108 116|compounds
P10550571A0000|77 84|patients
P10550571A0000|63 74|plasma levels
P10550571A0000|16 22|WR-2721
P10550571A0000|136 142|effects
P10550571A0000|43 49|studies
P10550571A0000|121 124|none
P10550574A1038|119 119|%
P10550574A1038|92 96|grade
P10550574A1038|66 89|serum alkaline phosphatase
P10550574A1038|26 35|toxicities
P10550574A1038|122 127|cycles
P10550574A1038|37 44|diarrhea
P10550574A1038|46 54|infection
P10550574A1038|4 9|regard
P10551788A0229|0 5|LHbeta
P10551788A0229|75 90|trophoblast cells
P10551788A0229|47 52|CGbeta
P10551788A0229|28 43|gonadotrope cells
P10551796T0000|0 9|Regulation
P10551796T0000|12 29|HIV-1 transcription
P10551816A0162|5 10|LTBP-1
P10551816A0162|36 40|forms
P10551848A0000|43 46|Tada
P10551848A0000|48 49|M.
P10551848A0000|24 25|Y.
P10551848A0000|40 41|K.
P10551848A0000|11 15|study
P10551848A0000|54 62|MacLennan
P10551848A0000|64 65|D.
P10551848A0000|17 22|Kimura
P10551848A0000|27 38|Kurzydlowski
P10551867A0350|16 32|amino acid residues
P10551867A0350|109 124|rat cDNA libraries
P10551867A0350|43 60|9-kilobase pair mRNA
P10551867A0350|69 82|splice variants
P10551879T0000|134 154|protein fusion proteins
P10551879T0000|81 115|fluorescence resonance energy transfer
P10551879T0000|41 65|A-kinase anchoring proteins
P10551879T0000|68 78|living cells
P10551879T0000|19 38|protein kinase binding
P10552357A1936|0 10|CONCLUSIONS
P10552357A1936|132 135|OCTA
P10552357A1936|232 234|AIR
P10552357A1936|203 209|effects
P10552357A1936|216 227|echogenicity
P10552357A1936|88 99|microspheres
P10552357A1936|64 75|microspheres
P10552357A1936|168 177|LV function
P10552357A1936|122 129|efficacy
P10552357A1936|103 117|LV opacification
P10552357A1936|27 37|superiority
P10552357A1936|14 21|addition
P10553551A0000|43 50|disorder
P10553551A0000|72 78|pathway
P10553551A0000|0 17|Factor XI deficiency
P10553959A0812|3 16|Ishasha samples
P10553959A0812|51 56|levels
P10553959A0812|22 26|range
P10554946A0082|87 91|drugs
P10554946A0082|24 40|clomiphene citrate
P10554946A0082|153 158|uterus
P10554946A0082|146 151|breast
P10554946A0082|167 172|lipids
P10554946A0082|107 114|faslodex
P10554946A0082|94 103|raloxifene
P10554946A0082|137 143|actions
P10554946A0082|18 22|SERMS
P10554946A0082|160 163|bone
P10554946A0082|120 127|emphasis
P10554946A0082|44 52|tamoxifen
P10555079A0254|0 1|Ti
P10555079A0254|24 33|morphology
P10555285A1065|28 44|duplication events
P10555285A1065|72 92|FUT3-FUT5-FUT6 cluster
P10555285A1065|157 165|mechanism
P10555285A1065|205 217|globin cluster
P10555285A1065|4 15|organization
P10555964A0778|0 1|S.
P10555964A0778|7 8|S.
P10555964A0778|3 5|Kim
P10556028A0292|155 158|BD-2
P10556028A0292|94 105|repA promoter
P10556028A0292|107 110|Prep
P10556028A0292|81 89|structure
P10556028A0292|32 53|plasmid incompatibility
P10556028A0292|24 29|region
P10556028A0292|3 11|cop region
P10556028A0292|55 57|inc
P10556028A0292|148 151|BD-1
P10556028A0292|131 146|RepA binding sites
P10556029A0852|0 11|WA constructs
P10556029A0852|38 48|topoisomers
P10556029A0852|85 99|interconversion
P10556029A0852|53 71|cyclization kinetics
P10556029A0852|102 111|precursors
P10556029A0852|120 130|topoisomers
P10556033A0000|27 33|members
P10556033A0000|112 117|domain
P10556033A0000|38 42|yeast
P10556033A0000|45 50|humans
P10556033A0000|141 146|region
P10556033A0000|84 90|systems
P10556033A0000|3 18|RFX protein family
P10556044A0913|0 6|Binding
P10556044A0913|26 51|alpha-dystroglycan receptor
P10556044A0913|9 19|sulphatides
P10556044A0913|88 96|LG modules
P10556046A0328|89 92|side
P10556046A0328|55 70|signaling pathway
P10556046A0328|98 110|Xenopus embryo
P10556063A0092|45 56|Trk subfamily
P10556063A0092|24 32|subfamily
P10556063A0092|5 11|kinases
P10556089A0901|203 208|CUG-bp
P10556089A0901|182 193|gene function
P10556089A0901|168 179|conservation
P10556089A0901|110 119|processing
P10556089A0901|38 54|muscle development
P10556089A0901|126 140|muscle component
P10556089A0901|3 6|data
P10556089A0901|19 23|etr-1
P10556089A0901|84 87|role
P10556089A0901|57 65|C. elegans
P10556145A1034|0 9|Gentamicin
P10556145A1034|87 91|order
P10556145A1034|51 66|sputum Psa density
P10556145A1034|17 19|DPI
P10556145A1034|23 25|SVN
P10556145A1034|68 68|p
P10556145A1034|94 102|magnitude
P10556263A1035|0 10|CONCLUSIONS
P10556263A1035|75 76|AC
P10556263A1035|37 41|space
P10556263A1035|22 26|value
P10556263A1035|82 86|space
P10556595A0391|56 67|transversion
P10556595A0391|48 48|G
P10556595A0391|77 79|end
P10556595A0391|50 50|C
P10556595A0391|12 19|sequence
P10556595A0391|91 96|region
P10556595A0391|53 53|T
P10556595A0391|31 38|recN gene
P10556595A0391|2 9|analysis
P10556751A0758|157 161|staff
P10556751A0758|76 87|immunization
P10556751A0758|52 54|HGV
P10556751A0758|89 91|HGV
P10556751A0758|33 49|transmission rates
P10556751A0758|61 64|lack
P10556751A0758|132 137|hazard
P10556751A0758|15 18|view
P10557008T0000|0 8|Detection
P10557008T0000|11 19|poisoning
P10557008T0000|51 56|mother
P10557008T0000|22 27|Impila
P10557008T0000|60 64|child
P10557072A0127|70 73|ULK1
P10557072A0127|26 30|mouse
P10557072A0127|63 68|kinase
P10557072A0127|39 43|cDNAs
P10557072A0418|130 130|C
P10557072A0418|99 100|PS
P10557072A0418|7 12|UNC-51
P10557072A0418|80 93|proline/serine
P10557072A0418|102 107|domain
P10557072A0418|26 40|domain structure
P10557072A0418|132 137|domain
P10557072A0418|59 70|kinase domain
P10557072A0418|0 3|ULKs
P10557072A1218|5 11|results
P10557072A1218|92 96|cells
P10557072A1218|23 26|ULK2
P10557072A1218|65 80|signaling pathway
P10557308A0000|0 16|Connector enhancer
P10557308A0000|19 21|KSR
P10557308A0000|23 25|CNK
P10557308A0000|41 47|protein
P10557308A0000|59 70|RAS signaling
P10559207A0207|156 161|course
P10559207A0207|105 109|genes
P10559207A0207|22 35|ATP sulfurylase
P10559207A0207|9 17|organisms
P10559207A0207|39 56|APS kinase reactions
P10559207A0207|126 131|fusion
P10559207A0207|79 85|enzymes
P10559207A0207|164 172|evolution
P10559207A0207|197 202|enzyme
P10559207A0207|142 146|genes
P10559303A0000|28 42|membrane protein
P10559303A0000|12 16|virus
P10559303A0000|45 48|LMP1
P10559303A0000|76 89|transformation
P10559303A0000|18 20|EBV
P10559303A0000|99 110|B lymphocytes
P10559320A0080|115 118|RNAs
P10559320A0080|67 77|protein nsP1
P10559320A0080|35 41|homolog
P10559320A0080|23 24|1a
P10559320A0080|44 53|alphavirus
P10559320A0080|17 20|half
P10559324A0716|33 43|Ad5 E4orf6/7
P10559324A0716|21 22|Ad
P10559324A0716|62 69|rat cells
P10559324A0716|111 112|Ad
P10559324A0716|51 59|apoptosis
P10559364A0846|2 5|HCMV
P10559364A0846|22 28|HF cells
P10559364A0846|185 187|SSB
P10559364A0846|262 265|BrdU
P10559364A0846|75 100|DNA replication compartments
P10559364A0846|114 141|polymerase processivity factor
P10559364A0846|37 37|h
P10559364A0846|167 183|DNA binding protein
P10559364A0846|189 192|UL57
P10559364A0846|39 41|IE2
P10559364A0846|244 260|bromodeoxyuridine
P10559364A0846|143 146|UL44
P10559364A0846|198 222|UL112-113 accessory protein
P10559364A0846|7 11|Towne
P10560014A0000|95 100|system
P10560014A0000|63 79|angioarchitecture
P10560014A0000|23 42|heart vascularization
P10560014A0000|127 136|myocardium
P10560997A1072|0 9|CONCLUSION
P10560997A1072|51 56|method
P10560997A1072|11 11|S
P10560997A1072|71 79|ovulation
P10560997A1072|30 37|LH levels
P10561095A2141|131 148|hypoparathyroidism
P10561095A2141|35 41|disease
P10561095A2141|8 18|reoperation
P10561095A2141|111 119|incidence
P10561095A2141|71 86|calcitonin levels
P10561095A2141|43 47|group
P10561153A0225|130 134|month
P10561153A0225|62 64|SSc
P10561153A0225|10 13|case
P10561153A0225|116 122|failure
P10561153A0225|16 24|carcinoma
P10561153A0225|30 35|breast
P10561251A0000|0 6|PURPOSE
P10561251A0000|229 232|HDCT
P10561251A0000|216 227|chemotherapy
P10561251A0000|184 198|modality therapy
P10561251A0000|127 135|stage IIIB
P10561251A0000|107 115|mortality
P10561251A0000|79 85|factors
P10561251A0000|248 271|stem-cell transplantation
P10561251A0000|118 122|women
P10561251A0000|65 66|OS
P10561251A0000|42 44|DFS
P10561251A0000|161 163|IBC
P10561251A0000|56 63|survival
P10561251A0000|200 202|CMT
P10561251A0000|33 40|survival
P10561251A0000|148 159|breast cancer
P10561460A0615|112 124|signal peptide
P10561460A0615|88 91|cDNA
P10561460A0615|3 17|GPI anchor moiety
P10561460A0615|61 71|polypeptide
P10561460A0615|51 55|level
P10561460A0615|128 145|GPI signal sequences
P10561546A0000|118 135|localization signal
P10561546A0000|76 83|antibody
P10561546A0000|34 40|protein
P10561546A0000|138 156|NF-kappaB p65 subunit
P10562418A0238|42 46|cells
P10562418A0238|17 22|events
P10562456T0000|99 105|walbaum
P10562456T0000|10 16|regions
P10562456T0000|38 43|intron
P10562456T0000|49 65|growth hormone gene
P10562456T0000|22 29|promoter
P10562456T0000|68 79|rainbow trout
P10562456T0000|81 92|Oncorhynchus
P10562495A0188|84 87|gene
P10562495A0188|102 111|production
P10562495A0188|12 19|SFV genes
P10562495A0188|136 140|virus
P10562495A0188|24 31|homologs
P10562495A0188|66 74|SFV genome
P10562495A0188|46 61|Chordopoxvirinae
P10563212A0514|47 49|QoL
P10563212A0514|106 113|controls
P10563212A0514|21 38|SF-36 questionnaire
P10563605A0773|40 43|IENF
P10563605A0773|9 13|trend
P10563605A0773|22 32|association
P10563605A0773|91 91|p
P10563605A0773|52 56|nerve
P10563605A0773|69 82|fiber densities
P10563605A0773|84 84|r
P10563789A1951|2 9|addition
P10563789A1951|78 79|CG
P10563789A1951|26 42|F beta alpha/CG beta
P10563789A1951|11 15|media
P10563789A1951|83 94|FSH receptors
P10563836A1234|2 9|contrast
P10563836A1234|11 29|AP-2 binding activity
P10563836A1234|68 79|Western blots
P10563836A1234|122 126|cells
P10563836A1234|98 114|AP-2 protein levels
P10563836A1234|55 63|T47D cells
P10564231A0315|13 14|M.
P10564231A0315|0 8|N. van Hoek
P10564280A0140|161 172|Src substrate
P10564280A0140|54 60|YT521-B
P10564280A0140|114 147|component scaffold attachment factor B
P10564280A0140|197 201|Sam68
P10564280A0140|46 52|protein
P10564280A0140|189 195|mitosis
P10564472A0853|5 11|mutants
P10564472A0853|38 47|TraR fusion
P10564472A0853|63 68|system
P10564474T0000|9 18|homologues
P10564474T0000|65 89|outer-membrane protein OprH
P10564474T0000|93 112|polymyxin B resistance
P10564474T0000|50 59|expression
P10564479A0384|0 7|Deletion
P10564479A0384|37 42|effect
P10564479A0384|88 96|activator
P10564479A0384|10 13|fdsR
P10564479A0384|137 143|absence
P10564479A0384|123 131|repressor
P10564479A0384|112 118|formate
P10564479A0384|146 152|formate
P10564479A0384|102 109|presence
P10564479A0384|54 62|fds operon
P10564479A0384|45 48|FdsR
P10564484A0859|43 46|gene
P10564484A0859|151 154|site
P10564484A0859|27 37|binding site
P10564484A0859|162 169|promoter
P10564484A0859|107 118|requirements
P10564484A0859|123 130|function
P10564484A0859|4 13|constructs
P10564484A0859|57 64|promoter
P10564495A0444|116 118|CEA
P10564495A0444|212 216|cells
P10564495A0444|182 186|CD66d
P10564495A0444|19 29|Opa proteins
P10564495A0444|77 80|cDNA
P10564495A0444|176 179|CGM1
P10564495A0444|127 134|subgroup
P10564495A0444|120 124|CD66e
P10564495A0444|166 172|tropism
P10564495A0444|108 114|antigen
P10564495A0444|191 193|NCA
P10564495A0444|140 149|CD66 family
P10564495A0444|53 61|HeLa cells
P10564495A0444|195 199|CD66c
P10564495A0444|32 35|C751
P10564495A0444|2 9|addition
P10564593A0428|74 83|chromosome
P10564593A0428|87 99|MCF-7 AdVp3000
P10564593A0428|154 166|translocation
P10564593A0428|103 109|MCF-7 MX
P10564593A0428|51 64|rearrangements
P10564593A0428|26 30|paint
P10564593A0428|15 24|chromosome
P10564593A0428|116 123|S1-M1-80
P10564593A0428|0 3|FISH
P10564593A1618|60 67|evidence
P10564593A1618|92 98|regions
P10564593A1618|195 207|drug transport
P10564593A1618|154 172|MXR half-transporter
P10564593A1618|112 118|partner
P10564593A1618|70 84|coamplification
P10564593A1618|18 33|half-transporter
P10564593A1618|3 9|MXR gene
P10564593A1618|40 46|absence
P10564939A0981|3 8|effect
P10564939A0981|11 17|smoking
P10564939A0981|38 42|study
P10564939A0981|50 53|data
P10566630A0371|0 4|Serum
P10566630A0371|37 43|SD score
P10566630A0371|133 138|months
P10566630A0371|110 115|months
P10566630A0371|31 35|IGF-I
P10566630A0371|76 80|women
P10566630A0371|17 29|growth factor I
P10566630A0371|70 72|men
P10566862A0000|45 53|distances
P10566862A0000|109 118|evaluation
P10566862A0000|24 35|stereoacuity
P10566862A0000|11 21|Measurement
P10566862A0000|142 150|imbalance
P10566862A0000|72 93|depth stereoacuity tests
P10566862A0000|153 162|strabismus
P10566862A0000|121 128|patients
P10566862A0000|0 9|BACKGROUND
P10567430A0785|146 151|Galpha
P10567430A0785|47 50|q/11
P10567430A0785|183 186|GRK5
P10567430A0785|79 87|construct
P10567430A0785|124 129|Galpha
P10567430A0785|102 108|binding
P10567430A0785|171 180|constructs
P10567430A0785|90 93|GRK2
P10567430A0785|189 192|GRK6
P10567430A0785|131 131|s
P10567430A0785|134 139|Galpha
P10567430A0785|111 116|Galpha
P10567430A0785|10 16|studies
P10567430A0785|35 45|brain Galpha
P10567430A0785|118 121|q/11
P10567524T0000|57 61|yeast
P10567524T0000|32 47|signaling network
P10567524T0000|3 21|elm1 kinase functions
P10567533A0818|21 22|RT
P10567533A0818|113 127|tyrosine kinases
P10567533A0818|68 74|primers
P10567533A0818|25 35|PCR products
P10567533A0818|7 19|transcription
P10567533A0818|98 103|motifs
P10567538A1028|14 38|acetyltransferase activity
P10567538A1028|114 116|CH3
P10567538A1028|91 108|activation function
P10567538A1028|41 44|p300
P10567538A1028|135 140|region
P10567538A1028|2 9|addition
P10567581A0119|176 185|expression
P10567581A0119|206 220|hepatocyte entry
P10567581A0119|168 172|liver
P10567581A0119|58 64|HFH-11B
P10567581A0119|87 89|Win
P10567581A0119|25 29|HNF-3
P10567581A0119|94 105|family member
P10567581A0119|127 150|head transcription factors
P10567581A0119|240 245|S phase
P10567581A0119|225 238|DNA replication
P10567581A0119|31 56|fork head homolog-11B protein
P10567581A0119|77 83|Trident
P10567582A1334|31 36|embryo
P10567582A1334|76 88|embryogenesis
P10567582A1334|11 15|CtBP1
P10567582A1334|48 52|CtBP2
P10567582A1334|5 9|mouse
P10567589A1268|87 102|Pmt3p conjugation
P10567589A1268|11 19|functions
P10567589A1268|22 26|Pmt3p
P10567589A1268|65 72|proteins
P10568275A0679|3 6|role
P10568275A0679|9 17|transport
P10568275A0679|47 57|Arctic Ocean
P10568275A0679|20 25|sea ice
P10568275A0679|87 92|GEOMAR
P10568275A0679|33 39|Kara Sea
P10568275A0679|77 84|subgroup
P10568455A0000|151 152|CL
P10568455A0000|37 64|slow-release estradiol-17beta
P10568455A0000|26 34|injection
P10568455A0000|156 170|pseudopregnancy
P10568455A0000|66 69|SRE2
P10568455A0000|114 122|PGF2alpha
P10568455A0000|82 96|pseudopregnancy
P10568455A0000|138 149|corpora lutea
P10568455A0000|99 103|gilts
P10568728A1445|82 85|week
P10568728A1445|10 28|serum creatine kinase
P10568728A1445|50 53|days
P10568728A1445|3 7|level
P10568728A1445|59 63|ESWIB
P10568744A0728|82 86|sites
P10568744A0728|114 117|role
P10568744A0728|36 44|promoters
P10568744A0728|134 142|direction
P10568744A0728|66 70|genes
P10568744A0728|145 163|mating type switching
P10568744A0728|19 23|sites
P10570262A0000|0 9|Activation
P10570262A0000|24 26|TCR
P10570262A0000|74 90|signaling cascades
P10570262A0000|12 17|T cells
P10570262A0000|66 71|number
P10570262A0000|48 56|receptors
P10570996A1213|183 189|insulin
P10570996A1213|76 87|scavenger RTK
P10570996A1213|205 213|receptors
P10570996A1213|110 118|signature
P10570996A1213|125 131|TK class
P10570996A1213|13 20|analysis
P10570996A1213|134 142|receptors
P10570996A1213|92 98|domains
P10570996A1213|46 54|sequences
P10570996A1213|28 36|TK domains
P10571047A1009|88 103|HindIII fragments
P10571047A1009|7 9|7SL
P10571047A1009|51 57|spacers
P10571047A1009|22 30|sequences
P10571047A1009|120 121|kb
P10571474A0571|0 6|Results
P10571474A0571|46 52|atrophy
P10571474A0571|20 25|stress
P10571474A0571|34 36|CA3
P10571474A0571|56 65|tianeptine
P10572087A0326|85 93|screening
P10572087A0326|15 28|binding partner
P10572087A0326|62 66|FANCC
P10572087A0326|42 60|anemia group C protein
P10572087A0326|70 74|yeast
P10572130A1623|118 121|role
P10572130A1623|91 103|RNA polymerase
P10572130A1623|141 151|DNA geometry
P10572130A1623|124 132|formation
P10572130A1623|81 88|subunits
P10572130A1623|5 11|results
P10572130A1623|27 49|transcription activators
P10572131A0000|0 16|Klebsiella oxytoca
P10572131A0000|54 60|enzymes
P10572131A0000|73 87|nasFEDCBA operon
P10572866A0481|61 70|phosphorus
P10572866A0481|37 48|plasma values
P10572866A0481|6 14|hemolysis
P10572866A0481|51 59|potassium
P10572866A0481|77 83|protein
P10572866A0481|88 112|aspartate aminotransferase
P10573781A0631|0 6|Studies
P10573781A0631|27 37|involvement
P10573781A0631|61 71|chromosomes
P10573781A0631|48 51|loci
P10573781A0631|75 80|excess
P10573781A0631|85 95|chromosomes
P10574913A1108|80 88|processes
P10574913A1108|95 108|Src recruitment
P10574913A1108|129 143|internalization
P10574913A1108|177 189|ERK activation
P10574913A1108|224 236|ERK activation
P10574913A1108|34 56|receptor phosphorylation
P10574929A0583|18 30|fractionation
P10574929A0583|41 53|P-CIP2 protein
P10574982A1075|0 14|Supershift EMSAs
P10574982A1075|88 96|complexes
P10574982A1075|77 80|part
P10574982A1075|48 55|factor-1
P10574982A1075|62 66|USF-1
P10574992A0901|116 126|irradiation
P10574992A0901|91 113|cell death susceptibility
P10574992A0901|11 20|E1A binding
P10574992A0901|163 199|PARP chemical inhibitor 3-aminobenzamide
P10574992A0901|56 73|PARP enzyme activity
P10574992A0901|46 53|increase
P10574992A0901|27 34|p300/CBP
P10575231A0355|0 7|Analysis
P10575231A0355|78 84|introns
P10575231A0355|20 25|region
P10575231A0355|46 53|Cdc6 gene
P10575231A0355|69 73|exons
P10575545A0147|15 19|CACCC
P10575545A0147|23 32|CAAT motifs
P10575642T0000|0 12|Skin pH changes
P10575642T0000|27 39|iontophoresis
P10576177A0308|70 74|range
P10576177A0308|37 45|diagnosis
P10576177A0308|77 85|prognoses
P10576177A0308|107 117|implication
P10576177A0308|4 14|distinction
P10576545A0926|33 44|DNA cassettes
P10576545A0926|113 122|expression
P10576545A0926|63 77|D1A gene promoter
P10576545A0926|125 134|transgenes
P10576545A0926|3 14|availability
P10578528A0730|63 71|character
P10578528A0730|75 87|manifestation
P10578528A0730|121 134|symptomatology
P10578528A0730|46 48|EEG
P10578528A0730|29 33|focus
P10578528A0730|18 25|location
P10579331A1225|42 68|rat HDL receptor SR-BI promoter
P10579331A1225|110 113|dSRE
P10579331A1225|127 134|SREBP-1a
P10579331A1225|103 106|pSRE
P10579331A1225|153 165|transcription
P10579331A1225|172 175|gene
P10579331A1225|80 101|sterol response elements
P10579331A1225|3 9|results
P10579331A1225|17 23|studies
P10579722T0000|45 61|myosin phosphatase
P10579722T0000|39 41|MBS
P10579722T0000|64 73|Rho-kinase
P10579722T0000|0 14|Phosphorylation
P10579722T0000|31 37|subunit
P10580071A0436|100 109|transplant
P10580071A0436|49 63|transplantation
P10580071A0436|7 14|patients
P10580071A0436|42 45|list
P10580438A0508|118 130|preadipocytes
P10580438A0508|36 39|EMSA
P10580438A0508|106 113|extracts
P10580438A0508|142 151|adipocytes
P10580438A0508|46 66|GLUT4 repressor element
P10580438A0508|68 71|G4RE
P10580438A0508|17 34|mobility shift assay
P10580438A0508|90 94|bands
P10582831T0000|75 82|patients
P10582831T0000|22 35|redistribution
P10582831T0000|48 60|complications
P10582831T0000|0 8|Syndromes
P10584138T0001|30 41|radiotherapy
P10584138T0001|64 67|head
P10584138T0001|71 80|neck tumors
P10584138T0001|18 27|amifostine
P10584138T0001|44 61|radio-chemotherapy
P10584138T0001|0 13|Cytoprotection
P10584704A0913|183 190|sections
P10584704A0913|109 119|cytokeratin
P10584704A0913|76 81|HMB-45
P10584704A0913|41 45|S-100
P10584704A0913|88 88|%
P10584704A0913|52 56|cases
P10584704A0913|19 26|staining
P10584704A0913|165 169|block
P10584704A0913|144 151|melanoma
P10584704A0913|126 130|cases
P10585311A0494|125 130|biopsy
P10585311A0494|98 102|onset
P10585311A0494|24 27|MPGN
P10585311A0494|42 44|age
P10585311A0494|78 85|interval
P10585311A0494|105 112|symptoms
P10585311A0494|61 63|age
P10585311A0494|12 16|types
P10585311A0494|115 123|diagnosis
P10585311A0494|66 74|diagnosis
P10585311A0494|55 59|onset
P10585311A0494|0 7|Patients
P10585311A1542|87 90|MPGN
P10585311A1542|59 66|patients
P10585311A1542|82 85|type
P10585311A1542|71 74|type
P10585311A1542|15 27|abnormalities
P10585417A1412|14 24|differences
P10585417A1412|39 54|tissue expression
P10585417A1412|127 134|function
P10585417A1412|27 35|signaling
P10585417A1412|108 111|PRLr
P10585417A1412|86 89|PRLr
P10585440A0204|85 87|arm
P10585440A0204|37 48|FAK homologue
P10585440A0204|99 108|chromosome
P10585440A0204|50 55|DFak56
P10585440A0204|68 74|band 56D
P10585453A1029|158 163|hGH LCR
P10585453A1029|141 144|role
P10585453A1029|25 41|hGH-N gene promoter
P10585453A1029|90 93|data
P10585453A1029|10 19|Pit-1 sites
P10585453A1029|64 77|gene activation
P10585453A1029|148 152|Pit-1
P10585463A0859|44 74|baculovirus-Sf9 expression system
P10585463A0859|11 29|prenylcysteine lyase
P10585480A0157|83 85|Rac
P10585480A0157|77 79|Ras
P10585480A0157|22 30|SH3 domain
P10585480A0157|43 73|guanine nucleotide exchange factor
P10585480A0157|38 40|Sos
P10585480A0265|0 13|Point mutations
P10585480A0265|24 32|SH3 domain
P10585480A0265|56 66|interaction
P10585491A0945|319 327|seedlings
P10585491A0945|45 47|CBF
P10585491A0945|340 348|seedlings
P10585491A0945|212 226|binding activity
P10585491A0945|104 111|extracts
P10585491A0945|256 262|tissues
P10585491A0945|360 368|cytokinin
P10585491A0945|154 161|extracts
P10585491A0945|244 251|extracts
P10585491A0945|191 199|seedlings
P10585491A0945|62 81|AtpC promoter sequence
P10585491A0945|271 290|AtpC expression levels
P10585491A0945|129 148|AtpC expression levels
P10585491A0945|116 121|tissue
P10585491A0945|296 303|extracts
P10585491A0945|2 23|gel mobility shift assays
P10585491A0945|28 42|binding activity
P10585808A0000|0 26|Mycoplasma hominis infections
P10585808A0000|80 88|detection
P10585808A0000|61 67|methods
P10586074A0129|30 46|plasmid constructs
P10586074A0129|22 27|series
P10586074A0129|100 109|flavivirus
P10586074A0129|7 13|purpose
P10586074A0129|74 94|envelope glycoprotein E
P10586074A0129|64 68|forms
P10586074A0129|120 136|encephalitis virus
P10586107A0160|73 92|cell surface receptors
P10586107A0160|24 28|types
P10586107A0160|41 60|transduction pathways
P10586115A0477|73 80|IL-1beta
P10586115A0477|103 106|IL-6
P10586115A0477|174 180|inducer
P10586115A0477|82 90|TNF-alpha
P10586115A0477|212 215|% FCS
P10586115A0477|94 97|IL-6
P10586115A0477|63 71|IL-1alpha
P10586115A0477|45 53|cytokines
P10586115A0477|201 208|cultures
P10586115A0477|149 153|cells
P10586115A0477|132 137|PKCeta
P10586626A0607|130 133|ADEM
P10586626A0607|76 83|presence
P10586626A0607|105 115|involvement
P10586626A0607|13 20|diseases
P10586626A0607|37 42|matter
P10586626A0607|118 125|patients
P10587460A0302|83 93|hVDR mutants
P10587460A0302|47 50|hVDR
P10587460A0302|183 190|bacteria
P10587460A0302|104 111|Delta113
P10587460A0302|113 120|Delta102
P10587460A0302|130 136|Delta84
P10587460A0302|95 102|Delta134
P10587460A0302|18 34|VDRE binding domain
P10587460A0302|43 45|VDR
P10587460A0302|122 128|Delta90
P10587460A0302|138 144|Delta80
P10587460A0302|54 59|series
P10587460A0302|149 155|Delta60
P10587461A0341|60 68|formation
P10587461A0341|40 48|anticodon
P10587461A0341|78 92|transition state
P10587461A0341|25 32|contacts
P10587461A0341|96 99|site
P10587461A0341|15 23|mechanism
P10587576A0596|46 47|kb
P10587576A0596|86 100|SH3GL pseudogene
P10587576A0596|12 19|clusters
P10587576A0596|5 8|REPs
P10587576A0596|51 56|harbor
P10587576A0596|68 71|ESTs
P10587576A0596|32 35|loci
P10588946A0432|42 49|proteins
P10588946A0432|68 72|ORP-6
P10588946A0432|61 65|ORP-1
P10588946A0432|13 19|minimum
P10589562A1208|56 66|BB resonator
P10589562A1208|20 28|inability
P10589562A1208|9 14|result
P10589562A1208|2 5|part
P10589562A1208|82 100|RF power requirements
P10589711A1228|105 109|cells
P10589711A1228|185 190|milieu
P10589711A1228|11 24|narZ expression
P10589711A1228|2 9|addition
P10589711A1228|72 82|Madin-Darby
P10589711A1228|89 94|kidney
P10589711A1228|135 145|salts medium
P10590092A0124|8 17|mechanisms
P10590092A0124|52 54|CNS
P10590092A0124|28 46|HIV-1 gene expression
P10590368X0000|27 37|alternative
P10590368X0000|211 223|survival rates
P10590368X0000|183 188|cervix
P10590368X0000|104 113|BACKGROUND
P10590368X0000|141 149|lymph node
P10590368X0000|74 91|stage IA-B carcinoma
P10590368X0000|47 58|hysterectomy
P10590368X0000|97 102|cervix
P10590368X0000|164 177|stage carcinoma
P10590368X0000|9 21|trachelectomy
P10590368X0000|62 69|patients
P10590368X0000|237 237|%
P10590368X0000|118 126|prognosis
P10591633A0138|71 77|vesicle
P10591633A0138|163 173|recognition
P10591633A0138|91 94|view
P10591633A0138|179 192|membrane fusion
P10591633A0138|101 124|SNARE protein interactions
P10591633A0138|36 46|recognition
P10591633A0138|143 146|role
P10591633A0138|4 8|event
P10591633A0138|15 21|process
P10591633A0138|52 65|target membrane
P10591933A0798|13 16|Type
P10591933A0798|49 54|values
P10591933A0798|150 157|distance
P10591933A0798|75 79|angle
P10591933A0798|18 30|configuration
P10591933A0798|83 90|coracoid
P10591976A0317|0 11|Measurements
P10591976A0317|72 79|patients
P10591976A0317|25 30|LWS lat
P10591976A0317|62 66|total
P10591976A0317|37 40|Ward
P10591976A0317|17 23|LWS p.a.
P10591976A0317|43 50|triangle
P10591990A0178|1 5|group
P10591990A0178|88 91|BPRS
P10591990A0178|37 47|in-patients
P10591990A0178|10 15|DSM-IV
P10591990A0178|65 69|times
P10591990A0178|78 81|SAPS
P10591990A0178|95 97|PAS
P10591990A0178|83 86|SANS
P10592791A0370|342 348|ability
P10592791A0370|382 391|SET-EIA kit
P10592791A0370|78 85|SET-RPLA
P10592791A0370|316 329|test procedures
P10592791A0370|89 102|RIDASCREEN kits
P10592791A0370|368 379|practicality
P10592791A0370|238 247|background
P10592791A0370|16 23|TECRA kit
P10592791A0370|132 144|investigation
P10592791A0370|220 230|SET-RPLA kit
P10592791A0370|66 72|strains
P10592791A0370|161 164|lack
P10592791A0370|209 215|testing
P10592791A0370|421 436|research purposes
P10592791A0370|394 402|screening
P10592791A0370|194 197|time
P10592791A0370|336 339|lack
P10592791A0370|167 173|ability
P10592791A0370|147 153|SE types
P10592791A0370|55 56|SE
P10592791A0370|2 11|conclusion
P10592791A0370|257 269|RIDASCREEN kit
P10592791T0001|0 9|Comparison
P10592791T0001|12 26|immunoassay kits
P10592791T0001|55 66|enterotoxins
P10592791T0001|30 38|detection
P10592824A1157|145 145|%
P10592824A1157|130 130|%
P10592824A1157|244 253|Chi-square
P10592824A1157|107 113|vaccine
P10592824A1157|179 186|children
P10592824A1157|206 209|dose
P10592824A1157|156 156|%
P10592824A1157|168 168|%
P10592824A1157|64 74|JEV antibody
P10592824A1157|14 22|frequency
P10592824A1157|101 104|dose
P10592824A1157|212 221|JE vaccines
P10592824A1157|57 61|rates
P10592824A1157|236 236|P
P10592824A1157|32 40|infection
P10592824A1157|257 265|trend test
P10593939A0747|144 150|members
P10593939A0747|160 164|SRZ22
P10593939A0747|152 156|SRZ21
P10593939A0747|115 125|SR45 protein
P10593939A0747|78 88|SR33 protein
P10593939A0747|173 178|family
P10593939A0747|208 218|Arabidopsis
P10593939A0747|230 234|U-70K
P10593939A0747|43 64|interaction experiments
P10593950A1113|2 8|summary
P10593950A1113|92 102|protein p116
P10593950A1113|34 47|chromatography
P10593950A1113|10 12|WT1
P10593950A1113|64 65|U5
P10593950A1113|106 112|hnRNP A1
P10593950A1113|31 32|dT
P10593950A1113|54 59|U2AF65
P10594130A0652|59 65|degrees
P10594130A0652|11 16|hearts
P10594130A0652|76 83|staining
P10594130A0652|39 45|infants
P10594239A0614|154 160|alleles
P10594239A0614|16 23|mouse Chr
P10594239A0614|33 39|Chr 1q31
P10594239A0614|75 82|evidence
P10594239A0614|102 109|contrast
P10594239A0614|116 119|Tih1
P10594239A0614|52 58|regions
P10594239A0614|112 114|Ipl
P10594239A0614|0 7|Tih1 maps
P10594239T0000|61 66|TDAG51
P10594239T0000|113 120|location
P10594239T0000|91 100|expression
P10594239T0000|51 59|Ipl/Tssc3
P10594239T0000|6 15|pleckstrin
P10594239T0000|71 74|Tih1
P10594239T0000|32 41|gene family
P10594903A0000|29 41|nanoparticles
P10594903A0000|166 175|laboratory
P10594903A0000|96 105|substances
P10594903A0000|139 140|VX
P10594903A0000|115 129|warfare agents GA
P10594903A0000|3 11|potential
P10594903A0000|134 135|HD
P10594903A0000|43 45|RNP
P10594903A0000|131 132|GB
P10595315A0344|76 85|blood gases
P10595315A0344|66 71|status
P10595315A0344|24 30|effects
P10595315A0344|46 55|parameters
P10596955A1032|114 119|Immuno
P10596955A1032|101 108|microg/l
P10596955A1032|36 43|troponin
P10596955A1032|18 32|failure patients
P10596955A1032|66 76|Axsym method
P10596955A1032|53 60|microg/l
P10596955A1032|84 89|levels
P10597222A1371|54 66|HMBA signaling
P10597222A1371|89 91|p21
P10597222A1371|23 25|p27
P10597222A1371|44 51|molecule
P10597223A0339|191 210|transcription factors
P10597223A0339|114 115|bp
P10597223A0339|129 155|transcription initiation site
P10597223A0339|56 65|activation
P10597223A0339|68 70|p21
P10597223A0339|20 33|Ras-expression
P10597223A0339|97 107|p21 promoter
P10597223A0339|166 177|binding sites
P10597223A0339|89 94|region
P10597232A0000|3 23|RET/PTC3 rearrangement
P10597232A0000|34 39|fusion
P10597232A0000|52 59|RET genes
P10597232A0000|123 139|thyroid carcinomas
P10597232A0000|45 48|ELE1
P10597317A1156|0 8|Apoptosis
P10597317A1156|73 80|addition
P10597317A1156|204 207|LMP1
P10597317A1156|126 131|masses
P10597317A1156|16 20|cells
P10597317A1156|41 55|co-transfection
P10597317A1156|215 221|RS cells
P10597317A1156|94 104|HD-MyZ cells
P10597317A1156|179 181|JNK
P10597317A1156|193 201|apoptosis
P10597317A1156|167 176|inhibition
P10597317A1156|64 67|LMP1
P10597317A1156|58 60|JBD
P10598101A0000|98 100|box
P10598101A0000|51 64|maize endosperm
P10598101A0000|2 9|addition
P10598101A0000|105 124|kDa zein gene promoters
P10598101A0000|72 79|proteins
P10598101A0000|15 32|bZIP protein Opaque2
P10598101A0754|74 81|pentamer
P10598101A0754|95 104|yeast cells
P10598101A0754|179 193|expression assay
P10598101A0754|207 225|maize endosperm cells
P10598101A0754|152 166|kDa zein promoter
P10598101A0754|89 92|site
P10598101A0754|3 16|mEmBP-1 protein
P10598101A0754|134 146|transcription
P10598101A0754|55 62|promoter
P10598101A0754|28 40|transcription
P10598316A1534|0 2|GHB
P10598316A1534|8 10|HMB
P10598316A1534|32 41|substances
P10598316A1534|5 6|CB
P10599013A0505|11 16|deaths
P10599727A1567|13 36|estrogen treatment regimen
P10599727A1567|51 52|TS
P10599727A1567|106 110|peers
P10599727A1567|8 9|GH
P10599727A1567|80 89|conformity
P10599727A1567|42 46|girls
P10600171A1066|70 76|binding
P10600171A1066|50 55|result
P10600171A1066|39 44|CYP3A2
P10600171A1066|23 36|responsiveness
P10600171A1066|79 85|COUP-TF
P10600171A1066|91 107|CYP3A2 DexRE-1 site
P10600171A1432|18 25|activity
P10600171A1432|51 59|3A23SiteA
P10600171A1432|6 12|CYP3A23
P10600171A1432|77 80|USF1
P10600171A1432|93 129|bHLH/leucine zipper transcription factor
P10600171A1432|44 48|E-box
P10601280A0674|28 34|element
P10601280A0674|100 109|activation
P10601280A0674|59 77|ST3 promoter activity
P10601290A0742|101 111|differences
P10601290A0742|137 139|I1Y
P10601290A0742|192 196|class
P10601290A0742|76 82|peptide
P10601290A0742|162 183|x-ray crystal structures
P10601290A0742|114 129|T cell recognition
P10601290A0742|15 19|basis
P10601290A0742|35 54|cell surface stability
P10601290A0742|198 217|MHC-peptide complexes
P10601290A0742|143 145|I1F
P10601335A0892|0 13|Redistribution
P10601335A0892|63 71|degrees C.
P10601335A0892|45 49|cells
P10601335A0892|16 26|mannosidase
P10601344A1653|85 90|beta1A
P10601344A1653|27 40|activity assays
P10601344A1653|52 58|GTPases
P10601344A1653|153 156|RhoA
P10601344A1653|92 97|beta1D
P10601344A1653|114 117|GE11
P10601344A1653|101 111|IL2R-beta1A
P10601344A1653|73 82|expression
P10601344A1653|160 163|Rac1
P10601344A1653|120 128|GD25 cells
P10601344A1653|137 146|activation
P10601344A1653|2 9|addition
P10601344A1653|173 177|Cdc42
P10601410A0977|113 126|conduction time
P10601410A0977|33 36|role
P10601410A0977|49 61|remyelination
P10601410A0977|2 11|conclusion
P10601410A0977|78 93|sclerosis lesions
P10601410A0977|16 19|data
P10601410A0977|40 43|IVIg
P10601606A0152|3 21|rhabdomyosarcoma R1H
P10601606A0152|50 60|WAG/Rij rats
P10601606A0152|83 90|degrees C
P10601606A0152|95 103|degrees C.
P10601606A0152|39 43|flank
P10601606A0152|78 78|h
P10601747A0482|75 83|anomalies
P10601747A0482|98 107|N400 effect
P10601747A0482|141 149|word onset
P10601747A0482|18 29|control words
P10601747A0482|132 135|msec
P10602419A1253|16 22|effects
P10602502A0422|58 62|G0/G1
P10602502A0422|7 16|Tob protein
P10602502A0422|65 71|S phases
P10602502A0422|18 21|Tob2
P10602502A0422|31 50|cell cycle progression
P10602507A0652|96 108|cyclin D1/cdk4
P10602507A0652|23 30|cyclin D1
P10602507A0652|34 36|p21
P10602507A0652|110 112|p53
P10602507A0652|86 93|activity
P10602507A0652|13 20|increase
P10602507A0652|132 145|CSF-1 induction
P10602507A0652|148 150|p21
P10602507A0652|43 48|effect
P10602507A0652|183 195|p53 expression
P10602516A0182|75 79|M-NAP
P10602516A0182|104 111|function
P10602516A0182|11 13|SLK
P10602516A0182|26 33|homology
P10602516A0182|36 46|microtubule
P10602516A0182|67 73|protein
P10602516A0182|84 89|AT1-46
P10602516A0182|2 9|addition
P10602838A0127|13 20|patients
P10602838A0127|24 30|females
P10602838A0127|35 39|males
P10602838A0127|6 10|study
P10603349A1667|58 67|activation
P10603349A1667|145 164|Myf5 expression domain
P10603349A1667|70 73|Myf5
P10603349A1667|34 41|hedgehog
P10603349A1667|104 109|somite
P10603349A1667|84 98|progenitor cells
P10603349A1667|170 182|mesencephalon
P10603349A1667|3 25|signalling molecules Wnt1
P10603349A1667|131 139|viscinity
P10604246A0523|0 10|STUDY DESIGN
P10604246A0523|209 216|patients
P10604246A0523|178 179|V4
P10604246A0523|106 106|V
P10604246A0523|148 150|MNC
P10604246A0523|52 61|collection
P10604246A0523|227 232|donors
P10604246A0523|23 27|study
P10604246A0523|89 96|AutoPBSC
P10604246A0523|191 203|cell tubing set
P10604246A0523|163 166|cell
P10604246A0523|14 20|METHODS
P10604246A0523|98 104|version
P10604246A0523|79 84|device
P10604246A0523|64 68|PBPCs
P10604246A0523|168 176|procedure
P10604246A0523|115 131|AutoPBSC tubing set
P10604583T0000|43 49|patient
P10604583T0000|25 31|removal
P10604583T0000|141 151|elimination
P10604583T0000|63 75|Wilson disease
P10604583T0000|167 172|toxins
P10604583T0000|34 39|copper
P10604583T0000|124 134|possibility
P10604583T0000|99 118|liver transplantation
P10604583T0000|0 14|Albumin dialysis
P10604945A0731|176 181|factor
P10604945A0731|80 86|ethanol
P10604945A0731|50 57|Sp1 sites
P10604945A0731|91 96|others
P10604945A0731|122 133|organization
P10604945A0731|197 211|ethanol response
P10604945A0731|14 31|promoter constructs
P10604945A0731|147 160|promoter region
P10606245A0906|0 13|Overexpression
P10606245A0906|34 50|osteosarcoma cells
P10606245A0906|126 132|OC box I.
P10606245A0906|25 27|ROS
P10606245A0906|16 22|CDP/cut
P10606245A0906|95 104|repression
P10606245A0906|60 69|repression
P10606245A0906|72 89|OC promoter activity
P10606272A1241|0 8|Injection
P10606272A1241|26 28|RNA
P10606272A1241|78 84|SF1 gene
P10606272A1241|33 41|C. elegans
P10606272A1241|105 109|yeast
P10606272A1241|129 136|metazoan
P10606272A1241|60 68|lethality
P10606515A0389|131 136|strand
P10606515A0389|62 80|acid receptor element
P10606515A0389|92 96|DNase
P10606515A0389|34 43|DNA binding
P10606515A0389|4 10|domains
P10606515A0389|98 106|footprint
P10606664A0000|0 18|Snail family proteins
P10606664A0000|108 128|cell fate determination
P10606664A0000|22 31|zinc finger
P10606664A0000|47 56|regulators
P10606664A0000|101 105|roles
P10607566A0880|74 76|RAR
P10607566A0880|160 162|TCF
P10607566A0880|166 184|beta-catenin binding
P10607566A0880|137 139|RXR
P10607566A0880|63 72|RA receptor
P10607566A0880|26 37|beta-catenin
P10607566A0880|18 24|finding
P10607566A0880|99 104|manner
P10607566A0880|119 135|retinoid X receptor
P10607566A0880|145 147|RAR
P10607899A0605|114 140|estrogen receptor binding site
P10607899A0605|92 95|CREB
P10607899A0605|88 90|Sp1
P10607899A0605|63 84|consensus binding motifs
P10607899A0605|0 15|Sequence analysis
P10607899A0605|21 34|promoter region
P10607899A0605|43 49|TATA box
P10607899A0605|100 108|half sites
P10607900T0000|0 21|Sak kinase gene structure
P10607900T0000|40 49|regulation
P10608053A0923|0 11|Thrombolysis
P10608053A0923|174 176|p NS
P10608053A0923|123 127|Group
P10608053A0923|101 106|groups
P10608053A0923|91 94|hour
P10608053A0923|43 58|platelet activity
P10608053A0923|149 149|p
P10608053A0923|154 170|001versus baseline
P10608053A0923|70 75|values
P10608053A0923|116 120|IU/ml
P10608053A0923|187 192|groups
P10608053A0923|33 40|increase
P10608053A0923|142 146|Group
P10608893A0727|32 34|DNA
P10608893A0727|62 72|specificity
P10608893A0727|9 13|Hp140
P10608893A0727|106 108|DNA
P10608893A0727|47 54|strength
P10608893A0727|23 26|Hp55
P10610716A1127|16 32|missense mutations
P10610716A1127|40 44|R254G
P10610716A1127|49 53|P362R
P10610716A1127|89 98|FD patients
P10610716A1127|79 84|AC gene
P10610716A1127|34 38|E138V
P10611225A1127|83 93|translation
P10611225A1127|105 115|interaction
P10611225A1127|24 34|interaction
P10611225A1127|162 165|role
P10611225A1127|140 145|region
P10611225A1127|37 41|eIF4A
P10611225A1127|5 8|data
P10611225A1127|63 68|eIF4GI
P10611225A1127|55 60|region
P10611225A1127|118 122|eIF4A
P10611228A1388|41 48|DAP5/p97
P10611228A1388|66 71|assays
P10611228A1388|20 23|form
P10611228A1388|3 10|DAP5/p86
P10611235A1927|118 134|Ste5p-MAPK cascade
P10611235A1927|33 37|model
P10611235A1927|23 26|step
P10611235A1927|77 77|G
P10611235A1927|140 153|plasma membrane
P10611235A1927|79 87|betagamma
P10611235A1927|43 52|activation
P10611235A1927|58 66|MAPK Fus3p
P10611235A1927|99 112|relocalization
P10611242A0541|87 90|SAGA
P10611242A0541|104 107|Spt8
P10611242A0541|62 73|HIS3 promoter
P10611242A0541|47 56|TBP binding
P10611242A0541|35 38|SAGA
P10611242A0541|18 24|finding
P10611242A0541|98 101|Spt3
P10611320A0816|73 76|CAK1
P10611320A0816|105 116|Cak1p protein
P10611320A0816|65 71|CAK gene
P10611320A0816|128 131|Cdk7
P10611353A0458|0 11|Northern blot
P10611353A0458|110 115|retina
P10611353A0458|80 82|RNR
P10611353A0458|195 214|Northern blot analysis
P10611353A0458|22 46|transcription-PCR analyses
P10611353A0458|54 64|mRNA samples
P10611353A0458|150 151|kb
P10611353A0458|169 170|kb
P10611353A0458|121 131|transcripts
P10611353A0458|191 192|kb
P10612044A1180|42 56|AP-4 binding site
P10612044A1180|26 37|conservation
P10612044A1180|66 76|nucleotides
P10612044A1180|90 116|transcription initiation site
P10612044A1180|123 131|Aal-rpL34
P10612044A1180|135 147|Aal-rpL8 genes
P10612505A1317|135 135|%
P10612505A1317|28 32|study
P10612505A1317|130 130|%
P10612505A1317|73 88|group differences
P10612505A1317|8 11|type
P10612505A1317|91 105|treatment effect
P10612505A1317|64 64|%
P10612505A1317|13 17|error
P10612505A1317|37 41|power
P10612773A1210|0 10|CONCLUSIONS
P10612773A1210|12 22|Serum levels
P10612773A1210|92 98|surgery
P10612773A1210|25 33|S-100beta
P10612773A1210|45 51|markers
P10612773A1210|72 79|outcomes
P10612805A0716|17 26|alteration
P10612805A0716|48 54|cancers
P10612918A0318|3 10|problems
P10612918A0318|44 49|screws
P10613816X0000|0 6|Statins
P10613816X0000|179 188|treatments
P10613816X0000|13 18|lipids
P10613816X0000|97 101|study
P10613816X0000|84 88|drugs
P10613816X0000|140 146|effects
P10613816X0000|225 236|osteoporosis
P10613816X0000|207 218|bone diseases
P10613816X0000|28 32|bones
P10613816X0000|149 152|bone
P10613816X0000|42 48|statins
P10613816X0000|119 127|compounds
P10613843A0107|14 21|products
P10613843A0107|76 80|genes
P10613843A0107|106 107|Ca
P10613843A0107|112 122|ion channels
P10613843A0107|31 47|duplication events
P10613863T0000|88 94|repeats
P10613863T0000|115 126|pfoA promoter
P10613863T0000|3 23|VirR response regulator
P10613863T0000|28 49|Clostridium perfringens
P10613874A0663|0 6|Cloning
P10613874A0663|86 87|bp
P10613874A0663|56 63|presence
P10613874A0663|117 124|proteins
P10613874A0663|143 146|GlnR
P10613874A0663|10 19|sequencing
P10613874A0663|133 140|homology
P10613874A0663|33 38|region
P10613874A0663|69 72|ORFs
P10613874A0663|150 161|GlnA proteins
P10613874A0663|41 44|pepX
P10614676A0000|0 8|Objective
P10614676A0000|104 111|tibolone
P10614676A0000|138 148|mg estradiol
P10614676A0000|115 116|mg
P10614676A0000|153 175|mg norethisterone acetate
P10614676A0000|64 71|bleeding
P10614676A0000|191 215|hormone replacement therapy
P10614676A0000|88 92|women
P10614676A0000|46 54|incidence
P10614676A0000|177 182|E+NETA
P10614676A0000|31 39|thickness
P10614857A0584|0 16|Leukocyte cultures
P10614857A0584|123 130|children
P10614857A0584|203 203|P
P10614857A0584|150 159|adenovirus
P10614857A0584|51 58|children
P10614857A0584|62 67|months
P10614857A0584|87 92|yields
P10614857A0584|70 72|age
P10614857A0584|182 182|P
P10614857A0584|95 97|IFN
P10614857A0584|192 201|rhinovirus
P10614857A0584|161 161|P
P10614857A0584|170 180|coronavirus
P10614857A0584|30 34|blood
P10616948A0998|27 30|dose
P10616948A0998|74 94|seizure threshold level
P10616948A0998|5 14|BF ECT group
P10617126A1005|214 218|group
P10617126A1005|41 44|loss
P10617126A1005|12 19|analysis
P10617126A1005|168 170|CA3
P10617126A1005|119 122|rats
P10617126A1005|105 107|CA1
P10617126A1005|62 66|group
P10617126A1005|162 164|CA1
P10617126A1005|100 103|area
P10617126A1005|131 142|dentate gyrus
P10617126A1005|157 160|area
P10617126A1005|185 188|rats
P10617144A0386|99 99|%
P10617144A0386|12 26|phosphorylation
P10617144A0386|76 80|sites
P10617144A0386|37 41|Ser64
P10617144A0386|3 9|extents
P10617144A0386|29 33|Ser44
P10617232A0393|117 124|patients
P10617232A0393|104 112|treatment
P10617232A0393|18 25|serology
P10617232A0393|67 80|liver histology
P10617232A0393|30 41|liver enzymes
P10617232A0393|0 11|Serum HBV-DNA
P10617613A1192|0 3|Chem
P10618645A0750|0 15|Maximum induction
P10618645A0750|35 47|concentration
P10618645A0750|61 64|CalC
P10618645A0750|18 21|AP-1
P10618645A0750|53 58|nmol/L
P10619062T0000|0 23|Haycocknema perplexum n. g.
P10619062T0000|25 28|n. sp
P10619169A0411|42 51|orchimetry
P10619169A0411|18 27|testis size
P10619169A0411|58 67|time period
P10619169A0411|0 3|Rams
P10619254A1055|0 12|Animal studies
P10619254A1055|23 38|beam equalization
P10619254A1055|87 98|image quality
P10619353T0000|103 129|promoter transcription factor
P10619353T0000|131 137|COUP-TF
P10619353T0000|64 74|interaction
P10619353T0000|6 27|estrogen receptor ligand
P10619353T0000|79 94|chicken ovalbumin
P10619353T0000|31 61|estrogen response element sequence
P10619353T0000|0 3|Role
P10620010A1155|103 108|kinase
P10620010A1155|51 73|tyrosine phosphorylation
P10620010A1155|171 180|activation
P10620010A1155|41 49|cell cycle
P10620010A1155|91 100|activation
P10620010A1155|13 16|Cdks
P10620010A1155|151 156|T-loop
P10620010A1155|137 145|threonine
P10620010A1155|120 134|phosphorylation
P10620010A1155|0 9|CONCLUSION
P10620335A0749|32 38|COUP-TF
P10620335A0749|52 60|CV-1 cells
P10620335A0749|16 18|AHR
P10620777A1399|0 7|AB004534
P10622574A0000|15 29|hepatitis C virus
P10622574A0000|35 43|infection
P10622574A0000|107 107|%
P10622574A0000|61 69|childhood
P10622574A0000|120 124|world
P10622574A0000|31 33|HCV
P10622574A0000|3 12|prevalence
P10622574A0000|83 97|prevalence rates
P10622576A0552|116 125|risk groups
P10622576A0552|74 83|prevention
P10622576A0552|52 59|patients
P10622576A0552|67 71|means
P10622576A0552|23 33|information
P10622576A0552|95 103|attention
P10622576A0552|134 144|drug abusers
P10623758A0947|116 120|cells
P10623758A0947|35 41|ganglia
P10623758A0947|149 154|months
P10623758A0947|23 23|%
P10623758A0947|74 91|beta-galactosidase
P10623758A0947|26 32|neurons
P10623758A0947|6 12|latency
P10623758A0947|58 64|footpad
P10623758A0947|100 105|number
P10623804A0808|130 150|Fc gamma RIIB1 signaling
P10623804A0808|54 60|effects
P10623804A0808|115 127|decoy proteins
P10623804A0808|88 92|SHP-1
P10623804A0808|83 86|SHIP
P10623804A0808|96 100|SHP-2
P10623804A0808|15 22|approach
P10623804A0808|29 36|question
P10624787A0432|139 142|case
P10624787A0432|45 52|patients
P10624787A0432|145 148|Type
P10624787A0432|121 121|P
P10624787A0432|113 113|P
P10624787A0432|178 178|P
P10624787A0432|98 111|blood pressures
P10624787A0432|150 151|DM
P10624787A0432|205 205|P
P10624787A0432|164 176|body mass index
P10624787A0432|63 63|P
P10624787A0432|30 38|functions
P10624787A0432|190 203|waist-hip ratio
P10625438A1429|199 212|control samples
P10625438A1429|5 11|tissues
P10625438A1429|146 155|transcript
P10625438A1429|103 112|conditions
P10625438A1429|123 128|% level
P10625438A1429|24 34|transcripts
P10625438A1429|46 51|insert
P10625438A1429|131 136|insert
P10625438A1429|71 76|repeat
P10625438A1429|58 68|bp insertion
P10625494A1059|5 11|results
P10625494A1059|23 33|CAAT-region
P10625494A1059|61 72|MDR1 promoter
P10625494A1059|75 87|HL60/VCR cells
P10625683A0091|87 95|molecules
P10625683A0091|139 147|receptors
P10625683A0091|125 132|function
P10625683A0091|54 68|phosphorylation
P10625683A0091|98 104|process
P10625683A0091|20 41|protein tyrosine kinases
P10625683A0091|4 12|receptors
P10625683A0091|43 46|PTKs
P10625721T0101|30 33|HACA
P10625721T0101|23 28|Arrest
P10625721T0101|35 44|Study Group
P10625721T0101|0 10|Hypothermia
P10627518A0544|84 96|contributions
P10627518A0544|76 78|sum
P10627518A0544|112 115|UTRs
P10627518A0544|33 43|cooperation
P10627518A0544|14 19|effect
P10627532A0739|88 90|p38
P10627532A0739|25 25|Z
P10627532A0739|21 21|R
P10627532A0739|94 96|JNK
P10627532A0739|80 86|kinases
P10627532A0739|76 78|MAP
P10627532A0739|128 137|activation
P10627532A0739|152 174|transcription factor ATF2
P10627532A0739|109 123|phosphorylation
P10627532A0739|68 74|protein
P10627532A0739|45 50|stress
P10627834A0178|87 90|G120
P10627834A0178|99 118|New Zealand selections
P10627834A0178|124 129|Dublin
P10627834A0178|155 161|Stanley
P10627834A0178|25 30|Tehama
P10627834A0178|138 143|Meyric
P10627834A0178|63 71|cultivars
P10627834A0178|73 81|Esterhazy
P10627834A0178|132 136|Glory
P10627834A0178|15 23|cultivars
P10627834A0178|3 4|US
P10627834A0178|34 37|Vina
P10627834A0178|145 153|McKinster
P10627834A0178|120 122|Rex
P10628490T0000|0 6|Anatomy
P10628490T0000|19 24|artery
P10628748A0344|57 78|inhibin alpha expression
P10628748A0344|8 17|activation
P10628748A0344|23 33|cAMP pathway
P10628748A0344|107 110|SF-1
P10628748A0344|98 104|actions
P10628748A0746|0 7|Deletion
P10628748A0746|111 130|cAMP-response element
P10628748A0746|64 70|element
P10628748A0746|50 53|SF-1
P10628748A0746|24 34|mutagenesis
P10628748A0746|72 80|TCA GGGCCA
P10628748A0746|132 134|CRE
P10628750A0298|88 95|enhancer
P10628750A0298|33 40|cytokine
P10628750A0298|159 161|Rel
P10628750A0298|128 140|factor-kappaB
P10628750A0298|26 29|APRE
P10628750A0298|163 173|x NF-kappaB1
P10628750A0298|142 150|NF-kappaB
P10628750A0298|68 75|TNFalpha
P10628750A0298|42 66|tumor necrosis factor-alpha
P10628750T0000|0 10|Angiotensin
P10628750T0000|62 106|angiotensinogen gene acute-phase response element
P10628750T0000|27 32|factor
P10628750T0000|126 132|pathway
P10628750T0000|38 52|kappaB1 isoforms
P10628750T0000|34 35|NF
P10628750T0000|136 154|NF-kappaB activation
P10628755A0000|72 82|GH secretion
P10628755A0000|9 15|ligands
P10628755A0000|103 131|orphan GH-secretagogue receptor
P10628755A0000|56 60|cycle
P10628755A0000|133 137|GHS-R
P10628971A0824|42 48|defects
P10628971A0824|127 129|VPS
P10628971A0824|68 76|mutations
P10628971A0824|107 125|protein sorting genes
P10628971A0824|144 166|dynamin family member VPS1
P10628971A0824|57 63|members
P10628971A0824|32 34|TGN
P10628971A0824|3 12|collection
P10628971A0824|15 21|mutants
P10628971A1165|86 89|RIC1
P10628971A1165|40 46|defects
P10628971A1165|211 233|microtubule organization
P10628971A1165|19 25|mutants
P10628971A1165|76 84|following
P10628971A1165|50 57|isolates
P10628971A1165|100 106|product
P10628971A1165|270 303|inositol polyphosphate 5-phosphatase
P10628971A1165|9 16|spectrum
P10628971A1165|140 157|ribosome biogenesis
P10628971A1165|62 70|mutations
P10628971A1165|159 162|LUV1
P10628971A1165|238 242|INP53
P10628971A1165|30 32|TGN
P10628971A1165|201 207|vacuole
P10628971A1165|173 179|product
P10629035A0827|130 146|cdc17/pol1 mutants
P10629035A0827|105 114|telomerase
P10629035A0827|9 20|strandedness
P10629035A0827|154 160|defects
P10629035A0827|44 52|extension
P10629035A0827|64 69|strand
P10629035A0827|186 194|synthesis
P10629035A0827|71 76|G tails
P10629176A0887|2 9|addition
P10629176A0887|74 81|FBP1 gene
P10629176A0887|11 16|CaMig1
P10629176A0887|31 39|complexes
P10629176A0887|47 56|URS1 region
P10629938A1352|143 153|development
P10629938A1352|106 109|tool
P10629938A1352|80 88|apparatus
P10629938A1352|128 136|cell cycle
P10629938A1352|19 30|distribution
P10629938A1352|36 50|GFP-POLO protein
P10629938A1352|56 67|compartments
P10629938A1352|119 125|studies
P10630471T0000|2 10|ASIC-chip
P10630471T0000|26 38|depth analysis
P10630471T0000|77 88|cell behavior
P10630630A0614|29 37|inhibitor
P10630630A0614|40 42|PKC
P10630630A0614|77 89|CFI mRNA levels
P10630630A0614|67 74|increase
P10630630A0614|8 18|calphostin C
P10633075A1111|45 52|polymers
P10633075A1111|9 11|IgG
P10633075A1111|65 83|N-acetylglucosamine
P10633075A1111|22 33|Fab fragments
P10633075A1111|89 94|effect
P10633499A1306|0 22|Arhythmacanthus Yamaguti
P10633499A1306|103 111|hook types
P10633499A1306|134 143|transition
P10633499A1306|172 176|hooks
P10633499A1306|74 84|distinction
P10633499A1306|43 49|synonym
P10634007A0202|73 74|HD
P10634007A0202|11 14|case
P10634007A0202|112 124|drug clearance
P10634007A0202|79 81|NAC
P10634007A0202|60 71|hemodialysis
P10634007A0202|17 37|acetaminophen overdose
P10634007A0202|93 104|intoxication
P10635209A0419|29 32|coat
P10635209A0419|35 42|adhesive
P10635209A0419|9 20|conditioning
P10637149A0806|85 87|REF
P10637149A0806|33 34|RD
P10637149A0806|36 37|CC
P10637149A0806|39 39|E
P10637149A0806|15 28|G-A anastomosis
P10637149A0806|46 54|loop areas
P10637149A0806|118 120|A-A
P10637149A0806|41 41|p
P10637230A0332|74 78|cells
P10637230A0332|91 94|IFNs
P10637230A0332|49 61|proliferation
P10637230A0332|7 16|expression
P10637230A0332|19 23|c-myc
P10637230A0332|81 88|response
P10637238A0291|0 40|Eastern Cooperative Oncology Group trial E3186
P10637238A0291|66 73|question
P10637337A0545|15 23|DNA repair
P10637337A0545|36 39|TFA1
P10637337A0545|51 59|mutations
P10638607A0000|176 189|adenocarcinoma
P10638607A0000|66 70|phase
P10638607A0000|72 77|trials
P10638607A0000|5 12|articles
P10638607A0000|95 102|patients
P10638607A0000|128 137|esophageal
P10638607A0000|26 32|results
P10638607A0000|121 126|N0-1 M0
P10638607A0000|84 92|treatment
P10638607A0000|146 158|cell carcinoma
P10638607A0000|160 162|SCC
P10639585A0157|0 6|Studies
P10639585A0157|9 25|MPO gene regulation
P10639585A0157|47 55|mechanism
P10639585A0157|82 96|differentiation
P10640683A0204|44 49|lysate
P10640683A0204|104 115|NDRF/NeuroD2
P10640683A0204|52 61|COS-7 cells
P10640683A0204|34 36|PKN
P10640683A0204|81 100|expression constructs
P10640683A0204|119 121|PKN
P10640683A0204|0 11|NDRF/NeuroD2
P10640683A0670|88 102|transactivation
P10640683A0670|180 192|co-expression
P10640683A0670|315 327|transcription
P10640683A0670|52 61|expression
P10640683A0670|284 291|increase
P10640683A0670|246 255|derivative
P10640683A0670|220 222|PKN
P10640683A0670|135 139|RIPE3
P10640683A0670|214 217|form
P10640683A0670|108 132|rat insulin promoter element
P10640683A0670|9 26|transfection assays
P10640683A0670|64 75|NDRF/NeuroD2
P10640683A0670|141 148|enhancer
P10640683A0670|32 39|P19 cells
P10640701T0000|19 23|sites
P10640701T0000|26 35|Engrailed2
P10640701T0000|91 100|expression
P10640701T0000|56 65|initiation
P10640734A0190|59 61|SH2
P10640734A0190|111 131|tyrosine phosphatase-1
P10640734A0190|79 90|phosphatases
P10640734A0190|153 164|cell activity
P10640734A0190|32 36|ITIMs
P10640734A0190|4 26|tyrosine phosphorylation
P10640734A0190|43 51|molecules
P10641037A1371|0 7|AF154055
P10641688A0341|0 8|Alignment
P10641688A0341|54 64|disc changes
P10641688A0341|22 26|spine
P10641688A0341|37 49|abnormalities
P10642524A0156|14 24|interaction
P10642524A0156|36 40|hsp70
P10642524A0156|123 128|motifs
P10642524A0156|136 142|regions
P10642524A0156|27 31|mSTI1
P10642524A0156|54 54|N
P10642524A0156|44 48|hsp90
P10642524A0156|95 117|tetratricopeptide repeat
P10642524A0156|119 121|TPR
P10642531A2322|76 94|RGD recognition sites
P10642531A2322|52 63|relationship
P10642531A2322|0 21|Competition experiments
P10642889A0393|0 15|Sequence analysis
P10642889A0393|40 45|region
P10642889A0393|93 99|TATA box
P10642889A0393|59 66|ATG codon
P10643313A0345|100 102|BSS
P10643313A0345|110 114|ml SF6
P10643313A0345|63 73|conjunctiva
P10643313A0345|77 91|micrograms rt-PA
P10643313A0345|46 57|disinfection
P10643313A0345|5 22|i.v. administration
P10643313A0345|97 98|ml
P10643313A0345|28 42|mg acetazolamide
P10644357A0935|118 120|VP2
P10644357A0935|23 25|VP1
P10644357A0935|5 11|results
P10644357A0935|124 126|VP3
P10644357A0935|56 62|nucleus
P10644357A0935|98 104|regions
P10644414T0000|57 85|mosquito ultraspiracle isoforms
P10644414T0000|12 21|expression
P10644414T0000|25 34|regulation
P10644414T0000|37 54|20-hydroxyecdysone
P10644753A0725|116 133|glycosaminoglycans
P10644753A0725|79 92|heparan sulfate
P10644753A0725|37 58|antibody affinity column
P10644753A0725|8 15|isoforms
P10644753A0725|96 102|heparin
P10644753A0725|70 76|sulfate
P10644760A0000|73 83|interaction
P10644760A0000|35 59|neurotransmitter phenotype
P10644760A0000|95 98|cues
P10644760A0000|21 31|maintenance
P10644760A0000|3 17|differentiation
P10644760A0000|119 127|machinery
P10644760A0956|29 32|Arix
P10644760A0956|20 26|domains
P10644760A0956|52 67|activation domain
P10644760A0956|82 97|repression domain
P10644760A0956|0 7|Analysis
P10645921A0000|0 9|BACKGROUND
P10645921A0000|53 60|disorder
P10645921A0000|26 36|hypertrophy
P10645921A0000|73 84|morphologies
P10645921A1320|105 106|SD
P10645921A1320|176 184|odds ratio
P10645921A1320|47 47|P
P10645921A1320|36 45|remodeling
P10645921A1320|56 64|odds ratio
P10645921A1320|12 21|predictors
P10645921A1320|167 167|P
P10645921A1320|87 102|ejection fraction
P10645921A1320|119 119|P
P10645921A1320|149 165|circumflex disease
P10646820T0000|3 6|case
P10646820T0000|23 37|lymphadenectomy
P10646820T0000|104 112|carcinoma
P10646820T0000|81 92|hysterectomy
P10646820T0000|50 59|lymph nodes
P10646863A0838|0 13|Overexpression
P10646863A0838|63 72|expression
P10646863A0838|41 45|cells
P10646863A0838|85 104|topoisomerase IIalpha
P10646863A0838|16 21|ICBP90
P10647177A0599|57 62|bulges
P10647177A0599|113 117|sites
P10647177A0599|88 91|fold
P10647177A0599|43 46|pair
P10647177A0599|136 139|base
P10647177A0599|146 154|formation
P10647177A0599|3 12|RNA aptamer
P10647633A1685|41 49|sphincter
P10647633A1685|120 125|rectum
P10647633A1685|90 95|stools
P10647633A1685|110 114|colon
P10647633A1685|55 57|RSJ
P10647633A1685|19 26|presence
P10647633A1685|3 7|study
P10647633A1685|81 87|passage
P10647817T0000|0 8|Isolation
P10647817T0000|11 15|cDNAs
P10647817T0000|74 77|PTA1
P10647817T0000|24 29|gibbon
P10647817T0000|50 71|T cell activation antigen
P10647817T0000|33 46|monkey platelet
P10647859A0000|235 240|levels
P10647859A0000|222 223|QB
P10647859A0000|275 279|cmH2O
P10647859A0000|250 257|pressure
P10647859A0000|302 302|P
P10647859A0000|304 306|CO2
P10647859A0000|356 358|gas
P10647859A0000|212 220|breathing
P10647859A0000|329 336|eucapnia
P10647859A0000|158 165|subjects
P10647859A0000|259 263|Pappl
P10647859A0000|171 179|occasions
P10647859A0000|117 125|diaphragm
P10647859A0000|338 340|CO2
P10647859A0000|104 111|activity
P10647859A0000|193 197|rates
P10647859A0000|86 89|IPPV
P10647859A0000|66 84|pressure ventilation
P10647859A0000|33 38|effect
P10647859A0000|291 300|hypocapnia
P10648020A0151|0 6|METHODS
P10648020A0151|50 82|factors tissue plasminogen activator
P10648020A0151|188 194|markers
P10648020A0151|211 218|patients
P10648020A0151|8 26|Von Willebrand factor
P10648020A0151|145 149|PAI-1
P10648020A0151|114 142|plasminogen activator inhibitor
P10648020A0151|162 171|fibrinogen
P10648020A0151|99 109|tPA capacity
P10648020A0151|84 86|tPA
P10648020A0151|241 242|RA
P10648020A0151|152 160|platelets
P10648020A0151|28 30|vWF
P10648211A0000|8 26|signaling properties
P10648211A0000|52 59|quantity
P10648211A0000|63 73|combination
P10648211A0000|76 86|ion channels
P10648489A1117|57 59|sum
P10648489A1117|64 80|segment depression
P10648489A1117|87 92|trough
P10648489A1117|96 113|peak concentrations
P10648489A1117|30 33|dose
P10648489A1117|0 8|Treatment
P10648489A1117|43 51|reduction
P10648619A0000|89 104|promoter activity
P10648619A0000|144 144|C
P10648619A0000|223 238|promoter activity
P10648619A0000|21 32|contribution
P10648619A0000|55 61|protein
P10648619A0000|181 184|lack
P10648619A0000|260 263|tRNA
P10648619A0000|131 142|silkworm tRNA
P10648619A0000|242 245|silk
P10648619A0000|63 65|TBP
P10648619A0000|147 149|Ala
P10648619A0000|273 276|gene
P10648619A0000|194 213|interactions accounts
P10648619A0000|151 154|gene
P10648619A0000|68 83|TATA interactions
P10648619A0000|269 271|Ala
P10648619A0000|265 266|SG
P10649449A0413|158 164|domains
P10649449A0413|41 61|squalene synthase genes
P10649449A0413|27 36|homologies
P10649449A0413|77 82|number
P10649449A0413|65 71|enzymes
P10649449A0413|109 129|amino acid conservation
P10649449A0413|90 98|organisms
P10649449A0413|139 145|binding
P10649449A0413|3 11|sequences
P10649456A1061|85 93|Frankfurt
P10649456A1061|12 18|strains
P10649456A1061|75 83|EUROSCARF
P10649456A1061|63 73|stock centre
P10649456A1061|49 55|EUROFAN
P10649456A1061|3 8|clones
P10649738A0953|72 85|patient-months
P10649738A0953|40 46|patient
P10649738A0953|3 10|episodes
P10649738A0953|61 69|episode/3
P10649738A0953|55 58|CAPD
P10649738A0953|13 23|peritonitis
P10650104X0284|0 8|Copyright
P10650104X0284|30 41|Radiologists
P10650104X0284|16 27|Royal College
P10650938T0000|44 63|estrogen dependencies
P10650938T0000|20 21|ER
P10650938T0000|23 30|isoforms
P10650938T0000|83 93|trout ER gene
P10650938T0000|3 18|estrogen receptor
P10650939A0789|0 8|Induction
P10650939A0789|61 64|AP-1
P10650939A0789|22 33|coexpression
P10650939A0789|36 40|A-Fos
P10650939A1542|101 109|PGDH-2368
P10650939A1542|54 57|PR-B
P10650939A1542|89 98|activation
P10650939A1542|12 14|SMC
P10650939A1542|33 52|progesterone receptor
P10650939A1542|61 64|PR-A
P10650939A1542|20 27|isoforms
P10650939A1542|111 114|luc3
P10650958A1315|144 161|mobility shift assay
P10650958A1315|88 96|complexes
P10650958A1315|34 42|% homology
P10650958A1315|46 66|consensus c-myb element
P10650958A1315|119 123|c-myb
P10650958A1315|0 7|Element B
P10651076T0000|4 13|resolution
P10651076T0000|66 74|arthritis
P10651076T0000|37 41|lungs
P10651076T0000|22 31|tomography
P10651076T0000|44 51|patients
P10651805A1600|60 82|mouse L1210 leukemia cells
P10651805A1600|93 110|folate accumulation
P10651805A1600|197 208|methotrexate
P10651805A1600|144 165|acid growth requirements
P10651805A1600|184 194|sensitivity
P10651805A1600|126 135|leucovorin
P10651805A1600|6 17|transfection
P10651805A1600|45 55|carrier cDNA
P10651805T0000|0 15|Characterization
P10651805T0000|66 72|carrier
P10651805T0000|83 100|folate accumulation
P10651805T0000|111 123|leukemia cells
P10652093A0139|0 7|Electron
P10652093A0139|112 121|collection
P10652093A0139|54 63|A118 genome
P10652093A0139|139 150|DNA molecules
P10652093A0139|31 38|analyses
P10652102A0620|73 88|Ty1 transposition
P10652102A0620|22 27|dosage
P10652102A0620|39 42|Fus3
P10652102A0620|57 66|inhibition
P10652102A0620|100 105|growth
P10652228A0759|58 66|Rho family
P10652228A0759|40 45|kinase
P10652228A0759|105 107|Dbl
P10652228A0759|13 22|activation
P10652228A0759|25 29|c-Jun
P10652228A0759|78 85|proteins
P10652324A0177|11 23|participation
P10652324A0177|26 40|collagen binding
P10652362A0933|14 17|data
P10652362A0933|196 203|vesicles
P10652362A0933|166 170|entry
P10652362A0933|77 97|internalization signal
P10652362A0933|50 53|CFTR
P10652362A0933|127 144|adaptor complex AP-2
P10652362A0933|32 47|carboxyl terminus
P10652362A0933|173 176|CFTR
P10652800A0984|145 157|insulin dosage
P10652800A0984|39 47|evolution
P10652800A0984|179 184|height
P10652800A0984|121 128|duration
P10652800A0984|77 88|relationship
P10652800A0984|169 175|control
P10652800A0984|106 108|age
P10652800A0984|111 119|diagnosis
P10652800A0984|53 60|patients
P10652800A0984|3 23|insulin therapy regimen
P10652800A0984|131 138|diabetes
P10652800A0984|187 189|BMI
P10653359A1297|0 8|Scmh1 maps
P10653359A1297|11 18|4D1-D2.1
P10653359A1297|21 24|mice
P10653400A0000|30 45|donor nephrectomy
P10653400A0000|79 83|donor
P10653400A0000|47 49|LDN
P10653400A0000|3 15|applicability
P10653550A1120|0 18|Hyaluronan treatment
P10653550A1120|119 124|region
P10653550A1120|93 100|meniscus
P10653550A1120|29 46|collagen remodeling
P10653550A1120|62 67|region
P10653693A0429|101 110|components
P10653693A0429|62 65|KRAB
P10653693A0429|20 25|issues
P10653693A0429|67 87|KAP-1-RBCC interaction
P10653693A0903|14 18|B2 box
P10653693A0903|54 68|oligomerization
P10653693A0903|148 156|functions
P10653693A0903|34 39|region
P10653693A0903|114 120|domains
P10653693A0903|3 12|RING finger
P10653693A0903|84 94|KRAB binding
P10653693A0903|98 106|mutations
P10653693A0903|71 80|KAP-1-RBCC
P10653697A0133|0 5|Actins
P10653697A0133|39 48|processing
P10653697A0133|22 26|forms
P10653697A0133|75 82|sequence
P10653733A0596|7 13|domains
P10653733A0596|49 56|peptides
P10654032A1133|0 3|JPEG
P10654032A1133|19 34|compression ratio
P10654032A1133|72 82|performance
P10655164A0546|136 136|H
P10655164A0546|130 134|solm0
P10655164A0546|148 148|p
P10655164A0546|105 110|limits
P10655164A0546|164 169|x10-10
P10655164A0546|117 121|parl0
P10655164A0546|142 146|parr0
P10655164A0546|35 47|uncertainties
P10655164A0546|73 83|Li abundance
P10655164A0546|123 124|Li
P10655230A0685|29 45|mouse GCN2 isoforms
P10655230A0685|105 110|domain
P10655230A0685|90 95|kinase
P10655230A0685|9 24|yeast counterpart
P10655230A0685|66 74|sequences
P10656154A0722|14 14|%
P10656154A0722|19 26|criteria
P10656154A0722|30 32|PMS
P10656154A0722|4 8|women
P10656161A0316|0 2|MBI
P10656161A0316|108 116|AUC values
P10656161A0316|23 32|Cmax values
P10656161A0316|6 9|MMBI
P10656161A0316|68 72|serum
P10656802A1724|95 98|site
P10656802A1724|25 51|cathepsin X amino acid sequence
P10656802A1724|11 19|insertion
P10657238A0541|129 137|construct
P10657238A0541|106 120|mouse NMuMG cells
P10657238A0541|91 103|transcription
P10657238A0541|76 84|mStaf gene
P10657238A0541|149 156|fragment
P10657238A0541|53 58|region
P10657238A0541|201 208|activity
P10657238A0541|0 22|Transfection experiments
P10657658A0165|189 194|manner
P10657658A0165|93 103|degradation
P10657658A0165|7 13|studies
P10657658A0165|170 177|NF-kappa
P10657658A0165|105 109|kappa
P10657658A0165|63 89|I kappa B alpha phosphorylation
P10657658A0165|118 139|reporter gene expression
P10657658A0165|41 51|HA fragments
P10657658A0165|144 165|ICAM-1 promoter activity
P10657658A0165|16 24|T-24 cells
P10657899A0685|43 58|oligonucleotides
P10657899A0685|98 101|AP-1
P10657899A0685|147 150|mice
P10657899A0685|21 29|mouse skin
P10657899A0685|104 111|JB6 cells
P10657899A0685|61 67|PKCzeta
P10657899A0685|86 95|activation
P10657899A0685|14 18|cells
P10657899A0685|0 11|Pretreatment
P10658425A1567|3 7|level
P10658425A1567|53 56|dogs
P10658425A1567|35 35|%
P10658425A1567|21 29|infection
P10658445A0208|0 6|METHODS
P10658445A0208|122 125|year
P10658445A0208|182 195|prostaglandins
P10658445A0208|104 118|treatment cycles
P10658445A0208|154 167|reference group
P10658445A0208|134 139|latter
P10658445A0208|17 21|group
P10658445A0208|30 37|patients
P10658445A0208|70 92|PGE1 alpha-ciclodestrina
P10658588A0304|0 26|Desmethylferrochloroquine 1a
P10658588A0304|127 129|HB3
P10658588A0304|82 95|schizontocides
P10658588A0304|139 158|Plasmodium falciparum
P10658588A0304|30 56|didesmethylferrochloroquine
P10658588A0304|100 101|CQ
P10658588A0304|119 125|strains
P10658588A0304|133 135|Dd2
P10660069A0819|99 106|RRD genes
P10660069A0819|61 64|PBS2
P10660069A0819|113 142|Hog1p signal transduction pathway
P10660069A0819|3 19|rrd1,2delta mutant
P10660069A0819|78 88|interaction
P10660069A0819|55 58|HOG1
P10660069A0819|41 52|inactivation
P10660304A0522|217 223|context
P10660304A0522|195 202|stimulus
P10660304A0522|12 24|JAK/Tyk family
P10660304A0522|73 78|Tyr705
P10660304A0522|27 41|tyrosine kinases
P10660304A0522|110 115|kinase
P10660304A0522|66 70|STAT3
P10660304A0522|49 63|phosphorylation
P10660304A0522|0 6|Members
P10660304A0522|85 97|CNTF signaling
P10660304A0522|130 144|phosphorylation
P10660304A0522|147 157|STAT3 Tyr727
P10660604A0748|32 44|transcription
P10660604A0748|7 22|CARbeta/RXRalpha
P10660604A0748|51 84|HD-PPRE luciferase reporter construct
P10660676A0000|0 15|Zebrafish cyclops
P10660676A0000|41 56|Growth Factor beta
P10660676A0000|58 64|TGFbeta
P10660676A0000|66 80|signaling factor
P10660676A0000|97 106|mouse Nodal
P10660676A0000|17 19|cyc
P10662550A0679|16 28|candidate gene
P10662550A0679|52 71|retardation phenotype
P10662550A0679|78 91|ATR-16 patients
P10662550A0679|5 8|SOX8
P10662614A0000|131 137|genomes
P10662614A0000|105 115|Potyviridae
P10662614A0000|93 99|members
P10662614A0000|65 68|WSMV
P10662614A0000|3 20|genome organization
P10662614A0000|161 184|amino acid dissimilarities
P10662614A0000|42 63|wheat streak mosaic virus
P10662614A0000|203 214|polyproteins
P10662614A0972|60 65|HC-Pro
P10662614A0972|67 68|P1
P10662614A0972|76 77|CP
P10662614A0972|13 17|assay
P10662614A0972|57 58|CI
P10662614A0972|50 54|genes
P10662614A0972|70 71|P3
P10662614A0972|96 107|interactions
P10663558T0000|119 123|chain
P10663558T0000|81 84|mice
P10663558T0000|40 65|basement membrane reactivity
P10663558T0000|112 113|Ig
P10663558T0000|17 27|light chains
P10664876A0000|0 8|Patch test
P10664876A0000|195 200|group A
P10664876A0000|229 238|acetonides
P10664876A0000|50 57|patients
P10664876A0000|290 295|esters
P10664876A0000|129 151|corticosteroid molecules
P10664876A0000|158 163|groups
P10664876A0000|113 126|classification
P10664876A0000|248 268|betamethasone type-non
P10664876A0000|222 227|group B
P10664876A0000|283 288|group D
P10664876A0000|74 93|corticosteroid series
P10664876A0000|202 219|hydrocortisone type
P10664876A0000|241 246|group C
P10664876A0000|180 188|molecules
P10664876A0000|28 41|corticosteroid
P10665308T0001|0 9|Mechanisms
P10665308T0001|12 24|tachyphylaxis
P10665308T0001|35 44|anesthesia
P10665308T0001|51 58|duration
P10665798A0598|41 61|aspartate transaminase
P10665798A0598|63 81|alkaline phosphatase
P10665798A0598|180 183|cell
P10665798A0598|130 153|D. russelli venom injection
P10665798A0598|22 33|serum enzymes
P10665798A0598|156 165|albino rats
P10665798A0598|105 124|lactate dehydrogenase
P10665798A0598|186 197|tissue damage
P10665798A0598|83 103|creatine phosphokinase
P10665798A0598|2 9|increase
P10665798A0598|15 19|level
P10665949A1131|66 72|lesions
P10665949A1131|10 19|farm budget
P10665949A1131|76 82|feedlot
P10665949A1131|34 43|importance
P10666222A0330|31 48|survivin cDNA clones
P10666222A0330|95 110|survivin proteins
P10666222A0330|75 83|existence
P10666238A1322|58 64|protein
P10666238A1322|8 16|induction
P10666238A1322|111 131|E2F-1 promoter activity
P10666238A1322|19 28|E2F binding
P10666238A1322|34 46|E2F-1 promoter
P10666238A1322|94 108|transactivation
P10666238A1322|52 55|E4-6
P10666253A1291|28 34|hairpin
P10666253A1291|45 50|amount
P10666253A1291|10 22|stabilization
P10666253A1291|53 62|tRNA primer
P10666253A1291|82 84|PBS
P10666509A0494|69 85|propranolol groups
P10666509A0494|55 65|zatebradine
P10666509A0494|24 34|arrhythmias
P10667597A0668|0 2|ZK7
P10667597A0668|65 68|gene
P10667597A0668|6 15|HZF16 genes
P10667597A0668|29 42|splice variants
P10668701A1311|0 9|CONCLUSION
P10668701A1311|91 96|effect
P10668701A1311|11 18|Presence
P10668701A1311|53 56|risk
P10668701A1311|114 126|atherogenesis
P10668701A1311|60 67|dementia
P10668701A1311|21 32|APOE epsilon4
P10668701A1311|71 72|AD
P10668701A1311|99 110|dyslipidemia
P10669319A1722|57 64|patients
P10669319A1722|79 83|phase
P10669319A1722|10 20|conclusions
P10669319A1722|49 54|number
P10669319A1722|86 90|trial
P10669594A0000|30 33|AgfA
P10669594A0000|37 40|SefA
P10669594A0000|21 28|fimbrins
P10669594A0000|157 191|16-amino acid Leishmania T-cell epitope
P10669594A0000|138 140|PT3
P10669594A0000|67 79|fimbriae SEF17
P10669594A0000|83 87|SEF14
P10669594A0000|206 224|metalloprotease gp63
P10669594A0969|40 51|SefA proteins
P10669594A0969|8 15|contrast
P10669594A0969|23 26|none
P10669594A0969|18 21|AgfA
P10669594A0969|80 87|fimbriae
P10669596A0430|189 194|nature
P10669596A0430|119 123|level
P10669596A0430|85 88|Abc2
P10669596A0430|139 154|nuclease activity
P10669596A0430|210 231|RecBCD nuclease activity
P10669596A0430|10 15|growth
P10669596A0430|18 25|phage P22
P10669596A0430|251 256|enzyme
P10669596A0430|75 82|presence
P10669596A0430|178 183|change
P10669633A0391|70 79|expression
P10669633A0391|38 47|mechanisms
P10669633A0391|115 124|THP-1 cells
P10669633A0391|103 112|activation
P10669633A0391|6 10|study
P10669633A0391|85 93|flt-1 gene
P10669736A0903|99 107|abundance
P10669736A0903|62 70|HeLa cells
P10669736A0903|49 59|transcripts
P10669736A0903|110 112|PTB
P10669736A0903|17 26|difference
P10669736A0903|29 31|CAT
P10669751T0000|84 96|c-jun promoter
P10669751T0000|65 78|cot oncoprotein
P10669751T0000|25 54|protein kinase signaling pathways
P10669751T0000|110 123|transformation
P10670358A0143|0 10|Dermatology
P10670358A0143|15 23|exception
P10671224A0254|60 74|CD95L expression
P10671224A0254|12 16|study
P10671224A0254|48 56|mechanism
P10671519A0641|0 22|Protein sequence analysis
P10671519A0641|184 189|emerin
P10671519A0641|110 118|LEM module
P10671519A0641|62 67|domain
P10671519A0641|169 179|polypeptide
P10671519A0641|136 151|membrane proteins
P10671519A0641|34 43|MAN1 shares
P10671519A0641|85 94|amino acids
P10671520T0000|29 33|I-mfa
P10671520T0000|9 15|cloning
P10671520T0000|114 128|HIV-1 expression
P10671520T0000|51 57|protein
P10671520T0000|87 109|T-cell leukemia virus type
P10671554A0492|146 153|sequence
P10671554A0492|10 27|amino acid sequences
P10671554A0492|94 110|amino acid residues
P10671554A0492|53 64|porcine cDNAs
P10671554A0492|166 181|Edman degradation
P10671554A0492|44 49|bovine
P10671606A0884|128 135|patients
P10671606A0884|92 99|patients
P10671606A0884|104 106|APA
P10671606A0884|90 90|%
P10671606A0884|126 126|%
P10671606A0884|69 74|images
P10671606A0884|4 23|chemical shift imaging
P10671606A0884|28 42|signal intensity
P10671606A0884|140 142|BAH
P10672433A0199|169 178|percentage
P10672433A0199|62 69|wake time
P10672433A0199|156 164|awakening
P10672433A0199|71 74|time
P10672433A0199|128 137|sleep onset
P10672433A0199|41 51|measurement
P10672433A0199|16 20|diary
P10672433A0199|206 211|person
P10672433A0199|77 79|bed
P10672433A0199|181 187|morning
P10672433A0199|102 107|number
P10672433A0199|119 122|wake
P10672433A0199|7 11|night
P10672433A0199|110 116|minutes
P10672433A0199|91 100|efficiency
P10672433A0199|139 142|WASO
P10672433A0199|145 153|alertness
P10672433A0199|81 83|TIB
P10672433A0199|197 201|alarm
P10672433A0199|54 60|bedtime
P10672899A0078|0 3|Acad
P10673335X0782|0 8|Copyright
P10673335X0782|13 25|Academic Press
P10673426A0168|13 18|domain
P10673426A0168|11 11|R
P10673426A0168|51 58|activity
P10673426A0168|96 108|translocation
P10673426A0168|80 80|T
P10673426A0168|82 87|domain
P10673426A0168|113 119|process
P10673426A0168|149 154|domain
P10673426A0168|197 208|cytotoxicity
P10673426A0168|188 191|site
P10673426A0168|175 182|receptor
P10674395A0262|131 155|signal transduction pathway
P10674395A0262|177 189|protein kinase
P10674395A0262|32 41|expression
P10674395A0262|126 129|cGMP
P10674395A0262|82 85|GnRH
P10674395A0262|69 80|neuropeptide
P10674395A0262|47 50|gene
P10674395A0262|122 124|GMP
P10674395A0262|229 241|cell line GT1-7
P10674484A0633|28 34|lesions
P10674484A0633|102 111|perception
P10674484A0633|75 82|rat brain
P10674484A0633|63 69|neurons
P10674484A0633|5 8|data
P10674484A0633|133 138|memory
P10675154T0000|16 29|botulinum toxin
P10675154T0000|7 13|potency
P10675331A0600|131 139|cortactin
P10675331A0600|45 67|tyrosine phosphorylation
P10675331A0600|106 128|tyrosine phosphorylation
P10675331A0600|11 15|c-Src
P10675331A0600|142 146|Stat3
P10675331A0600|2 9|contrast
P10675331A0600|70 72|Shc
P10675331A0600|27 39|isoproterenol
P10675331A0600|86 98|Erk activation
P10675610A0279|0 4|MSSPs
P10675610A0279|26 39|DNA replication
P10675610A0279|68 87|cell cycle progression
P10675610A0279|55 64|apopotosis
P10675610A0279|108 119|C-MYC protein
P10675610A0279|41 53|transcription
P10677214A1045|84 88|slope
P10677214A1045|197 202|values
P10677214A1045|260 271|acid catalyst
P10677214A1045|154 155|pH
P10677214A1045|240 243|base
P10677214A1045|47 49|log
P10677214A1045|319 325|dGTP-Mg
P10677214A1045|21 24|E53D
P10677214A1045|118 121|hump
P10677214A1045|143 149|maximum
P10677214A1045|168 174|plateau
P10677214A1045|51 51|k
P10677214A1045|7 14|type MutT
P10677214A1045|64 65|pH
P10677214A1045|106 109|limb
P10677214A1045|40 44|plots
P10677214A1045|330 336|complex
P10677214A1045|53 55|cat
P10677214A1045|28 38|E44D mutants
P10677214A1045|192 193|pK
P10677214A1045|307 313|MutT-Mg
P10677214A2842|44 47|E44D
P10677214A2842|10 16|changes
P10677214A2842|140 145|Glu-44
P10677214A2842|165 174|site region
P10677214A2842|108 118|loop I-helix
P10677214A2842|67 67|H
P10677214A2842|120 124|motif
P10677214A2842|73 84|N HSQC spectra
P10677297A0933|147 151|cells
P10677297A0933|117 124|location
P10677297A0933|7 16|expression
P10677297A0933|130 136|protein
P10677297A0933|50 57|nonsense
P10677297A0933|61 77|missense mutations
P10678144A0509|5 8|i.v.
P10678968A1096|186 191|season
P10678968A1096|154 159|period
P10678968A1096|28 39|I. scapularis
P10678968A1096|47 54|activity
P10678968A1096|18 21|mice
P10678968A1096|168 175|activity
P10678968A1096|62 67|summer
P10678968A1096|99 113|mouse population
P10678968A1096|84 93|proportion
P10678968A1096|0 7|Immunity
P10678968A1096|129 144|E. phagocytophila
P10679015A0216|79 81|set
P10679015A0216|11 14|view
P10679015A0216|84 91|proteins
P10679015A0216|46 50|class
P10679015A0216|22 28|studies
P10679015A0216|53 59|snoRNPs
P10679015A0216|31 35|yeast
P10679065A0711|209 218|CREB serine
P10679065A0711|135 149|protein kinase-2
P10679065A0711|48 70|protein kinase-2 activity
P10679065A0711|156 164|complexes
P10679065A0711|113 119|p38 MAPK
P10679065A0711|222 241|phosphoacceptor motif
P10679065A0711|180 195|peptide substrate
P10679065A0711|0 15|BCR cross-linking
P10679065A0711|74 79|enzyme
P10679065A1217|0 9|Activation
P10679065A1217|26 70|junB promoter/chloramphenicol acetyltransferase
P10679065A1217|72 74|CAT
P10679065A1217|93 95|BCR
P10679065A1217|112 119|SB203580
P10679065A1217|76 87|reporter gene
P10679190A0693|101 112|reading frame
P10679190A0693|114 117|mORF
P10679190A0693|66 76|translation
P10679190A0693|9 16|evidence
P10679190A0693|36 47|reading frame
P10679190A0693|49 52|uORF
P10679649A0311|0 6|METHODS
P10679649A0311|46 56|outpatients
P10679649A0311|184 188|years
P10679649A0311|159 170|chemotherapy
P10679649A0311|118 129|methotrexate
P10679649A0311|172 180|median age
P10679649A0311|134 147|5-fluorouracil
P10679649A0311|101 116|cyclophosphamide
P10679649A0311|190 194|range
P10679649A0311|8 22|TBN measurements
P10679649A0311|201 205|years
P10679649A0311|61 75|breast carcinoma
P10679649A0311|149 151|CMF
P10679781A1183|117 129|phorbol esters
P10679781A1183|4 31|bp Glucocorticoid Response Unit
P10679781A1183|91 104|dibutyryl-cAMP
P10679781A1183|33 35|GRU
P10679781A1183|55 77|glucocorticoid induction
P10679922A1110|69 93|tumor suppressor gene target
P10679922A1110|37 43|samples
P10679922A1110|103 112|neck cancer
P10679922A1110|9 17|mutations
P10679922A1110|59 62|ING1
P10679922A1110|96 99|head
P10681520A0525|0 7|Ras-GRF1
P10681520A0525|157 166|Gbetagamma
P10681520A0525|116 120|Cdc42
P10681520A0525|83 93|GEF activity
P10681520A0525|110 112|Rho
P10681520A0525|32 36|v-Src
P10681520A0525|100 102|Rac
P10681562A0263|125 139|PPARgamma action
P10681562A0263|12 31|PPARgamma antagonists
P10681562A0263|93 106|mutant receptor
P10681588A0899a|0 3|EMSA
P10681588A0899a|187 194|extracts
P10681588A0899a|43 44|C6
P10681588A0899a|249 256|factor Y.
P10681588A0899a|21 28|proteins
P10681588A0899a|47 55|Rat2 cells
P10681588A0899a|125 129|CCAAT
P10681588A0899a|225 231|complex
P10681588A0899a|63 65|CRE
P10681588A0899a|167 170|PC12
P10681588A0899a|213 221|CCAAT-box
P10681588A0899a|69 75|complex
P10681588A0899a|96 114|transcription factor
P10681588A0899a|33 36|PC12
P10681588A0899a|146 156|protein beta
P10681588A0899a|174 179|C6 cell
P10681588A0899a|116 118|ATF
P10681588A0899b|0 3|EMSA
P10681588A0899b|187 194|extracts
P10681588A0899b|43 44|C6
P10681588A0899b|249 256|factor Y.
P10681588A0899b|21 28|proteins
P10681588A0899b|47 55|Rat2 cells
P10681588A0899b|125 129|CCAAT
P10681588A0899b|225 231|complex
P10681588A0899b|63 65|CRE
P10681588A0899b|167 170|PC12
P10681588A0899b|213 221|CCAAT-box
P10681588A0899b|69 75|complex
P10681588A0899b|96 114|transcription factor
P10681588A0899b|33 36|PC12
P10681588A0899b|146 156|protein beta
P10681588A0899b|174 179|C6 cell
P10681588A0899b|116 118|ATF
P10681679A0220|27 33|portion
P10681679A0220|60 70|enlargement
P10681679A0220|39 43|tumor
P10681679A0220|112 120|diagnosis
P10681679A0220|91 95|years
P10681679A0220|7 16|resolution
P10681679A0220|81 89|tumor cyst
P10681679A0220|45 53|serial MRI
P10682570A0453|0 2|LPO
P10682570A0453|33 38|points
P10682570A0453|6 14|SOD levels
P10682570A0453|57 65|operation
P10683072T0000|47 57|prophylaxis
P10683072T0000|116 128|cell carcinoma
P10683072T0000|20 30|tachycardia
P10683072T0000|73 97|bolus interleukin-2 therapy
P10683244A0939|14 17|NBF1
P10683244A0939|19 26|R protein
P10683244A0939|177 180|NBF2
P10683244A0939|62 69|proteins
P10683244A0939|47 53|mixture
P10683244A0939|112 129|sieve chomatography
P10683244A0939|134 140|mixture
P10683244A0939|31 41|NBF2 protein
P10683244A0939|169 172|NBF1
P10683244A0939|174 174|R
P10683244A1860|159 169|interaction
P10683244A1860|55 61|R region
P10683244A1860|111 115|units
P10683244A1860|68 77|NBF2 domain
P10683244A1860|183 189|absence
P10683244A1860|50 53|NBF1
P10683244A1860|128 137|propensity
P10683244A1860|197 207|nucleotides
P10683244A1860|228 242|phosphorylation
P10683244A1860|18 28|experiments
P10683244A1860|44 47|CFTR
P10683244X2359|0 8|Copyright
P10683244X2359|13 25|Academic Press
P10683259A0774|0 18|Sulfhydryl titration
P10683259A0774|168 173|values
P10683259A0774|140 149|difference
P10683259A0774|95 113|maleimide derivative
P10683259A0774|23 35|iodoacetamide
P10683259A0774|179 187|cysteines
P10683259A0774|116 121|biotin
P10683259A0774|82 89|reaction
P10683259A0774|196 210|splice junctions
P10683259A0774|163 164|pK
P10683259A0774|71 76|thiols
P10683989A0251|30 36|results
P10683989A0251|106 117|Qs/Q tau ratio
P10683989A0251|51 59|increases
P10683989A0251|62 65|PaO2
P10683989A0251|11 25|oxide inhalation
P10683989A0251|69 72|SaO2
P10683989A0251|119 119|P
P10683989A0251|96 103|decrease
P10683989A0251|74 74|P
P10684069A0508|29 31|FIC
P10684069A0508|39 42|P0.1
P10684069A0508|20 22|MIP
P10684069A0508|33 37|Wimax
P10684069A0508|46 62|minute ventilation
P10684069A0508|114 129|methylphenidatum
P10684069A0508|24 27|MMIF
P10684069A0508|3 9|results
P10684069A0508|64 65|Vr
P10684069A0508|98 111|administration
P10684069A0508|133 145|aminophylline
P10684097A0175|102 112|ovariectomy
P10684097A0175|90 100|ovariectomy
P10684097A0175|23 26|rats
P10684097A0175|130 145|ethinyl estradiol
P10684097A0175|67 79|sham operation
P10684097A0175|54 59|groups
P10684097A0175|15 16|SD
P10684097A0175|163 165|g B.
P10684111A1411|45 51|factors
P10684111A1411|23 29|variety
P10684111A1411|87 103|MAPK family members
P10684111A1411|62 65|pair
P10684111A1411|68 74|MAPK p44
P10684111A1411|78 84|MAPK p42
P10684265T0000|60 74|cytomegalovirus
P10684265T0000|77 87|conjugation
P10684265T0000|130 135|hSMT3b
P10684265T0000|25 52|transactivator protein IE2-p86
P10684265T0000|8 19|modification
P10684265T0000|113 126|proteins SUMO-1
P10684304A1242|3 13|interaction
P10684304A1242|23 23|L
P10684304A1242|21 21|U
P10684534A0634|0 8|Protamine
P10684534A0634|12 23|heparin doses
P10684534A0634|72 76|doses
P10684534A0634|34 43|Sigma-dose
P10684534A0634|30 32|sum
P10684534A0634|90 102|clotting times
P10684646A0224|82 91|expression
P10684646A0224|19 27|mechanism
P10684646A0224|60 65|growth
P10684646A0224|94 101|caveolin
P10684646A0224|6 10|study
P10684660A1266|0 9|Comparison
P10684660A1266|33 48|processing enzyme
P10684660A1266|115 121|enzymes
P10684660A1266|56 60|plant
P10684660A1266|93 102|activities
P10684660A1266|15 19|plant
P10684660A1266|27 30|tRNA
P10684941A0722|3 13|requirement
P10684941A0722|110 113|side
P10684941A0722|37 52|ligation reaction
P10684941A0722|79 90|nt insertions
P10684941A0722|67 73|results
P10684941A0722|119 122|nick
P10684941A0722|18 32|complementarity
P10684967A0000|0 5|NKX2.1
P10684967A0000|20 28|NK2 family
P10684967A0000|53 72|transcription factors
P10684967A0000|9 14|member
P10684967A0000|115 121|absence
P10684967A0000|98 102|mouse
P10684967A0000|124 136|thyroid tissue
P10684967A0000|157 169|lung phenotype
P10684967A0000|86 95|disruption
P10687366A0000|0 19|National abortion laws
P10687366A0000|37 44|abortion
P10687366A0000|50 55|foetus
P10687366A0000|110 114|weeks
P10687366A0000|98 100|age
P10687855A1197|74 78|Zn-16
P10687855A1197|89 92|role
P10687855A1197|26 34|pituitary
P10687855A1197|57 61|cells
P10687855A1197|104 114|development
P10687855A1197|133 147|differentiation
P10687855A1197|0 9|Expression
P10687855T0000|0 41|Mouse growth hormone transcription factor Zn-16
P10687855T0000|93 109|zinc finger domains
P10687855T0000|58 66|structure
P10687855T0000|123 130|rat Zn-15
P10687862A1980|45 50|CI/CII
P10687862A1980|38 41|CIII
P10687862A1980|81 96|promoter activity
P10687862A1980|3 26|CCAAT core sequence mutants
P10687945A0000|0 10|Deglutition
P10687945A0000|37 43|infants
P10688639A1310|84 97|p300 expression
P10688639A1310|52 62|PEST domains
P10688639A1310|31 49|PU.1 transactivation
P10688639A1310|4 13|repression
P10688646A0535|85 96|alpha-globin
P10688646A0535|165 182|expression analysis
P10688646A0535|20 28|K562 cells
P10688646A0535|112 128|hormone hybrid gene
P10688646A0535|56 70|HS-40 mutants cis
P10688646A0535|150 161|footprinting
P10688660A0992|84 95|progesterone
P10688660A0992|174 176|PRE
P10688660A0992|146 172|progesterone response element
P10688660A0992|185 203|reporter DNA template
P10688660A0992|14 21|addition
P10688660A0992|57 65|T47D cells
P10688660A0992|112 124|transcription
P10688660A0992|32 34|CBP
P10688660A0992|47 54|extracts
P10688661A0237|133 139|mutants
P10688661A0237|25 33|REST/NRSF
P10688661A0237|10 23|binding protein
P10688661A0237|182 186|genes
P10688661A0237|155 164|expression
P10688661A0237|48 66|transcription factor
P10688661A0237|75 83|mutations
P10688661A0237|101 109|lethality
P10688663A0207|0 6|Removal
P10688663A0207|79 94|core histone tails
P10688663A0207|63 73|acetylation
P10688663A0207|12 33|core histone tail domains
P10688663A0207|43 60|trypsin proteolysis
P10688663A0207|139 144|TFIIIA
P10688663A0207|187 189|DNA
P10688663A0207|120 129|inhibition
P10688666A1010|47 50|part
P10688666A1010|52 71|homo-oligomerization
P10688666A1010|11 19|mechanism
P10688666A1010|22 35|ASK1 activation
P10690702A0065|0 6|OUTCOME
P10690702A0065|94 109|myasthenia gravis
P10690702A0065|54 67|electromyogram
P10690702A0065|83 91|diagnosis
P10690702A0065|8 38|Acetylcholine receptor antibodies
P10690725A1037|8 15|patients
P10690725A1037|25 28|PRFR
P10690866A0783|41 64|TSH frequency distribution
P10690866A0783|67 73|mothers
P10690866A0783|77 84|neonates
P10690866A0783|33 38|shifts
P10690866A0783|3 12|variations
P10691972T0000|0 15|Characterization
P10691972T0000|81 84|gene
P10691972T0000|91 100|regulation
P10691972T0000|76 79|MRP2
P10691972T0000|129 145|resistance protein
P10691972T0000|103 119|comparison withthe
P10691972T0000|148 151|MRP3
P10691972T0000|153 156|gene
P10691972T0000|32 37|region
P10691972T0000|57 73|resistance protein
P10692167A0364|13 21|mechanism
P10692167A0364|63 72|M. synoviae
P10692167A0364|49 60|observations
P10692374A1873|216 218|PAN
P10692374A1873|108 110|PAN
P10692374A1873|61 74|20S proteasomes
P10692374A1873|167 174|proteins
P10692374A1873|26 37|M. jannaschii
P10692374A1873|139 148|hydrolysis
P10692374A1873|250 257|reaction
P10692374A1873|197 213|amino acid residues
P10692374A1873|5 11|results
P10692374A1873|83 101|nucleotidase complex
P10692433A0000|41 44|role
P10692433A0000|90 98|cell cycle
P10692433A0000|47 47|G
P10692433A0000|3 24|transcription factor E2F
P10692433A0000|53 68|S phase transition
P10693246A0252|30 39|components
P10693246A0252|108 117|dissection
P10693246A0252|167 177|mediastinum
P10693246A0252|137 156|laryngeal nerve chains
P10693246A0252|16 25|dissection
P10693314A0521|57 64|patients
P10693314A0521|8 15|patients
P10693314A0521|24 35|CK-MB results
P10693314A0521|87 87|%
P10693314A0521|89 96|patients
P10693314A0521|66 68|ECG
P10693314A0521|77 79|AMI
P10693314A0521|55 55|%
P10694189A0469|3 8|effect
P10694189A0469|11 13|MIB
P10694189A0469|56 68|noradrenaline
P10694189A0469|32 36|curve
P10694210A0385|73 89|cingulate cortices
P10694210A0385|181 183|H1R
P10694210A0385|124 141|d-chlorpheniramine
P10694210A0385|178 178|%
P10694210A0385|11 18|blockade
P10694210A0385|156 159|dose
P10694210A0385|108 121|administration
P10694210A0385|21 23|H1R
P10694210A0385|162 163|mg
P10694210A0385|196 203|cortices
P10694511A0570|113 114|Ca
P10694511A0570|34 37|mid1
P10694511A0570|103 110|increase
P10694511A0570|74 82|phenotype
P10694511A0570|25 28|cDNA
P10694511A0570|119 132|uptake activity
P10694511A0570|18 21|yam8
P10694511A0570|44 48|cells
P10694511A0570|3 12|expression
P10694605A1327|17 30|infection rates
P10694605A1327|109 109|P
P10694605A1327|97 107|double-lung
P10694605A1327|111 112|NS
P10694605A1327|32 53|events/100 patient-days
P10694605A1327|117 122|months
P10694609A0309|174 178|hours
P10694609A0309|42 50|induction
P10694609A0309|16 25|compliance
P10694609A0309|122 125|hour
P10694609A0309|53 62|anesthesia
P10694609A0309|104 119|operating theater
P10694609A0309|131 136|return
P10694609A0309|89 98|filtration
P10694609A0309|160 167|care unit
P10694609A0309|187 195|operation
P10695685T0000|30 38|rationale
P10695685T0000|11 17|therapy
P10695685T0000|74 85|consequences
P10695685T0000|50 61|implications
P10696007A1325|27 45|C2-C3 disk morphology
P10696007A1325|76 83|response
P10696007A1325|9 19|correlation
P10698516T0000|0 2|KFC
P10698516T0000|46 55|capability
P10698516T0000|69 83|SAPK/JNK pathway
P10698516T0000|15 20|kinase
P10698937T0000|0 4|TIP30
P10698937T0000|44 56|up-regulation
P10698937T0000|77 81|genes
P10698937T0000|19 32|kinase activity
P10698937T0000|60 65|subset
P10698974A0951|38 43|region
P10698974A0951|20 28|STAG3 gene
P10698974A0951|46 55|chromosome
P10698974A0951|249 256|deletion
P10698974A0951|185 195|breakpoints
P10698974A0951|79 83|genes
P10698974A0951|236 243|syndrome
P10698974A0951|129 132|gene
P10698974A0951|245 247|WBS
P10699354A0557|0 11|Reaction time
P10699354A0557|13 14|RT
P10699354A0557|19 22|P300
P10699653A0967|27 32|access
P10699653A0967|16 19|rats
P10699653A0967|116 122|sucrose
P10699653A0967|102 108|ethanol
P10699653A0967|111 111|%
P10699653A0967|2 11|experiment
P10699653A0967|127 134|solution
P10699653A0967|65 72|tap water
P10699653A0967|38 44|bottles
P10699653A0967|125 125|%
P10699684A0661|43 48|number
P10699684A0661|51 58|patients
P10699684A0661|104 105|M.
P10699684A0661|12 16|Zelen
P10699684A0661|76 81|groups
P10699684A0661|92 102|institution
P10699684A0661|19 24|method
P10699896A0455|14 18|group
P10699896A0455|34 39|gender
P10699896A0455|21 28|patients
P10699896A0455|41 41|P
P10699896A0455|0 6|RESULTS
P10700262A0000|90 104|brain structures
P10700262A0000|39 47|interplay
P10700262A0000|66 79|control systems
P10700262A0000|15 23|attention
P10701534A0164|101 105|years
P10701534A0164|108 110|age
P10701534A0164|54 65|hemidystonia
P10701534A0164|78 87|head trauma
P10701534A0164|32 50|low-frequency tremor
P10701534A0164|3 9|patient
P10702241A0357|58 59|a2
P10702241A0357|101 105|brain
P10702241A0357|52 56|heart
P10702241A0357|11 19|a1 isoform
P10702241A0357|84 88|liver
P10702241A0357|95 99|heart
P10702241A0357|70 75|kidney
P10702241A0357|44 48|brain
P10702241A0357|62 66|liver
P10702241A0357|90 93|lung
P10702241A0357|107 112|spleen
P10702241A0357|117 122|kidney
P10702241A0357|80 81|a3
P10702253A0357|103 112|cDNA clones
P10702253A0357|143 150|splicing
P10702253A0357|156 169|HIF-1alpha gene
P10702253A0357|25 61|transcriptase-polymerase chain reaction
P10702253A0357|9 15|cloning
P10702253A0357|72 88|HIF-1alpha subunit
P10702285A0855|30 30|G
P10702285A0855|216 216|q
P10702285A0855|214 214|G
P10702285A0855|133 135|p85
P10702285A0855|92 98|pathway
P10702285A0855|146 152|subunit
P10702285A0855|162 180|wortmannin treatment
P10702285A0855|100 109|expression
P10702285A0855|235 257|GLUT4-EGFP translocation
P10702285A0855|35 35|G
P10702285A0855|40 47|function
P10702285A0855|11 22|relationship
P10702285A0855|32 32|q
P10702285A0855|55 82|phosphatidylinositol 3-kinase
P10702389A1148|83 91|cytoplasm
P10702389A1148|9 10|BL
P10702389A1148|59 65|protein
P10702389A1148|47 51|cases
P10702389A1148|15 26|RB2/p130 gene
P10702794A1495|141 157|feedback mechanism
P10702794A1495|134 137|part
P10702794A1495|50 55|target
P10702794A1495|26 29|ERK2
P10702794A1495|96 100|HePTP
P10702794A1495|58 62|HePTP
P10702794A1495|120 131|ERK2 activity
P10702794A1495|14 17|data
P10702794A1495|84 88|model
P10702926T0089|0 13|Cross-reaction
P10702926T0089|32 39|antibody
P10702926T0089|46 68|alpha beta T cell receptors
P10703633A0747|0 15|Strontium nitrate
P10703633A0747|222 234|mean magnitude
P10703633A0747|100 107|duration
P10703633A0747|184 186|min
P10703633A0747|81 81|p
P10703633A0747|154 156|SEM
P10703633A0747|158 160|min
P10703633A0747|240 258|irritation sensation
P10703633A0747|173 176|mean
P10703633A0747|62 65|acid
P10703633A0747|40 49|comparison
P10703633A0747|113 131|irritation sensation
P10703633A0747|264 273|time points
P10703633A0747|205 205|p
P10703633A0747|33 36|acid
P10703633A0747|180 182|SEM
P10703633A0747|147 150|mean
P10704196A1051|17 32|sulfhydryl groups
P10704196A1051|136 139|side
P10704196A1051|69 72|half
P10704196A1051|78 91|plasma membrane
P10704196A1051|145 151|helices
P10704196A1051|119 123|model
P10704283A0649a|100 113|gene candidates
P10704283A0649a|150 172|IL-4 cytokine gene cluster
P10704283A0649a|11 12|Mb
P10704283A0649a|24 31|sequence
P10704283A0649a|0 7|Analysis
P10704283A0649a|39 44|region
P10704283A0649a|135 139|genes
P10704283A0649a|56 62|synteny
P10704283A0649a|70 87|chromosome 5q31-q33
P10704285A0536|103 115|AP-2alpha gene
P10704285A0536|5 11|AP-2rep
P10704285A0536|25 42|reporter expression
P10704285A0536|70 86|AP-2alpha promoter
P10704285A0536|152 160|AP-2alpha
P10704338A0354|56 61|domain
P10704338A0354|205 213|structure
P10704338A0354|229 242|leucine residue
P10704338A0354|74 80|protein
P10704338A0354|153 157|turns
P10704338A0354|244 255|P-position-L
P10704338A0354|71 72|CA
P10704338A0354|67 69|p24
P10704338A0354|19 25|insight
P10704338A0354|124 138|proline residues
P10704338A0354|92 102|replication
P10704338A0354|194 196|p24
P10704338A0354|33 36|role
P10704338A0354|2 6|order
P10704338A0354|172 184|alpha-helices
P10704410T0000|30 35|export
P10704410T0000|41 74|replication initiator proteins Mcm2-7
P10704410T0000|0 15|Clb/Cdc28 kinases
P10704499A0682|149 151|fyn
P10704499A0682|154 156|PLC
P10704499A0682|158 160|PKC
P10704499A0682|54 63|antibodies
P10704499A0682|105 114|inhibitors
P10704499A0682|131 147|tyrosine kinase p59
P10704499A0682|219 221|PMA
P10704499A0682|164 166|MEK
P10704499A0682|69 90|fibroblast growth factor
P10704499A0682|187 217|phorbol-12-myristate-13-acetate
P10704499A0682|183 185|PKC
P10704499A0682|92 94|FGF
P10704499A0682|41 49|treatment
P10704499A0682|14 25|PC12-E2 cells
P10704499A0682|96 103|receptor
P10704499A0682|172 180|activator
P10704853T0000|0 15|Cooperative roles
P10704853T0000|18 31|Bozozok/Dharma
P10704853T0000|48 55|proteins
P10704853T0000|92 100|zebrafish
P10704853T0000|61 69|formation
P10704853T0000|75 89|dorsal organizer
P10704975A0479|0 16|Thiopentone sodium
P10704975A0479|38 40|min
P10704975A0479|66 73|exposure
P10704975A0479|76 80|NOC-5
P10704975A0479|58 60|min
P10704975A0479|132 144|neurotoxicity
P10704975A0479|157 164|controls
P10705380A0629|110 123|UV-irradiation
P10705380A0629|34 51|Xretpos transcripts
P10705380A0629|91 97|regions
P10705380A0629|171 173|way
P10705380A0629|127 145|BMP-4 overexpression
P10705380A0629|175 181|genesis
P10705783A0433|74 78|means
P10705783A0433|38 45|chemical
P10705783A0433|97 119|concentration gentamicin
P10705783A0433|10 14|cases
P10705783A0433|26 35|neurectomy
P10705783A0433|56 70|labyrinthectomy
P10705783A0433|123 127|mg/mL
P10706475A0644|27 30|DSPP
P10706475A0644|50 52|DPP
P10706475A0644|44 46|DSP
P10706513A0843|40 45|months
P10706513A0843|11 19|prognosis
P10706513A0843|64 74|ventilation
P10706513A0843|27 36|% mortality
P10706688A0376|66 85|fasl promoter function
P10706688A0376|89 95|fashion
P10706688A0376|47 50|site
P10706688A0376|11 22|TCR signaling
P10706688A0376|107 122|NF-kappaB binding
P10706688A0376|30 40|AP-1 binding
P10706736A1091|83 88|T cells
P10706736A1091|143 150|epitopes
P10706736A1091|27 34|melanoma
P10706736A1091|68 76|detection
P10706736A1091|79 81|CD8
P10706736A1091|108 112|HLA-A
P10706736A1091|5 12|patients
P10706736A1091|56 57|Ag
P10706887A0281|15 15|%
P10706887A0281|18 22|ALCLs
P10706887A0281|34 36|ALK
P10706887A0281|52 52|t
P10706887A0281|85 97|abnormalities
P10706887A0281|117 129|ALK expression
P10706887A1457|43 50|function
P10706887A1457|126 130|drugs
P10706887A1457|95 100|tumors
P10706887A1457|137 148|methotrexate
P10706887A1457|72 80|lymphomas
P10706887A1457|19 27|decreases
P10706887A1457|2 9|addition
P10706887A1457|30 33|ATIC
P10708243A0000|45 54|antibodies
P10708243A0000|85 96|preeclampsia
P10708243A0000|69 81|pregnancy loss
P10708243A0000|12 22|observation
P10708243A0000|101 104|role
P10708243A0000|121 130|antibodies
P10708424A0800|59 63|BGLF4
P10708424A0800|9 12|ions
P10708424A0800|38 56|autophosphorylation
P10708424A0800|92 99|activity
P10708424A0800|68 76|magnesium
P10708769A0433|88 96|induction
P10708769A0433|61 67|element
P10708769A0433|17 22|region
P10708769A0433|3 6|Mif1
P10708769A0433|99 109|tunicamycin
P10708769A0433|42 43|ER
P10709705T0000|5 28|point feature registration
P10709705T0000|40 50|information
P10710499A0000|0 11|Methysergide
P10710499A0000|64 77|wound blood flow
P10710499A0000|81 94|edema formation
P10710499A0000|15 33|serotonin antagonist
P10710742T0000|0 24|Serum leptin concentrations
P10710742T0000|27 31|women
P10710742T0000|38 66|gonadotropin stimulation cycles
P10710985T0000|22 33|work practice
P10710985T0000|51 70|strengths perspective
P10710985T0000|38 45|families
P10710985T0000|7 14|families
P10711674A0000|46 51|family
P10711674A0000|117 127|keratoconus
P10711674A0000|103 105|MIM
P10711674A0000|74 78|Leber
P10711674A0000|99 101|LCA
P10711674A0000|89 97|amaurosis
P10711674A0000|0 6|PURPOSE
P10712512A0506|0 5|Ste18p
P10712512A0506|54 64|prenylation
P10712512A0506|22 35|plasma membrane
P10712512A0506|45 51|absence
P10712512A0506|67 79|thioacylation
P10712599A0349|15 19|IRF-1
P10712599A0349|56 62|pathway
P10712618A0181|161 170|aspartases
P10712618A0181|73 81|% homology
P10712618A0181|116 116|%
P10712618A0181|12 29|sequence comparison
P10712618A0181|86 110|Bacillus subtilis aspartase
P10712618A0181|42 64|Bacillus YM55-1 aspartase
P10713083A0170|32 35|TraR
P10713083A0170|12 17|system
P10713083A0170|22 29|activity
P10713083A0170|80 83|TraM
P10713083A0560|74 85|TraR function
P10713083A0560|135 152|DNA recognition site
P10713083A0560|61 64|TraM
P10713083A0560|103 121|transcription factor
P10713083A0560|20 24|assay
P10713083A0560|50 59|DNA binding
P10713155A0151|160 167|extracts
P10713155A0151|113 117|cells
P10713155A0151|119 123|Ad-NE
P10713155A0151|14 33|IIIa pre-mRNA splicing
P10713155A0151|169 175|HeLa-NE
P10713155A0151|145 152|HeLa cell
P10713155A0151|70 77|extracts
P10713161A0985|0 11|Inactivation
P10713161A0985|39 42|ulp1
P10713161A0985|47 53|defects
P10713161A0985|92 113|Smt3-protein conjugates
P10713161A0985|130 135|mutant
P10713161A0985|14 17|Ulp2
P10713161A0985|44 45|ts
P10713175A1399|102 107|import
P10713175A1399|113 127|ARF-Mdm2 complex
P10713175A1399|46 49|Mdm2
P10713175A1399|34 43|ARF binding
P10713175A1399|144 158|cell cycle arrest
P10713175A1399|16 22|results
P10713175A1399|72 77|change
P10713176A0422|0 16|Cyclin A expression
P10713176A0422|75 97|pocket protein partners Rb
P10713176A0422|167 168|Rb
P10713176A0422|107 110|p130
P10713176A0422|39 43|cells
P10713176A0422|194 210|E2F-p107 complexes
P10713176A0422|138 144|control
P10713176A0422|225 241|mitogen withdrawal
P10713176A0422|46 48|E2F
P10713176A0422|120 124|v-Jun
P10713176A0422|57 67|conjunction
P10713176A0422|99 102|p107
P10713176A0885|0 19|D-cyclin-cdk activity
P10713176A0885|154 165|DNA synthesis
P10713176A0885|69 73|cells
P10713176A0885|169 185|cell proliferation
P10713176A0885|123 134|inhibitor p16
P10713176A0885|33 49|Rb phosphorylation
P10713176A0885|87 96|expression
P10713176A0885|136 140|INK4A
P10713176A0885|102 105|cdk4
P10713239A0988|0 9|CONCLUSION
P10713239A0988|79 86|IOL optic
P10713239A0988|22 30|mechanism
P10713239A0988|42 57|capsulorhexis rim
P10713453A0172|127 132|Hrb57A
P10713453A0172|63 66|gene
P10713453A0172|76 78|57A
P10713453A0172|40 50|antibody Q18
P10713453A0172|81 99|polytene chromosomes
P10713453A0172|3 9|protein
P10714985A1057|41 49|structure
P10714985A1057|2 23|RNA boundary experiments
P10714985A1057|69 71|G/U
P10714985A1057|107 126|leader RNA association
P10714985A1057|60 65|number
P10714985A1057|73 81|AG repeats
P10715322A0000|0 12|Gene silencing
P10715322A0000|35 46|DNA sequences
P10715322A0000|69 78|eukaryotes
P10715322A0000|89 94|plants
P10715325A0834|147 150|EIN2
P10715325A0834|62 77|stress conditions
P10715325A0834|103 110|salinity
P10715325A0834|114 120|drought
P10715325A0834|3 12|AtERF genes
P10715325A0834|176 183|pathways
P10715325A0834|125 145|ETHYLENE-INSENSITIVE2
P10715325A0834|42 49|ethylene
P10715325A0834|85 92|wounding
P10715602A0149|0 6|Animals
P10715602A0149|38 42|mg/kg
P10715602A0149|22 34|dexamethasone
P10715602A0149|172 176|rSP-C
P10715602A0149|160 166|Germany
P10715602A0149|182 191|surfactant
P10715602A0149|103 115|phospholipids
P10715602A0149|70 97|surfactant preparation Exosurf
P10715602A0149|150 158|Burgwedel
P10715602A0149|126 135|surfactant
P10715602A0149|137 148|Wellcome GmbH
P10715602A0149|16 19|dose
P10717612A0000|0 9|BACKGROUND
P10717612A0000|163 175|interleukin-2
P10717612A0000|23 27|study
P10717612A0000|74 81|regimens
P10717612A0000|61 68|toxicity
P10717612A0000|14 16|aim
P10717612A0000|45 57|response rates
P10717612A0000|187 195|treatment
P10717612A0000|225 237|cell carcinoma
P10717612A0000|177 180|IL-2
P10717612A0000|198 205|patients
P10717612A0000|139 144|GM-CSF
P10717612A0000|121 137|stimulating factor
P10717612A0000|148 158|combination
P10720434A0291|116 118|UTR
P10720434A0291|9 17|injection
P10720434A0291|75 84|repression
P10720434A0291|52 60|sequences
P10720434A0291|29 33|mRNAs
P10720434A0291|87 98|cyclin B1 mRNA
P10721698A1195|156 159|CSTB
P10721698A1195|80 83|CSTB
P10721698A1195|141 153|transcription
P10721698A1195|103 110|function
P10721698A1195|5 8|data
P10721698A1195|35 49|dodecamer repeat
P10721698A1195|21 29|expansion
P10721698A1195|70 77|promoter
P10721698A1195|116 123|promoter
P10721704A1155|190 198|cell types
P10721704A1155|170 177|activity
P10721704A1155|136 151|sequence analysis
P10721704A1155|81 90|Elav family
P10721704A1155|20 31|organization
P10721704A1155|34 37|mHuA
P10721704A1155|95 109|promoter element
P10721704A1155|69 75|members
P10721704X0000|0 7|Analysis
P10721704X0000|15 17|end
P10721704X0000|132 137|Elavl1
P10721704X0000|222 231|cell growth
P10721704X0000|77 83|element
P10721704X0000|127 130|mHuA
P10721704X0000|23 33|mouse Elavl1
P10721704X0000|35 38|mHuA
P10721704X0000|87 94|evidence
P10721704X0000|114 125|organization
P10721704X0000|270 282|mRNA stability
P10721704X0000|40 43|gene
P10721704X0000|172 176|genes
P10721704X0000|196 203|proteins
P10721704X0000|164 169|family
P10721704X0000|235 247|proliferation
P10721704X0000|258 267|regulation
P10721714A1087|88 95|promoter
P10721714A1087|46 48|Sp1
P10721714A1087|68 74|regions
P10721714A1087|105 111|Sp1 site
P10721714A1087|142 147|region
P10721714A1087|15 33|mobility shift assays
P10721717A0676|0 3|Fgd3
P10721717A0676|7 10|FGD1
P10721717A0676|21 26|degree
P10721717A0676|29 44|sequence identity
P10721717A0676|68 84|amino acid residues
P10721726T0000|18 43|mouse thioredoxin reductases
P10721726T0000|9 15|cloning
P10722063A0328|58 64|mixture
P10722063A0328|128 132|phase
P10722063A0328|116 118|v/v
P10722063A0328|23 43|octadecylsilane column
P10722063A0328|3 12|HPLC method
P10722063A0328|136 144|detection
P10722063A0328|48 55|degrees C
P10722063A0328|150 151|nm
P10722063A0328|101 104|acid
P10722509A0392|69 76|patients
P10722509A0392|24 25|mg
P10722509A0392|112 113|kg
P10722509A0392|100 108|dipivoxil
P10722509A0392|48 49|kg
P10722509A0392|88 89|mg
P10722509A0392|52 61|body weight
P10722509A0392|36 44|dipivoxil
P10722509A0392|5 12|patients
P10722661A0146|0 3|CYC2
P10722661A0146|18 24|protein
P10722661A0146|92 102|PHO80 cyclin
P10722661A0146|32 47|sequence identity
P10722661A0146|53 73|Neurospora crassa PREG1
P10722661A0406|27 33|complex
P10722661A0406|81 87|kinases
P10722661A0406|193 199|control
P10722661A0406|89 92|CRKs
P10722661A0406|98 105|CYC2 gene
P10722661A0406|119 130|TY epitope tag
P10722661A0406|149 165|trypanosome genome
P10722661A0406|58 68|trypanosome
P10722661A0406|13 16|CYC2
P10722737A1726|45 47|Inr
P10722737A1726|67 76|regulation
P10722737A1726|157 161|S gene
P10722737A1726|24 34|involvement
P10722737A1726|115 117|Sp1
P10722737A1726|37 39|Sp1
P10722737A1726|151 153|LTC
P10722737A1726|93 111|transcription factor
P10722737A1726|136 145|regulation
P10722737A1726|5 12|findings
P10722969A0510|32 35|area
P10722969A0510|12 19|progress
P10722969A0510|22 25|date
P10723723A0781|16 28|mouse promoter
P10723723A0781|105 108|exon
P10723723A0781|39 44|copies
P10723723A0781|48 75|CT dinucleotide repeat sequence
P10723723A0781|99 100|bp
P10723727A0713|15 20|region
P10723727A0713|74 103|polyadenylation signal sequences
P10723727A0713|31 36|intron
P10724436A0085|71 76|system
P10724436A0085|19 22|U3O8
P10724436A0085|31 48|reference materials
P10724483A0540|80 89|HOG pathway
P10724483A0540|51 60|HEM13 genes
P10724483A0540|21 31|cAMP control
P10724483A0540|44 47|SRP1
P10724519A1185|67 74|elements
P10724519A1185|38 41|RNAs
P10725017A0673|145 172|Healthcare Record Architecture
P10725017A0673|52 57|CEN ENV
P10725017A0673|4 8|paper
P10725017A0673|123 128|CEN ENV
P10725017A0673|35 42|approach
P10725017A0673|100 115|healthcare record
P10725017A0673|71 84|specialisation
P10725382A0398|0 15|Sequence analyses
P10725382A0398|71 76|domain
P10725382A0398|111 114|SOS2
P10725382A0398|103 108|domain
P10725382A0398|18 21|sos2
P10725382A0398|28 34|alleles
P10725433A0543|157 164|sequence
P10725433A0543|136 144|consensus
P10725433A0543|105 112|mutation
P10725433A0543|183 198|promoter function
P10725433A0543|26 32|binding
P10725433A0543|86 95|B cell lines
P10725433A0543|40 46|factors
P10725433A0543|54 71|Wp reporter activity
P10725433A0543|1 8|mutation
P10725433A0543|129 132|site
P10727247A0461|123 132|TEF-1gamma
P10727247A0461|111 119|TEF-1beta
P10727247A0461|97 109|TEF-1 isoforms
P10727247A0461|40 56|expression pattern
P10727247A0461|17 23|cloning
P10727247A0461|71 86|characterization
P10727413A1244|61 73|hamster CYP7A1
P10727413A1244|12 23|binding sites
P10727413A1244|82 89|promoter
P10727413A1244|153 156|unit
P10727413A1244|41 47|factors
P10727413A1244|194 210|tissue restriction
P10727413A1244|181 190|expression
P10727413A1244|97 104|vicinity
P10727413A1244|224 231|hormones
P10727413A1244|124 130|species
P10727413A1244|216 221|action
P10727413A1244|238 244|insulin
P10727426A1280|56 65|olomoucine
P10727426A1280|19 23|PfPK6
P10727426A1280|37 49|CDK inhibitors
P10727426A1280|69 79|roscovitine
P10727426A1280|3 16|kinase activity
P10727428A0000|29 35|protein
P10727428A0000|113 116|role
P10727428A0000|37 43|kinases
P10727428A0000|79 93|differentiation
P10727428A0000|59 75|cell proliferation
P10727428A0000|8 10|MAP
P10727428A0000|138 148|hypertrophy
P10727428A0000|100 108|cell types
P10727428A0000|119 128|MAP kinases
P10727433A0560|204 206|ras
P10727433A0560|115 130|activator protein
P10727433A0560|145 155|uPA promoter
P10727433A0560|64 73|activation
P10727433A0560|107 113|Ets/AP1
P10727433A0560|79 95|signalling pathway
P10727433A0560|17 39|CSF-1R expression plasmid
P10727433A0560|187 192|target
P10727433A0560|210 231|protein kinase C pathways
P10727433A0560|0 11|Transfection
P10727433A0560|133 139|element
P10727433T0000|0 9|Regulation
P10727433T0000|130 134|CSF-1
P10727433T0000|63 68|RAW264
P10727433T0000|12 57|urokinase plasminogen activator gene transcription
P10727433T0000|95 104|macrophage
P10727433T0000|173 180|receptor
P10727433T0000|154 158|level
P10727433T0000|123 128|factor
P10727433T0000|75 92|macrophage cell line
P10727511A0294|0 7|Molecule
P10727511A0294|53 61|induction
P10727511A0294|94 110|signaling pathways
P10727511A0294|9 9|s
P10727511A0294|64 68|GLT-1
P10727511A0294|124 133|regulation
P10727511A0294|29 36|cultures
P10727515A1202|75 82|receptor
P10727515A1202|111 117|PLCbeta
P10727515A1202|35 35|G
P10727515A1202|159 172|pertussis toxin
P10727515A1202|47 55|receptors
P10727515A1202|97 108|stimulations
P10727515A1202|37 37|q
P10727515A1202|125 133|responses
P10727515A1202|0 11|Coactivation
P10728945A0233|0 7|Patients
P10728945A0233|71 83|Thrombosis-II
P10728945A0233|21 30|Integrilin
P10728945A0233|95 99|trial
P10728945A0233|85 93|IMPACT-II
P10728945A0233|41 59|Platelet Aggregation
P10728986A0000|76 92|cell fate decisions
P10728986A0000|50 66|animal development
P10728986A0000|3 21|Wnt signaling pathway
P10729151A1160|32 37|HPV-11
P10729151A1160|73 90|reporter expression
P10729151A1160|4 11|mutation
P10729155A0653|87 91|betaI
P10729155A0653|48 57|carboxy end
P10729155A0653|74 85|beta-strand I
P10729155A0653|146 149|face
P10729155A0653|170 176|subunit
P10729155A0653|108 115|residues
P10729155A0653|17 26|MVMi capsid
P10729155A0653|32 39|sequence
P10729220A0000|16 19|IGF2
P10729220A0000|38 49|growth factor
P10729220A0000|102 106|mouse
P10729220A0000|56 63|H19 genes
P10729220A1569|68 70|H19
P10729220A1569|13 23|methylation
P10729220A1569|56 65|disruption
P10729220A1569|95 99|brain
P10729221A0798|46 61|Kv4 family members
P10729221A0798|18 35|expression patterns
P10729221A0798|67 84|subtype specificity
P10729221A0798|3 12|comparison
P10730292T0000|28 42|Class II division
P10730292T0000|5 22|treatment mechanics
P10730292T0000|44 55|malocclusion
P10730763A1491|115 129|disease severity
P10730763A1491|103 112|assessment
P10730763A1491|81 92|research tool
P10730763A1491|67 77|development
P10730763A1491|11 13|use
P10730763A1491|19 47|Nottingham Eczema Severity Score
P10730763A1491|162 168|studies
P10731411A0958|158 164|residue
P10731411A0958|37 44|residues
P10731411A0958|25 34|importance
P10731411A0958|62 67|motifs
P10731411A0958|140 149|importance
P10731411A0958|3 11|consensus
P10731411A0958|180 184|motif
P10731411A0958|94 113|DEAD-box RNA helicases
P10731411A0958|156 156|A
P10731411A0958|175 178|DEAD
P10731926A0775|0 14|Advanced adenoma
P10731926A0775|48 49|mm
P10731926A0775|101 109|dysplasia
P10731926A0775|66 69|size
P10731926A0775|54 60|adenoma
P10731926A0775|120 128|carcinoma
P10731926A0775|81 89|component
P10731926A0775|29 35|adenoma
P10732669A0510|152 173|reporter gene constructs
P10732669A0510|11 16|assays
P10732669A0510|106 111|Oshox1
P10732669A0510|142 149|activity
P10732669A0510|23 26|rice
P10732669A0510|64 82|particle bombardment
P10732669A0510|186 203|HD-Zip binding sites
P10732669A0510|46 50|cells
P10732669A1336|0 6|Results
P10732669A1336|180 185|family
P10732669A1336|163 170|proteins
P10732669A1336|90 97|proteins
P10732669A1336|121 130|homodimers
P10732669A1336|19 24|assays
P10732669A1336|138 149|heterodimers
P10732669A1336|100 107|families
P10732669A1336|43 61|mobility shift assays
P10733569A0364|14 17|HSFs
P10733569A0364|51 60|regulation
P10733569A0364|109 116|function
P10733569A0364|78 97|stress gene expression
P10733569A0364|125 138|stress response
P10733569A0364|19 22|HSF1
P10733569A0364|119 122|HSF2
P10733581A1391|62 70|V12N38 Ras
P10733581A1391|94 97|loss
P10733581A1391|56 58|Raf
P10733581A1391|23 32|expression
P10733581A1391|100 112|TTF-1 activity
P10733591A0146|89 90|S6
P10733591A0146|159 175|cell proliferation
P10733591A0146|23 29|targets
P10733591A0146|143 155|transcription
P10733591A0146|116 121|kinase
P10733591A0146|131 140|regulation
P10733591A0146|73 82|activation
P10733591A0146|101 105|c-jun
P10733591A0146|123 125|JNK
P10733591A0146|40 49|remodeling
P10733591A0146|92 97|kinase
P10733591A0146|85 87|p70
P10733591A0146|55 71|actin cytoskeleton
P10733591A0533|0 9|Expression
P10733591A0533|126 139|plasma membrane
P10733591A0533|53 61|PKClambda
P10733591A0533|102 110|PKClambda
P10733591A0533|38 50|translocation
P10733591A0533|94 98|Cdc42
P10733591A0533|21 32|Cdc42 results
P10733591A0533|148 156|cytoplasm
P10733591A0533|69 75|nucleus
P10733591A0533|83 89|cytosol
P10733880X1783|0 8|Copyright
P10733880X1783|13 25|Academic Press
P10734312A0503|120 147|Ras membrane localization motif
P10734312A0503|19 33|Shc localization
P10734312A0503|36 48|membrane rafts
P10734312A0503|153 162|C-terminus
P10734312A0503|71 81|Shc function
P10734312A0503|97 106|Shc chimera
P10735272A0649|104 107|gene
P10735272A0649|139 148|expression
P10735272A0649|194 231|chromosome 19q glioma tumor suppressor gene
P10735272A0649|25 62|strand conformation polymorphism analyses
P10735272A0649|181 185|ANOVA
P10735272A0649|151 165|glioma cell lines
P10735272A0649|87 97|alterations
P10735272A0649|110 116|gliomas
P10735272A0649|120 132|RT-PCR studies
P10735272A0649|0 15|Southern blotting
P10735848A1440|0 3|RegA
P10735848A1440|30 38|regulator
P10735848A1440|41 58|tol-oprL expression
P10736161T0000|0 6|Enzyme I
P10736161T0000|32 60|sugar phosphotransferase system
P10736161T0000|12 30|phosphoenolpyruvate
P10736223A1227|176 188|mRNA stability
P10736223A1227|88 91|PrgX
P10736223A1227|153 163|readthrough
P10736223A1227|12 15|data
P10736223A1227|80 83|prgQ
P10736223A1227|68 77|Qa promoter
P10736223A1227|108 120|transcription
P10736223A1227|31 43|transcription
P10736223A1227|46 49|prgX
P10737366A0280|75 83|threshold
P10737366A0280|109 120|formalin test
P10737366A0280|97 103|stimuli
P10737366A0280|123 126|rats
P10737366A0280|48 51|PTFL
P10738139A0681|34 61|cytokine response pathway genes
P10738139A0681|64 67|KSHV
P10738139A0681|9 15|mimicry
P10738139A0681|23 30|cytokine
P10739408A0896|0 16|Family environment
P10739408A0896|55 67|relationships
P10739408A0896|91 97|support
P10739408A0896|69 80|substance use
P10739408A0896|31 39|influence
P10739671A0136|177 188|fibroblast WI
P10739671A0136|162 171|leukemia HL
P10739671A0136|251 258|fragment
P10739671A0136|97 107|c-myb intron
P10739671A0136|109 132|transcription pause region
P10739671A0136|315 318|IRFs
P10739671A0136|41 46|probes
P10739671A0136|143 150|extracts
P10739671A0136|191 195|cells
P10739671A0136|307 313|factors
P10739671A0136|71 78|segments
P10739671A0136|287 296|interferon
P10739671A0136|327 334|proteins
P10739671A0136|269 280|binding sites
P10739671A0136|233 239|complex
P10739671A0136|2 35|electrophoresis mobility shift assays
P10740602A0141|0 10|STUDY DESIGN
P10740602A0141|41 46|smears
P10740602A0141|12 31|Fine needle aspiration
P10740602A0141|91 96|breast
P10740602A0141|75 83|carcinoma
P10740602A0141|53 57|cases
P10740602A0141|85 87|ILC
P10740602A0141|135 142|analysis
P10741850A0452|74 77|GCSh
P10741850A0452|56 64|sequences
P10741850A0452|170 177|exposure
P10741850A0452|138 150|gene induction
P10741850A0452|81 96|GCSl subunit genes
P10741850A0452|29 33|EpREs
P10741850A0452|0 27|Electrophile Response Elements
P10741947T0000|4 12|technique
P10741947T0000|61 68|hemoclip
P10741947T0000|52 54|LAD
P10741947T0000|33 40|stenosis
P10742114A0486|0 3|Dll3
P10742114A0486|60 66|variety
P10742114A0486|83 89|defects
P10742114A0486|31 35|mouse
P10742114A0486|48 49|pu
P10742114A0486|99 110|SD phenotypes
P10742114A0486|42 46|pudgy
P10742216A0555|0 7|Schlegel
P10742216A0555|9 10|J.
P10743608A1154|116 122|mitosis
P10743608A1154|49 55|TbRAB31
P10743608A1154|181 184|body
P10743608A1154|163 168|manner
P10743608A1154|39 47|cell cycle
P10743608A1154|188 198|kinetoplast
P10743608A1154|82 90|structure
P10743608A1154|226 237|microtubules
P10743608A1154|137 149|daughter cells
P10743608A1154|213 223|involvement
P10743608A1154|0 15|TbRAB31 behaviour
P10743719A0223|13 21|rejection
P10743719A0223|8 9|dg
P10743719A0223|105 124|rejection nephropathy
P10743719A0223|62 71|management
P10743719A0223|82 85|risk
P10743719A0223|40 48|rejection
P10744026A0000|0 9|Invertases
P10744026A0000|50 57|fructose
P10744026A0000|61 67|glucose
P10744026A0000|41 47|sucrose
P10744026A0000|30 38|breakdown
P10744749A0315|103 110|activity
P10744749A0315|53 62|inhibition
P10744749A0315|77 82|effect
P10744749A0315|25 34|mechanisms
P10744749A0315|165 171|factors
P10744749A0315|124 134|MyoD protein
P10744749A0315|151 158|paradigm
P10744749T0000|119 127|KIX domain
P10744749T0000|8 12|T cell
P10744749T0000|77 89|transcription
P10744749T0000|130 133|p300
P10744749T0000|44 53|Tax protein
P10744749T0000|34 42|virus type
P10744974T0000|0 14|Phosphorylation
P10744974T0000|95 99|yeast
P10744974T0000|50 55|Cdc15p
P10744974T0000|18 44|spindle pole body localization
P10744974T0000|73 85|protein kinase
P10745563A0409|100 109|gold stents
P10745563A0409|128 135|capacity
P10745563A0409|140 144|steel
P10745563A0409|12 22|hyperplasia
P10745563A0409|36 48|complications
P10745563A0409|168 182|neo-endothelium
P10747053A1102|30 36|defects
P10747053A1102|181 183|SBF
P10747053A1102|78 81|role
P10747053A1102|169 178|activation
P10747053A1102|187 189|MBF
P10747053A1102|45 49|taf17
P10747053A1102|51 56|slm7-1
P10747053A1102|152 156|TAF17
P10747053A1102|121 130|activation
P10747053A1102|84 86|TAF
P10747053A1102|94 103|modulators
P10747053A1102|3 11|cell cycle
P10747053A1102|145 148|role
P10747099A0507|30 32|ERK
P10747099A0507|23 28|kinase
P10747099A0507|112 114|CAS
P10747099A0507|56 63|coupling
P10747099A0507|119 125|c-CrkII
P10747099A0507|102 110|substrate
P10747099A0507|229 242|collagen matrix
P10747099A0507|191 195|cells
P10747099A0507|127 129|Crk
P10747099A0507|200 208|apoptosis
P10747099A0507|69 87|adaptor proteins p130
P10747099A0507|169 180|cell invasion
P10747099A0507|151 158|pathways
P10747099A0507|34 43|activation
P10747782A0390|58 63|extent
P10747782A0390|35 43|complexes
P10747782A0390|104 112|molecules
P10747782A0390|13 16|Mbp1
P10747782A0390|138 155|DNA binding activity
P10747782A0390|169 179|core domains
P10747782A0390|20 23|Swi4
P10747782A0390|71 79|sequences
P10747782A0390|0 10|Proteolysis
P10747879A0607|54 65|reading frame
P10747879A0607|104 115|reading frame
P10747879A0607|35 40|region
P10747879A0607|88 94|domains
P10747879A0607|3 11|evolution
P10747879A0607|17 20|CCR5
P10747890A1096|145 151|lesions
P10747890A1096|5 11|results
P10747890A1096|108 127|base pair interactions
P10747890A1096|24 30|residue
P10747890A1096|44 56|protein sensor
P10747890A1096|72 89|groove interactions
P10747987A0658|14 20|enzymes
P10747987A0658|28 35|monomers
P10748054T0048|1 7|pathway
P10748054T0048|11 20|regulation
P10748054T0048|23 40|B lymphocyte antigen
P10748054T0048|57 67|calcium flux
P10748113A0187|97 101|brain
P10748113A0187|37 40|RIM2
P10748113A0187|20 29|RIM protein
P10748113A0187|66 69|RIM1
P10748125A0000|0 10|Inhibitor-1
P10748125A0000|53 56|type
P10748125A0000|19 29|inhibitor-2
P10748125A0000|94 96|PP1
P10748125A0000|12 14|I-1
P10748125A0000|58 92|protein serine/threonine phosphatases
P10748125A0000|31 33|I-2
P10748164A1284|30 38|AC element
P10748164A1284|53 61|induction
P10748164A1284|115 121|factors
P10748164A1284|137 142|probes
P10748164A1284|124 125|AC
P10748164A1284|162 168|factors
P10748164A1284|97 101|sites
P10748164A1284|0 16|Scanning mutations
P10748175A0000|129 140|transporters
P10748175A0000|46 50|Golgi
P10748175A0000|3 12|substrates
P10748175A0000|64 69|sugars
P10748175A0000|36 40|lumen
P10748175A0000|16 30|glycan synthesis
P10748175A0000|98 104|cytosol
P10748194T0000|34 53|density protein PSD-95
P10748194T0000|79 95|trafficking signal
P10748194T0000|8 16|targeting
P10748204A0238|6 7|J.
P10748672A0130|0 4|Bites
P10748672A0130|92 98|failure
P10748672A0130|19 24|adders
P10748672A0130|10 16|species
P10748672A0130|26 36|Vipera aspis
P10748672A0130|40 50|Vipera berus
P10749145T0000|150 159|kinase ERK1
P10749145T0000|25 36|PCPH proteins
P10749145T0000|106 108|Ras
P10749145T0000|81 91|oncoprotein
P10749145T0000|50 70|diphosphatase activity
P10749166A0991|150 157|bacteria
P10749166A0991|164 176|A. tumefaciens
P10749166A0991|5 11|results
P10749166A0991|119 128|B. henselae
P10749166A0991|44 48|genes
P10749166A0991|75 85|arrangement
P10749849A0000|83 97|cell cycle arrest
P10749849A0000|155 163|WAF1/Cip1
P10749849A0000|64 72|stability
P10749849A0000|136 153|kinase inhibitor p21
P10749849A0000|105 114|activation
P10749849A0000|11 19|mechanism
P10749849A0000|30 47|tumor suppressor p53
P10749849A0000|165 168|gene
P10749932A0000|0 7|Paxillin
P10749932A0000|33 49|integrin signaling
P10749932A0000|16 30|adaptor molecule
P10750020A0843|58 70|ER/Sp1 binding
P10750020A0843|104 110|pathway
P10750020A0843|41 55|transactivation
P10750020A0843|5 26|growth factor activation
P10750020A0843|80 84|sites
P10750020A0843|132 139|ER action
P10750020A0843|29 30|ER
P10750021A0728|74 81|activity
P10750021A0728|114 115|P2
P10750021A0728|106 111|region
P10750021A0728|12 19|analysis
P10750021A0728|22 56|deletion promoter-reporter constructs
P10750021A0728|84 85|P2
P10750524A0724|0 6|RESULTS
P10750524A0724|128 128|p
P10750524A0724|77 86|proportion
P10750524A0724|16 25|thresholds
P10750524A0724|52 56|tests
P10750524A0724|122 126|group
P10750524A0724|91 93|age
P10751398A1135|88 92|virus
P10751398A1135|2 9|addition
P10751398A1135|99 113|membrane protein
P10751398A1135|70 73|CD40
P10751398A1135|14 26|transcription
P10751398A1135|29 42|c-IAP2 promoter
P10752450A0288|1 7|variety
P10752450A0288|116 121|market
P10752450A0288|37 52|fluoride products
P10752450A0288|71 93|fluoride delivery systems
P10752475A1376|118 125|ligation
P10752475A1376|224 233|antibodies
P10752475A1376|286 296|mouse models
P10752475A1376|128 131|CD20
P10752475A1376|260 275|tumor regressions
P10752475A1376|190 194|cells
P10752475A1376|308 313|trials
P10752475A1376|158 165|presence
P10752475A1376|70 78|apoptosis
P10752475A1376|216 222|mouse Ig
P10752475A1376|5 11|studies
P10752475A1376|143 152|antibodies
P10752475A1376|90 95|B cells
P10752475A1376|32 56|signal-transduction events
P10752475A1376|206 209|goat
P10752807A1598|0 9|CONCLUSION
P10752807A1598|11 19|Treatment
P10752807A1598|106 113|survival
P10752807A1598|54 75|factor antagonist BB-882
P10752807A1598|144 151|function
P10752807A1598|22 27|sepsis
P10752807A1598|97 103|placebo
P10752807A1598|155 172|organ failure scores
P10752807A1598|126 131|status
P10752807A1598|84 92|advantage
P10753553T0000|0 8|Phenazone
P10753553T0000|39 44|effect
P10753553T0000|58 61|mice
P10753553T0000|47 55|lidocaine
P10754312A0798|28 35|proteins
P10754312A0798|3 12|solubility
P10756007A0575|74 79|genome
P10756007A0575|18 29|RBE sequences
P10756007A0575|55 63|locations
P10756007A1512|0 9|EM analysis
P10756007A1512|40 46|complex
P10756007A1512|58 71|ch-19 target DNA
P10756020A0571|3 9|protein
P10756020A0571|92 98|virions
P10756020A0571|35 56|vaccinia virus particles
P10756020A0571|64 72|membranes
P10756020A0571|147 151|cells
P10756020A0571|119 136|electron microscopy
P10756032A0599|130 134|cells
P10756032A0599|90 105|hypersensitivity
P10756032A0599|77 86|protection
P10756032A0599|38 52|cyclin E promoter
P10756032A0599|6 32|dimethyl sulfate footprinting
P10756032A0599|68 74|regions
P10756094A0671|53 68|marker resolution
P10756094A0671|92 93|kb
P10756094A0671|35 36|Mb
P10756094A0671|11 14|STSs
P10756094A0671|1 5|total
P10756094A0671|24 31|interval
P10756100A0457|59 66|diabetes
P10756100A0457|23 36|amino-terminus
P10756100A0457|10 17|mutation
P10756100A0457|39 41|IB1
P10756225A1464|85 92|response
P10756225A1464|45 52|rhinitis
P10756225A1464|21 21|%
P10756225A1464|24 31|patients
P10756225A1464|76 82|surgery
P10756225A1464|117 121|cells
P10756225A1464|132 139|IL-5 mRNA
P10756225A1464|56 58|CRS
P10756225A1464|145 158|ethmoid sinuses
P10756225A1464|0 9|CONCLUSION
P10757975A0509|0 3|Biol
P10757983A0733|12 15|size
P10757983A0733|20 30|CRS sequence
P10757983A0733|137 153|zinc finger protein
P10757983A0733|156 175|mouse ZBP-89 homologue
P10757983A0733|5 9|basis
P10757983A0733|61 74|identification
P10757983A0733|78 94|zinc finger protein
P10757983A0733|96 104|Adx factor
P10758289A0141|0 6|METHODS
P10758289A0141|121 129|specimens
P10758289A0141|21 32|muscle fibres
P10758289A0141|96 107|pisiform bone
P10758289A0141|58 70|finger flexors
P10758489A0206|28 31|ICK2
P10758489A0206|103 109|Cdc2bAt
P10758489A0206|59 65|Cdc2aAt
P10758489A0206|84 86|CDK
P10758489A0206|17 25|isolation
P10758489A0206|91 101|Arabidopsis
P10758726T0000|28 39|arrangements
P10758726T0000|8 13|impact
P10759693A0201|0 6|METHODS
P10759693A0201|223 227|users
P10759693A0201|250 258|phenytoin
P10759693A0201|132 141|antagonist
P10759693A0201|211 220|nizatidine
P10759693A0201|22 30|odds ratio
P10759693A0201|181 196|agents ranitidine
P10759693A0201|198 207|famotidine
P10759693A0201|89 99|interaction
P10759693A0201|59 62|risk
P10759693A0201|241 248|warfarin
P10759693A0201|39 45|measure
P10759693A0201|231 238|nonusers
P10759693A0201|262 273|theophylline
P10759693A0201|32 33|OR
P10759693A0201|113 115|use
P10759693A0201|143 152|cimetidine
P10760109A1050|86 86|%
P10760109A1050|180 194|blood hemoglobin
P10760109A1050|103 110|patients
P10760109A1050|144 154|plasma IGF-1
P10760109A1050|172 174|SCr
P10760109A1050|88 88|P
P10760109A1050|134 137|tHcy
P10760109A1050|40 47|patients
P10760109A1050|15 26|malnutrition
P10760109A1050|156 170|serum creatinine
P10760109A1050|115 117|CVD
P10760109A1050|55 57|CVD
P10760109A1050|32 32|%
P10760109A1050|3 12|prevalence
P10760109A1050|139 142|SAlb
P10760132A1169|70 87|protein prenylation
P10760132A1169|112 130|vesicle polarization
P10760132A1169|60 64|level
P10760132A1169|32 42|temperature
P10760132A1169|3 6|data
P10760169A1142|56 83|transcription initiation sites
P10760169A1142|25 33|CreA sites
P10760169A1142|19 22|pair
P10760950A1133|30 39|N-utrophin
P10760950A1133|9 23|staining pattern
P10760950A1133|93 109|actin stress fibers
P10761263A1108|14 18|model
P10761263A1108|123 138|prostate patients
P10761263A1108|34 42|Hotelling
P10761263A1108|103 114|displacement
P10761263A1108|45 55|T2 statistic
P10761263A1108|4 12|Newcastle
P10762254A0954|115 135|TMA methyltransferases
P10762254A0954|65 88|MMA methyltransferase gene
P10762254A0954|7 9|DMA
P10762254A0954|93 97|genes
P10762254A0954|162 171|amber codon
P10762254A0954|3 5|MMA
P10762254A0954|109 111|DMA
P10762254A0954|14 34|TMA methyltransferases
P10762254A0954|41 48|homologs
P10762348A0269|86 93|activity
P10762348A0269|54 60|nucleus
P10762348A0269|5 19|phosphorylation
P10762348A0269|21 32|STAT proteins
P10763823A0824|0 13|Overexpression
P10763823A0824|64 75|transfection
P10763823A0824|93 99|plasmid
P10763823A0824|49 57|apoptosis
P10763823A0824|106 114|cell death
P10763823A0824|79 83|mcl-1
P10763823A0824|16 20|mcl-1
P10763827A1158|139 155|senescence program
P10763827A1158|64 74|ras oncogene
P10763827A1158|76 87|inactivation
P10763827A1158|53 60|response
P10763827A1158|90 106|TGFbeta1 secretion
P10763827A1158|21 38|senescence pathways
P10763827A1158|109 116|response
P10764150A0000|15 23|abilities
P10764150A0000|110 120|FDC-P1 cells
P10764150A0000|90 107|cytokine dependency
P10764150A0000|52 56|forms
P10764150A0000|6 10|study
P10764150A0000|67 76|Raf kinases
P10764574A0718|0 10|Application
P10764574A0718|60 78|Arabidopsis thaliana
P10764574A0718|51 55|genes
P10764574A0718|109 126|prediction accuracy
P10764574A0718|152 167|alignment methods
P10764574A0718|39 41|set
P10764574A0718|96 106|improvement
P10764574A0718|16 21|method
P10764729A1846|71 85|accession number
P10764729A1846|66 67|TM
P10764729A1846|11 22|cDNA sequence
P10764729A1846|30 42|betaV spectrin
P10764729A1846|58 64|GenBank
P10764760T0000|0 14|Transactivation
P10764760T0000|64 82|JNK signaling pathway
P10764760T0000|52 58|repeats
P10764760T0000|35 39|HIV-1
P10764802A1258|43 46|Kip2
P10764802A1258|155 163|mechanism
P10764802A1258|212 214|p57
P10764802A1258|257 271|differentiation
P10764802A1258|39 41|p57
P10764802A1258|115 125|interaction
P10764802A1258|193 200|activity
P10764802A1258|216 219|Kip2
P10764802A1258|5 8|data
P10764802A1258|31 36|domain
P10764802A1258|221 233|family members
P10764802A1258|70 84|Cip/Kip proteins
P10764970A1009|88 92|cases
P10764970A1009|21 45|quinupristin/dalfopristin
P10764970A1009|210 217|practice
P10764970A1009|9 18|resistance
P10764970A1009|157 168|introduction
P10764970A1009|3 6|mode
P10764970A1009|140 147|isolates
P10764970A1009|106 114|existence
P10764970A1009|188 192|class
P10764970A1009|75 77|PCR
P10765095A0308|200 211|PRL secretion
P10765095A0308|192 196|tests
P10765095A0308|113 118|L-Dopa
P10765095A0308|88 97|conditions
P10765095A0308|55 76|prostate cancer patients
P10765095A0308|122 135|metoclopramide
P10765095A0308|103 110|response
P10765095A0308|4 8|study
P10765095A0308|31 42|PRL secretion
P10766246A0000|0 24|Integrin adhesion receptors
P10766246A0000|99 112|gene expression
P10766246A0000|59 71|cell functions
P10766246A0000|87 96|regulation
P10766246A0000|34 40|signals
P10766246A0000|152 159|survival
P10766246A0000|120 132|proliferation
P10766246A0000|134 148|differentiation
P10766493T0000|0 12|Recombination
P10766493T0000|26 31|repair
P10766493T0000|14 24|replication
P10766493T0000|37 46|complexity
P10766493T0000|49 55|harmony
P10766556T0000|3 21|somatoform conundrum
P10766556T0000|24 31|question
P10766556T0000|45 50|valves
P10767091A0133|15 24|ultrasound
P10767091A0133|26 29|IOUS
P10767091A0133|52 58|attempt
P10767091A0133|193 202|techniques
P10767091A0133|151 167|image obliteration
P10767091A0133|126 146|inter-user variability
P10767091A0133|74 85|difficulties
P10767091A0133|119 124|nature
P10767251A1046|146 154|pressures
P10767251A1046|54 60|sealant
P10767251A1046|104 117|lung resections
P10767251A1046|84 93|air leakage
P10767251A1046|40 47|Vivostat
P10767251A1046|26 30|study
P10767251A1046|120 123|pigs
P10767251A1046|0 10|CONCLUSIONS
P10767338T0000|30 38|mutations
P10767338T0000|61 62|Ca
P10767338T0000|13 19|disease
P10767338T0000|67 70|pump
P10767338T0000|41 46|ATP2C1
P10767553A0100|0 2|Hex
P10767553A0100|66 89|helix transcription factor
P10767553A0100|108 118|Factor 3beta
P10767553A0100|91 100|Hepatocyte
P10767553A0100|120 127|HNF3beta
P10767553A0100|29 33|liver
P10767560A0105|28 43|characterization
P10767560A0105|172 184|transcription
P10767560A0105|126 147|mouse Pkr promoter region
P10767560A0105|77 88|mouse Pkr gene
P10767560A0105|4 12|extension
P10767560A0105|60 71|organization
P10769144A0000|43 59|consensus sequence
P10769144A0000|66 76|cis-element
P10769144A0000|10 19|TGACGTCA-3
P10769144A0000|3 5|CRE
P10769144A0000|102 115|gene expression
P10770041A0731|44 48|right
P10770041A0731|97 100|size
P10770041A0731|65 75|kidney width
P10770041A0731|105 105|p
P10770041A0731|85 93|thickness
P10770041A0731|0 11|Kidney length
P10770065A0264|57 75|lymph node dissection
P10770065A0264|21 26|T1N0M0
P10770065A0264|11 15|stage
P10770065A0264|77 77|R
P10770065A0264|79 79|b
P10770065A0264|32 52|S2 sleeve segmentectomy
P10770471T0000|0 10|Benztropine
P10770471T0000|33 43|night sweats
P10771528T0036|1 5|cause
P10771528T0036|39 46|children
P10771528T0036|8 15|increase
P10771528T0036|18 36|alkaline phosphatase
P10771709A0291|26 33|patients
P10771709A0291|80 87|presence
P10771709A0291|202 214|questionnaire
P10771709A0291|103 108|Q fever
P10771709A0291|90 92|IgM
P10771709A0291|15 20|charge
P10771709A0291|158 173|Coxiella burnetii
P10771709A0291|132 147|IgG antibody titer
P10771709A0291|150 155|phase I
P10771709A0291|119 125|disease
P10771709A0291|38 45|evidence
P10771709A0291|60 73|seroconversion
P10771709A0291|53 58|Q fever
P10771709A0291|3 12|physicians
P10772856X1492|0 8|Copyright
P10772856X1492|13 25|Academic Press
P10772977A0222|17 24|movement
P10772977A0222|27 37|PVX CP mutant
P10772977A0222|55 72|Nicotiana tabacum cv
P10773351A0672|131 138|elements
P10773351A0672|53 61|IFN-gamma
P10773351A0672|40 48|U937 cells
P10773351A0672|11 24|CD86 expression
P10773351A0672|27 37|stimulation
P10773351A0672|73 80|presence
P10773351A0672|96 98|GAS
P10773351A0672|100 129|gamma-interferon activation site
P10773351A0672|0 8|Induction
P10773455A1268|204 211|MEL cells
P10773455A1268|154 163|activation
P10773455A1268|39 43|sites
P10773455A1268|273 277|ALAS2
P10773455A1268|69 74|region
P10773455A1268|105 122|mouse ALAS2 promoter
P10773455A1268|98 99|bp
P10773455A1268|226 235|importance
P10773455A1268|257 267|specificity
P10773455A1268|293 302|activation
P10773455A1268|187 201|differentiation
P10773458A0000|0 6|SNAP-23
P10773458A0000|44 61|vesicle trafficking
P10773458A0000|23 26|role
P10773458A0000|32 41|regulation
P10773458A0000|73 77|cells
P10773667A0351|70 70|%
P10773667A0351|52 61|yeast NHP6A
P10773667A0351|18 30|HMG20 proteins
P10773667A0351|65 65|%
P10773667A0351|3 11|HMG domain
P10773951A0000|13 13|A
P10773951A0000|73 86|O group husbands
P10773951A0000|50 62|O group mothers
P10773951A0000|21 35|B antibody status
P10773951A0000|6 8|IgG
P10773951A0000|0 2|IgM
P10775038A0142|43 51|cell cycle
P10775038A0142|23 36|Wee1 regulation
P10775038A0142|106 112|protein
P10775038A0142|53 57|yeast
P10775038A0142|114 114|s
P10775038A0142|4 10|attempt
P10775038A0142|68 76|screening
P10775267A0363|147 156|pre-B-cell
P10775267A0363|104 106|BMT
P10775267A0363|108 112|model
P10775267A0363|24 26|T/T
P10775267A0363|10 21|transduction
P10775267A0363|170 177|lymphoma
P10775267A0363|28 28|L
P10775267A0363|83 102|bone marrow transplant
P10775267A0363|125 125|F
P10775267A0363|67 73|disease
P10775267A0363|121 123|T/T
P10775267A0363|134 145|long-latency
P10775585A0754|178 190|kinase pathway
P10775585A0754|23 28|P70/S2
P10775585A0754|104 118|signaling events
P10775585A0754|174 176|MAP
P10775585A0754|166 172|protein
P10775585A0754|46 56|NIH 3T3 cells
P10775585A0754|0 12|Ab-MLV strains
P10775585A0754|87 94|capacity
P10775623A0120|3 12|codon usage
P10775623A0120|50 57|env genes
P10775623A0120|39 41|gag
P10775623A0120|43 45|pol
P10777217A0536|100 107|residues
P10777217A0536|92 98|p73beta
P10777217A0536|140 151|PIG3 promoter
P10777217A0536|55 62|contrast
P10777217A0536|65 67|p53
P10777217A0536|37 48|PIG3 promoter
P10777217A0536|84 89|domain
P10777217A0536|3 20|p53-homolog p73beta
P10777499A0883|0 6|Results
P10777499A0883|94 94|B
P10777499A0883|78 89|phytochromes
P10777499A0883|67 73|signals
P10777499A0883|56 58|DE1
P10777499A0883|20 25|assays
P10777499A0883|36 42|mutants
P10777499A0883|149 155|element
P10777499A0883|117 123|element
P10777586A1022|0 21|Co-immunoprecipitation
P10777586A1022|59 61|Sp1
P10777586A1022|213 227|band shift assays
P10777586A1022|25 49|DNA affinity chromatography
P10777586A1022|81 86|ZBP-89
P10777586A1022|193 196|HeLa
P10777586A1022|101 115|silencer element
P10777586A1022|135 141|complex
P10777586A1022|204 210|extract
P10777586A1022|147 154|mobility
P10777669A0582|3 12|ZNF274 gene
P10777669A0582|76 84|RH mapping
P10777669A0582|29 39|marker RP S28
P10777669A0582|51 72|chromosome 19qter region
P10778740A1493|88 95|activity
P10778740A1493|142 146|pho85
P10778740A1493|13 27|Cdk2 truncations
P10778740A1493|164 168|locus
P10778740A1493|149 152|HIS3
P10778740A1493|112 117|region
P10778740A1493|62 68|strains
P10778740A1493|101 105|pho85
P10778757A0000|157 161|INCW2
P10778757A0000|79 84|allele
P10778757A0000|139 155|cell wall invertase
P10778757A0000|101 103|Mn1
P10778757A0000|105 113|seed locus
P10778757A0000|90 99|Miniature1
P10778757A0000|47 52|mutant
P10778757A0000|54 59|mn1-89
P10778757A0000|26 31|nature
P10779313A1842|40 53|Xenopus oocytes
P10779313A1842|182 185|beta
P10779313A1842|105 116|GIRK channels
P10779313A1842|121 127|pathway
P10779313A1842|70 80|stimulation
P10779313A1842|153 167|phosphorylation
P10779313A1842|189 190|AR
P10779313A1842|27 34|myocytes
P10779329T0000|0 3|Slap
P10779329T0000|23 25|Src
P10779329T0000|35 42|function
P10779329T0000|70 90|cell morphology changes
P10779352T0000|0 13|Identification
P10779352T0000|22 32|E2F3 product
P10779352T0000|78 87|repression
P10779352T0000|90 99|Rb proteins
P10779352T0000|65 75|specificity
P10779352T0000|42 50|mechanism
P10779508A0452|43 46|SFRE
P10779508A0452|8 37|footprinting protection analysis
P10779508A0452|75 121|glutathione S-transferase-ERRalpha1 fusion protein
P10779508A0452|50 59|ERE regions
P10779508A0452|2 6|DNase
P10779508A0897|29 33|SRC1a
P10779508A0897|36 40|GRIP1
P10779508A0897|89 96|activity
P10779508A0897|17 27|coactivator
P10779508T0000|0 7|Estrogen
P10779508T0000|51 61|coactivator
P10779508T0000|24 36|receptor alpha
P10779508T0000|125 139|lactoferrin gene
P10779508T0000|91 114|estrogen response elements
P10780018A0539|16 21|models
P10780018A0539|36 40|aging
P10780018A0539|47 58|response time
P10780018A0539|27 33|effects
P10780518A1270|28 42|protein function
P10780518A1270|57 67|examination
P10780518A1270|3 9|effects
P10780518A1270|17 25|mutations
P10780764A0722|116 120|range
P10780764A0722|65 68|PM10
P10780764A0722|9 14|levels
P10780764A0722|76 81|microm
P10780764A0722|51 59|diameters
P10780764A0722|17 25|particles
P10780764A0722|83 85|PM2
P10780764A0722|133 136|x m-3
P10780764A0722|32 32|%
P10780764A0722|97 101|range
P10780883T0000|107 112|effect
P10780883T0000|26 36|herpesvirus
P10780883T0000|75 84|resistance
P10780883T0000|115 130|interferon-alpha
P10780883T0000|42 51|interferon
P10780883T0000|0 5|Kaposi
P10780883T0000|62 67|factor
P10781109T0000|61 79|Arabidopsis thaliana
P10781109T0000|27 38|interference
P10781109T0000|56 58|RNA
P10781423A0993|0 9|Comparison
P10781423A0993|33 34|bp
P10781423A0993|12 20|sequences
P10781423A0993|131 135|TTF-1
P10781423A0993|45 65|consensus binding sites
P10781423A0993|72 129|homeodomain transcription factor thyroid transcription factor-1
P10781541A1063|98 101|role
P10781541A1063|23 31|sequences
P10781541A1063|62 70|promoters
P10781541A1063|168 176|promoters
P10781541A1063|51 56|region
P10781541A1063|110 118|sequences
P10781541A1063|146 158|transcription
P10781541A1063|134 143|regulation
P10781552A0000|0 5|Purple
P10781552A0000|107 117|respiration
P10781552A0000|92 105|photosynthesis
P10781552A0000|126 134|oxidation
P10781552A0000|58 63|energy
P10781552A0000|20 27|bacteria
P10781552A0000|75 81|sources
P10781552A0000|122 122|H
P10781604A0827|2 9|analysis
P10781604A0827|89 100|Rsp5 WW domain
P10781604A0827|102 108|Rsp5 WW2
P10781604A0827|137 142|assays
P10781604A0827|122 126|yeast
P10781604A0827|21 28|peptides
P10781604A0827|45 55|CTD sequence
P10781611A1023|30 40|macrophages
P10781611A1023|12 15|bone
P10781611A1023|139 142|mice
P10781611A1023|100 109|comparison
P10781611A1023|115 125|macrophages
P10781611A1023|58 61|mice
P10781611A1023|88 97|efficiency
P10781990A0455|74 92|hyperintense lesions
P10781990A0455|11 13|MRI
P10781990A0455|36 38|day
P10781990A0455|98 111|globus pallidus
P10782640A0444|101 111|astigmatism
P10782640A0444|51 71|CM300 FEG/UT microscope
P10782640A0444|76 85|correction
P10782640A0444|3 8|method
P10782640A0444|29 47|aberration constants
P10782989A0575|115 130|DNA binding domain
P10782989A0575|144 153|amino acids
P10782989A0575|66 81|DNA binding domain
P10782989A0575|87 104|amino acid sequences
P10782989A0575|32 39|presence
P10782989A0575|3 13|interaction
P10784367A0133|0 5|METHOD
P10784367A0133|125 132|subjects
P10784367A0133|10 15|sample
P10784367A0133|180 187|patients
P10784367A0133|166 170|study
P10784367A0133|146 154|disorders
P10784367A0133|100 104|study
P10784367A0133|18 25|subjects
P10784367A0133|205 213|disorders
P10784367A0133|41 72|Suffolk County Mental Health Project
P10784393A0000|0 14|Marrow dysplasia
P10784393A0000|23 36|characteristic
P10784393A0000|105 113|cytopenia
P10784393A0000|66 73|syndrome
P10784393A0000|128 136|anomalies
P10784393A0000|39 46|patients
P10784393A0000|75 77|MDS
P10784393A0000|89 103|marrow blastosis
P10785294A0720|55 66|restorations
P10785294A0720|24 36|inlays/onlays
P10785294A0720|113 126|resin composite
P10785294A0720|93 96|ones
P10785668A0000|146 155|ecologists
P10785668A0000|89 95|subject
P10785668A0000|110 117|research
P10785668A0000|49 57|pathogens
P10785668A0000|36 45|herbivores
P10785668A0000|29 33|range
P10785668A0000|18 23|attack
P10785668A0000|133 142|biologists
P10785668A0000|79 83|field
P10785668A0000|3 8|plants
P10785880A0947|0 9|CONCLUSION
P10785880A0947|96 100|class
P10785880A0947|42 54|complications
P10785880A0947|81 88|patients
P10785880A0947|102 114|HELLP syndrome
P10785880A0947|14 24|probability
P10786671A0182|144 148|hTERT
P10786671A0182|53 62|expression
P10786671A0182|113 122|telomerase
P10786671A0182|77 83|subunit
P10786671A0182|150 153|gene
P10786671A0182|23 40|telomerase activity
P10786671A0182|89 94|enzyme
P10786671A0182|16 19|step
P10786671A0182|130 142|transcriptase
P10786742A0670|43 43|h
P10786742A0670|49 55|surgery
P10786742A0670|5 16|control group
P10786742A0670|18 32|platelet markers
P10787437A1616|69 73|SRE-1
P10787437A1616|11 17|element
P10787437A1616|31 52|transcription start site
P10787804T0000|0 3|AMDA
P10787804T0000|9 13|paper
P10787804T0000|24 27|ways
P10787804T0000|51 54|care
P10787804T0000|57 60|SNFs
P10788320A1034|163 173|U4/U6 snRNPs
P10788320A1034|158 159|U5
P10788320A1034|79 90|interactions
P10788320A1034|108 119|102kD protein
P10788320A1034|23 33|TPR elements
P10788320A1034|193 201|particles
P10788320A1034|138 146|tri-snRNP
P10788320A1034|5 12|proteins
P10788476A0891|0 9|Antibodies
P10788476A0891|126 143|stomatitis G protein
P10788476A0891|158 166|cell assay
P10788476A0891|78 94|ER-Golgi transport
P10788476A0891|34 40|portion
P10788476A0891|43 67|Sec31A co-precipitate Sec13
P10788480T0000|0 9|Regulation
P10788480T0000|51 76|protein gene expression links
P10788480T0000|116 125|drosophila
P10788480T0000|100 113|DNA replication
P10790390X0000|262 275|gene expression
P10790390X0000|218 240|gypsy insulator sequences
P10790390X0000|160 172|gene silencing
P10790390X0000|71 74|mdg4
P10790390X0000|135 141|variety
P10790390X0000|19 28|complexity
P10790390X0000|110 110|E
P10790390X0000|209 215|control
P10790390X0000|112 114|var
P10790390X0000|242 251|regulation
P10790390X0000|34 69|position effect variegation modifier mod
P10790390X0000|93 96|mdg4
P10790390X0000|116 120|3-93D
P10790390X0000|144 152|processes
P10790390X0000|201 203|PEV
P10790390X0000|290 298|cell death
P10790390X0000|175 199|position effect variegation
P10790390X0000|89 91|mod
P10791251A0110|48 56|functions
P10791251A0110|75 80|humans
P10791251A0110|33 38|things
P10791251A0110|20 24|kinds
P10791819A0771|4 11|tendency
P10791819A0771|104 112|selection
P10791819A0771|60 74|asparagus genome
P10791819A0771|124 129|codons
P10791819A0771|34 54|nucleotide composition
P10791901A0609|57 77|MRP1-PG13 supernatants
P10791901A0609|123 123|%
P10791901A0609|194 201|presence
P10791901A0609|126 140|target K562 cells
P10791901A0609|30 41|cell line K562
P10791901A0609|98 105|MRP1 gene
P10791901A0609|234 242|etoposide
P10791901A0609|218 231|concentrations
P10791901A0609|0 11|Transduction
P10792583A0000|0 9|Regulation
P10792583A0000|110 113|ACTH
P10792583A0000|130 139|adaptation
P10792583A0000|142 147|stress
P10792583A0000|21 43|vasopressin V1b receptors
P10792583A0000|115 123|secretion
P10792583A0000|58 61|role
P10792583A0000|102 108|hormone
P10792718T0000|0 13|Identification
P10792718T0000|76 84|regulator
P10792718T0000|18 30|AfsA homologue
P10792718T0000|32 35|BarX
P10792718T0000|96 120|autoregulator biosynthesis
P10792718T0000|122 146|virginiamycin biosynthesis
P10792718T0000|150 174|virginiamycin M1 resistance
P10793143A1533|57 64|Abf1 ARS1
P10793143A1533|153 162|initiation
P10793143A1533|88 94|results
P10793143A1533|76 83|activity
P10793143A1533|121 128|activity
P10793143A1533|165 178|DNA replication
P10793143A1533|106 109|Cdc6
P10793143A1533|27 36|DNA binding
P10793143A1533|144 147|role
P10793991A0569|16 24|longevity
P10793991A0569|90 101|telemedicine
P10793991A0569|65 72|position
P10793991A0569|34 47|TIE researchers
P10793991A0569|30 32|Web
P10793991A0569|82 87|trends
P10794405A0000|127 128|H1
P10794405A0000|86 89|step
P10794405A0000|99 111|understanding
P10794405A0000|13 17|study
P10794405A0000|131 139|chromatin
P10794405A0000|50 56|domains
P10794405A0000|20 27|peptides
P10794405A0000|117 124|function
P10794405A0000|59 67|histone H1
P10794936A0241|143 143|%
P10794936A0241|208 208|%
P10794936A0241|22 28|MB/BacT
P10794936A0241|109 121|recovery rates
P10794936A0241|46 50|media
P10794936A0241|243 254|mycobacteria
P10794936A0241|161 181|M. tuberculosis complex
P10794936A0241|30 33|MGIT
P10794936A0241|93 104|mycobacteria
P10794936A0241|3 15|recovery rates
P10794936A0241|72 72|%
P10795098A0253|29 33|Crohn
P10795098A0253|61 70|phenomenon
P10795098A0253|36 42|disease
P10795098A0253|8 17|vasculitis
P10796465A0373|60 70|acupuncture
P10796465A0373|98 105|symptoms
P10796465A0373|78 83|asthma
P10796465A0373|49 54|trials
P10796465A0373|0 16|SELECTION CRITERIA
P10796486A0817|0 16|SELECTION CRITERIA
P10796486A0817|114 129|asthma medication
P10796486A0817|71 77|therapy
P10796486A0817|28 33|trials
P10796486A0817|135 142|children
P10796486A0817|43 50|children
P10796486A0817|99 109|conjunction
P10796486A0817|91 96|family
P10796486A0817|149 164|asthma medication
P10797125A0000|59 73|core temperature
P10797125A0000|248 255|exercise
P10797125A0000|107 119|sweating onset
P10797125A0000|205 218|passive heating
P10797125A0000|222 229|degrees C
P10797125A0000|160 164|women
P10797125A0000|243 245|min
P10797125A0000|137 144|estrogen
P10797125A0000|80 103|core temperature threshold
P10797125A0000|179 190|degrees C rest
P10797125A0000|260 268|degrees C.
P10797125A0000|9 18|hypothesis
P10797125A0000|41 49|increases
P10797125A0000|172 173|yr
P10797125A0000|200 202|min
P10797586A0402|82 88|bladder
P10797586A0402|69 74|signal
P10797586A0402|34 41|response
P10797586A0402|44 55|disturbances
P10797586A0402|3 8|models
P10798607A1359|29 35|killing
P10798607A1359|38 49|meningococci
P10798607A1359|123 130|immunity
P10798607A1359|157 164|patients
P10798607A1359|75 79|assay
P10798607A1359|3 6|data
P10798607A1359|84 102|antibody titer levels
P10799501A1391|74 87|SPRK activation
P10799501A1391|50 60|environment
P10799501A1391|90 94|Cdc42
P10799501A1391|5 11|studies
P10799501A1391|31 39|component
P10799576A0196|0 1|M.
P10799590A0431|0 5|Jkappa
P10799590A0431|106 118|transcription
P10799590A0431|91 96|Jkappa
P10799590A0431|232 237|Jkappa
P10799590A0431|143 149|EBNA-3C
P10799590A0431|165 171|EBNA-3C
P10799590A0431|44 53|activation
P10799590A0431|183 195|transcription
P10799590A0431|65 78|EBNA-3C protein
P10799590A0431|17 21|sites
P10799590A0431|204 212|mechanism
P10799595A1454|74 88|HPV-6 E1 promoter
P10799595A1454|102 113|HPV life cycle
P10799595A1454|36 45|regulators
P10799595A1454|9 11|YY1
P10799595A1454|15 17|CDP
P10799863T0000|101 108|MHC class
P10799863T0000|110 128|antigen presentation
P10799863T0000|10 17|cleavage
P10799863T0000|40 50|proteasomes
P10799863T0000|20 36|metallopeptidases
P10799863T0000|73 87|HIV-1 ENV epitope
P10799879T0000|0 6|Cloning
P10799879T0000|10 25|characterization
P10799879T0000|78 88|Src homology
P10799879T0000|111 125|T cell activation
P10799879T0000|90 96|domains
P10799879T0000|39 52|adaptor protein
P10799879T0000|57 74|pleckstrin homology
P10799879T0000|33 35|Lnk
P10801244A0578|0 13|Vancomycin data
P10801244A0578|57 61|model
P10801244A0578|66 68|use
P10801244A0578|71 86|NONMEM population
P10801244A0578|102 109|software
P10801330A1714|133 135|FAK
P10801330A1714|77 81|state
P10801330A1714|36 64|membrane cytoskeleton fractions
P10801330A1714|8 10|Cas
P10801330A1714|26 32|cytosol
P10801330A1714|109 127|platelet aggregation
P10801330A1714|165 172|fraction
P10801482A0968|14 16|p65
P10801482A0968|29 35|targets
P10801482A0968|51 58|affinity
P10801482A0968|75 82|residues
P10801482A0968|95 99|roles
P10801482A0968|118 130|kappaB targets
P10801809T0000|30 46|yeast PHO8 promoter
P10801809T0000|49 58|comparison
P10801809T0000|75 86|PHO5 promoter
P10801809T0000|15 24|regulation
P10801860A0000|118 122|acids
P10801860A0000|3 9|Siglecs
P10801860A0000|80 85|sugars
P10801860A0000|39 71|immunoglobulin superfamily proteins
P10801860A0000|31 37|lectins
P10801860A0000|14 22|subfamily
P10802669A1434|43 52|similarity
P10802669A1434|71 73|A-T
P10802669A1434|77 79|NBS
P10802669A1434|26 36|explanation
P10802669A1434|55 63|phenotype
P10802669A1434|3 6|data
P10802909A0478|0 9|PATIENTS OR
P10802909A0478|48 55|criteria
P10802909A0478|34 41|children
P10802909A0478|15 26|PARTICIPANTS
P10804379T0001|0 5|Update
P10804379T0001|22 31|infections
P10804379T0001|51 65|cytomegalovirus
P10804379T0001|45 47|HIV
P10804379T0001|34 43|hepatitis C
P10805286A0233|186 193|androgen
P10805286A0233|113 122|HepG2 cells
P10805286A0233|104 111|cell line
P10805286A0233|178 183|effect
P10805286A0233|140 159|rat PCI mRNA expression
P10805286A0233|12 16|study
P10805286A0233|33 44|cis-elements
P10805286A0233|211 217|tissues
P10805286A0233|196 198|rat
P10805286A0233|55 61|PCI gene
P10805286A0233|73 82|expression
P10805286A0914|12 28|PCI mRNA expression
P10805286A0914|46 51|organs
P10805286A0914|116 132|PCI mRNA expression
P10805286A0914|5 9|study
P10805286A0914|103 110|androgen
P10805286A0914|66 75|rat PCI cDNA
P10805286A0914|95 100|effect
P10805390A0340|60 86|GaAs/AlGaAs heterostructures
P10805390A0340|27 38|measurements
P10805390A0340|41 57|photoluminescence
P10805390A0340|15 25|performance
P10805729A0987|59 65|C strand
P10805729A0987|151 169|acid binding surfaces
P10805729A0987|81 84|DDP1
P10805729A0987|102 110|KH domains
P10805729A0987|21 29|complexes
P10805729A0987|3 15|stoichiometry
P10805737T0000|117 128|eIF5 function
P10805737T0000|64 67|role
P10805737T0000|104 107|eIF2
P10805737T0000|91 101|beta subunit
P10805737T0000|58 61|eIF5
P10805737T0000|111 114|eIF5
P10805737T0000|10 17|analysis
P10805737T0000|70 80|interaction
P10805737T0000|29 55|translation initiation factor
P10805738A0799|84 93|expression
P10805738A0799|370 376|embryos
P10805738A0799|43 46|MyoD
P10805738A0799|222 231|activation
P10805738A0799|254 262|reporters
P10805738A0799|182 203|Gal4-MyoD fusion protein
P10805738A0799|25 27|p38
P10805738A0799|335 345|fibroblasts
P10805738A0799|51 67|p38 kinase activity
P10805738A0799|32 40|activator
P10805738A0799|300 309|conversion
P10805738A0799|111 115|genes
P10805738A0799|140 142|p38
P10805738A0799|129 137|induction
P10805738A0799|171 178|activity
P10805738A0799|357 364|p38alpha
P10805738A0799|4 11|evidence
P10805738A0799|265 268|MyoD
P10805738A0799|321 325|mouse
P10805739A0343|54 66|eIF2B subunits
P10805739A0343|26 41|complex formation
P10805739A0343|4 11|activity
P10805739A0640|57 68|eIF2Bepsilon
P10805739A0640|139 142|eIF2
P10805739A0640|113 120|activity
P10805739A0640|46 54|C terminus
P10805739A0640|70 77|residues
P10805739A0640|124 134|interaction
P10805739A0640|3 10|analysis
P10805739A0640|13 29|nonsense mutations
P10805747A0633|116 133|septin organization
P10805747A0633|53 59|kinases
P10805747A0633|83 87|Kcc4p
P10805747A0633|108 113|effect
P10805747A0633|11 19|mutations
P10805747A0633|2 9|contrast
P10805747A0633|75 79|Hsl1p
P10805823A1920|89 94|stroke
P10805823A1920|77 86|prevention
P10805823A1920|65 70|pacing
P10805823A1920|121 126|causes
P10805823A1920|97 101|death
P10805823A1920|23 28|pacing
P10805823A1920|43 49|benefit
P10805823A1920|0 10|CONCLUSIONS
P10807900A0933|144 152|diagnosis
P10807900A0933|5 18|non-cirrhotics
P10807900A0933|32 48|vein visualisation
P10807900A0933|20 23|lack
P10807900A0933|115 115|%
P10807900A0933|104 108|value
P10807900A0933|70 81|% specificity
P10807900A0933|55 66|% sensitivity
P10807900A0933|175 186|hypertension
P10807900A0933|85 85|%
P10807900A0933|134 138|value
P10807903A0362|0 4|D5/D1
P10807903A0362|18 19|CT
P10807903A0362|21 43|tail substitution mutants
P10807903A0362|185 206|cAMP accumulation assays
P10807903A0362|54 62|rank order
P10807903A0362|75 91|agonist affinities
P10807903A0362|301 308|agonists
P10807903A0362|241 255|exhibit receptor
P10807903A0362|11 16|D5/D1D
P10807903A0362|223 233|D1 receptors
P10807903A0362|278 291|responsiveness
P10807903A0362|6 7|CT
P10807903A0362|123 133|D1 receptors
P10807903A0362|65 71|potency
P10807903A0362|268 275|activity
P10807903A0362|150 162|ligand binding
P10809233A0606|0 7|Modeling
P10809233A0606|101 103|H11
P10809233A0606|87 90|loop
P10809233A0606|51 57|absence
P10809233A0606|95 96|H4
P10809233A0606|36 42|surface
P10809233A0606|60 62|H12
P10809233A0606|72 79|residues
P10809233A0606|84 85|H3
P10810083A1283|19 28|kinase gene
P10810083A1283|58 72|zinc finger motif
P10810294A0730|0 13|Stat activation
P10810294A0730|50 70|reporter gene induction
P10810294A0730|26 27|GH
P10810294A0730|31 34|IL-6
P10810294A0730|16 23|response
P10810745A0677|0 6|HFA 134a
P10810745A0677|34 41|moisture
P10810745A0677|49 59|environment
P10810745A0677|67 69|HFA
P10810745A0677|18 25|tendency
P10811079A0555|102 102|%
P10811079A0555|108 123|epilepsy patients
P10811079A0555|76 96|vigabatrin monotherapy
P10811079A0555|16 30|color perception
P10811079A0555|135 158|carbamazepine monotherapy
P10811079A0555|49 64|epilepsy patients
P10811079A0555|43 43|%
P10811079A0555|0 6|RESULTS
P10811079A1277|27 32|plates
P10811079A1277|50 55|groups
P10811079A1277|5 21|SPP2 screening test
P10811804A0000|29 47|kinase phosphatase-3
P10811804A0000|25 27|MAP
P10811804A0000|135 137|ERK
P10811804A0000|139 148|MAP kinases
P10811804A0000|49 53|MKP-3
P10811804A0000|128 133|kinase
P10811804A0000|17 23|protein
P10811804A0000|62 83|specificity phosphatase
P10811804A0800|29 36|peptides
P10811804A0800|49 60|docking sites
P10811804A0800|98 100|rsk
P10811804A0800|70 90|target substrates Elk-1
P10811804A0800|94 96|p90
P10811804A0800|122 131|activation
P10811804A0800|134 138|MKP-3
P10811908A0938|0 24|HPLC phosphopeptide mapping
P10811908A0938|87 90|NCLK
P10811908A0938|114 116|I-1
P10811908A0938|26 44|amino acid sequencing
P10811908A0938|62 72|mutagenesis
P10811908A0938|105 107|Ser
P10812294X0000|28 30|SBF
P10812294X0000|95 100|ponies
P10812294X0000|117 126|ingredient
P10812294X0000|76 78|SBF
P10812294X0000|41 50|feed intake
P10812294X0000|13 16|diet
P10814989T0000|0 23|Hepatitis C virus infection
P10814989T0000|46 53|diseases
P10814989T0000|72 76|study
P10814989T0000|56 61|France
P10815410A0000|41 60|neuroendocrine system
P10815410A0000|82 90|increases
P10815410A0000|9 14|system
P10815410A0000|93 101|cytokines
P10815410A0000|161 166|system
P10815410A0000|113 116|IL-6
P10815410A0000|108 111|IL-1
P10815410A0000|135 141|effects
P10815410A0000|120 122|TNF
P10815807A1271|104 114|T-cell lines
P10815807A1271|54 66|c-Myb promoter
P10815807A1271|24 36|transcription
P10815807A1271|87 92|HTLV-I
P10817754T0000|0 2|H19
P10817754T0000|87 92|region
P10817754T0000|21 30|expression
P10817754T0000|6 9|Igf2
P10817754T0000|103 105|H19
P10817754T0000|68 70|cis
P10817754T0000|55 58|ways
P10819327T0000|0 14|C. elegans KLP-11
P10819327T0000|22 26|KAP-1
P10819327T0000|28 36|orthologs
P10819327T0000|65 100|mouse KIF3A/KIFB/KAP3 kinesin complexes
P10819327T0000|16 20|OSM-3
P10819327T0000|42 60|sea urchin kinesin-II
P10820829T0000|0 9|Flavonoids
P10820829T0000|14 32|Brosimum acutifolium
P10820904A0000|0 9|BACKGROUND
P10820904A0000|51 58|syndrome
P10820904A0000|109 120|liver disease
P10820904A0000|78 89|liver failure
P10820904A0000|18 31|encephalopathy
P10820904A0000|137 147|anastomosis
P10821836A0842|21 32|S transcripts
P10821836A0842|64 80|sense S transcripts
P10822117A1386|96 106|information
P10822117A1386|9 18|adjustment
P10822117A1386|114 127|subject-models
P10822117A1386|43 47|model
P10822117A1386|69 80|observations
P10823630A1124|99 108|prediction
P10823630A1124|11 18|presence
P10823630A1124|65 73|parameter
P10823630A1124|21 30|effacement
P10823837A1213|27 30|idea
P10823837A1213|213 220|alpha1-4
P10823837A1213|253 261|GPI anchor
P10823837A1213|35 50|YLL031c transfers
P10823837A1213|164 168|Mcd4p
P10823837A1213|115 119|group
P10823837A1213|100 106|mannose
P10823837A1213|132 145|GPI lipid anchor
P10823837A1213|240 247|mannoses
P10823837A1213|54 74|ethanolaminephosphate
P10823837A1213|172 205|Gpi7p transfer ethanolaminephosphate
P10823837A1213|148 155|proteins
P10823837A1213|3 6|data
P10823961A0664|25 32|CBP/p300
P10823961A0664|138 149|interactions
P10823961A0664|127 131|means
P10823961A0664|112 124|transcription
P10823961A0664|36 42|DRIP130
P10823961A0664|3 11|C terminus
P10823961A0664|45 53|component
P10823961A0664|59 78|DRIP/TRAP/ARC complex
P10823961A0664|14 17|TRBP
P10823961A0664|97 100|TRBP
P10824485A0393|3 10|patients
P10824485A0393|107 115|illnesses
P10824485A0393|61 77|T lymphocyte counts
P10824485A0393|40 46|disease
P10824485A0393|57 59|CD4
P10824485A0393|95 98|AIDS
P10824958A1109|57 58|CO
P10824958A1109|119 121|age
P10824958A1109|40 42|use
P10824958A1109|86 100|broiler breeders
P10824958A1109|16 21|energy
P10824958A1109|80 83|PSHL
P10824958A1109|69 70|PF
P10824958A1109|115 116|wk
P10824958A1109|31 33|PAB
P10825000A1245|27 34|Coquelle
P10825000A1245|3 24|gene amplification model
P10825200T0000|88 91|Jak3
P10825200T0000|143 156|STAT activation
P10825200T0000|114 116|Lck
P10825200T0000|64 73|activation
P10825200T0000|54 62|signaling
P10825200T0000|11 32|protein tyrosine kinases
P10825200T0000|108 110|Syk
P10825200T0000|49 52|IL-2
P10825200T0000|35 47|interleukin-2
P10825200T0000|76 78|syk
P10825200T0000|0 8|Hierarchy
P10825293T0000|61 80|cell contact formation
P10825293T0000|82 93|contribution
P10825293T0000|11 16|dimers
P10825293T0000|19 38|N-cadherin-Fc chimera
P10825293T0000|123 129|signals
P10825294A0473|156 167|AML C terminus
P10825294A0473|73 84|BSP promoters
P10825294A0473|11 20|OC promoter
P10825294A0473|112 121|mechanisms
P10825294A0473|63 65|MDR
P10825294A0473|35 43|C terminus
P10825294A0473|206 222|pentapeptide VWRPY
P10825294A0473|53 58|manner
P10825294A0473|67 69|LTR
P10826861A0000|164 170|failure
P10826861A0000|145 154|neuropathy
P10826861A0000|116 126|amyloidosis
P10826861A0000|13 34|immunoglobulin products
P10826861A0000|78 91|manifestations
P10826861A0000|37 54|plasma cell neoplasm
P10826861A0000|128 143|cryoglobulinemia
P10826861A0000|69 75|variety
P10826861A0000|101 114|hyperviscosity
P10826946A1198|0 12|Investigation
P10826946A1198|67 71|gp120
P10826946A1198|89 96|gp120 SAg
P10826946A1198|136 138|Igs
P10826946A1198|38 48|interaction
P10826946A1198|117 122|subset
P10826946A1198|130 130|V
P10826946A1198|132 132|H
P10826946A1198|61 63|Igs
P10826946A1198|28 32|basis
P10827885T0059|31 35|trial
P10827952A0158|69 86|bromodomain modules
P10827952A0158|126 142|histone H4 peptides
P10827952A0158|37 43|subunit
P10827952A0158|46 50|TFIID
P10827952A0158|18 25|TAFII250
P10828022A0877|0 18|Endostatin treatment
P10828022A0877|24 30|minutes
P10828022A0877|35 39|hours
P10828022A0877|78 86|formation
P10828022A0877|47 69|tyrosine phosphorylation
P10828022A0877|72 74|Shb
P10828022A0877|101 109|complexes
P10828319A0342|85 93|psoriasis
P10828319A0342|19 27|vitamin D3
P10828319A0342|10 16|analogs
P10828319A0342|51 56|number
P10828319A0342|59 64|trials
P10828319A0342|72 82|improvement
P10828591A0080|114 128|markers D11S1765
P10828591A0080|177 183|disease
P10828591A0080|101 106|region
P10828591A0080|62 67|course
P10828591A0080|83 95|transcript map
P10828591A0080|45 56|cDNA sequence
P10828591A0080|162 165|gene
P10828591A0080|132 142|uteroglobin
P10828591A0080|3 12|transcript
P10828751A2258|84 92|treatment
P10828751A2258|37 46|management
P10828751A2258|49 56|patients
P10828751A2258|22 27|future
P10828751A2258|7 15|challenge
P10829973T0000|0 24|Iodine deficiency disorders
P10829973T0000|27 36|Bangladesh
P10830395A0408|3 18|network evolution
P10830395A0408|37 44|approach
P10830395A0408|55 64|Flory model
P10831972A0744|102 109|controls
P10831972A0744|59 71|endometriosis
P10831972A0744|50 54|women
P10831972A0744|78 86|treatment
P10831972A0744|0 6|RESULTS
P10831972A0744|15 24|CD23 levels
P10831972A1091|103 109|danazol
P10831972A1091|62 71|CD23 levels
P10831972A1091|33 45|endometriosis
P10831972A1091|112 137|leuprolide acetate injection
P10831972A1091|14 21|findings
P10831972A1091|0 9|CONCLUSION
P10833461A0603|43 45|PAC
P10833461A0603|47 53|library
P10833461A0603|122 127|length
P10833461A0603|74 90|length UGT2B7 probe
P10833461A0603|32 41|chromosome
P10833461A0603|118 119|kb
P10833461A0603|19 21|P-1
P10833461A0603|95 99|clone
P10833461A0603|13 16|gene
P10833486A0598|0 2|Age
P10833486A0598|77 82|mmol/L
P10833486A0598|50 51|OR
P10833486A0598|124 125|2N
P10833486A0598|24 25|OR
P10833486A0598|58 70|triglycerides
P10833486A0598|127 128|OR
P10833486A0598|14 22|odds ratio
P10833486A0598|93 115|alanine aminotransferase
P10833486A0598|42 45|kg/m
P10833486A0598|117 119|ALT
P10833486A0598|34 36|BMI
P10833486A0598|8 12|years
P10833486A0598|171 178|fibrosis
P10833486A0598|84 85|OR
P10834707A1533|73 79|sorbent
P10834707A1533|23 29|amounts
P10834707A1533|95 107|treatment time
P10834707A1533|32 55|platelet activating factor
P10834781A0693|18 22|group
P10834781A0693|115 120|period
P10834781A0693|52 65|residence times
P10834781A0693|80 94|plasma clearance
P10834781A0693|67 70|MRTs
P10834781A0693|141 145|group
P10834781A0693|147 147|P
P10834781A0693|97 105|lidocaine
P10835355A0225|150 153|SSA3
P10835355A0225|18 38|zinc finger protein Gis1
P10835355A0225|77 92|rim15Delta defect
P10835355A0225|62 71|suppressor
P10835355A0225|136 147|derepression
P10835355A0225|95 102|nutrient
P10835485A0941|101 117|amino acid residues
P10835485A0941|150 154|mouse
P10835485A0941|124 130|factors
P10835485A0941|13 15|SH3
P10835485A0941|17 23|segment
P10835485A0941|44 51|contrast
P10835485A0941|134 139|cattle
P10835485A0941|74 89|sequence identity
P10835485A0941|29 40|linker domain
P10835732A0911|2 12|differences
P10835732A0911|67 73|aymaras
P10835732A0911|20 36|cholesterol levels
P10835732A0911|56 63|mapuches
P10836542A0363|42 53|UV-A waveband
P10836542A0363|62 63|nm
P10836542A0363|6 6|%
P10836542A0363|17 26|UV exposure
P10836786A0516|131 141|RNase MRP RNA
P10836786A0516|33 43|RNA subunits
P10836786A0516|24 27|role
P10836786A0516|114 117|MRP3
P10836786A0516|121 122|P3
P10836786A0516|63 82|substrate specificity
P10836786A0516|46 59|enzyme function
P10836786A0516|145 153|RNase P RNA
P10836786A0516|96 112|hairpin structures
P10837126A1004|45 59|signaling factor
P10837126A1004|37 42|Xwnt-8
P10837126A1004|91 101|marker genes
P10837126A1004|79 88|repertoire
P10837126A1004|24 34|pMesogenin1
P10837126A1004|121 129|phenotype
P10837126A1004|5 9|genes
P10838139A1447|14 24|Ha-ras codon
P10838139A1447|68 73|tumors
P10838139A1447|27 35|mutations
P10838399A0525|59 69|bone disease
P10838399A0525|13 18|PET FDG
P10838399A0525|33 45|lung infection
P10838399A0525|74 95|reconstruction artifact
P10838531A0675|0 10|Tumor stages
P10838531A0675|30 33|IIIA
P10838531A0675|51 51|%
P10838531A0675|19 22|T3 N0
P10838531A0675|38 38|%
P10838531A0675|15 17|IIB
P10838531A0675|43 46|IIIB
P10838531A0675|54 61|patients
P10838531A0675|28 28|%
P10839470A1148|72 79|exercise
P10839470A1148|10 19|comparison
P10839470A1148|114 119|Malays
P10839470A1148|90 104|measure analysis
P10839470A1148|172 172|p
P10839470A1148|55 60|supine
P10839470A1148|22 41|percentage reductions
P10839470A1148|145 150|change
P10839470A1148|44 52|heart rate
P10839547A0978|17 21|model
P10839547A0978|47 60|DNA methylation
P10839547A0978|23 33|CTCF binding
P10839593A0000|43 55|amphotericin B
P10839593A0000|82 90|treatment
P10839593A0000|93 103|fluconazole
P10839593A0000|35 40|safety
P10839593A0000|142 153|HIV infection
P10839593A0000|24 31|efficacy
P10839593A0000|118 128|candidiasis
P10839593A0000|60 69|suspension
P10839593A0000|71 74|ABOS
P10839593A0000|131 137|persons
P10839593A0000|0 8|OBJECTIVE
P10840001A0188|0 18|Mucin gene expression
P10840001A0188|79 85|cancers
P10840001A0188|107 111|tract
P10840001A0188|58 65|diseases
P10841537A0669|32 35|RPB5
P10841537A0669|51 62|interactions
P10841537A0669|23 29|regions
P10841537A0669|114 123|structures
P10841593A0780|27 36|% reduction
P10841593A0780|92 106|nicotine patches
P10841593A0780|39 58|cigarette consumption
P10841593A0780|78 89|availability
P10841593A0780|3 7|model
P10841601T0000|0 9|Paper alert
P10843716A0406|73 78|mastin
P10843716A0406|108 113|humans
P10843716A0406|81 84|gene
P10843716A0406|52 62|pseudogenes
P10843716A0406|96 99|dogs
P10843716A0406|3 15|tryptase locus
P10843810A0802|54 61|homology
P10843810A0802|11 14|part
P10843810A0802|100 103|gene
P10843810A0802|135 143|direction
P10843810A0802|33 37|clone
P10843810A0802|66 69|exon
P10843810A0802|165 167|LTR
P10843810A0802|80 98|tyrosine phosphatase
P10845522A0000|57 88|99mTc-sestamibi scintimammography
P10845522A0000|107 116|evaluation
P10845522A0000|166 176|mammography
P10845522A0000|92 101|sonography
P10845522A0000|119 131|breast lesions
P10845522A0000|187 197|examination
P10845522A0000|50 54|roles
P10845522A0000|14 18|study
P10845522A0000|0 8|OBJECTIVE
P10846054A0573|141 143|RNA
P10846054A0573|10 17|analyses
P10846054A0573|75 78|ORFs
P10846054A0573|40 45|codons
P10846054A0573|158 165|proteins
P10846054A0573|178 195|LIYV RNA replication
P10846054A0573|122 124|RNA
P10846054A0573|91 102|accumulation
P10846054A0573|105 118|progeny LIYV RNA
P10846054A0573|71 73|RNA
P10846069T0000|0 3|Role
P10846069T0000|6 7|NH
P10846069T0000|96 106|replication
P10846069T0000|80 92|transcription
P10846069T0000|55 76|parainfluenza virus type
P10846069T0000|28 34|domains
P10846069T0000|40 47|P protein
P10848605T0000|0 14|Phosphorylation
P10848605T0000|106 115|activities
P10848605T0000|53 71|juxtamembrane region
P10848605T0000|38 49|kinase domain
P10848605T0000|17 32|tyrosine residues
P10848605T0000|118 129|Eph receptors
P10848848A0413|0 6|RESULTS
P10848848A0413|8 15|Fournier
P10848848A0413|18 25|gangrene
P10848993A0000|161 164|gene
P10848993A0000|140 147|sequence
P10848993A0000|209 211|amk
P10848993A0000|179 207|serine/threonine protein kinase
P10848993A0000|63 67|mutAB
P10848993A0000|25 32|vicinity
P10848993A0000|95 122|Amycolatopsis mediterranei U32
P10848993A0000|35 61|methylmalonyl-CoA mutase gene
P10848993A0000|7 19|DNA sequencing
P10848993A0000|134 138|clone
P10848993A0000|74 82|rifamycin
P10850329A0248|0 3|IL-2
P10850329A0248|114 121|melanoma
P10850329A0248|25 33|treatment
P10850329A0248|48 58|combination
P10850329A0248|77 86|biotherapy
P10850329A0248|140 152|cell carcinoma
P10850329A0248|63 74|chemotherapy
P10850329A0248|92 101|management
P10850453A0713|88 96|TGF-beta1
P10850453A0713|9 18|expression
P10850453A0713|165 185|V12Ha-Ras transfection
P10850453A0713|113 131|TGF-beta1 inhibition
P10850453A0713|54 58|Raf-1
P10850453A0713|99 105|TSU-Pr1
P10850453A0713|152 162|stimulation
P10850453A0713|80 85|effect
P10850453A0713|134 138|DU145
P10850453A0713|30 35|Ha-Ras
P10850453A1292|101 115|growth advantage
P10850453A1292|57 81|Ras/MAPK pathway activation
P10850453A1292|127 145|TGF-beta1 production
P10850453A1292|17 20|data
P10850453A1292|32 49|prostate carcinomas
P10850719A0680|129 140|Jbeta12-RSSs
P10850719A0680|114 125|Vbeta 23-RSSs
P10850719A0680|67 71|Vbeta
P10850719A0680|74 78|Jbeta
P10850719A0680|26 45|DJbeta rearrangements
P10850719A0680|99 111|compatibility
P10850719A0680|0 12|Vbeta segments
P10850849A0730|86 90|hours
P10850849A0730|51 61|microg x h/ml
P10850849A0730|149 152|Cmax
P10850849A0730|205 209|hours
P10850849A0730|177 190|absorption time
P10850849A0730|113 116|Cmax
P10850849A0730|63 70|t1/2beta
P10850849A0730|214 228|bioavailability
P10850849A0730|133 141|microg/ml
P10850849A0730|22 34|AUC0-infinity
P10850849A0730|167 171|hours
P10850849A0730|92 111|maximum concentration
P10850849A0730|241 241|%
P10850849A0730|7 20|administration
P10850849A0730|143 146|time
P10850942A0989|59 66|% glucose
P10850942A0989|35 42|emptying
P10850942A0989|47 54|% peptone
P10850942A0989|127 135|nutrition
P10850942A0989|95 97|TPN
P10850942A0989|82 85|rats
P10850942A0989|16 25|difference
P10850942A0989|145 148|days
P10850942A0989|2 11|experiment
P10850997A1016|59 61|Fur
P10850997A1016|23 32|regulation
P10850997A1016|11 14|H-NS
P10850997A1016|50 56|absence
P10850997A1016|2 9|contrast
P10851089A1248|46 50|yeast
P10851089A1248|62 75|ubiquitination
P10851089A1248|92 100|cell cycle
P10851089A1248|111 118|proteins
P10851089A1248|24 43|cell cycle progression
P10851089A1248|79 89|degradation
P10851089A1248|5 7|SAG
P10851267A0000|0 2|E2F
P10851267A0000|8 26|transcription factor
P10851267A0000|64 70|S-phase
P10851267A0000|40 59|cell cycle progression
P10851745A0624|29 33|moods
P10851745A0624|46 51|health
P10851745A0624|76 83|capacity
P10851745A0624|53 57|sleep
P10851745A0624|13 19|fatigue
P10851745A0624|59 64|safety
P10852221A0422|87 93|surgery
P10852221A0422|67 72|period
P10852221A0422|20 28|treatment
P10852221A0422|107 112|effect
P10852221A0422|34 38|graft
P10852221A0422|147 153|neurons
P10852221A0422|118 125|survival
P10852460A0170|60 67|selenium
P10852460A0170|21 39|blood concentrations
P10852460A0170|157 164|age range
P10852460A0170|69 72|zinc
P10852460A0170|172 173|yr
P10852460A0170|74 80|retinol
P10852460A0170|42 56|thyroid hormones
P10852460A0170|189 196|criteria
P10852460A0170|85 100|alpha-tocopherol
P10852460A0170|202 216|SENIEUR protocol
P10852460A0170|123 130|Northern
P10852460A0170|3 15|relationships
P10852460A0170|148 155|subjects
P10852485A0477|14 15|CS
P10852485A0477|7 12|Spring
P10852485A0477|77 78|q5
P10852485A0477|110 114|Q gene
P10852485A0477|43 64|chromosome deletion line
P10852485A0477|92 92|%
P10852485A0477|67 68|CS
P10852485A0477|28 32|Q gene
P10852485A0477|95 97|5AL
P10852953A0000|0 13|Investigations
P10852953A0000|112 130|gamma frequency range
P10852953A0000|181 185|range
P10852953A0000|192 193|Hz
P10852953A0000|92 106|field potentials
P10852953A0000|30 35|slices
P10852953A0000|137 138|Hz
P10852953A0000|73 78|bursts
P10852953A0000|176 179|beta
P10852953A0000|160 170|oscillation
P10853059X0751|0 7|Karger AG
P10853059X0751|9 13|Basel
P10853778A0316|44 53|bone grafts
P10853778A0316|6 21|surgery bone cysts
P10853850A1103|29 38|challenges
P10853850A1103|7 10|LTE4
P10853850A1103|104 104|p
P10853850A1103|82 102|inhalation provocation
P10853850A1103|42 45|rise
P10854004A0788|65 77|noradrenaline
P10854004A0788|35 35|%
P10854004A0788|51 62|FVR responses
P10854004A0788|38 40|ERT
P10854004A0788|109 121|nitroprusside
P10854004A0788|93 105|acetylcholine
P10854004A0788|79 89|angiotensin
P10854004A0788|5 7|FVR
P10854004A0788|44 46|HRT
P10854699A0424|113 126|FGF-AS sequence
P10854699A0424|5 15|FGF-AS cDNAs
P10854699A0424|70 83|splice variants
P10854699A0424|91 94|exon
P10854699A0424|98 102|exons
P10854699A0424|43 52|FGF-AS mRNA
P10855690A0870|60 72|hPL-B enhancer
P10855690A0870|38 46|MAP kinase
P10855690A0870|94 100|pathway
P10855690A0870|19 25|results
P10855793A1418|0 15|Characterization
P10855793A1418|102 115|identification
P10855793A1418|52 56|genes
P10855793A1418|166 174|disorders
P10855793A1418|121 130|candidates
P10855793A1418|134 138|genes
P10855793A1418|79 82|cord
P10855793A1418|29 32|TNRs
P10855796A1160|58 64|pattern
P10855796A1160|108 113|region
P10855796A1160|124 129|tectum
P10855796A1160|67 85|EphA8 gene expression
P10855796A1160|145 155|development
P10855796A1160|14 36|RNA hybridization studies
P10856298A0798|185 190|enzyme
P10856298A0798|150 154|level
P10856298A0798|106 111|growth
P10856298A0798|93 97|level
P10856298A0798|141 146|growth
P10856298A0798|60 76|hamster ovary cells
P10856298A0798|33 39|enzymes
P10856298A0798|121 125|T339I
P10856298A0798|14 18|cDNAs
P10856298A0798|0 11|Transfection
P10856491A0178|0 6|SETTING
P10856491A0178|52 56|women
P10856491A0178|37 43|Patient
P10856491A0178|8 17|University
P10856491A0178|86 90|myoma
P10856491A0178|98 108|pregnancies
P10856491A0178|20 35|Paris VII hospital
P10856491A0178|45 45|s
P10856491A0178|60 71|embolization
P10856805T0000|0 29|Improving fissure sealant quality
P10856805T0000|41 51|preparation
P10856805T0000|62 66|level
P10857215A0000|3 24|Menopause-Rating-Scale
P10857215A0000|26 29|MRS I
P10857215A0000|48 55|practice
P10857215A0806|71 80|population
P10857215A0806|32 39|standard
P10857215A0806|44 53|instrument
P10857215A0806|3 7|MRS II
P10857262A0186|100 102|BTB
P10857262A0186|22 35|fruA transcript
P10857262A0186|126 131|domain
P10857262A0186|149 153|exons
P10857262A0186|3 9|protein
P10857262A0186|168 168|%
P10857262A0186|72 83|type A protein
P10857262A0186|58 59|D.
P10857751A0304|89 94|CEHARP
P10857751A0304|28 41|Mharp/Smarcal1
P10857751A0304|2 9|addition
P10857751A0304|114 128|GenBank database
P10857751A0304|59 87|Caenorhabditis elegans ortholog
P10857751A0304|14 26|mouse ortholog
P10858355A0920|15 27|clinafloxacin
P10858355A0920|48 72|Enterococcus faecium SF2149
P10858355A0920|76 100|Enterococcus faecalis WH245
P10858355A0920|0 11|Sparfloxacin
P10858988A0786|0 2|ECP
P10858988A0786|22 26|serum
P10858988A0786|64 72|challenge
P10858988A0786|6 19|tryptase levels
P10860131A0847|0 15|Tolterodine users
P10860131A0847|23 27|times
P10860131A0847|75 76|RR
P10860131A0847|70 73|drug
P10860131A0847|83 85|% CI
P10860196A0876|28 32|costs
P10860196A0876|89 93|years
P10860196A0876|63 66|year
P10860196A0876|17 23|program
P10860752A1601|26 28|RNA
P10860752A1601|75 88|autoregulation
P10860752A1601|30 42|binding domain
P10860752A1601|91 127|bacteriophage T4 DNA polymerase synthesis
P10860752A1601|52 60|mechanism
P10860752A1601|145 148|mRNA
P10860752A1601|3 10|presence
P10860827A0399|0 7|Deletion
P10860827A0399|76 81|region
P10860827A0399|62 69|elements
P10860827A0399|21 28|analyses
P10860827A0399|101 114|CSX1 expression
P10860827A0399|117 130|cardiomyocytes
P10860846A0480|157 160|role
P10860846A0480|10 16|studies
P10860846A0480|74 98|cotransfection experiments
P10860846A0480|166 188|HGF gene promoter activity
P10860846A0480|137 139|AP2
P10860846A0480|106 124|AP2 expression vector
P10860846A0480|46 65|AP2 core binding region
P10860846A0480|33 40|mutation
P10861080A0433|15 22|transfer
P10861080A0433|81 89|TNF-alpha
P10861080A0433|38 63|IkappaBalpha overexpression
P10861080A0433|127 127|%
P10861080A0433|25 36|IkappaBalpha
P10861080A0433|69 78|production
P10861080A0433|104 106|GBS
P10861086A0259|60 62|RAW
P10861086A0259|45 54|expression
P10861086A0259|170 176|Fc gamma
P10861086A0259|207 218|phagocytosis
P10861086A0259|88 96|Src kinase
P10861086A0259|139 157|gain-of-function Csk
P10861086A0259|238 243|manner
P10861086A0259|68 75|cell line
P10861086A0259|187 195|signaling
P10861086A0259|2 26|reconstitution experiments
P10861086A0259|98 100|Csk
P10861086A0904|2 9|contrast
P10861086A0904|79 87|membranes
P10861086A0904|115 135|phagocytosis signaling
P10861086A0904|107 112|series
P10861086A0904|24 32|construct
P10861086A0904|34 38|a-Src
P10861906A0999|100 107|mutation
P10861906A0999|136 139|IME1
P10861906A0999|198 209|DNA synthesis
P10861906A0999|119 133|transcript level
P10861906A0999|85 88|IME1
P10861906A0999|179 185|defects
P10861906A0999|92 95|IME2
P10861906A0999|74 78|genes
P10861906A0999|40 55|transcript levels
P10861906A0999|3 20|delta srb10 mutation
P10861906A0999|156 159|IME2
P10861906A0999|213 219|meiosis
P10861906A1479|41 47|meiosis
P10861906A1479|91 94|CCL1
P10861906A1479|166 171|medium
P10861906A1479|152 163|alkalization
P10861906A1479|65 80|transcript levels
P10861906A1479|104 121|nitrogen starvation
P10861906A1479|83 87|KIN28
P10861906A1479|28 37|conditions
P10861909A0502|230 252|transcription efficiency
P10861909A0502|128 131|ura4
P10861909A0502|187 188|3X
P10861909A0502|121 122|S.
P10861909A0502|327 342|restriction sites
P10861909A0502|47 52|marker
P10861909A0502|77 79|LEU
P10861909A0502|102 103|S.
P10861909A0502|81 84|gene
P10861909A0502|285 295|cloning site
P10861909A0502|136 139|his3
P10861909A0502|114 117|gene
P10861909A0502|190 192|41X
P10861909A0502|3 12|pJR vectors
P10861909A0502|315 319|sites
P10861909A0502|196 198|81X
P10861909A0502|174 185|nmt1 promoter
P10861909A0502|141 145|genes
P10862289A0289|13 19|montoux
P10862289A0289|93 98|bodies
P10862289A0289|35 40|adults
P10862289A0289|101 110|A60 antigen
P10862289A0289|86 88|IgG
P10862289A0289|68 74|control
P10862289A0289|5 8|Sera
P10862289A0289|42 48|age/sex
P10862289A0289|1 3|GUT
P10863048A0000|99 106|stimulus
P10863048A0000|35 45|cord lesions
P10863048A0000|142 142|s
P10863048A0000|129 131|CRD
P10863048A0000|135 138|mmHg
P10863048A0000|182 185|rats
P10863048A0000|65 72|activity
P10863048A0000|3 8|effect
P10863048A0000|118 127|distension
P10863352T0001|0 12|Franz Schubert
P10863352T0001|23 27|music
P10863352T0001|31 38|diseases
P10863352T0001|18 21|life
P10864271A0504|126 132|mammals
P10864271A0504|63 79|Trichinella larvae
P10864271A0504|48 60|dissemination
P10864271A0504|162 169|behavior
P10864271A0504|24 27|role
P10864271A0504|137 145|scavenger
P10864271A0504|82 87|nature
P10864271A0504|3 9|results
P10864271A0504|30 42|S. argyrostoma
P10864271A0504|99 108|comparison
P10864271A0504|114 117|role
P10864496A0401|60 63|TnrA
P10864496A0401|47 57|interaction
P10864496A0401|71 91|nrgAB promoter fragment
P10864496A0401|108 117|conditions
P10864496A0401|3 32|equilibrium dissociation binding
P10864496A0401|98 99|nM
P10864641A1400|131 136|glycan
P10864641A1400|91 100|regulators
P10864641A1400|27 35|N-glycans
P10864641A1400|103 122|influenza virus growth
P10864641A1400|5 11|results
P10864641A1400|167 172|Asn123
P10864641A1400|139 144|Asn149
P10864641A1400|72 81|HA molecule
P10864641A1400|63 66|site
P10864989A0484|0 6|RESULTS
P10864989A0484|189 189|%
P10864989A0484|128 130|FIP
P10864989A0484|92 97|median
P10864989A0484|113 119|numbers
P10864989A0484|194 207|separation time
P10864989A0484|63 71|reduction
P10864989A0484|132 137|median
P10864989A0484|55 55|p
P10864989A0484|168 185|separation efficacy
P10864989A0484|11 22|introduction
P10864989A0484|87 90|WBCs
P10864989A0484|28 31|PAIP
P10865422A0138|72 80|histories
P10865422A0138|48 52|level
P10865422A0138|34 43|hemoglobin
P10865422A0138|95 113|iron supplementation
P10865422A0138|45 46|Hb
P10865422A0138|30 31|SF
P10865422A0138|16 28|serum ferritin
P10865422A0138|83 91|donations
P10865838A0000|88 96|migration
P10865838A0000|129 133|cells
P10865838A0000|19 30|growth factor
P10865838A0000|32 35|VEGF
P10865838A0000|45 51|agonist
P10865838A0000|74 78|cells
P10865838A0000|100 107|division
P10865940A0000|89 90|EC
P10865940A0000|83 87|cells
P10865940A0000|142 160|NF-kappaB activation
P10865940A0000|14 44|agent pyrrolidine dithiocarbamate
P10865940A0000|46 49|PDTC
P10866323A0666|28 48|SIE-1 hypermethylation
P10866323A0666|51 66|p21WAF1 induction
P10866323A0666|19 25|effects
P10866323A0666|69 82|STAT activation
P10866677A1839|0 2|Phd
P10866677A1839|26 33|peptides
P10866677A1839|56 60|mouse
P10866677A1839|87 94|extracts
P10866689A0295|97 99|pRb
P10866689A0295|194 213|tal-1-E12 heterodimer
P10866689A0295|52 66|reporter plasmid
P10866689A0295|11 24|SAOS-2 cell line
P10866689A0295|153 180|tal-1-E12-Lmo2-Ldb1 complexes
P10866689A0295|126 133|activity
P10866689A0295|80 95|tal-1 binding site
P10866689A0295|5 7|pRb
P10866689A0295|136 149|tal-1-E12-Lmo2
P10866886A1277|4 9|effect
P10866886A1277|37 45|oxycodone
P10866886A1277|22 32|conjunction
P10866886A1277|61 78|mu-receptor agonist
P10867199A0230|129 140|insect orders
P10867199A0230|66 72|studies
P10867199A0230|28 35|criteria
P10867199A0230|2 9|contrast
P10867199A0230|107 110|EPVs
P10867199A0230|85 89|level
P10867199A0230|43 46|data
P10867496T0001|0 16|Neurofibromatosis
P10867496T0001|22 27|breast
P10867496T0001|31 37|patient
P10867496T0001|42 64|Morbus von Recklinghausen
P10868488A0921|14 19|period
P10868488A0921|24 27|rate
P10868488A0921|30 39|aggression
P10868488A0921|73 89|testosterone level
P10869076A1384|41 48|presence
P10869076A1384|109 112|boxA
P10869076A1384|64 71|ribosome
P10869076A1384|93 95|Rho
P10869076A1384|22 31|hypothesis
P10869076A1384|51 60|tryptophan
P10869076A1384|98 103|access
P10869076A1384|5 11|results
P10869076A1384|83 86|tnaC
P10869076A1384|116 123|rut sites
P10869076A1384|142 165|transcription termination
P10869465A1054|155 163|cell types
P10869465A1054|90 95|clones
P10869465A1054|63 79|expression changes
P10869465A1054|128 141|germ cell stages
P10869465A1054|6 18|hybridization
P10869465A1054|111 117|changes
P10869465A1054|35 43|RNA probes
P10869465A1054|165 171|Sertoli
P10869465A1054|199 203|cells
P10870043A0621|71 75|femur
P10870043A0621|82 82|%
P10870043A0621|3 16|administration
P10870043A0621|22 32|GnRH agonist
P10870043A0621|94 105|control group
P10870043A0621|43 60|bone mineral density
P10870391T0034|0 9|Prevention
P10870391T0034|23 31|diagnosis
P10870391T0034|35 41|therapy
P10870391T0034|44 57|travel diarrhea
P10871045A1221|43 54|C/EBP isoform
P10871045A1221|18 26|C/EBPbeta
P10871045A1221|196 201|effect
P10871045A1221|167 174|promoter
P10871045A1221|204 215|acetaldehyde
P10871045A1221|119 134|C/EBPbeta binding
P10871045A1221|4 8|study
P10871045A1221|146 161|C/EBP binding site
P10871045A1221|71 83|stellate cells
P10871045A1221|100 115|C/EBPbeta protein
P10871347A0477|0 15|Mutation analysis
P10871347A0477|35 45|motif TCCCCT
P10871347A0477|59 74|PyRo1 interaction
P10871379A0261|14 36|transactivation function
P10871379A0261|61 63|HCF
P10871379A0261|39 43|Luman
P10871379A0261|6 9|VP16
P10871412A0369|18 23|rounds
P10871412A0369|37 55|focus formation assay
P10871412A0369|26 34|selection
P10871412A0369|79 83|Rz007
P10871412A0369|70 77|ribozyme
P10871615A0368|0 1|G.
P10871615A0368|11 12|C.
P10871615A0368|6 9|Hyde
P10871842A0988|70 76|members
P10871842A0988|48 59|upregulation
P10871842A0988|142 154|proliferation
P10871842A0988|21 40|proteasome inhibition
P10871842A0988|79 105|transcription factor families
P10871842A0988|125 138|stress response
P10871842A0988|3 9|results
P10872473A2286|41 47|XH2 gene
P10872473A2286|61 71|X chromosome
P10872473A2286|104 109|factor
P10872473A2286|124 137|gene expression
P10872473A2286|73 78|Xq13.3
P10872473A2286|3 15|ATR-X syndrome
P10872473A2286|27 35|mutations
P10872535A0000|0 3|AIMS
P10872535A0000|50 56|factors
P10872535A0000|153 161|responses
P10872535A0000|105 118|susceptibility
P10872535A0000|275 287|abnormalities
P10872535A0000|73 84|birthweights
P10872535A0000|192 195|OGTT
P10872535A0000|217 227|association
P10872535A0000|18 21|role
P10872535A0000|121 128|diabetes
P10872535A0000|171 190|glucose tolerance test
P10872535A0000|241 262|birthweight differences
P10872535A0000|87 91|twins
P10872535A0000|295 298|life
P10872756A1325|13 34|randomization imbalance
P10872756A1325|150 165|dose control group
P10872756A1325|81 88|patients
P10872756A1325|2 10|NASCIS III
P10872756A1325|122 127|chance
P10872756A1325|95 106|motor deficit
P10872756A1325|131 138|recovery
P10872756A1325|73 78|number
P10872827A0000|0 16|Penicillin acylase
P10872827A0000|63 73|heterodimer
P10872827A0000|89 91|kDa
P10872827A0000|18 19|PA
P10872827A0000|110 112|kDa
P10872827A0000|40 48|ATCC11105
P10872827A0000|97 103|subunit
P10872827A0000|118 124|subunit
P10872831A0000|74 77|EPOR
P10872831A0000|97 107|EST database
P10872831A0000|39 46|homology
P10872831A0000|51 72|erythropoietin receptor
P10872831A0000|28 30|EST
P10872831A0000|16 26|sequence tag
P10872851A0714|75 77|AoP
P10872851A0714|106 107|SV
P10872851A0714|139 139|P
P10872851A0714|109 109|P
P10872851A0714|79 79|P
P10872851A0714|7 9|LCx
P10872851A0714|45 55|tachycardia
P10872851A0714|121 125|LVEDP
P10873158A0000|30 35|kappaB
P10873158A0000|64 77|gene expression
P10873158A0000|26 27|NF
P10873158A0000|85 90|airway
P10873158A0000|19 24|factor
P10873158A0000|128 133|stress
P10873158A0000|101 105|cells
P10873158A0000|0 9|Activation
P10873286X0000|0 11|GAP JUNCTIONS
P10873286X0000|23 29|PREFACE
P10873286X0000|17 21|BRAIN
P10873386A0000|60 68|C2 subunit
P10873386A0000|74 86|20S proteasome
P10873386A0000|45 53|mouse gene
P10873387A0816|125 128|Xp11
P10873387A0816|81 102|mouse synaptophysin gene
P10873387A0816|106 111|region
P10873387A0816|73 75|end
P10873387A0816|34 36|end
P10873387A0816|24 27|gene
P10873387A0816|42 56|Cacna1f gene maps
P10873387A0816|64 65|kb
P10873388A0623|27 31|probe
P10873388A0623|109 116|prostate
P10873388A0623|33 53|Northern hybridization
P10873388A0623|102 106|level
P10873388A0623|12 23|Rhotekin cDNA
P10873388A0623|129 133|level
P10873388A0623|142 148|tissues
P10873388A0623|189 199|lung tissues
P10873388A0623|73 82|transcript
P10873388A0623|181 185|liver
P10874044A0647|73 76|ERK2
P10874044A0647|10 22|co-expression
P10874044A0647|78 81|JNK1
P10874044A0647|120 134|pE1-luc activity
P10874044A0647|51 58|p38alpha
P10874044A0647|68 71|ERK1
P10874044A0647|43 48|mutant
P10874044A0647|85 88|JNK2
P10874151A0000|0 9|BACKGROUND
P10874151A0000|57 67|alternative
P10874151A0000|11 32|Gamma knife radiosurgery
P10874151A0000|92 98|lesions
P10874151A0000|70 76|surgery
P10874151A0000|34 36|GKR
P10878398A0542|117 121|group
P10878398A0542|104 106|Epo
P10878398A0542|36 40|group
P10878398A0542|23 25|Epo
P10878398A0542|91 102|CAPD patients
P10878398A0542|42 53|leptin levels
P10878398A0542|14 21|patients
P10878606A0876|29 38|structures
P10878606A0876|97 108|interactions
P10878606A0876|54 59|organs
P10878675A1278|122 129|subjects
P10878675A1278|84 91|activity
P10878675A1278|98 114|energy expenditure
P10878675A1278|0 9|CONCLUSION
P10878675A1278|31 48|antagonist idazoxan
P10878944A0000|76 86|Switzerland
P10878944A0000|8 37|diphtheria toxin polymer particle
P10878944A0000|157 159|St.
P10878944A0000|125 133|Institute
P10878944A0000|113 122|laboratory
P10878944A0000|67 74|DiaMed AG
P10878944A0000|48 52|agent
P10878944A0000|136 154|Childhood Infections
P10880486A0790|29 37|mutations
P10880486A0790|79 84|zipper
P10880486A0790|86 88|Ebr
P10880486A0790|101 109|RhoA locus
P10880702A0966|103 111|component
P10880702A0966|173 180|behavior
P10880702A0966|13 19|results
P10880702A0966|114 126|sensitization
P10880702A0966|40 47|exposure
P10880702A0966|63 73|apomorphine
P10880702A0966|129 139|amphetamine
P10880702A0966|50 60|amphetamine
P10881275T0000|27 40|GM1 ganglioside
P10881275T0000|51 58|practice
P10881275T0000|10 24|serum IgM binding
P10882163A1077|0 17|Objective responses
P10882163A1077|128 133|mg/day
P10882163A1077|182 191|exemestane
P10882163A1077|90 106|aminoglutethimide
P10882163A1077|194 199|mg/day
P10882163A1077|154 172|aromatase inhibitors
P10882163A1077|110 110|%
P10882163A1077|81 87|failure
P10882163A1077|32 38|studies
P10882163A1077|66 75|exemestane
P10882163A1077|115 124|exemestane
P10882163A1077|177 177|%
P10882163A1077|61 63|use
P10882213A0163|0 5|Topics
P10882213A0163|367 373|factors
P10882213A0163|252 266|classifications
P10882213A0163|305 312|myositis
P10882213A0163|161 168|patients
P10882213A0163|105 114|malignancy
P10882213A0163|288 296|childhood
P10882213A0163|26 29|data
P10882213A0163|334 341|entities
P10882213A0163|204 213|usefulness
P10882213A0163|149 158|assessment
P10882213A0163|433 442|approaches
P10882213A0163|269 278|discussion
P10882213A0163|451 461|limitations
P10882213A0163|91 101|evaluations
P10882213A0163|43 53|association
P10882213A0163|344 349|review
P10882213A0163|68 73|cancer
P10882213A0163|397 406|management
P10882213A0163|136 143|approach
P10882213A0163|492 497|damage
P10882213A0163|409 424|myositis patients
P10882213A0163|56 63|myositis
P10882213A0163|173 199|dermatomyositis sine myositis
P10882213A0163|118 132|myositis patient
P10882213A0163|474 488|disease activity
P10882462T0000|3 9|science
P10882462T0000|12 28|tissue engineering
P10882850A0000|86 107|pyrimidine base residues
P10882850A0000|16 18|Nth
P10882850A0000|69 75|removal
P10882850A0000|112 114|DNA
P10882850A0000|40 53|DNA glycosylase
P10882850A0000|0 11|Endonuclease
P10884978A0633|72 76|males
P10884978A0633|80 86|females
P10884978A0633|55 64|difference
P10884978A0633|109 111|age
P10884978A0633|21 29|hyperemia
P10884978A0633|3 10|duration
P10884978A0633|43 47|aging
P10885708T0000|45 49|agent
P10885708T0000|25 29|entry
P10885708T0000|68 74|abscess
P10885708T0000|8 23|bile duct blockage
P10885731A0915|60 70|block length
P10885731A0915|136 145|solubility
P10885731A0915|74 86|crystallinity
P10885731A0915|39 57|synthesis conditions
P10885731A0915|31 36|impact
P10885731A0915|151 158|polymers
P10885731A0915|94 99|impact
P10885731A0915|120 132|crystallinity
P10885731A0915|16 20|study
P10885750A0236|41 48|function
P10885750A0236|51 56|CREB-2
P10885750A0236|81 95|organ physiology
P10885750A0236|68 78|development
P10886067A0520|52 53|mm
P10886067A0520|8 15|diameter
P10886067A0520|36 40|rotor
P10886067A0520|22 30|thickness
P10886067A0520|46 47|mm
P10887912A0740|71 87|temporalis muscles
P10887912A0740|45 52|masseter
P10887912A0740|17 34|maximum EMG activity
P10887912A0740|137 147|subjects bit
P10887912A0740|7 10|MVBF
P10887912A0740|120 129|muscle pain
P10887912A0740|160 163|side
P10887921A0718|0 10|CONCLUSIONS
P10887921A0718|20 27|relation
P10887921A0718|111 117|rim area
P10887921A0718|33 42|topography
P10887921A0718|75 78|SWAP
P10887921A0718|153 161|follow-up
P10887921A0718|132 135|role
P10887921A0718|55 64|field areas
P10887921A0718|173 180|glaucoma
P10887921A0718|141 149|diagnosis
P10888570A0678|99 104|limits
P10888570A0678|78 83|Puebla
P10888570A0678|8 16|alkaloids
P10888570A0678|51 58|Marciana
P10888570A0678|37 43|Atzimba
P10888570A0678|69 73|Murca
P10888570A0678|45 49|Lopez
P10888570A0678|31 34|peel
P10888570A0678|119 128|food safety
P10888570A0678|60 67|Montsama
P10889399A0243|3 22|detection success rate
P10889399A0243|64 66|MEK
P10889399A0243|48 54|markers
P10890911A0470|113 125|transcription
P10890911A0470|73 79|TGFbeta
P10890911A0470|62 65|LEF1
P10890911A0470|17 21|Smad3
P10890911A0470|131 153|Xenopus homeobox gene twin
P10890911A0470|48 59|HMG box domain
P10890911A0470|83 93|Wnt pathways
P10890911A0470|155 158|Xtwn
P10891093A0000|3 23|transmembrane topology
P10891093A0000|26 27|Na
P10891093A0000|112 124|fusion vectors
P10891093A0000|36 48|exchanger NHE3
P10891093A0000|75 99|transcription/translation
P10891093A0000|168 180|cDNA sequences
P10891093A0000|105 109|types
P10891093A0000|32 32|H
P10891093A0000|139 165|membrane insertion properties
P10891093A0000|197 208|NHE3 membrane
P10891093A0000|225 228|msds
P10891093A0000|217 223|domains
P10891266A0421|0 4|ACE-2
P10891266A0421|20 28|C terminus
P10891266A0421|31 35|H type
P10891286A0000|29 45|chain kinase family
P10891286A0000|87 110|actin/myosin cytoskeleton
P10891286A0000|12 23|titin/myosin
P10891286A0000|144 151|function
P10891286A0000|133 140|assembly
P10891286A0000|61 64|role
P10891286A0000|70 81|organization
P10891286A0000|0 6|Members
P10891399A1185|27 33|c-fosER
P10891399A1185|116 123|AP-1 site
P10891399A1185|69 71|p21
P10891399A1185|167 173|control
P10891399A1185|195 199|genes
P10891399A1185|145 148|role
P10891399A1185|57 66|inhibition
P10891399A1185|176 184|cell cycle
P10891399A1185|73 81|Cip1/WAF1
P10891399A1185|152 156|c-fos
P10891399A1185|15 24|activation
P10891441A0871|63 66|Sos1
P10891441A0871|91 110|phosphatidylinositol
P10891441A0871|79 88|p85 subunit
P10891441A0871|13 36|pTyr317 Shc phosphopeptide
P10891441A0871|123 131|mast cells
P10891441A0871|68 71|SHIP
P10891441A0871|113 118|kinase
P10891441A0871|58 61|Grb2
P10891441A0871|150 165|mass spectrometry
P10891489A0152|147 154|proteins
P10891489A0152|71 83|proliferation
P10891489A0152|32 46|HMG-I/Y proteins
P10891489A0152|95 108|transformation
P10891489A0152|136 139|role
P10891489A0152|174 183|malignancy
P10891489A0152|125 131|cancers
P10891489A0152|160 171|pathogenesis
P10891489A0152|17 26|expression
P10891632A0435|162 170|increases
P10891632A0435|173 190|withdrawal symptoms
P10891632A0435|204 215|side-effects
P10891632A0435|83 100|withdrawal syndrome
P10891632A0435|126 142|treatment schedule
P10891632A0435|3 34|naltrexone/lofexidine combination
P10891632A0435|62 71|resolution
P10892300A0268|70 73|cows
P10892300A0268|47 51|March
P10892300A0268|26 35|calcinosis
P10892300A0268|8 15|symptoms
P10892300A0268|83 104|locomotor abnormalities
P10892823A1040|0 8|Screening
P10892823A1040|77 86|components
P10892823A1040|36 42|alcohol
P10892823A1040|10 19|counseling
P10892823A1040|53 59|drug use
P10892823A1040|24 32|treatment
P10892823A1040|102 108|HBP care
P10893243T0000|30 34|mouse
P10893243T0000|138 167|factor family zinc finger proteins
P10893243T0000|93 127|selenocysteine tRNA gene transcription
P10893243T0000|15 24|regulation
P10893243T0000|44 89|chaperonin subunit gene Ccta/t-complex polypeptide
P10893258T0000|103 125|reticulum quality control
P10893258T0000|64 88|membrane protein biogenesis
P10893258T0000|11 25|protein response
P10893258T0000|43 49|aspects
P10894149T0000|45 51|protein
P10894149T0000|157 162|factor
P10894149T0000|25 32|receptor
P10894149T0000|107 115|receptors
P10894149T0000|80 89|activation
P10894149T0000|168 176|ERRalpha1
P10894149T0000|193 207|receptor alpha-1
P10894149T0000|178 185|estrogen
P10894149T0000|125 142|orphan receptors SF1
P10894149T0000|0 3|PNRC
P10894816A0836|0 6|Studies
P10894816A0836|122 125|IL-6
P10894816A0836|112 119|response
P10894816A0836|79 81|SRE
P10894816A0836|71 77|element
P10894816A0836|13 27|reporter plasmid
P10894886A0375|29 34|tumors
P10894886A0375|50 56|changes
P10894886A0375|21 26|subset
P10894886A0375|64 68|genes
P10895417A0000|132 140|clearance
P10895417A0000|143 150|morphine
P10895417A0000|77 85|liposomes
P10895417A0000|27 29|EPI
P10895417A0000|31 38|delivery
P10895417A0000|164 172|analgesia
P10895417A0000|87 112|DepoFoam drug delivery system
P10895417A0000|41 48|morphine
P10895417A0669|101 107|arousal
P10895417A0669|9 17|EPI-C0401
P10895417A0669|25 30|saline
P10895417A0669|85 99|food consumption
P10895417A0669|33 47|DepoFoam vehicle
P10895417A0669|109 126|hindlimb muscle tone
P10895417A0669|131 145|body temperature
P10895417A0669|71 72|hr
P10895851A0696|87 87|g
P10895851A0696|92 93|g.
P10895851A0696|66 66|%
P10895851A0696|20 39|Owen Mumford filaments
P10895851A0696|0 16|Bailey Instruments
P10896008A0531|0 11|PARTICIPANTS
P10896008A0531|24 29|sample
P10896008A0531|42 52|outpatients
P10896008A0531|130 130|n
P10896008A0531|93 96|type
P10896008A0531|67 71|motor
P10896008A0531|150 157|controls
P10896008A0531|99 99|n
P10896008A0531|82 91|neuropathy
P10896008A0531|159 159|n
P10896008A0531|120 128|dystrophy
P10896859A0000|144 151|cortisol
P10896859A0000|120 127|infusion
P10896859A0000|79 81|ADX
P10896859A0000|165 176|steroid sheep
P10896859A0000|11 26|water deprivation
P10896859A0000|3 8|effect
P10896859A0000|83 87|sheep
P10896859A0000|32 32|h
P10896859A0000|130 140|aldosterone
P10896859A0000|40 50|Na excretion
P10896859A0838|17 21|cause
P10896859A0838|48 58|Na retention
P10897233A1057|0 9|CONCLUSION
P10897233A1057|20 24|fever
P10897233A1057|30 41|Nazareth area
P10897973T0001|45 51|heparin
P10897973T0001|72 75|role
P10897973T0001|78 89|antithrombin
P10897973T0001|53 65|Thrombosis ABC
P10897973T0001|0 24|Antithrombin III deficiency
P10897973T0001|30 39|substitute
P10898795A0527|82 85|BCoR
P10898795A0527|63 66|BCoR
P10898795A0527|8 12|class
P10898795A0527|39 43|HDACs
P10898795A0527|113 119|classes
P10898795A0527|19 37|histone deacetylases
P10898795A0527|122 126|HDACs
P10899128A0661|14 20|example
P10899128A0661|138 147|regulation
P10899128A0661|34 59|transcription factor complex
P10899128A0661|75 82|MADS-box
P10899128A0661|87 101|forkhead protein
P10899128A0661|120 131|implications
P10899128A0661|159 172|gene expression
P10899142A0000|121 121|G
P10899142A0000|35 55|Genome Project database
P10899142A0000|213 218|DLGR-2
P10899142A0000|232 235|cDNA
P10899142A0000|209 211|LGR
P10899142A0000|146 148|LGR
P10899142A0000|137 144|receptor
P10899142A0000|17 24|Berkeley
P10899142A0000|192 195|gene
P10899142A0000|60 68|sequences
P10899142A0000|165 170|DLGR-1
P10900129A0138|0 16|Degenerate primers
P10900129A0138|90 96|RT-PCRs
P10900129A0138|58 71|CYP3A sequences
P10900129A0138|44 50|regions
P10900269A0396|99 111|recombination
P10900269A0396|149 149|%
P10900269A0396|91 97|TK genes
P10900269A0396|125 135|frequencies
P10900269A0396|141 145|range
P10900269A0396|4 8|cells
P10900269A0396|169 178|background
P10900269A0396|30 33|TFOs
P10900269A0396|56 69|polypurine site
P10901133A0381|0 15|Methyllevamisole
P10901133A0381|36 43|standard
P10902348A0566|0 15|Resistance ratios
P10902348A0566|66 73|R5 strain
P10902348A0566|103 113|application
P10902348A0566|135 148|glass jar method
P10902348A0566|49 58|comparison
P10902348A0566|27 38|field strains
P10903440A0515|84 90|puparia
P10903440A0515|53 65|testes tissues
P10903440A0515|26 31|TSGF-2
P10903440A0515|4 14|transcripts
P10903440A0515|45 49|ovary
P10903440A0515|104 107|gene
P10903440A0515|68 73|adults
P10903440A0515|147 152|stages
P10903495A0533|27 31|HepG2
P10903495A0533|61 68|sequence
P10903495A0533|39 46|extracts
P10903495A0533|3 21|gel retardation assay
P10903495A0533|95 98|band
P10903583T0000|0 10|Reliability
P10903583T0000|28 33|motion
P10903583T0000|21 25|range
P10903583T0000|51 69|spine motion analyser
P10903583T0000|98 105|subjects
P10903583T0000|42 46|OSI CA
P10903733A0540|0 31|Coimmunoprecipitation experiments
P10903733A0540|109 112|TRAF
P10903733A0540|54 58|cells
P10903733A0540|69 72|BCMA
P10903733A0540|116 120|TRAF2
P10903733A0540|125 144|TRAF3 adaptor proteins
P10903733A0540|102 107|factor
P10903837A1208|70 73|VSX1
P10903837A1208|8 15|RINX gene
P10903837A1208|84 108|Gene Nomenclature Committee
P10903837A1208|26 33|ortholog
P10903837A1208|39 54|goldfish Vsx1 gene
P10903843A0447|14 25|localization
P10903843A0447|56 62|cluster
P10903843A0447|111 115|Tapa1
P10903843A0447|74 78|genes
P10903843A0447|34 43|chromosome
P10903843A0447|119 128|Kcnq1 genes
P10903877A0879|100 107|decrease
P10903877A0879|110 120|3TP activity
P10903877A0879|66 76|calphostin C
P10903877A0879|61 63|PKC
P10903877A0879|12 14|PKA
P10903877A0879|136 152|ERK kinase activity
P10903877A0879|31 33|AMP
P10903877A0879|49 58|inhibition
P10903877A0879|36 44|forskolin
P10903877A0879|155 158|CRAC
P10903877A0879|0 9|Activation
P10904191A0000|94 101|San Diego
P10904191A0000|53 63|specificity
P10904191A0000|103 104|CA
P10904191A0000|179 181|FVU
P10904191A0000|183 191|specimens
P10904191A0000|122 130|specimens
P10904191A0000|208 215|patients
P10904191A0000|106 108|USA
P10904191A0000|151 158|patients
P10904191A0000|10 14|study
P10904191A0000|39 49|sensitivity
P10904191A0000|72 92|Gen-Probe Incorporated
P10904191A0000|169 177|void urine
P10904191A0000|66 70|AMP CT
P10905349A0329|0 5|Mus81p
P10905349A0329|44 69|XPF endonuclease superfamily
P10905349A0329|28 33|motifs
P10905349A0329|16 23|homology
P10905349A0609|41 46|Mus81p
P10905349A0609|12 19|analysis
P10905349A0609|68 73|repair
P10905349A0609|32 37|Rad54p
P10905349A0609|101 109|DNA damage
P10905349A0609|55 61|pathway
P10905349A0609|79 87|tolerance
P10905352A0000|100 105|helper
P10905352A0000|9 20|plasmid pCLU1
P10905352A0000|112 123|plasmid pGKL2
P10905352A0000|75 83|cytoplasm
P10905352A0000|152 157|primer
P10905352A0000|146 147|TP
P10905352A0000|138 144|protein
P10905352A0000|92 94|aid
P10905352A0000|46 51|lactis
P10905352A0000|28 32|yeast
P10906176A0000|88 98|mouse genome
P10906176A0000|33 38|family
P10906176A0000|22 31|transposon
P10906176A0000|13 15|ETn
P10906176A0000|41 49|sequences
P10906176A0000|75 81|mutagen
P10906317A0351|129 129|%
P10906317A0351|22 30|variables
P10906317A0351|74 83|proportion
P10906317A0351|62 66|right
P10906317A0351|102 106|shift
P10906317A0351|56 59|left
P10906317A0351|46 54|hemifield
P10906317A0351|134 134|%
P10906317A0351|117 125|hemifield
P10906317A0351|86 91|trials
P10906999T0000|42 58|chemiluminescence
P10906999T0000|30 36|systems
P10906999T0000|3 13|measurement
P10906999T0000|16 17|NO
P10907348A0508|104 111|activity
P10907348A0508|129 130|AP
P10907348A0508|43 52|metabolism
P10907348A0508|68 84|PTH concentrations
P10907348A0508|114 126|bone isoenzyme
P10907348A0508|11 22|examinations
P10907348A0508|61 64|ions
P10907348A0508|87 96|blood serum
P10907971A0806|0 11|Atorvastatin
P10907971A0806|36 60|HMG-CoA reductase inhibitor
P10907971T0000|16 25|assessment
P10907971T0000|28 59|HMG-CoA reductase inhibitor therapy
P10907971T0000|81 91|CURVES study
P10907971T0000|63 70|analysis
P10908317A1459|87 92|domain
P10908317A1459|22 29|E domains
P10908317A1459|136 155|estradiol sensitivity
P10908317A1459|109 119|counterpart
P10908317A1459|40 48|receptors
P10908317A1459|185 199|transactivation
P10908317A1459|95 98|rtER
P10908317A1459|70 80|replacement
P10908317A1459|161 168|increase
P10908317A1459|174 182|magnitude
P10908364A0000|0 4|G-DNA
P10908364A0000|62 66|roles
P10908364A0000|21 32|DNA structure
P10908462A3159|18 20|NRT
P10908462A3159|55 63|intensity
P10908462A3159|76 82|support
P10908462A3159|96 101|smoker
P10908462A3159|3 15|effectiveness
P10908478A0717|74 82|illnesses
P10908478A0717|99 108|quetiapine
P10908478A0717|110 116|placebo
P10908478A0717|52 64|schizophrenia
P10908478A0717|135 139|drugs
P10908478A0717|42 47|adults
P10908478A0717|166 173|outcomes
P10908478A0717|31 36|trials
P10908478A0717|0 16|SELECTION CRITERIA
P10908822A0519|1 1|%
P10908822A0519|5 7|% CI
P10908822A0519|16 18|.3%
P10909973A1508|126 134|substrate
P10909973A1508|78 84|isoform
P10909973A1508|32 34|CRE
P10909973A1508|22 26|GLP-1
P10909973A1508|50 63|cotransfection
P10909973A1508|2 9|contrast
P10909973A1508|68 74|M1-CREB
P10909973A1508|150 164|phosphorylation
P10909973A1508|95 116|consensus serine residue
P10909973A1508|14 19|action
P10910073A0876|129 138|patient RNA
P10910073A0876|10 25|PDGFbetaR fusions
P10910073A0876|101 113|amplification
P10910073A0876|77 80|gene
P10910073A0876|50 57|splicing
P10910073A0876|124 126|PCR
P10910073A0876|67 70|exon
P10910073A0876|116 119|cDNA
P10910439A1196|0 10|CONCLUSIONS
P10910439A1196|71 73|GFR
P10910439A1196|111 119|treatment
P10910439A1196|23 34|hypertension
P10910439A1196|42 52|protein load
P10910439A1196|61 68|decrease
P10910908A0767|27 51|PI3K-Akt activation pathway
P10910908A0767|83 88|effect
P10910908A0767|91 93|EPO
P10910908A0767|4 10|finding
P10910908A0767|61 64|role
P10913094A0424|99 124|gel mobility shift-PCR method
P10913094A0424|90 95|cycles
P10913094A0424|72 75|AdpA
P10913094A0424|4 15|DNA fragments
P10913172A0442|86 91|lysine
P10913172A0442|110 114|motif
P10913172A0442|51 63|Rad24 function
P10913172A0442|32 36|motif
P10913172A0442|97 103|residue
P10913276A0510|59 69|interaction
P10913276A0510|40 43|SOS1
P10913276A0510|77 95|PLC-gamma1 SH3 domain
P10913276A0510|32 37|domain
P10913276A0684|56 64|SH3 domain
P10913276A0684|67 76|PLC-gamma1
P10913276A0684|13 29|expression studies
P10913276A0684|94 104|association
P10913276A0684|109 112|SOS1
P10913304A0894|59 62|Elk1
P10913304A0894|11 18|Ets mRNAs
P10913304A0894|67 69|PE1
P10913304A0894|54 57|SAP1
P10913304A0894|39 42|Fli1
P10913304A0894|34 37|Ets2
P10913304A0894|44 52|GABPalpha
P10913304A1180|128 130|PE1
P10913304A1180|29 33|brain
P10913304A1180|150 155|domain
P10913304A1180|61 70|kDa protein
P10913304A1180|84 90|protein
P10913304A1180|2 13|kb transcript
P10913304A1180|170 177|homology
P10913304A1180|117 125|Ets domain
P10913304A1180|186 188|ERF
P10915728A0216|14 21|patients
P10915728A0216|65 72|patients
P10915728A0216|106 113|IFN-beta
P10915728A0216|92 96|units
P10915728A0216|26 34|cirrhosis
P10915728A0216|140 147|patients
P10915728A0216|56 61|groups
P10915728A0216|120 123|week
P10915728A0216|155 164|IFN therapy
P10915728A0216|129 134|months
P10915780A1063|73 86|overexpression
P10915780A1063|106 110|gland
P10915780A1063|154 167|cyclin D1 levels
P10915780A1063|140 150|ILK activity
P10915780A1063|123 126|mice
P10915780A1063|38 42|cells
P10915780A1063|50 61|cyclin D1 mRNA
P10915780A1063|89 93|Wnt-1
P10915780A1063|0 18|Wnt-1 overexpression
P10917402T0000|52 59|patients
P10917402T0000|69 78|depression
P10917402T0000|21 34|administration
P10917402T0000|37 49|amitriptyline
P10918059A0569|0 7|Deletion
P10918059A0569|32 35|loss
P10918059A0569|38 39|Ca
P10918059A0569|54 63|activation
P10918059A0569|13 21|RVH domain
P10918164A0878|136 154|% confidence interval
P10918164A0878|171 171|P
P10918164A0878|158 160|% CI
P10918164A0878|55 59|times
P10918164A0878|124 132|detectors
P10918164A0878|38 47|physicians
P10918164A0878|8 25|regression analysis
P10918164A0878|82 88|lesions
P10918164A0878|97 98|mm
P10918440T0000|0 28|Erythema exsudativum multiforme
P10918440T0000|67 72|factor
P10918440T0000|97 114|blood stem cell donor
P10918440T0000|38 48|granulocyte
P10918572A0794|0 2|VaI
P10918572A0794|65 69|ErbB4
P10918572A0794|35 39|ErbB2
P10918572A0794|51 55|ErbB1
P10918572A0794|6 9|VaII
P10918572A0794|57 61|ErbB3
P10918572A1547|146 164|TGF-alpha precursors
P10918572A1547|187 199|ErbB signaling
P10918572A1547|47 51|ErbBs
P10918572A1547|19 20|WT
P10918572A1547|63 77|ErbB2 activation
P10918572A1547|109 120|consequences
P10918572A1547|31 39|TGF-alpha
P10918572A1547|5 16|interactions
P10918596A0000|26 38|p53 C-terminus
P10918596A0000|72 79|activity
P10918596A0000|94 101|molecule
P10918596A0000|52 55|role
P10918599A0071|2 9|contrast
P10918599A0071|23 27|E2F-3
P10918599A0071|113 118|levels
P10918599A0071|54 65|G1/S boundary
P10918599A0071|121 122|GO
P10918599A0071|146 147|Rb
P10918599A0071|67 72|E2F-3B
P10918599A0071|96 104|cell cycle
P10918612A0000|100 107|patterns
P10918612A0000|68 80|growth signals
P10918612A0000|26 30|c-Jun
P10918612A0000|110 123|gene expression
P10918612A0000|3 24|transcription factor Jun
P10918943T0000|48 62|agent almokalant
P10918943T0000|26 30|class
P10918943T0000|65 68|mice
P10918943T0000|13 20|toxicity
P10918948A0110|118 125|diseases
P10918948A0110|56 63|Debridat
P10918948A0110|30 39|metabolite
P10918948A0110|65 67|CAS
P10918948A0110|4 11|compound
P10918948A0110|42 52|trimebutine
P10919971A0606|74 81|vitamin E
P10919971A0606|65 72|exercise
P10919971A0606|36 53|neutrophil response
P10919971A0606|2 9|addition
P10919971A0606|96 103|increase
P10919971A0606|174 185|muscle repair
P10919971A0606|117 138|creatine kinase activity
P10919971A0606|15 20|effect
P10920186A0528|99 101|use
P10920186A0528|74 83|transcript
P10920186A0528|125 127|PCR
P10920186A0528|104 113|MLL primers
P10920186A0528|34 42|templates
P10920186A0528|89 92|loop
P10920186A0528|50 60|fusion point
P10920186A0528|14 22|formation
P10920906A0759|101 106|margin
P10920906A0759|14 20|authors
P10920906A0759|114 115|cm
P10920906A0759|63 65|STS
P10920906A0759|0 9|CONCLUSION
P10920906A0759|44 53|management
P10921197A0179|0 11|Measurements
P10921197A0179|102 103|b.
P10921197A0179|85 99|ADAC Pinnacle3 V4
P10921197A0179|43 66|treatment planning systems
P10921197A0179|78 81|VO5B
P10924061A0588|0 9|Activation
P10924061A0588|49 57|treatment
P10924061A0588|35 37|min
P10924061A0588|43 43|h
P10925159A1353|99 106|extracts
P10925159A1353|108 113|MARTA2
P10925159A1353|77 85|fractions
P10925159A1353|39 45|lysates
P10925159A1353|7 12|MARTA1
P10925159A1353|149 168|salt-wash preparation
P10925207A0634|30 41|kb transcript
P10925207A0634|12 16|exons
P10925207A0634|114 117|UTRs
P10925207A0634|106 112|regions
P10926776A0731|57 66|amino acids
P10926776A0731|46 54|insertion
P10926776A0731|9 20|PDP1 isoforms
P10926776A0731|32 43|substitution
P10926776A0731|93 99|protein
P10928179A0101|86 91|debate
P10928179A0101|37 47|examination
P10928179A0101|10 18|technique
P10928179A0101|50 67|sentinel lymph nodes
P10928179A0101|69 72|SLNs
P10928337A0590|87 90|mass
P10928337A0590|7 16|correction
P10928337A0590|94 99|volume
P10928337A0590|19 24|anemia
P10928337A0590|45 58|erythropoietin
P10928477A0764|75 90|platelet function
P10928477A0764|149 166|patient populations
P10928477A0764|129 139|shear stress
P10928477A0764|105 119|platelet defects
P10928477A0764|4 8|study
P10928477A0764|28 42|PFA-100 analyzer
P10930526A0174|30 36|cloning
P10930526A0174|60 67|HuPLSCR1
P10930526A0174|40 51|PL scramblase
P10930526A0174|72 82|mouse origin
P10931524A0313|74 81|sequence
P10931524A0313|22 29|activity
P10931524A0313|107 111|assay
P10931524A0313|32 34|Gtx
P10931927A0655|61 75|template-primer
P10931927A0655|24 24|A
P10931927A0655|231 234|size
P10931927A0655|26 31|GGGTTA
P10931927A0655|142 144|HIV
P10931927A0655|44 49|TAACCC
P10931927A0655|54 56|T-3
P10931927A0655|152 164|transcriptase
P10931927A0655|209 216|products
P10931927A0655|7 20|oligomer duplex
P10931927A0655|240 250|template DNA
P10931927A0655|94 107|Klenow fragment
P10931927A0655|176 195|telomere DNA sequences
P10931927A0655|125 137|DNA polymerase
P10931950A0869|0 3|Cdk2
P10931950A0869|7 10|MAPK
P10931950A0869|94 104|T187A mutant
P10931950A0869|36 47|tumor lysates
P10931950A0869|82 84|p27
P10931960A0630|100 107|addition
P10931960A0630|9 26|avirulence activity
P10931960A0630|154 164|protein VP16
P10931960A0630|36 44|mutations
P10931960A0630|136 148|herpes simplex
P10931960A0630|113 128|activation domain
P10931960A0630|71 86|activation domain
P10931960A0630|3 6|loss
P10932196A0359|14 21|RP2 locus
P10932196A0359|54 54|%
P10932196A0359|85 98|linkage studies
P10932196A0359|24 29|Xp11.3
P10932196A0359|57 68|XLRP patients
P10932196A0359|0 8|Mutations
P10932329A0597|67 91|sulcus cecocolicus dorsalis
P10932329A0597|18 22|cecum
P10932329A0597|38 42|colon
P10932329A0597|95 103|ventralis
P10932329A0597|3 7|limit
P10932527A0947|60 76|epithelialization
P10932527A0947|13 14|HD
P10932527A0947|24 30|healing
P10932527A0947|96 107|inflammation
P10932527T0000|87 92|ponies
P10932527T0000|78 83|horses
P10932527T0000|64 75|wound healing
P10932527T0000|21 44|haemodialysate Solcoseryl
P10932527T0000|3 15|effectiveness
P10932679A0049|73 76|role
P10932679A0049|94 104|expenditure
P10932679A0049|139 148|food intake
P10932679A0049|82 91|absorption
P10932679A0049|21 28|evidence
P10932679A0049|107 112|energy
P10932679A0049|133 136|role
P10932679A0049|33 47|diet composition
P10933154A1118|5 12|findings
P10933154A1118|92 100|rejection
P10933154A1118|64 79|donor transplants
P10933154A1118|31 38|analysis
P10933728A1398|227 240|responsiveness
P10933728A1398|152 159|evidence
P10933728A1398|5 11|results
P10933728A1398|44 47|CBF2
P10933728A1398|95 110|hnRNP protein AUF1
P10933728A1398|37 40|role
P10933728A1398|191 208|CBF1 binding element
P10933728A1398|59 78|EBNA2 transactivation
P10933728A1398|243 247|EBNA2
P10933728A1398|119 127|component
P10933728A1398|130 133|CBF2
P10933728A1398|173 180|sequence
P10933732A0000|176 181|family
P10933732A0000|47 53|cluster
P10933732A0000|74 77|ORFs
P10933732A0000|60 72|reading frames
P10933732A0000|87 94|proteins
P10933732A0000|165 170|factor
P10933732A0000|99 106|homology
P10933732A0000|19 29|herpesvirus
P10933732A0000|120 139|transcription factors
P10933732A0000|145 154|interferon
P10933732A0000|172 174|IRF
P10933732A0000|32 36|HHV-8
P10933732A0000|3 8|genome
P10934073A1433|110 113|home
P10934073A1433|12 22|limitations
P10934073A1433|26 37|CHIME monitor
P10934073A1433|48 58|opportunity
P10934073A1433|80 83|data
P10934310A0698|74 83|weaknesses
P10934310A0698|27 36|ultrasound
P10934310A0698|94 104|angiography
P10934310A0698|0 12|DATA SYNTHESIS
P10934640A1114|67 72|menses
P10934640A1114|20 25|height
P10934640A1114|49 54|colony
P10934640A1114|11 11|p
P10934640A1114|35 39|years
P10934640A1114|56 56|p
P10934640A1114|90 94|TB BMC
P10934640A1114|74 74|p
P10934640A1114|0 9|TB bone area
P10934640A1114|27 27|p
P10934751T0001|0 12|CREST syndrome
P10934751T0001|31 42|significance
P10935488A1033|103 108|A-FABP
P10935488A1033|114 123|expression
P10935488A1033|56 63|T24 cells
P10935488A1033|84 101|acid binding protein
P10935488A1033|35 53|PPARgamma target gene
P10935488A1033|145 172|bladder cancer differentiation
P10935488A1033|0 11|Troglitazone
P10935880A1049|0 6|Viruses
P10935880A1049|46 56|NCP BVDV type
P10935880A1049|24 28|lungs
P10935880A1049|71 76|BVHV-1
P10935880A1049|35 39|PI-3V
P10935880A1049|80 83|BVDV
P10936051T0000|13 25|megasatellite
P10936051T0000|3 7|RS447
P10936051T0000|79 84|enzyme
P10936051T0000|100 107|promoter
P10936051T0000|42 49|sequence
P10936920A0105|31 34|cues
P10936920A0105|83 92|prediction
P10936920A0105|8 17|experience
P10936920A0105|47 54|elements
P10936920A0105|60 69|generation
P10938102A0265|18 23|effect
P10938102A0265|36 42|targets
P10938102A0265|82 99|translation factors
P10938102A0265|45 68|NS1 influenza virus protein
P10938102A1359|73 78|eIF4GI
P10938102A1359|62 64|NS1
P10938102A1359|52 56|model
P10938102A1359|40 43|data
P10938102A1359|180 203|influenza virus messengers
P10938102A1359|110 115|region
P10938102A1359|164 174|translation
P10938102A1359|133 136|mRNA
P10938102A1359|119 121|UTR
P10938102T0000|60 69|NS1 protein
P10938102T0000|51 56|target
P10938102T0000|10 39|translation initiation factor 4GI
P10938102T0000|96 109|influenza virus
P10938102T0000|85 93|activator
P10938105A0000|29 32|exon
P10938105A0000|149 158|splice site
P10938105A0000|38 67|fibroblast growth factor receptor
P10938105A0000|102 113|sequence IAS1
P10938105A0000|69 72|gene
P10938105A0000|0 7|Splicing
P10938109A1361|18 24|PKCbeta
P10938109A1361|12 16|cells
P10938109A1361|67 73|insulin
P10938109A1361|111 117|signals
P10938109A1361|52 55|role
P10938109A1361|80 82|EGF
P10938109A1361|90 101|growth factor
P10938113A0388|154 164|Vav isoforms
P10938113A0388|191 200|activities
P10938113A0388|113 119|classes
P10938113A0388|63 66|Vav3
P10938113A0388|48 59|isoforms Vav2
P10938113A0388|122 130|receptors
P10938120A1093|88 90|PKA
P10938120A1093|27 48|fbp1 promoter constructs
P10938120A1093|94 107|MAPK regulation
P10938120A1093|124 128|sites
P10938120A1093|69 72|UAS2
P10938120A1093|63 66|UAS1
P10938120A1093|15 24|regulation
P10938130A0338|0 4|X-ray
P10938130A0338|36 52|PLZF BTB/POZ domain
P10938130A0338|91 99|interface
P10938130A0338|21 24|data
P10938130A0338|68 76|homodimer
P10938135A0259|118 148|tyrosine kinase signaling pathways
P10938135A0259|12 15|SMRT
P10938135A0259|106 115|activation
P10938135A0259|75 84|repression
P10938135A0259|36 55|transcription factors
P10938135A0259|185 204|growth factor receptor
P10938135A0259|3 9|ability
P10938556A0248|30 33|rats
P10938556A0248|56 60|cells
P10938556A0248|75 84|ventricles
P10938556A0248|2 9|addition
P10938556A0248|41 47|neurons
P10939030A0986|81 89|survival p
P10939030A0986|99 103|grade
P10939030A0986|106 122|granulocytopenia p
P10939030A0986|38 50|response rate p
P10939030A0986|3 13|differences
P10939030A0986|141 152|neutropenia p
P10939030A0986|76 76|%
P10939030A0986|67 67|p
P10939030A0986|58 62|power
P10939785A0540|0 7|Patients
P10939785A0540|149 157|treatment
P10939785A0540|46 68|ACE inhibitor perindopril
P10939785A0540|182 188|placebo
P10939785A0540|30 38|treatment
P10939785A0540|131 146|contraindication
P10939785A0540|84 93|indapamide
P10939785A0540|116 125|indication
P10939785A0540|190 190|s
P10940413A1153|158 163|defect
P10940413A1153|64 72|stiffness
P10940413A1153|137 140|bone
P10940413A1153|37 42|effect
P10940413A1153|76 101|stress concentration effects
P10940413A1153|122 129|strength
P10940413A1153|3 9|results
P10940553A0912|75 84|regulation
P10940553A0912|96 117|hPer1 gene transcription
P10940553A0912|5 11|regions
P10940553A0912|41 58|tissue-specificity
P10940557A1687|31 71|Broad Complex Z2 transcription factor elements
P10940557A1687|114 118|genes
P10940557A1687|103 105|MIH
P10940557A1687|94 100|regions
P10940557A1687|21 27|CF1/USP
P10940562A0379|0 15|Sequence analysis
P10940562A0379|65 74|pseudogene
P10940562A0379|45 53|oasA2 gene
P10940562T0000|90 96|enzymes
P10940562T0000|77 81|thiol
P10940562T0000|41 53|oas gene family
P10940562T0000|143 161|Arabidopsis thaliana
P10940562T0000|83 88|lyases
P10940562T0000|62 75|O-acetylserine
P10940562T0000|115 118|step
P10940562T0000|20 35|characterization
P10940562T0000|121 140|cysteine biosynthesis
P10940892A0573|74 76|Chr
P10940892A0573|41 50|vasculitis
P10940892A0573|105 113|progenies
P10940892A0573|91 98|D4Mit147
P10940892A0573|63 72|chromosome
P10940892A0573|81 87|D4Mit89
P10940892A0573|20 37|susceptibility loci
P10942587A0981|187 188|Rb
P10942587A0981|128 134|changes
P10942587A0981|76 79|mRNA
P10942587A0981|41 42|Rb
P10942587A0981|179 184|levels
P10942587A0981|140 148|E7 protein
P10942587A0981|71 74|form
P10942587A0981|19 38|phosphorylation state
P10942587A0981|6 14|treatment
P10942587A0981|86 98|HPV E6/E7 genes
P10942587A0981|218 227|antibodies
P10942599A1298|150 162|embryogenesis
P10942599A1298|92 104|Hoxa-1 protein
P10942599A1298|110 133|differentiation processes
P10942599A1298|78 86|functions
P10942599A1298|38 54|Hoxa-1 target genes
P10942599A1298|7 22|characterization
P10943891A1062|154 157|site
P10943891A1062|166 176|spliceosome
P10943891A1062|134 142|formation
P10943891A1062|39 46|fidelity
P10943891A1062|12 24|U6-U57 mutants
P10943891A1062|68 88|splice site recognition
P10943891A1062|159 159|s
P10943891A1062|105 114|nucleotide
P10943891A1062|3 9|ability
P10943891A1062|53 62|branch site
P10944466A0451|19 27|structure
P10944466A0451|33 42|WNT-2B gene
P10945010T0001|59 66|leukemia
P10945010T0001|23 38|induction therapy
P10945010T0001|9 20|daunorubicin
P10945010T0001|3 6|role
P10945781A0412|63 81|enterotoxin activity
P10945781A0412|9 24|Aeromonas strains
P10945781A0412|33 47|V cholerae non-O1
P10946303A0000|0 8|TNF-alpha
P10946303A0000|105 112|NCI-H292
P10946303A0000|66 70|COX-2
P10946303A0000|39 46|increase
P10946303A0000|85 97|PGE2 formation
P10946303A0000|72 81|expression
P10946303A0000|49 64|cyclooxygenase-2
P10946303A0000|17 20|dose
P10946303A0000|123 127|cells
P10947274A0839|26 28|NCS
P10947274A0839|98 100|10B
P10947274A0839|63 67|times
P10947274A0839|78 82|157Gd
P10947274A0839|51 57|RBE-cGy
P10947274A0839|3 13|therapy time
P10947274A0839|40 43|dose
P10947840A0762|0 3|Mis3
P10947840A0762|18 26|formation
P10947840A0762|64 68|level
P10947840A0762|71 78|proteins
P10947840A0762|29 42|18S ribosome RNA
P10947840A0762|93 100|coupling
P10950398T0100|0 19|Losartan Intervention
P10950398T0100|23 30|Endpoint
P10950415A0866|0 9|CONCLUSION
P10950415A0866|77 85|procedure
P10950415A0866|126 131|vision
P10950415A0866|11 20|Vitrectomy
P10950415A0866|113 123|improvement
P10950415A0866|32 41|hemorrhage
P10950415A0866|44 57|Terson syndrome
P10950924A0393|0 2|RNA
P10950924A0393|50 56|embryos
P10950924A0393|92 96|areas
P10950924A0393|24 36|brain sections
P10950924A0393|9 21|hybridization
P10950924A0393|110 115|cortex
P10950924A0393|72 79|labeling
P10950935A0111|60 65|method
P10950935A0111|117 120|PACs
P10950935A0111|38 46|sequences
P10950935A0111|12 23|manipulation
P10950935A0111|126 130|yeast
P10950935A0111|93 94|P1
P10950935A0111|105 115|chromosomes
P10950935A0111|153 156|YACs
P10950935A0111|141 151|chromosomes
P10951579A1238|104 117|gene expression
P10951579A1238|36 42|F9 cells
P10951579A1238|26 33|majority
P10951579A1238|130 134|cells
P10951579A1238|5 21|gamma-irradiation
P10951579A1238|71 76|wt-p53
P10951579A1238|50 58|apoptosis
P10951579A1238|83 90|triggers
P10951579A1238|120 122|DNA
P10951848A0230|0 11|Mobilization
P10951848A0230|53 69|stimulating factor
P10951848A0230|96 104|cell shift
P10951848A0230|84 88|terms
P10951848A0230|117 121|blood
P10951848A0230|16 31|cyclophosphamide
P10951848A0230|187 202|megachemotherapy
P10951848A0230|174 181|recovery
P10951848A0230|91 94|CD34
P10951848A0230|132 147|quality autograft
P10952828A2638|190 201|image quality
P10952828A2638|82 107|ejection fraction estimation
P10952828A2638|143 152|3D approach
P10952828A2638|110 129|heart failure patients
P10952828A2638|169 178|ventricles
P10952828A2638|38 46|resonance
P10952828A2638|61 69|technique
P10952828A2638|73 78|volume
P10954093A0000|72 78|strains
P10954093A0000|25 27|Pat
P10954093A0000|11 23|DNA transposon
P10954093A0000|47 53|genomes
P10954093A0000|95 117|fungus Podospora anserina
P10954525A1161|56 62|profile
P10954525A1161|65 72|proteins
P10954525A1161|11 18|presence
P10954525A1161|37 42|extent
P10954525A1161|21 23|Tax
P10954525A1161|80 84|TRE-2
P10954564A1262|42 44|ORF
P10954564A1262|47 53|protein
P10954564A1262|104 106|ORF
P10954564A1262|31 36|domain
P10954564A1262|72 82|gene product
P10954913A0152|31 51|Atlantic halibut Mx gene
P10954913A0152|68 83|liver cDNA library
P10954913A0152|18 26|cDNA clone
P10955313A0000|0 5|PLUS-3
P10955313A0000|36 41|speech
P10955313A0000|19 26|protocol
P10955313A0000|54 61|children
P10955913A0827|4 8|HIT II
P10955913A0827|52 59|heparins
P10955913A0827|21 27|heparin
P10955998A1124|96 107|DNA mutations
P10955998A1124|10 19|efficiency
P10955998A1124|25 43|glycosylase activity
P10955998A1124|78 86|S120K MutY
P10955998A1124|69 75|ability
P10958271A0365|0 6|METHODS
P10958271A0365|215 218|ERNA
P10958271A0365|290 297|patients
P10958271A0365|82 97|ejection fraction
P10958271A0365|107 113|volumes
P10958271A0365|53 64|measurements
P10958271A0365|224 231|patients
P10958271A0365|136 145|Technetium
P10958271A0365|99 102|LVEF
P10958271A0365|258 265|function
P10958271A0365|156 169|perfusion SPECT
P10958271A0365|270 285|echocardiography
P10958271A0365|150 154|Tc99m
P10958271A0365|10 16|RESULTS
P10958271A0365|174 213|equilibrium radionuclide angiocardiography
P10958271A0365|238 247|assessment
P10958456A0529|72 73|bp
P10958456A0529|76 77|Cp
P10958456A0529|119 139|polyadenylation signal
P10958456A0529|86 87|bp
P10958456A0529|22 27|length
P10958456A0529|79 80|F6
P10958456A0529|4 8|cDNAs
P10958456A0529|90 91|Cp
P10958456A0529|93 95|F10
P10958456A0529|59 65|regions
P10958673A0142|61 63|UPR
P10958673A0142|45 59|protein response
P10958673A0142|91 113|ER stress response element
P10958673A0142|115 118|ERSE
P10958673A0142|122 128|mammals
P10958673A0142|17 25|signaling
P10958688A0265|1 23|Y. lipolytica Kar2p mutant
P10958688A0265|47 57|interaction
P10958688A0265|93 103|interaction
P10958688A0265|64 74|Sls1p mutant
P10958688A0265|136 147|conformation
P10958688A0265|108 112|Sls1p
P10958688A0265|120 129|nucleotide
P10958698A0280|85 92|function
P10958698A0280|59 72|Cse4p N terminus
P10958698A0280|43 53|mutagenesis
P10958698A0485|58 60|HFD
P10958698A0485|34 39|domain
P10958698A0485|111 123|Cse4p function
P10958698A0485|103 108|effect
P10958698A0485|3 9|spacing
P10958698A0485|41 43|END
P10959676A0200|14 23|comparison
P10959676A0200|3 7|bases
P10959838A0153|16 19|Fhit
P10959838A0153|32 44|fusion protein
P10959838A0153|54 59|member
P10959838A0153|49 51|Nit
P10959838A0153|65 84|nitrilase superfamily
P10959838A0153|2 14|invertebrates
P10961046A0342|0 13|Platelet counts
P10961046A0342|33 42|fibrinogen
P10961046A0342|17 24|function
P10961046A0342|70 75|levels
P10961046A0342|66 68|vWF
P10961046A0342|96 101|sample
P10961046A0342|46 64|von Willebrand factor
P10961585A0273|71 79|hemolysis
P10961585A0273|38 53|thrombocytopenia
P10961585A0273|3 16|manifestations
P10962564A0883|60 68|cytosines
P10962564A0883|167 172|manner
P10962564A0883|74 84|sense strand
P10962564A0883|121 124|loss
P10962564A0883|127 134|activity
P10962564A0883|99 105|thymine
P10962564A0883|1 26|beta2 RARE reporter construct
P10962593A0580|17 23|AFP rate
P10962738A0000|45 50|memory
P10962738A0000|54 63|perception
P10962738A0000|28 36|attention
P10962738A0000|0 12|Consciousness
P10962881A0900|43 46|risk
P10962881A0900|25 30|effect
P10962881A0900|50 52|% CI
P10962881A0900|0 10|Multiparity
P10963577T0016|0 6|Picture
P10963577T0016|10 14|smell
P10963735A0193|184 212|polyacrylonitrile membrane AN69
P10963735A0193|88 90|CRF
P10963735A0193|72 74|CTL
P10963735A0193|48 53|stress
P10963735A0193|11 15|study
P10963735A0193|63 70|controls
P10963735A0193|32 36|level
P10963735A0193|138 152|dialysis session
P10963735A0193|3 5|aim
P10963735A0193|94 103|HD patients
P10963735A0651|30 37|vitamin E
P10963735A0651|51 60|acid levels
P10963735A0651|39 43|thiol
P10963735A0651|8 23|plasma parameters
P10964833A1696|41 44|POAG
P10964833A1696|132 135|mmHg
P10964833A1696|89 89|%
P10964833A1696|11 22|participants
P10964833A1696|119 121|IOP
P10964833A1696|27 27|%
P10964995A2152|60 66|cancers
P10964995A2152|141 145|HER-2
P10964995A2152|46 50|women
P10964995A2152|106 114|treatment
P10964995A2152|35 41|concern
P10964995A2152|55 56|ER
P10964995A2152|120 125|tumors
P10965135A0735|0 15|Promoter activity
P10965135A0735|197 212|inhibitor PD98059
P10965135A0735|70 72|ras
P10965135A0735|193 195|MKK
P10965135A0735|91 108|oncogene inhibition
P10965135A0735|75 86|mos oncogenes
P10965135A0735|46 59|cotransfection
P10965135A0735|154 158|cells
P10965135A0735|177 191|MAP kinase kinase
P10965135A0735|133 140|activity
P10965135A1207|116 124|MKK levels
P10965135A1207|153 180|transcription factor complexes
P10965135A1207|25 34|expression
P10965135A1207|70 80|development
P10965135A1207|47 50|gene
P10965135A1207|37 44|Cktsf1b1
P10965135A1207|84 101|cell transformation
P10965135A1207|3 9|results
P10965830A0305|0 12|INTERVENTIONS
P10965830A0305|116 125|volunteers
P10965830A0305|38 49|PCO2 tensions
P10965830A0305|95 103|fasciitis
P10965830A0305|26 34|tissue PO2
P10965830A0305|155 164|conditions
P10965830A0305|72 79|patients
P10965905A1618|87 94|LY294002
P10965905A1618|337 341|cells
P10965905A1618|311 329|MAP kinase activation
P10965905A1618|284 287|PI3K
P10965905A1618|263 268|target
P10965905A1618|72 84|concentration
P10965905A1618|101 108|findings
P10965905A1618|17 29|Akt activation
P10965905A1618|226 233|activity
P10965905A1618|124 144|wortmannin sensitivity
P10965905A1618|290 298|mediation
P10965905A1618|274 281|addition
P10965905A1618|194 212|MAP kinase activation
P10965905A1618|270 270|s
P10965905A1618|58 62|cells
P10965905T0000|0 14|Insulin receptor
P10965905T0000|86 108|protein kinase activation
P10965905T0000|48 53|growth
P10965905T0000|35 45|enhancement
P10967361A0000|132 141|resolution
P10967361A0000|111 117|feature
P10967361A0000|78 90|brain function
P10967361A0000|18 33|resonance imaging
P10967361A0000|35 38|fMRI
P10967531A1025|172 177|microm
P10967531A1025|56 68|fibre necrosis
P10967531A1025|151 154|type
P10967531A1025|20 24|aorta
P10967531A1025|139 144|microm
P10967531A1025|83 92|leucocytes
P10967531A1025|45 49|edema
P10967531A1025|184 187|type
P10967531A1025|73 80|adhesion
P10967531A1025|101 116|muscle fibre areas
P10967890A1120|44 56|comprehension
P10967890A1120|3 9|results
P10967890A1120|92 97|stages
P10967890A1120|25 36|relationship
P10967890A1120|100 110|development
P10967890A1120|60 69|production
P10970048A0352|27 33|RH level
P10970048A0352|61 66|orders
P10970048A0352|133 136|drop
P10970048A0352|50 55|values
P10970048A0352|124 128|times
P10970048A0352|95 107|voltage values
P10970048A0352|142 143|RH
P10970048A0352|79 90|contrariwise
P10970048A0352|14 21|increase
P10970048A0352|69 77|magnitude
P10972688A1272|42 51|difference
P10972688A1272|11 19|follow-up
P10972688A1272|57 65|incidence
P10972688A1272|68 83|hospitalizations
P10972894A0488|170 176|library
P10972894A0488|34 41|cultures
P10972894A0488|52 57|format
P10972894A0488|97 104|colonies
P10972894A0488|7 15|libraries
P10972894A0488|108 113|plates
P10972894A0488|122 128|library
P10972894A0488|148 154|library
P10972980A0295|115 115|C
P10972980A0295|19 22|mTOR
P10972980A0295|186 195|amino acids
P10972980A0295|9 17|cell lines
P10972980A0295|38 44|targets
P10972980A0295|61 80|phosphatidylinositol
P10972980A0295|160 165|kinase
P10972980A0295|131 140|G-proteins
P10972980A0295|94 108|protein kinases A
P10972980A0295|110 110|B
P10972980A0295|168 174|calcium
P10972980A0295|82 83|PI
P10972980A0295|85 92|3-kinase
P10972990A0196|59 67|stability
P10972990A0196|19 28|protein p53
P10972990A0526|144 180|hypoxanthine phosphoribosyl transferase
P10972990A0526|182 185|HPRT
P10972990A0526|63 81|mutation frequencies
P10972990A0526|115 116|TK
P10972990A0526|12 22|p53 function
P10972990A0526|25 26|E6
P10972990A0526|99 113|thymidine kinase
P10972990A0526|39 46|increase
P10972990A0526|187 191|locus
P10972990A0526|118 122|locus
P10972990A0526|0 9|Abrogation
P10972990A0966|147 160|amplifications
P10972990A0966|21 30|LOH mutants
P10972990A0966|173 186|translocations
P10972990A0966|127 145|chromosome deletions
P10972990A0966|11 18|analysis
P10972990A0966|100 109|chromosome
P10972990A0966|33 50|chromosome painting
P10972990A0966|80 90|aberrations
P10972990A0966|219 224|mutant
P10972990A0966|61 66|mosaic
P10972990A1518|58 68|maintenance
P10972990A1518|109 114|repair
P10972990A1518|78 86|integrity
P10972990A1518|20 24|model
P10972990A1518|5 11|results
P10972990A1518|32 41|p53 protein
P10973151A0883|73 82|Pernambuco
P10973151A0883|37 43|profile
P10973151A0883|152 162|environment
P10973151A0883|135 146|interference
P10973151A0883|94 97|fact
P10973151A0883|66 70|State
P10973151A0883|46 60|schistosomiasis
P10973151A0883|3 12|importance
P10973385A1423|159 173|survival benefit
P10973385A1423|30 36|pattern
P10973385A1423|20 25|tumors
P10973385A1423|48 53|spread
P10973385A1423|137 149|esophagectomy
P10973385A1423|125 135|artery nodes
P10973385A1423|204 211|patients
P10973385A1423|2 9|patients
P10973385A1423|186 196|gastrectomy
P10973385A1423|14 17|type
P10973385A1423|101 109|curvature
P10973400A0664|0 6|RESULTS
P10973400A0664|91 98|injuries
P10973400A0664|134 140|flexion
P10973400A0664|21 31|deformation
P10973400A0664|66 89|flexion-distraction Stage
P10973400A0664|119 123|range
P10973400A0664|43 52|artery flow
P10974541A0389|56 60|MZF1B
P10974541A0389|11 25|K562 cDNA library
P10974541A0389|64 68|MZF1C
P10974541A0389|44 54|transcripts
P10975465A0134|43 50|KIAA0170
P10975465A0134|140 150|BRCT domains
P10975465A0134|115 118|mass
P10975465A0134|89 94|length
P10975465A0134|77 86|amino acids
P10975465A0134|65 71|protein
P10975465A0134|8 21|cDNA clone NFBD1
P10975465A0134|126 126|D
P10975465A0134|172 188|amino acid residues
P10975465A0134|156 170|carboxy terminus
P10976413A0514|0 6|RESULTS
P10976413A0514|82 91|predictors
P10976413A0514|127 129|day
P10976413A0514|41 48|FSH level
P10976413A0514|131 138|FSH level
P10976413A0514|207 215|pregnancy
P10976413A0514|20 27|FSH level
P10976413A0514|181 186|mIU/ml
P10976413A0514|94 103|IVF success
P10976413A0514|163 165|day
P10976413A0514|115 121|patient
P10976413A0514|168 175|FSH level
P10976413A0514|144 149|mIU/ml
P10980416T0000|30 45|bone sialoprotein
P10980416T0000|11 27|hormone regulation
P10980416T0000|132 136|motif
P10980416T0000|126 130|Pit-1
P10980416T0000|142 159|rat BSP gene promoter
P10980416T0000|51 67|gene transcription
P10980416T0000|47 49|BSP
P10980416T0000|104 124|transcription factor-1
P10981094A0779|95 101|premise
P10981094A0779|153 161|magnitude
P10981094A0779|109 117|intensity
P10981094A0779|76 80|JNC VI
P10981094A0779|35 45|Sixth Report
P10981094A0779|164 179|pretreatment risk
P10981094A0779|120 128|treatment
P10981094A0779|6 18|target BP goals
P10981094A0779|53 74|Joint National Committee
P10982076A0000|148 157|indicators
P10982076A0000|93 100|sampling
P10982076A0000|74 76|ILI
P10982076A0000|171 187|influenza activity
P10982076A0000|66 72|illness
P10982076A0000|125 129|value
P10982076A0000|32 49|morbidity recording
P10982143A0346|3 8|muskox
P10982143A0346|28 35|T. gondii
P10982143A0346|15 24|host record
P10982391A0425|277 284|elements
P10982391A0425|24 30|leucine
P10982391A0425|37 42|repeat
P10982391A0425|12 21|NPF repeats
P10982391A0425|230 237|segments
P10982391A0425|115 118|site
P10982391A0425|134 139|domain
P10982391A0425|159 170|membrane core
P10982391A0425|193 210|transmembrane spans
P10982391A0425|60 67|residues
P10982391A0425|99 100|WW
P10982825A0363|38 45|presence
P10982825A0363|49 63|Mot3 binding site
P10982825A0363|18 27|difference
P10982825A0363|66 68|OpA
P10983344A0000|3 9|article
P10983344A0000|35 44|correction
P10983344A0000|22 31|diagnosing
P10983344A0000|57 64|ischemia
P10983344A0000|70 78|intestine
P10983857A0923|128 134|stomach
P10983857A0923|7 17|application
P10983857A0923|48 58|PD reduction
P10983857A0923|162 165|rats
P10983857A0923|69 69|H
P10983857A0923|20 27|NCX-4016
P10983857A0923|94 102|hyperemia
P10983857A0923|117 122|damage
P10983857A0923|71 74|loss
P10983979T0000|43 53|U5 tri-snRNP
P10983979T0000|25 34|splice site
P10983979T0000|91 109|spliceosome assembly
P10983979T0000|37 41|U4/U6
P10983979T0000|10 20|recognition
P10983979T0000|80 83|step
P10984122A0911|72 77|mU6-C2
P10984122A0911|2 8|control
P10984122A0911|37 47|DNA mixtures
P10984122A0911|13 17|cells
P10984122A0911|58 69|vector mU6-C1
P10987280A0604|128 137|matrilysin
P10987280A0604|119 125|feature
P10987280A0604|22 33|matrilysin-2
P10987280A0604|47 62|threonine residue
P10987280A0604|3 19|amino acid sequence
P10987280A0604|86 89|site
P10987301A0332|319 329|development
P10987301A0332|332 337|Kaposi
P10987301A0332|257 260|VEGF
P10987301A0332|76 83|receptor
P10987301A0332|128 138|herpes virus
P10987301A0332|284 293|stimulator
P10987301A0332|102 107|Kaposi
P10987301A0332|244 255|growth factor
P10987301A0332|306 312|mitogen
P10987301A0332|187 198|angiogenesis
P10987301A0332|214 222|secretion
P10987301A0332|340 346|sarcoma
P10987301A0332|151 161|herpes virus
P10987301A0332|6 11|regard
P10987301A0332|140 143|KSHV
P10987301A0332|85 88|GPCR
P10987301A0332|60 60|G
P10989777A1286|88 97|assignment
P10989777A1286|20 26|clients
P10989777A1286|137 141|group
P10989777A1286|10 17|subgroup
P10989777A1286|44 46|URD
P10989777A1286|68 72|study
P10991383A0289|40 40|%
P10991383A0289|46 50|atoms
P10991383A0289|21 25|sites
P10991383A0289|121 125|state
P10991383A0289|108 109|3D
P10991383A0289|93 93|%
P10991383A0289|65 70|energy
P10991383A0289|5 11|lattice
P10991383A0289|79 86|sublevel
P10991383A0289|15 15|%
P10991648T0000|38 50|half syndromes
P10992299A0745|72 85|PI12 expression
P10992299A0745|139 158|brain cancer cell lines
P10992299A0745|114 130|tumor brain tissues
P10992299A0745|169 170|H4
P10992299A0745|29 42|gene expression
P10992299A0745|17 23|members
P10992299A0745|160 165|U-87 MG
P10992299A0745|58 70|tumorigenesis
P10992983T0000|48 57|penile size
P10992983T0000|13 20|relation
P10992983T0000|62 63|A.
P10992983T0000|34 44|orientation
P10993773A0717|146 156|min ischemia
P10993773A0717|169 179|microm/mmHg
P10993773A0717|4 8|slope
P10993773A0717|96 108|control values
P10993773A0717|44 54|min ischemia
P10993773A0717|67 77|microm/mmHg
P10993773A0717|132 141|myocardium
P10993787A0369|42 51|transition
P10993787A0369|61 63|PHI
P10993787A0369|91 99|reduction
P10993787A0369|35 37|SHG
P10993787A0369|162 168|factors
P10993787A0369|102 104|MAP
P10993787A0369|11 13|MAP
P10993787A0369|17 28|MSNA increase
P10993787A0369|145 154|separation
P10993787A0369|56 58|SHG
P10993787A0369|117 125|elevation
P10993787A0369|128 131|MSNA
P10995121A0569|0 7|Analysis
P10995121A0569|40 52|Infant Formula
P10995121A0569|10 38|Standard Reference Material 1846
P10995121A0569|63 67|value
P10995121A0569|99 100|K1
P10995121A0569|96 96|K
P10995121A0569|82 94|mg vitamin K/kg
P10995121A0569|104 104|n
P10995121A0569|114 124|coefficient
P10995121A0569|127 135|variation
P10995751A0093|64 73|C/EBP-beta
P10995751A0093|82 98|gene transcription
P10995751A0093|173 179|element
P10995751A0093|51 62|protein-beta
P10995751A0093|112 129|IFN response element
P10997330A0361|0 19|Northern blot analysis
P10997330A0361|62 68|pattern
P10997330A0361|39 47|STORP gene
P10997330A0361|71 80|expression
P10997330A0361|99 105|PML gene
P10997863A0753|110 121|seizure focus
P10997863A0753|19 21|NAA
P10997863A0753|70 80|FLE patients
P10997863A0753|47 58|seizure focus
P10997863A0753|5 15|TLE patients
P10997863A0753|25 30|ratios
P10997904A1258|129 136|residues
P10997904A1258|153 181|response regulator-kinase pairs
P10997904A1258|62 79|response regulators
P10997904A1258|38 42|patch
P10997904A1258|3 15|Spo0F residues
P10997904A1258|97 103|binding
P10998679A0500|31 33|wth
P10998679A0500|57 65|prognoses
P10998679A0500|136 139|pain
P10998679A0500|41 47|illness
P10998679A0500|88 95|scenario
P10998679A0500|14 20|factors
P10999205A0607|98 100|VOI
P10999205A0607|20 29|resolution
P10999205A0607|109 119|acquisition
P10999205A0607|76 79|area
P10999205A0607|137 143|spectra
P10999205A0607|46 53|interest
P10999301A0000|161 165|scale
P10999301A0000|115 124|technology
P10999301A0000|110 113|SNOM
P10999301A0000|130 134|study
P10999301A0000|12 21|evaluation
P10999301A0000|137 145|magnetism
P10999301A0000|99 108|microscope
P10999301A0000|39 48|parameters
P10999301A0000|62 66|order
P10999301A0000|74 81|scanning
P10999369A0192|99 104|microV
P10999369A0192|53 61|amplitude
P10999369A0192|122 127|microV
P10999369A0192|67 75|N2/P2 peak
P10999369A0192|132 133|mA
P10999369A0192|108 109|mA
P10999369A0192|14 22|amplitude
P10999369A0192|42 51|potentials
P11000203A0752|215 223|RNA export
P11000203A0752|178 187|activities
P11000203A0752|140 143|type
P11000203A0752|108 119|K-Rev mutants
P11000203A0752|48 57|properties
P11000203A0752|91 99|RNA export
P11000203A0752|5 13|mutations
P11000203A0752|16 20|K-Rev
P11000250A0200|0 4|LMP-1
P11000250A0200|47 50|TRAF
P11000250A0200|52 56|TRADD
P11000250A0200|61 72|JAK molecules
P11000250A0200|117 124|pathways
P11000250A0200|94 97|AP-1
P11000250A0200|20 33|plasma membrane
P11000250A0200|131 134|CD40
P11000250A0200|83 91|NF-kappaB
P11000266T0000|71 91|alpha-fetoprotein gene
P11000266T0000|60 65|intron
P11000266T0000|18 25|enhancer
P11000266T0000|42 49|promoter
P11000266T0000|0 13|Identification
P11000521A0588|224 251|phosphatidylinositol 3-kinase
P11000521A0588|282 288|PKB/AKT
P11000521A0588|68 81|transformation
P11000521A0588|253 262|PI 3-kinase
P11000521A0588|267 280|protein kinase B
P11000521A0588|212 221|activation
P11000521A0588|101 111|NIH3T3 cells
P11000521A0588|191 195|IRS-2
P11000521A0588|21 37|signaling pathways
P11000521A0588|147 161|phosphorylation
P11000521A0588|164 189|insulin receptor substrate-2
P11002236A0328|28 34|authors
P11002236A0328|105 116|Associations
P11002236A0328|142 156|Oncology centers
P11002236A0328|45 52|PPB cases
P11002236A0328|120 138|Pediatric Hematology
P11002236A0328|20 24|study
P11002236A0328|66 84|retrospective search
P11002236A0328|0 6|METHODS
P11003471A1149|70 74|group
P11003471A1149|112 116|India
P11003471A1149|12 19|analysis
P11003471A1149|77 83|viruses
P11003471A1149|50 58|Bangalore
P11003471A1149|33 45|ToLCV isolates
P11003641A0811|141 147|ability
P11003641A0811|51 57|subunit
P11003641A0811|165 177|transcription
P11003641A0811|123 129|mutants
P11003641A0811|109 116|fcp1 tfg1
P11003641A0811|39 43|RAP74
P11003641A0811|150 154|Fcp1p
P11003641A0811|45 49|Tfg1p
P11003641A0811|90 99|phenotypes
P11003641A0811|24 33|motif KEFGK
P11003641A0811|209 216|promoter
P11003641A0811|60 64|TFIIF
P11003652A0961|116 119|role
P11003652A0961|90 98|PAK Ste20p
P11003652A0961|48 64|pheromone response
P11003652A0961|33 36|fact
P11003652A0961|23 28|Cdc42p
P11003652A0961|5 11|results
P11003652A0961|72 82|interaction
P11003653A0198|0 7|Deletion
P11003653A0198|107 111|gamma
P11003653A0198|169 178|PYR complex
P11003653A0198|61 85|beta-globin locus construct
P11003653A0198|198 203|switch
P11003653A0198|147 150|mice
P11003653A0198|44 50|complex
P11003653A0198|33 36|site
P11003653A0198|115 134|beta-globin switching
P11003669A0000|116 128|kinase domains
P11003669A0000|12 18|rat gene
P11003669A0000|94 112|ErbB-2 juxtamembrane
P11003669A0000|56 62|protein
P11003669A0000|76 81|screen
P11003669A0000|3 9|product
P11003669A0000|131 134|bait
P11003805A0443|0 6|Studies
P11003805A0443|53 60|symptoms
P11003805A0443|32 41|acid reflux
P11003805A0443|21 24|DGOR
P11003805A0443|118 129|oesophagitis
P11003805A0443|70 79|acid reflux
P11003807A0303|44 55|oesophagitis
P11003807A0303|104 120|oesophageal damage
P11003807A0303|69 76|symptoms
P11003807A0303|0 7|Symptoms
P11004369A0000|0 8|OBJECTIVE
P11004369A0000|23 34|relationship
P11004369A0000|166 174|carcinoma
P11004369A0000|135 152|growth factor levels
P11004369A0000|56 60|tumor
P11004369A0000|94 111|microvessel density
P11004369A0000|42 50|blood flow
P11004369A0000|71 92|color Doppler ultrasound
P11005808A1082|45 61|ERK MAPK activation
P11005808A1082|23 25|Ras
P11005808A1082|93 101|heat shock
P11005808A1082|5 11|results
P11005808A1082|71 83|cell viability
P11005831A0242|162 182|element binding protein
P11005831A0242|37 40|bZIP
P11005831A0242|23 35|leucine zipper
P11005831A0242|127 131|AREB1
P11005831A0242|142 146|AREB3
P11005831A0242|104 109|system
P11005831A0242|43 46|type
P11005831A0242|5 9|cDNAs
P11005831A0242|59 66|proteins
P11005831A0242|133 137|AREB2
P11005831A0242|89 93|yeast
P11006283A1180|62 65|poly
P11006283A1180|56 58|DNA
P11006283A1180|11 18|AROM-p64
P11006283A1180|116 119|role
P11006283A1180|122 146|mRNA maturation/metabolism
P11006283A1180|67 67|A
P11006283A1180|69 80|homopolymers
P11006283A1180|32 38|binding
P11006283A1180|99 105|protein
P11006284T0000|19 27|kinase fer
P11006284T0000|70 95|insulin receptor substrate-1
P11006284T0000|51 59|complexes
P11006284T0000|99 126|phosphatidylinositol 3-kinase
P11006331A0319|72 84|abnormalities
P11006331A0319|25 39|allotetraploids
P11006331A0319|11 19|phenotype
P11007509A1271|39 42|area
P11007509A1271|5 17|PMR target area
P11007509A1271|76 86|flow reserve
P11007509A1271|45 55|improvement
P11007509A1271|95 106|wall segments
P11007509A1271|147 161|stress perfusion
P11007777A0813|0 7|Analysis
P11007777A0813|10 30|intron/exon boundaries
P11007777A0813|132 139|splicing
P11007777A0813|87 110|aspartyl beta-hydroxylase
P11007777A0813|149 152|gene
P11007777A0813|67 73|junctin
P11007777A0813|75 82|junctate
P11007777A0813|43 51|BAC clones
P11007949A1395|41 44|PTEN
P11007949A1395|72 77|tumors
P11007949A1395|60 64|forms
P11007949A1395|20 38|inactivation mutants
P11007949A1395|54 54|%
P11007949A1607|64 67|PTEN
P11007949A1607|25 32|activity
P11007949A1607|74 78|cells
P11007949A1607|35 37|ILK
P11007954A0170|29 35|protein
P11007954A0170|184 186|Sos
P11007954A0170|221 223|Ras
P11007954A0170|71 73|Son
P11007954A0170|209 218|activation
P11007954A0170|106 108|Ras
P11007954A0170|192 199|membrane
P11007954A0170|90 103|exchange factor
P11007954A0170|38 41|Grb2
P11007954A0170|159 166|receptor
P11007954A0170|43 49|adaptor
P11007954A0170|67 69|Sos
P11007954A0170|135 142|tyrosine
P11007954A0170|169 171|Ras
P11007954A0170|120 125|signal
P11007954A0170|3 14|growth factor
P11007961A0930|0 8|Mutations
P11007961A0930|11 15|genes
P11007961A0930|112 121|fostriecin
P11007961A0930|92 104|PP2A inhibitor
P11007961A0930|24 37|PR65/A subunits
P11007961A0930|150 153|drug
P11007961A0930|79 85|cancers
P11007968A0255|85 87|PCR
P11007968A0255|25 27|dxr
P11007968A0255|79 81|DNA
P11007968A0255|93 108|oligonucleotides
P11007968A0255|7 13|purpose
P11007968A0255|121 127|regions
P11007968A0255|16 22|segment
P11008139T0000|22 46|pattern discrimination task
P11008139T0000|10 17|learning
P11008420A0580|71 84|complex changes
P11008420A0580|17 25|advantage
P11008420A0580|3 10|detector
P11008420A0580|107 122|characterization
P11008420A0580|41 57|segment deviations
P11008420A0580|145 150|events
P11011139A0000|144 147|Sin4
P11011139A0000|62 76|mediator complex
P11011139A0000|153 162|alteration
P11011139A0000|114 120|studies
P11011139A0000|50 58|component
P11011139A0000|177 194|chromatin structure
P11011139A0000|91 103|RNA polymerase
P11011139A0000|32 46|SIN4 gene product
P11011139A0000|131 141|involvement
P11012568A0192|43 49|obesity
P11012568A0192|32 40|ACTH drive
P11012568A0192|14 29|hypersensitivity
P11012671A0576|74 82|C/EBPbeta
P11012671A0576|37 40|site
P11012671A0576|50 68|Gadd45gamma promoter
P11012671A0576|86 95|C/EBPdelta
P11012671A0576|163 182|reporter gene analysis
P11012671A0576|155 158|EMSA
P11012671A0576|136 153|mobility shift assay
P11012671A0576|2 9|addition
P11012680A0676|0 12|Src activation
P11012680A0676|71 79|inhibitor
P11012680A0676|52 54|Src
P11012680A0676|22 25|FGF1
P11012680A0676|58 60|PP2
P11012680A0676|82 84|Src
P11012680A0676|41 49|SH2 domain
P11012680A1020|116 122|PDGF-BB
P11012680A1020|103 113|stimulation
P11012680A1020|51 73|calcium chelator BAPTA-AM
P11012680A1020|76 82|oocytes
P11012680A1020|194 197|GVBD
P11012680A1020|37 44|neomycin
P11012680A1020|11 18|PLCgamma
P11012680A1020|165 183|PLCgamma binding site
P11012680A1020|125 131|oocytes
P11012680A1020|3 5|use
P11012680A1020|93 97|FGFR1
P11012680A1020|142 152|PDGFR-FGFR1
P11012680A1020|201 219|ERK2 phosphorylation
P11012680A1020|29 35|peptide
P11013079A0927|132 139|promoter
P11013079A0927|8 30|transcription start sites
P11013079A0927|193 204|SV40 promoter
P11013079A0927|86 107|transfection constructs
P11013079A0927|45 67|primer extension analysis
P11013079A0927|164 171|activity
P11013079A0927|73 81|mouse gene
P11014197A0339|60 69|inhibitors
P11014197A0339|106 116|subfamilies
P11014197A0339|7 24|inhibitor scaffolds
P11014197A0339|83 89|kinases
P11014213A1019|238 260|transcription factor GAL4
P11014213A1019|203 209|ERalpha
P11014213A1019|31 38|arsenite
P11014213A1019|227 232|domain
P11014213A1019|95 104|COS-1 cells
P11014213A1019|76 93|receptor activation
P11014213A1019|61 66|domain
P11014213A1019|195 200|domain
P11014213A1019|18 28|interaction
P11014213A1019|281 295|CAT reporter gene
P11014213A1019|148 162|receptors GAL-ER
P11014215A1092|129 134|region
P11014215A1092|191 205|down-regulation
P11014215A1092|213 233|GnRHR promoter activity
P11014215A1092|145 153|GnRHR gene
P11014215A1092|92 111|translation start site
P11014215A1092|55 65|DNA fragment
P11014215A1092|16 30|deletion studies
P11014465A0479|12 20|diagnosis
P11014465A0479|90 92|PVL
P11014465A0479|99 102|days
P11014465A0479|73 76|days
P11014465A0479|38 50|echodensities
P11014465A0479|104 108|range
P11014465A0479|64 68|range
P11014465A0479|7 9|day
P11014465A0479|59 62|days
P11014465A0479|113 116|days
P11014821T0000|3 21|LAMMER protein kinase
P11014821T0000|134 141|isoforms
P11014821T0000|34 41|Doa locus
P11014821T0000|152 162|development
P11014821T0000|80 92|germline cells
P11014821T0000|44 53|Drosophila
P11015197A0310|71 73|TM4
P11015197A0310|67 69|TMS
P11015197A0310|48 55|residues
P11015197A0310|30 33|time
P11015197A0310|15 22|cysteine
P11015200A0156|6 7|J.
P11016014A0181|132 139|patients
P11016014A0181|56 69|susceptibility
P11016014A0181|23 27|study
P11016014A0181|182 195|angina pectoris
P11016014A0181|157 165|syndromes
P11016014A0181|14 16|aim
P11016014A0181|98 109|lipoproteins
P11016014A0181|124 129|status
P11016014A0181|0 9|HYPOTHESIS
P11016014A0181|72 85|apolipoprotein
P11016724A0536|26 45|99mTc-HSA nanocolloid
P11016724A0536|10 12|MBq
P11016724A0536|18 23|microL
P11016724A0536|91 97|surgery
P11016724A0536|102 109|aliquots
P11016724A0536|2 7|group B
P11016724A0536|84 84|h
P11016737A0275|24 30|outcome
P11016737A0275|65 70|status
P11016850A0423|70 79|similarity
P11016850A0423|48 54|protein
P11016850A0423|9 19|DNA fragment
P11016850A0423|82 88|members
P11016850A0423|94 103|LysR family
P11016850A0423|121 130|regulators
P11016850A0423|132 136|LTTRs
P11016850A0423|41 44|part
P11016954A0438|42 46|RDE-1
P11016954A0438|15 19|QDE-2
P11016954A0438|58 61|RNAi
P11016954A0438|0 3|AGO1
P11017876A0787|123 128|mDAP-3
P11017876A0787|40 45|mDAP-3
P11017876A0787|147 152|matrix
P11017876A0787|65 81|cell fractionation
P11017876A0787|13 31|localization studies
P11017876A0787|47 63|EGFP fusion protein
P11017876A0787|85 113|protease protection experiments
P11018028A0263|88 94|CDC25Mm
P11018028A0263|21 31|involvement
P11018028A0263|126 131|RasGEF
P11018028A0263|142 151|mouse brain
P11018028A0263|164 172|membranes
P11018028A0263|97 107|fibroblasts
P11018028A0263|71 85|phosphorylation
P11018028A0263|48 60|protein kinase
P11018028A0263|62 64|PKA
P11018264A0397|0 29|Reporter gene expression analyses
P11018264A0397|67 72|levels
P11018264A0397|75 84|expression
P11018264A0397|109 117|cell lines
P11018264A0397|46 58|WASP promoters
P11019257A0159|69 77|decay rate
P11019257A0159|10 16|3T1-3T2
P11019257A0159|174 184|distortions
P11019257A0159|37 42|effect
P11019257A0159|80 87|emission
P11019257A0159|48 56|line shape
P11019257A0159|149 157|magnitude
P11019257A0159|95 102|3T2 state
P11019257A0159|113 118|extent
P11020375A0134|1 5|total
P11020375A0134|153 155|CLI
P11020375A0134|20 36|Ross broiler chicks
P11020375A0134|119 123|parts
P11020375A0134|104 106|g kg
P11020375A0134|169 173|ppb AF
P11020375A0134|160 164|ppb AF
P11020375A0134|90 96|control
P11020375A0134|111 114|diet
P11020375A0134|178 180|CLI
P11020375A0134|98 100|CLI
P11020375A0134|144 148|ppb AF
P11020375A0134|187 190|days
P11020375A0134|135 137|ppb
P11020375A0134|52 66|treatment groups
P11020375A0134|139 140|AF
P11023074A1105|3 6|cost
P11023074A1105|10 13|test
P11023074A1105|35 38|kEIA
P11023074A1105|32 33|CC
P11023074A1105|42 46|PACE2
P11023832A1038|15 21|results
P11023832A1038|138 150|protein kinase
P11023832A1038|152 160|MAP kinase
P11023832A1038|165 183|NF-kappaB signalling
P11023832A1038|76 81|PC-PLC
P11023832A1038|46 53|TNFalpha
P11023832A1038|36 44|KG1a cells
P11023832A1038|94 106|lipid products
P11023832A1038|117 120|turn
P11023832A1038|85 87|PLD
P11023853A0188|263 270|activity
P11023853A0188|230 241|energy budget
P11023853A0188|24 40|weather conditions
P11023853A0188|210 218|partition
P11023853A0188|183 199|energy expenditure
P11023853A0188|92 105|laboratory data
P11023853A0188|167 175|estimates
P11023853A0188|222 228|verdins
P11023853A0188|163 165|TAL
P11023853A0188|279 288|components
P11023853A0188|84 88|birds
P11023853A0188|124 127|rate
P11023853A0188|201 203|DEE
P11023853A0188|152 161|laboratory
P11023853A0188|61 70|budget data
P11023934A0855|0 2|L/H
P11023934A0855|94 103|predictors
P11023934A0855|106 111|events
P11023934A0855|45 58|filling pattern
P11023934A0855|21 21|P
P11023934A0855|9 11|chi
P11023934A0855|71 71|P
P11023934A0855|60 62|chi
P11024026A0133|88 94|binding
P11024026A0133|20 28|arrestins
P11024026A0133|7 17|selectivity
P11024026A0133|62 69|receptor
P11024026A0133|56 59|form
P11024026A0133|98 109|dissociation
P11024036A0984|117 126|constructs
P11024036A0984|62 83|reporter gene expression
P11024036A0984|35 60|C/EBP alpha expression vector
P11024036A0984|19 29|fibroblasts
P11024047A0626|29 33|Smad2
P11024047A0626|104 112|treatment
P11024047A0626|64 89|luciferase reporter activity
P11024047A0626|57 61|level
P11024047A0626|0 9|Expression
P11024182A0781|59 60|AR
P11024182A0781|13 13|I
P11024182A0781|6 11|alpha1
P11024182A0781|182 184|pCI
P11024182A0781|136 144|reduction
P11024182A0781|155 162|ribozyme
P11024182A0781|63 64|IR
P11024182A0781|120 120|%
P11024182A0781|186 194|neo vector
P11024182A0781|46 54|reduction
P11024182A0781|84 104|pHbetaAPr-1-neo vector
P11024182A0781|15 26|collagen mRNA
P11024300A1579|157 164|portions
P11024300A1579|181 192|reading frame
P11024300A1579|102 109|proteins
P11024300A1579|74 84|polypeptide
P11024300A1579|139 141|ARC
P11024300A1579|25 42|amino acid sequences
P11024300A1579|120 137|chromatin structure
P11024300A1579|195 203|TIG-1 mRNA
P11024300A1579|93 99|complex
P11024300A1579|45 60|peptide fragments
P11024300A1579|0 5|Nature
P11025367A1009|15 35|plasma cholecystokinin
P11025367A1009|54 61|patients
P11025367A1009|80 87|emptying
P11025367A1009|0 12|Abnormalities
P11027027A0061|75 79|LC/MS
P11027027A0061|85 106|electrospray ionization
P11027027A0061|2 16|Sunset Yellow FCF
P11027027A0061|43 73|chromatography/mass spectrometry
P11027267A0752|0 7|Polysome
P11027267A0752|11 30|40S ribosome fractions
P11027267A0752|57 66|krr1 mutant
P11027267A0752|84 88|cells
P11027274A1682|29 38|PI 3-kinase
P11027274A1682|108 116|structure
P11027274A1682|48 55|activity
P11027274A1682|123 129|isoform
P11027274A1682|70 76|extents
P11027280A0536|0 8|Cam kinase
P11027280A0536|49 53|Smad4
P11027280A0536|74 78|Smad3
P11027280A0536|24 38|phosphorylation
P11027280A0536|67 72|extent
P11027280A0536|41 45|Smad2
P11027289A0000|218 223|region
P11027289A0000|81 97|RNA binding protein
P11027289A0000|128 142|RNA accumulation
P11027289A0000|25 34|suppressor
P11027289A0000|180 199|transposon insertions
P11027289A0000|167 171|genes
P11027289A0000|99 100|SU
P11027289A0000|50 50|s
P11027289A0000|153 159|alleles
P11027289A0000|42 45|gene
P11027289A0000|102 102|S
P11027289A0321|72 89|RNA binding activity
P11027289A0321|39 44|motifs
P11027289A0321|95 95|S
P11027289A0321|3 8|result
P11027289A0321|92 93|SU
P11027289A0321|46 49|ARM1
P11027289A0321|53 56|ARM2
P11027294A0483|60 63|p300
P11027294A0483|26 57|histone acetyltransferase activity
P11027294A0483|126 135|alteration
P11027294A0483|83 91|reduction
P11027294A0483|105 122|histone acetylation
P11027294A0483|138 155|chromatin structure
P11027294A0483|4 14|interaction
P11027724A0335|45 47|Ser
P11027724A0335|66 73|residues
P11027724A0335|38 43|serine
P11027724A0335|78 82|p-Ser
P11027724A0335|11 17|BRI1-KD
P11027724A0335|52 60|threonine
P11027724A0335|62 64|Thr
P11027833A0362|0 11|Flow cytomery
P11027833A0362|22 38|cell cycle analysis
P11028131A1374|102 106|costs
P11028131A1374|7 14|research
P11028131A1374|109 118|IFN beta-1b
P11028131A1374|57 68|modification
P11028131A1374|71 72|MS
P11028131A1374|80 86|history
P11028131A1374|121 124|RRMS
P11028131A1374|33 55|measure treatment effects
P11028131T0000|0 17|Cost-effectiveness
P11028131T0000|54 83|sclerosis disability progression
P11028131T0000|20 36|interferon beta-1b
P11028944A1020|14 22|AUC values
P11028944A1020|7 10|Cmax
P11028944A1020|55 58|dose
P11029045A0000|0 14|Hyperactivation
P11029045A0000|41 45|cells
P11029045A0000|23 34|fission yeast
P11029045A0000|91 101|catastrophe
P11029045A0000|17 20|Cdc2
P11029045A0000|71 77|mitosis
P11029262T0000|0 4|Diary
P11029458A0000|0 4|Cells
P11029458A0000|50 56|stimuli
P11029458A0000|20 27|response
P11029459A0000|31 39|TGF-beta1
P11029459A0000|124 127|cell
P11029459A0000|50 64|tumor suppressor
P11029459A0000|12 29|growth factor-beta1
P11029459A0000|95 109|characteristics
P11029459A0000|68 80|tumor promoter
P11029467T0000|163 175|cell line THP-1
P11029467T0000|39 47|adenylate
P11029467T0000|20 26|peptide
P11029467T0000|114 127|gene activation
P11029467T0000|66 76|polypeptide
P11029467T0000|91 102|factor-kappa
P11029467T0000|138 143|levels
P11029656A0640|0 2|Mn2
P11029656A0640|67 74|proteins
P11029656A0640|20 34|junction binding
P11029656A0640|46 55|activities
P11029700A0295|17 18|Os
P11029700A0295|63 73|transcripts
P11029700A0295|44 50|tissues
P11029700A0295|8 11|cycH
P11029700A0295|105 109|cells
P11029700A0295|5 6|Pt
P11029700A0295|20 23|cycH
P11029700A0746|85 92|rice CDKs
P11029700A0746|45 48|CycH
P11029700A0746|70 71|R2
P11029700A0746|27 31|assay
P11029700A0746|42 43|Os
P11029704A0378|295 298|ABI3
P11029704A0378|79 87|distB ABRE
P11029704A0378|210 220|RY/G complex
P11029704A0378|128 142|transactivation
P11029704A0378|24 42|particle bombardment
P11029704A0378|232 240|RY repeats
P11029704A0378|11 18|analysis
P11029704A0378|278 292|transactivation
P11029704A0378|166 173|response
P11029704A0378|188 195|tetramer
P11029704A0378|45 63|tobacco leaf sections
P11029704A0378|112 118|element
P11029704A0378|145 148|ABI3
P11029704A0378|245 249|G-box
P11029704A0378|66 73|tetramer
P11029704A0378|176 178|ABA
P11030066A0142|20 33|manifestations
P11030066A0142|54 59|babies
P11030066A0142|36 46|brain injury
P11030066A0142|70 82|motor deficits
P11030476A0685|0 5|Spores
P11030476A0685|52 56|water
P11030476A0685|10 27|Rhizopus stolonifer
P11030476A0685|65 73|spores/mL
P11030744A0763|0 13|Overexpression
P11030744A0763|25 28|dpm1
P11030744A0763|46 47|S.
P11030744A0763|95 113|DPM synthase activity
P11030744A0763|77 84|increase
P11030744A0763|34 42|his7/dpm1
P11030744A0763|16 21|Trdpm1
P11031252A0646|142 147|amount
P11031252A0646|150 157|PKC delta
P11031252A0646|26 41|PKC epsilon levels
P11031252A0646|93 97|level
P11031252A0646|104 113|PKC isotype
P11031252A0646|66 75|HMW isoform
P11031252A0646|55 62|contrast
P11031252A0646|3 10|LMW FGF-2
P11031366T0001|0 17|Helicobacter pylori
P11031366T0001|21 35|stomach diseases
P11031366T0001|49 53|point
P11031366T0001|56 59|view
P11031773A0174|43 62|formalin induced-pain
P11031773A0174|7 13|purpose
P11031773A0174|26 29|test
P11031773A0174|65 68|mice
P11031773A0174|31 39|capsaicin
P11032599T0000|33 35|use
P11032599T0000|12 26|recommendations
P11032599T0000|69 75|factors
P11032599T0000|100 117|practice guidelines
P11032677A0230|59 63|plugs
P11032677A0230|147 153|atrophy
P11032677A0230|106 114|steatitis
P11032677A0230|189 197|glossitis
P11032677A0230|128 135|myopathy
P11032677A0230|9 16|findings
P11032677A0230|155 165|candidiasis
P11032677A0230|28 39|pancreatitis
P11034392A1072|41 56|survival pathways
P11034392A1072|138 150|proliferation
P11034392A1072|76 83|receptor
P11034392A1072|92 104|NF-kappaB/Rel
P11034392A1072|108 112|PI-3K
P11034392A1072|17 20|data
P11034547A0674|119 145|homeodomain recognition sites
P11034547A0674|40 48|multimers
P11034547A0674|82 84|DB1
P11034547A0674|95 101|element
P11034547A0674|8 11|Arix
P11034547A0674|70 76|binding
P11034547A0674|15 20|NBPhox
P11034547A1355|118 128|DBH promoter
P11034547A1355|18 22|study
P11034547A1355|34 39|NBPhox
P11034547A1355|27 30|Arix
P11034547A1355|103 112|properties
P11034933A0389|103 114|prolongation
P11034933A0389|143 159|nmol/L domperidone
P11034933A0389|124 137|repolarization
P11034933A0389|50 64|guinea pig hearts
P11034933A0389|10 16|RESULTS
P11034933A0389|18 24|Studies
P11034933A0389|0 6|METHODS
P11035037A0183|27 37|yeast TAF145
P11035037A0183|75 85|TBP function
P11035037A0183|39 45|yTAF145
P11035037A0183|18 24|segment
P11035037A0183|54 56|TBP
P11035867A0000|0 8|OBJECTIVE
P11035867A0000|287 305|blood pressure curves
P11035867A0000|107 115|Braun GmbH
P11035867A0000|248 266|blood pressure values
P11035867A0000|192 195|data
P11035867A0000|225 233|algorithm
P11035867A0000|211 219|selection
P11035867A0000|126 132|Germany
P11035867A0000|86 105|Braun PrecisionSensor
P11035867A0000|148 175|ANSI/AAMI SP10-1992 guidelines
P11035867A0000|117 124|Kronberg
P11035867A0000|60 84|wrist blood pressure monitor
P11035867A0000|30 40|performance
P11036786A0628|102 108|Animals
P11036786A0628|77 98|Drinking Water Standards
P11036786A0628|12 18|results
P11036786A0628|50 62|target animals
P11036786A0628|34 44|experiments
P11036938A1162|173 177|surge
P11036938A1162|24 33|expression
P11036938A1162|113 128|steroid secretion
P11036938A1162|148 150|day
P11036938A1162|180 192|gonadotropins
P11036938A1162|51 63|erbB receptors
P11036938A1162|92 103|augmentation
P11036938A1162|2 9|increase
P11036939A2149|28 35|pathways
P11036939A2149|53 73|planar polarity pathway
P11036939A2149|40 49|Wnt pathway
P11036939A2149|0 2|Dsh
P11037759T0000|0 13|Catch-up growth
P11037759T0000|48 61|administration
P11037759T0000|81 96|agent vincristine
P11037759T0000|29 38|dimensions
P11037759T0000|104 107|rats
P11037823A1134|0 10|CONCLUSIONS
P11037823A1134|12 27|LSCC malformation
P11037823A1134|155 158|SNHL
P11037823A1134|104 111|deafness
P11037823A1134|125 130|gusher
P11037823A1134|168 174|hearing
P11037823A1134|80 87|aqueduct
P11037823A1134|151 153|CHL
P11037823A1134|43 58|ear malformations
P11038042A0948|81 98|platelet nadir count
P11038042A0948|44 62|blood cell nadir count
P11038042A0948|77 77|l
P11038042A0948|15 19|mg/m2
P11038042A0948|0 9|Escalation
P11038118A0000|0 12|Methyl formate
P11038118A0000|64 74|fabrication
P11038118A0000|47 57|oligoesters
P11038118A0000|77 88|microspheres
P11038118A0000|111 122|serum albumin
P11038118A0000|124 126|BSA
P11038317A0000|130 134|cells
P11038317A0000|69 76|elements
P11038317A0000|82 90|machinery
P11038317A0000|103 117|membrane traffic
P11038317A0000|41 52|RAB subfamily
P11038317A0000|28 35|proteins
P11038366A1322|89 93|Rts1p
P11038366A1322|50 60|association
P11038366A1322|81 87|subunit
P11038366A1322|12 15|loss
P11038366A1322|18 28|methylation
P11038366A1322|70 74|yeast
P11038366A1417|71 79|complexes
P11038366A1417|5 15|methylation
P11038366A1417|49 52|PP2A
P11038366A1417|38 46|formation
P11038366A1417|18 23|Pph21p
P11038366A1417|100 111|PP2A function
P11039341A0180|157 160|task
P11039341A0180|95 104|components
P11039341A0180|3 9|purpose
P11039341A0180|44 58|characteristics
P11039341A0180|16 20|study
P11039341A0180|72 78|mapping
P11039341A0180|117 119|ICA
P11039780A0770|101 111|gene therapy
P11039780A0770|68 79|animal models
P11039780A0770|3 9|authors
P11039780A0770|184 206|osteoarthritis treatment
P11039780A0770|171 181|gene therapy
P11039780A0770|125 132|overview
P11039780A0770|27 33|studies
P11039780A0770|212 217|future
P11039780A0770|82 95|osteoarthritis
P11039780A0770|142 151|strategies
P11039780A0770|158 168|development
P11040101A1180|14 20|results
P11040101A1180|199 206|VEGF gene
P11040101A1180|181 193|transcription
P11040101A1180|110 115|levels
P11040101A1180|48 65|VEGF gene expression
P11040101A1180|165 168|turn
P11040101A1180|120 127|IL-1 beta
P11040101A1180|33 40|IL-1 beta
P11040101A1180|225 229|sites
P11040101A1180|134 140|p38 MAPK
P11040101A1180|144 156|JNK signalings
P11040219A0548|40 40|N
P11040219A0548|9 12|NusA
P11040219A0548|23 30|presence
P11040219A0548|117 120|NusA
P11040219A0548|65 80|S1 homology region
P11040219A0548|33 37|alpha
P11040219A0548|15 17|RNA
P11040219A0548|0 6|Binding
P11041308A0156|101 123|South Oaks Gambling Screen
P11041308A0156|36 41|DSM-IV
P11041308A0156|3 10|subjects
P11041308A0156|92 98|Version
P11041308A0156|125 128|SOGS
P11041308A0156|54 69|gambling criteria
P11041308A0156|29 33|basis
P11042197A0386|0 2|Lys
P11042197A0386|50 51|HD
P11042197A0386|11 13|Arg
P11042197A0386|45 47|end
P11042197A0386|68 79|dimerization
P11042199A0572|0 8|Elevation
P11042199A0572|137 142|medium
P11042199A0572|24 25|Ca
P11042199A0572|109 113|MK801
P11042199A0572|174 189|calcium elevation
P11042199A0572|58 66|treatment
P11042199A0572|98 107|nifedipine
P11042199A0572|115 121|removal
P11042199A0572|217 220|CREB
P11042199A0572|205 214|activation
P11042199A0572|146 155|dantrolene
P11042199A0572|124 125|Ca
P11042199A0572|90 96|protein
P11042199A0572|30 35|levels
P11042204A0186|62 80|p38 kinase activation
P11042204A0186|111 118|activity
P11042204A0186|24 43|phosphatidylinositol
P11042204A0186|10 14|study
P11042204A0186|126 136|neutrophils
P11042204A0186|90 107|Akt phosphorylation
P11042703A0875|96 97|mo
P11042703A0875|100 103|boys
P11042703A0875|87 91|girls
P11042703A0875|80 84|birth
P11042703A0875|65 74|increments
P11042703A0875|21 29|reference
P11042703A0875|4 7|BFDS
P11042703A0875|31 40|W/A Z scores
P11043469A0440|99 106|pTiChry5
P11043469A0440|114 120|T-right
P11043469A0440|13 27|border sequences
P11043469A0440|137 146|production
P11043469A0440|89 96|T-region
P11043469A0440|152 164|Amadoriopines
P11043469A0440|64 72|T-regions
P11043469A0440|122 123|TR
P11044097A0422|98 116|transcription factor
P11044097A0422|24 26|HMG
P11044097A0422|124 128|sites
P11044097A0422|72 76|sites
P11044097T0000|47 66|transcription factors
P11044097T0000|124 131|promoter
P11044097T0000|38 44|binding
P11044097T0000|90 114|immunodeficiency virus type
P11044097T0000|72 79|U5 region
P11044097T0000|19 25|protein
P11044105A0616|31 48|splicing suppressor
P11044105A0616|82 91|splice site
P11044105A0616|51 54|ESS1
P11044105A0616|66 68|use
P11044105A0616|74 75|nt
P11044105A0616|17 23|element
P11045180A1892|0 10|Leptinaemia
P11045180A1892|80 91|hypertension
P11045180A1892|109 122|classification
P11045180A1892|46 65|blood pressure reading
P11045180A1892|73 77|stage
P11045607A0239|61 62|bp
P11045607A0239|91 99|start site
P11045607A0239|31 57|transcription initiation site
P11045607A0239|3 14|RACE analysis
P11046146A1202|30 37|extracts
P11046146A1202|218 222|cells
P11046146A1202|99 112|concentrations
P11046146A1202|197 204|extracts
P11046146A1202|138 145|extracts
P11046146A1202|115 128|dithiothreitol
P11046146A1202|160 164|cells
P11046146A1202|189 194|levels
P11046146A1202|56 62|binding
P11046146A1202|5 20|diamide treatment
P11046146A1202|65 75|NFI proteins
P11046146A1202|173 186|NFI-DNA binding
P11046146A1202|83 90|addition
P11046148A0716|0 4|LMP2A
P11046148A0716|78 95|Nedd4 family members
P11046148A0716|13 15|Lyn
P11046148A0716|68 75|activity
P11046148A0716|19 35|Syk ubiquitination
P11046148A0716|133 149|Lyn tyrosine kinase
P11046148A0716|45 51|fashion
P11046148A0716|113 127|destabilization
P11046153A1052|61 70|expression
P11046153A1052|20 28|apoptosis
P11046153A1052|76 90|p300 coactivator
P11046517A0619|3 9|results
P11046517A0619|51 51|Z
P11046517A0619|34 34|Z
P11048832A0271|0 5|Fisher
P11048832A0271|19 25|Pearson
P11048832A0271|13 16|test
P11048832A0271|28 35|chi2 test
P11048832A0271|58 65|analysis
P11049241A0659|0 6|RESULTS
P11049241A0659|94 103|difference
P11049241A0659|21 25|group
P11049241A0659|177 177|p
P11049241A0659|76 77|ET
P11049241A0659|144 148|group
P11049241A0659|161 164|days
P11049241A0659|122 126|group
P11049241A0659|27 49|serum PP14 concentrations
P11049241A0659|174 175|ET
P11049889A1271|0 18|Thromboelastography
P11049889A1271|107 119|weight heparin
P11049889A1271|62 67|degree
P11049889A1271|22 25|test
P11049889A1271|70 84|anticoagulation
P11050084A0000|4 13|expression
P11050084A0000|94 96|fat
P11050084A0000|138 151|lipid oxidation
P11050084A0000|128 135|capacity
P11050084A0000|65 73|PPARalpha
P11050084A0000|51 63|receptor alpha
P11050084A0000|19 28|peroxisome
P11050084A0888|15 21|element
P11050084A0888|39 47|PPARgamma
P11050084A0888|27 35|PPARalpha
P11050084A0888|60 65|nuclei
P11050168A1185|164 184|stability determinants
P11050168A1185|144 150|protein
P11050168A1185|5 11|results
P11050168A1185|85 93|mRNA decay
P11050168A1185|25 32|evidence
P11050168A1185|48 61|susceptibility
P11050168A1185|122 129|affinity
P11051364A0890|44 49|group A
P11051364A0890|21 21|%
P11051364A0890|78 96|variceal eradication
P11051364A0890|23 30|patients
P11051364A0890|98 103|group B
P11051364A0890|34 36|PHG
P11051364A0890|70 72|PHG
P11051364A0890|59 59|%
P11051364A0890|0 6|RESULTS
P11051370A1906|0 7|Response
P11051370A1906|33 41|Americans
P11051370A1906|54 64|HCV genotype
P11053009A0000|0 6|Aspirin
P11053009A0000|19 24|ulcers
P11053009A0000|81 88|activity
P11053009A0000|92 113|prostaglandin synthesis
P11053009A0000|62 75|cyclooxygenase
P11053009A0000|77 79|COX
P11053263A0200|56 58|end
P11053263A0200|1 5|total
P11053263A0200|12 17|clones
P11053263A0200|41 50|sequencing
P11053370A0708|0 9|Expression
P11053370A0708|77 100|glutathione S-transferase
P11053370A0708|13 25|hybrid protein
P11053370A0708|124 135|Uhp signaling
P11053370A0708|66 69|UhpB
P11053370A0708|60 63|half
P11053370A0708|102 104|GST
P11054011A1685|0 10|CONCLUSIONS
P11054011A1685|106 113|survival
P11054011A1685|125 132|patients
P11054011A1685|189 195|Ecuador
P11054011A1685|69 87|locoregional control
P11054011A1685|98 98|%
P11054011A1685|183 187|Quito
P11054011A1685|49 52|MSGT
P11054011A1685|145 162|oncology department
P11054011A1685|38 46|treatment
P11054011A1685|91 91|%
P11054011A1685|117 122|series
P11054011A1685|173 180|hospital
P11054341A0599|0 6|RESULTS
P11054341A0599|89 105|SWAP abnormalities
P11054341A0599|64 67|SWAP
P11054341A0599|80 83|risk
P11054341A0599|113 116|risk
P11054341A0599|128 137|SWAP result
P11054341A0599|8 23|Glaucoma suspects
P11054341A0599|42 47|groups
P11054539A0114|97 98|bp
P11054539A0114|135 151|amino acid residues
P11054539A0114|61 72|reading frame
P11054539A0114|43 49|introns
P11054539A0114|118 128|polypeptide
P11054539A0114|87 95|base pairs
P11054539A0114|3 6|gene
P11054539A0114|26 30|exons
P11054565A0654|142 150|GAP domain
P11054565A0654|85 90|GTPase
P11054565A0654|7 16|p190-B exon
P11054565A0654|108 115|residues
P11054565A0654|32 37|p190-A
P11054565A0654|100 106|domains
P11054565A0654|188 196|structure
P11054565A0654|167 178|conservation
P11054565A0654|207 215|p190 genes
P11054565A0654|62 67|length
P11054565A0654|58 59|kb
P11054565A0654|26 29|exon
P11054571A0230|14 23|teneurin-1
P11054571A0230|93 101|locus Xq25
P11054571A0230|25 28|TEN1
P11054571A0230|52 60|PAC clones
P11054571A0230|73 76|part
P11054571A0230|30 33|gene
P11054970A0282|44 56|neurofibromas
P11054970A0282|3 23|plexiform neurofibroma
P11054970A0282|76 78|NF1
P11055513A0564|94 100|testing
P11055513A0564|9 16|lookback
P11055513A0564|40 44|blood
P11055513A0564|65 74|hepatitis C
P11055513A0564|21 28|patients
P11055786A0306|37 41|steps
P11055786A0306|11 19|algorithm
P11056007A0224|115 117|SET
P11056007A0224|180 183|rMTM
P11056007A0224|50 56|stretch
P11056007A0224|87 89|Gln
P11056007A0224|167 172|domain
P11056007A0224|128 144|Enhancer-of-zeste
P11056007A0224|98 100|Phe
P11056007A0224|21 30|amino acids
P11056007A0224|174 176|SID
P11056007A0224|64 71|sequence
P11056007A0224|33 39|FVVLNLQ
P11056007A0224|119 126|Suvar3-9
P11056007A0224|146 154|Trithorax
P11056019A0926|102 115|ethyl carbamate
P11056019A0926|45 50|adduct
P11056019A0926|53 53|N
P11056019A0926|12 30|glycosylase activity
P11056019A0926|86 98|vinyl chloride
P11056019A0926|74 83|metabolite
P11056019A0926|0 3|MED1
P11056019A0926|58 71|ethenocytosine
P11058008A0159|27 38|flap necrosis
P11058008A0159|50 54|flaps
P11058008A0159|11 19|instances
P11058008A0159|61 72|tip ischaemia
P11058119A0957|83 85|XPA
P11058119A0957|69 80|localization
P11058119A0957|23 26|XAB1
P11058119A0957|5 11|results
P11058119A0957|46 51|GTPase
P11058120A0256|71 75|IRF-1
P11058120A0256|10 16|factors
P11058120A0256|89 97|potential
P11058120A0256|18 22|IRF-2
P11058120A0256|58 68|counterpart
P11058132A0264|57 72|Bacillus subtilis
P11058132A0264|154 163|B.subtilis
P11058132A0264|38 45|proteins
P11058132A0264|101 110|comparison
P11058132A0264|21 35|% match sequences
P11058132A0264|135 143|organisms
P11058132A0264|80 80|%
P11058132A0264|118 125|proteins
P11058132A0264|13 16|CDSs
P11058406A0447|32 35|i.v.
P11058406A0447|52 66|circulation time
P11058406A0447|80 83|i.v.
P11058406A0447|96 113|tobramycin solution
P11058406A0447|17 19|SLN
P11059492A0376|0 8|Bacteriol
P11059777A0813|182 191|expression
P11059777A0813|85 94|activation
P11059777A0813|130 138|apoptosis
P11059777A0813|44 64|nick end labeling assays
P11059777A0813|174 178|BCL-X
P11059777A0813|157 171|down-regulation
P11059777A0813|8 23|deoxynucleotidyl
P11059777A0813|100 113|PAX3 repressors
P11059777A0813|180 180|L
P11059786A0682|0 19|VEGF promoter activity
P11059786A0682|141 142|PI
P11059786A0682|146 151|kinase
P11059786A0682|105 107|Ras
P11059786A0682|100 103|EGFR
P11059786A0682|31 43|transfections
P11059786A0682|111 130|phosphatidylinositol
P11059786A0682|88 97|inhibition
P11059786A0682|134 139|kinase
P11059786T0000|166 171|kinase
P11059786T0000|200 206|hypoxia
P11059786T0000|127 133|pathway
P11059786T0000|143 162|phosphatidylinositol
P11059786T0000|9 28|growth factor receptor
P11059786T0000|77 98|growth factor expression
P11059786T0000|106 122|glioblastoma cells
P11062047A1208|28 39|densoviruses
P11062047A1208|5 9|IHHNV
P11062047A1208|122 155|virus Penaeus stylirostris densovirus
P11062047A1208|157 162|PstDNV
P11062047A1208|70 87|family Parvoviridae
P11062047A1208|45 64|genus Brevidensovirus
P11062067A0000|16 28|protein kinase
P11062067A0000|63 68|kinase
P11062067A0000|144 151|stresses
P11062067A0000|48 52|c-Jun
P11062067A0000|70 72|JNK
P11062067A0000|125 133|cytokines
P11062067A0000|99 106|response
P11062067A0000|31 35|SAPK1
P11062068T0000|46 48|MAP
P11062068T0000|50 68|kinase phosphatase-1
P11062068T0000|142 151|regulation
P11062068T0000|80 91|p38 MAP kinase
P11062068T0000|38 44|protein
P11062068T0000|110 112|p38
P11062068T0000|9 18|activation
P11062068T0000|123 128|domain
P11062068T0000|101 104|role
P11062257A0977|58 64|docking
P11062257A0977|163 178|transport process
P11062257A0977|40 48|reactions
P11062257A0977|76 83|vesicles
P11062257A0977|133 143|specificity
P11062257A0977|91 97|vacuole
P11062257A0977|8 24|class C-Vps complex
P11062257A0977|68 73|fusion
P11062257A0977|147 156|efficiency
P11062274T0000|88 93|stroke
P11062274T0000|47 72|tissue plasminogen activator
P11062705A0658|56 69|cancer cell line
P11062705A0658|23 26|role
P11062705A0658|43 47|ATF-2
P11063127A0000|0 17|Signal transduction
P11063127A0000|134 137|acid
P11063127A0000|139 140|OA
P11063127A0000|21 30|modulation
P11063127A0000|151 157|effects
P11063127A0000|93 94|PP
P11063127A0000|62 71|inhibition
P11063127A0000|121 124|role
P11063127A0000|33 47|phosphorylation
P11063127A0000|74 91|protein phosphatase
P11063127A0000|103 106|PP2A
P11063169T0000|0 14|Botulinum toxin A
P11063169T0000|48 55|foot drop
P11063169T0000|79 86|outcomes
P11063169T0000|20 28|treatment
P11063252A0437|28 29|kb
P11063252A0437|37 59|HSL translation start site
P11063252A0437|0 4|Exon A
P11063742A0000|0 8|NF-kappaB
P11063742A0000|27 45|transcription factor
P11063742A0000|89 96|chemical
P11063742A0000|110 119|reductants
P11063742A0000|75 80|stress
P11064829T0058|0 24|Cardiovascular risk factors
P11064829T0058|44 52|treatment
P11066245T0000|45 52|mistakes
P11066245T0000|59 62|SNFs
P11066245T0000|20 35|compliance review
P11067797A1306|92 99|function
P11067797A1306|135 148|BV distribution
P11067797A1306|170 179|components
P11067797A1306|110 119|assessment
P11067797A1306|12 25|EBCT technology
P11067797A1306|49 58|evaluation
P11067797A1306|0 10|CONCLUSIONS
P11067928A0532|71 81|Jkappa genes
P11067928A0532|23 23|V
P11067928A0532|25 25|H
P11067928A0532|61 66|Vkappa
P11067928A0532|32 32|H
P11067928A0532|8 11|mAbs
P11067928A0532|59 59|D
P11067928A0532|34 45|gene segments
P11067928A0532|30 30|J
P11069011A0224|0 13|SSF experiments
P11069011A0224|65 67|CO2
P11069011A0224|152 160|pesticide
P11069011A0224|127 135|materials
P11069011A0224|103 109|mixture
P11069011A0224|41 51|bioreactors
P11069011A0224|86 90|traps
P11069075T0000|0 15|Characterization
P11069075T0000|82 96|cell development
P11069075T0000|54 65|implications
P11069075T0000|19 51|Xenopus laevis CXC chemokine receptor
P11069075T0000|102 117|vertebrate embryo
P11069223A0593|0 7|Patients
P11069223A0593|25 29|liver
P11069223A0593|40 54|marrow functions
P11069307A0546|0 9|Inhibition
P11069307A0546|46 51|effect
P11069307A0546|82 92|translation
P11069307A0546|110 128|replication factor 1a
P11069307A0546|95 97|BMV
P11069307A0546|12 26|RNA2 translation
P11069307A0546|162 171|antagonist
P11069307A0546|69 79|translation
P11069307A0546|149 151|p20
P11069307A0546|174 185|DED1 function
P11069307A0546|188 198|translation
P11069756A2618|425 426|PS
P11069756A2618|148 160|GRK interacter
P11069756A2618|208 210|GRK
P11069756A2618|386 405|paxillin kinase linker
P11069756A2618|144 146|GIT
P11069756A2618|281 283|ERK
P11069756A2618|520 521|SH
P11069756A2618|445 460|phosphothreonine
P11069756A2618|96 118|Papillomavirus E6 protein
P11069756A2618|42 43|CH
P11069756A2618|442 443|PT
P11069756A2618|93 94|E6
P11069756A2618|465 479|phosphotyrosine
P11069756A2618|338 346|subdomain
P11069756A2618|285 287|p38
P11069756A2618|318 320|PBS
P11069756A2618|382 384|PKL
P11069756A2618|162 165|GPCR
P11069756A2618|481 483|RTK
P11069756A2618|267 279|protein kinase
P11069756A2618|535 540|domain
P11069756A2618|428 440|phosphoserine
P11069756A2618|412 418|partner
P11069756A2618|199 206|receptor
P11069756A2618|289 291|JNK
P11069756A2618|407 410|POR1
P11069756A2618|83 91|SRC kinase
P11069756A2618|129 142|adhesion kinase
P11069756A2618|348 350|PIX
P11069756A2618|294 296|PAK
P11069756A2618|32 40|substrate
P11069756A2618|212 243|G-protein-coupled-receptor kinase
P11069756A2618|462 463|PY
P11069756A2618|421 423|Rac
P11069756A2618|69 71|CSK
P11069756A2618|311 316|kinase
P11069756A2618|120 122|FAK
P11069756A2618|14 16|CAS
P11069756A2618|0 12|Abbreviations
P11069756A2618|245 248|MAPK
P11069756A2618|485 518|growth factor receptor tyrosine kinase
P11069756A2618|62 67|domain
P11069756A2618|367 380|exchange factor
P11069788A0531|92 94|Pga
P11069788A0531|175 177|cm H
P11069788A0531|151 154|PEEP
P11069788A0531|70 83|difference PEEP
P11069788A0531|159 164|dyn ref
P11069788A0531|107 110|mean
P11069788A0531|25 26|SB
P11069788A0531|126 128|cm H
P11069788A0531|47 54|patients
P11069788A0531|132 132|O
P11069788A0531|181 181|O
P11069788A0531|101 105|decay
P11069788A0531|114 115|SD
P11069791A0226|57 58|mg
P11069791A0226|48 51|dose
P11069791A0226|74 75|mo
P11069791A0226|170 172|IPT
P11069791A0226|109 111|IPT
P11069791A0226|135 142|Regimen B
P11069791A0226|13 20|subjects
P11069791A0226|42 44|IPT
P11069791A0226|176 177|mg
P11069791A0226|77 84|Regimen A
P11069791A0226|132 133|mo
P11069791A0226|187 188|mo
P11069791A0226|115 116|mg
P11069791A0226|190 197|Regimen C
P11069825A0530|52 60|follow-up
P11069825A0530|73 81|incidence
P11069825A0530|12 16|cases
P11069825A0530|19 30|tuberculosis
P11069825A0530|48 49|yr
P11069897A1112|5 11|results
P11069897A1112|25 30|BACH1t
P11069897A1112|63 65|BTB
P11069897A1112|39 43|BACH1
P11069897A1112|81 91|interaction
P11069897A1112|49 55|nucleus
P11069999A1602|3 9|U17/U16
P11069999A1602|49 54|HIV LTR
P11069999A1602|20 31|gene products
P11069999A1602|16 18|U16
P11070007A0136|73 78|B cells
P11070007A0136|134 136|end
P11070007A0136|113 114|Wp
P11070007A0136|147 152|genome
P11070007A0136|21 29|EBNA genes
P11070007A0136|108 109|Cp
P11070007A0136|98 106|promoters
P11070007A0136|0 12|Transcription
P11070056A0704|54 61|Lian-Aa1
P11070056A0704|64 71|mosquito
P11070056A0704|25 34|similarity
P11070056A0704|40 51|RNaseH domain
P11070056A0704|79 93|retrotransposon
P11070056A0704|3 17|Cili-2 sequences
P11070078A1153|199 203|cells
P11070078A1153|100 109|repression
P11070078A1153|48 72|Rb tumor suppressor pathways
P11070078A1153|11 18|response
P11070078A1153|187 193|signals
P11070078A1153|136 143|pathways
P11070078A1153|112 116|HPV E6
P11070078A1153|42 44|p53
P11070078A1153|171 176|growth
P11070078A1153|120 121|E7
P11070078A1153|84 92|HeLa cells
P11070078A1153|155 161|fashion
P11071651A1308|33 39|pathway
P11071651A1308|92 108|retinoid induction
P11071651A1308|111 127|FR-beta expression
P11071651A1308|58 72|differentiation
P11071789T0000|30 42|ACE inhibitors
P11071789T0000|52 63|heart failure
P11071789T0000|18 27|dose levels
P11071852A0297|57 62|SOCS-3
P11071852A0297|18 23|SOCS-3
P11071852A0297|126 135|muscle mRNA
P11071852A0297|96 108|chain reaction
P11071852A0297|38 42|IGFIR
P11071924A0588|151 158|activity
P11071924A0588|134 140|domains
P11071924A0588|46 53|activity
P11071924A0588|106 110|SLI-1
P11071924A0588|87 103|RING finger domains
P11071924A0588|24 40|RING finger domains
P11071924A0588|81 83|SH2
P11071924A0588|67 73|protein
P11071924A0588|18 20|SH2
P11071924A0588|143 147|c-Cbl
P11071924A0588|1 7|protein
P11071974A0155|13 19|effects
P11071974A0155|100 111|lipid profile
P11071974A0155|150 173|plasma homocysteine levels
P11071974A0155|91 97|changes
P11071974A0155|179 187|treatment
P11071974A0155|113 123|coagulation
P11071974A0155|127 145|fibrinolysis markers
P11071974A0155|63 66|ESRD
P11071974A0155|32 38|factors
P11071974A0155|22 24|HRT
P11071974A0155|55 61|disease
P11071974A0155|68 75|patients
P11072155A0764|42 48|TGF beta
P11072155A0764|24 34|correlation
P11072155A0764|50 55|levels
P11072155A0764|65 84|cell radiosensitivity
P11072155A0764|86 98|lymphocyte SF2
P11072388T0000|28 51|smoking reduction strategy
P11072388T0000|19 24|safety
P11072388T0000|66 78|schizophrenia
P11072388T0000|5 15|feasibility
P11072388T0000|55 61|smokers
P11073163A0131|133 144|cell survival
P11073163A0131|25 35|degradation
P11073163A0131|81 84|role
P11073163A0131|90 99|proteasome
P11073163A0131|113 129|cell proliferation
P11073163A0131|38 45|proteins
P11073163A0131|57 72|cell cycle control
P11073218A0800|78 83|region
P11073218A0800|51 57|U.G pair
P11073218A0800|8 17|nucleotide
P11073539A0866|29 34|desmin
P11073539A0866|47 51|cells
P11073539A0866|10 17|analysis
P11073539A0866|37 40|SW13
P11073539A0866|85 90|clumps
P11073539A0866|107 114|material
P11073539A0866|137 145|cytoplasm
P11073539A0866|42 44|vim
P11073539A0866|58 68|aggregation
P11073870A0375|86 88|PRC
P11073870A0375|12 18|lesions
P11073870A0375|179 180|s.
P11073870A0375|107 116|oculomotor
P11073870A0375|124 135|response task
P11073870A0375|66 72|lesions
P11073870A0375|47 49|PHC
P11073870A0375|54 61|patients
P11073870A0375|31 33|PRC
P11073870A0375|92 94|PHC
P11073870A0375|159 170|memory delays
P11073870A0375|0 7|Patients
P11073919A0631|288 305|dimer stabilization
P11073919A0631|133 136|D361
P11073919A0631|88 91|E274
P11073919A0631|39 41|E94
P11073919A0631|138 141|D364
P11073919A0631|98 101|R277
P11073919A0631|208 216|formation
P11073919A0631|156 159|F397
P11073919A0631|43 46|D134
P11073919A0631|93 96|G276
P11073919A0631|248 253|domain
P11073919A0631|148 151|Y389
P11073919A0631|48 51|R154
P11073919A0631|103 106|Y278
P11073919A0631|128 131|C360
P11073919A0631|68 71|G235
P11073919A0631|78 81|G237
P11073919A0631|123 126|D332
P11073919A0631|73 76|G236
P11073919A0631|277 282|domain
P11073919A0631|83 86|F238
P11073919A0631|143 146|G387
P11073919A0631|31 33|K69
P11073919A0631|35 37|D88
P11073919A0631|323 326|ODCs
P11073919A0631|118 121|Y331
P11073919A0631|63 66|D233
P11073919A0631|108 111|K294
P11073919A0631|161 177|mouse ODC numbering
P11073919A0631|13 29|amino acid residues
P11073919A0631|2 9|addition
P11073919A0631|53 56|K169
P11073919A0631|347 362|S. ruminantium LDC
P11073919A0631|58 61|H197
P11073919A0631|113 116|Y323
P11073954A0337|26 37|reading frame
P11073954A0337|50 66|CP2 family proteins
P11073954A0337|3 10|Psc2 cDNA
P11074003A0741|73 77|CGNPs
P11074003A0741|22 24|Shh
P11074003A0741|3 9|results
P11074003A0741|42 48|cycling
P11074210A0623|87 104|insulin sensitivity
P11074210A0623|82 83|BP
P11074210A0623|47 71|insulin resistance syndrome
P11074210A0623|32 41|components
P11074210A0623|3 12|QT interval
P11075678A0298|3 13|wavenumbers
P11075678A0298|76 78|DFT
P11075678A0298|180 189|force field
P11075678A0298|90 90|G
P11075678A0298|38 42|modes
P11075678A0298|94 106|approximation
P11075678A0298|80 86|B3LYP/6
P11075678A0298|115 123|agreement
P11075678A0298|139 144|values
P11075678A0298|45 53|vibration
P11075929A1657|81 89|formation
P11075929A1657|51 60|metabolism
P11075929A1657|114 121|function
P11075929A1657|3 6|data
P11075929A1657|20 27|evidence
P11075929A1657|124 127|ThlB
P11075929A1657|32 35|ThlA
P11075929A1657|67 70|acid
P11075944A0691|85 93|androgens
P11075944A0691|45 48|fgf8
P11075944A0691|11 14|npm3
P11075944A0691|51 63|MMTV insertion
P11075944A0691|96 104|SC-3 cells
P11075944A0691|2 9|addition
P11076860A0872|45 49|UEV1A
P11076860A0872|174 185|localization
P11076860A0872|79 81|Kua
P11076860A0872|113 122|structures
P11076860A0872|141 149|Kua domain
P11076860A0872|60 66|protein
P11076860A0872|29 36|proteins
P11076860A0872|188 194|Kua-UEV
P11076860A0872|85 91|Kua-UEV
P11076860A0872|0 10|Experiments
P11078726X0000|225 231|enzymes
P11078726X0000|14 28|phosphorylation
P11078726X0000|197 202|domain
P11078726X0000|41 46|Ser315
P11078726X0000|260 263|role
P11078726X0000|246 251|domain
P11078726X0000|105 123|transcription factor
P11078726X0000|36 38|p53
P11078726X0000|84 101|p53 protein activity
P11078726X0000|70 82|transcription
P11078726X0000|290 303|gene expression
P11078726X0000|146 155|antibodies
P11080796A0883|73 80|IKKgamma
P11080796A0883|24 31|cell line
P11080796A0883|52 54|IKK
P11080796A0883|37 46|expression
P11080796A0883|65 71|protein
P11080796A1277|145 147|Tax
P11080796A1277|70 77|IKKalpha
P11080796A1277|49 51|IKK
P11080796A1277|81 87|IKKbeta
P11080796A1277|61 68|subunits
P11080796A1277|41 43|Tax
P11080796A1277|3 25|Tax/IKKgamma interaction
P11080796A1277|96 106|recruitment
P11080796A1277|171 173|IKK
P11080796A1277|161 168|activity
P11080796A1277|129 137|mechanism
P11081962T0000|51 55|Avena
P11081962T0000|39 41|map
P11081962T0000|10 13|AFLP
P11082185A0415|29 32|type
P11082185A0415|80 84|IRF-1
P11082185A0415|68 77|amino acids
P11082185A0415|124 131|activity
P11082185A0415|45 50|domain
P11082185A0415|2 9|addition
P11082587X0000|0 6|Effects
P11082587X0000|170 173|SBBS
P11082587X0000|105 113|influence
P11082587X0000|116 133|laser beam smoothing
P11082587X0000|92 101|model limit
P11082587X0000|225 233|spot model
P11082587X0000|201 205|limit
P11082587X0000|48 66|brillouin scattering
P11082587X0000|27 35|smoothing
P11082587X0000|146 168|Brillouin backscattering
P11082715X0001|178 188|metabolites
P11082715X0001|27 38|theophylline
P11082715X0001|105 110|method
P11082715X0001|45 55|metabolites
P11082715X0001|160 171|theophylline
P11082715X0001|194 201|caffeine
P11082715X0001|100 103|HPLC
P11082715X0001|208 218|metabolites
P11082715X0001|68 78|performance
P11082715X0001|145 157|determination
P11082715X0001|12 24|determination
P11082715X0001|58 61|HPLC
P11082715X0001|85 98|chromatography
P11083154A0881|54 62|heart rate
P11083154A0881|38 52|oxygen uptake VO2
P11083154A0881|64 82|minute ventilation VE
P11083154A0881|21 34|test conditions
P11083154A0881|93 100|exertion
P11083154A0881|110 118|shrinkage
P11083154A0881|3 7|males
P11083358A1071|0 9|CONCLUSION
P11083358A1071|50 57|patients
P11083358A1071|11 13|SPT
P11083358A1071|30 32|WST
P11083358A1071|71 80|aspiration
P11083432A0332|29 35|control
P11083432A0332|50 50|n
P11083432A0332|37 37|n
P11083432A0332|62 62|n
P11083432A0332|57 60|FK-3
P11083432A0332|7 12|groups
P11083432A0332|45 48|FK-1
P11083868A0386|0 9|DNA binding
P11083868A0386|113 133|transactivation domain
P11083868A0386|82 86|Elk-1
P11083868A0386|67 73|binding
P11083868A0386|46 51|assays
P11083868A0386|13 36|glutathione S-transferase
P11084022A1178|45 50|change
P11084022A1178|82 95|cell flattening
P11084022A1178|53 66|cell morphology
P11084022A1178|13 25|ALK7 signaling
P11084022A1178|123 135|cell processes
P11084022A1178|99 109|elaboration
P11084334A0590|186 193|proteins
P11084334A0590|107 111|motif
P11084334A0590|95 97|TPR
P11084334A0590|53 65|point mutation
P11084334A0590|39 44|screen
P11084334A0590|161 171|interaction
P11084334A0590|3 14|swa2-1 allele
P11084334A0590|144 151|proteins
P11084334A0590|122 128|auxilin
P11084334A0590|99 104|domain
P11084334A0590|71 93|tetratricopeptide repeat
P11084556T0000|0 10|Association
P11084556T0000|13 18|stress
P11084556T0000|111 119|cord blood
P11084556T0000|25 32|delivery
P11084556T0000|64 68|cells
P11084556T0000|46 52|numbers
P11084556T0000|85 99|progenitor cells
P11084649A0497|155 162|mesoderm
P11084649A0497|50 53|side
P11084649A0497|87 98|gastrulation
P11084649A0497|59 64|embryo
P11084649A0497|122 129|epiblast
P11084649A0497|100 109|expression
P11084649A0497|26 35|expression
P11084649A0497|15 21|embryos
P11084649A0497|80 84|onset
P11084649A0497|179 184|streak
P11084649A0497|70 71|E6
P11084649A0497|139 146|endoderm
P11085267A0562|0 13|Transformation
P11085267A0562|35 39|sconB
P11085267A0562|19 30|sconC3 mutant
P11085267A0562|61 69|phenotype
P11085600A0123|41 46|inputs
P11085600A0123|80 85|region
P11085600A0123|62 67|cortex
P11085600A0123|137 147|information
P11085600A0123|3 9|authors
P11086872A0000|0 8|Influence
P11086872A0000|11 22|oil emulsions
P11086872A0000|26 33|diphenyl
P11086872A0000|66 72|changes
P11086872A0000|86 103|Citrus aurantifolia
P11086872A0000|75 84|Kagzi limes
P11087141A0977|119 126|evidence
P11087141A0977|8 15|analysis
P11087141A0977|26 38|GT transcripts
P11087141A0977|66 81|splicing patterns
P11087141A0977|102 107|region
P11087141A0977|18 23|alpha1
P11087141A0977|112 114|UTR
P11087141A0977|135 150|splicing activity
P11087141A0977|179 184|manner
P11088635A0200|119 131|usage patterns
P11088635A0200|88 93|source
P11088635A0200|63 70|computer
P11088635A0200|52 59|coupling
P11088635A0200|8 37|Kubo-Martin-Schwinger condition
P11088635A0200|137 142|system
P11089911A1267|118 129|ATLN elements
P11089911A1267|95 112|retrotransposition
P11089911A1267|76 88|transcription
P11089911A1267|45 51|regions
P11089911A1267|17 25|sequences
P11090172A0612|15 29|RNA1 replication
P11090172A0612|33 45|RNA3 synthesis
P11090172A0612|103 114|FHV virion RNA
P11090172A0612|76 80|yeast
P11090172A0612|55 59|yeast
P11090172A0612|3 12|time course
P11090272A1240|30 37|splicing
P11090272A1240|52 55|GAIP
P11090272A1240|45 48|ORL1
P11090272A1240|3 15|transcription
P11090762A0527|144 156|power increase
P11090762A0527|23 32|muscle pain
P11090762A0527|55 65|stimulation
P11090762A0527|97 104|increase
P11090762A0527|107 111|delta
P11090762A0527|141 142|Hz
P11090762A0527|177 189|parietal locus
P11090762A0527|116 117|Hz
P11090762A0527|15 20|effect
P11090762A0527|119 123|power
P11090762A0527|129 135|alpha-1
P11090762A0527|0 6|RESULTS
P11092770A0238|132 132|%
P11092770A0238|105 114|extraction
P11092770A0238|116 126|specificity
P11092770A0238|82 90|predictor
P11092770A0238|73 78|class C
P11092770A0238|136 146|sensitivity
P11092770A0238|3 12|extraction
P11092770A0238|157 157|%
P11092809A0823|14 20|results
P11092809A0823|74 81|mesoderm
P11092809A0823|36 40|PI3Ks
P11092809A0823|62 69|ectoderm
P11092809A0823|2 9|addition
P11092809A0823|29 32|ERKs
P11092850A1023|56 63|tuf genes
P11092850A1023|149 155|lineage
P11092850A1023|98 104|species
P11092850A1023|78 85|ancestor
P11092850A1023|118 121|copy
P11092850A1023|7 33|16S rRNA gene sequence analysis
P11092850A1023|40 46|species
P11092850A1023|172 179|ancestor
P11092886A0341|45 53|CREMalpha
P11092886A0341|13 37|protein kinase A stimulation
P11092886A0341|67 73|complex
P11092886A0341|93 124|phosphoenolpyruvate carboxykinase
P11092886A0341|132 135|gene
P11092886A0341|80 87|promoter
P11092886A0341|126 130|PEPCK
P11093745A0563|15 22|HNF3 site
P11093745A0563|92 98|element
P11093745A0563|43 53|NF1/CTF site
P11093745A0563|30 39|apposition
P11094066A0505|19 28|regulation
P11094066A0505|140 145|manner
P11094066A0505|108 122|FKHR-L1 activity
P11094066A0505|42 51|modulation
P11094066A0505|95 98|IL-3
P11094066A0505|57 90|forkhead transcription factor FKHR-L1
P11094066A1194|181 193|proliferation
P11094066A1194|55 57|p27
P11094066A1194|132 140|mechanism
P11094066A1194|64 76|transcription
P11094066A1194|59 62|KIP1
P11094066A1194|19 30|observations
P11094066A1194|96 117|FKHR-L1 phosphorylation
P11094066A1194|170 177|survival
P11094066A1194|43 52|inhibition
P11094072A0842|0 4|DNase
P11094072A0842|77 83|fashion
P11094072A0842|40 48|c-Myb site
P11094072A0842|13 24|footprinting
P11094072A1234|14 18|c-Myb
P11094072A1234|31 43|RAG-2 promoter
P11094072A1234|88 91|site
P11094072A1234|67 80|consensus c-Myb
P11094072A1234|46 51|T cells
P11094073A0000|131 135|yeast
P11094073A0000|20 25|member
P11094073A0000|73 104|Ros receptor protein tyrosine kinase
P11094073A0000|106 109|RPTK
P11094073A0000|49 52|Vav3
P11094073A0000|122 128|protein
P11094073A0000|146 154|screening
P11094073A0000|31 47|Vav family proteins
P11094075A0257|72 86|rat thyroid cells
P11094075A0257|26 37|reexpression
P11094075A0257|131 147|v-ras-Ki oncogenes
P11094075A0257|172 180|phenotype
P11094075A0257|123 127|v-mos
P11094075A0257|100 111|retroviruses
P11094075A0257|43 54|r-PTPeta gene
P11094087T0000|121 133|kinase pathway
P11094087T0000|7 16|expression
P11094087T0000|39 52|transformation
P11094087T0000|19 22|Rnd3
P11094087T0000|74 78|cells
P11094091A0000|87 101|phosphorylation
P11094091A0000|65 71|stimuli
P11094091A0000|113 125|serine residue
P11094091A0000|127 132|Ser133
P11094091A0000|16 38|transcription factor CREB
P11094091A0000|3 10|activity
P11094109A0600|15 17|age
P11094109A0600|39 43|years
P11094109A0600|20 31|symptom onset
P11094109A0600|0 6|RESULTS
P11094590A0617|116 118|VAP
P11094590A0617|72 79|bacteria
P11094590A0617|129 131|PTC
P11094590A0617|249 249|%
P11094590A0617|105 113|diagnosis
P11094590A0617|123 125|PSB
P11094590A0617|204 208|value
P11094590A0617|165 175|specificity
P11094590A0617|62 69|presence
P11094590A0617|163 163|%
P11094590A0617|184 184|%
P11094590A0617|217 217|%
P11094590A0617|145 155|sensitivity
P11094590A0617|6 11|fields
P11094590A0617|237 241|value
P11094590A0617|32 43|relationship
P11094590A0617|82 93|Gram staining
P11095248A0423|18 25|proteins
P11095248A0423|157 160|gp27
P11095248A0423|77 80|gp31
P11095248A0423|64 75|glycoprotein
P11095248A0423|107 114|cleavage
P11095248A0423|27 31|XFGF3
P11095248A0423|149 155|product
P11095248A0423|56 57|Mr
P11095248A1523|22 28|Xenopus
P11095248A1523|41 45|FGF3s
P11095248A1523|92 99|activity
P11095248A1523|61 72|prerequisite
P11095981A0254|45 55|replication
P11095981A0254|22 33|cis-elements
P11095981A0254|107 114|plasmids
P11095981A0254|130 138|mutations
P11095981A0254|68 77|bp promoter
P11095981A0254|142 150|deletions
P11096662T0000|14 20|Therapy
P11096662T0000|31 43|Artery Disease
P11096662T0000|0 8|Tranilast
P11097040A0000|112 119|freezing
P11097040A0000|221 234|dog spermatozoa
P11097040A0000|47 53|effects
P11097040A0000|150 154|rates
P11097040A0000|25 29|study
P11097040A0000|62 66|Equex
P11097040A0000|239 247|degrees C.
P11097040A0000|211 218|survival
P11097040A0000|70 82|TRIS-extender
P11097040A0000|95 99|semen
P11097040A0000|106 110|steps
P11097040A0000|162 173|interactions
P11097040A0000|186 195|treatments
P11097040A0000|132 138|methods
P11097040A0000|3 12|objectives
P11097079A0525|4 8|study
P11097079A0525|50 58|clinician
P11097079A0525|35 44|validation
P11097079A0525|64 73|NIMH-LCM-p
P11098217A0674|3 11|Aie1 locus
P11098217A0674|23 43|mouse chromosome 7A2-A3
P11098217A0674|63 75|hybridization
P11098420A0175|120 126|suicide
P11098420A0175|11 19|disorders
P11098420A0175|33 43|adolescents
P11098420A0175|22 29|children
P11098420A0175|109 117|mortality
P11098420A0175|77 87|development
P11098420A0175|61 69|morbidity
P11099377T0000|49 96|proteoglycan core protein beta-d-xylosyltransferase
P11099377T0000|9 15|cloning
P11099377T0000|108 119|isoform XT-II
P11099377T0000|36 47|UDP-d-Xylose
P11099377T0000|19 28|expression
P11100515A0282|0 13|Thyrotoxicosis
P11100515A0282|19 28|amiodarone
P11100515A0282|140 145|effect
P11100515A0282|89 97|potential
P11100515A0282|151 170|amiodarone withdrawal
P11100515A0282|100 113|thyrotoxicosis
P11101008A0649|0 14|Chaperones/HSPs
P11101008A0649|32 36|roles
P11101008A0649|43 60|cell cycle processes
P11101847A0159|99 102|refs
P11101847A0159|48 60|stabilization
P11101847A0159|9 18|signalling
P11101847A0159|64 73|activation
P11101847A0159|21 24|E2F1
P11101847A0159|79 97|tumour suppressor p53
P11102367A1170|42 49|identity
P11102367A1170|23 33|conclusions
P11102367A1170|105 114|Drosophila
P11102367A1170|147 154|approach
P11102367A1170|193 201|mutations
P11102367A1170|74 84|development
P11102367A1170|52 59|proteins
P11102367A1170|97 102|system
P11102367A1170|4 8|study
P11102367A1170|221 227|screens
P11102367A1170|128 134|example
P11102367A1170|171 175|masse
P11102458A0000|147 148|nm
P11102458A0000|156 159|type
P11102458A0000|107 109|kDa
P11102458A0000|95 101|protein
P11102458A0000|13 26|identification
P11102458A0000|135 138|site
P11102458A0000|181 194|protein kinase A
P11102458A0000|55 66|neurobeachin
P11102458A0000|37 52|characterization
P11102458A0000|196 201|PKA RII
P11102458A0000|140 140|K
P11102458A0000|142 142|d
P11102458A0000|172 178|subunit
P11103472A0802|101 110|amplitudes
P11103472A0802|12 14|ADD
P11103472A0802|58 62|trend
P11103472A0802|79 83|CNV-1
P11103472A0802|40 53|CNV-1 amplitude
P11103472A0802|87 91|CNV-2
P11103472A0802|0 7|Children
P11103601T0025|5 9|UMDNJ
P11103792A0755|0 13|Overexpression
P11103792A0755|193 200|bax-null
P11103792A0755|57 61|cells
P11103792A0755|110 117|presence
P11103792A0755|228 232|mouse
P11103792A0755|242 252|fibroblasts
P11103792A0755|143 147|serum
P11103792A0755|16 20|c-Myc
P11103792A0755|120 125|growth
P11103792A0755|69 77|apoptosis
P11103792A0755|43 47|mouse
P11103792A0755|162 170|apoptosis
P11105129T0000|29 38|Klebsiella
P11105129T0000|49 88|Producing Extended-Spectrum beta-lactamase
P11105129T0000|116 121|Brazil
P11105129T0000|13 26|Susceptibility
P11105129T0000|90 93|ESBL
P11105129T0000|105 113|Hospitals
P11105716A0782|0 9|CONCLUSION
P11105716A0782|103 105|CBV
P11105716A0782|88 100|determination
P11105716A0782|78 82|error
P11105716A0782|109 117|CBF values
P11105716A0782|182 199|MR perfusion studies
P11105716A0782|148 154|account
P11105716A0782|32 48|AIF peak saturation
P11105716A0782|14 20|results
P11105717A0123|0 6|METHODS
P11105717A0123|148 157|hemoglobin
P11105717A0123|8 9|T2
P11105717A0123|177 192|microvasculature
P11105717A0123|163 173|vasculature
P11105717A0123|51 56|images
P11105717A0123|92 115|susceptibility difference
P11106216A0918|72 77|FOT Rrs
P11106216A0918|5 16|COPD patients
P11106216A0918|50 50|%
P11106216A0918|21 31|variability
P11106216A0918|44 46|Rrs
P11106216A0918|81 81|%
P11106428A0635|71 75|FAP-1
P11106428A0635|140 164|glutathione-S-transferase
P11106428A0635|114 117|form
P11106428A0635|63 68|domain
P11106428A0635|129 131|Ser
P11106428A0635|90 99|amino acids
P11106428A0635|10 12|end
P11106428A0635|166 168|GST
P11106428A0635|33 40|proteins
P11106428A0635|119 125|Cys2408
P11106667A1061|71 84|Cox2p synthesis
P11106667A1061|91 102|mitochondria
P11106667A1061|36 55|membrane localization
P11106667A1061|25 29|roles
P11106667A1061|5 11|Pet111p
P11106667A1061|59 68|regulation
P11106668A0875|120 125|c-IAP1
P11106668A0875|38 54|spacer-RING domain
P11106668A0875|109 117|BIR domain
P11106668A0875|26 30|cells
P11106668A0875|12 23|transfection
P11106668A0875|136 144|apoptosis
P11106668A0875|86 93|function
P11107637X0001|27 32|bounds
P11107637X0001|187 194|patients
P11107637X0001|132 137|method
P11107637X0001|251 262|heart disease
P11107637X0001|208 215|diseases
P11107637X0001|225 239|atherosclerosis
P11107637X0001|282 286|ozone
P11107637X0001|103 114|significance
P11107637X0001|75 89|pathophysiology
P11107637X0001|167 172|lipids
P11107637X0001|268 279|use titration
P11107637X0001|66 70|ozone
P11107637X0001|140 149|definition
P11107637X0001|158 164|binders
P11107637X0001|53 61|titration
P11107637X0001|122 128|article
P11107637X0001|35 50|blood serum lipids
P11107637X0001|3 15|determination
P11107637X0001|175 184|blood serum
P11108151A0560|145 160|tyrphostin AG1478
P11108151A0560|44 56|PKC inhibitors
P11108151A0560|181 195|fibronectin mRNA
P11108151A0560|170 178|induction
P11108151A0560|13 27|fibronectin mRNA
P11108151A0560|131 141|EGF-R mutant
P11108151A0560|59 70|PKC depletion
P11108151A0560|99 111|EGF-R function
P11108151A0560|0 2|Ang
P11108151A0560|87 96|inhibition
P11108374A1466|0 5|Acoust
P11108523A0326|0 10|Video images
P11108523A0326|69 76|centroid
P11108523A0326|134 143|anisometry
P11108523A0326|125 127|I11
P11108523A0326|120 123|axes
P11108523A0326|92 98|moments
P11108523A0326|169 185|internostril angle
P11108523A0326|129 131|I22
P11108523A0326|16 23|nostrils
P11108523A0326|59 67|perimeter
P11108523A0326|54 57|area
P11108523A0326|200 204|angle
P11108523A0326|145 153|bulkiness
P11108523A0326|87 90|axis
P11108548A0710|0 16|MS characteristics
P11108548A0710|117 121|basis
P11108548A0710|78 97|substitution patterns
P11108548A0710|150 162|APcI interface
P11108548A0710|19 27|coumarins
P11108548A0710|127 134|response
P11108548A0710|57 64|flavones
P11108548A0710|29 37|psoralens
P11108616A0000|0 8|Young fish
P11108616A0000|10 31|Oreochromis mossambicus
P11108616A0000|74 77|days
P11108616A0000|64 64|g
P11108616A0000|137 140|days
P11108616A0000|117 128|hypergravity
P11108616A0000|46 57|microgravity
P11108616A0000|106 111|STS-84
P11108616A0000|84 102|space missions STS-55
P11108616A0000|130 131|hg
P11108720A0124|213 216|S6K2
P11108720A0124|107 113|regions
P11108720A0124|33 42|core kinase
P11108720A0124|24 27|S6K1
P11108720A0124|187 204|localization signal
P11108720A0124|62 68|domains
P11108720A0124|83 86|S6K1
P11108720A0124|92 92|N
P11108720A0124|46 51|linker
P11108720A0124|153 159|nucleus
P11108720A0124|0 3|S6K2
P11108720A1130|0 11|Pretreatment
P11108720A1130|80 91|kinase kinase
P11108720A1130|120 133|S6K2 activation
P11108720A1130|154 157|S6K1
P11108720A1130|144 149|extent
P11108720A1130|97 110|inhibitor U0126
P11108720A1130|14 18|cells
P11108720A1130|93 95|MEK
P11108839A0401|0 5|T cells
P11108839A0401|34 36|kDa
P11108839A0401|16 23|isoforms
P11108839A0401|61 70|kDa isoform
P11108839A0401|48 53|kinase
P11108839A0401|93 104|localisation
P11108839A0401|26 29|S6k1
P11110040A0000|0 9|Ketanserin
P11110040A0000|205 214|metabolite
P11110040A0000|109 115|corneal
P11110040A0000|80 87|infusion
P11110040A0000|23 26|drug
P11110040A0000|165 172|pressure
P11110040A0000|126 137|applications
P11110040A0000|31 53|5-HT2 receptor antagonism
P11110040A0000|181 185|times
P11110040A0000|95 106|% w/v solution
P11110040A0000|190 197|activity
P11110040A0000|216 227|ketanserinol
P11110528A0414|71 79|direction
P11110528A0414|38 53|velocity encoding
P11110528A0414|93 98|region
P11110528A0414|123 126|cm/s
P11110528A0414|26 33|sequence
P11110528A0414|108 115|velocity
P11110528A0414|19 20|2D
P11111051A0051|59 61|HAT
P11111051A0051|26 30|Tip60
P11111051A0051|63 70|activity
P11111051A0051|34 57|histone acetyltransferase
P11112417A1126|3 6|data
P11112417A1126|23 38|MLSN1 transcripts
P11112417A1126|137 151|MLSN1 expression
P11112417A1126|109 121|melanoma cells
P11112417A1126|182 194|transcription
P11112417A1126|198 211|mRNA processing
P11112417A1126|171 175|level
P11112438X0847|0 8|Copyright
P11112438X0847|13 25|Academic Press
P11112700A1936|0 6|Plectin
P11112700A1936|53 61|C-termini
P11112700A1936|39 45|domains
P11112700A1936|128 138|desmoplakin
P11112700A1936|114 120|plectin
P11112700A1936|106 111|domain
P11112700A1936|10 20|desmoplakin
P11112700A1936|149 151|MTs
P11112700T0000|0 15|Characterization
P11112700T0000|21 44|microtubule binding domain
P11112700T0000|117 127|microtubule
P11112700T0000|138 145|proteins
P11112700T0000|82 85|MACF
P11112700T0000|110 114|group
P11112700T0000|47 80|microtubule actin crosslinking factor
P11112700T0000|88 101|identification
P11112790A0989|5 11|results
P11112790A0989|26 36|involvement
P11112790A0989|62 64|UPR
P11112790A0989|49 56|elements
P11113179A0541|113 119|adaptor
P11113179A0541|50 65|estrogen receptor
P11113179A0541|22 25|SRC1
P11113179A0541|135 138|p300
P11113179A0541|42 44|CBP
P11113179A0541|33 39|binding
P11113179A0541|87 99|SRC1 functions
P11113179A0541|129 131|CBP
P11113179A0541|12 19|contrast
P11113179A1020|144 149|assays
P11113179A1020|12 20|construct
P11113179A1020|36 43|residues
P11113179A1020|90 98|AD1 region
P11113179A1020|101 104|SRC1
P11113179A1020|120 138|coactivator activity
P11113179A1020|73 83|LXXLL motifs
P11113199A0800|26 31|anchor
P11113199A0800|109 130|ERK2-Delta19-25 mutants
P11113199A0800|38 41|ERKs
P11113199A0800|5 7|MEK
P11113199A0800|53 66|MEK interaction
P11113199A0800|46 49|lack
P11113199A0800|146 150|cells
P11113199A0800|95 106|localization
P11113201A1114|83 96|target proteins
P11113201A1114|61 64|step
P11113201A1114|16 32|six-protein family
P11113201A1114|7 12|member
P11113201A1114|35 39|yeast
P11113201A1114|67 80|O mannosylation
P11113201A1114|0 3|Pmt2
P11113546A0728|42 44|end
P11113546A0728|5 11|samples
P11113546A0728|111 121|Giardia cyst
P11113546A0728|51 61|trial period
P11113546A0728|30 38|beginning
P11113546A0728|96 107|nematode eggs
P11113692A0169|85 87|PDR
P11113692A0169|133 136|type
P11113692A0169|78 80|BDR
P11113692A0169|203 207|entry
P11113692A0169|174 180|mean age
P11113692A0169|48 57|background
P11113692A0169|138 145|diabetes
P11113692A0169|163 167|years
P11113692A0169|12 16|study
P11113692A0169|214 217|mm Hg
P11113692A0169|66 76|retinopathy
P11113692A0169|34 44|risk factors
P11113692A0169|188 200|blood pressure
P11113692A0169|110 117|patients
P11113692A0169|170 172|age
P11113692A0169|3 5|aim
P11113822A0999|29 36|controls
P11113822A0999|76 86|jaw pathoses
P11113822A0999|7 15|quadrants
P11113823A0197|4 8|cases
P11113823A0197|19 32|chondromatosis
P11114294A0075|180 183|CFTR
P11114294A0075|107 116|expression
P11114294A0075|195 202|T84 cells
P11114294A0075|128 168|fibrosis transmembrane conductance regulator
P11114294A0075|170 173|CFTR
P11114294A0075|47 79|cytokines tumor necrosis factor alpha
P11114294A0075|83 97|interferon gamma
P11114294A0075|8 14|studies
P11114294A0075|175 178|gene
P11114294A0075|187 191|HT-29
P11114521A0282|0 9|Regulation
P11114521A0282|56 60|cells
P11114521A0282|36 43|adhesion
P11114521A0282|12 15|RhoA
P11114521A0282|82 94|cell spreading
P11114521A0282|98 106|migration
P11114718A0349|12 27|mouse fibroblasts
P11114718A0349|78 80|p21
P11114718A0349|47 51|v-Src
P11114718A0349|63 75|protein levels
P11114718A0349|105 111|cyclin E
P11114718A0349|93 100|cyclin D1
P11114718A0349|56 59|mRNA
P11114718A0349|82 90|WAF1/CIP1
P11114924A0808|0 3|ORFA
P11114924A0808|7 10|ccdA
P11114924A0808|56 78|primer extension analysis
P11116084A0000|0 10|Mouse Impact
P11116084A0000|33 36|gene
P11116084A0000|70 76|protein
P11116084A0000|86 93|function
P11116131A0863|18 20|P2Y
P11116131A0863|25 28|mRNA
P11116131A0863|35 41|culture
P11116131A0863|5 9|cells
P11116148A0741|0 18|Coexpression studies
P11116148A0741|41 43|PKB
P11116148A0741|52 66|transactivation
P11116148A0741|137 145|C/EBPbeta
P11116148A0741|113 134|transactivation domains
P11116148A0741|69 77|C/EBPbeta
P11116148A0741|85 94|C/EBPalpha
P11116148A0741|31 37|insulin
P11117263A0570|147 150|acid
P11117263A0570|152 154|DMA
P11117263A0570|208 213|epiHMA
P11117263A0570|104 110|cereale
P11117263A0570|79 83|roots
P11117263A0570|246 249|acid
P11117263A0570|251 253|HMA
P11117263A0570|215 223|H. vulgare
P11117263A0570|255 263|S. cereale
P11117263A0570|22 28|species
P11117263A0570|203 206|acid
P11117263A0570|172 175|acid
P11117263A0570|36 49|Ids3 expression
P11117263A0570|177 178|MA
P11117263A0570|86 94|H. vulgare
P11117523A0650|101 112|cell cultures
P11117523A0650|68 75|P19 cells
P11117523A0650|2 9|contrast
P11117523A0650|120 126|neurons
P11117523A0650|51 65|differentiation
P11117523A0650|15 32|COUP-TFI expression
P11117523A0650|87 88|RA
P11117826A0788|28 39|pretreatment
P11117826A0788|93 100|patients
P11117826A0788|66 68|use
P11117826A0788|150 153|data
P11117826A0788|120 129|comparison
P11117826A0788|43 61|follow-up evaluation
P11117826A0788|7 9|PET
P11117826A0788|83 85|PET
P11117826A0788|176 179|data
P11118062A1691|131 139|phenotype
P11118062A1691|61 69|K-ras gene
P11118062A1691|48 55|mutation
P11118062A1691|22 26|model
P11118062A1691|100 113|aggressiveness
P11118062A1691|93 97|level
P11118062A1691|31 42|localization
P11118438A0411|57 73|plant species apple
P11118438A0411|176 182|juglone
P11118438A0411|75 88|Malus domestica
P11118438A0411|37 49|Pin1 homologue
P11118438A0411|18 26|isolation
P11118438A0411|137 156|substrate specificity
P11118438A0411|205 208|Pin1
P11118438A0411|198 201|case
P11118438A0411|29 34|MdPin1
P11118440T0000|62 89|candidate tumor suppressor ING1
P11118440T0000|35 56|alternative transcripts
P11118440T0000|25 32|products
P11118440T0000|12 22|association
P11118440T0000|97 107|mSin3/HDAC1
P11118440T0000|123 140|corepressor complex
P11118619A0835|13 16|data
P11118619A0835|51 78|host cell transcription factors
P11118619A0835|44 49|models
P11118619A0835|102 110|infection
P11118619A0835|37 39|TAg
P11118619A0835|160 173|transformation
P11118619A0835|130 134|event
P11118712A1296|175 188|within-herd PTB
P11118712A1296|45 50|limits
P11118712A1296|255 259|herds
P11118712A1296|82 85|test
P11118712A1296|193 202|prevalence
P11118712A1296|217 222|reason
P11118712A1296|99 108|estimation
P11118712A1296|275 282|herd size
P11118712A1296|148 163|confidence limits
P11118712A1296|237 251|herd specificity
P11118712A1296|56 63|accuracy
P11118712A1296|118 131|herd prevalence
P11118712A1296|4 22|sensitivity analysis
P11119611A0428|0 5|ORFK10
P11119611A0428|109 115|tissues
P11119611A0428|132 133|CD
P11119611A0428|126 128|PEL
P11119611A0428|58 62|LANA2
P11119611A0428|140 148|KS lesions
P11119611A0428|49 55|antigen
P11119611A0428|16 22|protein
P11120441A1193|15 23|believers
P11120441A1193|93 101|asymmetry
P11120441A1193|114 123|complexity
P11120441A1193|62 71|activation
P11121043A0074|28 35|inducers
P11121043A0074|65 76|neurogenesis
P11121043A0074|10 13|BMPs
P11121043A0074|53 62|regulators
P11121043A0074|2 8|Xenopus
P11121118A0075|43 54|GAF sequences
P11121118A0075|19 26|variants
P11121118A0075|70 75|region
P11121118T0000|29 55|phosphodiesterase PDE11A gene
P11121118T0000|7 18|organization
P11121397A0587|120 129|initiation
P11121397A0587|10 17|findings
P11121397A0587|145 158|heparan sulfate
P11121397A0587|133 142|elongation
P11121397A0587|55 94|alpha1,4-N-acetylglucosaminyltransferase
P11121397A0587|33 44|rib-2 protein
P11121434A0915|0 9|Inhibition
P11121434A0915|104 111|recovery
P11121434A0915|31 43|Rat1/ras cells
P11121434A0915|66 72|PD98059
P11121434A0915|53 64|Mek inhibitor
P11121434A0915|15 28|Mek/Erk pathway
P11121434A0915|147 150|HR12
P11121490A0000|87 95|apoptosis
P11121490A0000|57 62|stress
P11121490A0000|3 37|transcription factor CHOP/GADD153 gene
P11122381A0908|0 7|Addition
P11122381A0908|129 138|activation
P11122381A0908|42 49|peptides
P11122381A0908|93 109|GM-CSF stimulation
P11122381A0908|141 145|STAT5
P11122381A0908|77 85|tyrosines
P11122588A0549|0 18|MAIN OUTCOME MEASURES
P11122588A0549|182 186|sleep
P11122588A0549|20 35|Percentage change
P11122588A0549|55 59|index
P11122588A0549|176 179|hour
P11122588A0549|77 90|hypopnea events
P11122588A0549|143 145|SDB
P11122588A0549|65 75|apnea events
P11122588A0549|158 160|AHI
P11122588A0549|100 104|sleep
P11122588A0549|210 215|weight
P11122588A0549|94 97|hour
P11122588A0549|109 112|odds
P11122588A0549|167 172|events
P11122588A0549|193 199|respect
P11122588A0549|61 63|AHI
P11123054T0000|23 31|syndromes
P11123089A0362|102 113|vasculitides
P11123089A0362|40 48|frequency
P11123089A0362|24 34|information
P11123089A0362|125 132|patients
P11123089A0362|50 64|characteristics
P11123089A0362|154 167|tissue diseases
P11123089A0362|4 10|article
P11123089A0362|87 96|mechanisms
P11123316T0000|0 17|Tec kinase signaling
P11123316T0000|20 25|T cells
P11123316T0000|39 66|phosphatidylinositol 3-kinase
P11123316T0000|73 99|Tec pleckstrin homology domain
P11123701A0442|28 30|DNA
P11123701A0442|68 75|coupling
P11123701A0442|171 190|transcription complex
P11123701A0442|112 120|promoters
P11123701A0442|22 25|type
P11123701A0442|142 154|DNA constructs
P11123701A0442|277 285|DNA duplex
P11123701A0442|255 263|diffusion
P11123701A0442|7 14|evidence
P11123701A0442|225 237|DNA supercoils
P11123701A0442|100 109|activities
P11123912A0306|129 136|T antigen
P11123912A0306|111 122|polyomavirus
P11123912A0306|93 99|peptide
P11123912A0306|21 29|SH2 domain
P11123912A0306|138 139|MT
P11123912A0306|3 11|structure
P11123912A0306|56 58|SH2
P11124024A1098|72 77|repeat
P11124024A1098|36 51|protein complexes
P11124024A1098|28 32|sites
P11124024A1098|54 63|palindrome
P11124024A1098|83 93|C+T sequence
P11124024A1098|116 125|GAGA motifs
P11124024A1098|142 147|strand
P11124902X1337|0 8|Copyright
P11124902X1337|13 25|Academic Press
P11125151T0000|0 17|Nucleotide sequence
P11125151T0000|52 59|analysis
P11125151T0000|94 100|virus-2
P11125151T0000|19 36|genome organization
P11125151T0000|62 78|pineapple mealybug
P11125363A0525|0 7|Patients
P11125363A0525|90 98|cisplatin
P11125363A0525|138 141|days
P11125363A0525|122 135|5-fluorouracil
P11125363A0525|109 110|gm
P11125363A0525|50 61|tumor mapping
P11125363A0525|113 114|m.
P11125363A0525|87 88|m.
P11125363A0525|159 170|radiotherapy
P11125363A0525|83 84|mg
P11125363A0525|17 38|pretreatment cystoscopy
P11125363A0525|101 103|day
P11125411A0857|30 40|laparoscopy
P11125411A0857|94 99|testes
P11125411A0857|113 118|testis
P11125411A0857|132 136|canal
P11125411A0857|13 20|patients
P11125872A0133|58 74|phosphodiesterase
P11125872A0133|77 85|inhibitor
P11125872A0133|4 13|philosophy
P11125872A0133|125 132|delivery
P11125872A0133|155 160|routes
P11125872A0133|33 42|compound RP
P11125872A0133|163 176|administration
P11126275A1068|59 66|bleeding
P11126275A1068|9 14|levels
P11126275A1068|17 46|anticardiolipin immunoglobulin G
P11126353A0582|44 44|%
P11126353A0582|47 55|diagnosis
P11126353A0582|76 77|3y
P11126353A0582|73 73|%
P11126353A0582|20 26|obesity
P11126353A0582|8 17|Prevalence
P11126353A0582|28 33|BMI SDS
P11126353A0582|0 6|RESULTS
P11126806A0206|74 84|circulation
P11126806A0206|8 15|sequelae
P11126806A0206|21 47|antiphospholipid-antibodies
P11127161T0000|14 29|smoking cessation
P11127161T0000|0 8|Bupropion
P11127200A1024|61 63|ROS
P11127200A1024|70 74|cells
P11127200A1024|51 58|activity
P11127200A1024|124 132|TGF-beta1
P11127200A1024|152 161|expression
P11127200A1024|241 247|hormone
P11127200A1024|168 173|alpha1
P11127200A1024|249 251|PTH
P11127200A1024|279 286|receptor
P11127200A1024|215 224|expression
P11127200A1024|175 187|collagen I gene
P11127200A1024|273 277|PTHrP
P11127200A1024|92 115|AP-1 transcription factors
P11127200A1024|32 35|AP-1
P11127200A1024|265 271|peptide
P11127250A1111|0 1|PM
P11127250A1111|100 103|cure
P11127250A1111|31 34|dose
P11127250A1111|119 120|VL
P11127250A1111|8 12|mg/kg
P11127250A1111|107 114|patients
P11127250A1111|37 38|SB
P11127250A1111|44 47|days
P11127250A1111|129 133|India
P11127250A1111|81 82|SB
P11127250A1111|123 127|Bihar
P11127955X0001|30 36|Surgery
P11127955X0001|8 14|therapy
P11127955X0001|91 102|colon cancers
P11127955X0001|18 28|colon cancer
P11127955X0001|68 73|number
P11128312A1238|87 94|femur BMD
P11128312A1238|49 56|fracture
P11128312A1238|125 130|radius
P11128312A1238|133 133|%
P11128312A1238|98 98|%
P11128312A1238|20 30|differences
P11128312A1238|181 181|%
P11128312A1238|149 157|dimension
P11128312A1238|111 113|BMD
P11128312A1238|163 173|radiographs
P11128312A1238|71 76|groups
P11128312A1238|32 32|p
P11128312A1238|175 177|FD2
P11128925A0000|0 9|BACKGROUND
P11128925A0000|23 27|study
P11128925A0000|103 105|GCF
P11128925A0000|129 136|findings
P11128925A0000|71 76|levels
P11128925A0000|97 101|fluid
P11128925A0000|161 169|arthritis
P11128925A0000|182 194|periodontitis
P11128925A0000|52 64|interleukin-6
P11128925A0000|171 172|RA
P11128925A0000|196 197|AP
P11128925A0000|14 16|aim
P11128925A0000|66 69|IL-6
P11128925A0000|139 146|patients
P11129515A0000|128 130|PMS
P11129515A0000|119 126|syndrome
P11129515A0000|34 41|efficacy
P11129515A0000|26 30|trial
P11129515A0000|94 101|patients
P11129515A0000|46 71|Vitex agnus castus L extract Ze
P11129724A0904|0 6|Studies
P11129724A0904|38 50|contamination
P11129724A0904|63 66|role
P11129724A0904|30 35|source
P11129724A0904|95 106|transmission
P11129724A0904|109 112|MRSA
P11129724A0904|86 89|milk
P11129724A0904|115 122|neonates
P11131321T0000|0 6|Effects
P11131321T0000|65 91|homidum chloride chemotherapy
P11131321T0000|9 24|Trypanosoma vivax
P11131321T0000|38 49|Yankasa sheep
P11131321T0000|56 62|results
P11131321T0000|27 35|pregnancy
P11131634A0955|0 7|NF kappa B
P11131634A0955|71 77|Y8 cells
P11131634A0955|60 64|cells
P11131634A0955|34 39|extent
P11131634A0955|42 52|roscovitine
P11132063A0250|195 201|effects
P11132063A0250|11 28|treatment exposures
P11132063A0250|118 127|hepatitis C
P11132063A0250|84 90|effects
P11132063A0250|161 174|cardiomyopathy
P11132063A0250|41 50|population
P11132063A0250|98 106|cirrhosis
P11132063A0250|218 228|dysfunction
P11132148A0162|3 10|presence
P11132148A0162|54 67|promoter region
P11132148A0162|27 34|residues
P11132148A0162|107 110|loci
P11132148A0162|98 105|HLA class
P11132195A0000|172 187|input/output data
P11132195A0000|76 81|length
P11132195A0000|99 103|order
P11132195A0000|209 215|systems
P11132195A0000|18 27|parameters
P11132195A0000|158 169|measurements
P11132195A0000|122 128|methods
P11132195A0000|148 153|models
P11132195A0000|109 120|nonlinearity
P11132195A0000|39 52|Volterra series
P11132195A0000|87 92|memory
P11132195A0000|10 15|number
P11132195A0000|235 242|memories
P11132790A0609|43 47|score
P11132790A0609|53 55|S-B
P11132790A0609|11 16|method
P11132790A0609|152 163|risk children
P11132790A0609|66 73|subtests
P11132790A0609|82 86|score
P11133741A0617|0 3|NiCl
P11133741A0617|126 129|loss
P11133741A0617|141 156|promoter activity
P11133741A0617|37 46|activation
P11133741A0617|63 70|mutation
P11133741A0617|49 57|NF-kappaB
P11133741A0617|100 107|promoter
P11133741A0617|90 94|sites
P11133741A0617|15 28|MCP-1 synthesis
P11133830A0174|0 9|Engagement
P11133830A0174|31 35|pairs
P11133830A0174|124 140|kDa phosphoprotein
P11133830A0174|103 110|proteins
P11133830A0174|160 178|proto-oncogene c-Cbl
P11133830A0174|82 87|number
P11133830A0174|56 78|tyrosine phosphorylation
P11133830A0174|17 19|CD2
P11133830A0174|46 48|mAb
P11133927T0000|75 78|rate
P11133927T0000|51 56|muscle
P11133927T0000|10 24|NIR spectroscopy
P11133927T0000|81 88|exercise
P11133927T0000|0 7|Validity
P11133986A0350|151 155|c-Jun
P11133986A0350|189 196|3T3 cells
P11133986A0350|142 146|c-Fos
P11133986A0350|115 122|function
P11133986A0350|170 176|kappaE3
P11133986A0350|81 84|PU.1
P11133986A0350|52 71|transcription factors
P11133986A0350|8 14|studies
P11133986A0350|111 113|PIP
P11133986A0350|179 186|enhancer
P11133986A0350|88 109|PU.1 interaction partner
P11134033A0000|58 62|mouse
P11134033A0000|70 81|tumor viruses
P11134033A0000|9 18|int-6 locus
P11134033A0000|113 143|translation initiation factor eIF3
P11134033A0000|41 55|integration site
P11134033A0000|99 110|eIF3e subunit
P11134033A0639|15 23|int6Delta
P11134033A0639|62 67|medium
P11134033A0639|25 30|mutant
P11134033A0639|2 13|int6 deletion
P11134351A1405|30 39|cell growth
P11134351A1405|13 18|MIP-2A
P11134351A1405|50 53|role
P11134351A1405|56 60|MBP-1
P11134508A0317|62 66|AtHD1
P11134508A0317|68 71|gene
P11134508A0317|20 25|plants
P11134508A0317|48 60|Arabidopsis HD
P11134822A0629|26 44|accelerations/30 min
P11134822A0629|11 11|P
P11137296A0923|178 202|transcription-PCR analysis
P11137296A0923|258 269|mouse tissues
P11137296A0923|286 291|levels
P11137296A0923|101 108|cDNA ends
P11137296A0923|135 136|bp
P11137296A0923|229 238|PFK-C genes
P11137296A0923|215 219|PFK-A
P11137296A0923|110 117|RLM-RACE
P11137296A0923|4 31|transcription initiation sites
P11137296A0923|63 65|RNA
P11137296A0923|221 225|PFK-B
P11137296A0923|86 98|amplification
P11137296A0923|144 169|translation initiation codon
P11137296A1216|0 8|PFK-A mRNA
P11137296A1216|66 75|PFK-C genes
P11137296A1216|40 46|tissues
P11137296A1216|58 62|PFK-B
P11137367A0297|83 89|circuit
P11137367A0297|9 25|Toshiba IIDR system
P11137367A0297|46 58|X-ray TV system
P11137367A0297|70 74|image
P11137551A0437|21 24|acid
P11137551A0437|75 79|limit
P11137551A0437|38 43|levels
P11137551A0437|7 13|sardine
P11138009A1032|71 81|USH1 patient
P11138009A1032|36 45|Delta M1281
P11138009A1032|49 53|IVS51
P11138009A1032|26 34|mutations
P11138009A1032|56 56|G
P11138009A1032|2 9|addition
P11138231T0000|0 6|Closeup
P11138231T0000|9 16|resource
P11138231T0000|20 25|nurses
P11138694A0000|220 226|ganglia
P11138694A0000|165 170|ligand
P11138694A0000|74 97|acetylcholine transporter
P11138694A0000|231 233|PET
P11138694A0000|11 32|fluorobenzyltrozamicol
P11138694A0000|125 130|neuron
P11138694A0000|203 209|density
P11138694A0000|177 181|study
P11138694A0000|1 3|18F
P11138694A0000|34 36|FBT
P11139148A0421|127 134|activity
P11139148A0421|47 51|SAF-A
P11139148A0421|88 91|MARs
P11139148A0421|36 44|homologue
P11139148A0421|20 26|protein
P11139148A0421|155 163|fractions
P11139336A0257|33 46|INCENP behavior
P11139336A0257|53 59|mitosis
P11139336A0257|12 23|associations
P11139469A0402|102 125|protein kinase C inhibitors
P11139469A0402|25 45|Ang2 mRNA accumulations
P11139469A0402|144 145|Ca
P11139469A0402|62 65|Ang1
P11139469A0402|68 81|Tie2 expression
P11139469A0402|159 164|agents
P11139469A0402|0 4|Ang II
P11139473A0696|0 15|Promoter analysis
P11139473A0696|54 62|consensus
P11139473A0696|108 120|SMemb promoter
P11139473A0696|35 42|sequence
P11139473A0696|78 84|element
P11139473A0696|86 88|CRE
P11139473A0696|135 151|Hex responsiveness
P11139567A1440|0 22|LH/CG receptor activation
P11139567A1440|44 53|activation
P11139567A1440|56 83|phosphatidylinositol 3-kinase
P11139567A1440|25 28|ARNO
P11139567A1440|85 94|PI 3-kinase
P11139567A1440|100 124|G protein beta gamma subunits
P11139605A0811|0 15|Deletion analysis
P11139605A0811|186 188|Sp1
P11139605A0811|195 200|region
P11139605A0811|132 150|mobility shift assays
P11139605A0811|164 174|interaction
P11139605A0811|80 95|promoter activity
P11139605A0811|37 44|sequence
P11139605A0811|177 182|C/EBPs
P11139605A0811|99 113|auto-activation
P11139974A0762|0 10|Termination
P11139974A0762|90 90|%
P11139974A0762|69 69|%
P11139974A0762|56 63|BV pacing
P11139974A0762|77 84|RV pacing
P11139974A0762|20 21|VT
P11139974A0762|32 38|attempt
P11140472A0497|176 180|noise
P11140472A0497|89 97|algorithm
P11140472A0497|25 33|algorithm
P11140472A0497|101 111|monochannel
P11140472A0497|12 18|results
P11140472A0497|144 152|algorithm
P11140472A0497|68 77|algorithms
P11140472A0497|126 130|noise
P11140472A0497|201 216|cases improvement
P11140472A0497|41 47|results
P11141003T0000|0 6|Changes
P11141003T0000|45 52|cochlear
P11141003T0000|36 42|nucleus
P11141003T0000|9 25|stimulation levels
P11141003T0000|60 64|users
P11141003T0000|30 33|time
P11142380A0389|0 7|Nuclease
P11142380A0389|36 46|mutagenesis
P11142380A0389|124 130|helices
P11142380A0389|157 163|regions
P11142380A0389|68 69|TE
P11142380A0389|71 75|TE105
P11142380A0389|101 109|structure
P11143384A0267|0 8|Tele-Talk
P11143384A0267|20 29|capability
P11143384A0267|47 66|conference situations
P11143384A0267|32 40|operating
P11143384A0267|72 86|microphone input
P11145562A0000|149 153|state
P11145562A0000|7 14|decrease
P11145562A0000|63 68|IGF-IR
P11145562A0000|50 52|IGF
P11145562A0000|37 48|growth factor
P11145562A0000|78 85|prostate
P11145562A0000|20 23|type
P11145562A0000|107 120|transformation
P11145562A0000|96 100|cells
P11145562A0000|54 61|receptor
P11145562A0468|73 77|cells
P11145562A0468|96 103|T antigen
P11145562A0468|55 62|prostate
P11145562A0468|3 13|P69 cell line
P11145562A0468|26 40|immortalization
P11145563A0202|27 38|StAR promoter
P11145563A0202|93 98|SREBPs
P11145563A0202|53 58|sterol
P11145563A0202|84 91|proteins
P11145563A0303|30 49|StAR promoter activity
P11145563A0303|82 102|granulosa-lutein cells
P11145563A0303|12 19|SREBP-1a
P11145563A0303|64 73|COS-1 cells
P11145563A0303|55 61|context
P11145563A0303|0 9|Expression
P11145566A0000|161 175|HDL-R regulation
P11145566A0000|42 46|HDL-R
P11145566A0000|63 84|cholesterol homeostasis
P11145566A0000|22 40|lipoprotein receptor
P11145566A0000|109 114|target
P11145566A0000|54 60|element
P11145566A0000|138 142|drugs
P11145566A0000|146 158|understanding
P11145571A0788|74 88|response element
P11145571A0788|14 25|gene factor-3
P11145571A0788|29 43|STAT1 homodimers
P11145571A0788|126 132|element
P11145571A0788|113 120|sequence
P11145571A0788|122 124|GAS
P11145571A0788|90 93|ISRE
P11145590A0217|118 136|TGF-beta1 regulation
P11145590A0217|77 78|TG
P11145590A0217|63 75|thyroglobulin
P11145590A0217|155 174|transcription factors
P11145590A0217|107 115|attention
P11145590A0217|34 43|mechanisms
P11145590A0217|80 93|gene expression
P11145590A0217|46 60|TGF-beta1 action
P11145717A0936|98 101|K713
P11145717A0936|75 84|sequencing
P11145717A0936|27 27|K
P11145717A0936|47 57|TPO fragment
P11145717A0936|20 25|lysine
P11145743A0170|100 104|TTF-1
P11145743A0170|170 177|activity
P11145743A0170|48 59|thyroid cells
P11145743A0170|183 201|deiodinase promoters
P11145743A0170|24 33|regulation
P11145743A0170|41 45|genes
P11145743A0170|135 141|protein
P11145743A0170|64 69|effect
P11145743A0170|72 97|thyroid transcription factor
P11145743A0170|144 148|Pax-8
P11145813A0668|0 16|Regional blood blow
P11145813A0668|37 48|microspheres
P11145813A0668|30 34|means
P11145813A0668|61 67|regions
P11145813A0668|76 78|T11
P11145813A0668|73 74|C6
P11145813A0668|83 93|L6 vertebrae
P11145887A1393|0 9|Activation
P11145887A1393|81 85|c-Jun
P11145887A1393|35 42|AP-1 site
P11145887A1393|161 163|Tax
P11145887A1393|87 90|JunB
P11145887A1393|12 24|transcription
P11145887A1393|132 136|level
P11145887A1393|95 109|c-Fos activation
P11145887A1393|45 55|Jurkat cells
P11145887A1393|68 72|Fra-2
P11145887A1393|58 61|JunD
P11145955A0189|30 50|estrogen receptor alpha
P11145955A0189|52 58|ERalpha
P11145955A0189|82 95|gene expression
P11145955A0189|156 163|analysis
P11145955A0189|183 195|protein kinase
P11145955A0189|106 108|SRE
P11145955A0189|197 200|MAPK
P11145955A0189|134 141|analysis
P11145955A0189|221 222|E2
P11145955A0189|278 284|control
P11145955A0189|257 265|TGF-alpha
P11145955A0189|3 11|mechanism
P11145955A0189|202 218|pathway activation
P11145955A0189|70 79|activation
P11145955A0189|147 154|promoter
P11145955A0189|239 255|growth factor alpha
P11146961T0000|0 17|Perfusion technique
P11146961T0000|66 71|PADCAB
P11146961T0000|53 64|artery bypass
P11148042A1258|97 116|peptide immiscibility
P11148042A1258|126 141|gel state bilayers
P11148042A1258|38 45|chain PEs
P11148042A1258|76 85|variations
P11148042A1258|7 14|mixtures
P11148042A1258|18 19|LA
P11148589A1124|0 10|CONCLUSIONS
P11148589A1124|24 44|immunization practices
P11148589A1124|169 174|future
P11148589A1124|122 138|United States today
P11148589A1124|49 55|authors
P11148589A1124|198 217|liver carcinoma deaths
P11148589A1124|88 110|Pacific Islander children
P11148589A1124|161 163|HBV
P11149472A1257|44 54|osteoblasts
P11149472A1257|59 70|chondrocytes
P11149472A1257|10 30|NP/NMP4/CIZ expression
P11149472A1257|73 79|rat bone
P11149472A1257|33 42|osteocytes
P11150114T0000|0 8|Chlamydia
P11150114T0000|20 25|cancer
P11150114T0000|32 42|association
P11150315A0226|164 184|DNA recognition library
P11150315A0226|117 125|signaling
P11150315A0226|40 68|transcription factor activities
P11150315A0226|202 219|DNA binding proteins
P11150315A0226|6 13|approach
P11150315A0226|235 242|extracts
P11150315A0226|138 158|oligonucleotide clones
P11150315A0226|224 227|PC12
P11150315A0844|0 2|NGF
P11150315A0844|34 51|ERK phosphorylation
P11150315A0844|56 58|EGF
P11150315A0844|82 88|reports
P11150315A1126|0 2|NGF
P11150315A1126|10 12|EGF
P11150315A1126|65 69|Fra-2
P11150315A1126|30 34|bands
P11150439A0701|0 16|Energy expenditure
P11150439A0701|111 138|isotope ratio mass spectroscopy
P11150439A0701|81 82|CO
P11150439A0701|64 65|CO
P11150439A0701|168 185|regression equation
P11150439A0701|86 108|enrichment determination
P11150439A0701|71 76|breath
P11150439A0701|57 59|NaH
P11150439A0701|47 54|infusion
P11150439A0701|146 156|application
P11151826T0000|0 7|Workload
P11151826T0000|9 12|UAPs
P11152070A0573|38 43|genome
P11152070A0573|29 32|copy
P11152070A0573|46 58|A. chrysogenum
P11152070A0573|99 116|cefEF cephalosporin
P11152070A0573|150 174|cephalosporin fermentation
P11152070A0573|92 95|pcbC
P11152070A0573|66 80|expression level
P11152070A0573|196 205|transcript
P11152070A0573|3 10|actA gene
P11152070A0573|129 133|genes
P11152081A0413|31 40|inhibition
P11152081A0413|79 93|sulfur oxidation
P11152081A0413|8 16|mmol SDS/l
P11152081A0413|43 55|acidification
P11152081A0413|57 75|metal solubilization
P11152283A0223|42 58|gene transcription
P11152283A0223|61 64|PC12
P11152283A0223|81 85|order
P11152283A0223|68 77|INS-1 cells
P11152283A0223|21 24|role
P11152283A0223|117 121|genes
P11152283A0223|27 29|NGF
P11152344A0416|172 175|cord
P11152344A0416|103 111|placement
P11152344A0416|154 160|surface
P11152344A0416|26 32|animals
P11152344A0416|134 139|sponge
P11152344A0416|64 76|arachnoid scar
P11152344A0416|79 83|C1-C2
P11152344A0416|4 10|animals
P11152344A0416|43 49|animals
P11152451A0529|31 37|SmSmad2
P11152451A0529|111 120|antibodies
P11152451A0529|68 88|Sj26-GST fusion protein
P11152451A0529|57 64|bacteria
P11152451A0529|3 29|Schistosoma mansoni homologue
P11152451A1580|218 231|TGF-beta effect
P11152451A1580|61 71|interaction
P11152451A1580|76 84|receptor I
P11152451A1580|138 144|nucleus
P11152451A1580|165 187|target gene transcription
P11152451A1580|24 30|SmSmad2
P11152451A1580|5 8|data
P11152451A1580|44 58|TGF-beta signals
P11152521A0181|17 31|protein products
P11152521A0181|65 81|expression vectors
P11152521A0181|94 111|ORF40/41 transcript
P11152521A0181|174 179|intron
P11152521A0181|137 145|component
P11152963A0000|28 30|SH3
P11152963A0000|125 131|culture
P11152963A0000|80 83|gene
P11152963A0000|151 155|brain
P11152963A0000|64 73|astrocytes
P11152963A0000|75 78|SETA
P11152963A0000|15 25|src homology
P11152963A0000|135 140|tumors
P11152963A0000|100 122|astrocyte transformation
P11152963A0000|0 9|Expression
P11153302A0000|0 22|Naltrexone hydrochloride
P11153302A0000|35 58|opioid receptor antagonist
P11153302A0000|100 113|detoxification
P11153302A0000|73 79|efforts
P11154491A0322|160 166|needles
P11154491A0322|80 85|masses
P11154491A0322|37 44|patients
P11154491A0322|50 52|age
P11154491A0322|97 98|CT
P11154491A0322|136 148|echoendoscope
P11154491A0322|109 115|EUS-FNA
P11154491A0322|55 59|years
P11154491A0322|0 6|METHODS
P11155096A0222|0 6|METHODS
P11155096A0222|180 183|mU/l
P11155096A0222|206 207|T4
P11155096A0222|186 204|serum thyroxin levels
P11155096A0222|71 85|serum antibodies
P11155096A0222|126 130|IU/ml
P11155096A0222|106 112|TPO-Abs
P11155096A0222|155 157|TSH
P11155096A0222|8 20|Thyroid status
P11155096A0222|34 41|baseline
P11155096A0222|133 146|serum TSH levels
P11155096A0222|88 104|thyroid peroxidase
P11155096A0222|59 68|assessment
P11156303A1098|103 110|children
P11156303A1098|93 100|drainage
P11156303A1098|70 80|alternative
P11156303A1098|171 179|infection
P11156303A1098|130 138|adhesions
P11156303A1098|146 152|history
P11156303A1098|30 37|shunting
P11156413T0000|102 108|utility
P11156413T0000|75 86|polyomavirus
P11156413T0000|114 124|development
P11156413T0000|39 43|mouse
P11156413T0000|20 35|characterization
P11156413T0000|51 63|tumor cell line
P11156413T0000|93 100|T antigen
P11156413T0000|132 149|cancer therapeutics
P11156413T0000|0 9|Derivation
P11156484A0223|0 10|TBARS levels
P11156484A0223|125 133|existence
P11156484A0223|51 60|AFR release
P11156484A0223|91 99|resonance
P11156484A0223|35 47|capacity assay
P11156484A0223|71 78|electron
P11156484A0223|153 160|diabetes
P11156484A0223|101 103|EPR
P11156484A0223|145 150|stress
P11156618T0000|30 41|mouse SCL loci
P11156618T0000|52 58|regions
P11156618T0000|146 154|sequences
P11156618T0000|10 19|comparison
P11156618T0000|61 71|sensitivity
P11156618T0000|74 97|restriction endonucleases
P11156618T0000|121 125|peaks
P11156789A1669|290 292|CSF
P11156789A1669|125 143|oxygen concentration
P11156789A1669|155 162|propofol
P11156789A1669|108 114|changes
P11156789A1669|77 84|children
P11156789A1669|41 46|causes
P11156789A1669|16 26|observation
P11156789A1669|227 242|CSF protein levels
P11156789A1669|252 266|propofol binding
P11156789A1669|189 194|oxygen
P11156789A1669|63 74|CSF pulsation
P11156789A1669|280 285|uptake
P11156789A1669|218 224|changes
P11156789A1669|93 106|motion artifact
P11156789A1669|269 276|proteins
P11157035A1405|142 148|therapy
P11157035A1405|25 29|study
P11157035A1405|107 117|IFN alpha-2b
P11157035A1405|67 80|determinations
P11157035A1405|91 96|trials
P11157035A1405|133 139|benefit
P11157035A1405|3 11|utilities
P11157334A1107|0 7|Serum PTH
P11157334A1107|47 53|WM group
P11157334A1107|29 35|WL group
P11157334A1107|55 55|P
P11157763T0000|14 25|EMAPII domain
P11157763T0000|33 63|aminoacyl-tRNA synthetase complex
P11157763T0000|83 94|dimer mimicry
P11157763T0000|0 8|Structure
P11157774A0789|62 70|sterility
P11157774A0789|11 22|dSLBP alleles
P11157774A0789|37 47|development
P11157784A0141|131 135|locus
P11157784A0141|64 67|sc11
P11157784A0141|101 104|gene
P11157784A0141|22 36|chromosome 22q11
P11157784A0141|11 19|DGCR6 gene
P11157784A0141|106 111|DGCR6L
P11157784A0141|92 95|copy
P11157784A0141|47 56|copy repeat
P11157784A0141|149 150|b.
P11157784A0141|143 146|sc11
P11157879A0192|0 6|METHODS
P11157879A0192|86 96|fluorometry
P11157879A0192|11 17|passive
P11157879A0192|38 48|fluorescein
P11157879A0192|27 35|transport
P11157879A0192|59 61|BRB
P11158236A0000|0 16|Nerve growth factor
P11158236A0000|33 36|acid
P11158236A0000|64 72|PC12 cells
P11158236A0000|38 39|RA
P11158236A0000|55 61|actions
P11158236A0000|18 20|NGF
P11158288T0000|0 10|Recruitment
P11158288T0000|82 85|CREB
P11158288T0000|64 79|activation domain
P11158288T0000|102 120|CREB phosphorylation
P11158288T0000|30 36|complex
P11158288T0000|15 27|RNA polymerase
P11158290A0728|87 90|beta
P11158290A0728|96 102|epsilon
P11158290A0728|57 70|destruction box
P11158290A0728|23 29|serines
P11158290A0728|3 8|region
P11158290A0728|73 84|IkappaBalpha
P11158295A0158|71 73|SH3
P11158295A0158|78 87|SH2 regions
P11158295A0158|44 46|Csk
P11158295A0158|30 41|kinase domain
P11158295A0158|4 11|function
P11158295A0158|58 68|Src homology
P11158310A0993|59 62|beta
P11158310A0993|44 52|ATF6alpha
P11158310A0993|37 40|NF-Y
P11158310A0993|24 27|ERSF
P11158310A0993|117 119|UPR
P11158310A0993|84 87|ERSE
P11158324A1073|471 493|anion transporter protein
P11158324A1073|165 191|triglyceride transfer protein
P11158324A1073|279 297|lipoprotein receptor
P11158324A1073|137 151|apolipoprotein B
P11158324A1073|124 128|genes
P11158324A1073|357 361|liver
P11158324A1073|78 97|lipoprotein secretion
P11158324A1073|50 59|disruption
P11158324A1073|247 256|expression
P11158324A1073|299 317|scavenger receptor BI
P11158324A1073|338 351|bile acid uptake
P11158324A1073|367 381|down-regulation
P11158324A1073|216 232|cholesterol uptake
P11158324A1073|328 335|decrease
P11158324A1073|112 121|expression
P11158324A1073|11 20|phenotypes
P11158324A1073|199 206|increase
P11158324A1073|403 460|bile acid transporters sodium taurocholate cotransporter protein
P11158326A1032|56 64|SH2 domain
P11158326A1032|5 11|effects
P11158326A1032|43 50|mutation
P11158326A1032|66 69|R47G
P11158326A1032|27 31|SHIP2
P11158337A0000|240 243|SF-1
P11158337A0000|70 73|gene
P11158337A0000|50 61|GnRH receptor
P11158337A0000|231 238|factor-1
P11158337A0000|171 174|GRAS
P11158337A0000|245 255|binding site
P11158337A0000|199 202|AP-1
P11158337A0000|63 68|GnRH-R
P11158337A0000|162 169|sequence
P11158337A0000|35 44|expression
P11158337A0000|204 210|element
P11158337A0000|95 114|transcription factors
P11158337A0000|146 151|GnRH-R
P11158337A0000|180 197|activator protein-1
P11158456A0223|0 6|METHODS
P11158456A0223|159 166|sequelae
P11158456A0223|46 49|time
P11158456A0223|19 27|interview
P11158456A0223|185 187|age
P11158456A0223|110 113|type
P11158456A0223|92 100|intervals
P11158456A0223|168 180|family history
P11158456A0223|190 200|termination
P11158456A0223|131 136|spells
P11158456A0223|59 70|consultation
P11158456A0223|120 128|frequency
P11158456A0223|148 157|phenomenon
P11158456A0223|203 208|spells
P11158456A0223|116 118|BHS
P11159081A1155|71 75|tumor
P11159081A1155|7 11|cases
P11159081A1155|90 95|seroma
P11159081A1155|23 31|MR imaging
P11159081A1155|17 17|%
P11159081A1155|98 107|reexcision
P11159363A1251|0 10|Methylation
P11159363A1251|52 53|CG
P11159363A1251|38 47|E2F element
P11159363A1251|57 58|CG
P11159363A1251|50 50|m
P11159363A1251|107 113|complex
P11159363A1251|17 32|cytosine residues
P11159363A1251|55 55|m
P11160096A1067|5 13|mutations
P11160096A1067|63 71|phenotype
P11160096A1067|37 50|fliF background
P11160280A1275|59 68|IRF element
P11160280A1275|36 40|IRF-1
P11160280A1275|24 33|expression
P11160280A1275|47 53|binding
P11160307A0394|215 220|region
P11160307A0394|13 21|wH22xeGFP
P11160307A0394|254 262|FcgammaRI
P11160307A0394|177 181|Fc end
P11160307A0394|226 228|Fab
P11160307A0394|65 70|mAb H22
P11160307A0394|166 171|region
P11160307A0394|119 127|CH3 domain
P11160307A0394|4 11|molecule
P11160307A0394|110 112|end
P11160307A0394|75 78|eGFP
P11160307A0394|129 137|wH22xeGFP
P11160656A0000|0 9|Inactivity
P11160656A0000|126 131|region
P11160656A0000|256 270|NTera2 carcinoma
P11160656A0000|20 34|cytomegalovirus
P11160656A0000|78 82|MIERR
P11160656A0000|156 159|lack
P11160656A0000|136 144|modulator
P11160656A0000|71 76|region
P11160656A0000|276 280|cells
P11160656A0000|162 176|HCMV replication
P11160656A0000|111 118|enhancer
P11160656A0000|195 199|cells
P11160656A0000|223 231|cell types
P11160656A0000|102 109|promoter
P11160656A0000|36 39|HCMV
P11160656A0000|272 274|NT2
P11160683A1220|59 67|C/EBP site
P11160683A1220|4 14|interaction
P11160683A1220|135 138|CREB
P11160683A1220|102 114|ATF/CREB sites
P11160683A1220|83 99|CREB-1 recruitment
P11160683A1220|33 49|C/EBP dimer binding
P11160688A1726|60 67|cyclin D3
P11160688A1726|76 88|translocation
P11160688A1726|12 17|events
P11160688A1726|100 108|cytoplasm
P11160688A1726|39 47|structure
P11160688A1726|91 94|ICP0
P11160721A0932|62 81|TBLV enhancer activity
P11160721A0932|9 21|transfections
P11160721A0932|39 46|mutation
P11160721A0932|110 120|T-cell lines
P11160721A0932|48 51|556M
P11160732A0464|0 11|Vector stocks
P11160732A0464|116 124|SIVmac316
P11160732A0464|157 166|SIVmac1A11
P11160732A0464|56 67|SIVmac clones
P11160732A0464|126 141|macrophage tropic
P11160732A0464|22 37|envelope proteins
P11160732A0464|86 103|T-lymphocyte tropic
P11160732A0464|76 84|SIVmac239
P11160732A1199|233 238|import
P11160732A1199|210 222|transcription
P11160732A1199|178 195|SIVmac239 infection
P11160732A1199|12 21|PCR studies
P11160732A1199|246 248|DNA
P11160732A1199|74 80|nucleus
P11160732A1199|47 55|transport
P11160732A1199|95 105|macrophages
P11160732A1199|35 43|synthesis
P11160732A1199|135 145|pseudotypes
P11160732A1199|164 174|restriction
P11160732A1199|121 125|clone
P11160732A1199|58 66|vector DNA
P11160738A1414|58 70|establishment
P11160738A1414|89 97|infection
P11160738A1414|23 31|functions
P11160738A1414|34 39|vIRF-2
P11160742A0696|4 4|Z
P11160742A0696|8 18|R expression
P11160742A0696|56 60|cells
P11160742A0696|29 41|PML dispersion
P11160860A0662|181 207|IkappaBalpha phosphorylation
P11160860A0662|27 39|IkappaB kinase
P11160860A0662|104 125|IkappaB phosphorylation
P11160860A0662|72 75|role
P11160860A0662|41 48|IKK-beta
P11160860A0662|78 96|NF-kappaB activation
P11160860A0662|165 169|cells
P11160860A0662|17 24|activity
P11160896A0713|0 24|Immunofluorescence studies
P11160896A0713|27 39|C2C12 myotubes
P11160896A0713|56 71|MEF2A co-localise
P11160896A0713|112 126|differentiation
P11160896A0713|77 83|nucleus
P11160896A0713|98 105|myotubes
P11160896A0713|48 52|Smad2
P11160902A0962|72 81|expression
P11160902A0962|38 46|potential
P11160902A0962|154 163|expression
P11160902A0962|129 136|settings
P11160902A0962|170 173|gene
P11160902A0962|84 109|c-sis/PDGF-B proto-oncogene
P11160902A0962|13 16|TFOs
P11160929T0000|30 33|site
P11160929T0000|51 63|endonucleases
P11160929T0000|36 44|LAGLIDADG
P11160929T0000|5 13|evolution
P11161455A1286|43 53|cell hybrids
P11161455A1286|88 95|cDNA maps
P11161455A1286|98 107|chromosome
P11161455A1286|0 19|Southern blot analysis
P11161455A1286|29 31|DNA
P11161720X1294|0 8|Copyright
P11161720X1294|13 25|Academic Press
P11161793A1033|47 53|species
P11161793A1033|122 133|EGFR activity
P11161793A1033|22 37|receptor isoforms
P11161793A1033|105 109|roles
P11161793A1033|71 78|proteins
P11161793A1033|3 10|presence
P11161816A0851|17 28|similarities
P11161816A0851|141 146|action
P11161816A0851|68 75|sequence
P11161816A0851|81 92|SH3GLB family
P11161816A0851|36 53|endophilin proteins
P11161816A0851|111 114|fold
P11161816A0851|135 138|mode
P11162278A0629|74 79|lobule
P11162278A0629|104 108|gyrus
P11162278A0629|39 48|activation
P11162278A0629|22 28|figures
P11162278A0629|6 13|rotation
P11162576A0213|17 30|identification
P11162576A0213|67 71|exons
P11162576A0213|103 111|PDE5A gene
P11162576A0213|51 61|alternative
P11162576A0213|85 92|promoter
P11162666A0442|76 80|acids
P11162666A0442|46 53|addition
P11162666A0442|3 28|glucose/insulin stimulation
P11162936A2727|118 134|tissue selectivity
P11162936A2727|13 23|development
P11162936A2727|83 89|ERalpha
P11162936A2727|67 79|antiestrogens
P11162936A2727|92 97|ERbeta
P11162936A2727|142 147|agents
P11162936A2727|26 32|ligands
P11162936A2727|192 200|treatment
P11162936A2727|216 227|breast cancer
P11162936A2727|56 64|estrogens
P11162936A2727|204 213|prevention
P11162936A2727|161 185|hormone replacement therapy
P11163932A0000|128 136|pulmonate
P11163932A0000|11 15|tests
P11163932A0000|161 171|temperature
P11163932A0000|177 186|substratum
P11163932A0000|105 121|thermopreferendum
P11163932A0000|36 65|roman garden snail Helix pomatia L.
P11163932A0000|23 30|specimen
P11163932A0000|81 85|order
P11163932A0000|196 209|air temperature
P11163968A0152|28 42|genome sequences
P11163968A0152|68 83|Pyrococcus abyssi
P11163968A0152|45 64|Pyrococcus horikoshii
P11163968A0152|122 129|archaeon
P11163968A0152|12 15|work
P11163968A0152|98 102|genus
P11163968A0152|173 191|genome polymorphisms
P11163968A0152|202 237|restriction-modification gene homologs
P11163968A0152|88 94|species
P11163968A0152|131 145|archaebacterium
P11164078A0833|44 46|NAD
P11164078A0833|59 67|viewpoint
P11164078A0833|37 41|model
P11164078A0833|70 87|treatment-response
P11164078A0833|49 51|man
P11164078A0833|4 14|animal model
P11164078A0833|17 24|dystonia
P11166478T0000|60 68|pain model
P11166478T0000|47 51|mouse
P11166478T0000|29 43|antinociception
P11166863A0167|72 75|RTOG
P11166863A0167|63 70|toxicity
P11166863A0167|52 56|grade
P11166863A0167|27 27|%
P11166863A0167|13 13|%
P11166863A0167|18 20|% CI
P11166863A0167|29 36|patients
P11167019A1249|3 6|TATA
P11167019A1249|50 81|ATPsynCF6 transcription start sites
P11167019A1249|39 47|GABPalpha
P11167019A1249|8 12|motif
P11167111A0957|76 78|LPD
P11167111A0957|95 99|weeks
P11167111A0957|105 106|TX
P11167111A0957|64 73|recipients
P11167111A0957|19 40|lung function parameters
P11167111A0957|88 93|grafts
P11167778T0000|32 37|sepsis
P11167778T0000|8 29|antithrombin deficiency
P11168366A0569|85 91|GGT mRNA
P11168366A0569|33 40|fragment
P11168366A0569|66 74|sequences
P11168366A0569|94 103|HepG2 cells
P11168366A0569|2 9|addition
P11168422A0248|42 58|metal fluoride ions
P11168422A0248|6 11|Nature
P11168422A0248|105 115|iron protein
P11168422A0248|67 75|phosphate
P11168422A0248|95 99|sites
P11168422A0248|117 119|Kp2
P11168446T0000|34 41|patients
P11168446T0000|79 89|alterations
P11168446T0000|9 31|erythropoietin synthesis
P11168446T0000|56 67|heart failure
P11168446T0000|97 109|haemodynamics
P11168588T0000|0 9|Expression
P11168588T0000|92 107|kinase activation
P11168588T0000|77 81|c-Jun
P11168588T0000|12 33|herpes simplex virus type
P11168588T0000|48 63|Cdc42/Rac pathway
P11168588T0000|35 37|US3
P11169080T0000|46 48|Bok
P11169080T0000|10 18|education
P11169080T0000|35 43|ignorance
P11169080T0000|51 53|Law
P11169113A0555|29 39|phi29 mutant
P11169113A0555|73 76|gene
P11169113A0555|22 24|p16
P11169113A0555|63 70|mutation
P11169113A0555|16 19|role
P11169149A0097|14 22|knowledge
P11169149A0097|24 28|SNTCS
P11170476A1546|147 155|molecules
P11170476A1546|36 48|gp96 complexes
P11170476A1546|55 64|plasticity
P11170476A1546|168 178|recognition
P11170476A1546|27 33|peptide
P11170476A1546|123 130|peptides
P11170476A1546|85 90|pocket
P11170476A1546|109 113|relay
P11170476A1546|16 24|stability
P11170476A1546|133 135|MHC
P11171118A0836|86 97|interactions
P11171118A0836|13 19|binding
P11171118A0836|62 72|competition
P11171118A0836|22 25|NF-1
P11171118A0836|123 132|antibodies
P11171118A0836|105 119|NF-1 DNA elements
P11171118A0836|28 32|PSE-B
P11171118A0836|42 46|PSE-A
P11171320A0894|0 11|Coexpression
P11171320A0894|22 24|ctn
P11171320A0894|49 56|deletion
P11171320A0894|26 32|protein
P11171320A0894|138 158|amino acid substitution
P11171320A0894|249 261|EalphaCL cells
P11171320A0894|160 167|tyrosine
P11171320A0894|214 224|aggregation
P11171320A0894|17 20|p120
P11171320A0894|86 113|tyrosine phosphorylation sites
P11171320A0894|201 208|increase
P11171320A0894|244 245|EL
P11171320A0894|120 126|protein
P11171320A0894|175 187|phenylalanine
P11172610A0508|41 46|number
P11172610A0508|10 12|p73
P11172610A0508|65 73|promoters
P11172944A0548|0 6|RESULTS
P11172944A0548|54 58|Grade
P11172944A0548|34 44|pneumonitis
P11172944A0548|60 70|pneumonitis
P11172944A0548|15 22|patients
P11172944A0548|28 32|Grade
P11172944A0826|72 91|radiation pneumonitis
P11172944A0826|37 47|correlation
P11172944A0826|55 68|plasma TNFalpha
P11172944A0826|2 9|contrast
P11175333A0336|19 41|co-precipitation methods
P11175333A0336|64 71|proteins
P11176098A0342|15 18|pigs
P11176098A0342|51 61|shock groups
P11176098A0342|0 6|METHODS
P11176290T0000|90 92|MRI
P11176290T0000|73 84|fibrillation
P11176290T0000|25 36|vein stenosis
P11176290T0000|42 63|radiofrequency ablation
P11176290T0000|0 13|Identification
P11177538A0655|28 30|MOI
P11177538A0655|50 72|% gene transfer efficiency
P11177538A0655|38 41|days
P11177538A0655|0 13|Tumor cell lines
P11177686A0243|0 8|Treatment
P11177686A0243|39 45|options
P11177686A0243|114 121|dilation
P11177686A0243|58 64|therapy
P11178248A1042|103 111|positives
P11178248A1042|33 51|screening techniques
P11178248A1042|86 95|occurrence
P11178248A1042|54 58|terms
P11178248A1042|61 71|sensitivity
P11178248A1042|73 82|efficiency
P11178696A0301|92 100|injection
P11178696A0301|75 75|s
P11178696A0301|148 151|PD US
P11178696A0301|107 119|contrast agent
P11178696A0301|104 104|g
P11178696A0301|6 13|US images
P11178765A0642|44 47|acid
P11178765A0642|52 62|development
P11178765A0642|74 83|metastasis
P11178765A0642|135 139|cells
P11178765A0642|128 132|colon
P11178765A0642|100 118|mouse adenocarcinoma
P11178765A0642|16 22|effects
P11179272T0000|16 24|Chlamydia
P11179272T0000|73 82|restenosis
P11179272T0000|39 69|Helicobacter pylori IgG antibodies
P11179272T0000|93 104|implantation
P11179272T0000|136 150|ultrasound study
P11179272T0000|0 14|Cytomegalovirus
P11179400T0000|0 8|Responses
P11179400T0000|54 57|rats
P11179400T0000|22 46|carotid body chemoreceptors
P11179664T0000|74 102|transcription factor RUNX1/AML1
P11179664T0000|34 38|locus
P11179664T0000|0 11|Architecture
P11179664T0000|15 21|anatomy
P11179668A0869|29 36|proteins
P11179668A0869|53 62|PLTP family
P11179687A0280|119 129|subfamilies
P11179687A0280|79 82|PTPs
P11179687A0280|66 77|phosphatases
P11179687A0280|39 45|enzymes
P11179687A0280|141 144|PTPs
P11179687A0280|6 10|paper
P11179687A0280|151 162|receptor PTPs
P11179687A0280|164 168|RPTPs
P11179687A0280|14 21|tyrosine
P11179687A1118|30 35|module
P11179687A1118|127 131|group
P11179687A1118|115 120|member
P11179687A1118|53 62|disulphide
P11179687A1118|21 28|metazoan
P11179687A1118|70 78|Ig members
P11179689A0000|82 87|domain
P11179689A0000|136 143|sequence
P11179689A0000|24 33|HMG box gene
P11179689A0000|105 114|amino acids
P11179689A0000|62 72|DNA sequence
P11179689A0000|152 161|DNA binding
P11179689A0000|3 15|Sox gene family
P11179689A0000|17 19|Sry
P11179956A1818|74 79|domain
P11179956A1818|52 58|effects
P11179956A1818|152 158|domains
P11179956A1818|10 16|results
P11179956A1818|180 194|proton transport
P11179956A1818|82 98|nucleotide binding
P11179956A1818|123 134|interactions
P11180027A1306|60 69|depression
P11180027A1306|11 20|parameters
P11180027A1306|34 36|M6G
P11180027A1306|74 81|morphine
P11180255A0776|60 66|effects
P11180255A0776|141 145|space
P11180255A0776|90 98|mechanism
P11180255A0776|20 28|arguments
P11180255A0776|124 129|energy
P11180255A0776|35 47|improbability
P11180255A0776|69 82|UHF frequencies
P11180255A0776|134 137|time
P11180688A0000|56 63|children
P11180688A0000|151 153|MFT
P11180688A0000|105 113|illnesses
P11180688A0000|139 149|Fitness Test
P11180688A0000|41 48|Hong Kong
P11180688A0000|161 167|shuttle
P11180688A0000|212 216|years
P11180688A0000|183 196|schoolchildren
P11180688A0000|31 31|V
P11180688A0000|35 37|max
P11180688A0000|11 29|maximum oxygen uptake
P11180688A0000|171 174|test
P11180688A0000|79 89|association
P11181516A0119|136 142|regions
P11181516A0119|201 208|elements
P11181516A0119|213 214|E2
P11181516A0119|67 79|transfections
P11181516A0119|219 222|Flat
P11181516A0119|88 102|INS-1 beta-cells
P11181516A0119|152 170|rat insulin I promoter
P11181516A0119|224 228|A2/A3
P11181516A0119|14 55|deletion insulin promoter-reporter constructs
P11181525T0000|61 70|regulation
P11181525T0000|20 21|AR
P11181525T0000|73 88|AR gene expression
P11181525T0000|23 36|amino-terminus
P11181525T0000|3 18|androgen receptor
P11181525T0000|100 107|enhancer
P11181531A0464|71 83|transcription
P11181531A0464|137 158|cytokines interleukin-6
P11181531A0464|38 49|osteoporosis
P11181531A0464|162 174|interleukin-1
P11181531A0464|6 14|mechanism
P11181531A0464|22 30|estrogens
P11181531A0464|86 105|NF-kappa B target genes
P11181531A0464|59 68|repression
P11181548A0214|70 75|region
P11181548A0214|39 45|element
P11181548A0214|94 103|expression
P11181548A0214|62 67|tissue
P11181548A0214|128 138|DNA fragment
P11181548A0214|109 119|mE-RABP gene
P11181548A0214|47 47|s
P11181564A0733|15 19|genes
P11181564A0733|50 59|chromosome
P11181564A0733|5 9|mouse
P11181564A0733|39 47|region 8E1
P11181995A1093|0 7|Analysis
P11181995A1093|209 216|evidence
P11181995A1093|176 187|mouse matches
P11181995A1093|167 171|genes
P11181995A1093|57 67|transcripts
P11181995A1093|13 26|genome sequence
P11181995A1093|103 110|evidence
P11182520A0889|42 52|restriction
P11182520A0889|65 69|assay
P11182520A0889|16 23|genotype
P11182746A0872|13 20|patients
P11182746A0872|35 40|levels
P11182746A0872|55 65|drug therapy
P11185475T0034|2 8|Caveman
P11187016T0000|41 52|implications
P11187016T0000|10 15|models
P11187016T0000|22 39|A-bomb survivor data
P11187016T0000|68 77|mechanisms
P11188971A0000|29 37|Parkinson
P11188971A0000|104 109|target
P11188971A0000|82 92|methodology
P11188971A0000|19 25|surgery
P11188971A0000|40 46|disease
P11188971A0000|48 49|PD
P11188971A0000|60 69|discussion
P11188993A0298|0 6|Corneal
P11188993A0298|116 121|Gomori
P11188993A0298|124 146|methenamine silver stains
P11188993A0298|94 104|acid-Schiff
P11188993A0298|106 111|Giemsa
P11188993A0298|30 35|biopsy
P11188993A0298|72 81|evaluation
P11189314A1000|5 11|results
P11189314A1000|78 81|GLCM
P11189314A1000|24 27|BACM
P11189314A1000|67 73|effects
P11191208A0000|236 244|PDR3 genes
P11191208A0000|143 172|ABC binding cassette transporters
P11191208A0000|64 77|overexpression
P11191208A0000|80 84|genes
P11191208A0000|182 188|control
P11191208A0000|125 136|facilitators
P11191208A0000|9 18|resistance
P11191208A0000|194 216|transcription regulators
P11191208A0000|229 232|PDR1
P11191208A0000|97 115|membrane efflux pumps
P11191365A0682|0 13|Susceptibility
P11191365A0682|132 132|%
P11191365A0682|190 191|VT
P11191365A0682|75 75|%
P11191365A0682|248 248|P
P11191365A0682|162 173|fibrillation
P11191365A0682|223 224|VF
P11191365A0682|227 227|%
P11191365A0682|203 203|%
P11191365A0682|124 125|VT
P11191365A0682|112 122|tachycardia
P11191365A0682|195 195|%
P11191365A0682|234 246|non-diabetics
P11191365A0682|141 148|episodes
P11191365A0682|199 200|VF
P11191365A0682|175 176|VF
P11191365A0682|59 67|diabetics
P11191365A0682|86 91|hearts
P11191365A0682|32 42|arrhythmias
P11193045A1193|57 59|p63
P11193045A1193|89 99|development
P11193045A1193|36 43|function
P11193045A1193|71 86|tumor suppression
P11193045A1193|53 55|p73
P11193045A1193|49 51|p53
P11193045A1193|1 7|picture
P11193045A1193|26 33|gradient
P11193666A1269|82 85|herd
P11193666A1269|25 33|outbreaks
P11193666A1269|36 56|Babesia carrier animals
P11193704A0000|16 30|pleuropneumonia
P11193704A0000|39 44|threat
P11193704A0000|48 53|cattle
P11193704A0000|56 61|Africa
P11194101A0532|0 16|Baseline BMD values
P11194101A0532|240 249|user groups
P11194101A0532|123 126|view
P11194101A0532|78 83|others
P11194101A0532|89 93|level
P11194101A0532|102 106|spine
P11194101A0532|199 199|P
P11194101A0532|315 319|femur
P11194101A0532|286 289|bone
P11194101A0532|61 65|group
P11194101A0532|190 193|g x cm
P11194147A1496|3 14|distribution
P11194147A1496|37 44|Sri Lanka
P11194147A1496|20 34|rice cultivation
P11194147A1496|64 75|HIDD villages
P11194183A0866|29 33|hairs
P11194183A0866|216 242|placebo control group subjects
P11194183A0866|330 330|P
P11194183A0866|244 257|procyanidin B-2
P11194183A0866|67 72|microm
P11194183A0866|278 279|SD
P11194183A0866|75 82|diameter
P11194183A0866|175 179|trial
P11194183A0866|347 351|t test
P11194183A0866|120 126|cm2 area
P11194183A0866|52 56|hairs
P11194183A0866|99 102|area
P11194183A0866|286 288|cm2
P11194183A0866|133 159|procyanidin B-2 group subjects
P11194183A0866|271 274|mean
P11194183A0866|13 18|number
P11194183A0866|326 328|cm2
P11194183A0866|318 319|SD
P11194183A0866|290 296|placebo
P11194183A0866|107 114|cm square
P11194183A0866|3 10|increase
P11194183A0866|311 314|mean
P11195338A0494|36 44|Lg3 allele
P11195338A0494|65 73|phenotype
P11195338A0494|7 16|expression
P11195401A1030|4 18|plasma AVP levels
P11195401A1030|92 96|SIADH
P11195401A1030|51 55|SSRIs
P11195401A1030|65 76|AVP secretion
P11195401A1030|35 39|cases
P11196191A1789|42 48|synergy
P11196191A1789|32 35|IL-6
P11196191A1789|7 30|T47D breast carcinoma cells
P11196191A1789|53 80|EGF receptor autocrine activity
P11196191A1789|99 115|MAPK/PI3K pathways
P11196199T0000|87 90|CREB
P11196199T0000|93 106|binding protein
P11196199T0000|72 85|element binding
P11196199T0000|5 13|homologue
P11196199T0000|147 149|p53
P11196199T0000|137 144|activity
P11196199T0000|16 33|yeast Rad23 protein A
P11196340A1046|44 51|antigens
P11196340A1046|100 112|aescin analogs
P11196340A1046|24 37|identification
P11196340A1046|70 80|variability
P11196340A1046|125 132|validity
P11196340A1046|16 22|methods
P11197288A0855|62 68|strains
P11197288A0855|112 119|regimens
P11197288A0855|92 95|rate
P11197288A0855|21 33|metronidazole
P11197288A0855|4 11|patients
P11197328T0000|0 6|Binding
P11197328T0000|143 156|mesophyll cells
P11197328T0000|65 105|maize C4 phosphoenolpyruvate carboxylase gene
P11197328T0000|128 140|transcription
P11197328T0000|9 12|cell
P11197328T0000|57 62|region
P11197328T0000|33 40|proteins
P11197549A0748|70 80|arrhythmias
P11197549A0748|62 65|mm Hg
P11197549A0748|17 35|stabilization period
P11197549A0748|37 41|PaCO2
P11197549A0748|50 51|SD
P11197549A0748|43 46|mean
P11197549A0748|0 6|RESULTS
P11197926A0000|0 9|BACKGROUND
P11197926A0000|67 74|versions
P11197926A0000|128 134|effects
P11197926A0000|80 105|General Health Questionnaire
P11197926A0000|184 192|intervals
P11197926A0000|170 174|times
P11197926A0000|107 109|GHQ
P11197926A0000|19 25|studies
P11198053T0000|115 117|rat
P11198053T0000|49 54|St John
P11198053T0000|73 84|constituents
P11198053T0000|101 109|responses
P11198053T0000|29 47|Hypericum perforatum
P11198053T0000|5 11|effects
P11198053T0000|20 26|extract
P11198053T0000|14 15|LI
P11198053T0000|57 60|wort
P11198289T0000|30 41|copper levels
P11198289T0000|52 59|dystonia
P11198289T0000|9 26|serum ceruloplasmin
P11198385A0000|73 78|adults
P11198385A0000|22 33|algerae Vavra
P11198385A0000|64 69|larvae
P11198385A0000|128 145|Gharbia Governorate
P11198385A0000|82 97|laboratory colony
P11198385A0000|100 113|Culex pipiens L.
P11198424T0000|44 47|gene
P11198424T0000|9 15|cloning
P11198424T0000|57 65|precursor
P11198424T0000|19 34|characterization
P11198424T0000|37 41|OsPSK
P11198424T0000|69 88|phytosulfokine-alpha
P11198424T0000|101 121|rice cell proliferation
P11200568A0830|84 96|IgG antibodies
P11200568A0830|65 75|measurement
P11200568A0830|9 12|dams
P11200568A0830|99 108|M. pulmonis
P11200568A0830|54 61|necropsy
P11200568A0830|48 51|time
P11200568A0830|78 80|IgM
P11200568A0830|32 42|inoculation
P11200568A0830|0 4|Blood
P11201250A0849|0 21|Plasma DHE concentration
P11201250A0849|90 93|skin
P11201250A0849|53 63|application
P11201250A0849|40 44|ng/ml
P11201250A0849|104 106|rat
P11201250A0849|69 75|PSA tape
P11202434T0000|91 95|ACBP2
P11202434T0000|69 88|palmitoyl-CoA binding
P11202434T0000|49 54|domain
P11202434T0000|126 132|protein
P11202434T0000|6 27|amino acid substitutions
P11202434T0000|67 67|C
P11202434T0000|99 109|Arabidopsis
P11202434T0000|137 150|ankyrin repeats
P11202705A1112|0 11|Implications
P11202705A1112|94 110|Posidonia oceanica
P11202705A1112|40 59|accumulation patterns
P11202705A1112|85 91|tissues
P11202705A1112|14 26|biomonitoring
P11203702A1307|189 194|Xlim-1
P11203702A1307|142 150|mechanism
P11203702A1307|179 186|activity
P11203702A1307|46 61|activation domain
P11203702A1307|5 10|Xlim-1
P11203702A1307|104 112|CT239-403
P11203702A1307|96 101|domain
P11203702A1307|200 208|organizer
P11204897A0797|31 42|participants
P11204897A0797|13 16|time
P11204897A0797|53 71|bridge simulator task
P11204897A0797|20 29|absorption
P11207216A0296|75 87|chain reaction
P11207216A0296|91 110|cDNA library screening
P11207216A0296|9 18|PGHS-2 cDNA
P11207216A0296|31 41|combination
P11207216A0719|28 34|protein
P11207216A0719|103 131|phorbol 12-myristate 13-acetate
P11207216A0719|140 141|nM
P11207216A0719|15 24|PGHS-2 mRNA
P11207216A0719|3 12|regulation
P11207216A0719|54 61|cultures
P11207216A0719|133 135|PMA
P11207216A0719|84 88|cells
P11207261A1421|267 276|coligation
P11207261A1421|10 17|analysis
P11207261A1421|303 310|receptor
P11207261A1421|169 180|phosphatases
P11207261A1421|279 288|BCR complex
P11207261A1421|40 53|DT40 B cell lines
P11207261A1421|182 186|SHP-1
P11207261A1421|190 194|SHP-2
P11207261A1421|139 149|Src homology
P11207261A1421|87 114|Fc gamma RIIB1-PECAM-1 receptor
P11207261A1421|253 262|regulation
P11207269A0745|45 54|properties
P11207269A0745|14 16|mAb
P11207269A0745|61 72|p95 component
P11207282A0729|172 189|IgH gene transcripts
P11207282A0729|51 54|form
P11207282A0729|161 169|reduction
P11207282A0729|100 114|down-regulation
P11207282A0729|18 27|expression
P11207282A0729|81 89|B cell line
P11207282A0729|57 69|chicken Notch1
P11207282A0729|117 136|surface IgM expression
P11207282A0729|72 77|Notch2
P11207288A0897|0 12|Substitutions
P11207288A0897|105 111|binding
P11207288A0897|38 40|ABR
P11207288A0897|18 20|YFV
P11207288A0897|31 36|region
P11207288A0897|78 85|residues
P11207288A0897|129 144|class Ia molecules
P11207288A0897|114 123|peptide-Ag
P11207308A0999|153 168|kinase activation
P11207308A0999|57 61|agent
P11207308A0999|200 205|ERK1/2
P11207308A0999|138 142|c-Jun
P11207308A0999|19 35|diferuloylmethane
P11207308A0999|195 198|JAK3
P11207308A0999|190 193|JAK2
P11207308A0999|87 106|STAT1 phosphorylation
P11207308A0999|129 133|STAT1
P11207308A0999|10 17|curcumin
P11207308A0999|119 126|activity
P11207308A0999|210 227|p38 phosphorylation
P11207308A0999|185 188|JAK1
P11207609A0994|146 149|HeLa
P11207609A0994|153 160|NRK cells
P11207609A0994|131 134|VSVG
P11207609A0994|185 195|differences
P11207609A0994|212 222|trafficking
P11207609A0994|136 143|chimeras
P11207609A0994|78 91|ER localization
P11207609A0994|103 129|stomatitis virus glycoprotein
P11207609A0994|54 57|tail
P11207609A0994|38 42|TGN46
P11207609A0994|14 20|failure
P11207609A0994|2 9|contrast
P11207609A0994|26 34|QKTT motif
P11208017A0070|1 9|cDNA clone
P11208017A0070|67 73|soybean
P11208017A0070|18 43|C2H2-type zinc finger protein
P11208017A0070|45 50|SCOF-1
P11208814A0673|88 104|sequence alignment
P11208814A0673|79 86|proteins
P11208814A0673|42 52|interaction
P11208814A0673|156 170|phosphorylation
P11208814A0673|17 27|specificity
P11208814A0673|184 192|subdomain
P11208814A0673|211 218|proteins
P11208814A0673|124 125|m7
P11208814A0673|173 176|CKII
P11208814A0673|140 152|consensus site
P11208814A0673|130 131|m8
P11208814A0673|121 122|m5
P11208814A0673|55 65|DmCKIIalpha
P11209100A0069|84 90|effects
P11209100A0069|93 103|stimulation
P11209100A0069|39 42|data
P11209100A0069|116 134|cytokine antagonists
P11209100A0069|173 178|IL-1ra
P11209100A0069|107 113|release
P11209100A0069|55 57|PMN
P11209100A0069|22 31|properties
P11209100A0069|141 171|interleukin-1 receptor antagonist
P11209814A0243|177 187|bioceramics
P11209814A0243|16 28|investigation
P11209814A0243|82 94|tissue capsule
P11209814A0243|125 148|aluminum calcium phosphate
P11209814A0243|111 122|implantation
P11209814A0243|3 9|purpose
P11209814A0243|150 154|ALCAP
P11209814A0243|55 69|characteristics
P11209814A0243|174 175|HA
P11209814A0243|159 172|hydroxyapetite
P11210401A0000|0 21|Sevelamer hydrochloride
P11210401A0000|118 125|patients
P11210401A0000|23 29|Renagel
P11210401A0000|83 91|treatment
P11210401A0000|94 110|hyperphosphatemia
P11210401A0000|62 68|polymer
P11210401A0000|135 146|hemodialysis
P11210401A0544|28 34|digoxin
P11210401A0544|89 102|administration
P11210401A0544|38 45|warfarin
P11210401A0544|105 113|sevelamer
P11210401A0544|18 25|profiles
P11210839A0282|87 91|drugs
P11210839A0282|107 117|ethionamide
P11210839A0282|48 55|patients
P11210839A0282|41 41|%
P11210839A0282|32 35|half
P11210839A0282|6 22|PO3 administration
P11210839A0282|93 103|ethambutole
P11210839A0282|134 145|oprofloxacin
P11210839A0282|120 130|ethambutole
P11210988T0000|3 10|survival
P11210988T0000|25 32|patients
P11210988T0000|54 67|prostate cancer
P11211759A0165|126 145|humidification system
P11211759A0165|103 122|transtracheal heating
P11211759A0165|148 161|ANAMED HUMITUBE
P11211759A0165|89 94|group B
P11211759A0165|26 30|group
P11211759A0165|32 44|Control group A
P11211759A0165|53 61|hot-water
P11211759A0165|183 197|cancer operation
P11211759A0165|73 78|system
P11211759A0165|0 7|Patients
P11211936A1490|85 87|JNK
P11211936A1490|89 102|SAPK activation
P11211936A1490|52 55|blr1
P11211936A1490|157 168|growth arrest
P11211936A1490|10 13|data
P11211936A1490|40 49|expression
P11211936A1490|139 153|differentiation
P11211936A1490|65 80|JNK/SAPK activity
P11212249A0993|88 95|activity
P11212249A0993|65 80|activator protein
P11212249A0993|53 62|antagonism
P11212249A0993|26 34|receptors
P11212249A0993|83 86|AP-1
P11212249A0993|3 9|effects
P11212327A1564|177 187|interaction
P11212327A1564|113 124|p59Lyn kinase
P11212327A1564|63 74|PIG compounds
P11212327A1564|192 199|caveolin
P11212327A1564|130 133|site
P11212327A1564|26 38|rat adipocytes
P11212327A1564|136 145|cross-talk
P11212327A1564|6 12|studies
P11212327A1564|82 110|IRS1/3 tyrosine phosphorylation
P11212327A1564|223 225|PIG
P11212327A1564|158 167|regulation
P11213342A0492|73 82|test period
P11213342A0492|11 23|parameters SF2
P11213342A0492|34 43|efficiency
P11213342A0492|0 6|RESULTS
P11214177A1125|43 48|nt RNAs
P11214177A1125|103 111|satellite
P11214177A1125|11 15|sense
P11214177A1125|64 69|satRNA
P11214354A1104|116 118|I-R
P11214354A1104|36 36|p
P11214354A1104|61 77|lipid peroxidation
P11214354A1104|132 141|CON animals
P11214354A1104|94 106|protein thiols
P11214354A1104|6 12|animals
P11214354A1104|43 48|levels
P11214354A1104|87 87|p
P11215622A0949|0 7|Grippers
P11215622A0949|63 68|strain
P11215622A0949|36 47|force sensors
P11216247T0000|3 7|child
P11218739A0811|0 9|Transition
P11218739A0811|22 27|H-BPPV
P11218739A0811|39 43|cases
P11218739A0811|17 17|P
P11220166A0616|14 20|effects
P11220166A0616|244 254|cortex loops
P11220166A0616|197 208|intervention
P11220166A0616|35 45|stimulation
P11220166A0616|274 282|behaviour
P11220166A0616|114 122|existence
P11220166A0616|76 82|aspects
P11220166A0616|51 66|motor performance
P11220166A0616|257 261|motor
P11220166A0616|169 190|brain dopamine receptors
P11220166A0616|94 103|processing
P11220166A0616|132 143|interactions
P11220306A0911|0 5|HexA71
P11220306A0911|101 104|HexA
P11220306A0911|81 84|HexA
P11220306A0911|106 111|strain
P11220306A0911|23 26|RpoS
P11220306A0911|56 66|sigma factor
P11220306A0911|33 38|levels
P11220306A1753|58 67|production
P11220306A1753|111 114|copy
P11220306A1753|90 96|effects
P11220306A1753|21 23|DNA
P11220306A1753|35 38|hand
P11220306A1753|8 13|copies
P11220306A1753|16 19|rsmB
P11220306A1753|117 120|hexA
P11220486A0686|1 1|%
P11220486A0686|6 10|IL-12
P11220486A0686|16 16|%
P11220487T0000|43 56|trichomoniasis
P11220487T0000|10 15|review
P11220487T0000|28 32|tests
P11220857T0000|0 3|CHAP
P11220857T0000|10 19|Department
P11220857T0000|22 36|Veterans Affairs
P11221836A0981|20 25|fusion
P11221836A0981|78 84|potency
P11221836A0981|49 55|vaccine
P11221836A0981|126 131|tumors
P11221845A0295|118 136|Restriction Landmark
P11221845A0295|23 39|methylation status
P11221845A0295|194 203|loci/spots
P11221845A0295|103 111|MT-D2 mice
P11221845A0295|53 57|liver
P11221845A0295|167 172|RLGS-M
P11221845A0295|155 165|Methylation
P11221845A0295|61 71|liver tumors
P11221845A0295|98 101|mice
P11221845A0295|242 252|liver tumors
P11221845A0295|144 151|Scanning
P11221845A0295|74 87|SV40 T/t antigen
P11221845A0800|143 160|SNAG repressor motif
P11221845A0800|191 215|C2H2-type zinc finger motifs
P11221845A0800|110 129|493-amino acid protein
P11221845A0800|178 183|region
P11221845A0800|33 44|reading frame
P11221845A0800|234 237|half
P11221845A0800|65 68|gene
P11221845A0800|3 17|Genescan program
P11221845A0800|82 89|B236 spot
P11221845A1370|57 61|brain
P11221845A1370|81 85|liver
P11221845A1370|32 34|mlt
P11221845A1370|63 68|spleen
P11221845A1370|70 76|stom ach
P11221845A1370|0 19|Northern blot analysis
P11221845A1713|0 8|Treatment
P11221845A1713|125 127|mlt
P11221845A1713|79 88|expression
P11221845A1713|91 93|mlt
P11221845A1713|245 256|SV40 T antigen
P11221845A1713|41 45|agent
P11221845A1713|216 233|liver tumorigenesis
P11221845A1713|47 65|5-aza-deoxycytidine
P11221845A1713|161 163|mlt
P11221845A1713|173 182|target gene
P11221845A1713|11 22|N18TG-2 cells
P11221845A1713|113 122|repression
P11221845A1713|199 209|methylation
P11221845A1713|145 155|methylation
P11222387A1497|41 46|action
P11222387A1497|109 115|promise
P11222387A1497|65 91|ABL tyrosine kinase inhibition
P11222387A1497|30 38|mechanism
P11222387A1497|93 103|FTI SCH66336
P11222387A1497|122 130|treatment
P11222387A1497|17 24|compound
P11222387A1497|148 155|leukemia
P11222639A1273|30 33|role
P11222639A1273|61 70|regulation
P11222639A1273|37 51|tyrosine residue
P11222639A1273|5 11|results
P11222639A1273|73 85|L1 endocytosis
P11222720A1699|14 17|RPMS
P11222720A1699|109 126|corepressor complex
P11222720A1699|33 41|regulator
P11222720A1699|75 86|interactions
P11222720A1699|44 48|EBNA2
P11222720A1699|52 64|Notch activity
P11223131A0000|0 15|Folate metabolism
P11223131A0000|135 139|class
P11223131A0000|153 158|agents
P11223131A0000|26 60|malaria parasite Plasmodium falciparum
P11223131A0000|171 173|use
P11223131A0000|98 108|replication
P11223131A0000|85 94|cell growth
P11223131A0000|74 81|activity
P11223131A0000|116 121|target
P11223153A0533|59 78|microsphere technique
P11223153A0533|18 25|text file
P11223153A0533|121 126|pixels
P11223153A0533|137 141|flows
P11223153A0533|3 11|BFA System
P11223153A0533|147 157|color schema
P11223153A0533|96 106|lung anatomy
P11223153A0533|30 34|flows
P11223153A0533|83 92|constructs
P11223164A0000|0 8|Retinoids
P11223164A0000|63 72|inhibition
P11223164A0000|88 94|variety
P11223164A0000|48 56|apoptosis
P11223164A0000|32 46|differentiation
P11223164A0000|25 29|onset
P11223164A0000|75 80|growth
P11223164A0000|115 119|cells
P11223186A1095|105 108|GATA
P11223186A1095|129 129|s
P11223186A1095|79 85|regions
P11223186A1095|124 127|site
P11223186A1095|113 120|sequence
P11223186A1095|96 103|AP-1 site
P11223186A1095|17 50|oIFNtau enhancer-reporter constructs
P11223186A1095|0 14|Transactivation
P11223199A0751|57 66|WB analysis
P11223199A0751|24 33|evaluation
P11223199A0751|69 73|serum
P11223199A0751|5 11|results
P11223199A0751|36 43|exposure
P11223199A0751|46 54|S. neurona
P11223199A0751|96 101|horses
P11223240A0655|45 64|polyadenylation sites
P11223240A0655|10 30|Menin1 gene transcripts
P11223240A0655|86 93|messages
P11223246A0359|0 15|Sequence analysis
P11223246A0359|128 133|region
P11223246A0359|79 86|proteins
P11223246A0359|29 47|RBP21 shares homology
P11223246A0359|103 112|motif LxCxE
P11223255A1034|14 36|consensus amino acid motif
P11223255A1034|2 9|addition
P11223255A1034|40 69|serine threonine receptor kinases
P11223256A1212|42 47|region
P11223256A1212|53 64|pea 33RNP gene
P11223257A0404|0 5|OsBBPI
P11223257A0404|210 215|manner
P11223257A0404|221 229|induction
P11223257A0404|159 167|endothall
P11223257A0404|104 123|protein phosphatase 2A
P11223257A0404|284 294|requirement
P11223257A0404|254 266|cycloheximide
P11223257A0404|125 128|PP2A
P11223257A0404|176 185|light/dark
P11223257A0404|153 154|CN
P11223257A0404|325 333|induction
P11223257A0404|268 270|CHX
P11223257A0404|88 89|JA
P11223257A0404|304 319|protein synthesis
P11223257A0404|188 191|time
P11223257A0404|130 139|inhibitors
P11223257A0404|52 59|response
P11223257A0404|169 170|EN
P11223257A0404|34 49|rice seedling leaf
P11223257A0404|141 151|cantharidin
P11223257A0404|83 86|acid
P11223938X1218|28 31|Ltd.
P11223938X1218|13 21|John Wiley
P11223938X1218|23 26|Sons
P11223938X1218|0 8|Copyright
P11224226A0000|3 9|effects
P11224226A0000|186 193|paradigm
P11224226A0000|12 27|chlordiazepoxide
P11224226A0000|116 144|benzodiazepine receptor agonist
P11224226A0000|49 77|benzodiazepine receptor agonist
P11224226A0000|37 41|mg/kg
P11224226A0000|82 91|bretazenil
P11224226A0000|101 105|mg/kg
P11226228A0899|37 40|gene
P11226228A0899|27 31|yeast
P11226228A0899|8 15|plasmids
P11226752A0750|147 153|protein
P11226752A0750|197 200|form
P11226752A0750|208 213|Notch1
P11226752A0750|105 112|activity
P11226752A0750|11 28|tissue culture cells
P11226752A0750|115 117|E47
P11226752A0750|158 163|manner
P11226752A0750|173 183|suppression
P11226752A0750|221 224|DTX1
P11226752A0750|30 43|overexpression
P11226752A0750|58 76|mouse deltex homologs
P11227039A0953|31 33|BMI
P11227039A0953|11 15|women
P11227039A0953|49 49|P
P11227039A0953|35 35|P
P11227039A0953|88 93|groups
P11227039A0953|68 72|primi
P11227039A0953|45 47|PBF
P11227182A1475|55 64|parameters
P11227182A1475|91 102|leptin levels
P11227182A1475|113 122|bone marrow
P11227182A1475|78 87|bone marrow
P11227182A1475|36 47|correlations
P11227182A1475|105 109|serum
P11227182A1475|70 75|lipids
P11227182A1475|3 9|authors
P11227484T0000|44 65|ion-association complex
P11227484T0000|70 79|rhodamine B
P11227484T0000|12 24|determination
P11227484T0000|27 39|methylmercury
P11227484T0000|95 100|iodide
P11227484T0000|85 92|presence
P11228700T0000|3 10|position
P11228700T0000|44 48|today
P11228700T0000|25 30|expert
P11228700T0000|16 22|analyst
P11228700T0000|32 40|yesterday
P11230145A0732|40 49|Notch-CBF1
P11230145A0732|156 165|conversion
P11230145A0732|51 76|RBP-Jkappa signaling pathway
P11230145A0732|3 9|results
P11230145A0732|31 34|role
P11230145A0732|79 95|cell fate decisions
P11230145A0732|133 143|replication
P11230145A0732|118 125|pathways
P11230169A0480|120 128|DNA domain
P11230169A0480|11 16|method
P11230169A0480|181 183|20p
P11230169A0480|174 179|invdup
P11230169A0480|64 81|array hybridization
P11230169A0480|26 53|chromatin immunoprecipitation
P11230169A0480|159 169|20p12 region
P11230169A0480|190 205|marker chromosome
P11230534A0688|44 50|species
P11230534A0688|11 15|total
P11230534A0688|20 32|DEAH helicases
P11230889A1151|100 105|months
P11230889A1151|25 38|arm lymphoedema
P11230889A1151|79 87|arm volume
P11230889A1151|124 127|HBO2
P11230889A1151|111 119|treatment
P11230889A1151|65 76|improvements
P11230889A1151|3 7|cases
P11231287A0158|73 84|thapsigargin
P11231287A0158|21 45|neuroblastoma cells SK-N-SH
P11231287A0158|3 13|sensitivity
P11231287A0158|55 63|apoptosis
P11232947A1451|59 63|chain
P11232947A1451|80 89|recurrence
P11232947A1451|12 30|lymph node dissection
P11232947A1451|125 132|survival
P11232947A1451|33 48|radiation therapy
P11233643A0000|104 106|PDT
P11233643A0000|152 156|mg/kg
P11233643A0000|96 102|therapy
P11233643A0000|21 23|use
P11233643A0000|142 148|ALA dose
P11233643A0000|43 46|acid
P11233643A0000|48 50|ALA
P11233643A0000|122 128|maximum
P11233643A0000|76 79|PPIX
P11233643A0000|59 72|protoporphyrin
P11234223A1451|172 175|MEPM
P11234223A1451|147 149|IPM
P11234223A1451|31 36|groups
P11234223A1451|194 200|killing
P11234223A1451|94 98|class
P11234223A1451|63 70|activity
P11234223A1451|153 156|PAPM
P11234223A1451|13 23|antibiotics
P11234223A1451|143 145|AMK
P11234223A1451|168 170|CAZ
P11234223A1451|101 111|antibiotics
P11234223A1451|130 136|killing
P11235335T0000|8 10|HIV
P11235777A0878|15 22|syndrome
P11235777A0878|89 113|dihydrotestosterone levels
P11235777A0878|81 85|range
P11235777A0878|67 69|end
P11235777A0878|24 28|47XXY
P11235777A0878|2 12|Klinefelter
P11235777A0878|31 53|serum testosterone levels
P11235817A0000|174 179|adults
P11235817A0000|91 96|relief
P11235817A0000|63 67|class
P11235817A0000|142 151|conditions
P11235817A0000|34 47|antihistamines
P11235817A0000|163 170|children
P11235817A0000|105 112|symptoms
P11235817A0000|3 32|histamine H1 receptor antagonists
P11235817A0000|70 80|medications
P11236056A0374|0 9|Conclusion
P11236056A0374|19 24|levels
P11236056A0374|32 39|children
P11236056A0374|14 15|Lp
P11237038A0889|44 62|pressure flow studies
P11237038A0889|96 99|HIFU
P11237038A0889|107 131|bladder outflow obstruction
P11237038A0889|9 16|patients
P11237038A0889|18 18|n
P11237038A0889|1 6|subset
P11237491A0000|0 3|AIMS
P11237491A0000|151 169|serum concentrations
P11237491A0000|218 231|concentrations
P11237491A0000|245 255|individuals
P11237491A0000|43 54|fluctuations
P11237491A0000|188 199|fluctuations
P11237491A0000|17 24|baseline
P11237491A0000|77 78|CA
P11237491A0000|118 123|cancer
P11237491A0000|91 98|patients
P11237491A0000|137 146|hypothesis
P11237491A0000|84 85|CA
P11237491A0000|60 75|tumour markers CEA
P11237598A0962|59 68|structures
P11237598A0962|24 32|framework
P11237598A0962|40 46|enzymes
P11237598A0962|114 122|mechanism
P11237598A0962|87 95|evolution
P11238105A0959|87 93|alpha-2
P11238105A0959|170 174|Jak-2
P11238105A0959|206 209|CD86
P11238105A0959|129 135|ability
P11238105A0959|52 57|term-3
P11238105A0959|181 190|substrates
P11238105A0959|145 167|tyrosine phosphorylation
P11238105A0959|100 105|domain
P11238105A0959|45 50|domain
P11238105A0959|0 4|Cells
P11238105A0959|15 27|alpha subunits
P11238375A0617|70 73|ERK6
P11238375A0617|75 82|p38 gamma
P11238375A0617|11 14|RhoA
P11238375A0617|58 67|activation
P11238375A0617|104 109|member
P11238375A0617|33 45|kinase cascade
P11238375A0617|115 123|p38 family
P11238375A0617|126 130|MAPKs
P11238402A0191|59 79|DAN/TIR gene expression
P11238402A0191|32 41|mechanisms
P11238405A0817|16 20|tup11
P11238405A0817|33 41|atf1-pcr1
P11238405A0817|177 186|activation
P11238405A0817|24 28|tup12
P11238405A0817|89 92|role
P11238405A0817|57 65|activator
P11238405A0817|148 151|atf1
P11238405A0817|95 113|fbp1-lacZ expression
P11238405A0817|123 145|spc1 MAPK phosphorylation
P11238405A0817|2 8|strains
P11238447A0524|161 165|nup98
P11238447A0524|36 41|eIF-5A
P11238447A0524|7 20|binding studies
P11238447A0524|77 83|Rev-NES
P11238447A0524|64 74|interaction
P11238447A0524|170 174|nup62
P11238447A0524|154 159|nup153
P11238447A0524|109 114|eIF-5A
P11238447A0524|88 101|CRM1/exportin1
P11238447A0524|131 152|nucleoporins CAN/nup214
P11238586A0000|30 34|class
P11238586A0000|182 184|MHC
P11238586A0000|221 232|interactions
P11238586A0000|41 65|histocompatibility complex
P11238586A0000|140 147|contacts
P11238586A0000|112 114|TCR
P11238586A0000|255 261|binding
P11238586A0000|155 160|alpha1
P11238586A0000|10 16|studies
P11238586A0000|117 127|alpha/betas
P11238586A0000|164 176|alpha2 helices
P11238586A0000|67 69|MHC
P11238586A0000|98 110|T cell receptor
P11238882A0157|62 65|gene
P11238882A0157|26 29|eIF6
P11238884A0892|0 3|Mice
P11238884A0892|20 30|dlg mutation
P11238884A0892|67 76|hypoplasia
P11238884A0892|38 54|growth retardation
P11238884A0892|57 61|utero
P11238884A0892|109 113|cleft
P11238884A0892|123 128|palate
P11238884A0892|82 91|premaxilla
P11238884A0892|95 102|mandible
P11238916A0838|176 183|paxillin
P11238916A0838|34 41|paxillin
P11238916A0838|113 129|macrophage lysates
P11238916A0838|10 16|complex
P11238916A0838|27 32|PTP phi
P11238916A0838|154 159|PTP phi
P11238916A0838|81 84|Pyk2
P11238916A0838|66 79|tyrosine kinase
P11238916A0838|187 190|Pyk2
P11238916A0838|146 151|domain
P11238947A0636|45 58|hnRNP A2 binding
P11238947A0636|74 79|A2RE-2
P11238947A0636|18 20|A8G
P11238947A0636|7 16|base change
P11238947A0636|89 100|RNA transport
P11238947A0636|30 37|sequence
P11238947A0636|68 71|case
P11239184A1340|0 16|Baseline variables
P11239184A1340|150 159|artery sign
P11239184A1340|112 116|edema
P11239184A1340|101 109|CT changes
P11239184A1340|68 74|aspirin
P11239184A1340|119 128|mass effect
P11239184A1340|54 56|use
P11239184A1340|85 93|incidence
P11239184A1340|31 32|CD
P11239529A0981|0 7|IL-1beta
P11239529A0981|64 76|localizations
P11239529A0981|50 56|lesions
P11239529A0981|32 43|endometrioma
P11240600A0523|54 61|duration
P11240600A0523|9 19|drug history
P11240600A0523|64 76|VGB medication
P11240600A0523|45 50|amount
P11241166A0677|143 152|regulators
P11241166A0677|227 234|sequence
P11241166A0677|210 217|cytokine
P11241166A0677|107 110|Ob-R
P11241166A0677|122 129|increase
P11241166A0677|176 186|suppressors
P11241166A0677|112 115|mRNA
P11241166A0677|16 29|gene expression
P11241166A0677|155 168|STAT signalling
P11241166A0677|189 206|cytokine signalling
P11241166A0677|46 56|FA treatment
P11241166A0677|71 78|decrease
P11241166A0677|236 238|CIS
P11241166A0677|6 13|analysis
P11241166A0677|92 105|leptin receptor
P11241166A0677|84 89|amount
P11241166A0677|170 174|SOCS3
P11241215A0566|130 140|performance
P11241215A0566|121 125|phase
P11241215A0566|69 79|thioredoxin
P11241215A0566|9 17|receptors
P11241215A0566|51 64|fusion proteins
P11241215A0566|175 183|digestion
P11241215A0566|162 168|RP-HPLC
P11241215A0566|147 160|chromatography
P11241215A0566|188 199|enterokinase
P11241215A0566|27 34|sBMPR-IA
P11241243A0693|102 110|component
P11241243A0693|56 69|quantification
P11241243A0693|112 115|% PSC
P11241243A0693|33 40|analysis
P11241243A0693|3 9|authors
P11241243A0693|120 132|p53 expression
P11241243A0693|75 84|percentage
P11241243A0693|43 51|pathology
P11241332A0393|172 176|foams
P11241332A0393|124 129|anchor
P11241332A0393|75 84|variations
P11241332A0393|53 69|fixation strengths
P11241332A0393|7 13|purpose
P11241332A0393|192 195|bone
P11241332A0393|134 144|screw anchor
P11241332A0393|210 218|densities
P11241332A0393|99 115|bone anchor designs
P11241356T0000|125 137|stellate cells
P11241356T0000|37 48|localization
P11241356T0000|12 26|phosphorylation
P11241356T0000|51 55|Smad3
P11241356T0000|82 106|collagen gene transcription
P11241672T0000|44 63|integrin gene promoter
P11241672T0000|10 25|characterization
P11241672T0000|106 112|element
P11241672T0000|65 78|identification
P11241672T0000|31 40|murine beta
P11241672T0000|128 133|STAT-6
P11241672T0000|116 125|regulation
P11241672T0000|83 95|interleukin-4
P11241672T0000|0 6|Cloning
P11243306A0961|0 10|CONCLUSIONS
P11243306A0961|23 28|levels
P11243306A0961|129 136|presence
P11243306A0961|31 45|oxLDL antibodies
P11243306A0961|174 179|levels
P11243306A0961|139 150|hypertension
P11243306A0961|68 79|hypertension
P11243306A0961|101 113|artery disease
P11243336A0000|31 34|film
P11243336A0000|11 17|MD-55-2
P11243336A0000|110 131|brachytherapy dosimetry
P11243336A0000|73 84|applications
P11243494A0833|0 6|RESULTS
P11243494A0833|64 66|CRF
P11243494A0833|69 73|rates
P11243494A0833|53 58|heroin
P11243494A0833|23 28|groups
P11243494A0833|15 18|days
P11243494A0833|98 108|performance
P11243777A0000|10 22|CCAAT elements
P11243777A0000|53 67|promoter regions
P11243980A0510|31 45|PET examinations
P11243980A0510|11 18|patients
P11243980A0510|55 71|staging procedures
P11244568A0506|99 104|larvae
P11244568A0506|80 85|amount
P11244568A0506|23 26|gene
P11244568A0506|62 72|development
P11244568A0506|48 51|mRNA
P11244568A0506|3 8|Gap69C
P11244733A0782|0 4|Cases
P11244733A0782|35 44|metastasis
P11244733A0782|7 16|lung cancer
P11244733A0782|83 87|death
P11245986T0000|50 73|rat aldolase B gene promoter
P11245986T0000|27 33|protein
P11246679A0000|0 8|OBJECTIVE
P11246679A0000|73 76|CCHB
P11246679A0000|96 102|disease
P11246679A0000|26 36|association
P11246679A0000|83 87|fetus
P11246679A0000|62 71|heart block
P11246887A0000|88 91|CETP
P11246887A0000|138 145|activity
P11246887A0000|214 221|subjects
P11246887A0000|20 23|role
P11246887A0000|285 287|CAC
P11246887A0000|180 198|artery calcification
P11246887A0000|261 264|loss
P11246887A0000|51 53|CET
P11246887A0000|200 202|CAC
P11246887A0000|93 100|activity
P11246887A0000|270 282|sex difference
P11246887A0000|117 131|transfer protein
P11246887A0000|133 136|PLTP
P11246887A0000|160 169|prevalence
P11246887A0000|4 8|study
P11246887A0000|56 86|cholesteryl ester transfer protein
P11246887A0000|245 252|subjects
P11246887A0000|290 297|diabetes
P11246887A0000|26 49|cholesteryl ester transfer
P11247663A1447|60 70|individuals
P11247663A1447|38 49|DNAH9 alleles
P11247663A1447|25 35|inheritance
P11247663A1447|3 10|families
P11248463A0187|3 13|blood levels
P11248463A0187|24 31|pyruvate
P11248463A0187|35 44|amino acids
P11248463A0187|16 22|lactate
P11248626T0000|0 7|Efficacy
P11248626T0000|53 60|function
P11248626T0000|91 103|prostatectomy
P11248626T0000|72 77|nerves
P11248626T0000|125 134|evaluation
P11248626T0000|26 33|Cavermap
P11248626T0000|42 49|location
P11248626T0000|148 155|surgeons
P11250196A0455|14 23|domain fold
P11250196A0455|142 150|Protein S.
P11250196A0455|39 57|calcium binding sites
P11250196A0455|105 140|betagamma-crystallin fold family member
P11250196A0455|33 36|pair
P11250942A0626|86 89|AF-2
P11250942A0626|36 40|GRIP1
P11250942A0626|109 119|interaction
P11250942A0626|10 17|analyses
P11250942A0626|91 96|domain
P11250942A0626|20 22|VDR
P11250942A0626|44 47|RAC3
P11250942A0626|64 84|VDR activation function
P11250942A0626|149 155|regions
P11250942A0626|161 163|VDR
P11251083T0000|0 8|Mechanism
P11251083T0000|33 46|cell morphology
P11251083T0000|50 60|S phase entry
P11251083T0000|24 30|control
P11251083T0000|72 83|growth factor
P11251083T0000|100 117|MEK/ERK activations
P11251104A0526|99 101|GA.
P11251104A0526|52 75|transcription factor GAMyb
P11251104A0526|3 12|expression
P11251104A0526|15 27|alpha-amylase
P11251252A0494|0 17|3D image-processing
P11251252A0494|110 116|3D views
P11251252A0494|127 130|mode
P11251252A0494|78 83|planes
P11251252A0494|85 95|section mode
P11251252A0494|34 47|ultrasound data
P11251276A0793|27 33|surgery
P11251276A0793|8 15|patients
P11251697T0000|86 106|electron spin resonance
P11251697T0000|71 83|determination
P11251697T0000|65 69|drugs
P11251697T0000|115 128|spin trap method
P11251697T0000|6 33|superoxide scavenging activity
P11251951A0000|89 99|skin lesions
P11251951A0000|35 43|technique
P11251951A0000|172 175|CMIS
P11251951A0000|11 20|Dermoscopy
P11251951A0000|157 164|melanoma
P11251951A0000|136 143|patients
P11251951A0000|70 77|accuracy
P11251951A0000|125 133|diagnosis
P11251951A0000|193 200|melanoma
P11251951A0000|0 9|BACKGROUND
P11254134A0648|73 80|sequence
P11254134A0648|52 54|PTF
P11254134A0648|9 12|PTax
P11254134A0648|105 110|region
P11254134A0648|123 138|background levels
P11254134A0648|28 47|background activities
P11254504A0766|122 125|MyoD
P11254504A0766|77 79|Sp1
P11254504A0766|194 201|homeobox
P11254504A0766|103 120|activator protein-2
P11254504A0766|139 151|factor-kappaB
P11254504A0766|127 130|p300
P11254504A0766|216 239|Cdx protein-2 binding sites
P11254504A0766|160 178|zinc finger protein-1
P11254504A0766|86 101|growth response-1
P11254504A0766|203 205|Cdx
P11254504A0766|11 24|promoter region
P11254504A0766|207 211|gene A
P11254504A0766|63 70|elements
P11254713A1029|31 40|components
P11254713A1029|8 18|interaction
P11254713A1029|111 121|alterations
P11254713A1029|128 134|complex
P11254713A1029|180 200|IL-2 gene transcription
P11254713A1029|170 177|decrease
P11254713A1029|137 146|activation
P11254713A1029|47 53|rel/AP1
P11254713A1029|65 71|complex
P11254713A1029|21 23|Tat
P11254864T0000|33 44|breast cancer
P11254864T0000|22 30|treatment
P11255035A0331|31 35|brain
P11255035A0331|37 55|SVZa progenitor cells
P11255035A0331|63 70|capacity
P11255035A0331|11 25|progenitor cells
P11255035A0331|109 117|phenotype
P11255252A0961|8 18|ER3 sequence
P11255252A0961|99 111|yeast extracts
P11255252A0961|59 64|FXR HRE
P11255252A0961|21 23|DNA
P11255423A0211|0 8|OBJECTIVE
P11255423A0211|24 34|association
P11255423A0211|91 103|CD4 lymphocyte
P11255423A0211|124 126|HIV
P11255423A0211|82 88|decline
P11255423A0211|115 119|women
P11255423A0211|47 54|symptoms
P11255423A0211|70 78|mortality
P11256845A0340|29 59|Scotland Coronary Prevention Study
P11256845A0340|23 26|West
P11256845A0340|126 131|events
P11256845A0340|177 183|WOSCOPS
P11256845A0340|90 104|statin treatment
P11256845A0340|141 148|patients
P11256845A0340|223 227|event
P11256845A0340|69 76|findings
P11256845A0340|272 277|pounds
P11256845A0340|152 161|population
P11256845A0340|195 195|%
P11256845A0340|10 17|analysis
P11256845A0340|242 245|cost
P11256845A0340|61 67|WOSCOPS
P11256845A0340|202 205|risk
P11256944A1144|29 32|ATF6
P11256944A1144|104 126|ER stress response element
P11256944A1144|77 88|point mutants
P11256944A1144|39 52|G13 gene product
P11256944A1144|22 26|forms
P11256944A1144|153 160|ER stress
P11256962A0233|215 221|portion
P11256962A0233|169 172|exon
P11256962A0233|125 145|GlyR alpha subunit genes
P11256962A0233|227 238|GlyR beta mRNA
P11256962A0233|103 109|regions
P11256962A0233|69 83|beta subunit gene
P11256962A0233|35 45|differences
P11256962A0233|58 63|region
P11256962A0233|0 15|Sequence analysis
P11256962A0233|174 177|exon
P11257870A0000|237 239|HRT
P11257870A0000|51 56|hybrid
P11257870A0000|129 131|ASP
P11257870A0000|115 127|sludge process
P11257870A0000|223 235|retention time
P11257870A0000|100 101|TF
P11257870A0000|192 202|temperature
P11257870A0000|67 73|reactor
P11257870A0000|161 177|trichloroethylene
P11257870A0000|10 14|study
P11257870A0000|39 47|potential
P11257870A0000|141 150|wastewater
P11257870A0000|93 98|filter
P11257870A0000|179 181|TCE
P11258906A0743|61 64|Rec2
P11258906A0743|106 109|RecA
P11258906A0743|75 85|pairing bias
P11258906A0743|33 48|oligonucleotides
P11258906A0743|2 27|DNA strand exchange reactions
P11259347A0000|43 52|literature
P11259347A0000|106 112|ability
P11259347A0000|9 20|observations
P11259347A0000|128 136|chemicals
P11259347A0000|70 74|clues
P11259347A0000|99 104|humans
P11259347A0000|87 96|variations
P11259503A0212|44 48|cells
P11259503A0212|56 56|h
P11259503A0212|21 26|microM
P11259503A0212|73 82|luciferase
P11259503A0212|0 17|Forskolin treatment
P11259593A1094|0 7|Analysis
P11259593A1094|53 66|cell separation
P11259593A1094|10 23|ace2Delta cells
P11259593A1094|35 39|Ace2p
P11259593A1094|85 90|growth
P11260468A1179|131 141|protein H-NS
P11260468A1179|31 33|AR1
P11260468A1179|107 113|absence
P11260468A1179|80 97|papBA transcription
P11260468A1179|56 65|CAP subunit
P11260468A1179|3 9|results
P11260662X0000|0 1|A.
P11260662X0000|11 12|D.
P11260662X0000|3 9|Slatkin
P11263622A0683|116 116|r
P11263622A0683|74 87|vessel wall area
P11263622A0683|125 125|r
P11263622A0683|101 114|histopathology
P11263622A0683|95 97|MRI
P11263622A0683|32 32|p
P11263622A0683|20 30|correlation
P11263622A0683|58 70|wall thickness
P11263622A0683|0 6|RESULTS
P11263664A1085|42 59|XBra gene expression
P11263664A1085|65 72|mesoderm
P11263664A1085|19 22|SIP1
P11263664A1085|3 6|data
P11263664T0000|0 3|SIP1
P11263664T0000|5 26|Smad interacting protein
P11263664T0000|116 125|repressors
P11263664T0000|57 77|enhancer binding factor
P11263664T0000|32 39|deltaEF1
P11264176A0181|0 4|B-myb
P11264176A0181|19 32|G1/S transition
P11264176A0181|71 90|cyclin A2/cdk2 complex
P11264177T0000|0 17|Nucleotide sequence
P11264177T0000|91 96|B-cell
P11264177T0000|19 34|transcription map
P11264177T0000|115 122|leukemia
P11264177T0000|39 54|mutation analysis
P11264177T0000|76 81|region
P11264177T0000|60 64|13q14
P11264182A0000|175 188|T-cell leukemia
P11264182A0000|37 39|Tax
P11264182A0000|64 72|regulator
P11264182A0000|113 117|genes
P11264182A0000|154 167|leukemogenesis
P11264182A0000|5 27|T-cell leukemia virus type
P11264182A0000|30 35|HTLV-I
P11264372T0000|75 92|herpes simplex virus
P11264372T0000|37 49|translocation
P11264372T0000|52 71|infected-cell protein
P11264372T0000|0 11|Requirements
P11264375A0000|49 58|protein IE2
P11264375A0000|24 27|HCMV
P11264375A0000|8 22|cytomegalovirus
P11264375A0000|105 113|regulator
P11264375A0000|134 143|infections
P11264375A0000|69 82|phosphoprotein
P11264561A0167|74 82|occlusion
P11264561A0167|48 54|anatomy
P11264561A0167|28 31|RSTD
P11264561A0167|0 8|OBJECTIVE
P11265853A0000|44 54|Novacor Corp
P11265853A0000|38 41|LVAS
P11265853A0000|56 62|Oakland
P11265853A0000|25 36|Assist System
P11265853A0000|64 65|CA
P11265853A0000|3 9|Novacor
P11265853A0000|131 143|configuration
P11266184A0000|0 7|Atheroma
P11266184A0000|162 163|SE
P11266184A0000|96 97|MR
P11266184A0000|112 121|components
P11266184A0000|152 160|spin-echo
P11266184A0000|165 170|images
P11266184A0000|25 43|signal intensity area
P11266184A0000|133 149|signal intensities
P11266184A0000|74 76|TOF
P11266184A0000|99 104|images
P11266184A0000|59 72|time-of-flight
P11266184A0000|86 94|resonance
P11266194A0743|0 3|Body
P11266194A0743|7 18|distribution
P11266194A0743|51 60|tomography
P11266227A0295|14 24|p-toluidine
P11266227A0295|39 45|pH value
P11266227A0295|51 63|donor solution
P11266227A0295|3 11|flux rates
P11266540A0328|32 51|Groucho family members
P11266540A0328|103 122|Tcf/Lef family members
P11266540A0328|60 66|ability
P11266558A1470|127 149|recruiting RNA polymerase
P11266558A1470|88 103|initiator element
P11266558A1470|24 43|transcription extract
P11266558A1470|157 173|SL RNA gene promoter
P11266558A1470|53 67|binding activity
P11266615A0258|3 9|protein
P11266615A0258|60 71|linker region
P11266615A0258|76 92|amino acid residues
P11266615A0258|30 36|domains
P11267679A0102|100 106|protein
P11267679A0102|75 86|reading frame
P11267679A0102|112 121|amino acids
P11267679A0102|6 20|bp EcoRI fragment
P11267679A0102|40 60|Southern hybridization
P11268459A0167|98 105|response
P11268459A0167|149 160|tissue tumors
P11268459A0167|193 201|prognosis
P11268459A0167|38 49|relationship
P11268459A0167|178 189|chemotherapy
P11268459A0167|113 120|decrease
P11268459A0167|107 110|rate
P11268459A0167|78 80|%DB
P11268459A0167|123 133|tumor volume
P11268459A0167|21 25|study
P11268459A0167|60 76|DOX binding ability
P11268887A1174|100 102|FVC
P11268887A1174|7 24|misinterpretations
P11268887A1174|106 109|FEV1
P11268887A1174|92 97|regard
P11268887A1174|66 79|preadolescents
P11268887A1174|33 47|reference values
P11271297T0000|0 13|Nephrotoxicity
P11271297T0000|79 86|patients
P11271297T0000|66 67|FK
P11271297T0000|51 62|cyclosporin A
P11271297T0000|29 48|liver transplantation
P11273995A1148|122 135|relaxation time
P11273995A1148|92 101|velocities
P11273995A1148|25 32|subjects
P11273995A1148|39 49|TOF patients
P11274109A0129|0 6|Acetoin
P11274109A0129|61 73|carbon sources
P11274109A0129|23 30|bacteria
P11274109A0129|47 51|phase
P11274149A0625|86 90|basis
P11274149A0625|61 68|proteins
P11274149A0625|44 53|RING finger
P11274149A0625|10 17|analysis
P11274149A0625|112 120|E2 enzymes
P11274149A0625|31 35|U-box
P11274149A0625|97 107|interaction
P11274179A0610|67 76|activation
P11274179A0610|90 99|disruption
P11274179A0610|53 57|Raf-1
P11274179A0610|37 42|module
P11274179A0610|8 14|studies
P11274179A0610|21 33|Rac/Cdc42/Pak
P11274184A0000|0 3|Nrf2
P11274184A0000|65 79|heme oxygenase-1
P11274184A0000|13 22|expression
P11274184A0000|49 59|antioxidant
P11274184A0000|25 29|genes
P11274184A0000|38 44|enzymes
P11274184A0000|81 84|HO-1
P11274184A0000|99 112|detoxification
P11274184A1068|60 69|expression
P11274184A1068|5 11|results
P11274184A1068|24 27|ATF4
P11274184A1068|99 104|manner
P11274184A1068|119 125|complex
P11274184A1068|45 48|CdCl
P11274184A1068|75 82|ho-1 gene
P11274184A1068|130 133|Nrf2
P11274357A0724|170 204|nucleoside diphosphate kinase activity
P11274357A0724|255 258|form
P11274357A0724|76 81|mutant
P11274357A0724|44 47|type
P11274357A0724|133 136|RhoA
P11274357A0724|209 214|nm23H1
P11274357A0724|21 34|overexpression
P11274357A0724|124 128|Cdc42
P11274357A0724|153 157|forms
P11274357A0724|266 272|GTPases
P11274357A0724|10 13|hand
P11274357A0724|112 116|forms
P11274357A0724|119 122|Rac1
P11274357A0724|84 89|nm23H1
P11274368A0469|41 56|protein synthesis
P11274368A0469|76 101|histone deacetylase activity
P11274368A0469|4 9|effect
P11274368A0469|26 32|absence
P11274368A0818|0 7|Deletion
P11274368A0818|22 37|initiator element
P11274368A0818|51 60|repression
P11274368A0818|79 83|c-Myc
P11274368A0818|66 76|p21 promoter
P11274563T0000|16 25|estimation
P11274563T0000|45 51|results
P11274563T0000|5 14|lung volume
P11274563T0000|28 29|MR
P11275986A0091|41 65|p53 tumor suppressor protein
P11275986A0091|5 16|gene products
P11275986A0091|18 19|E6
P11275986A0091|98 108|degradation
P11276426A0501|57 73|% sequence identity
P11276426A0501|8 12|Mmip1
P11276426A0501|50 54|share
P11276426A0501|2 6|mouse
P11276426A0501|80 87|products
P11276426A0501|34 40|protein
P11276426A0501|97 100|gene
P11276426A0501|14 22|Mad member
P11277913T0000|83 97|mRNA translation
P11277913T0000|45 53|Hsp70 mRNA
P11277913T0000|73 80|enhancer
P11277913T0000|32 37|region
P11277913T0000|2 8|element
P11278286A0456|118 127|regulation
P11278286A0456|133 141|rat 5-HT1A
P11278286A0456|258 265|promoter
P11278286A0456|233 242|inhibition
P11278286A0456|66 77|inactivation
P11278286A0456|193 201|inclusion
P11278286A0456|40 54|5-HT1A receptors
P11278286A0456|156 164|promoters
P11278286A0456|15 19|cells
P11278286A0456|96 98|GRE
P11278286A0456|56 63|deletion
P11278286A0456|167 181|corticosteroids
P11278286A0456|34 35|GR
P11278286A0456|31 32|MR
P11278286A0456|83 86|nGRE
P11278286A1083|90 91|GR
P11278286A1083|68 78|combination
P11278286A1083|38 47|inhibition
P11278286A1083|61 65|MR/GR
P11278286A1083|86 87|MR
P11278290A1220|69 78|activation
P11278290A1220|105 109|cells
P11278290A1220|38 45|TGF-beta
P11278290A1220|81 93|Agc expression
P11278290A1220|168 180|Agc expression
P11278290A1220|111 125|Smad2 activation
P11278290A1220|7 11|Smad2
P11278290A1220|161 165|level
P11278310A1516|63 82|caspase-3 stimulation
P11278310A1516|109 118|cell number
P11278310A1516|99 106|decrease
P11278310A1516|32 37|mutant
P11278390A0632|118 123|levels
P11278390A0632|60 69|PKRDeltaE7
P11278390A0632|7 49|transcriptase-polymerase chain reaction assays
P11278390A0632|101 107|tissues
P11278390A0632|89 93|range
P11278400A0668|67 76|OCT binding
P11278400A0668|63 65|POU
P11278400A0668|78 96|homeodomain proteins
P11278400A0668|27 35|cell lines
P11278400A0668|55 60|number
P11278400A0668|122 139|mobility shift assay
P11278440A0095|0 2|SV1
P11278440A0095|67 68|S1
P11278440A0095|76 89|hydrophobicity
P11278440A0095|102 112|S0-S1 linker
P11278440A0095|30 50|S1 transmembrane domain
P11278440A0095|15 24|acid insert
P11278461A0637|45 54|amino acids
P11278461A0637|103 131|rainbow trout HIF-1alpha protein
P11278461A0637|78 81|part
P11278461A0637|40 43|part
P11278461A0637|10 19|antibodies
P11278461A0637|157 186|chinook salmon HIF-1alpha protein
P11278461A0637|142 153|rainbow trout
P11278461A0637|189 207|Western blot analysis
P11278461A0637|83 92|amino acids
P11278488T0000|73 86|adhesion kinase
P11278488T0000|53 63|association
P11278488T0000|3 16|v-Src SH3 domain
P11278488T0000|29 32|cell
P11278521A0849|146 153|promoter
P11278521A0849|157 177|lacZ reporter construct
P11278521A0849|41 47|nonamer
P11278521A0849|8 26|pair oligonucleotide
P11278521A0849|108 112|acids
P11278521A0849|55 67|up-regulation
P11278521A0849|80 89|inhibition
P11278521A0849|70 76|hypoxia
P11278563A0917|0 15|Deletion analyses
P11278563A0917|61 74|ankyrin repeats
P11278563A0917|53 57|Grb14
P11278563A0917|41 50|amino acids
P11278563A0917|107 117|interaction
P11278563A0917|82 90|tankyrase
P11278583A0873|0 10|Mutagenesis
P11278583A0873|48 61|effector motifs
P11278583A0873|228 238|recruitment
P11278583A0873|18 20|IRS
P11278583A0873|22 23|CX
P11278583A0873|186 189|Grb2
P11278583A0873|68 70|SNT
P11278583A0873|173 183|recruitment
P11278583A0873|298 300|Sos
P11278583A0873|196 216|phosphotyrosine motifs
P11278583A0873|39 45|classes
P11278583A0873|13 16|SNT1
P11278583A0873|241 244|Shp2
P11278583A0873|95 107|ERK activation
P11278583A0873|141 161|phosphotyrosine motifs
P11278583A0873|119 133|differentiation
P11278583A0873|262 266|motif
P11278594A0618|131 137|chimera
P11278594A0618|184 198|MIC-1 propeptide
P11278594A0618|34 40|chimera
P11278594A0618|208 214|peptide
P11278594A0618|18 27|propeptide
P11278594A0618|67 85|TGF-beta1 propeptide
P11278594A0618|96 104|secretion
P11278594A0618|60 64|MIC-1
P11278594A0618|158 168|interaction
P11278604A0300|121 128|CHO cells
P11278604A0300|169 175|ability
P11278604A0300|133 149|Lec20 cell extracts
P11278604A0300|186 188|Gal
P11278604A0300|51 56|5Lec20
P11278604A0300|209 217|acceptors
P11278604A0300|23 31|N-glycans
P11278604A0300|102 108|species
P11278610A0902|14 20|SOCS box
P11278610A0902|35 42|Cullin-2
P11278610A0902|70 77|TEL-JAK2
P11278610A0902|54 67|ubiquitination
P11278671T0000|15 27|Bcl-2 homology
P11278671T0000|76 82|neurons
P11278671T0000|40 52|splice variant
P11278671T0000|55 57|Bak
P11278671T0000|114 118|cells
P11278713A1054|58 61|site
P11278713A1054|76 94|instability elements
P11278713A1054|143 165|coding region determinant
P11278713A1054|38 41|exon
P11278713A1054|21 26|region
P11278713A1054|110 120|transcripts
P11278819A0565|0 17|Sequence comparison
P11278819A0565|21 34|binding studies
P11278819A0565|124 135|half sequence
P11278819A0565|57 61|sites
P11278819A0565|164 174|MOK2 binding
P11278819A0565|150 160|core element
P11278819A0565|71 76|intron
P11278819A0565|96 109|mouse IRBP genes
P11278848A1316|85 89|cells
P11278848A1316|40 49|activation
P11278848A1316|126 145|Sp1 consensus sequence
P11278848A1316|106 112|plasmid
P11278848A1316|12 19|SB203580
P11278848A1316|67 82|promoter activity
P11278848A1316|52 54|Sp1
P11278855A0205|14 24|interaction
P11278855A0205|38 40|p65
P11278855A0205|114 124|Western blot
P11278855A0205|138 141|cell
P11278855A0205|73 103|coimmunoprecipitation experiment
P11278855A0205|32 34|TLS
P11278855A0205|55 59|assay
P11278870A0123|0 7|Analysis
P11278870A0123|157 163|element
P11278870A0123|75 86|fission yeast
P11278870A0123|52 72|copper transporter gene
P11278870A0123|193 215|transcription factor Cuf1
P11278870A0123|165 168|CuSE
P11278870A0123|45 48|ctr4
P11278870A0123|20 26|regions
P11278870A0123|32 39|promoter
P11278870A0123|121 128|identity
P11278928A1634|115 134|C/EBPepsilon isoforms
P11278928A1634|136 138|p32
P11278928A1634|76 88|mRNA structure
P11278928A1634|68 73|effect
P11278928A1634|17 20|data
P11278928A1634|91 101|translation
P11278928A1634|32 44|mRNA structure
P11278928A1634|142 144|p30
P11279038A0194|0 10|WRN helicase
P11279038A0194|76 92|Holliday junctions
P11279038A0194|69 71|DNA
P11279038A0194|28 40|DNA structures
P11279086A1350|118 125|activity
P11279086A1350|160 169|regulation
P11279086A1350|36 40|roles
P11279086A1350|20 28|ADAM-TS12
P11279086A1350|52 56|cells
P11279086A1350|83 96|tumor processes
P11279086A1350|172 183|cell adhesion
P11279086A1350|5 8|data
P11279086A1350|68 78|development
P11279086A1350|131 138|molecule
P11279108T0000|0 6|Binding
P11279108T0000|9 27|serum response factor
P11279108T0000|113 123|muscle cells
P11279108T0000|30 45|CArG box sequences
P11279108T0000|83 96|gene expression
P11279207A0904|14 20|results
P11279207A0904|50 61|TCR signaling
P11279207A0904|39 47|component
P11279207A0904|29 32|HPK1
P11279217A0273|0 3|Biol
P11279324A0710|12 18|infarct
P11279324A0710|62 67|method
P11279324A0710|3 6|size
P11279324A0710|40 53|creatine kinase
P11279385A3917|189 194|method
P11279385A3917|21 29|technique
P11279385A3917|114 120|ability
P11279385A3917|143 150|pathways
P11279385A3917|161 170|conduction
P11279385A3917|58 62|M mode
P11279385A3917|75 76|2D
P11279385A3917|88 94|Doppler
P11279720A0844|0 16|SELECTION CRITERIA
P11279720A0844|114 122|Parkinson
P11279720A0844|159 173|levodopa therapy
P11279720A0844|93 101|diagnosis
P11279720A0844|144 156|complications
P11279720A0844|72 79|patients
P11279720A0844|46 56|cabergoline
P11279720A0844|38 43|trials
P11279720A0844|125 131|disease
P11279720A0844|63 69|placebo
P11280495A1330|0 10|CONCLUSIONS
P11280495A1330|93 106|Amadori albumin
P11280495A1330|55 62|PD fluids
P11280495A1330|82 90|formation
P11280495A1330|110 113|AGEs
P11280799A1025|149 152|IL-8
P11280799A1025|36 43|peptides
P11280799A1025|111 120|antibodies
P11280799A1025|137 146|production
P11280799A1025|69 82|IL-8 production
P11280799A1025|20 28|PTHrP1-34
P11280799A1025|166 170|PTHrP
P11280799A1025|2 9|contrast
P11281201T0000|13 19|effects
P11281268A0000|133 164|sea anemone Anthopleurura japonicus
P11281268A0000|114 116|AKs
P11281268A0000|65 69|times
P11281268A0000|175 204|clam Pseudocardium sachalinensis
P11281268A0000|33 35|AKs
P11281268A0000|96 112|phosphagen kinases
P11281268A0000|85 93|evolution
P11281268A0000|17 31|arginine kinases
P11282029A0075|42 62|beta-receptor promoter
P11282029A0075|106 109|role
P11282029A0075|115 127|transcription
P11282029A0075|72 81|CCAAT motif
P11282029A0075|37 40|PDGF
P11282029A0075|24 35|growth factor
P11282029A0075|86 89|NF-Y
P11282029A0075|3 7|mouse
P11282088A0837|0 10|Baseline MBF
P11282088A0837|37 37|P
P11282088A0837|57 61|males
P11282088A0837|13 19|females
P11282394A0841|59 77|antigen reactivities
P11282394A0841|109 126|cross-reactivities
P11282394A0841|86 89|mAbs
P11282394A0841|14 25|VH/VL-chains
P11282395A0530|83 90|activity
P11282395A0530|31 44|RAG1/2 proteins
P11282395A0530|111 124|protein complex
P11282395A0530|130 162|DNA repair proteins Nbs1/Mre11/Rad50
P11282395A0530|54 64|DNA hairpins
P11282395A1073|86 104|kappaL chain gene loci
P11282395A1073|167 177|individuals
P11282395A1073|125 140|blood lymphocytes
P11282395A1073|145 154|NBS patient
P11282395A1073|49 61|CDR3 sequences
P11282395A1073|36 46|differences
P11282395A1073|2 9|addition
P11282395A1073|74 82|Ig lambdaL
P11282433T0000|42 49|patients
P11282433T0000|31 39|etoposide
P11282433T0000|7 11|study
P11282433T0000|90 103|cell lung cancer
P11282433T0000|14 23|paclitaxel
P11282433T0000|0 4|Phase
P11282761A0531|4 18|supplementation
P11282761A0531|99 110|NO production
P11282761A0531|21 30|L-arginine
P11282761A0531|53 70|plasma L-citrulline
P11282761A0531|86 96|enhancement
P11283010A0701|4 13|activation
P11283010A0701|30 38|CGS 12066A
P11283014A0921|101 104|role
P11283014A0921|34 46|transcription
P11283014A0921|3 9|results
P11283014A0921|122 140|actin polymerization
P11283014A0921|21 24|WASP
P11283014A0921|56 69|TCR stimulation
P11283014A0921|73 78|manner
P11283168A0738|55 64|expression
P11283168A0738|143 143|d
P11283168A0738|109 123|mid-development
P11283168A0738|94 102|endosperm
P11283168A0738|24 28|lines
P11283168A0738|70 76|Gus gene
P11283168A0738|149 156|anthesis
P11283256A0258|60 68|complexes
P11283256A0258|27 30|MRCK
P11283354A0548|5 8|data
P11283354A0548|130 152|heterochromatin assembly
P11283354A0548|117 127|inheritance
P11283354A0548|25 31|pathway
P11283354A0548|49 68|histone modifications
P11283354A0548|80 90|histone code
P11285054A0781|0 17|Regression analyses
P11285054A0781|79 84|amount
P11285054A0781|87 94|REM sleep
P11285054A0781|135 142|arousals
P11285054A0781|147 155|NREM sleep
P11285054A0781|28 49|SOREMP dream occurrences
P11285054A0781|101 121|NREMP dream occurrences
P11285235A0466|85 95|GATA factors
P11285235A0466|8 12|TRPS1
P11285235A0466|60 69|activation
P11285329A0682|33 37|women
P11285329A0682|39 39|P
P11285329A0682|6 8|% CI
P11285329A0682|18 27|micromol/L
P11286833A0959|147 151|range
P11286833A0959|56 65|leucovorin
P11286833A0959|5 12|patients
P11286833A0959|68 90|maintenance chemotherapy
P11286833A0959|116 122|females
P11286833A0959|141 145|years
P11286833A0959|39 52|5-fluorouracil
P11286833A0959|31 36|cycles
P11286833A0959|158 162|years
P11286833A0959|134 136|age
P11286833A0959|92 98|RESULTS
P11286833A0959|106 110|males
P11287555A1057|88 94|CEMx174
P11287555A1057|98 105|MT4 cells
P11287555A1057|71 84|infectiousness
P11287555A1057|3 16|Delta6CCI virus
P11287555A1057|41 59|replication capacity
P11287578A1311|0 8|Secretion
P11287578A1311|11 23|interleukin-8
P11287578A1311|54 66|protein 1alpha
P11287578A1311|32 41|macrophage
P11287578A1311|100 106|protein
P11287578A1311|25 30|RANTES
P11287578A1311|137 149|keratinocytes
P11287578A1311|152 153|E6
P11287579A1084|14 18|T255A
P11287579A1084|68 86|late-gene expression
P11287579A1084|7 12|mutant
P11287579A1084|40 45|E4orf6
P11287579A1084|27 33|ability
P11287611A0802|124 133|expression
P11287611A0802|79 86|BRL49653
P11287611A0802|53 55|PGD
P11287611A0802|6 14|PPARgamma
P11287611A0802|40 46|15d-PGJ
P11287611A0802|90 101|troglitazone
P11287611A0802|71 77|ligands
P11287611A0802|139 150|cyclin D1 gene
P11287623A0286|167 173|variety
P11287623A0286|81 83|ERK
P11287623A0286|85 100|signaling pathway
P11287623A0286|148 163|integrin subunits
P11287623A0286|184 197|mouse cell lines
P11287623A0286|74 79|kinase
P11287623A0286|126 135|expression
P11287654A0150|72 80|C terminus
P11287654A0150|51 57|domains
P11287654A0150|14 20|protein
P11287654A0150|0 3|PABP
P11288208A0712|0 7|Children
P11288208A0712|53 55|PCP
P11288208A0712|112 117|months
P11288208A0712|68 72|rates
P11288208A0712|36 50|tract infections
P11288208A0712|75 81|decline
P11288208A0712|120 123|life
P11288208A0712|84 96|CD4 cell counts
P11288930A0000|15 21|effects
P11288930A0000|152 157|mating
P11288930A0000|85 88|rats
P11288930A0000|112 122|generations
P11288930A0000|173 181|lactation
P11288930A0000|161 169|gestation
P11288930A0000|135 140|mating
P11288930A0000|73 76|acid
P11288930A0000|27 40|administration
P11288930A0000|78 81|MCPA
P11289135A0975|87 99|protein kinase
P11289135A0975|288 296|apoptosis
P11289135A0975|198 204|pathway
P11289135A0975|182 191|disruption
P11289135A0975|274 285|potentiation
P11289135A0975|12 13|FP
P11289135A0975|247 260|inhibitor U0126
P11289135A0975|136 155|protein kinase cascade
P11289135A0975|227 245|protein kinase kinase
P11289135A0975|55 64|activation
P11289135A0975|161 172|PMA treatment
P11289135A0975|0 9|Coexposure
P11289149A0658|121 123|CBP
P11289149A0658|67 87|transactivation domain
P11289149A0658|8 17|EWS protein
P11289149A0658|93 100|cofactor
P11289149A0658|113 119|protein
P11289149A0658|28 40|transcription
P11290415A0288|58 66|screening
P11290415A0288|100 110|PCR analysis
P11290415A0288|37 55|ICBP90 gene structure
P11290415A0288|12 16|study
P11290415A0288|75 82|placenta
P11290415A0288|90 96|library
P11290906T0000|24 34|Tl-201 SPECT
P11290906T0000|64 73|infarction
P11290906T0000|10 21|accumulation
P11291552A0156|0 6|METHODS
P11291552A0156|11 18|patients
P11291552A0156|46 48|MFH
P11292335A0852|59 78|sequence substitution
P11292335A0852|18 24|dnaE173
P11292335A0852|33 47|mutator mutation
P11292335A0852|125 133|frequency
P11292335A0852|147 164|frameshift mutation
P11292335A0852|98 107|frameshift
P11292839A0531|114 122|construct
P11292839A0531|25 27|pol
P11292839A0531|161 163|TBP
P11292839A0531|153 159|protein
P11292839A0531|46 52|factors
P11292839A0531|76 84|exception
P11292839A0531|100 107|TATA-box
P11292839A0531|203 207|TBPwt
P11292839A0531|3 15|transcription
P11292839A0531|165 170|mutant
P11292839A0531|190 192|TBP
P11292839A0531|172 178|TBP-DR2
P11292839A0531|58 63|U6 gene
P11292844A0081|0 2|HSF
P11292844A0081|34 40|trimers
P11292844A0081|8 10|DNA
P11292844A0081|48 50|DNA
P11292844A0081|14 19|trimer
P11294895A0292|32 42|gene product
P11294895A0292|92 96|Sec14
P11294895A0292|24 28|spo20
P11294895A0292|106 140|phosphatidylinositol transfer protein
P11294895A0292|150 154|yeast
P11295470A0954|71 75|B cell
P11295470A0954|20 40|linkage disequilibrium
P11295470A0954|62 65|site
P11295470A0954|10 17|evidence
P11295470A0954|107 109|UTR
P11295470A0954|84 91|promoter
P11295523A0218|42 50|mid-1970s
P11295523A0218|5 11|numbers
P11295760A1374|0 20|Specimen mass reduction
P11295760A1374|79 82|W/cm
P11295760A1374|54 54|%
P11295760A1374|34 43|irradiance
P11295760A1374|67 70|mass
P11296288A1107|88 96|sequences
P11296288A1107|76 80|orf-x
P11296288A1107|65 67|gag
P11296288A1107|39 53|pCMVJS21DeltaGP
P11296288A1107|18 27|derivative
P11296288A1107|69 71|pol
P11296288A1107|127 130|foci
P11296288A1107|2 9|addition
P11296288A1107|30 37|pCMVJS21
P11296442A0565|87 94|tube size
P11296442A0565|38 44|formula
P11296442A0565|13 20|tube size
P11296442A0565|32 35|Cole
P11296442A0565|169 176|tube size
P11296442A0565|114 123|anesthesia
P11296442A0565|149 155|formula
P11296442A0565|2 11|conclusion
P11297419A0894|2 6|F222W
P11297419A0894|66 72|changes
P11297419A0894|47 63|fluorescence probe
P11297419A0894|104 110|residue
P11297419A0894|8 19|W21F rGST A1-1
P11297419A0894|78 88|environment
P11297514A0218|131 135|genes
P11297514A0218|38 46|induction
P11297514A0218|12 23|hos1 mutation
P11297514A0218|52 74|CBF transcription factors
P11297514A0218|80 90|temperature
P11297545A0948|188 190|p38
P11297545A0948|6 17|transfection
P11297545A0948|182 184|hGH
P11297545A0948|94 101|mediator
P11297545A0948|25 32|CHOP cDNA
P11297545A0948|205 210|manner
P11297545A0948|163 171|apoptosis
P11297545A0948|149 158|protection
P11297545A0948|44 57|carcinoma cells
P11297545A0948|74 77|CHOP
P11297545A0948|118 128|mitogenesis
P11297866A0484|2 9|contrast
P11297866A0484|74 83|propulsion
P11297866A0484|60 61|BF
P11297866A0484|52 57|effect
P11297866A0484|18 28|I. argentina
P11297866A0484|32 41|I. theezans
P11298326A0677|1 10|comparison
P11298326A0677|94 100|regions
P11298326A0677|53 61|selection
P11298326A0677|26 36|Vkappa genes
P11298326A0677|116 120|genes
P11298326A0677|123 136|point mutations
P11301189A1396|2 9|contrast
P11301189A1396|40 44|INK4d
P11301189A1396|24 33|expression
P11301189A1396|90 103|B-lineage cells
P11301189A1396|36 38|p19
P11302072A0508|27 37|stimulation
P11302072A0508|114 125|intervention
P11302072A0508|82 104|Word List Recognition Task
P11302072A0508|62 77|Boston Naming Test
P11302072A0508|157 168|significance
P11302072A0508|46 56|performance
P11302072A0508|3 9|results
P11302566A1318|17 26|flattening
P11302566A1318|78 95|psychomotor slowing
P11302566A1318|48 74|dopamine receptor sensitivity
P11302704T0000|0 19|Homo-oligomerisation
P11302704T0000|30 41|localisation
P11302704T0000|44 66|mouse histone deacetylase
P11303027A0954|99 107|potential
P11303027A0954|63 71|ARF family
P11303027A0954|51 57|GTPases
P11303027A0954|5 8|data
P11303027A0954|111 120|cross-talk
P11303027A0954|23 29|network
P11303027A0954|80 88|effectors
P11303027A0954|32 43|interactions
P11303638A0559|4 20|NEU overexpression
P11303638A0559|54 54|%
P11303638A0559|27 33|control
P11303638A0559|49 49|%
P11303638A0559|56 56|p
P11303890A0996|42 47|values
P11303890A0996|64 71|microg/l
P11303890A0996|5 8|time
P11303890A0996|30 34|doses
P11305129T0000|57 63|courses
P11305129T0000|23 35|tetanus toxoid
P11305129T0000|10 20|booster dose
P11305129T0000|106 113|globulin
P11305129T0000|78 89|implications
P11305129T0000|66 76|vaccination
P11305129T0000|95 97|use
P11305129T0000|0 6|Effects
P11306101A0000|166 187|3alpha-hydroxysteroids
P11306101A0000|140 162|17beta-hydroxy-steroids
P11306101A0000|125 132|alcohols
P11306101A0000|51 62|hamster liver
P11306101A0000|5 18|RACE techniques
P11306101A0000|85 98|dehydrogenases
P11306463A0383|26 30|L901Q
P11306463A0383|14 20|C domain
P11306463A0383|107 113|C domain
P11306463A0383|23 24|Rb
P11306463A0383|1 8|mutation
P11306463A0383|72 93|cdk4/D1 phosphorylation
P11306511A1476|2 12|association
P11306511A1476|105 124|progesterone receptor
P11306511A1476|38 47|expression
P11306511A1476|86 94|mdm2 mRNAs
P11306511A1476|99 102|lack
P11306845A0168|58 73|blister formation
P11306845A0168|12 22|examination
P11306845A0168|38 44|changes
P11306845A0168|86 98|keratinocytes
P11308851A0333|13 28|response function
P11308851A0333|106 123|material parameters
P11308851A0333|77 90|frequency range
P11308851A0333|52 55|GSER
P11308851A0333|133 136|bead
P11308851A0333|143 149|network
P11308877A0213|70 80|input phases
P11308877A0213|94 107|discharge times
P11308877A0213|55 62|relation
P11308877A0213|37 39|map
P11308877A0213|146 175|orientation preserving circle map
P11308877A0213|28 32|input
P11309077A0953|42 47|jejuni
P11309077A0953|30 35|jejuni
P11309077A0953|78 86|biotype I.
P11309077A0953|25 28|Camp
P11309077A0953|4 10|strains
P11309077A0953|72 75|ones
P11309373A0783|0 7|Analysis
P11309373A0783|66 69|rise
P11309373A0783|53 61|promoters
P11309373A0783|10 18|mCTR mRNAs
P11309373A0783|144 150|regions
P11309373A0783|166 172|lengths
P11309373A0783|103 108|region
P11309373A0783|84 95|mCTR isoforms
P11309373A0783|114 117|gene
P11309389A0273|248 262|down-regulation
P11309389A0273|106 108|PMA
P11309389A0273|165 168|GHBP
P11309389A0273|26 36|proteolysis
P11309389A0273|192 194|GHR
P11309389A0273|280 290|GH signaling
P11309389A0273|122 144|metalloprotease activity
P11309389A0273|64 104|phorbol ester phorbol 12-myristate 13-acetate
P11309389A0273|265 276|GHR abundance
P11309389A0273|220 232|domain remnant
P11309400T0000|0 6|Effects
P11309400T0000|48 52|decay
P11309400T0000|11 31|terminus modifications
P11309400T0000|34 37|mRNA
P11309400T0000|66 81|protein synthesis
P11309677A0000|118 121|GV-F
P11309677A0000|110 116|fatigue
P11309677A0000|144 147|GV-H
P11309677A0000|135 142|veterans
P11309677A0000|70 83|Gulf War Illness
P11309677A0000|58 65|veterans
P11309677A0000|85 87|GWI
P11309677A0000|32 38|battery
P11309678A0489|100 107|splicing
P11309678A0489|34 37|mRNA
P11309678A0489|7 31|transcription-PCR analysis
P11309678A0489|42 49|patients
P11309678A0489|74 82|mutations
P11310937A0548|100 102|CRP
P11310937A0548|49 52|time
P11310937A0548|203 210|tertiles
P11310937A0548|139 145|tertile
P11310937A0548|90 96|tertile
P11310937A0548|162 170|TNF-alpha
P11310937A0548|57 62|months
P11310937A0548|106 109|IL-6
P11310937A0548|149 158|fibrinogen
P11310937A0548|16 24|mortality
P11310937A0548|0 6|RESULTS
P11311153T0000|101 106|enzyme
P11311153T0000|63 74|polymorphism
P11311153T0000|3 14|relationship
P11311153T0000|20 40|factor V Leiden mutation
P11311153T0000|80 90|angiotensin
P11311153T0000|122 141|thromboembolic events
P11311153T0000|161 172|arthroplasty
P11311464A0362|60 67|sciatica
P11311464A0362|130 147|bladder dysfunction
P11311464A0362|116 125|paraplegia
P11311464A0362|73 85|motor weakness
P11311464A0362|5 13|disorders
P11311464A0362|96 106|extremities
P11311464A0362|34 49|saddle anesthesia
P11311464A0362|29 32|pain
P11311480A0079|134 137|loss
P11311480A0079|109 119|perineurium
P11311480A0079|61 71|alterations
P11311480A0079|5 15|nerve biopsy
P11311480A0079|163 168|fibers
P11311480A0079|88 103|cell infiltration
P11311480A0079|41 51|perineurium
P11311550A0253|186 199|rat cardiocytes
P11311550A0253|121 128|elements
P11311550A0253|24 33|regulation
P11311550A0253|176 183|cultures
P11311550A0253|99 110|contribution
P11311550A0253|62 83|rat eIF4E promoter region
P11311550A0253|39 50|rat eIF4E gene
P11311550A0253|141 153|transcription
P11311550A0253|221 236|myoblast cell line
P11311550A0253|55 56|kB
P11311550A0253|212 212|C
P11311550A0253|216 216|C
P11311563A0423|95 102|CCAAT box
P11311563A0423|62 72|OA induction
P11311563A0423|8 15|CCAAT box
P11311563A0423|44 60|promoter construct
P11311687A0231|27 33|studies
P11311687A0231|88 95|relation
P11311687A0231|117 125|morbidity
P11311687A0231|42 52|RLS severity
P11311687A0231|104 111|measures
P11311687A0231|3 8|JHRLSS
P11311687A0231|140 142|RLS
P11311909A0938|14 17|case
P11311909A0938|22 29|aneurysm
P11311909A0938|55 57|end
P11311909A0938|73 86|A1 fenestration
P11311980A1049|0 3|GABA
P11311980A1049|5 5|B
P11311980A1049|7 9|R1g
P11311980A1049|46 52|tissues
P11311980A1049|28 32|brain
P11312108A2853|0 3|Raes
P11312108A2853|5 6|P.
P11312120A1311|0 25|NF-kappaB pathway activation
P11312120A1311|106 108|Ras
P11312120A1311|79 87|oncogenes
P11312120A1311|98 104|Bcr/Abl
P11312120A1311|112 114|Rac
P11312120A1311|38 51|transformation
P11312120A1311|149 157|potential
P11312120A1311|62 67|number
P11312326A0169|177 182|genome
P11312326A0169|7 9|rev
P11312326A0169|51 55|clone
P11312326A0169|113 121|isolation
P11312326A0169|205 220|virus replication
P11312326A0169|36 40|HIV-1
P11312326A0169|96 101|method
P11312326A0169|197 202|rescue
P11312326A0169|153 160|elements
P11312326A0169|27 33|HIV type
P11312326A0169|58 83|complementation experiments
P11312584X1846|0 8|Copyright
P11312584X1846|13 25|Academic Press
P11313249T0000|88 103|activation domain
P11313249T0000|55 61|protein
P11313249T0000|24 32|zebrafish
P11313342A0224|56 74|center cleft residues
P11313342A0224|140 142|PAP
P11313342A0224|25 44|alanine substitutions
P11313342A0224|130 137|activity
P11313342A0224|112 119|ribosome
P11313342A0224|97 108|depurinating
P11313386A0704|0 18|SH2D1A protein levels
P11313386A0704|36 52|CD40 cross-linking
P11313386A0704|72 92|B cell receptor ligation
P11313398A0687|0 20|Cross-linking FcalphaR
P11313398A0687|96 103|PKBalpha
P11313398A0687|23 29|wt-ITAM
P11313398A0687|64 65|PI
P11313398A0687|84 93|activation
P11313398A0687|32 44|IIA-ITAM cells
P11313946A0449|74 78|M-Ras
P11313946A0449|82 87|p21 Ras
P11313946A0449|24 28|Nore1
P11313946A0449|17 20|AF-6
P11313946A0449|0 7|RPM/RGL3
P11313946T0000|58 60|p21
P11313946T0000|33 38|p21 Ras
P11313946T0000|89 98|cell growth
P11313946T0000|25 29|M-Ras
P11313946T0000|15 22|effector
P11313946T0000|73 85|gene induction
P11313961A1323|71 73|age
P11313961A1323|127 133|p53 gene
P11313961A1323|56 61|tumors
P11313961A1323|77 84|contrast
P11313961A1323|106 112|strains
P11313961A1323|3 6|mice
P11313961A1323|97 99|p53
P11314030A1264|101 103|FAK
P11314030A1264|95 97|Abl
P11314030A1264|34 39|region
P11314030A1264|176 178|SH3
P11314030A1264|113 126|signal pathways
P11314030A1264|165 170|region
P11314030A1264|71 78|elements
P11314030A1264|138 145|paradigm
P11314030A1264|196 204|SH3 domain
P11314030A1264|3 9|results
P11314030A1264|42 44|Crk
P11314046A0000|0 6|Cyclins
P11314046A0000|25 36|determinants
P11314046A0000|47 66|cell cycle progression
P11314373T0000|23 29|formula
P11314373T0000|14 17|care
P11314373T0000|38 44|problem
P11314428A0651|144 144|P
P11314428A0651|26 32|ability
P11314428A0651|103 124|months width differences
P11314428A0651|38 51|hydroxyapatite
P11314428A0651|152 154|LHS
P11314428A0651|82 93|significance
P11314428A0651|57 63|sockets
P11314428A0651|137 142|region
P11314428A0651|159 159|P
P11314428A0651|167 169|RHS
P11315633A0920|28 30|RNA
P11315633A0920|22 24|VPg
P11315633A0920|88 112|amino acid sequence analysis
P11315633A0920|3 14|cleavage site
P11315633A0920|69 77|E445-T446
P11315633A0920|118 128|polyprotein
P11315633A0920|40 52|RNA polymerase
P11315633A0920|142 154|sobemoviruses
P11316127A0485|54 59|values
P11316127A0485|74 86|Control groups
P11316127A0485|11 15|HCM-I
P11316127A0485|65 70|HCM-II
P11316127A0485|3 8|%SVend
P11317256A0361|113 119|abscess
P11317256A0361|39 46|isolates
P11317256A0361|19 31|S. intermedius
P11317256A0361|49 62|S. constellatus
P11317256A0361|9 16|isolates
P11317256A0361|83 93|S. anginosus
P11317256A0361|73 73|%
P11318363A0085|0 5|DESIGN
P11318363A0085|20 24|study
P11318608A0669|40 52|amplification
P11318608A0669|113 124|reading frame
P11318608A0669|157 163|protein
P11318608A0669|208 211|NLSs
P11318608A0669|188 206|localization signals
P11318608A0669|230 236|regions
P11318608A0669|81 89|DENTT cDNA
P11318608A0669|5 29|brain cDNA library screening
P11318608A0669|55 58|cDNA
P11318608A1155|0 11|Transfection
P11318608A1155|25 50|DENTT NLS deletion constructs
P11318608A1155|94 102|nucleolus
P11318608A1155|70 74|NLS-1
P11319098A0164|131 138|addition
P11319098A0164|177 191|LacI-GalR family
P11319098A0164|141 144|PkwR
P11319098A0164|37 67|protein translocase component SecE
P11319098A0164|165 171|protein
P11319098A0164|5 9|genes
P11319098A0164|113 123|proteins L11
P11319098A0164|127 128|L1
P11319098A0164|86 96|protein NusG
P11319098A0164|17 32|tryptophanyl tRNA
P11319880A1108|0 8|Rapamycin
P11319880A1108|10 27|FRAP/mTOR inhibitor
P11319880A1108|65 76|predominance
P11319880A1108|107 110|band
P11319880A1108|36 56|4E-BP1 phosphorylation
P11319880A1108|82 86|alpha
P11321187A0355|60 68|synthesis
P11321187A0355|26 35|MS patients
P11321187A0355|71 72|C.
P11321187A0355|121 128|controls
P11321187A0355|92 94|IgG
P11321187A0355|41 41|%
P11321187A0355|133 133|%
P11323411A0505|0 21|Far Western blot analysis
P11323411A0505|56 59|SHP2
P11323411A0505|44 53|SH2 domains
P11323411A0505|103 113|N-SH2 domain
P11323411A0505|121 135|phosphotyrosine
P11323411A0505|176 176|P
P11323411A0505|137 139|Tyr
P11323411A0505|141 141|P
P11323411A0505|81 91|orientation
P11323411A0505|66 69|Gab1
P11323411A0505|172 174|Tyr
P11323411A0505|154 164|C-SH2 domain
P11323419T0000|126 147|mouse uterine epithelium
P11323419T0000|78 100|fucosyltransferase genes
P11323419T0000|35 44|expression
P11323419T0000|24 30|mapping
P11323419T0000|9 15|cloning
P11323419T0000|58 72|blood group alpha
P11323419T0000|167 171|tract
P11323716A0413|15 19|RAD23
P11323716A0413|23 26|DDI1
P11323716A0413|46 57|interactions
P11323716A0413|3 12|UBA domains
P11324516A0159|74 104|D1/D2 receptor agonist apomorphine
P11324516A0159|25 38|administration
P11324516A0159|40 43|i.t.
P11324516A0159|114 126|pain threshold
P11324516A0159|154 155|AA
P11324516A0159|134 151|potentiating effect
P11324516A0159|47 71|D2 receptor agonist LY171555
P11325195A0661|54 57|lamb
P11325195A0661|61 75|pork longissimus
P11325195A0661|12 14|MFI
P11325195A0661|31 36|muscle
P11325195A0661|3 4|R2
P11325391A0498|59 67|saline key
P11325391A0498|77 85|schedules
P11325391A0498|8 12|doses
P11325391A0498|15 27|d-amphetamine
P11325685A1624|94 100|fatigue
P11325685A1624|11 30|L-carnitine treatment
P11325685A1624|118 124|decline
P11325685A1624|40 68|plasma carnitine concentrations
P11325685A1624|131 146|exercise capacity
P11325685A1624|149 168|hemodialysis patients
P11325944A0511|31 34|UhpB
P11325944A0511|8 17|expression
P11325944A0511|47 59|hybrid protein
P11325944A0511|193 195|uhp
P11325944A0511|75 98|glutathione S-transferase
P11325944A0511|61 66|GST-Bc
P11325944A0511|166 173|blockage
P11325944A0511|100 102|GST
P11325944A0511|199 204|strain
P11325944A0511|135 141|portion
P11325944A0511|144 147|UhpB
P11325944A0511|176 189|uhpT expression
P11327292A0190|58 61|risk
P11327292A0190|82 87|vision
P11327292A0190|10 17|location
P11327292A0190|73 76|loss
P11327292A0190|29 40|malformation
P11327698A0191|380 384|U0126
P11327698A0191|216 225|HepG2 cells
P11327698A0191|14 16|PKC
P11327698A0191|392 409|Sp1 phosphorylation
P11327698A0191|135 137|PMA
P11327698A0191|304 313|IGF-II mRNA
P11327698A0191|331 340|HepG2 cells
P11327698A0191|81 88|IGF-II P4
P11327698A0191|20 40|p44/p42MAPK signalings
P11327698A0191|231 243|PKC inhibition
P11327698A0191|411 420|P4 activity
P11327698A0191|104 111|activity
P11327698A0191|424 433|IGF-II mRNA
P11327698A0191|271 288|Sp1 phosphorylation
P11327698A0191|140 158|PKC expression vector
P11327698A0191|246 263|PKC inhibitor Go6976
P11327698A0191|189 198|P4 activity
P11327698A0191|365 377|MEK activation
P11327698A0191|353 362|inhibition
P11327698A0191|168 185|Sp1 phosphorylation
P11327698A0191|451 460|HepG2 cells
P11327698A0191|120 132|PKC activation
P11327698A0191|290 299|P4 activity
P11327858A0087|15 24|mechanisms
P11327858A0087|40 54|oncoprotein Hdm2
P11327858A0087|26 28|Arf
P11327858A0087|76 78|p53
P11327858A0087|65 73|regulator
P11328699A0000|70 73|wall
P11328699A0000|48 51|time
P11328699A0000|60 64|close
P11328699A0000|26 33|test mice
P11328699A0000|120 132|test situation
P11328699A0000|79 87|container
P11328853A0644|0 10|Examination
P11328853A0644|82 95|promoter region
P11328853A0644|107 123|promoter sequences
P11328853A0644|20 42|promoter deletion mutants
P11328853A0644|56 59|SF-1
P11331589A0113|41 55|male X chromosome
P11331589A0113|69 78|expression
P11331589A0113|3 12|MSL complex
P11331596A0710|0 3|Prrp
P11331596A0710|27 36|EVH1 domain
P11331596A0710|39 42|Mena
P11331596A0710|75 81|protein
P11331604A0267|0 4|Srb10
P11331604A0267|103 114|srb10 mutants
P11331604A0267|32 44|Gcn4 stability
P11331604A0267|56 70|phosphorylation
P11331604A0267|21 29|regulator
P11331604A0267|84 87|Gcn4
P11331604A0267|74 81|turnover
P11331613A0827|68 75|subclass
P11331613A0827|10 16|effects
P11331613A0827|49 57|mutations
P11331613A0827|19 30|pVHL function
P11333263A0240|37 42|middle
P11333263A0240|63 76|leader sequence
P11333263A0240|108 123|promoter activity
P11333263A0240|4 9|intron
P11333263A0240|15 23|base pairs
P11333268A1521|171 173|Ras
P11333268A1521|205 210|switch
P11333268A1521|176 178|Sos
P11333268A1521|219 228|disruption
P11333268A1521|77 83|regions
P11333268A1521|252 255|site
P11333268A1521|50 52|Sos
P11333268A1521|160 168|anchoring
P11333268A1521|11 18|analysis
P11333268A1521|36 47|interactions
P11333268A1521|111 122|consequences
P11333268A1521|127 137|interaction
P11333268A1521|70 75|switch
P11333268A1521|190 200|interaction
P11333268A1521|86 88|Ras
P11333268A1521|60 65|switch
P11333268A1521|259 273|GDP dissociation
P11333268A1521|142 147|switch
P11334124A0903|97 105|dose range
P11334124A0903|48 55|increase
P11334124A0903|11 23|dose-response
P11334124A0903|69 75|AUC0-6 h
P11334124A0903|67 67|h
P11334124A0903|120 127|Respimat
P11334124A0903|84 87|FEV1
P11334124A0903|58 61|FEV1
P11335116A1099|0 19|Bandshift experiments
P11335116A1099|183 188|BmHR3A
P11335116A1099|176 179|role
P11335116A1099|243 256|vitellogenesis
P11335116A1099|120 128|sequences
P11335116A1099|134 142|promoters
P11335116A1099|216 225|BmGATAbeta
P11335116A1099|229 236|ESP genes
P11335116A1099|204 213|expression
P11335116A1099|35 40|BmHR3A
P11335116A1099|85 113|Orphan receptor Response Element
P11335116A1099|149 153|genes
P11335116A1099|60 63|RORE
P11335710A0320|44 56|Erk activation
P11335710A0320|37 41|phase
P11336211A0132|28 36|Bengtsson
P11336211A0132|12 17|method
P11336211A0132|38 41|Appl
P11336698A0075|58 81|yeast remodeler RSC complex
P11336698A0075|22 26|Rsc30
P11336698A0075|34 43|components
P11336698A0075|15 18|Rsc3
P11337859A0651|40 40|%
P11337859A0651|45 49|FeCl3
P11337859A0651|9 21|color removals
P11337859A0651|190 199|H2O2 dosage
P11337859A0651|150 186|hydrogen peroxide oxidation pretreatment
P11337859A0651|74 80|dosages
P11337859A0651|119 123|mol/L
P11337859A0651|91 101|coagulation
P11337859A0651|62 72|coagulation
P11337859A0651|206 210|mol/L
P11337859A0651|3 5|COD
P11340048A0432|42 54|flux densities
P11340048A0432|79 85|sensors
P11340048A0432|21 31|correlation
P11340048A0432|114 126|flux densities
P11340048A0432|147 153|sensors
P11340048A0432|98 108|differences
P11340080A0096|28 46|checkpoint signaling
P11340080A0096|10 17|proteins
P11340080A0096|128 134|studies
P11340080A0096|113 117|yeast
P11340080A0096|61 64|Rad9
P11340080A0096|53 56|Hus1
P11340080A0096|48 51|Rad1
P11340080A0096|91 109|immunoprecipitation
P11340085A0211|177 180|frog
P11340085A0211|169 175|species
P11340085A0211|127 143|amino acid sequence
P11340085A0211|246 266|transactivation domain
P11340085A0211|10 19|hypothesis
P11340085A0211|221 227|regions
P11340085A0211|47 53|regions
P11340085A0211|229 235|CR1-CR4
P11340085A0211|101 112|coactivators
P11340085A0211|146 155|C/EBPalpha
P11340516A0509|0 8|Tolerance
P11340516A0509|61 66|ADAL-2
P11340516A0509|50 58|tolerance
P11340516A0509|86 94|Tisuacryl
P11340516A0509|11 16|ADAL-2
P11340516A0509|35 46|Vicryl suture
P11340525A0737|94 101|regimen B
P11340525A0737|115 115|%
P11340525A0737|86 86|%
P11340525A0737|60 60|%
P11340525A0737|36 49|study end points
P11340525A0737|123 130|regimen C
P11340525A0737|5 12|patients
P11340525A0737|19 25|regimen
P11340525A0737|137 161|treatment success criterion
P11340525A0737|68 75|regimen A
P11341349T0000|70 74|women
P11341349T0000|20 25|effect
P11341349T0000|5 14|indicators
P11341349T0000|29 56|breast cancer screening program
P11341405A0146|17 19|MCB
P11341405A0146|6 15|POPULATION
P11341405A0146|25 40|racing Greyhounds
P11341405A0146|56 62|reasons
P11341405A0146|74 89|MCB abnormalities
P11341405A1154|0 10|CONCLUSIONS
P11341405A1154|214 222|responses
P11341405A1154|22 30|RELEVANCE
P11341405A1154|287 292|tracks
P11341405A1154|153 159|osteons
P11341405A1154|129 136|turnover
P11341405A1154|271 276|racing
P11341405A1154|165 179|dorsal quadrants
P11341405A1154|49 57|thickness
P11341405A1154|99 108|Greyhounds
P11341405A1154|253 259|loading
P11341405A1154|186 188|MCB
P11341405A1154|96 96|V
P11341405A1154|140 150|orientation
P11341405A1154|70 79|properties
P11341405A1154|86 91|MCB-IV
P11341405A1154|263 268|result
P11341828A0744|81 89|molecules
P11341828A0744|26 35|D-peptides
P11341828A0744|64 69|domain
P11342479A0430|131 141|evaporation
P11342479A0430|55 64|paclitaxel
P11342479A0430|10 16|RESULTS
P11342479A0430|18 36|Palmaz-Schatz stents
P11342479A0430|98 106|immersion
P11342479A0430|80 94|microgram/stent
P11342479A0430|0 6|METHODS
P11342479A0430|118 127|paclitaxel
P11344530A0320|0 10|Percentages
P11344530A0320|24 31|overload
P11344530A0320|13 20|recovery
P11344530A0320|35 47|dilution tests
P11344530A0320|67 67|%
P11345435A0199|41 42|P3
P11345435A0199|90 101|localization
P11345435A0199|17 29|RNA subdomains
P11345445A0533|159 172|concentrations
P11345445A0533|92 102|springtails
P11345445A0533|11 18|OECD soil
P11345445A0533|139 140|Zn
P11345445A0533|65 80|Cd concentrations
P11345445A0533|126 131|levels
P11345445A0533|134 135|Cu
P11345445A0533|28 35|Cd levels
P11347201X0001|58 67|BACKGROUND
P11347201X0001|94 101|vitamin D
P11347201X0001|111 113|n-3
P11347201X0001|53 56|diet
P11347201X0001|69 77|Plant food
P11347201X0001|83 92|vitamin B12
P11347201X0001|19 24|adults
P11347201X0001|134 138|acids
P11347201X0001|0 16|Nutritional status
P11348318A0940|41 48|patients
P11348318A0940|74 80|breasts
P11348318A0940|87 102|characterization
P11348318A0940|23 33|mammography
P11348318A0940|113 118|masses
P11348318A0940|14 20|adjunct
P11349796A0950|0 11|Measurements
P11349796A0950|67 70|days
P11349796A0950|111 114|days
P11349796A0950|58 59|D0
P11349796A0950|121 123|D30
P11349796A0950|49 56|exposure
P11349796A0950|97 98|D3
P11349796A0950|85 95|measurement
P11350038A0459|70 82|stem structure
P11350038A0459|39 42|Stem
P11350038A0459|117 120|role
P11350038A0459|93 98|hY RNAs
P11350038A0459|34 37|half
P11350038A0459|126 138|export process
P11350038A0459|13 20|evidence
P11350165A1606|0 6|Changes
P11350165A1606|51 63|stem structure
P11350165A1606|12 21|DB sequence
P11350165A1606|76 81|losses
P11350165A1606|84 104|translation efficiency
P11350175A0173|77 93|chaperone activity
P11350175A0173|22 28|members
P11350175A0173|65 73|isomerase
P11350175A0173|35 47|protein family
P11350812A0829|132 151|stress fiber formation
P11350812A0829|90 102|ERK activation
P11350812A0829|36 38|MEK
P11350812A0829|67 74|Rp-cAMPS
P11350812A0829|104 127|caldesmon phosphorylation
P11350812A0829|15 34|Raf-1 target ERK kinase
P11350812A0829|0 9|Inhibition
P11350957A0457|0 8|PACAP mRNA
P11350957A0457|65 69|PACAP
P11350957A0457|38 44|tissues
P11350957A0457|96 104|cytoplasm
P11350957A0457|59 63|cells
P11350982A0560|70 79|activation
P11350982A0560|35 45|involvement
P11350982A0560|21 28|evidence
P11350982A0560|48 67|GCN1-GCN2 interaction
P11350982A0560|82 85|GCN2
P11352423A0084|71 74|flap
P11352423A0084|77 82|choice
P11352423A0084|9 19|forearm flap
P11352423A0084|56 62|arm flap
P11352423A0084|92 101|situations
P11352663A0138|100 106|binding
P11352663A0138|75 81|binding
P11352663A0138|38 42|class
P11352663A0138|2 11|comparison
P11352663A0138|44 53|expression
P11352663A0138|109 117|NF-kappaB
P11352663A0138|29 36|Ad5 cells
P11352663A0138|84 90|COUP-TF
P11352671A0492|141 149|hPIV2 cDNA
P11352671A0492|111 114|site
P11352671A0492|48 63|nucleotide change
P11352671A0492|179 185|viruses
P11352671A0492|24 31|genetics
P11352671A0492|187 192|rPIV2V
P11352671A0492|4 14|application
P11352671A0492|65 67|UCU
P11352671A0492|204 207|cDNA
P11352671A0492|70 72|ACU
P11352671A0492|120 124|V gene
P11353392A1127|3 12|frameshift
P11353392A1127|24 28|ADEx2
P11353392A1127|56 69|coding sequence
P11353392A1127|96 107|ASIP mutation
P11353770A0085|156 161|places
P11353770A0085|65 85|N-glycosylase activity
P11353770A0085|101 120|8-oxoguanine residues
P11353770A0085|20 27|activity
P11353770A0085|47 48|S3
P11353770A0085|123 125|DNA
P11353770A0085|92 98|removal
P11353770A0085|144 148|sites
P11353774A0255|119 128|hepatocyte
P11353774A0255|212 218|protein
P11353774A0255|197 198|NR
P11353774A0255|108 113|member
P11353774A0255|48 64|forkhead homologue
P11353774A0255|67 82|rhabdomyosarcoma
P11353774A0255|181 195|hormone receptor
P11353774A0255|27 42|characterization
P11353774A0255|136 151|factor 3/forkhead
P11353774A0255|84 87|FKHR
P11353774A0255|160 169|gene family
P11353774A0255|15 23|isolation
P11354406A1373|97 107|ICP waveform
P11354406A1373|11 31|CSF outflow conductance
P11354406A1373|58 67|compliance
P11354975A0850|13 23|Euspondylus
P11354975A0850|88 92|Sucre
P11354975A0850|4 10|species
P11354975A0850|106 114|Venezuela
P11354975A0850|62 70|bromeliad
P11354975A0850|43 48|female
P11354975A0850|81 86|El Humo
P11355576A1125|85 106|tumor suppressor protein
P11355576A1125|202 224|E2F transcription factors
P11355576A1125|112 132|pRb controls commitment
P11355576A1125|239 255|cell proliferation
P11355576A1125|154 159|S phase
P11355576A1125|69 78|inhibition
P11355576A1125|150 151|G1
P11355576A1125|46 60|phosphorylation
P11355576A1125|30 32|CDK
P11355576A1125|108 110|pRb
P11355576A1125|189 196|activity
P11355576A1125|3 9|cyclins
P11355576A1125|170 173|part
P11355615A0766|98 105|practice
P11355615A0766|81 93|incorporation
P11355615A0766|10 18|education
P11355615A0766|54 62|direction
P11355615A0766|66 77|intervention
P11355615A0766|22 29|research
P11355668T0000|113 125|syndrome virus
P11355668T0000|80 86|porcine
P11355668T0000|13 24|vasculopathy
P11355668T0000|37 47|hemorrhages
P11355668T0000|50 64|porcine neonates
P11356214A0794|42 50|specimens
P11356214A0794|177 182|cavity
P11356214A0794|124 137|resin specimens
P11356214A0794|67 91|Knoop hardness measurements
P11356214A0794|114 121|surfaces
P11356214A0794|162 171|dimensions
P11356214A0794|3 12|difference
P11356214A0794|145 154|Teflon mold
P11356214A0794|193 198|dentin
P11356214A0794|15 22|hardness
P11356214A0794|27 30|time
P11356716A0372|14 18|clone
P11356716A0372|54 66|GHS-R variants
P11356716A0372|28 36|sequences
P11356835A0000|43 49|network
P11356835A0000|114 130|protein precursors
P11356835A0000|64 70|control
P11356835A0000|105 111|amounts
P11356835A0000|87 90|cell
P11356835A0000|137 155|amino acid starvation
P11356853A0429|72 78|control
P11356853A0429|12 15|CoCl
P11356853A0429|42 63|luciferase reporter gene
P11356853A0429|2 10|Ka13 cells
P11356853A0429|93 113|pair mouse ho-1 promoter
P11356853A0429|115 122|pHO15luc
P11356853A0429|29 38|expression
P11356853A0554|46 54|sequences
P11356853A0554|84 88|StREs
P11356853A0554|75 82|elements
P11356853A0554|0 15|Mutation analyses
P11356853A0873|0 6|Members
P11356853A0873|12 26|AP-1 superfamily
P11356853A0873|64 67|StRE
P11356853A0873|29 54|basic-leucine zipper factors
P11357063A0138|0 11|Descriptions
P11357063A0138|83 90|features
P11357063A0138|116 119|loci
P11357063A0138|18 22|locus
P11357063A0138|33 42|comparison
P11357063A0138|98 104|species
P11357063A0138|174 202|LHbeta-CGbeta gene cluster locus
P11357063A0138|148 160|LH/CGbeta gene
P11357063A1053|120 140|translation start codon
P11357063A1053|91 102|TATA sequence
P11357063A1053|105 106|bp
P11357063A1053|61 75|gpLH/CGbeta gene
P11357063A1053|25 34|LHbeta gene
P11357063A1053|7 15|consensus
P11357063A1053|50 55|region
P11358801A1046|43 56|NHEJ deficiency
P11358801A1046|15 24|situations
P11358801A1046|36 41|breaks
P11358801A1046|112 118|studies
P11358801A1046|71 84|rearrangements
P11358801A1046|88 96|agreement
P11358958A0878|0 9|Expression
P11358958A0878|116 124|apoptosis
P11358958A0878|91 100|tumor cells
P11358958A0878|53 68|growth inhibition
P11358958A0878|17 21|RACK1
P11358958A0878|71 74|HF7c
P11358962A0344|0 4|Foxp1
P11358962A0344|62 77|mouse development
P11358962A0344|8 12|Foxp2
P11358962A0344|82 96|Foxp2 expression
P11358962A0344|31 36|levels
P11358962A0344|42 45|lung
P11358962A0344|55 57|E12
P11358962A0344|112 127|airway epithelium
P11359568T0000|89 108|nucleoprotein complex
P11359568T0000|116 135|plasmid partition site
P11359568T0000|45 48|ParB
P11359568T0000|9 16|analysis
P11359568T0000|22 43|pRA2 partitioning region
P11359568T0000|137 140|parS
P11359568T0000|62 79|parAB transcription
P11359827T0000|90 94|SPE-J
P11359827T0000|80 80|J
P11359827T0000|27 42|characterization
P11359827T0000|67 75|exotoxins
P11359827T0000|82 86|SPE-I
P11359907A0099|89 92|VEGF
P11359907A0099|76 87|growth factor
P11359907A0099|7 23|dozen HIF-1 targets
P11359907A0099|45 48|gene
P11360190A0178|58 67|G0/G1 phase
P11360190A0178|24 26|Tax
P11360190A0178|34 53|cell cycle progression
P11360190A0178|107 111|cells
P11360190A0178|74 83|G2/M phases
P11360190A0178|91 103|T-cell line Kit
P11360190A0178|70 70|S
P11361338A0093|42 45|type
P11361338A0093|20 33|matrix proteins
P11361338A0093|68 82|targeting signal
P11361338A0093|104 116|tripeptide SKL
P11361338A0093|84 87|PTS1
P11361338A0093|4 8|yeast
P11361338A0447|87 95|construct
P11361338A0447|106 119|Pex5p chimaeras
P11361338A0447|8 22|PEX5-TPR domains
P11361338A0447|77 81|yeast
P11361338A0447|44 51|nematode
P11361338A0447|33 39|tobacco
P11361493T0000|0 4|HIV-1
P11361493T0000|35 45|adolescents
P11361493T0000|8 32|hepatitis B virus infections
P11361493T0000|54 71|security institutes
P11361493T0000|74 84|Buenos Aires
P11367523A1684|0 24|Immunofixation experiments
P11367523A1684|50 58|allotypes
P11367523A1684|76 83|proteins
P11367523A1684|27 29|C4A
P11367523A1684|67 73|classes
P11367523A1684|33 35|C4B
P11367523A2624|44 48|genes
P11367523A2624|103 110|C4A genes
P11367523A2624|8 18|C4B proteins
P11367523A2624|72 85|concentrations
P11368363A0129|86 88|MPO
P11368363A0129|153 155|DNA
P11368363A0129|90 97|promoter
P11368363A0129|139 142|cDNA
P11368363A0129|212 224|mobility group
P11368363A0129|70 84|myeloperoxidase
P11368363A0129|249 256|proteins
P11368363A0129|25 44|transcription factors
P11368363A0129|5 10|course
P11368363A0129|112 115|time
P11368363A0129|164 167|HBP1
P11368363A0129|197 202|member
P11368363A0129|169 192|HMG-Box containing protein
P11368363A1103|162 171|rat protein
P11368363A1103|76 82|rat HBP1
P11368363A1103|51 56|domain
P11368363A1103|8 22|protein sequence
P11368363A1103|91 98|homology
P11368363A1103|106 115|activation
P11368363A1103|119 134|repressor domains
P11368787A0180|0 7|Promoter
P11368787A0180|89 90|bp
P11368787A0180|54 60|portion
P11368787A0180|137 160|transcription start points
P11368787A0180|23 30|activity
P11368787A0180|71 83|annexin A5 gene
P11368901A0327|2 9|contrast
P11368901A0327|48 57|repeat unit
P11368901A0327|21 25|mouse
P11368901A0327|30 37|proteins
P11368901A0327|81 87|portion
P11368911T0000|60 68|C. elegans
P11368911T0000|25 29|smg-4
P11368911T0000|9 22|identification
P11368911T0000|42 57|mRNA surveillance
P11368914T0071|98 104|control
P11368914T0071|19 23|exons
P11368914T0071|121 128|promoter
P11368914T0071|87 89|ORF
P11368914T0071|33 53|complement C3 gene locus
P11368914T0071|73 75|end
P11369066A1210|148 166|radiation dermatitis
P11369066A1210|18 20|MMF
P11369066A1210|36 49|corticosteroid
P11369066A1210|64 68|cream
P11369066A1210|123 127|cream
P11369066A1210|0 10|CONCLUSIONS
P11369106A0428|44 49|result
P11369106A0428|117 124|food webs
P11369106A0428|77 99|transformation processes
P11369106A0428|62 73|interactions
P11369106A0428|35 40|sulfur
P11369106A0428|6 13|advances
P11369410A0949|118 127|processing
P11369410A0949|44 62|stimulus differences
P11369410A0949|35 39|sense
P11369410A0949|8 17|hypothesis
P11369410A0949|136 147|participants
P11369410A0949|74 82|behaviour
P11369453A1083|42 48|element
P11369453A1083|10 17|increase
P11369453A1083|20 33|protein binding
P11369453A1083|58 73|peptide treatment
P11369700A0074|28 40|chain isotypes
P11369700A0074|55 69|B cell activators
P11369700A0074|43 51|cytokines
P11369700A0074|124 125|GL
P11369700A0074|128 128|C
P11369700A0074|115 122|germline
P11369700A0074|132 142|region genes
P11369700A0074|80 92|transcription
P11369700A0074|130 130|H
P11369700A0074|0 2|CSR
P11369700A0616|42 49|Ets sites
P11369700A0616|145 154|expression
P11369700A0616|158 179|luciferase reporter gene
P11369700A0616|110 113|PU.1
P11369700A0616|55 74|mouse GL alpha promoter
P11369700A0616|191 205|GL alpha promoter
P11369700A0616|6 15|manuscript
P11369700A0616|82 106|transcription factors Elf-1
P11369700A0616|127 130|site
P11369759A0605|0 3|Cell
P11370174A0447|54 59|months
P11370174A0447|65 74|withdrawal
P11370174A0447|7 26|serum creatinine level
P11370174A0447|77 79|MMF
P11371115A0962|3 12|proportion
P11371115A0962|18 25|biopsies
P11371115A0962|89 91|MGN
P11371115A0962|50 59|HBs antigen
P11371115A0962|67 67|%
P11371115A0962|94 104|MPGN pattern
P11371160A0193|16 26|nucleotides
P11371160A0193|57 76|discriminator base A73
P11371160A0193|111 118|molecule
P11371160A0193|39 53|base-pair C1-G72
P11371160A0193|82 86|amino
P11371160A0193|100 105|branch
P11371160A0854|29 41|anticodon loop
P11371160A0854|113 122|efficiency
P11371160A0854|64 67|acts
P11371160A0854|81 96|TyrRS interaction
P11371160A0854|47 54|tyrosine
P11371160A0854|125 136|tyrosylation
P11371160A0854|4 9|domain
P11371160A0854|72 77|anchor
P11371343A0125|70 76|protein
P11371343A0125|25 32|separase
P11371343A0125|15 23|cell cycle
P11371343A0125|83 89|securin
P11371417A0744|289 306|preventilation data
P11371417A0744|359 360|LA
P11371417A0744|103 121|tumor necrosis factor
P11371417A0744|143 147|pg/ml
P11371417A0744|85 100|lung lavage levels
P11371417A0744|262 267|levels
P11371417A0744|313 318|change
P11371417A0744|191 200|macrophage
P11371417A0744|270 278|cytokines
P11371417A0744|321 330|percentage
P11371417A0744|162 163|IL
P11371417A0744|46 54|% decrease
P11371417A0744|213 221|protein-2
P11371417A0744|150 160|interleukin
P11371417A0744|223 227|MIP-2
P11371417A0744|123 125|TNF
P11371417A0744|181 185|pg/ml
P11371417A0744|23 34|control lungs
P11371417A0744|75 82|increase
P11371417A0744|128 132|alpha
P11371417A0744|10 20|ventilation
P11371417A0744|239 243|pg/ml
P11371417A0744|167 170|beta
P11371417A0744|57 71|chord compliance
P11371417A0744|348 357|aggregates
P11372882A1143|61 66|levels
P11372882A1143|12 14|DDE
P11372882A1143|79 82|PCBs
P11372882A1143|8 8|p
P11372882A1143|10 10|p
P11372882A1143|71 76|levels
P11372882A1143|18 31|beta-HCH levels
P11372959A1447|180 180|%
P11372959A1447|114 125|relationship
P11372959A1447|197 209|tick abundance
P11372959A1447|186 194|variation
P11372959A1447|80 88|abundance
P11372959A1447|150 164|habitat category
P11372959A1447|127 140|R2 coefficients
P11372959A1447|8 25|regression analysis
P11372959A1447|99 103|sites
P11372959A1447|63 69|factors
P11373277A0812|205 220|corepressor CtBP1
P11373277A0812|106 111|effect
P11373277A0812|156 172|AP-2alpha promoter
P11373277A0812|90 102|AP-2alpha gene
P11373277A0812|37 50|oncoprotein E1A
P11373277A0812|188 190|E1A
P11373277A0812|175 185|interaction
P11373277A0812|139 150|derepression
P11373277A0812|2 8|summary
P11373277A0812|60 72|transcription
P11374051A0437|147 150|risk
P11374051A0437|10 16|factors
P11374051A0437|118 125|diseases
P11374051A0437|51 65|corticosteroids
P11374051A0437|31 33|age
P11374051A0437|153 160|bleeding
P11374051A0437|68 81|anticoagulants
P11374051A0437|46 48|use
P11374051A0437|88 105|ulcer complications
P11374559A0103|0 10|SERS spectra
P11374559A0103|69 79|island films
P11374559A0103|92 115|colloidal silver solutions
P11374559A0103|25 41|vacuum evaporation
P11374559A0103|45 51|casting
P11374559A0103|54 58|p-NTP
P11374866X0914|0 8|Copyright
P11374866X0914|13 25|Academic Press
P11375392T0000|85 87|Sp1
P11375392T0000|22 41|thioredoxin reductase
P11375392T0000|92 101|Sp3 binding
P11375392T0000|79 83|Oct-1
P11375392T0000|44 50|cloning
P11375392T0000|67 74|activity
P11375392T0000|126 133|promoter
P11375392T0000|164 167|gene
P11375392T0000|3 14|core promoter
P11376007A0584|156 175|protein phosphatase 2A
P11376007A0584|253 263|microcystin
P11376007A0584|193 204|reactivation
P11376007A0584|135 152|protein phosphatase
P11376007A0584|177 180|PP2A
P11376007A0584|90 97|addition
P11376007A0584|120 126|subunit
P11376007A0584|37 40|loss
P11376007A0584|225 251|protein phosphatase inhibitor
P11376007A0584|46 66|protein kinase activity
P11376007A0584|69 74|DNA-PK
P11376119A0346|85 86|bp
P11376119A0346|99 102|exon
P11376119A0346|56 61|region
P11376119A0346|8 11|exon
P11376119A0346|109 115|GHR gene
P11376119A0346|67 75|GHR 1A mRNA
P11376119A0346|13 18|exon 1A
P11376134A1506|58 76|transcription factor
P11376134A1506|84 88|sites
P11376134A1506|5 15|corrections
P11376134A1506|28 36|sequences
P11376165T0000|0 2|FLP
P11376165T0000|6 27|Cre recombinase function
P11376165T0000|30 43|Xenopus embryos
P11376279A0000|60 70|angiography
P11376279A0000|47 55|resonance
P11376279A0000|81 91|extremities
P11376279A0000|105 121|volume acquisition
P11376279A0000|57 58|MR
P11376279A0000|1 6|method
P11376687A0344|30 32|SNP
P11376687A0344|125 127|AUG
P11376687A0344|136 144|MTH1 mRNAs
P11376687A0344|74 84|GTG83/ATG83
P11376687A0344|178 180|p26
P11376687A0344|162 176|MTH1 polypeptide
P11376687A0344|36 39|exon
P11376687A0344|7 28|nucleotide polymorphism
P11376687A0344|219 233|targeting signal
P11376687A0344|70 72|SNP
P11376946A0000|74 84|phosphatase
P11376946A0000|126 133|lineages
P11376946A0000|106 110|cells
P11376946A0000|38 40|SH2
P11376946A0000|11 17|studies
P11376946A0000|165 169|cells
P11376946A0000|215 222|promoter
P11376946A0000|31 35|SHP-1
P11376946A0000|178 184|control
P11376946A0000|224 225|P1
P11377975A0898|124 133|conditions
P11377975A0898|56 73|proteinase activity
P11377975A0898|28 36|COS1 cells
P11377975A0898|94 103|substrates
P11377975A0898|140 144|study
P11378898A0164|0 3|ORF1
P11378898A0164|12 23|EMBL databank
P11378898A0164|25 36|Accession No.
P11378898A0164|9 10|bp
P11379106A0372|43 67|deammonification processes
P11379106A0372|81 84|flow
P11379106A0372|95 104|pilot plant
P11379106A0372|5 12|meantime
P11380028A0000|3 9|purpose
P11380028A0000|124 131|131I-OIH
P11380028A0000|89 97|pentetate
P11380028A0000|101 118|orthoiodohippurate
P11380028A0000|157 160|cats
P11380028A0000|133 147|plasma clearance
P11380028A0000|16 20|study
P11380028A0000|44 50|methods
P11380028A0000|54 63|estimation
P11380028A0000|170 181|blood samples
P11380028A0000|66 77|Technetium Tc
P11380028A0000|150 153|dogs
P11380028A0000|82 86|99mTc
P11380370A0000|60 61|KS
P11380370A0000|23 33|skin lesions
P11380370A0000|52 58|sarcoma
P11380370A0000|44 49|Kaposi
P11380370A0000|1 7|patient
P11380837A1505|0 12|Interventions
P11380837A1505|113 117|costs
P11380837A1505|128 144|access dysfunction
P11380837A1505|45 53|processes
P11380837A1505|33 41|mediators
P11381094A0797|40 53|synaptotagmins
P11381094A0797|11 16|stonin
P11381094A0797|2 9|addition
P11381094A0797|28 37|C2B domains
P11382701A0688|58 65|response
P11382701A0688|75 78|rise
P11382701A0688|11 21|transection
P11382701A0688|81 105|plasma sodium concentration
P11382701A0688|33 43|vasopressin
P11382948A0793|150 154|USPIO
P11382948A0793|27 33|MRI data
P11382948A0793|122 133|permeability
P11382948A0793|183 192|tumor grade
P11382948A0793|91 107|breast cancer model
P11382948A0793|2 11|conclusion
P11382948A0793|59 84|tumor microvessel properties
P11383860A0661|86 90|brain
P11383860A0661|41 49|excretion
P11383860A0661|52 69|99mTc ciprofloxacin
P11383860A0661|121 131|liver uptake
P11383860A0661|135 143|excretion
P11383860A0661|92 95|lung
P11383860A0661|3 8|images
P11383860A0661|99 114|bone marrow uptake
P11384225A0634|12 29|expression cassette
P11384225A0634|136 144|sequences
P11384225A0634|69 75|protein
P11384225A0634|6 8|end
P11384225A0634|77 79|GFP
P11384225A0634|45 48|gene
P11384225A0634|95 97|end
P11384229A1669|117 122|factor
P11384229A1669|62 72|interaction
P11384229A1669|11 22|N63S mutation
P11384229A1669|37 49|VP5 background
P11384229A1669|87 112|beta-galactosidase activity
P11384229A1669|143 153|PR7 mutation
P11384576A1132|40 49|interferon
P11384576A1132|68 78|retinopathy
P11384576A1132|17 26|vision loss
P11384576A1132|2 9|addition
P11384880A0719|42 55|gene expression
P11384880A0719|3 11|mechanism
P11384880A0719|81 87|ZR-75-1
P11384880A0719|93 109|breast cancer cells
P11384880A0719|17 25|induction
P11384880A0719|28 40|3beta-HSD type
P11385840A1684|35 50|wastewater system
P11385840A1684|114 133|optimization routines
P11385840A1684|12 23|RTC algorithm
P11385840A1684|67 76|parameters
P11387208T0000|0 33|SKP1-SnRK protein kinase interactions
P11387208T0000|52 58|binding
P11387208T0000|62 84|plant SCF ubiquitin ligase
P11387351A0092|0 7|PATIENTS
P11387351A0092|106 110|2-CDA
P11387351A0092|37 44|December
P11387351A0092|193 195|MDS
P11387351A0092|116 123|children
P11387351A0092|77 104|analog 2-chlorodeoxyadenosine
P11387351A0092|26 29|June
P11387351A0092|184 191|syndrome
P11387351A0092|143 150|children
P11387351A0092|11 17|METHODS
P11387351A0092|164 166|AML
P11387351A0092|135 137|AML
P11387940A0647|3 10|severity
P11387940A0647|23 29|changes
P11387940A0647|57 66|percussion
P11387940A0647|46 54|magnitude
P11387950X0001|117 121|study
P11387950X0001|292 301|lung injury
P11387950X0001|102 111|objectives
P11387950X0001|304 306|ANP
P11387950X0001|388 399|TNF secretion
P11387950X0001|335 340|effect
P11387950X0001|19 28|ta chengchi
P11387950X0001|283 289|changes
P11387950X0001|151 171|leukocyte adhesiveness
P11387950X0001|209 213|stage
P11387950X0001|54 63|lung injury
P11387950X0001|357 365|Decoction
P11387950X0001|368 384|leukocyte adhesion
P11387950X0001|343 352|ta chengchi
P11387950X0001|195 197|TNF
P11387950X0001|245 247|ANP
P11387950X0001|12 16|study
P11387950X0001|142 148|changes
P11387950X0001|232 243|pancreatitis
P11387950X0001|33 41|decoction
P11387950X0001|268 275|relation
P11387950X0001|86 97|pancreatitis
P11387950X0001|175 193|tumor necrosis factor
P11389077A0000|1 7|variety
P11389077A0000|27 43|signaling pathways
P11389077A0000|95 104|regulators
P11389085A0290|0 6|TT cells
P11389085A0290|92 98|nucleus
P11389085A0290|78 81|RelA
P11389085A0290|35 46|MEN 2A type RET
P11389085A0290|83 85|p65
P11389085A0290|14 24|MTC cell line
P11389085A1032|116 118|RET
P11389085A1032|24 40|NF-kappaB activity
P11389085A1032|77 90|focus formation
P11389085A1032|121 131|NIH 3T3 cells
P11389085A1032|109 113|forms
P11389085A1032|50 58|cell death
P11389085A1032|61 67|TT cells
P11389085A1032|0 9|Inhibition
P11390395A1018|94 108|transactivation
P11390395A1018|13 28|HMGI-C expression
P11390395A1018|67 76|repression
P11390581A1203|44 51|sequence
P11390581A1203|8 14|finding
P11390581A1203|155 162|promoter
P11390581A1203|142 149|activity
P11390581A1203|64 71|Cp region
P11390581A1203|20 33|identification
P11390650A0562|90 95|region
P11390650A0562|125 133|P-1 domain
P11390650A0562|10 26|deletion mutations
P11390650A0562|98 103|SLP-76
P11390650A0562|63 68|domain
P11390663A1400|88 103|Gcn4p target genes
P11390663A1400|20 28|gcn4Delta
P11390663A1400|8 16|profiling
P11390663A1400|123 127|cells
P11390663A1400|57 81|induction pathway operating
P11390684A1170|0 7|Evidence
P11390684A1170|77 95|jadomycin B synthesis
P11390684A1170|47 60|jadM expression
P11390684A1170|13 33|Northern hybridization
P11391303A0807|46 73|intraobserver reproducibility
P11391303A0807|9 13|R-LHR
P11391303A0807|5 7|LHR
P11391303A0807|30 42|interobserver
P11391303A1023|90 115|Tl-201 lung uptake evaluation
P11391303A1023|28 41|LHR measurement
P11391303A1023|76 87|contribution
P11391303A1023|0 10|CONCLUSIONS
P11391303A1023|15 25|methodology
P11391531A1157|0 7|Mutation
P11391531A1157|55 63|induction
P11391531A1157|66 74|TNF-alpha
P11391531A1157|31 43|Mdr1b promoter
P11391531A1157|13 25|NF-kappaB site
P11391793A0856|175 180|clones
P11391793A0856|160 169|chromosome
P11391793A0856|21 30|complexity
P11391793A0856|99 101|SRO
P11391793A0856|87 89|map
P11391793A0856|60 65|tumors
P11391793A0856|171 173|PAC
P11391793A0856|43 48|region
P11391793A0856|127 139|bacteriophage
P11392306T0000|15 20|design
P11392306T0000|24 33|techniques
P11392306T0000|6 13|teaching
P11392772A0182|3 13|application
P11392772A0182|172 178|Dnieper
P11392772A0182|112 115|city
P11392772A0182|155 159|water
P11392772A0182|46 54|treatment
P11392772A0182|19 31|biotechnology
P11392772A0182|95 106|zone Telychka
P11392772A0182|206 210|times
P11392772A0182|135 141|content
P11392772A0182|60 77|surface storm waters
P11392772A0182|37 42|plants
P11392772A0182|118 121|Kyiv
P11392772A0182|144 152|petroleum
P11393463A0274|0 3|Data
P11393463A0274|223 231|occasions
P11393463A0274|151 164|informant group
P11393463A0274|138 145|interval
P11393463A0274|183 189|ratings
P11393463A0274|211 219|relatives
P11393463A0274|245 257|month interval
P11393463A0274|107 115|occasions
P11393463A0274|202 208|friends
P11393463A0274|34 47|student samples
P11393463A0274|67 67|n
P11393463A0274|166 166|n
P11393463A0274|61 65|group
P11393463A0274|84 103|NEO-PI-R self-ratings
P11393791A1153|0 19|Northern blot analysis
P11393791A1153|123 132|expression
P11393791A1153|93 103|osteoclasts
P11393791A1153|22 25|RNAs
P11393791A1153|168 190|polymerase chain reaction
P11393791A1153|62 66|Atp6i
P11393791A1153|31 36|number
P11393791A1153|226 233|analysis
P11393791A1153|199 203|assay
P11393791A1153|39 50|mouse tissues
P11393791A1153|192 197|RT-PCR
P11395469A1373|27 32|motifs
P11395469A1373|111 114|iron
P11395469A1373|7 14|mutation
P11395469A1373|93 102|regulation
P11395469A1373|105 108|sid2
P11395469A1373|54 63|regulation
P11395469A1373|66 69|sid1
P11396685A0477|185 191|cheeses
P11396685A0477|110 111|mg
P11396685A0477|88 93|sample
P11396685A0477|12 18|results
P11396685A0477|80 85|amount
P11396685A0477|136 146|information
P11396685A0477|167 175|compounds
P11396685A0477|159 164|groups
P11396685A0477|27 29|DTD
P11397652A0381|117 128|difficulties
P11397652A0381|69 79|test methods
P11397652A0381|31 41|spiral assay
P11397652A0381|182 191|volatility
P11397652A0381|193 196|etc.
P11397652A0381|99 105|variety
P11397652A0381|165 179|sample viscosity
P11397652A0381|146 163|sample availability
P11397652A0381|0 9|Guidelines
P11398134A1565|119 131|hyperuricemia
P11398134A1565|13 19|obesity
P11398134A1565|52 60|disorders
P11398134A1565|21 33|alcohol intake
P11398134A1565|106 116|development
P11398134A1565|2 11|conclusion
P11398134A1565|90 99|predictors
P11398899A1183|0 3|Fans
P11398899A1183|75 84|likelihood
P11398899A1183|20 26|windows
P11398899A1183|6 12|tunnels
P11398899A1183|91 107|PH3 concentrations
P11398899A1183|40 48|locations
P11398899A1183|118 122|areas
P11399064T0000|90 102|transcription
P11399064T0000|47 78|CCAAT/enhancer binding protein beta
P11399064T0000|80 88|C/EBP beta
P11399064T0000|30 37|pathways
P11399064T0000|0 13|Autoregulation
P11399834T0000|14 30|HCV seroconversion
P11399834T0000|8 11|case
P11399834T0000|63 77|HCV NAT screening
P11399834T0000|33 40|Portugal
P11399834T0000|49 60|introduction
P11400644A0435|15 27|uncertainties
P11400644A0435|33 41|estimates
P11400644A0435|55 61|sources
P11400644A0435|3 12|reflection
P11400644A0435|70 80|percentiles
P11400644A0435|117 124|g I-TEQ/y
P11400644A0435|83 96|PCDD/F releases
P11401105T0000|0 9|Gabapentin
P11401105T0000|26 34|myoclonus
P11401105T0000|37 50|cancer patients
P11401611A1703|15 27|meta-analysis
P11401611A1703|114 122|fractures
P11401611A1703|50 55|trials
P11401611A1703|91 99|reduction
P11401611A1703|58 60|HRT
P11401611A1703|0 10|CONCLUSIONS
P11402674T0000|0 28|Newcastle disease antibody titre
P11402674T0000|42 66|serum calcium concentration
P11403173A0192|1 5|total
P11403173A0192|10 17|patients
P11403173A0192|31 42|brain tumours
P11403663A0359|30 37|bearings
P11403663A0359|92 100|2-D theory
P11403663A0359|51 58|impeller
P11403663A0359|74 84|predictions
P11403663A0359|18 21|drag
P11403663A0359|3 6|lift
P11403719A1257|41 47|control
P11403719A1257|76 82|insulin
P11403719A1257|50 64|egr-1 expression
P11403719A1257|22 25|Gab1
P11403719A1257|3 9|results
P11404010A0235|42 47|repeat
P11404010A0235|11 19|triplexes
P11404010A0235|31 36|length
P11404016A1922|115 120|number
P11404016A1922|39 42|PKSs
P11404016A1922|156 171|peptide synthases
P11404016A1922|90 94|TE IIs
P11404016A1922|86 88|TEs
P11404016A1922|17 25|TE domains
P11404016A1922|173 176|NRPS
P11404016A1922|3 14|co-existence
P11404016A1922|130 139|polyketide
P11404019A0532|26 41|mGSTM2 regulation
P11404019A0532|73 86|promoter region
P11404019A0532|8 20|understanding
P11404312A0660|19 19|P
P11404312A0660|10 17|pmol/24 h
P11406007A0292|0 16|SELECTION CRITERIA
P11406007A0292|41 46|trials
P11406007A0292|157 161|years
P11406007A0292|128 135|outcomes
P11406007A0292|69 73|forms
P11406007A0292|56 59|IUSs
P11406007A0292|138 142|women
P11406007A0292|86 99|contraceptives
P11406025A0204|29 34|review
P11406025A0204|64 69|safety
P11406025A0204|50 62|effectiveness
P11406025A0204|73 85|acceptability
P11406025A0204|91 99|diaphragm
P11406025A0204|114 123|spermicide
P11406025A0204|14 22|objective
P11406025A0204|0 9|OBJECTIVES
P11406277A0598|28 35|elements
P11406277A0598|142 149|elements
P11406277A0598|154 161|activity
P11406277A0598|50 65|promoter activity
P11406277A0598|80 105|reporter expression activity
P11406277A0598|126 134|mutations
P11406277A0598|9 18|hypothesis
P11406277A0598|167 191|parent Hlx promoter sequence
P11406277A0598|108 115|segments
P11406642A0792|12 16|cases
P11406642A0792|43 47|genes
P11406642A0792|18 27|expression
P11407289A1507|78 85|BIS index
P11407289A1507|162 167|agents
P11407289A1507|40 49|anesthesia
P11407289A1507|0 10|CONCLUSIONS
P11407448A0815|251 264|speech training
P11407448A0815|49 56|patients
P11407448A0815|3 9|results
P11407448A0815|172 186|voice prosthesis
P11407448A0815|124 144|tract voice restoration
P11407448A0815|222 229|puncture
P11407448A0815|71 95|jejunum flap reconstruction
P11407650A0661|0 12|Hypercalcemia
P11407650A0661|115 115|%
P11407650A0661|142 149|patients
P11407650A0661|154 166|thyroid cancer
P11407650A0661|135 139|women
P11407650A0661|35 55|serum PTH concentration
P11407650A0661|73 91|hyperparathyroidism
P11407650A0661|122 125|none
P11407650A0661|103 112|BC patients
P11408099A0518|72 79|Se levels
P11408099A0518|22 33|correlations
P11408099A0518|53 57|weeks
P11408099A0518|114 114|r
P11408099A0518|89 89|r
P11408099A0518|122 122|P
P11408099A0518|82 87|kidney
P11408099A0518|108 112|heart
P11408099A0518|97 97|P
P11408099A0518|60 68|pregnancy
P11408338A1686|4 8|study
P11408338A1686|21 23|PSP
P11408338A1686|103 107|cases
P11408338A1686|93 100|majority
P11408338A1686|133 144|neurologists
P11408575A0000|120 123|form
P11408575A0000|105 107|Clb
P11408575A0000|50 59|activation
P11408575A0000|35 41|mitosis
P11408575A0000|26 30|entry
P11408575A0000|81 91|kinase Cdc28
P11408575A0000|97 103|cyclin B
P11408591A0000|71 75|cells
P11408591A0000|40 41|HA
P11408591A0000|17 26|production
P11408591A0000|49 54|effect
P11408591A0000|89 100|v-src mutants
P11408591A0000|29 38|hyaluronan
P11408591A0000|57 68|cell motility
P11408604A1440|157 164|pathways
P11408604A1440|31 32|2L
P11408604A1440|137 146|activation
P11408604A1440|149 154|ERK1/2
P11408604A1440|34 42|receptors
P11408604A1440|22 22|D
P11408604A1440|101 112|PDGF receptor
P11408604A1440|183 204|receptor tyrosine kinase
P11408604A1440|54 69|ERK kinase cascade
P11408604A1440|3 9|results
P11408604A1440|29 29|D
P11408604A1440|87 95|signaling
P11408774X0893|0 7|Karger AG
P11408774X0893|9 13|Basel
P11409425A0000|257 260|risk
P11409425A0000|100 125|tissue plasminogen activator
P11409425A0000|132 142|Stroke Trial
P11409425A0000|191 193|Apo
P11409425A0000|247 252|stroke
P11409425A0000|45 61|National Institute
P11409425A0000|127 130|t-PA
P11409425A0000|155 166|relationship
P11409425A0000|228 234|outcome
P11409425A0000|76 83|Diseases
P11409425A0000|314 324|t-PA therapy
P11409425A0000|94 98|NINDS
P11409425A0000|195 196|E2
P11409425A0000|293 300|response
P11409425A0000|12 24|plasma samples
P11409425A0000|276 285|hemorrhage
P11409425A0000|176 189|apolipoprotein
P11409425A0000|236 241|months
P11409425A0000|32 39|patients
P11409425A0000|201 214|Apo E4 phenotype
P11409425A0000|87 92|Stroke
P11410110A0190|0 3|NIRS
P11410110A0190|75 90|forearm blood flow
P11410110A0190|52 62|consumption
P11410110A0190|64 65|mV
P11410110A0190|107 114|subjects
P11410110A0190|92 94|FBF
P11410110A0190|67 67|O
P11410110A0190|29 39|measurement
P11410110A0190|42 48|muscle O
P11410563A0363|98 106|valve size
P11410563A0363|78 80|age
P11410563A0363|26 29|risk
P11410563A0363|154 164|risk factors
P11410563A0363|50 67|regression analysis
P11410563A0363|82 96|body surface area
P11410563A0363|108 128|shop order fracture rate
P11410563A0363|168 170|OSF
P11410563A0363|133 151|manufacturing period
P11410563A0363|18 23|factor
P11410664A0963|115 127|up-regulation
P11410664A0963|95 99|order
P11410664A0963|225 240|repair activities
P11410664A0963|181 183|BER
P11410664A0963|42 70|breast carcinoma MDA-MB231 cells
P11410664A0963|185 189|hOGG1
P11410664A0963|16 24|technique
P11410664A0963|211 218|reversal
P11410664A0963|158 165|activity
P11410664A0963|220 223|MGMT
P11410664A0963|193 199|APE/ref
P11410664A0963|140 143|step
P11410664A0963|90 92|MPG
P11410664A0963|6 11|report
P11410664A0963|146 148|BER
P11410679A0000|129 131|use
P11410679A0000|78 82|genes
P11410679A0000|92 114|LOX recognition sequences
P11410679A0000|152 161|constructs
P11410679A0000|12 21|alteration
P11410679A0000|63 75|rearrangement
P11410679A0000|38 51|Cre recombinase
P11410679A0000|183 185|cre
P11410679A0000|233 240|LOX sites
P11410679A0000|210 213|gene
P11410679A0000|216 223|interest
P11410679A0000|27 32|genome
P11411198A0711|119 131|stomach cancer
P11411198A0711|91 94|risk
P11411198A0711|54 66|Ashkenazi Jews
P11411198A0711|10 15|cancer
P11411198A0711|149 156|lymphoma
P11411623T0000|0 8|Influence
P11411623T0000|11 28|compression therapy
P11411623T0000|52 63|tissue injury
P11411623T0000|84 91|exercise
P11411623T0000|31 38|symptoms
P11411961A0735|0 24|Keratoconjunctivitis sicca
P11411961A0735|79 81|JRA
P11411961A0735|67 74|children
P11411961A0735|49 60|complication
P11411961A0735|121 127|battery
P11411961A0735|130 134|tests
P11413148A0573|0 14|STAT5A mutations
P11413148A0573|20 30|Src homology
P11413148A0573|33 35|SH2
P11413148A0573|76 98|tyrosine phosphorylation
P11413148A0573|40 49|SH3 domains
P11413277A1121|43 49|dose MTX
P11413277A1121|77 81|PCNSL
P11413277A1121|53 57|ara-C
P11413277A1121|20 31|chemotherapy
P11413277A1121|2 11|conclusion
P11413310A0148|0 5|RANTES
P11413310A0148|211 222|RSV infection
P11413310A0148|140 150|eosinophils
P11413310A0148|115 123|monocytes
P11413310A0148|79 89|CC chemokine
P11413310A0148|39 44|T-cell
P11413310A0148|20 29|activation
P11413310A0148|155 163|cell types
P11413310A0148|125 135|lymphocytes
P11413310A0148|192 201|infiltrate
P11413310A0148|176 179|lung
P11413319A0000|0 12|Reovirus mRNAs
P11413319A0000|62 68|absence
P11413319A0000|87 91|tails
P11413319A0000|43 51|host cells
P11413641A0373|57 67|quadrat area
P11413641A0373|49 54|effect
P11413641A0373|20 31|scale matters
P11413641A0373|0 7|Analyses
P11413760A0000|0 9|Myasthenia
P11413760A0000|65 74|antibodies
P11413760A0000|53 62|production
P11413760A0000|115 121|synapse
P11413760A0000|85 96|ACh receptors
P11413760A0000|30 36|disease
P11414754X1099|0 8|Copyright
P11414754X1099|13 25|Academic Press
P11415633A1253|80 90|compression
P11415633A1253|30 34|input
P11415633A1253|19 27|force data
P11415633A1253|54 58|model
P11415952A0369|0 5|Angina
P11415952A0369|9 19|persistence
P11415952A0369|93 117|electrocardiogram ischemia
P11415952A0369|66 75|infarction
P11415952A0369|32 43|associations
P11415952A0369|145 162|heart disease events
P11415952A0369|7 7|Q
P11415952A0369|86 91|angina
P11415952A0369|167 168|Q5
P11415958A0000|100 103|data
P11415958A0000|50 52|use
P11415958A0000|37 44|advances
P11415958A0000|77 84|analysis
P11415958A0000|63 73|methodology
P11415958A0000|9 14|decade
P11415958A0000|132 141|advantages
P11415958A0000|155 162|approach
P11416012A1982|44 45|LH
P11416012A1982|109 110|bp
P11416012A1982|196 198|PKI
P11416012A1982|48 59|contribution
P11416012A1982|112 126|reporter plasmid
P11416012A1982|78 82|drive
P11416012A1982|33 41|mediation
P11416012A1982|200 207|minigene
P11416012A1982|161 194|rabbit muscle protein kinase inhibitor
P11416012A1982|87 97|LDL receptor
P11416012A1982|235 254|sarcoma virus promoter
P11416012A2511|265 270|microM
P11416012A2511|369 378|derivative
P11416012A2511|340 345|microM
P11416012A2511|194 203|inhibitors
P11416012A2511|254 255|LY
P11416012A2511|234 243|wortmannin
P11416012A2511|82 92|stimulation
P11416012A2511|314 315|PD
P11416012A2511|388 393|microM
P11416012A2511|26 29|role
P11416012A2511|152 156|cells
P11416012A2511|35 62|insulin/IGF-I effector pathway
P11416012A2511|248 249|nM
P11416012A2511|332 336|U0126
P11416012A2511|95 123|LDL receptor promoter expression
P11416012A2511|380 384|U0124
P11416012A2511|324 329|microM
P11416012A2511|176 178|min
P11416012A2511|294 312|protein kinase kinase
P11416012A2511|353 358|latter
P11416012A2511|206 232|phophatidylinositol 3-kinase
P11416012T0000|74 80|insulin
P11416012T0000|177 204|phosphatidylinositol 3-kinase
P11416012T0000|112 118|porcine
P11416012T0000|95 101|hormone
P11416012T0000|24 33|activation
P11416012T0000|135 139|cells
P11416012T0000|162 174|protein kinase
P11416012T0000|42 71|density lipoprotein receptor gene
P11416012T0000|226 255|protein kinase signaling pathways
P11416012T0000|149 159|convergence
P11416132A1351|72 94|repeat binding activities
P11416132A1351|64 64|d
P11416132A1351|40 50|recognition
P11416132A1351|5 11|studies
P11416132A1351|66 67|GA
P11416132A1351|116 124|silencing
P11416132A1351|56 61|bxd PRE
P11416132A1351|70 70|n
P11416144A1324|87 95|mechanism
P11416144A1324|106 115|p53 protein
P11416144A1324|54 70|cell proliferation
P11416144A1324|39 44|ZBP-89
P11416144A1324|21 33|understanding
P11416144A1324|3 10|findings
P11416260A0000|149 160|data analysis
P11416260A0000|40 44|point
P11416260A0000|13 18|method
P11416260A0000|92 99|patients
P11416260A0000|57 64|activity
P11416393A0000|466 468|day
P11416393A0000|411 415|drugs
P11416393A0000|259 275|sodium restriction
P11416393A0000|156 165|body weight
P11416393A0000|181 184|risk
P11416393A0000|376 382|numbers
P11416393A0000|431 448|alcohol consumption
P11416393A0000|32 41|approaches
P11416393A0000|92 98|control
P11416393A0000|300 308|assurance
P11416393A0000|367 372|dosage
P11416393A0000|419 428|moderation
P11416393A0000|460 464|ounce
P11416393A0000|509 517|cessation
P11416393A0000|109 130|blood pressure elevation
P11416393A0000|336 343|pressure
P11416393A0000|134 148|weight reduction
P11416393A0000|187 198|hypertension
P11416393A0000|488 502|exercise program
P11416393A0000|287 287|g
P11416393A0000|228 236|morbidity
P11416393A0000|4 13|modalities
P11416393A0000|520 537|tobacco consumption
P11416393A0000|68 88|lifestyle modification
P11416393A0000|289 291|day
P11416393A0000|240 248|mortality
P11416650T0000|31 36|Update
P11416650T0000|16 27|Hypertension
P11416737T0000|0 4|Ga-67
P11416737T0000|8 25|Tl-201 scintigraphy
P11416737T0000|56 65|case report
P11416737T0000|42 53|plasmacytoma
P11416879A1589|44 59|ventilation modes
P11416879A1589|8 23|blood gas tensions
P11418130A0499|21 33|loxP sequences
P11418130A0499|66 78|recombination
P11418662A0917|101 109|NF-kappaB
P11418662A0917|13 19|portion
P11418662A0917|82 91|p50 subunit
P11418662A0917|22 26|Notch
P11418662A0917|40 52|p50 DNA binding
P11418662A0917|96 98|p65
P11418662A0917|28 29|IC
P11419938T0000|59 73|metal activation
P11419938T0000|14 20|changes
P11419938T0000|93 100|evidence
P11419938T0000|77 86|DNA binding
P11419938T0000|130 153|diphtheria toxin repressor
P11419938T0000|113 122|homologies
P11419938T0000|32 54|uptake regulation protein
P11420612A0303|129 136|interest
P11420612A0303|26 32|mapping
P11420612A0303|120 126|regions
P11420612A0303|36 52|sequencing efforts
P11420612A0303|90 93|maps
P11420612A0303|3 12|complement
P11420612A0303|97 108|sequence data
P11422200A0000|0 10|Granulocyte
P11422200A0000|29 34|factor
P11422200A0000|110 118|infection
P11422200A0000|42 55|administration
P11422200A0000|130 137|microbes
P11422200A0000|36 40|G-CSF
P11422200A0000|86 102|defence mechanisms
P11422757A0737|69 76|baseline
P11422757A0737|25 31|changes
P11422757A0737|5 15|individuals
P11422757A0737|58 66|ACR levels
P11423991A1393|113 121|responses
P11423991A1393|8 13|screen
P11423991A1393|55 65|p53 variants
P11423991A1393|34 38|yeast
P11423991A1393|22 31|p53 mutants
P11423991A1393|93 95|p53
P11423991A1393|146 160|cancer therapies
P11424992A0712|28 36|diagnoses
P11424992A0712|95 102|criteria
P11425076A0364|41 45|flows
P11425076A0364|137 143|inertia
P11425076A0364|161 185|perturbation theory results
P11425076A0364|62 66|alpha
P11425076A0364|50 55|result
P11425076A0364|89 94|values
P11425076A0364|100 113|Reynolds number
P11425076A0364|188 197|comparison
P11425076A0364|232 236|model
P11425076A0364|212 222|integration
P11425877A1026|0 4|Cells
P11425877A1026|150 157|decrease
P11425877A1026|12 15|p116
P11425877A1026|220 233|F-actin content
P11425877A1026|73 82|structures
P11425877A1026|186 196|aggregation
P11425877A1026|43 51|formation
P11425877A1026|96 104|reduction
P11425877A1026|32 37|defect
P11425877A1026|110 113|rate
P11425877A1026|163 172|efficiency
P11425877A1026|202 209|decrease
P11425877A1026|116 136|fluid phase pinocytosis
P11427329A1077|127 132|sample
P11427329A1077|108 108|N
P11427329A1077|79 79|r
P11427329A1077|75 77|VAS
P11427329A1077|101 101|r
P11427329A1077|3 10|validity
P11427329A1077|16 20|FPS-R
P11427329A1077|56 67|correlations
P11427329A1077|97 99|CAS
P11427329A1077|86 86|N
P11427611A0000|30 38|fumigatus
P11427611A0000|171 175|NCCLS
P11427611A0000|101 106|agents
P11427611A0000|235 246|phenyl-amino
P11427611A0000|74 81|compound
P11427611A0000|352 361|microscopy
P11427611A0000|248 255|carbonyl
P11427611A0000|282 284|XTT
P11427611A0000|313 325|determination
P11427611A0000|259 280|H-tetrazolium hydroxide
P11427611A0000|339 349|alterations
P11427611A0000|41 53|mulundocandin
P11427611A0000|151 169|Laboratory Standards
P11427611A0000|304 308|assay
P11427611A0000|177 187|M38-P method
P11427611A0000|123 139|National Committee
P11427611A0000|3 16|susceptibility
P11428276A0352|58 68|calcium salt
P11428276A0352|80 87|increase
P11428276A0352|9 13|Hoeve
P11428276A0352|90 99|phosphates
P11428276A0352|16 30|syndrome lesions
P11428276A0352|3 5|Van
P11428283A0228|42 48|stridor
P11428283A0228|12 17|infant
P11428283A0228|68 75|distress
P11428435A0446|0 5|DESIGN
P11428435A0446|21 31|chart review
P11428435A0446|39 46|patients
P11428435A0446|65 74|procedures
P11428435A0446|80 92|period January
P11428435A0446|99 106|December
P11428487T0000|20 30|association
P11428487T0000|53 64|vein stenosis
P11428487T0000|9 17|vein varix
P11428897A0318|220 223|CopG
P11428897A0318|196 201|repeat
P11428897A0318|68 76|target DNA
P11428897A0318|35 38|CopG
P11428897A0318|11 21|experiments
P11428897A0318|90 98|DNA ratios
P11428897A0318|131 135|turns
P11428897A0318|160 164|helix
P11428897A0318|82 88|protein
P11428897A0318|171 180|directions
P11428897A0318|231 236|target
P11428897A0318|145 148|face
P11429702A0917|165 178|K650E receptors
P11429702A0917|142 151|activation
P11429702A0917|232 254|receptor phosphorylation
P11429702A0917|196 205|aFGF ligand
P11429702A0917|107 118|FGFR3 mutants
P11429702A0917|157 161|Y373C
P11429702A0917|183 190|addition
P11429702A0917|225 229|level
P11429702A0917|85 90|levels
P11429702A0917|37 46|conditions
P11429702A0917|48 53|KMS-11
P11429702A0917|57 66|OPM-2 cells
P11430042A0000|135 140|liquid
P11430042A0000|11 14|text
P11430042A0000|86 102|tetrafluoroborate
P11430042A0000|19 40|Stille coupling reaction
P11430042A0000|142 145|RTIL
P11430042A0000|104 110|BMIM BF4
P11430042A0000|1 6|figure
P11430976X0000|70 79|substances
P11430976X0000|25 36|biosynthesis
P11430976X0000|39 59|woody plant biopolymers
P11430976X0000|7 12|issues
P11431348A0000|135 145|MAPK pathway
P11431348A0000|165 171|variety
P11431348A0000|22 46|checkpoint abrogator UCN-01
P11431348A0000|130 132|MEK
P11431348A0000|118 121|MAPK
P11431348A0000|104 116|protein kinase
P11431348A0000|179 195|leukemia cell lines
P11431348A0000|72 81|inhibitors
P11431348A0000|123 128|kinase
P11431348A0000|0 11|Interactions
P11431472A0540|47 47|d
P11431472A0540|87 87|A
P11431472A0540|45 45|K
P11431472A0540|20 28|Rab6A-GTP
P11431472A0540|52 57|microm
P11431472A0540|67 71|Rab1B
P11431472A0540|3 17|affinity binding
P11431857A0186|3 10|students
P11431857A0186|123 135|urine analysis
P11431857A0186|75 87|urine analysis
P11431857A0186|25 38|urine screening
P11431857A0186|56 59|time
P11431857A0186|94 97|days
P11432112A0000|71 71|h
P11432112A0000|47 60|embryo cleavage
P11432112A0000|11 19|objective
P11432112A0000|62 64|FEC
P11432112A0000|26 30|study
P11432112A0000|131 152|embryo selection process
P11432112A0000|108 111|ICSI
P11432112A0000|93 106|sperm injection
P11432112A0000|116 124|parameter
P11432112A0000|0 6|PURPOSE
P11432748T0000|0 9|Regulation
P11432748T0000|12 42|laminin beta2 chain gene expression
P11432748T0000|50 64|cancer cell lines
P11432776A0421|0 7|Northern
P11432776A0421|93 102|expression
P11432776A0421|113 118|muscle
P11432776A0421|11 29|Western blot analyses
P11432776A0421|46 50|Graf2
P11432776A0421|71 77|tissues
P11433014A0683|45 58|core histone H2A
P11433014A0683|90 92|MCB
P11433014A0683|61 63|H2B
P11433014A0683|37 42|fusion
P11433014A0683|79 82|tail
P11433014A0683|134 140|protein
P11433018A0756|112 120|stability
P11433018A0756|48 59|H/ACA snoRNAs
P11433018A0756|86 97|H/ACA snoRNPs
P11433018A0756|5 8|data
P11433018A0756|134 143|components
P11433018A0756|76 83|assembly
P11433018A0756|32 38|binding
P11433018A0756|41 45|Nhp2p
P11433024A0260|0 9|Telomerase
P11433024A0260|101 108|template
P11433024A0260|87 98|RNA component
P11433024A0260|68 78|chromosomes
P11433024A0260|13 36|ribonucleoprotein complex
P11433024A0260|61 63|DNA
P11433379A0000|0 2|SIT
P11433379A0000|115 125|lymphocytes
P11433379A0000|82 95|adaptor protein
P11433379A0000|33 46|adaptor protein
P11434084A0508|71 77|d-dimer
P11434084A0508|11 20|patients DD
P11434084A0508|40 54|microlatex tests
P11435428A0000|46 52|acetate
P11435428A0000|86 99|lipid synthesis
P11435428A0000|9 28|acetyl-CoA synthetase
P11435428A0000|64 68|cells
P11435428A0000|30 35|AceCS1
P11435428A0000|73 82|acetyl-CoA
P11435517A0396|85 85|P
P11435517A0396|102 106|diets
P11435517A0396|25 26|OM
P11435517A0396|72 73|GE
P11435517A0396|95 98|dogs
P11435517A0396|129 133|fiber
P11435517A0396|156 166|control diet
P11435517A0396|22 23|DM
P11435517A0396|49 51|TDF
P11435517A0396|5 19|digestibilities
P11435517A0396|65 70|energy
P11435517A0396|43 47|fiber
P11435517A0396|146 149|dogs
P11435517A0396|28 29|CP
P11435560A1322|83 95|target HFV mRNA
P11435560A1322|48 54|nucleus
P11435560A1322|13 16|data
P11435560A1322|77 80|fate
P11435560A1322|29 38|HFV R region
P11435578A0760|45 47|CRE
P11435578A0760|69 76|TGACGTCA
P11435578A0760|36 43|elements
P11435578A0760|78 86|consensus
P11435578A0760|151 158|TGACCTCA
P11435578A0760|5 8|TxRE
P11435578A0760|142 149|TGACGGCA
P11435578A0760|121 126|strain
P11435578A0760|133 140|AGACGTCA
P11435578A2231|148 160|transcription
P11435578A2231|64 72|enhancers
P11435578A2231|37 48|consensus CRE
P11435578A2231|82 88|binding
P11435578A2231|91 106|CREB/ATF proteins
P11435578A2231|124 133|repression
P11435578A2231|20 33|reconstitution
P11435605A0587|117 121|Tyr83
P11435605A0587|26 28|CAR
P11435605A0587|89 103|contact residues
P11435605A0587|72 77|Lys123
P11435605A0587|185 188|Ad12
P11435605A0587|109 113|Tyr80
P11435605A0587|152 169|binding interaction
P11435605A0587|181 183|Ad9
P11435605A0587|193 207|Ad41L fiber knobs
P11435605A0587|41 56|CAR residues Leu73
P11435605A0587|13 23|mutagenesis
P11435605A0587|177 179|Ad5
P11435605A0587|60 65|Lys121
P11435688A0262|56 65|N-terminus
P11435688A0262|45 50|domain
P11435688A0262|4 12|subfamily
P11435688A0262|91 111|transmembrane segments
P11435688A0262|15 19|genes
P11435688A0262|86 88|set
P11435983T0000|0 8|Tolerance
P11435983T0000|46 55|bone marrow
P11435983T0000|16 30|transplantation
P11435983T0000|78 86|follow-up
P11437439A0201|71 83|prestalk cells
P11437439A0201|63 68|subset
P11437439A0201|3 18|promoter activity
P11437439A0201|32 37|region
P11437660A1219|0 11|Substitution
P11437660A1219|62 81|phosphorylation sites
P11437660A1219|127 137|replication
P11437660A1219|33 42|C-terminus
P11437660A1219|111 123|transcription
P11437660A1219|103 108|effect
P11437660A1219|56 59|loss
P11437660A1219|14 27|serine residues
P11438651A1365|116 120|Orc2p
P11438651A1365|50 55|origin
P11438651A1365|137 156|replication initiator
P11438651A1365|123 131|component
P11438651A1365|75 95|replication initiation
P11438651A1365|32 34|HML
P11438651A1365|5 27|replication fork movement
P11438654A1237|27 37|adapter Gab1
P11438654A1237|70 73|PI3K
P11438654A1237|49 62|c-Met signaling
P11438654A1237|5 12|findings
P11438654A1237|83 111|c-Akt/Pak1 cell survival pathway
P11438666A0555|143 156|TFIID component
P11438666A0555|110 128|immunoprecipitation
P11438666A0555|61 76|plant homeodomain
P11438666A0555|31 33|TAF
P11438666A0555|18 29|mouse protein
P11438666A0555|78 80|PHD
P11438666A0555|54 56|HFD
P11438666A0555|82 87|finger
P11438838A0788|27 34|TAR decoy
P11438838A0788|73 76|U6-P
P11438838A0788|61 71|RNA promoter
P11438838A0788|8 16|inhibitor
P11438838A0788|47 48|U6
P11439343A0785|2 9|contrast
P11439343A0785|36 47|Pc protein M33
P11439343A0785|12 15|MPc3
P11439343A0785|67 69|AF9
P11439343A0785|17 20|data
P11441163T0000|0 9|Foreigners
P11441311X0001|180 182|NHL
P11441311X0001|9 15|results
P11441311X0001|69 78|BACKGROUND
P11441311X0001|115 134|chemotherapy regimens
P11441311X0001|170 178|lymphomas
P11441311X0001|148 154|factors
P11441311X0001|89 95|results
P11441311X0001|20 26|MACOP-B
P11441311X0001|30 45|radiation therapy
P11441311X0001|59 67|lymphomas
P11441952A0414|117 126|difference
P11441952A0414|153 153|b
P11441952A0414|68 77|percentage
P11441952A0414|42 45|rats
P11441952A0414|93 100|controls
P11441952A0414|17 22|months
P11441952A0414|180 183|test
P11441952A0414|205 207|TBI
P11441952A0414|9 9|D
P11441952A0414|138 151|months post-TBI
P11441952A0414|162 174|avoidance test
P11441952A0414|80 88|avoidance
P11441952A0414|4 7|days
P11441974A0320|40 51|hemolymph PO2
P11441974A0320|19 27|migration
P11441974A0320|123 129|reserve
P11441974A0320|68 70|kPa
P11441974A0320|156 161|mmol x l
P11441974A0320|5 7|end
P11441974A0320|78 87|hemocyanin
P11441974A0320|14 16|day
P11443509A0293|0 5|DESIGN
P11443509A0293|78 94|Examination Survey
P11443509A0293|36 36|y
P11443509A0293|126 130|Study
P11443509A0293|18 28|cohort study
P11443509A0293|96 101|NHANES
P11443509A0293|56 74|First National Health
P11443509A0293|46 51|period
P11443509A0293|132 136|NHEFS
P11443999A0573|0 19|Mean Hg concentrations
P11443999A0573|33 36|mice
P11443999A0573|50 59|Isle Royale
P11443999A0573|25 30|livers
P11443999A0573|128 145|government agencies
P11443999A0573|167 177|consumption
P11443999A0573|43 47|sites
P11443999A0573|85 85|P
P11443999A0573|96 111|Hg concentrations
P11444762A0373|84 89|action
P11444762A0373|21 29|proposals
P11444762A0373|77 81|onset
P11444762A0373|57 60|data
P11444762A0373|47 54|analysis
P11445008A0816|32 41|comparison
P11445008A0816|52 71|FGFR expression levels
P11445008A0816|113 126|RNA pool samples
P11445008A0816|90 96|RNA pool
P11445008A0816|3 7|assay
P11447490A0598|41 45|fluid
P11447490A0598|66 75|assessment
P11447490A0598|18 25|effusion
P11447490A0598|3 8|amount
P11448051A0093|188 194|polymer
P11448051A0093|196 208|Eudragit RS100
P11448051A0093|124 129|matrix
P11448051A0093|155 158|NaCl
P11448051A0093|53 72|intestine transit time
P11448051A0093|3 8|system
P11448051A0093|160 167|mannitol
P11448051A0093|172 176|Emdex
P11448051A0093|149 153|agent
P11448051A0093|100 103|core
P11449014A0000|0 13|STUDY OBJECTIVE
P11449014A0000|108 113|trials
P11449014A0000|183 185|E/B
P11449014A0000|115 118|CCTs
P11449014A0000|53 59|aspects
P11449014A0000|72 78|quality
P11449014A0000|19 23|study
P11449014A0000|152 181|epidemiologist/biostatistician
P11449014A0000|135 147|participation
P11449014A0000|122 129|relation
P11450490A0565|159 163|range
P11450490A0565|94 98|lines
P11450490A0565|41 46|acuity
P11450490A0565|54 71|range hand motions/0
P11450490A0565|146 151|acuity
P11450490A0565|175 175|P
P11450776T0000|18 22|group
P11450776T0000|37 47|peritonitis
P11450776T0000|5 8|case
P11451447A0205|0 4|Gimpl
P11451447A0205|6 7|F.
P11451682A0190|54 86|benzimidazole carbamate derivatives
P11451682A0190|10 21|chemotherapy
P11451682A0190|38 51|administration
P11451682A0190|24 25|AE
P11451682A0190|108 118|albendazole
P11451682A0190|94 104|mebendazole
P11451995T0000|72 77|member
P11451995T0000|24 31|analysis
P11451995T0000|83 130|isoprenylcysteine carboxyl methyltransferase family
P11451995T0000|57 62|Ste14p
P11454004T0000|120 142|hormone-response element
P11454004T0000|96 109|identification
P11454004T0000|58 94|glycerol-3-phosphate dehydrogenase gene
P11454004T0000|158 167|promoter B.
P11454004T0000|8 17|regulation
P11454004T0000|28 36|promoters
P11454004T0000|42 44|rat
P11454190A0000|16 25|Hepatitis C
P11454190A0000|41 57|fatty liver disease
P11454190A0000|59 62|NAFL
P11454190A0000|107 118|United States
P11454190A0000|90 101|liver disease
P11454190A0000|83 87|forms
P11454190A0000|0 14|BACKGROUND/AIMS
P11454239A0478|245 249|alpha
P11454239A0478|79 105|Principal Components Analysis
P11454239A0478|109 136|Discriminant Function Analysis
P11454239A0478|27 31|ANOVA
P11454239A0478|172 176|alpha
P11454239A0478|190 200|Sensitivity
P11454239A0478|166 170|alpha
P11454239A0478|234 242|Chronbach
P11454239A0478|261 265|scale
P11454239A0478|156 163|Cronbach
P11454239A0478|143 153|calculation
P11454239A0478|36 77|Pearson Product Moment Correlation Coefficient
P11454239A0478|11 18|Analysis
P11454239A0478|204 214|specificity
P11454239A0478|178 184|RESULTS
P11454703A0000|45 55|maintenance
P11454703A0000|196 208|tumorigenesis
P11454703A0000|129 133|cells
P11454703A0000|72 85|chromosome ends
P11454703A0000|67 69|DNA
P11454703A0000|24 30|complex
P11454703A0000|3 12|telomerase
P11454703A0000|172 186|immortalization
P11456259A0142|44 47|TBII
P11456259A0142|10 42|TSH binding inhibitor immunoglobulin
P11456259A0142|65 65|%
P11456259A0142|75 86|presentation
P11456259A0142|102 106|weeks
P11456259A0142|3 7|titer
P11456259A0142|98 98|%
P11457139A0604|103 108|GlcNAc
P11457139A0604|18 20|CVN
P11457139A0604|70 75|GlcNAc
P11457139A0604|56 66|affinity Man
P11457139A0604|97 99|Man
P11457139A0604|3 9|results
P11457139A0604|85 94|D1D3 isomer
P11459048A0485|27 39|uncertainties
P11459048A0485|79 88|atmosphere
P11459048A0485|93 97|Venus
P11459048A0485|63 69|planets
P11459048A0485|45 50|models
P11459048A0485|132 145|rotation states
P11459304T0078|0 19|Enantiomer separation
P11459304T0078|65 70|plasma
P11459304T0078|36 57|O-desmethylvenlafaxine
P11459304T0078|22 32|venlafaxine
P11459794A1172|0 10|TE-671 cells
P11459794A1172|110 124|GnRH-II promoter
P11459794A1172|34 52|cAMP response element
P11459794A1172|97 104|activity
P11459794A1172|59 68|constructs
P11459960A1109|67 76|heat labile
P11459960A1109|32 41|components
P11459960A1109|46 49|heat
P11459962A0785|186 191|growth
P11459962A0785|133 140|degrees C
P11459962A0785|57 69|repair pathway
P11459962A0785|162 169|degrees C
P11459962A0785|37 41|Rad52
P11459962A0785|97 113|rad27 Delta strains
P11459962A0785|171 182|temperatures
P11459962A0785|145 158|semipermissive
P11459962A0785|27 31|genes
P11459962A0785|87 94|survival
P11460035A0548|74 85|imputability
P11460035A0548|9 12|case
P11460035A0548|53 63|fluvoxamine
P11460035A0548|37 49|carbamazepine
P11460035A0548|18 35|hydroxychloroquine
P11461595A0000|102 104|B+B
P11461595A0000|76 90|coalescence type
P11461595A0000|142 146|flows
P11461595A0000|93 100|reaction
P11461595A0000|108 108|B
P11461595A0000|48 56|particles
P11461595A0000|61 67|inertia
P11461595A0000|16 31|reaction kinetics
P11462004A0886|56 64|advantage
P11462004A0886|24 32|infection
P11462004A0886|3 6|role
P11462004A0886|96 97|N.
P11462004A0886|80 94|complementation
P11462004A0886|67 69|NLS
P11462004A0886|12 17|Vp1 DBD
P11462004A1500|171 173|Vp1
P11462004A1500|77 79|Vp2
P11462004A1500|64 70|nucleus
P11462004A1500|27 30|Vp1s
P11462004A1500|157 168|localization
P11462004A1500|134 139|signal
P11462004A1500|83 85|Vp3
P11462004A1500|114 117|NLS1
P11462024A0306|0 2|Zhu
P11462024A0306|4 5|V.
P11462952A1040|59 62|mU/L
P11462952A1040|81 84|mU/L
P11462952A1040|27 31|range
P11462952A1040|39 42|mU/L
P11462952A1040|7 19|gastrin levels
P11462952A1040|71 74|mean
P11463359A0167|18 32|phorbol ester PMA
P11463359A0167|165 182|H4IIE hepatoma cells
P11463359A0167|127 140|G6Pase promoter
P11463359A0167|115 121|control
P11463359A0167|93 106|luciferase gene
P11463359A0167|80 89|expression
P11463834A0606|115 120|region
P11463834A0606|90 95|region
P11463834A0606|37 46|amino acids
P11463834A0606|7 25|deletion mutagenesis
P11463834A0606|124 137|Tax interaction
P11463834A0606|98 100|CR2
P11463834A0606|59 61|CBP
P11464997A0566|84 89|family
P11464997A0566|61 70|counseling
P11464997A0566|25 33|diagnosis
P11464997A0566|51 57|patient
P11464997A0566|37 45|treatment
P11464997A0566|4 12|knowledge
P11465518A0000|0 9|BACKGROUND
P11465518A0000|47 59|investigators
P11465518A0000|164 174|individuals
P11465518A0000|88 91|ways
P11465518A0000|41 44|part
P11465518A0000|109 118|treatments
P11465518A0000|66 71|public
P11465518A0000|28 35|interest
P11465518A0000|188 192|risks
P11465655A0439|98 103|mg/day
P11465655A0439|77 82|mg/day
P11465655A0439|9 12|week
P11465655A0439|111 114|week
P11465655A0439|69 72|dose
P11465655A0439|32 49|antagonist atenolol
P11465844T0000|74 88|Rickettsia typhi
P11465844T0000|108 135|Ehrlichia phagocytophila group
P11465844T0000|24 39|Kawasaki syndrome
P11465844T0000|43 51|infection
P11465844T0000|56 72|Rickettsia conorii
P11465844T0000|6 16|association
P11465844T0000|90 105|Coxiella burnetii
P11465844T0000|0 3|Lack
P11466227A1665|71 72|EB
P11466227A1665|75 90|mTf-CAT construct
P11466227A1665|56 65|activation
P11466227A1665|33 38|effect
P11466227A1665|114 123|activation
P11466227A1665|3 10|presence
P11466227A1665|13 20|AS-oligo
P11467349A0452|18 21|task
P11467349A0452|37 44|measures
P11467349A0452|47 56|ISF glucose
P11468958A0122|141 149|donations
P11468958A0122|220 227|concerns
P11468958A0122|79 84|recall
P11468958A0122|87 91|blood
P11468958A0122|154 164|individuals
P11468958A0122|126 133|decision
P11468958A0122|97 101|donor
P11468958A0122|244 246|CJD
P11468958A0122|177 189|travel history
P11468958A0122|29 42|policy analysis
P11468958A0122|64 72|decisions
P11468958A0122|11 17|results
P11468958A0122|195 196|UK
P11468958A0122|113 115|CJD
P11469701A0377|76 89|insulin therapy
P11469701A0377|91 95|CIIIT
P11469701A0377|105 111|insulin
P11469701A0377|155 174|insulin concentration
P11469701A0377|186 189|vein
P11469701A0377|8 15|approach
P11469701A0377|18 38|insulin administration
P11469701A0377|124 130|fashion
P11469737A1791|73 73|%
P11469737A1791|89 92|test
P11469737A1791|68 68|%
P11469737A1791|109 116|recovery
P11469737A1791|22 25|test
P11469737A1791|2 6|visit
P11469737A1791|40 61|muscle function recovery
P11469853A0702|101 105|yeast
P11469853A0702|12 17|system
P11469853A0702|21 35|domain shuffling
P11469853A0702|60 68|C1 domains
P11469853A0702|50 57|function
P11469853A0702|78 86|Raf kinase
P11469853A0702|90 98|rat PKC eta
P11469853A1053|29 36|evidence
P11469853A1053|100 107|C1 domain
P11469853A1053|110 114|yeast
P11469853A1053|87 94|function
P11469853A1053|62 67|GTPase
P11469853A1053|16 19|data
P11469853A1053|41 51|interaction
P11469926T0000|43 53|crystal ball
P11469926T0000|0 25|Breast cancer risk assessment
P11469970A0873|0 7|Patients
P11469970A0873|126 132|ampulla
P11469970A0873|51 55|trial
P11469970A0873|12 15|type
P11469970A0873|37 48|hyperalgesia
P11469970A0873|96 118|botulinum toxin injection
P11469970A0873|19 21|SOD
P11469970A0873|180 186|therapy
P11469970A0873|58 72|antidepressants
P11469970A0873|87 91|trial
P11470914A0305|13 16|Rac1
P11470914A0305|47 53|nucleus
P11470914A0305|24 41|STAT3 translocation
P11470914A0305|83 96|gene expression
P11470914A0305|3 10|activity
P11471077A0382|71 74|TRA2
P11471077A0382|88 94|results
P11471077A0382|124 129|survey
P11471077A0382|101 103|TRA
P11471077A0382|55 61|results
P11471077A0382|64 67|TRA1
P11471077A0382|36 44|variation
P11471077A0382|28 33|amount
P11471077A0382|0 6|RESULTS
P11471231A0964|165 174|procedures
P11471231A0964|101 108|spectrum
P11471231A0964|58 68|differences
P11471231A0964|2 9|addition
P11471231A0964|16 23|patients
P11472523A0535|44 55|inactivation
P11472523A0535|11 26|Extrusion cooking
P11472523A0535|94 107|metabisulphite
P11472523A0535|58 60|DON
P11472523A0535|75 79|value
P11472523A0535|83 86|AFB1
P11472523A0535|0 9|CONCLUSION
P11472696A0387|3 13|differences
P11472696A0387|78 80|ACS
P11472696A0387|50 57|patients
P11472696A0387|25 27|CRP
P11472696A0387|19 23|CPIgG
P11472696A0387|32 47|fibrinogen levels
P11473254A0000|0 3|NaeI
P11473254A0000|32 44|topoisomerase
P11473254A0000|48 68|recombinase activities
P11473254A0000|11 25|DNA endonuclease
P11473254A0000|74 83|Lys residue
P11473254A0000|100 102|Leu
P11473261A0587|0 3|Mss4
P11473261A0587|68 70|GEF
P11473261A0587|36 66|guanine nucleotide exchange factor
P11474642A1451|30 39|resistance
P11474642A1451|94 100|control
P11474642A1451|49 61|hexamethonium
P11474642A1451|65 70|mm Hg ml
P11474642A1451|3 12|decrements
P11474642A1451|76 78|min
P11478627A0573|82 95|transformation
P11478627A0573|63 64|Y1
P11478627A0573|145 153|criterion
P11478627A0573|51 57|optimum
P11478627A0573|73 74|Yn
P11478627A0573|109 116|property
P11478627A0573|66 67|Y2
P11478627A0573|35 40|search
P11478627A0573|133 137|scale
P11478627A0573|3 22|desirability function
P11478627A0573|59 59|D
P11479104A0446|164 168|woman
P11479104A0446|239 243|cause
P11479104A0446|115 124|CONCLUSION
P11479104A0446|129 136|presence
P11479104A0446|77 84|criteria
P11479104A0446|45 52|antibody
P11479104A0446|154 160|disease
P11479104A0446|196 204|clinician
P11479104A0446|96 113|lupus erythematosis
P11479104A0446|173 175|POF
P11479501A0744|0 6|RESULTS
P11479501A0744|123 123|%
P11479501A0744|60 68|variation
P11479501A0744|129 146|St Jude Medical valve
P11479501A0744|70 77|SD/mean x
P11479501A0744|95 104|valve sizes
P11479501A0744|156 156|%
P11479501A0744|47 57|coefficient
P11479501A0744|118 118|%
P11479501A0744|81 81|%
P11479501A0744|161 161|%
P11479501A0744|28 39|distribution
P11479501A0744|167 181|Omnicarbon valve
P11480490A0443|73 79|current
P11480490A0443|68 68|I
P11480490A0443|97 106|occurrence
P11480490A0443|58 65|blockade
P11480490A0443|109 118|arrhythmia
P11480490A0443|70 71|Kr
P11480490A0443|29 33|signs
P11480497T0000|0 6|Effects
P11480497T0000|83 88|memory
P11480497T0000|22 32|JP-8 jet fuel
P11480497T0000|94 96|rat
P11480497T0000|61 67|battery
P11480497T0000|72 79|learning
P11480555A0928|15 22|ceramide
P11480555A0928|36 42|fixture
P11480555A0928|55 63|cell death
P11480555A0928|3 12|production
P11481625A0202|103 105|MIU
P11481625A0202|127 146|peginterferon alfa-2b
P11481625A0202|124 125|QW
P11481625A0202|80 100|interferon alfa-2b dose
P11481625A0202|23 30|subjects
P11481625A0202|161 169|microg/kg
P11481625A0202|76 78|TIW
P11484028T0000|2 14|cross purposes
P11484578A1132|0 9|CONCLUSION
P11484578A1132|37 51|measurement data
P11484578A1132|67 72|method
P11484578A1132|141 153|design program
P11484578A1132|103 108|object
P11484578A1132|21 31|differences
P11484578A1132|82 96|measurement data
P11486032A1261|74 78|RUNX1
P11486032A1261|108 114|E2A-HLF
P11486032A1261|8 27|transcription factors
P11486032A1261|62 68|protein
P11486141A0424|72 76|power
P11486141A0424|127 133|sources
P11486141A0424|45 52|students
P11486141A0424|36 42|outcome
P11486141A0424|136 140|error
P11486141A0424|4 10|factors
P11486141A0424|84 95|meta analysis
P11486399A0000|103 109|disease
P11486399A0000|27 36|epirubicin
P11486399A0000|67 80|salvage regimen
P11486399A0000|50 52|IEV
P11486399A0000|40 48|etoposide
P11486399A0000|3 13|combination
P11486399A0000|16 25|ifosfamide
P11486476A0147|199 208|proportion
P11486476A0147|125 133|myoglobin
P11486476A0147|282 290|admission
P11486476A0147|52 66|characteristics
P11486476A0147|223 225|ACS
P11486476A0147|69 76|patients
P11486476A0147|211 218|patients
P11486476A0147|108 123|markers troponin T
P11486476A0147|183 191|chest pain
P11486476A0147|81 89|chest pain
P11486476A0147|237 243|markers
P11486476A0147|269 279|information
P11486476A0147|12 16|trial
P11486476A0147|137 145|CK-MB mass
P11486476A0147|94 98|value
P11486476A1512|73 81|diagnosis
P11486476A1512|36 44|myoglobin
P11486476A1512|105 107|ECG
P11486476A1512|24 32|CK-MB mass
P11486476A1512|7 22|markers troponin T
P11486476A1512|84 92|chest pain
P11489597A0379|117 123|fetuses
P11489597A0379|38 44|females
P11489597A0379|105 111|outcome
P11489597A0379|2 12|termination
P11489597A0379|55 59|group
P11489597A0379|168 180|malformations
P11489597A0379|85 90|status
P11489597A0379|14 15|gd
P11489597A0561|45 54|weight gain
P11489597A0561|112 112|%
P11489597A0561|24 33|body weight
P11489597A0561|11 15|death
P11489597A0561|87 100|pregnancy rates
P11489597A0561|73 76|dose
P11489597A0561|120 124|group
P11490862A0141|120 126|support
P11490862A0141|89 99|bone anchors
P11490862A0141|25 45|bladder neck suspension
P11490862A0141|12 22|development
P11490862A0141|57 70|Stamey-Pereyra
P11490862A0141|75 77|use
P11494391A0579|41 60|artery-alone ALT graft
P11494391A0579|79 87|structure
P11494391A0579|105 109|month
P11494391A0579|128 140|bile secretion
P11494391A0579|3 9|results
P11494391A0579|28 28|%
P11495833T0000|67 71|model
P11495833T0000|13 18|impact
P11495833T0000|90 99|properties
P11495833T0000|39 43|means
P11495920A0504|41 46|region
P11495920A0504|52 61|CYP3A4 gene
P11495920A0504|91 106|enhancer activity
P11495920A0504|7 18|pair mismatch
P11496495A0000|43 52|conditions
P11496495A0000|16 23|analysis
P11496495A0000|108 115|children
P11496495A0000|64 76|possibilities
P11496495A0000|3 9|authors
P11496495A0000|102 105|care
P11496617A0301|0 6|METHODS
P11496617A0301|276 286|anaesthesia
P11496617A0301|301 305|mg DHB
P11496617A0301|330 338|induction
P11496617A0301|180 186|minutes
P11496617A0301|155 166|mg dolasetron
P11496617A0301|205 215|anaesthesia
P11496617A0301|229 240|mg dolasetron
P11496617A0301|25 32|patients
P11496617A0301|194 202|induction
P11496617A0301|372 376|group
P11496617A0301|10 15|female
P11496617A0301|43 56|thyroid surgery
P11496617A0301|217 221|group
P11496617A0301|364 370|placebo
P11496617A0301|265 273|induction
P11496617A0301|353 357|group
P11496617A0301|341 351|anaesthesia
P11496617A0301|288 292|group
P11496617A0301|145 151|regimes
P11498795A0716|61 75|phosphorylation
P11498795A0716|81 89|RB protein
P11498795A0716|115 130|S phase transition
P11498795A0716|103 107|delay
P11498795A0716|8 18|progression
P11498795A0716|34 41|G1-phase
P11500377A0518|43 52|Wnt pathway
P11500377A0518|2 8|mammals
P11500377A0518|28 37|repressors
P11500512A0000|73 91|transporter proteins
P11500512A0000|114 124|macrophages
P11500512A0000|25 30|member
P11500512A0000|8 16|ABCG1 gene
P11500512A0000|60 70|superfamily
P11500512A0000|141 150|oxysterols
P11500512A0000|47 54|cassette
P11500512A0000|56 58|ABC
P11500571A0976|15 24|expression
P11500571A0976|53 58|pollen
P11500571A0976|27 44|NtmybAS transcripts
P11500571A0976|95 100|pollen
P11500571A0976|60 75|gPAL1 transcripts
P11500913A1238|0 11|C/EBPbeta LIP
P11500913A1238|48 62|beta-casein mRNA
P11500913A1238|129 136|hormones
P11500913A1238|26 34|HC11 cells
P11500913A1238|109 116|response
P11500913A1238|81 105|cell differentiation marker
P11502738A1457|61 67|mutants
P11502738A1457|9 15|effects
P11502738A1457|92 99|bp region
P11502738A1457|105 120|cyclin D1 promoter
P11502738A1457|32 41|inhibitors
P11502758A0869|45 48|role
P11502758A0869|52 56|LAD-1
P11502758A0869|66 78|FGFR signaling
P11502758A0869|5 12|findings
P11502778A0941|201 210|pmol/liter
P11502778A0941|109 113|rates
P11502778A0941|67 76|pmol/liter
P11502778A0941|35 49|estradiol levels
P11502778A0941|127 132|levels
P11502778A0941|179 193|estradiol levels
P11502778A0941|116 123|bone loss
P11502778A0941|135 155|bone resorption markers
P11502778A0941|58 63|median
P11502778A0941|80 84|pg/ml
P11502778A0941|160 162|men
P11502778A0941|16 18|men
P11504545A0393|0 10|Competition
P11504545A0393|42 58|immunoshift assays
P11504545A0393|26 38|mobility shift
P11504545A0393|98 105|extracts
P11504545A0393|108 111|HeLa
P11504545A0393|115 123|CV-1 cells
P11504545A0393|72 81|NF1 factors
P11504545A0393|133 139|BKV-MLP
P11504709A0981|153 162|activation
P11504709A0981|67 69|TPO
P11504709A0981|62 64|PMA
P11504709A0981|110 117|promoter
P11504709A0981|90 96|Ets site
P11504709A0981|4 8|study
P11504709A0981|46 53|response
P11504709A0981|120 123|GPIX
P11504709A0981|34 43|expression
P11504709A0981|199 204|kinase
P11505407A0461|0 6|RESULTS
P11505407A0461|64 68|cells
P11505407A0461|123 130|TNFalpha
P11505407A0461|51 55|EpCAM
P11505407A0461|41 48|activity
P11505407A0461|19 26|fragment
P11505407A0461|98 121|tumor necrosis factor alpha
P11509266A0955|74 76|BPF
P11509266A0955|96 96|P
P11509266A0955|171 178|survival
P11509266A0955|159 168|predictors
P11509266A0955|78 78|P
P11509266A0955|130 130|P
P11509266A0955|92 94|age
P11509266A0955|49 49|P
P11509266A0955|17 47|hazards regression adenocarcinoma
P11509266A0955|124 128|stage
P11509266A0955|2 4|Cox
P11509266A0955|61 71|development
P11509615T0000|89 100|IL-2 receptor
P11509615T0000|58 75|T cell proliferation
P11509615T0000|0 27|Phosphatidylinositol 3-kinase
P11509673A0574|158 159|AA
P11509673A0574|25 32|BM3 cells
P11509673A0574|78 84|F87V BM3
P11509673A0574|11 23|transfectants
P11509673A0574|148 156|14,15-EET
P11509673A0574|172 180|apoptosis
P11509673A0574|138 141|acid
P11509673A0574|215 223|apoptosis
P11509673A0574|60 76|P450 AA epoxygenase
P11511544T0000|88 97|heat stress
P11511544T0000|63 73|specificity
P11511544T0000|77 85|responses
P11511544T0000|3 12|loop domain
P11511544T0000|15 42|heat shock transcription factor
P11512925A0000|0 16|EXAFS measurements
P11512925A0000|108 116|structure
P11512925A0000|66 71|alloys
P11512925A0000|124 129|Ge atom
P11512925A0000|83 86|time
P11512925A0000|30 33|edge
P11513121T0000|134 138|PCOCs
P11513121T0000|51 75|quantum chemical parameters
P11513121T0000|35 43|QSAR model
P11513121T0000|11 15|study
P11513121T0000|89 91|BCF
P11513121T0000|124 132|compounds
P11513121T0000|19 32|robustness test
P11513180A1257|57 58|CT
P11513180A1257|8 12|cases
P11513180A1257|24 32|polyposis
P11513180A1257|34 37|none
P11513180A1257|90 94|bowel
P11513579A0372|18 23|system
P11513579A0372|75 81|Rho-GDI
P11513579A0372|142 157|complex formation
P11513579A0372|129 139|interaction
P11513579A0372|48 51|Rac1
P11513579A0372|107 110|role
P11516890A0236|44 49|system
P11516890A0236|40 42|CYP
P11516890A0236|24 38|cytochrome P-450
P11516890A0236|51 61|venlafaxine
P11516890A0236|79 81|3A4
P11516890A0236|109 113|SSRIs
P11516890A0236|94 99|extent
P11516890A0236|70 75|CYP 2D6
P11517190A0352|0 7|Analysis
P11517190A0352|150 159|expression
P11517190A0352|91 97|TATA box
P11517190A0352|40 47|presence
P11517190A0352|122 129|elements
P11517190A0352|109 111|cis
P11517190A0352|182 188|element
P11517190A0352|71 79|start site
P11517190A0352|13 28|promoter sequence
P11517190T0000|66 78|transcription
P11517190T0000|13 20|promoter
P11517190T0000|26 39|rat ER alpha gene
P11517190T0000|89 96|receptor
P11517269A0472|0 4|Pitx2
P11517269A0472|24 44|differentiation defect
P11517269A0472|196 200|genes
P11517269A0472|110 116|mutants
P11517269A0472|67 78|axon guidance
P11517269A0472|92 101|phenotypes
P11517269A0472|151 162|conservation
P11517269A0472|133 138|degree
P11517399A0858|156 166|splice sites
P11517399A0858|190 196|species
P11517399A0858|173 182|generation
P11517399A0858|188 188|T
P11517399A0858|25 41|protein expression
P11517399A0858|136 146|utilization
P11517399A0858|111 122|acceptor site
P11517399A0858|18 21|mRNA
P11517399A0858|91 98|mutation
P11517399A0858|104 104|T
P11517399A0858|54 60|mutants
P11517399A0858|3 10|patterns
P11517445A0221|16 22|cholera
P11517445A0221|9 13|cases
P11517445A0221|35 46|V. cholerae O1
P11518505A0107|74 79|organs
P11518505A0107|64 70|tissues
P11518868A0559|43 54|risk behavior
P11518868A0559|65 73|knowledge
P11518868A0559|25 31|history
P11518868A0559|79 93|hepatitis C virus
P11518868A0559|98 128|healthcare provider communication
P11519466A0196|37 42|impact
P11519466A0196|12 15|diet
P11520436A0705|84 93|connection
P11520436A0705|51 54|mice
P11520436A0705|101 109|infection
P11520436A0705|5 14|BALB/c mice
P11520436A0705|43 48|strain
P11520436A0705|64 70|studies
P11520436A0705|132 137|asthma
P11520436A0705|114 120|T. canis
P11521191A0000|142 156|phosphorylation
P11521191A0000|63 83|phosphorylation status
P11521191A0000|38 50|12S E1A protein
P11521191A0000|93 96|p107
P11521191A0000|124 132|cell cycle
P11521191A0000|112 118|changes
P11521191A0000|162 182|retinoblastoma protein
P11521191A0000|86 89|p130
P11522431A0673|15 31|tobacco dependence
P11522431A0673|140 147|drinkers
P11522431A0673|153 153|%
P11522431A0673|121 131|nondrinkers
P11522431A0673|97 107|individuals
P11522431A0673|113 113|%
P11522431A0673|3 12|prevalence
P11522431A0673|55 68|ICD-10 criteria
P11522584A0882|58 66|MMF lesion
P11522584A0882|89 89|P
P11522584A0882|76 87|muscle biopsy
P11522584A0882|7 14|myalgias
P11522584A0882|33 40|patients
P11522626A1374|32 32|G
P11522626A1374|116 132|estrogen receptors
P11522626A1374|82 91|activation
P11522626A1374|36 52|gene transcription
P11522626A1374|107 113|pathway
P11522626A1374|20 29|regulation
P11522626A1374|97 104|Mek-Erk1
P11522658A0086|121 126|BT-474
P11522658A0086|79 105|ErbB kinase inhibitor AG1478in
P11522658A0086|25 44|ErbB1/ErbB2 signaling
P11522658A0086|130 135|SKBR-3
P11522658A0086|141 157|breast cancer cells
P11522658A0086|62 68|process
P11522658A0870|40 43|MAPK
P11522658A0870|66 68|p27
P11522658A0870|35 37|p27
P11522658A0870|94 97|Cdk2
P11522658A0870|18 32|phosphorylation
P11522658A0870|104 116|stoichiometry
P11522658A0870|55 63|stability
P11522658A0870|132 145|kinase activity
P11523446A0523|43 44|LC
P11523446A0523|8 24|reference solution
P11523446A0523|63 65|TOF
P11523446A0523|102 118|nitrogen detection
P11523446A0523|120 126|LC-CLND
P11523446A0523|48 61|time-of-flight
P11523446A0523|67 68|MS
P11523446A0523|84 85|LC
P11523446A0523|0 2|ICA
P11524015A0937|42 51|H4 promoter
P11524015A0937|65 87|CAT reporter gene activity
P11524015A0937|53 54|nt
P11524015A0937|6 15|expression
P11524015A0937|18 23|BZAP45
P11524815A0753|83 92|2N0M0 cases
P11524815A0753|76 76|%
P11524815A0753|37 46|lung cancer
P11524815A0753|50 50|%
P11524815A0753|23 23|%
P11524815A0753|61 70|lung cancer
P11524815A0753|80 81|T1
P11524815A0753|5 16|control rates
P11524823X0001|0 6|Utility
P11524823X0001|21 23|GSI
P11524823X0001|123 129|ability
P11524823X0001|33 42|evaluation
P11524823X0001|189 195|infants
P11524823X0001|99 103|study
P11524823X0001|73 81|emissions
P11524823X0001|45 61|distortion product
P11524823X0001|180 187|neonates
P11524823X0001|163 177|cochlea function
P11524823X0001|135 148|OAE screener GSI
P11524823X0001|9 19|OAE screener
P11524823X0001|86 92|purpose
P11524823X0001|199 204|adults
P11525102A0970|40 53|ACP Journal Club
P11525102A0970|103 103|%
P11525102A0970|110 110|%
P11525102A0970|24 30|reviews
P11525102A0970|88 98|sensitivity
P11525102A0970|55 55|n
P11525102A0970|105 106|CI
P11525102A0970|6 11|sample
P11525102A0970|65 78|PubMed strategy
P11525102A0970|115 115|%
P11525486A0350|14 22|CaCO3-CO2
P11525486A0350|65 66|pH
P11525486A0350|24 25|N2
P11525486A0350|34 41|solution
P11525640A0560|0 9|Inhibition
P11525640A0560|133 135|ERK
P11525640A0560|19 37|ERK kinase activities
P11525640A0560|137 144|PD098059
P11525640A0560|91 99|treatment
P11525640A0560|12 15|JNK1
P11525640A0560|171 181|UV induction
P11525640A0560|83 86|JNK1
P11525640A0560|46 55|expression
P11525640A0560|114 130|chemical inhibitor
P11525640A0560|187 200|GADD45 promoter
P11528127A1402|95 97|% GC
P11528127A1402|117 121|L1/L2
P11528127A1402|100 104|mouse
P11528127A1402|72 78|segment
P11528127A1402|25 31|segment
P11528127A1402|18 18|%
P11528127A1402|5 13|GC content
P11528127A1402|58 59|H1
P11528127A1402|82 84|% GC
P11528253X1211|0 8|Copyright
P11528253X1211|13 14|S.
P11528500A0571|15 21|NRL gene
P11528500A0571|43 50|families
P11528500A0571|2 9|mutation
P11529914T0000|0 8|NF-kappaB
P11529914T0000|53 62|expression
P11529914T0000|24 33|regulation
P11529914T0000|77 82|T cells
P11529914T0000|36 40|CD154
P11529914T0000|42 51|CD40 ligand
P11530684A0667|88 114|drive NK1-receptor mechanisms
P11530684A0667|52 58|neurons
P11530684A0667|313 340|drive NMDA-receptor mechanisms
P11530684A0667|77 84|C-fibers
P11530684A0667|206 213|C-fibers
P11530684A0667|301 308|A-fibers
P11530684A0667|217 244|drive NMDA receptor-mechanisms
P11530684A0667|251 254|type
P11530684A0667|47 50|type
P11530684A0667|184 187|ones
P11530684A0667|258 261|ones
P11530684A0667|31 39|responses
P11530684A0667|123 138|pain transmission
P11530684A0667|169 175|changes
P11530684A0667|5 15|nerve injury
P11530684A0667|178 181|type
P11530829A0000|131 139|equipment
P11530829A0000|30 40|development
P11530829A0000|21 26|design
P11530829A0000|76 82|testing
P11530829A0000|68 70|use
P11530829A0000|45 56|ECG simulator
P11530829A0000|4 10|article
P11530829A0000|84 94|calibration
P11530829A0000|98 108|maintenance
P11532556A0000|60 66|disease
P11532556A0000|40 43|SDAE
P11532556A0000|76 83|etiology
P11532556A0000|20 38|angioencephalopathy
P11532556A0000|99 105|thalami
P11532856A1175|0 4|Third
P11532856A1175|211 217|p38 MAPK
P11532856A1175|130 135|kinase
P11532856A1175|220 234|HIF-1 activation
P11532856A1175|75 77|HGF
P11532856A1175|137 140|MAPK
P11532856A1175|80 101|stress kinase activities
P11532856A1175|108 120|p42/44 mitogen
P11532856A1175|25 28|data
P11532856A1175|67 72|effect
P11532856A1175|197 202|kinase
P11532856A1175|168 178|involvement
P11532856A1175|204 206|JNK
P11532856A1175|30 45|N-acetylcysteine
P11533238A1137|0 7|Mutation
P11533238A1137|54 60|ability
P11533238A1137|63 67|HDAC1
P11533238A1137|76 85|repression
P11533238A1137|97 121|HLA-DRA promoter activation
P11533238A1137|13 26|octamer element
P11533340A1285|59 64|months
P11533340A1285|21 30|difference
P11533340A1285|74 83|PDF infants
P11533340A1285|101 114|point advantage
P11533340A1285|46 51|scores
P11533340A1285|117 138|Bayley motor score scales
P11533863A0125|67 80|presupposition
P11533863A0125|47 53|routine
P11533863A0125|11 14|case
P11533863A0125|94 100|therapy
P11533863A0125|18 28|restoration
P11534132A0219|75 81|experts
P11534132A0219|12 24|search engines
P11534132A0219|50 56|results
P11534132A0219|61 66|domain
P11534900A0000|136 137|PB
P11534900A0000|185 200|Lymnaea acuminata
P11534900A0000|118 134|piperonyl butoxide
P11534900A0000|80 95|Cedrus deodara oil
P11534900A0000|142 152|fruit powder
P11534900A0000|155 166|Embelia ribes
P11534900A0000|20 31|combinations
P11534900A0000|47 76|molluscicides Azadirachta indica
P11534900A0000|100 116|synergists MGK-264
P11535014A1157|39 49|seizure type
P11535014A1157|63 71|frequency
P11535014A1157|161 168|patients
P11535014A1157|12 18|results
P11535014A1157|132 140|latencies
P11535014A1157|103 120|precipitate factors
P11535014A1157|74 80|seizure
P11535014A1157|143 146|P300
P11535014A1157|52 54|TLE
P11535140T0000|22 30|pregnancy
P11535140T0000|12 19|findings
P11535532A0189|41 48|response
P11535532A0189|51 54|IL-2
P11535532A0189|66 73|function
P11535532A0189|19 29|enzyme DUB-2
P11535832A0586|3 9|isoform
P11535832A0586|47 55|C terminus
P11535832A0586|60 64|HDAC9
P11535832A0586|21 26|HDAC9a
P11535832A0586|33 34|aa
P11536063A0178|74 91|heart-lung-machine
P11536063A0178|23 41|lung transplantation
P11536063A0178|52 62|indications
P11536063A0178|9 19|embolectomy
P11536063A0178|69 71|use
P11538437A0568|171 171|C
P11538437A0568|75 76|N2
P11538437A0568|195 195|X
P11538437A0568|86 87|N2
P11538437A0568|192 193|N2
P11538437A0568|189 190|M2
P11538437A0568|82 82|V
P11538437A0568|92 93|N2
P11538437A0568|36 44|reactions
P11538437A0568|89 89|X
P11538437A0568|185 185|V
P11538437A0568|183 183|B
P11538437A0568|207 208|N2
P11538437A0568|98 99|N2
P11538437A0568|202 203|CN
P11538437A0568|156 158|CH4
P11538437A0568|95 95|A
P11538437A0568|103 103|V
P11538437A0568|153 153|A
P11538437A0568|101 101|X
P11538437A0568|150 151|N2
P11538437A0568|197 197|V
P11538437A0568|213 214|CN
P11538437A0568|67 68|N2
P11538437A0568|130 146|N2 post-discharges
P11538437A0568|70 70|A
P11538437A0568|216 216|B
P11538437A0568|78 78|C
P11538437A0568|121 121|V
P11538437A0568|175 176|M2
P11538437A0568|80 80|B
P11538437A0568|220 220|V
P11538437A0568|218 218|A
P11538437A0568|173 173|N
P11538437A0568|61 62|N2
P11538437A0568|110 111|N2
P11538437A0568|113 113|X
P11538437A0568|64 64|A
P11538437A0568|210 210|X
P11538437A0568|180 181|CN
P11538437A0568|6 15|conditions
P11538437A0568|230 248|% CH4 post-discharges
P11538437A0568|162 169|products
P11538437A0568|119 119|B
P11538437A0568|116 117|N2
P11539522A0612|27 35|knowledge
P11539522A0612|59 62|time
P11539522A0612|38 47|LET spectra
P11539522A0612|65 78|space dosimetry
P11539522A0612|3 16|NAUSICAA system
P11540991A0127|2 6|order
P11540991A0127|124 128|space
P11540991A0127|136 146|EASE program
P11540991A0127|112 117|flight
P11540991A0127|30 34|tests
P11540991A0127|22 28|effects
P11540991A0127|91 100|NASA KC-135
P11540991A0127|156 181|Shuttle Atlantis mission 61-B
P11540991A0127|53 84|NASA MSFC Neutral Buoyancy Simulator
P11542677A0411|85 108|composting facility design
P11542677A0411|112 118|control
P11542677A0411|37 50|Generic Systems
P11542677A0411|71 82|alternatives
P11542677A0411|4 10|article
P11542780A0086|188 200|energy tranfer
P11542780A0086|26 34|detectors
P11542780A0086|64 75|contribution
P11542780A0086|206 214|component
P11542780A0086|167 170|PNTD
P11542780A0086|90 112|energy transfer component
P11542780A0086|36 38|TLD
P11542780A0086|152 165|track detectors
P11542780A0086|114 116|LET
P11542780A0086|120 133|keV/micrometer
P11542780A0086|202 204|LET
P11543154T0000|0 8|Responses
P11543154T0000|67 75|particles
P11543154T0000|11 20|TLD Mg2SiO4
P11543154T0000|79 92|space radiation
P11543154T0000|22 23|Tb
P11543154T0000|48 52|glass
P11543317A0203|28 38|combination
P11543317A0203|105 108|TDMS
P11543317A0203|11 14|dose
P11543317A0203|141 144|PNTD
P11543317A0203|83 91|dosemeter
P11543317A0203|94 100|Mg2SiO4
P11543317A0203|127 139|track detector
P11543317A0203|55 63|detectors
P11543317A0203|102 103|Tb
P11543662A0562|13 19|mutants
P11543662A0562|51 51|C
P11543662A0562|88 95|L protein
P11543662A0562|64 69|defect
P11543662A0562|8 11|gstC
P11543662A0562|75 81|ability
P11543662A0562|45 48|half
P11545594A1556|96 112|amino acid residues
P11545594A1556|23 32|Myb domains
P11545594A1556|75 83|Myb domain
P11545594A1556|61 68|function
P11545594A1556|145 151|protein
P11545594A1556|132 138|surface
P11547819A0532|0 6|METHODS
P11547819A0532|254 275|tissue penetration rates
P11547819A0532|211 216|tissue
P11547819A0532|126 136|divergences
P11547819A0532|103 122|laser output beam sizes
P11547819A0532|67 74|catheter
P11547819A0532|141 150|evaluation
P11547819A0532|164 179|matter generation
P11547819A0532|327 342|vessel wall injury
P11547819A0532|221 231|measurement
P11547819A0532|186 193|ablation
P11547819A0532|234 250|ablation hole sizes
P11547819A0532|32 39|catheter
P11547819A0532|8 18|Experiments
P11547819A0532|295 305|examination
P11547819A0532|87 97|measurement
P11548027A0163|192 201|indicators
P11548027A0163|137 160|service quality indicators
P11548027A0163|96 105|indicators
P11548027A0163|129 133|water
P11548027A0163|13 33|performance indicators
P11548027A0163|118 127|indicators
P11548027A0163|1 8|proposal
P11548027A0163|58 63|groups
P11548027A0163|162 180|personnel indicators
P11550795A2583|0 13|Overexpression
P11550795A2583|67 75|apoptosis
P11550795A2583|78 92|T cell hybridomas
P11550795A2583|119 128|Fas-ligand
P11550795A2583|45 49|T cell
P11550795A2583|108 116|induction
P11550795A2583|132 142|interleukin
P11550795A2583|16 23|RORgamma
P11552058A0235|71 74|days
P11552058A0235|22 27|values
P11552058A0235|37 46|herniation
P11552058A0235|4 6|ICP
P11552058A0235|32 35|mm Hg
P11552058A0833|122 133|barbiturates
P11552058A0833|5 13|therapies
P11552058A0833|50 63|saline solution
P11552058A0833|65 68|THAM
P11552058A0833|70 101|Tris-hydroxy-methyl-aminomethane
P11552058A0833|103 108|buffer
P11552724A0527|219 225|failure
P11552724A0527|125 131|disease
P11552724A0527|73 83|vessel lumen
P11552724A0527|143 151|blood flow
P11552724A0527|228 234|allergy
P11552724A0527|247 249|use
P11552724A0527|55 63|blood flow
P11552724A0527|202 209|patients
P11552724A0527|187 199|interventions
P11552724A0527|252 264|contrast media
P11552724A0527|30 33|IVUS
P11552724A0527|0 10|CONCLUSIONS
P11552922A0361|0 14|CYP2C19 genotype
P11552922A0361|33 99|polymerase chain reaction-restriction fragment length polymorphism method
P11553091A1472|129 140|relationship
P11553091A1472|41 49|diagnosis
P11553091A1472|3 9|results
P11553091A1472|105 114|correction
P11553091A1472|60 71|relationship
P11553091A1472|117 121|Class
P11553704A0674|7 10|data
P11553704A0674|102 115|MAPK activation
P11553704A0674|53 62|EGFR-CD533
P11553704A0674|81 86|Ras N17
P11554469A1386|59 76|cellulose synthases
P11554469A1386|168 173|plants
P11554469A1386|23 30|question
P11554469A1386|157 165|synthases
P11554469A1386|104 110|members
P11554469A1386|44 52|CesA genes
P11554469A1386|5 12|analyses
P11554566A0668|3 19|hatcher incubators
P11554566A0668|26 34|companies
P11554566A0668|118 125|company A
P11554566A0668|156 164|company B.
P11554566A0833|6 19|companies sites
P11554566A0833|65 69|Tr104
P11554566A0833|109 117|locations
P11554727A0890|73 75|PTH
P11554727A0890|82 95|GGGGGAGGGGAG-3
P11554727A0890|108 112|PTHSR
P11554727A0890|61 70|repression
P11554727A0890|3 21|mutation experiments
P11554727A0890|47 54|sequence
P11555516A0639|34 37|COAT
P11555516A0639|61 71|cutoff value
P11555516A0639|46 50|L/min
P11555516A0639|24 32|threshold
P11555516A0639|127 130|risk
P11555516A0639|105 117|artery disease
P11555516A0639|7 12|output
P11555669A0464|0 9|Experience
P11555669A0464|25 32|sections
P11555669A0464|47 62|Vrinnevi Hospital
P11555669A0983|39 45|tissues
P11555669A0983|70 74|pairs
P11555669A0983|11 13|mix
P11555669A0983|48 53|stains
P11555669A0983|19 26|sections
P11555669A0983|30 36|samples
P11556809A2085|161 170|P450 enzyme
P11556809A2085|95 110|1-deoxycapsidiol
P11556809A2085|184 197|hydroxylations
P11556809A2085|33 46|enzyme activity
P11556809A2085|113 121|capsidiol
P11556809A2085|147 152|notion
P11556809A2085|73 91|5-epi-aristolochene
P11556809A2085|203 222|hydrocarbon substrate
P11557127A0991|2 11|conclusion
P11557127A0991|13 16|NF-Y
P11557127A0991|20 34|Sp1 binding sites
P11557127A0991|102 109|MRP2 gene
P11557127A0991|77 87|rat mrp2 gene
P11557127A0991|48 51|role
P11557127A0991|62 71|expression
P11559366T0000|77 80|gene
P11559366T0000|28 37|inhibition
P11559366T0000|43 75|plasminogen activator inhibitor type
P11559547T0000|102 110|receptors
P11559547T0000|78 86|ERR family
P11559547T0000|48 72|pS2 breast cancer marker gene
P11559547T0000|15 24|regulation
P11559564A0459|0 5|NB-506
P11559564A0459|110 123|splicing factor
P11559564A0459|37 49|topoisomerase
P11559564A0459|27 34|capacity
P11559564A0459|125 131|SF2/ASF
P11559564A0459|83 96|splicing factor
P11559789A0314|233 239|inducer
P11559789A0314|198 213|producer cell line
P11559789A0314|185 189|level
P11559789A0314|91 102|progesterone
P11559789A0314|65 85|ASF/SF2 splicing factor
P11559789A0314|123 134|gene cassette
P11559789A0314|47 51|virus
P11559789A0314|17 20|work
P11559789A0314|152 158|ASF/SF2
P11559789A0314|224 230|absence
P11559821A1315|0 15|DNA binding assays
P11559821A1315|66 78|CREB-Tax-p300
P11559821A1315|95 103|complexes
P11559821A1315|56 63|assembly
P11559821A1315|111 132|repeat oligonucleotides
P11559821A1315|80 82|CBP
P11559821A1315|28 39|interference
P11559821A1315|42 44|p30
P11560292A0557|28 36|structure
P11560292A0557|39 49|domain model
P11560292A0557|51 62|prototype DSS
P11560292A0557|66 86|dipslide urine cultures
P11560509T0000|0 13|DNA recognition
P11560509T0000|53 59|binding
P11560509T0000|77 79|DNA
P11560509T0000|16 28|F factor TraI36
P11560990A0272|0 15|E47 protein levels
P11560990A0272|61 65|stage
P11560990A0272|173 177|stage
P11560990A0272|107 112|levels
P11560990A0272|74 78|point
P11560990A0272|144 153|transition
P11560992A0000|61 66|kinase
P11560992A0000|154 167|protein kinases
P11560992A0000|125 137|stress kinases
P11560992A0000|56 59|MAPK
P11560992A0000|199 202|JNKs
P11560992A0000|42 54|protein kinase
P11560992A0000|169 173|SAPKs
P11560992A0000|90 98|molecules
P11560992A0000|76 79|MKK4
P11560992A0000|191 197|kinases
P11560992A0000|176 180|c-Jun
P11560992A0000|7 24|specificity kinases
P11560992A0000|68 70|MKK
P11560992A0000|240 246|stimuli
P11560992A0000|206 213|response
P11560992A0651|0 17|SAPK/JNK activation
P11560992A0651|152 155|MKK4
P11560992A0651|109 112|mkk7
P11560992A0651|81 84|MKK4
P11560992A0651|54 57|MKK7
P11560992A0651|192 204|stress stimuli
P11560992A0651|69 78|expression
P11560992A0651|135 149|phosphorylation
P11560992A0651|45 51|absence
P11560992A0651|118 130|mast cell lines
P11560992A0651|174 181|response
P11560992A1184|178 182|cells
P11560992A1184|113 124|growth factor
P11560992A1184|128 134|antigen
P11560992A1184|78 86|mast cells
P11560992A1184|5 8|MKK7
P11560992A1184|33 41|regulator
P11560992A1184|90 93|MKK7
P11560992A1184|150 162|proliferation
P11560992A1184|58 75|SAPK/JNK activation
P11561623A0897|162 168|biomass
P11561623A0897|104 107|fall
P11561623A0897|8 40|copepod Pseudonychocamptus proximus
P11561623A0897|70 81|Tisbe furcata
P11561623A0897|142 149|increase
P11561623A0897|182 187|spring
P11561623A0897|84 94|sand filters
P11561626A0197|209 211|Pb2
P11561626A0197|217 219|Zn2
P11561626A0197|192 195|nH2O
P11561626A0197|80 86|cadmium
P11561626A0197|20 28|solutions
P11561626A0197|153 158|Cd-TMT
P11561626A0197|183 188|S3C3N3
P11561626A0197|202 202|M
P11561626A0197|269 271|air
P11561626A0197|172 177|Pb-TMT
P11561626A0197|224 224|n
P11561626A0197|75 78|zinc
P11561626A0197|45 53|solutions
P11561626A0197|204 206|Cd2
P11561626A0197|31 36|TMT-55
P11561626A0197|94 98|salts
P11561626A0197|122 127|Zn-TMT
P11561626A0197|180 181|M3
P11562278A0169|146 154|cell death
P11562278A0169|72 75|role
P11562278A0169|37 48|G1 regulation
P11562278A0169|18 22|genes
P11562278A0169|92 106|differentiation
P11562278A0169|156 164|apoptosis
P11562278A0169|78 90|proliferation
P11562278A0169|119 132|transformation
P11562870A0892|29 39|lamotrigine
P11562870A0892|110 110|%
P11562870A0892|103 107|years
P11562870A0892|91 91|%
P11562870A0892|61 66|months
P11562870A0892|83 88|months
P11562870A0892|3 13|probability
P11562870A0892|16 24|treatment
P11562870A0892|72 72|%
P11564871A1184|121 124|need
P11564871A1184|152 161|eukaryotes
P11564871A1184|23 30|presence
P11564871A1184|176 187|TATA elements
P11564871A1184|128 130|TBP
P11564871A1184|141 144|Pols
P11564871A1184|79 88|eukaryotes
P11564871A1184|5 11|results
P11564871A1184|45 64|transcription systems
P11564871A1184|195 203|promoters
P11564871A1184|99 105|insight
P11564871A1184|170 173|lack
P11564893A1068|154 160|respond
P11564893A1068|163 170|mutagens
P11564893A1068|48 56|6RG lesion
P11564893A1068|135 138|cell
P11564893A1068|21 32|conformation
P11564893A1068|75 89|DNA repair factor
P11564893A1068|37 42|repair
P11564893A1068|116 121|R-MGMT
P11564893A1068|58 61|MGMT
P11564893A1068|93 114|transcription regulator
P11564893A1068|141 145|sense
P11564893A1068|13 18|change
P11565747A1020|58 79|competition experiments
P11565747A1020|96 106|correlation
P11565747A1020|184 191|splicing
P11565747A1020|194 205|P element IVS3
P11565747A1020|167 173|ability
P11565747A1020|117 133|binding affinities
P11565747A1020|15 28|splicing assays
P11565747A1020|136 138|PSI
P11565747A1020|30 43|UV crosslinking
P11565747A1020|145 158|SELEX sequences
P11565747A1020|0 3|Data
P11566874T0000|31 36|dynein
P11566874T0000|6 16|motor domain
P11566948A1217|14 28|nephrosclerosis
P11566948A1217|112 117|events
P11566948A1217|96 104|incidence
P11566948A1217|62 72|combination
P11566948A1217|49 52|ACEI
P11566948A1217|30 36|therapy
P11566961A0472|0 18|Body weight reduction
P11566961A0472|76 95|blood pressure control
P11566961A0472|28 45|insulin sensitivity
P11566961A0472|61 72|blood glucose
P11566996A1391|27 57|nucleotide excision repair pathway
P11566996A1391|74 79|repair
P11566996A1391|158 160|pH.
P11566996A1391|145 152|S. mutans
P11566996A1391|94 102|DNA damage
P11566996A1391|133 142|adaptation
P11566996A1391|17 20|uvrA
P11568988A0960|59 62|time
P11568988A0960|88 100|antibody titer
P11568988A0960|104 113|Pa elastase
P11568988A0960|47 50|WCXR
P11568988A0960|35 41|changes
P11568988A0960|7 21|regression model
P11568988A0960|78 84|culture
P11569800T0000|0 21|Temperature measurement
P11569800T0000|36 42|systems
P11569900A0660|0 13|APC-resistance
P11569900A0660|70 80|specificity
P11569900A0660|56 66|sensitivity
P11569900A0660|42 47|method
P11569900A0660|87 107|factor V Leiden mutation
P11569949A2087|0 4|Zarix
P11569949A2087|13 29|patient enrollment
P11569949A2087|62 67|Spring
P11569949A2087|48 52|sites
P11570735A1097|239 245|control
P11570735A1097|182 190|reduction
P11570735A1097|145 153|reduction
P11570735A1097|248 261|feedback groups
P11570735A1097|11 18|subjects
P11570735A1097|33 45|feedback group
P11570735A1097|83 101|ground reaction force
P11570735A1097|71 74|peak
P11570735A1097|117 126|conditions
P11570735A1097|0 6|RESULTS
P11570820T0000|60 66|nucleus
P11570820T0000|4 15|casein kinase
P11570820T0000|17 24|isoforms
P11570820T0000|70 78|cytoplasm
P11572377T0000|0 2|Use
P11572377T0000|62 76|cavitation field
P11572377T0000|16 27|lithotripter
P11572388A0000|97 101|LSERs
P11572388A0000|108 117|prediction
P11572388A0000|136 144|compounds
P11572388A0000|39 43|study
P11572388A0000|49 59|application
P11572388A0000|68 95|solvation energy relationships
P11572388A0000|183 186|RPLC
P11572388A0000|21 27|results
P11572388A0000|188 204|method development
P11572388A0000|4 8|paper
P11572467A0658|67 70|t-PA
P11572467A0658|113 116|clot
P11572467A0658|56 64|injection
P11572467A0658|7 15|blood clot
P11572467A0658|37 42|cavity
P11572467A0658|81 91|plasminogen
P11572467A0658|94 100|plasmin
P11572467T0000|0 9|Management
P11572467T0000|56 81|tissue plasminogen activator
P11572467T0000|42 51|hemorrhage
P11572467T0000|119 127|exchanger
P11572467T0000|83 86|t-PA
P11572467T0000|91 96|volume
P11573771T0000|0 5|Effect
P11573771T0000|8 21|heat treatments
P11573771T0000|27 37|meltability
P11573771T0000|40 46|cheeses
P11573891A0525|0 6|RESULTS
P11573891A0525|126 134|exposures
P11573891A0525|101 106|whites
P11573891A0525|16 19|cent
P11573891A0525|98 98|%
P11573891A0525|49 66|community outbreaks
P11573891A0525|29 37|Americans
P11573891A0525|71 73|TST
P11574088A1687|14 17|time
P11574088A1687|77 89|PAK recipients
P11574088A1687|61 63|SPK
P11574088A1687|54 57|days
P11574088A1687|30 47|pancreas transplant
P11574088A1687|91 91|P
P11574088A1687|3 6|mean
P11574088A1687|70 73|days
P11574105A0727|314 327|antibody titers
P11574105A0727|121 123|GBS
P11574105A0727|251 256|damage
P11574105A0727|174 176|GBS
P11574105A0727|51 58|increase
P11574105A0727|225 240|IgM antibody peaks
P11574105A0727|134 149|disability scores
P11574105A0727|61 73|antibody titer
P11574105A0727|12 24|antibody peaks
P11574105A0727|267 282|IgM antibody peaks
P11574105A0727|113 118|course
P11574105A0727|210 212|IgG
P11574105A0727|295 302|patients
P11574105A0727|93 105|antibody titer
P11574105A0727|167 171|weeks
P11574105A0727|194 200|outcome
P11574105A0727|0 7|Patients
P11575109A0214|57 63|therapy
P11575109A0214|158 164|gingiva
P11575109A0214|118 123|grafts
P11575109A0214|9 16|baseline
P11575109A0214|95 101|surgery
P11575109A0214|25 35|examination
P11575109A0214|127 135|treatment
P11575109A0214|67 74|patients
P11575977A1133|28 45|office hypertension
P11575977A1133|8 15|patients
P11575977A1133|76 88|complications
P11576158A1371|28 40|skin blood flow
P11576158A1371|74 81|controls
P11576158A1371|5 16|TVD-patients
P11576776T0081|20 44|microcrystalline cellulose
P11576776T0081|12 17|moduli
P11577094A1226|44 55|HSAL2 pathway
P11577094A1226|5 12|findings
P11577094A1226|64 67|role
P11577094A1226|39 42|WT-1
P11577094A1226|70 80|development
P11577094A1226|84 96|hematopoiesis
P11578685A0077|0 5|ICAM-1
P11578685A0077|37 41|onset
P11578685A0077|23 31|predictor
P11578685A0077|44 45|GO
P11579100T0000|0 21|Phosphotyrosyl peptides
P11579100T0000|41 58|DNA binding activity
P11579100T0000|78 95|cell transformation
P11579100T0000|60 73|gene regulation
P11580173A0181|0 16|Plane wave geometry
P11580173A0181|50 56|results
P11580173A0181|63 66|work
P11580173A0181|150 154|paper
P11580173A0181|126 133|geometry
P11580173A0181|41 43|use
P11580173A0181|98 112|P3 approximation
P11580301A1161|58 63|factor
P11580301A1161|86 98|polyarthritis
P11580301A1161|3 11|diagnosis
P11580301A1161|14 25|HCV arthritis
P11580301A1161|28 35|patients
P11580757A0304|59 65|surgery
P11580757A0304|35 46|TFCD patients
P11580757A0304|213 222|recordings
P11580757A0304|143 148|lesion
P11580757A0304|129 130|MR
P11580757A0304|171 174|zone
P11580757A0304|95 97|aim
P11580757A0304|80 87|epilepsy
P11580757A0304|119 127|resonance
P11580757A0304|0 6|METHODS
P11580941A0815|85 91|therapy
P11580941A0815|32 38|UPDRS II
P11580941A0815|66 66|%
P11580941A0815|123 126|time
P11580941A0815|103 112|% reduction
P11580941A0815|42 50|III scores
P11580941A0815|16 26|examination
P11580941A0815|97 100|mean
P11580941A0815|0 6|RESULTS
P11580941A0815|70 80|stimulation
P11583428A0191|2 4|Exp
P11583621A0301|90 94|delta
P11583621A0301|80 83|hTAF
P11583621A0301|159 162|hTAF
P11583621A0301|118 121|hTAF
P11583621A0301|106 110|delta
P11583621A0301|70 77|cleavage
P11583621A0301|40 49|expression
P11583621A0301|145 151|complex
P11583621A0301|96 99|hTAF
P11583621A0301|24 30|stimuli
P11583880T0000|33 49|AneuRx stent-graft
P11583880T0000|12 25|aneurysm repair
P11584107T0000|47 56|assessment
P11584107T0000|67 71|field
P11584107T0000|38 43|origin
P11584107T0000|18 25|diseases
P11584328A0532|0 15|Drug interactions
P11584328A0532|77 83|statins
P11584328A0532|33 37|drugs
P11584328A0532|59 74|CYP450 isoenzymes
P11585856A0285|0 6|METHODS
P11585856A0285|113 132|photon energy recovery
P11585856A0285|65 66|AC
P11585856A0285|52 53|RR
P11585856A0285|28 34|benefit
P11585856A0285|134 136|PER
P11585856A0285|95 111|scatter correction
P11585856A0285|73 90|scanning line source
P11585856A0285|159 172|backprojection
P11586096A0699|45 63|control measurements
P11586096A0699|22 43|patient characteristics
P11586096A0699|9 19|differences
P11586096A0699|97 104|patients
P11586096A0699|86 91|muscle
P11587514A0758|44 57|ABA suppression
P11587514A0758|11 27|abi1-1 gene product
P11587514A0758|74 90|alpha-amylase gene
P11587514A0758|33 38|effect
P11587980A1039|57 59|FOT
P11587980A1039|51 51|n
P11587980A1039|113 120|subgroup
P11587980A1039|74 93|interrupter technique
P11587980A1039|61 68|contrary
P11587980A1039|128 135|children
P11587980A1039|2 9|children
P11587980A1039|162 169|baseline
P11587980A1039|197 211|bronchodilation
P11587980A1039|41 49|maneuvers
P11587980A1039|144 159|resistance values
P11589568A0744|130 141|kinetochores
P11589568A0744|25 42|checkpoint response
P11589568A0744|78 81|Bub3
P11589568A0744|9 13|yeast
P11589568A0744|54 65|proteins Mad1
P11589568A0744|98 109|counterparts
P11589568A0744|71 74|Bub1
P11589779T0000|15 21|Th2 type
P11589779T0000|30 37|response
P11589779T0000|52 67|strongyloidiasis
P11589779T0000|40 47|patients
P11589779T0000|0 5|HTLV-1
P11590364A1056|47 52|retina
P11590364A1056|11 29|beta5L splice variant
P11592315A0325|0 8|PROCEDURE
P11592315A0325|10 17|Cannulas
P11592315A0325|55 58|body
P11592315A0325|81 84|calf
P11592315A0325|69 74|antrum
P11592532A0188|71 77|degrees
P11592532A0188|126 131|method
P11592532A0188|80 90|degrees grid
P11592532A0188|8 33|Humphrey Field Analyzer model
P11592532A0188|38 40|HFA
P11592532A0188|0 6|METHODS
P11592532A0188|43 49|program
P11593394A0000|60 64|cells
P11593394A0000|181 183|p15
P11593394A0000|104 104|D
P11593394A0000|194 196|p27
P11593394A0000|12 28|growth factor-beta
P11593394A0000|115 135|cyclin kinase complexes
P11593394A0000|46 57|growth arrest
P11593394A0000|185 189|Ink4b
P11593394A0000|73 82|regulation
P11593394A0000|88 97|activities
P11593394A0000|198 201|Kip1
P11593394A0000|169 178|regulation
P11593394A0000|30 37|TGF-beta
P11593394A0000|203 224|cyclin kinase inhibitors
P11595170A0582|157 161|exons
P11595170A0582|20 24|cDNAs
P11595170A0582|180 186|introns
P11595170A0582|107 118|organization
P11595170A0582|36 39|hB1F
P11595170A0582|137 138|kb
P11595170A0582|59 66|sequence
P11595170A0582|81 91|delineation
P11595170A0582|30 34|NR5A2
P11595170A0582|41 44|gene
P11595170A0582|0 8|Alignment
P11595176T0000|29 37|SPEC1 gene
P11595176T0000|52 59|splicing
P11595176T0000|63 84|close promoter proximity
P11595176T0000|90 110|AF1q translocation gene
P11595176T0000|10 18|structure
P11595478A1014|0 1|Hp
P11595478A1014|52 61|prevalence
P11595478A1014|64 70|atrophy
P11595478A1014|10 18|relatives
P11595478A1014|103 117|cancer relatives
P11595478A1014|28 33|cancer
P11595478A1014|84 95|Hp negativity
P11595813A0633|116 125|activities
P11595813A0633|138 153|5alpha-reductase
P11595813A0633|36 40|place
P11595813A0633|10 19|metabolism
P11595813A0633|77 80|unit
P11595813A0633|128 136|aromatase
P11595813A0633|22 30|androgens
P11595813A0633|167 174|presence
P11595813A0633|50 54|areas
P11595813A0633|180 196|androgen receptors
P11595813A0633|100 110|differences
P11595840A0000|61 65|tumor
P11595840A0000|22 39|fluorodeoxyglucose
P11595840A0000|41 47|F-18 FDG
P11595840A0000|78 94|blood glucose level
P11595840A0000|3 8|uptake
P11596104A0614|0 19|Northern blot analysis
P11596104A0614|95 96|kb
P11596104A0614|110 118|cell lines
P11596104A0614|61 66|signal
P11596104A0614|32 37|PARNAs
P11596104A0614|85 93|kilobases
P11596838A1357|28 48|fluticasone propionate
P11596838A1357|90 97|patients
P11596838A1357|51 56|microg
P11596838A1357|79 87|treatment
P11596838A1357|112 117|asthma
P11596838A1357|23 25|use
P11596838A1357|4 11|analysis
P11596838A1357|151 163|beta2-agonist
P11597185A0477|62 80|computer simulations
P11597185A0477|125 131|regimes
P11597185A0477|53 58|models
P11597185A0477|134 155|metapopulation dynamics
P11597185A0477|32 45|metapopulation
P11597936A0570|42 49|patients
P11597936A0570|180 184|drugs
P11597936A0570|79 96|density lipoprotein
P11597936A0570|112 124|triglycerides
P11597936A0570|102 106|mg/dL
P11597936A0570|61 65|years
P11597936A0570|53 55|age
P11597936A0570|5 15|CAD patients
P11597936A0570|68 75|baseline
P11597936A0570|199 206|controls
P11597936A0570|131 135|mg/dL
P11599079A1040|42 52|instruments
P11599079A1040|67 69|API
P11599079A1040|65 65|V
P11599079A1040|84 84|V
P11599079A1040|108 110|API
P11599079A1040|106 106|V
P11599079A1040|16 30|orifice voltages
P11599079A1040|86 88|API
P11599797A0732|14 17|gene
P11599797A0732|0 6|RESULTS
P11599840A0813|57 59|kPa
P11599840A0813|126 128|kPa
P11599840A0813|176 178|kPa
P11599840A0813|61 64|mean
P11599840A0813|111 117|section
P11599840A0813|98 100|kPa
P11599840A0813|156 162|section
P11599840A0813|207 213|section
P11599840A0813|76 84|deviation
P11599840A0813|191 193|kPa
P11599840A0813|38 43|matter
P11599840A0813|11 20|elasticity
P11599840A0813|3 8|moduli
P11599840A0813|141 143|kPa
P11600252A0795|115 123|mortality
P11600252A0795|107 112|change
P11600252A0795|61 66|series
P11600252A0795|3 4|LA
P11600252A0795|31 34|data
P11600314A0000|119 126|analysis
P11600314A0000|13 24|polarography
P11600314A0000|139 140|B2
P11600314A0000|129 137|vitamin B1
P11600314A0000|40 44|pulse
P11600314A0000|58 64|methods
P11600314A0000|144 145|B6
P11600365A0471|129 146|reference compounds
P11600365A0471|91 102|tosufloxacin
P11600365A0471|39 44|E-5065
P11600365A0471|20 28|organisms
P11600365A0471|30 35|E-4767
P11600467A1436|31 40|alteration
P11600467A1436|58 69|permeability
P11602353A0770|29 33|HFH-2
P11602353A0770|128 131|gene
P11602353A0770|13 21|HNF-3 beta
P11602353A0770|23 27|HFH-1
P11602353A0770|105 122|expression profiles
P11602353A0770|35 39|HFH-3
P11602353A0770|50 58|C/EBP beta
P11602353A0770|41 45|C/EBP
P11603271T0001|18 33|vertigo syndromes
P11603271T0001|8 14|vertigo
P11604152A0526|203 208|effect
P11604152A0526|220 229|bandwidths
P11604152A0526|70 72|VLF
P11604152A0526|107 108|LF
P11604152A0526|183 189|purpose
P11604152A0526|157 158|Hz
P11604152A0526|174 176|CCF
P11604152A0526|64 68|range
P11604152A0526|139 143|range
P11604152A0526|244 251|mean CCFs
P11604152A0526|10 21|MCBFV signals
P11604152A0526|88 105|low-frequency range
P11604152A0526|145 146|HF
P11604152A0526|3 6|MABP
P11604152A0526|84 85|Hz
P11604152A0526|119 120|Hz
P11604152A0526|26 33|bandpass
P11605207T0001|0 8|Treatment
P11605207T0001|19 30|heart disease
P11605598A0785|0 9|Hepatitis B
P11605598A0785|123 129|climate
P11605598A0785|68 73|El Paso
P11605598A0785|133 150|prevention programs
P11605598A0785|92 104|US populations
P11605598A0785|47 57|adolescents
P11605598A0785|13 32|C seroprevalence rates
P11606538A1002|28 32|genes
P11606538A1002|34 36|Nrk
P11606538A1002|8 16|insertion
P11606538A1002|54 75|receptor tyrosine kinase
P11606538A1002|80 82|Tpp
P11606538A1002|97 110|neuropeptidase
P11614398T0000|42 50|Mormonism
P11614398T0000|9 14|people
P11614398T0000|33 39|aspects
P11639485A0478|78 86|languages
P11639485A0478|10 13|work
P11639485A0478|126 133|scholars
P11639485A0478|112 122|day students
P11639485A0478|66 69|Urdu
P11639485A0478|93 99|benefit
P11642687T0000|0 9|Comparison
P11642687T0000|63 70|outcomes
P11642687T0000|18 33|language versions
P11642687T0000|48 52|SF-36
P11642687T0000|39 44|QWB-SA
P11642687T0000|86 100|prostate disease
P11642687T0000|74 81|patients
P11653491T0000|21 32|DNA violation
P11653491T0000|12 17|action
P11669281A0653|61 68|evidence
P11669281A0653|71 81|competition
P11669281A0653|10 21|cytotoxicity
P11669281A0653|84 92|synergism
P11669281A0653|32 42|antibiotics
P11669476A0346|16 23|cytokine
P11669476A0346|81 87|tissues
P11669476A0346|129 132|role
P11669476A0346|95 102|subjects
P11669476A0346|143 159|insulin resistance
P11669476A0346|51 59|TNF-alpha
P11669476A0346|25 49|tumor necrosis factor-alpha
P11675912A0131|27 30|week
P11675912A0131|90 102|acetaminophen
P11675912A0131|107 117|alleviation
P11675912A0131|80 86|aspirin
P11675912A0131|8 14|alcohol
P11675912A0131|120 128|headaches
P11675912A0131|58 68|preparation
P11676899A0704|16 26|risk factors
P11676899A0704|71 83|mononucleosis
P11676899A0704|109 124|immunodeficiency
P11676899A0704|140 147|exposure
P11676899A0704|55 59|virus
P11676899A0704|152 163|wood industry
P11677363A0775|71 72|PP
P11677363A0775|101 107|measure
P11677363A0775|39 47|IMT values
P11677363A0775|122 134|PP variability
P11677363A0775|117 119|SBP
P11677363A0775|91 91|P
P11677363A0775|65 68|h SBP
P11677363A0775|81 89|deviation
P11677363A0775|16 22|finding
P11677839A0876|73 73|p
P11677839A0876|37 44|controls
P11677839A0876|23 30|patients
P11677839A0876|3 12|difference
P11678437A0000|141 167|petroleum development company
P11678437A0000|16 26|oil spillage
P11678437A0000|29 34|growth
P11678437A0000|124 137|manifold sample
P11678437A0000|51 64|nutrient uptake
P11678437A0000|36 47|productivity
P11678437A0000|186 192|gravity
P11678437A0000|3 8|effect
P11678437A0000|67 71|maize
P11678437A0000|73 81|Zea mays L.
P11678437A0000|97 109|pot experiment
P11679441A0429|121 124|cGMP
P11679441A0429|45 59|nitrate/nitrite
P11679441A0429|98 119|guanosine monophosphate
P11679441A0429|157 161|urine
P11679441A0429|65 87|micromol/mmol creatinine
P11679441A0429|148 153|plasma
P11679441A0429|32 42|measurement
P11679441A0429|126 144|nmol/mmol creatinine
P11679441A0429|61 63|NOx
P11679441A0429|0 12|NO metabolites
P11680835A0756|14 21|analysis
P11680835A0756|70 73|acid
P11680835A0756|34 38|costs
P11680835A0756|84 94|pamidronate
P11680835A0756|42 48|patient
P11683558A0446|3 6|diet
P11683558A0446|78 88|differences
P11683558A0446|9 16|migrants
P11683558A0446|63 76|micronutrients
P11683558A0446|108 111|diet
P11683558A0446|36 49|macronutrients
P11684665A0000|44 51|sequence
P11684665A0000|64 76|cell divisions
P11684665A0000|120 135|nematode body plan
P11684665A0000|0 21|C. elegans embryogenesis
P11685047A0301|41 58|thrombin inhibition
P11685047A0301|65 79|substrate S-2238
P11685047A0301|20 25|method
P11685284X0000|30 36|B37-B44
P11685284X0000|22 26|Suppl
P11685284X0000|1 12|Diabetologia
P11686239A0464|13 20|sequence
P11686239A0464|122 139|sequence similarity
P11686239A0464|72 80|stretches
P11686239A0464|65 67|G/C
P11686239A0464|145 150|G boxes
P11686239A0464|45 45|T
P11686239A0464|195 212|Dictyostelium genes
P11686239A0464|26 31|3B gene
P11686378A0326|248 257|phenomenon
P11686378A0326|76 81|values
P11686378A0326|147 157|E coli/cfu mL
P11686378A0326|18 24|reactor
P11686378A0326|68 71|LD50
P11686378A0326|200 206|Pn decay
P11686378A0326|320 324|cells
P11686378A0326|271 275|cells
P11686378A0326|52 60|discharge
P11686378A0326|228 235|colonies
P11686378A0326|110 123|concentrations
P11686378A0326|129 133|range
P11686378A0326|330 332|EHD
P11686378A0326|305 311|numbers
P11687083A0218|29 34|review
P11687083A0218|103 108|labour
P11687083A0218|58 85|prophylactic prostaglandin use
P11687083A0218|96 100|stage
P11687083A0218|49 55|effects
P11687083A0218|14 22|objective
P11687083A0218|0 9|OBJECTIVES
P11687180A3209|58 63|rHu EPO
P11687180A3209|89 93|onset
P11687180A3209|80 85|delays
P11687180A3209|70 75|speeds
P11687180A3209|9 12|term
P11687180A3209|14 22|questions
P11687180A3209|96 103|dialysis
P11687352A0215|0 6|METHODS
P11687352A0215|83 91|September
P11687352A0215|67 75|September
P11687352A0215|25 30|review
P11687352A0215|55 59|LASIK
P11687352A0215|44 47|eyes
P11687517A1619|2 6|ISREs
P11687517A1619|29 41|mouse promoter
P11687737A0000|0 9|BACKGROUND
P11687737A0000|62 70|mortality
P11687737A0000|121 123|age
P11687737A0000|50 58|morbidity
P11687737A0000|76 84|diabetics
P11687737A0000|19 30|heart disease
P11687737A0000|43 47|cause
P11687869A0000|31 37|colitis
P11687869A0000|12 16|woman
P11687869A0000|59 69|sarcoidosis
P11689217T0000|0 30|Cholesteryl ester transfer protein
P11689217T0000|59 66|subjects
P11689217T0000|69 73|study
P11689217T0000|34 48|atherosclerosis
P11689217T0000|89 99|angiography
P11691585A1174|76 79|homo
P11691585A1174|37 64|coimmunoprecipitation studies
P11691585A1174|84 101|heterodimerization
P11691585A1174|115 132|cKrox family members
P11691585A1174|15 33|mobility shift assays
P11691585T0000|3 18|hcKrox gene family
P11691585T0000|49 59|matrix genes
P11692004A1200|12 21|literature
P11692004A1200|91 102|relationship
P11692004A1200|54 60|studies
P11692004A1200|128 136|aneurysms
P11692004A1200|110 112|NF1
P11692004A1200|1 6|review
P11693461A1649|96 97|RA
P11693461A1649|65 66|US
P11693461A1649|109 118|population
P11693461A1649|79 92|TNF antagonists
P11693461A1649|31 39|drug costs
P11693461A1649|5 19|utilisation data
P11693461A1649|45 49|range
P11693461A1649|53 54|US
P11695481A0310|54 68|degradation rate
P11695481A0310|22 37|combination O3/UV
P11695481A0310|8 17|conditions
P11695481A0310|79 87|ozonation
P11697760A0000|74 75|E2
P11697760A0000|138 144|OVX rats
P11697760A0000|48 54|ability
P11697760A0000|90 96|hormone
P11697760A0000|98 100|PTH
P11697760A0000|57 72|17beta-estradiol
P11697760A0000|111 121|bone quality
P11697760A0000|4 8|study
P11697760A0000|28 32|boron
P11703464A0560|42 48|regions
P11703464A0560|110 117|response
P11703464A0560|19 30|subjects rCBF
P11703464A0560|152 164|reinforcement
P11703464A0560|100 107|circuits
P11703464A0560|132 137|reward
P11703558A0000|0 10|Doxorubicin
P11703558A0000|12 14|DOX
P11703558A0000|36 44|treatment
P11703558A0000|68 73|tumors
P11704380A1608|98 106|Sta-nrMFP
P11704380A1608|43 50|Un-nrMFP
P11704380A1608|33 40|Irr-rMFP
P11704380A1608|88 95|Rev-rMFP
P11704380A1608|3 11|event rate
P11704380A1608|14 21|patients
P11704829A0312|0 23|Subtraction hybridization
P11704829A0312|119 125|changes
P11704829A0312|84 87|gene
P11704829A0312|67 72|gene-7
P11704829A0312|133 145|melanoma cells
P11704829A0312|34 56|melanoma differentiation
P11704829A0312|74 78|mda-7
P11705093A2016|57 62|effect
P11705093A2016|10 27|vitamin D3 analogues
P11706668A0000|0 9|Hydrocoele
P11706668A0000|20 22|men
P11706668A0000|52 56|areas
P11706668A0000|97 108|intervention
P11706668A0000|61 69|treatment
P11706949T0000|0 12|Growth hormone
P11706949T0000|72 76|joint
P11706949T0000|82 84|rat
P11706949T0000|28 49|growth factor I receptors
P11707977A0750|56 63|survival
P11707977A0750|10 13|hand
P11707977A0750|66 75|H3 patients
P11707977A0750|30 44|infusion therapy
P11708032A0183|59 70|levoforinate
P11708032A0183|183 193|medications
P11708032A0183|100 103|5-FU
P11708032A0183|72 75|l-LV
P11708032A0183|136 145|metastases
P11708032A0183|80 81|mg
P11708032A0183|108 109|mg
P11708032A0183|49 56|infusion
P11708032A0183|2 9|addition
P11708032A0183|169 171|day
P11708032A0183|216 220|hours
P11708032A0183|233 243|infuser pump
P11708032A0183|85 98|5-fluorouracil
P11708362A0889|27 33|payload
P11708362A0889|49 57|operation
P11708362A0889|3 15|astronaut crew
P11708431A0904|59 72|oligoarthritis
P11708431A0904|75 79|onset
P11708431A0904|19 30|introduction
P11708431A0904|8 15|patients
P11708431A0904|120 132|patient groups
P11708431A0904|42 49|category
P11708761A1388|58 70|ACE inhibitors
P11708761A1388|94 109|diabetes mellitus
P11708761A1388|53 55|use
P11708761A1388|24 29|number
P11708761A1388|32 40|arguments
P11708761A1388|82 89|patients
P11709561T0000|0 4|Phase
P11709561T0000|7 11|trial
P11709561T0000|24 25|D2
P11709561T0000|37 47|antibody 3F8
P11709561T0000|100 112|neuroblastoma
P11709561T0000|91 96|factor
P11709890T0000|0 9|Hepatitis A
P11709890T0000|18 28|food handler
P11709890T0000|55 66|food facility
P11709890T0000|33 40|Edmonton
P11709890T0000|74 99|health protection strategies
P11709890T0000|42 48|Alberta
P11710233T0000|0 8|Hydrogels
P11710233T0000|12 28|tissue engineering
P11710685A0994a|14 19|subset
P11710685A0994a|22 26|ASCUS
P11710685A0994a|37 50|ASCUS/SIL ratio
P11710685A0994a|84 94|sensitivity
P11710685A0994a|100 115|Papanicolaou test
P11710685A0994b|14 19|subset
P11710685A0994b|22 26|ASCUS
P11710685A0994b|37 50|ASCUS/SIL ratio
P11710685A0994b|84 94|sensitivity
P11710685A0994b|100 115|Papanicolaou test
P11711701A0602|197 201|hours
P11711701A0602|152 156|hours
P11711701A0602|126 132|minutes
P11711701A0602|48 55|findings
P11711701A0602|10 27|medicine physicians
P11711701A0602|141 147|minutes
P11711701A0602|79 84|images
P11711701A0602|171 175|hours
P11711701A0602|160 166|minutes
P11711701A0602|95 121|Tc-99m MIBI image combinations
P11711701A0602|231 257|pertechnetate thyroid imaging
P11711701A0602|182 188|minutes
P11714429X0000|2 12|clopidogrel
P11714429X0000|72 82|cornerstone
P11714429X0000|41 50|prevention
P11714429X0000|124 138|thienopyridines
P11714429X0000|23 29|aspirin
P11714429X0000|259 262|Risk
P11714429X0000|211 217|disease
P11714429X0000|114 121|efficacy
P11714429X0000|170 176|aspirin
P11714429X0000|274 284|Events trial
P11714429X0000|249 256|Patients
P11714429X0000|223 233|Clopidogrel
P11714429X0000|191 200|prevention
P11714429X0000|240 246|Aspirin
P11714429X0000|140 150|clopidogrel
P11714429X0000|93 100|evidence
P11714429X0000|152 162|ticlopidine
P11714429X0000|61 67|disease
P11715079A1016|132 141|mismatches
P11715079A1016|223 225|eye
P11715079A1016|212 217|motion
P11715079A1016|255 260|organs
P11715079A1016|193 199|command
P11715079A1016|89 96|response
P11715079A1016|54 66|efference copy
P11715079A1016|17 30|proprioception
P11715079A1016|149 170|eye movement information
P11715079A1016|73 83|development
P11715079A1016|99 111|perturbations
P11716043A0380|84 116|Helsinki University Central Hospital
P11716043A0380|22 29|patients
P11716043A0380|39 45|surgery
P11716043A0380|76 82|Surgery
P11716043A0380|64 73|Department
P11716043A0380|56 58|PTC
P11716441A0585|72 80|admission
P11716441A0585|34 49|health evaluation
P11716441A0585|51 56|APACHE
P11716441A0585|14 23|physiology
P11716441A0585|0 2|ISS
P11718197A1282|3 11|procedure
P11722993A0276|0 10|Paul Monagle
P11722993A0276|23 34|epidemiology
P11722993A0276|81 86|system
P11722993A0276|139 143|utero
P11722993A0276|110 118|locations
P11722993A0276|45 54|thrombosis
P11723500X0000|88 97|BACKGROUND
P11723500X0000|82 86|women
P11723500X0000|107 119|cell carcinoma
P11723500X0000|27 41|characteristics
P11723500X0000|134 139|cavity
P11723500X0000|161 170|population
P11723500X0000|52 64|cell carcinoma
P11723500X0000|121 123|SCC
P11723500X0000|74 79|cavity
P11723511A0780|127 135|category D
P11723511A0780|106 114|category C
P11723511A0780|123 123|%
P11723511A0780|54 66|category A risk
P11723511A0780|78 78|%
P11723511A0780|150 159|category X.
P11723511A0780|102 102|%
P11723511A0780|146 146|%
P11723511A0780|82 90|category B
P11723511A0780|20 23|risk
P11723511A0780|42 42|%
P11723511A0780|30 34|drugs
P11723675A1022|142 147|group A
P11723675A1022|210 214|point
P11723675A1022|184 188|point
P11723675A1022|21 26|course
P11723675A1022|48 56|SOFA score
P11723675A1022|79 84|group B
P11723675A1022|102 107|group C
P11723675A1022|203 204|.2
P11723675A1022|113 114|.3
P11723675A1022|71 77|.3 point
P11723675A1022|128 140|APACHE II score
P11723675A1022|41 45|means
P11723675A1022|159 163|point
P11723675A1022|96 100|point
P11723675A1022|119 123|point
P11723675A1022|165 170|group B
P11723675A1022|190 195|group C
P11723675A1022|3 10|severity
P11723675A1022|58 63|group A
P11723928A0294|3 9|process
P11723928A0294|47 60|Yangpu District
P11723928A0294|76 80|China
P11723928A0294|63 74|Shanghai City
P11723928A0294|29 44|river reclamation
P11724510T0000|31 39|apheresis
P11724510T0000|8 17|principles
P11726022A0909|42 52|penetration
P11726022A0909|144 148|model
P11726022A0909|5 11|results
P11726022A0909|31 39|estimates
P11726022A0909|94 109|time calculations
P11726022A0909|69 80|calculations
P11726022A0909|88 91|root
P11726068A0539|0 3|Rind
P11726068A0539|11 15|study
P11726068A0539|62 65|data
P11726068A0539|22 32|conclusions
P11726164A0215|87 94|residues
P11726164A0215|61 72|food products
P11726164A0215|162 172|food allergy
P11726164A0215|141 149|reactions
P11726164A0215|7 13|concern
P11726164A0215|16 29|food processors
P11726164A0215|46 58|cross-contact
P11726262A0692|0 22|Lactate accumulation peak
P11726262A0692|38 52|supplementation
P11726262A0692|99 100|mM
P11726262A0692|70 72|LEU
P11726262A0692|67 68|mM
P11726262A0692|54 56|HMB
P11726262A0692|83 84|mM
P11726262A0692|86 88|CON
P11726413A1756|36 42|infants
P11726413A1756|12 20|clearance
P11726413A1756|62 68|opioids
P11726413A1756|47 54|contrast
P11726574A1304|5 11|results
P11726574A1304|36 54|baseline assumptions
P11726574A1304|24 30|changes
P11726574A1304|60 64|model
P11727073A0842|0 9|CONCLUSION
P11727073A0842|36 48|MIST-VR yields
P11727073A0842|107 110|task
P11727073A0842|24 30|novices
P11727073A0842|61 67|changes
P11727073A0842|70 74|skill
P11727073A0842|160 167|training
P11727073A0842|129 135|results
P11727073A0842|14 21|training
P11727209A0502|84 87|test
P11727209A0502|91 101|orthostasia
P11727209A0502|64 74|examination
P11727209A0502|19 26|families
P11727209A0502|3 10|patients
P11728771A0187|50 65|contrast material
P11728771A0187|36 43|reaction
P11730182A0984|118 121|Acer
P11730182A0984|212 218|Poaceae
P11730182A0984|162 162|p
P11730182A0984|153 158|Betula
P11730182A0984|107 116|Cherry Hill
P11730182A0984|254 258|Rumex
P11730182A0984|125 125|p
P11730182A0984|177 177|r
P11730182A0984|179 179|p
P11730182A0984|90 101|Philadelphia
P11730182A0984|203 203|p
P11730182A0984|201 201|r
P11730182A0984|33 43|correlation
P11730182A0984|260 260|r
P11730182A0984|262 262|p
P11730182A0984|144 144|p
P11730182A0984|142 142|r
P11730182A0984|160 160|r
P11730182A0984|220 220|r
P11730182A0984|188 199|Cupressaceae
P11730182A0984|76 87|pollen levels
P11730182A0984|271 271|P
P11730182A0984|134 140|Quercus
P11730182A0984|222 222|p
P11730182A0984|123 123|r
P11730182A0984|240 240|r
P11730182A0984|242 242|p
P11730182A0984|171 175|Pinus
P11730182A0984|231 238|Ambrosia
P11730262A0874|28 46|etidronate/fluoride
P11730262A0874|18 22|study
P11730262A0874|105 107|men
P11730262A0874|91 100|pilot study
P11730262A0874|193 200|fluoride
P11730262A0874|66 77|osteoporosis
P11730262A0874|226 229|days
P11730262A0874|136 147|osteoporosis
P11730262A0874|164 173|etidronate
P11730262A0874|179 182|days
P11730262A0874|205 220|calcium/vitamin D
P11730712A0416|28 32|weeks
P11730712A0416|88 88|P
P11730712A0416|75 86|MCA occlusion
P11730712A0416|62 66|edema
P11730712A0416|45 58|infarction size
P11730712A0416|0 16|Treadmill training
P11732088A0471|131 135|SSEUS
P11732088A0471|92 99|secretin
P11732088A0471|33 40|readings
P11732088A0471|184 189|method
P11732088A0471|120 129|ultrasound
P11732088A0471|211 219|diagnosis
P11732088A0471|162 169|response
P11732088A0471|2 6|order
P11732088A0471|58 75|sphincter manometry
P11732417A0571|103 114|serum samples
P11732417A0571|10 34|percentage positivity value
P11732417A0571|169 176|ELISA kit
P11732417A0571|129 137|reference
P11732417A0571|143 152|sample data
P11736254A0000|144 153|structures
P11736254A0000|51 56|models
P11736254A0000|97 108|partitioning
P11736254A0000|125 133|landscape
P11736254A0000|76 82|glasses
P11736254A0000|2 9|analysis
P11736254A0000|15 22|dynamics
P11736792A0204|131 140|morphology
P11736792A0204|39 43|study
P11736792A0204|90 120|World Health Organization criteria
P11736792A0204|176 183|criteria
P11736792A0204|61 62|G1
P11736792A0204|9 20|semen samples
P11736792A0204|80 81|G2
P11737056A0680|40 47|ET mucosa
P11737056A0680|20 29|leucocytes
P11737056A0680|63 66|BrdU
P11737056A0680|35 36|ME
P11737056A0680|6 14|timepoint
P11737056A0680|92 98|subsets
P11737056A0680|82 82|%
P11737158A1517|60 68|Broca BA44
P11737158A1517|109 120|computations
P11737158A1517|83 87|gyrus
P11737158A1517|137 143|contact
P11737158A1517|46 58|fusiform gyrus
P11737158A1517|33 40|Wernicke
P11737158A1517|165 174|dimensions
P11737158A1517|17 21|areas
P11737900A0700|70 70|P
P11737900A0700|62 63|r2
P11737900A0700|9 19|correlation
P11737900A0700|39 48|body weight
P11737900A0700|58 60|age
P11737900A0700|27 35|plasma COP
P11738404A0120|187 207|alpha-diacetoxy-8 beta
P11738404A0120|234 273|alpha-benzoyloxy-13-isobutanoyloxy-4 beta
P11738404A0120|106 117|alpha-methyl
P11738404A0120|421 431|analyses NMR
P11738404A0120|47 82|alpha-diacetoxy-8 beta-isobutanoyloxy
P11738404A0120|445 448|data
P11738404A0120|333 409|alpha,13-tetraacetoxy-9 alpha-benzoyloxy-2 alpha-hydroxy-beta-dihydroagarofuran
P11738404A0120|276 312|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|210 213|beta
P11738404A0120|320 324|alpha
P11738404A0120|119 135|butanoyloxy-4 beta
P11738404A0120|40 44|alpha
P11738404A0120|138 174|beta-dihydroxy-beta-dihydroagarofuran
P11738404A0120|327 330|beta
P11738404A0120|5 22|chemical structures
P11738404A0120|85 103|alpha-benzoyloxy-13
P11738404A0120|180 184|alpha
P11738404A0120|215 230|furancarbonyloxy
P11738404A0120|435 436|MS
P11740571A0114|13 16|dose
P11740571A0114|110 120|brain tissue
P11740571A0114|77 84|activity
P11740571A0114|212 220|processes
P11740571A0114|131 137|toluene
P11740571A0114|37 43|maximum
P11740571A0114|189 198|activation
P11740571A0114|55 67|concentration
P11740571A0114|4 9|toxins
P11740571A0114|87 107|glutathione peroxidase
P11740571A0114|147 172|chemiluminescence intensity
P11740806X0810|0 14|Saunders Company
P11741259A1233|100 103|part
P11741259A1233|75 78|drug
P11741259A1233|3 13|performance
P11741259A1233|56 62|ability
P11741259A1233|109 117|intestine
P11741259A1233|141 144|form
P11741259A1233|28 36|particles
P11741554T0000|0 9|Comparison
P11741554T0000|60 64|women
P11741554T0000|24 43|lipoprotein particles
P11741554T0000|105 107|men
P11741554T0000|87 99|artery disease
P11741554T0000|120 132|artery disease
P11742432A0798|89 96|patients
P11742432A0798|342 353|cells/microL
P11742432A0798|316 324|CD4 counts
P11742432A0798|257 271|discontinuation
P11742432A0798|53 60|efficacy
P11742432A0798|274 293|macrolide prophylaxis
P11742432A0798|299 310|AIDS patients
P11742432A0798|115 125|combination
P11742432A0798|73 86|MAC prophylaxis
P11742432A0798|230 234|tract
P11742432A0798|163 171|incidence
P11742432A0798|7 13|results
P11742432A0798|202 213|colonization
P11742432A0798|140 146|therapy
P11742432A0798|32 37|trials
P11742432A0798|241 245|trial
P11743360A2491|111 112|ml
P11743360A2491|107 108|pg
P11743360A2491|74 74|%
P11743360A2491|34 43|mean amount
P11743360A2491|63 67|urine
P11743360A2491|46 49|IL-6
P11743360A2491|5 10|stress
P11743360A2491|14 17|rats
P11743612A1179|0 7|Patients
P11743612A1179|63 71|diagnosis
P11743612A1179|81 92|survival rate
P11743612A1179|113 124|CF population
P11743612A1179|12 13|CF
P11743612A1179|55 60|status
P11743612A1179|17 29|meconium ileus
P11744290T0045|1 9|Cactaceae
P11744290T0045|11 21|waste matter
P11744953A0878|0 10|Skin cancers
P11744953A0878|82 92|age patients
P11744953A0878|38 42|tract
P11744953A0878|57 62|system
P11752821A1365|0 9|CONCLUSION
P11752821A1365|44 48|signs
P11752821A1365|64 82|Adamantiades-Behcet
P11752821A1365|11 13|MMF
P11752821A1365|18 22|g/day
P11752821A1365|85 91|disease
P11755894A0466|116 125|management
P11755894A0466|102 103|mg
P11755894A0466|89 91|ADL
P11755894A0466|141 145|ileus
P11755894A0466|185 197|bowel function
P11755894A0466|213 224|hospital stay
P11755894A0466|80 83|pain
P11755894A0466|47 53|surgery
P11755894A0466|5 13|treatment
P11755894A0466|166 169|time
P11755894A0466|65 71|opioids
P11755894A0466|147 149|POI
P11755894A0466|27 34|patients
P11760398A0553|102 109|presence
P11760398A0553|134 135|BS
P11760398A0553|22 29|patients
P11760398A0553|124 131|features
P11760398A0553|112 118|absence
P11760398A0553|189 199|ISG criteria
P11760398A0553|138 142|means
P11760398A0553|154 157|form
P11760398A0553|74 83|conditions
P11760398A0553|34 35|BS
P11760398A0553|42 49|patients
P11760398A0553|0 6|METHODS
P11760796A0698|0 7|Evidence
P11760796A0698|65 76|phakomatosis
P11760796A0698|46 56|association
P11760796A0698|20 33|PHACES syndrome
P11760796A0698|108 112|light
P11760796A0698|131 140|background
P11760796A0698|85 91|studies
P11761601A0133|86 110|contaminant concentrations
P11761601A0133|52 65|airflow pattern
P11761601A0133|135 153|inhalation exposures
P11761601A0133|70 80|time history
P11761601A0133|124 127|zone
P11761601A0133|17 26|ACCESS-IAQ
P11761601A0133|1 15|computer program
P11763176A0918|86 95|experiment
P11763176A0918|123 123|%
P11763176A0918|26 45|antithrombin activity
P11763176A0918|69 79|experiments
P11763176A0918|16 23|decrease
P11764062A0000|116 123|children
P11764062A0000|106 113|tendency
P11764062A0000|179 186|Chorpita
P11764062A0000|193 197|Behav
P11764062A0000|173 177|worry
P11764062A0000|3 29|Penn State Worry Questionnaire
P11764062A0000|33 40|Children
P11764062A0000|42 47|PSWQ-C
P11764062A0000|59 82|self-report questionnaire
P11764226A0798|0 13|Classification
P11764226A0798|100 105|months
P11764226A0798|56 63|patients
P11764226A0798|80 94|disease duration
P11764226A0798|137 149|EULAR criteria
P11764226A0798|68 75|patients
P11764226A0798|28 39|ILAR criteria
P11765448A0588|41 48|patients
P11765448A0588|9 23|X-ray projection
P11766747A0000|72 79|teratoma
P11766747A0000|33 38|review
P11766747A0000|45 52|patients
P11768467A0000|0 21|Pyrethroid insecticides
P11768467A0000|37 47|agriculture
P11768467A0000|58 67|households
P11769229A0357|58 64|process
P11769229A0357|32 41|adsorption
P11769229A0357|78 85|sorption
P11769229A0357|3 20|sorption mechanisms
P11769229A0357|44 52|partition
P11771979A1141|29 39|variability
P11771979A1141|95 99|range
P11771979A1141|135 137|LDF
P11771979A1141|111 117|methods
P11771979A1141|153 159|mapping
P11771979A1141|200 212|heterogeneity
P11771979A1141|75 83|microflow
P11771979A1141|42 51|LDF signals
P11771979A1141|128 133|organs
P11771979A1141|233 243|vasculature
P11773168A0915|113 113|P
P11773168A0915|122 122|P
P11773168A0915|16 23|survival
P11773168A0915|47 54|survival
P11773168A0915|96 96|%
P11773168A0915|81 81|%
P11773168A0915|104 104|%
P11773168A0915|25 26|OS
P11773168A0915|56 58|PFS
P11773168A0915|108 111|arm B
P11773168A0915|73 73|%
P11773168A0915|85 88|arm A
P11773168A0915|60 64|rates
P11773921A0397|0 6|METHODS
P11773921A0397|344 345|mg
P11773921A0397|146 149|days
P11773921A0397|336 339|dose
P11773921A0397|190 197|patients
P11773921A0397|221 231|clopidogrel
P11773921A0397|217 218|mg
P11773921A0397|72 75|flow
P11773921A0397|154 161|patients
P11773921A0397|107 117|clopidogrel
P11773921A0397|259 266|patients
P11773921A0397|200 204|group
P11773921A0397|242 253|implantation
P11773921A0397|366 371|groups
P11773921A0397|298 308|clopidogrel
P11773921A0397|8 27|P-selectin expression
P11773921A0397|269 273|group
P11773921A0397|348 358|clopidogrel
P11773921A0397|316 319|dose
P11773921A0397|60 68|platelets
P11773921A0397|174 186|artery disease
P11773921A0397|125 128|dose
P11775180A0379|43 48|survey
P11775180A0379|54 73|gamma-detecting probe
P11775180A0379|19 29|exploration
P11775301A0797|13 24|intervention
P11775301A0797|2 7|effect
P11775301A0797|27 42|depression scores
P11776922A0830|56 60|group
P11776922A0830|73 77|group
P11776922A0830|38 46|skull base
P11776922A0830|49 53|cases
P11776922A0830|23 32|resorption
P11776922A0830|11 19|sclerosis
P11776922A0830|62 68|lesions
P11776922A0830|80 86|lesions
P11777575A0363|130 137|networks
P11777575A0363|30 39|bulgaricus
P11777575A0363|139 142|ANNs
P11777575A0363|77 82|pellet
P11777575A0363|96 99|data
P11777575A0363|17 26|population
P11777575A0363|3 10|quantity
P11777575A0363|41 54|S. thermophilus
P11777575A0363|85 88|PyMS
P11777632A1678|0 1|AF
P11777632A1678|110 115|breast
P11777632A1678|125 131|lesions
P11777632A1678|152 155|loss
P11777632A1678|90 98|component
P11777632A1678|158 169|AF expression
P11777632A1678|33 39|pattern
P11777632A1678|197 208|breast cancer
P11777632A1678|42 51|expression
P11777632A1678|219 224|stroma
P11778044A0000|223 241|climate observations
P11778044A0000|138 148|simulations
P11778044A0000|64 73|properties
P11778044A0000|165 186|complexity climate model
P11778044A0000|79 91|climate system
P11778044A0000|107 128|fingerprinting approach
P11778044A0000|204 214|diagnostics
P11778044A0000|13 43|probability density distributions
P11778804A0179|0 8|Frequency
P11778804A0179|60 62|FDT
P11778804A0179|17 22|curves
P11778804A0179|41 46|method
P11781615A0000|32 36|cGVHD
P11781615A0000|24 30|disease
P11781615A0000|83 101|cell transplantation
P11781615A0000|46 57|complication
P11782218A0349|29 37|perimetry
P11782218A0349|128 142|media absorption
P11782218A0349|10 23|white-on-white
P11782218A0349|25 27|W-W
P11782218A0349|39 42|SWAP
P11782218A0349|72 82|variability
P11782218A0349|112 120|threshold
P11782218A0349|187 200|learning effect
P11782218A0349|100 109|estimation
P11782218A0349|153 171|examination duration
P11783457A0000|0 12|Preservatives
P11783457A0000|27 35|component
P11783457A0000|83 90|activity
P11783457A0000|115 127|decomposition
P11783457A0000|96 101|bottle
P11783457A0000|48 59|preparations
P11783457A0000|136 139|drug
P11785085X0001|59 66|patients
P11785085X0001|212 219|PVM-R-01
P11785085X0001|11 18|analysis
P11785085X0001|104 111|efficacy
P11785085X0001|193 210|pneumovibromassage
P11785085X0001|166 177|Introl-4 unit
P11785085X0001|49 56|drainage
P11785085X0001|238 245|patients
P11785085X0001|149 164|vacuum aspiration
P11785085X0001|28 37|techniques
P11785085X0001|123 130|drainage
P11785085X0001|268 278|prostatitis
P11785085X0001|89 99|prostatitis
P11785827A0986|175 190|transmissibility
P11785827A0986|44 49|models
P11785827A0986|198 210|communication
P11785827A0986|155 171|selection pressure
P11785827A0986|24 31|relation
P11785827A0986|118 128|degradation
P11785827A0986|3 9|results
P11785827A0986|136 141|forest
P11785827A0986|71 80|physiology
P11785827A0986|57 67|propagation
P11786248A1162|0 10|Consumption
P11786248A1162|49 55|lesions
P11786248A1162|112 112|%
P11786248A1162|61 64|PPTg
P11786248A1162|118 125|% sucrose
P11786248A1162|69 72|PPTg
P11786248A1162|81 84|rats
P11786248A1162|130 141|sham controls
P11786248A1162|14 21|% sucrose
P11786945A0958|31 41|arrhythmias
P11786945A0958|9 15|freedom
P11786945A0958|75 80|group A
P11786945A0958|50 58|follow-up
P11786945A0958|72 72|%
P11787041A0167|6 16|development
P11787322X0001|0 8|Influence
P11787322X0001|286 293|diseases
P11787322X0001|102 112|instruments
P11787322X0001|180 190|impressions
P11787322X0001|262 273|transmission
P11787322X0001|62 71|properties
P11787322X0001|141 154|prosthodontics
P11787322X0001|252 259|vehicles
P11787322X0001|74 77|type
P11787322X0001|163 167|stone
P11787322X0001|20 26|methods
P11787322X0001|205 211|records
P11787322X0001|83 89|V gypsum
P11787322X0001|239 248|literature
P11787322X0001|116 124|materials
P11787322X0001|29 48|chemical disinfection
P11787720A1313|115 115|%
P11787720A1313|108 109|n6
P11787720A1313|49 52|acid
P11787720A1313|66 66|%
P11787720A1313|103 105|C20
P11787720A1313|76 76|P
P11787720A1313|12 15|milk
P11787720A1313|31 38|decrease
P11787720A1313|117 117|P
P11787720A1313|54 56|C18
P11787720A1313|59 60|n6
P11787720A1313|98 101|acid
P11787746A0374|0 9|Vitrectomy
P11787746A0374|13 19|removal
P11787746A0374|99 106|majority
P11787746A0374|61 66|acuity
P11787746A0374|109 116|patients
P11787746A0374|86 93|glaucoma
P11787746A0374|30 42|lens fragments
P11789206A1182|15 23|mechanism
P11789206A1182|102 103|Qi
P11789206A1182|75 84|principles
P11789206A1182|26 29|MIRI
P11789206A1182|32 43|Qi deficiency
P11789206A1182|47 57|blood stasis
P11789206A1182|60 62|TCM
P11789206A1182|118 128|blood stasis
P11789206A1182|0 10|CONCLUSIONS
P11789216T0001|0 6|Effects
P11789216T0001|56 68|barrier action
P11789216T0001|19 34|blood circulation
P11789216T0001|78 81|wall
P11789216T0001|99 107|gastritis
P11789216T0001|43 53|blood stasis
P11790897T0000|59 67|potential
P11790897T0000|9 16|patterns
P11790897T0000|105 116|breast cancer
P11790897T0000|19 24|nipple
P11790897T0000|94 102|diagnosis
P11790897T0000|49 57|SELDI-TOF
P11790897T0000|33 38|fluids
P11790897T0000|74 83|biomarkers
P11791292A0193|72 78|problem
P11791292A0193|54 60|network
P11791292A0193|35 45|application
P11791292A0193|14 23|laboratory
P11791571T0000|61 75|electrophoresis
P11791571T0000|97 118|plasma mass spectrometry
P11791571T0000|1 48|high-efficiency cross-flow micronebulizer interface
P11791585A0287|56 58|use
P11791585A0287|121 127|surface
P11791585A0287|3 12|electrodes
P11791853A0532|15 21|results
P11791853A0532|95 99|color
P11791853A0532|106 108|COD
P11791853A0532|128 137|wastewater
P11791853A0532|35 69|coagulation-electrooxidation process
P11792586A0290|85 96|tissue matrix
P11792586A0290|65 75|microcracks
P11792586A0290|6 12|loading
P11792586A0290|106 109|bone
P11792586A0290|36 43|activity
P11792586A0290|54 62|formation
P11792586A0290|15 18|bone
P11793172A0545|29 34|PE head
P11793172A0545|134 139|PE head
P11793172A0545|53 56|time
P11793172A0545|62 64|THA
P11793172A0545|17 23|surface
P11793172A0545|72 90|friction coefficient
P11793614A0000|0 8|OBJECTIVE
P11793614A0000|24 27|lack
P11793614A0000|182 196|anticoagulation
P11793614A0000|156 162|disease
P11793614A0000|103 111|inhibitor
P11793614A0000|30 35|effect
P11793614A0000|50 63|concentrations
P11793614A0000|66 75|cilomilast
P11793614A0000|118 126|treatment
P11793614A0000|85 101|phosphodiesterase
P11796977T0000|0 7|Postdocs
P11796977T0000|26 39|mainland Europe
P11796977T0000|12 19|hardship
P11800119A0814|3 17|design principle
P11800119A0814|33 45|vibration mode
P11800586A1090|127 135|diagnosis
P11800586A1090|138 149|tuberculosis
P11800586A1090|107 110|tool
P11800586A1090|47 53|bacilli
P11800586A1090|10 17|DPPD gene
P11800586A1090|82 89|molecule
P11800586A1090|60 66|results
P11800878T0000|0 13|Dynamic imaging
P11800878T0000|40 62|ultrashort UV laser pulses
P11800878T0000|23 35|wave functions
P11801459T0000|0 7|Efficacy
P11801459T0000|52 67|atherothrombosis
P11801459T0000|11 16|safety
P11801459T0000|19 25|aspirin
P11801459T0000|40 49|management
P11802580A0000|103 116|patient records
P11802580A0000|128 135|practice
P11802580A0000|45 49|world
P11802580A0000|154 171|health research tool
P11802580A0000|35 38|GPRD
P11802580A0000|3 33|General Practice Research Database
P11802580A0000|59 78|computerized database
P11802601A0107|4 8|paper
P11802601A0107|76 90|aldicarb sulfone
P11802601A0107|94 110|aldicarb sulfoxide
P11802601A0107|64 74|metabolites
P11802601A0107|46 53|aldicarb
P11802601A0107|19 25|results
P11802601A0107|29 43|laboratory study
P11803325A0868|79 80|DC
P11803325A0868|7 21|DC cardioversion
P11803325A0868|86 93|GIK group
P11803325A0868|38 45|HBS group
P11803325A0868|62 69|CBC group
P11803325A0868|55 56|DC
P11804081A0552|84 93|Everglades
P11804081A0552|5 10|August
P11804081A0552|50 51|TP
P11804081A0552|19 22|ENRP
P11804081A0552|44 47|tons
P11804100A0365a|39 43|NH3-N
P11804100A0365a|17 29|disappearance
P11804100A0365a|104 112|TP removal
P11804100A0365a|79 86|kinetics
P11804100A0365a|94 101|kinetics
P11804100A0365a|32 35|BOD5
P11804100A0365b|39 43|NH3-N
P11804100A0365b|17 29|disappearance
P11804100A0365b|104 112|TP removal
P11804100A0365b|79 86|kinetics
P11804100A0365b|94 101|kinetics
P11804100A0365b|32 35|BOD5
P11804510A0730|0 5|Losses
P11804510A0730|24 24|%
P11804510A0730|8 20|dichlofluanid
P11804510A0730|196 205|processing
P11804510A0730|115 120|apples
P11804510A0730|42 42|%
P11804510A0730|27 38|chlozolinate
P11804510A0730|152 157|levels
P11804510A0730|48 58|etridiazole
P11804510A0730|170 170|%
P11804510A0730|62 62|%
P11804510A0730|103 112|processing
P11806132A0253|26 29|area
P11806132A0253|20 24|AIRIN
P11806132A0253|78 81|rate
P11806132A0253|43 53|% TB patients
P11806132A0253|3 13|TB incidence
P11810685A0147|131 131|q
P11810685A0147|105 119|long-wavelength
P11810685A0147|148 149|3D
P11810685A0147|74 85|displacement
P11810685A0147|191 196|DT-MRI
P11810685A0147|133 138|limits
P11810685A0147|158 181|displacement distribution
P11810685A0147|57 59|MRI
P11810685A0147|16 39|displacement distribution
P11810685A0147|97 97|r
P11811743A0800|58 67|Class III FI
P11811743A0800|3 11|procedure
P11811743A0800|109 117|clinician
P11811743A0800|26 34|retention
P11811743A0800|71 76|manner
P11811743A0800|96 102|patient
P11811825A0972|3 9|results
P11811825A0972|75 80|system
P11811825A0972|23 49|cross-validation experiments
P11811825A0972|64 70|average
P11811825A0972|93 103|specificity
P11811825A0972|133 148|sensitivity level
P11815644A0081|117 133|muscle recruitment
P11815644A0081|140 151|echolocation
P11815644A0081|87 92|timing
P11815644A0081|63 72|variations
P11815644A0081|33 37|calls
P11815644A0081|56 58|bat
P11815644A0081|11 25|characteristics
P11815644A0081|47 53|species
P11815644A0081|96 103|patterns
P11816458A0319|98 110|review article
P11816458A0319|22 33|Explanations
P11816458A0319|53 62|help system
P11816458A0319|11 18|Examples
P11816458A0319|87 94|sections
P11816458A0319|112 125|journal article
P11816458A0319|136 145|experiment
P11816458A0319|36 42|APA Form
P11816458A0319|179 189|experiments
P11816458A0319|149 162|journal article
P11816458A0319|67 74|examples
P11816779A0343|3 13|drug packets
P11816779A0343|53 67|chloramphenicol
P11816779A0343|23 35|acetyl aspirin
P11816779A0343|37 49|acetaminophen
P11818675X0897|0 7|Karger AG
P11818675X0897|9 13|Basel
P11819326A0000|105 107|PSE
P11819326A0000|168 170|PSE
P11819326A0000|19 22|role
P11819326A0000|36 41|status
P11819326A0000|110 116|METHODS
P11819326A0000|53 60|patients
P11819326A0000|90 103|encephalopathy
P11819326A0000|140 147|patients
P11819326A0000|219 228|volunteers
P11819326A0000|152 160|cirrhosis
P11819326A0000|0 2|AIM
P11821098A0269|56 57|B.
P11821098A0269|39 40|LH
P11821098A0269|45 52|inhibin A
P11821098A0269|22 32|Serum levels
P11821098A0269|35 37|FSH
P11821098A0269|19 19|S
P11821098A0269|0 17|MAIN OUTCOME MEASURE
P11822790A0907|40 46|patient
P11822790A0907|18 25|SIP score
P11822790A0907|162 166|items
P11822790A0907|101 115|study population
P11822790A0907|177 187|improvement
P11822790A0907|71 77|example
P11822790A0907|3 10|instance
P11822790A0907|194 213|reproducibility noise
P11822790A0907|91 95|score
P11822790A0907|53 53|%
P11822790A0907|144 144|%
P11822811A0319|0 4|Group
P11822811A0319|109 120|intoxication
P11822811A0319|50 72|microg/kg ivermectin p.o.
P11822811A0319|99 103|hours
P11822811A0319|21 27|Collies
P11822811A0319|94 97|VMTH
P11824701A0894|29 33|event
P11824701A0894|126 130|event
P11824701A0894|77 89|Bortner scores
P11824701A0894|47 50|Type
P11824701A0894|52 67|behavior patterns
P11824701A0894|94 101|patients
P11824701A0894|0 7|Patients
P11824801A0661|117 124|minority
P11824801A0661|53 60|presence
P11824801A0661|14 25|continuation
P11824801A0661|80 91|exacerbation
P11824801A0661|94 104|sarcoidosis
P11824801A0661|127 134|patients
P11824801A0661|150 165|organ involvement
P11824801A0661|31 47|interferon therapy
P11825801A1212|24 32|mortality
P11825801A1212|54 62|follow-up
P11825801A1212|67 72|months
P11826141T0000|73 80|amygdala
P11826141T0000|11 17|effects
P11826141T0000|130 137|behavior
P11826141T0000|46 52|rostral
P11826141T0000|20 40|lidocaine inactivation
P11826141T0000|140 143|rats
P11826141T0000|100 112|reinstatement
P11826141T0000|86 96|maintenance
P11828186A0239|57 61|years
P11828186A0239|78 89|heart disease
P11828186A0239|166 174|NHANES III
P11828186A0239|139 164|Nutrition Examination Survey
P11828186A0239|97 111|CRP measurements
P11828186A0239|33 35|men
P11828186A0239|3 12|population
P11828186A0239|117 135|Third National Health
P11828186A0239|43 47|women
P11830544A0335|118 129|WIBC-9 tumors
P11830544A0335|57 60|size
P11830544A0335|150 166|control MC-5 tumors
P11830544A0335|64 65|nm
P11830544A0335|28 32|HER-2
P11830544A0335|73 79|1B4M-Gd
P11830544A0335|34 43|neu antigen
P11830544A0335|189 200|angiogenesis
P11830544A0335|0 8|Herceptin
P11831512A0468|199 205|lactose
P11831512A0468|74 83|treatments
P11831512A0468|147 150|gram
P11831512A0468|98 104|lactose
P11831512A0468|37 37|d
P11831512A0468|154 157|gram
P11831512A0468|40 42|age
P11831512A0468|186 187|DE
P11831512A0468|218 222|DE-42
P11831512A0468|131 137|lactose
P11831512A0468|11 14|pigs
P11831512A0468|87 93|control
P11831512A0468|110 127|carbohydrate source
P11831512A0468|163 165|CSS
P11831512A0468|167 184|dextrose equivalent
P11832019A0668|43 58|emergency disease
P11832019A0668|12 15|AMVT
P11832019A0668|0 10|CONCLUSIONS
P11833863A0987|59 67|positions
P11833863A0987|10 19|difference
P11833863A0987|22 34|apnea duration
P11833863A0987|45 50|supine
P11834476A1187|234 243|protection
P11834476A1187|18 28|animal model
P11834476A1187|79 81|min
P11834476A1187|60 70|transfusion
P11834476A1187|87 94|ischemia
P11834476A1187|118 138|hemoglobin transfusion
P11834476A1187|45 52|ischemia
P11834476A1187|149 163|oxygen transport
P11834476A1187|177 182|cortex
P11834476A1187|190 197|increase
P11835109A0000|100 103|life
P11835109A0000|142 150|disorders
P11835109A0000|112 119|patients
P11835109A0000|169 174|trials
P11835109A0000|105 108|HRQL
P11835109A0000|91 97|quality
P11835109A0000|54 63|importance
P11835109A0000|40 48|awareness
P11836046A0549|196 203|estrogen
P11836046A0549|67 68|mg
P11836046A0549|93 95|end
P11836046A0549|244 248|month
P11836046A0549|118 123|group A
P11836046A0549|47 62|calcium carbonate
P11836046A0549|99 102|meal
P11836046A0549|172 177|mg/day
P11836046A0549|132 147|calcium carbonate
P11836046A0549|157 162|manner
P11836046A0549|108 112|times
P11836046A0549|208 228|mg medrogestone acetate
P11836046A0549|43 44|mg
P11836046A0549|125 125|n
P11836046A0549|80 86|calcium
P11836046A0549|257 257|n
P11836046A0549|233 235|day
P11836046A0549|114 116|day
P11836046A0549|250 255|group B
P11836303A0518|0 7|TNFalpha
P11836303A0518|11 20|IL-6 levels
P11836303A0518|40 58|culture supernatants
P11836303A1191|14 18|study
P11836303A1191|46 56|disturbance
P11836303A1191|138 142|stage
P11836303A1191|82 96|cytokine biology
P11836303A1191|74 79|change
P11837409A0584|88 101|symptomatology
P11837409A0584|21 45|National Longitudinal Study
P11837409A0584|117 124|interval
P11837409A0584|69 75|measure
P11837409A0584|48 63|Adolescent Health
P11838058A0084|0 6|METHODS
P11838058A0084|40 54|tissue expansion
P11838058A0084|117 120|CPTE
P11838058A0084|65 69|cases
P11838058A0084|138 142|study
P11838058A0084|9 13|cases
P11838058A0084|56 59|CITE
P11838058A0084|101 115|tissue expansion
P11838102T0001|0 6|Wegener
P11838102T0001|9 22|granulomatosis
P11840365A0949|28 37|hematocrit
P11840365A0949|43 60|General Health scale
P11840365A0949|20 25|effect
P11840365A0949|66 70|SF-36
P11840365A0949|72 72|P
P11842037A0327|72 76|value
P11842037A0327|31 53|% urine-plasma difference
P11842037A0327|15 24|precisions
P11842728X0001|76 86|blood flukes
P11842728X0001|34 47|Schistosomosis
P11842728X0001|92 107|Schistosoma genus
P11842728X0001|60 67|diseases
P11842728X0001|18 32|schistosomiasis
P11843252A0907|28 46|% confidence interval
P11843252A0907|7 18|response rate
P11843252A0907|24 24|%
P11843252A0907|81 88|survival
P11843252A0907|56 56|%
P11843252A0907|50 52|% CI
P11843252A0907|94 99|months
P11843252A0907|60 60|%
P11844591A0329|55 57|APT
P11844591A0329|17 25|parameter
P11844591A0329|30 34|angle
P11844591A0329|44 53|peak torque
P11844812A0915|110 115|PSA-TZ
P11844812A0915|101 101|P
P11844812A0915|162 162|P
P11844812A0915|129 138|PSA density
P11844812A0915|147 160|prostate volume
P11844812A0915|97 99|PSA
P11844812A0915|34 44|ANN ROC curve
P11844812A0915|12 21|ng/mL model
P11844812A0915|74 77|AUCs
P11844812A0915|117 117|P
P11844812A0915|26 28|AUC
P11844812A0915|81 90|percentage
P11845547A0449|62 77|21-aminosteroids
P11845547A0449|26 35|dobutamine
P11845547A0449|37 57|KATP channel activators
P11845547A0449|9 18|treatments
P11846167A0000|0 7|Selenium
P11846167A0000|61 74|microorganisms
P11846167A0000|52 58|species
P11846167A0000|38 44|animals
P11846167A0000|21 27|element
P11846167A0000|31 36|humans
P11846187A0894|3 21|GT-foreign-pictures
P11846187A0894|81 102|permeability directions
P11846187A0894|35 42|judgment
P11846187A0894|50 57|subjects
P11847580T0000|38 45|findings
P11847580T0000|13 25|cholecystitis
P11849417A0900|144 153|HD patients
P11849417A0900|57 63|RESULTS
P11849417A0900|25 30|groups
P11849417A0900|118 122|years
P11849417A0900|70 79|initiation
P11849417A0900|82 99|dialysis PD patients
P11849417A0900|131 131|P
P11849417A0900|0 2|Age
P11849796A0452|0 6|RESULTS
P11849796A0452|102 111|IMRT fields
P11849796A0452|39 44|3D-CRT
P11849796A0452|11 20|target dose
P11849796A0452|66 77|improvements
P11849796A0452|48 56|IMRT plans
P11851941A0372|61 71|blood volume
P11851941A0372|184 186|HES
P11851941A0372|117 127|haemoglobin
P11851941A0372|32 49|serumalbumin method
P11851941A0372|77 89|haemodilution
P11851941A0372|131 140|comparison
P11851941A0372|165 182|hydroxyethyl starch
P11851941A0372|146 162|reference solution
P11852907A0871|113 117|order
P11852907A0871|75 84|SRP content
P11852907A0871|39 49|surface soil
P11852907A0871|32 35|EPC0
P11852907A0871|120 128|magnitude
P11852907A0871|106 109|farm
P11852907A0871|3 30|equilibrium phosphorus content
P11852907A0871|87 99|drainage water
P11853943A0122|45 65|R-R interval estimation
P11853943A0122|12 21|prediction
P11853943A0122|33 41|algorithm
P11858256A0102|30 40|explanation
P11858256A0102|47 52|effect
P11858256A0102|19 26|research
P11858548A0241|3 11|structure
P11858548A0241|64 73|NMR spectra
P11858548A0241|33 37|study
P11858548A0241|77 92|mass spectrometry
P11858548A0241|43 46|mono
P11858635A0896|27 34|property
P11858635A0896|61 79|LOO cross-validation
P11858635A0896|37 46|QSAR models
P11859400A0229|13 20|efficacy
P11859400A0229|182 190|acyclovir
P11859400A0229|130 133|APCT
P11859400A0229|75 77|HSV
P11859400A0229|195 208|HSV prophylaxis
P11859400A0229|157 164|controls
P11859400A0229|31 42|valacyclovir
P11859400A0229|55 69|HSV reactivation
P11859400A0229|24 28|costs
P11859400A0229|100 128|progenitor cell transplantation
P11859400A0229|135 142|patients
P11859943A0150|101 126|General Health Questionnaire
P11859943A0150|21 37|outpatient clinics
P11859943A0150|78 81|days
P11859943A0150|3 8|adults
P11859943A0150|55 62|hospital
P11860097A1695|101 115|prosthesis users
P11860097A1695|6 18|prosthesis use
P11860097A1695|91 97|outcome
P11860097A1695|52 56|study
P11860097A1695|119 127|non-users
P11860097A1695|0 3|Data
P11860723A0182|13 26|Georgia members
P11860723A0182|32 46|American College
P11860723A0182|49 61|Obstetricians
P11860723A0182|65 77|Gynecologists
P11860723A0182|1 10|mail survey
P11860876A0409|0 12|HIV-1 C subtype
P11860876A0409|35 35|%
P11860876A0409|15 18|IDUs
P11861092A0730|260 273|HDI5000 scanner
P11861092A0730|277 285|C5-2 probe
P11861092A0730|249 251|Pim
P11861092A0730|14 24|enhancement
P11861092A0730|134 136|FGS
P11861092A0730|43 48|lesion
P11861092A0730|150 162|colour Doppler
P11861092A0730|180 191|power Doppler
P11861092A0730|128 132|scale
P11861092A0730|299 300|WA
P11861092A0730|164 166|FCD
P11861092A0730|193 195|FPD
P11861092A0730|99 111|scanning modes
P11861092A0730|222 224|HGS
P11861092A0730|216 220|scale
P11861092A0730|287 289|ATL
P11861092A0730|5 11|plateau
P11861092A0730|55 61|patient
P11861092A0730|291 297|Bothell
P11861092A0730|235 247|inversion mode
P11862350T0000|131 137|traffic
P11862350T0000|50 81|NMDA receptor antagonist remacemide
P11862350T0000|112 122|performance
P11862350T0000|22 28|effects
P11862350T0000|12 16|study
P11862350T0000|84 95|road tracking
P11862350T0000|31 43|carbamazepine
P11863811A0259|58 62|range
P11863811A0259|65 66|Pr
P11863811A0259|21 33|Nusselt number
P11863811A0259|50 50|%
P11863811A0259|79 88|experiment
P11864173T0000|27 32|causes
P11864173T0000|67 76|bronchitis
P11864173T0000|35 38|type
P11864173T0000|45 57|exacerbations
P11864173T0000|16 24|pathogens
P11865218A0069|0 8|Treatment
P11865218A0069|44 55|wax softening
P11865218A0069|38 40|use
P11865218A0069|68 72|agent
P11865218A0069|16 24|condition
P11866130A0419|2 9|addition
P11866130A0419|11 20|benzocaine
P11866130A0419|96 113|quinaldine sulphate
P11866130A0419|70 81|phagocytosis
P11866130A0419|24 39|2-phenoxyethanol
P11866130A0419|88 92|MS222
P11866130A0419|49 66|complement activity
P11867388A0502|202 202|P
P11867388A0502|44 56|concentration
P11867388A0502|81 96|fear conditioning
P11867388A0502|77 77|%
P11867388A0502|155 170|fear conditioning
P11867388A0502|128 128|%
P11867388A0502|34 39|memory
P11867388A0502|113 113|%
P11867388A0502|12 22|suppression
P11867388A0502|130 133|mean
P11867388A0502|99 105|context
P11867388A0502|184 184|%
P11867388A0502|199 199|%
P11867388A0502|173 176|tone
P11867388A0502|67 72|memory
P11867388A0502|3 4|EC
P11867388A0502|144 146|SEM
P11870646A0668|3 9|utility
P11870646A0668|110 115|damage
P11870646A0668|78 87|resistance
P11870646A0668|37 67|ceramic/substrate bilayer systems
P11870646A0668|29 34|design
P11870646A0668|16 23|analyses
P11872359A0000|131 133|CVD
P11872359A0000|184 194|Australians
P11872359A0000|21 37|insulin resistance
P11872359A0000|39 40|IR
P11872359A0000|75 81|disease
P11872359A0000|52 58|cluster
P11872359A0000|121 128|syndrome
P11872359A0000|160 168|mortality
P11872359A0000|83 85|CVD
P11872359A0000|144 148|cause
P11872359A0000|87 97|risk factors
P11872570T0000|0 7|Dementia
P11872570T0000|36 39|care
P11872570T0000|24 26|NHS
P11873003X0000|0 13|HIV-1 infection
P11873003X0000|159 172|HIV-1 infection
P11873003X0000|67 74|survival
P11873003X0000|21 26|Africa
P11873003X0000|252 257|Uganda
P11873003X0000|177 190|seroconversion
P11873003X0000|141 156|progression times
P11873003X0000|193 196|AIDS
P11873003X0000|60 63|AIDS
P11873003X0000|240 244|death
P11873003X0000|36 45|difference
P11873003X0000|211 214|time
P11873003X0000|54 57|time
P11873003X0000|234 237|AIDS
P11873003X0000|107 115|countries
P11873003X0000|117 126|OBJECTIVES
P11873003X0000|202 206|death
P11874637A0212|72 83|improvements
P11874637A0212|123 130|decrease
P11874637A0212|34 40|therapy
P11874637A0212|211 222|malignancies
P11874637A0212|136 144|incidence
P11874637A0212|179 196|deficiency syndrome
P11874637A0212|89 97|treatment
P11874637A0212|3 5|use
P11874637A0212|148 155|severity
P11874637A0212|198 201|AIDS
P11874637A0212|42 46|HAART
P11874637A0212|100 111|HIV infection
P11875695A0718|0 3|Time
P11875695A0718|87 89|% CI
P11875695A0718|61 72|registration
P11875695A0718|49 56|survival
P11875695A0718|6 16|progression
P11875695A0718|78 83|months
P11875695A0718|21 26|months
P11875695A0718|94 99|months
P11875695A0718|31 36|months
P11876937A0261|13 14|kg
P11876937A0261|20 22|day
P11876937A0261|107 109|day
P11876937A0261|11 11|U
P11876937A0261|58 61|rats
P11876937A0261|81 86|saline
P11876937A0261|64 69|H group
P11876937A0261|96 101|N group
P11876937A0261|0 6|Heparin
P11879108A0719|0 17|MAIN OUTCOME MEASURE
P11879108A0719|155 175|immunodeficiency virus
P11879108A0719|77 100|ligase chain reaction assay
P11879108A0719|63 71|infection
P11879108A0719|19 19|A
P11879108A0719|137 146|test result
P11879108A0719|111 124|outcome measure
P11879108A0719|28 37|test result
P11879108A0719|177 179|HIV
P11881268A0000|3 9|purpose
P11881268A0000|65 98|exercise self-efficacy questionnaire
P11881268A0000|122 126|women
P11881268A0000|16 20|study
P11881923A1256|116 126|POST periods
P11881923A1256|11 25|lymphocyte ratio
P11881923A1256|27 43|plasma haptoglobin
P11881923A1256|92 97|period
P11881923A1256|69 69|P
P11881923A1256|149 158|treatments
P11881923A1256|111 113|PRE
P11881923A1256|48 56|CBG levels
P11881923A1256|0 9|Neutrophil
P11882054A0568|128 131|ROIs
P11882054A0568|194 205|lesion volume
P11882054A0568|51 60|structures
P11882054A0568|110 116|regions
P11882054A0568|89 93|pairs
P11882054A0568|15 21|lesions
P11882054A0568|161 166|slices
P11882054A0568|119 126|interest
P11882054A0568|62 71|FMZ binding
P11882054A0568|212 223|mirror region
P11882054A1250|220 229|epilepsies
P11882054A1250|180 189|mechanisms
P11882054A1250|114 123|epilepsies
P11882054A1250|63 77|spiking activity
P11882054A1250|39 47|decreases
P11882054A1250|50 59|FMZ binding
P11882054A1250|167 174|relation
P11882054A1250|146 155|FMZ binding
P11882054A1250|192 206|epileptogenesis
P11882054A1250|13 23|correlation
P11882747A0354|0 1|CD
P11882747A0354|23 42|Farnsworth D-15 method
P11883682A0162|43 47|spill
P11883682A0162|77 82|metals
P11883682A0162|88 105|estuarine sediments
P11883682A0162|18 27|monitoring
P11883682A0162|58 69|distribution
P11883763A1062|174 184|Pu transport
P11883763A1062|8 13|fluxes
P11883763A1062|105 109|slope
P11883763A1062|126 130|layer
P11883763A1062|211 222|East China Sea
P11883763A1062|70 78|particles
P11883763A1062|23 24|Pu
P11883763A1062|59 67|transport
P11883763A1062|201 205|slope
P11884014A0665|29 40|diet delivery
P11884014A0665|64 70|effects
P11884014A0665|55 56|GI
P11884014A0665|8 25|treatment protocols
P11885053A1897|54 60|objects
P11885053A1897|115 121|objects
P11885053A1897|139 152|memorial shrine
P11885053A1897|39 44|groups
P11885053A1897|30 35|Volkan
P11885737A1713|3 7|range
P11885737A1713|23 40|spermatozoa/microl
P11885737A1713|64 73|compromise
P11885737A1713|81 88|criteria
P11886473A0796|0 13|Gastritis score
P11886473A0796|72 72|p
P11886473A0796|80 82|nod
P11886473A0796|106 109|CagA
P11886473A0796|112 112|p
P11886473A0796|91 91|p
P11886473A0796|129 134|antrum
P11886473A0796|101 103|nod
P11886473A0796|42 45|CagA
P11886473A0796|47 54|children
P11886473A0796|138 143|corpus
P11886473A0796|66 69|CagA
P11886473A0796|37 39|nod
P11886473A0796|85 88|CagA
P11886473A0796|61 63|nod
P11887803A1455|200 200|p
P11887803A1455|150 153|CAPD
P11887803A1455|192 198|Balance
P11887803A1455|137 140|rats
P11887803A1455|66 72|animals
P11887803A1455|125 134|peritoneum
P11887803A1455|104 111|fibrosis
P11887803A1455|187 190|CAPD
P11887803A1455|3 15|mean thickness
P11887803A1455|169 175|animals
P11887803A1455|29 38|peritoneum
P11887803A1455|58 63|groups
P11888183A0541|72 79|duration
P11888183A0541|48 63|maximum intensity
P11888183A0541|8 15|analysis
P11888183A0541|110 115|maxima
P11888183A0541|92 94|hrs
P11888183A0541|40 45|series
P11888867A0000|176 183|survival
P11888867A0000|186 193|patients
P11888867A0000|148 158|correlation
P11888867A0000|57 63|TA90-IC
P11888867A0000|210 218|melanomas
P11888867A0000|105 111|antigen
P11888867A0000|0 9|BACKGROUND
P11888867A0000|118 125|antibody
P11888867A0000|163 172|recurrence
P11888867A0000|45 54|serum level
P11888867A0000|73 79|complex
P11890354A0000|0 16|Genetics Institute
P11890354A0000|40 49|oprelvekin
P11890354A0000|80 83|form
P11890354A0000|91 95|IL-11
P11890354A0000|51 57|rhIL-11
P11890354A0000|59 65|Neumega
P11890438A0838|0 7|Patients
P11890438A0838|45 48|days
P11890438A0838|74 82|dressings
P11890438A0838|33 38|clinic
P11890438A0838|58 63|wounds
P11893403A0252|73 80|exposure
P11893403A0252|130 139|toxicology
P11893403A0252|92 98|analogy
P11893403A0252|31 46|safety evaluation
P11893403A0252|111 126|pharmacokinetics
P11893403A0252|49 65|flavor ingredients
P11893403A0252|100 109|metabolism
P11893403A0252|0 7|Elements
P11893767A0356|75 75|O
P11893767A0356|23 39|minute ventilation
P11893767A0356|41 41|E
P11893767A0356|169 171|day
P11893767A0356|123 138|breathing pattern
P11893767A0356|113 116|ages
P11893767A0356|71 72|VE
P11893767A0356|60 69|equivalent
P11894605A1429|0 13|INTERPRETATION
P11894605A1429|195 205|advertising
P11894605A1429|66 82|health information
P11894605A1429|177 182|amount
P11894605A1429|165 171|changes
P11894605A1429|118 127|motivation
P11894605A1429|148 153|result
P11894605A1429|85 91|smoking
P11894605A1429|43 52|dissonance
P11894605A1429|186 192|content
P11895024A1054|4 8|cases
P11895024A1054|11 13|GBS
P11895024A1054|23 24|TM
P11895024A1054|44 58|AFP surveillance
P11895024A1054|76 91|hospital searches
P11895184A0000|56 67|object-place
P11895184A0000|127 150|cheeseboard maze apparatus
P11895184A0000|12 15|rats
P11895184A0000|69 78|odor-place
P11895184A0000|20 26|control
P11895184A0000|109 112|task
P11895184A0000|3 9|ability
P11895184A0000|40 46|lesions
P11897449A0566|171 174|mean
P11897449A0566|21 34|activation site
P11897449A0566|91 93|RFA
P11897449A0566|161 169|beats/min
P11897449A0566|182 190|beats/min
P11897449A0566|40 53|administration
P11897449A0566|95 101|RESULTS
P11897449A0566|106 114|heart rate
P11897449A0566|56 62|esmolol
P11897449A0566|81 85|shift
P11897449A0566|135 139|state
P11897449A0566|117 120|rest
P11897449A0566|3 7|shift
P11897888A0590|29 42|administration
P11897888A0590|50 60|supplements
P11897888A0590|0 11|Urine samples
P11897950A0617|0 10|CONCLUSIONS
P11897950A0617|117 123|eyelids
P11897950A0617|82 97|drainage pathways
P11897950A0617|157 162|eyelid
P11897950A0617|12 29|Lymphoscintigraphy
P11897950A0617|35 57|cynomolgus monkey eyelids
P11897950A0617|132 138|pathway
P11898018T0000|30 37|research
P11898018T0000|0 13|Data management
P11898797A0124|174 184|innervation
P11898797A0124|92 99|patients
P11898797A0124|149 152|loss
P11898797A0124|113 122|head injury
P11898797A0124|39 70|choline acetyltransferase activity
P11898797A0124|84 89|cortex
P11898797A0124|31 36|levels
P11899479A0122|58 63|palate
P11899479A0122|21 27|lesions
P11899479A0122|51 56|cheeks
P11899479A0122|157 172|CHROMagar Candida
P11899479A0122|97 111|cotton wool swabs
P11899479A0122|184 195|yeast species
P11899479A0122|276 287|kit AuxaColor
P11899479A0122|213 220|germ tube
P11899479A0122|44 49|tongue
P11899479A0122|81 94|denture surface
P11899479A0122|11 16|smears
P11899479A0122|37 42|mucosa
P11899479A0122|237 253|assimilation tests
P11899479A0122|143 153|glucose agar
P11899489A0119|3 9|effects
P11899489A0119|51 54|care
P11899489A0119|106 110|stage
P11899489A0119|27 35|treatment
P11899489A0119|79 86|dementia
P11899489A0119|58 64|support
P11900770T0000|30 40|attenuation
P11900770T0000|67 92|dopamine receptor antagonism
P11900770T0000|55 60|impact
P11900770T0000|19 28|incentives
P11902068T0000|15 21|journey
P11902068T0000|3 12|CKD patient
P11902738A0185|0 7|PATIENTS
P11902738A0185|44 54|cohort study
P11902738A0185|110 114|fever
P11902738A0185|23 27|study
P11902738A0185|149 163|neutrophil count
P11902738A0185|60 67|children
P11902738A0185|11 17|METHODS
P11902738A0185|118 128|neutropenia
P11902738A0185|168 176|cells/mm3
P11902738A0185|95 105|institution
P11902738A0185|72 77|cancer
P11902738A0185|187 192|period
P11902781A0550|0 13|Concentrations
P11902781A0550|108 113|season
P11902781A0550|37 45|Deoprayag
P11902781A0550|79 82|mg/L
P11902781A0550|27 27|N
P11902781A0550|34 34|N
P11902781A0550|18 19|O3
P11902781A0550|23 23|N
P11902781A0550|16 16|N
P11902781A0550|29 30|H3
P11904017A0000|88 90|bed
P11904017A0000|124 129|region
P11904017A0000|111 114|flow
P11904017A0000|26 32|process
P11904017A0000|149 154|system
P11904017A0000|49 57|blood flow
P11907691A0214|43 51|locations
P11907691A0214|81 84|mass
P11907691A0214|65 70|object
P11907691A0214|20 34|contact surfaces
P11907691A0214|3 14|orientations
P11907691A0214|73 78|center
P11908529A0553|26 31|number
P11908529A0553|21 24|flux
P11908529A0553|153 159|objects
P11908529A0553|100 111|AgCl crystals
P11908529A0553|91 98|plastics
P11908529A0553|62 71|comparison
P11908529A0553|113 115|LiF
P11908529A0553|132 137|region
P11908529A0553|42 44|cm3
P11908529A0553|46 51|charge
P11908529A0553|118 127|energy loss
P11908529A0553|81 89|detectors
P11908529A0553|34 38|stars
P11908529A0553|3 9|results
P11908529A0553|57 60|ions
P11909404A0000|28 35|function
P11909404A0000|47 50|sign
P11909404A0000|5 11|domains
P11909404A0000|15 21|regions
P11910310A0279|0 5|DESIGN
P11910310A0279|53 57|trial
P11910344A1119|0 10|CONCLUSIONS
P11910344A1119|69 72|type
P11910344A1119|41 45|study
P11910344A1119|57 64|patients
P11910344A1119|137 144|increase
P11910344A1119|111 118|function
P11910344A1119|74 76|HRS
P11910344A1119|147 154|survival
P11911552A0776|86 94|remission
P11911552A0776|105 109|range
P11911552A0776|69 72|dose
P11911552A0776|120 123|mg/d
P11911552A0776|22 31|quetiapine
P11911552A0776|33 39|therapy
P11911552A0776|2 9|patients
P11912261A0284|75 82|receptor
P11912261A0284|12 17|agents
P11912261A0284|117 126|experience
P11912261A0284|33 44|PTH secretion
P11912261A0284|99 104|glands
P11912677A0281|85 91|data set
P11912677A0281|8 15|analysis
P11912677A0281|62 72|variability
P11912677A0281|45 53|structure
P11912677A0281|27 36|hypotheses
P11913427A0290|96 100|error
P11913427A0290|111 112|g.
P11913427A0290|62 74|accelerations
P11913427A0290|55 59|value
P11913427A0290|3 10|subjects
P11915436A0491|47 51|rates
P11915436A0491|11 24|incidence rates
P11915436A0491|64 73|population
P11917061A0922|144 144|P
P11917061A0922|60 70|cyclosporin
P11917061A0922|111 119|remission
P11917061A0922|74 83|prednisone
P11917061A0922|50 57|response
P11917061A0922|18 25|response
P11917061A0922|7 15|predictor
P11917061A0922|136 136|%
P11917061A0922|121 133|remission rate
P11917061A0922|28 37|tacrolimus
P11917882A0326|71 77|dentine
P11917882A0326|120 136|adhesion-strategy
P11917882A0326|44 52|interface
P11917882A0326|21 25|study
P11917882A0326|60 68|selection
P11917882A0326|86 92|systems
P11920455X1195|0 8|Copyright
P11920455X1195|13 33|American Cancer Society
P11920455X1195|35 37|DOI
P11920455X1195|50 55|.10318
P11920896A0298|128 130|FPR
P11920896A0298|101 105|women
P11920896A0298|49 52|test
P11920896A0298|30 31|DR
P11920896A0298|6 10|study
P11920896A0298|123 126|rate
P11920896A0298|140 140|%
P11920896A0298|68 77|population
P11921126A1196|59 65|aspects
P11921126A1196|22 28|STN-DBS
P11921126A1196|93 94|PD
P11921126A1196|68 70|QoL
P11921126A1196|73 80|patients
P11921126A1196|15 20|PDQ-39
